<SEC-DOCUMENT>0001193125-22-295370.txt : 20221130
<SEC-HEADER>0001193125-22-295370.hdr.sgml : 20221130
<ACCEPTANCE-DATETIME>20221130160529
ACCESSION NUMBER:		0001193125-22-295370
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		116
FILED AS OF DATE:		20221130
DATE AS OF CHANGE:		20221130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Company/DE
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268603
		FILM NUMBER:		221435621

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d374624ds1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:sclx="http://www.vickersvantagecorp.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To09_30_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden61004188" contextRef="P01_01_2022To09_30_2022">Scilex Holding Company/DE</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To09_30_2022">0001820190</ix:nonNumeric><ix:footnote id="FN_208988" xml:lang="en-US">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</ix:footnote ><ix:footnote id="FN_208990" xml:lang="en-US">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented.</ix:footnote ><ix:footnote id="FN_208989" xml:lang="en-US">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20220930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_17_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_02_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:ScilexCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ApprovalBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:StatementAxis" >sclx:DecemberOptionalRepurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:StatementAxis" >sclx:FebruaryOptionalRepurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:StatementAxis" >sclx:AprilOptionalRepurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >sclx:AccountsReceivableRevolvingLoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:CumulativeSalesRelatedContingencyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >sclx:IndefiniteCarryforwardPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >sclx:FundingCommitmentLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >sclx:FundingCommitmentLetterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-17</xbrli:startDate> <xbrli:endDate>2022-10-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >sclx:SoleDistributorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventTypeAxis" >sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis" >sclx:NonPayrollCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventTypeAxis" >sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis" >sclx:PayrollCostsBasisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-17</xbrli:startDate> <xbrli:endDate>2022-03-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-10</xbrli:startDate> <xbrli:endDate>2022-09-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-11</xbrli:startDate> <xbrli:endDate>2022-07-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AsRestatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AdjustmentsRestatement2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-05</xbrli:startDate> <xbrli:endDate>2021-01-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-02</xbrli:startDate> <xbrli:endDate>2020-07-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-01</xbrli:startDate> <xbrli:endDate>2020-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-03</xbrli:startDate> <xbrli:endDate>2021-01-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-10</xbrli:startDate> <xbrli:endDate>2022-10-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-09</xbrli:startDate> <xbrli:endDate>2022-09-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:AmendmentToTwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:ItochuMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >sclx:SoleDistributorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >sclx:SoleDistributorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:ReorganizationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:ReorganizationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:ContributionAndLoanAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:RegulatoryBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:LetterOfCreditDrawnDownMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-15</xbrli:startDate> <xbrli:endDate>2022-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-15</xbrli:startDate> <xbrli:endDate>2022-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-01</xbrli:startDate> <xbrli:endDate>2018-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-06-30</xbrli:startDate> <xbrli:endDate>2017-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:ItochuMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AsRestatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AsRestatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-08-07</xbrli:startDate> <xbrli:endDate>2019-08-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-10</xbrli:startDate> <xbrli:endDate>2020-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-10</xbrli:startDate> <xbrli:endDate>2020-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-01-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-22</xbrli:startDate> <xbrli:endDate>2018-10-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-14</xbrli:startDate> <xbrli:endDate>2022-06-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-02</xbrli:startDate> <xbrli:endDate>2018-10-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-07</xbrli:startDate> <xbrli:endDate>2018-09-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-28</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-28</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >sclx:PaloAltoAadministrativeFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-30</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-30</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-30</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-07</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-07</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >sclx:IfLetterOfCreditIsDrawnMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >sclx:MarketingApprovalLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:PrimeRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-14</xbrli:startDate> <xbrli:endDate>2020-12-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-12</xbrli:startDate> <xbrli:endDate>2022-09-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-10</xbrli:startDate> <xbrli:endDate>2022-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-10</xbrli:startDate> <xbrli:endDate>2022-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-16</xbrli:startDate> <xbrli:endDate>2022-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-01</xbrli:startDate> <xbrli:endDate>2020-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:AccountsPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_11_2022To11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-11</xbrli:startDate> <xbrli:endDate>2022-11-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-17</xbrli:startDate> <xbrli:endDate>2022-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PeriodAxis" >sclx:DueOnOrAfterFebruaryTwoThousandAndThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-11</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-21</xbrli:startDate> <xbrli:endDate>2021-12-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-11</xbrli:startDate> <xbrli:endDate>2022-07-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-10</xbrli:startDate> <xbrli:endDate>2022-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_61002555" toRefs="FN_208988"/><ix:relationship fromRefs="Fact_61002556" toRefs="FN_208988"/><ix:relationship fromRefs="Fact_61002968" toRefs="FN_208990"/><ix:relationship fromRefs="Fact_61002969" toRefs="FN_208990"/><ix:relationship fromRefs="Fact_61002970" toRefs="FN_208990"/><ix:relationship fromRefs="Fact_61003170" toRefs="FN_208989"/><ix:relationship fromRefs="Fact_61003171" toRefs="FN_208989"/></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As filed with the U.S. Securities and Exchange Commission on November </div></div></div><div style="font-weight:bold;display:inline;"><div style="font-size: 8pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>,</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022 </div></div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To09_30_2022">S-1</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden61004188">Scilex Holding Company</span> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Delaware</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2836</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">92-1062542</div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Primary Standard Industrial</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Classification Code Number)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification Number)</div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">960 San Antonio Road </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, CA 94303 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jaisim Shah </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer&#160;&amp; President </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">960 San Antonio Road </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, CA 94303 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">516-4310</div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jeffrey T. Hartlin, Esq. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth A. Razzano, Esq. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Hastings LLP </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1117 S. California Avenue </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, CA 94304 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">320-1800</div> </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public: </div></div>As soon as practicable after this registration statement becomes effective. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;&#160;&#9746; </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 67%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Large&#160;accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Smaller&#160;reporting&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td>
<td colspan="2" style="height: 3.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Emerging&#160;growth&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#eb0029"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center"><span style="color:#eb0029"><span style="font-weight:bold">PRELIMINARY &#8212; SUBJECT TO COMPLETION, DATED NOVEMBER&#160;30, 2022 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><span style="color:#eb0029"><span style="font-weight:bold">PRELIMINARY PROSPECTUS </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 144,975,423 Shares of Common Stock </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 11,003,988 Shares of Common Stock Issuable Upon the Exercise of Warrants </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 5,265,776&#160;Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">This prospectus relates to the issuance by us of up to an aggregate of 11,003,988 shares of our common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), issuable upon the exercise of (i) 4,104,000 private placement warrants (the &#8220;Private Warrant Shares&#8221;) originally sold in a private placement in connection with the initial public offering of Vickers Vantage Corp. I (and a portion of which were subsequently transferred to Sorrento Therapeutics in connection with the Business Combination (as defined below)) (the &#8220;Private Warrants&#8221;) and (ii)&#160;6,899,988 public warrants (the &#8220;Public Warrant Shares&#8221;) originally sold to the public investors in connection with the initial public offering of Vickers Vantage Corp. I (the &#8220;Public Warrants&#8221; and together with the Private Warrants, the &#8220;Warrants&#8221;). We will not receive the proceeds from the resale of the Private Warrant Shares or the Public Warrant Shares hereunder; however, we will receive the proceeds from any exercise of the Private Warrants and the Public Warrants. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">This prospectus also relates to the offer and sale from time to time by: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">(a) the selling stockholders named in this prospectus (including their permitted transferees, donees, pledgees and other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest)</span></span> (collectively, the &#8220;Selling Stockholders&#8221;)&#160;of up to an aggregate of 144,975,423&#160;shares (the &#8220;Resale Shares&#8221;) of our Common Stock, consisting of: </p> <p style="margin-top:3pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:8pt; font-family:Times New Roman">(i) up to 3,983,057 shares of Common Stock (the &#8220;Sponsor Shares&#8221;) held by Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Pei Wei Woo, Suneel Kaji and Steve Myint (collectively, the &#8220;Sponsors&#8221;), comprised of 3,450,000 shares that were issued on November&#160;9, 2022 upon conversion of the same number of our former ordinary shares in connection with the Domestication and the Business Combination (each as defined below) and 533,057 shares that were also issued on November&#160;9, 2022 upon the contribution of certain indebtedness by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd in connection with the Business Combination pursuant to a debt contribution agreement; </p> <p style="margin-top:3pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:8pt; font-family:Times New Roman">(ii) up to 135,726,590 shares of Common Stock (the &#8220;Merger Shares&#8221;) issued to Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;) on November&#160;10, 2022 in connection with the Business Combination; </p> <p style="margin-top:3pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:8pt; font-family:Times New Roman">(iii) up to 4,104,000 Private Warrant Shares; and </p> <p style="margin-top:3pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:8pt; font-family:Times New Roman">(iv) up to 1,161,776 Public Warrant Shares issuable to Sorrento pursuant to Public Warrants held by Sorrento; and </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">(b)&#160;the selling warrantholders named in this prospectus (including their permitted transferees, donees, pledgees and other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest)</span></span> (collectively, the &#8220;Selling Warrantholders&#8221; and, together with the Selling Stockholders, the &#8220;Selling Securityholders&#8221;) of up to 4,104,000 Private Warrants and 1,161,776 Public Warrants. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the previously announced business combination (the &#8220;Business Combination&#8221;) pursuant to that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022 (as amended, restated or supplemented from time to time, including by Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022) (the &#8220;Merger Agreement&#8221;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the &#8220;Merger Sub&#8221;), and the <span style="white-space:nowrap">pre-Business</span> Combination Scilex Holding Company (&#8220;Legacy Scilex&#8221;). We are registering the issuance by us of up to 6,899,988 shares of Common Stock upon the exercise of the Public Warrants as required under the terms of the Warrant Agreement, dated as of January&#160;6, 2021, between Vickers Vantage Corp. I (now known as Scilex Holding Company), and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, which governs the Public Warrants. We are also registering the resale of the Sponsor Shares, the Merger Shares, the Private Warrant Shares and the Private Warrants as required by that certain Amended and Restated Registration Rights Agreement by and among us, the Sponsors and certain other stockholders, dated November&#160;10, 2022 (the &#8220;Registration Rights Agreement&#8221;). </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our registration of the Resale Shares and the Private Warrants covered by this prospectus does not mean that the Selling Securityholders will offer or sell any of the Resale Shares or the Private Warrants. The Selling Securityholders may sell the Resale Shares and the Private Warrants covered by this prospectus in a number of different ways and at varying prices. For additional information on the possible methods of sale that may be used by the Selling Securityholders, you should refer to the section of this prospectus titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; beginning on page&#160;231 of this prospectus. We will receive the proceeds from any exercise of the Warrants for cash, but will not receive any of the proceeds from the resale of the Resale Shares or the Private Warrants sold by the Selling Securityholders. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">No underwriter or other person has been engaged to facilitate the sale of the shares of our Common Stock or the Warrants in these offerings. The Selling Securityholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) of the Resale Shares and the Private Warrants that they are offering pursuant to this prospectus. We will bear all costs, expenses and fees in connection with the registration of the shares of our Common Stock and Warrants hereunder. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their respective sales of the Resale Shares and the Private Warrants. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. On November&#160;29, 2022, the last reported sales price per share of our Common Stock was $4.64. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;SCLXW.&#8221; On November&#160;29, 2022, the closing sale price per warrant of our Public Warrants was $0.225. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings with the Securities and Exchange Commission. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read this prospectus, together with additional information described under the heading &#8220;Where You Can Find More Information&#8221;, and any amendments or supplements carefully before you invest in any of our securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><span style="font-weight:bold">INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;</span><span style="font-weight:bold"><span style="font-style:italic"><a href="#rom374624_11">RISK FACTORS</a></span></span><span style="font-weight:bold">&#8221; BEGINNING ON PAGE 9 OF THIS PROSPECTUS. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">v</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_2">CERTAIN DEFINED TERMS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">vii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_4">The Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_5">Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_6">Recent Developments</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_7">Emerging Growth Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_8">Summary Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_9">Corporate Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_10">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_11">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_12">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_13">Risks Related to our Commercial Operations and Product Development</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_14">Risks Related to our Business and Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_15">Risks Related to Scilex&#8217;s Intellectual Property</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_16">Risks Related to Government Regulations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_17">Risks Related to our Relationship with Sorrento</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_18">Risks Related to Ownership of our Common Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_19">MARKET AND INDUSTRY DATA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_20">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_21">DETERMINATION OF OFFERING PRICE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_22">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_23">Market Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_24">Dividend Policy</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_25">Securities Authorized for Issuance under Equity Compensation Plans</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_26">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_27">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_28">Overview</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_29">Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_30">Recent Developments</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_31">Impact of <span style="white-space:nowrap">COVID-19</span> on Our Business</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_32">Comparability of Our Results and Our Relationship with Sorrento</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_33">Components of Our Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_34">Operating Costs and Expenses</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_35">Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">107</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_36">Comparison of Nine Months Ended September&#160;30, 2022 and 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_37">Comparison of Years Ended December&#160;31, 2021 and 2020</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_38">Comparison of Years Ended December&#160;31, 2020 and 2019</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">112</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_39">Liquidity and Capital Resources</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_40">Debt Financings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_41">Critical Accounting Policies and Estimates</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_42">Recent Accounting Pronouncements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_43">Quantitative and Qualitative Disclosures About Market Risk</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_43a">Emerging Growth Company </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_44">Smaller Reporting Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_45">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_46">The Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_47">Our Marketed Product and Pipeline</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_48">Our Strategy</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_49">Our Management Team</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_50">Our Product Portfolio</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_51">Commercialization and Market Access</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_52">Clinical Development Overview</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_53">Medical Affairs</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_54">Manufacturing and Supply Chain</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_55">Competition</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_56">Material Agreements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_57">Intellectual Property</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_58">Government Regulation and Product Approval</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_59">Employees and Human Capital Resources</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_60">Facilities and Properties</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_61">Legal Proceedings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_62">Our Corporate History</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_63">Website</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_64">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_65">Executive Officers and Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_66">Family Relationships</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_67">Board Composition</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_68">Controlled Company Exemption</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_69">Director Independence</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_70">Role of Board in Risk Oversight Process</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_71">Board Leadership Structure</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_72">Board Diversity</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_73">Committees of our Board</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_74">Code of Business Conduct and Ethics</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_75">Compensation Committee Interlocks and Insider Participation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_76">Limitation of Liability and Indemnification of Directors and Officers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_77">EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_78">Executive Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_79">Summary Compensation Table</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_80">Narrative Disclosure to Summary Compensation Table</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_81">Potential Payments upon Termination or Change in Control</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_82">Perquisites, Health, Welfare and Retirement Benefits</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_83">Pension Benefits and Nonqualified Deferred Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_84">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_85">Equity-Based Incentive Plans</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_86">Emerging Growth Company Status</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_87">Director Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_88">Director Compensation Policy</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_89">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_90">Certain Relationships of Vickers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_91">Certain Relationships of Legacy Scilex</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_92">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_93">SELLING SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_94">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_95">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_96">DESCRIPTION OF OUR SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_97">General</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_98">Authorized and Outstanding Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_99">Our Preferred Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_100">Registration Rights</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_101">Anti-Takeover Matters in our Governing Documents and Under Delaware Law</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_102">Conflicts of Interest</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_103">Rights of Appraisal and Payment</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_104">Stockholders&#8217; Derivative Actions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_105">Warrants</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_106">Transfer Agent and Registrar</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_107">Listing</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_108">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_109">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_109a">CHANGE IN AUDITORS </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_110">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom374624_111">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus supplement and any related free writing prospectus. Neither we nor the Selling Securityholders have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document, regardless of the time of delivery of this prospectus or any sale of a security. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">For Investors Outside the United States</span>: The Selling Securityholders are offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Securityholders have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on <span style="white-space:nowrap">Form&#160;S-1</span> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus entitled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the previously-announced Business Combination pursuant to the Merger Agreement, by and among us, Merger Sub and Legacy Scilex. Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised) and a domestication under Section&#160;388 of the Delaware General Corporation Law, as amended (the &#8220;DGCL&#8221;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the &#8220;Domestication&#8221;), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221; or the &#8220;Business Combination&#8221;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Scilex,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I, and its consolidated subsidiaries. References to &#8220;Legacy Scilex&#8221; refer to the private Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of federal securities laws. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;intend,&#8221; &#8220;outlook,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a statement is not forward-looking. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this prospectus and our managements&#8217; current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the Company and our directors, officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in &#8220;<span style="font-style:italic">Risk Factors,</span>&#8221; our periodic filings with the SEC and the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our public securities&#8217; liquidity and trading; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to raise financing in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract and retain qualified directors, officers, employees and key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to compete effectively in a highly competitive market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competition from larger pharmaceutical companies that have greater resources, technology, relationships and/or expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to protect and enhance our corporate reputation and brand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact from future regulatory, judicial and legislative changes in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain regulatory approval of any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to research, discover and develop additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to grow and manage growth profitably; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to execute our business plans and strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of the <span style="white-space:nowrap">COVID-19</span> pandemic and other similar disruptions in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">v </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the continuing <span style="white-space:nowrap">COVID-19</span> pandemic, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">vi </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_2">CERTAIN DEFINED TERMS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Board</span>&#8221; means the board of directors of the Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Business Combination</span>&#8221; means the merger contemplated by the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Bylaws</span>&#8221; means the Bylaws of Scilex Holding Company, effective as of November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Designations</span>&#8221; means the Certificate of Designations of the Company, designating the series of preferred stock, par value $0.0001 per share, of the Company as &#8220;Series A Preferred Stock&#8221;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Incorporation</span>&#8221; means the Restated Certificate of Incorporation of Scilex Holding Company, filed with Secretary of State of the State of Delaware on November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing</span>&#8221; means the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing Date</span>&#8221; means date of the Closing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Code</span>&#8221; means the Internal Revenue Code of 1986, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Common Stock</span>&#8221; means the common stock, par value $0.0001 per share, of Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Continental</span>&#8221; means Continental Stock Transfer&#160;&amp; Trust Company, our transfer agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Debt Exchange Agreement</span>&#8221; means the Contribution and Satisfaction of Indebtedness Agreement, dated as of September&#160;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">DGCL</span>&#8221; means the General Corporation Law of the State of Delaware, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Domestication</span>&#8221; means the change of our domicile pursuant to a transfer by way of continuation of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our <span style="white-space:nowrap">de-registration</span> in the Cayman Islands. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Effective Time</span>&#8221; means the time at which the Business Combination became effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Equity Incentive Plan</span>&#8221; means the Scilex Holding Company 2022 Equity Incentive Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">ESPP</span>&#8221; means the Scilex Holding Company 2022 Employee Stock Purchase Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Exchange Act</span>&#8221; means the Securities Exchange Act of 1934, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">founder shares</span>&#8221; means the 3,450,000 outstanding Vickers Ordinary Shares held by the Sponsors and the following directors of Vickers: Pei Wei Woo, Suneel Kaji and Steve Myint, which were converted into 3,450,000 shares of Common Stock in connection with the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Funding Commitment Letter</span>&#8221; means that certain letter agreement, dated as of October&#160;17, 2022, between Sorrento and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">GAAP</span>&#8221; means accounting principles generally accepted in the United States of America. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">HSR Act</span>&#8221; means Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Initial Shareholders</span>&#8221; means the Sponsors, Pei Wei Woo, Suneel Kaji and Steve Myint, each as the holders of founder shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IPO</span>&#8221; refers to the initial public offering of 13,800,000 Units of Vickers consummated on January&#160;11, 2021. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IRS</span>&#8221; means the United States Internal Revenue Service. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Board</span>&#8221; means the board of directors of Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Common Stock</span>&#8221; means the common stock of Legacy Scilex, par value $0.0001 per share, prior to the Effective Time. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">vii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Preferred Stock</span>&#8221; means the Series A Preferred Stock, par value $0.0001 per share, of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Maxim</span>&#8221; means Maxim Group LLC, the representative of the underwriters in the IPO. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement</span>&#8221; means that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement Amendment</span>&#8221; means that Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022, by and among us, Merger Sub and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Sub</span>&#8221; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq</span>&#8221; means The Nasdaq Stock Market LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq Listing Rules</span>&#8221; means the rules and listing standards of Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Private Placement Warrants</span>&#8221; means the 6,840,000 warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&#160;11, 2021 (of which 2,736,000 were forfeited pursuant to the Sponsor Support Agreement and 3,104,000 were transferred to Sorrento pursuant to the Warrant Transfer Agreement, in each case in connection with the Business Combination). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">public shareholders</span>&#8221; means the holders of the public shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">public shares</span>&#8221; means the Vickers Ordinary Shares which were sold as part of the IPO, whether they were purchased in the IPO or in the aftermarket, including any of our Initial Shareholders to the extent that they purchase such public shares (except that our Initial Shareholders will not have conversion or tender rights with respect to any public shares they own). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Public Warrants</span>&#8221; means the redeemable warrants that were included in the Units that entitle the holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">SEC</span>&#8221; means the U.S. Securities and Exchange Commission. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Securities Act</span>&#8221; means the Securities Act of 1933, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Series A Preferred Stock</span>&#8221; means the preferred stock, par value $0.0001 per share, of the Company, designated as Series A Preferred Stock pursuant to the Certificate of Designations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento</span>&#8221; means Sorrento Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Group</span>&#8221; means Sorrento together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Trigger Event</span>&#8221; means the time that the Sorrento Group first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsors</span>&#8221; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsor Support Agreement</span>&#8221; means that certain Sponsor Support Agreement, dated March&#160;17, 2022, by and among the Initial Shareholders and with Scilex, Inc. (f/k/a Scilex Holding Company).</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Stockholder Agreement</span>&#8221; means the Stockholder Agreement, dated as of September&#160;12, 2022, between Vickers and Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Trust Account</span>&#8221; means the Trust Account of Vickers that held the proceeds from Vickers&#8217;s IPO and the private placement of the Private Placement Warrants. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">viii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Units</span>&#8221; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <span style="white-space:nowrap">one-half</span> of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and <span style="white-space:nowrap">one-half</span> of one warrant to purchase one share of Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers</span>&#8221; means Vickers Vantage Corp. I, our predecessor company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Debt Agreement</span>&#8221; means that certain Debt Contribution Agreement, dated as of October&#160;17, 2022, by and among Vickers and the Sponsors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Ordinary Shares</span>&#8221; means (i)&#160;the ordinary shares, par value $0.0001 per share, of Vickers prior to the Domestication and (ii)&#160;the Common Stock following the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Warrant Transfer Agreement</span>&#8221; means that certain Warrant Transfer Agreement, dated as of October&#160;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ix </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the section of this prospectus titled &#8220;Risk Factors&#8221;. You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_4">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> pain management products for the treatment of acute and chronic pain. We believe that our innovative <span style="white-space:nowrap">non-opioid</span> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate and a Phase 1 candidate that is expected to enter into Phase 2 studies in the first half of 2023. Our commercial product, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;) is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration, for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;) which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. Scilex licenses the rights to ZTlido from and relies exclusively on Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu,&#8221; and together with Oishi, the &#8220;Developers&#8221;) pursuant to the Product Development Agreement and Commercial Supply Agreement (both as defined below). The Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances as more fully described in the sections titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement&#8221; and &#8220;Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement,</span>&#8221; including, among other things, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of its net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <span style="white-space:nowrap">(i)&#160;SP-102</span> (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (&#8220;LBP&#8221;), and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;),</span> a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. In addition, on June&#160;14, 2022, we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liquid formulations of colchicine for the prophylactic treatment of gout (a painful arthritic disorder) in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. GLOPERBA is an <span style="white-space:nowrap">FDA-approved,</span> oral medication for the treatment of gout in adults and we are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Marketed Product and Innovative <span style="white-space:nowrap">Non-Opioid</span> Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on developing and commercializing innovative <span style="white-space:nowrap">non-opioid</span> therapies that will provide safe, substantial and localized pain relief for large market opportunities. The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization rights, except with respect to Japan for ZTlido and <span style="white-space:nowrap">SP-103.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g374624g75s68.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <span style="white-space:nowrap">516-4310.</span> For additional information about us, please see the sections of this prospectus titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; in this prospectus for a discussion of some of the risks related to the execution of our business strategy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_5">Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022 (the &#8220;Closing Date&#8221;), Vickers consummated the previously announced Business Combination pursuant to the terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&#160;prior to the Closing, Vickers changed its jurisdiction of incorporation by deregistrating as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the &#8220;Domestication&#8221;) and (ii)&#160;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#8217;s shareholders at a meeting held on November&#160;9, 2022. In connection with the Business Combination, Vickers changed its name to &#8220;Scilex Holding Company.&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective Time, (i)&#160;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive 0.673498 shares of our Common Stock, (ii)&#160;each share of Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of our Common Stock, and (iii)&#160;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the right to receive a comparable option to purchase shares of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq Capital Market under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common Stock and Warrants are governed by the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement, dated January&#160;6, 2021, between Vickers and Continental (the &#8220;Warrant Agreement&#8221;). See sections of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>&#8221; and &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_6">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into a standby equity purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;YA II&#8221;), pursuant to which we will have the right, but not the obligation, to sell to YA II up to $500,000,000 of our Common Stock. YA II is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to YA II&#8217;s purchase obligation set forth in the Yorkville Purchase Agreement, including that an initial registration statement with respect to the shares of Common Stock issuable pursuant thereto be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the right, but not the obligation, from time to time at our discretion until the first day of the month next following the <span style="white-space:nowrap">36-month</span> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct YA II to purchase a specified amount of shares of Common Stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to YA II (each, an &#8220;Advance Notice&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Advance, an Advance may be for a number of shares of Common Stock not to exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the date of the Advance Notice. The shares of Common Stock, if any, that we elect to sell to YA II pursuant to an Advance will be purchased at a price equal to 98% of the lowest daily VWAP (as defined below) during the two consecutive trading days commencing on the date of delivery of an Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Common Stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. See the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Recent Developments</span>&#8221; for addition information regarding the Yorkville Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_7">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Emerging Growth Company</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_8">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate sufficient revenue to support our operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Commercial Operations and Product Development </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Business and Operations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on the intellectual property we <span style="white-space:nowrap">in-license</span> from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <span style="white-space:nowrap">SP-103</span> would be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We recently entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Government Regulations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Relationship with Sorrento </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Ownership of our Common Stock </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_9">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#8220;Vickers Vantage Corp. I&#8221; on February&#160;21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&#160;9, 2022, we changed our jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&#160;9, 2022, we changed our name to &#8220;Scilex Holding Company&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <span style="white-space:nowrap">516-4310.</span> Our website address is <span style="font-style:italic">www.scilexholding.com</span>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC&#8217;s website at <span style="font-style:italic">http://www.sec.gov.</span> </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_10">THE OFFERING </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Issuance of Common Stock </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by us </p></td>
<td>Up to 11,003,988&#160;shares, issuable upon the exercise of (i) 4,104,000 Private Warrants by the holders thereof and (ii) 6,899,988 Public Warrants by the holders thereof. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding prior to exercise of all Warrants<sup style="font-size:75%; vertical-align:top">(1)</sup> </p></td>
<td>141,348,856 shares of Common Stock (as of November&#160;30, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding assuming exercise of all Warrants </p></td>
<td>152,352,844 shares (based on total shares outstanding as of November&#160;30, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Exercise price of Warrants </p></td>
<td>$11.50 per share, subject to adjustment as described herein. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will receive up to an aggregate of approximately $126.5&#160;million from the exercise of the Warrants, consisting of up to 4,104,000 Private Warrants and up to 6,899,988 Public Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for cash for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. See &#8220;<span style="font-style:italic">Use of Proceeds</span>&#8221; elsewhere in this prospectus. </td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resale of Common Stock and Private Warrants </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by the Selling Securityholders </p></td>
<td>Up to&#160;144,975,423&#160;shares of our Common Stock, consisting of: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:40%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">3,983,057 Sponsor Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:40%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">135,726,590 Merger Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:40%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">4,104,000 Private Warrant Shares; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:40%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,161,776 Public Warrant Shares. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrants offered by the Selling Warrantholders </p></td>
<td>Up to 4,104,000 Private Warrants and up to 1,161,776 Public Warrants. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Redemption </p></td>
<td>The Warrants are redeemable in certain circumstances. See &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Warrants</span>&#8221; for further discussion. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td>We will not receive any proceeds from the sale of shares of Common Stock or Private Warrants by the Selling Securityholders, except with respect to amounts received by us upon the exercise of the Private Warrants for cash. </td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Lock-up</span> restrictions </p></td>
<td>Certain of the securities held by the Selling Securityholders are subject to certain restrictions on transfer until the date that is&#160;180&#160;days after the Closing Date. See the section of this prospectus titled &#8220;<span style="font-style:italic">Selling Securityholders</span>&#8221;. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock and Public Warrants </p></td>
<td>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;SCLXW&#8221;. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>See &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page&#160;9 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The number of shares of Common Stock outstanding is based on an aggregate of 141,348,856 shares outstanding as of November&#160;30, 2022, and excludes: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">744,201 shares of Common Stock issuable upon the exercise of stock options outstanding under the&#160;Scilex Pharma 2017 Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">16,195,178 shares of Common Stock issuable upon the exercise of stock options outstanding under the&#160;2019 Stock Option Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">11,003,988 shares of Common Stock issuable upon the exercise of the Warrants, with an exercise price of $11.50&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to&#160;14,622,712 shares of Common Stock available for future issuance under the Equity Incentive Plan (which number does not include a possible annual increase on January&#160;1 of each year beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to up to 4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to&#160;1,462,271 shares of Common Stock available for future issuance under the ESPP (which number does not include a possible annual increase on January&#160;1 of each year beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to up to 1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any shares that may be issued pursuant to the Yorkville Purchase Agreement (except the 250,000 commitment shares that have already been issued to YA II pursuant to such agreement, which shares are included in the total shares outstanding as of November&#160;30, 2022). See the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217; Discussion and Analysis of Financial Condition and Results of Operations &#8212;Recent Developments</span>&#8221; for additional information regarding the Yorkville Purchase Agreement and the commitment shares. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_11">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_12">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate sufficient revenue to support our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is our only product approved for commercial sale and we are entirely dependent upon its sales to generate revenue. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in the United States in October 2018. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido will gain market acceptance among physicians, health care payors, patients and the medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido depends on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by physicians, major operators of clinics and patients of the drug as a safe and effective treatment for the relief of neuropathic pain associated with PHN; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability, cost and potential advantages of alternative treatments, including less expensive generic products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our sales and marketing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of other competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product labeling or any product inserts required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of adverse side effects. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to successfully commercialize ZTlido, we will need to expand our marketing efforts to develop new relationships and expand existing relationships. Physicians may decide not to prescribe ZTlido for a variety of reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido or the utilization of products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we succeed in increasing market acceptance of ZTlido, maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido will also depend on pricing and cost-effectiveness, including our ability to produce at a competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be successful. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March 2019, our operations were conducted through Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential <span style="white-space:nowrap">non-opioid</span> pain therapy candidates, undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. All of our revenue to date is attributable to sales of ZTlido, and we expect that sales of ZTlido will account for all of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete ongoing <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials and obtain regulatory approvals for our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identify new acquisition or <span style="white-space:nowrap">in-licensing</span> opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully identify new product candidates and advance those product candidates into <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">raise additional funds when needed and on terms acceptable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain experienced management and advisory teams; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">add operational, financial and management information systems and personnel, including personnel to support clinical, <span style="white-space:nowrap">pre-clinical</span> manufacturing and planned future commercialization efforts and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launch commercial sales of our product candidates, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, expand and protect our intellectual property portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $88.4&#160;million, $47.5&#160;million, and $178.6&#160;million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, we had an accumulated deficit of approximately $352.6&#160;million. For the foreseeable future, we expect to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to incur significant expenses related to the commercialization of ZTlido and GLOPERBA and the research and development of our product candidates, <span style="white-space:nowrap">SP-102</span> (10 mg dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), <span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> and <span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;).</span> We anticipate that our expenses will increase substantially due to the completion of the pivotal Phase 3 trial for SEMDEXA, commencement of the Phase 2 clinical trial for <span style="white-space:nowrap">SP-103</span> and multiple Phase 1 trials for <span style="white-space:nowrap">SP-104.</span> Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, or the Semnur Equityholders, and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0&#160;million in contingent cash consideration based on the achievement of certain milestones. A $40.0&#160;million payment will be due upon obtaining the first approval of a new drug application by the FDA (&#8220;NDA&#8221;) of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido and GLOPERBA, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, our cash and cash equivalents were approximately $2.5&#160;million and we had an accumulated deficit of approximately $358.0&#160;million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of public shares that are redeemed by our public shareholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#8220;<span style="font-style:italic">Liquidity and Going Concern</span>&#8221; of our consolidated financial statements included elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December&#160;31, 2021, which stated that substantial doubt existed about our ability to continue as a going concern. We have negative working capital and have incurred significant operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $352.6&#160;million as of December&#160;31, 2021 and approximately $264.1&#160;million as of December&#160;31, 2020. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and expenditures through additional debt and equity financing. Our plans are substantially dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of our marketing of ZTlido and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements for the years ended December&#160;31, 2021 and 2020, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2021 and 2020, the material weakness identified in our internal control over financial reporting related to ineffective control activities in the areas of revenue, debt, derivative liabilities, cash flows and leases caused by a lack of sufficient accounting resources. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance resource requirements and hiring other personnel with sufficient accounting expertise at Sorrento to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at Legacy Scilex and she became Chief Financial Officer of the Company in connection with the closing of the Business Combination. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, in order to properly manage our internal control over financial reporting, we may need to take additional measures to further augment our finance resources, and we cannot be certain that the measures we have taken, and expect to take, to improve our internal controls will be sufficient to ensure that our internal controls will remain effective and eliminate the possibility that other material weaknesses or deficiencies may develop or be identified in the future. If we experience future material weaknesses or deficiencies in internal controls and we are unable to correct them in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act as, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section&#160;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_13">Risks Related to our Commercial Operations and Product Development </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a number of sole or single source suppliers and manufacturers, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the commercial supply of ZTlido; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of <span style="white-space:nowrap">SP-103;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer for the clinical supply of SEMDEXA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, dated as of May&#160;11, 2011, by and among Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;) (as amended, the &#8220;Product Development Agreement&#8221;), and the Commercial Supply Agreement, dated as of February&#160;16, 2017, by and among Scilex Pharma and Oishi and Itochu (as amended, the &#8220;Commercial Supply Agreement&#8221;), we license the rights to ZTlido from and rely exclusively on Oishi and Itochu for the manufacturing and supply of ZTlido and <span style="white-space:nowrap">SP-103</span> (collectively, the &#8220;Products&#8221;). Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and <span style="white-space:nowrap">SP-103</span> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b) after 30&#160;days of good-faith </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and <span style="white-space:nowrap">SP-103</span> depend. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our exclusive Supply Agreement, dated December&#160;17, 2015 (the &#8220;Genzyme Supply Agreement&#8221;), with Genzyme Corporation (&#8220;Genzyme&#8221;), we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA. Genzyme has the right to terminate the Supply Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice of such breach, (2)&#160;if our development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January&#160;1, 2020, or (3)&#160;if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#8217; notice. We did not file for regulatory approval for SEMDEXA by January&#160;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with the preceding clause (3), Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May 31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Master Services Agreement, dated January&#160;27, 2017 (as amended, the &#8220;Lifecore Master Services Agreement&#8221;), with Lifecore Biomedical, LLC (&#8220;Lifecore&#8221;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&#160;if we (a)&#160;become insolvent, (b)&#160;cease to function as a going concern, (c)&#160;become convicted of or plead guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engage in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name; (3)&#160;if we fail to pay past due invoices upon 30 days&#8217; written notice, or (4)&#160;if we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#8217;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer may be difficult. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Master Services Agreement (the &#8220;Tulex Master Services Agreement&#8221;) and statement of work with Tulex Pharmaceuticals Inc. (&#8220;Tulex&#8221;), we depend on Tulex to develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104.</span> Tulex has the right to terminate the Tulex Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable statement of work) or (2)&#160;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&#160;without cause upon 30 days prior written notice to Tulex or (b)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an alternative manufacturer and supplier on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There are a limited number of manufacturers that operate under current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA <span style="white-space:nowrap">pre-approval</span> inspection and inspections by other health authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability of ZTlido and the development of SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#8220;Cardinal Health 105&#8221;) as our third-party logistics distribution provider for ZTlido in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&#160;31, 2019, 2020 and 2021, and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. Beginning on April&#160;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation (&#8220;McKesson&#8221;), Cardinal Health 110, LLC (&#8220;Cardinal Health 110&#8221;) and AmerisourceBergen Corporation (&#8220;AmerisourceBergen&#8221;), as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health 105 (or with any of our other two distributors), we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics provider, may negatively impact our sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies. We discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. Any disruption in the abovementioned distribution channel would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example, under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith negotiation. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice (&#8220;GCP&#8221;) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;), to conduct <span style="white-space:nowrap">GCP-compliant</span> clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our <span style="white-space:nowrap">GCP-compliant</span> clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our programs. Although we rely on these third parties to conduct our <span style="white-space:nowrap">GCP-compliant</span> clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future enter into collaborations, <span style="white-space:nowrap">in-licensing</span> arrangements, joint ventures, or strategic alliances with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business, we may enter into collaborations, additional <span style="white-space:nowrap">in-licensing</span> arrangements (such as, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, <span style="white-space:nowrap">in-licensing</span> arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such transactions or arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and generate additional revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with regulatory authorities on trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in identifying prospective clinical investigators or clinical trial sites that have necessary qualifications, interest and capacity to perform a requested protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining approval from one or more institutional review boards (&#8220;IRBs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes to the clinical trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in recruiting suitable subjects to participate in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with GCPs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in subjects completing participation in a trial or returning for post-treatment <span style="white-space:nowrap">follow-up,</span> including, for example, as a result of reluctance to visit medical facilities as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites or subjects dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjects experiencing severe or unexpected drug-related adverse effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other sponsors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any changes to our manufacturing process that may be necessary or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased knowledge over time. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of <span style="white-space:nowrap">SP-103,</span> <span style="white-space:nowrap">SP-104</span> and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face potential business disruptions and related risks resulting from the <span style="white-space:nowrap">COVID-19</span> pandemic, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, or <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2,</span></span> was reported to have surfaced in Wuhan, China. <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> is the virus that causes <span style="white-space:nowrap">COVID-19.</span> The <span style="white-space:nowrap">COVID-19</span> outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been experiencing extreme fluctuations that may cause a contraction in available liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global outbreak of <span style="white-space:nowrap">COVID-19</span> continues to rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. The extent to which <span style="white-space:nowrap">COVID-19</span> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease and variants, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are monitoring the potential impact of the <span style="white-space:nowrap">COVID-19</span> outbreak, and if <span style="white-space:nowrap">COVID-19</span> or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely impact the development of our product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to visit clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators, clinical site staff and potential closure of clinical facilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreases in patients seeking treatment for chronic pain; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in local regulations as part of a response to the <span style="white-space:nowrap">COVID-19</span> outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risk that participants enrolled in our clinical trials will acquire <span style="white-space:nowrap">COVID-19</span> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <span style="white-space:nowrap"><span style="white-space:nowrap">shelter-in-place</span></span> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to <span style="white-space:nowrap">COVID-19</span> or other infectious diseases could impact personnel at third-party suppliers in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities. For example, we obtain our commercial supply of ZTlido and our clinical supply of <span style="white-space:nowrap">SP-103</span> exclusively from Oishi and Itochu in Japan. The <span style="white-space:nowrap">COVID-19</span> pandemic may result in delays in the procurement and shipping of ZTlido, which may have an adverse impact on our operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;24, 2021, the Safer Federal Workforce Task Force issued written guidance to implement Executive Order 14042, which was signed by President Biden on September&#160;9, 2021. A number of federal courts have issued orders enjoining enforcement of the Executive Order, including one on a nationwide basis. As a result, the government stated that it will take no action to enforce the requirements of the Executive Order at this time. As a federal contractor, we have mandated that all of our employees and, in addition, contractors that enter our U.S. buildings and certain other locations, be fully vaccinated against <span style="white-space:nowrap">COVID-19,</span> subject to disability and religious exemptions, by December&#160;8, 2021. Despite the government&#8217;s <span style="white-space:nowrap">no-action</span> position, we continue to comply with the Executive Order. We may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and difficulty retaining and securing employees who are vaccinated, all of which could negatively affect our business and operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of <span style="white-space:nowrap">COVID-19,</span> which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of, <span style="white-space:nowrap">COVID-19</span> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <span style="white-space:nowrap">COVID-19</span> could materially affect our business and the value of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the continued spread of <span style="white-space:nowrap">COVID-19</span> globally could materially and adversely impact our operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, travel and employee health and availability, which may have a material and adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends <span style="white-space:nowrap">non-approval</span> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;). The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
post-marketing clinical trials. In addition, the FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed or fail in obtaining marketing approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications or patient populations that are not as broad as we intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to changes in the way the products are administered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be sued and held liable for harm caused to patients; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience damage to our reputation. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required <span style="white-space:nowrap">follow-up</span> periods. If patients are unwilling to participate in our clinical trials due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed. We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials altogether. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity of patients to clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the eligibility and exclusion criteria for the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that enrolled patients will not complete a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to monitor patients adequately during and after treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential disruptions caused by the <span style="white-space:nowrap">COVID-19</span> pandemic, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate in relation to other available products. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are common but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective eligibility criteria in place to reduce the placebo effect and the impacts of <span style="white-space:nowrap">COVID-19,</span> and may experience similar issues with enrollment of our other planned clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or <span style="white-space:nowrap">in-licensing</span> product candidates and determining indications on which to focus in preclinical studies or clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition and our competitors may discover, develop or commercialize products faster or more successfully than us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <span style="white-space:nowrap">SP-103,</span> face and will likely face competition from prescription and generic topical lidocaine patches, including Lidoderm<sup style="font-size:75%; vertical-align:top">&#174;</sup> (a branded, prescription 5% lidocaine patch product) (&#8220;Lidoderm&#8221;) and generic lidocaine patches manufactured by Mylan N.V., Teva Pharmaceutical Industries Limited (&#8220;Teva&#8221;) and Par Pharmaceutical, Inc. Additionally, <span style="white-space:nowrap">SP-103,</span> if approved, will likely compete with various opioid pain medications, nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;), muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of acute LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product for the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain <span style="white-space:nowrap">non-steroid</span> product candidates in development. SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <span style="white-space:nowrap">off-label</span> and unapproved use of branded and generic injectable steroids. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain <span style="white-space:nowrap">non-opioid</span> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <span style="white-space:nowrap">SP-104,</span> will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <span style="white-space:nowrap">in-license</span> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA or our product candidates, if approved, could decrease our ability to generate product revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market acceptance and sales of ZTlido, GLOPERBA and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs (such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outside of the United States. Assuming that coverage is obtained for a given product, the resulting reimbursement rates might not be adequate or may require <span style="white-space:nowrap">co-payments</span> or <span style="white-space:nowrap">co-insurance</span> that patients find unacceptably high. Patients, physicians, and other healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#8217; drug formularies for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#8220;buy and bill&#8221; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement. <span style="white-space:nowrap">J-Codes</span> are codes maintained by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), which are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific <span style="white-space:nowrap">J-Code</span> for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a <span style="white-space:nowrap">J-Code</span> will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific <span style="white-space:nowrap">J-Code</span> is not available, physicians would need to use a <span style="white-space:nowrap">non-specific</span> miscellaneous <span style="white-space:nowrap">J-Code</span> to bill third-party payors for these physician-administered drugs. Because miscellaneous <span style="white-space:nowrap">J-Codes</span> may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from our <span style="white-space:nowrap">FDA-approved</span> product, ZTlido, we currently have several product candidates that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional <span style="white-space:nowrap">in-licenses</span> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates. They may also not agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial commenced in the second quarter of 2022 for <span style="white-space:nowrap">SP-103,</span> and multiple Phase 1 trials were initiated in the first quarter of 2022 for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">SP-104.</span> We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and preclinical studies in addition to those we have planned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA, which results reflect achievement of primary and secondary endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may disagree with our assumptions and require us to conduct an additional Phase 3 trial before submitting an NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that product or indication for use. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the <span style="white-space:nowrap">&#8220;top-line&#8221;</span> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive <span style="white-space:nowrap">non-clinical</span> studies, <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis regarding safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for clinical trials and approval may be different. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business may suffer reputational harm due to failures of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA and our product candidates. In the event that ZTlido or GLOPERBA is identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido or GLOPERBA or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or maintaining market acceptance of ZTlido or GLOPERBA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is possible that as we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido, GLOPERBA and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA and our product candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA or our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <span style="white-space:nowrap">scale-up,</span> process reproducibility, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stability issues, compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_14">Risks Related to our Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular, we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Elizabeth Czerepak, our Executive Vice President, Chief Financial Officer and Chief Business Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido and GLOPERBA. We do not carry &#8220;key person&#8221; insurance on any of our executive officers or other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for key executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to qualified candidates than what we have to offer. In addition, we may experience employee turnover as a result of the ongoing &#8220;great resignation&#8221; occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need to increase the size of our company and may not effectively manage our growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, we had approximately 85 full-time employees. We may need to continue to expand our managerial, operational, sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including <span style="white-space:nowrap">co-promotion</span> activities. Future growth would impose significant added responsibilities on members of management, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, recruiting, integrating, maintaining and motivating additional employees; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">improving our operational, financial and management controls, reporting systems and procedures. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry insurance for all categories of risk that our business may encounter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming increasingly expensive. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido and clinical testing of our product candidates may expose us to individual product liability claims, class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue from product sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates or products that we develop; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiation of investigations by regulators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs to defend the related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a diversion of management&#8217;s time and our resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0&#160;million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area, California. Our facilities may be affected by natural or <span style="white-space:nowrap">man-made</span> disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or <span style="white-space:nowrap">man-made</span> disaster, we may be forced to curtail our operations and/or rely on third-parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without implementation difficulties, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be costly and dilutive. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and significant <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that does not materially disrupt existing relationships and that allows us to achieve development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or may take longer to realize than expected. In particular, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <span style="white-space:nowrap">one-time</span> expenses or acquire intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business, financial condition and results of operations could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International components of our business expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <span style="white-space:nowrap">non-compliance.</span> Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting business internationally involves a number of risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates, if approved, in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency exchange rate fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in duties and tariffs, license obligations and other <span style="white-space:nowrap">non-tariff</span> barriers to trade; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the imposition of new trade restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities associated with managing multiple payor-reimbursement regimes or <span style="white-space:nowrap">self-pay</span> systems; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#8217; activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The increasing use of social media platforms presents new risks and challenges. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of <span style="white-space:nowrap">non-compliance</span> with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business and operations would suffer in the event of system failures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity attacks or hacking, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation, suffer loss or harm to our intellectual property rights and the further research, development and commercial efforts of ZTlido, GLOPERBA and our product candidates, if approved, could be delayed. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters, or from some other matter, that claim could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a cybersecurity attack, data breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resulting in increased costs or loss of revenue. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems may experience interruptions, delays or cessations of service or produce errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are evolving and include, but are not limited to, threats, malicious software, ransom ware, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information and corruption of data. If we are unable to prevent such cybersecurity attacks, data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, governmental investigations, claims or litigation that may not be covered by insurance, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years and especially in 2020 and 2021 due to the impacts of the <span style="white-space:nowrap">COVID-19</span> pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;ACA&#8221;), may decrease the demand for healthcare services and pharmaceuticals. If fewer patients seek medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to the environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning corporate responsibility and sustainability matters, specifically related to environmental, social and governance (&#8220;ESG&#8221;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, companies&#8217; efforts and impacts on climate change and human rights, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ethics and compliance with law, diversity and the role of companies&#8217; board of directors in supervising various sustainability issues. In light of investors&#8217; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our Board accountable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are rapid and ongoing developments and changing expectations relating to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to adequately recognize and respond to such developments and governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our emphasis on ESG issues may not maximize short-term financial results and may yield financial results that conflict with the market&#8217;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals, which we believe will improve our financial results over the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_15">Risks Related to Scilex&#8217;s Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on the intellectual property we <span style="white-space:nowrap">in-license</span> from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <span style="white-space:nowrap">SP-103</span> would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and <span style="white-space:nowrap">SP-103</span> lidocaine tape products and the lidocaine in such products, including, among other things: (1)&#160;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications, (2)&#160;all <span style="white-space:nowrap">know-how,</span> work product, trade secrets, invents, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not, (3)&#160;copyrightable works, copyrights and applications, registrations and renewals, (4)&#160;logos, trademarks, service marks, and all applications and registrations relating thereto, (5)&#160;other proprietary rights, (6)&#160;abbreviated new drug applications or other applications to market, and (7)&#160;any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop <span style="white-space:nowrap">SP-103</span> depends on the effectiveness and continuation of the Product Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and <span style="white-space:nowrap">SP-103</span> as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Development Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and <span style="white-space:nowrap">SP-103</span> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, Scilex&#8217;s net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating to ZTlido and <span style="white-space:nowrap">SP-103,</span> to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We recently entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA.&#8221; Under the Romeg Agreement, among other things, Romeg granted us (1)&#160;a transferable license, with the right to sublicense, under the patents and <span style="white-space:nowrap">know-how</span> specified therein to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to <span style="white-space:nowrap">know-how</span> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <span style="white-space:nowrap">non-exclusive.</span> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&#160;1, 2027 and, thereafter, is <span style="white-space:nowrap">co-exclusive</span> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&#160;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the date of the Romeg Agreement. Our ability to commercialize GLOPERBA and develop Licensed Products depends on the effectiveness and continuation of the Romeg Agreement. If we lose the right to license the intellectual property rights granted by the Romeg Agreement, our ability to develop GLOPERBA as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a)&#160;in the event we are in material breach of the Romeg Agreement, unless we have cured any such breach within 60 days after any notice thereof was provided; (b)&#160;upon </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&#160;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties; or (e)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our failure to timely pay milestone payments, we will be required upon Romeg&#8217;s request to transfer all licensed intellectual property rights, including those relating to the GLOPERBA and the Licensed Products, to Romeg or their designee, within thirty days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our financial or other obligations under the license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense intellectual property rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA and our product candidates. Our success </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
depends in part on our ability to obtain and maintain patent protection in the United States, for GLOPERBA, and in the United States and other countries with respect to ZTlido and our product candidates. We seek to protect our proprietary position by filing and/or <span style="white-space:nowrap">in-licensing</span> patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or <span style="white-space:nowrap">in-license</span> may fail to result in issued patents with claims that protect ZTlido, GLOPERBA and our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover ZTlido, GLOPERBA and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. Patent and Trademark Office (&#8220;PTO&#8221;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the <span style="white-space:nowrap">non-compliance</span> with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications may not result in any patents being issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&#160;16, 2013. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or <span style="white-space:nowrap">in-license</span> with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido, GLOPERBA and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA and our product candidates. Any such outcome could have a materially adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to product components and processes and brands for our development pipeline through acquisitions and <span style="white-space:nowrap">in-licenses.</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties related to ZTlido, <span style="white-space:nowrap">SP-103,</span> and GLOPERBA. Because our programs for ZTlido, GLOPERBA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <span style="white-space:nowrap">in-license</span> or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA and our product candidates. If ZTlido, GLOPERBA or any of our product candidates, methods, processes and other technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">result in costly litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">divert the time and attention of our technical personnel and management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cause development delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to develop <span style="white-space:nowrap">non-infringing</span> technology, which may not be possible on a cost-effective basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain <span style="white-space:nowrap">non-infringing</span> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">some patent applications in the United States may be maintained in secrecy until the patents are issued; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States are typically not published until 18 months after the priority date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publications in the scientific literature often lag behind actual discoveries. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our strategic partners&#8217; or licensees&#8217; rights to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement claims, which could severely harm our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and key personnel. For example, on June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp. and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section titled &#8220;<span style="font-style:italic">Business &#8212; Legal Proceedings</span>&#8221; for additional information regarding such proceedings. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <span style="white-space:nowrap">non-litigious</span> action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new product candidates to the market and for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is subject to change over time. In the United States, for small molecule drug products, such as ZTlido and GLOPERBA, the Hatch-Waxman Act provides </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark &#8220;ZTlido,&#8221; &#8220;SCILEX&#8221; and &#8220;RESPONSIBLE BY DESIGN,&#8221; and we have filed trademark applications for the marks &#8220;SEMNUR PHARMACEUTICALS&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also have trademark registrations for ZTlido in the UK and Greece, we have a pending trademark application for ZTlido in China and we are appealing a decision refusing to register a trademark application for ZTlido in China. In China, we detected a third-party trademark registration for ZTlido and filed an invalidation proceeding &#8212; Invalidation of TM Registration No.&#160;36299669 &#8220;ZTlido&#8221; in Class&#160;5 in the name of <span style="font-family:pmingliu">&#31206;&#30343;&#23798;&#24646;&#39423;&#21830;&#36031;&#26377;&#38480;&#20844;&#21496;</span><span style="font-family:Times New Roman"> (Qinhuangdao Hengjun Trading Co., Ltd.) (the &#8220;China ZTlido Trademark Invalidation Proceeding&#8221;). The China ZTlido Trademark Invalidation Proceeding is pending. Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#8220;AIA&#8221;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-invent&#8221;</span></span> to a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <span style="font-style:italic">inter partes </span>review or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <span style="white-space:nowrap">in-licensed</span> patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <span style="white-space:nowrap">COVID-19</span> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <span style="white-space:nowrap">non-compliance</span> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA and our product candidates, our competitors may be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help protect our proprietary <span style="white-space:nowrap">know-how</span> and our inventions for which patents may be unobtainable or difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our <span style="white-space:nowrap">know-how</span> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential <span style="white-space:nowrap">know-how</span> is expensive, time-consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information is disclosed, the value of our trade secrets, <span style="white-space:nowrap">know-how</span> and other proprietary rights would be significantly impaired and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, <span style="white-space:nowrap">know-how,</span> patented inventions or other proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us from successfully commercializing ZTlido, GLOPERBA and our product candidates, if approved. Moreover, any such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have preexisting or competing obligations to a third party. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against infringement claims by third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation relating to the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against claims that ZTlido, GLOPERBA or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including new procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any future additional litigation to which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including PTO administrative proceedings, such as <span style="font-style:italic">inter partes </span>reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that ZTlido, GLOPERBA or our product candidates may give rise to claims of infringement of the patent rights of others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions, third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA or our product candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA or our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA or any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize ZTlido and GLOPERBA, or develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido or GLOPERBA, or developing our product candidates, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido or GLOPERBA, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents on ZTlido and all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido and our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian, patent applications. Recent Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative, recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to help manufacture and supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <span style="white-space:nowrap">know-how</span> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may be able to make products that are similar to ZTlido, GLOPERBA or our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our pending patent applications may not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not develop additional proprietary technologies that are patentable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents being issued that protect ZTlido, GLOPERBA and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party <span style="white-space:nowrap">pre-issuance</span> submission of prior art to the PTO or become involved in opposition, derivation, reexamination, <span style="font-style:italic">inter partes </span>review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA or our product candidates. Generally, patents are granted a term of 20 years from the earliest claimed <span style="white-space:nowrap">non-provisional</span> filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in examining the patent application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_16">Risks Related to Government Regulations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval from the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to support a 505(b)(2) NDA submission for SEMDEXA. However, the FDA may disagree and may require us to conduct additional clinical studies before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate. Our future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny approval of a product candidate for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with the design or implementation of our clinical trials; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to such authorities&#8217; satisfaction that a product candidate is safe and effective for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or ambiguous results from our clinical trials may not meet the level of statistical significance required for approval by the FDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if our clinical trials are successful. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&#160;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&#160;505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104,</span> we may seek FDA approval through the Section&#160;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&#160;505(b)(2) to the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;). Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&#160;505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section&#160;505(b)(2) regulatory pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the Section&#160;505(b)(2) regulatory pathway, we cannot assure that our product candidates will receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights of sponsors of previously approved drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&#160;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investigation or additional study obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">communications to prescribers or patients about specific information or issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning or untitled letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or government regulations may also alter the competitive landscape, potentially to our disadvantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> (&#8220;OTC&#8221;) and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#8217;s petition asking the FDA to clarify its requirements and take enforcement action against such products. The FDA has not responded with a decision or action. The FDA has generally held the position that requests for enforcement action via citizen petition are not allowed, which may reduce the likelihood of the FDA taking action explicitly in response to our December 2018 petition. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual property. In February 2021, we filed a complaint against such manufacturers to seek an award of damages and the entry of injective relief enjoining further dissemination of such false and deceptive advertisement. In addition, on March&#160;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law, which included statutory provisions reforming FDA&#8217;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#8220;GRASE&#8221;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by <span style="white-space:nowrap"><span style="white-space:nowrap">notice-and-comment</span></span> rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process. Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally market these products <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> and compete with ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition and results of operations may be negatively affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A fast track product designation, breakthrough therapy designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designation. We have received fast track designation for SEMDEXA for the treatment of sciatica and <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. Even though SEMDEXA and <span style="white-space:nowrap">SP-103</span> have received fast track designation, we may not experience a faster process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA. Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied for breakthrough therapy designation and expect to seek priority review for SEMDEXA for the treatment of sciatica. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to provide such designation. In any event, the receipt of a breakthrough therapy designation may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if SEMDEXA qualifies as a breakthrough therapy for sciatica, the FDA may later decide that SEMDEXA no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If approved, our products candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;), which created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (the &#8220;PHSA&#8221;) for biological products that are biosimilar to or interchangeable with an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application (&#8220;BLA&#8221;) for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#8217;s own <span style="white-space:nowrap">pre-clinical</span> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s biological product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#8220;first licensure&#8221;. Not every licensure of a biological product is considered a &#8220;first licensure&#8221; that gives rise to its own exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our product candidates in a way that is similar to traditional generic substitution for <span style="white-space:nowrap">non-biological</span> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for biosimilars referencing our product candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <span style="white-space:nowrap">COVID-19</span> pandemic, on March&#160;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10, 2020, the FDA announced its intention to resume certain <span style="white-space:nowrap">on-site</span> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. Increased cases associated with a <span style="white-space:nowrap">COVID-19</span> variant led the FDA to again pause inspections, although the FDA announced in February 2022 that it would resume routine domestic surveillance inspections and that it would proceed with certain foreign surveillance inspections where country conditions permit. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <span style="white-space:nowrap">COVID-19</span> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators are subject to federal, state and foreign data protection laws and regulations which address privacy and data security. In the United States, such laws may include, but are not limited to, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and its implementing regulations, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section&#160;5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as defined in HIPAA), we may have access to very sensitive data regarding patients who participate, or whose tissue samples or other biospecimens are used, in our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens, and litigation risks. In addition, we may obtain health information from </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties, including research institutions from which we obtain clinical trial data that are subject to privacy and security requirements under HIPAA and other privacy and data security and consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a HIPAA-Covered Entity in a manner that is not authorized or permitted by HIPAA, and subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, states are constantly adopting new laws or amending existing laws relating to the data privacy and security and consumer protection, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which creates new individual privacy rights for California consumers and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to <span style="white-space:nowrap">opt-out</span> of certain sales or transfers of personal information, and provide consumers with a private right of action in connection with certain types of incidents. The CCPA has been amended several times, and will be significantly updated from the California Privacy Rights Act (the &#8220;CPRA&#8221;), a ballot initiative that passed in November 2020 and which will go into effect on January&#160;1, 2023. The CPRA introduced significant amendments to the CCPA and also created a new state agency vested with authority to implement and enforce the CCPA and the CPRA, the California Privacy Protection Agency (the &#8220;CPPA&#8221;). New implementing regulations are expected to be introduced by the CPPA. Virginia also recently enacted a CCPA/CPRA-like law, the Virginia Consumer Data Privacy Act (the &#8220;VDCPA&#8221;), to provide its residents with similar rights, and Colorado, Connecticut and Utah have passed similar laws. New legislation enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CCPA, CPRA, VDCPA and other similar state laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Privacy laws and regulations are constantly evolving and there are a number of legislative proposals at both the state and federal level that could impose new obligations or limitations in areas affecting our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Trade Commission (the &#8220;FTC&#8221;) also sets expectations for failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&#160;5(a) of the Federal Trade Commission Act (the &#8220;FTC Act&#8221;). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#8217; personal information. Any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (the &#8220;GDPR&#8221;), may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes several data protection requirements in the European Union, as well as imposes potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenue. The regulation imposes numerous requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information, including the right to access, correct and delete their data. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual European Union countries. Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has led and could also lead to legislative and regulatory changes and may increase our compliance costs. As of January&#160;1, 2021 and the expiry of transitional arrangements agreed to between the United Kingdom and the European Union, data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June&#160;28, 2021, the European Commission adopted an Adequacy Decision for the United Kingdom, allowing for the relatively free exchange of personal information between the European Union and the United Kingdom, however, the European Commission may suspend the Adequacy Decision if it considers that the United Kingdom no longer provides for an adequate level of data protection. Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly <span style="white-space:nowrap">clean-up</span> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including <span style="white-space:nowrap">non-compliance</span> with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs &#8212; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of <span style="white-space:nowrap">off-label</span> uses (i.e., uses not expressly approved by the FDA in a drug&#8217;s label); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, which imposes criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services &#8212; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing metrics to government agencies, including CMS and Department of Veterans Affairs (&#8220;VA&#8221;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer&#8217;s ability to offer certain marketplace discounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future research and development of our product candidates outside the United States, and any future sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses of ZTlido, GLOPERBA or our product candidates, if approved, or if we are found to have improperly engaged in <span style="white-space:nowrap">pre-approval</span> promotion prior to the approval of such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as ZTlido, GLOPERBA and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved label, if the physicians believe in their professional medical judgment it could be used in such manner. However, if we are found to have promoted our product for any <span style="white-space:nowrap">off-label</span> uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted at the end of 2017 includes provisions that, effective January&#160;1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the <span style="white-space:nowrap">so-called</span> &#8220;individual mandate.&#8221; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the <span style="white-space:nowrap">COVID-19</span> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <span style="white-space:nowrap">COVID-19</span> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#8220;<span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs once our products come to market, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects</span>.&#8221; While any proposed measures may require authorization through additional legislation to become effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA and our product candidates, if approved, or additional pricing pressures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA and our product candidates, if approved, or put pressure on our product pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April&#160;1, 2016, to implement the changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program may have a similar impact. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&#160;1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or <span style="white-space:nowrap">single-use</span> packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125&#160;percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Resources and Services Administration (&#8220;HRSA&#8221;) issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&#160;1, 2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then publishes </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January&#160;13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations and negatively affect results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil monetary penalties can be applied if a manufacturer (i)&#160;is found to have knowingly submitted any false price or product information to the government, (ii)&#160;is found to have made a misrepresentation in the reporting of its average sales price, (iii)&#160;fails to submit the required price data on a timely basis, or (iv)&#160;is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#8217;s covered outpatient drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program, civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125&#160;percent of the discount that was due. Furthermore, Congress could enact a Medicare Part D inflation rebate, under which manufacturers would owe additional rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress could also enact additional changes that affect our overall rebate liability and the information we report to the government as part of price reporting calculations. In addition, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the <span style="white-space:nowrap">non-federal</span> average manufacturer price. This or any other legislative change could impact the market conditions for our products. We expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies and are seeing an increase in state interest in price reporting, transparency and other policies to address drug pricing concerns. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_17">Risks Related to our Relationship with Sorrento </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Jaisim Shah, Dr.&#160;Henry Ji, Mr.&#160;Dorman Followwill, Ms.&#160;Laura&#160;J. Hamill, <span style="white-space:nowrap">Dr.&#160;Tien-Li</span> Lee, Mr.&#160;David Lemus and Mr.&#160;Tommy Thompson serve on our Board. Mr.&#160;Jaisim Shah and Dr.&#160;Henry Ji, who are our executive officers, are also members of the board of directors of Sorrento (and in the case of Dr.&#160;Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our Board has determined that Mr.&#160;Dorman Followwill, Ms.&#160;Laura&#160;J. Hamill, <span style="white-space:nowrap">Dr.&#160;Tien-Li</span> Lee, Mr.&#160;David Lemus and Mr.&#160;Tommy Thompson are &#8220;independent directors&#8221; within the meaning of applicable regulatory and stock exchange requirements in the United States, both Mr.&#160;David Lemus and Mr.&#160;Dorman Followwill have served, and continue to serve, as directors of Sorrento (and in the case of Mr.&#160;Dorman Followwill, the Lead Independent Director of Sorrento) and Tommy Thompson has served, and continues to serve, as special consultant to the Chief Executive Officer of Sorrento, Dr.&#160;Henry Ji. Further, <span style="white-space:nowrap">Dr.&#160;Tien-Li</span> Lee is the founder, the Chief Executive Officer and a director of Aardvark, which has been involved in an asset </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase transaction with Sorrento in connection with Sorrento&#8217;s acquisition of Aardvark&#8217;s delayed burst release low dose naltrexone formulation asset and intellectual property rights. As part of Sorrento&#8217;s investment in Aardvark relating to such asset purchase transaction, Sorrento paid cash for shares of Aardvark&#8217;s Series B Preferred Stock, resulting in Sorrento holding approximately 8% of Aardvark&#8217;s ownership interest as of December&#160;31, 2021. Also as part of such investment, Dr.&#160;Henry Ji joined the board of directors of Aardvark in May 2021. Sorrento and Aardvark may enter into more commercial arrangements in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such directors and officers may own shares of Sorrento common stock, options to purchase shares of Sorrento common stock or other Sorrento equity awards. These individuals&#8217; holdings of Sorrento common stock, options to purchase shares of Sorrento common stock or other equity awards of Sorrento may be significant for some of these persons compared to these persons&#8217; total assets. Their position at Sorrento and the ownership of any Sorrento equity or equity awards creates, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different implications for Sorrento than the decisions have for us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Sorrento and us regarding the terms of the agreements governing the transition services and the relationship thereafter between the companies. Potential conflicts of interest may also arise if we enter into commercial arrangements with Sorrento in the future. As a result of these actual or apparent conflicts, we may be precluded from pursuing certain growth initiatives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sorrento currently performs or supports many of our important corporate functions. Our financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we will incur incremental costs as a stand-alone public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to replicate or replace certain functions, systems and infrastructure to which we will no longer have the same access after the Business Combination. We may also need to make investments or hire additional employees to operate without the same access to Sorrento&#8217;s existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento currently performs or supports many important corporate functions for our company. Our financial statements reflect charges for these services on an allocation basis. As a result, our historical financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. Pursuant to agreements we expect to enter into with Sorrento, we expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including costs, comparable to those that we will receive from Sorrento under our agreements with Sorrento. Additionally, after the agreements terminate, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Sorrento. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Sorrento, which may not be addressed in our agreements with Sorrento. The level of this informal support will diminish or cease following the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, Sorrento controls approximately 96.8% of our voting power, which means that, based on its percentage voting power, Sorrento controls the vote of all matters submitted to a vote of our stockholders. This control will enable Sorrento to control the election of the members of our Board and all other corporate decisions. In particular, for so long as Sorrento continues to own a majority of our Common Stock, Sorrento will be able to cause or prevent a change of control of the Company or a change in the composition of our Board and could preclude any unsolicited acquisition of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement and the Certificate of Incorporation, Sorrento has certain rights, and the ability to take certain actions, that are not otherwise available to all of our stockholders. For example, the Registration Rights Agreement provides Sorrento the right, subject to certain conditions, to demand that we file a registration statement or request that their shares of our Common Stock be covered by a registration statement that we are otherwise filing. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Registration Rights</span>&#8221; for additional information regarding these rights. We have filed the registration statement of which this prospectus forms a part in order to satisfy these obligations. In addition, until such time as Sorrento first ceases to own greater than 50% of the outstanding voting power of our Common Stock, the Certificate of Incorporation effectively provides Sorrento with the ability to fill vacancies on our Board, remove directors (with or without cause), call a special meeting of our stockholders, amend the Certificate of Incorporation (subject to approval of our Board) and amend the Bylaws. The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock, implement stock repurchase programs, declare dividends and make other decisions. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Anti-Takeover Matters in our Governing Documents and Under Delaware Law</span>&#8221; for additional information regarding Sorrento&#8217;s ability to take such actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when Sorrento ceases to control a majority of the total voting power of Scilex, for so long as Sorrento continues to own a significant percentage of our Common Stock and for so long as the Sorrento Group owns any shares of Series A Preferred Stock, Sorrento will still be able to significantly influence the composition of our Board and the approval of actions requiring stockholder approval. Accordingly, for such period of time, Sorrento will have significant influence with respect to our management, business plans and policies. Because of the significant ownership position held by Sorrento, our classified board structure and the rights granted to Sorrento under the Stockholder Agreement, new investors may not be able to effect a change in our business or management. The concentration of ownership and availability of the foregoing rights could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of the Company and ultimately might affect the market price of our Common Stock. See the risk factor below titled &#8220;<span style="font-style:italic">Sorrento, as the holder of Series A Preferred Stock, will have rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the interests of Sorrento may not be aligned with those of our other stockholders and this could lead to actions that may not be in the best interests of our other stockholders. For example, Sorrento may have different tax positions or strategic plans for the Company, which could influence its decisions regarding whether and when we should dispose of assets or incur new or refinance existing indebtedness. Additionally, Sorrento&#8217;s significant ownership in the Company may discourage someone from making a significant equity investment in the Company, or could discourage transactions involving a change in control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Sorrento and its affiliates engage in a broad spectrum of activities, including investments in our industry generally. In the ordinary course of their business activities, Sorrento and its affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or those businesses that are suppliers or customers of ours. The Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Sorrento and its affiliates and any person or entity who, while a stockholder, director, officer or agent of us or any of our affiliates, is a director, officer, principal, partner, member, manager, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee, agent and/or other representative of Sorrento and its affiliates (each an &#8220;Identified Person&#8221;) will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&#160;otherwise investing in or providing services to any person that competes with us or our affiliates engaging, directly or indirectly, in the same or similar business activities or lines of business in which we operate. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. This means that Sorrento may pursue acquisition opportunities that may be complementary to our business and, as a result, those acquisition opportunities may not be available to us. In addition, Sorrento may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve risks to our stockholders or may not prove beneficial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although Sorrento has previously announced that its board of directors has authorized Sorrento to explore and consider a potential dividend to Sorrento stockholders of shares of our Common Stock that are currently held by Sorrento, there can be no assurance that Sorrento&#8217;s exploration and consideration of&#160;any dividend of any shares of our Common Stock will ultimately result in any such dividend. Furthermore, any declaration, as well as the potential timing, of any such dividend is subject to the satisfaction of a number of conditions, including an evaluation and consideration of the potential legal and tax consequences of any such dividend to Sorrento and its stockholders, submission of required filings, receipt of any approvals or consents determined to be required and other conditions that may be deemed to be applicable. Even if Sorrento were to make a dividend to Sorrento stockholders of shares of our Common Stock that are currently held by Sorrento, Sorrento would still hold shares of our Series A Preferred Stock, which shares have the rights, preferences and privileges described below, and Sorrento would still have significant rights that are not otherwise available to holders of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sorrento, as the holder of Series A Preferred Stock, has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock is issued only to Sorrento and is not convertible into shares of our Common Stock. The holders of Series A Preferred Stock have rights, preferences and privileges that are senior, or in addition, to the rights, preferences and privileges of the holders of our Common Stock, including the right to receive, in the event of a change of control, liquidation dissolution or winding up of the Company, a preference amount out of the assets available for distribution to stockholders before any distribution can be made to holders of our Common Stock. The preference amount is $10.00 per share (subject to adjustment as set forth in the Certificate of Designations). If our Board declares or pays a dividend on our Common Stock, the holders of Series A Preferred Stock will participate, on a deemed <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-common</span></span></span> stock basis, in such dividend with the holders of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock will have certain voting rights over our corporate actions (including, among others, any change to the shares of Series A Preferred Stock into cash or other property, the issuance of equity securities that rank on a parity with or senior to Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company and the amendment of the Certificate of Incorporation in a manner that adversely affects the holders of shares of Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of Series A Preferred Stock, among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
created by the departure of any director or increase in the authorized number of members of our Board, or the size of our Board and (ii)&#160;we are required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of our Board. Notwithstanding the foregoing, the parties have agreed to ensure that our Board complies with all applicable requirements of the stock exchange, including independence requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we are prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of our Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on the terms of Series A Preferred Stock, see the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Series A Preferred Stock</span>&#8221; and the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Vickers &#8212; Stockholder Agreement with Sorrento.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to recently enacted state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, California enacted Senator Bill 826 (&#8220;SB 826&#8221;), which generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five directors, and at least three female directors on its board of directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May&#160;13, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down SB 826, holding that the statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On September&#160;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#8217;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to SB&#160;826, pending a further order of the appellate court. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on September&#160;30, 2020, California enacted Assembly Bill 979 (&#8220;AB 979&#8221;), which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#8220;underrepresented communities&#8221;. A director from an &#8220;underrepresented community&#8221; means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By December&#160;31, 2021, each public company with principal executive offices in California was required to have at least one director from an underrepresented community. By December&#160;31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities, and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April&#160;1, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down AB 979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June&#160;6, 2022, a notice of appeal was filed. On September&#160;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#8217;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB&#160;979, pending a further order of the appellate court. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. Litigation regarding AB&#160;979 will continue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_18">Risks Related to Ownership of our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to commercialize ZTlido, GLOPERBA or our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the status and cost of our marketing commitments for ZTlido, GLOPERBA and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements regarding results of any clinical trials relating to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA or any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to ZTlido, GLOPERBA or our product candidates, including but not limited to clinical trial requirements for approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our dependence on third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the introduction of new products by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions and trends in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements concerning product development results or intellectual property rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future issuances of common stock or other securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated variations in quarterly operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to meet or exceed the estimates and projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in financial estimates by the Company or by any securities analysts who might cover our stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuation of the market values of any of our potential strategic investments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances of debt or equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with our contractual obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Common Stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffectiveness of our internal controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports about the Company or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to effectively integrate the operations of Semnur; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general political and economic conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of natural or <span style="white-space:nowrap">man-made</span> catastrophic events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of public health crises, pandemics and epidemics, such as the <span style="white-space:nowrap">COVID-19</span> pandemic; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other events or factors, many of which are beyond our control. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;, could have a dramatic and material adverse impact on the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy Scilex has not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex has not paid cash dividends on its common stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#8217;s ability to receive a return on such stockholder&#8217;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Sorrento and certain directors and equityholders of Vickers, including the Sponsors, are subject to <span style="white-space:nowrap">lock-up</span> provisions that restrict their ability to transfer certain of their shares of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock until 180 days from the Effective Time, subject to certain exceptions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our operating results may fluctuate significantly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">variations in the level of expenses related to our development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the addition or termination of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any intellectual property infringement lawsuit in which we may become involved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments affecting ZTlido, GLOPERBA or our product candidates, regulatory approvals of our product candidates, and the level of underlying demand for such products and purchasing patterns; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about the Company or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to ZTlido or our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock. The issuance of additional equity securities, including pursuant to the Yorkville Purchase Agreement described elsewhere in this prospectus, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Equity Incentive Plan, which became effective on November&#160;9, 2022, we are authorized to grant equity awards to our employees, directors and consultants. In addition, pursuant to the ESPP, which became effective on November&#160;9, 2022, we are authorized to sell shares to our employees. A total of 14,622,712 and 1,462,271 shares of our Common Stock have been reserved for future issuance under the Equity Incentive Plan and the ESPP, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January&#160;1, 2023. As a result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Business Combination, certain stockholders of Vickers and Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering such securities and certain of our other securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to ZTlido or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our principal stockholders, directors and executive officers will own a significant percentage of our capital stock, and have significant influence over our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of 5% or more of our capital stock and their respective beneficially own, in the aggregate, approximately 97% of our outstanding voting stock. This concentration of voting power may make it less likely that any other holder of our Common Stock will be able to affect the way we are managed and could delay or prevent an acquisition of the Company on terms that other stockholders may desire. This could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market prices. See &#8220;<span style="font-style:italic">Risk Factors &#8212; We are controlled by Sorrento, whose interests may differ from those of our public shareholders</span>&#8221; above for additional information regarding Sorrento&#8217;s influence and control in the Company. See &#8220;<span style="font-style:italic">Security Ownership of Certain Beneficial Owners and Management</span>&#8221; for information regarding the ownership of our outstanding Common Stock by our directors, executive officers, and current beneficial owners of 5% or more of our voting securities and their respective affiliates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#8217;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past, some ownership changes as a result of the Business Combination and/or some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss (&#8220;NOL&#8221;) carryforwards. Under the TCJA, as modified by the CARES Act, limits a taxpayer&#8217;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and certain other tax attributes, into account) for taxable years beginning after December&#160;31, 2020. In addition, NOLs arising in tax years ending after December&#160;31, 2017 and before January&#160;1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&#160;31, 2020 and before January&#160;1, 2026 may not be carried back. NOLs arising in tax years beginning after December&#160;31, 2017 can be carried forward indefinitely. NOLs generated in tax years beginning before January&#160;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&#160;1, 2018 will continue to have a <span style="white-space:nowrap">two-year</span> carryback and <span style="white-space:nowrap">20-year</span> carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when the NOL is expected to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws and the DGCL contains provisions that could make it more difficult for a third party to acquire the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for a classified board of directors with staggered three-year terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, at any time after the Sorrento Group first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our Common Stock entitled to vote generally in the election of directors (the &#8220;Sorrento Trigger Event&#8221;), directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prohibit stockholder action by written consent from and after the Sorrento Trigger Event; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, at any time after the Sorrento Trigger Event, special meetings may only be called by or at the direction of the Chairman of the Board, the Board or the Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, at any time after the Sorrento Trigger Event, any alteration, amendment or repeal, in whole or in part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for nominations for elections to the Board and for proposing matters that can be acted upon by stockholders at stockholder meetings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the stockholder became an interested stockholder. We have expressly elected not to be governed by Section&#160;203 of the DGCL until the occurrence of a Sorrento Trigger Event. At that time, such election shall be automatically withdrawn and we will thereafter be governed by Section&#160;203 of the DGCL, except that the restrictions on business combinations of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate transaction. For information regarding these and other provisions, see the section titled &#8220;<span style="font-style:italic">Description of Our Securities.</span>&#8221; In addition, if prospective takeovers are not consummated for any reason, we may experience negative reactions from the financial markets, including negative impacts on the price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders; (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL; <span style="font-style:italic">provided that</span>, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation described above. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Anti-Takeover Measures in our Governing Documents and Under Delaware Law &#8212; Exclusive Forum</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and could have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by <span style="white-space:nowrap">non-affiliates</span> to equal or exceed $700&#160;million as of the last business day of the second fiscal quarter of such year, and (2)&#160;the date on which we have issued more than $1&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt during the prior three-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power of our outstanding shares of Common Stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements. For example, controlled companies, within one year of the date of the listing of their common stock: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have a board that is composed of a majority of &#8220;independent directors&#8221; as defined under the Nasdaq Listing Rules; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have a compensation committee that is composed entirely of independent directors or have a written charter addressing the committee&#8217;s purpose and responsibilities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have director nominations be made, or recommended to the full board of directors, by its independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as we remain a controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cease to be a &#8220;controlled company&#8221; in the future, we will be required to comply with the Nasdaq listing standards, which may require replacing a number of our directors and will require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase our legal and administrative costs, will make some activities more difficult, time-consuming and costly and may also place additional strain on our personnel, systems and resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for the Company to obtain directors&#8217; and officers&#8217; liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect that we will need to implement an enterprise resource planning (&#8220;ERP&#8221;) system. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section&#160;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within the prescribed period, we will be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#8220;<span style="font-style:italic">Risk Factors &#8212; We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements.</span>&#8221; above for additional information regarding a previously identified material weakness. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to satisfy Nasdaq&#8217;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#8217;s ability to sell or purchase our Common Stock when a stockholder wishes to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comprehensive U.S. federal income tax reform could adversely affect the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCJA, which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a &#8220;worldwide&#8221; system of taxation to a modified territorial system. On March&#160;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S. economy in light of the <span style="white-space:nowrap">COVID-19</span> pandemic, including temporary </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock <span style="white-space:nowrap">buy-backs,</span> and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Warrants will become exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outstanding warrants to purchase an aggregate of 11,003,988 shares of our Common Stock are exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised, additional shares of our Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. However, there is no guarantee that the Warrants will ever be in the money prior to their expiration, and as such, the Warrants may expire worthless. See below risk factor, &#8220;<span style="font-style:italic">The Warrants may never be in the money, and they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants were issued in registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The Warrant Agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding Warrants to make any change that adversely affects the interests of the registered holders of Warrants. Accordingly, we may amend the terms of the Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. Although our ability to amend the terms of the Warrants with the consent of majority of the then-outstanding Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem any unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the Warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) on each of the 20 trading days within any <span style="white-space:nowrap"><span style="white-space:nowrap">30-trading-day</span></span> period commencing after the Warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given. If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Warrants could force the holders thereof to: (i)&#160;exercise such Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&#160;sell such Warrants at the then-current market price when a holder might otherwise wish to hold such Warrants; or (iii)&#160;accept the nominal redemption price that, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the market value of such Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem the Warrants at any time after they become exercisable and prior to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_19">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_20">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will receive no proceeds from the sale of the Resale Shares or the Private Warrants by the Selling Securityholders. The Selling Securityholders will pay any underwriting discounts, selling commissions or transfer taxes incurred in disposing of the Resale Shares and the expenses of any attorney or other advisor they decide to employ. We will bear all other costs, fees and expenses incurred in effecting the registration of the Resale Shares and the Warrants covered by this prospectus. These may include, without limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable securities laws and the fees and disbursements of our counsel and of our independent accountants and reasonable fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will receive up to an aggregate of approximately $126.5&#160;million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. We expect to use the proceeds from the exercise of the Warrants for cash for working capital and general corporate purposes, which may include capital expenditures, commercial, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any proceeds we receive from the exercise of the Warrants. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the proceeds as described above, we intend to invest such proceeds in interest-bearing instruments. There is no assurance that the holders of the Warrants will elect to exercise any or all of such Warrants. To the extent that the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants will decrease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_21">DETERMINATION OF OFFERING PRICE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price of the shares of Common Stock underlying the Warrants offered hereby is determined by reference to the exercise price of the Warrants of $11.50 per share. The Public Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;SCLXW&#8221;. On November&#160;29, 2022, the closing price of our Public Warrants was $0.225&#160;per Public Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock or Private Warrants may be sold by the Selling Securityholders under this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_22">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_23">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. Prior to the consummation of the Business Combination, Vickers&#8217;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#8220;VCKA,&#8221; &#8220;VCKAU&#8221; and &#8220;VCKAW,&#8221; respectively. At the Effective Time, without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and <span style="white-space:nowrap">one-half</span> of one warrant to purchase one share of Common Stock. As of November&#160;10, 2022, there were eleven holders of record of our Common Stock and four holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_24">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_25">Securities Authorized for Issuance under Equity Compensation Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;30, 2022, there were up to 14,622,712 shares of Common Stock initially authorized for future issuance under our Equity Incentive Plan and 1,462,271 shares of Common Stock initially authorized for future issuance under our ESPP, each of which our stockholders approved on November&#160;9, 2022 in connection with the Business Combination and became effective upon the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <span style="white-space:nowrap">S-8</span> under the Securities Act to register the shares of Common Stock issued or issuable under the Equity Incentive Plan, the ESPP and the assumed Legacy Scilex options and other awards outstanding under the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. Any such Form <span style="white-space:nowrap">S-8</span> registration statement will become effective automatically upon filing. Once these shares are registered, they can be sold in the public market upon issuance, subject to applicable restrictions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_26">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 and the unaudited pro forma condensed combined statements of operations for the year ended December&#160;31, 2021 and nine months ended September&#160;30, 2022 present the combined financial information of Vickers and Legacy Scilex after giving effect to the Business Combination and related adjustments described in the accompanying notes. Vickers and Legacy Scilex are collectively referred to herein as the &#8220;Companies,&#8221; and the Companies, subsequent to the Business Combination, are referred to herein as &#8220;New Scilex.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <span style="white-space:nowrap">S-X,</span> Pro Forma Financial Information, as amended by the final rule, Release 33 10786. The following unaudited pro forma condensed combined statements of operations for the year ended December&#160;31, 2021 and nine months ended September&#160;30, 2022 give pro forma effect to the Business Combination as if it had occurred on January&#160;1, 2021. The unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 gives pro forma effect to the Business Combination as if it was completed on September&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information are based on and should be read in conjunction with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the accompanying notes to the unaudited pro forma condensed combined financial information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the audited historical financial statements and the unaudited historical financial statements of each of Vickers and Legacy Scilex as of and for the year ended December&#160;31, 2021, and as of and for the nine months ended September&#160;30, 2022, respectively, and the related notes thereto, and; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other information relating to Vickers and Legacy Scilex contained in this prospectus, including the Merger Agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part, and the disclosures contained in the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span>&#8221;. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and do not necessarily reflect what the combined company&#8217;s financial condition or results of operations would have been had the Business Combination occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial information also may not be useful in predicting the future financial condition and results of operations of the combined company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2022, Vickers Vantage Corp. I (&#8220;Vickers&#8221;) entered into the Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;Merger Agreement&#8221;) with Vantage Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Vickers (&#8220;Merger Sub&#8221;), and Scilex Holding Company, a Delaware corporation (&#8220;Legacy Scilex&#8221;) under which Merger Sub was merged with and into Legacy Scilex with Legacy Scilex continuing as the surviving corporation and a wholly owned subsidiary of Vickers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the Business Combination occurred on November&#160;10, 2022 (the &#8220;Closing&#8221;), in which Vickers was renamed &#8220;Scilex Holding Company&#8221; (&#8220;New Scilex&#8221;). At the Closing, each outstanding share of Legacy Scilex Common Stock as of immediately prior to the time in which the Business Combination became effective as stated in the Merger Agreement (&#8220;Effective Time&#8221;) was exchanged for shares of Common Stock and each outstanding share of Legacy Scilex Preferred Stock as of immediately prior to the Effective Time was exchanged for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of Common </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock. Each Legacy Scilex stock option outstanding immediately prior to the Effective Time was converted into a stock option to acquire a share of Common Stock upon substantially the same terms and conditions with respect to existing vesting and termination-related provisions. On November&#160;11, 2022, shares of Common Stock and Public Warrants started trading on the Nasdaq Capital Market under the ticker symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate consideration paid to the equityholders of Legacy Scilex upon the Closing of the Business Combination was 133,060,532 shares of Common Stock. The unaudited pro forma condensed combined financial information contained herein incorporates the results of Vickers&#8217;s public shareholders having elected to redeem 8,576,838 shares of their public shares for $89,884,677 in cash based upon actual redemptions as of the Closing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">As of September&#160;30, 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="text-decoration:underline">(Note 2)<br /></span>Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex<br />Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro&#160;Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(B)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,643</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(C)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(K)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,246</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(B)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#8217; Equitv</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,862</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(G)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,862</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,475</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(G)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(G)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(174,482</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,108</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">251,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(219,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(62,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(1)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(465</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(J)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">863</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">863</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(C)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(293,332</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="text-decoration:underline">(Note 2)<br /></span>Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex<br />Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro&#160;Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September&#160;30, 2022 and December&#160;31, 2021 at redemption value of approximately $10.41 and $10.00, respectively per share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <span style="white-space:nowrap">non-redeemable</span> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Preferred stock, $0.0001 par value; 45,000,000 shares authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Common stock, $0.0001 par value; 740,000,000 shares authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(D)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized 197,566,338 and 197,266,338 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021 respectively</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(D)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">407,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(D)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,415</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(F)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">284,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(1)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(J)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(358,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(359,464</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(K)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(F)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(229,395</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">289,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Nine Months Ended September&#160;30, 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:53%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Nine Months Ended September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="text-decoration:underline">(Note 2)<br /></span>Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(690</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(BB)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(690</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32,615</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(878</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(CC)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,374</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income on mandatorily redeemable ordinary shares liability</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(FF)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(AA)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,036</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,434</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,516</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Scilex common stock, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,549,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to New Scilex common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of New Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Year Ended December&#160;31, 2021 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Year Ended December&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="text-decoration:underline">(Note 2)<br /></span>Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(BB)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(DD)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(EE)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(BB)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,015</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(37,858</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">716</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(CC)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(775</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(AA)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) before income taxes</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,396</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,401</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,820,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,834,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Scilex common stock, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,266,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to New Scilex common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of New Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTES TO THE UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 1 &#8212; Description of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2022, Vickers entered into the Merger Agreement with Merger Sub and Legacy Scilex. Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, Merger Sub merged with and into Legacy Scilex and with Legacy Scilex becoming a wholly owned subsidiary of Vickers. After giving effect to the Business Combination, Vickers owned all of the issued and outstanding equity interests of Legacy Scilex and its subsidiaries. In connection with the consummation of the Business Combination, Vickers was renamed as &#8220;Scilex Holding Company&#8221; (&#8220;New Scilex&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, each outstanding share of Legacy Scilex Common Stock as of immediately prior to the time the Business Combination became effective as stated in the Merger Agreement was exchanged for shares of Common Stock and each outstanding share of Legacy Scilex Preferred Stock as of immediately prior to the Effective Time was exchanged for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of Common Stock. Each Legacy Scilex stock option outstanding immediately prior to the Effective Time was converted into a number of options exercisable for newly issued shares of Common Stock based upon the Exchange Ratio and on substantially the same terms and conditions with respect to existing vesting and termination-related provisions. The exercise price per share for each option for Common Stock is equal to (i)&#160;the existing exercise price per Legacy Scilex stock option, divided by (ii)&#160;the Exchange Ratio (defined below) (rounded up to the nearest whole cent). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock issuable to Legacy Scilex stockholders and optionholders is equal to (i) $1,500,000,000, minus (ii)&#160;the Specified Indebtedness Amount (defined below), divided by $10 (&#8220;Merger Consideration&#8221;). The &#8220;Specified Indebtedness Amount&#8221; had pertained to the aggregate amount owed by Legacy Scilex in respect of senior secured notes due 2026 issued under Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) and with Sorrento as the parent guarantor. On September&#160;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7&#160;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&#160;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&#160;million of principal amount of the Scilex Pharma Notes in connection with the repurchase. This repurchase reduced the Specified Indebtedness Amount to $0, resulting in Merger Consideration transferred to Legacy Scilex common stockholders and optionholders at Closing of 150,000,000 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock and options to acquire shares of Common Stock, respectively, in each case based on the &#8220;Exchange Ratio,&#8221; which is equal to (a)&#160;the number of shares constituting the Merger Consideration, divided by (b)&#160;the sum of (i)&#160;issued and outstanding Legacy Scilex Common Stock and (ii)&#160;issued and outstanding Legacy Scilex stock options as of immediately prior to the Effective Time. As there were 197,566,338 and 25,151,428 shares of Legacy Scilex Common Stock and Legacy Scilex stock options, respectively, the Exchange Ratio was calculated to be 0.673498. Upon the Effective Time, 133,060,532 shares of Common Stock were transferred to Legacy Scilex stockholders as part of the Merger Consideration. The remaining portion of the Merger Consideration, equal to 16,939,379 shares of Common Stock, is reserved for the Legacy Scilex optionholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i)&#160;Sorrento contributed to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy Scilex and Scilex Pharma that remained outstanding as of immediately prior to the Closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness,&#8221;) in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&#160;Legacy Scilex contributed to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness was deemed satisfied in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the Closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of preferred stock, par value $0.0001 per share, of Legacy Scilex (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) that was equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share). In addition, prior to the Closing, Legacy Scilex entered into agreements with certain creditors and Sorrento in which Legacy Scilex was legally released from being the primary obligor under certain liabilities from the creditors. The obligations to these creditors were transferred to Sorrento. Immediately prior to the Closing, the total amount of liabilities transferred from Legacy Scilex to Sorrento was $11,880,945, which were also subject to the Debt Exchange Agreement. The Aggregate Outstanding Amount subject to this conversion at Closing was $290,570,964 which was converted to aggregate number of shares of Legacy Scilex Preferred Stock issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement of 29,057,097 shares and then at the Effective Time such shares were exchanged for 29,057,097 shares of Series A Preferred Stock and 2,905,710 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, Sorrento and Legacy Scilex entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;). Pursuant to the terms of the Funding Commitment Letter, to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net tangible assets as of immediately following the time in which the Business Combination becomes effective (the &#8220;Net Tangible Assets Condition&#8221;), Sorrento would fund one or more loans to Legacy Scilex up to (a)&#160;$10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. At Closing, New Scilex was able to achieve the Net Tangible Assets Condition without requiring a loan from Sorrento under the Funding Commitment Letter. As such, no amount was requested by Legacy Scilex under the Funding Commitment Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below illustrates the number of shares of Series A Preferred Stock and Common Stock held by Legacy Scilex stockholders at the Closing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Series&#160;A<br />Preferred&#160;Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Common<br />Stock</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) Merger Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,060,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) Aggregate Outstanding Amount converted under the Debt Exchange Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,905,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,966,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the then-outstanding Public Warrants and Private Placement Warrants has an exercise price of $11.50 per share (the &#8220;Exercise Price&#8221;) to acquire one share of Vickers Ordinary Shares. The exercise price of the warrants is subject to a down-round provision that is only effective prior to the Closing of the Business Combination and is therefore not, on its own, considered to have an impact to the classification of warrant on Legacy Scilex&#8217;s Unaudited Pro Forma Condensed Combined Balance Sheet. Concurrently with the execution of the Merger Agreement, Vickers also entered into the Sponsor Support Agreement. In the event that Vickers&#8217;s public shareholders exercise redemption rights that results in the redemption of 75% or more of the issued and outstanding Vickers Ordinary Shares as were outstanding as of March&#160;17, 2022, the Sponsors agreed to be subject to a 40% forfeiture of Private Placement Warrants held by each Sponsor immediately prior to Closing. At Closing, actual redemption was 91.7% and therefore 40% of the Private Placement Warrants were forfeited pursuant to the Sponsor Support Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, as consideration for Sorrento agreeing to provide funding, as necessary, under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders have redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&#160;17, 2022, then in addition to the forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors will transfer to Sorrento, and Sorrento will acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as equitably adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar transaction, or any share dividend or distribution paid in shares) pursuant to the Warrant Transfer Agreement. Actual redemptions were 91.7% at Closing, which resulted in 3,104,000 Private Placement Warrants being transferred to Sorrento and 1,000,000 Private Placement Warrants being retained by Sponsors pursuant to the Warrant Transfer Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on October&#160;17, 2022, Vickers and the Sponsors entered into the Vickers Debt Agreement, pursuant to which the Working Capital Loans will be cancelled in exchange for the issuance of common stock, par value $0.0001, of Vickers prior to the consummation of the Business Combination. Pursuant to the terms of the Vickers Debt Agreement, the aggregate amount of Working Capital Loans at Closing of $5,330,557 was converted to 533,057 shares of New Scilex Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the pro forma ownership and voting power of Common Stock and Series A Preferred Stock, excluding the potentially dilutive effect of all the Public Warrants, the Private Placement Warrants, any Working Capital Warrants and all outstanding New Scilex stock options issued to Legacy Scilex option holders in connection with the Business Combination: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:56%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Shares of<br />Common Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">%&#160;of<br />Ownership</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Shares of<br />Preferred<br />Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">%&#160;of<br />Ownership</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">%&#160;of<br />Voting<br />Power</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers public shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,149,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers initial shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,983,057</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy Scilex common stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,966,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy Scilex preferred stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shares at the Closing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Expected Accounting Treatment for the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded in accordance with GAAP. Under this method of accounting, Vickers was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Scilex issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers will be recognized at historical cost, with no goodwill or other intangible assets recorded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was determined to be the accounting acquirer based on evaluation of the following facts and circumstances: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex stockholders have the majority of the voting power; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex appointed the majority of the board of directors of New Scilex; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex&#8217;s existing management comprise the management of New Scilex; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex comprise the ongoing operations of New Scilex; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex is the larger entity based on historical revenues and business operations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New Scilex assumes Legacy Scilex&#8217;s name. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 2&#160;&#8212;&#160;Accounting Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of preparing these unaudited pro forma condensed combined financial statements, certain reclassifications were made to align Vickers and Legacy Scilex&#8217;s financial statement presentation. Following the consummation of the Business Combination, we are performing a comprehensive review of the two entities&#8217; accounting policies. As a result of the review, we may identify differences between the accounting policies of the two entities which, when conformed, could have a material impact on the financial statements of the post-combination company. Based on our initial analysis, we did not identify any differences that would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited pro forma condensed combined financial information does not assume any differences in accounting policies. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#8217; Equity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(809</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatorily redeemable ordinary shares liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note&#160;&#8212;&#160;related party, net of debt discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion option liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September&#160;30, 2022 and December&#160;31, 2021 at redemption value of approximately $10.41 and $10.00, respectively, per share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares. $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <span style="white-space:nowrap">non-redeemable</span> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Preferred stock, $0.0001 par value; 45,000,000 shares authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Common stock, $0.0001 par value; 740,000,000 shares authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021, respectively</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Nine Months ended September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,189</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#8212; debt discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income on mandatorily redeemable ordinary shares liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,036</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,036</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Year Ended December&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,378</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,599</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#8212; debt discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,820,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,820,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,834,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,834,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 3 &#8212; Transaction Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of September&#160;30, 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the Business Combination. No tax adjustment has been computed for the pro forma New Scilex financial results, as it expects to maintain a full valuation allowance against its U.S. deferred tax assets. The unaudited pro forma information does not purport to project the future financial position or operating results of New Scilex. The pro forma transaction adjustments included in the unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(A)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects reclassification of Vickers Ordinary Shares to permanent equity upon consummation of the Business Combination, after final redemption. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(B)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects release of the restricted investments and cash held in the Trust Account upon consummation of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(C)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the settlement in cash of all deferred underwriting fees payable to Maxim. A reduction of $5.2&#160;million was reflected in cash and cash equivalents. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(D)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of Legacy Scilex Common Stock into Common Stock pursuant to the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(E)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents transaction costs incurred by Vickers and Legacy Scilex that are allocated between the instruments issued and assumed in the Business Combination and recorded as a reduction to additional <span style="white-space:nowrap">paid-in</span> capital or expense. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(F)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of Vickers&#8217;s historical accumulated deficit. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(G)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects $8,337,491 of Legacy Scilex liabilities assumed by Sorrento as of September&#160;30, 2022. Such amount was included in the Outstanding Indebtedness which was contributed to Legacy Scilex as a capital contribution in exchange for the issuance of Legacy Scilex Common Stock pursuant to the Debt Exchange Agreement and at the Effective Time such shares of Legacy Scilex Common Stock were exchanged for shares of Series A Preferred Stock and Common Stock in Note (H). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(H)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of Outstanding Indebtedness of $284.3&#160;million as of September&#160;30, 2022 into shares of Common Stock and Series A Preferred Stock pursuant to the Debt Exchange Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(I)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of the Working Capital Loans of $5.0&#160;million as of September&#160;30, 2022 to Common Stock pursuant to the Vickers Debt Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(J)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the forfeiture of 40% of the value of the outstanding Private Placement Warrants. Pursuant to the Sponsor Support Agreement, 40% of the Private Placement Warrants are forfeited if 75% or more of the Vickers&#8217;s public shareholders exercise their right to redeem their Vickers Ordinary Shares. A reduction of $0.5&#160;million was reflected against derivative liabilities with an offset to additional <span style="white-space:nowrap">paid-in</span> capital. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(K)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects a cash payment of $1.2&#160;million made in conjunction with the Closing for costs associated with directors&#8217; and officers&#8217; (&#8220;D&amp;O&#8221;) insurance policies covering current or former directors and officers of Vickers and Legacy Scilex, which are required to be maintained for a period of six (6)&#160;years from the effective date pursuant to the Merger Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 4 &#8212; Transaction Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(AA)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of interest earned on investment held in the Trust Account. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(BB)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents an adjustment to reflect previously expensed transaction costs as a reduction to additional <span style="white-space:nowrap">paid-in</span> capital (see Note&#160;(E)) as part of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(CC)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the 40% of Private Placement Warrants forfeited, which resulted in a gain from derivative liabilities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(DD)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects an incremental amount of transaction costs expensed that are allocated to the Private Placement Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(EE)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the immediate expense of costs incurred on D&amp;O insurance policies obtained in connection with the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(FF)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of interest income on mandatorily redeemable ordinary shares liability related to the redemption of 4,073,605 Vickers Ordinary Shares made in connection with the Extension Proposal. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 5 &#8212; Net Income (Loss) per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share is calculated based on the weighted average of Common Stock outstanding and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January&#160;1, 2021. As the Business Combination is being reflected as if it had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net income (loss) per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire periods presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potential outstanding securities were excluded from the computation of pro forma net loss per share, basic and diluted, because their effect would have been anti-dilutive or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared using the actual redemptions at Closing related to Common Stock for the nine months ended September&#160;30, 2022 and the year ended December&#160;31, 2021 (in thousands, except number of shares and per share amounts): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine&#160;Months<br />Ended<br />September&#160;30,&#160;2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year ended<br />December&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net (loss) income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,401</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_27">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the section of this prospectus titled &#8220;Unaudited Pro Forma Condensed Combined Financial Statements&#8221; and the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_28">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> management products for the treatment of acute and chronic pain. According to the Centers for Disease Control and Prevention, an estimated 51.4&#160;million adults in the United States suffered from chronic pain in 2019. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain. We launched our first commercial product in October 2018 and are developing our late-stage pipeline. Our commercial product, ZTlido is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We market ZTlido through a dedicated sales force of <span style="white-space:nowrap">60-70</span> sales representatives, targeting 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We <span style="white-space:nowrap">in-licensed</span> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <span style="white-space:nowrap">FDA-approved</span> prophylactic treatment for painful gout flares in adults, in the U.S. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of three product candidates, <span style="white-space:nowrap">(i)&#160;SP-102</span> (&#8220;SEMDEXA&#8221;) (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of acute LBP, and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules), a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> alternative to <span style="white-space:nowrap">off-label</span> ESIs, which are administered over 12&#160;million times annually in the United States. <span style="white-space:nowrap">Top-line</span> results from the completed Phase 3 study have been received in November 2021 and reflected achievement of primary and secondary endpoints. <span style="white-space:nowrap">SP-103</span> has also been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. <span style="white-space:nowrap">SP-103</span> is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine threefold higher than any lidocaine topical product that we are aware of, either approved or in development. We are examining <span style="white-space:nowrap">SP-103</span> as a treatment for acute LBP, a condition with high unmet need which, as of 2019, affected over 22&#160;million patients in the United States. According to the CDC in 2020, LBP was the most common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months. We initiated a Phase 2 trial of <span style="white-space:nowrap">SP-103</span> in acute LBP in the second quarter of our fiscal year 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health, for ZTlido distribution in the United States. Cardinal Health purchased and shipped ZTlido to customer wholesale distribution centers. Cardinal Health also performed order management services on our behalf. On April&#160;2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. We acquired Semnur and its lead product candidate, SEMDEXA, in the first quarter of 2019, and we intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of <span style="white-space:nowrap">SP-103.</span> Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our product, ZTlido, and the development of our product candidates. For the years ended December&#160;31, 2021, 2020 and 2019, our net loss was $88.4&#160;million, $47.5&#160;million and $178.6&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, we had a net loss of $5.5&#160;million and $46.5&#160;million, respectively. As of September&#160;30, 2022, we had an accumulated deficit of $358.0&#160;million. As of September&#160;30, 2022, we had cash and cash equivalents of $2.5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido and GLOPERBA and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103,</span> and <span style="white-space:nowrap">SP-104</span> (which product candidate we acquired from Sorrento in May 2022). As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_29">Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2022, Vickers Vantage Corp. I (&#8220;Vickers&#8221;) entered into an Agreement and Plan of Merger (the &#8220;BCA&#8221;) with Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;), and Scilex Holding Company, a Delaware corporation (&#8220;Legacy Scilex&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into Legacy Scilex, with Legacy Scilex surviving the merger and becoming a wholly- owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, Vickers consummated the Business Combination pursuant to the terms of the BCA, with Legacy Scilex and Vickers Merger Sub. Pursuant to the BCA, Vickers acquired all of the outstanding equity interests of Legacy Scliex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $12.0&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness and payables between Legacy Scilex, Scilex Pharma, and Sorrento, totaling $290.6&#160;million, was converted into equity interests of New Scilex in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 10 titled &#8220;Related Party Transactions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;11, 2022. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Scilex issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_30">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into the Yorkville Purchase Agreement with YA II. YA II is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to YA II up to $500,000,000 of shares of Common Stock at any time during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. To request a purchase, we would submit an Advance Notice to YA II specifying the number of shares we intend to sell to YA II. While there is no mandatory minimum amount for any Advance, an Advance may not be for a number of shares of Common Stock exceeding 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the Advance Notice Date. The shares of Common Stock, if any, that we elect to sell to YA II pursuant to an Advance will be purchased at a price equal to 98% of the lowest daily VWAP (as defined below) during the two consecutive trading days commencing on the date of delivery of an Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Common Stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Advance. In no event is YA II obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of Common Stock. Moreover, under the applicable Nasdaq Listing Rules, in no event will we issue to YA II shares that, in the aggregate, would exceed the 19.9% Exchange Cap, unless the Company has received stockholder approval for such issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for YA II&#8217;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, we issued to YA II 250,000 shares of Common Stock (the &#8220;Commitment Shares&#8221;). YA II&#8217;s obligation to purchase shares of Common Stock pursuant to the Yorkville Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Commitment Shares and the shares to be issued pursuant to any Advance under the Securities Act, and that the registration statement is declared effective by the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_31">Impact of <span style="white-space:nowrap">COVID-19</span> on Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are closely monitoring the <span style="white-space:nowrap">COVID-19</span> pandemic and its potential impact on our business. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the outbreak, including implementing social distancing policies at our facilities, facilitating remote working arrangements and imposing employee travel restrictions. The extent to which <span style="white-space:nowrap">COVID-19</span> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_32">Comparability of Our Results and Our Relationship with Sorrento </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate as a majority-owned subsidiary of Sorrento. As a result, our historical financial statements may not be reflective of what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. In particular, certain legal, finance, human resources and other functions have historically been provided to us by Sorrento at cost plus an agreed-upon markup. We expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_33">Components of Our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue consists solely of product sales of ZTlido in the United States. For product sales of ZTlido, we record <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> sales adjustments for government and commercial rebates, chargebacks, wholesaler and distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for our product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_34">Operating Costs and Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists of the cost of purchasing ZTlido from our manufacturing partners and inventory write-downs related to expiration dates for <span style="white-space:nowrap">on-hand</span> inventory. We expect the cost of revenue to fluctuate with related sales revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the development of our product candidates, and include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in research and development functions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to outside consultants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect to incur significant research and development expenses in connection with our ongoing Phase 3 clinical trial for SEMDEXA, our planned Phase 2 and Phase 3 clinical trials for <span style="white-space:nowrap">SP-103,</span> and initiation of Phase 2 trials for <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-process</span> Research and Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <span style="white-space:nowrap">up-front</span> payments to acquire a new drug compound or drug delivery device, as well as future </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <span style="white-space:nowrap">in-process</span> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <span style="white-space:nowrap">in-process</span> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, we amortize the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selling, General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs, including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses from Sorrento for rent and maintenance of facilities and other operating costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year over year in the future as we adapt our commercial strategies to changes in the business environment. We also expect to incur increased expenses as a result of the Business Combination and operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to adjust the size of our administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired <span style="white-space:nowrap">in-process</span> research and development and assembled workforce. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on derivative liability consists of the changes to fair value of derivative liabilities between reporting periods relating to certain embedded derivative features within the Scilex Pharma Notes, and is recorded as other income or expense. See Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements appearing elsewhere in this prospectus and the section titled &#8220;Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Legacy Scilex &#8212; Indenture and Letter of Credit&#8221; for a description of the Scilex Pharma Notes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Gain) loss on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net consists of gains earned or losses incurred as a result of exercising our optional prepayment rights, which are treated as partial extinguishments, and the Early Paydown Provision, which is treated as a debt extinguishment, under the Scilex Pharma Notes, offset, for the year ended December&#160;31, 2021, by a gain on debt extinguishment as a result of the forgiveness of the loan in the amount of $1.6&#160;million received from Bank of America in May 2020 pursuant to the Paycheck Protection Program of the CARES Act (the &#8220;PPP Loan&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of interest related to the Scilex Pharma Notes and related party note payables to Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Gain) loss on Foreign Currency Exchange </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu, a manufacturer and supplier of lidocaine tape products, including ZTlido and <span style="white-space:nowrap">SP-103.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_35">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the years ended December&#160;31, 2021, 2020 and 2019 and the nine months ended September&#160;30, 2022 and 2021 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine Months Ended<br />September&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(in thousands, except for per share amounts)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,516</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(46,449</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(46,459</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(in thousands, except for per share amounts)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2019</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <span style="white-space:nowrap">in-process</span> research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(138,695</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(800</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,897</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,572</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(178,592</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,519</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(178,594</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_36">Comparison of Nine Months Ended September&#160;30, 2022 and 2021 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the nine months ended September&#160;30, 2022 and 2021 was $26.1&#160;million and $23.1&#160;million, respectively. The increase of $3.0&#160;million primarily driven by an increase in gross revenues by approximately 37% offset by increase in rebates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the nine months ended September&#160;30, 2022 and 2021 was $6.3&#160;million and $2.5&#160;million, respectively, and relate to product sales. The increase of $3.8&#160;million was primarily due to an approximately 37% increase in gross revenue for the nine months ended September&#160;30, 2022, compared to the nine months ended September&#160;30, 2021, royalty payments to our manufacturer beginning in the second quarter of 2022, and a $0.5&#160;million inventory reserve reversal in May 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the nine months ended September&#160;30, 2022 and 2021 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine Months Ended<br />September&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Increase<br />(Decrease)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,681</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(194</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(617</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,011</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the nine months ended September&#160;30, 2022 and 2021 were $6.5&#160;million and $7.0&#160;million, respectively. The $0.5&#160;million decrease in research and development expenses was primarily attributed to the completion of the Phase 3 <span style="white-space:nowrap">SP-102</span> trial in November 2021, and was partially offset by clinical <span style="white-space:nowrap">start-up</span> costs in the development of Phase 2 <span style="white-space:nowrap">SP-103</span> in the fourth quarter of 2021, the Phase 1 <span style="white-space:nowrap">SP-104</span> study in the fourth quarter of 2021, and an additional Phase 1 <span style="white-space:nowrap">SP-104</span> study in the second quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the nine months ended September&#160;30, 2022 and 2021 were $41.4&#160;million and $36.1&#160;million, respectively. The increase of approximately $5.3&#160;million was primarily due to a $7.7&#160;million increase in legal expenses related to the ZTlido patent infringement in which we were the plaintiff in September 2022, $0.9&#160;million increase in travel and entertainment expenses, $0.2&#160;million increase in consulting expenses, and a $0.4&#160;million increase in insurance expense, offset by a $1.2&#160;million decrease in commercial operations caused by fluctuation in fleet and electronics expenses, $2.0&#160;million decrease in personnel expense caused by $1.0&#160;million increase in personnel compensation that was offset by $3.0&#160;million decrease in bonus, a $0.5&#160;million decrease in marketing expense, and a $0.2&#160;million decrease in other expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the nine months ended September&#160;30, 2022 and 2021 was $2.9&#160;million and $2.8&#160;million, respective. The increase of $0.1 is related to the amortization of acquired licenses for the exclusive license of GLOPERBA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on derivative liability for the nine months ended September&#160;30, 2022 and 2021 was $5.3&#160;million and $0.1&#160;million, respectively. The gain recognized during the nine months ended September&#160;30, 2022 and 2021 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised sales forecasts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(Gain) Loss on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net for the nine months ended September&#160;30, 2022 and 2021 was $(28.6) million and $12.5&#160;million, respectively. The gain and loss incurred during the nine months ended September&#160;30, 2022 and 2021, respectively, was attributed to Scilex Pharma&#8217;s repurchase of the Scilex Pharma Notes of $20.0&#160;million and $41.4&#160;million in February 2022 and June 2022, respectively, as well as the Early Paydown Provision of $39.7&#160;million in September 2022 (see Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information) and $20.0&#160;million in each of February 2021 and April 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the nine months ended September&#160;30, 2022 and 2021 remained consistent and was $8.6&#160;million for each period </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Tax (Benefit) Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense for the nine months ended September&#160;30, 2022 and 2021 was $(36.0) thousand and $10.0&#160;thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_37">Comparison of Years Ended December&#160;31, 2021 and 2020 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the years ended December&#160;31, 2021 and 2020 was $31.3&#160;million and $23.6&#160;million, respectively. The increase of $7.7&#160;million was due to increased product sales of ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&#160;31, 2021 and 2020 was $3.6&#160;million and $2.1&#160;million, respectively, and relate to product sales. The increase of $1.5&#160;million is mainly due to the temporary switch of shipping method from ocean to air shipment in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&#160;31, 2021 and 2020 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Increase<br />(Decrease)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(689</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(529</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&#160;31, 2021 and 2020 were $9.2&#160;million and $10.0&#160;million, respectively. The $0.8&#160;million decrease in research and development expenses was attributed to the completion of Phase 3 <span style="white-space:nowrap">SP-102</span> trials in November 2021 as well as CMC and regulatory related expenses incurred in 2020 to prepare for <span style="white-space:nowrap">SP-103</span> clinical trials in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&#160;31, 2021 and 2020 were $50.6&#160;million and $43.0&#160;million, respectively. The increase of approximately $7.6&#160;million was primarily due to $4.0&#160;million in additional expenses in marketing and commercial operations, $7.6&#160;million in legal and audit fees, and $1.2&#160;million in additional other administrative expenses, offset by $5.2&#160;million of savings in sales expenses as a result of realigning our &#8220;sales force&#8221; territories resulting in the significant reduction of salesforce. The $7.6&#160;million increase in legal and audit fees was primarily due to a $6.6&#160;million increase in litigation expenses related to the ZTlido patent infringement in which we were the plaintiff and $1.0&#160;million increase in legal intellectual property and other legal corporate matters. The $4.0&#160;million increase in marketing and commercial operations was due to $1.4&#160;million increase in product promotion expenses, $1.0&#160;million increase in dues and subscriptions, $1.0&#160;million increase in consulting expenses and $0.6&#160;million increase in personnel cost. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the years ended December&#160;31, 2021 and 2020 was $3.7&#160;million, which is related to the amortization of developed technology upon commercialization of ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss (Gain) on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability for the years ended December&#160;31, 2021 and 2020 was $0.3&#160;million and $(0.8) million, respectively. The loss incurred during the year ended December&#160;31, 2021 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised probabilities related to marketing approval timing for <span style="white-space:nowrap">SP-103</span> and revised sales forecasts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment net for the years ended December&#160;31, 2021 was $12.5&#160;million. The loss incurred was attributed to our exercise of the optional principal repurchase payments on the Scilex Pharma Notes, offset by a gain on debt extinguishment of $1.5&#160;million related to the forgiveness on the entire PPP Loan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Pharma Notes Principal Increase </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal increase on the Scilex Pharma Notes for the years ended December&#160;31, 2021 was $28.0&#160;million. Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $481.0&#160;million. As a result, we recorded the increase of $28.0&#160;million in principal as <span style="white-space:nowrap">non-operating</span> expense at December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2021 and 2020 was $11.8&#160;million and $13.1&#160;million, respectively. The $1.3&#160;million decrease in interest expense was primarily due to the $2.8&#160;million decrease in interest expense incurred on the Scilex Pharma Notes partially offset by a $1.1&#160;million increase in interest expense related to related party notes with Sorrento and $0.4&#160;million increase in interest expense related to the CNH Revolving Loan during the year ended December&#160;31, 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Tax Expense (Benefit) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit) for the years ended December&#160;31, 2021 and 2020 was $5.0&#160;thousand and $(53.0) thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_38">Comparison of Years Ended December&#160;31, 2020 and 2019 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the years ended December&#160;31, 2020 and 2019 was $23.6&#160;million and $21.0&#160;million, respectively. The increase of $2.6&#160;million was due to product sales of ZTlido, which was commercially launched in October 2018. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&#160;31, 2020 and 2019 was $2.1&#160;million and $5.8&#160;million, respectively, and relate to product sales. The decrease of $3.7&#160;million is mainly due to establishing an E&amp;O inventory provision in 2019 for short-dated products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&#160;31, 2020 and 2019 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:67%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December 31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Increase<br />(Decrease)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(608</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,948</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&#160;31, 2020 and 2019 were $10.0&#160;million and $10.2&#160;million, respectively. The $0.2&#160;million decrease was primarily due to a slow down of clinical activities in the development of <span style="white-space:nowrap">SP-102</span> due to the <span style="white-space:nowrap">COVID-19</span> pandemic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-process</span> Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquired IPR&amp;D expenses for the years ended December&#160;31, 2020 and 2019 were $0 and $75.3&#160;million, respectively. The decrease was due to acquired IPR&amp;D expenses associated with our acquisition of Semnur&#8217;s assets in March 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&#160;31, 2020 and 2019 were $43.0&#160;million and $64.7&#160;million, respectively. The decrease of approximately $21.7&#160;million was primarily due to $16.6&#160;million of savings in sales and marketing as a result of realigning our &#8220;sales force&#8221; territories resulting in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the significant reduction of salesforce as well as achieving cost-saving within our marketing programs, a reduction of $2.4&#160;million in third-party services within the market access department, and $2.7&#160;million in savings from lower legal and audit fees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense remained the same at $3.7&#160;million between the years ended December&#160;31, 2020 and 2019, which is related to the amortization of developed technology upon commercialization of ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(Gain) Loss on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the years ended December&#160;31, 2020 and 2019 was a gain of $0.8&#160;million and a loss of $23.3&#160;million, respectively. The gain incurred during the year ended December&#160;31, 2020 and loss incurred during the year ended December&#160;31, 2019 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised probabilities related to marketing approval timing for <span style="white-space:nowrap">SP-103</span> and revised sales forecasts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2020 and 2019 was $13.1&#160;million and $16.9&#160;million, respectively. The decrease in interest expense was primarily due to the $4.4&#160;million decrease in interest expense incurred on the Scilex Pharma Notes issued in September 2018 partially offset by a $0.6&#160;million increase in interest expense related to related party notes with Sorrento during the year ended December&#160;31, 2020. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income for the years ended December&#160;31, 2020 and 2019 was $0 and $0.5&#160;million, respectively. The decrease in interest income was primarily due to lower cash balances during the year ended December&#160;31, 2020. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Tax (Benefit) Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense for the years ended December&#160;31, 2020 and 2019 was $(53.0) thousand and $2.0&#160;thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_39">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, we had cash and cash equivalents of $2.5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through the issuance of the Scilex Pharma Notes, related party notes with Sorrento, and the 2020 revolving credit facility. The following table summarizes the aggregate indebtedness of these issuances as of September&#160;30, 2022, December&#160;31, 2021, and December&#160;31, 2020 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:55%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">September&#160;30,<br />2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">December&#160;31,<br />2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">December&#160;31,<br />2020</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes with Sorrento</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Revolving Credit Facility</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">113,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_40">Debt Financings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Pharma Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2022, Sorrento and the Company entered into a Consent Under and Amendment No.&#160;4 with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Agent&#8221;), and the beneficial owners of those certain senior secured notes due 2026 issued by Scilex Pharma in September 2018 (the &#8220;Scilex Pharma Notes&#8221;) listed on the signature pages thereto (the &#8220;Holders&#8221;), which amended that certain Indenture, dated September&#160;7, 2018, by and among Scilex Pharma, Sorrento, the Trustee and the Agent, as amended (the &#8220;Indenture&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amendment to the Indenture (1)&#160;on June&#160;3, 2022, Scilex Pharma repurchased $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&#160;the Holders agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September&#160;30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Holders will forgive and discharge $28.0&#160;million of the aggregate principal amount of the Scilex Pharma Notes, (3)&#160;the minimum cash requirement under the Indenture was reduced to $5.0&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&#160;the maximum aggregate principal amount of that certain intercompany promissory note issued by Scilex Pharma to Sorrento on October&#160;5, 2018 was increased from up to $25.0&#160;million to up to $50.0&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&#160;million. On September&#160;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7&#160;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&#160;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&#160;million of principal amount of the Scilex Pharma Notes in connection with the repurchase. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarterly principal payments, based on a percentage of projected net sales of ZTlido, optional and contingently accelerated repurchases, and the Early Paydown Provision under the Scilex Pharma Notes since January&#160;1, 2021 are as follows (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap">Three Months Ended,</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Prinicipal<br />Payments</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&#160;31, 2021*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&#160;30, 2021*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&#160;30, 2022*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&#160;30, 2022*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payments since January&#160;1, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes repurchase or Early Paydown Provision during the period (see Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements elsewhere in this prospectus). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Royalties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the quarterly royalty payment of net sales of ZTlido associated with the Indenture, Scilex Pharma is a party to the Product Development Agreement with the Developers, pursuant to which the Developers will manufacture and supply lidocaine tape products, including the Products, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and 35% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. As of September&#160;30, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.1&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Scilex Pharma is in a net profit position, as defined in the Product Development Agreement, Scilex Pharma will first attempt to make aggregate royalty payments with cash generated from its operations. If these sources are insufficient, Scilex Pharma may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Contingent Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $280.0&#160;million, $13.0&#160;million, and $23.0&#160;million in aggregate contingent consideration obligations in connection with the Merger of Semnur, Romeg license, and <span style="white-space:nowrap">SP-104</span> acquisitions (see Note 3 titled &#8220;Acquisitions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information), respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the achievement of certain amounts of net sales (see Note 3 titled &#8220;Acquisitions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Deferred Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $3.7&#160;million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license (see Note 3 titled &#8220;Acquisitions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). Deferred consideration minimum royalty payments begin the first full quarter following June&#160;14, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Standby Equity Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into the Yorkville Purchase Agreement with YA II, whereby we have the right, but not the obligation, to sell to YA II up to $500.0&#160;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future Liquidity Needs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA, and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103,</span> and <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA, or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we raise additional funds by issuing equity or convertible debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, or our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#8220;Liquidity and Going Concern&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information. Proceeds from the Business Combination are dependent on the amount of redemptions by Vickers&#8217;s public shareholders. Net proceeds from this Business Combination, together with our existing cash and cash equivalents and proceeds from any Advances made under the Yorkville Purchase Agreement, may be insufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the periods presented: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:55%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine Months Ended<br />September&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash Flow Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,664</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31,461</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(60,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,624</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,067</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used for) financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,170</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(50,656</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(62,269</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,855</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, net cash used for operating activities was approximately $28.7&#160;million, primarily from our net loss of $88.4&#160;million offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $46.1&#160;million related to depreciation and amortization, principal increase to the Scilex Pharma Notes, stock-based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, <span style="white-space:nowrap">non-cash</span> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net loss on debt extinguishment, and a loss on derivative liabilities, and by changes in operating assets and liabilities that provided $13.6&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2020, net cash used for operating activities was approximately $31.5&#160;million, primarily from our net loss of $47.5&#160;million, offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $9.0&#160;million related to depreciation and amortization, stock based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, amortization of debt issuance costs and debt discount, interest on the Scilex Pharma Notes, and a gain on derivative liabilities, and changes in operating assets and liabilities of $7.0&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2019, net cash used for operating activities was approximately $60.4&#160;million, primarily from our net loss of $178.6&#160;million, which was offset by charges related to acquired IPR&amp;D of $75.3&#160;million, a loss on derivative liability of $23.3&#160;million, other <span style="white-space:nowrap">non-cash</span> reconciling items of $23.6&#160;million related to depreciation and amortization, stock based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost and amortization of debt issuance costs and debt discount, and changes in operating assets and liabilities that used $4.0&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2022, net cash used for operating activities was approximately $20.5&#160;million, primarily from our net loss of $5.5&#160;million, other <span style="white-space:nowrap">non-cash</span> reconciling items of $44.7&#160;million related to depreciation and amortization, stock-based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, <span style="white-space:nowrap">non-cash</span> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net gain on debt extinguishment, and a gain on derivative liabilities and offset by changes in operating assets and liabilities that provided $29.7&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2021, net cash used for operating activities was approximately $22.7&#160;million, primarily from our net loss of $46.5&#160;million, offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $14.0&#160;million related to depreciation and amortization, stock based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, amortization of debt issuance costs and debt discount, interest on the Scilex Pharma Notes, net loss on debt extinguishment, and a net loss on derivative liabilities, and changes in operating assets and liabilities of $9.8&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, no cash was used for investing activities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2020, net cash used for investing activities was approximately $25.0&#160;thousand, attributed to property and equipment purchases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2019, net cash used for investing activities was approximately $17.6&#160;million, primarily attributed to approximately $17.0&#160;million of cash paid for the acquisition of Semnur-related IPR&amp;D expenses and $0.6&#160;million of property and equipment purchases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2022, net cash used for investing activities was approximately $2.1&#160;million attributed to cash paid for the acquisition of GLOPERBA licenses from Romeg and $7.0&#160;thousand attributed to cash paid for property, plant, and equipment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2021, no cash was used for investing activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, net cash provided by financing activities was approximately $28.2&#160;million and was primarily related to $47.9&#160;million in proceeds from related party payables, $47.8&#160;million in proceeds from the CNH Revolving Loan, $14.7&#160;million in proceeds from related party note payable with Sorrento, and offset by $48.8&#160;million repayment of the CNH Revolving Loan and $33.4&#160;million repayment of the Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2020, net cash used by financing activities was approximately $19.2&#160;million and is primarily related to $58.9&#160;million repayment of the Scilex Pharma Notes, offset by $18.4&#160;million in proceeds from related party payables, $11.0&#160;million in proceeds from other loans, and $10.3&#160;million in proceeds from related party notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2019, net cash provided by financing activities was approximately $15.8&#160;million and is primarily related to $16.6&#160;million of related party note proceeds, which were utilized to finance the acquisition of Semnur, plus $5.0&#160;million of promissory note proceeds offset by repayment of the related party note payable of $3.5&#160;million and $2.3&#160;million repayment of the Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2022, net cash provided by financing activities was approximately $20.7&#160;million and is primarily related to $51.9&#160;million in proceeds from related party payables, $62.5&#160;million in proceeds from related party note payables, $9.9&#160;million in proceeds from the CNH Revolving loan, $96.0&#160;thousand in proceeds from the exercise of stock options, offset by $18.8&#160;million repayment on CNH Revolving Loan and $84.8&#160;million repayment of the Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2021, net cash provided by financing activities was approximately $22.1&#160;million and is primarily related to $45.1&#160;million in proceeds from related party payables, $34.8&#160;million in proceeds from the CNH Revolving Loan, and $11.5&#160;million in proceeds from related party notes, offset by a $32.4&#160;million repayment of the Scilex Pharma Notes and a $36.9&#160;million repayment on CNH Revolving Loan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_41">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to derivative liabilities, income taxes and stock-based compensation and others listed below. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in greater detail in the audited financial statements for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus, we believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our reported financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue to date has been generated from product sales of ZTlido. We do not have significant costs associated with obtaining contracts with our customers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the consideration we expect to receive from the customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from product sales relates solely to sales of ZTlido. Our performance obligations with respect to sales of ZTlido are satisfied at a certain point in time, and we consider control to have transferred upon delivery to the customer. We consider control to have transferred upon delivery to the customer because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and the date on which payment is due is not significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For product sales, we record <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> sales adjustments for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary industry practices and current government regulations. <span style="white-space:nowrap"><span style="white-space:nowrap">Gross-to-net</span></span> adjustments are generally recorded as contract liabilities under accrued expenses within our consolidated balance sheet. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rebates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare providers. Both types of rebates vary over time. We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Service Fees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our customers and others in the distribution chain for wholesaler and distribution services. We have determined such services received to date are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a reduction of revenue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Product Returns </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We may authorize the return of products sold in accordance with the term of its sales contracts, and estimate allowances for such amounts at the time of sale. We estimate the amount of our product sales that may be returned by our customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate our product returns using historical trends and product return rates typically experienced in the industry. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Co-payment</span> Assistance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <span style="white-space:nowrap">co-</span> payment assistance. We accrue for <span style="white-space:nowrap">co-payment</span> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities result from the Scilex Pharma Notes. For the Scilex Pharma Notes, interest payments and repayments of the principal are based on a percentage of net sales of ZTlido and could be accelerated if certain net sales targets are not met or if marketing approval of <span style="white-space:nowrap">SP-103,</span> or a similar product with a lidocaine concentration of not less than 5%, is delayed or in the event of a qualified initial public offering. In estimating the fair value of such financial instruments, we may apply significant assumptions and estimates, including estimates involving future net product sales and timing and probability of marketing approvals and the probability of a qualified initial public offering event, which could be impacted in the future based on market conditions. As of December&#160;31, 2021, the fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4 (see Debt note). Significant Level&#160;3 assumptions used in the measurement included a 6.2% risk adjusted net sales forecast and an effective debt yield of 15.0% on December&#160;31, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform a Level&#160;3 based assessment to identify the embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting as a single compound derivative. Certain of these embedded features include default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining derivative liabilities as of September&#160;30, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for stock-based compensation in accordance with FASB ASC Topic 718 &#8220;Compensation &#8211; Stock Compensation&#8221;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <span style="white-space:nowrap">non-employee&#8217;s</span> vesting period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, we use historical data in estimating the expected terms of options and determine an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy Scilex Common Stock Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for the Legacy Scilex Common Stock to date, the estimated fair value of the Legacy Scilex Common Stock was determined by the Legacy Scilex Board, considering our most recently available third-party valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#8217;s assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the stock option grant. Prior to the Business Combination, given the absence of a public trading market for the Legacy Scilex Common Stock, the valuations of the Legacy Scilex Common Stock were determined in accordance with the &#8220;American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation.&#8221; The Legacy Scilex Board exercised its reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of the Legacy Scilex Common Stock, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Independent valuations of the Legacy Scilex Common Stock performed at periodic intervals by an independent third-party valuation firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The likelihood of achieving a liquidity event, such as an initial public offering or sale of the company and the potential value of a strategic merger or sale at different time points, given prevailing market conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our historical operating and financial performance as well as our estimates of future financial performance, including the regulatory status of ZTlido and GLOPERBA and the timing and probability of continuing growth since commercialization of ZTlido and GLOPERBA under different operational scenarios; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The status of research and development efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our stage of development and commercialization and our business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Industry information such as market trends and macro-economic events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Valuations of comparable companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adjustments to recognize a relative lack of marketability of the Legacy Scilex Common Stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Additional objective and subjective factors relating to our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our valuations have not always coincided with the dates of our stock option grants. In determining the exercise prices of the stock options at each grant date, the Legacy Scilex Board considered, among other things, the most recent valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#8217;s assessment of additional objective and subjective factors we believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent valuation and the grant dates included our operating and financial performance and current business conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying the valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Scilex Common Stock and Legacy Scilex&#8217;s stock-based compensation expense could have been materially different. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">March&#160;17 and March&#160;31, 2019 Valuations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on March&#160;17, 2019 and March&#160;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using the market and income approaches. Legacy Scilex weighted a guideline </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. Legacy Scilex then used the Option Pricing Method (&#8220;OPM&#8221;) to allocate the concluded equity value amongst the different equity classes and determine the value of Legacy Scilex Common Stock. These valuations resulted in a valuation of Legacy Scilex Common Stock of $1.16 per share as of March&#160;17, 2019 and March&#160;31, 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">May&#160;31, 2019 Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on May&#160;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;), which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income and market approaches in line with the March&#160;31, 2019 valuation and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of Legacy Scilex Common Stock of $1.16 per share as of May&#160;31, 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">December&#160;31, 2019 Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on December&#160;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income approach in line with the March&#160;31, 2019 valuation and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of the Legacy Scilex Common Stock of $1.16 per share as of December&#160;31, 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">July&#160;31, 2020 Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on July&#160;31, 2020, the fair value of the Legacy Scilex Common Stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of the Legacy Scilex Common Stock of $1.16 per share as of July&#160;31, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a public trading market for our Common Stock has been established in connection with the Closing of the Business Combination, it will no longer be necessary for the Vickers Board to estimate the fair value of our Common Stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our Common Stock will be determined based on the quoted market price of our Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for debt as liabilities measured at amortized cost and amortize the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. We consider whether there are any embedded features in the debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to FASB, ASC, Topic 815, &#8220;Derivatives and Hedging.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, as well as the classification between current and long-term portions. In estimating future net product sales, we assessed prevailing market conditions using various external market data against our anticipated sales and planned commercial activities as well as actual ZTlido sales as of the Scilex Pharma Note extinguishment. See Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements appearing elsewhere in this prospectus and the section titled &#8220;Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Legacy Scilex&#8212;Indenture and Letter of Credit&#8221; for a description of the Scilex Pharma Notes, which provide for repayments based on a percentage of net sales of ZTlido. Consequently, we imputed interest on the carrying value of the debt and recorded interest expense using an imputed effective interest rate. We reassessed the expected payments each reporting period and accounted for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of our current and long-term portions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Leases </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning January&#160;1, 2019, at the inception of a contractual agreement and at transition to the new lease standard, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, we calculate the associated lease liability and corresponding <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of ASC Topic <span style="white-space:nowrap">740-10,</span> Income Taxes &#8212; Overall, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <span style="white-space:nowrap">740-10,</span> we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. We have determined that we have immaterial uncertain tax positions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely will not be realized. As of September&#160;30, 2022 and December&#160;31, 2021, we maintained a full valuation allowance against our deferred tax assets, with the exception of an amount equal to our deferred tax liabilities that are scheduled to reverse against Legacy Scilex&#8217;s deferred tax assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are carried at their initial valuation or acquisition price and amortized on a straight-line basis over the estimated useful lives of the assets. If the useful life is indefinite, we will <span style="white-space:nowrap">re-evaluate</span> the asset </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
annually for impairment and make adjustments as necessary. Our patents were initially valued using the multi- period excess earnings method and the useful life of 15 years was determined by management based on the patent expiration date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our developed technology was valued based on a <span style="white-space:nowrap">15-year</span> projection using the excess earnings approach. We commenced amortization of IPR&amp;D upon commercialization of ZTlido in October 2018. We review our long-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. There have not been any impairment losses of long-lived assets through September&#160;30, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Goodwill </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. We have determined that only one reporting unit exists for examination under impairment review. During our goodwill impairment review, we may assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting units are less than their carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of our company. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting units are less than their carrying amounts, then no additional assessment is deemed necessary. Otherwise, we perform a quantitative goodwill impairment test. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. We performed our annual assessment for goodwill impairment in the fourth quarters of 2021, 2020, and 2019 and determined there was no impairment as of December&#160;31, 2021, 2020 and 2019, respectively. No interim impairment test was considered necessary during the nine months ended September&#160;30, 2022 as we believe that it is more likely than not that the fair value of our goodwill was in excess of the carrying value </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-Process</span> Research and Development Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <span style="white-space:nowrap">up-front</span> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired IPR&amp;D provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired IPR&amp;D related to the asset acquisition of IPR&amp;D from Semnur in March 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material Cash Commitments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, our contractual obligations are as follows (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:61%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Payments Due by Period</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Less than<br />1 year</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">1-3</span> years</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">3-5&#160;years</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">More&#160;than<br />5 years</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes Payable<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on Related Party Notes Payable<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial obligations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Note 8 titled &#8220;Commitments and Contingencies&#8221; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The related party notes payable and interest on related party notes payable were eliminated at the close of the Business Combination under the terms of the Debt Exchange Agreement. See Note 10 titled &#8220;Related Party Transactions&#8221; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Note 3 titled &#8220;Acquisitions&#8221; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_42">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, the FASB issued ASU <span style="white-space:nowrap">2021-08,</span> Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <span style="white-space:nowrap">2021-08</span> is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <span style="white-space:nowrap">No.&#160;2019-12,</span> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_43">Quantitative and Qualitative Disclosures About Market Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Rate Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to market risk is confined to our cash and cash equivalents and debt securities. We have cash and cash equivalents and invest primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Additionally, all interest rates associated with our related party notes outstanding as of September&#160;30, 2022 are capped, therefore we are not subject to interest rate risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Concentration Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to April&#160;2, 2022, sales to our sole customer and third-party logistics distribution provider, Cardinal Health, represented 100% of our net revenue. On April&#160;2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. Additionally, during the nine months ended September&#160;30, 2022 and 2021, we purchased inventory from our sole supplier, Itochu. This exposes us to concentration of customer and supplier risk. We monitor the financial condition of our customers, limit our credit exposure by setting credit limits, and have not experienced any credit losses for the nine months ended September&#160;30, 2022 and 2021. As we continue to expand the commercialization of our product, we are not limited to the current customer and have elected to expand our distribution network. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on April&#160;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation, Cardinal Health, and AmerisourceBergen Corporation, as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health (or with any of our other two distributors), we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health, as our only third- party logistics provider, may negatively impact our sales. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have, during the periods presented, and we do not currently have, any <span style="white-space:nowrap">off-balance</span> sheet arrangements, as defined under applicable SEC rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our related party transactions, see the section of this prospectus titled &#8220;Certain Relationships and Related Party Transactions&#8221;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_43a">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;emerging growth company&#8221; as defined in the JOBS Act is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding <span style="white-space:nowrap">non-binding</span> advisory votes on executive compensation or golden parachute arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will qualify and will remain as an emerging growth company until the earlier of (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity of that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than $1.00&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_44">Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We expect that we will not be a smaller reporting company to the extent we remain a majority-owned subsidiary of Sorrento. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_45">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_46">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in the first half of 2023. Our commercial product, ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. Scilex licenses the rights to ZTlido from and relies exclusively on Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu,&#8221; and together with Oishi, the &#8220;Developers&#8221;) pursuant to the Product Development Agreement and Commercial Supply Agreement. The Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances as more fully described in the sections titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement,</span>&#8221; including, among other things, if Scilex&#8217;s total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters. As of the date of this prospectus, Scilex&#8217;s net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <span style="white-space:nowrap">(i)&#160;SP-102</span> (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of LBP; and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;),</span> a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. Most recently, on June&#160;14, 2022, Scilex entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, among other things, Romeg granted Scilex (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. GLOPERBA is an <span style="white-space:nowrap">FDA-approved,</span> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 8.7&#160;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. <span style="white-space:nowrap">Non-steroidal</span> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. Scilex is planning to commercialize GLOPERBA in 2023 and believes it is well-positioned to market and distribute the product. Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout all U.S. states. For more information on Scilex, please see the sections titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Romeg License and Commercialization Agreement</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of these pipeline product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently available prescription and OTC lidocaine patches, of which over 147&#160;million and 136&#160;million of such patches were sold in the United States in 2021 and 2020, respectively, according to Symphony Healthcare. We have sold 6,336,032 and 7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <span style="white-space:nowrap">SP-102</span> from Semnur in March 2019 and are developing it to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <span style="white-space:nowrap">off-label</span> epidural steroid injections (&#8220;ESI&#8221;), which are administered over 12&#160;million times annually in the United States. See the section titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Semnur Merger Agreement</span>&#8221; for a description of our acquisition of Semnur and our ongoing obligations to Semnur&#8217;s former equityholders. SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the only <span style="white-space:nowrap">FDA-approved</span> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it is estimated that over 4.8&#160;million patients will suffer from sciatica in the United States in 2022. <span style="white-space:nowrap">SP-103</span> has also been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. We are developing <span style="white-space:nowrap">SP-104</span> as a novel delayed-release formulation of <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia. There are no <span style="white-space:nowrap">low-dose</span> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could uniquely address what we believe are the significant unmet needs of the targeted populations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_47">Our Marketed Product and Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization rights, except with respect to Japan for ZTlido and <span style="white-space:nowrap">SP-103.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g374624g75s68.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_48">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel <span style="white-space:nowrap">non-opioid</span> and <span style="white-space:nowrap">non-addictive</span> treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Maximize the commercial potential of ZTlido</span>. We have assembled an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately <span style="white-space:nowrap">60-70</span> people, targeting over 10,000 primary care physicians, pain specialists, neurologists, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating contracts and have already achieved significant uptake by adding ZTlido to key formularies such as Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem Blue Cross Blue Shield (&#8220;BCBS&#8221;), BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of sciatica</span>. We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used <span style="white-space:nowrap">off-label.</span> Many of these products contain potentially neurotoxic preservatives and particulates, and are administered over 12&#160;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full <span style="white-space:nowrap">6-month</span> data analysis was completed in February 2022 and we have recently completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We have extensive clinical and <span style="white-space:nowrap">pre-clinical</span> data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of <span style="white-space:nowrap">SP-102.</span> We expect to present the robust data collected over the course of our multi-year clinical development program to the FDA as part of a NDA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of <span style="white-space:nowrap">SP-103</span> for the first approved topical treatment in patients with acute LBP</span>. We are developing <span style="white-space:nowrap">SP-103</span> as a triple-strength lidocaine topical system for the treatment of acute LBP, to be used where we believe a high-dose strength and superior adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. <span style="white-space:nowrap">SP-103</span> is designed to use ZTlido&#8217;s delivery and adhesion technology to deliver a dose of lidocaine that is threefold higher than any other approved lidocaine topical products. We initiated a Phase 2 trial in acute LBP in the second quarter of 2022. <span style="white-space:nowrap">SP-103</span> has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of <span style="white-space:nowrap">SP-104</span> for the treatment of fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects</span>. We are developing <span style="white-space:nowrap">SP-104</span> for fibromyalgia. <span style="white-space:nowrap">Low-dose</span> naltrexone hydrochloride delayed-release capsules are routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia and other chronic pain conditions such as complex regional pain. <span style="white-space:nowrap">SP-104</span> addresses the shortcomings of using the high-dose commercial products and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
pharmacy-compounded products by delivering a <span style="white-space:nowrap">low-dose</span> of naltrexone hydrochloride (approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. <span style="white-space:nowrap">SP-104</span> has completed two Phase 1 studies to characterize the pharmacokinetics and safety of the product, and we expect to commence Phase 2 studies in the first half of 2023. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Expand our product portfolio by developing or acquiring <span style="white-space:nowrap">non-opioid</span> assets that leverage our novel delivery and adhesion technologies or our existing commercial infrastructure</span>. We are continuously evaluating opportunities to leverage our research and development experience to develop <span style="white-space:nowrap">non-opioid</span> therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to <span style="white-space:nowrap">in-license</span> or acquire <span style="white-space:nowrap">non-opioid</span> therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, Scilex intends to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Leverage our management team&#8217;s experience to further develop and commercialize its current and future product portfolio</span>. Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully commercializing products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our innovative <span style="white-space:nowrap">non-opioid</span> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_49">Our Management Team </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in pharmaceutical industry, in addition to strong transactional and business development track records. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairman, Henry Ji, Ph.D. They collectively have over 40 years of global biopharmaceutical and biotechnology experience. Mr.&#160;Shah served as the Chief Executive Officer of Semnur from its inception in 2013 until our acquisition of Semnur in March 2019. He also has over 15 years of senior management experience in leading business development, commercial operations, investor relations, marketing and medical affairs. Dr.&#160;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Our Chief Financial Officer, Elizabeth Czerepak, has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel <span style="white-space:nowrap">non-opioid</span> and <span style="white-space:nowrap">non-addictive</span> treatments to provide safe, effective and durable relief of multiple pain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver effective first-class pain management therapies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_50">Our Product Portfolio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketed product, ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prescription Lidocaine Patch Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by the nerve injury can persist for months to years surrounding the affected area. According to Evaluate Ltd., there were over 3.5&#160;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, there were more than 147&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of this, five lidocaine patch manufacturers accounted for approximately 92% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system, ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <span style="white-space:nowrap"><span style="white-space:nowrap">drug-to-drug</span></span> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various <span style="white-space:nowrap">off-label</span> treatments, including NSAIDS and opioids. These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <span style="white-space:nowrap">12-month</span> period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well-supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well-suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#8220;FAERS&#8221;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#8220;TDSs&#8221;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#8217;s past experience with regulatory agencies, shows the FDA&#8217;s interest and the importance of adhesion performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following figure depicts data derived from FAERS as of December&#160;31, 2020: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g38a43.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch to deliver sufficient drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers 3&#177; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product&#8217;s pliability can be compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a bioavailability of 3 &#177; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the <span style="white-space:nowrap">12-hour</span> administration period, as captured in a bolded warning on the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal marketing status. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#8220;Mylan&#8221;), while providing bioequivalent delivery of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Key Advantages of ZTlido vs. Lidoderm and Associated Generics </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g37x44.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = <span style="white-space:nowrap"><span style="white-space:nowrap">Drug-in-adhesive</span></span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Source: A Scilex-sponsored <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> comparative adhesion study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">(SCI-LIDO-ADH-003)</span></span></span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products. ZTlido uses an advanced <span style="white-space:nowrap">hot-melt</span> technology, which uses premixing and <span style="white-space:nowrap">hot-melt</span> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm and Mylan&#8217;s generic lidocaine patch at 12 hours after application. In a <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> study of 44 subjects, ZTlido showed statistically significant adhesion at <span style="white-space:nowrap">all-time</span> points compared to Lidoderm. Further, ZTlido maintained greater than 90% mean adhesion over the labeled <span style="white-space:nowrap">12-hour</span> administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#8217;s generic lidocaine patch. In this <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> study, ZTlido maintained greater than 90% mean adhesion throughout the labeled <span style="white-space:nowrap">12-hour</span> administration period, while Mylan&#8217;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile without creating dermal sensitization and maintaining a benign irritation profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#8217;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol where adhesion could not be enhanced (<span style="font-style:italic">i.e.</span>, no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#8217;s NDA approval. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g374624g37g45.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from the patch to the skin. This was supported by a clinical study in which our product achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the <span style="white-space:nowrap">12-hour</span> administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to Lidoderm and Teva&#8217;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material allows for a product that maintains contact with the skin in contoured areas of the body, when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#8217;s generic lidocaine patch is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4 sessions of <span style="white-space:nowrap">30-minutes</span> of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire <span style="white-space:nowrap">12-hour</span> administration period. Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is supported by an adhesion or pharmacokinetic study showing that while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no clinically meaningful change in pharmacokinetics. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (<span style="font-style:italic">e.g.</span>, heating pad or blanket), the <span style="white-space:nowrap">FDA-approved</span> ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities. We market ZTlido through a dedicated <span style="white-space:nowrap">65-person</span> sales force, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key formularies, including Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem BCBS, BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sciatica Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning LBP combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like numbness and tingling. The estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about <span style="white-space:nowrap">one-third</span> of these cases will develop symptoms lasting over a year. According to a report by Decision Resources Group, it is estimated that over 4.8&#160;million patients will suffer from sciatica in the United States in 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from 2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are numerous etiologies of sciatica, and therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with severe adverse events. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and <span style="white-space:nowrap">non-invasive</span> treatment options. Surgical intervention options include such as vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&#160;nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy, traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&#160;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants; and (iii)&#160;injectable pharmaceutical therapies such as <span style="white-space:nowrap">off-label</span> use of ESIs or nerve blocks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#8217;s pain is inadequately controlled with oral pain medications, topical systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being <span style="white-space:nowrap">FDA-approved</span> for the treatment of lumbosacral radicular pain, currently-used ESIs also present various risks and challenges. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or betamethasone sodium phosphate or betamethasone sodium acetate) instead of a <span style="white-space:nowrap">non-particulate</span> steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage: (1)&#160;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(2)&#160;several particulate steroids have an immediate and massive effect on microvascular perfusion because of formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently <span style="white-space:nowrap">off-label</span> use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-102</span> to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. <span style="white-space:nowrap">SP-102</span> is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a <span style="white-space:nowrap">pre-filled</span> glass syringe for delivery via an epidural injection. <span style="white-space:nowrap">SP-102</span> allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated without the use of preservatives and packaged in a <span style="white-space:nowrap">pre-filled</span> syringe, so as to confer greater physician convenience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks of serious neurologic complications. Unlike currently-used steroids, <span style="white-space:nowrap">SP-102</span> does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe <span style="white-space:nowrap">SP-102</span> may substantially reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, <span style="white-space:nowrap">SP-102,</span> which uses a biocompatible, biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe <span style="white-space:nowrap">SP-102,</span> if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, <span style="white-space:nowrap">SP-102</span> could become the first <span style="white-space:nowrap">FDA-approved</span> ESI product. We believe an <span style="white-space:nowrap">FDA-approved</span> therapy for the treatment of sciatica could potentially benefit from <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-market</span></span> advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. <span style="white-space:nowrap">SP-102</span> benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in <span style="white-space:nowrap">SP-102.Our</span> complex manufacturing process, specialized equipment and <span style="white-space:nowrap">know-how</span> for sterile viscous product candidates are also key to our competitive edge. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating data on <span style="white-space:nowrap">SP-102</span> from a pivotal Phase 3 CLEAR trial, which was designed to evaluate the safety and efficacy in the proposed indication. The CLEAR clinical trial is a randomized, double-</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of <span style="white-space:nowrap">SP-102,</span> compared to an intramuscular injection of placebo over four weeks. A full <span style="white-space:nowrap">6-months</span> data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR trial summary results, which results reflect achievement of primary and secondary endpoints, are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy) experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference <span style="white-space:nowrap">-1.08</span> (0.17), with a <span style="white-space:nowrap">p-value</span> &lt; 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-Meier estimation. By contrast, <span style="white-space:nowrap">off-label</span> injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and estimating quality of life, showed a 28% improvement at 4 weeks on <span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) compared to baseline (minimal clinically meaningful improvement <span style="white-space:nowrap">8%-12%)15.</span> The LS Mean (SEM) difference as compared to placebo was <span style="white-space:nowrap">-6.28</span> (1.49), with a <span style="white-space:nowrap">p-value</span> &lt; 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There were no adverse events (&#8220;AEs&#8221;) of special interest reported, such as paraplegia, hematoma, or infection at the injection site, which events are associated with the <span style="white-space:nowrap">off-label</span> use of <span style="white-space:nowrap">non-approved</span> injectable steroid preparations. Of the 354 patients receiving at least a single injection of <span style="white-space:nowrap">SP-102,</span> there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#8220;TEAEs&#8221;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%) patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) patients experiencing serious AEs, and one (0.3%) patients experiencing AEs related to early withdrawal. Of the 47 patients only receiving a single placebo injection (and no repeat injection of <span style="white-space:nowrap">SP-102),</span> there were 14 (29.8%) patients experiencing TEAEs with (i)&#160;two (4.3%) patients experiencing treatment-related AEs, (ii)&#160;two (4.3%) patients experiencing medication-related AEs, (iii)&#160;one (2.1%) patient experiencing procedure-related AEs, (iv)&#160;one (2.1%) patient experiencing serious AEs, (v)&#160;one (2.1%) patient experiencing AEs related to early withdrawal, and (vi)&#160;one (2.1%) patient death. TEAEs occurring in &#8805; two percent of patients were headache <span style="white-space:nowrap">(SP-102:</span> 13 (6.4%), 17 events; placebo: 11 (5.5%), 11 events), injection site pain <span style="white-space:nowrap">(SP-102:</span> 4 (2.0%), four events; placebo: zero (0.0%), 0 events), upper respiratory tract infection <span style="white-space:nowrap">(SP-102:</span> two (1.0%), 2 events; placebo: four (2.0%) events), sinusitis <span style="white-space:nowrap">(SP-102:</span> 4 (2.0%), four events; placebo zero (0.0%), 0 events) and hypertension <span style="white-space:nowrap">(SP-102:</span> four (2.0%), four events; placebo: one (0.5%), two events). The C.L.E.A.R trial also established the safety of repeat injections, as patients who experienced <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> radicular pain between 4 and 23 weeks were allowed to receive open-label additional <span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Phase 3 <span style="white-space:nowrap">SP-102</span> C.L.E.A.R Trial &#8211; Primary Endpoint </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g374624g24q49.jpg" alt="LOGO" />
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g374624g24p49.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-103</span> to be a triple-strength, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system for the treatment of acute LBP. <span style="white-space:nowrap">SP-103</span> leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acute LBP Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute LBP represents a high unmet needs and creates large market opportunities. LBP affects about 70% of people in resource-rich countries at some point in their lives. Acute LBP </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate-intensity pain and 15% have severe pain. Acute LBP has a high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5&#160;billion in 2016 on treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18 &#8211; 44, 45 &#8211; 64, and 75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group <span style="white-space:nowrap">65-74</span> years. Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or possible osteoporosis), major or progressive motor or sensory deficit, <span style="white-space:nowrap">new-onset</span> bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our triple-strength <span style="white-space:nowrap">SP-103</span> is an investigational, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system undergoing clinical development in acute LBP conditions. If approved, we believe that <span style="white-space:nowrap">SP-103</span> could become the lidocaine topical product for acute LBP indications. All current uses of topical lidocaine products for LBP are <span style="white-space:nowrap">off-label.</span> This program builds on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-103</span> to deliver a dose of lidocaine that is at least threefold higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture <span style="white-space:nowrap">SP-103</span> to have a drug load of 108 mg lidocaine in a similar adhesive formulation as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> has demonstrated delivery of threefold the level of drug of ZTlido, and consequently delivers threefold the level of drug of Lidoderm and associated generics by extrapolation. <span style="white-space:nowrap">SP-103</span> has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. We believe <span style="white-space:nowrap">SP-103,</span> if successfully developed and approved, may be able to address the limitations of prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site, but with systemic exposure of drug remaining well below established safety thresholds. <span style="white-space:nowrap">SP-103</span> has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver threefold the level of the drug within a targeted area, with the convenience of a single topical system. This level of dosage for <span style="white-space:nowrap">SP-103</span> is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a <span style="white-space:nowrap">24-</span> hour period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not increase drug delivery to a localized area under the topical system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the acute LBP market presents an attractive commercial opportunity due to the large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical <span style="white-space:nowrap">non-opioid</span> product targeting this segment of the pain population represents a commercially attractive strategy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend initially to evaluate <span style="white-space:nowrap">SP-103</span> in a Phase 2 trial in subjects who have acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <span style="white-space:nowrap">two-period</span> cross-over, multicenter study of <span style="white-space:nowrap">SP-103</span> and placebo in subjects with acute LBP. The study consists of a <span style="white-space:nowrap">7-day</span> open-label <span style="white-space:nowrap">run-in</span> period where all subjects receive active treatment. Responders to treatment then will be randomized to blinded Treatment A, consisting of 30 days treatment with <span style="white-space:nowrap">SP-103</span> or Treatment B, consisting of 30 days treatment with placebo patch with no lidocaine. Scilex initiated the Phase 2 trial in the second quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-104</span> for the treatment of fibromyalgia. <span style="white-space:nowrap">Low-dose</span> naltrexone hydrochloride delayed-release capsules is routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia and other chronic pain conditions such as complex regional pain. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fibromyalgia Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&#160;million people in the United States and an estimated 3% to 6% of the world population. While it is most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12&#160;billion to $14&#160;billion each year and the condition accounts for a loss of 1% to 2% of the national overall productivity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Complications of Fibromyalgia </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a <span style="white-space:nowrap">non-exhaustive</span> list of complications of fibromyalgia: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extreme allodynia with high levels of distress; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">opioid or alcohol dependence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">marked functional impairment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severe depression and anxiety; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obesity and physical deconditioning; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">metabolic syndrome. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia is detailed in the chart below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g46h52.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran, have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new treatments with higher efficacy are needed to improve management of fibromyalgia. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span> has key clinical data supporting its use in fibromyalgia. There are investigational trials that support use and development of <span style="white-space:nowrap">SP-104</span> for fibromyalgia. Currently there are no <span style="white-space:nowrap">low-dose</span> formulations (i.e., less than 5&#160;mg) available. Physicians currently use the commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This can lead to errors in dosing and challenges with titration. The commercial products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria, insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">SP-104</span> uses delayed burst release technology that bypasses the stomach and releases the drug in the gut (upper intestine). When taking <span style="white-space:nowrap">SP-104</span> at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#8217;s potential to elicit compensatory response. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to develop <span style="white-space:nowrap">SP-104</span> for fibromyalgia. Phase 1 studies are to characterize the pharmacokinetic and safety profile of <span style="white-space:nowrap">SP-104,</span> and Scilex intends to initiate a Phase 2 study in the first half of 2023. If successful, we believe <span style="white-space:nowrap">SP-104</span> can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_51">Commercialization and Market Access </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales&#160;&amp; Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our marketed product, ZTlido, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical lidocaine product market, where we believe we have the only actively promoted product. Our dedicated <span style="white-space:nowrap">65-person</span> sales force has broad experience in pain management and is exclusively focused on promoting ZTlido. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN patients. We believe these same call points provide treatment for the sciatica and acute LBP patients that could benefit from SEMDEXA and <span style="white-space:nowrap">SP-103,</span> if approved. Our sales representatives typically have over 10 years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2022, ZTlido had gained approximately 11.6% market share of the lidocaine patch prescription market across the territories we cover in the United States. The total prescriptions of ZTlido for the nine months ended September 30, 2022 grew by more than 47.9% over the nine months ended September 30, 2021, according to Symphony Healthcare&#8217;s national prescription data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics team is conducting market research to support the launch of <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104,</span> if any of these candidates is approved. We believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other <span style="white-space:nowrap">non-opioid</span> pain management therapeutics. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Market Access </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#8217; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275&#160;million of the over 300&#160;million lives, with the remaining 25&#160;million to be considered in the future. Currently, ZTlido is covered for over </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
200&#160;million lives in the United States and coverage continues to improve. As of January 2021, we have secured coverage for ZTlido on Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem BCBS, BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Formulary Coverage &#8212; Over 90% of Lives Covered or In Negotiation </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g42n54.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket.</span></span> With the copay assistance program, qualifying patients do not have to pay any copayment for their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_52">Clinical Development Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstrated bioequivalence to Lidoderm in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PK-002A;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <span style="white-space:nowrap">12-hour</span> administration period in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-001;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed superior adhesion to Lidoderm and Mylan&#8217;s generic lidocaine patch in studies <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-AHD-002</span></span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-003;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was not meaningfully impacted by heat or exercise in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-HEX-001;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was able to be used under showering and bathing conditions in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-004;</span></span></span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">did not show clinically meaningful dermal irritation in study <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-DERM-001.</span></span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Study Details </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Bioequivalence Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PK-002A</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose pharmacokinetic (&#8220;PK&#8221;) study between ZTlido and Lidoderm designed as a <span style="white-space:nowrap">two-way</span> cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#8217;s analgesic effects for ZTlido&#8217;s approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Mean Lidocaine Plasma Concentration Time Profiles &#8212; Semilog Scale </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g47j55.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Adhesion Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-001</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the <span style="white-space:nowrap">12-hour</span> administration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the <span style="white-space:nowrap">12-hour</span> administration period, over 90% of the subjects (49&#160;out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Maintained Greater Than 90% Adhesion Over the <span style="white-space:nowrap">12-Hour</span> Time Period </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g47l56.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the product label. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Head-to-Head</span></span> Adhesion Study versus Lidoderm</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-002</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a <span style="white-space:nowrap">12-hour</span> administration period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the <span style="white-space:nowrap">12-hour</span> administration period, while Lidoderm fell below 90% mean adhesion within three hours. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g45m57.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Head-to-Head</span></span> Adhesion Study versus Mylan&#8217;s Generic</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-003</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, <span style="white-space:nowrap">two-period,</span> single-application adhesion performance study in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a <span style="white-space:nowrap">12-hour</span> administration period. The purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a <span style="white-space:nowrap">non-aqueous</span> formulation. We selected Mylan&#8217;s generic lidocaine patch as a comparator because it has similar product characteristics, including a <span style="white-space:nowrap">non-aqueous</span> polymer <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> system allowing for a thinner patch and a lower drug load as compared to Lidoderm. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance compared to Mylan&#8217;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the <span style="white-space:nowrap">12-hour</span> administration period, while the generic product had a mean adhesion score of only 80% immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Demonstrated Superior Adhesion Compared to Mylan&#8217;s Generic Lidocaine Patch </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g45v58.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PK and Adhesion Study under Exercise and Heat Conditions</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-HEX-001</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, randomized, three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal conditions, respectively. The three treatment periods were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment period, topical systems were applied to the <span style="white-space:nowrap">mid-lower</span> back and worn for 12 hours. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It was observed that heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance, either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under normal conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g43v59.jpg" alt="LOGO" />
 </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dermal Sensitization and Irritation Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-DERM-001</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test, intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and healthy subjects. We used a <span style="white-space:nowrap">7-point</span> scale where a score of 0 indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Photoallergy and Phototoxicity Studies &#8212; </span><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOT0-001</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-002</span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <span style="white-space:nowrap">6-week</span> randomized study, <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-001,</span></span> to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we observed that ZTlido was not photoallergenic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <span style="white-space:nowrap">4-day,</span> randomized study, <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-002,</span></span> to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Studies for ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Water Stress Study (Shower and Swimming) &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-004</span></span></span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (pharmacokinetics) of ZTlido when it is exposed to two separate water stress conditions of (1)&#160;showering (10 minutes) and (2)&#160;swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the <span style="white-space:nowrap">12-hour</span> administration period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investigator-Sponsored Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a Phase 3 pivotal study of <span style="white-space:nowrap">SP-102.</span> The Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (&#8220;CLEAR&#8221;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of <span style="white-space:nowrap">SP-102</span> to placebo. We announced final results from this study in March 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> has been evaluated in a number of preclinical studies and clinical trials as a potential treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Repeat injections of <span style="white-space:nowrap">SP-102</span> showed continued pain reduction with no unexpected adverse events based on preliminary results from the <span style="white-space:nowrap"><span style="white-space:nowrap">SP-102-03</span></span> study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> showed an extended local activity with epidural administration in the <span style="white-space:nowrap">ES-1504</span> study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> showed an extended residence time and tolerability in the 1014-1512 and the 1014-2847, preclinical studies; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The introduction of <span style="white-space:nowrap">SP-102</span> into blood vessels did not result in neurological complications in the UPD003-IS21 preclinical toxicology study. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) Study Details Phase 3 Pivotal Clinical Trial &#8212; CLEAR </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study includes an open-label extension where subjects will be followed for up to 24 weeks after treatment to evaluate the safety of administering <span style="white-space:nowrap">SP-102</span> in a larger patient population. After week 4, subjects who met certain pain criteria received open-label <span style="white-space:nowrap">SP-102</span> to investigate the safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of <span style="white-space:nowrap">SP-102.</span> The schematic of this Phase 3 trial is demonstrated in the flowchart below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic effect of <span style="white-space:nowrap">SP-102</span> on average leg pain, measured using the Numeric Pain Rating Scale (&#8220;NPRS&#8221;) following a single transforaminal injection. These results were compared to an intra-muscular injection of placebo over a four-week period. The secondary objectives of this study include (i)&#160;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&#160;characterization of the change of the subject&#8217;s radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&#160;evaluation of the safety of a single and repeat <span style="white-space:nowrap">SP-102</span> injections. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Schematic of CLEAR &#8212; <span style="white-space:nowrap">SP-102</span> (SEMDEXA) Phase 3 Pivotal Trial </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g64p61.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022. The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of <span style="white-space:nowrap">-1.08</span> (0.17) compared to placebo with a <span style="white-space:nowrap">p-value</span> less than 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The two key secondary endpoints assessing Oswestry Disability Index (&#8220;ODI&#8221;) and Time to open-label repeat injection have been demonstrated for <span style="white-space:nowrap">SP-102.</span> The LS Mean (SE) group difference in ODI compared to placebo at week 4 was <span style="white-space:nowrap">-6.28</span> (1.49) with a <span style="white-space:nowrap">p-value</span> less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial <span style="white-space:nowrap">SP-102</span> (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI) 0.49 (0.36, 0.65), with a <span style="white-space:nowrap">p-value</span> less than 0.001. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 2 Repeat Dose Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap">SP-102-03</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <span style="white-space:nowrap">single-arm,</span> pharmacodynamics (&#8220;PD&#8221;) and safety study of repeat epidural injections of <span style="white-space:nowrap">SP-102</span> in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat <span style="white-space:nowrap">SP-102</span> epidural injections 4 to 8 weeks after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the <span style="white-space:nowrap">28-day</span> observation period for both treatments. Based on a preliminary review of the results, <span style="white-space:nowrap">SP-102</span> injections were generally well-tolerated and there were no new unexpected adverse events observed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g374624g42x62.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1 Trial of <span style="white-space:nowrap">SP-102</span> (SEMDEXA) Compared to Reference Listed Drug </span>&#8212; <span style="white-space:nowrap">ES-1504</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <span style="white-space:nowrap">single-arm,</span> <span style="white-space:nowrap">two-period,</span> fixed sequential-dose study to evaluate the PK, PD and safety of <span style="white-space:nowrap">SP-102</span> when administered by epidural injection. <span style="white-space:nowrap">SP-102</span> was compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received <span style="white-space:nowrap">SP-102</span> followed by the intravenous dexamethasone sodium phosphate injection (Reference Listed Drug) administered one month later. A Reference Listed Drug is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of this study was to establish the pharmaceutical bridge between <span style="white-space:nowrap">SP-102</span> and the Reference Listed Drug. The Tmax observed with the administration of <span style="white-space:nowrap">SP-102</span> was four hours, compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and safety results of both products were similar, and <span style="white-space:nowrap">SP-102</span> did not prolong cortisol suppression time. <span style="white-space:nowrap">SP-102</span> also maintained analgesic effects throughout a <span style="white-space:nowrap">one-month</span> observation period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar, whether administered as <span style="white-space:nowrap">SP-102</span> or injected intravenously, with a mean AUCinf of 0.916 &#181;g*h/mL (observed with <span style="white-space:nowrap">SP-102)</span> compared to 0.943 &#181;g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a <span style="white-space:nowrap">16-fold</span> increase in the time to maximum serum concentration (&#8220;Tmax&#8221;) following epidural injection of <span style="white-space:nowrap">SP-102.</span> The median Tmax was 4.00 hours for <span style="white-space:nowrap">SP-102</span> compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the <span style="white-space:nowrap">one-month</span> observation period following a single epidural injection of <span style="white-space:nowrap">SP-102.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic exposure to dexamethasone following epidural injection of <span style="white-space:nowrap">SP-102</span> did not exceed the exposure following intravenous injection of the Reference Listed Drug. The PD effects, measured as white blood cell count, cortisol levels and glucose levels, as well as the safety profile, were similar between the two treatments. <span style="white-space:nowrap">SP-102</span> injections were generally well-tolerated and did not result in new unexpected side effects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Toxicology Studies</span> &#8212; Study Nos. 1014-1512 and 1014-2847 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two <span style="white-space:nowrap">non-rodent</span> animal species to assess <span style="white-space:nowrap">SP-102</span> administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended residence time of the viscous gel formulation of <span style="white-space:nowrap">SP-102</span> at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with administration of dexamethasone sodium phosphate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical Toxicology Study</span> &#8212; UPD003-IS21 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates.A2 mL (10 mg of dexamethasone) injection of <span style="white-space:nowrap">SP-102</span> was injected over <span style="white-space:nowrap">1-2</span> minutes into the vertebral artery of large animal species. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-</span> and post-dose angiography showed no remarkable changes and all animals survived for approximately 24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hydrodynamic Study</span> &#8212; <span style="white-space:nowrap">SP-PC002</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of <span style="white-space:nowrap">SP-102</span> in <span style="white-space:nowrap">non-rodent</span> animal species, which showed that epidural administration of <span style="white-space:nowrap">SP-102</span> demonstrated an increased local residence half-life and a decreased flow from the injection site. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intravascular Injection Study</span> &#8212; <span style="white-space:nowrap">SEM-005</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of <span style="white-space:nowrap">SP-102</span> into the vertebral artery of <span style="white-space:nowrap">non-rodent</span> animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of <span style="white-space:nowrap">SP-102</span> following a <span style="white-space:nowrap">24-hour</span> survival period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> is an investigational, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, <span style="white-space:nowrap">SP-103</span> will build on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. A Phase 1 study was completed that demonstrated bioequivalent pharmacokinetics between the administration of a single <span style="white-space:nowrap">SP-103</span> and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of SP-103 (i.e., 1, 2 or 3 patches) over a <span style="white-space:nowrap">12-hour</span> administration period. Adhesion performance was assessed and found to be comparable between <span style="white-space:nowrap">SP-103</span> and ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, we plan to evaluate <span style="white-space:nowrap">SP-103</span> in the following studies: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-103-02</span></span> is a Phase 2 study of <span style="white-space:nowrap">SP-103</span> in subjects with acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <span style="white-space:nowrap">two-period,</span> cross-over, multicenter study of <span style="white-space:nowrap">SP-103</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
versus placebo. The study is expected to consist of a <span style="white-space:nowrap">7-day</span> open-label <span style="white-space:nowrap">run-in</span> period where all subjects receive active treatment. Responders to treatment will then be randomized to receive blinded treatment of either <span style="white-space:nowrap">SP-103</span> or placebo. This study will inform on the pivotal Phase 3 study design to support market approval. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In addition to a pivotal Phase 3 program, we intend to perform a <span style="white-space:nowrap">3-day</span> PK study of <span style="white-space:nowrap">SP-103,</span> an adhesion performance study of <span style="white-space:nowrap">SP-103</span> and an investigational study to evaluate the effects of heat and exercise on the PK and adhesion of <span style="white-space:nowrap">SP-103</span> to support the NDA submission. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 trial of <span style="white-space:nowrap">SP-103</span> was initiated in the second quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been completed for <span style="white-space:nowrap">SP-104</span> at investigative sites in New Zealand: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-104-01</span></span> is a food effect and bridging pharmacokinetic study comparing <span style="white-space:nowrap">SP-104</span> to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment, randomized study to characterize the PK and safety and tolerability of <span style="white-space:nowrap">SP-104</span> under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The study also serves as a &#8220;pharmaceutical bridge&#8221; between <span style="white-space:nowrap">SP-104</span> and the commercial reference listed drug (the &#8220;RLD&#8221;) (Naltrexone HCI tablets, USP 50 mg) to support the eventual Section&#160;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for <span style="white-space:nowrap">SP-104</span> will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#8217;s findings of safety for the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficiacy of <span style="white-space:nowrap">SP-104</span> in the treatment of fibromyalgia. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-104-02</span></span> is a Phase 1 study of <span style="white-space:nowrap">SP-104</span> conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, <span style="white-space:nowrap">two-period,</span> <span style="white-space:nowrap">two-treatment</span> crossover study to evaluate the safety of <span style="white-space:nowrap">SP-104,</span> compared to immediate release naltrexone capsules. The primary purpose of the study is to test the hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over trial in healthy volunteers comparing <span style="white-space:nowrap">SP-104</span> (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#8220;compared drug&#8221;), there were no serious adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single injection of <span style="white-space:nowrap">SP-104,</span> there were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one treatment-related TEAE within 72 hours after first administration of <span style="white-space:nowrap">SP-104.</span> Notable AEs of special interest were nausea and headache within 72 hours after first administration of <span style="white-space:nowrap">SP-104.</span> <span style="white-space:nowrap">SP-104</span> administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least one AE within 72 hours after the first administration of <span style="white-space:nowrap">SP-140</span> when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of <span style="white-space:nowrap">SP-104</span> (n=9; 12 events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea <span style="white-space:nowrap">(SP-104:</span> n=0; the compared drug: n=3) and headache <span style="white-space:nowrap">(SP-104:</span> n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market applications. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#8220;adequate and well-controlled&#8221; study to establish the efficacy of <span style="white-space:nowrap">SP-104</span> in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of <span style="white-space:nowrap">SP-104</span> or as an additional Phase 3 study may be required. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_53">Medical Affairs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes <span style="white-space:nowrap">in-house</span> medical expertise, health economics and third-party payor support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. Medical Affairs team also develops lifecycle planning and works with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_54">Manufacturing and Supply Chain </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our Quality System, Standard Operating Procedures and contract manufacturing organizations (&#8220;CMOs&#8221;) comply with cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) in Japan. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. ZTlido is manufactured using premixing and <span style="white-space:nowrap">hot-melt</span> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement</span>&#8221; for additional information regarding the manufacturing and supply chain of ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics distribution provider, Cardinal Health 105, ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson, Cardinal Health 110 and AmerisourceBergen. Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&#160;31, 2019, 2020, and 2021, and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies in the second quarter of 2022. In April 2022, we discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a <span style="white-space:nowrap">pre-filled</span> glass syringe with a 2 mL deliverable volume. <span style="white-space:nowrap">SP-102</span> also contains sodium hyaluronate, which is a novel, biocompatible, viscosity-enhancing excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for <span style="white-space:nowrap">SP-102</span> from the manufacturer and supplier. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> is manufactured by a single-source manufacturer, which supports the clinical development, including the completed Phase 3 clinical trial of <span style="white-space:nowrap">SP-102.</span> In March 2022, we announced final results of the Phase 3 clinical trial, satisfying the primary efficacy and key secondary efficacy endpoints. The manufacturing process is proprietary and includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of <span style="white-space:nowrap">SP-102,</span> if approved. We plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#8220;Sanofi&#8221;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage Sanofi for commercial supply of dexamethasone sodium phosphate for <span style="white-space:nowrap">SP-102,</span> if approved. See the section of prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Genzyme Supply Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Lifecore Master Services Agreement</span>&#8221; for additional information regarding the manufacturing and supply of the proprietary excipient and contact manufacturing of <span style="white-space:nowrap">SP-102</span> product, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi, using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the <span style="white-space:nowrap">SP-103</span> manufacturing protocols in a supplemental new drug application. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-104,</span> a novel <span style="white-space:nowrap">low-dose,</span> naltrexone hydrochloride delayed release formulation for treating fibromyalgia. <span style="white-space:nowrap">SP-104</span> is 4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed release capsule product in clinical development, currently undergoing Phase 1 studies. It is manufactured by a contract manufacturer, Tulex, located in Cranbury, NJ. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_55">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily available capital, and established research and development organizations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <span style="white-space:nowrap">SP-103,</span> if approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm and generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc. Additionally, <span style="white-space:nowrap">SP-103,</span> if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of acute LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102,</span> if approved, has the potential to become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product for the treatment of sciatica. While there are currently no <span style="white-space:nowrap">FDA-approved</span> ESIs indicated for the treatment of sciatica, we are aware of certain <span style="white-space:nowrap">non-steroid</span> product candidates in development. <span style="white-space:nowrap">SP-102,</span> if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <span style="white-space:nowrap">off-label</span> and unapproved use of branded and generic injectable steroids. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain <span style="white-space:nowrap">non-opioid</span> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <span style="white-space:nowrap">SP-104,</span> will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <span style="white-space:nowrap">in-license</span> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido, <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> are likely to be their efficacy, durability, safety, price and the availability of reimbursement from government and other third-party payors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_56">Material Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Product Development Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu,&#8221; and together with Oishi, the &#8220;Developers&#8221;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and <span style="white-space:nowrap">SP-103</span> (the &#8220;Products&#8221;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&#160;source and provide the active pharmaceutical ingredient for the Products for manufacturing, (2)&#160;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&#160;conduct product development activities necessary to support the filing of applications for regulatory approvals for the Products and (4)&#160;conduct manufacturing <span style="white-space:nowrap">scale-up</span> activities and preclinical studies for the Products. We are responsible for, among other things, (a)&#160;conducting all pivotal human clinical trials for the Products, (b)&#160;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and (c)&#160;commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable, worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#8217; development obligations under the Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters after the commercial launch equals a negative amount (a &#8220;Net Loss&#8221;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with GAAP. Under the Product Development Agreement, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee to the Developers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will continue until October&#160;2, 2028, which is the 10th anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive <span style="white-space:nowrap">one-year</span> renewal periods unless we or the Developers terminate it upon <span style="white-space:nowrap">six-month</span> written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;our total net profits of the Products are equal to or less than five percent of our net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Additionally, we may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is commercially unreasonable to <span style="white-space:nowrap">re-file.</span> The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any breach of our respective representations, warranties or obligations under the Product Development Agreement, (2)&#160;any failure by either of us to comply with all applicable laws, or (3)&#160;our respective negligence or willful misconduct. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Commercial Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;16, 2017, Scilex Pharma entered into the Commercial Supply Agreement with Itochu and Oishi. Pursuant to the Itochu and Oishi Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido placebo samples, in each case subject to certain minimum order quantities. We are required to provide a <span style="white-space:nowrap">12-month</span> rolling purchase forecast of the estimated quantities of the Products in writing on a monthly basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the year ended December&#160;31, 2020, under the Itochu and Oishi Commercial Supply Agreement, we purchased inventory in the amount of $0.8&#160;million. During the year ended December&#160;31, 2021, we purchased inventory in the amount of approximately $5.7&#160;million. The significant increase in inventory purchased was largely due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement. Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&#160;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving written notice specifying the nature of the breach, or (2)&#160;in the event of any of the parties&#8217; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product Development Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Genzyme Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;17, 2015, through our wholly owned subsidiary, Semnur, we entered into the Genzyme Supply Agreement with Genzyme, an affiliate of Sanofi-Aventis U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial requirements for sodium hyaluronate in specified territories, including the United States and all countries of the European Union (&#8220;EU), exclusively from Genzyme. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial supply, the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January&#160;1, provided that in no case will the price be increased by more than 5% each year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Genzyme Supply Agreement provides for a five year exclusivity period in favor of us and will remain in effect until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity are met by us as set forth therein, and for additional <span style="white-space:nowrap">two-year</span> periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term. Either party may terminate the Genzyme Supply Agreement if (1)&#160;the other party is in material breach of the agreement and fails to cure within 30 days, or (2)&#160;if the development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January&#160;1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#8217; notice. We did not file for regulatory approval for SEMDEXA by January&#160;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#8217;s right terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&#160;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any material breach of our respective representations, warranties and obligations thereunder, or (2)&#160;our respective gross negligence or willful misconduct. In addition, we have agreed to indemnify Genzyme against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization of sodium hyaluronate by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Lifecore Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;27, 2017, through our wholly owned subsidiary, Semnur, we entered into the Lifecore Master Services Agreement. Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#8220;Lifecore Statement of Work&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties entered into a Lifecore Statement of Work on January&#160;27, 2017, pursuant to which Lifecore agreed to provide, among other things, (1)&#160;project management support, (2)&#160;development services, (3)&#160;clinical trial materials, and (4)&#160;stability studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was invoiced at the completion of each service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#8217;s development and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right, title or interest in our intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expires on December&#160;31, 2022, unless the parties negotiate and execute a renewal of the agreement. Either party may terminate the Lifecore Master Services Agreement (1)&#160;if the other party is in material breach of the agreement and fails to cure such breach within 30 days of written notice, subject to certain exceptions; or (2)&#160;immediately upon written notice to the other party if the other party (a)&#160;becomes insolvent, (b)&#160;ceases to function as a going concern, (c)&#160;is convicted of or pleads guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engages in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name. In addition, Lifecore may terminate the agreement if (i)&#160;we fail to pay past due invoices upon 30 days&#8217; written notice, or (ii)&#160;we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#8217;s written and approved acceptance criteria in its product specifications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendment thereto in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendment for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Semnur Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#8220;Semnur Merger Agreement&#8221;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#8220;Sigma Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub merged with and into Semnur (the &#8220;Semnur Merger&#8221;), with Semnur surviving as Legacy Scilex&#8217;s wholly owned subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital stock it owned to Legacy Scilex in exchange for one share of Legacy Scilex Common Stock (the &#8220;Contribution&#8221;). As a result of the Contribution, and prior to the consummation of the Semnur Merger, Scilex Pharma became a wholly owned subsidiary of Legacy Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#8217;s issued and outstanding capital stock. As a result of the Semnur Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of Legacy Scilex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Semnur Merger, Legacy Scilex issued to the holders of Semnur&#8217;s capital stock (the &#8220;Semnur Equityholders&#8221;) and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (i)&#160;a cash payment of approximately $15.0&#160;million, and (ii) $55.0&#160;million of shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#8220;Stock Consideration&#8221;). A portion of the cash consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#8217; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to Semnur Equityholders were placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and escrow have since been </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
released per the terms of the escrow agreement. The Semnur Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described below. Following the issuance of the Stock Consideration, Sorrento ownership in Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#8217;s issued and outstanding capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur Merger Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (ii)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (iii)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (iv)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. As of the date of this prospectus, none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Merger Agreement also provided that following the consummation of Legacy Scilex&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to Legacy Scilex of at least $40.0&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (i)&#160;the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger Agreement, and (ii)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with Legacy Scilex (as amended, the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the <span style="white-space:nowrap">60-day</span> period commencing the date that was the 18 month anniversary of the closing of the Semnur Merger (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $55.0&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the <span style="white-space:nowrap">30-day</span> trailing volume weighted average price of one share of Sorrento&#8217;s common stock as reported on Nasdaq as of the consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#8217; Representative on September&#160;28, 2020, on October&#160;9, 2020, Sorrento paid $55.0&#160;million in cash to the Semnur Equityholders in lieu of issuing $55.0&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the Semnur Merger Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Aardvark Asset Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;) with Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;), pursuant to which, among other things, Sorrento </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquired Aardvark&#8217;s Delayed Burst Release Low Dose Naltrexone <span style="white-space:nowrap">(DBR-LDN)</span> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <span style="white-space:nowrap">&#8220;SP-104</span> Assets&#8221;), which includes a Statement of Work dated November&#160;18, 2020 (the &#8220;Tulex Statement of Work&#8221;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104</span> for Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to <span style="white-space:nowrap">SP-104</span> and on May&#160;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <span style="white-space:nowrap">SP-104</span> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <span style="white-space:nowrap">&#8220;SP-104</span> Acquisition&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#8220;Promissory Note&#8221;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#8220;Consideration Shares&#8221;) or any combination thereof, at Legacy Scilex&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this prospectus none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <span style="white-space:nowrap">SP-104</span> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the board of directors of Aardvark. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the forms of these agreements for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tulex Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in connection with the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex acquired the Tulex Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplies of <span style="white-space:nowrap">SP-104</span> for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master services agreement (the &#8220;Tulex Master Services Agreement&#8221;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&#160;15, 2022 and will remain in effect until five years after the effective date, unless terminated early by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&#160;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2)&#160;in the event of the other party&#8217;s insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any Tulex Statement of Work (1)&#160;without cause upon 30 days prior written notice to Tulex or (2)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party under the Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&#160;such party&#8217;s breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&#160;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex Master Services Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Investor LP Assignment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;6, 2013, through Semnur, we entered into an Assignment Agreement with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who served on our board of directors from March 2019 to October 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned to us certain intellectual property related to pharmaceutical compositions of corticosteroids (the &#8220;Assigned IP&#8221;). As consideration for the Assigned IP, we agreed to pay a contingent quarterly royalty in the <span style="white-space:nowrap">low-single</span> digits to Shah Investor based on the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing the Assigned IP (a &#8220;Royalty Product&#8221;). We expect that SEMDEXA, if approved, will constitute a Royalty Product. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as a Royalty Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the first Royalty Product in the United States, whichever is longer. We also agreed to use commercially reasonable efforts to maximize the scope and coverage of the patents contained in the Assigned IP. As of the date of this prospectus, no royalty payments have been made as we have not yet commercialized any applicable products and therefore such payments have not been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assignment Agreement will remain in effect on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis until royalties are no longer due on any Royalty Product. Either party may terminate the Assignment Agreement upon sixty days&#8217; prior written notice, in the event the other party seeks to avoid a provision of the Assignment Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, unless such assertion is eliminated and the effect of such assertion cured within such sixty day period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Assignment Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Romeg License and Commercialization Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&#160;14, 2022, we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, Romeg granted to us (1)&#160;the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Romeg Agreement, among other things, Romeg granted us (1)&#160;a transferable license, with the right to sublicense, under the patents and <span style="white-space:nowrap">know-how</span> specified therein to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to <span style="white-space:nowrap">know-how</span> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <span style="white-space:nowrap">non-exclusive.</span> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&#160;1, 2027 and, thereafter, is <span style="white-space:nowrap">co-exclusive</span> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&#160;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the date of the Romeg Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1)&#160;an <span style="white-space:nowrap">up-front</span> payment of $2.0&#160;million, (2)&#160;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million and (3)&#160;certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1)&#160;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&#160;at any time, without cause, upon written notice to Romeg, which termination will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0&#160;million shall be paid to Romeg depending on when during the 10 year period following the date of the agreement any such termination notice set forth in the immediately preceding clause (2)&#160;has been provided. Romeg may terminate the Romeg Agreement (a)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we has made such payment in full or delivered such quarterly report within such 30 day period; (b)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; or (c)&#160;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg Agreement (1)&#160;in the event the other party materially breaches the agreement, unless the breaching party has cured any such breach within 60 days after any notice thereof was provided or (2)&#160;in the event the other party (a)&#160;files in any court or agency a petition in bankruptcy or insolvency, (b)&#160;is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c)&#160;makes an assignment of substantially all of its assets for the benefit of its creditors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the license. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_57">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <span style="white-space:nowrap">know-how,</span> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and <span style="white-space:nowrap">know-how</span> relating to our novel adhesion and delivery technology, platforms and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed <span style="white-space:nowrap">non-provisional</span> filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of November&#160;23, 2022 contains approximately sixteen issued and unexpired U.S. patents, six pending U.S. patent applications, and one pending Patent Cooperation Treaty (PCT) application. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada, China, Hong Kong, India, Indonesia, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Russian Federation, Singapore, South Africa, Taiwan, Ukraine, and certain countries within the European Patent Convention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and <span style="white-space:nowrap">SP-103,</span> our patents and patent applications cover compositions and methods of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With respect to <span style="white-space:nowrap">SP-104,</span> our pending Patent Cooperation Treaty application is WO 2022/076470 (and all patents and patent applications that claim priority rights thereto), which covers oral delayed burst formulations of <span style="white-space:nowrap">low-dose</span> naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have five issued U.S. patents and two pending U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640 and 11,278,623 all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and 10,383,821, which relate to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No.&#160;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we have certain <span style="white-space:nowrap">know-how</span> and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trademarks, Trade Secrets and Other Proprietary Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for the marks &#8220;SCILEX,&#8221; &#8220;ZTlido&#8221; and &#8220;RESPONSIBLE BY DESIGN.&#8221; We also own pending trademark applications for &#8220;SEMNUR PHARMACEUTICALS&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also license the GLOPERBA trademark as discussed in relation to the Romeg Agreement described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <span style="white-space:nowrap">know-how,</span> we rely on trade secret protection and confidentiality agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#8217;s relationship with us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and <span style="white-space:nowrap">know-how</span> for sterile viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_58">Government Regulation and Product Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are marketing and developing. <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103,</span> <span style="white-space:nowrap">SP-104</span> and any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Drug Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such as inspection scrutiny, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (&#8220;GLPs&#8221;) or other applicable regulations; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an IRB covering each clinical site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials according to the laws and regulations pertaining to the conduct of human clinical trials, collectively referred to as GCP requirements to establish the safety and efficacy of the proposed drug for its intended use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an NDA or other marketing application (collectively, an &#8220;NDA&#8221;), for a proposed new drug, including its specific formulation and labeling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA advisory committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#8217;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that <span style="white-space:nowrap">30-day</span> time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, <span style="white-space:nowrap">non-compliance,</span> or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#8217;s regulations and GCP requirements. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 1</span></span>. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 2</span></span>. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 3</span></span>. The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3 trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase 1, Phase 2 and Phase 3 clinical trials may not yield positive results, or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to study subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the Phase 3 clinical trials that they believe will support approval of the new drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Review and Approval Processes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the manufacturing process and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, original NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a REMS is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <span style="white-space:nowrap">pre-use</span> submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With passage of the 21st Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained fast track designation for SEMDEXA for the treatment of lumbosacral radicular pain and have applied for breakthrough therapy designation for the treatment of lumbosacral radicular pain based on the <span style="white-space:nowrap">top-line</span> results obtained from the pivotal Phase 3 trial, which results reflect achievement of primary and secondary endpoints. We have also obtained fast track designation for <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. We may seek additional designations for SEMDEXA, <span style="white-space:nowrap">SP-103</span> or our other product candidates. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#8217;s approved labeling, which is known as <span style="white-space:nowrap">&#8220;off-label</span> use,&#8221; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for <span style="white-space:nowrap">off-label</span> uses, manufacturers may not market or promote such <span style="white-space:nowrap">off-label</span> uses. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Hatch-Waxman Amendments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product, but some of the data are not owned by or licensed to the applicant. Section&#160;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application (&#8220;ANDA&#8221;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be substituted by pharmacists under prescriptions written for the branded reference drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&#160;no patent information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the Paragraph IV Certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <span style="white-space:nowrap">30-month</span> stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s or patent owner&#8217;s decision to initiate patent litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation that required the new clinical data, but generally allows the approval for <span style="white-space:nowrap">non-protected</span> characteristics and labeling. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA for the drug for the rare disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication not protected by the exclusive approval, but that could be used <span style="white-space:nowrap">off-label</span> in the orphan indication. The FDA also has authority to withdraw exclusive marketing rights if the holder of an approved orphan drug cannot assure the availability of sufficient quantities of the drug within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated. Once withdrawn under such circumstances, exclusive approval may not be reinstated for that drug. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-Party Payor Coverage, Pricing and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the <span style="white-space:nowrap">FDA-approved</span> products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order to be considered as a formulary option. Nonetheless, product candidates may not be considered by individual payors to be medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (&#8220;EEA&#8221;) (which is currently comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some EEA countries operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <span style="white-space:nowrap">low-priced</span> markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was enacted, which is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things, (1)&#160;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for <span style="white-space:nowrap">follow-on</span> biologic products, (2)&#160;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (4)&#160;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, (5)&#160;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, (6)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (7)&#160;expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research, and (9)&#160;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and Administrative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The TCJA included a provision that repealed, effective January&#160;1, 2019, the <span style="white-space:nowrap">tax-based</span> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Further, the Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;), among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50% to 70% the <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. On June&#160;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the <span style="white-space:nowrap">COVID-19</span> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <span style="white-space:nowrap">COVID-19</span> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, these include proposed measures to permit Medicare to negotiate the price of certain drugs, to establish rebates under Medicare Part B and Part D where the average sales price or the average manufacturer price of a drug respectively increases faster than the pace of inflation and to eliminate the existing manufacturer coverage gap discount program under Part D and replace it </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with a new program that would require manufacturer discounts in both the initial and catastrophic phases of the program. On May&#160;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#8217;s prescription drug benefit. Similarly, since 2021, Part D Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; <span style="white-space:nowrap"><span style="white-space:nowrap">annual&#160;out-of-pocket&#160;drug</span></span> expenses at $2,000. The second provision imposes a requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to limit price increases. The new rebate applies to drugs covered by Medicare under Part B or Part D. The rebate obligation applies if the average sales price (for Part B) or average manufacturers price (for Part D) of a single source drug or biologic increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is subject to a penalty of 125% of the original rebate amount. The provision for Part D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part B takes effect in 2023. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other U.S. Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (<span style="font-style:italic">e.g.</span>, the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us. Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#8220;remuneration&#8221; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of <span style="white-space:nowrap">off-label</span> uses (<span style="font-style:italic">i.e.</span>, uses not expressly approved by the FDA in a drug&#8217;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under the HIPAA impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities may be limited by, data privacy and security regulation by both the federal government and the states in which we conduct our business. For example, HIPAA and its implementing regulations, impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses), and their respective business associates, certain individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a specified service or performing a function for or on behalf of a covered entity. The FTC also sets expectations that failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to an individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&#160;5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#8217; personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. Further, various states have implemented similar privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. California has also recently adopted the CCPA. The CCPA established a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches of certain personal information. Penalties for violations of the CCPA include civil penalties. In addition, a new California privacy law, CPRA, was passed by California votes on November&#160;3, 2020, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the CPPA. The amendments introduced by the CPRA are scheduled to take effect on January&#160;1, 2023 (with certain provisions having retroactive effect to January&#160;1, 2022). Further, a new Virginia privacy law, the VCDPA, was signed into law on March 2, 2021 and is also scheduled to take effect on January&#160;1, 2023, and the Colorado Privacy Act (&#8220;CPA&#8221;) will take effect on July&#160;1, 2023. The VCDPA and CPA will impose many similar obligations regarding the processing and storing of personal information as the CCPA and the CPRA. Other states in the United States are considering omnibus privacy legislation, and industry organizations regularly adopt and advocate for new standards in these areas. The uncertainty, ambiguity, complexity and potential inconsistency surrounding the implementation and interpretation of CCPA and other enacted or potential laws in other states exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the event of <span style="white-space:nowrap">non-compliance</span> with such laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for <span style="white-space:nowrap">non-compliance.</span> The European Union&#8217;s GDPR which imposes fines of up to EUR 20&#160;million or 4% of the annual global revenue of a noncompliant company, whichever is greater, and other data protection, privacy and similar national, state/ provincial and local laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused by such breaches. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&#160;1, 2022, these reporting obligations are extended to include transfers of value made to certain <span style="white-space:nowrap">non-physician</span> providers such as physician assistants and nurse practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign government officials, they may also potentially be subject to the FCPA. If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Many of our current as well as possible future activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at <span style="text-decoration:underline">www.ClinicalTrials.gov</span>. We are subject to various environmental, health and safety regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <span style="white-space:nowrap">pre-marketing</span> product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hatch-Waxman Exclusivity</span>. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#8217;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of <span style="white-space:nowrap">non-patent</span> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section&#160;505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or <span style="white-space:nowrap">non-infringement</span> to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Exclusivity</span>. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This <span style="white-space:nowrap">six-month</span> exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe/Rest of World Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#8220;CTA&#8221;) must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#8220;Clinical Trials Directive&#8221;) and the related national implementing provisions of the relevant individual EEA country&#8217;s requirements, the clinical trial described in that CTA may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#8220;Clinical Trials Regulation&#8221;) was adopted. The Clincial Trials Regulation entered into force on January&#160;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the current Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to start and conduct a clinical trial in accordance with the Clinical Trials </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directive during a transitional period of one year after the application date, i.e. January&#160;31, 2022. The transition period for the trials ongoing at the moment of applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&#160;31, 2023 can continue to be conducted under the Clinical Trials Directive until January&#160;31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided into two parts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EEA, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can be commercialized only after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis. There is a &#8220;centralized&#8221; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#8220;EMA&#8221;). If the EMA issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#8220;centralized&#8221; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#8220;centralized&#8221; procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#8220;decentralized&#8221; procedure allowing companies to file identical applications to several EEA countries simultaneously for product candidates that have not yet been authorized in any EEA country and a &#8220;mutual recognition&#8221; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities in other EEA countries. Under the &#8220;decentralized&#8221; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January&#160;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in the EEA could be negatively affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (&#8220;SmPC&#8221;), as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <span style="white-space:nowrap">off-label</span> and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited by, data privacy and security regulations in the EEA where the legislative and regulatory landscape continues to evolve. There has been increased attention to privacy and data security issues that could potentially affect our business, including the GDPR which imposes strict obligations on the processing of personal data, including relating to the transfer of personal data from the EEA to third countries such as the United States. If we act in violation of the GDPR we may face significant penalties of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain violations, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious violations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data privacy and security regulations, including the GDPR, generally restrict the transfer of personal data from Europe, including the EEA, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards allowing U.S. companies to import personal data from Europe had been certification to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#8220;CJEU&#8221;) in a case known colloquially as &#8220;Schrems II.&#8221; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#8220;FDPIC&#8221;) announced that the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to the United States. While the FDPIC does not have authority to invalidate the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield regime, the FDPIC&#8217;s announcement casts doubt on the viability of the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield as a future compliance mechanism for <span style="white-space:nowrap">Swiss-U.S.</span> data transfers. The CJEU&#8217;s decision in Schrems II also raised questions about whether one of the primary alternatives to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in Schrems </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
II, it made clear that reliance on those Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in Schrems II and subsequent draft guidance from the European Data Protection Board (the &#8220;EDPB&#8221;) would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a compliant &#8220;transfer mechanism.&#8221; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that no combination of such measures could be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8220;in the clear&#8221; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8220;necessary and proportionate in a democratic society&#8221; &#8212; which may, following the CJEU&#8217;s conclusions in Schrems II on relevant powers of United States public authorities and commentary in that draft EDPB guidance, include the United States in certain circumstances (e.g., where Section&#160;702 of the US Foreign Intelligence Surveillance Act applies). At present, there are few, if any, viable alternatives to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and the Standard Contractual Clauses. However, the CJEU recently invalidated the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield. The decision in Schrems II also affects transfers from the United Kingdom to the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, if we are unable to implement a valid solution for personal data transfers from Europe, including, for example, obtaining individuals&#8217; explicit consent to transfer their personal data from Europe to the United States or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from Europe. Inability to import personal data from Europe may also restrict our clinical trials activities in Europe; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to European data privacy and security laws; and require us to increase our data processing capabilities in Europe at significant expense. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The types of challenges we face in Europe will likely also arise in other jurisdictions that adopt laws similar in construction to the GDPR or regulatory frameworks of equivalent complexity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_59">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, we had approximately 85 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our workforce, six employees were primarily engaged in research and development, 70 were primarily engaged in sales and marketing and nine were primarily engaged in general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve our human capital management strategies and find ways to foster engagement and growth within our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly benchmark total rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equity and cash incentive plans are to attract, retain and reward selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#8217; lives. The success of our business is fundamentally connected to the well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the <span style="white-space:nowrap">COVID-19</span> outbreak, which included implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_60">Facilities and Properties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 6,000 square feet of leased office space. The lease term expires in October 2024. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_61">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, we filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#8220;Sanofi-Aventis&#160;&amp; Hisamitsu Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. We cannot make any predictions about the outcome in this matter or the timing thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Former Employee Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, we filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his <span style="white-space:nowrap">non-compete</span> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <span style="white-space:nowrap">non-compete</span> agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his <span style="white-space:nowrap">non-compete</span> agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#8217;s <span style="white-space:nowrap">non-compete</span> agreement. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. Post-trial briefing is underway and closing arguments remain to be concluded. We cannot make any predictions about the outcome in this matter or the timing thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Patent Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;Aveva Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a <span style="white-space:nowrap">30-month</span> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. We cannot make any predictions about the final outcome of this matter or the timing thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_62">Our Corporate History </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&#160;18, 2019, Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#8220;Contribution&#8221;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5&#160;million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#8217;s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes (as amended, the &#8220;Semnur Merger Agreement&#8221;). Pursuant to the Semnur Merger Agreement, Sigma Merger Sub, Inc. merged with and into Semnur (such transaction, the &#8220;Semnur Merger&#8221;), with Semnur surviving the Semnur Merger as Legacy Scilex&#8217;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex Pharma and Semnur became Legacy Scilex&#8217;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June 2013. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_63">Website </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is <span style="font-style:italic">www.scilexholding.com</span>. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_64">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_65">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of November&#160;30, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:30%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:60%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Officers</span>:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">62</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">58</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Executive Chairperson and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth A. Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">67</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors</span>:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">59</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">58</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.<sup style="font-size:75%; vertical-align:top">(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">48</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">60</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">81</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the compensation committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jaisim Shah. </span></span>Mr.&#160;Shah has served as our Chief Executive Officer and President and a member of our Board since November&#160;10, 2022. Mr.&#160;Shah has also served as Legacy Scilex&#8217;s President, Chief Executive Officer and a board member since March 2019. He has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as the Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Scilex in March 2019. Mr.&#160;Shah has served on the board of directors of Scilex Pharma since November 2016. Prior to Semnur, Mr.&#160;Shah was a consultant to several businesses, including Sorrento Therapeutics, Inc., a publicly traded company, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&#160;Shah led a successful sale of Elevation to Sunovion Pharmaceuticals Inc. in September 2012. Prior to Elevation, Mr.&#160;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to Zelos, Mr.&#160;Shah was the Senior Vice President and Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&#160;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic transactions with pharmaceutical and biotech companies. Prior to PDL, Mr.&#160;Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the &#8220;President&#8217;s Award&#8221; for completing one of the most significant collaborations in the company&#8217;s history. Previously, Mr.&#160;Shah was at F. <span style="white-space:nowrap">Hoffman-La</span> Roche AG in international marketing and was global business leader for corporate alliances with Genentech, Inc. and IDEC Corporation. Mr.&#160;Shah previously served as a director of Celularity Inc. from June 2017 to July 2021. He has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since September 2013. Mr.&#160;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&#160;Shah&#8217;s extensive operational, executive and business development experience qualifies him to serve on our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Henry Ji, Ph.D. </span></span>Dr.&#160;Ji has served as our Executive Chairperson and a member of our Board since November&#160;10, 2022. Prior to that, he served as Legacy Scilex&#8217;s Executive Chairperson and a board member from March 2019 to November 2022. Dr.&#160;Ji has served on the board of directors of Scilex Pharma since November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016 to March 2019. He <span style="white-space:nowrap">co-founded</span> and has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since January 2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief Executive Officer and President since September 2012 and as Chairman of its board of directors since August 2017. In 2002, Dr.&#160;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr.&#160;Ji served as Vice President of CombiMatrix Corporation, a publicly-traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr.&#160;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr.&#160;Ji served as Director of Business Development, and in 2001 as Vice President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr.&#160;Ji <span style="white-space:nowrap">co-founded</span> Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr.&#160;Ji previously served as a director of Celularity Inc. from June 2017 to July 2021. Dr.&#160;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Dr.&#160;Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&#160;Ji has demonstrated significant leadership skills as President and Chief Executive Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on the Scilex Board. We believe that Dr.&#160;Ji&#8217;s extensive knowledge of the industry in which we operate allows him to bring to our Board a broad understanding of the operational and strategic issues we face. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Elizabeth A. Czerepak</span></span>. Ms.&#160;Czerepak has served as our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary since November&#160;10, 2022. Prior to that, she served on the Legacy Scilex Board from September 2019 to October 2020 and on the board of directors of Sorrento from October 2021 to May 2022. Ms.&#160;Czerepak has over 35 years of experience in big pharma, biotechnology and venture capital. Since September 2020, she has served as the Chief Financial Officer of BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. From May 2018 to January 2020, Ms.&#160;Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a technology-focused lipid nanoparticle delivery company, From 2015 to 2018 she served as the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015, she served as the Chief Financial Officer and the Chief Business Officer of Isarna Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014, Ms.&#160;Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a Managing Director at JPMorgan Chase&#160;&amp; Co. and Bear, Stearns&#160;&amp; Co., a General Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63). Since February 2020, Ms.&#160;Czerepak has served as a director and chair of the audit committee of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms.&#160;Czerepak previously served on the board of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. She holds a B.A. magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020, Ms.&#160;Czerepak earned a Corporate Director Certificate from Harvard Business School. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dorman Followwill</span></span>. Mr.&#160;Followwill has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento since October 2017 and as its lead independent director since August 2020. Mr.&#160;Followwill was Senior Partner of Transformational Health at Frost&#160;&amp; Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, from 2016 to September 2020. Prior to that time, he served in various roles at Frost&#160;&amp; Sullivan, including Partner on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost&#160;&amp; Sullivan to help found the Consulting practice in January 1988. Mr.&#160;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&#160;Followwill&#8217;s extensive knowledge and understanding of the healthcare and life sciences industries qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Laura J. Hamill. </span></span>Ms.&#160;Hamill has served as a member of our Board since November&#160;10, 2022. Prior to that, she served as a director of Legacy Scilex from April 2022 to November 2022 and has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial operational roles in a variety of executive leadership positions. Since <span style="white-space:nowrap">mid-2019,</span> Ms.&#160;Hamill has served as the founder and a consultant at Hamill Advisory Group, LLC. From September 2018 to July 2019, Ms.&#160;Hamill served as the Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a research-based biopharmaceutical company, where she was responsible for leading the company&#8217;s global commercial strategic direction and delivering annual revenue of $20&#160;billion. Prior to joining Gilead, Ms.&#160;Hamill held a number of U.S. and international executive positions at Amgen Corporation, a biotechnology company focused on discovering and delivering innovative human therapeutics, from July 2000 to August 2018, most recently as Senior Vice President, U.S. Commercial Operations. During her time at Amgen, Ms.&#160;Hamill established the company&#8217;s intercontinental region and managed the company&#8217;s international marketing and business operations while living abroad in Switzerland for three years. She also served as a member of the company&#8217;s corporate governance team, such as business development, global commercial operations, the Amgen foundation and chair for the company&#8217;s Senior Women&#8217;s Leadership Council. In addition, Ms.&#160;Hamill previously held a variety of executive roles in the biopharmaceutical industry, including positions at Klemtner Inc. and F. <span style="white-space:nowrap">Hoffmann-La</span> Roche AG. Ms.&#160;Hamill has served on the board of directors of a number of public companies, including AnaptysBio, Inc. since September 2019, <span style="white-space:nowrap">Y-mAbs</span> Therapeutics, Inc. since April 2020, Pardes Biosciences, Inc. since August 2021 and BB Biotech AG since March 2022. She previously served as a director at Acceleron Pharma Inc. (acquired by Merck) from September 2020 to December 2021. Ms.&#160;Hamill holds a B.A. in business administration from the University of Arizona. We believe that Ms.&#160;Hamill is qualified to serve on our Board because of her extensive leadership experience in the biopharmaceutical industry and her global commercial operations and strategic planning expertise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D. </span></span>Dr.&#160;Lee has served as a member of our Board since November&#160;10, 2022. Prior to that, Dr.&#160;Lee had served as a director of Legacy Scilex from March 2019 to November 2022 and as a director of Scilex Pharma since November 2018. Dr.&#160;Lee has over 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. He is the founder and has served as the Chief Executive Officer of Aardvark Therapeutics, Inc. since March 2017. Prior to that, Dr.&#160;Lee joined NantKwest, Inc., a publicly-traded immunotherapy company in 2014 and served as its Chief Strategy Officer until March 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and infectious disease indications. Dr.&#160;Lee is also an inventor or <span style="white-space:nowrap">co-inventor</span> of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc., Sorrento and Aardvark Therapeutics, Inc. Dr.&#160;Lee earned his M.D. degree from the University of California, San Diego and his B.A. degree from the University of California, Berkeley in Molecular Biology. We believe that Dr.&#160;Lee is qualified to serve on our Board because of his experience in management roles at life sciences companies and extensive academic and professional background in the field of biotechnology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">David Lemus. </span></span>Mr. Lemus has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022 and as a director of Sorrento since October 2017. Mr. Lemus has served as Chief Executive Officer of IronShore Pharmaceuticals Inc. since January 2020 as well as the founder and Chief Executive Officer of LEMAX LLC since 2017. He also currently serves as a <span style="white-space:nowrap">non-executive</span> board member of Silence Therapeutics, plc and BioHealth Innovation, Inc. and served previously on several other boards of public and private companies as a <span style="white-space:nowrap">non-executive</span> director. He served from November 2017 to September 2018 as the Chief Operating Officer and Chief Financial Officer of Proteros biosciences GmbH. Previously, from January 2016 to May 2017, he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG. Prior to that time, at Sigma Tau Pharmaceuticals, Inc., he served as Chief Executive Officer from January 2013 to July 2015, as Chief Operating Officer from March 2012 to December 2012, and as V.P. Finance from July 2011 to February 2012. Mr. Lemus previously served as Chief Financial Officer and Executive V.P. of MorphoSys AG from January 1998 to May 2011. Prior to his role at MorphoSys AG, he held various positions, including Operations Manager and Controller (Pharma International Division) and Global IT Project Manager (Pharma Division) at F. <span style="white-space:nowrap">Hoffmann-La</span> Roche AG, Group Treasurer of Lindt &amp; Spruengli AG and Treasury Consultant for Electrolux AB. Mr. Lemus received a M.S. from the Massachusetts Institute of Technology Sloan School of Management in 1988 and a B.S. in Accounting from the University of Maryland in 1984. Mr.&#160;Lemus is also a certified public accountant licensed in the State of Maryland. We believe that Mr.&#160;Lemus&#8217; extensive accounting and financial background and business experience in the life sciences industry qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Tommy Thompson. </span></span>Mr.&#160;Thompson has served as a member of our Board since November&#160;10, 2022. Prior to that, Mr.&#160;Thompson served on the Legacy Scilex Board from July 2022 to November 2022. Mr.&#160;Thompson currently serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. From July 2020 to March 2022, Mr.&#160;Thompson served as University of Wisconsin System President. From 2005 to 2012, Mr.&#160;Thompson was a partner in the law firm of Akin Gump Strauss Hauer&#160;&amp; Feld LLP in Washington, D.C, and as an Adjunct Senior Advisor from 2017 to 2020. February 2005 to January 2011, Mr.&#160;Thompson served as President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions. Prior to entering the private sector in 2005, Mr.&#160;Thompson enjoyed a long and distinguished career in public service. From February 2001 to January 2005, Mr.&#160;Thompson served as the former Secretary of the U.S. Department of Health&#160;&amp; Human Services, where he served as the nation&#8217;s leading advocate for the health and welfare of all Americans. Prior to that, Mr.&#160;Thompson served four terms as Governor of Wisconsin from January 1987 to February 2001, where he was best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding health care access across all segments of society. Mr.&#160;Thompson currently serves as Chairman of the board of directors of Physicians Realty Trust (NYSE: DOC) and of TherapeuticsMD, Inc. and also serves as a member of the board of directors of United Therapeutics Corporation (Nasdaq: UTHR). He previously served on the boards of directors of various other companies, including Logistics Health, Inc. Health Solutions, a health care consulting company, C. R. Bard, Inc. (NYSE: BCR), Centene Corporation (NYSE: CNC), Plus Therapeutics, Inc. (formerly Cytori Therapeutics, Inc.) (Nasdaq: PSTV), CareView Communications, Inc. (OTCQB: CRVW), Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) (Nasdaq: VYNT), and Pure Bioscience, Inc. (Nasdaq: PURE). Mr.&#160;Thompson received both his B.S. and J.D. from the University of Wisconsin-Madison. We believe that Mr.&#160;Thompson is qualified to serve on our Board because of his experience in public service, particularly his services and knowledge related to the health care industry as a whole, and extensive board experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_66">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_67">Board Composition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of seven members. Dr.&#160;Ji serves as Executive Chairperson of our Board. The primary responsibilities of our Board are to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <span style="font-style:italic">ad hoc </span>basis as required. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Certificate of Incorporation and the Bylaws, our Board is divided into three classes with staggered three-year terms, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;I directors are Dorman Followwill, David Lemus, and Tommy Thompson, and their term will expire at the annual meeting of stockholders to be held in 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;II directors are <span style="white-space:nowrap">Tien-Li</span> Lee, M.D. and Laura J. Hamill and their term will expire at the annual meeting of stockholders to be held in 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;III directors are Henry Ji, Ph.D. and Jaisim Shah and their term will expire at the annual meeting of stockholders to be held in 2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board will be determined exclusively by our Board; <span style="font-style:italic">provided </span>that, at any time the Sorrento Group beneficially owns, in the aggregate, at least 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, the stockholders may also fix the number of directors by resolutions adopted by the stockholders. Any increase or decrease in the number of directors will be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of <span style="white-space:nowrap">one-third</span> of the directors. No decrease in the number of directors constituting our Board will shorten the term of any incumbent director. Our directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of such directors; <span style="font-style:italic">provided, however</span>, that, from and after the Sorrento Trigger Event any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the Certificate of Incorporation and subject to the rights of the holders of any series of our preferred stock (including pursuant to the Stockholder Agreement), any vacancy on our Board may be filled by our Board or our stockholders; <span style="font-style:italic">provided, however</span>, that from and after the Sorrento Trigger Event, any such vacancy shall be filled only by our Board and not by our stockholders. Any director elected in accordance with the preceding sentence shall hold office until the annual meeting of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#8217;s earlier death, resignation, retirement, removal or disqualification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_68">Controlled Company Exemption </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power for the election of directors. As a result, We are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance standards, including, but not limited to, the requirements (i)&#160;that a majority of its board of directors consist of independent directors, (ii)&#160;that its board of directors have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;that director nominees must be selected or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or a nominating and corporate governance committee comprised solely of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. If we cease to be a &#8220;controlled company&#8221; and our shares of Common Stock continue to be listed on Nasdaq, we will be required to comply with these standards and, depending on our Board&#8217;s independence determination with respect to its then-current directors, we may be required to add additional directors to our Board in order to achieve such compliance within the applicable transition periods. See the section titled &#8220;<span style="font-style:italic">Risk Factors &#8212; We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_69">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#8217;s criteria for &#8220;independence.&#8221; As a &#8220;controlled company&#8221;, we are largely exempted from such requirements. Our Board has determined that each of the directors on our Board, other than Dr.&#160;Ji and Mr.&#160;Shah (as a result of their positions as our Executive Chairperson and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules and our Board consists of a majority of &#8220;independent directors&#8221; as defined under the rules of the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_70">Role of Board in Risk Oversight Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into its corporate strategy and <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> business operations. Management discusses strategic and operational (including cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing the Company. Throughout the year, senior management reviews these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#8217;s risk oversight process builds upon management&#8217;s risk assessment and mitigation processes, which include reviews of long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic and reputational risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_71">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of our Board. Our Board is chaired by Dr.&#160;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#8217;s performance and enhances the effectiveness of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to periodically review its leadership structure and may make such changes in the future as it deems appropriate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_72">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#8217;s qualifications, our Board assesses whether a candidate possesses the integrity, judgment, knowledge, experience, skills and expertise that are likely to enhance our ability, as well as the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly-held company; and experience as a board member or executive officer of another publicly-held company. In addition, our Board may consider diversity in identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_73">Committees of our Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has an audit committee, compensation committee and nominating and corporate governance committee. Our Board has adopted a new charter for each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. Copies of the charters for each committee are available on the investor relations portion of our website. The composition and responsibilities of each of the committees of our Board are as set forth below. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee consists of David Lemus, Laura J. Hamill and Dorman Followwill, with David Lemus serving as the chairperson of the committee. Each of the members of the audit committee satisfies the independence requirements under the applicable Nasdaq Listing Rules and SEC rules. Each member of the audit committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the audit committee are included in a written charter. The audit committee assists our Board in fulfilling our Board&#8217;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this purpose, the audit committee performs several functions. The audit committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for the Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between the Company, or persons in financial oversight roles with the Company, and such independent registered public accounting firm or their affiliates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving engagements of the independent registered public accounting firm, prior to commencement of the engagement, and the scope of and plans for the audit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management and the independent registered public accounting firm any fraud that includes management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the results of management&#8217;s efforts to monitor compliance with our programs and policies designed to ensure compliance with laws and rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing our programs, policies and procedures related to our information technology systems, including information asset security and data protection; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm&#8217;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the audit committee by the independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#8217;s review of our quarterly financial information prior to public disclosure and our disclosures in our periodic reports filed with the SEC. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Lemus qualifies as an audit committee financial expert within the meaning of SEC regulations and each of David Lemus, Laura J. Hamill and Dorman Followwill meet the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management periodically meet separately with the audit committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews, discusses and assesses its own performance and composition at least annually. The audit committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the audit committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee consists of <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill, with <span style="white-space:nowrap">Tien-Li</span> Lee, M.D. serving as the chairperson of the committee. <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the compensation committee is be a <span style="white-space:nowrap">non-employee</span> director as defined in Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The compensation committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing our compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to our executive officers and <span style="white-space:nowrap">non-employee</span> directors. The responsibilities of the compensation committee are included in its written charter. The compensation committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding) our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of employment agreements and severance agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">change-of-control</span></span> protections and other compensatory arrangements for our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducting periodic reviews of the base compensation levels of all of our employees generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the type and amount of compensation to be paid or awarded to <span style="white-space:nowrap">non-employee</span> directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, the responsibilities of the compensation committee will also include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive compensation to be included in our annual meeting proxy statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on Form <span style="white-space:nowrap">10-K,</span> registration statements and our annual meeting proxy statements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the compensation committee may form, and delegate authority to, subcommittees as appropriate. The compensation committee reviews, discusses and assesses its own performance and composition at least annually. The compensation committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill, with Dorman Followwill serving as the chairperson of the committee. <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. The responsibilities of the nominating and corporate governance committee are included in its written </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
charter. The nominating and corporate governance committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing all aspects of our nominating and corporate governance functions. The responsibilities of the nominating and corporate governance committee include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making recommendations to our Board regarding corporate governance issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria approved by our Board); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the minimum qualifications for service on our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and evaluating incumbent directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">instituting and overseeing director orientation and director continuing education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serving as a focal point for communication between candidates, <span style="white-space:nowrap">non-committee</span> directors and our management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making other recommendations to our Board regarding matters relating to the directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing succession plans for our Chief Executive Officer and our other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and overseeing matters of corporate responsibility and sustainability, including potential <span style="white-space:nowrap">long-and</span> short-term trends and impacts to our business of environmental, social and governance issues, and our public reporting on these topics; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering any recommendations for nominees and proposals submitted by stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee periodically reviews, discusses and assesses the performance of our Board and the committees of our Board. In fulfilling this responsibility, the nominating and corporate governance committee seeks input from senior management, our Board and others. In assessing our Board, the nominating and corporate governance committee evaluates the overall composition of our Board, our Board&#8217;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The nominating and corporate governance committee reviews, discusses and assesses its own performance and composition at least annually. The nominating and corporate governance committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommend any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the nominating and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_74">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, on November&#160;10, 2022, our Board approved and adopted a written code of business conduct and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of business conduct and ethics is posted on our website at <span style="font-style:italic">www.scilexholding.com</span>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_75">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is currently, or has been at any time in the past year, one of our officers or employees. Other than Dr.&#160;Ji and Mr.&#160;Shah, none of our executive officers currently serves, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or compensation committee. Please see the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>&#8221; for information regarding the compensation of Dr.&#160;Ji and Mr.&#160;Shah. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_76">Limitation of Liability and Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;), and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer, employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. We also maintain directors&#8217; and officers&#8217; liability insurance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <span style="white-space:nowrap">non-employee</span> directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_77">EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_78">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Vickers Executive Officers and Director Compensation Prior to Completion of the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing of the Business Combination, none of Vickers&#8217;s executive officers or directors received any cash compensation for services rendered to Vickers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy Scilex and Current Executive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Legacy Scilex&#8217;s named executive officer 2021 who became an executive of ours. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Scilex Board or the Compensation Committee of the Legacy Scilex Board, with input from its Executive Chairman and Chief Executive Officer, historically determined the compensation for Legacy Scilex&#8217;s named executive officers. Legacy Scilex&#8217;s named executive officer for the year ended December&#160;31, 2021, who became an executive officer of ours at the Closing, was Jaisim Shah, Legacy Scilex&#8217;s Chief Executive Officer and President. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_79">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to Legacy Scilex&#8217;s named executive officer for the fiscal year ended December&#160;31, 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and principal position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Bonus&#160;($)(1)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />awards&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">579,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">290,509</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">869,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer, President and Director</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents discretionary bonus amounts awarded to Legacy Scilex&#8217;s named executive officer by the Legacy Scilex Board. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_80">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex has entered into an offer letter with its named executive officer. The material terms of the offer letter are described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Offer Letter and Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex entered into an offer letter with Mr.&#160;Shah (the &#8220;Shah Offer Letter&#8221;) dated April&#160;19, 2019, pursuant to which Mr.&#160;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&#160;Shah&#8217;s annual base salary was initially set at $407,925, which was most recently increased to $579,280 in 2020. Mr.&#160;Shah&#8217;s employment with Legacy Scilex is <span style="white-space:nowrap">at-will,</span> and either Legacy Scilex or Mr.&#160;Shah may terminate the terms and conditions of the employment relationship at any time, with or without cause and with or without notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;6, 2019, Legacy Scilex issued to Mr.&#160;Shah an option to purchase 12,066,608 shares of Legacy Scilex Common Stock, with an exercise price equal to $1.16 per share, whereby 25% of the shares vested on March&#160;18, 2020, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&#160;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. On December&#160;21, 2020, Legacy Scilex issued to Mr.&#160;Shah an additional option to purchase 2,415,000 shares of Legacy Scilex Common Stock, with an exercise price equal to $1.16 per share, whereby 25% of the shares vested on December&#160;21, 2021, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&#160;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Mr.&#160;Shah&#8217;s continuous service terminates due to an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in Control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, on November&#160;11, 2022, our compensation committee approved the following base salaries and target bonuses (on terms and conditions determined by our Board) of our executive officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target<br />Bonus</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">792,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">792,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing of the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> with respect to the 2022 Equity Incentive Plan, we anticipate that our Compensation Committee will approve the following stock option grants thereunder, subject to the continued service of the individuals: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Options</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">350,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_81">Potential Payments upon Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2021, Legacy Scilex did not have any arrangement with any of its named executive officers providing for potential payments, compensation or other benefits upon termination or the occurrence of a change of control, other than accelerated vesting provisions pursuant to previously granted options as described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_82">Perquisites, Health, Welfare and Retirement Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in limited circumstances. We do, however, pay the premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_83">Pension Benefits and Nonqualified Deferred Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not provide a pension plan for our employees, and none of Legacy Scilex&#8217;s named executive officers participated in a nonqualified deferred compensation plan during the year ended December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_84">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> 2021 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity awards held by each of Legacy Scilex&#8217;s named executive officers as of December&#160;31, 2021. Following the Business Combination, each outstanding equity award with respect to Legacy Scilex Common Stock reflected in the table below was equitably adjusted in accordance with the terms of the Merger Agreement and the 2019 Stock Option Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:36%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="22"><span style="font-weight:bold">Option awards<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting<br />Commencement<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />securities<br />underlying<br />unexercised<br />options (#)<br />exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />securities<br />underlying<br />unexercised<br />options (#)<br />unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />exercise<br />price<br />per<br />share($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />expiration<br />date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/6/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/18/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,295,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,770,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/6/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">603,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,811,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/21/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on November&#160;10, 2022, outstanding equity awards were adjusted as follows: (i)&#160;each option to purchase Legacy Scilex Common Stock that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the &#8220;Option&#8221;) except that (x)&#160;such Option relates to that whole number of shares of Common Stock (rounded down to the nearest whole share) equal to the number of shares of Legacy Scilex Common Stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1, and (y)&#160;the exercise price per share for each such share of Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the share numbers outstanding as of December&#160;31, 2021 and do not reflect these adjustments that occurred in connection with the closing of the Business Combination on November&#160;10, 2022. However, on November&#160;10, 2022, these numbers were all adjusted pursuant to the Merger Agreement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option was granted under the 2019 Stock Option Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option vested as to 1/4th of the shares subject to the option on the one year anniversary of the vesting commencement date and 1/48th of the shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_85">Equity-Based Incentive Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of Scilex Pharma originally adopted and its stockholders approved the 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;) on June&#160;26, 2017. The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma 2017 Plan, as amended and restated, provided that Scilex Pharma could grant incentive stock options, <span style="white-space:nowrap">non-statutory</span> stock options, stock awards, stock unit awards, stock appreciation rights and other stock awards. The only form of equity award granted under the Scilex Pharma 2017 Plan was options to purchase shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the corporate reorganization that was effected in March 2019, the maximum number of shares of common stock of Scilex Pharma that could be issued under the Scilex Pharma 2017 Plan was 24,000,000, of which 18,099,000 remained available for future grants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. Each option to purchase shares of common stock of Scilex Pharma outstanding and unexercised immediately prior to the Contribution was cancelled and substituted for an option to purchase the equivalent number of shares of Legacy Scilex Common Stock. Each new option was subject to the same terms and conditions as were in effect immediately prior to the Contribution. No stock options of Scilex Pharma were outstanding following the reorganization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;30, 2022, options to purchase 744,201 shares of our Common Stock were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company 2019 Stock Option Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Scilex Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by Legacy Scilex&#8217;s stockholders on June&#160;24, 2019. Upon adoption, 30,000,000 shares of Legacy Scilex Common Stock were authorized for issuance under the 2019 Stock Option Plan. The Legacy Scilex Board and Legacy Scilex&#8217;s stockholders approved an amendment to the 2019 Stock Option Plan on December&#160;21, 2020 to increase the number of shares authorized thereunder by 15,000,000 shares. As of November&#160;30, 2022, options to purchase 16,195,178 shares of our Common Stock were outstanding under the 2019 Stock Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Stock Option Plan has terminated at the Closing, and no further awards has been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the 2019 Stock Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized Shares</span>. Under the 2019 Stock Option Plan, an aggregate of 30,000,000 shares of Legacy Scilex Common Stock were initially reserved for future issuance, which number was increased to 45,000,000 in December 2020. The authorized shares are subject to adjustment in the event of a change that occurs with respect to the common stock without the receipt of consideration by Scilex, including a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, recapitalization, reincorporation, reorganization, change in corporate structure, or similar equity restructuring transaction. Additionally, shares issued pursuant to awards under the 2019 Stock Option Plan that are repurchased or that are forfeited, as well as shares reacquired as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will become available for future grant under the 2019 Stock Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Types of Awards</span>. The 2019 Stock Option Plan provided for the granting of (1)&#160;incentive stock options intended to qualify as incentive stock options under the Code, (2)&#160;nonstatutory stock options that do not qualify as an incentive stock option, (3)&#160;stock appreciation rights, (4)&#160;restricted stock awards, (5)&#160;restricted stock unit awards and (6)&#160;other stock awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eligibility. </span>Incentive stock options could only be granted to Legacy Scilex&#8217;s employees or employees of its affiliates, and stock awards other than incentive stock options may be granted to employees, directors and consultants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Options and Stock Appreciation Rights</span>. The Legacy Scilex Board determined the exercise price for stock options and stock appreciation rights, provided that the exercise price generally could not be less than 100% of the fair market value of Legacy Scilex Common Stock on the date of grant, subject to certain exceptions relating to the assumption or substitution of options or stock appreciation rights in connection with a corporate transaction in a manner consistent with Section&#160;409A or, if applicable, Section&#160;424(a) of the Code. Unless an award agreement provides otherwise, the termination date shall be: (1)&#160;the earlier of 18 months or upon the expiration of the option or stock appreciation right, if termination is due to death; (2)&#160;the earlier of 12 months or upon the expiration of the option or stock appreciation right, if termination is due to disability; or (3)&#160;three months, if termination is due to reasons other than for death, disability or cause. If the termination of service is due to cause, the stock option or stock appreciation right will terminate immediately upon such termination of service, and the participant will be prohibited from exercising the option or stock appreciation right. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock and Restricted Stock Unit Awards</span>. Each restricted stock and restricted stock unit award agreement is in the form and contains such terms and conditions as the Legacy Scilex Board deemed appropriate. Unless otherwise provided in the award agreement, the Legacy Scilex Board held certificates or, if not certificated, other indicia representing the restricted shares. If a recipient&#8217;s service terminates, Legacy Scilex could receive through a forfeiture condition or a repurchase right, any or all of the shares of common stock held by the recipient as of the date of termination. Restricted stock units not yet vested shall be forfeited upon termination of the recipient&#8217;s employment unless otherwise set forth in the award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability</span>. Stock options or stock appreciation rights are generally not transferable except by will or by the laws of descent and distribution or as otherwise provided under the 2019 Stock Option Plan. Restricted stock awards could be transferable by the participant only upon such terms and conditions as are set forth in the restricted stock award agreement, as the Legacy Scilex Board determines in its sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Administration</span>. The 2019 Stock Option Plan is administered by our Board, although our Board may delegate the administration of the 2019 Stock Option Plan to a committee. The administrator has full power to determine, among other things: (1)&#160;who will be granted awards; (2)&#160;when and how each award will be granted; (3)&#160;what type of award will be granted; (4)&#160;the provisions of each award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or shares of common stock under the award; (5)&#160;the number of shares of common stock subject to an award; and (6)&#160;the fair market value applicable to an award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Control/Corporate Transactions</span>. The 2019 Stock Option Plan provides that in the event of a change in control transaction (as defined in the 2019 Stock Option Plan), a stock award may be subject to additional acceleration of vesting and exercisability as may be provided in the stock award agreement for such stock award or as may be provided in any other written agreement between us or our affiliate and the participant, but in the absence of such provision, no such acceleration will occur. In addition, the 2019 Stock Option Plan provides that in the event of a corporate transaction (as defined in the 2019 Stock Option Plan), our Board has the discretion to take a number of actions with respect to awards contingent upon the closing of the transaction, including arranging for the assumption or substitution of awards, arranging for the assignment of repurchase rights in respect of awards, accelerating the vesting of awards, canceling awards or making payments in respect of awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment</span>. Our Board generally has the authority to amend awards, subject to the award recipient&#8217;s consent if the amendment is not favorable to the participant, except in connection with a capitalization adjustments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company 2022 Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, our Board adopted, subject to the approval by our stockholders, the Equity Incentive Plan. On November&#160;9, 2022, our stockholders approved the Equity Incentive Plan. The Equity Incentive Plan became effective on November&#160;9, 2022, the day immediately preceding the date on which the Closing occurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose of the Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for our success and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) within the meaning of Section&#160;422 of the Code, to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#8217; employees and consultants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it becomes effective will not exceed (i) 14,622,712 shares of our Common Stock, plus (ii)&#160;an additional number of shares of Common Stock equal to the number of shares subject to outstanding awards granted under the 2019 Stock Option Plan, that, following the effective date of the Equity Incentive Plan, (a)&#160;are not issued because the award or any portion of the award expires or otherwise terminates without all of the shares covered by the award having been issued, (b)&#160;are not issued because the award or any portion thereof is settled in cash, (c)&#160;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, (d)&#160;are withheld or reacquired to satisfy the exercise, strike or purchase price or (e)&#160;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will automatically increase on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (1) 4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year, (2) 7,311,356 shares of Common Stock, and (3)&#160;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&#160;1 of a given year. Notwithstanding anything to the contrary in the foregoing sentence, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan is 14,622,712 shares, which amount will be increased commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&#160;31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii)&#160;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&#160;1 of a given year. All of the foregoing share numbers are subject to adjustment as necessary to implement any changes in our capital structure (as described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of Common Stock withheld under an award to satisfy the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Plan Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, will administer the Equity Incentive Plan. Our Board, or a duly authorized committee of our Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted by applicable law, the terms of such awards; and (ii)&#160;determine the number of shares of Common Stock to be subject to such awards granted to such employees. Under the Equity Incentive Plan, our Board, or a duly authorized committee of our Board, will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; the fair market value applicable to an award; and the terms of any performance award that is not valued in whole or in part by reference to, or otherwise based on, Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, (i)&#160;our Board will not, without stockholder approval, (a)&#160;reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&#160;at any time when the exercise or strike price of an option or stock appreciation right is above the fair market value of a share of our Common Stock, cancel and <span style="white-space:nowrap">re-grant</span> or exchange such option or stock appreciation right for a new award with a lower (or no) purchase price or for cash, and (ii)&#160;a participant&#8217;s rights under any award will not be materially adversely impaired by any amendment without the participant&#8217;s written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except the exercise price of a stock option generally will not be less than 100% (or 110% in the case of ISOs granted to a person who owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be determined by our Board. The terms and conditions of separate options need not be identical. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months following the cessation of service. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#8217;s stock option agreement or other written agreement between an optionholder and us, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the optionholder&#8217;s option would be prohibited solely because the issuance of shares of common stock upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares of common stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by our Board and may include (i)&#160;cash or check, bank draft or money order payable to us; (ii)&#160;a broker-assisted cashless exercise; (iii)&#160;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&#160;a net exercise of the option if it is an NSO; or (v)&#160;other legal consideration acceptable to our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitations on ISOs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or plans of our affiliates may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the term of the ISO does not exceed five years from the date of grant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Unit Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our Board. A restricted stock unit award represents a participant&#8217;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#8217;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of common stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by our Board and set forth in the restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by our Board and specified in the applicable restricted stock award agreement. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the participant&#8217;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Performance Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain <span style="white-space:nowrap">pre-established</span> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <span style="white-space:nowrap">spin-off,</span> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the performance award agreement or the written terms of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved during a performance period and the other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Limit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for service as a <span style="white-space:nowrap">non-employee</span> director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees paid by us to such <span style="white-space:nowrap">non-employee</span> director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a <span style="white-space:nowrap">non-employee</span> director is first appointed or elected to our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our Board will appropriately and proportionately adjust (i)&#160;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity Incentive Plan; (ii)&#160;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&#160;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards granted under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&#160;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as our board of directors determines (or, if our board of directors does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by our Board, equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, a &#8220;corporate transaction&#8221; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&#160;a sale or other disposition of all or substantially all, as determined by our board of directors, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may not be transferred or assigned by a participant. After the vested shares </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clawback/Recovery </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback, recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the time during which an award grant under the Equity Incentive Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our Board will have the authority to amend, suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments will also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company 2022 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&#160;9, 2022, our stockholders approved the ESPP. The ESPP became effective on November&#160;9, 2022, the day immediately preceding the date on which the Closing occurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purpose </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our Common Stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code (the &#8220;423 Component&#8221;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section&#160;423 of the Code. We intend (but make no undertaking or representation to maintain) the 423 Component to qualify as an employee stock purchase plan, as that term is defined in Section&#160;423(b) of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the <span style="white-space:nowrap">&#8220;Non-423</span> Component&#8221;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by our Board, it will operate and be administered in the same manner as the 423 Component. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share Reserve </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the ESPP will not exceed&#160;1,462,271 shares of our Common Stock. The number of shares of our Common Stock that will be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reserved for issuance will automatically increase on January&#160;1 of each year for a period of up to ten years, commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding calendar year; (ii) 1,827,839 shares of our Common Stock; and (iii)&#160;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&#160;1 of a given year, provided however, that our Board may act prior to January&#160;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i)&#160;to (iii) above. For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to satisfy purchases of our Common Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to satisfy the purchases of our Common Stock under the <span style="white-space:nowrap">Non-423</span> Component. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not purchased under such purchase right will again become available for issuance under the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by us on the open market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board. All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the 423 Component or the <span style="white-space:nowrap">Non-423</span> Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and revoke rules and regulations for the ESPP&#8217;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of us and our related corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the 423 Component; and to adopt such rules, procedures and <span style="white-space:nowrap">sub-plans</span> as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Offerings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the 423 Component, will comply with the requirements of Section&#160;423(b)(5) of the Code. The provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed 27 months beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&#160;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&#160;a purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock on the first day of that offering, then (i)&#160;that offering will terminate immediately as of that first trading day, and (ii)&#160;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the first trading day of such new purchase period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or related corporations as designated by our Board) on the first day of an offering if such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed two years) as our Board may require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service requirements with respect to the 423 Component: (i)&#160;being customarily employed by us, or any of our related corporations or affiliates, for more than 20 hours per week and more than five months per calendar year; or (ii)&#160;such other criteria as our Board may determine consistent with Section&#160;423 of the Code with respect to the 423 Component. Our Board may provide that each person who, during the course of an offering, first becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person becomes an eligible employee or which occurs thereafter, receive a purchase right under that offering, and the purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital stock (or the stock of any related corporation) determined in accordance with the rules of Section&#160;424(d) of the Code. As specified by Section&#160;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase rights, together with any other rights granted under all employee stock purchase plans of ours or any of our related corporations, do not permit such eligible employee&#8217;s rights to purchase our stock or the stock of any of our related corporations to accrue at a rate which, when aggregated, exceeds $25,000 (based on the fair market value per share of such common stock on the date that the purchase right is granted) for each calendar year such purchase rights are outstanding at any time. Our Board may also exclude from participation in the ESPP or any offering employees of ours, or of any of our related corporation, who are highly compensated employees, as within the meaning of Section&#160;423(b)(4)(D) of the Code, or a subset of such highly compensated employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in the case of an offering under the <span style="white-space:nowrap">Non-423</span> Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its sole discretion, that participation of such eligible employee is not advisable or practical for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase Rights; Purchase Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to purchase up to that number of shares of our Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed 15% of such employee&#8217;s earnings (as defined by our Board) during the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which date will be no later than the end of the offering. Our Board will establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase of up to 10,000 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&#160;a maximum number of shares of our Common Stock that may be purchased by any participant on any purchase date during an offering, (ii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#8217;s accumulated contributions, will be made in as nearly a uniform manner as will be practicable and equitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock acquired pursuant to purchase rights will not be less than the lesser of (i) 85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Common Stock on the date of purchase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Participation; Withdrawal; Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by our Board. Each participant&#8217;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire transfer prior to a purchase date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the offering by delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#8217;s purchase right in that offering will immediately terminate and we will distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#8217;s purchase right in that offering shall then terminate. A participant&#8217;s withdrawal from that offering will have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the participant either (i)&#160;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&#160;is otherwise no longer eligible to participate. We will distribute the individual&#8217;s accumulated but unused contributions as soon as practicable to such individual. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such designated companies) will not be treated as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the 423 Component to an offering under the <span style="white-space:nowrap">Non-423</span> Component, the exercise of the participant&#8217;s purchase right will be qualified under the 423 Component only to the extent such exercise complies with Section&#160;423 of the Code. If a participant transfers from an offering under the <span style="white-space:nowrap">Non-423</span> Component to an Offering under the 423 Component, the exercise of the purchase right will remain <span style="white-space:nowrap">non-qualified</span> under the <span style="white-space:nowrap">Non-423</span> Component. Our Board may establish different and additional rules governing transfers between separate offerings within the 423 Component and between offerings under the 423 Component and offerings under the <span style="white-space:nowrap">Non-423</span> Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchase of Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase date, each participant&#8217;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the ESPP and the applicable offering, at the purchase price specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#8217;s account after the purchase of shares on the final purchase date of an offering, then such remaining amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be exercised to any extent unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material compliance with all applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such compliance, no purchase rights will be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except that the purchase date will in no event be more than 27 months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in material compliance with all applicable laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the payment of interest is otherwise required by applicable law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of our Common Stock subject to purchase rights unless and until the participant&#8217;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our transfer agent). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the ESPP; (ii)&#160;the class(es) and maximum number of securities by which the share reserve is to increase automatically each year; (iii)&#160;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&#160;the class(es) and number of securities that are subject to purchase limits under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then (i)&#160;the participants&#8217; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&#160;our Board, in its discretion, may terminate outstanding offerings, cancel the outstanding purchase rights and refund the participants&#8217; accumulated contributions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ESPP, a &#8220;corporate transaction&#8221; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&#160;a sale or other disposition of all or substantially all, as determined by our Board, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#8217;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tax Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to fulfill any withholding obligation for taxes arising out of or in relation to a participant&#8217;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by (i)&#160;withholding from the participant&#8217;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&#160;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP, either through a voluntary sale or a mandatory sale arranged by us; or (iii)&#160;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment, Suspension or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any outstanding purchase right granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&#160;with the consent of the person to whom such purchase rights were granted, (ii)&#160;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&#160;423 of the Code), or (iii)&#160;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or listing requirements. No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_86">Emerging Growth Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_87">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex&#8217;s only <span style="white-space:nowrap">non-employee</span> director during 2021, <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., received the following compensation in connection with providing consulting services to Legacy Scilex in 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:52%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees<br />Earned&#160;or<br />Paid&#160;in<br />Cash&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.(2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Ji, Legacy Scilex&#8217;s Executive Chairperson, and Mr.&#160;Shah, Legacy Scilex&#8217;s Chief Executive Officer and President, are not included in this table, as each of them was an employee of Legacy Scilex and therefore receives no compensation for his service as a director. Mr.&#160;Shah&#8217;s compensation as a named executive officer is included in the section titled &#8220;&#8212; <span style="font-style:italic">Summary Compensation Table</span>&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2021, Dr.&#160;Lee held options to purchase an aggregate of 635,000 shares of Legacy Scilex Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of fees earned by Dr.&#160;Lee for <span style="white-space:nowrap">non-employee</span> consulting services provided to Legacy Scilex under a consulting agreement dated October&#160;27, 2020, as amended on March&#160;17, 2021. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2022, the Legacy Scilex Board determined that the annual cash compensation of Legacy Scilex&#8217;s <span style="white-space:nowrap">non-employee,</span> independent directors would be $82,500. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_88">Director Compensation Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined the following compensation for our <span style="white-space:nowrap">non-employee</span> directors: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Annual Cash Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Equity Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our non-employee directors are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, pro-rated for any partial months of service. The equity compensation paid to our non-employee directors will vest monthly over a period of 48&#160;months from the date of grant with respect to the initial stock option grants and over a period of 12&#160;months from the date of grant with respect to the annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses related to such director&#8217;s attendance at Board and committee meetings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_89">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&#160;1, 2019 and any currently proposed transactions to which Vickers or Legacy Scilex was or is to be a participant in which the amount involved exceeded or will exceed $120,000, and in which any of Vickers&#8217;s or Legacy Scilex&#8217;s directors, executive officers or, to Vickers&#8217;s or Legacy Scilex&#8217;s knowledge, beneficial owners of more than 5% of Vickers&#8217;s or Legacy Scilex&#8217;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_90">Certain Relationships of Vickers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Founder Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;16, 2020, Vickers issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, Vickers effected a share capitalization of 0.2 shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 Vickers Ordinary Shares, which were cancelled by Vickers, and on January&#160;6, 2021, Vickers effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 Vickers Ordinary Shares issued and outstanding. All share and <span style="white-space:nowrap">per-share</span> amounts have been retroactively restated to reflect the share transactions. The founder shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of founder shares will equal, on an <span style="white-space:nowrap">as-converted</span> basis, approximately 20% of the issued and outstanding Vickers Ordinary Shares after the IPO. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no founder shares are currently subject to forfeiture. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of their founder shares until six months after the consummation of the Business Combination or earlier if we consummates a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their Vickers Ordinary Shares for cash, securities or other property. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Promissory Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;16, 2020, Vickers issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which Vickers may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <span style="white-space:nowrap">non-interest</span> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the IPO. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the IPO on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to Vickers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Loans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;20, 2021, the Sponsors loaned Vickers an aggregate of $500,000 for working capital purposes. On January10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account, to provide Vickers with an additional three&#160;months to consummate an initial business combination pursuant to Vickers&#8217;s Amended and Restated Memorandum and Articles of Association (&#8220;Vickers&#8217;s Charter&#8221;). On January&#160;27, 2022, the Sponsors loaned Vickers an additional aggregate principal amount of $500,000 for working capital purposes. On April&#160;10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account to provide Vickers with an additional three&#160;months to consummate an initial business combination pursuant to Vickers&#8217;s Charter. On June&#160;30, 2022, Vickers&#8217;s shareholders approved an amendment (the &#8220;Extension Amendment&#8221;) to its amended and restated memorandum and articles of association to extend the deadline by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which it must complete an initial business combination from July&#160;11, 2022 to January&#160;11, 2023. Each extension was made on a monthly basis and was conditioned on the deposit into the Trust Account of a payment equal to $0.0333 per public share outstanding. In connection with the shareholder vote on the Extension Amendment, Vickers was required to provide its shareholders with the right to redeem their public shares. Holders of 4,073,605 public shares elected to redeem their shares at a per share redemption price of $10.27 thereby reducing the amount in the Trust Account by an aggregate of approximately $41.8&#160;million. On July&#160;8, 2022, the Sponsors deposited an aggregate of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#8217;s Charter. After the redemption of the 4,073,605 public shares, there were 9,726,395 public shares remaining. On each of August&#160;11, 2022, September&#160;9, 2022 and October&#160;10, 2022, the Sponsors deposited an additional payment of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#8217;s Charter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, the Sponsors and Vickers entered into the Vickers Debt Agreement, which provides that, effective as of immediately prior to the Effective Time, all of the issued and outstanding loans made by the Sponsors to Vickers prior to such Effective Time shall be contributed by the Sponsors to Vickers in exchange for a number of shares of our Common Stock determined by dividing the aggregate amount of such indebtedness by $10.00. As of immediately prior to the Effective Time, the outstanding indebtedness was $5.3&#160;million, which resulted in the issuance of an additional 533,057 shares of our Common Stock to the Sponsors, in accordance with the Vickers Debt Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Advances from Related Party </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced Vickers an aggregate of $30,000 to fund expenses in connection with the IPO. The advances are <span style="white-space:nowrap">non-interest</span> bearing and payable upon demand. As of June&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. The outstanding amount of $30,000 as of December&#160;31, 2020 was repaid on February&#160;26, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administrative Service Fee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the registration statement of the IPO through the acquisition of a target business, the Sponsors have provided Vickers with office space and certain office and secretarial services at no cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including any finder&#8217;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to the Sponsors, officers and directors, or any of their affiliates, prior to, or in connection with any services rendered in order to effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to the Sponsors, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred by such persons in connection with activities on our behalf. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of Series A Preferred Stock, among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board or the size of our Board and (ii)&#160;we are required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties have agreed that our Board will continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director independence. Sorrento also have the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we shall not, and shall cause our subsidiaries not to, among others, without the prior written consent of Sorrento: (i)&#160;amend, alter, modify or repeal (whether by merger, consolidation, by operation of law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations) or our Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&#160;take any action that would have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&#160;amend, alter, modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&#160;file any voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our subsidiaries; (v)&#160;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in excess of $10,000,000) (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts) or (B)&#160;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of $10,000,000 (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts); (vi) consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture or corporate reorganization by the Company or any of our subsidiaries; (vii)&#160;declare or pay any dividend or distribution on our Common Stock, other Junior Security or Parity Security; or (viii)&#160;purchase, redeem or otherwise acquire for consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect (A)&#160;a reclassification of any Junior Security for or into other Junior Securities, (B)&#160;a reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&#160;a reclassification of any Parity Security into a Junior Security, (D)&#160;the exchange or conversion of any Junior Security for or into another Junior Security, (E)&#160;the exchange or conversion of any Parity Security for or into another Parity Security with the same or lesser per share liquidation amount, (F)&#160;the exchange or conversion of any Parity Security for or into any Junior Security or (G)&#160;the settlement of incentive equity awards (including any applicable withholdings and the net exercise of options) in accordance with the terms thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement will terminate and be of no further force and effect upon the earlier of (i)&#160;mutual written agreement of the parties thereto and (ii)&#160;the date upon which Sorrento (together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries)) ceases to own any shares of Series A Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant Transfer Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders had redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&#160;17, 2022, then in addition to the forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors would transfer to Sorrento, and Sorrento would acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as equitably </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar transaction, or any share dividend or distribution paid in shares) as determined in accordance with the following schedule: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Redemptions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Private<br />Placement<br />Warrants to be<br />Transferred to<br />Sorrento</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Private<br />Placement<br />Warrants to be<br />Retained by<br />Sponsors</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />Private<br />Placement<br />Warrants</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90% or greater</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85% to 89.99%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,600,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,504,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75% to 84.99%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,052,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,052,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50% to 74.99%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,840,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Below 50%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,840,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,840,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the public shareholders redeemed an aggregate of 8,576,838 Vickers Ordinary Shares, which redeemed shares, together with the shares redeemed in connection with the Extension Proposal, represented an aggregate of 91.67% of the public Vickers Ordinary Shares outstanding as of March&#160;17, 2022. Accordingly, the Sponsors transferred 3,104,000 Private Placement Warrants to Sorrento pursuant to the Warrant Transfer Agreement and forfeited 2,736,000 Private Placement Warrants pursuant to the Sponsor Support Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_91">Certain Relationships of Legacy Scilex </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Reorganization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex completed a corporate reorganization. In connection with the corporate reorganization, the existing stockholders of Scilex Pharma exchanged their shares for the same number of newly issued shares of Legacy Scilex Common Stock, pursuant to a Contribution and Loan Agreement. As a result, Scilex Pharma and Semnur became Legacy Scilex&#8217;s wholly owned subsidiaries. In connection with the reorganization, each option issued by Scilex Pharma to acquire shares of common stock granted under the Scilex Pharma 2017 Plan was cancelled and substituted for an option to purchase an equivalent number of shares of Legacy Scilex Common Stock. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Our Corporate History</span>&#8221; for further information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Relationship with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex was a majority-owned subsidiary of Sorrento. Following the Closing of the Business Combination, Sorrento continues to beneficially own a significant percentage of our outstanding Common Stock. In connection with the Business Combination, Legacy Scilex and Sorrento entered into certain agreements that relate to Legacy Scilex&#8217;s relationship with Sorrento prior to the Business Combination and provides a framework for our ongoing relationship with Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;1, 2017, Scilex Pharma entered into a transition services agreement with Sorrento. Pursuant to this transition services agreement, Sorrento agreed to provide, directly or indirectly, certain administrative, financial, legal, tax, insurance, facility, information technology and other services to Scilex Pharma. In addition to the services provided under this transition services agreement, Sorrento retains insurance coverage on behalf of Scilex Pharma. For the years ended December&#160;31, 2021 and 2020, the total cost of services and insurance, including an agreed-upon markup, provided to Scilex Pharma was $4.0&#160;million and $2.3&#160;million, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Product Development Agreement and Commercial Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to the Product Development Agreement with Oishi and Itochu, who are responsible for supplying ZTlido and <span style="white-space:nowrap">SP-103</span> for development and commercialization purposes. We are also a party to the Itochu </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Oishi Commercial Supply Agreement, pursuant to which Itochu agreed to purchase Products (as defined in the Itochu and Oishi Commercial Supply Agreement) from Oishi and handles the shipping of the Products. As of December&#160;31, 2020, Itochu held approximately 14.7% of Legacy Scilex&#8217;s outstanding capital stock, representing a noncontrolling interest. Itochu ceased to be a shareholder of Legacy Scilex on January&#160;13, 2021. Its Managing Executive Officer, Kenji Hakoda, served on the Legacy Scilex Board from March 2019 to October 2020. During the years ended December&#160;31, 2021 and 2020, pursuant to the aforementioned Product Development Agreement and the Itochu and Oishi Commercial Supply Agreement, Legacy Scilex purchased inventory from Itochu in the amount of $5.7&#160;million and $1.0&#160;million, respectively, on terms Legacy Scilex considers to be arms&#8217; length between the parties. See the sections of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement</span>&#8221; for additional information regarding such agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indenture and Letter of Credit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;7, 2018, Scilex Pharma entered into the Purchase Agreements with the Purchasers and Sorrento, which is a beneficial owner of more than 5% of Legacy Scilex&#8217;s capital stock. Pursuant to the Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Purchasers the Scilex Pharma Notes for an aggregate purchase price of $140.0&#160;million. The Scilex Pharma Notes are governed by the Indenture with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as the Trustee and Collateral Agent, and Sorrento, as guarantor. The Indenture provides that the holders of the Scilex Pharma Notes will be entitled to receive quarterly payments in an amount equal to a fixed percentage, ranging from 15% to 25%, of the net sales of ZTlido for the prior fiscal quarter on each February&#160;15, May&#160;15, August&#160;15 and November 15. As security for the Scilex Pharma Notes, Scilex Pharma has granted to the Collateral Agent, for the benefit of the Purchasers, a continuing security interest in and lien on Scilex Pharma&#8217;s right, title, and interest in and to ZTlido and all property and assets of Scilex Pharma that are necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan). Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture. Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (as amended, the &#8220;Letter of Credit&#8221;) which provides that, in the event that (1)&#160;Scilex Pharma does not hold at least $29.0&#160;million in unrestricted cash (inclusive of cash equivalents in the collateral account) as of any calendar month ending March&#160;31, 2020 through and including the month ending March&#160;31, 2021 or at least $35.0&#160;million in unrestricted cash (inclusive of cash equivalents in the collateral account) at the end of any calendar month after March&#160;31, 2021, (2) actual cumulative net sales of ZTlido from September&#160;7, 2018 through December&#160;31, 2021 are less than a specified sales threshold for such period, or (3)&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the 2022 calendar year, are less than a specified sales threshold for such calendar year, Scilex Pharma, as beneficiary of the Letter of Credit, will draw, and Sorrento will pay to Scilex Pharma, $35.0&#160;million in a single <span style="white-space:nowrap">lump-sum</span> amount as a subordinated loan. The Letter of Credit will terminate upon the earliest to occur of: (a)&#160;the repayment of the Scilex Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock exchange by us that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;14, 2020, the parties entered into a Consent Under and Amendment No.&#160;3 to Indenture and Letter of Credit (&#8220;Amendment No.&#160;3&#8221;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of Credit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;14, 2020, and in connection with Amendment No.&#160;3, the aggregate $45.0&#160;million in restricted funds held in previously established reserve and collateral accounts were released and Scilex Pharma utilized such funds to repurchase an aggregate of $45.0&#160;million in principal amount of the Scilex Pharma Notes. Scilex </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharma also repurchased an aggregate of $20.0&#160;million in principal amount of the Scilex Pharma Notes on December&#160;16, 2020. Pursuant to the foregoing repurchases, the aggregate principal amount of the Scilex Pharma Notes was reduced by an aggregate of $65.0&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further related to Amendment No.&#160;3, the Purchasers also consented to Scilex Pharma incurring up to $10.0&#160;million of indebtedness in connection with an accounts receivable revolving loan facility with another lender and the incurrence of liens and the pledge of collateral to such lender in connection therewith. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&#160;million in a single <span style="white-space:nowrap">lump-sum</span> amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February 2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $20.0&#160;million at a purchase price in cash equal to 100% of the principal amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $28.0&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $481.0&#160;million sales threshold for such period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2022, Sorrento and Scilex Pharma, entered into a Consent Under and Amendment No.&#160;4 to Indenture (&#8220;Amendment No.&#160;4&#8221;) with the Trustee, Collateral Agent, and the Purchasers, which amended the Indenture. Pursuant to Amendment No.&#160;4, (1) on June&#160;3, 2022, Scilex Pharma repurchased approximately $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof (the &#8220;Repurchase&#8221;), (2) the Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September&#160;30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Purchasers will forgive and discharge $28.0&#160;million of the aggregate principal amount of the Scilex Pharma Notes, and (3)&#160;the minimum cash requirement under the Indenture was reduced to $5.0&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month. Scilex Pharma funded the Repurchase with <span style="white-space:nowrap"><span style="white-space:nowrap">cash-on-hand</span></span> and $15.0&#160;million received from Sorrento on June&#160;2, 2022. We paid off all the amounts outstanding under the Scilex Pharma Notes as of immediately prior to the Closing of the Business Combination, which payment was funded by Sorrento and treated as intercompany debt in exchange for Series A Preferred Stock pursuant to the terms of the Debt Exchange Agreement described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;28, 2022, we repurchased the remaining outstanding principal balance of the Scilex Pharma Notes with <span style="white-space:nowrap"><span style="white-space:nowrap">cash-on-hand</span></span> and $34.0&#160;million received from Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oaktree Guaranty </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;7, 2018, Sorrento and certain of its domestic subsidiaries entered into a Term Loan Agreement, as amended on May&#160;3, 2019 and December&#160;6, 2019 (as amended, the &#8220;Oaktree Loan Agreement&#8221;) with certain funds and accounts managed by Oaktree Capital Management, L.P. and Oaktree Fund Administration, LLC, as administrative and collateral agent, for an initial term loan of $100.0&#160;million and a delayed draw term loan of $20.0&#160;million that was provided to Sorrento on May&#160;3, 2019. On April&#160;12, 2019, Legacy Scilex and Semnur entered into a Joinder Agreement to the Oaktree Loan Agreement whereby each entity became a guarantor under the Oaktree Loan Agreement and pledged all of their respective assets (other than equity of Scilex Pharma) as collateral for the loans made to Sorrento under the Oaktree Loan Agreement. All obligations owed under the Oaktree Loan Agreement were paid off in full on June&#160;12, 2020 and both Legacy Scilex and Semnur ceased to be a guarantor under the Oaktree Loan Agreement as of such date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intercompany Promissory Note and Sale of Shares to Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;5, 2018, Scilex Pharma issued to Sorrento an intercompany promissory note in the amount of approximately $21.7&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). On October&#160;22, 2018, Sorrento purchased from Legacy Scilex 24,117,608 shares of Legacy Scilex Common Stock in exchange for the cancellation of $21.7&#160;million of indebtedness under the Intercompany Note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $8.1&#160;million and $10.3&#160;million, respectively, under the Intercompany Note. As of December&#160;31, 2021 and 2020, the outstanding principal balance under the Intercompany Note was approximately $23.5&#160;million and $15.4&#160;million, respectively. In connection with Amendment No.&#160;4 to the Indenture, the maximum aggregate principal amount of the Intercompany Note was increased from up to $25.0&#160;million to up to $50.0&#160;million. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the Intercompany Note was $23.5&#160;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Note Payable to Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex entered into a note payable with Sorrento with an initial principal amount of $16.5&#160;million. Legacy Scilex may borrow up to an aggregate of $20.0&#160;million of principal amount under the note payable. The note is interest bearing at the lesser of (i) 10% simple interest per annum, and (ii)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note as of December&#160;31, 2021 and 2020 was $19.6&#160;million and $13.0&#160;million, respectively. Accrued interest of $3.9&#160;million and $2.6&#160;million was recognized under related party payable in Legacy Scilex&#8217;s consolidated balance sheet as of December&#160;31, 2021 and 2020, respectively. During the six months ended June&#160;30, 2022 and 2021, Sorrento made advances to Legacy Scilex in the amount of $27.5&#160;million and $0, respectively, under the note payable. The outstanding principal balance of the note on June&#160;30, 2022 and December&#160;31, 2021 was $47.1&#160;million and $19.6&#160;million, respectively, which was recorded under the current related party note payable in Legacy Scilex&#8217;s consolidated balance sheets. As of June&#160;30, 2022 and December&#160;31, 2021, Legacy Scilex had ending balances resulting from the accrued interest on the note payable of $5.6&#160;million and $3.9&#160;million, respectively, which was recorded under the related party payable in Legacy Scilex&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur and to finance Legacy Scilex&#8217;s operations. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the foregoing notes was $54.3&#160;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Debt Exchange Agreement and Related Matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement with Sorrento (the &#8220;Debt Exchange Agreement&#8221;), pursuant to which (i)&#160;Sorrento shall contribute to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy Scilex and Scilex Pharma that remain outstanding as of immediately prior to the Closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness&#8221;), including with respect to the Scilex Pharma Notes, the Intercompany Note, and the other notes payable to Sorrento described above, in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&#160;Legacy Scilex shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the Closing of the Business Combination, Sorrento has elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of Legacy Scilex Preferred Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) that is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $310,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, Sorrento and Legacy Scilex entered into the Funding Commitment Letter. Pursuant to the terms of the Funding Commitment Letter, upon the written request of Legacy Scilex (which request Legacy Scilex shall make to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net tangible assets as of immediately following the Effective Time) (the &#8220;Net Tangible Assets Condition&#8221;), Sorrento shall fund one or more loans to Legacy Scilex in the amount set forth in such written request (a &#8220;Loan Request&#8221;), provided, that any amounts funded by Sorrento in respect of any Loan Request shall be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and included in the calculation of the Aggregate Outstanding Amount thereunder. The Funding Commitment Letter also provides that in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a)&#160;$10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. As consideration for the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement, which is more fully described elsewhere in this prospectus. No Loan Requests were made under the Funding Commitment Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Debt Contribution, Legacy Scilex filed, with the Secretary of State of the State of Delaware, (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of Legacy Scilex from 20,000,000 to 45,000,000 and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Exchange Shares. Following the issuance thereof to Sorrento and in connection with the Closing of the Business Combination, such shares were converted into the right to receive (i)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(ii)&#160;one-tenth</span> of one share of our Common Stock, which shares of Series A Preferred Stock shall then have the rights set forth in the Certificate of Designations. Sorrento is entitled to the rights set forth in the Stockholder Agreement as a result of Sorrento&#8217;s ownership thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the Closing, the Outstanding Indebtedness (including amounts related to the transfer of certain liabilities to Sorrento and repayment of Scilex Pharma Notes) was $290,570,964, which was contributed by Sorrento, in accordance with the Debt Exchange Agreement, in exchange for 29,057,097 shares of Legacy Scilex Preferred Stock, which were in turn converted into the right to receive 29,057,097 shares of Series A Preferred Stock and 2,905,710 shares of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Investor LP Assignment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex, through Semnur, is a party to the Assignment Agreement with Shah Investor LP, pursuant to which Shah Investor LP assigned Legacy Scilex certain intellectual property and Legacy Scilex agreed to pay Shah Investor LP a contingent quarterly royalty in the <span style="white-space:nowrap">low-single</span> digits based on the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing such intellectual property, which would include SEMDEXA. Mahendra Shah, Ph.D., who served on the Legacy Scilex Board from March 2019 to October 2020, is the managing partner of Shah Investor LP. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Shah Investor LP Assignment Agreement</span>&#8221; for additional information regarding the Assignment Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Acquisition of <span style="white-space:nowrap">SP-104</span> Assets from Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;) with Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;), pursuant to which, among other things, Sorrento acquired Aardvark&#8217;s Delayed Burst Release Low Dose Naltrexone <span style="white-space:nowrap">(DBR-LDN)</span> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <span style="white-space:nowrap">&#8220;SP-104</span> Assets&#8221;), which includes a Statement of Work dated November&#160;18, 2020 (the &#8220;Tulex Statement of Work&#8221;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to <span style="white-space:nowrap">SP-104</span> and on May&#160;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement, pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <span style="white-space:nowrap">SP-104</span> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <span style="white-space:nowrap">&#8220;SP-104</span> Acquisition&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#8220;Promissory Note&#8221;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#8220;Consideration Shares&#8221;) or any combination thereof, at Legacy Scilex&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this prospectus none of the foregoing payments have been triggered </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <span style="white-space:nowrap">SP-104</span> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the board of directors of Aardvark. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Guaranty of Lease </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2019, Legacy Scilex entered into a new office lease for approximately 6,000 square feet for its executive offices in Palo Alto, California, as amended on September&#160;15, 2019. The term of the lease commenced on September&#160;15, 2019 and will expire on November&#160;30, 2024. We will be obligated to pay an average of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately $0.5&#160;million in annual rent over the term of the lease. In connection with the lease, on August&#160;8, 2019, Sorrento executed a Guaranty of Lease, guaranteeing the performance of our obligations under the lease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officer and Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>&#8221; for information regarding the compensation of our executive officers and <span style="white-space:nowrap">non-employee</span> directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an offer letter agreement with our named executive officer that, among other things, provides for certain compensatory and change in control benefits, as well as severance benefits. For a description of such agreement, see the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation &#8212; Arrangements with Executive Officers.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Officers and Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#8220;<span style="font-style:italic">Management &#8212; Limitation of Liability and Indemnification of Directors and Officers</span>&#8221; for information regarding our arrangements to provide indemnification to our officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Combination Related Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Vickers, Legacy Scilex and Sorrento entered into a Company Stockholder Support Agreement, pursuant to which Sorrento agreed to vote all Legacy Scilex Common Stock beneficially owned by it, including any additional shares of Legacy Scilex it acquires ownership of or the power to vote, in favor of the Business Combination and related transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, in connection with the closing of the Business Combination, Scilex, Sorrento, the Sponsors, and Vickers&#8217;s former directors Pei Wei Woo, Suneel Kaji and Steve Myint, entered into the Registration Rights Agreement, whereby, subject to certain exceptions, the parties agreed, among other things, not to transfer any of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which we complete a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of our Common Stock for cash, securities or other property. The Registration Rights Agreement governs the registration of certain shares of our Common Stock for resale and includes certain customary demand and &#8220;piggy-back&#8221; registration rights with respect to shares of our Common Stock held by the parties thereto. As of the date of this prospectus, 139,709,647 shares of our Common Stock are subject to the Registration Rights Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Person Transaction Policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their respective immediate family members and any entity owned or controlled by such persons. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks, costs and benefits to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of other sources for comparable services or products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our Board, determines in the good faith exercise of our discretion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_92">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of November&#160;30, 2022 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person or &#8220;group&#8221; known to be the beneficial owner of more than 5% of our outstanding Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our current executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently exercisable or exercisable within 60 days of the Closing Date are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common Stock is based on 141,348,856 shares of such common stock outstanding as of November&#160;30, 2022. Voting power is based on 141,348,856 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of November&#160;30, 2022. Shares of Series A Preferred Stock are held solely by Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information available to us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:66%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Common<br />Shares<br />Beneficially<br />Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Total<br />Common<br />Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Total<br />Vote</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Directors and Executive Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,635,350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,947,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">336,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">427,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All Directors and Executive Officers as a Group (8 individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,346,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">5% Beneficial Owners</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorrento Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139,992,366</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, the business address of each of the following individuals is 4955 Directors Place, San Diego, CA 92121. None of the following individuals own shares of Series A Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 8,635,350 shares subject to options exercisable within 60 days of November&#160;30, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 1,947,053 shares subject to options exercisable within 60 days of November&#160;30, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 336,749 shares subject to options exercisable within 60 days of November&#160;30, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 427,670 shares subject to options exercisable within 60 days of November&#160;30, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 3,104,000 shares subject to Private Warrants and 1,161,776 shares subject to Public Warrants exercisable within 60 days of November&#160;30, 2022. The business address of Sorrento Therapeutics, Inc. is 4955 Directors Place, San Diego, CA 92121. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_93">SELLING SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale from time to time by: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Selling Stockholders&#160;of up to an aggregate of 144,975,423 Resale Shares, consisting of: (i)&#160;up to 3,983,057 Sponsor Shares; (ii)&#160;up to 135,726,590 Merger Shares; (iii)&#160;up to 4,104,000 Private Warrant Shares; and (iv)&#160;up to 1,161,776 Public Warrant Shares issuable to Sorrento pursuant to Public Warrants held by Sorrento and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;the Selling Warrantholders, of up to 4,104,000 Private Warrants and 1,161,776 Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of our relationships with certain of the Selling Securityholders and their affiliates is set forth in &#8220; <span style="font-style:italic">Certain Relationships and Related Person Transactions</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Registration Rights Agreement, the Selling Securityholders, including the Sponsors, are subject to <span style="white-space:nowrap">lock-up</span> arrangements that restrict their ability to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of our Common Stock, options or warrants to purchase shares of our Common Stock or securities convertible into or exchangeable for or that represent the right to receive shares of our Common Stock for 180 days from the Closing of the Business Combination (i.e., May&#160;9, 2023), subject to certain exceptions. The Resale Shares sold in this offering will become eligible for sale upon expiration of the applicable <span style="white-space:nowrap">lock-up</span> period or release by competent parties, except for any Resale Shares held by our affiliates as defined in Rule 144 under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such shares of Common Stock or Warrants. In particular, the Selling Securityholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities in transactions exempt from registration under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the footnotes below, no Selling Securityholder has had any material relationship with us or any of our affiliates within the past three years other than as a securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information provided by or on behalf of the Selling Securityholders as of November&#160;30, 2022 concerning the Resale Shares and Warrants that may be offered from time to time by each Selling Securityholder with this prospectus. See &#8220;<span style="font-style:italic">Plan of Distribution.</span>&#8221; For the purposes of the following table, we have assumed that the Selling Securityholders will have sold all of the securities covered by this prospectus upon the completion of the offering. The beneficial ownership of Common Stock is based on 141,348,856&#160;shares of such common stock outstanding as of November&#160;30, 2022. Voting power is based on an aggregate of 170,405,953 shares of our capital stock outstanding as of November&#160;30, 2022, comprised of 141,348,856&#160;shares of Common Stock and 29,057,097 shares of Series A Preferred Stock. Shares of Series A </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock are held solely by Sorrento. Up to 5,738,212&#160;shares of our Common Stock issuable upon the exercise of the Public Warrants that are not held by Sorrento, which are also covered by this prospectus, are not included in the table below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Selling<br />Securityholder<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial Ownership<br />of Common Stock<br />Prior to the Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants<br />Beneficially<br />Owned<br />Prior to the<br />Offering</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Shares of<br />Common<br />Stock Being<br />Offered</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants<br />Being<br />Offered</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Beneficial<br />Ownership of<br />Common Stock<br />After the Offered<br />Shares are Sold</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants<br />Beneficially<br />Owned<br />After the<br />Offered<br />Warrants<br />are Sold</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Total<br />Voting<br />Power<br />After<br />this<br />Offering</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Shares of<br />Common<br />Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Class</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />of<br />Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorrento Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,726,590</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,265,776</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,726,590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,265,776</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers Venture Fund VI Pte Ltd<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,521,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">901,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,521,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">901,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers Venture Fund VI (Plan) Pte Ltd<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">386,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">386,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pei Wei Woo<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suneel Kaji<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Myint<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, the business address of each of the Selling Securityholders listed in the table above is 4955 Directors Place, San Diego, CA 92121. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of Sorrento Therapeutics, Inc. is 4955 Directors Place, San Diego, CA 92121. The number of shares of Common Stock beneficially owned excludes the 3,104,000 Private Warrants and the 1,161,776 Public Warrants held by Sorrento. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Comprised of 3,104,000 Private Warrants and 1,161,776 Public Warrants. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of Vickers Venture Fund Pte Ltd is 1 Harbourfront Avenue, <span style="white-space:nowrap">#16-06</span> Keppel Bay Tower, Singapore 098632. Dr.&#160;Jeffrey Chi and Mr.&#160;Chris Ho have voting and dispositive power over these shares held by this Sponsor through their positions with such Sponsor. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of Vickers Venture Fund (Plan) Pte Ltd is 1 Harbourfront Avenue, #16-06 Keppel Bay Tower, Singapore 098632. Dr. Jeffrey Chi and Mr. Chris Ho have voting and dispositive power over these shares held by this Sponsor through their positions with such Sponsor. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pei Wei Woo served a member of our Board from October 2020 to November&#160;10, 2022. The address of the Selling Securityholder is 1 Harbourfront Avenue, <span style="white-space:nowrap">#16-06</span> Keppel Bay Tower, Singapore 098632. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Suneel Kaji served a member of our Board from October 2020 to November&#160;10, 2022. The address of the Selling Securityholder is 1 Harbourfront Avenue, <span style="white-space:nowrap">#16-06</span> Keppel Bay Tower, Singapore 098632. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Steve Myint served a member of our Board from October 2020 to November&#160;10, 2022. The address of the Selling Securityholder is 1 Harbourfront Avenue, <span style="white-space:nowrap">#16-06</span> Keppel Bay Tower, Singapore 098632. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_94">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the issuance by us of up to an aggregate of 11,003,988 shares of Common Stock, comprised of (i) 4,104,000 Private Warrant Shares and (ii)&#160;6,899,988 Public Warrants Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also registering the offer and sale from time to time by: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Selling Stockholders&#160;of up to an aggregate of 144,975,423 Resale Shares, consisting of: (i)&#160;up to 3,983,057 Sponsor Shares; (ii)&#160;up to 135,726,590 Merger Shares; (iii)&#160;up to 4,104,000 Private Warrant Shares and (iv) up to 1,161,776 Public Warrant Shares issuable to Sorrento pursuant to Public Warrants held by Sorrento; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#160;the Selling Warrantholders of up to 4,104,000 Private Warrants and 1,161,776 Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from the sale by the Selling Securityholders of the securities offered by them described in this prospectus, except with respect to amounts received by us upon the exercise of the Private Warrants for cash. The aggregate proceeds to the Selling Securityholders will be the purchase price of the securities less any discounts and commissions borne by the Selling Securityholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Securityholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Securityholders in disposing of the securities. We are required to pay all other fees and expenses incident to the registration of the securities to be offered and sold pursuant to this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock and the Private Warrants beneficially owned by the Selling Securityholders covered by this prospectus may be offered and sold from time to time by the Selling Securityholders. The term &#8220;Selling Securityholders&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a Selling Securityholder as a gift, pledge, partnership distribution or other transfer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also registering the issuance by us of up to 6,899,988&#160;shares of our Common Stock that are issuable upon exercise of the Public Warrants. We will receive proceeds from the Public Warrants exercised in the event that such Public Warrants are exercised for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. Each Selling Securityholder reserves the right to accept and, together with its respective agents, to reject, any proposed purchase of securities to be made directly or through agents. The Selling Securityholders and any of their permitted transferees may sell their securities offered by this prospectus on any stock exchange, market or trading facility on which the securities are traded or in private transactions. If underwriters are used in the sale, such underwriters will acquire the shares for their own account. These sales may be at a fixed price or varying prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to prevailing market prices or at negotiated prices. The securities may be offered to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. The obligations of the underwriters to purchase the securities will be subject to certain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders may sell their shares and warrants by one or more of, or a combination of, the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer so engaged will attempt to sell the offered securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> distribution in accordance with the rules of Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through trading plans entered into by a Selling Securityholder pursuant to Rule <span style="white-space:nowrap">10b5-1</span> under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the distribution of the securities by any Selling Securityholder to its partners, members or stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through one or more underwritten offerings on a firm commitment or best efforts basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">agreements with broker-dealers to sell a specified number of the securities at a stipulated price per share or warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in options transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through a combination of any of the above methods of sale; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable laws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that the Selling Securityholders will sell all or any of the securities offered by this prospectus. In addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. The Selling Securityholders have the sole and absolute discretion not to accept any purchase offer or make any sale of securities if they deem the purchase price to be unsatisfactory at any particular time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the agreement(s) governing the registration rights applicable to a Selling Securityholder&#8217;s shares of Common Stock, such Selling Securityholder may transfer shares of Common Stock to one or more &#8220;permitted transferees&#8221; in accordance with such agreements and, if so transferred, such permitted transferee(s) will be the selling beneficial owner(s) for purposes of this prospectus. Upon being notified by a Selling Securityholder that it intends to sell our securities, we will, to the extent required, promptly file a supplement to this prospectus to name specifically such person as a Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to a particular offering of the securities held by the Selling Securityholders, to the extent required, an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement of which this prospectus is part, will be prepared and will set forth, to the extent required, the following information: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the specific securities to be offered and sold; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the names of the Selling Securityholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the respective purchase prices and public offering prices, the proceeds to be received from the sale, if any, and other material terms of the offering; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">settlement of short sales entered into after the date of this prospectus; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the names of any participating agents, broker-dealers or underwriters, if not already named herein; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any applicable commissions, discounts, concessions and other items constituting compensation from the Selling Securityholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with distributions of the Resale Shares or otherwise, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of shares of Common Stock in the course of hedging transactions, broker-dealers or other financial institutions may engage in short sales of shares of Common Stock in the course of hedging the positions they assume with Selling Securityholders. The Selling Securityholders may also sell shares of Common Stock short and redeliver the shares to close out such short positions. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Selling Securityholders may also pledge shares to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities offered by this prospectus, any underwriters or agents, as the case may be, involved in the offering of such securities may engage in transactions that stabilize, maintain or otherwise affect the price of our securities. Specifically, the underwriters or agents, as the case may be, may over-allot in connection with the offering, creating a short position in our securities for their own account. In addition, to cover overallotments or to stabilize the price of our securities, the underwriters or agents, as the case may be, may bid for, and purchase, such securities in the open market. Finally, in any offering of securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allotted to an underwriter or a broker-dealer for distributing such securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. The underwriters or agents, as the case may be, are not required to engage in these activities, and may end any of these activities at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders may solicit offers to purchase the securities directly from, and may sell such securities directly to, institutional investors or others. In this case, no underwriters or agents would be involved. The terms of any of those sales, including the terms of any bidding or auction process, if utilized, will be described in the applicable prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that one or more underwriters may make a market in our securities, but such underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for our securities. Our shares of Common Stock and Public Warrants are currently listed on the Nasdaq Capital Markets under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholders may authorize underwriters, broker-dealers or agents to solicit offers by certain purchasers to purchase the securities at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we or the Selling Securityholders pay for solicitation of these contracts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Selling Securityholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may use securities pledged by any Selling Securityholder or borrowed from any Selling Securityholder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from any Selling Securityholder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any Selling Securityholder may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In effecting sales, broker-dealers or agents engaged by the Selling Securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at the time of any offering made under this prospectus a member of FINRA participating in the offering has a &#8220;conflict of interest&#8221; as defined in FINRA Rule 5121 (&#8220;Rule 5121&#8221;), that offering will be conducted in accordance with the relevant provisions of Rule 5121. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To our knowledge, there are currently no plans, arrangements or understandings between the Selling Securityholders and any broker-dealer or agent regarding the sale of the securities by the Selling Securityholders. Upon our notification by a Selling Securityholder that any material arrangement has been entered into with an underwriter or broker-dealer for the sale of securities through a block trade, special offering, exchange distribution, secondary distribution or a purchase by an underwriter or broker-dealer, we will file, if required by applicable law or regulation, a supplement to this prospectus pursuant to Rule 424(b) under the Securities Act disclosing certain material information relating to such underwriter or broker-dealer and such offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents may facilitate the marketing of an offering online directly or through one of their affiliates. In those cases, prospective investors may view offering terms and a prospectus online and, depending upon the particular underwriter, broker-dealer or agent, place orders online or through their financial advisors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In offering the shares covered by this prospectus, the Selling Securityholders and any broker-dealers who execute sales for the Selling Securityholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any discounts, commissions, concessions or profit they earn on any resale of those securities may be underwriting discounts and commissions under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the Selling Securityholders and their affiliates. In addition, we will make copies of this prospectus available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of Warrants may exercise its Warrants in accordance with the Warrant Agreement on or before the expiration date set forth therein by surrendering, at the office of the warrant agent, Continental, the certificate evidencing such Warrant, with the form of election to purchase set forth thereon, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes due in connection with the exercise of the Warrant, subject to any applicable provisions relating to cashless exercises in accordance with the Warrant Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_95">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax considerations generally applicable to the purchase, ownership and disposition of our Common Stock and Warrants, which we refer to collectively as our &#8220;securities.&#8221; This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences relating to the purchase, ownership and disposition of our securities. In addition, this discussion does not address all aspects of U.S. federal income tax consequences to particular holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S. federal 3.8% Medicare tax imposed on certain net investment income or any aspects of U.S. federal taxation other than those pertaining to the income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S. state and local, or <span style="white-space:nowrap">non-U.S.</span> tax laws. Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect to the U.S. federal income tax consequences to a holder of the purchase, ownership or disposition of our securities; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our securities as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment under the U.S. tax laws, such as, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks or other financial institutions, underwriters, or insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">traders in securities who elect to apply a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts and regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts, or other <span style="white-space:nowrap">tax-</span> deferred accounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subchapter S corporations, partnerships or other pass-through entities or investors in such entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities, commodities or currencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">grantor trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to the alternative minimum tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. persons whose &#8220;functional currency&#8221; is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who received our securities through the issuance of restricted stock under an equity incentive plan or through a <span style="white-space:nowrap">tax-qualified</span> retirement plan or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding our securities as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221; as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction transaction; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to which there are one or more United States shareholders within the meaning of Treasury Regulation <span style="white-space:nowrap">Section&#160;1.367(b)-3(b)(1)(ii);</span> or </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our securities that is, for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust (i)&#160;if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">&#8220;Non-U.S.</span> Holder&#8221; means a beneficial owner of our securities, that is neither a U.S. Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S. federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S. federal income tax purposes, holds our securities, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax advisors with regard to the U.S. federal income tax consequences of the ownership and disposition of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE OWNERSHIP AND DISPOSITION OF OUR SECURITIES. IN ADDITION, THE U.S. FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR SECURITIES MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR SECURITIES SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND DISPOSITION OF OUR SECURITIES INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#8220;<span style="font-style:italic">U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <span style="white-space:nowrap">non-corporate</span> U.S. Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. <span style="white-space:nowrap">Non-corporate</span> U.S. Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4) of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including on a redemption that is treated as a sale or exchange under Section&#160;302 of the Code. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#8217;s acquisition cost for such Common Stock (or, in the case of Common Stock received upon exercise of a Warrant, the U.S. Holder&#8217;s initial basis for such Common Stock, as discussed below), less any prior distributions treated as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder&#8217;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. Holder on the sale or exchange of our Common Stock will generally be treated as U.S. source gain or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as discussed below with respect to the cashless exercise of a Warrant, a U.S. Holder generally will not recognize taxable gain or loss upon the exercise of a Warrant for cash. The U.S. Holder&#8217;s initial tax basis in the share of our Common Stock received upon exercise of the Warrant will generally be an amount equal to the sum of the U.S. Holder&#8217;s acquisition cost of the Warrant and the exercise price of such Warrant. It is unclear whether a U.S. Holder&#8217;s holding period for the Common Stock received upon exercise of the Warrant would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; however, in either case the holding period will not include the period during which the U.S. Holder held the Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax consequences of a cashless exercise of a Warrant are not clear under current tax law. A cashless exercise may be nontaxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either situation, a U.S. Holder&#8217;s initial tax basis in the Common Stock received generally should equal the holder&#8217;s adjusted tax basis in the Warrant. If the cashless exercise were treated as not being a realization event, it is unclear whether a U.S. Holder&#8217;s holding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period for the Common Stock would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; in either case, the holding period would not include the period during which the U.S. Holder held the Warrant. If, instead, the cashless exercise were treated as a recapitalization, the holding period of the Common Stock generally would include the holding period of the Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that a cashless exercise of a Warrant could be treated in part as a taxable exchange in which gain or loss is recognized. In such event, a U.S. Holder could be deemed to have surrendered a portion of the Warrants being exercised having a value equal to the exercise price of such Warrants in satisfaction of such exercise price. Although not free from doubt, such U.S. Holder generally should recognize capital gain or loss in an amount equal to the difference between the fair market value of the Warrants deemed surrendered to satisfy the exercise price and the U.S. Holder&#8217;s adjusted tax basis in such Warrants. In this case, a U.S. Holder&#8217;s initial tax basis in the Common Stock received would equal the sum of the exercise price and the U.S. holder&#8217;s adjusted tax basis in the Warrants exercised. It is unclear whether a U.S. Holder&#8217;s holding period for the Common Stock would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; in either case, the holding period would not include the period during which the U.S. Holder held the Warrant. Due to the uncertainty and absence of authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder&#8217;s holding period would commence with respect to the Common Stock received, U.S. Holders are urged to consult their tax advisors regarding the tax consequences of a cashless exercise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sale, Exchange, Redemption or Expiration of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a sale, exchange (other than by exercise), redemption (other than a redemption for Common Stock), or expiration of a Warrant, a U.S. Holder will recognize taxable gain or loss in an amount equal to the difference between (1)&#160;the amount realized upon such disposition or expiration and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in the Warrant. A U.S. Holder&#8217;s adjusted tax basis in its Warrants will generally equal the U.S. Holder&#8217;s acquisition cost, increased by the amount of any constructive distributions included in income by such U.S. Holder (as described below under &#8220;<span style="font-style:italic">U.S. Holders-Possible Constructive Distributions</span>&#8221;). Such gain or loss generally will be treated as long-term capital gain or loss if the Warrant is held by the U.S. Holder for more than one year at the time of such disposition or expiration. If a Warrant is allowed to lapse unexercised, a U.S. Holder will generally recognize a capital loss equal to such holder&#8217;s adjusted tax basis in the Warrant. The deductibility of capital losses is subject to certain limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A redemption of Warrants for Common Stock described in this prospectus under &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Warrants</span>&#8221; should be treated as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. Accordingly, you should not recognize any gain or loss on the redemption of Warrants for shares of our Common Stock. Your aggregate initial tax basis in the shares of Common Stock received in the redemption should equal your aggregate adjusted tax basis in your Warrants redeemed and your holding period for the shares of Common Stock received in redemption of your Warrants should include your holding period for your surrendered Warrants. However, there is some uncertainty regarding this tax treatment and, accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a redemption of Warrants for Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Warrants</span>&#8221;. An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a U.S. Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. Such constructive distribution would be subject to tax as described above under &#8220;<span style="font-style:italic">U.S. Holders-Taxation of Distributions</span>&#8221; in the same manner as if such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-U.S.</span> Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any distributions (including constructive distributions) we make to a <span style="white-space:nowrap">Non-U.S.</span> Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">Non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> as applicable). Special certification and other requirements apply to certain <span style="white-space:nowrap">Non-U.S.</span> Holders that are pass-through entities rather than corporations or individuals. In the case of any constructive dividend (as described below under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Possible Constructive Distributions</span>&#8221;), it is possible that this tax would be withheld from any amount owed to a <span style="white-space:nowrap">Non-U.S.</span> Holder by the applicable withholding agent, including cash distributions on other property or sale proceeds from Warrants or other property subsequently paid or credited to such holder. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis in its shares of our Common Stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock and Warrants</span>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;United States real property holding corporation&#8221; (see &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <span style="white-space:nowrap">Non-U.S.</span> Holder that are effectively connected with such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (or if a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> Holder) will generally not be subject to U.S. withholding tax, provided such <span style="white-space:nowrap">Non-U.S.</span> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <span style="white-space:nowrap">W-8ECI).</span> Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <span style="white-space:nowrap">Non-U.S.</span> Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax treatment of a <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s exercise of a Warrant will generally correspond to the U.S. federal income tax treatment of the exercise of a Warrant by a U.S. Holder, as described under &#8220;<span style="font-style:italic">U.S. Holders-Exercise of a Warrant</span>&#8221; above, although to the extent a cashless exercise results in a taxable exchange, the tax consequences to the <span style="white-space:nowrap">Non-U.S.</span> Holder would be the same as those described below in &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Common Stock and Warrants</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Redemption of Warrants for Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A redemption of Warrants for Common Stock described in this prospectus under &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Warrants</span>&#8221; should be treated as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. Accordingly, you should not recognize any gain or loss on the redemption of Warrants for shares of our Common Stock. Your aggregate initial tax basis in the shares of Common Stock received in the redemption should equal your aggregate adjusted tax basis in your Warrants redeemed and your holding period for the shares of Common </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock received in redemption of your Warrants should include your holding period for your surrendered Warrants. However, there is some uncertainty regarding this tax treatment and, accordingly, <span style="white-space:nowrap">Non-U.S.</span> Holders should consult their tax advisors regarding the tax consequences of a redemption of Warrants for Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock and Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock or Warrants or an expiration or redemption of our Warrants, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">Non-U.S.</span> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">Non-U.S.</span> Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <span style="white-space:nowrap">Non-U.S.</span> Holder held our Common Stock or Warrants and, in the case where shares of our Common Stock are regularly traded on an established securities market, the <span style="white-space:nowrap">Non-U.S.</span> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">Non-U.S.</span> Holder were a U.S. resident. Any gains described in the first bullet point above of a <span style="white-space:nowrap">Non-U.S.</span> Holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <span style="white-space:nowrap">Non-U.S.</span> Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock or Warrants will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock or Warrants from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding the application of these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Warrants</span>&#8221;. An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a <span style="white-space:nowrap">Non-U.S.</span> Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. A <span style="white-space:nowrap">Non-U.S.</span> Holder would be subject to U.S. federal income tax withholding as described above under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Taxation of Distributions</span>&#8221; under that section in the same manner as if such <span style="white-space:nowrap">Non-U.S.</span> Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Foreign Account Tax Compliance Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) a 30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (b)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which our securities are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an investor that is a <span style="white-space:nowrap">non-financial</span> <span style="white-space:nowrap">non-U.S.</span> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&#160;certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. Department of Treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our shares of Common Stock and Warrants. A <span style="white-space:nowrap">Non-U.S.</span> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">Non-U.S.</span> Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK AND WARRANTS BASED ON YOUR CIRCUMSTANCES. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_96">DESCRIPTION OF OUR SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_97">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of our securities. The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws and the provisions of applicable law. A copy of the Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_98">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of Common Stock, $0.0001 par value per share and (ii) 45,000,000 shares of preferred stock, $0.0001 par value per share (the &#8220;Preferred Stock&#8221;), of which 29,057,097 shares have been designated as Series A Preferred Stock. As of November&#160;30, 2022, there were 141,348,856 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock issued and outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be declared and paid to stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders at a duly called or convened meeting, at which a quorum is present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon, except that our directors will be elected by a plurality of the votes cast. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Right to Receive Liquidation Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Preemptive or Similar Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fully Paid and <span style="white-space:nowrap">Non-Assessable</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Vickers Ordinary Shares and the shares of our Common Stock issued in the Business Combination are fully paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_99">Our Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to 45,000,000 shares of preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders. The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our outstanding stock entitled to vote thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred Stock issued to Sorrento in connection with the Closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Number and Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed the Certificate of Designations, designating 29,057,097 shares of our preferred stock as &#8220;Series A Preferred Stock&#8221;. As of the date of this prospectus, 29,057,097 shares of the Series A Preferred Stock have been issued to Sorrento pursuant to the terms of the Merger Agreement and such shares have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Rank </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock shall rank (i)&#160;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Junior Securities&#8221;); and (ii)&#160;on parity with each class or series of our capital stock, created specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Parity Securities&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidation Preference </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company, whether voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to receive an amount per share of Series A Preferred Stock equal to the greater of (i)&#160;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&#160;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conversion and Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-</span></span></span> Common Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designation (a &#8220;Deemed Conversion&#8221;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&#160;stated value by (ii) $10.00 (subject to anti-dilution adjustments). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting and Other Preferred Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a majority of the outstanding shares of Series A Preferred Stock (a)&#160;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms of the Certificate of Designations; (b)&#160;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company, or increase the authorized amount of any such other class or series; or (c)&#160;amend the Certificate of Incorporation or the Certificate of Designations in any manner that adversely affects the holders of Series A Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Stockholder Agreement with Sorrento</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of New Scilex Series A Preferred Stock, among other things, (i) Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the Board, or the size of the Board and (ii) we will be required to take all actions reasonably necessary, and not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to the Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. Notwithstanding the foregoing, the parties have agreed to ensure that the Board complies with all applicable requirements of the stock exchange, including independence requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of the Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. For more information on the Stockholder Agreement, see the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Vickers &#8212;</span> <span style="font-style:italic">Stockholder Agreement with Sorrento.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_100">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Closing of the Business Combination, certain of our stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering the resale of all such registrable securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of these securities will enable the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_101">Anti-Takeover Matters in our Governing Documents and Under Delaware Law </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized but Unissued Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the rules of the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term (except that the term of our current Class&#160;I directors shall expire at the first annual meeting of stockholders following the Closing of the Business Combination and the term of our current Class&#160;II directors shall expire at the second annual meeting of stockholders following the Closing of the Business </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. See the section of this prospectus titled &#8220;<span style="font-style:italic">Management</span>&#8221; for more information on the classified board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board; provided that, at any time prior to a Sorrento Trigger Event, the stockholders may also fix the number of directors by resolution adopted by the stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of Directors; Vacancies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of such directors; provided, however, that, from and after the Sorrento Trigger Event, any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, may be filled by a majority of the directors then in office, although less than a quorum, or by our stockholders; provided, however, that from and after the Sorrento Trigger Event, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes in our management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware Anti-Takeover Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we will opt out of Section&#160;203 of the DGCL until the occurrence of a Sorrento Trigger Event, at which time we shall immediately and automatically become governed by Section&#160;203 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in the election of directors beneficially owned by them. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Stockholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairman of our Board, our Board or the Chief Executive Officer; provided, however, that at any time prior to the Sorrento Trigger Event, special meetings of our stockholders shall also be called by or at the direction of our Board or the Chairman of our Board at the request of Sorrento, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Nominations and Stockholder Proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#8217;s notice must be delivered to our secretary at our principal executive offices not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the first anniversary of the preceding year&#8217;s annual meeting (in the case of the first annual meeting of stockholders held after January&#160;1, 2023, the date of the preceding year&#8217;s annual meeting of the stockholders shall be deemed to be June 30, 2022); provided, however, that, if the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&#8217;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting and the 10th day following the day on which public announcement of the date of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#8217;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Action by Written Consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;228 of the DGCL and the terms of the Certificate of Incorporation , any action required or permitted to be taken by our stockholders must be effected by a duly called annual or special meeting of such stockholders; provided, however, that prior to the Sorrento Trigger Event, any action required or permitted to be taken at any annual or special meeting of our stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is signed by or on behalf of the holders of record of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and voted, is delivered to us in accordance with the DGCL, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Certificate of Incorporation or Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article V (Board of Directors), Article VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article VII (Limitation of Liability), Article VIII (Corporate Opportunities and Competition), Article IX (Exclusive Forum), Article X (Section 203 of the DGCL) and Article XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention of the provisions set forth in any of such Articles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. Upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exclusive Forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders, (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v) any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;) and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <span style="white-space:nowrap">non-employee</span> directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_102">Conflicts of Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&#160;otherwise investing in or providing services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_103">Rights of Appraisal and Payment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to Section&#160;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_104">Stockholders&#8217; Derivative Actions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#8217;s name to procure a judgment in its favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_105">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a warrant to purchase shares of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. As of the date of this prospectus, there are 6,899,988 outstanding Public Warrants and 4,104,000 outstanding Private Placement Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently to all of the warrants, provided that we will provide at least 20 days&#8217; prior written notice to registered holders of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five years from the consummation of the Business Combination (i.e., November&#160;10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Placement Warrants), in whole and not in part, at a price of $0.01 per warrant: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at any time while the warrants are exercisable, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than 30 days&#8217; prior written notice of redemption to each warrantholder, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share <span style="white-space:nowrap">sub-divisions,</span> share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of the Public Warrants, and a current prospectus relating thereto, available throughout the <span style="white-space:nowrap">30-day</span> redemption. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#8217;s warrant upon surrender of such warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#8220;cashless basis.&#8221; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y)&#160;the fair market value. The &#8220;fair market value&#8221; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held 150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#8220;cashless basis&#8221; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants are issued in registered form under a warrant agreement (the &#8220;Warrant Agreement&#8221;) between Continental, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any change that adversely affects the interests of the registered holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of (i)&#160;a stock dividend or split up, (ii)&#160;a consolidation, combination, reverse stock split or reclassification of the Common Stock, (iii)&#160;extraordinary dividend or (iv)&#160;reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state of residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#8217;s affiliates) would beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_106">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#8217;s address is 1 State Street, 30th Floor, New York, New York 10004. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom374624_107">Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on Nasdaq under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW&#8221; respectively. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_108">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_109">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Vickers Vantage Corp. I as of December&#160;31, 2021 and 2020, for the year then ended December&#160;31, 2021, and for the period from February&#160;21, 2020 (inception) through December&#160;31, 2020, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and for the period from January&#160;1, 2021 through December&#160;31, 2021, appearing in this prospectus have been audited by WithumSmith+Brown, PC, independent registered public accounting firm, as set forth in their report thereon (which includes explanatory paragraphs relating to the correction of certain misstatements related to the January&#160;11, 2021 financial statement and Vickers Vantage Corp. I&#8217;s ability to continue as a going concern), appearing elsewhere in this prospectus and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company at December&#160;31, 2021 and 2020, and for the years then ended, appearing in this prospectus, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about our ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Scilex Holding Company for the period ended December&#160;31, 2019, included in this prospectus have been audited by Deloitte&#160;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_109a">CHANGE IN AUDITORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the Closing, on November&#160;10, 2022, the Board dismissed WithumSmith+Brown, PC (&#8220;Withum&#8221;), which served as Vickers&#8217;s independent registered public accounting firm prior to the Business Combination.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The report of Withum on the financial statements of Vickers as of December&#160;31, 2020 and 2021 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles except for an explanatory paragraph in such report regarding substantial doubt about Vickers&#8217;s ability to continue as a going concern and emphasized the restatement of Vickers&#8217;s financial statement as of January&#160;11, 2021 due to its change in accounting for warrants and Vickers Ordinary Shares subject to possible redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&#160;31, 2020 and 2021 and the subsequent interim period through November&#160;10, 2022, there were no disagreements (as defined in Item&#160;304(a)(1)(iv) of <span style="white-space:nowrap">Regulation&#160;S-K)</span> with Withum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of the disagreements in its reports covering such periods. In addition, no &#8220;reportable events,&#8221; as defined in Item&#160;304(a)(1)(v) of <span style="white-space:nowrap">Regulation&#160;S-K,</span> occurred within the period of Withum&#8217;s engagement and the subsequent interim period preceding Withum&#8217;s dismissal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provided Withum with a copy of the disclosures made by us in response to Item&#160;304(a) of <span style="white-space:nowrap">Regulation&#160;S-K</span> and has requested that Withum furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by us in response to Item&#160;304(a) of <span style="white-space:nowrap">Regulation&#160;S-K</span> and, if not, stating the respects in which it does not agree. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, the Board approved the engagement of Ernst&#160;&amp; Young LLP (&#8220;EY&#8221;) as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2022. EY audited the consolidated balance sheets of Scilex as of December&#160;31, 2020 and December&#160;31, 2021 and the related consolidated statements of operations, stockholders&#8217; deficit and cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2020 and 2021 and the subsequent interim period through November&#160;10, 2022, neither the Company nor anyone on its behalf consulted with EY regarding (i)&#160;the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s financial statements, and no written report or oral advice was provided to the Company that EY concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii)&#160;any matter that was the subject of a disagreement within the meaning of Item&#160;304(a)(1)(iv) of <span style="white-space:nowrap">Regulation&#160;S-K&#160;or</span> any reportable event within the meaning of Item&#160;304(a)(1)(v) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom374624_110">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <span style="white-space:nowrap">S-1,</span> including exhibits, under the Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement of which this prospects is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries of those documents&#8217; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#8217;s website at<span style="font-style:italic">&#160;http://www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="hidden61009247" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="0">2483</ix:nonFraction><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="hidden61003888" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3">2483000</ix:nonFraction><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" id="hidden61004186" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3">92255000</ix:nonFraction><ix:nonNumeric name="sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" id="hidden61004144" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">P5D</ix:nonNumeric><ix:nonNumeric name="sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" id="hidden61004145" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">P2D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20220930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div id="rom374624_111" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div><div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_1">Report of Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_2">Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_3">Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_4">Statements of Changes in Shareholders&#8217; (Deficit) Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_5">Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_6">Notes to Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_7">Condensed Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_8">Unaudited Condensed Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-26</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_9">Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-27</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_10">Unaudited Condensed Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-28</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_11">Notes to Unaudited Condensed Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-29</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 24pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="4" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED FINANCIAL STATEMENTS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_12">Report of Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-55</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_13">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_14">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_15">Consolidated Statements of Stockholders&#8217; Deficit for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_16">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-60</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_17">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-61</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_18">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-89</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_19">Consolidated Statements of Operations as of September&#160;30, 2022 and December&#160;31, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-90</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_20">Consolidated Statements of Stockholders&#8217; Deficit as of September&#160;30, 2022 and December&#160;31, 2021 </a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-91</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_21">Consolidated Statements of Cash Flows for the Nine Months Ended September&#160;30, 2022 and 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-92</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin374624_22">Notes to Unaudited Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-93</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and the Board of Directors of </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying balance sheet of Vickers Vantage Corp. I (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related statements of operations, changes in shareholders&#8217; (deficit) equity and cash flows for the year ended December&#160;31, 2021 and for the period from February&#160;21, 2020 (inception) through December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the year ended December&#160;31, 2021 and for the period from February&#160;21, 2020 (inception) through December&#160;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs as well as complete a Business Combination by the close of business on April&#160;11, 2022, then the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement of Previously Issued Financial Statement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 10 to the financial statements, the Company&#8217;s previously issued January&#160;11, 2021 financial statement has ben restated herein to correct certain misstatements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ WithumSmith+Brown, PC </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, New York </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;24, 2022 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PCAOB ID Number 100 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BALANCE SHEETS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">512,457</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">168,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;US Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">199,484</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdvancesFromRelatedParty" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdvancesFromRelatedParty" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory note&#160;&#8212;&#160;related party</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">180,760</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible promissory note&#160;&#8212;&#160;related party, net of discount</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">483,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion option liability</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,240,295</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">180,760</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption <ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction> as of December&#160;31, 2021 and <ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares as of December&#160;31, 2020 at redemption value of $<ix:nonFraction name="sclx:SubjectToPossibleRedemptionPerShares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; (Deficit) Equity</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares issued and outstanding at December&#160;31, 2021 and 2020<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_61002555">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_61002556">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; (Deficit) Equity</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,724</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">199,484</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, includes an aggregate of up to <ix:nonFraction name="sclx:OrdinarySharesRedemptionSubjectedToForfeiture" contextRef="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction> ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January&#160;6, 2021, the Company effected a share capitalization of <ix:nonFraction name="sclx:SharesCapitalization" contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction> shares for each share outstanding, resulting in <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January&#160;11, 2021, <ix:nonFraction name="sclx:OrdinarySharesRedemptionSubjectedToForfeiture" contextRef="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares were forfeited. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 30pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF OPERATIONS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>February&#160;21,<br/>2020<br/>(Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and formation costs</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,005,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,005,498</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income:</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrants</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfWarrantLiability" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,377,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfWarrantLiability" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" sign="-" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of private warrants</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense&#160;&#8212;&#160;debt discount</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to warrant liabilities</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" sign="-" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income, net</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,788,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average shares outstanding, ordinary shares<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_61003170">16,820,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_61003171">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share, ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average shares outstanding, ordinary shares</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,834,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per share, ordinary shares</div></div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;"></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, excludes an aggregate of up to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:OrdinarySharesRedemptionSubjectedToForfeiture" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction></div> ordinary shares that were subject to forfeiture. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; (DEFICIT) EQUITY </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/>Paid in<br/>Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;<br/>Equity<br/>(Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;&#8212;&#160;February&#160;21, 2020 (inception)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares to Sponsor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancellation of ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares to Sponsor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;&#8212;&#160;December&#160;31, 2020 (audited)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,724</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of ordinary shares subject to redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,474,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;&#8212;&#160;December&#160;31, 2021 (audited)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin374624_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF CASH FLOWS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>February&#160;21,<br/>2020<br/>(Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formation cost paid through advances from affiliate of Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt; width: 8%;;text-align:right;"><ix:nonFraction name="sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%; text-align: right;"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,377,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to private warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">801,330</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Units, net of underwriting discounts paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">135,600,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from promissory note &#8212; related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt; width: 8%;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromPromissoryNoteRelatedParty" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromPromissoryNoteRelatedParty" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of promissory note &#8212; related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from convertible promissory note &#8212; related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">416,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">118,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">140,658,740</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">31,787</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">477,410</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#160;&#8212;&#160;Beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#160;&#8212;&#160;End of period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs included in accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:OfferingCostIncludedInAccruedOfferingCost" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:OfferingCostIncludedInAccruedOfferingCost" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid through promissory note&#160;&#8212;&#160;related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 20pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002219"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of <ix:nonFraction name="sclx:Numberofshares" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of <ix:nonFraction name="sclx:Numberofshares" contextRef="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="sclx:ProceedsOfInitialPublicOffering" contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction> which is described in Note 3. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction name="sclx:Saleofwarrants" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per Private Placement Warrant in a private placement to Vickers Venture Fund&#160;VI Pte Ltd and Vickers Venture Fund&#160;VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="sclx:Grossproceedsofwarrants" contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, which is described in Note 4. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $<ix:nonFraction name="sclx:Transactioncostsamount" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,149,473</ix:nonFraction>, consisting of $<ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,400,000</ix:nonFraction> in cash underwriting fees, $<ix:nonFraction name="sclx:DeferredUnderwritingFees" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction> in deferred underwriting fees, and $<ix:nonFraction name="sclx:Otherofferingcosts" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">559,473</ix:nonFraction> of other offering costs. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction> ($<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction> per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. <ix:nonNumeric name="sclx:SaleOfStockDescriptionOfTransactions" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_61002325">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below)</ix:nonNumeric>&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:continuation id="TextSelection_61002219" continuedAt="TextSelectionAppend_61002219_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_61002325">(less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.</ix:continuation> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of <ix:nonFraction name="sclx:Numberofbusinessdays" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_Day" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> business days prior to the consummation of the Business Combination (initially anticipated to be $<ix:nonFraction name="sclx:PricePerPublicShare" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction> per Public Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction name="sclx:NetTangibleAssets" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction> and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of <ix:nonFraction name="sclx:PercentageOfPublicShares" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Public Shares without the Company&#8217;s prior written consent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem <ix:nonFraction name="sclx:BusinessCombinationRedeemPercentage" contextRef="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002219_1" continuedAt="TextSelectionAppend_61002219_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. In connection with the extension, the Sponsors deposited $<ix:nonFraction name="sclx:Depositintotrustaccount" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loan. The Company will have until April&#160;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&#160;11, 2022, the Company may extend the period of time to consummate a Business Combination by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination (the &#8220;Combination Period&#8221;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $<ix:nonFraction name="sclx:Depositintotrustaccount" contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> ($<ix:nonFraction name="sclx:PricePerPublicShare" contextRef="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">0.075</ix:nonFraction> per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem <ix:nonFraction name="sclx:BusinessCombinationRedeemPercentage" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $<ix:nonFraction name="sclx:Interestexpenses" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)&#160;$10.10 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002219_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern and Liquidity </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction> in its operating bank accounts, and working capital of $<ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">303,753</ix:nonFraction>. As of December&#160;31, 2021, approximately $<ix:nonFraction name="us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">31,000</ix:nonFraction> of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through July&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002409"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2&#160;&#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002406"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002409" continuedAt="TextSelectionAppend_61002409_1"><ix:continuation id="TextSelection_61002406"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></ix:continuation><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction> were charged to temporary equity upon the completion of the Initial Public Offering, and $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction> of the offering costs were related to the warrant liabilities and charged to the statements of operations. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002403"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-11 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002409_1" continuedAt="TextSelectionAppend_61002409_2"><ix:continuation id="TextSelection_61002403"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; (deficit) equity section of the Company&#8217;s balance sheets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GrossProceeds" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OrdinarySharesIssuanceCost" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:SharesSubjectToPossibleRedemption" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002401"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions </div></div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-12 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002409_2" continuedAt="TextSelectionAppend_61002409_3"><ix:continuation id="TextSelection_61002401"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002400"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase <ix:nonFraction name="us-gaap:ExcessStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,740,000</ix:nonFraction> ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the <ix:nonFraction name="sclx:Foundershares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction> founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-13 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:continuation id="TextSelectionAppend_61002409_3" continuedAt="TextSelectionAppend_61002409_4"><ix:continuation id="TextSelection_61002400"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,820,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,834,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002397"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for fiscal&#160;years beginning after December&#160;15, 2023, </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-14 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002409_4"><ix:continuation id="TextSelection_61002397"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. </div></div></ix:continuation></ix:continuation><ix:nonNumeric name="sclx:ProposedPublicOfferingTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3&#160;&#8212;&#160;PUBLIC OFFERING </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to <ix:nonFraction name="sclx:NumberOfSaleUnits" contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="sclx:NumberOfSaleUnits" contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at a purchase price of $<ix:nonFraction name="sclx:PurchasePricePerShare" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit. <ix:nonNumeric name="us-gaap:SaleOfStockDescriptionOfTransaction" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</ix:nonNumeric> </div></ix:nonNumeric> <ix:nonNumeric name="sclx:PrivatePlacementTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4&#160;&#8212;&#160;PRIVATE PLACEMENT </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per Private Placement Warrant, for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002599"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,593,750</ix:nonFraction> ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>. In August&#160;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, the Company effected a share capitalization of <ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction> shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,437,500</ix:nonFraction> ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of <ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction> shares for each share outstanding, resulting in <ix:nonFraction name="sclx:OrdinarySharesIssuedAndOutstanding" contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction> ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction> shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&#160;months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-15 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002599" continuedAt="TextSelectionAppend_61002599_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $<ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> to fund expenses in connection with the Initial Public Offering. The advances are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. As of December&#160;31, 2021 and 2020, there was $<ix:nonFraction name="us-gaap:DueToAffiliateCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueToAffiliateCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> advances outstanding, respectively. The outstanding amount of $<ix:nonFraction name="sclx:RepaidAmount" contextRef="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> was repaid on February&#160;26, 2021. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction> was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes. <ix:nonNumeric name="us-gaap:BusinessCombinationControlObtainedDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</ix:nonNumeric> Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the Working Capital Loans. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered into two convertible promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="sclx:AggregatePrincipalAmount" contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> (the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&#160;be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $<ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> of the Convertible Promissory Notes may be converted into warrants at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. As of December&#160;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. Subsequent to December&#160;31, 2021, on January&#160;10, 2022, the Company borrowed an additional $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&#160;loan&#160;the Company up to an aggregate principal amount of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. Subsequent to December&#160;31, 2021, the&#160;principal balance of the Convertible Promissory Notes amounted to an aggregate of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction> (see Note 11). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&#160;2022, the Company&#8217;s expected Business Combination date. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-16 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002599_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company recorded $<ix:nonFraction name="us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826</ix:nonFraction> of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&#160;31, 2021&#160;amounted to $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction>. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination). <ix:nonNumeric name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case).</ix:nonNumeric> Any such deposits would be made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant insider&#8217;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $<ix:nonFraction name="sclx:PricePerWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated, to fund the Trust Account to extend the time for the Company to complete a Business Combination. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002548"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-17 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002548"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:OtherCommitmentsDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.</ix:nonNumeric> The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div></div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7&#160;&#8212;&#160;SHAREHOLDERS&#8217; EQUITY </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December&#160;31, 2021 and 2020, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preference shares issued or outstanding. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction> ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. Holders of ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction> shares of ordinary shares issued and outstanding, excluding <ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction> ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2020, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction> ordinary shares issued or outstanding. </div></ix:nonNumeric> <ix:nonNumeric name="sclx:WarrantsTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002107"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8&#160;&#8212;&#160;WARRANTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, there were <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,900,000</ix:nonFraction> and <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90&#160;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div><ix:nonNumeric name="sclx:PublicWarrantsRedemptionDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_61002100"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; </div></div></td></tr></table></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-18 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002107"><ix:continuation id="TextSelection_61002100">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></td></tr></table></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div><ix:nonNumeric name="sclx:CapitalRaisingDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div></div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021 and 2020, there were <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> and <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> Private Placement Warrants outstanding, respectively. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-19 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002488"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9&#160;&#8212;&#160;FAIR VALUE MEASUREMENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 96%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;1:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;2:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;3:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</td></tr></table><div style="clear:both;max-height:0pt;"></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, assets held in the Trust Account were comprised of $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction> in money market funds which are invested primarily in U.S. Treasury Securities. Through December&#160;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&#160;31, 2020, there were no assets in the Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability&#160;&#8212;&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div><ix:nonNumeric name="us-gaap:FairValueMeasurementsHighestAndBestUseDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_61002448"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002488" continuedAt="TextSelectionAppend_61002488_1"><ix:continuation id="TextSelection_61002448"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </div></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the year ended December&#160;31, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueMeasurementStrikePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in&#160;years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" format="ixt-sec:duryear">5.28</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueOfWarrantsinDollars" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,377,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;20,<br/>2021<br/>(Initial<br/>Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-21 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002488_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001837"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10&#160;&#8212;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 1 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company previously accounted for its outstanding Private Placement Warrants (the &#8220;Warrants&#8221;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies titled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#8220;SPACs&#8221;)&#8221; (the &#8220;SEC Statement&#8221;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In further consideration of the SEC Statement, the Company&#8217;s management further evaluated the Warrants under Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Contracts in Entity&#8217;s Own Equity. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s ordinary shares. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15,</div></div> a warrant is not indexed to the issuer&#8217;s ordinary shares if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that the Company&#8217;s Private Placement Warrants are not indexed to the Company&#8217;s ordinary shares in the manner contemplated by ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> because the holder of the instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on equity shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 2 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition, in connection with the preparation of the Company&#8217;s financial statements as of September&#160;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&#160;30, 2021 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q/A,</div> filed with the SEC on December&#160;8, 2021, includes the restatement of the unaudited March&#160;31, 2021 and June&#160;30, 2021 financial information. Included in the table below is the restatement </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61001837"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">of the audited IPO Balance Sheet as of January&#160;11, 2021 originally filed on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed with the SEC on January&#160;15, 2021. In accordance with ASC 480, paragraph <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99,</div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction> per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $<ix:nonFraction name="us-gaap:IntangibleAssetsCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction>. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the ordinary shares subject </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to possible redemption with the offset recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available), accumulated deficit and ordinary shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the change in presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, ordinary shares share pro&#160;rata in the income (loss) of the Company. </div></div><ix:nonNumeric name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of these adjustments to the financial statement, as previously reported, is presented below. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet as of January&#160;11, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,345,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,074,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">129,999,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">17,110,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,006,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,629,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,635,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,629,412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,474,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,110,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">17,110,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,110,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002214"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11&#160;&#8212;&#160;SUBSEQUENT EVENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:SponsorLoan" contextRef="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-23 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002214"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">total amount into warrants at a price of $<ix:nonFraction name="sclx:WarrantExercisePrice" contextRef="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;27, 2022, the Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $<ix:nonFraction name="sclx:AdditionalPrincipalAmount" contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. The aggregate principal balance of the Convertible Promissory Notes amounted to $<ix:nonFraction name="sclx:ConvertiblePromissoryNote" contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction>. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;"></a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">CONDENSED CONSOLIDATED BALANCE SHEETS</div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Audited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">34,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">130,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">165,749</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">512,457</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,458,835</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#8217; DEFICIT</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">809,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">809,292</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible promissory notes &#8212; related party, net of discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">483,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion option liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simple promissory notes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermNotesPayable" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,971,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermNotesPayable" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,168,759</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,240,295</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption&#160;<ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,726,395</ix:nonFraction>&#160;and&#160;<ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively, at redemption value of $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.41</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>, respectively, per share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; Deficit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value;&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized;&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;issued or outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value;&#160;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized;&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Deficit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,010</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#8217; DEFICIT</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,458,835</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-25 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and formation costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">657,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">283,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,412,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">620,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss from operations</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">657,746</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">283,346</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,412,297</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">620,642</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expense):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">68,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,188,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,872,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of private warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to warrant liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest on mandatorily redeemable ordinary shares liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense &#8212; debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income earned on investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">459,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">664,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income (expense), net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">526,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,161,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,035,813</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">271,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">623,516</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">349,248</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,176,395</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,862,288</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,675,824</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share, ordinary shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.08</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.04</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-26 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div id="fin374624_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8212; January&#160;1, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">806,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">806,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8211; March&#160;31, 2022 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,538,666</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,538,321</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,561,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,561,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8211; June&#160;30, 2022 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,765,076</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,764,731</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,106,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,106,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8211; September&#160;30, 2022 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,355</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,010</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&#160;30, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8212; January&#160;1, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,724</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,474,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,328,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,328,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8211; March&#160;31, 2021 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,152,029</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,151,684</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">233,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">233,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8211; June&#160;30, 2021 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,385,778</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,385,433</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8211; September&#160;30, 2021 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,830,130</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,829,785</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">623,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">349,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income earned on investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">664,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest on mandatorily redeemable ordinary shares liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,188,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,872,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of private warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to warrant liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">126,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">116,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">600,588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">43,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,937,961</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">693,609</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,041,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash withdrawn from Trust Account in connection with redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDecommissioningFund" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">41,824,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDecommissioningFund" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">38,782,626</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Units, net of underwriting discounts paid</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">135,600,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of advances from related party</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from convertible promissory note&#160;&#8211;&#160;related party</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,535,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from simple promissory note&#160;&#8211;&#160;related party</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromSimplePromissoryNoteRelatedParty" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,971,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromSimplePromissoryNoteRelatedParty" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of promissory note&#160;&#8211;&#160;related party</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RepaymentOfPromissoryNoteRelatedParty" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfPromissoryNoteRelatedParty" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">416,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfOtherEquity" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">41,824,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfOtherEquity" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) provided by financing activities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">37,317,625</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">140,158,740</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">472,960</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">85,131</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash &#8211; Beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash &#8211; End of period</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">34,961</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">115,642</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> investing and financing activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-28 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div id="fin374624_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002154"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one wholly owned subsidiary which was formed on February&#160;2, 2022, Vantage Merger Sub Inc., a Delaware corporation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through September&#160;30, 2022 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of&#160;<ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of&#160;<ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;per Unit, generating gross proceeds of $<ix:nonFraction name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction>&#160;which is described in Note 3. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, which is described in Note 4. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,149,473</ix:nonFraction>, consisting of $<ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,400,000</ix:nonFraction>&#160;in cash underwriting fees, $<ix:nonFraction name="sclx:DeferredUnderwritingFees" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction>&#160;in deferred underwriting fees, and $<ix:nonFraction name="us-gaap:OtherOwnershipInterestsOfferingCosts" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">559,473</ix:nonFraction>&#160;of other offering costs </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction>&#160;($<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction>&#160;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S.&#160;Treasuries and meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. On July&#160;11, 2022, the Company extended the period of time to </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-29 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <ix:continuation id="TextSelection_61002154" continuedAt="TextSelectionAppend_61002154_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">consummate a Business Combination to August&#160;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business Combination to November&#160;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $<ix:nonFraction name="us-gaap:NoninterestBearingDepositLiabilities" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,365,554</ix:nonFraction> into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans as of the date of this filing. The Company will have until November&#160;11, 2022 to consummate a Business Combination. As a result, an aggregate of $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction>&#160;as of September&#160;30, 2022 is held in the Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&#160;<ix:nonNumeric name="sclx:SaleOfStockDescriptionOfTransactions" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.</ix:nonNumeric> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $<ix:nonFraction name="sclx:PricePerPublicShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.38</ix:nonFraction>&#160;per Public Share as of the date of this filing), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction>&#160;and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-30 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <ix:continuation id="TextSelectionAppend_61002154_1" continuedAt="TextSelectionAppend_61002154_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of&#160;<ix:nonFraction name="sclx:PercentageOfPublicShares" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Public Shares without the Company&#8217;s prior written consent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem&#160;<ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" contextRef="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem&#160;<ix:nonFraction name="sclx:BusinessCombinationRedeemPercentage" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $<ix:nonFraction name="us-gaap:OtherExpenses" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>&#160;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($<ix:nonFraction name="sclx:DepositIntoTheTrustAccountPerShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.38</ix:nonFraction>&#160;per share). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-31 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:continuation id="TextSelectionAppend_61002154_2" continuedAt="TextSelectionAppend_61002154_3"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trust Account to below (1) $<ix:nonFraction name="sclx:LesserPublicPerShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction>&#160;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#8220;Meeting&#8221;), to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (the &#8220;Extension Amendment&#8221;) to (i)&#160;extend the date by which the Company has to consummate an initial business combination from July&#160;11, 2022 (the &#8220;Original Termination Date&#8221;) to August&#160;11, 2022 (the &#8220;Extended Date&#8221;) and (ii)&#160;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the Extended Date, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023 or a total of up to nine months after the Original Termination Date (the &#8220;Extension Proposal&#8221;). The Company&#8217;s shareholders approved the Extension Amendment at the Meeting. On July&#160;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:BusinessCombinationAcquiredReceivablesDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.</ix:nonNumeric></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deposited an aggregate of $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,295,556</ix:nonFraction>&#160;into the Trust Account to extend the date to consummate a business combination to November&#160;11, 2022 (the &#8220;Combination Period&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern and Liquidity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the Company had $<ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">34,961</ix:nonFraction>&#160;in its operating bank accounts, and working capital deficit of $<ix:nonFraction name="sclx:WorkingCapital" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">643,543</ix:nonFraction>. As of September&#160;30, 2022, approximately $<ix:nonFraction name="us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">696,000</ix:nonFraction>&#160;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-32 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_61002154_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Codification Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> &#8220;Presentation of Financial Statements &#8211; Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through November&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001905"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001844"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-33 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_61001905" continuedAt="TextSelectionAppend_61001905_1"><ix:continuation id="TextSelection_61001844"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> </ix:continuation><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EquityMethodInvestmentsPolicy" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments Held in Trust Account </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-34 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_61001905_1" continuedAt="TextSelectionAppend_61001905_2"><ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction>&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction>&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; deficit section of the Company&#8217;s condensed consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GrossProceeds" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OrdinarySharesIssuanceCost" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccretionOfCarryingValueToRedemptionValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="sclx:SharesSubjectToPossibleRedemption" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityOtherChanges" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">41,824,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccretionOfCarryingValueToRedemptionValue" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,737,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="sclx:SharesSubjectToPossibleRedemption" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table></ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-35 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_61001905_2" continuedAt="TextSelectionAppend_61001905_3"><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001808"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;<ix:nonFraction name="us-gaap:ExcessStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,740,000</ix:nonFraction>&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-36 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_61001905_3" continuedAt="TextSelectionAppend_61001905_4"><ix:continuation id="TextSelection_61001808"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">623,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">349,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,176,395</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,862,288</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,675,824</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.08</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.04</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001926"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed consolidated financial statements. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-37 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61001926"><ix:continuation id="TextSelectionAppend_61001905_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, <div style="letter-spacing: 0px; top: 0px;;display:inline;">accounting </div>standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. </div></div> </ix:continuation></ix:continuation> <ix:nonNumeric name="sclx:ProposedPublicOfferingTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at a purchase price of $<ix:nonFraction name="sclx:PurchasePricePerShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit. <ix:nonNumeric name="us-gaap:SaleOfStockDescriptionOfTransaction" contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</ix:nonNumeric> </div></ix:nonNumeric> <ix:nonNumeric name="sclx:PrivatePlacementTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per Private Placement Warrant, for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction>&#160;per share, subject to adjustment (see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002212"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,593,750</ix:nonFraction>&#160;ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share capitalization of <ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,437,500</ix:nonFraction> ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of&#160;<ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;shares for each share outstanding, resulting in&#160;<ix:nonFraction name="sclx:OrdinarySharesIssuedAndOutstanding" contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction>&#160;ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction>&#160;shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, approximately&#160;<ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-38 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><ix:continuation id="TextSelection_61002212" continuedAt="TextSelectionAppend_61002212_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $<ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction>&#160;to fund expenses in connection with the Initial Public Offering. The advances were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note &#8212; Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>&#160;was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes.&#160;<ix:nonNumeric name="us-gaap:BusinessCombinationControlObtainedDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</ix:nonNumeric>&#160;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>&#160;(the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $<ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>&#160;of the Convertible Promissory Notes may be converted into warrants at a price of $<ix:nonFraction name="sclx:WarrantsExercisePrice" contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company borrowed an additional $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Convertible Promissory Notes amounted to an aggregate of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction>&#160;and $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-39 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002212_1" continuedAt="TextSelectionAppend_61002212_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended September&#160;30, 2022, the Company recorded $<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,155</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction>&#160;of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at September&#160;30, 2022 and December&#160;31, 2021 amounted to $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0 </ix:nonFraction>and $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;(the &#8220;Simple Promissory Notes&#8221;). The Simple Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On April&#160;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,971,667</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&#160;<ix:nonNumeric name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension.</ix:nonNumeric>, </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $<ix:nonFraction name="sclx:WarrantsExercisePrice" contextRef="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to August&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to&#160;September&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-40 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002212_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;9, 2022, the Company extended the period of time to consummate a Business Combination to October&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002082"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:OtherCommitmentsDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.</ix:nonNumeric>&#160;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-41 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002082" continuedAt="TextSelectionAppend_61002082_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Merger Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) by and among Scilex Holding Company (&#8220;Scilex&#8221;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (&#8220;Sorrento&#8221;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#8220;Merger Sub&#8221;). Parent and Merger Sub are sometimes referred to collectively as the &#8220;Parent Parties.&#8221; Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies Law (the &#8220;Domestication&#8221;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the &#8220;Merger&#8221;). Upon the closing of the Merger (the &#8220;Closing&#8221;), it is anticipated that VCKA will change its name to &#8220;Scilex Holding Company&#8221;. The board of directors of VCKA has (i)&#160;approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&#160;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&#160;1 to the Merger Agreement (the &#8220;Amendment&#8221;). The Amendment amends the Merger Agreement to, among other things, provide that: (i)&#160;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&#160;388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&#160;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of Domesticated Parent Common Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#8217;s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of whom will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&#160;at the Effective Time, by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-tenth</div> of one Domesticated Parent Common Share; (v)&#160;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the Merger Agreement; (vi)&#160;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on the Stock Exchange; (vii)&#160;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii)&#160;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from Nasdaq of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-42 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002082_1" continuedAt="TextSelectionAppend_61002082_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with Nasdaq&#8217;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix)&#160;extend the Outside Date to November&#160;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of preferred stock set forth therein from&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction>&#160;to&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">45,000,000</ix:nonFraction>&#160;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from&#160;<ix:nonFraction name="us-gaap:PreferredUnitsAuthorized" contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000,000</ix:nonFraction>&#160;to&#160;<ix:nonFraction name="us-gaap:PreferredUnitsAuthorized" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">785,000,000</ix:nonFraction>&#160;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of certain other customary closing conditions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><ix:nonNumeric name="sclx:MergerConsiderationDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#8220;Merger Consideration&#8221;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#8220;Closing Date&#8221;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#8220;VCKA Common Stock&#8221;).</ix:nonNumeric>&#160;The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a)&#160;<ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>&#160;share of Series A Preferred Stock of Vickers (following the Domestication), par value $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;per share (the &#8220;New Scilex Series A Preferred Stock&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(b)&#160;one-tenth</div> of one share of New Scilex Common Stock, and (iii)&#160;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued shares of New Scilex Common Stock with an aggregate value equal to $<ix:nonFraction name="sclx:CommonStockAggregateValue" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;billion, subject to adjustments for certain debt obligations of Scilex (the &#8220;Merger Consideration&#8221;).&#160;<ix:nonNumeric name="us-gaap:BusinessCombinationReasonForBusinessCombination" contextRef="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#8220;Preferred Consideration&#8221;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#8217;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.</ix:nonNumeric> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-43 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002082_2" continuedAt="TextSelectionAppend_61002082_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Representations and Warranties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;capital structure; (vi)&#160;organizational documents; (vii)&#160;assumed names; (viii)&#160;subsidiaries; (ix) financial statements; (x)&#160;absence of certain changes; (xi)&#160;properties and title to assets; (xii)&#160;litigation; (xiii) contracts; (xiv)&#160;licenses and permits; (xv)&#160;compliance with laws; (xvi)&#160;intellectual property; (xvii)&#160;customers and suppliers; (xviii)&#160;employees and employee benefits; (xix)&#160;employment matters; (xx)&#160;withholding; (xxi) real property; (xxii)&#160;tax matters; (xxiii)&#160;environmental laws; (xiv)&#160;finders&#8217; fees; (xv)&#160;directors and officers; (xvi)&#160;certain business practices; (xvii)&#160;international trade matters and anti-bribery compliance; (xviii)&#160;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&#160;insurance; (xxxi)&#160;related party transactions; (xxxii)&#160;privacy and data security and (xxxiii)&#160;exclusivity of representations and warranties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of the Parent Parties with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;finders&#8217; fees; (vi)&#160;issuance of shares; (vii)&#160;capitalization; (viii) information supplied; (ix)&#160;amount in the trust account; (x)&#160;listing of VCKA securities; (xi)&#160;that VCKA is a reporting company; (xii)&#160;no market manipulation; (xiii)&#160;board approval; (xiv)&#160;SEC documents and financial statements; (xv)&#160;absence of changes; (xvi)&#160;litigation; (xvii) compliance with laws; (xviii)&#160;money laundering laws; (xix)&#160;OFAC; (xx) that VCKA is not an investment company; (xxi)&#160;tax matters; (xxii)&#160;contracts; (xxiii) investigation; and (xiv)&#160;exclusivity of representations and warranties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All representations and warranties by all parties shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Covenants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (the &#8220;Registration Statement&#8221;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party&#8217;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conduct between Signing and Closing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of VCKA, Merger Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-44 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002082_3" continuedAt="TextSelectionAppend_61002082_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conditions to Closing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the Merger is conditioned upon, among other things, (i)&#160;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&#160;the Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); (iii) approval by VCKA&#8217;s shareholders of the Merger and related transactions; (iv)&#160;approval by Scilex&#8217;s stockholders of the Merger and related transactions; and (v)&#160;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&#160;Scilex having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#8217;s ability to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Company Material Adverse Effect; (iv)&#160;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&#160;Scilex providing VCKA a certificate from the secretary which has attached true and complete copies of (a)&#160;Scilex&#8217;s organizational documents, (b)&#160;Scilex&#8217;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&#160;Scilex&#8217;s stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&#160;certified certificate of good standing; (vi)&#160;Scilex shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi)&#160;Sorrento shall have executed the Registration Rights Agreement (as defined below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Solely with respect to Scilex, the consummation of the Merger is conditioned upon, among other things: (i)&#160;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&#160;each of the Parent Parties providing Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v)&#160;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); (vi)&#160;each of VCKA the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&#160;the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&#160;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&#160;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;3a51-1(g)(1)&#160;of</div> the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&#160;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-45 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002082_4" continuedAt="TextSelectionAppend_61002082_5"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Scilex, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&#160;12, 2022 (the &#8220;Debt Exchange Agreement&#8221;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $<ix:nonFraction name="sclx:NetTangibleAssets" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction>&#160;in net tangible assets (as determined in accordance with Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3a51-1(g)(1)</div> of the United States Securities and Exchange Act of 1934) (the &#8220;Net Tangible Assets Condition&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement may be terminated as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">i.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By the mutual consent of VCKA and Scilex; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">ii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&#160;the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">iii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&#160;the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">iv.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either VCKA or Scilex </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on or after November&#160;11, 2022 (the &#8220;Outside Date&#8221;), if the Merger shall not have been consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section&#160;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to such party&#8217;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions shall have become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">v.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-46 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><ix:continuation id="TextSelectionAppend_61002082_5" continuedAt="TextSelectionAppend_61002082_6"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">vi.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;), provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">vii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, in the event that Scilex&#8217;s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on or before March&#160;31, 2022 and remain undelivered prior to the termination of the Merger Agreement </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&#160;17, 2022 (the &#8220;Sponsor Support Agreement&#8221;) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers and Scilex entered into Amendment No.&#160;1 to the Original Support Agreement with the Vickers Shareholders (the &#8220;Support Agreement Amendment&#8221;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (<ix:nonFraction name="sclx:AggregatePercentage" contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>%) of the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&#160;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (<ix:nonFraction name="sclx:WarrantsPercentage" contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">40</ix:nonFraction>%) of all Parent Warrants held by such Vickers Shareholder immediately prior to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Company Stockholder Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March&#160;17, 2022 (the &#8220;Company Stockholder Support Agreements&#8221;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the &#8220;Stockholder Agreement&#8221;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $<ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;per share (&#8220;New Scilex Series A Preferred Stock&#8221;), among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of (i)&#160;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#8220;New Scilex Board&#8221;) at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the New Scilex Board, or (ii)&#160;the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-47 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_61002082_6"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each Stockholder Designee to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common Stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement Amendment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#8220;Maxim&#8221;) entered into an amendment (the &#8220;UWA Amendment&#8221;) of the underwriting agreement between VCKA and Maxim dated January&#160;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&#160;(as defined in the UWA Amendment) as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#8217;s shareholders, the balance in the trust account is $<ix:nonFraction name="sclx:BalanceInTheTrustAccount" contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction>&#160;or less, then the Deferred Underwriting Commission will be payable as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(A)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:DeferredUnderwritingCommission" contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(B)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the remaining&#160;<ix:nonFraction name="sclx:DeferredUnderwritingCommissionPayable" contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the effective date of a Business Combination. </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA Amendment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreements to be Executed at Closing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002128"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#8212;</div></div>&#160;The Company is authorized to issue&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction>&#160;preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;preference shares issued or outstanding. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-48 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><ix:continuation id="TextSelection_61002128"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div>&#160;&#8212; The Company is authorized to issue&#160;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction>&#160;ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;per share. Holders of ordinary shares are entitled to one vote for each share. At September&#160;30, 2022, there were&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction>&#160;shares of ordinary shares issued and outstanding, excluding&#160;<ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,726,395</ix:nonFraction>&#160;ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2021, there were&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction>&#160;shares of ordinary shares issued and outstanding, excluding&#160;<ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;ordinary shares subject to possible redemption which are presented as temporary equity. </div> </ix:continuation> <ix:nonNumeric name="sclx:WarrantsTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61002101"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. WARRANTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, there were&#160;<ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,900,000</ix:nonFraction></ix:nonFraction>&#160;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <ix:nonNumeric name="sclx:PublicWarrantsRedemptionDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $<div style="display:inline;">0.01 </div>per warrant; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than <div style="display:inline;">30 </div>days&#8217; prior written notice of redemption to each warrant holder; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $<div style="display:inline;">18.00&#160;</div>per share (subject to adjustment) for any <div style="display:inline;">20 </div>trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-49 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_61002101"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div> <ix:nonNumeric name="sclx:CapitalRaisingDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $<div style="display:inline;">9.20 </div>per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <div style="display:inline;">60</div>% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the <div style="display:inline;">20 </div>trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $<div style="display:inline;">9.20 </div>per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <div style="display:inline;">115</div>% of the higher of the Market Value and the Newly Issued Price, the $<div style="display:inline;">18.00 </div>per share redemption trigger price will be adjusted (to the nearest cent) to be equal to <div style="display:inline;">180</div>% of the higher of the Market Value and the Newly Issued Price. </div></div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;<ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction></ix:nonFraction>&#160;Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001944"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. FAIR VALUE MEASUREMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;1:</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></div></td></tr></table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-50 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div> <ix:continuation id="TextSelection_61001944" continuedAt="TextSelectionAppend_61001944_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;2:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;3:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, assets held in the Trust Account were comprised of $<ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction>, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through September&#160;30, 2022, the Company did not withdraw any interest earned on the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at September&#160;30, 2022 and December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability &#8211; Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Private Placement Warrants were accounted for as liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and are presented within warrant liabilities on our accompanying September&#160;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div> <ix:nonNumeric name="us-gaap:FairValueMeasurementsHighestAndBestUseDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_61001929"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-51 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <ix:continuation id="TextSelectionAppend_61001944_1" continuedAt="TextSelectionAppend_61001944_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_61001929"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </div> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&#160;30, 2022 and 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div> <ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueMeasurementStrikePrice" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueMeasurementStrikePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" format="ixt-sec:duryear">5.00</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" format="ixt-sec:duryear">5.28</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueOfWarrantsinDollars" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueOfWarrantsinDollars" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001762"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,104,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,625,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">68,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,693,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of September&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,856,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,504,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">410,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,762,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,530,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,231,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">68,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-52 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_61001944_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div> <ix:continuation id="TextSelection_61001762"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;10, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;27, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">69,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">76,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">76,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022 and September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_61001725"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10. SUBSEQUENT EVENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="us-gaap:LeaseDepositLiability" contextRef="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-53 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <ix:continuation id="TextSelection_61001725"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment of certain outstanding loans (the &#8220;Company Obligations&#8221;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt Contribution Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in exchange for the issuance of that number of shares of shares of common stock, par value $<ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;per share, of the Company, determined by dividing the Company Obligations by $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;(the &#8220;Contribution Shares&#8221;) to the Sponsors immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Debt Exchange Agreement, on October&#160;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set forth in such written request. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#8220;Warrant Transfer Agreement&#8221;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">On October&#160;17, 2022, the Company entered into a Letter Agreement with Sorrento and the Sponsors (the &#8220;Letter Agreement&#8221;) to provide that certain shares held by the Sponsors will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> restrictions only in an amount necessary to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&#160;<ix:nonFraction name="sclx:NumberOfSharesLimits" contextRef="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the Company&#8217;s shareholders ahead of the extraordinary general meeting of the Company&#8217;s shareholders on November&#160;9, 2022. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-54 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Stockholders of Scilex Holding Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, stockholders&#8217; deficit and cash flows for each of the two years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Ability to Continue as a Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May&#160;13, 2022 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-55 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">To the stockholders and the Board of Directors of </div></div><div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated statements of operations, stockholders&#8217; equity, and cash flows of Scilex Holding Company and subsidiaries (the &#8220;Company&#8221;) for the year ended December&#160;31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the results of the Company&#8217;s operations and cash flows for the year ended December&#160;31, 2019, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered negative working capital, recurring losses from operations, recurring negative cash flows from operations and cumulative net losses that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matter </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1 to the financial statements, the accompanying financial statements have been prepared from the separate records maintained by the Company and may not necessarily be indicative of the conditions that would have existed or the results of operations if the Company had been operated as an unaffiliated company of Sorrento Therapeutics, Inc. Portions of certain income and expenses represent allocations made from home-office items applicable to the Company as a whole. </div></div><div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Deloitte&#160;&amp; Touche LLP </div></div><div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;23, 2020 </div></div><div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">We began serving as the Company&#8217;s auditor in 2018. In 2020 we became the predecessor auditor. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-56 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div><div id="fin374624_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for par value and share amounts) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;"><div style="line-height: 8pt; font-size: 8pt;;font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current assets</div></div>:</div></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accounts receivable, net</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Inventory</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Intangibles, net</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Goodwill</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Long-term deposit</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accrued payroll</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Current portion of debt</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Related party payable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Related party note payable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Long-term debt, net of discount</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Related party note payable</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Derivative liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">301,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">223,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (See Note 11)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Deficit:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>shares issued or outstanding at December&#160;31, 2021 and 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">197,266,338</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">264,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; deficit</div></div></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to consolidated financial statements </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-57 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div><div id="fin374624_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for net loss per share amounts) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,317</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating costs and expenses:</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AcquiredinprocessresearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AcquiredinprocessresearchAndDevelopment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AcquiredinprocessresearchAndDevelopment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible amortization</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating costs and expenses</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">159,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">138,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other expense</div></div>:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss (gain) on derivative liability</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on debt extinguishment, net</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Pharma Notes principal increase</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss (gain) on foreign currency exchange</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other expense</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,897</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,419</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-comma-decimal">88.424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share&#160;&#8212;&#160;basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares during the period&#160;&#8212;&#160;basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,266</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,315</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">187,524</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="margin-top: 180pt; margin-bottom: 0px; text-align: center;"><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">See accompanying notes <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> consolidated financial statements</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-58 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares issued related to Semnur Acquisition</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to Sorrento</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">216,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options excercised</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to Sorrento</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancellation of shares held in escrow related to Semnur Acquisition</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">264,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to shares issued in Semnur Acquisition</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 265pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">See accompanying notes to consolidated financial statements</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-59 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019</div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used for operating activities:</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs and debt discount</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Pharma Notes principal increase</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:IncreaseInNotesPayableOne" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:IncreaseInNotesPayableOne" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:IncreaseInNotesPayableOne" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on debt extinguishment, net</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease cost</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss (gain) on derivative liability</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur-related IPR&amp;D</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,417</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term deposits</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,836</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party payable</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Net cash used for operating activities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31,461</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">60,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Semnur, net of cash acquired</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Net cash used for investing activities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">&#8212;<div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of principal on the Scilex Pharma Notes</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment on other loans</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from other loans</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,007</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from stock options exercised</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party payable</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party note payable</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party note payable</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,518</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used for) financing activities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">501</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">50,656</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62,269</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of year</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,495</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,764</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px; width: 75%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of year</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,495</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures:</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;">Supplemental disclosures of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> investing and financing activities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> consideration in Semnur acquisition</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,591</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur acquisition costs incurred but not paid in accounts payable</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">601</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other loan forgiveness</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,536</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> distribution to Sorrento</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashDistributionToAcquiree" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashDistributionToAcquiree" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,600</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashDistributionToAcquiree" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,800</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 3em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%; padding-bottom: 0.375pt;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; padding-bottom: 0.375pt;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%; padding-bottom: 0.375pt;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; padding-bottom: 0.375pt;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%; padding-bottom: 0.375pt;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; padding-bottom: 0.375pt;"><div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Pharma Notes principal increase</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashIncreaseInPrincipal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashIncreaseInPrincipal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashIncreaseInPrincipal" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of cash, cash equivalents and restricted cash within the Company&#8217;s balance sheet</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,295</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,200</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px; width: 75%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"><div style="text-indent: -1em; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Cash, cash equivalents and restricted cash</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,495</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td></tr></table><div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;;text-indent: 0px;">&#160;</div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="margin-block: 0em; text-indent: 0px; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to consolidated financial statements </div></div><div style="clear: both; max-height: 0px;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-60 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="clear: both; max-height: 0px;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY </div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fin374624_17">Notes to Consolidated Financial Statements </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; and together with its wholly owned subsidiaries, <div style="display:inline;">the</div> &#8220;Company&#8221;) was incorporated in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P02_01_2019To02_28_2019" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric> in February&#160;2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;). The Company is a commercial-stage, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> pain management company focused on the development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October&#160;2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company is currently developing two product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase&#160;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;),</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction>&#160;million <div style="letter-spacing: 0px; top: 0px;;display:inline;">in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger&#8221;), with Semnur surviving as the Company&#8217;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company. Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding.</div> </div></div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP-103</div> and the commercialization of ZTlido. </div> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="sclx:LiquidityAndGoingConcernTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61001984"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern at least one year after the date the financial statements are issued. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61001984"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, the Company&#8217;s negative working capital was $<ix:nonFraction name="sclx:NetWorkingCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">146.4</ix:nonFraction>&#160;million, including cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2021, the Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>had operating losses of $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">35.8</ix:nonFraction>&#160;million and negative cash flows from operations of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">28.7</ix:nonFraction>&#160;million. The Company had an accumulated deficit of approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">352.6</ix:nonFraction>&#160;million as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018, Scilex Pharma issued $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.0</ix:nonFraction>&#160;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">140.0</ix:nonFraction>&#160;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum unrestricted cash balance of $<ix:nonFraction name="sclx:MinimumUnrestrictedCashBalance" contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction>&#160;million at the end of each month. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">2020, Scilex Pharma repurchased an aggregate of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">65.0</ix:nonFraction>&#160;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $<ix:nonFraction name="sclx:RestrictedFundsRelesableForFutureRepurchaseOfDebt" contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction>&#160;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the purpose of consummating the repurchase of an aggregate of $45.0&#160;million of principal amount. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021 and <div style="letter-spacing: 0px; top: 0px;;display:inline;">April&#160;</div>2021, Scilex Pharma effected specified principal repurchases totaling $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction>&#160;million of the principal amount of the Scilex Pharma Notes. On December&#160;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction>&#160;million. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2022, Scilex Pharma drew down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#8217;s obligation to repurchase $<ix:nonFraction name="sclx:DebtInstrumentRepurchaseObligation" contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash balance of $<ix:nonFraction name="sclx:MinimumUnrestrictedCashBalance" contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div></div>18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least </div></div>twelve&#160;months from the issuance of these consolidated financial statements through debt and equity financing. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61002600"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant Accounting Policies </div></div></div></td></tr></table> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div> </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61002600" continuedAt="TextSelectionAppend_61002600_1"> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. </div></div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. As of December&#160;31, 2021 and 2020, the Company&#8217;s inventory was primarily comprised of finished goods. </div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61002600_1" continuedAt="TextSelectionAppend_61002600_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004040"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and services that will be used </div></div></div></ix:nonNumeric> <div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61002600_2" continuedAt="TextSelectionAppend_61002600_3"> <ix:continuation id="TextSelection_61004040"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 730, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development</div></div>. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:InProcessResearchAndDevelopmentPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#8217;s deferred tax assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></div></div></ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-65 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61002600_3" continuedAt="TextSelectionAppend_61002600_4"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition&#160;</div> </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#8217;s revenue and accounts receivable result from a sole customer. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For product sales, the Company records <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div> sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#8217;s consolidated balance sheet. </div></div></ix:nonNumeric> <ix:nonNumeric name="sclx:RebatesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.</div></div></div></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="sclx:ServiceFeesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div></div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="sclx:SalesReturnsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</div></div></div></ix:nonNumeric><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><ix:nonNumeric name="sclx:CoPaymentAssistancePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrators. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-66 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61002600_4" continuedAt="TextSelectionAppend_61002600_5"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Customer Concentration Risk </div></div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">During the fiscal years ended December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, 2020 and 2019, sales to the Company&#8217;s sole distributor represented <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts </div></div> for stock-based compensation in accordance with FASB ASC Topic 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Compensation</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of determining </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#8217;s consolidated statement of operations. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div> are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-opioid<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <br/></div></ix:nonNumeric> </ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61002600_5" continuedAt="TextSelectionAppend_61002600_6"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004044"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October</div></div>&#160;2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</div></div>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal&#160;years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.</div></ix:nonNumeric></ix:continuation><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-67 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61002600_6"><ix:continuation id="TextSelection_61004044"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div>2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </div></ix:continuation></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004045">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur Acquisition </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">70.0</ix:nonFraction>&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million, and (b)&#160;$<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction>&#160;million of shares of the Company&#8217;s common stock (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction> shares issued and <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction> shares issuable, valued at $<ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction> per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately <ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction>% of the Company&#8217;s issued and outstanding capital stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">280.0</ix:nonFraction>&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction>&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of a Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product, (2)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product, (3)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">500.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product, and (4)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">750.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;7, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&#160;the </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued liabilities.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2019, the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>following the closing of the Merger, </div><ix:nonFraction name="sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodDuringWhichTheSharesMayBeExchanged" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durday">60</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div><ix:nonNumeric name="sclx:PeriodDuringWhichShareTransferIsRestricted" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durmonth">18</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div><ix:nonFraction name="sclx:CommonStockValueToBeExchanged" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durday">30</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price of one share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b)&#160;$</div><ix:nonFraction name="sclx:PricePerShareForDeterminingTheExchangeOfShares" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.55</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div>9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-68 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004045"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;">common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;31, 2020, Sorrento held approximately <ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction>% of the outstanding common stock of the Company. On January&#160;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately <ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction>% of the outstanding common stock of the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million was expensed as a component of acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development during the year ended December&#160;31, 2019. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004050"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></td></tr></table><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs&#160;(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">in&#160;Active</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004050" continuedAt="TextSelectionAppend_61004050_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative liabilities </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded a loss of $</div><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, a gain of $</div><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">0.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss of $</div><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on derivative liabilities for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded features as further described in Note </div>8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model. This involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions.</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-69 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004050_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">6.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast and an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast, an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">15</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and an estimated probability of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included an </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast, an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">19.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and estimated probabilities of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">55</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring prior to October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div></td></tr></table> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers&#160;&amp; equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">691</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">934</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, <div style="letter-spacing: 0px; top: 0px;;display:inline;">net</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense<div style="display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div><ix:nonFraction name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">39</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, $</div><ix:nonFraction name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and $</div><ix:nonFraction name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, respectively.</div></div></ix:nonNumeric><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004073">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had recorded goodwill of $</div><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.5</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. </div><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-70 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004073"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004090">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):</ix:nonNumeric></div><ix:continuation id="TextSelection_61004090"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:continuation><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the weighted average remaining life for identifiable intangible assets is </div><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">10.6</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Aggregate amortization expense was $</div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">15</ix:nonNumeric></ix:nonNumeric>-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">5</ix:nonNumeric>-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period.</div></div><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment charges related to intangible assets were recorded during the&#160;years ended </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020. </div></div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004098">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;</div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements, on September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear">2026</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">140.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bank </div></div></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-71 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004098" continuedAt="TextSelectionAppend_61004098_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net proceeds of the Offering were approximately $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">89.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, after deducting the Offering expenses payable by Scilex Pharma and funding a segregated reserve account with $</div><ix:nonFraction name="sclx:PaymentToDepositIntoASeggregateReserveFund" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Reserve Account&#8221;) and a segregated collateral account with $</div><ix:nonFraction name="sclx:PaymentToDepositIntoASegregatedCollateralAccount" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Collateral Account&#8221;) pursuant to the terms of the Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#8217;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with respect to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or a similar product with a concentration of not less than </div><ix:nonFraction name="sclx:PercentageOfConcentrationOnASimilarProduct" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% (the &#8220;Marketing Approval Letter&#8221;) on or prior to July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Funds in the Collateral Account were to be released to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On each February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, May&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, August&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and November&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, beginning with February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the holders of the Scilex Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed&#160;percentage, ranging from </div><ix:nonFraction name="sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex Pharma did not receive the Marketing Approval Letter by March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the&#160;percentage of net sales payable was increased to be in the range of </div><ix:nonFraction name="sclx:PercentageOfNetSalesPayable" contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfNetSalesPayable" contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. If actual cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">218.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">218.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the Indenture, the aggregate principal amount due under the Scilex Pharma Notes was to be increased by $</div><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">481.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not equal or exceed the $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million threshold for such period, the Company recorded the increase of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If actual cumulative net sales of ZTlido for the period from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">290.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on </div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">November 15, 2023</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by between approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">84.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the principal increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> is less than approximately $</div>290.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The final maturity date of the Scilex Pharma Notes is </div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">August 15, 2026</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Scilex Pharma Notes may be redeemed in whole at any time upon </div><ix:nonNumeric name="sclx:DebtInstrumentredemptionPeriod" contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt-sec:durday">30</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; written notice at Scilex Pharma&#8217;s option prior to August&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2026<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a redemption price equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the then-outstanding principal amount of the Scilex Pharma Notes. In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#8217;s Scilex Pharma Note at a repurchase price in cash equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">101</ix:nonFraction>% of the then-outstanding principal amount </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thereof. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The 2018 Purchase&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreements include the terms and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">type. </div></div></div></ix:continuation></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-72 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004098_1" continuedAt="TextSelectionAppend_61004098_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least </div><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare </div><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become due and payable.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger, amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#8220;Collateral Agreement&#8221;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or modifications of such product made, developed or licensed (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensed)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by Scilex Pharma or any of its affiliates or licensees (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensees)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (including </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (the &#8220;Letter of Credit&#8221;), which provides that, in the event that </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma did not hold at least $</div><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in unrestricted cash as of the end of any calendar month during the term of the Scilex Pharma Notes, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than a specified sales threshold for such period, or </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento would be required to pay to Scilex Pharma, $</div><ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&#160;the repayment of the Scilex Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exchange by the Company that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes.</div></div></div></ix:continuation></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004098_2" continuedAt="TextSelectionAppend_61004098_3"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On December&#160;14, 2020, Scilex,</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex Note Purchasers entered into a Consent Under and Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Indenture and Letter of Credit (&#8220;Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8221;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit. </div></div></div><div style="font-size: 8pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-73 </div></div></div><div style="margin-top: 4pt; margin-bottom: 6pt; break-before: page; padding-top: 0pt; padding-bottom: 0pt;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004098_3" continuedAt="TextSelectionAppend_61004098_4"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders agreed to release all of the aggregate $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in restricted funds held in the Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount of the Scilex Pharma Notes from the Holders on a pro&#160;rata basis at a purchase price equal to </div><ix:nonFraction name="sclx:PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof (such repurchase, the &#8220;Scilex Repurchase&#8221;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&#160;Sorrento&#8217;s obligations under the Indenture to repurchase $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&#160;Scilex Pharma&#8217;s obligation to repurchase $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing Approval Letter on or prior to</div> <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis" format="ixt:date-monthname-day-year-en">July 1, 2023</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, be equal to at least $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate, provided that if Scilex Pharma did not effectuate (i)&#160;the December Optional Repurchase (as defined below) and (ii)&#160;at least one of either (x)&#160;the February Optional Repurchase (as defined below) or (y)&#160;the April Optional Repurchase (as defined below), then, commencing with the month ending April&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and for each month thereafter, such amount would have been required to be at least $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will be required to draw on the Letter of Credit.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also provided Scilex Pharma with the option, in its sole and absolute discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis on each of December&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;December Optional Repurchase&#8221;), February&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;February Optional Repurchase&#8221;) and April&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;April Optional Repurchase&#8221;), in each case in an aggregate amount equal to the lesser of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to </div><ix:nonFraction name="sclx:PercentageOfThePrincipalAmountOfTheNotes" contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and resulted in the minimum unrestricted requirement remaining at $</div><ix:nonFraction name="sclx:MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> further provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis in an aggregate amount equal to the lesser of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to </div><ix:nonFraction name="sclx:PercentageOfThePrincipalAmountOfTheNotes" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on, Scilex Pharma is required to have minimum cash of $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at all times thereafter. In February&#160;</div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the principal amount of the Scilex Pharma Notes and became subject to a minimum cash requirement of $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders also consented to Scilex Pharma incurring up to $</div><ix:nonFraction name="sclx:LineOfCreditFacilityindebtednessAmount" contextRef="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below).</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounted for Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as a debt modification under ASC Topic </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as modified terms were not substantially different than the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-modified</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> terms. The execution of Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> resulted</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>in an additional derivative liability of $</div><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which pertains to a $</div><ix:nonFraction name="sclx:AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $</div><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million reduction to the debt discount on the Scilex Pharma Notes.</div><br/></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow method under the income approach, which involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and the discounted rate of return reflective of the Company&#8217;s credit </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risk. </div></div></div><div style="font-size: 8pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-74 </div></div></div><div style="margin-top: 4pt; margin-bottom: 6pt; break-before: page; padding-top: 0pt; padding-bottom: 0pt;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004098_4" continuedAt="TextSelectionAppend_61004098_5"><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Pharma Notes are as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden61004186">92,25</span>8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtfutureMinimumPaymentYearOne" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum future payments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPayment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made principal payments of $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">69.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the fiscal&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and debt issuance costs, which are presented as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a&#160;percentage of net sales of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, respectively. The amount of debt discount and debt issuance costs included in interest expense for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was approximately $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note </div>5)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> this assessment each reporting period.</div></div></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004098_5" continuedAt="TextSelectionAppend_61004098_6"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the holders of at least </div><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes of the Scilex Pharma Notes, an event of default includes, among other things, (i)&#160;Scilex Pharma&#8217;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&#160;Scilex Pharma&#8217;s breach of its representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&#160;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma. The Company is in compliance with event of default clauses.</div><br/></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-75 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><ix:continuation id="TextSelectionAppend_61004098_6"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma issued to Sorrento a promissory note (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a note payable with Sorrento (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund&#160;I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $</div><ix:nonFraction name="sclx:LineOfCreditFacilityindebtednessAmount" contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.75</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2024<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">; unless the Credit Agreement is earlier terminated. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the outstanding balance was $</div><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company notified CNH that it was terminating the Credit Agreement, effective </div><ix:nonNumeric name="sclx:DebtInstrumentTerminationDate" contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">March 18, 2022</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Upon termination, all principal balances and interest accrued were </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">settled.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Paycheck Protection Program </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May&#160;</div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received the proceeds from a loan in the amount of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;PPP Loan&#8221;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The PPP Loan matures on </div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en">May 05, 2022</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and bears interest at a rate of </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% per annum. The PPP Loan is evidenced by a promissory note dated May </div>03<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Note&#8221;), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warranties.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $</div><ix:nonFraction name="sclx:MaximumCompensationCostToBeAvailableProratedBasis" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, prorated annually. Not more than </div><ix:nonFraction name="sclx:PercentageOfLoanForgivenessUnderTheAct" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the forgiven amount may be for </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payroll</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $</div><ix:nonFraction name="sclx:MinimumPayrollCostToBeAvailable" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or less annually are reduced by more than </div><ix:nonFraction name="sclx:PercentageOfLoanForgivenessUnderTheAct" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a gain on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Equity </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of authorized shares of preferred stock of Scilex Holding is </div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares were issued and outstanding at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The total number of authorized shares of common stock of Scilex Holding is </div><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,266,338</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares were issued and outstanding at&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020. </div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004058">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June&#160;</div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan (the &#8220;Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan&#8221;). The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan reserved </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan was amended and restated on July&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-76 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><ix:continuation id="TextSelection_61004058" continuedAt="TextSelectionAppend_61004058_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the Merger Closing, the Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors of the Company adopted the Scilex Holding Company </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan (the &#8220;</div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan&#8221;) on May&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. On December&#160;</div>21<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the board of directors approved an amendment to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan to reserve an additional </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</ix:nonNumeric></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, options to purchase </div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">28,163,510</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">26,743,510</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan and options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,420,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">18,256,490</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total unrecognized compensation costs related to unvested employee and nonemployee stock option grants as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">1.8</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Valuation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004091">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below:</ix:nonNumeric></div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004058_1" continuedAt="TextSelectionAppend_61004058_2"><ix:continuation id="TextSelection_61004091">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">89.00</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">104.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.53</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.63</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">5.60</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.76</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">6.08</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:continuation></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-77 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004058_2" continuedAt="TextSelectionAppend_61004058_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#8217;s common stock.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected stock-price volatility</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bonds with maturities similar to those of the expected term of the award being valued.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term of options</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Holding issued stock options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">March&#160;17 and March&#160;31, 2019 Valuations </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performed on March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the Company&#8217;s common stock was estimated using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#8220;OPM&#8221;) to allocate the concluded equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#8217;s common stock of $</div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn03_17_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">May&#160;31, 2019 Valuation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on May&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the Company&#8217;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;), which estimates the value by<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $</div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn05_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of May&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December&#160;31, 2019 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on December&#160;31, 2019, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company </div></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-78 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004058_3" continuedAt="TextSelectionAppend_61004058_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction> per share as of December&#160;31, 2019. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">July&#160;31, 2020 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on July&#160;31, 2020, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn07_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction> per share as of July&#160;31, 2020. </div></div><br/></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>average<br/>exercise&#160;price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,641</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.68</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,163</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">915</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.11</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table></ix:nonNumeric></ix:continuation></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004058_4"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a defined contribution </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan totaling $</div><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-79 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004095">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2013<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> parties (the &#8220;Developers&#8221;), </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">35</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> aggregate royalty payments. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:AgreementExpirationDate" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en">October 2, 2028</ix:nonNumeric></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ten</div> years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">one-year</ix:nonNumeric></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the Developers terminate it upon </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">6-month</ix:nonNumeric></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div><ix:nonNumeric name="sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">180</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days after notice requesting to cure; </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div><ix:nonFraction name="sclx:ThresholdMinimumPercentageOfSales" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of </div>four<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b)&#160;after </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days of good-faith discussion; </div>(4)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or </div>(5)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma or either </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of the Developers are bankrupt or make assignment for the benefit of creditors.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Up to the date the financial statements were issued, Scilex&#8217;s net profits for ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> have not exceeded </div>five<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within </div>three<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Developers to provide commercial supply of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-80 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004095" continuedAt="TextSelectionAppend_61004095_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Distribution Agreement</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August&#160;</div>2015<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div><ix:nonFraction name="sclx:PercentageOfAnnualAdjustmentToFees" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen"><div style="letter-spacing: 0px; top: 0px;;display:inline;">three</div> years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year each, unless written notice of termination is given by either party at least </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to early </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in </div>April 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma began directly selling and transferring title to distributors.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January&#160;</div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September&#160;</div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will remain in effect until June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and may be extended for additional periods of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year upon the mutual agreement of both parties. Either party may terminate the work order with </div><ix:nonNumeric name="sclx:NoticePeriodForTerminationOfWorkOrder" contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">90</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; notice. Scilex Pharma paid an implementation fee of $</div><ix:nonFraction name="sclx:WorkOrderImplementationFee" contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">59.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">63.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">65.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing services.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more lawsuits. Other than the following </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lawsuits, the Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> manufacturers of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (OTC) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax Pharmaceuticals, Inc., a company now headed by Mr.&#160;Mack,</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-81 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004095_1" continuedAt="TextSelectionAppend_61004095_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">alleging</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, among other things, breach by Mr.&#160;Mack of his </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> agreement with the Company and his fiduciary duties to the Company, and tortious interference by Virpax with that </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> agreement. Both lawsuits are ongoing.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases administrative and research and development facilities under various </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s leases have remaining lease terms of approximately </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">2.7</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">2.9</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. The term of the Company&#8217;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company has </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> finance leases.</div></div><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease expense were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_61002970">623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_61002969">904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_61002968">776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. </div></div></div></td></tr></table></ix:nonNumeric> </ix:continuation></div></div> <div style="text-align: center;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004095_2" continuedAt="TextSelectionAppend_61004095_3"><ix:nonNumeric name="sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">2.8</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">3.8</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004095_3" continuedAt="TextSelectionAppend_61004095_4"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-82 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><ix:continuation id="TextSelectionAppend_61004095_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Operating</div> lease expense totaled approximately $</div><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004049">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</div><br/></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense limitations</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsInterestExpenseLimitations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsInterestExpenseLimitations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,285</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); width: 73%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,939</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,412</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">56,643</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,514</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,296</ix:nonFraction></div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,898</ix:nonFraction></div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0);">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Liabilities</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,296</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,898</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">56.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">43.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million against its deferred tax assets as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively. Realization of the deferred tax assets will <div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">e </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-83 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;;text-indent: 0px;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004049" continuedAt="TextSelectionAppend_61004049_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">primarily<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses.</div></div><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s benefit from income taxes are as follows for the year ended December 31: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal Income Tax Rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal tax benefit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and interest limitation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">10.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">11.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to provision adjustments and carryback</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">11.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">14.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">13.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">14.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Tax Benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had net operating loss carryforwards of approximately $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">167.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal and $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">81.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in </div><ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2034</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for state and </div><ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2035</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for federal, except for $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">154.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the federal net operating losses that have an indefinite carryforward period.</div></div></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004049_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the&#160;years ended December&#160;31, 2021, 2020, and 2019, there was no impact of such limitations on the Company&#8217;s income tax provision.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also has research and development and orphan drug credits of approximately $</div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in </div><ix:nonNumeric name="sclx:TaxCreditCarryforwardExpirationYear" contextRef="P01_01_2021To12_31_2021">2035</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the Company&#8217;s tax&#160;years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the accounting guidance for uncertainty in income taxes pursuant to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC-740-10.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#8220;more likely than not&#8221; to be sustained upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a </div><ix:nonFraction name="sclx:MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% likelihood of being sustained.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unrecognized tax benefits balances as of December&#160;31, 2021, 2020 and 2019 and the related increases and decreases to the balances were immaterial.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. </div><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> interest and penalties have been recognized as of and for the periods ended December&#160;31, 2021, 2020 and 2019.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that no material amount of liabilities for uncertain tax positions will expire within 12&#160;months of December&#160;31, 2021.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-84 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004035">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b)&#160;$</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div><ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;31, 2019. Following the completion of the Semnur Share Exchange and as of December&#160;31, 2020, Sorrento held approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, 2020 and 2019, the Company purchased approximately $</div><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations. As of December&#160;31, 2020, approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">14.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;13, 2021, </div><ix:nonFraction name="sclx:NumberOfSharesOutstanding" contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;13, 2021. On January&#160;29, 2021, Sorrento acquired </div><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who has served on the Company&#8217;s board of directors since March&#160;2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> To date, the Company has made no royalty payments pursuant to the Assignment Agreement.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the&#160;years ended December&#160;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The note is interest bearing at the lesser of (a)&#160;</div><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&#160;31, 2021 and 2020 was $</div><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the note payable of $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). Scilex Pharma may borrow up to an aggregate of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a)&#160;</div><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-85 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004035"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn10_02_2018" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,117,608</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $</div><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.1</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.3</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the promissory note of $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.5</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.4</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, in February&#160;2021 and April&#160;2021, respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February&#160;2021 and April&#160;2021, totaling $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 8. The $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">37.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February&#160;2021 and April 2021 is due on demand to Sorrento and was recorded under the related party payables in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021, related party payables due to Sorrento included $</div><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><ix:nonFraction name="us-gaap:LegalFees" contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 11). As of December&#160;31, 2020, related party payables due to Sorrento consisted of $</div><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements and $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes.</div><br/></div></ix:continuation></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">187,524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share&#160;</div><div style="font-size: 10pt; line-height: 107%; font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">187,524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the&#160;years ended December&#160;31, 2021, 2020, and 2019 of </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively. </div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_61004022">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following events were identified subsequent to the balance sheet date. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SPAC Transaction </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#8220;Merger Agreement&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of Vickers (&#8220;Merger Sub&#8221;). Pursuant to the terms of the Merger Agreement, (i)&#160;Merger </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sub will </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-86</div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004022" continuedAt="TextSelectionAppend_61004022_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">merge with and into the Company</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">, with the Company surviving the merger (&#8220;combined company&#8221;) and (ii)&#160;become a wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>owned subsidiary of Vickers (collectively, the &#8220;SPAC Transaction&#8221;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Pharma Note </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February&#160;2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at a purchase price in cash equal</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>to <ix:nonFraction name="sclx:PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the principal amount. In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million at all times going </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">forward. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $</div><ix:nonFraction name="sclx:SalesThresholdLimit" contextRef="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">481.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million sales threshold for such period.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances on Related Party Note Payable </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2022, Sorrento made advances to the Company in the amount of $</div><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million under the related party note payable entered into on March&#160;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payable. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition from Sorrento </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On May&#160;12, 2022</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(DBR-LDN)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets&#8221;) and the Company is currently analyzing the accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;2022 Promissory Note&#8221;). The 2022 Promissory Note matures </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.66</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#8220;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration Shares&#8221;) or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within </div><ix:nonNumeric name="sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durday">60</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days of the issuance of such Consideration Shares.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i)&#160;$</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in</div></div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-87 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004022_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Aardvark Asset Purchase Agreement) (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii)&#160;$</div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with its acquisition of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets, the Company has agreed that if it issues any shares of the Company&#8217;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within </div><ix:nonNumeric name="sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" contextRef="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durday">60</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>days following the date on which any such shares are issued.</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder, chief executive officer and a member of the board of directors of Aardvark.</div></div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_181" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF SEPTEMBER&#160;30, 2022 AND DECEMBER&#160;31, 2021 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands, except for par value and share amounts; unaudited) </div></div></div></div><div id="fin374624_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">September&#160;30,<br/>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December&#160;31,<br/>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term deposit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of deferred consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of debt</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">166,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party note payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">251,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term deferred consideration</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party note payable, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">318,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">301,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (See Note 8)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Deficit:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding at September&#160;30, 2022 and December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">197,566,338</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">197,266,338</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">358,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">229,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div>9</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin374624_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021 </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands, except for net loss per share amounts; unaudited) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating costs and expenses:</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,549</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible amortization</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating costs and expenses</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense:</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on derivative liability</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Gain) loss on debt extinguishment, net</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Gain) loss on foreign currency exchange</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other (income) expense</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,377</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax (benefit) expense</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares during the period &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,550</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,266</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statements </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin374624_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands; unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Common Stock</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Accumulated<br/>Deficit</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Total</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Aardvark <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> license transfer from Sorrento, net of discount</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Aardvark <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> discount amortization</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">358,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">229,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Common Stock</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Accumulated<br/>Deficit</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Total</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">264,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to shares issued in Semnur Acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, September&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">310,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">183,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statements </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands; Unaudited) </div></div></div></div> <div id="fin374624_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows for the Nine Months Ended September&#160;30, 2022 and 2021 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine Months Ended<br/>September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used for operating activities:</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs and debt discount</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,813</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(Gain) loss on debt extinguishment, net</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease cost</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on derivative liability</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables, net</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term deposits</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Related party payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used for operating activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition consideration paid in cash for Romeg intangible asset acquisition</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property, plant, and equipment</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used for investing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of principal on the Scilex Pharma Notes</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,376</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment on other loans</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from other loans</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from stock options exercised</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party payable</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party note payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at beginning of period</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at end of period</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 9pt; line-height: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures of non-cash investing and financing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deferred consideration for Romeg intangible asset acquisition</div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,650</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash consideration in Semnur acquisition</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 9pt; line-height: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other loan forgiveness</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,536</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PromissoryNoteIssuedNetOfDiscount" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,162</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PromissoryNoteIssuedNetOfDiscount" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="line-height: 9pt; font-size: 9pt;"> <div style="margin-left: 0in; font-size: 9pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div>Fair value adjustment to derivative liability in troubled debt restructuring</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashFairValueAdjustmentToDerivativeLiability" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,400</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashFairValueAdjustmentToDerivativeLiability" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Live Action right-of-use asset in Palo Alto</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashRightOfUseAsset" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">320</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashRightOfUseAsset" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statement </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-92</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div><div id="fin374624_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Unaudited Consolidated Financial Statements </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In connection with the business combination with Vickers Vantage Corp. I (as more fully described in these notes to the financial statements), Scilex Holding Company was renamed Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior <div style="display:inline;">to</div> the completion of such business combination. </div></div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004023">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#8220;Sorrento&#8221;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10&#160;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> naltrexone hydrochloride delayed-release capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-104&#8221;),</div> a novel formulation for the treatment of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fibromyalgia. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired </div><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly-owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger of Semnur&#8221;), with Semnur surviving as the Company&#8217;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and the commercialization of ZTlido.</div></div><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"></div><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"></div> <ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004024"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;BCA&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition</div></div></ix:nonNumeric></ix:nonNumeric> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004023" continuedAt="TextSelectionAppend_61004023_1"><ix:continuation id="TextSelection_61004024"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company, and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#8220;Legacy Scilex&#8221;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $</div><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">290.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;</div>11<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill or other intangible assets recorded.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had capitalized $</div><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of costs incurred in relation to the Business Combination. There were </div><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capitalized costs in relation to the Business Combination as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#8217;s </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fiscal year, or any subsequent period.</div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004023_1"> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there have been </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> beginning on page </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> thereof.</div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="sclx:LiquidityAndGoingConcernTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004029">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year after the date the financial statements are issued.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s negative working capital was $</div><ix:nonFraction name="sclx:NetWorkingCapital" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">219.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, including cash and cash equivalents of approximately $</div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had operating losses of $</div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">30.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and cash flows used for operations of $</div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">20.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company had an accumulated deficit of approximately $</div><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">358.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In </div>August 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. Pursuant to Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, a principal balance of $</div><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was forgiven by the Scilex Pharma Note Purchasers (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> upon the Company&#8217;s exercise of the Early Paydown Provision. The Company funded the principal payments with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-on</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> hand and $</div><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received from Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento and Scilex entered into a Funding Commitment Letter (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company, Sorrento shall fund </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more loans to the Company in the amount to achieve $</div><ix:nonFraction name="us-gaap:MinimumNetWorthRequiredForCompliance" contextRef="PAsOn10_17_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets immediately following the effective time of the Business Combination. Such related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $</div><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $</div><ix:nonFraction name="sclx:AggregateOutstandingAmount" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">310,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company did not draw funds from the Funding Commitment Letter at the effective time of the Business Combination.</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004029"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (see Note 3). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of the acquired licenses. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are issued. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004034"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Semnur Acquisition</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">70.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock </div>(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately </div><ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the holders of Semnur equity (the &#8220;Semnur Equityholders&#8221;) up to $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">280.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-96 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004034" continuedAt="TextSelectionAppend_61004034_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">500.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, and </div>(4)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">750.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liabilities. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months following the closing of the Merger, </div><ix:nonFraction name="sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodDuringWhichTheSharesMayBeExchanged" contextRef="P03_01_2019To03_31_2019" format="ixt-sec:durday">60</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div><ix:nonNumeric name="sclx:PeriodDuringWhichShareTransferIsRestricted" contextRef="P03_01_2019To03_31_2019" format="ixt-sec:durmonth">18</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div><ix:nonFraction name="sclx:CommonStockValueToBeExchanged" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durday">30</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $</div><ix:nonFraction name="sclx:PricePerShareForDeterminingTheExchangeOfShares" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.55</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div>9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was expensed as a component of acquired </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> research and development during the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;DBR-LDN&#8221;)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets&#8221;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in </div>April 2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> pursuant to an asset purchase agreement</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004034_1" continuedAt="TextSelectionAppend_61004034_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition&#8221;). </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;</div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note&#8221;). Upon issuance of the note, the Company recorded a related party note payable liability of $</div><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note matures </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.66</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note is payable in cash, shares of the Company&#8217;s common stock or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">penalty. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Derivatives and Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#8217;s accounting policy for contingent consideration in an asset acquisition. </div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized at September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">,&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder and chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Aardvark.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GLOPERBA License Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with the right to sublicense, under the patents and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> specified therein (with such license to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> being exclusive for the limited purposes specified therein) to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States of America (including its territories) (the &#8220;Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States in 2020. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for the license under the Romeg License Agreement, the Company paid Romeg an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> license fee of $</div><ix:nonFraction name="sclx:UpfrontlicenseFee" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $</div><ix:nonFraction name="sclx:MilestonePayment" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, (b)&#160;certain royalties in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digit to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-double</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $</div><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million commencing on the first year anniversary of the</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">98</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004034_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effective date of the Romeg License Agreement and ending on the later of (i)&#160;expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the effective date of the Romeg License Agreement. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $</div><ix:nonFraction name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is comprised of the upfront license fee of $</div><ix:nonFraction name="sclx:UpfrontlicenseFee" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a deferred consideration of $</div><ix:nonFraction name="sclx:DeferredConsideration" contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent s</div>ale<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">s milestones and sales volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and will not be recognized until the contingencies are realized. </div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized as a liability or included in the fair value of the asset as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company determined the useful life of the intangible asset to be approximately </div><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen">15 years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, which approximates the life of the licensed patents covering the Initial Licensed Product.</div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004057"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Fair value measurements at September&#160;30, 2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Balance</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level&#160;1)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><span style="-sec-ix-hidden:hidden61009247">2.4</span>83</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 0pt; line-height: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"><span style="-sec-ix-hidden:hidden61003888">2.4</span>83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;">Balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative liabilities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded a gain of $</div><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">5.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">0.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on derivative liabilities for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $</div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million immediately after the entry into Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> associated with the Scilex Pharma Notes on June&#160;</div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was accounted</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">99</div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004057"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4. Significant Level&#160;3 assumptions used in the measurement included a </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">6.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast and an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">21.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% as of June&#160;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were </div><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> remaining derivative liabilities as of September&#160;30, 2022.</div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>value</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value measurement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004086"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had recorded goodwill of $</div><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.5</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. The conclusion has not changed as of September&#160;30, 2022 and </div><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the nine months ended September&#160;30, 2022 and 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004088">A summary of the Company&#8217;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):</ix:nonNumeric></div> <ix:continuation id="TextSelection_61004088"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/>amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/>amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,871</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,089</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired licenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>31.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/>amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/>amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $</div><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was assigned to acquired licenses with an amortization period of approximately </div><ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">15</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-100</div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004086"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the weighted average remaining life for identifiable intangible assets was </div></div><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">10.6</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">years. Aggregate amortization expense was $</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2022 and 2021, respectively. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">15</ix:nonNumeric>-year</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">5-year</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> period.</div><br/></div> <ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in thousands):</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amount</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining three months)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004131"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;2018 Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the 2018 Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear">2026</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">140.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">481.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which resulted in a $</div><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million increase in the principal amount of the Scilex Pharma Notes, effective <div style="letter-spacing: 0px; top: 0px;;display:inline;">February&#160;15, 2022</div>. As a result, the Company recorded the increase of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in principal and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> expense at December&#160;31, 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $</div><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&#160;4 to Indenture (the &#8220;Amendment No.&#160;4&#8221;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;4, (1)&#160;on </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> June&#160;3, 2022, Scilex Pharma repurchased approximately $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction>&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at <ix:nonFraction name="sclx:DebtInstrumentPercentageOfPrincipalAmountRepurchased" contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the principal amount thereof, (2)&#160;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before <ix:nonNumeric name="us-gaap:DebtInstrumentRepurchaseDate" contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">September 30, 2022</ix:nonNumeric> for $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction>&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $<ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction>&#160;million of the aggregate principal amount of the Scilex Pharma Notes (the &#8220;Early Paydown Provision&#8221;), (3) the minimum </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cash</div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-101 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a>&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004131" continuedAt="TextSelectionAppend_61004131_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirement under the Indenture was reduced to $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction></div>&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&#160;the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento on October&#160;5, 2018 was increased from up to $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to up to $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company funded the repurchase with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cash-on-hand</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received from Sorrento on June&#160;2, 2022, which was recorded under the current related party notes payable in the Company&#8217;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&#160;4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&#160;4, and accordingly, </div><ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> gain was recognized in the quarter ended June&#160;30, 2022. Due to a decrease of $</div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&#160;4, the carrying value of the Scilex Notes was increased by $</div><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">39.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. Pursuant to Amendment No.&#160;4, $</div><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The C<div style="display:inline;">o</div>mpany recorded a gain on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">33.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as a result of the extinguishment. There are </div><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> derivative liabilities as of September&#160;30, 2022.</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Notes consisted of the following (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">September&#160;30,&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;">December&#160;31,&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnamortizedDebtDiscount" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:UnamortizedDebtDiscount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made principal payments of $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">106.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">44.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the nine months ended September&#160;30, 2022 and 2021, respectively. The imputed effective interest rate at December&#160;31, 2021 was </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&#160;30, 2022 and 2021 was approximately $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. The Company recorded a gain on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in connection with its repayments of principal made during the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&#160;18, 2019, the Company entered into a note payable with Sorrento (see Note 10). On February&#160;14, 2022, Sorrento paid to Scilex Pharma $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan (see Note 10). On May&#160;12, 2022, the Company issued Sorrento a promissory note of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in exchange for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (see Note 3).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-102 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004131_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $<ix:nonFraction name="sclx:LineOfCreditFacilityindebtednessAmount" contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.75</ix:nonFraction>%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;1, 2024; unless the Credit Agreement is earlier terminated. As of December&#160;31, 2021, the outstanding </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">balance was $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.8</ix:nonFraction>&#160;million. On February&#160;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective <ix:nonNumeric name="sclx:DebtInstrumentTerminationDate" contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">March 18, 2022</ix:nonNumeric>. Upon termination, all principal balances and interest accrued were settled. </div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004114"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In June </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). The Scilex Pharma 2017 Plan reserved </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</ix:nonNumeric> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> acquire common stock of Scilex </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;7, 2019. As of December&#160;31, 2019, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction>&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. On December&#160;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the 2019 Stock Option Plan. As of December&#160;31, 2020, </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</ix:nonNumeric></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,159,760</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,054,760</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,105,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. As of September&#160;30, 2022, </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">20,945,240</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">T</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">he total unrecognized compensation costs related to unvested employee and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> stock option grants as of September&#160;30, 2022 was $</div><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:duryear">1.4</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years.</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-103 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004114"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $</div><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the nine months ended September&#160;30, 2022 and 2021, respectively.</div><br/></div> </ix:continuation></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004084"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with two parties (the &#8220;Developers&#8221;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">between </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">35</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div><ix:nonNumeric name="sclx:AgreementExpirationDate" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en">October 2, 2028</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">one-year</ix:nonNumeric></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the Developers terminate it upon </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">6-month</ix:nonNumeric></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div><ix:nonNumeric name="sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">180</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;31, 2023, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div><ix:nonFraction name="sclx:ThresholdMinimumPercentageOfSales" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, the Company&#8217;s net profits for ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma. </div></div></ix:nonNumeric> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-104 </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_61004084" continuedAt="TextSelectionAppend_61004084_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Distribution Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div><ix:nonFraction name="sclx:PercentageOfAnnualAdjustmentToFees" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to distributors.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until June&#160;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with </div><ix:nonNumeric name="sclx:NoticePeriodForTerminationOfWorkOrder" contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">90</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days&#8217; notice. Scilex Pharma paid an implementation fee of $</div><ix:nonFraction name="sclx:WorkOrderImplementationFee" contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">59.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">63.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">65.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">services. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the nine months ended September&#160;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-105 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; font-size: 10pt; background: none;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004084_1" continuedAt="TextSelectionAppend_61004084_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#8220;Sanofi- Aventis&#160;&amp; Hisamitsu Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement. The case was tried from September <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-14,</div> 2022. Post-trial briefing is underway and closing arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;Aveva Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.</div></div></ix:continuation><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-106 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div><ix:continuation id="TextSelectionAppend_61004084_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div><ix:nonNumeric name="sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 14%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating cash flows from operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ROU assets obtained in exchange for new operating lease</div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;">liabilities</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn09_30_2022" format="ixt-sec:duryear">2.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn09_30_2021" format="ixt-sec:duryear">3.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">11.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>June 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a new </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is </div><ix:nonNumeric name="us-gaap:LessorOperatingLeaseTermOfContract" contextRef="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durmonth">26</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months and the Company expects to exercise the extension option at the end of the lease.</div><br/></div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (Remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#8217;s ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company&#8217;s deferred tax assets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s income tax (benefit) expense of $</div>(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-2" scale="3" sign="-" format="ixt:num-dot-decimal">36.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) thousand and $</div><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand reflect effective tax rates of </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.02</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the expected statutory federal tax rate of </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and the </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% effective tax rate for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was primarily attributable to income tax expense associated with changes in a valuation </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">allowance. </div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004076"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive </div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-107 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004076" continuedAt="TextSelectionAppend_61004076_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">. Following the completion of the Share Exchange and as of December&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfCapitalSharesOutstanding" contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">14.7</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NumberOfSharesOutstanding" contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company purchased approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations.</div></div></ix:continuation> <div style="margin-top: 1em; margin-bottom: 1em"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004076_1" continuedAt="TextSelectionAppend_61004076_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who served on the Company&#8217;s board of directors from March 2019 through September 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single</div> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div> Through September&#160;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&#160;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction></div>&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to the Company in the amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.4</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the note payable. The outstanding principal balance of the note on September&#160;30, 2022 and December&#160;31, 2021 was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">47.1</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.6</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.8</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. During the nine months ended September&#160;30, 2022, the proceeds from the note payable were used to finance the operations of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note i</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">n the amount of approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under </div><br/></div></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-108 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_61004076_2" continuedAt="TextSelectionAppend_61004076_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,117,608</ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">0</ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.1</ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.9</ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.5</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in February 2022 to fund the payment of Scilex Pharma Notes in February 2022 totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 6. The $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February 2022 is due no earlier than February 2030 and was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional funding received from Sorrento is due on demand and recorded under the related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022, related party payables due to Sorrento included $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">48.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LegalFees" contextRef="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for litigation fees (see Note 8). As of December&#160;31, 2021, related party payables due to Sorrento consisted of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LegalFees" contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 8).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;May&#160;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.66</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. As of September&#160;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.2</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt Exchange Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i)&#160;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">27.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Debt Exchange Agreement effective</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as of immediately prior to, and contingent upon, the closing of the</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Business Combination, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento has elected to contribute the Outstanding Indebtedness</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the Company in exchange for the issuance by the Company to</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento of that number of shares of preferred stock, par value $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) </div><br/></div></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-109 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><ix:continuation id="TextSelectionAppend_61004076_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">tha</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">t is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfOutstandingAmountIndebtedness" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Aggregate Outstanding Amount divided by (ii) $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PerShareCalculationOfOutstandingAmountInExchangeOfShares" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:LimitationOfOutstandingAmountInExchangeOfShares" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">310,000,000</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of September&#160;30, 2022, the Aggregate Outstanding Amount was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">276.8</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, pursuant to the terms of the Debt Exchange Agreement, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">290.6</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, was contributed by Sorrento to the Company in exchange for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">29,057,097</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s preferred stock. At the Effective Time, such shares were then exchanged for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">29,057,097</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex preferred stock and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,905,710</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex common stock.</div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004030"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the nine months ended September&#160;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method. </div></div></ix:nonNumeric> </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004030"> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&#160;30, 2022 and 2021 were </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_61004025"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of September&#160;30, 2022, and the nine months then ended, through November&#160;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through November&#160;30, 2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Commitment Letter </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;October&#160;17, 2022, Sorrento and the Company entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined company to have $</div><ix:nonFraction name="us-gaap:MinimumNetWorthRequiredForCompliance" contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets as of immediately following the effective time of the Business Combination (the &#8220;Effective Time&#8221;) under the BCA (the &#8220;Net Tangible Assets Condition&#8221;)), Sorrento agreed to fund one or more loans to the Company in the amount set forth in such written request (a &#8220;Loan Request&#8221;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-110</div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_61004025"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $<ix:nonFraction name="sclx:AggregateOutstandingAmount" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">310,000,000</ix:nonFraction>. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment to Amended and Restated Certificate of Incorporation</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from </div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">45,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $</div><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share, of Legacy </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Absorbed Liabilities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October </div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">and November 2022, Sorrento entered into agreements with certain of the Company&#8217;s third party professional service providers to assume $</div><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million of liabilities accrued by the Company, of which $</div><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&#160;10, 2022 under the terms of the Debt Exchange </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Agreement (see </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Note 10).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">Committed Equity Financing</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;YA II&#8221;). Pursuant to the Yorkville Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $</div><ix:nonFraction name="us-gaap:CommonStockSharesSubscriptions" contextRef="PAsOn11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to YA II&#8217;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the </div><div style="font-size: 10pt; text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" contextRef="P11_11_2022To11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" format="ixt-sec:durmonth">36</ix:nonNumeric>-month</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to YA II (each, an &#8220;Advance Notice&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">While</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;there is no mandatory minimum amount for any Advance, an Advance may be for a number of shares of New Scilex common stock not to exceed </div><ix:nonFraction name="sclx:MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">200</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the </div><span style="-sec-ix-hidden:hidden61004144">five</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> trading days immediately preceding the date of the Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to an Advance will be purchased at a price equal to </div><ix:nonFraction name="sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% of the lowest daily VWAP (as defined below) during the </div><span style="-sec-ix-hidden:hidden61004145">two</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> consecutive trading days commencing on the date of delivery of an Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the New Scilex common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Advance.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">As</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;consideration for YA II&#8217;s commitment to purchase shares of New Scilex common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued </div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> shares of New Scilex common stock to YA II.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-111 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN THE PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Expenses of Issuance and Distribution. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by Scilex Holding Company (the &#8220;Registrant&#8221;) in connection with the sale of the Common Stock being registered. The security holders will not bear any portion of such expenses. All amounts shown are estimates except for the registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,826.82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing, transfer agent fees and miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">293,826.82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Indemnification of Directors and Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) permits a corporation to eliminate or limit the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or derived an improper personal benefit, or, with respect to any officer, any action by or in the right of the corporation. The Registrant&#8217;s restated certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;) contains provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the DGCL. Consequently, the Registrant&#8217;s directors and officers will not be personally liable to the Registratnt or its stockholders for monetary damages for any breach of fiduciary duty as a director, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to the Registrant or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any officer, any action by or in the right of the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of the Registrant&#8217;s directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with such action, suit or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The Certificate of Incorporation permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant&#8217;s bylaws (the &#8220;Bylaws&#8221;) provide that the Registrant will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors&#8217; and officers&#8217; liability insurance. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Recent Sales of Unregistered Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth information as to all of the Registrant&#8217;s securities sold in the last three years which were not registered under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The descriptions of these issuances are historical and have not been adjusted to give effect to the Business Combination. Capitalized terms used and not defined in this Item 15 have the meaning given to them in the prospectus which forms a part of this registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On July&#160;16, 2020, the Registrant issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of Venture Fund VI (Plan) Pte Ltd (&#8220;Sponsor One&#8221;) and Vickers Venture Fund VI Pte Ltd (&#8220;Sponsor Two&#8221; and, together with Sponsor One, the &#8220;Sponsors&#8221;) for an aggregate purchase price of $25,000, or approximately $0.007 per share. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On January&#160;11, 2021, the Registrant consummated the sale of 6,840,000 private placement warrants at a price of $0.75 per private placement warrant in a private placement to the Sponsors, generating gross proceeds of $5,130,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On October&#160;17, 2022, the Registrant issued an aggregate of 533,057 shares of Common Stock to the Sponsors pursuant to the Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;), dated as of October&#160;17, 2022, between the Sponsors and the Registrant, in exchange for the Sponsors&#8217; contribution to the Registrant of approximately $5.3&#160;million of indebtedness described in the Debt Contribution Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On November&#160;17, 2022, the Registrant issued 250,000 shares of Common Stock to the Selling Securityholder in consideration for the Selling Securityholder&#8217;s irrevocable commitment to purchase shares of Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act in reliance on the exemption afforded by Section&#160;4(a)(2) thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;16.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits and Financial Statements Schedules </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(a) Exhibits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following exhibits are filed as part of this registration statement: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:87%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d1.htm">Agreement and Plan of Merger, dated as of March&#160;18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section&#160;1.8(a), Section&#160;3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d2.htm">Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of August&#160;7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely as the representative of the Equityholders and, solely with respect to Section&#160;1.8(a), 3.11 and Article X of the Agreement and Plan of Merger, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.2 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on October June&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.3#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d3.htm">Bill of Sale and Assignment and Assumption Agreement, dated May&#160;12, 2022, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.3 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.4&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d4.htm">Asset Purchase Agreement, dated April&#160;23, 2021, between Sorrento Therapeutics, Inc. and Aardvark Therapeutics, Inc., as assumed by Scilex Holding Company on May&#160;12, 2022, pursuant to the Bill of Sale and Assignment and Assumption Agreement, dated as of such date, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.4 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex2-1_vickers1.htm">Agreement and Plan of Merger, dated as of March&#160;17, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex2-1.htm">Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex31.htm">Restated Certificate of Incorporation of Scilex Holding Company (incorporated by reference to Exhibit 3.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex32.htm">Certificate of Designations of Scilex Holding Company (incorporated by reference to Exhibit 3.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex33.htm">Bylaws of Scilex Holding Company (incorporated by reference to Exhibit 3.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390021001411/ea133037ex4-1_vickers1.htm">Warrant Agreement, dated as of January&#160;6, 2021, by and between Vickers Vantage Corp. I and Continental Stock Transfer&#160;&amp; Trust Company (incorporated by reference to Exhibit 4.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on January&#160;11, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;5.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d374624dex51.htm">Opinion of Paul Hastings LLP. </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex101.htm">Amended and Restated Registration Rights Agreement, dated as of November&#160;10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex102.htm">Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d7.htm">Scilex Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.4*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d8.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.5*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d9.htm">Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.9 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d10.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.10 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.7*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex105.htm">Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.8*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex106.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 of our Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.9*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex107.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex108.htm">Scilex Holding Company 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-1_vickers1.htm">Sponsor Support Agreement, dated as of March&#160;17, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex10-2.htm">Amendment No.&#160;1 to Sponsor Support Agreement, dated as of September&#160;12, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.2 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on September&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.13</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-2_vickers1.htm">Company Stockholder Support Agreement, dated as of March&#160;17, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on March&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.14*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d17.htm">Offer Letter, dated as of April&#160;19, 2019, between Scilex Pharmaceuticals Inc. and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.15*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d21.htm">Offer Letter, dated as of April&#160;27, 2022, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.21 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.16&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-22.htm">Commercial Supply Agreement, dated as of February&#160;16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.17&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-23.htm">First Addendum to Commercial Supply Agreement, dated as of August&#160;31, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.18&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-24.htm">Second Addendum to Commercial Supply Agreement, dated as of May&#160;9, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.19</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-25.htm">Third Addendum to Commercial Supply Agreement, dated as of August&#160;30, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.20#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d26.htm">Exclusive Distribution Agreement, dated as of August&#160;6, 2015, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.26 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d27.htm">Amendment to Exclusive Distribution Agreement, dated as of May&#160;24, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.27 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.22#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d28.htm">Second Amendment to Exclusive Distribution Agreement, dated as of September&#160;19, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.28 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.23</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d29.htm">Third Amendment to Exclusive Distribution Agreement, dated as of October&#160;1, 2021, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, LLC (f/k/a Cardinal Health 105, Inc.). (incorporated by reference to Exhibit 10.29 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.24&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-33.htm">Supply Agreement, dated as of December&#160;17, 2015, by and between Genzyme Corporation and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.25&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-34.htm">Product Development Agreement, dated as of May&#160;11, 2011, by and between Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation. (incorporated by reference to Exhibit 10.34 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-35.htm">First Amendment to Product Development Agreement, dated as of April&#160;2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.27&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-36.htm">Second Amendment to Product Development Agreement, dated as of February&#160;20, 2017, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.28&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-37.htm">Third Amendment to Product Development Agreement, dated as of August&#160;29, 2018, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-38.htm">Fourth Amendment to Product Development Agreement, dated as of December&#160;13, 2019, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.30</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-39.htm">Fifth Amendment to Product Development Agreement, dated as of April&#160;30, 2021, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.31&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d40.htm">Master Services <span style="white-space:nowrap">Agreement&#160;&#8212;&#160;SP-102,</span> dated as of January&#160;27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.32</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d41.htm">Amendment No.&#160;1 to Master Services Agreement, dated as of April&#160;26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.41 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.33</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d42.htm">Novation Agreement re Master Services Agreement, dated as of June&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.42 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.34#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d43.htm">Master Services Agreement, dated as of November&#160;23, 2020, by and between Aardvark Therapeutics Inc. and Tulex Pharmaceuticals Inc. as assumed by Scilex Holding Company on May&#160;12, 2022, as novated to Scilex Holding Company, pursuant to the Novation Agreement re Master Services Agreement, dated as of June&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit&#160;10.43 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.35&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d44.htm">License and Commercialization Agreement, dated as of June&#160;14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.36&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-45.htm">Indenture, dated as of September&#160;7, 2018, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent (incorporated by reference to Exhibit 10.45 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.37#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-46.htm">Omnibus Amendment No.&#160;1 to Indenture and Letter of Credit, dated as of October&#160;1, 2019, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.46 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.38&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-47.htm">Omnibus Amendment No.&#160;2 to Indenture and Letter of Credit, dated as of March&#160;30, 2020, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.47 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.39#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-48.htm">Consent Under and Amendment No.&#160;3 to Indenture and Letter of Credit, dated as of December&#160;14, 2020, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.48 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.40#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-49.htm">Consent Under and Amendment No.&#160;4 to Indenture, dated June&#160;2, 2022, among Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., U.S. Bank Trust Company, National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.49 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.41#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-50.htm">Collateral Agreement, dated as of September&#160;7, 2018, by and between Scilex Pharmaceuticals Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 10.50 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.42&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-51.htm">Irrevocable Standby Letter of Credit, dated as of September&#160;7, 2018, issued by Sorrento Therapeutics, Inc. in favor of Scilex Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.51 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-52.htm">Subordinated Promissory Note, dated as of February&#160;14, 2022, issued by Scilex Pharmaceuticals Inc. in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.52 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.44#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-53.htm">Contribution and Loan Agreement, dated as of March&#160;18, 2019, by and among Scilex Holding Company, Sorrento Therapeutics, Inc., the stockholders of Scilex Pharmaceuticals Inc. signatories thereto, and Scilex Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.53 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.45</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-54.htm">Promissory Note, dated as of March&#160;18, 2019, issued by Scilex Holding Company in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.54 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-55.htm">Intercompany Promissory Note, dated as of October&#160;5, 2018, issued by Scilex Pharmaceuticals Inc. in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.55 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.47#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-56.htm">Credit and Security Agreement, dated as of December&#160;14, 2020, by and between Scilex Pharmaceuticals Inc. and CNH Finance Fund I, L.P. (incorporated by reference to Exhibit 10.56 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.48&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d57.htm">Assignment Agreement, dated August&#160;6, 2013, between Semnur Pharmaceuticals, Inc. and Shah Investor LP (incorporated by reference to Exhibit 10.57 of Amendment No.&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on June&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.49#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-58.htm">Promissory Note, dated as of May&#160;12, 2022, issued by Scilex Holding Company in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.58 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.50&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-59.htm">Office Lease, dated as of August&#160;8, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San&#160;Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.51&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-60.htm">First Amendment to Office Lease, dated as of September&#160;15, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.52&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-61.htm">Sublease Agreement, dated as of May&#160;18, 2022, by and between Scilex Holding Company and Live Action, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.&#160;2 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on July&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d59.htm">Stockholder Agreement, dated as of September&#160;12, 2022, between Vickers Vantage Corp. I and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.59 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.54#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d60.htm">Contribution and Satisfaction of Indebtedness Agreement, dated as of September&#160;12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60 of Amendment No.&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> <span style="white-space:nowrap">(File&#160;No.&#160;333-264941),</span> filed with the SEC on September&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.55</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-61.htm">Letter Agreement, dated October 17, 2022, between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on October&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.56#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-62.htm">Warrant Transfer Agreement, dated October&#160;17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd and for the limited purposes set forth therein, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.62 of Amendment No.&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on October&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.57#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-63.htm">Debt Contribution Agreement, dated October&#160;17, 2022, by and among Vickers Vantage Corp. I, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (incorporated by reference to Exhibit 10.63 of Amendment No.&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on October&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.58</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-64.htm">Letter Agreement, dated October&#160;17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.64 of Amendment No.&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File <span style="white-space:nowrap">No.&#160;333-264941),</span> filed with the SEC on October&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.59</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287974/d401087dex101.htm">Standby Equity Purchase Agreement, dated as of November&#160;17, 2022, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;18, 2022) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;16.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex161.htm">Letter from WithumSmith+Brown, PC. to the Securities and Exchange Commission (incorporated by reference to Exhibit 16.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex211.htm">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-39852),</span> filed with the SEC on November&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d374624dex231.htm">Consent of WithumSmith+Brown, PC, independent registered public accounting firm of Vickers Vantage Corp, I. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.2+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d374624dex232.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm of Scilex Holding Company. </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.3+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d374624dex233.htm">Consent of Deloitte&#160;&amp; Touche LLP, former independent registered public accounting firm of Scilex Holding Company. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.4+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d374624dex51.htm">Consent of Paul Hastings LLP (included in Exhibit 5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;24.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (included on the signature page to this Registration Statement). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d374624dexfilingfees.htm">Filing Fee Table. </a></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#094;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation <span style="white-space:nowrap">S-K</span> because such information is both (i)&#160;not material and (ii)&#160;information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Undertakings. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided, however, </span>that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, State of California, on the 30th day of November 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Scilex Holding Company</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:&#160;&#160;&#160;&#160;&#160;&#160; Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Chief Executive Officer and President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints each of Jaisim Shah and Elizabeth Czerepak, acting alone or together with another <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact,</span></span> as his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement (and any additional registration statement related hereto permitted by Rule 426(b) promulgated under the Securities Act (and all further amendments, including post-effective amendments thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer, President and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elizabeth A. Czerepak</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Elizabeth A. Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal&#160;Financial and Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Henry Ji, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Executive Chairperson and Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dorman Followwill</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura J. Hamill</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Laura J. Hamill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <span style="white-space:nowrap">Tien-Li</span> Lee, M.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Lemus</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tommy Thompson</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">November&#160;30, 2022</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-11 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d374624dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g374624g1126224419389.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94303 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re:&nbsp;&nbsp;&nbsp;&nbsp;Scilex
Holding Company Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Scilex Holding Company, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the preparation and
filing with the U.S. Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;), pursuant to the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> of the Company (the &#147;<B><I>Registration Statement</I></B>&#148;), including a related prospectus filed with the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), relating to (a)&nbsp;the
issuance of shares of the Company&#146;s common stock, par value $0.0001 per share (&#147;<B><I>Common Stock</I></B>&#148;), upon the exercise of warrants issued by the Company, and (b)&nbsp;the resale of shares of Common Stock and warrants to
purchase Common Stock issued by the Company and held by certain securityholders of the Company, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issuance of up to 4,104,000 shares (the &#147;<B><I>Private Warrant Shares</I></B>&#148;) of Common Stock
upon the exercise of outstanding private placement warrants (the &#147;<B><I>Private Warrants</I></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the issuance of up to 6,899,988 shares (the &#147;<B><I>Public Warrant Shares</I></B>&#148; and, together with
the Private Warrant Shares, the &#147;<B><I>Warrant Shares</I></B>&#148;) of Common Stock upon the exercise of outstanding public warrants (the &#147;<B><I>Public Warrants</I></B>&#148; and, together with the Private Warrants, the
&#147;<B><I>Warrants</I></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the resale of up to 4,104,000 Private Warrants and 1,161,776&nbsp;Public Warrants (collectively,
&#147;<B><I>Resale Warrants</I></B>&#148;) held by certain securityholders of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the resale of up to 144,975,423 shares of Common Stock (collectively, the &#147;<B><I>Resale
Shares</I></B>&#148;), consisting of (a) 139,709,647 shares of Common Stock held by certain stockholders of the Company, (b)&nbsp;up to 4,104,000 Private Warrant Shares held by certain securityholders of the Company, and (c)&nbsp;1,161,776 Public
Warrant Shares, held by Sorrento Therapeutics, Inc. ( &#147;<B><I>Sorrento</I></B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants were issued pursuant to a
Warrant Agreement, dated January&nbsp;6, 2021 (the &#147;<B><I>Warrant Agreement</I></B>&#148;), between Vickers Vantage Corp. I, the Company&#146;s predecessor, and Continental Stock Transfer&nbsp;&amp; Trust Company, as warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under
the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">Paul Hastings
LLP&nbsp;&nbsp;|&nbsp;&nbsp;1117 S. California Avenue&nbsp;&nbsp;|&nbsp;&nbsp;Palo Alto, California 94304 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">t:
+1.650.320.1800&nbsp;&nbsp;|&nbsp;&nbsp;www.paulhastings.com </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g374624g1126225135828.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion letter, we have examined and relied upon the Registration Statement, the
Prospectus, the Company&#146;s Restated Certificate of Incorporation and the Company&#146;s Bylaws, each as currently in effect, the Warrant Agreement, a certificate of the Secretary of State of the State of Delaware certifying as to the formation
and good standing of the Company under the laws of the State of Delaware as of November&nbsp;30, 2022 (the &#147;<B><I>Good Standing Certificate</I></B>&#148;), and originals or copies certified to our satisfaction of such records, documents,
certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinions expressed below. In addition to the foregoing, we have made such investigations of law as we have deemed necessary or
appropriate as a basis for the opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In such examination and in rendering the opinions expressed below, we have assumed, without
independent investigation or verification: (i)&nbsp;the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii)&nbsp;the legal capacity, competency and authority of all
persons or entities executing all agreements, instruments, corporate records, certificates and other documents submitted to us; (iii)&nbsp;the authenticity and completeness of all agreements, instruments, corporate records, certificates and other
documents submitted to us as originals; (iv)&nbsp;that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform to the
originals thereof, and that such originals are authentic and complete; (v)&nbsp;the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the
Company); (vi) that no documents submitted to us have been amended or terminated orally or in writing, except as has been disclosed to us in writing; (vii)&nbsp;that the Warrant Agreement is the valid and binding obligation of each of the parties
thereto, enforceable against such parties in accordance with its terms; (viii)&nbsp;that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on
which we have relied for the purposes of this opinion letter are true and correct on and as of the date hereof; (ix)&nbsp;that at or prior to the time of the delivery of any of the Warrant Shares, the Registration Statement will have been declared
effective under the Securities Act; and (x)&nbsp;that there has not been nor will there be any change in the good standing status of the Company from that reported in the Good Standing Certificate. As to all questions of fact material to this
opinion letter and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation or verification) upon representations and certificates or comparable documents of officers and representatives
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Warrants and the Warrant Shares, we express no opinion to the extent that, notwithstanding the Company&#146;s current
reservation of shares of Common Stock, future issuances of securities of the Company, including the Warrant Shares and/or antidilution adjustments to outstanding securities of the Company, including the Warrants, may cause the Warrants to be
exercisable for more shares of Common Stock than the number that then remain authorized but unissued. Further, we have assumed that the exercise price of the Warrants will not be adjusted to an amount below the par value per share of the shares of
Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and in reliance thereon, and subject to the assumptions, exceptions, qualifications and limitations set forth
herein, we are of the opinion that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The Warrant Shares have been duly authorized and, when issued in accordance
with the terms of the Warrants and the Warrant Agreement, will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;The Resale Warrants constitute valid and binding obligations of the Company, enforceable against the Company in
accordance with their terms except as such enforceability may be limited by (i)&nbsp;any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g374624g1126225135828.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">generally including, without limitation, fraudulent transfer or fraudulent conveyance laws; (ii)&nbsp;public
policy considerations, statutes or court decisions that may limit rights to obtain exculpation, indemnification or contribution (including, without limitation, indemnification regarding violations of the securities laws and indemnification for
losses resulting from a judgment for the payment of any amount other than in United States dollars); and (iii)&nbsp;general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing)
and the availability of equitable remedies (including, without limitation, specific performance and equitable relief), regardless of whether considered in a proceeding in equity or at law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;The Resale Shares (other than the Public Warrant Shares held by Sorrento and the Private Warrant Shares) have been
duly authorized and are validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to opinion paragraph 2: (i) our opinion is subject to the qualification
that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought; (ii)&nbsp;we express no opinion as to any provision of the Resale Warrants, that
(a)&nbsp;provides for liquidated damages, <FONT STYLE="white-space:nowrap">buy-in</FONT> damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties,
(b)&nbsp;relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (c)&nbsp;restricts <FONT
STYLE="white-space:nowrap">non-written</FONT> modifications and waivers, (d)&nbsp;provides for the payment of legal and other professional fees where such payment is contrary to law or public policy, (e)&nbsp;relates to exclusivity, election or
accumulation of rights or remedies, (f)&nbsp;authorizes or validates conclusive or discretionary determinations, or (g)&nbsp;provides that provisions of the Resale Warrants are severable to the extent an essential part of the agreed exchange is
determined to be invalid and unenforceable; and (iii)&nbsp;we express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the
Resale Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without limiting any of the other limitations, exceptions, assumptions and qualifications stated elsewhere herein, we express no opinion
with regard to the applicability or effect of the laws of any jurisdiction other than the laws of the State of New York and the General Corporation Law of the State of Delaware as in effect on the date hereof. We are not rendering any opinion as to
compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter
deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter. This opinion letter is rendered solely in connection
with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Securities Act solely for such purpose. This opinion letter is rendered as of the date hereof, and we
assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters set forth herein even if the change may affect the legal analysis or a legal
conclusion or other matters in this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement
and to the reference to our firm in the Prospectus under the heading &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act or the rules or regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Paul Hastings LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d374624dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> of
our report dated February&nbsp;24, 2022, (which includes explanatory paragraphs relating to the correction of certain misstatements related to the January&nbsp;11, 2021 financial statement and Vickers Vantage Corp. I&#146;s ability to continue as a
going concern) relating to the financial statements of Vickers Vantage Corp. I, which is contained in that Prospectus. We also consent to the reference to our Firm under the caption &#147;Experts&#148; in the Prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ WithumSmith+Brown, PC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New York, New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">November&nbsp;30, 2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d374624dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm of Scilex Holding Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated May&nbsp;13, 2022, in the Registration
Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> and related Prospectus of Scilex Holding Company for the registration of up to 144,975,423 shares of its common stock, up to 11,003,988 shares of common stock issuable upon the
exercise of warrants and up to 5,265,776 warrants to purchase shares of its common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>d374624dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> of our report dated April&nbsp;23, 2020,
relating to the financial statements of Scilex Holding Company. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;30, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>d374624dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form&nbsp;Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Scilex
Holding Company </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Table&nbsp;1: Newly Registered Securities </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Security&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Type&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Security</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Class</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Fee&nbsp;<BR>Calculation&nbsp;<BR>Rule&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Amount&nbsp;to&nbsp;be</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Registered<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Proposed&nbsp;<BR>Maximum&nbsp;<BR>Offering&nbsp;<BR>Price&nbsp;Per&nbsp;<BR>Security&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Proposed</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Maximum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Aggregate</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Price</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Amount
of&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Registration&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Fee&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" COLSPAN="17" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman" ALIGN="center">Newly
Registered Securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Fees to
be</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, par value&nbsp;<BR>$0.0001 per share&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(g)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">11,003,988<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$11.50<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$126,545,862.00&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$0.00011020&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$13,945.36&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Equity&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Common Stock, par value&nbsp;<BR>$0.0001 per share&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">144,975,423<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$5.00<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$724,877,115.00&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$0.00011020&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$79,881.46&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Other&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Warrants to purchase Common&nbsp;<BR>Stock&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">457(i)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">5,265,776<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Fees</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>previously</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">N/A&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Total Offering Amounts&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$851,422,977.00&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$93,826.82&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Total Fees Previously Paid&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Total Fee Offsets&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Net Fee Due&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">$93,826.82&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) promulgated under the U.S. Securities Act of 1933, as amended (the &#147;Securities
Act&#148;), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 11,003,988 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of
Scilex Holding Company, a Delaware corporation (the &#147;Company&#148;), issuable upon the exercise of (i) 4,104,000 Private Warrants (as defined in this registration statement) by the holders thereof and (ii) 6,899,988 Public Warrants (as defined
in this registration statement) by the holders thereof. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The price per share is based upon the exercise price per Private Warrant and per Public Warrant of $11.50 per
share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 144,975,423 shares of Common Stock registered for resale by the Selling Securityholders named in
this registration statement, including (i) 3,983,057 Sponsor Shares (as defined in this registration statement); (ii) 135,726,590 Merger Shares (as defined in this registration statement); (iii) 4,104,000 shares of Common Stock issuable upon the
exercise of Private Warrants by the holders thereof; and (iv) and 1,161,776 shares of Common Stock issuable upon the exercise of Public Warrants held by Sorrento Therapeutics, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the
Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on November&nbsp;25, 2022 (such date
being within five business days of the date that this registration statement was filed with the U.S. Securities and Exchange Commission). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the resale of 4,104,000 Private Warrants and 1,161,776 Public Warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with Rule 457(i), the entire registration fee for the Warrants is allocated to the shares of
Common Stock underlying the Warrants, and no separate fee is payable for the Warrants. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sclx-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [01:37:04] {PM}-->
<schema targetNamespace="http://www.vickersvantagecorp.com/20220930" elementFormDefault="qualified" xmlns:sclx="http://www.vickersvantagecorp.com/20220930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" id="CondensedConsolidatedBalanceSheetsParentheticals">
<link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" id="UnauditedCondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Unaudited Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" id="UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals">
<link:definition>1005 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<link:definition>1006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" id="UnauditedCondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations" id="DescriptionOfOrganizationAndBusinessOperations">
<link:definition>1008 - Disclosure - Description of Organization and Business Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
<link:definition>1010 - Disclosure - Liquidity and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PublicOffering" id="PublicOffering">
<link:definition>1011 - Disclosure - Public Offering</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacement" id="PrivatePlacement">
<link:definition>1012 - Disclosure - Private Placement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" id="Acquisitions">
<link:definition>1013 - Disclosure - Acquisitions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1014 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1015 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1016 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" id="GoodwillAndIntangibleAssets">
<link:definition>1017 - Disclosure - Goodwill and Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Debt" id="Debt">
<link:definition>1018 - Disclosure - Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Warrants" id="Warrants">
<link:definition>1019 - Disclosure - Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficit" id="ShareholdersDeficit">
<link:definition>1020 - Disclosure - Shareholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" id="StockIncentiveAndEmployeeBenefitPlans">
<link:definition>1021 - Disclosure - Stock Incentive and Employee Benefit Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1022 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements" id="RestatementOfPreviouslyIssuedFinancialStatements">
<link:definition>1023 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1024 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShare" id="LossPerShare">
<link:definition>1025 - Disclosure - Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1026 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies" id="AccountingPoliciesByPolicyPolicies">
<link:definition>1027 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1030 - Disclosure - Property and Equipment  (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" id="GoodwillAndIntangibleAssetsTables">
<link:definition>1031 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtTables" id="DebtTables">
<link:definition>1032 - Disclosure - Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" id="StockIncentiveAndEmployeeBenefitPlansTables">
<link:definition>1033 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1034 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" id="RestatementOfPreviouslyIssuedFinancialStatementsTables">
<link:definition>1035 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1036 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShareTables" id="LossPerShareTables">
<link:definition>1037 - Disclosure - Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" id="DescriptionOfOrganizationAndBusinessOperationsDetails">
<link:definition>1038 - Disclosure - Description of Organization and Business Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>1039 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" id="SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled">
<link:definition>1040 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" id="SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare">
<link:definition>1041 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" id="SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals">
<link:definition>1042 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails" id="LiquidityAndGoingConcernDetails">
<link:definition>1043 - Disclosure - Liquidity and Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PublicOfferingDetails" id="PublicOfferingDetails">
<link:definition>1044 - Disclosure - Public Offering (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails" id="PrivatePlacementDetails">
<link:definition>1045 - Disclosure - Private Placement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>1046 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>1047 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" id="CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail">
<link:definition>1048 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" id="CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<link:definition>1049 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" id="CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail">
<link:definition>1050 - Disclosure - Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails" id="ShareholdersDeficitDetails">
<link:definition>1051 - Disclosure - Shareholders' Deficit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/WarrantsDetails" id="WarrantsDetails">
<link:definition>1052 - Disclosure - Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
<link:definition>1053 - Disclosure - Fair Value Measurements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" id="FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs">
<link:definition>1054 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" id="FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability">
<link:definition>1055 - Disclosure - Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" id="FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel">
<link:definition>1056 - Disclosure - Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" id="FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue">
<link:definition>1057 - Disclosure - Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" id="FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs">
<link:definition>1058 - Disclosure - Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" id="FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<link:definition>1059 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" id="FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability">
<link:definition>1060 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" id="PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted">
<link:definition>1061 - Disclosure - Property and Equipment (Details) - Property and equipment consisted</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
<link:definition>1062 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" id="GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets">
<link:definition>1063 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" id="GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense">
<link:definition>1064 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails" id="GoodwillAndIntangibleAssetsDetails">
<link:definition>1065 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtDetails" id="DebtDetails">
<link:definition>1066 - Disclosure - Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" id="DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes">
<link:definition>1067 - Disclosure - Debt (Details) - Summary of borrowings of the scilex pharma notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" id="DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<link:definition>1068 - Disclosure - Debt (Details)  - Summary of future minimum payments under the scilex pharma notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails" id="StockIncentiveAndEmployeeBenefitPlansDetails">
<link:definition>1069 - Disclosure - Stock Incentive and Employee Benefit Plans (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" id="StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions">
<link:definition>1070 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" id="StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding">
<link:definition>1071 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsDetails" id="AcquisitionsDetails">
<link:definition>1072 - Disclosure - Acquisitions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" id="RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<link:definition>1073 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" id="RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported">
<link:definition>1074 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>1075 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" id="IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit">
<link:definition>1076 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" id="IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<link:definition>1077 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" id="IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation">
<link:definition>1078 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate reconciliation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetails" id="LossPerShareDetails">
<link:definition>1079 - Disclosure - Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" id="LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare">
<link:definition>1080 - Disclosure - Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>1081 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="AccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedPayroll" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RelatedPartyNotePayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RelatedPartyNotePayableCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdvancesFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AdvancesFromRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DerivativeLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DerivativeLiabilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RelatedPartyNotePayableNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RelatedPartyNotePayableNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="VickersVantageMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_VickersVantageMember" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesSubjectToPossibleRedemption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_OrdinarySharesSubjectToPossibleRedemption" substitutionGroup="xbrli:item" />
<element name="SubjectToPossibleRedemptionPerShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SubjectToPossibleRedemptionPerShares" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesRedemptionSubjectedToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OrdinarySharesRedemptionSubjectedToForfeiture" substitutionGroup="xbrli:item" />
<element name="SharesCapitalization" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesCapitalization" substitutionGroup="xbrli:item" />
<element name="TransactionCostsAllocatedToWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsAllocatedToWarrantLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_GainLossOnDerivative" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainLossOnExtinguishmentOfDebtt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_GainLossOnExtinguishmentOfDebtt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScilexPharmaNotesPrincipalIncrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNotesPrincipalIncrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AcquiredinprocessresearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AcquiredinprocessresearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossOnInitialIssuanceOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_LossOnInitialIssuanceOfWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInFairValueOfConversionOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfConversionOptionLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransactionsCostsAllocatedToPrivateWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionsCostsAllocatedToPrivateWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInNotesPayableOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncreaseInNotesPayableOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashOperatingLeaseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashOperatingLeaseCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InvestmentOfCashInTrustAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_InvestmentOfCashInTrustAccounts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromSimplePromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromSimplePromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OfferingCostIncludedInAccruedOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OfferingCostIncludedInAccruedOfferingCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherLoanForgiveness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OtherLoanForgiveness" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PromissoryNoteIssuedNetOfDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteIssuedNetOfDiscount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashFairValueAdjustmentToDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashFairValueAdjustmentToDerivativeLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashDistributionToAcquiree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashDistributionToAcquiree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashIncreaseInPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashIncreaseInPrincipal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DescriptionofOrganizationandBusinessOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DescriptionOfOrganizationAndBusinessOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernAbstract" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernTextBlock" substitutionGroup="xbrli:item" />
<element name="ProposedPublicOfferingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProposedPublicOfferingAbstract" substitutionGroup="xbrli:item" />
<element name="PublicOfferingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicOfferingDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PublicOfferingDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicOfferingDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="ProposedPublicOfferingTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProposedPublicOfferingTextBlock" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementAbstract" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PrivatePlacementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementTextBlock" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RelatedPartyTransactionsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RelatedPartyTransactionsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsAbstract" substitutionGroup="xbrli:item" />
<element name="WarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="WarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsTextBlock" substitutionGroup="xbrli:item" />
<element name="CompensationAndEmployeeBenefitPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CompensationAndEmployeeBenefitPlansAbstract" substitutionGroup="xbrli:item" />
<element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsandContingenciesDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsandContingenciesDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="RebatesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RebatesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ServiceFeesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ServiceFeesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="SalesReturnsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SalesReturnsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CoPaymentAssistancePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CoPaymentAssistancePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionofOrganizationandBusinessOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DescriptionofOrganizationandBusinessOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredUnderwritingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SaleOfStockDescriptionOfTransactions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SaleOfStockDescriptionOfTransactions" substitutionGroup="xbrli:item" />
<element name="PricePerPublicShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PricePerPublicShare" substitutionGroup="xbrli:item" />
<element name="PercentageOfPublicShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfPublicShares" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRedeemPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_BusinessCombinationRedeemPercentage" substitutionGroup="xbrli:item" />
<element name="DepositIntoTheTrustAccountPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DepositIntoTheTrustAccountPerShare" substitutionGroup="xbrli:item" />
<element name="LesserPublicPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_LesserPublicPerShare" substitutionGroup="xbrli:item" />
<element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Numberofshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Numberofshares" substitutionGroup="xbrli:item" />
<element name="ProceedsOfInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsOfInitialPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Saleofwarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Saleofwarrants" substitutionGroup="xbrli:item" />
<element name="Grossproceedsofwarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Grossproceedsofwarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Transactioncostsamount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Transactioncostsamount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Otherofferingcosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Otherofferingcosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Numberofbusinessdays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Numberofbusinessdays" substitutionGroup="xbrli:item" />
<element name="NetTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NetTangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Depositintotrustaccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Depositintotrustaccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Interestexpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Interestexpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScilexPharmaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaMember" substitutionGroup="xbrli:item" />
<element name="VantageMergerSubIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_VantageMergerSubIncMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementWarrantMember" substitutionGroup="xbrli:item" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SponsorMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="ContributionAndLoanAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ContributionAndLoanAgreementMember" substitutionGroup="xbrli:item" />
<element name="DebtExchangeAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DebtExchangeAgreementMember" substitutionGroup="xbrli:item" />
<element name="SorrentoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SorrentoMember" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventDomain" substitutionGroup="xbrli:item" />
<element name="ReorganizationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ReorganizationMember" substitutionGroup="xbrli:item" />
<element name="Foundershares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Foundershares" substitutionGroup="xbrli:item" />
<element name="SoleDistributorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SoleDistributorMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" substitutionGroup="xbrli:item" />
<element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_GrossProceeds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LessAbstract" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OrdinarySharesIssuanceCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PlusAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PlusAbstract" substitutionGroup="xbrli:item" />
<element name="AccretionOfCarryingValueToRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccretionOfCarryingValueToRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SharesSubjectToPossibleRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesSubjectToPossibleRedemption" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LessAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LessAbstract0" substitutionGroup="xbrli:item" />
<element name="ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" substitutionGroup="xbrli:item" />
<element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NumeratorAbstract" substitutionGroup="xbrli:item" />
<element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DenominatorAbstract" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LiquidityAndGoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernLineItems" substitutionGroup="xbrli:item" />
<element name="NetWorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NetWorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MinimumUnrestrictedCashBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_MinimumUnrestrictedCashBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestrictedFundsRelesableForFutureRepurchaseOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentRepurchaseObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentRepurchaseObligation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregateOutstandingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AggregateOutstandingAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SeniorSecuredNotesDueTwoThousandAndTwentySixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" substitutionGroup="xbrli:item" />
<element name="CumulativeSalesRelatedContingencyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CumulativeSalesRelatedContingencyMember" substitutionGroup="xbrli:item" />
<element name="LetterOfCreditDrawnDownMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LetterOfCreditDrawnDownMember" substitutionGroup="xbrli:item" />
<element name="ScilexPharmaNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNotesMember" substitutionGroup="xbrli:item" />
<element name="FundingCommitmentLetterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FundingCommitmentLetterMember" substitutionGroup="xbrli:item" />
<element name="PurchasePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PurchasePricePerShare" substitutionGroup="xbrli:item" />
<element name="NumberOfSaleUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfSaleUnits" substitutionGroup="xbrli:item" />
<element name="CapitalizationOfShareOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CapitalizationOfShareOutstanding" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OrdinarySharesIssuedAndOutstanding" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsExercisePrice" substitutionGroup="xbrli:item" />
<element name="aggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_aggregatePurchasePrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DepositedInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DepositedInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetAcquisitionPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AssetAcquisitionPricePerShare" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwnershipInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfOwnershipInterest" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="PaymentToAcquireInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToAcquireInventory" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesAcquired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfSharesAcquired" substitutionGroup="xbrli:item" />
<element name="PercentageOfSimpleInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfSimpleInterest" substitutionGroup="xbrli:item" />
<element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedInterest" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PricePerWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PricePerWarrants" substitutionGroup="xbrli:item" />
<element name="AggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AggregatePrincipalAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaidAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfCapitalSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfCapitalSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalRequirements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WorkingCapitalRequirements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfOutstandingAmountIndebtedness" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfOutstandingAmountIndebtedness" substitutionGroup="xbrli:item" />
<element name="PerShareCalculationOfOutstandingAmountInExchangeOfShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" substitutionGroup="xbrli:item" />
<element name="LimitationOfOutstandingAmountInExchangeOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LimitationOfOutstandingAmountInExchangeOfShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConvertiblePromisoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConvertiblePromisoryNoteMember" substitutionGroup="xbrli:item" />
<element name="FounderSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FounderSharesMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteRelatedPartyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteRelatedPartyMember" substitutionGroup="xbrli:item" />
<element name="SenmurMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SenmurMember" substitutionGroup="xbrli:item" />
<element name="ItochuMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ItochuMember" substitutionGroup="xbrli:item" />
<element name="InvesteeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_InvesteeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvesteeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_InvesteeDomain" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyTwoPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PeriodDomain" substitutionGroup="xbrli:item" />
<element name="DueOnOrAfterFebruaryTwoThousandAndThirtyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" substitutionGroup="xbrli:item" />
<element name="MergerConsiderationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MergerConsiderationDescription" substitutionGroup="xbrli:item" />
<element name="CommonStockAggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockAggregateValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregatePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AggregatePercentage" substitutionGroup="xbrli:item" />
<element name="WarrantsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WarrantsPercentage" substitutionGroup="xbrli:item" />
<element name="BalanceInTheTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_BalanceInTheTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingCommission" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingCommission" substitutionGroup="xbrli:item" />
<element name="DeferredUnderwritingCommissionPayable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingCommissionPayable" substitutionGroup="xbrli:item" />
<element name="PercentageOfAggregateRoyalityPayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfAggregateRoyalityPayments" substitutionGroup="xbrli:item" />
<element name="AgreementExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementExpirationDate" substitutionGroup="xbrli:item" />
<element name="AgreementExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementExpirationTerm" substitutionGroup="xbrli:item" />
<element name="AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" substitutionGroup="xbrli:item" />
<element name="NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" substitutionGroup="xbrli:item" />
<element name="TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" substitutionGroup="xbrli:item" />
<element name="ThresholdMinimumPercentageOfSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ThresholdMinimumPercentageOfSales" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualAdjustmentToFees" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfAnnualAdjustmentToFees" substitutionGroup="xbrli:item" />
<element name="PercentageOfDistributionFeeReceivedOverThePeriod" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfDistributionFeeReceivedOverThePeriod" substitutionGroup="xbrli:item" />
<element name="NoticePeriodForTerminationOfWorkOrder" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NoticePeriodForTerminationOfWorkOrder" substitutionGroup="xbrli:item" />
<element name="WorkOrderImplementationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WorkOrderImplementationFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SalesOperationsServicesMonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SalesOperationsServicesMonthlyFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SellingGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SellingGeneralAndAdministrativeExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScilexCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexCommonStockMember" substitutionGroup="xbrli:item" />
<element name="ProductDevelopmentAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProductDevelopmentAgreementMember" substitutionGroup="xbrli:item" />
<element name="ExclusiveDistributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ExclusiveDistributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="ProjectAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProjectAgreementMember" substitutionGroup="xbrli:item" />
<element name="PaloAltoAadministrativeFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PaloAltoAadministrativeFacilityMember" substitutionGroup="xbrli:item" />
<element name="OperatingCashFlowsFromOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingCashFlowsFromOperatingLeases" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="WarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsOutstandingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WarrantsOutstandingShares" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsRedemptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantsRedemptionDescription" substitutionGroup="xbrli:item" />
<element name="CapitalRaisingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CapitalRaisingDescription" substitutionGroup="xbrli:item" />
<element name="MeasurementInputRiskadjustedNetSalesForecastMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputRiskadjustedNetSalesForecastMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputEffectiveDebtYieldMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputEffectiveDebtYieldMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" substitutionGroup="xbrli:item" />
<element name="MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" substitutionGroup="xbrli:item" />
<element name="InitialMeasurementOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_InitialMeasurementOne" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInValuationInputsOrOtherAssumptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInValuationInputsOrOtherAssumptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOptionLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOptionLiabilityMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" substitutionGroup="xbrli:item" />
<element name="UnderlyingWarrantValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_UnderlyingWarrantValue" substitutionGroup="xbrli:item" />
<element name="HoldingPeriod" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_HoldingPeriod" substitutionGroup="xbrli:item" />
<element name="ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementStrikePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FairValueMeasurementStrikePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantsinDollars" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FairValueOfWarrantsinDollars" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" substitutionGroup="xbrli:item" />
<element name="AssembledWorkforceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AssembledWorkforceMember" substitutionGroup="xbrli:item" />
<element name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetSalesPayable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfNetSalesPayable" substitutionGroup="xbrli:item" />
<element name="PaymentToDepositIntoASeggregateReserveFund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToDepositIntoASeggregateReserveFund" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentToDepositIntoASegregatedCollateralAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToDepositIntoASegregatedCollateralAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfConcentrationOnASimilarProduct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfConcentrationOnASimilarProduct" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentredemptionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentredemptionPeriod" substitutionGroup="xbrli:item" />
<element name="PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" substitutionGroup="xbrli:item" />
<element name="MinimumCashRequirementsToRepurchaseOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumCashRequirementsToRepurchaseOfNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfThePrincipalAmountOfTheNotes" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfThePrincipalAmountOfTheNotes" substitutionGroup="xbrli:item" />
<element name="MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LineOfCreditFacilityindebtednessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LineOfCreditFacilityindebtednessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentTerminationDate" substitutionGroup="xbrli:item" />
<element name="MaximumCompensationCostToBeAvailableProratedBasis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MaximumCompensationCostToBeAvailableProratedBasis" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfLoanForgivenessUnderTheAct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfLoanForgivenessUnderTheAct" substitutionGroup="xbrli:item" />
<element name="MinimumPayrollCostToBeAvailable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumPayrollCostToBeAvailable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentPercentageOfPrincipalAmountRepurchased" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" substitutionGroup="xbrli:item" />
<element name="ScilexPharmaNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNoteMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenPurchaseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandAndEighteenPurchaseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="IfLetterOfCreditIsDrawnMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IfLetterOfCreditIsDrawnMember" substitutionGroup="xbrli:item" />
<element name="MarketingApprovalLetterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MarketingApprovalLetterMember" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableRevolvingLoanFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AccountsReceivableRevolvingLoanFacilityMember" substitutionGroup="xbrli:item" />
<element name="StatementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StatementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="StatementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StatementDomain" substitutionGroup="xbrli:item" />
<element name="DecemberOptionalRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DecemberOptionalRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="FebruaryOptionalRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FebruaryOptionalRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="AprilOptionalRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AprilOptionalRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="PaycheckProtectionProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PaycheckProtectionProgramMember" substitutionGroup="xbrli:item" />
<element name="EventTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventTypeDomain" substitutionGroup="xbrli:item" />
<element name="CoronavirusAidReliefAndEconomicSecurityActMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CoronavirusAidReliefAndEconomicSecurityActMember" substitutionGroup="xbrli:item" />
<element name="ClassificationOfCostAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ClassificationOfCostAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ClassificationOfCostDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ClassificationOfCostDomain" substitutionGroup="xbrli:item" />
<element name="NonPayrollCostsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NonPayrollCostsMember" substitutionGroup="xbrli:item" />
<element name="PayrollCostsBasisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PayrollCostsBasisMember" substitutionGroup="xbrli:item" />
<element name="AmendmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AmendmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentDomain" substitutionGroup="xbrli:item" />
<element name="AmendmentNoFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentNoFourMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" substitutionGroup="xbrli:item" />
<element name="IndebentureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IndebentureMember" substitutionGroup="xbrli:item" />
<element name="UnamortizedDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_UnamortizedDebtDiscount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" substitutionGroup="xbrli:item" />
<element name="LongtermDebtfutureMinimumPaymentYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtfutureMinimumPaymentYearOne" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearTwo" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearThree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearFive" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CompensationAndEmployeeBenefitPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CompensationAndEmployeeBenefitPlansTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CompensationAndEmployeeBenefitPlansLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CompensationAndEmployeeBenefitPlansLineItems" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" substitutionGroup="xbrli:item" />
<element name="ScilexPharmaTwoThousandSeventeenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaTwoThousandSeventeenPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandNineteenStockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandNineteenStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToTwoThousandNineteenStockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="OperatingExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_OperatingExpensesMember" substitutionGroup="xbrli:item" />
<element name="FourHundredAndOneKPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FourHundredAndOneKPlanMember" substitutionGroup="xbrli:item" />
<element name="RevenueToBeEarnedByTheAcquireeValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RevenueToBeEarnedByTheAcquireeValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" substitutionGroup="xbrli:item" />
<element name="PeriodDuringWhichShareTransferIsRestricted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PeriodDuringWhichShareTransferIsRestricted" substitutionGroup="xbrli:item" />
<element name="PeriodDuringWhichTheSharesMayBeExchanged" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PeriodDuringWhichTheSharesMayBeExchanged" substitutionGroup="xbrli:item" />
<element name="CommonStockValueToBeExchanged" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockValueToBeExchanged" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" substitutionGroup="xbrli:item" />
<element name="PricePerShareForDeterminingTheExchangeOfShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PricePerShareForDeterminingTheExchangeOfShares" substitutionGroup="xbrli:item" />
<element name="PaymentMadeInSurrenderingTheShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentMadeInSurrenderingTheShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontlicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_UpfrontlicenseFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AardvarkMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AardvarkMember" substitutionGroup="xbrli:item" />
<element name="RomegLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RomegLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="MilestoneAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MilestoneAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MilestoneDomain" substitutionGroup="xbrli:item" />
<element name="RegulatoryBasedMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RegulatoryBasedMilestoneMember" substitutionGroup="xbrli:item" />
<element name="ReveueBasedMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ReveueBasedMilestoneMember" substitutionGroup="xbrli:item" />
<element name="ApprovalBasedMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ApprovalBasedMilestoneMember" substitutionGroup="xbrli:item" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="TrancheOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheOneMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheTwoMember" substitutionGroup="xbrli:item" />
<element name="TrancheThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheThreeMember" substitutionGroup="xbrli:item" />
<element name="TrancheFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheFourMember" substitutionGroup="xbrli:item" />
<element name="AsRestatedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AsRestatedMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyTwoPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="AdjustmentsRestatement2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsRestatement2Member" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationYear" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TaxCreditCarryforwardExpirationYear" substitutionGroup="xbrli:item" />
<element name="MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" substitutionGroup="xbrli:item" />
<element name="IndefiniteCarryforwardPeriodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IndefiniteCarryforwardPeriodMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsInterestExpenseLimitations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsInterestExpenseLimitations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentEventsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentEventsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesLimits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfSharesLimits" substitutionGroup="xbrli:item" />
<element name="SponsorLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SponsorLoan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantExercisePrice" substitutionGroup="xbrli:item" />
<element name="AdditionalPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdditionalPrincipalAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConvertiblePromissoryNote" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" substitutionGroup="xbrli:item" />
<element name="MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" substitutionGroup="xbrli:item" />
<element name="SalesThresholdLimit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SalesThresholdLimit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" substitutionGroup="xbrli:item" />
<element name="MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" substitutionGroup="xbrli:item" />
<element name="NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" substitutionGroup="xbrli:item" />
<element name="PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" substitutionGroup="xbrli:item" />
<element name="AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" substitutionGroup="xbrli:item" />
<element name="StandbyEquityPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StandbyEquityPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="YorkvilleMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_YorkvilleMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sclx-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [01:37:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" />
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_SCLX_AcquiredinprocessresearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_SCLX_AcquiredinprocessresearchAndDevelopment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_SCLX_ChangeInFairValueOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_ChangeInFairValueOfWarrantLiability" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_SCLX_TransactionCostsAllocatedToWarrantLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_TransactionCostsAllocatedToWarrantLiabilities" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_SCLX_GainLossOnDerivative" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_GainLossOnDerivative" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_SCLX_GainLossOnExtinguishmentOfDebtt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_GainLossOnExtinguishmentOfDebtt" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_SCLX_ScilexPharmaNotesPrincipalIncrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_ScilexPharmaNotesPrincipalIncrease" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="22" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_LongTermInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredCosts" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_SCLX_AccruedPayroll" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_AccruedPayroll" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_SCLX_RelatedPartyNotePayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_RelatedPartyNotePayableCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLongTermNotesPayable" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilities" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_SCLX_RelatedPartyNotePayableNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_RelatedPartyNotePayableNoncurrent" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_SCLX_DerivativeLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_DerivativeLiabilityNoncurrent" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_SCLX_AdvancesFromRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_AdvancesFromRelatedParty" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="45" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_SCLX_InvestmentOfCashInTrustAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SCLX_InvestmentOfCashInTrustAccounts" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromDecommissioningFund" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_SCLX_ProceedsFromSimplePromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromSimplePromissoryNoteRelatedParty" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_SCLX_RepaymentOfPromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_RepaymentOfPromissoryNoteRelatedParty" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_SCLX_ProceedsFromPromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromPromissoryNoteRelatedParty" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" use="optional" order="36" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" use="optional" order="37" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_SCLX_LossOnInitialIssuanceOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_LossOnInitialIssuanceOfWarrantLiability" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_SCLX_ChangeInFairValueOfConversionOptionLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_ChangeInFairValueOfConversionOptionLiability" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_SCLX_TransactionsCostsAllocatedToPrivateWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_TransactionsCostsAllocatedToPrivateWarrants" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_SCLX_IncreaseInNotesPayableOne" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_IncreaseInNotesPayableOne" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestPaidNet" use="optional" order="44" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="45" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_SCLX_NonCashOperatingLeaseCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_NonCashOperatingLeaseCosts" use="optional" order="46" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="47" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="48" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess" use="optional" order="49" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="51" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_SCLX_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" use="optional" order="52" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="53" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="loc_SCLX_DeferredTaxAssetsInterestExpenseLimitations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsInterestExpenseLimitations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPayment" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_SCLX_LongtermDebtfutureMinimumPaymentYearOne" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtfutureMinimumPaymentYearOne" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFive" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_SCLX_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_SCLX_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sclx-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [01:37:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOffering" roleURI="http://www.vickersvantagecorp.com/role/PublicOffering" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacement" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactions" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Warrants" roleURI="http://www.vickersvantagecorp.com/role/Warrants" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficit" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingencies" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatements" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEvents" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AccountingPoliciesByPolicyPolicies" roleURI="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsTables" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcernDetails" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOfferingDetails" roleURI="http://www.vickersvantagecorp.com/role/PublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacementDetails" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficitDetails" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#WarrantsDetails" roleURI="http://www.vickersvantagecorp.com/role/WarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetails" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AcquisitionsDetails" roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEventsDetails" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CoverPage" roleURI="http://www.vickersvantagecorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlans" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansTables" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcern" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareTables" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Acquisitions" roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipment" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentTables" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxes" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Debt" roleURI="http://www.vickersvantagecorp.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesTables" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtTables" roleURI="http://www.vickersvantagecorp.com/role/DebtTables" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635010" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_AssetsAbstract_32" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsCurrentAbstract_33" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_Cash_37" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_38" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AssetsCurrent_39" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2146635255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_InventoryNet_2146635255" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_Goodwill_2146635266" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2146635267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_LongTermInvestments_2146635267" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_2146635611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_DeferredCosts_2146635611" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Assets_41" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LiabilitiesCurrent_43" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2146635268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableCurrent_2146635268" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_sclx_AccruedPayroll_2146635274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AccruedPayroll_2146635274" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146635280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146635280" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_sclx_AdvancesFromRelatedParty_2146635619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AdvancesFromRelatedParty_2146635619" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2146635886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2146635886" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_44" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_45" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_46" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DerivativeLiabilities_48" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146635294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146635294" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Liabilities_50" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_CommitmentsAndContingencies_51" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquityAbstract_36" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_PreferredStockValue_53" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_CommonStockValue_54" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquity_57" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StatementTable_2146635007" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635007" xlink:to="loc_dei_LegalEntityAxis_2146635012" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635012" xlink:to="loc_dei_EntityDomain_2146635013" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635013_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635012" xlink:to="loc_dei_EntityDomain_2146635013_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635013" xlink:to="loc_sclx_VickersVantageMember_2146635014" use="optional" order="57" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635028" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_76" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesIssued_77" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesIssued_81" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_StatementTable_2146635025" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_dei_LegalEntityAxis_2146635031" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635031" xlink:to="loc_dei_EntityDomain_2146635032" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635031" xlink:to="loc_dei_EntityDomain_2146635032_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635032" xlink:to="loc_sclx_VickersVantageMember_2146635033" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635316" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635316" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635317" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635317_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635316" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635317_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_2146635318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146635317" xlink:to="loc_us-gaap_CommonClassAMember_2146635318" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2146637181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2146637181" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubjectToPossibleRedemptionPerShares" xlink:label="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesCapitalization" xlink:label="loc_sclx_SharesCapitalization_2146637182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SharesCapitalization_2146637182" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635039" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingIncomeLoss_103" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherIncomeAbstract_102" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_104" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_105" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestExpense_109" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestIncomeOther_110" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_sclx_GainLossOnDerivative_2146635366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnDerivative_2146635366" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2146635371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2146635371" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_NetIncomeLoss_112" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareBasic_114" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_StatementTable_2146635036" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635036" xlink:to="loc_dei_LegalEntityAxis_2146635042" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635042" xlink:to="loc_dei_EntityDomain_2146635043" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635043_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635042" xlink:to="loc_dei_EntityDomain_2146635043_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635043" xlink:to="loc_sclx_VickersVantageMember_2146635044" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2146635331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_Revenues_2146635331" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2146635336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_CostOfRevenue_2146635336" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2146635341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2146635341" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635350" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635051" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_EarningsPerShareDiluted_122" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_StatementTable_2146635048" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635048" xlink:to="loc_dei_LegalEntityAxis_2146635054" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635054" xlink:to="loc_dei_EntityDomain_2146635055" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635054" xlink:to="loc_dei_EntityDomain_2146635055_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635055" xlink:to="loc_sclx_VickersVantageMember_2146635056" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_143" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StatementTable_141" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_142" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_142" xlink:to="loc_us-gaap_EquityComponentDomain_147" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_142" xlink:to="loc_us-gaap_EquityComponentDomain_147_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_CommonStockMember_144" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_dei_LegalEntityAxis_2146635061" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635061" xlink:to="loc_dei_EntityDomain_2146635062" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635061" xlink:to="loc_dei_EntityDomain_2146635062_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635062" xlink:to="loc_sclx_VickersVantageMember_2146635063" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockholdersEquity_148" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_SharesOutstanding_149" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:label="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetIncomeLoss_152" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635069" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetIncomeLoss_203" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_206" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_sclx_IncreaseInNotesPayableOne_2146635581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_IncreaseInNotesPayableOne_2146635581" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_2146635594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestPaidNet_2146635594" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_sclx_NonCashOperatingLeaseCosts_2146635610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_NonCashOperatingLeaseCosts_2146635610" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2146635613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ShareBasedCompensation_2146635613" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_sclx_InvestmentOfCashInTrustAccounts_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_sclx_InvestmentOfCashInTrustAccounts_213" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_ProceedsFromDecommissioningFund_198" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="loc_sclx_DeferredUnderwritingFeePayable_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_DeferredUnderwritingFeePayable_226" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_2146635734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NotesIssued1_2146635734" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OtherLoanForgiveness" xlink:label="loc_sclx_OtherLoanForgiveness_2146635873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OtherLoanForgiveness_2146635873" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteIssuedNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:label="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashRightOfUseAsset" xlink:label="loc_sclx_NonCashRightOfUseAsset_2146635880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashRightOfUseAsset_2146635880" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:label="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashDistributionToAcquiree" xlink:label="loc_sclx_NonCashDistributionToAcquiree_2146635904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashDistributionToAcquiree_2146635904" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashIncreaseInPrincipal" xlink:label="loc_sclx_NonCashIncreaseInPrincipal_2146635907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashIncreaseInPrincipal_2146635907" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_StatementTable_2146635066" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635066" xlink:to="loc_dei_LegalEntityAxis_2146635072" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635072" xlink:to="loc_dei_EntityDomain_2146635073" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635072" xlink:to="loc_dei_EntityDomain_2146635073_default" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635073" xlink:to="loc_sclx_VickersVantageMember_2146635074" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" use="optional" order="81" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xlink:to="loc_dei_LegalEntityAxis_2146635117" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635117" xlink:to="loc_dei_EntityDomain_2146635118" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635117" xlink:to="loc_dei_EntityDomain_2146635118_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635118" xlink:to="loc_sclx_VickersVantageMember_2146635119" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xlink:to="loc_dei_LegalEntityAxis_2146635078" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635078" xlink:to="loc_dei_EntityDomain_2146635079" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635079_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635078" xlink:to="loc_dei_EntityDomain_2146635079_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635079" xlink:to="loc_sclx_VickersVantageMember_2146635080" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOffering">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_2146634968" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="loc_sclx_ProposedPublicOfferingTextBlock_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_2146634968" xlink:to="loc_sclx_ProposedPublicOfferingTextBlock_248" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_2146634966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_2146634968" xlink:to="loc_sclx_PublicOfferingDetailsTable_2146634966" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PublicOfferingDetailsTable_2146634966" xlink:to="loc_dei_LegalEntityAxis_2146634972" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634972" xlink:to="loc_dei_EntityDomain_2146634973" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634972" xlink:to="loc_dei_EntityDomain_2146634973_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634973" xlink:to="loc_sclx_VickersVantageMember_2146634975" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementTextBlock" xlink:label="loc_sclx_PrivatePlacementTextBlock_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" xlink:to="loc_sclx_PrivatePlacementTextBlock_254" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_2146635094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" xlink:to="loc_sclx_PrivatePlacementDetailsTable_2146635094" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PrivatePlacementDetailsTable_2146635094" xlink:to="loc_dei_LegalEntityAxis_2146635096" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635096" xlink:to="loc_dei_EntityDomain_2146635097" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635096" xlink:to="loc_dei_EntityDomain_2146635097_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635097" xlink:to="loc_sclx_VickersVantageMember_2146635098" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xlink:to="loc_dei_LegalEntityAxis_2146634969" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634969" xlink:to="loc_dei_EntityDomain_2146634970" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634969" xlink:to="loc_dei_EntityDomain_2146634970_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634970" xlink:to="loc_sclx_VickersVantageMember_2146634971" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635166" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635166" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_288" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635166" xlink:to="loc_us-gaap_StatementTable_2146635163" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635164" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635164" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635165" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635165_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635164" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635165_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_dei_LegalEntityAxis_2146635167" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635167" xlink:to="loc_dei_EntityDomain_2146635168" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635168_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635167" xlink:to="loc_dei_EntityDomain_2146635168_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635168" xlink:to="loc_sclx_VickersVantageMember_2146635169" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Warrants">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsLineItems" xlink:label="loc_sclx_WarrantsLineItems_2146634997" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTable" xlink:label="loc_sclx_WarrantsTable_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_WarrantsLineItems_2146634997" xlink:to="loc_sclx_WarrantsTable_280" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsTable_280" xlink:to="loc_dei_LegalEntityAxis_2146634994" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634994" xlink:to="loc_dei_EntityDomain_2146634995" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634995_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634994" xlink:to="loc_dei_EntityDomain_2146634995_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634995" xlink:to="loc_sclx_VickersVantageMember_2146634996" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTextBlock" xlink:label="loc_sclx_WarrantsTextBlock_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsLineItems_2146634997" xlink:to="loc_sclx_WarrantsTextBlock_282" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635183" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635183" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635183" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xlink:to="loc_dei_LegalEntityAxis_2146635184" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635184" xlink:to="loc_dei_EntityDomain_2146635185" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635185_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635184" xlink:to="loc_dei_EntityDomain_2146635185_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635185" xlink:to="loc_sclx_VickersVantageMember_2146635186" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xlink:to="loc_dei_LegalEntityAxis_2146635101" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635101" xlink:to="loc_dei_EntityDomain_2146635102" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635102_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635101" xlink:to="loc_dei_EntityDomain_2146635102_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635102" xlink:to="loc_sclx_VickersVantageMember_2146635104" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xlink:to="loc_dei_LegalEntityAxis_2146635271" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635271" xlink:to="loc_dei_EntityDomain_2146635272" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635271" xlink:to="loc_dei_EntityDomain_2146635272_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635272" xlink:to="loc_sclx_VickersVantageMember_2146635273" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635158" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635158" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_294" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635158" xlink:to="loc_us-gaap_StatementTable_2146635155" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635156" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635156" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635157" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635157_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635156" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635157_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_dei_LegalEntityAxis_2146635159" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635159" xlink:to="loc_dei_EntityDomain_2146635160" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635160_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635159" xlink:to="loc_dei_EntityDomain_2146635160_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635160" xlink:to="loc_sclx_VickersVantageMember_2146635161" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_314" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_UseOfEstimates_316" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_318" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_319" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_321" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_322" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_324" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xlink:to="loc_dei_LegalEntityAxis_2146635059" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635059" xlink:to="loc_dei_EntityDomain_2146635060" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635060_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635059" xlink:to="loc_dei_EntityDomain_2146635060_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635060" xlink:to="loc_sclx_VickersVantageMember_2146635064" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2146635669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2146635669" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_2146635679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DebtPolicyTextBlock_2146635679" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RebatesPolicyTextBlock" xlink:label="loc_sclx_RebatesPolicyTextBlock_2146635702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_RebatesPolicyTextBlock_2146635702" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ServiceFeesPolicyTextBlock" xlink:label="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesReturnsPolicyTextBlock" xlink:label="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoPaymentAssistancePolicyTextBlock" xlink:label="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2146635859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2146635859" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xlink:to="loc_dei_LegalEntityAxis_2146635016" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635016" xlink:to="loc_dei_EntityDomain_2146635017" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635016" xlink:to="loc_dei_EntityDomain_2146635017_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635017" xlink:to="loc_sclx_VickersVantageMember_2146635018" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635175" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_StatementTable_2146635172" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635173" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635173" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635174" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635173" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635174_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_dei_LegalEntityAxis_2146635176" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635176" xlink:to="loc_dei_EntityDomain_2146635177" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635177_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635176" xlink:to="loc_dei_EntityDomain_2146635177_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635177" xlink:to="loc_sclx_VickersVantageMember_2146635178" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xlink:to="loc_dei_LegalEntityAxis_2146635281" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635281" xlink:to="loc_dei_EntityDomain_2146635282" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635281" xlink:to="loc_dei_EntityDomain_2146635282_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635282" xlink:to="loc_sclx_VickersVantageMember_2146635283" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_508" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_508" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_508" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_ScilexPharmaMember_2146635406" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VantageMergerSubIncMember" xlink:label="loc_sclx_VantageMergerSubIncMember_2146635932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_VantageMergerSubIncMember_2146635932" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_509" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_509" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_509" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_IPOMember_514" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_OverAllotmentOptionMember_515" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="loc_sclx_PrivatePlacementWarrantMember_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_sclx_PrivatePlacementWarrantMember_516" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_dei_LegalEntityAxis_2146634946" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634946" xlink:to="loc_dei_EntityDomain_2146634948" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634948_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634946" xlink:to="loc_dei_EntityDomain_2146634948_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634948" xlink:to="loc_sclx_VickersVantageMember_2146635075" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146635348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146635348_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorMember" xlink:label="loc_sclx_SponsorMember_2146635351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" xlink:to="loc_sclx_SponsorMember_2146635351" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146635403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_AgreementAxis_2146635403" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146635404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146635403" xlink:to="loc_sclx_AgreementDomain_2146635404" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146635404_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146635403" xlink:to="loc_sclx_AgreementDomain_2146635404_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ContributionAndLoanAgreementMember" xlink:label="loc_sclx_ContributionAndLoanAgreementMember_2146635405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_ContributionAndLoanAgreementMember_2146635405" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146635936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146635936" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635408" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635408_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635408" xlink:to="loc_sclx_SorrentoMember_2146635409" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_EventAxis_2146635410" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventAxis_2146635410" xlink:to="loc_sclx_EventDomain_2146635411" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventAxis_2146635410" xlink:to="loc_sclx_EventDomain_2146635411_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635411" xlink:to="loc_sclx_ReorganizationMember_2146635412" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SharesIssued_517" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_518" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:label="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaap_OtherUnderwritingExpense_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherUnderwritingExpense_522" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFees" xlink:label="loc_sclx_DeferredUnderwritingFees_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DeferredUnderwritingFees_523" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:label="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestBearingDepositLiabilities" xlink:label="loc_us-gaap_NoninterestBearingDepositLiabilities_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_NoninterestBearingDepositLiabilities_526" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_AssetsHeldInTrust_527" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="loc_sclx_SaleOfStockDescriptionOfTransactions_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_SaleOfStockDescriptionOfTransactions_528" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerPublicShare" xlink:label="loc_sclx_PricePerPublicShare_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PricePerPublicShare_529" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_530" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPublicShares" xlink:label="loc_sclx_PercentageOfPublicShares_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PercentageOfPublicShares_531" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="loc_sclx_BusinessCombinationRedeemPercentage_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_BusinessCombinationRedeemPercentage_533" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherExpenses_534" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositIntoTheTrustAccountPerShare" xlink:label="loc_sclx_DepositIntoTheTrustAccountPerShare_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DepositIntoTheTrustAccountPerShare_535" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LesserPublicPerShare" xlink:label="loc_sclx_LesserPublicPerShare_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_LesserPublicPerShare_536" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_RestrictedCashCurrent_538" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_WorkingCapital_539" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofshares" xlink:label="loc_sclx_Numberofshares_2146635285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofshares_2146635285" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Saleofwarrants" xlink:label="loc_sclx_Saleofwarrants_2146635310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Saleofwarrants_2146635310" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Grossproceedsofwarrants" xlink:label="loc_sclx_Grossproceedsofwarrants_2146635319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Grossproceedsofwarrants_2146635319" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Transactioncostsamount" xlink:label="loc_sclx_Transactioncostsamount_2146635332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Transactioncostsamount_2146635332" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Otherofferingcosts" xlink:label="loc_sclx_Otherofferingcosts_2146635334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Otherofferingcosts_2146635334" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofbusinessdays" xlink:label="loc_sclx_Numberofbusinessdays_2146635343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofbusinessdays_2146635343" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_2146635346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_NetTangibleAssets_2146635346" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Depositintotrustaccount" xlink:label="loc_sclx_Depositintotrustaccount_2146635354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Depositintotrustaccount_2146635354" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Interestexpenses" xlink:label="loc_sclx_Interestexpenses_2146635365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Interestexpenses_2146635365" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_2146635368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_Cash_2146635368" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2146635402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2146635402" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" use="optional" order="75" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_554" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_554" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_554" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" xlink:to="loc_us-gaap_IPOMember_557" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_dei_LegalEntityAxis_2146634981" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634981" xlink:to="loc_dei_EntityDomain_2146634982" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634982_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634981" xlink:to="loc_dei_EntityDomain_2146634982_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634982" xlink:to="loc_sclx_VickersVantageMember_2146634983" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_2146635766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" xlink:to="loc_us-gaap_SalesRevenueNetMember_2146635766" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2146635767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_srt_MajorCustomersAxis_2146635767" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2146635768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2146635767" xlink:to="loc_srt_NameOfMajorCustomerDomain_2146635768" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2146635768_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2146635767" xlink:to="loc_srt_NameOfMajorCustomerDomain_2146635768_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SoleDistributorMember" xlink:label="loc_sclx_SoleDistributorMember_2146635769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2146635768" xlink:to="loc_sclx_SoleDistributorMember_2146635769" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="loc_us-gaap_OtherDeferredCostsNet_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_OtherDeferredCostsNet_558" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaap_ExcessStockSharesIssued_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ExcessStockSharesIssued_559" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_CashFDICInsuredAmount_560" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Foundershares" xlink:label="loc_sclx_Foundershares_2146635399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_sclx_Foundershares_2146635399" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GrossProceeds" xlink:label="loc_sclx_GrossProceeds_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_GrossProceeds_362" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract" xlink:label="loc_sclx_LessAbstract_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract_359" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="loc_sclx_OrdinarySharesIssuanceCost_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LessAbstract_359" xlink:to="loc_sclx_OrdinarySharesIssuanceCost_363" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PlusAbstract" xlink:label="loc_sclx_PlusAbstract_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_PlusAbstract_360" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="loc_sclx_SharesSubjectToPossibleRedemption_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_SharesSubjectToPossibleRedemption_365" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract0" xlink:label="loc_sclx_LessAbstract0_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract0_361" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LessAbstract0_361" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_366" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xlink:to="loc_dei_LegalEntityAxis_2146634986" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634986" xlink:to="loc_dei_EntityDomain_2146634987" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634987_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634986" xlink:to="loc_dei_EntityDomain_2146634987_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634987" xlink:to="loc_sclx_VickersVantageMember_2146634988" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumeratorAbstract" xlink:label="loc_sclx_NumeratorAbstract_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_NumeratorAbstract_376" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_NumeratorAbstract_376" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_378" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DenominatorAbstract" xlink:label="loc_sclx_DenominatorAbstract_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_DenominatorAbstract_377" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareBasic_380" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635665" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xlink:to="loc_dei_LegalEntityAxis_2146634991" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634991" xlink:to="loc_dei_EntityDomain_2146634992" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634992_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634991" xlink:to="loc_dei_EntityDomain_2146634992_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634992" xlink:to="loc_sclx_VickersVantageMember_2146634993" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_EarningsPerShareDiluted_388" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xlink:to="loc_dei_LegalEntityAxis_2146635003" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635003" xlink:to="loc_dei_EntityDomain_2146635004" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635003" xlink:to="loc_dei_EntityDomain_2146635004_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635004" xlink:to="loc_sclx_VickersVantageMember_2146635005" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_2146635455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_dei_LegalEntityAxis_2146635514" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635514" xlink:to="loc_dei_EntityDomain_2146635515" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635515_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635514" xlink:to="loc_dei_EntityDomain_2146635515_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635515" xlink:to="loc_sclx_ScilexPharmaMember_2146635517" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635518" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635519" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635519_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635519_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:label="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635519" xlink:to="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_sclx_EventAxis_2146635523" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventAxis_2146635523" xlink:to="loc_sclx_EventDomain_2146635524" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventAxis_2146635523" xlink:to="loc_sclx_EventDomain_2146635524_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CumulativeSalesRelatedContingencyMember" xlink:label="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LetterOfCreditDrawnDownMember" xlink:label="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2146635528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2146635528" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146635529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2146635528" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146635529" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146635529_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2146635528" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146635529_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2146635530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146635529" xlink:to="loc_us-gaap_SubsequentEventMember_2146635530" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636050" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636050" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636051" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636051_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636050" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636051_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636051" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636052" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636053" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636053" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636054" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636054_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636053" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636054_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636054" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636055" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetWorkingCapital" xlink:label="loc_sclx_NetWorkingCapital_2146635459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_NetWorkingCapital_2146635459" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashBalance" xlink:label="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:label="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentRepurchaseObligation" xlink:label="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2146635573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_OperatingIncomeLoss_2146635573" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636049" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOfferingDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_576" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_PublicOfferingDetailsTable_574" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_575" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_IPOMember_578" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_OverAllotmentOptionMember_579" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_dei_LegalEntityAxis_2146634940" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634940" xlink:to="loc_dei_EntityDomain_2146634941" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634941_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634940" xlink:to="loc_dei_EntityDomain_2146634941_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634941" xlink:to="loc_sclx_VickersVantageMember_2146634945" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasePricePerShare" xlink:label="loc_sclx_PurchasePricePerShare_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_PurchasePricePerShare_581" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSaleUnits" xlink:label="loc_sclx_NumberOfSaleUnits_2146636382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_NumberOfSaleUnits_2146636382" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_597" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_sclx_PrivatePlacementDetailsTable_595" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_596" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_596" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_596" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" xlink:to="loc_us-gaap_PrivatePlacementMember_598" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_dei_LegalEntityAxis_2146635105" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635105" xlink:to="loc_dei_EntityDomain_2146635107" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635105" xlink:to="loc_dei_EntityDomain_2146635107_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635107" xlink:to="loc_sclx_VickersVantageMember_2146635108" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_602" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_645" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_645" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_651" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_651_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_645" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_651_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromisoryNoteMember" xlink:label="loc_sclx_ConvertiblePromisoryNoteMember_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_sclx_ConvertiblePromisoryNoteMember_652" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_646" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_646" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_653" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_653_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_646" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_653_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_FounderSharesMember_654" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_660" xlink:to="loc_sclx_FounderSharesMember_661" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="loc_sclx_PromissoryNoteRelatedPartyMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_PromissoryNoteRelatedPartyMember_655" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_647" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_647" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_656" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_647" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_656_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_656" xlink:to="loc_us-gaap_SubsequentEventMember_657" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_648" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_648" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_648" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" xlink:to="loc_us-gaap_IPOMember_659" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_660" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_660_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_660_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_dei_LegalEntityAxis_2146634976" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634976" xlink:to="loc_dei_EntityDomain_2146634977" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634977_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634976" xlink:to="loc_dei_EntityDomain_2146634977_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_VickersVantageMember_2146634979" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_ScilexPharmaMember_2146635920" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635807" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635807" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635809" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635809_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635807" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635809_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635809" xlink:to="loc_sclx_SenmurMember_2146635810" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635852" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635852_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635852_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ItochuMember" xlink:label="loc_sclx_ItochuMember_2146635854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_ItochuMember_2146635854" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_SorrentoMember_2146635876" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146636066" xlink:to="loc_sclx_SorrentoMember_2146636067" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" xlink:to="loc_sclx_SorrentoMember_2146636078" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_EventAxis_2146635901" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventAxis_2146635901" xlink:to="loc_sclx_EventDomain_2146635902" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventAxis_2146635901" xlink:to="loc_sclx_EventDomain_2146635902_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635902" xlink:to="loc_sclx_ReorganizationMember_2146635903" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_InvesteeAxis_2146636065" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_InvesteeAxis_2146636065" xlink:to="loc_sclx_InvesteeDomain_2146636066" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636066_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_InvesteeAxis_2146636065" xlink:to="loc_sclx_InvesteeDomain_2146636066_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636071" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636071" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636072" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636072_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636071" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636072_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636072" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146636076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146636076" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146636076" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146636076" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_AgreementAxis_2146636315" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146636315" xlink:to="loc_sclx_AgreementDomain_2146636319" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146636315" xlink:to="loc_sclx_AgreementDomain_2146636319_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146636320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636319" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146636320" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2146636348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2146636348" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2146636349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2146636348" xlink:to="loc_us-gaap_EquityComponentDomain_2146636349" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2146636349_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2146636348" xlink:to="loc_us-gaap_EquityComponentDomain_2146636349_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2146636350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_PreferredStockMember_2146636350" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2146636351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_CommonStockMember_2146636351" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAxis" xlink:label="loc_sclx_PeriodAxis_2146636629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_PeriodAxis_2146636629" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain_2146636630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PeriodAxis_2146636629" xlink:to="loc_sclx_PeriodDomain_2146636630" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain_2146636630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PeriodAxis_2146636629" xlink:to="loc_sclx_PeriodDomain_2146636630_default" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:label="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PeriodDomain_2146636630" xlink:to="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="loc_sclx_CapitalizationOfShareOutstanding_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_CapitalizationOfShareOutstanding_664" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_668" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_669" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RepaymentsOfDebt_670" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ConvertibleDebt_672" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsExercisePrice" xlink:label="loc_sclx_WarrantsExercisePrice_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WarrantsExercisePrice_673" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AdditionalPaidInCapital_674" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_aggregatePurchasePrice" xlink:label="loc_sclx_aggregatePurchasePrice_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_aggregatePurchasePrice_676" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_677" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositedInTrustAccount" xlink:label="loc_sclx_DepositedInTrustAccount_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_DepositedInTrustAccount_680" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635838" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635839" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635849" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToAcquireInventory" xlink:label="loc_sclx_PaymentToAcquireInventory_2146635855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PaymentToAcquireInventory_2146635855" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesOutstanding" xlink:label="loc_sclx_NumberOfSharesOutstanding_2146635879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesOutstanding_2146635879" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesAcquired" xlink:label="loc_sclx_NumberOfSharesAcquired_2146635888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesAcquired_2146635888" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSimpleInterest" xlink:label="loc_sclx_PercentageOfSimpleInterest_2146635906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSimpleInterest_2146635906" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_2146635908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_NotesPayableCurrent_2146635908" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedInterest" xlink:label="loc_sclx_AccruedInterest_2146635924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AccruedInterest_2146635924" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerWarrants" xlink:label="loc_sclx_PricePerWarrants_2146635981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PricePerWarrants_2146635981" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146635982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146635982" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2146635983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2146635983" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePrincipalAmount" xlink:label="loc_sclx_AggregatePrincipalAmount_2146635990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AggregatePrincipalAmount_2146635990" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="loc_us-gaap_DueToAffiliateCurrent_2146636008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToAffiliateCurrent_2146636008" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaidAmount" xlink:label="loc_sclx_RepaidAmount_2146636011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_RepaidAmount_2146636011" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfCapitalSharesOutstanding" xlink:label="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2146636059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermNotesPayable_2146636059" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2146636070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_2146636070" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636074" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapitalRequirements" xlink:label="loc_sclx_WorkingCapitalRequirements_2146636097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WorkingCapitalRequirements_2146636097" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_2146636101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LegalFees_2146636101" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOutstandingAmountIndebtedness" xlink:label="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" use="optional" order="119" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" use="optional" order="120" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermDebt_2146636345" use="optional" order="121" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" use="optional" order="122" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" use="optional" order="123" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_719" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_719" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_725" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_719" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_725_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_725" xlink:to="loc_sclx_ScilexCommonStockMember_726" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_720" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_720" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_720" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_StatementClassOfStockAxis_721" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_721" xlink:to="loc_us-gaap_ClassOfStockDomain_729" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_721" xlink:to="loc_us-gaap_ClassOfStockDomain_729_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_729" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_730" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_732" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_722" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_722" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_722" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_srt_RangeAxis_723" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_723" xlink:to="loc_srt_RangeMember_733" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_733_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_723" xlink:to="loc_srt_RangeMember_733_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MinimumMember_734" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MaximumMember_735" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_dei_LegalEntityAxis_2146635081" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635081" xlink:to="loc_dei_EntityDomain_2146635082" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635082_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635081" xlink:to="loc_dei_EntityDomain_2146635082_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635082" xlink:to="loc_sclx_VickersVantageMember_2146635083" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146635917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146635917" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146635917" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146635917" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_2146635919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_2146635919" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProjectAgreementMember" xlink:label="loc_sclx_ProjectAgreementMember_2146635962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProjectAgreementMember_2146635962" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaloAltoAadministrativeFacilityMember" xlink:label="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" xlink:to="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OtherCommitmentsDescription_736" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_737" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsAuthorized" xlink:label="loc_us-gaap_PreferredUnitsAuthorized_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredUnitsAuthorized_738" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MergerConsiderationDescription" xlink:label="loc_sclx_MergerConsiderationDescription_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_MergerConsiderationDescription_739" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssued_740" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_741" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockAggregateValue" xlink:label="loc_sclx_CommonStockAggregateValue_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_CommonStockAggregateValue_742" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NetTangibleAssets_744" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePercentage" xlink:label="loc_sclx_AggregatePercentage_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AggregatePercentage_745" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsPercentage" xlink:label="loc_sclx_WarrantsPercentage_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WarrantsPercentage_746" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockNoParValue_747" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BalanceInTheTrustAccount" xlink:label="loc_sclx_BalanceInTheTrustAccount_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_BalanceInTheTrustAccount_748" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommission" xlink:label="loc_sclx_DeferredUnderwritingCommission_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommission_749" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommissionPayable" xlink:label="loc_sclx_DeferredUnderwritingCommissionPayable_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommissionPayable_750" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAggregateRoyalityPayments" xlink:label="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationDate" xlink:label="loc_sclx_AgreementExpirationDate_2146635921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationDate_2146635921" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationTerm" xlink:label="loc_sclx_AgreementExpirationTerm_2146635922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationTerm_2146635922" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:label="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:label="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:label="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ThresholdMinimumPercentageOfSales" xlink:label="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAnnualAdjustmentToFees" xlink:label="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:label="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticePeriodForTerminationOfWorkOrder" xlink:label="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkOrderImplementationFee" xlink:label="loc_sclx_WorkOrderImplementationFee_2146635953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WorkOrderImplementationFee_2146635953" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesOperationsServicesMonthlyFee" xlink:label="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SellingGeneralAndAdministrativeExpenses" xlink:label="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_2146635959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OperatingLeaseExpense_2146635959" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" use="optional" order="68" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635127" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_764" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesIssued_766" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_767" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_768" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesIssued_770" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_771" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xlink:to="loc_dei_LegalEntityAxis_2146635128" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635128" xlink:to="loc_dei_EntityDomain_2146635129" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635129_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635128" xlink:to="loc_dei_EntityDomain_2146635129_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635129" xlink:to="loc_sclx_VickersVantageMember_2146635130" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/WarrantsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsLineItems" xlink:label="loc_sclx_WarrantsDetailsLineItems_791" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsTable" xlink:label="loc_sclx_WarrantsDetailsTable_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_WarrantsDetailsTable_788" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_789" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_789" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_789" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" xlink:to="loc_us-gaap_PrivatePlacementMember_793" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_790" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_790" xlink:to="loc_us-gaap_EquityComponentDomain_794" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_794_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_790" xlink:to="loc_us-gaap_EquityComponentDomain_794_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_794" xlink:to="loc_us-gaap_WarrantMember_795" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_dei_LegalEntityAxis_2146634998" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634998" xlink:to="loc_dei_EntityDomain_2146634999" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634999_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634998" xlink:to="loc_dei_EntityDomain_2146634999_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634999" xlink:to="loc_sclx_VickersVantageMember_2146635000" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsOutstandingShares" xlink:label="loc_sclx_WarrantsOutstandingShares_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_WarrantsOutstandingShares_796" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="loc_sclx_PublicWarrantsRedemptionDescription_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_PublicWarrantsRedemptionDescription_797" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalRaisingDescription" xlink:label="loc_sclx_CapitalRaisingDescription_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_CapitalRaisingDescription_798" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146634958" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_805" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:label="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146634955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_StatementTable_2146634955" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146634956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146634956" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146634957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146634956" xlink:to="loc_us-gaap_ClassOfStockDomain_2146634957" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146634957_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146634956" xlink:to="loc_us-gaap_ClassOfStockDomain_2146634957_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_dei_LegalEntityAxis_2146635089" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635089" xlink:to="loc_dei_EntityDomain_2146635090" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635090_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635089" xlink:to="loc_dei_EntityDomain_2146635090_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635090" xlink:to="loc_sclx_VickersVantageMember_2146635091" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2146635787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2146635787" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2146635789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2146635787" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2146635789" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2146635789_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2146635787" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2146635789_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:label="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEffectiveDebtYieldMember" xlink:label="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636094" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636094" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636095" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636095_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636094" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636095_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636095" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636096" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_2146635649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_2146635649" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_2146635774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_2146635774" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636100" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146636312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146636312" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_408" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_409" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_dei_LegalEntityAxis_2146635112" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635112" xlink:to="loc_dei_EntityDomain_2146635113" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635113_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635112" xlink:to="loc_dei_EntityDomain_2146635113_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635113" xlink:to="loc_sclx_VickersVantageMember_2146635115" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_AssetsAbstract_406" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_406" xlink:to="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_LiabilitiesAbstract_407" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_411" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_412" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_445" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_445" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_445" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_us-gaap_PrivatePlacementMember_447" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConversionOptionLiabilityMember" xlink:label="loc_sclx_ConversionOptionLiabilityMember_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_sclx_ConversionOptionLiabilityMember_448" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_dei_LegalEntityAxis_2146635139" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635139" xlink:to="loc_dei_EntityDomain_2146635140" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635140_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635139" xlink:to="loc_dei_EntityDomain_2146635140_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635140" xlink:to="loc_sclx_VickersVantageMember_2146635141" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_us-gaap_DerivativeLiabilities_449" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InitialMeasurementOne" xlink:label="loc_sclx_InitialMeasurementOne_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_InitialMeasurementOne_450" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635146" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnderlyingWarrantValue" xlink:label="loc_sclx_UnderlyingWarrantValue_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_UnderlyingWarrantValue_463" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_HoldingPeriod" xlink:label="loc_sclx_HoldingPeriod_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_HoldingPeriod_465" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_StatementTable_2146635143" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635144" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635144" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635145" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635144" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635145_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_dei_LegalEntityAxis_2146635147" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635147" xlink:to="loc_dei_EntityDomain_2146635148" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635147" xlink:to="loc_dei_EntityDomain_2146635148_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635148" xlink:to="loc_sclx_VickersVantageMember_2146635149" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2146635565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2146635565" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2146635566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2146635566" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2146635567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2146635567" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2146635520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2146635520" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635531" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635135" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharePrice_424" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="loc_sclx_FairValueMeasurementStrikePrice_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueMeasurementStrikePrice_425" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="loc_sclx_FairValueOfWarrantsinDollars_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueOfWarrantsinDollars_430" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_StatementTable_2146635132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635133" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635133" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635134" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635133" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635134_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_dei_LegalEntityAxis_2146635136" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635136" xlink:to="loc_dei_EntityDomain_2146635137" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635137_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635136" xlink:to="loc_dei_EntityDomain_2146635137_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635137" xlink:to="loc_sclx_VickersVantageMember_2146635138" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xlink:to="loc_dei_LegalEntityAxis_2146635358" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635358" xlink:to="loc_dei_EntityDomain_2146635359" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635358" xlink:to="loc_dei_EntityDomain_2146635359_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635359" xlink:to="loc_sclx_VickersVantageMember_2146635360" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_2146635361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_2146635361" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2146635833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ComputerEquipmentMember_2146635833" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2146635835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2146635835" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2146635836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2146635836" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_2146635837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ConstructionInProgressMember_2146635837" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_PatentsMember_2146635542" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_sclx_AssembledWorkforceMember_2146635548" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636056" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_PatentsMember_2146635595" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_sclx_AssembledWorkforceMember_2146635597" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636064" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_srt_RangeAxis_2146635600" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146635600" xlink:to="loc_srt_RangeMember_2146635602" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146635600" xlink:to="loc_srt_RangeMember_2146635602_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_2146635603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635602" xlink:to="loc_srt_WeightedAverageMember_2146635603" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_Goodwill_2146635582" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2146635585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2146635585" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2146636083" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636084" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636084" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636085" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636085_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636084" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636085_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146636174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146636174" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146636141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_RangeAxis_2146636141" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146636142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146636141" xlink:to="loc_srt_RangeMember_2146636142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146636142_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146636141" xlink:to="loc_srt_RangeMember_2146636142_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146636143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MaximumMember_2146636143" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MinimumMember_2146636144" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_2146636145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_StatementScenarioAxis_2146636145" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2146636146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2146636145" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2146636146" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2146636146_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2146636145" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2146636146_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_2146636147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_2146636147" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IfLetterOfCreditIsDrawnMember" xlink:label="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MarketingApprovalLetterMember" xlink:label="loc_sclx_MarketingApprovalLetterMember_2146636248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_MarketingApprovalLetterMember_2146636248" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636207" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636207" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636208" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636207" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636208_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_2146636219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_LetterOfCreditMember_2146636219" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:label="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementAxis" xlink:label="loc_sclx_StatementAxis_2146636282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_StatementAxis_2146636282" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain_2146636283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_StatementAxis_2146636282" xlink:to="loc_sclx_StatementDomain_2146636283" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain_2146636283_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_StatementAxis_2146636282" xlink:to="loc_sclx_StatementDomain_2146636283_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DecemberOptionalRepurchaseMember" xlink:label="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FebruaryOptionalRepurchaseMember" xlink:label="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AprilOptionalRepurchaseMember" xlink:label="loc_sclx_AprilOptionalRepurchaseMember_2146636294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_AprilOptionalRepurchaseMember_2146636294" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_2146636383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_VariableRateAxis_2146636383" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_2146636384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2146636383" xlink:to="loc_us-gaap_VariableRateDomain_2146636384" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_2146636384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2146636383" xlink:to="loc_us-gaap_VariableRateDomain_2146636384_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_2146636385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2146636384" xlink:to="loc_us-gaap_PrimeRateMember_2146636385" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636389" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636389" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636390" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636390_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636389" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636390_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaycheckProtectionProgramMember" xlink:label="loc_sclx_PaycheckProtectionProgramMember_2146636391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_sclx_PaycheckProtectionProgramMember_2146636391" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146636404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146636404" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeAxis" xlink:label="loc_sclx_EventTypeAxis_2146636396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_EventTypeAxis_2146636396" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain_2146636397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventTypeAxis_2146636396" xlink:to="loc_sclx_EventTypeDomain_2146636397" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain_2146636397_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventTypeAxis_2146636396" xlink:to="loc_sclx_EventTypeDomain_2146636397_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventTypeDomain_2146636397" xlink:to="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostAxis" xlink:label="loc_sclx_ClassificationOfCostAxis_2146636400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_ClassificationOfCostAxis_2146636400" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain_2146636437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_ClassificationOfCostAxis_2146636400" xlink:to="loc_sclx_ClassificationOfCostDomain_2146636437" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain_2146636437_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_ClassificationOfCostAxis_2146636400" xlink:to="loc_sclx_ClassificationOfCostDomain_2146636437_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonPayrollCostsMember" xlink:label="loc_sclx_NonPayrollCostsMember_2146636438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_NonPayrollCostsMember_2146636438" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PayrollCostsBasisMember" xlink:label="loc_sclx_PayrollCostsBasisMember_2146636439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_PayrollCostsBasisMember_2146636439" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentAxis" xlink:label="loc_sclx_AmendmentAxis_2146636421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AmendmentAxis_2146636421" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain_2146636423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AmendmentAxis_2146636421" xlink:to="loc_sclx_AmendmentDomain_2146636423" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain_2146636423_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AmendmentAxis_2146636421" xlink:to="loc_sclx_AmendmentDomain_2146636423_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentNoFourMember" xlink:label="loc_sclx_AmendmentNoFourMember_2146636424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AmendmentDomain_2146636423" xlink:to="loc_sclx_AmendmentNoFourMember_2146636424" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146636426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" xlink:to="loc_us-gaap_RelatedPartyDomain_2146636426" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146636426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" xlink:to="loc_us-gaap_RelatedPartyDomain_2146636426_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146636426" xlink:to="loc_sclx_SorrentoMember_2146636427" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146636429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146636429_default" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteMember" xlink:label="loc_sclx_PromissoryNoteMember_2146636430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" xlink:to="loc_sclx_PromissoryNoteMember_2146636430" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146636431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146636431" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146636431" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146636431" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432_default" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AgreementAxis_2146636183" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146636183" xlink:to="loc_sclx_AgreementDomain_2146636184" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636184_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146636183" xlink:to="loc_sclx_AgreementDomain_2146636184_default" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndebentureMember" xlink:label="loc_sclx_IndebentureMember_2146636188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636184" xlink:to="loc_sclx_IndebentureMember_2146636188" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636090" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:label="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfNetSalesPayable" xlink:label="loc_sclx_PercentageOfNetSalesPayable_2146636138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfNetSalesPayable_2146636138" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2146636140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfDebt_2146636140" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:label="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:label="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfConcentrationOnASimilarProduct" xlink:label="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentredemptionPeriod" xlink:label="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:label="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:label="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LineOfCreditFacilityindebtednessAmount" xlink:label="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636334" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:label="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_LongTermDebt_2146636386" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentTerminationDate" xlink:label="loc_sclx_DebtInstrumentTerminationDate_2146636387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentTerminationDate_2146636387" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:label="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:label="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumPayrollCostToBeAvailable" xlink:label="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146636405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RestrictedCash_2146636405" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:label="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseDate" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" use="optional" order="119" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2146636356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_2146636355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentTable_2146636355" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2146636355" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636357" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636357" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636358" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636358_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636357" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636358_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636358" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636359" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebt_2146636363" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146636364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146636364" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146636365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146636365" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_2146636366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtFairValue_2146636366" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnamortizedDebtDiscount" xlink:label="loc_sclx_UnamortizedDebtDiscount_2146637483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_sclx_UnamortizedDebtDiscount_2146637483" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansTable" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2146635463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_PlanNameAxis_2146635463" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2146635464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2146635463" xlink:to="loc_us-gaap_PlanNameDomain_2146635464" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2146635464_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2146635463" xlink:to="loc_us-gaap_PlanNameDomain_2146635464_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:label="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2146635598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2146635598" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2146635599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2146635598" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2146635599" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2146635599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2146635598" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2146635599_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingExpensesMember" xlink:label="loc_sclx_OperatingExpensesMember_2146635604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2146635599" xlink:to="loc_sclx_OperatingExpensesMember_2146635604" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_2146635605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_RetirementPlanNameAxis_2146635605" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2146635606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2146635605" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2146635606" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2146635606_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2146635605" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2146635606_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FourHundredAndOneKPlanMember" xlink:label="loc_sclx_FourHundredAndOneKPlanMember_2146635607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_2146635606" xlink:to="loc_sclx_FourHundredAndOneKPlanMember_2146635607" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2146636114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_AwardTypeAxis_2146636114" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2146636114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2146636114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2146636116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2146636116" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaap_PaymentsToEmployees_2146636113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_PaymentsToEmployees_2146636113" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xlink:to="loc_srt_RangeAxis_2146635661" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146635661" xlink:to="loc_srt_RangeMember_2146635662" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635662_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146635661" xlink:to="loc_srt_RangeMember_2146635662_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146635663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MinimumMember_2146635663" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MaximumMember_2146635664" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AcquisitionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2146635723" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_2146635722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionTable_2146635722" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635739" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635739" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635740" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635739" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635740_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_SenmurMember_2146635743" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146636180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_AardvarkMember_2146636180" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_2146636237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_RomegLicenseAgreementMember_2146636237" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneAxis" xlink:label="loc_sclx_MilestoneAxis_2146635745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_MilestoneAxis_2146635745" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain_2146635747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_MilestoneAxis_2146635745" xlink:to="loc_sclx_MilestoneDomain_2146635747" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain_2146635747_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_MilestoneAxis_2146635745" xlink:to="loc_sclx_MilestoneDomain_2146635747_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RegulatoryBasedMilestoneMember" xlink:label="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReveueBasedMilestoneMember" xlink:label="loc_sclx_ReveueBasedMilestoneMember_2146635751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ReveueBasedMilestoneMember_2146635751" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ApprovalBasedMilestoneMember" xlink:label="loc_sclx_ApprovalBasedMilestoneMember_2146636609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ApprovalBasedMilestoneMember_2146636609" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheAxis" xlink:label="loc_sclx_TrancheAxis_2146635755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_TrancheAxis_2146635755" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain_2146635756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_TrancheAxis_2146635755" xlink:to="loc_sclx_TrancheDomain_2146635756" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain_2146635756_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_TrancheAxis_2146635755" xlink:to="loc_sclx_TrancheDomain_2146635756_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheOneMember" xlink:label="loc_sclx_TrancheOneMember_2146635757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheOneMember_2146635757" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheTwoMember" xlink:label="loc_sclx_TrancheTwoMember_2146635760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheTwoMember_2146635760" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheThreeMember" xlink:label="loc_sclx_TrancheThreeMember_2146635762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheThreeMember_2146635762" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheFourMember" xlink:label="loc_sclx_TrancheFourMember_2146635765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheFourMember_2146635765" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146635798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_InvesteeAxis_2146635798" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146635801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_InvesteeAxis_2146635798" xlink:to="loc_sclx_InvesteeDomain_2146635801" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146635801_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_InvesteeAxis_2146635798" xlink:to="loc_sclx_InvesteeDomain_2146635801_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146635801" xlink:to="loc_sclx_SorrentoMember_2146635803" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_srt_RestatementAxis_2146635897" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_2146635897" xlink:to="loc_srt_RestatementDomain_2146635898" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635898_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_2146635897" xlink:to="loc_srt_RestatementDomain_2146635898_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635898" xlink:to="loc_sclx_AsRestatedMember_2146635899" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636133" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636133" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636134" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636133" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636134_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636134" xlink:to="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635731" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635733" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:label="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:label="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:label="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:label="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockValueToBeExchanged" xlink:label="loc_sclx_CommonStockValueToBeExchanged_2146635780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_CommonStockValueToBeExchanged_2146635780" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:label="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:label="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentMadeInSurrenderingTheShares" xlink:label="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635793" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636128" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UpfrontlicenseFee" xlink:label="loc_sclx_UpfrontlicenseFee_2146636214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_UpfrontlicenseFee_2146636214" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestonePayment" xlink:label="loc_sclx_MilestonePayment_2146636223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_MilestonePayment_2146636223" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2146636233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_RoyaltyExpense_2146636233" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredConsideration" xlink:label="loc_sclx_DeferredConsideration_2146636247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_DeferredConsideration_2146636247" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" use="optional" order="62" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xlink:to="loc_dei_LegalEntityAxis_2146635325" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635325" xlink:to="loc_dei_EntityDomain_2146635326" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635325" xlink:to="loc_dei_EntityDomain_2146635326_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635326" xlink:to="loc_sclx_VickersVantageMember_2146635327" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_2146635329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_2146635329" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_dei_LegalEntityAxis_2146635296" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635296" xlink:to="loc_dei_EntityDomain_2146635297" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635296" xlink:to="loc_dei_EntityDomain_2146635297_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635297" xlink:to="loc_sclx_VickersVantageMember_2146635298" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_srt_RestatementAxis_2146635301" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_2146635301" xlink:to="loc_srt_RestatementDomain_2146635302" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635302_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_2146635301" xlink:to="loc_srt_RestatementDomain_2146635302_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_2146635303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_2146635303" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_2146635304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_RestatementAdjustmentMember_2146635304" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="loc_sclx_AdjustmentsRestatement2Member_2146635305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AdjustmentsRestatement2Member_2146635305" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AsRestatedMember_2146635320" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635306" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2146635307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_Liabilities_2146635307" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2146635309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_CommonStockValue_2146635309" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2146635311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2146635311" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2146635314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_StockholdersEquity_2146635314" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="loc_sclx_IncomeTaxDisclosureTable_2146636021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_IncomeTaxDisclosureTable_2146636021" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2146636025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_DomesticCountryMember_2146636025" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_2146636028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxPeriodAxis_2146636028" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_2146636029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_2146636028" xlink:to="loc_us-gaap_TaxPeriodDomain_2146636029" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_2146636029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_2146636028" xlink:to="loc_us-gaap_TaxPeriodDomain_2146636029_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_2146636029" xlink:to="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_2146636033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" xlink:to="loc_us-gaap_ResearchMember_2146636033" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2146636035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2146636035" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TaxCreditCarryforwardExpirationYear" xlink:label="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:label="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsLineItems" xlink:label="loc_sclx_SubsequentEventsDetailsLineItems_821" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsTable" xlink:label="loc_sclx_SubsequentEventsDetailsTable_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SubsequentEventsDetailsTable_819" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_820" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146634684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_820" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146634684" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146634684_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_820" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146634684_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146634684" xlink:to="loc_us-gaap_SubsequentEventMember_822" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_dei_LegalEntityAxis_2146635150" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635150" xlink:to="loc_dei_EntityDomain_2146635151" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635151_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635150" xlink:to="loc_dei_EntityDomain_2146635151_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_VickersVantageMember_2146635152" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635419" xlink:to="loc_sclx_SorrentoMember_2146635420" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" xlink:to="loc_sclx_SorrentoMember_2146635423" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_SorrentoMember_2146636600" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146635413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146635413" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146635414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146635413" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146635414" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146635414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146635413" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146635414_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146635416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146635414" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146635416" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635419" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635419_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635419_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146635421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146635421" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146635421" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146635421" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635424" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635424" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635425" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635425_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635424" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635425_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146635482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146635482" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635427" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635427" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635428" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635428_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635427" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635428_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146635429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635428" xlink:to="loc_sclx_AardvarkMember_2146635429" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_srt_RangeAxis_2146635501" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146635501" xlink:to="loc_srt_RangeMember_2146635503" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146635501" xlink:to="loc_srt_RangeMember_2146635503_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MaximumMember_2146635504" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MinimumMember_2146636323" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146636324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146636324" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146636325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146636324" xlink:to="loc_us-gaap_ClassOfStockDomain_2146636325" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146636325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146636324" xlink:to="loc_us-gaap_ClassOfStockDomain_2146636325_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2146636326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146636325" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2146636326" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636330" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636330" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636331" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636330" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636331_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636331" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636332" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_AgreementAxis_2146636593" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146636593" xlink:to="loc_sclx_AgreementDomain_2146636594" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146636593" xlink:to="loc_sclx_AgreementDomain_2146636594_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:label="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2146636601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2146636601" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2146636602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2146636601" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2146636602" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2146636602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2146636601" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2146636602_default" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember_2146636603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccountsPayableMember_2146636603" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2146636604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2146636604" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_InvesteeAxis_2146636610" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_InvesteeAxis_2146636610" xlink:to="loc_sclx_InvesteeDomain_2146636611" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_InvesteeAxis_2146636610" xlink:to="loc_sclx_InvesteeDomain_2146636611_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_YorkvilleMember" xlink:label="loc_sclx_YorkvilleMember_2146636612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146636611" xlink:to="loc_sclx_YorkvilleMember_2146636612" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability" xlink:label="loc_us-gaap_LeaseDepositLiability_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LeaseDepositLiability_823" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockNoParValue_824" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_825" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesLimits" xlink:label="loc_sclx_NumberOfSharesLimits_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfSharesLimits_826" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorLoan" xlink:label="loc_sclx_SponsorLoan_2146635252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SponsorLoan_2146635252" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantExercisePrice" xlink:label="loc_sclx_WarrantExercisePrice_2146635254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_WarrantExercisePrice_2146635254" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdditionalPrincipalAmount" xlink:label="loc_sclx_AdditionalPrincipalAmount_2146635256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AdditionalPrincipalAmount_2146635256" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromissoryNote" xlink:label="loc_sclx_ConvertiblePromissoryNote_2146635257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_ConvertiblePromissoryNote_2146635257" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:label="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146635436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_RestrictedCash_2146635436" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146635440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146635440" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:label="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesThresholdLimit" xlink:label="loc_sclx_SalesThresholdLimit_2146635461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SalesThresholdLimit_2146635461" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636329" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2146636592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2146636592" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_2146636606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_2146636606" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:label="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:label="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:label="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" use="optional" order="90" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sclx-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [01:37:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Assets Held-in-trust, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangibles, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred Costs, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_sclx_AccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedPayroll" xlink:to="lab_sclx_AccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-Term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_sclx_RelatedPartyNotePayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyNotePayableCurrent" xml:lang="en-US">Related Party Note Payable Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RelatedPartyNotePayableCurrent" xml:lang="en-US">Related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyNotePayableCurrent" xlink:to="lab_sclx_RelatedPartyNotePayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RelatedPartyNotePayableCurrent" xml:lang="en-US">Related party note payable, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_sclx_AdvancesFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdvancesFromRelatedParty" xml:lang="en-US">Advances From Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdvancesFromRelatedParty" xml:lang="en-US">Advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdvancesFromRelatedParty" xlink:to="lab_sclx_AdvancesFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdvancesFromRelatedParty" xml:lang="en-US">Advances from related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Promissory note &#8212; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Current portion of deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible promissory notes &#8212; related party, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Conversion option liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Conversion Option Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xml:lang="en-US">Other Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xml:lang="en-US">Simple promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermNotesPayable" xlink:to="lab_us-gaap_OtherLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xml:lang="en-US">Mandatorily redeemable ordinary shares liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long term portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_sclx_DerivativeLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DerivativeLiabilityNoncurrent" xml:lang="en-US">Derivative Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DerivativeLiabilityNoncurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DerivativeLiabilityNoncurrent" xlink:to="lab_sclx_DerivativeLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DerivativeLiabilityNoncurrent" xml:lang="en-US">Derivative liability, noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Long-term deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_sclx_RelatedPartyNotePayableNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyNotePayableNoncurrent" xml:lang="en-US">Related Party Note Payable Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RelatedPartyNotePayableNoncurrent" xml:lang="en-US">Related party note payable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyNotePayableNoncurrent" xlink:to="lab_sclx_RelatedPartyNotePayableNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RelatedPartyNotePayableNoncurrent" xml:lang="en-US">Related party note payable, non current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (See Note 8)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September 30, 2022 and December 31, 2021, respectively, at redemption value of $10.41 and $10.00, respectively, per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ordinary Shares Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional amount borrowed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Shareholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_VickersVantageMember" xml:lang="en-US">Vickers Vantage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_VickersVantageMember" xml:lang="en-US">Vicker's Vantage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_VickersVantageMember" xlink:to="lab_sclx_VickersVantageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_VickersVantageMember" xml:lang="en-US">Vickers vantage .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary Shares Subject To Possible Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" xml:lang="en-US">Subject to possible redemption shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary shares subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:to="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Ordinary shares subject to possible redemption per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preference shares, par value (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preference shares, authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preference shares, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preference shares, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ordinary shares, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubjectToPossibleRedemptionPerShares" xlink:label="loc_sclx_SubjectToPossibleRedemptionPerShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubjectToPossibleRedemptionPerShares" xml:lang="en-US">Subject To Possible Redemption Per Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubjectToPossibleRedemptionPerShares" xml:lang="en-US">Subject to possible redemption per shares (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubjectToPossibleRedemptionPerShares" xlink:to="lab_sclx_SubjectToPossibleRedemptionPerShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubjectToPossibleRedemptionPerShares" xml:lang="en-US">Subject To possible redemption per shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xml:lang="en-US">Ordinary Shares Redemption Subjected To Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xml:lang="en-US">Ordinary shares redemption subjected to forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:to="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xml:lang="en-US">Redemption subjected to forfeiture.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesCapitalization" xlink:label="loc_sclx_SharesCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesCapitalization" xml:lang="en-US">Shares Capitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesCapitalization" xml:lang="en-US">Shares capitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesCapitalization" xlink:to="lab_sclx_SharesCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesCapitalization" xml:lang="en-US">Shares capitalization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAbstract" xml:lang="en-US">Component of Operating Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAbstract" xlink:to="lab_us-gaap_OtherIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">Loss on initial issuance of private warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfDerivatives" xlink:to="lab_us-gaap_GainLossOnSaleOfDerivatives" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" xml:lang="en-US">Transaction Costs Allocated To Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" xml:lang="en-US">Transaction costs allocated to warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:to="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" xml:lang="en-US">Transaction costs allocated to warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Change in fair value of conversion option liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xml:lang="en-US">Distributions on Mandatorily Redeemable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xml:lang="en-US">Interest on mandatorily redeemable ordinary shares liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xml:lang="en-US">Interest on mandatorily redeemable ordinary shares liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:to="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Income earned on investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_sclx_GainLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GainLossOnDerivative" xml:lang="en-US">Gain (Loss) on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_GainLossOnDerivative" xml:lang="en-US">Gain on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GainLossOnDerivative" xlink:to="lab_sclx_GainLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GainLossOnDerivative" xml:lang="en-US">Gain (Loss) on derivative.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_sclx_GainLossOnExtinguishmentOfDebtt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GainLossOnExtinguishmentOfDebtt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debtt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_GainLossOnExtinguishmentOfDebtt" xml:lang="en-US">(Gain) loss on debt extinguishment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GainLossOnExtinguishmentOfDebtt" xlink:to="lab_sclx_GainLossOnExtinguishmentOfDebtt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GainLossOnExtinguishmentOfDebtt" xml:lang="en-US">Gain (Loss) on extinguishment of debtt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNotesPrincipalIncrease" xlink:to="lab_sclx_ScilexPharmaNotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">(Gain) loss on foreign currency exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_sclx_ChangeInFairValueOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfWarrantLiability" xlink:to="lab_sclx_ChangeInFairValueOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Total other (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net (loss) income per share, ordinary shares (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic and diluted net income (loss) per ordinary share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xml:lang="en-US">Operating costs and expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_sclx_AcquiredinprocessresearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquiredinprocessresearchAndDevelopment" xml:lang="en-US">Acquiredinprocessresearch and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquiredinprocessresearchAndDevelopment" xml:lang="en-US">Acquired&#160;in-process&#160;research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquiredinprocessresearchAndDevelopment" xlink:to="lab_sclx_AcquiredinprocessresearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquiredinprocessresearchAndDevelopment" xml:lang="en-US">Acquired&#160;in-process&#160;research and development</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Intangible amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Total operating costs and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net income (loss) per ordinary share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Basic and diluted net income (loss) per ordinary share (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Dilutive Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Basic and diluted weighted average ordinary shares outstanding (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:label="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xml:lang="en-US">Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xml:lang="en-US">Mandatorily redeemable ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:to="lab_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xml:lang="en-US">Stock Redeemed or Called During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xml:lang="en-US">Accretion of Ordinary shares subject to possible redemption amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Shares issued related to Semnur Acquisition , shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Shares issued related to Semnur Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Aggregate purchase price value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Distribution to Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Distribution to Sorrento , shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of aggregate ordinary shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock options excercised , shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock options excercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Cancellation of shares held in escrow related to Semnur Acquisition , shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Ordinary shares, subject to forfeiture (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xml:lang="en-US">Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xml:lang="en-US">Adjustment to shares issued in Semnur Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:to="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xml:lang="en-US">Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Cancellation of ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Cancellation of ordinary shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of ordinary shares to Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of ordinary shares to Sponsor (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xml:lang="en-US">Adjustments To Additional Paid In Capital Net Of Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xml:lang="en-US">Aardvark SP-104 license transfer from Sorrento, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:to="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xml:lang="en-US">Adjustments to additional paid in capital net of discount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xml:lang="en-US">Adjustments To Additional Paid In Capital Discount Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xml:lang="en-US">Aardvark SP-104 discount amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:to="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xml:lang="en-US">Adjustments to additional paid in capital discount amortization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xml:lang="en-US">Interest Income, Debt Securities, Held-to-Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xml:lang="en-US">Income earned on investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:to="lab_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_sclx_LossOnInitialIssuanceOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LossOnInitialIssuanceOfWarrantLiability" xml:lang="en-US">Loss On Initial Issuance Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LossOnInitialIssuanceOfWarrantLiability" xml:lang="en-US">Loss on initial issuance of private warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:to="lab_sclx_LossOnInitialIssuanceOfWarrantLiability" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_sclx_ChangeInFairValueOfConversionOptionLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfConversionOptionLiability" xml:lang="en-US">Change In Fair Value Of Conversion Option Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfConversionOptionLiability" xml:lang="en-US">Change in fair value of conversion option liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfConversionOptionLiability" xlink:to="lab_sclx_ChangeInFairValueOfConversionOptionLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfConversionOptionLiability" xml:lang="en-US">The amount of change in fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" xml:lang="en-US">Transactions Costs Allocated To Private Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" xml:lang="en-US">Transaction costs allocated to warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:to="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" xml:lang="en-US">Transaction costs allocated to warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Long-term deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivables, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_sclx_IncreaseInNotesPayableOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncreaseInNotesPayableOne" xml:lang="en-US">Increase In Notes Payable One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncreaseInNotesPayableOne" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncreaseInNotesPayableOne" xlink:to="lab_sclx_IncreaseInNotesPayableOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncreaseInNotesPayableOne" xml:lang="en-US">Increase in notes payable one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">(Gain) loss on debt extinguishment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on debt extinguishment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_sclx_NonCashOperatingLeaseCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashOperatingLeaseCosts" xml:lang="en-US">Non Cash Operating Lease Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashOperatingLeaseCosts" xml:lang="en-US">Non-cash operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashOperatingLeaseCosts" xlink:to="lab_sclx_NonCashOperatingLeaseCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashOperatingLeaseCosts" xml:lang="en-US">Non cash operating lease costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Semnur-related IPR&amp;D</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">In process research and development costs expensed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xml:lang="en-US">Cost, Depreciation and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xml:lang="en-US">Formation Cost Paid Through Advances From Affiliate Of Sponsor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xml:lang="en-US">Formation cost paid through advances from affiliate of Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:to="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xml:lang="en-US">Formation cost paid through advances from affiliate of Sponsor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used for operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash flow from operation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_sclx_InvestmentOfCashInTrustAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvestmentOfCashInTrustAccounts" xml:lang="en-US">Investment Of Cash In Trust Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_InvestmentOfCashInTrustAccounts" xml:lang="en-US">Investment of cash in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvestmentOfCashInTrustAccounts" xlink:to="lab_sclx_InvestmentOfCashInTrustAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_InvestmentOfCashInTrustAccounts" xml:lang="en-US">Investment of cash in Trust Account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDecommissioningFund" xml:lang="en-US">Proceeds from Decommissioning Trust Fund Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDecommissioningFund" xml:lang="en-US">Cash withdrawn from Trust Account in connection with redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDecommissioningFund" xlink:to="lab_us-gaap_ProceedsFromDecommissioningFund" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used for investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, plant, and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Acquisition consideration paid in cash for Romeg intangible asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition of Semnur, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from sale of Units, net of underwriting discounts paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from sale of Private Placement Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xml:lang="en-US">Proceeds from other loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xml:lang="en-US">Proceeds From Simple Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from simple promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:to="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from simple promissory note &#8211; related party.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_sclx_RepaymentOfPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment Of Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:to="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of promissory note &#8211; related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xml:lang="en-US">Payments for Repurchase of Other Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xml:lang="en-US">Redemption of ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xml:lang="en-US">Repayments of Senior Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xml:lang="en-US">Repayment of principal on the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xml:lang="en-US">Repayments of Other Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xml:lang="en-US">Repayment on other loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" xml:lang="en-US">Proceeds From Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:to="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from promissory note related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from stock options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xml:lang="en-US">Proceeds from Issuance of Medium-term Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xml:lang="en-US">Proceeds from related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xml:lang="en-US">Repayments of Medium-term Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xml:lang="en-US">Repayment of related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net change in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="loc_sclx_DeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred Underwriting Fee Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingFeePayable" xlink:to="lab_sclx_DeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred Underwriting Fees means the amount of deferred underwriting fees held in the Trust Account in connection with SPAC's initial public offering payable to the underwriters upon consummation of a business combination.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="loc_sclx_OfferingCostIncludedInAccruedOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" xml:lang="en-US">Offering Cost Included In Accrued Offering Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" xml:lang="en-US">Offering costs included in accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:to="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" xml:lang="en-US">Offering cost included in accrued offering cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Notes Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Offering costs paid through promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US">Deferred consideration for Romeg intangible asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Given</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xml:lang="en-US">Non-cash&#160;consideration in Semnur acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OtherLoanForgiveness" xlink:label="loc_sclx_OtherLoanForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OtherLoanForgiveness" xml:lang="en-US">Other Loan Forgiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OtherLoanForgiveness" xml:lang="en-US">Other loan forgiveness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OtherLoanForgiveness" xlink:to="lab_sclx_OtherLoanForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OtherLoanForgiveness" xml:lang="en-US">Other loan forgiveness.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteIssuedNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteIssuedNetOfDiscount" xml:lang="en-US">Promissory Note Issued Net Of Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PromissoryNoteIssuedNetOfDiscount" xml:lang="en-US">Promissory Note issued to Sorrento in exchange for the&#160;SP-104&#160;license, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteIssuedNetOfDiscount" xlink:to="lab_sclx_PromissoryNoteIssuedNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PromissoryNoteIssuedNetOfDiscount" xml:lang="en-US">Promissory note issued net of discount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:label="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xml:lang="en-US">Non Cash Fair Value Adjustment To Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xml:lang="en-US">Fair value adjustment to derivative liability in troubled debt restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:to="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xml:lang="en-US">Non cash fair value adjustment to derivative liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashRightOfUseAsset" xlink:label="loc_sclx_NonCashRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashRightOfUseAsset" xml:lang="en-US">Non Cash Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashRightOfUseAsset" xml:lang="en-US">Live Action&#160;right-of-use&#160;asset in Palo Alto</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashRightOfUseAsset" xlink:to="lab_sclx_NonCashRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashRightOfUseAsset" xml:lang="en-US">Non cash right of use asset.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:label="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xml:lang="en-US">Acquistion Costs Incurred But Not Paid Included In Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xml:lang="en-US">Semnur acquisition costs incurred but not paid in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:to="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xml:lang="en-US">Acquistion costs incurred but not paid included in accounts payable.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashDistributionToAcquiree" xlink:label="loc_sclx_NonCashDistributionToAcquiree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashDistributionToAcquiree" xml:lang="en-US">Non Cash Distribution To Acquiree</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashDistributionToAcquiree" xml:lang="en-US">Non-cash distribution to Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashDistributionToAcquiree" xlink:to="lab_sclx_NonCashDistributionToAcquiree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashDistributionToAcquiree" xml:lang="en-US">Non cash distribution to acquiree.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashIncreaseInPrincipal" xlink:label="loc_sclx_NonCashIncreaseInPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashIncreaseInPrincipal" xml:lang="en-US">Non Cash Increase In Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashIncreaseInPrincipal" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashIncreaseInPrincipal" xlink:to="lab_sclx_NonCashIncreaseInPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashIncreaseInPrincipal" xml:lang="en-US">Non cash increase in principal.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsTable" xml:lang="en-US">Description of Organization and Business Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xml:lang="en-US">Description of Organization and Business Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:to="lab_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernAbstract" xlink:label="loc_sclx_LiquidityAndGoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernAbstract" xml:lang="en-US">Liquidity And Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernAbstract" xlink:to="lab_sclx_LiquidityAndGoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernAbstract" xml:lang="en-US">Liquidity and going Concern.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTextBlock" xlink:label="loc_sclx_LiquidityAndGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity And Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernTextBlock" xlink:to="lab_sclx_LiquidityAndGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity and going concern.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="loc_sclx_ProposedPublicOfferingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProposedPublicOfferingAbstract" xml:lang="en-US">Public Offering [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProposedPublicOfferingAbstract" xlink:to="lab_sclx_ProposedPublicOfferingAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingDetailsTable" xml:lang="en-US">Public Offering (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingDetailsTable" xlink:to="lab_sclx_PublicOfferingDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingDetailsLineItems" xml:lang="en-US">Public Offering (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingDetailsLineItems" xlink:to="lab_sclx_PublicOfferingDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="loc_sclx_ProposedPublicOfferingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProposedPublicOfferingTextBlock" xml:lang="en-US">Proposed Public Offering Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProposedPublicOfferingTextBlock" xml:lang="en-US">PUBLIC OFFERING</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProposedPublicOfferingTextBlock" xlink:to="lab_sclx_ProposedPublicOfferingTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementAbstract" xlink:label="loc_sclx_PrivatePlacementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementAbstract" xml:lang="en-US">Private Placement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementAbstract" xlink:to="lab_sclx_PrivatePlacementAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementDetailsTable" xml:lang="en-US">Private Placement (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementDetailsTable" xlink:to="lab_sclx_PrivatePlacementDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementDetailsLineItems" xml:lang="en-US">Private Placement (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems" xlink:to="lab_sclx_PrivatePlacementDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementTextBlock" xlink:label="loc_sclx_PrivatePlacementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementTextBlock" xml:lang="en-US">Private Placement Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivatePlacementTextBlock" xml:lang="en-US">PRIVATE PLACEMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementTextBlock" xlink:to="lab_sclx_PrivatePlacementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivatePlacementTextBlock" xml:lang="en-US">The entire disclosure for private placement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAbstract" xml:lang="en-US">Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAbstract" xlink:to="lab_us-gaap_AssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Asset Acquisition [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsTable" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsTable" xml:lang="en-US">Related Party Transactions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable" xlink:to="lab_sclx_RelatedPartyTransactionsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsLineItems" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsLineItems" xml:lang="en-US">Related Party Transactions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="lab_sclx_RelatedPartyTransactionsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsAbstract" xlink:label="loc_sclx_WarrantsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsAbstract" xml:lang="en-US">Warrants Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsAbstract" xlink:to="lab_sclx_WarrantsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTable" xlink:label="loc_sclx_WarrantsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsTable" xml:lang="en-US">Warrants [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsTable" xlink:to="lab_sclx_WarrantsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsLineItems" xlink:label="loc_sclx_WarrantsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsLineItems" xml:lang="en-US">Warrants [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsLineItems" xlink:to="lab_sclx_WarrantsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsLineItems" xml:lang="en-US">Warrants [Line item]</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTextBlock" xlink:label="loc_sclx_WarrantsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsTextBlock" xml:lang="en-US">Warrants Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsTextBlock" xml:lang="en-US">WARRANTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsTextBlock" xlink:to="lab_sclx_WarrantsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">SHAREHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansAbstract" xml:lang="en-US">Compensation And Employee Benefit Plans [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:to="lab_sclx_CompensationAndEmployeeBenefitPlansAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansAbstract" xml:lang="en-US">Compensation and employee benefit plans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Stock Incentive and Employee Benefit Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsandContingenciesDetailsTable" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable" xlink:to="lab_sclx_CommitmentsandContingenciesDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsandContingenciesDetailsLineItems" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems" xlink:to="lab_sclx_CommitmentsandContingenciesDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xml:lang="en-US">Condensed Financial Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xml:lang="en-US">RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xml:lang="en-US">Equity Method Investments [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xml:lang="en-US">Investments Held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xml:lang="en-US">Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xml:lang="en-US">Ordinary Shares Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Income (Loss) per Ordinary Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Other Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">Acquired In-Process Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RebatesPolicyTextBlock" xlink:label="loc_sclx_RebatesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RebatesPolicyTextBlock" xml:lang="en-US">Rebates [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RebatesPolicyTextBlock" xml:lang="en-US">Rebates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RebatesPolicyTextBlock" xlink:to="lab_sclx_RebatesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RebatesPolicyTextBlock" xml:lang="en-US">Rebates.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ServiceFeesPolicyTextBlock" xlink:label="loc_sclx_ServiceFeesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ServiceFeesPolicyTextBlock" xml:lang="en-US">Service Fees [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ServiceFeesPolicyTextBlock" xml:lang="en-US">Service Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ServiceFeesPolicyTextBlock" xlink:to="lab_sclx_ServiceFeesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ServiceFeesPolicyTextBlock" xml:lang="en-US">Service fees.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesReturnsPolicyTextBlock" xlink:label="loc_sclx_SalesReturnsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SalesReturnsPolicyTextBlock" xml:lang="en-US">Sales Returns [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SalesReturnsPolicyTextBlock" xml:lang="en-US">Product Returns</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SalesReturnsPolicyTextBlock" xlink:to="lab_sclx_SalesReturnsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SalesReturnsPolicyTextBlock" xml:lang="en-US">Sales returns.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoPaymentAssistancePolicyTextBlock" xlink:label="loc_sclx_CoPaymentAssistancePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CoPaymentAssistancePolicyTextBlock" xml:lang="en-US">Co Payment Assistance [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CoPaymentAssistancePolicyTextBlock" xml:lang="en-US">Co-Payment Assistance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CoPaymentAssistancePolicyTextBlock" xlink:to="lab_sclx_CoPaymentAssistancePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CoPaymentAssistancePolicyTextBlock" xml:lang="en-US">Co payment assistance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xml:lang="en-US">Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of reconciliation of basic and diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value hierarchy of the valuation inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Fair Value, Concentration of Risk [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Schedule of quantitative information regarding Level 3 fair value measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of changes in the fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of valued using the compound option pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary Of Share Based Payment Award Options Issued To Employees And Nonemployees Valuation Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xml:lang="en-US">Schedule of change in the fair value of conversion option liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of the Company's Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Summary of Estimated Future Amortization Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Summary of Borrowings of the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule Of Future minimum payments Of Long Term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xml:lang="en-US">Summary of Future Minimum Payments Under the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xlink:to="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of future minimum payments of long term debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary Of The Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Summary of Components of Lease Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xlink:label="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule Of Supplemental Quantitative Information Related To Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Summary of Supplemental Quantitative Information Related To Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xlink:to="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule of supplemental quantitative information related to leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Maturities of Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xml:lang="en-US">Schedule of impact of these adjustments to the financial statement, as previously reported</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of components of income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of effective income tax rate reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xml:lang="en-US">Description of Organization and Business Operations (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xml:lang="en-US">Description of Organization and Business Operations (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Number of shares (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Preferred Stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Warrant price per share (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Contribution per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:label="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xml:lang="en-US">Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:to="lab_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Sale of warrants (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Aggregate purchase of private placement warrants (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Business Acquisition, Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Transaction costs amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaap_OtherUnderwritingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherUnderwritingExpense" xml:lang="en-US">Other Underwriting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherUnderwritingExpense" xml:lang="en-US">Cash underwriting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherUnderwritingExpense" xlink:to="lab_us-gaap_OtherUnderwritingExpense" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFees" xlink:label="loc_sclx_DeferredUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingFees" xml:lang="en-US">Deferred Underwriting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingFees" xml:lang="en-US">Deferred underwriting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingFees" xlink:to="lab_sclx_DeferredUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingFees" xml:lang="en-US">Deferred underwriting fees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:label="loc_us-gaap_OtherOwnershipInterestsOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOwnershipInterestsOfferingCosts" xml:lang="en-US">Other Ownership Interests, Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOwnershipInterestsOfferingCosts" xml:lang="en-US">Other offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="lab_us-gaap_OtherOwnershipInterestsOfferingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of units amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestBearingDepositLiabilities" xlink:label="loc_us-gaap_NoninterestBearingDepositLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestBearingDepositLiabilities" xml:lang="en-US">Noninterest-Bearing Deposit Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoninterestBearingDepositLiabilities" xml:lang="en-US">Non-interest-bearing loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestBearingDepositLiabilities" xlink:to="lab_us-gaap_NoninterestBearingDepositLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Assets Held-in-trust</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Deposited trust account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Trust account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Assets Held-in-trust</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrust" xlink:to="lab_us-gaap_AssetsHeldInTrust" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="loc_sclx_SaleOfStockDescriptionOfTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SaleOfStockDescriptionOfTransactions" xml:lang="en-US">Sale Of Stock Description Of Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SaleOfStockDescriptionOfTransactions" xml:lang="en-US">Sale of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SaleOfStockDescriptionOfTransactions" xlink:to="lab_sclx_SaleOfStockDescriptionOfTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SaleOfStockDescriptionOfTransactions" xml:lang="en-US">Sale of stock description of transaction.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerPublicShare" xlink:label="loc_sclx_PricePerPublicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerPublicShare" xml:lang="en-US">Price Per Public Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerPublicShare" xml:lang="en-US">Anticipated public share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerPublicShare" xlink:to="lab_sclx_PricePerPublicShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xml:lang="en-US">Other Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xml:lang="en-US">Net tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPublicShares" xlink:label="loc_sclx_PercentageOfPublicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfPublicShares" xml:lang="en-US">Percentage Of Public Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfPublicShares" xml:lang="en-US">Percentage of public shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfPublicShares" xlink:to="lab_sclx_PercentageOfPublicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfPublicShares" xml:lang="en-US">Percentage of public shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Redeem percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="loc_sclx_BusinessCombinationRedeemPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BusinessCombinationRedeemPercentage" xml:lang="en-US">Business Combination Redeem Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BusinessCombinationRedeemPercentage" xml:lang="en-US">Business combination redeem percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BusinessCombinationRedeemPercentage" xlink:to="lab_sclx_BusinessCombinationRedeemPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BusinessCombinationRedeemPercentage" xml:lang="en-US">Business combination redeem percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherExpenses" xml:lang="en-US">Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherExpenses" xml:lang="en-US">Dissolution expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositIntoTheTrustAccountPerShare" xlink:label="loc_sclx_DepositIntoTheTrustAccountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DepositIntoTheTrustAccountPerShare" xml:lang="en-US">Deposit Into The Trust Account Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DepositIntoTheTrustAccountPerShare" xml:lang="en-US">Deposit into the trust account per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DepositIntoTheTrustAccountPerShare" xlink:to="lab_sclx_DepositIntoTheTrustAccountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DepositIntoTheTrustAccountPerShare" xml:lang="en-US">Deposit into the trust account per share.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LesserPublicPerShare" xlink:label="loc_sclx_LesserPublicPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LesserPublicPerShare" xml:lang="en-US">Lesser Public Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LesserPublicPerShare" xml:lang="en-US">Lesser public per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LesserPublicPerShare" xlink:to="lab_sclx_LesserPublicPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LesserPublicPerShare" xml:lang="en-US">Lesser public per share</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesDescription" xml:lang="en-US">Business Combination, Acquired Receivables, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesDescription" xml:lang="en-US">Business combination description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:to="lab_us-gaap_BusinessCombinationAcquiredReceivablesDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Opening bank account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkingCapital" xlink:to="lab_sclx_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working capital.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xml:lang="en-US">Interest Income, Deposit with Financial Institution, Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xml:lang="en-US">Deposit interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:to="lab_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofshares" xlink:label="loc_sclx_Numberofshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Numberofshares" xml:lang="en-US">NumberOfShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Numberofshares" xml:lang="en-US">Number of shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Numberofshares" xlink:to="lab_sclx_Numberofshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Numberofshares" xml:lang="en-US">Number of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="loc_sclx_ProceedsOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsOfInitialPublicOffering" xml:lang="en-US">Proceeds Of Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsOfInitialPublicOffering" xml:lang="en-US">Proceeds of initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsOfInitialPublicOffering" xlink:to="lab_sclx_ProceedsOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsOfInitialPublicOffering" xml:lang="en-US">Proceeds Of Initial Public Offering.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Saleofwarrants" xlink:label="loc_sclx_Saleofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Saleofwarrants" xml:lang="en-US">SaleOfWarrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Saleofwarrants" xml:lang="en-US">Sale of warrants (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Saleofwarrants" xlink:to="lab_sclx_Saleofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Saleofwarrants" xml:lang="en-US">Sale Of Warrants.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Grossproceedsofwarrants" xlink:label="loc_sclx_Grossproceedsofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Grossproceedsofwarrants" xml:lang="en-US">GrossProceedsOfWarrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Grossproceedsofwarrants" xml:lang="en-US">Gross proceeds of amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Grossproceedsofwarrants" xlink:to="lab_sclx_Grossproceedsofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Grossproceedsofwarrants" xml:lang="en-US">Gross Proceeds Of Warrants.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Transactioncostsamount" xlink:label="loc_sclx_Transactioncostsamount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Transactioncostsamount" xml:lang="en-US">TransactionCostsAmount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Transactioncostsamount" xml:lang="en-US">Transaction costs amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Transactioncostsamount" xlink:to="lab_sclx_Transactioncostsamount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Transactioncostsamount" xml:lang="en-US">Transaction Costs Amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Otherofferingcosts" xlink:label="loc_sclx_Otherofferingcosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Otherofferingcosts" xml:lang="en-US">OtherOfferingCosts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Otherofferingcosts" xlink:to="lab_sclx_Otherofferingcosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Otherofferingcosts" xml:lang="en-US">OtherOfferingCosts.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofbusinessdays" xlink:label="loc_sclx_Numberofbusinessdays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Numberofbusinessdays" xml:lang="en-US">NumberOfBusinessDays</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Numberofbusinessdays" xml:lang="en-US">Number of business days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Numberofbusinessdays" xlink:to="lab_sclx_Numberofbusinessdays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Numberofbusinessdays" xml:lang="en-US">Number Of Business Days.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NetTangibleAssets" xml:lang="en-US">Net Tangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NetTangibleAssets" xml:lang="en-US">Net tangible assets (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NetTangibleAssets" xlink:to="lab_sclx_NetTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NetTangibleAssets" xml:lang="en-US">Net tangible assets.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Depositintotrustaccount" xlink:label="loc_sclx_Depositintotrustaccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Depositintotrustaccount" xml:lang="en-US">DepositIntoTrustAccount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Depositintotrustaccount" xml:lang="en-US">Deposit into trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Depositintotrustaccount" xlink:to="lab_sclx_Depositintotrustaccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Depositintotrustaccount" xml:lang="en-US">Deposit Into Trust Account.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Interestexpenses" xlink:label="loc_sclx_Interestexpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Interestexpenses" xml:lang="en-US">InterestExpenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Interestexpenses" xml:lang="en-US">Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Interestexpenses" xlink:to="lab_sclx_Interestexpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Interestexpenses" xml:lang="en-US">Interest expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Marketable Securities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Company place of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business combination equity interest acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Aggregate principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Gross proceeds from business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Equity interest from business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Business Combination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaMember" xlink:to="lab_sclx_ScilexPharmaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex pharma.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VantageMergerSubIncMember" xlink:label="loc_sclx_VantageMergerSubIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_VantageMergerSubIncMember" xml:lang="en-US">Vantage Merger Sub Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_VantageMergerSubIncMember" xlink:to="lab_sclx_VantageMergerSubIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_VantageMergerSubIncMember" xml:lang="en-US">Vantage merger sub inc.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">Initial Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="loc_sclx_PrivatePlacementWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementWarrantMember" xlink:to="lab_sclx_PrivatePlacementWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorMember" xlink:label="loc_sclx_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SponsorMember" xlink:to="lab_sclx_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SponsorMember" xml:lang="en-US">Sponsor Member.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementAxis" xlink:to="lab_sclx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementDomain" xlink:to="lab_sclx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ContributionAndLoanAgreementMember" xlink:label="loc_sclx_ContributionAndLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ContributionAndLoanAgreementMember" xml:lang="en-US">Contribution And Loan Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ContributionAndLoanAgreementMember" xlink:to="lab_sclx_ContributionAndLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ContributionAndLoanAgreementMember" xml:lang="en-US">Contribution and loan agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtExchangeAgreementMember" xml:lang="en-US">Debt Exchange Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtExchangeAgreementMember" xlink:to="lab_sclx_DebtExchangeAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtExchangeAgreementMember" xml:lang="en-US">Debt exchange agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SorrentoMember" xlink:to="lab_sclx_SorrentoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventAxis" xlink:to="lab_sclx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventAxis" xml:lang="en-US">Event.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventDomain" xlink:to="lab_sclx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventDomain" xml:lang="en-US">Event.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReorganizationMember" xml:lang="en-US">Reorganization [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReorganizationMember" xlink:to="lab_sclx_ReorganizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ReorganizationMember" xml:lang="en-US">Reorganization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="loc_us-gaap_OtherDeferredCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherDeferredCostsNet" xml:lang="en-US">Other Deferred Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherDeferredCostsNet" xml:lang="en-US">Offering costs amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDeferredCostsNet" xlink:to="lab_us-gaap_OtherDeferredCostsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaap_ExcessStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExcessStockSharesIssued" xml:lang="en-US">Excess Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExcessStockSharesIssued" xml:lang="en-US">Purchase of ordinary shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessStockSharesIssued" xlink:to="lab_us-gaap_ExcessStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Federal depository insurance coverage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Foundershares" xlink:label="loc_sclx_Foundershares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Foundershares" xml:lang="en-US">FounderShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Foundershares" xml:lang="en-US">Founder shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Foundershares" xlink:to="lab_sclx_Foundershares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Foundershares" xml:lang="en-US">Founder Shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Credit losses on accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SoleDistributorMember" xlink:label="loc_sclx_SoleDistributorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SoleDistributorMember" xml:lang="en-US">Sole Distributor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SoleDistributorMember" xlink:to="lab_sclx_SoleDistributorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SoleDistributorMember" xml:lang="en-US">Sole distributor.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xlink:label="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xml:lang="en-US">Schedule Of Ordinary Shares Reflected In Condensed Consolidated Balance Sheets Are Reconciled Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xlink:to="lab_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GrossProceeds" xlink:label="loc_sclx_GrossProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GrossProceeds" xml:lang="en-US">Gross Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_GrossProceeds" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GrossProceeds" xlink:to="lab_sclx_GrossProceeds" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract" xlink:label="loc_sclx_LessAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LessAbstract" xml:lang="en-US">Less Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LessAbstract" xml:lang="en-US">Less:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LessAbstract" xlink:to="lab_sclx_LessAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="loc_sclx_OrdinarySharesIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesIssuanceCost" xml:lang="en-US">Ordinary Shares Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_OrdinarySharesIssuanceCost" xml:lang="en-US">Ordinary shares issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesIssuanceCost" xlink:to="lab_sclx_OrdinarySharesIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OrdinarySharesIssuanceCost" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PlusAbstract" xlink:label="loc_sclx_PlusAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PlusAbstract" xml:lang="en-US">Plus Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PlusAbstract" xml:lang="en-US">Plus:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PlusAbstract" xlink:to="lab_sclx_PlusAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_sclx_AccretionOfCarryingValueToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccretionOfCarryingValueToRedemptionValue" xml:lang="en-US">Accretion Of Carrying Value To Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccretionOfCarryingValueToRedemptionValue" xml:lang="en-US">Accretion of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccretionOfCarryingValueToRedemptionValue" xlink:to="lab_sclx_AccretionOfCarryingValueToRedemptionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Accretion of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="loc_sclx_SharesSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesSubjectToPossibleRedemption" xml:lang="en-US">Shares Subject To Possible Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary shares subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesSubjectToPossibleRedemption" xlink:to="lab_sclx_SharesSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary shares subject to possible redemption.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract0" xlink:label="loc_sclx_LessAbstract0" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LessAbstract0" xml:lang="en-US">Less Abstract0</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LessAbstract0" xml:lang="en-US">Less:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LessAbstract0" xlink:to="lab_sclx_LessAbstract0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xml:lang="en-US">Temporary Equity, Other Changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xml:lang="en-US">Mandatorily redeemable ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:label="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xml:lang="en-US">Schedule Of Reflects The Calculation Of Basic And Diluted Net Income Loss Per Ordinary Share Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:to="lab_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumeratorAbstract" xlink:label="loc_sclx_NumeratorAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumeratorAbstract" xml:lang="en-US">Numerator Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumeratorAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumeratorAbstract" xlink:to="lab_sclx_NumeratorAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xml:lang="en-US">Temporary Equity, Net Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xml:lang="en-US">Allocation of net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DenominatorAbstract" xlink:label="loc_sclx_DenominatorAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DenominatorAbstract" xml:lang="en-US">Denominator Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DenominatorAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DenominatorAbstract" xlink:to="lab_sclx_DenominatorAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Basic and diluted weighted average ordinary shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity And Going Concern [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernTable" xlink:to="lab_sclx_LiquidityAndGoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity and going concern.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity And Going Concern [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems" xlink:to="lab_sclx_LiquidityAndGoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity and going concern.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetWorkingCapital" xlink:label="loc_sclx_NetWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NetWorkingCapital" xml:lang="en-US">Net Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NetWorkingCapital" xml:lang="en-US">Net working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NetWorkingCapital" xlink:to="lab_sclx_NetWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NetWorkingCapital" xml:lang="en-US">Net working capital.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US">Proceeds from Issuance of Secured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US">Proceeds from senior secured notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashBalance" xlink:label="loc_sclx_MinimumUnrestrictedCashBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumUnrestrictedCashBalance" xml:lang="en-US">Minimum Unrestricted Cash Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumUnrestrictedCashBalance" xml:lang="en-US">Minimum unrestricted cash balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumUnrestrictedCashBalance" xlink:to="lab_sclx_MinimumUnrestrictedCashBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumUnrestrictedCashBalance" xml:lang="en-US">Minimum unrestricted cash balance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt instrument face amount of debt repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:label="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xml:lang="en-US">Restricted Funds Relesable For Future Repurchase Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xml:lang="en-US">Restricted funds releasable for future repurchase of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:to="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xml:lang="en-US">Restricted funds relesable for future repurchase of debt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentRepurchaseObligation" xlink:label="loc_sclx_DebtInstrumentRepurchaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentRepurchaseObligation" xml:lang="en-US">Debt Instrument Repurchase Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentRepurchaseObligation" xml:lang="en-US">Debt instrument repurchase obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentRepurchaseObligation" xlink:to="lab_sclx_DebtInstrumentRepurchaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentRepurchaseObligation" xml:lang="en-US">Debt Instrument Repurchase Obligation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt instrument, annual principal payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDecreaseForgiveness" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentDecreaseForgiveness" xml:lang="en-US">Debt instrument, decrease, forgiveness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="lab_us-gaap_DebtInstrumentDecreaseForgiveness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes payable, related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Banking Regulation, Mortgage Banking, Net Worth, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Minimum net worth to consummate business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Minimum net worth to consummate business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumNetWorthRequiredForCompliance" xlink:to="lab_us-gaap_MinimumNetWorthRequiredForCompliance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregateOutstandingAmount" xml:lang="en-US">Aggregate Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregateOutstandingAmount" xml:lang="en-US">Aggregate Outstanding Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregateOutstandingAmount" xlink:to="lab_sclx_AggregateOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregateOutstandingAmount" xml:lang="en-US">Aggregate outstanding amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:label="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xml:lang="en-US">Senior Secured Notes Due Two Thousand And Twenty Six [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:to="lab_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xml:lang="en-US">Senior secured notes due two thousand and twenty six.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CumulativeSalesRelatedContingencyMember" xlink:label="loc_sclx_CumulativeSalesRelatedContingencyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CumulativeSalesRelatedContingencyMember" xml:lang="en-US">Cumulative Sales Related Contingency [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CumulativeSalesRelatedContingencyMember" xlink:to="lab_sclx_CumulativeSalesRelatedContingencyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CumulativeSalesRelatedContingencyMember" xml:lang="en-US">Cumulative sales related contingency.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LetterOfCreditDrawnDownMember" xlink:label="loc_sclx_LetterOfCreditDrawnDownMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LetterOfCreditDrawnDownMember" xml:lang="en-US">Letter Of Credit Drawn Down [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LetterOfCreditDrawnDownMember" xlink:to="lab_sclx_LetterOfCreditDrawnDownMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LetterOfCreditDrawnDownMember" xml:lang="en-US">Letter of credit drawn down.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNotesMember" xml:lang="en-US">Scilex Pharma Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNotesMember" xlink:to="lab_sclx_ScilexPharmaNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNotesMember" xml:lang="en-US">Scilex pharma notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FundingCommitmentLetterMember" xml:lang="en-US">Funding Commitment Letter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FundingCommitmentLetterMember" xlink:to="lab_sclx_FundingCommitmentLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FundingCommitmentLetterMember" xml:lang="en-US">Funding commitment letter.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasePricePerShare" xlink:label="loc_sclx_PurchasePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasePricePerShare" xml:lang="en-US">Purchase Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasePricePerShare" xml:lang="en-US">Purchase price per unit (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasePricePerShare" xlink:to="lab_sclx_PurchasePricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSaleUnits" xlink:label="loc_sclx_NumberOfSaleUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSaleUnits" xml:lang="en-US">Number Of Sale Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSaleUnits" xml:lang="en-US">Number of sale units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSaleUnits" xlink:to="lab_sclx_NumberOfSaleUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSaleUnits" xml:lang="en-US">Number of sale units</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Price per warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Ordinary share, per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Preferred Stock, par value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="loc_sclx_CapitalizationOfShareOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CapitalizationOfShareOutstanding" xml:lang="en-US">Capitalization Of Share Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CapitalizationOfShareOutstanding" xml:lang="en-US">Capitalization of share outstanding (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CapitalizationOfShareOutstanding" xlink:to="lab_sclx_CapitalizationOfShareOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CapitalizationOfShareOutstanding" xml:lang="en-US">Capitalization of share outstanding.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="loc_sclx_OrdinarySharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesIssuedAndOutstanding" xml:lang="en-US">Ordinary Shares Issued And Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OrdinarySharesIssuedAndOutstanding" xml:lang="en-US">Ordinary shares issued and outstanding (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesIssuedAndOutstanding" xlink:to="lab_sclx_OrdinarySharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OrdinarySharesIssuedAndOutstanding" xml:lang="en-US">Ordinary shares issued and outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Shareholder issued and outstanding shares percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Fund expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Outstanding balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="loc_us-gaap_BusinessCombinationControlObtainedDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationControlObtainedDescription" xml:lang="en-US">Business Combination, Control Obtained Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationControlObtainedDescription" xml:lang="en-US">Business combination, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationControlObtainedDescription" xlink:to="lab_us-gaap_BusinessCombinationControlObtainedDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsExercisePrice" xlink:label="loc_sclx_WarrantsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsExercisePrice" xml:lang="en-US">Warrant price per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsExercisePrice" xlink:to="lab_sclx_WarrantsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_aggregatePurchasePrice" xlink:label="loc_sclx_aggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_aggregatePurchasePrice" xml:lang="en-US">aggregate Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_aggregatePurchasePrice" xml:lang="en-US">Aggregate purchase price value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_aggregatePurchasePrice" xlink:to="lab_sclx_aggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_aggregatePurchasePrice" xml:lang="en-US">aggregate purchase price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xml:lang="en-US">Interest Expense, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_us-gaap_InterestExpenseRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Description of related party extension loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositedInTrustAccount" xlink:label="loc_sclx_DepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DepositedInTrustAccount" xml:lang="en-US">Deposited In Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DepositedInTrustAccount" xml:lang="en-US">Trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DepositedInTrustAccount" xlink:to="lab_sclx_DepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DepositedInTrustAccount" xml:lang="en-US">Deposited in trust account</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to Acquire Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to acquire productive assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset acquistion consideration transferred equity interest issued and issuable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock issued during period shares purchase of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common stock shares subscribed but not issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AssetAcquisitionPricePerShare" xml:lang="en-US">Asset Acquisition Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AssetAcquisitionPricePerShare" xml:lang="en-US">Asset acquisition price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AssetAcquisitionPricePerShare" xlink:to="lab_sclx_AssetAcquisitionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AssetAcquisitionPricePerShare" xml:lang="en-US">Asset acquisition price per share.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfOwnershipInterest" xml:lang="en-US">Percentage Of Ownership Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfOwnershipInterest" xml:lang="en-US">Percentage of ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfOwnershipInterest" xlink:to="lab_sclx_PercentageOfOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfOwnershipInterest" xml:lang="en-US">Percentage of ownership interest.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfSharesOutstanding" xml:lang="en-US">Percentage Of Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfSharesOutstanding" xml:lang="en-US">Percentage of shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfSharesOutstanding" xlink:to="lab_sclx_PercentageOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfSharesOutstanding" xml:lang="en-US">Percentage of shares outstanding.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToAcquireInventory" xlink:label="loc_sclx_PaymentToAcquireInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToAcquireInventory" xml:lang="en-US">Payment To Acquire Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToAcquireInventory" xml:lang="en-US">Payment to acquire inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToAcquireInventory" xlink:to="lab_sclx_PaymentToAcquireInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToAcquireInventory" xml:lang="en-US">Payment to acquire inventory.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesOutstanding" xlink:label="loc_sclx_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSharesOutstanding" xml:lang="en-US">Number Of Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSharesOutstanding" xml:lang="en-US">Capital stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSharesOutstanding" xlink:to="lab_sclx_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSharesOutstanding" xml:lang="en-US">Number of shares outstanding.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesAcquired" xlink:label="loc_sclx_NumberOfSharesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSharesAcquired" xml:lang="en-US">Number Of Shares Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSharesAcquired" xml:lang="en-US">Number of shares acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSharesAcquired" xlink:to="lab_sclx_NumberOfSharesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSharesAcquired" xml:lang="en-US">Number of shares acquired.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party transaction, selling, general and administrative expenses from transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSimpleInterest" xlink:label="loc_sclx_PercentageOfSimpleInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfSimpleInterest" xml:lang="en-US">Percentage Of Simple Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfSimpleInterest" xml:lang="en-US">Percentage of simple interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfSimpleInterest" xlink:to="lab_sclx_PercentageOfSimpleInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfSimpleInterest" xml:lang="en-US">Percentage of simple interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedInterest" xlink:label="loc_sclx_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedInterest" xml:lang="en-US">Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedInterest" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedInterest" xlink:to="lab_sclx_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedInterest" xml:lang="en-US">Accrued interest.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerWarrants" xlink:label="loc_sclx_PricePerWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerWarrants" xml:lang="en-US">Price Per Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerWarrants" xml:lang="en-US">Price per warrant (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerWarrants" xlink:to="lab_sclx_PricePerWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PricePerWarrants" xml:lang="en-US">Price per warrant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xml:lang="en-US">Related Party Tax Expense, Due to Affiliates, Deferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:to="lab_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Debt discount amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePrincipalAmount" xlink:label="loc_sclx_AggregatePrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregatePrincipalAmount" xml:lang="en-US">Aggregate Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregatePrincipalAmount" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregatePrincipalAmount" xlink:to="lab_sclx_AggregatePrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregatePrincipalAmount" xml:lang="en-US">Aggregate Principal Amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="loc_us-gaap_DueToAffiliateCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xml:lang="en-US">Due to Affiliate, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xml:lang="en-US">Advances outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaidAmount" xlink:label="loc_sclx_RepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaidAmount" xml:lang="en-US">Repaid Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepaidAmount" xml:lang="en-US">Repaid amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaidAmount" xlink:to="lab_sclx_RepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaidAmount" xml:lang="en-US">Repaid Amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfCapitalSharesOutstanding" xlink:label="loc_sclx_PercentageOfCapitalSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfCapitalSharesOutstanding" xml:lang="en-US">Percentage Of Capital Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfCapitalSharesOutstanding" xml:lang="en-US">Percentage of capital shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfCapitalSharesOutstanding" xlink:to="lab_sclx_PercentageOfCapitalSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfCapitalSharesOutstanding" xml:lang="en-US">Percentage of capital shares outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes payable, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt instrument, interest rate, stated percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapitalRequirements" xlink:label="loc_sclx_WorkingCapitalRequirements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkingCapitalRequirements" xml:lang="en-US">Working Capital Requirements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkingCapitalRequirements" xml:lang="en-US">Working capital requirements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkingCapitalRequirements" xlink:to="lab_sclx_WorkingCapitalRequirements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkingCapitalRequirements" xml:lang="en-US">Working capital requirements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xml:lang="en-US">Debt Instrument, Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xml:lang="en-US">Debt instrument, repurchase amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOutstandingAmountIndebtedness" xlink:label="loc_sclx_PercentageOfOutstandingAmountIndebtedness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfOutstandingAmountIndebtedness" xml:lang="en-US">Percentage of Outstanding Amount Indebtedness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfOutstandingAmountIndebtedness" xml:lang="en-US">Percentage of Outstanding Amount Indebtedness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfOutstandingAmountIndebtedness" xlink:to="lab_sclx_PercentageOfOutstandingAmountIndebtedness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfOutstandingAmountIndebtedness" xml:lang="en-US">Percentage of outstanding amount indebtedness</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Per share calculation of Outstanding Amount In Exchange of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Per share calculation of Outstanding Amount In Exchange of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:to="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Per share calculation of Outstanding Amount In Exchange of Shares</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Limitation of Outstanding Amount In Exchange of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Limitation of Outstanding Amount In Exchange of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:to="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Limitation of Outstanding Amount In Exchange of Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromisoryNoteMember" xlink:label="loc_sclx_ConvertiblePromisoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertiblePromisoryNoteMember" xml:lang="en-US">Convertible Promisory Note Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertiblePromisoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertiblePromisoryNoteMember" xlink:to="lab_sclx_ConvertiblePromisoryNoteMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FounderSharesMember" xml:lang="en-US">Founder Shares Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FounderSharesMember" xml:lang="en-US">Founder Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FounderSharesMember" xlink:to="lab_sclx_FounderSharesMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="loc_sclx_PromissoryNoteRelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteRelatedPartyMember" xml:lang="en-US">Promissory Note Related Party Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PromissoryNoteRelatedPartyMember" xml:lang="en-US">Promissory Note - Related Party [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteRelatedPartyMember" xlink:to="lab_sclx_PromissoryNoteRelatedPartyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SenmurMember" xml:lang="en-US">Senmur [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SenmurMember" xlink:to="lab_sclx_SenmurMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ItochuMember" xlink:label="loc_sclx_ItochuMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ItochuMember" xml:lang="en-US">Itochu [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ItochuMember" xlink:to="lab_sclx_ItochuMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ItochuMember" xml:lang="en-US">Itochu.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvesteeAxis" xml:lang="en-US">Investee [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvesteeAxis" xlink:to="lab_sclx_InvesteeAxis" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvesteeDomain" xml:lang="en-US">Investee [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvesteeDomain" xlink:to="lab_sclx_InvesteeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xml:lang="en-US">Two Thousand And Twenty Two Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:to="lab_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xml:lang="en-US">Two thousand and twenty two promissory note.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAxis" xlink:label="loc_sclx_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodAxis" xlink:to="lab_sclx_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodAxis" xml:lang="en-US">Period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodDomain" xlink:to="lab_sclx_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodDomain" xml:lang="en-US">Period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:label="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xml:lang="en-US">Due On Or After February Two Thousand And Thirty [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:to="lab_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xml:lang="en-US">Due on or after february two thousand and thirty.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDescription" xml:lang="en-US">Other Commitments, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCommitmentsDescription" xml:lang="en-US">Underwriting agreement, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDescription" xlink:to="lab_us-gaap_OtherCommitmentsDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsAuthorized" xlink:label="loc_us-gaap_PreferredUnitsAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredUnitsAuthorized" xml:lang="en-US">Preferred Units, Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredUnitsAuthorized" xml:lang="en-US">Stock authority to issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredUnitsAuthorized" xlink:to="lab_us-gaap_PreferredUnitsAuthorized" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MergerConsiderationDescription" xlink:label="loc_sclx_MergerConsiderationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MergerConsiderationDescription" xml:lang="en-US">Merger Consideration Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MergerConsiderationDescription" xml:lang="en-US">Merger consideration description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MergerConsiderationDescription" xlink:to="lab_sclx_MergerConsiderationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MergerConsiderationDescription" xml:lang="en-US">Merger consideration description.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockAggregateValue" xlink:label="loc_sclx_CommonStockAggregateValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockAggregateValue" xml:lang="en-US">Common Stock Aggregate Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockAggregateValue" xml:lang="en-US">Common stock aggregate value (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockAggregateValue" xlink:to="lab_sclx_CommonStockAggregateValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockAggregateValue" xml:lang="en-US">Common Stock with an aggregate value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaap_BusinessCombinationReasonForBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationReasonForBusinessCombination" xml:lang="en-US">Business Combination, Reason for Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationReasonForBusinessCombination" xml:lang="en-US">Business combination, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:to="lab_us-gaap_BusinessCombinationReasonForBusinessCombination" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePercentage" xlink:label="loc_sclx_AggregatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregatePercentage" xml:lang="en-US">Aggregate Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregatePercentage" xml:lang="en-US">Aggregate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregatePercentage" xlink:to="lab_sclx_AggregatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregatePercentage" xml:lang="en-US">Aggregate Percentage.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsPercentage" xlink:label="loc_sclx_WarrantsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsPercentage" xml:lang="en-US">Warrants Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsPercentage" xml:lang="en-US">Warrants percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsPercentage" xlink:to="lab_sclx_WarrantsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsPercentage" xml:lang="en-US">Warrants Percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockNoParValue" xml:lang="en-US">Preferred Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockNoParValue" xml:lang="en-US">Series A preferred stock, par value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNoParValue" xlink:to="lab_us-gaap_PreferredStockNoParValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BalanceInTheTrustAccount" xlink:label="loc_sclx_BalanceInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BalanceInTheTrustAccount" xml:lang="en-US">Balance In The Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BalanceInTheTrustAccount" xml:lang="en-US">Balance in the trust account (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BalanceInTheTrustAccount" xlink:to="lab_sclx_BalanceInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BalanceInTheTrustAccount" xml:lang="en-US">Balance in the trust account.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommission" xlink:label="loc_sclx_DeferredUnderwritingCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingCommission" xml:lang="en-US">Deferred Underwriting Commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingCommission" xml:lang="en-US">Deferred underwriting commission percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingCommission" xlink:to="lab_sclx_DeferredUnderwritingCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingCommission" xml:lang="en-US">Deferred Underwriting Commission.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommissionPayable" xlink:label="loc_sclx_DeferredUnderwritingCommissionPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingCommissionPayable" xml:lang="en-US">Deferred Underwriting Commission Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingCommissionPayable" xml:lang="en-US">Underwriting commission payable percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingCommissionPayable" xlink:to="lab_sclx_DeferredUnderwritingCommissionPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingCommissionPayable" xml:lang="en-US">Deferred Underwriting Commission Payable.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAggregateRoyalityPayments" xlink:label="loc_sclx_PercentageOfAggregateRoyalityPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfAggregateRoyalityPayments" xml:lang="en-US">Percentage of Aggregate Royality Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfAggregateRoyalityPayments" xml:lang="en-US">Percentage of aggregate royality payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfAggregateRoyalityPayments" xlink:to="lab_sclx_PercentageOfAggregateRoyalityPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfAggregateRoyalityPayments" xml:lang="en-US">Percentage of aggregate royality payments.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationDate" xlink:label="loc_sclx_AgreementExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementExpirationDate" xml:lang="en-US">Agreement Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementExpirationDate" xml:lang="en-US">Agreement expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementExpirationDate" xlink:to="lab_sclx_AgreementExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementExpirationDate" xml:lang="en-US">Agreement expiration date.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationTerm" xlink:label="loc_sclx_AgreementExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementExpirationTerm" xml:lang="en-US">Agreement Expiration Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementExpirationTerm" xml:lang="en-US">Agreement expiration term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementExpirationTerm" xlink:to="lab_sclx_AgreementExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementExpirationTerm" xml:lang="en-US">Agreement expiration term.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:label="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xml:lang="en-US">Agreement Automatic Renewal Period On Expiration Of Initial Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xml:lang="en-US">Agreement automatic renewal period on expiration of initial term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:to="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xml:lang="en-US">Agreement automatic renewal period on expiration of initial term.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:label="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xml:lang="en-US">Notice of Termination Period for Cancellation of Automatic Renewal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xml:lang="en-US">Notice of termination period for cancellation of automatic renewal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:to="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xml:lang="en-US">Notice of termination period for cancellation of automatic renewal.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:label="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xml:lang="en-US">Termination Of Agreement Notice Period For a Request To Cure Material Breach Of The Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xml:lang="en-US">Termination of aggrement notice period for a request to cure material breach of the agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:to="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xml:lang="en-US">Termination of agreement notice period for a request to cure material breach of the agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ThresholdMinimumPercentageOfSales" xlink:label="loc_sclx_ThresholdMinimumPercentageOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThresholdMinimumPercentageOfSales" xml:lang="en-US">Threshold Minimum Percentage Of Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThresholdMinimumPercentageOfSales" xml:lang="en-US">Threshold minimum percentage of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThresholdMinimumPercentageOfSales" xlink:to="lab_sclx_ThresholdMinimumPercentageOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThresholdMinimumPercentageOfSales" xml:lang="en-US">Threshold minimum percentage of sales.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAnnualAdjustmentToFees" xlink:label="loc_sclx_PercentageOfAnnualAdjustmentToFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfAnnualAdjustmentToFees" xml:lang="en-US">Percentage Of Annual Adjustment To Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfAnnualAdjustmentToFees" xml:lang="en-US">Percentage of annual adjustment to fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfAnnualAdjustmentToFees" xlink:to="lab_sclx_PercentageOfAnnualAdjustmentToFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfAnnualAdjustmentToFees" xml:lang="en-US">Percentage of annual adjustment to fees.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:label="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xml:lang="en-US">Percentage Of Distribution Fee Received Over The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xml:lang="en-US">Percentage of distribution fee received over the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:to="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xml:lang="en-US">Percentage of distribution fee received over the period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticePeriodForTerminationOfWorkOrder" xlink:label="loc_sclx_NoticePeriodForTerminationOfWorkOrder" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NoticePeriodForTerminationOfWorkOrder" xml:lang="en-US">Notice Period for Termination of Work Order</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NoticePeriodForTerminationOfWorkOrder" xml:lang="en-US">Notice period for termination of work order</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NoticePeriodForTerminationOfWorkOrder" xlink:to="lab_sclx_NoticePeriodForTerminationOfWorkOrder" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NoticePeriodForTerminationOfWorkOrder" xml:lang="en-US">Notice period for termination of work order.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkOrderImplementationFee" xlink:label="loc_sclx_WorkOrderImplementationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkOrderImplementationFee" xml:lang="en-US">Work Order Implementation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkOrderImplementationFee" xml:lang="en-US">Work order implementation fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkOrderImplementationFee" xlink:to="lab_sclx_WorkOrderImplementationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkOrderImplementationFee" xml:lang="en-US">Work order implementation fee.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesOperationsServicesMonthlyFee" xlink:label="loc_sclx_SalesOperationsServicesMonthlyFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SalesOperationsServicesMonthlyFee" xml:lang="en-US">Sales Operations Services Monthly Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SalesOperationsServicesMonthlyFee" xml:lang="en-US">Sales operations services monthly fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SalesOperationsServicesMonthlyFee" xlink:to="lab_sclx_SalesOperationsServicesMonthlyFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SalesOperationsServicesMonthlyFee" xml:lang="en-US">Sales operations services monthly fee.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SellingGeneralAndAdministrativeExpenses" xlink:label="loc_sclx_SellingGeneralAndAdministrativeExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SellingGeneralAndAdministrativeExpenses" xml:lang="en-US">Selling, General And Administrative Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SellingGeneralAndAdministrativeExpenses" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SellingGeneralAndAdministrativeExpenses" xlink:to="lab_sclx_SellingGeneralAndAdministrativeExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SellingGeneralAndAdministrativeExpenses" xml:lang="en-US">Selling, general and administrative expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Leases remaining lease terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating lease, expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xml:lang="en-US">Lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexCommonStockMember" xml:lang="en-US">Scilex Common Stock Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexCommonStockMember" xml:lang="en-US">Scilex Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexCommonStockMember" xlink:to="lab_sclx_ScilexCommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProductDevelopmentAgreementMember" xlink:to="lab_sclx_ProductDevelopmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product development agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="loc_sclx_ExclusiveDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExclusiveDistributionAgreementMember" xml:lang="en-US">Exclusive Distribution Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExclusiveDistributionAgreementMember" xlink:to="lab_sclx_ExclusiveDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExclusiveDistributionAgreementMember" xml:lang="en-US">Exclusive distribution agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProjectAgreementMember" xlink:label="loc_sclx_ProjectAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProjectAgreementMember" xml:lang="en-US">Project Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProjectAgreementMember" xml:lang="en-US">Project Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProjectAgreementMember" xlink:to="lab_sclx_ProjectAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProjectAgreementMember" xml:lang="en-US">Project agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaloAltoAadministrativeFacilityMember" xlink:label="loc_sclx_PaloAltoAadministrativeFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaloAltoAadministrativeFacilityMember" xml:lang="en-US">Palo Alto Aadministrative Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaloAltoAadministrativeFacilityMember" xlink:to="lab_sclx_PaloAltoAadministrativeFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaloAltoAadministrativeFacilityMember" xml:lang="en-US">Palo Alto Aadministrative Facility</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">2022 (Remaining three months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities as of December&#160;31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingCashFlowsFromOperatingLeases" xlink:label="loc_sclx_OperatingCashFlowsFromOperatingLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingCashFlowsFromOperatingLeases" xml:lang="en-US">Operating Cash Flows From Operating Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OperatingCashFlowsFromOperatingLeases" xml:lang="en-US">Operating cash flows from operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingCashFlowsFromOperatingLeases" xlink:to="lab_sclx_OperatingCashFlowsFromOperatingLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingCashFlowsFromOperatingLeases" xml:lang="en-US">Operating cash flows from operating leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate&#160;&#8212;&#160;operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">ROU assets obtained in exchange for new operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsTable" xlink:label="loc_sclx_WarrantsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsDetailsTable" xml:lang="en-US">Warrants (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsDetailsTable" xlink:to="lab_sclx_WarrantsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsLineItems" xlink:label="loc_sclx_WarrantsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsDetailsLineItems" xml:lang="en-US">Warrants (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsDetailsLineItems" xlink:to="lab_sclx_WarrantsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsOutstandingShares" xlink:label="loc_sclx_WarrantsOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsOutstandingShares" xml:lang="en-US">Warrants Outstanding Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsOutstandingShares" xml:lang="en-US">Warrants outstanding shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsOutstandingShares" xlink:to="lab_sclx_WarrantsOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsOutstandingShares" xml:lang="en-US">Warrants outstanding shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="loc_sclx_PublicWarrantsRedemptionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantsRedemptionDescription" xml:lang="en-US">Public Warrants Redemption Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicWarrantsRedemptionDescription" xml:lang="en-US">Public warrants redemption, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantsRedemptionDescription" xlink:to="lab_sclx_PublicWarrantsRedemptionDescription" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalRaisingDescription" xlink:label="loc_sclx_CapitalRaisingDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CapitalRaisingDescription" xml:lang="en-US">Capital Raising Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CapitalRaisingDescription" xml:lang="en-US">Capital raising, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CapitalRaisingDescription" xlink:to="lab_sclx_CapitalRaisingDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Public Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Assets Held-in-trust, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Assets held in the trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustCurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:label="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xml:lang="en-US">Fair Value Measurements, Highest and Best Use, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xml:lang="en-US">Initial measurement, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:to="lab_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative liability, Measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Change in fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:label="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xml:lang="en-US">Measurement Input, RiskAdjusted Net Sales Forecast [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:to="lab_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xml:lang="en-US">Measurement input, risk-adjusted net sales forecast .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEffectiveDebtYieldMember" xlink:label="loc_sclx_MeasurementInputEffectiveDebtYieldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputEffectiveDebtYieldMember" xml:lang="en-US">Measurement Input, Effective Debt Yield [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputEffectiveDebtYieldMember" xlink:to="lab_sclx_MeasurementInputEffectiveDebtYieldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputEffectiveDebtYieldMember" xml:lang="en-US">Measurement input, effective debt yield .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xml:lang="en-US">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before March 31, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:to="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xml:lang="en-US">Measurement input, estimated probability of not obtaining marketing approval before march 31, 2021 .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xml:lang="en-US">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before July 1, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:to="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xml:lang="en-US">Measurement input, estimated probability of not obtaining marketing approval before july 1, 2023 .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xlink:label="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xml:lang="en-US">Schedule Of Fair Value Hierarchy Of The Valuation Inputs Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xlink:to="lab_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasury" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeSecuritiesUSTreasury" xml:lang="en-US">Interest Income, Securities, US Treasury</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeSecuritiesUSTreasury" xml:lang="en-US">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:to="lab_us-gaap_InterestIncomeSecuritiesUSTreasury" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Warrant Liability &#8211; Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xml:lang="en-US">Schedule Of Changes In The Fair Value Of Warrant Liabilities And Conversion Option Liability Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xlink:to="lab_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InitialMeasurementOne" xlink:label="loc_sclx_InitialMeasurementOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InitialMeasurementOne" xml:lang="en-US">Initial Measurement One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_InitialMeasurementOne" xml:lang="en-US">Initial measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InitialMeasurementOne" xlink:to="lab_sclx_InitialMeasurementOne" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change In Valuation Inputs Or Other Assumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in valuation inputs or other assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:to="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in valuation inputs or other assumptions.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConversionOptionLiabilityMember" xlink:label="loc_sclx_ConversionOptionLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOptionLiabilityMember" xml:lang="en-US">Conversion Option Liability Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOptionLiabilityMember" xml:lang="en-US">Conversion Option Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOptionLiabilityMember" xlink:to="lab_sclx_ConversionOptionLiabilityMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xlink:label="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xml:lang="en-US">Schedule Of Valued Using The Compound Option Pricing Model Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xlink:to="lab_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnderlyingWarrantValue" xlink:label="loc_sclx_UnderlyingWarrantValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_UnderlyingWarrantValue" xml:lang="en-US">Underlying Warrant Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_UnderlyingWarrantValue" xml:lang="en-US">Underlying warrant value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_UnderlyingWarrantValue" xlink:to="lab_sclx_UnderlyingWarrantValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_UnderlyingWarrantValue" xml:lang="en-US">Underlying warrant value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_HoldingPeriod" xlink:label="loc_sclx_HoldingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_HoldingPeriod" xml:lang="en-US">Holding Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_HoldingPeriod" xml:lang="en-US">Holding period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_HoldingPeriod" xlink:to="lab_sclx_HoldingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_HoldingPeriod" xml:lang="en-US">Holding period return is the total return received from holding an asset or portfolio of assets over a period of time, generally expressed as a percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock-price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total assets measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Re-measurement&#160;of fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xlink:label="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xml:lang="en-US">Schedule Of Quantitative Information Regarding Level3 Fair Value Measurements Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xlink:to="lab_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="loc_sclx_FairValueMeasurementStrikePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementStrikePrice" xml:lang="en-US">Fair Value Measurement Strike Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueMeasurementStrikePrice" xml:lang="en-US">Strike price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementStrikePrice" xlink:to="lab_sclx_FairValueMeasurementStrikePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueMeasurementStrikePrice" xml:lang="en-US">Strike price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:to="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:to="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="loc_sclx_FairValueOfWarrantsinDollars" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfWarrantsinDollars" xml:lang="en-US">Fair Value Of Warrantsin Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfWarrantsinDollars" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfWarrantsinDollars" xlink:to="lab_sclx_FairValueOfWarrantsinDollars" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xml:lang="en-US">Schedule Of Change In The Fair Value Of Conversion Option Liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xlink:to="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xml:lang="en-US">Schedule of change in the fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xml:lang="en-US">Schedule Of Change In The Fair Value Of Conversion Option Liability [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:to="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xml:lang="en-US">Schedule of change in the fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xml:lang="en-US">Schedule Of Change In The Fair Value Of Conversion Option Liability [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:to="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xml:lang="en-US">Schedule of change in the fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair value, beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair value, ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xml:lang="en-US">Initial measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Servicing Liability at Fair Value, Other Changes in Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xml:lang="en-US">Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangibles, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Acquired technology</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled Workforce [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AssembledWorkforceMember" xlink:to="lab_sclx_AssembledWorkforceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Licensing Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Acquired licenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">2022 (Remaining three months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xml:lang="en-US">Finite lived intangible assets amortization expense after year four.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite lived intangible asset, useful life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite lived intangible asset, Useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite lived intangible assets, remaining amortization period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible assets excluding goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite lived intangible assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired finite lived intangible assets, weighted average useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-Term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-Term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:label="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xml:lang="en-US">Percentage Of Quarterly Payments Of The Principal Notes Equal To A Fixed Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xml:lang="en-US">Percentage of quarterly payments of the principal Notes equal to a fixed percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:to="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xml:lang="en-US">Percentage of quarterly payments of the principal notes equal to a fixed percentage.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfNetSalesPayable" xlink:label="loc_sclx_PercentageOfNetSalesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfNetSalesPayable" xml:lang="en-US">Percentage Of Net Sales Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfNetSalesPayable" xml:lang="en-US">Percentage of net sales payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfNetSalesPayable" xlink:to="lab_sclx_PercentageOfNetSalesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfNetSalesPayable" xml:lang="en-US">Percentage of net sales payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xml:lang="en-US">Revenue Not from Contract with Customer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xml:lang="en-US">Revenue not from contract with customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from issuance of long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:label="loc_sclx_PaymentToDepositIntoASeggregateReserveFund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" xml:lang="en-US">Payment To Deposit Into A Seggregate Reserve Fund</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" xml:lang="en-US">Payment to deposit into a seggregate reserve fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:to="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" xml:lang="en-US">Payment to deposit into a seggregate reserve fund.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:label="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xml:lang="en-US">Payment To Deposit Into A Segregated Collateral Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xml:lang="en-US">Payment to deposit into a segregated collateral account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:to="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xml:lang="en-US">Payment to deposit into a segregated collateral account.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfConcentrationOnASimilarProduct" xlink:label="loc_sclx_PercentageOfConcentrationOnASimilarProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfConcentrationOnASimilarProduct" xml:lang="en-US">Percentage of concentration on a similar product</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfConcentrationOnASimilarProduct" xml:lang="en-US">Percentage of concentration on a similar product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfConcentrationOnASimilarProduct" xlink:to="lab_sclx_PercentageOfConcentrationOnASimilarProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfConcentrationOnASimilarProduct" xml:lang="en-US">Percentage of concentration on a similar product.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt instrument, periodic payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt instrument, maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentredemptionPeriod" xlink:label="loc_sclx_DebtInstrumentredemptionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentredemptionPeriod" xml:lang="en-US">Debt Instrument,Redemption period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentredemptionPeriod" xml:lang="en-US">Debt instrument,redemption period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentredemptionPeriod" xlink:to="lab_sclx_DebtInstrumentredemptionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentredemptionPeriod" xml:lang="en-US">Debt instrument,redemption period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US">Debt instrument, redemption price, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from lines of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of lines of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:label="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xml:lang="en-US">Percentage Of The Principal Amount From Holders On Pro Rata Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xml:lang="en-US">Percentage of the principal amount from Holders on pro rata basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:to="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xml:lang="en-US">Percentage of the principal amount from Holders on pro rata basis.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum Cash Requirements To Repurchase Of Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum cash requirements to repurchase of Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:to="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum cash requirements to repurchase of notes.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:label="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" xml:lang="en-US">Percentage Of The Principal Amount Of The Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" xml:lang="en-US">Percentage of the principal amount of the Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:to="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" xml:lang="en-US">Percentage of the principal amount of the notes.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum Unrestricted Cash Requirements To Repurchase Of Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum unrestricted cash requirements to repurchase of Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:to="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum unrestricted cash requirements to repurchase of notes.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LineOfCreditFacilityindebtednessAmount" xlink:label="loc_sclx_LineOfCreditFacilityindebtednessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LineOfCreditFacilityindebtednessAmount" xml:lang="en-US">Line of Credit Facility ,indebtedness Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LineOfCreditFacilityindebtednessAmount" xml:lang="en-US">Line of credit facility, indebtedness amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LineOfCreditFacilityindebtednessAmount" xlink:to="lab_sclx_LineOfCreditFacilityindebtednessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LineOfCreditFacilityindebtednessAmount" xml:lang="en-US">Line of credit facility ,indebtedness amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:label="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xml:lang="en-US">Amount Distribution To Acquire Related Contingent Accelerated Repayment Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xml:lang="en-US">Amount distribution to acquire related contingent accelerated repayment notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:to="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xml:lang="en-US">Amount distribution to acquire related contingent accelerated repayment notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xml:lang="en-US">Debt instrument, unamortized discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt related commitment Fees and debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentTerminationDate" xlink:label="loc_sclx_DebtInstrumentTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentTerminationDate" xml:lang="en-US">Debt Instrument, termination Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentTerminationDate" xml:lang="en-US">Debt instrument, termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentTerminationDate" xlink:to="lab_sclx_DebtInstrumentTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentTerminationDate" xml:lang="en-US">Debt instrument, termination date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from issuance of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:label="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xml:lang="en-US">Maximum Compensation Cost To Be Available, Prorated Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xml:lang="en-US">Maximum compensation cost to be available, prorated basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:to="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xml:lang="en-US">Maximum compensation cost to be available, prorated basis.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:label="loc_sclx_PercentageOfLoanForgivenessUnderTheAct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" xml:lang="en-US">Percentage Of Loan Forgiveness Under The Act</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" xml:lang="en-US">Percentage of loan forgiveness under the act</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:to="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" xml:lang="en-US">Percentage of loan forgiveness under the act.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumPayrollCostToBeAvailable" xlink:label="loc_sclx_MinimumPayrollCostToBeAvailable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumPayrollCostToBeAvailable" xml:lang="en-US">Minimum payroll cost to be available</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumPayrollCostToBeAvailable" xml:lang="en-US">Minimum payroll cost to be available</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumPayrollCostToBeAvailable" xlink:to="lab_sclx_MinimumPayrollCostToBeAvailable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumPayrollCostToBeAvailable" xml:lang="en-US">Minimum payroll cost to be available.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:label="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xml:lang="en-US">Debt Instrument, Percentage of Principal Amount Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xml:lang="en-US">Debt instrument, percentage of principal amount repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:to="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xml:lang="en-US">Debt instrument, percentage of principal amount repurchased.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseDate" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseDate" xml:lang="en-US">Debt Instrument, Repurchase Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseDate" xml:lang="en-US">Debt instrument, repurchase date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseDate" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt Instrument, Collateral Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt instrument, collateral amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCollateralAmount" xlink:to="lab_us-gaap_DebtInstrumentCollateralAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xml:lang="en-US">Debt instrument, increase (decrease), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt instrument interest rate effective percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNoteMember" xml:lang="en-US">Scilex Pharma Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNoteMember" xlink:to="lab_sclx_ScilexPharmaNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNoteMember" xml:lang="en-US">Scilex pharma note.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xml:lang="en-US">Two Thousand and Eighteen Purchase Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xml:lang="en-US">2018 Purchase Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:to="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xml:lang="en-US">Scenario, Adjustment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioAdjustmentMember" xlink:to="lab_us-gaap_ScenarioAdjustmentMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IfLetterOfCreditIsDrawnMember" xlink:label="loc_sclx_IfLetterOfCreditIsDrawnMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IfLetterOfCreditIsDrawnMember" xml:lang="en-US">If Letter Of Credit Is Drawn [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IfLetterOfCreditIsDrawnMember" xlink:to="lab_sclx_IfLetterOfCreditIsDrawnMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MarketingApprovalLetterMember" xlink:label="loc_sclx_MarketingApprovalLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MarketingApprovalLetterMember" xml:lang="en-US">Marketing Approval Letter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MarketingApprovalLetterMember" xlink:to="lab_sclx_MarketingApprovalLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MarketingApprovalLetterMember" xml:lang="en-US">Marketing approval letter.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:label="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccountsReceivableRevolvingLoanFacilityMember" xml:lang="en-US">Accounts receivable revolving loan facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:to="lab_sclx_AccountsReceivableRevolvingLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccountsReceivableRevolvingLoanFacilityMember" xml:lang="en-US">Accounts receivable revolving loan facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementAxis" xlink:label="loc_sclx_StatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StatementAxis" xml:lang="en-US">Statement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StatementAxis" xlink:to="lab_sclx_StatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StatementAxis" xml:lang="en-US">Statement .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StatementDomain" xml:lang="en-US">Statement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StatementDomain" xlink:to="lab_sclx_StatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StatementDomain" xml:lang="en-US">Statement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DecemberOptionalRepurchaseMember" xlink:label="loc_sclx_DecemberOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DecemberOptionalRepurchaseMember" xml:lang="en-US">December Optional Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DecemberOptionalRepurchaseMember" xlink:to="lab_sclx_DecemberOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DecemberOptionalRepurchaseMember" xml:lang="en-US">December optional repurchase.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FebruaryOptionalRepurchaseMember" xlink:label="loc_sclx_FebruaryOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FebruaryOptionalRepurchaseMember" xml:lang="en-US">February Optional Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FebruaryOptionalRepurchaseMember" xlink:to="lab_sclx_FebruaryOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FebruaryOptionalRepurchaseMember" xml:lang="en-US">February optional repurchase.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AprilOptionalRepurchaseMember" xlink:label="loc_sclx_AprilOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AprilOptionalRepurchaseMember" xml:lang="en-US">April Optional Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AprilOptionalRepurchaseMember" xlink:to="lab_sclx_AprilOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AprilOptionalRepurchaseMember" xml:lang="en-US">April optional repurchase.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaycheckProtectionProgramMember" xlink:label="loc_sclx_PaycheckProtectionProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaycheckProtectionProgramMember" xml:lang="en-US">Paycheck Protection Program [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaycheckProtectionProgramMember" xlink:to="lab_sclx_PaycheckProtectionProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaycheckProtectionProgramMember" xml:lang="en-US">Paycheck protection program.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubordinatedDebtMember" xml:lang="en-US">Subordinated Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedDebtMember" xlink:to="lab_us-gaap_SubordinatedDebtMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeAxis" xlink:label="loc_sclx_EventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventTypeAxis" xml:lang="en-US">Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventTypeAxis" xlink:to="lab_sclx_EventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventTypeAxis" xml:lang="en-US">Event type.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventTypeDomain" xml:lang="en-US">Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventTypeDomain" xlink:to="lab_sclx_EventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventTypeDomain" xml:lang="en-US">Event type.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="lab_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus aid, relief, and economic security act.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostAxis" xlink:label="loc_sclx_ClassificationOfCostAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClassificationOfCostAxis" xml:lang="en-US">Classification of cost [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClassificationOfCostAxis" xlink:to="lab_sclx_ClassificationOfCostAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClassificationOfCostAxis" xml:lang="en-US">Classification of cost.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClassificationOfCostDomain" xml:lang="en-US">Classification of cost [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClassificationOfCostDomain" xlink:to="lab_sclx_ClassificationOfCostDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClassificationOfCostDomain" xml:lang="en-US">Classification of cost.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonPayrollCostsMember" xlink:label="loc_sclx_NonPayrollCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonPayrollCostsMember" xml:lang="en-US">Non Payroll Costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonPayrollCostsMember" xlink:to="lab_sclx_NonPayrollCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonPayrollCostsMember" xml:lang="en-US">Non-payroll costs.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PayrollCostsBasisMember" xlink:label="loc_sclx_PayrollCostsBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PayrollCostsBasisMember" xml:lang="en-US">Payroll Costs Basis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PayrollCostsBasisMember" xlink:to="lab_sclx_PayrollCostsBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PayrollCostsBasisMember" xml:lang="en-US">Payroll costs basis.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentAxis" xlink:label="loc_sclx_AmendmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentAxis" xml:lang="en-US">Amendment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentAxis" xlink:to="lab_sclx_AmendmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentAxis" xml:lang="en-US">Amendment.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentDomain" xml:lang="en-US">Amendment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentDomain" xlink:to="lab_sclx_AmendmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentDomain" xml:lang="en-US">Amendment.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentNoFourMember" xlink:label="loc_sclx_AmendmentNoFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentNoFourMember" xml:lang="en-US">Amendment No Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentNoFourMember" xlink:to="lab_sclx_AmendmentNoFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentNoFourMember" xml:lang="en-US">Amendment no four.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteMember" xlink:label="loc_sclx_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteMember" xml:lang="en-US">Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteMember" xlink:to="lab_sclx_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PromissoryNoteMember" xml:lang="en-US">Promissory note.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xml:lang="en-US">Two Thousand and Eighteen Purchase Agreements and Indenture [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xml:lang="en-US">2018 Purchase Agreements and Indenture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:to="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xml:lang="en-US">Two thousand and eighteen purchase agreements and indenture.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndebentureMember" xlink:label="loc_sclx_IndebentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IndebentureMember" xml:lang="en-US">Indebenture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IndebentureMember" xlink:to="lab_sclx_IndebentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IndebentureMember" xml:lang="en-US">Indebenture.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-Term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Unamortized debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long-Term Debt, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnamortizedDebtDiscount" xlink:label="loc_sclx_UnamortizedDebtDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_UnamortizedDebtDiscount" xml:lang="en-US">Unamortized Debt Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_UnamortizedDebtDiscount" xml:lang="en-US">Unamortized debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_UnamortizedDebtDiscount" xlink:to="lab_sclx_UnamortizedDebtDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_UnamortizedDebtDiscount" xml:lang="en-US">Unamortized debt discount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xml:lang="en-US">Schedule Of Future minimum payments Of Long Term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:to="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xml:lang="en-US">Schedule of future minimum payments of long term debt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xml:lang="en-US">Schedule Of Future minimum payments Of Long Term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:to="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xml:lang="en-US">Schedule of future minimum payments of long term debt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" xml:lang="en-US">LongTerm Debt,Future minimum payment , year one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:to="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" xml:lang="en-US">Long-Term Debt,&#160;Future minimum payment , year one.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xml:lang="en-US">Long-term debt, future minimum payment , year two.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" xml:lang="en-US">Long-term debt, future minimum payment , year three.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" xml:lang="en-US">Long-term debt, future minimum payment , year four.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" xml:lang="en-US">Long-term debt, future minimum payment , year five.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_sclx_LongtermDebtFutureMinimumPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPayment" xml:lang="en-US">LongTerm Debt, Future Minimum Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPayment" xml:lang="en-US">Total minimum future payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPayment" xlink:to="lab_sclx_LongtermDebtFutureMinimumPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPayment" xml:lang="en-US">Long-term debt, future minimum payment.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansTable" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansTable" xml:lang="en-US">Compensation And Employee Benefit Plans [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable" xlink:to="lab_sclx_CompensationAndEmployeeBenefitPlansTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansTable" xml:lang="en-US">Compensation and employee benefit plans.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansLineItems" xml:lang="en-US">Compensation And Employee Benefit Plans [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:to="lab_sclx_CompensationAndEmployeeBenefitPlansLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansLineItems" xml:lang="en-US">Compensation and employee benefit plans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares reserved for issuance under plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share based compensation arrangement,vesting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share based compensation arrangement,Options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Beginning, Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Ending, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Total unrecognized compensation costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted average period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Per Share Of Common Stock On Date Of Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Fair value per share of common stock on date of grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Fair value per share of common stock on date of grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:to="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined contribution plan matching contribution amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaap_PaymentsToEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToEmployees" xml:lang="en-US">Payments to Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToEmployees" xml:lang="en-US">Payment to employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToEmployees" xlink:to="lab_us-gaap_PaymentsToEmployees" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xml:lang="en-US">ShareBased Compensation Arrangement by ShareBased Payment Award, Option, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xml:lang="en-US">Share based compensation arrangement,Options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:to="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xml:lang="en-US">Number of options outstanding, including both vested and non-vested options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:label="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xml:lang="en-US">Scilex Pharma two thousand seventeen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xml:lang="en-US">Scilex Pharma 2017 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:to="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xml:lang="en-US">Scilex pharma two thousand seventeen plan.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_TwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Two thousand nineteen Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">2019 Stock Option Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandNineteenStockOptionPlanMember" xlink:to="lab_sclx_TwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Two thousand nineteen stock option Plan .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Amendment to two thousand nineteen Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Amendment to 2019 Stock Option Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:to="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Amendment to two thousand nineteen stock option plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingExpensesMember" xlink:label="loc_sclx_OperatingExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingExpensesMember" xml:lang="en-US">Operating Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingExpensesMember" xlink:to="lab_sclx_OperatingExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingExpensesMember" xml:lang="en-US">Operating expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xml:lang="en-US">Retirement Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xml:lang="en-US">Retirement Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FourHundredAndOneKPlanMember" xlink:label="loc_sclx_FourHundredAndOneKPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FourHundredAndOneKPlanMember" xml:lang="en-US">Four hundred and one (k) Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FourHundredAndOneKPlanMember" xml:lang="en-US">401(k) Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FourHundredAndOneKPlanMember" xlink:to="lab_sclx_FourHundredAndOneKPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FourHundredAndOneKPlanMember" xml:lang="en-US">Four hundred and one (k) Plan .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected stock-price volatility, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected stock-price volatility, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Forfeited/Cancelled, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, Beginning, Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, Ending, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited/Cancelled, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding, Beginning, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding, Ending, Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTable" xml:lang="en-US">Asset Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xml:lang="en-US">Asset Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset acquisition total consideration transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset acquisition, consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xml:lang="en-US">Asset acquistion contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:label="loc_sclx_RevenueToBeEarnedByTheAcquireeValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" xml:lang="en-US">Revenue To Be Earned By The Acquiree Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" xml:lang="en-US">Revenue to be earned by the acquiree value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:to="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" xml:lang="en-US">Revenue to be earned by the acquiree value.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:label="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xml:lang="en-US">Percentage Of Shares Issued Subject To Restriction Of Transfer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xml:lang="en-US">Percentage of shares issued subject to restriction of transfer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:to="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xml:lang="en-US">Percentage of shares issued subject to restriction of transfer.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:label="loc_sclx_PeriodDuringWhichShareTransferIsRestricted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" xml:lang="en-US">Period During Which Share Transfer Is Restricted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" xml:lang="en-US">Period during which share transfer is restricted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:to="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" xml:lang="en-US">Period during which share transfer is restricted.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:label="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xml:lang="en-US">Period During Which The Shares May Be Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xml:lang="en-US">Period during which the shares may be exchanged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:to="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xml:lang="en-US">Period during which the shares may be exchanged.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockValueToBeExchanged" xlink:label="loc_sclx_CommonStockValueToBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockValueToBeExchanged" xml:lang="en-US">Common Stock Value To Be Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockValueToBeExchanged" xml:lang="en-US">Common stock value to be exchanged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockValueToBeExchanged" xlink:to="lab_sclx_CommonStockValueToBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockValueToBeExchanged" xml:lang="en-US">Common stock value to be exchanged.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:label="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xml:lang="en-US">Number Of Days For Determining The Weighted Volume Average Price For Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xml:lang="en-US">Number of days for determining the weighted volume averge price of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:to="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xml:lang="en-US">Number of days for determining the weighted volume average price for shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:label="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" xml:lang="en-US">Price Per Share For Determining The Exchange Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" xml:lang="en-US">Price per share for determining the exchange of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:to="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" xml:lang="en-US">Price per share for determining the exchange of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentMadeInSurrenderingTheShares" xlink:label="loc_sclx_PaymentMadeInSurrenderingTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentMadeInSurrenderingTheShares" xml:lang="en-US">Payment Made In Surrendering The Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentMadeInSurrenderingTheShares" xml:lang="en-US">Payment made in surrendering the shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentMadeInSurrenderingTheShares" xlink:to="lab_sclx_PaymentMadeInSurrenderingTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentMadeInSurrenderingTheShares" xml:lang="en-US">Payment made in surrendering the shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UpfrontlicenseFee" xlink:label="loc_sclx_UpfrontlicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_UpfrontlicenseFee" xml:lang="en-US">Upfront License Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_UpfrontlicenseFee" xlink:to="lab_sclx_UpfrontlicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_UpfrontlicenseFee" xml:lang="en-US">up-front&#160;license fee</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestonePayment" xlink:label="loc_sclx_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MilestonePayment" xml:lang="en-US">Milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MilestonePayment" xlink:to="lab_sclx_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MilestonePayment" xml:lang="en-US">milestone payment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Residual Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Residual Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredConsideration" xlink:label="loc_sclx_DeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredConsideration" xml:lang="en-US">Deferred Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredConsideration" xml:lang="en-US">Deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredConsideration" xlink:to="lab_sclx_DeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredConsideration" xml:lang="en-US">deferred consideration</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AardvarkMember" xml:lang="en-US">Aardvark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AardvarkMember" xlink:to="lab_sclx_AardvarkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AardvarkMember" xml:lang="en-US">Aardvark.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RomegLicenseAgreementMember" xlink:to="lab_sclx_RomegLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneAxis" xlink:label="loc_sclx_MilestoneAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MilestoneAxis" xml:lang="en-US">Milestone [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MilestoneAxis" xlink:to="lab_sclx_MilestoneAxis" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MilestoneDomain" xml:lang="en-US">Milestone [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MilestoneDomain" xlink:to="lab_sclx_MilestoneDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RegulatoryBasedMilestoneMember" xlink:label="loc_sclx_RegulatoryBasedMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RegulatoryBasedMilestoneMember" xml:lang="en-US">Regulatory Based Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RegulatoryBasedMilestoneMember" xlink:to="lab_sclx_RegulatoryBasedMilestoneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReveueBasedMilestoneMember" xlink:label="loc_sclx_ReveueBasedMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReveueBasedMilestoneMember" xml:lang="en-US">Reveue Based Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReveueBasedMilestoneMember" xlink:to="lab_sclx_ReveueBasedMilestoneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ApprovalBasedMilestoneMember" xlink:label="loc_sclx_ApprovalBasedMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ApprovalBasedMilestoneMember" xml:lang="en-US">Approval Based Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ApprovalBasedMilestoneMember" xlink:to="lab_sclx_ApprovalBasedMilestoneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheAxis" xlink:label="loc_sclx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheAxis" xlink:to="lab_sclx_TrancheAxis" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheDomain" xlink:to="lab_sclx_TrancheDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheOneMember" xlink:label="loc_sclx_TrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheOneMember" xml:lang="en-US">Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheOneMember" xml:lang="en-US">Tranche 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheOneMember" xlink:to="lab_sclx_TrancheOneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheTwoMember" xlink:label="loc_sclx_TrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheTwoMember" xml:lang="en-US">Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheTwoMember" xml:lang="en-US">Tranche 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheTwoMember" xlink:to="lab_sclx_TrancheTwoMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheThreeMember" xlink:label="loc_sclx_TrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheThreeMember" xml:lang="en-US">Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheThreeMember" xml:lang="en-US">Tranche 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheThreeMember" xlink:to="lab_sclx_TrancheThreeMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheFourMember" xlink:label="loc_sclx_TrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheFourMember" xml:lang="en-US">Tranche Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheFourMember" xml:lang="en-US">Tranche 4 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheFourMember" xlink:to="lab_sclx_TrancheFourMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AsRestatedMember" xml:lang="en-US">As Restated [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AsRestatedMember" xml:lang="en-US">As Restated [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AsRestatedMember" xlink:to="lab_sclx_AsRestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AsRestatedMember" xml:lang="en-US">As restated.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyTwoPromissoryNoteMember" xml:lang="en-US">Two Thousand Twenty Two Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyTwoPromissoryNoteMember" xml:lang="en-US">2022 Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:to="lab_sclx_TwoThousandTwentyTwoPromissoryNoteMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Ordinary per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xml:lang="en-US">Intangible Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xml:lang="en-US">Net tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Adjustments Restatement 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="loc_sclx_AdjustmentsRestatement2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsRestatement2Member" xml:lang="en-US">Adjustments Restatement 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsRestatement2Member" xml:lang="en-US">Adjustments Restatement 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsRestatement2Member" xlink:to="lab_sclx_AdjustmentsRestatement2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsRestatement2Member" xml:lang="en-US">Adjustments restatement 2.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="loc_sclx_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxDisclosureTable" xlink:to="lab_sclx_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxDisclosureTable" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems" xlink:to="lab_sclx_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income Tax Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory federal tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory Federal Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforward expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_sclx_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TaxCreditCarryforwardExpirationYear" xlink:label="loc_sclx_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax Credit Carryforward, Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforward expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TaxCreditCarryforwardExpirationYear" xlink:to="lab_sclx_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforward, expiration year.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:label="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xml:lang="en-US">Minimum Threshold Percentage for Recognition of Uncertain Income Tax Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xml:lang="en-US">Minimum threshold percentage for recognition of uncertain income tax position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:to="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xml:lang="en-US">Minimum threshold percentage for recognition of uncertain income tax position.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income tax examination, penalties and interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="loc_sclx_IndefiniteCarryforwardPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IndefiniteCarryforwardPeriodMember" xml:lang="en-US">Indefinite Carryforward Period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IndefiniteCarryforwardPeriodMember" xlink:to="lab_sclx_IndefiniteCarryforwardPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IndefiniteCarryforwardPeriodMember" xml:lang="en-US">indefinite carryforward period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current expense:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" xml:lang="en-US">Deferred Tax Assets Interest expense limitations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" xml:lang="en-US">Interest expense limitations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:to="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" xml:lang="en-US">Deferred tax assets interest expense limitations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred tax assets operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Amortization of intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Operating lease&#160;right-of-use&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total Deferred Tax Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State taxes, net of federal tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xml:lang="en-US">Effective Income Tax Rate Reconciliation Debt Discount and Interest Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xml:lang="en-US">Debt discount and interest limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xml:lang="en-US">Effective income tax rate reconciliation debt discount and interest limitation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">In-process&#160;research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xml:lang="en-US">Effective Income Tax Rate Reconciliation Return to Provision Adjustments and Carryback</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xml:lang="en-US">Return to provision adjustments and carryback</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xml:lang="en-US">Effective income tax rate reconciliation return to provision adjustments and carryback.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Denominator for Basic Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Effect of Dilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities" xlink:to="lab_us-gaap_DilutiveSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsTable" xlink:label="loc_sclx_SubsequentEventsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentEventsDetailsTable" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentEventsDetailsTable" xlink:to="lab_sclx_SubsequentEventsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsLineItems" xlink:label="loc_sclx_SubsequentEventsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentEventsDetailsLineItems" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems" xlink:to="lab_sclx_SubsequentEventsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability" xlink:label="loc_us-gaap_LeaseDepositLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseDepositLiability" xml:lang="en-US">Lease Deposit Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseDepositLiability" xml:lang="en-US">Sponsors deposited (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseDepositLiability" xlink:to="lab_us-gaap_LeaseDepositLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common stock par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesLimits" xlink:label="loc_sclx_NumberOfSharesLimits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSharesLimits" xml:lang="en-US">Number Of Shares Limits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSharesLimits" xml:lang="en-US">Number of shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSharesLimits" xlink:to="lab_sclx_NumberOfSharesLimits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSharesLimits" xml:lang="en-US">Number of shares limits.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorLoan" xlink:label="loc_sclx_SponsorLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SponsorLoan" xml:lang="en-US">Sponsor Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SponsorLoan" xml:lang="en-US">Sponsor loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SponsorLoan" xlink:to="lab_sclx_SponsorLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SponsorLoan" xml:lang="en-US">Sponsor loan.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantExercisePrice" xlink:label="loc_sclx_WarrantExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantExercisePrice" xml:lang="en-US">Warrant Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantExercisePrice" xlink:to="lab_sclx_WarrantExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantExercisePrice" xml:lang="en-US">Warrant exercise price.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdditionalPrincipalAmount" xlink:label="loc_sclx_AdditionalPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdditionalPrincipalAmount" xml:lang="en-US">Additional Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdditionalPrincipalAmount" xml:lang="en-US">Additional principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdditionalPrincipalAmount" xlink:to="lab_sclx_AdditionalPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdditionalPrincipalAmount" xml:lang="en-US">Additional principal amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromissoryNote" xlink:label="loc_sclx_ConvertiblePromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertiblePromissoryNote" xml:lang="en-US">Convertible Promissory Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertiblePromissoryNote" xlink:to="lab_sclx_ConvertiblePromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertiblePromissoryNote" xml:lang="en-US">Convertible promissory note.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:label="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xml:lang="en-US">Percentage Of Purchase Price In Cash Equal Is To Principal Amount Of The Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xml:lang="en-US">Percentage of purchase price in cash equal is to principal amount of the loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:to="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xml:lang="en-US">Percentage of purchase price in cash equal is to principal amount of the loan.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:label="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xml:lang="en-US">Minimum Time Declared To File With SEC Regarding Resale Registration Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xml:lang="en-US">Minimum time declared to file with sec regarding resale registration statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:to="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xml:lang="en-US">Minimum time declared to file with sec regarding resale registration statement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesThresholdLimit" xlink:label="loc_sclx_SalesThresholdLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SalesThresholdLimit" xml:lang="en-US">Sales Threshold Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SalesThresholdLimit" xml:lang="en-US">Sales threshold limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SalesThresholdLimit" xlink:to="lab_sclx_SalesThresholdLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SalesThresholdLimit" xml:lang="en-US">Sales threshold limit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities assumed in a non cash transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common Stock, Value, Subscriptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common stock shares subscribed but not issued value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:label="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xml:lang="en-US">Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:to="lab_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xml:lang="en-US">Period after registration when the request could be made to the investee to purchase the shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:label="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xml:lang="en-US">Maximum Percentage Of Volume Weighted Average Price Of Shares Measured On A Daily Basis That Is Eligible To Be Received As Advance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:to="lab_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xml:lang="en-US">Maximum percentage of volume weighted average price of shares measured on a daily basis that is eligible to be received as advance.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number Of Threshold Trading Days Prior To Date Of Notice To The Shareholders For Determining The Volume Weighted Average Price Of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:to="lab_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number of threshold trading days prior to date of notice to the shareholders for determining the volume weighted average price of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:label="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xml:lang="en-US">Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:to="lab_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xml:lang="en-US">Percentage of daily volume weighted average price of shares at which the shares are eligible to be purchased.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number Of Consecutive Trading Days For Determining The Volume Weighted Average Price Of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:to="lab_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number of consecutive trading days for determining the volume weighted average price of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:label="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xml:lang="en-US">Agreement With Certain Of The Third Party Professional Service Providers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:to="lab_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xml:lang="en-US">Agreement with certain of the third party professional service providers.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_sclx_StandbyEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StandbyEquityPurchaseAgreementMember" xlink:to="lab_sclx_StandbyEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby equity purchase agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableMember" xml:lang="en-US">Accounts Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_YorkvilleMember" xlink:label="loc_sclx_YorkvilleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_YorkvilleMember" xml:lang="en-US">Yorkville [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_YorkvilleMember" xlink:to="lab_sclx_YorkvilleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_YorkvilleMember" xml:lang="en-US">Yorkville.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sclx-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-November-2022 [01:37:04] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CoverPage" roleURI="http://www.vickersvantagecorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcern" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOffering" roleURI="http://www.vickersvantagecorp.com/role/PublicOffering" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacement" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Acquisitions" roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactions" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipment" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Debt" roleURI="http://www.vickersvantagecorp.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Warrants" roleURI="http://www.vickersvantagecorp.com/role/Warrants" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficit" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlans" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingencies" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatements" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxes" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEvents" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AccountingPoliciesByPolicyPolicies" roleURI="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsTables" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentTables" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtTables" roleURI="http://www.vickersvantagecorp.com/role/DebtTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansTables" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesTables" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareTables" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcernDetails" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOfferingDetails" roleURI="http://www.vickersvantagecorp.com/role/PublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacementDetails" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficitDetails" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#WarrantsDetails" roleURI="http://www.vickersvantagecorp.com/role/WarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetails" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AcquisitionsDetails" roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEventsDetails" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2146634689" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2146634690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_DocumentType_2146634690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2146634691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_AmendmentFlag_2146634691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2146634692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityRegistrantName_2146634692" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2146634693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityCentralIndexKey_2146634693" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2146634810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityFilerCategory_2146634810" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_2146634811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntitySmallBusiness_2146634811" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2146634812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityEmergingGrowthCompany_2146634812" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_2146634813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityExTransitionPeriod_2146634813" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31" xlink:to="loc_us-gaap_StatementTable_2146635007" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635007" xlink:to="loc_dei_LegalEntityAxis_2146635012" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635012" xlink:to="loc_dei_EntityDomain_2146635013" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635013" xlink:to="loc_sclx_VickersVantageMember_2146635014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635007" xlink:to="loc_us-gaap_StatementLineItems_2146635010" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_AssetsAbstract_32" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsCurrentAbstract_33" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2146635255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_InventoryNet_2146635255" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_38" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_Cash_37" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AssetsCurrent_39" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_Goodwill_2146635266" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2146635267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_LongTermInvestments_2146635267" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_2146635611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_DeferredCosts_2146635611" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Assets_41" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2146635268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableCurrent_2146635268" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_sclx_AccruedPayroll_2146635274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AccruedPayroll_2146635274" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2146635886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2146635886" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146635280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146635280" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LiabilitiesCurrent_43" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_sclx_AdvancesFromRelatedParty_2146635619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AdvancesFromRelatedParty_2146635619" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146635294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146635294" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_44" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_45" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_46" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DerivativeLiabilities_48" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Liabilities_50" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_CommitmentsAndContingencies_51" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquityAbstract_36" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_PreferredStockValue_53" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_CommonStockValue_54" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquity_57" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72" xlink:to="loc_us-gaap_StatementTable_2146635025" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_dei_LegalEntityAxis_2146635031" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635031" xlink:to="loc_dei_EntityDomain_2146635032" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635032" xlink:to="loc_sclx_VickersVantageMember_2146635033" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635316" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635316" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635317" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_2146635318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146635317" xlink:to="loc_us-gaap_CommonClassAMember_2146635318" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2146637181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2146637181" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_StatementLineItems_2146635028" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_76" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesIssued_77" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesIssued_81" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubjectToPossibleRedemptionPerShares" xlink:label="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesCapitalization" xlink:label="loc_sclx_SharesCapitalization_2146637182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SharesCapitalization_2146637182" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_100" xlink:to="loc_us-gaap_StatementTable_2146635036" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635036" xlink:to="loc_dei_LegalEntityAxis_2146635042" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635042" xlink:to="loc_dei_EntityDomain_2146635043" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635043" xlink:to="loc_sclx_VickersVantageMember_2146635044" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635036" xlink:to="loc_us-gaap_StatementLineItems_2146635039" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2146635331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_Revenues_2146635331" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2146635336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_CostOfRevenue_2146635336" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2146635341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2146635341" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingIncomeLoss_103" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherIncomeAbstract_102" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_104" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_105" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestIncomeOther_110" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_sclx_GainLossOnDerivative_2146635366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnDerivative_2146635366" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestExpense_109" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2146635371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2146635371" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_NetIncomeLoss_112" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareBasic_114" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635350" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_120" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_120" xlink:to="loc_us-gaap_StatementTable_2146635048" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635048" xlink:to="loc_dei_LegalEntityAxis_2146635054" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635054" xlink:to="loc_dei_EntityDomain_2146635055" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635055" xlink:to="loc_sclx_VickersVantageMember_2146635056" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635048" xlink:to="loc_us-gaap_StatementLineItems_2146635051" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_EarningsPerShareDiluted_122" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_140" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_140" xlink:to="loc_us-gaap_StatementTable_141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_142" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_142" xlink:to="loc_us-gaap_EquityComponentDomain_147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_CommonStockMember_144" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_dei_LegalEntityAxis_2146635061" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635061" xlink:to="loc_dei_EntityDomain_2146635062" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635062" xlink:to="loc_sclx_VickersVantageMember_2146635063" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementLineItems_143" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockholdersEquity_148" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_SharesOutstanding_149" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:label="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetIncomeLoss_152" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockholdersEquity_153" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_SharesOutstanding_154" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_192" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192" xlink:to="loc_us-gaap_StatementTable_2146635066" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635066" xlink:to="loc_dei_LegalEntityAxis_2146635072" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635072" xlink:to="loc_dei_EntityDomain_2146635073" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635073" xlink:to="loc_sclx_VickersVantageMember_2146635074" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635066" xlink:to="loc_us-gaap_StatementLineItems_2146635069" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetIncomeLoss_203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_2146635594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestPaidNet_2146635594" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_sclx_NonCashOperatingLeaseCosts_2146635610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_NonCashOperatingLeaseCosts_2146635610" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2146635613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ShareBasedCompensation_2146635613" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_206" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_sclx_IncreaseInNotesPayableOne_2146635581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_IncreaseInNotesPayableOne_2146635581" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_sclx_InvestmentOfCashInTrustAccounts_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_sclx_InvestmentOfCashInTrustAccounts_213" use="optional" order="42" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_ProceedsFromDecommissioningFund_198" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" use="optional" order="48" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" use="optional" order="55" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" use="optional" order="57" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" use="optional" order="60" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" use="optional" order="61" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" use="optional" order="62" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_225" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OtherLoanForgiveness" xlink:label="loc_sclx_OtherLoanForgiveness_2146635873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OtherLoanForgiveness_2146635873" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteIssuedNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:label="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashRightOfUseAsset" xlink:label="loc_sclx_NonCashRightOfUseAsset_2146635880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashRightOfUseAsset_2146635880" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="loc_sclx_DeferredUnderwritingFeePayable_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_DeferredUnderwritingFeePayable_226" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_2146635734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NotesIssued1_2146635734" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:label="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashDistributionToAcquiree" xlink:label="loc_sclx_NonCashDistributionToAcquiree_2146635904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashDistributionToAcquiree_2146635904" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashIncreaseInPrincipal" xlink:label="loc_sclx_NonCashIncreaseInPrincipal_2146635907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashIncreaseInPrincipal_2146635907" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_233" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_233" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xlink:to="loc_dei_LegalEntityAxis_2146635117" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635117" xlink:to="loc_dei_EntityDomain_2146635118" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635118" xlink:to="loc_sclx_VickersVantageMember_2146635119" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xlink:to="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_241" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_241" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xlink:to="loc_dei_LegalEntityAxis_2146635078" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635078" xlink:to="loc_dei_EntityDomain_2146635079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635079" xlink:to="loc_sclx_VickersVantageMember_2146635080" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernAbstract" xlink:label="loc_sclx_LiquidityAndGoingConcernAbstract_2146635445" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTextBlock" xlink:label="loc_sclx_LiquidityAndGoingConcernTextBlock_2146635446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernAbstract_2146635445" xlink:to="loc_sclx_LiquidityAndGoingConcernTextBlock_2146635446" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOffering">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="loc_sclx_ProposedPublicOfferingAbstract_247" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_2146634966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ProposedPublicOfferingAbstract_247" xlink:to="loc_sclx_PublicOfferingDetailsTable_2146634966" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_2146634966" xlink:to="loc_dei_LegalEntityAxis_2146634972" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634972" xlink:to="loc_dei_EntityDomain_2146634973" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634973" xlink:to="loc_sclx_VickersVantageMember_2146634975" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_2146634968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_2146634966" xlink:to="loc_sclx_PublicOfferingDetailsLineItems_2146634968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="loc_sclx_ProposedPublicOfferingTextBlock_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_2146634968" xlink:to="loc_sclx_ProposedPublicOfferingTextBlock_248" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementAbstract" xlink:label="loc_sclx_PrivatePlacementAbstract_253" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_2146635094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementAbstract_253" xlink:to="loc_sclx_PrivatePlacementDetailsTable_2146635094" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_2146635094" xlink:to="loc_dei_LegalEntityAxis_2146635096" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635096" xlink:to="loc_dei_EntityDomain_2146635097" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635097" xlink:to="loc_sclx_VickersVantageMember_2146635098" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_2146635094" xlink:to="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementTextBlock" xlink:label="loc_sclx_PrivatePlacementTextBlock_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" xlink:to="loc_sclx_PrivatePlacementTextBlock_254" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Acquisitions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_2146635653" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_2146635716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_2146635653" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_2146635716" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_259" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_259" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xlink:to="loc_dei_LegalEntityAxis_2146634969" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634969" xlink:to="loc_dei_EntityDomain_2146634970" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634970" xlink:to="loc_sclx_VickersVantageMember_2146634971" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_287" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_287" xlink:to="loc_us-gaap_StatementTable_2146635163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635164" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635165" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_dei_LegalEntityAxis_2146635167" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635167" xlink:to="loc_dei_EntityDomain_2146635168" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635168" xlink:to="loc_sclx_VickersVantageMember_2146635169" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_us-gaap_StatementLineItems_2146635166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635166" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_288" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635813" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2146635814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635813" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2146635814" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2146635474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635472" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2146635474" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Debt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146635927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2146635929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146635927" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2146635929" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Warrants">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsAbstract" xlink:label="loc_sclx_WarrantsAbstract_279" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTable" xlink:label="loc_sclx_WarrantsTable_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsAbstract_279" xlink:to="loc_sclx_WarrantsTable_280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsTable_280" xlink:to="loc_dei_LegalEntityAxis_2146634994" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634994" xlink:to="loc_dei_EntityDomain_2146634995" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634995" xlink:to="loc_sclx_VickersVantageMember_2146634996" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsLineItems" xlink:label="loc_sclx_WarrantsLineItems_2146634997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsTable_280" xlink:to="loc_sclx_WarrantsLineItems_2146634997" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTextBlock" xlink:label="loc_sclx_WarrantsTextBlock_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsLineItems_2146634997" xlink:to="loc_sclx_WarrantsTextBlock_282" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_271" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_271" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xlink:to="loc_dei_LegalEntityAxis_2146635184" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635184" xlink:to="loc_dei_EntityDomain_2146635185" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635185" xlink:to="loc_sclx_VickersVantageMember_2146635186" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xlink:to="loc_us-gaap_ClassOfStockLineItems_2146635183" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635183" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635431" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2146635434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635431" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2146635434" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_265" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_265" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xlink:to="loc_dei_LegalEntityAxis_2146635101" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635101" xlink:to="loc_dei_EntityDomain_2146635102" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635102" xlink:to="loc_sclx_VickersVantageMember_2146635104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635259" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635259" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xlink:to="loc_dei_LegalEntityAxis_2146635271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635271" xlink:to="loc_dei_EntityDomain_2146635272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635272" xlink:to="loc_sclx_VickersVantageMember_2146635273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635890" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2146635892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635890" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2146635892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635543" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2146635547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635543" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2146635547" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_293" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_293" xlink:to="loc_us-gaap_StatementTable_2146635155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635156" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635156" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635157" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_dei_LegalEntityAxis_2146635159" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635159" xlink:to="loc_dei_EntityDomain_2146635160" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635160" xlink:to="loc_sclx_VickersVantageMember_2146635161" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_us-gaap_StatementLineItems_2146635158" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635158" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_294" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_312" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_312" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xlink:to="loc_dei_LegalEntityAxis_2146635059" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635059" xlink:to="loc_dei_EntityDomain_2146635060" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635060" xlink:to="loc_sclx_VickersVantageMember_2146635064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2146635859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2146635859" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_314" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_UseOfEstimates_316" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_319" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_321" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2146635669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2146635669" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_322" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_2146635679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DebtPolicyTextBlock_2146635679" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RebatesPolicyTextBlock" xlink:label="loc_sclx_RebatesPolicyTextBlock_2146635702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_RebatesPolicyTextBlock_2146635702" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ServiceFeesPolicyTextBlock" xlink:label="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesReturnsPolicyTextBlock" xlink:label="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoPaymentAssistancePolicyTextBlock" xlink:label="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_324" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_332" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_332" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xlink:to="loc_dei_LegalEntityAxis_2146635016" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635016" xlink:to="loc_dei_EntityDomain_2146635017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635017" xlink:to="loc_sclx_VickersVantageMember_2146635018" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2146635170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2146635170" xlink:to="loc_us-gaap_StatementTable_2146635172" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635173" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635173" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635174" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_dei_LegalEntityAxis_2146635176" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635176" xlink:to="loc_dei_EntityDomain_2146635177" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635177" xlink:to="loc_sclx_VickersVantageMember_2146635178" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_us-gaap_StatementLineItems_2146635175" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635816" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2146635820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635816" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2146635820" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2146635488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635485" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2146635488" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2146635489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635485" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2146635489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636344" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2146636346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636344" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2146636346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock_2146636352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636344" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock_2146636352" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635439" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2146635441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635439" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2146635441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2146635444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635439" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2146635444" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2146635844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2146635844" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xlink:label="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock_2146635848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" xlink:to="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock_2146635848" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2146635850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2146635850" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635276" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xlink:to="loc_dei_LegalEntityAxis_2146635281" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635281" xlink:to="loc_dei_EntityDomain_2146635282" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635282" xlink:to="loc_sclx_VickersVantageMember_2146635283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2146635965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2146635965" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2146635966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2146635966" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2146635967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2146635967" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635551" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2146635553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635551" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2146635553" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_506" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_506" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorMember" xlink:label="loc_sclx_SponsorMember_2146635351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" xlink:to="loc_sclx_SponsorMember_2146635351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_508" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_ScilexPharmaMember_2146635406" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VantageMergerSubIncMember" xlink:label="loc_sclx_VantageMergerSubIncMember_2146635932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_VantageMergerSubIncMember_2146635932" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_509" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_509" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_IPOMember_514" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_OverAllotmentOptionMember_515" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="loc_sclx_PrivatePlacementWarrantMember_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_sclx_PrivatePlacementWarrantMember_516" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_dei_LegalEntityAxis_2146634946" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634946" xlink:to="loc_dei_EntityDomain_2146634948" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634948" xlink:to="loc_sclx_VickersVantageMember_2146635075" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146635403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_AgreementAxis_2146635403" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146635404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146635403" xlink:to="loc_sclx_AgreementDomain_2146635404" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ContributionAndLoanAgreementMember" xlink:label="loc_sclx_ContributionAndLoanAgreementMember_2146635405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_ContributionAndLoanAgreementMember_2146635405" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146635936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146635936" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635408" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635408" xlink:to="loc_sclx_SorrentoMember_2146635409" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_EventAxis_2146635410" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventAxis_2146635410" xlink:to="loc_sclx_EventDomain_2146635411" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635411" xlink:to="loc_sclx_ReorganizationMember_2146635412" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SharesIssued_517" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_518" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:label="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaap_OtherUnderwritingExpense_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherUnderwritingExpense_522" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFees" xlink:label="loc_sclx_DeferredUnderwritingFees_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DeferredUnderwritingFees_523" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:label="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestBearingDepositLiabilities" xlink:label="loc_us-gaap_NoninterestBearingDepositLiabilities_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_NoninterestBearingDepositLiabilities_526" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_AssetsHeldInTrust_527" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="loc_sclx_SaleOfStockDescriptionOfTransactions_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_SaleOfStockDescriptionOfTransactions_528" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerPublicShare" xlink:label="loc_sclx_PricePerPublicShare_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PricePerPublicShare_529" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_530" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPublicShares" xlink:label="loc_sclx_PercentageOfPublicShares_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PercentageOfPublicShares_531" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="loc_sclx_BusinessCombinationRedeemPercentage_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_BusinessCombinationRedeemPercentage_533" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherExpenses_534" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositIntoTheTrustAccountPerShare" xlink:label="loc_sclx_DepositIntoTheTrustAccountPerShare_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DepositIntoTheTrustAccountPerShare_535" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LesserPublicPerShare" xlink:label="loc_sclx_LesserPublicPerShare_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_LesserPublicPerShare_536" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_RestrictedCashCurrent_538" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_WorkingCapital_539" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofshares" xlink:label="loc_sclx_Numberofshares_2146635285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofshares_2146635285" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Saleofwarrants" xlink:label="loc_sclx_Saleofwarrants_2146635310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Saleofwarrants_2146635310" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Grossproceedsofwarrants" xlink:label="loc_sclx_Grossproceedsofwarrants_2146635319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Grossproceedsofwarrants_2146635319" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Transactioncostsamount" xlink:label="loc_sclx_Transactioncostsamount_2146635332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Transactioncostsamount_2146635332" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Otherofferingcosts" xlink:label="loc_sclx_Otherofferingcosts_2146635334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Otherofferingcosts_2146635334" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofbusinessdays" xlink:label="loc_sclx_Numberofbusinessdays_2146635343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofbusinessdays_2146635343" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_2146635346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_NetTangibleAssets_2146635346" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Depositintotrustaccount" xlink:label="loc_sclx_Depositintotrustaccount_2146635354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Depositintotrustaccount_2146635354" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Interestexpenses" xlink:label="loc_sclx_Interestexpenses_2146635365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Interestexpenses_2146635365" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_2146635368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_Cash_2146635368" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2146635402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2146635402" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_552" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_552" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_dei_LegalEntityAxis_2146634981" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634981" xlink:to="loc_dei_EntityDomain_2146634982" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634982" xlink:to="loc_sclx_VickersVantageMember_2146634983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_554" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_554" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" xlink:to="loc_us-gaap_IPOMember_557" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_2146635766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" xlink:to="loc_us-gaap_SalesRevenueNetMember_2146635766" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2146635767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_srt_MajorCustomersAxis_2146635767" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2146635768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2146635767" xlink:to="loc_srt_NameOfMajorCustomerDomain_2146635768" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SoleDistributorMember" xlink:label="loc_sclx_SoleDistributorMember_2146635769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2146635768" xlink:to="loc_sclx_SoleDistributorMember_2146635769" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="loc_us-gaap_OtherDeferredCostsNet_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_OtherDeferredCostsNet_558" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaap_ExcessStockSharesIssued_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ExcessStockSharesIssued_559" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_CashFDICInsuredAmount_560" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Foundershares" xlink:label="loc_sclx_Foundershares_2146635399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_sclx_Foundershares_2146635399" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xlink:label="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract_358" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract_358" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xlink:to="loc_dei_LegalEntityAxis_2146634986" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634986" xlink:to="loc_dei_EntityDomain_2146634987" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634987" xlink:to="loc_sclx_VickersVantageMember_2146634988" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GrossProceeds" xlink:label="loc_sclx_GrossProceeds_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_GrossProceeds_362" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract" xlink:label="loc_sclx_LessAbstract_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract_359" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="loc_sclx_OrdinarySharesIssuanceCost_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LessAbstract_359" xlink:to="loc_sclx_OrdinarySharesIssuanceCost_363" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PlusAbstract" xlink:label="loc_sclx_PlusAbstract_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_PlusAbstract_360" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="loc_sclx_SharesSubjectToPossibleRedemption_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_SharesSubjectToPossibleRedemption_365" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract0" xlink:label="loc_sclx_LessAbstract0_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract0_361" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LessAbstract0_361" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_366" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:label="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_375" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_375" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xlink:to="loc_dei_LegalEntityAxis_2146634991" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634991" xlink:to="loc_dei_EntityDomain_2146634992" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634992" xlink:to="loc_sclx_VickersVantageMember_2146634993" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumeratorAbstract" xlink:label="loc_sclx_NumeratorAbstract_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_NumeratorAbstract_376" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_NumeratorAbstract_376" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_378" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DenominatorAbstract" xlink:label="loc_sclx_DenominatorAbstract_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_DenominatorAbstract_377" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareBasic_380" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635665" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:label="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_386" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_386" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xlink:to="loc_dei_LegalEntityAxis_2146635003" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635003" xlink:to="loc_dei_EntityDomain_2146635004" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635004" xlink:to="loc_sclx_VickersVantageMember_2146635005" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_EarningsPerShareDiluted_388" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernAbstract" xlink:label="loc_sclx_LiquidityAndGoingConcernAbstract_2146635452" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_2146635455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernAbstract_2146635452" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_2146635455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_dei_LegalEntityAxis_2146635514" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635514" xlink:to="loc_dei_EntityDomain_2146635515" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635515" xlink:to="loc_sclx_ScilexPharmaMember_2146635517" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635518" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635519" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:label="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635519" xlink:to="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_sclx_EventAxis_2146635523" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventAxis_2146635523" xlink:to="loc_sclx_EventDomain_2146635524" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CumulativeSalesRelatedContingencyMember" xlink:label="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LetterOfCreditDrawnDownMember" xlink:label="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2146635528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2146635528" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146635529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2146635528" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146635529" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2146635530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146635529" xlink:to="loc_us-gaap_SubsequentEventMember_2146635530" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636050" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636050" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636051" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636051" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636052" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636053" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636053" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636054" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636054" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636055" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetWorkingCapital" xlink:label="loc_sclx_NetWorkingCapital_2146635459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_NetWorkingCapital_2146635459" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2146635573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_OperatingIncomeLoss_2146635573" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashBalance" xlink:label="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:label="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentRepurchaseObligation" xlink:label="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636049" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOfferingDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="loc_sclx_ProposedPublicOfferingAbstract_573" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ProposedPublicOfferingAbstract_573" xlink:to="loc_sclx_PublicOfferingDetailsTable_574" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_dei_LegalEntityAxis_2146634940" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634940" xlink:to="loc_dei_EntityDomain_2146634941" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634941" xlink:to="loc_sclx_VickersVantageMember_2146634945" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_575" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_IPOMember_578" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_OverAllotmentOptionMember_579" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_sclx_PublicOfferingDetailsLineItems_576" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasePricePerShare" xlink:label="loc_sclx_PurchasePricePerShare_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_PurchasePricePerShare_581" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSaleUnits" xlink:label="loc_sclx_NumberOfSaleUnits_2146636382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_NumberOfSaleUnits_2146636382" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementAbstract" xlink:label="loc_sclx_PrivatePlacementAbstract_594" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementAbstract_594" xlink:to="loc_sclx_PrivatePlacementDetailsTable_595" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_dei_LegalEntityAxis_2146635105" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635105" xlink:to="loc_dei_EntityDomain_2146635107" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635107" xlink:to="loc_sclx_VickersVantageMember_2146635108" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_596" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_596" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" xlink:to="loc_us-gaap_PrivatePlacementMember_598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_sclx_PrivatePlacementDetailsLineItems_597" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_602" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_643" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_643" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_644" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_dei_LegalEntityAxis_2146634976" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634976" xlink:to="loc_dei_EntityDomain_2146634977" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_VickersVantageMember_2146634979" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_ScilexPharmaMember_2146635920" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_645" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_645" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_651" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromisoryNoteMember" xlink:label="loc_sclx_ConvertiblePromisoryNoteMember_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_sclx_ConvertiblePromisoryNoteMember_652" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_646" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_646" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_653" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_FounderSharesMember_654" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="loc_sclx_PromissoryNoteRelatedPartyMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_PromissoryNoteRelatedPartyMember_655" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_647" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_656" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_656" xlink:to="loc_us-gaap_SubsequentEventMember_657" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_648" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_648" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" xlink:to="loc_us-gaap_IPOMember_659" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_660" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_660" xlink:to="loc_sclx_FounderSharesMember_661" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635807" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635807" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635809" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635809" xlink:to="loc_sclx_SenmurMember_2146635810" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635852" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ItochuMember" xlink:label="loc_sclx_ItochuMember_2146635854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_ItochuMember_2146635854" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_SorrentoMember_2146635876" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_EventAxis_2146635901" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventAxis_2146635901" xlink:to="loc_sclx_EventDomain_2146635902" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635902" xlink:to="loc_sclx_ReorganizationMember_2146635903" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_InvesteeAxis_2146636065" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeAxis_2146636065" xlink:to="loc_sclx_InvesteeDomain_2146636066" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146636066" xlink:to="loc_sclx_SorrentoMember_2146636067" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636071" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636071" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636072" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636072" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146636076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146636076" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146636076" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" xlink:to="loc_sclx_SorrentoMember_2146636078" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_AgreementAxis_2146636315" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146636315" xlink:to="loc_sclx_AgreementDomain_2146636319" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146636320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636319" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146636320" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2146636348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2146636348" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2146636349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2146636348" xlink:to="loc_us-gaap_EquityComponentDomain_2146636349" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2146636350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_PreferredStockMember_2146636350" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2146636351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_CommonStockMember_2146636351" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAxis" xlink:label="loc_sclx_PeriodAxis_2146636629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_PeriodAxis_2146636629" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain_2146636630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PeriodAxis_2146636629" xlink:to="loc_sclx_PeriodDomain_2146636630" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:label="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PeriodDomain_2146636630" xlink:to="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="loc_sclx_CapitalizationOfShareOutstanding_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_CapitalizationOfShareOutstanding_664" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_668" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_669" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RepaymentsOfDebt_670" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ConvertibleDebt_672" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsExercisePrice" xlink:label="loc_sclx_WarrantsExercisePrice_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WarrantsExercisePrice_673" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AdditionalPaidInCapital_674" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_aggregatePurchasePrice" xlink:label="loc_sclx_aggregatePurchasePrice_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_aggregatePurchasePrice_676" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_677" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositedInTrustAccount" xlink:label="loc_sclx_DepositedInTrustAccount_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_DepositedInTrustAccount_680" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635838" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635839" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635849" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToAcquireInventory" xlink:label="loc_sclx_PaymentToAcquireInventory_2146635855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PaymentToAcquireInventory_2146635855" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfCapitalSharesOutstanding" xlink:label="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesOutstanding" xlink:label="loc_sclx_NumberOfSharesOutstanding_2146635879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesOutstanding_2146635879" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesAcquired" xlink:label="loc_sclx_NumberOfSharesAcquired_2146635888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesAcquired_2146635888" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSimpleInterest" xlink:label="loc_sclx_PercentageOfSimpleInterest_2146635906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSimpleInterest_2146635906" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_2146635908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_NotesPayableCurrent_2146635908" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedInterest" xlink:label="loc_sclx_AccruedInterest_2146635924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AccruedInterest_2146635924" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerWarrants" xlink:label="loc_sclx_PricePerWarrants_2146635981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PricePerWarrants_2146635981" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146635982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146635982" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2146635983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2146635983" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePrincipalAmount" xlink:label="loc_sclx_AggregatePrincipalAmount_2146635990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AggregatePrincipalAmount_2146635990" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="loc_us-gaap_DueToAffiliateCurrent_2146636008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToAffiliateCurrent_2146636008" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaidAmount" xlink:label="loc_sclx_RepaidAmount_2146636011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_RepaidAmount_2146636011" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2146636059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermNotesPayable_2146636059" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2146636070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_2146636070" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636074" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapitalRequirements" xlink:label="loc_sclx_WorkingCapitalRequirements_2146636097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WorkingCapitalRequirements_2146636097" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_2146636101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LegalFees_2146636101" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOutstandingAmountIndebtedness" xlink:label="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermDebt_2146636345" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_717" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_717" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_dei_LegalEntityAxis_2146635081" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635081" xlink:to="loc_dei_EntityDomain_2146635082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635082" xlink:to="loc_sclx_VickersVantageMember_2146635083" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_719" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_719" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_725" xlink:to="loc_sclx_ScilexCommonStockMember_726" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_720" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_720" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_StatementClassOfStockAxis_721" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_721" xlink:to="loc_us-gaap_ClassOfStockDomain_729" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_729" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_730" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_722" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_722" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_732" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_srt_RangeAxis_723" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_723" xlink:to="loc_srt_RangeMember_733" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MinimumMember_734" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MaximumMember_735" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146635917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146635917" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146635917" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_2146635919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_2146635919" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProjectAgreementMember" xlink:label="loc_sclx_ProjectAgreementMember_2146635962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProjectAgreementMember_2146635962" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaloAltoAadministrativeFacilityMember" xlink:label="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" xlink:to="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OtherCommitmentsDescription_736" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_737" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsAuthorized" xlink:label="loc_us-gaap_PreferredUnitsAuthorized_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredUnitsAuthorized_738" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MergerConsiderationDescription" xlink:label="loc_sclx_MergerConsiderationDescription_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_MergerConsiderationDescription_739" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssued_740" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_741" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockAggregateValue" xlink:label="loc_sclx_CommonStockAggregateValue_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_CommonStockAggregateValue_742" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NetTangibleAssets_744" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePercentage" xlink:label="loc_sclx_AggregatePercentage_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AggregatePercentage_745" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsPercentage" xlink:label="loc_sclx_WarrantsPercentage_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WarrantsPercentage_746" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockNoParValue_747" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BalanceInTheTrustAccount" xlink:label="loc_sclx_BalanceInTheTrustAccount_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_BalanceInTheTrustAccount_748" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommission" xlink:label="loc_sclx_DeferredUnderwritingCommission_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommission_749" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommissionPayable" xlink:label="loc_sclx_DeferredUnderwritingCommissionPayable_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommissionPayable_750" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAggregateRoyalityPayments" xlink:label="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationDate" xlink:label="loc_sclx_AgreementExpirationDate_2146635921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationDate_2146635921" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationTerm" xlink:label="loc_sclx_AgreementExpirationTerm_2146635922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationTerm_2146635922" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:label="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:label="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:label="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ThresholdMinimumPercentageOfSales" xlink:label="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAnnualAdjustmentToFees" xlink:label="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:label="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticePeriodForTerminationOfWorkOrder" xlink:label="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkOrderImplementationFee" xlink:label="loc_sclx_WorkOrderImplementationFee_2146635953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WorkOrderImplementationFee_2146635953" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesOperationsServicesMonthlyFee" xlink:label="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SellingGeneralAndAdministrativeExpenses" xlink:label="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_2146635959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OperatingLeaseExpense_2146635959" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_2146635857" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_2146635858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_2146635857" xlink:to="loc_us-gaap_OperatingLeaseCost_2146635858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2146636069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2146636069" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2146635866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2146635866" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2146635867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2146635867" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2146635868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2146635868" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2146635870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2146635870" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2146635871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2146635871" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2146635872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2146635872" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2146637275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2146637275" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2146635875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_OperatingLeaseLiability_2146635875" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingCashFlowsFromOperatingLeases" xlink:label="loc_sclx_OperatingCashFlowsFromOperatingLeases_2146635883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_sclx_OperatingCashFlowsFromOperatingLeases_2146635883" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2146636068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2146636068" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2146635884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2146635884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2146635885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2146635885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_763" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_763" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xlink:to="loc_dei_LegalEntityAxis_2146635128" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635128" xlink:to="loc_dei_EntityDomain_2146635129" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635129" xlink:to="loc_sclx_VickersVantageMember_2146635130" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xlink:to="loc_us-gaap_ClassOfStockLineItems_2146635127" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_764" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesIssued_766" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_767" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_768" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesIssued_770" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_771" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/WarrantsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsAbstract" xlink:label="loc_sclx_WarrantsAbstract_787" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsTable" xlink:label="loc_sclx_WarrantsDetailsTable_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsAbstract_787" xlink:to="loc_sclx_WarrantsDetailsTable_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_789" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" xlink:to="loc_us-gaap_PrivatePlacementMember_793" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_790" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_790" xlink:to="loc_us-gaap_EquityComponentDomain_794" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_794" xlink:to="loc_us-gaap_WarrantMember_795" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_dei_LegalEntityAxis_2146634998" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634998" xlink:to="loc_dei_EntityDomain_2146634999" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634999" xlink:to="loc_sclx_VickersVantageMember_2146635000" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsLineItems" xlink:label="loc_sclx_WarrantsDetailsLineItems_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_sclx_WarrantsDetailsLineItems_791" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsOutstandingShares" xlink:label="loc_sclx_WarrantsOutstandingShares_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_WarrantsOutstandingShares_796" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="loc_sclx_PublicWarrantsRedemptionDescription_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_PublicWarrantsRedemptionDescription_797" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalRaisingDescription" xlink:label="loc_sclx_CapitalRaisingDescription_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_CapitalRaisingDescription_798" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_804" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146634955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_804" xlink:to="loc_us-gaap_StatementTable_2146634955" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146634956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146634956" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146634957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146634956" xlink:to="loc_us-gaap_ClassOfStockDomain_2146634957" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_dei_LegalEntityAxis_2146635089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635089" xlink:to="loc_dei_EntityDomain_2146635090" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635090" xlink:to="loc_sclx_VickersVantageMember_2146635091" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2146635787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2146635787" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2146635789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2146635787" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2146635789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:label="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEffectiveDebtYieldMember" xlink:label="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636094" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636094" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636095" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636095" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636096" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146634958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_StatementLineItems_2146634958" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146636312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146636312" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_805" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:label="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_2146635649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_2146635649" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_2146635774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_2146635774" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636100" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xlink:label="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract_402" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract_402" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_408" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_409" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_dei_LegalEntityAxis_2146635112" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635112" xlink:to="loc_dei_EntityDomain_2146635113" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635113" xlink:to="loc_sclx_VickersVantageMember_2146635115" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_AssetsAbstract_406" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_406" xlink:to="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_LiabilitiesAbstract_407" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_411" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_412" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract_443" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract_443" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_445" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_us-gaap_PrivatePlacementMember_447" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConversionOptionLiabilityMember" xlink:label="loc_sclx_ConversionOptionLiabilityMember_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_sclx_ConversionOptionLiabilityMember_448" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_dei_LegalEntityAxis_2146635139" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635139" xlink:to="loc_dei_EntityDomain_2146635140" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635140" xlink:to="loc_sclx_VickersVantageMember_2146635141" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_us-gaap_DerivativeLiabilities_449" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InitialMeasurementOne" xlink:label="loc_sclx_InitialMeasurementOne_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_InitialMeasurementOne_450" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_us-gaap_DerivativeLiabilities_452" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xlink:label="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract_462" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract_462" xlink:to="loc_us-gaap_StatementTable_2146635143" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635144" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635144" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_dei_LegalEntityAxis_2146635147" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635147" xlink:to="loc_dei_EntityDomain_2146635148" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635148" xlink:to="loc_sclx_VickersVantageMember_2146635149" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_us-gaap_StatementLineItems_2146635146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnderlyingWarrantValue" xlink:label="loc_sclx_UnderlyingWarrantValue_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_UnderlyingWarrantValue_463" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_HoldingPeriod" xlink:label="loc_sclx_HoldingPeriod_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_HoldingPeriod_465" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2146635509" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2146635509" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2146635565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2146635565" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2146635566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2146635566" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2146635567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2146635567" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2146635520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2146635520" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635531" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2146635622" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2146635622" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635632" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xlink:label="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract_423" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract_423" xlink:to="loc_us-gaap_StatementTable_2146635132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635133" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635133" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_dei_LegalEntityAxis_2146635136" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635136" xlink:to="loc_dei_EntityDomain_2146635137" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635137" xlink:to="loc_sclx_VickersVantageMember_2146635138" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_us-gaap_StatementLineItems_2146635135" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharePrice_424" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="loc_sclx_FairValueMeasurementStrikePrice_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueMeasurementStrikePrice_425" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="loc_sclx_FairValueOfWarrantsinDollars_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueOfWarrantsinDollars_430" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract_2146635355" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract_2146635355" xlink:to="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xlink:to="loc_dei_LegalEntityAxis_2146635358" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635358" xlink:to="loc_dei_EntityDomain_2146635359" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635359" xlink:to="loc_sclx_VickersVantageMember_2146635360" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xlink:to="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_2146635361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_2146635361" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_2146635362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_2146635362" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635823" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635823" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2146635833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ComputerEquipmentMember_2146635833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2146635835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2146635835" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2146635836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2146635836" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_2146635837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ConstructionInProgressMember_2146635837" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635842" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_2146635843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635842" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_2146635843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635533" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635533" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_PatentsMember_2146635542" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636056" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_sclx_AssembledWorkforceMember_2146635548" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2146636058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2146636058" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2146635502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2146635502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2146635506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2146635506" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2146635507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2146635507" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2146635508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2146635508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2146635509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2146635509" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2146635510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2146635510" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_2146636060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_2146636060" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635512" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635564" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635564" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_PatentsMember_2146635595" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_sclx_AssembledWorkforceMember_2146635597" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636064" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_srt_RangeAxis_2146635600" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146635600" xlink:to="loc_srt_RangeMember_2146635602" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_2146635603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635602" xlink:to="loc_srt_WeightedAverageMember_2146635603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_Goodwill_2146635582" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2146635585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2146635585" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636080" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636080" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636084" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636084" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636085" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146636174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146636174" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146636141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_RangeAxis_2146636141" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146636142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146636141" xlink:to="loc_srt_RangeMember_2146636142" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146636143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MaximumMember_2146636143" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MinimumMember_2146636144" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_2146636145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_StatementScenarioAxis_2146636145" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2146636146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2146636145" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2146636146" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_2146636147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_2146636147" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IfLetterOfCreditIsDrawnMember" xlink:label="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MarketingApprovalLetterMember" xlink:label="loc_sclx_MarketingApprovalLetterMember_2146636248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_MarketingApprovalLetterMember_2146636248" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AgreementAxis_2146636183" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146636183" xlink:to="loc_sclx_AgreementDomain_2146636184" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndebentureMember" xlink:label="loc_sclx_IndebentureMember_2146636188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636184" xlink:to="loc_sclx_IndebentureMember_2146636188" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636207" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636207" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636208" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_2146636219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_LetterOfCreditMember_2146636219" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:label="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementAxis" xlink:label="loc_sclx_StatementAxis_2146636282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_StatementAxis_2146636282" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain_2146636283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementAxis_2146636282" xlink:to="loc_sclx_StatementDomain_2146636283" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DecemberOptionalRepurchaseMember" xlink:label="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FebruaryOptionalRepurchaseMember" xlink:label="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AprilOptionalRepurchaseMember" xlink:label="loc_sclx_AprilOptionalRepurchaseMember_2146636294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_AprilOptionalRepurchaseMember_2146636294" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_2146636383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_VariableRateAxis_2146636383" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_2146636384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2146636383" xlink:to="loc_us-gaap_VariableRateDomain_2146636384" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_2146636385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2146636384" xlink:to="loc_us-gaap_PrimeRateMember_2146636385" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636389" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636389" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636390" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaycheckProtectionProgramMember" xlink:label="loc_sclx_PaycheckProtectionProgramMember_2146636391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_sclx_PaycheckProtectionProgramMember_2146636391" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146636404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146636404" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeAxis" xlink:label="loc_sclx_EventTypeAxis_2146636396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_EventTypeAxis_2146636396" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain_2146636397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventTypeAxis_2146636396" xlink:to="loc_sclx_EventTypeDomain_2146636397" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventTypeDomain_2146636397" xlink:to="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostAxis" xlink:label="loc_sclx_ClassificationOfCostAxis_2146636400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_ClassificationOfCostAxis_2146636400" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain_2146636437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ClassificationOfCostAxis_2146636400" xlink:to="loc_sclx_ClassificationOfCostDomain_2146636437" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonPayrollCostsMember" xlink:label="loc_sclx_NonPayrollCostsMember_2146636438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_NonPayrollCostsMember_2146636438" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PayrollCostsBasisMember" xlink:label="loc_sclx_PayrollCostsBasisMember_2146636439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_PayrollCostsBasisMember_2146636439" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentAxis" xlink:label="loc_sclx_AmendmentAxis_2146636421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AmendmentAxis_2146636421" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain_2146636423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AmendmentAxis_2146636421" xlink:to="loc_sclx_AmendmentDomain_2146636423" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentNoFourMember" xlink:label="loc_sclx_AmendmentNoFourMember_2146636424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AmendmentDomain_2146636423" xlink:to="loc_sclx_AmendmentNoFourMember_2146636424" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146636426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" xlink:to="loc_us-gaap_RelatedPartyDomain_2146636426" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146636426" xlink:to="loc_sclx_SorrentoMember_2146636427" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteMember" xlink:label="loc_sclx_PromissoryNoteMember_2146636430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" xlink:to="loc_sclx_PromissoryNoteMember_2146636430" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146636431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146636431" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146636431" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2146636083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_ShortTermDebtLineItems_2146636083" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636090" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:label="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfNetSalesPayable" xlink:label="loc_sclx_PercentageOfNetSalesPayable_2146636138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfNetSalesPayable_2146636138" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2146636140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfDebt_2146636140" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:label="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:label="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfConcentrationOnASimilarProduct" xlink:label="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentredemptionPeriod" xlink:label="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:label="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:label="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LineOfCreditFacilityindebtednessAmount" xlink:label="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636334" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:label="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_LongTermDebt_2146636386" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentTerminationDate" xlink:label="loc_sclx_DebtInstrumentTerminationDate_2146636387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentTerminationDate_2146636387" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:label="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:label="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumPayrollCostToBeAvailable" xlink:label="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146636405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RestrictedCash_2146636405" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:label="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseDate" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636354" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_2146636355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636354" xlink:to="loc_us-gaap_DebtInstrumentTable_2146636355" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2146636355" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636357" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636357" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636358" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636358" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636359" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2146636356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2146636355" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2146636356" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnamortizedDebtDiscount" xlink:label="loc_sclx_UnamortizedDebtDiscount_2146637483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_sclx_UnamortizedDebtDiscount_2146637483" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebt_2146636363" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146636364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146636364" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146636365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146636365" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_2146636366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtFairValue_2146636366" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636368" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636368" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635457" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansTable" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635457" xlink:to="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2146635463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_PlanNameAxis_2146635463" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2146635464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2146635463" xlink:to="loc_us-gaap_PlanNameDomain_2146635464" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:label="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2146635598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2146635598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2146635599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2146635598" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2146635599" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingExpensesMember" xlink:label="loc_sclx_OperatingExpensesMember_2146635604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2146635599" xlink:to="loc_sclx_OperatingExpensesMember_2146635604" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_2146635605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_RetirementPlanNameAxis_2146635605" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2146635606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2146635605" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2146635606" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FourHundredAndOneKPlanMember" xlink:label="loc_sclx_FourHundredAndOneKPlanMember_2146635607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_2146635606" xlink:to="loc_sclx_FourHundredAndOneKPlanMember_2146635607" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2146636114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_AwardTypeAxis_2146636114" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2146636114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2146636116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2146636116" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaap_PaymentsToEmployees_2146636113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_PaymentsToEmployees_2146636113" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2146635658" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2146635658" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xlink:to="loc_srt_RangeAxis_2146635661" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146635661" xlink:to="loc_srt_RangeMember_2146635662" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146635663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MinimumMember_2146635663" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MaximumMember_2146635664" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635712" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2146635714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2146635714" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635715" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2146635772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2146635772" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635773" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2146635779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2146635779" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635782" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2146635784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2146635784" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2146635788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2146635788" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2146635792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2146635792" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635795" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2146635800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2146635800" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635802" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635804" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AcquisitionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_2146635721" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_2146635722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_2146635721" xlink:to="loc_us-gaap_AssetAcquisitionTable_2146635722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635739" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635740" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_SenmurMember_2146635743" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146636180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_AardvarkMember_2146636180" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_2146636237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_RomegLicenseAgreementMember_2146636237" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneAxis" xlink:label="loc_sclx_MilestoneAxis_2146635745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_MilestoneAxis_2146635745" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain_2146635747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneAxis_2146635745" xlink:to="loc_sclx_MilestoneDomain_2146635747" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RegulatoryBasedMilestoneMember" xlink:label="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReveueBasedMilestoneMember" xlink:label="loc_sclx_ReveueBasedMilestoneMember_2146635751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ReveueBasedMilestoneMember_2146635751" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ApprovalBasedMilestoneMember" xlink:label="loc_sclx_ApprovalBasedMilestoneMember_2146636609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ApprovalBasedMilestoneMember_2146636609" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheAxis" xlink:label="loc_sclx_TrancheAxis_2146635755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_TrancheAxis_2146635755" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain_2146635756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheAxis_2146635755" xlink:to="loc_sclx_TrancheDomain_2146635756" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheOneMember" xlink:label="loc_sclx_TrancheOneMember_2146635757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheOneMember_2146635757" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheTwoMember" xlink:label="loc_sclx_TrancheTwoMember_2146635760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheTwoMember_2146635760" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheThreeMember" xlink:label="loc_sclx_TrancheThreeMember_2146635762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheThreeMember_2146635762" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheFourMember" xlink:label="loc_sclx_TrancheFourMember_2146635765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheFourMember_2146635765" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146635798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_InvesteeAxis_2146635798" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146635801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeAxis_2146635798" xlink:to="loc_sclx_InvesteeDomain_2146635801" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146635801" xlink:to="loc_sclx_SorrentoMember_2146635803" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_srt_RestatementAxis_2146635897" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_2146635897" xlink:to="loc_srt_RestatementDomain_2146635898" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635898" xlink:to="loc_sclx_AsRestatedMember_2146635899" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636133" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636133" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636134" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636134" xlink:to="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2146635723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_2146635723" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635731" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635733" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:label="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:label="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:label="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:label="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockValueToBeExchanged" xlink:label="loc_sclx_CommonStockValueToBeExchanged_2146635780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_CommonStockValueToBeExchanged_2146635780" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:label="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:label="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentMadeInSurrenderingTheShares" xlink:label="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635793" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636128" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UpfrontlicenseFee" xlink:label="loc_sclx_UpfrontlicenseFee_2146636214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_UpfrontlicenseFee_2146636214" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestonePayment" xlink:label="loc_sclx_MilestonePayment_2146636223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_MilestonePayment_2146636223" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2146636233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_RoyaltyExpense_2146636233" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredConsideration" xlink:label="loc_sclx_DeferredConsideration_2146636247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_DeferredConsideration_2146636247" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635322" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xlink:to="loc_dei_LegalEntityAxis_2146635325" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635325" xlink:to="loc_dei_EntityDomain_2146635326" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635326" xlink:to="loc_sclx_VickersVantageMember_2146635327" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_2146635329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_2146635329" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635291" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_dei_LegalEntityAxis_2146635296" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635296" xlink:to="loc_dei_EntityDomain_2146635297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635297" xlink:to="loc_sclx_VickersVantageMember_2146635298" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_srt_RestatementAxis_2146635301" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_2146635301" xlink:to="loc_srt_RestatementDomain_2146635302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_2146635303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_2146635303" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_2146635304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_RestatementAdjustmentMember_2146635304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="loc_sclx_AdjustmentsRestatement2Member_2146635305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AdjustmentsRestatement2Member_2146635305" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AsRestatedMember_2146635320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635306" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2146635307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_Liabilities_2146635307" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2146635309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_CommonStockValue_2146635309" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2146635311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2146635311" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2146635314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_StockholdersEquity_2146635314" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635943" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="loc_sclx_IncomeTaxDisclosureTable_2146636021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635943" xlink:to="loc_sclx_IncomeTaxDisclosureTable_2146636021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2146636025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_DomesticCountryMember_2146636025" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_2146636028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxPeriodAxis_2146636028" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_2146636029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_2146636028" xlink:to="loc_us-gaap_TaxPeriodDomain_2146636029" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_2146636029" xlink:to="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_2146636033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" xlink:to="loc_us-gaap_ResearchMember_2146636033" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2146636035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2146636035" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TaxCreditCarryforwardExpirationYear" xlink:label="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:label="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2146635972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2146635972" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2146635973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2146635973" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2146635974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2146635974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2146635976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2146635976" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2146635977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2146635977" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2146635978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2146635978" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635980" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2146635985" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2146635985" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations_2146635989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations_2146635989" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2146635991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2146635991" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2146635992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2146635992" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2146635993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2146635993" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_2146635994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_2146635994" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2146635995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2146635995" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2146635996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2146635996" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146635997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146635997" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2146635999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2146635999" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2146635985" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2146636001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2146636001" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2146636002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2146636002" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2146636003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2146636003" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2146636004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2146636004" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146636012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146636012" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2146636013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2146636013" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation_2146636014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation_2146636014" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_2146636015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_2146636015" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback_2146636016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback_2146636016" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2146636017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2146636017" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2146636018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2146636018" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146636019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146636019" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635608" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2146635614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635608" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2146635614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635575" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2146635577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_NetIncomeLoss_2146635577" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2146635578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2146635578" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_2146635579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_DilutiveSecurities_2146635579" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2146635580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2146635580" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_2146635583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_EarningsPerShareBasic_2146635583" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635584" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_818" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsTable" xlink:label="loc_sclx_SubsequentEventsDetailsTable_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_818" xlink:to="loc_sclx_SubsequentEventsDetailsTable_819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_820" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146634684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_820" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146634684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146634684" xlink:to="loc_us-gaap_SubsequentEventMember_822" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_dei_LegalEntityAxis_2146635150" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635150" xlink:to="loc_dei_EntityDomain_2146635151" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_VickersVantageMember_2146635152" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_SorrentoMember_2146636600" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146635413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146635413" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146635414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146635413" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146635414" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146635416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146635414" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146635416" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635419" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635419" xlink:to="loc_sclx_SorrentoMember_2146635420" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146635421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146635421" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146635421" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" xlink:to="loc_sclx_SorrentoMember_2146635423" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635424" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635424" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635425" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146635482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146635482" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635427" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635427" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635428" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146635429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635428" xlink:to="loc_sclx_AardvarkMember_2146635429" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_srt_RangeAxis_2146635501" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146635501" xlink:to="loc_srt_RangeMember_2146635503" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MaximumMember_2146635504" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MinimumMember_2146636323" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146636324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146636324" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146636325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146636324" xlink:to="loc_us-gaap_ClassOfStockDomain_2146636325" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2146636326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146636325" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2146636326" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636330" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636330" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636331" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636331" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636332" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_AgreementAxis_2146636593" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146636593" xlink:to="loc_sclx_AgreementDomain_2146636594" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:label="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2146636601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2146636601" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2146636602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2146636601" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2146636602" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember_2146636603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccountsPayableMember_2146636603" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2146636604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2146636604" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_InvesteeAxis_2146636610" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeAxis_2146636610" xlink:to="loc_sclx_InvesteeDomain_2146636611" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_YorkvilleMember" xlink:label="loc_sclx_YorkvilleMember_2146636612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146636611" xlink:to="loc_sclx_YorkvilleMember_2146636612" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsLineItems" xlink:label="loc_sclx_SubsequentEventsDetailsLineItems_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_SubsequentEventsDetailsLineItems_821" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability" xlink:label="loc_us-gaap_LeaseDepositLiability_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LeaseDepositLiability_823" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockNoParValue_824" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_825" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesLimits" xlink:label="loc_sclx_NumberOfSharesLimits_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfSharesLimits_826" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorLoan" xlink:label="loc_sclx_SponsorLoan_2146635252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SponsorLoan_2146635252" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantExercisePrice" xlink:label="loc_sclx_WarrantExercisePrice_2146635254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_WarrantExercisePrice_2146635254" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdditionalPrincipalAmount" xlink:label="loc_sclx_AdditionalPrincipalAmount_2146635256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AdditionalPrincipalAmount_2146635256" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromissoryNote" xlink:label="loc_sclx_ConvertiblePromissoryNote_2146635257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_ConvertiblePromissoryNote_2146635257" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:label="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146635436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_RestrictedCash_2146635436" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesThresholdLimit" xlink:label="loc_sclx_SalesThresholdLimit_2146635461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SalesThresholdLimit_2146635461" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146635440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146635440" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:label="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636329" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2146636592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2146636592" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_2146636606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_2146636606" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:label="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:label="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:label="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g374624g1126224419389.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g1126224419389.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +@# 2(  A$! Q$!_\0
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M/SKNO%-W!8^%=5GN)%2-;609)[E2 /KFE#X/O'B4WB%;^[^2.;^#W_)-=/\
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M?[.G]CBZ^R&Z_P!O'/ZUZ!7C_P!H\,GX<'1CJ<7]H$?:2V#GS^O7_P =KO?
M^N?V[X8MII&S<0CR9O7<._XC!H G\4^(H_#>E"Z:(S32.(H8A_$QK"%U\0&A
M%R+/3U!&[R"WS8]/K6OXP\/#Q%ID4$=PMO=0RB6!VZ;AVK$6_P#B!IJA9],M
M=05>-\3X8_Y^E &WX4\3CQ#;W"36YMKZT?RYX3V/J/R--URZ\40Z@%T>QMI[
M7RP2\CX.[G(_E4'A/Q%9:S=WL7]G?8-4C(-S$R@,WOGOSZUU5 'G4'BGQA<Z
MS<Z3'IMD;RV0/(N_@ XQS^(KJ_#\^O3_ &C^V[2"WQM\KRGSGKG/Z5S^B_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g374624g1126225135828.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g1126225135828.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"7X:?#S1/%
MGAV>^U+[3YR7+1#RI=HP #TQ[U?\8>%;?X:VMEKOAO4;RWG^U)$\$DNY9@<G
M&._3]:H_#/PC>:_X<GNK?Q#J&G*MRR&*V?"D@ Y^O/Z5W%C\+;8:I;WVL:Q?
MZL;=@T4=R^5!]2.]<L(7@K+YGN5ZZA7ESU+K^6WX=COHF+Q(Y7!902/2O-_B
M1+)XCUS1_!%I(5^UO]IO77DI$N<?R)_ 5Z+<W$5G;2W,[A(8D+NQ[*!DUXIX
M9E\8ZKKNI^,M(TRSG6_=HHFNG(*1J< */P _"M:C^SW.#!PU=7:VU^_3_,ZS
MX4:I-'87_A>_)^VZ-.T0!ZF(DX/T!S^!%>BUX;=W7B/PM\0+#Q5KUC;6D%ZP
MM+DVK$JPQC+>_ /_  &O<00RA@001D$=Z=)Z6["QE.TU46TM=._4\Q^&O_([
M^.?^OT?^A/7?Z]_R+NI_]>DO_H!KS[X>R):_$7QK93,$N)+D2(AZLN6.1_WT
M/SKNO%-W!8^%=5GN)%2-;609)[E2 /KFE#X/O'B4WB%;^[^2.;^#W_)-=/\
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M?[.G]CBZ^R&Z_P!O'/ZUZ!7C_P!H\,GX<'1CJ<7]H$?:2V#GS^O7_P =KO?
M^N?V[X8MII&S<0CR9O7<._XC!H G\4^(H_#>E"Z:(S32.(H8A_$QK"%U\0&A
M%R+/3U!&[R"WS8]/K6OXP\/#Q%ID4$=PMO=0RB6!VZ;AVK$6_P#B!IJA9],M
M=05>-\3X8_Y^E &WX4\3CQ#;W"36YMKZT?RYX3V/J/R--URZ\40Z@%T>QMI[
M7RP2\CX.[G(_E4'A/Q%9:S=WL7]G?8-4C(-S$R@,WOGOSZUU5 'G4'BGQA<Z
MS<Z3'IMD;RV0/(N_@ XQS^(KJ_#\^O3_ &C^V[2"WQM\KRGSGKG/Z5S^B_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g374624g24p49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g24p49.jpg
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M ?_$ .(  0 " @,! 0$!           '" 8*! 4) P$+ @$! 0 # 0 # 0$
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MB.\0D@10
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MJ98H2JXQ&ZL!S8VM:8HQ-;592BB\W</OLI9==:65SI5:X13_ $_W
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M5QN&)"),^71.PPIZ2QI_<G8N3JW9JN)56$G4M6EJ2*)2;D17]I-B0-0$DA.
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M(F.4[LH:X<YNJICCK@FH9>E,JD3D7WT+_M-]=NUK/]EG)5<MZ,\9D'&8X]=
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MY\^)J)E+W?CV^?R&2R=ZM+MI2VYTE"E.12G_  I2:Z\ZXUDH*KG>K^D%VE?
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MN7<,1>A,CG->AA-*$'\+4^ZE:E[W=K8FD3&=*6U66$4
M5K^J_P#$I^<(99='0F33TI,Q5]&'3QD9D^UZ<B3RZ([Q"2!%
M                      !_@PLLTN\HVRPPHRRXLPLRVV\LPN^E;;[+[+J5
MMOLOMKN5I7V*T =8SL#%'D]Z-@96EC2&&W'F)6=N1MB>\^_V+SKR$1)!5QM]
M*>S=6F[4!VP
M      *U_5?^)3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$GET1WB$D"*
M
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M<^B<5\EC_=8_:/5_E]SX^'X3^<72E]XS#'E$B_*0?8G7/HG%?)8_W3[1ZO\
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M7K;ZGQ'S9_.AI'^\KA#REQ/E0/Y_@?+;KQ\/PGX"[=?<O6WU/B/FS^=#2/\
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MB7];NI;QG._[!(.\O=O["]6?1</?ES1VL]I.,\]/0I>/;O/
M   />SU"'\9\[^+!C_>L@<_?J!]2]7_2L?\ #;/]U_K#BO,X?C-HH<KMT@
M_GX>LH_KRU3^-R0_^7',':_VFXWST]Z'Z2OTL?\ 7?LA_9=S_P#DH^/-M_
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M\M4_C<D/_EQS!VO]IN-\]/>A^DK]+'_7?LA_9=STJ/CS;?P
M  #8E_Y=K^-FHCQ61K][:#:ONJ]8<7YG#\9]97_IM[!=F?[OO_\ CMLH;N?3
M8                     *U_5?^)3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$G
MET1WB$D"*                          #19]8E_6[J6\9SO\ L$@[R]V_
ML+U9]%P]^7-':SVDXSST]"EX]N\\                ][/4(?QGSOXL&/\
M>L@<_?J!]2]7_2L?\-L_W7^L>*\SA^,VBARNW2  #^?AZRC^O+5/XW)#_P"7
M',':_P!IN-\]/>A^DK]+'_7?LA_9=STJ/CS;?P               #8E_P"7
M:_C9J(\5D:_>V@VK[JO6'%^9P_&?65_Z;>P79G^[[_\ X[;*&[GTV
M              "M?U7_ (E/SA#++HZ$R:>E)F*OHPZ>,C,GVO3D2>71'>(2
M0(H @QKSLU2#+CWB6-0J;2.L55EMLQR$TFP0R Q%Y,8"Y%8RO=RB<)IM1PO2
MJ"":=SLB@GNLZA53*5*45)(Z!KU00=^0LSO'X[.GQEEKLG:<?O3>TL]R#(-I
MTJI$KG>,VGR A<3'RUN^5V+7(EO(6-5EZ])50CLO.MM"JR0B@
M         #18]8E_6]J6_7X3G;]@C_U#O+W;^PO5GT7#WY<T=K/:3C//3T*8
M#V[SP               #WL]0A_&?/'BP8OWK('/WZ@?4O5_TK'_  VS_=?Z
MQXKS.'XS:*'*[=(  /Y^/K*/Z\M4_P"CV,N2#V-S]/L)OU[OZ1S!VO\ :;C?
M/3WH?I*_2Q_UW[(?V7<]*CP\VW\                V)?\ EVOXV:B/%9&O
MWMH-J^ZKUAQ?F</QGUE?^FWL%V9_N^__ ..VRANY]-@
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MZ:UK417V 5K^J_\ $I^<(99='0F33TI,Q5]&'3QD9D^UZ<B3RZ([Q"2!%
M                       !HL^L2_K=U+>,YW_8)!WE[M_87JSZ+A[\N:.U
MGM)QGGIZ%+Q[=YX               ![V>H0_C/G?Q8,?[UD#G[]0/J7J_Z5
MC_AMG^Z_UCQ7F</QFT4.5VZ0  ?S\/64?UY:I_&Y(?\ <G',':_VFXWST]Z'
MZ2OTL?\ 7?LA_9=STJ/CS;?P               #8E_Y=K^-FHCQ61K][*4_
MW#:ONJ]8<7YG#\9]97_IM[!=F?[OO_\ CMLH;N?38
M  *U_5?^)3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$GET1WB$D"*
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MV[W&]Q;GAN&Q[J<>&M9W>+'QN[Q3AMLG%@PS<KC_ )?[6SWXZ==N9W_=</\
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M?W#,.;[&"0EQT\O&K)<H/,9D[S10564$TM*H4H4IK2:VW^SOJ5K6OZ-P<_\
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MP8_WK('/WZ@?4O5_TK'_  VS_=?ZQXKS.'XS:*'*[=(
M                            K7]5_P")3\X0RRZ.A,FGI29BKZ,.GC(S
M)]KTY$GET1WB$D"*                          #19]8E_6[J6\9SO^P2
M#O+W;^PO5GT7#WY<T=K/:3C//3T*7CV[SP               #WL]0A_&?._
MBP8_WK('/WZ@?4O5_P!*Q_PVS_=?ZQXKS.'XS:*'*[=(
M                             K7]5_XE/SA#++HZ$R:>E)F*OHPZ>,C,
MGVO3D2>71'>(20(H                          -%GUB7];NI;QG._P"P
M2#O+W;^PO5GT7#WY<T=K/:3C//3T*7CV[SP               #WL]0A_&?.
M_BP8_P!ZR!S]^H'U+U?]*Q_PVS_=?ZQXKS.'XS:*'*[=(
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MK80E2E6DD%4NONO,OWA=M*;MU:W5K[-:UK6M0'.
M:+/K$OZW=2WC.=_V"0=Y>[?V%ZL^BX>_+FCM9[2<9YZ>A2\>W>>
M       >]GJ$/XSYW\6#'^]9 Y^_4#ZEZO\ I6/^&V?[K_6/%>9P_&;10Y7;
MI                                             %:_JO_ !*?G"&6
M71T)DT]*3,5?1AT\9&9/M>G(D\NB.\0D@10
M :+/K$OZW=2WC.=_V"0=Y>[?V%ZL^BX>_+FCM9[2<9YZ>A2\>W>>
M        >]GJ$/XSYW\6#'^]9 Y^_4#ZEZO^E8_X;9_NO]8\5YG#\9M%#E=N
MD                                             5K^J_\2GYPAEET
M="9-/2DS%7T8=/&1F3[7IR)/+HCO$)($4                          &
MBSZQ+^MW4MXSG?\ 8)!WE[M_87JSZ+A[\N:.UGM)QGGIZ%+Q[=YX
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M4O5_TK'_  VS_=?ZQXKS.'XS:*'*[=(
M                K7]5_P")3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$GET1WB
M$D"*                          #19]8E_6[J6\9SO^P2#O+W;^PO5GT7
M#WY<T=K/:3C//3T*7CV[SP               #WL]0A_&?._BP8_WK('/WZ@
M?4O5_P!*Q_PVS_=?ZQXKS.'XS:*'*[=(
M                 K7]5_XE/SA#++HZ$R:>E)F*OHPZ>,C,GVO3D2>71'>(
M20(H                          -%GUB7];NI;QG._P"P2#O+W;^PO5GT
M7#WY<T=K/:3C//3T*7CV[SP               #WL]0A_&?._BP8_P!ZR!S]
M^H'U+U?]*Q_PVS_=?ZQXKS.'XS:*'*[=(
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MZL^BX>_+FCM9[2<9YZ>A3 >W>>                >]GJ$/XSYW\6#'^]9
MY^_4#ZEZO^E8_P"&V?[K_6/%>9P_&;10Y7;I
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ME ;6+/)2#J>QGWGM?QKY0&UBSR4@ZGL9]Y[7\:^4!M8L\E(.I[&?>>U_&OE
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M7];NI;QG._[!&.\O=O["]6?1</?ES1VL]I.,\]/0I>/;O/
M  />SU"'\9\[^+!C_>L@<_?J!]2]7_2L?\-L_P!U_K'BO,X?C-HH<KMT@
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M=J&VEZVXP\JRB2RZSA;;U5;KJ43VW%>VI6_<IO?9_0 Y0
M
M             "M?U7_B4_.$,LNCH3)IZ4F8J^C#IXR,R?:].1)Y=$=XAW\Q
MD#K&&,]V9H1*<AKRCTQ5D8ARJ&(WU38>;0LQ00?/9="(W0E'97?F4,<"S*V4
MKP=M]VY;6*I?J>CQ;O;AW*3/CJ'.,BBN=M/3YD)C>E""S-;+\YRV-,D?CL:D
M\;521M:'2.+9/8K7MQ:LUL>6ZQ<F*/H6N,5&$I;5 D:,E%6#"SO=0^W-BOUH
M.:FV67TMK1Y-C=LWSLTNC>JKN=T'1M-IA9VPQ+896XCYJ1-YMN[0I/=2T[R1
M;%]7T5PA7B9?A+'#W&(=DZ>I)C V&42VE+J63?*[^[R3)),XR'+%S%:[-JMQ
M51MRG#BUD55G-9;,@:RE!Z9_H879FO[.[NY#D>I$+?%<DC#2]K"4I1S@4>98
M8@,--;W!(6K4$('IMN46V*+6Q^0E%K4UAF[?80HMMNK=6E;JXLG8/C>Y.2+N
M9J?E<=5<,69\X(D38O.X.RE^_(X!V1K4F\-W:;MV\WU-SV*T]D(&'<T)OVLR
M'9F"='!:QFC7\*4O.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?
MM9D.S,$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]
MK,AV9@G1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M
M9D.S,$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K
M,AV9@G1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9
MD.S,$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,
MAV9@G1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D
M.S,$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,A
MV9@G1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D.
MS,$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,AV
M9@G1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D.S
M,$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,AV9
M@G1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D.S,
M$Z.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,AV9@
MG1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D.S,$
MZ.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,AV9@G
M1P*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D.S,$Z
M.!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,AV9@G1
MP*QFC64.:$W[69#LS!.C@5C-&LH<T)OVLR'9F"=' K&:-90YH3?M9D.S,$Z.
M!6,T:RAS0F_:S(=F8)T<"L9HUE#FA-^UF0[,P3HX%8S1K*'-";]K,AV9@G1P
M*QFC64.:$W[69#LS!.C@5C-&LH<T)OVM2'9F"=' K&:-91(:<LPH@DHX^]2:
M6266:IOL++O4&666VWGWEDV%DV7FW4K=6EEMMM*UW*4I017V 5K^J_\ $I^<
M(99='0F33TI,Q5]&'3QD9D^UZ<B3RZ([Q"2!%8Q9"887)SYL7$8Q9,U28A&I
MEUC U6R=0D2DFITR4]_M24=34R=.=>799<;6VRR^ZVE*4K6@#F%QF.%/ATG*
MC[(5)%)%4JB0EM2"Q\/2U+3%53'.UI%%YI%2D1-N\N,K;O2;*;FY;;N"D5KE
M?BZ,1MT(7I7*/,;BE=5Z5T=$RYI0*R')S0DH4Z)Q7DJ$YA:Q>D3MB:PHXREQ
MA=B<JVVM*%V4H'>
M                                            *U_5?^)3\X0RRZ.A
M,FGI29BKZ,.GC(S)]KTY$GET1WB$D"*
M
M    *U_5?^)3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$GET1WB$D"*
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M/SA#++HZ$R:>E)F*OHPZ>,C,GVO3D2>71'>(20(H
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M#U)G.]0X''%NRX]55310HOL4FFDEQ6"ZTXX_R_2'J:BL59721R:18+R@RL#
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MLBI;HE6%EDW&)UJ^Y/+.4M>H(B@
M  *U_5?^)3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$GET1WB$D"*
M
M                      *U_5?^)3\X0RRZ.A,FGI29BKZ,.GC(S)]KTY$G
MET1WB$D"*
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:_K(Y_?S&>3#N/K"_^C\U?_.#_=DY.@R/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g374624g24q49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g24q49.jpg
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M0.<6\=;1D8(#/8FT@^(-9)_''A)@%9$% 2%9(%3?V4A.4%!#\!.;F'\6<1*
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M.W2/J[FKR,9'6.G6^,ML3YXB[7AGBS)N\8KLI%)BHDY%)9G(*<ABB(D4 IN
M\,J9#WTM!& EJ'_#;4]1Q\1OR//!!T,[RC4/19G:QK(QUS7:EH_82F#\#GK+
MQJRE'UU0*U357I)%>%9*).GR:9T4G+IPZ</')T$E#J'20\0Y,"91$1 @!FN^
MQ;'!0$5JBJ,]<*H49^) R97N=W>ZW'=LL=SCIEV+$#X#.!,L<PS)TL=PL+_O
M%.7F[F6E6R?T"E(7D0;/44"?1+V\I0XCVCVB(Y3&)P>[T;^5*??T[_7ZRQ&(
M]WHW\J4^_IWVEB,3R5^+_P#"X=?$IT12-?4[9/\ +:[ZWOPW: D+&I.V"KRZ
M+N#?PDI$2L>60,JW<*)N4E&SM,#'0,F8O 2*F#*V3<P/E_Q_]IJIN5*FH?/;
M=E.GFNX#K\&/EKB>&?PM^M9S\)Z\SWPZ.NVN/*=KU+9$R-(WU%R,^RJU:L<\
MY4._CKLD#U)JSK\NN@FY;/$@ Z!%C'5*=,14)])[W]L<WV"JCG.5N]KYE8>J
M],]M\ ;DU^5T_,AU'4:&>![;]P\3WRRWB+FOG\-BEE38#J,DJVGS(V258:>&
MF,3]D\6RK4[&L)F%DUI:(E&C=_&RD9:)9]'R#%TD59L\9O&TJJW=-G")P.10
MAA*8H@("(9\_/5Q._P"[L;^5*??T[[2Q&!\8]WHW\J4^_IWVEB,1[O1OY4I]
M_3OM+$8CW>C?RI3[^G?:6(Q'N]&_E2GW].^TL1B/=Z-_*E/OZ=]I8C$>[T;^
M5*??T[[2Q&(]WHW\J4^_IWVEB,1[O1OY4I]_3OM+$8CW>C?RI3[^G?:6(Q'N
M]&_E2GW].^TL1B/=Z-_*E/OZ=]I8C$>[T;^5*??T[[2Q&(]WHW\J4^_IWVEB
M,1[O1OY4I]_3OM+$8CW>C?RI3[^G?:6(Q'N]&_E2GW].^TL1B/=Z-_*E/OZ=
M]I8C$>[T;^5*??T[[2Q&)7W?CORI3[^G?P?M'\&(VB/=Z-'_ 'I3[^G?:.(P
M)3W>C?RI3[^G?:6(Q'N]&_E2GW].^TL1B/=Z-_*E/OZ=]I8C$>[T;^5*??T[
M[2Q&(]WHW\J4^_IWVEB,1[NQOY4I]_3OM+$8CW=C?RI3[^G?:6(P/C'N]&_E
M2GW].^TL1B/=Z-_*E/OZ=]I8C$YF\*Q:K$<)"_%1,1$O?2\NY3[2B4>9!R^6
M1/V"/I*/ > ^D,1C$NV),8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2/-J&V86C38:A:5)[?CIMTX5"\
M.GS2M\%'*1'IWRL<U>.A,FR%04B]V8IE *!OH\<JM%C;53&PMAL]=N#G U!.
M<==,9.O26U&L$M9G(4[<?O>&?''X:].G6:Y]-&G=BZ^M5NLVP*Y!Q,G:F2!Y
M!W5]A*2E?<2)'!E5 84)AK^F04&)^\,8SHIUW"G8!Q'^UFY7J3AGC5%@N\$
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MNNUROD3.U.Y0?,3GSF=1B)%6Y[7/437\K<H$$#GK3B-EI=%P@5<J]<;/VXV
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M$313=W41L35]]DJI'-(I\BP<P.QUC+,5#*I:1@6JZ^TW2?=&$5Y:,.@0K<W
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MGSS\9D35HU8MF[)DW0:,VB*39JU;)$0;MFZ) 310013*5-))),H%*4H   '
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MXEQ&L>'LGR2L)_E]_P#Q,&(U\93P]E];0?\ EY__ !/B3'A[+ZV@_P#+S_\
MB?$3F;HSA5B&=R$4LW 1[Q-O#.VRQ@Y1X<BZD\[(G]/AZ4S=G9^$$2[8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B)'VSI&=CZ?*!7JO-6Q]((+Q9V$!+1$)*-&S]LN@M*-9":608HJ
M, ,!RB(B8#<! !X#F3FU?4<=^,Q*UV5NI<$>@%<9U_'_ )S1Q7[-RWZ%JV5@
MI!(8AAZ=/ ^,T#Z'XFQL+I8&,X]J16->B)-&"CJG9:A**<DL[B4WRT_'U^Z6
M=T@[YX5,Q0[LB1%E5AYS"< #W&O'(XCWL%%C%!A0=BKONM 30X -I49/R*H&
M<$SRVJ-7,2K+E5#G+D%V.VFLE^F6P@+';JY8D+D">GN>=-D8B,1&(C$1B(Q$
M8B,1/%K>+-QT ]8D1U+P"9V73GU(RS.J[TAFJ1PC:K>'8B5K=BIE.9-LF_<C
MXI82E#@H+GAQ[PI0_<O8'7^8WV4_VMR3N^Y_:T-G$8XW65#K5YG ](SX!?+,
M_(_>5/V-]V)]Q4>G[?\ <7"<E1\J6GI;\,G4_'=YSV=:.F[YLV>LUDG+1XW1
M=-7*!RJ(N&SA,JR"R2A1$ITE4C@8I@$0$!XY^'NC(Y1QAU)!!Z@CJ)^MJRNH
M=3E2,@^8,\;.O[X6 ;CN;+J_Z-+BKTU=>5!,23KVQ*\/@ZUM!)H4I%JKLV&*
M12.DR2+ #MBNU4%2J)G[AVFL@;@GP1G7QG8; P>D['P\?BFEZ@K?,])_5C4"
M]._7+K=/RZTZZG1\KA=F#'@F@ZMFLEG@E3?M7YC OX)-14X)'YT3*I )BP#X
M'K!'B.D]D\ZG,8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)3$2N(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(F/VMN5W5K(U.R=21',#,(&CV*WAWC\JT>X
M3,S:+\2B@Z<@;D(?B'*<P#\F8?<UW^V\A-K/FEQM7J?2=!UU/0=9KX#;.=2X
M94(M0[FZ+AAJ?@.I^$T0Z58.A,-A)/:($ZIXG64>I:HY6O*P3"EVDQ81I)P$
MFX<5B =2$FZ5CA.1$YS@U.DL8B:950X_0\A]QYCHROQFY *.-%<,]UA"#R4N
M3DY(5E0GTX'C(BH>(A1TN6IU9#JR[5J12[:@DA0N0<,5+#.<ST/SS)NC$1B(
MQ$8B,1&(C$1B)%.[]/U#?>J[GJ:\M"NJ_<8AQ'+* 4!<1KSAWL;,,3B("F^B
MGR::Z8@( (DY3<2F, ^O[%[US?M[W:CWCV]MO)H<'X,.C*?,,,@_CGK/-]X]
MJXGO?MMWM?.7=Q[D*GX'P8?%3@CXCRGGW\.3;UNJSJ]]#>ZG1PVGTXK^4TY\
MZYB>^>IVZ@(5N3C%%AYWK2+8"@1(X=I&JB28\#)B&?H_\S?9>%RUX_W_ .Q+
M_P#J/=!NM _RN2=75@.A9LD^;!B-#/A?L#W7E<9[_LOW@_\ [/V["UD_YE'1
M&7S"C ^ P#J#/5K/R&?ID\W_ (A7PUM/=>=0BI"06=:SZA=<J&F-*=0-0.M&
M76BV%N=)TR1=NF*K92<KBCYLD=1JN)A1,7O&YDE!,)ADJ=I^$T$Z5?B3;^Z>
MME%Z"/B;(0-+ZB3M"H=/W458#J1VH>H:*25)'1ZLU/QC4&T9955@3(L=,@<Z
MRI2+$26, '@'&ADD9&5GM/I>[;+OC:<EKC%42+B(VRWFH-"U:4GY!\XE:-=I
MBG/':WFD8R;$C7YX-5=+D,94"G(!@X\<Z8 '3.,3G,G3(B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)XUSW4%*Q.]][1
MMLV^-.=:F?-RZPZ<F:5"3G=ZU?\ E1$79>RQB$Y%.;W/NI6TNI*+:^2NT&[5
M2*,58ISB< \8<D4^SW>Y ?4<U6Y >K4=A:FQ66VC=ZZ@O(-C;D*6[ -U;&?;
MOQJ[?<^)[>;%X_&NKXY[IQAWMM='&3IBO"H4&'!RY)1T$@X/B';4DBK,:C4]
M,W-VE3I6_K66LWN=F:0A&Q6NWFP'U+/*L(IRK[^Q:;'PKI#@4B(KIG-R\>4=
M7,4<*KD7V^JCB"PNR]+EJ>E"]!.A1N[H3IIU/A3PZSS5XX3"<CEVTHJ-\]#7
M&T!>0O56';^7 .X,,#$N]N^(!L2F+P$/9(;2=2EYQ.U2Z,I;[_,0E6/%Q6N*
MWLB"@6;QW'H+O+?+M9M1EW)0$AET@,GSAQ#.N0GTW*OXI#66\4W*Z(,O=91?
M72RT+U.[N!E!]6A!ZB9O;KE]PX*\S K6T\,J6/HK3ET\BT&UN@V=@+H<%G S
M+/(_$LLR]ML=1K5&J[F91UX-IAHB;FY&)EH&RMK1J>M/Z[>8P"*S#)!%;9X\
M'"30B9SL3 D*H"(EN;A6_46<:ID<I[CQN.K@Y1DY'*?C%],X9=@?:<$@G0#!
M-!YM=?M]7N-R%4;AV6LGY@R\.SEJ!G&585E<X\5.<Y S<W6GL6C;/7H5WC:G
M*\VQKA4GZ,7847UB&6@ZG2I6)@*!3F<;%6N3A)1Y,/ \P<H/0:JD(5PJ0AP%
M/S^/R*K^/8]89F2CD6(--[FKD<U#OQZ:U5..I4D .N\ LZ'=I;N)RNS;VTS?
MQT8DX1%LX_$<E-P#.2_(]0!)4X.-KJ!AQ/B';7FY5A6Z=4]/VJ3FHF,LB4W#
M7>>DZI6D9"F;$M;R@6QY'QKEPTV;74Z$3QS$O8DA)(*& O, &MO(XO$MYEF6
MIXJ7N[+C;:M%5%Q-!.ATN*$GTA@NNI W4<<7E54J+K;4K5#\]3/R5H!N'50V
MXLGBQKM7&%R=NB;RG+YHB^7BM6S7.O)U'5U6M,'+3UB:.65#E;E1V5D:+[$2
M?II,H-HT</RF0.XXI*M>58X<O$N7>\\5N!9;16^>U[@:2P*C<J/3N16;*K<Z
MN5 ((4M6<'=B>9[-RU]RX]/** =[@+>%U)4N+@&91@M4I0$D$,VVT @KF:8Z
MZZA^HS;-DHU9U'=+9:'$&P2/=)::'2DW49:0A=EP<5<7TC;JG5H>-M-71JZ[
MQ&.<5DK(YWB?(I^=3.&;:N.A=>;8A'MQ-)((96[1[X?"YW"]S6.V<]H@K8%V
M-.+F=>$]-9#>Y;KU5E*E#8*:GHP<8[(>Q3:".ZJ[DW;AF;+[QZB)VC[$Z9R*
MW-GJ:)O&V+%3+-K>_P#N0RGKI$(ZSV1*Q<HUDG$[(N6$4>UPL81$6H)+*.%"
M)'.'>=T;S.'NMYEE(Q;8WMM]B5#YEN0U]L$+JS-E@%S@X.-QZ;^2*ZO;KKVQ
M6*N5QU[AQM='Y%26;<X "ULS,Q&0-?2!F:B&ZPY^+I%\LMUZL$J]%FU[!33^
M<;-M,1RVJ-W3-[L5:A=*-74[6%8..&;9,DU%T;$5X_;(,UG(KI)* 8G+Z<5%
MH9#R&LX@H9F&WDO=QK;>0C$879QV1&8U[&57V,Q82NHEN3NY"[*0O,-Z@'-%
M=%_&KHL"D%]UZV6JI?<KN 47 (FW-QZI;5J/2>A[_.EJ^TC;&B6M6DK52)9O
M(P4GM">@T5J(2%=5WQT2^@;58$%V2KEL<R2:JB0I@)##R[N70W^_?[50A1K5
M/:5@RYL5JRZG=JJ]@WW*6/2H*3EIGX=J?[.?<N0Z,M3@V$;=*CW%#>G0N+>Q
M6P&GK=NBXF3]/O5239MIV#1K^\U_6+E5KDA68:#K-O;V1*5(Z1G'+1%&;;+J
MQ;V>49P*RRT:0Q)!D!#=^@0@I**545U\G@5<SCMO9VL! Z#8E3G;^^%6T$NN
M4*LIR#E18[/5RGX_(4(JJIZ@G+.U?J_<)==JHP#$A@-V"1JYM+</58R4ZIK7
M6;3+1NO-7V>[UEH]D(^A%CXDL=%4!>LIT_P42%H=2Z4A,N_'*RBKA R1P A0
M,!1ROA;/IO;;N7__ &^?4GQ8?[W9Q&7 P!6>,FPY&_>"P;69O<+K WNM?$QO
MXG$M92 -J8]G3E G=J;!R'#K@[ N 0<3N,_B1NY*Q[ K+&.UVFW@;C6JY%7J
M6L[B(I58CK!=+-3E)?:"RZBLI54HYU7!3-XE)J)W2Z:8% ABG-QQ >5[;QN=
ME4[[#4GT$-Q#RE"G]]U 54)W L-P#96:KK$IY_(X84L**6;^]N3DU\9LC'R*
M7-C,/2:T9E)7#3"-E?$#VC*5OJ'@ZDSU]77>O-86V8A;Y#; K[QV66@:Y!S3
M.]14#)O%9:6UI/+2AB,Y C!1+N>14QA*8>&FFI393;9^G5_N'$4K9IA&]PHX
M]E5^,FMFK=F8G;A=-&99U8ZU6CC@)8&XM[;E.FX<3DW(]>3Z]CU*I&IR2?E5
MIEIOB+6U SM@$9IV35KZ+YXG/Q]]>JUS= ,[%"0 UK0KTC,PW&X-O-A,[;EY
MRHJBB4.(*<2N+7]7RE3:Z@V5)LQ^J>[;=7WD4]:%%.[?GHPZ=3342.*A=ZMS
M*Y-C'%:&NBBW9:P^6US<5"Z?PK" =N)ZRMG*B[=NX$BR(KH)+&15#\XB*A0.
M*2H</HG)Q$#?A#*[%"6,@((!(R.AP>O[9;2W=J6TKM+*#@]1D9P?PEW64.$4
MQ'F-_P",DOE#CP%&-X< X>C@/R9'Y!^)_P"$Y4#OOH/E7^UI;>\.!N/.?B #
MVF,/$! .4  ./S?BSF78'E F./:43</2( 8P@'S\>WL#YL1@>4%.8>T3CPXC
MQ_."7T (A\H< XAB,#RCG/S  &. <.SCQ$?1V\1#T_@Q&!Y0!S@;ASFX\/RA
M#AV!V^GMX<<1@>4"<_'CS& 1XB/TAX=H\/E'LQ&!Y2O,<!XB<2\>T"\3"'R<
M./$1X .(P/*4%101'Z1A >P  QA[?DY>W@'^C$8'E*<YPX?2.':(#](>STAP
M'Y>/X,1@>4KS*=GTS]O]D1,8.P/1^ ./8/\ 5B,#RE>8W ?SAA_K,;L[!X\.
MT.(^CY,1@>4SN@B?QS\!$P@#4H=HB/:"Q?G'CE]'4_A/+]UTK3'[QDIYIGB2
M/]EPMNFZT"-(F$(>P,9B$F&XNW#UHPE$8F3;/G4)(NXXQ7K=A*MT3(JBGQXE
M-P,!BB8H\Y=+4M7!"ELJ>A#(R:_X"P<#IE!^(G"O6];$J6 PPZ@AE;3_ !!2
MA/4!B1K(SU?JJZ4RV!:+#=W]@>6.#DW%W06FYQW#/K2^ER/8X*U7Y%\YC:]"
M5N,$[1 &Q$SK)F 5>8P<<O0U4TMQD!9 M05FQN+*&[MC'P[A*^D>E0 !TE5G
M<NN7D'"G=9E1\H0[.V@\RF&)8C+%B?' V,RJ637O?&P)FKT78HQRDQ0E(.FO
MYJ,V?(DJ!JKYHDCQ:P;,)*P^9>=O%S DEWT=W(G'Z)CFY2FI=L .6"[;4&T]
M; 6&0O7]N<'K@>,U<:M3<BL-ZLK9Q^3 ;U-TT&,Z9'3)&N)'U=94;AKJE65&
M89S_ )Q6HAVXEV#EHZ;/'IV20/U"KL!%H*A7I5"G*3@!#@)> "'#/1]PJ2GF
M65UC%6\[?+:=5(\P1@@^(GF\2PV<=68Y?&#^(T(/Q!T(\#I,H<R2Z"QT20\J
MZ*3EX.&P1W<J<2%,($\1(H*_1$>4>) [0'AV<!S)+\_"</G#G]WIO^OA$>UN
M.),IYNY_=Z<_^D?]LOB(\X=?N].?BB/:^)&?A'G#K]WIS\41[7Q)CSAU^[TY
M^*(]KXD9^$><.OW>G/Q0_M?$F>5WQ$=6W>$D:'UKZ2KDPRVOT^+A(6QLW18%
M&ZZN34!:?B97P,BNX>MHUD983$$A^1LLJ<O*9,!S]?\ Y9>]\'E)R/L+W\C_
M &;W,8K)_P GD?D9<]"QQY>H '()GYG]_>T\OCO1]Y>S _[I[><N /XM'YU;
M!U &3@YP,D#($W^TIO6M[WUA3]JTB,EGL!;HE"01 BD.H=@\X"E(Q3H?-$S%
M=1CY-1$_,4O,)>;AP$!S\W]^]EYGV[[O?[-SQCD4.5SX,/RL/@PP1/N?9_=>
M+[W[93[IPSFBY P\P?%3\5.0?PDI^<.OW>G/Q1'M?/(GI9^$T(^)/TB5[KJZ
M3MG:9DM<L9>_*5Z4E=.V.QLX4ZU(V0BQ63AIV*DRRH/(I90%#-ECIF JB*IB
MJ <G$,@_USI6VG/QGYC/A;]+OQZ^CN(V;/ZCI5"E:.ZNLW6K!IO=NSX^286"
MQT^7D8*Q6>C&A)R79U^23F8I5@NZ46;F>E3YC$4(1)3.5# Y_MG;E3H.D]:@
M^+EU]:.\ VZOOA(;\C&H*K(2UUZ?GY=N5IHDDHH)) Z588V-)JBJV*!N#EXV
M#G$0XAZ,ZR?$2-H\"),>M/\ J#/AN7U\UA+-?KYI*R.'BT<I";IU[+4[P<@V
M$Y7#:0F4596O18)G2,43NW;< ,7E-RF$"X!S(*,)Z;:RZIM#;JCR2>H-H:_V
M>Q4+Q!Q0=B:[M@$'LXD7)!VUZHV6*(\#$4 ARCV" #DSDY'63,$RX, &"OS8
ME$.(&#R<0$!^4!"7[0X8B5\X<_N_-_BB.W^K_%L1'G#K]WIS\41[7Q$Z0VE
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MV:X=2K2J[.9FDH%5W'%;NV,6C7Y"T2<E.,EG)3,F,/#Q:RCDZ8KB7E#D Y1
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MUJ]^J,:C,FA-A1L+$R+:.:FA/*F$/3&=+*VA5F/%VP3,P9=X0>\,9$YN!3<
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M:X[U--;%7'JK=#3E67.18>FT9UGF5)SDYE+H6/$2EU8@J15;;8H*]'5Q?8+
MVGI7 U,P23Z!7\##[>5H4E'2=MV;J8VJRVB]T6"DKRBU4U_$ZX\=)[/2CE+D
M^:)L8[S%9F)^Y=/>/'DY^8NKDA.<>53RDV<'G\_O7K5^GA++4:U5 T8K6'6G
M=D*2/"<<'D<?VY^'R:G2SE>W\95J[A#!GJ%CUY/5%>QE%A378#@$XF^=>J#J
MNP,)7V;!^9G!1$;#-#*H*"J9O%L463<YQ @ )C)H%$>'RY?S;[>;S+N98,66
MV,YTT!=BQ_K,R<!>-P.#3PDL4K34B Y&H10H/]4N_E,KZO>#Q$#?\!;MX 8
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MZ>D:T1JN[18G,T(NH;NAY.&:>=552Z)5M%G8J+@;MJVM6K6*-^']+$J0P!#
MK@8F>JQ+'L-1=N,+&"%@H8J-"?02I4L&[; G=7L;J9L/F.71B(Q$\)-I7;>\
M7U1WFOPVSV2<$\2MGADF=M,>L:IUXCI=@]C9B]T@E<46B[,PV9W[\LL#E8'$
M>Z02*!A**1?#077>WWUUL$Y!KOW6L<H+>_MXHK/6O%;+78F&W6*[ZALC[BS;
M7S>%:J;^-W./FL>EV0;SR<@G]0,%!1O2$'I(R,M'+#9/4JO1:W,46RN;5.T/
M8BM<D 97ZS7NM[E<A!1$U(35;G'VO:ZN_JL7'I/$'[!RBT2CE^8S9R[<$104
MW<BX5V#G!&3A'C\K],KED6L/^M\P[@R:^RQ*,]B=DJJN;5\M*[K*CQ1:AY:V
M<4]P-A;"[@&GH>T[!7[@ =4KL6YC^F4DNGWC:[3TYZ<GUI[86OJW9-H1]2W;
MM-VHS)9ZU6'E=F[ :P1DA'H.6T%%S-S5BX11R1,0ATW*J8&'N@5S5S.-QZO=
M:>-;8%X;<>_;L;(>ZK-=2/;@?Q2CW*X"BXBM %[VT.+RKKO;.5RUK/UZ/0=I
M7&RNVRDW%:R6(--3E&K8EJ_58S,:\ML-HZS2,EL:VP4;>;#?]=1FM-</JI8Y
MQ87QI9[(2-P;RTB,MX5L63>+I,6Y55>T3@0IA_M<1X4.W$OMY"!.0.=M QC]
M/Z7C.,#P!9F;\297O*^YI12[-Q?H@QR<_J?4\A&RWB0BH/P$VN 2^CCZ/F^0
M0#_[7#L$<S3T)7CQ$O9P](_C[>'X0$2\<1!>WAPXB81[>ST?-P]'I^7T8B?(
M^@/2 @''MX]O]7#B'#L]/9B)41#AV (=H</P#VB/ >/'L[,1*\! 0$?E#B/:
M A^,./ <1/D?G$!_L\?3\@]G'\?IQ$!V>D> _P!8_P!8" @ ]@!^'$1P[0'B
M/$0[> >D1+V@/-P$ #_MQ'X2G'L /D] B >G@(]H<?Z\1*CZ ](\.TIOH]@!
MV?)Q#B/$./S8B!-\O'@(=@=O]KC\W8 \?]'_ 'H@.WE[.'+Z1XB'$./^KT^G
M\.(ER5'_  IAZ!_OTEV?V@* (Q@!_7_KSK\@_$_\)2O\=_\ "O\ :TM@\1$/
ME^;Y.SYNWYO1G,NGUQ$.'#M]  /-V<![!X<> </3B)CEKF9>!AE9*#J,S=Y%
M)PT31KT ^K4;(N$UW*:3ATFZMT]7(,B3!(YEE .[*H8A!!,ISB!1Y)(=%QZ6
M;!/@HP3N/B1D 84$Y(TP"0P-K-GU 9 \6.1H/ =<Y8@8!US@'3O5^[2,=[=4
M-?N6S7DW!U<^N)>N0DF6.*%6+*PH-I^"B21+8C9P1C/.F[=4_.L/B% YE!X\
M<CAEG]J=E'>O7W&RI&&AM4U4&H#.,!K.ZJZ 9#9U!E?).SW- Y[5#>W5V.IZ
M5N+N5W,D9RPJ6IFU.FTC0B:HRG4;LAJ'53(;TD]Y:<C A-7S&MXUO$IT]&J3
M,U-[!K\?4*]<$RR#989P(J,<23Y0W<A_>%.*:)0*/)K)]FK%%JGW<^Y.@+'"
MDOQ.+8 P('Z''=K2<C)7&=S/B=M<J^\L;$8>SKP0QV@%L)R+D+@C_-O4*$&=
M"0N<+N/H7IC9*DMJ.!3):F&[=E5;7].D;=[DR$&FO89:=B!=,G3->7D(:#;#
M/ V551.X<MTSIASB)0,''TO=@J\FZ_B4L.*.0:PN@PP6MV'J(Z):CXSD*P&,
MZ3'[6SFBJGF6K]4U/<).3Z=]B Z Y]=;U[NA9&.FN-/IG=&S6O42#N>G+E1E
M8C9%9CW^GY)TP=P+'0"VGTK9;K[--X)28A7LI"WCQ3122:/7"*9FH(IG.!N(
MY_;?IU6][W%E(7E]UB"!4U9J'%";@".XK;LX];.Z_DGH<VHV]BN@.G)>OC]M
M1@FVVSD75VJV,@@5*K8)]&%8D%\3)MK+[ E;UN21UKNNT4BK5W42KQQ8;K9Y
M-KK=GL+8;J.-44HQ4D#)K04= PR)U5'#1-R=%5\3BF/* #G57XU-K<C&U?<*
M*@KDJS"N];.4JN,D;J_].GI."V03*K63E=L<0GNV<*^[<H#*@/'=..Q3<,XL
M/U#@C5:Q@ZD39GI6N<K>]21\M,M95%XSFY^%&0D+6^O+6PDBI S9*Q0%ME:]
M4Y*;KDH7Z399:.;'X%$O*(% QMW*K54HM4%>[0KE&4*Z$EAAP"==-P.=5920
M,X&3B.S/=4?5V[BNX'<C^E3E"0#M!.TCP8$9,V,$>T0'M[. "/9P$! >(@/9
MV!Q#,DVP',(B/'AQ#T=@B/$/D#L >S$3/*!_X]\''CP:% !_!WY?D_".7T=3
M/*]U_AI^)DJ9IGB3 MFVF.IU&L4U)2!(LH,3QS%T9@M+&&8EQ",AD$HELFJX
MDU7$FZ2(#<A3&5X\H!VYDYRVV\5^/Q__ ";494TSZBK'48.@ +-H0%!)$T\0
MUIR$NN'Z%;!GUQZ01G!R,$]!KU($T@Z/Y.]/M@V)L\O]KO\ 3F-6:E\PE)VP
M2U?8SJ@1A5Z_'L7U:@HZ%DZ^]1>(K)E.<PI"F4$D13,7/:<T/1?96":3<.TS
M'<UB%K6#AL^H&LUAL;LLI;<=PGEE;:[J*R1O%3=Q5&U5<"M=NW&%&X.R X(5
MMN--=[K5;V-;:.B)&8R5D\L?2$-4QFHF+EYX62"JYD6)9)R@ DX)#SJ<#%(
M"(\>'#/+ML*5NZ#<47)'D/WCUP!XG!/D"=)OKK#,H<[49MN<>/D.@)U&F1U&
M2)#D_OJ3B]#5[<S*DMGCZ>+6!/6'=DD&T=$EL,PUBG+J0L<14+ _\NA4W!EU
MEDHE0133'Z >G+N0!1R*J0P-=I7U'TA0U?<R>O\ A_;X3CBCZE+'.0U:VG P
MQ8UEAM&HU8KIY9\9,E%LZ=RJ,#:"*P*P3+!-X8]8FG5A@><PF*H6,FWL+7'<
MBV3.42@HJQ:G$0'BF40X99?6*;36-VW3&0 <$ @X!8:YTP3D2NM]Z[M.I&FO
M0D>(&NFHQH9>7$U&-%CMW#LB:R?+SD%-81#F(4Y>TJ9@[2F ?3E4G<)P>\<+
M^O$^?_A+_58DY$>\4+^O$_1+_58C<)7WBA?UXGZ)?ZK$C<L>\4+^O$_1+_58
MC<LI[QPOZ\3]$O\ 58DY$>\<+^O$_1+_ %6(R(]XH7]>)^B7^JQ&1'O%"_KQ
M/T2_U6)&Y9XW]4Q5^BSJBJ76UKA-=YJS9CUEKSJ>JS!%P""",@NF6)O0) D5
M%,Z"I.<%#<O*]3 AC"5V8 _</LZ^G[^^U+OL'W%@/>.(K7\"P]21\U/GKY:^
MDYQE!/R7[H2W[.^XZOO3@@GVODL*>:@Z 'Y+?V>?F,9PYQZ^0M[J5BB(R>A9
MMK(1$PQ;24<^;%640=LW:)%VZZ1RIB42*)' <_%.11=Q;WXW(4K?6Q5@>H(.
M")^K4WU7U+=2P:IU!!'0@]")=/>*%_7B?HE_JLJEN8]XH7]>)^B7^JQ&X2OO
M%"_KQ/T2_P!5B1N6/>*%_7B?HE_JL1N6/>*%_7B?HE_JL1N64]XX7]>)^B7^
MJQ)R!I'O%"_KQ/T2_P!5B-PE?>*%_7B?HE_JL2-PCWBA?UXGZ)?ZK$;ECWBA
M?UXGZ)?ZK$;ECWBA?UXGZ)?ZK$;EE/>*%_7B?HE_JL2<B5]XH7]>)^B7^JQ(
MW+*>\4+^O$_1+_58D[A'O%"_KQ/T2_R?_E8C<.LK[Q0OZ\3]$O\ 58D;EE/>
M.%_7B?HE_JL2<B/>.%_7B?HE_JL1D'25]XH7]>)^B7^JQ(W+*>\<+^O$_1+_
M %6).1*^\4+^O$_1+_58D;ECWBA?UXGZ)?ZK$;ECWBA?UXGZ)?ZK$;EGR-AA
M#!P,]3,';V"BN(=H" ]@I?,/#&8W"?)YZ!4)W:CI%1/L^@=!8Y.ST?1,B(=F
M1I)W 3[0DH-XL5NBHV666 I03\.;BH"("<A1$Z(%$$P*(AQ]'#LR0<'3KF,@
M^GPZ2]XDQB(Q$8B:*'WGI[^:4CJ0+S EV6T=IL9"M?GBR*+MQ!M;.TCW*YFY
M6H.UJ^_2=IHBKSF0/S%+PXYY_'7ZE7>@;JT+;O+*$*_X[20&QTR,Z$3Z^_\
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MH2EL=DUA>SV!XO&Q$6@Y.91Q(-7LA'>7BL5'PS9VH_BG"222AR'5.D8I ,/
M!IH4\K/TX+XKWZ?N[=^1YX3UD#)"^HZ:SOD8X>G).S#;=? [@H!^!=E4'IN.
M.LFSAVAV<>/XA$!XC\H=G#(B5XB/R@'$> @ "' 1$ ^0.S$0 "'#T<>4>/$0
M[/P^GY1Q$=H]OH 1X?((AS<?F#B " XB4[/1P$1[.(\0 ./S!V#Z<1/K@/#B
M(AV\0X&$>WAP$1]'  _UXB?/;V@'#M#Y/P<0X!Q[!X\<1*]G+\W9P^;B(#Q
M/G$<1*=O !#M#T<1'APXAVAP^?MQ$^B\.("<?H]G  _  !Z.'X\1' >''L'A
MP'E'@/T>(<.T.''MQ$IP#B'S]G#M^3L]/:;M .T/DX8B5-QX@'$O:/'B)N/
M0[1[0#AVB/S#Z,1.^L(C%,>T XO9'\''\S&B/: >GL_TYU^0?B?^$I7^._\
MA7^UI;O1P'L'T\0[!*/#L 0X&'B _P"C.9=*B4.WB(  !V"(#V^D.WT"41'Y
M.W$2SS]@@ZM%/)RQ2\=!0[!,IWDE*O$&3%N4YRD3[QPX.FF!U53%(0O]HYS
M!>(B #P]B5C+'J<#S)\@.I/P&LZ5&?Y1T&3Y >9/0 >).DU;D>L+5K6Q,XZ(
M@+A8X)1U3&5EV!$0\:WK536V'-N("EA-IS,I%61VE-R#43<S!B]*@@)%5A33
M.0PW<:IK[A2<5[[Q2A8XW7&I+A6 ,L&[=B$%@JY8+NW:3/=?736SJ2Y2AKG
M_+2CV5M9DX4KNJ<!5)8A&(4@9G%LOK*U?K*RV6%M-=N:M<I\ZSIMDO[*-@W5
M4C]@2%996^(I MUIU*S/9A_#23<4U48X[ CA<B)URJ")0JIW7JA4$&YK12#U
MN-+,EH3P&UD9<N4#%6VYQ.^5;7Q,FUEPB5M:0?X*VG%9?Q]0PV%W,%*L0 PE
MI8]6FN(&.L$^\U/LBJV(VT:%1;W FK]:<S,;+WR#K"E)L]BE(&RR,">OO:Y+
ML (L1\JLD!10%(JR9DPU4<=[KN/PJF3]:^^KJ=M=U2]RVMSCYR"K KN#*ZD$
MKTHOY5=/'MYUH;;7Q:KAH-ST66O56ZC.B]Q+ 5;:5(8D G7CN76Q3JA:M_UI
MUJ[:DDZT!46%EEY..K)%H^X)/P5Y8FH.P<BI*.DCIEYRE 1#B;Z/,02CYPO!
M]KL]S"G8E[U%#HQ*9&['[N0=>@&">NGH"H?[A1[?GUVU[]P&B^E&P?[Q#@!>
MI(QX@FY0_614IRXZ%I)-9[1;+]0%3?6>+?O:RDE&5%!H5$OEUW5,Y.$0^4%<
M2"F;B8! I> F-P#U3PC_ +CRO;=R%N-6'+?E<,I?"GQ; U&NOP&9Y=?/5O;.
M/[IM<+?:M87\RY8KD_W0=<Z974>4W(*!4B@FF0"$ "\$P H%#E#@  !>4"E*
M =@=G#,9U.3J9MP!*\/I<!^40^7T^CT\0X=GR\<28[!$> =G#Z/9_:'CPXB(
M#PX<?_7B)GM $/&OB\! 0:E$?F'\\3M_IZ,OHZG\)Y7NO\-/\1_LDIYIGB3"
M-A4>M;"K+BO6PTBC$%=Q\P+R)G92LR4>\A'B4FQD&DY#/8^0CU63EL4_.14G
M8';V96Y1"M[,4-9+!LXQE65LGR*,P.=,&=*"X-(7<+,#&,YPP9<#S#*I&-<B
M0CH&"T) 2$LSTYL"?M*IT'3U]&/MG72[Q*02$BJ]>2K5E/S$E%I.7\BX.H=R
MB7G5,<1YA 1XZE[OTVW;^@H11E0"H (51D948TP,#09Z"4.$^JWNQ^H;<3KU
M/I#$^!(P-3DB; 6*HP%I:N&\NQYE7#%U&EE&#AS$S[)H^2.BZ+%6&+5:3<0J
MHDH8.\;+I*!Q'@8!S,]:NI5LX; ."1D YP<8R/,'0C0C$T)8U9##'I.1D @'
MSP<C/3!^ F 1>BJ1"55K2XB1V/&U]BQ4C6;9IMS:"#INS5?)2 IHRA+:$H0Q
M5D@(4X+<Y$#&1*()'.0;;&-PQ8 1A!T\$#* ?,88A@=&PF[.Q<<5_I'*:'+'
M]K8R?QR,C]TEB,%FS(=5JL#2:]%U:LL"QD%#-@:Q[,JR[@4D^<ZIS*N'2JSE
MRLJJ<QSJ*'.HH<PF,(B(CDV6/:V]^N -    ,  #0    #IB<J@3.,Y)))))
M)+')))U))U),R'.)U&(C$1B(Q$8B,1&(C$3!-FZZJ^VZ!;=;72/3DJS<X-_!
M2S50I3#X=\@9(%T1, ]VZ:J&!5(X<!(H0# ("&;_ &KW/F>S>XT^Z<%BG+HL
M#J?B#T/P/0CQ$Q>X\#C>Z<&WV_F+NXUR%6'P(QI\1X'SGF-\/S85JTAL387P
M_=S2*BUCUH9>S:.L4@H<#775CY<YTV""RY^5T\A ,"J14P#\P95/E#PQA']6
M_F/[;Q/?_;.-_,?V-0.+RL5\I%Z5<@#4X T#?'QP<^N?G?V-S^3[/[AR/L7W
M9B;^-Z^,Q_S*#T&O4K\/#(_*9ZZ9^-3]1C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1/+8G0[*S>_-K[7O=CG9VF7+8
M-=O5>U,W9U?W1\PA=.5K5JDI:7+NJ'M[J2,$8[,1NWF"QQD3I"='O /QP<&E
MN)Q#2Z]RXV\E@3T1>0U9(4#&6(K&2X;!U3$^JY_.XG./'P^RNKB55L <%VJO
MY5PSU]('( PNTDAMV1B7:Y] U"MEJDK:R"]4=Y(:O?:O;1U'D(:'A89LY**#
M2U1<>YA7Y4[;%1ZRK-NLJ95KX-91(Z!RG'"56HMRZL+K*7.[U =ED;: =-EW
M;K6]2"+$15TQ*WY7#M[*%E I6X#;E<]Y6&XL,$-6;':I@04=F8=9&M>^&)3*
MLPDDX6Z;=9SSR2B9YC:&H:R9/(&PP6Q8?9\/*P\(QUTUJ:96-CA$2>%7CUVB
MK,3IJIG,85,U)=R:>UV,H:EV@_,2I7E5V!M^X'N5\R]&( V@@U[&4&4E^ ]-
MM%S*]5SNQ'3#,G&52-H&#6W%IL3KEP=^Y3MEZH'PW*1KJ^P6Q8V<O\]/1[]M
M-3A[9"ZDG36J>8S$G-L9IZ^7UDE)5Q\W>2I^'D*T2GRD3$I2G QS5\3=P?3Q
MT"TBLJHU].:>P3NSO.4Z@L5)SD%693US.11S\-R;MUV[);35>X+=FT@H 'S@
MA=X!^;*HR[VA6YSF#_"W(?)QX%^?T\>8?0'9E?;?REOUG&_?6/=R=#_Y:Y'C
MV]I"?/\ +Q'B/H[/1Z<=M_(Q]9QOWUCW;G/3Y:Z'B'#@ $ ?DX@/TNP/FQVW
M\C'UG&_?6?7NY.<.'ECDO OHY2\!,   "/ W'C_VX[;^1CZSC?OK/GW;G/5K
MGCPX\. < X?-Q-\W^O';?R,?6<;]]9]!6YSB'&-<?/\ V2CP'@/IYC#Z> 8[
M;^1CZSC?OB/=N;#A_ACG_P"Z3L[1_P!X! ?D#ACMOY&/K.-^^L^?=N<]6.?E
M](!VC\X<#=@\/GQVW\C'UG&_?65]W9[B(^6N1'M'CP*';Z.(<I@[<=M_(Q]9
MQOWUGR%:G/EC''RA_9#L[/3P WSX[;^1CZSC?OK*A6YS@(>6.>T!'CR% 0$.
MW@ \P>D<=M_(Q]9QOWUE1KD[P'C&.A'Y^!/2(]O#M$0#@(]N.V_D8^LXW[ZP
M-;F^P?+'/'@("'*7\ APX''@(CCMOY&/K.-^^L[RL!,#'-$BQ[D5".GZAR<I
M>8I5$F($$>)@+P.*9@#^K)[;[0,:Y/\ PE2\KC"YF+C:57^HM.@-;G!$!\K=
M<H=GH)QX!_I#([;^4M^LXO[X@:Y.^K77#MX#P*/H'_>#G_#CMOY&/K.-^^LQ
M.]:?BMF5A_3KW2VEGK4H9JJ\B)5J1=J9PP<I/H]V3B<%$'L>_;IKMUDS$517
M3*<A@,4!#A^.7*O@BQ&#*P.&5AG#*PU5ADX(UG2<_CKN7>O;=2K C(93U5@=
M"I\01@^,UM?]",.\L*$NG<=Q(1"I:<>R51W/P5BCKDYUS*O)F@NI^;M=;G;L
M*U;=/ 3 &\H@5VW;HI.05(G]*RM;ZW-GS/WN\A*KE.1V5I[XP!E]B(V&W)W$
M#[<E]U#W<%EVAP,TFAM2=W':QK#3ALA5W66 ,NUU2QE#:(4LMI^'M7[P_L1[
MC<]MV"#MTDQM5GK#M>@-XJ8V/%U-I38[9!G,=0F<RQL36)CFJ@-VSI&)%VT3
M7%F)A4!0M;JJA!M-)M:C'^0US;[2F<AMSL[8M%@4V/@8*A(NNX?(&+W#JZUK
M<, =Y:F)K%A !]((3<A1BB(I.A+<TMT%N9BES%6<;;W2G-V:]4V_6W8)6FH5
M+79'NO&$#&4J'<M'6KUZC'PD"RK3,I2,HQLNX.111950ZR@FM1[JN31R:E"F
MB^V[ &CW7C;98^=<E,5@*5545 !E=QX=^#9QK>+:^ZNSC5\<9ZI14[6K6I &
M?U'=RS[G)=AD*%5=R$:?+IH=VO&+O53M$6CMRY;,^]D2)I&3,+T&Z:""AE!4
M,(D*F5(!,8"E*7LRIT+EL( A).!G S^))^&I)TU)E]?+H15!MW.H W' )QXZ
M  9.N@ ST G,%5E@,BIY,ISH)F21,"28'13.!2G(D;_ED,4@!P+P > <?1D;
M+"22#D]9(Y?% "AUVCH/*<WNW.=G^&N1X^D3 ''T>CL4X@ B'R=N.V_D9/UG
M%_?$!79T!$/+7/:/;P*'*'9Z0^E\GX,=M_(Q]9QOWUGS[MSO'@,8YX<!#^R7
MT?Z# (\<=M_(Q]9QOWUF9TV*D&#QX=XU4;D.V I!.' #'[TIA]!C=O /]674
MHRDDSSO<;JK445L"0?\ A)#R^>3,0O9'ZM6EV[%O#N".FJS64"=>G81R,(Y2
M41EW2K@K1Z7G;,#G.4ITQ3,(<#" <1S'[@B6\*ZNTA:&IL#,3C [;8/0Z;L9
M/@N2,D '3PW>OE5V5 F];$*@>)WKI^.,D>9P-,Y&B711=K!+SLI47NW86_P=
M9J;%C#Q$<P("T<WCU6[)NL>8/I77+R4(1J!"]XK(OC*<0.("(\X^W:S\BF[E
M7J3R&L4EB-NIW[LKD8)8'/HT((].H/E )3?7QZ2HH", HU&FS&#@Z!6&,,,@
M@C(QCT<S!-D8B,1&(C$1B(Q$8B,1&(C$1B(Q$\MOB==/,U<J%7^I'52KN$W;
MT[*KV)A+0LO)UV5L%"+S.;)5SR\*]CI%(Z8%\0U4(J15$17(F<G?G$?U;^5W
MW#QN/S+OM+WOU_;WNH%;*0"$MZ5V#33KAL8SZ2?E$_.OY@^R\B_BU?<GM/I]
M[]M)L4C3?7U>L^!&F1GIZ@,;C,D^&_NW7._-;RUR@;E>9C8+:8LK>WU*X;2V
M?=CU"#D[A-O*2R2B;K:9R&(*5:;-D2/VR8NE"IF!98QSJ<_S?WI]E^[_ &9[
MD>)[BG^E=F[-@P5L53UTZ'!&0<'RR)[OVK]U>U_=7 '*X#_KH%[B'.48CH<]
M1H<$9S/27/C9]1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B0YOJ_Q^M]93E@E&L*Z8NG$56ER663)"UM).TR3
M:!4=6&54^@QA6J;\RCE3L'NRB " B Y1?57R=O"MV]N\LAW' QL=F&1KEE4J
MN-2Q $NIL?CD\M-V^D!QM&6SN4+CPP&8%B= H)/20'TJR.@;/(25BH$[7%=A
MLH]>O3U8@-DC<HZ.8Q"[.'//0K SY90L;8DXEJH+TR0'<@0G,83<1'U;'NLJ
M?D*6:J]@[D@95V>QMAQHHWFQU48!W;@,&8 M2W)QR%5J5*5X.C)MKU&=3M78
MA)R5V[<Z3=_,,TS&K;925*#=39H6PV$6PI$)$5>-\TF':BRA4BE;H'7:MDB%
M$W,HJNLB@D0!,<Y0#CE=E@K&YL[=<GH  "223@   _$G 4%B ;*ZS8VT$ _V
MGP QDDG_ -\#)G%2;A#W^J0=R@!=##V!BF_9 ]0%J\(F<3$,DZ;\Z@)+I*$$
MI@ Q@XAV"(=N:;JFHL-;8)P#D="" 0?#P,H1]XS@@@D$'J"I((TR-"/ XF59
M5.XQ$8B,1&(C$1B(Q$8B,1,(V4QI\I0+C%[!DH^'I,G7I2.M$K*R;6%CV$,^
M:J-7CIU*O546D>FDFMQ[U0P$*/#CV9IX?+NX'+JYO'TOJ=773(RIR,CQZ2CE
M<:KE\:SBW:TV(5;\",&>$?3Y\//5;UO9Y[I6ZQ[11MP05SV*U:>Z%[KD\@XI
M%<OTS7Z<]LM>@'2;N1@)F,9,W??KE4:._$D,0HE,01_:>1_.KD^\;>-]T^U<
M'F>V8&5*G<#CU,CL3M8^&,$><_*:/Y4<?VK/(^WO<.9Q?<,G#!@5(\%90 &
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M!*05!!9X[HJ#-'L+P#F4 #"( '$1 ,^5L_DW_,:M2S>W9 _=OX[']@%I)Z^
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MD9&".DO2<C'JE Z3]FJ3M#G3=(G)Q#TAS%.)>(97V[!H5.?P,M#*=01B=P!
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M'PZ>B)R0Q3=-VMTQ.("*B$:Y15X@;FX HF\ P (^D,]!?YF??J-O'NG*)^+
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M%.[&5R5W%E&58!5!&HV5IL5,P=5KT/8IM2R3L;$,F<M/+% BLL_00(FY?'*
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M=R=BKN;&=J *HT\@.O4G)))),U^W^V<#VJD\?V^I:J6=G(&<;F.2=<_@!T4
M*H"@ 9WF";HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1' !^3$2G /F#$2N(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1-?-VW.9B:?<D6JKJ@*QK=D,%=YRXTRF0$W(
M.3B)8R/G)/WE7CW("7@(.HL@*C] @\1XAFO=UK#H<7"P@)U+@*QR ,[@,9V;
ME9OAKC30J=W;8-U13)8=%)90 =0023C=AE74G. #F&D;%+VW4FO['/K.7$U+
M5J/=2;AXS*P7</!3$BS@S8@BF!%CDYB&+P*H00.  !@#/5]PKKJY;I4,5Z$#
MRR <8Z@^8.H.D\[BL[4CN$,X9AD$$'#$9!& 0<:$#!&LSYRXER+'*UC&CA .
M7NUE90S=0W$I1-S(A'N )RG$0#Z0\0#CV<> 8Y?DYQX3A\5/^IF'H]=*>R<2
M 6STTE?%3WJ=A]]*>R<1EO*/%3WJ=A]]*>R<1EO*/%3WJ=A]]*>R<1EO*4\5
M/>IV'WTI[)Q)R<=-97Q4]ZG8??2GLG$C)\H\5/>IV'WTI[)Q&3Y2GBI_U,P^
M^E/9.(RV.FL>*GO4[#[Z4]DXDY/E*^*GO4[#[Z4]DXD9;RE/%3WJ=A]]*>R<
M2<GRCQ4]ZG8??2GLG$9/E'BI[U,P^^E/9.(UCQ4]ZG8??2GLG$9/E'BI[U,P
M^^E/9.(UCQ4]ZG8??2GLG$9/E'BI[U.P^^E/9.)&3Y1XJ>]3L/OI3V3B3D^4
M>*GO4[#[Z4]DXC)\H\5/>IV'WTI[)Q&3Y1XJ>]3L/OI3V3B-?*5\5/>IV'WT
MI[)Q(RWE'BI[U.P^^E/9.(RWE*>*GO4S#[Z4]DXDY/E'BI[U,P^^E/9.(R?*
M/%3WJ=A]]*>R<1D^4>*GO4[#[Z4]DXC)\H\5/>IV'WTI[)Q&N<8TCQ4]ZG8?
M?2GLG$9/E*^*GO4[#[Z4]DXD9;RE/%3WJ9A]]*>R<2=8\5/>IF'WTI[)Q&3Y
M2OBI[U.P^^E/9.)&6\H\5/>IV'WTI[)Q&6\I3Q4]ZG8??2GLG$G)\IS-W$P=
M8A7,8S00'CWBJ<H==0@<IA#E1&-1 _$P ']L. #Q^3AB,GREUQ)C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$3C5226(9-9--5,W89-4A5"&^7Z1# )1[<1.0  .P.P [  /D#
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M(YVGM>E:9J;F\7]S/LZTR6*B\>5VD7B_.V@&17<&<NH:@5RSS;>/00;',LZ.
MW!LB4.*AR\0XT7<FGCX-S;5.=<': !DEFQM4 #JQ _;+J>/;?N%0!*@'&0"<
ML% 4$@L<L/2N6QDXP"1C^GNH'5.^6,C(:PGI:80B21BK]&;I-[HD@@WF682$
M0\")OU:K$JLPDV)@6;N$T3(K)B!BF$!#-CT6U;C8,%7*,-,JZ@$JR]58!AD$
M C,RI=6^W8<J]8L4CY61BRAE;Y64E6&03TDS95+)3^G^O$3&):Z5B#L-7J<K
M+(L[#=%)5.L1ATG1UI8\(R\QE014204;I>#9!WAN].0!#L#B/9G5:M:SK6,F
MNO>WP7<$S_W$#376=]M^R;\?HA@I/Q;.!^W$NDS+LH&+?3$CXSP,<@9PY\OC
M)*8>]T7@ ^'BX=H_DWRO$>PB"*AQ^0,Y&KJ@^9W5!Y9=@JY/11DC+,0JC+,0
MH)%;':C6'Y41F/B<*I8X U)P#A0"S' 4$D W3^GS8DQB):)Z=BJS"2]CG7A(
MZ%@HU[,2S]4BJB3*.CVZCMXZ4(@FJN=-!ND8P@0IC" =@"/9G+.J@%CH2!^T
MD #]I($LJJLOM6FH9L8X \S.2&F(VPQ$9.PSHCZ(F8]G*1CU,JA$W;!^@1RT
M<D(L1-8A5D%"F #%*8 'M ![,NMJLHM:FT8M4D$>1'42H$$9$N7]/_1Z<KDR
MS3]B@JM&FF+'+,86+*\C(\7\BX3:M@?3,DTAXEIWJ@@47$C*OD6Z)?2=54I0
M[1POJ=:UU=SA0.I."<#]@)_ 9G2H[AB@)"(SM@9PJ*6=C\%4%B?  F<A9IB:
M;5KX>-\R1CD94_-%RI8_P:[A9LGW<R9D$,L[[U W,V(X%P0G YB 0Q3#(!*E
MQT5L'\2,]#J1CQ&1G3.=(*D*&.,'/B/#&<CJ.HQG&?#H9QP]B@K :5+"2S&5
M-"2KJ"EP9."./+IACR^,C7?((]R\;=X7G(/TB\0XX"DHMOY&!P? @$@X_:,0
MZM6^QP0^U3@^3#*G\"-1.JG;ZXK;W=#3E$C6YC76%M=PH).070KLI)2,0PDS
M+"B#0R3F2B7"0%*H*@&2$1* " CRA[G<V:]HH'_NFP.4_P"X5OC'[ISC2'5J
MUJ=QA;NYL_O=GM=S_L[]6<]=XQG!QD>3.9;I>59P<5(S,AXOP,4R<R#P&$=(
MR[[PS-$ZZWA(J):OI22<]V0>1!NBJNJ;@4A#&$ $-65?%F"C\6( R>@&3J3@
M :D@ F=(C6,$7&X^9 '])( _:9WDE2K))+$ _(J0BA.\(=(_(<@'+SI*E(JF
M;@/:4P 8H]@@ Y)!!(/43@$$9'0S[_V?/_L].1)F,7"YUJ@P:ECMLH6(ADGL
M7'&>&:O7IA?34BUB(IJDUCFSMXLN^D7B2)"D3-Q.</D[<X9U5D0_.[A5&"26
M/0 #Q,[5&<,P^5$9V\ %4%F)SX  DRWTO8],V">QI5*7-)KU&80K]F:K1DO$
MO(6:<0L7848U^RF6$>[1=##3;5<2\@\H+ 4W X&*%QK?L)R,?HV[]I\#VW:I
M_P#ML1E/Q!\)4647/03^M7MW#RW*'7\<J001D8,QJV;VU51Y63A;1:1C9"%<
M5EM,E)!65^UB%KDJJA5BRDC&0[R.CRSCA$R:!UE2$,H $$0,( +BUOSF*<4;
MF%S4]<?JI73:R#.,L*[ZGP,Z/D9VMBS8V\U_Y@H%Q&F>TSVH'QY;J+1YC8<X
M!&9< 0, &#T" "']0AQ#.#D&<@@])9;+8H6H5V=MED?IQ=>K,/)3\Y)K$652
MCXB(9K/Y)ZJFV27<*)M6;<YQ*F0YQ O8 CV95=?5QZFOO.VI1DGR_HEW'X]W
M+Y"<7CKNOL<*HTU9C@#7 U)\=)'M^WOJG6,&G8KI:O+(Q:MK6] 64)8[!(.:
M\@[AH\9!M"UN'EYISWS^Q,D$42-S+N%G!2)$.?B 6<@_2VO1<"+DMKJ( +$6
M76=FI,+GU66950.N&(T5B*..5Y5"\FAE-#UO8I)"Y2NHW._J(.U*UW.V,+E0
M<,Z!HF5ZXNFY*-9R(VB]*+/IQY7$:VWT3OMU?"2L?%(3KHCS7+;62M^CF)(A
MRFN#QQ&I,SIJ%Y51Y@ >2ZBQ*L[G>M[ %]6%K>NMRQ7(3:]U2D-M.77 P9V4
M94+MZ5#(NNF38MK)MSC=N%-IRN1^F^<%3+NQZS>F=]![4L0;281\=I!.LJ;:
M3GX"WUJ7H7OC&-YBM)V"NV&OQ=A;.):/=$,1(&IE"F$4SE*H4Q0LV_IUV@AJ
MK>6W%0J0P;D*R(U0()]0:Q!Y:]=#CC/ZCU,"ME?&^H8,"N*=K-W#G&FU&/G@
M#349DJ#W;JRR5&+O<+<&3VH3-F<TZ/GBM91%BK9&DX[K;B-4%RQ15:&)/,56
MO>K%31,J  !QYB\;.S8+*:R/U+ZULK'[ZNG=4C\:_4!UQX=9R+*REMH([=#%
M7/[I5@AS^#$#3(S,LC[I6)6UV&D1\NBYM54C8*6L,.5%T5>-CK.:4)!.E5CH
M$:J$D#0KH"@FH<Q>Y'F O$O'A4=J3R%'Z M->?[ZJCE?Q"V(?+U>><7/6]81
MG&%L!*_$*<$_L.FLRG.9Q.A*2;&%C)"8E'!6D;%,G4C(.SE.8K9DS0.X=.#E
M3(=0Q444S&$"@(B =@#Z,XLL2I#98<(.IEE55EUJTU#=8Q  \R=!.I7+##6V
M A;377Z<I 6*+83<+))$622?Q<FV3>,7::;A-%P0CALJ4X%.0IP > @ ]F:+
MZ+>-<W'O&VY&*L/(C0C325^8\02/V@X/]<[#>59N9*1B4?%^,BDF"[SO8Z10
M:=W) Y,U\))+M4XZ04X-#]X1NJJ9 >7O0()R<U*X92Z_*'*_M"HQT.I&'7##
MTD[E!+*P$$X?8?F*!OA@LRC7IG*-E<[@,,0 RDW 1 H"81X  <1$?D  XY#,
M$4LWR@9/P D]9CM1MU=OE:AKA491*:K5A9$D8:502<(HOF2@F*1=-)VBW<D*
M8Q!#@<A3=GHSK!VH_P"5ZT=3YI8H=#^#*P(\===9+J:[;*'TMINLJ<?NV5.U
M=B_BKJRG&AQH2-9DF)$QQK;:Z^M$O2VLHDM9X&*BIJ7B2I. 691<XL_0B7BB
MIT2MCD>+1BY2@0YC *8\P!Q#C* V5-<FM26]LGR?:K[?QVNISTUZYZ<,Z+<*
M&.+FK[@'FA9DW?AN1AYZ>6)@LOO?5$%5)Z[R5M3+6ZS<%:!,/&<18)1TE=$9
MU&LFK;2'BXEY,RLH>=<$;$3:-U^\4,')S!VY)5@>.,'/*V]K&N_?G!TZ#0DE
ML!0"S$ $S0U%JFT,IS34;'_NHJ=PM^Q-<#7PQG22PBL1PBBX3Y^[72363[Q)
M5%3D5*4Y.\16(FLB?E'M*<I3%'L$ '(92K%3C(TZY_LT/XYE"L'4,N<$9Z8_
MJ.H_"<G]/^[T\<B=1B)T923CX2-?3$L];QT5%M'#^1D'BI46K)DT2,NY=.5C
MB!4D$$B"8QA[  ,KMNJHK:ZY@M2C))Z #QG===EM@JK!:QC@ =23T$Y63QK(
MLVD@Q<).F3]J@\9ND# =%RU=)$7;KHG]!TED5"F*/R@.7VUO38U5H*VJQ!!Z
M@@X(/X'24UV5W5K;40U3J&!'0@C((^!$LM6M]<NL>XE:O*HR\>TEI:#<.4$G
M"1$Y6#?*QLJS$KI%!03LWJ!TS& !((EXE$0[<Y )JKO'\*VM;$/[R-JK?M^.
MLG<ILLJ!_4JL9&'DRG##]GPTF29$ZC$2G]!_IQQ$=O\ 3_3B)&^T]OZWTI6%
M;EM&UL:C7$?'<TB\0?NQ/Y9#2=AD1091;1](.0804*[>+"FD8$FS=10W I1'
M*;;ZJ 6N.U51F)UPJKC+,0/2H)5=QP-[(@.YU!OHXM_)8)QU+.65<#Q+L$4?
MB68?@,L<*I(A^Y=;?2MK^'KL_<-T5B&A[9K-UN6OOU&\XZ1D-8,I6O0CBXE"
M/B7:C:*)*VE@B'? FJ8ZX\""":HDU64V5\VWVYQCFT/0KIXJW)L:J@$]/U+%
M95P?#)P"#,J6);PZ_<*]>';W=C#HW8K[MN/$[*_4=.F ,DXG=O?61TWZXG?=
M:S['*-H&LTNXI5FLU*]7NQ.JWL22EH>E2;*#HM8L<J^3L,A!NR(IHI'6 $!.
M<A2"!AJ&3==QU#-=Q[NU8 I.RSMM;M; ."*U+D] ,9(R,V:=FJ\E15?6SUDD
M#<BM6C, 2#C?:BC3U,2%SM;;2E=9733L*Q.:?6-I1ZEM84R<V!)U>;@;;4K%
M#5*M23B(GY.=A+= 0<G!JP[]J<KAH[21>)EX*"EW9BG'BRZFKB\CG,Z_2<6I
M;+7!#*B/O"DE<YUK=2!DJZ,C .-LZ2JQ[J>.JMW^1<U5:D$,]BK6Y4 X/R6U
MNI. R.K*2I!DF:MW1J_=<&ULFK[>QML,]A:_8VCQHVDF0KP5J8#)UV63;2S)
M@\%C+,BF.BIW?*(D,4>!BF*&JWCW4Y%JE=KE3\&"J^/^UU/[?QE*V*^"IR#N
MP? [7:ML'^ZZ,I\L ]""<VG+#$UMNW=3+A9HU<.#-@=$8OW;9L8C1T^47D5V
M35RE%L$FK-0QW3D4FY! "F.!C% V9[*ZQFP@+M8DG0 *I9B2=!@ XR1DZ#)(
M!M5'<'8"2"HP-22SJ@  U/J89P#@98X56(L],V'2]ALY"0I5A8V)A%/_ "Q\
M\8=^+9)[X5N^!(BRR*1'!3-'::A5$A.F8IPX&'+&4HI=P54,ZG.F&K8JX(.H
MVL"#^$Y(VML.-Q1&T(/I=0R'(TPRD$2Q:YW)KW;)YPM EI2;0KSM1C(2:U2N
M$)!KN4I"3BUBP<_8("*A+.F@_AW":BD:X=II\I3&,!5$Q.16LXJ<Q?X%GRYT
M8Z YV'#@$$%6*@-^4G!G=U;T7/Q[1BZMBK#KA@%)!QD9&X?MR.JL!)XB!0$1
M]  (B/S  <?_ $9PS!%+,?2!D_LG$QVI6VNWJN1-MJ<FE,UR<;>,B91!-PBD
M]; HHCWJ:;M%NY(7O4C!],A1[/1G0U1;!\CHKJ?-74.I_:K ^>NNLZ=37;90
M^EM5KUN/)ZW9'7_I=64XTTT)$BEEU,Z5D]J.-*1MM?2.R6DF\AWD$PIEZ>,V
M<C'13*:D$'EG;5E6IM2,(^2;BLHH^*DDJNFD8P+'*09XP/+K>SCZHBLQ)]/I
M6PU$C=C<.X&0;<[F1PN=C8<A#Q=@OPILQM&02=PW 8&2#M(8@X(5E8X#*3,D
MW-Q%:AY.P3\DTAX2&9.)*6E9!<C9C'L&B9EG3MVX4$$T4$$B"8QA'@ !G)."
M!XDA1\2Q 4#XDD #Q)DUUO:XKK!:QC@ :DGX"=L[QJDS/(*+ID9)MC/#N3&X
M(E:D2%8RXFX?\,$@YN/S9%S+QU=[O2J EB? #KG\)Q2.^5%/J+XVX\<],?C,
M5H&P*IM"KL;G29!W*UJ44=DCI)W"3L#XTK)TLS5<-F5BC(F058J+(&%%P"0H
M.4^"B1SIF*8;7K>L(7&-]:N.F=K@,N1U4X()5L,.A .D@,K,RJ02CE3C494X
M."-" ?$$CR,OCFP0K.9C*ZZE&2$Y--W[N)BE%B%?/VT85(T@NV0X\ZJ+,JY.
M\,'87G#CZ<K4AW:M=75-Y'B%W!=Q^&YE'XD26]"J[:*S[0?-MI;:/CM5C^ /
ME+O\_P#3_;DQ+,UL4$^F9:NLY9BYG8)&/<3,2BX34?1B$J152.5>MRB*B!'J
M:!Q2Y@#G H\/1D@$IW!J@;;G^]@''XX(,EU9-N\$;U)7X@'!(\\'0_&7K(D2
MT2L]#09HHDO)LXX\Y+-H*'*\7(D:2F'B3A=K&LP,/%=XNBU4,4@<1$I##\@Y
M U=:A_$;=@>)VHSMCSPBLQ^ )AB%0VMI6NW)\!N=47_N=E4?$@2*-C=1FG-4
MJ/6UUMRK618/HB+6A8&L6ZZV%:4G6+^4CHN/KM)@+%.2LF:(C%GJS=JW66;,
MB@X6*FB<AS<"Q&P%.<NR_@45'<L>BJBV)N=L("P!;=D2]>-<RE@,*$#Y) ]+
M.:U(R1DM8K(@&K,"%!(F#(=:G36YL<16&FP'[U[-(59PUE6.O=G/::U+=4BK
M59&<V"UIBU$K3V8*H4J;>1DFJY5#%(<A3F HZ*:K.1R;.)2,WUV&LC( +BI+
MBJ,?38>U8CX0ME6!$SV,*JQ;9D*4WXP=P46O22R?,@%M5B'>!AD;/22S;MT:
MJH5DC*?<;[7*_:)FOV.V1T#(/R$DUZQ468/K+/F:D ZB$1#M1YE7"O(F'H 1
M-V9E>^FNN^YF';XU/=M/797G&YL>!.@'4^ ,T5\7D7=KMH3WKEI3^_:WRHOF
M3\.GCC(D)(==W2PO"1UB#93Y&,DGPLP%[KC:K!_%I%29N#SEGAGU(;3%0J*;
M:006/-RK=E#D15*H+D"#S9K6BUN57PP/]38^P#(&'W]L5N2<5V&PA%K<J[.0
MJJ29F5E=6>L[E4;O3ZMR[2^ZL#)M78"VZO<N-<S;A,Y%4R*IG*HFH0ITU""!
MB'(<H&*<I@$0,4Q1X@/RAE9!!PPPPDJRLH92"I&0?,3[R),8B,1&(C$3%+U7
M5;?2;C4T')&*UGJU@KR3Q5,RJ352:B7<:FY42(8IU$T#.0,)0$!, <..8_<.
M,>9P+N&I"M;4R D9 W*1G]F9HXEPXW*JY!&178K8\]I!Q^W$\[;W\.IM=%"S
MR-QB*[L=E":<K=<VC$0!B7BH0FOJ2I3K:RK$RHN=Q%)71!8XJIIB"2B?*1P5
M8"E -WN1'.YW.Y5):H<WE<RU@",E.3Q+**ZW./4M=K)=@Y7*94!\-,/#1N-[
M9[?P'Q8>#QN)6,YVEN/S:^2[J,C:;*U:G(.[#:DKD3ZTGT)7?2_3%MC2$=>Z
M?8;%L612=)KW"JPECUL1N1@PBWR3F@-ZG78!LI9&;,ZL@(,W7B'RIG*PKJF.
M)Y]TL_W#B<?B!56NJW<RD @(; QKK)&%51I7Z,5GY5 P!HX+-Q>6_)=F+&H(
MK#1BP5@++"#N=R6]99R64*I;3,A+5OPHI77S )%S>]<RFPJ\UK3365N/KAJ0
M=>-8;;.[MCR$;!QS (>/CH>5C]JM(M5K'H,&RS:-Y#I]T<J9++[\\2JKC:<Q
M77NV-J;JEX5'$%3YR2K&IK&!)4EAD$J,:N_Q[-R7UYXY:UU1< (]IX[%DP,!
ME-+;7QO&\G.2^["W_P -#:^NZGLNY0M@J=GNSF7F=DT2@ZEH=5H4;#[6/34Z
M[6Y*N-"&I=9CV2-F8,)-ZJY*=X=N19)19T8"":FN^_A<'Z7V\GZWO9J=SE*0
M[<4E6&#^BHIN5A6H)2TD)O+,;*GXG+YEQ]T_\"^BJNW R["EN2S.N<YO?O U
ML[$+:BG<$"A<OB?A=7E)R6QDV#28BX7/3KRN;>M#VK-;+9K?LFWF<6&\3;>6
MD(H9RK0SN[RCIV1M%2R#8Z8E(HW,/ X:N,>'[9S]G!#'V>CF<%Z4)PYJX%W%
M=.XXP6>ROC8?=N3NV&P!3N#>)[B.5[Q[6R<DA/<^1Q^6MAR61&Y='(J"5J20
M$I[R*A 5^U4J9(QC8W3G0Y/ZRI?5+1RVRHQT)O\ +:1A&U?J[#QM>D+,VF$'
M4Y8K.2'@[1<'RQY,ICA).7ZY.00(YY1 I?*LH=OMJOV)&Q=4,(V,(H"J NT8
M#:IJ^ [9]18ZGV*>7VON8>_$%J]RDJ3EF(<L=3G:,'"H#L7HH4:2$;C\.7<F
MQ+'7;Y9-G:NB]B15I0F$;5#4M6=;U6-;UJJ5SA4J_?H^T,FM@<%K)5_,VZD9
M)(J&*5-R"8"4VYBIY;<JMGK:T7]PJ?41?=9;L1M&0 6%-RL-P.75L*!Y=-/T
M_$;B##H!0$#9V_HT+3NL7.VPG:&VLI"ZA2NYB8]A/A'W"&ITW77NS:7?#RCJ
M:2-"[%KJ<G0'2LK69"";[.7J55KU-;([GC',@9P$RL9\X<< !1<3D34)Q6P7
MZ8;57LA_EZU%K.(^[CG05Y'%*,H51BZU@<O8+-YN'UMG+R[;[:W()TM"?4?I
MW#4NH[X9222&JK!]*5[-DNI'H3O^\(_I[@HF^:W@8[2</2BDG);7$9,WA"Q5
M"9@G[E[4K3(,9&8KT38HV(%JY09N&+@/HG[\X<Q,U5<G9]U-]Q/_  ^X&5!@
M,0>]W$=AJRMW$*C.%9#Z2&TK#(/:#[9C.X6!LG<OJ""M@K9&ZLJ^202P?0J5
M!/-U3?#T1ZAIO95P9V6M0MPN3W59HU_*U2#G -7J!%2+&7IE@-9(&V,7=9L;
MYZF\4;@Q52.NU2,J0YB$,3SUJ[:XJ RW,NN;H RV<?C4U@G!):EJ&LK.FTV9
M4J<DS7:XM)L9NVO$KJ3&0R.MU]KL#D8%JVK6XSDJI!R#B:[2GPE)AZ[(J%OU
MO,M_<O5T/)_S+J##:$K:)O64]4YR-1DK'-5=A8X*K\E;,S!G&NT69FRPB+,I
MQ.8VRFX4<P\E?4!RJ[4S\^445FU[,EWO*[FW.7_4.X%1D2ROD>A%N4%QQ^54
M2H50!R!>55$"[%2JRU7K"JA45JFH5-N?._A?>$-7WT*[T[*>$CQ&[T:VT)X]
MUSMBP.++LF74EMAQ[1T5_.G@T;VU<19ES*JMI"&:G 2E33%+E'2OAIPE&:4H
MJJ7.G;9.-QZ'OKVXVWL]#L'&#BZS+;CNG%5S]C;:Q7D'EWW$I@!DMN-B<=LC
M6E4(0KT.U="N5,:RWPB+ ZG89_%;/JM;B6%ME+&X8U&N)0;XCZ<2JIG5RC)N
MQ0M^G([8\&:NG:1TN@Z1DDV*W(+P!%0#DM9+^X&< +M4C 9!W;K"5P!COFT'
MD*&"V&M=X<8Q9RN2MX0UU5J5497&4<[%0!E.59:PGZ6Y"5[EFW:-#LII7H(G
M=7#O4KFQ:^!?;&EPU*6?K=;F(^RV*1+-WV7'8^T'SF1.6Q7-^G="(NG"7*JJ
M5H7BIR@0I.+66_@V\0JB5VV<5NW6-M2#CAU8(!J.Z'#'7 ;<<9)8\<:WZ;W#
MA\O+VCB/R6WV'=;9]0>*5#OT(J^G*KD8VL   ,2+"?"W5JC>8=ZRF-.0,V\L
M*3AF2:U:WF(%2E/M'TS6UKH$K%+J+-G<#;;U O[(\1.DJV6?R)G"R"KKG5/9
M=:MB-2J@4O\ 4!EP-4LY1OI49! ^G4[:]"$.2@4$B:3R>,0S=LB_LTA6SJ+J
M[+#9:>A)NJ9*K"&#.J .Q 4#$X#X4M[A]:IT%3;-%.BPA-U0\>U:4=Q$P"I=
MORMNEXU>2@*XO7ZZ*NJE+.*=?!K'-TVY3KB0B0J\,[XE_P!/R>-R+-SFCZ=2
M2221Q[^XM@+%B+6J"T$YVBO*KZ=H%='*6KE?4; J_4):57 &E-%;U: ?IO96
MU[9!+6=MFW,&8R2Z^%S .9>;LXRM$"W2BUIF4;2>GJK3C.X26SF=WJUL2D5'
MAG:4S4(5!6.:.$SE6;@N?N3)D44*;#QT?C]M:VVJMU+G;H2%YEO(Y _'D46?
M3OG.Y!M?<@"C-[@_UU-U9^:SC6U G7&[VZGAT_LIOJ/)0#Y6;*XL]1MAOAI6
MVY/*VWW#<]872KT:I/:;5H *;,N6KENSHNQZG4[#/MIF4=LE[!$2-U;2/T$Q
M31<,@.B)5034)RE97V[D4@X]QOX0I6P:=JU5]O1;:_S XX3Z@A@;=#H<S=86
M][I]QIR.(G->]T.IL2Q^?8]1\-N[F*O3#)658$.1)KA^A12N:%V!I.N66MP3
M:Z676EI07BZ\NRB6,M4(ZDDM,DO&-W2??REQFZNX?+N $%%%W?>+"HISF-K]
MV=?<>VM(%=57,NM1?!:[+GL2I0,!16KA !Z1C0 2OVTMPF>RXFRVSA+2Q\6<
M4]HV$G).>NNN!C,U;F?A-79XILIU'[Z105V9&UF-E&#N +(QC!I3H76[)DQ@
MVDZWL$9$L;DZI[M*SIF9NDYEBHQ(L0W@2 -;8/$3C ;E6T6X;!!87\FS800<
MU;.0&"$86^ON+\[2^FWM\FSD$8+JZC:2"HLI6LOH03<I0!'R-M3VH/FR;V;X
M5,Z]K-8K$MM.*E(N,=4U:9C)N,<3+5ZPKQ[*I(UYH+)M6F#>NJDL'AV+1-B@
MW9LTBH%3Y"E#/2X?,HHO=^37WJ&N+X;4L#QO;>..X6+%WSP"SLQ/<[@W#(;-
M/%8\5KVK])MXJU +Z0A%_/N+( !M!^L&%7&UD;;@%0O<L_PLI9[,3Z--O=%I
M=<DYITYHDM%4^2:7KIUA V!9KJG#]/SYA*-8VE(S[2PECY9-N1L@L@V(4"&(
M!2%\>M;OHQQ[7;OBJU3:">Y8K);5738V<MQZD="J9T*G&/25WV<OCD@54(*0
MZ-L(]&X5\57NVC'ZQLHL</US:2227#XM+?"DL\K"R[#S3I]CFDI3):D%H<=K
MVSH:RCY62JBE<'>[*""<[XF^S+'\0>7_ .,)O^>*G%0=5]G>[VQ5K[S;D"@8
MX@#!NUQ1@!*7QML3 5ETVXRK9^'?])9PW<M<>(ZEBYR>60<[N5U-CK\U9).U
MF8YU!7<#<72W8MDSCRKJ2#D*E==#T;64O8V,C(Q*E8D-9;&B;>J9JM$3458F
M"UUC5UDF[J.53<,EV93F4*/=CCEFOG\J^Y\HC>[</FC!(9EHO%CT[E(*D!04
M;09=SH1ZLO$#<+V7C>W5[6MJX/,XI. 0#R>(M*6;&!5D#(=ZDDG], $%BL.6
MSX<LPTE&#C7-R.^C8W8MJNR![]MWJ597YXSM=.C:T$+.;AI&T8W9\TSK*L:
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M1^&_MU_!-*);-N:VGJ+Y[#6F82;:_>04A+2259UG5IN#+#0KUA5(NKKQNOC
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M'U+:U4B4J3Z:X'I[:2;($VC>Q*F;6@9"RM(]NNJ^CBP9)I%%J*BI50,4PE
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M0$@M9F=K)4'S>;4<-%BR",NOWJ"@**IJ77OOY'>I6NNLERU:JJ5,7Y?,Y&J
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MJRK>#\_9 V4@Y"JE0&W:0<UM)[3CCL5N?:5)QBEEW%FI'Y3<6W7'J[/826!
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MC]"IKGL6FO &*R'VV("M;A0K*RG \RBNVOCI78W<O6E%8L"RVLM8KW6AB0V
M/1N5BH9L$>,L5'X8\+1[)K2V1 ZJD9JF6ZIWBQKS=$!=2X6VOW;9$XO<9!V4
MQUU+B6L[ \ VD5 .X3\*!><$!!,M=5PH]RKY/'';X=84*B:; >%?QKBGD;;'
MHM(Z,:$WY95(U>ZLON'&>M01>Y<LS'=O_6X-M2V'0LJ#C7I@]!R7V@ N&EZY
M=-FR+)8MSH1;:BJ(6?;T1M>NSUQ):FIG3*2UE%T-]$PEMU_:*]L&A6RK.X Q
MDW[!0@*,72:1#?35!/%4KC@<>@G%G'?EID%@Q6_D-R5L!7JH%S4-6QPW:+'T
M[<VFQ5Y%]H9V3D4\?30JC4*M9K*,""K&I;PPU5[&P-PR>IJWH"A8F:G;?NB]
M6S:5RDF='2C95*\[(C(9@\IL.NQCI"6HRUM<T"[2L*Z.D>.?SD5(O"^%2.L<
MZ@<<MH#<5+CQW9>7;R6M[N$# MP^)Q2ZIM-==K-Q[+&:M%'ZNT:*)GL9K;TL
ML /%2G9V\MC'UG+Y(K+@BQZ@G(2H*[DD5DDY<S.]L](+C9M<KE;?[-L$ZM%T
M#=5"F+K>&<%(WJ;:;9J#VL-EG#^KPE3AP)71?"<A",TP.F0I?[?,<>;6M N?
MC"M+WXZ(IP2O<KL6Q'L&?5EE&X KU.W$];VCW,>UWU7%39VN?Q^0!D  4L24
M&FF[/77!ZYT B?\ _P L]3B_G2DG=-#23?8[RM-MNUGW=O;."L]5I\"R@(NO
M,'9))Q)(L9I!-<99%0!*[24! #$3YA-L^H4\JNQP?I4YMG+QG47O8C*0>C+5
MVU9 V,V %\IE&\/C4MQ>.M=+LO(3BU<=7&A[=:LI(QJECEL;EU1<["'*NOI8
M@3NT44Q(DF*:29!(@7D1)R$ O(B3LY4B\.!0^0,SL=S$ZG)\>O[?C+$7:@7
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MHRQS5Y%ZM_>#*E;/C*( /ATU"B #3[D:>+10O#9[+6M!+X) #6;5%B!25K0
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:$1B(Q$IV?@]'^K_9B)7$1B(Q$8B,1&(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g374624g37g45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g37g45.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1C24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+:^8R8X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B
M;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E
M='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93
M971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F
M0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T
M:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O
M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              38   *C    !@!G #, -P!G #0 -0
M  $                          0             "HP   38
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   38     4F=H
M=&QO;F<   *C    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   $V     %)G:'1L;VYG   "HP    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     #ET    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MV--CVG-+FVD16T_G$.:6!VZM
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         /_B__])0T-?4%)/1DE,
M10 !";[,_OX>  B <$%$0D4"$   <')T<D--64M,86(@!]  !P :  4 *0 U
M86-S<$%04$P     041"10                    $  /;6  $     TRU!
M1$)%
M       *9&5S8P   /P   !T8W!R=    7     K=W1P=    9P    403)"
M,    ;   *(&03)",@   ;   *(&03)",0  H[@  *(&0C)!,  !1<   CBT
M0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M=  '[]P  )"19&5S8P
M   :52Y3+B!796(@0V]A=&5D("A35T]0*2!V,@
M
M                      !T97AT     $-O<'ER:6=H=" R,# P($%D;V)E
M(%-Y<W1E;7,L($EN8RX  %A96B        "U6@  O&<  )(P;69T,@     $
M PD   $                    !                     0   0   @
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M1B2V*(E(-+6Q9HC^(2RN28GD"5VMFX95  "*18  A#G,F):%=5C&>)0'9AW
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MP+)]<WQZJ\Y]EWQ\E?Y]P'R/?U-]\WRY9]-^-WSW3QY^C7TT,Y!_$GUR#D&
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M*RR!>(9^!Q2!^(0HP52"O9EAKMB"#9;]FW6!>I2=ARF!!9)1<AN L) M7#6
MA(Y410" :(R\*GB A(P)!J. YH1]P#"![:.^K;B!0*"6FE> JYUDAA2 .)I%
M<1Q_YY=:6U%_MI3"1$1_H9*T*==_L)(3!D1__H0]OT2!2:XWK,N GZI.F62
M!:9+A2!_CJ);<#U_1)ZX6I)_&)N"0Z9^]IDB*5%^^)="!?9_/X0(OI" SKC:
MK!" )K0RF)E_A*]@A$Y_ JJ?;W-^MZ9.6=A^E:*I0PQ^=Z!P*-]^7IN"!;9^
MHX/<OA2 >,/!JX)_T[YCE^Q_)+C!@Y-^D[,U;L9^0*Y)645^(*IS0I-^!Z<P
M*'E]YIM>!8-^)H.ZMUR15V^QIC6/GG#ME"&.''(2@/2,R7,N;,N+F'145Y.*
ME76&0.^)X':D)H&*.W>! RJ*)'F]MEB/X7E3I4..1WF>DQZ,U'GI?_F+AWH_
M:]:*7WJI5JJ)9GLD0 J(M7N8);*(^GOT MN(A'UIM4F.BX+JI R- H)=D@.+
MDH'3?M>*4X%I:LR)-X$95;N(2H#C/S:'GH"Z)/J'SH"X I6'%H"BM"R-38R5
MHM2+RXL^D+:*:HGH?;F)*HBT:;V('X>L5,Z'/H;'/FN&F(8-)%"&MH7F EF%
MV8&6LP6,2Y9)H<**RY0XCYR);Y(M?(N(.I W:+"',8YK4]^&88SE/:6%O8NO
M([.%Q(NY B6$RH%SL@:+A: ?H+Z*"9U9CIB(K)J/>Y*'>9?:9\J&<95;4Q*%
MF),Q//Z$]Y&N(RR$[)$A ?F#Y8%6L36*Z:H.G^N)<::6C<"(#Z,->KR&V9^=
M9P6%U9Q[4FJ$_9G4/'6$2I@^(L"$,)6= =6#)X$]L)**<K0GGT"(_K "C0F'
MEJN^>@*&5J>79E&%4*/A4<:$@Z#T._"#SI]?(F&#E)<_ ;B"C8$IL""*&KZ+
MGKR(JKG"C&Z'.[3&>5V%[Z_N9;F$XJO 442$$ZCF.W^#9*4Q(?^#(I;\ :""
M$H$9J)N:Z6\(F(Z8<W!!AZ66/'%I=;"4/'*,8K62:'.W3I*0U73G.-2/PG7T
M'J.0AG:$  "*<GM%I\J9G7@GE]*7/7B AM>5#GC==.23#7E'8>N1.WG%3="/
MK'I0.!F.E7K,'@:/-7L+  "(V7Z3IN^85X$[EM&6"8#*A>F3VX!E<^V1Y8 <
M8060'7_Q30&.F'_?-V.-@7_6'7>-_G_S  "'<H  I?67-HI E<*4ZHD?A,:2
MQX@-<O:0S8</8!N/$X9!3#F-EH65-L",?H4;'/R,W85F  "&.X  I0N6+I-Q
ME,Z3[)&C@\N1T(_B<?:/W(XS7T:.%HRS2WZ,I8M]-BJ+C(JN'(^+T(KC  "%
M,(  I#25;YS&E V3+YI1@PJ1#I?><22/&I6&7G>-6I-H2LJ+WY&N-9B*Q9#'
M'".*\H^1  "$3X  HX&4VJ8NDU*2GJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+
M1I@_-26*%I>4&]&*+)+/  "#E8  HO&4::^[DKV2,:P+@:N0!ZA&;\>.!*2G
M72V,1*&*2::*SY]D-+2)F)W9&XN)AY*?  ""_8  HHJ4%KF:DDB1X+5;@2./
MKK#S;SB-H:R_7*J+V*E223>*8*=(-%*),*+7&S>)&))G  ""A(  FE*DVVZ$
MBSRANF^O>UF>W7#2:GN<.''T6)69QG,;16Z7KW0_,'*6974H%?^8374H  "&
M('YIF;*CNW<NBK2@I'>%>L.=P7?I:>2;$7A>5_R8FWCG1-V6@GEZ+^J5*GGM
M%::6U'G<  "% (  F0NBAG_!B>J??7]>>@J<EG\-:1^9[7[@5T:7>G[01#N5
M9G[9+V*4!W[H%525>'\(  "$!(  F$JA98A*B0V>8X=$>1B;AH93:$Z8V86$
M5H"6<X3C0Y.49(1J+MZ2_X0K%0>4/H2   "#*(  EWZ@?)#=B$.=?(]">$>:
MH8V]9W27]XQ85=&5@8L:0OR3>XHU+FR2#(G1%,J3&XE   "";(  EM>?L)FK
MAY><N9=Z=Y>9WY579LF7+Y-352^4MY&-0GN2FY! +@R1)Y .%)*2%(U&  "!
MSH  ED:?'**/AQB<*)_/=Q691)T-9CF6BIIT5)V4%9A!0?^1_);)+;20;9:%
M%&&1.(W(  "!2X  E<Z>L:N7AIV;O:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1
M@IX0+5B/Z9O@%#F0A(VL  " X(  E76>8K3PACN;:[$I=B*8>*U&94&5JJFN
M4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  " BX  C)RO-&X ?E>K>V\7;UVH
M W O7WFDP'%+3HRANW)H/$&?-W-W)\V=]W0D#2^@N'/%  ""?X  C"RN.79!
M?@:J>G:.;P"F[7;R7QJCE7=L3BN@@W?[.^B=]'B,)X2<F7CD#3J>XGC1  "!
MQ8  B[JM#7Y=?7.I6'W_;GREPGV[7HNB:7VB3:>?5GVH.WF<QWW&)S.;5WW>
M#3^=-GX[  "!(8  BS"KZH9G?,^H.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";
MM(,V)N":-8,M#3^;M8,1  " DX  BINJ^8Z#?#2G38T-;1ZCP8NT74&@8HJ!
M3(F=3(F).HV:P8CL)I29,8C_#3^:7(<]  " &H  BA"J09;$>ZZFEI3-;)BC
M!9+L7+J?H9$Y3 F<A8_1.C*9W8[T)EN8/X];#4*9)XCW  "  (  B:BIGI\@
M>T"E^)RK;":B9)I&7$B>_9@82Z&;WI9<.>.9+I6&)C:77I3<#4J8$8C\  "
M (  B4NI-*>G>P6EBJ2]:^>AY*'.6_B>8I\C2TJ;.9TY.8J8F9RL)?.6RYER
M#4J7.8C\  "  (  B0.HZ+"">KRE,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8
M'Z+$)<B649F,#4.6H(CW  "  (  ?W*Y_VUL<>&UP&YI8[&QO6]Q5*NMZ7"
M1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "  (  ?S.Y'W50<<>TR76,8Y&P
MGG7I5(JLJ79B1':I"7;P,NNF)G=U'L2E,'>2!B"E(7C%  "  (  ?OFW\7S^
M<6^SGWR=8T6O9WQ>5#.K:'Q41"JGPGQK,K:DU7R6'KFCM7RA!G*C-GVC  "
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M;]BOCJ%089"K/9[-4H:G&YRI0JRC7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "
M (  ?3:SFZQ';]"O*ZE6882JP:9=4F2F@J/K0I"BK:+#,92?CY_S'G:=R929
M!Z";Q84H  "  (  <J_%2&S>9:7 K&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q
M-'$M%):QZ7"X  "K*71[  "  (  <J+$=W1P9<._L72+6#J[!'352?&VAG5
M.I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "  (  <J/#.GNX9:J^<GM%6":Y
MM7K]2=:U)'KW.HBQ WL2*9ZM\GLX%6ZMWGL$ *.GTWTN  "  (  <I7![8+:
M98"])H'X5^>X:H%"2:BSTH#,.F:OK8"6*9RLBH"0%:^L,(#, 2&E^(#$  "
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M94.Y4*6B5[NT0Z,H26NO=Z%K.D6K*:!1*="GRIQ%%JBFCX]2 KJ?\X'8  "
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MEB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%. .9S9-S=_WYNU'?A_IY1$  "
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MC/V/"X.S?/:-?H,U; F,$(*X6?J*UH)81LZ)TX(),>6),('-&!&*$H'9  "
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MB82+>Z[Q>5:)W*LY:$Z(4J>05I&'!J240]6&!*+V+X:%.)\=%FN%2(\H  "
M (  D-B>X6C,@M><3&J-<]^: FPT8\27[VW%4H>6"V])/^R4AG"Q*TJ3Z'&S
M$&R6WG$O  "  'W0D$"=C7%C@DB;$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63
M*G7I*M.2=79Z$#B4]77R  "  (  CYB<(7G9@769NGH2<GV7;7I-8F"54WJ5
M43V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "  (  CL^:S((]@)*8;H';<826
M+8%Y89"4$X$F4'N2-X#J/BJ0LX#"*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH
M?\:768FY<+25'8C'8+23!X?>3]:1'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "
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M=CRE]FG@:!6C'FMX6.*@>&S^2(N>#FYR-K*<-6^W(EZ;XW!:"%B=KW @  "
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M<VB@3H\992Z=88W+5A6:F(R/1A.8$HN(-,B6!XKQ(2N5)(MB",R48(7S  "
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M:<JO*' =7%>KIG#Y3?FH5''=/G"E7G*\+3JC27-J&..CIW-& ?Z@-W5A  "
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M9^:IP9/*6FZF(Y)#3!BBK9#>/-2?FH_N+#"=.Y '&-J<E8Y9 U:7:H)"  "
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M79VXVG6 4-6TSW6X0R:P[789-%&MD'9\(Y&KB':N#QRLR'8F  "<B7PB  "
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M71>SGI?F4$2O69950I*K394(,^2GQY2V(YRE7I/,$#^E68K\  "82(    "
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MDJ>#16\)@H""Z'!M<36"GW&^7L.":W,$2Q>"6G0[-<""?74X&\B#;W5F  "
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MC5E\AIII?3U\5Y@N;"9\-)7D6C1\+I/)1S1\.)(*,J5\*Y$F&7%[QX[9  "
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MA1R*378.=AB)2';$9=2(9'=P5'V'GW@:0=>'$WBY+4F&[GD?$P.(?WB:  "
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M@0F$V9^6<>F#X9T;8<R"])J+4-6"-YA:/KF!LI;T*O"!.I9&$;*!$8OW  "
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M=_Z1_'Q,:<R077QS6J:.VGR72DN-C'S .)&,E'SE))R,6'SF"P&,O'T,  "
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M=1:-SJ1;9LN,%Z''5Y&*9Y\O1X2(]YU2-CR'Y9QP(NZ'.9>>"I6&1H<H  "
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M:XB:<H&Y7AZ8-8%V3\B6$X$M0&B4-(#X+V22[X#<&[62]8#8!(Z/_8"=  "
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M8@.J76.253JGMV6#1VFE.V=7.$VC'6CW)S:B%VH;$BJD?VFG  "8TVYB  "
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M7]FCI89W4R6@QX7D186>"X50-MB;JX3E)F^:*(35$I*; X2X  "1QH    "
M (  :V2EMXY]7Y&BTHVO4M^?YXRR13J='HN[-H::O(L;)CN9)8M*$J69J(FA
M  "0VX    "  (  :R2E#Y807U2B)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F8
M89&\$H*8K8R#  "0)X    "  (  :O"DH9WC7U:AI)RH4IF>F)KW1-B;HIE6
M-C.9%YC/)?R7:I;G$JJ7J8R>  N/BH (  "  (  8;.X?&")5?2U?&)22:&R
MD&08/&&OPV7#+;NMC&<E')*M1&>X"%RNI&=K  "36'+8  "  (  83"WD6?;
M5<>T3VD"29*Q%6HX/&^N"VMF+>6KGVQD'/"K"FRZ"/&L"6QI  "2%W=N  "
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M5+6MC8I]2)BJ'XF\.XNFX8D(+5VD,8BV'2NBWHD@"F6B2H:(  "-,X    "
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MD3AO6H4[@0AP=82W;]1Q@X0?7;1RE(.02E5SGX,7-7QT38*M'&ISA8)O  "
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MBDE_<&%&>QA_>&/X:I9_GF9V6-A_UVC51<: +FL-,.6 OFS>%K6"/6TT  "
M '9<EU-]&V>8B49].6FD>@%]9&N':9%]G&U-5^U]XV[^1/M^07"/,#E^O7')
M%C9_LW&[  "  'IGECEZUW"^B %[('(!>.5[8G,G:'A[L'0W5OI\"'4Z1"]\
M<'8I+Y=\VW;8%<5]2':%  "  'WSE05XQ'GGAKQY*GIR=Y=YA7K;9WEYX7LY
M5A!Z3GN.0W%ZP'O<+PE[&WP*%69['7NF  "  (  D]-W!X,.A:YW?X+S=H1W
MZH*P9DUX4H)251]XQX'[0I9Y2(&T+E=YDH%V%.EY38%3  "  (  DM1UI(Q+
MA*EV)HN'=81VEXJ195AW!HF#5#IW?HB#0>!W]H>N+<9X,(<M%(%WQH:F  "
M (  D@=T@I6)@]MU#)0C=+=U?9)\9)%U[I#!4WUV;(\I04%VXHWA+5IV_(U3
M%#EV?HL6  "  (  D6ISH)[,@S=T,)S*= MTGIIX8^=U")@34M=UAI7S0*%V
M )1F+-IV!Y/^$_5U=XU^  "  (  D/UR_:@<@KISCZ6*<WUS]**38U5T49^/
M4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "  (  BRR(?EWP?A&'K6#';].'
M'6-J8$>&N&7;3W2&<6@G/2N&9FH[*+R&[6NY#@:(_FM'  "  'G3BE&&-&:M
M?3J%I&BU;NR%+6J:7W.$SFQB3KJ$BFX//(^$?&^/*$"$WW"/#=>&26_U  "
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M>'E]S)$&:D=]C8^W6PU]3HY02MQ]*8T/.69]%HPL)?5\XXPZ#.I],HB6  "
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M<#J,Q6\C8N2+O'!B5$Z*T'&.1(N*#7*C,RZ)J7.&'S:*(W/,!G>)GW0K  "
M (  >\F+[77I;T2*[G:J8=Z)^7=44X6)$W?Q0]>(77A[,J.']GCG'MV(1GCM
M!GR'DGF_  "  (  >NF*2GX%;GB)6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&
M9WYW'IV&C'YC!HR%QGZO  "  (  >B*(^H9$;;F(%H7[8%Z'*H6'4@N&0H3X
M0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "  (  >8.'](Z,;3J'&HW.7^.&
M)XS*47>%,(NG0AF$:8JR,6"#WHHR'BF#HXJ)!HN"\X1L  "  (  >02'*I;=
M;+F&5)6Q7UV%690G4/6$59)\09J#@Y$Q,-2"^)#(';B"FX_6!HF!Y81K  "
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M8]&4EG2M5RN3!W5E28V1CW82.IF06W:H*>6/P7<)%=Z0V7:M **,:WE$  "
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M85^/?9GX5+F-U)A?1Q",():Q.'**L971*#F)Q94G%/R)R8XP 2>& X#(  "
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M5^&=4WE82]Z;.WFM/N.9/WGL,+27J7HG($V7+7HQ#(Z8 7HJ  "'T7^<  "
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M3AJO4ER-0F2M&5ZJ-9RK&&">)RRIXV(C%9.K86)H T6IMF-:  "(YW']  "
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M3%"G*GU*0-6DG7U.-%ZB-WT_)I*@='TS%AN@EWT6!/^<[WX6  "#7H    "
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MB,%IRW9^>8-K9W=&:3IL['?Y5[YN;'BC119OPGE!,,=PB7FW%\IO['F,  "
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MA"YB7:)G=/MD*9^$9-EEUIR<4]AG>IH70<%HV9A3+B)I&)=@%>5I3([.  "
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M?%!OF7T6;@MPJ7U77KAQI7UZ3EURGGV:/(IS?7VZ*-USQGW##Z%U)7V>  "
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M=5B!6%N79\:!6EZA6.R!?6%W2,&!N&0;-P.")V9Q(M&#'6?X".>$I&??  "
M 'ES@,M^MF#B=&A^RF-?9M1^[66U6!=_'F?G2 M_8&GR-G!_RFNY(F> A&S)
M"-^!Z6R:  "  'T&?[I\#6E=<SE\5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]
MEG$3(>9^&'&V",5_AG&;  "  (  ?IAYIG'*<@YZ#7+W9)9Z:'0%5BYZNW3W
M1EM[('73-1=[AW:((71[U';0"+)]<'<+  "  (  ?8!WB7I+</EX"WK<8XQX
M>7M)52QXVGN91;1Y/WOA-(MYJ7P;(1EYP'P@"*I[H7R6  "  (  ?(]UUX+>
M<"QV:X+?8LUVX8*M5%]W1H)<1.5WK((0,_)X H'?()]WXX'5"(-Z'X%<  "
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M:+.'F6)36^B'+F2>3?B&V6;%/JF&JVBY+8Z&XFI+&4^(,&J[ BR';&OZ  "
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M9&%^.H?&5\]^#8<]2BM]RH:4.W)]FX8+*RE]?874%_=]*H8= I9^=H'   "
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M7$".S&?]4%"-YVFM0QR-&VL]-(V,D6R5(^*,PFUN#UZ.@FSI  "$7G.G  "
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M60V&[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "
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M4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "
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M3@F0<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "
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M1"N@:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "
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MC5Y@L6!D?=IC)V,U;4)E?F7F6X1GMVAW2))IMFKD-!=K VT!&V=J36X@  "
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MAC]3!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "
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M@-UD<FA)<H]FC&I78NAH@6Q#4BEJ5FX70!9KZV_%+#ELI7$5$Q)N77$/  "
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M>S%8[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "
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M='!I#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "
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M<#)?J)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "
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M:$MNL'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "
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M88*"S57G54B"]%DL1\N#.5P].-:#H5\!)]F$>&$L$O2&NV&5  "#.F6N  "
M 'P#:Y9_A%I.8)!_P5TA5&: !U_01Q" 56)3.$. N620)W2!:V9$$M>"^V9?
M  "!"6IB  "  '\V:H1\4V(C7V]\RV1>4W9],F9\1BY]D&AN-XM]^&HG)NI^
MBFMG$I1_B6L_  "  &]Z  "  (  :6UY9FGX7DYZ!&NA4E%ZA6TM14MZ]VZ8
M-K][:&_.)DQ[VW"A$CE\CW!(  "  '3^  "  (  :&-VU7'3751WD'+U45UX
M)7/U1%%XHG31-B-Y"W6-)<AY8'8#$?5Y^'6>  "  'GB  "  (  9W-TH'G%
M7'!U>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "
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M52N)$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "
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M4-=]3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "
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M2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "
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M18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "
M (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L
M  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C
M&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\
M&46>H5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;
M;U^.)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z
M/(29;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "
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M.B60SH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "
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MA4-=85(@=EM?_58Y9GUBBEHO58%D^5W[0SUG%V&/+T]H0&2Q%JII=694  "
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M?81)N'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "
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M>4A?BUIW:V-A_EVV7'MD46#33%EF<F/#.LQH*69U)T)HAVB4#D-N$6C_  "
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M<HY./(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "
M (  ?A-']8VE<=),"HS#9*I/MHNR5G=2^(J<1R=5JHFX-H17"HDK)#=6PHEB
M#25IR(<V  "  (  ?8)&()9G<4A*4Y3R9!].$9,V5?-16Y%Z1KI4"Y 7-C%5
M3X]1(]]54(]D#.%J/(BU  "  (  ?)5I<TX3< 9K#5'\8KILMU725&%N6%F#
M1,9OW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "  '6&>K-DLE:1;IQFMUG<88-H
MJ5T+4UAJ?6 50^)L(6+J,M)M965H'T1M3V<*!Q]TZF>_  "  'FM>1U@15\K
M;1=BIF')8$EDVF1.4C=FVF:O0O%HF6CD,A!IRFK.'KII36OW!PUT%6RE  "
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M9Z]3HXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "
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M8/AFQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "
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M7,5: (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "
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M50-L!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "
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M3JN#ED_=0X2$!%,^-PJ$FE9A*+R%@%D"%U:'B5I<!'&'U5NB  "  &DU  "
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M24-R;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "
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M0CB)YE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "
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M/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "
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M-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "
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M,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "
M (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (
M  "  (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
M              $                    !   !   "   ") 0=!=H':0C9
M"C8+A0S'#?\/,1!>$8L2MQ/B%0L6,A=7&'D9F!JU&](<[QXE'UD@AR&R(MHC
M_R4C)D0G9BB&*:<JQROH+0@N*"](,&DQB3*F,\(TWC7[-Q@X-3E1.FT[B3RE
M/<(^WC_X01%"*4-"1%Q%=4:/1ZE(PTG=2O=,$DTL3D-/65!O4892G%.R5,E5
MWU;V6 U9(UHZ6U%<9EUX7HI?FV"M8;YBSV/@9/%F F<2:"-I,VI":U)L7FUG
M;G%O>G"#<8QRE'.<=*-UJG:Q=[=XO7G#>LA[S7S.?<U^S'_+@,F!QX+%@\*$
MOX6[AK>'LXBNB:F*I(N>C)B-D8Z&CWN0<)%DDEB33)1 E3.6)I<9F R8_YGR
MFN2;UIS(G;N>K9^?H(ZA?*)JHU>D1:4SIB"G#J?\J.JIUZK%J[.LH:V/KGVO
M:[!9L4>R-K,DM!*U +7MMMJWR+BUN:.ZD+M^O&N]6;Y'OS7 (L$0P?["[,/:
MQ,?%M<:CQY'(?LELREG+1,PNS1C. <[KS]70OM&GTI#3>=1AU4G6,=<8V #8
MYMG-VK+;F-Q]W6+>1]\LX!#@].'8XKOCGN1[Y5?F,^<.Y^CHP>F:ZG'K2.P=
M[/#MP^Z6[W;P5?$S\@_RZO/#])SU<_9)]Q[W\_C&^97Z8?LI^^O\I_U<_@O^
MM/]:__\   'H Z<%+ :$![\(YPH$"Q8,' T>#AP/&1 7$102$!,+% 04_!7S
M%N87V!C,&=8:WAOA'.$=WQ[;']8@T2'+(L0COB2X);,FKB>J**8IHBJ@*YXL
MG2V:+I4OD3"-,8DRAC.#-($U?S9_-W\X@#F".G\[?CQ\/7P^?#]]0']!@D*%
M0XE$C4621IA'FDB;29U*GTNC3*9-JDZO3[10NE' 4L=3SE355==6V5?;6-Y9
MX%KC6^=<ZEWM7O%?]6#X8?QC &0#90%E_V;\9_IH^&GU:O-K\&SN;>MNZ&_E
M<.%QWG+:<]9TS77#=KEWKWBE>9MZD'N%?'I];WYD?UB 38%!@C6#*80<A1"%
M_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ
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M?V=80(3]?WM#S(0L?[HO[H-N@"K0)HI4BKF]%HD%B36I@X?)A\J5-(:_AI.
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M?*.9N'WB?,&$GGX>?/MO:7YM?4]:47[1?;)%9G]=?C<Q ( A?N34(WOSAQ3
MUWPHA@2L[7Q@A0*84GRIA"B#97T!@VMN7'UP@L)9<7WQ@AA$N'Z8@7 PD7]U
M@+32GGJRD72_1'KOCVFK8'LUC6Z6]7N,BXR"+GP!B=1M57R)B"58GWTEAF9$
M'7WGA(LP+W[<@F?1+GFHF\:]W7GJF,VI_GHYE=V5HGJ=DOR!!7L=D"UL6WO
MC717W7QSBI=#D'U,AX$OVGY5@_?/^7C9IA*\K'D=HC"HTGEMGD*4@WG8FEJ
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M;8!3AJ M9H!Q@Y7!]8';H?6P.X$RGIN=TH"BFR2*VX TEZ1WL'_IE"EDB'_
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MEBME6YLRDS)7?)<UD#I)W9,MC3P\UX\$BC,PCXKGAQPETH:XA!&-UZ:]HQF
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MR80.HN5W[X,-GO=II8(3FJ];4X%/EF1-(X#'DA0_@X!9C;4R;8 >B2TFIH
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MAZTQ1H$/A=<HT8"X@_8AN("'@BUEWILQ6:%<YYD(7.53F9;G8$%)[92?8[]
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MDL]G255+D$Y9ZULAC=M,AF%'BV8_KV>JB.DS?&Y.AE$HOG39@[R,OF1=4&.
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MVH^?B-J/GXC:CY^(VH^?B-J/GXC:CY^(VO^G.#+_HT1+_J-)7_.I1F_HKD2
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
M_YY/5/JA3F3OI$]UY:91A=JE6)71HF*CR9]MK\6?=[7"GH"YOYV(OKR9B<.Y
ME(O'MH^-R[.*D,^QAI;4KH.@UZ>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU:>!
MH=6G@:'5IX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU?^C.2K_H$9 _YY.
M5/JB363PI4YTY:A/A-NG5932I5^ARJ-IK<6B=+3"H7VYOZ"%OKN=B,.XF(G(
MM9.+S;&.CM.NB9;8IX6=VJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UJ&%H-:A
MA:#6H86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UO^C.2K_H$9 _Y]-5/NC
M3&3PITQTYJE.@]RJ4Y+2J5N@RZ9FJ\:E<+/#I7JXOZ2"O;NBA\.XG8?)LYB)
MS["4CM6KDI?:H(J<W)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V)N)G]B;B9_8
MFXF?V)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V/^C."K_H$5 _Z!,5/ND2V/Q
MJ$MSYJM,@]VM4)'4K%B>S*IBJ<>J;+'$JG:VP*I^O+RHA,*XI(;)LZ&(SZR<
MC=6CEI3:FI&<W):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>
MV):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>V/^D."K_H$5 _Z!+4_NE2F/QJ4ER
MYZU*@=ZP39#5L%6<SK!>I\FP:*_&LG.SP[)\N+VP@,&VK(+)KJ>%SZ6ABM6<
MG)':E9F<W)&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4
MGMF1E)[9D92>V9&4GMF1E)[9D92>V?^D."K_H$5 _Z%*4_NF2&+RJTAQZ*](
M@-^S2H[6M5&:T+9:I,RX9:O*O7&NP;E[MK>R@,"NK(3(IJB%SIVDA]24H([8
MCI^9VXR;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,
MFY[9C)N>V8R;GMF,FY[9C)N>V?^D."K_H45 _Z))4_RG1V'RK49PZ;)&?^"W
M1XS9NTZ7T[]7G]#%8Z3%P'"MNKAYM["R@,"IK87'H*B$S9>EA=*.H8G7AZ"2
MV8>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8
MAZ&<V(>AG-B'H9S8AZ&<V/^D-RK_H41 _Z-(4ORI16'SKD1OZK5#?>*\1(G<
MPDJ3V,I4F<K&8J2\O6ZPLK9XN:JQ@,&DK87'FZF$S).FA-"*HX?4@Z*.UH*B
MEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6
MUH*BEM:"HI;6@J*6UO^E-RK_H41!_Z1&4OVJ1&#TL4)NZ[A!>^3!0H;?S$:-
MT\]2E\'$8:>SNVVSJ[5XNZ6Q@,&?KH3&F*N$RI"HA,Z(IH;1@J2,TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"D
MDM. I)+3@*22T_^E-RK_H41!_Z5%4?ZL0E_UM#]L[;P^>.?'0('@UD:'R<U1
MFKC"8*JLNFVUI;5XO*"Q@,&;KH3%E:R$R(ZJA,N'J(;.@J>+SW^FC]!_IH_0
M?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_
MIH_0?Z:/T/^E-BK_HD-!_Z=#4/^N/UWWMSQI\,([<^;0/WG3V3^*OLM1G:_
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MEK9[NI2S@KZ2LH7 C;&&P8FPA\.&KXC$@JZ*Q8"NC,6 KHS%@*Z,Q8"NC,6
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M@*&FSO^B-B+_GT,W_Z-%1_^J0E/^L4%?]KA!:O'!1'/JS$MYX-I6?,_57HW
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M)C;2X29!P>\L6K#M,VZAX3U_E==-C(W07I:)RVN=AL=THH/$>J9_PWVI?,&
MJWK @JQYOX2M=[Z&KW6^B;!SO8RQ<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ
M<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L?^I+B'_LRHK\L4B+-;>'"W#
M[2-'LODK7:+L-F^5XD)]B]I2B(748)""T&R6?LQSFWO*=YYXR7N@=LA^HG3'
M@*-SQH*D<<6$I7#$AZ9NQ(JG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+
MIV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+I_^L*B#ZO1\BW-D2&\7K&C.T^B-*
MH_DN7I7N/&V*Y4EY@]]6@G[:9(EZUFR.=M-QD7/2=91QT'F5;\][EVW.?IAL
MSH"9:\V"FFK-A)MIS(><:,R(G&C,B)QHS(B<:,R(G&C,B)QHS(B<:,R(G&C,
MB)QHS(B<:,R(G&C,B)QHS(B<:,R(G/^V'ACDT X3R.D1(+7Y&S>E_R9+E_HT
M7(OQ0FB"ZD]R?.5;>G?A9']RWFJ#;MQPAFS;=(AJV7>):-EYBV?8?(MFUWZ,
M9=: C636@HYCU86/8M6%CV+5A8]BU86/8M6%CV+5A8]BU86/8M6%CV+5A8]B
MU86/8M6%CV+5A8]BU86/8M6%C^G'#0S*V@L/M_<2)*?_'3F8_RM)C/XZ5X/V
M26%\\%5I=>Q>;V[I8W1JYVEW9^5N>67D<GMCXW5\8N)W?6'B>7Y@X7M_7^%]
M?U_@?X!>X(*!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!
M7=^#@5W?@X%=WX.!7=^#@<O0"0.ZX@L3J/\4)IK_(3>-_S%%A/] 4'S\3EAT
M^%=?;?1=9&?R8F=C\&AJ8>YL;%_M<&U=[7)O7.QU;UOL=W!:ZWEQ6NMZ<5GJ
M?')8ZG]R6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_
M<UCJ?W-8ZG]S6.I_<_^<.!K_FD8M_Y=10?^:4T_^G%5>]9Q:;.R;7WKDF6>'
MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MN<&#F;N_?YV^OGVBO[UZJ,"\>:_!M'FPP;!ZL,"P>K# L'JPP+!ZL,"P>K#
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MRC [VMTR/\KG.%6\[#UIK>5$>9_;3H>4TUR2C<QHFXC(<J&$Q'FF@,)]JGS
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M>>:L8(+@JFF+VJ9SE,^??)W&EX.HOI"*L+B+D;:RAIBZK8.@O:F!J+^E@+#
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MO/^:,Q3_F4(F_YQ&-/^C14#_J$5*_ZU'5?ZQ2E_UM5!HZ[E6<..]7G?9NVJ
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MJ6&ZP:EANL&I8;K!J?^9+ [_H#4:_ZHQ(/^V+B/PQ2TBW]@S'-#C.B[$Z$)
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M9DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09L3"!@"VT0<
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MP:F#BL&I@XK!J8.*P:F#BL&I@XK!J?^+)PG_CC<7_YP\'_^C.R;_JCTM_[%
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M9=N&R67;AO]X) ;_>#40_WY &_^(1R;_C4XQ_X]5//^.6T;_BV)0_X9I6?R
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M?#01_X@\&O^20R3_F$@M_YI,-_^:4D'_F5A*_)=?5/:39EWPC6YFZX=W;^:
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M<D[,Z7).S.ER3LSI<D[,Z7).S.ER3LSI<O^2$0'_IQ$ V+D) ,O&" #"U0H
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M//[.5CS^SE8\_LY6//[.5LZP @"]N@0 L<<$ *76!P";_1 "D?\@"8C_+1*
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M?_]K( /_>AX$_XLF!O^8+PK_H34-]Z<X$.RM/!/CLD(6U[%'(\NK4C+!I5I
MN)]B3+"9:5>HE'!@H8]W9YN+?FZ6B(9SD86.>(R"EGR(@)^ A'^J@H%_MX.
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M>5VAY'E=H>1Y7:'D>5VAY'E=H>1Y7:'D>?]]%0+_D!0!_Z$8 ?:Q% #9P0L
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M_X<C*/^0)"?_F24F_Z$F)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)I_
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M64C%^UI(Q?M:2,7[6DC%^UI(Q?M:2,7[6O>1! #4H@( QZ\$ +JY P"PQ 4
MI] ) )_A$ "8X2$#C^ P"8;@.Q)]WT0;==Y-)&[=52MGW%PR8MMD-UW;:SM9
MVG(_5=IZ0U+:@T5.VHU(3-J82DG:I4M(V[-,1]S$3$;<WDQ&VNU,1-CY3T/8
M^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0( N[," +"] P"ER04 F]8)
M )3H% &,Z24$A.@S"WOH/!1SZ$0;:^A+(F3G4BA>YUDM6>=@,E7G:#52YV\X
M3^=W.TSG@#U)YXD_1^B4043HGT)"Z:Q#0>FZ1$#JS41 ZN1$0.CU1$#G^$-
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M7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z# #]BPD VIL$ ,ZG!@#$L 8
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MY5&J/N-0LC_A3[M X$_'0-Y/V$'93^A!U$_T0]!._D7.3O]&R%#_1L)1_T?
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M66>#_%AG@_Q79X/\5V>#_%=G@_Q79X/\5_]L#@#_>PP \HD) -F5!@#/G@@
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M3TZD_T].I/]/3J3_3_I_  #8C@  R9L! +ZE @"TK0$ J[4  *&_! ";P10
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M#R7_H1 D_ZX1(_^Z$B+_RA(B_] 2(O_0$B+_T!(B_] 2(O_0$IRR  ".O
M@<<  '/1  !GW0  6>,  %/]!@!-_PX 2/\6 $/_'@$__R8".O\M C?_,P,S
M_SD#,/\_!"[_1 0K_TH%*?]0!2?_5@8D_UT&(O]E!R#_;@<=_WD(&_^%"!K_
MD@D9_YX)&/^H"1?_LPD7_[<)%_^W"1?_MPD7_[<)%_^W"9"Z  ""Q0  =-
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M3(]BZ$R.8_A+C6/_2HQD_TF+9/])BV3_28MD_TF+9/])BV3_2?]:$P'_9A
M_W$1 /]Z$@#W@A0 Z(<7 -V+' #0BRP#QX@["K^$1Q.X?U$<L7M:)*QW8BNG
M=&HQHW%R-I]O>3N;;8 _F&N(0I5ID$62:)E(CV:B2HQFK4R*9;I-B&7,3H=F
MYDZ&9_9,AF?_2X5H_TN$:/]*A&C_2H1H_TJ$:/]*A&C_2O]<$@'_: \ _W00
M /]]$ #SA1  Y(L1 -:/%P#+CBH"PHPX";J(1!*SA$\;K']8(Z=\8"NA>&@Q
MG75O-IES=CN5<7T_DF^%0HYMC46+;)9(B&N@2X5JJDV#:;=.@6G(3X!JXT^
M:_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+?VO_2_]>$ '_:PX _W8. /N
M#0#JB T VX\, -"2%0#'DB<"OH\V"+:,0A&NB$T:J(16(J* 7BJ<?64PEWIL
M-9-W<SJ/=7L^C'."0HARBT:%<)-)@F^=3']NJ$Y];K5/>VW&4'INX%!Y;_).
M>6_^37EO_TQY;_]+>6__2WEO_TMY;_]+>6__2_]@#P#_;0T _WD, .Z#"P#;
MBPD U)$* ,R5$P#"E24"N9,T![&/01"JC$L9HXA4(9V$7"F7@6,ODGYJ-8Y\
M<3F*>G@]AGB 0H-VB$5_=9%)?'.;3'ERIDYV<K-0=7+#4'-RW5!T<_!/='/]
M371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B#@#_;PP _'L* -Z&!@#5C@@
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M2UZ&_TM>AO]+7H;_2_]M!0#J?   U8@  ,J2 P#!F@, N: # +&F"0"IIQD
MHJ<I YJE-@F2HT$2BZ%*&H2?4B%^G5HH>9M@+G299S-OEVXX:Y9U/&>4?4!C
MDX9#8)&01ER1G$E:D*E+6)"X3%>0S$Q7D.=+5X_W2E>._TI8CO])6([_25B.
M_TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@( LJ0  *FJ!0"BK!4 FZPF
M I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!JGVPT99YS.6&=>SQ>FX1
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M(#G9PR YV=\@.=?O(#C5^2(WU/\C-]3_(S?4_R,WU/\C-]3_([F<  "KI
MGZP  ).U  "'O@  >\8  '#. P!EU@< 7>,. %KC&P!6XR<!4N0R D[D/ 1*
MY$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>: %#?GC!4UYYD6-.>H%S+H
MN!@RZ,P8,>CE&#'F]!@QY?P8,>7\&#'E_!@QY?P8,>7\&*ZB  "AJ@  E+,
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M!1'_L@41_[P%$?^\!1'_O 41_[P%$?^\!8RX  !]P@  ;\P  &+8  !4WP
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M8A/V2VT7\TEW&O!'@1SN1HH>[$62(.M$F2'I0Z BZ$.G(^9#KB/E0K8DY$+
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M.*=2[3FE4_HYHU/_.:)3_SFA5/\XH53_.*%4_SBA5/\XH53_./]/% '_61
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M+*%F>"^>9( SFV*'-IAACSB68)@[DU^A/9%>JS^/7KA C5[(08M>X4&*7_-
MB5__/XE@_SZ(8/\^B&#_/8A@_SV(8/\]B&#_/?]7#P#_8@P _VP, /AT# #I
M>@P WGX, -*!%0#(@2<!P'\V!KA\0@VR>$T5K'56&Z=R7R*B;V8GGFQN+)MJ
M=3"7:'PSE&>$-I%EC#F.9)4\C&.>/HEBJ$"'8K5"A6+%0H1BWD.#8_%"@F/]
M08)D_T""9/\_@F3_/X)D_S^"9/\_@F3_/_]9#@#_9 L _VX* .IW" #;?0@
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M-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!NT45P;^M$<&_Z0W%O_T%Q;_]
M<7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78  -1_ P#+A@4 Q8L& +Z-#0"U
MCQX KHXM Z:,.@F?B441F89.&).#5AZ.@%TDB7YD*85\:RV!>G(R?7AY-7IW
M@CEW=HL\<W65/W%TGT)N<ZQ$;'.[16MSSD5K<^E$:W/X0VMS_T)L<_]!;'/_
M0&QS_T!L<_] ;'/_0/]A!0#Z;@$ W7D  -"" @#'B00 P(X$ +F1# "QDAL
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M,D6IOS)$JMHR1*CO,D.G^S-#IO\S0Z7_-$.E_S1#I?\T0Z7_--"!  #!C@
MM9@  *F?  ">I0  DZP  (BR  !\N0( =KH1 '*[(0!NNRX":+LZ!F2Z0PI?
MNDP.6[E3$E>X6A94N&$94;=I'$ZW<1]+MGHB2+:$)46VD"=#M9TI0;6L*D"V
MOBH_MM@J/[3N*CZS^BP]LO\M/;'_+3VQ_RT]L?\M/;'_+<>)  "YE0  K)T
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M#BW@\@XLW_L/+-_]$"S?_1 LW_T0+-_]$*B@  "<IP  C[   (.X  !VP0
M:LD  %[/  !3U0$ 2=P& $7I#P!"Z1D 0.HD #WJ+@ ZZS8!..P^ 3;L1@(S
M[4T#,>U5 R_N700M[F4%*^YP!2GO>P8H[XD')O"7!R7PIP@D\;@((_',""+R
MY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP  A+@  '?!  !JR0  7=
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M'\5"\R'"0?XCP$'_)+Y!_R2]0?\EO4'_);U!_R6]0?\EO4'_)?]"& '_21,
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M,954_S&45/\PE%3_,)14_S"45/\PE%3_,/]/#@#_6 L _V + /MF# #P:PT
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M-7AD_S5X9/\U>&3_-?]7!0#_8@$ X6P  -1S @#+> 0 Q7L% +Y]#0"V?AT
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M-5*'OC51A]8U48;N-5*%^S12A?\T4H7_,U*%_S-2A?\S4H7_,^-L  #.>0
MP8,  +:+  "LD0  HI4  )>9  "/FPL BIT8 (2=)P%^G#0$>9L^"'.:1PUO
MF4\2:IA6%V:771MCE6,>7Y1J(ER3<B59DGLH59&%*U*1D"Y0D)TP3I"K,4R0
MO#),D-,R3(_M,DR.^C),C?\Q3(S_,4R,_S%,C/\Q3(S_,=QQ  #(?@  NX@
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M(#NN]R$ZK?\B.JS_(SJL_R,ZK/\C.JS_(\"&  "SD@  IYD  )R?  "0I@
MA*P  'FQ  !MMP  8;P% %V]$@!:OB  6+XM 52^. )1OD($3KY*!DR^4@A)
MOED*1KY@#$2^: Y!O7$1/[U\$SR]B!4ZO946.+VD%S>]M1@VO<H8-[SG%S6[
M]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF   GY\  ).F  "'K   >[,
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M QOI^0,;Z?D#&^GY YJD  "-K   ?[4  '*]  !EQ0  6<L  $S0  !!U0
M.-P  "_A @ M\0T *_$3 "CR'  F\B0 )/,K "+T,@ A]#D '_5! !WU20 ;
M]E$ &?=: 1?W90$5^'(!%/F! 1/YD@$2^J("$?JS A#[Q@(0^]T"$/OI A#[
MZ0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0  2],  $#9   UW@  +.,
M ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5_RX $_\U !+_/  0_T,
M#O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_K@$$_[P! __' 0/_QP$#
M_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P  #/A   IY0  (>P  ![]
M   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R, "_\H  C_+@ &_S4  _\]
M  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0  _Z4  /^L  #_K   _ZP
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M'JY!_QZM0?\>K$'_'JQ!_QZL0?\>K$'_'O]"$0#_1PT _T\. /]3$0#_5A4
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M*(=4_RB'5/\HAU3_*/],!0#_5@$ Z5T  -QC @#19P4 S&@' ,9H$ "]:B
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M+U]OO2]>;]0O7F_M+U]O^RU?;_\L8&__+&!O_RQ@;_\L8&__+.M>  #8:0
MQW(  +QY  "S?P  JX(  *&"  "9@PX E(0= (Z$*P&(@S8$@X) "'Z 20QY
M?U$0=7U8%')\7QAN>V4;:WIL'FAY=")E>'TE8G>')V!VDBI==9XL6W6K+EIT
MNR]9==$O673L+EET^BU:=/\L6G3_*UIT_RM:=/\K6G3_*^9A  #1;0  PW8
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M)TF)]RA)B/\G28?_)TF'_R=)A_\G28?_)]%O  #!>P  M80  *N,  "@D
ME90  (F7  !^F@  =YL. '.<' !OG2D!:YPU F:</P5BFT<(7YI/"UR:5@]8
MF5P259AC%5.8:Q=0EW,:399]'4J5B1]'E94A196D(T24LR-#E,@C0Y3E(T.2
M]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0  L(L  *21  ":E0  CYD
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M$C"S_Q,PL_\3,+/_$[*.  "EE0  FIL  (ZB  ""J   =:T  &FS  !>MP
M4[L  $? !0!#PA  0L(; $##)P _PS( /L0\ #S$1 $ZQ$T!.,15 C;$70,U
MQ&8$,\5P!#'%? 8OQ8H&+<6:!RO%J@@JQ;X(*L7:""K$\ @IPOL)*,'_"BC!
M_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP  :[4  %^[  !4OP  2<,
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M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   QV   )]T  !_A   9Z
M%O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^,  (_S@ !O]!  /_3
M_U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.  #_SP  _\\  /_/ '^R
M  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0  '.4  !3I   1]P  #_\!
M  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P  _RH  /\R  #_/   _T<
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M"LTJ_PO,*O\,RRK_#,LJ_PS+*O\,RRK_#/\R%P#_-1( _S@2 /\[& #_/2
M_SPJ /X[-0'W.4$!\39- NPT6 +H,V,#Y3)M!.,R=@3@,7\%WC&'!=PPC@;:
M,)4&V#";!]8OH@?4+ZD(TB^Q"- ON@G/,,8)S3#8"<DQZ@K&,?<,PS'_#L$Q
M_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\ _SX0 /]!% #_0QH _T(C
M /5!+@#M/CH!YSU& >$\4P+=.EX#V3EH!-0X<0;1.'H'SS>!",TWB G+-H\*
MRC:6"L@VG0O&-:0,Q36L#,,UM0W!-< -P#;/#KTVY@ZY-O00MS;_$;4V_Q*T
M-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L _T,- /]'$ #_2!0 ]4<< .M&
M)@#C1#( W$1! =1#30+/05@$RT!B!L@_:PC%/G0)PSU["\$]@PR_/(H-O3R0
M#KL\EP^Z.Y\0N#NG$+8[L!&U.[L2LSO)$K$[X!.N//$4JSS]%:D\_Q:H//\6
MJ#S_%J<\_Q:G//\6ISS_%O\]#0#_0@@ _T@* /]+# #Z3 \ [$P4 .%*'0#6
M2BP SDL[ <E*2 +$2%,$P$==![Q&9@FZ1&X+MT-V#;5#?0ZS0H00L4&+$;!!
MDA*N0)H3K$"B%*I JQ6I0+86IT#$%Z9 V1>C0>T8H$'[&)]!_QF>0?\9G4'_
M&9U"_QB=0O\8G4+_&/] "0#_1@4 _TP% /%/!P#F4 D XT\- -5/%0#,42<
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M)6M>O"9J7M$F:5[L)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70
MRV4  ,!K  "W;@  KV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65B
MNB9D8L\F9&+J)F5B^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@
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M)55P]B16;_\C5F__(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0
MGW\  ))^  "*?P< A( 3 ("!(0![@2X!=X Y W* 0@5N?TH(:WY1"VA]6 YD
M?%\18GMF%%]Z;1=<>74967A_'%=XBAY4=Y8A4G:D(E%VLR-0=L8D4';C(U!U
M]2-1=?\B473_(5%T_R%1=/\A473_(=AC  #%;0  N'8  *Y]  "E@@  FH,
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M&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0
M99L$ &"<$ !=G1T 6YXI %B>- %5GCT"4IU% U"=305-G50'2YQ;"4B<8PM&
MG&L-0YMU#T&;@!$^FHT3/)J;%#J:JQ4YFKT5.9K9%3F8[Q8YE_P6.);_%SB5
M_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-E0  @9H  '6=  !HH   6Z0
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M!:22  "8F   C)X  ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0
M*L<+ "C($P GR1T )LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =
MS7H ',V* !O-G  9SJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9
M  "/GP  @J8  '6M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- &
M !G5"P 6UQ  %=@9 !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T
M$-Y^  [?D0 .X*0 #>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%
MIP  =ZX  &JU  !=O   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>
M!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN
M  'K@   ZI0  .JG  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP
M:[<  %Z^  !1Q0  0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *
M]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V
M;@  ]H$  /:5  #WIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,
M %+(  !$S0  -]$  "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,
M /\(  #_#0  _A   /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P
M_VP  /^   #_D@  _Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0 _QHE /\5
M)P#_$2X _Q Z /\.1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_"HX!_PJ5
M ?\*FP'_": !_PFE /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)ZP#U"?8
M\PG_ /(*_P#Q"O\!\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA /\9) #_
M%RP _Q4W /\31 #_$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!_PZ2 ?\.
MF '_#IT!_PZC ?X.J '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N#O4 [ [_
M >L/_P'J#_\!ZA#_ >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?( #_'RD
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M"+DJ_PFY*O\)N2K_"?\P#P#_,@L _S8- /\X$ #_.14 ^3<> .\U* #G,S4
MX#)" -LR3P#5,5H!T#%D LTP;0++,'4#R3!\ \<O@P3%+XH$Q"^1!<(OEP7!
M+YX&OR^F!KTOKP:\+[D'NB_'![@PW0>U,.X)LC#["K P_PNN,/\+KC#_"ZTP
M_PNM,/\+K3#_"_\S# #_-@8 _SP) /\^# #]/1  [SP5 .0Y'P#;.2T TCH\
M ,TZ20'(.50!Q#E> L$X9P._-V\$O3=V!;LV?0:Y-H0'MS:+![8UD@BT-9H)
MLS6A";$UJ@JO-;0+KC7!"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB
M-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!
M1 &]04\"N4!9 [8_802T/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=
M#:4[I@VC.K .HCN\#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1
MF#S_$?\Z 0#_0   [T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S
M1TH"L$94!*Q%706J1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I
MH1&80*P2ET"X$I5 R!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_
M$_\\  #Y1   Y$H  -A.  #.3P( R4T& ,-+#P"[31T M4XM *]..@&K348"
MITQ/!*1+6 :A2F (GDEG"9Q(;@N:1W4-F$9\#I9&@P^418L1DD64$I!%G1..
M1:@4C$6T%8M%Q!:*1=P6B$;P%H9&_1:&1O\6A4?_%85'_Q6%1_\5A4?_%?\_
M  #L2   W4\  ,]3  #&50  P%,# +M1# "S4AD K5,I *A3-@&C4D("GU%+
M!)Q05 :93UP(EDYC"I1-:@R13'$.CTMX#XU+?Q&+2H<2B4J0%(=)FA6%2:47
M@TFQ&())P!B!2M89?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F
M3   UE,  ,E8  # 60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)55
M40:25%@(CU)?"HQ29@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN
M&7I.O1IX3M$:=T[K&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4
MT%<  ,1<  "[7@  M%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+
M6%4(B%=<"H968PR#56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2
MNAMQ4LT<<%+H&W!3^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH
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M'6!>]1Q@7O\;8%[_&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;
MHVP  )EI  "2:@L C&H6 (=K) "":S !?FHZ GII0P1V:$L&<V=2"'!G60IM
M9F -:V5F#VAD;A%F9'849&. %F)CBQA@8I<:7F*D'%QBLAU;8L4=6V+A'5MB
M]!Q;8O\;7&+_&EQB_QI<8O\:7&+_&N!5  #+7P  O6<  +)L  "I<   GV\
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M&4UO_QE-;_\936__&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P
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M#[5X  "J@@  GH@  ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ
M1Y\; $:@)@!$H#  0Z$Z $&A0@$_H4D!/:%1 CNA60(YH6$#-Z!K!#6@=@4S
MH(,&,:"2!S"@H@@NH+,(+J#)""Z?YP@MG?<)+9S_"BV;_PHMF_\*+9O_"J^
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M 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0
MB)L  'NA  !NI@  8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =
MPA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&
MD0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(
M '&I  !DKP  6+0  $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L
M#M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %
MU)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q
M  !9N   3+T  #_    TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-
M  3<$0 #W1@  =X@  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@
M .2;  #EK@  Y<$  .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-
MP0  0,0  #/(   HS   ']   !?4   0V0  "]T   7A    Y    .4'  #F
M#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**
M  #SG   \ZT  /2[  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0
M,\T  "?1   =U@  %-P   [@   (XP   >8   #J    [@   .X   #O!
M\ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_
MB0  _YH  /^F  #_L   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W
M /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P
M_P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N
M /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*
M00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*>
M /<"I #U JH \P&P /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\
MY@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_
M#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*
MH0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_
M -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0
M_A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E
M#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3
M_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+
M .X85@#J%V  YQ9J .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J(
MU!:I -(6L0#0%[L SA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+
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M!O\M!0#_,   _S," /8T!@#O,@H Z"X0 -PL& #1+B@ RR\W ,8P1 #!,$\
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M"Y [P R..]4,C#SL#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P
MW$4  ,Y)  #%20  OT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:
M0UL#F$-B!99":0:407 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5
MO ^$0,\/@D'I#X%!^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL
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M%&M.]!-K3O\2:T[_$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7
MIEH  )]6  "85@T DE<9 (Y8)@")6#( AE@] 8)710)_5DT#?%54!7E46P9W
M5&$(=5-H"7-3< MQ4G@-;U*!#VU2BQ!K49<2:5&C$V=1L11F4<,595+>%652
M\A1E4O\395+_$F52_Q)E4O\295+_$N1*  #/4P  P%H  +5>  "L8   HEX
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M$U==_Q)77?\25UW_$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90(
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M$,%C  "S;   J',  )MV  ".=0  @78  '5V  !I>   8WH" %Y\#@!<?1D
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M!C&/G@<PCJ\'+X[#!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P
MF(0  (J$  !]A0  <(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [
MF2@ .IHQ #F:.@ WFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:
MF@,IFJP$*)K !">9W@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD
M (2*  !VC   :H\  %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$
M+J0J "VD,@ LI3H *Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@
MIJ@!'Z6[ 1ZEUP$>I.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1
M  !OE   8Y@  %>=  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A
M ""P*0 ?L#$ 'K Z !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ(
M%+*V !.RS@ 3L>L $Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !H
MGP  6Z,  %"H  !%K   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\
M'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL
M  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@
M4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &
MR1P !<DD  3*+  #RC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+
MLP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@
M #N[   PO@  )L$  !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0
M -4:  #6(@  URH  -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I
MWK8  -[(  #>W@  WN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$
M   DQP  &\L  !//   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2
M  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4
M .ZT  #NP@  [L8  .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9
MT0  $=8   O;   #W@   .$   #E    Z    .D   #J    ZP8  .T+  #O
M#P  \!,  /(:  #T(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB
M  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X
M_P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V
M *< ]0"M /, M0#R +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H
M_P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6
M /\ 80#_ &L _0!S /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0
M[0"K .P L@#J +H Z #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A
M /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X
M7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H
M ., KP#A +@ WP## -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\
MU /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q
M!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&
MK0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_
M /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P
MX0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)
M#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?
M"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-?
M ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[
MNQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_
M(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >
M8@"^'FH O!]Q +H?> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W
M :PAQ@&K(=T!IR+O J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*
M\BH  .4K  #?* 4 W"$+ -(A% #))"0 PR4R +XF/P"Z)TH MR=4 +0G70"R
M)V0 L"=L *XG<@&M)WD!JR=_ :HGA@&H)XX!IR>6 J4GG@*C**@"HBBS J H
MP0*?*-4"G"GL YHJ^@.8*O\$ERK_!)<J_P26*O\$EBK_!/\H  #U+@  Y3,
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M"7L\\PE[//\)>CS_"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20
MKD8  *E!! "C01$ G4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%
M068#@T!M!(% = 6 0'L&?C^$!WP_C@AZ/YD)>#^E"G= L@IU0,,+=$#="W-!
M\0MR0?\*<D'_"G)!_PER0?\)<D'_">D\  #510  Q4L  +I.  "P3@  ITL
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M#&!-_PM@3?\+8$W_"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8
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M#,E4  "Y7   K6,  )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT
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M"3]NG@H];J\*/6[""CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0
MH&X  )%M  "$;0  >&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,
M=S$ 2W@Y $EX00!(>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEV
MG @W=:T(-W7 "#9UW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$
M (MQ  !^<0  <W(  &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP
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M 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@
M8H4  %>)  !-C@  0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ C
MGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?
MR0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\
M %"3  !&F   /)P  #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD
M%:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,
MJM\ #*GR  VH_  -J/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?
M   _HP  -:<  "NJ   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G
M  FV+P (MCD ![=#  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL
M +;E  "U\0  M?<  +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   W
MKP  ++(  ".U   :N   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #"
M)@  PB\  ,,Y  #$1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31
M  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0
M(KP  !F_   1P@  #,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0
MSR0  - M  #2.   U$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8
MS@  V-T  -C= 'N@  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8
M !#)   *S    M    #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD
M .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@
MZL,  .K# '"H  !BKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4
M    V0   -T   #A    XP   .0   #F    YP$  .D'  #K#   [!   .X5
M  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[
M /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_
M &L _P!S /T >P#[ (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$
ML #O +@ [@## .P T0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_
M /\.& #_"A4 _P$4 /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &<
M]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F
M +0 Y "_ ., S #A .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0
M$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K
M .P <@#J 'D Z !_ .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$
MV "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_
M#@T _PP- /\+$@#_!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$
M;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X
M ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8
M_Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0
M!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&
MP@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8#
M /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H
MP@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T +(/P0"Q
M$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\ IQ/_ /\:  #_&P  ^1L  .L9
M  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_%$L O!14 +D570"W%60 M15K
M +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7G "I%Z8 IQBP *88O0"D&,\
MHAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0  -TE  #4
M(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4 L!Y/ *T>5P"K'E\ J1]F *@?
M; "F'W, I1]Y *,?@ "B'X< H""/ )\@F "=(*( FR"L 9HAN0&8(<H!EB+D
M 90C]0&2(_\!D2/_ 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0
MP2<# +TB#0"V(QH L"4H *PF- "H)D  I2=) *(G4@"@)UH GB=A )PG9P";
M)VT F2=T )@G>P&6)X(!E2>+ 9,GE &1*)X!D"BI 8XHM0*-*<8"BRG? HDJ
M\@*'*O\"ABK_ H8J_P*&*O\"ABK_ O0H  #C,0  T38  ,4X  "\-@  MC
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M!6P\_P5L//\%;#S_!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L
MC3\5 (D_(0"%0"T @D W '] 0 !]0$@ >T!/ 7E 5@%W/UT!=3]C G,_:@)Q
M/W(#<#]Z VX_A 1L/Y %:S^<!FD_J09H/[@'9T#,!V9 Z =F0/D&94#_!F5
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M!LQ(  "\4   KU4  *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"
M:E J &=0,P!E4#P 8U!# &%02@%?4%$!75!8 EQ07P):4&<#65!P!%=0>@55
M4(8&5%"3!U)0H0A14+$)4%#$"5!0X0E04/0(45#_!U%/_P=13_\&44__!LE+
M  "Y4P  JU<  )Q6  "/50  A50  'Q0  !U40  <%() &M3$@!H5!T 950G
M &)4,0!@5#D 7E1! %Q42 %:5$\!6516 5=470)65&4#5%1N!%)4> 515(0&
M3U21!TY4H A,5*\(3%3""4M4WPE,5/,(3%/_!TQ3_P=-4_\&35/_!L5.  "V
M5@  IUH  )A9  "+6   @5<  '=4  !P50  :E8& &97$ !B5QH 8%@D %U8
M+@!;63< 65D_ %=91@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/
M!DE8G@=(6*X(1UC "$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60
MHUP  )1;  "'6P  ?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6
M730 5%X\ %->1 !17DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=
MG =#7:P'0EV^"$)=V@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\
M )!>  "#7@  >%T  &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$
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M!#!PT 0Q;^P$,6[[!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0
M:VD  &!K  !5;@  37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X
M>3T -WE% #9Y30 U>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIX
MS (J=^H"*G;Y RIU_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX
M %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@
M+H)  "V"2  L@E  *X): "J"9  H@G  )H)_ 26"CP$D@J !(X*R 2*"R0$B
M@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0  @W$  '9Q  !L<@  8'4  %9X
M  !,?   0X   #N#   SA@  +8D* "J*$0 IBQD )XLB ":+*@ EC#$ )(PY
M ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-B@ ;C9P &8VN !B,Q  8C.,
M&8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78  ')W  !E>0  6GP  %"   !&
MA   /(D  #2,   MD   )9," !^5#  =EA( ')8: !N7(@ :ERH &9<R !B8
M.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0F)8 $)BI  Z8OP .E]T #Y;R
M !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP
M-I,  "V7   FF@  'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -
MI#H #*1%  ND4  *I%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A
M\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX
M ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(
M + \  "P1P  L%,  +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP
MKO0  *[T (>)  !XB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN
M   6L0  $+0   NV   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ
M  "]/   OD@  +Y6  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L
M +WK '^2  !PE0  8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .
MO   ";\   +"    Q    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,
M,   SCP  ,Y)  #/60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_;
M '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP
M ,H   #.    T    -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)
MX"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE
M  !?K   4;(  $2Y   UO   *,   !S$   2R   #,L   //    TP   -@
M  #<    WP   -\   #A    XP   .0#  #F"   Z T  .D1  #L&   [B(
M /$N  #S/   ]$T  /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_
M !4 _P 5 /\ & #_ ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L
M=@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"]
M .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$
M_P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P
M 'D [P!_ .T A #K (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X
MQ@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P -
M /\ $@#_ !H _P F /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0
MXP!Z .( @ #@ (4 W@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#,
M -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\
M#P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U
M -( >P#0 (  S@"& ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L
MO0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_
M 1  \  9 .8 )0#A #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4
M=@## 'L P0"! ,  AP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#?
M + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH
MX@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W
M!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+
M\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+
M ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$
MJ@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7
M$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0
M#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R
M )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T
MBAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N
M&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?
M= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_
M 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$
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M M$[  # 0@  L$4  *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2,
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M U)'G 101ZL$4$>]!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30
MHTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=
M234 6TD] %E)1 !724H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*
MFP1,2ZH$2TN\!$I+TP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\
M )%/  "%3@  >TT  '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833(
M5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!3DYG 4Q.<@)+3GT"24Z+ TA.F01'
M3Z@$1D^Z!$9/T01&3^T$1D[\!$9._P-'3O\#1T[_ [U,  "N4@  G%$  (U1
M  "!40  =U   &Y,  !G3@  8D\  %U0#0!:4!0 5U$> %51)P!343  45(X
M %!2/P!.4D8 35)- $Q350!*4UT!25-E 4A3;P)&4WL"15.) T-3EP-"4Z<$
M05.X!$%3SP1!4^P$05+[ T)2_P-"4O\#0E'_ [I/  "J5   F%0  (E4  !]
M4P  <U,  &E1  !B4@  7%,  %A4"@!451( 4E4; $]6) !.5BT 3%<U $M7
M/ !*5T0 2%=+ $=84@!&6%H!1%AC 4-8;0%!6'D"0%B& CY8E0,]6*4#/%BW
M!#Q8S00\5^H#/%?Z SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@
M;U8  &55  !<5@  5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$
M74$ 0UU( $)=4 ! 75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=
MRP,V7.@#-USY S=;_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD
M &!:  !66P  45T  $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX
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M 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);
M0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C
M>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX
M_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<
M #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4(
M&(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2
M@O\ $H'_ )%N  "!;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#
M   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$
M  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P
M"(W_ (ES  ![<P  ;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   A
MD0  &I4  !.7   .F@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=
M2   G50  )UB  "<<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX
M ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0
M$J    ZC   )I@4  Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P
MJ4L  *E9  "I:   J7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V
M  !O@0  880  %6)  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P
M  >O    L@   +,'  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT
M +A.  "X70  N&X  +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !G
MBP  6I   $Z6  !"G   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\
M    O@   +X   "_!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"
M  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F
M4YX  $:D   ZJP  +[   "2U   9N   $+P   J_   !P0   ,0   #(
MR@   ,H   #,    S0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>
M0P  WU0  -]G  #@?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T
M #^T   RN   )+P  !B_   0PP  ",<   #*    S0   -$   #5    V
M -D   #;    W0   -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0
M\48  /)8  #S:P  \X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\
M%0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^
M /0 A #R (D \0". /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L
MXP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_
M !L _P H /\ - #^ $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D
M?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H
M -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8
M^P B /< +P#T #L \ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#:
M (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0
M\@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 =
M .L *0#G #8 XP!! -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L
MR "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T
M /H M #_ +0 _P"T /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X
M(@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![
M +D @0"W (< M0". +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /<
MIP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#'
M "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P
M? "J (( J0") *< D0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_
M )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\
MMP,L +,$-P"P!4( K09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?
M"'X G0B% )L)C@":"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X.
M_P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD
M *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D
MDA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""
M%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5
M*@"9%34 EA8^ )061P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\
M (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\
M>!W_ .4B  #0*0  ORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".
M'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@
M@0!Y(8P =R&7 '4BI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_
M -TI  #(,   MS(  *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H
M@B4T ( F/0!])D0 ?"9+ 'HF4@!X)E@ =R9> '4F90!T)VP <B=T '$G?0!O
M*(@ ;BB4 &PHH0!K*:\!:BG  6DJVP%G*O$!9RO_ 68K_P%F*O\!9BK_ =0O
M  #"-@  KS8  *$U  "6-   D#   (HM  "'*@8 @RD0 '\J&@!\*R4 >2LO
M '<L. !U+$  <RQ' '$L30!P+%0 ;BQ: &TL80!K+6@ :BUP &@M>@!G+H4
M92Z1 60NG@%B+ZP!82^] 6$PU0%@,.\!7S#] 5\P_P%?,/\!7S#_ <TT  "\
M.P  J3H  )LZ  "0.   B34  (,R  !_, $ >R\. '<P%@!T,"$ <3$K &\Q
M- !M,3P :S%# &HQ2@!H,E  9S)7 &4R70!D,F4 8C)M &$S=P!?,X(!7C..
M 5TTG %;-*H!6C6[ 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@
MI#X  )8]  "+/   @SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F
M-C@ 9#8_ &,V1@!A-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58Y
MF0%5.:@"5#FY E,ZSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$
M ))   "&/P  ?CT  '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0
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M D1&R0)$1N<"1$7X D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P
M<D8  &I"  !C0P  7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+
M1T$ 2D=) $E(4 !(2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*
MQP(_2N4"/TGW D!)_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD
M &5%  !>1P  64@  %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\
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M 3%6_P$Q5?\!,57_ :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5
M258  $17  ! 60@ /5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S
M74X ,5U7 #!=80 O76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;
M_@$K6_\!*UK_ :-5  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L
M #]=   Z7P0 -F - #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH
M*F13 "ED70 H9&D )V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D
M8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC
M   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/
M ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\
M'&C_ )5<  "#7   =5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O
M;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET
M5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_
M (Y@  !]8   ;V$  &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0
M(G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /
M?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E
M  !W90  :F4  &%F  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($
M !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50
M!(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q
M:@  9VL  %ML  !0<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/
M   ,D@8 !I,,  *3$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99
M  "6:0  E7H  )6.  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<
M8'(  %1U  !)>0  /WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $
MG0,  )X)  "?#@  GQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C
M7P  HW$  *.$  "BF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L
M $V   !"A0  .(L  "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@
M *L$  "K"@  K T  *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50
MLF8  +)Y  "RC@  L:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-
M   [DP  ,)D  ":>   <HP  $Z<   VK   'K@   +(   "U    MP   +@
M  "Y @  N0@  +H,  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH
M ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   S
MH@  **@  !VM   4L0  #;8   :Y    O    +\   ##    Q    ,4   #&
M    QP   ,D$  #*"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?
M  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0
M(+<  !6[   -O@  !,(   #%    R0   ,T   #0    T@   -(   #5
MU@   -D   #;    W@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N
M90  [WH  .^/  #PGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I
M /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0
M[@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#=
M /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X
M,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"%
M .  B@#> )  W "6 -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\
MRP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O
M #< ZP!" .< 3 #D %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\
MA0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_
M +P _P"\ /\ O #_ /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$
MVP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^
M (8 O "- +H E "Y )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T
M_P"M /\ K0#_ /\   #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V
M ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($
MK@"( *T CP"K )@ J0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@
M /\ H #_ /\   #V    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8
M.@"T $, L0!, *X 4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0""
M *  B@"> ), G "= )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\
MD@#_ /D%  #J"P  W T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G
M #T I !% *( 30"@ %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ),
MA@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_
M .\/  #>%   RA4  +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8
MF0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'
M"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87
M  #1'@  O1T  *\<  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y
M (P000"*$$@ B!!/ (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@
M>A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&
M)0  LR4  *4C  "<(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7
M/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0
M &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@
MJRH  )TJ  "3*   C24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V
M'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4B
MF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\
M )8O  ",+0  A2H  ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H
M:R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;
M*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S
M  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH]
M &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J,
M4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!
M-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO
M0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q
M $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0
M=#<  &XT  !I,P  93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3
M-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<X
MPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H
M &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$
M3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN  $4[C@!$/)X 0SRN 4(\P@%"
M/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@  C3X  '\^  !U/@  ;#T  &8Z
M  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,.R@ 2SLO $D\-@!'/#T 1SQ$
M $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _C0 _0)P /D"M 3U P $]0-T!
M/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$  'Q!  !Q00  :$   &$\  !;
M/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4 1D L $1 ,P!#0#H 0D%" $%!
M20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z1)L .42K 3E$O@$X1-L!.43Q
M 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#  !N0P  94,  %U   !60
M44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [
M1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'
M_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J1@  844  %E$  !11   3$8
M $A'  !$1PH 04@0 #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP
M-4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O
M2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+
M   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2
M "Y17  M46< +%%U "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\
M*D__ )Q*  ")2@  >DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y
M4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A7
M60 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_
M )9-  "$3@  =4X  &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6
M+UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @
M7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1
M  !^40  <%$  &12  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& #
M "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T
M%V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X
M50  :U4  &!6  !75@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ
M!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3;3D $FY" !%N3  0;E@ #VYE
M  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9  !R60
M9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\  !=R   2
M=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U( !W=?  5W
M;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M70  8EX
M %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\   -?P8
M"8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9  "":
M@GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@  7F(  %-D
M  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (B00  HL*
M  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".8   CG$
M (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D  $UL  !"
M<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0   )8'  "7
M#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P  G&@  )Q[
M  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W   [?
M,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!  "C!@
MI L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T  *QP  "L
MA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   TB@  *9
M !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q    L@,
M +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD  "^>0
MOI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0  (9\  !>D
M   0J0  ":X   "R    M@   +D   "]    OP   +\   #     P0   ,,
M  #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2:P  TX(
M -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX  !&T   )
MN0   +T   #!    Q    ,@   #+    S0   ,T   #/    T    -(   #4
M    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70  ZG(  .N(
M  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\ ,@#_ #T
M_P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$ .D B@#H
M )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\ V #_ -<
M_P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W #@ ] !#
M /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L A0#9 (L
MU0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_ ,8 _P#&
M /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #( Y@ ] .(
M1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#' (4 Q0",
M ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8 _P"V /\
MM@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W ,X 00#*
M $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (  M@"' +0
MC@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G /\ I@#_
M /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P .P"Z $0
MMP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"! *8 B0"D
M )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\ F #_ /T
M  #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K #X J !&
M *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@ @P"6 (P
ME0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_ /,"  #B
M!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #< G !  )H
M1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"* (@ B "2
M (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-  #0$
MOA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y (X!00",
M 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0 ?06. 'L%
MF@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$%P  L1<
M *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+.P"!"T(
M@ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V, ' -F0!O
M#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@  J!X  )L=
M  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W$3T =A%$
M '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83E@!E%*,
M8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0  )(C  ")
M(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@ ;!<_ &L7
M10!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<&Z$ 6QRP
M %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH  "")P
M>R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ &(>00!@
M'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX 4R*N %(C
MP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\+   ="H
M &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC/0!9)$,
M5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL $LIO@!+
M*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P  ;RX  &HK
M  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2*4  4"E&
M $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4NO !%+M8
M12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$  &4O  !@
M+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P 2BU# $DM
M2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _,M, /S+N
M $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R  !<,
M5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%  $,R1P!"
M,D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$ .C;M #LV
M_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7,P  4S0
M $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV1  ]-TP
M/#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL #8Z^P V
M.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@  3C<  $HX
M  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SM3
M #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^^@ R/?\
M,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L  $4\  !!
M/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!0 #%
M6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M0?\ +4'_
M )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!    \000
M.4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45. "Q%6  K
M1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\ *$7_ )5
M  ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W1@  -$<*
M #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+50 E2V
M)$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_ )!#  !^
M1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P  +DT' "M.
M#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?45T 'E%J
M !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&  !Y1P
M:T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%," "14"P B
M51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD %UAF !58
M=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T2@  9DL
M %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;!P :70T
M&%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B  ]?<0 .
M7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@  8DX  %A/
M  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 390D $68/
M !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G;  &9WT
M!6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(  %12  !,
M4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08 "W ,  AP
M$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90  <'8  '"*
M  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  /_B__])0T-?
M4%)/1DE,10 $"5%7  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W
M  YS   +=@0 !7@+  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0
M 'I0  !Z7P  >G   'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?
M6P  5EL  $Q<  !"8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^
M   $@0(  (((  "##0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)
M  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8
M46$  $9D   \:0  ,FT  "ER   A=P  &7L  !*    -@P  "(<   **
MC0   (X$  "."0  CPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "6
M3@  EE\  )5R  "5B   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH
M #]N   U=   *WD  "%_   9A   $8D   R-   &D0   )0   "8    F@
M )L   "< @  G0<  )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1
MIE4  *9H  "F?0  II0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[
M   M@0  (X<  !F-   1D@  "Y<   2<    H    *,   "F    J    *D
M  "J    K    *T$  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL
M +A<  "X<0  N(@  +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   F
MD   &Y<  !*=   ,H@   Z<   "K    K@   +(   "V    N    +@   "Z
M    NP   +T   "^    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0
M  #,9   S7H  ,V1  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H
M$Z8   RL   #L0   +8   "Z    O@   ,(   #&    R    ,@   #*
MRP   ,T   #.    T    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E
M5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A
M /\ +0#_ #@ _0!# /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H
MYP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2
M /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8
M* #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z
M -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X
MP #_ ,  _P"_ /\ O@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B
M "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,(
M>@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_
M *\ _P"O /\ L #_ /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@
MR0 R ,8 / #" $4 OP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q
M 'H KP"  *T B "L )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *
M_P"@ /\ H0#_ /\   #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L
M +0 -@"R #\ KP!' *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0
MH !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2
M /\ D0#_ /<   #G    TP   ,8   "[  ( LP , *T $@"J !P IP F *0
M, "C #@ H !  )X 1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T
M )  ? "/ (4 C0"/ (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\
M@P#_ .P   #3    P0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5
M #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (,
M=P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_
M -X*  #$"P  L@P  *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P
MAP T (4 .P"# $( @@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V
M 'L = "& ', D@!Q )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0
M  "W$0  IA(  )H1  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N
M 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@
M:@># &@(D !G"9T 90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M
M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,
M, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z!
M %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0
ME!X  (@>  !^'0  >!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F
M$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84
MBP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(
M ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT
M7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-
M&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG
M  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP
M %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90
M1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M
M*@  92D  & G  !<)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB
M,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C
M #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0
M82P  %PK  !8*   5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$
M)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@L
ML@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\
M %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S,
M/2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R
M,,< ,C#E #,P]P S,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q
M  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4
M+33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+
M,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T
M.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB
M "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@
M0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K
M.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\
M]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D
M #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX
M)3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?
M0/X (#__ (DY  !X.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^
M   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$
M !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T
M&D3_ (0\  !S/0  9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L
M1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*
M2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_
M '\_  !O0   84$  %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20
M(TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 1
M45( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#
M  !J1   740  %-%  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$
M !I3   45@D $5<. !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X
M"EA:  A8:  '6'D !EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D
M1P  64@  %!(  !(2   04D  #I*   R30  *U   "52   @50  &E@  !5:
M   0708 #& ,  I@$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5
M  !@8P  8',  &"&  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P
M54L  $Q,  !%3   /4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -
M900 "&<+  -G#@  :!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I
M70  :6T  &F   !IE   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\
M $I/  !!40  .%0  #!7   H6P  (5X  !IB   490  $&@   QK   ';@,
M 7 )  !P#0  <1   '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@
M<V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55
M   [6   ,EP  "I@   B9   &V@  !1L   /;P  "W(   9V    >0   'H&
M  !Z"@  >PX  'P1  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\
M (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U
M80  +&4  "-J   ;;P  %',   YW   )>P   W\   ""    A    (8!  "&
M!@  B H  (D-  "*$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H
M  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;
M)'$  !QW   4?   #H$   B%    B0   (T   "0    D@   ),   "4
ME@,  )<(  "8#   F@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@
M=   GXP  )^B  "?MP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\
M !2%   -BP  !I    "4    F    )P   "?    H0   *(   "D    I0
M *<   "H!   J@D  *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0
MLH   +*8  "QK   LK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5
M   &F@   )\   "D    J    *P   "O    L0   +$   "S    M0   +8
M  "X    N@   +P&  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(
M ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E
MJ@   *\   "S    MP   +P   "_    P0   ,(   #$    Q0   ,<   #)
M    RP   ,T   #/ P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[
M  #AD0  XJ(  .*M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #,
M^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@
M (4 W@", -P DP#9 )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L
M_P#& /\ P0#_ /\   #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y
M .@ 0@#C $L X !2 -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\
MR@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z
M /\ M@#_ /\   #_    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -,
M/0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "
M +8 B "T )  L@": +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\
MJ@#_ /\   #]    [@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[
M #\ MP!' +4 3@"R %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8
M@0"D (H HP"4 *$ GP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_
M /X   #N    W@   ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D
MIP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5
M (0 E ". )( F0"0 *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /
M  #;    QP   +H   "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [
M )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X
MA0"( (, E "" *  @ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&
M    M0   *H   "B    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@
M.P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "#
M '8 CP!U )P = "J '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@
MIP<  )L&  "3!   C@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z
M #P >0!" '< 1P!V $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L
MB@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX
M (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8
M;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!?
M I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43
M  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W
M &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y,
M5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T
M&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-
M.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B
M $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0
M9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1
M$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6
ML !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$
M %P?  !9'   5QD  %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C<
M21<] $<70P!&%TH 11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [
M',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C
M  !3(   41X  $\< @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY
M $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$
M-2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/
M)   3"(  $D@  !'( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA
M/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;<
M # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*
M2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S
M)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ
M\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@
M #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F
M+OT )RW_ (HK  !X+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL
M   W+   -"P) #(L#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]%
M "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P
M(C'_ (8M  !U+P  9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S
M,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T
M3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_
M ((P  !Q,@  8S,  %DT  !0-   230  $(S   ],P  -S,  #$T   N-0
M*S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;
M.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR
M  !M-   8#4  %4V  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH
M ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$
M%#]> !0_;  30'P $D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I
M-P  7#@  %(Y  !*.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!
M!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;
M  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@
M6#L  $\[  !'/   0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   5
M2 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+
M9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X
M $L^  !$/@  /3X  #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4
M#E$+  M1$  *410 "5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P
M4F\  %*!  !1E@  4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!
M  !!00  .T(  #1#   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*
M  98#@ "6!(  %D7  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD
M %E\  !9D   6:4  %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _
M10  -T<  "])   H3   (D\  !M2   650  $5@   U:   )70, !%\)  !@
M#0  8!   &$4  !A&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V
M  !BBP  8J   &&V  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@
M,DT  "I0   C4P  '%<  !9:   170  #6    AC   #9@$  &<&  !H"P
M:0X  &H1  !K%0  ;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !M
MA   ;)H  &RP  !KR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0
M "18   =7   %F   !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL
M '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?
M>90  'BJ  !XP0  =]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB
M   69P  $&L   MO   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*
M  "##0  A!$  (85  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L
M (BB  "'N0  A]$  (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0
M=   "GD   )]    @0   (4   "(    B@   (P   "-    CP   ) $  "2
M"   DPP  )40  "7%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:
M  "8L   F,<  )?> $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P
M 8@   ",    D0   )4   "8    F@   )L   "=    GP   *    "B
MI 4  *8*  "H#@  JA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "K
MIP  J[H  *O+ $5F   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@
M  "=    H0   *4   "H    JP   *L   "N    KP   +$   "S    M0
M +<!  "Y!P  O T  +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP
MP:T  ,&\ #YR   R>   )X   !R(   2D   "I<   "=    HP   *@   "M
M    L@   +8   "Y    NP   +P   "^    P    ,(   #$    Q@   ,@
M  #+    S@4  -$-  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\
M -RK /\   #_    _P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P
M $L [0!2 .H 60#G %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0
MC@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_
M /\   #_    _P   /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4
MV0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_
M )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\
M  #_    ^    .T   #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!'
M ,  3@"^ %, O !9 +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H
MJP"4 *D H "H *T I@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V
M    Y@   -<   #+  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T
M2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP".
M )D F0"7 *8 E@"V )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D
MT    ,$   "W  ( KP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@";
M $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H
MDP"( *  AP"O (4 P@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O
M *\   "F    G@ ' )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $(
MB@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z
M )H > "I '< N@!V -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\
M  "7    D  " (L "P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !!
M 'L 1@!Y $L > !0 '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4
M:P"C &H M !J ,D :0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(
M    @P   '\ !@![  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\
M00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "?
M %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@
M=P<  '0$  !Q  D ;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C
M $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4
MJP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X
M &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P
M6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+
M!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1
M  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^
M $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P
M0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6
M$P  5!$  %0." !3#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.
M00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6
M #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&
M3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _
M$D0 /1), #P35  [$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6
M[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H
M $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$
M-Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N
M&_L +AO_ (H>  !X(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;
M   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q&
M "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H
M*1__ (8@  !T(P  9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z
M'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA
M3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_
M ((C  !Q)0  8R8  %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@
M,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C
M)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE
M  !N)P  8"D  %8I  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28#
M "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E(
M'2M> !PK:P ;*WL &BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J
M*@  72L  %,L  !*+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K
M"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]<
M !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+
M6BT  % N  !(+@  02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?
M,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T
M9P 1-7< $36) ! UG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S
M $TP  !%,   /C   #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D
M%S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -
M.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS
M  !",P  .S,  #8S   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT,
M ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\
M!C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _
M-0  .34  #0U   N-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$
M#@ *1!, "409  A$(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\
M  !%D   1*0  $2Y  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.
M-S@  #$X   K.0  )3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $
M2Q$  4L6  !+'   2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+
MC   2Z$  $NU  !*S@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L
M "X\   G/@  (D$  !Q#   61@  $DD   Y+   +3@, !U (  )1#   41
M %(3  !3&   4Q\  %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP
M4IP  %*Q  !1R@  4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"
M   C1   '4<  !=*   230  #E    M3   &50(  %<'  !8"P  60X  %H1
M  !:%0  6QH  %PA  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<
M %NM  !:Q0  6N0  %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >
M3   %T\  !)3   .5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D
M$0  918  &8<  !G(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H
M  !EP   9-X  &3P $]&  !'1@  0$4  #='   O2@  )DT  !]1   850
M$ED   U<   (8    F,   !F    :    &H   !K!   ; @  &T,  !O#@
M<!(  '(7  !S'0  ="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !Q
MN   <=0  '#L $Q*  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60
M  =H    :P   &\   !R    =0   '8   !W    >0(  'H&  !\"@  ?@X
M ( 1  ""%@  A!X  (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0
M@,D  (#E $I.   _4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U
M    >0   'T   "!    @P   (4   "&    B    (D   "+!   C0@  (\-
M  "2$   E!8  )8@  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT
M )+5 $15   Y60  +UT  "1C   ::0  $F\   QU   $>P   (    "%
MB0   (T   "1    DP   )0   "6    F    )H   "<    G@   * &  "B
M"P  I1   *@7  "I(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7'
M #Y>   R8P  )VH  !UP   3>   #'\   .%    BP   )$   "6    FP
M )\   "B    I    *4   "G    J0   *L   "M    L    +(   "U @
MMPD  +L0  "^&   OB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J
M   K<   ('@  !:    -B   !8\   "6    G    *(   "G    K    +
M  "S    M@   +<   "Y    NP   +T   "_    P@   ,4   #(    R@
M ,X(  #2$   U1L  -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_
M    _P   /\ !0#_  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8
M4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"<
M ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_
M_P   /H  0#S  L [0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+
M %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0
MH0"R *\ L #" *X XP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@
M .8   #=  < T@ . ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X
MM0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A
M *@ GP"Y )X T@"= /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P
M  #!  ( N@ , +8 $@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!-
M *  4@"> %< G0!; )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$
MC@"Q (T Q@", .@ BP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L
M    I@ ( *$ #@"? !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )
M3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I
M 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<
ME  # )  # "- !$ BP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_
M $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\
MM !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O    H    )0   ",    A@
M ($ " !^  X ?  4 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4
M< !* &\ 3P!M %0 ; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A
M ,( 80#D &$ ^ !A /\ 80#_ +0   "@    D0   (8   !^    >0   '4
M P!Q  L ;P 0 &T %@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !%
M &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L
M5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G
M  < 9  - &, $0!A !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@
M10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #-
M $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$
M7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!.
M $< 30!- $L 50!* %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $,
MY@!# /4 0P#_ )4-  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$
M %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T,
M1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z
M!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-
M!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I'
M #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0
M,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!#
M#@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.
M30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_
M (,6  !R&0  9!H  %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0
M.Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M
M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9
M  !N&P  8!T  %8>  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14'
M #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U(
M)AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J
M'@  71\  %,@  !*(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8
M"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q;
M !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(
M6B$  % B  !((@  02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F
M'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA
M9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,
M $TD  !%)0  /B0  #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P
M("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4
M)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF
M  !")P  /"8  #8F   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8.
M !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$
M#RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  !
M*0  .2@  #0H   O*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L
M$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_
M  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P
M-RL  #$J   M*@  *2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /
M,A, #C(9  TR(  -,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0S
MC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T
M "\L   K+   )BP  "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$
M"3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP
M.)\  #BS   XR@  ..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO
M   I+P  )#   !\Q   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4
M   ^&@  /B$  #XH   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP
M #ZP   ]QP  />0  #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F
M,@  (#0  !LV   6.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%
M%@  11T  $4D  !%+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M
M  !$Q   0^,  $/R %4T  !*-0  034  #DU   S-   +C0  "@U   B-P
M'3H  !<\   2/P  #T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%
M31D  $X@  !.*   3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+
MP0  2^$  $KR % X  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$
M !-#   /1@  "TD   =+   "3@   % $  !1"   4@L  %,.  !4$0  514
M %8;  !7(P  5RP  %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0
M4]T  %/P $L\  !"/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+
M   +3P  !5$   !4    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6
M  !B'0  8B8  &(Q  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0
M %WN $=    _/P  .C\  #%    I0P  (48  !I*   33@  #E$   I5   $
M6    %L   !>    80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N
M%P  ;R   &\J  !O-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH
M $1$   ^0P  -40  "M'   C2P  &T\  !-4   .6   "%P   )@    9
M &<   !K    ;0   &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@
M?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'
M   Y20  +TP  "50   <50  %%L   Y@   '90   &H   !N    <@   '8
M  !Y    ?    'X   !_    @0   (,   "%    AP,  (H(  ",#0  CQ$
M )(9  "2)0  DC,  ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R
M40  *%8  !Y<   58@  #F@   =N    =    'D   !^    @@   (8   ")
M    C    (X   "0    D@   )0   "6    F    )L   ">!@  H0P  *01
M  "F&P  IBD  *8Z  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7
M(6(  !=I   /<   !W<   !^    A    (H   "/    E    )@   ";
MG@   )\   "B    I    *8   "H    JP   *T   "P    LP0  +<,  "[
M$@  NQ\  +LP  "[0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G
M !!X   )@    (@   "/    E@   )L   "A    I@   *H   "N    L
M +$   "T    M@   +@   "[    O0   ,    ##    QP   ,L#  #/#
MTQ4  -(E  #2.   T4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\
M P#_  L _  1 /D &P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9
M -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +(
MO #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M
M  < YP / .( %@#? "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,
M6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"]
M *< W@"F /D I0#_ *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  ,
MR@ , ,4 $@## !L P  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K
M %< J0!< *< 80"F &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8
MS0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 (
M *T #P"J !8 J  > *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$
ME@!5 )0 6@"3 &  D0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$
M .8 @P#] (0 _P"# /\ @0#_ .0   #+    N@   *P   "B    G  $ )@
M# "6 !$ E  9 ), (0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/
M (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0
M<P#T '0 _P!T /\ = #_ ,L   "V    I@   )H   "2    B@   (8 " "#
M  X @0 4 ($ &P"  ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0
M3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J
M &8 _P!F /\ 9P#_ +@   "D    E0   (H   "!    ?    '8 ! !T  P
M<@ 0 '$ %@!P !T <  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E
M $X 9 !4 &, 6P!A &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D
M^ !: /\ 6@#_ *@   "5    AP   'L   !S    ;@   &H  0!G  @ 90 .
M &0 $@!C !@ 8P ? &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D
M6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !.
M /\ 3P#_ )P   ")    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D
M#P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+
M $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H
M10#_ )($  " !P  <0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/
M !  3@ 5 $T &P!, "  2P F $H *P!) #  2  U $< .@!& $  10!& $,
M3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_
M (D*  !X#   :@X  %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T
M1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z
M %( .0!< #@ :  V '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-
M  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4.
M #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5
M,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L
M$0  7Q,  %04  !,%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)
M$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9
M "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%
M6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P
M#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",0
M90 A$', (!"$ !\0E@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@
M $T9  !%&0  /QD  #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X
M*1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <
M$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;
M  !"'   /!L  #8;   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W
M%1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _
M'@  .1T  #0=   O'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_
M ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](
M-A\  #$?   M'@  *1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6
M'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@
MCP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$
M "\A   J(   )A\  ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1,
M$2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '
M))X !R2Q  8DQP &(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC
M   H(@  )"$  "$A   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6
M  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L
M 2BO   HQ0 !*.$  2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F
M)   (B,  !\C   ;)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L
M&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM
M   LP@  +.   "SP %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@
M(28  !TF   9)P  %2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P
M,AX  #(E   R+0  ,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   Q
MP0  ,=\  #'P %8G  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD
M !HJ   6+   $BX   \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H
M #@B   X*@  .3,  #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP
M-]X  #;P %$K  !&+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O
M   3,0  $#,   TU   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >
M  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P
M #WP $TN  !"+P  .2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0
M-P  ##H   D\   %/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !(
M(0  2"H  $@U  !(00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P
M $@R   ^,@  -C(  # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P
M"$(   -$    1@   $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'
M4B4  %(P  !2/   44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V
M   [-@  -#4  "\T   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH
M  !-    3P   %$   !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\
M %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X
M.0  ,S@  "LY   C/   '#\  !5#   01P  "TH   5.    40   %0   !7
M    6@   %P   !=    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC
M  !J+@  :CP  &I-  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/
M+CT  "5    =1   %DD  !!-   *40  !%4   !:    70   &    !C
M9@   &@   !J    :P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![
M)P  >C4  'E%  !X60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4
M "!*   73@  $%0   I9   "7@   &,   !G    :P   &\   !R    =0
M '<   !Y    >P   'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@
MCBL  (X[  "-3@  BV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5
M   06P  "F$   %G    ;0   '(   !W    >P   '\   "#    A@   (@
M  "*    C0   (\   "1    E    )<   ": 0  G0<  *$-  "E%   I"$
M *0Q  "C1   HED  *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +
M:0   7    !W    ?0   (,   "(    C0   )$   "5    F    )H   "<
M    GP   *$   "C    I@   *D   "L    L    +0'  "X#@  NA@  +HG
M  "Y.0  N$X  +=E  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0
M ($   ")    CP   )8   ";    H    *0   "H    JP   *P   "O
ML@   +0   "V    N0   +P   #     Q    ,@   #-!P  TA   -(=  #1
M+P  T$0  ,];  #-<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  /
M /4 %P#T "  \0 J .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X
MS@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S
M /\ KP#_ *4 _P"> /\ FP#_ /T   #W    \@   /    #G  , X0 , -P
M$@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!=
M +4 8@"S &< L0!N *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D
MG@#_ )@ _P"2 /\ CP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[
M !8 N0 ? +< )P"S "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$
M6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_
M (H _P"% /\ @@#_ .<   #=    Q@   +@   "N    J  $ *4 # "A !(
MH0 9 *  (@"? "D FP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50",
M %H B@!A (@ : "' '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P
M_P!X /\ =@#_ -8   #     KP   *,   "9    DP   (\ "0"-  X BP 4
M (H ' "* ", B  J (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0
M>@!: '@ 80!V &D =0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K
M /\ :0#_ ,    "K    FP   (\   "'    @    'P ! !Z  P >  1 '@
M%P!X !X =P D '4 *@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4
M &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\
M70#_ *P   "9    B@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G
M !@ 9P ? &< )0!E "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L
M50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_
M )T   "+    ?    '$   !I    9    &    !>  4 7  + %L #P!; !0
M6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !.
M %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )
M  !^    <    &8   !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5
M $X &@!. "  30 E $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %,
M0P!= $$ : !  '4 /P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U
M P  : 8  %T'  !5!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4
M%@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9
M #@ 9  W '$ -@"! #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0
M8 L  %8,  !.#   2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [
M !< .P < #H (0 Y "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #
M8  O &T +@!] "T CP L *( + "V "P T  L .X + #\ '<*  !G#   6@X
M % .  !)#@  0PX  #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !,
M,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H
M &L )P%Z "8!C  E )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1
M  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04
M "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD
M( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  !
M$P  .A,  #42   Q$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(
M%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY
M !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0
M-Q4  #$4   M$P  *A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?
M#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0
MC0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<
M "\6   J%0  )Q0  "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4
M&! ; !<0(0 6$"@ %1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .
M$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8
M   H%P  )!8  "$6   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8
M !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH
M"1:M  @6P0 (%MT "17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E
M&0  (A@  !\8   <%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7
M'  .&", #1@J  P9,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ
M  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P
M(!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *
M'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >
MO0  '=@  !WL %@:  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP
M !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T
M!"$D  (B+  !(C4  ")    C30  (UH  "-K   C?@  (Y,  "*G   BO
M(=<  "'M %4=  !('P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=
M   6'0  $QX  !$? @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A
M   G*0  )S(  "<]   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8
M "7M %$@  !%(0  .R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4
M(   $2(   \C   -)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L
M)@  +2\  "TY   M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN
M $TB  !!)   ."0  # D   I)   )",  "$B   =(@  &2(  !4C   2)
M#R8   TH   **@( !BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@
M,RL  #,V   S0@  ,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE
M   ^)@  -"<  "TG   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P
M  HN   &, $  C($   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<
M #HR   Z/@  .DP  #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z
M*0  ,2D  "LI   F*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U
M   !-P   #D"   [!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N
M  !#.0  0T<  $)7  !":@  08$  $":   _L@  /L\  #[O #\L   V+
M+RP  "HK   E*@  'RL  !DM   4+P  $#(   TU   (.   !#H    \
M/P   $$   !# @  104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !-
M-   3$(  $Q1  !+9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\
M "@M   B+P  &S$  !4T   0-P  #3H   @]   "0    $,   !&    2
M $H   !,    3@$  $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@
M5SP  %=+  !67@  5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R
M   =-0  %C@  !$\   ,0   !T0   !'    2@   $T   !0    4P   %4
M  !7    60   %H   !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0
M &5$  !D5P  9&L  &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8
M/0  $4(   Q&   &2@   $\   !3    5@   %D   !<    7P   &$   !D
M    90   &<   !I    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]
M  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22
M#$T   52    5P   %P   !@    9    &@   !K    ;@   '$   !S
M=0   '<   !Z    ?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")
M10  AUL  (9R  "%BP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H
M  !A    9@   &L   !O    =    'D   !]    @    (,   "%    AP
M (H   ",    CP   )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P
MGU   )UG  ":@0  FID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P
M    =P   'T   ""    A@   (L   "/    DP   )4   "7    F@   )T
M  "@    HP   *8   "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4
M +5<  "T=   L8X  *^D ")4   86P  $&(   =J    <P   'L   ""
MB0   )    "5    F@   )\   "C    I@   *@   "K    K@   +    "S
M    M@   +H   "]    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1
M  #-:   RX$  ,J6 /P   #V    \@   /$   #S  4 ]  , /( $P#P !P
M[0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$
M &D P0!P +X > "\ ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H
M_P"4 /\ CP#_ /0   #L    Z    .<   #?    V0 ) -( $ #/ !< SP @
M ,P * #& #  P  W +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &(
MJP!I *D <0"G 'H I0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"(
M /\ A #_ .@   #?    V0   ,D   "_    N  $ +4 #0"S !( L0 : +
M(@"M "H J0 Q *8 . "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B
M )4 :0"3 '( D0!] (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\
M> #_ -D   #-    NP   *X   "E    GP   )P "0"9  \ F0 5 )D '0"8
M "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4 @P!; ((
M8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N /\ ; #_
M ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 (( %P"" !X
M@  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5 '  7 !O
M &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\ 8 #_ +0
M  "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O !@ ;P ?
M &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$ 50!? %X
M7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_ *$   ".
M    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !, 7P 9 %\
M'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2 %@ 40!A
M %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(   "
M<@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4 %( &@!1
M !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %( 10!< $0
M9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T    9P
M %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8 %0!& !H
M10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7 #H 8@ Y
M &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K    7@(  %0#
M  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \ !8 /  :
M #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$ 7@ P &L
M+P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<  $T(  !&
M"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !( ,P 6 #(
M&P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H &< )P!W
M "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,  ! #
M.@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3 "H %P I
M !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0 ( !S !\
MA0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \#@  -@X
M #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!%  B 1@
M(0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P !D!@@ 8
M )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$   ,A   "T/
M   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <!14 &P4:
M !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'@  2!Y0
M$@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$  "H1   F
M$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1( %@D7 !4)
M'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .#)0 #0NG
M  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2   C$0
M'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4 !$,&@ 1
M#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y, "0^F  @.
MN0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A$P  '1(
M !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0&  -$!X
M#! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D  ,1N  #
M$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%   &Q0  !@3
M   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )$QL "1,B
M  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4MP  %,\
M !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14  !84 0 4
M$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD !!<?  ,7
M)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP  %\\  !?J
M $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45 @ 3%04
M$10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=   <)
M'"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]   !KK $P8
M  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2%@0 $!<$
M  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A(@  (2H
M "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M $@:   ]
M'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$ #AH!  P<
M @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P  )R<  "<R
M   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=   Y'P
M,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\   HA   &
M(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20  "XN   N
M.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V(0  +2$
M "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F   "*
M "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J   U-@
M-4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)   *B0  "0C
M   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N    ,    #(
M   T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^,0  /C\
M #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8  ",E   ?
M)   &24  !0F   0*   #2L   DN   %,    #,    U    .    #H    \
M    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+   1SH  $=)
M  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G   <*
M%BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,   !&
M2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0  %-#  !2
M50  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8+@  $C(
M  TU   (.0   CT   !     0P   $8   !)    3    $X   !1    4P
M %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\  !@3@
M7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P  #CL   @_
M   !1    $@   !,    3P   %(   !5    6    %L   !=    8    &(
M  !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R10  <%D
M &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<   !,
M40   %4   !9    70   &$   !E    :    &L   !M    ;P   '(   !T
M    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0  A%(  (-G
M  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:    8
M &0   !I    ;@   '(   !V    >@   'T   "     @@   (4   "(
MBP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<  )I>  "8
M=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J    <0   '8
M  ![    @    (8   "*    C@   )$   "3    E@   )D   "<    H
M *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12  "R:@
MKX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P   (D   "/
M    E    )H   "?    H@   *0   "G    J@   *X   "Q    M    +@
M  "\    P0   ,<   #-    U 4  -@0  #5'@  TS$  -!(  #-7P  RW8
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M______________________________________________\
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MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
MLVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\
MNZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[
MQ+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6H
MB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NS
MI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1
ML**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'
MU:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:
MRPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?
MB-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;
MZ,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FK
MG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;9RPD;Y\X-
M.>C-$&#<R0V2R[LPJ\:X3[3 LV>]NZY[Q+6IB,NRIH?1KZ.'U:V@B-FKGHG<
MJ9R*WJ>;C."EF8_CH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2A
MF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.39RPD:Y,X-.>?.
M#F#:R@R2R[PNJ\6Y3;3 M&:]NJYZQ;6IA\NQIH?1KJ.'U:R@B-FJGHG<IYR*
MWJ6;B^"BFHWBGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_C
MGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^/8RPD:X<\,.>7/#F#9
MR@R1R[XLJ\6Y3+6^M&>]N:Y[Q;2JA\RPIH?1K:.'U:N@B-FHGHC;I9V)W:.<
MBM^?FHOAFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.
MXIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN+8RPD:W- +.>/0#6#8RPN1
MR[\KJ\2Z3+6]LV>^N*Y[Q;2IA\RPIH?1K*.'U:F@A]BFGXC;HYV(W:"<B=Z=
MFXK@F)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:
MC>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>'7S D:VM$+.-[1#%_6RPN1R\ I
MK,*Y3;:\LVB^MZY[QK.IA\ROIH?1JJ.&U:>AA]BDGX?:H9Z'W)Z=B-V:G(G>
ME9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5
MFXS@E9N,X)6;C."5FXS@E9N,X)6;C.#6S D9V=$+.-K3#%_4S N1R< IK<"Y
M3K:ZLVF_M:Y\QK*IA\RMIH;1J:.&U*6AAM>BH(;9GY^&VIN>A]R7G8C=DYR+
MWI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>
MDYR+WI.<B]Z3G(O>DYR+WI.<B][5S D9V-(+-]C3"U[2S N3Q[\KK;ZX4+>Y
MLFJ_M*U\QK"IA\RKIH;0IZ2%U*.BA=:?H878G*"%V9B?AMJ4GH?<D)V*W9"=
MBMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*
MW9"=BMV0G8K=D)V*W9"=BMW4S0D9UM(+-];4"U[0RPJ5Q+XMKKRX4;BWLFK
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MA+&)P8.QBL&"L8O"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MP8>K<L&(JW+ BJQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MCXS*M8R.S+2)D,ZSAY+0LH25TK&"F=.Q@9[4KH"BU*R H]*L@*/2K("CTJR
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MCZR$R(RKA<F)JX;*AZN&RH6JB,J#JHG+@:J+RX"JC,N JHS+@*J,RX"JC,N
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M;,6+I6S%BZ5LQ8NE;,6+I6S%BZ7$S@<*M]D')J/[#CV6_QY.C?HO6X;R/V>
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M_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K
MBI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAP%_ZHG
M%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\
MOX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAL%_ZHG%_^G
M-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K BY&\OXB3
MOKZ%EK^]@IC!O(";PKQ^GL*\?:'#NWNDQ+MZJ<2Z>:W$M7FNP[5YKL.U>:[#
MM7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL/_JQL%_ZLF%_^H-"__
MI$-*^9Y09>F877_:E6F5S91TJ,64?K3$E8:VPI6,N<&1CKN_C9"]OHF2O[V&
ME,&\@Y?#NX&:Q+I^G<6Z?:'&NGNEQKEZJL:U>JS&L7JMQ+%ZK<2Q>JW$L7JM
MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<3_JQH%_ZLE%_^I-"__I$)*
M^9]/9NB97(#:EF:6S)5QJ<65?+3$EH.WPI>+NL"3C+R^CXZ_O8N0P;R'D\.Z
MA);%N8&9QKE_G<>X?:'(N'RFR;5ZJLFP>ZO'K'NMQ:Q[K<6L>ZW%K'NMQ:Q[
MK<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<7_K!D%_ZPD%O^I,R__I4%*^9]/
M9NB96X'9F&.6S)9OJL66>;3#EX&WP9B)NK^5B[V^D8W O(V/PKJ(DL6YA97'
MN(*8R;=_G<JV?:++MGRHR[![J<JL?*K(J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H
M?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,7_K!D%_ZPD%O^J,B__I4%+^:!.9^>:
M68'9F6&7RY=MJ\67=[3#F7^WP9J'N[^7BKZ]DXS!NXZ.Q+F*D,>XAI/)MH*8
MR[5_G<VT?J/.L7RFSJQ]J,NH?:K)I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&
MI7ZLQJ5^K,:E?JS&I7ZLQJ5^K,;_K!D%_ZTC%O^J,B__ID!+^*!-9^><5X'9
MFEZ7RYAJK,69=+3#FGVWP9N%N[Z9B;^\E8K"NI",Q;B,C\BVAY++M(.7SK.
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M_Z@D#_^F,R7_HD(^_Z!*5/FD2F;MITIXXJE+BM:H49K-IENIQZ5ELL2G<+;
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M;6OK9'%GZ6ET9.=N=F+F<WA@Y7=Y7^1Z>UWC?GQ<XH%]6^*%?EKAB']9X(N
M5^"0@%;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8'4
MO04 Q,@' +39!0JC_@T<EO\:+(O_*SJ#_SI$?/](377_4E-N_5=89_I=7&/W
M8E]@]F=B7?1K9%OS;V59\G-G5_%W:%;Q>FE5\'UJ5.^ :U/OA&M2[H=L4.Z+
M;4_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;D_MD&[&P 4
MM- $ :/C @J6_Q 8B_\@)(+_,"]Z_S\W<O](/FK_3D-D_U1(7O]93%O_7T]8
M_V125?]I5%/_;552_G%74/UT6$_\>%E.^WM:3?M_6TSZ@UQ+^89=2?F+7DCX
MD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%^UQP( I-H
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MG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+<+:KRV^\J\APP*O$<<"JQ''
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MM+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+K_G! !_Z$F"O^@-AS_GD(Q_Z5
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MC5?6I8Y6U:R.5M6LCE;5K(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCE;5K([_KPT
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M?KBUFW^YM)E_NK.8@+JREX"[L9> N[&7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M23S_ETD[_YY*._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTNVN@(
MILH  )C<  ",_P@!@_\4!7C_'@QN_R829?\O&5W_-QY7_S\B4O]&)DW_3"A*
M_U(K1O]8+43_72Y"_V$O0/]F,3[_:S(\_W S.O]U-#G_>C4W_X V-O^&-S7_
MC#@S_Y0X,_^8.3/_F#DS_Y@Y,_^8.3/_F#DS_Y@Y,_^8.3/_F#FGPP  E]0
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MB+]GV8B_9]F(OV?9B+]GV8C_>A0!_W@> _]Y, W_>$$:_X%))_^&4C/_B%I
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M9D3RP6=#\M1G1>[G9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&?NH@
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M*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*BC_HRJAP@  D=$  (+A  !X_P
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M6/UV>&#X<H1G]6V.;?%IF'+O9J%V[&.K>>M@MGSI7L1^YU[8?]AAWW[*8]^
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M<)#8BG"0V(K_>Q$!_WP7 O^0%P+_HB$#_ZX@!/*['03ERAX#VMLD \S9-1+
MTT,DM,Y--JC)54><Q%U5D<!D8H:\:VU[N'-V<K5\?FJSAX5CL96*7K"EC%NQ
MO(U;K]6-7Z?5C6.AUHQFG->+:)G8BFJ6V8AJEMF(:I;9B&J6V8AJEMF(:I;9
MB&J6V8C_?! !_X$4 O^5%0'_IQT"_+46 NO&$ ':VP\ S> E!,/?-@^XVT$A
MK-5+,Z#14T.4S5I1B<EB77[&:6=TPW%P:\%[>&2_AGY=OI2"6+VEA5:^NX95
MO=N&6+/:AURKVH=?IMJ'8:';AF.=VX5CG=N%8YW;A6.=VX5CG=N%8YW;A6.=
MVX7_?A !_X<1 ?^:$0#_K10 VKX* -'-"@#+Y! !P>0E![?C-1.MX4 AH]Y)
M+Y?;4CZ+UUE+@-1@5W;1:&%MSW!I9<UZ<%[,AG58S)5Y5,RF>U'-O'Q0S.)\
M4\'@?U6WWX!8L=Z!6JO>@5RFWX%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX'_
M@ \!_XX. ?^B#0#;M0@ SL$( ,;0"0"^Z1("M.DE"JKH,Q>@YCXEEN5',HOC
M3C^ X55)=N!=4VW>9EMEW6]A7MUZ9UC<AFM3W)5O4-VF<4W>NW)-W^%Q3M'G
M=%#&YG=2ON1X4[CD>56RXWI5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWK_@PX!
M_Y8+ -VK! #-N 8 PL0& +K4"0"Q[Q0#I^XE#9[N,QJ4[3TGBNQ&,X#K3CYV
MZU5';.I;3F3J8U5=ZFU:6.IW7E/J@V).ZI%E2NNA9T?LLVE&[=!I2.;H:4O9
MZVI,S^QM3L?K;T_ ZG!/P.IP3\#J<$_ ZG!/P.IP3\#J<$_ ZG#_B0L Z: !
M -"Q! #!O 4 M\D& *[:"0"D]1<%F_4G$)+U-!R(]CXG?_9',G;V3CML]E1"
M9/9:2%WV8DU7]FM14O9U54WW@%A(^(U:1?B;7$+XJUY!][Y?0/??8$/N[&!'
MX_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0  U*D  ,*U
M P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C_U(Z7/]9
M/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^X54\^?!5
M0/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;   +6Z @"H
MQP( G=8$ )/\#@&+_QT&@_\K#WK_-1=Q_SP?:/]")F#_22Q9_T\Q4_]6-4[_
M73A)_V4[1?]M/4'_=C\^_X!!._^+0SG_F$4X_Z1&-O^R1S7_Q$@U_]U)-/_P
M23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X23?^^$G)JP  MK0  *C!  ";SP
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MA8"JA8%_O(: @-N%@(#=@X!_WH& ?N!_@'WA?8!]XWN ?.1Z@'SD>H!\Y'J
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M+*BZ5#R>M5Q)E+!C58JL:U^!J7)H>:5[;W*CA79KH)%[9I^??V*?L8%@G\J
M8IS@?V67X7YHD^)\:I#C>VR-Y'EMC.5X;8SE>&V,Y7AMC.5X;8SE>&V,Y7C_
M;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L S<X; <+,+PJWR3T9K,5)*:'
M4CB7O%I&C;AA48.U:%MZLG!D<J]Y:VNL@W%DJX]V7ZF>>ENIKWQ9JLE\6J?B
M>UZ@XWMAF^-Z8Y?D>6:4Y7=FDN9W9I+F=V:2YG=FDN9W9I+F=V:2YG?_<!(!
M_X . ?^2#@#RHPL V;,) ,^^"0#+S D Q-,7 +K2+ >PSSL6I<Q&)IK(4#6/
MQ%A!A<%?37R^9U9SO&]>:[EW962X@FM>MHYP6;6=<U6UKG54MLAU4[/G=E>K
MYG9:I.9V7*#G=5^<YW1@FNAT8)KH=&":Z'1@FNAT8)KH=&":Z'3_<A(!_X8,
M /N8"0#9J08 SK4' ,;!!P# SPD NML3 +':*06GV#<2G-1$(9+133"'SE4\
M?<M=1W3)95!LQVU79<5V7E[$@6-9PXYH5,.=:U'#KFQ/Q,AM3L+M;5"XZV]3
ML.MP5:OJ<%BFZW!9H^MP6:/K<%FCZW!9H^MP6:/K<%FCZW#_=P\!_XT( -Z@
M @#/K@4 Q+D% +O%!@"UTPH KN$6 :;A*0:=X#<1D]Y"'8G<3"E_VE0U===<
M/VW59$AETVQ/7])V5%G2@5E4T8Y=4-&=8$W2L&)+T\EB2M+M8DO(\F9-O_%H
M3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98  -*F 0#$
ML@, N;P# +#)!@"IV H H><9 IGG*@F0YS<4A^9"'WWE2BETY%$S:^-9.F3B
M84%>XFM'6.)U2U/A@$]/XHU32^*;54GCK%='Y,171N/I5T;=]EE'T/=<2<CW
M7DK!]F!+O?9@2[WV8$N]]F!+O?9@2[WV8$N]]F#_B0  V9X  ,>L 0"YM@(
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M_T'_41\"_TPI _]'- 7_338&_U$["/]51A#_5E 8_U5<'_]2:";_4'0L_TV
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M9EJ;\V5<E_-D7)?S9%R7\V1<E_-D7)?S9%R7\V3_< T _X0$ -V6  #.HP,
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MK?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $ L;4  *C
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M1D#._T9 SO]&0,[_1D#._T;6DP  Q*,  +2L  "GM@  F\$  )#, @"&V08
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M^DNJ/?A*M#_W2KY ]4G,0/%)X4'M2O!!ZDK\0N1*_T383/]%S$__1L90_T;
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M7FF$^5QJ@OI::X'[6FN!^UIK@?M::X'[6FN!^UK_8A  _W(' /B" P#;CP(
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M45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7  "^H@  LZH  *FS  "@O (
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M"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/__PH3__\*$___"A/__PJ:L0
MB[T  'S(  !MU   7^   %'F  !']0  0?\  #S_"0 W_Q  ,O\5 2[_'0$J
M_R,!)O\I 2+_+P(?_S4"'/\[ AG_0@,6_TD#$_]1 Q'_6@,/_V8$#?]T! O_
MA00*_Y8%"?^H!0C_N04'_] %!__C!0?_XP4'_^,%!__C!0?_XP6-N@  ?<<
M &W3  !?X   4.<  $+M   Z_P  -?\  "__ @ J_PH )O\/ "+_%  >_QH!
M&O\? 1;_(P$3_R@!$/\M 0[_,P$,_SD""O]! @?_20(#_U," /]> @#_; (
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M43X'_U%)#/]/5A+_3&(7_TIO'/]'>R#_188C_T.1)?]"FB?_0:(I_T&J*OU
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M475S_T]V<O]-=G'_3'9Q_TQV<?],=G'_3'9Q_TS_61  _V8' /]S! #A?P$
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M2V&#_TMA@_]+88/_2V&#_TO_9 4 ]70  -J"  #+C@  P9<  +B> 0"QI0
MJ:L' *.M&@"<K"P$E:LZ#(VH11:&ID\??Z17*'FB7R]SH&8U;9YN.VB<=T!C
MFH%%7YF,25N8F4Q7EZA.59>[3U27W$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*
M_TI;BO]*6XK_2EN*_TK_:   Y7D  -&'  #%D@  NYP  +&B  "IJ0  H;$"
M )NS%0"5LR@"CK(V"8:P0A)_KDP;>*Q4(W*J7"ILJ&0Q9Z=L-F*E=3M=I']
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M/D6I_S[@?0  R8T  +N:  "NH@  HZD  )BQ  ".N0  A,$" 'G)!P!TRQ0
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M&3+IQADRZ.H9,>7^&2_D_QPNY/\>+>+_("WB_R MXO\@+>+_("WB_R"ZF@
MJJ,  )VK  "0M   @[T  '?&  !KSP  7]8  %3>! !1\!  3? ; $KP)@%&
M\3 "0O(Z S[R0P0[\TL%./-4!S;T70@S]&@),/5T"R[U@0PL]I$.*O:B#RCW
MMQ G^-81)_;T$2;S_Q$F\?\1)?'_$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D
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M @#_M@( _\T# /_L P#_[ , _^P# /_L P#_[ .(N0  >,0  &G0  !;W0
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M4@G_0U\-_T%K$?\_=Q3_/8(7_CR,&?P\E1K[.YT<^3NE'?@ZK1[V.K8>]3K
M'_,ZSA_P.N,?ZSOQ'^@Z_2'F.O\CY#K_)>$Z_R78//\FT#W_)LT^_R;-/O\F
MS3[_)LT^_R;_.20!_T$> ?]'&P'_2QL!_T\B ?]1*P+_438$_T]!!O],30G_
M2UH._$EF$OA'<A;U17T9\T.'&_%"D1WO0ID?[4&A(.Q!J2'J0+(BZ$"\(N=
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M0H1C_T"#8_\^@F/_/8)C_SR"8_\\@F/_/()C_SS_4 \ _UL' /]F P#L;P(
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M/VUR_S]M<O\_;7+_/VUR_S__60< _V4  .)R  #1?   QX0  ,"* @"YCP(
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M+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F_S)!IO\R0:;_,D&F_S+5?
MPHH  +66  "HG0  G:,  )*J  "'L0  ?+<  '"^ P!HP@X 9L,= &/#+0%>
MPSD$6L-$"%;"3@Q2PE<03\%?%$O!:1=(P7,:1<!^'4+ C" _P)LB/<"M(SS!
MQ",\P.DC.K[^)CB\_R@WN_\I.+C_*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,
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M!R'L_P<AZ_\((.O_"A_J_PL?ZO\+'^K_"Q_J_PNHGP  FZ8  (VO  !_N
M<<$  &3*  !8T   3-8  $'=   XY   -?8, #/W%  P]QX +O@G "OY,  H
M^3@!)OI  2/[20$A^U(!'OQ= AS]:0(:_7D#&/Z+ Q?_G@,5_[,$%/_3!!3^
M] 03_/\#$_K_ Q/Y_P,3^?\#$_G_ Q/Y_P.=I0  CZX  ("X  !RP@  9,L
M %;3  !)V@  /M\  #3D   N]   *_\* "C_$  E_Q< (O\? !__)@ <_RT
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M1700X$1^$]U#AQ7;0I 7V$&8&-5 H!G30*D;T4"R',] O1W-0,P=RD'D'L9
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M+YI1_RZ84?\MEE+_+)12_RN44O\KE%+_*Y12_RO_1A  _TX) /]6!0#^7@8
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M,GEB_S%Y8O\Q>6+_,7EB_S'_3P< _UD  .9D  #7;   S',  ,1W @"_>00
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M-4^,O35/C-XU3XOW-$^*_S-0B?\R48;_,5*$_S%2A/\Q4H3_,5*$_S'J90
MTG,  ,)_  "VB   K)   **4  "8F   C)P  (2?"@" H!D ?*$I 7>@-@5R
MGT$*;9Y+#VB=4Q1DG%L98)MC'5R::R%8F70E59A^*5&7BBQ.EI@N2Y:H,$J6
MO#%)EMPP293V,$F3_S!)DO\P2I#_+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD
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M&C6V_QPTM/\>,[/_'S.R_R SLO\@,[+_(#.R_R#!@P  M)$  *:8  ";G@
MCZ4  (*K  !VL0  :[8  %^\  !4P0, 3,4- $O%&0!)QB@ 2,8U $7'0 %#
MQTH#0,=3!#['708[QV<(.<=S"C?'@ PTQY -,L>A#C'(M0\PR-,/,,;T$"[$
M_Q,MPO\5+,'_%BO _Q<KP/\7*\#_%RO _Q>XC0  JI<  )Z>  "1I0  A*P
M 'BR  !KN0  8+\  %3#  !*R ( 0,T' #K2#@ YTAL .-,H #?3-0 VU$
M--5+ 3/550$QUF "+]9L RW7>@0KV(L%*MB=!2C9L08GVLT&)]?O!B;4_PDE
MTO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@  H)T  )2D  "&K   >;0  &R[
M  !@P@  5,8  $C+   ^T   -=4$ "W="@ LX1, *^(? "GC*@ HY#4 )^0_
M ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWII (;Z;P"&NKB AKF_ (9Y?\#
M&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0  (BL  !ZM0  ;+T  %_$  !3
MR@  1\X  #S3   RV@  *M\  "7N"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT
M/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_
M 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU  !MO@  7\8  %+-  !%T@
M.=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -
M_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8  /^M  #_R@  __   /__  #_
M_P  __\  /__  #__P"-JP  ?;4  &Z_  !@R   4M   $/7   WW0  *^(
M "+F   9Z@  %?D  !+_   0_P@ #O\.  S_$0 )_Q8 !O\<  /_(@  _RH
M /\S  #_/0  _TD  /]7  #_:0  _WX  /^5  #_K   _\<  /_H  #_^@
M__H  /_Z  #_^@" M0  <+\  &')  !2TP  0]L  #7A   IY@  'NH  !7N
M   0^   #O\   O_   (_P  !/\&  #_"@  _PX  /\1  #_%0  _QL  /\C
M  #_*P  _S8  /]#  #_4P  _V4  /]Z  #_D0  _Z8  /^X  #_SP  _\\
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M&+<Z_QFV.O\9M3K_&+([_QBQ._\8L3O_&+$[_QC_.1( _S\- /]#"0#_2 P
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M)(E2_R.(4O\CB%+_(XA2_R/_10< _TL  /!5  #?6P  TV   ,QA P#(808
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M+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O_RA@;O\H8&[_*&!N_RCQ50
MWF(  ,IM  "]=0  LWL  *N   "B@@  F($  )&##P"-A1\ B(4N H.$.P5^
M@T4*>H%.#W6 5A1Q?UX8;GUF'&I\;2!G>W8C8WJ )V!YBRI=>)@L6G>F+EAW
MN"]7=]$O5W?Q+EAV_RQ8=O\J677_*5IT_RA:=/\G6G3_)UIT_R?M60  UV8
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M)46-_R5%C/\E1HO_)$:*_R1&BO\D1HK_)$:*_R38:0  PW8  +6!  "KB@
MGX\  )63  "*E@  ?IH  '"=  !KGPX :)\< &:@*@%BH#<"7Y]!!5N?2@A8
MGE(+5)Y:#E&=8A).G&L52YQU&$B;@1I%FX\=0IJ?'T":L" _FL@@/YGK'S^8
M_R ^EO\A/I7_(3^4_R$_E/\A/Y3_(3^4_R'-<   O'T  +"(  "DCP  F90
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M#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90  )F:  "-H0  ?Z<  '*M  !FLP
M6K@  $^[  !$OP  .L0" ##)"  NRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ H
MS58 )\YA ";.;P$DSG\!(\^1 B'/I0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)
M_P8=R?\&'<G_!AW)_P:HE   G)H  )"A  ""J   =*\  &>V  !;O   3L
M $/#   YQP  +\P  "?0!  ?U@H &]H0 !O;&@ :VR8 &MPQ !G=/  8W4@
M&-Y5 !??8@ 6X'( %>"% !3AF@ 3XK$ $N// !+@]  2WO\!$=W_ 1';_P(1
MV_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0  :+@  %N_  !.Q   0L@  #?,
M   MT   )-4  !S;   5WP4 %.D. !+J%  1ZQT $.LF  [L,  .[3H #>Y&
M  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3QY  "\?T  N__  /M_P #[?\
M ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(  $W(  ! S   --$  "K6   A
MVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4 !_L<  3\)  !_"P  /PW  #\
M0@  _%   /QA  #]=0  _(P  /RD  #\P0  _.L  /S_  #]_P  _?\  /W_
M  #]_P")J0  >;(  &J[  !<Q   3LP  #_1   RUP  )]T  !WA   5Y0
M#N@   KQ   (_0  !?\#  '_"0  _PX  /\2  #_%P  _Q\  /\G  #_,0
M_SX  /]-  #_7P  _W4  /^-  #_I@  _\(  /_G  #__   __\  /__  #_
M_P!\LP  ;+P  %W&  !.SP  /]8  #'=   EX@  &N8  !'J   ,[@  !?(
M  #_    _P   /\   #_    _P4  /\*  #_#@  _Q(  /\8  #_(0  _RL
M /\Y  #_2@  _UT  /]S  #_C   _Z0  /^Y  #_U   _]X  /_>  #_W@#_
M&"P _QDI /\9* #_%2L _Q P /\+. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\
M@@'_ (P!_P"4 ?\ G #_ *( _P"H /\ KP#_ +8 _P"^ /\ R #_ -< _P#G
M /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_&RD
M_QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA. ?\%6P'_ V@!_P)T ?\"?P'_
M H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;( _P&Z /\!Q #_ =$ _P#D /\
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M ]X<_P3='/\%W!S_!=P<_P7;'/\%VQS_!=L<_P7_*AD _RT3 /\M$0#_+1$
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M$Z([_Q.B._\2HCO_$J([_Q+_. H _SP  /]!  #U10  YD8" .%%!P#C0@T
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M&GU1_QK_0@  \$H  -]4  #.6@  Q%X  +Q?  "V7@  L5P+ *M>&@"E8"L
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M)6Q=N"5J7LXF:5[N)&E>_R)J7O\@:E[_'VI>_QYJ7O\=:E[_'6I>_QWY2@
MXU4  ,]?  #!90  MVH  *]L  "G;   GVH! )EK$0"4;2( D&XQ 8MM/02'
M;$<'@VM0"W]J6 ]\:& 3>&=G%G9G;QES9G@<<&6!'FUDC"%J8Y@C:&*F)69B
MMB9D8LPF9&+L)61B_R-D8O\A96+_'V5B_QYE8O\=96+_'65B_QWR3   WU@
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M)%-Q_")4<?\@5'#_'U5P_QY5;_\=56__'55O_QWE5P  S60  +YM  "R=0
MJ'L  )]^  "3?0  AWT  (!_!P!\@!4 >($D '6",@%Q@3T$;8!&!VF 3PIF
M?U8-8WY>$6!]9A1=?&X76GMW&E=Z@AU4>H\?47F=(4]YKB).><,B37CE(DUW
M^R%.=_\?3G;_'D]U_QU/=?\=3W7_'4]U_QW?7   R&@  +ER  "N>@  I8
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M%SJ._Q<ZCO\7.H[_%SJ._Q?%;@  MGL  *J%  ">BP  E(\  (B2  ![E
M;I<  &*;  !7G@  4J . %&@&P!/H2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"
MH6$'/Z!K"3V@=PLZH(4-.*"4#C:@I@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9
M_Q,SF?\3,YG_$S.9_Q.]=P  KX,  *.+  "8D0  C94  (&9  !SG   9Y\
M %NB  !/I@  1ZD( $2J$@!#JA\ 0:LK $"K-P _K$$ /:Q* 3NL4P(YK%P#
M-ZQG!#6L<P4RK($&,*R1!RZLHP@MK+@)+*S9""RJ]0HKJ/\+*J;_#"JE_PTJ
MI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@  A9P  'B@  !KI0  7Z@  %.L
M  !(KP  /;(  #:U"P TM14 ,[8A #*V+  QMS< ,+=! "^X2P NN%4 ++A@
M 2JX;0$IN7L")[F- B6YGP,DN;0#([G2 R.W] 0BM?\%(;3_!B&S_P<ALO\'
M(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,  &ZH  !AK0  5;$  $JT   _
MMP  -+L  "N^ P DP@P (L(4 "+#'P APRH (,0T !_$/P >Q4H '<96 !S&
M8P ;QW, &L>% !G'F0 8R*X %\C+ !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_
M Q;!_P.CD0  F)@  (N>  !]I0  <*L  &*Q  !6M@  2KD  #Z]   TP
M*L0  "+(   9S 0 $] * !'2$0 0TAH $-,E  _3,  .U#P #M1(  W55@ -
MU64 #-9X  S6C0 +V*0 "MB^  G9Y@ *UOX "]3_  O2_P +TO\!"]+_ 0O2
M_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)OP  /<(  #+&   HR0  '\T
M !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@)  "X2X  >(Z  #C1P  Y%8
M .1G  #E>P  YI(  .:J  #GR   Y_   .C_  #H_P  Z/\  .C_  #H_P"1
MGP  @J<  '2O  !EMP  5[X  $G#   \QP  ,,L  "7/   <U   %-D   [=
M   )X0   N4   #I!@  Z0T  .D1  #J&   ZR$  .TK  #O-P  \44  /)6
M  #S:   \WX  /27  #UL   ]M   /?S  #W_P  ]_\  /?_  #W_P"%IP
M=K   &:X  !8P0  2L@  #O,   NT0  (]8  !G<   1X   #.,   3G
MZ@   /4   #T    ]04  /4+  #V#P  ]A0  /@=  #Z)P  _#0  /]#  #_
M50  _VD  /^!  #_F@  _[(  /_/  #_[0  __D  /_Y  #_^0!XL   :+H
M %G#  !+RP  .]$  "W8   AW0  %N(   [F   (Z@   .T   #P    ^
M /\   #_    _P   /\   #_!@  _PP  /\0  #_&   _R(  /\P  #_0
M_U,  /]I  #_@0  _YD  /^O  #_PP  _]4  /_5  #_U0#_$R@ _Q,E /\1
M)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0
M /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\ P #_ ,P _P#? /\ [ #_ /@
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_
M$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (0 _P", /\
MDP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_
M /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D _P#_&B( _QH> /\8'0#_$QX
M_PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K /\ =@#_ '\ _P"( /\ CP#_
M )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0 ]0#2 /, Y@#R /0 \0#_ /
M_P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,>
M /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&<0#_!GH _P:# /X&BP#\!I(
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M \,<_P/#'/\#PQS_ \,<_P/_*!  _RD+ /\H!@#_*PL _RL0 /\I%P#])B(
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M#9$\_PW_-0  _SD  .I!  #=1@  T$<  ,E&  #&004 P$ 1 +E"(0"S1#(
MKT5  :M%2P*G154#I$1>!:%$9@>?0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^3
M0:01D4&P$I!!P!*.0=D2BT'Q$HE"_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="
M_P__.   \ST  .-'  #23   R$X  ,!-  "[2@( MD<. +!)'0"K2RT IDP[
M :),1P*>2U$$FTM:!IE*8@B626H*E$EQ#))(>0Z/2((/C4>+$8M'E1*)1J 4
MAT:L%85&NQ:$1M$6@D?N%H!'_Q5_1_\4?T?_$G]'_Q%_1_\1?T?_$7]'_Q'_
M.P  [D,  -Q,  #,40  P50  +E4  "T40  KDT+ *A/&0"C42D GE(W 9I2
M0P*744X$E%%6!I%07@F.3V8+C$YM#8E.=0^'37X1A4V'$X),D16 3)P6?DNI
M%WQ+N!A[2\T8>4SK&'A,_A=W3/\5=TS_%'=,_Q-W3/\2=TS_$G=,_Q+_/@
MZ$<  -50  #&5@  O%@  +19  "M5@  IU,' *%4%0"<5B4 F%<T 9170 *0
M5TH$C593!HI56PF'5&,+A%1J#H)3<A" 4GH2?5*#%'M1CA9X4)D8=E"F&710
MM1IS4,D:<5#H&G!1_!AP4?\7<%'_%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L
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M'%]=^!I?7?\87UW_%V!=_Q9@7?\58%W_%6!=_Q7K2@  U%8  ,->  "V90
MK&D  *)I  "89P  CV4  (EF# "%:!D @6DH 'YJ-0%Z:3\#=FE)!7-H40AP
M9UD*;6=@#6MF9Q!H97 2961Y%6-D@Q=@8X\97F*=&UQBK!Q:8K\<66+?'%EB
M]QI:8O\96F'_%UMA_Q9;8?\56V'_%5MA_Q7G30  SUD  +]B  "S:   J6T
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M%DIP_Q5+</\42W#_%$MP_Q346@  P&8  +-O  "H=@  G7D  (]X  "$>
M=WD  &]\  !J?0T 9WX9 &1_)@!B@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2
M?64,3WUO#DQ\>1%*?(831WN4%45[I!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W
M_Q1$=O\31';_$T1V_Q/-7P  NVL  *YT  "D?   EWX  (I]  !_?@  <G\
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M"RV2_PNV=0  JH$  )Z(  "3C0  AHX  'B/  !KD@  7Y4  %29  !)G0
M0*   #JB#0 XHQ< -Z,B #:D+0 UI#< -*1! #.E2P QI50!,*5> 2ZE:@$L
MI7@"*J6( RBEF@,GI:T$)J7& R:DZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>
M_P>O?@  HX@  )>.  "-DP  ?I4  '"8  !CFP  5Y\  $RB  !"I@  .*D
M "^L P JK@X *:X8 "BO(P GKRT )K W "6P00 DL$L ([%6 "*Q8P AL7$
M'[&" !ZRE $<LJD!&[+! 1NQYP$;K_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.H
MB   FX\  )&4  "$F@  =I\  &BB  !;I0  3ZD  $2M   YL   +[,  ":V
M   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4O4  $[Y+ !*^6  2OF< $;]X
M !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP
ME)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0  #JV   ON0  );P  !V_   5
MPP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC( !LL^  7+2P $S%H  \QJ  +,
M?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !RO\  <K_  '*_P"7E@  BIP
M 'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_   CPP  &\8  !/*   -S0
M"-$   '4"0  U X  -45  #6'@  V"<  -DQ  #;/@  W$L  -U;  #>;@
MWH0  -^;  #?M   WMD  -_W  #?_P  W_\  -__  #?_P"-G0  ?Z4  '"L
M  !ALP  4[H  $6_   XP@  +,8  "')   8S0  $-$   O5   $V@   -X
M  #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I+P  ZSP  .U+  #N70  [G$
M .^)  #PH@  \+P  /#C  #O^0  \/\  /#_  #P_P"!I0  <JT  &.U  !4
MO0  1L0  #?(   JS   ']   !75   .V@  !]X   #B    Y@   .D   #J
M    [    .X%  #O#   \1   /,7  #U(   ^"L  /LY  #]2@  _EX  /]T
M  #_C0  _Z8  /_   #_X0  __4  /_U  #_]0!TK@  9;<  %;   !'R
M.,T  "K2   =V   $]T   SB   #Y@   .D   #L    \    /,   #T
M]@   /@   #Z    _0<  /\-  #_$@  _QL  /\H  #_-P  _TH  /]>  #_
M=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_#R0 _PXB /\+(0#_ R0 _P I
M /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (0 _P", /\ D@#_ )D
M_P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_
M /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$ _Q > /\-'0#_!Q\ _P C /\
M+0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )4 _P";
M /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D X@#X /  ]P#\ /8 _P#U /\
M]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,: /\0&0#_"QD _P = /\ *0#_
M #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _@"# /P B@#Z )$ ^0"7 /@
MG0#W *, ]0"J /0 L@#R +L \0#( .\ W #N .P [0#Z .L _P#J /\ Z@#_
M .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3$P#_#A, _PL: /\') #_ C
M_P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^ /( A0#Q (P [P"3 .X F0#L
M *  ZP"F .D K@#G +< Y@## .0 U #B .D X0#W -\ _P#= /\ W0#_ -T
M_P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX
M /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"@ #F X< Y .. .(#E0#A YP
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M JX=_P+_)@8 _R4  /\F  #[)P  \24# / A"P#H'!( WAD= -0;+0#-'3P
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M!Y0UNPB3-= (D#7L"(XV_@B,-O\(BS;_"(LV_P>*-?\'BC7_!XHU_P?_+P
M\C0  .(\  #200  QT(  ,!   "[.@$ MC8. + Y' "J.RP ICPZ *,]1@"?
M/5 !G3U9 IH]80.8/6@$ECQP!90\=P:2/( 'D3R(!X\[D@B-.YT)BSNI"HD[
MMPN(.\H+A3SH"X,\^PN"//\*@3S_"H$\_PF!//\(@3S_"($\_PC_,P  [#H
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M$FM,]1%J3/\/:DS_#FI+_PUJ2_\,:DO_#&I+_PSP/0  VT@  ,=0  "Z50
ML%@  *56  "<4P  ET\  )%0#@",4AP B50K (54-P""5$(!?U1+ WQ44P1Z
M4UH&>%-B"'52:0ES4G$+<5%Z#6Y1A ]L4) 0:E"<$FA0JQ-F4+P395#8$V10
M\Q)D4/\09%#_#V10_PYE3_\-94__#&5/_PSL00  U$P  ,-4  "V60  K%P
M *!:  "75P  D50  (M5# "&5QD @U@G (!9- !]63\!>EE( W=84 1T6%@&
M<E=?!V]79@EM5FX+:U9W#6A5@0]F58T19%2:$F)4J1-@5+H47U33%%Y4\A->
M5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1   SU   +]8  "S70  J%\  )Q=
M  "26P  BU@  (5:"@"!6Q8 ?5PD 'I=,0!W73P!=%U& G%=3@1O7%4%;%Q=
M!VI<9 EH6VP+95IU#6-:?P]A68L17EF8$EQ8IQ1;6+@465G0%%E8\!-96/\1
M6EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,  +M;  "P80  I&(  )=A  ".
M7P  A5P  ']>!P![7Q, >&$A '5B+@!R8CD!;V)# FQA2P-J85,%9V%:!V5@
M8@EC8&H+8%]S#5Y>?0];7HD165V6$E==I1-57;845%W.%%1=[A-47?\155S_
M$%5<_PY56_\.5EO_#59;_PW>3   QU8  +A?  "M9   H&4  )-D  ")8P
M?V$  'EB P!U9!$ <F4> &]F*P!L9S<!:F=  F=F20-E9E$$8F58!F!E8 A=
M9&<*6V1P#%EC>PY68X805&*4$E)BHQ-08K033V+,$T]B[1)/8?\13V'_$%!@
M_PY08/\.4&#_#5!@_PW93P  PUH  +1C  "I:0  FV@  (]G  "$9P  >64
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M##]P_PS%7@  M6D  *EQ  "<=0  C70  (!T  !U=   :78  %YY  !8? $
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M RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=
MI7X  )F%  "*A   ?80  &^%  !CB   6(L  $V/  !#DP  .I<  #*:!P N
MFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L )YY5 ":>80 EGFX (YY^ 2*>
MD $@GJ,!'YZY 1Z>W0$>G/@"'IK_ AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4
M ).+  "%B@  =8L  &B.  !;D0  4)4  $:9   [G0  ,J   "JC   BI@D
M'Z<1 !ZG&@ =J"0 '*@M !NH-P :J4$ &:E, !BI6  7JF8 %JIV !6JB0 4
MJIX $ZNT !*KTP 2J/4 $Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1
M  !]D@  ;94  &"8  !4G   2*   #ZD   TIP  *JL  "&N   9L0  $K,'
M  ^U$  .M1< #K4A  VU*P -M38 #+9!  NV3@ *MEP ";9L  BV?P 'MI0
M!K:J  6VQ0 &MNH ![7_  BT_P (L_\ ";+_  FR_P":C0  D),  (28  !T
MG   9:   %>D  !+J   0*P  #6P   JLP  (;4  !BX   1NP  #+X"  ;
M"P "P!$  <$9  #!(@  PBL  ,(V  ##0@  PU   ,1?  #$<0  Q(<  ,2=
M  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##_P"3E   AYH  'B@  !JI@
M7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L   !##   *Q@   \H   #,!0
MS P  ,T1  #.&   SB$  - J  #1-0  TT,  -12  #48P  U7@  -6/  #5
MIP  UL(  -;I  #6_0  UO\  -;_  #6_P"*FP  >Z(  &RI  !>L   4+8
M $*Z   TO0  *,$  !W$   4QP  #<L   ;.    T@   -<   #9    V@4
M -P+  #=$   WQ4  .$=  #C)P  Y3,  .="  #H5   Z&<  .E^  #IEP
MZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP  ;JL  %^R  !1N@  0L   #3#
M   GQP  &\L  !+/   +TP   M@   #=    X0   .0   #E    YP   .D
M  #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y00  ^E4  /IJ  #[A   ^YT
M /RV  #\T@  _>T  /WT  #]] !QK   8;4  %*]  !$Q   -,D  ";-   :
MT@  $-@   C=    X0   .4   #H    [    .\   #Q    \P   /4   #W
M    ^0$  /L(  #^#@  _Q4  /\A  #_+P  _T$  /]6  #_;0  _X<  /^@
M  #_M@  _\H  /_4  #_U #_"R  _P<> /\ '0#_ "  _P E /\ +@#_ #L
M_P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_
M *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /  _@#] /T _P#] /\ _0#_ /T
M_P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_ !H _P ? /\ *@#_ #< _P!%
M /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\ B0#_ )  _P"6 /\ G #^ *(
M_ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y /, _P#R /\ \P#_ /, _P#S
M /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0 _P 9 /\ )0#_ #( _P!  /\
M3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W (L ]@"1 /0 EP#S )X \@"D
M /  K #N +0 [0#  .L SP#I .8 Z #U .8 _P#G /\ Y@#_ .4 _P#E /\
MY0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z
M %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8 Z@", .@ DP#G )D Y0"@ .,
MIP#A +  WP"Z -T R0#; .  V #P -< _@#5 /\ U #_ -, _P#3 /\ TP#_
M -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#&@#_ "8 _0 S /0 0 #O $T
MZP!8 .@ 80#E &H X@!R .  >@#> (  W "' -H C@#8 )4 U "< -( HP#0
M *P S@"V ,P Q #* -D R #M ,< ^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!
M_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\!Q\ \0,K .< .0#B $8 W@%1
M -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$B0#(!9  Q@68 ,0%H #"!JD
MP0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_
M&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8 XPDB -H), #3"CX S@M* ,H,
M50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\#XT NA"5 +@0G0"W$*< M1&R
M +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5_P"F%/\!IA3_ :84_P'_'P
M_QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y
M%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<
MO "D'<\ H1[J 9X>_ &<'_\!FQ__ 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$
M .PG  #@*@  U"D  ,TD  #*' @ Q!D2 +T<(@"W'C$ LR ^ *\A20"M(E,
MJB-< *@D9 "F)&P I"1S *,D>@"A)8(!H"6+ 9XEE &=)9X!FR:J 9DFMP&8
M)LD"E2?F I(G^0*0*/\"CRC_ HXG_P*.)_\"CB?_ HXG_P+_)@  \BD  .,Q
M  #2-   R#0  , P  "[*0( N",. +$F' "L*"L J"HX *0K1 "A+$X GRU7
M )TM7P";+6<!F2UN 9@N=0&6+GT"E"Z& I,ND *1+IH#CRZF XTNLP.,+L4#
MBB_A!(<O]@2%+_\$A"__ X0O_P.#+_\#@R__ X,O_P/[*0  ZS$  -DX  #)
M/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28 GC,T )HT0 "8-4H E353 ),U
M6P&1-6(!CS5I HTU<0*,-7D#BC6" X@UBP2&-98$A#6B!8(UKP6!-< &?S;<
M!GTV] 9[-O\%>S;_!7HV_P1Z-O\$>C7_!'HU_P3U+0  Y#<  - _  #"0P
MMT0  *U   "G.@  HS8& )TW$P"9.2( E3HO )(\.P"//$8 C#Q/ 8H\5P&(
M/%X"ACQE H0\;0."/'4$@#Q]!'\\AP5]/)(&>SN>!WD[K =W.[P(=CS5"'0\
M\0AS//\'<CS_!G(\_P5R//\%<CO_!7([_P7Q,@  WCT  ,E$  "\2   L$D
M *9&  "?00  FST! )4]$ "1/QT C4$K (I". "'0T( A$-+ 8)#4P& 0UL"
M?D)B WQ":01Z0G$%>$)Z!G9!A =T08\(<D&;"'!!J0EO0;D*;4'0"FQ![@EK
M0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P  UD(  ,1)  "W30  JTT  *!*
M  "81P  DT(  (Y##0")11H AD8H (-'- " 2#\ ?DA( 7M(4 )Y2%<"=TA?
M W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&I@MG1K8+9D;,"V5&[ MD1_\)
M9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8  +]-  "S40  I5$  )I.  "2
M2P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z33P =TU% 75-30)S354"<4U< V]-
M8P1M3&L%:TQS!VE+?0AF2XD)9$N6"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_
M"5Y*_PA>2O\'7DK_!UY*_P?C/P  RTD  +Q1  "P50  H50  )92  "-4
MATP  (%-" !]3Q, >E A '=1+@!T4CD <E)" 6]22P%M4E(":U%9 VE1801G
M46@&95!Q!V-0>PAA4(8*7T^3"UU/H0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/
M_PA93O\'64[_!UE._P??0P  QTT  +A4  "L60  G5<  )%5  "(5   @5
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M!TI:_P?.3@  O%@  *Y@  "?80  D6   (5?  ![7P  <%T  &I?  !E80H
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M!CQOE0<Z;Z8(.&^["#AOVP<X;O8'.&W_!SAL_P8Y:_\&.6K_!CEJ_P:]7
MKV8  *)M  "1;   @FL  '=K  !L;   86X  %=P  !0<P  3'4* $EV$P!'
M=Q\ 1G<I $5X,P!#>#P 0GA$ $%X30$_>%4!/7A> CMX: (Y>'0#-WB"!#5X
MDP4S=Z0%,G>Y!3%XUP4Q=O4%,73_!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT
M )QQ  "+<   ?7   ')P  !G<0  7',  %%W  !*>@  0GT# #]^#@ ]?Q@
M/'\C #N +0 Z@#8 .8$_ #B!2  V@5  -8%: 3.!9 $Q@7 !+X%_ BV!CP,L
M@:$#*H&V RF!T@,I?_,#*7W_ RE\_P,I>_\#*7O_ RE[_P.Q:@  I70  )5V
M  "%=0  >'4  &UU  !A=P  5WH  $Q^  !#@0  .X4  #6("0 RB1$ ,8D;
M #"))0 OBB\ +HHX "V+00 LBTH *HM4 "F+7P HBVL )HMZ 22+BP$CBYX!
M(HNS 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  "
M>@  <WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4
M'  BE28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N
M !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@
M;((  %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4
MH1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JB
MP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L
M %B.  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1(
M!JT;  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM
MKM4  *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":
M  !$GP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4
M  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0
M +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [
MK0  ,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&
M%   QQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:
M  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0
M)+P  !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0
MUQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #E
MY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<
M  _*   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D
M .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@
M^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
M    W0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#
M  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,
M /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_
M %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\
MKP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_
M /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H
M_P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W
M +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H
M_P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!?
M /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X
MZ "Y .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_
M#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\
M8@#L &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T
M -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P
M_PP' /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #>
M &4 VP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0
MNP#" ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX
M /\*  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\
MR0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T
M ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/
M  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A
M +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4
MI@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D
M&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T0
M8P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3>
M )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0
MRB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">
M&V4 G1ML )L<<P":''L F!R# )<=C0"5'9< DQZB )(>KP"0'K\ CQ_8 (P@
M\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z'@  ZR8  -HM  #*,   OBX
M +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB/@"9(T@ ER11 )4D60"3)6
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M VLV_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@
MD#8  (PU#0"(-Q@ A#@E ($Z,0!_.SP ?#M% 'H\30!X/%4!=SQ< 74\8P%S
M/&H"<3QS G \? -N.X<#;#N4!&H[H01H.[$%9SS%!64\Y05D//H$9#S_ V,[
M_P-C._\#8SO_ F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#  ".0   B3P
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M U-(_P/400  P$L  +)1  "@4   DD\  (=.  !^3   >$@  ')*  !N2PT
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M!4=7E09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3
MM58  *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!5
M7"8 4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=
MD@5 7:,&/UVV!CY=T 8]7/$%/EO_!#Y:_P0^6O\#/EG_ S]9_P/!4   L5H
M *%=  "07   @EL  '9;  !M6P  85L  %M=  !67@  4F - %!A%P!.8B(
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M BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P
M=&<  &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q
M>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)Z
MQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP
M &5L  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B<
M)((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8
M@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS
M  !4=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG
M !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^
M#HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-
M?@  0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:
M)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP
M  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0
M.XT  #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P
MIB@  *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E
M_   I?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH
M "B>   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\
M +,H  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P
MM/\  +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L
M   6L   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=
M  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X
M ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .
MO0  !L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4
M&P  V"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__
M  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0
M ,P   #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$
MZA@  .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T
M] !JJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P
M  #@    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X
M /P6  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_
M !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\
M;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_
M /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0
M_P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_
M '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$
MQP#O .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P .
M /\ #0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L
M\P!R /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@
M -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\
M!@#_  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L
M .( <P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D
MR0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_
M  0 _P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X
M;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#;
M +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^
M]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\
M &X N@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@
MZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0
M -H !P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@
MK !O *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":
M!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-
M  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ
M )\+<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P
MC!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S
M$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3
M; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_
M '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'
MI!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&
M'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+( >R#% 'DAY !W(OD =B+_ '4B
M_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V,0  J2X  * J  ";)@  F"$!
M )4>$ "0(!L C2$H (DC,P"')#T A21& (,E3@"!)E4 ?R9< 'XF8P!\)VL
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M 5PT_P'<,P  Q3P  +1!  "B0   E3X  (L\  "$.0  ?S8  'LT! !W-1
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M E __P)0/_\"43[_ 5$^_P'/.P  O44  *I'  "91@  BT4  (%$  !Y0@
M=#X  &\_  !K0 P 9T$5 &5"(0!C0RL 84,U %]$/@!>1$4 745- %M%5 !9
M15P!6$5D 59%;0%417@"4D6% E%$DP-/1*,#346T TQ%S -+1>T#2T3_ DM$
M_P)+0_\"3$+_ DQ"_P+*/P  N4@  *9*  "520  AT@  'U'  !U10  ;D(
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M CU._P*^2P  KE,  )I2  ")40  ?%$  '%0  !H4   7DX  %A1  !44@
M45,, $Y4% !,51\ 2U8I $E6,@!(5CH 1U=" $972@!$5U( 0U=: $%79 %
M5VX!/E=[ CQ7BP(Z5YL".%>M C=7Q (W5^<"-U;] C=5_P(W5/\"-U/_ CA3
M_P*Z3P  J58  )55  "%5   >%0  &U4  !D5   6%0  %)6  !.5P  2ED)
M $=:$0!&6AL 1%LE $-;+@!"7#8 05P^ #]<1@ ^74\ /5U7 #M=80 Z76P!
M.%UY 39=B $T79D",UVK C%=P@(Q7.4",5O\ C%:_P(Q6?\",EG_ 3)8_P&V
M5   I%D  )!8  " 6   <U<  &E7  !@6   5%D  $Y;  !(70  0U\$ $!@
M#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W8TL -F-4 #1C70 S8V@ ,6-V
M 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@_P$K7_\!*U__ 2M>_P&Q60
MGEP  (M<  ![6P  ;UL  &5;  !<7   45X  $E@  !#8@  /&4  #AG"@ U
M:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8 +6I/ "QJ60 K:V4 *6MR "AK
M@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C9O\!(V;_ 21E_P&L8   F&
M (5@  !V7P  :E\  &%@  !78   36,  $1F   ]:   -FL  #!N!  L< X
M*G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')* ")R5  A<V  ('-M !YS?0 =
M<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D
M  !Q9   9F0  %UD  !29@  2&D  #]L   W;P  ,',  "EV   B>0@ 'WL0
M !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\3@ 6?%H %7QG !1]>  2?8L
M$7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_ !)W_P">:P  BFH  'II  !M
M:0  8FD  %=J  !,;0  0W   #ET   Q>   *7L  ")_   ;@@  %(4) !&&
M$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8
M  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"_P"5<0  @V\  '1N  !I;@
M7&\  %!R  !&=0  /'D  #)]   J@0  (H4  !N)   4C   #X\#  J2"P &
MDA$ !)(8  *2(  !DBD  )(S  "3/@  DTL  )-9  "3:0  DWL  )*0  "2
MI@  D;\  )'E  "0^@  C_\  (__  "/_P"-=P  ?74  '!T  !B=0  57@
M $E\   _@   -(0  "N)   BC0  &I$  !.4   .EP  "9L   &="   G0X
M )T3  ">&@  GB(  )\K  "?-0  H$(  *!0  "@7P  H'$  *"'  "?G0
MG[4  )[:  "=]@  G?\  )S_  "<_P"&?0  >'P  &E\  !;?P  3H,  $&(
M   VC   +)$  ".6   :F@  $IX   VA   &I    *<   "I P  J0H  *H.
M  "K$P  K!D  *TB  "N*P  KS<  *]%  "O5   KV8  *][  "NE   KJL
M *[)  "N[P  K?\  *W_  "M_P"!A   <80  &&'  !3BP  1I   #F6   N
MFP  (Z   !JD   2J   #*P   2O    L@   +8   "W    MP(  +@(  "Y
M#0  NA(  +L8  "](0  OBL  , X  # 2   P%H  ,%N  #!A@  P:   ,&Z
M  #!XP  P/D  ,#_  # _P!YC0  :)   %F4  !+F@  /:   #&E   EJP
M&J\  !&S   +N    KL   "^    P0   ,0   #%    Q@   ,<   #(!0
MR@L  ,P/  #.%0  T!\  -,K  #5.@  U4P  -9@  #8=P  V)(  -BL  #9
MR0  V>P  -G[  #8_P!PF0  8)X  %&D  !#J@  -;   "BV   <N@  $;X
M  G!    Q0   ,@   #+    SP   -(   #3    U@   -@   #;    W0
M -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1  #N9P  [X$  .^<  #PMP
M\-,  /#L  #P] !GI@  6*T  $FT   ZN@  *KX  !S"   0Q@  !\H   #.
M    T@   -8   #<    X    .,   #D    Y@   .@   #K    [0   .\
M  #R @  ]0H  /@1  #\'   _RP  /\_  #_50  _VX  /^*  #_I   _[H
M /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_
M %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X
MI@#] *X _ "Y /H R #Y .( ^ #T /< _P#V /\ ]@#_ .\ _P#G /\ X@#_
M -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\ ( #_ "T _P Z /\ 1@#_ %$
M_P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"& /8 C #U )( \P"9 /( H #P
M *D [@"S .T P0#K -8 Z@#N .D _@#G /\ YP#_ .4 _P#= /\ U0#_ -$
M_P#_  T _P * /\ " #_  D _P 0 /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5
M /, 7@#Q &8 [@!M .P = #K 'H Z0"  .< A@#F (T Y "3 .( FP#@ *,
MW@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_
M  @ _P # /\   #_  , _P - /P %@#W "( \P N .\ .@#L $4 Z !/ .0
M6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1 (< SP". ,T E0#+ )X R0"G
M ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X _P"^ /\ O0#_ +L _P#_
M_P   /\   #_    ]@ ( .X $0#G !L X0 G -T ,P#9 #X TP!) ,\ 4@#+
M %D R !A ,8 9P#$ &T P@!S ,  >@"_ (  O0"( +L D "Y )@ N "B +4
MK0"S +L L0#. +  Z@"O /P K0#_ *T _P"N /\ K@#_ *X _P#_ @  _P
M /T   #R    Z    -X # #3 !4 S  A ,@ + #$ #@ P0!" +T 2P"Z %,
MN !: +8 80"T &< L@!M +  = "O 'H K0"" *P B@"J ), J "= *8 J "D
M +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\ G@#_ )X _P#_!@  ^P   .X%
M  #B!   U0   ,L !@##  \ O0 9 +@ )0"T #$ L0 [ *X 10"L $T J0!5
M *< 6P"E &( I !H *( ;@"A '4 GP!\ )X A0"< (X F@"8 )@ I "6 +
ME0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_ (\ _P#]"@  \ X  .$1  #.
M$   P@T  +L'  "W  H L0 2 *P '@"H "D I0 T *( /@"? $< G0!/ )L
M5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0!(H C@25 (P%H0"*!:X B0:^
M (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+_P#V$   YA<  -(<  # &@
MLQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN )8*. "4"T$ D@Q* ) ,40".
M#5@ C U> (L-90")#6P B YT (8.?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0
MVP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O%P  VR$  ,8D  "T(P  J"
M * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2,@")$SP AQ-$ (443 "#%%,
M@15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/ '88G !T&*H <QF[ '(9U !O
M&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(   T"D  +PK  "K*@  GB@  )8D
M  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5
M '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PAF !K(:< :2*X &@BSP!F(NX
M92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\  +0Q  "C,   EBX  (TK  "'
M*   A"0  ((@" !^(!( >R(> '@C*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG
M60!K)V  :B=H &DH<0!G*'L 92B( &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_
M %PI_P!<*?\ 7"G_ %PH_P#8+   PS4  *TU  "=-   D#,  (8Q  " +0
M?"L  'DH P!V)Q  <BD: ' J)0!M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D
M+ET 8RYE &$O;@!?+W@ 7B^$ %POD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O
M_P!5+_\ 52[_ %4N_P#0,0  O3H  *@Y  "7.   BC<  ( V  !Z,@  =3
M '(N  !N+@T :R\6 &DP(0!F,2L 9#(T &,R/0!A,T0 8#-+ %\T4@!=-%H
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M 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-   !K/P  93P  & \  !</@0
M63X/ %<_& !50"( 4T$K %)!- !00CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(
M0VX 1T-[ 45#B0%#0YD!0D.K 4!#P $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4!
M_P&_00  JD4  )9%  "&10  >40  &]$  !G0@  8#\  %M!  !70@  5$,-
M %%$%0!/11\ 3D4H $Q&,0!+1CD 2D=! $E'2 !(1U  1D=8 $5'80!#2&P
M0DAX 4!(AP$^2)<!/$BI 3M(O@$Z2-\!.D?X 3I&_P$Z1?\!.T7_ 3M$_P&[
M10  ID@  ))'  ""1P  =D<  &M'  !C1@  6T,  %9%  !21P  3D@* $Q)
M$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"3$T 04Q6 $!,7P ^3&H /$QV
M #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+_P$U2O\!-DG_ 39)_P&X20
MHDL  (Y*  !^2@  <DH  &A*  !?20  54@  %!*  !,2P  24P' $9-$ !$
M3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H .U%3 #I17  X46< -U%S #51
M@@ S49,!,E&E 3!1N@$O4=H!+U#V 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T
M (I-  !Z30  ;DT  &1-  !;30  44T  $M/  !&4   0E(# #]3#0 ]5!4
M/%0> #I5)P Y52\ .%4W #=6/P V5D< -590 #-660 R5V0 ,%=Q "]7@  M
M5Y$ *U>C "I7N  I5]8 *5;U "E5_P J5/\!*E/_ 2I2_P&O40  F%$  (51
M  !V4   :E   &!0  !840  3E(  $=3  !!50  .U@  #A9"@ U6A$ -%H:
M #-;(@ R6RL ,5LS "]<.P N7$, +5Q, "Q<5@ K76  *5UM "A=?  F78X
M)%VA "-=M0 B7=( (ESS ");_P C6O\ (UG_ "18_P"H50  DE0  (!4  !Q
M5   9E0  %Q4  !450  2E8  $-8   \6P  -ET  #!@!0 M80X *V$5 "IB
M'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B9%P (61I !]D>0 >9(H '&2>
M !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?_P"A60  C%@  'M8  !M6
M8E@  %E8  !060  1UL  #Y>   W8   ,6,  "IF   D:0D (6H0 "!J%P ?
M:B  'FLH !UK,  <:SD &VM" !IL3  9;%@ %VQE !9L=  4;(8 $VR: !)L
MKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"970  A5T  '5<  !H7   7EP
M %5<  !+7@  0F$  #ED   R9P  *VH  "1M   >< $ %W,+ !5T$0 4=!@
M$W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (
M=,, "73G  IS_0 +<?\ #''_  QP_P"18@  ?V$  '!A  !D80  6F$  $]B
M  !%90  /&@  #-L   K;P  )'(  !UV   7>0  $7P$  U_#  +?Q( "G\9
M  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_9P  ?WD  '^.  !_HP  ?KL
M 'W@  !]]P  ?/\  'O_  ![_P")9P  >&<  &MF  !A9@  5&<  $EI   _
M;0  -7$  "QU   D>0  '7P  !:    0@P  #(8"  :)"@ !B0\  (D4  "*
M&P  BB,  (LL  "+-P  BT,  (M0  "+7P  BW$  (N&  "+G   BK,  (G3
M  "(\P  B/\  (?_  "'_P"";0  <VP  &AL  !:;0  3F\  $)S   X=P
M+GL  "6    =A   %8@  !",   +CP  !)(   "4!@  E0P  )40  "6%0
MEQP  )@D  "8+@  F3D  )E'  "95@  F6@  )E]  "9E   F*L  )?(  "6
M[@  EO\  )7_  "5_P![=   ;W,  &%S  !3=@  1GH  #M_   PA   )H@
M !V-   4D@  #I8   F9   !G    *    "A    H@8  *(,  "D$   I10
M *4<  "G)   J"\  *@]  "I3   J5X  *ER  "HB0  J*(  *B\  "GY0
MIOL  *;_  "E_P!W>P  :'L  %E^  !+@@  /H<  #*-   GD@  '9<  !2<
M   .H   !Z0   "H    JP   *X   "O    L    +$$  "S"@  M X  +43
M  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[?0  NI<  +JQ  "ZT@  NO,
M +G_  "Y_P!O@P  7X8  %&+  !#D   -I<  "J=   ?H@  %:<   VL   %
ML    +0   "W    NP   +X   "_    P    ,$   ## 0  Q <  ,4-  #'
M$0  RAD  ,TD  #.,P  ST0  -!8  #0;@  T8@  -"D  #0P0  T>8  -'X
M  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M   6LP  #K@   :\    P
M ,,   #&    RP   ,T   #.    T    -$   #4    U@   -H"  #<"0
MWP\  .,7  #F)   YS8  .A)  #I7P  ZG@  .N4  #KKP  Z\P  .SH  #L
M]@!?G@  4*0  $*K   TL@  )KD  !F^   .P@  !,4   #*    S0   -$
M  #8    VP   -\   #@    X@   .0   #F    Z0   .L   #N    \04
M /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"  #_G0  _[4  /_+  #_Y #_
M !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\ _P [ /\ 1P#_ %( _P!; /\
M9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^ ), _0"9 /L H0#Z *D ^ "T
M /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D _P#@ /\ V #_ -, _P#_  X
M_P + /\ "@#_  L _P 1 /\ '0#_ "H _P V /\ 00#_ $P _P!6 /X 7P#[
M &8 ^0!M /< = #U 'H ] "  /( A@#P (T [P"4 .T FP#L *0 Z@"N .D
MN@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1 /\ S #_ ,@ _P#_  D _P $
M /\  0#_  0 _P . /\ & #_ "0 _0 P /L .P#W $8 \P!0 .\ 60#L &
MZ@!G .< ;@#F '0 Y !Z .( @ #@ (< W@". -P E0#: )X U@"H -0 LP#1
M ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\ OP#_ +P _P#_  ( _P   /\
M  #_    _0 + /< $P#Q !X [0 J .H -0#G $  X@!* -T 4@#9 %H U0!A
M -( 9P#0 &T S@!S ,P >@#* (  R "' ,8 CP#$ )@ P@"A ,  K0"^ +L
MO #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_ +  _P#_    _P   /\   #Y
M    [@ % .4 #@#> !@ V  C -( +@#/ #D RP!# ,< 3 #$ %0 P0!; +\
M80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R )( L "; *\ IP"L +0 JP#&
M *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0 _P#_    _P   /4   #J
MW@   -  "@#( !( P@ = +X * "[ #, N0 ] +4 1@"R $T L !5 *T 6P"L
M &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P H "6 )\ H0"= *X FP"^ )D
MV "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_    ]0   .<!  #4    R0
M ,  ! "X  X LP 6 *\ (0"K "P J  V *8 /P"C $< H0!/ )\ 50"= %L
MFP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1 )  G ". *D C "X (L S0")
M .L B #] (@ _P"( /\ B #_ (@ _P#Y!@  Z0P  -0.  ###   MPD  + "
M  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6 $$ E !) )( 4 "0 %8 C@!<
M (T 8@"+ &D B@!P (@ > "' ($ A0", (0 F "" *4 @ "T 'X R !] ><
M? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4  ,45  "T%   J1$  *$.  ">
M"@  FP,, )< $P"3 !X D $I (T",P"* SP B 1# (8%2P"%!E$ @P97 (('
M7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W"J, =0JS ',+QP!R#.8 < W[
M ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=  "I'   G1H  )46  "0$P
MCPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^ 'P.1@![#DT >0]3 '@06@!V
M$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:( :Q*R &D2QP!H$^< 9A/] &44
M_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@(P  E"$  (L?  "&&P  @Q<
M ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT
M:QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO & :Q !>&^0 71S[ %P<_P!<
M&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0  C"@  (,E  !](@  >1\  '@;
M P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A
M &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<BP !6(^$ 52/Y %0C_P!4(O\
M5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T  'PK  !V*   <B8  &\C  !M
M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG
M9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/*=X 3BGW $TI_P!-*?\ 32C_
M $XH_P#(,   L#(  )PR  ",,@  @#$  '8P  !P+0  :RL  &@I  !F* D
M8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1
M+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M
M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K,@  9B\  &(N  !?+04 7"X0
M %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R20!0,E  3C-8 $TS80!+,VL
M2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T $(T_P!",_\ 0C+_ $(R_P#
M.   IS@  ),X  "#.   =S@  &TW  !F-@  83,  %TR  !9,@( 5S,- %0T
M%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU
M $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX_P ]-_\ /3?_ #TV_P"[.P
MHCL  (\[  !_.P  <SL  &HZ  !B.0  73<  %@V  !4-P  43@+ $\Y$P!-
M.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]
M@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X._\ .#O_ #@Z_P"V/0  GCX
M (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z  !/.P  3#P( $D]$0!'/AD
M1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1 #U!6@ \060 .D%P #A!?P W
M08\ -4*A #1"M  R0LX ,D'P #) _P S0/\ ,S__ #0^_P"Q0   FD   (=
M  !X00  ;$$  &)   !;0   5#\  $X_  !*0   1D$% $1"#@!"0Q8 0$,?
M #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&6  V1F( -49N #-&?  Q1HT
M,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T
M0P  :$,  %]#  !70P  4$,  $A#  !$10  048! #Y'#  \2!, .D@< #E)
M)  X22P -DDT #5*.P T2D, ,TI, #)*50 P2U\ +TMK "U+>@ L2XL *DN=
M "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'_P"G1@  D48  ']&  !P1@
M948  %M&  !41@  3$<  $1(   _2@  .TL  #=,"0 U31  ,TX8 #).(  Q
M3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P *%!H "=0=P E4(@ )%"; ")0
MKP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A20  C$D  'I)  !L2@  84H
M %A*  !02@  24L  $!,   [3@  -5   #%2!  M4PT +%04 "I4'  I520
M*%4L "=5,P F53P )59% "163@ B5ED (59E !]6=  >5H4 '%:8 !M6K  9
M5L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30  ADT  '5-  !H30  74T  %1-
M  !-3@  14\  #Q1   V4P  ,54  "M8   F6@D (UL0 ");%P A7!\ (%PG
M !]<+@ =7#< '%U  !M=2@ :754 &%UA !==<  578$ %%V5 !-=J@ 17<(
M$5WG !);_@ 36O\ $UK_ !19_P"440  @%$  '!1  !D40  65$  %%1  !)
M4@  05,  #A6   R60  *UL  "5>   ?80, &F,, !AD$0 79!D %F0A !5D
M*0 493$ $V4Z !)E1  195  $&5=  ]E:P .97T #661  QEI0 *9+P "F3@
M  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5  !?50  5E4  $Y5  !$5P
M/%D  #1<   L7P  )F(  !]E   9:   $VL% !!M#0 .;A( #6X:  QN(@ ,
M;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8  FZ*  !MGP  ;;8  &S6  !L
M\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<60  4UD  $A:   _70  -F
M "YC   F9P  'VH  !EM   3<0  #G0#  IW"@ %=Q   7<5  !W'   =R0
M '@M  !X-P  >$,  'A0  !X7@  >&\  'B$  !XF0  =[   ';-  !U\
M=?\  '3_  !T_P!^7P  ;E\  &)>  !97@  35\  $)B   Y90  ,&@  "=L
M   ?<   &'0  !)W   ->P  "'X   * "   @0T  ($1  ""%P  @QX  (,F
M  "$,   A#L  (1(  "$5P  A&@  (1\  "$DP  @ZH  (+%  "!ZP  @?X
M (#_  " _P!W90  :60  %]C  !29   1V<  #QK   Q;P  *',  "!W   8
M?   $7\   R#   &AP   (H   ", P  C D  (T.  ".$0  CQ<  ) >  "1
M)P  DC(  )(_  "23@  DE\  ))S  "2BP  D:(  )&\  "0Y0  C_P  ([_
M  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V   J>P  ((   !>%   0B0
M"XT   21    E0   )@   "9    F@,  )L(  "<#0  GA$  )\6  "@'@
MHB@  *(U  "C1   HU4  *-I  "B@   HIH  *&S  "@V   H/8  )__  "?
M_P!N<0  7W(  %%U  !$>0  -WX  "R$   AB@  %X\  !"4   *F0   9T
M  "@    I    *<   "H    J0   *H   "L!@  K0L  *\0  "P%0  LAX
M +0I  "T.0  M$H  +5=  "U<P  M8X  +6H  "TQ@  L^T  ++_  "R_P!F
M>@  5WT  $F"   \AP  +XX  ".4   8F@  $)\   FD    J0   *T   "P
M    M    +<   "X    N0   +L   "\    O@(  , (  #"#@  Q!0  ,<>
M  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*N   RMT  ,KU  #*_P!>A@
M3XL  $&1   SF   )Y\  !NE   1JP  ";    "U    N0   +T   #!
MQ@   ,@   #)    RP   ,P   #.    T    -(   #4!0  V0P  -T2  #A
M'@  XBX  .-"  #D5P  Y6\  .:,  #FJ   Y<4  .7G  #F]@!6E   2)L
M #JB   LJ0  '[   !.V   +O    ,$   #%    R0   ,T   #2    U@
M -H   #;    W@   .    #B    Y    .<   #I    [0   / *  #T$0
M^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\  /W'  #]Y #_  X _P - /\
M# #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N
M /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D G #W *4 ]0"O /0 O #S ,\
M\0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_ ,H _P#_  H _P & /\ ! #_
M  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $< _@!1 /L 60#Y &$ ]@!H /0
M;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H )\ Y@"I ., M0#B ,8 X #C
M -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X _P#_  , _P   /\   #_  $
M_P - /\ % #] "  ^@ K /< -@#S $$ [P!+ .P 5 #H %L Y@!B ., : #A
M &X WP!T -P >@#: ($ V "( -0 D #2 )@ SP"B ,T K@#+ +P R0#3 ,<
M\ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_    _P   /\   #_    ]P (
M /  $ #K !H YP E .0 , #A #L W !% -4 30#1 %4 S@!; ,L 8@#) &<
MQP!M ,4 <P## 'H P0"! +\ B0"] )( NP"< +D IP"W +4 M0#( +, Y@"R
M /L L0#_ +  _P"N /\ J@#_ *< _P#_    _P   /X   #Q    Y0 " -P
M#0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\ $X N@!5 +< 6P"U &$ LP!G
M +( ;0"P ', K@!Z *P @@"J (L J "5 *< H "E *T HP"^ *$ VP"@ /0
MGP#_ )X _P"? /\ G0#_ )L _P#_    _    .X   #@    T    ,4 " "^
M !  N0 9 +4 (P"S "X L  W *T 0 "J $@ J !/ *4 50"C %L H@!@ *
M9@"? &P G0!S )L >P": (0 F ". )8 F@"5 *< DP"W )$ S "0 .P CP#_
M (X _P". /\ C@#_ (\ _P#\    [P   -L   #)    O0   +4  @"N  P
MJ0 3 *4 '0"B "< H  Q )T .@": $( F !) )8 3P"4 %4 DP!; )$ 8 "0
M &< C@!M (T =0"+ 'X B0") (@ E0"& *( A0"Q (, Q "! .0 @ #Y '\
M_P"  /\ @ #_ (  _P#T @  X D  ,<(  "W!P  K ,  *8   "@  < FP /
M )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D 20"' %  A@!5 (0 6P"# &$
M@0!H (  < !^ 'D ? "$ 'L D !Y )T > "L '8 O@!U -T <P#T ', _P!S
M /\ <P#_ ', _P#I#0  SQ   +D0  "I$   G@X  )<+  "3!@  D  + (P
M$0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\ $L >@!1 'D 5P!W %T =@!D
M '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#NP!I!-8 : ;Q &@'_P!G!_\
M9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4  (L2  "&$   A P" (,&#0"
M Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48 < I, &\*4P!M"UD ; MA &H+
M:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_
M %T._P#4'   N1T  *0>  "5'0  B1P  ($:  ![%P  >!,  '@0!@!W#0\
M<PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%) &813P!D$58 8Q)= &$29@!@
M$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4 517S %05_P!4%?\ 5!7_ %04
M_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S'@  ;QL  &X7  !M$PP :A04
M &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T82P!<&5( 6AE: %D98@!7&FP
M5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ $P<_P!,'/\ 31S_ $T;_P##
M)@  JB<  )8G  "'*   >R<  '(F  !L)   :"$  &8>  !D&P@ 8AL1 %\<
M&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T
M $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@
MI"L  )$K  ""+   =BL  &TJ  !F*0  8B8  %\D  !=(@0 6R$. %@B%@!6
M(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP 3"94 $LG7 !))V8 2"=Q $8G
M?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _*/\ 0"?_ $ G_P"W+0  GRX
M (PO  !]+P  <2\  &@N  !A+0  72L  %HH  !7)P  5"<, %(H$P!0*1P
M3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _
M+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\ .BS_ #HL_P"R,   FS$  (@R
M  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1+   3RT) $PM$0!*+AD 22\B
M $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL
M.#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_ #4P_P"M,P  EC0  (0U  !U
M-0  :34  & U  !9-   5#,  % P  !,,0  23$& $<R#P!%,Q8 0S,? $(T
M)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y-E\ -S9K #8V>  T-XD ,C>:
M #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T_P"I-@  DC8  ( W  !R.
M9C@  %TW  !6-P  4#8  $LT  !'-0  1#8# $$W#0 _.!0 /C@< #PY)  [
M.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT ,CMH # [=@ O.X< +3N9 "P[
MK  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D.   CCD  'PZ  !N.@  8SH
M %HZ  !3.@  33H  $8X  !".@  /SL  #P\"P Z/!$ .#T9 #<](0 V/BD
M-#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F "M =  I0(0 *$"7 "9 J@ E
M0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P  BCP  '@]  !J/0  7ST  %8]
M  !//0  23T  $(]   \/@  .3\  #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M
M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%<0 C18( (D65 "!%J  ?1;\
M'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\  '1   !G0   7$   %-   !,
M0   1D   #Y!   X0P  -$4  #!& P M1PT *T@2 "I(&@ I2"( *$DI "=)
M,0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@
M !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#  !C0P  6$,  %!#  !)0P
M0D0  #M%   U1P  ,$D  "M+   F30D )$X0 ").%@ A3QT ($\E !]/+  >
M3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P %%"/ !-0I  14+H $5#> !%/
M^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?1P  54<  $U'  !&1P  /T<
M #=*   Q3   *TX  "90   @4P, '%4, !I6$0 95A@ %U8@ !96)P 55C
M%%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,  U7H  +5[8 "U;4  M6]  ,
M5?\ #53_  Y3_P"(20  =DH  &=*  !;2@  44H  $I*  !#2@  .TP  #-.
M   L40  )E0  "%6   ;60  %5P' !%>#0 07A, $%X:  Y>(@ .7BH #5XS
M  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->FP "7K$  EW,  )=[@ #7/\
M!%O_  5;_P"!3@  <$X  &).  !73@  3DX  $=.   ^3P  -E$  "Y4   G
M5P  (5H  !M=   58   $&,#  QF"P (9Q  !F<5  5G'  $9R0  F<M  %G
M-P  9T(  &=.  !G7   9VT  &>   !FE0  9JP  &7'  !EZP  9/P  &3_
M  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3   Y50  ,%@  "A;   A7P
M&F(  !1E   0:   #&L!  9N"0  ;PX  &\2  !O&   <!\  ' G  !Q,
M<3L  '%(  !Q5@  <68  '%Y  !QCP  <*<  &_!  !OYP  ;OP  &W_  !M
M_P!S6   95<  %I7  !15@  1E<  #Q:   R70  *F$  ")D   ::   %&P
M  YO   *<@  !'8   !X!0  > L  'D.  !Z$P  >QD  'P@  !]*0  ?3,
M 'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ  ![X@  >OH  'G_  !X_P!M
M70  8%P  %=<  !+70  0%\  #5C   K9P  (VL  !IO   3<P  #G<   A[
M   "?@   ((   "# 0  A 8  (4+  "&#P  B!,  (D9  "*(0  BRL  (LW
M  ",1@  BU8  (MI  "+@   BYD  (JS  ")V   B/<  (C_  "'_P!H8P
M7F(  %%B  !$90  .&D  "YN   D<P  &G@  !-]   -@0  !H4   ")
MC0   )    "2    D@   )0%  "5"@  EPX  )@2  ":&   FR$  )PM  "=
M/   G4P  )Q?  "<=@  FY$  )NK  ":R0  FO   )G_  "8_P!E:0  5VD
M $EL   ]<0  ,'8  "5\   ;@0  $H<   R,   $D0   )4   "9    G0
M *    "A    H@   *0   "E 0  IP<  *D,  "J$0  K1@  *\B  "O,
MKT$  *]4  "O:P  KH4  *ZA  "NO@  K>8  *S\  "L_P!><0  3W0  $)Y
M   U?P  *(4  !V,   3D@  #)@   .=    H@   *8   "J    K@   +
M  "Q    LP   +0   "V    N    +H$  "\"@  OA   ,$7  ##)   PS4
M ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R  ##_P!6?   1X(  #J(   L
MCP  ()8  !2=   -HP   ZD   "N    L@   +<   "[    OP   ,(   #"
M    Q0   ,8   #(    R@   ,T   #/    T@@  -4.  #;&   W2<  -XZ
M  #?4   X&@  ."$  #AH0  X;T  .'B  #@] !.BP  0)(  #*9   EH0
M&*@   ZO   %M0   +H   "_    Q    ,@   #.    T0   -0   #5
MV    -H   #=    WP   .(   #D    YP   .L%  #O#@  ]!D  /4K  #V
M00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_  L _P ( /\ "0#_  P _P 2
M /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4
M_@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J /( MP#O ,D [0#F .P ^P#K
M /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0 _P   /\   #_  4 _P - /\
M%0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W %P ] !C /( :0#P &\ [@!U
M .P >P#J (( Z ") .< D0#D )H X@"D .  L #= ,  V@#< -@ ] #5 /\
MTP#_ ,L _P#! /\ NP#_ +< _P#_    _P   /\   #_    _P * /T $0#Y
M !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8 X0!< -X 8P#< &@ V0!N -4
M= #2 'L T "" ,T B@#+ ), R "= ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_
M +T _P"T /\ K@#_ *L _P#_    _P   /\   #Z    \@ % .H #@#E !8
MX  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6 ,0 7 #" &$ P !G +X ;0"\
M ', N@!Z +@ @@"V (L M "6 +( H0"P *\ K@#! *T X "K /< J@#_ *D
M_P"F /\ H0#_ )\ _P#_    _P   /<   #H    W    -  "@#* !$ Q0 ;
M ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +  50"N %L K !A *H 9@"H &P
MIP!S *4 >P"C (0 H0". )\ F@"= *< FP"X )H T "9 .\ F #_ )< _P"6
M /\ E #_ )( _P#_    ]@   .0   #2    Q0   +L !0"U  X L  5 *P
M'P"J "D J  R *4 .@"B $( H !) )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L
M ), = "2 'T D "' (X DP", *$ BP"P (H Q0"( .8 AP#[ (8 _P"' /\
MAP#_ (8 _P#X    Y0   ,T   "]    LP   *H   "C  H GP 1 )L &0"9
M ", EP L )4 - "2 #P D !# (X 20", $\ B@!4 (D 6@"' &  A@!F (0
M;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z -L > #U '@ _P!X /\ > #_
M '@ _P#M    T0(  +L"  "L 0  H@   )L   "6  4 D0 - (T % "+ !T
MB  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/ 'P 50!Z %L >0!A '< :0!U
M '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X ; #N &L _P!K /\ :P#_ &L
M_P#?"P  P@P  *X,  ">#   DPL  (P'  "( @  A0 ) ($ $ !_ !< ?  @
M 'H * !X #  =@ X '0 /@!S $0 <0!* '  4 !N %8 ;0!= &P 9 !J &T
M: !W &< A !E )( 9 "A &, L@!A ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0
M$   MA$  *(2  "3$@  B!$  ( /  !\#0  >0D! '@#"P!U !$ <P : '
M(P!N 2L ; $S &H".0!I T  9P-& &8$3 !E!%( 8P59 &(%80!@!6H 7P9T
M %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*^P!5"O\ 50K_ %8*_P#&%0
MK1<  )D8  "*&   ?Q<  '86  !Q$P  ;A   &T-!0!M"0T :@D4 &<*'0!E
M"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.
M@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-$/\ 31#_ $T0_P"\&P  I1P
M )(=  "#'@  =QT  &\<  !I&@  9A<  &04  !D$ @ 8@\0 %\0& !=$"$
M6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+
M%(P 212< $<5K@!&%<4 117H $46_@!%%O\ 117_ $45_P"U'P  GB$  (LB
M  !\(@  <2(  &@A  !B'P  7QT  %P:  !;%P( 6A4- %<6% !5%AT 5!<E
M %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD
M0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_ #X;_P"O(P  F"0  (8E  !W
M)@  ;"8  &,E  !=)   62(  %8?  !4'0  4QP+ %$<$@!.'1H 31TB $L>
M*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"(%\ 0"%J #\A=P ](8< .R&8
M #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A_P"J)@  E"<  ($I  !S*0
M9RD  %\I  !8*   5"8  %$C  !/(@  3"(' $HB$ !((A< 1R,? $4D)@!$
M)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP .B9G #DF=0 W)X0 -2>6 #0G
MJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E*0  CRH  'TL  !O+   9"T
M %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G#0!"*!0 02@< #\I(P ^*2L
M/2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L
M++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+   BRT  'DN  !K+P  8"\  %@O
M  !1+@  3"X  $@L  !%*P  02L  #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO
M #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP<  L,(  *C"2 "DPI0 G,+H
M)C#< "8P]P G+_\ *"__ "@N_P"<+@  AS   '8Q  !H,@  73(  %4R  !.
M,0  2#$  $0P  ! +P  /#   #HQ"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S
M,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G-7X )360 ",UHP B-;D (379
M "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T  !E-   6C4  %$U  !+-
M130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3 "\W&P N-R( +3@I "LX,0 J
M.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP (#J. !XZH@ <.K< &SG5 !PY
M]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A-P  5S<  $XW  !(-P  0C<
M #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\&  H/1\ )CTF "4]+@ D/34
M(SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^, !@_H  6/[4 %3[2 !8^\P 7
M/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@  4SH  $LZ  !%.@  /SH  #DZ
M   R/   +CX  "E    F00@ )$(. ")"%  A0AL ($,C !]#*@ >0S( '$,Z
M !M$0P :1$T &$19 !=$9P 51'< $T2* !)$G@ 11+, $$30 !!#\@ 10O\
M$D+_ !-!_P").P  =CP  &8]  !:/0  4#T  $@]  !"/0  /#T  #8^   O
M0   *D(  "5$   A1@, '4@, !M)$0 921< &$D> !=))@ 622X %4HV !1*
M0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,2K  "DK*  M)[  ,2/\ #4?_
M  U'_P"#/@  <3\  &)   !60   34   $5    _0   .4$  #)"   K10
M)D<  "%)   <2P  %DX' !-0#@ 24!, $5 9 !!0(0 /4"D #E Q  U0.P -
M448 "U%1  I17P )46\ !U"!  50E@ #4*L  E#%  -/Z  #3_L !4[_  9-
M_P!]0@  :T,  %U$  !21   2D0  $-#   \1   -44  "Y'   G2@  (4P
M !Q/   740  $E0#  Y7"@ +6!  "E@5  A8'  '6"0 !E@L  58-@ #6$
M 5A,  !86@  6&D  %A\  !8D0  5Z<  %?   !6Y0  5OD  %7_  !5_P!V
M1P  9D<  %E(  !/1P  1T<  $!'   X2   ,$H  "E-   B4   '%,  !95
M   16   #5L"  E>"0 $7PX  %\2  !?&   8!\  & G  !@,   8#L  &!'
M  !@5   8&,  &!V  !@BP  7Z(  %^[  !?X@  7OD  %W_  !=_P!O2P
M84P  %5,  !,2P  1$L  #M,   R3@  *U$  "-4   <5P  %EL  !%>   -
M8   "&,   )F!P  9PP  &</  !H$P  :1D  &HA  !J*0  :C0  &I   !J
M30  :ET  &IO  !JA0  :IT  &FV  !HW0  :/<  &?_  !F_P!I40  7%
M %)0  !*3P  /U   #53   M5@  )%D  !U=   68   $&0   QG   &:@
M &X   !O P  < @  '$-  !R$   =!0  '4;  !V(P  =RP  '<X  !V1@
M=E8  '9H  !V?@  =I<  '6Q  !TTP  <_4  '/_  !R_P!C5@  6%4  %!4
M  !$50  .5@  "];   F7P  '6,  !5G   0;   "G    1S    =@   'H
M  !\    ? ,  'X(  !_#   @1   ((4  "$&P  A20  (8O  "&/0  ADT
M (5?  "%=0  A8\  (2I  "#R0  @O$  ('_  " _P!?6P  5EH  $E;   ]
M7@  ,F$  "=F   >:P  %7    YU   )>0   7X   "!    A0   (@   "*
M    BP   (T!  ".!@  D L  )$/  "3%   E1L  )<F  "7-   ET0  )=6
M  "6;   E88  )6B  "4P0  D^H  )+_  "2_P!=80  3V$  $)D   V:0
M*FX  !]T   5>0  #G\   >$    B0   (X   "2    E@   )@   ":
MFP   )T   "?    H0,  *,(  "E#0  IQ,  *D<  "J*   JCD  *I+  "J
M80  J7H  *B9  "HM0  I]T  *?X  "F_P!6:   2&P  #IP   N=@  (GT
M !>$   .B@  !Y    "6    F@   )\   "C    IP   *H   "K    K0
M *\   "Q    LP   +4   "X!0  N@P  +T2  # '   P"T  ,!   "_50
MOVX  +Z+  "^J   OLD  +WO  "\_@!.=   0'D  #)_   EAP  &8X  !"5
M   'G    *(   "G    K    +    "U    N0   +P   "]    OP   ,$
M  ##    Q@   ,@   #*    S0(  - +  #5$@  UB$  -<T  #820  V6
M -I\  #:F@  V[4  -O9  #;\@!&@@  .(D  "N0   =F   $J    JG
MK@   +0   "Y    O@   ,(   #(    RP   ,X   #/    T@   -0   #6
M    V@   -T   #?    X@   .8   #J"@  [Q,  / E  #R.@  \U$  /1K
M  #TB0  ]:4  /6_  #UW0#_  8 _P # /\ !0#_  L _P 0 /\ %P#_ "(
M_P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D /\ :@#_ '  _0!V /L ? #Y
M (, ]P"* /4 D@#S )L \ "F .X LP#K ,0 Z0#D .< ^0#F /\ Y0#_ -,
M_P#' /\ OP#_ +L _P#_    _P   /\   #_  ( _P + /\ $@#_ !T _P H
M /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X 8P#L &D Z@!O .@ =0#F 'P
MY "# .( BP#? )4 W "? -D JP#5 +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z
M /\ M #_ +  _P#_    _P   /\   #_    _P & /D #P#U !< \P B /$
M+0#M #< YP!  .( 20#? %  VP!7 -< 70#4 &, T0!H ,\ ;@#, '4 R@!\
M ,@ A #% (T P@"8 ,  I "] +( NP#& +D Z "X /T MP#_ +8 _P"M /\
MIP#_ *, _P#_    _P   /\   #U    ZP ! .0 # #> !, V0 < -, )@#1
M #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P N0!A +< 9P"U &T LP!T +$
M? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C /4 HP#_ *( _P"> /\ F@#_
M )< _P#_    _@   .\   #?    T    ,< !P#!  \ O  7 +D ( "W "H
MM0 S +  .P"M $, JP!) *@ 3P"F %4 I !: *, 8 "A &8 GP!M )T = "<
M 'T F@"( )@ E "6 *( E "R )( R0"1 .L D0#_ )  _P"0 /\ C #_ (H
M_P#\    [    -D   #'    N@   +$  @"K  P IP 2 *0 &P"A "0 H  L
M )X -0"; #P F !# )8 20"4 $\ D@!4 )  6@"/ %\ C0!F (L ;0") '8
MB "  (8 C "$ )H @@"J ($ O@"  .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q
M    V    ,(   "S    J    *    "9  < E0 . )( %0"0 !X C@ F (T
M+@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z
M '< A@!U )0 = "C '( M0!R ,\ <0#Q '  _P!P /\ < #_ '$ _P#A
MQ    +    "B    EP   )$   "+  ( A@ + (, $0"! !@ ?P A 'T *0!\
M #  >0 W '@ /0!V $, = !) ', 3@!R %0 < !: &\ 8@!M &H :P!T &H
M@ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C /\ 8P#_ &0 _P#/!0  M@<
M *,(  "4"   B0<  ((#  !^    >P & '< #@!U !, <@ ; '$ (P!O "L
M;0 R &P . !J #X :0!$ &< 20!F $\ 90!6 &, 70!B &4 8 !O %\ >P!=
M (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\ 6 #_ %D _P#"#   J@T  )<.
M  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K !  :0 6 &< '@!E "8 8P M
M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H 60!8 &( 5P!L %4 > !3 (8
M4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_ $X#_P"X$   H1(  (X3  !_
M$P  =!,  &P2  !G$   90X  &,+ P!C!@P 8001 %X#&0!<!"$ 6P4H %D&
M+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4
M $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,_P"P%   F18  (<8  !X&0
M;1@  &47  !?%@  7!,  %H1  !:#@8 6@P- %<,% !5#!P 4PTD %(-*P!0
M#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0
MI@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I&0  DAL  ($<  !R'0  9QT
M %\<  !9&P  51D  %,6  !2$P  4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX
M2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E #X5<@ \%8$ .A62 #@5I  W
M%;D -178 #46]0 V%O\ -A;_ #<5_P"C'   C1X  'L@  !M(0  8B$  %HA
M  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'%Q4 11<< $08) !"&"H 01@Q
M $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;;P U&WX ,QN0 #(;H@ P&[<
M+QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(  '<C  !I)   7B0  %8D  !0
M(P  2R(  $@@  !&'0  11P" $,<# !!'!( /QT9 #X=(0 \'B< .QXN #H?
M-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O('P +2&. "PAH  J(;4 *2'0
M "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F  !E)P  6R<  %,G  !,)@
M1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S
M)#D ,B1! # D2@ O)5, +25> "LE:P J)7H *"6, "8EGP D);, (R7. ",E
M\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B*@  5RH  $\J  !)*0  1"@
M $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G&P Q*"( ,"@I "\H,  M*3<
M+"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?
M*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+   5"P  $PL  !&+   02L  #PK
M   X*@  -2H  #(K P P*PP +BP1 "TL&  L+!\ *BTF "DM+0 H+30 )RX\
M "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !POFP :+[  &"_* !@N[0 9+O\
M&RW_ !LM_P",*P  >"T  &@N  !;+P  42\  $DO  !#+P  /BX  #DN   T
M+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P )3(C "0R*@ C,C$ (3,Y " S
M0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_
M !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R  ! ,0  .S$  #8Q   Q,0
M*S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@ !XW)P =."X &S@V !HX/P 9
M.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T #CC'  XXZP 0./\ $#?_ !$V
M_P"#,0  <#(  &$T  !5-   2S0  $0T   ]-   .#0  #,T   M-0  *#<
M "0Y   @.@( '3L+ !L\$  9/14 &#T< !<](P 6/2L %3XS !0^/  2/D8
M$3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!  H]Y  +/?L ##S_  T[_P!]
M-   :S8  %TW  !1-P  2#<  $$W   [-P  -3<  # W   J.0  )3L  " ]
M   </P  %T$& !1##0 20Q( $4,8 !%#'P 01"< #T0O  Y$.0 -1$, #$1.
M  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#X  #0_8 !$+_  9!_P!X.
M9SD  %DZ  !..@  13H  #XZ   X.@  ,SH  "T[   G/0  (4   !Q"   7
M1   $T8#  ])"@ -2@\ #$H4  M*&P )2B, "$HK  =*-  %2CX !$I)  )*
M5@  2F4  $IW  !*BP  2J$  $FY  !)W0  2?4  $C_  !(_P!R/   8CT
M %4^  !*/@  0CT  #P]   V/0  +SX  "E    C0@  '44  !='   32@
M#TP"  M/"0 '4 T  U$1  !1%P  41X  %$F  !1+P  43D  %%$  !240
M4F   %%R  !1AP  49T  %&U  !0V   4/4  $__  !/_P!L0   74$  %%!
M  !'00  0$   #E    R00  *D,  "1&   >2   %TL  !).   .40  "U,!
M  96!P  5PP  %@0  !8$P  61D  %HA  !:*0  6C,  %H_  !:3   6EH
M %IL  !:@0  69D  %FQ  !8T0  6/0  %?_  !7_P!E10  6$4  $U%  !%
M1   /D0  #5%   M1P  )4H  !Y-   84   $E,   Y6   *60  !%P   !>
M!   7PD  & -  !A$   8A4  &,;  !D(P  9"T  &0X  !D10  9%0  &1F
M  !D>P  8Y,  &.M  !BS   8?(  &'_  !@_P!?2@  4TH  $I)  !#2
M.4D  "],   G3P  'U(  !A5   260  #5T   A@   "8P   &8   !H 0
M:04  &H*  !K#0  ;1$  &X6  !P'0  <28  '$Q  !P/@  <$X  '!?  !P
M<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:3P  4$X  $A-   ]3@  ,U$
M "E4   @6   &%P  !%@   ,9   !F@   !K    ;P   '(   !T    =0
M '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H  " -0  @$4  ']6  !_:P
M?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65   3E,  $)4   W5@  +%H  ")?
M   88P  $6@   MM   #<@   '8   !Z    ?0   (    "#    A    (8
M  "' @  B0<  (L,  "-$   D!8  )(?  "2+   DCL  ))-  "18@  D7H
M (^7  "/M   CN$  (S[  ",_P!560  2%H  #M=   O80  )&8  !EL   1
M<@  "G<   )]    @@   (8   "+    C@   )$   "3    E0   )<   "9
M    FP   )T$  "?"@  H@\  *06  "F(0  IC$  *9#  "E5P  I'   *..
M  "CJP  H=   *#U  "?_P!.80  0&0  #-I   G;@  &W4  !%\   +@P
M (D   ".    DP   )@   "=    H0   *0   "E    IP   *D   "K
MK0   +    "R    M0@  +@.  "\%@  O"4  +PW  "[3   NF0  +F!  "W
MH@  M\   +?J  "W_ !&:P  .7   "MW   ??P  $X8   N.   !E0   )L
M  "A    I@   *L   "P    LP   +<   "W    N@   +P   "_    P0
M ,0   #'    R@   ,T%  #1#@  U!D  -0K  #40   TU@  --T  #3D@
MTK   -+3  #2\@ ^>0  ,8   ".(   7D0  #9D   .@    IP   *X   "S
M    N    +T   #"    Q@   ,H   #*    S0   ,\   #2    U0   -D
M  #=    WP   .,   #G!0  ZP\  .P?  #M,P  [DL  .]D  #O@@  \)\
M /&Y  #QV #_    _P   /\ ! #_  D _P . /\ %0#_ !X _P I /\ - #_
M #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L ^P!Q /D =P#X 'X ]@"% /,
MC0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B /\ VP#_ ,L _P#! /\ N0#_
M +0 _P#_    _P   /\   #_    _P ) /\ $ #_ !D _P C /\ +@#] #D
M^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J .0 < #B '8 WP!] -T A@#9
M (\ U0": -$ IP#. +8 RP#. ,D \ #' /\ Q0#_ +L _P"T /\ K0#_ *D
M_P#_    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [
M -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (<
MO "2 +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M    _P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$
M/0"] $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"*
M *, E@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_
M]@   .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F
M #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )
MC@". )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP
M ,P   "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #<
MD0 ] (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\
M )0 >@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<
M  "H    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W
M 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T
M; "= &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
M    C0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\
M-P!N #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6
M %T J != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!
M?P(  '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B
M #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %(
MHP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL
M &P*  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #,
M5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!(
M +( 1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/
M  !>#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U
M $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\
M/@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6
M$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8)
M. !$"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S'
M #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P
M314  $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^
M#SP /0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1
M[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH
M $08  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD
M-A1  #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G
M%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <
M   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D]
M "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX
M(AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y
M'@  .!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?
M0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__
M !X>_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@
M,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B
M)$H (215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC
M_P"%(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0
M "LE   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@
M&RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P"
M)0  ;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I
M   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0
M !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*
M:BH  %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?
M+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S
M6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT
M %@N  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P
M%S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P )
M.&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q
M  !),0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH"
M ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$
M #YR   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&
M-   /C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!
M"  )0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M
M  !$@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.
M.S<  #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #
M20P  $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+
M?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H
M #,Y   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H
M % -  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P
M5(\  %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^
M   G0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+
M  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D
M %VC  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A
M2   &DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E
M"@  9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=
M  !HNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40
M$U4   Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0
M<PD  '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !W
MLP  =>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$
M  9F    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(
M (8'  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@
MB,\  (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M    >P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@
M  ":!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$
M )ON  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'
MC0   )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
M    L0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B
M  "P_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H
M *4   "J    K@   +$   "R    M0   +<   "Z    O    +\   ##
MQ@   ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+
M[P W<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D
M  "^    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@
M .$   #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M    _P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\
M2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "=
M .D J@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_
M_P   /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O
M $T [ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P
MH@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P
M /T   #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8
MS0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q
M *D K@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(
M  #G    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !%
M +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *
MF "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
M    O    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H
M1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H
M (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q
MI@   )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"%
M $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$
MLP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP
M (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T
M<@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A
M ,( 8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P
M  !W    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ]
M &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D
M5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M    9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %<
M/0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#.
M $D \P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!
M6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !,
M #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\
MZ@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D
M % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H
M0@!! $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V
M /D -@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-
M  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^
M #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4
M+0?_ "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  !
M#@  0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+
M0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_
M "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@
M.1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L
M$$L *A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0
M_P"&%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0
M #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@
M)!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""
M%P  ;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6
M   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1
M !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@
M:QT  %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G
M&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>
M6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\
M %DA  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( (
M(" * !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1
M(V< $"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C
M  !+)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4'
M !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0
M#"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !(
M)P  /R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K
M"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP
M  0M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0
M/"D  #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .
M,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R
M?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P
M #(K   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP
M!S<0  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?
M-Y(  #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N
M   K+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.
M   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\
M #VG   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I
M+P  )#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#
M$   1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D
M  !$P   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-
M(#4  !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@
M3!$  $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,
MO   2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP
M !4_   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X
M %<1  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP
M5>,  %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(
M   +2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.
M  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T
M &#\  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #
M5@   %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R
M#@  =1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W
M  !N_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P
M &@   !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"
MA@T  (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !_
M_P!&2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@
M  !\    @0   (0   "'    B    (L   ".    D    ),   "6    F0<
M )T-  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _
M4@  ,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
M    E    )<   "9    G    )\   "A    I    *<   "J    K0   +$&
M  "U#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7
M*V$  !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D
MJ    *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+
M!0  T0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W
M !9Y   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0
M ,    #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D
MZ 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\
M  #_  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5
M /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D
MWP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M    _  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8
M5 #B %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #%
M +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q
M\@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#"
M %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8
MW "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP
M ,@   #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P
MI@!1 *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP".
M /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H
M  "F  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!*
M (X 3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$
M>0#_ '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".
M  $ BP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D
M2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V
M &< _P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![
M>  % '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H
M $@ 9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D
M_P!9 /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 !
M &8 "0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $(
M6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!-
M /\ 30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H
M!0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!#
M $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\
M0P#_ $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.
M  D 30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $(
M10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_
M #D _P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8
M1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X
M $D -P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #
M_P","0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00(
M #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8
M+P!0 "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&
M#   <@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8(
M"@ U!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=.
M "<'60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@
M;1$  %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P
M"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-
M6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,
M %H5  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@
M*0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9
M$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7
M  !+&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+
M "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0
M$A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(
M&P  /QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6
M#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER
M  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0
M/!T  #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6
M'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>
M@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\
M #(?   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X
M$"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !
M(I$  "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A
M   J(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80
M  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\
M ":F   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H
M(P  )"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K
M$P $*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND
M   KO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0
M(R0  !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0
M,14  #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   P
MO   ,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28
M !PG   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(
M #@8   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@
M-N0  #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK
M   4+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4
M  ! &P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,
M #S\   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1
M,P  #38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*
M%@  2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\
M  !$_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P
M"#X   -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@
M51D  %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !.
M_P!%-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@
M  !*    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,
M &(;  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!
M/   .CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M    60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5
M  !R(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0
M.3X  "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E
M:    &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'
M%P  AB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4
M "A(   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@
M 'X   "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$
MGAH  )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3
M   560  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(
M  "5    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!
M +<>  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .
M:0  !7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
M    K    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4
M  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P
M (0   "-    E0   )T   "C    J0   *\   "T    N0   +P   "^
MP@   ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M
M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  (
M /X #@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P
M]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#*
M /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8
M"0#Z  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!;
M -8 8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\
MIP#_ )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@
M  L VP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@
M60"V %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_
M (L _P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8
MMP . +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40";
M %< F0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P
M_P!V /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 *
M )@ $ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %
M@P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I
M /\ 9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (
M#0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/
M &T 5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\
M6P#_ %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L
M  X :P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T
M3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_
M $\ _P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L
M6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!.
M %$ 30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4
M_P"?    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P -
M $X $0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P
M0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M    ?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $,
M#@!# !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0
M #< 6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")
M=@,  &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z
M !  .0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X
M5P M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@
M %\*  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X
M,0 1 #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F
M &  ) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-
M  !.#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/
M "H!$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T
M'@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*
M$   0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'
M$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK
M !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@
M/1(  #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?
M"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -
M?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0
M #(4   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A
M&0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +
M$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6
M   J%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2
M !(2&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T
M!!2C  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H
M&   (Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7
M%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A
M   7N0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@
M(1D  !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *
M&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;
MN0  &]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL
M !P:   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8
M R <  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N
M']X  ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<
M   8&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49
M   F(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\
M "/Y   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6
M'@  $QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L
M'0  +"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[
M   H_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0
M$",   XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0
M,R$  #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N
M_P!,)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@
M  LJ   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT
M #LF   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'
M*0  .RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q
M   !-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A
M  !%+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0
M."X  "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z
M/    #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0
M)P  3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$
M "XO   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P
M $D   !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(
M7BP  %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR
M   D,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8
M  !9    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4
M &TT  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >
M.P  %3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M    :P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L
M  " /@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@
M#TL   =1    5P   %P   !B    9@   &L   !O    =    '@   ![
M?@   (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":
M,P  ETD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H
M  !A    :    &X   !T    >0   '\   "$    B0   (T   "1    DP
M )8   "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*
MLCX  +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M    >P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T
M  "P    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(
M ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'
MD    )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
M    RP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_
M  #J6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$
M_P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q
M &H [@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X
M_P"6 /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2
M /< &P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &(
MR@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"(
M /\ @P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$
M%0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A
M *P :0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\
M=@#_ '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M
M !@ K0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$
M80"/ &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_
M &@ _P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !(
MCP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X
M &( =@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P
M_P"^    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4
M '< &@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H
M8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
M    GP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &,
M%0!C !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!<
M %( : !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B
MC0   'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4
M !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0
M80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P
M &\   !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$
M1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X
M &D -P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4
M  !8    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2
M #H %P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &,
M+0!S "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1
M @  2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$
M$P P !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N
M "0 @@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P
M0@@  #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H
M !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T
M?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L
M #4+   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !(
M(  6 !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5
M (\ %0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-
M   L#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04
M !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH
M$ &B  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H
M#P  ) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)
M%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?
M  H'MP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$
M(1   !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0
M#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,
MM  ##-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$
M !L1   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q<
M#! =  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M
M#M0   [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2
M   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:
M  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<
M !'U   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4
M$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6
M'P "%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W
M   3_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% ,
M$A,& ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'
M&R0  !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7
M_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$
M  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$
M "$J   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-
M&0  /QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9
M 0 +&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G
M   G,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0
M/!X  #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   (
M'P  !"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N
M+@  +CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$
M "XA   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0
M "<    I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0
M-C8  #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD
M   D(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\
M   R    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$
M $!    _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C
M)0  'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M    /@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ
M  !*3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P
M&R@  !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&
M2    $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !8
M1@  5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\
M ! R   *-@   SH    _    0@   $8   !)    3    $\   !2    50
M %@   !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0
M9U(  &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]
M   "0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@
M  !K    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D
M 'MA  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+
M40   %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M    @@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9
M  "1<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80
M &@   !N    <P   'D   !^    @P   (@   ",    CP   )(   "5
MF0   )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J
M:0  J(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P
M  "#    B0   (\   "5    FP   *    "C    I@   *D   "M    L0
M +4   "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7
MQ7P  ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
M    GP   *4   "M    LP   +@   "Z    O@   ,(   #&    R@   ,X
M  #3    V@   .    #G    [0   /,   #T#@  \AX  .\V  #L40  Z&X
M .20  #?L0                       0,$!08("0H+#0X/$1(3%!87&!H;
M'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-4
M55=865M<75Y@86)C969G:6IK;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.
MCY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'
MR,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__
M____________________________________________________
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M,0     #!"$   $                    !                     0
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MPG>P?,)WL'S"=[!\PG>P?,)WL'S"_ZDD!?^H, W_LSD4_L!"'O/-2BWIW4]
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M-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V] 8?]T05__>4->_WU$7?^
M15S_A$5;_X=&6O^*1UC_CT=8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(
M6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(Q,<' +?;!P&I_Q8&G_\J#9#_,!6#
M_S8<=_\^(F[_1RAF_U L8?]:+UW_9#%;_VPS6?]Q-5C_=396_WDV5O]\-U7_
M?S=4_X(X4_^%.5+_B3E2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*
M.5+_BCE2_XHY4O^*.5+_BCE2_XHY_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM
M_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/
M<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9
M//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFE
MS7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E
M9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&N
MJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_
MH6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QO
MM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;
M]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*
M;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX
M:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZM
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5
M@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
M_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?G
MCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y,=
M!/^0*0G_CS00_YH[%_^B1"#_J4TM_ZI8//^H8DS_I&Q<]9]V;.R9?WKDD8>&
MWHF-D-B#DYC3?IF?T'J=I,UVHJG+=*>LR7&MK\=OM++!;+FTO&R[L;QLN[&\
M;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQ_Y0=!/^1
M* G_D3,0_YPZ%O^D0R#_K$PM_ZU6/?^M8$W^J6I>]*5T;NJ??7WAEH.+V8Z*
MEM.'D*#.@96GRGR:K<=XG[+$=:6VPG*KN<!PM+NW;K6YLV^XM;-ON+6S;[BU
MLV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BU_Y0=!/^2* G_
MDS(/_YXZ%O^G0R#_KDLM_[%5/?^P7T[]KFA?\JIR<.>D>H'>FH"/U9*'G,Z+
MC*;)A)&OQ'Z7M<%YG+N^=J._O'2KPK1OKL.N<K.\JW.VN*MSMKBK<[:XJW.V
MN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:X_Y4<!/^2* G_E3(/
M_Z Z%O^I0A__L$HM_[14/?^T7D[]LV=@\:]P<N:I>(/;GWZ3TI>#H<N.B:S$
MAHZUP("4O;Q[FL.Z>J/%MWFKQZQSK,:G=;&_I7>UNJ5WM;JE=[6ZI7>UNJ5W
MM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6Z_Y4<!/^3* G_EC$/_Z$Y
M%?^J0A__LDHL_[93//^W74[[MF5A\+1N=.2M=8;9I'N6SYN I<>2A;'!BHN[
MO8>4P+N%G<2V@J3'L'ZJR*5WJLBA>;#!GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?
M>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\_Y4<!/^3* G_ES$/_Z,Y%?^L
M0A__M$HL_[E3//^Z7$[XNF1B[[AL=>.R<XC8J7F9S9]^J<68A+2_DXR\N(V3
MP;.)F<6NAJ'(JH2IR9]\J<J;?:["F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]
MF7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]_Y8<!/^3* G_F# ._Z0Y%?^M01[_
MM4DL_[M2//V]6T[VO6-B[KUK=N*V<8G5KG>;RZ5\JL*=@[2YEHF\LI&0P:R,
MEL:GB9W(HX>FRIF J,N6@:[$E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&Q
MOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^_Y8<!/^4)PG_F3 ._Z4Y%/^N01[_MTDK
M_[U1//R_6D[TP6)B[,%I=^&[<(O2L72=QZA[JKR@@;2TFH>\K)2-PJ:0E,:@
MC9O)G(NDRY6&J,N1A:W%D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%
ML;^0A;&_D(6QOY"%L;^0A;&__Y8<!/^4)PC_FC ._Z8X%/^P01W_N$DK_[]1
M//K"64[RQ&%CZ<5H=]V^;8S-M'.=PJMYJK>D?K2NG82\IIB*P:"4D<::D9C)
MEH^ARY"+J,R,B:S%C(FPP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",
MB;# C(FPP(R)L,",B;# _Y<<!/^5)PC_FS ._Z<X%/^Q01W_NDDK_\)0._C&
M6$[PR%]CYLAF>-C!:XW)MW&=O:]WJ;*G?+.IH8*[H9R(P9J8C\:4EI;)D)2?
MRXN1J,R'CJS&AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!
MAXVPP8>-L,&'C;#!_Y<; _^5)PC_G2\-_ZDX$_^S0!W_O$@J_,5/._;)5T[M
MS5YCXLMD>-+$:HS$NV^<N+)UJ:VK>[.CIH"[FZ&&P92=C<6.FY3(BIF=RH:9
MJ,N"DZS&@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!@I*O
MP8*2K\&"DJ_!_Y<; _^5)PC_GB\-_ZHX$_^U0!S_OD@I^<A..O/-5DWJTUQB
MWL]B>,W':(N_OFZ;LK=SJ*>P>;*>JWZZE:>$P(ZCB\2(H9+'@Y^:R8"@I\I]
MFJS&?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BOP7V8
MK\%]F*_!_Y@; _^6)PC_H"\-_ZPW$O^W0!O]P4@H]LM..>_35$SFV5IBV-1A
M=\?+9XJYPVR:K;QRIZ&V=[&8L7VXCZV"OHBJB<."J)#&?:>9R'JGI<EWHJS%
M>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%X
MG[#!_Y@; _^7)@C_HB\,_ZXW$O^Y/QKYQ$<G\<Y-..K;4TO@WUE@T-I?=L'0
M98FSR6N9IL)PI9N]=:^1N'NVB+6 O(&RAL![L(W#=JZ6Q7.NH<9RK:W$<JFP
MP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;#
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M0!]B_TDC6_]1)E?_6BA5_V(J4O]I*U'_;RQ0_W,M3_]W+D[_>BY._WTO3?^
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M)@?_D2X,_YTV$O^F/AK_K4<E_[-/-/^T6$3ZM&%6\[)J:.RO<WKAIGJ+UIV
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ME(>PL8^.MJN*E;NFAYV^HH6EP)^$K\&6?K#!E'^VN). N[*3@+NRDX"[LI.
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M95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E_ZT0 -;#" #(TPH
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M'P:L_S(2H/\['93_02>*_T<Q@?]..7K_6#]S_V)%;O]L26G_<TQF_WI/8_^
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M4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"_X\3 O^D$P'^N!( ULP+ ,SD$0'
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MCQXT_Y<>,O^@'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?IL
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ML3Q&_[T]1?_,/43_YCY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YSY$_^<^RZP
M +FV 0"LP@$ H- " )7E!P"._Q@#A/\D!GK_+ MP_S00:/\\%6'_1!E;_TL=
M5O]3(%/_6R)0_V,D3?]K)DO_<R=)_WHI2/^"*D;_BBM$_Y0L0O^>+4'_IRY
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M&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W
M>/<  &[_"@%C_Q "6O\5 U+_'01+_R0&1O\L"$'_,PD\_SH*.?] "S7_10PR
M_TH-,/]0#2[_5 XL_UD.*O]>#RC_9 \F_VH/)?]Q$"/_>! B_X 1(/^($1__
MD1$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1$?_Y$1_UPB _]7+07_6#,'_U\V
M"?]C/0W_9482_V90%_]E7AS_9&XB_V%\)_]?BBO_7I8N_URA,?];JC/_6K(U
M_UFZ-O]8PS?_6,TY_U?8.?]6X#K_5>8[_U3L//]3\3S\4O4]^%+Y/?51_3WS
M4?\]\U'_/?-1_SWS4?\]\U'_/?-1_SWS4?\]_UPB _]7+ 7_6C('_V$U"?]E
M/ W_9T42_VA/%_]H7!W_9FTB_V-[*/]AB"S_7Y0O_UZ?,O]=J37_6[$W_UJY
M./]:P3K_6<L[_UC5//]7WSW_5N8^_U7K/OU4\#_Y4_4_]E+Y0/-2_4#P4O\^
M\%+_/O!2_S[P4O\^\%+_/O!2_S[P4O\^_UTA _]8+ 7_7# '_V0S"?]H.@W_
M:T,2_VQ.%_]L6AW_:FHD_V=X*?]DA2[_8I$R_V&<-O]?ICC_7JXZ_UVV//]<
MOC[_6\@__UK20?]9W4+_5^5#_5;J1/E5\$3U5/5%\53Z1>Y4_D3L5/]"[%3_
M0NQ4_T+L5/]"[%3_0NQ4_T+L5/]"_UXA _]9+ 7_7RX&_V8R"?]L. S_;T$1
M_V],%_]Q5Q[_;F<E_VMU*_]H@C#_98XU_V29.?]BHSS_8*L^_U^S0?]>NT+_
M7<1$_US.1O]:W$?^6>1(^E?J2?56\$KP5?9*[57Z2NE6_D?G5O]%YU;_1>=6
M_T7G5O]%YU;_1>=6_T7G5O]%_UXA _]9*P7_8BT&_VHP"/]O-@S_<D 1_W1*
M&/]U51[_<F0F_V]R+?]L?S/_:8LX_V:6//]EH$#_8ZA#_V&P1O]@N$C_7L%*
M_UW+2_]<VDWZ6N-.]5GJ3_!7\5#K5O91YU?[3N18_TOA6?])X5G_2>%9_TGA
M6?])X5G_2>%9_TGA6?])_U\@ _]:*P7_92L&_VTN"/]S-0S_=SX1_WA(%_]Y
M4A__=V G_W1N+O]P>S7_;8<[_VJ20?]GFT7_9:1)_F.L3/UAM$[[8+Q1^E[&
M4_E=U%7U6^-6[UKJ6.E8\EGE6?=6X%K[4]M;_T_76_]-UUO_3==;_TW76_]-
MUUO_3==;_TW76_]-_V @ _]=*07_:"D&_W$K!_]X,PO_?#P0_WU&%_]^4!__
M?5TH_WEJ,/]U=CC_<8(__&V-1?IJETOX9Y]/]F6G4_1BKU;S8+A9\5_!7/!=
MS5[M7.!@Z%KL8>%:\F#:6_9;TUSZ5\]=_5/,7O]1S%[_4<Q>_U',7O]1S%[_
M4<Q>_U',7O]1_V$? _]@)P3_:R8%_W4I!_]\,0K_@3H0_X-$%_^$31__@UDH
M_W]F,OQZ<COX=7Y#]7&(2_)MDE'O:9I6[6:B6^ICJE_H8+)CYEZ\9N1<R&GA
M6]IKW5KJ:]-<\&;-7O5AR%_Y7,1@_%C!8?Y5P6'^5<%A_E7!8?Y5P6'^5<%A
M_E7!8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B
M,_6 ;CWP>GE'['6#4.EPC%CE:Y5>X6:=9-YCI&G;8*UMUU^W;]1>PW#17M)Q
MS5WG<<=?[FO"8?)FOF+V8;IC^5RW8_Q8MV/\6+=C_%BW8_Q8MV/\6+=C_%BW
M8_Q8_V,? _]F(P3_<B($_WTG!O^%+@G_BC<._XU %?^/21[ZCU,H](Q?-.Z&
M:C_I?W1+XWA^5=YRAE[8;8]ETVJ8:L]GH&W,9:APR6.Q<\9BO'3$8<EUP6'@
M=KQCZG&W9.]JM&7S9;!F]F"N9_E<KF?Y7*YG^5RN9_E<KF?Y7*YG^5RN9_E<
M_V,> _]H(03_=2 $_X$E!?^)+0C_CS4,_Y(^%/R41QWUED\H[I%;-.>+9D'@
MA&].V7UY6-%W@F#,<XIGQV^3;,1LFW# ::-SO6>L=KIFMGBX9<)YMF75>;)F
MYG:N:.QOJFGP::AI]&.F:O=?IFKW7Z9J]U^F:O=?IFKW7Z9J]U^F:O=?_V0>
M _]K( /_>!X$_X0D!?^-+ ?_DS0+_Y<\$OB911OPFTTGZ)=9-.&08D+7B6Q.
MSH-U6,A]?F'#>(9HOG2.;;EPEG*V;IYULFRG>*]JL7NM:;U\JFG-?:AJXWJE
M;.ERHFSM;*!M\F:>;O5BGF[U8IYN]6*>;O5BGF[U8IYN]6*>;O5B_V4= O]M
M'@/_>QT#_X<C!/^0*@;_ES(*_9P[$/2?0QGLH4LEXYQ6,]J68$'/CFE.QXAR
M6,"">F&Z?8)HM7F*;K%UDG.L<IIWJ7"C>J9NK'VC;;A^H6W'?Y]NX'Z<<.=U
MFG#K;YEQ\&B7<?-DEW'S9)=Q\V27<?-DEW'S9)=Q\V27<?-D_V4= O]O'0/_
M?AP#_XHB!/^3*07_FS$)^: Y#_"C01CGIDDCWJ%4,=*:7D#(DV=-P(QO6+F'
M=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2 F''"@99RV(&5=.5XDW3J
M<9)U[VN1=?)FD77R9I%U\F:1=?)FD77R9I%U\F:1=?)F_V8= O]Q&P/_@!L#
M_XPA _^6* 7_GB\(]J0W#>RH/Q7CJT@@V*92,,R>7$##EV5-NY%M5[.+=&&M
MAGQHIX*#;J)^BW2=>Y-XF7F<?)5WI7^2=K"!D'6^@HYVT8*.>.-ZC7CH<XQX
M[6R+>/%HBWCQ:(MX\6B+>/%HBWCQ:(MX\6B+>/%H_V<< O]S&@+_@AH"_X\@
M _^9)@3^HBX&\Z@U"^FM/1/?KT8>TJE1+\>B6C^^FV-,M95J5ZZ/<F"GBWEH
MH8>!;IR#B'27@)!XDGV9?(Y\HH"+>JV"B'J[@X=ZS8.'?.)\AWSG=89\[&Z&
M?/!IAGSP:89\\&F&?/!IAGSP:89\\&F&?/!I_V<< O]U&0+_A1D"_Y(? O^<
M)0/[I2P%\*PT">:R.Q#;LT0=S:U/+L.F63ZYGV%+L)EH5JB4<%^ACW=GFXM^
M;I:(AG.0A8YXC(*6?(B H("$?ZN"@7^X@W]_RH2!@>%]@8'F=H& ZV^ @.]J
M@(#O:H" [VJ @.]J@(#O:H" [VJ @.]J_V@< O]X%P+_AQ@"_Y0= O^?(P/X
MJ2H$[+$Q!^*W.0W5MT(<R;!.+;ZJ5SVTHU]*JYYG5:.8;E^<E'5FEI!\;9"-
M@W.+BHMXAHB4?(&&GH!]A*B">X2UA'F$QX1ZAN!_>X7F=WN%ZW![A.YK>X3N
M:WN$[FM[A.YK>X3N:WN$[FM[A.YK_VD; O]Z%@+_BA<"_Y<< O^C(0+TK2<#
MZ+4N!=Z]-0K0ND ;Q+1,++JN5CNOJ%Y)IJ)E5)Z=;%V7F7-FD)5Y;(J2@7*%
MD(EW?XV2?'N+FW]WBJ:"=(FS@W**Q(-TC.!_=(OE>'6)ZG%VB.UL=HCM;':(
M[6QVB.UL=HCM;':([6QVB.UL_VL: O]]% +_C18!_YH: ?^F'@'PL2,"Y+LI
M ]G", G+O3\9P+A**K6R5#JJK%Q'H:=C4IFC:ER1GW%DBIMW:X28?W%^EH9V
M>9./>W22F7YPD*2!;9"Q@FN0P8)MDMU_;I'E>&^/ZG%PCNUL<([M;'".[6QP
MCNUL<([M;'".[6QPCNUL_VX8 O^ $@'_D!4!_YX7 ?NK&@'LMQX!X,,A =+&
M+0C&P3T8NKQ)**^W4CBELEI%G*UA49.I:%J+I6]BA*)U:7Z??&]XG81T<YN-
M>6Z9EGQJF*)_9Y>N@&68OX%EF=A_:)CE>&F6ZG%JE.UL:I3M;&J4[6QJE.UL
M:I3M;&J4[6QJE.UL_W$6 O^#$0'_E!,!_Z(4 /6P% #FOA0 V<P5 ,S**P?
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M-#__XS0__^\U/__O-3__[S4__^\U/__O-3__[S4__^\UQ*H  +.S  "GOP
MFLL  (_: @"&_P\!?O\< W7_)09L_RT*9/\V#EW_/A)8_T454O]-&$__51I,
M_UP<2?]D'D?_:Q]$_W,@0O]\(D'_A2,__X\D/?^:)3O_I"8Z_Z\F.?^Z)SC_
MRB<X_]PH./_<*#C_W"@X_]PH./_<*#C_W"@X_]PHM:\  *>Z  ":Q@  C=0
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M4TG.^%!*R_].2LK_34K*_TU*RO]-2LK_34K*_TU*RO]-YX\  -&?  ##JP$
MM[0" *V_ P"CRP8 F]D* )3E&@&-Y2L&A.0U#7OC/Q9SXD@>;.%2)F;A6BQ@
MX&(R6^!J-E?@<CI3WWL]4-^%0$W?CT-*X)M%2."H1D;@N$=%X<Q'1>#H1T7?
M]D9%WO]$1=[_1$7>_T1%WO]$1=[_1$7>_T1%WO]$V9<  ,>F  "XL   K+D!
M *+% @"8T08 C^L- (GN'P* [BL&>.TT#'#M/1-H[4898NU.'EWM5R-9[6 G
M5>UH*E+M<2U/[7DO3.V#,DKNC31'[I@U1>ZE-T/OLSA"\,0X0?#?.4'O[SA
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M(#+_YR R_^<@,O_G(#+_YR R_^<@L*T  **W  "5Q   A]   'O=  !R_0D
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MP9]&&[>:42FOE5HTIY!B/J&+:D:;AW%,E81X4I"!?U>,?X=<B'V08(1[F6.
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M75BD]EA:H_]46Z'_4%NA_U!;H?]06Z'_4%NA_U!;H?]0_W<' /")  #6F
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M.4/8_SE#V/\Y0]C_.4/8_SE#V/\YT)8  ,&C  "RK   I[4  )S   "1R@,
MA]8' (#I$0!YZ2 "<NDL!6OI-@IDZ3\/7NE(%%GI41E5Z%H<4>EB($[I:R-+
MZ70E2.E])T;IB"I#Z9,K0>J@+4#JKRX^Z\ N/>S;+CWJ[RX]Z/PN/>?_+3WG
M_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0  G+P  )#'  "$T@$ >M\&
M '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),]5442?9=%T;V91A$]FX:
M0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;YXR(V^/,B-O?\(C;W_"(V
M]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0  (//  !WVP  ;_8* &?_
M$P%@_QT"6O\G U3_, 5/_S@(2O] "D;_2 Q#_T\.0/]6#SW_7A [_V42./]N
M$S;_=Q0T_X(5,O^/%C#_FQ<O_ZD7+O^W&"W_R!@L_^$8+/_O&"S_[Q@L_^\8
M+/_O&"S_[Q@L_^\8JZL  )ZU  "0P0  @LP  '79  !IY   8?\) %O_$0!4
M_QD!3O\B DG_*P1$_S(%0/\Z!CS_00<Y_T<(-O]."3/_5 HQ_UL++O]B#"S_
M:PPI_W4-)_^ #B7_C0XD_YH/(_^F$"+_LQ A_\$0(?_0$"'_T! A_] 0(?_0
M$"'_T! A_] 0G[(  )&^  "#R@  ==8  &?B  !;\0  5/\& $[_#@!(_Q0!
M0O\< CW_) (Y_RL#-?\R!#'_. 0N_SX%*_]#!2C_208E_T\&(_]6!R'_70<>
M_V4('/]O"!G_>@D7_X<)%O^4"17_GPH4_ZH*%/^S"A3_LPH4_[,*%/^S"A3_
MLPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P  2/\  $'_"@ [_Q !-O\5
M 3'_' $M_R("*?\H B7_+0(B_S(#'_\X QS_/0,:_T(#%_](!!7_3@03_U4$
M$?]=!0__9P4-_W(%#/]]!0K_B08*_Y,&"?^<!@G_G 8)_YP&"?^<!@G_G 8)
M_YP&_S\J O\_, /_1# #_T@S!/]).0;_2$((_T9-"_]%6P[_0VD1_T%W$_]
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M66B(]E)KBO]-;(K_2&R)_T=LB?]';(G_1VR)_T=LB?]'_VD+ /]X! #EAP
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M0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,  #(F0  O:,  +*K  "IL@
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M)#GB_R0YXO\DOYX  *^F  "CK@  E[@  (K"  !^S   <]8" &GE"0!D[Q0
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M= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8._[H&#O^Z!@[_N@8._[H&CKH
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M3W9U]D=X=_]">GC_/GMY_SI[>?\Z>WG_.GMY_SI[>?\Z_U\, /]L! #U>0(
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M/V.,_SQCC/\\8XS_/&.,_SQCC/\\_VH  .9Z  #5A@  R9$  ,"9 0"XGP$
ML*4  *BI#@"BJ2$!FJ@Q!I.E/@^+HT@8A*!1('Z>62=XG& M<YIG,F^8;C=J
MEG4\9I5]/V*4AT-?DI%&6Y*=25F1JTI7D;M+5I'32U>2[T=:DOU"7)/_/EV3
M_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP  Q)4  +J=  "QHP  J:D
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M,TBO_S-(K_\SVX(  ,>0  "[G   KJ,  *2J  "9L0  C[D  (3  P![Q@T
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MG1 N[ZT1+?# $2WPWA$L[O$1+.S^$2SK_Q LZ_\0+.O_$"SK_Q LZ_\0K:(
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M PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_P@,(_\(#BK@  'O#  !LS@
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M085D]SN&9O\UAV?_,8=H_RZ':?\MAVG_+8=I_RV':?\M_U<, /]A! #^; ,
MY'4! -M[!0#3@ @ T(,* ,>%&@"^A"T#MH$\":]]2!*H>5(9HG9;()US8R:9
M<&LKE6YR+Y%M>3..:X$VBVF).HAHDCR%9YP_@F:G08!FM$-^9L5$?&;A0WYH
M]3Q_:O\W@&O_,X%L_R^!;/\O@6S_+X%L_R^!;/\O_UD+ /]C 0#T;P  WW@
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M-G%X_S)Q>/\Q<7C_,7%X_S%Q>/\Q_U\" /=L  #>=P  T($  ,>( 0# C0,
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M,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "JG0  H:$  )>F! "1IQ4
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MHB8^NK,F/;K()CVZZ"8]N/DE/;?_)#VV_R,]MO\C/;;_(SVV_R,]MO\CQX@
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M"B?KU@HGZ? *)^?]"2;F_PHFYO\*)N;_"B;F_PHFYO\*J*   )RG  "/L
M@KD  '3"  !HR@  6]$  $_7  !%W0  /NX) #SR$0 Y\QL -O,E #3T+@ Q
M]#<!+O4_ 2SU1P$I]D\")_97 B7W80,C]VP#(?AZ!!_XB00>^9H%'/FK!1OZ
MP 4:^MX%&OGR!1KW_049]O\%&?;_!1GV_P49]O\%GJ8  )&O  "#N0  =<(
M &?+  !:TP  3=H  $+?   XY0  -?L' #'_#P N_Q8 *_\? "G_)@ E_RT
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M+YI3^BJ:5?\FF5;_(YE6_R&95_\?F5?_'YE7_Q^95_\?_TT- /]5!@#_704
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M*WQG_RA\9_\F?&?_)GQG_R9\9_\F_U4# /]@  #C:@  U7(  ,QX 0#%>P,
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M*6=W_REG=_\I_U\  .-L  #0=@  Q7\  +R%  "TB@  K(P  *.."@"=CAH
MEXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7. :B5O?W$I;'YY+&A]@B]E
M?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_+F!\_RMA?/\I87S_*6%\
M_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@  II$  )V2!@"7DQ< D9,H
M 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-JAF\G9H1W*V.#@"Y@@HHQ
M78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"_RI;@O\I6X+_*5N"_RE;
M@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4  ):8 0"0F1, BIDD 868
M,@1_ECX)>91(#G234!1OD5<9:Y!>'6B.92%DC6TE8(QU*%V+?BM:BH@N5XF4
M,52)H3-2B+ T48C#-5"(XC12B/8P4XC_+%2(_RE5B/\H58C_*%6(_RA5B/\H
MYFL  -!X  #"@P  MXP  *V2  "CE@  FIH  (Z>  "'GQ  @Y\@ 'Z?+P)X
MG3L'<YQ%#&Z;31%IF54699A<&F&78QY>EFHA6Y5R)5>4?"A4DX8K49*2+DZ2
MH#!,DJ\Q2Y+",4J1X#%,D?4M39'_*DZ0_RA.D/\F3I#_)DZ0_R9.D/\FWG
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M0@53N$L(4+=3"TVW6PY*MF,01[9K$T2U=19"M8$8/[6.&CVUG!P[M:P<.K7
M'3FUWQPYL_0<.;+_'#FQ_QLYL/\;.;#_&SFP_QLYL/\;P88  +23  "GF@
MG*   )&G  "%K0  >;,  &VX  !BO0$ 5L(' %/#% !2PR, 4,0P 4W$.P)*
MQ$4#1\1.!47$5P="PU\)0,-H"SW#<@T[PWX/.,.,$3;#FQ(UPZL3,\/ $S/#
MX!,SP?43,L#_%#*__Q0QOO\4,;[_%#&^_Q0QOO\4N)   *N9  "?H   DZ<
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M A+R_ (2\/\"$O#_ A+P_P(2\/\"FJ0  (VM  !_M@  <;\  &/'  !6S@
M2=,  #W:   SWP  *N,  ";T!0 D^PT (?P3 ![]&P <_2( &?XI !?^,0 5
M_SD $_]! !'_2@ 0_U4 #O]A  S_;P$,_X !"O^3 0G_I@$(_[H!!__4 0?_
MZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP  8\D  %;1  !(V   .]T
M ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1_QD #_\>  W_)  +_RL
M"?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_D   _Z,  /^T  #_Q@
M_]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,  $?;   ZX   +N4  "/I
M   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q  !/\3  '_&   _QX  /\D
M  #_*P  _S,  /\]  #_20  _U8  /]F  #_>   _XH  /^;  #_J   _[$
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M%[<__Q:U0/\4M$#_$[-!_Q&S0?\0LT'_$+-!_Q"S0?\0_T 0 /]&# #_2PH
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M'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L7   WV(  -1F 0#.: 4
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M$ "N<2( J' R J%N/P:<;$H+EVI3$))H6Q2.9F(8BV5I&XAC<!Z%8G@A@F&
M)(!@B29]7Y(I>UZ=*WA>J2UV7K@N=5[,+W1>Z2UU8/HG=F'_(W=B_R!W8O\>
M=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT  ,1R  "]=   MW0! +!T#@"I
M=1\ HG0O IQR/067<$<*D6Y1#XUL612):F 7A6EG&X)H;AY_9G4A?65])'ID
MAB=W8Y I=6.;+')BIRYP8K8O;V+)+VYBYBYO9/DH<&7_)'%F_R%Q9O\?<6;_
M'W%F_Q]Q9O\?_U0  .A?  #7:0  RG   ,!U  "Y>   LG@  *MX#0"D>1T
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M;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8   *" !P"9@1< E($H 8Z
M-0.(?D$(@WQ*#7YZ4A%Z>%D5=G=@&7-V9QQP=&X?;7-V(VIR?R9G<8DI9'&5
M*V)PH2U@<+ O7G#"+UUPWR]?<?4J8''_)F%R_R-B<O\@8G+_(&)R_R!B<O\@
M[UP  -QI  #*<@  OGH  +6   "MA   I(4  )J% P"4A10 CH8E 8F$,P.#
M@SX'?H%("WE_4!!U?E<4<7U>&&Y[91MK>FP>:'ET(F5X?25B=X<H7W:3*EQV
MGRQ:=:XN677 +EAUW2Y9=O,J6W;_)EQW_R-<=_\@7'?_(%QW_R!<=_\@ZF
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M)T>-U"='C/ D2(S_(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0
MK(T  **2  "7E@  C)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==
MG4T*6IQ4#5>;7!%4FF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7
MTR)!EN\@0I7^'D*5_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(
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M-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4  *^0  "CEP  F)T  (RC  "
MJ   =*T  &BR  !<M@  4+H! $F\#0!(O!D 1KTG $6],P!#O3T!0;U' 3^]
M4 (]O5@#.KUA!3B]:P8VO7<(-+V$"3*]DPHPO:0++[VW#"Z^T LNO.X,+;K^
M#2RY_PTLN/\.++C_#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL
M:K4  %ZZ  !2O@  1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P Q
MRU$!,,M; 2[,90(LS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(
M_P<CQ_\'(\?_!R/'_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X
M %+"  !'Q@  /<H  #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4
M(MQ0 "'=6P @W6@ 'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7
MVO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*
M   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M#
M !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\
M#.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   O
MV   )=T  !WA   8[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[
M/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]
M  #\_0  _/T BZL  'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0
M&>4  !/J   0^@  #O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,
M_SH  /]%  #_4P  _V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_
MY0  _^4 ?[0  '"]  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T
M  SZ   )_P  !O\   +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD
M /\T  #_0   _TX  /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0
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M!-XC_P3;)/\$V23_!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$
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M$*) _P^B0/\.HD'_#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL
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M%7Y5_Q5^5?\5_TH  .Y2  #>6P  SV$  ,9D  "_90  NF," +-B#P"L8R
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MH"1F8JXE96*_)F1BVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,
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M)51QT"54<>XB5G'^'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P
MM'H  *M_  "B@@  F(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ
M?E +9WU7#F1\7A%A>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]W
MSB-/=^PA4'?]'E%W_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\
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M%SZ/_Q8^C_\5/H__%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@
M?YD  '.<  !DGP  7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(
MH%H'19]C"4.?; M GG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::
M_Q(VF?\1-YG_$3>9_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z
M &ND  !?IP  4JH  $VK#@!+JQH 2JLG $BK,P!&JST!1*M& 4*K3@) JU8#
M/JM?!3NK: 8YJG,(-ZJ "32JCPLRJI\,,:JP##"JQPPPJ><,+Z?Z#2^F_PTO
MI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E   E)D  (>>  ![HP  ;Z@  &.L
M  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 ZMS0 .;<^ #>W1P VMU !-+=:
M 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBXQ04HM^8%)[7Y!R:S_P<FLO\(
M)K+_"":R_P@FLO\(KXT  **4  "7F@  BZ   'ZF  !QJP  9;   %FT  !-
MMP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD *L0S "G$/0 HQ4< )\51 ";%
M7  EQF@ (\9V 2+&A@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_
M!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P
M.,,  "_'   FRP0 'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5
MU5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1
M_P$0T?\!G)H  )&A  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P
M "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\
M">==  CG;0 &YH  !>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P
MYO\ DZ$  (6I  !WL0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;
M   2WP  #>,   OQ"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),
M  #R7   \FT  /*"  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L
MAZD  'FR  !JN@  7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *
MZ   !?,   /] 0  _ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^
M20  _EH  /YM  #_@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(
M &R[  !=Q   3\T  $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]
M /\   #_    _P   /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P
M_T8  /]8  #_:P  _X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<
M) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"*
M /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P
M_P#X /\ _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_
M'B$ _QDC /\3*0#_#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#
MCP#_ I8 _P*< /\"H@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V
M /@ _P#W O\ ]P/_ /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P
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M \,D_P/")/\#P23_ \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H
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M"Y)!_PN20?\+_ST  /]#  #I20  WDX  --/  #-3@, RDD( ,))% "[2B8
MM4LV *]+0P*K2DX#ITE7!:1(8 >A1V<)GD9O"IQ&=@R:17T.F$6%#Y9$CA"4
M1)<2DD.A$Y!#K!2/0[H5C4/-%8M$Z!6*1?H2B4;_$(E&_PZ(1O\-B$;_#8A&
M_PV(1O\-_T   /)'  #C3P  U%,  ,M5  #$5   P% $ +E/$0"R4"( K%$R
M *=1/P*B4$H#GD]3!9M.7 B836,*E4QJ#)-+<0V12GD/CDJ $8Q)B1**29(4
MB$B<%89(J!:%2+47@TC'&(%(Y!B!2O<5@$K_$H!+_Q" 2_\/@$O_#H!+_PZ
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MH1ET4:\;<U' &W%1VQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@
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M'5]>SAU?7NP;8%_]&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9
MN6H  +!N  "G<   GFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S
M:%((<&=9"FUF8 UK96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IB
MS!U:8NH<6V/\&%QC_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX
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M%TQR_Q5,<O\337+_$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0
MC($  'I^  !S?P( ;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7
M?5X+5'QF#5%\;@]/>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y
M_Q1&>/\21WC_$4=X_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8
M '>&  !KA@  9H<- &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(
M3H5C"DN$; Q)A'8/1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q)
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M"S&3_PLQD_\+N'H  *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H
M3J(  $6D"0!"I!, 0*0? #^D*@ ^I30 /*4^ #NE1P$YI4\!-Z58 C6E80(S
MI6P#,:5Y!"^DAP4MI)<&+*2I!BNDO08JI-X&*J+U!RFA_P<IH/\(*9__""F?
M_P@IG_\(L8(  *6+  ":D0  D)8  (.:  !VGP  :J(  %ZF  !2J0  1JL
M #RM   UKPP ,[ 5 #*P(0 QL"L +[ U "ZQ/@ ML4@ ++%1 "NQ6P IL6<!
M)[%T 2:Q@P$DL90"([&F B*RNP(ALML"(:_S R"N_P,@K?\$'ZS_!!^L_P0?
MK/\$JHL  )V1  "3EP  AYP  'JB  !MIP  8*L  %6O  !)L0  /K0  #.W
M   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?OCT 'KY' !V^4@ <OUX &K]L
M !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"
MH9(  ):8  "*G@  ?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    A
MQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.
M<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@
M (V>  !_I0  <:P  &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0
M$=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@
MWG,  -Z(  #?G0  W[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F
M  !SK@  9;4  %B]  !*P@  /<4  #')   FS   '=   !34   .V0  "=T
M  /A    XP<  .,-  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(
M .UV  #NC   [J$  .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !G
MMP  6;\  $O&   \R@  +\X  "32   :V   $MP   S@   %XP   .<   #K
M    ZP   .T%  #N"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC
M  #\=P  _8T  /VC  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0
M3,H  #S/   NU   (MH  !?>   0X@  ">8   #I    [    /    #V
M]@   /<   #X    ^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_
M8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD
M /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8
M_P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#]
M /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*
M)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8
M /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\
M] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_
M#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X
MFP#\ *$ ^@"G /@ K@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_
M .H!_P#I ?\ Z0'_ .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@
M_Q T /\-00#_#$X _PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S
M!IT \0:C .\&J@#M!K( _^+__TE#0U]04D]&24Q%  @)Z@:[ .@&R #F!MP
MY ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,_P#<#/\ _R,2 /\C$ #_
M(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5 /@/8 #T#VH \0]T .\.
M? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\ X ZX -X.Q0#<#MH UA#L
M -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2_P'*$O\!_R</ /\G# #_)0D
M_R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/ .H76@#F%F4 XQ9N . 6=P#>
M%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL SABU ,P8P0#+&-( QQKH <,;
M^ ' &_\!OAS_ ;T<_P*\'/\"O!O_ KP;_P*\&_\"_RL, /\K!0#_*P, _RT)
M /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5(%\ T2!H ,X@<0#,(7D
MRB&! <@AB '&(8\!Q"&6 <,AG@'!(J8!OR*O ;TBNP*\(\H"N2/C K4D] *S
M)/\#L23_ Z\D_P.O)/\#KB3_ ZXD_P.N)/\#_R\& /\O  #_,@  _S," /DR
M" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED PRIB < J:P&]*G,!NRIZ
M KDJ@@*X*HD"MBJ0 K0JF .S*J$#L2JJ Z\KM02N*\0$K"O;!*@L[P2F+/X%
MI"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(  /\S  #Y.   Z3D  .(Y  #>
M-0< WBX- -$O&P#),2P PS,[ +TS2 "Y-%,!MC-< ;,S90*P,VT"KC-T ZPR
M>P.K,H,$J3**!*<RDP6E,IL&I#*E!J(RL >@,KX'GS+1!YPSZ@>:,_L'F#3_
M!Y<T_P:6-/\&EC3_!98T_P66-/\%_S4  /\X  #J/@  WT(  -5"  #//P,
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M"W)*_PIR2O\*\D(  .!,  #.4P  P5@  +A:  "P60  J58  *)2!P";4A4
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ME!->6:(47%FR%5M9QA9:6>456UKY$EM:_Q!<6O\.7%K_#5Q:_PU<6O\-XT\
M ,U9  "^80  LV8  *EI  "@:@  EV@  (MB  "#8@P ?F,8 'IC)@!V8S(
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M%$MHP!1+:-X42V?U$DQG_P],9_\.36?_#4UG_PU-9_\-TEH  ,!D  "S;
MJ7(  *!V  "6=P  BG8  'EQ  !Q<0  :W$/ &AQ' !F<B@ 8W(T &!R/0%>
M<D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z #DMNC1!);IL11VVK$D9N
MOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-S%\  +QI  "P<0  I7<
M )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?>"0 77DP %IY.@%8>4("
M5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5UB@Y#=9D/0G6I$$!UO!!
M==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0  +=N  "K=@  HGP  )=_
M  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"  58 K %.!-@!1@#X!3X!&
M DV 3@)+?U4#27]=!49_9@9$?G (0GY["3]^B L]?9<,/'VG#3I]N@XZ?M8-
M.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D  +)T  "G?   G8$  )*$  "'
MA@  >X<  &Z'  !@AP  58<! %"(#@!.B!H 38DF $N), !)B3H 2(E" 4:)
M2@%$B5("0HE: T"(8P0]B&T%.XAX!CF'A@@WAY4)-8>F"C2'N0HSA],*,X;P
M"3.%_PDSA/\),X/_"3.#_PDS@_\)N7   *UZ  "B@@  EX<  (V*  "!C
M=8X  &B/  !:D   3Y$  $>2"@!$DA, 0Y,? $&3*@! DS0 /Y,] #V310 [
MDTT!.I-6 3B37P(VDVD#-)-U S*2@P0PDI,%+I*D!BV2MP8LDM$&+)'O!BN/
M_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B   D8P  (>0  !ZDP  ;94
M &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ TGBP ,YXU #*>/@ QGD<
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M  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>JP  4J\  $:R   ZM0
M+[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%'@ (Q2@ !\4R  ;&/0 %
MQDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2  #%[P  Q?P  ,7_  #%
M_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M   1K@  #J[   NO@  ),$
M !O$   3QP  #LH   C. 0 !T H  - 0  #0%@  T1X  -(G  #3,0  U#P
M -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6X   UO,  -;^  #6_P
MUO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$  "W$   BQP  &<L  !'.
M   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0  .$<  #B)   Y"X  .8Z
M  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0  Z>(  .GR  #I]0  Z?4
M@*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.   6T@  #]8   C;
MWP   .,   #E    YP   .@!  #J!P  ZPT  .T1  #O&   \2$  /,K  #V
M.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(  /K:  #ZWP  ^M\ =*X
M &6V  !6O@  2,8  #G+   KT   ']0  !3:   -WP  !>,   #F    Z0
M .T   #O    \0   /,   #U    ]@(  /@)  #Z#@  _1,  /\<  #_*
M_S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y  #_O   _[P _Q$@ /\0
M'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"#
M /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_ +@ _P#" /\ S@#_ .(
M_@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\ _Q0< /\2&@#_
M#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\
MAP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0 ^0"] /@ R0#W -P ]0#L
M /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P /\ _Q<8 /\5%@#_$14
M_PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /P @@#Z
M (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X .X PP#L -, Z@#G .D
M]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\ _QH3 /\8$0#_%!  _P\1
M /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z &P ]0!U /( ?0#P (0
M[@"+ .P D0#K )< Z0"> .< I #F *P Y "T .( OP#@ ,T W@#C -P \@#:
M /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0 /\<#0#_%PL _Q4. /\4
M%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8 Z@1O .8#=P#D!'\ X@2&
M . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0!LD S@?@ ,P(\0#)"O\
MQPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@!@#_' , _QT* /\;$ #_
M&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI -D-<0#5#7D TPV! -$-
MB #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@ PA#? +X1\@"[$O\ N1/_
M +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_(P  _R0# /\A"@#]'1$
M\1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6:P#%%G, PQ=[ ,$7@@#
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M!(4T_P2%-/\$_#,  .LZ  #<00  S40  ,-$  "]00  N#L! +(W#@"K.!P
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ME@MJ2*,,:$BR#6=(Q0UF2>0-9DGX"V9)_PEF2O\(9DG_!V9)_P=F2?\'Z$,
M -)-  #"4P  MU@  *U9  "D6   G%4  )-.  ",3@X AT\; ()/*0!_4#4
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M#E95O@]55=L/557S#555_PM65?\)5E7_"595_PA65?\(VTT  ,57  "X7@
MK6(  *-E  ":90  D&,  (-<  ![6P8 =5L2 '%;'P!N7"L :UPV &A;/P%E
M6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF "E59C M469H-4EFJ#E%9
MO Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(U%$  ,):  "T80  JF8
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M"T%H_PI!9_\)06?_"$)G_PA"9_\(Q5T  +9F  "J;0  H',  )9V  "+=P
M@'8  '!R  !E<0  7' ' %AP$0!6<!T 5'$H %)Q,P!0<3P 3W)$ 4UQ2P%+
M<5,"27%: T=Q8@1%<&P%0W!W!D%PA <_<),(/6^C"3MPM0H[<,T*.F_L"3MN
M_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P  G7D  ))[  "'?   >WP
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M R6'_P,EA_\#K78  *.   "7A0  C8D  (*,  !VC@  :9   %R2  !0DP
M1)0  #J5   QE@@ +9<1 "R7&@ KER0 *I<M "F7-@ HF#\ )YA( ":84@ E
MF%P (YAH "*8=P @F(< 'YB9 1V8K $<F,,!')?E 1R5^@$;E/\!&Y/_ AN3
M_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0  89@  %6;  !)G0  /9X
M #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;I#8 &J0_ !FD2@ 8I%4
M%J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B^  1H?\ $:#_ 1&@_P$1
MH/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$  $RD  ! I@  -:<  "JI
M   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L #;$U  VQ0  ,L4L "[%8
M  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %K_X !J[_  :N_P &KO\
MF(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M   UKP  *[$  "&T   8
MM@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK  "^-@  OD$  +].  "_
M7   OVT  +^   "^E0  OJH  +["  "]Y   O?8  +W_  "]_P  O?\ DI0
M (6:  !XH   :J8  %RK  !/L   0K,  #6V   JN   (+L  !>^   0P0
M"\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+*P  S34  ,Y!  #.4
MSV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X  #._@  SOX B)L  'JB
M  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@  %<8   [)   (S    -
M  #3    U0   -8&  #8#   V1$  -L6  #<'P  WB@  . T  #B00  XE$
M .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E\P  Y?, ?*,  &ZJ  !@
ML@  4;D  $.^   UP@  *,8  !S)   3S0  #-$   35    V@   -X   #A
M    X@   .0   #E P  YPD  .D.  #K$@  [1H  .\D  #R,0  ]$$  /13
M  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP  ]]\ <*P  &&T  !3NP
M1<,  #;'   GS   &]   !'5   *VP   -\   #B    Y0   .D   #L
M[0   /    #Q    \P   /4$  #W"@  ^A   /P6  #_(0  _RX  /]   #_
M4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\ _PT< /\*&P#_ AL _P >
M /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_ '< _P!_ /\ AP#_ (X
M_P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\ R0#^ -T _0#M /P ^@#[
M /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9 /\-%P#_!A8 _P 8 /\
M'@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '( _P![ /\ @@#_ (D _P"0
M /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T -( \P#G /( ]@#P /\
M[P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/$@#_"Q( _P 2 /\ &@#_
M "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V /D ?0#W (0 ]0"+ /0
MD0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L YP#A .4 \0#C /T XP#_
M .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_#0T _P</ /\"%0#_ "
M_P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T > #K '\ Z0"% .@ C #F
M )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9 -0 [ #2 /D T0#_ ,\
M_P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4 _PX+ /\,$0#_!QH _P$F
M /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#> 'D VP"  -D A@#6 (T
MTP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4 Z ## /8 P0#_ , "_P"_
M _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,% /\1#0#_#A0 ^0H? / &
M+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7, R@5Z ,@%@0#&!8< Q0:.
M ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U"_< LPW_ +$-_P"P#?\
ML [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46!0#V$0T ZPX5 .(+(@#8
M"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT +L/>P"Y#X( MQ"* +80
MD0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/< I17_ *,5_P"B%?\ HA7_
M *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<&04 VQ , - 1&0#($RD
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MF@-],Z<#?#.U!'HSR01Y-.8$=S7Y!'8U_P-U-?\#=37_ W4U_P-U-?\#\#,
M -T]  #*0P  OD4  +5&  "M0P  ICT  * V!@"9-A, E#@A ) Y+@",.3D
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M!V%#O0A@1-D(8$3S!V!$_P9?1/\%7T3_!&!$_P1@1/\$X$$  ,I*  "[4
ML%,  *=5  ">4P  E4\  (M)  "#1PL ?4<5 'E'(@!V2"X <T@X '%(00!N
M2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84> !6!'C09>1YH'7$>I"%M(
MNPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$VT0  ,9-  "X4P  K5<
M *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P3"L ;4PU &M,/@!H3$8
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M"$M4_@=+5/\&2U3_!4M4_P5+5/\%S$X  +M7  "N7@  I&(  )ID  "19
MAF(  '=;  !M6   9E@, &)8%@!?6"( 75DL %M9-@!963X 5UE& %9930%4
M650!4EE; E%98P-/66P#35EW!$M8A 5)6)('2%BB!T=9LPA&6<H(15GJ"$99
M_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80  H68  )AH  ".:0  @V<
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M!#5H_P0U:/\$N6   *QI  "A<   F'4  (UW  ""=P  =W<  &ET  !<<P
M47$  $AP"@!%<!( 0W$= $)Q)P! <C  /W(X #YR0  ]<D@ .W)0 #IR60$X
M<F,!-G)M C1R>@(S<HD#,7*: R]RK ,N<L$#+G+C RYQ^ ,N</\#+F__ RYO
M_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0  <GT  &1\  !7>P  3'H
M $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T>T0 ,WM, #)[50 P>U\
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M;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\ %(W_ !2,_P$4C/\!HWT
M )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%EP  .9@  "Z9   EF@
M'9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>00 0GDP #YY8  Z>9P -
MGG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_  N9_P +F?\ G(0  )&*
M  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H   ,*$  ":C   =I0  %:<
M !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "JD0  :I0  "J7@  JFX
M *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G_P  I_\ E8L  (R0  !_
ME0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL  !VM   4L   #K(   FU
M 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D  +A&  "X5   N&0  +AV
M  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P  MO\ CY(  (*7  !TG0
M9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X   -NP  !KX   #!
MP@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z  #)1P  R5<  ,EI  #)
M?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T A9D  '>?  !HI@  6JL
M $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #QP   ,H   #-    S@
M ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=.0  WDD  -Y:  #?;@
MWX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$  &NH  !<KP  3K4  $"[
M   QO@  ),$  !G%   0R   "<P   #/    TP   -D   #<    W0   -\
M  #A    X@4  .0+  #F$   Z!8  .H@  #M*P  \#H  /%+  #Q7@  \G,
M /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ  !0N0  0;\  #+$   D
MR   %\P   [0   &U0   -H   #>    X@   .8   #I    Z@   .P   #N
M    \    /(   #T!@  ]@P  /D2  #\'   _RD  /\Z  #_30  _V(  /]X
M  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_ !< _P : /\ (0#_ "L
M_P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\ @P#_ (H _P"0 /\ E@#_
M )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J /L ^ #Z /\ ^0#_ /@
M_P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !, _P 4 /\ &@#_ "< _P T
M /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_ (4 _@"+ /T D0#[ )<
M^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\ \P#N /\ [0#_ .P _P#K
M /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0 /\ %@#_ "( _P O /\
M/0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\ \P"& /$ C #O )( [@"8
M .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#? /L W@#_ -T _P#= /\
MW0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\ $@#_ !T _P I /L -P#X
M $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"  ., A@#A (P WP"3 -T
MF0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8 R@#_ ,H _P#) /\ R #_
M ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_ !8 ]P B .\ , #K #T
MZ !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -  @ #. (< S "- ,H E #(
M )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^ +D _P"X /\ N #_ +@
M_P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1  Z  : ., * #= #8 V !"
M -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_ ($ O0"( +L CP"Y )<
MMP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%_P"J!O\ J0;_ *D&_P"I
M!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2 -0#( #-!"T R 0Z ,,%
M1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L KPB" *X)B@"L"9( J@F;
M *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<#_\ FP__ )L/_P";#_\
M_QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+%@# #24 N@XR +8./P"R
M#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%] *$1A0"?$HX G1*7 )P2
MH@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\ CA?_ (X7_P".%_\ ^AT
M .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R%1X K18L *@7. "D&$,
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M G0MP )R+MT"<2[T G O_P)O+_\";R__ 6XO_P%N+_\!Z#$  -,Z  ##/P
MMT$  *Y!  "F/@  GC@  )<Q 0"1+A  C"\< (@P* "$,3, @3(] '\R1@!]
M,DT >S)4 'DR6P!W,F$ =3)I 70R< %R,GD!<#.$ 6\SD )M,YT";#.K FHT
MO )I--4#:#7Q F<U_P)G-?\"9C7_ F8U_P)F-/\"XC8  ,P_  "]1   LD<
M *A'  "@1   F#\  ) Y  "(- T @S47 '\V) !\-R\ >3<Y '<X0@!T.$D
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M!%-#_0-30_\#5$/_ U1#_P)40_\"T$(  +]*  "R4   IU,  )U4  "44P
MBE   ']*  !U10( ;D,. &M$&0!G120 944N &)%-P!A13\ 7T5& %U%30!;
M150 6D9; 5E&8P%71FP"5D9W E1&@P-31I$#44:A!%!'L01/1\<$3D?G!$Y'
M^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5   I%<  )I8  "15P  AE0
M 'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;23P 64E# %=)2@!625(
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M T!3_P- 4O\#P%   +)8  "F7@  G&(  ))E  "(90  ?6(  &Y<  !C60
M658# %16#@!15A@ 3U8B $U7+ !,5S0 2E<\ $E81 !(6$L 1UA3 $586P%$
M6&0!0EAN 4!8>P(_6(D"/5B9 SQ8J@,[6;\#.EG@ SI8]P,Z6/\#.U?_ SM7
M_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0  >6<  &MB  !@8   55T
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M<P L;((!*FR3 2ELI0$H;+D!)VW6 2=K\@$G:O\!)VK_ 2AI_P(H:?\"KF0
M *-L  "9<P  CG8  (1X  !Y>0  ;7@  &!W  !3=@  2'4  #YS   T<@H
M,7,1 #!S&@ O<R, +G,K "UT-  L=#P *W1$ "ET30 H=5< )W5C "5U;P D
M=7\ (G60 "%UH@ @=;< 'W72 !]T\0 ?<_\!'W+_ 2!Q_P$@<?\!J6L  )YS
M  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@  0WX  #A]   O?0( *'T-
M "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >?U( '7]> !Q_:P :?WH
M&7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[_P 7>_\ I'(  )IZ  "/
M?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@  #*(   HB   ((@% !J)
M#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP $HM8 !&+90 0BW4 #XN'
M  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .AO\ GWL  )2!  "*A0
M@(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2   ADP  &90  !*6!@ .
MEPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0  :77@ %EVX  Y:   &6
ME   E:@  )6^  "4X   E/0  )/_  &2_P !DO\ F((  (Z(  "%C   =X\
M &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9G@  $J    VB @ 'HPL
M :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D5@  I&4  *-W  "CBP
MHZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H  (F.  ![D@  ;9<  &";
M  !3G@  1J$  #FC   MI   (Z8  !FH   1J@  #*P   6N    KP<  *\-
M  "O$0  L!@  + @  "Q*   L3(  +(^  "R3   LEL  +)L  "R@0  L9<
M +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5  !QF@  8Y\  %6D  !'
MJ   .JH  "VL   BK@  &+   !"S   *M0   K@   "[    NP   +P'  "\
M#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\  ,-@  ##=   PXL  ,.A
M  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !EHP  5Z@  $FM   [L0
M+;,  "&V   6N0  #KL   >^    P0   ,4   #'    R    ,D   #*!0
MRPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3  #99@  V7P  -F4  #9
MJP  V<,  -GA  #9\   V?0 =I\  &>F  !9K   2[(  #RW   NN@  (;T
M !7    -Q   !<<   #*    S@   -(   #5    U@   -D   #;    W0
M -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N5@  [VL  .^$  #OG
M[[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP  "_    @Q   %,@   S,
M   "T    -0   #9    W@   .(   #E    Y@   .@   #I    [    .X
M  #P @  \@D  /4/  #X%P  _",  /\S  #_1@  _UH  /]Q  #_B0  _Y\
M /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\ '0#_ "@ _P W /\ 1 #_
M %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+ /\ D0#_ )< _P"= /\
MI #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\ ]P#_ /< _P#W /\ \ #_
M .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_ "0 _P R /\ /P#_ $P
M_P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H C #Y )( ^ "8 /8 GP#U
M *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_ .D _P#I /\ YP#_ .,
M_P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\ _P L /\ .@#_ $8 _@!2
M /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L (T Z@"3 .D F@#G *$
MY@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -< _P#5 /\ U0#_ -4 _P#4
M /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F /< - #T $  \@!, .X
M5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (< V@"- -8 E #4 )L T0"C
M ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P## /\ PP#_ ,, _P## /\
M_PL! /\#  #_    _P # /\ "P#S !( [@ ? .H +0#F #H X@!% -X 3P#9
M %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"' ,0 C@#" )8 P "> +X
MIP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\ L@#_ +$ _P"Q /\ _PT
M /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3 #( S@ ^ ,H 20#& %(
MPP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0 B "R )  L "9 *X H@"L
M *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_ *( _P"B /\ _Q   /L,
M  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H OP W +L 0@"W $L M !4
M +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D (L H@"4 *  G@"> :@
MG *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)_P"4"?\ _!$  /$5  #C
M&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N *X(.@"J"40 IPE- *0*
M50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8 E@R0 )0,F@"2#:8 D0VS
M (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'$?\ ]AD  .<@  #6)
MR"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0,P"=$3X FA%' )@23P"5
M$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+ (<4E@"&%:( A!6P (,6
MP0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\ [R$  -TI  #*+0  OB\
M +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1&C@ CAI! (L;20")&U
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M 6 O_0%@+_\!8"__ 6 O_P%@+O\!VC0  ,4\  "W00  K$,  *)#  "90
MD#H  (@T  " +@@ >BT2 '<N'@!S+RD <3 S &\P.P!M,$, :S%* &DQ40!G
M,5< 9C%> &0Q9@!C,F\ 83)Y & RA0%?,I(!73.A 5PSL0%;-,8!6C3F 5DU
M^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10  J$@  )Y(  "51@  BT
M (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E-C\ 8S9& &(V30!@-E0
M7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54XKP)4.<,"4SGD E,Z^0%3
M.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P  )I,  "12P  AT8  'U
M  !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP 73I# %LZ2@!:.U  6#M8
M %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K )./L$"33[A DT^^ )-/O\!
M33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1  ".3P  A$L  'E%  !N
M0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY  %4_1@!4/TT 4S]5 %)
M70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"2$+> DA"]@)(0O\"2$+_
M 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+4P  @%   '5*  !J1@
M84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"0P!/0TL 3D-2 $U$6@!+
M1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;< D-&]0)#1O\"0T;_ 4-%
M_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6   ?E4  '%/  !F2@  7$8%
M %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$
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M<P X4X(!-U.2 353I $T4[<!,U31 3-3\0$T4_\!-%+_ 312_P$T4O\!ME(
M *E:  ">8   E&0  (MF  " 90  =&,  &9>  !<7   45@  $=5!P!"51
M0%48 #]6(0 ]5BH /%8R #M6.0 Z5T$ .5=) #A740 W6%H -5AE #18<0 R
M6( !,5B0 2]9H@$N6;4!+5G/ 2U9[P$N6/\!+E?_ 2Y7_P$N5O\!LE<  *5?
M  ";90  D6D  (=J  !\:@  <6@  &-E  !88@  35\  $-= @ \6PT .EP4
M #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P7E< +UYB "U>;@ L7WT
M*E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=_P$H7/\!K5P  *)D  "8
M:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<  #]E   U8PD ,F,1 #!C
M&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950 )V5? "9F:P D9GH (V:+
M ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A8_\!J6(  )YJ  "5<
MBG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN   P;0, *6P- "=L%  F
M;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY; !UN9P <;G8 &FZ' !EO
MF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\ I&D  )IQ  "0=@  AGD
M 'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K=P  (G8' !UV#P <=Q8
M&W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X8P 2>'( $7B# !!XEP /
M>*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$  )5X  "+?   @G\  '>!
M  !J@@  78(  %""  !$@@  .((  "Z"   D@@  '((  !2""0 1@Q  $(,6
M !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )@VP "(-^  :#D0 %@J4
M X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^  "&@P  ?84  &^'  !B
MB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X   ^/ P *D P !I 1  2/
M&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4  (]V  "/B@  CI\  (ZT
M  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""B0  =(P  &:/  !9D0
M3),  $"5   TE@  *)8  !Z7   5F   #YH   J;   "G D  )P.  "<$P
MG!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN  "<@0  G)<  )RL  ";
MQ@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD   :I0  %R7  !/F@  0IT
M #:>   IGP  'Z$  !6B   .I   "*8   "H    J00  *D*  "I#@  J1,
M *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L=P  JXX  *ND  "KO
MJMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP  %&@  !$I   -J8  "JH
M   >J0  %*L   VN   &L    +(   "U    M0   +4#  "V"0  MPX  +@2
M  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P  O8$  +V9  "]L   O<P
M +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J   XK0  *J\  !ZQ   3
MM   #+<   .Y    O    +\   #"    P@   ,,   #$    Q@8  ,<,  #(
M$   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,  -*+  #2I   T[L  -/8
M  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   JM@  ';D  !*\   *OP
M ,,   #&    R0   ,T   #/    T    -(   #4    U@   -D"  #;"
MW@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\  #KE0  ZZP  .O"  #L
MU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P   $<0   G(    S    ,\
M  #3    V0   -T   #@    X0   .,   #E    YP   .H   #L    [@0
M /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_@P  _YL  /^N  #_O@
M_\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T /\ 00#_ $T _P!8 /\
M8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ), _P"9 /\ H #_ *< _@"O
M /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\
M_P / /\ #0#_  T _P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_
M &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\
MM #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P +
M /\ " #_  8 _P ) /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &
M\@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#=
M +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\
M  #_    _P $ /\ #0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B
M -\ :0#= &\ V@!V -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +,
MQ0#! ,( V #  .\ OP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_
M    _P   /0 !P#M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H
M8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y
M +$ RP"O .< K@#X *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V
M[@   .<   #?  P U@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W
M &, M0!I +, ;P"Q '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$
MPP"? -X G@#R )T _P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH
M -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P
MI@!C *0 : "B &\ H0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1
M -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01
M  "^#   N@(* +0 $@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)<
M )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\
MA KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q
M%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-
M70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L
M '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P
MH!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\
M%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:
M_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8
M ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D
M<!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A
M(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H
M  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1;
M &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\
M62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y
M*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ
M7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_
M %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0
M:RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5
M,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS
M_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#()
M & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$
M335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&
M-_\ P3X  +)%  "F2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV
M$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II
M $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\
MOD(  *])  "C3@  F5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1
M.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_
M<P! /X$ /S^1 #Y H@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4
M *Q,  "A40  EU0  (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q,
M24 < $= ) !&0"P 1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [
M0W\ .D2/ #E$H  X1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0
M  ">50  E%@  (M9  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09
M $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P
M-4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<
M60  DEP  (A=  !^70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)
M'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+
M "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970
MCV$  (9B  ![80  <%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U
M3R, -% K #-0,@ R4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3
MF@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68
M (-G  !X9@  ;64  &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\
M+58G "Q6+P K5S8 *E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @
M6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L
M  !U;   :FL  %UH  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC
M "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D
M%V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R
M<@  9G$  %AN  !,;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF
M)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]
M  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>
M8'<  %-V  !&=   .W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1
M<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9P
MT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X
M $U^  ! ?0  -7T  "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$
M!WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP
M>>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'
M   YAP  +8<  ".'   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C
M  ")+   B38  (E"  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8
M (3X  "$_P  A/\ D'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   P
MD0  ))$  !J2   2DP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6
M)   EBX  )8Y  "61@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U
M  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP
M&YP  !*=   ,GP  !*    "B    HP$  *,'  "C#   HQ   *05  "D'
MI24  *8O  "F/   IDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B
M_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<
M  JI   !JP   *T   "O    L    +    "P!0  L0L  +(/  "S%   M!L
M +4D  "W,   MS\  +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0
MM?X >Y,  &V8  !?G0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T
M    MP   +H   "\    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89
M  #))   RC(  ,M#  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8
M<)L  &&A  !2I@  1*L  #:P   GL@  &K4  !"X   'NP   +X   #!
MQ    ,@   #+    RP   ,T   #.    T    -(   #5 P  V H  -L0  #>
M&   XB0  .,U  #D2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0
M %6J  !&L   .+4  "BY   :O   #\    7$    QP   ,L   #/    U
M -@   #<    W0   -\   #A    XP   .4   #H    Z@   .T&  #Q#@
M]18  /@E  #Y.   ^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\
M#@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N
M /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,,
M]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_
M  @ _P * /\ $@#_ !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H
M< #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #-
M .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_
M_P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J
M '$ Z !W .8 ?0#D (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -
MW@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P
M /L "P#V !, \0 @ .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L
MT@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[
M .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X
M!0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J
M +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$
MIP#U *8 _P"E /\ I #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4
M  L S  3 ,< 'P#" "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P
M:0"K &\ J0!U *< ? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N
M )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0
MO@ . +@ %P"S ", KP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P";
M &D F@!O )@ =@"6 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (<
M^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 (
M *L $0"F !L H0 F )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &,
MC !I (H < "( '< A@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z
M!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%
M# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C
M 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\
M;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @".
M"PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$0
M90!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_
M &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@
M?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E
M%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<
M_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@.
M &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0
M6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2
M(O\ R"\  +@V  "K.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@
M$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J
M %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\
MPS0  +,[  "G/P  G$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<
M)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ
M<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@
M + _  "D0P  F44  (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8
M4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#
M,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#
M  "A1P  EDD  (Q)  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# <
M $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L
M/36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">
M2P  E$T  (I.  " 3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U
M(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F)
M #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@
MDE$  (A2  !^4   <TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^
M.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^
MF0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4
M (96  !\50  <5(  &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B,
M-SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K
M0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:
M  !Y6@  ;E<  &%2  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G
M #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@
M)$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W
M7@  :UP  %]8  !550  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M*
M*P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[
M !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P
M:6$  %Q>  !26P  1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C
M4"\ (E$W "%10  @44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53
MV0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<
M %ED  !-80  0E\  #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L
M&E@S !E8/  86$4 %EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 0
M6?, $%G_ !%8_P 16/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J
M  !(:   /F8  #-E   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N
M !%A-P 084  #V%+  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L
M"6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#
M<   .&\  "UN   D;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ
M,@ (:CP !VM'  5K4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX
M  !H_P  :/\ EVT  (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0
M,7@  "=W   ==@  %78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+
M=38  '5!  !U3@  =5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R
M_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(
M !^!   6@0  $((   J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\
M (([  ""1P  @E4  (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P
M??\ C7P  (2!  ![A   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,
M   0C0  "8X   */    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R
M  "0/P  D$T  )!=  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\
MB(0  ("(  !RBP  9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (
MF0   )L   "=    G0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@
M-0  H$,  *!4  "@9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL
M '6.  !GD@  698  $N9   ]G   ,)X  ".?   7H   #J(   >D    I@
M *@   "J    J@   *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0
ML3@  +%(  "Q6@  L6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6
M  !<F@  39\  #^C   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4
M  "W    MP   +@   "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L
M ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/
MI   0:@  #*L   DKP  %K$   VT   #MP   +H   "]    P    ,0   #&
M    Q@   ,@   #)    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM
M  #?0   X%0  .%K  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0
M-+(  "6U   7N0  #;P   &_    PP   ,<   #*    SP   -,   #6
MUP   -H   #<    WP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T
M,0  ]D8  /=<  #X=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P .
M /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '<
M_P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q
M /X \ #_ /  _P#F /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\
M$ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X
M /( ?@#P (0 [P"* .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /<
MW@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_
M !8 _  B /D +@#V #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .
M=P#? 'X W0"$ -L BP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_
M ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$
MZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#(
M '< Q@!] ,0 A #" (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$
M_P"P /\ L #_ *P _P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6
M -$ (@#- "T R@ W ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '
MLP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P">
M /\ G@#_ )X _P"< /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\
M&P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P
M *  =@"> 'X G "& )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\
MC0#_ (P _P"- /\ ^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K
M "  IP J *0 - "A #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$
M< "/ '< C0"  (L B@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_
M '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@
MF0 C )8 + "3 #4 D  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"!
M '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$
M_P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ;
M (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L
M<@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E
M"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&
M'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP
M &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\
MS2$  +PH  "O*P  I"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N
M#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1
M=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@
M +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P
M810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0
M&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T
M  "E-P  FC@  ) W  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA
M %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP
M1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A
M/   ESX  (T]  "#.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A
M)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026(
M #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0
ME$(  (I"  " /P  =CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!'
M)B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DK
MEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48
M (=&  !]1   <T   &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4
M/RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S
M,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*
M  ![20  <$4  &5   !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I
M #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8
M+#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y
M30  ;DH  &)%  !80   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S
M+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY
M "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@
M;$\  %])  !61@  3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M
M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^
MU  A/O, (CW_ ",]_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,
M %U/  !33   2D@  $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\
M)SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;
M0O$ '$+_ !U!_P >0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4
M  !14@  2$X  #U*   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T
M "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\
M%D?_ !=&_P 71O\ HE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/
M6   1%0  #E1   O3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+
M.  72T( %DQ, !5,5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_
M !%,_P 13/\ GE<  )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@
M/UL  #58   K5@  (E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  1
M4CX $%-(  ]35  .4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2
M_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(
M #!@   F7@  '5T  !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH
M"5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "
M6?\ EV0  (YK  "$;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II
M   A9P  &&8  !%F 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1
M  !D3   9%H  &1I  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\
MDVP  (EQ  " =0  >'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :
M<0  $G$   UQ   &<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O
M1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,
M (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?
M#7P   9]    ?04  'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0
M>TX  'M>  ![;P  >H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_
M  !X@@  :X,  %V%  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD
M  "*    B@   (D&  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8
M (E6  "):   B7P  (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !O
MB   88L  %.-  !%CP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7
M    F    )<   "7!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-
M  "97@  F7,  )B+  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP
M5I,  $B6   ZF0  +)H  !^;   4G   #)X   .?    H0   *,   "E
MI0   *4   "E    I@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L
M4P  K&<  *N   "JF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP
M #R?   MH@  (*,  !.E   +IP   :D   "K    K@   +$   "R    L@
M +,   "T    M0   +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P
MP%L  ,!R  # C0  P:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I
M   AJP  $ZT   NP    LP   +4   "X    O    +\   #!    P0   ,,
M  #$    Q@   ,<   #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT
M -MD  #;?@  W)D  -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4
MM0  "K@   "[    OP   ,,   #&    RP   ,X   #1    T0   -0   #6
M    V0   -L   #>    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5
M  #T;0  ](@  /2A  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P
M_P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[
M (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P
M_P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C
M /\ +P#_ #L _0!& /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X
MZ@"% .D C #G ), Y0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/
M /\ Q #_ +T _P"Y /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0
M*@#R #4 [@!  .D 2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^
M -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\
MM@#_ +  _P"M /\ _P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #>
M "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T
M?@"[ (8 N0". +< F "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_
M *, _P"@ /\ _P   /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D
MP@ S +\ /0"[ $4 N !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I
M '\ IP"' *4 D0"C )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8
M_P"3 /\ _0   /$   #E    V0   ,T   #$  8 O0 / +< & "S "( L  L
M *T -@"I #X IP!& *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '<
ME@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"&
M /\ \P   .,   #1    Q0   +T   "V    K@ + *@ $@"D !P H  F )P
M+P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y
M (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\
MYP<  -$,  ###0  N P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+
M #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8
M?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA
M ,84  "X%@  K14  *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H
M>P R 'D .0!W $  =0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G
M (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=
M  "P(   I1\  )L<  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K
M &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\
M6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I
M*   GB@  )0E  "+(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*
M+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z*
M $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P
MF2\  (\M  "&*0  ?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6
M$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83
MEP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34
M (LT  "!,0  >"L  &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H
M3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]
M&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z
M  !^-P  <S(  &HM  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM
M $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0
M-B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![
M/   <#@  &<R  !=+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@
M,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V
M "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00
M;CT  &,X  !:,P  42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U
M)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJ
MSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(
M &$]  !7.   3C,  $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3
M+RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D
M+^X )2__ "4O_P F+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"
M  !4/0  2SD  $$T   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU
M "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T
M'S/_ " S_P A,O\ ID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !2
M0P  23\  #\[   V-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T
M.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_
M !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020
M1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =
M.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\
M_P 6._\ H$L  )51  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L
M #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX
M%3]( !1 4P 30&  $D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 0
M0/\ G5   )-6  ")6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.
M   L2P  (T@  !M%"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%
M  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\
MFE4  )!;  "'8   ?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H
M4@  'U   !=.!  13 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-
M30 '3EH !DYI  1.>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL
M (UB  "$9@  >F@  '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@
M&E@  !)7 0 -5@D "54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@
M5E<  %9E  !5=P  58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH
M  " ;   =VX  &]O  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(
M  YA   )8 @  V -  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,
M %]A  !><@  7H<  %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]
M<@  =70  &IU  !==   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL
M   ":P8  &L+  !J#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<
M  !I;0  :((  &B8  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0
M<'L  &)[  !5>P  2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W
M=P(  '<(  !V#0  =A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U
M:   ='P  '22  !SJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($
M %J"  !,@@  /X,  #*$   E@P  &H,  !&#   *@P   H,   "$    A0
M (0#  "#"   @PT  (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8
M@G4  (*,  "!I   @+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*
M  !"BP  -8T  ">-   ;C0  $8X   J.    CP   )$   "2    D@   )(
M  "2 0  D@<  )(,  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL
M )."  "2G   D;8  )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   W
ME0  *98  !R7   1F   "9D   ";    G    )X   "@    H    *    "@
M    H0   *$$  "B"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X
M  "ED@  I*P  *3)  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@
M':   !&A   (HP   *4   "G    J0   *P   "N    K@   *X   "O
ML    +$   "R    LP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "Z
MA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H
M  >L    KP   +$   "T    N    +L   "\    O    +X   "_    P
M ,(   #$    Q@   ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@
MU)(  -6K  #5Q   U.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X
M    NP   +X   #"    QP   ,H   #,    S    ,X   #0    T@   -4
M  #8    VP   -\   #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((
M /"<  #PL@  \<4 _P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_
M #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4
MC #S )0 \@"= /  IP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_
M ,( _P"] /\ _P   /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #<
M^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A
M (X WP"6 -T H #; *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8
M_P"R /\ _P   /\   #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [
M ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (<
MQP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E
M /\ _P   /\   #^    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L
M/@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"(
M +$ D@"N )X K "J *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\
M_P   /L   #P    Y0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T
M $  L0!( *X 3@"L %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X
MBP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0
M .L   #=    SP   ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D
MGP!! )T 2 "; $X F0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"*
M (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H
M  #)    O@   +8   "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z
M (T 00"+ $< B0!- (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@
M> "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\
M"P  L0D  *@$  "A    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\
M.@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/
M &D G0!G *X 90## &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P
MIQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O
M #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P
MF !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP
M )49  "-%   A0\  'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0
M8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0
M :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B
M  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U
M %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J,
M10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  "
M)@  =R$  &X;  !F%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,
M-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V
M #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0
M<B@  &DC  !A'0  618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"
M$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05
MS0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX
M &4J  !<)   5!X  $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30
M.18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M
M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O
M  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW
M #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H
M)R#^ "@@_P H(/\ J38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6
M,   32L  $0E   [( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@
M.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7]
M "(D_P C)/\ ICH  )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@
M2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E
M)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI
M_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<
M #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\
M'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9
M+?\ H4$  )5'  "+2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX
M   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]&
M !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\
MGD4  )-+  ")3P  @%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q
M.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T
M3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD
M )%/  "'4P  ?E8  '56  !J50  8%,  %5/  !,3   0DD  #A%   N00
M)#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -
M.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4
M  "%6   ?%L  ');  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40
M !A" P 20 L $#\0  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058
M!D%E  1!=@ #08H  4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#
M7@  >6   '!@  !F8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*
M   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB
M  !(<P  2(8  $B;  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P
M=V4  &YF  !E9@  660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +
M4@< !5$-  %0$0  4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0
M;P  4(,  $^8  !/K@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P
M &QM  !A:P  4VD  $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8
M %L+  !:#P  6A,  %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P
M6'X  %B4  !7JP  5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R
M  !:<0  3'   #]N   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)
M  !E#0  91$  &05  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH
M &*0  !AIP  8,$  %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2
M=P  17<  #AV   K=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q
M"@  <0X  ' 1  !P%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+
M  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P
M/'\  "^    B?P  %WX   ]^   '?@   '\   !_    ?P   'X   !^!0
M?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![
MG   >K8  'G:  !X]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD
M "2)   8B0  #XD   >*    BP   (P   "-    C0   (P   ",    C ,
M (P(  "-#0  C1$  (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0
MBZX  (K-  ")[P  B?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3
M   .E   !I4   "6    F    )H   ";    FP   )L   ";    FP   )P
M  "=!0  G0L  )X0  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4
M )["  "=Z   G/D <(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %
MGP   *$   "C    I0   *@   "I    J0   *D   "J    JP   *P   "M
M    K@$  + )  "R#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T
M  "SU0  L_  9),  %67  !'FP  .)\  "FB   :I   #J8   2H    JP
M *T   "P    M    +8   "X    N    +D   "Z    O    +T   "_
MP    ,,   #%!P  R0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,
MP@  S.( 6)L  $F@   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H
M  "^    PP   ,8   #(    R    ,H   #+    S0   ,\   #2    U0
M -D   #=    X04  .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@
M[,( _P   /\   #_    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\
M3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7
M .L H0#I *T YP"] .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\
M_P   /\   #_    _P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M
M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0
MFP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P
M /\   #_    _P   /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D
MTP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\
M )\ N0"L +8 O@"T -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\
M  #Y    [P   .8   #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!*
M +L 4 "X %8 M@!; +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@
MI0"E *, M "@ ,L GP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J
M    W0   ,\   #'  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *<
M20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"=
M )  K ". +\ C #B (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4
MR    +\   "U  $ K@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4
M $D D@!. )  4P". %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\
MI !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N
M *\   "H    H  & )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $(
M@@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M
M *X ; #$ &H YP!I /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(
M  ";    E    (T "@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !!
M '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *<
M7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/
M"   B    (( !0![  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4
M00!C $8 8@!, &  4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U
M %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0
M?PT  '<&  !Q  @ :P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8
M $$ 5@!& %4 30!3 %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $<
MQP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4
M &\0  !H"P  800* %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L
M3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \
M!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8
M  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@]
M $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0
M,PWY #,-_P T#?\ K2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<
M&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-
M/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z
M "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0
M3QL  $<6  ! $0D .Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P
M$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86
M_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(
M $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D
M*!9* "<75  F%V  )!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @
M&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C
M   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM'
M "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\
MH3@  )4]  "+00  @4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U
M)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@
M3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP
M )-!  ")1   ?T8  '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P
M*B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5
M)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%
M  "'2   ?4H  '1*  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T
M " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E<
M$"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%
M3   ?$X  '-/  !I3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP
M!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C
M  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40
M>E,  '%4  !G4@  75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2
M- D #S,.  XS$P -,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V
M<0 "-H0  #:9   VKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@
M &]9  !E6   6U4  %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ <
M"SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@
M/($  #R7   \K   .\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>
M  !C70  6EP  $Y8  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,
M  -#$   0Q4  $,;  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX
M $.4  !"J@  0L,  $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B
M8P  5V$  $E=   ]6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,
M#@  3!,  $L8  !+'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0
M  !)IP  2<   $CD  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0
M4&8  $-D   W80  +%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0
M51   %45  !4&P  5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2
MI   4;T  %#B  !0^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP
M #UK   P:0  )6@  !IF   19   "V,   1B    8@$  &$&  !@"P  8 X
M %\2  !?%P  7QX  %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H
M6[D  %K?  !9]P  6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S
M   H<@  '7   !-O   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.
M  !K$@  :AD  &HB  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4
M &78  !D]0  9/\ @'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?
M>P  %'H   UZ   $>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X
M#@  >!,  '@:  !X)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.
M  !R\0  <?\ ?GT  '6   !G@0  6((  $J#   \A   +H4  "&%   5A0
M#84   .%    A@   (<   "(    B    (<   "'    AP   (<$  "'"0
MAPX  (@3  "('   B"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#
M[   @OX >(0  &J&  !<B   38H  #^,   QC@  (X\  !:/   -D    I$
M  "2    DP   )4   "6    E@   )8   "6    E@   )<   "7    EP<
M )@-  "9$P  FA\  )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@
MEO@ ;8H  %^-  !0D   09,  #.6   DEP  %I@   V9   !FP   )T   "?
M    H0   *0   "E    I    *4   "E    I@   *<   "H    J0   *H$
M  "L#   KA,  *XA  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\
M89$  %.5  !$F   -9P  ":?   7H0  #:,   "E    IP   *H   "L
ML    +(   "T    LP   +0   "U    MP   +@   "Y    NP   +T   "_
M 0  PPL  ,45  #%)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D
M $>=   XH@  *:8  !FH   -JP   *T   "Q    M    +<   "Z    OP
M ,$   #$    PP   ,4   #&    R    ,H   #-    SP   -(   #6
MVP   . ,  #A&   XRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\
M  #_    _P ! /\ "@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7
M /4 70#T &, \@!I /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@
MX@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_
M    _P   /\ !@#_  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .(
M6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O
M ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_
M^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#&
M %< Q != ,( 8@#! &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\
MMP"M -  JP#R *H _P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0
M .    #5  @ S@ 0 ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$
MKP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9
M ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\ _    /    #C    U    ,@
M  "_  , N0 - +, $P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0
M )L 50"9 %H EP!? )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@
MA0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N
M    IP ) *( $ "> !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D
M3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#'
M '( [ !Q /\ < #_ '  _P!N /\ W0   ,D   "\    L0   *D   "A
MF0 # ), # ". !( B@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X
M $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &,
MX0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0
M (8 " "!  X ?  4 '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $<
M: !, &8 4@!D %D 8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5
M /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L
M @!U  L <  0 &P %@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!&
M %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H
M20#^ $D _P!) /\ N1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K
M  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X
M1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X
M #X _P _ /\ LAD  *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"
M7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!#
M $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4
M_P U /\ K"   )\D  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P!
M $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4
M. -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L
M"/\ J"4  )LJ  "0+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.
M! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE)
M "X*4P L"EX *PML "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\
MI"H  )@O  "-,@  @S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \
M$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.
M4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\
M )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0
M,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >
M$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W
M  "(.@  ?CL  '0[  !K.   830  %<O  !.*P  128  #TA   T'   +1<%
M "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E<
M%Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&
M/@  ?#\  ',_  !I/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9
M"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC
M !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@
M>T0  '%#  !H0@  7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :
M'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA
M<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@
M '!(  !G1@  7$0  %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH
M$B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P '
M)H( !B:6  0FK  #)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],
M  !E2P  6T@  %!$  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-
M  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\
M "N4   KJ0  *\$  "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C
M4   6DT  $]*  !'1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN
M$  '+A4 !B\;  4O(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1
M   QIP  ,+\  ##A   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50
M6%,  $Y0  !%30  .DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !
M-A,  #89   V(   -BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   V
MI0  -KT  #;@   U]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD
M $Q6  ! 4@  -4X  "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$
M #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP
M/+L  #S>   []0  ._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;
M   Z5P  +U4  "52   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4
M  !&&@  1B(  $8L  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@
M $/<  !"]0  0O\ B%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T
M7@  *5P  !]:   55P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/
M%@  3QX  $\G  !/,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8
M  !*]0  2O\ A64  'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90
M(F0  !AB   08   "5\   !>    7@   %T#  !<"   6PP  %H/  !:$P
M61D  %DB  !9+0  63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4
M]   4_\ @6P  'EP  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP
M !%K   ):@   &H   !I    :0   &@   !G P  9@@  &8,  !F#P  910
M &4<  !E)P  9#0  &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0
M7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU
M    =0   '4   !V    =0   '0   !T    <P(  ','  !S#   <A   '(5
M  !R(   <BP  '([  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\
M>WL  ')^  !D?@  57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!
M@@   (,   "#    @P   ((   ""    @@   ((   ""!0  @@H  ((/  ""
M%P  @B,  ((R  ""0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(
M &B#  !9A0  2X<  #R)   NB@  ((L  !.+   *BP   (P   "-    CP
M )$   "2    D0   )$   "1    D0   )$   "2    D@(  ),)  "4#P
ME!D  )0G  "4.   E$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*
M  !-C0  /Y   #"2   AE   %)4   J6    EP   )D   ";    G0   )\
M  "@    H    *    "@    H0   *(   "C    I    *4   "F!P  J!
M *@<  "H+0  J4   *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!
ME@  ,YD  ".<   4G0  "I\   "A    HP   *8   "H    K    *X   "O
M    KP   +    "P    L@   +,   "T    M@   +<   "Z    O0<  +\0
M  "_'P  P#,  ,!)  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP
M)J,  !:E   +IP   *H   "M    L    +,   "V    NP   +T   #
MOP   ,$   #"    Q    ,8   #(    R@   ,P   #/    TP   -H'  #;
M$P  W24  -X[  #?4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P
M /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X
M[0!D .L :0#I &\ YP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2
M .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\
M @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !>
M -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D
MN0#W +@ _P"T /\ J0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G
M  H X0 1 -P &@#7 ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L
M70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M
M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4
MQ@ . ,$ %0"] !X N0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E
M %L HP!A *$ 9P"? &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X
M^P". /\ BP#_ (8 _P"# /\ ^    .D   #<    S    ,$   "X    L@ *
M *P $0"H !@ I0 A *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4
MD !: (\ 8 "- &< BP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![
M /\ >@#_ '< _P!U /\ Y@   -,   #&    NP   +$   "G    H0 % )L
M#0"7 !, DP ; )  (P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3
M 'T 60![ &  >0!H '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\
M:0#_ &D _P!G /\ TP   ,,   "U    JP   *,   ";    D@   (P "@"'
M !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T
M4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_
M %H _P!: /\ Q0   +8"  "I @  GP   )8   ".    AP   (  !0!Z  P
M=0 1 '$ & !N !X :P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!>
M %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X
M_P!- /\ NPH  *P-  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 .
M &4 $P!B !D 7P ? %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X
M4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!"
M /\ LA$  *44  "9%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L
M#P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0
M $, 60!! &, /P!O #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\
MK!<  )\;  "3'0  B1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !-
M !  2@ 5 $< &@!% "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D
M5  W %\ -@!K #0 >@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX
M )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T
M00 1 #X %@ \ !L .@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N
M %L +0!G "L =@ J (@ * "< "< L  F ,D )0#J "4!^P E ?\ HB,  )8H
M  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]!PD .0,.
M #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$30 F!5@
M)05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@  ),M  "(
M+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0 ,0L* "X(
M#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?"U4 '0MB
M !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q  "&-
M?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 & "8-"P D
M# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E, %@YA !0/
M<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$.   >CD
M ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1!P =$ T
M&P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)? ! 2;P .
M$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/   >#T  &\]
M  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9% H %1(.
M !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7;  +%W\
M"1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$  &U!  !D
M/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@ $A<- ! 7
M$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %''P !!V1
M  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%  !C1
M64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+  T=$  ,
M'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D  "&.   A
MI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B20  6$8
M $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC#@ &(Q(
M!2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,   FH@
M)KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@  5TL  $U(
M  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !*A$  "H6
M   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   KH   *[<
M "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$  $Q.  !#
M2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A   #$4   Q
M&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@  ,;4  ##4
M   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3   ^3P
M,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2   Y&
M.2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,  #?2   V
M\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X50  +5(
M ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!%0  01T
M $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0   ]\@
M//\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P  )ED  !Q6
M   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@  2AD  $HB
M  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%\0  1/\
M@6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V   !5>   -
M70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0  %0=  !4
M)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P  3O\ ?FH
M '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG   &9@
M &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7  !@(0
M7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\ >W(  '5V
M  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q    <0   '$
M  !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M&@  ;28
M &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H  '!\  !A
M?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0   'X   !_
M    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@  ?!T  'PL
M  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!  !6@P
M2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P   "-
MC0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,  (\A  ".
M,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+BP  /(T
M "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<    FP
M )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6  "C)@
MHSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP  ,)8  "&9
M   2F@  !YL   "=    H    *(   "D    J    *H   "K    J@   *L
M  "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y&@  NBT
M +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z   !.B   (
MI    *<   "J    K    *\   "R    MP   +D   "[    N@   +P   "]
M    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P  U1\  -<U
M  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\  P#_  T
M_P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!? .4 9 #C
M &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .  R0#[ ,<
M_P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V  L \0 1
M .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L 7@#) &,
MQP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R +  _P"L
M /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8 V0 . -(
M%@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R %T L !B
M *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L _P": /\
ME #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP + +H $0"V
M !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8 G !< )H
M8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"& /\ A #_
M '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4 #@"A !0
MG@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5 (@ 6P"&
M &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\ <P#_ '
M_P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0 !  C  7
M (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8 5 !T %H
M<P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_ &( _P!@
M /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T ?  2 '@
M&0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E %0 8P!;
M &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0 _P!4 /\
MO@   +    "D    F0   )    "(    @0   'D  @!S  H ;P / &L % !G
M !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X 5@!5 %0
M7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!' /\ M D
M *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\ $ !; !4
M6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0 $@ 6 !&
M &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\ K!   )\2
M  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1 !$ 3@ 6
M $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T 4P [ %T
M.0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8  )H9  ".
M&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X 1  2 $$
M%@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q %D +P!E
M "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@  "*(0
M?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  / #@ $@ V
M !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4 )@!A "4
M<  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&*   ?"<
M '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$ $  N !,
M+  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!> !T ;0 <
M 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0  >2T  ' K
M  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F Q  ) $3
M "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&:@ 4!WP
M$P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(  &XQ  !D
M+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T '0<0 !L'
M%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .#'L #@R0
M  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU  !C,P
M62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P. !0,$0 3
M#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D "!"-  <0
MH@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A.   6#4
M $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.#@ .#Q,
M#1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+  $4H
M$[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0  5SD  $TV
M  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *$Q( "107
M  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8GP  &+4
M !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\  $P[  !#
M-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$ !!D6  (9
M'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0  '+,  !S.
M   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M   !#/0
M.SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4   ?&P
M("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(  "'-   @
M[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"0P  .D
M "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F&0  )B$
M "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,   E[@
M)/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20  -40  "M
M   A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@  +1X  "TG
M   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J[@  *OX
MA4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D  "5&   <
M0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L  #0D   T
M+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@  ,/\ @U,
M 'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,   620
M#D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA   \*P
M/#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\ @5H  'E>
M  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   040  "D\
M  %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%)P  13,
M $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$  '9E  !O
M:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60   E@   !6
M    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@  3RX  $\\
M  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L  !N;P
M9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(   !A
M8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@  %HV  !:
M1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I=0  6W0
M $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M    ;
M &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O  !G/P
M9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@  4'H  $)Z
M   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z    >@   '@
M  !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V-@  =DD
M '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(  #:#   H
MA   &H0   Z#   $A    (0   "%    A@   (@   ")    B    (<   "'
M    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+   B#\  (A5
M  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,   ;C0
M#XT   2.    D    )$   "3    E0   )<   "8    E@   )<   "7
MEP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,  )U)  "<
M8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0E@  !)@
M  ":    G    )X   "A    I    *8   "G    I@   *<   "G    J
M *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]  "U50
MM7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0   *,   "F
M    J0   *P   "O    LP   +4   "W    M@   +<   "X    N@   +L
M  "]    OP   ,$   #$    QP   ,L   #-#   SAH  ,\O  #/2   T&(
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P$A   !                     0
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M__________^L4Q       !=MUO____________________________N ,0
M      EAS/___________________________]): @        !=S/______
M_____________________Z@U          !<T_______________________
M_____WT-          !4UO__________________________[GU%
M  !$U/___________________________*ID+P(   0B-TE8SO__________
M_________________^FD:T$H/V-_E:>ZVO__________________________
M____U;*LLLSD^O______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Y;N7=V+(____
M_____________________________]N>9S8*  *,____________________
M____________R'\_!0    !>S______________________________9@3D
M       \JO____________________________^>3          CD/______
M_____________________]QO&@         0??G_____________________
M_____Z](            ;^[__________________________X03
M    9.;_________________________[%$             5][_________
M________________N!4             2-;_________________________
M=!0             .,_________________________YHEH3
M(\7_________________________WYM<+           #;K_____________
M_____________^^Q?54Y(A$' 0(1(K+_____________________________
M_]^_I9F8FJ"LO=K_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^.^G8!\^_________________________________*W
MA%<P#@ =K/______________________________THI,%0      <O/_____
M_______________________6?S8         2\G_____________________
M______J1/@          +ZO__________________________\!:
M    &I7__________________________XTD            "(3_________
M________________YUX              '?_________________________
MM"4              &K_________________________?0
M %OT_______________________]*P               $SK____________
M__________^E                 #SA______________________\P#
M             "W9_____________________YF*82<              "?7
M_______________________MOHE5)P           "7<________________
M__________[*G79=2CPR+2PP.4?>_______________________________]
MYMW6TM#3V>3_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________[]2[UO______
M___________________________GN(]J2R\5;_______________________
M________Y*%G- <     /,G____________________________6@CL
M    $I?__________________________^V%,0           &__________
M_________________Z9"             %#A________________________
M[&D              #?)________________________LR\
M "*V________________________>0               !"G____________
M___________R-                 "9______________________^I
M              ",______________________]&                  !_
M_____________________]\                   !T________________
M_____Y<                   !J_____________________\X
M          !C______________________\I(@$               !A____
M__________________^YHX!7-Q<           !H____________________
M_______ZTZZ4AGQU<7!R=X&4____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________]NZ
MG8)I:=/______________________________\B393T9    '9[_________
M___________________;CDP3         &[_________________________
M_]M\+            $77_________________________XLJ
M "*T________________________PD0               .7____________
M____________?0$               !________________________G-@
M              !J______________________^=                  !8
M______________________]&                  !'^/______________
M_____^D                    UZ?___________________Y8
M           EV____________________[P                    8SO__
M_________________^L                    /PO__________________
M__\                    *N?____________________\G
M       *M?____________________]P                   -N?______
M_______________@G(QP54(S)AL4#PT.$AHFO_______________________
M______GDV-+.S,O,S];@_/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^O3O./_________________________
M_______2J85E2"P2 87____________________________QJW$\#P
M $_@_________________________]5_-0           !^R____________
M____________XW4=              ")________________________D",
M              !G_______________________50P                !(
M]O____________________^*                   NW?______________
M______\X                   7R/___________________[X
M           $MO___________________YP                     I?__
M_________________[H                     D___________________
M_]P                     @O____________________\
M        =/____________________\3                    :/______
M______________]"                    8/____________________]Z
M                    7?_____________________1
M    8?______________________)                   9O__________
M____________R:R9B7UV<6QI9V9G:W!ZC/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^+%JI%Y87?_____________
M________________W:9W4"P,     #'$_________________________^"2
M3A,           "/________________________TG =              !@
M_______________________N;P\                WXO______________
M______^6'                  4P/____________________]
M            H____________________ZX                     B?__
M_________________YX                     <O__________________
M_[P                     7____________________]H
M        3?____________________H                     ._______
M______________\.                    *OG___________________\S
M                    &^G___________________]>
M    #]O___________________^/                    !M#_________
M___________0                     ,K_____________________*P
M                 ,C_____________________@
M ,O_____________________]Q8!!04# 0       08-&,O_____________
M__________SKX=C/S,W/T-+4U]SBZO______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________QVL;_______________________________'&HX1H33(8 !6K
M__________________________^Y?$88          !Q________________
M________UWPO               [X______________________?9 D
M           ,M?____________________]T P                  C?__
M_________________\45                    :O__________________
M_YD                     2____________________[8
M        ,/W__________________]<                     &>?_____
M______________8                     !=/___________________\.
M                     ,'___________________\O
M     *____________________]2                     )[_________
M__________]Y                     ([___________________^E
M                 (#____________________8
M '3_____________________-@                   &W_____________
M________?                    &G_____________________UPT
M             &C______________________W                   &'_
M______________________]0/$9.5%E=861H;'!V?HG_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^_5NZ.+<UJ5___________________________XOXYD
M02$%      !2_/______________________]YU6&              7P?__
M___________________E;!8                 C?__________________
M__]C                    7O___________________YT
M        -?S__________________Z$                     $=G_____
M_____________\H                      +O__________________^X
M                     *'___________________\,
M     (K___________________\M                     ';_________
M__________]-                     &3___________________]O
M                 %+___________________^4
M $#___________________^\                     ##_____________
M_______J#@                   "+_____________________1
M             !7_____________________@0                    OU
M____________________R L                   +L________________
M_____UX                   #E_____________________\D<
M          #:______________________^= 0             '#A?%____
M____________________U;F\P<?.U=OAYNWT^_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^-_/____
M_________________________^S&I8AM5#LA!P RWO__________________
M_____]>262D             H/______________________B38
M        9_____________________]F                    ,O;_____
M_____________Y4                      \C__________________Z<
M                     *#__________________]<
M     'S___________________\                      %[_________
M__________\E                     $/___________________](
M                 "S___________________]J
M !C___________________^+                      7S____________
M______^O                      #A___________________5
M              #/____________________)                     "^
M____________________5                     "N________________
M____BP                    "?____________________RPX
M          "2_____________________U<                   "&____
M_________________ZH*                  !Y____________________
M__]M                  !F_______________________W50
M      !%_________________________VHC*S4_2E5@:G5^AY&<________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________H
MS[:=@VE.N?_________________________LLH-<.AT"        >_______
M________________Q6TI                0/____________________^#
M&P                  !\O__________________Y(
M     )C__________________Z0                      &K_________
M_________]T                      $'___________________\.
M                 !W___________________\Y
M  #H__________________]@                      #.____________
M______^%                      "W__________________^H
M              "C___________________+                      "0
M___________________O%@                    !]________________
M____/@                    !L____________________:0
M          !:____________________F0                    !)____
M________________TA8                    Y____________________
M_U@                    I_____________________Z(
M       9______________________56                   $________
M______________^[+P                  ^/______________________
MJRD                 S________________________\E'      <3("X^
M4FB$[?______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________35R?______________________
M______K2L))W74(H#   2O_______________________\5]11<
M    $=C____________________$4                    )__________
M_________Z(,                     &C__________________Y0
M                 #;__________________]H
M  ?L__________________\5                      #$____________
M______](                      "B__________________]U
M              "#__________________^=                      !I
M___________________#                      !2________________
M___G#P                     ^____________________,P
M           K____________________6                      8____
M________________@0                     %____________________
MK                       ____________________WB(
M        \O___________________UP                     W_______
M_____________Y\                     S/___________________^A*
M                    M_____________________^@%@
M    G/______________________>@(                 =___________
M_____________WH+               %3/________________________^B
M5VAT@(V<J[S0Y_______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________MX___________
M________________TJ-Z6#HI(QP6#@8  )______________________K%(.
M                 &G__________________^1#
M #3__________________WD                       #C____________
M_____\T                       "R__________________\3
M              "%__________________]/                      !=
M__________________^#                       Z________________
M__^R                       <___________________; P
M           "____________________*@                      ^___
M________________3P                      Y___________________
M=                       U/__________________FP
M        P/__________________Q <                     K?______
M____________\#,                     FO___________________V<
M                    AO___________________Z,
M    <O___________________^-$                    7/__________
M__________^1!@                  0?_____________________K7P
M                '?______________________RDL
M /_______________________\M7   ,&"0Q/TY@=(NGQ_______________
M____________U^?R____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z]3-Q\*^NK>SL*VIJ*7_____________
M_______=?E,_,",9$0D"          #;_________________W8
M              "G_________________[H                       !U
M__________________\'                      !&________________
M__].                       :__________________^,
M            _?_________________!                        V___
M_______________Q&0                      OO__________________
M1                       I/__________________:P
M        C?__________________D0                      >?______
M____________MP                      9O__________________WB$
M                    4____________________TH
M    /____________________W<                     *___________
M_________ZP*                    %O___________________^=%
M                 /____________________^*
M /_____________________630                   /W_____________
M________IRX                  -7______________________Y@J
M       &&"U%8.#_______________________^H8W2!CYRKN\WB^O______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________Y\NWJ9V5CHF$@'QX='!L:&60________________
M_[QJ2"T9"@                 Q__________________\
M           #__________________]"                        W/__
M______________^.                        LO_________________.
M                        C?__________________*0
M        :___________________6@                      3O______
M____________A@                      -/__________________K@
M                    'O__________________U!<
M    "O__________________^CT                      /__________
M_________V4                      /___________________XX
M                 /___________________[P9
M .____________________%.                     -C_____________
M______^+                     +_____________________,0P
M             *'_____________________D1D                  'K_
M____________________\G0*                $5__________________
M_____^AT$Q\L.$538G*%F[32]?__________________________U^CT____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________[]_/Q[NSKZ^SQ____
M_______________9LIF'>6UD75912T9!/#@R+2@CQ/________________]+
M)0L                     DO________________^(
M        9O_________________7                        /?______
M____________,P                      &/__________________;
M                     /__________________G0
M     /__________________R0P                      /;_________
M________\34                      -___________________UL
M                 ,O__________________X(
M +?__________________ZD&                     */_____________
M_____],O                     (W___________________]>
M             '?___________________^3!P                   %[_
M___________________-0P                   $#_________________
M____AQ                   !S_____________________V%X
M          #______________________[].       .'"P^4FJ&I<C_____
M___________________"?(R:I[;%UNC]____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________NX=?/R<.^NK:QK:FGIJ:GKO______
M__________^^AFU;3$ W+R@B'!80"P0     %/_________________7!0
M                     /__________________-
M     /;_________________=@                       -+_________
M________L                        ++_________________X20
M                 );__________________U$
M 'S__________________WD                      &;_____________
M_____Z                       %'__________________\<C
M             #S__________________^Y+                     "?_
M__________________]T                     !#_________________
M__^C%@                    #____________________83
M          #_____________________B \                   #_____
M________________RU,                   #_____________________
M_Z4X           )'31.:XS_______________________^9.4-17VY]CJ"U
MR^7_____________________________Z_G_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_________
M________844R(Q@.!@               )[_________________?@
M                 '7_________________PP
M %+_________________^S<                      #+_____________
M_____VH                      !;__________________Y8
M              #__________________[\;                      #_
M_________________^9"                      #_________________
M__]I                      #___________________^0 @
M          #___________________^Y+                     #T____
M_______________H7                     #9____________________
MD1@                   "\____________________RE,
M      "=_____________________Y@N             ! I1F;$________
M_____________^Y_'0P:*#=&5VE^E:_,[O_________________________G
MH*JYR-CI_/__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________WU\.OFXM_;V-32T=#2
MU^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____________
M____TB41 P                    #__________________T(
M              #__________________WT                       #_
M_________________[ +                      #V________________
M_]TY                      #<__________________]B
M          #%__________________^)                      "O____
M______________^O(@                    "9___________________6
M2                     ""____________________<@
M      !I____________________H2@                   !.________
M____________TUP                    S_____________________Y8N
M               5,E)W_____________________^!R$P   0\?+T)8<(NH
MR.S________________________*;VY^CIZPP]CO____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________G@TLC NK6PK*BEHI^=FYN<H*?_
M_________________X)D5DM#/#8P*R<B'1@3#@D$  #4________________
M_Y(                       "M_________________\P>
M          "+__________________M2                      !M____
M______________^                       !1__________________^I
M&P                     Z___________________00@
M       C___________________U:                      ,________
M____________CQ0                     ____________________N#X
M                    ____________________Y6T#
M    _____________________Y\W               0+U!T____________
M_________]UR%      &%RI!6G64MMK_______________________^\6$14
M9'6&FJ_(X_______________________________TLWA\?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U>'^0____
M_____________^M/.C H(1L5$ L' @         C__________________]I
M                        __________________^;"@
M        ___________________(.0                      ________
M___________P8P                      ____________________B@X
M                    ____________________L#0
M    ____________________U5L                     ____________
M_________X4:                   #[/___________________[%)
M           8.5V!_____________________^5['@      #"$X4F^/L]G_
M______________________^[6"DY25IL@)>PS>W_____________________
M________LYZTQ=?K____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^N_GX=S9UM32T-#0
MT=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q________
M__________^_,1\6$ H%                ___________________M5@
M                    Z/__________________@@0
M    S/__________________JR\                     L___________
M________TE<                     F___________________]WP0
M                A?___________________Z(W                  4K
ME/___________________\MA @            PL4':>T?______________
M______6-,       #2,[5W:9ON7________________________#8Q@J.TQ?
M=(VGQN?_____________________________J'^6J+O0Y_______________
M______________________W_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________W<[%O[RYMK2SL;*RM;G
MR=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__________
M________IR8.!P(                 5O__________________SE
M                .O__________________]'D+
M(?___________________Y\R                    #O______________
M_____\18                "#%:A/___________________^E_'P
M    !B=+<9K"Z?____________________^G20     "%R]*:(JNU?S_____
M___________________3=1XF.$I>=8^KR^__________________________
M____KG*%F*S"V_;__________________________________]_O________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________[^RJJ:CH:"?GZ&CIJRTP,W=
M[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______________
M_____YXN!@                   /___________________\-6
M           50?___________________^=[&@             )-&"+M/__
M__________________^?/P         $)4IQF<+K____________________
M___&9@\    3*D1B@Z?-]?_________________________KCC4K/E%H@9V\
MWO______________________________OG9_E*G!W/G_________________
M_________________]+8\_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________]O+P[^_O
M\?/X_?____________________________BPGYJ7EI:6F)N?I*RVPM'A[O__
M__________________Z.4$I'141$1$5&1TM16FB#J?__________________
M__^F00$           <V8X^ZX?_____________________&90H       0G
M3'.<Q.S________________________EB"\  !,J1&*"ILST____________
M________________JU V2F%[EK36^O______________________________
MTH=\F+'+Z?___________________________________]3.[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________[>7CX^3FZ.WQ
M^?_____________________________]L922DI69G:.ILKS0[?__________
M________________G5-'24U15F!SBJ_6_/__________________________
MLE8 &C50;8NNTO?_____________________________S6\^7WN9M]?Y____
M____________________________[I^#IL+A________________________
M_____________^/.Z___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________P
M
M
M____________________________________________________________
M____________________________________________________________
M__________________________________________________\     _^%
MMVAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@
M6$U0($-O<F4@-RXR+6,P,# @-SDN,6(V-6$W.2P@,C R,B\P-B\Q,RTQ-SHT
M-CHQ-" @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @
M(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @
M(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]E>&EF+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^36EC<F]S;V9TPJX@5V]R9" R,#$Y/"]P9&8Z4')O9'5C
M97(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@5V]R
M9" R,#$Y/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(R+3$Q+3(V5# R.C R.C(T*S U.C,P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C(M,3$M,C94,#,Z-#,Z
M-#4K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(R+3$Q+3(V5# S.C0S.C0U*S U.C,P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I
M9#IP:&]T;W-H;W Z8S4U.#(S8C@M939F,RTR9C0Y+3AD,3@M,#<X,F1B.3@W
M8V5A/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.F4T-C P83-A+6(P-S0M868T8BUB,V4W+34U-S0P,3!B
M8C8Y-SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$
M-#!&-C4T1D$U-CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z93)E83(U9C$M9F8U82UB.#0Q+3DX-S,M,6,R,6(R,61C,V,Q/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(R+3$Q+3(V5# S.C0S.C(W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C9D-&0P
M,S R+64R9F4M-#,T8RUB,SEC+3 R,SDS9#0Y.3 W8SPO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ,2TR
M-E0P,SHT,SHT-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.F4T-C P83-A+6(P-S0M868T8BUB,V4W+34U-S0P
M,3!B8C8Y-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,BTQ,2TR-E0P,SHT,SHT-2LP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @
M(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z
M-F0T9# S,#(M93)F92TT,S1C+6(S.6,M,#(S.3-D-#DY,#=C/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YU=6ED
M.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$-#!&-C4T1D$U-CPO<W12968Z
M9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$-#!&-C4T1D$U
M-CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-
M.D1E<FEV961&<F]M/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^4W1E<&AE;B!-
M83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D
M8SIF;W)M870^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z
M3W)I96YT871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C$P-C4W
M.3 O,3 P,# \+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE2
M97-O;'5T:6]N/C$P-C4W.3 O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @
M(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO
M;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z
M0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C8W
M-3PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L
M641I;65N<VEO;CXS,3 \+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" @
M(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E
M/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!796(@0V]A
M=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!%P)@ P$1  (1 0,1 ?_$ !X  0 " @,! 0$
M       %" 8' P0) 0(*_\0 91    8" 0("! 4,#@4&"0T! 0(#! 4&  <(
M$1(3% D5%B$U5764U!<8(B,Q-E1SDYBTTS@Y05%76'=XM;:WN-?8)#)A<;,E
M@9&RP? 9)C-"4F6#DJ$G-#=#2&)RA8>5EJ2QX?_$ !T! 0 !!0$! 0
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MJ)TKBLW3C?[9FFUBAT^XBRVXCHK4,J'0&TE:%S#98U  Q4PY<DCR:,E&<O\
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MJ-MFU&$[&XZA6@:>P98&W7OAJ[*;E1=0[>N^DV35T;9[!-5=2TP$6#4PA&<
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MD,QWD7GVGWW(>([G0\;V-;4;/<5_P\MC:]WQKZ^SVO8PGV5.*+%BK)U@(ER
M YA3^:!G.+5VN=STB"4JZJ.HZ]3:MK9E2=:T6G/+6I$-9!D1- DG8Y1_"L%S
M)"T021 &,2NY!11VY5.NLX$0S[VW0VX;%I-V%C9;:^=BW>MKK+]JL];1>JNE
M+3$CEC?<"))2A%2DC !$SD+B&FY+QP-?1]OCM'1:'0AK=-IM8_8V!;?K&F:M
MN_=MU$.A?MIE3_!=AS3>ZVPF.F(FL^O>%.VJCPHVEQ9D+7KIU/W:6N#V&M#,
MUE]3M6UTF33#XLFU7BTWH+QZAS-VGE2K)N2 "BQD3"),W.VY#K[^_P"-;A*;
M@*TD:H'I;"/<<&IZ]J4R#)&"?\^Y!S$+^/&2[GKDN+>GO(]'P/FG$[=S2.N<
MCM\CN4;5<[T5D'R,F$Y=N&U8;X5).(42@9+HB?,0S!G7H]=K3$W>;!*7G7[-
M]-1''L]:1CAM"[5M8M#(L$T"SI%H]H+F$L/@NO%!OXCIEU;G(BJ<#=D^OR^C
M2*BRO5M,*IR?E&Y.'PB!.ERA#JKDC(F4A:JJ)1J+KVS9[@D0C$$6BN^D&^W"
M=C5V>RU"$6N&<%T2#H'?-H;?@^S7N*[WBZLH3UMVV3DM6)>^%<%$(RQAP&5M
M."^TO$F++(7.@J71IR9DN1=219ELJ%766L%6&L3%:L:1F9GA"MTNU>+DF23M
M0#=X*H)%.8IM>'(J*:VHI)1:E%3AVYX7>-OLRTZ6UNE>&]4Z/Q&RIA0))9XK
M,!Z]SLNQVC/2_>6K>_VMS8ZJ-C9]4N.>JVE36FZND&TTFH1J&:?:R29:=!R%
M&2[5<">+6BV41[$ VQ].XY6'6_%"3T%5IV&E[/(U^TQYYNPGDVT"63N;Q^[E
M5B%9MWLBDP8FDW'JY J G,5%!-0$0.<Q-/O-DK=;-5@ULKTUIH4X@( K/TFO
MKJKK.8[%9V6"D29,E S)%^:>HF>XXKQ.UQ/B-G257HN;.RS>; F66V(H?B>\
MM6KSE"?@VPN@E]J05 JDQ2$=*B9\8T!J?@K>&1.,\5N2V4R1K?%>'ERT>/HJ
M<X9Y8K;)LS,6]DGGDTS8>01B$C%<,HIBFZ(J]0257="GW)9T6YY73MW.5;/7
M(N)O\JHKU;BL2D5T-?(2%H$>T9D]]L"-),; BI+#@ EG1QYYQ'TEW%#4>G/'
M>47=+;TOIM?_ !N@&K&X5C;[U!O/5VKLVTJ&G7U37?5I37)I/M+633A8^$X$
MCZ->?BM+;HUI$V.KO;9?(V?J=4V'/VC:<@JRI5BMB%K7CI>IO)21J4.[9.T1
M,!JK#($DW*AW3E9L=1<%[#Y<#;'&W2@TJU=O2W=G516H0-JSHJS:U9J+<J&\
M4- A"4V'^W77)"OW8%<#D5Z/VJM#GR$W:]K8<CI<OUNAV-[:\D-="AS.S%B_
M6N:@KEC3URIF1L78UU*'7& OW?IO<>1X\IZ._?+BZ/K6M==1)IR&S]([&6:)
M*7(QT?J00K&&-%I*&@R%.$R1H9<JYP+Y4QRD\-0 $^;"ER_45)J=UMDR*O\
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MO ,K4XO[F_P]IK9Y]"(%XG?4+W'1THH4D;/)M!<)>1=+QJR+Q$/#>LEB.$B
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M7">1U]'3H$B7IBK0TB$Z$NF"2*,D_DT$RI9G?RG86$7EFFF-C8VM/L+.P +
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M;G7I6(*+)M&JSUZJ1NT\5;P6I$TCJJF RAAFL54ZZ )5;7TJM"J!'YF**JX
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M3E)%TY>O5P32(==8P)))) 1(ES&>Y[0P *4A"*M="HF%(K55 BNA<$1EX+4
MC$F9F4Q)L,S(BFT D9:9L-S7N;9>YLC+'/><FUAR(@,213T(@(K6$"M8 L
M:W7?]L#XQ_S.>=/]M?H[,Q?K']T_],R?I/\ ?'^19<;*Y3&,8QC&,8QC&,9I
MO>NJY7<M!D:%'WE_1&LT"K::?Q\4VEE9&*7:KH+1ATG+IF**2BBJ2XK(KE5
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M<4IP(K=ZY1S6][K"U:OUQ.U,KDWK5(N6TW">S[C%5XM=@;YM*ER,S&:JC[7
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M6R^:0-9Y-52]Z?=^D4P*\,$"A?DL)&XS,["K4D4/2]=I; F5=6E)FNJT0K\
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M_=/_ $_\^W\OUK^D_P!\?Y%EQLKE,8QC&,8QC&,8QC&,8QC&,8QC&,8QGP0
M0$! ! 0$! 0Z@(#[A 0'W" A]T,??[X^WVS'9>GU.P(&;3E9@)=N?_71DHA@
M]3-U#H/<5P@H ]0]WO\ W,UUO4:J^$KNZVC;67?D%BHAPSW]^X8!1/\ CFRI
M[C;:\X;1V=^FP?[)UK=A)1U]NI6P9CKJ.NL\I^9_"JWWVS5<O'K4%$@H-K&O
M'=EE(=U5ZDO+33QT!$6SEBHHP,J1@V0%P5R4BA5U9 X&'O0]_P K^LWHOM]_
ML=7'I_Q#14J2J[G;*U4=K-2RU=:V(!;4D:),4+7+/.!*&'8+N8)?<_6'HKZW
M:?C^KVL^HG,=_?ONM)5K*EQ.TVZZE)*IDVK>(V($K#6>W*YD9 *T=1XLC/SQ
MXX+;-CZZNUV#;-IZ=M4<Z=>J9O7&SX9S#OH\"L 8HNX1HW?.$'B7BR"!EVTJ
MS1,V9- ,@"IS&4KZ?>AW)4:TU<@VW*>(;:NUL5;W'>3TV5'UND0@6T4@XUN'
MS>$FNRD/;0KL?,I(Z^HWKOQ>SL@=QW4<5YEJ;*E?5T>2\6NJNHLR5CZ@TWFM
M0HTEX5V0#*CCACW=,\1B!LB30O+JH!THO+7VD;E]Y&&SJ*QE#F O4027FC+3
MC\X&$"]RZ"+50 $P 4W3[/T4>">K6HCK1^K'XBN/LCDVB3:*>OF!9=]RZ\HG
MJ(DE@HNIGK[?F\U+G_I!N)[WWI%^&LG^T_B^]?5&)G[DND*Z%<>NYZ!AM'N(
M_-\QX_OVHY_U,>V4UQH[:#1 ?LEZM8)>J2:Y ^R,IW3;X6YA$.J9"(PR1^X
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MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8R)D8""F"F++0L3*%,':8)".9O
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MS6ME2B-^IDJ[UAN&+ 58F_5L/+*NUB=IDVMD9(BFE,,%#$*5;Q0\R!!-VJ&
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MT"G[,KCZIWB!C[#!2"9B*LWZ!%?".)1*5RU5$/%:.D@,/A.6YTU2=1 #=IC
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M.4DC]0'H A[\]?T?(M'R6F%_1;.GLZIQ$^Y5<+)#RCN!:ON&)/\ >+ $OO\
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MR>2;-VS&O;J.IW;HIHS5LL*Q"Z-RFP"BPM"_,V&$0R1\)(A(?- .;_I>Q_\
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M68U@W:^7$]%J(ND)&1;).V[!](',JZ62:Q9UC^8:[WH3=M49@7M'85:"S&3
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M8QC&,8QC&,8QC&,8QC(.>K-=M#-2/L<'$SK%9,R2C658-GR)DS_ZQ.QPFH
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M%%KHRAK @NK'76W+-717"4,R9?;HSO*_<F$54TSJ-^/Y2GC=4*HZ*Y<V8N9
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MO9XULN7/MHN:<M9:8_0\C-[Y96]ECC.=-(R\C_:^Y\=,B"CKJ)'^@RLNYU]
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M4[VSN5Z-19J6=FRP5*$WM!*ADRF(B388C'\9[GJ(F8GZW5['<6PH:JE8OW&
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MX=G_ ,7$?H[C&,#]\Y/D%3^D$L8R>QC&,8QC*<W?]L#XQ_S.>=/]M?H[,?\
MG_G\\K^D_P!\?Y%EQL93&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC,8NMSK.NJ?9[[=)=G 5*FP4I9;)-OU2HLXN
M%AF:S^0>KJ&$  B#9!0_:'4QS !" 8YB@,+87ZVKI6+]LY!%<((O 98UAD4+
M4A"A[-UFPXP160N)8][%I6)&8Q.>K6=<L*JH&":XX (DA 8_4C893 +4L8EC
M6G(@I8DPR$!F8K?*<W./\+I?2F]Y2Q23*D<@YK7=?U8BO$J$L<_*;/DV,764
M!@_&\=J4JD@BYE555/#C695%5C"<")*;9U5J-[K^.-@8VVR"PRM7@H*(75T[
M=W8-K![$ 533(D791+S6H9GR\HB(:NSK]KM4EY4-,5T+E@H(!\J.Q;JV"H3@
M383K26?3A(BQBAEDB,"?C;?(V9,8QC&,@*M][D*'_JYM_P ,,8S]2_PA5OEY
MQ_5BQXQD[C&,8QC&4YYY?L<G/\MW$S^]EI+&5C[_ .!?Y3EQL93&,8QC&,8Q
MC&,9B+/7]#CY.PS;"DU%C,VY(4+7+LZW#-I.SH"F9(4;"_19$=320I'.F*<D
MJY)X9S$[>TP@-O@$UCIR S4.6$=7QCZ8R;$PTC1U[12R)F&3(S)Q,P7<3.7>
M9^ZM_F7OJ@84[RGW5P$Q(PMG?F$#(C(^)1U(Q,=3$9#QVGM1PY6Q(C5FN8LK
M([A1F6.I%98E:*.V0QKL[8K:,2! [J.$6#@R0$,LR$6J@F0'P\O.98)BR9,6
M).NP3GR%E=LB3$'!=P26$ 2:BB0.0&2&9&.K B%R)!$ 0,6X"#\LBY4F2FC,
M=2+%RQDK..B"3.1F)(NX,_';C\HBW;J:+TX=NT3.DT0/K*E&1:I** LHFW2-
M""1%,ZQ05.1,I2F4 #F 3  Y=#&0P709PT95(M@BA@RB2E$B<3Y1*9(I5,3'
MMR12'7<XZCJ1ZCQF2*8ZCJ2.(@YF/M,G C!3]R@8[[ZC):XZ@U]?7L*]M5=C
MI8L(U<1I(UZR8O862AG7A&6@IJ&?M7<;*0XKMVKM)FX;"#=VU;N&QTE$P$<<
M1$-8XHAA-"!9#(@Q(P.32_HNYBR@B.4/B88$-:/<@PQF[LH2"!(EK6R& *YE
M?CT$K(/R]1*C7/@:IB0*(&>HD8F.R]U)J]^I'.5]=T7S\(L+J DPI]:4D:\_
M\BPC4Y&#<KQ:QHQ^@QBHIHBY; 0Y&T7'-_>@R;I)WD;9.6PYH/D'!%@#F'C%
MAS[+O%D]E'NV;-BRR)[%CWN:R"-K)*T16*HK^TLJW:9*J0Q].<5PA2!-,=!(
MJ5$*7\1*U?D7(C$1'10TWKM6#;P-FK41?T49QS9SO;_#05G?.;*[\0J\^KYR
M**R1E114,V3=,6304&G1L@5-$.S*3X^2"%:UE64:4$ ]$L''[ECQ*9DAFR[M
MUGHHAS9DSB9ZZK/D7U'F1'%DUDX2Z\#A @NL!!$0)A64M:D><$8+6$24E'E/
M35X_:%703:KZ1U$LU255<)-E=;4U1!-==!-LNLFB>%,F159LDDW54*4#J())
MI',*9"E"G_#_ /*) /\ \H%UY"/[A+Q'R&/B>H[CXC*]SV9=SY,-;#G]38DF
MFDSG[D:C>XUE/9 3FD,Q+#F9ZCZRI^NS3!JK%IQPS3A!5P1(C=!LU:LT0;QL
M1%LF:#5C%PL6W 4F$:R;(H( =0X@=5110U_N'*A41D?1FTV,*3:YS.H)KV%,
MDQD+!:0F9Z!*EJ"! (C,<+ 3DQ$0Z 5+ !$%I4)&<*4 Q$ $M8UQ1\R;6L84
MR13.9_EF7XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC()A\.S_X
MN(_1W&,9\'[YR?(*O]()8QD]C&,8QC&4YN_[8'QC_F<\Z?[:_1V93]?\)_Z?
M]LK^D_WQ_D67&RN4QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8SC5#N24+VF/W)G#M*<4C&ZE$.TJA3%,F8?N <IBB01 P
M& 0ZYC:/DI@P,E)+,8$3E9%V,QXBR)&0F?M!P42,SY1,3'>7!/1C/<1T0SW(
MP41U,?,C,3!1'WD9B8F/B8GO/YQZ1Z-;<T_N4K?8VECUG7%SN_)Q/9&RE]F:
MDW19W6O]D6JHW'5C%]5]YU_<$#;V%=F:DLL$%;*E8F]<5GC/:^V8R3<KYKBT
MM4%ZJM1V$C7]KB.FJ,!::U@6\CTN\LWZUETG7;!OC46&ZH=L$C?\6DLK,5Y.
M9E;2ZPKUB_2%MET<H4^K++5NO[/';G#=QQC;UD"FRB$(;>VE#;3K(**+HTPB
MVLZ6#7;<)7T4D-KJJ3K#CWM6"K,O-NXV1G&-YXN\5?9FTEK2,D^K<1*,N..J
M^*TTX(QM"\78V:\_9[#&,I6%CG(0B@$7*M&W2KES4WJ*(%HGK=XM-:76:YGL
M-EJ7:I-A5@;$TZ[E4[-ZJM]G77?:F_\ 5 (6*=1BL565!<K6&,<DEN0+&IE?
MYJ464V+=5O[*;9UK4UT!;KU;M-=ZH+]=>BU1N6$%7"5]&[S7D.+?%6E!N'3Z
MVQ=+M^/T4\J4CJ-X\C:BTU]L6N6J?D8&VI;K9LI%RS:1"!Y8A(5)S<THM"-8
MO:XFY**'16+(ES+5[T6>]679KG:L^S"7(37X;O-)*07)&VQ6=9V0J&O+(E%E
MI;3W&K5-,X"U3.GY%1: ^=ZSRM]-00N!L3NN2KV:62^5DVH\ZZY;Y2;4(4<4
MRK'8$[C?Z FI'*;5LF\72<NR-T2.G*#<S1%PY*F4JZZ+4R[HS9)54#*)MS.7
M!D2&!,5U1+XAH3)63&2H"6J3*5K,X88+DID )D N&$(]"1PL(*8DH >_&,B1
M:*5"]@->*P%S5KE*VM@8AC 3+'2H#.)(5RUL@,P,L.8\IY\LS)C&,@:M][D+
M\G-O^&&,8E_A"K?+SC^K%CQC)[&,8QC&,ISSR_8Y.?Y;N)G][+26,K'W_P "
M_P IRXV,IC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,@F'P[/_BXC]'<8QGP?OG)\@J?T@E_W^[_
M -/[C&3V,9T).5C(5BXDYF181,:T)XCJ0DWC=@Q;)]>GB.';I1)NB3J(!W**
M%+U'IURTB$>O(A'LH&/*8CLBGH1CO[D4_$1'S,_$9<(D<]")%/4ST,24]1\S
M/41/Q$?,S]H_7.=H[:/VR#UBY;O6;I(B[5VT63<MG*"I0.FL@NB8Z2R2A1 Q
M%$SF(<H@)3" ]<R$) 4@8D!C/1"42)#/[I&8B8G^$QF,2$Q@@(2$H[$AF"&8
MG[3$QW$Q/[XG*@W?]L#XQ_S.>=/]M?H[,M_7^?\ T_TR_P#2?[X_R++C8RF,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8R!J_WNPWR>W_ .H&,8F/A"J_+SC^K%CQC)[&,C)J7CZ_
M#RL]+."-(J$C7TM).U!Z)MF$<V5=NW!Q_P#11;HJ*&_V%',-FPNK7=9=,PI"
MC:R1B2+Q 9*8$8^2*>NA&/DBF!CYF,RH2RPY5=0^37M6E8_;R-A0 1W^G93$
M=_IFFM3;[A-JR3B(3KEBJ4F:N1-TA65D(P(O/4N>,H6(L3,C%V[\NDY\/JK'
MOO+R+,5$RNFR8G ,FG6:L;$,B L4K(T[]:9\F4[)JAPK80]K/L?(?-9F,,6:
MYF"'K(OO+(D^$^:+2VNIV8^%6EH;[+37$]'$"4B0^8C[BF T.P*)S6//+]CD
MY_ENXF?WLM)9@S-'W_P+_*<N-C*8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9Y@6*W^DP#;$Q&-J5KLNC_;!XT)-
M'UC3$)=/7POSIF?FM!.?D1,(/B0PF6]<DUI'ODE0\V6JH*E!B6/KO;951_6$
MHKJ.N7XF2CFE"AE1^[(L2S937B/T);+$A'S#._SCDO2:F-G4#[S0,)I"T!M0
MQD$'B)J<-(7>1=QX'"A+^S(E'Y2K1$6/6]'V/R7V9PSDDIIE<*)2]8*Z_P!&
M/FFT[-)W:+MTX&PN3$Y0H^>D)07=596%A64)V1%"8MKMD]<29Y)JSBUQU\_4
M1Q?8U4%:'3[C;U;5%M9<?3<6TM3CFP!CJSO;8O7MY@RIX)K0F*R6ZW6;)@PV
M]>)&1HK_ !G76#%3]CI=?MJNQ7:LDM^_V6QVNH*IKK)NACKJN)Q2MO.Y'UL"
M'(MAKE2$TA58M/Z)"U/+3PBUV>13V$H_B)V^1#N7V7&NV%CGU6URFCC++*NP
M(+\5P4 CET@FBW*^3=-DD4BH>&7J[XK^CXXQ0(4#>+Z&82B9D5R&O2LIZ*2.
M09(2U+6$9V$F#R(I9,SJ4R4;?EBC-["7RO=3+7Q,27O6/>@([^!E/G[1I'\M
M<PE$=>WGI?FLR=C&,@6'P[/_ (N(_1W&,8'[YR?(*O\ 2"6,9/8QE2^4IFZ;
MO1JUD.@37"&W(M6^F>B 1)6014F$*::$YBM@BRSHL17,[$6Q3@F*@"'3IC1[
M7XK7^H\/:G6[F*_N>/C]=-.?9_M?'G*?J(3$?FELCX_/67.ALZVY"(*6>_K/
M=\.O.:<7E3:B(_M>/CXRSQ_W(GOX[SN\/"O0T\N*@+%@E-C[15HY52JE3"AJ
M7F:/5A9%5 #A&C'"4T:'0">1%#POM79DJ8;&OT,6?/ZT=!JHO0SOW8L17CQA
MW<R7O16^GAT'/G[L'Y_F[S!,@6QWI(E<TRW-N:?M=>U[?MHBS*Y'H9"=C%V1
MD/R3$Q(?DZRG=^LW-@O//0"C72?%I650XL\UV]9:..46V6\?)U53<O XTQ*S
ML@GQ <N8*P,W+>IIQM?CXRQ1TDA+6)=U9HI2O1K>SX/G_P G^[^']_Z_]L_Q
MU/S/WC](_C_'+3>UWI ?XOO#K\\+=?\ D:ROS_Y/_;*?'[Y_E'^N/:[T@/\
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M_P#%Q'Z.XQC _?.3Y!5_I!+&,GL8SIOX]A*M%6$FQ9R3%P7M79OVR+QHL4!
M0*JW<$414* @ ]#D,'4 '[N4F(GKN(GJ8*.XB>BC[%'?VF/TF/F/TRL3(_,3
M,3,3$S$S'<3\3'Q^DQ\3'ZYSH-T&J*39J@BV;H)E20;H)D1112( %(FDDF4J
M::9"@ %(0H%*     9<1$4R13)%,]R13,S,S]YF9^9G^,Y;$0,0(Q C$=1$1
M$1$?NB(^(C^[,%<WC6J=]85-W8:L78Y8UVE&Q*SED-E2BY,S-\^:-.[J[1;R
M)H=@\<LDU" ]&+9N5$5?)('2HK]O[WL_M/IXF7>'YO;@?#R\NO\ @]Q?GUWX
M>8^?7<95G[*%2W\D.F(5)?'G,R41U_\ A2!0,SU!2,P/<QUF?XQC&,8QC&,8
MQC&,_"JJ:*:BRQR)))$,HJHH8"$33(43'.<QA "E*4!,8PB   "(CTRA$(Q)
M%,"(Q,S,SU$1'ZS.5B)F8B(F9F8B(C[S,_$1'\9G-6ZMF]/OT+3&ZCD:DX1;
M6N>GK<RJRS8?!M]RE7MDL$K+((B!RR=AEWK^7=NE2@+YTX7< <XF,.7P)$E=
MB!F4-(P6WJ? C7 RP8G_ (@@PDAGJ8@AF8ZF,M(H%IH*8ARQ$C7,_G$"DA$I
MC_ADEF,3'QV)1WW$QFU<MRN,8QC&,8QC&,8S';<RK$G5;'%W9&*<T^6@Y2*M
M#2<%$(9Y 2;)=C+LI0' E0.P>,%UVSM-40(H@J<AO<;+3,%C)F4 ,?>2GJ/G
MXB/[YGXB/O,_;+A$CF!&)*9^T1'<_P ?\(^\S]HCYG.I1I^FV.L1CV@2,5*5
M1LB$5$N(0Y5(Q)O% #$K-H8@ 0$F942MR%)U(4J8%*(@ 9E-9K\/,2'S 6!Y
M1U) 7?B74_/4]3]_GXRR"&2,8F))9^!Q$]^)^(GXSU\=^)C/QW\3&9;EF5QC
M&,8QC&,8QC&:DMMCTNCL*AQMSEZ:ELF&<OI'7K68=-"V&-=V"+?5U\YA"JF!
M5LO+Q+J0BCB42G=M57"! .43!E51+V,4F/<8J.V 'R0Q 2V>XC]87'N2,=EX
M?FZZ^<,GV5BUO[-1EXB9? E,$(?$S]X\C$._MY% ]]_&;;RF,8QC&,8QC&,8
MQF.VJW5>C0;RRW&?B:Q7X\H'>S$V^0CX]J4P]"^,Y<G(F43#[BAW=QA]P .4
M[CW$J[CW'M!"0_WFN87BM81]R,RGH1CYF<N$#/R\!(O "8?C$SX@/]HRZ^PQ
MW'<S\1W'[\P)>T:4U=,NU'$U3*9-[?L;2T/E%'32.=WBSKU^NU!E-.CB8OGI
M!:N5FL0+=TJ(&48Q$:T3,8$$RA> DRP54(DK(Q,DF(_:1UY3,2/W[_(?4?>?
M$NHGJ<QD8C7BT11%;J)ATS^S\9\9\H+[>/YQF2_LQY1,S'<9M\! 0 0$! 0Z
M@(>\! ?N" _N@.6Y=$]QW'VGYC(&K?>[#?)[;_J!C&)CX0JOR\X_JQ8\8R>Q
MC&,8QC-"[;W/)T";@JC4:46^W*:A+%:?4Z]B"K,FE9JK=->6>*2@0EA44D7!
MUD64-'!'$0?/E2IO)*,; =V2.=D%1=<V"BIJZ8W]BX.C:JL397$5T3(#8L3
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ITH\[I4KAXZ6=BB*RSQ8%E!! AB)%*)2)E*4I3&]P%ZB(]1'[F,9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g374624g37x44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g37x44.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[25Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )5Z^E68X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              <P   *Z    !@!G #, -P!X #0 -
M  $                          0             "N@   <P
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   <P     4F=H
M=&QO;F<   *Z    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   ',     %)G:'1L;VYG   "N@    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     &P4    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M_1L%5+G6%PAS0+OS'M]GH?GO
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         /_B__])0T-?4%)/1DE,
M10 !";[,_OX>  B <$%$0D4"$   <')T<D--64M,86(@!]  !P :  4 *0 U
M86-S<$%04$P     041"10                    $  /;6  $     TRU!
M1$)%
M       *9&5S8P   /P   !T8W!R=    7     K=W1P=    9P    403)"
M,    ;   *(&03)",@   ;   *(&03)",0  H[@  *(&0C)!,  !1<   CBT
M0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M=  '[]P  )"19&5S8P
M   :52Y3+B!796(@0V]A=&5D("A35T]0*2!V,@
M
M                      !T97AT     $-O<'ER:6=H=" R,# P($%D;V)E
M(%-Y<W1E;7,L($EN8RX  %A96B        "U6@  O&<  )(P;69T,@     $
M PD   $                    !                     0   0   @
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M1B2V*(E(-+6Q9HC^(2RN28GD"5VMFX95  "*18  A#G,F):%=5C&>)0'9AW
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MP+)]<WQZJ\Y]EWQ\E?Y]P'R/?U-]\WRY9]-^-WSW3QY^C7TT,Y!_$GUR#D&
M2'V#TP![TH=0OP=\ H9"JD%\,X5$E(%\<81O??Y\NX.]9J)]%8,F3@M]=H*8
M,I-][8(E#4Q^TH&#T6YZAI(8O65ZO) 9J*%Z]XXPDPU[0(QI?*I[H8K=97A\
M#(ER30E\=H@A,:U\WH<>#'A]C83\S_-Y<ISIN^]YJIH+IRUY[9=!D:1Z/Y28
M>V9ZI9(<9%M[(H_G3!E[DXWA,-Q[ZHQ_"\)\=X?SSK-XFZ?2NK-XU*0?I?)Y
M%:!QD')Y:ISF>DIYUIF18U9Z4Y:$2SYZS)/F,"%[%9*""RE[C8>+S:YW\;+3
MN;!X*JY.I.IX9:F_CVQXN:54>5IY+*$T8H5YKIUQ2H1Z(9I++X-Z7)AR"JIZ
MRX<VS.1W<[WQN.-WJKB@I!!WW+,UCHMX)ZWK>(%XFZD)8<1Y)Z2W2>5YG*%K
M+OQYP9U."D)Z+8;PS%5W'LD^N$IW4<,CHU]W=[S@C<MWM;;"=\AX)+$O82!X
ML*Q[251Y)ZCR+GUY09]O"?!YKX:XQGZ(&'"*L_R',W&^H)*&<G+:C!N%T7/N
M=K>%1W4+8%R$W'8U2+2$GG=5+<6$]'A2"-R&3WE@Q4:&@'JXLNJ%NWKJGW.%
M#'L;BP>$=7M7=:J#^7NG7UN#G'P)1[J#:'QI+-B#LGS ""^$JGUUQ!*%#H3Y
ML:B$7(0QGE^#LX-RB=F#+(+2=(>"NH)47E&":X'S1L>"1(&?*_N"A8%N!YB#
M.8$+PJV#QX\JL#&#%HV-G,F"?(OWB'&" (I\<T*!J(DV736!:X@21=6!2H<3
M*RR!>(9^!Q2!^(0HP52"O9EAKMB"#9;]FW6!>I2=ARF!!9)1<AN L) M7#6
MA(Y410" :(R\*GB A(P)!J. YH1]P#"![:.^K;B!0*"6FE> JYUDAA2 .)I%
M<1Q_YY=:6U%_MI3"1$1_H9*T*==_L)(3!D1__H0]OT2!2:XWK,N GZI.F62
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M>T"E^)RK;":B9)I&7$B>_9@82Z&;WI9<.>.9+I6&)C:77I3<#4J8$8C\  "
M (  B4NI-*>G>P6EBJ2]:^>AY*'.6_B>8I\C2TJ;.9TY.8J8F9RL)?.6RYER
M#4J7.8C\  "  (  B0.HZ+"">KRE,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8
M'Z+$)<B649F,#4.6H(CW  "  (  ?W*Y_VUL<>&UP&YI8[&QO6]Q5*NMZ7"
M1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "  (  ?S.Y'W50<<>TR76,8Y&P
MGG7I5(JLJ79B1':I"7;P,NNF)G=U'L2E,'>2!B"E(7C%  "  (  ?OFW\7S^
M<6^SGWR=8T6O9WQ>5#.K:'Q41"JGPGQK,K:DU7R6'KFCM7RA!G*C-GVC  "
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M;]BOCJ%089"K/9[-4H:G&YRI0JRC7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "
M (  ?3:SFZQ';]"O*ZE6882JP:9=4F2F@J/K0I"BK:+#,92?CY_S'G:=R929
M!Z";Q84H  "  (  <J_%2&S>9:7 K&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q
M-'$M%):QZ7"X  "K*71[  "  (  <J+$=W1P9<._L72+6#J[!'352?&VAG5
M.I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "  (  <J/#.GNX9:J^<GM%6":Y
MM7K]2=:U)'KW.HBQ WL2*9ZM\GLX%6ZMWGL$ *.GTWTN  "  (  <I7![8+:
M98"])H'X5^>X:H%"2:BSTH#,.F:OK8"6*9RLBH"0%:^L,(#, 2&E^(#$  "
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M94.Y4*6B5[NT0Z,H26NO=Z%K.D6K*:!1*="GRIQ%%JBFCX]2 KJ?\X'8  "
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MEB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%. .9S9-S=_WYNU'?A_IY1$  "
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MC/V/"X.S?/:-?H,U; F,$(*X6?J*UH)81LZ)TX(),>6),('-&!&*$H'9  "
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MB82+>Z[Q>5:)W*LY:$Z(4J>05I&'!J240]6&!*+V+X:%.)\=%FN%2(\H  "
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M?\:768FY<+25'8C'8+23!X?>3]:1'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "
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M=CRE]FG@:!6C'FMX6.*@>&S^2(N>#FYR-K*<-6^W(EZ;XW!:"%B=KW @  "
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M<VB@3H\992Z=88W+5A6:F(R/1A.8$HN(-,B6!XKQ(2N5)(MB",R48(7S  "
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M:<JO*' =7%>KIG#Y3?FH5''=/G"E7G*\+3JC27-J&..CIW-& ?Z@-W5A  "
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M9^:IP9/*6FZF(Y)#3!BBK9#>/-2?FH_N+#"=.Y '&-J<E8Y9 U:7:H)"  "
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M79VXVG6 4-6TSW6X0R:P[789-%&MD'9\(Y&KB':N#QRLR'8F  "<B7PB  "
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M71>SGI?F4$2O69950I*K394(,^2GQY2V(YRE7I/,$#^E68K\  "82(    "
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MDJ>#16\)@H""Z'!M<36"GW&^7L.":W,$2Q>"6G0[-<""?74X&\B#;W5F  "
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MC5E\AIII?3U\5Y@N;"9\-)7D6C1\+I/)1S1\.)(*,J5\*Y$F&7%[QX[9  "
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MA1R*378.=AB)2';$9=2(9'=P5'V'GW@:0=>'$WBY+4F&[GD?$P.(?WB:  "
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M@0F$V9^6<>F#X9T;8<R"])J+4-6"-YA:/KF!LI;T*O"!.I9&$;*!$8OW  "
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M=_Z1_'Q,:<R077QS6J:.VGR72DN-C'S .)&,E'SE))R,6'SF"P&,O'T,  "
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M=1:-SJ1;9LN,%Z''5Y&*9Y\O1X2(]YU2-CR'Y9QP(NZ'.9>>"I6&1H<H  "
M (  >I"BI6)P;A.@)F258*N=[F:@4B";YVB*0EB:'FI.,.*8_FO#'(&9P6P_
M ]^8H6R^  "  '_0>?RA06I[;:">S&OB8#2<?VU!4;F:76Z50@&8@&_2,*.7
M2G#4'&:7SW$'!""6$''2  "  (  >6N?HG)8;.Z=0G,A7YV:]'/F42&8T72L
M08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "  (  >,2>$'H=;#*;NWIA7LV9
M>'J<4'R76'K<0.R5@7L=+].4/'M/&_>49WLQ!'21P'Q,  "  (  >!N<OX'O
M:XB:<H&Y7AZ8-8%V3\B6$X$M0&B4-(#X+V22[X#<&[62]8#8!(Z/_8"=  "
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M8@.J76.253JGMV6#1VFE.V=7.$VC'6CW)S:B%VH;$BJD?VFG  "8TVYB  "
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M7]FCI89W4R6@QX7D186>"X50-MB;JX3E)F^:*(35$I*; X2X  "1QH    "
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M5<>T3VD"29*Q%6HX/&^N"VMF+>6KGVQD'/"K"FRZ"/&L"6QI  "2%W=N  "
M (  8.JV"V[L57>ROV^225VO<G!%/$.L47$'+=:ISG&G'12I!7')"5RII7&=
M  "0X7N   "  (  8*JT9'78526Q&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G
M,G<&":BG>G<X  "/OW\6  "  (  8&BR]7S25.FOK'R_2+ZL77RM.[FI-'R<
M+8ZFE7RB'1FECGR9">JEB'T9  ".P8    "  (  8"ZQVH/Q5,>N@8.72*.K
M)(,J.YNG\8+!+6^E2(*#'26D$(*@"B>CS((Y  "-XX    "  (  7_VP_(L4
M5+6MC8I]2)BJ'XF\.XNFX8D(+5VD,8BV'2NBWHD@"F6B2H:(  "-,X    "
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MD3AO6H4[@0AP=82W;]1Q@X0?7;1RE(.02E5SGX,7-7QT38*M'&ISA8)O  "
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MBDE_<&%&>QA_>&/X:I9_GF9V6-A_UVC51<: +FL-,.6 OFS>%K6"/6TT  "
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MA*EV)HN'=81VEXJ195AW!HF#5#IW?HB#0>!W]H>N+<9X,(<M%(%WQH:F  "
M (  D@=T@I6)@]MU#)0C=+=U?9)\9)%U[I#!4WUV;(\I04%VXHWA+5IV_(U3
M%#EV?HL6  "  (  D6ISH)[,@S=T,)S*= MTGIIX8^=U")@34M=UAI7S0*%V
M )1F+-IV!Y/^$_5U=XU^  "  (  D/UR_:@<@KISCZ6*<WUS]**38U5T49^/
M4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "  (  BRR(?EWP?A&'K6#';].'
M'6-J8$>&N&7;3W2&<6@G/2N&9FH[*+R&[6NY#@:(_FM'  "  'G3BE&&-&:M
M?3J%I&BU;NR%+6J:7W.$SFQB3KJ$BFX//(^$?&^/*$"$WW"/#=>&26_U  "
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M>'E]S)$&:D=]C8^W6PU]3HY02MQ]*8T/.69]%HPL)?5\XXPZ#.I],HB6  "
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M<#J,Q6\C8N2+O'!B5$Z*T'&.1(N*#7*C,RZ)J7.&'S:*(W/,!G>)GW0K  "
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M;+F&5)6Q7UV%690G4/6$59)\09J#@Y$Q,-2"^)#(';B"FX_6!HF!Y81K  "
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M8]&4EG2M5RN3!W5E28V1CW82.IF06W:H*>6/P7<)%=Z0V7:M **,:WE$  "
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M85^/?9GX5+F-U)A?1Q",():Q.'**L971*#F)Q94G%/R)R8XP 2>& X#(  "
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M5^&=4WE82]Z;.WFM/N.9/WGL,+27J7HG($V7+7HQ#(Z8 7HJ  "'T7^<  "
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M3AJO4ER-0F2M&5ZJ-9RK&&">)RRIXV(C%9.K86)H T6IMF-:  "(YW']  "
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M3%"G*GU*0-6DG7U.-%ZB-WT_)I*@='TS%AN@EWT6!/^<[WX6  "#7H    "
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MB,%IRW9^>8-K9W=&:3IL['?Y5[YN;'BC119OPGE!,,=PB7FW%\IO['F,  "
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MA"YB7:)G=/MD*9^$9-EEUIR<4]AG>IH70<%HV9A3+B)I&)=@%>5I3([.  "
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M?%!OF7T6;@MPJ7U77KAQI7UZ3EURGGV:/(IS?7VZ*-USQGW##Z%U)7V>  "
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M=5B!6%N79\:!6EZA6.R!?6%W2,&!N&0;-P.")V9Q(M&#'6?X".>$I&??  "
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M<"QV:X+?8LUVX8*M5%]W1H)<1.5WK((0,_)X H'?()]WXX'5"(-Z'X%<  "
M (  >\MT<8MJ;V9U$(K>8@QUB8H04Z5U\8DH1#1V6(A=,UQVH(?9($IV.X@/
M"')XV(55  "  (  >S%S4I/P;LYS^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU
M>HXK']QTX(X-"&-WSH6K  "  (  >KYR>)Q\;E=S)YK]8/-SFYD04I-S\I<.
M0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "  (  =4Z*MU?::8")^UKP7+*)
M?%W>3J2))V";/S2(_F,;+?.)2F4I&7^*^67S ?6*%&<8  "  'Q?=%B(&U_G
M:+.'F6)36^B'+F2>3?B&V6;%/JF&JVBY+8Z&XFI+&4^(,&J[ BR';&OZ  "
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M9&%^.H?&5\]^#8<]2BM]RH:4.W)]FX8+*RE]?874%_=]*H8= I9^=H'   "
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M7$".S&?]4%"-YVFM0QR-&VL]-(V,D6R5(^*,PFUN#UZ.@FSI  "$7G.G  "
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M60V&[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "
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M4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "
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M3@F0<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "
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M1"N@:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "
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MC5Y@L6!D?=IC)V,U;4)E?F7F6X1GMVAW2))IMFKD-!=K VT!&V=J36X@  "
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MAC]3!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "
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M@-UD<FA)<H]FC&I78NAH@6Q#4BEJ5FX70!9KZV_%+#ELI7$5$Q)N77$/  "
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M>S%8[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "
M (  A]E4NIV9>JI7O9N?;():9YE675Y<TI<(345? Y46._I@CY/3*0E?[Y-H
M$21E[XN7  "  (  A3!QDE- >&IREE;S:J5SLUIX6Z5TV%W)2UYU]V#G.9=W
M#F.[)9EW^677"[IZQ&8"  "  '7"@\=MTEP.=S=O,%\#:8%PA&'.6J5QS61S
M2H)S!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "  'GA@G!J763===)L 6<7:%AM
M@VDR68UN[FLI29AP0&S_."-Q7FZ>)()QO&^R"V5U@F^*  "  'V @0YG,VVP
M='!I#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "
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M<#)?J)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "
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M:$MNL'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "
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M88*"S57G54B"]%DL1\N#.5P].-:#H5\!)]F$>&$L$O2&NV&5  "#.F6N  "
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M7'!U>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "
M (  9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)
M  "  (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')S
MB8>;$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS
M- MR?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+
MJ5?]/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^
M52N)$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "
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M4-=]3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "
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M2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "
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M18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "
M (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L
M  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C
M&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\
M&46>H5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;
M;U^.)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z
M/(29;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "
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M.B60SH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "
M (  GOM3U4W5C\A7"%(=@ 1:(E90;UQ=+%IC7:5@&5Y12K]BM6(1-G%D8V6!
M'E]CEF?T 7M]@&L9G-%.A5@(CA12+EMO?H15LEZ^;@A9$6'R7&]<0V4&2:M?
M!V?V-8!@F&J?':U@,FQV 8M]9&_/FMI)K&(^C#M-P&2Y?.]1G&<B;(I506E[
M6R!8J&N^2(U;BFWH-)I<\V_:'0Y=2G$D 9I]2W3BF.A%/&QDBFM)LVWY>S)-
MU&^(:Q]1N7$-6=I55G*%1WY83G/P,\A9A74T'']:VG8& :9]-GF+EPI!-G9X
MB,M&"G<X>;Y*>7?U:;U.CWBJ6-A27'E>1IQ5:'H0,Q=69GJS' I8TWLJ ;%]
M)'V(E6<]J8!^AVM"U(!L>)M'BX!<:,-+W(!+5^]/QH ^1?=2WH!#,I%3H(!8
M&ZM7*8"H ;I]%(#EE HZEHIQADI #XF(=[%%!HBG: %)B8?45SM-DX<515Q0
MK89[,BY1-88A&V=5RH:2 <)]"($PDO4X!I0_A64]P))V=OE"[9#$9VY'F(\U
M5KE+NXW61-Q.U(RV,<-/&(P;&S%4KXO+ <A\_8$TDC,V#YVTA+X[\IL'=G%!
M0IB&9P1&"99+5FQ*/Y1C1*5-69+C,8E-7I)0&O=3SX_P <U\]8$XDX-:ODWN
MA4-=85(@=EM?_58Y9GUBBEHO58%D^5W[0SUG%V&/+T]H0&2Q%JII=694  "
M &W2D7E5F5>9@]58NUK^=2U;MEY*97]>C6%V5*-A,61X0H!C:F=*+KED76FW
M%DYF8&K:  "  '*PCYI0Y&%)@@)4;6/7<YE7N6909 ):SVBO4U9=I6KR06-?
M\6T0+=%@G6[:%;%CX&^*  "  '=BC<I,DVKK@$=0<VRG<?54 6Y68K174F_R
M4BE:67%X0&I<KW+G+1-="G08%3AAN'1S  "  'MVC!Q(KG2&?L5,VW5[<))0
MK79C86!4+'<\43177'@-/Y19NWC4+'%9NGE[%-5?YWFL  "  '[SBK%%2'X;
M?81)N'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "
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M>4A?BUIW:V-A_EVV7'MD46#33%EF<F/#.LQH*69U)T)HAVB4#D-N$6C_  "
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M<HY./(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "
M (  ?A-']8VE<=),"HS#9*I/MHNR5G=2^(J<1R=5JHFX-H17"HDK)#=6PHEB
M#25IR(<V  "  (  ?8)&()9G<4A*4Y3R9!].$9,V5?-16Y%Z1KI4"Y 7-C%5
M3X]1(]]54(]D#.%J/(BU  "  (  ?)5I<TX3< 9K#5'\8KILMU725&%N6%F#
M1,9OW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "  '6&>K-DLE:1;IQFMUG<88-H
MJ5T+4UAJ?6 50^)L(6+J,M)M965H'T1M3V<*!Q]TZF>_  "  'FM>1U@15\K
M;1=BIF')8$EDVF1.4C=FVF:O0O%HF6CD,A!IRFK.'KII36OW!PUT%6RE  "
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M9Z]3HXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "
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M8/AFQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "
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M7,5: (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "
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M50-L!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "
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M3JN#ED_=0X2$!%,^-PJ$FE9A*+R%@%D"%U:'B5I<!'&'U5NB  "  &DU  "
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M24-R;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "
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M0CB)YE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "
M (  2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z
M  "  ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$
MMV7"  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7
M&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]
M-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=
M/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "
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M-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "
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M,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "
M (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (
M  "  (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
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M_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ
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M?V=80(3]?WM#S(0L?[HO[H-N@"K0)HI4BKF]%HD%B36I@X?)A\J5-(:_AI.
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M?*.9N'WB?,&$GGX>?/MO:7YM?4]:47[1?;)%9G]=?C<Q ( A?N34(WOSAQ3
MUWPHA@2L[7Q@A0*84GRIA"B#97T!@VMN7'UP@L)9<7WQ@AA$N'Z8@7 PD7]U
M@+32GGJRD72_1'KOCVFK8'LUC6Z6]7N,BXR"+GP!B=1M57R)B"58GWTEAF9$
M'7WGA(LP+W[<@F?1+GFHF\:]W7GJF,VI_GHYE=V5HGJ=DOR!!7L=D"UL6WO
MC717W7QSBI=#D'U,AX$OVGY5@_?/^7C9IA*\K'D=HC"HTGEMGD*4@WG8FEJ
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M;8!3AJ M9H!Q@Y7!]8';H?6P.X$RGIN=TH"BFR2*VX TEZ1WL'_IE"EDB'_
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MEBME6YLRDS)7?)<UD#I)W9,MC3P\UX\$BC,PCXKGAQPETH:XA!&-UZ:]HQF
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MR80.HN5W[X,-GO=II8(3FJ];4X%/EF1-(X#'DA0_@X!9C;4R;8 >B2TFIH
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MAZTQ1H$/A=<HT8"X@_8AN("'@BUEWILQ6:%<YYD(7.53F9;G8$%)[92?8[]
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MDL]G255+D$Y9ZULAC=M,AF%'BV8_KV>JB.DS?&Y.AE$HOG39@[R,OF1=4&.
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MVH^?B-J/GXC:CY^(VH^?B-J/GXC:CY^(VO^G.#+_HT1+_J-)7_.I1F_HKD2
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MT\]2E\'$8:>SNVVSJ[5XNZ6Q@,&?KH3&F*N$RI"HA,Z(IH;1@J2,TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"D
MDM. I)+3@*22T_^E-RK_H41!_Z5%4?ZL0E_UM#]L[;P^>.?'0('@UD:'R<U1
MFKC"8*JLNFVUI;5XO*"Q@,&;KH3%E:R$R(ZJA,N'J(;.@J>+SW^FC]!_IH_0
M?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_
MIH_0?Z:/T/^E-BK_HD-!_Z=#4/^N/UWWMSQI\,([<^;0/WG3V3^*OLM1G:_
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MEK9[NI2S@KZ2LH7 C;&&P8FPA\.&KXC$@JZ*Q8"NC,6 KHS%@*Z,Q8"NC,6
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M@*&FSO^B-B+_GT,W_Z-%1_^J0E/^L4%?]KA!:O'!1'/JS$MYX-I6?,_57HW
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M)C;2X29!P>\L6K#M,VZAX3U_E==-C(W07I:)RVN=AL=THH/$>J9_PWVI?,&
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MN<&#F;N_?YV^OGVBO[UZJ,"\>:_!M'FPP;!ZL,"P>K# L'JPP+!ZL,"P>K#
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MRC [VMTR/\KG.%6\[#UIK>5$>9_;3H>4TUR2C<QHFXC(<J&$Q'FF@,)]JGS
M@:UYOH6O=[V(L'2\B[)RNY"S<+N5M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:
MM&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M/^D,!K_IS4J_[0O,/3#*C'>V"LM
MS.8N1;WR-5JM[CMLG^1$>Y/;48>+U%Z0AL]JF(++<YU^R'BA>L9\I'?$@*9U
MPX.H<\*&J7'!B:MOP(VL;<"2K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_
ME:ULOY6M;+^5K6R_E:ULOY6M;+^5K?^E+QK_K2TE_+PG*.70(23.Y"0SOO$L
M2J[X,UV@[3UMD^1'>HK=5(6#UV&,?])LDGO/<I=WS7>:=,M[G'+*?IYPR8&@
M;LB$H6W'AZ)KQHJC:<:.I&C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5H
MQ9&E:,61I6C%D:5HQ9&E:,61I?^G+!K_M24?[,D:'-#B&2&_\"(XK_TK3:#X
M-5Z3[D%LB>9-=X'@6(!]W&2&>-AKBW/5<8YPTW61;M)YDVS1?)1JT'^6:<^"
MEVC/A9AFSHB99<V,FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:
M9,V.FF3-CIIDS8Z:9,V.FO^N)!;UP1<4U-\.$,#O&":P_2,\H?\M3I3Y.EV)
M\4=H@>M2<7KF77ATXF1]<-]K@6W=<(1JW'2&:-MXB&;:>XEEV7V*9-B BV+8
M@XQAUH6-8-:)CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+
MCE_5BXY?U8N.7]6+COZY%@W4T@L&PNX.%K'\&2JB_R4]E/\R3(G\0%F!]DUB
M>O!8:7/L7V]LZ61S:.=J=F;E;WEDY'-Z8N-V?&'C>7U@XGM^7^%^?E[A@']=
MX(. 7."%@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?
MB(%;WXB!6]^(@=3("0/$UPH'LOL0&:/_'"N5_R@[BO\X2('_15)Z_%):<O=9
M8&OT7F1F\F1H8O!I:F#N;6Q>[7%M7.UT;EOL=F]:['EP6>M[<5CK?7%8ZG]R
M5^J"<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'-6
MZ81S5NF$<\3-" &TW0@+I/\2&I?_'RJ+_RXV@?\]07G_2DEQ_U)0:?]856/]
M75A?^V-;7/EG75KX:U]8]VY@5_=Q85;V=&%5]G9B5/5W8U/U>6-3]'QD4O1^
M9%'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E
M4?2 9?^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:
MC(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9S
MNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:C(66
MU8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9SNK+!
M=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LO^6
M,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:C(66U8>+
MG-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9SNK+!=;NR
MP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LO^6,Q3_
ME4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:C(66U8>+G-&#
MD*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9SNK+!=;NRP76[
MLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LO^6,Q3_E4,E
M_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:C(66U8>+G-&#D*'/
M@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9SNK+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LO^6,Q3_E4,E_Y)1
M-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:C(66U8>+G-&#D*'/@)6F
MS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LO^6,Q3_E4,E_Y-1-_^7
M4T7_F592_9E;8/688&WMEF=YY9-QA-^0>X[:C826U8B*G-&$D*+/@)6FS'V9
MJ<M[G:S)>:&NR'>EK\AVJK''=*ZRQW.TLL1TNK*_=;JROW6ZLK]UNK*_=;JR
MOW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLO^6,Q3_ED,E_Y50-_^9443_
MFU12_IQ87_6;76SMF61XYI9L@]^3=HW:CX"6U(R(G=&'CJ/-@Y.HRX"8J\E]
MG*[(>J&QQGBELL9WJK3%=;"UQ72XM;UWN+6X=[BUN'>XM;AWN+6X=[BUN'>X
MM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM?^7,Q3_ED,E_Y9.-_^:3T3_G5)1
M_IY57O:>6FKNG&!VYYIG@N"6<HS:DGN5U(Z$G="*BZ/-AI&IRH*6K<A^F[#&
M>Z"SQ7FFM<1WK+;#=K.WOG>WM[=XMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)Y
MMKBR>;:XLGFVN+)YMKBR>;:XLGFVN/^8,Q3_ET,E_Y=--_^;34/_GU!0_Z!3
M7?>@6&GOGUUUZ)UD@.&:;HO;EG>4U9& G-".B:/,B8^IR825KL> FK+%?:"U
MPWJGM\)XKKG =[6YN'BUN;%YM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL
M>K6YK'JUN:QZM;FL>K6YK'JUN?^8,Q3_F$,E_YA,-O^<3$/_H$Y/_Z)17/BC
M56CPHEMTZ:%A?^*>:HG<FG.3UI5\F]&1A:/,C(RIR8>3K\:"F;/#?J"WPGJH
MN<%XL;NY>+.\L7FSNZMZM+NG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z
MIWNUNJ=[M;JG>[6ZIWNUNO^9,Q3_F$,E_YE+-O^>2T+_H4Q._Z1/6_FE4V;Q
MI5ARZJ1>?>.B9H?=GG"1UYEXF=*5@:'-CXFIR8J1K\6#F+3"?Y^XO7RGN[IZ
ML+VR>K*^JWNRO:9\L[RC?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2ZHWVT
MNJ-]M+JC?;2ZHWVTNO^9,Q3_F$,F_YE*-O^?2D+_HTM._Z9.6?JH467RJ%9P
MZZA<>^6G8H7?HVR.V9]UE].:?I_-DX:HQ8V-K[^'E+6Y@YRYM7^CO+%]K+ZL
M?+&_I7RQOZ%^L[V>?K2[GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[GGZTNYY^
MM+N>?K2[GGZTN_^9,Q3_F4,F_YI)-?^@2$'_I$E-_Z=,6/JJ4&3SJU1N[:Q:
M>>:L8(+@JFF+VJ9SE,^??)W&EX.HOI"*L+B+D;:RAIBZK8.@O:F!J+^E@+#
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MO/^:,Q3_F4(F_YQ&-/^C14#_J$5*_ZU'5?ZQ2E_UM5!HZ[E6<..]7G?9NVJ
MR[)PD,"I=IVVHGRGK9R"KZ67B;:>DY"[F8^8OI2-H,&1C*G"C8JNPHV)L;^-
MB;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO?^;
M,Q3_FD(F_YU%-/^D1#__JD1)_Z]%4_RT25WRN4]EZ;Y6;.'#8'+3OFF QK5N
MC[NM=)RPIGJGIZ" KY^;AK68EXZ[DY65OHZ2G<&*DJ?"B)"NPHB.L,"(C;*]
MB(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO?^;,Q3_
MFD(F_YY$,_^E0C[_JT)(_[%$4OJW2%KPO4YAYL169][)8FW.P6=_P;EMCK:Q
M<INKJGBFHJ5^KIF@A+62G8NZC)J3OH>8F\"$EZ3"@I:OPH.3L,"$D;*^A)&R
MOH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROO^;,Q3_FD$F
M_Y]",_^F0#W_K4!'_[1"3_>[1U?MPTU=Y,Q88-G-8&S)Q69^O+UKC;"U<9JE
MKW:EG*I\K9.F@K2,HHFYAJ"0O8&>F;]]GJ+!>YZOP7V9L,!_EK*^?Y:ROG^6
MLKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROO^<,Q3_FD$F_Z!!
M,O^H/SS_L#Y%_[=!3?3 15/JR4Y6XM5:5]+17FO$R61]ML%JC*J[;YF?M72D
MEK!ZK(VL@+*&J8>W?Z>.NWJFEKYWI:"_=*:MOW>AL;]ZG;*^>IVROGJ=LKYZ
MG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROO^=,Q3_FT$F_Z(_,?^J
M/#K_LSQ"^[L^2?#&1$WFTD]-W-Q75LS576J^S6-[L,=HBZ3!;9>9O'.BC[AX
MJH:T?K!_LH6U>;",N'2OE;MQKI^\;J^KO7&JL[QTI;.\=*6SO'2EL[QTI;.\
M=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO/^=,Q3_FT F_Z0\,/^M.3C_
MMCD_]<$\0^G.1$3>W4U'TN!36,7;7&BWTV%ZJ<UFB9S(:Y61Q'&?B,!VIW^]
M?:UXNX2Q<[J+M&^XE+=LMYVX:K>HN6FVMKAMK[6Y;:^UN6VOM;EMK[6Y;:^U
MN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN?^>,A3_G3XE_Z<Y+O^Q-C7[O#8Z
M[<DZ/.#:1#K2XD=,Q^)-7KG>5&ZLV5M\G]1BB)30:).*S&^;@L=WHGS#?JAV
MP(2L<KZ*KV^\D;%MO)BR:[NALVJ[K;)GNK:T9[JVM&>ZMK1GNK:T9[JVM&>Z
MMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM/^?,A3_H#HD_ZHT+/^U,C'SPS(SX]0X
M,-/A/#_&Z$)2N>5(8ZSB37*?WU1_D]E=BHG29Y.#S7":?<EWGWC&?:1TQ(.G
M<,*(J6[!CJMLP)2L:K^;K6F_I:UHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUH
MOZZM:+^NK6B_KJUHOZZM:+^NK?^@,!3_HS8B_Z\P*/N\+2OHS2PHU> P,,?I
M.$2Y[#Y7K.E%9Y[G2W62X%. B=E>B8+4:)%\T'&6>,QWFW3*?9YPR(*A;L>'
MHVO%BZ5IQ)"F:,26IV;#GJAEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H
M9<.EJ&7#I:AEPZ6H9<.EJ/^A+Q3_J"\?_[4J(O#&)"'8W2,@R.DM-;KR-4FL
M\3Q:GO!#:9+H3'6(X55_@=MAAWO7:HUVTW&1<M%WE6_/?)=LS8"::LR%FVC+
MB9UFRHV>9<F2GV/)F*!BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>
MH6+(GJ%BR)ZA8LB>H?^C+13_KBD:^+\@&M[6&!/)Z"(ENO0K.JSX-$V>]SQ<
MDO%&:8CI4'-_XUE[>M]D@G3<:X9PV7&*;=9VC6K5>X]HTW^19M*#DF31AY1C
MT8J58="/EF#/E)=>SYF87L^9F%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F%[/
MF9A>SYF87L^9F/^G*!+_MQ\2YLX1#<OF%1:[]"$JK/XK/I[_-$Z2^C]<B/)*
M9G_L56]YZ%YU<N1D>V[A:WYJWW"!:-YUA&7<>85CVWV'8MJ!B&#:A(E?V8>*
M7=B+BUS7D(Q;UI2-6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-6]:4C5O6E(U;
MUI2-6]:4C?^P'@OMQ@X(S=L+"+OS%1JL_R$NGO\L/Y+_-TV'_418?_9/87CQ
M66AQ[5]M:NMD<6?H:G1DYV]W8N5T>6#D>'I?XWM[7>-^?%SB@7U;X81^6N&(
M?UG@C(!8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8X(^!
M6."/@?.]#03,SPD!O>4,#*S_%QZ>_R0ODO\O/8?_/4E__TE2>/Q46G#X6E]I
M]%]D9/)E9V'P:FE>[VYK7.YR;5OM=FY:['EO6.Q\<%?K?G!6ZX%Q5>J$<E3J
MB'-3Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+
M=,S&" "]U @#K?4.#Y__&A^3_R<MB/\T.7[_0D-W_TU*;O]34&?_655B_%Y8
M7OMD6UOY:%U9^&Q>5_=P8%;W<V%5]G9B5/5X8E/U>V-2]'UD4?2 9%#S@V5/
M\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9KW+
M!@"NVP8$G_\0$)/_'1V(_RHH?O\X,G;_1#IM_TM!9?]11E__5TE;_UU,6/]B
M3E7_9E!3_VI14O]M4E#_<%-/_W)43O]U5$W_=U5-_WE53/Y[5DO^?E=*_8%7
M2OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5_^-+0[_
MC#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+C=Q\
MD9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6CR&[&
MHLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_C#X=
M_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+C=Q\D9+:
M>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6CR&[&HLAN
MQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_C#X=_XI,
M+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+C=Q\D9+:>9>6
MV':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6CR&[&HLANQJ+(
M;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_C#X=_XI,+O^2
M4SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+C=Q\D9+:>9>6V':<
MF=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6CR&[&HLANQJ+(;L:B
MR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_C#X=_XI,+O^24SO_
ME%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+C=Q\D9+:>9>6V':<F=5S
MH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6CR&[&HLANQJ+(;L:BR&[&
MHLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_C3X=_XQ,+O^44SO_E59'
M_Y9;5/V586#VDFAK[X]P=>F+>G_DAX.'WX**C=Q^D)+9>I:7UG>;FM5TH)W3
M<J6?TG"IH=%NKJ+0;;2CT&RZI-!LPJ3*;L2DQ&_$I,1OQ*3$;\2DQ&_$I,1O
MQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I/^.+0[_CCX=_XY++O^543K_F%1'_YA8
M4_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN CI38?)28U7F:G--VGY_1<Z2B
MT'&JI,]OKZ7.;K:FSFV]I\INPJ?#<,*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]
M<<*GO7'"I[UQPJ>]<<*GO7'"I_^/+0[_CCX>_Y!*+?^73SK_F5%&_YM64OZ:
M6U[WF&%I\)5H=.J1<7[DCGR&WXF$CMN#BY37?Y*:U'N8GM)WGJ'0=*2DSG*J
MILUPL:C-;[FIRV_!J<-QP:F\<L"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"J
MMW/ JK=SP*JW<\"JMW/ JO^/+0[_CSX>_Y)*+?^833G_FT]%_YU34?^=6%SX
MFUYH\9EE<NJ5;7SDD7>&WXR!CMN'B976@9":TWV6G]!YG:/.=:.FS7*KJ<QP
MLZK+;[VKQ7*_J[USOZRV=+ZLL76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^
MK;%UOJVQ=;ZML76^K?^0+0[_D#X>_Y-)+?^93#G_G4Y$_Y]14/^?5EOYGEQF
M\IQB<>N8:7OEE'.$X(]]C=N*AI36A(V;TG^5H,]ZG*7-=J.HRW.KJ\IQM:W&
M<;ZMOG2]KK9UO:ZP=KVNK'>]KJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KJQW
MO:ZL=[VNK'>]KO^0+0[_D#X>_Y5)+/^;2CC_GDQ#_Z%/3_^B5%KZH5EE\Z!?
M;^R=9GGFF&^#X)-YC-N.@I/6AXJ;TH&2H<]\FJ;*>**JQW6KK<-SM*^_<[RP
MMW6\L+!WN["J>+NPIWF\L*=YO+"G>;RPIWF\L*=YO+"G>;RPIWF\L*=YO+"G
M>;RPIWF\L/^1+0[_D3X>_Y9(+/^<2#?_H$I"_Z--3?^D4EC[I5=C]*1=;>ZA
M8W?HGFN XIAUB=R2?I+3C(>:S(:/H<: EZ?!?)ZLO7FFK[EVK[&W=KJRKW>Z
MLJIYNK*E>KJRHGN[L:)[N[&B>[NQHGN[L:)[N[&B>[NQHGN[L:)[N[&B>[NQ
MHGN[L?^1+0[_D3X>_YA'+/^=1S?_H4A!_Z5+3/^G4%;\J%5A]:A;:^VG873E
MI&E^WI]SA]28?9#+D82:Q(J,HKZ$DZBX@)JMM'RBL+!ZJ[.M>;6TJ'JYM*1[
MN;2@?;FSG7VZLYU]NK.=?;JSG7VZLYU]NK.=?;JSG7VZLYU]NK.=?;JSG7VZ
ML_^2+0[_DCX>_YA&*_^>1C;_HT=!_Z=)2_^J3E7ZJU->\JQ9:.FL8''BJ6AZ
MV:5S@\V<>H_%E8&:O8Z(HK>(D*FQA)>NK("?L:A^I[2E?;&UH7VXMIU^N+6:
M?[FTF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"ZL_^2
M+0[_DCX>_YE%*_^?1#7_I$5 _ZE(2?^L3%/XKE)<[[!89>:Q7VW>L&EVTJEQ
M@LB@>(^_F'Z:MY*%HK",C*FJB)2NI(6<LJ""I+6=@:ZVFH"WMY>!M[:5@KFT
ME(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFSE(*YL_^3+0[_
MDCT>_YI$*O^@0S7_ID0^_ZM&2/^N2U'ULE!9[+578>2W7FG:M&ESS:QO@L*D
M=H^YG'R9L9:#HJJ1BJFCC)&NGHF9LIF'H;66A:NWDX6VMY&$M[>0A;BUD(6Y
MM)"%N;20A;FTD(6YM)"%N;20A;FTD(6YM)"%N;20A;FTD(6YM/^3+0[_DST>
M_YM#*O^B0C3_J$(]_ZU%1ORQ2D_RM4]6Z;I67>&]8&34N&=RR*]M@;VG=(ZT
MH'J9JYJ HJ25AZF=D8ZNEXZ6LI*+G[6/BJBWC(JSN(N)M[>+B+BUBXBYM(N(
MN;2+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FTBXBYM/^3+0[_DST>_YQ!
M*O^C0#/_J4$\_Z]$1?JT2$SPNDY3Y[]66=["8&#/NV9QP[-L@;BK<HZNI'B8
MI9Y^H9Z:A*B7EHRND9.4LHR1G+6(CZ:WA8^QN(6.MK>&C;BVAXRXM8>,N+6'
MC+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRXM?^4+ [_E#T>_YU *?^D
M/C+_JS\[_[%"0OBX1TGMODY/Y<974]K&7E_+OF1QOK9J@+.O<(VIJ7:8H*-\
MH9B?@JB1FXFMBIF2LH66FK6!E:2W?Y6NMWZ4M[>!D;>V@I"XM8*0N+6"D+BU
M@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM?^4+ [_E#T>_YX_*/^F/3'_
MK3XY_[1!0/2\1D7KQ$U)XLY82]/*7%[&PF-PN;IH?ZZT;HRCKG27FJEZGY*E
M@*>*H8>LA)^/L7^=E[1[G*&V>)NLMW>;M[9ZE[BU?)6YM'R5N;1\E;FT?)6Y
MM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM/^5+ [_E3T>_Z ])_^H.S#_L#PW
M_;@_//'!1$#HRTY"WM-52L[-6UW QF%NM+]G?JBY;8J=M'*5E*]XGHNK?J6$
MJ(6J?::,KWBDE;)THY^T<:.JM7"CN+5SGKFT=INYLW:;N;-VF[FS=INYLW:;
MN;-VF[FS=INYLW:;N;-VF[FS=INYL_^6+ [_ESP>_Z(Z)O^J.2[_LSHT^;T\
M..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*' :XF7NG"3C;9VG(2S?*)]L(.H
M=ZZ*K'*MDZ]NK)VQ:ZRHLFFMMK)LJ+NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%O
MH[NQ;Z.[L6^CN[%OH[NQ;Z.[L?^7+ [_FCL=_Z0W)?^M-BO_MS<P\\,Z,>;0
M0S#<WTHUS]]21\'86%JST5YKILMC>IK':8:/PFZ0AK]TF'V\>I]VNH&D<+B)
MJ&NWDJMHMYRM9;>GKF2WM*YEL[VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN
M:*V]KFBMO:YHK;VN:*V]KO^8+ [_G3D<_Z<T(_^Q,RCYO3(JZLLW*=S=/BG0
MXT8ZQ>)-2[C>55JLV5QHGM-B=Y+/9X*(RVV,?LESE';'>9IPQ8&?:L2)HF;#
MDJ5BPYRG8,.FJ%_#M*A?P<*H8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I8;K!
MJ6&ZP:EANL&I8;K!J?^9+ [_H#4:_ZHQ(/^V+B/PQ2TBW]@S'-#C.B[$Z$)
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M9DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09L3"!@"VT0<
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MP:F#BL&I@XK!J8.*P:F#BL&I@XK!J?^+)PG_CC<7_YP\'_^C.R;_JCTM_[%
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M9=N&R67;AO]X) ;_>#40_WY &_^(1R;_C4XQ_X]5//^.6T;_BV)0_X9I6?R
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M?#01_X@\&O^20R3_F$@M_YI,-_^:4D'_F5A*_)=?5/:39EWPC6YFZX=W;^:
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M<D[,Z7).S.ER3LSI<D[,Z7).S.ER3LSI<O^2$0'_IQ$ V+D) ,O&" #"U0H
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M//[.5CS^SE8\_LY6//[.5LZP @"]N@0 L<<$ *76!P";_1 "D?\@"8C_+1*
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M?_]K( /_>AX$_XLF!O^8+PK_H34-]Z<X$.RM/!/CLD(6U[%'(\NK4C+!I5I
MN)]B3+"9:5>HE'!@H8]W9YN+?FZ6B(9SD86.>(R"EGR(@)^ A'^J@H%_MX.
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M>5VAY'E=H>1Y7:'D>5VAY'E=H>1Y7:'D>?]]%0+_D!0!_Z$8 ?:Q% #9P0L
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M_X<C*/^0)"?_F24F_Z$F)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)I_
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M64C%^UI(Q?M:2,7[6DC%^UI(Q?M:2,7[6O>1! #4H@( QZ\$ +JY P"PQ 4
MI] ) )_A$ "8X2$#C^ P"8;@.Q)]WT0;==Y-)&[=52MGW%PR8MMD-UW;:SM9
MVG(_5=IZ0U+:@T5.VHU(3-J82DG:I4M(V[-,1]S$3$;<WDQ&VNU,1-CY3T/8
M^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0( N[," +"] P"ER04 F]8)
M )3H% &,Z24$A.@S"WOH/!1SZ$0;:^A+(F3G4BA>YUDM6>=@,E7G:#52YV\X
M3^=W.TSG@#U)YXD_1^B4043HGT)"Z:Q#0>FZ1$#JS41 ZN1$0.CU1$#G^$-
MY_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$ L+@! *3$ @"9T 4 C^$* (GQ
M&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6\U<G4O->*T_S92U,]&PP2?1S
M,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKWOSPY^,\\./?H/#CW[#PX]^P\
M./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\  )C* 0",V 0 A/H. 'S[&P)T
M^R8%;/PP"F7\.!!>_4 56/Y'&5/^31U/_U0@2_]:(DC_825%_V<F0O]M*$#_
M=2H]_WTK.O^&+3C_D2XV_YLO-/^F,#/_LC$R_[XR,?_0,C'_UC(Q_]8R,?_6
M,C'_UC(Q_]8R,?_6,K*O  "EN@  F,8  (O2  !_WP( >?\1 6__&0)G_R($
M8/\L!UK_- Q4_SP/3_]#$TK_215'_T\70_]5&4#_6QL^_V$<._]F'CG_;1\V
M_W0@-/]](3'_AB,O_Y$D+?^;)2S_I28K_Z\F*O^[)RG_OB<I_[XG*?^^)RG_
MOB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0< :_\/ 6+_%@);_QX#5/\F
M!4[_+@9)_S4(1?\\"T'_0PT^_T@.._].$#C_4Q$U_U@2,_]>$S'_9!0N_VH5
M+/]R%BK_>A<G_X,8)?^.&23_F!HC_Z :(O^J&R'_K1LA_ZT;(?^M&R'_K1LA
M_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0 7O\- %;_$@%/_QD"2?\@ T/_
M)P0__RX%.O\T!C?_.@<S_S\',/]$""[_20DL_TX)*?]3"B?_6 HE_UX+(_]D
M"R'_; P?_W0-'?]]#AO_APX9_X\/&/^9#QC_FQ 8_YL0&/^;$!C_FQ 8_YL0
M&/^;$/],*@/_2#,%_T\T!O]4-PC_6D$._UQ*%O]:5!W_5V D_U1K*O]0>"__
M380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+ /_]"R4#_0=5!_T'D0?]!
M[D+_0?9"_T']0O]"_T'Y1/]!]$;_0N]'_T+O1_]"[T?_0N]'_T+O1_]"[T?_
M0O]-*0/_2C($_U$R!O]7-@C_7#\._UY)%O]=4QW_6EXD_U=I*O]3=2__4($T
M_TV--_]*ESK_2)\\_T>G/?]&KC__1;5 _T2]0?]$QD+_0]%"_T/B0_]#[$/_
M0_5#_T/\0_Q$_T/U1_]#[TC_1.M)_T3K2?]$ZTG_1.M)_T3K2?]$ZTG_1/]-
M*0/_3# $_U0Q!?]9- C_7ST._V%'%O]@4AW_75PD_UIG*_]6<S#_4W\T_T^*
M./]-E#O_2YT]_TJD/_](K$#_2+-!_T>[0O]&PT/_1LY$_T7?1/]%ZD7]1?-%
M^T7[1?=&_T3P2?]%ZDK_1N5+_T?E2_]'Y4O_1^5+_T?E2_]'Y4O_1_].*0/_
M3RX$_U<N!?]=,@?_8SL._V5&%O]E4!W_85DD_UUD*_]:<##_5GPU_U.'.?]0
MD3S_3IH__TVB0/]+J4+_2K!#_TJW1/])P$7_2,I&_4C;1OI(YT?X2/)']4CZ
M1O%)_T?J2_](XTS_2=Y-_TK>3?]*WDW_2MY-_TK>3?]*WDW_2O]/* /_4BP$
M_UHL!?]A+P?_9SH._VI$%?]J3AS_9U<D_V)A*_]>;3'_6W@V_U>#.O]4C3W_
M4I9 _U">0OY/I43\3JU%^TVT1_I,O$CY3,=(]DO42?-+Y4GP2_!)[4SY2.E,
M_TKA3O]+VD__3--0_TW34/]-TU#_3=-0_TW34/]-TU#_3?]0* /_52H$_UTI
M!?]E+0?_;#@-_V]"%/]O2QS_;%4C_VA>*O]C:3'_7W0V_5Q_._M9B3_Y5I)"
M]U2:1/53HD;T4JE(\E&Q2?%0N4KO3\-+[D_/2^M/XDOG3^Y+Y$_X3=]/_D[5
M4?]/SE+_4,E3_U#)4_]0R5/_4,E3_U#)4_]0R5/_4/]1)P/_6"<$_V$G!/]J
M+ ;_<38,_W1 $_]T21K_<E(B_VY;*?UH9##Y97 V]F%[._->A4#P6XY#[EF6
M1NQ7GDCJ5:9*Z%2M3.=3M4WE4[].XU/,3N%3WT[=4^U/V%+W4=%3_5+*5/Y3
MQ%;_4[]7_U._5_]3OU?_4[]7_U._5_]3OU?_4_]2)P/_6R4#_V4D!/]N*@;_
M=C0+_WH]$?]Z1AC_>$\@^W18*/9O82_Q:VPV[6=V/.EC@$#F8(I%Y%V22.%;
MFDK?6:)-W5BJ3]I7LE#85KQ1U57(4M)5VU/.5NM3RU;V5<96_5:_6/U6NEG]
M5[9:_5>V6OU7MEK]5[9:_5>V6OU7MEK]5_]3)@/_7R(#_VDA _]S* 7_>S(*
M_W\[$/^ 1!;[?DP>]'M4)>YV72WI<6@TY&UR.^!I?$'<985&V&*.2M1?EDW1
M79U0SERE4LQ:K53)6;96QUG"5\99T%?"6>98OUGS6;M:^UFU6_M:L%W[6JU=
M^UFM7?M9K5W[6:U=^UFM7?M9K5W[6?]6) /_8B #_VT@ _]W)@3_?S (_X0Y
M#?V&013UA4D;[H)1(N=]6BKA>&0RW'-N.M1N=T'0:H!'S&:)3,ADD5#%8IA3
MPV"@5<!>J%B^7;%9NUV\6[E<R5RW7.!<M%WO7+!>^5VK7_E=J&#Y7*5A^5RE
M8?E<I6'Y7*5A^5RE8?E<I6'Y7/]8(@/_91X#_W$? _][) /_A"X'_XDV"_B+
M/A'OBT87Z(A.'N&$5R;9?F$QT7AJ.LMS<T+&;WQ(PFR$3;YIC%&[9I-5N&2;
M6+5CHUJS8:Q<L&"W7JY@Q%^L8-A?J6'K7Z=A]U^B8_=?GV3W7YUD^%Z=9/A>
MG63X7IUD^%Z=9/A>G63X7O];( +_:!P"_W0= O]^(P/_B"L%_8TT"?.0.P[J
MD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7& 3K5NB%*R:X]6KVF76JQG
MGURI9:A?IF2R8:1DOV*B9-!BH&3G8IYE]6*:9O5AF&?V8)9H]F"6:/9@EFCV
M8)9H]F"6:/9@EFCV8/]='P+_:AH"_W<< O^"(0+_BRD$^9$Q!^^5. OFEC\0
MW91'%]*.423*B%LOPH-D.;Q^;$&W>71(LG5\3JYRA%.J;XM7IFV36Z-KFUZ@
M:J1@G6BN8YMHNF29:,MEEVCC9)5I\V23:O1CD6OU8I!K]6&0:_5AD&OU89!K
M]6&0:_5AD&OU8?]?'0+_;1@"_WH; O^%'P+_CB<#]94N!>N9-0CAG#L,UIA#
M%LR33R+$C5@NO8=A.+:":4&P?G%(JWIY3J=W@%.C=(A8GW&06YMOF%^8;J%B
ME6VK9))LMV:0;,9FCVS?9HYM\66,;O-DBV[T8XIN]&**;O1BBF[T8HIN]&**
M;O1BBF[T8O]A' +_;Q8"_WP: ?^('@'_D20"\IDK!.>>,07=H#8)T9Q!%<>7
M32&_D58MMXQ?-[&'9T"K@FY(I7YV3J![?5.<>(58F':-7)1TE5^1<IYBCG&H
M98MPM&>)<,-HAW#;9X9Q[F:&<O)EA7+S9(1R]&.$<O1CA'+T8X1R]&.$<O1C
MA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG N.B+ /8I#((S)] %,.:2R"Z
ME54LLY!=-ZR+93^EAVQ'H(-S39N >U.6?8)7DGJ*7(YXDF"*=IMCAW6E9H1T
ML6>"=,!H@'35:(!U[&=_=O)F?W7S97]U\V1_=?-D?W7S9']U\V1_=?-D?W7S
M9/]E&0+_=!0!_X$7 ?^-&@'YEQX!ZZ C =^F)@+2IS 'R*,^$[^>21^VF5,K
MKI1;-J>/8S^@BVI&FX=Q396$>%*0@7]7C'^'7(A]D&"$>YEC@'JC9GYYKVA[
M>;UI>GG1:7EZZFAZ>O)F>GGR97IY\V1Z>?-D>GGS9'IY\V1Z>?-D>GGS9/]G
M%P+_=A0!_X06 ?^0%P'UFQH!YZ0= =NK'P'.JB\&Q*8]$KJA2!ZRG5$JJIA9
M-**483Z<D&A%EHQO3)")=E*+AGU7AH2%6X*"C5]^@)=C>G^A9G=^K&AU?;MI
M<W[.:7-^Z&AT?O%F='WR975\\V1U?/-D=7SS9'5\\V1U?/-D=7SS9/]I%@'_
M>!,!_X<4 /^3%0#QGA4 XZ@6 -6N&P'*K2T&P*D[$;:E1AVMH5 II9Q8,YZ8
M7SR7E&9$D)%M2XN.=%&&C'M6@8F#6WR'BU]XAI1B=(2?97&#JF=O@[AI;8/+
M:6V#YFAN@_)F;X+R97"!\V1P@?-D<('S9'"!\V1P@?-D<('S9/]K% '_>Q(!
M_XH2 /^6$@#MHA  WJT. -"Q&0#%L"L%NZTY#[*I1!NII4XGH*%6,IF=7CN2
MFF1#BY=K2H:4<E" DGE5>X^ 6G>-B5YRC))A;HJ<9&N)J&=IB;9H9XG(:&>)
MXV=HB?)F:8?S96J&\V1JAO-D:H;S9&J&\V1JAO-D:H;S9/]N$@'_?A  _XT0
M />:#@#;IPH T[ + ,JT%@# M"D$MK$W#JVN0QJDJDPEFZ95,).C7#F,H&-!
MAIUI2(":<$Y[F'=3=I9^6'&4AEQLDI!@:)&:8V60IF5CD+1F89#&9F&0X69A
MD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C9(ST8_]Q$ '_@@\ _Y$- -Z?
M"0#3J@D S+,) ,2X$P"ZN"8#L;8U#*>S01B>KTHCEJQ3+HZI6C>'IF$_@*1G
M1GJA;DQUGW51<)U\56N<A%IFFHY=8YF88%^8I&)=F+)D6YC#9%N8WF-;F/!C
M7)7U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B7I/U8O]U#@#_A@T ZY8( -6C!P#,
MK0@ Q;8' +V\$0"TO2,"J[LR"J&Y/Q68MD@@D+-1*XBP6#2 KE\\>JMF0W2I
M;$AOJ'-.:J9Z4F6E@E9AHXQ:7:*67%JBHE]7H;!@5J'!8%6BW&!5H>]@5I_W
M7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z# #]BPD VIL$ ,ZG!@#$L 8
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MY5&J/N-0LC_A3[M X$_'0-Y/V$'93^A!U$_T0]!._D7.3O]&R%#_1L)1_T?
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M66>#_%AG@_Q79X/\5V>#_%=G@_Q79X/\5_]L#@#_>PP \HD) -F5!@#/G@@
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M3TZD_T].I/]/3J3_3_I_  #8C@  R9L! +ZE @"TK0$ J[4  *&_! ";P10
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M#R7_H1 D_ZX1(_^Z$B+_RA(B_] 2(O_0$B+_T!(B_] 2(O_0$IRR  ".O
M@<<  '/1  !GW0  6>,  %/]!@!-_PX 2/\6 $/_'@$__R8".O\M C?_,P,S
M_SD#,/\_!"[_1 0K_TH%*?]0!2?_5@8D_UT&(O]E!R#_;@<=_WD(&_^%"!K_
MD@D9_YX)&/^H"1?_LPD7_[<)%_^W"1?_MPD7_[<)%_^W"9"Z  ""Q0  =-
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M3(]BZ$R.8_A+C6/_2HQD_TF+9/])BV3_28MD_TF+9/])BV3_2?]:$P'_9A
M_W$1 /]Z$@#W@A0 Z(<7 -V+' #0BRP#QX@["K^$1Q.X?U$<L7M:)*QW8BNG
M=&HQHW%R-I]O>3N;;8 _F&N(0I5ID$62:)E(CV:B2HQFK4R*9;I-B&7,3H=F
MYDZ&9_9,AF?_2X5H_TN$:/]*A&C_2H1H_TJ$:/]*A&C_2O]<$@'_: \ _W00
M /]]$ #SA1  Y(L1 -:/%P#+CBH"PHPX";J(1!*SA$\;K']8(Z=\8"NA>&@Q
MG75O-IES=CN5<7T_DF^%0HYMC46+;)9(B&N@2X5JJDV#:;=.@6G(3X!JXT^
M:_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+?VO_2_]>$ '_:PX _W8. /N
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M371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B#@#_;PP _'L* -Z&!@#5C@@
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M2UZ&_TM>AO]+7H;_2_]M!0#J?   U8@  ,J2 P#!F@, N: # +&F"0"IIQD
MHJ<I YJE-@F2HT$2BZ%*&H2?4B%^G5HH>9M@+G299S-OEVXX:Y9U/&>4?4!C
MDX9#8)&01ER1G$E:D*E+6)"X3%>0S$Q7D.=+5X_W2E>._TI8CO])6([_25B.
M_TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@( LJ0  *FJ!0"BK!4 FZPF
M I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!JGVPT99YS.6&=>SQ>FX1
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M(#G9PR YV=\@.=?O(#C5^2(WU/\C-]3_(S?4_R,WU/\C-]3_([F<  "KI
MGZP  ).U  "'O@  >\8  '#. P!EU@< 7>,. %KC&P!6XR<!4N0R D[D/ 1*
MY$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>: %#?GC!4UYYD6-.>H%S+H
MN!@RZ,P8,>CE&#'F]!@QY?P8,>7\&#'E_!@QY?P8,>7\&*ZB  "AJ@  E+,
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M!1'_L@41_[P%$?^\!1'_O 41_[P%$?^\!8RX  !]P@  ;\P  &+8  !4WP
M1^4  #[Q   Y_P$ -/\+ ##_$  L_Q8 *?\< ";_(@ B_R<!'_\L 1S_,0$:
M_S8!&/\\ 17_00$3_T@"$?]/ A#_5P(-_V$"#/]L @K_>0()_X8#"/^2 P?_
MG0,&_Z4#!O^E P;_I0,&_Z4#!O^E _\Q,0+_-BX"_SHO O\[,@/_.SD$_SM#
M!?\Y3P?_.%P*_S9H#?\T=!#_,H 2_S&+%/\PE!;_,)L7_R^B%_\OJ!C_+J\9
M_RZU&?\NO!G_+L4:_R[/&O\NX!K_+NL:_R[T&O\N_!K\+_\9^R__&OHN_QOZ
M+O\<^B[_'/HN_QSZ+O\<^B[_'/\S+P+_.2P"_STM O\^, /_/S8$_S]!!?\]
M30?_/%D*_SIE#O\X<A'_-GT3_S6(%?\TD1?_,YD8_S.@&?\RIAG_,JP:_S&S
M&O\QNAO_,<(;_S',&_\QW1O_,>D;_3'S&_HR^QOX,O\;]S+_'/8Q_QWU,?\>
M]3'_'O4Q_Q[U,?\>]3'_'O\U+ +_/"H"_T J O]"+0/_0S0$_T0_!?]"2@?_
M058*_S]B#O\];A'_.WH4_SF$%O\XCAC_-Y89_S:=&O\VI!O_-:H<_S6P'/\U
MMQW_-;\=_S7)'?PUV!WZ-><=]S7Q'?0U^AWR-?\>\37_'_ U_R#O-/\A[S3_
M(>\T_R'O-/\A[S3_(?\X*@+_/R<"_T,F O]&*0+_23(#_TD\!?](1P?_1E,+
M_T1?#_]":A+_0'85_SZ &/\\BAG_/)(;_SN:'/TZH!W\.J<=^SFM'OHYM!_Y
M.;P?^#G&'_8YTQ_R.>0?[SGP'^PZ^A_J.?\AZ3G_(^@Y_R3G.?\DYSG_)><Y
M_R7G.?\EYSG_)?\\)P+_0R,"_T@B O],)@+_3R\#_U Y!?].0P?_3$\+_TI;
M#_](9A/_17$6_$-\&?I"AAOX08X<]D"6'O4_G1_S/Z,@\CZJ(/$^L2'P/KDA
M[C[#(>T^SR'J/N(AYC_O(>,^^2/A/?\EWSW_)]X]_RC</?\HW#W_*-P]_RC<
M/?\HW#W_*/\_(P'_1R !_TP> ?]1) +_52P#_U8U!/]5/P;_4TH*_E!6#_I.
M8A/V2VT7\TEW&O!'@1SN1HH>[$62(.M$F2'I0Z BZ$.G(^9#KB/E0K8DY$+
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M.*=2[3FE4_HYHU/_.:)3_SFA5/\XH53_.*%4_SBA5/\XH53_./]/% '_61
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M+*%F>"^>9( SFV*'-IAACSB68)@[DU^A/9%>JS^/7KA C5[(08M>X4&*7_-
MB5__/XE@_SZ(8/\^B&#_/8A@_SV(8/\]B&#_/?]7#P#_8@P _VP, /AT# #I
M>@P WGX, -*!%0#(@2<!P'\V!KA\0@VR>$T5K'56&Z=R7R*B;V8GGFQN+)MJ
M=3"7:'PSE&>$-I%EC#F.9)4\C&.>/HEBJ$"'8K5"A6+%0H1BWD.#8_%"@F/]
M08)D_T""9/\_@F3_/X)D_S^"9/\_@F3_/_]9#@#_9 L _VX* .IW" #;?0@
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M-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!NT45P;^M$<&_Z0W%O_T%Q;_]
M<7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78  -1_ P#+A@4 Q8L& +Z-#0"U
MCQX KHXM Z:,.@F?B441F89.&).#5AZ.@%TDB7YD*85\:RV!>G(R?7AY-7IW
M@CEW=HL\<W65/W%TGT)N<ZQ$;'.[16MSSD5K<^E$:W/X0VMS_T)L<_]!;'/_
M0&QS_T!L<_] ;'/_0/]A!0#Z;@$ W7D  -"" @#'B00 P(X$ +F1# "QDAL
MJ9(K Z*0. B;C4,/E(I,%XZ(5!V)A5LCA(-B*("!:2U\?W Q>'YW-75\?SAQ
M>X@\;GJ2/VMYG4%H>*I#9GBX1&5XS$5E>.=$97CW0V9X_T)F>/]!9GC_0&9X
M_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C , NY$# +.4"0"LEA@ I98H
M IV4-@>6DD$.D(]*%8J-4AR$BUHB?XE@)WN'9RQWA6XP<X-U-&^"?3=L@88[
M:7^0/F9^FT%C?JA#87VV1&!]R41??>5#8'WV0F!]_T%A??] 87W_0&%]_T!A
M??] 87W_0/]G  #C=   TG\  ,>( 0"^CP( MI4! *Z8!@"FFA4 GYHF IB9
M,P:1ES\,BY5(%(634!I_D5@@>H]?)7:-92IRBVPN;HIS,FJ(>S9FAX0Y8X:.
M/&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#_T!;@_] 6X/_/UN#_S];@_\_
M6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@  *>= @"@GQ( F9\C 9.>,06,
MG3P+A9M&$G^93AAZEU8>=99=(W"48RALDFHL:)%Q,&60>31ACH(W7HV,.EJ,
MESU8C*0_5HNR0%2+Q4!4B^% 5(KS/U6*_C]5B?\^58G_/E6)_SY5B?\^58G_
M/N]O  #6?   R(<  +V1  "TF   JIP  *"B  "9I!  DZ4@ 8RD+@.%HSD)
M?Z)##WF@3!9TGU,;;YU:(&J<825FFF@I8YEO+5^8=S!;EX T6):*-U65E3E2
ME:([4)2P/4^4PSU/E-\\3Y/R/$^2_3Q/DO\\3Y'_/$^1_SQ/D?\\3Y'_/.1T
M  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T BZL; (6K*@)^JC8&>*E!
M#'*H21)MIU$8::98'&2D7R%@HV8E7:)M*5FA=2Q6H7XO4Z"(,D^?DS5-GZ W
M2YZO.$J>P3A)GMTX29WP.$F<_#A)F_\Y29O_.4F;_SE)F_\Y29O_.=MZ  #(
MAP  O)(  +&:  "FH   G*8  )&L  "'L0@ @;(6 'RS)@%VLC,$<;(]"6NQ
M1PYFL$\38J]6&%ZN71Q:K60@5ZQK(U2L<R90JWPI3:J&+$JJDB](J9\P1JFM
M,D6IOS)$JMHR1*CO,D.G^S-#IO\S0Z7_-$.E_S1#I?\T0Z7_--"!  #!C@
MM9@  *F?  ">I0  DZP  (BR  !\N0( =KH1 '*[(0!NNRX":+LZ!F2Z0PI?
MNDP.6[E3$E>X6A94N&$94;=I'$ZW<1]+MGHB2+:$)46VD"=#M9TI0;6L*D"V
MOBH_MM@J/[3N*CZS^BP]LO\M/;'_+3VQ_RT]L?\M/;'_+<>)  "YE0  K)T
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M#BW@\@XLW_L/+-_]$"S?_1 LW_T0+-_]$*B@  "<IP  C[   (.X  !VP0
M:LD  %[/  !3U0$ 2=P& $7I#P!"Z1D 0.HD #WJ+@ ZZS8!..P^ 3;L1@(S
M[4T#,>U5 R_N700M[F4%*^YP!2GO>P8H[XD')O"7!R7PIP@D\;@((_',""+R
MY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP  A+@  '?!  !JR0  7=
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M'\5"\R'"0?XCP$'_)+Y!_R2]0?\EO4'_);U!_R6]0?\EO4'_)?]"& '_21,
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M,954_S&45/\PE%3_,)14_S"45/\PE%3_,/]/#@#_6 L _V + /MF# #P:PT
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M-7AD_S5X9/\U>&3_-?]7!0#_8@$ X6P  -1S @#+> 0 Q7L% +Y]#0"V?AT
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M-5*'OC51A]8U48;N-5*%^S12A?\T4H7_,U*%_S-2A?\S4H7_,^-L  #.>0
MP8,  +:+  "LD0  HI4  )>9  "/FPL BIT8 (2=)P%^G#0$>9L^"'.:1PUO
MF4\2:IA6%V:771MCE6,>7Y1J(ER3<B59DGLH59&%*U*1D"Y0D)TP3I"K,4R0
MO#),D-,R3(_M,DR.^C),C?\Q3(S_,4R,_S%,C/\Q3(S_,=QQ  #(?@  NX@
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M(#NN]R$ZK?\B.JS_(SJL_R,ZK/\C.JS_(\"&  "SD@  IYD  )R?  "0I@
MA*P  'FQ  !MMP  8;P% %V]$@!:OB  6+XM 52^. )1OD($3KY*!DR^4@A)
MOED*1KY@#$2^: Y!O7$1/[U\$SR]B!4ZO946.+VD%S>]M1@VO<H8-[SG%S6[
M]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF   GY\  ).F  "'K   >[,
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M QOI^0,;Z?D#&^GY YJD  "-K   ?[4  '*]  !EQ0  6<L  $S0  !!U0
M.-P  "_A @ M\0T *_$3 "CR'  F\B0 )/,K "+T,@ A]#D '_5! !WU20 ;
M]E$ &?=: 1?W90$5^'(!%/F! 1/YD@$2^J("$?JS A#[Q@(0^]T"$/OI A#[
MZ0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0  2],  $#9   UW@  +.,
M ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5_RX $_\U !+_/  0_T,
M#O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_K@$$_[P! __' 0/_QP$#
M_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P  #/A   IY0  (>P  ![]
M   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R, "_\H  C_+@ &_S4  _\]
M  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0  _Z4  /^L  #_K   _ZP
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M'JY!_QZM0?\>K$'_'JQ!_QZL0?\>K$'_'O]"$0#_1PT _T\. /]3$0#_5A4
M\U<< .A6)0#@53$!UU,_ L]23 7*4%<)QDYA#<-,:A# 2G(2O4EZ%;M(@A:Y
M1XD8MT>0&;5&EQNS1I\<L46G';!%L1ZN1;P?K$7,'ZI%XR"G1O,AI4;_(:-&
M_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH _U,, /]7#0#Y6A  ZUL4
M -]:' #46BL S%H[ L982 7!5E,)O%1<#;E291&U4&T4LT]U%[!.?!FN380:
MK$R+'*I+DAZH2IH?IDJC(:1)K"*C2;@CH4G&))]*WB2=2O DFTK])9E+_R29
M2_\DF$O_))A+_R282_\DF$O_)/](# #_3P@ _U8( /5;"0#I7@H Y%X- -5?
M%0#+8"< Q%\V KY>0P6X6TX)M%E8#K!781*L56D5JE1P&*=3>!JE4G\<HE&&
M'J!0CB">3Y8BG$Z?(YI.J"683K,FET[")Y5.UB>33NPGD4_[)Y!/_R>04/\F
MCU#_)H]0_R:/4/\FCU#_)O]*"0#_4P4 ^%H$ .)? P#:8@8 U&,) ,UC$@#$
M92, O&4R K9C0 6Q84L)K%Y4#JA<71*E6V46H5EL&)]8<QN<5GH>FE6"()A4
MBB*55)(DDU.;)I%2I2>/4K IC5*^*HQ2T"J*4^DJB5/Y*8A4_RF'5/\HAU3_
M*(=4_RB'5/\HAU3_*/],!0#_5@$ Z5T  -QC @#19P4 S&@' ,9H$ "]:B
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M+U]OO2]>;]0O7F_M+U]O^RU?;_\L8&__+&!O_RQ@;_\L8&__+.M>  #8:0
MQW(  +QY  "S?P  JX(  *&"  "9@PX E(0= (Z$*P&(@S8$@X) "'Z 20QY
M?U$0=7U8%')\7QAN>V4;:WIL'FAY=")E>'TE8G>')V!VDBI==9XL6W6K+EIT
MNR]9==$O673L+EET^BU:=/\L6G3_*UIT_RM:=/\K6G3_*^9A  #1;0  PW8
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M)TF)]RA)B/\G28?_)TF'_R=)A_\G28?_)]%O  #!>P  M80  *N,  "@D
ME90  (F7  !^F@  =YL. '.<' !OG2D!:YPU F:</P5BFT<(7YI/"UR:5@]8
MF5P259AC%5.8:Q=0EW,:399]'4J5B1]'E94A196D(T24LR-#E,@C0Y3E(T.2
M]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0  L(L  *21  ":E0  CYD
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M$C"S_Q,PL_\3,+/_$[*.  "EE0  FIL  (ZB  ""J   =:T  &FS  !>MP
M4[L  $? !0!#PA  0L(; $##)P _PS( /L0\ #S$1 $ZQ$T!.,15 C;$70,U
MQ&8$,\5P!#'%? 8OQ8H&+<6:!RO%J@@JQ;X(*L7:""K$\ @IPOL)*,'_"BC!
M_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP  :[4  %^[  !4OP  2<,
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M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   QV   )]T  !_A   9Z
M%O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^,  (_S@ !O]!  /_3
M_U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.  #_SP  _\\  /_/ '^R
M  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0  '.4  !3I   1]P  #_\!
M  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P  _RH  /\R  #_/   _T<
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M"LTJ_PO,*O\,RRK_#,LJ_PS+*O\,RRK_#/\R%P#_-1( _S@2 /\[& #_/2
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M&9U"_QB=0O\8G4+_&/] "0#_1@4 _TP% /%/!P#F4 D XT\- -5/%0#,42<
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M)6M>O"9J7M$F:5[L)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70
MRV4  ,!K  "W;@  KV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65B
MNB9D8L\F9&+J)F5B^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@
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M)55P]B16;_\C5F__(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0
MGW\  ))^  "*?P< A( 3 ("!(0![@2X!=X Y W* 0@5N?TH(:WY1"VA]6 YD
M?%\18GMF%%]Z;1=<>74967A_'%=XBAY4=Y8A4G:D(E%VLR-0=L8D4';C(U!U
M]2-1=?\B473_(5%T_R%1=/\A473_(=AC  #%;0  N'8  *Y]  "E@@  FH,
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M&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0
M99L$ &"<$ !=G1T 6YXI %B>- %5GCT"4IU% U"=305-G50'2YQ;"4B<8PM&
MG&L-0YMU#T&;@!$^FHT3/)J;%#J:JQ4YFKT5.9K9%3F8[Q8YE_P6.);_%SB5
M_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-E0  @9H  '6=  !HH   6Z0
M %:E# !3IA< 4:<C $^G+P!,IS@!2J=! 4BG20)&IU $0Z=8!4&G7P8_IF@(
M/:9R"CJF?0LXIHH--J69#C2EJ0\SI;L/,Z74#S.D[@\RHOL0,J'_$3*A_Q$R
MH?\1,J'_$;2"  "HC   G9(  )*7  "&G   >:$  &VE  !AJ0  5:P  $NO
M!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]LDL!.[)3 CFR6P,WLF0$-;)N
M!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+
M*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [
MN@H .+L3 #>\'@ UO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^
M= (IOH(")[^1 R:_H@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_
M!:22  "8F   C)X  ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0
M*L<+ "C($P GR1T )LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =
MS7H ',V* !O-G  9SJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9
M  "/GP  @J8  '6M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- &
M !G5"P 6UQ  %=@9 !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T
M$-Y^  [?D0 .X*0 #>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%
MIP  =ZX  &JU  !=O   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>
M!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN
M  'K@   ZI0  .JG  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP
M:[<  %Z^  !1Q0  0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *
M]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V
M;@  ]H$  /:5  #WIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,
M %+(  !$S0  -]$  "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,
M /\(  #_#0  _A   /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P
M_VP  /^   #_D@  _Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0 _QHE /\5
M)P#_$2X _Q Z /\.1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_"HX!_PJ5
M ?\*FP'_": !_PFE /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)ZP#U"?8
M\PG_ /(*_P#Q"O\!\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA /\9) #_
M%RP _Q4W /\31 #_$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!_PZ2 ?\.
MF '_#IT!_PZC ?X.J '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N#O4 [ [_
M >L/_P'J#_\!ZA#_ >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?( #_'RD
M_QPT /\:0 #_%TP!_Q58 ?\48P'_$VX!_Q-W ?X3@ '\$X@!^A*. ?D2E0'X
M$IH!]A*@ ?42I@'T$JP!\Q*S ?$2O 'P$L<![1+8 >D3Z 'F$_4!Y!3_ >(4
M_P+A%?\"X17_ N 5_P+@%?\"X!7_ O\E&P#_)A< _R06 /\E' #_)B4 _R0P
M /\A.P#_'T@ _QU4 ?T;7P'Y&FD!]QIS ?09? 'R&80!\1F+ >\9D0'N&9<!
M[!F= >L9HP'I&:H!Z!FQ ><9N@'E&<4!XQG5 =\:Z '<&_4"V!O_ M4<_P/4
M'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$ _RPK /\I
M-P#])T, ]R5/ ?,C6@'O(F0!["%N >DA=P'G(7\!Y2&& >0AC0'B()0!X2":
M =\@H '>(*<!W"&O =HAN +8(<,"U2'3 M$BYP+-(O0#RB/_!,@C_P7'(_\&
MQB/_!L8C_P;&(_\&QB/_!O\L$@#_+@\ _S 0 /\S% #_,QL _S(E /HP, #R
M+CP ["Q) .<J50'C*E\!X"EI =TI<@':*'H!URB" M4HB0+3*) "T2B6 \\H
MG /.**,#S"BK \HHLP/)*+X$QRC,!,4IX@3!*O$&OBK^![PJ_PBZ*O\(NBK_
M"+DJ_PFY*O\)N2K_"?\P#P#_,@L _S8- /\X$ #_.14 ^3<> .\U* #G,S4
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M1TH"L$94!*Q%706J1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I
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M&7I.O1IX3M$:=T[K&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4
MT%<  ,1<  "[7@  M%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+
M6%4(B%=<"H968PR#56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2
MNAMQ4LT<<%+H&W!3^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH
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M'6!>]1Q@7O\;8%[_&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;
MHVP  )EI  "2:@L C&H6 (=K) "":S !?FHZ GII0P1V:$L&<V=2"'!G60IM
M9F -:V5F#VAD;A%F9'849&. %F)CBQA@8I<:7F*D'%QBLAU;8L4=6V+A'5MB
M]!Q;8O\;7&+_&EQB_QI<8O\:7&+_&N!5  #+7P  O6<  +)L  "I<   GV\
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M&4UO_QE-;_\936__&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P
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M#[5X  "J@@  GH@  ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ
M1Y\; $:@)@!$H#  0Z$Z $&A0@$_H4D!/:%1 CNA60(YH6$#-Z!K!#6@=@4S
MH(,&,:"2!S"@H@@NH+,(+J#)""Z?YP@MG?<)+9S_"BV;_PHMF_\*+9O_"J^
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M 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0
MB)L  'NA  !NI@  8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =
MPA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&
MD0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(
M '&I  !DKP  6+0  $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L
M#M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %
MU)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q
M  !9N   3+T  #_    TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-
M  3<$0 #W1@  =X@  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@
M .2;  #EK@  Y<$  .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-
MP0  0,0  #/(   HS   ']   !?4   0V0  "]T   7A    Y    .4'  #F
M#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**
M  #SG   \ZT  /2[  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0
M,\T  "?1   =U@  %-P   [@   (XP   >8   #J    [@   .X   #O!
M\ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_
MB0  _YH  /^F  #_L   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W
M /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P
M_P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N
M /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*
M00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*>
M /<"I #U JH \P&P /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\
MY@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_
M#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*
MH0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_
M -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0
M_A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E
M#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3
M_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+
M .X85@#J%V  YQ9J .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J(
MU!:I -(6L0#0%[L SA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+
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M!O\M!0#_,   _S," /8T!@#O,@H Z"X0 -PL& #1+B@ RR\W ,8P1 #!,$\
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M"Y [P R..]4,C#SL#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P
MW$4  ,Y)  #%20  OT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:
M0UL#F$-B!99":0:407 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5
MO ^$0,\/@D'I#X%!^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL
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M%&M.]!-K3O\2:T[_$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7
MIEH  )]6  "85@T DE<9 (Y8)@")6#( AE@] 8)710)_5DT#?%54!7E46P9W
M5&$(=5-H"7-3< MQ4G@-;U*!#VU2BQ!K49<2:5&C$V=1L11F4<,595+>%652
M\A1E4O\395+_$F52_Q)E4O\295+_$N1*  #/4P  P%H  +5>  "L8   HEX
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M$U==_Q)77?\25UW_$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90(
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M$,%C  "S;   J',  )MV  ".=0  @78  '5V  !I>   8WH" %Y\#@!<?1D
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M!C&/G@<PCJ\'+X[#!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P
MF(0  (J$  !]A0  <(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [
MF2@ .IHQ #F:.@ WFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:
MF@,IFJP$*)K !">9W@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD
M (2*  !VC   :H\  %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$
M+J0J "VD,@ LI3H *Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@
MIJ@!'Z6[ 1ZEUP$>I.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1
M  !OE   8Y@  %>=  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A
M ""P*0 ?L#$ 'K Z !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ(
M%+*V !.RS@ 3L>L $Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !H
MGP  6Z,  %"H  !%K   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\
M'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL
M  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@
M4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &
MR1P !<DD  3*+  #RC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+
MLP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@
M #N[   PO@  )L$  !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0
M -4:  #6(@  URH  -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I
MWK8  -[(  #>W@  WN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$
M   DQP  &\L  !//   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2
M  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4
M .ZT  #NP@  [L8  .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9
MT0  $=8   O;   #W@   .$   #E    Z    .D   #J    ZP8  .T+  #O
M#P  \!,  /(:  #T(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB
M  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X
M_P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V
M *< ]0"M /, M0#R +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H
M_P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6
M /\ 80#_ &L _0!S /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0
M[0"K .P L@#J +H Z #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A
M /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X
M7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H
M ., KP#A +@ WP## -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\
MU /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q
M!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&
MK0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_
M /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P
MX0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)
M#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?
M"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-?
M ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[
MNQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_
M(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >
M8@"^'FH O!]Q +H?> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W
M :PAQ@&K(=T!IR+O J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*
M\BH  .4K  #?* 4 W"$+ -(A% #))"0 PR4R +XF/P"Z)TH MR=4 +0G70"R
M)V0 L"=L *XG<@&M)WD!JR=_ :HGA@&H)XX!IR>6 J4GG@*C**@"HBBS J H
MP0*?*-4"G"GL YHJ^@.8*O\$ERK_!)<J_P26*O\$EBK_!/\H  #U+@  Y3,
M -HU  #0,P$ S"T& ,8J$ "^+1X N"XL +,O.@"O+T4 K#!/ *DO6 "G+U\!
MI2]F :,O;0&A+W,"H"YZ IXN@0*=+HD"FRZ1 YDNF@.8+J0$EB^O!)4OO023
M+\\$D3#H!8\P^ 6-,?\%C3'_!8PQ_P6,,?\%C#'_!?\M  #J-0  W#H  ,X]
M  #&/   P#<" +LS#0"S-!D KC8G *DW- "E-T  HC=* )\W4P&=-EH!FS9A
M 9DV: *7-6\"E35U Y0U? .2-80$D#6-!(\UE@6--: %BS6K!HHUN0:(-<H'
MAS;E!X4V]@>$-_\'@S?_!X,W_P>"-_\'@C?_!_0R  #C.P  TD$  ,9$  "]
M0P  MS\  +$["0"J.Q0 I3PB * ], "=/3L F3U% )8]3@&4/%8!DCQ= I \
M8P*..VH#C#MQ!(H[> 2(.H %ASJ(!H4ZD@:#.IP'@3JH"( ZM0E^.\8)?3OA
M"7L\\PE[//\)>CS_"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20
MKD8  *E!! "C01$ G4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%
M068#@T!M!(% = 6 0'L&?C^$!WP_C@AZ/YD)>#^E"G= L@IU0,,+=$#="W-!
M\0MR0?\*<D'_"G)!_PER0?\)<D'_">D\  #510  Q4L  +I.  "P3@  ITL
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M#&!-_PM@3?\+8$W_"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8
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M#,E4  "Y7   K6,  )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT
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M"3]NG@H];J\*/6[""CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0
MH&X  )%M  "$;0  >&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,
M=S$ 2W@Y $EX00!(>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEV
MG @W=:T(-W7 "#9UW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$
M (MQ  !^<0  <W(  &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP
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M 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@
M8H4  %>)  !-C@  0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ C
MGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?
MR0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\
M %"3  !&F   /)P  #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD
M%:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,
MJM\ #*GR  VH_  -J/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?
M   _HP  -:<  "NJ   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G
M  FV+P (MCD ![=#  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL
M +;E  "U\0  M?<  +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   W
MKP  ++(  ".U   :N   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #"
M)@  PB\  ,,Y  #$1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31
M  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0
M(KP  !F_   1P@  #,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0
MSR0  - M  #2.   U$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8
MS@  V-T  -C= 'N@  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8
M !#)   *S    M    #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD
M .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@
MZL,  .K# '"H  !BKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4
M    V0   -T   #A    XP   .0   #F    YP$  .D'  #K#   [!   .X5
M  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[
M /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_
M &L _P!S /T >P#[ (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$
ML #O +@ [@## .P T0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_
M /\.& #_"A4 _P$4 /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &<
M]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F
M +0 Y "_ ., S #A .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0
M$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K
M .P <@#J 'D Z !_ .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$
MV "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_
M#@T _PP- /\+$@#_!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$
M;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X
M ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8
M_Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0
M!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&
MP@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8#
M /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H
MP@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T +(/P0"Q
M$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\ IQ/_ /\:  #_&P  ^1L  .L9
M  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_%$L O!14 +D570"W%60 M15K
M +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7G "I%Z8 IQBP *88O0"D&,\
MHAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0  -TE  #4
M(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4 L!Y/ *T>5P"K'E\ J1]F *@?
M; "F'W, I1]Y *,?@ "B'X< H""/ )\@F "=(*( FR"L 9HAN0&8(<H!EB+D
M 90C]0&2(_\!D2/_ 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0
MP2<# +TB#0"V(QH L"4H *PF- "H)D  I2=) *(G4@"@)UH GB=A )PG9P";
M)VT F2=T )@G>P&6)X(!E2>+ 9,GE &1*)X!D"BI 8XHM0*-*<8"BRG? HDJ
M\@*'*O\"ABK_ H8J_P*&*O\"ABK_ O0H  #C,0  T38  ,4X  "\-@  MC
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M!6P\_P5L//\%;#S_!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L
MC3\5 (D_(0"%0"T @D W '] 0 !]0$@ >T!/ 7E 5@%W/UT!=3]C G,_:@)Q
M/W(#<#]Z VX_A 1L/Y %:S^<!FD_J09H/[@'9T#,!V9 Z =F0/D&94#_!F5
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M!LQ(  "\4   KU4  *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"
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M!DE8G@=(6*X(1UC "$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60
MHUP  )1;  "'6P  ?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6
M730 5%X\ %->1 !17DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=
MG =#7:P'0EV^"$)=V@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\
M )!>  "#7@  >%T  &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$
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M!#!PT 0Q;^P$,6[[!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0
M:VD  &!K  !5;@  37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X
M>3T -WE% #9Y30 U>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIX
MS (J=^H"*G;Y RIU_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX
M %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@
M+H)  "V"2  L@E  *X): "J"9  H@G  )H)_ 26"CP$D@J !(X*R 2*"R0$B
M@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0  @W$  '9Q  !L<@  8'4  %9X
M  !,?   0X   #N#   SA@  +8D* "J*$0 IBQD )XLB ":+*@ EC#$ )(PY
M ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-B@ ;C9P &8VN !B,Q  8C.,
M&8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78  ')W  !E>0  6GP  %"   !&
MA   /(D  #2,   MD   )9," !^5#  =EA( ')8: !N7(@ :ERH &9<R !B8
M.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0F)8 $)BI  Z8OP .E]T #Y;R
M !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP
M-I,  "V7   FF@  'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -
MI#H #*1%  ND4  *I%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A
M\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX
M ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(
M + \  "P1P  L%,  +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP
MKO0  *[T (>)  !XB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN
M   6L0  $+0   NV   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ
M  "]/   OD@  +Y6  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L
M +WK '^2  !PE0  8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .
MO   ";\   +"    Q    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,
M,   SCP  ,Y)  #/60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_;
M '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP
M ,H   #.    T    -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)
MX"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE
M  !?K   4;(  $2Y   UO   *,   !S$   2R   #,L   //    TP   -@
M  #<    WP   -\   #A    XP   .0#  #F"   Z T  .D1  #L&   [B(
M /$N  #S/   ]$T  /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_
M !4 _P 5 /\ & #_ ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L
M=@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"]
M .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$
M_P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P
M 'D [P!_ .T A #K (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X
MQ@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P -
M /\ $@#_ !H _P F /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0
MXP!Z .( @ #@ (4 W@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#,
M -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\
M#P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U
M -( >P#0 (  S@"& ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L
MO0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_
M 1  \  9 .8 )0#A #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4
M=@## 'L P0"! ,  AP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#?
M + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH
MX@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W
M!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+
M\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+
M ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$
MJ@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7
M$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0
M#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R
M )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T
MBAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N
M&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?
M= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_
M 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$
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M M$[  # 0@  L$4  *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2,
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M U)'G 101ZL$4$>]!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30
MHTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=
M234 6TD] %E)1 !724H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*
MFP1,2ZH$2TN\!$I+TP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\
M )%/  "%3@  >TT  '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833(
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M!#Q8S00\5^H#/%?Z SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@
M;U8  &55  !<5@  5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$
M74$ 0UU( $)=4 ! 75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=
MRP,V7.@#-USY S=;_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD
M &!:  !66P  45T  $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX
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M 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);
M0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C
M>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX
M_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<
M #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4(
M&(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2
M@O\ $H'_ )%N  "!;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#
M   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$
M  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P
M"(W_ (ES  ![<P  ;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   A
MD0  &I4  !.7   .F@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=
M2   G50  )UB  "<<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX
M ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0
M$J    ZC   )I@4  Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P
MJ4L  *E9  "I:   J7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V
M  !O@0  880  %6)  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P
M  >O    L@   +,'  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT
M +A.  "X70  N&X  +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !G
MBP  6I   $Z6  !"G   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\
M    O@   +X   "_!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"
M  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F
M4YX  $:D   ZJP  +[   "2U   9N   $+P   J_   !P0   ,0   #(
MR@   ,H   #,    S0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>
M0P  WU0  -]G  #@?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T
M #^T   RN   )+P  !B_   0PP  ",<   #*    S0   -$   #5    V
M -D   #;    W0   -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0
M\48  /)8  #S:P  \X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\
M%0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^
M /0 A #R (D \0". /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L
MXP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_
M !L _P H /\ - #^ $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D
M?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H
M -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8
M^P B /< +P#T #L \ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#:
M (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0
M\@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 =
M .L *0#G #8 XP!! -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L
MR "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T
M /H M #_ +0 _P"T /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X
M(@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![
M +D @0"W (< M0". +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /<
MIP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#'
M "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P
M? "J (( J0") *< D0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_
M )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\
MMP,L +,$-P"P!4( K09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?
M"'X G0B% )L)C@":"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X.
M_P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD
M *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D
MDA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""
M%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5
M*@"9%34 EA8^ )061P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\
M (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\
M>!W_ .4B  #0*0  ORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".
M'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@
M@0!Y(8P =R&7 '4BI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_
M -TI  #(,   MS(  *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H
M@B4T ( F/0!])D0 ?"9+ 'HF4@!X)E@ =R9> '4F90!T)VP <B=T '$G?0!O
M*(@ ;BB4 &PHH0!K*:\!:BG  6DJVP%G*O$!9RO_ 68K_P%F*O\!9BK_ =0O
M  #"-@  KS8  *$U  "6-   D#   (HM  "'*@8 @RD0 '\J&@!\*R4 >2LO
M '<L. !U+$  <RQ' '$L30!P+%0 ;BQ: &TL80!K+6@ :BUP &@M>@!G+H4
M92Z1 60NG@%B+ZP!82^] 6$PU0%@,.\!7S#] 5\P_P%?,/\!7S#_ <TT  "\
M.P  J3H  )LZ  "0.   B34  (,R  !_, $ >R\. '<P%@!T,"$ <3$K &\Q
M- !M,3P :S%# &HQ2@!H,E  9S)7 &4R70!D,F4 8C)M &$S=P!?,X(!7C..
M 5TTG %;-*H!6C6[ 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@
MI#X  )8]  "+/   @SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F
M-C@ 9#8_ &,V1@!A-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58Y
MF0%5.:@"5#FY E,ZSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$
M ))   "&/P  ?CT  '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0
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M D1&R0)$1N<"1$7X D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P
M<D8  &I"  !C0P  7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+
M1T$ 2D=) $E(4 !(2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*
MQP(_2N4"/TGW D!)_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD
M &5%  !>1P  64@  %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\
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M 3%6_P$Q5?\!,57_ :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5
M258  $17  ! 60@ /5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S
M74X ,5U7 #!=80 O76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;
M_@$K6_\!*UK_ :-5  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L
M #]=   Z7P0 -F - #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH
M*F13 "ED70 H9&D )V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D
M8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC
M   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/
M ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\
M'&C_ )5<  "#7   =5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O
M;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET
M5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_
M (Y@  !]8   ;V$  &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0
M(G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /
M?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E
M  !W90  :F4  &%F  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($
M !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50
M!(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q
M:@  9VL  %ML  !0<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/
M   ,D@8 !I,,  *3$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99
M  "6:0  E7H  )6.  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<
M8'(  %1U  !)>0  /WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $
MG0,  )X)  "?#@  GQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C
M7P  HW$  *.$  "BF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L
M $V   !"A0  .(L  "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@
M *L$  "K"@  K T  *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50
MLF8  +)Y  "RC@  L:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-
M   [DP  ,)D  ":>   <HP  $Z<   VK   'K@   +(   "U    MP   +@
M  "Y @  N0@  +H,  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH
M ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   S
MH@  **@  !VM   4L0  #;8   :Y    O    +\   ##    Q    ,4   #&
M    QP   ,D$  #*"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?
M  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0
M(+<  !6[   -O@  !,(   #%    R0   ,T   #0    T@   -(   #5
MU@   -D   #;    W@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N
M90  [WH  .^/  #PGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I
M /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0
M[@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#=
M /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X
M,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"%
M .  B@#> )  W "6 -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\
MRP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O
M #< ZP!" .< 3 #D %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\
MA0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_
M +P _P"\ /\ O #_ /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$
MVP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^
M (8 O "- +H E "Y )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T
M_P"M /\ K0#_ /\   #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V
M ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($
MK@"( *T CP"K )@ J0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@
M /\ H #_ /\   #V    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8
M.@"T $, L0!, *X 4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0""
M *  B@"> ), G "= )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\
MD@#_ /D%  #J"P  W T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G
M #T I !% *( 30"@ %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ),
MA@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_
M .\/  #>%   RA4  +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8
MF0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'
M"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87
M  #1'@  O1T  *\<  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y
M (P000"*$$@ B!!/ (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@
M>A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&
M)0  LR4  *4C  "<(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7
M/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0
M &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@
MJRH  )TJ  "3*   C24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V
M'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4B
MF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\
M )8O  ",+0  A2H  ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H
M:R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;
M*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S
M  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH]
M &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J,
M4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!
M-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO
M0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q
M $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0
M=#<  &XT  !I,P  93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3
M-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<X
MPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H
M &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$
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M 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#  !N0P  94,  %U   !60
M44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [
M1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'
M_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J1@  844  %E$  !11   3$8
M $A'  !$1PH 04@0 #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP
M-4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O
M2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+
M   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2
M "Y17  M46< +%%U "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\
M*D__ )Q*  ")2@  >DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y
M4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A7
M60 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_
M )9-  "$3@  =4X  &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6
M+UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @
M7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1
M  !^40  <%$  &12  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& #
M "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T
M%V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X
M50  :U4  &!6  !75@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ
M!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3;3D $FY" !%N3  0;E@ #VYE
M  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9  !R60
M9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\  !=R   2
M=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U( !W=?  5W
M;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M70  8EX
M %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\   -?P8
M"8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9  "":
M@GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@  7F(  %-D
M  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (B00  HL*
M  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".8   CG$
M (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D  $UL  !"
M<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0   )8'  "7
M#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P  G&@  )Q[
M  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W   [?
M,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!  "C!@
MI L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T  *QP  "L
MA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   TB@  *9
M !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q    L@,
M +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD  "^>0
MOI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0  (9\  !>D
M   0J0  ":X   "R    M@   +D   "]    OP   +\   #     P0   ,,
M  #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2:P  TX(
M -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX  !&T   )
MN0   +T   #!    Q    ,@   #+    S0   ,T   #/    T    -(   #4
M    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70  ZG(  .N(
M  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\ ,@#_ #T
M_P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$ .D B@#H
M )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\ V #_ -<
M_P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W #@ ] !#
M /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L A0#9 (L
MU0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_ ,8 _P#&
M /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #( Y@ ] .(
M1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#' (4 Q0",
M ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8 _P"V /\
MM@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W ,X 00#*
M $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (  M@"' +0
MC@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G /\ I@#_
M /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P .P"Z $0
MMP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"! *8 B0"D
M )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\ F #_ /T
M  #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K #X J !&
M *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@ @P"6 (P
ME0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_ /,"  #B
M!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #< G !  )H
M1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"* (@ B "2
M (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-  #0$
MOA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y (X!00",
M 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0 ?06. 'L%
MF@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$%P  L1<
M *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+.P"!"T(
M@ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V, ' -F0!O
M#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@  J!X  )L=
M  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W$3T =A%$
M '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83E@!E%*,
M8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0  )(C  ")
M(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@ ;!<_ &L7
M10!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<&Z$ 6QRP
M %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH  "")P
M>R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ &(>00!@
M'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX 4R*N %(C
MP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\+   ="H
M &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC/0!9)$,
M5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL $LIO@!+
M*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P  ;RX  &HK
M  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2*4  4"E&
M $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4NO !%+M8
M12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$  &4O  !@
M+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P 2BU# $DM
M2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _,M, /S+N
M $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R  !<,
M5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%  $,R1P!"
M,D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$ .C;M #LV
M_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7,P  4S0
M $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV1  ]-TP
M/#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL #8Z^P V
M.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@  3C<  $HX
M  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SM3
M #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^^@ R/?\
M,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L  $4\  !!
M/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!0 #%
M6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M0?\ +4'_
M )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!    \000
M.4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45. "Q%6  K
M1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\ *$7_ )5
M  ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W1@  -$<*
M #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+50 E2V
M)$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_ )!#  !^
M1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P  +DT' "M.
M#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?45T 'E%J
M !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&  !Y1P
M:T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%," "14"P B
M51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD %UAF !58
M=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T2@  9DL
M %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;!P :70T
M&%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B  ]?<0 .
M7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@  8DX  %A/
M  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 390D $68/
M !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G;  &9WT
M!6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(  %12  !,
M4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08 "W ,  AP
M$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90  <'8  '"*
M  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  /_B__])0T-?
M4%)/1DE,10 $"5%7  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W
M  YS   +=@0 !7@+  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0
M 'I0  !Z7P  >G   'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?
M6P  5EL  $Q<  !"8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^
M   $@0(  (((  "##0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)
M  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8
M46$  $9D   \:0  ,FT  "ER   A=P  &7L  !*    -@P  "(<   **
MC0   (X$  "."0  CPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "6
M3@  EE\  )5R  "5B   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH
M #]N   U=   *WD  "%_   9A   $8D   R-   &D0   )0   "8    F@
M )L   "< @  G0<  )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1
MIE4  *9H  "F?0  II0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[
M   M@0  (X<  !F-   1D@  "Y<   2<    H    *,   "F    J    *D
M  "J    K    *T$  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL
M +A<  "X<0  N(@  +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   F
MD   &Y<  !*=   ,H@   Z<   "K    K@   +(   "V    N    +@   "Z
M    NP   +T   "^    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0
M  #,9   S7H  ,V1  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H
M$Z8   RL   #L0   +8   "Z    O@   ,(   #&    R    ,@   #*
MRP   ,T   #.    T    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E
M5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A
M /\ +0#_ #@ _0!# /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H
MYP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2
M /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8
M* #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z
M -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X
MP #_ ,  _P"_ /\ O@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B
M "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,(
M>@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_
M *\ _P"O /\ L #_ /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@
MR0 R ,8 / #" $4 OP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q
M 'H KP"  *T B "L )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *
M_P"@ /\ H0#_ /\   #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L
M +0 -@"R #\ KP!' *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0
MH !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2
M /\ D0#_ /<   #G    TP   ,8   "[  ( LP , *T $@"J !P IP F *0
M, "C #@ H !  )X 1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T
M )  ? "/ (4 C0"/ (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\
M@P#_ .P   #3    P0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5
M #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (,
M=P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_
M -X*  #$"P  L@P  *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P
MAP T (4 .P"# $( @@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V
M 'L = "& ', D@!Q )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0
M  "W$0  IA(  )H1  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N
M 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@
M:@># &@(D !G"9T 90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M
M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,
M, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z!
M %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0
ME!X  (@>  !^'0  >!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F
M$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84
MBP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(
M ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT
M7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-
M&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG
M  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP
M %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90
M1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M
M*@  92D  & G  !<)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB
M,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C
M #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0
M82P  %PK  !8*   5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$
M)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@L
ML@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\
M %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S,
M/2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R
M,,< ,C#E #,P]P S,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q
M  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4
M+33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+
M,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T
M.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB
M "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@
M0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K
M.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\
M]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D
M #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX
M)3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?
M0/X (#__ (DY  !X.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^
M   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$
M !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T
M&D3_ (0\  !S/0  9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L
M1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*
M2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_
M '\_  !O0   84$  %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20
M(TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 1
M45( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#
M  !J1   740  %-%  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$
M !I3   45@D $5<. !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X
M"EA:  A8:  '6'D !EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D
M1P  64@  %!(  !(2   04D  #I*   R30  *U   "52   @50  &E@  !5:
M   0708 #& ,  I@$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5
M  !@8P  8',  &"&  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P
M54L  $Q,  !%3   /4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -
M900 "&<+  -G#@  :!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I
M70  :6T  &F   !IE   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\
M $I/  !!40  .%0  #!7   H6P  (5X  !IB   490  $&@   QK   ';@,
M 7 )  !P#0  <1   '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@
M<V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55
M   [6   ,EP  "I@   B9   &V@  !1L   /;P  "W(   9V    >0   'H&
M  !Z"@  >PX  'P1  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\
M (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U
M80  +&4  "-J   ;;P  %',   YW   )>P   W\   ""    A    (8!  "&
M!@  B H  (D-  "*$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H
M  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;
M)'$  !QW   4?   #H$   B%    B0   (T   "0    D@   ),   "4
ME@,  )<(  "8#   F@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@
M=   GXP  )^B  "?MP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\
M !2%   -BP  !I    "4    F    )P   "?    H0   *(   "D    I0
M *<   "H!   J@D  *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0
MLH   +*8  "QK   LK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5
M   &F@   )\   "D    J    *P   "O    L0   +$   "S    M0   +8
M  "X    N@   +P&  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(
M ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E
MJ@   *\   "S    MP   +P   "_    P0   ,(   #$    Q0   ,<   #)
M    RP   ,T   #/ P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[
M  #AD0  XJ(  .*M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #,
M^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@
M (4 W@", -P DP#9 )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L
M_P#& /\ P0#_ /\   #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y
M .@ 0@#C $L X !2 -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\
MR@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z
M /\ M@#_ /\   #_    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -,
M/0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "
M +8 B "T )  L@": +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\
MJ@#_ /\   #]    [@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[
M #\ MP!' +4 3@"R %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8
M@0"D (H HP"4 *$ GP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_
M /X   #N    W@   ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D
MIP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5
M (0 E ". )( F0"0 *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /
M  #;    QP   +H   "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [
M )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X
MA0"( (, E "" *  @ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&
M    M0   *H   "B    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@
M.P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "#
M '8 CP!U )P = "J '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@
MIP<  )L&  "3!   C@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z
M #P >0!" '< 1P!V $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L
MB@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX
M (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8
M;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!?
M I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43
M  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W
M &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y,
M5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T
M&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-
M.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B
M $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0
M9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1
M$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6
ML !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$
M %P?  !9'   5QD  %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C<
M21<] $<70P!&%TH 11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [
M',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C
M  !3(   41X  $\< @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY
M $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$
M-2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/
M)   3"(  $D@  !'( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA
M/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;<
M # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*
M2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S
M)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ
M\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@
M #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F
M+OT )RW_ (HK  !X+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL
M   W+   -"P) #(L#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]%
M "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P
M(C'_ (8M  !U+P  9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S
M,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T
M3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_
M ((P  !Q,@  8S,  %DT  !0-   230  $(S   ],P  -S,  #$T   N-0
M*S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;
M.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR
M  !M-   8#4  %4V  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH
M ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$
M%#]> !0_;  30'P $D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I
M-P  7#@  %(Y  !*.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!
M!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;
M  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@
M6#L  $\[  !'/   0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   5
M2 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+
M9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X
M $L^  !$/@  /3X  #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4
M#E$+  M1$  *410 "5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P
M4F\  %*!  !1E@  4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!
M  !!00  .T(  #1#   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*
M  98#@ "6!(  %D7  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD
M %E\  !9D   6:4  %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _
M10  -T<  "])   H3   (D\  !M2   650  $5@   U:   )70, !%\)  !@
M#0  8!   &$4  !A&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V
M  !BBP  8J   &&V  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@
M,DT  "I0   C4P  '%<  !9:   170  #6    AC   #9@$  &<&  !H"P
M:0X  &H1  !K%0  ;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !M
MA   ;)H  &RP  !KR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0
M "18   =7   %F   !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL
M '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?
M>90  'BJ  !XP0  =]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB
M   69P  $&L   MO   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*
M  "##0  A!$  (85  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L
M (BB  "'N0  A]$  (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0
M=   "GD   )]    @0   (4   "(    B@   (P   "-    CP   ) $  "2
M"   DPP  )40  "7%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:
M  "8L   F,<  )?> $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P
M 8@   ",    D0   )4   "8    F@   )L   "=    GP   *    "B
MI 4  *8*  "H#@  JA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "K
MIP  J[H  *O+ $5F   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@
M  "=    H0   *4   "H    JP   *L   "N    KP   +$   "S    M0
M +<!  "Y!P  O T  +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP
MP:T  ,&\ #YR   R>   )X   !R(   2D   "I<   "=    HP   *@   "M
M    L@   +8   "Y    NP   +P   "^    P    ,(   #$    Q@   ,@
M  #+    S@4  -$-  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\
M -RK /\   #_    _P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P
M $L [0!2 .H 60#G %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0
MC@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_
M /\   #_    _P   /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4
MV0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_
M )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\
M  #_    ^    .T   #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!'
M ,  3@"^ %, O !9 +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H
MJP"4 *D H "H *T I@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V
M    Y@   -<   #+  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T
M2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP".
M )D F0"7 *8 E@"V )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D
MT    ,$   "W  ( KP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@";
M $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H
MDP"( *  AP"O (4 P@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O
M *\   "F    G@ ' )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $(
MB@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z
M )H > "I '< N@!V -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\
M  "7    D  " (L "P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !!
M 'L 1@!Y $L > !0 '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4
M:P"C &H M !J ,D :0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(
M    @P   '\ !@![  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\
M00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "?
M %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@
M=P<  '0$  !Q  D ;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C
M $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4
MJP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X
M &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P
M6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+
M!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1
M  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^
M $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P
M0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6
M$P  5!$  %0." !3#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.
M00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6
M #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&
M3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _
M$D0 /1), #P35  [$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6
M[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H
M $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$
M-Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N
M&_L +AO_ (H>  !X(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;
M   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q&
M "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H
M*1__ (8@  !T(P  9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z
M'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA
M3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_
M ((C  !Q)0  8R8  %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@
M,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C
M)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE
M  !N)P  8"D  %8I  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28#
M "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E(
M'2M> !PK:P ;*WL &BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J
M*@  72L  %,L  !*+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K
M"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]<
M !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+
M6BT  % N  !(+@  02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?
M,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T
M9P 1-7< $36) ! UG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S
M $TP  !%,   /C   #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D
M%S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -
M.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS
M  !",P  .S,  #8S   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT,
M ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\
M!C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _
M-0  .34  #0U   N-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$
M#@ *1!, "409  A$(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\
M  !%D   1*0  $2Y  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.
M-S@  #$X   K.0  )3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $
M2Q$  4L6  !+'   2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+
MC   2Z$  $NU  !*S@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L
M "X\   G/@  (D$  !Q#   61@  $DD   Y+   +3@, !U (  )1#   41
M %(3  !3&   4Q\  %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP
M4IP  %*Q  !1R@  4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"
M   C1   '4<  !=*   230  #E    M3   &50(  %<'  !8"P  60X  %H1
M  !:%0  6QH  %PA  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<
M %NM  !:Q0  6N0  %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >
M3   %T\  !)3   .5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D
M$0  918  &8<  !G(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H
M  !EP   9-X  &3P $]&  !'1@  0$4  #='   O2@  )DT  !]1   850
M$ED   U<   (8    F,   !F    :    &H   !K!   ; @  &T,  !O#@
M<!(  '(7  !S'0  ="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !Q
MN   <=0  '#L $Q*  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60
M  =H    :P   &\   !R    =0   '8   !W    >0(  'H&  !\"@  ?@X
M ( 1  ""%@  A!X  (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0
M@,D  (#E $I.   _4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U
M    >0   'T   "!    @P   (4   "&    B    (D   "+!   C0@  (\-
M  "2$   E!8  )8@  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT
M )+5 $15   Y60  +UT  "1C   ::0  $F\   QU   $>P   (    "%
MB0   (T   "1    DP   )0   "6    F    )H   "<    G@   * &  "B
M"P  I1   *@7  "I(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7'
M #Y>   R8P  )VH  !UP   3>   #'\   .%    BP   )$   "6    FP
M )\   "B    I    *4   "G    J0   *L   "M    L    +(   "U @
MMPD  +L0  "^&   OB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J
M   K<   ('@  !:    -B   !8\   "6    G    *(   "G    K    +
M  "S    M@   +<   "Y    NP   +T   "_    P@   ,4   #(    R@
M ,X(  #2$   U1L  -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_
M    _P   /\ !0#_  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8
M4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"<
M ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_
M_P   /H  0#S  L [0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+
M %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0
MH0"R *\ L #" *X XP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@
M .8   #=  < T@ . ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X
MM0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A
M *@ GP"Y )X T@"= /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P
M  #!  ( N@ , +8 $@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!-
M *  4@"> %< G0!; )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$
MC@"Q (T Q@", .@ BP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L
M    I@ ( *$ #@"? !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )
M3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I
M 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<
ME  # )  # "- !$ BP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_
M $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\
MM !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O    H    )0   ",    A@
M ($ " !^  X ?  4 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4
M< !* &\ 3P!M %0 ; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A
M ,( 80#D &$ ^ !A /\ 80#_ +0   "@    D0   (8   !^    >0   '4
M P!Q  L ;P 0 &T %@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !%
M &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L
M5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G
M  < 9  - &, $0!A !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@
M10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #-
M $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$
M7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!.
M $< 30!- $L 50!* %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $,
MY@!# /4 0P#_ )4-  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$
M %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T,
M1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z
M!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-
M!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I'
M #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0
M,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!#
M#@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.
M30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_
M (,6  !R&0  9!H  %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0
M.Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M
M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9
M  !N&P  8!T  %8>  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14'
M #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U(
M)AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J
M'@  71\  %,@  !*(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8
M"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q;
M !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(
M6B$  % B  !((@  02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F
M'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA
M9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,
M $TD  !%)0  /B0  #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P
M("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4
M)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF
M  !")P  /"8  #8F   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8.
M !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$
M#RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  !
M*0  .2@  #0H   O*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L
M$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_
M  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P
M-RL  #$J   M*@  *2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /
M,A, #C(9  TR(  -,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0S
MC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T
M "\L   K+   )BP  "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$
M"3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP
M.)\  #BS   XR@  ..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO
M   I+P  )#   !\Q   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4
M   ^&@  /B$  #XH   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP
M #ZP   ]QP  />0  #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F
M,@  (#0  !LV   6.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%
M%@  11T  $4D  !%+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M
M  !$Q   0^,  $/R %4T  !*-0  034  #DU   S-   +C0  "@U   B-P
M'3H  !<\   2/P  #T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%
M31D  $X@  !.*   3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+
MP0  2^$  $KR % X  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$
M !-#   /1@  "TD   =+   "3@   % $  !1"   4@L  %,.  !4$0  514
M %8;  !7(P  5RP  %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0
M4]T  %/P $L\  !"/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+
M   +3P  !5$   !4    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6
M  !B'0  8B8  &(Q  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0
M %WN $=    _/P  .C\  #%    I0P  (48  !I*   33@  #E$   I5   $
M6    %L   !>    80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N
M%P  ;R   &\J  !O-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH
M $1$   ^0P  -40  "M'   C2P  &T\  !-4   .6   "%P   )@    9
M &<   !K    ;0   &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@
M?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'
M   Y20  +TP  "50   <50  %%L   Y@   '90   &H   !N    <@   '8
M  !Y    ?    'X   !_    @0   (,   "%    AP,  (H(  ",#0  CQ$
M )(9  "2)0  DC,  ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R
M40  *%8  !Y<   58@  #F@   =N    =    'D   !^    @@   (8   ")
M    C    (X   "0    D@   )0   "6    F    )L   ">!@  H0P  *01
M  "F&P  IBD  *8Z  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7
M(6(  !=I   /<   !W<   !^    A    (H   "/    E    )@   ";
MG@   )\   "B    I    *8   "H    JP   *T   "P    LP0  +<,  "[
M$@  NQ\  +LP  "[0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G
M !!X   )@    (@   "/    E@   )L   "A    I@   *H   "N    L
M +$   "T    M@   +@   "[    O0   ,    ##    QP   ,L#  #/#
MTQ4  -(E  #2.   T4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\
M P#_  L _  1 /D &P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9
M -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +(
MO #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M
M  < YP / .( %@#? "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,
M6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"]
M *< W@"F /D I0#_ *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  ,
MR@ , ,4 $@## !L P  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K
M %< J0!< *< 80"F &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8
MS0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 (
M *T #P"J !8 J  > *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$
ME@!5 )0 6@"3 &  D0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$
M .8 @P#] (0 _P"# /\ @0#_ .0   #+    N@   *P   "B    G  $ )@
M# "6 !$ E  9 ), (0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/
M (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0
M<P#T '0 _P!T /\ = #_ ,L   "V    I@   )H   "2    B@   (8 " "#
M  X @0 4 ($ &P"  ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0
M3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J
M &8 _P!F /\ 9P#_ +@   "D    E0   (H   "!    ?    '8 ! !T  P
M<@ 0 '$ %@!P !T <  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E
M $X 9 !4 &, 6P!A &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D
M^ !: /\ 6@#_ *@   "5    AP   'L   !S    ;@   &H  0!G  @ 90 .
M &0 $@!C !@ 8P ? &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D
M6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !.
M /\ 3P#_ )P   ")    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D
M#P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+
M $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H
M10#_ )($  " !P  <0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/
M !  3@ 5 $T &P!, "  2P F $H *P!) #  2  U $< .@!& $  10!& $,
M3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_
M (D*  !X#   :@X  %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T
M1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z
M %( .0!< #@ :  V '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-
M  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4.
M #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5
M,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L
M$0  7Q,  %04  !,%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)
M$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9
M "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%
M6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P
M#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",0
M90 A$', (!"$ !\0E@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@
M $T9  !%&0  /QD  #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X
M*1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <
M$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;
M  !"'   /!L  #8;   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W
M%1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _
M'@  .1T  #0=   O'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_
M ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](
M-A\  #$?   M'@  *1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6
M'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@
MCP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$
M "\A   J(   )A\  ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1,
M$2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '
M))X !R2Q  8DQP &(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC
M   H(@  )"$  "$A   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6
M  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L
M 2BO   HQ0 !*.$  2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F
M)   (B,  !\C   ;)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L
M&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM
M   LP@  +.   "SP %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@
M(28  !TF   9)P  %2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P
M,AX  #(E   R+0  ,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   Q
MP0  ,=\  #'P %8G  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD
M !HJ   6+   $BX   \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H
M #@B   X*@  .3,  #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP
M-]X  #;P %$K  !&+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O
M   3,0  $#,   TU   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >
M  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P
M #WP $TN  !"+P  .2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0
M-P  ##H   D\   %/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !(
M(0  2"H  $@U  !(00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P
M $@R   ^,@  -C(  # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P
M"$(   -$    1@   $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'
M4B4  %(P  !2/   44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V
M   [-@  -#4  "\T   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH
M  !-    3P   %$   !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\
M %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X
M.0  ,S@  "LY   C/   '#\  !5#   01P  "TH   5.    40   %0   !7
M    6@   %P   !=    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC
M  !J+@  :CP  &I-  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/
M+CT  "5    =1   %DD  !!-   *40  !%4   !:    70   &    !C
M9@   &@   !J    :P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![
M)P  >C4  'E%  !X60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4
M "!*   73@  $%0   I9   "7@   &,   !G    :P   &\   !R    =0
M '<   !Y    >P   'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@
MCBL  (X[  "-3@  BV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5
M   06P  "F$   %G    ;0   '(   !W    >P   '\   "#    A@   (@
M  "*    C0   (\   "1    E    )<   ": 0  G0<  *$-  "E%   I"$
M *0Q  "C1   HED  *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +
M:0   7    !W    ?0   (,   "(    C0   )$   "5    F    )H   "<
M    GP   *$   "C    I@   *D   "L    L    +0'  "X#@  NA@  +HG
M  "Y.0  N$X  +=E  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0
M ($   ")    CP   )8   ";    H    *0   "H    JP   *P   "O
ML@   +0   "V    N0   +P   #     Q    ,@   #-!P  TA   -(=  #1
M+P  T$0  ,];  #-<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  /
M /4 %P#T "  \0 J .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X
MS@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S
M /\ KP#_ *4 _P"> /\ FP#_ /T   #W    \@   /    #G  , X0 , -P
M$@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!=
M +4 8@"S &< L0!N *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D
MG@#_ )@ _P"2 /\ CP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[
M !8 N0 ? +< )P"S "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$
M6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_
M (H _P"% /\ @@#_ .<   #=    Q@   +@   "N    J  $ *4 # "A !(
MH0 9 *  (@"? "D FP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50",
M %H B@!A (@ : "' '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P
M_P!X /\ =@#_ -8   #     KP   *,   "9    DP   (\ "0"-  X BP 4
M (H ' "* ", B  J (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0
M>@!: '@ 80!V &D =0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K
M /\ :0#_ ,    "K    FP   (\   "'    @    'P ! !Z  P >  1 '@
M%P!X !X =P D '4 *@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4
M &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\
M70#_ *P   "9    B@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G
M !@ 9P ? &< )0!E "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L
M50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_
M )T   "+    ?    '$   !I    9    &    !>  4 7  + %L #P!; !0
M6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !.
M %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )
M  !^    <    &8   !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5
M $X &@!. "  30 E $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %,
M0P!= $$ : !  '4 /P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U
M P  : 8  %T'  !5!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4
M%@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9
M #@ 9  W '$ -@"! #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0
M8 L  %8,  !.#   2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [
M !< .P < #H (0 Y "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #
M8  O &T +@!] "T CP L *( + "V "P T  L .X + #\ '<*  !G#   6@X
M % .  !)#@  0PX  #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !,
M,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H
M &L )P%Z "8!C  E )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1
M  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04
M "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD
M( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  !
M$P  .A,  #42   Q$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(
M%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY
M !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0
M-Q4  #$4   M$P  *A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?
M#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0
MC0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<
M "\6   J%0  )Q0  "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4
M&! ; !<0(0 6$"@ %1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .
M$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8
M   H%P  )!8  "$6   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8
M !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH
M"1:M  @6P0 (%MT "17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E
M&0  (A@  !\8   <%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7
M'  .&", #1@J  P9,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ
M  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P
M(!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *
M'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >
MO0  '=@  !WL %@:  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP
M !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T
M!"$D  (B+  !(C4  ")    C30  (UH  "-K   C?@  (Y,  "*G   BO
M(=<  "'M %4=  !('P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=
M   6'0  $QX  !$? @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A
M   G*0  )S(  "<]   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8
M "7M %$@  !%(0  .R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4
M(   $2(   \C   -)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L
M)@  +2\  "TY   M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN
M $TB  !!)   ."0  # D   I)   )",  "$B   =(@  &2(  !4C   2)
M#R8   TH   **@( !BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@
M,RL  #,V   S0@  ,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE
M   ^)@  -"<  "TG   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P
M  HN   &, $  C($   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<
M #HR   Z/@  .DP  #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z
M*0  ,2D  "LI   F*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U
M   !-P   #D"   [!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N
M  !#.0  0T<  $)7  !":@  08$  $":   _L@  /L\  #[O #\L   V+
M+RP  "HK   E*@  'RL  !DM   4+P  $#(   TU   (.   !#H    \
M/P   $$   !# @  104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !-
M-   3$(  $Q1  !+9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\
M "@M   B+P  &S$  !4T   0-P  #3H   @]   "0    $,   !&    2
M $H   !,    3@$  $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@
M5SP  %=+  !67@  5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R
M   =-0  %C@  !$\   ,0   !T0   !'    2@   $T   !0    4P   %4
M  !7    60   %H   !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0
M &5$  !D5P  9&L  &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8
M/0  $4(   Q&   &2@   $\   !3    5@   %D   !<    7P   &$   !D
M    90   &<   !I    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]
M  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22
M#$T   52    5P   %P   !@    9    &@   !K    ;@   '$   !S
M=0   '<   !Z    ?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")
M10  AUL  (9R  "%BP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H
M  !A    9@   &L   !O    =    'D   !]    @    (,   "%    AP
M (H   ",    CP   )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P
MGU   )UG  ":@0  FID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P
M    =P   'T   ""    A@   (L   "/    DP   )4   "7    F@   )T
M  "@    HP   *8   "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4
M +5<  "T=   L8X  *^D ")4   86P  $&(   =J    <P   'L   ""
MB0   )    "5    F@   )\   "C    I@   *@   "K    K@   +    "S
M    M@   +H   "]    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1
M  #-:   RX$  ,J6 /P   #V    \@   /$   #S  4 ]  , /( $P#P !P
M[0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$
M &D P0!P +X > "\ ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H
M_P"4 /\ CP#_ /0   #L    Z    .<   #?    V0 ) -( $ #/ !< SP @
M ,P * #& #  P  W +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &(
MJP!I *D <0"G 'H I0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"(
M /\ A #_ .@   #?    V0   ,D   "_    N  $ +4 #0"S !( L0 : +
M(@"M "H J0 Q *8 . "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B
M )4 :0"3 '( D0!] (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\
M> #_ -D   #-    NP   *X   "E    GP   )P "0"9  \ F0 5 )D '0"8
M "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4 @P!; ((
M8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N /\ ; #_
M ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 (( %P"" !X
M@  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5 '  7 !O
M &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\ 8 #_ +0
M  "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O !@ ;P ?
M &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$ 50!? %X
M7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_ *$   ".
M    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !, 7P 9 %\
M'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2 %@ 40!A
M %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(   "
M<@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4 %( &@!1
M !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %( 10!< $0
M9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T    9P
M %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8 %0!& !H
M10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7 #H 8@ Y
M &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K    7@(  %0#
M  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \ !8 /  :
M #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$ 7@ P &L
M+P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<  $T(  !&
M"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !( ,P 6 #(
M&P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H &< )P!W
M "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,  ! #
M.@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3 "H %P I
M !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0 ( !S !\
MA0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \#@  -@X
M #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!%  B 1@
M(0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P !D!@@ 8
M )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$   ,A   "T/
M   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <!14 &P4:
M !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'@  2!Y0
M$@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$  "H1   F
M$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1( %@D7 !4)
M'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .#)0 #0NG
M  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2   C$0
M'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4 !$,&@ 1
M#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y, "0^F  @.
MN0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A$P  '1(
M !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0&  -$!X
M#! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D  ,1N  #
M$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%   &Q0  !@3
M   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )$QL "1,B
M  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4MP  %,\
M !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14  !84 0 4
M$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD !!<?  ,7
M)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP  %\\  !?J
M $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45 @ 3%04
M$10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=   <)
M'"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]   !KK $P8
M  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2%@0 $!<$
M  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A(@  (2H
M "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M $@:   ]
M'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$ #AH!  P<
M @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P  )R<  "<R
M   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=   Y'P
M,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\   HA   &
M(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20  "XN   N
M.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V(0  +2$
M "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F   "*
M "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J   U-@
M-4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)   *B0  "0C
M   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N    ,    #(
M   T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^,0  /C\
M #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8  ",E   ?
M)   &24  !0F   0*   #2L   DN   %,    #,    U    .    #H    \
M    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+   1SH  $=)
M  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G   <*
M%BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,   !&
M2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0  %-#  !2
M50  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8+@  $C(
M  TU   (.0   CT   !     0P   $8   !)    3    $X   !1    4P
M %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\  !@3@
M7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P  #CL   @_
M   !1    $@   !,    3P   %(   !5    6    %L   !=    8    &(
M  !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R10  <%D
M &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<   !,
M40   %4   !9    70   &$   !E    :    &L   !M    ;P   '(   !T
M    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0  A%(  (-G
M  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:    8
M &0   !I    ;@   '(   !V    >@   'T   "     @@   (4   "(
MBP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<  )I>  "8
M=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J    <0   '8
M  ![    @    (8   "*    C@   )$   "3    E@   )D   "<    H
M *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12  "R:@
MKX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P   (D   "/
M    E    )H   "?    H@   *0   "G    J@   *X   "Q    M    +@
M  "\    P0   ,<   #-    U 4  -@0  #5'@  TS$  -!(  #-7P  RW8
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M______________________________________________\
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MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MW9"=BMV0G8K=D)V*W9"=BMW4S0D9UM(+-];4"U[0RPJ5Q+XMKKRX4;BWLFK
MLZU\QJZIA\RIIH;0I:2%TZ"CA-6=HH36F:&%V)6@A=F1GX?:CIZ)VXZ>B=N.
MGHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>
MB=N.GHG;CIZ)VXZ>B=O3S0H8U=,+-M34"U_.RPF7P;XPK[JW4[BULFS L*U]
MQZRJALNGIX7/HJ6$T9ZDA-.:HX35EJ*$UI.AA=>/H(;8BZ")V8N@B=F+H(G9
MBZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+
MH(G9BZ")V8N@B=G2S@H7T]0+-='3"F++S F9OKTSL;>W5;FRL6W!K:U]QJJJ
MALNDJ(3.GZ>$T)NE@]*7I(/3DZ.$U)"CA=6,HH;6B:&(UXFAB->)H8C7B:&(
MUXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7
MB:&(UXFAB-?0SPH6T=0+-\[3"F7&R@N=N;PXLK2V6+JML6[!JJY]QJ>KA<FA
MJ83,G*B#SI>G@\^3IH/1D*6$THVEA=.*I(;3AZ.(U(>CB-2'HXC4AZ.(U(>C
MB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(
MU(>CB-3.T H5SM0*.LK3"FC R ^AM;L^M*VU6[NIL6_!IJ]]Q*.MA,>=JX/*
MF*J#RY.I@\V0J(3.C:>$SXJGA<^'IH?0A::(T86FB-&%IHC1A::(T86FB-&%
MIHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86F
MB-',T D8RM0*/L73"FVXQ1:EKKE$M:>U7KNCLG# H;!]PY^NA,69K8/'E*R$
MR9"KA,J-JH7+BJJ%RXBIALR%J8?-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-
M@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<W(
MT0D;Q=4*0K_3"G*QQ!ZGI;E)MJ&V8+N>LW"^G;%]P9NPA,.5KX3$D:Z$QHVM
MA<>*K8;'B*R&R(:LA\B$JXG)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*
MR8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLG$T@@@
MP-8)2+C4"GBISQ>8GKY'KIJV8KJ8M7&\E[-\OI>RA,"2L87"C;"%PXJOAL2(
MKX?$AJ^(Q82NB<6#KHK%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&N
MB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6_U <ENM<)
M3J[:"W"@VQ.'E\TYFI+#6*B1O&RRD;=ZN9*T@[V.LX:_B[*'P(BQA\"&L8C!
MA+&)P8.QBL&"L8O"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MP8>K<L&(JW+ BJQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
MBZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZS_N!0._[@>)_^T*D;WKS9IWJ="
MC\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-
MM(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;
M8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6
MS[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$
MFW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!
MF="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*V
MPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S
M@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_
MN<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1
MLG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";
MB+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^C
MT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^
MF8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MCXS*M8R.S+2)D,ZSAY+0LH25TK&"F=.Q@9[4KH"BU*R H]*L@*/2K("CTJR
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MCZR$R(RKA<F)JX;*AZN&RH6JB,J#JHG+@:J+RX"JC,N JHS+@*J,RX"JC,N
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M;,6+I6S%BZ5LQ8NE;,6+I6S%BZ7$S@<*M]D')J/[#CV6_QY.C?HO6X;R/V>
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M_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K
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MFEZ7RYAJK,69=+3#FGVWP9N%N[Z9B;^\E8K"NI",Q;B,C\BVAY++M(.7SK.
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M_Z@D#_^F,R7_HD(^_Z!*5/FD2F;MITIXXJE+BM:H49K-IENIQZ5ELL2G<+;
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M;6OK9'%GZ6ET9.=N=F+F<WA@Y7=Y7^1Z>UWC?GQ<XH%]6^*%?EKAB']9X(N
M5^"0@%;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8'4
MO04 Q,@' +39!0JC_@T<EO\:+(O_*SJ#_SI$?/](377_4E-N_5=89_I=7&/W
M8E]@]F=B7?1K9%OS;V59\G-G5_%W:%;Q>FE5\'UJ5.^ :U/OA&M2[H=L4.Z+
M;4_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;D_MD&[&P 4
MM- $ :/C @J6_Q 8B_\@)(+_,"]Z_S\W<O](/FK_3D-D_U1(7O]93%O_7T]8
M_V125?]I5%/_;552_G%74/UT6$_\>%E.^WM:3?M_6TSZ@UQ+^89=2?F+7DCX
MD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%^UQP( I-H
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MG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+<+:KRV^\J\APP*O$<<"JQ''
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MM+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+K_G! !_Z$F"O^@-AS_GD(Q_Z5
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MC5?6I8Y6U:R.5M6LCE;5K(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCE;5K([_KPT
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M?KBUFW^YM)E_NK.8@+JREX"[L9> N[&7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M23S_ETD[_YY*._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTNVN@(
MILH  )C<  ",_P@!@_\4!7C_'@QN_R829?\O&5W_-QY7_S\B4O]&)DW_3"A*
M_U(K1O]8+43_72Y"_V$O0/]F,3[_:S(\_W S.O]U-#G_>C4W_X V-O^&-S7_
MC#@S_Y0X,_^8.3/_F#DS_Y@Y,_^8.3/_F#DS_Y@Y,_^8.3/_F#FGPP  E]0
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MB+]GV8B_9]F(OV?9B+]GV8C_>A0!_W@> _]Y, W_>$$:_X%))_^&4C/_B%I
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M9D3RP6=#\M1G1>[G9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&?NH@
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M*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*BC_HRJAP@  D=$  (+A  !X_P
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M6/UV>&#X<H1G]6V.;?%IF'+O9J%V[&.K>>M@MGSI7L1^YU[8?]AAWW[*8]^
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M<)#8BG"0V(K_>Q$!_WP7 O^0%P+_HB$#_ZX@!/*['03ERAX#VMLD \S9-1+
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M23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X23?^^$G)JP  MK0  *C!  ";SP
MCM\! (?_$0%^_QT$=?\G"VS_+Q)D_S<87/\^'5;_12)0_TLE2_]2*$;_6"M!
M_U\M/O]G+SO_;S$X_W@S-O^"-#/_C38Q_YDW,/^E."__LCHN_\ [+O_3.RW_
MZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/"W_ZSRXL   J+P  )K)  ",V0  @?4#
M 'G_$ %N_Q8#9?\?!E[_)PM7_S /4?\W$TO_/A=&_T490?],&SW_4ATY_U@?
M-O]?(33_9B(Q_VXD+_]W)2W_@"8K_XPH*?^7*2C_HBHG_ZTK)O^Y+";_R2TF
M_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@  =?\% &G_
M# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P_T\2+O]5
M$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_L!T=_[ =
M'?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\  %K_!@%1
M_PT!2?\1 D/_%P,]_Q\$./\F!33_+08P_S,'+?\Y!RK_/@@G_T,()?])"2/_
M3@DA_U0)'_]:"AW_80H;_VD+&?]R#!?_? T6_X8-%/^/#A3_F@\4_YH/%/^:
M#Q3_F@\4_YH/%/^:#Q3_F@__7!P"_U<F _]1,@;_3CP(_U=%$/];3AG_7%@B
M_UMC*_]9;S+_5WHX_U2%/?]2D$'_4)E%_T^@1_].ITG_3:Y+_TRT3/]+NTW_
M2L-._TG-3_])W5#_2.E0_TCR4/M)]E#V2_E0\$W[3^I/^U#G3_Q0YT_\4.=/
M_%#G3_Q0YT_\4.=/_%#_7!P"_U@F _]2,@;_43H(_UI#$/]?31G_7U<C_UYA
M*_]<;3/_67DZ_U>$/_]4CD/_4I='_U"?2?]/IDO_3JU-_TVT3_],NU#_2\-1
M_TO.4O]*WU+_2>I3_4KR4_A+]E/Q3?A2ZT_Z4N50^E/B4?I3XE'Z4^)1^E/B
M4?I3XE'Z4^)1^E/_71L"_UDF _]3,0;_5#D(_UU"$/]B2QK_8E4C_V!?+/]?
M:S3_7'<[_UF"0/]6C$7_5)5(_U*>2_]1I4[_4*Q/_T^S4?].NU+_3<13_TS/
M5/]+X%7_2^M5^DSR5?1-]E7L4/A4YE'X5=]2^5;<4_E6W%/Y5MQ3^5;<4_E6
MW%/Y5MQ3^5;_7AL"_UHE _]4,0;_6#<(_V% $?]E21K_9E,C_V1=+?]B:#7_
M7W0\_UQ_0O]9BD?_5I-+_U2<3O]3I%#_4:M2_U"S5/]/NE7_3L16_TW05_]-
MXEC\3.U8]D[R6.Y0]5CF4_98WU3W6==5^%G35?A9TU7X6=-5^%G35?A9TU7X
M6=-5^%G_7QH"_ULE _]5, ;_7#0(_V4]$?]J1QK_:U$D_VE:+?]F9#;_8W ]
M_U]\0_]<ATG_69%-_U>:4/]5HE/_4ZI5_U*R5_]1NEG_4,5:_T_26_Q.Y%OX
M3^U<\%'R6^=4]%O>5?5<U5;V7<Y8]UW+6/==RUCW7<M8]UW+6/==RUCW7<M8
M]UW_8!H"_UPD _]6+P7_8#((_VH[$/]O1!K_<$XC_V]7+?]K83;_9VP^_V-X
M1?]@@TO_7(Y/_UJ84_]7H%;_5JE9_U2Q6_]3NES^4<9>_%#67_E0YU_R4NY?
MYU7Q7]U7\F#26/-ARUGU8L5;]6+#6_5BPUOU8L-;]6+#6_5BPUOU8L-;]6+_
M81D"_UTC _]:+07_92\(_V\X$/]T01G_=DLC_W54+?]Q73;_;&<__VAS1O]D
M?TS_8(I2_UV55O]:GEG_6*=<_E:P7_U4NF#\4\=B^5+<8_-3Z&/I5>YCWECP
M9-!:\67(7/)FPEWR9KU>\F:[7O)FNU[R9KM>\F:[7O)FNU[R9KM>\F;_8AD"
M_UXC _]>*@7_:2T(_W0U#_]Z/AC_?$@B_WM1+/]X6C;_<V,__VUM1_]I>D[_
M9(94_V"16/]=G%S]6J5@^UBP8OI6NV7X5<IF]53@9^Q6ZF??6NUGT%SO:<9=
M[VJ_7^]JN6#O:K5A[VJS8>]JLV'O:K-A[VJS8>]JLV'O:K-A[VK_8Q@"_V B
M _]B)P7_;BH'_WDR#O]_/!?_@D8A_X)/*_]_6#7_>V ^_W5I1_]O=$[[:H%5
M^&:,6_5BEU_S7Z%C\%RK9NY:MFGL6<1JZ5C::^%:ZFO07>QMQ5_L;KQAZV^V
M8NQOL6/L;JUD[&ZK9.UMJV3M;:MD[6VK9.UMJV3M;:MD[6W_9!@"_V$B _]F
M)03_<B<'_WXP#?^%.Q;_B$4?_XA-*?^&53/_@EX]^WUF1O9V<$[R<GQ5[FV'
M7.IHDF+F9)QFXV&F:N!?LFW=7;]OVEW3<-)>ZG#$8.ERNF+H<[-DZ'.M9>ES
MJ6;I<J9GZG&D9^IPI&?J<*1GZG"D9^IPI&?J<*1GZG#_91<"_V(A _]I(P3_
M=R4&_X(O#/^*.13_CD,=_X],)O^-4S#YBELZ\X5C1.U_;$WH>7=5XW2"7=YN
MC6/9:9=ITV:A;L]CK''+8;ETR&'*=<5AY7:Y9.9WL&;E=ZIHYG>E:>9VHFKG
M=9]JZ'.>:^ESGFOI<YYKZ7.>:^ESGFOI<YYKZ7/_9A<!_V,A _]M( 3_>R,%
M_X<N"_^/.!+_DT$:_Y5*(_J442WSD5DW[(U@0>6':4K?@713UGI^7<]TB&7*
M;Y%LQ6N;<<%HIG6]9K)XNF7">K=EW7NN:.-[IVKC>Z)KY'J>;.5XFVWE=YEM
MYW:8;N=UF&[G=9ANYW68;N=UF&[G=9ANYW7_9Q8!_V0@ _]P'@/_?B(%_XLL
M"?^3-Q#_F$ 8_9I((/2:3BGLF%4SY95=/-V/9D?3B&]3RX%Y7L5[@V:_=8QN
MN7&6=+5NH7BP:ZQ\K6J[?JIJTG^D;.!^GFWA?9IOXGR7<.-ZE7#D>9-PY7>3
M<>9WDW'F=Y-QYG>3<>9WDW'F=Y-QYG?_:!8!_V0@ _]S' /_@2 $_XXK"/^7
M-0[_G3X5^)]$'.^@2R7GGU(MWYU:-].58T;*CFQ3PX=U7KN!?F>U>XAOKW>1
M=:ISG'JE<*A^H6^V@9YORH*;<-Z!EG'?@)-RX7Z1<^)\D'/C>HYSY'F.<^5X
MCG/E>(YSY7B.<^5XCG/E>(YSY7C_:18!_V8> _]V&@/_A!\#_Y(J!_^;- S^
MH#L2\Z-!&.JF2"#BIT\GV*)6-LR:8$7#DVE2NXUR7K.&>F>L@81OIGV-=J!Y
MF'R;=J. EW2Q@Y1TQ821==V#CW;>@8UVX'^+=^%]BG?B>XEVY'J)=N1YB7;D
M>8EVY'F)=N1YB7;D>8EVY'G_:14!_VD= _]X&0+_AQX#_Y4H!O^>,@KZI#</
M[Z@]%.:L1!K=K4LDT*94-<:?7D2\F692M))O7:R,=V>DAX!OGH**=YA^E'V2
M>Z"!C7JMA(IYP(6(>MR$AWK=@H9ZWX"&>N!^A7KB?(5YXWJ%>>1YA7GD>85Y
MY'F%>>1YA7GD>85YY'G_:A4!_VL; O][%P+_BAP"_Y@F!?^B, CUJ#,,ZZXY
M$.*S0136L4<CRJM2-,"D7$.VGF11K9AL7*62=&:=C7UOEHB&=H^%D7V*@IR"
MA8"JA8%_O(: @-N%@(#=@X!_WH& ?N!_@'WA?8!]XWN ?.1Z@'SD>H!\Y'J
M?.1Z@'SD>H!\Y'K_:Q4!_VT9 O]^%0+_C1L"_YLD _ZE+ ;QK"\(Y[,T"]VZ
M.A#0M48AQ:]1,KJI6D*PHV)/IYUJ6YZ8<F66DWINCX^#=HB+CGR"B)F!?(:G
MA7F&N89WA]>%>(7=@WJ#WH%Z@N!_>X'A?7R XWM\?^-Z?'_C>GQ_XWI\?^-Z
M?'_C>GQ_XWK_:Q0!_W 8 O^!% '_D!D!_Y\B OJI)@3ML2D%XKHO!M:_-@_*
MND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY: =(ZDA'&-
MMH5OCM&%<8O=@W.)WX%UA^!^=H7A?7>$XWMW@^1Z=X/D>G>#Y'IW@^1Z=X/D
M>G>#Y'K_;!0!_W,6 O^%$P'_E!8!_Z(> ?6M( +GN"$"W<,F M##- W$OD(>
MN;E-+ZZS5CZDKEY,FJEE5Y&E;6*)H75K@)U^<GF:B'EREY1^;9:B@FF5LX1G
MELV#:9/>@FR/WX!OC.%^<(KB?'*(XWIRA^1Y<H?D>7*'Y'ERA^1Y<H?D>7*'
MY'G_;1,!_W83 ?^($@'_F!, _Z<9 >^S%@'BP!4 U<H> <G',@R^PT <L[Y+
M+*BZ5#R>M5Q)E+!C58JL:U^!J7)H>:5[;W*CA79KH)%[9I^??V*?L8%@G\J
M8IS@?V67X7YHD^)\:I#C>VR-Y'EMC.5X;8SE>&V,Y7AMC.5X;8SE>&V,Y7C_
M;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L S<X; <+,+PJWR3T9K,5)*:'
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M7DK!]F!+O?9@2[WV8$N]]F!+O?9@2[WV8$N]]F#_B0  V9X  ,>L 0"YM@(
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M_T'_41\"_TPI _]'- 7_338&_U$["/]51A#_5E 8_U5<'_]2:";_4'0L_TV
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M9EJ;\V5<E_-D7)?S9%R7\V1<E_-D7)?S9%R7\V3_< T _X0$ -V6  #.HP,
MQ*X$ +NW! "TP@4 KLT, *?.( *>S3$*E<L^%HO(22."QE(N>L-:.'+!8D!K
MP&I'9+YS35Z]?%-9O(A75+N56U"[I5U.N[E>3;S;74NY]U].L?9@4:KV8%.E
M]F!5H?9@5:'V8%6A]F!5H?9@5:'V8%6A]F#_=P@ ZXP  -.;  #&J ( N[$"
M +*[ @"JQP8 HM,* )W6&@&5UBP&C-0Z$8/21AUZT$\G<LY8,6K-8#ADRV@_
M7LIR15C*?$E4R8A-3\F544S)I5-*R;E42<K<4T?(]U5(P/Q82KC[64RR^UI.
MK?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $ L;4  *C
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M1D#._T9 SO]&0,[_1D#._T;6DP  Q*,  +2L  "GM@  F\$  )#, @"&V08
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M^DNJ/?A*M#_W2KY ]4G,0/%)X4'M2O!!ZDK\0N1*_T383/]%S$__1L90_T;
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M7FF$^5QJ@OI::X'[6FN!^UIK@?M::X'[6FN!^UK_8A  _W(' /B" P#;CP(
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M45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7  "^H@  LZH  *FS  "@O (
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M"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/__PH3__\*$___"A/__PJ:L0
MB[T  'S(  !MU   7^   %'F  !']0  0?\  #S_"0 W_Q  ,O\5 2[_'0$J
M_R,!)O\I 2+_+P(?_S4"'/\[ AG_0@,6_TD#$_]1 Q'_6@,/_V8$#?]T! O_
MA00*_Y8%"?^H!0C_N04'_] %!__C!0?_XP4'_^,%!__C!0?_XP6-N@  ?<<
M &W3  !?X   4.<  $+M   Z_P  -?\  "__ @ J_PH )O\/ "+_%  >_QH!
M&O\? 1;_(P$3_R@!$/\M 0[_,P$,_SD""O]! @?_20(#_U," /]> @#_; (
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M43X'_U%)#/]/5A+_3&(7_TIO'/]'>R#_188C_T.1)?]"FB?_0:(I_T&J*OU
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M475S_T]V<O]-=G'_3'9Q_TQV<?],=G'_3'9Q_TS_61  _V8' /]S! #A?P$
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M2V&#_TMA@_]+88/_2V&#_TO_9 4 ]70  -J"  #+C@  P9<  +B> 0"QI0
MJ:L' *.M&@"<K"P$E:LZ#(VH11:&ID\??Z17*'FB7R]SH&8U;9YN.VB<=T!C
MFH%%7YF,25N8F4Q7EZA.59>[3U27W$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*
M_TI;BO]*6XK_2EN*_TK_:   Y7D  -&'  #%D@  NYP  +&B  "IJ0  H;$"
M )NS%0"5LR@"CK(V"8:P0A)_KDP;>*Q4(W*J7"ILJ&0Q9Z=L-F*E=3M=I']
M6:.*0U6BET=1H:=)3Z&Z2DZBV4E.H/5)3I__25"9_TE2EO](5)+_1U22_T=4
MDO]'5)+_1U22_T?_;@  WG\  ,J-  "^F   LZ   *JG  "AK@  E[8  )&Z
M$ ",NB,!A;DR!GZX/@YWMDD7<;52'FNS6B5ELF(K8+%J,%NP<S57KWTY4ZZ)
M/4^MED!,K:5"2JVY0TFNV$)(J_5#1ZK_1$FE_T1+H/]$39S_1$V<_T1-G/]$
M39S_1$V<_T3J=0  TH8  ,.3  "WG0  K*0  **K  "8LP  CKL! (7!# "!
MPAT >\(M W7!.@EOP$41:;]/&&.^5QY>O5\C6;QH*%6[<2U1NWLP3;J'-$JZ
ME3='NJ4Y1;JX.D2ZUSE#N/4[0K;_/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_
M/D6I_S[@?0  R8T  +N:  "NH@  HZD  )BQ  ".N0  A,$" 'G)!P!TRQ0
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M&3+IQADRZ.H9,>7^&2_D_QPNY/\>+>+_("WB_R MXO\@+>+_("WB_R"ZF@
MJJ,  )VK  "0M   @[T  '?&  !KSP  7]8  %3>! !1\!  3? ; $KP)@%&
M\3 "0O(Z S[R0P0[\TL%./-4!S;T70@S]&@),/5T"R[U@0PL]I$.*O:B#RCW
MMQ G^-81)_;T$2;S_Q$F\?\1)?'_$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D
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M @#_M@( _\T# /_L P#_[ , _^P# /_L P#_[ .(N0  >,0  &G0  !;W0
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M4@G_0U\-_T%K$?\_=Q3_/8(7_CR,&?P\E1K[.YT<^3NE'?@ZK1[V.K8>]3K
M'_,ZSA_P.N,?ZSOQ'^@Z_2'F.O\CY#K_)>$Z_R78//\FT#W_)LT^_R;-/O\F
MS3[_)LT^_R;_.20!_T$> ?]'&P'_2QL!_T\B ?]1*P+_438$_T]!!O],30G_
M2UH._$EF$OA'<A;U17T9\T.'&_%"D1WO0ID?[4&A(.Q!J2'J0+(BZ$"\(N=
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M0H1C_T"#8_\^@F/_/8)C_SR"8_\\@F/_/()C_SS_4 \ _UL' /]F P#L;P(
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M/VUR_S]M<O\_;7+_/VUR_S__60< _V4  .)R  #1?   QX0  ,"* @"YCP(
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M+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F_S)!IO\R0:;_,D&F_S+5?
MPHH  +66  "HG0  G:,  )*J  "'L0  ?+<  '"^ P!HP@X 9L,= &/#+0%>
MPSD$6L-$"%;"3@Q2PE<03\%?%$O!:1=(P7,:1<!^'4+ C" _P)LB/<"M(SS!
MQ",\P.DC.K[^)CB\_R@WN_\I.+C_*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,
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M!R'L_P<AZ_\((.O_"A_J_PL?ZO\+'^K_"Q_J_PNHGP  FZ8  (VO  !_N
M<<$  &3*  !8T   3-8  $'=   XY   -?8, #/W%  P]QX +O@G "OY,  H
M^3@!)OI  2/[20$A^U(!'OQ= AS]:0(:_7D#&/Z+ Q?_G@,5_[,$%/_3!!3^
M] 03_/\#$_K_ Q/Y_P,3^?\#$_G_ Q/Y_P.=I0  CZX  ("X  !RP@  9,L
M %;3  !)V@  /M\  #3D   N]   *_\* "C_$  E_Q< (O\? !__)@ <_RT
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M1700X$1^$]U#AQ7;0I 7V$&8&-5 H!G30*D;T4"R',] O1W-0,P=RD'D'L9
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M+YI1_RZ84?\MEE+_+)12_RN44O\KE%+_*Y12_RO_1A  _TX) /]6!0#^7@8
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M,GEB_S%Y8O\Q>6+_,7EB_S'_3P< _UD  .9D  #7;   S',  ,1W @"_>00
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M-4^,O35/C-XU3XOW-$^*_S-0B?\R48;_,5*$_S%2A/\Q4H3_,5*$_S'J90
MTG,  ,)_  "VB   K)   **4  "8F   C)P  (2?"@" H!D ?*$I 7>@-@5R
MGT$*;9Y+#VB=4Q1DG%L98)MC'5R::R%8F70E59A^*5&7BBQ.EI@N2Y:H,$J6
MO#%)EMPP293V,$F3_S!)DO\P2I#_+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD
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M&C6V_QPTM/\>,[/_'S.R_R SLO\@,[+_(#.R_R#!@P  M)$  *:8  ";G@
MCZ4  (*K  !VL0  :[8  %^\  !4P0, 3,4- $O%&0!)QB@ 2,8U $7'0 %#
MQTH#0,=3!#['708[QV<(.<=S"C?'@ PTQY -,L>A#C'(M0\PR-,/,,;T$"[$
M_Q,MPO\5+,'_%BO _Q<KP/\7*\#_%RO _Q>XC0  JI<  )Z>  "1I0  A*P
M 'BR  !KN0  8+\  %3#  !*R ( 0,T' #K2#@ YTAL .-,H #?3-0 VU$
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M 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU  !MO@  7\8  %+-  !%T@
M.=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -
M_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8  /^M  #_R@  __   /__  #_
M_P  __\  /__  #__P"-JP  ?;4  &Z_  !@R   4M   $/7   WW0  *^(
M "+F   9Z@  %?D  !+_   0_P@ #O\.  S_$0 )_Q8 !O\<  /_(@  _RH
M /\S  #_/0  _TD  /]7  #_:0  _WX  /^5  #_K   _\<  /_H  #_^@
M__H  /_Z  #_^@" M0  <+\  &')  !2TP  0]L  #7A   IY@  'NH  !7N
M   0^   #O\   O_   (_P  !/\&  #_"@  _PX  /\1  #_%0  _QL  /\C
M  #_*P  _S8  /]#  #_4P  _V4  /]Z  #_D0  _Z8  /^X  #_SP  _\\
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M&+<Z_QFV.O\9M3K_&+([_QBQ._\8L3O_&+$[_QC_.1( _S\- /]#"0#_2 P
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M)(E2_R.(4O\CB%+_(XA2_R/_10< _TL  /!5  #?6P  TV   ,QA P#(808
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M+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O_RA@;O\H8&[_*&!N_RCQ50
MWF(  ,IM  "]=0  LWL  *N   "B@@  F($  )&##P"-A1\ B(4N H.$.P5^
M@T4*>H%.#W6 5A1Q?UX8;GUF'&I\;2!G>W8C8WJ )V!YBRI=>)@L6G>F+EAW
MN"]7=]$O5W?Q+EAV_RQ8=O\J677_*5IT_RA:=/\G6G3_)UIT_R?M60  UV8
M ,5Q  "Y>@  KX   *:$  "=A@  D8<  (J)# "&BAL @HLK 7V*. 1XB4((
M=(A,#6^'5!)LA5L6:(1C&F2#:QYA@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1
M?LXM47WO+%)]_RM2?/\I4WO_*%1Z_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V
M  "T?@  JX4  *&)  "7BP  B8T  (./" !^D!< >Y$G 7:1- -RD#\&;8])
M"VF.40]EC5D38HQ@%UZ+:!M;BG$>5XE[(52(AB11AY0G3X:B*4V&M"I+ALPJ
M2X7N*4R$_RE,@_\H3(/_)TV!_R9.@?\F3H'_)DZ!_R;A8P  R7   +M[  "P
MA   IHH  )N.  "1D0  A),  'J5 @!UEQ( <I@B &^8, )JESL$9I=%"&*6
M3@Q?E58/6Y1=$UB391=5DVX:49)X'4Z1A"!+D)$C29"A)$>0LB9%D,HF18_M
M)46-_R5%C/\E1HO_)$:*_R1&BO\D1HK_)$:*_R38:0  PW8  +6!  "KB@
MGX\  )63  "*E@  ?IH  '"=  !KGPX :)\< &:@*@%BH#<"7Y]!!5N?2@A8
MGE(+5)Y:#E&=8A).G&L52YQU&$B;@1I%FX\=0IJ?'T":L" _FL@@/YGK'S^8
M_R ^EO\A/I7_(3^4_R$_E/\A/Y3_(3^4_R'-<   O'T  +"(  "DCP  F90
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M#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90  )F:  "-H0  ?Z<  '*M  !FLP
M6K@  $^[  !$OP  .L0" ##)"  NRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ H
MS58 )\YA ";.;P$DSG\!(\^1 B'/I0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)
M_P8=R?\&'<G_!AW)_P:HE   G)H  )"A  ""J   =*\  &>V  !;O   3L
M $/#   YQP  +\P  "?0!  ?U@H &]H0 !O;&@ :VR8 &MPQ !G=/  8W4@
M&-Y5 !??8@ 6X'( %>"% !3AF@ 3XK$ $N// !+@]  2WO\!$=W_ 1';_P(1
MV_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0  :+@  %N_  !.Q   0L@  #?,
M   MT   )-4  !S;   5WP4 %.D. !+J%  1ZQT $.LF  [L,  .[3H #>Y&
M  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3QY  "\?T  N__  /M_P #[?\
M ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(  $W(  ! S   --$  "K6   A
MVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4 !_L<  3\)  !_"P  /PW  #\
M0@  _%   /QA  #]=0  _(P  /RD  #\P0  _.L  /S_  #]_P  _?\  /W_
M  #]_P")J0  >;(  &J[  !<Q   3LP  #_1   RUP  )]T  !WA   5Y0
M#N@   KQ   (_0  !?\#  '_"0  _PX  /\2  #_%P  _Q\  /\G  #_,0
M_SX  /]-  #_7P  _W4  /^-  #_I@  _\(  /_G  #__   __\  /__  #_
M_P!\LP  ;+P  %W&  !.SP  /]8  #'=   EX@  &N8  !'J   ,[@  !?(
M  #_    _P   /\   #_    _P4  /\*  #_#@  _Q(  /\8  #_(0  _RL
M /\Y  #_2@  _UT  /]S  #_C   _Z0  /^Y  #_U   _]X  /_>  #_W@#_
M&"P _QDI /\9* #_%2L _Q P /\+. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\
M@@'_ (P!_P"4 ?\ G #_ *( _P"H /\ KP#_ +8 _P"^ /\ R #_ -< _P#G
M /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_&RD
M_QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA. ?\%6P'_ V@!_P)T ?\"?P'_
M H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;( _P&Z /\!Q #_ =$ _P#D /\
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M ]X<_P3='/\%W!S_!=P<_P7;'/\%VQS_!=L<_P7_*AD _RT3 /\M$0#_+1$
M_RX9 /\M(@#_+"X _RDZ /\F1P'Z)%0!]B-@ ?(B:P'O(G4"[2)^ NLBAP+I
M(H\"YR*6 N4BG@+D(J4"XB*M N$CMP+?(\,"W2/6 M@DZ@/2)/D%SR7_!LTE
M_P?+)?\(RB7_",HD_PC*)/\(RB3_",HD_PC_+A0 _S$0 /\R#0#_- X _S44
M /\U' #_,R< ^C$T /,O00#N+4X!Z2Q: >4L90+B+' "WRMY MTK@@/:*XL#
MV"N2!-4KF@33*Z($T2NJ!<\KLP7-*[\&S"S/!L@MYP?$+?<)P2W_"K\M_PN]
M+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$ _S4, /\V!P#_.@L _SP0 /\[
M%0#X.1\ [S<K .<V.0#A-4< W#54 =4U8 +1-6H#SC1S!,PT? 7*-(4&R#2-
M!\8SE C$,YP)PC.E"<$SK@J_,[D+O3/("[LTX0NW-/,-M#3_#[$T_P^P-/\0
MKS3_$*XT_P^N-/\/KC3_#ZXT_P__-0X _S@' /\\ @#_0 8 _T$+ /I!#P#M
M/Q8 XSPB -H],0#2/D$ S#Y/ L@^6@/$/60%P3UN![\\=@B\/'X*NCN'"[@[
MCPRW.Y<-M3J?#K,ZJ0^Q.K00KSK"$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_
M$Z([_Q.B._\2HCO_$J([_Q+_. H _SP  /]!  #U10  YD8" .%%!P#C0@T
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M&GU1_QK_0@  \$H  -]4  #.6@  Q%X  +Q?  "V7@  L5P+ *M>&@"E8"L
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M)6Q=N"5J7LXF:5[N)&E>_R)J7O\@:E[_'VI>_QYJ7O\=:E[_'6I>_QWY2@
MXU4  ,]?  #!90  MVH  *]L  "G;   GVH! )EK$0"4;2( D&XQ 8MM/02'
M;$<'@VM0"W]J6 ]\:& 3>&=G%G9G;QES9G@<<&6!'FUDC"%J8Y@C:&*F)69B
MMB9D8LPF9&+L)61B_R-D8O\A96+_'V5B_QYE8O\=96+_'65B_QWR3   WU@
M ,IB  "]:0  LVX  *MP  "B<   F6X  )-P$ "/<A\ BG(N 89R.P."<44'
M?7!."WIN5@YV;5X2<VQE%7!K;1AM:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?
M9\DF7F?J)5YG_B-?9_\A7V;_'V!F_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E
M  "Z;0  L'(  *=U  "==   E',  (UT#0")=AP A7<K 8%W. -\=D,&>'5,
M"71T5 UQ<UL1;G)C%&MQ:Q=H<',:96]\'6)NAR!?;90B76RB)%ILLB59;,<E
M6&SH)5EL_2-9:_\A6FO_'UMK_QY;:O\>6VK_'EMJ_Q[K4P  TV   ,)I  "V
M<0  K'8  *-Y  "9>0  C7<  (=Y"P"#>Q@ ?WPH 'M\-0)W>T %<WI)"&]Y
M40QL>%D/:'=A$V5V:!9B=7 97W1Z'%QTA1]:<Y$A5W*@(U5RL"13<L4D4W+G
M)%-Q_")4<?\@5'#_'U5P_QY5;_\=56__'55O_QWE5P  S60  +YM  "R=0
MJ'L  )]^  "3?0  AWT  (!_!P!\@!4 >($D '6",@%Q@3T$;8!&!VF 3PIF
M?U8-8WY>$6!]9A1=?&X76GMW&E=Z@AU4>H\?47F=(4]YKB).><,B37CE(DUW
M^R%.=_\?3G;_'D]U_QU/=?\=3W7_'4]U_QW?7   R&@  +ER  "N>@  I8
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M%SJ._Q<ZCO\7.H[_%SJ._Q?%;@  MGL  *J%  ">BP  E(\  (B2  ![E
M;I<  &*;  !7G@  4J . %&@&P!/H2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"
MH6$'/Z!K"3V@=PLZH(4-.*"4#C:@I@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9
M_Q,SF?\3,YG_$S.9_Q.]=P  KX,  *.+  "8D0  C94  (&9  !SG   9Y\
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M Q;!_P.CD0  F)@  (N>  !]I0  <*L  &*Q  !6M@  2KD  #Z]   TP
M*L0  "+(   9S 0 $] * !'2$0 0TAH $-,E  _3,  .U#P #M1(  W55@ -
MU64 #-9X  S6C0 +V*0 "MB^  G9Y@ *UOX "]3_  O2_P +TO\!"]+_ 0O2
M_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)OP  /<(  #+&   HR0  '\T
M !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@)  "X2X  >(Z  #C1P  Y%8
M .1G  #E>P  YI(  .:J  #GR   Y_   .C_  #H_P  Z/\  .C_  #H_P"1
MGP  @J<  '2O  !EMP  5[X  $G#   \QP  ,,L  "7/   <U   %-D   [=
M   )X0   N4   #I!@  Z0T  .D1  #J&   ZR$  .TK  #O-P  \44  /)6
M  #S:   \WX  /27  #UL   ]M   /?S  #W_P  ]_\  /?_  #W_P"%IP
M=K   &:X  !8P0  2L@  #O,   NT0  (]8  !G<   1X   #.,   3G
MZ@   /4   #T    ]04  /4+  #V#P  ]A0  /@=  #Z)P  _#0  /]#  #_
M50  _VD  /^!  #_F@  _[(  /_/  #_[0  __D  /_Y  #_^0!XL   :+H
M %G#  !+RP  .]$  "W8   AW0  %N(   [F   (Z@   .T   #P    ^
M /\   #_    _P   /\   #_!@  _PP  /\0  #_&   _R(  /\P  #_0
M_U,  /]I  #_@0  _YD  /^O  #_PP  _]4  /_5  #_U0#_$R@ _Q,E /\1
M)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0
M /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\ P #_ ,P _P#? /\ [ #_ /@
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_
M$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (0 _P", /\
MDP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_
M /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D _P#_&B( _QH> /\8'0#_$QX
M_PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K /\ =@#_ '\ _P"( /\ CP#_
M )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0 ]0#2 /, Y@#R /0 \0#_ /
M_P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,>
M /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&<0#_!GH _P:# /X&BP#\!I(
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M \,<_P/#'/\#PQS_ \,<_P/_*!  _RD+ /\H!@#_*PL _RL0 /\I%P#])B(
M]",N .PA.P#F($D XB!5 -X@8 #:(6H UB%T -,A? '0(80!SR*, <TBDP'+
M(IL!R2*C <@CK +&([8"Q"/$ L(DVP*^)>X#NR7^!+@E_P6V)?\%M27_!K4E
M_P:U)?\%M27_!;4E_P7_+ T _RT% /\N 0#_,04 _S$+ /TO$ #Q*Q@ YRDE
M -\H,P#8*$( T2I/ ,TK6@#)*V4!QRMN <0L=@+"+'X"P"R& [XLC@.]+)8#
MNRR>!+DLIP2X++$%MBR_!;4MT06Q+>H&KB[[!ZLN_PBI+O\(J"[_"*@M_PBH
M+?\(J"W_"*@M_PC_+P@ _S$  /\U  #V-P  ZC8" .<S" #D+P\ V2X; ,\Q
M+ #),SP Q#1) , U50&\-5\"NC5H K<U< .U-'@$LS2 !;$TB :P-) &KC29
M!ZPTH@BK-*P)J32Y":<TR@JE->4*H37X"Y\U_PR=-?\,G37_"YPU_PN<-?\+
MG#7_"YPU_PO_,P( _S4  /8Z  #E/@  W$   -0]! #2-PD RS@5 ,,Z)@"]
M/38 N#Y$ ;0^4 &Q/5H#KCUC!*P]:P6I/',&ISQ["*8\@PFD.XL*HCN4"Z [
MG0R>.Z@-G3NT#IL[Q0Z9.^ .ECOT#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_
M#9$\_PW_-0  _SD  .I!  #=1@  T$<  ,E&  #&004 P$ 1 +E"(0"S1#(
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M%WQ+N!A[2\T8>4SK&'A,_A=W3/\5=TS_%'=,_Q-W3/\2=TS_$G=,_Q+_/@
MZ$<  -50  #&5@  O%@  +19  "M5@  IU,' *%4%0"<5B4 F%<T 9170 *0
M5TH$C593!HI56PF'5&,+A%1J#H)3<A" 4GH2?5*#%'M1CA9X4)D8=E"F&710
MM1IS4,D:<5#H&G!1_!AP4?\7<%'_%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L
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M'%]=^!I?7?\87UW_%V!=_Q9@7?\58%W_%6!=_Q7K2@  U%8  ,->  "V90
MK&D  *)I  "89P  CV4  (EF# "%:!D @6DH 'YJ-0%Z:3\#=FE)!7-H40AP
M9UD*;6=@#6MF9Q!H97 2961Y%6-D@Q=@8X\97F*=&UQBK!Q:8K\<66+?'%EB
M]QI:8O\96F'_%UMA_Q9;8?\56V'_%5MA_Q7G30  SUD  +]B  "S:   J6T
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M%DIP_Q5+</\42W#_%$MP_Q346@  P&8  +-O  "H=@  G7D  (]X  "$>
M=WD  &]\  !J?0T 9WX9 &1_)@!B@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2
M?64,3WUO#DQ\>1%*?(831WN4%45[I!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W
M_Q1$=O\31';_$T1V_Q/-7P  NVL  *YT  "D?   EWX  (I]  !_?@  <G\
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M"RV2_PNV=0  JH$  )Z(  "3C0  AHX  'B/  !KD@  7Y4  %29  !)G0
M0*   #JB#0 XHQ< -Z,B #:D+0 UI#< -*1! #.E2P QI50!,*5> 2ZE:@$L
MI7@"*J6( RBEF@,GI:T$)J7& R:DZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>
M_P>O?@  HX@  )>.  "-DP  ?I4  '"8  !CFP  5Y\  $RB  !"I@  .*D
M "^L P JK@X *:X8 "BO(P GKRT )K W "6P00 DL$L ([%6 "*Q8P AL7$
M'[&" !ZRE $<LJD!&[+! 1NQYP$;K_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.H
MB   FX\  )&4  "$F@  =I\  &BB  !;I0  3ZD  $2M   YL   +[,  ":V
M   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4O4  $[Y+ !*^6  2OF< $;]X
M !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP
ME)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0  #JV   ON0  );P  !V_   5
MPP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC( !LL^  7+2P $S%H  \QJ  +,
M?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !RO\  <K_  '*_P"7E@  BIP
M 'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_   CPP  &\8  !/*   -S0
M"-$   '4"0  U X  -45  #6'@  V"<  -DQ  #;/@  W$L  -U;  #>;@
MWH0  -^;  #?M   WMD  -_W  #?_P  W_\  -__  #?_P"-G0  ?Z4  '"L
M  !ALP  4[H  $6_   XP@  +,8  "')   8S0  $-$   O5   $V@   -X
M  #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I+P  ZSP  .U+  #N70  [G$
M .^)  #PH@  \+P  /#C  #O^0  \/\  /#_  #P_P"!I0  <JT  &.U  !4
MO0  1L0  #?(   JS   ']   !75   .V@  !]X   #B    Y@   .D   #J
M    [    .X%  #O#   \1   /,7  #U(   ^"L  /LY  #]2@  _EX  /]T
M  #_C0  _Z8  /_   #_X0  __4  /_U  #_]0!TK@  9;<  %;   !'R
M.,T  "K2   =V   $]T   SB   #Y@   .D   #L    \    /,   #T
M]@   /@   #Z    _0<  /\-  #_$@  _QL  /\H  #_-P  _TH  /]>  #_
M=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_#R0 _PXB /\+(0#_ R0 _P I
M /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (0 _P", /\ D@#_ )D
M_P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_
M /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$ _Q > /\-'0#_!Q\ _P C /\
M+0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )4 _P";
M /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D X@#X /  ]P#\ /8 _P#U /\
M]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,: /\0&0#_"QD _P = /\ *0#_
M #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _@"# /P B@#Z )$ ^0"7 /@
MG0#W *, ]0"J /0 L@#R +L \0#( .\ W #N .P [0#Z .L _P#J /\ Z@#_
M .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3$P#_#A, _PL: /\') #_ C
M_P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^ /( A0#Q (P [P"3 .X F0#L
M *  ZP"F .D K@#G +< Y@## .0 U #B .D X0#W -\ _P#= /\ W0#_ -T
M_P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX
M /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"@ #F X< Y .. .(#E0#A YP
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M JX=_P+_)@8 _R4  /\F  #[)P  \24# / A"P#H'!( WAD= -0;+0#-'3P
MR!]) ,4@50#!(5\ OR)H +PB< "Z(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q
M)*H"KR2V JTEQ@*K)=\"J";S Z4F_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F
M_P/_*0  _R@  /8M  #G,   WR\  -DK! #6(@H SB,6 ,8F)P# *#8 NRI$
M +@K3P"U+%D LBQB ; L:@&N+7(!K"UZ JHM@0*I+8H"IRV2 Z4MFP.D+:4$
MHBVQ!* MP 2?+=@$G"[O!9DN_P:7+_\&EB__!I4N_P65+O\%E2[_!94N_P7_
M+   _RX  .HU  #=.0  T3D  ,HV  #'+P8 P2T1 +HP(0"T,C$ L#0^ *PU
M2@"I-50!IS5= :0U90*B-6T"H#5T Y\U? 2=-80$FS6-!9HTEP:8-*$&EC2M
M!Y0UNPB3-= (D#7L"(XV_@B,-O\(BS;_"(LV_P>*-?\'BC7_!XHU_P?_+P
M\C0  .(\  #200  QT(  ,!   "[.@$ MC8. + Y' "J.RP ICPZ *,]1@"?
M/5 !G3U9 IH]80.8/6@$ECQP!90\=P:2/( 'D3R(!X\[D@B-.YT)BSNI"HD[
MMPN(.\H+A3SH"X,\^PN"//\*@3S_"H$\_PF!//\(@3S_"($\_PC_,P  [#H
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M$FM,]1%J3/\/:DS_#FI+_PUJ2_\,:DO_#&I+_PSP/0  VT@  ,=0  "Z50
ML%@  *56  "<4P  ET\  )%0#@",4AP B50K (54-P""5$(!?U1+ WQ44P1Z
M4UH&>%-B"'52:0ES4G$+<5%Z#6Y1A ]L4) 0:E"<$FA0JQ-F4+P395#8$V10
M\Q)D4/\09%#_#V10_PYE3_\-94__#&5/_PSL00  U$P  ,-4  "V60  K%P
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M$%5<_PY56_\.5EO_#59;_PW>3   QU8  +A?  "M9   H&4  )-D  ")8P
M?V$  'EB P!U9!$ <F4> &]F*P!L9S<!:F=  F=F20-E9E$$8F58!F!E8 A=
M9&<*6V1P#%EC>PY68X805&*4$E)BHQ-08K033V+,$T]B[1)/8?\13V'_$%!@
M_PY08/\.4&#_#5!@_PW93P  PUH  +1C  "I:0  FV@  (]G  "$9P  >64
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M##]P_PS%7@  M6D  *EQ  "<=0  C70  (!T  !U=   :78  %YY  !8? $
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M RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=
MI7X  )F%  "*A   ?80  &^%  !CB   6(L  $V/  !#DP  .I<  #*:!P N
MFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L )YY5 ":>80 EGFX (YY^ 2*>
MD $@GJ,!'YZY 1Z>W0$>G/@"'IK_ AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4
M ).+  "%B@  =8L  &B.  !;D0  4)4  $:9   [G0  ,J   "JC   BI@D
M'Z<1 !ZG&@ =J"0 '*@M !NH-P :J4$ &:E, !BI6  7JF8 %JIV !6JB0 4
MJIX $ZNT !*KTP 2J/4 $Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1
M  !]D@  ;94  &"8  !4G   2*   #ZD   TIP  *JL  "&N   9L0  $K,'
M  ^U$  .M1< #K4A  VU*P -M38 #+9!  NV3@ *MEP ";9L  BV?P 'MI0
M!K:J  6VQ0 &MNH ![7_  BT_P (L_\ ";+_  FR_P":C0  D),  (28  !T
MG   9:   %>D  !+J   0*P  #6P   JLP  (;4  !BX   1NP  #+X"  ;
M"P "P!$  <$9  #!(@  PBL  ,(V  ##0@  PU   ,1?  #$<0  Q(<  ,2=
M  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##_P"3E   AYH  'B@  !JI@
M7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L   !##   *Q@   \H   #,!0
MS P  ,T1  #.&   SB$  - J  #1-0  TT,  -12  #48P  U7@  -6/  #5
MIP  UL(  -;I  #6_0  UO\  -;_  #6_P"*FP  >Z(  &RI  !>L   4+8
M $*Z   TO0  *,$  !W$   4QP  #<L   ;.    T@   -<   #9    V@4
M -P+  #=$   WQ4  .$=  #C)P  Y3,  .="  #H5   Z&<  .E^  #IEP
MZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP  ;JL  %^R  !1N@  0L   #3#
M   GQP  &\L  !+/   +TP   M@   #=    X0   .0   #E    YP   .D
M  #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y00  ^E4  /IJ  #[A   ^YT
M /RV  #\T@  _>T  /WT  #]] !QK   8;4  %*]  !$Q   -,D  ";-   :
MT@  $-@   C=    X0   .4   #H    [    .\   #Q    \P   /4   #W
M    ^0$  /L(  #^#@  _Q4  /\A  #_+P  _T$  /]6  #_;0  _X<  /^@
M  #_M@  _\H  /_4  #_U #_"R  _P<> /\ '0#_ "  _P E /\ +@#_ #L
M_P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_
M *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /  _@#] /T _P#] /\ _0#_ /T
M_P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_ !H _P ? /\ *@#_ #< _P!%
M /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\ B0#_ )  _P"6 /\ G #^ *(
M_ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y /, _P#R /\ \P#_ /, _P#S
M /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0 _P 9 /\ )0#_ #( _P!  /\
M3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W (L ]@"1 /0 EP#S )X \@"D
M /  K #N +0 [0#  .L SP#I .8 Z #U .8 _P#G /\ Y@#_ .4 _P#E /\
MY0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z
M %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8 Z@", .@ DP#G )D Y0"@ .,
MIP#A +  WP"Z -T R0#; .  V #P -< _@#5 /\ U #_ -, _P#3 /\ TP#_
M -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#&@#_ "8 _0 S /0 0 #O $T
MZP!8 .@ 80#E &H X@!R .  >@#> (  W "' -H C@#8 )4 U "< -( HP#0
M *P S@"V ,P Q #* -D R #M ,< ^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!
M_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\!Q\ \0,K .< .0#B $8 W@%1
M -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$B0#(!9  Q@68 ,0%H #"!JD
MP0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_
M&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8 XPDB -H), #3"CX S@M* ,H,
M50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\#XT NA"5 +@0G0"W$*< M1&R
M +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5_P"F%/\!IA3_ :84_P'_'P
M_QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y
M%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<
MO "D'<\ H1[J 9X>_ &<'_\!FQ__ 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$
M .PG  #@*@  U"D  ,TD  #*' @ Q!D2 +T<(@"W'C$ LR ^ *\A20"M(E,
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M!GTV] 9[-O\%>S;_!7HV_P1Z-O\$>C7_!'HU_P3U+0  Y#<  - _  #"0P
MMT0  *U   "G.@  HS8& )TW$P"9.2( E3HO )(\.P"//$8 C#Q/ 8H\5P&(
M/%X"ACQE H0\;0."/'4$@#Q]!'\\AP5]/)(&>SN>!WD[K =W.[P(=CS5"'0\
M\0AS//\'<CS_!G(\_P5R//\%<CO_!7([_P7Q,@  WCT  ,E$  "\2   L$D
M *9&  "?00  FST! )4]$ "1/QT C4$K (I". "'0T( A$-+ 8)#4P& 0UL"
M?D)B WQ":01Z0G$%>$)Z!G9!A =T08\(<D&;"'!!J0EO0;D*;4'0"FQ![@EK
M0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P  UD(  ,1)  "W30  JTT  *!*
M  "81P  DT(  (Y##0")11H AD8H (-'- " 2#\ ?DA( 7M(4 )Y2%<"=TA?
M W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&I@MG1K8+9D;,"V5&[ MD1_\)
M9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8  +]-  "S40  I5$  )I.  "2
M2P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z33P =TU% 75-30)S354"<4U< V]-
M8P1M3&L%:TQS!VE+?0AF2XD)9$N6"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_
M"5Y*_PA>2O\'7DK_!UY*_P?C/P  RTD  +Q1  "P50  H50  )92  "-4
MATP  (%-" !]3Q, >E A '=1+@!T4CD <E)" 6]22P%M4E(":U%9 VE1801G
M46@&95!Q!V-0>PAA4(8*7T^3"UU/H0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/
M_PA93O\'64[_!UE._P??0P  QTT  +A4  "L60  G5<  )%5  "(5   @5
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M!TI:_P?.3@  O%@  *Y@  "?80  D6   (5?  ![7P  <%T  &I?  !E80H
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M!CQOE0<Z;Z8(.&^["#AOVP<X;O8'.&W_!SAL_P8Y:_\&.6K_!CEJ_P:]7
MKV8  *)M  "1;   @FL  '=K  !L;   86X  %=P  !0<P  3'4* $EV$P!'
M=Q\ 1G<I $5X,P!#>#P 0GA$ $%X30$_>%4!/7A> CMX: (Y>'0#-WB"!#5X
MDP4S=Z0%,G>Y!3%XUP4Q=O4%,73_!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT
M )QQ  "+<   ?7   ')P  !G<0  7',  %%W  !*>@  0GT# #]^#@ ]?Q@
M/'\C #N +0 Z@#8 .8$_ #B!2  V@5  -8%: 3.!9 $Q@7 !+X%_ BV!CP,L
M@:$#*H&V RF!T@,I?_,#*7W_ RE\_P,I>_\#*7O_ RE[_P.Q:@  I70  )5V
M  "%=0  >'4  &UU  !A=P  5WH  $Q^  !#@0  .X4  #6("0 RB1$ ,8D;
M #"))0 OBB\ +HHX "V+00 LBTH *HM4 "F+7P HBVL )HMZ 22+BP$CBYX!
M(HNS 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  "
M>@  <WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4
M'  BE28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N
M !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@
M;((  %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4
MH1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JB
MP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L
M %B.  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1(
M!JT;  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM
MKM4  *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":
M  !$GP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4
M  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0
M +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [
MK0  ,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&
M%   QQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:
M  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0
M)+P  !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0
MUQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #E
MY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<
M  _*   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D
M .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@
M^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
M    W0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#
M  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,
M /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_
M %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\
MKP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_
M /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H
M_P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W
M +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H
M_P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!?
M /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X
MZ "Y .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_
M#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\
M8@#L &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T
M -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P
M_PP' /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #>
M &4 VP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0
MNP#" ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX
M /\*  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\
MR0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T
M ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/
M  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A
M +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4
MI@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D
M&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T0
M8P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3>
M )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0
MRB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">
M&V4 G1ML )L<<P":''L F!R# )<=C0"5'9< DQZB )(>KP"0'K\ CQ_8 (P@
M\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z'@  ZR8  -HM  #*,   OBX
M +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB/@"9(T@ ER11 )4D60"3)6
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M VLV_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@
MD#8  (PU#0"(-Q@ A#@E ($Z,0!_.SP ?#M% 'H\30!X/%4!=SQ< 74\8P%S
M/&H"<3QS G \? -N.X<#;#N4!&H[H01H.[$%9SS%!64\Y05D//H$9#S_ V,[
M_P-C._\#8SO_ F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#  ".0   B3P
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M U-(_P/400  P$L  +)1  "@4   DD\  (=.  !^3   >$@  ')*  !N2PT
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M!4=7E09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3
MM58  *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!5
M7"8 4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=
MD@5 7:,&/UVV!CY=T 8]7/$%/EO_!#Y:_P0^6O\#/EG_ S]9_P/!4   L5H
M *%=  "07   @EL  '9;  !M6P  85L  %M=  !67@  4F - %!A%P!.8B(
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M BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P
M=&<  &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q
M>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)Z
MQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP
M &5L  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B<
M)((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8
M@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS
M  !4=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG
M !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^
M#HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-
M?@  0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:
M)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP
M  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0
M.XT  #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P
MIB@  *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E
M_   I?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH
M "B>   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\
M +,H  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P
MM/\  +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L
M   6L   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=
M  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X
M ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .
MO0  !L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4
M&P  V"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__
M  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0
M ,P   #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$
MZA@  .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T
M] !JJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P
M  #@    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X
M /P6  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_
M !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\
M;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_
M /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0
M_P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_
M '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$
MQP#O .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P .
M /\ #0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L
M\P!R /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@
M -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\
M!@#_  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L
M .( <P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D
MR0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_
M  0 _P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X
M;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#;
M +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^
M]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\
M &X N@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@
MZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0
M -H !P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@
MK !O *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":
M!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-
M  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ
M )\+<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P
MC!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S
M$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3
M; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_
M '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'
MI!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&
M'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+( >R#% 'DAY !W(OD =B+_ '4B
M_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V,0  J2X  * J  ";)@  F"$!
M )4>$ "0(!L C2$H (DC,P"')#T A21& (,E3@"!)E4 ?R9< 'XF8P!\)VL
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M 5PT_P'<,P  Q3P  +1!  "B0   E3X  (L\  "$.0  ?S8  'LT! !W-1
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M E __P)0/_\"43[_ 5$^_P'/.P  O44  *I'  "91@  BT4  (%$  !Y0@
M=#X  &\_  !K0 P 9T$5 &5"(0!C0RL 84,U %]$/@!>1$4 745- %M%5 !9
M15P!6$5D 59%;0%417@"4D6% E%$DP-/1*,#346T TQ%S -+1>T#2T3_ DM$
M_P)+0_\"3$+_ DQ"_P+*/P  N4@  *9*  "520  AT@  'U'  !U10  ;D(
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M CU._P*^2P  KE,  )I2  ")40  ?%$  '%0  !H4   7DX  %A1  !44@
M45,, $Y4% !,51\ 2U8I $E6,@!(5CH 1U=" $972@!$5U( 0U=: $%79 %
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M 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@_P$K7_\!*U__ 2M>_P&Q60
MGEP  (M<  ![6P  ;UL  &5;  !<7   45X  $E@  !#8@  /&4  #AG"@ U
M:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8 +6I/ "QJ60 K:V4 *6MR "AK
M@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C9O\!(V;_ 21E_P&L8   F&
M (5@  !V7P  :E\  &%@  !78   36,  $1F   ]:   -FL  #!N!  L< X
M*G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')* ")R5  A<V  ('-M !YS?0 =
M<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D
M  !Q9   9F0  %UD  !29@  2&D  #]L   W;P  ,',  "EV   B>0@ 'WL0
M !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\3@ 6?%H %7QG !1]>  2?8L
M$7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_ !)W_P">:P  BFH  'II  !M
M:0  8FD  %=J  !,;0  0W   #ET   Q>   *7L  ")_   ;@@  %(4) !&&
M$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8
M  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"_P"5<0  @V\  '1N  !I;@
M7&\  %!R  !&=0  /'D  #)]   J@0  (H4  !N)   4C   #X\#  J2"P &
MDA$ !)(8  *2(  !DBD  )(S  "3/@  DTL  )-9  "3:0  DWL  )*0  "2
MI@  D;\  )'E  "0^@  C_\  (__  "/_P"-=P  ?74  '!T  !B=0  57@
M $E\   _@   -(0  "N)   BC0  &I$  !.4   .EP  "9L   &="   G0X
M )T3  ">&@  GB(  )\K  "?-0  H$(  *!0  "@7P  H'$  *"'  "?G0
MG[4  )[:  "=]@  G?\  )S_  "<_P"&?0  >'P  &E\  !;?P  3H,  $&(
M   VC   +)$  ".6   :F@  $IX   VA   &I    *<   "I P  J0H  *H.
M  "K$P  K!D  *TB  "N*P  KS<  *]%  "O5   KV8  *][  "NE   KJL
M *[)  "N[P  K?\  *W_  "M_P"!A   <80  &&'  !3BP  1I   #F6   N
MFP  (Z   !JD   2J   #*P   2O    L@   +8   "W    MP(  +@(  "Y
M#0  NA(  +L8  "](0  OBL  , X  # 2   P%H  ,%N  #!A@  P:   ,&Z
M  #!XP  P/D  ,#_  # _P!YC0  :)   %F4  !+F@  /:   #&E   EJP
M&J\  !&S   +N    KL   "^    P0   ,0   #%    Q@   ,<   #(!0
MR@L  ,P/  #.%0  T!\  -,K  #5.@  U4P  -9@  #8=P  V)(  -BL  #9
MR0  V>P  -G[  #8_P!PF0  8)X  %&D  !#J@  -;   "BV   <N@  $;X
M  G!    Q0   ,@   #+    SP   -(   #3    U@   -@   #;    W0
M -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1  #N9P  [X$  .^<  #PMP
M\-,  /#L  #P] !GI@  6*T  $FT   ZN@  *KX  !S"   0Q@  !\H   #.
M    T@   -8   #<    X    .,   #D    Y@   .@   #K    [0   .\
M  #R @  ]0H  /@1  #\'   _RP  /\_  #_50  _VX  /^*  #_I   _[H
M /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_
M %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X
MI@#] *X _ "Y /H R #Y .( ^ #T /< _P#V /\ ]@#_ .\ _P#G /\ X@#_
M -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\ ( #_ "T _P Z /\ 1@#_ %$
M_P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"& /8 C #U )( \P"9 /( H #P
M *D [@"S .T P0#K -8 Z@#N .D _@#G /\ YP#_ .4 _P#= /\ U0#_ -$
M_P#_  T _P * /\ " #_  D _P 0 /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5
M /, 7@#Q &8 [@!M .P = #K 'H Z0"  .< A@#F (T Y "3 .( FP#@ *,
MW@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_
M  @ _P # /\   #_  , _P - /P %@#W "( \P N .\ .@#L $4 Z !/ .0
M6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1 (< SP". ,T E0#+ )X R0"G
M ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X _P"^ /\ O0#_ +L _P#_
M_P   /\   #_    ]@ ( .X $0#G !L X0 G -T ,P#9 #X TP!) ,\ 4@#+
M %D R !A ,8 9P#$ &T P@!S ,  >@"_ (  O0"( +L D "Y )@ N "B +4
MK0"S +L L0#. +  Z@"O /P K0#_ *T _P"N /\ K@#_ *X _P#_ @  _P
M /T   #R    Z    -X # #3 !4 S  A ,@ + #$ #@ P0!" +T 2P"Z %,
MN !: +8 80"T &< L@!M +  = "O 'H K0"" *P B@"J ), J "= *8 J "D
M +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\ G@#_ )X _P#_!@  ^P   .X%
M  #B!   U0   ,L !@##  \ O0 9 +@ )0"T #$ L0 [ *X 10"L $T J0!5
M *< 6P"E &( I !H *( ;@"A '4 GP!\ )X A0"< (X F@"8 )@ I "6 +
ME0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_ (\ _P#]"@  \ X  .$1  #.
M$   P@T  +L'  "W  H L0 2 *P '@"H "D I0 T *( /@"? $< G0!/ )L
M5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0!(H C@25 (P%H0"*!:X B0:^
M (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+_P#V$   YA<  -(<  # &@
MLQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN )8*. "4"T$ D@Q* ) ,40".
M#5@ C U> (L-90")#6P B YT (8.?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0
MVP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O%P  VR$  ,8D  "T(P  J"
M * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2,@")$SP AQ-$ (443 "#%%,
M@15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/ '88G !T&*H <QF[ '(9U !O
M&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(   T"D  +PK  "K*@  GB@  )8D
M  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5
M '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PAF !K(:< :2*X &@BSP!F(NX
M92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\  +0Q  "C,   EBX  (TK  "'
M*   A"0  ((@" !^(!( >R(> '@C*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG
M60!K)V  :B=H &DH<0!G*'L 92B( &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_
M %PI_P!<*?\ 7"G_ %PH_P#8+   PS4  *TU  "=-   D#,  (8Q  " +0
M?"L  'DH P!V)Q  <BD: ' J)0!M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D
M+ET 8RYE &$O;@!?+W@ 7B^$ %POD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O
M_P!5+_\ 52[_ %4N_P#0,0  O3H  *@Y  "7.   BC<  ( V  !Z,@  =3
M '(N  !N+@T :R\6 &DP(0!F,2L 9#(T &,R/0!A,T0 8#-+ %\T4@!=-%H
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M 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-   !K/P  93P  & \  !</@0
M63X/ %<_& !50"( 4T$K %)!- !00CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(
M0VX 1T-[ 45#B0%#0YD!0D.K 4!#P $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4!
M_P&_00  JD4  )9%  "&10  >40  &]$  !G0@  8#\  %M!  !70@  5$,-
M %%$%0!/11\ 3D4H $Q&,0!+1CD 2D=! $E'2 !(1U  1D=8 $5'80!#2&P
M0DAX 4!(AP$^2)<!/$BI 3M(O@$Z2-\!.D?X 3I&_P$Z1?\!.T7_ 3M$_P&[
M10  ID@  ))'  ""1P  =D<  &M'  !C1@  6T,  %9%  !21P  3D@* $Q)
M$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"3$T 04Q6 $!,7P ^3&H /$QV
M #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+_P$U2O\!-DG_ 39)_P&X20
MHDL  (Y*  !^2@  <DH  &A*  !?20  54@  %!*  !,2P  24P' $9-$ !$
M3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H .U%3 #I17  X46< -U%S #51
M@@ S49,!,E&E 3!1N@$O4=H!+U#V 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T
M (I-  !Z30  ;DT  &1-  !;30  44T  $M/  !&4   0E(# #]3#0 ]5!4
M/%0> #I5)P Y52\ .%4W #=6/P V5D< -590 #-660 R5V0 ,%=Q "]7@  M
M5Y$ *U>C "I7N  I5]8 *5;U "E5_P J5/\!*E/_ 2I2_P&O40  F%$  (51
M  !V4   :E   &!0  !840  3E(  $=3  !!50  .U@  #A9"@ U6A$ -%H:
M #-;(@ R6RL ,5LS "]<.P N7$, +5Q, "Q<5@ K76  *5UM "A=?  F78X
M)%VA "-=M0 B7=( (ESS ");_P C6O\ (UG_ "18_P"H50  DE0  (!4  !Q
M5   9E0  %Q4  !450  2E8  $-8   \6P  -ET  #!@!0 M80X *V$5 "IB
M'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B9%P (61I !]D>0 >9(H '&2>
M !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?_P"A60  C%@  'M8  !M6
M8E@  %E8  !060  1UL  #Y>   W8   ,6,  "IF   D:0D (6H0 "!J%P ?
M:B  'FLH !UK,  <:SD &VM" !IL3  9;%@ %VQE !9L=  4;(8 $VR: !)L
MKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"970  A5T  '5<  !H7   7EP
M %5<  !+7@  0F$  #ED   R9P  *VH  "1M   >< $ %W,+ !5T$0 4=!@
M$W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (
M=,, "73G  IS_0 +<?\ #''_  QP_P"18@  ?V$  '!A  !D80  6F$  $]B
M  !%90  /&@  #-L   K;P  )'(  !UV   7>0  $7P$  U_#  +?Q( "G\9
M  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_9P  ?WD  '^.  !_HP  ?KL
M 'W@  !]]P  ?/\  'O_  ![_P")9P  >&<  &MF  !A9@  5&<  $EI   _
M;0  -7$  "QU   D>0  '7P  !:    0@P  #(8"  :)"@ !B0\  (D4  "*
M&P  BB,  (LL  "+-P  BT,  (M0  "+7P  BW$  (N&  "+G   BK,  (G3
M  "(\P  B/\  (?_  "'_P"";0  <VP  &AL  !:;0  3F\  $)S   X=P
M+GL  "6    =A   %8@  !",   +CP  !)(   "4!@  E0P  )40  "6%0
MEQP  )@D  "8+@  F3D  )E'  "95@  F6@  )E]  "9E   F*L  )?(  "6
M[@  EO\  )7_  "5_P![=   ;W,  &%S  !3=@  1GH  #M_   PA   )H@
M !V-   4D@  #I8   F9   !G    *    "A    H@8  *(,  "D$   I10
M *4<  "G)   J"\  *@]  "I3   J5X  *ER  "HB0  J*(  *B\  "GY0
MIOL  *;_  "E_P!W>P  :'L  %E^  !+@@  /H<  #*-   GD@  '9<  !2<
M   .H   !Z0   "H    JP   *X   "O    L    +$$  "S"@  M X  +43
M  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[?0  NI<  +JQ  "ZT@  NO,
M +G_  "Y_P!O@P  7X8  %&+  !#D   -I<  "J=   ?H@  %:<   VL   %
ML    +0   "W    NP   +X   "_    P    ,$   ## 0  Q <  ,4-  #'
M$0  RAD  ,TD  #.,P  ST0  -!8  #0;@  T8@  -"D  #0P0  T>8  -'X
M  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M   6LP  #K@   :\    P
M ,,   #&    RP   ,T   #.    T    -$   #4    U@   -H"  #<"0
MWP\  .,7  #F)   YS8  .A)  #I7P  ZG@  .N4  #KKP  Z\P  .SH  #L
M]@!?G@  4*0  $*K   TL@  )KD  !F^   .P@  !,4   #*    S0   -$
M  #8    VP   -\   #@    X@   .0   #F    Z0   .L   #N    \04
M /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"  #_G0  _[4  /_+  #_Y #_
M !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\ _P [ /\ 1P#_ %( _P!; /\
M9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^ ), _0"9 /L H0#Z *D ^ "T
M /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D _P#@ /\ V #_ -, _P#_  X
M_P + /\ "@#_  L _P 1 /\ '0#_ "H _P V /\ 00#_ $P _P!6 /X 7P#[
M &8 ^0!M /< = #U 'H ] "  /( A@#P (T [P"4 .T FP#L *0 Z@"N .D
MN@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1 /\ S #_ ,@ _P#_  D _P $
M /\  0#_  0 _P . /\ & #_ "0 _0 P /L .P#W $8 \P!0 .\ 60#L &
MZ@!G .< ;@#F '0 Y !Z .( @ #@ (< W@". -P E0#: )X U@"H -0 LP#1
M ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\ OP#_ +P _P#_  ( _P   /\
M  #_    _0 + /< $P#Q !X [0 J .H -0#G $  X@!* -T 4@#9 %H U0!A
M -( 9P#0 &T S@!S ,P >@#* (  R "' ,8 CP#$ )@ P@"A ,  K0"^ +L
MO #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_ +  _P#_    _P   /\   #Y
M    [@ % .4 #@#> !@ V  C -( +@#/ #D RP!# ,< 3 #$ %0 P0!; +\
M80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R )( L "; *\ IP"L +0 JP#&
M *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0 _P#_    _P   /4   #J
MW@   -  "@#( !( P@ = +X * "[ #, N0 ] +4 1@"R $T L !5 *T 6P"L
M &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P H "6 )\ H0"= *X FP"^ )D
MV "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_    ]0   .<!  #4    R0
M ,  ! "X  X LP 6 *\ (0"K "P J  V *8 /P"C $< H0!/ )\ 50"= %L
MFP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1 )  G ". *D C "X (L S0")
M .L B #] (@ _P"( /\ B #_ (@ _P#Y!@  Z0P  -0.  ###   MPD  + "
M  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6 $$ E !) )( 4 "0 %8 C@!<
M (T 8@"+ &D B@!P (@ > "' ($ A0", (0 F "" *4 @ "T 'X R !] ><
M? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4  ,45  "T%   J1$  *$.  ">
M"@  FP,, )< $P"3 !X D $I (T",P"* SP B 1# (8%2P"%!E$ @P97 (('
M7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W"J, =0JS ',+QP!R#.8 < W[
M ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=  "I'   G1H  )46  "0$P
MCPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^ 'P.1@![#DT >0]3 '@06@!V
M$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:( :Q*R &D2QP!H$^< 9A/] &44
M_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@(P  E"$  (L?  "&&P  @Q<
M ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT
M:QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO & :Q !>&^0 71S[ %P<_P!<
M&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0  C"@  (,E  !](@  >1\  '@;
M P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A
M &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<BP !6(^$ 52/Y %0C_P!4(O\
M5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T  'PK  !V*   <B8  &\C  !M
M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG
M9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/*=X 3BGW $TI_P!-*?\ 32C_
M $XH_P#(,   L#(  )PR  ",,@  @#$  '8P  !P+0  :RL  &@I  !F* D
M8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1
M+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M
M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K,@  9B\  &(N  !?+04 7"X0
M %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R20!0,E  3C-8 $TS80!+,VL
M2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T $(T_P!",_\ 0C+_ $(R_P#
M.   IS@  ),X  "#.   =S@  &TW  !F-@  83,  %TR  !9,@( 5S,- %0T
M%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU
M $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX_P ]-_\ /3?_ #TV_P"[.P
MHCL  (\[  !_.P  <SL  &HZ  !B.0  73<  %@V  !4-P  43@+ $\Y$P!-
M.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]
M@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X._\ .#O_ #@Z_P"V/0  GCX
M (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z  !/.P  3#P( $D]$0!'/AD
M1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1 #U!6@ \060 .D%P #A!?P W
M08\ -4*A #1"M  R0LX ,D'P #) _P S0/\ ,S__ #0^_P"Q0   FD   (=
M  !X00  ;$$  &)   !;0   5#\  $X_  !*0   1D$% $1"#@!"0Q8 0$,?
M #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&6  V1F( -49N #-&?  Q1HT
M,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T
M0P  :$,  %]#  !70P  4$,  $A#  !$10  048! #Y'#  \2!, .D@< #E)
M)  X22P -DDT #5*.P T2D, ,TI, #)*50 P2U\ +TMK "U+>@ L2XL *DN=
M "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'_P"G1@  D48  ']&  !P1@
M948  %M&  !41@  3$<  $1(   _2@  .TL  #=,"0 U31  ,TX8 #).(  Q
M3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P *%!H "=0=P E4(@ )%"; ")0
MKP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A20  C$D  'I)  !L2@  84H
M %A*  !02@  24L  $!,   [3@  -5   #%2!  M4PT +%04 "I4'  I520
M*%4L "=5,P F53P )59% "163@ B5ED (59E !]6=  >5H4 '%:8 !M6K  9
M5L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30  ADT  '5-  !H30  74T  %1-
M  !-3@  14\  #Q1   V4P  ,54  "M8   F6@D (UL0 ");%P A7!\ (%PG
M !]<+@ =7#< '%U  !M=2@ :754 &%UA !==<  578$ %%V5 !-=J@ 17<(
M$5WG !);_@ 36O\ $UK_ !19_P"440  @%$  '!1  !D40  65$  %%1  !)
M4@  05,  #A6   R60  *UL  "5>   ?80, &F,, !AD$0 79!D %F0A !5D
M*0 493$ $V4Z !)E1  195  $&5=  ]E:P .97T #661  QEI0 *9+P "F3@
M  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5  !?50  5E4  $Y5  !$5P
M/%D  #1<   L7P  )F(  !]E   9:   $VL% !!M#0 .;A( #6X:  QN(@ ,
M;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8  FZ*  !MGP  ;;8  &S6  !L
M\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<60  4UD  $A:   _70  -F
M "YC   F9P  'VH  !EM   3<0  #G0#  IW"@ %=Q   7<5  !W'   =R0
M '@M  !X-P  >$,  'A0  !X7@  >&\  'B$  !XF0  =[   ';-  !U\
M=?\  '3_  !T_P!^7P  ;E\  &)>  !97@  35\  $)B   Y90  ,&@  "=L
M   ?<   &'0  !)W   ->P  "'X   * "   @0T  ($1  ""%P  @QX  (,F
M  "$,   A#L  (1(  "$5P  A&@  (1\  "$DP  @ZH  (+%  "!ZP  @?X
M (#_  " _P!W90  :60  %]C  !29   1V<  #QK   Q;P  *',  "!W   8
M?   $7\   R#   &AP   (H   ", P  C D  (T.  ".$0  CQ<  ) >  "1
M)P  DC(  )(_  "23@  DE\  ))S  "2BP  D:(  )&\  "0Y0  C_P  ([_
M  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V   J>P  ((   !>%   0B0
M"XT   21    E0   )@   "9    F@,  )L(  "<#0  GA$  )\6  "@'@
MHB@  *(U  "C1   HU4  *-I  "B@   HIH  *&S  "@V   H/8  )__  "?
M_P!N<0  7W(  %%U  !$>0  -WX  "R$   AB@  %X\  !"4   *F0   9T
M  "@    I    *<   "H    J0   *H   "L!@  K0L  *\0  "P%0  LAX
M +0I  "T.0  M$H  +5=  "U<P  M8X  +6H  "TQ@  L^T  ++_  "R_P!F
M>@  5WT  $F"   \AP  +XX  ".4   8F@  $)\   FD    J0   *T   "P
M    M    +<   "X    N0   +L   "\    O@(  , (  #"#@  Q!0  ,<>
M  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*N   RMT  ,KU  #*_P!>A@
M3XL  $&1   SF   )Y\  !NE   1JP  ";    "U    N0   +T   #!
MQ@   ,@   #)    RP   ,P   #.    T    -(   #4!0  V0P  -T2  #A
M'@  XBX  .-"  #D5P  Y6\  .:,  #FJ   Y<4  .7G  #F]@!6E   2)L
M #JB   LJ0  '[   !.V   +O    ,$   #%    R0   ,T   #2    U@
M -H   #;    W@   .    #B    Y    .<   #I    [0   / *  #T$0
M^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\  /W'  #]Y #_  X _P - /\
M# #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N
M /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D G #W *4 ]0"O /0 O #S ,\
M\0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_ ,H _P#_  H _P & /\ ! #_
M  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $< _@!1 /L 60#Y &$ ]@!H /0
M;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H )\ Y@"I ., M0#B ,8 X #C
M -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X _P#_  , _P   /\   #_  $
M_P - /\ % #] "  ^@ K /< -@#S $$ [P!+ .P 5 #H %L Y@!B ., : #A
M &X WP!T -P >@#: ($ V "( -0 D #2 )@ SP"B ,T K@#+ +P R0#3 ,<
M\ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_    _P   /\   #_    ]P (
M /  $ #K !H YP E .0 , #A #L W !% -4 30#1 %4 S@!; ,L 8@#) &<
MQP!M ,4 <P## 'H P0"! +\ B0"] )( NP"< +D IP"W +4 M0#( +, Y@"R
M /L L0#_ +  _P"N /\ J@#_ *< _P#_    _P   /X   #Q    Y0 " -P
M#0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\ $X N@!5 +< 6P"U &$ LP!G
M +( ;0"P ', K@!Z *P @@"J (L J "5 *< H "E *T HP"^ *$ VP"@ /0
MGP#_ )X _P"? /\ G0#_ )L _P#_    _    .X   #@    T    ,4 " "^
M !  N0 9 +4 (P"S "X L  W *T 0 "J $@ J !/ *4 50"C %L H@!@ *
M9@"? &P G0!S )L >P": (0 F ". )8 F@"5 *< DP"W )$ S "0 .P CP#_
M (X _P". /\ C@#_ (\ _P#\    [P   -L   #)    O0   +4  @"N  P
MJ0 3 *4 '0"B "< H  Q )T .@": $( F !) )8 3P"4 %4 DP!; )$ 8 "0
M &< C@!M (T =0"+ 'X B0") (@ E0"& *( A0"Q (, Q "! .0 @ #Y '\
M_P"  /\ @ #_ (  _P#T @  X D  ,<(  "W!P  K ,  *8   "@  < FP /
M )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D 20"' %  A@!5 (0 6P"# &$
M@0!H (  < !^ 'D ? "$ 'L D !Y )T > "L '8 O@!U -T <P#T ', _P!S
M /\ <P#_ ', _P#I#0  SQ   +D0  "I$   G@X  )<+  "3!@  D  + (P
M$0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\ $L >@!1 'D 5P!W %T =@!D
M '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#NP!I!-8 : ;Q &@'_P!G!_\
M9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4  (L2  "&$   A P" (,&#0"
M Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48 < I, &\*4P!M"UD ; MA &H+
M:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_
M %T._P#4'   N1T  *0>  "5'0  B1P  ($:  ![%P  >!,  '@0!@!W#0\
M<PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%) &813P!D$58 8Q)= &$29@!@
M$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4 517S %05_P!4%?\ 5!7_ %04
M_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S'@  ;QL  &X7  !M$PP :A04
M &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T82P!<&5( 6AE: %D98@!7&FP
M5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ $P<_P!,'/\ 31S_ $T;_P##
M)@  JB<  )8G  "'*   >R<  '(F  !L)   :"$  &8>  !D&P@ 8AL1 %\<
M&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T
M $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@
MI"L  )$K  ""+   =BL  &TJ  !F*0  8B8  %\D  !=(@0 6R$. %@B%@!6
M(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP 3"94 $LG7 !))V8 2"=Q $8G
M?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _*/\ 0"?_ $ G_P"W+0  GRX
M (PO  !]+P  <2\  &@N  !A+0  72L  %HH  !7)P  5"<, %(H$P!0*1P
M3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _
M+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\ .BS_ #HL_P"R,   FS$  (@R
M  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1+   3RT) $PM$0!*+AD 22\B
M $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL
M.#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_ #4P_P"M,P  EC0  (0U  !U
M-0  :34  & U  !9-   5#,  % P  !,,0  23$& $<R#P!%,Q8 0S,? $(T
M)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y-E\ -S9K #8V>  T-XD ,C>:
M #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T_P"I-@  DC8  ( W  !R.
M9C@  %TW  !6-P  4#8  $LT  !'-0  1#8# $$W#0 _.!0 /C@< #PY)  [
M.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT ,CMH # [=@ O.X< +3N9 "P[
MK  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D.   CCD  'PZ  !N.@  8SH
M %HZ  !3.@  33H  $8X  !".@  /SL  #P\"P Z/!$ .#T9 #<](0 V/BD
M-#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F "M =  I0(0 *$"7 "9 J@ E
M0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P  BCP  '@]  !J/0  7ST  %8]
M  !//0  23T  $(]   \/@  .3\  #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M
M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%<0 C18( (D65 "!%J  ?1;\
M'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\  '1   !G0   7$   %-   !,
M0   1D   #Y!   X0P  -$4  #!& P M1PT *T@2 "I(&@ I2"( *$DI "=)
M,0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@
M !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#  !C0P  6$,  %!#  !)0P
M0D0  #M%   U1P  ,$D  "M+   F30D )$X0 ").%@ A3QT ($\E !]/+  >
M3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P %%"/ !-0I  14+H $5#> !%/
M^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?1P  54<  $U'  !&1P  /T<
M #=*   Q3   *TX  "90   @4P, '%4, !I6$0 95A@ %U8@ !96)P 55C
M%%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,  U7H  +5[8 "U;4  M6]  ,
M5?\ #53_  Y3_P"(20  =DH  &=*  !;2@  44H  $I*  !#2@  .TP  #-.
M   L40  )E0  "%6   ;60  %5P' !%>#0 07A, $%X:  Y>(@ .7BH #5XS
M  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->FP "7K$  EW,  )=[@ #7/\
M!%O_  5;_P"!3@  <$X  &).  !73@  3DX  $=.   ^3P  -E$  "Y4   G
M5P  (5H  !M=   58   $&,#  QF"P (9Q  !F<5  5G'  $9R0  F<M  %G
M-P  9T(  &=.  !G7   9VT  &>   !FE0  9JP  &7'  !EZP  9/P  &3_
M  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3   Y50  ,%@  "A;   A7P
M&F(  !1E   0:   #&L!  9N"0  ;PX  &\2  !O&   <!\  ' G  !Q,
M<3L  '%(  !Q5@  <68  '%Y  !QCP  <*<  &_!  !OYP  ;OP  &W_  !M
M_P!S6   95<  %I7  !15@  1E<  #Q:   R70  *F$  ")D   ::   %&P
M  YO   *<@  !'8   !X!0  > L  'D.  !Z$P  >QD  'P@  !]*0  ?3,
M 'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ  ![X@  >OH  'G_  !X_P!M
M70  8%P  %=<  !+70  0%\  #5C   K9P  (VL  !IO   3<P  #G<   A[
M   "?@   ((   "# 0  A 8  (4+  "&#P  B!,  (D9  "*(0  BRL  (LW
M  ",1@  BU8  (MI  "+@   BYD  (JS  ")V   B/<  (C_  "'_P!H8P
M7F(  %%B  !$90  .&D  "YN   D<P  &G@  !-]   -@0  !H4   ")
MC0   )    "2    D@   )0%  "5"@  EPX  )@2  ":&   FR$  )PM  "=
M/   G4P  )Q?  "<=@  FY$  )NK  ":R0  FO   )G_  "8_P!E:0  5VD
M $EL   ]<0  ,'8  "5\   ;@0  $H<   R,   $D0   )4   "9    G0
M *    "A    H@   *0   "E 0  IP<  *D,  "J$0  K1@  *\B  "O,
MKT$  *]4  "O:P  KH4  *ZA  "NO@  K>8  *S\  "L_P!><0  3W0  $)Y
M   U?P  *(4  !V,   3D@  #)@   .=    H@   *8   "J    K@   +
M  "Q    LP   +0   "V    N    +H$  "\"@  OA   ,$7  ##)   PS4
M ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R  ##_P!6?   1X(  #J(   L
MCP  ()8  !2=   -HP   ZD   "N    L@   +<   "[    OP   ,(   #"
M    Q0   ,8   #(    R@   ,T   #/    T@@  -4.  #;&   W2<  -XZ
M  #?4   X&@  ."$  #AH0  X;T  .'B  #@] !.BP  0)(  #*9   EH0
M&*@   ZO   %M0   +H   "_    Q    ,@   #.    T0   -0   #5
MV    -H   #=    WP   .(   #D    YP   .L%  #O#@  ]!D  /4K  #V
M00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_  L _P ( /\ "0#_  P _P 2
M /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4
M_@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J /( MP#O ,D [0#F .P ^P#K
M /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0 _P   /\   #_  4 _P - /\
M%0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W %P ] !C /( :0#P &\ [@!U
M .P >P#J (( Z ") .< D0#D )H X@"D .  L #= ,  V@#< -@ ] #5 /\
MTP#_ ,L _P#! /\ NP#_ +< _P#_    _P   /\   #_    _P * /T $0#Y
M !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8 X0!< -X 8P#< &@ V0!N -4
M= #2 'L T "" ,T B@#+ ), R "= ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_
M +T _P"T /\ K@#_ *L _P#_    _P   /\   #Z    \@ % .H #@#E !8
MX  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6 ,0 7 #" &$ P !G +X ;0"\
M ', N@!Z +@ @@"V (L M "6 +( H0"P *\ K@#! *T X "K /< J@#_ *D
M_P"F /\ H0#_ )\ _P#_    _P   /<   #H    W    -  "@#* !$ Q0 ;
M ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +  50"N %L K !A *H 9@"H &P
MIP!S *4 >P"C (0 H0". )\ F@"= *< FP"X )H T "9 .\ F #_ )< _P"6
M /\ E #_ )( _P#_    ]@   .0   #2    Q0   +L !0"U  X L  5 *P
M'P"J "D J  R *4 .@"B $( H !) )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L
M ), = "2 'T D "' (X DP", *$ BP"P (H Q0"( .8 AP#[ (8 _P"' /\
MAP#_ (8 _P#X    Y0   ,T   "]    LP   *H   "C  H GP 1 )L &0"9
M ", EP L )4 - "2 #P D !# (X 20", $\ B@!4 (D 6@"' &  A@!F (0
M;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z -L > #U '@ _P!X /\ > #_
M '@ _P#M    T0(  +L"  "L 0  H@   )L   "6  4 D0 - (T % "+ !T
MB  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/ 'P 50!Z %L >0!A '< :0!U
M '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X ; #N &L _P!K /\ :P#_ &L
M_P#?"P  P@P  *X,  ">#   DPL  (P'  "( @  A0 ) ($ $ !_ !< ?  @
M 'H * !X #  =@ X '0 /@!S $0 <0!* '  4 !N %8 ;0!= &P 9 !J &T
M: !W &< A !E )( 9 "A &, L@!A ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0
M$   MA$  *(2  "3$@  B!$  ( /  !\#0  >0D! '@#"P!U !$ <P : '
M(P!N 2L ; $S &H".0!I T  9P-& &8$3 !E!%( 8P59 &(%80!@!6H 7P9T
M %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*^P!5"O\ 50K_ %8*_P#&%0
MK1<  )D8  "*&   ?Q<  '86  !Q$P  ;A   &T-!0!M"0T :@D4 &<*'0!E
M"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.
M@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-$/\ 31#_ $T0_P"\&P  I1P
M )(=  "#'@  =QT  &\<  !I&@  9A<  &04  !D$ @ 8@\0 %\0& !=$"$
M6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+
M%(P 212< $<5K@!&%<4 117H $46_@!%%O\ 117_ $45_P"U'P  GB$  (LB
M  !\(@  <2(  &@A  !B'P  7QT  %P:  !;%P( 6A4- %<6% !5%AT 5!<E
M %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD
M0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_ #X;_P"O(P  F"0  (8E  !W
M)@  ;"8  &,E  !=)   62(  %8?  !4'0  4QP+ %$<$@!.'1H 31TB $L>
M*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"(%\ 0"%J #\A=P ](8< .R&8
M #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A_P"J)@  E"<  ($I  !S*0
M9RD  %\I  !8*   5"8  %$C  !/(@  3"(' $HB$ !((A< 1R,? $4D)@!$
M)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP .B9G #DF=0 W)X0 -2>6 #0G
MJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E*0  CRH  'TL  !O+   9"T
M %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G#0!"*!0 02@< #\I(P ^*2L
M/2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L
M++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+   BRT  'DN  !K+P  8"\  %@O
M  !1+@  3"X  $@L  !%*P  02L  #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO
M #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP<  L,(  *C"2 "DPI0 G,+H
M)C#< "8P]P G+_\ *"__ "@N_P"<+@  AS   '8Q  !H,@  73(  %4R  !.
M,0  2#$  $0P  ! +P  /#   #HQ"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S
M,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G-7X )360 ",UHP B-;D (379
M "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T  !E-   6C4  %$U  !+-
M130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3 "\W&P N-R( +3@I "LX,0 J
M.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP (#J. !XZH@ <.K< &SG5 !PY
M]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A-P  5S<  $XW  !(-P  0C<
M #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\&  H/1\ )CTF "4]+@ D/34
M(SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^, !@_H  6/[4 %3[2 !8^\P 7
M/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@  4SH  $LZ  !%.@  /SH  #DZ
M   R/   +CX  "E    F00@ )$(. ")"%  A0AL ($,C !]#*@ >0S( '$,Z
M !M$0P :1$T &$19 !=$9P 51'< $T2* !)$G@ 11+, $$30 !!#\@ 10O\
M$D+_ !-!_P").P  =CP  &8]  !:/0  4#T  $@]  !"/0  /#T  #8^   O
M0   *D(  "5$   A1@, '4@, !M)$0 921< &$D> !=))@ 622X %4HV !1*
M0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,2K  "DK*  M)[  ,2/\ #4?_
M  U'_P"#/@  <3\  &)   !60   34   $5    _0   .4$  #)"   K10
M)D<  "%)   <2P  %DX' !-0#@ 24!, $5 9 !!0(0 /4"D #E Q  U0.P -
M448 "U%1  I17P )46\ !U"!  50E@ #4*L  E#%  -/Z  #3_L !4[_  9-
M_P!]0@  :T,  %U$  !21   2D0  $-#   \1   -44  "Y'   G2@  (4P
M !Q/   740  $E0#  Y7"@ +6!  "E@5  A8'  '6"0 !E@L  58-@ #6$
M 5A,  !86@  6&D  %A\  !8D0  5Z<  %?   !6Y0  5OD  %7_  !5_P!V
M1P  9D<  %E(  !/1P  1T<  $!'   X2   ,$H  "E-   B4   '%,  !95
M   16   #5L"  E>"0 $7PX  %\2  !?&   8!\  & G  !@,   8#L  &!'
M  !@5   8&,  &!V  !@BP  7Z(  %^[  !?X@  7OD  %W_  !=_P!O2P
M84P  %5,  !,2P  1$L  #M,   R3@  *U$  "-4   <5P  %EL  !%>   -
M8   "&,   )F!P  9PP  &</  !H$P  :1D  &HA  !J*0  :C0  &I   !J
M30  :ET  &IO  !JA0  :IT  &FV  !HW0  :/<  &?_  !F_P!I40  7%
M %)0  !*3P  /U   #53   M5@  )%D  !U=   68   $&0   QG   &:@
M &X   !O P  < @  '$-  !R$   =!0  '4;  !V(P  =RP  '<X  !V1@
M=E8  '9H  !V?@  =I<  '6Q  !TTP  <_4  '/_  !R_P!C5@  6%4  %!4
M  !$50  .5@  "];   F7P  '6,  !5G   0;   "G    1S    =@   'H
M  !\    ? ,  'X(  !_#   @1   ((4  "$&P  A20  (8O  "&/0  ADT
M (5?  "%=0  A8\  (2I  "#R0  @O$  ('_  " _P!?6P  5EH  $E;   ]
M7@  ,F$  "=F   >:P  %7    YU   )>0   7X   "!    A0   (@   "*
M    BP   (T!  ".!@  D L  )$/  "3%   E1L  )<F  "7-   ET0  )=6
M  "6;   E88  )6B  "4P0  D^H  )+_  "2_P!=80  3V$  $)D   V:0
M*FX  !]T   5>0  #G\   >$    B0   (X   "2    E@   )@   ":
MFP   )T   "?    H0,  *,(  "E#0  IQ,  *D<  "J*   JCD  *I+  "J
M80  J7H  *B9  "HM0  I]T  *?X  "F_P!6:   2&P  #IP   N=@  (GT
M !>$   .B@  !Y    "6    F@   )\   "C    IP   *H   "K    K0
M *\   "Q    LP   +4   "X!0  N@P  +T2  # '   P"T  ,!   "_50
MOVX  +Z+  "^J   OLD  +WO  "\_@!.=   0'D  #)_   EAP  &8X  !"5
M   'G    *(   "G    K    +    "U    N0   +P   "]    OP   ,$
M  ##    Q@   ,@   #*    S0(  - +  #5$@  UB$  -<T  #820  V6
M -I\  #:F@  V[4  -O9  #;\@!&@@  .(D  "N0   =F   $J    JG
MK@   +0   "Y    O@   ,(   #(    RP   ,X   #/    T@   -0   #6
M    V@   -T   #?    X@   .8   #J"@  [Q,  / E  #R.@  \U$  /1K
M  #TB0  ]:4  /6_  #UW0#_  8 _P # /\ !0#_  L _P 0 /\ %P#_ "(
M_P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D /\ :@#_ '  _0!V /L ? #Y
M (, ]P"* /4 D@#S )L \ "F .X LP#K ,0 Z0#D .< ^0#F /\ Y0#_ -,
M_P#' /\ OP#_ +L _P#_    _P   /\   #_  ( _P + /\ $@#_ !T _P H
M /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X 8P#L &D Z@!O .@ =0#F 'P
MY "# .( BP#? )4 W "? -D JP#5 +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z
M /\ M #_ +  _P#_    _P   /\   #_    _P & /D #P#U !< \P B /$
M+0#M #< YP!  .( 20#? %  VP!7 -< 70#4 &, T0!H ,\ ;@#, '4 R@!\
M ,@ A #% (T P@"8 ,  I "] +( NP#& +D Z "X /T MP#_ +8 _P"M /\
MIP#_ *, _P#_    _P   /\   #U    ZP ! .0 # #> !, V0 < -, )@#1
M #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P N0!A +< 9P"U &T LP!T +$
M? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C /4 HP#_ *( _P"> /\ F@#_
M )< _P#_    _@   .\   #?    T    ,< !P#!  \ O  7 +D ( "W "H
MM0 S +  .P"M $, JP!) *@ 3P"F %4 I !: *, 8 "A &8 GP!M )T = "<
M 'T F@"( )@ E "6 *( E "R )( R0"1 .L D0#_ )  _P"0 /\ C #_ (H
M_P#\    [    -D   #'    N@   +$  @"K  P IP 2 *0 &P"A "0 H  L
M )X -0"; #P F !# )8 20"4 $\ D@!4 )  6@"/ %\ C0!F (L ;0") '8
MB "  (8 C "$ )H @@"J ($ O@"  .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q
M    V    ,(   "S    J    *    "9  < E0 . )( %0"0 !X C@ F (T
M+@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z
M '< A@!U )0 = "C '( M0!R ,\ <0#Q '  _P!P /\ < #_ '$ _P#A
MQ    +    "B    EP   )$   "+  ( A@ + (, $0"! !@ ?P A 'T *0!\
M #  >0 W '@ /0!V $, = !) ', 3@!R %0 < !: &\ 8@!M &H :P!T &H
M@ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C /\ 8P#_ &0 _P#/!0  M@<
M *,(  "4"   B0<  ((#  !^    >P & '< #@!U !, <@ ; '$ (P!O "L
M;0 R &P . !J #X :0!$ &< 20!F $\ 90!6 &, 70!B &4 8 !O %\ >P!=
M (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\ 6 #_ %D _P#"#   J@T  )<.
M  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K !  :0 6 &< '@!E "8 8P M
M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H 60!8 &( 5P!L %4 > !3 (8
M4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_ $X#_P"X$   H1(  (X3  !_
M$P  =!,  &P2  !G$   90X  &,+ P!C!@P 8001 %X#&0!<!"$ 6P4H %D&
M+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4
M $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,_P"P%   F18  (<8  !X&0
M;1@  &47  !?%@  7!,  %H1  !:#@8 6@P- %<,% !5#!P 4PTD %(-*P!0
M#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0
MI@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I&0  DAL  ($<  !R'0  9QT
M %\<  !9&P  51D  %,6  !2$P  4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX
M2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E #X5<@ \%8$ .A62 #@5I  W
M%;D -178 #46]0 V%O\ -A;_ #<5_P"C'   C1X  'L@  !M(0  8B$  %HA
M  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'%Q4 11<< $08) !"&"H 01@Q
M $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;;P U&WX ,QN0 #(;H@ P&[<
M+QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(  '<C  !I)   7B0  %8D  !0
M(P  2R(  $@@  !&'0  11P" $,<# !!'!( /QT9 #X=(0 \'B< .QXN #H?
M-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O('P +2&. "PAH  J(;4 *2'0
M "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F  !E)P  6R<  %,G  !,)@
M1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S
M)#D ,B1! # D2@ O)5, +25> "LE:P J)7H *"6, "8EGP D);, (R7. ",E
M\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B*@  5RH  $\J  !)*0  1"@
M $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G&P Q*"( ,"@I "\H,  M*3<
M+"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?
M*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+   5"P  $PL  !&+   02L  #PK
M   X*@  -2H  #(K P P*PP +BP1 "TL&  L+!\ *BTF "DM+0 H+30 )RX\
M "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !POFP :+[  &"_* !@N[0 9+O\
M&RW_ !LM_P",*P  >"T  &@N  !;+P  42\  $DO  !#+P  /BX  #DN   T
M+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P )3(C "0R*@ C,C$ (3,Y " S
M0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_
M !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R  ! ,0  .S$  #8Q   Q,0
M*S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@ !XW)P =."X &S@V !HX/P 9
M.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T #CC'  XXZP 0./\ $#?_ !$V
M_P"#,0  <#(  &$T  !5-   2S0  $0T   ]-   .#0  #,T   M-0  *#<
M "0Y   @.@( '3L+ !L\$  9/14 &#T< !<](P 6/2L %3XS !0^/  2/D8
M$3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!  H]Y  +/?L ##S_  T[_P!]
M-   :S8  %TW  !1-P  2#<  $$W   [-P  -3<  # W   J.0  )3L  " ]
M   </P  %T$& !1##0 20Q( $4,8 !%#'P 01"< #T0O  Y$.0 -1$, #$1.
M  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#X  #0_8 !$+_  9!_P!X.
M9SD  %DZ  !..@  13H  #XZ   X.@  ,SH  "T[   G/0  (4   !Q"   7
M1   $T8#  ])"@ -2@\ #$H4  M*&P )2B, "$HK  =*-  %2CX !$I)  )*
M5@  2F4  $IW  !*BP  2J$  $FY  !)W0  2?4  $C_  !(_P!R/   8CT
M %4^  !*/@  0CT  #P]   V/0  +SX  "E    C0@  '44  !='   32@
M#TP"  M/"0 '4 T  U$1  !1%P  41X  %$F  !1+P  43D  %%$  !240
M4F   %%R  !1AP  49T  %&U  !0V   4/4  $__  !/_P!L0   74$  %%!
M  !'00  0$   #E    R00  *D,  "1&   >2   %TL  !).   .40  "U,!
M  96!P  5PP  %@0  !8$P  61D  %HA  !:*0  6C,  %H_  !:3   6EH
M %IL  !:@0  69D  %FQ  !8T0  6/0  %?_  !7_P!E10  6$4  $U%  !%
M1   /D0  #5%   M1P  )4H  !Y-   84   $E,   Y6   *60  !%P   !>
M!   7PD  & -  !A$   8A4  &,;  !D(P  9"T  &0X  !D10  9%0  &1F
M  !D>P  8Y,  &.M  !BS   8?(  &'_  !@_P!?2@  4TH  $I)  !#2
M.4D  "],   G3P  'U(  !A5   260  #5T   A@   "8P   &8   !H 0
M:04  &H*  !K#0  ;1$  &X6  !P'0  <28  '$Q  !P/@  <$X  '!?  !P
M<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:3P  4$X  $A-   ]3@  ,U$
M "E4   @6   &%P  !%@   ,9   !F@   !K    ;P   '(   !T    =0
M '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H  " -0  @$4  ']6  !_:P
M?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65   3E,  $)4   W5@  +%H  ")?
M   88P  $6@   MM   #<@   '8   !Z    ?0   (    "#    A    (8
M  "' @  B0<  (L,  "-$   D!8  )(?  "2+   DCL  ))-  "18@  D7H
M (^7  "/M   CN$  (S[  ",_P!560  2%H  #M=   O80  )&8  !EL   1
M<@  "G<   )]    @@   (8   "+    C@   )$   "3    E0   )<   "9
M    FP   )T$  "?"@  H@\  *06  "F(0  IC$  *9#  "E5P  I'   *..
M  "CJP  H=   *#U  "?_P!.80  0&0  #-I   G;@  &W4  !%\   +@P
M (D   ".    DP   )@   "=    H0   *0   "E    IP   *D   "K
MK0   +    "R    M0@  +@.  "\%@  O"4  +PW  "[3   NF0  +F!  "W
MH@  M\   +?J  "W_ !&:P  .7   "MW   ??P  $X8   N.   !E0   )L
M  "A    I@   *L   "P    LP   +<   "W    N@   +P   "_    P0
M ,0   #'    R@   ,T%  #1#@  U!D  -0K  #40   TU@  --T  #3D@
MTK   -+3  #2\@ ^>0  ,8   ".(   7D0  #9D   .@    IP   *X   "S
M    N    +T   #"    Q@   ,H   #*    S0   ,\   #2    U0   -D
M  #=    WP   .,   #G!0  ZP\  .P?  #M,P  [DL  .]D  #O@@  \)\
M /&Y  #QV #_    _P   /\ ! #_  D _P . /\ %0#_ !X _P I /\ - #_
M #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L ^P!Q /D =P#X 'X ]@"% /,
MC0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B /\ VP#_ ,L _P#! /\ N0#_
M +0 _P#_    _P   /\   #_    _P ) /\ $ #_ !D _P C /\ +@#] #D
M^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J .0 < #B '8 WP!] -T A@#9
M (\ U0": -$ IP#. +8 RP#. ,D \ #' /\ Q0#_ +L _P"T /\ K0#_ *D
M_P#_    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [
M -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (<
MO "2 +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M    _P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$
M/0"] $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"*
M *, E@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_
M]@   .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F
M #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )
MC@". )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP
M ,P   "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #<
MD0 ] (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\
M )0 >@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<
M  "H    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W
M 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T
M; "= &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
M    C0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\
M-P!N #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6
M %T J != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!
M?P(  '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B
M #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %(
MHP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL
M &P*  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #,
M5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!(
M +( 1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/
M  !>#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U
M $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\
M/@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6
M$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8)
M. !$"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S'
M #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P
M314  $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^
M#SP /0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1
M[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH
M $08  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD
M-A1  #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G
M%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <
M   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D]
M "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX
M(AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y
M'@  .!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?
M0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__
M !X>_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@
M,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B
M)$H (215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC
M_P"%(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0
M "LE   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@
M&RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P"
M)0  ;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I
M   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0
M !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*
M:BH  %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?
M+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S
M6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT
M %@N  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P
M%S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P )
M.&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q
M  !),0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH"
M ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$
M #YR   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&
M-   /C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!
M"  )0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M
M  !$@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.
M.S<  #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #
M20P  $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+
M?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H
M #,Y   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H
M % -  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P
M5(\  %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^
M   G0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+
M  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D
M %VC  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A
M2   &DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E
M"@  9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=
M  !HNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40
M$U4   Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0
M<PD  '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !W
MLP  =>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$
M  9F    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(
M (8'  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@
MB,\  (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M    >P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@
M  ":!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$
M )ON  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'
MC0   )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
M    L0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B
M  "P_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H
M *4   "J    K@   +$   "R    M0   +<   "Z    O    +\   ##
MQ@   ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+
M[P W<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D
M  "^    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@
M .$   #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M    _P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\
M2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "=
M .D J@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_
M_P   /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O
M $T [ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P
MH@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P
M /T   #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8
MS0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q
M *D K@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(
M  #G    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !%
M +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *
MF "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
M    O    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H
M1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H
M (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q
MI@   )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"%
M $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$
MLP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP
M (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T
M<@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A
M ,( 8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P
M  !W    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ]
M &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D
M5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M    9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %<
M/0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#.
M $D \P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!
M6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !,
M #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\
MZ@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D
M % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H
M0@!! $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V
M /D -@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-
M  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^
M #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4
M+0?_ "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  !
M#@  0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+
M0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_
M "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@
M.1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L
M$$L *A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0
M_P"&%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0
M #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@
M)!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""
M%P  ;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6
M   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1
M !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@
M:QT  %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G
M&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>
M6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\
M %DA  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( (
M(" * !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1
M(V< $"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C
M  !+)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4'
M !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0
M#"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !(
M)P  /R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K
M"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP
M  0M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0
M/"D  #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .
M,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R
M?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P
M #(K   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP
M!S<0  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?
M-Y(  #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N
M   K+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.
M   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\
M #VG   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I
M+P  )#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#
M$   1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D
M  !$P   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-
M(#4  !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@
M3!$  $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,
MO   2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP
M !4_   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X
M %<1  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP
M5>,  %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(
M   +2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.
M  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T
M &#\  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #
M5@   %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R
M#@  =1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W
M  !N_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P
M &@   !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"
MA@T  (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !_
M_P!&2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@
M  !\    @0   (0   "'    B    (L   ".    D    ),   "6    F0<
M )T-  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _
M4@  ,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
M    E    )<   "9    G    )\   "A    I    *<   "J    K0   +$&
M  "U#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7
M*V$  !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D
MJ    *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+
M!0  T0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W
M !9Y   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0
M ,    #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D
MZ 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\
M  #_  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5
M /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D
MWP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M    _  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8
M5 #B %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #%
M +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q
M\@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#"
M %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8
MW "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP
M ,@   #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P
MI@!1 *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP".
M /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H
M  "F  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!*
M (X 3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$
M>0#_ '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".
M  $ BP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D
M2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V
M &< _P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![
M>  % '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H
M $@ 9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D
M_P!9 /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 !
M &8 "0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $(
M6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!-
M /\ 30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H
M!0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!#
M $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\
M0P#_ $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.
M  D 30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $(
M10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_
M #D _P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8
M1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X
M $D -P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #
M_P","0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00(
M #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8
M+P!0 "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&
M#   <@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8(
M"@ U!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=.
M "<'60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@
M;1$  %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P
M"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-
M6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,
M %H5  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@
M*0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9
M$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7
M  !+&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+
M "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0
M$A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(
M&P  /QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6
M#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER
M  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0
M/!T  #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6
M'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>
M@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\
M #(?   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X
M$"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !
M(I$  "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A
M   J(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80
M  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\
M ":F   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H
M(P  )"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K
M$P $*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND
M   KO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0
M(R0  !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0
M,14  #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   P
MO   ,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28
M !PG   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(
M #@8   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@
M-N0  #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK
M   4+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4
M  ! &P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,
M #S\   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1
M,P  #38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*
M%@  2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\
M  !$_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P
M"#X   -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@
M51D  %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !.
M_P!%-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@
M  !*    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,
M &(;  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!
M/   .CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M    60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5
M  !R(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0
M.3X  "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E
M:    &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'
M%P  AB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4
M "A(   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@
M 'X   "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$
MGAH  )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3
M   560  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(
M  "5    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!
M +<>  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .
M:0  !7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
M    K    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4
M  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P
M (0   "-    E0   )T   "C    J0   *\   "T    N0   +P   "^
MP@   ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M
M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  (
M /X #@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P
M]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#*
M /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8
M"0#Z  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!;
M -8 8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\
MIP#_ )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@
M  L VP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@
M60"V %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_
M (L _P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8
MMP . +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40";
M %< F0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P
M_P!V /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 *
M )@ $ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %
M@P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I
M /\ 9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (
M#0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/
M &T 5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\
M6P#_ %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L
M  X :P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T
M3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_
M $\ _P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L
M6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!.
M %$ 30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4
M_P"?    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P -
M $X $0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P
M0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M    ?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $,
M#@!# !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0
M #< 6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")
M=@,  &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z
M !  .0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X
M5P M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@
M %\*  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X
M,0 1 #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F
M &  ) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-
M  !.#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/
M "H!$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T
M'@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*
M$   0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'
M$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK
M !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@
M/1(  #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?
M"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -
M?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0
M #(4   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A
M&0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +
M$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6
M   J%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2
M !(2&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T
M!!2C  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H
M&   (Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7
M%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A
M   7N0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@
M(1D  !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *
M&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;
MN0  &]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL
M !P:   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8
M R <  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N
M']X  ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<
M   8&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49
M   F(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\
M "/Y   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6
M'@  $QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L
M'0  +"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[
M   H_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0
M$",   XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0
M,R$  #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N
M_P!,)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@
M  LJ   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT
M #LF   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'
M*0  .RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q
M   !-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A
M  !%+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0
M."X  "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z
M/    #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0
M)P  3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$
M "XO   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P
M $D   !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(
M7BP  %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR
M   D,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8
M  !9    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4
M &TT  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >
M.P  %3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M    :P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L
M  " /@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@
M#TL   =1    5P   %P   !B    9@   &L   !O    =    '@   ![
M?@   (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":
M,P  ETD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H
M  !A    :    &X   !T    >0   '\   "$    B0   (T   "1    DP
M )8   "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*
MLCX  +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M    >P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T
M  "P    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(
M ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'
MD    )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
M    RP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_
M  #J6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$
M_P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q
M &H [@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X
M_P"6 /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2
M /< &P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &(
MR@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"(
M /\ @P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$
M%0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A
M *P :0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\
M=@#_ '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M
M !@ K0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$
M80"/ &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_
M &@ _P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !(
MCP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X
M &( =@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P
M_P"^    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4
M '< &@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H
M8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
M    GP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &,
M%0!C !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!<
M %( : !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B
MC0   'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4
M !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0
M80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P
M &\   !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$
M1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X
M &D -P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4
M  !8    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2
M #H %P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &,
M+0!S "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1
M @  2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$
M$P P !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N
M "0 @@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P
M0@@  #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H
M !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T
M?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L
M #4+   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !(
M(  6 !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5
M (\ %0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-
M   L#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04
M !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH
M$ &B  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H
M#P  ) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)
M%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?
M  H'MP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$
M(1   !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0
M#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,
MM  ##-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$
M !L1   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q<
M#! =  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M
M#M0   [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2
M   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:
M  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<
M !'U   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4
M$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6
M'P "%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W
M   3_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% ,
M$A,& ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'
M&R0  !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7
M_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$
M  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$
M "$J   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-
M&0  /QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9
M 0 +&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G
M   G,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0
M/!X  #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   (
M'P  !"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N
M+@  +CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$
M "XA   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0
M "<    I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0
M-C8  #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD
M   D(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\
M   R    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$
M $!    _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C
M)0  'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M    /@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ
M  !*3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P
M&R@  !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&
M2    $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !8
M1@  5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\
M ! R   *-@   SH    _    0@   $8   !)    3    $\   !2    50
M %@   !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0
M9U(  &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]
M   "0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@
M  !K    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D
M 'MA  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+
M40   %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M    @@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9
M  "1<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80
M &@   !N    <P   'D   !^    @P   (@   ",    CP   )(   "5
MF0   )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J
M:0  J(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P
M  "#    B0   (\   "5    FP   *    "C    I@   *D   "M    L0
M +4   "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7
MQ7P  ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
M    GP   *4   "M    LP   +@   "Z    O@   ,(   #&    R@   ,X
M  #3    V@   .    #G    [0   /,   #T#@  \AX  .\V  #L40  Z&X
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M____________________________________________________
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M,0     #!"$   $                    !                     0
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MPG>P?,)WL'S"=[!\PG>P?,)WL'S"_ZDD!?^H, W_LSD4_L!"'O/-2BWIW4]
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M-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V] 8?]T05__>4->_WU$7?^
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MP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;#
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M0!]B_TDC6_]1)E?_6BA5_V(J4O]I*U'_;RQ0_W,M3_]W+D[_>BY._WTO3?^
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M)@?_D2X,_YTV$O^F/AK_K4<E_[-/-/^T6$3ZM&%6\[)J:.RO<WKAIGJ+UIV
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ME(>PL8^.MJN*E;NFAYV^HH6EP)^$K\&6?K#!E'^VN). N[*3@+NRDX"[LI.
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M95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E_ZT0 -;#" #(TPH
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M'P:L_S(2H/\['93_02>*_T<Q@?]..7K_6#]S_V)%;O]L26G_<TQF_WI/8_^
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M4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"_X\3 O^D$P'^N!( ULP+ ,SD$0'
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MCQXT_Y<>,O^@'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?IL
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ML3Q&_[T]1?_,/43_YCY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YSY$_^<^RZP
M +FV 0"LP@$ H- " )7E!P"._Q@#A/\D!GK_+ MP_S00:/\\%6'_1!E;_TL=
M5O]3(%/_6R)0_V,D3?]K)DO_<R=)_WHI2/^"*D;_BBM$_Y0L0O^>+4'_IRY
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M&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W
M>/<  &[_"@%C_Q "6O\5 U+_'01+_R0&1O\L"$'_,PD\_SH*.?] "S7_10PR
M_TH-,/]0#2[_5 XL_UD.*O]>#RC_9 \F_VH/)?]Q$"/_>! B_X 1(/^($1__
MD1$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1$?_Y$1_UPB _]7+07_6#,'_U\V
M"?]C/0W_9482_V90%_]E7AS_9&XB_V%\)_]?BBO_7I8N_URA,?];JC/_6K(U
M_UFZ-O]8PS?_6,TY_U?8.?]6X#K_5>8[_U3L//]3\3S\4O4]^%+Y/?51_3WS
M4?\]\U'_/?-1_SWS4?\]\U'_/?-1_SWS4?\]_UPB _]7+ 7_6C('_V$U"?]E
M/ W_9T42_VA/%_]H7!W_9FTB_V-[*/]AB"S_7Y0O_UZ?,O]=J37_6[$W_UJY
M./]:P3K_6<L[_UC5//]7WSW_5N8^_U7K/OU4\#_Y4_4_]E+Y0/-2_4#P4O\^
M\%+_/O!2_S[P4O\^\%+_/O!2_S[P4O\^_UTA _]8+ 7_7# '_V0S"?]H.@W_
M:T,2_VQ.%_]L6AW_:FHD_V=X*?]DA2[_8I$R_V&<-O]?ICC_7JXZ_UVV//]<
MOC[_6\@__UK20?]9W4+_5^5#_5;J1/E5\$3U5/5%\53Z1>Y4_D3L5/]"[%3_
M0NQ4_T+L5/]"[%3_0NQ4_T+L5/]"_UXA _]9+ 7_7RX&_V8R"?]L. S_;T$1
M_V],%_]Q5Q[_;F<E_VMU*_]H@C#_98XU_V29.?]BHSS_8*L^_U^S0?]>NT+_
M7<1$_US.1O]:W$?^6>1(^E?J2?56\$KP5?9*[57Z2NE6_D?G5O]%YU;_1>=6
M_T7G5O]%YU;_1>=6_T7G5O]%_UXA _]9*P7_8BT&_VHP"/]O-@S_<D 1_W1*
M&/]U51[_<F0F_V]R+?]L?S/_:8LX_V:6//]EH$#_8ZA#_V&P1O]@N$C_7L%*
M_UW+2_]<VDWZ6N-.]5GJ3_!7\5#K5O91YU?[3N18_TOA6?])X5G_2>%9_TGA
M6?])X5G_2>%9_TGA6?])_U\@ _]:*P7_92L&_VTN"/]S-0S_=SX1_WA(%_]Y
M4A__=V G_W1N+O]P>S7_;8<[_VJ20?]GFT7_9:1)_F.L3/UAM$[[8+Q1^E[&
M4_E=U%7U6^-6[UKJ6.E8\EGE6?=6X%K[4]M;_T_76_]-UUO_3==;_TW76_]-
MUUO_3==;_TW76_]-_V @ _]=*07_:"D&_W$K!_]X,PO_?#P0_WU&%_]^4!__
M?5TH_WEJ,/]U=CC_<8(__&V-1?IJETOX9Y]/]F6G4_1BKU;S8+A9\5_!7/!=
MS5[M7.!@Z%KL8>%:\F#:6_9;TUSZ5\]=_5/,7O]1S%[_4<Q>_U',7O]1S%[_
M4<Q>_U',7O]1_V$? _]@)P3_:R8%_W4I!_]\,0K_@3H0_X-$%_^$31__@UDH
M_W]F,OQZ<COX=7Y#]7&(2_)MDE'O:9I6[6:B6^ICJE_H8+)CYEZ\9N1<R&GA
M6]IKW5KJ:]-<\&;-7O5AR%_Y7,1@_%C!8?Y5P6'^5<%A_E7!8?Y5P6'^5<%A
M_E7!8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B
M,_6 ;CWP>GE'['6#4.EPC%CE:Y5>X6:=9-YCI&G;8*UMUU^W;]1>PW#17M)Q
MS5WG<<=?[FO"8?)FOF+V8;IC^5RW8_Q8MV/\6+=C_%BW8_Q8MV/\6+=C_%BW
M8_Q8_V,? _]F(P3_<B($_WTG!O^%+@G_BC<._XU %?^/21[ZCU,H](Q?-.Z&
M:C_I?W1+XWA^5=YRAE[8;8]ETVJ8:L]GH&W,9:APR6.Q<\9BO'3$8<EUP6'@
M=KQCZG&W9.]JM&7S9;!F]F"N9_E<KF?Y7*YG^5RN9_E<KF?Y7*YG^5RN9_E<
M_V,> _]H(03_=2 $_X$E!?^)+0C_CS4,_Y(^%/R41QWUED\H[I%;-.>+9D'@
MA&].V7UY6-%W@F#,<XIGQV^3;,1LFW# ::-SO6>L=KIFMGBX9<)YMF75>;)F
MYG:N:.QOJFGP::AI]&.F:O=?IFKW7Z9J]U^F:O=?IFKW7Z9J]U^F:O=?_V0>
M _]K( /_>!X$_X0D!?^-+ ?_DS0+_Y<\$OB911OPFTTGZ)=9-.&08D+7B6Q.
MSH-U6,A]?F'#>(9HOG2.;;EPEG*V;IYULFRG>*]JL7NM:;U\JFG-?:AJXWJE
M;.ERHFSM;*!M\F:>;O5BGF[U8IYN]6*>;O5BGF[U8IYN]6*>;O5B_V4= O]M
M'@/_>QT#_X<C!/^0*@;_ES(*_9P[$/2?0QGLH4LEXYQ6,]J68$'/CFE.QXAR
M6,"">F&Z?8)HM7F*;K%UDG.L<IIWJ7"C>J9NK'VC;;A^H6W'?Y]NX'Z<<.=U
MFG#K;YEQ\&B7<?-DEW'S9)=Q\V27<?-DEW'S9)=Q\V27<?-D_V4= O]O'0/_
M?AP#_XHB!/^3*07_FS$)^: Y#_"C01CGIDDCWJ%4,=*:7D#(DV=-P(QO6+F'
M=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2 F''"@99RV(&5=.5XDW3J
M<9)U[VN1=?)FD77R9I%U\F:1=?)FD77R9I%U\F:1=?)F_V8= O]Q&P/_@!L#
M_XPA _^6* 7_GB\(]J0W#>RH/Q7CJT@@V*92,,R>7$##EV5-NY%M5[.+=&&M
MAGQHIX*#;J)^BW2=>Y-XF7F<?)5WI7^2=K"!D'6^@HYVT8*.>.-ZC7CH<XQX
M[6R+>/%HBWCQ:(MX\6B+>/%HBWCQ:(MX\6B+>/%H_V<< O]S&@+_@AH"_X\@
M _^9)@3^HBX&\Z@U"^FM/1/?KT8>TJE1+\>B6C^^FV-,M95J5ZZ/<F"GBWEH
MH8>!;IR#B'27@)!XDGV9?(Y\HH"+>JV"B'J[@X=ZS8.'?.)\AWSG=89\[&Z&
M?/!IAGSP:89\\&F&?/!IAGSP:89\\&F&?/!I_V<< O]U&0+_A1D"_Y(? O^<
M)0/[I2P%\*PT">:R.Q#;LT0=S:U/+L.F63ZYGV%+L)EH5JB4<%^ACW=GFXM^
M;I:(AG.0A8YXC(*6?(B H("$?ZN"@7^X@W]_RH2!@>%]@8'F=H& ZV^ @.]J
M@(#O:H" [VJ @.]J@(#O:H" [VJ @.]J_V@< O]X%P+_AQ@"_Y0= O^?(P/X
MJ2H$[+$Q!^*W.0W5MT(<R;!.+;ZJ5SVTHU]*JYYG5:.8;E^<E'5FEI!\;9"-
M@W.+BHMXAHB4?(&&GH!]A*B">X2UA'F$QX1ZAN!_>X7F=WN%ZW![A.YK>X3N
M:WN$[FM[A.YK>X3N:WN$[FM[A.YK_VD; O]Z%@+_BA<"_Y<< O^C(0+TK2<#
MZ+4N!=Z]-0K0ND ;Q+1,++JN5CNOJ%Y)IJ)E5)Z=;%V7F7-FD)5Y;(J2@7*%
MD(EW?XV2?'N+FW]WBJ:"=(FS@W**Q(-TC.!_=(OE>'6)ZG%VB.UL=HCM;':(
M[6QVB.UL=HCM;':([6QVB.UL_VL: O]]% +_C18!_YH: ?^F'@'PL2,"Y+LI
M ]G", G+O3\9P+A**K6R5#JJK%Q'H:=C4IFC:ER1GW%DBIMW:X28?W%^EH9V
M>9./>W22F7YPD*2!;9"Q@FN0P8)MDMU_;I'E>&^/ZG%PCNUL<([M;'".[6QP
MCNUL<([M;'".[6QPCNUL_VX8 O^ $@'_D!4!_YX7 ?NK&@'LMQX!X,,A =+&
M+0C&P3T8NKQ)**^W4CBELEI%G*UA49.I:%J+I6]BA*)U:7Z??&]XG81T<YN-
M>6Z9EGQJF*)_9Y>N@&68OX%EF=A_:)CE>&F6ZG%JE.UL:I3M;&J4[6QJE.UL
M:I3M;&J4[6QJE.UL_W$6 O^#$0'_E!,!_Z(4 /6P% #FOA0 V<P5 ,S**P?
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M-#__XS0__^\U/__O-3__[S4__^\U/__O-3__[S4__^\UQ*H  +.S  "GOP
MFLL  (_: @"&_P\!?O\< W7_)09L_RT*9/\V#EW_/A)8_T454O]-&$__51I,
M_UP<2?]D'D?_:Q]$_W,@0O]\(D'_A2,__X\D/?^:)3O_I"8Z_Z\F.?^Z)SC_
MRB<X_]PH./_<*#C_W"@X_]PH./_<*#C_W"@X_]PHM:\  *>Z  ":Q@  C=0
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M4TG.^%!*R_].2LK_34K*_TU*RO]-2LK_34K*_TU*RO]-YX\  -&?  ##JP$
MM[0" *V_ P"CRP8 F]D* )3E&@&-Y2L&A.0U#7OC/Q9SXD@>;.%2)F;A6BQ@
MX&(R6^!J-E?@<CI3WWL]4-^%0$W?CT-*X)M%2."H1D;@N$=%X<Q'1>#H1T7?
M]D9%WO]$1=[_1$7>_T1%WO]$1=[_1$7>_T1%WO]$V9<  ,>F  "XL   K+D!
M *+% @"8T08 C^L- (GN'P* [BL&>.TT#'#M/1-H[4898NU.'EWM5R-9[6 G
M5>UH*E+M<2U/[7DO3.V#,DKNC31'[I@U1>ZE-T/OLSA"\,0X0?#?.4'O[SA
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M(#+_YR R_^<@,O_G(#+_YR R_^<@L*T  **W  "5Q   A]   'O=  !R_0D
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MP9]&&[>:42FOE5HTIY!B/J&+:D:;AW%,E81X4I"!?U>,?X=<B'V08(1[F6.
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M75BD]EA:H_]46Z'_4%NA_U!;H?]06Z'_4%NA_U!;H?]0_W<' /")  #6F
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M.4/8_SE#V/\Y0]C_.4/8_SE#V/\YT)8  ,&C  "RK   I[4  )S   "1R@,
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M_YP&_S\J O\_, /_1# #_T@S!/]).0;_2$((_T9-"_]%6P[_0VD1_T%W$_]
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M66B(]E)KBO]-;(K_2&R)_T=LB?]';(G_1VR)_T=LB?]'_VD+ /]X! #EAP
MUI(# ,V<!0#&I 8 P:L& +FM%P"PK"L$IZDZ#I^F11F6HD\CCY]7+8B<7S6"
MF68[?9=L07B5<T9SDWM+;I&#3VJ/C5)FCI=58XVC6&"-L5E?C<-:7HW@6&*/
M]5)DD/]-9I#_2&:/_T=FC_]'9H__1V:/_T=FC_]'_VP( /Y\  #>B@  T)8"
M ,B?! # IP0 N:X# +*R% "JL2@#H:\W#)FL0Q>1J$TAB:55*H*C7#)\H&,Y
M=YYJ/G*<<41MFGE(:)F!3&27BU!@EI5379:B55J5L%=9E<%76)7>5EN6\U!=
ME_],7Y?_1V"6_T9@EO]&8);_1F"6_T9@EO]&_W # .N!  #6CP  RIH! ,&C
M P"YJ@( L;(! *JW$0"CMR0"F[4T"I.R0!2*KTH>@ZU3)WRK6BYVJ&$U<*=H
M.VNE;T!GHW=$8J)_2%ZAB4Q:H)1/5Y^@452?KE-3G\!34I_=4E6?\TY7H/]*
M6:#_1EF?_T59G_]%69__15F?_T59G_]%_W4  ."&  #/DP  Q)\! +JG 0"Q
MK@  J;8  *&]#0";O2 !E+PQ!XNZ/1"#MT@:?+50(G6S6"IOLE\P:K!F-F6O
M;3M@K74_7*Q^0UBKAT=5JI-*4:J?3$^JKDU-JL!-3:K<34ZJ\DE0JOY&4JG_
M0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,  #(F0  O:,  +*K  "IL@
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M)#GB_R0YXO\DOYX  *^F  "CK@  E[@  (K"  !^S   <]8" &GE"0!D[Q0
M7_ @ 5GP*P-4\#4%3_ ^!TOQ1@I'\4X,1/%7#D+Q7Q _\F<2/?)P%#KR>Q4X
M\X<6-O.4&#7THADS]+$9,O7%&C'UXAHQ]/$9,?'^&3'Q_QDQ\?\9,?'_&3'Q
M_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0  9=X  %[U"@!9_!, 4_P>
M 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV_UX+,_]G##'_< TN_WP.
M+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_]A$F__81)O_V$2;_]A$F
M__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<  %+_"0!-_Q$ 1_\9 4/_
M(@$^_RH".O\R S?_.0,S_S\$,/]&!2W_304K_U0&*/];!R;_8P<C_VT((?]Y
M"1__APD>_Y4*'?^C"AS_L0H;_\ +&O_6"QK_WPL:_]\+&O_?"QK_WPL:_]\+
MF[$  (V\  !^QP  <-(  &/>  !5Y   2_4  $;_!0! _PX ._\4 #?_&P$S
M_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#'?]. QK_5008_UX$%?]H!1/_
M= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8._[H&#O^Z!@[_N@8._[H&CKH
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M3W9U]D=X=_]">GC_/GMY_SI[>?\Z>WG_.GMY_SI[>?\Z_U\, /]L! #U>0(
MWH," -.+!0#-D@< R9<( ,"9&0"WF"P#KY4[#*>11Q:?C5 ?F8E9)Y.&82Z.
M@V@TB8%O.85_=CV!?7Y!?7N&17EZCTEV>)E,<W>E3G!WLE!N=\10;7?@3W!Y
M]4AR>_]#='S_/G5]_SMU??\[=7W_.W5]_SMU??\[_V$* /]O @#H?   V88!
M ,^.! #(E08 PYH& +N<%@"SG"H#JIDY"Z*5112;D4X=E(Y7)HZ+7RV)B&8S
MA(9M.("$=#U[@GM!=X"$171_C4AP?9=+;7RC3FI\L$]H?,%09WS=4&I^\TEM
M@/]#;H'_/V^!_SQO@?\\;X'_/&^!_SQO@?\\_V0( /]R  #A?P  TXD! ,J2
M P##F 0 O9X$ +:@$P"NH"<"I9TV"9V:0Q.6ETT<CY-5)(F172N$CF0Q?XQK
M-WJ*<CMVB'E <H:"1&Z%BT=J@Y5*9X*A362"KD]B@K]/88+:3V2$\DEFA?]#
M:(;_/VJ&_SQJAO\\:H;_/&J&_SQJAO\\_V<$ /9V  #<@@  SHT  ,65 @"^
MG , MZ$" *^D$0"HI"0"H*(T")B?0!&1G$H:BIE3(H276RE^E6(P>9)I-760
M<#IPCW<^;(U_0FB,B49EBI-)88F?2UZ)K$U=B;U.7(G635Z*\$A@B_Y#8HO_
M/V.,_SQCC/\\8XS_/&.,_SQCC/\\_VH  .9Z  #5A@  R9$  ,"9 0"XGP$
ML*4  *BI#@"BJ2$!FJ@Q!I.E/@^+HT@8A*!1('Z>62=XG& M<YIG,F^8;C=J
MEG4\9I5]/V*4AT-?DI%&6Y*=25F1JTI7D;M+5I'32U>2[T=:DOU"7)/_/EV3
M_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP  Q)4  +J=  "QHP  J:D
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M,TBO_S-(K_\SVX(  ,>0  "[G   KJ,  *2J  "9L0  C[D  (3  P![Q@T
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MG1 N[ZT1+?# $2WPWA$L[O$1+.S^$2SK_Q LZ_\0+.O_$"SK_Q LZ_\0K:(
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M PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_P@,(_\(#BK@  'O#  !LS@
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M085D]SN&9O\UAV?_,8=H_RZ':?\MAVG_+8=I_RV':?\M_U<, /]A! #^; ,
MY'4! -M[!0#3@ @ T(,* ,>%&@"^A"T#MH$\":]]2!*H>5(9HG9;()US8R:9
M<&LKE6YR+Y%M>3..:X$VBVF).HAHDCR%9YP_@F:G08!FM$-^9L5$?&;A0WYH
M]3Q_:O\W@&O_,X%L_R^!;/\O@6S_+X%L_R^!;/\O_UD+ /]C 0#T;P  WW@
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M-G%X_S)Q>/\Q<7C_,7%X_S%Q>/\Q_U\" /=L  #>=P  T($  ,>( 0# C0,
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M,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "JG0  H:$  )>F! "1IQ4
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MHB8^NK,F/;K()CVZZ"8]N/DE/;?_)#VV_R,]MO\C/;;_(SVV_R,]MO\CQX@
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M"B?KU@HGZ? *)^?]"2;F_PHFYO\*)N;_"B;F_PHFYO\*J*   )RG  "/L
M@KD  '3"  !HR@  6]$  $_7  !%W0  /NX) #SR$0 Y\QL -O,E #3T+@ Q
M]#<!+O4_ 2SU1P$I]D\")_97 B7W80,C]VP#(?AZ!!_XB00>^9H%'/FK!1OZ
MP 4:^MX%&OGR!1KW_049]O\%&?;_!1GV_P49]O\%GJ8  )&O  "#N0  =<(
M &?+  !:TP  3=H  $+?   XY0  -?L' #'_#P N_Q8 *_\? "G_)@ E_RT
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M+YI3^BJ:5?\FF5;_(YE6_R&95_\?F5?_'YE7_Q^95_\?_TT- /]5!@#_704
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M*WQG_RA\9_\F?&?_)GQG_R9\9_\F_U4# /]@  #C:@  U7(  ,QX 0#%>P,
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M*6=W_REG=_\I_U\  .-L  #0=@  Q7\  +R%  "TB@  K(P  *.."@"=CAH
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MH#!,DJ\Q2Y+",4J1X#%,D?4M39'_*DZ0_RA.D/\F3I#_)DZ0_R9.D/\FWG
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M0@53N$L(4+=3"TVW6PY*MF,01[9K$T2U=19"M8$8/[6.&CVUG!P[M:P<.K7
M'3FUWQPYL_0<.;+_'#FQ_QLYL/\;.;#_&SFP_QLYL/\;P88  +23  "GF@
MG*   )&G  "%K0  >;,  &VX  !BO0$ 5L(' %/#% !2PR, 4,0P 4W$.P)*
MQ$4#1\1.!47$5P="PU\)0,-H"SW#<@T[PWX/.,.,$3;#FQ(UPZL3,\/ $S/#
MX!,SP?43,L#_%#*__Q0QOO\4,;[_%#&^_Q0QOO\4N)   *N9  "?H   DZ<
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M A+R_ (2\/\"$O#_ A+P_P(2\/\"FJ0  (VM  !_M@  <;\  &/'  !6S@
M2=,  #W:   SWP  *N,  ";T!0 D^PT (?P3 ![]&P <_2( &?XI !?^,0 5
M_SD $_]! !'_2@ 0_U4 #O]A  S_;P$,_X !"O^3 0G_I@$(_[H!!__4 0?_
MZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP  8\D  %;1  !(V   .]T
M ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1_QD #_\>  W_)  +_RL
M"?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_D   _Z,  /^T  #_Q@
M_]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,  $?;   ZX   +N4  "/I
M   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q  !/\3  '_&   _QX  /\D
M  #_*P  _S,  /\]  #_20  _U8  /]F  #_>   _XH  /^;  #_J   _[$
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M%[<__Q:U0/\4M$#_$[-!_Q&S0?\0LT'_$+-!_Q"S0?\0_T 0 /]&# #_2PH
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M'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L7   WV(  -1F 0#.: 4
MRV<( ,)G%@"Z:"@!LV<X ZUE10>H8U ,HV%9$9]?816;76@8F%QP&Y5:=QZ3
M67\AD%B'(XY7CR6,5YDGB5:C*8=6KRJ%5;\KA%;5+(-7[RF#6/XD@UG_((1:
M_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P  V&8  ,YJ  #'; , PVL%
M +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A648F48D6!L&XY?=!Z,7GLA
MB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;["M\7/PF?%W_(GU>_Q]]
M7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH  ,EN  #"< $ O7 # +9P
M$ "N<2( J' R J%N/P:<;$H+EVI3$))H6Q2.9F(8BV5I&XAC<!Z%8G@A@F&
M)(!@B29]7Y(I>UZ=*WA>J2UV7K@N=5[,+W1>Z2UU8/HG=F'_(W=B_R!W8O\>
M=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT  ,1R  "]=   MW0! +!T#@"I
M=1\ HG0O IQR/067<$<*D6Y1#XUL612):F 7A6EG&X)H;AY_9G4A?65])'ID
MAB=W8Y I=6.;+')BIRYP8K8O;V+)+VYBYBYO9/DH<&7_)'%F_R%Q9O\?<6;_
M'W%F_Q]Q9O\?_U0  .A?  #7:0  RG   ,!U  "Y>   LG@  *MX#0"D>1T
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M;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8   *" !P"9@1< E($H 8Z
M-0.(?D$(@WQ*#7YZ4A%Z>%D5=G=@&7-V9QQP=&X?;7-V(VIR?R9G<8DI9'&5
M*V)PH2U@<+ O7G#"+UUPWR]?<?4J8''_)F%R_R-B<O\@8G+_(&)R_R!B<O\@
M[UP  -QI  #*<@  OGH  +6   "MA   I(4  )J% P"4A10 CH8E 8F$,P.#
M@SX'?H%("WE_4!!U?E<4<7U>&&Y[91MK>FP>:'ET(F5X?25B=X<H7W:3*EQV
MGRQ:=:XN677 +EAUW2Y9=O,J6W;_)EQW_R-<=_\@7'?_(%QW_R!<=_\@ZF
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M)T>-U"='C/ D2(S_(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0
MK(T  **2  "7E@  C)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==
MG4T*6IQ4#5>;7!%4FF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7
MTR)!EN\@0I7^'D*5_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(
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M-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4  *^0  "CEP  F)T  (RC  "
MJ   =*T  &BR  !<M@  4+H! $F\#0!(O!D 1KTG $6],P!#O3T!0;U' 3^]
M4 (]O5@#.KUA!3B]:P8VO7<(-+V$"3*]DPHPO:0++[VW#"Z^T LNO.X,+;K^
M#2RY_PTLN/\.++C_#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL
M:K4  %ZZ  !2O@  1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P Q
MRU$!,,M; 2[,90(LS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(
M_P<CQ_\'(\?_!R/'_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X
M %+"  !'Q@  /<H  #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4
M(MQ0 "'=6P @W6@ 'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7
MVO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*
M   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M#
M !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\
M#.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   O
MV   )=T  !WA   8[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[
M/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]
M  #\_0  _/T BZL  'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0
M&>4  !/J   0^@  #O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,
M_SH  /]%  #_4P  _V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_
MY0  _^4 ?[0  '"]  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T
M  SZ   )_P  !O\   +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD
M /\T  #_0   _TX  /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0
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M!-XC_P3;)/\$V23_!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$
M_S<3 /\Y&P#_."4 _S8Q ?\S/0'],4H!^"Y6 O0M8@/P+&T#[2MW ^HK@ 3H
M*H@$YBJ0!.4JEP3C*IX%X2JE!> JK07>*K8%W"K"!=HJT@;5*^<&T"OU!\TL
M_P?++/\'R2S_!\@L_P?'+/\&QRS_!L<L_P;'+/\&_S42 /\Y#@#_.@T _SX0
M /] %@#_/R  _STJ /D[-P'R.$0![#91 N<U7 /C-&<#X#-R!-TS>P7:,H,&
MUC*+!M0RDP?2,9H(T#&A",XQJ0G,,;()RS&\"LDQR@K&,N$+PC+Q"[\S_@N]
M,_\*NS/_"KHS_PFZ,_\)NC/_";HS_PFZ,_\)_SD0 /\]"P#_0 D _T0- /]&
M$0#_11D ]T0C .Y!+P#F/SP!X#Y* =H]5P+3/&($SSML!LPZ=0?).GT)QSF%
M"L4YC O#.)0,P3B;#< XHPV^.*P.O#BV#[HXPP^Y.-<0M3CL$+(Y^P^P.O\.
MKSK_#:XZ_PRM.O\+K3K_"ZTZ_PNM.O\+_SP- /] !@#_100 _TD) /]+#0#Y
M2A$ [4D: .-&)@#:1C8 T49% <M%40/&1%P%PD)F"+]";PJ\07<+ND!_#;@_
MA@ZV/XX0M#Z5$;(^G1*P/J83KSZP%*T^O12K/LT5J3[F%:8_]Q.D0/\2HT#_
M$*) _P^B0/\.HD'_#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL
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M%7Y5_Q5^5?\5_TH  .Y2  #>6P  SV$  ,9D  "_90  NF," +-B#P"L8R
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MH"1F8JXE96*_)F1BVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,
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M)51QT"54<>XB5G'^'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P
MM'H  *M_  "B@@  F(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ
M?E +9WU7#F1\7A%A>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]W
MSB-/=^PA4'?]'E%W_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\
M *>$  "=AP  DH<  (2'  !]APD >(@6 '2()@!PB#(";(<]!&B&1@9EA4X)
M8855#%Z$7 ];@V,268)K%5:!=!=3@'X:4(")'$Y_EAY,?Z4@2G^V(4E_S"%)
M?NL?2G[\'$M^_QI+?O\93'[_&$Q^_QA,?O\8U6<  ,-S  "V?   K(0  **)
M  "8BP  C8T  'R-  !UC@0 ;X\2 &V0(0!ID"X!98\Y F*.0@1>CDL'6XU2
M"EB,60Q6BV$/4XMH$E"*<11-B7L72HF'&4B(E1M&B*,=1(BT'4.(RAU#A^H<
M1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T  +UX  "Q@@  IXH  )R.  "2
MD   AI,  'F5  !LEP  9I<. &.8&P!AF"D 7I@U 5J7/@-7ET<%599/!U*6
M5@E/E5X,3)1F#DJ4;Q!'DWD31).%%4*2DQ= DJ(8/I*S&3V2R1D]D>D8/9#Z
M%SZ/_Q8^C_\5/H__%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@
M?YD  '.<  !DGP  7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(
MH%H'19]C"4.?; M GG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::
M_Q(VF?\1-YG_$3>9_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z
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M!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P
M.,,  "_'   FRP0 'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5
MU5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1
M_P$0T?\!G)H  )&A  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P
M "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\
M">==  CG;0 &YH  !>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P
MYO\ DZ$  (6I  !WL0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;
M   2WP  #>,   OQ"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),
M  #R7   \FT  /*"  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L
MAZD  'FR  !JN@  7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *
MZ   !?,   /] 0  _ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^
M20  _EH  /YM  #_@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(
M &R[  !=Q   3\T  $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]
M /\   #_    _P   /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P
M_T8  /]8  #_:P  _X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<
M) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"*
M /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P
M_P#X /\ _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_
M'B$ _QDC /\3*0#_#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#
MCP#_ I8 _P*< /\"H@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V
M /@ _P#W O\ ]P/_ /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P
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M \,D_P/")/\#P23_ \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H
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M"Y)!_PN20?\+_ST  /]#  #I20  WDX  --/  #-3@, RDD( ,))% "[2B8
MM4LV *]+0P*K2DX#ITE7!:1(8 >A1V<)GD9O"IQ&=@R:17T.F$6%#Y9$CA"4
M1)<2DD.A$Y!#K!2/0[H5C4/-%8M$Z!6*1?H2B4;_$(E&_PZ(1O\-B$;_#8A&
M_PV(1O\-_T   /)'  #C3P  U%,  ,M5  #$5   P% $ +E/$0"R4"( K%$R
M *=1/P*B4$H#GD]3!9M.7 B836,*E4QJ#)-+<0V12GD/CDJ $8Q)B1**29(4
MB$B<%89(J!:%2+47@TC'&(%(Y!B!2O<5@$K_$H!+_Q" 2_\/@$O_#H!+_PZ
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MH1ET4:\;<U' &W%1VQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@
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M'5]>SAU?7NP;8%_]&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9
MN6H  +!N  "G<   GFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S
M:%((<&=9"FUF8 UK96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IB
MS!U:8NH<6V/\&%QC_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX
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M%TQR_Q5,<O\337+_$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0
MC($  'I^  !S?P( ;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7
M?5X+5'QF#5%\;@]/>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y
M_Q1&>/\21WC_$4=X_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8
M '>&  !KA@  9H<- &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(
M3H5C"DN$; Q)A'8/1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q)
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M"S&3_PLQD_\+N'H  *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H
M3J(  $6D"0!"I!, 0*0? #^D*@ ^I30 /*4^ #NE1P$YI4\!-Z58 C6E80(S
MI6P#,:5Y!"^DAP4MI)<&+*2I!BNDO08JI-X&*J+U!RFA_P<IH/\(*9__""F?
M_P@IG_\(L8(  *6+  ":D0  D)8  (.:  !VGP  :J(  %ZF  !2J0  1JL
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M<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@
M (V>  !_I0  <:P  &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0
M$=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@
MWG,  -Z(  #?G0  W[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F
M  !SK@  9;4  %B]  !*P@  /<4  #')   FS   '=   !34   .V0  "=T
M  /A    XP<  .,-  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(
M .UV  #NC   [J$  .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !G
MMP  6;\  $O&   \R@  +\X  "32   :V   $MP   S@   %XP   .<   #K
M    ZP   .T%  #N"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC
M  #\=P  _8T  /VC  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0
M3,H  #S/   NU   (MH  !?>   0X@  ">8   #I    [    /    #V
M]@   /<   #X    ^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_
M8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD
M /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8
M_P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#]
M /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*
M)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8
M /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\
M] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_
M#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X
MFP#\ *$ ^@"G /@ K@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_
M .H!_P#I ?\ Z0'_ .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@
M_Q T /\-00#_#$X _PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S
M!IT \0:C .\&J@#M!K( _^+__TE#0U]04D]&24Q%  @)Z@:[ .@&R #F!MP
MY ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,_P#<#/\ _R,2 /\C$ #_
M(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5 /@/8 #T#VH \0]T .\.
M? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\ X ZX -X.Q0#<#MH UA#L
M -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2_P'*$O\!_R</ /\G# #_)0D
M_R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/ .H76@#F%F4 XQ9N . 6=P#>
M%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL SABU ,P8P0#+&-( QQKH <,;
M^ ' &_\!OAS_ ;T<_P*\'/\"O!O_ KP;_P*\&_\"_RL, /\K!0#_*P, _RT)
M /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5(%\ T2!H ,X@<0#,(7D
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M!Y<T_P:6-/\&EC3_!98T_P66-/\%_S4  /\X  #J/@  WT(  -5"  #//P,
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M"W)*_PIR2O\*\D(  .!,  #.4P  P5@  +A:  "P60  J58  *)2!P";4A4
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ME!->6:(47%FR%5M9QA9:6>456UKY$EM:_Q!<6O\.7%K_#5Q:_PU<6O\-XT\
M ,U9  "^80  LV8  *EI  "@:@  EV@  (MB  "#8@P ?F,8 'IC)@!V8S(
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M%$MHP!1+:-X42V?U$DQG_P],9_\.36?_#4UG_PU-9_\-TEH  ,!D  "S;
MJ7(  *!V  "6=P  BG8  'EQ  !Q<0  :W$/ &AQ' !F<B@ 8W(T &!R/0%>
M<D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z #DMNC1!);IL11VVK$D9N
MOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-S%\  +QI  "P<0  I7<
M )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?>"0 77DP %IY.@%8>4("
M5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5UB@Y#=9D/0G6I$$!UO!!
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M"3.%_PDSA/\),X/_"3.#_PDS@_\)N7   *UZ  "B@@  EX<  (V*  "!C
M=8X  &B/  !:D   3Y$  $>2"@!$DA, 0Y,? $&3*@! DS0 /Y,] #V310 [
MDTT!.I-6 3B37P(VDVD#-)-U S*2@P0PDI,%+I*D!BV2MP8LDM$&+)'O!BN/
M_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B   D8P  (>0  !ZDP  ;94
M &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ TGBP ,YXU #*>/@ QGD<
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M  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>JP  4J\  $:R   ZM0
M+[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%'@ (Q2@ !\4R  ;&/0 %
MQDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2  #%[P  Q?P  ,7_  #%
M_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M   1K@  #J[   NO@  ),$
M !O$   3QP  #LH   C. 0 !T H  - 0  #0%@  T1X  -(G  #3,0  U#P
M -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6X   UO,  -;^  #6_P
MUO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$  "W$   BQP  &<L  !'.
M   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0  .$<  #B)   Y"X  .8Z
M  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0  Z>(  .GR  #I]0  Z?4
M@*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.   6T@  #]8   C;
MWP   .,   #E    YP   .@!  #J!P  ZPT  .T1  #O&   \2$  /,K  #V
M.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(  /K:  #ZWP  ^M\ =*X
M &6V  !6O@  2,8  #G+   KT   ']0  !3:   -WP  !>,   #F    Z0
M .T   #O    \0   /,   #U    ]@(  /@)  #Z#@  _1,  /\<  #_*
M_S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y  #_O   _[P _Q$@ /\0
M'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"#
M /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_ +@ _P#" /\ S@#_ .(
M_@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\ _Q0< /\2&@#_
M#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\
MAP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0 ^0"] /@ R0#W -P ]0#L
M /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P /\ _Q<8 /\5%@#_$14
M_PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /P @@#Z
M (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X .X PP#L -, Z@#G .D
M]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\ _QH3 /\8$0#_%!  _P\1
M /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z &P ]0!U /( ?0#P (0
M[@"+ .P D0#K )< Z0"> .< I #F *P Y "T .( OP#@ ,T W@#C -P \@#:
M /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0 /\<#0#_%PL _Q4. /\4
M%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8 Z@1O .8#=P#D!'\ X@2&
M . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0!LD S@?@ ,P(\0#)"O\
MQPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@!@#_' , _QT* /\;$ #_
M&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI -D-<0#5#7D TPV! -$-
MB #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@ PA#? +X1\@"[$O\ N1/_
M +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_(P  _R0# /\A"@#]'1$
M\1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6:P#%%G, PQ=[ ,$7@@#
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M!(4T_P2%-/\$_#,  .LZ  #<00  S40  ,-$  "]00  N#L! +(W#@"K.!P
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ME@MJ2*,,:$BR#6=(Q0UF2>0-9DGX"V9)_PEF2O\(9DG_!V9)_P=F2?\'Z$,
M -)-  #"4P  MU@  *U9  "D6   G%4  )-.  ",3@X AT\; ()/*0!_4#4
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M#E95O@]55=L/557S#555_PM65?\)5E7_"595_PA65?\(VTT  ,57  "X7@
MK6(  *-E  ":90  D&,  (-<  ![6P8 =5L2 '%;'P!N7"L :UPV &A;/P%E
M6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF "E59C M469H-4EFJ#E%9
MO Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(U%$  ,):  "T80  JF8
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M"T%H_PI!9_\)06?_"$)G_PA"9_\(Q5T  +9F  "J;0  H',  )9V  "+=P
M@'8  '!R  !E<0  7' ' %AP$0!6<!T 5'$H %)Q,P!0<3P 3W)$ 4UQ2P%+
M<5,"27%: T=Q8@1%<&P%0W!W!D%PA <_<),(/6^C"3MPM0H[<,T*.F_L"3MN
M_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P  G7D  ))[  "'?   >WP
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M R6'_P,EA_\#K78  *.   "7A0  C8D  (*,  !VC@  :9   %R2  !0DP
M1)0  #J5   QE@@ +9<1 "R7&@ KER0 *I<M "F7-@ HF#\ )YA( ":84@ E
MF%P (YAH "*8=P @F(< 'YB9 1V8K $<F,,!')?E 1R5^@$;E/\!&Y/_ AN3
M_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0  89@  %6;  !)G0  /9X
M #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;I#8 &J0_ !FD2@ 8I%4
M%J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B^  1H?\ $:#_ 1&@_P$1
MH/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$  $RD  ! I@  -:<  "JI
M   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L #;$U  VQ0  ,L4L "[%8
M  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %K_X !J[_  :N_P &KO\
MF(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M   UKP  *[$  "&T   8
MM@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK  "^-@  OD$  +].  "_
M7   OVT  +^   "^E0  OJH  +["  "]Y   O?8  +W_  "]_P  O?\ DI0
M (6:  !XH   :J8  %RK  !/L   0K,  #6V   JN   (+L  !>^   0P0
M"\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+*P  S34  ,Y!  #.4
MSV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X  #._@  SOX B)L  'JB
M  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@  %<8   [)   (S    -
M  #3    U0   -8&  #8#   V1$  -L6  #<'P  WB@  . T  #B00  XE$
M .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E\P  Y?, ?*,  &ZJ  !@
ML@  4;D  $.^   UP@  *,8  !S)   3S0  #-$   35    V@   -X   #A
M    X@   .0   #E P  YPD  .D.  #K$@  [1H  .\D  #R,0  ]$$  /13
M  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP  ]]\ <*P  &&T  !3NP
M1<,  #;'   GS   &]   !'5   *VP   -\   #B    Y0   .D   #L
M[0   /    #Q    \P   /4$  #W"@  ^A   /P6  #_(0  _RX  /]   #_
M4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\ _PT< /\*&P#_ AL _P >
M /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_ '< _P!_ /\ AP#_ (X
M_P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\ R0#^ -T _0#M /P ^@#[
M /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9 /\-%P#_!A8 _P 8 /\
M'@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '( _P![ /\ @@#_ (D _P"0
M /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T -( \P#G /( ]@#P /\
M[P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/$@#_"Q( _P 2 /\ &@#_
M "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V /D ?0#W (0 ]0"+ /0
MD0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L YP#A .4 \0#C /T XP#_
M .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_#0T _P</ /\"%0#_ "
M_P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T > #K '\ Z0"% .@ C #F
M )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9 -0 [ #2 /D T0#_ ,\
M_P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4 _PX+ /\,$0#_!QH _P$F
M /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#> 'D VP"  -D A@#6 (T
MTP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4 Z ## /8 P0#_ , "_P"_
M _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,% /\1#0#_#A0 ^0H? / &
M+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7, R@5Z ,@%@0#&!8< Q0:.
M ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U"_< LPW_ +$-_P"P#?\
ML [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46!0#V$0T ZPX5 .(+(@#8
M"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT +L/>P"Y#X( MQ"* +80
MD0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/< I17_ *,5_P"B%?\ HA7_
M *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<&04 VQ , - 1&0#($RD
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MF@-],Z<#?#.U!'HSR01Y-.8$=S7Y!'8U_P-U-?\#=37_ W4U_P-U-?\#\#,
M -T]  #*0P  OD4  +5&  "M0P  ICT  * V!@"9-A, E#@A ) Y+@",.3D
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M!V%#O0A@1-D(8$3S!V!$_P9?1/\%7T3_!&!$_P1@1/\$X$$  ,I*  "[4
ML%,  *=5  ">4P  E4\  (M)  "#1PL ?4<5 'E'(@!V2"X <T@X '%(00!N
M2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84> !6!'C09>1YH'7$>I"%M(
MNPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$VT0  ,9-  "X4P  K5<
M *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P3"L ;4PU &M,/@!H3$8
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M"$M4_@=+5/\&2U3_!4M4_P5+5/\%S$X  +M7  "N7@  I&(  )ID  "19
MAF(  '=;  !M6   9E@, &)8%@!?6"( 75DL %M9-@!963X 5UE& %9930%4
M650!4EE; E%98P-/66P#35EW!$M8A 5)6)('2%BB!T=9LPA&6<H(15GJ"$99
M_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80  H68  )AH  ".:0  @V<
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M!#5H_P0U:/\$N6   *QI  "A<   F'4  (UW  ""=P  =W<  &ET  !<<P
M47$  $AP"@!%<!( 0W$= $)Q)P! <C  /W(X #YR0  ]<D@ .W)0 #IR60$X
M<F,!-G)M C1R>@(S<HD#,7*: R]RK ,N<L$#+G+C RYQ^ ,N</\#+F__ RYO
M_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0  <GT  &1\  !7>P  3'H
M $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T>T0 ,WM, #)[50 P>U\
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M;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\ %(W_ !2,_P$4C/\!HWT
M )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%EP  .9@  "Z9   EF@
M'9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>00 0GDP #YY8  Z>9P -
MGG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_  N9_P +F?\ G(0  )&*
M  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H   ,*$  ":C   =I0  %:<
M !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "JD0  :I0  "J7@  JFX
M *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G_P  I_\ E8L  (R0  !_
ME0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL  !VM   4L   #K(   FU
M 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D  +A&  "X5   N&0  +AV
M  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P  MO\ CY(  (*7  !TG0
M9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X   -NP  !KX   #!
MP@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z  #)1P  R5<  ,EI  #)
M?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T A9D  '>?  !HI@  6JL
M $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #QP   ,H   #-    S@
M ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=.0  WDD  -Y:  #?;@
MWX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$  &NH  !<KP  3K4  $"[
M   QO@  ),$  !G%   0R   "<P   #/    TP   -D   #<    W0   -\
M  #A    X@4  .0+  #F$   Z!8  .H@  #M*P  \#H  /%+  #Q7@  \G,
M /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ  !0N0  0;\  #+$   D
MR   %\P   [0   &U0   -H   #>    X@   .8   #I    Z@   .P   #N
M    \    /(   #T!@  ]@P  /D2  #\'   _RD  /\Z  #_30  _V(  /]X
M  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_ !< _P : /\ (0#_ "L
M_P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\ @P#_ (H _P"0 /\ E@#_
M )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J /L ^ #Z /\ ^0#_ /@
M_P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !, _P 4 /\ &@#_ "< _P T
M /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_ (4 _@"+ /T D0#[ )<
M^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\ \P#N /\ [0#_ .P _P#K
M /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0 /\ %@#_ "( _P O /\
M/0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\ \P"& /$ C #O )( [@"8
M .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#? /L W@#_ -T _P#= /\
MW0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\ $@#_ !T _P I /L -P#X
M $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"  ., A@#A (P WP"3 -T
MF0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8 R@#_ ,H _P#) /\ R #_
M ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_ !8 ]P B .\ , #K #T
MZ !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -  @ #. (< S "- ,H E #(
M )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^ +D _P"X /\ N #_ +@
M_P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1  Z  : ., * #= #8 V !"
M -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_ ($ O0"( +L CP"Y )<
MMP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%_P"J!O\ J0;_ *D&_P"I
M!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2 -0#( #-!"T R 0Z ,,%
M1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L KPB" *X)B@"L"9( J@F;
M *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<#_\ FP__ )L/_P";#_\
M_QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+%@# #24 N@XR +8./P"R
M#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%] *$1A0"?$HX G1*7 )P2
MH@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\ CA?_ (X7_P".%_\ ^AT
M .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R%1X K18L *@7. "D&$,
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M G0MP )R+MT"<2[T G O_P)O+_\";R__ 6XO_P%N+_\!Z#$  -,Z  ##/P
MMT$  *Y!  "F/@  GC@  )<Q 0"1+A  C"\< (@P* "$,3, @3(] '\R1@!]
M,DT >S)4 'DR6P!W,F$ =3)I 70R< %R,GD!<#.$ 6\SD )M,YT";#.K FHT
MO )I--4#:#7Q F<U_P)G-?\"9C7_ F8U_P)F-/\"XC8  ,P_  "]1   LD<
M *A'  "@1   F#\  ) Y  "(- T @S47 '\V) !\-R\ >3<Y '<X0@!T.$D
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M!%-#_0-30_\#5$/_ U1#_P)40_\"T$(  +]*  "R4   IU,  )U4  "44P
MBE   ']*  !U10( ;D,. &M$&0!G120 944N &)%-P!A13\ 7T5& %U%30!;
M150 6D9; 5E&8P%71FP"5D9W E1&@P-31I$#44:A!%!'L01/1\<$3D?G!$Y'
M^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5   I%<  )I8  "15P  AE0
M 'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;23P 64E# %=)2@!625(
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M T!3_P- 4O\#P%   +)8  "F7@  G&(  ))E  "(90  ?6(  &Y<  !C60
M658# %16#@!15A@ 3U8B $U7+ !,5S0 2E<\ $E81 !(6$L 1UA3 $586P%$
M6&0!0EAN 4!8>P(_6(D"/5B9 SQ8J@,[6;\#.EG@ SI8]P,Z6/\#.U?_ SM7
M_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0  >6<  &MB  !@8   55T
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M<P L;((!*FR3 2ELI0$H;+D!)VW6 2=K\@$G:O\!)VK_ 2AI_P(H:?\"KF0
M *-L  "9<P  CG8  (1X  !Y>0  ;7@  &!W  !3=@  2'4  #YS   T<@H
M,7,1 #!S&@ O<R, +G,K "UT-  L=#P *W1$ "ET30 H=5< )W5C "5U;P D
M=7\ (G60 "%UH@ @=;< 'W72 !]T\0 ?<_\!'W+_ 2!Q_P$@<?\!J6L  )YS
M  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@  0WX  #A]   O?0( *'T-
M "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >?U( '7]> !Q_:P :?WH
M&7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[_P 7>_\ I'(  )IZ  "/
M?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@  #*(   HB   ((@% !J)
M#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP $HM8 !&+90 0BW4 #XN'
M  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .AO\ GWL  )2!  "*A0
M@(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2   ADP  &90  !*6!@ .
MEPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0  :77@ %EVX  Y:   &6
ME   E:@  )6^  "4X   E/0  )/_  &2_P !DO\ F((  (Z(  "%C   =X\
M &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9G@  $J    VB @ 'HPL
M :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D5@  I&4  *-W  "CBP
MHZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H  (F.  ![D@  ;9<  &";
M  !3G@  1J$  #FC   MI   (Z8  !FH   1J@  #*P   6N    KP<  *\-
M  "O$0  L!@  + @  "Q*   L3(  +(^  "R3   LEL  +)L  "R@0  L9<
M +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5  !QF@  8Y\  %6D  !'
MJ   .JH  "VL   BK@  &+   !"S   *M0   K@   "[    NP   +P'  "\
M#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\  ,-@  ##=   PXL  ,.A
M  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !EHP  5Z@  $FM   [L0
M+;,  "&V   6N0  #KL   >^    P0   ,4   #'    R    ,D   #*!0
MRPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3  #99@  V7P  -F4  #9
MJP  V<,  -GA  #9\   V?0 =I\  &>F  !9K   2[(  #RW   NN@  (;T
M !7    -Q   !<<   #*    S@   -(   #5    U@   -D   #;    W0
M -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N5@  [VL  .^$  #OG
M[[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP  "_    @Q   %,@   S,
M   "T    -0   #9    W@   .(   #E    Y@   .@   #I    [    .X
M  #P @  \@D  /4/  #X%P  _",  /\S  #_1@  _UH  /]Q  #_B0  _Y\
M /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\ '0#_ "@ _P W /\ 1 #_
M %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+ /\ D0#_ )< _P"= /\
MI #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\ ]P#_ /< _P#W /\ \ #_
M .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_ "0 _P R /\ /P#_ $P
M_P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H C #Y )( ^ "8 /8 GP#U
M *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_ .D _P#I /\ YP#_ .,
M_P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\ _P L /\ .@#_ $8 _@!2
M /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L (T Z@"3 .D F@#G *$
MY@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -< _P#5 /\ U0#_ -4 _P#4
M /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F /< - #T $  \@!, .X
M5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (< V@"- -8 E #4 )L T0"C
M ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P## /\ PP#_ ,, _P## /\
M_PL! /\#  #_    _P # /\ "P#S !( [@ ? .H +0#F #H X@!% -X 3P#9
M %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"' ,0 C@#" )8 P "> +X
MIP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\ L@#_ +$ _P"Q /\ _PT
M /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3 #( S@ ^ ,H 20#& %(
MPP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0 B "R )  L "9 *X H@"L
M *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_ *( _P"B /\ _Q   /L,
M  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H OP W +L 0@"W $L M !4
M +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D (L H@"4 *  G@"> :@
MG *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)_P"4"?\ _!$  /$5  #C
M&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N *X(.@"J"40 IPE- *0*
M50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8 E@R0 )0,F@"2#:8 D0VS
M (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'$?\ ]AD  .<@  #6)
MR"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0,P"=$3X FA%' )@23P"5
M$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+ (<4E@"&%:( A!6P (,6
MP0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\ [R$  -TI  #*+0  OB\
M +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1&C@ CAI! (L;20")&U
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M 6 O_0%@+_\!8"__ 6 O_P%@+O\!VC0  ,4\  "W00  K$,  *)#  "90
MD#H  (@T  " +@@ >BT2 '<N'@!S+RD <3 S &\P.P!M,$, :S%* &DQ40!G
M,5< 9C%> &0Q9@!C,F\ 83)Y & RA0%?,I(!73.A 5PSL0%;-,8!6C3F 5DU
M^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10  J$@  )Y(  "51@  BT
M (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E-C\ 8S9& &(V30!@-E0
M7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54XKP)4.<,"4SGD E,Z^0%3
M.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P  )I,  "12P  AT8  'U
M  !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP 73I# %LZ2@!:.U  6#M8
M %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K )./L$"33[A DT^^ )-/O\!
M33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1  ".3P  A$L  'E%  !N
M0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY  %4_1@!4/TT 4S]5 %)
M70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"2$+> DA"]@)(0O\"2$+_
M 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+4P  @%   '5*  !J1@
M84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"0P!/0TL 3D-2 $U$6@!+
M1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;< D-&]0)#1O\"0T;_ 4-%
M_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6   ?E4  '%/  !F2@  7$8%
M %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$
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M<P X4X(!-U.2 353I $T4[<!,U31 3-3\0$T4_\!-%+_ 312_P$T4O\!ME(
M *E:  ">8   E&0  (MF  " 90  =&,  &9>  !<7   45@  $=5!P!"51
M0%48 #]6(0 ]5BH /%8R #M6.0 Z5T$ .5=) #A740 W6%H -5AE #18<0 R
M6( !,5B0 2]9H@$N6;4!+5G/ 2U9[P$N6/\!+E?_ 2Y7_P$N5O\!LE<  *5?
M  ";90  D6D  (=J  !\:@  <6@  &-E  !88@  35\  $-= @ \6PT .EP4
M #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P7E< +UYB "U>;@ L7WT
M*E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=_P$H7/\!K5P  *)D  "8
M:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<  #]E   U8PD ,F,1 #!C
M&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950 )V5? "9F:P D9GH (V:+
M ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A8_\!J6(  )YJ  "5<
MBG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN   P;0, *6P- "=L%  F
M;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY; !UN9P <;G8 &FZ' !EO
MF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\ I&D  )IQ  "0=@  AGD
M 'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K=P  (G8' !UV#P <=Q8
M&W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X8P 2>'( $7B# !!XEP /
M>*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$  )5X  "+?   @G\  '>!
M  !J@@  78(  %""  !$@@  .((  "Z"   D@@  '((  !2""0 1@Q  $(,6
M !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )@VP "(-^  :#D0 %@J4
M X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^  "&@P  ?84  &^'  !B
MB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X   ^/ P *D P !I 1  2/
M&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4  (]V  "/B@  CI\  (ZT
M  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""B0  =(P  &:/  !9D0
M3),  $"5   TE@  *)8  !Z7   5F   #YH   J;   "G D  )P.  "<$P
MG!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN  "<@0  G)<  )RL  ";
MQ@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD   :I0  %R7  !/F@  0IT
M #:>   IGP  'Z$  !6B   .I   "*8   "H    J00  *D*  "I#@  J1,
M *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L=P  JXX  *ND  "KO
MJMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP  %&@  !$I   -J8  "JH
M   >J0  %*L   VN   &L    +(   "U    M0   +4#  "V"0  MPX  +@2
M  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P  O8$  +V9  "]L   O<P
M +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J   XK0  *J\  !ZQ   3
MM   #+<   .Y    O    +\   #"    P@   ,,   #$    Q@8  ,<,  #(
M$   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,  -*+  #2I   T[L  -/8
M  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   JM@  ';D  !*\   *OP
M ,,   #&    R0   ,T   #/    T    -(   #4    U@   -D"  #;"
MW@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\  #KE0  ZZP  .O"  #L
MU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P   $<0   G(    S    ,\
M  #3    V0   -T   #@    X0   .,   #E    YP   .H   #L    [@0
M /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_@P  _YL  /^N  #_O@
M_\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T /\ 00#_ $T _P!8 /\
M8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ), _P"9 /\ H #_ *< _@"O
M /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\
M_P / /\ #0#_  T _P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_
M &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\
MM #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P +
M /\ " #_  8 _P ) /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &
M\@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#=
M +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\
M  #_    _P $ /\ #0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B
M -\ :0#= &\ V@!V -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +,
MQ0#! ,( V #  .\ OP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_
M    _P   /0 !P#M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H
M8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y
M +$ RP"O .< K@#X *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V
M[@   .<   #?  P U@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W
M &, M0!I +, ;P"Q '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$
MPP"? -X G@#R )T _P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH
M -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P
MI@!C *0 : "B &\ H0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1
M -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01
M  "^#   N@(* +0 $@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)<
M )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\
MA KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q
M%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-
M70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L
M '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P
MH!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\
M%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:
M_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8
M ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D
M<!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A
M(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H
M  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1;
M &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\
M62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y
M*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ
M7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_
M %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0
M:RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5
M,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS
M_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#()
M & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$
M335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&
M-_\ P3X  +)%  "F2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV
M$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II
M $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\
MOD(  *])  "C3@  F5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1
M.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_
M<P! /X$ /S^1 #Y H@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4
M *Q,  "A40  EU0  (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q,
M24 < $= ) !&0"P 1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [
M0W\ .D2/ #E$H  X1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0
M  ">50  E%@  (M9  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09
M $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P
M-4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<
M60  DEP  (A=  !^70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)
M'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+
M "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970
MCV$  (9B  ![80  <%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U
M3R, -% K #-0,@ R4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3
MF@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68
M (-G  !X9@  ;64  &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\
M+58G "Q6+P K5S8 *E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @
M6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L
M  !U;   :FL  %UH  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC
M "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D
M%V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R
M<@  9G$  %AN  !,;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF
M)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]
M  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>
M8'<  %-V  !&=   .W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1
M<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9P
MT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X
M $U^  ! ?0  -7T  "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$
M!WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP
M>>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'
M   YAP  +8<  ".'   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C
M  ")+   B38  (E"  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8
M (3X  "$_P  A/\ D'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   P
MD0  ))$  !J2   2DP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6
M)   EBX  )8Y  "61@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U
M  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP
M&YP  !*=   ,GP  !*    "B    HP$  *,'  "C#   HQ   *05  "D'
MI24  *8O  "F/   IDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B
M_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<
M  JI   !JP   *T   "O    L    +    "P!0  L0L  +(/  "S%   M!L
M +4D  "W,   MS\  +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0
MM?X >Y,  &V8  !?G0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T
M    MP   +H   "\    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89
M  #))   RC(  ,M#  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8
M<)L  &&A  !2I@  1*L  #:P   GL@  &K4  !"X   'NP   +X   #!
MQ    ,@   #+    RP   ,T   #.    T    -(   #5 P  V H  -L0  #>
M&   XB0  .,U  #D2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0
M %6J  !&L   .+4  "BY   :O   #\    7$    QP   ,L   #/    U
M -@   #<    W0   -\   #A    XP   .4   #H    Z@   .T&  #Q#@
M]18  /@E  #Y.   ^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\
M#@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N
M /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,,
M]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_
M  @ _P * /\ $@#_ !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H
M< #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #-
M .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_
M_P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J
M '$ Z !W .8 ?0#D (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -
MW@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P
M /L "P#V !, \0 @ .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L
MT@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[
M .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X
M!0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J
M +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$
MIP#U *8 _P"E /\ I #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4
M  L S  3 ,< 'P#" "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P
M:0"K &\ J0!U *< ? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N
M )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0
MO@ . +@ %P"S ", KP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P";
M &D F@!O )@ =@"6 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (<
M^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 (
M *L $0"F !L H0 F )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &,
MC !I (H < "( '< A@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z
M!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%
M# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C
M 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\
M;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @".
M"PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$0
M90!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_
M &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@
M?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E
M%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<
M_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@.
M &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0
M6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2
M(O\ R"\  +@V  "K.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@
M$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J
M %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\
MPS0  +,[  "G/P  G$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<
M)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ
M<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@
M + _  "D0P  F44  (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8
M4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#
M,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#
M  "A1P  EDD  (Q)  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# <
M $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L
M/36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">
M2P  E$T  (I.  " 3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U
M(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F)
M #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@
MDE$  (A2  !^4   <TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^
M.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^
MF0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4
M (96  !\50  <5(  &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B,
M-SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K
M0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:
M  !Y6@  ;E<  &%2  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G
M #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@
M)$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W
M7@  :UP  %]8  !550  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M*
M*P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[
M !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P
M:6$  %Q>  !26P  1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C
M4"\ (E$W "%10  @44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53
MV0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<
M %ED  !-80  0E\  #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L
M&E@S !E8/  86$4 %EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 0
M6?, $%G_ !%8_P 16/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J
M  !(:   /F8  #-E   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N
M !%A-P 084  #V%+  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L
M"6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#
M<   .&\  "UN   D;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ
M,@ (:CP !VM'  5K4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX
M  !H_P  :/\ EVT  (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0
M,7@  "=W   ==@  %78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+
M=38  '5!  !U3@  =5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R
M_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(
M !^!   6@0  $((   J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\
M (([  ""1P  @E4  (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P
M??\ C7P  (2!  ![A   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,
M   0C0  "8X   */    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R
M  "0/P  D$T  )!=  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\
MB(0  ("(  !RBP  9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (
MF0   )L   "=    G0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@
M-0  H$,  *!4  "@9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL
M '6.  !GD@  698  $N9   ]G   ,)X  ".?   7H   #J(   >D    I@
M *@   "J    J@   *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0
ML3@  +%(  "Q6@  L6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6
M  !<F@  39\  #^C   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4
M  "W    MP   +@   "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L
M ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/
MI   0:@  #*L   DKP  %K$   VT   #MP   +H   "]    P    ,0   #&
M    Q@   ,@   #)    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM
M  #?0   X%0  .%K  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0
M-+(  "6U   7N0  #;P   &_    PP   ,<   #*    SP   -,   #6
MUP   -H   #<    WP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T
M,0  ]D8  /=<  #X=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P .
M /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '<
M_P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q
M /X \ #_ /  _P#F /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\
M$ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X
M /( ?@#P (0 [P"* .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /<
MW@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_
M !8 _  B /D +@#V #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .
M=P#? 'X W0"$ -L BP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_
M ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$
MZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#(
M '< Q@!] ,0 A #" (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$
M_P"P /\ L #_ *P _P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6
M -$ (@#- "T R@ W ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '
MLP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P">
M /\ G@#_ )X _P"< /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\
M&P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P
M *  =@"> 'X G "& )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\
MC0#_ (P _P"- /\ ^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K
M "  IP J *0 - "A #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$
M< "/ '< C0"  (L B@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_
M '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@
MF0 C )8 + "3 #4 D  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"!
M '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$
M_P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ;
M (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L
M<@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E
M"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&
M'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP
M &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\
MS2$  +PH  "O*P  I"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N
M#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1
M=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@
M +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P
M810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0
M&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T
M  "E-P  FC@  ) W  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA
M %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP
M1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A
M/   ESX  (T]  "#.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A
M)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026(
M #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0
ME$(  (I"  " /P  =CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!'
M)B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DK
MEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48
M (=&  !]1   <T   &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4
M/RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S
M,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*
M  ![20  <$4  &5   !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I
M #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8
M+#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y
M30  ;DH  &)%  !80   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S
M+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY
M "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@
M;$\  %])  !61@  3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M
M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^
MU  A/O, (CW_ ",]_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,
M %U/  !33   2D@  $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\
M)SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;
M0O$ '$+_ !U!_P >0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4
M  !14@  2$X  #U*   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T
M "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\
M%D?_ !=&_P 71O\ HE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/
M6   1%0  #E1   O3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+
M.  72T( %DQ, !5,5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_
M !%,_P 13/\ GE<  )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@
M/UL  #58   K5@  (E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  1
M4CX $%-(  ]35  .4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2
M_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(
M #!@   F7@  '5T  !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH
M"5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "
M6?\ EV0  (YK  "$;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II
M   A9P  &&8  !%F 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1
M  !D3   9%H  &1I  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\
MDVP  (EQ  " =0  >'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :
M<0  $G$   UQ   &<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O
M1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,
M (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?
M#7P   9]    ?04  'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0
M>TX  'M>  ![;P  >H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_
M  !X@@  :X,  %V%  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD
M  "*    B@   (D&  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8
M (E6  "):   B7P  (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !O
MB   88L  %.-  !%CP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7
M    F    )<   "7!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-
M  "97@  F7,  )B+  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP
M5I,  $B6   ZF0  +)H  !^;   4G   #)X   .?    H0   *,   "E
MI0   *4   "E    I@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L
M4P  K&<  *N   "JF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP
M #R?   MH@  (*,  !.E   +IP   :D   "K    K@   +$   "R    L@
M +,   "T    M0   +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P
MP%L  ,!R  # C0  P:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I
M   AJP  $ZT   NP    LP   +4   "X    O    +\   #!    P0   ,,
M  #$    Q@   ,<   #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT
M -MD  #;?@  W)D  -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4
MM0  "K@   "[    OP   ,,   #&    RP   ,X   #1    T0   -0   #6
M    V0   -L   #>    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5
M  #T;0  ](@  /2A  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P
M_P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[
M (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P
M_P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C
M /\ +P#_ #L _0!& /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X
MZ@"% .D C #G ), Y0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/
M /\ Q #_ +T _P"Y /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0
M*@#R #4 [@!  .D 2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^
M -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\
MM@#_ +  _P"M /\ _P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #>
M "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T
M?@"[ (8 N0". +< F "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_
M *, _P"@ /\ _P   /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D
MP@ S +\ /0"[ $4 N !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I
M '\ IP"' *4 D0"C )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8
M_P"3 /\ _0   /$   #E    V0   ,T   #$  8 O0 / +< & "S "( L  L
M *T -@"I #X IP!& *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '<
ME@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"&
M /\ \P   .,   #1    Q0   +T   "V    K@ + *@ $@"D !P H  F )P
M+P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y
M (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\
MYP<  -$,  ###0  N P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+
M #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8
M?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA
M ,84  "X%@  K14  *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H
M>P R 'D .0!W $  =0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G
M (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=
M  "P(   I1\  )L<  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K
M &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\
M6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I
M*   GB@  )0E  "+(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*
M+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z*
M $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P
MF2\  (\M  "&*0  ?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6
M$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83
MEP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34
M (LT  "!,0  >"L  &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H
M3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]
M&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z
M  !^-P  <S(  &HM  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM
M $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0
M-B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![
M/   <#@  &<R  !=+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@
M,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V
M "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00
M;CT  &,X  !:,P  42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U
M)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJ
MSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(
M &$]  !7.   3C,  $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3
M+RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D
M+^X )2__ "4O_P F+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"
M  !4/0  2SD  $$T   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU
M "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T
M'S/_ " S_P A,O\ ID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !2
M0P  23\  #\[   V-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T
M.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_
M !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020
M1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =
M.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\
M_P 6._\ H$L  )51  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L
M #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX
M%3]( !1 4P 30&  $D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 0
M0/\ G5   )-6  ")6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.
M   L2P  (T@  !M%"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%
M  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\
MFE4  )!;  "'8   ?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H
M4@  'U   !=.!  13 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-
M30 '3EH !DYI  1.>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL
M (UB  "$9@  >F@  '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@
M&E@  !)7 0 -5@D "54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@
M5E<  %9E  !5=P  58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH
M  " ;   =VX  &]O  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(
M  YA   )8 @  V -  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,
M %]A  !><@  7H<  %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]
M<@  =70  &IU  !==   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL
M   ":P8  &L+  !J#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<
M  !I;0  :((  &B8  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0
M<'L  &)[  !5>P  2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W
M=P(  '<(  !V#0  =A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U
M:   ='P  '22  !SJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($
M %J"  !,@@  /X,  #*$   E@P  &H,  !&#   *@P   H,   "$    A0
M (0#  "#"   @PT  (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8
M@G4  (*,  "!I   @+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*
M  !"BP  -8T  ">-   ;C0  $8X   J.    CP   )$   "2    D@   )(
M  "2 0  D@<  )(,  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL
M )."  "2G   D;8  )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   W
ME0  *98  !R7   1F   "9D   ";    G    )X   "@    H    *    "@
M    H0   *$$  "B"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X
M  "ED@  I*P  *3)  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@
M':   !&A   (HP   *4   "G    J0   *P   "N    K@   *X   "O
ML    +$   "R    LP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "Z
MA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H
M  >L    KP   +$   "T    N    +L   "\    O    +X   "_    P
M ,(   #$    Q@   ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@
MU)(  -6K  #5Q   U.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X
M    NP   +X   #"    QP   ,H   #,    S    ,X   #0    T@   -4
M  #8    VP   -\   #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((
M /"<  #PL@  \<4 _P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_
M #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4
MC #S )0 \@"= /  IP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_
M ,( _P"] /\ _P   /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #<
M^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A
M (X WP"6 -T H #; *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8
M_P"R /\ _P   /\   #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [
M ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (<
MQP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E
M /\ _P   /\   #^    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L
M/@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"(
M +$ D@"N )X K "J *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\
M_P   /L   #P    Y0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T
M $  L0!( *X 3@"L %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X
MBP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0
M .L   #=    SP   ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D
MGP!! )T 2 "; $X F0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"*
M (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H
M  #)    O@   +8   "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z
M (T 00"+ $< B0!- (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@
M> "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\
M"P  L0D  *@$  "A    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\
M.@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/
M &D G0!G *X 90## &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P
MIQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O
M #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P
MF !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP
M )49  "-%   A0\  'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0
M8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0
M :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B
M  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U
M %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J,
M10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  "
M)@  =R$  &X;  !F%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,
M-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V
M #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0
M<B@  &DC  !A'0  618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"
M$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05
MS0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX
M &4J  !<)   5!X  $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30
M.18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M
M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O
M  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW
M #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H
M)R#^ "@@_P H(/\ J38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6
M,   32L  $0E   [( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@
M.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7]
M "(D_P C)/\ ICH  )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@
M2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E
M)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI
M_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<
M #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\
M'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9
M+?\ H4$  )5'  "+2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX
M   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]&
M !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\
MGD4  )-+  ")3P  @%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q
M.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T
M3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD
M )%/  "'4P  ?E8  '56  !J50  8%,  %5/  !,3   0DD  #A%   N00
M)#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -
M.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4
M  "%6   ?%L  ');  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40
M !A" P 20 L $#\0  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058
M!D%E  1!=@ #08H  4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#
M7@  >6   '!@  !F8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*
M   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB
M  !(<P  2(8  $B;  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P
M=V4  &YF  !E9@  660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +
M4@< !5$-  %0$0  4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0
M;P  4(,  $^8  !/K@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P
M &QM  !A:P  4VD  $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8
M %L+  !:#P  6A,  %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P
M6'X  %B4  !7JP  5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R
M  !:<0  3'   #]N   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)
M  !E#0  91$  &05  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH
M &*0  !AIP  8,$  %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2
M=P  17<  #AV   K=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q
M"@  <0X  ' 1  !P%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+
M  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P
M/'\  "^    B?P  %WX   ]^   '?@   '\   !_    ?P   'X   !^!0
M?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![
MG   >K8  'G:  !X]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD
M "2)   8B0  #XD   >*    BP   (P   "-    C0   (P   ",    C ,
M (P(  "-#0  C1$  (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0
MBZX  (K-  ")[P  B?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3
M   .E   !I4   "6    F    )H   ";    FP   )L   ";    FP   )P
M  "=!0  G0L  )X0  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4
M )["  "=Z   G/D <(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %
MGP   *$   "C    I0   *@   "I    J0   *D   "J    JP   *P   "M
M    K@$  + )  "R#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T
M  "SU0  L_  9),  %67  !'FP  .)\  "FB   :I   #J8   2H    JP
M *T   "P    M    +8   "X    N    +D   "Z    O    +T   "_
MP    ,,   #%!P  R0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,
MP@  S.( 6)L  $F@   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H
M  "^    PP   ,8   #(    R    ,H   #+    S0   ,\   #2    U0
M -D   #=    X04  .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@
M[,( _P   /\   #_    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\
M3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7
M .L H0#I *T YP"] .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\
M_P   /\   #_    _P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M
M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0
MFP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P
M /\   #_    _P   /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D
MTP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\
M )\ N0"L +8 O@"T -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\
M  #Y    [P   .8   #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!*
M +L 4 "X %8 M@!; +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@
MI0"E *, M "@ ,L GP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J
M    W0   ,\   #'  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *<
M20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"=
M )  K ". +\ C #B (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4
MR    +\   "U  $ K@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4
M $D D@!. )  4P". %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\
MI !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N
M *\   "H    H  & )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $(
M@@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M
M *X ; #$ &H YP!I /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(
M  ";    E    (T "@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !!
M '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *<
M7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/
M"   B    (( !0![  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4
M00!C $8 8@!, &  4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U
M %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0
M?PT  '<&  !Q  @ :P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8
M $$ 5@!& %4 30!3 %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $<
MQP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4
M &\0  !H"P  800* %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L
M3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \
M!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8
M  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@]
M $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0
M,PWY #,-_P T#?\ K2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<
M&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-
M/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z
M "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0
M3QL  $<6  ! $0D .Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P
M$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86
M_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(
M $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D
M*!9* "<75  F%V  )!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @
M&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C
M   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM'
M "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\
MH3@  )4]  "+00  @4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U
M)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@
M3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP
M )-!  ")1   ?T8  '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P
M*B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5
M)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%
M  "'2   ?4H  '1*  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T
M " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E<
M$"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%
M3   ?$X  '-/  !I3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP
M!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C
M  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40
M>E,  '%4  !G4@  75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2
M- D #S,.  XS$P -,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V
M<0 "-H0  #:9   VKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@
M &]9  !E6   6U4  %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ <
M"SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@
M/($  #R7   \K   .\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>
M  !C70  6EP  $Y8  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,
M  -#$   0Q4  $,;  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX
M $.4  !"J@  0L,  $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B
M8P  5V$  $E=   ]6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,
M#@  3!,  $L8  !+'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0
M  !)IP  2<   $CD  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0
M4&8  $-D   W80  +%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0
M51   %45  !4&P  5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2
MI   4;T  %#B  !0^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP
M #UK   P:0  )6@  !IF   19   "V,   1B    8@$  &$&  !@"P  8 X
M %\2  !?%P  7QX  %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H
M6[D  %K?  !9]P  6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S
M   H<@  '7   !-O   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.
M  !K$@  :AD  &HB  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4
M &78  !D]0  9/\ @'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?
M>P  %'H   UZ   $>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X
M#@  >!,  '@:  !X)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.
M  !R\0  <?\ ?GT  '6   !G@0  6((  $J#   \A   +H4  "&%   5A0
M#84   .%    A@   (<   "(    B    (<   "'    AP   (<$  "'"0
MAPX  (@3  "('   B"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#
M[   @OX >(0  &J&  !<B   38H  #^,   QC@  (X\  !:/   -D    I$
M  "2    DP   )4   "6    E@   )8   "6    E@   )<   "7    EP<
M )@-  "9$P  FA\  )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@
MEO@ ;8H  %^-  !0D   09,  #.6   DEP  %I@   V9   !FP   )T   "?
M    H0   *0   "E    I    *4   "E    I@   *<   "H    J0   *H$
M  "L#   KA,  *XA  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\
M89$  %.5  !$F   -9P  ":?   7H0  #:,   "E    IP   *H   "L
ML    +(   "T    LP   +0   "U    MP   +@   "Y    NP   +T   "_
M 0  PPL  ,45  #%)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D
M $>=   XH@  *:8  !FH   -JP   *T   "Q    M    +<   "Z    OP
M ,$   #$    PP   ,4   #&    R    ,H   #-    SP   -(   #6
MVP   . ,  #A&   XRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\
M  #_    _P ! /\ "@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7
M /4 70#T &, \@!I /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@
MX@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_
M    _P   /\ !@#_  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .(
M6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O
M ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_
M^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#&
M %< Q != ,( 8@#! &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\
MMP"M -  JP#R *H _P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0
M .    #5  @ S@ 0 ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$
MKP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9
M ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\ _    /    #C    U    ,@
M  "_  , N0 - +, $P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0
M )L 50"9 %H EP!? )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@
MA0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N
M    IP ) *( $ "> !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D
M3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#'
M '( [ !Q /\ < #_ '  _P!N /\ W0   ,D   "\    L0   *D   "A
MF0 # ), # ". !( B@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X
M $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &,
MX0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0
M (8 " "!  X ?  4 '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $<
M: !, &8 4@!D %D 8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5
M /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L
M @!U  L <  0 &P %@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!&
M %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H
M20#^ $D _P!) /\ N1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K
M  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X
M1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X
M #X _P _ /\ LAD  *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"
M7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!#
M $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4
M_P U /\ K"   )\D  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P!
M $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4
M. -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L
M"/\ J"4  )LJ  "0+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.
M! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE)
M "X*4P L"EX *PML "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\
MI"H  )@O  "-,@  @S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \
M$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.
M4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\
M )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0
M,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >
M$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W
M  "(.@  ?CL  '0[  !K.   830  %<O  !.*P  128  #TA   T'   +1<%
M "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E<
M%Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&
M/@  ?#\  ',_  !I/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9
M"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC
M !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@
M>T0  '%#  !H0@  7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :
M'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA
M<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@
M '!(  !G1@  7$0  %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH
M$B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P '
M)H( !B:6  0FK  #)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],
M  !E2P  6T@  %!$  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-
M  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\
M "N4   KJ0  *\$  "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C
M4   6DT  $]*  !'1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN
M$  '+A4 !B\;  4O(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1
M   QIP  ,+\  ##A   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50
M6%,  $Y0  !%30  .DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !
M-A,  #89   V(   -BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   V
MI0  -KT  #;@   U]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD
M $Q6  ! 4@  -4X  "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$
M #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP
M/+L  #S>   []0  ._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;
M   Z5P  +U4  "52   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4
M  !&&@  1B(  $8L  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@
M $/<  !"]0  0O\ B%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T
M7@  *5P  !]:   55P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/
M%@  3QX  $\G  !/,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8
M  !*]0  2O\ A64  'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90
M(F0  !AB   08   "5\   !>    7@   %T#  !<"   6PP  %H/  !:$P
M61D  %DB  !9+0  63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4
M]   4_\ @6P  'EP  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP
M !%K   ):@   &H   !I    :0   &@   !G P  9@@  &8,  !F#P  910
M &4<  !E)P  9#0  &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0
M7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU
M    =0   '4   !V    =0   '0   !T    <P(  ','  !S#   <A   '(5
M  !R(   <BP  '([  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\
M>WL  ')^  !D?@  57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!
M@@   (,   "#    @P   ((   ""    @@   ((   ""!0  @@H  ((/  ""
M%P  @B,  ((R  ""0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(
M &B#  !9A0  2X<  #R)   NB@  ((L  !.+   *BP   (P   "-    CP
M )$   "2    D0   )$   "1    D0   )$   "2    D@(  ),)  "4#P
ME!D  )0G  "4.   E$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*
M  !-C0  /Y   #"2   AE   %)4   J6    EP   )D   ";    G0   )\
M  "@    H    *    "@    H0   *(   "C    I    *4   "F!P  J!
M *@<  "H+0  J4   *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!
ME@  ,YD  ".<   4G0  "I\   "A    HP   *8   "H    K    *X   "O
M    KP   +    "P    L@   +,   "T    M@   +<   "Z    O0<  +\0
M  "_'P  P#,  ,!)  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP
M)J,  !:E   +IP   *H   "M    L    +,   "V    NP   +T   #
MOP   ,$   #"    Q    ,8   #(    R@   ,P   #/    TP   -H'  #;
M$P  W24  -X[  #?4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P
M /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X
M[0!D .L :0#I &\ YP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2
M .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\
M @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !>
M -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D
MN0#W +@ _P"T /\ J0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G
M  H X0 1 -P &@#7 ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L
M70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M
M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4
MQ@ . ,$ %0"] !X N0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E
M %L HP!A *$ 9P"? &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X
M^P". /\ BP#_ (8 _P"# /\ ^    .D   #<    S    ,$   "X    L@ *
M *P $0"H !@ I0 A *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4
MD !: (\ 8 "- &< BP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![
M /\ >@#_ '< _P!U /\ Y@   -,   #&    NP   +$   "G    H0 % )L
M#0"7 !, DP ; )  (P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3
M 'T 60![ &  >0!H '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\
M:0#_ &D _P!G /\ TP   ,,   "U    JP   *,   ";    D@   (P "@"'
M !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T
M4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_
M %H _P!: /\ Q0   +8"  "I @  GP   )8   ".    AP   (  !0!Z  P
M=0 1 '$ & !N !X :P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!>
M %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X
M_P!- /\ NPH  *P-  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 .
M &4 $P!B !D 7P ? %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X
M4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!"
M /\ LA$  *44  "9%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L
M#P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0
M $, 60!! &, /P!O #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\
MK!<  )\;  "3'0  B1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !-
M !  2@ 5 $< &@!% "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D
M5  W %\ -@!K #0 >@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX
M )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T
M00 1 #X %@ \ !L .@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N
M %L +0!G "L =@ J (@ * "< "< L  F ,D )0#J "4!^P E ?\ HB,  )8H
M  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]!PD .0,.
M #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$30 F!5@
M)05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@  ),M  "(
M+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0 ,0L* "X(
M#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?"U4 '0MB
M !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q  "&-
M?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 & "8-"P D
M# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E, %@YA !0/
M<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$.   >CD
M ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1!P =$ T
M&P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)? ! 2;P .
M$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/   >#T  &\]
M  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9% H %1(.
M !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7;  +%W\
M"1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$  &U!  !D
M/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@ $A<- ! 7
M$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %''P !!V1
M  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%  !C1
M64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+  T=$  ,
M'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D  "&.   A
MI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B20  6$8
M $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC#@ &(Q(
M!2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,   FH@
M)KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@  5TL  $U(
M  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !*A$  "H6
M   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   KH   *[<
M "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$  $Q.  !#
M2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A   #$4   Q
M&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@  ,;4  ##4
M   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3   ^3P
M,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2   Y&
M.2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,  #?2   V
M\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X50  +5(
M ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!%0  01T
M $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0   ]\@
M//\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P  )ED  !Q6
M   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@  2AD  $HB
M  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%\0  1/\
M@6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V   !5>   -
M70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0  %0=  !4
M)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P  3O\ ?FH
M '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG   &9@
M &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7  !@(0
M7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\ >W(  '5V
M  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q    <0   '$
M  !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M&@  ;28
M &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H  '!\  !A
M?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0   'X   !_
M    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@  ?!T  'PL
M  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!  !6@P
M2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P   "-
MC0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,  (\A  ".
M,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+BP  /(T
M "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<    FP
M )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6  "C)@
MHSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP  ,)8  "&9
M   2F@  !YL   "=    H    *(   "D    J    *H   "K    J@   *L
M  "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y&@  NBT
M +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z   !.B   (
MI    *<   "J    K    *\   "R    MP   +D   "[    N@   +P   "]
M    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P  U1\  -<U
M  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\  P#_  T
M_P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!? .4 9 #C
M &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .  R0#[ ,<
M_P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V  L \0 1
M .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L 7@#) &,
MQP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R +  _P"L
M /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8 V0 . -(
M%@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R %T L !B
M *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L _P": /\
ME #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP + +H $0"V
M !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8 G !< )H
M8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"& /\ A #_
M '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4 #@"A !0
MG@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5 (@ 6P"&
M &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\ <P#_ '
M_P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0 !  C  7
M (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8 5 !T %H
M<P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_ &( _P!@
M /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T ?  2 '@
M&0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E %0 8P!;
M &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0 _P!4 /\
MO@   +    "D    F0   )    "(    @0   'D  @!S  H ;P / &L % !G
M !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X 5@!5 %0
M7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!' /\ M D
M *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\ $ !; !4
M6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0 $@ 6 !&
M &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\ K!   )\2
M  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1 !$ 3@ 6
M $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T 4P [ %T
M.0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8  )H9  ".
M&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X 1  2 $$
M%@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q %D +P!E
M "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@  "*(0
M?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  / #@ $@ V
M !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4 )@!A "4
M<  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&*   ?"<
M '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$ $  N !,
M+  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!> !T ;0 <
M 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0  >2T  ' K
M  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F Q  ) $3
M "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&:@ 4!WP
M$P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(  &XQ  !D
M+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T '0<0 !L'
M%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .#'L #@R0
M  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU  !C,P
M62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P. !0,$0 3
M#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D "!"-  <0
MH@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A.   6#4
M $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.#@ .#Q,
M#1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+  $4H
M$[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0  5SD  $TV
M  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *$Q( "107
M  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8GP  &+4
M !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\  $P[  !#
M-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$ !!D6  (9
M'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0  '+,  !S.
M   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M   !#/0
M.SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4   ?&P
M("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(  "'-   @
M[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"0P  .D
M "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F&0  )B$
M "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,   E[@
M)/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20  -40  "M
M   A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@  +1X  "TG
M   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J[@  *OX
MA4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D  "5&   <
M0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L  #0D   T
M+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@  ,/\ @U,
M 'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,   620
M#D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA   \*P
M/#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\ @5H  'E>
M  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   040  "D\
M  %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%)P  13,
M $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$  '9E  !O
M:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60   E@   !6
M    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@  3RX  $\\
M  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L  !N;P
M9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(   !A
M8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@  %HV  !:
M1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I=0  6W0
M $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M    ;
M &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O  !G/P
M9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@  4'H  $)Z
M   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z    >@   '@
M  !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V-@  =DD
M '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(  #:#   H
MA   &H0   Z#   $A    (0   "%    A@   (@   ")    B    (<   "'
M    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+   B#\  (A5
M  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,   ;C0
M#XT   2.    D    )$   "3    E0   )<   "8    E@   )<   "7
MEP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,  )U)  "<
M8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0E@  !)@
M  ":    G    )X   "A    I    *8   "G    I@   *<   "G    J
M *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]  "U50
MM7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0   *,   "F
M    J0   *P   "O    LP   +4   "W    M@   +<   "X    N@   +L
M  "]    OP   ,$   #$    QP   ,L   #-#   SAH  ,\O  #/2   T&(
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P$A   !                     0
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M__________^L4Q       !=MUO____________________________N ,0
M      EAS/___________________________]): @        !=S/______
M_____________________Z@U          !<T_______________________
M_____WT-          !4UO__________________________[GU%
M  !$U/___________________________*ID+P(   0B-TE8SO__________
M_________________^FD:T$H/V-_E:>ZVO__________________________
M____U;*LLLSD^O______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Y;N7=V+(____
M_____________________________]N>9S8*  *,____________________
M____________R'\_!0    !>S______________________________9@3D
M       \JO____________________________^>3          CD/______
M_____________________]QO&@         0??G_____________________
M_____Z](            ;^[__________________________X03
M    9.;_________________________[%$             5][_________
M________________N!4             2-;_________________________
M=!0             .,_________________________YHEH3
M(\7_________________________WYM<+           #;K_____________
M_____________^^Q?54Y(A$' 0(1(K+_____________________________
M_]^_I9F8FJ"LO=K_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^.^G8!\^_________________________________*W
MA%<P#@ =K/______________________________THI,%0      <O/_____
M_______________________6?S8         2\G_____________________
M______J1/@          +ZO__________________________\!:
M    &I7__________________________XTD            "(3_________
M________________YUX              '?_________________________
MM"4              &K_________________________?0
M %OT_______________________]*P               $SK____________
M__________^E                 #SA______________________\P#
M             "W9_____________________YF*82<              "?7
M_______________________MOHE5)P           "7<________________
M__________[*G79=2CPR+2PP.4?>_______________________________]
MYMW6TM#3V>3_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________[]2[UO______
M___________________________GN(]J2R\5;_______________________
M________Y*%G- <     /,G____________________________6@CL
M    $I?__________________________^V%,0           &__________
M_________________Z9"             %#A________________________
M[&D              #?)________________________LR\
M "*V________________________>0               !"G____________
M___________R-                 "9______________________^I
M              ",______________________]&                  !_
M_____________________]\                   !T________________
M_____Y<                   !J_____________________\X
M          !C______________________\I(@$               !A____
M__________________^YHX!7-Q<           !H____________________
M_______ZTZZ4AGQU<7!R=X&4____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________]NZ
MG8)I:=/______________________________\B393T9    '9[_________
M___________________;CDP3         &[_________________________
M_]M\+            $77_________________________XLJ
M "*T________________________PD0               .7____________
M____________?0$               !________________________G-@
M              !J______________________^=                  !8
M______________________]&                  !'^/______________
M_____^D                    UZ?___________________Y8
M           EV____________________[P                    8SO__
M_________________^L                    /PO__________________
M__\                    *N?____________________\G
M       *M?____________________]P                   -N?______
M_______________@G(QP54(S)AL4#PT.$AHFO_______________________
M______GDV-+.S,O,S];@_/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^O3O./_________________________
M_______2J85E2"P2 87____________________________QJW$\#P
M $_@_________________________]5_-0           !^R____________
M____________XW4=              ")________________________D",
M              !G_______________________50P                !(
M]O____________________^*                   NW?______________
M______\X                   7R/___________________[X
M           $MO___________________YP                     I?__
M_________________[H                     D___________________
M_]P                     @O____________________\
M        =/____________________\3                    :/______
M______________]"                    8/____________________]Z
M                    7?_____________________1
M    8?______________________)                   9O__________
M____________R:R9B7UV<6QI9V9G:W!ZC/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^+%JI%Y87?_____________
M________________W:9W4"P,     #'$_________________________^"2
M3A,           "/________________________TG =              !@
M_______________________N;P\                WXO______________
M______^6'                  4P/____________________]
M            H____________________ZX                     B?__
M_________________YX                     <O__________________
M_[P                     7____________________]H
M        3?____________________H                     ._______
M______________\.                    *OG___________________\S
M                    &^G___________________]>
M    #]O___________________^/                    !M#_________
M___________0                     ,K_____________________*P
M                 ,C_____________________@
M ,O_____________________]Q8!!04# 0       08-&,O_____________
M__________SKX=C/S,W/T-+4U]SBZO______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________QVL;_______________________________'&HX1H33(8 !6K
M__________________________^Y?$88          !Q________________
M________UWPO               [X______________________?9 D
M           ,M?____________________]T P                  C?__
M_________________\45                    :O__________________
M_YD                     2____________________[8
M        ,/W__________________]<                     &>?_____
M______________8                     !=/___________________\.
M                     ,'___________________\O
M     *____________________]2                     )[_________
M__________]Y                     ([___________________^E
M                 (#____________________8
M '3_____________________-@                   &W_____________
M________?                    &G_____________________UPT
M             &C______________________W                   &'_
M______________________]0/$9.5%E=861H;'!V?HG_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^_5NZ.+<UJ5___________________________XOXYD
M02$%      !2_/______________________]YU6&              7P?__
M___________________E;!8                 C?__________________
M__]C                    7O___________________YT
M        -?S__________________Z$                     $=G_____
M_____________\H                      +O__________________^X
M                     *'___________________\,
M     (K___________________\M                     ';_________
M__________]-                     &3___________________]O
M                 %+___________________^4
M $#___________________^\                     ##_____________
M_______J#@                   "+_____________________1
M             !7_____________________@0                    OU
M____________________R L                   +L________________
M_____UX                   #E_____________________\D<
M          #:______________________^= 0             '#A?%____
M____________________U;F\P<?.U=OAYNWT^_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^-_/____
M_________________________^S&I8AM5#LA!P RWO__________________
M_____]>262D             H/______________________B38
M        9_____________________]F                    ,O;_____
M_____________Y4                      \C__________________Z<
M                     *#__________________]<
M     'S___________________\                      %[_________
M__________\E                     $/___________________](
M                 "S___________________]J
M !C___________________^+                      7S____________
M______^O                      #A___________________5
M              #/____________________)                     "^
M____________________5                     "N________________
M____BP                    "?____________________RPX
M          "2_____________________U<                   "&____
M_________________ZH*                  !Y____________________
M__]M                  !F_______________________W50
M      !%_________________________VHC*S4_2E5@:G5^AY&<________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________H
MS[:=@VE.N?_________________________LLH-<.AT"        >_______
M________________Q6TI                0/____________________^#
M&P                  !\O__________________Y(
M     )C__________________Z0                      &K_________
M_________]T                      $'___________________\.
M                 !W___________________\Y
M  #H__________________]@                      #.____________
M______^%                      "W__________________^H
M              "C___________________+                      "0
M___________________O%@                    !]________________
M____/@                    !L____________________:0
M          !:____________________F0                    !)____
M________________TA8                    Y____________________
M_U@                    I_____________________Z(
M       9______________________56                   $________
M______________^[+P                  ^/______________________
MJRD                 S________________________\E'      <3("X^
M4FB$[?______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________35R?______________________
M______K2L))W74(H#   2O_______________________\5]11<
M    $=C____________________$4                    )__________
M_________Z(,                     &C__________________Y0
M                 #;__________________]H
M  ?L__________________\5                      #$____________
M______](                      "B__________________]U
M              "#__________________^=                      !I
M___________________#                      !2________________
M___G#P                     ^____________________,P
M           K____________________6                      8____
M________________@0                     %____________________
MK                       ____________________WB(
M        \O___________________UP                     W_______
M_____________Y\                     S/___________________^A*
M                    M_____________________^@%@
M    G/______________________>@(                 =___________
M_____________WH+               %3/________________________^B
M5VAT@(V<J[S0Y_______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________MX___________
M________________TJ-Z6#HI(QP6#@8  )______________________K%(.
M                 &G__________________^1#
M #3__________________WD                       #C____________
M_____\T                       "R__________________\3
M              "%__________________]/                      !=
M__________________^#                       Z________________
M__^R                       <___________________; P
M           "____________________*@                      ^___
M________________3P                      Y___________________
M=                       U/__________________FP
M        P/__________________Q <                     K?______
M____________\#,                     FO___________________V<
M                    AO___________________Z,
M    <O___________________^-$                    7/__________
M__________^1!@                  0?_____________________K7P
M                '?______________________RDL
M /_______________________\M7   ,&"0Q/TY@=(NGQ_______________
M____________U^?R____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z]3-Q\*^NK>SL*VIJ*7_____________
M_______=?E,_,",9$0D"          #;_________________W8
M              "G_________________[H                       !U
M__________________\'                      !&________________
M__].                       :__________________^,
M            _?_________________!                        V___
M_______________Q&0                      OO__________________
M1                       I/__________________:P
M        C?__________________D0                      >?______
M____________MP                      9O__________________WB$
M                    4____________________TH
M    /____________________W<                     *___________
M_________ZP*                    %O___________________^=%
M                 /____________________^*
M /_____________________630                   /W_____________
M________IRX                  -7______________________Y@J
M       &&"U%8.#_______________________^H8W2!CYRKN\WB^O______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________Y\NWJ9V5CHF$@'QX='!L:&60________________
M_[QJ2"T9"@                 Q__________________\
M           #__________________]"                        W/__
M______________^.                        LO_________________.
M                        C?__________________*0
M        :___________________6@                      3O______
M____________A@                      -/__________________K@
M                    'O__________________U!<
M    "O__________________^CT                      /__________
M_________V4                      /___________________XX
M                 /___________________[P9
M .____________________%.                     -C_____________
M______^+                     +_____________________,0P
M             *'_____________________D1D                  'K_
M____________________\G0*                $5__________________
M_____^AT$Q\L.$538G*%F[32]?__________________________U^CT____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________[]_/Q[NSKZ^SQ____
M_______________9LIF'>6UD75912T9!/#@R+2@CQ/________________]+
M)0L                     DO________________^(
M        9O_________________7                        /?______
M____________,P                      &/__________________;
M                     /__________________G0
M     /__________________R0P                      /;_________
M________\34                      -___________________UL
M                 ,O__________________X(
M +?__________________ZD&                     */_____________
M_____],O                     (W___________________]>
M             '?___________________^3!P                   %[_
M___________________-0P                   $#_________________
M____AQ                   !S_____________________V%X
M          #______________________[].       .'"P^4FJ&I<C_____
M___________________"?(R:I[;%UNC]____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________NX=?/R<.^NK:QK:FGIJ:GKO______
M__________^^AFU;3$ W+R@B'!80"P0     %/_________________7!0
M                     /__________________-
M     /;_________________=@                       -+_________
M________L                        ++_________________X20
M                 );__________________U$
M 'S__________________WD                      &;_____________
M_____Z                       %'__________________\<C
M             #S__________________^Y+                     "?_
M__________________]T                     !#_________________
M__^C%@                    #____________________83
M          #_____________________B \                   #_____
M________________RU,                   #_____________________
M_Z4X           )'31.:XS_______________________^9.4-17VY]CJ"U
MR^7_____________________________Z_G_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_________
M________844R(Q@.!@               )[_________________?@
M                 '7_________________PP
M %+_________________^S<                      #+_____________
M_____VH                      !;__________________Y8
M              #__________________[\;                      #_
M_________________^9"                      #_________________
M__]I                      #___________________^0 @
M          #___________________^Y+                     #T____
M_______________H7                     #9____________________
MD1@                   "\____________________RE,
M      "=_____________________Y@N             ! I1F;$________
M_____________^Y_'0P:*#=&5VE^E:_,[O_________________________G
MH*JYR-CI_/__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________WU\.OFXM_;V-32T=#2
MU^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____________
M____TB41 P                    #__________________T(
M              #__________________WT                       #_
M_________________[ +                      #V________________
M_]TY                      #<__________________]B
M          #%__________________^)                      "O____
M______________^O(@                    "9___________________6
M2                     ""____________________<@
M      !I____________________H2@                   !.________
M____________TUP                    S_____________________Y8N
M               5,E)W_____________________^!R$P   0\?+T)8<(NH
MR.S________________________*;VY^CIZPP]CO____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________G@TLC NK6PK*BEHI^=FYN<H*?_
M_________________X)D5DM#/#8P*R<B'1@3#@D$  #4________________
M_Y(                       "M_________________\P>
M          "+__________________M2                      !M____
M______________^                       !1__________________^I
M&P                     Z___________________00@
M       C___________________U:                      ,________
M____________CQ0                     ____________________N#X
M                    ____________________Y6T#
M    _____________________Y\W               0+U!T____________
M_________]UR%      &%RI!6G64MMK_______________________^\6$14
M9'6&FJ_(X_______________________________TLWA\?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U>'^0____
M_____________^M/.C H(1L5$ L' @         C__________________]I
M                        __________________^;"@
M        ___________________(.0                      ________
M___________P8P                      ____________________B@X
M                    ____________________L#0
M    ____________________U5L                     ____________
M_________X4:                   #[/___________________[%)
M           8.5V!_____________________^5['@      #"$X4F^/L]G_
M______________________^[6"DY25IL@)>PS>W_____________________
M________LYZTQ=?K____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^N_GX=S9UM32T-#0
MT=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q________
M__________^_,1\6$ H%                ___________________M5@
M                    Z/__________________@@0
M    S/__________________JR\                     L___________
M________TE<                     F___________________]WP0
M                A?___________________Z(W                  4K
ME/___________________\MA @            PL4':>T?______________
M______6-,       #2,[5W:9ON7________________________#8Q@J.TQ?
M=(VGQN?_____________________________J'^6J+O0Y_______________
M______________________W_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________W<[%O[RYMK2SL;*RM;G
MR=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__________
M________IR8.!P(                 5O__________________SE
M                .O__________________]'D+
M(?___________________Y\R                    #O______________
M_____\18                "#%:A/___________________^E_'P
M    !B=+<9K"Z?____________________^G20     "%R]*:(JNU?S_____
M___________________3=1XF.$I>=8^KR^__________________________
M____KG*%F*S"V_;__________________________________]_O________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________[^RJJ:CH:"?GZ&CIJRTP,W=
M[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______________
M_____YXN!@                   /___________________\-6
M           50?___________________^=[&@             )-&"+M/__
M__________________^?/P         $)4IQF<+K____________________
M___&9@\    3*D1B@Z?-]?_________________________KCC4K/E%H@9V\
MWO______________________________OG9_E*G!W/G_________________
M_________________]+8\_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________]O+P[^_O
M\?/X_?____________________________BPGYJ7EI:6F)N?I*RVPM'A[O__
M__________________Z.4$I'141$1$5&1TM16FB#J?__________________
M__^F00$           <V8X^ZX?_____________________&90H       0G
M3'.<Q.S________________________EB"\  !,J1&*"ILST____________
M________________JU V2F%[EK36^O______________________________
MTH=\F+'+Z?___________________________________]3.[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________[>7CX^3FZ.WQ
M^?_____________________________]L922DI69G:.ILKS0[?__________
M________________G5-'24U15F!SBJ_6_/__________________________
MLE8 &C50;8NNTO?_____________________________S6\^7WN9M]?Y____
M____________________________[I^#IL+A________________________
M_____________^/.Z___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________P
M
M
M____________________________________________________________
M____________________________________________________________
M__________________________________________________\     _^%
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M 0$! 0$! 0$!_\  $0@!D0)@ P$1  (1 0,1 ?_$ !X   $$ P$! 0
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MH2%-\KX^P>6RN<X0LX^DVTBA<)EQJY"!0$W*#.8^<QG;D4PO=B>PS\M?NO\
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M@P0S*SV*(F)F-IC63RT4232A3R<>287:G?(Q)WK8LFLR3.*9WB3 50=*-2*
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MHYI*+W.-;O8YD21C'CXII1&NM5%P;>8\0@FS1H[,C>3@+F4F6U:$8Y44(O\
M-8<?A'0XGQ4738WJ-@+,H)*V662A;X_S%Q0L"(X=WVC8'AH54\CFRXBN%E6X
MF1QU2O&0K'24EF29DD*.O6EM$7K:Q-%06K"3 :6-<Q;)))C_ !*,).ZI:[2\
MJN2H;\,?ADJ4))1]3-+V):U6.5JT<W@_I]P?1OFIRT,^(Z-*R,6DFB0BR:JI
M5"@.1\)WX9CEK?4?.2L&@)5-F?#\F(5FR:^#K <K^SV=080+FDP"2*I9(B6
M>UO >#S=VQC\O35A*X6"&R.,@[\MXB?PLM-*4Y)JX8682").X=1 *L)L&T4P
MXU%EWU0DQ6KHYIM(S!!)T]_2FLS=5J?19:-A0MZ-=EXTKN%ELA1#P#/XJ:\D
MZ3I%N\:K(/0(V5<H-D'62.&F+M8Z+=O'RNW?O5!1+[0>)/&V74[*Q>BH[IQ+
M@ @8$'/3,2Y8@7RG&Y[2Z]K'YP\7B^(%%BL9AK]C)12Q3ET5YR@&3J-*G:RU
M9CY77AB7J*%Q%CE!9LZB);9C"V>J_G DZ[JU<N#*!AG3AE'VR<CHUI 6Q6/E
M9."E3P"K&7D7::D;*1+E%XPF6D3(I(K,GA&BC)ZV<*<J_B78]%5UAM<6V@4[
MP0F96D(LU:]VH]T2N%$JS7LA*S2UO*Q;T.A3TL7'KL!Q15XALY)-*I?\+C;-
MBE&5<NN%"_<H7;.-R2*G3L,L@VC=J,6X+=>K+%FFS5\15<MY3KKE:]/HTTT:
M::---&FFC331IIHTTT:::---&FFC331IIHTTU4??)4IV];;+S5:S69NUS\LX
MK:<9&5Z):34JFJWL<6[6?-F;Y%PS$S%J@NXZW*"R "0"JI*D.9,W8X=<NMQ!
MA;#G#637OK<YYE( I2UMEDF6T[08[JVCN<L@!VDHF/%>T:G8R/ O$]"K3L7[
M5S&%7K5*J LV&/:](J)*600$2#V?S&) N%2PAF!VU1:CP>]+$]2>1^'Z2M'Q
M=LW#RDY(V>W52/B+E*5!S7*^BC(VNAP-=GX:!C5Y=FYAW"E/K%967BV:$BDC
M"/';E^/L&.X>R%S#*R]A8KI8"XEM>C9;9IA9G,67J%5VR\+)6FTK3;@JLY"P
ME%T@KRQ]104X^24ZOM$X?P^<9PKC;!'E.,L;8"[F:%?'9AF.CAO'T[+;6'Q^
M+LX]%.ODZ%?'$W&X6H^YBQ?=D*V2<S)RZFV3_$0:R>56;*GV^Q DUR0%$5LM
M'IT#%-086V%3I;F)DHNMMEI)^ZJ2TZLV1F6DB@Z=-6/JX]9;S$7?,"GPRS'X
M8G/16>8<.SEF)LO;;%CIR49L?#$;$@*^7%R<I64JZEF4E,#$!V8S?M61FN+%
M(QMW(UU,XR_PXJ[CZ5/%2NL&$+AN%Y!-1-I_5,\\->;1E-D$U MQ)LATQ7D;
M&FZ*Z/I'(5UJ-JN>0XO!]28UDC#'=3G:RM;5,AN$I9N,1;:!'*LIM>EN#'L@
M-8R';@JJY<1R3)N#)JS[6,N8"A<2BLVO6IMXPP[KS2MV4-#%U\?6?<95?6ON
M8--&21%C'PRS9LJ>I"VNL,%AM\OQ#A.-\]1L9'*T\G?R];V;\15L367A\7=J
M'G[F2O4L:FY6R?#]99Y&]B+GV?G"51H4;%!]^S5J8];$+JV9H_\ I8Q,J]?R
M$EE<4)C<9,N'\2O5: \;+XS>2,,C D:O7];<.(NNH0HOUI0B2\6^!1$XM;-$
M.VR<;,\*/L,DXM!ACS-7#;0LN)]M>V7$KYM<Z$N7#G\X5XJ0)0N8<'-4OJ+D
MJ_0JY<9KLYEY6.(^F[C*NVFB*.)-?V 5;&K3205C'/-%$V6[#+L\@O":#E#E
M<.7/8L27F><W4DS$$)0XZ4_ADYCX1N@>(B8%W%O(A]$6H+Y*3DW(04C,Q5QA
M)%*KIT>+CGK>+DB.G@R<?)]74SY&/3AVXC)%>/:] Y* $C8#%0%6B6%C'@MB
MPLS<N'>5E?$B[H5@":_ACB'L[O$%OC)/%.(5AUMC"D&)DBKUJKJ[S;D;X<2%
MF;%BN^Q1+&X<*%KAZ*+*XVLDQJ[@9%,^#7#5=QW>,8;!FD+$X@L-RS-,B5^]
MKTQ5X5Q.-[S)O21@6^PQ3!BR9R!ZY&H-GJ3A=J[>O$X]F5=5TN;S1[>8LT\I
MQ;34.051PZQ55B[4:V5U,<5<W7UUI8;)2ZV;;2N1<K6-BR<@*1WY?(\/XO)\
M.>RO(LGAZ[G.)[+K62;C,E3J1<R.<\4NKC;5]5:HI=A-%%:BR6L0]S:5)<-Z
MY>;2N^&VO^AY%XUH^WV]NYJDV&C1L:O-T9J2WV9PM8(2WY&M246L8SF.C9*2
M*^\]151 'BZ)FB+8C-%J52U&2-G&6-R;\G334=9(V BV1UJ6,Q]:W0Q=2PW>
M>8UJ.)6J9:4BR'M.7-9 \RQPTA?LGR6!QW"V6LY.O5K*6=W#@K)9+.97)U,I
MG\C7JE RI#7"9,L"*%C.]5"0K(5!_3+>.LAP&XZM6+$^(+,UIRQ<%J2!X;'=
M<?UTC5MD"4LUR*[0E(YW])DX=&1/*&=Q01\FPDCF],[ZNI,V&#N5YI7T9+(5
MS:-S,^&FQ=>L]@X1=B<<Q+E,!A).Q**.Q$:FU28#%FL=QSXOQ&11G<19X<X=
MR"ZI8[A<K 4,'1=5*?\ T@8S/Y2K=39KM6ER*:[V4DDBFW6R2Z[*]@',(6,^
M'C]Z33)N3<IK4ZW)7V9HM>K#R=3IU53;0T5&Y7??66.-V@1CF,L[^,H;Q*1K
M![4UFUY!T=PH_%^*!(XT@7#XXC'T!LJ\*>4JWK2R<R+;WMX9*".\'- U4EGU
M+IW9IPGHX^88N5M+Q0RT>/?\39[,?9V0G)#@LEC:%D*%/P%.FCC0"4K$LZ,_
M:%V.%'LR>-')>,&QF0-#@;7'P)=3<'/\DR>+ZJ]RVT(SO:S5?ZNF*#=H[52*
M[7)&NI1DR0:L6,PZCBM7$JR8MD&39\HNDV112*5(GD\L%(+S!H2$HZ:)(5&Q
MB%V20N;:JS6D;6UEV9:%=C3-A*@9,V3N9?7.%FYAV%K,SHLB_++,05A:47'4
MQLM&@^_7KJ17KWWTX2VXBNE2%V",5J4.R@EC7-UZ'7$OQ1,OW''.Y3877JTG
M5#QUUR X8SAK!1*9;'Y4"WW%S$/H\I9H.6D:\MY$DY$7,$YCW K W<"KY[1J
MHE\G]H64M4,]P<BO%:0MW2!W7IU;)Q'C,>'[IEA+#3.S"]Y1!._*6^XC,?OC
M]D?@C!<4^RO]HK)94LR-K \-K?0C&<19W#5Y9/#G%UC_ #U3$Y"G5R:X955^
MZR";*X"6*@.FYPG.LS3UIW>#/7&R[=;D^JE0%&N8_>,*:U4A;C9[R+9C?LEV
M6QF$"$B8B&!&)C4GRRJOI6[U1JT_MTBA^B<48JX;<D,O4KVLHUX6$/L$$X[$
M8\G7$UEHVV.UE\C)O9"XGM-862,]0M?R?SB)L^TFOD+'!^8LTL NB>.R%+%+
M:K,\0Y=-7'6,G9O<XRNEP[A@14"7D&QQ=E:V2E4E'%NP7)2="W_L83 LTWG+
M9)*)8@!*D,F+B99+U>$KARU10A4P(U-*,%G1R$,@06Q220E_,!M6:&3Z2/9P
MQV3'>EQ$J]F *R9MKU?\4AF1.V,S,Q(8^"#:9(@9,U>TS(ZYMWALBL>W9-/A
M5ZHRO#+:/##58M*57[<<#VL 2L48B,;LR3(@=H6+ *+/EL6H\R=6]VUCQYE/
M'<9CN\&I-QD[R==-KCJE-K-:%V]1IYJ/'2QDX5N*<">2:S:*MC;I(68SZ+AV
MCF;*@*GJM] L*NSB+-FU4FU1=C;"QBY8BHD@XM>W(69D63(65XJ*UE%8"&HZ
M'6S8AI; /.X@3QQ<PO$N*I8O+QCLK6RU,^7$8Z,C84S@"LG$8[8Z_O8]^<*[
M4OWS%F1K,120J[641D=V,2S>Z4F8*] 6. ?1V)6D%Z%RQ?1$0T@HVNL:571K
MDFRG4XG\2.+^YMAIF.GX)[,+PS:*03.W8,UB ]7YEP<$VEEK$N!F0.Q::I@L
M9UBO'G+ A70F&#79B#PDA:FT29L^.Y!A\+(J\^RP3N.$9OA^@VH]&!3C<97?
M7.M7BBO&*X645BW8N$F;Z^)5<4@% : VO SB2:R:1.$<@%\=>1U]9T:::---
M&FFC331IIHTTU!VYR8>UW;9N%L$<#09""P=EF88 _8,I5B+V,H4^]:@]BY)N
MZCI)H*Z"8.6#]JY9/$>MNZ;K(**)FY'$#31@<V]?+U$XC)-#G &!SKIN,>=;
M!);!W&.8#$@*-Q(9&9C7T#V34493VJ>S3&VI=%7(^T#@VC9FM9L4[$(M\1XV
MNZ:]NJQ-JJ[IL+I6:SE6$,Y6I8#!$HYE45U;<S>'GLXLB^/7-^L1\G4&YSC"
MB4&#291T!4<MR;RPND*[!,HR'BVYX./.D+./9(%DEQ.D*2JS@XGM^Q[(D5+
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M(B14?TJ;KKX[^.9NSO:_(ON)&#=F<(J&<Q#X#&]9&+"=DYZA\]$_.JBK5E$
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M9ZRVQ[?6CQFNBZ:.VV&\=H.6KENH59!PW72KI545T52%5253,4Z:A2G(8#
MAN+B'/F)"6;RQ"43!"61MS!1,3$Q,2[:8F)F)B?.)G5-?LU]G:F U7 ?!JVJ
M,6+8OAG# :V 4$!@8TH(3$H@A(9B1F(F)B8UMS&T_:W89>4GY_;=@>;G9R1?
M3$U-2^(J!(RLO+2;I5[)2DG(/(!9V^D)!XNL[>O72RKETY55774.J<QAQ7GL
MXE:U*S.44I0"M2UW[0+6L!@0  %L"( ,0(B,1 C$1$1$:V6?9WP!=LV+ES@C
MA&W;MO;9M6K/#F(?8LV7L)K[#W-IDQSG-,F-:PB-AD1F4E,S*M8-MNW>VM*^
MPM6!\-V5C4XH(*K,Y_&5+F&M;A"JF7+#P+>0A7"41%E7.=8&# C=J"ISJ EU
MF$1UIS.8KDXT97(I.PR6O)5VRLG-F-I8V09$L9,1$29[EM$1OM&K%S@;@K(K
MIIR'"/#-Y6.KQ4QZKF"Q=E=&K!2<5J@.JF-:O!E)0E, N"F2Y=YF=)Y-K&V-
M. <55/;M@TE7=S#*PNZX3$]$+!.9Z-9/XV.FW$2$"#!:681\K)L&<BHW,\;,
MY%\V16(B[7(IG.=S<M%\YC)R\5DD73?M=45&0&:A9U>:%F:P(@B>4B "F)D8
MF-,>S[@,:9XX>"N$XH-LJNLHQP]B8J,N(4Y";1UXJ=$K*4V+"5/()8M3W+$H
M%AQ.8G:SME@"2J<%MWP="DG8IU!39(K%%$CR3$(]Z!>0\H5I H@_BW?EI^I8
M.@5:K]!/-2-TAP9G<VZ5RW,91DJ8+E2R_:.5M#?D8$DV>5@[SRF.Q1O.T]]3
M6]G_  )3BQ%3@OA2K%NNRG;BOP]B4Q9J-VZM:Q"Z@]:NS:.=+.99;1S#.T:^
M<'M4VP5F7CK!6]N6"J_/1#I)]%34+B6A1<M&/41Y1=Q\BQ@$'C-RD/=-=NLF
MJ0>Y3 .I;GLX]9J=F,HU3!D6+9?M&!C/F)@39$AGUB8F)]=8U/9[P#0LHNT>
M">$J=RLP6U[57AW$(L(:,[BQ+E4P8I@SW$P(2B>\3J+=Q&T3;A<\79SD5<-[
M?Z_>+70<FO5<J6/'=$CWD):IVNS:Y\@3UQ<0Q)!DYC9=T-BE+*N^(\;*HKRB
MKLJQ#+!RLSE,S8X?RN,'-WJU9^'O48AN0LKIUT-I-KQ#!EL+764LO?C: !0S
M&T#&O=>S?A7@?$^U;@+BYGL^P>8RF,]H7"W$9C0X8QEW/Y6_2XDHY,AI2-,[
M5O,7K"IBM,$5A]UH3$DP]YB[:'LKVZ1>VC$$-><;[;\Z6.&KC]@[R@RI-"R!
M'69/\2SKI!6.MCN*DU91HS3=>@ P/%2(KMET"](IB4.;P3>S.%X7Q.-K<06G
M*K); NQV3L%3;)V'')))3NF4>]RE([^\)1YQKV'[2F'X']H?MNX]XPRGLQQ^
M*N9C(4F'C>+>$L?7X@I"C$8^L"<A7NT8LH,H5UU+9$?N7+(8V*)FVKC;;MW>
M52.H;O ^&W5'AY-W-Q-.<8RI:U6BYE^3RWTM'P"D*:*923Q/\CI\V:)NG!/R
MJJG#MKT@YK,#8.T.5R(VFK%3+ W;,/8H>XK-L-YR 9[B$E(Q/E$:^.'P-P4S
M'(Q#.$>&68FM89;KXP\%BRQ]>TZ.5ME-,JLUU/;'9C06+#CL13K0B]K&V2$;
MS+2&V[8-B6ECBQ@[ VC,3T1BWG847K*2&(F$6L"DG)1@R,;'OQ8/"K-1>,6;
MD4O.;(G)DS.YMLK)F8RC"2SJID[]HI4V!,(8N9;,@?(9AS#L7*9#OL4Q.FO[
M/N Z@6EU>"N$ZR[U>:EU:.'L2H+=66J?-:R*Z@B]'70EW1;!KZJ5,Y>=83'T
MK>UW;13IR,L]1V]80JUDA7)7L/8*[BJBPLW$O"E,0KJ-E8V";/F+DI#G*5=L
MNDJ!3F*!N#" G9S-65&BQE\F]+1Y6)=?M,4P?_*:S;(D/;R*)C4T> .!<9;1
M?QO!G"N/O560VM<I</XFK:KMB)B&(L(J U3(@IB# Q+:9C?O.D^0VD;5)9^]
ME)7;1@*2DY)TX?2$B_P_CYX^?O7:IEW3MX[<5Y1=RZ<KG.LX764.JLJ<RBAS
M',(CF'$&>6 K7FLL  (B #D;8B C$"(B,.B!@8B(B(B(B(B([:U.]G'L]LN;
M8L<"\'O>]AN<YW#6&8UK6%)L:QATY(V&4R1F4R1%,S,S,ZW9K:SMDLKAFZL6
MW;!L\ZCXJ+@F#F9Q11)-=E"0C-*.AH=HL]@5U&T7$QZ"#&-8(F(U8M$4FS9)
M)%,I P7G<VF"%.8R:A-C&G"[]H()K2DVL*!;$2;#F3,Y]XRF2*9F9G6RW[/N
M [QJ9>X*X4N,17KU$G:X>Q-@U5:BA35K+)M0R!%9("I"1F%I4(K6(@,1&^XV
MW;>'E2CZ"[P1AQU1HB4=3<53'&,Z6M58R:>D%)Y+Q]?4A31+.3=IB*;E\W:)
MNER")553%'C6 YG+C8.V.4R(VF+A3+,7;,/-0]Q6;89U" 9[P$E(Q/E&MQ\#
M\%MQR<.SA'AEF)K6&6J^+/!8PL>BTV.5ME-,JLUUO8/9C07##CL13&DZ+VK;
M8H-&9;PNW3!D0A8HA2 L",9B:AL$IR"5>L9)6%ETVL"D22BE9&+C7ZD>\!9H
M=Y'LG)D16:H')FS.YMLKEN8RC)2R')D[]HI4V!,(8N2;,@R 8808[%RF0[[%
M,3IK^S[@.H-D*O!7"=8+M8J=P4</8E(VZA-4\JMD5U!A]<G5T.)+8)<M2IDC
MSK"8]U[:UMEJ,Y%V:J;=\'5FR0CM-_#3\!BBB0\U$OD>11>1DI'P+=\Q=)"(
MBFX:KI*D$1Z3ASH[.YNPHT6,ODWI:,@Q3;]IBV!/F)@;9$AGU$HF)^&II>S_
M ($QMNO?Q_!?"E&]48+JMRGP]B:UJLX/X6HL)J U+!_Z368E'I,:2W&S_:8[
M76=.ML.WMRY<K*.'#A?#6.UEUUUCF466654KIE%555#F444.8QSG,8QA$PB(
MYQQ#GQB!'-Y:!&(B(C(VXB(B-HB(ZW:(CM$:KG[-?9TPS8S@+@TV&1&9GPSA
M2,S*9(B(II3)$13,E,S,S,S,SOI9L&V+;;;#Q*EIV_83LBD! 1-5@CSV+*/+
MGAJQ H"U@ZY%&?P;@T?!0S81;Q42T%%A'H"*31NDF/3K6G-YFO#(1ELDF'-8
M]L*O65PU[9YFN9R-CG:PN[&%N1SW*9G5JYP%P/D9K%D.#>%KQ4Z=?'U)MX#%
M69JT*8=.I2KRZH<IJ5E^Y7K+Y4I#W5@,=M#G;#ML>UR+I[S;[A-U4H.0D9>%
MJ[C%E'6KT1*S";9*6DXR&4@S1S&0DTF;1.0>-6R3AXFU;D<**%03 H<WF1<R
MP.6R8V&@"VO&]:AK%KF96!LAO.0!)%("4S R12,1,SO!\!<#-HU\8S@WA5F-
MJ.?9JT#X?Q14JUBS #9>BJ524J=8%2A<Q8";86$&10 [?&)VL[9(!&:;P6W;
M!L,A9(=:NV%"*Q11(]*=@'#UA)+P<RFT@4B2<0M(1<8_5C7H+,U'D<Q<G1%9
MH@=.69W-ME<MS&49*60Y,LOVCE31 UBU<DV9!D PP@QV* ,QWV*8G&M[/^ Z
M8V@J<%\*50O52I70K\/8E(VZ9M2\ZED5U!A]8GUT.)#8)4M0IDCSK"8S7=K6
MV:H3<79JIMXP=6;'".TW\-/U_%%$AYJ)?(\^4\C92/@F[UBZ2Y'RW#5=)4G(
M])PYT=G<W84:'YC)N2T9!B6W[3%,"?,3 VR)#.T;B43$^L:FE[/^!,;;KW\=
MP7PI0O56"ZK<I\/8FM:KN'^%J+":@-4P?^DUF)1Z3K4E-I>U>;DGTQ,[:\"2
MTO*.W#^2E)/$&/WTC(/G:IEW3UZ]=5]5RZ=.5CG67<+J**JJG,HH<QC"(Y!G
M\ZH 6O,Y5:UB(  9"V(  Q B(C#8@1&(B(B(B(B(B(VUJL>SGV?6WMLVN!N$
M+-FPPW/L/X;P[GN<PI)C6M93(V,,IDC,RDB*9DIF9G6Q,;5ML5A48+3^W3!D
MVK%Q$9 1BLOB:AR*D=!0K1-A#0K$[R!6,TBHEBDDSC8] 4VC%JFFW:HI)$*0
M,5YW-I@X5F,HJ&,-QPN_:"#:PI)C"@6Q!,84R1G.Y$4S)3,S,ZSM>SW@*Z2B
MN<$\)VRKUD4T%9X=Q#R33JK%-:JJ65"E=>NH14A(;+4L1 !$8B-"^U;;$ZAF
M%<<[=<&.*]%/'TA%P2^)Z&K#QS^3*W))/6,8I F9-';\C1J5ZY0136=%;H%7
M.<$B 5&=S8M-PYC*0Y@B#&Q?M0PP#>0$CAO,0AS%RQ,S \Q;;;SO)^S[@-E5
M-%G!7"9TJS6NKU#X=Q!5D.? 0]J434E2V.A:X:8#!,@ @YGEC92@]N&WJL0]
MGKU;P3AVOP%V9M8^Y0D)C2F1<1;&#%55=DRLL:QA4&<XT9K+KK-6\FBZ1;JK
M*J)$(=0XC@W,Y=[$-=E,BYM4B.LQMVR;*YG$09),F22B*(B"D)&2B(B9F(UO
MJ<#\%T*M^E1X2X9I4\JM:<I4JX+&5ZV12DB-2KR%507;6HC,E@\6"!$4C$3,
MS*5"[4]K];EH^>KNW'!,#.1+E-[%S,-B6A1DK&O$1$4G3"090"#MHY2$1%-=
MNJFJ01$2F#6QN>SCEFIV8RC5,&1-;+]HP,9\Q,";(D,^L3$Q.J]7V>< T;*;
ME+@GA*I;KL%M>S6X=Q"+"&C_  L2Y5,6+,?0P*"CTG2>KL\VDKJ*++;7]O2R
MRRAU5E5<,XZ44554,)U%%#GK@F.H<XB8YS")C&$3&$1'G6<<19^(B(SF7B(B
M(B(R-SM$>6W[[TUH+V:>SDR(SX!X,(CF2(BX8PLD1%,R4E,TMYF9F9F9[S,[
MSIR6W;;MWO\ +%GKU@?#=SG"LF4:69M>,J7894L=&H@WCF!9"6A7;L&3!N4$
M&;4%?(:H@"2)"$ "ZT5\SF*B^E5RN1K*YB/IHNV5!SG/,9\@,$>8R]XBVW*=
MYF9G5[)<#\%YBQ%S+\(\,Y2W"E(BUD,%C+MB$('D2F'6:K&=)(>XI?-R+'W1
MB([:T%]K.V1U",*RYV[8-<5R*?/9.+@%\4416%CI*2(@G(R#"+4@3,FCU^FU
M:D>NFZ":[HC= JYSE23 N<9W-BTWCE\G#F"(&V+]J&& 3,@!'#>8A"2*1&9F
M(F9F(C>=:3]G_ ;*B:#."N$SHUG-L5Z9\/8DJJ'O@!<Y->:DJ6UPK6+6 $&R
M ""F8$=MZ$VV[=ZS$V:!KF!\-P$'=&+>,N$-"XRI<7%6N.9K'<-&%DCV4*@T
MFV35PHHNW:R23E!%8YU4R%.83#@W,YA[$-=E<BUM8I.NQEVR;$&40)$DR9)*
M(AB!F0D9F(VF=M;JG W!="M?IT>$>&:=3**!&3JU<%C*]?((6<FM-Y*JH+M*
M69$8+>+!$BDAB)F9TE0^U#:Y796/G8#;?@>#FXEVB_BY>(Q'08V4C7S<X*-W
MC!^S@$73-T@H4JB+ANJFJD<H&(<I@ =;&9[..6:FYG*-4P9!BV7[1@8E&TB8
M$V1(9CM,3$Q.J]7V=\ 4;";=+@CA&I:K,%U>S6X<PZ'H:$\P-2Y5,6*8!=Q,
M"$AGO$Q.M);9]M+<K*N'&V#;VNX<*'6776PUCM59994XJ**JJ'KICJ**',8Y
MSG,)CF,)C"(B(ZRCB+/C$#&;RT#$1$1&1MQ$1$;1$1#MHB([1'I&M1^S3V=,
M,C/@+@TS,B,S+AC"D1$4S)$132F9(IF9F9F9F9F9TY+?MPV]9!E4YV^8)P[=
M9M%@RBDIBV8TIEBE$HR.3%*/CDW\O"O'1&+%(139M"J@@V3$2(ID*(AK37S.
M7IKE53*9&LJ3)DKKW;*0DS[F<@M@CS'/<BVW*>\S.KV2X'X+S-@;>7X2X:RM
MH4JKC9R."QEVP-=$<J40ZS58R%)'LI<%R+CL,1&DY;:QMD<0;&L.-NV#5ZW&
M2#Z7CJ^MB>B*0K"5DT6C>1DV46>!,Q:R#]NP8H/7B"!'#I%FU374.1NB4F<9
MW-BTGCF,G#C 5FV+]J&FL)*0 F0WF(!DRD1F9B)(IB(WG6@O9_P&=15 ^"N$
MSHH<VRBF7#V(*JFP\5@]ZJ\U)4MS@2H&M$(-@J6)E, ,1AEM6VQ1T7,0<?MT
MP8QA;"# )^(9XFH;:,FPBW!W48$NP1@2-9((YTH=RQ!XDMZ1<YU4/+4,)A%G
MLV;%M/,90FJY^DPK]J37U(Y6<A2V2#G&($^68YH[3O&BO9]P$FO:J)X*X355
MN]'QE9?#N(!%KPYRQ'B5#3A;NBPB-74$NF120;3,SK;JFV7;A1)YE::1@'"U
M.LT:1ZG'6*K8NI$!.,"23!U%2)&<M%0C1^U*_BWSV->%07(#E@\=-%@.W753
M/%C-YFTHD6LMDK*#Y>=+[UEJBY#%@<RV-(9Y#$3'>/=,1*-IB)ULQW ?!&(N
M*R&*X.X7QM]$-A%VA@,53MIAZ65WPJQ7JK<N'5W-0V .(8EK%EN!D,H:^S_:
M8Z76<NML.WQPY<JJKN'"^&L=JKKKK'%199952NF.JJJH8QU%#F,<YS"8PB81
M'6R.(<^,0(YO+0(Q$1$9&W$1$1M$1'6[1$=HC51GLU]G33-C. N#6,81&PSX
M9PI&9E,R1&14IDB*9F2F9F9F9F=*<]M9VR6J47F[/MVP;8IET1!-U+3N**)+
M2;A-JW2:MB+OG\"X=*D;M446Z!5%3 D@DFD0"ID*4,%9W-H6*D9C)I4/-(K5
M?M  R1213 BV!CF*9*=H[S,S/>=;[GL_X#R%@[=_@OA2[:9 0RS;X>Q-AYPL
M!6N#:ZH;"@%B(!$E," B([1$1K>D=MNW>8K5>IDM@?#<G3ZD>14JM5D,94MY
M7*TI+O'$C*G@(1Q"J1L.>3D';I](&CVS<SQXY7<N!4664.; ,SEUO=97E<B%
MBQ 0]X7;(N="Q@%]5D,@V<@"(!SS/*(P([1$1K<[@;@JS0I8NQPCPR_&XV7E
MC\>[!8MM*B5EIOLS3JG5)%:;#F,<Z4@$M:9L/F(IF=%CM9VR1<7,PD9MVP;'
MPUC(Q3L,2QQ11&D9.DC'!G4:288H0*;62+'NCG<,BO$E@:KG.J@!%#&,.9YW
M-L8MIYC*&U,G*F%?M$:I8/*<K*6R028^Z7+,<T=IWC6E/L_X#KU[51'!?"B:
MMZ$Q=K*X>Q*T6XKG+$194%2%OA+"(U0T2A9S)#M,[ZVJGMGVXT*?8VNCX"PO
M3;1&%>%C;'5L7TFOSL>618.HJ0*REXJ$:/VI7T8^>QSP$'! <L7;IHMUH+JI
MGQL9K,6TG7M97)64'RR:7W;+5'(&)A)+8T@+E,!,=XG8A$HVF(F-F.X$X(Q%
MQ61Q/!_"^,R"(;"+V/P.+IW$PY+*[H59KU5N7#4-:EG(<<ZF,66X&42A.-G^
MTQTNLZ=;8=OCERY64<.'"^&L=K+KKK',HJLLJI73**JJJ',HHH<QCG.8QC")
MA$1VCQ#GQB!'-Y81B(&(C(W(B(CM$1$.VB(B(VC50_9K[.F&;&<!<&FPR(S,
M^&<*1F93)$1%-*9(B*9DIF9F9F9F=]*,YM6VQ6>15F+)MTP98)9=-LBO*3>)
MJ'*R"R+-NDT:)*O7T"NY43:M$$6S<AE!*BW2313 J9"E#!6=S: A:,QE$KB2
MF 5?M $21293 BV(B2*9*9V[E,S/>=;[?L^X"OO*S>X*X3N62$!*Q:X>Q-AQ
M"H!6L2:VH9R*UB*PB2V$!@1B!B(T/MJ^V*4C82&DMNN#)"(K3=ZTKD6]Q/0W
M4= -9*0<2TBVAF2\"HVBV[^5=NY)XBR303<OW3AXL4[A910P<[FP-K S&4!C
MI$G&-^T)M( A8$PH;$G(K$0&2F9@!@8[1$:.]GW 5A%2L_@KA-U:B#54J[>'
M<0Q--;W'9<NJHZD@@'6&L>T5"(FYAM*),B*7SC_$N*\3M9%EBW&M!QNSF%T'
M4LTH=/K]1;2CEJF=)LXD4("/CTGJ[=)11-!5R511)-0Y$S%*8P#5MY"]?("O
M7;=PEQ(K*U8;8D!*8DH"6F<C!3$3,#M$S$;^4:ZV&X<X>X=6]7#^"P^#59,&
M65XC&T\:%ABXD0-P4TI%I@)$(D<%(P4Q$Q$SJJ&[KG\25#CV^B/A'_WX/]^/
MD>/U'53Z_E^/U]^NL>WX^4?#S^MY](\_2)J&/'L'M\\\\ /ZCWX]_C@>?<=3
MMZ]OS_IY_/X:QB?6=]Y\MHCO'U'KO\H]8SV$.0#O[^X!\_//'(<_;W$..>VG
MP_W^ON^.G>-XGR[QWB?AZ>>T[1VW\H[[;:Q[<<B/MSQSQW#X'GOQVX ?\_O&
MIW\]HCMYSY]I]8V[;]]YCMZ]O/; \\B/P(?KP/;X'CO^G[<^P:G^?RV^_P H
M^_\ 3;0=HC;?RG?OZ=]OCVCMWCY[1/?6>..W_-'YX[@ \^PA]^?GO^GWC2>_
M?_JCTW[3/;SB?AMWV[=O/X'8 Y'N/V[!R//N/'L(<]_\]3Y^OE'K_+4=]YB(
MG;XQO/:8V]?..T=_EVWUCD.X#WX]A ?GY[C_ "_3MV_5W]/7M\=_+?\ T_O&
MLIW[;=O6=X\HWG;R_'?OZSOM'D< (>_?@.1'GY^!^/V]Q$ ^VFVT;[QWCR\]
M_KY_AWCM$3.\]IF(F>T1Y;>L>OW^G?Y[:.XCP)@]^1$!_;C[!\  >X@/(Z3$
M]NWRC^6V_;X?SGUTWB(F8COMY;?G/K.W?>9\MMHWT"  '^+[?KP AWX#]>>?
M]NF\_7RCMI$[[^[\?QG?>._GY_[1$=@ X'V[AW^W(#^@^W'O^_8?C3>>_P"?
MX_'\?+\>^DSO$3';?W>W?;Y=O.)_/;O'K&HWRSA5WN'ICK#C*Q,JFZNTQ5V"
M5@D&:C]G&BULT3)>:NS1<M5%P.5F*(%*X3X,H4W(@'2/<X<RPX3+ULD:#LC7
M&P,I H BZU=B.Q$)1'++>;^&9[3';>)CP/M-X.9Q[P5EN%4Y!6,9DCQQ#>L)
M)ZD^"R=2\4$H#41=4:O2']Y&Q'$]^61GH+X?6T62V:8DMF.)2^1.05[%D:0N
MR<O#Q2\0V:(O*S5H$(U1NX?R!U%DSU\[D5@6(4Q'29/+ 4Q.>YQ;Q '$>01=
M"JRI":85I6QD,(I%[V\\% !M$];EVVGN,SOWVCB^QKV;O]F/#F1P=C+ULR=W
M-NRL6:M<ZP+%M#'TX02S<Z9(9I2SG@HB89$<L2,S-\->6U]<T:::---&FFC3
M31IIHTTT:::---&FFC337%SQ-]O^9LO[CMBMKQGCRP7&N8XOSB3O,O#I-U&M
M98&O>,I(KJ2,LX1.1(6,/)N0%(BIO+9K#QR  /RKC_"Y7*9WA"SCZ+K2*%PF
M7&J@>6N$W*#.8^8HG;D4PNT3V"=?N_\ 9.]I/ O!/LN_:%PW%?$V-P>4XHX=
M75X?I7C:+LK8CA[BNI*:L+48D<6+M16QD$<[PC?:9V?%YW>9@POEO/Z&<)*;
MK%(K,'DVWXBJ]7Q;6["G?\=TBL1TBI8\?Y(>7"+K[^^58RDG+7?&V17E5EC)
M-$RUQK(QARNUOI>-L0S%MBX+"S$9)5:RD0A,T$9+BL\-A[]:"+H97".H6,7X
MRU48[(X^^^PNY33 H6W\.A5:[.8Y"%*/&6IH(KL-I].[?/%C=MXJZQ<%8Q62
M?<1>1CY-(XZW0\*]-PG^,&M*H^)+B>,GLE5B<QIGAHIBBKW&?EK,K5:$ZAK<
M>@TBLW^<CJBW@<DRTRXEG=6M<1+,D9:%@XL@K+LGLFP=-5$0W67BFGD,@220
MNED&T9JM=72<ROB8N%C?XNT]..KT$9&5,L7LC>I)K8]L7K1)4FYX:CCULN#B
M! Y<.3I8>R%R5% 1]LXF]EJ,-KI%EGQ%E6*RBAK4Z]HO%TR0J&#8HLM0.EXI
M]35>0V=I:*NU!VPEPYEBQR\3<H_$3JP35FH>0,84^%L-0NM'RO<:*^K4Z]R"
M,&B_?75A70<-@DG<FQCT7#THSFBO+%> S80<"%AJD#X.X#N*LOQ7AY1:'(S2
M0L;+,+4MUVV7J!=0CL=24N5S:@<-RQ1KTH+93^*XREKD992:,#@\+FCFLNF-
MFTPZ:;EH;"TUC>U^U<%&Q<QJ7+1X@^*\F[>D\A[>\L4Z*R2\CZ]<F..+#*4.
MP7Y.IHWJ,K5C/(5."M4^U<1"PJ.XQ.V5Z5F8 5%47T1,OD3(*J;B4P<G@DK(
M;56QG.&*F4A*W"2:'$CJR419AZD6<=8)=U%A(VDJ810L9"5M@IU^-3%#*O.(
M2]%+B *,.:F1?D<-6ML/PQI:Y%Y:CIN)D5VL"5J=S$!*9 +E@\2G$]2N=^HL
M_C3+B4CBVP4*'O\ ,QSS!4W6JS"9'>V2)K%^FY*$SA(J0-4<3%6?Q[^/GVL5
M?88SN)?2M*:1,BA(C3KW4V:*\B,$NNR_D\5//*S)64QN)KYD<;)UV/0^UD*5
MCEH13=:2=I+:EIU1\H!W1L5G59$3Y&$>/#)5X67*=NJ-VE0NM0A_1LB..=?K
M'8*RFN%A1.G&'D&5+:T1C/\ C';8:U;9^A2E.S*2\56HQ%OL=.;LL2N;3#MY
MF#@K:WC'5?1R^:6.]3I=EA+6I(MFCBJKM7AZ_'V-]>&4A5&EBL8VR9")YP7F
M*&#)HQ)KC(7,I1P+E%TX,U_9N>OKQ%P6@#7/58NXM>2PZXR9TK3HJ8^ODG#(
MU[>+R>:JP1I4Q^,QP9EZ;2NNU2RC*5,%?N44]3KUZ_AOME6)=:2DNH=3GE[1
M6X:PN:].U1:88HOQKMG"'+/Q1%P$R3>5) S$]$I.A2Z%3I-)=Z"15"IK'3<$
M612VL62R@#Y89TU$P!(3Z+36!MKF822F-K,(J[F5V.JFU1E5L6:\J>S)31<$
ML"#A<L:*C,"7+D@TP3:!9P+EJMJ$+*%V5HMK2U87*M6T+JRG#K#6S1IIKF_N
M7O&Y9GN:J.-,/YLJV-:O+[;\LY:<,K1C.!MC$UFQ?::%%-49&;>R#*29P,XS
MNZI9;THE<,0C$%V*I3K+\\KQS:E?CS(.A5E7"F/X.RM6HSF0%A6?CC@+U-KU
M3+(D)X/4RLX8DH9D' 8D"E1KH364T>&E##5,S66RV*>]6S6+\'6QEE%A*3CD
MED3D9 UE[ABD9B8(IU4S"_B$9;LN.L\9GR;D"BTRMQN',#3V/H>RP-?K-8I5
M\S*:Q0RDG-V^1E6:LQ4(R6@DYIJ:4<LS+0#A<5%Q4*B;75RJ2K8ZXFM;0C)6
M^-RP.(MY+92Z=%O"/"7& 5KR%Q(3?K(XGLXXYG:#LXVL!<IV7%KCT'F[+PBP
MJ6U,9P_<O9(:8/:.1N8_B?B7AF7U#4NQ830R+^'4V$,!;80G*&YDPBM!1<*B
MY6F=WOAP7>RP<C7<@Y%N.!LSXWFE<=K-GM:LF68*NVW'\Z2G+HN5V;N$G[7'
MJNZNY;O%F3Z'DXQVV<G:N$U!T<74I?A;TX^I:4K/<*KRF,I6=O&)#.80;2L=
M9[\L7J#[!XRZ$S^[O5;"BGF"=>Z]C^8I8?VJ<$7\S?KHH\*^U3!1E<F<A"%X
MO"\6TK"\NX4$Z$JN8,*N:Z,23$U[8 0P8R$0!0R[J=M/AZ[78*GTR?@+=59=
MPTS;',:E#7W(E+Q\,U>)A_+5S'DC-Q9;B[;KG@EI>(@G4C:0K3F2>5F&EYA!
MNQ4\AP>JSAL'P]6S MQU6ICLJ>1,ZS+(U[BVRS'+R05(;=1B70QWC;U!%AU1
MD5":*J9VK*/I7[2V?PO&GMJ]IG$/"60I9VEE\OASPMU%F*U>_6C%XNM?/'NM
M JJ>07T&KIU\@RI4>8.$WPP4@V2O_E%JE3AJJ4K$96S:YL-3PN#![B:BX\BJ
MY9YC*Y;L:)LT"A=\I5BT1;-Y)5%]79: LK*.>5J019J+HJLEI.18^W>U2W/2
M*6",7LK76XGU7KY,-P=6XR<:WUFFBQ4R&!BYE\?<41+8%=U9LH,J W/ST-A,
MB#)?$"R4LE9(L*;7#(\8%PA5K65-2#AN4,LRMC[R 63)-G66MDPY:4_)7B=4
M->1_A5BVDY?/D^WX?DLDU.S*5_%R]<J+<*',W9K+6ZNSF5(RZNH&*1B#QTU8
M8"G6&G)3ZS>L(6)S/.46!JC2<^,P%)@!]BP#[%U@R=4Z\,P\C,0(G8K%D0S-
M16-5D:]*Q=YK%FJIE6C=L5^KC KO9PZZR)%6S^01157!@+M0;LG=Q;A'F,4N
M=39C[5JVJFZT=6H*+%H5*N59=O8D\53;3-VUEAO)5^C*ED:L8TKUJR7=+++4
M*I8YB9YU2:W<YF-<ED;JG;H))O$V:+?(STS3XZAOE72L-"VZ4FXZ2C6?6<-5
MS<RZH8HHX[(W*:9L- BL>"RL86Q"F+)H*:G*<]0*F0.EDK@*9?HT[6-B+L\O
M=U::-9XMLV;,1+2179 UA:FU;JLL\PK"0LTZXNZM*;=>N;Z]:XVM:;"(5[-O
MTAL-6G-D[D)RZR+AZ-O^%XG'=DQ\ZQ*R1@JYE6@UR8;/G3FV9+ISN_1;B;E0
M=,5J.UMEF<,GI 9P+MNB10>9CV,8].'O+.OE7\;9CA9+6K(8)@T^&+^,IV**
MH;>584SB$Z+'IIL0*:L7,@VJ,.9&NQ;6,9+)H>E^'H<$XOBHA04,(U3;XL1D
M+%>V7+3:MU;A]-E"FVE$;G37J0XC6$^KSXI6$,9M\E*Y QQF:GKXGL#BM7!G
M84\,Q1F+]U)5V+I;M21>9G1@F$#DIS9XX].LTY+1%>0;(R;FY2=12C'IDM:[
MB65<?:C<?M&P5!:#)0,KY=#+L7L+;83(J)RM"ICK>3;7BR8VL=%9V+;D&9'&
M)N=)B34UX%$DNO7"Z5A2W.4>/:N21D%BI1V)JOL=.B',@7C<:2VI4NID&TY6
MVS;[,9;K[(]@L6T;*98Z,J<#;I*YSK+'Z=-9L[*U]1#QQ9.!R)8'LA*NED9!
MEY<3&2#$JL6Y=B_^D.HF2DNH-4RK6;<E"TU[2ZB^NNPAULW4ZF04::SDA82$
MT[J'&%]5.P@NI6L(3<6=>*AMA;*BB NI;79<("2CZ:J=_(8VRQI@PER"[N/E
M0&DVA9"W5L5"L5IL.KW9U6UMT:::I3O<OF7J'5<0#AZ_,,>S-VSO0,<3,N_I
MD1=BC V\\@U=F;1\PNW;H/6BB"+ANL!S 8Q124()#CK"LMEG.8BCUNG6N!E8
M>,+$CDJF,L7DD)SW'8ZW3(=I@@84]B$9UO*5*PW$%XE=1V-Q]:W6W80!SGEL
M=18)P/\ $)*N',>4P8#,=IG52*YN4W/NLTU3"DSD^HNW-#W6EPED&WP..8D8
M[*51D<2JY8C%"-G,@NG3+=&HD2KUD0A55VB*R@O&R2(J(HDQPUD<DW%6FI%:
M+.-X[KVZ:V%T&Y3A'(T*"<E1M%NZ:5J,B),KGS]*[4LU8:8 1:Y^4EM";=5;
M"-LV>%+=6TU8BU%#B(\N+J#ZX_NC=7+#,)%B.4FU;E=IA!Q.\S;6][<=G?=#
MG[$2.2,7VN"KJ*DGC>O4V3B'MMK4=4;$_HUU9W]%G*NG[:4=6)F24BT'L>R#
MZ([9KI&537 VF%EV0P3\FP09(VZME5BNP&U9Q.858;B!AJ98@V]&I+FE#8:)
M6N@Y2V(F-7,O'V=F*N.(11U*CTFEKP.R[(T1I6;E@$Q M14A&4K59!HS(W*M
MD8*9@A#I/K;K#1IIHTTT:::---&FFC331IIHTTT:::---&FFC335%][^4\\8
MEK]&L^)RKL*2UEIMUF"V0]$;Y2L5.K3*!>.HR<+CTLK'3L[5D)A-N-Q<U%O+
MV:)A 7?,(Q4B:RR% [0ULBJ;UA=+$> LD=QH255>0\3356#).7S.Q]":S;;(
MR'3FHBXNJ.0=7I,:X;:42Y(C7KG<NS?I#X)3@3;LT>8SN+QD-B$6<D< M::C
M6 ;5&Z:@/N"BNR(K!XD]$QU8Y6$E:=FW+2C:#I#AF]QK4,4)UN80E\8RV4%+
MK6G5@R]7YI6 L-?C9)1-E/LHV1B'D(=H+(47[)X^LV[E2E.5*Y#,<C%Y'BD+
M[+GOSBJO"R.';&3&SX2+'B%UJ&>IY=3J@6+%JM9=6%$7ZP4"Y]"9NC@EHL)N
MNS53A^:;$":EW;/$=C,5<9 #8A9).Q:PUJL8%^YKS*7-<->7O2T\]>)S6T8_
M.6-L'57)9,KT/;K<,Z0F0I& Q@_QY",8'&C?)4,ZL];D\H-,F(Q$X@^BX)I(
MJ8Z")DI5V]:0\H[5AY19AOFO:FW=1,16^PN+,/@<M#MC"P3.*\?@;]"NROUX
M39LJ=;95\5-5_A4SD 7*#JG8Z?#@TLS<X)$I:REQPO&LQYJV79KU,S7<Q%YB
MW2N&32B%G9"O-I:;#*M6U(%8Y8E2@>*/M*M&2K_B*P9&BJ-8,30C!Y>;C>[!
M0:K0B2@OZ[ R<:F\<W56P03M"PVB$C61;G6ZLTL"\DB6INY\B3DZ.:91>3;N
M4R@:J\N6+J+<42ZV1V<Q7KS6)<L0UA'@LG#*1.#*("N-FS035LU'OXBGN4G%
M!<$BL7,0&1M-4HQK5#&EC;K5V29"Y7U$Y)+J[E"ZDT0LJ"U+ZKU+2&F^]MC&
M7MC7*Z,K?8":W+.L18YL]&5Q'$-(N*FVM14IS:3C+1DZIV*W%>/;0BU0DJ#
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M*Q#DZK)66>"D"Y^W=K!6BGR[B=BA6LN5)FV$/;!0Q:WG6J185N,,6T$0'(R
M@F$!&5*C:.S-Z"B.2M?=52R!!9.4L%&+&("Q:E#()AJ);&PPNG#B4CJPD+3:
MHZO:---<\MXN[^X;<\H8%IM0AHVUIY$GTD+;67-(F'TJ:KJR\;"KS<%?1R%5
M*]!O8][)M4AACU:]RD@+E)P9C%QJ#F0)RSOO7?NUU4FY%=3#V;DHJS*+47?
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M-R&"M54-%2U4H&M"#4U$@ G*WHR#<K7?LV#AC:^2>^ZHF\\@]]B8VA[H/*R
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MQ!3!8R2S1%=V1^FF:.%JW<.!=@BW6.G\\6!-*F"XDRON96J1'>6V%>#ZB?\
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M+18?BW/5U"ROF>1==?9+=N0J%C+A@(AU\.ZICZ%S$$,#(Q4NT<:BK8<,#D0
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M\N]D'K"OLWZ+=V4C7J=R*3MI&F=@V.L-BH'B[V-Q^\ILY#J&0,$MJ=0,E1Q
MW[,Q&X5#OWP#G* ,*Z;%HP%01)8OL+57N64[V5UDB2^ERC-JVRM>N*QR",A6
M=UM6@;1$3-438IK)L,?L$D8KW&9:9W>@_BRZ/;U3<B[G,VX 0BY6HUF-G84D
M(C+6V@32;ZIP5;*DWAXF(?UJ:)*1[E1P@>*=NG RJ;YX^I8%C;E?%HMRMMFY
MPQQ/DBM#/3GQ?!W&V0X:<PQ#_+MG,4"IO="00E-ZJ9TUJ1:\*K3;<P;67?7/
MDJT>).'L>-1L /\ D>)>#\+FA%1''B)=C\G:?"@,W,91L,\29'3AQ=0M6=7=
M&FFC331IIHTTT:::![@(??43&\3$^4Q,?GIKF$Z\)O;5(92BLMRDYD::L46\
MGSD86!MAZQPJT1.6Z=O*5=1)/8@DIB#:0-CM%A=PL]59FOWHJ4H=K*VV5;L8
MHC"GCZ*,=2G'JDV5CQ:,6SJ% /,:V/N8E-N+=8:]I5J,9<\"85W)I.570QU-
ME@K3K.=IAVN?>>E,YB_FU=/WP19RC<-8R*A18Z]9]>U;P=*WM=3:?5;-@*+Z
MM=TH%0NGACT2\UJGU*4W$[D6</0XNXU^K!'$VW!(,*W<JLK27$"ZE9';C(R,
MVUA*NNK$5^0GW,I/M43%5>S$@Y2163M )!8&Y+".WX2O5=8D$@5J:N4P^83:
M>I*E5XMQ=P.,)C$)2#E5^DY; ,XG4*U#6=2A0>";;&RNL1-(:JXJY2J=*NTF
M39\$R,O<=*WO>U3B&:SD+YUFW4_"?Q@N9Z:>W%[GK.9Y.35K \FYVZ1:S.X3
M$I3YM*TM'-1VY5ET62AI:BUQ[%,UUEX 1:KMI2&DV+M=J>%*&O9IW:^Z+N.\
M5-"R,\Y52OY_+\1Y Q2[JU7S=R&=R@."VBPH:EKPZ%IA227J*J@QL*,.9%SI
MC=1)' 6U)X=I<+*2;!(;" 5B<=1%9TW5GA:K#;%T.8\FN&8\+O$,VG%>JS#N
M 1>1<C+VLTHSE,0-I"1R;*Y*A\M%RJ]4+ADS=&V1MW@(B0CH>*;1F./1LPAW
M]#?Q2[IHOC40K'6*=C&C-$\92H8_&"HB<NA5IGFBL+6-V;4VOM8.(LXG)3D9
MN\RLBV*44C35.OG84%SQ4W8\5-]N09D).>C-T;^)Q>%Z3)J>&FN-.GA,/-)U
M":EQ=G'JL.LO:VW-B*Y#PW[K6=PF*<CXRMT(]K%!<J6-_9\C/L?S&0)"[2MI
MFK9<)US7'VV*T1)%;<[EE6)U\7WK!?T!%8SE@R=&8L6I9Q,'C+%TP5754"C5
MQV*I*FRQ<8]- J5C'V+!/5DJ_C.O>,KL9#(*45G<\5:1UZEG'(5PN5&+YS;:
MN6SNW&V!" "_XFJVGD5H#GH/+&^!Q[DU)QM5UEN/4#LL!,"U4O1MKP(GA=ID
M::D8V BK?E>_S-ZLL959F:GZQ""]6.#&$KLC/Q<)(#&(E,O*+H!#130LU+2R
MS5BF1<3J;*RU4L7CL77YY536QC"9 \YVK)0;1ZD;FVO3 4XZ@;IZT8ZG56R!
MY(6&;@%^4R&3(9AMR*U>)DX*9KTEDM3)B%+Z3;;66,A;3!/$;MRS(V'04'-F
MM3K/1IIHTTT:::---&FFJ=[I]WT;M:=55.6Q?=+ZRLT!?;$K(526I3!.&88Y
M@%+38@>-[38H-RY6"OMGS]FG'INA<J,Q9%Z72[=-2N-I7C'56\R0KTZ5YMF1
MZ@17MYS'8 I%:^9YG7N9:@; !<DQ+B),,)3 BP%5K@JPCE;9O9&,75J[],FV
MSHV[J8)S.6NI;1IM5U&M 5G(DR17,E%0LY>)=#R6.,R,<0QV0:39(:DY-=XU
MRNXC*%)PS^_XIIT'?+#6W=5G#V*38-T8V:CVJ[RPU1LQE$%GH0D@DY(T?EO5
M*S;&2PJ#F%"SB_ TGUBF"C)X.?:76]GV;,7+@IKP5R+RT!#JM^!%%M>RY(9Y
M;;R@QN1N*6;>E@;;I9(R!8[)W^![/%N!DU&038WK%5>1@#Z8O$ZEF"D6+U)U
MC\2.*IS3,",U@+*SF>P(5LODB&8RN-SOF\/)R]:BZS8XT#6])L]8W%M8OK4$
MT(LF_,SC))LY;-WR*;=2G7?XJ,,P$L4O,\28?A*>>0F<;Q%F\ZO U\7<Y2*2
M8BQ9Q]ESD=5$X_(5;:F, C@+#RBI5O.<U;)QV R7$9R)"'BL1B<)9S=N\J#Y
M.0"32MUP%@A,7$,04!([Z9-H\7'&%&BK/(7/"698%W K&C(V*\JGS+RS6-'*
M,1B5Y 1@0-DDQ16:V2=BUA>O"(LG#!P<[955=%1 *Z,A7M!C_#<[G9(\?X:N
M %+"1>Q_&&0\1,[<FR%\"<1J)?-U&MKU^D)!;4<Y,,$V;"&E"UU(RTV+)3 J
M46*9PHH@*"D3YK!<987DV'E5!V.O*_#E$V.VW[U8W<O/7>'K.&\H5)O0J]69
MR:DKRG78(0<W"L1UH@((D,K,FGT)1RS>.47(/HQJW8JL#J.5B(.V2B_0L!-?
M%7\J4B2Z=R_26@2&76FX]%>TZ0F)E2HE%NO.SV 0-,DG L4R!06UFA5,26=Z
MBC)1)1N**CLEFL03&;;D73O8.R$0J#ERFI>GG7U)"O\ 4_%=Q_99J BGN#LM
MUAK/%I#LLU-/\=?2X^'O]UO>.H"9?J,[DY53:&N&/)V/<ID2.Y18BUF!2&/4
M.JG"1ERA;'*J"4D_WYBJ ;;X8'BN@EAE/($VL:-H";)=&K9J&NP8"U!LVW5.
MI';!BB9-.SQ!59T=F21\+9K$X7.2L8]\_"LSV&L*"!ZEM-V10).K6%K8=C\6
MU-&:1_!^ ;=8*_4I?,C+*@%L] /)-H_%6'(7,:<G1Y$+>V@)]G,UVP1[AL[*
M[51<%*LW; 8YD5SUEV1\--YZW*I_8[\C$RN1LILUN,%<(/JV*S.5@].RSQ,$
M$$3$FOEB)YX'J)Q9/LUL:HQ9D<GDL)2Q! T)I6TYF,AT;)/@2B!)N-L5XCG&
M4L&2;$Q[L21)^)(PJ[:]V^P8/SDG%5F-Q%*NJR:1PT\%E5LK1LW*56W0K*+G
MR6-XXDDH\4[# OY62DH<B*+I&(8M$)1SK==F<>UU9_(35<09KAQYRP 54RV'
MQJKPUV/*5H"C>AJ@7D6[UZCFR5^Q5K#)!R*A_:./Q61K*VKY##4LXHH@Y8W'
M7[U*F]S@DF?OL9-GGBO7@&7EP:J2[UME51](:!:C7FDU6Y&BU(3\404;.DB5
M92&FU&*4FV3=(H&EZZ^DX.0$J2I!]5%2#QDKU=2+A0OYM7+M4J5M]0RYF5V2
MID\C%[,#:&!R- &1R'S!,D,<TCS#N,Q,U*%L;]-%P%DL+(=58&2S+I$4],BE
M1F$2:^4Y""DE\W(>QB40[M5=6]&FFC331IIJAV[L>+'4 ^\&^_R?!_O]_L/.
MGU]?ZZQ*-]OE_7Z\_3UU44.0 !$0#VX$/L/<>0XX#]^/CN.IB>_:-_E/Y]]M
MM_+[M83WF8C?UW\O..T;;[SY^F\^?;7GD0'X* @/Q^G;GMW^!]NW/\M/2?EM
M/^WW_KM\M3M$[>93]_G&_GY^7G&^_G]^^LB''/(^P=@Z> [\>W'W'M^G?]]1
MI$_"//SF"WGMOYQ/?TW^?EW\M' AWY[\<]^WM]^_(A[_ ,^.>P:F=_7^41_+
MZ\OEIN/EMY3MZSVGX>??M^6^W?6.W(@' \!^40'N/]!XY#]N1X_J_"._QWV^
MO3_73OMWF8[^]]3';?MZ[=_+;7H1$ Y^>X '/< #GN//("/^P??OJ-1$1,[>
MG:9G;M,SMVC;:8C^L>7;7D.! P#P'M^P#R/]/?@ Y_VZGO\ ?Z>6^V_\M]27
M:8F._P#.8B(\Y]8[;S.CD>.>>0 1]Q[_ *<\"''[AW[\>VFT[^4[_KI[N^W;
MO&\S$1MVWWV\]X[>4]HVW\] ^WN'//5VY$!$1'G]/M_0?OI_KY;?'Y?/].WE
M.D1O/K$>7?;>-HC;;UW\Y^&^T^F@H]^/Z<A[_;G[<!\AQ]Q'4?7UMJ2CMO\
MGW\H]=M_/>?C,_#;6>X<B( '8>_(=N/8O;W]@[_;MIJ.T]HF9_"?7S+OY><]
MOCWU4G?,/.V/(?5W#U%,XX^XWBN!Q]_?W#W[<\?&O:>S_P#[UXWS_P"7>_\
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MC?"1Q:/X=)PA$NV=?QSBO'-(1EF2#I9%2T#5#V^53%()RPR@MVPI=";1[42
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M"IO^*U6LEE<WF4GIUA ,73&P/8N)@%XA))O/)$,W2CJ]&/"J"43>8]5*(B
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MF0P_$>$RM"WDU6'8VK=Q^3JVZMG()IK=<=10](-MJJ)=98@& A3&R 2P=O\
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M\>G;B+%1M^&VWY^DQJV'@2 (;6<G@/\ Z?IW[?\ HZQK]O\ ?GO\ZZ_M2_\
M7M+_ .Y*OQ_SE[OZ?[;1KQG[)'_L_P ]_P#?C<__  +@M=M-?--?J?1IIHTT
MT:::---&FFC331IIHTTT:::---<"/%UC))]NK\.9=C'/GJ33)+D[I5JT<.$F
MQ/XCXB/U.%$4SD1+TD.;E42ATD.;G@IA#XS[3%L/B+@8@69B-\I*1 B@8\=C
M)W*8B8CM$SWV[1.OZ/?L5VZM?V/?M/KL6:Z&.X64*0<Y2C<7^%^-1B%@9B3)
MYB@=AB9B2B/,HB>\TQ,1-?BI&=G9)C#0L0R<R,K+2;I%C'1L>S2,NZ>OGCDZ
M;=JU;(D.JNNLH1-),ICG,!0$=?87O154;[+5H2N.9C6F*UA&\1N1E,#&\S$1
MO/>9B([SK^<BE,<P%) VM84 "UC)&93.T"(C$S,S\(C4/L=S6W63B*+8(_.>
M)WL'D^8/7L<R[:_5E:.O,ZDJ9!2'JKLDD*$Y))KD,B=E''<."JAY8I@?@-6>
MDR;2J/(7C'5"O)J[3XAM((YBM+5_&=<8[RT1D(VF-]XU6\0B$/M=9?AJSQK6
M+'./118+;E2UF_(#9YAF *8+:8G;:=].&"S;AVT!8QK>4:#/!3[6THMK&(MD
M)(?ARZ/W35DRJDUZ5ZK]-L+MX]9M6\0[\I\JNY02(@)U"@.I,Q833L(F'5\@
M5@*+E>^JX=6&E9&LP=Q?-<4/)T+DI6*F2>T 4QO,26ZQ78)+?40-FTDXD6UZ
MYKAP.<!1!*4:I@Q,X@2&8D9G>-2AJ=1J*'.=\*L[W_"YWEC'C;)'U:+@?P&O
M;H-*W?6YN'>V"'B?P^=Z63^H2L'&R,O'M/3>>\CF+MX@11!NJ<D5R&W_ -EF
M+&Q9(/W,PSW\.-(\L/N;^]C0R6/.]'G5&[5)W)#UR6-@AJ=/Q)#7ZH5&+ZTP
MOJ!D'VZM$PY]N8;EFC=16*-X<ZI86N2-+(&5]3K+26WG(9U+2$"VE&"\U%-F
M3R3B472*D@P:R0N CW+QH4XKMT7HM7(-E%2%(L*"H)B;RS<!]Z"(>X@?3.8[
MP+.6#Y"GT+DF"VGORS$^6LB P%1&)"+H82I*)B&"HA%DA,_Q0!& G,;P,D,3
MWF-*FFL=(B=EKRU@<5-*;BE;.TBT9MU7DW[8\RVAW#@S1O*+QQ5!=HL%W1#M
MTG2B145%BF3(<3 (:Q A;U^F0GX8TKL<DP7098!K$ [;?IFX$.-0GM)BHR&)
M@9F(.862 .8 K(6&5Q+W2>NH=<+)JB=I8%<[58'$.\+)ZA*8DQB6PWRUBYWD
M20Q&UR)2W&4HF(;V"3QVC98A2Z,(-T9,C:6=ULKL99"/7,LB5)VHT*B<54^D
MX^83F43%H+3*TP\*+E5[IJ_>#5>X&&I-@AWA3& EI ![$4+9,1/(6TNF*Y5A
M?/1*Z#&5(;[DV04?(PT06W5%9^Z4AO$%VGOJ0M3IJON[1)5?:MN90134666V
M^YF2122(915553'-D(FFFF4#&.H<X@4A"E$QC"!0 1$ UQ>)8F>'<_$1,S.%
MRL1$1O,S-%\1$1'>9F>T1'GKZ5[&#!?MA]E#&$( 'M*X%,S,H$  >*,61$1%
M,0(C$3)%,Q$1$S,[1J"_"_:NF6PO;BU>MEVCI*J3@+-W**B"Z1C7>T' %$E2
ME4((E,4P 8H")3 8.0$!UQ_9^)!P=@A,2$HK-W$HD2C_ #=B>\3M,=OCKZ%^
MULY+_P!HOVHMKM6])YC'\C5&+%G$</X@9D3"9$MIB8G:>TQ,3WB=7!LN2<?4
MV:JM;MMVJU:L-ZDCP],@YR=C8R6M4JF@HY4CJ_'NW"3J6>)MTE5CH,4EE"))
MG.8H%*(Z]@!@QY50(3LC5L7B0,P31IU0)EFT2XW(:Z%B1M;,0 ",R11$3K\Y
MLGI)\0W]VCKHK=8_=5XBTT$5D<\[#U7N,%*7OS,,Q$8F2B)CAGNIVT2"[-LQ
MSYB!VXD;N?&K!%#(-745>Y"30,Y4I+0A9,3.+01N0RYX1$#R!4@$XH 7OJ4S
M%DZ*Z\P\\G6M7,<"O?*]4I$H+EFJ([R]%4WI![5P0*)JQ.8DQB<GB54;9V8E
M 4.AXTG1TQJ39ED5XL26T)E\I;"H9(RSILY=^0MIJC9F)F0?#$R;&3",D7,1
M(BQ=(N@8RK,$Q=QSH4#G!!ZU!5/U#93I61\PH*$*(AH!0:UN"8)389*F#W!D
M*<VNR0*.Q0NPAR3F)F!:I@3L0%$:^8>HU6\=1!+!R]_?43:Z;:A8/F!,K6*]
M@(*(DDN4R-Q,9E$N=]I&.8A&?O\ ;:[2X->5B8-"7L\PQA(U69GGZ,7"Q2;V
M17;MS2$M).6[".: H*[QVNDW0(=4Y2B&8)U>L,\UBTR55DQW;8:*S:2TA'O,
M.%+8R1")F  BVV&9C/E+IV'<L]*JAEJRS:>2O63&[7N+R6E<=S8<P QW*8C6
M*3?Z/DJ#&S8]M];N]="3EH89RJS+"=B@EX&0<1,W&"_C5W#8'\1*-7,=)-!4
M!=D];K-G!$UDSD#*(DDU;(Q,U[U5-VFZ.ZK5.Q$DBU7./=;7<,22FA) <1N)
M3&L9(8=:KS,18I6"JW$S,=6K9 %M*O87_$IPK:IDK.!. 8!;<I#,KLM,14#'
MKRLW(LHF,:BB#E_(.4FC1 7"Z35 %7"QB)$%9RLB@GU&#K55(0O)C  X20B2
MAF8@GOKU4C,]VV;;UU:J%QYDVQ8:I"5QN3&L !B2*(D4P -:4P*T)?9<93L*
MJ]91OL.84]A4E"V-:<S @L",I@1F=*.LM3I)G9Z$K$2^GK'+QL#"1B!G,C+2
M[UO'QS%N3_$LZ>.E$FZ"1>0Y.HH4O?WUB1@$K@B$9:U2%Q,Q$L<]@J2H(_ZF
M-80K6$;D9E C$S,1I/83*>PK6;6%/\(+6,FQASY"  ,D93M C$S,Q$:1[??Z
M-C^I2%]O-OK=0I,4S)(R=MLDRPAJZP8*@44WCN7D%T&+=LH!R"195<I#=1>D
M1Y#6%EZ:<Q%MJZTDX:X]<Q5S/,N0$QSS&["+<8"/>F8GMVG6:%G9V\.!/W7U
M8Z0R>Z]HGJ>[$^YM,3S>6TQWTKU^P05L@XFS5B9B[#79Z/:RL).PKYM)Q$O&
M/4BKLY"-D&:BS5ZS=(G(J@X;JJ)*IF Q#" @.K3T/JN97LI8AZ3);4N EM68
MSL0&!Q!"43YQ,1.JR+"+25V*SE6$."#4Y)BQ3 *-X(#"9$AF/*8F=*^M6MVC
M331IIHTTT:::---&FFC331IIHTTT:::---&FFC331IIJ.768,4L;L[QJ]R12
M&F0F%?6MCVDN;/#H6EI6&Q3&<6!S!JNRR*,.@0ICK2"C<K5,@"<ZH%[ZU==/
M0R%GJK\/B8 LH_G'I8\6!+ FXS?EKP01)C+9&)&-XUF2F"=-9+.&9$S"@$B4
M%=-90)C5';=Y 4P)0N"F)[3IJPFYC;M9#48E?SEBB:/DV4DH/'1(N^UE\>\3
M,.4YI6*JA6\DH:=D(XJ:AGK2-!PNW HBJ0H:WB)&X:P"16#H3E 1$3+2QL<V
M]\5_Q33CE+>Q$=*.4MR]TMM1F*U.<9"":]Q6/>TIB%IO/-:T5&'/NA9<QR04
MDIAAFU8B,R8Q,NQ,U#SS91["2C"7:).W3%1U'.T'C=-ZQ6,W>-#JMSJ$*X:K
MD.BX1$W6BJ4Q#E*8!#6 S!K6T)@EN#J*9'<&KYB&#64=C"2$A@AF1F1F(GMJ
M>8>=J]XZB&2IP;^\IL")RM@^8G &!2,[3L0SMWC3>NV1\?XU9Q4AD*Z5>DL9
MV;8UJ%>6F;CH)M*V&3\SZ="1Z\BX;INY5]Y*H-&"!CN7 IG!),XE$-8$U0&"
MC8 L8NRT (H@S52K,N6V",SN05JB6V7E$;*0LVG, )3&T%-,&L!9DM @;S$9
MD$@QJT ;2B-@$W-4H2*8B6, (GF*(G<IEWIV1JU&7*@6F NE2FDU%HBRU>69
M3D')I)+*-U5&$I'+.&;HB:Z2J)S(K' JJ9TS"!BB ;S6Q?3E@$$-2FPKF&1Z
MB+"Q<AP;_P 2G*,&*.-Q,"$AF1F)UH!BSEH@8D2'OJO@2B959JM-%E#(CN#D
M. U-66Q+8) 4043&E.9G86NLOJ4]*Q\-'^K8,?6R;M%DU];*/4(V-:^>X.FG
MZA](.FS)HEU=:[I=)%,#**%*.(Q),6H?>8TB%01W-A"LW$(#YD0J4QDQ$3,
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MN/[=Y]//\/KY:;^>^\;;;1VB8]8]._?MWCM$[^L['8!X]N?N <=/?^G\^XB
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M2/\ &/\ YHWF8F)3$Q,39GEKQ,3$O+WYY4Q/_-G9;)V#FGW#_P#*6U0*%O\
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M=DMY9#,32 DJ-*J,5OITY0)Z[NG0E62+%@X92*+-5,+?^'6**(I\2U,I8JY
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M645AB$0^V0].M#7*!AS&[!&"*)2,.:"A,8DS,=_>* A0B;R*%B;.6NLQ:_D
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MK[BK-@LQ=MY*'.W>NU9L-0Y)N,ITE7449$2AD#EJU6GD.FYJB?5IXQ.%0B#
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M6V!O$/\ A:]W:A.T;'6G8/8=TYD*//UY_(-6SDH**1;]RYBW8<D=LUTQ$HX
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MDN-=6J'(N&N*!)SC*3:]Q",M<QAR(\VT9S+&/MVG,EK[ED[+2F3Y CD6E%=
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M64Q(E'1SAV@D^?A-H*BS;G.4%7 )E5$5/**(FZ0 1'CMSIJ-R[]NV_;YQO\
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MDQ(OI:2=U:;.[D)-VX?OG)R7:SI%.X=NU%7"YBID(F4RJAC 0A2 (%* !R.
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M_A'G'>8YHWSA9DMK1 I6@5DYD1,@H6O5643"\AAEAZ4!,S',UH!&Y%$:5#F
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MCAZJ=EZ3MEX7W<_"QSM?\?QT;_$:I8RL+ZUY#36JM6ROF"WU7%&,[A6H4(R
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M2J$R(&>/5=XRO1>N55HRN(Q^7I'D713K4U7\9?OPKB&Q NC#DIV/96(Q"ZN
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M,X"U5:8IAPQ8QO$]?.5R6AKR33MIFM"X5:9T+-9%6QC5'8;"<A>X>IP\J_\
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MZDVV42326Y;KPHR%"F02P;(N?9Z11-JM219H57WP0R%I;6J-R-;QALM(E(-
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MHF4<I.:ZLY$01.B":R'2;S"G MSC#/5>),C6NUZ[4@BFNOR6.G)]0'V'0P9
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M^9?PT[8[EE7,!7MME,K+S%A*FXQ[76=Y-36=U97A[?(><80\Y'S4,K4HR:=
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M.B33$6[+W$N2'Q*[-55=?/,' A8QQJ)^.L2IS*S;5DZY5FEU"Y[9!\-7+6/
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MIKW89+:M3&9S&<078R%MP\E8D8QE''E;N*6E=I&5J"9))U5D3QMY\0+(N?\
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M/;@?<.KV^0[\\ '_ ,>/G4_?\_J>_;Z\](]>WE/+Y]HCX1,_Z;;]MM'/!?8
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MXZYR\+546R\5:K6:MR^M%6DZRRP5Q)DG(%D>8S?-C'/GG*(BPNAD<ID8Q^0
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M6068<!IKN43[->T<J U-S#30E1!2"<G:395%"N3631\-RV5LF6V?$Q:*1BM
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M."2IBF$)&ABQ:DELCFUM%[!KV:L2,HN0D;"R6LX9%=X6%1N8D01#%CSP$C#
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M?$$5G=PH[=6NGQ.&AI)Z-V+M:R+F3U&V3HY@ZK:X! !613?2I2Z;#V'<FZP
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M9@/#J2KH5ETC S"%>*&RU%I2J_5K7/UU=&FFC335#MW?'XCJ//L,(^#]?^/
M/;^G]>--8EZ;;[_?]T>G?U_+?51."@'W[\#Q\]A]@Y^_'].0U,?CV\MOOCZ^
M_;6,R4SMVC>-]I]/T^_>/A,[Z#  <\!SP(<_M]N_[>X>W/&G?O\ "=_3X>GW
M;S'R\OAJ(F9V^Z=OOW\_RW\_/:?CKR(\@ _UYXY]@^W?CGG_ &C]G?;U[[_=
M,=H_IW_#X:RB(B9C[O+T[SW[]M]MI_E'Q]"/;C@.1[=P[A[#[#R(]Q^?G[_+
MUCM/W?4?'Y?+OJ(C>9G?M'?S[>L>FVW;;>(]/AZ A[\#P(!W'L "'S[?;^?
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MI:Y:<M;( (RQA;1+#D8B3.8B(DBWF=O/3RUJULT:::---&FFC331IIHTTUP
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MH+)%6*04S*I*D PG3. =CVHS$YRE,3$Q]DJC>)WC?QEV9C[XWC?7BOV3 -7
M&>%@$LIXPN3 F,A,Q]BX*-X@HB9C>)C?XQ.NT'\0:'Z,9#\:U3T . 9B]_$,
M3Z0'9DA6*U%QZOR0<&1*94$>OS!3*)P+T@(Z^:Z_4F\?&/SU]V%XI<J+D(RW
M5F1%FU5?.P8SL6Z%JR0*)EW;@$'1_);(E 3*KJ=*290$3F  YTVGX?+\?AIO
M'QC6HED?'JZJ2"-ZIZRRRA$D44K)#J*JJJ& B:::97@F.H<YBD(0H"8QC 4
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M?>/O%+EE%DHNVUF25;ME7CA-A.QCM1!H@7J7=+$;NE#)MT2_F56.!4TP[G,
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M@41V1THUNE4<)LFXNWAT+#$JD:-0520%RY,1V8$$ 7711%902I@JLDGU=:A
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M!IIO'EO'UV_GK74R5CM(YDU+Y34SD,8AR'LT*4Y#D'I,4Q3/0$IBB @8! !
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M_+U^Z(_T]-(C+;;B]@\:/V[*7!PR<H.T!-+N#%!9NJ59(3D$O!B@H0HB4?<
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M[1RCC,(U],CD6BA#QA69I*6&W5\(V/+(]/T\SY]]0]*T*_ZB^C%PJF#KJ+Y
MGY#G0<PN!DY@()TUQD_=@GB$-) S.V[A7,,E<;G 3!R/+.^MX?O"D5_O"A4N
MD0]XH3!$$MF!WF%08&$LF.6" AWW&8AGO-PN(V-NBJDXNU:3&6IJUX0LJEFJ
M[>J$B1E BHQ#ZNZFT!>/YY5M..HE*+;/VYF58GEWSIB+=H1Z"9-MM,B:V5(H
MS,,&1FP5T;9R%:-IEA4EUZ[+T3 = ,IBRB6>+CDDH(0JLY9)=MMU"C".<!=0
M\#UUM*/=6PIR"!0LI@WD%GI"457RM8M^;\/T*(G)RVY+I,+'URN'M\R+BQQ1
MW;.LE)Y@38QR#I5^K'+%$H-G*+91-R<Q"(&4.<I1P:Y:.;JG <EJM19OO^ZM
MVW*170V(B94QC7J&!9R[0<$6P^]J!W,1,/?$T.LK(/>AJ*ZVN>U4QOU06M+3
M*0YMH6?J,QJ/LE;K,28VK]7LRLL2X1-DM./JVX5ILY2G2]6:9+>-65:MUI:S
MEL@'#"IF,^:+NWK-.1D2M%@<M(IXF1029SN&2JXQL=$[-O(X\K+"'PE2]C,=
M=R3JEM@29K<U6/L*2(*9$/Y!>2%%+8T-L+#'MR(;O6":%A:$QS6+5?(9*GBU
MOJ@7*#%*?>2;IE@S"H9*A:T845AX^1CY=BTE(I\SDXR0;I.V$C'ND'K%ZU7(
M"B+EH[;'5;N6ZQ# =)9%0Z:A! Q#" @.LS UE(&) 8SL0F,B0S\)&8B8G[XU
MN$A*-Q*"C<HW&8F-QF1*-X]1*)$H\XF)B>\3K<UCJ=-6\VD*/3;1<30<S925
M>"DYY6!KQX4DY+(Q315ZLRBC6.9KT$#Y9)$Y6_U6;BV8J< L\1*/4%2]<"A4
M?<:MK%5PZC!3"Y9TXF.<QAC%#,+&9,HY^:1&8 3.1 K-.L5VU7J Q:CLN! &
M[J0L384 '/*EM.(DIB-Q66V^\Q$;S$'7#=51*7MPB]S,G7;JXJ4U!5F:C:LT
M;5=.Y*JVU=FTB(=R>2M<?2(MZ+M\@V>R,M=F-8CQ!1R\L"+(AG6M^5:.*LU:
MI1-QEVY3HU9J<H@YMX18@X.Z5.%KE9<Y=;IL[=,%FX@65/''&1K/M1!5%UD7
MGV1L"3&*''L:JP/)2BX360:B$!1#8+L7- 01# E/\3? =KOM>QVXJ^6:C,V'
M%1<K%<VNNUA!C&LE'$VV;U9RE"W.<F).R/#U^0] \J\38*2_.>.;,[@N]EHQ
MJ[S A=]I^'F;$XT,>0 (&EV09D:F!N(K5*]L:UBO8!?$N(6U>65C-G-MK63)
MQF3FGJBP,12ZPS7\9<RE-A--$IHSB;62IV+-JVES:;*ANQ-XDOH6+L=!:;+H
M37MTVOLGGYS%V?:KFQW93S-&A+!M^R2O/JO8EK,6"HQ,KCJ:/*+.H*.F 9RD
MO!,UUU%8AE/D0>O&IF2$L0BI79>=Q*E08?/UWV!%(XS*)=:2LGB"HJO!CU**
M4FZ!'F8 3*B9M [A,[Q]#]D=FZ'M.]F-S%T!OY$./."[..QEJV.."[='B'&M
MIT;%Z$W!HA:?"T-M^'M15%A.E#N3IE4C:]DR!V_; L$S.-:;ES<O3XNL6ERE
M)4:OXUQ_.IUR*G;9,S5HL$?E[,%*J5>CXXR+AD5D:_2,Q(*%15C8YR0[DK/S
MG"5BECN$\5*G/LXROCKMIF4.N-9:T5[+".6U9L.L]4Y,X4BL%IABEA3 ^[$_
M1?VDRSF7]N_M#LY[%4^'\_:S>*18X?JY8\\";3\+CEI36RB<=17:7*5+<RRZ
MI22HW#7DB;*^J_EO$7PO%K-%;74,L4JN+5AO+O;E98&JIUR&M;C'+W+/\*9/
MZ5=)6;'(:-#CGLRLG'PK^GE4;FBR6]26,1B?V=DQK-S2(F;3\,S**!-43:S+
MGA;^,Q>5'$C(ASE3R&8Q]60O_9YV2:UM(;->I<<C\_U(.\6.&J$O\?X$C-1
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MLS6 DR.M!!"!@))Y& *@R,8G)"SLLKJ1'4.V\JM:!F)Z]@2D32J=]C8LA*&
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M).F4<@^8@K(F5=HIG[3ZS*[;:SY)&K<91%PENNVZO)C;*J,P+I34:(UW->I
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M=XCXSM\=OAO.CCW#V$>X#R ]7R CVY#^7OW]^-1IOVB?.([3&T^[OVF//O\
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M(\&U[+@( /BG'@8B8R%W>"&"&=J-F?*=XGOM,3MZ;Z^)_M%.<CV1<3M0UJ&
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MY.D"%7'X_.<.8P"M; *QR/$5BFRP^ILV)KV%8[[--CUM2IN4-:09=0E@WO\
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M%XBG6;[PG$&D)VV[3VC&/8&$YC,69A5."JHBV1$5% $1!0XB3DYP$QA YN3
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ML.9F9DB-C")C&,*9-C6$3&F1&PB,B*7 0A$RE(0I2$( %*0A0*4I0#@"E*
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M5J4I2X4I2P&($%K5$+ !B!$(@(B![:5BE*4I2E*!2E "E*4  I2@' %* <
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M[54')DHY;IF2Y)8;=;&N.\U).6RKC,WJ$$UTCKH?AQH3STB*%,HEU /)?,3
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M,-/3Y_'3WOE'R\_6/.=OAO&VWX_#W7*+ER-G(U].98";B&SDJKZ*^@MFPOD
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M/<PZ:3S>FT3M/Y]OE\-]:+&B9=0C)EJ[RT#M^]*R"+?_ $%LF,89%<YW1O*
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M2$)@YCDF)UXV_P >\,8O+6<+?MVZ=NIX(K;GXG+CCJHY,R50:_+S2^RU*N-
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M[<=^>!#V ..=/*>VVWSVGR^/UW]-1,=O*/3>=YC[_.-MXGUG>8]>^JD[YO\
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MF<IP Q0, #W !Y#69@2S-9QRFLB QG;<2&9$HG;>.TQ,=IF-0I@.6MRB@UM
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M"5_!6<C0MS#+5VSELVS$<26J-A516.L852JEVRVU9MGTAM05[Q+>:!Y++FN
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M\_%\]O=F4E$YFP2C-0SQLJR:,'$9&+-*$5!Z;%,:URSS<9X09TN1=P,2.)2
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M5TUTUY2Q0GST<WC^)* 2<3_Q+"X3(X+%4[-ER[%EN,&AE<C4?UIM713=::+
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ML9%,S$I(M]]MBCMOOKD^ROVC4?:9@;V;QN(=AD4\LW%E7>U+3:Q=*E;)XD@
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M77Y"?J/,Z% +QZCS?+X#_M?3SWT^IU'O?^[^._\ 3T^'KK=D39T_#=?&,3I
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M/F^G3]4!NA0"]/J?-\KL ^5T\]^1T^IT[]_+Y?TW[Q^/Z?"1\?<+].A?IZ5
M^J"W>?70<"^]*#GZ@X]#Z'I4 WEC&^F%?K$1]2*G ]/ ::1S;QOMMZ_?W^?E
MY?VCOI[4$V1Q;2/\1B5TCL%T/IGX>%P*0M_+/Y_J?/,8?,\SH\OIX#IZN>^G
M;\?7^FD;[S\.VT?#XZJ;NZX_$E/Y]@A'P^PC_P#3P^WQJ8W^[?\ G&WKZ>>_
MY?AB7EM'G_?^<SM,1MW\_P :B>_< XYXX$!#M]^?MV^P?/?XTV[;_?\ I_O$
M1_34;[=IF9V\XF//T[;^??OW_#UT  _(AQ[C[?//'<>P\_KW]M1I,QZ1._E'
MGZ;;]H[QM\NWGH]NWMR ]Q$>0_EP <CQQV[]N=/KZVT\_GW\HB.\_*=Y[1OO
MW[=]MO30(#P7D>.0$/U$1^X#Q_/O[_;2?K_7X:1,>]VCM,3\HV^$Q$^7IVC>
M/CHX^ Y^_'[@/;_U1]_?GGL/?329^,1W[;_=,=__ 'H\NW;RF->>_/R''OQ[
M]^ _EV]@#VX#]1U/R_*?3ZGY^7KMWVF=MM^W??M/R[_/?:=]_CO/GVC7KL'<
M1]^0Y'N(=OG^G''V$>^GIO\ 7U^GSU'>>T1Y;3V[1/?T\OCY^LQ';6!^1XX#
MD0#X^/M^H!]@_4?C3_7?O]?UW^_M$C/IY]H^?ZQ\)GX]HCR]9SWX 1#GCW >
M.GC@..!]OVX^1']A?7]/3?\ O]_G,1MO/S\MM^;?O,QZ3/SF=HVB/7R '@..
M/GC[CP(\_80'D/Z_'QI]_P OA^';U[?ZZ3&\[Q,]XF?A&\=O6=XVGR^'W;ZP
M/ =O?[CSWY[\CQS\<^WN/ZZ?7]_+Y>?XZ1OVGO'?M&W;:>\1O,>LQ'?RCMY:
MJ3OE_P"]BR'\CZFF=P'D?^7%=[<#W_7CC@?;7L_9_M_BO';_ /DN^7_ZA9]?
MK^FOA_[1W_L?XH\XCJX#MMMY\18KOV[?+XQZ^NIO\&[+&+L,[-<HW++N1J-B
MZI%W&2<::SY M4'3Z^61?X^QLFR8&F)]\PCP>/% $C5L+CSES!T)$.(<:Z/M
M5>A7$.*2QJUMMXU::JC,199<-C(M)2 F8)K(4MC) ((H!9GMRC,QX_\ 9&4P
M_9YQ(P%F2Z_%UQKS$9($KG$8!<,:41LL)8P @CF(YC$?.8C7<2B9"H>4:TQN
M>-;I5,@5"3,X)'6BEV"*L]??':+';NB-)B%=/8]P=LX3.@N1)P8R*I#)J 4Y
M1 /G[4N1(0Y3%2U2WKZ@$'42T>930YHCG6P?> QW$H[Q,Z_4"VJ;+(4P&2EI
M); &)2IP;2:F0,SR,&"&2 MB'>-XC>-?5"]TAU<GV.FUOK+B_P 7"-;+)4A&
M=C%+8PKKYRHS93SRO$<C+-H=V\15:MI)9H1FLX34136,H0Q0TJF'!98G]ZNF
M]56V:_?"M9>F;":]@AWA+VHB7+4R1,U1+!&0B9UL/]U*!9^[FT#F5H/W9>NN
M8+>Q,3M+ 2;5@T@W%9L 2F)(8EUZG334MM[I-!:1;^\VZM4YC-S\-5(9Y:)R
M-@6LK:+$\)'0%=CG$HY:I/9R;?J)LHF*;G4?2+M0C=H@JJ8I!@)@[%>H$P=J
MV3AJUAF)?9*O7=<>*%1^\=*:E=]EL+$I6A+6GL $49<I=&S8Y2Z%-!6;;MIZ
M5:N)@LGV&?PI2)L6$L9(A!&(S.Y1NZ]3K'1IIHTTT:::;DM<*G I3B\W9H&'
M1K$.:PV-:3EF#%*!@2$<*FFIE1RND6-BBIM'2AI!X*+4"-US"KPD<2Z6V$)2
M^PYRE(K% 6',,04@R 60#F%, LI Q.!.8F1(2B-IB=9J W6%5$@3;3X$D5UQ
M)O<),E(DI0[F<$T27$B,Q)Q(_P 4;:W*_8(*UP<39JO-15CKD_'-)>#GX.0:
MRL-,Q3]$CEC)1<FQ579OV#QNHFNU=M5E4%T3E424,0P"-IR6UVFEZF)<LI!B
MF@2V+*/,3 X@A*/6"B)UJ P8/,!B8\Q#S"4%',!2!CO$S&X&)"4><$,Q.TQ,
M:34+Q3'5QD,=MK;6W%^BH%C:I.DHS<:K;(ZLR;QQ'1UA>UXCD95K"/Y!F[8L
MY19H1DY=MEVZ*YUDCD+J5,/&T:9AHT7UZMTES!C4LVT,M5:]F1WA#K-93;"%
M-Y3<E9L7! !3$L(5'64V86RXFS8J+.8 [2*;4(MNKB6TN55=:K*L,7!"EEA
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M)[#.OWQ^RG[4.!. _9C^T#A.+.(:F&RG%G#RZG#U2P#R9D[$</<55)4F5*8
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M_KU\_C]>?II$3O.\=_.=_+;RCM'\M^^WQVG0/L'(\]P'MQW#CC]/80XY^W]
M;?U_3ZCX:1YSM&W;:-]^W?\ KOOM\M #W#L/(CR/ ^_R <<^W A\_P"K4:3'
MW=HF(WCRVVB9W[3OO'I$_AOK !\B;Y_S^??MVY]PY^^I^_\ KV^'Q\OQ[:F?
MA ^GP].^V^T>NWEV[]M   CV[=O80[ 'SWY_41#_ &:C]/K^^HF9VC>(GO'>
M)CO/Y?+;60#OV$0X ?MP ]N0[\<@'Z]A_00'EI/IO$3OM]\QWVGMOMO\N_;U
M[;>?OSR/'Z^W81[CW^>.!]A_RU/I'S[_ -/Z=_P_"=_AM'E$]O/O'IV\H\_.
M8[QV\YR'/[\EX#OQ[B/'O[^P]@^-.WQ[_=V_/S_32?/X;%O/K/:(W[1&WK'?
M?6!'N(#\<\^_<>_QR(!WYX^._M\:=O\ 7TW_ "CM\O3]-(WV[;;SMV[=HG]9
M[1WW\]MH[]]>N._'?V]^/?\ 3N(\=@_3_5S'GJ-XVCR[3Y3/E\)[1&_S\_Y[
M5(WS  ;8\A_;U%-Y#GY"\5W_ "Y[<_?GCC7M/9__ -Z\=_\ T[WZ4+/]/K?7
MP_\ :.G_ .I_BC?O^^P$Q/RGB+%?E,^>WI&VGUX5>:8G!>Q?*-F?1UAF96>W
M.'HU1A*J%="?E[?;*+C.,@VD>O<)&)J;14KA071G-BDF<2FFW,#DZG45%7;[
M8K#%YK&U:TLB[>PUH:IA"9Z/V?7SF8N6CA^ZR73QV.MVV+Y6-<*94A+G&M1>
M3_9"%8^SSB6T^5C5I<7/=8ZLL@&0W'<-U$5XZ7[R#MV[**JYB0@3<)&Q003!
MLO@SQ.952D4J!R3AW,5YO;6M85E+Y?8?^"$/72H9SLEQJE.F%69,AUX.M"Q4
MR5@IYA!P'G-G3<)./8.H-=*0-XF^ZLF>JD"BN.0G <TSM#LW7X,X>XPZ:H:0
MG"<GC\_7;5>R 36;#$7RI3"H9^H;XQ0=<W(V*%^;NK7RP3J6)H\8Y#AF MF
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M7A4W)H9A+SCMC$F6204.P;MU%$$#G,D3-O26G&T:[#=6P^%P>!K6&J%#K5?
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MOT:::---&FFC331IIHTTT:::---4.W=_\I*>'Q]%>_\ Y\/U#^G?MR/QJ?\
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MNO\ R5K'LYG*W9S]-BNA[&W[H%'C4CRBPJ;0[EN5RJ5NV Z;8RQ 7,'%C/\
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M]E#K>?Q-]EY?"K7J%:N(?MK]\!BNNTL#GKV(?6Q[G''B+F3HC1S>,K*"R\J
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MELULML,VKCFAXOBG2$DM#.,ER3JSLIZN-I\T4[:Q<HE6Y&$(],S:2DI&KR+
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MG?RU4G?-Q_HQY"$>W#BF!P \_P#CO7! ?]GZ^_/'O[3V?QOQ7C8CO[E[Y?\
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M.=MJPBM=L>*R60&,O0LIQ*E:3-5KO)S%U<1*3UR20932IC+GZ1,YN*6\1[;
MZYC+DICD"\@\3FHS*4T[ZU@JM7R)Q-+-I&B0Y"ER*#PI+$]45U97PVK P2R8
MBO80+C6;:3_%8>SAV3=H-:;+0UUVBMX\3NP56ZM;C)\00%.&V7;!([?[WN.M
M[ZP8_GT<[9.1R"R"K8Q<4BR0S=O7(>M)QEMLB]UM 7F071A$9=_-)Q59*ZGY
M*:D C42ORMV^-0_#X2EB2B.>ID,[>)B(Z%0_MK+W,MTETOWDIBD5PJ=>9L-V
MII2O:)&2*W:$7Y%-T9/E5@L-A?\ ,E%BV7V37Z,OFW ICDL%)%T.C^[6%=?5
M9*9-EP=8:G1IIHTTUP,\7.9F(S=1X=+>-E9*/;OLDN4WS=B_=-$7J89&Q&GY
M;M)!4A'!/+55(!52G#I4.7CI.8!^->TMS5\1<#BMK%B=\H,0,A@X\=C8V*!F
M(*-IF.^_:9^.OZ.?L6T*-OV/_M/-MTJEEM?A91(98K)<Q!?X7XT+F2; (ESS
M ,[A,3N,3YC&W4B9P!;I3=O6MQ:5NH"%5@,33>,U*@MC67<7URK-RS676F6^
M2BY%;Q+-NV49(-VT6?';I0J"KX#21C.2"A]BI!%8.)5MF2C/KQBA.K/AF5QQ
M8VH1+R+KQ:*3OVR@@BMR1*!B)E1D[^<UTHL5\.I0"MN,OW+;'.W=UE7*XH96
M0 =":P[J2TC8=F#8N)Z8]MN=U#\(.;QRQO+:$SI4IR5LV06]T@[A>\4W.VV:
MO$1E))V#QRS=YT1I,Q=T(Z8?Q;6U#3V# R9D3R=:DT2+-%\,&K['1P>B9$YX
M9?CIM-K#-9F1J8Y&)02*Q-.U.,;DXP]<\J\)LBYC'LKIK,."'3F%KRUWB&VQ
M:R#-IR,*J6.=E>J_)/REDY;%8Z9VJU)F49&,5S(?3!*8BV9J2Q7;E(IR))D4
M4%50J9"G5$I2"H<I0 R@D( $*)S )NDH 4O/!0  #6^9B9F8C:)F9B-YG:-^
MT;SWG;RWGO.I&)@1@BYB@8@BVB.:8C:2VCM&\]]H[1OM&O>HUEHTTT:::---
M&FFC331IIHTTU7[=DNLVVK[EW+=91NX;[?LRKH+HJ'26062QS9%$EDE4S%.F
MHD<I3D4(8IR&*!BF 0 =<7B29'AW/D,R)#A<K(E$S$Q,47S$Q,=XF)[Q,=XG
M7TGV,K6WVP>RE30!JF^TG@5;%L$36Q9\48L3 P*)$P,9D2$HD2&9B8F)USVV
MG8:M^X/8AL<3_%]2;0%4FINVY#B;]2)O(#C(-:7>Y-I4K5&;]ID"HIP"[^"M
M,HD$O)LK6W25(RZX==NBLW<\3V>C#N%L25[FLT[6!R^/>H2)5N77+)]"TNZ4
MMA?AFH2SEBL32Y9Z5A#.1@?4?VK+ XGV_>V"GC$*J-L9?AT*K$B"ZU,:%?AC
M-[C44"N8VVL=7&)%RA%9OY@,V :].T^$J:2@FU=A,ZD>1B%ERPL@WR?CH^12
M0U3R@E4$&IJR=.[UE>(RECIK3V<?0LFK+2 QT<Z=-G]9D3J&7-[&(<UU%MRR
MYK$XO%4+=^O(U,P=G$9^YG59''WQ%B\?8R173K9V)JV0R4)K.CP[%1O^<7V@
M-$)KHA2D,$Z=)Q>(Q<)^RK&,*A>IP*CNXU,V"LX^O%BN=%FZP>Q,\D=@X6-"
M&AXF'*Y<O2Q48QC0>/%/-=NP8M4FH.72O;S'*X)>:N?@.I4YC<!SJU9=-FQ8
ML2 +E[FNE:XV6N6L(Y (] 'FY1CT&(C7+J5XJ5:U6&&V*U=->&MG=C(2L5PQ
MDQMN9P/,4^I3,Z4]:=6-&FFC331IIHTTT:::---&FFC337D_4)3 02@?I'H$
MY1,4#<#TB8H&*)B@/ B4#%$0Y # /<,2YI$H"1@^6>62&2&"V]V2&"&2&)VF
M1@AF8[043WB8VWCFB9'>.:(F(F8W[Q$S$Q$S'E,Q,1/?:?+7-,OA^S$W-UN[
MW'+L<SR'!Y:MUSE)_%M$DZ+'7+'MBE9>?A\>VN*G,@7IT_DJ78)IW-UBX-Y=
MH:-?*. ;P2+60DF[OG1C(&OCD!8< HX:R."R  6R+=ZU@<O@*6>JIG>:.0H4
MLL]$R3+7BZANJO.=J+:&LQAAODUI,1XBH9S&DP2)]1-?+8G,7\789!BNY4R5
MG%(EL=% J)55H+EB7%:?NSC9>\VL3%\FY&^P%K<VR!IM2:LZ=C\^.(I>)I#B
MQ.&%OO# UMMI;CF"P%L1VMSR"@>OMYYI%0Z1*VP,U447[*&]'&%0D8YW9*,F
M[IS*Z%5HX?%8>*N&HSSSC*#%XL;KZTV;4MOV7NZHAR+'6Q'-=39@BD*U2U44
M;9EM^R%O).R)%D[ON1>FH3(1CYBN@JZV7)(FE:_=7QUIUOT:::---&FFC331
MIIHTTT:::---&FFJK;B-NTKGVS8L+(3]*2QE4WEK6OU*L=&FK#-7-I9*T^K:
M+>OVB.OU99TYQ&IR"T@D_=5JT+^O09KM09';]2FJ%<SK1-8P5MQ\UZIU"FM>
MI9 +:+E?(IMEU@B:SJM<U*BN!\X%,OD2Y!Z*,@=6A<JH6,NNOI=9CMFUBI5F
M$Q]1E7E"6>+B>BPS?*_#DU9(.608T?E?"E?/8W'L,3/83#:ISEY=RLY>,<C:
M+H1A;<VGS(UG,>V-O=H0E!RDQ/Y=8D;^:-L3>9C?/7&M,5%2))6*33KY7%Y1
MW*P\?2X,4R*XC4;8M\'5G)@1:,,!&%SYV&?;N'A+/$U^2NJXGEZFN;EQ')X_
M)4%DZNN[5R&/1#6^*57HY#A^CP\$L A6RS?PU>BNQ@;Y. Z-GE.P%V1.6]B=
M8:G1IIHTTT:::---&FFC331IIHTTT:::---4.W="/XDJ  'O"/N1_3UY?OV]
MN?CYT^OKZ_UP*/69\O+YSW^'?X?6^U0^P /'OW[_  /P/'<?V_<?CX?'ZW^_
M3OO&^VW;MVWCMO'I&VWG]T3'?U!Y$.P<AQQ[@(]N>!_3GO\ [![AJ?2?T[?U
M^OP]8\IC>?.=Y\XCOMV^?S\O3>)VG8^0^X<!QV .P^W(^_WX_7]-1J?C\)WG
M?O,]XGO$1';X;S/IZ;Z/?CD Y-\@(\?[>_/O]AXYY#G4^7^L>OZ_7II&^T[3
MVCT\Y^_?MVV\N\]O*=]M!>/GCCG_ !#^G'L'O]OV^WOS'W?=V^O74%^/EWCT
M[[^<^7;X[;]O/UUD/?M["(]P#V[ /R''P'&FHGR[^<;><^>TS'I.\S\>\?W]
M#R'(_'\@[?H/<>>?^KXXGMV]/K^7Z_?J(V[?'[M^\3Y3'EM,?/X>7>9\<_L/
M/W]PX#]NXAS[\"(ZC66VWQC;X>7>9^>\1.WEVVG\9UG\PCR(\>W;@0#D?8/G
MGOQSW]A^.X!/;;Y_[>O]/J8[1O&T3Y]]XF>TSO/Y>4_&/6)C6![B'(]N!'MW
M$.W(A_L !$>-/*?3UCOWC^VICL,]IB>T>L;]]H\IF?OVVWWVCXZR(\AV#N//
M[]N_;CCGV[?MJ-(C;SG:(V[>G?XQ.^T]^\?/51]\O;;%D/MT_P!XIH"/<0_Y
M<5WX'GO\?]'?7M/9_P#]Z\=WC^"]\?\ ]@L_+Y?K]^WP_P#:._\ 8_Q1W_\
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M_.5P[>W_  G$\A_/Z%S^NIW^4?KZ_CIR_.?T[_I\-H^[\= [4,;#[R5P^_\
MW3B?GW_\!?/O^_MJ-_E'Z_WTY=O*9CR^'?;?;?M\]'^BAC;XD[@'[2<3_G_P
M%P/^O3?Y1W[^O]].2/C,]MN^T_T]/3_?0.U'&XAP,G</_P 3B?\ ] Z;_P#N
MQ^O]]1 1'K/K^OX:/]%#&W_G*X=__:<3]N/_ #%]NVF\?"/U_OJ>7YSV^[X[
M_#X]]9#:CC</:3N'_P")Q/\ ^@=-X^$?K_?42$3YS/U^&L!M0QL'_A*X?O\
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M2GSUT>*.&_;1=M43X6]HF'PM56+HHO(M8''6RLY12H&]= WX>T2UV6[L!(D
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M1\-;L[PM[>+69R-C ^T["8S#.M,9CL>_AW%V74ZLS^[0Q[<$]C2'U,W,*?\
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M996.\(^)]#WBL2>1-Y^.+91V,NU<6BMQ^):5&/9J(3,(NF#9^TQK'N6BJX<
M5=%\V4)W$JI1U:N9/@AE5X4^&[J+1KD4.._9,5,]#D"O&)1'K$@43\-<O"\*
M^WNME:%C-^T_!Y'$JLK._13PYBT-M5AF98E;E8)#%D<;1!BY<QWV*)[RUGN
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,IIHTTT:::---?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g374624g38a43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g38a43.jpg
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M(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.^*
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M1 ]JM5'.15:G7;1NR=CSG2>[93(9D\<R2*SG;T:CA5$+%&MQ;&!*N40RN+)
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M*5U<SLA\L+-&9\C&_G9.:U,E:ZT[\T^XWOJ*0:G>R9*.-Y4D'1-&VH+,BM;
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ML8-NN5[5>IL,;JAYF)CSO \[D,FDA?:DR"2[:<[FSI:,1IB.)R%#7NGHN#C
M-)\&BD;UXP#C'UQ"0D<+%XN/WU9=*^CCS\0UP6:F.%@!YR0E'AL'NG9^]7!!
MTE!Y!:1R[:H4K%B[.0C99"9 %<#([#7HN%PI\/&#9?&XK%P0E"5+)J'\SH9Z
M_G3+[47:F9J,[X0B!?;\:V'%IJ910DVV8QL+=Q R2CN!)X+U1&MX+Z8%PV,M
M=;.HL6+Q6?[1AF:DDF=W!ZT&T]KT*]+GW4;%J(@B\&71Y53/AUY*B?:O*IG
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MM6^3EU*VU/ ]0!=B;>BX+76JM@Z< FHHOJJ.296'[&UL!U62=D78G5#46K-
M\6C8S"/[":!V4W:+W((/CQ$25(BW(NDN>?!K1<N'+@S^?4N:YG8C:/#=K;<$
M7UK$)H@5<A-5F5CT9;#G347@H15U1/\ 3R>11NS8)L7+1K&=C''K8<W:,Q^!
MML)<9-LV#-0:X$1<M7OPHOH)N?X)]9R!N*:K2W9K)N)U[KO6R6#8U&G6;H+
M=L ]OOGI!<U$2SAV4V6<CPX%M#NU;"I+%4L&#44((M!I9B"*J>_.GIX#=(%P
MO:_USL5ILT$6EJ\@:X;YNH@3> G ]\\XB]L"=O[#(OLD(ZT++.['8Y%@ +'
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MN^R9( [/\4\KK8M\1UUL<<,D+Y7M%>\D_P 3776O^KJOYO\ X/.3NRPAFO\
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'=3Y.[_ %R-,?\
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M%J%% * 4 H!0"@% * 4 H!0"@% * 4 H!0'KV^4$T--.(J-:KU]!'<?9G+3
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M?FF3_!%.^IAO]A=O-:;VT?!MQ]\NPQUA<?P@PI_Y+;B-CC%N_?G=49H.34;
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MOUD^\<\E]:G^/'^M,EY%Z%&FS]9OUD^\FL%52^=&YO\ 2)_OV4+Y/[>/[_\
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M3P?-1>:VNU=;#6T:SX@Y;H]4J.:18N2-7?[!V3#4M@%6#M](R$*#-XVBY8,
MZ39V+GGK^S7Q9^7@Z<S8]F:BXU)R9<-VI5O:,,)7%IQI%<I(XIC(]5&!<?F0
MZ4(;/>-!:R$P<9R$['B>O'\>0D/>$>%DATEYI^IE<X+FG)RYY<?"BIR?.GVZ
MS,%H=QV2J(;8#$BI< ^DNN-CYZG>QZ>P<(6B4[) ]E- @2<NQX-XJLQ7<2'6
M3J*$X>9NZC4@A)Q4D?;@75D94)P<'S:_G^=/=.+YSBXN]4[,./\ :YL1%Y'+
M\=R<.\'T'I\\(:YR(QPG[EP,;D>/MZOV0M1W*1PIT_G6JB1:8:G82&8L3&H
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M*A/-'Y3?Z,8=_?S_ .7U)\_==]'BT4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MV*1=7E;M0I50HH!0"@% * G6X.B7:/5U-NS1.JW6G.FTCM2\R["BU"B@% *
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MA]I5"$ZW!T2[1ZNIMV:)U6ZTYTVD=J7F784!#^ CZI/^3&H4Y: 4 H!0"@%
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MH44 H!0"@% 3K<'1+M'JZFW9HG5;K3G3:1VI>9=A1:A10"@% * 4 H!0"@%
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M]$.JNLAUV8*5VMN3?UQ<_P!VI_%0GFC\IO\ 1C#O[^?_ "^I/G[KOH\6B@%
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M'O\ P(-_RMC_ .A3LBH_;S?VK_\ >'85'\DIO["+_<'S<CW_ ($&_P"5L?\
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MM5=?D;L0%*J 4 H!0"@% 36"^=&Y^LH5[GM455U-YO2I$UNY_0A2JA10"@%
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M,REB,*B(5)]326>BV)1B-2UR82[WV(YIP9\>73Q<')P+P?/E\Y!7W$]O %J
M/MDP4E$4@,<U(BX+2C9(K4RD@?[L 3K:P/?,?VTW@P[P<PC.DH_K@>1:F]/1
M;O$X%-R386:YJ*P$RU7#)%7).%<^+DXM?*JZE7/BX%4]C^IY6O+(2'=/TI2F
M:&L10L_E- P>/29T7L"$DE2)<+'W3P*)?E6Q)J4>"&"J=@CMXN%=LAA$<\&,
MQC[^_P#>?S:_FN*ZRM,>^&"U4U^1VQ2+J\K=J%*J%% * 4 H!0$ZW!T2[1ZN
MIMV:)U6ZTYTVD=J7F784!#^ CZI/^3&H4Y: 4 H!0"@% 374'1X ]8;[0%:J
MZ_(W8@*54 H!0"@% * FL%\Z-S]90KW/:HJKJ;S>E2)K=S^A"E5"B@% * 4
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MY-_7%S_=J?Q4)YI_*;_1C#O[^?\ R^I/G[KOH\6B@/K9T#$H[-^$W0L>E W
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MH!0"@% * G6X.B7:/5U-NS1.JW6G.FTCM2\R["@(?P$?5)_R8U"G+0"@% *
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MU5U^1NQ 4JH!0"@% * 4!-8+YT;GZRA7N>U1574WF]*D36[G]"%*J%% * 4
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MKS)M<4NH44 H!0"@% 3:4](.K?7S+LY>LD^*[Z.TQ7XS?I;"DUB9"@% * 4
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M0%:JZ_(W8@*54 H!0"@% * FL%\Z-S]90KW/:HJKJ;S>E2)K=S^A"E5"B@%
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MW\_^7U)ZZ?DUO]<76/\ Y?/O=_)J["W1OT1N7^TH/X^F.CMP;_G/L'^PO/\
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M&#Z1DPSYD^=-?O\ WY<' 4_4G#%"].2=26 I1L&0E50TD"JYS,X+.9N$I4=
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M2JA10"@% * 4!.MP=$NT>KJ;=FB=5NM.=-I':EYEV% 0_@(^J3_DQJ%.6@%
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M&\7>KJ:)E4R."K2BWAZ5=+-2/5^\TT<F;63.<W1>GYR)GFF:+[#:X =V"@%
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2NIMV:)U6ZTYTVD=J7F78?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g374624g42n54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g42n54.jpg
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M;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (  @ X0DE-!"4
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M#T;CO7$_\J[1[\8& ]&X[UQ/_*NT>_&!@/1N.]<3_P J[1[\8& ]&X[UQ/\
MRKM'OQ@8#T;CO7$_\J[1[\8& ]&X[UQ/_*NT>_&!@/1N.]<3_P J[1[\8& ]
M&X[UQ/\ RKM'OQ@8#T;CO7$_\J[1[\8& ]&X[UQ/_*NT>_&!@/1N.]<3_P J
M[1[\8& ]&X[UQ/\ RKM'OQ@8#T;CO7$_\J[1[\8& ]&X[UQ/_*NT>_&!@/1N
M.]<3_P J[1[\8& ]&X[UQ/\ RKM'OQ@8#T;CO7$_\J[1[\8& ]&X[UQ/_*NT
M>_&!@/1N.]<3_P J[1[\8& ]&X[UQ/\ RKM'OQ@8#T;CO7$_\J[1[\8& ]&X
M[UQ/_*NT>_&!@/1N.]<3_P J[1[\8& ]&X[UQ/\ RKM'OQ@8#T;CO7$_\J[1
M[\8& ]&X[UQ/_*NT>_&!@/1N.]<3_P J[1[\8& ]&X[UQ/\ RKM'OQ@8#T;C
MO7$_\J[1[\8& ]&X[UQ/_*NT>_&!@/1N.]<3_P J[1[\8& ]&X[UQ/\ RKM'
MOQ@8'"XKK C=<Y74^!B(JF*;TKM'D,4AA ?;C[ A@8%QA%%%86(55.=556+C
MU%%%#&.HHH=HD8YU#F$3'.<P]1$?*(X"W(NF"1@# & , 8 P!@# & , 8 P!
M@%AK?M47W0FORU(8(1?L$C & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# *=W_%7/WNM_!FP"@K_ +0PGN1&_@:."%N1=\$C & , 8 P!@# & , 8 P!
M@# +#6_:HONA-?EJ0P0B_8)& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M>%IF3VU:B\-.7VDSTRO>*7P,LIDTV?(*%8+*"!13L-5O]:*F8?L*.IVIL&(
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M ]<UJTXOA:P:,M336*W')D$C & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MU##F$7G?_IZF\+&RO*OLW3II^A*H_12,BH=V&:S6-S<4(>QXIORJ*\I[A&^
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M , 8 P!@# *=W_%7/WNM_!FP"@K_ +0PGN1&_@:."%N1=\$C & , 8 P!@#
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M_LV]1P?,UOC)<N$XM2CT-'4&6W]',["E?V_Y*K!2\#Y8OIB\4^E'J>>6?<,
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MKF%);[;*^5?2LLMR#,W3N:-G.52VE1@N)<+E7[.K*'%Q;9M82;YE%;5X.?9
M\O[WJ6J>\;2<;C++W/*-*US2C?5YNC+M84LO=Q:0K=DH=6C&2E3C#%OB=6;<
M95-C/$\*^=U;Y((>95;17(K86PN.^YP2(E&UBKVYJZ:S] MSI(@)1T=Y^X(!
M5ENA"HM&+Y4P@*QQ-31534VE)Y++&IFME1IW%'EE.#3C4@N5X<BY9."Y"YF$
MK;NF[XZ&O(\%MH[/+VYRR^PPC2I5TU4MJTMT8\3V-[%&%.M)[9/&Y4"%/,>+
MXE:[=%=[.VOAJ]V<G'SC0JKJINI.ZC'U2/2:.BJ)Q$]5Z*FSC'1VX$[;I-RI
MUZK'$UN^JJEW<RM[>7O5/,E2QB]DTJ>,WBM\95.*23QV<*Y#ZLAM7<_6BAF&
M9T\;NYTN[M1J+%T7.XX:,4GBH5*-NJ=*;CAC-3EZMX]F\62!@Y*I\$W,C#1;
MYPZY4:EKSIP[8-7"[B DXUZI(PBZRR1U%8E^=$AEFQA%%0Q $Q1$ SY>[FK5
MA/,U"4DEEU22P;V26&$ETKD>]'J_6?LK.O0TG4KTJ<ZDM3VM)N48MNG)3<J;
M;6+A)I.4?->"Q1/_ )H2=>JO$G?*+N#KDS%1NF+NZ/0I)W(0["Q5:!@Q&;@&
M@UN4@YJ-;J1!O-B.&2I18G53/V3  )FQ;3%.O7U#:.$YPJ.Y@NT23<92EU9/
MB4HO;MPDNM@UTK</>M<6.7=VF<QJ4:%6WIY5</XO)RA&I1IT_?*:[*=.I%.'
M54J;79N47@UL<0*SR_F=+1G ^L2E1I5#X];VXP5^:KME(2VV1]0;=5]/QMI;
MZW5,]L8.99@NR69(QKIPJ9\^.)D#%,H4SG,AKZ=I9G4S:O"I5JYQ:7\HRCU(
MJI"59Q=79'!/'B<DEPQW[NJ:QR_O/N]*4-'9?<VUI9Z'SC3U*=*K[]5E;5J-
ME&JK5\57&<7%TXTIR;J5'C!IR3F=INW.#<%;V%:].0.J6MRVSJC0U,VS?:E5
MZEL&T+6ZYVQ_%K+:PI8U89GT5;14"[./I!*&>-EWJB9 :D*!NMFUTOEU>SIY
ME5N'2R^XNYTJ<Y3IQX(03]]GQ</$W)?DX\+2Q?$ST<V[W-46&=W.EK++8W6I
M<MR:A>7%&E1N:KK5ZTHMVE#LN/L5"FW_ &FJZD93<8JFMIV>K\Y'5DY,RG'R
M;90>I[(E:JPVJ5!VE7+5!6_9&NY>JQTW(W>H6]20;U)2?:2SIPT+73M1<"DT
M.H5RJN"C5*Q<:6C1R..<47.XH.G)SJ4I1E"G44W%0G#!SX7%)]ICAB\.%+"3
M^_+^]ZI?]X%31%W"CEM^KFDJ-O=TJU.M=6TZ,:DKBC6XE1[13<H*V<.)J#DJ
MDIJ5..1_,+-[&*?QH_J!;*_K9K'Y\PV9]W9_.ZA^CJ^XD<X_6M^A;,/E-I_F
M*9E8S 3HX@-PE_GAS-_U7[*_*CK+U7S8^Q*8[V3YRR5# +9,N)-K%2#B%CTI
M:72:+&C(Y=X2/;.WXD$&J+M^=-;S)D*PE%94J:JB:0&$B:AP*0P,AM0]Z[>K
MNU]PZYWPRH3F+U]JXNX&UPUVVG&48R@074(O"RR,Z]>J^?&10740$>Z,)&:A
MA[93E$E;C%Q4HX[RE-IM/# L.B=W[LVNQN=B6V5Q=L%>@:I)OVS+6;/8<I:H
M>Q=$G,,E9XBT/8 R4*=J@Z*=0G=F76( )&Z <2S*,8X1ZR?2$VSM/'+DM8KW
M6]MLMNQD-#[&TY,J%L$35&CYLREJU(QWLC59:$8RDE(/5EIX$5DT"=\;O1%$
M0[(K 4$X)-<.YA2Q1S<0-O;&VRWV\G?4:FP_L[VG9:$RCZS&R:(BK'N?/7;M
MW*2$T_!\ K/#)D C9N'9)VA\INR$3C&+6'*L1'=XSG=;HV2GS(9:!27J 4=S
MK8-BG>'KDH:S% D@YCSPI9 +26-Z'.V[8.!9=2@;L]V(AVLE179N>W'$8OBP
M/3MV[#FJ$OJAM"V&D5Y2X[4K-5DS7EA9W*$Q#2)UDW\%6'->9N6K6YR!C)BP
M*^.DW.4B@B/0AA"F*3QW[B6\"^Q^\=82R]I:QEC6?.J38(RJVIJVKMH5=0EB
MF9/V'BXAXW+"BMYX^DQ!%,I"FZF,7[ @(QPO9TC%%>WW!K5U8E*JA;8Y292F
M9>N"7L/"1I[' 1J<O.5Q">4:E@7%@AXQ3OW+%-R9T@F0XG3#NS]EPL8K<5M3
MV;2;PLW0K$NM)"]APL,<L:'G8]G*P)G*;1.:AW\G&,V,Q%+KJD!-PU4525*8
M#$,)1 <--;6$T]QWW()*&3]K9#[Q=_@ZF 0C\-[ZI&O_ '7O/SSF\N5?RC^S
MD*(;B=66RL8 P!@# .MW&<+6*E:+(<0 L!7IF9'KZ@C&1SEZ!>GV>T*(!T^S
MUS%M<ZACI'1>;ZJGAPY;EEU=;=S["A.JEXW'##EQ/3R7+WFN<6N6+'&XN:=+
MV\U'[9KVJJ'64465,9154YU5#G'M&.H<PF.<QA\HF,81$1^SG\SM6K4K5)5J
MTG*K.3E)O:VV\6V^5M[6?HU&,814(+""6"7,EN/QE!42.XHU@+/O&H@HF"C2
MO^>V=T'3KV1B&QQCU/M ))E=L/7_ -F=1?4WTBM6_6!R558\5GEKJW]3H^+4
MVZ,O%=2H?_DUGWNYJ\JT'><#PK7/#0C_ /))<:\=)3,P]OA36*KSL(G-3M<4
MDHURW2G:P_+&6")5$G;2?1+Y1!TDW>('(!B]M)5,WJ'(8HB4?WL.'#4:\'#F
MOLSF-Q2E#\J_$!WC$<F-H\P)[CCI!K0K1I^#N*$2GJ"@W=G8V>NY&BO&,U#U
M]Y(S+M\^<,5T!(W(W[0'$I30GBL2[.*332V88F=6+YUZVXUTB%TGR'V!9=L\
MC>-O%37NU^:,]K6F2%Q1US$Q-/A6]WVWL(T S:LXYO895!Y,(Q,:DZFU(OM/
M$H[S, 5R2CA;VK<WL.Q;:\5'A9I:=X[0]QV1,O&?+"IN;EQ[L])H=RV#5]HQ
M+1HS>J-*Q(TN&FUY"Q+)RK!-O%D1&1=N9%JW015<+%2P0HMX]&\\CKOC;\!K
M)%\>Y=I;MJ(,^4,ML&MZ935T;M!Y(VNVZNGRUJZTYO$0M<E98]MC)5TS22CT
MD57+U22:IMBJK*]V43P2] HE_'!X'M=;;5V8YD]YHL="["7UOONKCQVVXI=M
M&S#:9;U\TGMR 0K*H4*OKS;GS-NXD%D3.WB+AL@FJY:.D41/!+'#8266\17B
MY_;WH?C<PM5BFME\G=3K[NT(2%I=B?U;9NMT*38-@A.P5O*R) (&<5JL.E$T
M':S9<Q^[)V0%5/M"G!X8\AB=\33Q3HG87A9\F.4/ '=.Q*)?N.&_:!J">L7H
M<YJ<M#W5:Z4J!N=1E*_?Z\Z;2[%.!NX")R(&(1V0HD4[21@$5PAUU&>Y_9R&
M2UQXA^D=75NOU"\S=LOVX*?Q)K'*K<U8U_6PLEEINGDX6.)8-I6%@FXBD'#,
MTJ94XQ\7Y[+B004(R[DZ1C"GA>_DQ/SL;Q7^#^KM<\9]QV7:<@OJ+EQ,,8#2
M6RX.DV^9JDU,OG:+((V?<-(@7]-?,ESJ%=HRK=HJT,V<$5*11!4A0X9-M8;4
M>0J>.'P&;TN,V ^LFX(JL2O(6Q<5TWDWH?:$$M'[UK;2&DG%"L3*9K[!W591
M]%3J#EN$F1I^]D<%5[I5HZ31#@EY,?$9(*1N2LWV^[-US$15O:3^I7%997!S
M,UI[&P"<A;8!K:(F-B; <3QDU(E@7[=TY0;J'4:)N416 G>I]H1A@8:>5O.?
M;^R_%EX[^%#H6ZO]15EY3G^XN5&W:TTB7.QE:TPJ=AN<-J?7[R=CI9A4!L$=
M$,2R4RBW-)II3*8LEFIVJ@N!4HI0<WSD_)O1'(RC<C.-MJU+R!V!)<8XVR7U
M/D7I?94[%W=P=@OIG9#6AW&M[,N35_M=9DUV4YBB2<(O,OVIU3M';9-HDT=@
MX%.S#I+35?%$X=7&5UZ$/?Y3T!V_N*<X^:AW:]K,LRTMM#=E=.Z1D->4^]+)
M@@Z?NGD>Z;1D@X1;0LX[:JH1KUVJ7L"&#."J^*%Q7N=FY8TR"=[-4M7"."E+
M%R/@'^KK5$R=*BHA>3*[<,6LHT:*6TIV,*\>HFB?/$W#)OWJ9C JW!8.%K!\
MY>=G^)-Q?U%.7"MW"7NQ9G5&JJENS?3"(H<],.N/.LKNNS0KU@W&U9I'=5Y^
MY![WZD.T)(3B#%)1XHR*S)W^!@V=+WGXM?"GCMM(-.;)N]R+>GVDO\1%38U#
M65WOS+86I31<K+)6C7\I38>;96ANJU@) Q@0-T01CW+E<4FB"K@HE1DUBMQ3
M,?%OX:V&HH7&BV2[[%;-N-I.75M@Z;1I1W:]>\>1<.&;C8=PKLJI$/R(L7+-
M8%HZ/+(2P)$*X*U,V6065#@DG@STV:\1[B4QJ/&.VUS8JFQ1YFO!8<7JO0(2
M3E[AM]RW;HNI@8F%?HQ(5MG5D5RA,NIY6):Q"P]P[417$$Q#AEMZ-YYY7/%N
MX/V74VV]S)W^[PE.T?L"-T_L+THTUMJMR;;=4K**PC72]70E*<W:;$VBA+D(
MB[B:ZO*K,2+HKN12:K)KF#A>)*C2')O5N_)S:]-I[N8BMCZ)M$53MRZQMT9[
M"7G74[88!K:JP6;CTW#Z.>15IK3U-[&R,>[>QSQ,%"IKBJBNFD(PP,:7CFZQ
M)9^,]'V6W;@I(ZMV2T0<+]D1\WK5\CUHB2#M!Y2]]8HZ'#R^0>GV^F;Q[ALU
M=KJBOE<GA3N[5M+GG2?%'^A*H:X[R[-5LFI7B\^C67M9II_TE$U0LZX-&GS
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M]"V8?*;3_,4S*QF G1Q ;A+_ #PYF_ZK]E?E1UEZKYL?8E,=[)\Y9*A@# &
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M'E:B]X:EU_M1E6Y!TD^?5Y*]5>,L8P3I^BBV1?KQ!Y 6YER)ID6%/ME*4#
M"&L'@SV23]K9#[Q=_@ZF""$?AO?5(U_[KWGYYS>7*OY1_9R%$-Q.K+96, 8
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M5SI-5(I=,G'A\9[VE[]9;G]K=S>%-5.&7-PS7 V_ I8^(WL<X(.FA@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & :XWCU[<3$=%Z)9.>TH09K;%D: ?\
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MYQ^M;]"V8?*;3_,4S*QF G1Q ;A+_/#F;_JOV5^5'67JOFQ]B4QWLGSEDJ&
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M9A/*:SPH7&V&/)42W?A1V>&,4MYM69R:;O& , 8 P!@# & , 8 P!@# & ,
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MF<W!3ZE_%7] &J?F9$9&JOG-?_+*ONV5=SWT4Z<_@MG^H@2MSP#8XP!@# &
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MJ;>Q-^NAYLN7%<6&$D=*:9SVEG^5PNDTKJ/5JQ7)-+TI><NAX;TR9.849",
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MIV]2*E%KE3])\C3VI['M.W9\9?& , 8 P!@# & , 8 P!@# & , 8!\']O\
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M@# & , 8 P!@# & , 8 P!@%AK?M47W0FORU(8(1?L$C & , 8 P!@# & ,
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MO4\DYKSML8]7%O;^BM%NDX9SF\,*BP=*F^3FG-/EY8QY-[VX);#V<Y&V1@#
M& , 8 P!@# & , 8 P!@# & , IW?\5<_>ZW\&; *"O^T,)[D1OX&C@A;D7?
M!(P!@# & , 8 P!@# & , 8 P"PUOVJ+[H37Y:D,$(OV"1@# & , 8 P!@#
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M')M_QV=*5Y-PRTOJZZ[(DB]M-*7M;AE0JSVA\B;IN1,+#8GZ1?5%)5HP,;U
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MB84U45DE *HFJF<H@8H@ @(=!\N;LC*,HJ46G%K8T:\::>#V-'%DD# & ?<
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MJI;%MX8Q3:-X9!I;+-/T\;>/'>-82JR\Y\Z7)&/0MKV<3EAB3<S!C)!@# &
M, 8 P!@# & , 8 P!@# & , 8 P"G=_Q5S][K?P9L H*_P"T,)[D1OX&C@A;
MD7?!(P!@# & , 8 P!@# & , 8 P"PUOVJ+[H37Y:D,$(OV"1@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# (/<GO#TXS<JBO)2[TX*W?ET^B>RZ*+: MHJ
ME+V4S3!@:N(FT$*!2E_\R;.52)AV4E$NO7,ZTMWC:HTFU2L*_:Y>OS%7&=/\
M':I0Y^I**QVM,QK.M)Y-GB<[FGP737Y2'5E^%LPE^$F\-S1K[<A_!@Y,ZI.^
MF-3K1>^:BB8ZJ1( $X"^M&Q>INKRGR;LZ$B<H"!2EC'SY=4>H]P0/('1&G.^
MW2^;*-'-U/+[QKU?7I-]%1+&/_R0BEZYFJ\V[N\YL6ZEAPW5!>MZLTNF+>W\
M&3?08FK-5;/2IEY7+C7)VIV"//W;^#LD2_@YADIU$.P[C)-!J\;GZ@/D.0N;
M?M;NUOJ,;FRJ4ZUO+=*$E*+\$HMIF"5J-:WJ.C<0E3JK?&2<6O"G@T6#/H+8
MP!@# & , 8 P  "80* "(CT  #RB(B/D  #R]<<F+)Y">.@/#8Y<<AU&3RO:
MT?4FHN^[4].MFE=TVO"U4Z"5W'MGC16QS[=0.O9/'L720B'0QR^KFO\ 4/>;
MH_3BE"YNHU[R/YJAA4GCS-IJ$'T3E%]!DV5Z/S[-FI4J+IT'ZNIC".'.L5Q2
M_!3,^?&+P:./6GCQUEW X4WS>&QDG(-)MD$7K:-=$$#@#:H$6<J6#NA,)#&E
M7#EJN  ;S1(WD#GW5/?5J+.E*UR9++[%[,8OBK-=-3!<&/WB4EZ]FT<F[O<I
MR]QK9A_:KE;<&L*:_!V\7X3:?K49@&3)G',VL?'M&S!@R;HM&;%D@DU:-&K=
M,J2#9JV0(FBW;H)% I"$*!2E    #--3G.K-U*C<JDGBVWBVWO;;WM\YG\8Q
MA%0@DHI8)+<ET%5E)(P!@# & , 8 P!@# & , 8 P!@# & , 8 P"G=_Q5S]
M[K?P9L H*_[0PGN1&_@:."%N1=\$C & , 8 P!@# & , 8 P!@# +#6_:HON
MA-?EJ0P0B_8)& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#S?9.G=4
M[BB@A-J:ZIFP8PA3E0;VRO1DT9D*G[I6-<O6ZKJ,<_:5;G24*/J&#/3RS.<V
MR:KV^4W->WJX[73G*./LDGA)=#31\=YE]CF$.SOJ-.K#[Z*>'@;VKPK QE[3
M\%/B!>3N7E)]/M02"H&.BC5K(,_7RKG\HF7B+FWGGXH]H>H)MW[4I?4+T+Y,
MVAE/?AK*P2A??%[VFO\ U(<$_%*FX+QN$C#;WNYR"Y;E;=K;RYHRXH^A-2?B
M4D0!OO@*;78"LIK+>] M*?43(M[O7;!1U^QUZ@D9Q"'OJ*BI0\@&[*93#Y1
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, IW?\5<_>ZW\&; *"O^T,)[D1OX&C@A;D7?!(P!@# & , 8 P!@# & , 8
MP"PUOVJ+[H37Y:D,$(OV"1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@%.[_BKG[W6_@S8!05_VAA/<B-_ T<$+<B[X)& , 8 P!@# & , 8 P!@#
M& ><LO9#NUO8OTX\R\_E.Z[G^SSN>W[)._..X\^_XWS?SGM]WWOW?8Z=?+AE
M.WDQ\A5_"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^
M0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]
M_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>
MGR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?
M'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#
M;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"
M#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C
M@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#
MX0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ
M,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^
M0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]
M_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0?"#X]_1C@;>
MGR#X0?'OZ,<#;T^0?"#X]_1C@;>GR#X0?'OZ,<#;T^0XEO9WN5>\]/.[[L_>
M?_YE^X[(]O\ ^'"WC;T^0[?#]Q[$Q?FO?>:^QS+S;SCL><=QYLEW/?\ =_O?
;?=WT[79\G:Z]/)@J6XN. , 8 P!@# & ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g374624g42x62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g42x62.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1/X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $]R^4(0X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              48   *[    !@!G #0 ,@!X #8 ,@
M  $                          0             "NP   48
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   48     4F=H
M=&QO;F<   *[    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %&     %)G:'1L;VYG   "NP    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     "80    !
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M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_B__])0T-?4%)/1DE,10 !";[,_OX>  B <$%$0D4"$   <')T<D--
M64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M      $  /;6  $     TRU!1$)%
M                               *9&5S8P   /P   !T8W!R=    7
M   K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&03)",0
MH[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M
M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V
M,@
M                                              !T97AT     $-O
M<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U
M6@  O&<  )(P;69T,@     $ PD   $                    !
M             0   0   @   B0$'07:!VD(V0HV"X4,QPW_#S$07A&+$K<3
MXA4+%C(75QAY&9@:M1O2'.\>)1]9((<ALB+:(_\E(R9$)V8HABFG*L<KZ"T(
M+B@O2#!I,8DRIC/"--XU^S<8.#4Y43IM.XD\I3W"/MX_^$$10BE#0D1<175&
MCT>I2,-)W4KW3!)-+$Y#3UE0;U&&4IQ3LE3)5=]6]E@-62-:.EM17&9=>%Z*
M7YM@K6&^8L]CX&3Q9@)G$F@C:3-J0FM2;%YM9VYQ;WIP@W&,<I1SG'2C=:IV
ML7>W>+UYPWK(>\U\SGW-?LQ_RX#)@<>"Q8/"A+^%NX:WA[.(KHFIBJ2+GHR8
MC9&.AH][D'"19))8DTR40)4SEB:7&9@,F/^9\IKDF]:<R)V[GJV?GZ".H7RB
M:J-7I$6E,Z8@IPZG_*CJJ=>JQ:NSK*&MCZY]KVNP6;%'LC:S)+02M0"U[;;:
MM\BXM;FCNI"[?KQKO5F^1[\UP"+!$,'^PNS#VL3'Q;7&H\>1R'[);,I9RT3,
M+LT8S@'.Z\_5T+[1I]*0TWG48=5)UC'7&-@ V.;9S=JRVYC<?=UBWD??+. 0
MX/3AV.*[XY[D>^57YC/G#N?HZ,'IFNIQZTCL'>SP[</NEN]V\%7Q,_(/\NKS
MP_2<]7/V2?<>]_/XQOF5^F'[*?OK_*?]7/X+_K3_6O__   !Z .G!2P&A >_
M".<*! L6#!P-'@X<#QD0%Q$4$A 3"Q0$%/P5\Q;F%]@8S!G6&MX;X1SA'=\>
MVQ_6(-$ARR+$([XDN"6S)JXGJBBF*:(JH"N>+)TMFBZ5+Y$PC3&),H8S@S2!
M-7\V?S=_.( Y@CI_.WX\?#U\/GP_?4!_08)"A4.)1(U%DD:81YI(FTF=2I]+
MHTRF3:I.KT^T4+I1P%+'4\Y4U5775ME7VUC>6>!:XUOG7.I=[5[Q7_5@^&'\
M8P!D V4!9?]F_&?Z:/AI]6KS:_!L[FWK;NAOY7#A<=YRVG/6=,UUPW:Y=Z]X
MI7F;>I![A7QZ?6]^9']8@$V!08(U@RF$'(40A?Z&[8?;B,J)N(JFBY6,@XUQ
MCF"/3I ]D2R2&Y,*D_J4Z979ELF7NIBGF9.:@)MMG%J=2)XVGR6@%*$$H?6B
MYJ/8I,JEO::QIZ:HFZF1JH>K?ZQWK6^N9Z]@L%JQ5+)/LTRT2;5&MD6W1+A%
MN4:Z2+M*O$Z]4KY7OUW 8\%JPG+#>\2$Q8K&D,>6R)W)I<JMR[;,O\W(SM+/
MW-#FT?'2^]0&U1+6'M<JV#?91-I1VU[<:]UYWH;?E."<X:+BJ..MY++EMN:Z
MY[WHP.G#ZM3KY>SU[@3O$O @\2SR./-#]$[U6?9C]VKX;OEO^FS[9/Q6_43^
M+_\7__\   (% ]@%: ;&" 8),@I2"V4,<@UX#GH/>A!Z$7D2=1-P%&@57A92
M%T48-QDI&C0;/1Q '3\>.A\T("PA(R(9(P\D!"3Y)>XFXR?8*,PIP2JV*ZLL
MGRV3+H<O?#!P,60R63---$$U-C8K-R$X%CD+.@ Z]COM/.,]VS[3/\M Q$&]
M0K=#LD2L1:9&H4><2)=)E$J02XY,BTV*3HE/B%"(48E2B%.(5(A5B%:)5XI8
MBUF-6H];D5R3799>F%^;8)UAGV*@8Z%DHV6D9J9GIVBH::EJJFNJ;*MMJVZK
M;ZMPJ7&H<J5SHW2@=9UVF7>5>)%YC'J'>X)\?'UV?F]_:8!A@5J"48-(A#Z%
M-88KAR&(%XD,B@**]XOMC.*-V([-C\.0N9&ODJ63G)22E8F6@)=XF'"9:IIC
MFUZ<69U5GE*?4*!/H4^B4*-2I%6E6:9?IV:H;JEXJH*KCJR<K:NNNZ_,L-^Q
M\[,)M""U.+91MVRXA[FDNL*[X;T!OB&_0\!EP8?"JL/.Q/'&%<<YR%[)@LJF
MR\K,[<X0SS+05-%TTI33LM3/U>O7!M@>V3;:3-MAW'3=A]Z8WZ?@L^&^XL?C
MS>31Y=+FT.?,Z,3INNJLZYOLA^UO[ECO7/!;\5;R3/,]]"KU$O7V]M;WL_B-
M^6+Z+_KT^['\9OT1_;/^3?[A_W'__P   =D#C04)!E0'?PB6":$*I N?#),-
M@@YP#U\03!$W$B$3"1/P%-85NQ:?%X,8@1E]&G0;9AQ5'4$>+!\7(  @ZB'3
M(KTCIB20)7HF9"=.*#DI)2H0*OTKZBS7+<0NL2^>,(PQ>3)G,U4T1#4R-B(W
M$3@!./$YXCK3.\0\M3VF/I@_BD!]06]"8D-51$E%/$8P1R-(%TD+2?]*\TOH
M3-Q-T$[%3[E0K5&A4I53B%1Z56U67U=16$-9-5HF6QA<"5SZ7>M>W%_,8+UA
MK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G- ="EU$G7[
M=N1WS7BV>9YZAGMN?%9]/GXE?PU_](#;@<*"J(.-A'*%5X8[AR"(!8CJB<^*
MLXN8C'V-8HY'CRV0$I#XD=Z2Q).JE)&5>)9@ET>8+YD8F@&:ZIO4G+^=JIZ6
MGX.@<:%?HD^C/Z0PI2*F%:<(I_VH\ZGJJN*KVZS5K="NRZ_'L,2QPK+!L\&T
MPK7%MLBWS;C3N=NZX[OMO/B^!+\1P"#!,,) PU+$9L5ZQH_'ILB^R=;*\<P,
MS2K.1\]CT(#1G]*_T^#5 ]8GUTS8<]F;VL3;[]T:WD;?<^"AX<_C N1-Y9GF
MY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"  (
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M-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2 ,H>,;(:
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MACN;:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  "
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M?#2G38T-;1ZCP8NT74&@8HJ!3(F=3(F).HV:P8CL)I29,8C_#3^:7(<]  "
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M<>&UP&YI8[&QO6]Q5*NMZ7" 1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "
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M<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>HX32  "
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M9<._L72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "
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M93^Z8I;@5ZZU?Y4*26.PSY.-.C^LD)+"*;:I.),'%F"H+8\A D>AM(&*  "
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M*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6 0G?=67"
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MEY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!6(W=  "
M((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z
M'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%.
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MBH>,6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T%O^&LH^-  "
M (  F1R-:*C,B?6+V*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)+^:%O9HI
M%KZ%X8]A  "  (  F+V-"+)6B82+>Z[Q>5:)W*LY:$Z(4J>05I&'!J240]6&
M!*+V+X:%.)\=%FN%2(\H  "  (  D-B>X6C,@M><3&J-<]^: FPT8\27[VW%
M4H>6"V])/^R4AG"Q*TJ3Z'&S$&R6WG$O  "  'W0D$"=C7%C@DB;$')1<SR8
MPW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (  CYB<(7G9
M@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "
M (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"*=Z/XH"I
M#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1'(<,/9N/
MH(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)! 8 J2'XZZ
M3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5SYGX;X*3
MB9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (  C%67F:2_
M?B*54J)#;P"3 Y^37O:0S9SQ3AV.W)K4/":-3YG<*&N,.)@:#TN,K(I7  "
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M=)"B.H  9E^?3G^V5TZ<C'^"1QR:&']I-8N8*7]?(:&7=7]8"*Z7BW^3  "
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M<GV>MZ;L9"Z;IJ0R5/J8K:&E10*6#: M,]F3_)Y\()F2V)8*"..1.X8"  "
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M:'^K6(4N6P6GSX2'3+>D;8/S/7*A9(./+)"?,H-K&-F>]X._ NV:.X'[  "
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M7<Z[0&@.4..WEFEP0R.T!6K&-"JPZ&OT(Q^O/FRB#B&Q2&OC  "?!'.P  "
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M71ZU'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "
M (  :2FX?Y'^712T1Y#(4#^P&(^"0I2L&XYL,_&HFXWA(Z>F,HY%$"*F68KI
M  "8WX    "  (  :0VW\YE971>SGI?F4$2O69950I*K394(,^2GQY2V(YRE
M7I/,$#^E68K\  "82(    "  (  :/JWCZ#K72.S$Y])4%&NM9U\0I:JFYPE
M,^FG"YMN([&DE)@B$%:D@XL,  "7LH    "  (  S5!L;69$N>=N,&AUI=-O
MV&J0D.!Q8VR4>PYRWVZ-9%5T3W!]3&QUI')0,:UVJ7/6#<=X,7.VRUQI[G%4
MN%AKYW)GI&UMMG-WCY]O9W2&>>-Q!G678SYREG:E2V%S^G>;,+%TW'A5#.9V
M='?ER8AGR7Q@MI%IW'Q<HN%KRWQ?CB9MF7Q]>)%O5GRJ8A)P_WS>2EER;WT$
M+\9S*WT$#"%T[GR#Q[MEXH=0M,)H"H90H1MJ"X5@C)IK\H2'=RIMS8/38-MO
MC(,O251Q!8*-+NEQF8'K"W9SFX"XQAAD1I(TLREF?)!4GX-HC8Y^BP]J@XR[
M===L;HL77[)N0XFB2&!OPHA!+AYP*X<?"N1R>(12Q,5C )TAL=UE/YIPGCAG
M59>UB<II4Y4*=*9K1Y*%7J5M(9 S1X)NIHXI+6ENYHS%"FAQA(<)P[9A_:@3
ML-1D0*27G2IF5:#ZB+MH5)UK<ZEJ4IH37<AL,Y;_1L=ML914+-)MRY+S"@)P
MN8;$PNUA/+,)L UC?Z[$G%-EC:I,A]MGA:7;<LIIA*&X7/]K;9X%1B1LZIK]
M+$]LV9A<":]P%(:,PFI@N[W^KX5B^KCGF[)D^+.3AR5FXJY.<A=HVJES7%UJ
MPJ4^18ML-Z(^*\9L )RH"6UP$H9?OJ]TCF5@K01U@F>^FFQV<6GOAKYW6FO]
M<@]X0FW[7%IY+&_N15-Z#W&[*P-ZWW,9!X!]%G-]O49R/6_PJ^ES9G$[F5IT
M=7)PA;9U=G.8<0YV<W2]6VIW<77?1'9X77;D*CAY!7>0!O5[6W@4N\!P+GIK
MJCYQ<GJVE]-RFGKYA#]SMGM";\%TSWN56D1UY'OL0W-VUGPR*5AW3GP_!GIY
MUGQLNBEN783*J)IOLH0SEC%P[(.6@M=R&X+^;GAS3X* 62=T>((.0H5U;H&?
M*)%UMX$N!@]XA8 QN*YLT8\IIR=N,HW#E+]O?(Q0@6QPN(K?;49Q]XF$6!IS
M-(A20:AT+8<[)]YT1(9Y!;1W9(-LMWAKEIF:I?1L_Y=MDX]N394C@$-OD9+:
M;#!PV9"O5RER%HZW0.)S$XT2)SYR^XQ6!6=VWH.GMH)JFZ04I/QL"*$DDI)M
M5)X%?TENFIKF:T=OZY?Y5F!Q+I560#YR'Y,X)KQQWI(C!2=W2H-\M<MIWZZ7
MI#YK3*KGD<5LD:;X?G9MSZ,&:G=O(I]A5:-P;IPW/Z9Q79GS)DEPZI;B!/1W
MH8-9M59I8KDDH[AJR;2WD2-K_J_X?<9M+ZL^:<]N>J;R50]OQ:-G/QAPKJ$-
M)<=P%9F+!,IWYX,]L'!\_V2LH$U]'6<=CQ%]5&E7?)9]G&MG:/Y]\6UE5$1^
M5F]3/A%^U7$/) !_JW(F ?>!9W0!KU-ZT6Z@GS-[)W 3C=][>G%H>W5[U7*I
M9_-\.G/C4U-\KW44/3A]+'8=(T-]R7:? ;9_KGAQKAUXU7B1G>!Y37D9C+YY
MMGF1>DMZ)GH 9N1ZG'IV4F9['WKM/'![G7M,(IQ\ GM4 7U^*WQ7K+AW$()G
MG'-WF((EBS=X%H'/>/IXEH%R9:YY)X$F45IYO(#E.X]Z.H"C(>9Z9(!6 4M]
MT7^ZJV9UEXQ FR!V*HM B>5VM(HE=[%W/XD 9)QWUX?K4&9X?8;[.L=X^H8K
M(4EXZ(7, 2!^&(##JD]T:98RF@EU Y1XB-%UD9*6=J1V(Y"I8Z%VP8[63Y)W
M8XTW.AEWWXOY(+]WF(NV /U^58"KJ7!S>* OF25T%YV^A^ITHYL6=<%U-9AE
M8LQUVI7B3MMV@).Q.8IVZY(H(%%V<Y#, -]^AX"7J,IRP:HYF'-S8J<6ARMS
MZ*.L=/]T<J Y8@YU&)T33BMUQYIX./UV+)D0'^]U>I3T ,=^L("&J%QR1+18
ME_!RXK"*AH]S6ZQB=%ISUZ@X87-T=J2!3:5U(J&P.'QU@Y^&'W=TJ)5& +1^
MT8!YHG^%Q609DZ"%%F:)@Y>$G&C"<C^$1VK17[B$"VS*2_&#\FZL-H&$('!(
M'&6%87#F  " 3':ZH9B#N&V#DJ>#16\)@H""Z'!M<36"GW&^7L.":W,$2Q>"
M6G0[-<""?74X&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+@5V!.W@K<!*! WC
M7<" WGE52CB UWGD-06 \WI/&S>!FGHL  "  'XZGV: &8 ED#-_W8 B@!=_
MIX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (  GCM^L(E]
MCR1^?8C/?P=^4(?_;>1^*X<=6]9^'H9*2)%^,H69,[)^0H4-&CE^684,  "
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MAO*-G67Q=_",>6@@9Y^+B6HG5AN*NVP50SV**FWA+G:**6]'$\B,FV\4  "
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M@E2&2HZR<T.%8(UW8R*$A8PG4B2#S(KP/_*#1(H *]*"_8F>$A^#9X@Z  "
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M><^5'VT":YF3:6YG7$61VV^_2[R0>W$&.;Z/@7(G)7B/=G+("RZ1&')%  "
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M=?&.W9/P9[R-.Y)B6(:+J)#%2&N*38]H-Q2)0HZ8(YZ(LH[&"L:('8=)  "
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M;.Z=0G,A7YV:]'/F42&8T72L08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "
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M:DN8!IB#7-V5KI;+3G.3894,/QZ199/6+F./^Y/2&S"/C)$]!-6,'(-%  "
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M8*^F WA34_VC+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU  "4,'QC  "
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M7U:AI)RH4IF>F)KW1-B;HIE6-C.9%YC/)?R7:I;G$JJ7J8R>  N/BH (  "
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M5.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".P8    "
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ME )S'W-N@^1T#G1T<FAT^'5F7^QUX'933$9VQW<V-Q%WA7?M'9UWDG@'  "
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MCHIKXZ!7?EAM!9V1;35N'9J\6S9O0I@K2#!P4I89,]%PU)4?&SIO-9%Z  "
M (  G51I\:R7C@AK/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX
M&L1N1Y(9  "  (  F%!_EUY:BDE_<&%&>QA_>&/X:I9_GF9V6-A_UVC51<:
M+FL-,.6 OFS>%K6"/6TT  "  '9<EU-]&V>8B49].6FD>@%]9&N':9%]G&U-
M5^U]XV[^1/M^07"/,#E^O7')%C9_LW&[  "  'IGECEZUW"^B %[('(!>.5[
M8G,G:'A[L'0W5OI\"'4Z1"]\<'8I+Y=\VW;8%<5]2':%  "  'WSE05XQ'GG
MAKQY*GIR=Y=YA7K;9WEYX7LY5A!Z3GN.0W%ZP'O<+PE[&WP*%69['7NF  "
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M@KISCZ6*<WUS]**38U5T49^/4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "
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M>?V &X"C:\)_WX"67(M_IH!N3&=_>X!).JA_?8 M)MQ_CH 0#5)__G_H  "
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M<=J0D6 :9&F/<6*F5;J.@V4'1;Z-PV<Y-!^-<FD;']*.5FH7!DZ.F6H4  "
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M;;F(%H7[8%Z'*H6'4@N&0H3X0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "
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M96>81V9O6+26HFA 2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "
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M8?60U8JA552/18GD1[.-OXD5.0:,=HAV*,^+G8A1%76+XX@$ 0.'WX"O  "
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M60R@N&NX31F>E&SQ/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*>W>B  "
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M5LR:2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%(8    "
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M3-^J)F_]05>GJ'"Y-.>E57%M)M^CO''L%@JD3G&K!(2A7'+\  "%07Z*  "
M (  5U*J_78<3(JH@G:*002E_W;J-(JCIG<S)KJA]7=M%@FB77<I!,*?!GCA
M  "$/H    "  (  5O^IK7TC3%"G*GU*0-6DG7U.-%ZB-WT_)I*@='TS%AN@
MEWT6!/^<[WX6  "#7H    "  (  5KJHH(0M3"FF$H060+FC=8/'-$&A H-L
M)G2?-(-'%AV?+8.'!3Z;(8)Z  ""K8    "  (  5H6GTHM#3!.E,HK]0*JB
M@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (  5F*G-))^
M3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!@(    "
M (  M29A4UFRH_YCT5T#DC9F+V W?X9H<6-,:]YJGV9&5RALKFDE02IN8FO/
M)^MNVFW=!KETHV[%LRI=SF1AHG%@FF:LD-1C-FCF?DMEKFL0:KIH#6TH5AYJ
M0&\N0#5K_'$&)QAL$G)>!F-U-7-!L4Y:L6\!H*I=LW!*CTU@@W&,?-9C)G+.
M:6YEK'0-5/MG_G5#/SYINW96)E%I97<*!A=UM7@BKW17Y7F!GMU;%GG<C8Q>
M"7HY>UE@TGJ7:!1C?WL!4]1EZGMK/DYGJ'O$)9=FW7OK!=5V)'R:K;Y5>(/R
MG498SH-UC 1;XX+V>=Y>Q8)Y9N)AC(((4LAD$8&O/79ERH%8)/)DA($1!9UV
M@X!MK%)3=HYFF_=6Z8T8BLQ:%(O >+A=#8IJ9<Y?Y(DH4>=B<(@*/+YD)8<9
M)&)B=8:=!6YVTX.FJRU1SYC5FNI56):VB=!8D92#=\I;F))99.]>@)!4421A
M%(Z%/"EBN(T,(_!@R(RB!49W%H.1JE!0A*,VFAY4&Z!#B0I76ITW=PQ:9)H[
M9#==5)> 4'A?\94>.YQABI-6(XY?;)'L!29W3(-[J<%/F*UUF9)3-*F@B'A6
M;*6Y=GE9<*'X8[!<7IZ94 1>^IO%.RA@?YH%(R)>198>!0UW=X-JJ!=HVUE)
MF&-JJ5ROA\]L:U_F=B5N'V+P8V5ORF7<3W]Q7VBG.B)RKVLJ(.AR\6S, 4Q]
MSV[SIH%EB&-WES1GI67DAKUIFF@Q=2UK=FIC8H!M0FQ]3K-N\6Y_.71P/G!%
M(%MP G%, 2Y^ 7/'I-YBB&V.E7]DV6\.A3=F^W!X<[AH_W'483AJ[W,F399L
MN'1I.(%M_75\'YUM+G7Y 11^+7AEHS1?UW>(D]5B4'@P@Y9DE'C'<E]FN'E1
M7_YHS7G<3(QJJGIC-ZMKYGK/'OIJG7KA /U^5'QFH:A=?X%]DF!@&8%=@BUB
M?($F</YDN(#B7NAFX8"D2Y=HU(!W-NAJ X!+'FMH=( = .I^=7_4H&-;D(M[
MD2M>0HJ6@0E@N(F2;^EC"8B#7>9E0(>"2LEG-8:C-D-H6(7X'>YFJX7: -E^
MD8"3GU]9^95TD#)<O)/,@!I?/I'[;P9AFY D71%CXHYO2A-EW(SS-;]FY8OA
M'8]E,XN, ,Q^J("*GIU8NY]ACW-;B)SW?UE>#9I;;DI@;)>_7%IBN)5A26AD
MN9-I-3=ELI(W'3ID!) V ,%^NH""GAU7V*DVCNI:I:8,?L-=(Z*G;;)?>Y].
M6]!AQ)Q82/5CPIH'-,-DHICE',MC#9-X +A^R8!\FS9PLECWC-5QS%Q@?6=R
M\5^0;+QT&V*,6N%U1&5D1\%V9V@3,O)W:&I@&5YWS6M:  "  '(=F>%MAV*-
MBZ-N[F4/?#%P06=I:Z-QC&FA6>5RT6N^1N9T!VVZ,CAT]6]@&-)TR6_<  "
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MA65D9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK(XG'  "
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M?KUT"6QY<'MTXVX=8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY$'++  "
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M><UK6)9$:Y5L?)2!7%UMB9*I3"-NCI$/.JIO6X_V)X!O)X_L#P!Q4(HE  "
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M<@YZ#7+W9)9Z:'0%5BYZNW3W1EM[('73-1=[AW:((71[U';0"+)]<'<+  "
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M;E=S)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "
M (  =4Z*MU?::8")^UKP7+*)?%W>3J2))V";/S2(_F,;+?.)2F4I&7^*^67S
M ?6*%&<8  "  'Q?=%B(&U_G:+.'F6)36^B'+F2>3?B&V6;%/JF&JVBY+8Z&
MXFI+&4^(,&J[ BR';&OZ  "  '^#<VJ%D6?G9ZR%/FFS6PN$Z6MF32.$H6SY
M/?B$>&YD+0>$H6]]&0"%F6^@ DZ%$W$V  "  (  <G"#/V_?9J&#"'$96?:"
MQW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (  <7V!0G?@
M9;F!'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "
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M7="32%GW4:Z255S%1%&1E5]B-7F1)6&P)'*1HF-5#T^4C&,G  "("6F:  "
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M6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PN'$GVU  " &X    "
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M4:R;65]51C>9]&%Y.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "
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M3I:2/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "
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M12VDEF...D&BZV48+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "
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M0TJ<<X1Q.(&:MH0R+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "
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MB'5777M?>4E::GN]:1Y=/GP*6 )?ZGQ618YB*'RD,:UC&WSE&;!C1'SN  "
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M@YYK3%<O=/-L\%K,91MND%XW5!!P(V%X0:QQF&2 +75RI6<)$]%SQF?'  "
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M?-)<:H(';J)>\H'?7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "
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M=S=O,%\#:8%PA&'.6J5QS61S2H)S!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "
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M<5YB6H?*9 ]D3(<T5:YF#8:&1CUGF(7K-7!HDX6"(J1GI(6*"LMNSX1#  "
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M:K!T%V747?QU"6?S3_QUZFGK0+EVOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "
M '_O=41P!6O?:7-Q.FU]7+IR3V[^3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B
M!)]YL70H  "  (  =!-M5W0W:$MNL'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER
M>W@2&UAQ[G@B!*UX&7FS  "  (  <PYK&'R>9V]LCWT36MIMSWU:33)NXGU^
M/FIOSGV<+@!P4GV]&N%OB'W"!)AX/'Z"  "  (  <CII,X3Y9J%JOH3D6A9L
M"H213'AM)80B/;IN$(/$+6YN=8.7&IAMB(/>!)IX.(*#  "  (  <9)GIXU&
M9@!I0XRQ67AJEHO-2^1KL(K./2ALDXH&+-QLWXFZ&BMK]HG,!)EX.H,<  "
M (  <15F<96-981H&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(
M!&QXAX+]  "  (  ;,6"V5)[88*"S57G54B"]%DL1\N#.5P].-:#H5\!)]F$
M>&$L$O2&NV&5  "#.F6N  "  'P#:Y9_A%I.8)!_P5TA5&: !U_01Q" 56)3
M.$. N620)W2!:V9$$M>"^V9?  "!"6IB  "  '\V:H1\4V(C7V]\RV1>4W9]
M,F9\1BY]D&AN-XM]^&HG)NI^BFMG$I1_B6L_  "  &]Z  "  (  :6UY9FGX
M7DYZ!&NA4E%ZA6TM14MZ]VZ8-K][:&_.)DQ[VW"A$CE\CW!(  "  '3^  "
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M6KYQ*)#J3NMQX(_;0A-R2XZS- MR?HX")"]R(8XV$1%S/XKP  "  (    "
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M4DZ!$G!Q1O2!''&%.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "
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M2HR5\5-5/XF53U9*,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "
M (  4YZ3_5<_2;R31%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I
M  "  ''X  "  (  4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1
MI&6. @:-RV=G  "  ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA
M(U2- 6K0$DJ.DVJ= A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*
M]VZU,'2*CV^>(N.*BG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW.
M1IF)9W1<.]*(_74-+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "
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M/?B>[%=W,WB>&EG%)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "
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M.L^36G<Y,(*2KG>6)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "
M (  0\F207V0.FV1]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18
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M@$=0<VRG<?54 6Y68K174F_R4BE:67%X0&I<KW+G+1-="G08%3AAN'1S  "
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M>QQ##)@6;59'BI7U7H9+DI/R3J!/"I)%/8)119$=*N%0K9$3$]]>:8U   "
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M=*I3]'.J9T%7*72Y6-1:#W6R25Q<GW:=.$Q>2W=Q)6==@W@)#7YI,7@Z  "
M (  ?^M-(7NG<X!0X7P79C941WQO5]]75GRU2'M9]GSY-[);D'U#)/9:S'V)
M#5)I?'X)  "  (  ?N%*382T<HY./(1X95M1RH095QA4^(.P1\!7I8-9-QE9
M)H,I)*98D8-$#3QIH8,3  "  (  ?A-']8VE<=),"HS#9*I/MHNR5G=2^(J<
M1R=5JHFX-H17"HDK)#=6PHEB#25IR(<V  "  (  ?8)&()9G<4A*4Y3R9!].
M$9,V5?-16Y%Z1KI4"Y 7-C%53X]1(]]54(]D#.%J/(BU  "  (  ?)5I<TX3
M< 9K#5'\8KILMU725&%N6%F#1,9OW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "
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M:4)8:7G'7+!;*WI.3Q%=EGJ\0%1?B7LB, =@6'N#'4]@B7N[!M9T<GSJ  "
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M8[MN:ED35U]OW%PN2>EQ-E\A.PUR:F'0*E)S6F0#%D-T"637 ,Y^I&<A  "
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M7>U=XW[T4AM@'W\,139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "
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M5UUR[E\72^YT$F&0/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "
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M4J1D;8-!1WUF(8,'.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "
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M2S%XDF/]0%9Y567D-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "
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M1V]L 8;I/-QM089X,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "
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M/R=_CV?.-,)__FDW*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "
M (  1[I[XFU,/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95
M  "  (    "  (  1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\
M-G9L  "  'M'  "  (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P
M&?IXA'O["FUZ;WRM  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W
M((*?)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK
M-[*8K4OE+:.8E$[4(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "
M (  /S>5O$\$-E25CE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1
M  "  '4!  "  (  /D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0
MSUXN  "  &DC  "  'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H
M#_^0UV$J JJ-!F,Z  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+
MK65T'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=
M,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "
M (  .Q6%*7 I,?2%_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$Q713  "  'V8
M  "  (    "  (  .GR"NW<*,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ#
M GHK  "  (    "  (    "  (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!
M#I&"7'XN HF!B'[_  "  (    "  (    "  (    #__P  __\  /__  !M
M9G0R      0#"0   0                    $                    !
M   !   "   ") 0=!=H':0C9"C8+A0S'#?\/,1!>$8L2MQ/B%0L6,A=7&'D9
MF!JU&](<[QXE'UD@AR&R(MHC_R4C)D0G9BB&*:<JQROH+0@N*"](,&DQB3*F
M,\(TWC7[-Q@X-3E1.FT[B3RE/<(^WC_X01%"*4-"1%Q%=4:/1ZE(PTG=2O=,
M$DTL3D-/65!O4892G%.R5,E5WU;V6 U9(UHZ6U%<9EUX7HI?FV"M8;YBSV/@
M9/%F F<2:"-I,VI":U)L7FUG;G%O>G"#<8QRE'.<=*-UJG:Q=[=XO7G#>LA[
MS7S.?<U^S'_+@,F!QX+%@\*$OX6[AK>'LXBNB:F*I(N>C)B-D8Z&CWN0<)%D
MDEB33)1 E3.6)I<9F R8_YGRFN2;UIS(G;N>K9^?H(ZA?*)JHU>D1:4SIB"G
M#J?\J.JIUZK%J[.LH:V/KGVO:[!9L4>R-K,DM!*U +7MMMJWR+BUN:.ZD+M^
MO&N]6;Y'OS7 (L$0P?["[,/:Q,?%M<:CQY'(?LELREG+1,PNS1C. <[KS]70
MOM&GTI#3>=1AU4G6,=<8V #8YMG-VK+;F-Q]W6+>1]\LX!#@].'8XKOCGN1[
MY5?F,^<.Y^CHP>F:ZG'K2.P=[/#MP^Z6[W;P5?$S\@_RZO/#])SU<_9)]Q[W
M\_C&^97Z8?LI^^O\I_U<_@O^M/]:__\   'H Z<%+ :$![\(YPH$"Q8,' T>
M#AP/&1 7$102$!,+% 04_!7S%N87V!C,&=8:WAOA'.$=WQ[;']8@T2'+(L0C
MOB2X);,FKB>J**8IHBJ@*YXLG2V:+I4OD3"-,8DRAC.#-($U?S9_-W\X@#F"
M.G\[?CQ\/7P^?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC3*9-JDZO3[10
MNE' 4L=3SE355==6V5?;6-Y9X%KC6^=<ZEWM7O%?]6#X8?QC &0#90%E_V;\
M9_IH^&GU:O-K\&SN;>MNZ&_E<.%QWG+:<]9TS77#=KEWKWBE>9MZD'N%?'I]
M;WYD?UB 38%!@C6#*80<A1"%_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;
MDPJ3^I3IE=F6R9>ZF*>9DYJ FVV<6IU(GC:?): 4H02A]:+FH]BDRJ6]IK&G
MIJB;J9&JAZM_K'>M;ZYGKV"P6K%4LD^S3+1)M4:V1;=$N$6Y1KI(NTJ\3KU2
MOE>_7<!CP6K"<L-[Q(3%BL:0QY;(G<FERJW+MLR_S<C.TL_<T.;1\=+[U ;5
M$M8>URK8-]E$VE';7MQKW7G>AM^4X)SAHN*HXZWDLN6VYKKGO>C Z</JU.OE
M[/7N!.\2\"#Q+/(X\T/T3O59]F/W:OAN^6_Z;/MD_%;]1/XO_Q?__P   @4#
MV 5H!L8(!@DR"E(+90QR#7@.>@]Z$'H1>1)U$W 4:!5>%E(711@W&2D:-!L]
M'$ =/QXZ'S0@+"$C(ADC#R0$)/DE[B;C)]@HS"G!*K8KJRR?+9,NAR]\,' Q
M9#)9,TTT034V-BLW(3@6.0LZ #KV.^T\XSW;/M,_RT#$0;U"MT.R1*Q%ID:A
M1YQ(ETF42I!+CDR+38I.B4^(4(A1B5*(4XA4B%6(5HE7BEB+68U:CUN17)-=
MEEZ87YM@G6&?8J!CH62C9:1FIF>G:*AIJ6JJ:ZILJVVK;JMOJW"I<:ARI7.C
M=*!UG7:9=Y5XD7F,>H=[@GQ\?79^;W]I@&&!6H)1@TB$/H4UABN'(8@7B0R*
M HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9: EWB8<)EJFF.;7IQ9G56>4I]0
MH$^A3Z)0HU*D5:59IE^G9JANJ7BJ@JN.K)RMJZZ[K\RPW['SLPFT(+4XME&W
M;+B'N:2ZPKOAO0&^(;]#P&7!A\*JP\[$\<85QSG(7LF"RJ;+RLSMSA#/,M!4
MT732E-.RU,_5Z]<&V![9-MI,VV'<=-V'WIC?I^"SX;[BQ^/-Y-'ETN;0Y\SH
MQ.FZZJSKF^R'[6_N6.]<\%OQ5O),\SWT*O42]?;VUO>S^(WY8OHO^O3[L?QF
M_1']L_Y-_N'_<?__   !V0.-!0D&5 =_")8)H0JD"Y\,DPV"#G /7Q!,$3<2
M(1,)$_ 4UA6[%I\7@QB!&7T:=!MF'%4=01XL'Q<@ "#J(=,BO2.F)) E>B9D
M)TXH.2DE*A J_2OJ+-<MQ"ZQ+YXPC#%Y,F<S531$-3(V(C<1. $X\3GB.M,[
MQ#RU/:8^F#^*0'U!;T)B0U5$244\1C!'(T@720M)_TKS2^A,W$W03L5/N5"M
M4:%2E5.(5'I5;59?5U%80UDU6B9;&%P)7/I=ZU[<7\Q@O6&L8IMCB61X969F
M5&=":#!I'FH+:OAKY6S2;;YNJF^6<()Q;')6<T!T*742=?MVY'?->+9YGGJ&
M>VY\5GT^?B5_#7_T@-N!PH*H@XV$<H57ACN'((@%B.J)SXJSBYB,?8UBCD>/
M+9 2D/B1WI+$DZJ4D95XEF"71Y@OF1B: 9KJF]2<OYVJGI:?@Z!QH5^B3Z,_
MI#"E(J85IPBG_:CSJ>JJXJO;K-6MT*[+K\>PQ+'"LL&SP;3"M<6VR+?-N-.Y
MV[KCN^V\^+X$OQ' (,$PPD##4L1FQ7K&C\>FR+[)ULKQS S-*LY'SV/0@-&?
MTK_3X-4#UB?73-ASV9O:Q-OOW1K>1M]SX*'AS^,"Y$WEF>;GZ#;IANK8["OM
M@.[7\#'QD/+O]$WUJO<$^%KYJ_KV_#K]>_Z[____ (  @ #F3W_.?UC-F7^H
M?LVTVG^9?GF<%'^C?F6#3'_&?H5JA7_^?L!1OX!C?STY ($2@ _\Q7Y\BS3D
MM7YCB6S,0'Y=A\RSFGYNAF::V'Z8A4."&'[9A$]I6G\O@V=0KG^O@J$X%(!V
M@>;ZO'TVEG'B^WTPDY+*RWT^D,^R.GUICEZ9DWVLC"R [WX'BB)H3GYUB!-/
MP7\,A@ W07_H@ZSXXWPNH;?A07PSG;_),WQ-F?"PPGR%EE>817S?DQI_RWU/
MC_-G5GW1C+5.[WY\B4TVAW]GA5SW-WMCK0/?I7MFI^O'JGN'HPJO8'O)GFF6
M^'PKF?A^LGROE;=F;GU#D4%.+GW]C'LUY7[TAN_UO'K*N%7>+WK'LA3&0WKD
MK!2N&7LLIF&5W'N9H-I]I'PDFUEEE7S(E:A-@GV1CX$U6WZ1B%_T=WI2PZK<
M['I&O#+%"7I=M0JL^7JGKCN4Z7L?IYM\V7NVH.ADV'Q@F=U,[7TUDE TZ'X]
MB:?S8WGWSP';V'GCQD##^GGRO>2K]WHZM>R4 GJXKB1\('M;ID!D2'P0G>5,
M;WSJE.,TB7WWBL7R=7FTVEK:ZWF7T#+##WF?QI2K&'GCO6J3.WIDM&I[=WL-
MJT!CPGO,H99,"7ROES,T/7V^B[;N4XC;?C;7AH?$?<+ GX;#?7"IC(7F?562
M4H4J?75[!X2&?<9CQ(/Q?C5,CX-X?NDUDH,H@ #L/8=]B,O6%(9PAT"_:X6#
MA>.H8X2[A,&1'H0;@]]YU(.4@RUBG(,=@HU+DH+#@A8TV(*0@<'J>H9'DV74
M=(5-D-J]_(1OCG.G"X/$C%B/[8,YBG=XRH+*B+UAMH)IAP-*S8(FA4PT,X('
M@V_HVX5/G?[2X(1?FG2\>H..EQ2EJX+GD^B.M()RD0MWNX(5CD%@UH''BV1*
M&(&7B&@SHH&+A03G7(2+J*#1;(.=I!6[$(+4G[JD6X(WFY2-@('"EY5VNH%X
MD[M@"($YC[))=8$:BV4S)($?AGOF (/QLTO0&X,$K;JYS8(ZJ%BC,H&CHRV,
M>X$VGB!UR(#NF11?2H"^D]M(Y("OCCHRN8#!A\_DU8-SO?C.^H*'MU:XM8&\
ML.*B+X$FJJB+GX#$I(IU$8"#GE5>IX!4E]%(:8!3D-DR8(!RB/OCUH,.R*7.
M!8(DP.*WQH%7N5.A2H"_L?J*T(!AJKMT:X NHUQ>*8 'FY5( H 'DSLR%X P
MB?[C (*]TU3--X'6REFV^H$'P9J@B(!NN1.*(X 1L*)SVG_BJ 9=MW_&GOU'
MJW_0E58QW'_[BM?>$I'B?+#([H_Q?&.SL8X8?#J>.XQH?$>(C8K>?(]RQ8EI
M?0I=$8?\?:A'>X:9?I,R484Y?_'<*I"TAI?'E([!A5*RDHSTA#R=-HM7@UN'
MCHGD@K9QTHB(@CU<*X<S@=A&N87I@:(QRX2B@9W:HX^.D)7&.8VHCE>Q<HO=
MC#Z<%8I7BG"&>(CXB-EPT(>UAVA;2(9WA?Q&!85&A)\Q5(09@S390HZ;FI?$
MV(R_EVRP!XL'E&N:R(F"D:2%4H@YCQUOV8<%C*A:@X78BB9%;X2ZAX\P[(.@
MA*_7[HWAI)3#AXP)H(&NNHI;G)N9CXC>F.2$.H>-E4]N\(9KD=59SH5*CC1$
MZ(0]BELPD8,UA@O6M8U+KIS"7(MWJ9VMF8G*I,28@HA2H!>#3(<(FWYN&H7A
MEN)9*X3.DAU$<X/0C/\P18+:AT35IXS0N*/!7(K_LK"LH8E1K-J7FX?=IRJ"
MAH:;H8IM=X5ZF]!8H81BE=!$$H-SCVPP!8*-B%;4PHQJPJ; AHJ=N[*KSXCQ
MM-26T8=[KA*!SH8]IUMLXX4IH()8-H06F4Y#P8,GD9POT8).B4'4!(P3S*F_
MU8I-Q*"K'XBCO*66)X<MM+Z!-X7QK-YL9X3@I-57U(/9G&U#>(+TDX4OIX(;
MB@7.3YL;>X"ZHIA9>U&F[Y6L>T:3"I,G>W-^Z)#&>]IJJ(YU?'=6B(PB?3E"
MEHG"?E O0H="?^+,G9H/A-*Y@9<\@[ZF!I27@M62-)(@@B1^$X_3@:UIVHV8
M@6-5QHM9@3%!_(D1@3<N[X:F@7K+0ID1CB&X1)9%C"ZD^9.=BEJ1+I$WB-5]
M(([ZAWUI HS1ADI5#HJEA1]!=(APA HNI88;@OK*(9@>EXZW&)5CE+FCRY+)
MD@&0&Y!7CXQ\'8XMC5%H((P4BRE46(GYB/E \H?;AL$N986?A%[(_Y=FH/:V
M!Y2MG42BKY(;F;^.^H^]EFE[((V)DS-G48M_D!%3OHEMC,U BH==B6$N+H4T
MA:''[);8JF"T_I0BI=>AKI&2H7"."X\YG3%Z3(T)F0)FEXKXE,Y3-HCPD'1
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MB!K*"H9UQ<VW X4\OL"C6800MWV/68,2L"5[8H)1J-1GC8' H6A4!H$_F;!
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M?LO%LX3AA,JT (0MA *AHH.!@T*.6H+U@IYZQ8)Y@AIG&X(7@:Q3GX'*@41
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MD/98@'5OC4=$/W>UB4HPG'H[A,'14&F!K9>]RVM)J0VIOVT"I%B536[%GYV
MOG"JFNYL+7*REC)7W73:D4-#SW<VC 0P6WG/AB+0B&COM^R]!FJVLG>HZVQH
MK+F4<6XGIMY_Z7 4H0UK>'(KFRU7571DE0A#;W;.CGLP)WEUAU//_FB0P@.\
M?&I3NY2H2&OWM,23NVVMK<=_.&^8ILUJWG&XG[]6TG/]F&=##W9VD*(O_7DL
MB%/+Q'H9;"2YEWJ>;?*FO7LH;ZB3+'NV<51_(GQ,<PQJZGSQ=-]6UGVK=M!"
MZ7Z/>0 OFG^W>YC*8'@O=HNX?7C@=SREK7F(=^F2)WHP>)U^*'KB>61J!GNI
M>D)6#GR)>S)"3GV7?$DO.7[G?9/(Z':"@-VVY7=)@(&D.7@'@"J0QWC,?^I\
M]GF??[]I WJ+?Z95.GN-?Y!!LGR\?X,NXWXK?W/'9'4-BPNU4W7AB;RBJW:P
MB'"/<'>)AS![Q7A]AA!H!'F'A/94='JI@]-!)GOY@ITNF'V$@37%^7/3E2>S
M\'2PDO*A2W6.D+:.'G9WCGUZIG=[C$]G%'BDBC%3O7GAA_= J7M-A9 N6'SR
M@M+$SG+<GSFRQW._G"2@)G2AF/&-!'64E;9YIW:GDGYF.G?=CT-3&'DUB_!
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M28]@>\6#AHVC>_YT 8O_?$5D*(ID?*-4/(C5?1A$JH=$?9PUC(7 ?CPGEX1
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MB]0Q\)(GB.4I?8R$AA<BC8<<@YO.H6T89OJ[Z&[L:3VHM7"M:W&4ZG)>;9R
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MAE7$&F'WN>NQ]&1@M%*?&6:?KE>+V&CHJ"UXD6MKH@=E;6XIF]!2IW$5E5Q
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MC7_/=P$K"("Z>E6QQ'L,;TNB:GMI<,^2&WO'<CZ!$WPR<Z=OA'RM=1U=RGU
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M_GX)AN(H:W['@X:?2GPTHLB1!GPDG[N"%'P&G$-RHGO\F(QC WPDE,A3<WR
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MGHT!F#ANX8LQE85ANHE>DI%4A8>OCYI'?(8GC*$[&82BB:4O78-"AHDD_8(
M@V^':(Y&H9Y[1HR5GK)N?XJ\FS)A68C?EUU4-(<LDX='0H6IC[$Z\80SB]@O
M38+GA^HE$(&SA!N 0J ,9%MT]ITX9K]I))J":2%<RY?":XU0+93=;A5#E)';
M<,LW@(Z_<ZLL XN5=MXAV(AN>F1_NIZZ:_UTD)OT;9EHO9DR;T%<=I9D</]/
MZY-_<MQ#:I"*=.(W<XV =PHL)(IM>7,B.(=??!)_-ITR<V-S\9J#=%-H.I?'
M=4Y;^)4"=F%/B9(L=Y%#*X]->.,W6XQ;>DXL/HEC>^4BC(9R?9Q^GINU>IMS
M29D3>O-GAY9H>TQ;<).P>[5/%Y#R?#1"X(XK?,DW.XM3?6\L3XAX?C BU86D
M?O]^!)IV@<%RL9?@@8AF[Y4]@4):W)*-@/9.LX_9@+M"EHTJ@) W&HII@&HL
M7(>I@% C$H3U@#M]?9E^B-UR-);QB!)F>)1/AR)::)&@AA].38[PA1Y"98Q
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M@LW"SV@.8."Q2FI.8[^?46QY9HR,PFZ9:4UYPW##;!-FEG,(;O!3GW5R<?)
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M<R%G/(*-=(%938([=?%+2X']=WD]NH'/>1HPMH'$>N4E 8':?-R,[8'O>'"
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MA'EFI')U@]A8_W07@S1+4W7N@I@^('?U@?\Q?WHZ@5XF.7RC@+.,6FS.C7R
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M9(T*=(XV,HK5=H<MJHBD>)HEW(:1>M@?8X2R?1MC<Y-7=#-:L)&B=4E1FH_
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MPDZ.ER2%(5--E()UXE@0D=IF1%T3CS=6GV)EC(U'A&?[B<\X^6WFANLKO70
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M?!\NMW_<?14FX8!%?A8@:8"\?PUD=GUD?GU;NWW+?M)2LGX!?OM);7XA?Q%
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M;5MF>DM3?6$_>SQ%$V=;?#\W1&W3?6HJXW1J?KV9*D+N@':,&4BO@&5^>$Y
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M_P  __\  &UF=#$      P0A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MV8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V?^D."K_H45
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MCCX=_XY++O^543K_F%1'_YA84_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN
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MESP>_Z(Z)O^J.2[_LSHT^;T\..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*'
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MH9IZA)J6@8N4DHB1CH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR
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M2SS_G$P\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3+>\ P"IRP(
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M7T+SS&!!\^=@0?/H8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8-ZG @#+M@4
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M;4_"Y&Q/O>QN4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X
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M23G\XTDY_.-).?SC23G\XTDY_.-).?SC2<>M  "WMP( JL," )[0! "3XPD
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M1$#JS41 ZN1$0.CU1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$
ML+@! *3$ @"9T 4 C^$* (GQ&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6
M\U<G4O->*T_S92U,]&PP2?1S,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKW
MOSPY^,\\./?H/#CW[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\
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M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0
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M5$NYV%1+M^U42K;Y54JS_E9*L_Y62K/^5DJS_E9*L_Y62K/^5OJ' @#6F
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M+S;Q\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL   G[L  )+&  "&T $
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MFDP?H)=4*9F37#&3D&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^
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M6%F4U%=9E.Q769/Y5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0
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M04.]_T)#O/]#0[S_0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@
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M&RO[ZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP  9]X  %[R" !9_A$
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M4&A\U5!H?.U/:7S[3FE\_TUJ>_],:GO_3&I[_TQJ>_],:GO_3/]F"@#_=0@
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M2%&7_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@
MJZ@  *&P  ":LA$ E+,B 8VR, 6%L3P,?J]&%'BN3AMRK%8A;:M<)VBI8RQD
MJ&HP8*=Q-%RF>3A8I8([5:2,/E&CF$!/HZ5"3:.T0TRCR$-,H^1#2Z'T0TN@
M_T1+H/]$2Z#_1$N@_T1+H/]$2Z#_1.-]  #/BP  PI8  +>?  "MI@  HZT
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M+CS%_RX\Q?\N/,7_+L23  "VGP  J:8  )VN  "2MP  AK\  'O' P!PSP<
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M"9BP  "*N@  ?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP
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M1'9JU$5V:^U#=FO[0G9K_T%V;/] =FS_0'9L_T!V;/] =FS_0/]="@#_:0<
M['0# -I\! #0@P8 R8@' ,.*#P"ZBR !LHHO!*N(/ JDA4<2G8%0&9A^6!^3
M?%\ECGEF*HIW;2Z&=70R@G1\-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!N
MT45P;^M$<&_Z0W%O_T%Q;_] <7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78
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M0F!]_T%A??] 87W_0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP(
MMI4! *Z8!@"FFA4 GYHF IB9,P:1ES\,BY5(%(634!I_D5@@>H]?)7:-92IR
MBVPN;HIS,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#
M_T!;@_] 6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@
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M.4F;_SE)F_\Y29O_.=MZ  #(AP  O)(  +&:  "FH   G*8  )&L  "'L0@
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M&K.9  "FH0  FJD  (ZQ  "!N0  =<   &K'  !>S0, 5-0( $S=#0!*W1@
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M!!G^F 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP
M>,   &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F
M_R< (_\M "#_,P >_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_
MAP(._Y8"#?^D @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D
M %[3  !0VP  0^   #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX
M&/\C !7_*  3_RT $?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$
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M-H=:UC:&6^TVA5O[-85<_S2$7/\SA%S_,X1<_S.$7/\SA%S_,_]3"@#_708
M]68$ -]M P#5<@8 T'4) ,EV$0# =R( N'8Q [%T/@>K<4D.IFY2%*%L6QF=
M:6(=F6=J(I9F<2639'@HD&-_*XUAARZ*8) PB%^9,X5?HS6#7J\V@5Z^.(!>
MT3A_7^HW?E_Z-GY@_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D
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M.&UK_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@(
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M-5A^_S58?O\U6'[_->EH  #4=   QGX  +N'  "RC0  J)$  )Z4  "6E@X
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M8;0S EZT/01:M$8'5K-."E.S50U0LUP03;)C$TJR:Q9'L7081;%^&D*PBAU
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M#C'+L@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@
ME:4  (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [
MUS$ .=@[ #C910$VV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<
MK08HW<$&*-W>!B?;[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT
M 'ZT  !QO   9<,  %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H
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M 03_K@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0
M/]P  #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -
M_R, "_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_
MF0  _Z4  /^L  #_K   _ZP  /^L /\G+ '_*BH!_RLJ ?\J+@'_)C0"_R4_
M O\C2P/_(5@#_R!D!/\>< 3_'7L$_QV%!?\=C@7_'98%_QV<!O\=H@;_'*@&
M_QRN!_\<M ?_'+L'_QS#!_\<S@?_'=\'_QWK!_P=]0?Y'?X&]Q[_!_<=_PCV
M'?\)]AW_"?8=_PGV'?\)]AW_"?\I*@'_+"<!_RXG ?\M*@'_+#(!_RL] O\I
M20/_)U4#_R5A!/\C;03_(G@%_R*"!?\ABP;_(9,&_R&:!_\AH ?_(:4'_R&K
M"/\AL0C_(;@(_R'!"/\ARPC\(=P(^2'I"/8A] CS(OT'\B+_"?$B_PKQ(?\+
M\"'_"_ A_POP(?\+\"'_"_\L)@'_,"0!_S$C ?\Q)@'_,B\!_S$Z O\O1@/_
M+5(#_RM>!/\I:07_*'4%_R=_!O\GB ?_)I '_R:6"/\FG0C^)J,)_2:I"?PF
MKPG[)K8)^B:^"?@FR GV)MD)\B;H">\G\PGM)_T*ZR;_"^HF_PWI)O\-Z";_
M#N@F_P[H)O\.Z";_#O\O(P'_,R !_S4? ?\W(P'_."P!_S@W O\V0@+_-$X#
M_S):!/\P907_+G &_BU[!_PMA CZ+(P)^"R3"?<LF0KV*Z *]"NF"O,KK OR
M*[,+\2N["^\KQ@ON+-0+ZBSF"^8L\@OD+/P-XBS_#^$L_Q#@+/\0WRS_$=\L
M_Q'?+/\1WRS_$?\S'P'_-QL!_SH: ?\]( '_/R@!_S\R ?\]/@+_.TD#_SE5
M!/LW80;W-6P']31V"/(S?PGP,H<*[S*/"^TRE@OL,9P,ZC&B#.DQJ0SH,; -
MYC&Y#>4QPPWC,M$-WS+E#-PR\0_8,?P1U3'_$M(Q_Q/1,?\4T#'_%- Q_Q30
M,?\4T#'_%/\W&P'_.Q< _S\6 /]#' #_1B0!_T8N ?]$.0+\0D0#]C]0!/$]
M7 ;M/&<'ZCMQ">@Z>@KE.8,+XSB+#.(XD@W@-YD-WS>?#MTWI@[;-ZT/V3:V
M$-<VP1#5-LX0T3?C$<TW\1/*-_L5R#?_%L8W_Q?%-_\8Q#?_&,0W_QC$-_\8
MQ#?_&/\[%P#_0!, _T43 /])& #_3"  _TPI ?I+,P'R2#X"[$9*!.=$5@;C
M0V((WT%L"MQ =0S9/WX-U3Z&#],]C1#1/901SSR;$LT\HA/,/*D4RCNQ%,@[
MNQ7'.\@6Q3S<%L$\[1>^//D9NSS_&KH\_QNY//\;N#S_&[@\_QNX//\;N#S_
M&_\^% #_1!  _TH1 /]/% #_41L ^U(C /%1+0'I3S@!XDU% ]Q+407625P(
MT4=F"\Y&< [+17@0R$2 $L9#AQ3$0HX5PT*5%L%!G!>_0:08O4"L&;Q MAJZ
M0,(:N$#2&[5!Z!NR0?8=L$'_'JY!_QZM0?\>K$'_'JQ!_QZL0?\>K$'_'O]"
M$0#_1PT _T\. /]3$0#_5A4 \U<< .A6)0#@53$!UU,_ L]23 7*4%<)QDYA
M#<-,:A# 2G(2O4EZ%;M(@A:Y1XD8MT>0&;5&EQNS1I\<L46G';!%L1ZN1;P?
MK$7,'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_
M2PH _U,, /]7#0#Y6A  ZUL4 -]:' #46BL S%H[ L982 7!5E,)O%1<#;E2
M91&U4&T4LT]U%[!.?!FN380:K$R+'*I+DAZH2IH?IDJC(:1)K"*C2;@CH4G&
M))]*WB2=2O DFTK])9E+_R292_\DF$O_))A+_R282_\DF$O_)/](# #_3P@
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M+7I<_RQY7/\K>ES_*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0  ,]J  #';@(
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M+&5K_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX  *9^ 0"??Q
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M'3Z?LAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB
MJ9   )Z6  "3FP  AY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4
MKD #4:U(!4ZM3P=+K5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFK
ML!<XJ\,7.*KA%S>I\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8
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M B#3ZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN
M8+X  %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @
MX#< '^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13G
MW0$3Y>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8
M $C*   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT
M%.\U !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )
M]MD "/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2
M   QV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI
M  K^,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L
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M#KTVY@ZY-O00MS;_$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L
M_T,- /]'$ #_2!0 ]4<< .M&)@#C1#( W$1! =1#30+/05@$RT!B!L@_:PC%
M/G0)PSU["\$]@PR_/(H-O3R0#KL\EP^Z.Y\0N#NG$+8[L!&U.[L2LSO)$K$[
MX!.N//$4JSS]%:D\_Q:H//\6J#S_%J<\_Q:G//\6ISS_%O\]#0#_0@@ _T@*
M /]+# #Z3 \ [$P4 .%*'0#62BP SDL[ <E*2 +$2%,$P$==![Q&9@FZ1&X+
MMT-V#;5#?0ZS0H00L4&+$;!!DA*N0)H3K$"B%*I JQ6I0+86IT#$%Z9 V1>C
M0>T8H$'[&)]!_QF>0?\9G4'_&9U"_QB=0O\8G4+_&/] "0#_1@4 _TP% /%/
M!P#F4 D XT\- -5/%0#,42< Q5$V ;]00P*Z3TX%MDU8"+-,80JP2FD-K4EP
M#ZM(>!&I1W\2IT>&%*5&C16C1I46H46>&)]%IQF>1;(:G$6_&II%T1N81>D;
MED;X')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#9
M5@4 TU4) ,Q5$@##5B( O%<R ;=6/P*R5$H%K5-4"*I170NG4&0.I$YL$*)-
M<Q*?3'H4G4R!%IM+B1>92I$9ETJ9&I5)HQN32:X=DDF['I!)S!Z.2N4>C4KV
M'HM+_QZ+2_\=BDO_'8I+_QV*2_\=BDO_'?]%  #_30  Y50  -E9  #/6P,
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M(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P  LVP  *QJ! "D:Q(
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M($M]L2%*?<0B2GWA(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@
MM'L  *J"  "@A@  E8@  (>(  !\B@  =HP. '*-&@!NCB< :HXR 6:-/ -C
MC40%8(Q,"%R+4PI:BUH-5XIA$%2):!)1B'$53XAZ%TR'A1I*AI(<2(:@'4:&
MKQY%A<(>187?'D6$\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$
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M#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G
M>:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]
MLDL!.[)3 CFR6P,WLF0$-;)N!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP
M[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@
M &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40
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M  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0
M+LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )
MZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L
M[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8
M !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X
M /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT
M^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D
M   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I
M  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,
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M =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A,
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M#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D
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M%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  # 60  NE@! +16"0"L5Q8
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M&U=FL!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@
MNFH  *]P  "F<P  FG,  (]P  "'<04 @7(1 'QS'@!X<RH =',U 7!S/P-M
M<D<%:G%.!V=Q50ED<%P+8F]C#E]O:A!=;G(26FU\%5AMAA=6;),95&R@&U)K
MKQQ1:\$<46O<'%%K\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX
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M%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P
MA80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.,@!5CCL!4XY# E".2@-.
MC5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8$3R*IQ([BK@2.HK/$CN(
MZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD
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M!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@
M2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  F
MN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT
M_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8
M #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H
M%L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0
MP_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!
M   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))
M  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8
M =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9
MS@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A
M1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G
M (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0
M"]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0
M[T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M
M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8
M  #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4
M /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_
M%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\
M@P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1
M /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T
M_Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_
M X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!
MXP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8
M /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H,
M]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B
M"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<
M&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"&
M .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?
MTA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_
M(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06<@#B%GH X!:" -X6
MB #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?) ,P8W@#(&>X!Q1K[
M <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L _R@, /\I$ #_*!8
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M"I(W_PJ2-_\*DC?_"O\S  #V.@  Y#\  -A"  #.0@$ R3X& ,0[#P"[/AT
MM3\L +$_.@"M/T4!J3]/ :8^6 *C/5\#H3UG!)\\;06=/'0&G#M[!IH[@@>8
M.XH(ECN3"94ZG J3.J8+D3JR"Y [P R..]4,C#SL#8H\^PV)//\-B3S_#(@\
M_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20  OT8" +I## "S1!D K44G
M *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:407 'DD%V")! ?@F.0(8*
MC4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!^0^ 0?\/@$+_#H!"_PZ
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M$.Q#  #93   R%,  +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4
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M%&)5KQ5A5<$68%7;%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@
MO5T  +)A  "H8P  G6$  )5=  "-7@D AUX3 (-?( !_7RP >U\W 7=>0 )T
M7D@#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I\#V):AQ%@69,27EF@%%U9
MKA5;6;\66UG8%EM9[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF
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M%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@
MC&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q-@%A<3X!7G%& EQP30-9
M<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8$4ELIQ)(;+@31VS-$T=L
MZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X  *%R  "3<@  AW$
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M##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP
M58H  $Z,!@!*CA  2(\: $>/)0!%D"\ 1) X $*00 ! D$<!/Y!/ 3V05@([
MD%\".9!H S>/<P0UCX %,X^.!C&/G@<PCJ\'+X[#!R^.X0<OC/0(+XO_""^*
M_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0  <(<  &6*  !:C@  3Y(
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M 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0
M(+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -
MOF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4
M  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$
M !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD
M ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\
MH0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.
M   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:
M  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0
M9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -T@  !]8   #;
MW@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L
M6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D
M $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@   .$   #E    Z
M .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@
M_%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!
M( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ",
M /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L
M[0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_
M R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0
MCP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U
M ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R(
M_P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J
M )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -<
M_0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH
M /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT
MWP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(
M#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1
M+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/
M - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\
MNQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F
M%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5
MD0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_
M :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH
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M!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J.Q0 I3PB * ], "=/3L
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M"V]$KPQN1, ,;479#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20
MP4\  +52  "K4@  H4\  )M*  "42@P CTL7 (M,) "'3"\ A$PZ (%,0P%^
M2TL!>TM2 GE*6 -W2E\$=4EF!7-);09Q274';TE^"&U(B EK2),+:DB?#&A(
MK0UG2;T-9DG4#F5)[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(
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M#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70
MCUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;-P!H6T !95M' 6-:3@)A
M6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8#5-8I@Y26;8.45G*#U%9
MYPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60  L%\  *-A  "68   BU\
M (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C8#T!85]% 5]?3 )=7U,#
M6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=I U-7;0.3%W(#DQ=Y@Y-
M7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,  )]C  "28P  AV(  'Q@
M  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L 7&1# 5ID2@)89%$"5F18
M U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(8K(-1V+'#4=BY U(8?8,
M2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF  "-9@  @F4  '9D  !N
M90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI  55J1P%3:DX"46I5 T]I
M701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,0F?%#$)GX@Q"9O4,0V;_
M"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0  ?6D  '%I  !G:@
M8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P10%.<$P!3'!3 DIP6@-(
M<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6[""CQNX H];?0*/6S_"CUK
M_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0  >&T  &QN  !A<   6W(
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M!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4
M-9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P G
ME',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\
M  "7@   AW\  'N   !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP)
M "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT
M&Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/
MA@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH
M"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT
M  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C
M>HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /
MM0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W
M>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<
M &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4
M \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P
MQ8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI
M  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'
M  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,
M -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%
MN   .+P  "N_   AP@  %\8  !#)   *S    M    #4    UP   -@   #:
M!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW
M  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP
M+,0  "#(   6S   #M    ?4    V0   -T   #A    XP   .0   #F
MYP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y
M>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R
M /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )(
M]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H
M /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\
M.P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4
M .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\
MW0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_
M $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .(
ME@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_
M ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P
M[P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2
M )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "
M_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-"
M -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90
MQ 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T
M#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,
M1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8
M +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\
MIQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_
M%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7
MG "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_
M ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4
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M X,OL@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P
MR3T  +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"-
M-5  BS57 (DU7@&'-60!A31K 80T<@*"-'D"@#2" GXTBP-]-)8#>S6A!'DU
MK@1X-;X%=S;4!78V[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(
M +A$  "L0@  I#X  )\Y  ":. X E#H9 ) Z)@"-.S$ BCL[ (<[1 "$.TP
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M"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30
MDDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P24( ;DE) 6Q(4 %J
M2%8!:$A= F9(9 )E2&P#8TAU!&%'?P5@1XH&7DB7!UU(I0A;2+0(6TC'"5I(
MY A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3   LE(  *-1  "74   C4X
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M!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6   @5<  '=4  !P50
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M!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X
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M;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2
M%@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E  *X): "J"9  H@G  )H)_
M 26"CP$D@J !(X*R 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0
M@W$  '9Q  !L<@  8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 I
MBQD )XLB ":+*@ EC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-
MB@ ;C9P &8VN !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78
M ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD   )9," !^5#  =EA(
M')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0
MF)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^
M  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2
M !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX
M!*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8
MC   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O
M$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7
M  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F
M19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@
MNA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^
MGP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L
M #*O   HM   'K8  !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X
M ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP
MSZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ
M   =O0  $\    W$   &QP   ,H   #.    T    -$   #2 @  TP@  -4,
M  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@
M .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2
MR   #,L   //    TP   -@   #<    WP   -\   #A    XP   .0#  #F
M"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9
M  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@
M_P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q
M )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0
M_P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/
M /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H
MY0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8
M /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$
M50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "<
M -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\
MR #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A
M %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,<
MH #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_
M /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %,
MS@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y
M *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0
M  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016
M +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$
MJP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\
M$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.
M5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I
M )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P
MX!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D
M%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9
ML@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD
M ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0
MEQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&
M(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ
M  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F1P"/)D\ C296
M (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0& *),!?BB> 7TIJP%[*;D!
M>BG- 7@JZ %W*_D!=BO_ 78K_P%U*_\!=2K_ >4L  #0-   P3@  +,X  "H
M-0  HC$  )TM  "9*@X E"L8 ) L) "-+3  BBTZ (<M0P"%+4H @RU1 ($N
M6 " +EX ?BYD 'TN:P![+G,!>2Y[ 7@NA0%V+H\!="^; 7,OJ )Q+[8"<##)
M F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@
MFC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!],T8 >S-- 'DS5 !W
M,UH =C-A '0S9P%R-&\!<31W 6\T@0%N-(P";#28 FHUI0)I-;,#:#7& V<V
MX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@  M4(  *9!  ";/P  DSP
M (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U.4( <SE) '$Y4 !P.5<
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M U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P
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M [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451(
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M 3-CD0(R8Z$",6.S C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70
MBET  'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [
M:"( .6DK #AI,@ W:CH -FI! #5J20 T:E( ,VI; #%J90 P:G !+FI^ 2UJ
MC@$L:I\!*VJP 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&
M '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X
M,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D
M<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D
M  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA
M "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@
M&WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C
M:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$
M(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F
M !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<
M4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2
MD"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0
MLP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T
M $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H
M!YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@
MF[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,
M   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<
M  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4
M *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   J
MG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S#   LQ   +05  "T
M&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^
M  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP
M&:\  !&S   +M@  !+D   "\    O@   +X   "_!@  P L  ,$/  #"$P
MPQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*
MP0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P
M  J_   !P0   ,0   #(    R@   ,H   #,    S0,  ,X(  #0#0  T1
M -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@
MX+X  .## &:?  !9I@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*
M    S0   -$   #5    V    -D   #;    W0   -\   #A!   XPH  .4.
M  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X
M /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^
M &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P
MI@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_
M /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\
M\0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#>
M *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\
M#0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B
M .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8
MRP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_
M  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -(
M8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K
M +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_
M_P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#!
M &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X
ML@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,
M .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\
ML@!E +  :@"O '  K0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@
M +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/
M  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=?
M *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H
MDPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^
M%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/
M8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++
M (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P
MJQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",
M%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<
MX@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",
M )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP
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M 5\P_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.   B34  (,R  !_, $
M>R\. '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H,E  9S)7 &4R70!D
M,F4 8C)M &$S=P!?,X(!7C.. 5TTG %;-*H!6C6[ 5HUT@%9->T!637\ 5@U
M_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/   @SH  'TW  !X-   =#0+
M ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A-DT 8#93 %XW6@!=-V(
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M/A< 7CXA %P^*0!:/C$ 6#XY %<^0 !5/T8 5#]- %,_50!20%P 4$!E $]
M;P%.07H!34&' 4M!E@%*0:4"24*U DE"RP))0N@"24+Y DE!_P))0?\!24'_
M ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H0   8T$! %]!#0!<010
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M 3U-D $\3: !.TZQ CI.Q@(Z3N0".TWV CM-_P$[3/\!/$S_ ;--  ">3
MC4P  '],  !T3   :DP  &!*  !92P  5$P  %!-!0!,3@X 24\5 $=/'@!%
M3R8 1% N $)0-0!!4#T 0%%$ #]12P ^45, /5)< #Q29@ Z4G( .5)_ 3A2
MC@$W4IX!-E*O 352Q $U4N(!-E+U 391_P$V4/\!-U#_ :Y/  "93P  B4\
M 'M/  !P3P  9D\  %Q.  !43P  3U$  $I2 0!&4PP 0U02 $%4&P! 52,
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M "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60
M6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G
M:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MK
MN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX
M $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@
M'70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1
M=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG
M   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ
M !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8
M"GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y
M<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)
M*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:
M  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0
M*H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)
ME2P  )4U  "50   E4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2
MY@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT
M !N1   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24
M *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW
MH>L  *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>
M   .H0  ":0   *G    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D
M  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>
M +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   '
MK@   +(   "U    MP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_
M(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3:
M &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4L0  #;8   :Y    O
M +\   ##    Q    ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&
MTB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6
M  !1G   1*,  #BJ   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T
M  #0    T@   -(   #5    U@   -D   #;    W@4  . *  #B#P  Y18
M .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_
M  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8
M;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S
M ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H
M_P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I
M &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -(
MN@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P %
M /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H
MV !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#!
M ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D
M!P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J
M ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T
ML0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C
M  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8
M:@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#(
M *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8
MR0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G
M &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4
MW "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  *
M +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0
MF@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(
M!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&
M#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE
M (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\
M? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=
M#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((1
M9P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;]
M '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L
MC104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V
M&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>
M_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0
M '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4
M:R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?
M)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C
M%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I
M &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\
M6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K
M*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL
M;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__
M ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@
M8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2
M,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY
M  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,>
M %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4
M2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B
M/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W
M(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN
M $4[C@!$/)X 0SRN 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@
MC3X  '\^  !U/@  ;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,
M.R@ 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _
MC0 _0)P /D"M 3U P $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$
M 'Q!  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4
M1D L $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z
M1)L .42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#
M  !N0P  94,  %U   !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D
M-$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J
M1@  844  %E$  !11   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*
M+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH
M "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20
M74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S
M3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2
MN0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP
M %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\
M+%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B
M5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0
M  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS
M "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P
M&UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!
M5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD
M-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G
M !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7
M-E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3
M;3D $FY" !%N3  0;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK
M\P -:_T #6K_ ()9  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68
M "II   D;   '6\  !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S,
M"G<\  EW1P (=U( !W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "
M=/8  G3\ 'M=  !M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R
M   >=0  %WD  !)\   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V
M  ""0   @DP  ()9  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(
M '[Y '1B  !H8@  7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7
M@   $8,   V&   (B00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  ".
M.0  CD0  (Y1  ".8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV
M &YH  !D9P  6&D  $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C
M#(\   :2    E0   )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,
MG#L  )Q(  "<5P  G&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM
M  !>;P  47(  $9W   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P
M  "@    H@   *,!  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$
M *L^  "L30  K%T  *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7
M>0  2WX  #^$   TB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N
M    L    +    "Q    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS
M  "]00  O5(  +UD  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0
M1(L  #B2   LF0  (9\  !>D   0J0  ":X   "R    M@   +D   "]
MOP   +\   #     P0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0
M-0  T44  -)7  #2:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H
M #"B   EJ   &JX  !&T   )N0   +T   #!    Q    ,@   #+    S0
M ,T   #/    T    -(   #4    V    -H&  #=#   X!$  .,:  #F)P
MYS@  .A*  #I70  ZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\
M$ #_ !H _P F /\ ,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U
M .X >@#L '\ ZP"$ .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L
MVP#F -D ]P#8 /\ V #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_
M !4 _@ A /H + #W #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .
M=0#> 'H W0!_ -L A0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#=
M ,@ \0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$
M\0 < .P )P#I #( Y@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #,
M '4 R@!Z ,D ?P#' (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@
MZP"W /L M@#_ +8 _P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6
M -L (0#5 "T T0 W ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\
MNP!T +D >@"W (  M@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H
M /4 IP#_ *< _P"G /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,<
M' #" "8 OP Q +P .P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O
M *H = "I 'H IP"! *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\
MF0#] )@ _P"8 /\ F #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S
M "  L  K *T -0"K #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T
M;@"; '4 F@![ )@ @P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X
M (P _P", /\ C #_ /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D
MI  D *  +@"> #< G !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/
M &\ C0!V (L ?@"* (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\
M_P!_ /\ ?P#_ .@-  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  =
M )4 )P"2 #$ D  Y (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL
M@0-R ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S
M"O\ <PK_ -T5  #$%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)
M( "("2H A0HS (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN
M '4-=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\
M:1#_ - =  "Y'@  J!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^
M$"0 >Q M 'D0-@!W$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2
M<P!I$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_
M ,<B  "P(P  GR0  )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\
M<18H &\7, !N%S@ ;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@
M&7D 7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G
M  "I*   F2@  (LH  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC
M &<=+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8
M5B&" %4AD !4(IX 4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C
M+   DRP  (8M  !\+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C
M)P!=(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_
M $XGC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P
MCC   ($P  !W+P  ;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6
M*"L 52@R %,H.0!2*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@L
MBP!'+9H 1BVJ $4NO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,
M 'PS  !R,P  :S$  &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@
M3BTO $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!
M,9@ 03*H $ RNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV
M  !N-0  9C4  &$R  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8
M.S:G #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K
M.   8S<  %TV  !7,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U
M+P! -38 /S8] #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE
M #8ZN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P
M7SH  %DY  !3-@  3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^
MM@ Q/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T
M %4\  !..@  23L  $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K
M0LL +$+I "Q"^0 M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_
M  !)/@  1#\  $!    \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V
M "]$/0 N144 +45. "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D
M)D;G "=&^  H1?\ *$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%
M0@  /T0  #M%   W1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*
M.@ H2D( )TI+ "9+50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF
M "%+]P B2O\ (DK_ )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P
M/$@  #=)   R2P  +DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B
M4#\ (5!( "!04@ ?45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0
M]@ ;3_\ '$__ (I&  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P
M #-.   N4   *%," "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL
M&E=$ !E73@ 85UD %UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  4
M5?\ %%7_ (1)  !T2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4
M   I5@  )%D  !Y;!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY
M !%?2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P
M#ES_ 'Y-  !N3@  8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D
M70  'U\  !EB 0 390D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG
M10 *9U  "6==  =G;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\
M '=1  !I4@  75(  %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9
M&6<  !-J   /;08 "W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P
M<$H  '!7  !P90  <'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6
M  !C5@  658  /_B__])0T-?4%)/1DE,10 $"5%7  !'6   /EL  #9?   N
M8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y
M'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"
M  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;
M('   !ET   3=P  #GL   E^   $@0(  (((  "##0  @Q   (04  "%&0
MAB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%
MTP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L
M !*    -@P  "(<   **    C0   (X$  "."0  CPT  ) 0  "1%   DAD
M ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R
MD^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-
M   &D0   )0   "8    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8
M  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$
M *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<
MH    *,   "F    J    *D   "J    K    *T$  "N"0  L T  +$1  "S
M%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0
M %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@
M +(   "V    N    +@   "Z    NP   +T   "^    P 4  ,$+  ##$
MQA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#
M  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8   "Z    O@   ,(
M  #&    R    ,@   #*    RP   ,T   #.    T    -(!  #5"   V0X
M -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_
M  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /
M8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J
M -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_
M_P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#?
M &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,<
ML #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P
M /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\
MR0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V
M +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H
M @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !?
M +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$
MI #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+
M  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *<
M7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z
M )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  (
MLP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7
M %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8
MQP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ '
M *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@
MB0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y
M -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4
M"@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8
M 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8
M;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'
M!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%
M60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL
M &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8
M? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G
M#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1
M_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$)
M &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@
M7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1
M%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85
M#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA<
M %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\
M2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;
M&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?
M80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_
M *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\
M4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#
M)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J
M  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43
M $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68
M/"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*
M+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J
M%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP
M #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0
M=S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]
M+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S
M?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0
M &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD
M-C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K
M-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W
M  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@=
M "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D
M)3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8
M.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H]
M(0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9
M !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/
M33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C
M0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&
MJ0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\
M $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22(
M'$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 2
M2[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"
M   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E
M !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@
M#%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V
M2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8
M*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*
M  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2   04D  #I*   R30
M*U   "52   @50  &E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %
M8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>
MX@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8
M "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28
M &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW
M9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB
M   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H
M  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L
M '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /
M;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  "
M*@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ
M %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P  %',   YW   )>P
M W\   ""    A    (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@
MCRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=
M  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$   B%    B0   (T
M  "0    D@   ),   "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,
M * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !'
M:   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4    F    )P   "?
M    H0   *(   "D    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C
M  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P
M-7H  "J!   ?B   %8X   Z5   &F@   )\   "D    J    *P   "O
ML0   +$   "S    M0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%
M)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD
M "*0   7F   #Y\   >E    J@   *\   "S    MP   +P   "_    P0
M ,(   #$    Q0   ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@
MW2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\
M# #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I
M .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,
MSP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[
M !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -,
M:0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#-
M +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T
MY  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_
M &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P
MX0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1
M ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &,
MK !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@";
M .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0
M% "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B
M )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8
MBP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P    J  * *0 $ "@
M !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P
M80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R
M 'T _P!] /\ ?0#_ .    #&    M0   *H   "B    FP % )4 #0"2 !,
MD  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^
M &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '
M^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6
M ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T
M<0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E
M /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '<
M& !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!?
M &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX
M6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L
M!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)
M8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_
M *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4
M80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2
M#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49
M  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8
M %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V<
M2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",
M(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6
M' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP
M #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P
M>"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'
M&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?
M>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<
M &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P
M/R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R
M)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J
M  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20?
M #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8<
M+"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9
M+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H
M(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7
M "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P
M3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K
M+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$R
MIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$
M $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0
M)3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;
M-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S
M   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H
M !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[<
M%3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z
M-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^
M+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#.
M !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0
M,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 3
M1#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%
MY0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX
M "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT
M#4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %
M2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%
M   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R
M  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X
M %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;
M30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9
M-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V
M &-$  !610  344  $5%   _10  -T<  "])   H3   (D\  !M2   650
M$5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0
M8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(
M  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6
M  AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30
M &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.
M30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N
M    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY
M  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40
M0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %<P   '<   !Z
M?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*
M/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H
M #)?   H9   'VD  !9O   0=   "GD   )]    @0   (4   "(    B@
M (P   "-    CP   ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-
MFT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ
M   A<0  %W<  !!]   )@P   8@   ",    D0   )4   "8    F@   )L
M  "=    GP   *    "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D
M *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9
M?P  $(8   F-    DP   )@   "=    H0   *4   "H    JP   *L   "N
M    KP   +$   "S    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)
M  #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D
M"I<   "=    HP   *@   "M    L@   +8   "Y    NP   +P   "^
MP    ,(   #$    Q@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #9
M20  VEX  -MU  #;C   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9
M /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X
MW@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#&
M /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X
M'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M
M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L
MM #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2
M "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4
M;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_
M *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\
MN0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A
M &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ),
M_P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP + *L $0"G !D I0 B
M *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8
MD !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$
M /\ A #_ .4   #-    O    *\   "F    G@ ' )H #@"6 !0 E  = )(
M)0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G
M (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\
M=0#_ -    "[    JP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( ""
M "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ',
M:0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_
M ,    "L    G (  ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "(
M=  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E
M &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'
M  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C
M &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@
M6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6
M#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X
M)0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O
M $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@
M?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5
M!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+
M>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@
M &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2(
M3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^
M$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=
M  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D
M $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84
M-A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:
M(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5
M)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4
M "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P
M3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U
M&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?
MI  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4
M $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8
M+A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B
M)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G
M   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J
M "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0
M'2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \
M*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H
M+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S)
M !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P
M-"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <
M+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,P
MY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T
M "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$
M%C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0
M-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ
M   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV
M ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$
M##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A
M-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^
M/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W
M &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P
M&CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #
M14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V
M  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(
M !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX
M $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2
M.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+
M   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%
M  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@
M13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   230  #E    M3   &
M50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<
M30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(
M #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@  "ED   5;    7@
M & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@
M9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='
M   O2@  )DT  !]1   850  $ED   U<   (8    F,   !F    :    &H
M  !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X
M '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I
M4@  (%8  !A;   27P  #60   =H    :P   &\   !R    =0   '8   !W
M    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16
M  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7
M&6(  !)G   ,;   !7$   !U    >0   'T   "!    @P   (4   "&
MB    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "5
M8   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\
M  QU   $>P   (    "%    B0   (T   "1    DP   )0   "6    F
M )H   "<    G@   * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@
MJ&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%
M    BP   )$   "6    FP   )\   "B    I    *4   "G    J0   *L
M  "M    L    +(   "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$
M +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -B   !8\   "6
MG    *(   "G    K    +    "S    M@   +<   "Y    NP   +T   "_
M    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N
M  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H
M]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3
M 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T
M_P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N
M -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ',
MO0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I
M /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4
M,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S
M *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\
MF0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M
M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )<
M= "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_
M .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X
MEP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"%
M '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D
M  #!    L0   *0   "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O
M (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '
M=0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O
M    H    )0   ",    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '<
M, !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T
M &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@
MD0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I
M #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H
M>@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<
M 'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L
M70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/
M (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -
M  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K
M %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (
M10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@
M$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"
M+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:.
M #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0
M5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!
M"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-
MGP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@
M $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H
M.0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L
M$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:
M  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M
M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;
M)17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^
M'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5
M,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$
M !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@
M-QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D
M&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>
MX  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R
M # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C(
M'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5
M(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB
M   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X
M !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$
M$B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F
M)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I
M/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[
M &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*
M'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .
M+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G
M  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT
M !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T(
M"3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6
M+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R
M   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*
M   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@
M2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /
M.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _
M4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(
M #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P,
M"$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@
M1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU
M   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&
M  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@
M $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q
M-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1
M"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C
M  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/
M)C\  !]"   910  $T@   Y+   +3P  !5$   !4    5P   %@!  !:!0
M6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A
M<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\  #%    I0P  (48
M !I*   33@  #E$   I5   $6    %L   !>    80   &,   !D 0  900
M &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:
M;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4
M   .6   "%P   )@    9    &<   !K    ;0   &\   !P    <@   '0"
M  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<
M 'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '
M90   &H   !N    <@   '8   !Y    ?    'X   !_    @0   (,   "%
M    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&
M  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@  #F@   =N    =
M 'D   !^    @@   (8   ")    C    (X   "0    D@   )0   "6
MF    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "C
ME   H:L  *&_ #97   L7   (6(  !=I   /<   !W<   !^    A    (H
M  "/    E    )@   ";    G@   )\   "B    I    *8   "H    JP
M *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP
MMZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/    E@   )L   "A
M    I@   *H   "N    L    +$   "T    M@   +@   "[    O0   ,
M  ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98
M ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I
M $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@
M@@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_
M /\   #_    ^P   /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L
MS !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R
M (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T
M  #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \
M +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T
MG@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F
M    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\
M/ "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "!
M (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+
MN@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+
M #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H
MA@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@
M )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8
M>@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I
M (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H
M  "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U
M &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (<
M6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S
M    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X
M-0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1
M $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P
M8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2
M #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4
MG0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D
M %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #
M2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \
M *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,
M  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q
M #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@
M,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$
M#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#
M,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z
M "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@
M/!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O
M"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-
MT@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,
M #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0
M* X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =
M$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5
M   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y
M "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X
M&!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J
M%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5
M/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z
M &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0
M)!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5
M&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;
M  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L
M !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4
M$!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7
M'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@
M   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-
M  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0
M22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3
M) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H
M50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4
M #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)   &"4  !0F   1* ,
M#RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@
M+F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG
M   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'
M  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT
M #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P
M*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U
M"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI
M   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+
M*BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@
M/ T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _
M>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X
M "(O   =,   &#(  !,U   0-P  ##H   D\   %/@   $$$  !""   0PL
M $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P
M1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T
M   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+
M  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0
M $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4
M/@  $$$   Q$   '1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7
M"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7
M  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P
M"TH   5.    40   %0   !7    6@   %P   !=    7P   & $  !B!P
M9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !F
MJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD  !!-   *40  !%4
M  !:    70   &    !C    9@   &@   !J    :P   &T   !O @  <08
M '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP
M=;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G
M    :P   &\   !R    =0   '<   !Y    >P   'T   !_    @@   (0#
M  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T
M (?% #9'   L2P  (D\  !E5   06P  "F$   %G    ;0   '(   !W
M>P   '\   "#    A@   (@   "*    C0   (\   "1    E    )<   ":
M 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW
M #!0   E50  &UL  !)B   +:0   7    !W    ?0   (,   "(    C0
M )$   "5    F    )H   "<    GP   *$   "C    I@   *D   "L
ML    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;
M   >8@  %&D   QQ   ">0   ($   ")    CP   )8   ";    H    *0
M  "H    JP   *P   "O    L@   +0   "V    N0   +P   #     Q
M ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_
M    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X
M20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2
M +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W
M\@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_
M $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@
MEP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP
M -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $,
MJ !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3
M )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@
M  "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!"
M )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8
M?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9
M    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (
M0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"?
M &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K    FP   (\   "'
M@    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N
M #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\
MJ@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@   '\   !W    <0
M &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D
M8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2
M +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$   !I    9    &
M  !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X
M %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$
M1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>    60   %8   !3
M  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@
M. !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0##
M #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0
M20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^
M #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0
MW0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4!
M #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4
M-  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L
M .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@)
M P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X
M "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@
M)0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P
M"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%
M/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S
M &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@,
M*@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >
M"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0
M  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $
M ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0
M%PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7
M%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1
M!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A).
M !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@
M21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9
M$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X6
M5P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH
M #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0
M$Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )
M&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<
M   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'
M  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX
M A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P
M'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?
M"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K
M   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P  /B   #4@   N(
M*"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &
M)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G
M>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$
M "(A   >(   &Q\  !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T
M "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P
M+(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B
M   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .
M   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH
M #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;
M)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X
M#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>
M   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0
M$RL  ! N   -,   "3(   4U   !-P   #D"   [!0  / @  #X+   _#0
M01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _
ML@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(
M  TU   (.   !#H    \    /P   $$   !# @  104  $8(  !("P  2@X
M $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0
M2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]
M   "0    $,   !&    2    $H   !,    3@$  $\$  !1!P  4PL  %4.
M  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(
M %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,0   !T0   !'
M2@   $T   !0    4P   %4   !7    60   %H   !< P  7@<  &$+  !D
M#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[<
M #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@   $\   !3    5@
M %D   !<    7P   &$   !D    90   &<   !I    ; $  &X&  !Q"P
M= \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z
M   K.P  (C\  !I#   22   #$T   52    5P   %P   !@    9    &@
M  !K    ;@   '$   !S    =0   '<   !Z    ?    '\   ""!   A@H
M (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E
M1   '$D  !-.   -5   !%H   !A    9@   &L   !O    =    'D   !]
M    @    (,   "%    AP   (H   ",    CP   )(   "6    F0(  )X)
M  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@
M%50   Y;   %8@   &D   !P    =P   'T   ""    A@   (L   "/
MDP   )4   "7    F@   )T   "@    HP   *8   "J    K@   +(   "W
M"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(
M  =J    <P   'L   ""    B0   )    "5    F@   )\   "C    I@
M *@   "K    K@   +    "S    M@   +H   "]    P@   ,<   #, 0
MTPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$
M  #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/
M ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L
ML0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?
M    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4
M3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V
M )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?    V0   ,D   "_
MN  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 ">
M $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D
MQ0"( .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP   *X   "E    GP
M )P "0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8
MB !+ (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V
M .  =0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D   "/    B0   (4
M! "$  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$
M '4 20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P
M90#U &0 _P!A /\ 8 #_ +0   "@    D    (4   !]    =P   ',   !P
M  @ ;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4
M0P!C $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J
M %< _P!6 /\ 5 #_ *$   ".    ?P   '4   !L    :    &0   !A  0
M8  + %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6
M $, 50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H
M^@!* /\ 2@#_ )(   "     <@   &<   !?    6@   %<   !5  $ 4P '
M %( # !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T
M20!# $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!
M /\ 0 #_ (4   !T    9P   %T   !5    3P   $P   !*    2  $ $<
M"@!'  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^
M #T 10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X
M-@#_ 'P   !K    7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]
M  L /0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0
M00 S $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_
M ',!  !D!0  5P<  $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @
M-  , #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K
M $4 *@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&
M  !>"0  4@L  $@,  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 *
M "P #0 L !  *P 3 "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $(
M(@!+ "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9
M#   30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$
M"P E PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %)
M !L!5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@
M20\  $ 0   X$   ,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?
M!PP '@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&
M4@ 5!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A
M #P1   U$0  +Q$  "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH
M&0H- !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0
M#%\ #PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3
M   R$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+
M !,,#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX
M"P]M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P
M%   *10  "44   A$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .
M#  .#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J
M  82?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@
M)Q8  "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,
M$@X "Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5
M>@  %8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<
M "$6   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T
M"!80  86$P %%AD !!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P
M&8P  !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8
M   ;%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.
M  (;$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H
M !R@   <M@  &]   !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9
M&0  %Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @
M$   (!0  "$:   A(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?
M   @M@  ']$  !_M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@
M%AD! !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@
M)A(  "88   G'P  )R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   E
MM   )-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P
M !$<   .'0  #1\   HA   &(@$  R0$   F!@  * @  "H+   K#0  +1
M "T5   M'   +20  "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@
M*M   "GO $ @   V(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A
M   -(@  "B0   8F   "*    "L"   M!   +P8  # )   R#   - X  #42
M   U&   -2   #4J   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T
M ##O #PC   R)   *B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )
M*0  !2L   $N    ,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^
M%   /AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM
M #<G   O)P  *"8  ",E   ?)   &24  !0F   0*   #2L   DN   %,
M #,    U    .    #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0
M21<  $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J
M   L*@  )R@  "(G   <*   %BH  !$M   -,   "3,   ,V    .0   #P
M   ^    00   $,   !&    2    $H   !, P  3@8  % *  !3#@  5!,
M %0<  !3)P  4S0  %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K
M+   )BL  !\L   8+@  $C(   TU   (.0   CT   !     0P   $8   !)
M    3    $X   !1    4P   %4   !7    60$  %P&  !?"@  8@X  &,5
M  !C'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P
M(C   !HS   3-P  #CL   @_   !1    $@   !,    3P   %(   !5
M6    %L   !=    8    &(   !D    9@   &D   !M!0  < L  '00  !T
M&   <R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@
M !0\   .00  !T<   !,    40   %4   !9    70   &$   !E    :
M &L   !M    ;P   '(   !T    =P   'H   !^    @@0  (8+  "*$0
MB1P  (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](
M   (3@   %0   !:    8    &0   !I    ;@   '(   !V    >@   'T
M  "     @@   (4   "(    BP   (X   "2    E@   )L#  "@#   HA,
M * A  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   92   $4X   E5
M7    &,   !J    <0   '8   ![    @    (8   "*    C@   )$   "3
M    E@   )D   "<    H    *,   "G    JP   +    "V!   O T  +H7
M  "Y*   MSP  +12  "R:@  KX4  *V< !Q.   35   "UP   %D    ;
M '0   !\    @P   (D   "/    E    )H   "?    H@   *0   "G
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M____________________________________________________
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M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
MLVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\
MNZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[
MQ+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN;9RPD;Y\X-.>C-$&#<R0V2R[LPJ\:X3[3 LV>]NZY[Q+6I
MB,NRIH?1KZ.'U:V@B-FKGHG<J9R*WJ>;C."EF8_CH9B0Y*&8D.2AF)#DH9B0
MY*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#D
MH9B0Y*&8D.39RPD:Y,X-.>?.#F#:R@R2R[PNJ\6Y3;3 M&:]NJYZQ;6IA\NQ
MIH?1KJ.'U:R@B-FJGHG<IYR*WJ6;B^"BFHWBGIF/XYZ9C^.>F8_CGIF/XYZ9
MC^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/
MXYZ9C^/8RPD:X<\,.>7/#F#9R@R1R[XLJ\6Y3+6^M&>]N:Y[Q;2JA\RPIH?1
MK:.'U:N@B-FHGHC;I9V)W:.<BM^?FHOAFYF.XIN9CN*;F8[BFYF.XIN9CN*;
MF8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9
MCN+8RPD:W- +.>/0#6#8RPN1R[\KJ\2Z3+6]LV>^N*Y[Q;2IA\RPIH?1K*.'
MU:F@A]BFGXC;HYV(W:"<B=Z=FXK@F)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWA
MF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>'7
MS D:VM$+.-[1#%_6RPN1R\ IK,*Y3;:\LVB^MZY[QK.IA\ROIH?1JJ.&U:>A
MA]BDGX?:H9Z'W)Z=B-V:G(G>E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,
MX)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C.#6S D9
MV=$+.-K3#%_4S N1R< IK<"Y3K:ZLVF_M:Y\QK*IA\RMIH;1J:.&U*6AAM>B
MH(;9GY^&VIN>A]R7G8C=DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<
MB]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B][5S D9V-(+
M-]C3"U[2S N3Q[\KK;ZX4+>YLFJ_M*U\QK"IA\RKIH;0IZ2%U*.BA=:?H878
MG*"%V9B?AMJ4GH?<D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0
MG8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMW4S0D9UM(+-];4
M"U[0RPJ5Q+XMKKRX4;BWLFK LZU\QJZIA\RIIH;0I:2%TZ"CA-6=HH36F:&%
MV)6@A=F1GX?:CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;
MCIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=O3S0H8U=,+-M34"U_.
MRPF7P;XPK[JW4[BULFS L*U]QZRJALNGIX7/HJ6$T9ZDA-.:HX35EJ*$UI.A
MA=>/H(;8BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")
MV8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=G2S@H7T]0+-='3"F++S F9
MOKTSL;>W5;FRL6W!K:U]QJJJALNDJ(3.GZ>$T)NE@]*7I(/3DZ.$U)"CA=6,
MHH;6B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFA
MB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB-?0SPH6T=0+-\[3"F7&R@N=N;PX
MLK2V6+JML6[!JJY]QJ>KA<FAJ83,G*B#SI>G@\^3IH/1D*6$THVEA=.*I(;3
MAZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'
MHXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-3.T H5SM0*.LK3"FC R ^AM;L^M*VU
M6[NIL6_!IJ]]Q*.MA,>=JX/*F*J#RY.I@\V0J(3.C:>$SXJGA<^'IH?0A::(
MT86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1
MA::(T86FB-&%IHC1A::(T86FB-',T D8RM0*/L73"FVXQ1:EKKE$M:>U7KNC
MLG# H;!]PY^NA,69K8/'E*R$R9"KA,J-JH7+BJJ%RXBIALR%J8?-@ZB)S8.H
MB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)
MS8.HB<V#J(G-@ZB)S8.HB<W(T0D;Q=4*0K_3"G*QQ!ZGI;E)MJ&V8+N>LW"^
MG;%]P9NPA,.5KX3$D:Z$QHVMA<>*K8;'B*R&R(:LA\B$JXG)@JN*R8*KBLF"
MJXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*K
MBLF"JXK)@JN*R8*KBLG$T@@@P-8)2+C4"GBISQ>8GKY'KIJV8KJ8M7&\E[-\
MOI>RA,"2L87"C;"%PXJOAL2(KX?$AJ^(Q82NB<6#KHK%@:Z+Q8&NB\6!KHO%
M@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!
MKHO%@:Z+Q8&NB\6_U <ENM<)3J[:"W"@VQ.'E\TYFI+#6*B1O&RRD;=ZN9*T
M@[V.LX:_B[*'P(BQA\"&L8C!A+&)P8.QBL&"L8O"@+",PH"PC,* L(S"@+",
MPH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"
M@+",PH"PC,+WP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.Y
MFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&
MMYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(
MRK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KW
MP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65
MB<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5
M^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VS
MDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6
M,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0
ML8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F]
M(%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+
MTK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/J
MMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",
MC=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\
MS*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2O
MBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$
MJL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6
MKHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E
M7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3
MV*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"
MHW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&
MF-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=KWP \5^, 6,/F](%/JN"=\S*A$J\:E7;3"I'"Z
MOJ)_O[R@B,.YFXC'MYB(RK65B<ZSDHK0L8^+T["-C=6OBH_7K8B3V:V&F-JK
MAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&
MG=JKAIW:JX:=VJN&G=KWP0\5]\$6,/B^'U/JN"9\RZE#J\:F7+3"I&^ZOJ)^
MO[N@B,.YG8?(MIJ'S+.7B,^QE(G2L)**U:Z/C->MC8[9K(J2W*N)F=VGB)S;
MIXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NG
MB)S;IXB<VZ>(G-OVP0X4]\$5,/B_'E/JN25\RZE"J\:G6[/"I6ZZOJ-^O[NA
MB,2XGH?)M9R'S;*9A]&PEHC4KI2)UZV2B]JKD(W<J8V2WZB-FM^CBYS<HXN<
MW*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<
MHXN<W*.+G-SVP0X4]L(5,/>_'E/JNB1\RZE!K,:G6K/"I6VZOJ-]O[NCB,2W
MH(?)M)V'SK&;A].OF8C6K9>)VJN5BMRIDXW?IY*1XJ21F>"@CIS<H(Z<W*".
MG-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<
MW*".G-SUP@X4]<(4,/; '5/JNB-\RZI!K,:H6;/"IFVZOJ1]O[JDA\6WH8?*
MLY^'S["=A]2NFXC8JYF)W*F8B]^GF([BI9>2YJ"6F>"<DYO=G).;W9R3F]V<
MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3
MF]WTP@T4]<,4,/; '%/JNR)\RJI K,:H6+/"IFRZOJ1\O[JEA<6VHX?+LZ&'
MT+"?A]6MG8C:JIV*W:>;C."DFH[BGYB/XYV:F.&9EYO=F9>;W9F7F]V9EYO=
MF9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]WR
MPPT4],,3,/7!&U/JO"%\RJL_K<:I5[/"IVNZOJ5[O[JFA,6VI8?+LJ.'T:^A
MA]:KGXC:IYV)W:2<BM^@FXO@FYJ-XI>:D^&7G)O>EYR;WI><F]Z7G)O>EYR;
MWI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F][PPPT4
M],03+_7"&E+JO2!\RJL^K,:J5K/"J&NZOJ=YO[JH@\6VIX?,LJ6'T:RBA]:H
MH(?9I)Z(W*&=B-V<G(G>EYN+X).;C^"2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=
ME]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E][MQ P3\\42
M+_3"&5+JO1]\RJP\K,:K5;/"J&JYOJEWO[JJ@,6UJ8?,KZ6'TJJBA]:EH(;8
MH9^&VIV>A]N9G8?=E)V)WI"<C=Z.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.
MG9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]WJQ0P3\L41+_/#
M&%+JOAU\RZTZK,:L5+/"J6FYOJQSO[JM?L6RJ8?,K*6&T:>CAM6BH877GJ"%
MV)J@A=J6GX;;D9Z(W(V>B]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<
MBYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]SFQ0L3\<81+_+$%U+J
MP!M\RZ\XK,:M4K+"JV:YO[!OOK>M?L:PJ8?-JJ:&T:2DA=.?HX35FZ*$UI>A
MA=B3H(79CZ"'V8N?BMJ(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-
MVHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=KAQ@H3\,<0+O#&%E'JP1E\
MR[ UJ\>O3[+#L&"XO+)LO[*M?L>MJ8;,IZ>%SZ&EA-*<I(33F*.$U)2CA-60
MHH76C:&&UXFAB-B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>A
MB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]C;QPD2[LD/+N[(%%'KQ!9\S+,P
MJ\>Q3+'$N%:WMK%NP:ZM?\>IJH;+HZB$SIZG@\^9IH/1E:6#TI&DA-..I(74
MBZ.&U(BCB-6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%
MHXK5A:.*U86CBM6%HXK5A:.*U86CBM7:R D2Z\L-+>O*$5#KQQ)\S+8JJLBW
M1+"ZMEFZK[%PPJJM?\>FJX7*H*J$S)JH@\V6J(/.DJ>#SX^FA-",IH71B:6&
MT8>EA]*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2
MA:6)TH6EB=*%I8G2A:6)TH6EB=+8R0D1W\T++.?-#T_HRPY[S;PBJ,*\/+&Q
MM5Z\J;%RPJ:N?\6BK83'G*N#R9>J@\J3JH3+D*F$S(VIA,V+J(7-B*B&SH:G
MA\Z$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)
MSX2GB<^$IXG/A*>)SX2GB<_5R0D0V,\**]K3"T[8T MZS<,6J+.Z1K6IM&*]
MI+%TP:&P?\.>KH3%F:V$QY2LA,B0JX3)CJN$RHNJA<N)JH;+AZF'S(6IB,R#
MJ8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.I
MB<R#J8G,@ZF)S(.IB<S2RPD/U-$**=75"TS0T I^N+\EKJBX3[BAM&:\GK)U
MOYVQ?\&;L(3#EJZ$Q9&NA,:.K87'BZR%QXFLALB'K(?)AJN'R82KB<F"JXK*
M@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"
MJXK*@JN*RH*KBLK/S D-T-(**,[4"E+%T0J#JL,MJ)ZW5[B;M6B[FK1UOIFR
M?[^7L83!D["%PH^OA<.,KX7$BJZ&Q8BNA\6&KHC&A*V(QH.MBL:!K8O'@:V+
MQX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'
M@:V+QX&MB\?,S0D,R],*+<?4"EFRV N GLTKFIC!4*N6N&>WE;5UO)2T?KZ4
MLX6_D+*%P(RQAL&*L8?"B+"'PH:PB,*%L(G#@["*PX*OB\.!KXS#@:^,PX&O
MC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,
MPX&OC,/'SP@0Q=0)-+C9"ENBYQ)VE]HEB9#/19B.QUVCC<%NJXV]>;&,NH&T
MB;B#MX:WA;F$MH:Z@[6'NX*UB+R!M(F]@+2*O7^TB[Y^LXR^?K.,OGZSC+Y^
MLXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZS
MC+["T0<6O=8(.J?Q#E6;\1MHD>8M>(G=0(6%U5:/@\]GEX++<YU^R'BA>\9\
MI'G$?Z9WPX*H=<*$J73"A:ISP8>K<L&(JW+ BJQQP(NL<<"+K'' BZQQP(NL
M<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZS_
MN!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1
MB\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0.
M_[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:X
MC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>
M)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(
MMXJ/RK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T
M*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/
MRK:(D<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;W
MKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(
MD<RUA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9I
MWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RU
MA9/-M(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="
MC\>;8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-
MM(.6S[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;
M8K'$FW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6
MS[.!F="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$
MFW*VPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!
MF="S@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*V
MPIM_N<";B+V^F8G O)6*P[J1B\:XC8W(MXJ/RK:(D<RUA9/-M(.6S[.!F="S
M@)W1LG^CT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-'_N!0._[@=)_^U*4;WL#5IWJA!D,><8;'$G'&VPIM^
MN;^=AKV]FHG!NY>)Q+F3BL>WCXS*M8R.S+2)D,ZSAY+0LH25TK&"F=.Q@9[4
MKH"BU*R H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L
M@*/2K("CTJR H]+_N1,._[D<)_^V*$;WL#1JW:A D,>=8+'$G'&VPIQ\NK^>
MA;Z\G(C"NIF(Q;B5B<FVD8K,M(Z,S[*+CM&QB)'3L(:4U:^$F=:O@Y_7JH*A
MU:>"HM.G@J+3IX*BTZ>"HM.G@J+3IX*BTZ>"HM.G@J+3IX*BTZ>"HM.G@J+3
MIX*BTZ>"HM/_N1,._[D<)_^V*$;WL3-JW:D_D<>=8+'$G7"VPIY[NK^?@[Z\
MGHC"N9N(Q[>7B,JUE(G.LY"+T;&-C=.OBI#6KHB3V*V&F=FJA9[9I82AU:2$
MHM2DA*+4I(2BU*2$HM2DA*+4I(2BU*2$HM2DA*+4I(2BU*2$HM2DA*+4I(2B
MU*2$HM3_NA(._[H;)_^W)T;WL3)JW:D^D<>>7['$G6^VP9]YNKZ@@K^[H(C#
MN)R'R+:9B,RSEHC0L9**TZ^/C-:NC([8K(J3VZN)F=RFAYW:HH:@UJ"&HM2@
MAJ+4H(:BU*"&HM2@AJ+4H(:BU*"&HM2@AJ+4H(:BU*"&HM2@AJ+4H(:BU*"&
MHM3_NA(._[H;)O^W)D;VLC%JW:H]D<>>7K'$G6^VP:!XNKZA@;^[H8C$N)Z'
MR;6;A\VRF(C1L)6)U:Z2B]BLCXW;JHV2WJB,FM^BBIW:GHF@UIR)H=2<B:'4
MG(FAU)R)H=2<B:'4G(FAU)R)H=2<B:'4G(FAU)R)H=2<B:'4G(FAU)R)H=3^
MNA$._[L:)O^X)D;VLC!JW:H\D<>>7;'$GFZVP:%VNKZB?[^[HXC$MZ"'RK2=
MA\^QFH?3KIB(UZR5BMNJDXW>J)&2XJ20F>">C9W;FHR@UYF+H=69BZ'5F8NA
MU9F+H=69BZ'5F8NAU9F+H=69BZ'5F8NAU9F+H=69BZ'5F8NAU9F+H=7^NQ$.
M_KL:)O^X)4;VLS!JW*L[DL>?7;'$GVRVP:)TNKZD?K^ZI(?%MZ*'RK.?A]"P
MG(?5K9J(V:J9BMZHF([BI9>3YI^5F>":D9S;EX^?UY:.H=66CJ'5EHZAU9:.
MH=66CJ'5EHZAU9:.H=66CJ'5EHZAU9:.H=66CJ'5EHZAU9:.H=7]NQ$._KL:
M)O^Y)4;VLR]JW*LZDL>?7+'$H&JVP:-SNKZE?,"ZI87%MJ.'R[.AA]&OGX?6
MK)Z)VZB<B]^DFHWAGYF/XYR:F.&7EIS<E).?V).2H-:3DJ#6DY*@UI.2H-:3
MDJ#6DY*@UI.2H-:3DJ#6DY*@UI.2H-:3DJ#6DY*@UI.2H-;]NQ$-_;P9)OZY
M)$;VM"YJW*LZDL>@7+'$H6BVP:5QNKZG>L"ZIX3%MJ:'S+*DA]&NHH?7J9^(
MVZ2=B=Z@FXK@FIJ,X9:;D^&5FYO=DI>>V)&5H->1E:#7D96@UY&5H->1E:#7
MD96@UY&5H->1E:#7D96@UY&5H->1E:#7D96@UY&5H-?\O! -_;P9)OZZ(T;V
MM"UJW*PYDL>@6['$HV:UP:9NNKZI>,"ZJ8+%MJB(S+"EA]*JHH?7II^'VJ&>
MA]R;G8C>EIR*WY&;D-^1G9G=CYN>V8^9G]>/F9_7CYF?UX^9G]>/F9_7CYF?
MUX^9G]>/F9_7CYF?UX^9G]>/F9_7CYF?UX^9G]?\O! -_+P8)OVZ(D7VM2QJ
MW*TWD\>A6K'%I6.UPJEKNKZL=;^ZK7_%LZF'S*VEAM*GHH;6HJ&&V)V?AMJ8
MGH?;DIV)W8Z=C=V,GI3<C:">V8R>G]>,GI_7C)Z?UXR>G]>,GI_7C)Z?UXR>
MG]>,GI_7C)Z?UXR>G]>,GI_7C)Z?UXR>G]?[O1 -^[T7)?V[(D7VMBMJVZTV
MD\>B6;'%IU^UPJUFN;^Q<+ZWK7[&L*F'S:JFAM&DI(74GJ*%UIFAA=B4H(;9
MCY^'VHN?B]N(GY#;B*"8V(BAG=>(H9W7B*&=UXBAG=>(H9W7B*&=UXBAG=>(
MH9W7B*&=UXBAG=>(H9W7B*&=UXBAG=?ZO0X-^KX6)?R\($7VMRIJVZ\TE,BD
M5;'&JUBTP[-?M[NR;K^RK7['K*F&S*:GA="@I832FZ2$U):CA-61HH76C:&&
MUXFAB=B&H8W8A*&3UX2BE]:$HI?6A**7UH2BE]:$HI?6A**7UH2BE]:$HI?6
MA**7UH2BE]:$HI?6A**7UH2BE];YO@X,^;\5)?J]'T7VN"=JV[ QE,BH3:_'
MLDZRP;A8N+2Q<,&MK7_'J:J%RZ*HA,Z=IX/0EZ:#T9*EA-*.I(73BZ.&U(BC
MB-6$HXO5@J.0U8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3
MU8&CD]6!HY/5@:.3U8&CD]7TP T,]\ 3)/F_'43VNB5JVK(NE<JO0*W(O3VO
MM[9=NJZQ<L*IK7_&I:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$
MI8K2@:6-TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"E
MC]* I8_2@*6/TH"EC]+LP0L,]<(2)/;!&D3WO2%JVK0IELV\**F[NT.SKK5A
MO*BQ<\&EKG_%H:V$QYNL@\F6JX/*D:J$RXZIA,R+J87-B*B&SH:HA\Z#J(G.
M@:>,SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MKWRHRZ]\J,O_LA<)_[(A'O^O+SK_JCQ9[*1)>MB;6IG&EG&RQ)AXM<*9@;G
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M@:.1U("DF=. IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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M9>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG
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M&RSET \RR.D/2K3R%6>BXB)]EM8WC8_.3YB,R&&@BL1NIHK!>*J'OWVMA+Z
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
M>*Z\P'>TN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QX
MM+O_H1@#_Z,K$/^@.B7_G$@\_Y=64_B38VCLDFEZX9%SBMB/?)C0CH2DRHZ,
MK<:-D+3$BI.WPX:5N,*$F+G!@9NZP7^=N\!]H+S >Z2\P'JGO<!YK+W >+"]
MO7BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[S_
MH1@#_Z,J$/^A.27_G4@]_YA55/>486GKE&9[X))OC-:1>)K.D(*FR(^)L,2/
MC[;#BY&WPHB4N<&$E[K @IJ\P'^=O;]]H+Z_>Z2^OGJHO[YXK;^]>+&^N'BR
MOK1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[W_HA@#
M_Z0I$/^A."7_G4<]_YE55/>67FGKE6-[X)1LC=62=9S-D7^HQY&'LL21CK;#
MC9"XP8F3NL"&EKR_@IF]OW^<OKY]H+^]>Z7 O7FJP+UXL,"X>;# M'FQOZ]Z
MLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO:]ZLKW_HQ@#_Z0I
M$/^B."7_GD8]_YE45?>77&GKEV!\WY9IC=63<IW,DGRJQ9*%M,22C+;"CX^Y
MP8N2N\"'E;V^@YB_O8"<P+U]H,&\>Z7"O'FKPKEYK\*T>:_!L'JPP*Q[LKZL
M>[*^K'NROJQ[LKZL>[*^K'NROJQ[LKZL>[*^K'NROJQ[LK[_HQ@"_Z4H$/^B
M-R7_GT8]_YI35?>96FGKF5Y\WY=ECM25;YW+E'FKQ9."M,24BK?"D8ZYP(R0
MO+^(D[Z]A)? O(";PKM]H,.[>Z;$NGJMQ;1ZKL2O>J_"K'NPP*A\L;^H?+&_
MJ'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&_J'RQOZA\L;__I!@"_Z4H$/^C-B7_
MGT4]_YI35?>:5VGKFUM\WYEBCM27:Y[+E7:LQ92 M,.5B+?!DXVZP(Z/O;Z)
MDL"\A97"NX&:Q+E]H,:Y>ZC'M'JKQZ][K<6K>Z[#IWROP:1]L;^D?;&_I'VQ
MOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_I'VQOZ1]L;__I!@"_Z8G$/^C-B7_H$0]
M_YM25O><56GKG%A\WYM>CM299Y[*EW.LQ99\M,.7A;?!EHN[OY&-OKV+D,&[
MAI3$N8&9Q[=^H,FV?*G*KGNJR*I\K,:F?:W$HWZOP:!^L;^@?K&_H'ZQOZ!^
ML;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;__I1@"_Z8F#_^D-27_H$0]_YQ1
M5O>>4VGKGE5[WYY:C=2;9)[*F6^LQ9AYM,.9@KC!F8J[OI2,O[R.CL.YB)+'
MMX*8R[5^H<VO?*?-J7VIRJ5^J\>B?ZW$GW^OPIV L;^=@+&_G8"QOYV L;^=
M@+&_G8"QOYV L;^=@+&_G8"QOYV L;__IA@"_Z<F#_^D-27_H$,^_YU05?>?
M46CKH%-[X*!7C=2>7Y[*FVNLQ9MUM,.;?KC FX>\O9>*P+J1C,6WBI#*M(27
MS[* H]*H?Z7/HX"HRZ" J\>=@:W%FX&OPIF"L;^9@K&_F8*QOYF"L;^9@K&_
MF8*QOYF"L;^9@K&_F8*QOYF"L;__IA@"_Z<E#_^E-"7_H4,^_YY.5?BA3FCL
MHE!ZX*-2C-6A6YW+GF:LQIUQM,.>>KC GH2\O)N(PKF5BL>UC8W.L(:6U*F"
MH-:A@J30G8*HRYJ#JLB9@ZW%EX2OPI:$L,"6A+# EH2PP):$L,"6A+# EH2P
MP):$L,"6A+# EH2PP):$L,#_IA@"_Z<E#_^E-"7_H4(^_Y],5?BB3&?LI4UY
MX:9.B]6D5IS,H6&JQJ%LL\.B=K? HH"]O*"'P[>:B,JRDXK2K(N4VZ"'G]B:
MAJ31EX:GS)6&JLB4AZS%DX>NPY*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'
ML,"2A[# DH>PP)*'L,#_IQ@"_Z@D#_^F,R7_HD(^_Z!*5/FD2F;MITIXXJE+
MBM:H49K-IENIQZ5ELL2G<+; IWJ\O*:#P[:BA\NOG8C6I9>5YI>/GMJ3C:/2
MD8NGS9"+JLF0BJS&CXJNPX^)L,&/B;#!CXFPP8^)L,&/B;#!CXFPP8^)L,&/
MB;#!CXFPP8^)L,'_IQ@"_Z@D#_^F,R7_HD$^_Z)(5/FF1V;NJD=WXZU'B-FM
M2YC/K%2FR*Q>K\:O:+/"L7.YOK)]P+*JA\NEHH;5E)R+WH^:G=J-E:+3C)*F
MSHN0J<J+CJO'BXVMQ(R,K\&,C*_!C(ROP8R,K\&,C*_!C(ROP8R,K\&,C*_!
MC(ROP8R,K\'_J!@"_ZDD#_^G,B7_HT$^_Z1&4_JI1&3OK4-UY+%"A=NT1)32
MM4JAR[=3J\J^7ZV]MVZXLK!\PJFJALN<I832C:"'V(:@E]F'GJ+3AYBESX>5
MJ,N'DZK(B)&MQ8B0K\*(D*_"B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"B)"O
MPHB0K\+_J!@"_ZDC#_^G,B7_HT ^_Z9#4ONK06/PL3]SY[<]@MZ^.X_6Q#^:
MS,5*IKR\7;*QM6^[JK!]PZ.KA,F6IX/.BJ2&TX&CD-6!I9_2@J&ESX*<J,R#
MF:K)A):LQH64KL.%E*[#A92NPX64KL.%E*[#A92NPX64KL.%E*[#A92NPX64
MKL/_J1@"_ZHC#_^H,27_I#\^_ZA 4?RO/&'SMCEPZK\W?>/*-8?4T3>5OL)+
MJ;"Y8+6HM'"]H[!^PIVMA,>2JH3+B*>&SH"FC=!]IYC0?:BDSGZDJ,M_GZK)
M@)NKQH&8K<2!F*W$@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!F*W$@9BMQ(&8K<3_
MJA<"_ZHB#_^H,"7_I3X^_ZL[3_^T-UWVO3-JZ\HQ==S:*8+$SCB9LL%/JZ>X
M8[>AM'.\GK%_P9BOA,2/K(3(AZJ'RH"IC,Q\J9/,>JJ<RWFKILIZIZK(?**K
MQWV>K<1]GJW$?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<3_JA8"
M_ZLA#O^I+B7_ISP^_[ V3/RZ,%GOR"QBWMDG;<O<)H:VS#R;J,%4JY^Y9K:;
MM72\F;)_OY6PA,*-KX7$AJV'QH&LB\A]K)#(>ZR8R'FMG\=WK:?'=ZJLQGFE
MK<1YI:W$>:6MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$>:6MQ'FEK<3_JQ4"_ZP@
M#O^K+23_JS8[_[8O2//$*%'@UB96S.0B<;O:*(BJS$&;G\-7J9F\:;*6MW:Y
ME+2 O9&RA<"+L8;!AK"(PX&OB\1^KH_%>ZZ4Q7JOFL1XKZ#$=:^GQ'2MKL-T
MK:[#=*VNPW2MKL-TK:[#=*VNPW2MKL-TK:[#=*VNPW2MKL/_K!0"_ZT?#O^L
M*R3_L"\W^K\E0>31($7.Y!U;O>DB=*W:+(F?SD69E\9:I)/ :JV1NW:SD+A_
MMXVVA+N)M(:]A;*(OX*QB\%_L8[!?+&2PGJQEL%YL9O!>+*AP'2QI\%TL:?!
M=+&GP72QI\%TL:?!=+&GP72QI\%TL:?!=+&GP72QI\'_KA(!_Z\=#?^N*"3_
MN"0QZLL:-=#B%T._\!U>K^@E=:#;,8>6T4B4D,I<GHW%:J6+P7:JB;Y]KX6\
M@+*"NH.T?KF&MGRXB;=YMXRX=[>/N7:VD[IUMI>Z=+:=NG.WI+ESMZ2Y<[>D
MN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+G_L! !_[$:#?^Q)2/SQ!<G
MU-\0*\'O%TBP]R!@H>HK<Y7?.8*-UTR-B-%=E8;,:IN$R72@@,9YI'W$?:9Z
MPH"I=\&#JG7 AJQSOXJM<;^-KF^^D*]NOI2O;+Z9KVN^H*]KOJ"O:[Z@KVN^
MH*]KOJ"O:[Z@KVN^H*]KOJ"O:[Z@KVN^H*__LPX!_[06#/R\%QK6U@L6P^T0
M,++\&4JB^25>ENTS;HSE07J%WD^#@=E>BG_5:H]ZTG"3=L]UEW/.>9EQS'V;
M;\N G6W*A)YKR8>?:<F*H&C(CJ%GQY*B9<>6HF3'G*-DQYRC9,><HV3'G*-D
MQYRC9,><HV3'G*-DQYRC9,><HV3'G*/TM@H!_[@2"]7,"@O$VPH9LOP1,Z/_
M'4B6_"Q8C/,[983L26]^YU5V>N-@?'7?9X%QW6V$;=MRAVK9=HEHV'J+9M=]
MC636@8YCU82/8=2(D&#3BY%?TX^27M*4DES2F9-<TIF37-*9DUS2F9-<TIF3
M7-*9DUS2F9-<TIF37-*9DUS2F9/<NP0 V,,'!,31" >SZ H<H_\4,9;_)$.,
M_S10A/M"6GWV3V)X\5IH<>Y?;6OK9'%GZ6ET9.=N=F+F<WA@Y7=Y7^1Z>UWC
M?GQ<XH%]6^*%?EKAB']9X(N 5^"0@%;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5
M@5;?E8%6WY6!5M^5@5;?E8'4O04 Q,@' +39!0JC_@T<EO\:+(O_*SJ#_SI$
M?/](377_4E-N_5=89_I=7&/W8E]@]F=B7?1K9%OS;V59\G-G5_%W:%;Q>FE5
M\'UJ5.^ :U/OA&M2[H=L4.Z+;4_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;D_M
MD&Y/[9!N3^V0;D_MD&[&P 4 M- $ :/C @J6_Q 8B_\@)(+_,"]Z_S\W<O](
M/FK_3D-D_U1(7O]93%O_7T]8_V125?]I5%/_;552_G%74/UT6$_\>%E.^WM:
M3?M_6TSZ@UQ+^89=2?F+7DCXD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%](
M^)!?2/B07TCXD%^UQP( I-H  9;_!@>*_Q01@?\D&GG_,R)P_SLJ:/]",6'_
M2C9<_U$[5_]7/U/_74)0_V)$3O]G1DS_;$A*_W!)2?]T2DC_=TM&_WM,1?]_
M343_@TY#_X=.0O^+3T'_D5!!_Y%00?^14$'_D5!!_Y%00?^14$'_D5!!_Y%0
M0?^14$'_D5#_D1(!_Y4G"_^5.QS_DTLO_X]90_^,9%3[C&MC\HIR<>J(?'WC
MAH2'WH**C]I_CY;6?92;TWJ8G]%XG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQP
MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MA]_&6X[6R&N4QKUQIK6S>+6EJ('#E)^-S8F<HM*'E*?,B)&KQXF/KL.)CK#
MB8VROHJ,L[R*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+K_
MG! !_Z$F"O^@-AS_GD(Q_Z5 /O^K0$S_L4!9^K=!9/.]1&_NQ4EWY<Y2?-W6
M8G_,SFB2O,5NI*N[=K2:L7_!BJJ*RW^GG<^ GZC,@IFKQX.5K<2$DZ_!A9&Q
MOX:/L[V'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+O_G1 !
M_Z(F"O^@-1S_H#\P_Z<]/?^N/$K_M3Q5^KT]8/#&0F?FT4ILWMY.=LW:5X>^
MT&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2 F:_"@9:PP(*4
MLKZ#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[S_GA !_Z(F
M"O^A-!S_HCPN_ZHZ._^R.$?\NS=1\L4Z6.;105S;WD)IS>)&?+[748RNS%^;
MH<-MJ)B\>;*1M82[A;&)PGRND<5XKI_%=:VLQ7BEKL1ZH*_"?)RPP'Z9L;Y_
MEK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKW_GA !_Z,E"?^B
M-!S_I3DM_ZXU./^X,T+TPS-*Y] X3MG>.5K+YCUNON!"@*[44)"ARU^=F,-M
MJ)&]>;&+N(.X@[2(O7VQD,%YL9K!=;&EP7*OK\)UJ*_!=Z.PP'F?L;][G+*]
M>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKW_H! !_Z0D"?^C,AS_
MJ#0K_[,O-/F_+3SIS2] V=XO2LKG-%^]ZCISK]Y!@Z'349&7RV"=D,1NIHR_
M>JV&NX&S?[B'N'JVC;MWM96\=;6?O'*TJ+UNL[*^<:RROG2GLKYVH[*]=J.R
MO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKW_H1 !_Z4C"?^D,1S_K2XG
M_[DI+^[()C/:W"8WRN<L3[WR,F.OZ#EUH=U"A);44Y"/S6*:BL=PHH;#>JB
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MA! !_X,: _^+*@S_G#$2_Z4T&O^L-B'^LSHH\[M +>G#2#'ARU$WTL=62\7
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M*2C_HBHG_ZTK)O^Y+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP
MFL4  (O3  !]X@  =?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[
M_ST--_]##S/_21$P_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__
MD1H>_YP;'O^E'!W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X
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M^5;<4_E6W%/Y5MQ3^5;<4_E6W%/Y5MQ3^5;_7AL"_UHE _]4,0;_6#<(_V%
M$?]E21K_9E,C_V1=+?]B:#7_7W0\_UQ_0O]9BD?_5I-+_U2<3O]3I%#_4:M2
M_U"S5/]/NE7_3L16_TW05_]-XEC\3.U8]D[R6.Y0]5CF4_98WU3W6==5^%G3
M5?A9TU7X6=-5^%G35?A9TU7X6=-5^%G_7QH"_ULE _]5, ;_7#0(_V4]$?]J
M1QK_:U$D_VE:+?]F9#;_8W ]_U]\0_]<ATG_69%-_U>:4/]5HE/_4ZI5_U*R
M5_]1NEG_4,5:_T_26_Q.Y%OX3^U<\%'R6^=4]%O>5?5<U5;V7<Y8]UW+6/==
MRUCW7<M8]UW+6/==RUCW7<M8]UW_8!H"_UPD _]6+P7_8#((_VH[$/]O1!K_
M<$XC_V]7+?]K83;_9VP^_V-X1?]@@TO_7(Y/_UJ84_]7H%;_5JE9_U2Q6_]3
MNES^4<9>_%#67_E0YU_R4NY?YU7Q7]U7\F#26/-ARUGU8L5;]6+#6_5BPUOU
M8L-;]6+#6_5BPUOU8L-;]6+_81D"_UTC _]:+07_92\(_V\X$/]T01G_=DLC
M_W54+?]Q73;_;&<__VAS1O]D?TS_8(I2_UV55O]:GEG_6*=<_E:P7_U4NF#\
M4\=B^5+<8_-3Z&/I5>YCWECP9-!:\67(7/)FPEWR9KU>\F:[7O)FNU[R9KM>
M\F:[7O)FNU[R9KM>\F;_8AD"_UXC _]>*@7_:2T(_W0U#_]Z/AC_?$@B_WM1
M+/]X6C;_<V,__VUM1_]I>D[_9(94_V"16/]=G%S]6J5@^UBP8OI6NV7X5<IF
M]53@9^Q6ZF??6NUGT%SO:<9=[VJ_7^]JN6#O:K5A[VJS8>]JLV'O:K-A[VJS
M8>]JLV'O:K-A[VK_8Q@"_V B _]B)P7_;BH'_WDR#O]_/!?_@D8A_X)/*_]_
M6#7_>V ^_W5I1_]O=$[[:H%5^&:,6_5BEU_S7Z%C\%RK9NY:MFGL6<1JZ5C:
M:^%:ZFO07>QMQ5_L;KQAZV^V8NQOL6/L;JUD[&ZK9.UMJV3M;:MD[6VK9.UM
MJV3M;:MD[6W_9!@"_V$B _]F)03_<B<'_WXP#?^%.Q;_B$4?_XA-*?^&53/_
M@EX]^WUF1O9V<$[R<GQ5[FV'7.IHDF+F9)QFXV&F:N!?LFW=7;]OVEW3<-)>
MZG#$8.ERNF+H<[-DZ'.M9>ESJ6;I<J9GZG&D9^IPI&?J<*1GZG"D9^IPI&?J
M<*1GZG#_91<"_V(A _]I(P3_=R4&_X(O#/^*.13_CD,=_X],)O^-4S#YBELZ
M\X5C1.U_;$WH>7=5XW2"7=YNC6/9:9=ITV:A;L]CK''+8;ETR&'*=<5AY7:Y
M9.9WL&;E=ZIHYG>E:>9VHFKG=9]JZ'.>:^ESGFOI<YYKZ7.>:^ESGFOI<YYK
MZ7/_9A<!_V,A _]M( 3_>R,%_X<N"_^/.!+_DT$:_Y5*(_J442WSD5DW[(U@
M0>6':4K?@713UGI^7<]TB&7*;Y%LQ6N;<<%HIG6]9K)XNF7">K=EW7NN:.-[
MIVKC>Z)KY'J>;.5XFVWE=YEMYW:8;N=UF&[G=9ANYW68;N=UF&[G=9ANYW7_
M9Q8!_V0@ _]P'@/_?B(%_XLL"?^3-Q#_F$ 8_9I((/2:3BGLF%4SY95=/-V/
M9D?3B&]3RX%Y7L5[@V:_=8QNN7&6=+5NH7BP:ZQ\K6J[?JIJTG^D;.!^GFWA
M?9IOXGR7<.-ZE7#D>9-PY7>3<>9WDW'F=Y-QYG>3<>9WDW'F=Y-QYG?_:!8!
M_V0@ _]S' /_@2 $_XXK"/^7-0[_G3X5^)]$'.^@2R7GGU(MWYU:-].58T;*
MCFQ3PX=U7KN!?F>U>XAOKW>1=:ISG'JE<*A^H6^V@9YORH*;<-Z!EG'?@)-R
MX7Z1<^)\D'/C>HYSY'F.<^5XCG/E>(YSY7B.<^5XCG/E>(YSY7C_:18!_V8>
M _]V&@/_A!\#_Y(J!_^;- S^H#L2\Z-!&.JF2"#BIT\GV*)6-LR:8$7#DVE2
MNXUR7K.&>F>L@81OIGV-=J!YF'R;=J. EW2Q@Y1TQ821==V#CW;>@8UVX'^+
M=^%]BG?B>XEVY'J)=N1YB7;D>8EVY'F)=N1YB7;D>8EVY'G_:14!_VD= _]X
M&0+_AQX#_Y4H!O^>,@KZI#</[Z@]%.:L1!K=K4LDT*94-<:?7D2\F692M))O
M7:R,=V>DAX!OGH**=YA^E'V2>Z"!C7JMA(IYP(6(>MR$AWK=@H9ZWX"&>N!^
MA7KB?(5YXWJ%>>1YA7GD>85YY'F%>>1YA7GD>85YY'G_:A4!_VL; O][%P+_
MBAP"_Y@F!?^B, CUJ#,,ZZXY$.*S0136L4<CRJM2-,"D7$.VGF11K9AL7*62
M=&:=C7UOEHB&=H^%D7V*@IR"A8"JA8%_O(: @-N%@(#=@X!_WH& ?N!_@'WA
M?8!]XWN ?.1Z@'SD>H!\Y'J ?.1Z@'SD>H!\Y'K_:Q4!_VT9 O]^%0+_C1L"
M_YLD _ZE+ ;QK"\(Y[,T"]VZ.A#0M48AQ:]1,KJI6D*PHV)/IYUJ6YZ8<F66
MDWINCX^#=HB+CGR"B)F!?(:GA7F&N89WA]>%>(7=@WJ#WH%Z@N!_>X'A?7R
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M>&V,Y7AMC.5X;8SE>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L
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M1#?_ZD4V_/U%._+_1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP
MO:P  *ZU  "BP@  E<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7
M_TH@4?]1)$S_6"=(_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__
MT#@N_^\Y+?__.3'__SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$
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M$1/_NA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP
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M:7A\\&EX?/!I>'SP:7A\\&G_8!<!_VX2 ?]^$ #_C!$ _YD1 /&D$P#CKA8
MUK8< <NT, C!L#\7MZM+):VF5#.DH5U G)UE2I28;%.,E71;AI%]8G^.AVAY
MC))M=(J><7"(K71MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72
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M4T?(]U5(P/Q82KC[64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P
MW),  ,JB  "\K $ L;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=Q
MW4T@:MQ6*&/;7R]=VF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38
M]$E"T_]-1,G_3T7"_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL
M +^G  "RL   I[L  )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=
M7^=2(UGG6RE5YV0M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]
MYO\_/>#_0C_7_T1 SO]&0,[_1D#._T9 SO]&0,[_1D#._T;6DP  Q*,  +2L
M  "GM@  F\$  )#, @"&V08 @/(2 'GR'P)Q\BL&:O(V#&/S/Q)=\T<85_-/
M'5+S5R%-]& D2?1I*$;T<RI"]7XM/_6++SSVF3$Z]JDS./>^-#;XX34V]?DU
M-?/_-#?L_S8YY?\X.>7_.#GE_S@YY?\X.>7_.#GE_SC(G@  MJD  *BR  ";
MO0  C\@  (/4  !YZ < <_P2 6O]'0)D_2<$7OXQ"%C^.PU3_T,13?]+%4G_
M4QA%_UH:0?]C'3[_;!\[_W8A-_^"(S3_D"4R_Y\G,/^P*"[_R"DM_^HJ+/__
M*BS__RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0
M@=$  '7>  !M^@D 9?\1 5[_&@)7_R,#4O\L!4S_- =(_SP*0_]$##__3 X\
M_U,0./];$C7_8Q0R_VP6+_]W%RS_A!DI_Y,:)_^B'"7_M!TD_\P>(__M'B+_
M_1\B__\?(O__'R+__Q\B__\?(O__'R+__Q^LJP  G;8  (_"  " S@  <]P
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M&P+_9QL"_VXB _]S*@3_=S4)_WA $/EW2ACR<U0@[&]>*.=K:C#B9W4VWF.
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M6(-O_%B#;_Q8@V_\6(-O_%C_5A@!_V01 ?]R#@#_?A  _X@1 /61% #HF!D
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M75:=ZUQ7FOI;6I7Z6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H
M_WP  -R,  #-F   PZ,# +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%
MM5 G?;-9,':Q8#AOKV@_::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"G
MZE=0I?Q74Y_]5U6:_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(
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M0$##_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP
MH+0  )6^  "+R , @-$' 'CA#0!TX1T!;N$K VC@-PAAX$(.7.!-%%?@5AE3
MX%\=3^!I(DO@<R5'X'XH1."+*T+@FBT_X:LO/N+!+S[BY2\\W_HQ.=[_-#G9
M_S8ZT/\X.\S_.3O,_SD[S/\Y.\S_.3O,_SG-D@  O*   *VH  "AL0  E;L
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M$Q[__Q,>__\3'O__$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP
M3O\$ $G_#@!#_Q0 /_\= 3K_)0(V_RP",O\S R__.@,K_T$$*/](!"7_3P4B
M_U<%(/]@!AW_; <:_WD'&/^*"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/_
M_PH3__\*$___"A/__PJ:L0  B[T  'S(  !MU   7^   %'F  !']0  0?\
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M5F=_XU5H@/I3:7[_46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY_TS_7@P
M_VP! .9Z  #6A@  RX\" ,27! "^G00 N*(. +&C(0&IHC('H9\_$9F<2AN2
MF5,EBY9<+8638S5_D6L[>HYS076,?$9PBH5+:XB13V>'G5)DAJQ48H:_56&&
MX51AAOE28X3_4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_80H _V\
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M25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F
MLZ   *JG  "AK@  E[8  )&Z$ ",NB,!A;DR!GZX/@YWMDD7<;52'FNS6B5E
MLF(K8+%J,%NP<S57KWTY4ZZ)/4^MED!,K:5"2JVY0TFNV$)(J_5#1ZK_1$FE
M_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "WG0  K*0
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M+3;*_RTVRO\M-LK_+3;*_RW%D   MIT  *BE  "<K0  C[8  (.^  !WQP
M;,\" &+6!P!:Y X 6.0< %3D*0%0Y#4#3.4_!4CE20=%Y5,*0N9<#3_F9@\\
MYG$2.N=^%#?GC!8UYYP7,^BN&3+IQADRZ.H9,>7^&2_D_QPNY/\>+>+_("WB
M_R MXO\@+>+_("WB_R"ZF@  JJ,  )VK  "0M   @[T  '?&  !KSP  7]8
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M!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P<
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M4@X _UT# /UI  #A<@  UGH" ,Y_!0#*@P@ Q882 +R')@&UAC8&KH-##Z>
M3ABA?%@@FWE@)Y9W:2V2=' SCG)Y-XIP@3R&;HL_@VV50W]LH45\:ZY'>FN_
M2'AKW4AX;/9&>&S_1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P
M_U\  /)L  #==@  T'T" ,F#! #$AP8 OXH0 +>,(P&PBC0%J8A!#J*%3!><
M@54?EG]>)I%\9BV,>6XRB'=V-X1U?SN =(@_?'*20WAQGD9U<*Q(<V^]27%P
MV4EQ</1'<7'_1')P_T)R;_]!<F[_/W)N_SYR;O\^<F[_/G)N_S[_5@H _V(
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M1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A
MOHP  +:3  "NEP  IIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95'WJ4729U
MDF4L<)!L,6R.=39GC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$6(C_0UF&
M_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$
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M-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP
MA;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B'%*U:R!.
MM'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F
M_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0  ?+<
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M%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0
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M 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0
M@K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9
M_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_
M<P$ _X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$
M &7,  !6V   1]\  #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL
M#?\.  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7
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M4A&L9EP8J&1E':1B;2*A8'4FGEY^*9M=ABV87(\OE5J9,I-9I#206; VCEG
M-HQ9VS>*6?,VB5K_-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP
M_U0  /M>  #B90  V&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F
M:UD8H6EA'9UG:B*997(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=
MU#F"7O X@5__-H!?_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8
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M.6UL_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P
MPWH  +M^  "U@0  KH,) *B%&@"BA2L"FX0Z!Y6"10Z0?T\5BGU8&X9[7R"!
M>6<E?7=O*GIV=RYV=( R<W.+-6]RECAL<:,Z:7"R/&APQCQG<.<[9W'\.6AQ
M_S=H</\U:6__-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(  -AN  #)=@  OWT
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M,UE]_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP
ME)8  (V9#@")FAX A)HN GZ9.@=YET4-=)9.$V^55AAJDUX=9I)E(6*1;29>
MCW8J6XZ!+5>-C3!4C)HS48RJ-4^,O35/C-XU3XOW-$^*_S-0B?\R48;_,5*$
M_S%2A/\Q4H3_,5*$_S'J90  TG,  ,)_  "VB   K)   **4  "8F   C)P
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M)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT  !>N08
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M!2C9L08GVLT&)]?O!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@
MH)T  )2D  "&K   >;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ L
MX1, *^(? "GC*@ HY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWI
MI (;Z;P"&NKB AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0
M (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$
M(?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/
M^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU
M  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3
M !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8
M /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@
MR   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_
M$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5
M  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP
M0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@
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M'Z=&X""D1O0@H4;_(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_0 T
M_T8$ /],  #X4@( Z%4$ .%5" #B50T U549 ,Q7+ #%5SP"OU9*!KI550JV
M4U\.LE)H$J]0<16L3WD8JDZ!&JA-BAVE3)(?HTR<(*%+IB*?2[$CG4O ))M+
MV"692_ EEDS_))5,_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H _TD
M /]1  #F5P  W5L! -5<!0#26PD RUP4 ,->* "\7C@"MEU&!K%;40JM65L/
MJ5AD$Z96;!>C570:H%1]'9Y3A1^;4HXBF5&7))=0H2:54*TGDE"\*)%0T"B.
M4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10< _TL  /!5
M  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE7U</H5U@
M%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4RRN%5>DK
MA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\  .=8  #9
M8   S60  ,9F 0#!9@0 NV8. +1I( "N:3$"J&@_!:-F2@J?950/FF-=%)=A
M91B38&T<D%YU'XY=?2*+7(8EB%N0*(5:FBJ#6:8L@%FT+7]9QRY]6>8M?%KZ
M+'M:_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P
MQV@  ,!K  "Z:P( M6L- *YM'0"H;BX!HVT\!9UK2 J9:E$/E&A:%)!F8AB-
M96H<BF-R((=B>B.$88,F@6",*7Y?ERM[7J,M>5ZQ+W==Q"]U7N(O=5[Y+75?
M_RMU7_\I=5__*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P  PVP
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M*65J_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0
MGGT  )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W>6 :<W=H'F]V<"%L
M=7@E:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O
M_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@  F($
M )&##P"-A1\ B(4N H.$.P5^@T4*>H%.#W6 5A1Q?UX8;GUF'&I\;2!G>W8C
M8WJ )V!YBRI=>)@L6G>F+EAWN"]7=]$O5W?Q+EAV_RQ8=O\J677_*5IT_RA:
M=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@  D8<  (J)
M# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA@G0A78%]
M)%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z_R=4>O\G
M5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T  (./" !^
MD!< >Y$G 7:1- -RD#\&;8])"VF.40]EC5D38HQ@%UZ+:!M;BG$>5XE[(52(
MAB11AY0G3X:B*4V&M"I+ALPJ2X7N*4R$_RE,@_\H3(/_)TV!_R9.@?\F3H'_
M)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0  A),  'J5 @!UEQ(
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M%SJFKQ@YIL<8.:7J&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>
MM84  *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-
MLR@ 2[,U $FS/P%&LTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.S
MK1 RL\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX
M *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X
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M !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0
M:+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1
MZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3Q
MY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(
M $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4
M!_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0
M_.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1
M   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2
M  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(
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M +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA.
M ?\%6P'_ V@!_P)T ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;(
M_P&Z /\!Q #_ =$ _P#D /\ \0#_ /P _ '_ /P"_P#\ _\ _ 3_ ?P%_P'\
M!?\!_ 7_ ?P%_P'_'R8 _R$B /\@(0#_'B, _Q@G /\3, #_$3P!_PY* ?\-
M5P'_"V,!_PIO ?\*>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*J '_"J\!_PJW
M ?\*P #_"LP _PK@ /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_ O0-_P+T#?\"
M] W_ O0-_P+_(B( _R0= /\D' #_(AT _QXB /\<+ #_&3@ _Q9% ?\34@'_
M$EX!_Q!J ?\0=0'_$'\!_Q"( ?\0D '_$)<!_Q"> ?\0I0']$*P!_!"S ?H0
MO0'Y$<D!]1'= ?$1[0'N$?D![!+_ NL3_P+J$_\#Z1/_ ^D3_P/I$_\#Z1/_
M ^D3_P/_)AT _R@8 /\H%@#_)A8 _R8= /\F* #_(S0 _R!  /\=30'_&UD!
M_QEE ?X9< '\&'H!^1B# ?<8C 'V&),!]!B: ?,8H0'Q&:@!\!FP NX9N@+M
M&<8"ZAK9 N8:ZP'B&_D"X!O_ ]X<_P3='/\%W!S_!=P<_P7;'/\%VQS_!=L<
M_P7_*AD _RT3 /\M$0#_+1$ _RX9 /\M(@#_+"X _RDZ /\F1P'Z)%0!]B-@
M ?(B:P'O(G4"[2)^ NLBAP+I(H\"YR*6 N4BG@+D(J4"XB*M N$CMP+?(\,"
MW2/6 M@DZ@/2)/D%SR7_!LTE_P?+)?\(RB7_",HD_PC*)/\(RB3_",HD_PC_
M+A0 _S$0 /\R#0#_- X _S44 /\U' #_,R< ^C$T /,O00#N+4X!Z2Q: >4L
M90+B+' "WRMY MTK@@/:*XL#V"N2!-4KF@33*Z($T2NJ!<\KLP7-*[\&S"S/
M!L@MYP?$+?<)P2W_"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$
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M&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40
MT50  ,I4 0#&4@4 P5$1 +E3(@"S53,!KE1! JI43 6F4U8(HE%?#)]09P^=
M3V\1FDYW%)A.?Q:638@8DTR1&9%,FQN/2Z8=C4NS'HM+Q1Z)2^(>ATSW'H9,
M_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #55@  RED
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M'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:
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M'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0  C7<  (=Y"P"#>Q@
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M'DF!K!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680
MPFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T :(\: &:/*0!B
MD#4!7X\_ UR/2 59CE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH818J9&D.*
MJAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0
M *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7(P!:F"\
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M""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@
MA9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A #*V+  Q
MMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#([G2 R.W
M] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,
M &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P APRH
M(,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+ !?&\0$7
MQ/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0  <*L  &*Q
M  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0TAH $-,E
M  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9Y@ *UOX
M"]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)
MOP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@
M)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR   Y_   .C_
M  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP
M,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&
MZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W
M_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8
M !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0
M /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0
M__D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F
M   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@  _PP  /\0
M  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4
M /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_
M &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\
MP #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0
M_P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^
M ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D
M_P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K
M /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0
M]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_
M'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&
M<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07.
M .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@
M_R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V
M#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_, .$/
MXP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1, _R40
M /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P79@#I%W
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M!ZLN_PBI+O\(J"[_"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$  /\U  #V-P
MZC8" .<S" #D+P\ V2X; ,\Q+ #),SP Q#1) , U50&\-5\"NC5H K<U< .U
M-'@$LS2 !;$TB :P-) &KC29!ZPTH@BK-*P)J32Y":<TR@JE->4*H37X"Y\U
M_PR=-?\,G37_"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E/@  W$
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M$G]'_Q%_1_\1?T?_$7]'_Q'_.P  [D,  -Q,  #,40  P50  +E4  "T40
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M$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y5W<3=E:
M%716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K5?\4
M:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "0
M8!\ C&$N (AA.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]%6Y:
MB!=K6I09:5FA&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\495G_
M%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P  E6$  (]B#@"+9!P
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M&E9GJAM59[T<5&?<'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E_Q7B40
MRET  +MF  "O;   IG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A ')S+P%O
M<SH";'-$!&ER3 9F<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL74VV9&5%M
MJ!I/;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$
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M$SR"\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[  "?@@
MDH(  (6"  !Y@P  ;88  %^*  !8C0$ 5(X/ %*/&P!0CR< 3Y S $V0/0%+
MD$4"29!. T:05@1$CU\%0H]H!S^/<PD]CH +.HZ/##B.H TWCK,.-H[,#C:-
M[PXUB_\.-8G_#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP  C(@
M '^(  !RB@  9HT  %J1  !0E0  29<) $>8$P!%F"  1)DK $.9-@!!FD
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M AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB  !;I0
M3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4
MO4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z
M_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0
M #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC(
M!LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !
MRO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_
M   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ
M  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\
M -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8
MS0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I
M+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_
M  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75   .V@
M!]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7  #U(
M^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_
M]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #Y@   .D
M  #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL
M /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_
M#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\
M>@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3
M /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$
M_Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_
M '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D
MX@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,:
M /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H
M_@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N
M .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3
M$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^
M /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D
MX0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_
M$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"
M@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX
M ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L
M_Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9
M#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y +\3
M_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04 _Q\,
M /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6=0#)%WT
MQQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV ;(=_P*P
M'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P  \24# / A
M"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z(W@ N2-_
M ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F_P.C)O\#
MHB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\  -DK! #6
M(@H SB,6 ,8F)P# *#8 NRI$ +@K3P"U+%D LBQB ; L:@&N+7(!K"UZ JHM
M@0*I+8H"IRV2 Z4MFP.D+:4$HBVQ!* MP 2?+=@$G"[O!9DN_P:7+_\&EB__
M!I4N_P65+O\%E2[_!94N_P7_+   _RX  .HU  #=.0  T3D  ,HV  #'+P8
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M//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@  K3X* *9
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M"W%&_POS.0  X$0  ,Q,  "^40  M%,  *I2  "B3@  G4H! )=+$0"332
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M$F)4J1-@5+H47U33%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1
MSU   +]8  "S70  J%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD 'I=,0!W
M73P!=%U& G%=3@1O7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L17EF8$EQ8
MIQ1;6+@465G0%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,
M +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B+@!R8CD!
M;V)# FQA2P-J85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6$E==I1-5
M7;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3   QU8  +A?
M  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L9S<!:F=
M F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)BHQ-08K03
M3V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH  +1C  "I
M:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0 9&P] 6)L
M1@)?:TX$76M6!5IJ70=8:F4)5FEN"U-I> U1:(0/3FB2$$QGH1)+9[(226?)
M$DEGZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G  "F;0
MEVP  (IK  !_:P  <VL  &UM  !H;@P 97 7 &)Q) !@<3  7G$Z 5QQ0P)9
M<4L#5W%3!%5P6@92<&('4'!K"4YO=0M+;X(-26Z/#T=NGQ!%;K 11&['$4-M
MZA!$;/\/1&O_#D5K_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0  DG
M (5O  !Z;P  ;G   &5S  !@=0< 7782 %MW'P!9>"L 5W@V %5X/P%3>$@"
M47A/ T]W5P1,=U\%2G=H!TAV<PE%=G\+0W6-#$%UG0X_=:X./G7%#CUUZ X^
M<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0  C70  (!T
M  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,@$,!2H!+
M DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]Y@LW>_P+
M-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD  'MY  !P
M>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X 08E' 4")
M3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <PA?L(,(/_
M"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_  !J@
M7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)  #:220 T
MDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-
M_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB   6(L
M $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L
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M  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P   JLP
M(;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@
MPU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##
M_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L
M !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,
M -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*
MFP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.
M    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="
M  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP
M;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@   #=
MX0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y
M00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4
M %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H    [
M .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P
M_T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\
M'0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"'
M /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /
M_@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_
M !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\
MB0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y
M /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0
M_P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W
M (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8
M_P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5
M /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8
MZ@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5
M /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#
M&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "'
M -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\
MQ '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\
M!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$
MB0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_
M +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8
MXPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\
M#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5
M_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8
M ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@
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M X,O_P/[*0  ZS$  -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28
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M"'!!J0EO0;D*;4'0"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P
MUD(  ,1)  "W30  JTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'- "
M2#\ ?DA( 7M(4 )Y2%<"=TA? W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&
MI@MG1K8+9D;,"V5&[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8
M +]-  "S40  I5$  )I.  "22P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z33P
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M#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P
MF5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;10%C
M6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC##4Y8
MY Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@  E5T
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M"#]E_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I  "6:   AV<  'MG  !Q9P
M96@  %QJ  !8; $ 5&X. %)O& !0;R0 3G N $UP. !+<4$ 2G%) 4AQ40%&
M<5D"1'!B T)P; 1 <'@%/G"&!CQOE0<Z;Z8(.&^["#AOVP<X;O8'.&W_!SAL
M_P8Y:_\&.6K_!CEJ_P:]7   KV8  *)M  "1;   @FL  '=K  !L;   86X
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M B&%_P*K<@  H7P  (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@
M-(T  "R1   FDPP ))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <
MEF0 &I=T !F7A@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0
M_P&E>P  F8,  (F!  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<
M "6:   =G@$ %J , !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP
M#J-K  VC?0 -HY( #*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">
MA   DHD  (.(  !SB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE
M   5J   #ZL$  JN#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA
M  "N<P  KH<  *Z=  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP
MC)   'N0  !KD@  798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .
MM   ";<   &X"0  N X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\
M9P  O'L  +R1  "\J0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@
M '.;  !CGP  5:,  $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP
M ,,   #$ @  Q0H  ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60
MS6P  ,Z#  #.FP  S;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF
M  !:K   3+(  #ZV   PN0  )+P  !F_   1P@  "L4   +)    S    -
M  #1    T@$  -,(  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT
M .1R  #DBP  Y:4  .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-
MM@  /[P  #"_   CPP  %\<   _*   'S@   -$   #6    W    -\   #@
M    X@   .0   #F P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A
M  #W>0  ^),  /BM  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0
M,<4  "+)   6S@  #=(   38    W0   .$   #D    Z    .L   #M
M[P   /$   #S    ]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_
M9@  _W\  /^9  #_KP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B
M /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\
M_P"5 /\ FP#_ *$ _P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[
M /\ ^P#_ /H _P#T /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\
M)@#_ #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0
M /P E@#Z )T ^0"C /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\
M[P#_ .X _P#N /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_
M "X _P \ /\ 20#_ %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /
MD@#O )@ [0"? .P I@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_
M .$ _P#A /\ X0#_ .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@
M_  V /D 0P#V $X \@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A
M ), WP": -T H0#; *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T
M_P#, /\ S #_ ,P _P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O
M .P / #I $@ Y0!3 .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X
MS "5 ,H G0#( *4 Q@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\
M /\ O #_ +P _P#_$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X
M-0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0
M +P F "Z *$ N "K +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\
MK03_ *T$_P#_%   _Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#(
M CH Q -% , #4 "]!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(
ME0"M"9X JPFH *H*M0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_
M )\._P#_%P  _Q,  .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##(
MMPT^ +0.20"Q#E, KQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A
M$IL H!.F )X3LP"<$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6
M_P#_&@  ]!T  .4C  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X
M *<80P"E&4T HAE6 * :70">&V4 G1ML )L<<P":''L F!R# )<=C0"5'9<
MDQZB )(>KP"0'K\ CQ_8 (P@\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z
M'@  ZR8  -HM  #*,   OBX  +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB
M/@"9(T@ ER11 )4D60"3)6  DB5G ) F;@".)G8 C29_ (LFB &*)Y,!B">>
M 88GJP&$)[L!@RC1 8 H[@%^*?\!?2G_ 7PH_P%\*/\!?"C_ 7PH_P'U)
MXRX  ,\U  #!.   M#8  *LQ  "E+   HB8& )XF$P"9*"$ E2HN )(K.0"/
M+$0 C2U, (LM5 ")+EP ARYC (8N:@&$+G(!@BYZ 8$OA %_+X\"?2^: GLO
MIP)Z+[<">"_, G8PZ@)U,/X"<S#_ G,P_P)S+_\"<R__ G,O_P+P*@  W#4
M ,<[  "Z/P  K#P  *(X  "<,P  F"\  )4N$ "0,!P C#(I (DS-0"&-#\
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M!EY!X@9>0?D%74'_!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P
MFTD  )!'  "(1   @T$  'Y!!@!Z0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K
M1D\!:D96 6A&70)F1F4"9$9M V)&=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&
MWP981O<%5T7_!%=%_P171/\#6$3_ UA$_P/:/0  Q$<  +5.  "D3@  EDP
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M!4A1_P1)4?\$25#_ TE0_P/*2   N5(  *I7  "85@  BE4  ']4  !V4P
M;%$  &=3  !B5 @ 7U82 %U7'@!;5RD 65@S %A8/ !6640 55E, 5-94P%1
M65L"3UAD DU8;0-+6'@$25B&!4=7E09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5
M_P1$5?\$1%3_ T14_P/&3   M58  *5:  "460  AE@  'M8  !Q5P  9E8
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M S)D_P.W6P  J60  )9D  "&8P  >&,  &UC  !D9   664  %!H  !):P
M0VT$ $!N#@ ^;Q@ /6\B #QP*P Z<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R
M<6T!,7%Z 2]QB@(M<9P"*W&O BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML
M_P*Q80  I&D  )!H  " 9P  =&<  &EG  !?:   56L  $MN  !#<0  /'0
M #=V"@ T=Q( ,W@< #)X)0 Q>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@
M*'IV "9ZAP$E>ID!(WJL 2)ZQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L
M:   G6X  (IM  ![;   ;VP  &5L  !:;@  4'$  $5U   ]>   -GP  "Y_
M @ I@0T )X(4 ":"'@ E@B< )((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q
M !R$@@ ;A)4 &H2I !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<
ME7,  (1R  !V<0  :W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @
MBP4 &XT. !J-%0 9C1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/
M>P 0CX\ #X^D  Z/NP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD
M 'YW  !R=P  9'@  %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0
M$I@%  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $
MFH8  IJ;  ":L0 !F<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^
M  !K?@  78$  %"%  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"
M  :E"@ !I1   *46  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP
M *>1  "FJ   IL,  *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !C
MB   58P  $F1   ]E@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q
M!@  L0P  +(1  "R%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&
M  "UG0  M;8  +7<  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0
M39H  $"?   UI   *J@  ""L   6L   #[0   FW   !N0   +T   "^
MO@8  +\,  # $   P18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'
MD0  QZD  ,?'  #'[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D
M #BN   LLP  (+<  !:Z   .O0  !L    ##    QP   ,D   #*    S
M ,T#  #."0  T X  -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0
MWIP  -^U  #?V0  W_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[
M   ?OP  %,(   S&   #R0   ,P   #0    U0   -D   #:    W    -X
M  #@    X@4  .0+  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H
M /2D  #TOP  ]-\  /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3
MR@  "\X   #2    UP   -P   #@    Y0   .<   #I    ZP   .T   #O
M    \0   /,   #V!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1
M  #_J0  _[X  /_8  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8
M_P!# /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_
M )P _P"C /\ JP#_ +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4
M_P#N /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^
M /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@
M]P"> /4 I@#T *X \@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E
M /\ X #_ -X _P#_ Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\
M10#^ %  ^P!: /@ 8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9
M .< H #F *D Y "S .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\
MU #_ -( _P#_!PT _P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R
M $H [0!4 .H 70#G &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0
MFP#2 *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_
M ,< _P#_"@8 _P$  /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $,
MW0!. -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#!
M )X OP"H +T LP"Z ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4
M_P#_#   _P0  /\   #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!'
M ,8 40## %D P !@ +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H
ML "D *X KP"L +T J@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_
M#0  _P<  /0)  #J"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +<
M2@"T %, L@!; +  8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@
M *$ JP"? ;D G0/, )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$
M]Q   .@4  #<%0  SA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H
M"$T I@A5 *0)7 "B"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-
MJ@"4#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H
M -T@  #,(0  OQT  +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4<
MFA%0 )@25P"6$EX E1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(
M%K4 AA;) (07YP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I
M  # *@  LR8  *HB  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+
M (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+(
M>R#% 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V
M,0  J2X  * J  ";)@  F"$! )4>$ "0(!L C2$H (DC,P"')#T A21& (,E
M3@"!)E4 ?R9< 'XF8P!\)VL >R=S 'DG? !X*(< =BB3 '0HH %R**\!<2G!
M 6\IX %M*?<!;"G_ 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(  , X  "N-P
MH34  )@R  "2+0  CBD  (LG# "'*!< @RHC ( K+P!^+#D ?"Q" 'HM2@!X
M+E$ =RY8 '4N8 !S+V< <B]O ' O>0%O+X,!;2^0 6LOG0%I+ZP!:#"^ 6<P
MVP%E,/4!9##_ 6,P_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]  "H/   FCH
M )$W  "*,P  AC   (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^ '(T1@!P-$X
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M/@  >3L  '0Z  !Q.@X ;3P8 &L]) !I/B\ 9S\X &4_0 !D0$@ 8D!/ &%
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M T=)R@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13
MA$L  'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !3
M34  4DU( %%.3P!/3E< 3DY? 4Q.:0%*3G,"2$V  D9-CP-%39\#0TVQ T)-
MR -!3>H#04S_ D%,_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X
M '5-  !L3   8TH  %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT
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M C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6
M5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W
M8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@
M_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X
M $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8
M+6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C
M9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F
M   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')*
M ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\
M&V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W
M;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\
M3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_
M !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>
M*7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,
MAU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"
M_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4
M !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL
M )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-
M=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4
M   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0
M  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0
M>'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &
MI    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O
M5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80
M &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O    L@
M +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2
MP%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4
M  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^    P0   ,0
M  #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P
M -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#
MJ@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP   -(   #3
M    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1
M  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@
M*KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,   #D
MY@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_
M50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9
M /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4
M_P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V
M /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\
M( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"&
M /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\
MYP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_
M "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .<
MA@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_
M -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "(
M\P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1
M (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X
M_P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G
M -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (
MO0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N
M /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A ,@
M+ #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0""
M *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\
MG@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T
M #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X
MA0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_
M (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D
MI0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0
M!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+
M_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN
M )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H<
M@PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O
M%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2
M,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/
M '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(
MT"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^
M'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PA
MF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\
M +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#,
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M 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/
MA3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;
M.$$ 6CE( %DY4 !7.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!3#JN 4LZ
MPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X
M '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X
M5#Y& %,^30!2/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L 44_P0%$
M/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-
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M 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@
M6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"
M3$T 04Q6 $!,7P ^3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+
M_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@
M %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H
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M "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P
M-ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B
M9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?
M_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,
M "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@
M%VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"9
M70  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M
M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?
M  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@
M?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7
M>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_
M9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<
M &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P
M#(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P
MBW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL
M  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +CP  !)(
M  "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@
M )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3
M=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G    *    "A
M    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER
M  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@
M/H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O
ML    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[
M?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<
M "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_    P
M ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@
MT8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M
M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.    T    -$
M  #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@
M .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .
MP@  !,4   #*    S0   -$   #8    VP   -\   #@    X@   .0   #F
M    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"
M  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\
M_P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^
M ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D
M_P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V
M /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T
M[P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1
M /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L
M.P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@".
M -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\
MOP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G
M $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8
MCP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_
M +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D
MRP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R
M )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0
M_P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ]
M +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P
MH "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_
M    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8
M/P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1
M )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@
MZ0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6
M $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0
MF "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4
M ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP
MB 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W
M"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=
M  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^
M 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:(
M:Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@
M(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(6
M00!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO
M & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0
MC"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H
M'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<B
MP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T
M 'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$
M7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/
M*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P
M  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$
M %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L
M2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K
M,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R
M20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T
M $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@
M83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*
M-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX
M_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<
M %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L
M1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X
M._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z
M  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1
M #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\
M,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*
M0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&
M6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_
M "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10
M048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P
M2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'
M_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL
M #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P
M*%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A
M20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2
M!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E
M !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30
MADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F
M6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==
M<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$
M '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80,
M&F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .
M97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5
M  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL%
M !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8
M FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<
M60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW
M"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$
M  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@
M35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "
M@0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$
MDP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<
M #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ", P  C D
M (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP
MD:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V
M   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9    F@,  )L(
M  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH
M *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   A
MB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0   *H   "L
M!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H
M  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@
M$)\   FD    J0   *T   "P    M    +<   "X    N0   +L   "\
MO@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*
MN   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";
M  "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.    T
M -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ
MY<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%
M    R0   ,T   #2    U@   -H   #;    W@   .    #B    Y    .<
M  #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\
M /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_
M $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D
MG #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_
M ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $<
M_@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H
M )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X
M_P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+
M .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@
MSP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_
M    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4
M30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"<
M +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_
M_P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\
M $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *<
MH "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _
M .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@
MJ !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5
M *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L
M  #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !)
M )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *(
MA0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W
M!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D
M20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L
M '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$
MG@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\
M $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#
MNP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4
M (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48
M< I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@
M#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:
M  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%)
M &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4
M517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S
M'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T8
M2P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ
M $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)
M:"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4
M($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C
M_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8
M %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP
M3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _
M*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH
M  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1
M $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\
M.BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1
M+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q
M5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_
M #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0
M23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y
M-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T
M_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8#
M $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT
M,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D
M.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\
M"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F
M "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P
MBCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T
M00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%
M<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\
M '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT
M*T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =
M2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#
M  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0
M ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P
M%%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?
M1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6
M$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,
M  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@
M44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 0
M7A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->
MFP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX
M $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q
M!F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0
M9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3
M   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2
M  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<
M &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R
M70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z
M$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ
M  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P
M(VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P
MB!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")
MV   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@
M !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5"@  EPX
M )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0
MFO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,
M   $D0   )4   "9    G0   *    "A    H@   *0   "E 0  IP<  *D,
M  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8
M *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=
MH@   *8   "J    K@   +    "Q    LP   +0   "V    N    +H$  "\
M"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R
M  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N    L@
M +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T   #/
MT@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@
M] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_    Q    ,@
M  #.    T0   -0   #5    V    -H   #=    WP   .(   #D    YP
M .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_
M  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\
M6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J
M /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0
M_P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W
M %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .
ML #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P
M /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8
MX0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$
M +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\
M  #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6
M ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\
MK@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H
M    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +
M50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X
M )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2
MQ0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"<
M %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H
MQ0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP
M *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\
MB@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z
M -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L
M  "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/
M 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X
M; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "(
M @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '
M4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I
M &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0
M>0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E
M!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*
M^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A
M &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\
M6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-
M$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04
M  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3
M %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\
M117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;
M%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:
M6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_
M #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0
M4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"
M(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A
M_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"('
M $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP
M.B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E
M*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G
M#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME
M #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+
MBRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]
M+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP
M<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS
M '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1
M-C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G
M-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T
M  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3
M "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP
M(#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A
M-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\
M&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^,
M !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@
M4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A
M0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$
MG@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T
M $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921<
M&$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,
M2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5
M   _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9
M !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L
M E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \
M1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8
M'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?
M  !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2
M,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&
M8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?
MX@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$
M "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D
M &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0
M:/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=
M   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;
M  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4
M '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0
M;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$
M&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_
M  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0
M 7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/  "3%
ME1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2
M_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$    B0   (X
M  "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E#0  IQ,
M *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6
M:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C
M    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0  N@P  +T2
M  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=
M0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +    "U
MN0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(  - +  #5
M$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D
M "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(    RP
M ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8   #J"@
M[Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\
M!0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D
M /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0
MZ0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_
M  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X
M8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4
M ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_
M_P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4
M &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D
MZ "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP !
M .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P
MN0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C
M /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?    T    ,<
M!P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !:
M *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L
MD0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@   +$  @"K
M  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )
M6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y
M '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *    "9  <
ME0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_
M %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '
M_P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+  ( A@ +
M (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0
M< !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C
M /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '<
M#@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6
M &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\
M6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K
M !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H
M60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_
M $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P
M8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0
M"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,
M_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P-
M %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX
M1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I
M&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0
M$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E
M #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'
MC1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'
M%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;
M;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(
M '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!(
M/QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O
M('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F
M  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6
M #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H
M*"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B
M*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G
M&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ*
M "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+
M5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L
M+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !PO
MFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\
M $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P
M)3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4
M,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R
M  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@
M !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T
M#CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]
M-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<]
M(P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!
M  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P
M-3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 0
M1"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#
MX  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH
M "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B,
M"$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0
M2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E
M   C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F
M  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4
M $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,  "1&   >
M2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:
M*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_
M  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84
M$E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P
M9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@
M_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   260  #5T
M  A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28
M '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:
M3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K
M    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H
M  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65
M3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z
M?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2
M+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H
M #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+    C@
M )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06  "F(0
MIC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I
M   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=    H0   *0
M  "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\%@  O"4
M +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ?
M?P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP   +<   "W
M    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K
M  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0
M#9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H   #*
MS0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M
M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P .
M /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L
M^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B
M /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\
M$ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J
M .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\
MQ0#_ +L _P"T /\ K0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q
M !, [0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D
M: #& &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_
M *P _P"E /\ H #_ )P _P#_    _P   /L   #N    Y    -P " #3 !
MSP 8 ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N
M &< K !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P
M_P"6 /\ DP#_ )  _P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3
M +$ ' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &
MF !F )8 ;@"4 '< D@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"'
M /\ A0#_ (( _P#S    XP   ,P   "\    L    *<   "A  @ G@ / )L
M%@"9 !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@
M (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\
M=P#_ '4 _P#F    RP   +<   "H    G@   )8   "/  0 BP , (@ $@"'
M !D A0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0
M80!R &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_
M &D _P#2    N    *4   "7    C0   (8   "!    ?  ( 'D #@!W !0
M=@ < '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E
M &, 8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P
M_P#"    J@$  )@#  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7
M &@ '@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X
M6 !H %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V
M!P  GPD  (T+  !^#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T
M&@!< "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D
M $T ;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#
ME0X  (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3
M !P 4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#
M;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(
M 'P3  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q<
M2P@? $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \
M"WD .@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87
M  !I&   7A@  %88  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T:
M $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D
M,A"* #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D
M'   61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2
M'@ [$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6(
M "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P
M5A\  $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U
M&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:
MF0 B&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(
M $HB  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\
M+ATE "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP =
M'ZL &Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E
M  !!)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C
M "<B*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H
M%B3! !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^
M)P  .28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G
M)P A*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G
M !$HY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0
M-BD  #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;
M+2L &BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TM
MWP -+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L
M "\K   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@
M%#(P !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (
M,O0 "C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN
M   I+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L
M  XX-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$
M S;_  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E
M,@  (#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @]
M,0 &/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_
M   \_P!M,@  73,  % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@
M'3@  !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0
M1#8  $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"
M_P!H-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T
M !-    00@  #44!  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(
M $L]  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B
M.@  5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'
M   ,20  "$P   )/!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W
M  !41   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P
M3S\  $4_   ^/@  -ST  "\^   G0   ($,  !E&   320  #TP   M/   &
M4@   %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>
M/0  7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,
M $-"   \00  ,D(  "E%   A2   &DL  !-.   .4@  "E4   -9    6P
M %X   !@    8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@
M:T4  &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&
M   W1P  +$H  "--   ;40  $U4   Y9   (70   6$   !D    9P   &H
M  !L    ;@   '    !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT
M 'I.  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P
M3P  )E,  !Q8   37   #6$   9F    :@   &\   !R    =@   'D   !\
M    ?0   '\   "!    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$
M  ",6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@
M'E\  !1E   -:@  !7    !V    >P   '\   "#    AP   (H   "-
MC@   )$   "3    E0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A
M3@  H&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX
M  YU   %>P   ($   "'    C0   )(   "6    F@   )T   "?    H0
M *0   "F    J    *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P
MMUH  +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'
M    C@   )0   ":    H    *4   "J    K@   +$   "R    M0   +<
M  "Z    O    +\   ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\
M ,YJ  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":
MH0   *<   "M    LP   +D   "^    P@   ,4   #&    R0   ,P   #.
M    T@   -4   #:    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>
M  #J>@  ZYD  .NU  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L
M_P E /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V
M '@ ] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X
M_P"U /\ L #_ *T _P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ?
M /\ *0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$
MV@!X -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H
M /\ I #_ *$ _P#_    _P   /T   #Z    ^    /  "0#L !$ Z  9 .<
M(P#E "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P
M +P > "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\
ME@#_ )0 _P#_    ^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#"
M "8 OP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *,
M< "A 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_
M (8 _P#W    [    -X   #)    O    +0   "O  H JP 0 *D %P"H "
MIP H *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "-
M '$ BP![ (D B "' )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D
M_P#I    UP   ,$   "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B
M (X *@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D
M> !S '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:
M    OP   *P   ">    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P
M) !Z "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L
M &< > !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%
MK0   )L   "-    @P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K
M "4 :0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H
M<@!9 (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP
M (T   !_    =0   &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "
M70 F %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !.
M 'H 3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('
M  !T"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B
M %$ * !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4
M0P"% $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L
M#0  80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D
M(P!' "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@""
M #D E  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0
M6Q$  %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !
M R4 /@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&
MD@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510
M $X4  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B(
M. HH #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H
M#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7
M  !#%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE
M #$/+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*<
M'Q"] !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  !
M&@  .QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3
M*0 J$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[
M !@5W@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0
M-QP  #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D
M&"T (Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9
MVP 3&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\
M #$>   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H
M'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /
M'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA
M   J(   )R   "0?   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O
M !<B.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O
M#"+_  TA_P!V'P  9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H
M(P  )",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G
M-0 1*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^
M  @F_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0
M(B4  !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -
M+3L "RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K
M_P!M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@
M !LJ   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C<
M!3)"  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H
M*0  6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N
M   3,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^
M   X2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+
M5"X  $@O   ^+P  -BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0
M-0  #C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^
M1@  /E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$
M $0R   [,@  -#$  "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P
M"CT   5 !0  00H  $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00
M1D\  $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U
M   Y-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T   U    )0@  !$4
M  !' P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH
M $]:  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W
M.   ,3<  "DW   A.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/
M    400  %('  !4"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4
M  !89P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P
M+#P  "0^   <00  %40  !!(   +2P  !4X   !1    5    %<   !9
M6P   %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E
M8   97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,
M !Y&   52@  $$X   I2   #5@   %H   !=    8    &,   !E    9P
M &D   !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60
M=&\  '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1
M   05@  "5H   %?    8P   &@   !K    ;P   '(   !U    =P   'D
M  ![    ?0   ( #  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8
M (6!  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )
M9    &D   !O    =    '@   !\    @0   (0   "'    B    (L   ".
M    D    ),   "6    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV
M  "9E@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =
M 'L   "!    A@   (L   "0    E    )<   "9    G    )\   "A
MI    *<   "J    K0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "R
MB0  L*H  *[/  "M]0 W7   *V$  !YH   3<   "W@   "     AP   (X
M  "5    F@   )\   "D    J    *P   "M    L    +,   "U    N
M +L   "_    PP   ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@
MR9X  ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3    FP   *(   "H
M    K@   +0   "X    O0   ,    #"    Q0   ,@   #+    S@   -$
M  #6    VP   -\   #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,
M ..S  #CU #_    _P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_
M #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\
MA #M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_
M *( _P#_    _P   /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X
M]  X /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#-
M (4 R@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4
M_P#_    ^@   /0   #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q
M -  .0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P
ML0"( *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y
M    [P   .<   #?    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0
M,@"Q #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^
M )8 C "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M
MX    -$   "_    LP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8
M #( E0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V ((
M@@"  )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP
M +8   "G    G0   )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P
M@@ R '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M
M (D ; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$
M  "3    B0   ((   ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L
M &X ,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (
M70"2 %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#
M    >0   '$   !M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &
M+ !> #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "*
M $\ G@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J    E    ((   !U
M:P   &0   !@    70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2
M "P 40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0
MEP!# *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800
M %H#  !5 0  4@   %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "<
M1P M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y
M *8 . "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*
M  !,"   208  $<#  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I
M #T +@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$
M, "X "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%
M#0  00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4
M*P T #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S
M "< T0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $
M/ \  #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N
M!BX +08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &
MRP ?!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(
M #01   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L
M)PPR "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7
M#.L %PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4
M   M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q
M " 0.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X
M$A#^ !(0_P!W$P  914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I
M%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3
M-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^
M  X3_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&
M)!@  "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4
M&#T $AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7
M_P!O&   7AH  % <  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H
M !X:   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L
M#AU%  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K
M&@  6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=
M   8'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!
M  DB30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0
M5Q\  $HA  ! (0  -R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6
M(0  $B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G
M20 !)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(
M $<C   ])   -"0  "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)
M$"8"  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10
M+%,  "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F
M   Z)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"
M  LM!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\
M #)?   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W
M*0  +RD  "DH   E)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R
M!0 #- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;
M   X;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+
M+2L  "@J   D*0  'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!
M.@<  #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  !
M:0  0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T
M "<L   @+0  &B\  !4Q   1,P  #38   DX   %.P   #T   !  0  000
M $,'  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9
M2'L  $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q
M   <,P  %C4  !$X   -.P  "#X   -!    0P   $8   !(    2@   $P$
M  !.!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0
M %*0  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7
M.@  $3T   Q!   '1    $@   !*    30   %    !3    50   %<   !8
M @  6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)
M  !=IP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P
M#$<   9+    3P   %,   !6    60   %P   !?    80   &,   !E
M9P$  &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !M
MGP  :\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0
M  !8    70   &$   !E    :    &L   !N    <0   ',   !U    >
M 'L   !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@
M?K8  'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H
M    ;0   '$   !V    >@   'X   "!    @P   (8   ")    BP   (X
M  "2    E0$  )D)  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H
M )+4  "0^@ X2P  +$X  "!3   560  #6    -G    ;@   '0   !Z
M@    (0   "*    C@   )(   "5    EP   )H   "=    H    *,   "G
M    JP   *\   "T"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!
M  "I[@ Q50  )%L  !AA   .:0  !7$   !Y    @0   (@   "/    E
M )H   "?    I    *@   "I    K    *\   "S    M0   +D   "]
MP0   ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##
MW@ I8@  '&D  !%Q   '>P   (0   "-    E0   )T   "C    J0   *\
M  "T    N0   +P   "^    P@   ,4   #(    S    -    #4    V@
M -\   #D    Z@   .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_
M    _P   /\   #\  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\
M0@#_ $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5
M .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_
M^P   /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I
M $, Y@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,(
MF@"_ *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0
M .H   #G    YP   .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L
MP@!" +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F
M *$ HP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H
M  #3    Q@   +\   "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [
M *0 00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )<
MC "I (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V
M    J0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P
M.@"* #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@
M '4 M@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=
MDP   (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U
M #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0
MJP!B ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@
M '@   !S    ;P ! &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #(
M8P W &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3
M +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<
M  !C    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q
M %, -@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$
M1@#8 $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L    8@   %L   !6
M    4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@
M,0!' #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#'
M #L \P [ /\ .P#_ #P _P"3    ?@   &X   !A    6    %$   !,
M20   $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ]
M #( .P X #H /P Y $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$
MYP Q /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,
M #X!   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X
M,P T #( .P P $, +P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I
M /L *0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(
M   U!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P
M "H -P I #\ * !) "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /,
M(0#_ "( _P!["0  : P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N
M"P  +0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0
M-  C 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_
M !H _P!U#   9 X  %4/  !*$   0!   #D0   S$   +P\  "P.   I#@
M)PT! "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =
M!SH ' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%
M_P!Q#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q
M "(.!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D
M%@U# !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M
M$   7!$  $X3  !#%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1
M P <$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$
M ! 04  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0
M6!0  $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9
M$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P4
M2P +%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518
M $@7   ]&   -!@  "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00
M%!4% !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %
M&%0 !!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:
M   [&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@%
M ! 9!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$
M !U@   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X
M'   +QT  "D<   C'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=
M!P ,'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=
M   A;P  (88  "">   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P
M+1\  "<>   B'0  'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )
M(@H !2,-  (D$   )1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F
M;   )H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$
M "4@   @'P  '1X  !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD
M "@+   J#@  *Q$  "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0
M+(   "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B
M   ?(0  '"   !<@   3(0  $",   XD   +)@  ""@   0J!   + <  "X)
M   P#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL
M #*7   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >
M(P  &2,  !0D   1)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W
M"@  .0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2
M   XL   -]L  #;\   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P
M%2@  !$J   .+   "B\   8Q   !-    #8    X    .P$  #T$   _!P
M00H  $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!
MJP  0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X
M  TQ   )-   !#<    Z    /    #\   !!    1    $8   !( P  2@<
M $P+  !.#@  4!,  % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I
M2LH  $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ
M   "/0   $    !$    1P   $D   !,    3P   %$   !3    50$  %@&
M  !:"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\
M %7R  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%
M20   $P   !0    4P   %8   !9    6P   %T   !@    8@   &4   !H
M!0  :PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I
M  !B_P X.0  ,C<  "@Y   >.P  %3\   Y$   '20   $T   !2    5@
M %H   !>    8@   &4   !H    :P   &T   !P    <P   '8   !Y
M?00  ($+  "%$0  A!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U
M_0 X/0  +#X  ")!   71@  #TL   =1    5P   %P   !B    9@   &L
M  !O    =    '@   ![    ?@   (    "#    A@   (H   "-    D0
M )8#  ";#   G1,  )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q
M1   )4@  !I-   04P  "%H   !A    :    &X   !T    >0   '\   "$
M    B0   (T   "1    DP   )8   "9    G0   *    "D    J    *P
M  "R P  MPT  +<7  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P
M'E0  !);   *8@   &H   !S    >P   ((   ")    C@   )0   ":
MGP   *0   "F    J0   *T   "P    LP   +<   "[    P    ,4   #+
M    T00  -4.  #3'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(
M  QK   !=    'T   "'    D    )<   ">    I    *L   "Q    M@
M +H   "\    P    ,0   #(    RP   ,\   #4    V@   .    #F
MZP   /$&  #P$P  [B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8
M  #S    ]  % /8 # #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !,
M /H 4@#W %@ ]0!> /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +(
MV #. -( ]@#! /\ K0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I
M    Z0   .P !0#R  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T
M2P#8 %  TP!6 -  7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_
M +0 Z "N /\ G0#_ )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:
MVP   -P   #8  < T0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W
M $D M0!/ +( 50"P %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L
MU0"9 /P C #_ (( _P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O
M +8   "P  $ KP + *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $(
MF0!' )< 30"5 %, DP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@""
M /  ? #_ ', _P!M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@
M  "4    D0 & )  #0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!
M (  10!^ $L ? !2 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\
M; #_ &4 _P!@ /\ 7@#_ %P _P"^    L0   *    "2    B0   ((   !\
M    >@ ! '@ "0!W  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L
M/@!I $0 : !* &8 40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W
M %< _P!4 /\ 4@#_ %$ _P"P    GP   (T   !_    =    &X   !J
M9@   &4 ! !C  L 8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9
M #T 5P!# %8 2P!5 %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L
M_P!) /\ 1P#_ $< _P"B    C0   'P   !N    90   %X   !9    5P
M %4  0!4  < 4P - %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #<
M2@ ] $D 1 !' $P 1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^
M /\ /0#_ #X _P"4    ?P   &\   !C    60   %$   !-    2@   $@
M  !'  0 1P * $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W
M #T /@ \ $< .@!0 #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\
M- #_ #4 _P"(    =    &4   !8    3P   $@   !#    /P   #T    \
M  ( /  ' #L #  [  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #,
M.0 Q $$ , !+ "\ 5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_
M "P _P!_    ;    %T!  !1 @  2 ,  $ #   [ @  -P   #0    S
M,@ % #( "0 R  T ,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I
M #T * !& "< 40 F %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0
M_P!W    900  %8&  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P #
M "H !P I  L *0 . "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D
M(0!# "  3@ ? %H '@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P
M!0  7P@  %$*  !&"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$
M!@ C @D (@$, "( #P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _
M !D 2@ 8 %< %P!F !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"
M6PL  $T,  !"#0  .0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =
M" @ '08+ !P%#0 <!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$
M1P 3 U0 $@-C !$#=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT
M $D.   ^#P  -0\  "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# <
M& L) !<)#  7"0X %@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /
M"5( #@EA  T)<P ,"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80
M   [$0  ,A$  "L1   E$   (1   !T0   :#P  & \! !8.!  5#@< % T)
M !,-"P 3# T $@P0 !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$
M"0U@  @-<0 &#88 !0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X
M$@  +Q(  "@2   C$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /
M"@ 0#@P #@X.  X/$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=
M  ,0;P !$(0  !"<   /M   #M0   [S   ._P!<$   31(  $ 3   V%
M+10  "84   A$P  '!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -
M$0L #!$-  L2$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3
M;   $X(  !*;   2M   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8
M "05   ?%0  &A0  !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH
M"10-  <5#P &%A, !!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@
M%H   !:9   5M   %=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7
M   =%@  &18  !85   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,
M  ,:#@ !&A$  !H6   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT
M !N7   :LP  &=L  !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;
M&   &!<  !46 0 3%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >
M#0  (!   " 3   @&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5
M   ?L0  'ML  !WZ   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@
M%Q@  !07 @ 2%P( $!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P
M)0X  "81   F%@  )AX  "<G   G,@  )S\  "9.   F8   )G<  "62   D
MKP  (]H  "+[   A_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH
M !(:   0&P  #1P   L=   ('P  !"$   $C @  )00  "<&   I"0  + P
M "X/   N$P  +AH  "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK
M*M0  "G[   H_P!$(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >
M   .'P  "R$   <C   #)0   "<    I    + $  "X#   P!@  ,PH  #4-
M   V$0  -A<  #8?   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\
M ##Z   O_P _)   -"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *
M)0  !B@   (J    +0   "\    R    -    #<    Y P  .P8  #X*  !
M#@  01(  $$:  ! )0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX
M   X_P Z*   ,"@  "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0
M #     S    -@   #@    [    /@   $    !"    10(  $<&  !*"@
M30X  $T5  !,'P  3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"
M_P V+   +2L  "<I   C)P  &R@  !0J   .+0  "C    0S    -P   #H
M   ]    0    $,   !&    2    $L   !-    4    %,!  !6!@  60L
M %L0  !;&0  6B4  %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S
M,   +"X  "<L   >+0  %B\  ! R   *-@   SH    _    0@   $8   !)
M    3    $\   !2    50   %@   !:    70   &    !C    9P8  &L,
M  !L$@  :QX  &LL  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P
M+#$  "(R   9-0  $3D   H]   "0@   $<   !,    4    %0   !8
M6P   %\   !B    90   &@   !K    ;@   '$   !U    >0   'T&  ""
M#0  @A8  ( D  !^-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@
M !P[   20   "T4   )+    40   %8   !;    8    &4   !I    ;@
M '(   !V    >0   'P   !^    @@   (4   ")    C@   ),   "8!@
MG X  )L:  "8*P  ED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'
M   -30   E0   !;    80   &@   !N    <P   'D   !^    @P   (@
M  ",    CP   )(   "5    F0   )T   "A    I0   *H   "P    MP<
M +@1  "U(0  LC4  *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $
M7    &0   !M    =0   'P   "#    B0   (\   "5    FP   *    "C
M    I@   *D   "M    L0   +4   "Y    O@   ,0   #*    T@   -H*
M  #6%@  TBD  ,Y!  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@
M '<   !_    B    )    "8    GP   *4   "M    LP   +@   "Z
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M_/[______________________________________________________P
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M8F'VC&)A]HQB\\0/ ,[:"P"]\QT'L?\R%*/_.A^5_S\JB?]&,X#_3SIX_UM
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
ME9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340
M_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8
M?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[
M%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9
MU'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@
M1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@
MGM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_
MIDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%U
MI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM
M_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/
M<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9
M//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFE
MS7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VN_Y,=!/^0*0G_CS00_YH[%_^B1"#_J4TM_ZI8//^H
M8DS_I&Q<]9]V;.R9?WKDD8>&WHF-D-B#DYC3?IF?T'J=I,UVHJG+=*>LR7&M
MK\=OM++!;+FTO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQ
MO&R[L;QLN[&\;+NQ_Y0=!/^1* G_D3,0_YPZ%O^D0R#_K$PM_ZU6/?^M8$W^
MJ6I>]*5T;NJ??7WAEH.+V8Z*EM.'D*#.@96GRGR:K<=XG[+$=:6VPG*KN<!P
MM+NW;K6YLV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^X
MM;-ON+6S;[BU_Y0=!/^2* G_DS(/_YXZ%O^G0R#_KDLM_[%5/?^P7T[]KFA?
M\JIR<.>D>H'>FH"/U9*'G,Z+C*;)A)&OQ'Z7M<%YG+N^=J._O'2KPK1OKL.N
M<K.\JW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MS
MMKBK<[:X_Y4<!/^2* G_E3(/_Z Z%O^I0A__L$HM_[14/?^T7D[]LV=@\:]P
M<N:I>(/;GWZ3TI>#H<N.B:S$AHZUP("4O;Q[FL.Z>J/%MWFKQZQSK,:G=;&_
MI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE
M=[6Z_Y4<!/^3* G_EC$/_Z$Y%?^J0A__LDHL_[93//^W74[[MF5A\+1N=.2M
M=8;9I'N6SYN I<>2A;'!BHN[O8>4P+N%G<2V@J3'L'ZJR*5WJLBA>;#!GWJS
MO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\
M_Y4<!/^3* G_ES$/_Z,Y%?^L0A__M$HL_[E3//^Z7$[XNF1B[[AL=>.R<XC8
MJ7F9S9]^J<68A+2_DXR\N(V3P;.)F<6NAJ'(JH2IR9]\J<J;?:["F7ZRO9E^
MLKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]_Y8<
M!/^3* G_F# ._Z0Y%?^M01[_M4DL_[M2//V]6T[VO6-B[KUK=N*V<8G5KG>;
MRZ5\JL*=@[2YEHF\LI&0P:R,EL:GB9W(HX>FRIF J,N6@:[$E8&QOI6!L;Z5
M@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^_Y8<!/^4
M)PG_F3 ._Z4Y%/^N01[_MTDK_[U1//R_6D[TP6)B[,%I=^&[<(O2L72=QZA[
MJKR@@;2TFH>\K)2-PJ:0E,:@C9O)G(NDRY6&J,N1A:W%D(6QOY"%L;^0A;&_
MD(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&__Y8<!/^4)PC_
MFC ._Z8X%/^P01W_N$DK_[]1//K"64[RQ&%CZ<5H=]V^;8S-M'.=PJMYJK>D
M?K2NG82\IIB*P:"4D<::D9C)EH^ARY"+J,R,B:S%C(FPP(R)L,",B;# C(FP
MP(R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# _Y<<!/^5)PC_FS .
M_Z<X%/^Q01W_NDDK_\)0._C&6$[PR%]CYLAF>-C!:XW)MW&=O:]WJ;*G?+.I
MH8*[H9R(P9J8C\:4EI;)D)2?RXN1J,R'CJS&AXVPP8>-L,&'C;#!AXVPP8>-
ML,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!_Y<; _^5)PC_G2\-_ZDX
M$_^S0!W_O$@J_,5/._;)5T[MS5YCXLMD>-+$:HS$NV^<N+)UJ:VK>[.CIH"[
MFZ&&P92=C<6.FY3(BIF=RH:9J,N"DZS&@I*OP8*2K\&"DJ_!@I*OP8*2K\&"
MDJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!_Y<; _^5)PC_GB\-_ZHX$_^U
M0!S_OD@I^<A..O/-5DWJTUQBWL]B>,W':(N_OFZ;LK=SJ*>P>;*>JWZZE:>$
MP(ZCB\2(H9+'@Y^:R8"@I\I]FJS&?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!
M?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!_Y@; _^6)PC_H"\-_ZPW$O^W0!O]
MP4@H]LM..>_35$SFV5IBV-1A=\?+9XJYPVR:K;QRIZ&V=[&8L7VXCZV"OHBJ
MB<."J)#&?:>9R'JGI<EWHJS%>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^P
MP7B?L,%XG[#!>)^PP7B?L,%XG[#!_Y@; _^7)@C_HB\,_ZXW$O^Y/QKYQ$<G
M\<Y-..K;4TO@WUE@T-I?=L'098FSR6N9IL)PI9N]=:^1N'NVB+6 O(&RAL![
ML(W#=JZ6Q7.NH<9RK:W$<JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*I
ML,!RJ;# <JFPP'*IL,!RJ;# _YD; _^8)@C_I"X+_[$V$?Z]/QGTR$<EZ]1-
M-N7C4$G9XU=?R=]>=+K79(:LSVF6G<=MHY' <:R&NW6S?K=ZN7>T?[URLH6_
M;;&-P6JPE\)IL:7!;+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RTLKUL
MM+*];+2RO6RTLKULM+*]_YH; _^9)@C_IRT*_[4V#_G!/Q?NSD8CY-Q,,MWG
M3TG/Z%9>P.1=<K+>9(*CU&F1E<MMG(G%<*5_P'.L=[QWL7"Y?+5KMX&X9[:'
MNF.UD+MAM9N\8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y
M8[>FN6.WIKECMZ:Y_YL; _^;)0?_JRT)_[DU#?+'/A7EU48?VN-),\_K3DG&
M[51=M^I<;JCB8WV:V6F*CM)ME(3,<9M[R'6A<\1XIF["?*EIP(&L9;Z'KF*]
MCK!?O9>Q7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>
ML5Z\GK%>O)ZQ_YP: _^@) ;_L"P(^< T"^G//1#:WT(=SNE),\3Q3DB[\E):
MK?!;:9[G8W:2X&F!A]IOB7[4<Y!WT7>5<<Y[F6S,?YQHRH.>9,F(H&''CJ)>
MQI6D7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&
MFZ1<QIND_YX: _^E(P7_MRH%\,@R!]S;-0S.YT(?PO%(-+CY3$:O]U%5HO5;
M8I7M9&V*YVMV@.)P?7G>=8)SVWJ';ME^BFO7@HQGU8:.9-2+D&'3D))>T9:4
M7-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<
MT9N5_Z$9 O^M(0/XOR8#XM0E \[E,P_"\$(AMOI',ZO^2T*B_E!/E_M;6HOU
M96."\&QJ>NQR<'3I>'1OYWQW;.6!>FCCA'QFXHA]8^&,?V#@D8%>WY:"7-Z:
M@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#
M_Z,9 O^V'0'IS!<!S^,> \+P,Q*U^D BJ?]$,)W_23V5_U!(B_];4(+]95=Z
M^6U==/9S86_T>61K\GYG:/&":6;PAFID[XIL8NZ.;6#MDFY=[)=P7.N;<5SK
MFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ_ZP5
M ?/#$ #1V@L P>\?!K3[,Q.H_SP@F_]"+)#_2#:'_T\_?_]:1GC_94MQ_VU/
M;/]S4FG_>55F_GY79/V"6&+\AEEA^XI:7_J.6U[ZDEQ<^9==6_B;7EOXFUY;
M^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+
M"0# Y@T!LOP@"*?_,Q.:_SD=C?\_)H+_1BYZ_TXU<_]8.FW_8S]I_VQ"9?]R
M1&+_=T9@_WQ'7_^!2%W_A4E<_XA*6_^,2UK_D$Q8_Y5-5_^935?_F4U7_YE-
M5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-S<$& +[0!P"Q
M]@X"I?\A"9G_+A*,_S09@/\[(';_0R=M_TPL9O]4,&+_8#->_VDU7/]O-UK_
M=#A9_WDY6/]].E?_@#M6_X0[5?^'/%3_BSU3_Y ]4O^3/E+_DSY2_Y,^4O^3
M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^O<4% +#7!0"C_Q #
MF?\B"8O_*0]^_S 5<_\X&FG_0!]B_TDC6_]1)E?_6BA5_V(J4O]I*U'_;RQ0
M_W,M3_]W+D[_>BY._WTO3?^ +TS_A#!+_X@P2_^+,$O_BS!+_XLP2_^+,$O_
MBS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP_XL<!/^(* C_A#0._X\Z
M%/^70AS_GDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&
MX72CBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^7
M0AS_GDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72C
MBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^70AS_
MGDLG_YY7-/^=8D+_F6U/___B__])0T-?4%)/1DE,10 '"9-X7/B-@F?RB(MQ
M[(*3>>A\F8#D>)Z&X72CBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,
M9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(
M* C_A#0._X\Z%/^70AS_GDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3
M>>A\F8#D>)Z&X72CBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_
MA#0._X\Z%/^70AS_GDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\
MF8#D>)Z&X72CBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0.
M_X\Z%/^70AS_GDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D
M>)Z&X72CBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^)* C_A3,._Y Y
M%/^80AS_GDLG_Y]6-/^>84+_FFU0_Y5W7?>/@6CQB8MRZX.2>^=]F(+C>)V(
MX'2CC-URJ)#;;ZV3VFZSEMALNIC6:\*;T6G*G,IFRIS*9LJ<RF;*G,IFRIS*
M9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<_XP< _^))PC_B#(._Y,X%/^;
M01S_HDHG_Z14-/^B7T/_GVI1_9IT7_64?FSMCHAXYX>/@>* E8K=>YJ0VG>@
MEM9TIIK4<:R>TF^RH=!MN://;,.FQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>A
MP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_
MI4DG_Z=3-/^G74/_I&A3_*!R8O*:?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!U
MI*3-<JJHRV^PJ\EMN*[":;RPO&O JK=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$
MI;=MQ*6W;<2EMVW$I;=MQ*6W;<2E_XT; _^+)PC_C# -_Y@W$_^@0!O_IT@F
M_ZM2-/^K7$3_J694^J5P9/"?>7/GF(*!WX^(C=F(CY?2@96@SGN;I\IVH:W'
M<ZBQQ7"OM<%MM[>Y:[BULVZ]KK!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!P
MP:BP<,&HL'#!J+!PP:BP<,&H_XX; _^+)@C_CC -_YHV$O^B/QK_J4@F_ZY1
M-/^N6T3_K&15^:IN9>^E=W;EG7^%W)2%DM2,C)W.A)*GR7V8K\1XGK7"=:>Y
MP72QN[APL[NQ;[:XK'&[L:ESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI
M<[^KJ7._JZESOZNI<[^K_XX; _^,)@C_D"\-_YLV$O^D/QK_JT<F_[%0-/^Q
M643\L&-5]JYL9^VJ=7CCH7R(V9B#EM&0B:/*AX^MQ8*7M,)_H+B^?*B[NWJP
MO;%TLKVI<K2[IG2YLZ-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZM
MHW:^K:-VOJVC=KZM_X\; _^,)@?_D2X,_YTV$O^F/AK_K4<E_[-/-/^T6$3Z
MM&%6\[)J:.RO<WKAIGJ+UIV FLV4AJ?&C8VOOX>4M;J"G+FU?Z2\LGVLOJMY
ML;^C=K*]H'BXM9YYO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]
MKYYYO:^>>;VO_X\; _^-)@?_DRX,_YXU$?^H/AG_KT8E_[9.,_ZW5T3WMV!6
M\+9H:>BS<'O>JG>-T)]\G<>7@Z>_D(JON(N1MK*&F+JM@Z"]J8&IOZ5^L,"<
M>;&_FGNWMYA]N["8?;NPF'V[L)A]N["8?;NPF'V[L)A]N["8?;NPF'V[L)A]
MN["8?;NP_Y : _^-)@?_E"T,_Z U$?^I/AG_L48D_[A-,_R[5D3UNU]6[;MG
M:>.U;GW6K'./RJ-ZG<&;@*>XE(>PL8^.MJN*E;NFAYV^HH6EP)^$K\&6?K#!
ME'^VN). N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3
M@+NR_Y : _^.)@?_E2T,_Z$U$?^K/1C_LT8D_[I-,_J^543SOUU6ZK]E:M^X
M:W[0KW&/Q:9XG+N??J>RF(6OJY.+MJ6.D[N?BYJ^FXFBP9B(K,*0@J_"CX.U
MN8^$NK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK./A+JS
M_Y : _^.)0?_EBP+_Z(U$/^L/1C_M44C_[Q,,OC!5$/PPUQ6Y\-C:MJ[:7[,
MLG"/P*IVG+:B?*>MG(*OI9>)MIZ3D+N9CYB^E(V@P9&,J<*+B*["BHBTNHJ(
MN;2*B+FTBHBYM(J(N;2*B+FTBHBYM(J(N;2*B+FTBHBYM(J(N;2*B+FT_Y$:
M _^/)0?_F"P+_Z0T$/^N/1C_MT4C_[],,O;%4T/NR%M6X\9A:M2_:'['MFZ.
MNZUTG+&F>J:GH("OGYN&M9B7CKN3E96^CI*=P8J2I\*&CJ["A(VTNX6,N;2%
MC+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FT_Y$: _^/
M)0?_F2P+_Z8T#_^P/!?_N40B_,%+,?3)4D+KS5E5W\E@:L_"9GW"N6R-MK%R
MFZNK>*:BI7ZNF:"$M9*=B[J,FI.^AYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU
M@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU_Y(: _^0)0?_
MFRP*_Z<T#_^R/!;_NT0A^<5+,/'.44'GTEA4VLY>:<K&97R]O6N,L+9PFJ6P
M=J6<JGRMDZ:"M(RCB;F&H)"]@9Z9OWV>HL%[GJ_!>9FSO'J7N+5ZE[BU>I>X
MM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU_Y(9 _^0)0?_G2L*
M_ZHS#O^U/!7\OT0@],A*+NW34#_CV%93T])=:,7*8WNWPFF+JKMOF)^V=*.5
ML7JLC:V LH6JA[=_IXZ[>J:7OG>FH+]TIJV_<Z&TNW2>N+5TGKBU=)ZXM72>
MN+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU_Y,9 _^1) ?_GRL)_ZPS
M#?^X.Q3XPT,>[\U*+.?:3SW=WE51S=A;9[[/8GJPR&>)I,)MEYF\<J&/N'BI
MAK5^L'^RA;5YL(RX=*^5NW"OG[QNKZR\;:NUN6ZGN;1NI[FT;J>YM&ZGN;1N
MI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT_Y09 _^2) ?_HBH(_[ R#/Z\
M.A+RQT(<Z--)*>'A3#O4XU-1QMU:9;?58'BISV:'G<EKE)'%<)Z'P7:F?[Y\
MK'B\A+%RNHNT;;F3MFJXG+AGMZ>X9[>WMFBRN[%HLKNQ:+*[L6BRN[%HLKNQ
M:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ_Y48 _^5(P;_I2D'_[0Q"OC!.A#K
MSD(8X-U')=7E2SO+YU%0O>-98Z_>7W2BV&6#EM-JCXK.;YE_R'.A=<1XIV[!
M?:MIOH2N9;V+L6&\D[)?O)VR7[RLL6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^
MK6*_OJUBO[ZM8K^^K6*_OJUBO[ZM_Y88 _^9(07_JB@&_[DP"/#(. WAV$ 3
MU.-%)LKK2SO![$]/L^A78*;E7V^:XF9\CMQLAH35<8]ZT'65<\UZFVS*?Y]G
MQX2B8\:*I%_$D:9<Q)FG6L.DIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$
ML*=:Q+"G6L2PIUK$L*=:Q+"G_Y@7 O^>( 3_KR8%^, N!N;0,PC5X3P4R>I%
M*+_R2CNU\4Y,J>]66YWM7VB2ZF=SA^-M?'[><H)VVGB(<-=]C&O4@I!FTH>2
M8]&,E5_/DI9<SIF86<ZBF5C-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8
MS:N:6,VKFEC-JYI8S:N:_YH7 O^E'@/_MR,#[<DF ];>*0;)Z3L7OO-$*;/X
M23JH]TU(G_95593U7V")\6AH@.QO<'CH=75RY7IY;>)_?6G@A(!EWXF"8MV.
MA%_<DX9=VYF'6MJAB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)
M6-FHB5C9J(E8V:B)_YP6 O^M&P+VP1T!V]H3 <GH*0F]\SL9LOU#**;^1S:<
M_4Q#D_U538K]7U:!^6E=>?5P8G/R=F=N\'QJ:NZ!;6?LAF]DZXMQ8>J/<E_I
ME'1=Z)EU6N>@=UCFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F
M>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL RN<3 KSS*0NQ_3L9I/] )IG_13*/_TL\
MA_]41'__7TMX_VE0<?]P5&S]=EAI^WQ:9OJ!7&/XAEYA]XM?7_:085[VE6)<
M]9IC6O2@9%CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CS
MI658\Z5E_ZT0 -;#" #(TPH N_05 Z__*@VC_S<8E_\](HO_0RR!_THT>O]2
M.G/_7C]N_VA#:?]O1V;_=4EC_WM+8?^!3%__A4Y=_XI/7/^/4%K_DU%9_YA2
M5_^>4U;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16
M_Z-4V;H% ,7'!P"YV0@ K/\7!:+_*PV5_S,6B?\Y'G[_0"5U_T@K;?]0,&?_
M6C1C_V4W8/]M.5[_<SM<_W@]6O]]/EC_@C]7_X9 5O^+0%7_CT%4_Y1"4_^:
M0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#
MQKX% +?-!0"JY @!G_\9!I3_* R'_RX3>_\U&7'_/1YI_T4C8O]-)EO_5BE8
M_U\L5O]H+53_;B]3_W,P4O]X,5'_?#%0_X R3_^$,T[_B#--_XPT3/^2-$O_
MEC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8UM\0#
M *G4 @"<^0L"D_\;!87_(PIY_RD/;O\Q%&7_.1A=_T$;5_]*'E/_4B!0_UDB
M3?]@(TO_9B1*_VLE2?]O)4C_<R9'_W<F1O][)T7_?B=%_X(H1/^'*$/_BRE#
M_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI_X,< _^
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M.!'_N4 9^,)')N[+337DT%1&U<M;6\?#8FZZNVA^KK1NBZ.N<Y::J7J?DJ6
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M44__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-1VJ\" ,:\!0"YR04
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M?R<'_XHL"O^3-0[_F3T6_YY&'_^A3BO[H%DX]9QC1N^8;53HD'=BXHA_;]J
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MA966EH*>FI* IYV/?[.>C8#"GHN S)J+@=*2BH#8B8F VX:)@-N&B8#;AHF
MVX:)@-N&B8#;AHF VX:)@-N&_WD: O][(03_BR(%_Y@H!_^C, K_JS@0^;)
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M=4_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T_X\/ ?^D#@#;N @
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M?UZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ,
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M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@
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MAA(E_Y 3)/^9$R/_HQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X
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M7VB2]U]HDO=?:)+W7VB2]U]HDO=?_V\1 ?^!#@#_D0X \J , -JM"0#3N H
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MTRL&F= Z$H_.11^%RTXJ?<E6-'7'73UNQ65$:,1L26/"<TY>P7M36<&$5E7
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MJRH]_+DK._W+*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@
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M#AS_H0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@
M:^,  %_V  !6_P  3O\* $?_$ %!_Q8"//\= C?_) ,R_RH#+_\P!"O_-@4G
M_SL%)?] !2+_108@_TH&'O]0!AO_5@<9_UP'%_]D"!7_;0@3_W<($?^!"1#_
MBPD0_Y4)#_^8"0__F D/_Y@)#_^8"0__F D/_Y@)_TDG O]$,03_2S$$_U T
M!O]2.@C_4D,+_U%.#_]/7!/_36L6_TQY&?]+AQO_29,=_TB='_](IB#_1ZXA
M_T>U(O]&O2/_1L8C_T;0)/]&X"3_1NHE_T;S)?]&^B7_1O\E_T;_)?]&_R7_
M1O\D_4;_(_U&_R/]1O\C_4;_(_U&_R/]1O\C_TDG O]&+P/_32\$_U(R!O]5
M.0C_54(+_U1-#_]261/_4&@7_T]W&O].A!W_3)$?_TN;(?]*I"+_2JPC_TFS
M)/])NR7_2,0F_TC-)O](W2?_2.@G_TCQ*/](^2C_2/\H_TC_*/Y(_RC[2/\G
M^4C_)OE(_R;Y2/\F^4C_)OE(_R;Y2/\F_THG O](+0/_4"T$_U4P!O]8-@C_
M64 +_UA+#_]55A/_5&88_U)T&_]1@1[_3XXA_TZ8(_]-H27_3:DF_TRQ)_]+
MN"C_2\$I_TO**O]*V2K_2N8K_TKP*_]*^"S_2O\L_4K_+/I*_ROW2O\I]4K_
M*/5*_RCU2O\H]4K_*/5*_RCU2O\H_TLF O]+*P/_4BL$_U@N!?];- C_73X+
M_UU)#_]:5!3_66(8_U=Q'?]5?B#_4XHC_U*5)O]1GBC_4*8J_T^N*_].M2S_
M3KTM_TW'+O]-TR__3.,P_TSM,/Q,]C'Z3/XQ]TS_,?5-_R_R3?\M\$W_*_!-
M_ROP3?\K\$W_*_!-_ROP3?\K_TLF O].*0/_5BD$_UPK!?]@,0?_8CL+_V)&
M#_]@413_7E\9_UQM'O]:>B/_6(8F_U:1*?]5FBS_4Z(N_U*J,/]1L3'_4;DS
M_U##-/Y/SC7[3]\V^$[K-_5.]3CR3OTX\$__->Y0_S/K4?\QZ5'_+^E1_R_I
M4?\OZ5'_+^E1_R_I4?\O_TPE O]1)P/_6B8#_V H!?]E+P?_:#D*_VA##_]G
M3A7_95H:_V)H(/]?=B7_78$J_UJ,+OY8EC'\5YXT^U6F-OE4K3CX4[4Z]U*^
M._51R3WS4=H^\%#H/^Q0\T#I4?T^Z%/_.^94_SCC5?\UX57_,^%5_S/A5?\S
MX57_,^%5_S/A5?\S_TTD O]4) /_72,#_V4E!/]J+0;_;38*_VY #O]M2Q3_
M:U8;_VAD(?YE<2C[8GTM^%^',O9<D3;S6IDZ\EBA/?!7J4#N5;%"[%2Y1.M3
MQ$;I4M)(Y5'E2>)2\DC?5/Q$W5;_0-M8_SW66?\ZTEG_.-)9_SC26?\XTEG_
M.-)9_SC26?\X_TXD O]8(0/_82 #_VHC!/]P*P7_<S0)_W0^#O]T2!3_<E(;
M^V]?(_9K;"KR9W<Q[V."-^Q@BSWI791!YEJ<1>18I$GB5JQ,X%2T3MU4OU#;
M5,U0UU/B4=)4\$[05_M*SEK_1<U<_T+)7/\^Q5S_/,5<_SS%7/\\Q5S_/,5<
M_SS%7/\\_T\C O];'P+_91T"_VXA _]U*07_>3$(_WH[#/]Z1!/Z>4X;]'9;
M(^YQ9RSI;'(UY6A\/.%CA4/=8(Y(V5V73-5<GT_26J=1SUFP4\U8NE3+6,95
MR5?:5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z
M8/] _U(A O]>'0+_:1H"_W,? _]Z)@3_?B\&_X$X"_N!01+S@$L:['Q7(^9W
M8RW@<6TXVFUW0--I@$;/98E+RV.13\A@F5+%7Z%5PEVJ5\!<LUF^7+]:O%O.
M6[A;Y5NW7O55MV+_3[5C_TJR9/]&L&3_0[!D_T.P9/]#L&3_0[!D_T.P9/]#
M_U4? O]A&@+_;1@"_W<= O]^) /_A"P%_H<U"?6(/A#MAT@8Y8-4(MY^7R[4
M>&DXSG-S0,EN?$?$:X1,P&B,4;UEE%2Z8YQ7MV*E6K1@KERR8+E>L%_'7JU?
MWU^L8O%9K&7^4ZIG_TZH9_]*IF?_1J9G_T:F9_]&IF?_1J9G_T:F9_]&_U<=
M O]D& +_<!8"_WL< O^#(@+_B2H$^8PR!^^..PWGCD06WHI1(=2$7"W,?F8X
MQ7AO0<!T=TB[<(!-MVV(4K-JD%:P:)A9K&:@7*IEJ5^G9+1@I6/"8:-CU6*B
M9>U=HFG[5Z%J_U&?:_],GFO_29YK_TF>:_])GFO_29YK_TF>:_])_UD< O]G
M%@'_<Q4!_WX: ?^'( +_C2<#])(O!NJ4. OAE$(3UH].(,R)62W%@V,WOGUK
M0+AY=$BS=7Q.KG*$4ZIOC%>G;91;HVN<7J!II6">:+!CFV>]9)EGSF28:>AA
MFFWY6IEN_U27;O]/EF[_2Y9N_TN6;O]+EF[_2Y9N_TN6;O]+_UL: O]I% '_
M=A0!_X$8 ?^*'0'\D20"\)<L!.6:- C<FC\1SY1,'\:.5RR^B& WMX)I0+%^
M<4BL>GE.IW> 4Z-TB%B?<9!<FV^87YAMH6*5;*QDDVRY9I%KR6:0;>1DD7'V
M7)%R_E:0<O]1D'+_39!R_TV0<O]-D'+_39!R_TV0<O]-_UT8 ?]K$P'_>1,!
M_X06 ?^.&P'XE2$!ZYLH ^&@, ;5GCT0RIA*'L&25"NYC%XVL8=F/ZN";D>F
M?G9.H7M]4YQXA5B8=HU<E'257Y%RGF..<:EEBW"U9XEPQ6>(<.!FBG3T7HMV
M_%B*=O]2B7;_3HEV_TZ)=O].B7;_3HEV_TZ)=O]._U\7 ?]N$0'_>Q(!_X<4
M /^1& 'TF1T!YZ C MVE*P3/H3L/Q9Q(';R64RJTD%PUK(MD/Z:';$>@@W--
MFX!Z4Y9]@E>2>HI<CGB28(IVG&.'=:9FA'2R:()TPFB =-MH@WCR8(1Z^UF$
M>?]4A'G_3X1Y_T^$>?]/A'G_3X1Y_T^$>?]/_V$5 ?]P$ '_?A$ _XH2 /^4
M%0#PG1D XZ4> =>H* /+I3D.P9]&&[>:42FOE5HTIY!B/J&+:D:;AW%,E81X
M4I"!?U>,?X=<B'V08(1[F6. >J-F?7FP:'MYOVEZ>=9I?'SP87Y^^EI^??Y5
M?GW_47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#L
MH1, WZH6 -&L)@/'J#<-O*-$&K.>3R>JF5@SHY1@/9R0:$66C&],D(EV4HN&
M?5>&A(5;@H*.7WZ EV-Z?Z%F=WZM:'5^O6ES?M)I=H'N8GB"^EMX@OY6>8'_
M47F!_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX _Y . /6;#@#HI@X
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MLTA&RLA(1LKF1T?)]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT
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M(C;YXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0
MD,0  (//  !WVP  ;_8* &?_$P%@_QT"6O\G U3_, 5/_S@(2O] "D;_2 Q#
M_T\.0/]6#SW_7A [_V42./]N$S;_=Q0T_X(5,O^/%C#_FQ<O_ZD7+O^W&"W_
MR!@L_^$8+/_O&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL  )ZU  "0P0  @LP
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MX&%Y,]Q>@CC87(L\TUJ4/]!8G$+.5Z-$RU6L1LE5M4?'5,!)Q5302<)3YDG
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M1(AT_T.(=/]#B'3_0XAT_T.(=/]#_UT2 ?]K#@#_> X _X,/ /V,$ #ME!(
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MKE-3G\!34I_=4E6?\TY7H/]*6:#_1EF?_T59G_]%69__15F?_T59G_]%_W4
M ."&  #/DP  Q)\! +JG 0"QK@  J;8  *&]#0";O2 !E+PQ!XNZ/1"#MT@:
M?+50(G6S6"IOLE\P:K!F-F6O;3M@K74_7*Q^0UBKAT=5JI-*4:J?3$^JKDU-
MJL!-3:K<34ZJ\DE0JOY&4JG_0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,
M  #(F0  O:,  +*K  "IL@  H+L" )?$"0"2Q1L B\0L!(/".@Q[P405=+].
M'6Z]5B1HO%TJ8[MD,%^Z;#1:N70Y5KA\/%.WAS]/MY)"3+:?1$JVK49(ML!&
M2+?=14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!
MGP  M*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)
M4QUAR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?
M/$3$\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI
MJZP  *"T  "6O@  B\<$ ('0" !XV0X ==D@ 6_8+P1IV#P)8]9&$%[64!59
MU5@:5=1@'U'4:").U'$F2]-[*4C3A2M%TY(N0M2?+T'4KS _U<(Q/]7A,#_3
M\C _TOTO/]'_+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0  +NA  "MJ0  HK$
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M$2;_]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@
M6.<  %+_"0!-_Q$ 1_\9 4/_(@$^_RH".O\R S?_.0,S_S\$,/]&!2W_304K
M_U0&*/];!R;_8P<C_VT((?]Y"1__APD>_Y4*'?^C"AS_L0H;_\ +&O_6"QK_
MWPL:_]\+&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4
M $;_!0! _PX ._\4 #?_&P$S_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#
M'?]. QK_5008_UX$%?]H!1/_= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8.
M_[H&#O^Z!@[_N@8._[H&CKH  '_%  !PT0  8MX  %3E  !&ZP  /_X  #G_
M   T_PD +_\. "O_%  G_QH!(_\A 1__)0$<_RH!&?\O 1;_- (4_SH"$?]
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M'@'_4QP"_UD> O]=)@/_7S $_U\Z!_]=10O_6E 0_5A>%?A5:AGU4W8=\E&
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M-IME_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX _W00 /][$@#U@1<
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M1U&;[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D
MOIH  +.A  "JIP  H:X  )>U!@"2MA@ C+4J X6T-PE^LD(1=[!,&'&N5!]L
MK5LE9ZMB*F*J:2]>J7$S6JAZ-U:G@SI3IHX]4*:;0$VEJ4%+I;I"2Z;10DNE
M[3]-I?P\3J3_.4^D_S=/I/\W3Z3_-T^D_S=/I/\WY'H  ,^)  #"E0  MI\
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M)3O*_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP
M><<  &_.! !DU@D 7MX1 %O>( !7WBT"4]\Z!%#?1 9,WTX)2=]7#$;?7P]#
MWV@10=]Q$S[??!4\WXD7.N"6&3C@I1HWX+<:-N'-&C;?[!HUWOD:--W_&S3<
M_QLTW/\;--S_&S3<_QLTW/\;N9P  *JD  ">JP  DK4  (6^  !YQP  ;<\
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M!A/_Z083_^D&EZ\  (BZ  !ZQ0  ;,\  %[:  !0X   1.8  #SU   W_P0
M,_\- "__$P K_QH */\A "7_)P$A_RT!'O\R 1O_. $9_S\!%O]& A3_30(1
M_U8"$/]@ @[_; (,_WL#"_^+ PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_
MP@,(_\(#BK@  'O#  !LS@  7ML  $_B  !"YP  -NP  #'_   L_P  )_\'
M "/_#@ @_Q( '/\8 !C_'0 5_R$ $O\F !#_+ $._S$!#?\W 0K_/@$(_T8!
M!?]/ 0'_60$ _V8! /]T 0#_@@( _Y " /^< @#_I@( _Z8" /^F @#_I@(
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M1&!_[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@
MQX<  +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]Z
MCUXE=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%
MZC]<AOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP
M +F3  "PF0  J)T  )^@"0"9H1H DZ K XR?. B%G4,0?YI,%WF85!UTEUPB
M<)5C)VN3:BQGDG$P9)%Y,V"/@C=<CHTZ68V9/5>-IC]4C;9 4XW+0%2-Z3U6
MC?HY5XW_-5F._S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28
M  "JG0  H:$  )>F! "1IQ4 C*<G H6F-09_I$ ->:)*%'.@4AINGUD?:9U@
M)&6<9RAAFV\L7IIW,%J8@#-6EXLV4Y>7.5&6I3M/EK0\3I;)/$Z6Z#I/EODV
M49;_,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "C
MH0  F:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F
M921;I&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__
M,$N?_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@
MD:P  (:R  !]M@T >;8= '6V+ )OM3D&:K1#"V6S3!%@LE067+%;&EBP8QY5
MKVLA4:]S)4ZN?2A+K8@J2*V5+46MHRY$K;,O0ZW(+T*LYR]#J_DM1*O_*T2J
M_RE$JO\I1*K_*42J_RE$JO\IT8   ,&-  "UF   J9\  )ZE  "3K   B+(
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M$R_4_Q,OU/\3LYH  *:A  ":J0  C;$  ("Z  !TP0  :,D  %S/  !2U0,
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M90$%_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<
M '?!  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP
M%/\0 !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@
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M_Q^95_\?_TT- /]5!@#_704 ^V0' .]I"0#I:PP X6P0 --M'@#);#$"PFI
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M.FUKZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<
MS7@  ,1^  "\@@$ MH0! *Z%#@"GAB  H(4P YJ"/0B3@$@/CGU1%8E[61J$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7"<-VIOJ#EH;[<Z9V_+.F=P
MZ3=I<?HR:W+_+6QS_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L
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M+5N"_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@
MH)4  ):8 0"0F1, BIDD 868,@1_ECX)>91(#G234!1OD5<9:Y!>'6B.92%D
MC6TE8(QU*%V+?BM:BH@N5XF4,52)H3-2B+ T48C#-5"(XC12B/8P4XC_+%2(
M_RE5B/\H58C_*%6(_RA5B/\HYFL  -!X  #"@P  MXP  *V2  "CE@  FIH
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M($"D_R! I/\@RGX  +N+  "OE0  I)L  )FA  ".I@  @JP  '>Q  !JM@
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MCP,CY:$$(N6T!"'ES00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X
M )BE  "+K@  ?;8  '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1
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M  #_D   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0
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M+GM;["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P
MTFH  ,EN  #"< $ O7 # +9P$ "N<2( J' R J%N/P:<;$H+EVI3$))H6Q2.
M9F(8BV5I&XAC<!Z%8G@A@F& )(!@B29]7Y(I>UZ=*WA>J2UV7K@N=5[,+W1>
MZ2UU8/HG=F'_(W=B_R!W8O\>=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT
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M)F9M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P
MJ8   *" !P"9@1< E($H 8Z -0.(?D$(@WQ*#7YZ4A%Z>%D5=G=@&7-V9QQP
M=&X?;7-V(VIR?R9G<8DI9'&5*V)PH2U@<+ O7G#"+UUPWR]?<?4J8''_)F%R
M_R-B<O\@8G+_(&)R_R!B<O\@[UP  -QI  #*<@  OGH  +6   "MA   I(4
M )J% P"4A10 CH8E 8F$,P.#@SX'?H%("WE_4!!U?E<4<7U>&&Y[91MK>FP>
M:'ET(F5X?25B=X<H7W:3*EQVGRQ:=:XN677 +EAUW2Y9=O,J6W;_)EQW_R-<
M=_\@7'?_(%QW_R!<=_\@ZF   -5L  #%=@  NGX  +&$  "HB   GXD  )2*
M  "-BA$ B(LA (.*, )^B3L%>8=%"G2&3@YPA%42;(-<%FF"8QIF@6H=8H!R
M(%]_>R-<?H4F67V1*5=\GBM5?*PL4WR^+5)\VBU3?/(I57S_)59\_R)7?/\@
M5WS_(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&
MD X @9$= 'V0+ %XCS@$<XY""&Z-2PQJC%,09XI:%&.)81=@B&@;78=P'EJ&
M>2%6A8,D5(6/)E&$G"A/A*HJ382\*DV$URI-@_$G3X/_)%"#_R)0@_\?4(/_
M'U"#_Q]0@_\?WFD  ,EU  "\@   LH@  *B-  "=D0  DY,  (66  !^EPL
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MEA,WKZ84-J^X%#6PT10UKN\4-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4
M *^0  "CEP  F)T  (RC  " J   =*T  &BR  !<M@  4+H! $F\#0!(O!D
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M 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP
M>;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;
MZ1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [P
MLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P
M %_$  !2R@  1<X  #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!<
M$/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP
M_+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-
M  !$T@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4
M  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\
M /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]  !AQP  4]   $/6   V
MW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\   +_!   _PD  /\-  #_
M$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX  /]>  #_<@  _X<  /^:
M  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_(B<!_Q\J ?\9, '_$CD!
M_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)E@'_"9T!_PFC ?\)J0'_
M"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[ /\(_P#_"/\ _PG_ ?\)
M_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20 _R,G ?\=+ '_&#4!_Q5"
M ?\24 '_$%T"_PYJ O\.=@+_#H "_PZ* O\.D@+_#IH"_PZ@ O\.I@'_#:T!
M_PVS ?\-NP'_#<4!_PW1 ?\-XP'_#>\!_@WZ ?H-_P'Y#O\!^0[_ ?D._P'X
M#O\!^ [_ ?@._P'X#O\!_R8C /\H( #_*"  _R8B /\B* '_(#(!_QP_ ?\9
M3 '_%UD"_Q5E O\3<0+_$WP"_Q.& O\3C@+_$I8"_Q*= O\2HP+_$JD"_Q*P
M O\2MP+_$L$"_Q+, ?T2WP'Y$^T!]1/X ?,3_P'R$_\!\1/_ O 4_P+P%/\"
M\!3_ O 4_P+P%/\"_RH? /\L' #_+!L _RL= /\I) #_*"\!_R4[ ?\B2 '_
M'U0"_QUA O\;;0+_&G<"_QJ! O\:B@+_&I("_QJ9 OT:GP+\&J8"^QJL OD:
MM +X&KT"]AK( O,:VP+O&NH"[!OW ND;_P+H&_\#YQS_ ^8<_P/E'/\#Y1O_
M ^4;_P/E&_\#_RT; /\P%P#_,14 _S 6 /\Q( #_,"H _RXV ?\K0P'_*$\"
M_R9< O\D9P+\(W(#^2-\ _<BA0/U(HT#\R*5 _(BFP/P(J(#[R*I ^TBL0/L
M(KD#ZB+% ^@BU0/D(^D#X"/V!-XC_P3;)/\$V23_!-@D_P37)/\$UB3_!-8D
M_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4 _S8Q ?\S/0'],4H!^"Y6
M O0M8@/P+&T#[2MW ^HK@ 3H*H@$YBJ0!.4JEP3C*IX%X2JE!> JK07>*K8%
MW"K"!=HJT@;5*^<&T"OU!\TL_P?++/\'R2S_!\@L_P?'+/\&QRS_!L<L_P;'
M+/\&_S42 /\Y#@#_.@T _SX0 /] %@#_/R  _STJ /D[-P'R.$0![#91 N<U
M7 /C-&<#X#-R!-TS>P7:,H,&UC*+!M0RDP?2,9H(T#&A",XQJ0G,,;()RS&\
M"LDQR@K&,N$+PC+Q"[\S_@N],_\*NS/_"KHS_PFZ,_\)NC/_";HS_PFZ,_\)
M_SD0 /\]"P#_0 D _T0- /]&$0#_11D ]T0C .Y!+P#F/SP!X#Y* =H]5P+3
M/&($SSML!LPZ=0?).GT)QSF%"L4YC O#.)0,P3B;#< XHPV^.*P.O#BV#[HX
MPP^Y.-<0M3CL$+(Y^P^P.O\.KSK_#:XZ_PRM.O\+K3K_"ZTZ_PNM.O\+_SP-
M /] !@#_100 _TD) /]+#0#Y2A$ [4D: .-&)@#:1C8 T49% <M%40/&1%P%
MPD)F"+]";PJ\07<+ND!_#;@_A@ZV/XX0M#Z5$;(^G1*P/J83KSZP%*T^O12K
M/LT5J3[F%:8_]Q.D0/\2HT#_$*) _P^B0/\.HD'_#J)!_PZB0?\._S\) /]$
M  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33  QDT_ <!,3 2[2U<&MTEA
M";1(:0RQ1W$.KD9Y$*Q&@!&J18@3J$20%*9$F!:D0Z$7HD.K&*!#MQF?0\<9
MG4/@&IM$\Q>91?\5F$;_$YA&_Q&81O\0ET;_$)=&_Q"71O\0_T(% /]'  #W
M3P  Y5,  -U5 0#7508 U5(+ ,M3&0##5"L O%0[ ;922 2Q45('K5!<"JE.
M9 VF36P/I$QT$:%+>Q.?2H(5G4J*%YM)DQB929P:ETBF&Y5(LAR42,$=DDC8
M'9!)[QN/2OX8CTO_%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4  /]+  #I4P
MWE@  --;  #-6P0 RE@' ,)8%0"Z6B< LUHW :Y81 2I5T\'I%58"J%48 V>
M4V@0FU%O$YA0=A664'X7E$^&&9).CAJ/3I@<C4VB'8M-KA^*3;P@B$W0((=-
MZQ^&3_P;AE#_&(90_Q:&4/\4AE'_%(91_Q2&4?\4_T<  /A/  #D5P  U5T
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M''%=_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@  QV@  +UL  "V;0
MKVP  *=K"P"@;!D FVPJ 95K-P*0:4,%BVA,"8=F5 R#95L0@&-B$WUB:15Z
M87 8>&%X&G5@@1US7XL?<%Z6(FY>HB1L7K E:U[!)FE>WB9J7_0A:V#_'6MA
M_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90  PVL  +EO  "Q<0  JG$
M *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^:5D/>VA@$G=F9A1U9FX7
M<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1BVB9D8_(B963_'F9D_QMG
M9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\  +9S  "N=0  IG4  )US
M!0"6<Q0 D70D (MS,@*&<CX$@7!'"'UO3PMY;5<.=FQ>$7-K9!1P:FP7;6IS
M&FMI?!QH:(8?9F>1(F-GGB1A9JPE8&:])E]GUB9?9_$B8&C_'F%H_QQB:/\:
M8FC_&6)H_QEB:/\9[%<  -EB  #':P  O'(  +-W  "J>0  H7D  )=W 0"0
M>!$ BW@A (9X+P&!=SL$?'5%!WAT30IT<E4.<7%<$6YP8Q1K;VH6:&YQ&69N
M>AQC;80>8&R/(5YLG"-<:ZHE6FN[)EELTR9:;.\C6VS_'UQM_QQ=;?\:76W_
M&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F?@  G7X  )%\  "*? \
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ME1M&B*,=1(BT'4.(RAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T
M +UX  "Q@@  IXH  )R.  "2D   AI,  'F5  !LEP  9I<. &.8&P!AF"D
M7I@U 5J7/@-7ET<%599/!U*65@E/E5X,3)1F#DJ4;Q!'DWD31).%%4*2DQ=
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M##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E
ME)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 Z
MMS0 .;<^ #>W1P VMU !-+=: 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBX
MQ04HM^8%)[7Y!R:S_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ
M 'ZF  !QJP  9;   %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD
M*L0S "G$/0 HQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@QI@!'\:K 1['P0$>
MQN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N
M  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0 'M * !O1$0 :TAH &=(E
M !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X
M$-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#J   =;   &BW  !;
MO0  3L$  $+%   WR   +<P  "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D
M(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5  3FJP "YL0  >;F
M  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@
M0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "
M\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #T
MY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],
M "C8   >W0  %>$   _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8
M /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P
M_]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T  $#2   RV0  )MX  !OB
M   2Y@  #.H   7M    ]    /\   #_    _P   /\$  #_"0  _PX  /\2
M  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P  _X   /^5  #_I@  _[,
M /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_
M %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\
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M ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4 _PJK /\*L@#_"KL
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M":TS]0FK,_\)JC/_"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<' /\Z  #_/@
M^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30' /%@"O#MA [D[:@6V
M.G(&M#IZ![(Y@0BP.8@)KSF0"JTXF JK.*$+J3BJ#*@XM@VF.,4-I#C>#J$Y
M\0V?.O\,GCK_"YTZ_PJ<.O\)G#K_"9PZ_PF<.O\)_SL" /\^  #W1   YD<
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M$H!+_Q" 2_\/@$O_#H!+_PZ 2_\._T,  .Q+  #=4P  SE@  ,1:  "]6@
MN%<! +%4#@"J5AX I58N )]6.P&;548#EU10!9-36 B04E\*C5%F#(M0;0Z(
M3W00AD]\$H1.A1."3HX5@$V9%WY-I!A\3;(9>DW#&GE-WQIX3O07>$__%'A/
M_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P  R%P  +]?  "W7P  L5P
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M$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K;   HFH  )EG @"29Q$
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ME!E3;*,;46RS'%!LR!Q/;.<;46SZ&%%L_Q52;/\44FS_$U)L_Q-2;/\3W%P
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M%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q! @/\0QFL  +=V  "L?P
MHH4  )>)  ",BP  @8T  '..  !ECP  78\) %J0% !8D"$ 5I$M %.0. %1
MD$$"3I!) TR04 1*CU@%1X]@!T6.:0E"CG,+0(U_#3Z-C0\\C9P0.HVL$3F-
MP1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.OW(  +)]  "GA@  G(H
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M R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP  AYP  'JB  !MIP
M8*L  %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?
MOCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\
M_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0
M $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\
M#LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )
MR_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[
M   RPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN
M  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H
M -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   F
MS   '=   !34   .V0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G
M*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V
M  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V
M$MP   S@   %XP   .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@
M]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_
MWP  _]\ =[   &BY  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8
M  #I    [    /    #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD
M /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@
M_[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\
M= #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#'
M /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\
M_QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_
M 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H
MT #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT<
M /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4
M_P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@ K@#U +4 \P"_ /$ RP#P
M -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_ .D!_P#I ?\ _R 7 /\?
M% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X _PE: /\(9@#_"'  _@=Y
M /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M!K( _^+__TE#0U]04D]&
M24Q%  @)Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_
M -P,_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD
M_!!5 /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B
M#J\ X ZX -X.Q0#<#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2
M_P'*$O\!_R</ /\G# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/
M .H76@#F%F4 XQ9N . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL
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MM02N*\0$K"O;!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(
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M#H8_X Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@
MS$\  ,-0  "\3@  MTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.2
M1UX%CT9E!HU&; >+17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$
MVA%[1/$/>D7_#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0
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M$693_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@
MGU\  )9:  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W65$$=%A8!G%87P=O
M5V8);5=M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5R!9?5><58%;Z$F!6
M_P]A5_\.85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0
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M#5)B_PU28O\-V58  ,1@  "W:   K&X  *-Q  ":<P  CW$  ']K  !X:P4
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MB L]?9<,/'VG#3I]N@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D
M +)T  "G?   G8$  )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H
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M B2>M0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@
MBY(  '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  G
MJB( )JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JK
ML0 9J\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD
M '6>  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ<
M%[<A !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -
MN<0 #;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF
M  !>JP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45
M  G%'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8
M ,;2  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3
MM   1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0
M%@  T1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_
M  #6X   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0
M.<$  "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P
MWQ0  .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #I
MQ0  Z>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H
M "#.   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT
M .T1  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP
M^L(  /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:
M   -WP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)
M  #Z#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL
M /^Y  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_
M %D _P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\
ML #_ +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_
M /H _P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4
M_P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[
M +0 ^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /
M_P#P /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!<
M /\ 9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +
M\ "X .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E
M /\ _QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X
M8@#Z &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T
M .( OP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\
M_QX0 /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N
M!&8 Z@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%
MNP#0!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$,
M /\@!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6
MW0UI -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$
M$,@ PA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C
M  #_(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C
M ,@6:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L(
MM!K6 + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^
M*@  [RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA
M90"W(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3.
M :,DZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@
MXC0  -HS  #3+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J
M*V<!J"MO :8K=@&D*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<L
MX@.4+?4$DBW_ Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT
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M20  KT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X=
M9P.%/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\
M"'1 _P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P
MITH  *!$!P":110 E48B )!&, ",1SP B49% 89&3@&#1E4"@45< WY%8P1\
M1&H$>D1Q!7E$>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$R0QM1.<,;47Z"FQ%
M_PAL1?\';$7_!VQ%_P=L1?\'[#\  -A)  #'4   NU0  +%5  "I5   H5
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M"%M1_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H
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MB I*8Y<+2&.F#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@
M +IB  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$
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M!S5XLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0
MF'X  (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!
M@C( 0(([ #Z"0P ]@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!
ML04M@<@%+8'I!"U__ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,
M (B&  !]AP  <(@  &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P
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M !&B^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@
M6*$  $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .
ML2L #;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P
M[P %K_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL
M $&M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(
M +XK  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y
MO?8  +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V
M   JN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB
M  #+*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L
M ,[X  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >
MP@  %<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<
M'P  WB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J
M  #E\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0
M#-$   35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@
M[1H  .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #W
MWP  ]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\
M  #B    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A
M /P6  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP
M_[\ _PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\
M;0#_ '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"]
M /\ R0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\
M_Q 9 /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_
M '( _P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8
MPP#T -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4
M /\/$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T
M^P!V /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H
M ,L YP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1
M#@#_#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P
M .T > #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4
MU@#9 -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_
M#P4 _PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .
M<@#> 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0
M ,4 Z ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%
M_Q,% /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,
M!7, R@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*
MY0"U"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH
M /46!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT
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M HLG_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@
MNBL" +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8*UP EBMC )0K:@&2
M*W$!D"QX 8\L@0&-+(H!BRR4 HHLGP*(+*L"ABRZ H4MS@.#+NH#@2[\ X N
M_P)_+O\"?R[_ GXN_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4
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M!&8__P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T
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MB 934)8'4E"E"%!0MPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L
M +]4  "R6@  IUX  )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0
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M!T%>L0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@
MGFH  )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.
M9#@ 361  $MD2 !*9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQC
ML 8[9,8&.V3F!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\
M )%R  "&<@  >W$  &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0
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M B9Z]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P
M;(0  %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 J
MA3X *85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$
M]0$>@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L
M %B,  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38
M'I%  !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4
MCO\ %(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5
M  !%EP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW
M !&>00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X
M"YK_  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \
MH   ,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J
M.  "JD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_
M  "G_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@
M)JL  !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P
MN#D  +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V
M_P  MO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8
M !.X   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX
M ,@Z  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0
MR/T A9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#
M   #QP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM
M  #=.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0
M>:$  &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/
MTP   -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M
M*P  \#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H
M %ZQ  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@
M .8   #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'
M_RD  /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!
M%P#_ !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![
M /\ @P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4
M_ #J /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_
M !, _P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\
M?@#_ (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C
M .\ \P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \
M_P 0 /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T
M '\ \P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$
M[0#? /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P ,
M /\ $@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H
MY0"  ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#,
M /8 R@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\
M#@#_ !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z
M -  @ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$
MNP#^ +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X
M 1  Z  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$
M>@"_ ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[
M *L%_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@
MW0,2 -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q
M"'L KPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T.
M_P"<#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+
M ,<+%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78
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M 7@H_P%X*/\![RL  -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q,
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M) !\-R\ >3<Y '<X0@!T.$D <CA0 '$X5P!O.%X ;3AE 6PX;0%J.'4!:#B
M F<XC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"
MW3L  ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T
M/"L <CPU &\]/@!M/48 :SU- &D]4P!H/5H 9CUA 60]:0%C/7(!83U] F ]
MB0)>/98#73ZE UL^M@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\
M ,-'  "U3   JE   *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@
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M!$M+L 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P
MH5L  )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!6
M33H 5$U! %-.2 !23D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/
MK@1%3\,$1%#D!$1/^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX
M )5@  "+8   @%X  ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C<
M3U(_ $Y21@!-4TT 3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1
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M S1>]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@
M=FP  &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \
M9$4 .V1- #ED50 X9%\ -F1I 35D=@$S9(4!,665 C!EIP(O9;L"+F7: BYD
M] (N8_\"+V/_ B]B_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(
M &1P  !8;@  36P  $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$
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M !9[_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B
M/(@  #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3
MBDP $HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&
M_P .AO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(
M "J2   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0
M")=0  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !
MDO\ F((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=
M   9G@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(
M  "D5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\
MD8H  (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1
MJ@  #*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R
M3   LEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)
M '^5  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0
M K@   "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0
MPT\  ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=
M  !EHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4
M  #'    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$
M -A3  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9
MK   2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
M    U@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#
M  #N5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@
M/KP  "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E
MY@   .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_
M1@  _UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7
M /\ '0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4
M_P"+ /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X
M /\ ]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\
M%P#_ "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "&
M /H C #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X
MZ@#_ .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_
M !\ _P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X
MAP#L (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_
M -< _P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D
M^P F /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#<
M (< V@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,,
M_P## /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ?
M .H +0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($
MQ@"' ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R
M /\ L@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H
M)0#3 #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"!
M +0 B "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\
MH@#_ *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$
M "H OP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8
M@P"D (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_
M )0)_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$
ML@8N *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7
M#(8 E@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1
M_P"'$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G
M *$0,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$
MB12+ (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![
M&?\ [R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09
M+0"1&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V&
M 'P>D0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\
MZ"@  -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&
M(C( @R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$F
MC0!O)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X
M ,LV  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T
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M 54XKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20
MI$P  )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>
M.CP 73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]
MK )./L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5
M )=1  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@
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M CY*\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7
M>UD  &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%
M3$8 1$Q. $--5@!"35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y3[D".4_4 CE/
M\@$Y3O\!.4[_ 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X
M &E8  !?5@  5%(  $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440
M/U%, #Y25  \4ET .U)G #I2<P X4X(!-U.2 353I $T4[<!,U31 3-3\0$T
M4_\!-%+_ 312_P$T4O\!ME(  *E:  ">8   E&0  (MF  " 90  =&,  &9>
M  !<7   45@  $=5!P!"51  0%48 #]6(0 ]5BH /%8R #M6.0 Z5T$ .5=)
M #A740 W6%H -5AE #18<0 R6( !,5B0 2]9H@$N6;4!+5G/ 2U9[P$N6/\!
M+E?_ 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !8
M8@  35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>
M3@ P7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_
M 2A=_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0
M26<  #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H
M950 )V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C
M_P$A8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\
M #IN   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E
M'FY; !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8
M:_\ I&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X
M   K=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6
M !-X8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\
MGW$  )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D
M@@  '((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#
M70 )@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD
M )!^  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0
M%8X   ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@
MCV4  (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%
M  ""B0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH
M  J;   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P
M )UN  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !X
MD   :I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
M    J00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC
M  "L=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP
M7YP  %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U
MM0   +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]
M:P  O8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4
M $:J   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@
M ,,   #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@
MTG,  -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS
M   JM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(
M  #4    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60
M .I\  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =
MP   $<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
M    YP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ
M  #_@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8
M_P T /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_
M ), _P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4
M_P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N
M /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X
M]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F
M /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\
M-@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP".
M .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\
MSP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P
M #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -
MCP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_
M +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4
MVP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\
M )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P
M_P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z
M ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H
MJ0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P";
M /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +,
M/0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"-
M )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\
M^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B
M #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%
MD@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14
M . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@
MDPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^
M#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F
M  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[
M (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8
M<1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\
M,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;
M/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@
M &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.
MJCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M
M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TG
MK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\
M )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P
M8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4
M+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$
M  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]
M %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L
M3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+
M1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T
M0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3
M 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P
M?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,
M.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]
M\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP
M &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0
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M #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@
M4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T
M3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,
M_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\  &);  !86   3E4
M $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45,
M+5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G
M4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8
M   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA:
M "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\
MJ%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q
M7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?
M8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&
M )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P
M(V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3
M:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O
M  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$
M !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D
M"W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'
M>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\
M!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT
M  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@
M>8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &
MB0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(
M@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D
M &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP  #90   :5    E@8
M )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>
ME8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4
M  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'
M  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80
M *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!
MH   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O    L    +    "P
M!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0
M  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0
M)JL  !JM   0KP  ";(   "T    MP   +H   "\    O0   +X   "^
MP (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,
MG   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4
M !"X   'NP   +X   #!    Q    ,@   #+    RP   ,T   #.    T
M -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0
MYJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$
M    QP   ,L   #/    U    -@   #<    W0   -\   #A    XP   .4
M  #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4
M /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_
M $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X
MFP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_
M -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0
M_P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O
M )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X
M_P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!)
M /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )<
MW "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^
M /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T + #J #@ YP!# .,
M30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9
M ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\
M_P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#*
M $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$
MG "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P
M /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@
MM0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"?
M *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %
M  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!*
M *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L
MC@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1
M$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4
M2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C
M 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0
MNAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&
M!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*
MKP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28
M *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4
M> Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F
M$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M
M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15&
M &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P
M7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2
M,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=
M2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2
M %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.
M@S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8
M(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH
M[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD
M '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8
M4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$
M+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y
M  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U*
M $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X
M/S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C
M.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R
M3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_
M #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@
M5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \
M-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z
M_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\
M $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%,
M-CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P
M/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5
M P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%;
M #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\
MKDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z
M0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&
M9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\
M )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@<
M,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C
M3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:
M  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E ,
M "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT
M&E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/
M90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7
M#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ
M !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P
M@FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 5
M8!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MB
MB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,
M '5U  !J=   7',  $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P
M#6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA
M:I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![
M  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/
M  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),
M '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;
M@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""
M$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B
M  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@
M18L  #F,   LC   (8P  !>,   0C0  "8X   */    D ,  (\)  "/#@
MCQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".
MLP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4
M "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0   )T#  "="0  G0T
M )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP
MG<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?
M   7H   #J(   >D    I@   *@   "J    J@   *H   "K 0  JP<  *P,
M  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H
M *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .
MJP  !:X   "P    L@   +4   "W    MP   +@   "Y    N@   +P#  "]
M"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(
M  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP
M +H   "]    P    ,0   #&    Q@   ,@   #)    RP   ,P   #.
MT 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #A
MSP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<
M  #*    SP   -,   #6    UP   -H   #<    WP   .$   #C    Y@
M .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN
M^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\
M60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G
M /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\
M_P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[
M %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@
MJP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P
M /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %<
MZ0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/
M *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\
M  #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8
M -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@
MN0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z
M    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T
M60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N
M *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K
MX0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I
M %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0
MM@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $
M ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %(
MF !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"#
M ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+
M  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1
M (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L
M= #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C
M$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L
M40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7.
M &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P
MDA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M
M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.
M[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\
M ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T
M81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2
M%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA
M  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/
M %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T
M2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L
M(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=
M4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_
M $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@
M7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&
M(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG
M_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H
M %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0
M/BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X
M+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK
M!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U;
M #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\
ML3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"
M+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R
M9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$
M *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL
M.3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L
M-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+
M  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/
M #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T
M)3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "2
M4P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]
M$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z
M !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06
MAEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E
M0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'
MB@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&
M 'IA  !P8   95X  %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A,
M'4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  1
M39P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F
M  !M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6
M !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@
M"52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K
M;   7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:
M&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH
M  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0
M67   $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #
M9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !C
MNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8
M $9U   Y=   +G0  "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<
M &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@
M;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^
M   R?@  )GT  !Q\   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9
M  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X
M '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   I
MAP  '8<  !2'   -B   !HD   "*    B@   (D&  ")#   B0\  (D3  ")
M&@  BB(  (HL  "*.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J
M  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@
M%)(   V3   $E    )8   "7    F    )<   "7!0  EPL  )@.  "8$P
MF1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6
M]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X
M  .?    H0   *,   "E    I0   *4   "E    I@(  *<(  "G#0  J!$
M *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P
MJ?L =8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K
M    K@   +$   "R    L@   +,   "T    M0   +8   "X!   N0L  +L0
M  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO,
M:I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP    LP   +4   "X
MO    +\   #!    P0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1
M#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\
M $^E  ! J@  ,J\  "*R   4M0  "K@   "[    OP   ,,   #&    RP
M ,X   #1    T0   -0   #6    V0   -L   #>    X    .0   #G!@
MZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\
M!@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E
M /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D
M\0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_
M    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /(
M9@#P &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#!
M -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_
M_P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #>
M &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4
MS0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0
M /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &
MQ0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N
M .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$
M  #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!?
M +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X
MF@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$
M  8 O0 / +< & "S "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\
M7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C
M (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1    Q0   +T   "V
MK@ + *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "-
M %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@
M\@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ %
M )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %<
M?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J
M /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )
M"0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7
M &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@
M7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^
M! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$
M60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_
M %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@,
M;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7
M#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1
M_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$'
M %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5<
M3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#
M%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4
M#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!==
M $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\
MM3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,
M&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>
M9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0
M *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX
M0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T
M(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^
M  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1
M #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P
M+BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "4
M1@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H
M%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY
M "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220
MB$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N
M+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(R
MB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\
M 'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A<
M*#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;
M-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4
M  !Q4P  9E   %I,  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@;
M "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D
M%#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N
M6   9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^
M'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L
M  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70
M8EL  %97  !,50  05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 3
M12( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'
MO@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$
M %->  !'6@  /%<  #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X
M#4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@
M3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D
M  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B
M  -5*@ "530  %4^  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0
M %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]
M:   ,F8  "=E   =8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?
M)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO
M  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !==   3W,  $)R   V<
M*V\  "!N   7;0  $&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0
M:2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E
M_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD
M !EX   1=P  "G<   -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,
M '8N  !U.@  =4<  '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P
M</\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#
M   *@P   H,   "$    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F
M  "$,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\
M@H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.
MCP   )$   "2    D@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4
M*   E#8  )1%  "35P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<
M '"*  !AC0  4Y   $63   WE0  *98  !R7   1F   "9D   ";    G
M )X   "@    H    *    "@    H0   *$$  "B"0  HPX  *04  "E'0
MIBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21
M  !6E0  1YD  #F<   JG@  ':   !&A   (HP   *4   "G    J0   *P
M  "N    K@   *X   "O    L    +$   "R    LP8  +4-  "W$P  N1X
M +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*
MG@  .Z(  "RF   =J   $:H   >L    KP   +$   "T    N    +L   "\
M    O    +X   "_    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@
M  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP
M+ZP  !^O   1L0  ![4   "X    NP   +X   #"    QP   ,H   #,
MS    ,X   #0    T@   -4   #8    VP   -\   #B    Y@L  .L3  #L
M)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P )
M /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T
M^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J
M /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\
M# #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M
M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /
MT #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W
M !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$
M; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[
M +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T
MWP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z
M &P N !R +8 > "U (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0
M_P"C /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1
M ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4
MI0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1
M /\ D #_ (T _P"+ /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +
M%0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D
M )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\
M?P#_ '\ _P!^ /\ [    -H   #)    O@   +8   "N    IP ) *$ $ "<
M !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != ((
M9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_
M '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !,
MB@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R
M &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &(
M_P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5
M 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\
M9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7
M /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X
M%P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B
M %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\
MOQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!?
M AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(
M9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20
M *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A,
M4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"
M#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O
M  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6
M $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT
M.1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7
M-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4
M&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY
M # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P
MBCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X
M&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>
MB  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$
M 'U   !T/@  :3H  %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD
M,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C
M(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$
M  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(=
M "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)<
M'2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P
M1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G
M(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI
M !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3
M9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >
M+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$R
MOP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX
M %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B(
M%S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  -
M-]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/
M  !,3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF
M !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4
M"#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)
M4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q
M*P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N
M  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P
M.E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #
M2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'
M^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L
M "I9   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X
M % X  !00P  4%   %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P
M3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A
M   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS
M  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\
MC&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4
M:   #6<   =G    9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D
M.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\
M ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P
M!W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P
M;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[
M  !S?0  97X  %=_  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\
M  !_    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D
M 'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I
M@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*    BP   (P   "-
M    C0   (P   ",    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_
M  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@
M4(T  $*/   TD0  )I(  !F3   .E   !I4   "6    F    )H   ";
MFP   )L   ";    FP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@
M1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8
M #:9   GFP  &9P   ^=   %GP   *$   "C    I0   *@   "I    J0
M *D   "J    JP   *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0
MM4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB
M   :I   #J8   2H    JP   *T   "P    M    +8   "X    N    +D
M  "Z    O    +T   "_    P    ,,   #%!P  R0\  ,H:  #++   S$
M ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /
MK@  !+$   "T    MP   +H   "^    PP   ,8   #(    R    ,H   #+
M    S0   ,\   #2    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(
M  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4
M_P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T
M 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .
M_P#0 /\ Q #_ +P _P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P <
M /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ',
MWP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#!
M /\ MP#_ *\ _P"K /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H
M(@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S
M ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\
MJ #_ *( _P"> /\ _P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #,
M "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +
M<@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_
M )0 _P"1 /\ _P   /8   #J    W0   ,\   #'  8 P  / +L %P"W "
MLP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P";
M '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8
M_P"# /\ ]    .0   #4    R    +\   "U  $ K@ + *D $@"E !L H0 C
M )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L
MAP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U
M /\ Y0   -$   ##    N    *\   "H    H  & )H #@"5 !4 D0 > (X
M)@"+ "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M
M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\
MU0,  ,,'  "V"   JP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\
M "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &<
M< !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T
M +D0  "L$0  H1   )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$
M;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9
M '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8
M  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B
M %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '
M3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">
M(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0
M(P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y
M $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0
MCBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(
M!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+
MAP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\
M ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\
M/@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N
M$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT
M  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A
M #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4
M)A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q
M-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4
M)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG
M !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P
M93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F
M&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>
MO  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP
M %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20
M(!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3
M(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\
M  !-.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H
M !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8
M$"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,
M/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H
M+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO
M  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1
M0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /
M+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P
M_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8
M #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$
M"C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !
M-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(
M   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX
M  $\0P  /$\  #Q>   \;@  /($  #R7   \K   .\4  #OG   [^   ._\
MD5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C
M2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#
M0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@
M (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P
M%5$   Y/   )304  DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0
M2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D
M  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D
M  I8   #5P,  %<)  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4
M %13  !49   4W<  %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W
M;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B
M    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/
M  !>7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0
M:W8  %UU  !/=   0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N
M;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I
M6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL
M %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@
M 'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@
M=V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#
M   \A   +H4  "&%   5A0  #84   .%    A@   (<   "(    B    (<
M  "'    AP   (<$  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT
M (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   Q
MC@  (X\  !:/   -D    I$   "2    DP   )4   "6    E@   )8   "6
M    E@   )<   "7    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH
M  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP
M%I@   V9   !FP   )T   "?    H0   *0   "E    I    *4   "E
MI@   *<   "H    J0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N
M=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,
M  "E    IP   *H   "L    L    +(   "T    LP   +0   "U    MP
M +@   "Y    NP   +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':
MQH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q
M    M    +<   "Z    OP   ,$   #$    PP   ,4   #&    R    ,H
M  #-    SP   -(   #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0
M .:1  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_
M #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L
M@0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_
M +4 _P"P /\ _P   /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X
M\  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1
M (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@
M_P"D /\ _P   /\   #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R
M -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L
MN0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7
M /\ _P   /\   #T    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P
M-0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\
M *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\
M_    /    #C    U    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E
M #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )
M?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0
M -T   #,    P0   +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\
MD0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\
M (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D
M  "\    L0   *D   "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P
M '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L
M:@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O
M!0  I0(  )P   "4    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '
M, !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"!
M %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P
MFPX  )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A
M #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\
MB@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8
M (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H
M5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!#
M )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<
M  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K
M $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ),
M. "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U
M(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\
M*P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C
M "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P
M:"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U
M""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,
MMP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D
M %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@
M*PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <
M$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ
M  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J
M ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$
M%A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.
M*P  128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4
M+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO
M !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,
M0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7
M&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=
M_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(
M #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C(
M$1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +
M(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T
M   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y
M  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\
ME4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M
M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J
M0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8
M (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/
M(#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P
M,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90
M  !]5   =58  &M6  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X
M !0[   ..04 "3<+  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD
M #=7   W9P  -WD  #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\
M6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#
M   +000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4
M   ^9   /G8  #V,   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P
M<&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &
M2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&
M8   17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<
M &=H  !;9@  3F,  $%A   T7@  *5P  !]:   55P  #E8   =4    4P$
M %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70
M3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M
M  !4:P  1VD  #IG   M90  (F0  !AB   08   "5\   !>    7@   %T#
M  !<"   6PP  %H/  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L
M %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,
M<0  /W   #)O   E;@  &FP  !%K   ):@   &H   !I    :0   &@   !G
M P  9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[
M  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0
M-G@  "EX   <=P  $78   IU    =0   '4   !V    =0   '0   !T
M<P(  ','  !S#   <A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !P
MC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(
M !Z!   2@0  "H$   "!    @@   (,   "#    @P   ((   ""    @@
M ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@
M?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+
M   *BP   (P   "-    CP   )$   "2    D0   )$   "1    D0   )$
M  "2    D@(  ),)  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@
M )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   AE   %)4   J6
MEP   )D   ";    G0   )\   "@    H    *    "@    H0   *(   "C
M    I    *4   "F!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH
M  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP
M *8   "H    K    *X   "O    KP   +    "P    L@   +,   "T
MM@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  #
MMP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H   "M    L    +,
M  "V    NP   +T   #     OP   ,$   #"    Q    ,8   #(    R@
M ,P   #/    TP   -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0
MW<( _P   /\   #_    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D
M0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"-
M .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\
M_P   /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B
M $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8
MD #" )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P
M /\   #_    ]@   .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\
MQ !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M
M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P
M  #N    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!
M *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P
MEP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<
M    S    ,$   "X    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D
M/P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1
M (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&
MNP   +$   "G    H0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "&
M #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '
MF !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP
M *,   ";    D@   (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@
M=  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!?
M *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8
M  ".    AP   (  !0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W
M &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L
M40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "#
M @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@
M-@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H
M $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0
M<P@  &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+
M #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H
MN  Y -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!
M &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$
M/P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O
M ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3
M  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R
M #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D
M)0#J "4!^P E ?\ HB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2
M%0  2Q   $,, @ ]!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#
M-  J SL *01# "@$30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G
M !T(^  ="?\ GR@  ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'
M1Q<  #\2   X#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C
M"3< (0I  " *2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-
M^0 6#?\ G"T  ) Q  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T
M #P8   T$P  +1 & "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30
M&@X] !D.1P 7#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1
M$/\ F3$  (XU  "$.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?
M   Q&@  *A4! ",1!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z
M !,110 2$E$ $1)? ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\
MES4  (PY  ""/   >#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O
M(0  *!P  " 8 P 9% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \5
M0@ .%D\ #19<  P7;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@
M (H]  " 0   =T$  &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P
M)R,  !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *
M&TP "1M:  <<:0 %''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!
M  !_1   =44  &Q%  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H
M !TE   4(00 #QT+  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H
M R%7  $A9P  (7D  "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]
M2   =$H  &M*  !B20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK
M   2* 0 #20*  DC#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95
M   F90  )G<  ":,   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30
M<T\  &I/  !@3@  5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /
M+@, "BP*  4K#@ !*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L
M8@  +'4  "R*   KH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50
M &A4  !?4P  5E$  $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@,
M!C,)   R#0  ,A   #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8
M,G(  #*'   QG@  ,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99
M  !>60  55<  $E3   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(
M   [#   .@\  #D2   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\
M #B%   XG   -[,  #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=
M7P  4EP  $18   X50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$
M"@  0PT  $(0  !!%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!
M   _F0  /[$  #[0   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99
M2V$  #Y>   R6P  )ED  !Q6   25   #%(   11    3P   $X#  !-"
M3 P  $L.  !+$@  2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(
ME@  1Z\  $;-  !%\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8
M #=D   J8@  'V   !5>   -70  !EL   !:    60   %@   !7!   5@@
M %8,  !5$   5!0  %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@
M4:L  %#*  !/[P  3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L
M   B:@  %VD   YG   &9@   &4   !E    90   &,   !B    8@0  &$(
M  !A#0  8!   & 7  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<
M %O%  !:[0  6?\ >W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9
M<P  $'(   =Q    <0   '$   !Q    <0   &\   !O    ;@   &X"  !N
M"   ;0P  &T1  !M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^
M  !GZ   9OX >7H  '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0
M!WT   !]    ?0   'X   !_    ?@   'T   !]    ?    'P   !\
M? 8  'P,  !\$@  ?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !X
MWP  =_H <X   &6!  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@
M  ")    B@   (P   "-    C0   (P   ",    C    (P   ",    C0
M (T$  ".#   CA,  (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@
MBO, :(8  %J(  !+BP  /(T  "V/   >D   $9$   >2    DP   )4   "7
M    F0   )L   "<    FP   )L   "<    G    )T   ">    G@   )\
M  "A P  H@P  *(6  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@
M7(T  $V0   _DP  ,)8  "&9   2F@  !YL   "=    H    *(   "D
MJ    *H   "K    J@   *L   "L    K0   *X   "O    L0   +(   "T
M    MP$  +D-  "Y&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4
M $&8   RG   (Z   !.B   (I    *<   "J    K    *\   "R    MP
M +D   "[    N@   +P   "]    OP   ,    #"    Q    ,8   #)
MS0   -(!  #4#P  U1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\
M  #_    _P   /\  P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!.
M .L 5 #I %H YP!? .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T
MSP"K ,T O0#+ .  R0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_
M    _P   /P   #V  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$
M3@#/ %0 S0!9 ,L 7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C
M +8 M "T ,T L@#R +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z
M\0   .@   #@  8 V0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X
M $T M@!3 +0 6 "R %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$
MJP"? ,  G0#F )L _P": /\ E #_ (X _P"* /\ _P   /8   #H    W
M ,X   #&  $ OP + +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $<
MH0!, )\ 40"> %8 G !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+
M +4 B0#3 (< ]P"& /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H
M  "Q    JP ' *4 #@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!%
M (T 2@"+ %  B0!5 (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L
M=@#$ '0 ZP!S /\ <P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A
M    F@ " )0 "P"0 !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L
M1 !Y $D > !. '8 5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X
M &0 W@!C /L 8@#_ &( _P!@ /\ S    +P   "O    I0   )T   "4
MC    (8 !P"!  T ?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J
M $( : !( &< 3@!E %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8
MRP!5 /( 5 #_ %0 _P!4 /\ O@   +    "D    F0   )    "(    @0
M 'D  @!S  H ;P / &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P
M6P!" %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !(
M .@ 1P#_ $< _P!' /\ M D  *8+  ";#   D H  (8%  !^    =@   &\
M  !H  4 8P , %\ $ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \
M $T 0@!+ $@ 20!0 $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T
M/ #X #P _P \ /\ K!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@
M  $ 60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $(
M/ !  $, /@!+ #T 4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q
M #$ _P Q /\ IA8  )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P
M40 $ $P "@!(  X 1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V
M #X - !& #, 3P Q %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@
M_@ H /\ H1P  )4@  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<
M $0 !@!   L /  / #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H
M*P!" "H 2P H %4 )@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ?
M /\ G2(  )$F  "&*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+
M   X!0< -  , #$ $  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^
M "( 1P @ %( 'P!> !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\
MFB<  (XK  "$+0  >2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T
M#0( +0D) "D%#0 F Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%
M1  9!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL
M (PO  "!,0  =S(  &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@
M*0X$ ",,"0 ?"0T '0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2
M"TT $0M: ! +:0 .#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS
M  !_-@  =C8  &PU  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,
M " 0!0 9#@H %0P. !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH
M# ]8  L/9P *$'D "!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^
M.@  =#L  &LZ  !A.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6
M 0 7$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5
M  8390 $$W8  Q.+  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@
M<S\  &H_  !@/0  5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6
M&@( $!4)  P3#@ *$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   7
M8@  &'0  !B)   8GP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,
M &A#  !?0@  5C\  $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P(
M#1L)  D9#0 &&1$ !!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8
M'7(  !V'   <G0  '+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(
M  !>1@  540  $M   !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()
M  4@#0 !'Q   !\4   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G
M "*%   AFP  (;(  "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=
M2P  5$D  $I&  !"0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G
M#   )@X  "42   F&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"
M   GF0  )K   "7,   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40
M4T\  $I,  !!20  -40  "M    A/   %SD  ! V   *,@$  S '   O"P
M+@X  "T1   M%@  +1X  "TG   M,0  +3T  "U*   M60  +6L  "V    L
MEP  +*\  "O+   J[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4
M $=1   [30  ,$D  "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T
M #4/   T%   -!L  #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0
M,JT  #'*   Q[@  ,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6
M   V4@  *D\  "!,   620  #D<   A$    0@   $$#   _!P  /@L  #T.
M   ]$0  /!@  #PA   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL
M #G(   X[0  -_\ @5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O
M6   )%4  !E3   040  "D\   %-    3    $H   !)!   2 @  $<,  !&
M#P  1A0  $4<  !%)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&
M  ! [   /_\ ?F$  '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P
M'5T  !);   +60   E@   !6    5@   %0   !3    4@0  %$)  !0#0
M4!   $\8  !/(@  3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)
MZ@  2/\ >VD  '1L  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4
M  UD   #8@   &(   !A    8    %\   !>    70   %P$  !<"0  6PT
M %L2  !;'   6B@  %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z
M4_X >7   '-T  !I=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M
M    ;0   &T   !M    ;    &L   !J    :0   &D   !I P  : D  &@.
M  !H%0  9R$  &<O  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P
M=W@  &UZ  !?>@  4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y
M>0   'H   !Z    >@   '@   !X    =P   '<   !W    =P$  '<(  !W
M#@  =Q@  '<F  !V-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X
M &-_  !4@   18(  #:#   HA   &H0   Z#   $A    (0   "%    A@
M (@   ")    B    (<   "'    AP   (<   "'    B    (@   "(!P
MB1   (D<  ")+   B#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&
M  !(B   .8H  "J,   ;C0  #XT   2.    D    )$   "3    E0   )<
M  "8    E@   )<   "7    EP   )@   "8    F0   )H   ";    G0<
M )T1  "=(0  G3,  )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \
MD0  +9,  !Z5   0E@  !)@   ":    G    )X   "A    I    *8   "G
M    I@   *<   "G    J    *D   "J    K    *T   "O    L0   +,)
M  "S%0  M"<  +0]  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@
M()T  !&?   %H0   *,   "F    J0   *P   "O    LP   +4   "W
MM@   +<   "X    N@   +L   "]    OP   ,$   #$    QP   ,L   #-
M#   SAH  ,\O  #/2   T&(  -"   #0G0  T+@
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P$A   !
M     0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05
M%A<8&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C]
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M_______/=#4+    "E*G______________________________^6-
M $^G______________________________9I'0  "0P&"5*Q____________
M_________________\L[#A,U3%M-3%[#____________________________
M_ZE@-F"&G[:LJ;C9_____________________________^"7C;[E________
M_______________________________M^?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z]G*O,?_________
M_________________________\^:@6U:1HCJ________________________
M________Q'P^)A   %2P_______________________________@@SP
M "Z'[?____________________________^L4Q       !=MUO__________
M__________________N ,0        EAS/__________________________
M_]): @        !=S/___________________________Z@U          !<
MT____________________________WT-          !4UO______________
M____________[GU%          !$U/___________________________*ID
M+P(   0B-TE8SO___________________________^FD:T$H/V-_E:>ZVO__
M____________________________U;*LLLSD^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Y;N7=V+(_________________________________]N>9S8*
M  *,________________________________R'\_!0    !>S___________
M___________________9@3D        \JO__________________________
M__^>3          CD/___________________________]QO&@         0
M??G__________________________Z](            ;^[_____________
M_____________X03            9.;_________________________[%$
M            5][_________________________N!4             2-;_
M________________________=!0             .,__________________
M_______YHEH3            (\7_________________________WYM<+
M        #;K__________________________^^Q?54Y(A$' 0(1(K+_____
M_________________________]^_I9F8FJ"LO=K_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^.^G8!\^___________
M______________________*WA%<P#@ =K/__________________________
M____THI,%0      <O/____________________________6?S8
M2\G___________________________J1/@          +ZO_____________
M_____________\!:            &I7__________________________XTD
M            "(3_________________________YUX              '?_
M________________________M"4              &K_________________
M________?0               %OT_______________________]*P
M         $SK______________________^E                 #SA____
M__________________\P#                "W9____________________
M_YF*82<              "?7_______________________MOHE5)P
M     "7<__________________________[*G79=2CPR+2PP.4?>________
M_______________________]YMW6TM#3V>3_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[]2[UO_________________________________GN(]J2R\5
M;_______________________________Y*%G- <     /,G_____________
M_______________6@CL         $I?__________________________^V%
M,0           &___________________________Z9"             %#A
M________________________[&D              #?)________________
M________LR\              "*V________________________>0
M         !"G_______________________R-                 "9____
M__________________^I                  ",____________________
M__]&                  !______________________]\
M      !T_____________________Y<                   !J________
M_____________\X                   !C______________________\I
M(@$               !A______________________^YHX!7-Q<
M  !H___________________________ZTZZ4AGQU<7!R=X&4____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________]NZG8)I:=/_____________________________
M_\B393T9    '9[____________________________;CDP3         &[_
M_________________________]M\+            $77________________
M_________XLJ             "*T________________________PD0
M          .7________________________?0$               !_____
M___________________G-@                !J____________________
M__^=                  !8______________________]&
M      !'^/___________________^D                    UZ?______
M_____________Y8                    EV____________________[P
M                   8SO___________________^L
M   /PO____________________\                    *N?__________
M__________\G                   *M?____________________]P
M               -N?_____________________@G(QP54(S)AL4#PT.$AHF
MO_____________________________GDV-+.S,O,S];@_/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O3O./_
M_______________________________2J85E2"P2 87_________________
M___________QJW$\#P       $_@_________________________]5_-0
M         !^R________________________XW4=              ")____
M____________________D",               !G____________________
M___50P                !(]O____________________^*
M       NW?____________________\X                   7R/______
M_____________[X                    $MO___________________YP
M                    I?___________________[H
M    D____________________]P                     @O__________
M__________\                     =/____________________\3
M                :/____________________]"
M8/____________________]Z                    7?______________
M_______1                    8?______________________)
M            9O______________________R:R9B7UV<6QI9V9G:W!ZC/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^+%JI%Y87?_____________________________W:9W4"P,     #'$____
M_____________________^"23A,           "/____________________
M____TG =              !@_______________________N;P\
M       WXO____________________^6'                  4P/______
M______________]                     H____________________ZX
M                    B?___________________YX
M    <O___________________[P                     7___________
M_________]H                     3?____________________H
M                ._____________________\.
M*OG___________________\S                    &^G_____________
M______]>                    #]O___________________^/
M            !M#____________________0                     ,K_
M____________________*P                   ,C_________________
M____@                    ,O_____________________]Q8!!04# 0
M     08-&,O_______________________SKX=C/S,W/T-+4U]SBZO______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________QVL;_____________________
M__________'&HX1H33(8 !6K__________________________^Y?$88
M      !Q________________________UWPO               [X_______
M_______________?9 D                ,M?____________________]T
M P                  C?___________________\45
M    :O___________________YD                     2___________
M_________[8                     ,/W__________________]<
M                &>?___________________8
M!=/___________________\.                     ,'_____________
M______\O                     *____________________]2
M             )[___________________]Y                     ([_
M__________________^E                     (#_________________
M___8                     '3_____________________-@
M         &W_____________________?                    &G_____
M________________UPT                  &C_____________________
M_W                   &'_______________________]0/$9.5%E=861H
M;'!V?HG_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^_5NZ.+<UJ5________
M___________________XOXYD02$%      !2_/______________________
M]YU6&              7P?_____________________E;!8
M    C?____________________]C                    7O__________
M_________YT                     -?S__________________Z$
M                $=G__________________\H
M +O__________________^X                      *'_____________
M______\,                     (K___________________\M
M             ';___________________]-                     &3_
M__________________]O                     %+_________________
M__^4                     $#___________________^\
M         ##____________________J#@                   "+_____
M________________1                    !7_____________________
M@0                    OU____________________R L
M      +L_____________________UX                   #E________
M_____________\D<                  #:______________________^=
M 0             '#A?%________________________U;F\P<?.U=OAYNWT
M^___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________^-_/_____________________________^S&I8AM5#LA
M!P RWO_______________________]>262D             H/__________
M____________B38                 9_____________________]F
M                ,O;__________________Y4
M \C__________________Z<                      *#_____________
M_____]<                      'S___________________\
M             %[___________________\E                     $/_
M__________________](                     "S_________________
M__]J                     !C___________________^+
M          7S__________________^O                      #A____
M_______________5                      #/____________________
M)                     "^____________________5
M      "N____________________BP                    "?________
M____________RPX                   "2_____________________U<
M                  "&_____________________ZH*
M  !Y______________________]M                  !F____________
M___________W50                !%_________________________VHC
M*S4_2E5@:G5^AY&<____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________HS[:=@VE.N?_________________________L
MLH-<.AT"        >_______________________Q6TI
M0/____________________^#&P                  !\O_____________
M_____Y(                      )C__________________Z0
M             &K__________________]T                      $'_
M__________________\.                     !W_________________
M__\Y                      #H__________________]@
M          #.__________________^%                      "W____
M______________^H                      "C___________________+
M                      "0___________________O%@
M      !]____________________/@                    !L________
M____________:0                    !:____________________F0
M                  !)____________________TA8
M   Y_____________________U@                    I____________
M_________Z(                    9______________________56
M               $______________________^[+P
M^/______________________JRD                 S_______________
M_________\E'      <3("X^4FB$[?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________35
MR?____________________________K2L))W74(H#   2O______________
M_________\5]11<             $=C____________________$4
M             )___________________Z(,                     &C_
M_________________Y0                      #;_________________
M_]H                       ?L__________________\5
M          #$__________________](                      "B____
M______________]U                      "#__________________^=
M                      !I___________________#
M      !2___________________G#P                     ^________
M____________,P                     K____________________6
M                   8____________________@0
M   %____________________K                       ____________
M________WB(                     \O___________________UP
M                W____________________Y\
MS/___________________^A*                    M_______________
M______^@%@                  G/______________________>@(
M            =________________________WH+               %3/__
M______________________^B5VAT@(V<J[S0Y_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MX___________________________TJ-Z6#HI(QP6#@8  )__
M____________________K%(.                 &G_________________
M_^1#                     #3__________________WD
M          #C_________________\T                       "R____
M______________\3                      "%__________________]/
M                      !=__________________^#
M       Z__________________^R                       <________
M___________; P                     "____________________*@
M                    ^___________________3P
M    Y___________________=                       U/__________
M________FP                      P/__________________Q <
M                K?__________________\#,
MFO___________________V<                     AO______________
M_____Z,                     <O___________________^-$
M            7/____________________^1!@                  0?__
M___________________K7P                  '?__________________
M____RDL                  /_______________________\M7   ,&"0Q
M/TY@=(NGQ___________________________U^?R____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z]3-Q\*^
MNK>SL*VIJ*7____________________=?E,_,",9$0D"          #;____
M_____________W8                       "G_________________[H
M                      !U__________________\'
M      !&__________________].                       :________
M__________^,                        _?_________________!
M                    V__________________Q&0
M    OO__________________1                       I/__________
M________:P                      C?__________________D0
M                >?__________________MP
M9O__________________WB$                     4_______________
M_____TH                     /____________________W<
M            *____________________ZP*                    %O__
M_________________^=%                     /__________________
M__^*                     /_____________________630
M         /W_____________________IRX                  -7_____
M_________________Y@J           &&"U%8.#_____________________
M__^H8W2!CYRKN\WB^O__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Y\NWJ9V5CHF$@'QX
M='!L:&60_________________[QJ2"T9"@                 Q________
M__________\                        #__________________]"
M                    W/________________^.
M    LO_________________.                        C?__________
M________*0                      :___________________6@
M                3O__________________A@
M-/__________________K@                      'O______________
M____U!<                     "O__________________^CT
M             /___________________V4                      /__
M_________________XX                      /__________________
M_[P9                     .____________________%.
M         -C___________________^+                     +______
M_______________,0P                   *'_____________________
MD1D                  'K_____________________\G0*
M    $5_______________________^AT$Q\L.$538G*%F[32]?__________
M________________U^CT________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______[]_/Q[NSKZ^SQ___________________9LIF'>6UD75912T9!/#@R
M+2@CQ/________________]+)0L                     DO__________
M______^(                        9O_________________7
M                /?__________________,P
M&/__________________;                        /______________
M____G0                       /__________________R0P
M             /;_________________\34                      -__
M_________________UL                      ,O_________________
M_X(                      +?__________________ZD&
M         */__________________],O                     (W_____
M______________]>                     '?___________________^3
M!P                   %[____________________-0P
M     $#_____________________AQ                   !S_________
M____________V%X                   #______________________[].
M       .'"P^4FJ&I<C________________________"?(R:I[;%UNC]____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________NX=?/
MR<.^NK:QK:FGIJ:GKO________________^^AFU;3$ W+R@B'!80"P0
M%/_________________7!0                       /______________
M____-                        /;_________________=@
M             -+_________________L                        ++_
M________________X20                      );_________________
M_U$                      'S__________________WD
M         &;__________________Z                       %'_____
M_____________\<C                     #S__________________^Y+
M                     "?___________________]T
M     !#___________________^C%@                    #_________
M___________83                     #_____________________B \
M                  #_____________________RU,
M  #______________________Z4X           )'31.:XS_____________
M__________^9.4-17VY]CJ"UR^7_____________________________Z_G_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z\RYK*&9D8N&
M@7QX='!K:&9F:/'_________________844R(Q@.!@               )[_
M________________?@                       '7_________________
MPP                       %+_________________^S<
M         #+__________________VH                      !;_____
M_____________Y8                       #__________________[\;
M                      #__________________^9"
M      #___________________]I                      #_________
M__________^0 @                    #___________________^Y+
M                  #T___________________H7
M  #9____________________D1@                   "\____________
M________RE,                   "=_____________________Y@N
M         ! I1F;$_____________________^Y_'0P:*#=&5VE^E:_,[O__
M_______________________GH*JYR-CI_/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______WU\.OFXM_;V-32T=#2U^#_________________SIZ*?'%I85M644Q(
M0SXZ-C(O+C'_________________TB41 P                    #_____
M_____________T(                       #__________________WT
M                      #__________________[ +
M      #V_________________]TY                      #<________
M__________]B                      #%__________________^)
M                  "O__________________^O(@
M  "9___________________62                     ""____________
M________<@                    !I____________________H2@
M              !.____________________TUP                    S
M_____________________Y8N               5,E)W________________
M_____^!R$P   0\?+T)8<(NHR.S________________________*;VY^CIZP
MP]CO________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________G@
MTLC NK6PK*BEHI^=FYN<H*?__________________X)D5DM#/#8P*R<B'1@3
M#@D$  #4_________________Y(                       "M________
M_________\P>                      "+__________________M2
M                  !M__________________^
M  !1__________________^I&P                     Z____________
M_______00@                     C___________________U:
M               ,____________________CQ0
M____________________N#X                     ________________
M____Y6T#                    _____________________Y\W
M       0+U!T_____________________]UR%      &%RI!6G64MMK_____
M__________________^\6$149'6&FJ_(X___________________________
M____TLWA\?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________/OZ^_W______________________^ZYJ)V6
MCXJ&@G][>'9T<G-U>'^0_________________^M/.C H(1L5$ L' @
M   C__________________]I                        ____________
M______^;"@                      ___________________(.0
M                ___________________P8P
M____________________B@X                     ________________
M____L#0                     ____________________U5L
M            _____________________X4:                   #[/__
M_________________[%)               8.5V!____________________
M_^5['@      #"$X4F^/L]G_______________________^[6"DY25IL@)>P
MS>W_____________________________LYZTQ=?K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^N_GX=S9UM32T-#0T=/9X.OW__________________^XBGYW<6QH
M9&%>6UE85U=97F5Q__________________^_,1\6$ H%
M___________________M5@                      Z/______________
M____@@0                     S/__________________JR\
M            L___________________TE<                     F___
M________________]WP0                    A?__________________
M_Z(W                  4KE/___________________\MA @
M  PL4':>T?____________________6-,       #2,[5W:9ON7_________
M_______________#8Q@J.TQ?=(VGQN?_____________________________
MJ'^6J+O0Y_____________________________________W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____W<[%O[RYMK2SL;*RM;G R=7C____________________EVQD7EE544],
M2DA'1DA+4%EFH?__________________IR8.!P(                 5O__
M________________SE                      .O__________________
M]'D+                    (?___________________Y\R
M        #O___________________\18                "#%:A/______
M_____________^E_'P          !B=+<9K"Z?____________________^G
M20     "%R]*:(JNU?S________________________3=1XF.$I>=8^KR^__
M____________________________KG*%F*S"V_;_____________________
M_____________]_O____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_[^RJJ:CH:"?GZ&CIJRTP,W=[/___________________XI:4T]+2$9$0T)!
M0D-'3EEI??___________________YXN!@                   /______
M_____________\-6                   50?___________________^=[
M&@             )-&"+M/____________________^?/P         $)4IQ
MF<+K_______________________&9@\    3*D1B@Z?-]?______________
M___________KCC4K/E%H@9V\WO______________________________OG9_
ME*G!W/G__________________________________]+8\_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________]O+P[^_O\?/X_?____________________________BP
MGYJ7EI:6F)N?I*RVPM'A[O____________________Z.4$I'141$1$5&1TM1
M6FB#J?____________________^F00$           <V8X^ZX?__________
M___________&90H       0G3'.<Q.S________________________EB"\
M !,J1&*"ILST____________________________JU V2F%[EK36^O______
M________________________TH=\F+'+Z?__________________________
M_________]3.[?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[>7CX^3FZ.WQ^?_____________________________]L922
MDI69G:.ILKS0[?__________________________G5-'24U15F!SBJ_6_/__
M________________________LE8 &C50;8NNTO?_____________________
M________S6\^7WN9M]?Y________________________________[I^#IL+A
M_____________________________________^/.Z___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________P
M
M
M                        ____________________________________
M____________________________________________________________
M____________________________________________________________
M______________\     _^% MVAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z
M3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A
M+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-RXR+6,P,# @-SDN,6(V-6$W
M.2P@,C R,B\P-B\Q,RTQ-SHT-CHQ-" @(" @(" @(CX*(" @/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*
M(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M
M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S;V9TPJX@5V]R
M9" R,#$Y/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O
M;VP^36EC<F]S;V9TPJX@5V]R9" R,#$Y/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(R+3$Q+3(V5# R.C R.C(T*S U
M.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C(M,3$M,C94,#0Z,3DZ,3 K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3$Q+3(V5# T.C$Y.C$P
M*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP34TZ1&]C
M=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z,35A-&4R8S@M-C1A8BUF
M,C0T+3@T,30M93)F-&4W,V,R965F/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C0Y.#<U,31A+3$U.38M
M,S@T8BTY-3 Q+30R,F5E9C5F,C(Y,3PO>&UP34TZ26YS=&%N8V5)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$
M+3A%,SDM-#%&1BU!,$$P+39$-#!&-C4T1D$U-CPO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8S R,V5B9&0M-6%A-RUD8S0W+6)A
M-38M-3)B83%C8C5F8S1F/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3$Q+3(V5# T.C$X.C4W*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C4W9#(W-64S+68T,S(M8S(T82TY,69B+60V.6%B,C5F
M-#$R-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,BTQ,2TR-E0P-#HQ.3HQ,"LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R
M86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N
M<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C0Y.#<U,31A+3$U
M.38M,S@T8BTY-3 Q+30R,F5E9C5F,C(Y,3PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ,2TR-E0P-#HQ
M.3HQ,"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII
M;G-T86YC94E$/GAM<"YI:60Z-3=D,C<U93,M9C0S,BUC,C1A+3DQ9F(M9#8Y
M86(R-68T,3(T/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$
M-#!&-C4T1D$U-CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&
M1BU!,$$P+39$-#!&-C4T1D$U-CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \9&,Z
M8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^4W1E<&AE;B!-83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O
M<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QT:69F.D]R
M:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT:69F
M.EA297-O;'5T:6]N/C$Q,34S,#<O,3 P,# \+W1I9F8Z6%)E<V]L=71I;VX^
M"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C$Q,34S,#<O,3 P,# \+W1I
M9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET
M/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R
M4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z
M4&EX96Q81&EM96YS:6]N/C8Y.3PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @
M(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXS,C8\+V5X:68Z4&EX96Q9
M1&EM96YS:6]N/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R
M;V9I;&4^52Y3+B!796(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#
M0U!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!&0): P$1  (1 0,1
M ?_$ !X  0 !! ,! 0             %! 8'" (#"0$*_\0 8!    8"  ,"
M!PL&" H&!PD  0(#! 4&  <1$A,(%!4A-55UE;4)%B(Q-E1TE-/4U2-!49;1
MUC)387&2L[3P%R0E)C-E@9&ALAE79)>QQD)#A9/7X?$8-$1&1V-F@\'_Q  ;
M 0$  @,! 0              ! 4! @,&!__$ $<1  (#  (! P,!!00' PL$
M P$"  ,$!1$2!A,A%"(Q014C,E%A)'&!L19"4H*1H<$',_ E-$-55F)RE9;1
MUC53U?%$<^'_V@ , P$  A$#$0 _ /W\8B4SU<S5F[<D*!S-VJZY2FX@4QD4
MCJ%*80\8 (E !X>/@/BQ$A&Q[.Y;MW +0) 7026 HM) PEZJ93\O,#T 'AS<
M.( ''$3NY+/\X@?J<A]^Q$^\EF_CX+ZI(??<1/G)9_G$#]3D/OV(CDL_SB!^
MIR'W[$1R6?YQ _4Y#[]B(Y+/\X@?J<A]^Q$<EG^<0/U.0^_8B.2S_.('ZG(?
M?L1')9_G$#]3D/OV(CDL_P X@?J<A]^Q$<EG^<0/U.0^_8B.2S_.('ZG(??L
M1')9_G$#]3D/OV(CDL_SB!^IR'W[$1R6?YQ _4Y#[]B(Y+/\X@?J<A]^Q$<E
MG^<0/U.0^_8B.2S_ #B!^IR'W[$1R6?YQ _4Y#[]B(Y+/\X@?J<A]^Q$<EG^
M<0/U.0^_8B.2S_.('ZG(??L1')9_G$#]3D/OV(CDL_SB!^IR'W[$1R6?YQ _
M4Y#[]B(Y+/\ .('ZG(??L1')9_G$#]4D/B^N_P#'_AB(Y+/\X@?J<A]^Q$<E
MG^<0/U.0^_8B.2S_ #B!^IR'W[$1R6?YQ _4Y#[]B(Y+/\X@?J<A]^Q$<EG^
M<0/U.0^_8B.2S_.('ZG(??L1')9_G$#]3D/OV(CDL_SB!^IR'W[$1R6?YQ _
M4Y#[]B)UD=S3:1CFK\8M5!^9T3F9HNTE4S-VQW "(K.5B&*;DY1#E 0X\0'$
M2XL1(-W)OB21XYA'(/#I,F[U91>0%D4I'*[I!,A"E9.A.("T.8PB)  #%  '
MQ\$3CWRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$=\L7F./]>G_
M  ?$1WRQ>8X_UZ?\'Q$=\L7F./\ 7I_P?$1WRQ>8X_UZ?\'Q$XIRDFF^8-'\
M6V;$D%5T4EF\F9V)%$&B[O@=(S!M\$Q$#%Y@4$0,)?@B''@B7!B(Q$CI?R3*
M>CGO]F5Q$YQGDV/^@M/ZA/$2NQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$@9+RS7/I$E[,7Q$
MGL1(%+Y4/_0,3[1FOS_W_P".(D]B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B) RGE:L^D'_ +%D<1)[$1B)'R_D
MF3]'/?[,KB)RC/)L?Q^/N+3C_P"X3Q$KL1&(C$1B)Y!;LWCOZK^ZL:&T'7]T
M72/T==NS?M'=5GU?&572:R,K8=92+!JPA&=KL6KY*ZQ\'847*OAM(EN1D.\=
M(\1-02)3D-PXK1W9ZWLU5G95Z>X7#R>*@D5$V[]56*Q'>IJ"ZYUL;3E#6*?J
M57ZE]&;RS--Y'*HXOTM?G?Z;1S/JJ_@=5WS8JYJ.%V<JEJ5NMH6^R_/71<P5
MD^E+BJJO01>MIUOW9'6VSZM8D*]JC;]"LS[L\=H+=5.=RJ>N)===+0-D<4NZ
MLF;,MK<12TU%R72F8=&96:P4ZS2,@=\D<5$\Y;K2.*Y'9GO-=F3T[Z6]2]K4
MMEJ<1ZMMMSX=:5V^-+VY=%8KU9G</^\K:OW$)(TQ(C<KQ^6^M;*=/J?G_3!)
MM=*WY/TW0FW9G9ZE:ZNG5E+&C16C>#*RV!' !MB&]U3MKAMK*K1.O+?=VT][
MGI+=LVV;7<(ZZK5L18MVDDU8K-=?FLI*F271=Q+U](PK>5<QBC@[)BR.9DHX
M=(3?4J-QU_KVA3] OI6OBLZ79@-P79S%HKJT5KK-9OHSH+']JU4>RU&#E:P@
MNY\#4=]?HEU_MUOJCG^1XT9[_P"R!JN+KJMLJLMS^0I>]]6:D75!E6IGL %@
M(7)1/=4J9J;L_=D_9.SJKM&]Q>[=::0GYG9J45K:LOR.=JNX"N-)Z5U[%6U9
M5)P:<FFKJP1U/;R4'!][*U9/G("@D>WY#&C>LW],9ZJ\5NSELG%X$6^S3G35
MR631KQTBVU3I^GZSO1]7IK4&W\AU2QUIZM39_3>KG-%C:TXRCF-.TBJO/<^?
MA.1&'9:E:M[+.OFMJ4U.7:D!G%;NJ'GV0.T3OS= ^Z>UFZ[9F7"N@.T'L#7V
MFK1'U36,=8J35V% B;+$-DD4Z&:LV%Q%2$@KW9Y;ZW85W"!4DI,T@(&.?S6J
MRVOT#QW-H[+RC5^I7NT>*%=!X?E=>;*+*60TH+*<Z)<**Z2X9VK-3E67TGMT
M#U>G'"E&X^S-Z>L^F+7>*OR-?]J(M%HT?)8,@:Y@C#H#Q[4Z_P#8_P#=,MBU
M3LF=D?8G:26VAVCME]KW;&T]?P<Q#1&D*=&5&7I#RXEB(7P56('6C=*%DH2E
M.7:LD\;6.03FG#H7$@UC%6+)G8Z[::EXRA*/&U_05/K/7H\R1:*^(X_D^2H4
M-9XI[1VE<2+4@-("776W#W&KL.;1K7G]9M04<7ZMM]-59PI\Q4>;V<5CUD^)
M:RP^%(V?O I(%F?/6/=!V+A/=-J7M"Q=A"V5(]_I>L^T]%[GFW[22KE"DF::
MFK(B;3GZ[=I1S/FG:TK6Y* E'K>5IC:892XM2H.'!&:Q3YG0E?&[^93=<AR\
M=_V?T^M@Y#K4>/UCB-E>RMT4WG31DY&NM\5]:5,;;&\S90H/+W3?DQ#/38=>
MOURWI!5'36_59SRU#5&MB*3EW681=5I1VT5JE2FI1=9XT=%]VO[).QJ7-VVI
MFFIEX6:UC!T2I1<Q2I6RW]YN.X.Z-KQNBUC+(Z1ITC*SC!XK(PUW6@Y6"AT?
M"\FT1:J)B8,^IUXU*\[6;>3WU<=3B5T)KTV\0.= LT]G*5JXT6-I9+6^GU56
M8K -"^,W=Z:[.29[57#Q>'D.1NW^+FNS-QG()Q>EZJ/$:6\MUV:O-Y5*--6K
M/HJ)IL#"_=J^Z#7^A[I['^ED>S/=(VT=I:+WE9+#!VNQ4N/L%(@])P0.Y)NW
M%O8EX*1D9-[(PK]@Z+)JQ[B#47%$%'RB:24?M7LYX):?I^#])U>I+]%:=V@Z
MM*Y:<YHM\"KY[$O&E3Y$VK2E:M59;?3-7*WT%.IAXW:?4F7T_167!I)L(L?6
M;$#FRJVCL9U3P93YO:5*)5=A+4?NN= 3[/>LKO9XS:&UKK:Z5V@-OV%B2N:Z
MIEGK>H]%7R?@+G:)N(A[0K5%"5]%DC&Q$= 2CZ8M!&@.RM$WRSE(DG4*<KYZ
M[75*<OI?T;S7+;QYO72/5&7#5AT74>/NK?R&RZRZ[+F2RG'XWBMSGJK+1J:G
MTZ-%= [NU^IO4/#</@8JME[\3;IONS47'I6SX<RTTKKU&JV\V4-:ONVN1>DM
M[LIHB,O#NN(ZWV7+5!O-=F)FWV?&K4]:K/X#M8.&336=K:,CV%.P#'I.GZ!)
MU@I&$E62/.X3:KIESK1BOLY(<3<%S;#ZOY/T1X6'S7]N<=Q;<M6@:KS!S;<P
M1:- [5+;$6X(.V$+1KJHQ6[QY654>E*/6%R=>W;5Q;\G^RM*65V>)77BTA_>
MI/\ %[;+4SN/&>P&1)*C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$@9+RS7/I$E[,7Q$GL1(%+Y4/_0,3[0F<1)[$1B(Q$^#QX#P$ '@/ 1#
MB #^81#B'$ '\W$./Z0S![Z/B0&Z/1() /7P2 5) /Y 8$CX['YC^_\ \?YS
M\TFSO=3.V-KS>/:XT@WOO98G-E:1V]KW6>@-2*]F[<L5.=IB5O57CKBG3V6Q
M"]HV2J=&MR$<\68-E7T7,).C-%9D(@K4IV1-.':_D>+XG770-_(:_47J+A]?
M'46?1>''^G==&71S56B]-"FM4M?7JS*ES9*J@C7.;JG,K>N7-RW(YG>S!Q>;
M@.(Y>GD+BNYJ]?,Y+KLG&Z*:5S%BVE<^.G1_9UTV7]I764=5]@YOMTZFUS8=
M>ZWW $G4MK6&NZN?[$@89FI9JUI^>VM(LJO5HF]6QH*3*+:3U\<GJ%>DCI'3
MDGQ4E5"-6RH+!8&BC3RF_#Q5S;<V?DM/&XMKH:*^0U5Y[]^?%1Y_!Y+3QM'U
MB8^_+Q=*PQL=%:MJ;57Q./D>1H7+?;QPY'9D2P769,U)IKY#8R@!CQ^&^UEN
MU%0H2NVSQZKL\;+KONG'9HG[H>EN$-IU@S?>3_LX2-JMNNI2%I$1N-LU6>Q]
M0E;*=PLT9KV1LB92N/#D%A('.B@=PW<KHHGA82N^GCKZ65$Y;'R.SC1>12VT
M<19>G)9: W\6W&,NFVW/V&:K/<]1L%; 2-/>6WE*G!=^%?&.4]HBP8Z>03*^
M/7:01UDO.S-6MH!867(KHH92;XI?;^[.6P9NW0E1F+9-J5BN7:U13^.ILU(1
M^R876TTA6[\XU6:/2=N[RK4["Z9PLLUC&8.0?/&Q6B3I%3K 'DV%MZU6E5HX
MW7]-X$;3AYE[:^)Y 9STWT7(/1:M&ABJCP[N]I70MWLH>K97BL:I7LU:L!N]
MU#FJY#%17IUX+KP?!->?/9[EE/9/5=JJ6>IU&MNVO===%4WL\]H#<=-JVQ[!
M:] VFFZ]MFL9VIJP%IA+ILCP,2C>'6*K\Y$(.1&?CUEG#=XH[)P68G;H/BBF
M3HE=EM_IM*5^HI]1>I*?3M5V9DN]G2FQ:>0K(#!7TTYQ;;EJ5C7K?VE2T)9Y
MC1E6FODK=9.9>.X"_P!0E;NZ3HQ5I8*C665C6'T*E-[65ALH<N]3%? \/=!N
MU_VD=#4WL>W71)=<59+M$=H;6&B;76-[ZEMMEL=<3V<C)KHV!!*K;CH*<9(U
MXL0JDZKKU.5)(G=IG+,1X-3)N62E[O6'$>GGNI;)RE'(V&^D%K:7XW.FQP+&
M8)9[]5@H\?:0Y[JV8M<K^%>" WI7U%SJI8FK@<->[V;>EJTK;NS\>M?B%+U
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M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B) R7EFN?2)+V:OB)/8B0*7RH?\
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M^-KV5Y,K]N@&]!3I:^T>+VN]"(BE5J"6>=@7IE1.H9_V!R? NWFG,9*L6_4
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M8A3&*4R"?,4IA 1 IOS@ \!_/QQ^O?ZGKL_J>OD?\#\C^4?GX/X^?C^_X/\
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M).$HE9RHBU3$H**%;HG,JIR\P")2%$>'$>'BS&>BS3=715XFRUO! S!5+'\
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M'$3L"<*8 ,$5-B!@ P#X/'Q@/C ?])^<,1/OAL/-,WZO'[3$3[X:_-X)FOJ
M_P#CU>&(GSPV'FF;]7C]IB)\-.%(4QS14T4I2B8PBP'@!2@(B(_E?S  C^G$
M26;.$G;=NZ1$3(N44G"1A 2B*2Q"J)B)1\8")3 (@/C ?$.(D/)>6:[](DO9
MJ_\ O_N.(D]B) )?*A_Z B?:,UB),.'+9HD*[MP@U1*( 99PJFBD F'@4!44
M,4@"8?$ "/$1\0>/$3&NP+!!EC(5P67;K=VN=-.9..DFO5$KBPL& G< 0RIA
M9(=\[P\^"!002.8ZB1 ,H6HYDE,^6P+<WM\IQ?Q1WY?O=U- +^*N34IN#VCH
M#P4DLH!87WI[IM6VLMG3W.%YH!M 'CW5QVC1XU]L@%[^S[=/R278!59B%-]>
M^"!\]Q'K)E]MEO*&/?! ^>XCUDS^VQ$>^"!\]Q'K)G]MB(]\$#Y[B/63/[;$
M1[X('SW$>LF7VV(CWP0/GN(]9,OML1'O@@?/<1ZR9?;8B/?! ^>XCUDS^VQ$
M>^"!\]Q'K)G]MB(]\$#Y[B/63/[;$1[X('SW$>LF?VV(CWP0/GN(]9,OML1'
MO@@?/<1ZR9_;8B/?! ^>XCUDS^VQ$>^"!\]Q'K)E]MB(]\$#Y[B/63/[;$1[
MX('SW$>LF?VV(GWP_!>>XCUDS^VQ$^>^"!\]Q'K)G]MB(]\$#Y[B/63+[;$1
M[X('SW$>LF?VV(CWP0/GN(]9,_ML1'O@@?/<1ZR9?;8B/?! ^>XCUDS^VQ$>
M^"!\]Q'K)G]MB(\/P/Q^&XCA^GPDS^VQ$>^"!\]Q'K)E]MB)]\/P7GN(]9,_
MML1)0AR*%*<ABG(<I3D.0P&*<A@ 2F*8!$#%, @)3 (@(" @/#$2#E/*U9](
M/_8LCB)/8B:[]HV28P59A;%,Z?4W#!04NH]D(YLS;6%[5EC,ET(^W-*2[35+
M;#13E4.]-XQ)>QQ\<J]>5]H_?!W!U%NL]JP6="IAEUK3M96L3-H9:_;2U:PU
MU5&A0]=VJE7:E1X6K]/;<Z=ZE-E;5AO)6NSO=F#K4VG/6;'L"6.179;4XJLI
MRW,M-UPKM\EOST&:6>Y^O-P[6J^S-M[XJ&GT'+2QV-AIFZ:S:U)G(.J8NU?M
M):(D7%-<'7&(;N$6B7@6V"A-IR;0YYZ$9RD4T,C:UUC-Q/'M:63E==+_ +2"
M.EF?1G/TM^6WW*2V6XM>+VILRV74_3+G>NWSMM$A7/[G*[ZJ5!XO.U)Q+=6U
M>C/J#:Z[D:F]$TYK4RMG2U;DJN%E^NDAJ"/+U-C/)L?\0_XBT_F_T"?_  R)
M.TQ?;=GT.L;&I-2G;(TCI^:0?)LF*B+U0A3RKAA'1 2#UNU5CXCPO)!X-B#2
M[IB64DC$CX\7#Q5-$VU*M>[U4J7L0%B .N_&FZ]JT8]*]RYZ;M!H0M<,]-MY
MK]JMW76T^TB6V'QK9B.^^SUYUU>XR+VRTBVVJHWLHI6VRNMK [JIN39T6$UK
MJ\1?3ZPNZM-D32X<146)'KJHD#Q#XS*ID !X"("(" <0SMD?PTYW[Z NK[/\
MAY $_P" ^9!Y:HW<7R%2H'9\>@*AZZ=A4Q5?D$?+ #Y$L#4\FX>R49(N$6:1
M;EI_6]A.H#XJK]S/Q02T;9 5:&<G4,W9MY"M(%>)-BD,L=1-PN=044R4=B-F
M]5\O2%I6C5@QW4L+.K[;\>SD,^HM27^*J\]W&!+$K'W.R6.?W8'I,5YY#T%Z
M<UV-<=67;KSZ:C46ST5;^.XO7F1=(K"M:^NCERU3VEO%%=*U'N%L\Y:2KC$2
MU;5;JG3D8=[;)9A$)RD]&U^$5>@8RCNP32AF$<P8D3356,[=BJJB ID "(&7
M.L=-N"IP+]]M5"_-M[,M2#^)RE;VOU^@"UHS,Q(4 ?)[(!R017=<?BK/7[MS
MG^&M/)4\B?ZLRJH';,S *"3U+JQ,1B(Q$8B8SV%MC6NLS17O_GV\.9\+AXQ$
M\5+2PM&S$")OIQ\,3'2/@.%C2.B%DK'*BPAHU-P O9!N13B.:@;M"9JONNL-
M05>PH\K[DST*UC>-:/?HL2BA'=6ON=:J@[D+,LK)2UY5C6GGV54NY-=3WV!*
MD#6VFNFM[;!6C%*U+MTH[F2BF*<I3D,4Y#E Q#E$#%,4P )3%, B!BF 0$!
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M%)$ $132  #B(B0H  !\8B/#Q &(D>1HS(\<RG41$CEFQ:" @ET2%9+R"I5
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MC@V^;O3U-H38^6VQ+DHQ4O;?XI4;=UV_DVL%%"N[+CIPCCJ*K'8FW17J;O\
MU4VRN%SV=$EB&E1I3I=F4J;5Q).FC273>,_!<>Y"8C$(J<!T@FT55=,31TPT
MCWCQT@*C4IFA2*.*HM;U8P0=BC4R5,?N-U%M:Y_)@2AKUAB JN+:D\WM]IE
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M$8B,1&(C$1B(Q$8B,1&(D#)>6:Y](DO9B^(D]B) )?*A_P"@(GQ?^T9K^_\
MLQ$G\1,(=IAN^==G+?:,6'^5?\#6S%8@>)2\LNA3)E>+/Q/\#\F_3;GX* 9(
MW+RJE,F)BC/XM:7Y/CTT*'SONRIH4]]-0]Z+<IZ(/35E@>B#\_!!Z,\_ZK;8
MGI?U'9QKFKD:N"Y:WC[1T#5OJP7V8[!Y!E[KTK4X\E925^Y67L&[=2FYM6ZY
M#I-T!2H]7;F1:/5Y)JB=K"LFYTF[]TX=NGB*9DA(FY=.G#I8H =RLJN*AQ\O
MZ<1J_3_"5.M:/3Q/'T.M-]FJI7IRU5.M>FU[;;ZPR$)=;99;8O36.[EF/O\
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M)>6:Y](DO9B^(D]B) )?*A_Z B?'_P"T9K^_^W$2?Q$8B:N]GA3HVC>\7WQ
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MVVC1KZ[J/<M6['?1;13K*UU_6<IEV[+.1&>E/NJRX\6GB,O=O;-I6XLWN6>
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M%9-%6>O0[&O5R6AJ?(NS<@]2W457V$.^7*::?W=2M[GB6;(8        >(
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MD+T<1SFH@$A$X\YG;I2?$#D;<0!)^P>;*/(]DA.V%,AM#8$BEU&&@K^P.;F
MB-JG]=Q)P$.)2]8T';+61,IE/'Q(982H""@AU>+<-GQYJV*MR66P#K[J*]3@
M_@_'NT4'X!_4#Y!'X^9RIYCDM%?FGIKE<S$-U5R&CBJ7!!('D<F_>H\B.QXL
M_2$,1Y=H.3>U;V>.SICJ.GQ+$#$!)X]VFJ^='*;E YU8UG1T2(BE\,0(626Z
MP 7X20B( :GC512-U[N>_)!B"*O7?75C:3Y=_'^H.OZQ5M]267.C\%@SYP4]
MN]N;-UCAA]Y?.G&H*_ _@"^SS^/E?GK-9>82E$X !^4.8"CQ*!N'P@ 1 !$
M'B "(!Q#Q\ RO_NGH1WU\_G]>OQW(.2\LUSZ1)>S5\1)[$2 2^5#_P#1X B?
M:,U_\L1)_$1B)JO7G#IAVI[PQ.]E4V,S76+QO'HB8T*LX9P5;(HY>@"X%3D"
MB+@&7,@IS(@\Y5$O&56+R5OCO],5A] %V#U"MB*#]*[T:N,>IKCY@"Y:[;!1
M^[;M3?\ <A #Z\%18U/KZQZLK+3R?HZW/<Y!V55Z..Y>G0E/:%A39=34= %@
M'DM!\6[[3:C)4VC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$@93RM6?2#_V+(XB3V(F'NT)&3TUHK;\35XR#FK%):YM[*%B
M;-&14U7Y*1<0;U)LRF(>=D8B$E(]PH8$G$?,2L;%O$S"WD'S5HHJN2!R:NV.
MP5JKD69G8-73:157IILO>NK0]>>R^NE;+,Z7V)2UZUBUE0L1.XQUKWY;&9T"
M7*0Z6VTLKCOVS[U%=M]2^?CYV4U66HGDU:,X /E[[E'3]OTNK]H^.VU7J#"N
M%)"JN8%UKK7>B=;P<BR6JSY=<JL1I&U6IJ[DF"RI6<@[G72*B;Q-=E'=Y;-C
MNE;XLAX?.A)%]?+\FM@]^ZVMD&3B52ZA6JKJKJM9;/#K]_8%%ER5J]2"D8/^
MV;V4#Z=N(X\JQ2E;5N_:',EZKBKO<;$I-#,I+9Z_/QILL;WFGLK&>38_Z"T_
MJ$\@2;(J0^4E<^B3W_)&YG]/\1_U_P#'_CYU/\2_[W^4N/,3:,1,);*(@QV-
MHRPJFZ9BVJR51,W-RE.I9ZE(N")'^$0I^/@$YDRFYA*8HF(01XB%AD+-DY&I
M1V#33>WQWTM-Z GO]/FT=G]?@$_,\]RRTU\KZ<UV,5<;=>&G[BH=]N&Y_ CL
M!CXY690>^BI('Y(GY/6K:;GYMY*R*BM;G2Q*[^LM4.Y%?R<3TRI.I2406!Z\
M:F1131-&E%!HHF)BN2N $ #R&C@:]>W7;HO9L.P9FNX^M/:%U^;Q\;=&A&%U
MJ>*A?8!2LCOW _?0^D9?4MN'C\-.3.$Y/ VM*.3ML]\Y\NOR+4Y<MB&FFT.[
M.-)]RU6 ]HU_)EVV2!1G*W*0*96Z .X]5NR%1$AV[-TF3FCW (<HEY6;HB"Y
M2%+P#I  !^;++?C79AT8P$7W*&2DL@9*K%7NA_ CHBJP(X7KK[>I4\;O?#R6
M7D&:US5H2R_Q<BVZIFZTU^9/?E=4UE98G_7))E'1IX;%6(Z05627?)"ZBI<4
M2+ID3G(1XO$3*'2<HMW"8HR3)R3E602/P # 0"F*(\^)V?78*+F='N4VYM)0
M.%&O):^74GC8E;J4T56*0R*1U\#KJ=N=P#C>4TYT1ZZ']G7C%AK9FP[J:]F)
M_*I[*V\\M]3=I8X[)'D2#+MRQE1&(C$2QI6]QS5X6'A&KNT3RPOT4F,,F==B
MT>,6_5,A/S29%8^ (94Z#<QWQ^N"BY>DU7$IRA4Z.8H2T9<B6<AL<WHM652]
M-5M*%BFW4JM3B!8I7W<?/R=?&M_D"\R\#IMI.S=;5Q>!!GL>_:PKONIOL\0^
M#$S)HY!@@LL"T+[96L^5M8*DQ!*7,VI(%MCR"+ELZ9().Z/!N%O>J@X2>HO1
M,L_4;,)>=$#-T$#F>$9LW"/>4SQA$'2B 11Q6KDE#<[<EE=E*+;Q&1W_ &:E
MBVI=VU[5T:MO1K1";EJJL7W <ZI:U8FGF\7$N4]-9WKMJOL:KG=]:?M:RMJ7
MHZ3.EM^/ .K'L44FZ^M_:8:C94MAR4V;-V;=%JT01;-6R2:#=N@F1%!!%(@)
MI))))@4B::9"E(0A"@4I0 I0   ,O:ZTJ1*JD6NNM52NM%"(B( JHBJ JJJ@
M!5     '4\S999=8]MUCVVVNUEEEC,]ECN2S.[L2S,S$EF8DDDDGN=V;S2,1
M&(C$1B):4G?Z+#.CL9>YU6,?)B('9/K!%-7I1#B(@+19V1P @ "(AT_$ "(\
M  1SNF;38OFF>YT_VUJ<I\_ ^X+X_)^!\_)^) NY7C,]HHOY'#3>>^J;-5"7
M'H$GJIK YZ )/2_ !)_$M60WIIZ*(*C_ &-5$2%$ $P2B*P<3"(% !0%3B)N
M'B ./$. _$(#G:OCMUI"UY;F)[( 0@_'Y_/4AZ?4G XT-FGE<52#KMFN4C[O
MA?E>_P G\2A/OO6XE$[%[8)LH>/C7J7;Y[FX% X\H14([$W*02F,!0$0 Y!$
M/AEXY_9VK\,M=?\ _MOIK_I_KV"/](>,9?.JS3I7^>3#LU=_'?Q[%%A/P1W_
M "['?YE.TWE&R:8J1.M]VO?&< ([U-;*NH(D O-P)=&=:$ XF*4AC<"J#S&3
M$Z::AR;6<<]1ZLU<>/@'M-U&@?)ZZ[S-<.QU\C\@?)_([XY_4=&M"^?BO4)
M+#QT\'R''N?'KLA.2JQMT>QXGKINCX]^)Z[@V=>G2YD(_L^[1!,""8LC,SNG
M(F-4, E+T@(CM*3G2J<Q^83*01$!236.1=10$4E\''G5?)N4Q$]]&NNOD'L
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M[>_TMJKH'D ?E0&7J%^SYKZ03Z4TK<YTI@3!09&^VY,RHIB!P,<T;+1YN)E
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M0"*S$G^0"@DGY'P/YR*=V:N, 5,^L$(R*@J5%<SN58-@16/QY$E16<$!-4_
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MR8BF;NTY>G9"W*P" E.14T.%)C73=0S9Y#NDQ.=1]5ES]C)F%CCOK3M"VO\
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MB(Q$8B,1&(C$1B(Q$XG4(D0ZBIR)IIE$YU#F A"$* B8QS&$"E*4 $1,(@
M B(\,?G\3!( ))  ^22>@!_,D_B8HF-Y:MAW81WOK:3,J;J@E$59!Y:I-8Z/
M^D23:5]O(G%8@\ %(W*H!A .7CDQ./UN/+V6K3X[>XK2@[^ 2UI0=?U_'Y_D
M937^H>(H<5?6)HO;W/&C$EFVYC4.W1:\JVGS7\%#TW?QUW(0VR-H6!0R-$TM
M)H-C 04[%M2R,-?PYRJ"/,9"%BV=RO1UT"@50S63JD&BL)TT22)#]X.VZ_2X
MZOG3O0GM@:L=3:;!UUT38[49BK$D!DOL("DE.BOE&_:W,:CUQO 7!"M;KKYG
M77Q>=@[,'5:*J]_)BVI5#-7?@S(WFJ+=V+/;[5*)MNPJ)JVK< 0;43&%6!UA
M4F=?;F1, @5NYL=F?6VP.%4N(<7\4>M@L8 ,#! HBGF!HQ5 BG#[C=#JW7>U
MA!'Y*U5+14 W^Q8+NA_K$_,V/'<WI96V<[].@9_+-Q&&O,C(PZ5+-6RS=J9Z
MS\B[.V/R/YJ4?$K6.A=7MUR/96OGN$B4$.:0O<C(7%PH=L8%$5CI3SEZQ!PF
MJ4%BKIM"*@J!5 ,!BE$NK<EL;L):*%)8^&9%H #CIE!K"MXE?M\2Q'78ZZ)F
M]7IKAU\6OS'?8%J4V\G;;R#N:6#UNXU-96;%<!_<%8;S ;OR ,RZ@W0:HIMV
MR*3=NB4")(()D112(4.!2)I)E*0A0#Q 4I0  ^(,A$DDDDDGY))[)/\ ,D_F
M7JJJ@*JA5'P%4  #^0 Z G;F)F,1&(D#*>5JSZ0?^Q9'$2>Q$8B1TOY)E/1S
MWXOC_P#NROQ8B:Z7YOVBG4G7O\'JE9:5!%HT(]22>@2?>MSEB3+NE',FP[I'
M/VZ(2C=BQ02E&;@%$73EXU7*1)/DHM/OEV"L:[!G\0&K1Q7K]IW\NFL9KOH?
M.OQ6NNKZGIKB4ZW)0>V% (\ZFL9_/R8>:>]7X(5"U>U[Q2Q;/>:[V05KK%GE
MEJ*+8TW=#2LQV"\PG6'!)IVR,8A'$^5A$EEU$6X(D129G=@J=L*:@CR'Y13(
M4I1-,TF@Z-!S!ES&^PYU8DLM!=_:#$DDL*_$$GL]]]GO\Q*!<*LPO/=PI07'
M[3W;[8]P]H%0_=W\JJJ?DJH'0&0LX21&(C$35APVW(PV?LVNT:NL8F&M[BM3
M[39\_P!)Y!P!O :$=-$:UU!9N_L<_P!=F0&;)5VPC4_@.'KPJ1>ZKW ^@;'D
MMT7,]E(MK?'7]MMG[PM7W:05JJZ/W-XLQ[(1>^R/&L/4%?,<ODX_)31FVG+I
MIYC2191G;Z=*M &12EFK2'4>W6;*Z@ 'ML (1LE0&DJ)%1<XSF8\;M*6U("W
M*RW $9B;LYQ)RF*\642*BQ8)#Q\'PT2BQB8HG*G'LT"D 1BV<AI=ZS6_TZ4G
M]Q31W773_50#VSG_ %K'+.Y[+,29;YO3_'4TZ4OK.^[</[?KW>-^C62 #[C%
M0E=:]=544I712O2U5J !+0\&;!TH4H5E&9VEJY$2@2JKK%?;$I+?X7.C6Y1R
M=,]S@$^)1:P\XX]\$87J(MIN28@SCX_MYYN0/[XUX]9[[O *Y=!)_-R $9[/
MSY65CVG^"U:-Y.\%JN3]/J3D31S/#H.QA+>YRN! I[3':Y!Y#,"%]O/I;ZNH
MEU33=5[5-,F22WE>P+X+BX?3D J<AC2EB31M]\7:"8><&-=;+(5R!>*)\.DZ
MFG\]W-3B"\ [+XLT\./S_P ;V;K1W]E7[C,&_P#>M8-;:H/?8K2OR'R+5G;W
M?4/(D"FFC@LA()NTA=W).G?R*\J,F7*[*?MLT6Z34XZ?':)-5S2%(A91.QRY
M9:_7$A> W'8#\+)-D$1(90(U$Z#:#KK910A5O!M8AX6+25 #(,4N <-+>0T6
M*:Z_#+0?_095-5?7SUY'LV6D E?.ZRQR/@L>YWR>GN/SVKJT>_RF\* =_*6#
M7H_U2WM+X)FR(SHMAIQ9\V=7'E74GQ,O             '   /$   >(  /B
M#(,O)]Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1(&2\LUSZ1)>S%\1)[$2!2^5#_P! 1/M&:Q$GL1&(F%]J)K$N79Y?I&$B
M;+<4DD^Y3"4RK*4TEN*+30$H" *)C,.XARHF;Q!W4JW\)$N6&(K]/RJD E\"
M>'8_A=.2X^PL#^A]I+%['^UU^#/.\W7:W(^D[:W*I1Z@O.D ]>Y1=Z:]0YUK
M(_U@-5N6TJ>Q^Z#==J",T97ST48B6;=Z^[G(E)Q#%8%M-?>$G:HZD4SG:MYE
MLDLAT7!DA!5-I*L'+V'?*I@<Z+206733.LDF&57+XK-F=+,JT?M'#:-G&6:
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M!JW2+RI(-TB(HIE#XBD23*4A _D*4 RTKKKJ1:ZD2NM!TJ5JJ(H_DJJ H']
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M?'LUL01\.UGR9MGX:W5?7OYYZMFJITNRXJPS<;QMB?*M0CJIU:4;Y&W0@<,
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ML1'7L?FJ$_6!_P#NUB(Z]C\U0GZP/_W:Q$=>Q^:H3]8'_P"[6(CKV/S5"?K
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-C$1B(Q$8B,1&(G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g374624g43v59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g43v59.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1DZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &1Z^9# X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              >T   *-    !@!G #0 ,P!V #4 .0
M  $                          0             "C0   >T
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   >T     4F=H
M=&QO;F<   *-    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   'M     %)G:'1L;VYG   "C0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     #L4    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MDD.<!8X EL1O$^_Z/YR?,Z?5F;?4LNKV @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M_^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0  !P<G1R0TU92TQA
M8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M 0  ]M8  0    #3+4%$0D4
M                          ID97-C    _    '1C<')T   !<    "MW
M='!T   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "CN
MH@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT  ?O
MW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                         '1E>'0     0V]P>7)I
M9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:  "\
M9P  DC!M9G0R      0#"0   0                    $
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M\=+[U ;5$M8>URK8-]E$VE';7MQKW7G>AM^4X)SAHN*HXZWDLN6VYKKGO>C
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MAR=7BI3OAF9 O)+NA>@FCI(XAEL$+Y"T@M2Y?*,;E?6F_9^CDWJ3_YQ9D3F
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M*8$%DE%R&X"PD"U<-8"$CE1% (!HC+PJ>("$C D&HX#FA'W ,('MH[ZMN(%
MH)::5X"KG62&%( XFD5Q''_GEUI;47^VE,)$1'^ADK0IUW^PDA,&1'_^A#V_
M1(%)KC>LRX"?JDZ99( %IDN%('^.HEMP/7]$GKA:DG\8FX)#IG[VF2(I47[X
MET(%]G\_A B^D(#.N-JL$( FM#*8F7^$KV"$3G\"JI]O<WZWIDY9V'Z5HJE#
M#'YWH' HWWY>FX(%MGZC@]R^%(!XP\&K@G_3OF.7['\DN,&#DWZ3LS5NQGY
MKDE917X@JG-"DWX'IS H>7WFFUX%@WXF@[JW7)%7;[&F-8^><.V4(8X<<A*
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MHYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (  @ !_<KG_;6QQX;7
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M?H-8>7[X?HU!NG\G?I(G;G^.?GP$8H"1?I*WO'V4B-6F7'V&A^Z4#GU\AOZ
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M%'F#K>EH.7FHJ9=3C'GNID$]EWH:HWPD"WG-F%\"_'M>@@2LV(N]:=J<^8J
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MN*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (  @ !J,K\#9K1=SKM
M: Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,  )\$<[   (  @ !I
M[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8  )W
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MRFE3E0ITIFM'DH5>I6TAD#-'@FZFCBDM:6[FC,4*:'&$APG#MF']J!.PU&1
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MQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\>T\;]Y1G>S$$=)'
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MC\H'?'-9A1"VCEE_JPZE!5QBIWR2G%[^H[Y_7V%VH AK;F/GG)E6K68LF8]
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M9&@@YY\398H+^Z&[91H  (V4;=(  (  @ !DLZ3,8R=9IJ*.9/%-DZ!M9K!
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M;=T&N72C;L6S*EW.9&&B<6":9JR0U&,V:.9^2V6N:Q!JNF@-;2A6'FI ;RY
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M7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)<"I"98L%<3PS[(J
M<B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:EHJ\=A5.FXGQ=L)!
MGHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (  @ !D]XGB?/!9[HDP
M?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4  ( ;@    (  @ !D
M6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (
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MB))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (
M@    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'
M<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ79
M7/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(N
MA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (  @ !//:938>]%+:26
M8XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.
MQZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (
M??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X
M-98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7
M=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/?; L
MMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#2IQS
MA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (  @ !,
M\9TIBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8  (
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M8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (
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MIHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (
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M]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (
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MGI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (
M<?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"
M!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!
M:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P
M=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG
M=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/
MXH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (
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MFYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (
M>:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\
M (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,
M;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E
M3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:
M=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#
MR9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (
M@    (  @ !#@)$$A,8Z)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@
M ()Q@    (  @    (  @ ">^U/53=6/R%<(4AV !%HB5E!O7%TL6F-=I6 9
M7E%*OV*U8A$V<61C98$>7V.69_0!>WV :QF<T4Z%6 B.%%(N6V]^A%6R7KYN
M"%D18?)<;UQ#909)JU\'9_8U@&"8:I\=K6 R;'8!BWUD;\^:VDFL8CZ,.TW
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M 4F)A]17.TV3AQ5%7%"MAGLR+E$UAB$;9U7*AI(!PGT(@3"2]3@&E#^%93W
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M6MLAE'Z 70T,S("@77@  (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5
M*GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N
M7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@
ML&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (
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M8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (
M@    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$
M<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q
M7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU
M/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B2
M8_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4
M&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (
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M[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (
M;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8
M (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?4
M8(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ
M 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/
M9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'
MNGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (
M@    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP
M (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$
M>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G
M.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM
M2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _
M-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (
M=0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX
M (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#7
M82H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=
MF8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB'
M:H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (  @  [
M%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (
M@    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL
M (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<
M?BX"B8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF=#(
M    ! ,)   !                     0                    $   $
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M@2:JJ(N?@,2DBG41@(.>55ZG@%27T4AI@%.0V3)@@'*(^^/6@P[(I<X%@B3
MXK?&@5>Y4Z%*@+^Q^HK0@&&JNW1K@"ZC7%XI@ >;E4@"@ >3.S(7@#")_N,
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MHYR#<*OBG_*"?)G.G'.!M8=NF1^!)73%E>^ TF(*DL> KD^)CX^ ICUNC#6
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MB5X:CRJ>I$R9C""7@3N?B1R0%"O%A?2(B;"=KBAZ)I^*J<UZ"8Z.I7YZ&WV
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M>;F$S]HM>C2#RL,J>K."Z*O/>SN",I0T>]"!JGR(?':!0F3A?2Z XTU5?A"
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ML(F#ZHI=J^*"]GO2IT*"*FSHHK2!G5WAGB"!/D[SF7>!!D""E)^ XC+'CXJ
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MA.&$RK0 A"V$ J&B@X&#0HY:@O6"GGK%@GF"&F<;@A>!K%.?@<J!1$!A@9V
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MO0."D&U<MX&!N6&AL<F!#U7GJ]> HDH\I;& ;3[EGU* 6#1%F+" 62J8D<^
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M6##I>KR#,M)8:DFC&+[/; ^?=JK(;<F;R)94;XB8(X&K<5^4C&ST<U:0]EB
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MC]N#[Y%(CAF#<H)TC&Z"[G,DBM*":F-DB5"!^U.EA]B!ED1#AE^!-#59A/>
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MAG5GD-&@2V=&CD6;RUDJB^"724M$B:&2P3W[AV..+3%CA4")@"8T@R6$](B
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M[B'.B@%]'WPEK;]WK'#(J9EX!64?I5AX?%D:H/QY)$T"G'UY\D$2E]QZZ#7
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MZB40@;.$&X!"H QD6W3VG3AFOVDDFH)I(5S+E\)KC5 ME-UN%4.4D=MPRS>
MCK]SJRP#BY5VWB'8B&YZ9'^ZGKIK_720F_1MF6B]F3)O05QVEF1P_T_KDW]R
MW$-JD(ITXC=SC8!W"BPDBFUY<R(XAU]\$G\VG3)S8W/QFH-T4V@ZE\=U3EOX
ME0)V84^)DBQWD4,KCTUXXS=;C%MZ3BP^B6-[Y2*,AG)]G'Z>F[5ZFW-)F1-Z
M\V>'EFA[3%MPD[![M4\7D/)\-$+@CBM\R3<[BU-];RQ/B'A^,"+5A:1^_WX$
MFG:!P7*QE^"!B&;OE3V!0EK<DHV ]DZSC]F NT*6C2J D#<:BFF :BQ<AZF
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M[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU
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M5ZN#Q*"76T6#1)!@7KR"P7^?8B^"0&Z49<R!R5U6::2!9$Q];:V _CP9<@B
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MD,& Z5GBCS6! %#IC6> WT>^BVV ICZAB7: ?C78AXV ;BV[A;. ;B9(A!2
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M7,:!Y()27_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N Z3]2<0: N3*@=2F
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M9T(1=XUZ@S;K>9)[L2QL>\E\^R-3?@]^5WEQ;5E\[V\0;Q=]:&0C<,%]NEC
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M@DU^IR2P@=A_/!]G@85_OUJ'A4:!<%*EA/V!@4J/A&B!5$)<@Z*!$CHT@MV
MY3)0@C> RBL_@9. Q"3;@3* L!^7@0R BEHSA$B'2%*!A">&ZTIY@Z:&"4)?
M@L^$]#IB@?N$#C*@@5J#32M\@-^"I23]@+*!ZA^]@*R!+U3<G(94(TV+FEI7
MUT7[F"!;KSX?E:Y?P#8FDOYD%BY@D#5HL2=%C6UM?"#OBLQRBAO2B'YWFE0$
MFCQ::DS>F%-=IT55EBIA"CVDD[EDGC7ID0]H:"YACEUL;">%B[5PE2%AB3]T
M]QQMAR!Y4E-]E[]@E$Q,E?QC6D39D_UF/3TYD:=I4C6LCR%LC2Y:C)EO^R>W
MBA]SA2'"A]QW.QSRA>]ZX5,(E5)FHTO)DZ]H[$1.D=!K43S<CZAMVC5RC5!P
MBRY.BOIS7R?;B+-V2B(0AJ9Y51UDA.E\1E*)DRELI4M.D;-N=$/GC^YP4SR#
MC=YR135.B[-T9"Y)B8MVHB?WAW=XZR)0A9I[1AW%A I]@5(-D51RHTKBD MS
M^$.6CF-U2CQ-C&EVIC4OBE1X'RY7B$EYO2@8AF%[9"*%A+1]#1X6@U!^DE&A
MC\IX=4J(CJQY44-4C1MZ$#P<BS1ZSS4+B39[JBY0AT9\H2@[A7-]IB*U@_)^
MH!Y8@K=_>5%*CH=^&4I!C8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@X
MA+I_JB+=@U!__QZ.@CJ .5$1C7^#FTH-C*"#?4+TBSV# #OEB6N":S3]AW^!
M_"Y1A;R!J2A4A!N!:2+]@M&!(!ZY@=> U:(U5IM/JI/D6BE4(X5"7;]8F'8=
M87A="V:'96AAAU;&:9IF(T=F;@IJ]CAW<MIP+2K'=_MV!* H4<I9GY)-5=I=
M,(/A6>Q@NG3L7AAD0V5]8GQGU%7J9R-KA4:^; UO9S@:<5ASIRK/=NIX;)Y-
M37%CBY"34?EF*()M5G=HPW.76PMK8F1>7]5N#E4&9.IPV$8=:D1SRC?(< !W
M"RK7=?AZL9QW28-M58[B3GQO!8#64UAPNG)46$AR<F-(77ET.%0O8O)V%T6,
M:+-X%3> ;M1Z3RK>=2)\SIJT1?YV^XU@2V!WR7^"4)QXFW$:5>!Y;6)M6V9Z
M2U-]83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \
M4]> 0F&H6:> -%+\7\F -$2W9C> /#<5;/J 4RKH<\V >9?B0$R)O8L-1F&(
MPGVD3#Z'R6^14AN&T6$/6#&%W%*#7I6$ZD1T94&#]S;S;$."_"KL<TJ!_I;?
M/A^2LXHY1'J0QGS]2I:.X&\/4*N- V"B5OJ+*U(?79F)3$0L9'V'8C;8:ZV%
M7BKO<MZ#2Y8H/'6;(8F>0P"8.WR!24>5:FZR3X:2LF!A5?Z0 U'T7,>-0T0$
M8]>*:S:[:S2':BKR<HB$89=D765/_HH98&%4:7QM8W-8T6X[9JE=-U^<:A!A
MJU#=;;9F14*)<9EK&#2T==QP5B@O>F=V,)5Z6,=9:HC'7$E<_WM;7\U@CVU;
M8VMD'E[B9SMGM5!,:TYK;D(F;Z%O6#2+=%ASJ"A,>4]X?9.Z5)IBS(<86))E
M@WGN7'QH-FP-8'UJZEW,9+-MJD]R:3%PBD&/;?!SDC1&<PUV["AE>%=ZII((
M4-)L$(5_53)M['AS67=OR&KI7=%QI%S28FMSBDZU9TMUBT$4;&UWJS00<>9Z
M""A[=WU\II!V375U-X0<4C!V/W<S5LYW0VG!6WMX0UP(8&AY34X39:1Z;$"L
M:QY[GS/F<.A\^2B.=L%^>8\C2HY^/(+U3Y=^<78X5(-^FFCH67Y^O5M*7K5^
MY4V:9#A_'4!=:?]_8C/$<!!_MRB>=B& &8X/2!2'"X(&36.&:'5M4I"%LF@[
M5\V$]5JQ74>$/4TF8PJ#C4 D:0R"XS.N;UF"-2BK=9V!A(TY1@R/BX%+2Y..
M$'3+4/:,>6>S5F>*V%H[7!:)0$R\8A2'JS_?:$J&%C.<;L.$;BBU=3""NXRB
M1'J7EH#!2BN52'1.3[22SV=)54N03EGK6R&-VTR&84>+9C^O9ZJ(Z3-\;DZ&
M42B^=-F#O(R^9%U08X!P9LE4MW.Z:519#F9^; %=:%C>;MAAU4LE<>AF;3W@
M=3%K/S$E>-=P@"7 ?+UV6(KL7_A9,G\78N5<R'*19=M@6F6':.AC[E@0;"1G
MD4J&;YYK6SUV<U)O6#$!=U]SMB7Q>YMXBXE46_%B#7VG7U-DV'%]8JEGH&21
M9A%J:%=/::AM/TGZ;81P-CTD<9US5S#K=@MVRB8<>IQZF8?"6%%JSGPO7!1L
MSW 37\!NSV-Z8WUPS59@9W=RU4E(:[)T^CRS<"AW/S#"=.MYP29!>;Q\?H98
M51IS='KD62UTL&[G72MUXV)J83IW$56J98-X2DBX:A=YF#Q=;N!Z_#"H<^U\
MB29A>/Q^-H4J4E-[_'G75JU\=&W\6O)\V&&:7TI],E3X8]I]DDA*:+%^!3P;
M;<-^B#"3<Q1_'29[>%E_O80V3_>$37C]5(R$ FT\60V#DV#R7:2#%%1D8G2"
MG4?=9XB",COM;-"!TC")<EN!<B:1=]&!$(-Y3@:,5'A44LV+1FR@5W^* F!K
M7$6(IU/K84F'5T=T9I:&$#NM;!"$T#!_<<2#@R:C=V*",(+T3(*3]'?747*2
M,&PG5D:0%E_\6R^-W5.58%>+LD<Z9<N)D#MZ:W*'<#!?<5&%0B:Q=PJ#'X(;
M:XY0PW:V;6U4_FKN;W!90UZK<8]=E%(.<\YA_D5E=CYFESD\>-]K:BVM>])P
MKR-[?OAV>X!B9V%9 '5Q:;A<DFG?;!M@)5W.;I-COU%=<2]G;D3D= )K1SCO
M=P=O4RVC>EESP"/ ?<QXEG[O8XMA2'059DYD(VC/:0IF_ES>:]=IW%"C;LQL
MSD1@<?UOXSBF=6!S(RV:>0EVL2/\?,-ZBWV(8 UIB7+"8RUKJ&>:9CMMQUP.
M:59OZD_[;*1R%D/R<"MT8#AS<^1VS"V;=]]Y=B0Q>]U\5GPZ7/QQL7&I8&=S
M&6:58\!T>EL,9R9UUD]):L!W/T-D;IUXP#@?<J1Z6"V(=N1\&21=>Q9]]7LG
M6E-YNW"M7?UZ<&6U89A[#EI&941[H$ZD:2%\/$,";3Q\[3?J<8E]KRU_=@A^
MA22">F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'
M<)6 Q"V =4R M"2A>>2 H'F;5BZ)&6])6D"(;F1Q7C^'?EDI8E&&<$VI9IN%
M;D(^:R>$>3>/;]2#D"U]=+*"H"2Z>7.!K7D>5+202F[66.V._6/^70Z-15B^
M84"+8$U59:N)B4(':EV'P3=@;S>& BUC=$"$/B3.>1B"BG=L<P91!6SQ=%=5
M*V(<=<Q99%;5=U5=L4M">/!B'3^R>K%FO32O?)AKF"I7?L1PX"%D@1-VF778
M;QA8O6O/<-5<3&$N<IY?XE8;='-CA4JV=F)G0S]6>'YK,#2&>L%O3RIL?41S
MRR&]?]IXG72':W%@@FJ4;9)C:F T;ZUF5E5!<=%I2TH.=!-L6#[C=H9OC#1/
M>2%R["IU>_)VEB(*?LAZ>W-,:!YH.6EG:I)J=5\7;/ELM51\;V1N^TEL<?QQ
M4SY[=,)SRS0A=ZYV92I_>LEY.")-?=E\+W(?92EOXVA29^5Q<UX@:I!S %.B
M;4)TBTCV<!YV*3XJ<S)WX30$=F9YL"J0><1[J2*%?0Q]MW$A8IQW=F>"99=X
M85UP:']Y-U+Z:W!Z!$A>;HEZWCW1<=A[TC/5=4M\V"J0>.9]\B*U?&!_#W!3
M8&M^TF;%8YQ_&5S'9KE_-5)E:>!_0$??;3%_5SUY<+5_@C.Z=%=_O2J9>"A_
M_2+<>]& .&^P7IF%Y68T8?>%C5Q!94&$[U'P:).$,T=X;!&#A#TA;\F"YS.-
M<Y6"62J@=XJ!QR+\>UV!,F\Y722,JF7'8*J+OUO69!:*95&.9XB(VT<N:R6'
M8#SS;P"%^3-G<OB$GRJ.=Q>#1B,5>P"!_VS2>LU1%6-*>X=5+EEM?&)98$\I
M?45=KT2D?BUB)3HP?RUFU3!5@$IKOB<X@9IQ#A^ @P1VLFMH=Q]856)$>#Q;
MY5B5>5Y?@TZ$>H)C-40O>[-G"3GN?01K#S!*?G)O1R=H@!)SUA_L@;]XHFI
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M9SV"N5TY:>Z"K%0O;'R"7$K>;OZ!\D%V<9R!G#@Z=&J!7"_ =T*!+B?U>C^
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M_P  ;69T,0     #!"$   $                    !
M     0    $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)3
M5%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^
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M14#_H$M3^Z5*8_&I27+GK4J!WK!-D-6P59S.L%ZGR;!HK\:R<[/#LGRXO;"
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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M:&;/I6YUQ9UU@;R6?(NUD(.4KHJ+FZB&DJ"C@IJEGH"BJ)M^K*J8?KBKEG[
MJY1_P*J3@,&HDH#"J)* PJB2@,*HDH#"J)* PJB2@,*HDH#"J)* PJB2@,*H
M_XDG"?^*.!?_F#\@_Y\_*?^E03+_JD4Z_*Y)0?*Q3TGIM590X;=?5]6Q967*
MJ&QTP*%S@+>:>HNOE(&4J(^(FZ**CZ"<AY>EEX2@J)2"J:J1@K6KCX*_JXZ#
MP*J-@\&IC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&H_XHG
M"?^+.!?_F3X@_Z$^*/^F0##_K$,X^;%(/_"U3D7GNE5+WKM>5-"T9&7%K&MS
MNZ1Q@+&>>(JIF'Z3HI.%FIN/C:"6C)6ED8F=J(V'IZN*A[*LB(>_K(B'P*N(
MAL"IB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&H_XHG"?^,
M-Q?_FST?_Z(])_^H/R__KD(V][1'/.VZ34'DP%9&V;]<4\NW8V3 KVESMJAO
M?ZRB=8JDG'R3G)B#FI64BJ"/D9*EBHZ;J(:-I*N#C*^L@8V]K(*,OZN#BL"I
M@XK!J8.*P:F#BL&I@XK!J8.*P:F#BL&I@XK!J8.*P:F#BL&I_XLG"?^.-Q?_
MG#P?_Z,[)O^J/2W_L4 S]+A%..J_3#SBQU5 T\):4L>Z86.[LV=RL*UM?J>G
M<XF>H7J2EIV F8^:B)^)EY"DA)28J'^3HJI\DJVK>I*ZK'N1P*M]C\&I?H[!
MJ'Z.P:A^CL&H?H[!J'Z.P:A^CL&H?H[!J'Z.P:A^CL&H_XPG"?^/-A;_G3H>
M_Z4Z)?^M.RO\M#XP\;Q#-.?%3#;>RU(_SL994<*^8&*VN&9PJ[%L?:&L<HB8
MIWB1D*-^F(F@A9Z"G8VC?9N6IWB9GZEUF*JJ<YFWJW28P*IWE,&I>)/"J'B3
MPJAXD\*H>)/"J'B3PJAXD\*H>)/"J'B3PJAXD\*H_XPG"?^1-1;_GS@=_Z<X
M(_^O.2CYN#PL[L)"+N7-3"W8T$\]R<E74+S#7F"PO&1OI;=J?)NR<(:2K7:/
MBJE\EH*F@YQ\I(NA=J*3I7*AG:=OH*BI;:"UJ6V@P:APF\*G<IG"IW*9PJ=R
MF<*G<IG"IW*9PJ=RF<*G<IG"IW*9PJ=RF<*G_XTF"?^4-!7_H38;_ZHV(?^S
M-B7UOCDGZLE )N#622C1U4X\P\Y63K;(7%^JPF-MG[UH>I2X;H2+M'2-@[%Z
ME'RN@9IUK(B><*N1HFNIFZ1HJ::F9JFSIF:JPZ5II,2E:Z'$I6NAQ*5KH<2E
M:Z'$I6NAQ*5KH<2E:Z'$I6NAQ*5KH<2E_XXF"?^7,Q3_HS0:_ZTS'OZX,B#P
MQ34@X],_'-C>12;*VTTZO=-43+#.6UVCR6%KF,1G=XW ;(&$O7*)?+IXD'6X
M?Y9OMH>::K60G66TFJ!BLZ6A8;2QHF"UPJ%BK\:B9*O&HF2KQJ)DJ\:B9*O&
MHF2KQJ)DJ\:B9*O&HF2KQJ)DJ\:B_Y F"?^;,1+_IC$7_[$N&O>^+1KGSC$7
MV=XY&<WC1"C"X$TXM=M32JC565J<T%]HD,QE<X;):WU]QG&%=<1WBV[#?I!I
MP8:49,"/EV# FII=P*6;6\"QFUK!P9M;O,J<7;?*G5VWRIU=M\J=7;?*G5VW
MRIU=M\J=7;?*G5VWRIU=M\J=_Y$F"?^?+Q'_JBT4_[<H%>W()A+:W"D.S.0V
M'<'F0"ZVXT@^JN!.3)[=5EF2VEUEB-9C;W[4:GAVTG!_;M!WA6C/?XECSH>-
M7\Z0D%O-FI)9S:635\ZRDU;/PI-6R]"45\7/E5?%SY57Q<^55\7/E5?%SY57
MQ<^55\7/E5?%SY57Q<^5_Y,F"?^C+ [_L"8/]< ?#=_5&P?-Y"<3P>LT([7J
M/3.IYT5"G>5+4)'C4ER&XEAF?.!?;G3?9G5LWFUZ9MYU?V'=?8)=W(:%6MN/
MB%C9F(I6V*&+5-BLBU38MXQ3V,F+4];6BU/6UHM3UM:+4];6BU/6UHM3UM:+
M4];6BU/6UHM3UM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC [B87M/ R**CN.SB<
M[4-&D>Q+4H;L4EQ\ZUED<^M>:VKJ9'!EZ&QU8>9T>%[D?'M;XH-]6>"+?U;?
MDH%5WIJ#4]ZB@U+=JH11W;:$4=V_A%'=OX11W;^$4=V_A%'=OX11W;^$4=V_
MA%'=OX11W;^$_Y\A!O^P&P7IQ0T#T-D+ L#N& RS]B8<I_4Q+)OU.SJ0]41'
MA?5,47SU4UIS]5E@:_-?9F7P9FIA[6UM7>MT<%KJ>G-8Z(%T5N>'=E3FC7A3
MY91Y4>2;>E#DH7M/XZI\3N.P?$[CL'Q.X[!\3N.P?$[CL'Q.X[!\3N.P?$[C
ML'Q.X[!\_Z@< NN\# '-S D P> ,!++Z&1"E_"<@FOTR+H_]/3N%_D5%>_]-
M3G+_5%5K^UI:9/A@7V#V9V)<]&UE6?)R9U?Q>&E5\'YJ4^^#;%'NB6U0[8]N
M3NR4;TWKFG!,ZZ%Q2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+
MZJ9R][,- ,S#" "_T0@ L>\.!J3_&Q.9_RDACO\T+H3_/SE[_T=!<?].2&K_
M5$YC_UI27OY@5EK\9EA7^VQ:5?IQ7%/Y=EY1^'I?3_=_8$[VA&%,]8EB2_6.
M8TKTE&1)\YIE2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF
MS;L% +W'!@"QV <!H_\0")C_'Q2-_RP@@_\W*WK_031P_T<[:/]-06'_5$5<
M_UI)6/]?2U7_94U2_VI/4/]N44[_<E),_W=32_][5$G_?U5(_H161_Z(5T;]
MC5=$_9-81/R6643\EEE$_)991/R6643\EEE$_)991/R6643\EEE$_)99O;\$
M +#.! "BX 8"E_\3"(S_(A.#_RX=>?\X)6[_/BUF_T4R7_],-UG_4CM5_U@^
M4?]=0$__8D),_V9#2O]J1$G_;D5'_W)&1O]V1T7_>DA#_WY(0O^"24'_ADI
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MFI:!BY22B)&.CY"6B8R9FH2*HIV!BJV??XJ[GWZ*R)Y_B<F=@(C*G("(RYN
MB,N;@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;_X$B!O^)+@__F345_Z(X&_^I
M.B#[L#TD\+A"*.:_2BK=PT\TSKU61L*V7E:WL&5DK:EK<*2D<7J<GWB#E)M^
MBHZ7AI"(E8Z5@I*6F7Z0H)QZCZN>>(^XGW>0R9YYCLJ=>HS+FWN,RYM[C,N;
M>XS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;_X$B!O^++0[_FS04_Z0W&?^L.![X
MM#HA[;U (^3&22/7QTPSR<%51;VZ7%6RM&-CJ*YI;Y^I;WF6I7:"CJ%\B8>=
M@X^!FXN4?)B4F'>7G9MSEJB=<9:UGG"6QIURE,J<=)++FW61RYIUD<N:=9'+
MFG61RYIUD<N:=9'+FG61RYIUD<N:_X(B!O^-+ W_G303_Z8T&/^O-1OTN#<<
MZ<,^'.#-11_1RTLRQ,540[B_6U.MN6%AHK1H;9FO;G>0JW2 B*=ZAX&D@8U[
MHHF2=:"1EG">FYEMG::;:IVSG&F>PYQKG,N;;IC,FF^7S)EOE\R9;Y?,F6^7
MS)EOE\R9;Y?,F6^7S)EOE\R9_X,A!O^0*PW_H#,1_ZDR%?VS,1?POC07Y<L[
M%=K4/QW+STDPOLE20K+$65&GOV!?G+IF:Y*V;'6)LG)^@:]XA7JL?XMTJH>0
M;ZB/DVJGF99GIJ289*:QF6.GP9EDI<V89Z#-F&B?S9=HG\V7:)_-EVB?S9=H
MG\V7:)_-EVB?S9=HG\V7_X0A!O^3*0O_HC /_ZTN$OBX+!+KQB\0X-4X"]+:
M/1S%U$@NN,]00*S*6$^@Q5Y=E<%D:(N]:G*#NG!Z>[=V@72U?8=NLX6+:+*.
MCV2QF))AL*.47K"PE5VQOY5=L="48*K0E&&HT)1AJ-"48:C0E&&HT)1AJ-"4
M8:C0E&&HT)1AJ-"4_X8A!O^7* K_IBP-_[$H#O+ )@SCT"@'U-\R"\G?/AF]
MVT<LL=9//:315DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W ?()HOH2&8[V-B5^\
MEXQ;O**.6;ROCUB]OHY7OM2.6;;3CUJTTY!:M-.06K33D%JTTY!:M-.06K33
MD%JTTY!:M-.0_X@A!O^<)PC_JB<*_+@A">G*&P75WB $R>4P#[[C/1VTX48L
MJ-Y..IS:54B1UEM5AM-A8'S09VETSFYP;<UU=F?+?'MBRX1^7LJ-@EK*EX17
MRJ.&5<JOAE3+OH93S-6&5,39B%7!V8E5P=F)5<'9B57!V8E5P=F)5<'9B57!
MV8E5P=F)_XT=!?^B)0;_L!\%\L(4 ]G;#@')YB 'O>@O%++G.B*GY4,QF^-*
M/I#A4$J&WU=4?-Y>773=961LVVQJ9MMT;V':?'-<V81V6=F.>579F'M3VJ-\
M4=JP?5#;OGU0W--\4-3@?E'0X']1T.!_4=#@?U'0X']1T.!_4=#@?U'0X']1
MT.!__Y4: _^I'P/[NA("U,T+ ,GF#P*\[2 +L.TN&:7L.2>:ZT(UC^I)087I
M4$M[Z%=3<NA=6FKG8V!DYVIE7^=R:5OG>FQ7YX)N4^>+<5#GE7).Z)]T3.BJ
M=4OHM79*Y\-V2NC==DODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U
M_YT6 ?^Q$@'3PPD Q]$* +OR$02O\R$/H_,N'9GS.2J.\T(VA/-*07OS4DER
M\U=0:?-<5F/S8UI=\VE>6?-P857S=V-2\W]F3_*'9TWPCVE+[YAK2N^@;$GN
MJ6U([K-M1^W ;D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';D;MQVY&[<=N_Z</
M -.Z!P#%QP< NM8) *WZ$P:B^B(2E_HO'XW[.BN#_$,U>OU,/G']445H_59+
M8?Y;3US^8E-7_FA65/UO6%'[=5I.^GQ<3/F#74KXBE](]Y%@1_:984;VH&)%
M]:=C1/2Q9$/TM61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5DUK($ ,2^
M!@"WS 8 K-P) :#_%@B5_R44B_\R'X+_/"EY_T4R;_]*.6?_3S]?_U5#6O];
M1U7_84I2_V=,3_]L3DW_<D]+_WA12?]^4D?_A%-%_XM40_^154+^F%9!_9Y7
M0/VF6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E8QK@$ +;$! "J
MTP4 GO(- I3_&@F*_R@3@?\T'7?_/"5M_T(L9?]',EW_3397_U,Z4_]9/4__
M7S],_V1!2O]I0TC_;D1&_W-%1/]Y1D+_?D=!_X1(/_^*23[_D$H]_Y5+//^<
M3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],M[P# *G+ @"<VP,
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M7^=TT%_G=-!?YW307^=T_VPC!/]K,0K_<SL4_WU"'?^"2B?_A%$R_X-9._^
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M8$'SYV!!\^A@0?/H8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@WJ<" ,NV!0"]P04
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M;$^][&Y0N>QO4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO_XD0 ?^=#@#:KP@
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M<%Z:ZW!@ENMO897L;V&5[&]AE>QO897L;V&5[&]AE>QO_W<2 ?^)$0'_F1$
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M1$#JY$1 Z/5$0.?X0T#G^$- Y_A#0.?X0T#G^$- Y_A#S:,  +VN 0"PN $
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M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP  <.,  &?_! !>_PT
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MICT2NJ%('K*=42JJF%DTHI1A/IR0:$66C&],D(EV4HN&?5>&A(5;@H*-7WZ
MEV-Z?Z%F=WZL:'5]NVES?LYI<W[H:'1^\69T??)E=7SS9'5\\V1U?/-D=7SS
M9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0; J3L1
MMJ5&':VA4"FEG%@SGIA?/)>49D20D6U+BXYT48:,>U:!B8-;?(>+7WB&E&)T
MA)]E<8.J9V^#N&EM@\MI;8/F:&Z#\F9O@O)E<('S9'"!\V1P@?-D<('S9'"!
M\V1P@?-D_VL4 ?][$@'_BA( _Y82 .VB$ #>K0X T+$9 ,6P*P6[K3D/LJE$
M&ZFE3B>@H58RF9U>.Y*:9$.+EVM*AI1R4("2>55[CX!:=XV)7G*,DF%NBIQD
M:XFH9VF)MFAGB<AH9XGC9VB)\F9IA_-E:H;S9&J&\V1JAO-D:H;S9&J&\V1J
MAO-D_VX2 ?]^$ #_C1  ]YH. -NG"@#3L L RK06 ,"T*02VL3<.K:Y#&J2J
M3"6;IE4PDZ-<.8R@8T&&G6E(@)IP3GN8=U-VEGY8<92&7&R2D&!HD9IC99"F
M96.0M&9AD,9F89#A9F&0\F5CCO-D9(ST8V2,]&-DC/1C9(ST8V2,]&-DC/1C
M_W$0 ?^"#P#_D0T WI\) -.J"0#,LPD Q+@3 +JX)@.QMC4,I[-!&)ZO2B.6
MK%,NCJE:-X>F83^ I&=&>J%N3'6?=5%PG7Q5:YR$6F::CEUCF9A@7YBD8EV8
MLF1;F,-D6YC>8UN8\&-<E?5B7I/U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B_W4.
M /^&#0#KE@@ U:,' ,RM" #%M@< O;P1 +2](P*KNS(*H;D_%9BV2""0LU$K
MB+!8-("N7SQZJV9#=*EL2&^H<TYJIGI29:6"5F&CC%I=HI9<6J*B7U>AL&!6
MH<%@5:+<8%6A[V!6G_=?5YSW7U><]U]7G/=?5YSW7U><]U]7G/=?_WH, /V+
M"0#:FP0 SJ<& ,2P!@"\N00 M<$. *S"( &DP3 (FK\\$Y&]1AV)ND\G@;A6
M,'JV73ASM&0_;K)J1&BQ<4EDL'E-7ZZ!45NMBE18K9575*RA65*LKUM0K,!;
M4*S:6D^K[EM/JOI;4:;Z6U&F^EM1IOI;4:;Z6U&F^EM1IOI;_X ) .&2 0#1
MH 0 QJL% +RT! "SO0, J\<+ *3)' &<R"P&D\<Y#XK%1!F!PTTC>L%4+'._
M6S-MOF(Y9[QI/F*[<$->NG='6KF 2U:YB4Y3N)104+B@4DVXKE1,N+]42[G8
M5$NW[51*MOE52K/^5DJS_E9*L_Y62K/^5DJS_E9*L_Y6^H<" -:8  #)I0,
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M+S;Q\R\V\?,O-O'S+S;Q\R\V\?,ON:<  *NP  "?NP  DL8  (;0 0![W04
M=/<1 &WW' %F^"8#7_@O!EKY. I4^4 .4/I'$4SZ3A1(^U461?M;&$+[8AI
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M5UF4[%=9D_E66Y'^55N0_E5;D/Y56Y#^55N0_E5;D/Y5_W,) /6$! #8D0,
MS)P% ,.E!0"[K00 L[,, *NU' &CM"P%F[(Y#I*P1!>*K4T@@ZM4*7VI7#!W
MIV(V<:5I/&RD;T%HHG=%9*%_25^?B$Q<GI)/6)Z>4E:=JU-4G;Q44YW15%.=
MZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@( QJ$#
M +RI P"SL $ J[@( *2Z& "<NBD#E+DV"XRW012$M4H=?+-2)7:Q6BQPKV R
M:ZYG.&:M;CQBJW5 7JI]1%JIADA6J)%*4ZB=35&GJDY/J+I/3JC/3TZGZ4]-
MIO=/3:7_3TZD_T].I/]/3J3_3TZD_T].I/]/^G\  -B.  #)FP$ OJ4" +2M
M 0"KM0  H;\$ )O!% "4P24"C, S"(2_/A%\O4@9=;Q0(6^Z6"=JN5\M9;AE
M,F"W;#9<MG0Z6+5\/E6TA4%1M)!$3K.<1DRSJ4A*L[E(2;3.2$FSZ4A(L?9)
M2+#_2DBP_TI(L/]*2+#_2DBP_TI(L/]*XH8  ,Z4  #"H0  MJD  *NQ  "A
MN@$ F,,% )#)$ "*R2 !@\DO!7O(.PUTQT44;L9.&VC%5B%CQ%TG7L-D*UK"
M:R]6P7(S4\%[-D_ A#E,P(\\2L";/D? J#]&P+A 1<#-0$7 Z#]$OO9!0[W_
M0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0  K:X  **V  "8OP(
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M4&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],_V8* /]U" #A@0(
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M1U&6_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0  OYL! +2B  "KJ
MH;   )JR$0"4LR(!C;(P!86Q/ Q^KT84>*Y.&W*L5B%MJUPG:*EC+&2H:C!@
MIW$T7*9Y.%BE@CM5I(P^4:.80$^CI4)-H[1#3*/(0TRCY$-+H?1#2Z#_1$N@
M_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0  F;4
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M+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP  >\<# '#/!P!GU@T
M9-<: &#8*@%<V#8#6-A!!E382@I0V%(-3=A:$$K78A-'UVD61==R&$+7?!I
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M@@@A_Y ((/^="1__JPD>_[H)'?_)"1S_W0D<_]T)'/_="1S_W0D<_]T)F+
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M179K[4-V:_M"=FO_079L_T!V;/] =FS_0'9L_T!V;/] _UT* /]I!P#L= ,
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M06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P  QX@! +Z/ @"VE0$
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M.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@  D:P  (>Q" "!LA8
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MFA8VT:D7-=&[%S32TA<UT.P6-,_W&#/._QHSSO\:,\[_&C/._QHSSO\:LYD
M *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @ 3-T- $K=& !(WB8
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M!!C_J 07_[<$%O_(!!;_X 06_^0$%O_D!!;_Y 06_^0$DZX  (6W  !XP
M:LD  %W2  !0V0  1-\  #KD   U]P, ,O\, "[_$@ K_QH */\A ";_)P C
M_RT (/\S ![_.0$<_S\!&?]% 1?_30$5_U4!$_]? 1'_:@(0_W@"#O^' @[_
ME@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0  7M,
M %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q, 'O\9 !O_'@ 8_R,
M%?\H !/_+0 1_S( $/\X  [_/P ,_T8!"O]/ 0?_60$$_V4! ?]R 0#_@0$
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M-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_,X1<_S.$7/\S_U,* /]=!@#U9@0
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M<F?_-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=;@  SW8! ,=[ P#
M?P0 N8 , +&"&@"J@BH"HX W!9U]0@N7>TL1DGA4%XUV6QN)=&(@A7)I)(%Q
M<"=^;W<K>VY_+GAMB#%V;)(T<VN<-G!JJ#AN:K<Z;6K).FQJY#IM:_4X;6O_
M-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0  S'D  ,-^ @"[@@,
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M-5A^_S58?O\UZ6@  -1T  #&?@  NX<  +*-  "HD0  GI0  ):6#@"1EQP
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MF29#I*@G0J2X*$&DSB=!H^HG0*+X*$"A_RE H/\I0*#_*4"@_RE H/\IR7X
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M#S#,QP\PR^4.+\GU#R[(_1$NQ_\2+L?_$B['_Q(NQ_\2KI<  *&>  "5I0
MB:T  'RT  !PNP  9,$  %G&  !.RP, 1= ( #[5#@ ]U1H /-8F #O7,0 Y
MV#L .-E% 3;930$UV58",]I> C':: ,PVW,$+MM_!2S;C04JW)T&*=RM!BC=
MP08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0  ?K0
M '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ NYC,
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M 03_O $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@  6L\  $O5   _W
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M))U*\"2;2OTEF4O_))E+_R282_\DF$O_))A+_R282_\D_T@, /]/" #_5@@
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M+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @# < 0
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M+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@  IGX! )]_$ "9@!\
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MFBE0@J<J3X*W*TZ"S"M.@N@K3H'X*D^ _RI/@/\I3X#_*4^ _RE/@/\IVVH
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M'CV?QAX]G^,=/9WT'CV<_Q\\F_\?/)O_(#R;_R \F_\@PGP  +6(  "ID
MGI8  ).;  "'GP  >Z0  &^H  !CK 0 7ZT1 %RM'P!:KBL 5ZXV 52N0 -1
MK4@%3JU/!TNM5PE)K5X+1JQF#42L;@]!K'@1/ZN$$SRKD14ZJZ 6.:NP%SBK
MPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@  EYL
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M B#2]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0  >;$  &VX  !@O@
M5,,  $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  BWR4 (> N "#@-P ?
MX4  'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;FK $5YL !%.?= 1/E
M[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@  2,H
M #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4[S4
M$_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GVV0 (
M]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](  #'8
M   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D "OXP
M  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP  _\X
M /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A   <
MY0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C  #_
M*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(  /^R
M  #_L@  _[( _R(I ?\C)P'_(R@!_R K ?\<,0'_&CT!_QA) ?\65@+_%&("
M_Q-N O\2> +_$H("_Q*+ O\2D@+_$ID"_Q*> O\2I +_$JD"_Q*O O\2M@+_
M$KT"_Q+' O\2U +]$N4"^A+Q O<2^@+U$_\"]!/_ _03_P/T$_\#]!/_ _03
M_P/T$_\#_R0G ?\F) '_)B0!_R0G ?\B+P'_(#H!_QY& ?\<4P+_&E\"_QAJ
M O\7=0+_%W\"_Q>( O\7CP+_%Y8"_Q>< O\7H0+_%Z<"_Q>M O\7LP/^%[L#
M_1?% _H7T0/W%^0"]!?O O$8^@+O&/\#[AC_!.X8_P3M&/\%[1C_!>T8_P7M
M&/\%_R<C ?\I( #_*2  _R@C /\I+0'_)S<!_R5# ?\C3P+_(5L"_Q]F O\=
M<0+_'7L#_QV$ _\=C /^'9,#_!R9 _L<GP/Z'*0#^1RJ _<<L0/V'+D#]1W"
M _,=S@/P'>$#[!WN ^D>^03H'O\%YA[_!N4>_P;E'O\'Y1[_!^4>_P?E'O\'
M_RL? /\M' #_+1L _RX@ /\O*0#_+S0!_RP_ ?\J2P+_*%<"_R9B OTE;0/Z
M)'<#^".  _8CB /U(X\#\R.5!/(CFP3Q(Z$$[R.H!.XCK@3M([8$ZR._!.HC
MS 3G(^ $XR3M!. D^0;>)/\'W"3_"-LD_PG:)/\)VB3_"=HD_PG:)/\)_RX;
M /\Q%P#_,A8 _S4< /\V)0#_-B\!_S0Z ?\Q1@'[+U("]RU= O,L: /P*W(#
M[BI[!.PJA 3J*HL$Z"J2!><IF 7F*9X%Y"FE!>,IK 7A*;0%X"J]!=XJR@7;
M*MX%UBKM!](J^ G/*_\*S2K_"\PJ_PS+*O\,RRK_#,LJ_PS+*O\,_S(7 /\U
M$@#_.!( _SL8 /\]( #_/"H _CLU ?<Y00'Q-DT"[#18 N@S8P/E,FT$XS)V
M!. Q?P7>,8<%W#".!MHPE0;8,)L'UB^B!]0OJ0C2+[$(T"^Z"<\PQ@G-,-@)
MR3'J"L8Q]PS#,?\.P3'_#\ Q_P^_,?\/OS'_$+\Q_Q"_,?\0_S83 /\Y#P#_
M/A  _T$4 /]#&@#_0B, ]4$N .T^.@'G/48!X3Q3 MTZ7@/9.6@$U#AQ!M$X
M>@?/-X$(S3>("<LVCPK*-I8*R#:="\8UI S%-:P,PS6U#<$UP W -L\.O3;F
M#KDV]!"W-O\1M3;_$K0V_Q.S-O\3LS;_$[,V_Q.S-O\3_SD0 /\]"P#_0PT
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M'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5   V5D  ,]; P#*6P8
MQ%H/ +M;'@"U7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<4V@1F5)O$Y=1=A65
M4'T7DU"$&9!/C1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.XB&$3_,@@T__((-/
M_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0 O5X-
M +5@&@"N82H J6 W J1>0P2?74T(FUM5"YA970Z56&01DE=K$X]6<A:-57D8
MBU2!&HA3B1R&4Y(>A%*<'X)2IR& 4K0B?U+$(WU2WB-\4_$B?%/^(7M4_R%[
M5/\@>U3_('M4_R![5/\@_TH  .E4  #:7   S&$  ,-D  "\9 ( MF,* *]D
M%P"I92< HV0T IYC0 2984H'E5]2"Y%>6@Z.76$1BUMH$XE:;Q:&6788A%A]
M&H%8AAQ_5X\>?5:9('M6I")Y5K$C=U;!)'96VB1U5^\D=5?](W58_R)U6/\A
M=5C_(758_R%U6/\A_TT  .57  #37P  R&0  +]G  "W:   L6<' *EH% "C
M:20 GF@R 9EG/02494<'D&1/"HQB5PV(85X0A5]E$X->;!: 77,8?5UZ&GM<
M@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:U25O6^TE;UO\(V];_R)O6_\B;UO_
M(6];_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;   K&H$ *1K$@">;"$
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MFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ_R-<:O\B7&K_(EQJ_R)<:O\BXUL
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M(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T>P
MJH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.)P!JCC(!9HT\ V.-1 5@
MC$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%&DJ&DAQ(AJ =1H:O'D6%
MPAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT  +IX  "O@0  I8<
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M#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@  DI<  (:<  !YH0
M;:4  &&I  !5K   2Z\% $>P$ !%L!P 1+$G $*Q,@!!LCL /[)# 3VR2P$[
MLE,".;); S>R9 0ULFX%,[)Y!C&RAP<OL98(+K*F""VRN DLLM (++#L"2NO
M^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ   9*T
M %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  QODP
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M  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   NS0
M)=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ.P '
MZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO  #L
M[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@  &]L
M !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@  ]3<
M /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #XT
M^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<   8X   $>0   SG
M   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:  #_(0  _RD  /\S
M  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT  /^S  #_LP  _[,
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M' #_(1P _Q\@ /\?*0#_'#0 _QI  /\73 '_%5@!_Q1C ?\3;@'_$W<!_A.
M ?P3B 'Z$HX!^1*5 ?@2F@'V$J !]1*F ?02K 'S$K,!\1*\ ? 2QP'M$M@!
MZ1/H >83]0'D%/\!XA3_ N$5_P+A%?\"X!7_ N 5_P+@%?\"_R4; /\F%P#_
M)!8 _R4< /\F)0#_)#  _R$[ /\?2 #_'50!_1M? ?D::0'W&G,!]!E\ ?(9
MA 'Q&8L![QF1 >X9EP'L&9T!ZQFC >D9J@'H&;$!YQFZ >49Q0'C&=4!WQKH
M =P;]0+8&_\"U1S_ ]0<_P/3'/\$TAS_!-(<_P32'/\$_RD7 /\J$P#_*1(
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M#J,W_PZB-_\.HC?_#J(W_PZB-_\._S<' /\[ @#_0 , \D(% .E""0#E/PX
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M%GU+_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $ M%8) *Q7%@"F6"4
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MFAIH6J<<9EJV'65:R!UE6N0=95KV'&5:_QME6O\:95K_&65:_QEE6O\9Z$\
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M'%9FPQU69M\=5F;S'%=F_QM79O\:5V;_&E=F_QI79O\:VUD  ,=B  "Z:@
MKW   *9S  ":<P  CW   (=Q!0"!<A$ ?',> 'AS*@!T<S4!<',_ VUR1P5J
M<4X'9W%5"61P7 MB;V,.7V]J$%UN<A):;7P56&V&%U9LDQE4;* ;4FNO'%%K
MP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P  ,-F  "V;@  K'0
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M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0  GX(  )*#  "%A
M>84  &J)  !DB@, 8(P0 %V-&P!;CB< 6(XR %6..P%3CD,"4(Y* TZ-4@5,
MC5D&28Q@"$>,: I%BW(,0HM]#D"*B0\^BI@1/(JG$CN*N!(ZBL\2.XCK$CN'
M^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<  (R(  !_B0  <XP
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M!26G_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@  7Z8  %.J  !(K0
M/;   #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ HMT, )[=, ":X50 D
MN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV\@$;M?P"&[3_ ANT
M_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@  -;D
M "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6Q54
M%<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0
MP_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$  "/%
M   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD "=-5
M  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !U?8
MCIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.   2
MT@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'  #B
M5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN< @Z0
M '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +W0
M!>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O10
M\%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT  &JU
M  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@   .H
M  #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0  _4,
M /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5(0#_
M$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"# /\
MB@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$ \@#D
M /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_%1T
M_Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#AP#_
M XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C .H!
M[P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4=
M /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH
M]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*\ #?
M"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;
M(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8 ZA",
M .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P VA#A -41\ #2$OL
MSQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_(0\ _R(4 /\B' #_
M("< _QTR /@;/@#R&4L [AA6 .H78 #G%FH Y!9R .(6>@#@%H( WA:( -P6
MCP#;%I4 V1:; -86H@#4%JD TA:Q - 7NP#.%\D S!C> ,@9[@'%&OL!PQK_
M L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8. /\E"P#_* P _RD0 /\H%@#^)B
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M"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8 Q#L/ +L^'0"U/RP
ML3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<.WL&FCN"!Y@[B@B6
M.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\_PV)//\,B#S_#(@\
M_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,, +-$&0"M12< J$8U
M *1%00&@14L"G413 II#6P.80V(%ED)I!I1!< >2078(D$!^"8Y A@J-0(X+
MBT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/@4'Y#X!!_P^ 0O\.@$+_#H!"_PZ
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MG!!V2:@2=$FV$G-)R!-R2N,3<4KU$G%*_Q%Q2_\1<4O_$'%+_Q!Q2_\0[$,
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M9U&Q%&91PQ5E4MX595+R%&52_Q-E4O\295+_$F52_Q)E4O\2Y$H  ,]3  #
M6@  M5X  *Q@  "B7@  FED  )):"P"-6Q8 B%PC (1<+P" 6SH!?5M# GE:
M2P-V65($=%A8!G%87P=O5V8);5=M"VM6=0UI5GX/9U:)$655E1)C5:$48E6O
M%6%5P19@5=L68%;Q%6!6_A1@5O\385;_$F%6_Q)A5O\2X$T  ,M6  "]70
MLF$  *AC  "=80  E5T  (U>"0"'7A, @U\@ ']?+ ![7S<!=UY  G1>2 -Q
M74\$;UQ6!6Q<7 =J6V,):%MK"V9:<PUD6GP/8EJ'$6!9DQ)>6: 475FN%5M9
MOQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%   ,=9  "Z8   KV0
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M%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@  I6\  )AN  ",;0
M@&P  '=M  !Q;@L ;6\4 &EP(0!F<2P 9'$V 6%Q/@%><48"7'!- UEP5 57
M<%L&56]B"%-O:@I0;G,,3FY^#DQMBA!*;9@126RG$DALN!-';,T31VSJ$TAK
M^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(  )-R  "'<0  >G$
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M##: _PPV@/\,MF\  *IX  "??P  D'X  (-_  !W@   :X(  %Z'  !5B@
M3HP& $J.$ !(CQH 1X\E $60+P!$D#@ 0I!  $"01P$_D$\!/9!6 CN07P(Y
MD&@#-X]S!#6/@ 4SCXX&,8^>!S".KP<OCL,'+X[A!R^,] @OB_\(+XK_""^*
M_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H  %J.  !/D@  1I4
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M;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT
M )"2  "$EP  =9H  &B?  !;HP  4*@  $6L   [L   ,;(  ">U   @N
M&+H' !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .ODP #KY7  V^90 ,
MOW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0  (>9
M  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0  $<0!
M  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60  RV@
M ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA  !O
MIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX   32
M @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H  -UJ
M  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !DL
M5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>
MWP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:  #M
M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0  2\
M #W%   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H    Z0
M .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\6P
M_6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@ /\
M* #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2
M /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M /<
M[ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#)0#_
M #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/ /(
ME #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4 XP#^
M .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_""T
M_P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H
M )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#] -4"
M_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT
M /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?!I(
MW0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'
M#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N /,0
M.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\ T V5
M ,X-G #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4 O1+_ +P2_P"[$O\
MNA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X&AL [A8F .84,P#@
M$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85A #$%8H PQ61 ,$6
MF # %I\ OA:G +P7L "[%[P N1?+ +<8X@"S&?(!L1K_ :\;_P&N&_\!KAO_
M :T;_P&M&_\!_R($ /\B  #_)0( _"0' /<A# #L'1( X1H< -@:*@#0&S@
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MH 6+-:L&BC6Y!H@UR@>'-N4'A3;V!X0W_P>#-_\'@S?_!X(W_P>"-_\']#(
M .,[  #200  QD0  +U#  "W/P  L3L) *H[% "E/"( H#TP )T].P"9/44
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M#&Y$P QM1=D-;$7O#&M%_0MK1O\+:T;_"FM&_PIK1O\*Y4   ,])  #!3P
MM5(  *M2  "A3P  FTH  )1*# "/2Q< BTPD (=,+P"$3#H @4Q# 7Y+2P%[
M2U(">4I8 W=*7P1U268%<TEM!G%)=0=O27X(;4B("6M(DPMJ2)\,:$BM#6=)
MO0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0  ,M-  "]4@  LE8
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M#E95^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7   IUX  )I=  "/7
MAE@  ']9  !Y6@T =%L7 '%;(P!N6RX :ULW &A;0 %E6T<!8UI. F%:50-?
M6EP$75IC!5Q::P9:670(6%E_"E99BPM469@-4UBF#E)9M@Y16<H/45GG#E%8
M^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$  )9@  "+7P  @5L
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M"T-E_PM#9?\+OUP  +%D  "F:@  EFD  (EI  !]:0  <6D  &=J  !B; $
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M> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&[@,IA?P$*83_!"F$_P0IA/\$JG0
M )Y[  ".>@  @'H  '1[  !H?@  78$  %*%  !)B0  08P  #F0!0 UD0\
M,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$ +)-* "N44@ JE%P *)1G ">4<P$E
ME((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/_P(@C_\"I'P  )>
M  "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8  #*9   JG D *)T1
M ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4 'I]@ !R?;0 ;GWP
M&I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&  ""
MA@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+ !JI
M$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0 #JN&
M  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !ZC0
M;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U"@ -
MMA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[  "W
MC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP  99P
M %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #P0T
M ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%@0
MQ94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D  %"N
M  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <  ,P-
M  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P  UH<
M -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X   X
MO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%  #;
M"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<  .F,
M  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    LQ
M(,@  !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G 0
MZ0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ  #Z
MC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #( _P _
M /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V )@
M]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@ _P#H
M /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [ /\
M1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0 [ ":
M .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#= /\
MW0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z
M $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6 .$
MG #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\ S0#_
M ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O $D
MZ@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -( F #0
M )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_ , "
M_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T( WP-.
M -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L
MP@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,_P"T
M#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,
M40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@
M +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\
M_QH  /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\
M%%0 N15= +<59 "U%6L M!5Q +(5> "Q%GX KQ:% *X6C "L%I0 JQ>< *D7
MI@"G&+  IAB] *08SP"B&N< GQKW )T;_P&<&_\!G!O_ 9L;_P&;&_\!_QT
M /<A  #H)   W24  -0A 0#/&P@ RA<1 ,(:( "\'"T MQTZ +,>10"P'D\
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M X(OP@.!,-H#?S#O WTQ_@-],?\#?#'_ WPQ_P-\,?\#[2\  -LW  #)/0
MOCX  +,\  "L.   IS,$ *(R$0"=-!T F34J )4U-0"2-4  CS5) (TU4 "+
M-5< B35> 8<U9 &%-&L!A#1R H(T>0* -(("?C2+ WTTE@-[-:$$>36N!'@U
MO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@  N$0
M *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL ASM$ (0[3 "".U,!
M@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N
M.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"  "^1P  L4@  *5&
M  "=0P  ES\  )(^"P"-/Q4 B3\A (5 +0""0#< ?T!  'U 2 ![0$\!>4!6
M 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$!&P_D 5K/YP&:3^I!F@_N =G0,P'
M9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%W#X  ,=&  "Y2P  K$P  *!*  "7
M1P  D4,  (M#" "&0Q( @D0> 'Y$*0![130 >44] '9%10!T1$P!<D13 7!$
M60%N1& ";$-G FM#;P-I0W<$9T.!!69#C09D0YD&8D.G!V%$M@A@1,H(8$3F
M"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@  IT\  )M-  "22P
MC$<  (5'! " 1Q  ?$@: 'A()@!U23  <TDZ '!)0@!N24D!;$A0 6I(5@%H
M2%T"9DAD F5(; -C2'4$84=_!6!'B@9>2)<'74BE"%M(M A;2,<)6DCD"%I)
M]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$  )=0  "-3@  ADH
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M!TU3_P9-4_\&Q4X  +96  "G6@  F%D  (M8  "!5P  =U0  '!5  !J5@8
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M>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H[@4W9_P%.&;_!3AF_P4X9O\%M%X
M *=E  "590  AF0  'IE  !O90  9&8  %EH  !2:@  36P$ $EN#@!';A8
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M 22"H $C@K(!(H+) 2*!YP$B?_<!(G[_ B)]_P(B??\"I7$  )-Q  "#<0
M=G$  &QR  !@=0  5G@  $Q\  !#@   .X,  #.&   MB0H *HH1 "F+&0 G
MBR( )HLJ "6,,0 DC#D (XQ" "*-2@ AC50 ((U> !^-:P =C7D '(V* !N-
MG  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@  <G<
M &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <EAH
M&Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8E@ 0
MF*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX  %^!
M  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ( $*,9
M  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $HZ$
M J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,  !-
MD0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2  *O
M&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<  *^J
M  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%G0
M.Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z$P
MNQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?  "]
MLP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP  ,J\
M "BT   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@  QQ(
M ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/I@
MS[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H  !V]
M   3P   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P  -80
M  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF   Y:D
M .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(   ,
MRP   \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(  #H
M#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD  /BE
M  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0
M_P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$ G@#P
M *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_ .0
M_P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!:
M /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E *
MY "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@ _P#8
M /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5 .T
M7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P U0"C
M -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#( /\
M_PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$ 60#>
M &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@ ,4
MJ ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\ _PX%
M /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#. %L
MRP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D I "W
M *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q   /\.
M  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8 O@5=
M +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL
MJ0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L
M$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7 + .
M7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D GQ"U
M )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@'P
MTA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *0660"B
M%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88FP"4&*8 DQFR )$9
MP0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T  .0E  #3*0  QRH
M +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0 FQY, )D>5 "7'UL
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M FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@  K#T  *$Z  ":-P
ME3,  ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![,TT >3-4 '<S6@!V
M,V$ =#-G 7(T;P%Q-'<!;S2! 6XTC )L-)@":C6E FDULP-H-<8#9S;B V8V
M]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$  )L_  "3/   C3@
M (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D <3E0 ' Y5P!N.5T
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M U1#_P-40_\#R$(  +A)  "G2P  F$H  (U)  "#1P  ?4,  '9#  !Q1 H
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M>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3[ 1!4OL#0E+_ T)2_P-"4?\#ND\
M *I4  "85   B50  'U3  !S4P  :5$  &)2  !<4P  6%0* %15$@!251L
M3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL 1UA2 $986@%$6&,!0UAM 4%8>0)
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M C)CH0(Q8[,",6/( C%BYP(Q8?@",6'_ C)@_P(R8/\"KEP  )M=  "*70
M?%T  '!=  !F70  7%X  %)@  !,8@  164  $%F"@ ^9Q$ /&@: #MH(@ Y
M:2L .&DR #=J.@ V:D$ -6I) #1J4@ S:EL ,6IE #!J< $N:GX!+6J. 2QJ
MGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$  )5@  "$8   =V
M &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX -' 5 #-P'@ R<28
M,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G<GL )G*+ "1RG $C
M<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD  !_9   <F0  &AE
M  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1 "IY&  I>B$ )WHH
M "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8 '7R& !Q[F  ;>ZH
M&GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J  !9
M;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B !R%
M*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[
M !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3<P
M27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0(@ 1
MD"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/
MR0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0  0X$
M #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ 'G"(
M!IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";OP
MFML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P  #*1
M   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P  *@C
M  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0  J,L
M *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>   A
MH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;  "U
M(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X  +?2
M  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9KP
M$;,   NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##&0
MQ"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!  #)
MT0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O   "K\
M  '!    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$   TQ8
M -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@O@
MX,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H   #-
M    T0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X  .<3
M  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@  ]+(
M_P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X 8P#[
M &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F .H
MK@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\ _P 0
M /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q &8
M[P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X J@#;
M +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P - /\
M"0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &( X@!I
M .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+ *\
MR0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\  0#_
M  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C ,\
M:@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L NP"V
M +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_
M_P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$ 9 "_
M &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R *P
MOP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P  Z
M .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R &4
ML !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *  NP">
M <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\  ,X+
M  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\ I0=E
M *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3"\P
MD@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5  "Y
M$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@ )@0
M9@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL AA/F
M (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K&@
MJ10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P780"+
M%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB 'H=
M]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P  G1\
M )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 " 'V(
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M 5\P_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0  @S(  '\P 0![+PX
M=S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G,E< 93)= &0R90!B
M,FT 83-W %\S@@%>,XX!732< 5LTJ@%:-;L!6C72 5DU[0%9-?P!6#7_ 5@U
M_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<  '@T  !T- L <#43
M &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E, 7C=: %TW8@!<-VH
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M>@%-08<!2T&6 4I!I0))0K4"24++ DE"Z ))0OD"24'_ DE!_P%)0?\!O4,
M *I%  "810  BD4  ']%  !V0P  ;T   &A   !C00$ 7T$- %Q!% !90AT
M5T(F %5"+@!30C8 44(] $]"0P!/0TL 3D-2 $U$6@!,1&, 2D1M 4E%> %(
M184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%_P)%1?\!ND8  *9(
M  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+ %9%$@!41AL 448C
M $]&*P!.1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$ 1DEK $1)=@%#28,!
M0DF2 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P) 2/\!MDD  *)*  "1
M2@  @TH  '=*  !N20  944  %Y'  !92   54D( %%*$ !/2A@ 3$HA $I+
M*0!)2S$ 1TLX $9,/P!%3$8 1$Q. $--5@!"35\ 04UH $!-= $^38$!/4V0
M 3Q-H $[3K$".D[& CI.Y ([3?8".TW_ 3M,_P$\3/\!LTT  )Y,  "-3
M?TP  '1,  !J3   8$H  %E+  !43   4$T% $Q.#@!)3Q4 1T\> $5/)@!$
M4"X 0E U $%0/0! 440 /U%+ #Y14P ]4EP /%)F #I2<@ Y4G\!.%*. 3=2
MG@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\  )E/  ")3P  >T\
M '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!( 050; $!5(P ^52L
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M ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:6@
M4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J+@ F
M:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ !IK
MU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@  3&$
M $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  ==#
M''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%TSP 2
M<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<  #YK
M   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ
M !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *?>0
M"GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES   Q
M=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK  F)
M,P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H  (;L
M  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J@0
M(X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5+
ME34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F  "2
M\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0  &Y$
M !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0  HBT
M *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "AZP
MH/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X   ZA
M   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0  + M
M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX   L>D
M;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N
ML@   +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C  #!
M+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H 98D
M %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\    OP
M ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2(0
MU2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8  %&<
M  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0   -
M  #2    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@  Z"
M .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\ #@#_
M  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M /0
M= #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +, XP#
M .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_  D
M_P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D ;P#G
M '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z -
MR@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4 _P ,
M /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8 '
MU0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$ PP"_
M -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 ' /$
M$ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H Q0!P
M ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q ,\
MKP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! ., # #:
M !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J +0
M;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@ H@#B
M *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)  \
MP@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *< :@"F
M &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#< )0
M[P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H M@ 1
M +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ": &H
MF !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&[0"(
M!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8- *<#
M%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4 C0IK
M (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\#_T
M>P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-#P"8
M#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G ( 1
M;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT <1;_
M '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-%!0
MB14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88:0!T
M&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_ &<>
M_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q  ?QP:
M 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K(&T
M:2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?
M)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5 ',C
M( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD 829R
M %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\
MQ3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI&P!I
M*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO %@M
M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\ P38
M *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B+B$
M8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1
M,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y
M  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX 6C,F
M %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+-X(
M2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\  "1
M/   @SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C %(W
M*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X  13N.
M $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-/@
M?SX  '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[* !+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$/EP 0SYF $(_<0!!/WX 0#^- #]
MG  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD   )I   ")00  ?$$
M '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4 23\= $= )0!&0"P
M1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \0WP .T.+ #I$FP Y
M1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#  "&0P  >$,  &Y#
M  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0: $)$(@!!1"H /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH -DB) #5(F0 T2*H
M-$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&  !A
M10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN #E*
M-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@ +DV[
M "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=2
M54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/,P R
M4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y "A2
MT@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3   44P
M $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L5C<
M*U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7SP B
M5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35   $52
M   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#, )%TZ
M "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;7>D
M&USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7   [
M60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME
M/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.< $V/W
M !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V7P
M,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M.0 2
M;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK
M_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD
M "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP
M"7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "
M=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU
M   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()
M  ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD
M=&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1
M@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".
M1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@
M &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP
M!I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P
MG$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO
M  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *
M  "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX
M *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+
M?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P
M    L    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!
M  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP
M.)(  "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_
MOP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #1
M10  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(
M "6H   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0
M ,\   #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.
MZ$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\
M&@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z
M .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8
MV0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^
M "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X
M>@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q
M ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P
M[  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#*
M 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +<
M^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A
M -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0
MN0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G
M /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,(
M)@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T
M *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T
MF #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P
M "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L
M=0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_
M (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0
MH  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"-
M '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\
M_P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G
M )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W(
M@ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S
M"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)
M*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV
M '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\
MT!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![
M$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3
M?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(
M + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@
M;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?
M&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH
M  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL
M &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8(
M52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3
M+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC
M+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>-
M $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,
M@3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5
M*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<M
MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,
M '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\
M32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!
M,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU
M  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J<
M.S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C
M-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U
M-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX
M #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@
M63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^
MS0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P
M $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L
M0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^
M  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0]
M "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N<
M)T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _
M1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*
M0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW
M ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2
M-TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A
M4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/
M_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX
M "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0
M&5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 4
M5?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6
M   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]*
M !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\
M?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?
M7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG
M4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$
M &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P
M$VH   ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@
M<%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6
M  !95@  _^+__TE#0U]04D]&24Q%  0)45<  $=8   ^6P  -E\  "YB   F
M9@  'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?  !Z
M)@  >B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(  'C?
M  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @<
M&70  !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&(
MAB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73  "$
MZ@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P  $H
M  V#   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0  DR
M )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3X@
MD^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T   :1
M    E    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@  *,@
M  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0  I.0
M6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@
MHP   *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7  "U
M(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]  5'8
M $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N    L@
M +8   "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&%@
MR2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,  $&*
M   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@   ,8
M  #(    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@  W14
M .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\ !0#_
M  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C .X
M:0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H V@"V
M -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_  $
M_P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\ 9 #=
M &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P ,8
MO@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_    ^@ '
M /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#) &4
MQP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8 MP"T
M ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ " .$
M# #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\ MP!D
M +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D ,$
MHP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L " ##
M !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!> *8
M8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H E #/
M ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S  P
MK0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )< 70"6
M &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#' (4
MY "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  < H  .
M )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ") %T
MB !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D W0!X
M /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 * )$
M$0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@ ? !>
M 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M NT
M; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%# "$
M 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059 ' &
M7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ
M &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\"@X
M> H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E
M#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61'] %D1
M_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D ;Q 1
M &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\
M6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1
M%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4. &,6
M%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P 4AED
M %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*'?\
MK"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;$@!9
M'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?
M:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\ IB<
M ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2(18
M4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D:0!"
M)74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK
M  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1, 2B8:
M $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \*G(
M.RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN  ![
M+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J
M'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G  -B]_
M #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W,@
M:S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN'  [
M+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-] # S
MC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-   :#4
M %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V,R
M-#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LWBP J
M.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<  %LW
M  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T +S@D
M "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E/)L
M)#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z  !1
M.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA "D]
M*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D 'T&K
M !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-/
M1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#)0 B
M0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I !A&
MO@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P  1#\
M #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <22D
M&THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+O  1
M2]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(  #I#
M   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4 %% L
M !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,4=$
M#5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(   O
M2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H  U8
M,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H !5?F
M  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K4
M)5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@*P $
M8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B  !>
M\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@  (%D
M !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@  :2X
M &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F[@
M9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(  !1E
M   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@  ',Q
M  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP  </0
M85,  %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O   +
M<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J  "
M-0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$ 7%@
M %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #?P
M ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/+
MCS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T  $Y?
M  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0   )
M  "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P  H"X
M * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H   \
M;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\   "A
M    H@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,  +(Q
M  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U>@
M*H$  !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q
ML0   +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F  #%
M-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0  (I
M !>8   /GP  !Z4   "J    KP   +,   "W    O    +\   #!    P@
M ,0   #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=*@
MWCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P , /\
M$P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D YP!O
M .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/ -H
MS@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L $ #V
M !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I -$
M;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T O #J
M +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D !0
MWP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\ :0"]
M &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A *L
M]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$ QP 9
M ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L &@
MJP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L [@":
M /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4 +$
M'@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &( FP!G
M )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+ /D
MB@#_ (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *  & "=
M "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A (L
M9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /( ?0#_
M 'T _P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0 !P
MC0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X 8@!]
M &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[ '
M_P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8 @0 >
M '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q &,
M;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4 _P!E
M /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4
M(0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\ 90!G
M &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;!O\
MM1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$&P!I
M!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC %H)
M;0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\ K14
M )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A#!T
M7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.:P!0
M#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D  )(<
M  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@
M %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(%',
M1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@  !]
M(0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8< $X6
M(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7  /QI]
M #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X)
M;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;( !%
M&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@
MBP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P  :"@
M %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _(",
M/B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q
M)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H  %PJ
M  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\ -R0F
M #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L*9@
M*RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM  !1
M+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C # H
M*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9< )BZH
M "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.+P
M2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM)P J
M+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G "$R
MNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0  13$
M $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E,RL
M)3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;
M-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,  #TS
M   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P
M !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5.]
M%CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV   T
M-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^
M-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X $3_K
M !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q.@
M*SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$,0 2
M1#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E  U$
M]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@  *$
M "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -2S8
M#$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*\  &
M2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4  !]'
M   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43( !%([
M  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@  4/<
M:$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-   6
M4   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV  !9
M00  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8 8T0
M %9%  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   16
M#5H   E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B.P
M8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@  %))
M  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8   "&,
M  -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-   ;4
M &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-  !(
M3   /DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X   !P
M    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD  'I'
M  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"4@
M.%4  "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\
M?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^  ")
M30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@  ,E\
M "AD   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*    C
M (T   "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";1
MFE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH  "%Q
M   7=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP   )T
M  "?    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0  K4L
M *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_   0
MA@  "8T   "3    F    )T   "A    I0   *@   "K    JP   *X   "O
M    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD   ,)4
M  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *EP
M )T   "C    J    *T   "R    M@   +D   "[    O    +X   #
MP@   ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)  #:
M7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D _@ D
M /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#> ',
MW !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8 _P#%
M /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ? .L
M*@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T QP!S
M ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T /\
MM #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -( ) #/
M "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M +,
M<P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\ HP#_
M *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y "@
MMP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$ ; "@
M ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_ ),
M_P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "( HP K
M *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0 &T
MCP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0 _P"$
M /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E )$
M+0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &< @ !N
M 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U /\
MT    +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ (( )P"!
M "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I '$
M<0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\ P
M *P   "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T "D
M<P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4 ; !D
M '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <  * )
M  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ", :  J
M &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !: '(
M6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.  "'
M$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E %T
M*P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[
M $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^%
M<Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4')P!3
M!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,
MB !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&   ;!D
M &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,#2@
M2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]
M$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT  %X=
M  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20 1!$J
M $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V%98
M-!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@  !3
M(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G #L5
M+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0 +ANE
M "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/(@
M2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:*0 T
M&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D "@@
MMP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0  1R0
M $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N'RT
M+1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(DM0 B
M),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<  #\F
M   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH )R,Q
M "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =*,H
M'2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH   W
M)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N "$I
M-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D &"SG
M !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T*@
M,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM,P ;
M+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E !0P
M]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0  +"T
M "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6,SD
M%3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T]0 0
M-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$  "0R
M   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38 $#E
M ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,./P
M;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V   =
M.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\  L_
M1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O< :3,
M %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :/
M%C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%0@ "
M14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8  %<W
M  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@  $D0
M  Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@  3$D
M $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([  !(
M.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL   M.
M P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4  %-2
M  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%/@
M/CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95 @
M5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-  !<
M6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@  /$(
M #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>    8 0
M &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G50
M9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<  "]*
M   F30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@   &L$
M  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@  <U\
M '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2   @
M5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<   !Y
M @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8  (-J
M  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   98@
M$F<   QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(
MB0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@  "5
M=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P  #'4
M  1[    @    (4   ")    C0   )$   "3    E    )8   "8    F@
M )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H;0
MIH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4   "+
M    D0   )8   ";    GP   *(   "D    I0   *<   "I    JP   *T
M  "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80  O'H
M +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<
MH@   *<   "L    L    +,   "V    MP   +D   "[    O0   +\   #"
M    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX  -2&
M  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V #0
M\0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -, >0#0
M (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_ +<
M_P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X WP X
M -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"] 'H
MNP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D _P"F
M /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R ,
M.@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ', J0![
M *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9 /\
M_    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T - "I
M #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T )4
M?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\ [0
M -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7 #4
ME0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4 =@"$
M (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0   ,$
M  "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\ A0 V
M (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U 'H
M<P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\   "@
M    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P '4
M-@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0 9@"
M &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1
MA@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D , !H
M #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z %D
MB !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P  >@<
M '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!= #
M6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\ A !.
M ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T  &@-
M  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q
M %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !% )
M1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1  !:
M$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D"
M,@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX / >?
M #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4%
M4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)+@!
M"3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V? #,-
ML0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&   2A8
M $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y#3
M. XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K
M$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH  $(8
M   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T ,A$S
M # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E%<8
M)17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<   Z
M&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P "H5
M-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0 'QGB
M " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W'0
M-!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:-0 C
M&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@ !H=
M\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(   ,!\
M "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >'SH
M'1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6
M(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(  "DA
M   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@ &"1!
M !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2)?T
M<"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D   B
M)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I
M20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0
M %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >*0
M&RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN1@ -
M+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<  %HI
M  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0  &"X
M !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ ),TX
M"#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L  !+
M+0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(  !(T
M P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H  #E7
M   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(+P
M/S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y P ,
M.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3   _
M80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@  /#(
M #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (00@
M!$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&70
M1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34  #,T
M   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8  $D*
M  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6   36D
M $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W   J
M.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(  !2
M"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,  %9W
M  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F/P
M'T(  !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;"
M7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P  !@
MB   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@  &DH
M !-.   .40  "E4   18    6P   %X   !A    8P   &0!  !E!   9P@
M &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M?P
M;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0   Y8
M   (7    F    !D    9P   &L   !M    ;P   '    !R    = (  '4&
M  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P  ?)
M 'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E
M:@   &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4   "'
M P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8  (Z?
M  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T    >0
M 'X   ""    A@   (D   ",    C@   )    "2    E    )8   "8
MFP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4  "A
MJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@   (\
M  "4    F    )L   ">    GP   *(   "D    I@   *@   "K    K0
M +    "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "WH0
MM[, ,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$   "F
M    J@   *X   "P    L0   +0   "V    N    +L   "]    P    ,,
M  #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@  S*D
M_P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D 0 #F
M $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R "" ,8
MC ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\ _P
M /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#, $(
MR !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +( A0"P
M )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0   /8
M  #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P LP!#
M +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0"> (@
MG "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8   #1
M    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \ )T
M0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($ B@"-
M (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z
MK    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L / ")
M $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"& '@
ME !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F    F@
M )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z #L
M> !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D C0!H
M )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@   ($
M  !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4 :@ Z
M &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!; )8
M6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',   !N
M    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U %T
M.@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B
M $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B 0
M7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %( - !1
M #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"= $4
ML !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0  50<
M %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !( #4
M1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P JP \
M ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P  $L+
M  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$ /@ V
M #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S +P
M,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.  !"
M#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R #8$
M.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H *P?2
M "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \$
M.@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*-@ N
M"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2 ",-
MZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P  -1$
M #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H#CL
M)PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =
M$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4  "X3
M   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D (1%"
M " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8$_H
M<!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6   H
M% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H6
M20 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H ;!D
M %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D&
M(A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:1P 4
M&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L  %H=
M  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P  '1L!
M !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0'U
M#R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,
M(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2   !8@
M!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T "R19
M  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)(P
M0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D P 1
M)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5  4I
M9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0  /24
M #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /*0@
M#"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N8
M+G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<  #,G
M   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@< "3 ,
M  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70  ,VT
M #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J   K
M*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+  (V
M#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D  #E]
M   XDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J*P
M)2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \#0
M/0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X   _
MCP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@  (B\
M !TP   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P  1 T
M $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'B@
M1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0  !DV
M   3.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L  $X.
M  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A   3YT
M $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^   0
M00  #$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+  !9
M#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<  %FO
M  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +2@
M!4X   !1    5    %<   !:    7    %T   !?    8 0  &('  !D"P
M9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H  !E
MP@  9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50   %H
M  !=    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@  = H
M '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !UMP
M=-( /$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<   !K
M    ;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,  (<)
M  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0  A\4
M-D<  "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![
M?P   (,   "&    B    (H   "-    CP   )$   "4    EP   )H!  "=
M!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;< ,%
M "55   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-    D0
M )4   "8    F@   )P   "?    H0   *,   "F    J0   *P   "P
MM <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L  !YB
M   4:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I    *@
M  "K    K    *\   "R    M    +8   "Y    O    ,    #$    R
M ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\   #[
M    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!) -H
M3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )( NP">
M +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R
M\    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\ 20"\
M $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7 *4
MI@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C    TP
M ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H $@
MI@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ), G@"1
M +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N    *X
M  "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $( D@!'
M )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_ *<
M?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D   "3
M    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !  '\
M10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\ ;@"R
M &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "
M?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X /P!M
M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J %X
MP@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q    ;0
M &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@ #X
M7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %( N !1
M -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8    %X
M!0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@ 4P ]
M %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!' ,P
M1@#P $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,  0!2
M  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X $<
M/@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,, /0#F
M #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)  0
M1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X .@ ]
M $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #= #0
M]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$ /P$'
M #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T #P
M,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P [@ L
M /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D# #<%
M"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@ + !
M "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E /<
M<@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +!0 P
M" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04] "0%
M1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?, ;0X
M %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J#0<
M*0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+1  =
M"T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1   %H2
M  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0 (PX(
M ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7#E
M%@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4  !+
M%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$& !T0
M"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX $1):
M ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)&
M/QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2!@ 7
M$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97  T6
M90 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@  /1H
M #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3%@D
M$18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:80 '
M&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP  #,<
M   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P< #AL,
M  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "'VX
M 1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >   J
M'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+  H@
M#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL  "-^
M   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H(
M(Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E#0 $
M)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[   G
MD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0  (B$
M !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0  *P\
M "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   LC0
M+*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(  !TB
M   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X  #(0
M   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@  ,J$
M #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE   6
M)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.   Z
M$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X  #BV
M   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3*P
M$"X   TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!$
M0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R   ^
MSP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@  #34
M  @X   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@  3!$
M $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(R@
M1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T   )
M    0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X  %@2
M  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@  4N8
M.#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*
M30   %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.  !F
M$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP -3<
M # U   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6    60
M %P   !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T#P
M=Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H  "L[
M   B/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :    &L
M  !N    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@  B@\
M (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$   <
M20  $TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T   "
M    @P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D  *(0
M  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   55
M#EL   5B    :0   '    !W    ?0   ((   "&    BP   (\   "3
ME0   )<   ":    G0   *    "C    I@   *H   "N    L@   +<*  "[
M$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@  !VH
M  !S    >P   ((   ")    D    )4   ":    GP   *,   "F    J
M *L   "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3"P
MU!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0   /,
M!0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\ S@!4
M ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q ,
MKP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\   #9
M  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!. +,
M4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8 FP#4
M )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X  0
MM0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X 3 "<
M %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#% (@
M[@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?    G  )
M )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L
MA@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U
M /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0
M# "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!)
M ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4
M9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O
M  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &,
M2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_
M %8 _P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L
M7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5
M $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H
M_P!* /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ ,
M %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $,
M2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!
M /\ A0   '0   !G    70   %4   !/    3    $H   !(  0 1P * $<
M#0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!%
M #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\
M?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]
M  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #,
M20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$
M &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P
M-  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J
M $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)
M  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  -
M "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L
M(@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-
M#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4#
M#@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4
M !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P
M0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >
M!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'
M7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$
M #41   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T
M& D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /
M#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3
M   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP-
M !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT
M"@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I
M%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.
M#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\
M  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@
M(A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +
M$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5
MC@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18
M !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A
M!A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C
M&*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7
M   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2
M  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*
M !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7
M&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @
M%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V
M   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$
M$QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@
M)A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   D
MT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P
M  X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14
M "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT
M*>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB
M   *)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48
M   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\
M/",  #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %
M*P   2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^
M'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<
M "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P
M #4    X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P
M2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ
M   G*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X
M  !!    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P
M %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F
M*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,
M    3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?
M  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,
M&C,  !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8
M6P   %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S
M)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P
M  Y!   '1P   $P   !1    50   %D   !=    80   &4   !H    :P
M &T   !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'
MB"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.
M    5    %H   !@    9    &D   !N    <@   '8   !Z    ?0   (
M  ""    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$
M )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<
M8P   &H   !Q    =@   'L   "     A@   (H   ".    D0   ),   "6
M    F0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH
M  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =
M 'P   "#    B0   (\   "4    F@   )\   "B    I    *<   "J
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P0A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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M@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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MQ]7&" G9S H@Y<\-0-C5"U^]U@N(I<0TIIRW6KB9M6N[E[1WO9:S?[Z5LH7
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MS/^R%@G_LR$>_[ N.O^K.UGLI$AZUYQ9FL:7;[+$F7:VPIM_N<"<A[V]FHG
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M@*29TX"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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ME)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'#
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M5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$_WA%0O]]1D'_@4=
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M*B?_K2LF_[DL)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+:JW  ":Q0
MB],  'WB  !U_P4 :?\, 5__$0)7_Q<#4/\?!4G_)@=$_RX)/_\V"SO_/0TW
M_T,/,_])$3#_3Q(N_U43+/];%"K_8A4G_VD6)?]R%R/_>Q@A_X89'_^1&A[_
MG!L>_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@  ?-X
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M13;\_44[\O]$/NK_1#[F_T8^YO]&/N;_1C[F_T8^YO]&/N;_1M"?  "]K
MKK4  *+"  "5SP  BMT# (3_$@%[_QX#=/\J"6S_,P]D_SL67?]#&U?_2B!1
M_U$D3/]8)TC_8"I$_V@L0/]Q+CS_>S$Y_X@R-?^6-#/_I#8Q_[8W+__0."[_
M[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0  HKT
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M$1/_PQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S   =]L  &GG  !<_0
M5/\  $O_!0!#_PP!/?\1 C?_%P(R_QX#+O\D RK_*@0E_R\$(O\U!1__.@4=
M_S\%&O]%!AC_2P86_U(&%/]:!Q+_8@<0_VP'#_]W" W_A @,_Y (#/^<" S_
MH@@,_Z((#/^B" S_H@@,_Z((#/^B"/]0( +_2RH#_T0V!?]'.@;_2C\(_TY)
M#_]/5!?_3V >_TUL)/]*>2K_2(4N_T:0,O]$FC3_0Z(W_T*J./]!L3K_0+D[
M_T#!//\_RSW_/MP^_S[H/O\]\S[_/?L__S[_/O] _S[Z0_\]]$3_/NY&_S_N
M1O\_[D;_/^Y&_S_N1O\_[D;_/_]0( +_2RH#_T4U!?]*. ;_33T(_U%(#_]2
M4A?_45X>_T]J)?]-=RO_2H,O_TB.,_]&F#;_1*$X_T.I.O]"L#S_0K@]_T'!
M/O] RS__0-Q _S_I0/\_]$#_/OU!_T#_0/U"_T#V1?] \$;_0>E(_T'I2/]!
MZ4C_0>E(_T'I2/]!Z4C_0?]1'P+_3"D#_T<T!?]--@;_43L(_U5&$/]64!C_
M55P?_U)H)O]0="S_38 Q_TJ,-?](ESC_1J [_T6H//]$L#[_0[@__T/!0?]"
MS$'_0=Y"_T'K0_] ]4/_0/U#_T/_0_A&_T+P2/]#ZDG_1.-*_T7C2O]%XTK_
M1>-*_T7C2O]%XTK_1?]2'P+_32D#_THR!/]0,P;_53D(_UE#$/]:31C_65@@
M_U9D)_]3<2W_4'TS_TV)-_]+E#K_29X]_T>F/_]&KD'_1;="_T3!1/]$S$7_
M0]]%_T+M1O]"]T;_0_U&^4;_1O!)_T;I2_]'XDS_2-M-_TC;3?](VTW_2-M-
M_TC;3?](VTW_2/]3'@+_3B@#_TXO!/]4, ;_6C8(_UY $/]@2AC_7E4@_UM@
M*/]8;2__5'DT_U&%.?].D3W_3)M _TJD0O])K43_2+9&_T?!1_]&S4C_1>%)
M_T3O2O]%^$K[1_U*\4K_2>A-_TO?3O],UT__3,]1_TS/4?],SU'_3,]1_TS/
M4?],SU'_3/]4'0+_4"<#_U(L!/]9+07_7S((_V0\$/]F1QC_9%(@_V%<*/]=
M:##_6G4V_U:!._]2C3__3YA#_TVB1?],JTC_2K5)_TF_2_](S$S_2.%-_TCN
M3?Q(^4[R2_Q-YT[]3]U0_5#24OY0S%/_4<94_U'&5/]1QE3_4<94_U'&5/]1
MQE3_4?]5'0+_42<#_U8I!/]>*@7_9"\(_VHZ#_]L11?_;$\@_VA9*/]D8S#_
M8' W_UQ\/?]8B$+_59-&_U.=2?]1IDO_3[!-_TZZ3_U-QE#Z3=E1]DSJ4?)-
M]U'G4/I2VU+[5,Y4_%7'5OU5P5?^5;Q8_E6\6/Y5O%C^5;Q8_E6\6/Y5O%C^
M5?]7' +_4B8#_UHF!/]B)@3_:BP'_W$W#O]S0A;_<TP?_W!6*/]K8##_9FLX
M_V-W/OY?@T3[6XY(^5B83/=6H4_U5:M1\U.U4_%2P53O4=!5ZU'G5>92]E;:
M5/E8S%;Z6<-8^UJ\6OM:MUO[6;-<^UFS7/M9LUS[6;-<^UFS7/M9LUS[6?]8
M&P+_4R4#_UXC _]G(P3_<"H&_W<U#?]Z0!7_>DH=_WA3)O]S7"_\;F8W^&ER
M/_1E?D7Q88E*[EZ33NM<G5+H6:95YEBP5^17O%CB5LQ9WE;D6=A6]%O*6/==
MP%KX7KA<^%ZS7?A>KE[X7:M?^5RK7_E<JU_Y7*M?^5RK7_E<JU_Y7/]9&P+_
M5B,#_V(@ _]L( /_=2@%_WTS"_^ /1/_@4<;_W]0)/E[62WT=F(V[G%M/NIL
M>47F:(1+XF2.4=YAF%7;7J)9UERL6]-;N%[06L9?S5K?8,A:\F&^7/5BM5[T
M8JY@]6*J8?5AIF+V8:-C]U^C8_=?HV/W7Z-C]U^C8_=?HV/W7_]:&@+_62$"
M_V8= O]P'@/_>B8$_X(Q"?^&.Q#_B$09^89-(?*#5BOK?EXTY7EI/>!T=$7:
M;W],TVJ)4\]FDEC+8YQ=QV&F8,1?L6/!7K]DOE[29;I?[&:R8/)FJV+R9J5D
M\F6A9?-DGV7T8YQF]6*<9O5BG&;U8IQF]6*<9O5BG&;U8O];&@+_7!\"_VD;
M O]U' +_?B0#_X<N"/^,. [[CD(6\HY*'NN+4B?DAULPW8%F.M-Z<$7-=7I.
MR'"#5<-LC5N^:99@NF:@9+=DJV>T8[AIL6+*:JYCYFJH9.]JHF;O:9UG\&B:
M:/%GF&GR9I9I\V26:?-DEFGS9)9I\V26:?-DEFGS9/];&0+_7QP"_VP8 O]Y
M&P+_@R$#_XPL!O^1-@OUE#\2[)5'&>233R+<CE@MTH=B.LJ!;$7#>W5.OG9_
M5KARB%VT;I%BKVN;9JMIIFJH9[-LI6?#;J)GX&Z>:>UMF6KN;)9K[VJ3;/!I
MDFSQ9Y!L\F:0;/)FD&SR9I!L\F:0;/)FD&SR9O]<&0'_8AH"_W 6 O]\&0+_
MAA\"_Y I!/J6,PGPFCP.YYM$%=^:2QW3E%4LRHU?.<*':46[@7%/M7Q[5Z]X
MA%ZJ=(UCI7&7:*%NHFR=;*YOFFR^<)ALV7&5;>MOD6[L;H]O[6R-;^]JC&_P
M:8MO\6>+;_%GBV_Q9XMO\6>+;_%GBV_Q9_]=&0'_9!D"_W(4 ?]_& '_BAT!
M_Y0F _:;, ;KGS@*XJ(_$-B?1QS-F5(KQ))=.;N,9D2TAVY.K8)W5Z=]@%ZB
M>8EDG7:3:9ASGFV4<:IQD'&Z<HYQT7.,<NIQBG/K;XAS[6V'<^YKAW/O:H9R
M\&B&<O!HAG+P:(9R\&B&<O!HAG+P:/]>& '_9Q<!_W43 ?^#%@'_CAH!_I@C
M O&?+ 3GI3,'W:@Y#-&C11O'G5 JOI=:.+628T2MC&Q.IH=T5Z"#?%Z:?X9D
ME7R/:I!YFFZ+=Z9RB':V=(5VS'2$=^ER@W?J<()W[&Z"=NUL@G;O:H%V\&F!
M=O!I@7;P:8%V\&F!=O!I@7;P:?]>& '_:14!_W@2 ?^&% '_D1@!^IP? >VD
M)P+BJBP$UJPT"\NG0QK!HDXIN)Q8-J^784.GD6E-H(UQ5IF(>5Z3A8)DC8&,
M:HA_EV^#?:1R?WRS='U\R'5\?>AS?'SJ<7Q[[&]]>NUM?7GN:WUY\&E]>?!I
M?7GP:7UY\&E]>?!I?7GP:?]?& '_:Q,!_WL1 ?^)$P#_E14 ]: : >BI( '=
ML"0!T+ R"L:L01B\IDPGLZ%6-:J<7T&BEV=,FI)O59..=UV,BX!DAHB*:8&%
ME6Y\@Z%R=X*P='6"Q75T@^=S=8'J<79_ZV]W?NUM>'WN:WA\\&EX?/!I>'SP
M:7A\\&EX?/!I>'SP:?]@%P'_;A(!_WX0 /^,$0#_F1$ \:03 ..N%@#6MAP!
MR[0P",&P/Q>WJTLEK:94,Z2A74"<G65*E)AL4XR5=%N&D7UB?XZ':'F,DFUT
MBIYQ<(BM=&V(P71MB>1S;X?J<7"$[&]R@^UM<X'N:W2 \&ET@/!I=(#P:72
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M54C _%A*N/M93++[6DZM^EI.K?I:3JWZ6DZM^EI.K?I:3JWZ6O]_  #<DP
MRJ(  +RL 0"QM0  J, # )_+!@"6V0L D> ; 8K?+ :"WSD.>=Y#%W'=32!J
MW%8H8]M?+UW:9S58V7$Z4]E[/D_9B$)+V99%2-FF1T;:NDA%V]M'1-CT24+3
M_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP  OZ<
M +*P  "GNP  G,8# )/1!@"+Z@X A>@? G[H+09VZ#@.;NA!%F;G2AU?YU(C
M6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z0^B@/$#ILCX_ZLL^/NCO/CWF_S\]
MX/]"/]?_1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V
M  ";P0  D,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7
M(4WT8"1)]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T
M-^S_-CGE_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/
MR   @]0  'GH!P!S_!(!:_T= F3])P1>_C$(6/X[#5/_0Q%-_TL52?]3&$7_
M6AI!_V,=/O]L'SO_=B$W_X(C-/^0)3+_GR<P_[ H+O_(*2W_ZBHL__\J+/__
M*B_Y_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@  G+D  ([%  "!T0
M==X  &WZ"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#_T0,/_],#CS_4Q X
M_UL2-?]C%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_S!XC_^T>(O_]'R+_
M_Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW   9^D
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M7%>:^EM:E?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?C?Q77XW\5_]J"@#_?
MW(P  ,V8  ##HP, NJH" +.S 0"LO H IKT= 9Z\+P:6NCP1C;A''(6U4"=]
MLUDP=K%@.&^O:#]IK7!%8ZMY2EZJA$]:J9!25:B>55*GKU=1J,974*?J5U"E
M_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@  TI$
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M0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@M
ME;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@7QU/
MX&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_-CK0
M_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP  B<4
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M$Q[__Q,>__\3'O__$Z:I  "8LP  BK\  'O*  !NU0  8-\  %3G  !._P0
M2?\. $/_%  __QT!.O\E C;_+ (R_S,#+_\Z RO_000H_T@$)?]/!2+_5P4@
M_V &'?]L!QK_>0<8_XH(%O^;"!7_K0D4_\,)$__C"1/_^ D3__\*$___"A/_
M_PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8  $?U  !!_P  //\)
M #?_$  R_Q4!+O\= 2K_(P$F_RD!(O\O A__-0(<_SL"&?]" Q;_20,3_U$#
M$?]: P__9@0-_W0$"_^%! K_E@4)_Z@%"/^Y!0?_T 4'_^,%!__C!0?_XP4'
M_^,%!__C!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_
M"@ F_P\ (O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_])
M @/_4P( _UX" /]L @#_? , _XT# /^= P#_K , _[4# /^U P#_M0, _[4#
M /^U _\Y)P+_,S("_S4T _\X-@/_.#L$_S9#!?\S3@?_,5L)_R]H#?\M=A'_
M*X04_RF1%O\IFQC_**09_RBM&O\HM1O_)[X<_R?('/\GU!W_)^0=_R?O'O\G
M^1[_)_\>_R?_'O\G_QW_*/\=_RO_'O\M_Q_\+_\?_"__'_PO_Q_\+_\?_"__
M'_\Z)P+_-#$"_S@Q _\[- /_.SD$_SI!!?\W2P?_-5@*_S-E#O\Q<Q+_+X$5
M_RV.%_\MF!G_+*$;_RRJ'/\KLAW_*[L>_RO$'_\KT!__*N$@_RKM(/\J]R#_
M*O\@_RO_(/\K_Q__+/\?_R__(?PQ_R+W,_\B]S/_(O<S_R+W,_\B]S/_(O\[
M)@+_-3 "_SLO O\^,0/_/S8$_SX]!?\\2 ?_.U4+_SEB#_\W;Q/_-7T7_S.*
M&?\RE1O_,9X=_S"G'O\PKQ__,+<@_R_ (?\ORR+_+]PB_R_J(_\O]2/_+_XC
M_R__(O\P_R+_,/\C^S/_)?4U_R7P-_\F\#?_)O W_R;P-_\F\#?_)O\\)@+_
M.2T"_S\L O]#+0/_1#($_T,Y!?]#10?_0E(+_T!?$/\^:Q7_.W@8_SF%&_\W
MD![_-YH@_S:C(?\UJR+_-;,C_S2\)/\TQB7_--0E_S3F)O\T\2;_-/LF_S7_
M)?XU_R;Z-O\H\SC_*>PZ_RGF//\JYCS_*N8\_RKF//\JYCS_*O\])0+_/2H"
M_T,H O]'*0/_22T$_THV!?]*00?_24T,_T=:$?]%9Q;_0G0:_T" '?\^C"#_
M/94B_SR>)/\[IB;_.ZXG_SJW*/\ZP2C_.LTI_SKA*?XZ[BG[.ODI]SO_*?8Z
M_ROP._\MZ#W_+N$__R[;0?\NVT'_+MM!_R[;0?\NVT'_+O\^)0+_028"_T@D
M O],)0+_3RD#_U(S!?]1/@?_44D,_T]6$O],8A?_2F\<_T=[(/]%AB/_0Y$E
M_T*:)_]!HBG_0:HJ_4"R*_Q O"S[/\@M^#_;+?1 ZRWP0/<M[4#_+^L__S'D
M0?\RVT/_,]%$_S/+1O\SRT;_,\M&_S/+1O\SRT;_,_] ) +_12,"_TP@ O]2
M(0+_5B8#_UDO!/]9.@?_648,_U91$O]471C_46H=_DYU(?Q,@27Y2HLH]TF5
M*_5'G2SS1Z8N\D:N+_!%N##O1<0Q[473,>A&Z#'E1O8RXD7_-=]$_S;31_\W
MRDC_.,1*_SB_2_\WOTO_-[]+_S>_2_\WOTO_-_]!(P'_21\!_U$< ?]7' +_
M7","_V L _]@-@;_8$$+_UY-$?U;6!CX6&0=]%5P(_%3?"?N4(8KZT^0+NE-
MF3#G3*$RY4RJ,^-+M#3B2\ UX$O/-=M+YC;52O0XT4K_.LY*_SS$3/\\O4W_
M/+A/_SRT3_\[M$__.[1/_SNT3_\[M$__._]"(@'_3!P!_U48 ?]<&0'_8R "
M_V8H _]H,@7_:#T)^F9($/1C4Q?N8%\=ZEUK(^9:=BCB5X$MWU6+,-Q3E#/9
M49TVU5"F.--/KSK03[L[SD[)/,M/X3W'3_(^PT__0,!/_T&W4?]!L5+_0*U3
M_T"J5/\_JE3_/ZI4_S^J5/\_JE3_/_]&'P'_4!D!_UD5 ?]B%P'_:!T!_VPD
M O]O+@/Y;S@'\6Y$#NMK3A7E:%L<WV1G(]I@<2K477LOT%N%-,Q8CCC)5Y<[
MQU6@/<14J3_"4[1!OU/"0KU3UD.Y4^U$ME/]1;-4_T6L5O]$IU?_1*18_T.A
M6/]"H5C_0J%8_T*A6/]"H5C_0O]('0'_4Q8!_UT2 ?]F% '_;1D!_W(A ?MU
M*0+R=C,%Z78^"^)S2A+;;U<:TFMB(\UG;"O(9'8QQ&%_-\!>B3N]7)(^NEN:
M0;=9I$2U6*Y&LE>[1[!7S4BM6.A(JECZ2:=9_TBA6O](G5O_1YM<_T:97/]%
MF5S_19E<_T697/]%F5S_1?]+&@'_5Q,!_V$0 /]K$@#_<A8 _W@< ?5[) 'K
M?2T#XGXY!]E[1A#0=E,:R7%>),-M:"R^:G$SNF=[.+9D@SVR8HQ!KV"51:Q>
MGT>I7:E*IERV2Z1<QTRB7.)-GUWW3)Q>_TR87_]*E6#_29-@_TB18/]'D6#_
M1Y%@_T>18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A, _'T7 .^!'@'DA"<"
MVX0T!="!0P_(?$\9P7A:([MS9"RU<&TSL6QV.JUJ?S^I9XA#I6611Z)CFTJ?
M8J5-G&&Q3YE@P5"78-Q0E6'S3Y-B_TZ08_],CF3_2XQD_TJ+9/](BV3_2(MD
M_TB+9/](BV3_2/]0%@'_7!  _V@- /]R#@#_>A  ]H$2 .F&%P#>BB !THHP
M!,F&0 [!@DT9NGU7([1Y82RN=6HTJ7)R.J1O>T"@;(1$G6J-2)EHETR59Z%/
MDF:M49!EO5*.9=13C&;P48MG_U"(9_].AVC_3(9H_TN%9_])A6?_285G_TF%
M9_])A6?_2?]2% '_7PX _VL+ /]U# #Y?@T \(4. ..+$ #6CQH S(XN!,.+
M/0V[ATH8M(-5(JU^7BNG>V<SHG=O.IUT>$"9<H!%E6^)29%MDTV-;)Y0BFJJ
M4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_38!K_TR :_]*@&O_2H!K_TJ :_]*
M@&O_2O]4$@'_80P _VX* /UX"0#H@@@ W(D) -B/"P#0DQ< QI,K [Z0.PRV
MC$@7KHA2(:>$7"NA@&0SG'QM.I=Y=4"2=WU%CG6&2HIRD$Z&<9M1@F^G5']O
MME5];\M6?&_K5'QP_U)[</]0>V__3GMO_TU[;O]+>V[_2WMN_TM[;O]+>V[_
M2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0 P9<I [F4.0NQD$86
MJ8U0(**)6BJ<A6(REH)J.9%_<C^,?'I%AWJ#2H-XC4Y_=IA1>W6D5'ATLU9V
M=,A6=73H575U_5-U=/]1=7/_3W9R_TUV<?],=G'_3'9Q_TQV<?],=G'_3/]9
M$ #_9@< _W,$ .%_ 0#6B 0 SY & ,J6" #$FA( O)LF K28-PFLE404I)%.
M'YV.5RB6BF QD(=H.(N$<#^&@GA$@7^!27U]BTUX>Y91='JB5'%YL59O><56
M;GKF56YZ_%-O>?]1<'?_3W%V_TUQ=?],<77_3'%U_TQQ=?],<77_3/];#@#_
M:00 ]G<  -V"  #0BP, R9,% ,29!@"^GA  MI\D JZ=- BFFD$3GY9,'9B3
M52>1D%XOBXUE-X6*;3V B'5#>X5^2':#B$QR@I-0;H"@4VM_KE5H?\)69W_C
M56B ^E-I?O]1:GS_3VM[_TUL>?],;'G_3&QY_TQL>?],;'G_3/]># #_; $
MYGH  -:&  #+CP( Q)<$ +Z=! "XH@X L:,A :FB,@>AGS\1F9Q*&Y*94R6+
MEEPMA9-C-7^1:SMZCG-!=8Q\1G"*A4MKB)%/9X>=4F2&K%1BAK]588;A5&&&
M^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P  X'X
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M25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P  RHT  +Z8  "SH
MJJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=QM5(>:[-:)66R8BM@
ML6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK]4-'JO]$2:7_1$N@
M_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,  +>=  "LI   HJL
M )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\88[Y7'EZ]7R-9O&@H
M5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"MO\]0K/_/D2N_SY%
MJ?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB  "CJ0  F+$  (ZY
M  "$P0( ><D' '3+% !PS"8!:\LU!67+0 I@RDL06\I4%E?)71I2R64?3LAO
M(TO(>B9'R(8I1,B4+$+(I"Y R+@O/\G7+S_']3 ]Q/\S.\/_-3R^_S8]N/\W
M/;C_-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":KP  CK<  (._  !X
MQP, ;L\' &77#0!CV!T 8-@M EO8.@17V$8)4]A0#4_861%+UV(51]=L&$37
M=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6\B,WU/\G-M+_*331_RLVRO\M-LK_
M+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@  @[X  '?'  !LSP(
M8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"YEP-/^9F#SSF<1(Z
MYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D_QXMXO\@+>+_("WB
M_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8  &O/  !?U@  5-X$
M %'P$ !-\!L 2O F 4;Q, )"\CH#/O)#!#OS2P4X\U0'-O1="#/T: DP]70+
M+O6!#"SVD0XJ]J(/*/>W$"?XUA$G]O01)O/_$2;Q_Q$E\?\3)?'_$R7Q_Q,E
M\?\3)?'_$ZVA  "@J0  DK,  (2\  !VQ@  :<\  %W8  !1WP  2>X$ $;\
M#@!"_1< /OXA #O^*@$W_S,"-/\Z C#_0@,M_TH#*_]3!"C_7 4E_V8%(O]S
M!B#_@P<?_Y0('?^F"!S_O @;_^()&O_Y"1K__PD9__\)&?__"1G__PD9__\)
M&?__":*G  "3L0  A;L  ';&  !IT   6]H  $[@  !#Y0  /OL! #K_#  V
M_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A_S\"'_]& AS_3@(9_U@#%O]C Q/_
M< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_]@4.__\%#O__!0[__P4.__\%#O__
M!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P  ,O\  "[_!P J_PX
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M2'AL]D9X;/]$=VS_0G=K_T!W:O\_=VK_/G=J_SYW:O\^=VK_/O]4# #_7P
M\FP  -UV  #0?0( R8,$ ,2'!@"_BA  MXPC ;"*- 6IB$$.HH5,%YR!51^6
M?UXFD7QF+8QY;C*(=W8WA'5_.X!TB#]\<I)#>'&>1G5PK$AS;[U)<7#927%P
M]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_/O]6"@#_8@  YF\
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M0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0  UGD  ,B$  "^C
MMI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B EE4?>I1=)G6292QP
MD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B([418B/]#68;_05N#
M_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX  ,.(  "YD0  L)<
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M-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@  FZ0  )"K  "%L0
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M%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@  3M,  $3;!  _Z0T
M/>D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J[FL$*.YX!2;OB 8E
M[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J_PL?ZO\+'^K_"ZB?
M  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T  #CD   U]@P ,_<4
M ##W'@ N^"< *_DP "CY. $F^D !(_M) 2'[4@$>_%T"'/UI AK]>0,8_HL#
M%_^> Q7_LP04_],$%/[T!!/\_P,3^O\#$_G_ Q/Y_P,3^?\#$_G_ YVE  "/
MK@  @+@  '+"  !DRP  5M,  $G:   ^WP  -.0  "[T   K_PH */\0 "7_
M%P B_Q\ '_\F !S_+0 9_S0 %_\\ !3_1 $2_TX!$/]9 0[_9P$,_W<!"_^*
M @K_GP()_[4""/_5 @?_] ('__\"!___ @?__P('__\"!___ I&M  ""N
M<\(  &3,  !6U0  2-T  #OB   PYP  )^X  "/_   @_P0 '/\, !G_$0 6
M_Q8 $_\; !'_(0 ._R< #?\N  K_-@ '_SX !/](  #_5   _V(! /]S 0#_
MAP$ _YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0  9<P
M %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P  $?\$  __"P -_PX
M"?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00  _TT  /]<  #_;0
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M-XI9\S:)6O\TB%O_,X=;_S&&6_\PA5O_+X5;_R^%6_\OA5O_+_]+# #_5
M^UX  .)E  #8:P$ SVX% ,QP" #&<A( OG,F ;=S-@2Q<$0*JVY/$:9K61BA
M:6$=G6=J(IEE<B>68WHJDV*#+I!@C#&-7Y4TBEZ@-H=>K3B%7;PY@UW4.8)>
M\#B!7_\V@%__-(!?_S-_7_\Q?E__,'Y?_S!^7_\P?E__,/]-"0#_5@  [F$
M -UI  #1;P  RG,# ,5U!@# =A  N'@C +%X,P.K=D$)I7-,$)]P5A>;;E\=
MEFQG(I-J;R>/:'<KC&=_+XEEB#*%9)(U@F.=-X!BJCE]8KDZ>V+/.WIB[CEZ
M8_\X>F/_-GEC_S1Y8_\R>6+_,7EB_S%Y8O\Q>6+_,?]/!P#_60  YF0  -=L
M  #,<P  Q'<" +]Y! "Y>@X LGP@ *Q\,0.E>CX)GWA*$)IU4Q>5<UP=D7%D
M(HUO;">);70KA6Q\+X)JA3)_:8\U?&B;.'EGISIV9K8[=&;,/'-GZSMS9_\X
M<VC_-G-H_S5S9_\S<V;_,G-F_S)S9O\R<V;_,O]1! #_7   XF<  -)P  #'
M=@  P'H  +I] @"T?PP K8$= *>!+@*@?SP(FGU'#Y5Z41:0>%H<BW9B(8=T
M:2:#<G$K?W%Z+WQO@S)X;HTU=6V8.')LI3MP:[0\;FO)/&UKZ3MM;/XY;6S_
M-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P  WFH  ,US  ##>@
MNWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*?5@;AGM?((%Y9R5]
M=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=PYSMG<?PY:''_-VAP
M_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X  ,EV  "_?0  MX(
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M,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP  J)   )^3  "4E@
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M)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP  :;0  %ZY!@!;NA0
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M!B?:S08GU^\&)M3_"272_PLDT?\,(]#_#2/0_PTCT/\-(]#_#:Z6  "@G0
ME*0  (:L  !YM   ;+L  &#"  !4Q@  2,L  #[0   UU00 +=T* "SA$P K
MXA\ *>,J "CD-0 GY#\ )N5* "3F50 CYF$!(>=N 2#G?@(>Z) "'>FD AOI
MO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC_P48X_\%&./_!:.=  "6I   B*P
M 'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP  )>X) "/P$0 A\1D
M'_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1]X !$/B4 0_YJ@$.
M^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC  "+K   ?+4  &V^
M  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L& !G_#@ 7_Q, %/\:
M !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP  O^   '_E@  _ZT
M /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(  !2
MT   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1  G_
M%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4  /^L
M  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP  8<D  %+3  !#VP
M->$  "GF   >Z@  %>X  !#X   ._P  "_\   C_   $_P8  /\*  #_#@
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M(*1&]""A1O\AGT?_()Y'_R">1_\?FT?_'II'_QZ:1_\>FD?_'O] #0#_1@0
M_TP  /A2 @#H500 X54( .)5#0#551D S%<L ,57/ *_5DH&NE55"K937PZR
M4F@2KU!Q%:Q/>1BJ3H$:J$V*':5,DA^C3)P@H4NF(I]+L2.=2\ DFTO8)9E+
M\"663/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20  _U$
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M*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@  XUP  -)C  #':
MP&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4:%H4D&9B&(UE:AR*
M8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>XB]U7ODM=5__*W5?
M_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\  ,UG  ##;   NV\
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M*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P  KWL  *=]  ">?0
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M)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP  >I4" '67$@!RF"(
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M&#FFQQ@YI>H8.*/_&C>A_QLWH/\<-Y__'#>?_QPWG_\<-Y__',1X  "UA0
MJ8\  )V5  "2F@  AI\  'JC  !NJ   8JP  %6P  !0L@X 3K(; $VS* !+
MLS4 2;,_ 4:S20)$LU($0;-;!C^S9 @\LV\*.K-[##>SB@XULIH/,[.M$#*S
MQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@  H94
M )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^OBL
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M !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !HN
M6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K'0 0
MZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D  +Q
M_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@  3<@
M $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '^QP
M!/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\ZP
M_/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$  #+7
M   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(  /\7
M  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@  _^<
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M +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT /\+0 '_"$X!_P5;
M ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4 _P&L /\!L@#_ ;H
M_P'$ /\!T0#_ .0 _P#Q /\ _ #\ ?\ _ +_ /P#_P#\!/\!_ 7_ ?P%_P'\
M!?\!_ 7_ ?\?)@#_(2( _R A /\>(P#_&"< _Q,P /\1/ '_#DH!_PU7 ?\+
M8P'_"F\!_PIZ ?\*A '_"HT!_PJ4 ?\*FP'_"J(!_PJH ?\*KP'_"K<!_PK
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M!\0M]PG!+?\*ORW_"[TM_PR\+?\,O"S_#+LL_PR[+/\,NRS_#/\Q$0#_-0P
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M&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P  ZTL  -U1  #15
MRE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB45\,GU!G#YU/;Q&:
M3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+XAZ'3/<>ADS_'85,
M_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5   -56  #*60  PEH
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M'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@  LV@  *QH  "E9@4
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M'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P  AWD+ (-[& !_?"@
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M'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<27S_'-9A  #";@
MM'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!HCQH 9H\I &*0-0%?
MCS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*BAA%BID:0XJJ&T**
MOQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=   KWX
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M"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP  G)$  )&6  "%G
M>*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 SMB$ ,K8L #&W-P P
MMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2YM ,CN=(#([?T!"*U
M_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<  (B=  ![HP  ;J@
M &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0 (L,? "'#*@ @Q#0
M'\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7R,L %\;Q 1?$_P$6
MP_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE  !PJP  8K$  %:V
M  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1 !#2&@ 0TR4 #],P
M  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X "=GF  K6_@ +U/\
M"]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_   ]
MP@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D  +A
M+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\  .C_
M  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   PRP
M)<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K(0
M[2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_  #W
M_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@  &=P
M !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%   ^!T
M /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_^0
M__D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8   CJ
M    [0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q   /\8
M  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0  _]4
M /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\ :0#_
M '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#  /\
MS #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_ '
M_P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X R #]
M -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_ /\:
M(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L _P!V
M /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U -(
M\P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>'0#_
M'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q /\&
M>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X ZP7D
M .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_(1,
M_R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.=0#T
M#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/O0#E#\P X0_C -T0
M\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_ O\E$P#_)1  _R0-
M /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL [!=F .D7< #F%WD
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M"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0  _S4  /8W  #J-@(
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M$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5   N50  +11  "N30L
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M%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580  CV(. (MD' "'92L
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M&U5GO1Q49]P<5&?V&E1F_QA59O\7567_%E9E_Q569?\55F7_%>)1  #*70
MNV8  *]L  "F<0  F7   (YO  "#;@  ?7 % 'AR$@!U<R$ <G,O 6]S.@)L
M<T0$:7),!F9R5 AC<5L+8'!C#5UP:Q!;;W036&Y_%55NBQ=3;9D946VH&D]M
MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_%=U5  #%80  MVH
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M$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0  JGL  )^"  "2@@
MA8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/D#, 39 ] 4N010))
MD$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.LPXVCLP.-HWO#C6+
M_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(  )F'  ",B   ?X@
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M QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP  :*(  %NE  !/J0
M1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6O"H %;TU !2]0  3
MODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]^P /O/\ $+K_ 1"Z
M_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M   .K8
M "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &RSX
M!<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*_P !
MRO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\  "/#
M   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$  -L^
M  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P  W_\
M -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-   0
MT0  "]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO  #K
M/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\  /#_
M (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   'W@
M .(   #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X*P
M^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U '2N
M  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0   .P
M  #P    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P  _R@
M /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/) #_
M#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\
MA #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -, _P#G
M /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_$!X
M_PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_
M (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B /@
M\ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH _Q 9
M /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^ (,
M_ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X [ #M
M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3 /\.
M$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X \@"%
M /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A /<
MWP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2#@#_
M$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*  .8#
MAP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@ S@K_
M ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_&!$
M_Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-@P#6
M#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81Z0#"$OD OQ/_ +T3
M_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R   /\A!0#_'PP _QP1
M /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT RQ9U ,D7?0#'%X4
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M!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0  RC8  ,<O!@#!+1$
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M"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$ ETL1 )--( "/3RX
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M$V!4NA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-7U/_#>=$  #/4
MOU@  +-=  "H7P  G%T  ));  "+6   A5H* (%;%@!]7"0 >ETQ '==/ %T
M748"<5U.!&]<505L7%T':EQD"6A;; ME6G4-8UI_#V%9BQ%>69@27%BG%%M8
MN!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_#>-(  #+4P  NUL
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M$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@  L6<  *9M  "7;
MBFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !><3H!7'%# EEQ2P-7
M<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5NL!%$;L<10VWJ$$1L
M_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P  *%Q  "2<   A6\
M 'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8 57@_ 5-X2 )1>$\#
M3W=7!$QW7P5*=V@'2'9S"45V?PM#=8T,076=#C]UK@X^=<4./77H#CYS_0T^
M<O\-/G'_##]Q_PP_</\,/W#_#,5>  "U:0  J7$  )QU  "-=   @'0  '5T
M  !I=@  7GD  %A\ 0!4?0X 4GX: %%_)@!/?S$ 38 [ $R 0P%*@$L"2']4
M D9_7 1#?V4%07]P!C]^? @\?HH).GZ:"CE^K LW?L,+-WWF"S=[_ LW>O\+
M-WG_"CAX_PHX>/\*.'C_"KYD  "P;P  I7@  )9Y  "'>0  >WD  '!Z  !D
M?   6(   %"#  !+A0H 2(84 $>'( !%B"L 1(@U $.(/@!!B4<!0(E/ 3Z(
M6 (\B&$#.HAL!#>(> 4UB(<&,XB8!S*'J@<PB, ',(?D!S"%^P@P@_\(,(+_
M"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@  =G\  &J   !>@P
M4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P WDD  -I)) #234@ S
MDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0^@0GCO\%)XW_!2>,
M_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4  &.(  !8BP  38\
M $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@ *9U! "B=2P GGE4
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M )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   AM0
M&+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##4
MQ%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_ ).4
M  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P   $,,
M  K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P  U%(
M -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;  ![
MH@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX   #2
M    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(  .A4
M  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !NJP
M7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A
MY    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!  #Z
M50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0  4KT
M $3$   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L    [P
M /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_00
M_U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P = /\
M( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (< _P".
M /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^ /T
M_0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\ &@#_
M !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P") /\
MD #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D \P#_
M /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_ !D
M_P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /< BP#V
M )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_ .<
M_P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4 _P @
M /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J (P
MZ "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4 _P#4
M /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,: /\
M)@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (< V@".
M -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$ ?\
MPP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P''P#Q
M RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2) ,@%
MD #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\ M W_
M +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C"2(
MV@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/C0"Z
M$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5_P"G%?\ IQ7_ *84
M_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4% -X.#0#3#A@ RQ$H
M ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@ KQJ  *X:B "L&Y
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M _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L IR\7 *(Q)@">,S0
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M"6]!N0IM0= *;$'N"6M"_PAJ0O\':D'_!FI!_P9J0?\%:D'_!>TW  #60@
MQ$D  +=-  "K30  H$H  )A'  "30@  CD,- (E%&@"&1B@ @T<T (!(/P!^
M2$@!>TA0 GE(5P)W2%\#=4AF!'-';@5Q1W8&;T> !VU&C EK1I@*:4:F"V=&
MM@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_!N@[  #01@  OTT
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M#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4   M5@  *A;  "96@
MC5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G6ST!95M% 6-;30)A
M6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8K@U/6,,-3ECD#$Y8
M^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP  *->  "570  B5P
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M!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P  >V<  '%G  !E:
M7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*<4D!2'%1 49Q60)$
M<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN]@<X;?\'.&S_!CEK
M_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL  &QL  !A;@  5W
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M JMR  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0
M+)$  ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :
MEW0 &9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[
M  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H
M !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL
M#:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2
MB0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H
M   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS
M  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D
M>Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )
MMP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\
M>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL
M &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_    PP
M ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;
MSH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL
M  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T    -$
M  #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(
M .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _
MO   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .    #B
M    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y
M  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0
M(LD  !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O
M\0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_
M?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K
M /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4
M_P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[
M /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\
M- #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6
M /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\
M[@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_
M #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\
MF #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_
M .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8
M^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#?
M )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P
M_P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \
M .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4
MR@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\
M /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D
M00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8
M +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\
MK03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$
M T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)
MG@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_
M /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X
MM Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@
M$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:
M  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA#
M *4930"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J(
MDAZO ) >OP"/']@ C"#Q 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K
M)@  VBT  ,HP  "^+@  M2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC
M2 "7)%$ E219 ),E8 "2)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K
M 80GNP&#*-$!@"CN 7XI_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@
MSS4  ,$X  "T-@  JS$  *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-
M+4P BRU4 (DN7 "'+F, ABYJ 80N<@&"+GH!@2^$ 7\OCP)]+YH">R^G GHO
MMP)X+\P"=C#J G4P_@)S,/\"<S#_ G,O_P)S+_\"<R__ O J  #<-0  QSL
M +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD B3,U (8T/P"$-4D
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M!EY!^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P  N4H  *E+  ";20
MD$<  (A$  "#00  ?D$& 'I"$0!V0QX =$4J '%%-0!O1C\ ;49' &M&3P%J
M1E8!:$9= F9&90)D1FT#8D9V!&!&@@1>1HX%7$6<!EM%K 991K\'6$;?!EA&
M]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X  *1.  "63   BTL
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M!$E1_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50  ?U0  '93  !L40
M9U,  &)4" !?5A( 75<> %M7*0!96#, 6%@\ %991 !564P!4UE3 5%96P)/
M6&0"35AM TM8> 1)6(8%1U>5!D57I09$5[@&0UC2!D-7\@9#5O\%0U7_!$15
M_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@  '%7  !F5@  85@
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M [=;  "I9   EF0  (9C  !X8P  ;6,  &1D  !990  4&@  $EK  !#;00
M0&X. #YO&  ];R( /' K #IP-  Y<3T .'%% #=Q3@ V<5< -'%A 3)Q;0$Q
M<7H!+W&* BUQG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A
M  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=   -W8*
M #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H>G8
M)GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=
M;@  BFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\" "F!
M#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2"
M !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P
MA'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;
MC0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/
MCP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<
M ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2F 4
M#IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "
MFIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^
M  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*
M  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$
M *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5
MC   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&  "Q
M#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=
M  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@
M0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^!@
MOPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'
MJ0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X
M "RS   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,    S0,
M ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G
MW[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_
M   4P@  #,8   /)    S    -    #5    V0   -H   #<    W@   .
M  #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0
M /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +
MS@   -(   #7    W    .    #E    YP   .D   #K    [0   .\   #Q
M    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I
M  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $,
M_P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_
M *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X
M_P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!*
M /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X
M]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@
M /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X
M4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@
M .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\
MT@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M
M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U "; -(
MI #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_
M /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X
MV0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_
M *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,
M  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1
M ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0
MK@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_
M!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0
M4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K
M )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$
MZ!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F
M"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-
MN "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2
M ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5
MF!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&
M%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J
M  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2
M (L<60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4
M>2'D '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I
M+@  H"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F
M50!_)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@
M 6TI]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0
MF#(  )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W
M+E@ =2Y@ ',O9P!R+V\ <"]Y 6\O@P%M+Y !:R^= 6DOK %H,+X!9S#; 64P
M]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT  *@\  ":.@  D3<
M (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX <C1& ' T3@!O-54
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M.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7 %]
M7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#4D#/ U% [P-00/_B__])
M0T-?4%)/1DE,10 &"?\"4#__ E __P)1/O\!43[_ <\[  "]10  JD<  )E&
M  "+10  @40  'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4 7T0^
M %Y$10!=14T 6T54 %E%7 %8160!5D5M 51%> )2184"4423 T]$HP--1;0#
M3$7, TM%[0-+1/\"2T3_ DM#_P),0O\"3$+_ LH_  "Y2   IDH  )5)  "'
M2   ?4<  '5%  !N0@  :4,  &5$"0!B11, 7T8> %U'* !<2#( 6D@[ %E)
M0P!724H 5DE2 %1)60%326$!44EK 4])=@)-28("2TF1 TI)H0-(2;,#1TG*
M T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3   HDP  )%,  "$2P
M>4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!63"\ 54TX %--0 !2
M34@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-GP-#3;$#0DW( T%-
MZ@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\  (U.  " 3@  =4T
M &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P 3U$U $Y2/0!-4D4
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M C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P  :5<  &!8  !460
M3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y8CH .&-" #=C2P V
M8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2ICXP$J8OL!*F#_ 2M?
M_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L  %Q<  !17@  26
M $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34 +VH] "YJ1@ M:D\
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M )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I>P
M(G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'4P +
MAV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_ )5Q
M  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0  &XD
M !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P  DUD
M )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW  !]
M=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0   Z7
M   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%   *!?
M  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X?
M:7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D
MIP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4  "O
M9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA   88<
M %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R    M@
M +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  # 6@
MP6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690  $N:
M   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q    ,4
M  #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53   UF
M -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J   U
ML   *+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,   #6
M    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$  .YG
M  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   JO@
M',(  !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F
MZ    .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5  #_
M;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D _P E
M /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_ (L
M_P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8 _P#V
M /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @ /\
M+0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8 ]@",
M /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G /\
MY0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\ * #_
M #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"& .8
MC0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\ T@#_
M ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S "X
M[P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$ AP#/
M (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_ +X
M_P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "< W0 S
M -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "] (@
MNP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X _P"N
M /\ K@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L ,0
M. #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M (( K "*
M *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P"> /\
MG@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0 ,0"Q
M #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"% )P
MC@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\ CP#_
M /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E #0
MH@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $B@".
M!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_ /80
M  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X E@HX
M )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"##I,
M@0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7  #;
M(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R (D3
M/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\ =AB<
M '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0*0
MO"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<-P!\
M'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8 &LA
MIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P  M#$
M *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S)3P
M<25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(II !@
M*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34  )TT
M  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@ :BQ
M &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0 7"^2 %HOH0%9+[(!
M6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "].@  J#D  )<X  "*
M-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q*P!D,C0 8S(] &$S
M1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360 50UGP%2-; !437&
M 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0  HSP  )(\  "%.P
M>SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>-S$ 73@Z %LX00!:
M.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZG0%,.JX!2SK# 4HZ
MY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\  (X_  "!/@  =ST
M ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X 5STW %8]/@!4/D8
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M 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P  :T<  &-&  !;0P
M5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%2SX 0TM& $),30!!
M3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,W0$U2_<!-4O_ 35*
M_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H  %])  !52   4$H
M $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L /E!# #Q12@ [45,
M.E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O4/8!+T__ 3!._P$P
M3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-  !130  2T\  $90
M  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_ #961P U5E  ,U99
M #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4 *57_ "I4_P$J4_\!
M*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5   [
M6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6 "M=
M8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\ )%C_
M *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V70
M,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D7  A
M9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__ *%9
M  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P  *F8
M "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7;&4
M%FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=  "%
M70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T  !YP
M 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\ #75N
M  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_80
M<&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y   1
M? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G  !_
M>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P  :V8
M &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,A@(
M!HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+<0
MBX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P  %IM
M  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@   )0&
M  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:   F7T
M )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V  !&
M>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$   "B
M!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(  *B)
M  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^AP
M,HT  ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P
ML00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]  "Z
MEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP  *IT
M !^B   5IP  #:P   6P    M    +<   "[    O@   +\   #     P0
M ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1B
MT*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T  !:S
M   .N   !KP   #     PP   ,8   #+    S0   ,X   #0    T0   -0
M  #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>   ZY0
M .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["   $
MQ0   ,H   #-    T0   -@   #;    WP   .    #B    Y    .8   #I
M    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(  /^=
M  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_ #L
M_P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X DP#]
M )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_ .
M_P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8 _P!!
M /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O )0
M[0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$ _P#,
M /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [ /<
M1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X W "5
M -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_ /\
MO #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .< 0 #B
M $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/ ,0
MF #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\ L #_
M /\   #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+ $,
MQP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +( D@"P
M )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_ /\
M  #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T M0!&
M +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@ )8
MGP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\   #U
M    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _ *,
M1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$ D "<
M (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I#
MU X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8 00"4
M $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8 ((
MI0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0  Q14
M +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(!$,
MA@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*HP!U
M"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T  *D<
M  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX ? Y&
M 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K$K(
M:1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C  "4
M(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9! '$6
M2 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\ 8!K$
M %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",*
M@R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>1 !F
M'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+  %8C
MX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0  ?"L
M '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?)D@
M729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\IW@!.
M*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C   ' M
M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0 5RU,
M %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(+_8
M1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR  !F
M+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43)) % R
M4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0 0C3_
M $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A,P
M73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW3@!)
M.%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_ #TW
M_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P  6#8
M %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$/%,
M0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[_P X
M._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH  $\[
M  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$ /4%:
M #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S/_\
M-#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I   !&
M004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98 #9&
M8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\ +D/_
M *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!1@$
M/D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+7P O
M2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_ *=&
M  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P  -TP)
M #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H4&@
M)U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)  ",
M20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($ "U3
M#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4 'U9T
M !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&30
M=4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:"0 C
M6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP !5=
M@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40  <%$
M &11  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :8PP
M&&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE?0 -
M99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4  %]5
M  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4 $&T-
M  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ ";HH
M &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9  !3
M60  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*  5W
M$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0  'B9
M  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-7P
M0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!#0
M@1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23  "#
MJ@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P  /&L
M #%O   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0  C0X
M (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1H@
MD;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8  "I[
M   @@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@  )P-
M  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@  H;,
M *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*   7
MCP  $)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&  "M
M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@  +3&
M  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0GP
M":0   "I    K0   +    "T    MP   +@   "Y    NP   +P   "^ @
MP @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX  #*
MW0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L    +4
M  "Y    O0   ,$   #&    R    ,D   #+    S    ,X   #0    T@
M -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #EQ0
MY><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4   #)
M    S0   -(   #6    V@   -L   #>    X    .(   #D    YP   .D
M  #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP  _<<
M /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\ 30#_
M %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"< /<
MI0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\ R@#_
M /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^ %$
M^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@ GP#F
M *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_ /\
M P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L [ !4
M .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/ *(
MS0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\   #_
M    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!- -$
M50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P N0"G
M +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_
M_@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P 3@"Z
M %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@ *4
MK0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\    [@
M .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H $\
MI0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4 IP"3
M +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP   ,D
M  "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D E@!/
M )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"% +$
M@P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'  "L
M P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!) (<
M4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P =@"^
M '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">#@
MEPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P 2P!Z
M %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[ &D$
MU@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0  BQ(
M (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P"DP
M;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -V !>
M#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H  'L7
M  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D 9A%/
M &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5%?,
M5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>  !O
M&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+ %P9
M4@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$ 3!S_
M $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H(0
M9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@3P!3
M(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_ $4B
M_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@  7R0
M %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,)E0
M2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H_P!
M)_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@  %<G
M  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$ 12Q:
M $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z+/\
M.BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L  !/
M+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ
M80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\ -3#_
M *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !),08
M1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV7P W
M-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_ *DV
M  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@, 03<-
M #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R.V@
M,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X  ".
M.0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+ #H\
M$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8 *T!T
M "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*/
M>#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!#P R
M0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q "-%
M@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P  =$
M &=   !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K2!(
M*D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*?P ;
M2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,  &-#
M  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A  (DX6
M "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  44(\
M$U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'  !5
M1P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81 !E6
M&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP #5>@
M  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !12@
M2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>$P 0
M7AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;  )>
ML0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@  1TX
M #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &9Q4
M!6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !FK
M9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,  #E5
M   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(  &\8
M  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP  ;\$
M &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=   J
M80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3  ![
M&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H  'OB
M  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C:P
M&F\  !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "($P
MB1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8  "(
M]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>   $WT
M  V!   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@  F!(
M )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":\
MF?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P   21
M    E0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P  *H1
M  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@  K/P
M *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B
MI@   *H   "N    L    +$   "S    M    +8   "X    N@0  +P*  "^
M$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(  ,/_
M %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R    MP
M +L   "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2"
MU0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T $Z+
M  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R    ,X
M  #1    U    -4   #8    V@   -T   #?    X@   .0   #G    ZP4
M .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\ "P#_
M  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!: /\
M8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H \@"W
M .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_
M_P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /< 7 #T
M &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P -T
MP #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_    _P
M /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A %P
MW@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0 MP#!
M ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P   /H
M  #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8 Q !<
M ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N ,$
MK0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@   #<
M    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5 *X
M6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@ F@#0
M )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%
MNP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P 50":
M %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#% (@
MY@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S    J@
M *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"* %0
MB0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H VP!X
M /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP   )8
M!0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\ ? !5
M 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L .X
M:P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"  "%
M  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0 &X
M5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D 8 #\
M &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y"0$
M> ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$4@!C
M!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[ %4*
M_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$   ;0T%
M &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;#58
M60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0_P!-
M$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0  &00
M" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U, 41-;
M % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%%?\
M117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7 @!:
M%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8 $@:
M8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\ /AO_
M *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3' L
M41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@7P!
M(6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_ *HF
M  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@< 2B(0
M $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z)F<
M.29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I  "/
M*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<- $(H
M% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4 ,RMR
M #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "++0
M>2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL$0 [
M+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P "PP
M@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',   =C$
M &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V,A8
M-3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U?@ E
M-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0  &4T
M  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q, +S<;
M "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @.HX
M'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W  !7
M-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8 "@]
M'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP &#^@
M !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3.@
M2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"&P @
M0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2> !%$
MLP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0  2#T
M $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 821X
M%TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*L  *
M2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14   #]
M   Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D $% A
M  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "4,4
M T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$   U
M10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<  =8
M)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\   %;E
M  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P2@
M*4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@'P
M8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B  !>
M^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40  (U0
M !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0  :B$
M &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H]P
M9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T  !9@
M   09   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L  '8C
M  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0  <_\
M '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L   *
M<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;  "%
M)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\  (#_
M %];  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !?@
M ($   "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5&P
MER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_ %UA
M  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@   )(
M  "6    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P  J1P
M *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H  !(
M;   .G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,   "G
M    J@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(  , <
M  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  ! >0
M,G\  "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y
MO    +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42  #6
M(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0  *Y
M !V8   2H   "J<   "N    M    +D   "^    P@   ,@   #+    S@
M ,\   #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O$P
M\"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P % /\
M"P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0 _P!J
M /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I .0
MYP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\  @#_
M  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C .P
M:0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0 SP#R
M ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_  8
M^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0 8P#1
M &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H +@
M_0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $ Y  ,
M -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y &$
MMP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *, ]0"C
M /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP ' ,$
M#P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H HP!@
M *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1 /\
MD #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L # "G
M !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !: (\
M7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D ?P#_
M '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5  X
MD@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\ 60!^
M &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_ '
M_P!P /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L @P 1
M ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P %H
M;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &, _P!C
M /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P . '4
M$P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8 8P!=
M &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8 /\
M60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L $ !I
M !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9 %@
M8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\ 3@/_
M +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A!!$
M7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )7P!.
M"6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_ + 4
M  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T 5PP4
M %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'#V@
M10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9  "2
M&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0 $X1
M& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4 /A5R
M #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-'@
M>R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7%0!%
M%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO #4;
M?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@  =R,
M &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _'1D
M/ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@?  M
M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8  &4G
M  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8 ."(>
M #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H)8P
M)B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J  !7
M*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<; #$H
M(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH (2J=
M !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4+
M3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL'P J
M+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^; !HO
ML  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P  22\
M $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E,B,
M)#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0SK@ 3
M,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(  $ Q
M   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R  'C<G
M !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 ..,<
M#CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT   X
M-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC !8]
M*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$ "CWD
M  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U-P
M,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$)P /
M1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@  -#
M]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@  +3L
M "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (2BL
M!THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)]0
M2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4   "-"
M   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428  %$O
M  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0  3_\
M $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(   7
M2P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI  !:
M,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\  %?_
M &5%  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   24P
M#E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D+0
M9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_ %]*
M  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70  "&
M  )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@  <3$
M ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/  !0
M3@  2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L   !O
M    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@  ( U
M  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.4P
M0E0  #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]
M@    (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L  "2
M.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@  .UT
M "]A   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".    D0
M ),   "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F,0
MID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD  "=N
M   ;=0  $7P   N#    B0   (X   "3    F    )T   "A    I    *4
M  "G    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0  O#<
M +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_   3
MA@  "XX   &5    FP   *$   "F    JP   +    "S    MP   +<   "Z
M    O    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L  -1
M  #36   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -F0
M Z    "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-
MSP   -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS  #N
M2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X _P 5
M /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[ '$
M^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .( _P#;
M /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0 /\
M&0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H Y !P
M .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#% /\
MNP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$ $P#M
M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8
M;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_
M *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/ !@
MRP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L
M &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8
M_P"3 /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !, L0 <
M *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8
ME@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (< _P"%
M /\ @@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6 )D
M'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G
M (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\
M=0#_ .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (< &0"%
M "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '(
M:0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_
M -(   "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V !P
M=  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C
M &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(
M  "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !< :  >
M &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@
M5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?
M"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P
M(0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O
M $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@
M@Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2
M ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#
M>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,
M &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\
M20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z
M#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8
M  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA
M $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H
M,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9
M'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3
M)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6:
M "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P
M3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S
M&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:
MK0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(
M $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24
M+1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;
M'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D
M   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I
M "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$
M%23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y
M)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H
M+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD
M !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0
M,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :
M+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM
M^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P  +RL
M "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C
M$S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *
M,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN
M   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U
M  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\
M!3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @
M,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^
M.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\  #S_
M &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =.
M&#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@
M1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V
M  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0  $T
M !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@  2ST
M $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4
M.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<   Q)
M   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$
M  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P
M13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92
M5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>
M3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(
M #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;    7@
M &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10
M:U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048  #='
M   L2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@   &P
M  !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX
M 'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F
M4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P   !]
M    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8
M  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P
M%&4   UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".
MD0   ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@
M90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@  #G4
M  5[    @0   (<   "-    D@   )8   ":    G0   )\   "A    I
M *8   "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@
MM78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".
M    E    )H   "@    I0   *H   "N    L0   +(   "U    MP   +H
M  "\    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P  SFH
M ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A
MIP   *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X   #2
M    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ
M  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4
M_P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T
M (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4
M_P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\ _P I
M /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@
MU@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D
M /\ H0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C .4
M+0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X
M +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\
ME #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_
M "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$
M>0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_
M /<   #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G "@
MH@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+
M 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D
M  #7    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J
M (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ',
M=@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_
M    K    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D 'H
M*P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X
M &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M
MFP   (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L )0!I
M "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D
M@ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0
M '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8
M6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!,
M (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(
M  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "( 40 H
M %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4
M00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A
M#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $<
M*0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4
M #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0
M4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^
M RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &
MI0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0
M $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@
M-PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G
M#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7
M   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L
M # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T
M'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :   [
M&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3
M,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7>
M !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W'
M-!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C
M&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9
M]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P  ,1X
M "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3(
M'!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0
M'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@
M   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X
M !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\
M#2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C   D
M(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H
M/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_
M '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B)0
M'2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P +
M+48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE
M  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*   &RH
M !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(
M S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8
M*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX  !,P
M   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*
M   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@
M2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U   .
M-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^
M5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(
M #LR   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   */0
M!4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&3P
M1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU
M   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10   $<#
M  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH
M $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q
M-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\   !1
M!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650  %AG
M  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L/
M)#X  !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;
M70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@  !E
M=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P  'D8
M !5*   03@  "E(   -6    6@   %T   !@    8P   &4   !G    :0
M &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T;P
M<XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6
M   )6@   5\   !C    :    &L   !O    <@   '4   !W    >0   'L
M  !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$
M (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED
M:0   &\   !T    >    'P   "!    A    (<   "(    BP   (X   "0
M    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6
M  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T    >P
M ($   "&    BP   )    "4    EP   )D   "<    GP   *$   "D
MIP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "P
MJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@   )4
M  ":    GP   *0   "H    K    *T   "P    LP   +4   "X    NP
M +\   ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@
MR+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@   "N
M    M    +@   "]    P    ,(   #%    R    ,L   #.    T0   -8
M  #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,
M ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_
M #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T
MC@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_
M /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@
M\ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#*
M )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\
M  #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y
M ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@
MK@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O
M    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$
M.@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@",
M )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@
MT0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5
M #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (
MD@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@
M *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + "" #(
M?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L
M )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),
M  ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R
M &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )(
M6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y
M    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X
M,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P">
M $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K
M9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1
M #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $,
MK !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,
M %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T
M10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X
M +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(
M  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N
M #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@
M+P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!
M#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0
M,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +, )P#1
M "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \#P
M.0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M
M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%
M[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$
M #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##(
M)@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7
M#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3
M   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y
M !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X
M$A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6   G
M%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D4
M0  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_
M ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D&
M(A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2
M&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8
M  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@  'AH
M !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44
M#1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;
M'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>
M   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-
M  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P
M2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A   2
M(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G
M5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,
M #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0)@(
M#B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P
M+&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF
M   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&
M  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\
M #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I   O
M*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T
M"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN
M   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M*P
M*"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z!P
M.PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  !
M@   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0  )RP
M " M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!   0P<
M $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P
M2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS
M   6-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0  $X'
M  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=   4I
M %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z   1
M/0  #$$   =$    2    $H   !-    4    %,   !5    5P   %@"  !;
M!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG
M  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,1P
M!DL   !/    4P   %8   !9    7    %\   !A    8P   &4   !G 0
M:@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !K
MP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5    %@
M  !=    80   &4   !H    :P   &X   !Q    <P   '4   !X    >P
M 'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^M@
M?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@   !M
M    <0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@   )(
M  "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0
M )#Z #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "
MA    (H   ".    D@   )4   "7    F@   )T   "@    HP   *<   "K
M    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN
M #%5   D6P  &&$   YI   %<0   'D   "!    B    (\   "4    F@
M )\   "D    J    *D   "L    KP   +,   "U    N0   +T   #!
MQ@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB
M   <:0  $7$   =[    A    (T   "5    G0   *,   "I    KP   +0
M  "Y    O    +X   #"    Q0   ,@   #,    T    -0   #:    WP
M .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_
M    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\
M20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C
M .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[
M]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F
M $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\
MJ@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@
M .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $(
MOP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C
M +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,
M  #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L I !!
M *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D
MB0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8   "I
M    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H
M/P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V
M ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3
MB@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T
M #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &(
MR0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^    >
M ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #<
M8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2
M .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P   &,
M  !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V
M %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@
M1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8   !3
M    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $<
M-P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S
M #L _P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)
M1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [
M #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$
M_P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P  /@$
M #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0
M,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I
M /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%
M   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W
M "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A /\
M(@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+   M
M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!
M/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_
M '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G#0$
M)PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <
M"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.
M  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$   (@X$
M "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4,
M%0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<
M$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0
M!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0
M  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%
M2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2!  7
M$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L4
M6  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<
M #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4%04
M$A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $
M&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:
M   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'
M  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6
M !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O
M'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>
M"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T  "%O
M   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P
M)QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %
M(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L   F
M@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0  )2
M " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0  * L
M "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L@
M*YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A
M   <(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D  # ,
M   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<
M #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC   9
M(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*   Y
M#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP
M   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5*
M$2H   XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!"@
M0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  !
MT@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$
M  DT   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P  3 L
M $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*R@
M2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H   (]
M    0    $0   !'    20   $P   !/    40   %,   !5 0  6 8  %H+
M  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(
M %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)
M3    %    !3    5@   %D   !;    70   &    !B    90   &@%  !K
M"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_
M #@Y   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6    6@
M %X   !B    90   &@   !K    ;0   '    !S    =@   'D   !]!
M@0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]
M   L/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P   &\
M  !T    >    'L   !^    @    (,   "&    B@   (T   "1    E@,
M )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$   E
M2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0   ")
M    C0   )$   "3    E@   )D   "=    H    *0   "H    K    +(#
M  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >5
M$EL   IB    :@   ',   ![    @@   (D   ".    E    )H   "?
MI    *8   "I    K0   +    "S    MP   +L   #     Q0   ,L   #1
M!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L
M  %T    ?0   (<   "0    EP   )X   "D    JP   +$   "V    N@
M +P   #     Q    ,@   #+    SP   -0   #:    X    .8   #K
M\08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,
M  #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2
M /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X
MT@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D   #I
M    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@
M4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H
M *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;
MW    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U
M $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D
M_ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\    M@
M +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $<
MEP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\
M /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F    )0
M  "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !%
M 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\
M90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P   !Z
M  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D
M1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_
M %0 _P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F
M90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7
M $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D
M_P!' /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7    50 !
M %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T
M20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ]
M /\ /@#_ )0   !_    ;P   &,   !9    40   $T   !*    2    $<
M! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^
M #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\
M-0#_ (@   !T    90   %@   !/    2    $,    _    /0   #P  @ \
M  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$
M00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\ + #_
M '\   !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R  4
M,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D /0 H
M $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<
M  !E!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  , *@ '
M "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A $,
M( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?
M"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0& ","
M"0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!*
M !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P
M30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =
M!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#
M5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X
M #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD
M%PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ .
M"6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1
M   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+
M !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6
M" UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O
M$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .
M#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O
M  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M%
M)A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,
M$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3
M@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@  )!4
M !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T
M!Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6@
M%ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6
M   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.
M  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<
M !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8   8
M%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @
M$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q
M   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7&
M%!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E#@
M)A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O   C
MV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH
M ! ;   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#   +@\
M "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   JU
M*?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X   X?
M   +(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T  #81
M   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H
M "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE   &
M*    BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .  !!
M$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_
M #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M    ,
M #,    V    .    #L    ^    0    $(   !% @  1P8  $H*  !-#@
M314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L
M   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@   #T
M  !     0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P  6Q
M %L9  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P   L
M+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D   !,
M    3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP  &P2
M  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0
M(C(  !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;
M7P   &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-  ""
M%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.   '#L
M !)    +10   DL   !1    5@   %L   !@    90   &D   !N    <@
M '8   !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<#@
MFQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<   U-
M   "5    %L   !A    :    &X   !S    >0   'X   "#    B    (P
M  "/    D@   )4   "9    G0   *$   "E    J@   +    "W!P  N!$
M +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<
M9    &T   !U    ?    (,   ")    CP   )4   ";    H    *,   "F
M    J0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H  -86
M  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N    =P
M '\   "(    D    )@   "?    I0   *T   "S    N    +H   "^
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M____________________________________________________
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M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
ME:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:
M_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'
M?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA'
M)O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQ
MQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N
M433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>
MM<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_
MKUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)V
MH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%
M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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M6%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUC6Q @
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ML,&'C;#!AXVPP8>-L,&'C;#!AXVPP8>-L,'_EQL#_Y4G"/^=+PW_J3@3_[-
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M_XXE!_^6+ O_HC40_ZP]&/^U12/_O$PR^,%40_##7%;GPV-JVKMI?LRR<(_
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M0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT/&O@4
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
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M9$G_G6]8^IAY9?&2@W'JBXQ\Y(.2AM]]F8[:>*"5UG2GFM-PKI_1;;:CSVO
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M;%3NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&W_HQ
M\;D, ,[)"0#$WPL MO<?!JS_,A*@_SL=E/]!)XK_1S&!_TXY>O]8/W/_8D5N
M_VQ):?]S3&;_>D]C_X!18/^&4U[_C%1<_Y)56OZ85UG]G5A7_*195?NK6E3[
ML5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5OPKP@ S;\'
M ,#-" "T[@X"J?\A")__,1&2_S<:A_\^(GW_12EU_TTP;O]5-6G_8#EE_VH\
M8?]Q/E__=T!<_WY"6O^$0UG_B417_X]%5O^41E7_FD=3_Z!(4O^G25'_K4I1
M_ZU*4?^M2E'_K4I1_ZU*4?^M2E'_K4I1_ZU*4?^M2E'_K4K/N 0 OL,% ++4
M!@"F_A #G/\C")#_+0^$_S,6>?\[''#_0R)I_THG8O]2*EW_7"U:_V4P6/]M
M,5;_<S-4_WDT4_]^-5+_A#90_XDW3_^..$[_DSA-_YDY3/^@.DO_ICI+_Z8Z
M2_^F.DO_ICI+_Z8Z2_^F.DO_ICI+_Z8Z2_^F.DO_ICJ_O , L,H# */< P&9
M_Q(#C_\B"(+_* UV_R\2;?\W%V7_/QM>_T<>6/].(53_5R-1_U\E3O]E)DW_
M;"=+_W$H2O]V*4G_>RI(_X J1_^%*T;_B2M%_XXL1/^4+$/_FBU#_YHM0_^:
M+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBVQP@$ H](  )7K P&,_Q,#
M@/\<!G3_(PII_RH.8/\R$EG_.A53_T(73O])&4O_41I(_U@<1O]='43_8QU#
M_V<>0?]L'T#_<!\__W0@/O]X(#W_?" \_X$A._^'(3O_C"([_XPB._^,(CO_
MC"([_XPB._^,(CO_C"([_XPB._^,(CO_C"+_>AT#_W8H!O]R,PO_?#</_X0_
M%?^(2!W_BU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B7?QQJ&'Z;JYD
M^&NT9_=INFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9SW5OF<]U;YG/=
M6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/_>AT#_W8H!O]R,PO_?#</_X0_%?^(
M2!W_BU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B7?QQJ&'Z;JYD^&NT
M9_=INFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9SW5OF<]U;YG/=6^9S
MW5OF<]U;YG/=6^9SW5OF<]U;YG/_>AT#_W8H!O]R,PO_?#</_X0_%?^(2!W_
MBU,G_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B7?QQJ&'Z;JYD^&NT9_=I
MNFGU:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9SW5OF<]U;YG/=6^9SW5OF
M<]U;YG/=6^9SW5OF<]U;YG/_>AT#_W8H!O]R,PO_?#</_X0_%?^(2!W_BU,G
M_XE@,?^&;3O_@GE$_WZ&3/][D5/_=YI8_W2B7?QQJ&'Z;JYD^&NT9_=INFGU
M:,%K\V;(;>]CS6_L8=-PYU_=<>)=Y7/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;
MYG/=6^9SW5OF<]U;YG/_>AP#_W<G!O]T,@O_?S8/_X8]%?^+1QW_CE$G_XQ>
M,?^):SS_A7=&_X&#3O]]CU;_>9A<_'6@8?ERIF7W;ZUI]6RS;/-JN6_R:,!Q
M\&;(<^QDS77H8=1VXU_>=]M=XWG57>5VU5WE=M5=Y7;57>5VU5WE=M5=Y7;5
M7>5VU5WE=M5=Y7;_>QP#_W<G!O]W, K_@C4._XH\%?^/1AW_DD\G_Y%<,O^.
M:#W_BG1(_X: 4O^!BUK\?95A^'B=9_5TI&WR<:IQ\&ZP=.YKMG?L:;YZZF?'
M?>=ESG_B8M: V5_=@=!?X'[,8.-[S&#C>\Q@XWO,8.-[S&#C>\Q@XWO,8.-[
MS&#C>\Q@XWO_?!P#_W@F!O]Z+PK_A3,._XT[%/^21!S_EDXG_Y5:,O^293[_
MCG%*_XI]5?Z%B%[Y@))G]'N:;O!VH7/M<J=XZF^N?>ALM(#F:;R#Y&?&AN%E
MSXC98M>*SV'9B,ABW8+$8^!_Q&/@?\1CX'_$8^!_Q&/@?\1CX'_$8^!_Q&/@
M?\1CX'__?1L#_WDF!O]\+@K_B#(._Y Z%/^50QS_FDPG_YE8,_^68S__DFY,
M_XYZ5_R)A6+UA(]K\'Z7<^QYGGKH=*6 Y7"KA>)LLXG@:KN,WFC&C]IFT9+.
M8M&2QV35C,%EVX:]9MV"O6;=@KUFW8*]9MV"O6;=@KUFW8*]9MV"O6;=@KUF
MW8+_?1L#_WHF!O]_+ K_BS$-_Y,Z$_^80AS_G4LF_YU6,_^;84#_EVQ-^Y)V
M6O>-@6;RB(QP[(*4>>=[FX'C=:*(WW&ICMQML9+9:[N6UVG(F<QDRYO%9<Z7
MP&?2D;IHV(JV:=N&MFG;AK9IVX:V:=N&MFG;AK9IVX:V:=N&MFG;AK9IVX;_
M?AL#_WLF!O^!*PG_C3$-_Y4Y$_^;0AO_H$HF_Z%4,_^?7T'[G&E/]I=S7?&2
M?FKLC(AUYX61@.)^F(G=>*"1V'*GE])MKYW/;+F?S&O%H,-GQZ"\:,N;MVK0
ME+)LU8VO;-F)KVS9B:]LV8FO;-F)KVS9B:]LV8FO;-F)KVS9B:]LV8G_?AH#
M_WLE!O^#*@G_CS ,_Y@X$O^>01O_HTDF_Z92,_VD74'WH6=0\9QQ7^N7>VWE
MCX-ZWH>+AM5^DI'/>)F7RG2AG,=QJI_#;[.AP6Z_H[IKQ:.S:\B?KVW-F*MO
MTI&I<-:,J7#6C*EPUHRI<-:,J7#6C*EPUHRI<-:,J7#6C*EPUHS_?QH#_WPE
M!O^&*0C_DB\,_YLX$O^A0!K_IT@E_ZI1,OFI6T'SIF11[*)N8>6:=G#<D7Y_
MTHF&B\N"C9/%?969P'B=GKQUI:&Y<ZZDMG*YI;)PPZ:K;\:BJ''+FZ1ST).B
M=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU([_@!H#_WPE!O^(
M* C_E"\+_YTW$?^D/QG_JD<D_:Y/,O:M64'OJV)2YZ9K8MZ><G/2E7J!RHV"
MB\.'BI.]@9&:MWV9G[-YH:.O=ZJFK':TIZIVP:BC<\.EH'7)GIYWSY:<=]*1
MG'?2D9QWTI&<=]*1G'?2D9QWTI&<=]*1G'?2D9QWTI'_@!H#_WTE!O^*)PC_
MEBX+_Y\V$/^G/QC_K4<C^[).,?.R5T'KL6!2XJIH9-:B<'3,F7>!PY)_B[R+
MAI2UAHZ:KX&5H*I^G:2F>Z:GHWJPJ:%YO*F;=\&HF7G'H)AZS9B7>]&3EWO1
MDY=[T9.7>]&3EWO1DY=[T9.7>]&3EWO1DY=[T9/_@1H#_WXD!O^,)@?_F"X*
M_Z(V$/^I/AC_KT8C^+5-,/"W5D#GM5Y2W:YF9-"E;G/&G76 O99\B[60@Y2N
MBHN;J(:2H*."FJ6??Z.HFWZMJIA]N:N4>\"JDWW&HI)^S)F1?]"4D7_0E)%_
MT)21?]"4D7_0E)%_T)21?]"4D7_0E)%_T)3_@1D#_WXD!O^-)@?_FBT*_Z0U
M#_^L/1?^LD4B]KA,,.V\5$#DN%U1U[)D8\NI;'/ H7. MYIZBZ^4@).HCXB;
MHHJ/H)R'EZ67A*"HE(*IJI&"M:N-@;^KC8'%I(R"RYN,@L^5C(+/E8R"SY6,
M@L^5C(+/E8R"SY6,@L^5C(+/E8R"SY7_@AD#_W\D!O^/)0?_G"T)_Z8U#O^N
M/1;\M44A\[Q++NK!4C_@O%M1T;5C8\:M:G*[I7%_LIYWBJF8?I.BDX6:FX^-
MH):,E:61B9VHC8>GJXJ'LJR'A[^LAH;$I8>&RIR'ALZ7AX;.EX>&SI>'ALZ7
MAX;.EX>&SI>'ALZ7AX;.EX>&SI?_@AD#_X C!?^1)0;_GBP)_Z@T#?^Q/!7Z
MN$0?\+]++>?%43W<P%I0S;AA8L&P:'&VJ6]^K*)UB:2=?)*<F(*:E92*H(^1
MDJ6*CINHAHVEJX.,L*R!C;ZL@(O#IH&+R9V!B\V8@8O-F(&+S9B!B\V8@8O-
MF(&+S9B!B\V8@8O-F(&+S9C_@QD#_X(B!?^3) ;_H"P(_ZLS#?^T/!3WO$,>
M[L1**^3)43O5Q%A/R+Q@8;RT9W"QK6U]IZ=SB9ZB>9*6G8"9CYJ(GXF7D*2#
ME)BH?Y.BJGR2K:MZDKNL>I'#IGN0R9Y\C\V8?(_-F'R/S9A\C\V8?(_-F'R/
MS9A\C\V8?(_-F'R/S9C_@Q@"_X0A!?^5) ;_HBL(_ZTS"_ZW.Q+TP$(<ZLE)
M*.#-3SG0QU=.P\!>8+>X96^KLFM\H:QQAYBG>)"0HWZ8B:"%GH*=C:-]FY:G
M>)F@J769JZISF;BK<YC#IG66R9YVE<V9=I7-F7:5S9EVE<V9=I7-F7:5S9EV
ME<V9=I7-F7:5S9G_A!@"_X<@!?^7(P7_I2H'_[$R"ON[.A#QQ4$9Y\]()=O2
M33C+RU5,O<1=7K&^8VZEN&I[F[)OAI*N=H^)JGR6@J>#G'NDBZ%VHI2E<:&=
MIVZ@J:ELH;:I;:'#IF^=R9YPG,V8<)S-F'"<S9APG,V8<)S-F'"<S9APG,V8
M<)S-F'"<S9C_A1@"_XH>!/^:(@3_J"D&_[4P"/; . [KRT 5X=A&(-/82S;%
MT%1+M\E;7*O#8FR?OFAXE+EN@XNU<XR#LGJ3>Z^!F76MB9YOJY*B:ZJ<I&BJ
MIZ5FJK2F9JO%I&BFRIQII,V7::3-EVFDS9=II,V7::3-EVFDS9=II,V7::3-
MEVFDS9?_AA<"_XT<!/^>(03_K"<%_;HO!N_'-@KCU#X0V-]#'\O>2C2^UE)(
ML-!:6J3*8&F8QF9VC<%L@(2^<HE[NWB0=+E_E6ZWAYIIMI"=9;6;H&*TIJ%@
MM;.A7[;%H&&QS)IBKL^58J[/E6*NSY5BKL^58J[/E6*NSY5BKL^58J[/E6*N
MSY7_AQ<"_Y$: _^B( /_LB4#]< K!.;/,0;8WC@/S.5#(,/B23.VWE%&J=A8
M5YS27F60SF1RALMJ?'S(<(1TQG>*;L1^CVC#AY1CPI"77\&;F5S!III;PK.;
M6L/%FEN^SY5<NM*17+K2D5RZTI%<NM*17+K2D5RZTI%<NM*17+K2D5RZTI'_
MB18"_Y89 O^H'0+^N"$"[,DB MG=)03,Y3<1PNI#(K?G2#.LY$]$H.!64Y3=
M76"(VF-K?M9J=774<'UNTG>#9]%_B&+0AXM>T)&.6M"<D%C0IY%6T+625=+'
MD5;-U(Y6R-:+5LC6BU;(UHM6R-:+5LC6BU;(UHM6R-:+5LC6BU;(UHO_BQ4"
M_YT7 ?^O&0'TP1@!W=@1 ,SE)@7![C<3MN]"(ZOM1S*AZTQ ENE538OG75B"
MYF5A>>1L:7+D=&]LXWQT9^*$>&+BC7M>XI5^6^">@%C?IX)5WK&#4]Z^@U+>
MTH-1V=R"4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"4=G<@E'9W(+_CQ,"_Z03
M ?ZX$@#6S L S.01 <#O)@>U]3@5JO1 (I_S1C"5\DL\C/%41H+P74]Z\&96
M=/!N7&[O=F%I[WYD9>^&:&'OCFI>[I9M6^V>;UCKI7!6ZZYQ5.JX<E+JQW-1
MZ=5S4>G5<U'IU7-1Z=5S4>G5<U'IU7-1Z=5S4>G5<U'IU7/_F! !_ZX. -3!
M"0#)SPD OO 2 K/Y)PJI^S@5GOL^(9/[1"R)^DHU@?I3/GGZ745R^F9*;?IO
M3FCZ=E)D^GY58?J&5U_[CEI<^I9;6OF=75?XI5Y5]ZQ@4_>U85+VP6%0]LIB
M4/;*8E#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF+_HPL UK@& ,;$!P"[
MU D L/P4 Z;_*0N<_S45D/\['H;_0B9]_TDN=?]1-&__6SII_V4^9?]N06+_
M=41?_WQ&7/^#2%K_BTE8_Y-+5O^;3%7_HDU3_ZE.4?^Q3U#_NU!/_\-13__#
M44__PU%/_\-13__#44__PU%/_\-13__#44__PU':KP( QKP% +G)!0"MVP@
MH_\7!)K_*PN._S$2@_\X&GG_0"!P_T<F:?]/*V/_6"]?_V(R7/]K-%K_<C98
M_W@X5O]_.53_ACM2_XT\4?^5/4__G#Y._Z,^3?^J/TO_LT!*_[E!2O^Y04K_
MN4%*_[E!2O^Y04K_N4%*_[E!2O^Y04K_N4'(M0( N,$$ *O0 P"?ZPD!EO\:
M!8O_)@I__RT/=?\U%6S_/1IE_T0>7O],(EC_5"55_UTG4O]E*5#_;"I._W,K
M3?]Y+$S_?RU*_X4N2?^,+TC_DC!'_YDP1?^@,43_J3)#_ZXR0_^N,D/_KC)#
M_ZXR0_^N,D/_KC)#_ZXR0_^N,D/_KC*XN@( JL@  )W9  "2_PP"B?\:!'W_
M(0AR_R@,:/\P$&#_.!1:_T 75/](&D__3QQ,_U<=2?]='D?_8R!%_VD@1/]O
M(4+_=")!_WHB0/^ (S__AB0^_XPD/?^2)3S_F24[_YXF._^>)CO_GB8[_YXF
M._^>)CO_GB8[_YXF._^>)CO_GB:KP0  G=   (_A  "&_PX">O\5 V[_' 9D
M_R,)7/\K#%7_,P]/_SL12?]"$T;_211"_T\60/]5%C[_6A<\_U\8._]D&#G_
M:!DX_VT9-_]R&C;_=QHU_WP:-/^!&S/_B!LR_XT;,O^-&S+_C1LR_XT;,O^-
M&S+_C1LR_XT;,O^-&S+_C1O_<!X#_VPI!O]I,PG_<C<-_WD^$O]]1QG_@%$A
M_WY?*?]\;3+_>7LY_W:(0/]SDT7_<)U*_VZF3O]KK5'_:;13_VB[5?]FPU?_
M8\=9^V',6_=?TUSS7MU=\%SC7NM;Z5_G6>]@Y5GQ7^59\5_E6?%?Y5GQ7^59
M\5_E6?%?Y5GQ7^59\5__<!X#_VPI!O]I,PG_<C<-_WD^$O]]1QG_@%$A_WY?
M*?]\;3+_>7LY_W:(0/]SDT7_<)U*_VZF3O]KK5'_:;13_VB[5?]FPU?_8\=9
M^V',6_=?TUSS7MU=\%SC7NM;Z5_G6>]@Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E
M6?%?Y5GQ7^59\5__<!X#_VPI!O]I,PG_<C<-_WD^$O]]1QG_@%$A_WY?*?]\
M;3+_>7LY_W:(0/]SDT7_<)U*_VZF3O]KK5'_:;13_VB[5?]FPU?_8\=9^V',
M6_=?TUSS7MU=\%SC7NM;Z5_G6>]@Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E6?%?
MY5GQ7^59\5__<!X#_VPH!O]K,0G_=38-_WL\$O]_1AG_@U A_X%>*O]^:S/_
M>W@[_WB&0O]UDDC_<IM-_W"D4?]MK%3_:[)7_VFY6O]GP5S\9<=>^&+,7_5@
MTV'P7MUB[%SD8^A;Z63B6N]DX%KP8N!:\&+@6O!BX%KP8N!:\&+@6O!BX%KP
M8N!:\&+_<1T#_VTH!O]N, G_>#0,_W\[$O^#1!G_ATXA_X9;*_^#:#3_?W4]
M_WR"1?]YCDS_=IE2_W*A5O]OJ5K^;;!>_&JW8?MHOF/Y9L9E]&/,9_!ATVGK
M7]YKYEWE;.!;Z6W97.YHUESO9]9<[V?67.]GUESO9]9<[V?67.]GUESO9]9<
M[V?_<AT#_VXH!O]Q+@G_>S(,_X,Z$?^'0QC_BDPA_XI9*_^'937_@W(__W]^
M2/]\BU#_>996_W6?7/URIF#Z;JUD^&RT:/9IO&OT9\5M\&3,<.MATW+E7]]S
MWESE=-9<Z''/7NULS5[N:\U>[FO-7NYKS5[N:\U>[FO-7NYKS5[N:\U>[FO_
M<QP#_V\G!O]T+0C_?C$,_X8Y$?^+0AC_CDLA_XY6*_^+8S;_AV]!_X-[2_]_
MAU/^?));_'B<8?ETI&?V<*MK\VVR;_%JNG/O:,-VZV7,>.9BU7K>7]]\TUWC
M>\U?YG;'8.IPQF#L;L9@[&[&8.QNQF#L;L9@[&[&8.QNQF#L;L9@[&[_=!P#
M_W G!O]V*PC_@2\+_XDX$/^.0!C_DDDA_Y-4+/^08#?_C&Q#_X=W3?N#@U?X
M?XY@]GJ79_-VH&[P<JAS[6ZO>.MKN'SH:,)_YF;-@M]BV(317]R%RF#@?\5A
MXWJ_8^ATOF/I<KYCZ7*^8^EROF/I<KYCZ7*^8^EROF/I<KYCZ7+_=!P#_W F
M!O]Y*@C_A2X+_XTW$/^2/Q?_ED@@_Y=2+/^57CC^D6E$^HQT4/6'?UOR@HEE
M[GV3;NIWFW7G<J-\Y&ZK@>%JLX;>9[V*VF7*C=)BU([(8MB*PF/<A+QEX'ZW
M9N5XMF;F=K9FYG:V9N9VMF;F=K9FYG:V9N9VMF;F=K9FYG;_=1L#_W$F!O]\
M* ?_B"T*_Y V#_^6/A;_FD<@_YQ0*_^:6SCYEV9%]))P4N^,>U_JA85JY7Z-
M=.!XE7W;<IV%U&VDB]!JK8[-:+>0RVC#D<AGT9*_9=2/N6?9B;1HW8*P:>)\
MKFKD>:YJY'FN:N1YKFKD>:YJY'FN:N1YKFKD>:YJY'G_=AL#_W(F!?]_)P?_
MBBP*_Y,U#O^9/1;_GD8?_Z%.*_N@63CUG&-&[YAM5.B0=V+BB']OVH"'>])Z
MCX/-=9>)R7&?C<5NJ)'";+&3OVN\E;UKRY6V:="4L6O5C:QLVX:H;>!_IVWB
M?*=MXGRG;>)\IVWB?*=MXGRG;>)\IVWB?*=MXGS_=AL#_W,E!?^!)@?_C2P)
M_Y8T#O^=/!7_H40>_J5,*O>E5SCPHF%'Z9QJ5N&4<F78C'MSSX6#?,E_BX3#
M>I.*OW:;C[ISHY.W<*R6M&^WE[%OQ)BL;<V8J6_3D*5PV(FA<=Z"H''@?Z!Q
MX'^@<>!_H''@?Z!QX'^@<>!_H''@?Z!QX'__=QL#_W0E!?^#)0;_D"L)_YDS
M#?^@.Q3_I4,=^ZE+*?.J5#CLJ%Y'XZ%G5]J9;V?/D7ASQXJ ?<&$B(6[?X^+
MM7J7D+%WGY2M=*B7JG.RF:=ROYJD<LN:H7/0DYYTUHR;==R$FG7>@9IUWH&:
M==Z!FG7>@9IUWH&:==Z!FG7>@9IUWH'_>!H#_W8D!?^&(P;_DBH(_YLR#/^C
M.A/_J$(<^*U**/"O4C?GK%Q'WJ5D6-&=;6;(E75SP(Y\?;F)A(6S@XR,K7^3
MD:E[FY6E>:29H7>NFYYVNIR==\J<F7?/EI=XU(Z5>-N&E'C=@Y1XW8.4>-V#
ME'C=@Y1XW8.4>-V#E'C=@Y1XW8/_>!H#_W@C!?^((P;_E"H(_YXQ"_^F.A+^
MJT(;];!))^RU4#;CL%I&V*EC5\RA:V;"FG)RNI-Z?+.-@86LB(F,IH20D:&
MF):=?:&:F7NJG)9[MIV4>\:>DGO-F)%\TY"/?-F(CWS<A8]\W(6/?-R%CWS<
MA8]\W(6/?-R%CWS<A8]\W(7_>1H#_WHB!?^*(@7_EBD'_Z Q"_^H.1'[KT$:
M\K1()NFY3S3?M%E%TJUA5L>E:66]GG!RM)=W?*V1?H6FC(:,H(B-D9J%E9:6
M@IZ:DH"GG8]_LYZ-@,*>BX#,FHN!TI**@-B)B8#;AHF VX:)@-N&B8#;AHF
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M?1@"_X<: _^8'@/_IB,#_[,I!// ,0?GRS@+W=@Z%LW21BK S% ^L\983Z?
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M=$_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW3_CP\!_Z0. -NX" #-Q0D
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M>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7C_>A4"_XX2 ?^?$P#_L!,
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M9U>O\6=7K_%G5Z_Q9U>O\6?_?PX!_Y,+ .&E!0#2LP< R;X' ,++" "\W0X
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M&S#_H1LO_ZH<+_^U'"[_OQPN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQRIM0
MFL(  (S/  !_W@  =O\% &S_#@%B_Q0"6O\; U/_) 5-_RL'1_\S"4/_.@H_
M_T$+._]'##C_30TU_U,.,_]8#S'_7@\O_V00+?]K$2O_<Q$I_WP2)_^&$B7_
MD!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@  C<L
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M7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P VJT) -.X"@#.PPX
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M.$+PQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA [/\X0.S_.$#L_SC+H
MNJL  *VT  "AP   ELP! (O9!0"$^!$!?/@? G3X*09L^#(*9/@[#U[Y0Q-8
M^4L74_E3&E#Y6QU-^F0?2OIL(4CZ="-&^GXE1/N()D'[DRA ^YXI/ORK*CW\
MN2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J   KK
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M#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !KXP
M7_8  %;_  !._PH 1_\0 4'_%@(\_QT"-_\D S+_*@,O_S $*_\V!2?_.P4E
M_T %(O]%!B#_2@8>_U &&_]6!QG_7 <7_V0(%?]M"!/_=P@1_X$)$/^+"1#_
ME0D/_Y@)#_^8"0__F D/_Y@)#_^8"0__F G_22<"_T0Q!/]+,03_4#0&_U(Z
M"/]20PO_44X/_T]<$_]-:Q;_3'D9_TN'&_])DQW_2)T?_TBF(/]'KB'_1[4B
M_T:](_]&QB/_1M D_T;@)/]&ZB7_1O,E_T;Z)?]&_R7_1O\E_T;_)?]&_R3]
M1O\C_4;_(_U&_R/]1O\C_4;_(_U&_R/_22<"_T8O _]-+P3_4C(&_U4Y"/]5
M0@O_5$T/_U)9$_]0:!?_3W<:_TZ$'?],D1__2YLA_TJD(O]*K"/_2;,D_TF[
M)?](Q";_2,TF_TC=)_](Z"?_2/$H_TCY*/](_RC_2/\H_DC_*/M(_R?Y2/\F
M^4C_)OE(_R;Y2/\F^4C_)OE(_R;_2B<"_T@M _]0+03_53 &_U@V"/]90 O_
M6$L/_U56$_]49AC_4G0;_U&!'O]/CB'_3I@C_TVA)?]-J2;_3+$G_TNX*/]+
MP2G_2\HJ_TK9*O]*YBO_2O K_TKX+/]*_RS]2O\L^DK_*_=*_RGU2O\H]4K_
M*/5*_RCU2O\H]4K_*/5*_RC_2R8"_TLK _]2*P3_6"X%_ULT"/]=/@O_74D/
M_UI4%/]98AC_5W$=_U5^(/]3BB/_4I4F_U&>*/]0IBK_3ZXK_TZU+/].O2W_
M3<<N_TW3+_],XS#_3.TP_$SV,?I,_C'W3/\Q]4W_+_)-_RWP3?\K\$W_*_!-
M_ROP3?\K\$W_*_!-_RO_2R8"_TXI _]6*03_7"L%_V Q!_]B.PO_8D8/_V!1
M%/]>7QG_7&T>_UIZ(_]8AB;_5I$I_U6:+/]3HB[_4JHP_U&Q,?]1N3/_4,,T
M_D_.-?M/WS;X3NLW]4[U./)._3CP3_\U[E#_,^M1_S'I4?\OZ5'_+^E1_R_I
M4?\OZ5'_+^E1_R__3"4"_U$G _]:)@/_8"@%_V4O!_]H.0K_:$,/_V=.%?]E
M6AK_8F@@_U]V)?]=@2K_6HPN_EB6,?Q7GC3[5:8V^52M./A3M3KW4KX[]5')
M/?-1VC[P4.@_[%#S0.E1_3[H4_\[YE3_..-5_S7A5?\SX57_,^%5_S/A5?\S
MX57_,^%5_S/_320"_U0D _]=(P/_924$_VHM!O]M-@K_;D ._VU+%/]K5AO_
M:&0A_F5Q*/MB?2WX7X<R]ER1-O-:F3KR6*$]\%>I0.Y5L4+L5+E$ZU/$1NE2
MTDCE4>5)XE+R2-]4_$3=5O] VUC_/=99_SK26?\XTEG_.-)9_SC26?\XTEG_
M.-)9_SC_3B0"_U@A _]A( /_:B,$_W K!?]S- G_=#X._W1(%/]R4AO[;U\C
M]FML*O)G=S'O8X(W[&"+/>E=E$'F6IQ%Y%BD2>)6K$S@5+1.W52_4-M4S5#7
M4^)1TE3P3M!7^TK.6O]%S5S_0LE<_S[%7/\\Q5S_/,5<_SS%7/\\Q5S_/,5<
M_SS_3R,"_UL? O]E'0+_;B$#_W4I!?]Y,0C_>CL,_WI$$_IY3AOT=ELC[G%G
M+.EL<C7E:'P\X6.%0]U@CDC979=,U5R?3]):IU'/6;!3S5BZ5,M8QE7)5]I6
MQ5?L5<-;^4_"7O]*P%__1KU@_T*Z8/] NF#_0+I@_T"Z8/] NF#_0+I@_T#_
M4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O. 2QKL?%<CYG=C+>!Q
M;3C:;7= TVF 1L]EB4O+8Y%/R&"94L5?H57"7:I7P%RS6;Y<OUJ\6\Y;N%OE
M6[=>]56W8O]/M6/_2K)D_T:P9/]#L&3_0[!D_T.P9/]#L&3_0[!D_T/_51\"
M_V$: O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X:3C.
M<W- R6Y\1\1KA$S :(Q1O6645+ICG%>W8J5:M&"N7+)@N5ZP7\=>K5_?7ZQB
M\5FL9?Y3JF?_3JAG_TJF9_]&IF?_1J9G_T:F9_]&IF?_1J9G_T;_5QT"_V08
M O]P%@+_>QP"_X,B O^)*@3YC#('[XX[#>>.1!;>BE$AU(1<+<Q^9CC%>&]!
MP'1W2+MP@$VW;8A2LVJ05K!HF%FL9J!<JF6I7Z=DM&"E8\)AHV/58J)E[5VB
M:?M7H6K_49]K_TR>:_])GFO_29YK_TF>:_])GFO_29YK_TG_61P"_V<6 ?]S
M%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M N'ET
M2+-U?$ZN<H13JF^,5Z=ME%NC:YQ>H&FE8)YHL&.;9[UDF6?.9)AIZ&&:;?E:
MF6[_5)=N_T^6;O]+EF[_2Y9N_TN6;O]+EF[_2Y9N_TO_6QH"_VD4 ?]V% '_
M@1@!_XH= ?R1) +PERP$Y9HT"-R:/Q'/E$P?QHY7++Z(8#>W@FE L7YQ2*QZ
M>4ZG=X!3HW2(6)]QD%R;;YA?F&VA8I5LK&23;+EFD6O)9I!MY&21<?9<D7+^
M5I!R_U&0<O]-D'+_39!R_TV0<O]-D'+_39!R_TW_71@!_VL3 ?]Y$P'_A!8!
M_XX; ?B5(0'KFR@#X: P!M6>/1#*F$H>P9)4*[F,7C:QAV8_JX)N1Z9^=DZA
M>WU3G'B%6)AVC5R4=)5?D7*>8XYQJ66+<+5GB7#%9XAPX&:*=/1>BW;\6(IV
M_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0 _Y$8
M ?29'0'GH","W:4K!,^A.P_%G$@=O)93*K207#6LBV0_IH=L1Z"#<TV;@'I3
MEGV"5Y)ZBER.>))@BG:<8X=UIF:$=+)H@G3":(!TVVB#>/)@A'K[681Y_U2$
M>?]/A'G_3X1Y_T^$>?]/A'G_3X1Y_T__814!_W 0 ?]^$0#_BA( _Y05 /"=
M&0#CI1X!UZ@H \NE.0[!GT8;MYI1*:^56C2GD&(^H8MJ1IN'<4R5A'A2D(%_
M5XQ_AUR(?9!@A'N98X!ZHV9]>;!H>WF_:7IYUFE\?/!A?G[Z6GY]_E5^??]1
M?GW_47Y]_U%^??]1?GW_47Y]_U'_8Q0!_W(/ ?^!$ #_C1$ _)@2 .RA$P#?
MJA8 T:PF \>H-PV\HT0:LYY/)ZJ96#.CE& ]G)!H19:,;TR0B792BX9]5X:$
MA5N"@HY??H"78WI_H69W?JUH=7Z]:7-^TFEV@>YB>(+Z6WB"_E9Y@?]1>8'_
M47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X ]9L. .BF#@#9KP\
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M4DJ[QE)*N^113+OV3DVZ_TM.N?])3KG_24ZY_TE.N?])3KG_24ZY_TGOA0
MU)4  ,>C  "ZK $ L+0  *>_ P">R08 E=0+ )#5'0&)U"X&@-(\$'C01AEQ
MST\A:LY8*63-7R]?S&<T6LMN.5;*=SU2RH! 3\F+0TS)ET5)R:1'1\FS2$;*
MR$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0  RYP
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M(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@  J:X  )RY  "0Q
M@\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*_T *1O](#$/_3PY
M_U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__J1<N_[<8+?_(&"S_
MX1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S   ==D
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M0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\ _8P0 .V4$@#@FA4
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M5UF5P5=8E=Y66Y;S4%V7_TQ?E_]'8);_1F"6_T9@EO]&8);_1F"6_T;_< ,
MZX$  -:/  #*F@$ P:,# +FJ @"QL@$ JK<1 *.W) *;M30*D[) %(JO2AZ#
MK5,G?*M:+G:H835PIV@[:Z5O0&>C=T1BHG](7J&)3%J@E$]7GZ!15)^N4U.?
MP%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0  X(8
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M.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "KK
MH+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ ECUD807M90%5G56!I5
MU& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5PC$_U>$P/]/R,#_2
M_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0  EKL
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M$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0  <-,  &3>  !8YP
M4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P_T8%+?]-!2O_5 8H
M_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_P L:_]8+&O_?"QK_
MWPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0  1O\%
M $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=_TX#
M&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_N@8.
M_[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\  #3_
M"0 O_PX *_\4 "?_&@$C_R$!'_\E 1S_*@$9_R\!%O\T A3_.@(1_T "$/]&
M @[_3@(,_U8""?]@ P?_; ,$_W@# _^& P+_D0,!_YT# ?^A P'_H0,!_Z$#
M ?^A P'_H0/_-BT"_SDN O\^+@/_0#(#_T X!/\^00;_/$P(_SI:"O\X: S_
M-G8._S6##_\TCQ#_,YD1_S.A$?\SJ1+_,K 2_S*W$O\ROQ+_,L@3_S+3$_\R
MXQ/_,NT3_S+V$O\S_A+_,_\2_S/_$O\S_Q'_,_\1_S/_$/\S_Q#_,_\0_S/_
M$/\S_Q#_-BT"_SLL O] + /_0R\#_T,U!/]"/@;_0$H(_SY7"_\\90W_.G,/
M_SB $/\WC!'_-Y82_S:?$_\VIQ/_-JX4_S:U%/\VO!3_-<45_S70%?\UX!7_
M-NL5_S;T%?\V_13_-O\4_S;_%/XW_Q/^-O\3_3;_$OTV_Q+]-O\2_3;_$OTV
M_Q+_-RP"_SXJ O]#*@+_1BT#_T<R!/]&/ ;_14@(_T-5"_]!8@W_/W 0_SU]
M$?\\B1/_.Y,4_SN<%?\ZI!;_.JL6_SJR%_\ZN1?_.<(7_SG,%_\YW1C_.>D8
M_SGS&/\Z^QC\.O\7^CK_%_DZ_Q;X.O\6^#K_%?@Z_Q7X.O\5^#K_%?@Z_Q7_
M.2L"_T$G O]&)P+_2BD#_TLO!/],.0;_2T4(_TA1"_]&7@[_1&P1_T)Y$_]!
MA17_0(\7_T"8&/\_H!C_/Z<9_SZN&O\^MAK_/KX;_S[(&_\]UAS^/>8<^S[Q
M'/@^^ASU/O\<\S[_&O(__QGQ/_\9\3__&/$__QCQ/_\8\3__&/$__QC_/2@"
M_T4D O]*(P+_3B4#_U$L!/]2-@;_44$(_T]-#/],6@__2F<2_TAT%?]'@!?_
M1HL9_T64&_]$G!S_0Z0=_D.K'OU"LA_\0KH@^D+$(/E"T"'V0>(A\D+N(N]"
M^2+M0O\@ZT/_'^I#_QWI1/\<Z$3_&^A$_QOH1/\;Z$3_&^A$_QO_0"4"_T@A
M O]/( +_4R$"_U<I _]9,P7_6#X(_U9)#/]251#_46,4_T]O%_Y->QK[2X8=
M^4J/'_=)F"'V2)\B]$>F)/-'KB7Q1K8F\$:_)^]%RRCL1=XIZ$7L*>5&^"CB
M1_\FX4C_)-])_R+>2?\@W4G_']U)_Q_=2?\?W4G_']U)_Q__0R("_TP> ?]3
M' +_61X"_UTF _]?, 3_7SH'_UU%"_]:4!#]6%X5^%5J&?53=AWR48 A[T^*
M).U-DR;K3)HIZ4NB*^=*J2SE2;$NY$B[+^)(QS'@2-DQW$CJ,=A)]B[42_\K
MTDS_*=!-_R;/3O\ESD[_(\Y._R/.3O\CSD[_(\Y._R/_1Q\!_U : ?]7& '_
M7AP!_V,C O]F+ 3_9C8&_V1!"OIB3 _T7UD5[UQE&^M9<"#G5GLEY%2$*>%1
MC2W>4)4PW$^=,ME.I3/63:TUTTVW-M%,PC?/3-$XS$SF.,E-]#7'3_\QQ5'_
M+L12_RO#4_\IPE/_)\)3_R?"4_\GPE/_)\)3_R?_2AP!_U07 ?]<%0'_8QD!
M_VD@ O]L*0/_;3(%^6P]"?)I1P[K9E05Y6-@'.!?:R+;7'4HUEE_+=)7B##/
M59 SS%28-LI3H#C'4J<ZQ5&P.\-0NSS!4,D]OU#?/;Q1\#NZ4_PWN57_,[A7
M_R^W6/\MMUC_*[=8_RNW6/\KMUC_*[=8_RO_31H!_U<4 ?]@$@'_:!<!_VX=
M ?]R)0+[<RX#\G,X!^EQ0PWB;E 4VVE<'--E9B3.8G JR5]Z+\9<@C/#6XHV
MP%F2.;U8FCN[5J(^N%6K/[95M4&T5,)"LE340K!5ZD&N5_D\KEG_-ZU;_S.M
M7/\PK5W_+JU=_RZM7?\NK5W_+JU=_R[_4!<!_UH2 ?]D$ #_;10 _W,: ?]W
M(0'T>2D"ZGHS!>)X/PK9=$P3SW!8',EK8B3$:&PKOV5U,+MB?36X8(4XM5Z-
M/+)<E3ZO6YU!K5JF0ZM9KT2I6;Q%IUC,1J18Y4:D6_9 HU[_.Z-?_S>C8/\S
MHV'_,:-A_S&C8?\QHV'_,:-A_S'_4Q4!_UT0 /]H#P#_<!( _W<6 /M\' 'N
M?R0!Y( M ]I_.PC/>DD2QW54&\%Q7R2[;6@KMFIP,;)G>3:O98 ZJV.(/:AA
MD$"F8)A#HUZA1:!>JT>>7;=(G%W&29I<WTF:7_)$FF+_/IIC_SF;9?\VFV7_
M,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!  _WL2 /6!%P#HA!X
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M3VA\P5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO@?\\;X'_/&^!_SS_9 @
M_W(  .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@)P*EG38)G9I#$Y:731R/
MDU4DB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+1VJ#E4IG@J%-9(*N3V*"
MOT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0 ]G8
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M1%.;_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=   V8,  ,B0  "^F@
MLZ$  *JG  "AK@  E[4& )*V& ",M2H#A;0W"7ZR0A%WL$P8<:Y4'VRM6R5G
MJV(J8JII+UZI<3-:J'HW5J>#.E.FCCU0IIM 3:6I04NEND)+IM%"2Z7M/TVE
M_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP  K*4
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M)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@  D;8  (6_  !YQP
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M!A/_Z0:7KP  B+H  'K%  !LSP  7MH  %#@  !$Y@  //4  #?_!  S_PT
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M,?\/^3'_#_@Q_P[W,?\.]S'_#O8Q_P[V,?\.]C'_#O8Q_P[_-2@!_SPE ?]
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M1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_6P@
M_V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *LB3@'I85$$)Z"3AB8
M?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EPET!V;Z)"<VZO1'%N
MP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708 _VD
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M0&* _#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9   Y7(  --^  #'AP
MOH\  +:5  "NF0  IIL, *"<'@"9FRX$DID["HN61A*%E$\9?Y%7'WJ/7B5U
MCF4J<8QL+FV*<S)IB7LV9HB$.6*&CSU?A9H_7(6H05J%MT)9A<Q"6H7J/UR&
M^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C   N9,
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M+DN?_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@  IJ   )RF  "1K
MAK(  'VV#0!YMAT =;8L F^U.09JM$,+9;-,$6"R5!9<L5L:6+!C'E6O:R%1
MKW,E3JY]*$NMB"I(K94M1:VC+D2MLR]#K<@O0JSG+T.K^2U$J_\K1*K_*42J
M_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@  ?;@
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M$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0  7,\  %+5 P!(W @
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M A'_B (0_YH"$/^K P[_O@,._]4##O_M P[_\ ,.__ ##O_P P[_\ .3K@
MA+@  ';"  !GS   6M4  $S<   _X0  ->8  "WT   J_P( )O\+ "/_$0 @
M_Q< '?\= !G_(P 6_RD %/\O !+_-0 0_ST #O]% 0S_3@$*_U@!!_]E 07_
M= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP  =\$
M &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P  &_\% !?_#  4_Q
M$?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0  _T<  /]2  #_7@
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M-8I9QC:(6>$VB%ST,(A=_RN)7O\HB5__)8E?_R.)7_\CB5__(XE?_R/_40D
M_UH  /5D  #@;   UW$# -!T!@#-=0D Q'87 +QV*@&T=#H%KG%&#*=N41*B
M:UH8GFEB'9IG:2&697$EDV1X*)!B@"N-88@NBV"1,8A?FC.&7J4U@UZR-X)>
MPC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8 _UT
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M-V]M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60  ZV4  -MP  #->
MQ'X  +R" 0"VA $ KH4. *>&( "@A3 #FH(]"). 2 ^.?5$5B7M9&H1Y8!^
M=V<C?'5N)WET=2IV<WTN<W*&,7!QD#1M<)PW:F^H.6AOMSIG;\LZ9W#I-VEQ
M^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P  P((
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M*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP  LXX  *F2  "@E0
MEI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEKD%X=:(YE(62-;25@
MC'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(]C!3B/\L5(C_*56(
M_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@  CIX
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M($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K   =[$  &JV  !CN X
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M"2W3J0DLT[X*+-/?"2O1\PHJS_X+*<[_#"G-_PTIS?\-*<W_#2G-_PVNF
MHI\  ):F  ")K@  ?+8  &^]  !CPP  5\@  $S-  !"T@, .=D) #7?$  T
MWQL ,N G #'A,@ PX3T +N)' "WB4 $KXEH!*N-E BCC<0(FY'\#)>2/ R/E
MH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@  F*4
M (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K[A@
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M  #_HP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0  <[\  &3)  !6TP
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M(J1(SR*A2.@BH$GX'I]+_QN>2_\9G4S_%YU,_Q:=3/\6G4S_%IU,_Q;_1PL
M_TT" /]4 @#W6@0 ZUT' .=="P#A7!  TUT> ,I=, '#7#\$O5I,"+=85PRS
M5F 1KU1I%*Q3<1>I47@:IU" '*1/AQZB3X\@H$Z8(9Y-H2.<3:LDFDVX)9E,
MR":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@ _U
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M*WQ<_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4   ]5D  .%C  #2:@
MR6X  ,)P 0"]< , MG 0 *YQ(@"H<#("H6X_!IQL2@N7:E,0DFA;%(YF8AB+
M96D;B&-P'H5B>"&"88 D@&"))GU?DBE[7ITK>%ZI+79>N"YU7LPO=%[I+75@
M^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0  Q'(
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M(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@  N7P  +%_  "I@
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M'U"#_Q_>:0  R74  +R   "RB   J(T  )V1  "3DP  A98  'Z7"P!YEQD
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M&CVCIQL\H[D<.Z/2&SNB[QL[H/X:.Y__&3R?_Q@\G_\8/)__&#R?_QC$?
MMHD  *J2  "?EP  E9P  (FA  !]I@  <:H  &2N  !:L0@ 5[$4 %6R(P!3
MLC !4+([ DVR1 -+L4T%2+%5!T6Q70E#L64+0+!O#3ZP>@\[L(<1.:^6$S>O
MIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K_Q0TJ_\4-*O_%#2K_Q2[A0  KY
M *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$ 2;P- $B\&0!&O2<
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M 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G   E*,  (>K  !YLP
M;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >Z X '>@5 !OI'@ 9
MZ2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#NB@ .[YX #O"S  WP
MS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO   7\0
M %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0^!X
M#ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\M0
M_-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT  $32
M   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0 !/\:
M  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP  _[,
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M"L8RX0O",O$+OS/^"[TS_PJ[,_\*NC/_";HS_PFZ,_\)NC/_";HS_PG_.1
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M&X]*_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10  _TL  .E3  #>6
MTUL  ,U;! #*6 < PE@5 +I:)P"S6C<!KEA$!*E73P>D55@*H51@#9Y3:!";
M46\3F%!V%990?A>43X89DDZ.&H].F!R-3:(=BTVN'XI-O""(3= @ATWK'X9/
M_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\  .17  #570  S&
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M&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D  --B  #':   O6P  +9M  "O;
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M&5UM_QGH6@  TF8  ,-O  "X=@  KWL  *9^  "=?@  D7P  (I\#P"%?1X
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M'DQ_I2!*?[8A27_,(4E^ZQ]*?OP<2W[_&DM^_QE,?O\83'[_&$Q^_QC59P
MPW,  +9\  "LA   HHD  )B+  "-C0  ?(T  '6.! !OCQ( ;9 A &F0+@%E
MCSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3BV@24(IQ%$V)>Q=*B8<92(B5&T:(
MHQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_%T6%_Q?-;0  O7@
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M##"IYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA   JHX  )Z4  "4F0
MAYX  'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]MAX .[8I #JW-  Y
MMSX -[=' #:W4 $TMUH!,K=D C"W;P,NMWP$++>+!2JWG 4IMZX&*+C%!2BW
MY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0  )>:  "+H   ?J8
M '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ( +,,> "O#*0 JQ#,
M*<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?QJL!'L?! 1[&Y $=
MQ/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA  "!IP  <ZX  &>T
M  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1 !K2&@ 9TB4 &-,O
M !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0 $-F[ !#9W@ 0U?,
M$-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]  !.
MP0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C  WE
M+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y
M  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!R@
M-<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R(@
M\BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E  #T
M]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP  *-@
M ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@  _!X
M /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_V
M_^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9   FW@  &^(  !+F
M   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)  #_#@  _Q(  /\8
M  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4  /^F  #_LP  _[L
M /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\ 7@'_
M &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y /\
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M ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL _PJR /\*NP#]"L8
M^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\ [0S_ >T,_P'M#/\![0S_ >T,_P'_
M)1L _R88 /\E%P#_(1@ _R A /\>*P#_&C< _Q=% /\440'_$EX!_Q%I ?\1
M= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0H0'W$*@!]A"O ?00MP#S$,( \1#0
M .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_ >(2_P'A$O\!X1+_ >$2_P'_*18
M_RH3 /\I$@#_)Q, _R@< /\G)P#_(S, _R _ /\=3 #_&U@!_!ED ?@9;@'V
M&'@!\QB! ?$8B0'O&) ![AB7 >P8G@'J&*0!Z1BL ><8M 'F&+\!Y!C- > 9
MXP'<&O$!V!K^ M0;_P+2&_\"T1O_ M ;_P+0&_\"T!O_ M ;_P+_+1( _RX/
M /\N#0#_+Q  _R\7 /\N(0#_+"T _RDY /DF1@#T)%,![R)> >LB:0'H(7,!
MYB%\ >,AA 'A(8P!X"&3 =XAF@'<(:$!VB&I =@AL0+5(;P"TR+) M BWP+,
M(_ #R"/] \8D_P/$)/\#PR3_ \(D_P/!)/\#P23_ \$D_P/_, \ _S(+ /\S
M" #_-@T _S82 /\U&@#],B4 ]# R .TM/P#G+$P XBM8 =TK8P'9*FT!U2IV
M M(J?P+0*H8"SBJ. \PJE0/**IP#R2JC!,<JK 3%*K8$PRK#!<(JU06^*^L%
MNBOY!K@L_P:V+/\%M2S_!;0L_P6T+/\%M"S_!;0L_P7_- P _S8% /\Y P#_
M/ @ _SP- /T[$P#Q.!T Z#4I . T-P#9,T8 T312 <TS70'),V<"QC-P \0R
M> 3!,H $OS*'!;XRCP:\,I8&NC&>![@QI@>W,; (M3*\"+,RS FQ,N4)K3/U
M":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_!Z<S_P?_-P< _SH  /\^  #Z00$
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MB4;_#HA&_PV(1O\-B$;_#8A&_PW_0   \D<  .-/  #44P  RU4  ,14  #
M4 0 N4\1 +)0(@"L43( IU$_ J)02@.>3U,%FTY<")A-8PJ53&H,DTMQ#9%*
M>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(M1>#2,<8@4CD&(%*]Q6 2O\2@$O_
M$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L  -U3  #.6   Q%H  +U:  "X5P$
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M$F=<_Q+M3@  VED  ,AA  "\9P  LVH  *ML  "B:@  F6<" ))G$0"-9R$
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M&EAGI!Q69[0=56?*'55GZ!M69_L85V?_%E=H_Q189_\36&?_$UAG_Q/A6
MRV,  +UK  "R<@  J78  *!X  "6=P  B',  (%S"P!\=!< >'0F '1T,@%P
M<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?;VH07&YS$EIN?!57;8@756R4&5-L
MHQM1;+,<4&S('$]LYQM1;/H846S_%5)L_Q12;/\34FS_$U)L_Q/<7   QV<
M +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10 <GHC &YZ+P%K>3H"
M:'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/5W1P$51T>A-2<X863W.3&$URH1E,
M<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--<O\237+_$DUR_Q+48   PFL  +5T
M  "K>P  HG\  )>!  ",@0  >GX  '-_ @!N?Q$ :X > &B + !E@#<!8H!
M U]_2 1<?E &67Y7"%=]7@M4?&8-47QN#T][>!%,>X,42GJ1%DAZGQ=&>J\8
M17K$&$1ZY!A%>?@61GG_%$9X_Q)'>/\11WC_$4=X_Q'-90  O7   +%Y  "G
M@   G(0  )*&  "&A@  =X8  &N&  !FAPT 8X<9 &"()P!>B#,!6X@\ EB'
M10-6ATT$4X94!E"&6PA.A6,*2X1L#$F$=@]&@X$11(./$T*#G11 @JX5/X/"
M%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P  MW8  *Q_  "BA0
MEXD  (R+  "!C0  <XX  &6/  !=CPD 6I 4 %B0(0!6D2T 4Y X 5&000).
MD$D#3)!0!$J/6 5'CV '18YI"4*.<PM C7\-/HV-#SR-G! ZC:P1.8W!$3B-
MX1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT  *>&  "<B@  D8X
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M R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G   >J(  &VG  !@JP
M5:\  $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  AO2H (+TS !^^/0 >
MOD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3 TP 5OO$ %;S_ 16[
M_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M   2K<
M #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .S3H
M#LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+_P )
MR_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L   #+#
M   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX  =LY
M  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@  W_\
M -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,   =
MT   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K  #I
M-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8  /#V
M  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2W
M#.    7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T)P
M]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?  #_
MWP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@   .D
M  #L    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0  _R,
M /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_N@#_
M%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\
M?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,< _P#6
M /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_&B
M_QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_
M (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0 /@
MXP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P _QP9
M /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_ 'X
M_P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /  WP#N
M .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!_P#_(!< _Q\4 /\<
M$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF /\(< #^!WD _ >!
M /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__24-#7U!23T9)3$4
M" GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\ W S_
M -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\$%4
M^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.KP#@
M#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_ <H2
M_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\ ZA=:
M .8690#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP TA>C - 7JP#.&+4
MS!C! ,L8T@#'&N@!PQOX < ;_P&^'/\!O1S_ KP<_P*\&_\"O!O_ KP;_P+_
M*PP _RL% /\K P#_+0D _RP. /\I%0#W)B  [B,M .<A.@#A'T@ VQ]4 -4@
M7P#1(&@ SB!Q ,PA>0#*(8$!R"&( <8ACP'$(98!PR&> <$BI@&_(J\!O2*[
M KPCR@*Y(^,"M23T K,D_P.Q)/\#KR3_ Z\D_P.N)/\#KB3_ ZXD_P/_+P8
M_R\  /\R  #_,P( ^3(( /<O#@#K*Q8 X2<B -@G,@#0*4$ RRI. ,8J60##
M*F(!P"IK ;TJ<P&[*GH"N2J" K@JB0*V*I "M"J8 [,JH0.Q*JH#KRNU!*XK
MQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@  _S,
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M#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/   ZT,  -Q*  #,3P
MPU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&82$X"E$=7 Y)'7@6/
M1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#KQ!^0\ 0?$3:$7M$
M\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5   O54
M +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'2V$&
MA4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)[A%R
M2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H  +!9
M  "I5@  HE(' )M2%0"64R0 D5,R (U3/@&)4D<"AE%0!(-15P6 4%X&?D]E
M"'M/; EY3G,+=TY[#75-A0YS39 0<4V<$F]-J1-N3;D4;$W.%&Q-ZQ-L3OT0
M;$__#FQ/_PQL3_\+;$__"VQ/_PON10  W%   ,E7  "]7   M%X  *Q>  "D
M6P  G%8$ )56$@"05R$ BU@O (=7.P&#5D0"?U9- WQ55 5Z5%L&=U1B"'53
M: ES4W +<5)X#6]2@@]M48T1:U&9$FE1IA1G4;859E'+%652Z11E4OL19E/_
M#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P  L&(  *AB  "?7P
MEEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T6%@&<5A?!V]79@EM
M5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5YQ5@5OH28%;_#V%7
M_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9   D%X
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M#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0  ?VL  'AK!0!R:Q(
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M#D-UF0]"=:D00'6\$$!UV1! =/,/0'3_#D%S_PU!<_\,07/_#$%S_PS&9
MMVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %> ( !5
M@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ("SU]
MEPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0  LG0
M *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-B28
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M B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0  H(@  )6.  "+D@
M?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 IJ0\ **D8 ">J(@ F
MJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VKBP ;JYT &JNQ !FK
MR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0  =9X
M &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7MR$
M%K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VYQ  -
MN.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8  %ZK
M  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14 "<4>
M  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@  QM(
M ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T  !&
MN   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6  #1
M'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\  -;@
M  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   YP0
M+<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?%
MX1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%  #I
MX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@  (,X
M !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0  [1$
M .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #ZP@
M^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H   W?
M   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D  /H.
M  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP  _[D
M /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\ 60#_
M &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P /\
MN #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\ ^@#_
M /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_ &$
M_P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L M #Y
M +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_ /
M_P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P _P!G
M /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P +@
M[@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4 _P#_
M&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B /H
M; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0 X@"_
M .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_'A
M_QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$9@#J
M!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[ - &
MR0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P _R &
M /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=#6D
MV0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00R #"
M$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,  /\C
M  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6, R!9K
M ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D MQFT +4:P@"T&M8
ML!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_*   _R<  /XJ  #O
M*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@4P"\(5T N2%E +<B
M;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O :<CO &F),X!HR3H
M J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+   _RT  .TR  #B-
MVC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O*U< K"M@ *HK9P&H
M*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHKM@.9+,<#ERSB Y0M
M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0  S#P
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M!W1 _P9S0/\&<T#_!G- _P;Q.P  WT4  ,Q,  "_3P  ME   *Y/  "G2@
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M8$[_"&!._PCC1P  S5   +Y7  "S6P  JET  *%=  "86@  C5,  (92# "
M4Q@ ?%,E 'E4,0!U5#P <U-$ 7!33 )M4E,":U)9 VE28 1G46@&95%P!V-1
M>0AA480*8%"1#%Y0G@U<4*T.6U' #EI1W@]:4?4,6E+_"EM2_PE;4?\(6U'_
M"%M1_PC?2@  R5,  +M:  "P7P  IF$  )UA  "47@  B%<  (!6"@!Z5Q4
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M"T]=F0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)3%W_"$Q=_PC/5
MOEX  +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I9 X 9609 &)D)0!@
M93  7F4Z %QE0@%:94H"6&11 E9D6 -49%\$4F1G!5!C<0=.8WL)3&.("DIC
MEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6   NF(
M *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!::BT
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M!S1XRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:   K7$  *)Y  "8?@
MC8   (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#@1X 0H(I $&",@!
M@CL /H)# #V"2P [@E,!.8)< 3>"9@(U@G$#,X)_ S&!C@0P@9\$+H&Q!2V!
MR 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P  B(8
M 'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  VC#4
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M !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8H0
M3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ*P -
ML34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O  6O
M_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP  0:T
M #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@  OBL
M +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]]@
MO?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8  "JX
M   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(  ,LK
M  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP  SO@
M ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["   5
MQ@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?  #>
M*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H  .7S
M  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,T0
M!-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M&@
M[R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??  #W
MWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP   .(
M  #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$   _!8
M /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_OP#_
M#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M /\
M=P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T _P#)
M /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_$!D
M_PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\ <@#_
M 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@## /0
MT@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0 _P\2
M /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[ '8
M^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@ RP#G
M .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$. /\-
M#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '  [0!X
M .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6 -D
MU #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/!0#_
M#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R -X
M>0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -  Q0#H
M ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_$P4
M_Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%<P#*
M!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE +4+
M]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@  ]18%
M /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]#G0
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M HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.   Q#<  +XR  "Z*P(
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M!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@  D40  (I!#0"$0AD
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M!EA+F =73*<(5DRY"55,T0E43.\(5$W_!E5,_P953/\%54S_!55,_P752
MPE$  +57  "J6P  H%P  )=<  "-60  @5,  '=/! !Q3Q  ;E < &I0* !H
M4#( 95 [ &-00P!A4$H!7U!1 5U06 )<4%\"6E!G UA0<0174'L%55"(!E-0
ME@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P  OU0
M +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B5"\
M8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4E =-
M5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<  *Y>
M  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P 6UDV
M %E9/@!7648 5EE- 5195 %265L"45EC T]9; --67<$2UB$!4E8D@=(6*('
M1UFS"$99R@A%6>H(1EG]!D98_P9&6/\%1UC_!4=8_P7'4@  N%L  *MA  "A
M9@  F&@  (YI  "#9P  <F   &A>  !A70D 7%T3 %I='@!772D 5EXS %1>
M.P!27D, 45Y* 4]>4@%.7ED"3%YA DI>:@-(7G4$1EZ"!41=D 9#7J '05ZQ
M!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@  M%\  *AF  ">:@
ME6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!28R4 4&,O $YD. !-
M9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]CC@4]8YX&/&.P!CMD
MQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P  D7(
M (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !':CT
M16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35JQ 4U
M:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<  ()W
M  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@ /G)
M #UR2  [<E  .G)9 3AR8P$V<FT"-')Z C-RB0,Q<IH#+W*L RYRP0,N<N,#
M+G'X RYP_P,N;_\#+F__ RYO_P.S9@  IV\  )UV  "3>@  B'P  'Y]  !R
M?0  9'P  %=[  !,>@  0GD# #QY#@ Z>A< .7HA #AZ*@ W>S, -GL[ #1[
M1  S>TP ,GM5 #![7P O>VH!+7MW 2M[AP$J>Y@"*'NJ B=[OP(F>^$")GKW
M B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P  A((  'B#  !LA
M7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  LA2T *X4U "J%/@ I
MA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&O $>AMX 'H3U 1Z"
M_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP  6(P
M $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >D4
M'9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2._P 4
MC?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4  $67
M   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC< $9Y!
M !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +FO\
M"YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@   P
MH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX  *J
M1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\  *?_
M  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   FJP
M':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X.0
MN$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_  "V
M_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@  $[@
M  V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@  R#H
M ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(_0"%
MF0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,   /'
M    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT  -TY
M  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !YH0
M:Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
MV0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK  #P
M.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@  7K$
M %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B    Y@
M .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_*0
M_SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7 /\
M%P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L _P"#
M /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\ .H
M^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\ $P#_
M !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^ /\
MA0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q ., [P#S
M .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_ !
M_P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0 ?P#S
M (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M -\
M^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P _P 2
M /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E (
MXP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P ]@#*
M /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P . /\
M%@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H T "
M ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[ /X
MN0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!$ #H
M !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z +\
M@0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L JP7_
M *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #= Q(
MU ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(>P"O
M"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_ )P/
M_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L QPL6
M , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B$7T
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M 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P  H2@' )LG$P"6*"
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M F4XF0-D.:@#8CFY V$ZT -@.NX#8#K_ U\Z_P)?.O\"7SK_ E\Z_P+=.P
MQT,  +E)  "N2P  I$P  )M*  "210  B3\  ($Z"0![.A0 =SL@ '0\*P!R
M/#4 ;ST^ &T]1@!K/4T :3U3 &@]6@!F/6$!9#UI 6,]<@%A/7T"8#V) EX]
ME@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P  PT<
M +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K03(
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M!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20  N%$  *Q7  "A6P
MF%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:32@ 6$TQ %9-.@!4
M34$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/C0-'3YT$1D^N!$5/
MPP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@  E6
M (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/4C\
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M S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;   C&X  (%N  !V;
M9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^8S4 /60] #QD10 [
M9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]ENP(N9=H"+F3T BYC
M_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@  9'
M %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S;$D
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M !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \B
M,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*3  2
MBU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_  Z&
M_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@  *I(
M "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (EU
M!I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2_P"8
M@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT  !F>
M   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@  *16
M  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1B@
MB8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J   ,
MK   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),  "R
M6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D   ?Y4
M '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "N
M +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##3P
MPV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT  &6C
M  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0   ,<
M  #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800  V%,
M -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL  !+
ML@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4   #6
M    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,  .Y6
M  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^O
M+\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
MZ    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&  #_
M6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !< _P =
M /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_ (L
M_P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@ _P#W
M /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7 /\
M) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8 ^@",
M /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J /\
MZ0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\ 'P#_
M "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"' .P
MC0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\ UP#_
M -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[ "8
M]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P AP#:
M (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_ ,,
M_P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\ Z@ M
M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#& (<
MQ ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +( _P"R
M /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E -,
M,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($ M "(
M +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B /\
MH@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0 *@"_
M #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"# *0
MBP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\ E G_
M )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R!BX
MK@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,A@"6
M#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_ (<1
M_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R< H1 S
M )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")%(L
MAQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O
M(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM )$:
M. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88 ?!Z1
M 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H*
MTC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B,@"#
M(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:- &\F
MF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@  RS8
M +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y*C<
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M E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/   O$0  *])  "D3
MFDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C.BL 8#HT %XZ/ !=
M.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\C0%0/9P!3SVL DX^
MP0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4   EU$
M (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7/D
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M CY*_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P  D%T  (9<  ![60
M;5,  &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'2S@ 1DP_ $5,1@!$
M3$X 0TU6 $)-7P! 36H /TUV 3U.A $\3I0!.TZE 3E/N0(Y3]0".4_R 3E.
M_P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@  :5@
M %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _44P
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M 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)9P
M/V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE5  G
M95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_ 2%C
M_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P  .FX
M #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >;EL
M'6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK_P"D
M:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@  "MW
M   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8 $WAC
M !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?<0
ME7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"   <
M@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=  F#
M;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0  D'X
M (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5C@
M#X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/90
MCW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4  (*)
M  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@  "IL
M  *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7   G6X
M )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0  !J
ME   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@   "I
M!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,  *QW
M  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?G
M4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
MM0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK  "]
M@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0  1JH
M #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"    PP
M ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2<P
MTHL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,  "JV
M   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@   -0
M  #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9   ZGP
M .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W    1
MQ   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4   #G
M    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH  /^#
M  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_ #0
M_P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\ DP#_
M )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_ /$
M_P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X _P \
M /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V )0
M] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@
M /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V /\
M0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X Y0"5
M ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/ /\
MRP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /  / #M
M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/ ,T
ME@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\ O #_
M +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#; $$
MU@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P D "Z
M )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_ *L
M_P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H PP!$
M ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I )(
MIP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L _P#_
M!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ] +
M1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T F0"7
M )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y#@
MZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *( /P"@
M $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62 (H&
MG@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T
M ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3#$$
MD Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\
M#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J
M  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL A!-#
M ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q%Z0
M;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P
M,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<
M10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z  92"P
M &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J.0
MH3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K
M(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M %LH
MP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P  G#\
M ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C*4,
M82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3
M+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0  (]!
M  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]&
M %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I< 3C*H $TSNP!---@
M3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">20  E4D  (M'  "!
M0@  =ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S-0!5,SP 4S1# %(T
M2@!1-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ
M 48X_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30  DDT  (A+  !^1P
M<T(  &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/.#D 33A  $PX1P!+
M.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$.Y, 0SRD 4(\M@%!/= !03WP 4$]
M_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$  (50  ![3   ;T8
M &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&/4L
M13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$ /D"B #U M0$\0<X!/$'N 3Q!_P$\
M0/\!/$#_ 3T__P&Z10  K$P  *%1  "75   C54  (-4  !X40  ;$L  &%'
M  !60@  3T , $P_$P!)0!P 1T D $9 + !$0#, 0T Z $)!0@!!04D 0$)1
M #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@ #A%LP$W1<L!-T7L 3=%_P$W1/\!
M.$3_ 3A#_P"W20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,  !3
M2   2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/ #I'
M6  Y1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\ ,DC_
M #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !03@
M1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,5@ S
M3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_ "U,
M_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50  0U$!
M #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M4ET
M+%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1_P"L
M50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@  #56
M"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H )5AG
M "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H6@
MG6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%> P J
M70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@
M<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8   F6@
M )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C9@@
M'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H;@ 2
M:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\  (QS
M  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0  %G *
M !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +<7H
M"G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y  !^
M?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$  Q\
M#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0  'R'
M  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y@P
M;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)"@ !
MB0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!  "'
ME0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0  8XL
M %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@  E@P
M )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5C@
ME:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690  $R7
M   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<  *,,
M  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA   I9L
M *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@   S
MH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %  "Q
M"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY   +:I
M  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   FJP
M&JT  !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #  @
MP0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<  #+
MM0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0  $+@
M  >[    O@   ,$   #$    R    ,L   #+    S0   ,X   #0    T@
M -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #FI0
MYKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0   #'
M    RP   ,\   #4    V    -P   #=    WP   .$   #C    Y0   .@
M  #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0  _*H
M /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\ 20#_
M %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@"; /T
MHP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\ W #_
M -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_ $\
M_P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M
M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L
M_P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D \P!3
M /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#< )\
MV0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X _P#_
M    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!- .
M5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D Q "C
M ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_
M_P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H 3P#'
M %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"< *\
MIP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_    _
M /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U %
MLP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\ H0"=
M *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'
M  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H HP!1
M *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP". *<
MC "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2  #%
M$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!* ),
M40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *, ?@"Q
M 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z'
ML1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&2P"$
M!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO '$+
MP0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@  J"0
M * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X#DL
M=PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82P !E
M$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T  )@H
M  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48 ;!5,
M &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<&M@
M6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q  ")
M*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =
M3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=( 4B+Q
M %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#,@
M>BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7
M(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI
M_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0  =3,
M &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0*4T
M3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N_P!$
M+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D  &<T
M  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2
M $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _,O\
M/S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y  !:
M-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S
M6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_
M #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6.0
M334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [
M.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z
M_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P  2#H&
M $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V/%T
M-3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q
M1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 # #\^
M#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L ,$%G
M "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N2@
MH5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#"@ V
M0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D "E'
M<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P  GU4
M )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P20X
M+DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,<  A
M3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?
M  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P )T\2
M "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :4WT
M&5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E  "%
M:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<. !Y7
M%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH $EJ-
M !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  "";0
M>&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@$  4
M8!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)  IA
MG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P  =74
M &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -:A(
M#&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !JF
M:JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L  &-[
M  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\  '85
M  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP  =*@
M '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"  !.
M@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1  ""
M%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(  '^Z
M  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%BP
M.8P  "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/$@
MD!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS  "-
MT   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0  +I8
M "*6   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0  GA$
M )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=Q@
MG>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\  !>@
M   .H@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P  *T0
M  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@  K]T
M *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK   %
MK@   +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)  "^
M#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@  ,7E
M  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W    N@
M +T   #     Q    ,8   #&    R    ,D   #+    S    ,X   #0!@
MTPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/  #A
MY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP   ,H
M  #/    TP   -8   #7    V@   -P   #?    X0   .,   #F    Z0$
M .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #XR0#_
M  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9 /\
M8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *< ]P"Q
M /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_  <
M_P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L 70#Y
M &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K .8
MM@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_    _P
M /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I %X
MY@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\ KP#-
M +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P   /\
M  #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@ T !?
M ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y +8
MMP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H   #Q
M    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9 +H
M7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X I0"^
M *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A
MU@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D 6 "G
M %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V )(
MR@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0  Q
M +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8 %@
ME@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (, P0"!
M .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L  *\#
M  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$ B !7
M (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T -0
M<@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0  "=
M"@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1 'D
M5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L
M &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2%
MC X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*4@!L
M"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M %P/
M_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P  @A@
M 'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A$%,
M7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5_P!2
M%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$  '(:
M  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6
M %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*'/\
M2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC  !D
M' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=
M6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_
M $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>) (
M5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C5P!$
M(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG
M_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@  424+
M $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^*%T
M/2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U
M.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L' $<I
M#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF
M #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@
MI$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N#0 _
M+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D #$R
M<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00  HD@
M )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y,Q$
M-S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW;P K
M-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL  )1/
M  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \ ,C@5
M #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E/'T
M)#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3  ")
M5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3 "L]
M&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H 'D&-
M !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&6P
M?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#%@ D
M0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>* !='
MG@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8   >F$
M '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =2AH
M'$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-G  0
M3;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8  &UF
M  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8 %%(=
M !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )5*T
M"%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML  !?
M:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8  U;
M(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@  %O
M  !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9<
M3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D&P "
M9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[  !B
MW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@  1G4
M #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P  ;Q\
M &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !LU@
M:_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX  #)^
M   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D  'PA
M  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@  =^\
M ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'   =
MAP  %(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:  "*
M(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H  (7[
M  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4D@
M#9,   24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9&@
MF2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W  "5
M_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@   Y\
M  "A    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0  J1D
M *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I^P!U
MCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L   "N
M    L0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ   +T8
M  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!JEP
M6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\
MOP   ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/  #5
M&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP  3Z4
M $"J   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+    S@
M -$   #1    U    -8   #9    VP   -X   #@    Y    .<&  #K#@
M[QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P & /\
M!P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L
M /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q ,L
M\ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\   #_
M  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F /
M; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$ W0#=
M -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_
M_P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X 9@#<
M &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#- ,,
MZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y    \@ &
M .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #% &8
MPP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X X "L
M /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0   -8
M# #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\ L !E
M *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@": .X
MF0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0 !@"]
M  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!> )T
M9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") ., B #Y
M (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N  L
MJ  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T 70"+
M &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R '@
M_P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4 FP .
M )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!] %T
M>P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H _ !J
M /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  ) (H
M$ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %< ;@!>
M &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !> O\
M7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$"P!Y
M !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19 &$$
M8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_
M %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N"0T
M:0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5
M#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0
M_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0< 7PX0
M %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F
M2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z
M*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0- %04
M$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT 0QAG
M $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U,
MJ#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9$ !*
M&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L>
M<0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-   I#H
M )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#'Q0
M01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C;@ S
M)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX  )9"
M  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$ .R08
M #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L
M+"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&  "*
M1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5 #,H
M'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D )RV+
M "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(2P
M?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM&0 M
M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*) "$R
MG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P  ?%
M '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H,AX
M)C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LWFP :
M-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0  '%3
M  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L (3@B
M " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4/*T
M$SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8  !D
M5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX> !H^
M)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P #D+$
M  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B6P
M5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%(@ 2
M12D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^  A'
MX  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80  4UX
M $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -324
M#$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-VP !
M3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0  $)A
M   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(  U4J
M  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U   5/$
M %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH   R
M9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F  !?
M+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\  %O]
M  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K;P
M(&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I*@
M:30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\  !D
M_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0  &7@
M !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P  =BX
M '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P_P"&
M>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,   J#
M   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8  (0R
M  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""@
M>H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/
MD0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H  "4
M-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP  <(H
M &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<    G@
M *    "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F*@
MICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$  %:5
M  !'F0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K    *X
M  "N    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@  N2X
M +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>   [
MH@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P   "\
M    O@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2   -$R
M  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   OK
M'Z\  !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,
MS@   -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD  #M
M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D _P /
M /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z ',
M^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H ^ #I
M /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P , /\
M% #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T Z !S
M .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0 /\
MS@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /< $ #S
M !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L ,\
M<@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L N #_
M +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#? !4
MV@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H ; "X
M '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_ *,
M_P"A /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$ P@ :
M +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E &L
MI !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$ _P"0
M /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5 *P
M'@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J
M )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_ /\
M?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P & "8
M "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D ($
M:P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\ < #_
M '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"* !L
MAP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '( 9 !P
M &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_ &,
M_P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4 >@ >
M '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D &<
M8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&
M%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7 &H
M'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L
M %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_'0
ML"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"&0!=
M R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG $L(
M<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)   JBD
M )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3"QL
M40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.< !
M#G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR
M  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8 2! =
M $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y$WP
M-Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W  ",
M.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09 #\4
M(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D ,!F*
M "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*/
M@#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V
M&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ( "D?
MFP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00  ?4
M '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P'B
M+QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",CF0 B
M)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0  ')#
M  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT *2(C
M "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =**L
M&RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'  !F
M1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A ",H
M)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D %BW!
M !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D20
M6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =
M+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$R
MX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@  5DD
M $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD
M%C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TWW0 -
M-O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\  $Q,
M  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN
M ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (//
M"3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2   ^
M3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K  M
M-  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X  4'\
M  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z5
M+U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(,0 "
M2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[  !'
M_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P  *ED
M "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@  4#@
M %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-_P"/
M80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$  !I?
M   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,  %D_
M  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",:
M@FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H   -
M9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z  !C
M1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P  ?W0
M 'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '<@
M '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O0
M;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L  '-]
M  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P   '\
M  !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0  ?4@
M 'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#  !;
MA0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T   "-
M    C    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\  (U0
M  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0C0
M0H\  #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";
MFP   )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&  "@
M60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@  -ID
M ">;   9G   #YT   6?    H0   *,   "E    J    *D   "I    J0
M *H   "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U30
MM&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(  !JD
M   .I@  !*@   "K    K0   +    "T    M@   +@   "X    N0   +H
M  "\    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0   S58
M ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N   $
ML0   +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L   #-
M    SP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@  .I@
M  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_ "$
M_P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0 >@#R
M (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_ -
M_P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P _0 G
M /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#? 'D
MW0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W
M /\ KP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B .8
M+ #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y
M ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H /\
MH@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P )@#(
M #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R *X
M>@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\ E #_
M )$ _P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S "H
ML  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L <@"9
M 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_ (,
M_P#T    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ", G@ L
M )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"' ',
MA0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E
M    T0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F (L
M+0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T =@!V
M ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5 P
MPP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P )P!Z
M "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P &4
M>P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0  N1
M *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L "@
M:@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D =0!7
M (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@  *0:
M  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "( 7@ I
M %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !, 'T
M2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB  "3
M(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C %(
M*@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD 00.)
M $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".*0
MA"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&) !'
M!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N' #<+
MF0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P  @"X
M '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^#"4
M/ TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0F  M
M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30  '0Q
M  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G
M #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F%*D
M)17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V  !G
M,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D "P4
M*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:< 'QF^
M !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E-P
M6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89)P E
M&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?
MW0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/   63<
M $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @'BL
M'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,CV@ 4
M(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP  $TX
M  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@ &B,P
M !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0*/0
M$2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^  !#
M.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H
M-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\ #2S_
M  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"0
M.3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N,P .
M+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\  @P
M_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@  -4(
M "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *-3L
M"#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U_P"4
M30  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@  "=$
M   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@  3Q#
M   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"14@
MB%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+   :
M20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-   !#
M30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6   AEX
M 'UA  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   540
M#D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+20
M2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0  'IG
M  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060  "E@
M  -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410  5%,
M %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N  !O
M<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(   !B
M 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\  %Y?
M  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K=@
M774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N
M; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:  !I
M;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P  5'P
M $9\   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z    >0
M 'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W90
M=GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,  #R$
M   NA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP   (<
M  "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70  AG,
M (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.   C
MCP  %H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8   "6
M    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@  )F#
M  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6F
M#9D   &;    G0   )\   "A    I    *4   "D    I0   *4   "F
MIP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV  "N
MDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP   *4
M  "G    J@   *P   "P    L@   +0   "S    M    +4   "W    N
M +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&A0
MQJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$   "T
M    MP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@   ,T
M  #/    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=   YI$
M .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\ - #_
M #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"! .D
MB0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_
M +  _P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P #@
MZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$ @@#/
M (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_ *0
M_P#_    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #( TP \
M ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y (0
MMP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )< _P#_
M    _P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U +D
M/0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P H@"&
M *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\
M\    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4 -@"C
M #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^ (X
MB@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M    W0
M ,P   #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1 #<
MCP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P @@!Z
M (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0   +P
M  "Q    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #  ?P W
M 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J (@
M: "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%  "E
M @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P &X
M-@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($ 6P"0
M %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";#@
MD@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$ , !@
M #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"* $T
MFP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@  BA,
M ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4 #
M4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $, EP!!
M *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P  'H8
M  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L 2  P
M $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X *4
M-@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@  !L
M&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K #X!
M,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:, +0:X
M "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H(@
M7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(+  S
M"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW "0,
MTP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0  7"0
M %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K#2X
M*@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0U  =
M$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H  % E
M  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H (Q$R
M "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6%?$
M%Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK  !%
M)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O !P5
M-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\ $AG_
M !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#+
M.B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6
M&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_  \=
M_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@  .2T
M #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1'SP
M$!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA_P"7
M/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0  "\P
M   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D #"1$
M  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"50@
MBD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV   D
M,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"  8J
M3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@  B$L
M ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @.
M%S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P3
M,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE   'U4
M  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@  %#L
M  XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20  -U<
M #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:  !R
M6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,   M!
M!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0  #YD
M   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P80
M:&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9* P
M20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@  !%
M<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P  9V@
M %MF  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0  4@8
M %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.;P
M3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT  %1K
M  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,  %P(
M  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P  5X$
M %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ   _
M<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#  !F
M"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL  &*4
M  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V>
M*7@  !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S @
M<P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".  !O
MJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@  'H$
M !*!   *@0   ($   ""    @P   (,   "#    @@   ((   ""    @@
M ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_H0
M?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL   J+
M    C    (T   "/    D0   )(   "1    D0   )$   "1    D0   )(
M  "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F   DK,
M )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7
MF0   )L   "=    GP   *    "@    H    *    "A    H@   *,   "D
M    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@  *?'
M  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C    I@
M *@   "L    K@   *\   "O    L    +    "R    LP   +0   "V
MMP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W  "_
MV !3EP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP   +8
M  "[    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*    S
M ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=P@#_
M    _P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!# /4
M2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T X "7
M -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_
M_P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .( 10#>
M $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0 ,(
MFP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_    _P
M /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$ $8
MP0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T DP"J
M *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _    .X
M  #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $  K !&
M *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7 )D
ME "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P   #,
M    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _ )<
M10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$ @@"@
M (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[
ML0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8 /@"$
M $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8 &\
MJ0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K    HP
M )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T #T
M<@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\ H@!>
M +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@   (X
M  "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #< 9  \
M &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1 *X
M4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"  !\
M    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V %8
M.P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@ 1 "_
M $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S"
M;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L -@!)
M #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X #D
MV0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$   9 P
M %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _ #8
M/@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\ S@ O
M .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,  %<.
M  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #( -  X
M #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E .H
M)0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+
M$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#
M.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX
M !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P
M/Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A
M"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-
M_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@
M #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT
M&0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9
M,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:
M   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%%
M !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0
MC#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H
M'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X6
M3P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT
M (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P
M'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )
M&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$
M  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24
M !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<
M 2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T
M2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H
M!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E
M   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P
M:D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *
M+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L
M=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0
M %]3  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD
M #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@
M,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9
M  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,
M   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4
M #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !2
M7   1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !#
M#0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9
M   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80
M/EX  #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#
M2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'
MKP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0
M "IB   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P
M %40  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP
M4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J
M   7:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-
M  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4
M %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0
M<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M
M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H
M  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0
M 'T   !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@
M? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W
M^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D
M  "*    C    (T   "-    C    (P   ",    C    (P   "-    C00
M (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!H
MA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9
M    FP   )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#
M  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0
M39   #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H
MJ@   *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W
M 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@
M #*<   CH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0
M +L   "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-
MT@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\
M  #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4
M .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L
MS0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_
M    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\
M5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T
M +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q
MZ    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V
M %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\
MP "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@
M ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P
MGP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0")
M -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$
M  "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!*
M (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0
M= #K ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":
M  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D
M20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #>
M &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",
MA@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H
M $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4
M\@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 "
M ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $(
M60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !'
M /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@
M!0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!"
M $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@
M/ #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9
M  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $
M0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_
M #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0
M3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T
M $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@
M_P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  &
M $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $(
M*@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=
M(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%
M!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!'
M "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P
MCBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M
M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%
M3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\
M ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0
M(PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1
M"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V
M  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! %
M !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@
M"P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T
M.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3
M!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E
M  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P
M:C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0
M%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8
M=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,
M %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD
M"1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@
M'8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&
M  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -
M  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4
M "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !4
M20  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F
M#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9
M   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P
M2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@
M+1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   L
MKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$
M #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\
M #04   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0
M,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92
M   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1
M   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@
M #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D
M50  &5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&
M%   11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L
M   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70
M$EL   M9   "6    %8   !6    5    %,   !2!   40D  % -  !0$
M3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(
M_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60
M  -B    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(
M %L<  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y
M<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M
M    ;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5
M  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>
M;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y
M>@   'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W
M&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\
M %2   !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B
M (D   "(    AP   (<   "'    AP   (<   "(    B    (@'  ")$
MB1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(
M   YB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@
M  "6    EP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$
M )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   M
MDP  'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F
M    IP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5
M  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0
M$9\   6A    HP   *8   "I    K    *\   "S    M0   +<   "V
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M_/[______________________________________________________P
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M_______N?44          $34___________________________\JF0O @
M!"(W25C.____________________________Z:1K02@_8W^5I[K:________
M_______________________5LJRRS.3Z____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______ENY=W8LC_________________________________VYYG-@H  HS_
M_______________________________(?S\%     %[/________________
M_____________]F!.0       #RJ_____________________________YY,
M         ".0____________________________W&\:         !!]^?__
M________________________KT@           !O[O__________________
M________A!,           !DYO_________________________L40
M      !7WO________________________^X%0            !(UO______
M__________________]T%              XS_______________________
M__FB6A,            CQ?_________________________?FUPL
M   -NO__________________________[[%]53DB$0<! A$BLO__________
M____________________W[^EF9B:H*R]VO__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________X[Z=@'S[________________
M________________\K>$5S . !VL_______________________________2
MBDP5      !R\____________________________]9_-@        !+R?__
M________________________^I$^           OJ___________________
M________P%H            :E?__________________________C20
M       (A/_________________________G7@              =_______
M__________________^T)0              :O______________________
M__]]                6_3_______________________TK
M    3.O______________________Z4                 /.'_________
M_____________S ,                +=G_____________________F8IA
M)P              )]?______________________^V^B54G
M)=S__________________________LJ==EU*/#(M+# Y1][_____________
M__________________WFW=;2T-/9Y/______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU+O6_________________________________^>XCVI++Q5O____
M___________________________DH6<T!P     \R?__________________
M_________]:".P         2E___________________________[84Q
M        ;___________________________ID(             4.'_____
M___________________L:0              -\G_____________________
M__^S+P              (K;_______________________]Y
M    $*?_______________________(T                 )G_________
M_____________ZD                  (S______________________T8
M                 '______________________WP
M '3_____________________EP                   &K_____________
M________S@                   &/______________________RDB 0
M             &'______________________[FC@%<W%P           &C_
M__________________________K3KI2&?'5Q<')W@93_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________V[J=@FEIT_______________________________R)-E
M/1D    =GO___________________________]N.3!,         ;O______
M____________________VWPL            1=?_____________________
M____BRH             (K3________________________"1
M     Y?_______________________]] 0               '__________
M_____________^<V                 &K______________________YT
M                 %C______________________T8
M $?X____________________Z0                   #7I____________
M________E@                   "7;____________________O
M             !C.____________________ZP                    _"
M_____________________P                    JY________________
M_____R<                   JU_____________________W
M          VY_____________________^"<C'!50C,F&Q0/#0X2&B:_____
M________________________^>38TL[,R\S/UN#\____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z].\X_______
M_________________________]*IA65(+!(!A?______________________
M______&K<3P/        3^#_________________________U7\U
M    '[+________________________C=1T              (G_________
M______________^0(P               &?______________________]5#
M                 $CV_____________________XH
M "[=_____________________S@                  !?(____________
M________O@                    2V____________________G
M              "E____________________N@                    "3
M____________________W                     ""________________
M_____P                    !T_____________________Q,
M          !H_____________________T(                   !@____
M_________________WH                   !=____________________
M_]$                   !A______________________\D
M      !F_______________________)K)F)?79Q;&EG9F=K<'J,________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________XL6J
MD7EA=______________________________=IG=0+ P     ,<3_________
M________________X)).$P           (_________________________2
M<!T              &#______________________^YO#P
M #?B_____________________Y8<                 !3 ____________
M_________T                    "C____________________K@
M              ")____________________G@                    !R
M____________________O                     !?________________
M____V@                    !-____________________^@
M           [_____________________PX                    J^?__
M_________________S,                    ;Z?__________________
M_UX                    /V____________________X\
M       &T/___________________]                      RO______
M______________\K                    R/____________________^
M                    R______________________W%@$%!0,!       !
M!@T8R________________________.OAV,_,S<_0TM37W.+J____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________':QO__________________________
M____\<:CA&A-,A@ %:O__________________________[E\1A@
M ''________________________7?"\              #OC____________
M_________]]D"0                RU_____________________W0#
M              "-____________________Q14                   !J
M____________________F0                    !+________________
M____M@                     P_?__________________UP
M           9Y___________________]@                     %T___
M_________________PX                     P?__________________
M_R\                     K____________________U(
M        GO___________________WD                     CO______
M_____________Z4                     @/___________________]@
M                    =/____________________\V
M    ;?____________________]\                    :?__________
M___________7#0                  :/______________________<
M                8?_______________________U \1DY465UA9&AL<'9^
MB?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[]6[HXMS6I7_____________
M______________B_CF1!(04      %+\_______________________WG588
M             !?!_____________________^5L%@                "-
M_____________________V,                   !>________________
M____G0                     U_/__________________H0
M           1V?__________________R@                      N___
M________________[@                      H?__________________
M_PP                     BO___________________RT
M        =O___________________TT                     9/______
M_____________V\                     4O___________________Y0
M                    0/___________________[P
M    ,/___________________^H.                    (O__________
M__________]$                    %?____________________^!
M                "_7____________________("P
M NS_____________________7@                   .7_____________
M________R1P                  -K______________________YT!
M          <.%\7________________________5N;S!Q\[5V^'F[?3[____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________XW\______________________________[,:EB&U4.R$' #+>
M________________________UY)9*0            "@________________
M______^)-@                !G_____________________V8
M           R]O__________________E0                     #R/__
M________________IP                      H/__________________
MUP                      ?/___________________P
M        7O___________________R4                     0_______
M_____________T@                     +/___________________VH
M                    &/___________________XL
M    !?/__________________Z\                      .'_________
M_________]4                      ,____________________\D
M                 +[___________________]4
M *[___________________^+                     )______________
M_______+#@                   )+_____________________5P
M             (;_____________________J@H                  'G_
M_____________________VT                  &;_________________
M______=5                 $7_________________________:B,K-3]*
M56!J=7Z'D9S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^C/MIV#:4ZY_________________________^RR@UPZ
M'0(       ![_______________________%;2D               ! ____
M_________________X,;                   'R___________________
MD@                      F/__________________I
M        :O__________________W0                      0?______
M_____________PX                     '?___________________SD
M                     .C__________________V
M     ,[__________________X4                      +?_________
M_________Z@                      */__________________\L
M                 )#__________________^\6
M 'W___________________\^                     &S_____________
M______]I                     %K___________________^9
M             $G____________________2%@                   #G_
M____________________6                    "G_________________
M____H@                   !G_____________________]58
M          3______________________[LO                  #X____
M__________________^K*0                #/____________________
M____R4<     !Q,@+CY2:(3M____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________]-7)____
M________________________^M*PDG==0B@,  !*____________________
M____Q7U%%P             1V/___________________\10
M        G___________________H@P                     :/______
M____________E                       -O__________________V@
M                    !^S__________________Q4
M     ,3__________________T@                      *+_________
M_________W4                      (/__________________YT
M                 &G__________________\,
M %+__________________^</                     #[_____________
M______\S                     "O___________________]8
M             !C___________________^!                      7_
M__________________^L                      #_________________
M___>(@                    #R____________________7
M          #?____________________GP                    #,____
M________________Z$H                   "W____________________
M_Z 6                  "<______________________]Z @
M      !W________________________>@L               5,________
M_________________Z)7:'2 C9RKO-#G____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^WC___________________________2HWI8.BDC'!8.!@  G_______
M______________^L4@X                 :?__________________Y$,
M                    -/__________________>0
M     ./_________________S0                       ++_________
M_________Q,                      (7__________________T\
M                 %W__________________X,
M #K__________________[(                      !S_____________
M_____]L#                      +___________________\J
M              #[__________________]/                      #G
M__________________]T                      #4________________
M__^;                      # ___________________$!P
M          "M___________________P,P                    ":____
M________________9P                    "&____________________
MHP                    !R____________________XT0
M      !<_____________________Y$&                  !!________
M_____________^M?                   =_______________________*
M2P                  ________________________RU<   P8)#$_3F!T
MBZ?'___________________________7Y_+_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________KU,W'PKZZM[.P
MK:FHI?___________________]U^4S\P(QD1"0(          -O_________
M________=@                       *?_________________N@
M                 '7__________________P<
M $;__________________TX                      !K_____________
M_____XP                       #]_________________\$
M              #;__________________$9                      "^
M__________________]$                      "D________________
M__]K                      "-__________________^1
M          !Y__________________^W                      !F____
M_______________>(0                    !3____________________
M2@                     _____________________=P
M       K____________________K H                    6________
M____________YT4                     _____________________XH
M                    _____________________]9-
M    _?____________________^G+@                  U?__________
M____________F"H           88+45@X/_______________________ZAC
M=(&/G*N[S>+Z________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________GR[>IG96.B82 ?'AT<&QH
M99#_________________O&I(+1D*                 #'_____________
M_____P                        /__________________T(
M              #<_________________XX                       "R
M_________________\X                       "-________________
M__\I                      !K__________________]:
M          !.__________________^&                       T____
M______________^N                       >___________________4
M%P                     *___________________Z/0
M        ____________________90                      ________
M____________C@                      ____________________O!D
M                    [___________________\4X
M    V/___________________XL                     O___________
M_________\Q#                    H?____________________^1&0
M                >O_____________________R= H                1
M7_______________________Z'03'RPX15-B<H6;M-+U________________
M___________7Z/3_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__OW\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$
M_________________TLE"P                    "2________________
M_X@                       !F_________________]<
M           ]__________________\S                       8____
M______________]L                        __________________^=
M                        ___________________)#
M        ]O_________________Q-0                      W_______
M____________6P                      R___________________@@
M                    M___________________J08
M    H___________________TR\                     C?__________
M_________UX                     =____________________Y,'
M                7O___________________\U#
M0/____________________^'$                   '/______________
M_______87@                   /______________________OTX
M  X<+#Y2:H:ER/_______________________\)\C)JGML76Z/W_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^[AU\_)P[ZZ
MMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____
M_____________]<%                        __________________\T
M                        ]O________________]V
M        TO________________^P                        LO______
M___________A)                       EO__________________40
M                    ?/__________________>0
M    9O__________________H                       4?__________
M________QR,                     //__________________[DL
M                )____________________W0
M$/___________________Z,6                     /______________
M_____]A,                     /____________________^(#P
M             /_____________________+4P                   /__
M____________________I3@           D=-$YKC/__________________
M_____YDY0U%?;GV.H+7+Y?_____________________________K^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KS+FLH9F1BX:!?'AT
M<&MH9F9H\?________________]A13(C& X&                GO______
M__________]^                        =?_________________#
M                    4O_________________[-P
M    ,O__________________:@                      %O__________
M________E@                       /__________________OQL
M                 /__________________YD(
M /___________________VD                      /______________
M_____Y "                     /___________________[DL
M             /3__________________^A<                     -G_
M__________________^1&                    +S_________________
M___*4P                   )W_____________________F"X
M    $"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN________
M_________________^>@JKG(V.G\________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV
M,B\N,?_________________2)1$#                     /__________
M________0@                       /__________________?0
M                 /__________________L L
M /;_________________W3D                      -S_____________
M_____V(                      ,7__________________XD
M             *___________________Z\B                     )G_
M_________________]9(                     (+_________________
M__]R                     &G___________________^A*
M         $[____________________37                    #/_____
M________________EBX              !4R4G?_____________________
MX'(3   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^>#2R,"Z
MM;"LJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00
M -3_________________D@                       *W_____________
M____S!X                      (O_________________^U(
M             &W__________________X                       %'_
M_________________ZD;                     #K_________________
M_]!"                     "/___________________5H
M          S___________________^/%                     #_____
M______________^X/@                    #____________________E
M;0,                   #_____________________GS<
M ! O4'3_____________________W7(4      87*D%:=92VVO__________
M_____________[Q81%1D=8::K\CC_______________________________2
MS>'Q________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________\^_K[_?______________________[KFHG9:/BH:"
M?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_
M_________________VD                       #_________________
M_YL*                      #__________________\@Y
M          #___________________!C                      #_____
M______________^*#@                    #___________________^P
M-                     #____________________56P
M      #_____________________A1H                   /L________
M____________L4D              !@Y78'_____________________Y7L>
M       ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__
M__________________________^SGK3%U^O_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___Z[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;
M65A75UE>97'__________________[\Q'Q80"@4               #_____
M_____________^U6                      #H__________________^"
M!                     #,__________________^K+P
M      "S___________________25P                    ";________
M___________W?!                    "%____________________HC<
M                !2N4____________________RV$"            #"Q0
M=I[1____________________]8TP       -(SM7=IF^Y?______________
M_________\-C&"H[3%]TC:?&Y_____________________________^H?Y:H
MN]#G_____________________________________?__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________=
MSL6_O+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&
M2$M066:A__________________^G)@X' @                !6________
M___________.4                      Z___________________T>0L
M                   A____________________GS(
M   .____________________Q%@                (,5J$____________
M________Z7\?           &)TMQFL+I_____________________Z=)
M  (7+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[_______
M______________________^N<H68K,+;]O__________________________
M________W^__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________O[*J
MIJ.AH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.
M66E]____________________GBX&                    ____________
M________PU8                  !5!____________________YWL:
M          DT8(NT_____________________Y\_          0E2G&9PNO_
M_____________________\9F#P   !,J1&*#I\WU____________________
M_____^N.-2L^46B!G;S>______________________________^^=G^4J<'<
M^?__________________________________TMCS____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________V\O#O[^_Q\_C]____________________________^+"?FI>6
MEI:8FY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I
M_____________________Z9! 0          !S9CC[KA________________
M_____\9E"@      !"=,<YS$[/_______________________^6(+P  $RI$
M8H*FS/3___________________________^K4#9*87N6M-;Z____________
M___________________2AWR8L<OI________________________________
M____U,[M____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______MY>/CY.;H[?'Y______________________________VQE)*2E9F=
MHZFRO-#M__________________________^=4T=)35%68'.*K];\________
M__________________^R5@ :-5!MBZ[2]___________________________
M___-;SY?>YFWU_G________________________________NGX.FPN'_____
M________________________________X\[K________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '+ F # 1$  A$! Q$!_\0
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MN,D^=5WU5%")P<]UD3]GK#^CVRK/]R_>$2X0B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B4&L]N,D^=5WU5%")UN>ZR(?\ -VP_KLJS^X(EQ!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$H-9[<9)\ZKOJJ*$3@X7^-D0_P";M@7^NRK/[@B7"$0$0$0$3#&Y
M]TU.E:_%K.ZQS)+V)E.74N'MR*&+&>CU,V]E(API=O(E28[<:&I]Q+9*2;CJ
MUF2$-J,PQP<C4<+3E^&S.:Q:[7\5*U:&PJ2 27902J*"Q"L?1?-+ON<+-S3\
M:X5/>>I?-KH" S*#L J;[LS%5&X&^Y$Q]M_BJQW4F47>,OX;E&4.8CAM9GV9
MS:5VFCHH<7MKARFBS(T.TL(<_(I)2&)#CT"A8FRFFVDI4@G7V&W*8I&39:/-
M=-.J:9H[WE6<>_ZMV_=*Q56&M-9-U*O=P[:FS;<E'VON0U)3ML]V1@ZIJ%-/
M((&QM(K[F6S7V%:*W #<*W<,RJ7V"D$^^^XG\4I<DFU3>.Y%8XY066+4N99K
M'*N9I\1N,S-GR#7V4.5+:MI#KGC43QY<&&^BM*7'.6;9+[LE*&Z\4DK6+,_*
MTO%M8AJLO4,*L67T5,G(A1N$KN<"JRW>M6+ S"]@7&7(16?_ ,74ZM;4%*6X
M^G7N5KON5^/%ME=VI&]JUUNY7823"5$I*5),C2HB4DR\QD9<R,OU&1\Q8002
M"-B/!!]0?H9>"" 0=P0""/0@^0?SGZ$K 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1*#6>W&2?.J[ZJBA$X.
M>ZN+^ST_ZRK0B7"$0$0$0$2)G&#BV?9G@.)TNOL O<^LXVS<&R2PBTMO@U/Y
M/J,9NF+:?(D/9QE^)1GE/,L*CQ&(#TQ]R2M!/-QX_7(0Q&[6N:+E6*5QL+)M
MOR+CQ*JKT68X0(I:YG)N[AXUE1779\7<[==E;@'TS5Z%8=[+T^[%HKV;DUEI
M5E;D5[:HI39BSJV[+Q5AR*X0XG=0[AV'L/U48[K*SR"5$U_31=.Y/191@./R
M=5[$1=IL[B7LYB_R>N?R#&W^PJ>IC%XN=I*+!LX<>I)V>F4]3"%N-F95M5M5
M&4=4TMZLZU;+=.R-&QT*YF-;CHK97O1[N=VBV(#9[SB'WG%.-O7=>U-V+B5W
M56VX@Q-3&;A5NJ9_O]ZH,*[$M9EQ46M%52[9B"N]&=J,FI_/?DND-T.S=D:^
M8QF/=8_NK.=>Y_>;.B6^-PJ;$WJ)NA3F%7-HI]O%RJ5*ENX\RYC:J2AL8*DS
MG$6$NL-@NTS8O82W3Z@&Q\/0^H=2U?$:TFRS,P\FVS+P\914;"N77D.:LIK^
MS3V%5Z[KG)K$:T9!Q;[;&2_.U'IO$T3*6H!%HS*TMQ\G+'<5*FQ&HR++*5KY
M7=Y K4(K=P;#WH2'Z]VN4])90]#7".1$?<BS&D.,&P;T:2RI+L:2@CZV7VE)
M<9=)+B%$I)&+&;DS-MMR8ML/0;G?8?PF1%XHJ[[\55=_KL -Y ?2&#V&GN,3
M8.KZ[:N[\]PN9PTZZSUJIW#MS--JE5Y1-VCLK'IMC2OYE9V;]2<VIJ*V-+:A
M+:9?*(TMQ)K3S%LO/D?CO\MAX_@//]/SFP0)2 B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MCI99D\:D6S$I6SFCU=[)I-QHLN5NTN0F]:)76]PN)M97"U*;<:L++_=ZB++
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M9(RV3++3)<C)IIMLC+GR,D))/=U*4KEW?YRE'^E1GWGA9N3,Q]68L?3YDGY
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MVQ*K4>NZJIS25N05]K(0KJ>-QH9D1+JF1GHO%;BRMPR'G59R2L.A6RFQJZ[
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MZG;\OA'^I,EL-%(L!$!$!$C#Q04JW,9H<LC$HIF,731&X7=T0[$T)4?,O?\
M'H\ DD?=R4O])\]SHUNUUM#?NW5D[?5D^6_RW1FW_@))QF^)DVW#K_IO_(@F
M2 Q:X;R#'*2Z;42RLZR)+4HB(B[5QE)O$1%R(N3O67(B(N[S%YAJ[JS5=96?
M\#LOY G;^6TP,.+,OT)$KPQ2V B B B B B B B B B B B B B B B B B
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M3CW5A-SVKTMK86+L.2\'&X(,U:#EEK:!24MT_'LJL";7VU666VUN'VV?'*N
M@!/"T6 [-N!. 0Y,@(@(@(D.*T_^$$S0O^IQK$^?/N_RV;<][S?O"5W\;?CO
MOOX_3T_.3'"4@(@(@(@(@(@(@(@(@(@(@(@(@(G!QQ#3;CKADE#:%.+4?F2A
M"34HS_41$9@!N=AZGP(D3^&=MRSM-F94^DS797;++:SYFKK<>L+"6DU>8S/Q
MB(9\N\CYF?(C+GO-8(1,.@?]76Q(_ !$7_W6DK)\"I?HOI\O0 ;?S_E)9C1R
M+ 1 1 1/)8/*CP)KZ"2:V8DEY!++F@U-LK6DE$1ES29I(E%S+F7,N9"Y!NZ
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M8]"?I)=#0R) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M8@@CU!\$?E/8+92 B B B B B B B B B B B B B B B B B B B B B B
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M6GJ4XI)))*.:CY]Q&8R55M:ZHJLV[*#Q!8@$[;^ ?YRJ@L0 "2?H-_Y2%O\
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M)2#:2@FR0I)D9*3T%TF1D9&7<9# S%F9CY+$L3]23N?YS*JA%5%\*JA0/P4
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M364J!E$FS%VXWJH#<>TNKN@M&ZWTQNM/9Z:WML5KM2T6L*EO<V9[0M"%C1F
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MD-,L,H0TTV@B2A"4I21$1$(2J%557?90%&Y+'8#8;EB6)V'DDDGU))GH<
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MJT[EV/W"B\'>W%*7* RD,3CW[%@-UY#9@0)!<X]SMBV%7?L+9VRS<EJ:Q@C
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MPAOA*K;J&E&P O62=K:MC8FQ6Y/ >>4OM0?90HUJI=2QF%6;2N^@]6XU8^\
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MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M$0$2@UGMQDGSJN^JHH1.#GNLB>?W.V']'ME6?U_H_>$2X0B B B B B B B
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MA/A:)I6F8=W5FL5U%J<S4]1U''HJS++,FB[)NITQ,HX.E8ST)W,S*Q/VC?\
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MT+CZHR+NGLZA<E""=5'190GX2GTM*4@G%-$\;A(-:26:22:DD?,LE5AJMJM
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MR*(DE0$2@UGMQDGSJN^JHH1.#GNKB_L]8?65;^__ '_H")<(1 1 1 1 1 1
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MC7TUE5>VIZPS@E5YJ5)(4@G8$D 'UV^4RT.E=U5CABM=BN0I 8\2& !((&Y
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MPBL4^5T[TQ4]UDBGE8MDR^IIBW@09:&E=BDD[#)M%VIX6HJ@=:-/S,&[&O\
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MUA*AQ8CBNF8MENM=9D)FFR:D1734IMEQ1.*0OI))X;4>PUINO9+CWE=R'>D
MEJZV&X1K#LK.02J%BHY 3+4ZIS8@FP(>P=@46[<<7L4_OH@W;@".3!03Q+3!
MSVL=YHUUZAJB_P!54;3TQN-+CUM7E[,5W'%M*5:Q3M/*1W*K>_F./.V=H:TO
M$T^\49;;[A/MY[^%[8P=%?'K4K;CL-J375Q7$QD0;CW6E%465N2;^/!]T9^6
M*DO2+V5V&0Q#TY)(>WONW._*M+#B;B?%(11742"$XUI6,YZZILGH,7AU.5+Q
M5,R"M46O@X773:S':FDC-,QJJK@L6#\B8LHL=GFX\\I/-;AMMMI::1SRW6=Y
MEL9K++W[KY-MI!-MUF1=8&4#T5*7JI\DL[5-:VQ<J,52&OF@"+4I1<=$Y;I6
MM%2MW&8GF[WK=;N-@%L5/)4LU]##,LL#9=9GUSB<ZLUQ<T%!D<U3;";7(8MA
M+BQH2U$4PX[=:\R^B:MGJ;C/&I2&%J[4VUF@DGBLK-AK4[=@L?>$#,CVU['[
MI'7S6';86,/BX<@A5B&&6MU3FQ!-@7[D[*46S<;.ZM^\%&Y"^A;;EN-P<0UG
M#Y$R;%*O'-NU^,SD8E.=DX(SKVSSS$FJ!4FH763Y\FSA9% N+.VLCDSE3)$A
M\VS9E/-DE2I$A2\^0*[6%Z!DR_=LG#Y^%IJP[FQ&KPZJ$VK./6V#C6%74_'6
MBJ%2M=\-)>L/42IQWMHR;%(Y6W9E;Y3V9=MS#GW;!E,IXD L#:Y9W'"O<->C
MHW#]K*)@+5DJWD-VMW9R[ IES(8>.SMIDZ,AEFYL+%V+XO%D-1WDL+;;?>;7
M)6A3KBEGELO:S'T^@[?V/ Q<5CQ4<[::4KNL7B 0EEBEZZR>-2D5H%4 3&*E
M7*U'(7<#-SK\E%+,W;J=MZJVY$AG1?#V <K3\3EF\S/XP3++"S_66%[0KZVK
MS:KE6<2HM&KNL\2O<AQZ5"M68\B*U-8GXW:U$]#J(\J0TDO&31TO+]AS/F+.
M"]Y+QN+:Z[JD8,PVKO""Y2H(5@X15/)20O)00&8-?S85V4[CMVFLV*0#R-+B
MRK<D;[)8%L ! [B(^W)$*P=HN!FYPFLBM8GE]%8.L;%V7ELS&\W;RO)<)O*;
M.5S&JJ#:UTZ\ERCN,;@RS2BT962K"82Y<SM9"DO) .V#I^#::W7'Z=?1<BT5
MJMB95MYMLU' *@#&9E"5"@ 5HG<[? V.6H"JY.H9"<T;(UC$U/'XL25IQ,7'
MI&'D\B>\KW5V7FT\G^*M&Y)4JB9>D]<R=2ZOQ+7TR^D9+)QNO5$=MY).I-\U
MR'I'9,(>=?=:AQ2=*-#:<=<6W&::0I1F0FYF0,FU7 8!*,>GE80UMIHI2HWW
M,  UUW#N6L!L78G\9%QJ30MH/ =W)R<@5U K32N1?9<**58DK33S[=:[^$4
M #P,J"+)$!$H-9[<9)\ZKOJJ*$3@Y[K(A_S>L/Z[*L_N")<(1 1 1 1 1 1
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MU#FO(S]+TC)NS:E\'WFS)OM9F#JH-K,5;B%EB4)=EZVN[(^FZ[UG[F%)4&O
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M^79V4V7/ER5*D29#KJE+/'F+[[4]5W$*U8J7M)74M2H/N^U74J5UBL@,H15
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+!$!$!$!$!$!$_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g374624g45m57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g45m57.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[17@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %<2^57(X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))301$       0     @   D    )
M #A"24T$'@      !      X0DE-!!H      T$    &              ')
M   "J@    8 9P T #4 ;0 U #<    !                          $
M             JH   ')                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ')     %)G:'1L;VYG   "J@    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MR0    !29VAT;&]N9P   JH    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M(0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^+_
M_TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0  !P<G1R0TU92TQA8B '
MT  ' !H !0 I #5A8W-P05!03     !!1$)%                     0
M]M8  0    #3+4%$0D4
M                      ID97-C    _    '1C<')T   !<    "MW='!T
M   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "CN   H@9"
M,D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT  ?OW
MD)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                     '1E>'0     0V]P>7)I9VAT
M(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:  "\9P
MDC!M9G0R      0#"0   0                    $
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MU.OE[/7N!.\2\"#Q+/(X\T/T3O59]F/W:OAN^6_Z;/MD_%;]1/XO_Q?__P
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M@H.;:*KD@9F)?J;:@.!V^Z,3@&-CJ)^;@"9/4YQ_@",Y=)H%@$P?H9F6@1<
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MKP.7HJ=]JKB%PJ-RIL-S0)^LHT-@*9PVH$],09D<GCLV]I: G7T=\Y7(E$
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MB=6-FK/>B$E\SZ\:ANYK5:JCA>U9'J9ZA31%X:+&A,PP^I_LA,07@: <A@0
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MM(R+(K#4K]MZ5ZP#JZMHZ:=YJ#%6WZ-+I;!#_)^5I)XOG)R&H#$7%9P7CYL
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MD&N Z+TCCE]PZ;>\C)5@:[*&BR9/.JVRBB4] *EJB9,H]J9(B>,/VJ<$B0(
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MN<E_KKHMM)MO[;2;L"U?AZ]1K/I.>ZIPJUP\@*8@I_4HW*+(FZ 0L**XBT@
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MEH5U6,9XE =F'<!PD?!6:KJ7D$E&(;45CR0TQ+!5CM\A6JT@CWL)S*Q"AJ
M (I8@ "$'<O4GB%U4,6DFQIF*+^.F)!6@[FOEIE&.+0OE4LTXZ]=E4HADJP8
ME$ *-*L;AN8  (IH@ "#_LLLI<]U2L3OHCEF-[[,GSM6H;CIG/U&7+-NF[DU
M#JZ:FZTAS:LREML*D:H?AR4  (IU@ "#W,J:K:9U1<14J79F2KXHI@%6PK@]
MHXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J @ "#OLH2M<5U1</%L.IF
M9+V3K/)6\K>CJF9&PK(EJ-\UB*U6I#(B9:G;ET$+1ZBPAZ   (J(@ #RAGM&
M>8K:]WN<>:7"_7OV>=&J?7Q8>AR1<'S#>HIWNWT[>Q9<]GW#>ZH_UGYX?%P;
M%G_1?0_P7'F0A._9.GH'@^C!<7J @P2I%7K^@DZ0'7N%@<AV>7P7@61;NGRR
M@0H^EWUG@-09=7Y?@-ON:G@FD'37:'BLCE&_UWDWC%&GDGG,BI^.O'IIB25U
M-WL1A]5:D7NZAI4]=GQKA8D7]GSOA1CLF';XG ;5GW>%F-.^('@:E=&F 7B\
MDPV-4GEOD*9S]7HGCFM9=7K;C$T\;'N%BH(6FGN(B-_J\'8%IZ/4 ':3HVR\
MBG<MGV^DA7?7F[F+[WB1F$9ROGE:E2Q89WH7DCD[=7JWC]459'I7C!3I@G5+
MLU+2F775KB*[*79LJ2BC-7<9I'Z*O7?:H")QF'BGG!-7;'EKF&8ZEGH"E:X4
M5GEGC<#H4'2YOQW1;74]N/2Y_G7.LO^B$W9ZK62)N7=#J"QPLW@6HTY6D7C8
MGNLYUGEFG"H3<GBFC2;G5W1,RPO0>73*P^JY!G52O0"A&77YMG:(S';$L&AO
MZ'>>JN%5YWADIAPY,WCCH=$2N7@(C*CFD70#URG/N'1YSPRX.G3VQS&@1764
MO\B'_W9<N/=O+W<XLNA51G@ KBTXIGAWIDT2)7>+C$3AXX0N=^7,,X.C>#NU
M\H,N>)B>_H+1>0R'6H*+>9UN\()=>DM58()/>P(Y)H*9>],3WX2=?([@'X*@
M@KW*]X(I@?>TW8'%@4V=WX%Y@,R&(X%#@'1MLX$I@$!4'H$P@!XW[H&#@"P2
M>(,@@*;>A(%*C:O)3H#AB]ZS48"'BB^<9X!1B,.$U( RAXQLAH NAH%3#(!
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MF8J==IF3EP2+<I;BE*=XLY1EDG-E,9(;D()0MI SCNXZRHZGC=PA%XYMCB\
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M=#F3GZ;L=+R"L:-\=4]Q!:!%=?Q><YU*=L5*O)JH=Z(U5YB^>&L;0)EK>.P
M (V>?Q&C,*F6?..3"Z7G?)N")*)P?'-P=I\T?'!=VIPY?)=*(IF;?-XTOY>M
M?2T:T)@U?9@  (QL@ "B<ZB*A8B2/Z3DA(6!;*%F@Z1OLIXQ@OY='YL\@HA)
M>9BC@D0T+):R@BL:;9<9@L8  (M@@ "AL*>5CB^18Z/VC(. ?:" BOYNVYU$
MB;)<59I9B*M(RY?%A^$SH971AW@:$Y8:B#@  (IW@ "@XZ;4EN:0EZ,UE)I_
MJ9_"DG]N IR(D)];G)F)CO9(+);]C;\S)I4"C2\9R)4MC.T  (FO@ "@.J8B
MG]Z/[:*)G/-^_)\6FC5M5IO:E[9:^)C:E89'H)8YD^4RNY0[DXD9A)16D.H
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M? &&'Z_%>[1V-*N>>Y!ECJ>R>Y93^Z01>\A!.*#I?!HLCY[)?&D25*"=?*\
M (C$@ "4U;,9A"R%C*[#@S1UL*J3@F5D_*:I@=A3;Z,'@7] O9_@@5LL+YVT
M@6<2/Y\_@@D  (@A@ "43K(?C%.$[*W/BL)T^ZFDB6!D6:6QB#]2UJ(8AVA
M/9[RAM@KTIRZAL$2*YX&ALH  (>3@ "3N[%3E)*$5*T$DG!T6:C<D(ACLJ3I
MCM]22J% C80_R)X?C*$K@9O;C*@2&YSNBN(  (<9@ "3*K"WG/F#RZQFFDMS
MU*@XE]5C+Z1!E:U1SJ"4D^4_9IU9DL,K0)L+DQ,2$)ORC#8  (:S@ "2OK E
MI86#8*O5HDMS:*>EGTIBQJ.MG*=1;J !FHX_&YR_F7HK$)I&F)02"9L,C#(
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M@NEY8KC]@?1J7K0F@2Y:EJ^/@+5)]JM,@'0X&J>L@&PD$Z6!@)0*WZ:#@28
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MJI5WU;5:IQYHQK!KH_99#ZNSH65(FJ=>G^4W%*.FGPHCJJ#\F!T+P*"TA_(
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MB11M?<)SAYY?%[T1AF=0);?4A85 7K,!A0(O2J\"A-\;K:T=A80%$JJ;@VX
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MKSYM/K[AJY-?";DXJ%M0*K/,IC- A:[7I,XON:JPH$4<LZ@QDV<&R*5&A)8
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MHGT5@R9."WUV@I@RDWWM@B4-3'[2@8/1;GJ&DAB]97J\D!FHH7KWCC"3#7M
MC&E\JGNABMUE>'P,B7)-"7QVB"$QK7S>AQX,>'V-A/S/\WERG.F[[WFJF@NG
M+7GMET&1I'H_E)A[9GJEDAQD6WLBC^=,&7N3C>$PW'OJC'\+PGQWA_/.LWB;
MI]*ZLWC4I!^E\GD5H'&0<GEJG.9Z2GG6F9%C5GI3EH1+/GK,D^8P(7L5DH(+
M*7N-AXO-KG?QLM.YL'@JKDZDZGAEJ;^/;'BYI51Y6GDLH31BA7FNG7%*A'HA
MFDLO@WI<F'(*JGK+AS;,Y'=SO?&XXW>JN*"D$'?<LS6.BW@GK>MX@7B;J0EA
MQ'DGI+=)Y7F<H6LN_'G!G4X*0GHMAO#,57<>R3ZX2G=1PR.C7W=WO."-RW>U
MML)WR'@DL2]A('BPK'M)5'DGJ/(N?7E!GV\)\'FOAKC&?H@8<(JS_(<S<;Z@
MDH9R<MJ,&X71<^YVMX5'=0M@7(3<=C5(M(2>=U4MQ83T>%((W(9/>6#%1H:
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MBD"5PI3JB1^$QI+'B UR]I#-AP]@&X\3AD%,.8V6A94VP(Q^A1L<_(S=A68
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MN9J22)'@M5N!(X^NL/-O.(VAK+]<JHO8J5))-XI@IT@T4HDPHM<;-XD8DF<
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MD-V(0YU\CT)X1YJAC;UG=)?WC%A5T96!BQI"_)-[BC4N;)(,B=$4RI,;B4
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M;@!^5ZM[;Q=O7:@#<"]?>:3 <4M.C*&[<F@\09\W<W<GS9WW="0-+Z"X<\4
M ()_@ ",+*XY=D%^!JIZ=HYO *;M=O)?&J.5=VQ.*Z"#=_L[Z)WT>(PGA)R9
M>.0-.I[B>-$  ('%@ "+NJT-?EU]<ZE8??]N?*7"?;M>BZ)I?:)-IY]6?:@[
M>9S'?<8G,YM7?=X-/YTV?CL  ($A@ "+,*OJAF=\SZ@ZA7=MPZ2KA*)=ZZ%-
M@_E-$9Y#@X$[ )NT@S8FX)HU@RT-/YNU@Q$  ("3@ "*FZKYCH-\-*=-C0UM
M'J/!B[1=0:!BBH%,B9U,B8DZC9K!B.PFE)DQB/\-/YI<AST  ( :@ "*$*I!
MEL1[KJ:6E,ULF*,%DNQ<NI^AD3E,"9R%C]$Z,IG=CO0F6Y@_CUL-0IDGB/<
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M=5!QQ[3)=8QCD;">=>E4BJRI=F)$=JD)=O RZZ8F=W4>Q*4P=Y(&(*4A>,4
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MF^9P"[ 2F;9AQJO)EYE2OJ>OE<1"XJ/VE((QTJ#>E'H>?I\NDJ<'3IUXA/$
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M>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR>S@5;JW>>P0 HZ?3?2X
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MH&!E/;G,GAI7L;35F^Y)9+ 6FCHZ.JO2F;8IMZA]F'D6A:=-CSH"C:"S@;H
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M<V6<!XCX=%6*[H@,=3)XN8<_=@AE<8:-=N)1!X8&=[P[$87 >'@@]H9J>,<
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MHS*6R(-%H(B%K8)VG:QSF8'"FLI@Q($WF"9- (#-E?(WQX!VE+H>48!LDE<
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M>TZ.$)!B>WU^(8[&>Z=M (U8>]A:X(P-?!A'CHL!?%\R?HIC?)$8?HM\?&P
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MJ,R)]8O8I>EYW(I$HLUHW(C)G[=7$H>(G0]$0(:+FTDOYH6]FBD6OH7ACV$
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M@CV DIAN@=MQA)8M@7EAD)03@290>Y(W@.H^*I"S@,(IWH_B@*D/TI&2@*H
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MK<1]PY3TJMQND9*:IZA>@I!6I)%-M(Y;HE$[SXS&H/4H'XNOFR$/'(OYBC<
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MB$=S\*$DAWAEM9X\AJU6GYMYA?%&EICZA5PU&Y</A0(A6I9"A10(O)7?@]$
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M9W]I]; X:0A<@*SE:HQ.&*F\; (^AZ;B;5PM/:3K;FL8N:67;FP!B:*J< (
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MC8IH**IUC'):KZ;CBUA,7Z-YBE@]'J!HB9HL7YX8B6@8TIVVB8,#(YBV@A\
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M;C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8  )W >"D
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MD?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8RCD40(J99BND  )C?@
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M9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+\8/R;JPV@80@<$@<985A<.8
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MDNZ.)'UED95^"GTZD ]L\GT9CG=:]7T.C/A'UWT9B[$S''TDBMT9QWS[BF8
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M;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3<S\MWXA]=!X38HI]<ZP
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MF+6!FH5XEQ=RA82)E3EB9X.IDT91;8+RD8H_58)ED$(K;X'[D!T1Y8(>C!D
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M<]MX[I.(=*5JTI'9=61;>Y!1=AY+#([U=M0Y+HWZ=W0E#HW4=[L+'([(=WT
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MG<YU=HY"G 5G.HR7F>]8!(KVE\Q'ZHF3EAHVCXB,E6LC-(?IE!4*MH<0ASX
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M>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\>T\;]Y1G>S$$=)' ?$P
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MHBMJ I>-H'M<BY4GGEQ.')+,G$0^TI#$FQDN)X]+F? ;!X[-DD8$V(M2@T8
M (  @ !N!JTY89-B ZI=8Y)5.J>W98-'::4[9U<X3:,=:/<G-J(7:AL2*J1_
M::<  )C3;F(  (  @ !M@ZP0:3]ANJD;:H]4_:9&:^%'0*.@;2HX-Z%@;E,G
M/Z Q;QL2<:(M;HH  )<M<VD  (  @ !M%ZJ!<+-A.:>3<7-4F*2T<C=&WJ(#
M<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (  @ !LH:CJ> A@KZ8#>%-3
M_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4  )0P?&,  (  @ !L**>0
M?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP?O(2DIR&?N,  )+H@
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M8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$9[@(7*ZD9VL  )-8<M@
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M@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00@J *)Z/,@CD  (WC@
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M>_>2C7$7?$^"6'(??(QQ&7,>?+E>N'0E?.E+/'4>?1@V-775?38<\W5W?0,
M (  ?J*@;&XFA9R1.&]:A3N!"'!UA+=OU'&#A!]=M'*4@Y!*57.?@Q<U?'1-
M@JT<:G.%@F\  (  @ "?4&ROCU:0(&WOCCY_^&\3C/=NS7 LBYU<O7%%BE5)
MC7),B38TVW+RB&,;[W'+B$L  (  @ ">;6N F1.//&S(ET=_%&WNE3]M\&\+
MDR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (  @ "=Q&J6HM..BFOCH%=^
M6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;.F\UD7H  (  @ "=5&GQ
MK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*G0,S5F__FW@:Q&Y'DAD
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M@PZ%KG=_@O-VA'?J@K!F37A2@E)5'WC'@?M"EGE(@;0N5WF2@784Z7E-@5,
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M7?!^$8>M8,=OTX<=8VI@1X:X9=M/=(9Q:"<]*X9F:CLHO(;M:[D.!HC^:T<
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MB4]Y-G[8B--K GZ;B"-;PGY>AU9+C7XWAI<Y_7XLA@DF47XDA=D-#7YZA*,
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M9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M];D4?CHPG;N &:HOV;O
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MCHQM.H<:C<Y?XX8GC,I1=X4PBZ="&81IBK(Q8(/>BC(>*8.CBHD&BX+SA&P
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M;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"<<H6%9+<<84 <XYP=#,
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MDPIAL9 7DC55$HYYD0%':8S3C[$XO(MTCM,H<(J>CP05&8K'C* !&H;1@+X
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M<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>=,,,CIH9=%4  (D4>^4
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MELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);D>\,OY'LB)\  (2<@
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M=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)==RD$PI\&>.$  (0^@
M (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\FDJ!T?3,6&Z"7?18$_YSO
M?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U@\<T0:$"@VPF=)\T@T<6
M'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,$Z4RBOU JJ*#BF<T,I_^
MB<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (  @ !68J<TDGY,#*1ZDB)
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ME720,ER\D\R &E\^D?MO!F&;D"1=$6/BCF]*$V7<C/,UOV;EB^$=CV4SBXP
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M;""*/VQ ;<=[$6V];U5JA6\F<,98[G"#<BA&&'')<W0QF7*E='P88W(F=),
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MFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2D;(NDVHND2465FH5C>4
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M<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/=_LICG6]>&D0 W;L=_
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MH+-Y3VI_GK1K"FN>G%%;T&RAF=Y+IVV=E](Z16Y?EJXG%6X)E64.IW"1B>@
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M>DMP^7@+>MQCC'AY>TE5+'C:>YE%M'D_>^$TBWFI?!LA&7G ?" (JGNA?)8
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M5]II@(G[6O!<LHE\7=Y.I(DG8)L_-(C^8QLM\XE*92D9?XKY9?,!]8H49Q@
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M?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I?^48,W[S?^@"C7^]?_@
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M7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<:%L/:9%M9_H  (8B;F0
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MA(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @
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M9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0
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MB&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @
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M:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\
M (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98
M=0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.
MV)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/?; LMYHW
M?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#2IQSA'$X
M@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (  @ !,\9TI
MBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8  (  @
M (  @ "ISEKJ4ZF9K5W'5WR(\V"&6S5W4&,L7LQDJ&6Z8D-0X6@5994[PFG=
M:*,C)6EP:ND#YWEG;,NGPE:C7B"8%%G@8/Z'AUSN8\9V#5_89GAC@&*?:1!/
MUF4B:XTZTV;G;= B9678;VP#R'F<<6>EW%+,:(V61U95:G.%^UFG;$QTE5S&
M;AQB,E^[;]].MF)><9 YY608<Q4AL6*Q=!D#K7G*=F*C^4]3<MV4>E,@<]J$
M/%:A=-1S'UGQ=<A@X5T4=KM-F5_0=Z@Y 6%\>'@A"F $>/D#E7GR>O6B,DQ
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M4X".I&1E5UA^]F:56P9N.FBW7HA<86K%8>9)46RI91<TLVX&9^T;UVV":9L
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MA+6'/%4!A&1X*U@Q@_IH%5LE@X)7#%WC@Q)$U6 D@KDQ&F#T@H$92&&E@J$
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M7+Z"4V? 7[=SMFFA8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(
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MBT][YUI]BIYMQ5T8B;Q>EE]_B,A.9&&NA^T\^F-+AT(IZ6,GAO\1LV>PAD,
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M9-UUTFP!9Q=H6&V#:3)9C6[N:RE)F'! ;/\X(W%>;IXD@G&\;[(+976";XH
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MD.5PLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*BZ4B+F78B^D*LVWJASP
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M:]]I<W$Z;7U<NG)/;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@
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ME8UEA&@:E(Y8]VEPDR)+96J#D9X\O6M8D( LBFN%D%\9T&JTCH@$;'B'@OT
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M<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(
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M49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D
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M=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @
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M5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@
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M>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @
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M6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D
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M?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @
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MS7SU@3B3@UJ^3>Z%0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA
M9+$6JFEU9E0  (  ;=*1>5695YF#U5B[6OYU+5NV7DIE?UZ-8794HV$Q9'A"
M@&-J9THNN61=:;<63F9@:MH  (  <K"/FE#D84F" E1M8]=SF5>Y9E!D EK/
M:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (  =V*-RDR3:NN 1U!S;*=Q
M]50!;E9BM%=2;_)2*5I9<7A :ERO<N<M$UT*=!@5.&&X=',  (  >W:,'$BN
M=(9^Q4S;=7MPDE"M=F-A8%0L=SQ1-%=<> T_E%F[>-0L<5FZ>7L4U5_G>:P
M (  ?O.*L45(?AM]A$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5;
M?PD4AUYD?U@  (  @ ")B$);AYY\?D<&APUNETM$AFU?GD\>A<U/E%)^A4,^
M6%34A-\KFU1,A,0455VBA/H  (  @ "(H3_PD/][LD3*CZUMXDDPCDI? 4TF
MC/-/ U"5B] ]RU+<BODK+5)'BL84*EWKB9L  (  @ "'_SX1FAY['$,,F!9M
M5D>*E?5>ADN2D_).H$\*DD4]@E%%D1TJX5"MD1,3WUYIC4   (  @ "('6'L
M3@QZPV0'4AULL68F5A==FV@Y6>Q-5FHN79$[I&O:8.\G\FR88ZD.DW#K9&@
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M>Z=S@%#A?!=F-E1'?&]7WU=6?+5(>UGV?/DWLEN0?4,D]EK,?8D-4FE\?@D
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M5I%NG&:W6=QA@VBI70M36&I]8!5#XFPA8NHRTFUE96@?1&U/9PH''W3J9[\
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M@;EH8%7/@<9;X5BQ@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D
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M7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H
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MAL!=1%N[AH]1>5X+AA=$H%_CA8DVB6$(A2DFM&!AA284!F54A40!,'W^@,X
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M9#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$
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MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @
M (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?5
M6Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6
M\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?
M8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U
M5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y
M:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(
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M2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T
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M;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @
M (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (
M>T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*
M;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y
M@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4M
MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\
M3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$
M (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (
M:2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"
MJHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB
M9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$H
MD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I
M<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @
M (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (
M@    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"
MB8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF=#(
M! ,)   !                     0                    $   $   (
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M>9P4?Z-^98-,?\9^A6J%?_Y^P%&_@&-_/3D @1* #_S%?GR+-.2U?F.);,Q
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MWWRR@Q>=RFBD@G.8H%39@=V3/4%7@7*-?BZ @1:')\J@AL>\#[><A8JV :0
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M.X7J<W6K?G!@=0JCIUL3=KV;=T7W>)R2QC%1>J^)8=<@?Q5R&L.:?QES.:^
M?RAT3IK)?T!U:(6J?V1VEW!B?Y9WY5LS?]AY3D8>@#YZ]3%^@-Y\_=6C?69\
MF<)R?8M\FJYH?;-\HYFX?>)\P82>?AY\^V]I?FU]3UI1?M%]LD5F?UU^-S$
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MC/Y[2TB4BL)\+#A(B(1]0BD'AC5^F:G#ET.!+)I_E-B OHJRDH* 7GHZD$^
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ML8Q"FN*51'V-E\:2SFY^E+>05%]7D;*-W5!(CKB+:$&UB[J(YS/)B+6&2"=
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MZ['T9&"T4I\99I^N5XO8:.BH+7B1:VNB!V5M;BF;T%*G<1657$ _=$".C"[
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M?Q]^II>O=YB"W8I\>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6
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M@5!YV&9J@0AZ>5B8@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%"
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MC=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU DK*
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M36-9A^)]KUEHANE][T\MA>%^'D3LA.%^53KF@_%^HC%<@Q]^_"B7@FY_6B%
M@=I_MFQ:AX6#\F+4AL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!
M@RBR@;V!'"%Q@5& L&ONAIB*=6*:A>R)Q%B^A0&(JDZ4@_2'541U@P:&$SJ*
M@DF$YS%+@9Z#TBC#@2J"JR&9@."!@FN8A>&0OV))A3F/BEAMA%.-NDY-@TB+
MG$1!@EN)F#IM@::'K3%&@0^%URC1@+B#]B&X@(>"+67>FS%9H5SGF0A<Y5.9
MEN=@04GME)]COT 9DB)G:#9FCXEK3"U7C.=O7R4#BE=SQQX'A_QX8F4BF4=@
M?5QKES]C*5,NE1IE\4FEDLQHVC_UD%AKZ39JC=EO*RV$BU=RER5;B.YV2AZ,
MAKMZ'624ER=G+%O4E3]I3%*WDS-K@$D]D/EMUC^TCJ%P2C96C$1RZBV?B>EU
MK"6DAZQXIA\ A:-[L&0$E1IMMULXDTMO4%(6D5EP]TC-CSURM3]DC0ITCC8R
MBM5VARVJB*1XFB7<AI%ZV!]CA+)]&V-SDU=T,UJPD:)U25&:C\!V8$A8C;9W
M>C\DBZ!XL#8/B9%Z BVLAX=[9"8'A9Q\XA^W@^1^6V+PD>IZI5H]D$M[.E$W
MCG5[N$@%C'=\*S[BBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,&
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M83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]>
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M>F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6
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M^3$D@0]_,"M4@,I_?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P
M;69T,0     #!"$   $                    !
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M=)=USG>8<\UYFG+->YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N
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M@*:<T("CI<^ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#_YXW&O^;1"[_FTQ
M_Z!,3?^D35KXID]G\*A3=.BH5X#@IUZ,VJ1HEM.A<9_.G7JGR9F#K\65BK7!
MCX^[O8F5P;J%G<2V@J3'L("JR*=]JLBB?JS%GW^NPY]_KL.??Z[#GW^NPY]_
MKL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#_YXW&O^;1"[_G$L__Z%*
M3/^E2UGYJ$YF\:I1<^FK57_BJUN*VZEEE-6F;IW/HW>ERI^ K,69AK2_DXR\
MN(V3P;*)F<6NAJ'(JH2IR:& J<J<@:S&FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;
M@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$_YXV&O^<1"[_G$H__Z))3/^F
M2EGYJ4QE\:Q/<>JN5'WCKUF(W:YBD=:M:YK1JG6BRZ5]J\&=@[2YEHF\LI&0
MP:R,EL:GB9W(HX>FRIN#J,N8@ZO'EH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%
MEH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%_YXV&O^<0R[_G4D__Z-(2_^G25CZ
MJTMD\JY.<.NQ4GODLU>%W[1@CMFS:I;1L76>QJA[J[R@@;2SFH>\K)2-PJ:0
ME,:@C9O)G(NDRY:'J,N3AZO(DH>LQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>L
MQ9*'K,62AZS%DH>LQ9*'K,62AZS%_Y\V&O^<0R[_GD@__Z-'2_^H2%?[K4EC
M\[!,;^RT4'GFN%:#X;M>B]J[:I+-M'.>P:MYJK>D?[2NG82\IIB*P:"4D<::
MD9C)EH^ARY&,J,R/BJK(CHJLQHZ*K,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*
MK,:.BJS&CHJLQHZ*K,:.BJS&_Y\V&O^<0R[_GD<^_Z1&2O^J1E;\KDAB]+-+
M;>ZX3W?HO55_X<%>AM; ;([(MW&=O:YWJK*G?;2IH8*[H9R(P9J8C\:4EI;)
MD)2?RXR2J,R*CZK)BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*
MCJS&BHZLQHJ.K,:*CJS&_Y\V&O^<0R[_GT8^_Z5%2O^K157\L$9A]K9):_"\
M3G3GPE5[W\AA@-'#:HW$NG"=N+)UJ:VK>[.CI8"[FZ&&P92=C<6.FY3(BIF=
MRH:9J,N&E*K)AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&
MAI*KQH:2J\:&DJO&_Y\U&O^=0B[_H$4]_Z=$2?^M0U3^LT1?][I':._!37#E
MR59UW,YD>LS&:8V^OFZ<LK9TJ*>P>;*>JWZZE::$P(ZCB\2(H9+'A)^:R8"?
MI\J!FJK(@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&@IBK
MQH*8J\:"F*O&_Z U&O^=0B[_H40]_ZA"2/^O05/_MD)=][Y&9>S'36OCTEAM
MUM-A>L?*9XRYPFV;K+QRIZ&V=[&8L7VYCZV"OHBJB<."J)#&?:>9R'JGI<E[
MHJO(?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>
MK,9]GJS&_Z U&O^=0B[_HD(\_ZI 1_^R/E']ND!9\\-$8.C/3F/?W%EGS]A@
M><#/9HJRR&N:IL)PIIN\=J^1N'NWB;6!O(*RA\!]L([#>*Z6Q7:MH<9UK*S&
M=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5W
MIJW%_Z T&O^>02[_I$ [_ZP]1?^U.T[WOSY5[,M$6>':3UK4WU%LQMI:?;C3
M8HNKSFF8G\9QI)7 =ZV.NWZTA[>#N8&TA[U\LHR_>;&3P7:PF\)TL*;"<K"M
MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"
M_Z$S&O^>02__ISTZ_[ Z0_VZ.$KPQCM/X]5%3M7A1E_(XDMQNMU2@:S56X^?
MS&:;EL9PI(_ >*N*O'^QA+F#M8"WA[A\MHN[>;20O'>TE[UVM*&]=+.EOG2S
MI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^_Z(S
M&O^@/B[_JCDW_[0U/_; -43GSSE%U]\\4,GG062[Y49VK-Q.A9_36I*5S&><
MCL9QI(K">:J%OWZN@+R"LGVZAK1ZN8JV=[B.N'6WD[ESMYJY<[>@N7.WH+ES
MMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y_Z,R&O^C
M.BS_KC0T_KHQ.NW*,#O:W3(_RN<X5;SL/6FMY41YG]M.AY337)*-S&B;B,AR
MH83$>:: PGVJ?,"!K7F^A:]WO8BP=+R+LG*[D+-PNY6T;[J:M&^ZFK1ONIJT
M;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT_Z0P&O^G-2K_
MM"\P],,J,=[8*RW,YBY%O?(U6JWN.VR?Y$1[D]M1AXO47I"&SVJ8@LMSG7[(
M>*%ZQGRD=\2 IG7#@ZASPH:I<<&)JV_ C:QMP)*M;+^5K6R_E:ULOY6M;+^5
MK6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M_Z4O&O^M+27\O"<H
MY= A),[D)#.^\2Q*KO@S7:#M/6V3Y$=ZBMU4A8/788Q_TFR2>\]REW?-=YIT
MRWN<<LI^GG#)@:!NR(2A;<>'HFO&BJ-IQHZD:,61I6C%D:5HQ9&E:,61I6C%
MD:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E_Z<L&O^U)1_LR1H<T.(9
M(;_P(CBO_2M-H/@U7I/N06R)YDUW@>!8@'W<9(9XV&N+<]5QCG#3=9%NTGF3
M;-%\E&K0?Y9ISX*7:,^%F&;.B)EES8R:9,V.FF3-CIIDS8Z:9,V.FF3-CIID
MS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:_ZXD%O7!%Q34WPX0P.\8)K#]
M(SRA_RU.E/DZ78GQ1VB!ZU)Q>N9=>'3B9'UPWVN!;=UPA&K<=(9HVWB(9MI[
MB679?8IDV("+8MB#C&'6A8U@UHF.7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.
M7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N._KD6#=32"P;"[@X6L?P9*J+_)3V4
M_S),B?Q 68'V36)Z\%AI<^Q?;VSI9'-HYVIV9N5O>63D<WIBXW9\8>-Y?6#B
M>WY?X7Y^7N& ?UW@@X!<X(6!6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(
M@5O?B(%;WXB!6]^(@5O?B(%;WXB!U,@) \37"@>R^Q 9H_\<*Y7_*#N*_SA(
M@?]%4GK\4EIR]UE@:_1>9&;R9&AB\&EJ8.YM;%[M<6U<[71N6^QV;UKL>7!9
MZWMQ6.M]<5CJ?W)7ZH)S5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;I
MA'-6Z81S5NF$<U;IA'-6Z81SQ,T( ;3=" ND_Q(:E_\?*HO_+C:!_SU!>?]*
M27'_4E!I_UA58_U=6%_[8UM<^6==6OAK7UCW;F!7]W%A5O9T857V=F)4]7=C
M4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51
M](!E4?2 95'T@&51](!E_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5
M:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6I
ML,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GE
MDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=T
MKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$
MWX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''
M<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\
MCMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.R
MQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,
MA9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.RQG.Z
MLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
M_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\CMJ,A9;5
MAXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.RQG.ZLL%U
MN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR_Y8S
M%/^50R7_DU$W_Y=31?^95E+]F5M@]9A@;>V69WGEDW&$WY![CMJ-A);5B(J<
MT820HL^ E:;,?9FIRWN=K,EYH:[(=Z6OR':JL<=TKK+'<[2RQ'2ZLK]UNK*_
M=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JR_Y8S%/^6
M0R7_E5 W_YE11/^;5%+^G%A?]9M=;.V99'CFEFR#WY-VC=J/@);4C(B=T8>.
MH\V#DZC+@)BKR7V<KLAZH;'&>*6RQG>JM,5UL+7%=+BUO7>XM;AWN+6X=[BU
MN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BU_Y<S%/^60R7_
MEDXW_YI/1/^=4E'^GE5>]IY::NZ<8';GFF>"X)9RC-J2>Y74CH2=T(J+H\V&
MD:G*@I:MR'Z;L,9[H+/%>::UQ'>LML-VL[>^=[>WMWBVN+)YMKBR>;:XLGFV
MN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:X_Y@S%/^70R7_ETTW
M_YM-0_^?4%#_H%-=]Z!8:>^?777HG62 X9INB]N6=Y35D8"<T(Z)H\R)CZG)
MA)6NQX":LL5]H+7#>J>WPGBNN<!WM;FX>+6YL7FUN:QZM;FL>K6YK'JUN:QZ
MM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6Y_Y@S%/^80R7_F$PV_YQ,
M0_^@3D__HE%<^*-5:/"B6W3IH6%_XIYJB=R:<Y/6E7R;T9&%H\R,C*G)AY.O
MQH*9L\-^H+?">JBYP7BQN[EXL[RQ>;.[JWJTNZ=[M;JG>[6ZIWNUNJ=[M;JG
M>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z_YDS%/^80R7_F4LV_YY+0O^A
M3$[_I$];^:539O&E6'+JI%Y]XZ)FA]V><)'7F7B9TI6!H<V/B:G)BI&OQ8.8
MM,)_G[B]?*>[NGJPO;)ZLKZK>[*]IGRSO*-]M+JC?;2ZHWVTNJ-]M+JC?;2Z
MHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2Z_YDS%/^80R;_F4HV_Y]*0O^C2T[_
MIDY9^JA19?*H5G#KJ%Q[Y:=BA=^C;([9GW67TYI^G\V3AJC%C8VOOX>4M;F#
MG+FU?Z.\L7VLOJQ\L;^E?+&_H7ZSO9Y^M+N>?K2[GGZTNYY^M+N>?K2[GGZT
MNYY^M+N>?K2[GGZTNYY^M+N>?K2[_YDS%/^90R;_FDDU_Z!(0?^D24W_ITQ8
M^JI09/.K5&[MK%IYYJQ@@N"J:8O:IG.4SY]\G<:7@ZB^D(JPN(N1MK*&F+JM
M@Z"]J8&HOZ6 L,"??[# G("RO9J!L[N:@;.[FH&SNYJ!L[N:@;.[FH&SNYJ!
ML[N:@;.[FH&SNYJ!L[N:@;.[_YHS%/^90R;_FT@U_Z%'0?^E2$S_J4I7^ZQ.
M8O6O4FSNL%AVZ+%>?]^P:(C5K'20RJ-ZG<";@:BXE(>PL8^.MJN*E;NFAYV^
MHH6EP)^$K\&9@:_!EX*ROI6#L[R5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[R5
M@[.\E8.SO)6#L[R5@[.\_YHS%/^90R;_G$<U_Z)&0/^G1TO_JTE6_:],8/:R
M46KNM%=SY;=>?-VV:H//KW*0Q:9XG;N>?J>RF(6PJY.+MJ6.D[N?BYJ^FXFB
MP9B(K,*3A:_"DH:QOY&&L[R1AK.\D8:SO)&&L[R1AK.\D8:SO)&&L[R1AK.\
MD8:SO)&&L[R1AK.\_YHS%/^90B;_G$8T_Z-%0/^H14K_K4=5_K%*7_6U4&CK
MN59PX[U>=]F[:H#+LG"0P*EVG;:B?*>MG(*OI9>)MIZ3D+N9CYB^E(V@P9&,
MJ<*-BJ["C8FQOXV)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FR
MO8V)LKV-B;*]_YLS%/^:0B;_G44T_Z1$/_^J1$G_KT53_+1)7?*Y3V7IOE9L
MX<-@<M.^:8#&M6Z/NZUTG+"F>J>GH("OGYN&M9B7CKN3E96^CI*=P8J2I\*(
MD*["B(ZPP(B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-
MLKV(C;*]_YLS%/^:0B;_GD0S_Z5"/O^K0DC_L412^K=(6O"]3F'FQ%9GWLEB
M;<[!9W_!N6V.MK%RFZNJ>*:BI7ZNF:"$M9*=B[J,FI.^AYB;P(27I,*"EJ_"
M@Y.PP(21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$
MD;*^_YLS%/^:02;_GT(S_Z9 /?^M0$?_M$)/][M'5^W#35WDS%A@V<U@;,G%
M9GZ\O6N-L+5QFJ6O=J6<JGRMDZ:"M(RBB;F&H)"]@9Z9OWV>HL%[GJ_!?9FP
MP'^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^
M_YPS%/^:02;_H$$R_Z@_//^P/D7_MT%-],!%4^K)3E;BU5I7TM%>:\3)9'VV
MP6J,JKMOF9^U=*26L'JLC:R LH:IA[=_IXZ[>J:6OG>EH+]TIJV_=Z&QOWJ=
MLKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^_YTS
M%/^;02;_HC\Q_ZH\.O^S/$+[NSY)\,9$3>;23TW<W%=6S-5=:K[-8WNPQVB+
MI,%MEYF\<Z*/N'BJAK1^L'^RA;5YL(RX=*^5NW&NG[QNKZN]<:JSO'2EL[QT
MI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\_YTS%/^;
M0";_I#PP_ZTY./^V.3_UP3Q#Z<Y$1-[=34?2X%-8Q=M<:+?387JIS6:)G,AK
ME9'$<9^(P':G?[U]K7B[A+%SNHNT;[B4MVRWG;AJMZBY:;:VN&VOM;EMK[6Y
M;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y_YXR%/^=/B7_
MISDN_[$V-?N\-CKMR3H\X-I$.M+B1TS'XDU>N=Y4;JS96WR?U&*(E-!HDXK,
M;YN"QW>B?,-^J'; A*QROHJO;[R1L6V\F+)KNZ&S:KNMLF>ZMK1GNK:T9[JV
MM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T_Y\R%/^@.B3_JC0L
M_[4R,?/#,C/CU#@PT^$\/\;H0E*YY4ACK.)-<I_?5'^3V5V*B=)GDX/-<)I]
MR7>?>,9]I'3$@Z=PPHBI;L&.JVS E*QJOYNM:;^EK6B_KJUHOZZM:+^NK6B_
MKJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM_Z P%/^C-B+_KS H^[PM
M*^C-+"C5X# PQ^DX1+GL/E>LZ45GGN=+=9+@4X")V5Z)@M1HD7S0<99XS'>;
M=,I]GG#(@J%NQX>C:\6+I6G$D*9HQ):G9L.>J&7#I:AEPZ6H9<.EJ&7#I:AE
MPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H_Z$O%/^H+Q__M2HB\,8D(=C=
M(R#(Z2TUNO(U2:SQ/%J>\$-IDNA,=8CA57^!VV&'>]=JC7;3<9%RT7>5;\]\
MEVS-@)IJS(6;:,N)G6;*C9YER9*?8\F8H&+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA
M8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA_Z,M%/^N*1KXOR :WM88$\GH(B6Z
M]"LZK/@T39[W/%R2\49IB.E0<W_C67MZWV2"=-QKAG#9<8IMUG:-:M5[CVC3
M?Y%FTH.29-&'E&/1BI5AT(^68,^4EU[/F9A>SYF87L^9F%[/F9A>SYF87L^9
MF%[/F9A>SYF87L^9F%[/F9A>SYF8_Z<H$O^W'Q+FSA$-R^85%KOT(2JL_BL^
MGO\T3I+Z/UR(\DIF?^Q5;WGH7G5RY&1[;N%K?FK?<(%HWG6$9=QYA6/;?8=B
MVH&(8-J$B5_9AXI=V(N+7->0C%O6E(U;UI2-6]:4C5O6E(U;UI2-6]:4C5O6
ME(U;UI2-6]:4C5O6E(U;UI2-_[ >"^W&#@C-VPL(N_,5&JS_(2Z>_RP_DO\W
M38?]1%A_]D]A>/%9:''M7VUJZV1Q9^AJ=&3G;W=BY71Y8.1X>E_C>WM=XWY\
M7.*!?5OAA'Y:X8A_6>",@%C@CX%8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8
MX(^!6."/@5C@CX%8X(^!\[T-!,S/"0&]Y0P,K/\7'I[_)"^2_R\]A_\]27__
M25)X_%1:</A:7VGT7V1D\F5G8?!J:5[O;FM<[G)M6^UV;EKL>6]8['QP5^M^
M<%;K@7%5ZH1R5.J(<U/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT
M4^F+=%/IBW13Z8MTS,8( +W4" .M]0X/G_\:'Y/_)RV(_S0Y?O]"0W?_34IN
M_U-09_]956+\7EA>^V1;6_EH75GX;%Y7]W!@5O=S857V=F)4]7AB4_5[8U+T
M?611](!D4/.#94_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&
M9D_SAF9/\X9FO<L& *[;!@2?_Q 0D_\='8C_*BA^_S@R=O]$.FW_2T%E_U%&
M7_]725O_74Q8_V).5?]F4%/_:E%2_VU24/]P4T__<E1._W543?]W54W_>55,
M_GM62_Y^5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]
M@5=*_8%7_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\
M?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FB
MT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\?^2%
MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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M#O^4/1[_G4 I_Z0^,O^K/SO_L4)"^+A'2>V^3D_EQE=3VL9>7\N^9'&^MFJ
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M=LR:FG?-F9EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8_WXB!O^
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MD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[*>C8#!GHR R9Z+@,J=BH#+FXJ
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M6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E8QK@$ +;$! "JTP4
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M?<ICX'[#9.!_O6;?@+=GWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TK@[&=*W^QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG_YP- -NQ!@#*O0<
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ML4<CRZM2,L&E6D"XGV),L)EI5ZB4<&"ACW=GFXM^;I:(AG.1A8YXC(*6?(B
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M=%2PYW56K.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U_X,2 ?^6$0#_J!$
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M<F62ZG%GC^IP9X[J<&>.ZG!GCNIP9X[J<&>.ZG!GCNIP_W,5 O^%$P'_E!0
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MQP< M= 0 *S0(P.CSS,,F<T_&(_*2"2&R%$N?<98.';$7S]OPF9&:<%L2V3
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M3$;:[4Q$V/E/0]C[3T/8^T]#V/M/0]C[3T/8^T]#V/M/VYH  ,JI @"[LP(
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M)0/_920$_VXJ!O]V- O_>CT1_WI&&/]X3R#[=%@H]F]A+_%K;#;M9W8\Z6.
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M6D^K[EM/JOI;4:;Z6U&F^EM1IOI;4:;Z6U&F^EM1IOI;_X ) .&2 0#1H 0
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M.#WB^S@]XOLX/>+[.#WB^S@]XOLXQJ$  +>K  "JM   GKX  )/) @"(U 8
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M2(@L_T:2+O]%FS#_1*(R_T.I,_]"L#3_0K<U_T&_-O]!R3;_0-<W_T#E-_U
M\#?Z0/@W]T'_-O9!_S?R0?\X[$/_.>I$_SGJ1/\YZD3_.>I$_SGJ1/\Y_T4K
M _])+ /_4"P$_U4O!?]9-PC_7$(._UM-%?]85QO_5F,@_U)O)?]/>BK_3(4M
M_TJ/,/](F#+_1Y\T_T:F-?]%K3;_1;0W_T2\./Y$QCC\1-(Y^4/B.?9$[CGS
M1/<Y\43_.>]$_SKK1?\[Y$;_/.-&_SSC1O\\XT;_/.-&_SSC1O\\_T8K _]-
M*0/_5"D$_UDL!?]>-0?_84 -_V%*%/]>5!K_6E\@_U=K)O]4=BK_48$N_TZ+
M,?Y,E#3\2YPU^TJC-_I)JCCX2+$Y]TBY.O9'PCOU1\T[\D??.^Y'[#OK2/8[
MZ4?_/>='_S[A2/\_VDK_0-A*_T#82O] V$K_0-A*_T#82O] _T<J _]0)P/_
M6"8#_UXJ!/]C,P?_9CT-_V9'$_]D41K_8%L@_UQG)OU9<BOZ5GTO^%.',_91
MD#7T4)@W\DZ?.?%-ICOO3*T\[DRU/>Q+OCWK2\H^Z4O</N5,ZCWB2_4_WTO^
M0=Q*_T+43/]#S4W_0\M._T/+3O]#RT[_0\M._T/+3O]#_THH _]4) /_7",#
M_V,H!/]H, ;_;#L+_VQ$$O]J3AG^9E@?^6%B)?5>;2OR6W@P[UB"-.Q6BS?J
M5)0YZ%.;.^91HSWE4:H^XU"R/^%/NT#@3\= WD_80=E/Z$'43_1#T$[^1<Y.
M_T;(4/]&PE'_1\!1_T? 4?]'P%'_1\!1_T? 4?]'_TTE O]7(0+_8" #_V@F
M _]N+@7_<C@*_W)!$/UP2Q?W;50=\FA>).UD:2KI870PY5Y^-.);ASC@68\[
MW5>7/MM5GT#85*9"U5.N0])2MT304L)%SE+01LM2Y4;(4O)(Q5+]2<)2_TJ\
M5/]*MU7_2K95_TJV5?]*ME7_2K95_TJV5?]*_U C O];'@+_9!X"_VTD _]S
M*P3_=S4(_G@^#O9W1Q3P=% ;ZF]:(N1K92G@9V\OVV-Y-=9@@CK278H^SUN2
M0<Q9FD/*6*%%R%>I1\96LDG$5KQ*PE7)2[]5WTN\5NY,N5;Z3;=6_TVR6/]-
MKEG_3:Q9_TVL6?]-K%G_3:Q9_TVL6?]-_U,@ O]>' +_:!P"_W$B O]X* /_
M?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5 Q&"-0\%>
ME4:_79Q(O%ND2[I:K4RX6;=.MEG#3[19U4^Q6NI0KEKW4*Q:_U"H6_]0I%S_
M4*1=_T^D7?]/I%W_3Z1=_T^D7?]/_U8> O]A&0+_;!H"_W4@ O]\)0/]@2X%
M\X0W">J$/P[B@4@5VWU3'=%W72?+<F<PQFYP-\)J>#R^9X!!NF6(1;=CD$BT
M89A+LE^?3:]>J$^M7;)1JUV^4JE=SE.F7>53I%[T4Z)>_U.?7_]2G&#_4IM@
M_U*;8/]2FV#_4IM@_U*;8/]2_U@< O]D%P'_<!D!_WD= ?^ (P+XABH#[8DR
M!N2*.PK<B$42T8)0',I]6B;$>&,OOG-L-[EO=#VU;'Q"LFJ$1JYGC$JK99--
MJ&2;3Z5BI%*C8:Y4H6&Y59]AR%:=8>%6FV+Q59EB_5678_]4E63_5)1D_U.4
M9/]3E&3_4Y1D_U.49/]3_UH: O]G%0'_<Q<!_WT; ?^$( 'SBB8"Z(XN!-^0
M-@?4C$$1RX=-&\2"5R:]?6 OMWAI-K)T<3VN<7A"JFZ 1Z9LB$JC:H].H&B8
M49UGH%.:9JI5F&6U5Y5EQ%B49=M8DF;O5Y%F_%>/9_Y6CF?^58UH_E6-:/Y5
MC6C^58UH_E6-:/Y5_UP8 ?]I$P'_=A8!_X 9 ?V('0'OCB(!Y),I MJ4,0;.
MD#\/QHM+&KZ&526W@5XNL7UF-JQY;CRG=G5"HW-]1Y]PA$N<;HQ.F&R44I5K
MG522:J=7D&FR68UIP%J,:=5:BFKL68IJ^EB):_U7AVO]5H=K_E:':_Y6AVO^
M5H=K_E:':_Y6_UX7 ?]L$@'_>!0!_X,7 /F+&@#KDAT!X)@C =.8+P7*E#T.
MP8])&;F*4R2RAELMK(%D-:9^:SRA>G)"G7=Z1YEU@4N5<XE/D7&14HYOFE6+
M;J18B&VO6H9MO5N$;=!;@V[I6H-N^%F";_Q8@F_]5X)O_5>";_U7@F_]5X)O
M_5>";_U7_V 5 ?]N$0'_>Q, _X84 /:/%@#GEA@ VYP< ,^;+03%ESL-O)-'
M&+2.42.MBEDLIX9A-*&":3N<?W!!EWQW1I-Y?DN/=X9/BW6.4HASEU6$<J%8
M@G&L6G]QNEQ^<<Q<?7+G6WUR]EI\<OQ9?'+\5WQR_5=\<OU7?'+]5WQR_5=\
M<OU7_V(4 ?]Q$0'_?1$ _X@2 /*2$@#CFA( U9\9 ,J>*P3!FSD,N)=%%["2
M3R*ICE@KHHI?,YR&9SJ7@VY DH!U18U^?$J)?(1.A7J,4H)XE59^=Y]8>W:J
M6WEUN%QW=<I<=W;E7'=W]5IW=OM9=W;\6'=V_%=W=OQ7=W;\5W=V_%=W=OQ7
M_V02 ?]S$ #_@!  _XL0 .^5#@#?G@T T*(7 ,:A*0.]GC<+M)I#%JR632"D
MDE8JG8Y>,I>+93F2B&Q C85S18B#>DJ$@(%.@'^*4GQ]DU5X?)U8=7NH6W-Z
MMEQQ>L=<<7KB7'%[\UIQ>_M9<GK\6')Z_%AR>OQ8<GK\6')Z_%AR>OQ8_V<1
M ?]U#P#_@PX ](X- -N9"@#4H0L S*05 ,*D)P.XHC8*L)Y"%:>:3!^@EU0I
MF9-<,9.08SB-C6H_B(IQ1(.(>$E^AG]->H2(47:"D55S@9M8;X"F6FU_M%QK
M?\5<:X#?7&N \EIK@/M9;'[\6&U^_%AM?OQ8;7[\6&U^_%AM?OQ8_VD0 ?]X
M#@#_A0P XI(( -6;"0#.HPD QZ@2 +VH)0*TIC0)JZ) $Z.?2AZ;FU(GE)A:
M,(Z583>(DF@]@I!O0WZ.=DAYC'U,=8J%4'&(CE1MAYE7:H:D66>%L5MEA<);
M987<6V6%\%IFA?M99X/\6&>#_%=G@_Q79X/\5V>#_%=G@_Q7_VP. /][# #R
MB0D V94& ,^>" #)I@@ P:L0 +BK(@*OJC((IJ<^$IZD2!R6H5$ECYY8+HB;
M7S6"F68\?99M07B4=$9SDGM+;Y"#3VN/C%)GCI959(VB6&&,KUE?C,!:7XS9
M65^,[EE?C/M888K]5V&)_5=AB?U788G]5V&)_5=AB?U7_V\, /]_"0#?C0,
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M2DBP_TI(L/]*2+#_2DBP_TI(L/]*XH8  ,Z4  #"H0  MJD  *NQ  "AN@$
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M4&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO=_],_V0- /]R"@#P?@8
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M2EB._TE8CO])6([_25B._TE8CO])_W$! ."   #/C   Q)8" +N> @"RI
MJ:H% **L%0";K"8"E*LT!XRJ/P^%J$@7?J90'GBD6"5SHEXK;J%E,&J?;#1E
MGG,Y89U[/%Z;A$!:FHY#5YF:1529IT=2F;9(49G*2%&8YDA1E_5(49?_1U&6
M_T=1EO]'49;_1U&6_T=1EO]']G<  -B%  #)D0  OYL! +2B  "KJ   H;
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M-T"W_S= M_\WSHL  +^8  "RH0  IZD  )RP  "1N   AL " 'O(!P!TRQ(
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MCPXK]9T/*O:K$"GVO! H]LX1)_?F$2?U\1$G]?$1)_7Q$2?U\1$G]?$1HZ@
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M1'QG[T-\9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\:/\__UL, /]G"0#W<0<
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M:W/_0FQS_T%L<_] ;'/_0&QS_T!L<_] _V$% /IN 0#=>0  T((" ,>)! #
MC@0 N9$, +&2&P"IDBL#HI X")N-0P^4BDP7CHA4'8F%6R.$@V(H@(%I+7Q_
M<#%X?G<U=7Q_.'%[B#QN>I(_:WF=06AXJD-F>+A$97C,165XYT1E>/=#9GC_
M0F9X_T%F>/] 9GC_0&9X_T!F>/] _V0# .YQ  #8?   RX4" ,., P"[D0,
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M/$^1_SQ/D?\\Y'0  ,^!  #"C   N)8  *V<  "CH0  F*@  )"J#0"+JQL
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MG!\\PZL@.\.\(3K#U2$[PNXA.<#Y(CB__R0XO_\D.+__)#B__R0XO_\DO9$
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M""3QN @C\<P((O+E""+P\P@B[_4((N_U""+O]0@B[_4(GJ8  )&O  "$N
M=\$  &K)  !=T   4=<  $;=   _Z@4 //8. #GV%P V]R  ,_<H #'X,  N
M^38!*_D] 2GZ1 $G^DH")?M2 B/[6@(@_&,#'OQN QS]>P,;_HD$&?Z8!!C_
MJ 07_[<$%O_(!!;_X 06_^0$%O_D!!;_Y 06_^0$DZX  (6W  !XP   :LD
M %W2  !0V0  1-\  #KD   U]P, ,O\, "[_$@ K_QH */\A ";_)P C_RT
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M-(Y7\#2-5_TSC%C_,XQ8_S*,6/\QC%C_,8Q8_S&,6/\Q_U$, /];"0#_8P@
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M-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=;@  SW8! ,=[ P# ?P0
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M-5YX_S5>>/\U]60  -QP  #*>@  P(,  +:)  "NC0  I(\  )V1$ "7DB
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MFRQ(FJDM1YFZ+4::T"U&F.LM1I?Y+D:6_RY&EO\N1I;_+D:6_RY&EO\NT7<
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M&#:]RA@WO.<7-;OV&36Z_QHTN?\;-+G_&S2Y_QLTN?\;N(\  *J8  "?GP
MDZ8  (>L  ![LP  ;[D  &.^  !8Q 0 4,@, $W(%P!,R24 2LHQ $?*.P%%
MRD0"0\I, T'*5 0^REP&/,ID!SK+;@DXRW@*-LN%##3+D@TRRZ(.,<NR#S#,
MQP\PR^4.+\GU#R[(_1$NQ_\2+L?_$B['_Q(NQ_\2KI<  *&>  "5I0  B:T
M 'RT  !PNP  9,$  %G&  !.RP, 1= ( #[5#@ ]U1H /-8F #O7,0 YV#L
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M A#[W0(0^^D"$/OI A#[Z0(0^^D"CZL  (&T  !SO0  9L8  %G-  !+TP
M0-D  #7>   LXP  )O$  "3^"@ A_Q  '_\6 !S_'  9_R( %_\H !7_+@ 3
M_S4 $O\\ !#_0P ._TP #?]6  O_8@ )_V\ "/]_ 0?_D $%_Z !!/^N 03_
MO $#_\<! __' 0/_QP$#_\<!@[0  '6]  !GQ@  6L\  $O5   _W   ,^$
M "GE   A[   'OT  !K_!0 7_PP %?\0 !+_%  0_QD #O\>  W_(P +_R@
M"/\N  ;_-0 #_ST  /]&  #_40  _UT  /]K  #_>P  _XL  /^9  #_I0
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M(*=&\R&E1O\AHT;_(J)&_R&B1O\AHD;_(:)&_R&B1O\A_T4. /]+"@#_4PP
M_U<- /E:$ #K6Q0 WUH< -1:*P#,6CL"QEA(!<%64PF\5%P-N5)E$;50;12S
M3W47L$Y\&:Y-A!JL3(L<JDN2'JA*FA^F2J,AI$FL(J-)N".A2<8DGTK>))U*
M\"2;2OTEF4O_))E+_R282_\DF$O_))A+_R282_\D_T@, /]/" #_5@@ ]5L)
M .E>"@#D7@T U5\5 ,M@)P#$7S8"OEY#!;A;3@FT65@.L%=A$JQ5:16J5' 8
MIU-X&J52?QRB488>H%".()Y/EB*<3I\CFDZH)9A.LR:73L(GE4[6)Y-.[">1
M3_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0 XE\# -IB
M!@#48PD S6,2 ,1E(P"\93("MF- !;%A2PFL7E0.J%Q=$J5;91:A66P8GUAS
M&YQ6>AZ:58(@F%2*(I54DB234YLFD5*E)X]2L"F-4KXJC%+0*HI3Z2J)4_DI
MB%3_*8=4_RB'5/\HAU3_*(=4_RB'5/\H_TP% /]6 0#I70  W&," -%G!0#,
M: < QF@0 +UJ( "V:2\!L&@\!*IE1PFE8U$-H6%:$IU?81::7FD9EUQP')5;
M=QZ26GXAD%F&(XU8CB6+5Y<GB5>A*896K2N%5KHL@U;,+()7YBR!5_<K@%C_
M*H!8_RJ 6/\I@%C_*8!8_RF 6/\I_T\" /U9  #B8   U6<  ,QJ P#&; 4
MP&P. +=M'0"P;BP!JFPY!*5J1 B@:$X-FV97$9=D7A648F49D6!L'(Y?<QZ+
M7GLAB5V")(9<BR:$6Y0H@5N>*G]:JBQ]6K<M?%K)+GI:XRYZ6_4M>ES_+'E<
M_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @# < 0 NG ,
M +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC<!Z%8G@A
M@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__+'1@_RMT
M8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P( M7,) *UU
M%P"G=2<!H70T YMR/P>5<$D+D6Y2$(QL612):F 8A6EG&X)H;AY_9G4A?65]
M)'IDA29W9(\I=6.:*W)BI2UP8K,O;V+$+VYBWB]N8_(N;F/^+6YC_RQN8_\K
M;F/_*VYC_RMN8_\K_U4  .5@  #3:0  R'   +]T  "W=P$ L'<' *AX%0"B
M>20 G'@R I9V/0:1=$<+C')/#XAP5Q.$;UX7@&UD&GUL:QUZ:W,@=VIZ(W1I
M@R9R:(TI;V>7+&UGHRYK9K$O:6;!,&EFVS!I9_ O:6?]+6EG_RQJ9_\K:F?_
M*VIG_RMJ9_\K_E@  .%C  #/;   Q',  +MX  "S>@  JWH$ *1[$@">?"(
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MG"M6>ZDL5'NY+5-[SBU4>NHM5'KY+%1Y_RM5>?\J57G_*E5Y_RI5>?\JX64
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M(T.4R"-#E.4C0Y+U)$.1_R1#D/\D0Y#_)$.0_R1#D/\DRG4  +N!  "PBP
MI)$  )J5  "/F0  @YT  '2B  !NHPL :J07 &:E)0!CI3$!7Z0[ UND1 58
MI$L(5:-3"U*C6@U/HF$03:)H$TJA<15'H'L81*"&&D*?DQQ GZ(=/I^R'CV?
MQAX]G^,=/9WT'CV<_Q\\F_\?/)O_(#R;_R \F_\@PGP  +6(  "ID   GI8
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M""G"^PDHP?\**,'_"RC!_PLHP?\+J)4  )V;  "1H@  A*D  'BO  !KM0
M7[L  %2_  !)PP  /\@$ #;-"0 SSA$ ,L\< #'/)P PT#$ +] Z "[10P M
MT4P *])5 "K27P$HTVD!)]-V 273A (DU)0"(M2F B'5N0(AU=("(-/K B#2
M]@,?T?\$']'_!!_1_P0?T?\$GYL  )2B  "'J0  >;$  &VX  !@O@  5,,
M $G'   ^RP  -= ! "W5!@ EVPL )-X2 "/>'  BWR4 (> N "#@-P ?X4
M'N%* !WB4P <XUX &^-J !KD>  8Y(@!%^6: 1;FK $5YL !%.?= 1/E[P$3
MX_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@  2,H  #W/
M   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4[S4 $_ ]
M !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GVV0 (]>T
M"/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](  #'8   G
MW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D "OXP  C_
M.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP  _\X  /_/
M  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A   <Y0
M%.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C  #_*@
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M"L8Q]PS#,?\.P3'_#\ Q_P^_,?\/OS'_$+\Q_Q"_,?\0_S83 /\Y#P#_/A
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M&Y1&_QN31O\;DT?_&Y-'_QN31_\;_T(% /]* 0#R4   X50! -E6!0#350D
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M(758_R%U6/\A_TT  .57  #37P  R&0  +]G  "W:   L6<' *EH% "C:20
MGF@R 9EG/02494<'D&1/"HQB5PV(85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY
M6XP?=EN7(71:HB-R6J\D<5J_)7!:U25O6^TE;UO\(V];_R)O6_\B;UO_(6];
M_R%O6_\A^D\  .%:  #/8@  Q&<  +MK  "S;   K&H$ *1K$@">;"$ F6PO
M 91K.@./:40&BFA-"89F50V#95P0@&1B$WUB:15Z8G 8>&%X&G5@@!US7XH?
M<%^4(6Y>H"-L7JTE:UZ\)FI>T29I7NPE:E_[)&I?_R-J7_\B:E__(FI?_R)J
M7_\B\%(  -U=  #+90  P&L  +=N  "O;P  IVX! *!O$ ":<!\ E' L 8]O
M. .*;4(&AFQ+"8)J4@Q^:5D/>VA@$G=F9A1U9FX7<F5U&G!D?AUM8X@?:V.2
M(FEBGB1G8JLE96*Z)F1BSR9D8NHF96+Z)&5C_R-E8_\B96/_(F5C_R)E8_\B
MZU4  -A@  #(:   O&X  +-Q  "K<P  HG$  )MR#@"5<QP D'0J 8IS-@*%
M<D %@7!("'UO4 MY;5<.=FQ>$7-K9!1P:FP7;6ES&FMI?!QH:(8?9F>0(61G
MG"-B9JDE8&:Y)E]FS29?9N@F8&;Y)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@
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M(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T_R%1=/\AV&,  ,5M  "X=@
MKGT  *6"  ":@P  C8,  (2$ P!]A1  >88> '6'*P%QAS8";88_!&F%1P=E
MA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]
MQ")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T>P  JH(
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M%CF7_!8XEO\7.)7_%SB5_Q<XE?\7NWH  *^%  "DC   F)$  (V5  "!F@
M=9T  &B@  !;I   5J4, %.F%P!1IR, 3Z<O $RG. %*IT$!2*=) D:G4 1#
MIU@%0:=?!C^F: @]IG(*.J9]"SBFB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B
M^Q RH?\1,J'_$3*A_Q$RH?\1M((  *B,  "=D@  DI<  (:<  !YH0  ;:4
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M AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<N0  4+T  $3!   YQ
M,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H] !+;2  1
MW%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO< #-W[  S=
M^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   NS0  )=$
M ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4
M!>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO  #L[P
M[.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@  &]L  !/?
M   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@  ]3<  /9"
M  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #XT   ^-
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M ?\.BP'_#I(!_PZ8 ?\.G0'_#J,!_@ZH ?P.K@'[#K4 ^@Z^ /@.R0#U#ML
M\@[J .X.]0#L#O\!ZP__ >H/_P'J$/\!Z1#_ >D0_P'I$/\!_R(? /\B' #_
M(1P _Q\@ /\?*0#_'#0 _QI  /\73 '_%5@!_Q1C ?\3;@'_$W<!_A.  ?P3
MB 'Z$HX!^1*5 ?@2F@'V$J !]1*F ?02K 'S$K,!\1*\ ? 2QP'M$M@!Z1/H
M >83]0'D%/\!XA3_ N$5_P+A%?\"X!7_ N 5_P+@%?\"_R4; /\F%P#_)!8
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M"ZXP_PNN,/\+K3#_"ZTP_PNM,/\+_S,, /\V!@#_/ D _SX, /T]$ #O/!4
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M%85'_Q6%1_\5_S\  .Q(  #=3P  SU,  ,95  # 4P, NU$, +-2&0"M4RD
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MG!IN5JD;;%:X'&M6RQUJ5N8<:E?W&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP
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M85ZT'6!>QQU@7N,=8%[U'&!>_QM@7O\:85[_&F%>_QIA7O\:Y%(  ,]<  #
M9   MFD  *QL  "C;   F6D  ))J"P",:A8 AVLD ()K, %^:CH">FE#!'9H
M2P9S9U((<&=9"FUF8 UK968/:&1N$69D=A1D8X 68F.+&&!BEQI>8J0<7&*R
M'5MBQ1U;8N$=6V+T'%MB_QM<8O\:7&+_&EQB_QI<8O\:X%4  ,M?  "]9P
MLFP  *EP  "?;P  E&P  (QM" "&;A, @F\A 'UO+0%Y;S@"=6Y! W)M205N
M;% ':VM7"FEK7@QF:F4.9&EL$6%I=!-?:'X676>)&%MGE1I99J(;5V:P'%9F
MPQU69M\=5F;S'%=F_QM79O\:5V;_&E=F_QI79O\:VUD  ,=B  "Z:@  KW
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M&$=V_!A'=O\81W7_%T=U_Q='=?\7R64  +IO  "N=P  I'T  )A_  "+?P
M?G\  '.!  !L@PD :(03 &6%( !BABP 7X8V 5R&/P)9A48#5X5.!52%50=2
MA%P)3X-C"TV#:PU+@G0/2()_$4:!C!-$@9H50H"I%D& NA9 @-(607_M%D%^
M^Q9!??\607W_%D%]_Q9!??\6PFH  +5U  "J?0  GX(  )*#  "%A   >84
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M"BV;_PHMF_\*KX   *.)  "7C@  C9,  '^5  !RF   9IP  %N@  !/I
M1:<  #ZI#  \JA0 .JH? #FJ*0 XJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $O
MK&8"+:QQ BNL?P,JK(X#**R>!">LL 0FK,4$)JOD R6I]00EJ/\%):?_!26G
M_P4EI_\%IXD  )N/  "1E   A)D  'B>  !KH@  7Z8  %.J  !(K0  /;
M #2S P OM0X +;46 "RU(  KMBD *K8R "FW.@ HMT, )[=, ":X50 DN%\
M([AK "*X> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;
MM/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@  -;D  "R\
M   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A
M !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\
MEY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$  "/%   ;
MR0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD "=-5  G3
M8@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !U?8 CIT
M ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.   2T@
M#=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'  #B5
MXV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN< @Z0  '6L
M  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +W0  !>$
M  #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O10  \%,
M /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT  &JU  !<
MO0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@   .H   #N
M    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0  _4,  /Y2
M  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5(0#_$2$
M_PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"# /\ B@#_
M )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$ \@#D /$
M\0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_%1T _Q ?
M /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#AP#_ XT
M_0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C .H![P#H
M OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3
M)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0
M /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*\ #?"_L
MW@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_
M&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8 ZA", .D0
MD@#H$)@ Y@^> .4/I0#C#ZP X0^T . /O@#>#\P VA#A -41\ #2$OL SQ+_
M <X3_P'-$_\!S1/_ <P3_P',$_\!_R(2 /\B#P#_(0\ _R(4 /\B' #_("<
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M")PQ_PB<,?\(_S   /\U  #O.   XCH  -LY! #6-0D SC03 ,8V(@"_.#$
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MGP]^1*L0?$6Y$7M%RQ%Z1>81>4;W$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\
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M%&91PQ5E4MX595+R%&52_Q-E4O\295+_$F52_Q)E4O\2Y$H  ,]3  # 6@
MM5X  *Q@  "B7@  FED  )):"P"-6Q8 B%PC (1<+P" 6SH!?5M# GE:2P-V
M65($=%A8!G%87P=O5V8);5=M"VM6=0UI5GX/9U:)$655E1)C5:$48E6O%6%5
MP19@5=L68%;Q%6!6_A1@5O\385;_$F%6_Q)A5O\2X$T  ,M6  "]70  LF$
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M%5)A^Q128?\34V'_$E-A_Q)38?\2T58  ,!?  "S9@  J6L  )QK  "0:@
MA6<  'UI  !W:@T <VL7 &]K) !L;"\ :6PX 69K00)C:TD#86M0!%YJ5P9<
M:ET'6FEE"5AI;0M5:'8-4VB!#U%GC1%/9YH23F>I%$UGN11,9\\43&;K%$UF
M^Q--9O\23F7_$DYE_Q).9?\2S%H  +QC  "P:@  I6\  )AN  ",;0  @&P
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M#CUW_PX]=_\.O&@  *]R  "D>0  EGH  (AZ  !\>@  <'P  &-_  !<@@
M5X0+ %.%% !1AB  3X8J $Z'- !,ASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1
MAFP&/H5V!SN%@P@YA9$*.(2@"S:$L0LVA,8+-H/D"S:"]@LV@?\,-H#_##:
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M=@$CI84!(J66 2"FJ $?I;L!'J77 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8
M )>,  "+CP  ?9$  &^4  !CF   5YT  $VA  !#I0  .*@  #"K   HK@<
M)*\0 ".O%P AKR$ (+ I !^P,0 >L#H ';%" !RQ3  ;L58 &K%A !FR;P 8
MLGX %K*0 !6RH@ 4LK8 $[+. !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2
M  "$EP  =9H  &B?  !;HP  4*@  $6L   [L   ,;(  ">U   @N   &+H'
M !2\#@ 3O!4 $KP> !&])@ 1O2X $+TW !"^00 .ODP #KY7  V^90 ,OW0
M"[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0  (>9  !Z
MGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0  $<0!  S(
M"  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60  RV@  ,MY
M  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA  !OIP
M8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX   32 @
MTPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H  -UJ  #=
M?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !DL   5K<
M $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>    WP,
M . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:  #M;
M[H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0  2\   #W%
M   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H    Z0   .H
M  #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\6P  _6T
M /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@ /\ * #_
M #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2 /D
MEP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M /< [ #_
M .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#)0#_ #$
M_P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/ /( E #Q
M )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4 XP#^ .(
M_P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y
M /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H )8
MYP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#] -4"_P#4
M O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*
M00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?!I( W0:8
M -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\
MQPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M
M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-
MG #-#J, RPZK ,D.M #(#L  Q@[/ ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_
M ;H2_P&Z$O\!_Q\* /\<! #_'P@ _Q\- /\=$@#X&AL [A8F .84,P#@$S\
MVA-+ -035@#0$U\ SA1H ,L4;P#)%'< QQ5] ,85A #$%8H PQ61 ,$6F #
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MI 26+Z\$E2^]!),OSP21,.@%CS#X!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT
M .HU  #<.@  SCT  ,8\  # -P( NS,- +,T&0"N-B< J3<T *4W0 "B-TH
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M"G5 PPMT0-T+<T'Q"W)!_PIR0?\*<D'_"7)!_PER0?\)Z3P  -5%  #%2P
MNDX  +!.  "G2P  HD8  )M&#@"61QH D4@G (Y(,P"*2#T AT=& 81'3@&"
M1E4"@$9< WY%8@1\16D$>D5P!7A$> 9V1($(=$2+"7)$E@IP1*(+;T2O#&Y$
MP QM1=D-;$7O#&M%_0MK1O\+:T;_"FM&_PIK1O\*Y4   ,])  #!3P  M5(
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M#EM1^@U;4?\,6U'_#%M1_PM;4?\+UDH  ,-3  "V60  JUP  )Y:  "360
MBU0  (16 P!^5A  >E<: '97)@!S6#$ <%<Z &U70@%J5TD":%90 F965P-D
M5EX$8E5E!6!5;0=>578(756!"EM5C0M95)H-6%2G#E95N ]65<P/5E7I#E95
M^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7   IUX  )I=  "/7   AE@
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M"TE@_PM)8/\+Q%@  +5@  "J9@  FV8  (UF  ""90  =F0  &YE  !H9@4
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M? 0T?XH$,G^:!3%^J@8P?KT&,'[:!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P
M *1U  "4=0  AG4  'EV  !N=P  8WD  %=]  !/@0  1X0  $*&#  _AQ,
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M !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&  ""A@
M=(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+ !JI$0 8
MJ1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0 #JN&  ZK
MF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !ZC0  ;)$
M &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U"@ -MA
M#+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[  "WC@
MMZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP  99P  %BA
M  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #P0T  ,$1
M  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%@0  Q94
M ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D  %"N  !$
MLP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <  ,P-  #-
M$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P  UH<  -:;
M  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X   XO
M*[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%  #;"P
MW X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<  .F,  #J
MGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    LQ   (,@
M !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G 0  Z0<
M .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ  #ZC@
M^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #( _P _ /\
M2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V )@ ]0"=
M /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@ _P#H /\
MZ #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_
M %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0 [ ": .L
MGP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#= /\ W0#_
M -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z $X
M] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6 .$ G #?
M *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\ S0#_ ,T
M_P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O $D Z@!3
M .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -( F #0 )X
MS@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_ , "_P#
M O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T( WP-. -L$
M5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C
M , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,_P"T#/\
M_Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,40#)
M#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.
MJ0"T#[0 L@_! +$0U "N$>L JQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH
M /\;  #Y&P  ZQD  .44!@#E$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\%%0
MN15= +<59 "U%6L M!5Q +(5> "Q%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G
M&+  IAB] *08SP"B&N< GQKW )T;_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A
M  #H)   W24  -0A 0#/&P@ RA<1 ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7
M *L>7P"I'V8 J!]L *8?<P"E'WD HQ^  *(?AP"@((\ GR"8 )T@H@";(*P!
MFB&Y 9@AR@&6(N0!E"/U 9(C_P&1(_\!D"/_ 9 C_P&0(_\!_R(  .LI  #=
M+@  SR\  ,<M  #!)P, O2(- +8C&@"P)2@ K"8T *@F0 "E)TD HB=2 * G
M6@">)V$ G"=G )LG;0"9)W0 F"=[ 98G@@&5)XL!DR>4 9$HG@&0**D!CBBU
M HTIQ@*+*=\"B2KR H<J_P*&*O\"ABK_ H8J_P*&*O\"]"@  .,Q  #1-@
MQ3@  +PV  "V,   LBL) *LL% "F+2( HBXO )XN.@";+D0 F"]- )8O50"4
M+EP DBYB ) N:0&/+F\!C2YV 8PN?@&*+H8"B"Z/ H<NF@*%+Z4#@R^R X(O
MP@.!,-H#?S#O WTQ_@-],?\#?#'_ WPQ_P-\,?\#[2\  -LW  #)/0  OCX
M +,\  "L.   IS,$ *(R$0"=-!T F34J )4U-0"2-4  CS5) (TU4 "+-5<
MB35> 8<U9 &%-&L!A#1R H(T>0* -(("?C2+ WTTE@-[-:$$>36N!'@UO@5W
M-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@  N$0  *Q"
M  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL ASM$ (0[3 "".U,!@#I:
M 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&
M;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"  "^1P  L4@  *5&  "=
M0P  ES\  )(^"P"-/Q4 B3\A (5 +0""0#< ?T!  'U 2 ![0$\!>4!6 7<_
M70%U/V,"<S]J G$_<@-P/WH#;C^$!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H
M!V9 ^09E0/\&94#_!F5 _P5E0/\%W#X  ,=&  "Y2P  K$P  *!*  "71P
MD4,  (M#" "&0Q( @D0> 'Y$*0![130 >44] '9%10!T1$P!<D13 7!$60%N
M1& ";$-G FM#;P-I0W<$9T.!!69#C09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%
M^ =?1?\'8$7_!F!$_P9@1/\&UD$  ,-)  "V3@  IT\  )M-  "22P  C$<
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M!U%/_P913_\&R4L  +E3  "K5P  G%8  (]5  "%5   ?%   '51  !P4@D
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M?01 8HL%/V*:!CYBJ@8]8KP'/&+6!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D
M *MA  ":80  BV$  ']A  !T80  :6$  %]B  !99   5&8) %%G$0!.9QH
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M BMXHP(J>+4"*GC, BIWZ@(J=OD#*G7_ RIT_P,J=/\#JFH  )IM  ");
M?&T  '!M  !F;@  6W$  %!U  !(>   07L  #I^!0 V?PX -( 6 #.!(  R
M@2@ ,($P "^".  N@D  +8)( "R"4  K@EH *H)D "B"<  F@G\!)8*/ 22"
MH $C@K(!(H+) 2*!YP$B?_<!(G[_ B)]_P(B??\"I7$  )-Q  "#<0  =G$
M &QR  !@=0  5G@  $Q\  !#@   .X,  #.&   MB0H *HH1 "F+&0 GBR(
M)HLJ "6,,0 DC#D (XQ" "*-2@ AC50 ((U> !^-:P =C7D '(V* !N-G  9
MC:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@  <G<  &5Y
M  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <EAH &Y<B
M !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8E@ 0F*D
M#IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX  %^!  !4
MA@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ( $*,9  ^C
M(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $HZ$  J.T
M  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,  !-D0
M0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2  *O&0 !
MKR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<  *^J  "O
MOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%G0  .Z(
M #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z$P  NQD
M +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?  "]LP
MOL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP  ,J\  "BT
M   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@  QQ(  ,@8
M  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/I@  S[@
M ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H  !V]   3
MP   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P  -80  #9
M%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF   Y:D  .6V
M  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(   ,RP
M \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(  #H#0
MZ1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD  /BE  #X
ML   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!>
M /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$ G@#P *0
M[@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D
M /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!: /<
M8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E *  Y "G
M .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@ _P#8 /\
M_PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5 .T 7@#J
M &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P U0"C -,
MJP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#( /\ _PP,
M /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$ 60#> &$
MVP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@ ,4 J ##
M +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\ _PX% /\)
M  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#. %L RP!C
M ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D I "W *X
MM0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q   /\.  #_
M#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8 O@5= +P%
M9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW
M *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L$P
MXA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7 + .7P"N
M#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D GQ"U )T1
MQ0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@'P  TA\
M ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *0660"B%F
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M 7<K^0%V*_\!=BO_ 74K_P%U*O\!Y2P  - T  #!.   LS@  *@U  "B,0
MG2T  )DJ#@"4*Q@ D"PD (TM, "*+3H ARU# (4M2@"#+5$ @2Y8 ( N7@!^
M+F0 ?2YK 'LN<P%Y+GL!>"Z% 78NCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ
M]P)M,?\";3'_ FTQ_P)M,?\"WS(  ,DY  "[/@  K#T  *$Z  ":-P  E3,
M ) Q"@",,10 AS(@ (0S*P"!,S4 ?S,^ 'TS1@![,TT >3-4 '<S6@!V,V$
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M UD__P-9/_\#S#\  +Q&  "K2   G$<  )%&  "(1   @D   'P_  !W0 P
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M?0))3HL#2$Z9!$=/J 1&3[H$1D_1!$9/[01&3OP$1D[_ T=._P-'3O\#O4P
M *Y2  "<40  C5$  (%1  !W4   ;DP  &=.  !B3P  75 - %I0% !741X
M55$G %-1, !14C@ 4%(_ $Y21@!-4DT 3%-5 $I370%)4V4!2%-O D93>P)%
M4XD#0U.7 T)3IP1!4[@$05//!$%3[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4
M  "85   B50  'U3  !S4P  :5$  &)2  !<4P  6%0* %15$@!251L 3U8D
M $Y6+0!,5S4 2U<\ $I71 !(5TL 1UA2 $986@%$6&,!0UAM 4%8>0) 6(8"
M/EB5 SU8I0,\6+<$/%C-!#Q7Z@,\5_H#/5;_ SU6_P,]5O\#ME,  *57  "4
M5P  A58  'E6  !O5@  954  %Q6  !76   4ED' $Y:$ !,6A@ 2ELA $A<
M*@!'7#( 15PZ $1=00!#74@ 0EU0 $!=6  _76$!/5UK 3Q==@(Z780".5V3
M CA=HP,W7;4#-EW+ S9<Z ,W7/D#-UO_ SA;_P,X6O\#LE<  *!:  "/60
M@5D  '59  !K60  8%H  %9;  !170  3%X" $A@#0!%8!0 1&$> $)B)@!
M8BX /V(V #YC/@ ]8T4 /&-- #MC50 Y8UX .&-H 39C= $U8X$!,V.1 C)C
MH0(Q8[,",6/( C%BYP(Q8?@",6'_ C)@_P(R8/\"KEP  )M=  "*70  ?%T
M '!=  !F70  7%X  %)@  !,8@  164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L
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M !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J  !9;
M3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B !R%*@ ;
MA3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%
MU@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3<P  27<
M $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0(@ 1D"H
M$)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 '
MC^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0  0X$  #F&
M   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ 'G"( !IPJ
M  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";OP  FML
M )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P  #*1   I
ME0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P  *@C  "H
M*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0  J,L  *?D
M  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>   AH@
M&:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;  "U(@
MMBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X  +?2  "W
MY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9KP  $;,
M  NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##&0  Q"
M ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!  #)T0
MR=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O   "K\   '!
M    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$   TQ8  -8>
M  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@O@  X,,
M9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H   #-
MT0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X  .<3  #J
M'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@  ]+( _P 3
M /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X 8P#[ &L
M^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F .H K@#H
M +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\ _P 0 /\
M#@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M
M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X J@#; +0
MV0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P - /\ "0#_
M  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &( X@!I .
M;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+ *\ R0"Z
M ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\  0#_  8
M_P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C ,\ :@#-
M '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L NP"V +D
MQ "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_    _P &
M .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$ 9 "_ &H
MO0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R *P OP"J
M -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P  Z    .$
M!P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R &4 L !J
M *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *  NP"> <T
MG0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\  ,X+  #(
M PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\ I0=E *,'
M:P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3"\P D@SE
M ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5  "Y$
MMPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@ )@09@"7
M$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL AA/F (44
M]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K&@  J10&
M *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P780"+%V<
MB1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y
M'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P  G1\  )H:
M#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I
M 'T@< !\('@ >B"! 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D\P!O)/\
M;R3_ &XD_P!N)/\ W2D  ,@P  "W,@  J#   )XN  "7*@  DR<  ) C"@",
M(Q, B"0? (0E*@"")30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX =29E '0G
M; !R)W0 <2=] &\HB !N*)0 ;"BA &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_
M 68J_P%F*O\!U"\  ,(V  "O-@  H34  )8T  "0,   BBT  (<J!@"#*1
M?RH: 'PK)0!Y*R\ =RPX '4L0 !S+$< <2Q- ' L5 !N+%H ;2QA &LM: !J
M+7  :"UZ &<NA0!E+I$!9"Z> 6(OK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P
M_P%?,/\!S30  +P[  "I.@  FSH  ) X  ")-0  @S(  '\P 0![+PX =S 6
M '0P(0!Q,2L ;S$T &TQ/ !K,4, :C%* &@R4 !G,E< 93)= &0R90!B,FT
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M? %2/8D!43V7 4\]I@)./K<"3C[- DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\
M *Y#  "<0P  CD,  ()"  !Z0   <ST  &T\  !H/04 9#T. &$^%P!>/B$
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M 4%)H@) 2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P) 2/\!MDD  *)*  "12@
M@TH  '=*  !N20  944  %Y'  !92   54D( %%*$ !/2A@ 3$HA $I+*0!)
M2S$ 1TLX $9,/P!%3$8 1$Q. $--5@!"35\ 04UH $!-= $^38$!/4V0 3Q-
MH $[3K$".D[& CI.Y ([3?8".TW_ 3M,_P$\3/\!LTT  )Y,  "-3   ?TP
M '1,  !J3   8$H  %E+  !43   4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X
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M 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6  !>5@
M5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K "]C,@ N
M8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D (V2] ")D
MV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:6@  4%P
M $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J+@ F:S4
M)6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;
M:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@  3&$  $-D
M   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  ==#  ''0X
M !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%TSP 2<^P
M$G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<  #YK   W
M;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^
M.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST
M  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES   Q=P
M*GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK  F),P (
MB3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H  (;L  "&
M]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J@0  (X4
M !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5+   E34
M )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F  "2\@
MDO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0  &Y$  !24
M   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0  HBT  *(W
M  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "AZP  H/(
M<W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X   ZA   )
MI    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0  + M  "Q
M.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX   L>D ;'X
M %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N    L@
M +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C  #!+0
MPCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H 98D  %B.
M  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\    OP   ,,
M  #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2(0  U2T
M -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8  %&<  !$
MHP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0   -    #2
M    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@  Z"   .PM
M  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\ #@#_  X
M_P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M /0 = #R
M 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +, XP#  .$
MT@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_  D _P /
M /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D ;P#G '4
MY0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z -  R@#.
M ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4 _P , /P
M% #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8 '  U0!U
M -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$ PP"_ -H
MO@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 ' /$ $ #J
M !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H Q0!P ,,
M=0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q ,\ KP#H
M *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! ., # #: !0
MT0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J +0 ;P"S
M '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@ H@#B *$
M\P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)  \ P@ 8
M +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *< :@"F &\
MI !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#< )0 [P"3
M /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H M@ 1 +$
M' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ": &H F !P
M )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&[0"(!_H
MAPC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8- *<#%0"B
M!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4 C0IK (L*
M<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\#_T >P__
M 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-#P"8#AD
ME XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_
M$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT <1;_ '$6
M_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-%!0 B14?
M (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88:0!T&'$
M<QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_ &<>_P!G
M'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=
M) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K(&T :2!V
M &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?)/\
MRBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5 ',C( !Q
M)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD 829R %\G
M?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$
M *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI&P!I*24
M9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO %@M>@!7
M+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\ P38  *HV
M  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J
M %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0
M3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5
M.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX 6C,F %@S
M+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+-X( 2C>0
M $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\  "1/
M@SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0
M-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X  13N. $0\
MG@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-/@  ?SX
M '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\
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M #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&  !A10
M640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN #E*-@ X
M2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-
MU0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=2   54@
M $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/,P R4#H
M,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I
M4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3   44P  $A-
M  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L5C< *U8^
M "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7SP B5^P
M(U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35   $52   _
M4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#, )%TZ "-=
M0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;7>D &USY
M !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7   [60
M-5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :
M94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.< $V/W !1B
M_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V7P  ,&(
M "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M.0 2;D(
M$6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -
M:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L
M   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='
M  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P
M>UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7
M>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""
M3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(
M &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P
M#88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1
MCE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G
M  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(
M  "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@
M )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1
M<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
M    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-
M  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@
M/X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P
ML    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]
M4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(
M "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP
M ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110
MTE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H
M   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\
M  #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H
M .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_
M "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P
M?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W
M -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$
M^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#=
M '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,<
M_P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G
M .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H
MR0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V
M /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4
M+0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z
M +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\
MIP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_
M #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D
M>@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_
M )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L
MK0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0":
M 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P
M_P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N
M )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8
MBP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_
M /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )(
M,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z
M 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\
MW14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%
M"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-
M@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T
M +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T
M>1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H
M$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C
M  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P
M &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4
M71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9
M*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=
M,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0
M %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+
MABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<
M(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $TH
MG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3
M '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#(
M4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&
M+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S
M  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV
M $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@
M0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F
M-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q
M.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y
M #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P
M738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _
M-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4Z
MSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D
M %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL
M.3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q
M/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ
M  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]
M #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND
M+$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$
M/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%
M10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X
M "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1
M.T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G
M2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*
M_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD
M #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@
M(%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <
M3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0
M   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=.
M !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\
MA$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D
M60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?
M50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT
M &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P
M&6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )
M9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2
M  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH
M  ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<
M '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !9
M5@  _^+__TE#0U]04D]&24Q%  0)45<  $=8   ^6P  -E\  "YB   F9@
M'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?  !Z)@
M>B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(  'C?  !X
M[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @<   &70
M !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&(   AB@
M (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73  "$Z@
MA/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P  $H    V#
M   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0  DR   )0I
M  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3X@  D^X
M864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T   :1
ME    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@  *,@  "E
M*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0  I.0 6VP
M $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@    HP
M *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7  "U(
MMBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]  5'8  $A\
M   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N    L@   +8
M  "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&%@  R2
M ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,  $&*   U
MD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@   ,8   #(
M    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@  W14  .$A
M  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\ !0#_  8
M_P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C .X :0#L
M &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H V@"V -<
MQ@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_  $ _P ,
M /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\ 9 #= &H
MVP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P ,8 O@#$
M -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_    ^@ ' /$
M#P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J
M ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8 MP"T ,H
ML@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ " .$ # #7
M !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\ MP!D +4
M:0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D ,$ HP#<
M *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L " ## !
MO0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!> *8 8P"E
M &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H E #/ ),
MZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S  P K0 2
M *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )< 70"6 &,
ME0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#' (4 Y "$
M /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  < H  . )T
M%@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ") %T B !C
M (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D W0!X /$
M=P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 * )$ $0".
M !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@ ? !> 'L
M9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M NT ; /Z
M &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%# "$ 1,
M@0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059 ' &7P!N
M!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ &(,
M_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\"@X > H6
M '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E#6,
M8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61'] %D1_P!9
M$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0
M&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H
M %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1%_\
MLB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4. &,6%0!A
M%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P 4AED %$9
M;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*'?\ K"0
M )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;$@!9'!H
M5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(
M('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I
M  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2(18 4"$>
M $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D:0!")74
M0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK  !_
M+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1, 2B8: $@F
M(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \*G( .RJ!
M #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN  ![+P
M;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!
M*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G  -B]_ #4O
MCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W,@  :S(
M &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN'  [+B(
M.2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-] # SC0 O
M-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-   :#4  %XU
M  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V,R  -#,F
M #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LWBP J.)P
M*3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<  %LW  !4
M-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T +S@D "XX
M*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E/)L )#RM
M ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z  !1.0
M2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA "D]*  H
M/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D 'T&K !Y!
MP  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-/   1SP
M $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#)0 B0RP
M(40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I !A&O@ 7
M1=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P  1#\  #U
M   V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <22D &THP
M !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+O  12]D
M$DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(  #I#   R
M10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4 %% L !-1
M-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L
M  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(   O2@
M*4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H  U8,  -
M6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H !5?F  57
M\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K4   )5(
M "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@*P $8#0
M V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B  !>\
M7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@  (%D  !I<
M   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@  :2X  &DX
M  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F[@  9O<
M9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(  !1E   0
M:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@  ',Q  !S
M/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP  </0 85,
M %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O   +<@
M!G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J  " -0
M@$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$ 7%@  %18
M  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #?P   ((
M  "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/+   CS@
M (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T  $Y?  !#
M8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0   )    "2
M    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P  H"X  * \
M  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H   \;0
M,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\   "A
MH@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,  +(Q  "R
M0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U>@  *H$
M !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q    L0
M +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F  #%-P
MQDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0  (I   !>8
M   /GP  !Z4   "J    KP   +,   "W    O    +\   #!    P@   ,0
M  #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=*@  WCP
M -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P , /\ $P#_
M !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D YP!O .4
M= #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/ -H S@#Q
M ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L $ #V !D
M\@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/
M '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T O #J +L
M_ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D !0 WP ?
M -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\ :0"] &X
MNP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A *L ]@"J
M /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$ QP 9 ,0
M(P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L &@ JP!M
M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L [@": /\
MF@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4 +$ '@"N
M "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &( FP!G )H
M;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+ /D B@#_
M (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *  & "= "$
MFP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A (L 9P"*
M &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /( ?0#_ 'T
M_P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0 !P C0 D
M (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X 8@!] &@
M>P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[ '  _P!P
M /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8 @0 > '\
M)P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q &, ;P!K
M &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4 _P!E /\
MP P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S
M "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\ 90!G &,
M< !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;!O\ M1
M *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$&P!I!2,
M9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC %H);0!8
M"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\ K14  )D7
M  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A#!T 7PPE
M %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.:P!0#W8
M3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D  )(<  "#
M'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41
M)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(%', 1A2
M $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@  !](0
M<2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8< $X6(P!,
M%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7  /QI] #X;
MC0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X)   ;"4
M &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;( !%&R8
M1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W
M(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P  :"@  %\H
M  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _(", /B I
M #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H
M,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H  %PJ  !5
M*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\ -R0F #8D
M+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L*9@ *RJJ
M "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM  !1+0
M3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C # H*0 O
M*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9< )BZH "4N
MO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.+P  2"X
M $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM)P J+BT
M*BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G "$RNP @
M,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0  13$  $ P
M   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E,RL )3,R
M "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;-M(
M'#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,  #TS   W
M,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX
M-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL
M !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV   T-@
M+C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^-  7
M/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X $3_K !(_
M^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q.@  *SP
M "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$,0 21#H
M$45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E  U$]@ -
M1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@  *$   "-"
M   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -2S8 #$M
M  M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*\  &2?H
M;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4  !]'   :
M20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43( !%([  -2
M1@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@  4/< :$
M %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-   64
M$5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV  !900
M64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8 8T0  %9%
M  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   16   #5H
M  E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B.P  8D<
M &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@  %))  !*
M2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8   "&,   -F
M 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-   ;4   &U.
M  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-  !(3
M/DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X   !P
M<@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD  'I'  !Z
M5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"4@  .%4
M "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\    ?@
M '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^  ")30
MB5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@  ,E\  "AD
M   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*    C    (T
M  "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";1   FE8
M )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH  "%Q   7
M=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP   )T   "?
M    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0  K4L  *U?
M  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_   0A@
M"8T   "3    F    )T   "A    I0   *@   "K    JP   *X   "O
ML0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD   ,)4  #!
M:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *EP   )T
M  "C    J    *T   "R    M@   +D   "[    O    +X   #     P@
M ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)  #:7@
MVW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D _@ D /P
M+P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#> ', W !Y
M -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8 _P#% /\
MQ0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ? .L *@#I
M #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T QP!S ,4
M>0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T /\ M #_
M +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -( ) #/ "X
MRP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M +, <P"Q
M 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\ HP#_ *,
M_P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q
M +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$ ; "@ ',
MG@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_ ), _P"3
M /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "( HP K *(
M,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0 &T CP!T
M (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0 _P"$ /\
MY0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E )$ +0"0
M #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &< @ !N 'X
M=P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U /\ T
M +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ (( )P"! "\
M?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I '$ <0!P
M 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\ P    *P
M  "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T "D <P P
M '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4 ; !D '8
M8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <  * )  "0
M"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ", :  J &<
M,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !: '( 6 !^
M %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.  "'$
M>A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E %T *P!<
M #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$
MB@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^%   <Q0
M &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4')P!3!RT
M4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$
M#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&   ;!D  &,9
M  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN
M $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@
M.Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT  %X=  !8
M'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20 1!$J $(1
M, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V%98 -!:G
M #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@  !3(
M3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G #L5+0 Z
M%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0 +ANE "T;
MN  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/(@  2B$
M $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:*0 T&C
M,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G
M(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0  1R0  $(C
M   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S
M "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(DM0 B),P
M(B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<  #\F   [
M)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH )R,Q "8D
M.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH
M !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH   W)P
M-"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @
M*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D &"SG !DK
M]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T*@  ,"H
M "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM,P ;+CP
M&BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E !0P]@ 5
M+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0  +"T  "<O
M   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6,SD %3-#
M !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T]0 0-/\
M<BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$  "0R   A
M,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y
M2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,./P ;B\
M %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V   =.
M&3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\  L_1P *
M/U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O< :3,  %LT
M  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :/   %C\
M !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%0@ "14X
M $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8  %<W  !,
M.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@  $D0   Y'
M!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@  3$D  $Q7
M  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([  !(.P
M0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL   M. P '
M4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4  %-2  !3
M80  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%/@  /CX
M #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95 @  5P<
M %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-  !<6P
M7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@  /$(  #1#
M   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>    8 0  &$(
M  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G50  9V8
M &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<  "]*   F
M30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@   &L$  !L
M"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@  <U\  '1R
M  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2   @5@
M&%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<   !Y @
M>@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8  (-J  "#
M@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   98@  $F<
M  QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(    B0
M (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@  "5=@
ME)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P  #'4   1[
M    @    (4   ")    C0   )$   "3    E    )8   "8    F@   )P
M  ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H;0  IH<
M *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4   "+
MD0   )8   ";    GP   *(   "D    I0   *<   "I    JP   *T   "P
M    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80  O'H  +N4
M  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<    H@
M *<   "L    L    +,   "V    MP   +D   "[    O0   +\   #"
MQ0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX  -2&  #4
MFP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V #0 \0 ]
M .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -, >0#0 (
MS@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_ +< _P"R
M /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X WP X -@
M0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"] 'H NP"!
M +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D _P"F /\
M_P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R ,  .@"\
M $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ', J0![ *<
MA "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9 /\ _
M .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T - "I #P
MI@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T )4 ?0"3
M (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\ [0   -@
M  #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7 #4 E0 \
M ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4 =@"$ (
M@@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0   ,$   "Q
M    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\ A0 V (,
M/ "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U 'H <P"&
M '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\   "@
ME    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P '4 -@!T
M #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0 9@"  &4
MC@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1    A@
M 'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D , !H #8
M9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z %D B !8
M )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P  >@<  '(&
M  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!= #  6P V
M %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\ A !. ),
M30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T  &@-  !B
M#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$
M-@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !% )  1 "A
M $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1  !:$
M5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D",@!(
M C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX / >? #L'
ML0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4%   4!,
M $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)+@! "3,
M/PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V? #,-L0 R
M#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&   2A8  $<5
M  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y#3  . XW
M #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K$<@
M*Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH  $(8   _
M%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T ,A$S # 1
M.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E%<8 )17D
M "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<   Z&@
M.!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P "H5-P I
M%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0 'QGB " 9
M]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W'0  -!P
M #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:-0 C&CT
M(AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;
M'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(   ,!\  "T=
M   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >'SH '1]#
M !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6(?X
M<R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(  "DA   F
M(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D
M2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2)?T <"(
M &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D   B)0
M'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1
M*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF
M  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >*0  &RH
M !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN1@ -+E(
M#2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<  %HI  !.
M*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0  &"X  !4O
M!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ ),TX "#-;
M  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L  !++0
M0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(  !(T P /
M-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H  #E7   Y
M90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(+P  /S
M #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y P ,.P@
M"#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3   _80
M/W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@  /#(  #4R
M   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (00@ !$,,
M  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&70  1FX
M $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34  #,T   N
M-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8  $D*  !*
M#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6   36D  $U]
M  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W   J.0
M)#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(  !2"P
M4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,  %9W  !6
MC@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F/P  'T(
M !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;"   7 P
M %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P  !@B
M8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@  &DH  !-.
M   .40  "E4   18    6P   %X   !A    8P   &0!  !E!   9P@  &@+
M  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M?P  ;9@
M &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0   Y8   (
M7    F    !D    9P   &L   !M    ;P   '    !R    = (  '4&  !W
M"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P  ?)   'NH
M  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E    :@
M &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4   "' P
MB@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8  (Z?  "-
MM0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T    >0   'X
M  ""    A@   (D   ",    C@   )    "2    E    )8   "8    FP
M )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4  "AJP
MH;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@   (\   "4
M    F    )L   ">    GP   *(   "D    I@   *@   "K    K0   +
M  "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "WH0  M[,
M,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$   "F
MJ@   *X   "P    L0   +0   "V    N    +L   "]    P    ,,   #'
M    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@  S*D _P
M /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D 0 #F $@
MX@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R "" ,8 C ##
M )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\ _P   /\
M  #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#, $( R !(
M ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +( A0"P )
MK@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0   /8   #K
M    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P LP!# +
M2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0"> (@ G "5
M )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8   #1
MP@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \ )T 0@";
M $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($ B@"- (@
MFP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z    K
M *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L / ") $$
MB !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"& '@ E !W
M *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F    F@   )(
M  "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z #L > !
M '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D C0!H )T
M9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@   ($   !\
M    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4 :@ Z &D
M/P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H
M %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',   !N
M:@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U %T .@!<
M #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X
MM0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B 0  7P
M %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %( - !1 #D
M4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"= $4 L !$
M ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0  50<  %0$
M  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !( #4 1P Z
M $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P JP \ ,$
M.P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P  $L+  !*
M" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$ /@ V #T
M/  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S +P ,P#8
M #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.  !"#0
M00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R #8$.0 U
M!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H *P?2 "L'
MZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \$   .@X!
M #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*-@ N"CT
M+0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2 ",-ZP C
M#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P  -1$  #,0
M P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H#CL )PY$
M "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D
M<Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4  "X3   M
M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D (1%" " 2
M2P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8
M & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6   H% $
M)A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9
M%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H ;!D  %T;
M  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D&   (A<$
M " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:1P 4&U(
M$QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L  %H=  !.
M'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P  '1L! !L;
M!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0'U  #R!=
M  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,(0
M0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2   !8@!  4
M( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T "R19  HD
M9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)(P  0",
M #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D P 1)0@
M#R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5  4I9  $
M*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0  /24  #4E
M   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /*0@ #"P,
M  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N8   +G$
M "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<  #,G   M
M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@< "3 ,  8Q
M#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70  ,VT  #.!
M   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J   K*0
M)R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+  (V#@
M-Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D  #E]   X
MDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J*P  )2L
M " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \#0  /0\
M #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X   _CP
M/J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@  (B\  !TP
M   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P  1 T  $80
M  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'B@  1J(
M $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0  !DV   3
M.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L  $X.  !/
M$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A   3YT  $ZU
M  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^   000
M#$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+  !9#@
M6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<  %FO  !8
MRP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +2@  !4X
M  !1    5    %<   !:    7    %T   !?    8 0  &('  !D"P  9@X
M &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H  !EP@
M9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50   %H   !=
M    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@  = H  '8.
M  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !UMP  =-(
M/$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<   !K
M;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,  (<)  "*
M#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0  A\4 -D<
M "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![    ?P
M (,   "&    B    (H   "-    CP   )$   "4    EP   )H!  "=!P
MH0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;< ,%   "55
M   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-    D0   )4
M  "8    F@   )P   "?    H0   *,   "F    J0   *P   "P    M <
M +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L  !YB   4
M:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I    *@   "K
M    K    *\   "R    M    +8   "Y    O    ,    #$    R    ,T'
M  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\   #[
M^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!) -H 3P#6
M %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )( NP"> +D
MK@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R    \
M .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\ 20"\ $X
MN@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7 *4 I@"C
M +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C    TP   ,@
M  #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H $@ I@!-
M *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ), G@"1 +
MD #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N    *X   "H
M  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $( D@!' )
M2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_ *< ?0"\
M 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D   "3
MCP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !  '\ 10!^
M $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\ ;@"R &T
MSP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "     ?  $
M 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X /P!M $0
M; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J %X P@!>
M .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q    ;0   &H
M" !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@ #X 7P!#
M %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %( N !1 -P
M40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8    %X !0!<
M  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@ 4P ] %(
M0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!' ,P 1@#P
M $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,  0!2  @
M4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X $< /@!&
M $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,, /0#F #T
M^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)  0 1P *
M $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X .@ ] $
M.P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #= #0 ]0 U
M /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$ /P$' #X
M"P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T #P ,P!#
M #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P [@ L /P
M=PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D# #<%"  V
M @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@ + !  "L
M20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E /< <@T
M &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +!0 P" H
M+P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04] "0%1@ C
M!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?, ;0X  %X1
M  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J#0< *0L+
M "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+1  ="T\
M' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1   %H2  !.
M%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0 (PX( ",-
M#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7#E  %@]<
M !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4  !+%@
M0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$& !T0"0 <
M$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX $1): ! 2
M:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)&   /QD
M #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2!@ 7$@L
M%1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97  T690 ,
M%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@  /1H  #4;
M   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3%@D $18-
M ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:80 '&W$
M!AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP  #,<   L
M'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P< #AL,  T<
M$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "'VX  1^
M   ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >   J'@
M)1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+  H@#@ (
M(!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL  "-^   C
MDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H(   (Q\
M " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E#0 $)1
M B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[   GD
M)Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0  (B$  !X@
M   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0  *P\  "P2
M   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   LC0  +*0
M "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(  !TB   9
M(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X  #(0   S
M%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@  ,J$  #&X
M   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE   6)@
M$B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.   Z$@
M.A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X  #BV   W
MU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3*P  $"X
M  TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!$   0Q0
M $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R   ^SP
M/N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@  #34   @X
M   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@  3!$  $T6
M  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(R@  1^P
M.S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T   )
M0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X  %@2  !9
M&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@  4N8 .#,
M #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*    30
M %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.  !F$P
M9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP -3<  # U
M   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6    60   %P
M  !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T#P  =Q4
M '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H  "L[   B
M/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :    &L   !N
M    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@  B@\  (P7
M  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$   <20
M$TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T   "
M@P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D  *(0  "B
M&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   55   #EL
M  5B    :0   '    !W    ?0   ((   "&    BP   (\   "3    E0
M )<   ":    G0   *    "C    I@   *H   "N    L@   +<*  "[$0
MNA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@  !VH   !S
M    >P   ((   ")    D    )4   ":    GP   *,   "F    J    *L
M  "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3"P  U!4
M -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0   /, !0#T
M  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\ S@!4 ,L
M60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q ,  KP#F
M *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\   #9  D
MT@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!. +, 4P"Q
M %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8 FP#4 )D
M^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X  0 M0 -
M +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X 3 "< %$
MFP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#% (@ [@"&
M /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?    G  ) )D
M#P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0
M (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\
M<@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # ""
M !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ',
M3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_
M &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X
M;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B
M $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8
M_P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P /
M %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D
M4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!*
M /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %(
M$ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !*
M $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\
MA0   '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!&
M !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P
M3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?
M &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X
M/  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R
M %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%
M  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  /
M #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\
M*0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2
M"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P
M$  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7
M "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0
M0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D
M 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!
M80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!
M #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X
M'@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4
M!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41
M   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0
M !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X
M#@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L
M$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,
M$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_
M  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%
M)10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .
M#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42
MD  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4
M !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$
M"A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@
M%:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6
M   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83
M  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(
M !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8
M%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;
M%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV
M   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&
M%!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%
M(1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?
MT0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD!
M !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@
M "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0
M(^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=
M   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<
M   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\
M0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *
M)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U
M(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",
M #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P
M 2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'
M/B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G
M   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4
M   X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$
M $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G
M*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G
M  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P
M'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,
M3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B
M+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,
M !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P
M %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0
M<C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!
M   '1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T
M  !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L
M (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.
M5    %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
M    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S
M  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P
M &H   !Q    =@   'L   "     A@   (H   ".    D0   ),   "6
MF0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W
M/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P
M  "#    B0   (\   "4    F@   )\   "B    I    *<   "J    K@
M +$   "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0
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M__________________________________________\
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M_/W^_VUF=#$      P0A   !                     0
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MQ\S-"0S+TPHMQ]0*6;+8"X">S2N:F,%0JY:X9[>5M76\E+1^OI2SA;^0LH7
MC+&&P8JQA\*(L(?"AK"(PH6PB<.#L(K#@J^+PX&OC,.!KXS#@:^,PX&OC,.!
MKXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,P\?/
M"!#%U DTN-D*6Z+G$G:7VB6)D,]%F(['7:.-P6ZKC;UYL8RZ@;2)N(.WAK>%
MN82VAKJ#M8>[@K6(O(&TB;V M(J]?[2+OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^
M?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OL+1!Q:]
MU@@ZI_$.59OQ&VB1YBUXB=U A8755H^#SV>7@LMSG7[(>*%[QGRD><1_IG?#
M@JAUPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+
MK'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K/^X% [_N!XG
M_[0J1O>O-FG>IT*/QYMBL<2;<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BW
MBH_*MHB1S+6%D\VT@Y;/LX&9T+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J
M1O>O-FG>IT*/QYMBL<2;<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*
MMHB1S+6%D\VT@Y;/LX&9T+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J1O>O
M-FG>IT*/QYMBL<2;<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1
MS+6%D\VT@Y;/LX&9T+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J1O>O-FG>
MIT*/QYMBL<2;<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%
MD\VT@Y;/LX&9T+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J1O>O-FG>IT*/
MQYMBL<2;<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT
M@Y;/LX&9T+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^
MI-&P?J31L'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J1O>O-FG>IT*/QYMB
ML<2;<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/
MLX&9T+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P
M?J31L'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J1O>O-FG>IT*/QYMBL<2;
M<K;"FW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9
MT+. G=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31
ML'ZDT;!^I-&P?J31L'ZDT?^X% [_N!XG_[0J1O>O-FG>IT*/QYMBL<2;<K;"
MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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M@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
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ME*^$PY"OA<2-KH7%BJZ&QHBMAL:'K8?&A:V(QX.MB<>!K8O'@*R+QX"LB\>
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M'DZ-^B];AO(_9X#K3G%[Y5MY=N!E@''=;(1NVG*(:]EWBVG7>HUGUGZ.9M6
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M#$FI]!1EF>8E>([<.8:(U$^0AL]@EX3,;9R#R76@?\=XHGW&>Z1ZQ7VF><2
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MJK!YPZ>MA,>?JH3+F*B#S9"GA-")I8;2A*2*TX"DD--_I9?2?Z:@T'^EILZ
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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ME)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'#
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M)"J4_S YBO\Z18'_1D]Z_5%8<OA87FOU7F-E\F5H8.]L:UWM<FY:ZWEP5^J
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MKRD1^KLI$^S(+!/>V#<0T^%!'LG?23"\VE%$K]-85J'-7V:4R&5TB,1L@'S
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M.B[_P#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO
MFLD  (S9  "!]0, >?\0 6[_%@-E_Q\&7O\G"U?_, ]1_S<32_\^%T;_11E!
M_TP;/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^ )BO_C"@I_Y<I*/^B*B?_
MK2LF_[DL)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+:JW  ":Q0  B],
M 'WB  !U_P4 :?\, 5__$0)7_Q<#4/\?!4G_)@=$_RX)/_\V"SO_/0TW_T,/
M,_])$3#_3Q(N_U43+/];%"K_8A4G_VD6)?]R%R/_>Q@A_X89'_^1&A[_G!L>
M_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@  ?-X  '#U
M  !E_P  6O\& 5'_#0%)_Q$"0_\7 SW_'P0X_R8%-/\M!C#_,P<M_SD'*O\^
M""?_0P@E_TD)(_]."2'_5 D?_UH*'?]A"AO_:0L9_W(,%_]\#1;_A@T4_X\.
M%/^:#Q3_F@\4_YH/%/^:#Q3_F@\4_YH/%/^:#_]<' +_5R8#_U$R!O]./ C_
M5T40_UM.&?]<6"+_6V,K_UEO,O]7>CC_5(4]_U*00?]0F47_3Z!'_TZG2?]-
MKDO_3+1,_TN[3?]*PT[_2<U/_TG=4/](Z5#_2/)0^TGV4/9+^5#P3?M/ZD_[
M4.=/_%#G3_Q0YT_\4.=/_%#G3_Q0YT_\4/]<' +_6"8#_U(R!O]1.@C_6D,0
M_U]-&?]?5R/_7F$K_UQM,_]9>3K_5X0__U2.0_]2ET?_4)])_T^F2_].K4W_
M3;1/_TR[4/]+PU'_2\Y2_TK?4O])ZE/]2O)3^$OV4_%-^%+K3_I2Y5#Z4^)1
M^E/B4?I3XE'Z4^)1^E/B4?I3XE'Z4_]=&P+_628#_U,Q!O]4.0C_74(0_V)+
M&O]B52/_8%\L_U]K-/]<=SO_68) _U:,1?]4E4C_4IY+_U&E3O]0K$__3[-1
M_TZ[4O]-Q%/_3,]4_TO@5?]+ZU7Z3/)5]$WV5>Q0^%3F4?A5WU+Y5MQ3^5;<
M4_E6W%/Y5MQ3^5;<4_E6W%/Y5O]>&P+_6B4#_U0Q!O]8-PC_84 1_V5)&O]F
M4R/_9%TM_V)H-?]?=#S_7']"_UF*1_]6DTO_5)Q._U.D4/]1JU+_4+-4_T^Z
M5?].Q%;_3=!7_TWB6/Q,[5CV3O)8[E#U6.93]EC?5/=9UU7X6=-5^%G35?A9
MTU7X6=-5^%G35?A9TU7X6?]?&@+_6R4#_U4P!O]<- C_93T1_VI'&O]K423_
M:5HM_V9D-O]C<#W_7WQ#_UR'2?]9D4W_5YI0_U6B4_]3JE7_4K)7_U&Z6?]0
MQ5K_3]);_$[D6_A/[5SP4?);YU3T6]Y5]5S55O9=SECW7<M8]UW+6/==RUCW
M7<M8]UW+6/==RUCW7?]@&@+_7"0#_U8O!?]@,@C_:CL0_V]$&O]P3B/_;U<M
M_VMA-O]G;#[_8WA%_V"#2_]<CD__6IA3_U>@5O]6J5G_5+%;_U.Z7/Y1QE[\
M4-9?^5#G7_)2[E_G5?%?W5?R8-)8\V'+6?5BQ5OU8L-;]6+#6_5BPUOU8L-;
M]6+#6_5BPUOU8O]A&0+_72,#_UHM!?]E+PC_;S@0_W1!&?]V2R/_=50M_W%=
M-O]L9S__:'-&_V1_3/]@BE+_7956_UJ>6?]8IUS^5K!?_52Z8/Q3QV+Y4MQC
M\U/H8^E5[F/>6/!DT%KQ9<A<\F;"7?)FO5[R9KM>\F:[7O)FNU[R9KM>\F:[
M7O)FNU[R9O]B&0+_7B,#_UXJ!?]I+0C_=#4/_WH^&/]\2"+_>U$L_WA:-O]S
M8S__;6U'_VEZ3O]DAE3_8)%8_UV<7/U:I6#[6+!B^E:[9?A5RF;U5.!G[%;J
M9]]:[6?07.]IQEWO:K]?[VJY8.]JM6'O:K-A[VJS8>]JLV'O:K-A[VJS8>]J
MLV'O:O]C& +_8"(#_V(G!?]N*@?_>3(._W\\%_^"1B'_@D\K_W]8-?][8#[_
M=6E'_V]T3OMJ@57X9HQ;]6*77_-?H6/P7*MF[EJV:>Q9Q&KI6-IKX5KJ:]!=
M[&W%7^QNO&'K;[9B[&^Q8^QNK63L;JMD[6VK9.UMJV3M;:MD[6VK9.UMJV3M
M;?]D& +_82(#_V8E!/]R)P?_?C -_X4[%O^(11__B$TI_X95,_^"7CW[?69&
M]G9P3O)R?%7N;8=<ZFB28N9DG&;C8:9JX%^R;=U=OV_:7=-PTE[J<,1@Z7*Z
M8NASLV3H<ZUEZ7.I9NERIF?J<:1GZG"D9^IPI&?J<*1GZG"D9^IPI&?J</]E
M%P+_8B$#_VDC!/]W)0;_@B\,_XHY%/^.0QW_CTPF_XU3,/F*6SKSA6-$[7]L
M3>AY=U7C=()=WFZ-8]EIEVG39J%NSV.L<<MAN73(8<IUQ6'E=KEDYG>P9N5W
MJFCF=Z5IYG:B:N=UGVKH<YYKZ7.>:^ESGFOI<YYKZ7.>:^ESGFOI<_]F%P'_
M8R$#_VT@!/][(P7_ARX+_X\X$O^301K_E4HC^I11+?.163?LC6!!Y8=I2M^!
M=%/6>GY=SW2(9<IOD6S%:YMQP6BF=;UFLGBZ9<)ZMV7=>ZYHXWNG:N-[HFOD
M>IYLY7B;;>5WF6WG=IANYW68;N=UF&[G=9ANYW68;N=UF&[G=?]G%@'_9" #
M_W > _]^(@7_BRP)_Y,W$/^80!C]FD@@])I.*>R853/EE5T\W8]F1].(;U/+
M@7E>Q7N#9K]UC&ZY<99TM6ZA>+!KK'RM:KM^JFK2?Z1LX'Z>;>%]FF_B?)=P
MXWJ5<.1YDW#E=Y-QYG>3<>9WDW'F=Y-QYG>3<>9WDW'F=_]H%@'_9" #_W,<
M _^!( 3_CBL(_Y<U#O^=/A7XGT0<[Z!+)>>?4BW?G5HWTY5C1LJ.;%/#AW5>
MNX%^9[5[B&^O=Y%UJG.<>J5PJ'ZA;[:!GF_*@IMPWH&6<=^ DW+A?I%SXGR0
M<^-ZCG/D>8YSY7B.<^5XCG/E>(YSY7B.<^5XCG/E>/]I%@'_9AX#_W8: _^$
M'P/_DBH'_YLT#/Z@.Q+SHT$8ZJ9((.*G3R?8HE8VS)I@1<.3:5*[C7)>LX9Z
M9ZR!A&^F?8UVH'F8?)MVHX"7=+&#E'3%A)%UW8./=MZ!C7;@?XMWX7V*=^)[
MB7;D>HEVY'F)=N1YB7;D>8EVY'F)=N1YB7;D>?]I%0'_:1T#_W@9 O^''@/_
ME2@&_YXR"OJD-P_OJ#T4YJQ$&MVM2R30IE0UQI]>1+R99E*TDF]=K(QW9Z2'
M@&^>@HIWF'Z4?9)[H(&->JV$BGG A8AZW(2'>MV"AGK?@(9ZX'Z%>N)\A7GC
M>H5YY'F%>>1YA7GD>85YY'F%>>1YA7GD>?]J%0'_:QL"_WL7 O^*' +_F"8%
M_Z(P"/6H,PSKKCD0XK-!%-:Q1R/*JU(TP*1<0[:>9%&MF&Q<I9)T9IV-?6^6
MB(9VCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\
MY'J ?.1Z@'SD>H!\Y'J ?.1Z@'SD>O]K%0'_;1D"_WX5 O^-&P+_FR0#_J4L
M!O&L+PCGLS0+W;HZ$-"U1B'%KU$RNJE:0K"C8D^GG6I;GIAR99:3>FZ/CX-V
MB(N.?(*(F8%\AJ>%>8:YAG>'UX5XA=V#>H/>@7J"X'][@>%]?(#C>WQ_XWI\
M?^-Z?'_C>GQ_XWI\?^-Z?'_C>O]K% '_<!@"_X$4 ?^0&0'_GR("^JDF!.VQ
M*07BNB\&UK\V#\JZ1""_M$\QM*Y80*JH8$ZAHV=:F)YO9(^:=VV(EH!U@)*+
M>WJ/EH!TCJ2$<8VVA6^.T85QB]V#<XG?@76'X'YVA>%]=X3C>W>#Y'IW@^1Z
M=X/D>G>#Y'IW@^1Z=X/D>O]L% '_<Q8"_X43 ?^4%@'_HAX!]:T@ N>X(0+=
MPR8"T,,T#<2^0AZYN4TOKK-6/J2N7DR:J657D:5M8HFA=6N G7YR>9J(>7*7
ME'YMEJ*":96SA&>6S8-ID]Z";(_?@&^,X7YPBN)\<HCC>G*'Y'ERA^1Y<H?D
M>7*'Y'ERA^1Y<H?D>?]M$P'_=A,!_X@2 ?^8$P#_IQD![[,6 >+ %0#5RAX!
MR<<R#+[#0!RSODLLJ+I4/)ZU7$F4L&-5BJQK7X&I<FAYI7MO<J.%=FN@D7MF
MGY]_8I^Q@6"?RH!BG.!_99?A?FB3XGQJD.-[;(WD>6V,Y7AMC.5X;8SE>&V,
MY7AMC.5X;8SE>/]N$P'_>Q$!_XT0 /^=$ #ZK!$ VKL+ -7)"P#-SAL!PLPO
M"K?)/1FLQ4DIH<!2.)>\6D:-N&%1@[5H6WJR<&1RKWEK:ZR#<62KCW9?J9YZ
M6ZFO?%FJR7Q:I^)[7J#C>V&;XWICE^1Y9I3E=V:2YG=FDN9W9I+F=V:2YG=F
MDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD S[X) ,O,"0#$TQ< NM(L![#/
M.Q:ES$8FFLA0-8_$6$&%P5]-?+YG5G.\;UYKN7=E9+B":UZVCG!9M9US5;6N
M=52VR'53L^=V5ZOF=EJDYG9<H.=U7YSG=&":Z'1@FNAT8)KH=&":Z'1@FNAT
M8)KH=/]R$@'_A@P ^Y@) -FI!@#.M0< QL$' ,#/"0"ZVQ, L=HI!:?8-Q*<
MU$0ADM%-,(?.53Q]RUU'=,EE4&S';5=EQ79>7L2!8UG#CFA4PYUK4<.N;$_$
MR&U.PNUM4+CK;U.PZW!5J^IP6*;K<%FCZW!9H^MP6:/K<%FCZW!9H^MP6:/K
M</]W#P'_C0@ WJ " ,^N!0#$N04 N\4& +73"@"NX18!IN$I!IW@-Q&3WD(=
MB=Q,*7_:5#5UUUP_;=5D2&73;$]?TG946=*!6531CEU0T9U@3=*P8DO3R6)*
MTNUB2\CR9DV_\6A/N/!I4;+P:5*O[VE2K^]I4J_O:5*O[VE2K^]I4J_O:?]_
M"@#ME@  TJ8! ,2R P"YO , L,D& *G8"@"AYQD"F><J"9#G-Q2'YD(??>5*
M*73D43-KXUDZ9.)A05[B:T=8XG5+4^& 3T_BC5-+XIM52>.L5T?DQ%=&X^E7
M1MWV64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9
MG@  QZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN
M4"]B[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W
M3D+F^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@
MN[   *Z[ 0"BR ( F-4% )#X#P&)^" $@O@N"WGY-Q-P^3\;:/E&(F#Z32A:
M^E0M5/I<,4_[935+^VTX1_QW.T/\@ST__9 _//V?03K^KT,X_\9$-__J13;\
M_44[\O]$/NK_1#[F_T8^YO]&/N;_1C[F_T8^YO]&/N;_1M"?  "]K   KK4
M *+"  "5SP  BMT# (3_$@%[_QX#=/\J"6S_,P]D_SL67?]#&U?_2B!1_U$D
M3/]8)TC_8"I$_V@L0/]Q+CS_>S$Y_X@R-?^6-#/_I#8Q_[8W+__0."[_[SDM
M__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0  HKT  )3*
M  "'V   ??,' ';_$@%M_QH#9?\D!5[_+0I8_S8/4O\]$TS_119(_TP90_]3
M&S__6AX\_V$@./]I(37_<B,Q_WTE+O^*)BO_F2@I_Z<I)_^Y*R;_TBPE_^\L
M)/__+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !Y
MX0  <?\( &?_#P%?_Q4"5_\> U'_)@5+_RX'1O\V"D'_/0P]_T0..?]+$#;_
M41(R_U@3+_]?%2S_9Q8I_W$7)O]\&"/_B1H@_Y@;'_^F'!W_MQT<_\H>'/_F
M'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5P@  AL\  '?>  !K]
M8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_- 8R_SH'+O] ""O_1@@H
M_TP))?]2"2+_60H@_V(+'?]K#!K_=@T7_X0.%?^2#Q3_H! 3_ZT1$_^Z$1/_
MPQ(3_\,2$__#$A/_PQ(3_\,2$__#$I>^  "&S   =]L  &GG  !<_0  5/\
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M45X>_T]J)?]-=RO_2H,O_TB.,_]&F#;_1*$X_T.I.O]"L#S_0K@]_T'!/O]
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M7TZQ]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC
MTYL  ,:H @"[L0( LKL" *K'!@"BTPH G=8: 976+ :,U#H1@])&'7K03R=R
MSE@Q:LU@.&3+:#]>RG)%6,I\253)B$U/R9513,FE4TK)N51)RMQ31\CW54C
M_%A*N/M93++[6DZM^EI.K?I:3JWZ6DZM^EI.K?I:3JWZ6O]_  #<DP  RJ(
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M-CGE_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R
M@]0  'GH!P!S_!(!:_T= F3])P1>_C$(6/X[#5/_0Q%-_TL52?]3&$7_6AI!
M_V,=/O]L'SO_=B$W_X(C-/^0)3+_GR<P_[ H+O_(*2W_ZBHL__\J+/__*B_Y
M_RHO^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@  G+D  ([%  "!T0  ==X
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M"0W_TPD-_],)#?_3"9&\  "!R0  <M<  &3D  !4ZP  2_\  $3_   ]_P0
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M\E24//!2G3_N4:9![%"O0^I/ND3H3L=$YD_=1>%/[D7=3OM(U$__2<A1_TK
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M7UZ0^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P,
MXX<  -.3 0#*G@0 PJ<$ +NO! "UM@T KK<A J6V,@F=LS\5E+!*((RM4RN$
MJELT?:AC/':E:D-PHW)*:J%[3V6@AE1@GI%86YV?6UB=L%U6G<==5IWK7%>:
M^EM:E?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?C?Q77XW\5_]J"@#_?   W(P
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M2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP
MH+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9(5K18B=5
MT&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_] 0,/_0D&]
M_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@M   E;X
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M'2KW_QTJ]_\=*O?_';.C  "DJP  E[8  (G!  ![RP  ;]8  &/?  !;]08
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M56YZ_%-O>?]1<'?_3W%V_TUQ=?],<77_3'%U_TQQ=?],<77_3/];#@#_:00
M]G<  -V"  #0BP, R9,% ,29!@"^GA  MI\D JZ=- BFFD$3GY9,'9B352>1
MD%XOBXUE-X6*;3V B'5#>X5^2':#B$QR@I-0;H"@4VM_KE5H?\)69W_C56B
M^E-I?O]1:GS_3VM[_TUL>?],;'G_3&QY_TQL>?],;'G_3/]># #_; $ YGH
M -:&  #+CP( Q)<$ +Z=! "XH@X L:,A :FB,@>AGS\1F9Q*&Y*94R6+EEPM
MA9-C-7^1:SMZCG-!=8Q\1G"*A4MKB)%/9X>=4F2&K%1BAK]588;A5&&&^5)C
MA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P  X'X  -")
M  #&DP$ OYL# +BA @"QI@L JJ@> :.G+P6;I3T/E*)(&8R?42*%G%DK?YIA
M,GF8:3ETE7$_;Y-Y1&J2@TAED(Y,88^;3UZ.JE);CKU26H[>4EN-^%!<B_]/
M7HC_3F"%_TQA@_]+88/_2V&#_TMA@_]+88/_2_]D!0#U=   VH(  ,N.  #!
MEP  N)X! +&E  "IJP< HZT: )RL+ 25JSH,C:A%%H:F3Q]_I%<H>:)?+W.@
M9C5MGFX[:)QW0&.:@45?F8Q)6YB93%>7J$Y5E[M/5)?<3E26]DY5E/]-6)#_
M3%F-_TM;BO]*6XK_2EN*_TI;BO]*6XK_2O]H  #E>0  T8<  ,62  "[G
ML:(  *FI  "AL0( F[,5 )6S* *.LC8)AK!"$G^N3!MXK%0C<JI<*FRH9#%G
MIVPV8J5U.UVD?T!9HXI#5:*71U&AITE/H;I*3J+924Z@]4E.G_])4)G_25*6
M_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P  RHT  +Z8  "SH   JJ<
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M-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":KP  CK<  (._  !XQP,
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M":*G  "3L0  A;L  ';&  !IT   6]H  $[@  !#Y0  /OL! #K_#  V_Q,
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M1W]G^$5^:/]#?FC_07UG_S]\9_\^?&?_/7QG_SU\9_\]?&?_/?]2#@#_70,
M_6D  .%R  #6>@( SG\% ,J#" #%AA( O(<F ;6&-@:N@T,/IX!.&*%\6"";
M>6 GEG=I+9)T<#..<GDWBG"!/(9NBS^#;95#?VRA17QKKD=Z:[](>&O=2'AL
M]D9X;/]$=VS_0G=K_T!W:O\_=VK_/G=J_SYW:O\^=VK_/O]4# #_7P  \FP
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M0V=X_T%H=O\_:';_/VAV_S]H=O\_:';_/_];! #W:0  W78  ,V   ##B
MNXX  +23 0"MEPD IY@: *"8+ .9ECH*DI1%$HR23QJ&CU<B@(U?*'N+9RYV
MB6\S<H=W.&V%@3QIA(M 9H*70V*!I49@@;9'7H'-1UZ![T9?@?]$8'__0F%]
M_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0  UGD  ,B$  "^C   MI,
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M.U"/_SM0C_\[4(__.^MM  #3?   PXD  +>3  "LF@  HI\  )FE  ".JP
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M(;Z/  "OF@  HJ$  ):I  "*L   ?;@  '&_  !FQ@  6\P" %#2!P!'V@P
M1MP8 $7<)P!$W34!0=U  C_>2P,]WE4$.M]?!CC?:0<UWW8),^"$"S'@E PO
MX:8-+N&\#BWBX XMWO@/*]W_$BK<_Q0IVO\6*-K_%BC:_Q8HVO\6*-K_%K.8
M  "EH   F:<  (NP  !^N   <<   &7(  !9S@  3M,  $3;!  _Z0T />D7
M #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J[FL$*.YX!2;OB 8E[YH'
M(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J_PL?ZO\+'^K_"ZB?  ";
MI@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T  #CD   U]@P ,_<4 ##W
M'@ N^"< *_DP "CY. $F^D !(_M) 2'[4@$>_%T"'/UI AK]>0,8_HL#%_^>
M Q7_LP04_],$%/[T!!/\_P,3^O\#$_G_ Q/Y_P,3^?\#$_G_ YVE  "/K@
M@+@  '+"  !DRP  5M,  $G:   ^WP  -.0  "[T   K_PH */\0 "7_%P B
M_Q\ '_\F !S_+0 9_S0 %_\\ !3_1 $2_TX!$/]9 0[_9P$,_W<!"_^* @K_
MGP()_[4""/_5 @?_] ('__\"!___ @?__P('__\"!___ I&M  ""N   <\(
M &3,  !6U0  2-T  #OB   PYP  )^X  "/_   @_P0 '/\, !G_$0 6_Q8
M$_\; !'_(0 ._R< #?\N  K_-@ '_SX !/](  #_5   _V(! /]S 0#_AP$
M_YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0  9<P  %;8
M  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P  $?\$  __"P -_PX "?\1
M  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00  _TT  /]<  #_;0  _X(
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MX#O"%M\[TA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ_Q_$._\?P#S_'L \_Q[
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M-)-5]C.25?\RD5;_,8]6_S"-5O\NC%?_+8Q7_RV,5_\MC%?_+?])#@#_404
M_UH! .YB  #?9P, V&H& -5K"@#-;14 Q6XI ;YM.02W:T<+L6A2$:QF7!BH
M9&4=I&)M(J%@=2:>7GXIFUV&+9A<CR^56IDRDUFD-)!9L#:.6< VC%G;-XI9
M\S:)6O\TB%O_,X=;_S&&6_\PA5O_+X5;_R^%6_\OA5O_+_]+# #_5   ^UX
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M-G-H_S5S9_\S<V;_,G-F_S)S9O\R<V;_,O]1! #_7   XF<  -)P  #'=@
MP'H  +I] @"T?PP K8$= *>!+@*@?SP(FGU'#Y5Z41:0>%H<BW9B(8=T:2:#
M<G$K?W%Z+WQO@S)X;HTU=6V8.')LI3MP:[0\;FO)/&UKZ3MM;/XY;6S_-VYL
M_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P  WFH  ,US  ##>@  NWX
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MC ( G(X4 )>/)@&1CC0%BXQ "X6*2A& B%,8>X9;'7:%8R)R@VHG;H)R*VJ
M>R]G?X8S8WZ1-F!]GCE=?*XZ6WS!.UM\XSI;?/HX7'O_-UU[_S5>>?\T7W?_
M,U]W_S-?=_\S7W?_,_Y<  #A:@  S74  ,!^  "VA@  KHL  *6.  ";D0
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M*]=R  ##@   MHP  *J4  "?F0  E)X  (FC  !^J   <*X  &JP#@!HL1T
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M#S#(TP\PQO00+L3_$RW"_Q4LP?\6*\#_%RO _Q<KP/\7*\#_%[B-  "JEP
MGIX  )&E  "$K   >+(  &NY  !@OP  5,,  $K( @! S0< .M(. #G2&P X
MTR@ -],U #;40  TU4L!,]55 3'68 (OUFP#+==Z!"O8BP4JV)T%*-FQ!B?:
MS08GU^\&)M3_"272_PLDT?\,(]#_#2/0_PTCT/\-(]#_#:Z6  "@G0  E*0
M (:L  !YM   ;+L  &#"  !4Q@  2,L  #[0   UU00 +=T* "SA$P KXA\
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M  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(  !2T
M0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1  G_%@ &
M_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4  /^L  #_
MQP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP  8<D  %+3  !#VP  ->$
M "GF   >Z@  %>X  !#X   ._P  "_\   C_   $_P8  /\*  #_#@  _Q$
M /\5  #_&P  _R,  /\K  #_-@  _T,  /]3  #_90  _WH  /^1  #_I@
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M&J]!]QRM0?\=JT'_':E!_QRI0?\<ID'_&Z5!_QNE0?\;I4'_&_\]$ #_0@D
M_T@% /]-" #_4 L ^5$/ .M0%0#A3R  V% Q ,]000+)3TX%Q$Y:"<!,9 V]
M2VT0NDIV$[=)?A6U2(<7LT>/&;%'EQNO1J <K4:J'JM%MA^I1<8?IT;@(*1&
M]""A1O\AGT?_()Y'_R">1_\?FT?_'II'_QZ:1_\>FD?_'O] #0#_1@0 _TP
M /A2 @#H500 X54( .)5#0#551D S%<L ,57/ *_5DH&NE55"K937PZR4F@2
MKU!Q%:Q/>1BJ3H$:J$V*':5,DA^C3)P@H4NF(I]+L2.=2\ DFTO8)9E+\"66
M3/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20  _U$  .97
M  #=6P$ U5P% -);"0#+7!0 PUXH +Q>. *V748&L5M1"JU96P^I6&03IE9L
M%Z-5=!J@5'T=GE.%'YM2CB*949<DEU"A)I50K2>24+PHD5#0*(Y0["B-4?XG
MBU'_)HM1_R6*4O\DB5+_(XA2_R.(4O\CB%+_(_]%!P#_2P  \%4  -];  #3
M8   S&$# ,AA!@##81$ NV0D +5D- *O8T(%JF%."J5?5P^A76 4GEQH&)M;
M<!N867@>E5B!(9-7BB205I,FCE6>*(M5J2J)5+<KAU3+*X55Z2N$5?PJ@U;_
M*(-6_R>"5O\E@5;_)(%6_R2!5O\D@5;_)/]' P#_3P  YU@  -E@  #-9
MQF8! ,%F! "[9@X M&D@ *YI,0*H:#\%HV9*"I]E5 ^:8UT4EV%E&)-@;1R0
M7G4?CEU](HM<AB6(6Y HA5J:*H-9IBR 6;0M?UG'+GU9YBU\6OHL>UK_*GM;
M_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@  XUP  -)C  #':   P&L
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M*&IF_R=J9O\G:F;_)_]0  #G6P  TV8  ,5N  "[<P  LW<  *MY  "D> ,
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M(#^:R" _F>L?/YC_(#Z6_R$^E?\A/Y3_(3^4_R$_E/\A/Y3_(<UP  "\?0
ML(@  *2/  "9E   CI@  (.=  !WH   ::0  &"G" !=J!0 6ZDD %FI,0%6
MJ3P"4ZE%!%"H3@9-J%<)2JA?#$>G: Y$IW,10:9_%#ZFC18\IIT7.J:O&#FF
MQQ@YI>H8.*/_&C>A_QLWH/\<-Y__'#>?_QPWG_\<-Y__',1X  "UA0  J8\
M )V5  "2F@  AI\  'JC  !NJ   8JP  %6P  !0L@X 3K(; $VS* !+LS4
M2;,_ 4:S20)$LU($0;-;!C^S9 @\LV\*.K-[##>SB@XULIH/,[.M$#*SQ1 R
MLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@  H94  )::
M  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^OBL /+XV
M #N_00 YOTL!-[]4 C7 7P(SP&H$,<!W!2_ A@8MP)<'*\"J""K!P@@JP.<'
M*;W]"BB\_PPGNO\-)[G_#B>Y_PXGN?\.)[G_#K*,  "EE   F9H  (VA  !_
MIP  <JT  &:S  !:N   3[L  $2_   ZQ ( ,,D( "[*$0 MRAT +,LI "O+
M-0 KS$  *LU* "C-5@ GSF$ )LYO 23.?P$CSY$"(<^E B#0O0(@S^0"'\WZ
M Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4  "<F@  D*$  (*H  !TKP
M9[8  %N\  !.P   0\,  #G'   OS   )] $ !_6"@ ;VA  &]L: !K;)@ :
MW#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4 %.&: !/BL0 2X\\ $N#T !+>
M_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !HN   6[\
M $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K'0 0ZR8
M#NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D  +Q_0 "
M[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@  3<@  $#,
M   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '^QP !/PD
M  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\ZP  _/\
M /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$  #+7   G
MW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(  /\7  #_
M'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@  _^<  /_\
M  #__P  __\  /__ 'RS  !LO   7<8  $[/   _U@  ,=T  "7B   :Y@
M$>H   SN   %\@   /\   #_    _P   /\   #_!0  _PH  /\.  #_$@
M_Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,  #_I   _[D  /_4  #_
MW@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#  _PLX ?\#1 '_ %$!_P!>
M ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_ *@ _P"O /\ M@#_ +X
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M ](D^07/)?\&S27_!\LE_PC*)?\(RB3_",HD_PC*)/\(RB3_"/\N% #_,1
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M-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_#_\U#@#_. < _SP" /]
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M%YA!_Q>80?\6ET'_%9=!_Q670?\5ET'_%?\[!@#_/P  ^48  .5+  #<3@
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M''96_QMV5O\;=E;_&_]%  #L3@  VE@  ,E>  "_8@  MV0  +%C  "K80@
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M(DYYPR)->.4B37?[(4YW_Q].=O\>3W7_'4]U_QU/=?\=3W7_'=]<  #(:
MN7(  *YZ  "E@   FH(  (Z"  " @P  >84" '2&$0!QB"  ;H@N 6J(.0)G
MAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748* &DZ!C1Q+@9L>28&L'TB
MP2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<27S_'-9A  #";@  M'@
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M$#.<_Q(SFO\2,YG_$S.9_Q,SF?\3,YG_$[UW  "O@P  HXL  )B1  "-E0
M@9D  '.<  !GGP  6Z(  $^F  !'J0@ 1*H2 $.J'P!!JRL 0*LW #^L00 ]
MK$H!.ZQ3 CFL7 ,WK&<$-:QS!3*L@08PK)$'+JRC""VLN DLK-D(+*KU"BNH
M_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP  G)$  )&6  "%G   >*
M &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 SMB$ ,K8L #&W-P PMT$
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M  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_   ]P@
M,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D  +A+@ !
MXCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\  .C_  #H
M_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   PRP  )<\
M !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K(0  [2L
M .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_  #W_P
M]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@  &=P  !'@
M   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%   ^!T  /HG
M  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_^0  __D
M /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8   CJ
M[0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q   /\8  #_
M(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0  _]4  /_5
M /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\ :0#_ '0
M_P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#  /\ S #_
M -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6
M)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z
M /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X R #] -D
M^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_
M&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\
M?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U -( \P#F
M /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>'0#_'AD
M_QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q /\&>@#_
M!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X ZP7D .D&
M\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_(1, _R 1
M /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.=0#T#GX
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M!;8E_P6U)?\&M27_!K4E_P6U)?\%M27_!?\L#0#_+04 _RX! /\Q!0#_,0L
M_2\0 /$K& #G*24 WR@S -@H0@#1*D\ S2M: ,DK90''*VX!Q"QV L(L?@+
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MD3S_#9$\_PV1//\-D3S_#?\U  #_.0  ZD$  -U&  #01P  R48  ,9!!0#
M0!$ N4(A +-$,@"O14 !JT5+ J=%50.D1%X%H41F!Y]#;@B=0W8*FT)^"YE"
MA@V708\.E4&9#Y-!I!&10; 2D$' $HY!V1*+0?$2B4+_$HA"_Q&(0O\0AT+_
M$(="_P^'0O\/AT+_#_\X  #S/0  XT<  -),  #(3@  P$T  +M* @"V1PX
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M%/)#  #?3P  RU@  +U=  "S80  JV(  *)@  ";7   E5X0 )!@'P",82X
MB&$Z H1@102!8$X&?E]6"7M>70MX764.=EQL$'-<=!-P6WT5;EJ(%VM:E!EI
M6:$;9UFP'&59PQQD6>,<9%GZ&F19_QAD6?\795G_%659_Q1E6?\495G_%.]&
M  #:4@  QEL  +IA  "P90  IF8  )UC  "580  CV(. (MD' "'92L @V4W
M 7]E0@-\9$L&>&-3"'5C6PMS8F(.<&%J$&U@<A-K8'L5:%^&%V9>D1EC7I\;
M85VN'&!=P1Q?7>$<7UWX&E]=_QA?7?\78%W_%F!=_Q5@7?\58%W_%>M*  #4
M5@  PUX  +9E  "L:0  HFD  )AG  "/90  B68, (5H&0"!:2@ ?FHU 7II
M/P-V:4D%<VA1"'!G60IM9V -:V9G$&AE<!)E9'D58V2#%V!CCQE>8IT;7&*L
M'%IBOQQ98M\<66+W&EIB_QE:8?\76V'_%EMA_Q5;8?\56V'_%>=-  #/60
MOV(  +-H  "I;0  GFT  )-K  "):0  @VL) ']M%0!\;B4 >&XR 75N/0)Q
M;D8$;FU/!VML5@EH;%X,96ME#V-J;1%@:78476F!%EMHC1A89YL:5F>J&U5G
MO1Q49]P<5&?V&E1F_QA59O\7567_%E9E_Q569?\55F7_%>)1  #*70  NV8
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M%D-Y_Q5#>/\41'?_%$1V_Q-$=O\31';_$\U?  "[:P  KG0  *1\  "7?@
MBGT  ']^  !R?P  9H,  &&$" !>AA, 7(<A %J'+@!8AS@!58=" E.'2@-0
MAU(%3H9:!TN&8@E)A6P+1H5W#4.$@P]!A)(1/X2B$CV$M1,\A,\3/(+P$CR!
M_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0  JGL  )^"  "2@@  A8(
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M!B2>_P<DGO\'))[_!Z]^  "CB   EXX  (V3  !^E0  <)@  &.;  !7GP
M3*(  $*F   XJ0  +ZP# "JN#@ IKA@ **\C ">O+0 FL#< );!! "2P2P C
ML58 (K%C "&Q<0 ?L8( 'K*4 1RRJ0$;LL$!&['G 1NO_@(:K?\"&JS_ QJK
M_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP  :*(  %NE  !/J0  1*T
M #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6O"H %;TU !2]0  3ODL
M$KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]^P /O/\ $+K_ 1"Z_P$0
MNO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M   .K8  "^Y
M   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &RSX !<M+
M  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*_P !RO\
M <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\  "/#   ;
MQ@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$  -L^  #<
M2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P  W_\  -__
M (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-   0T0
M"]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO  #K/
M[4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\  /#_ (&E
M  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   'W@   .(
M  #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X*P  ^SD
M /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U '2N  !E
MMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0   .P   #P
M    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P  _R@  /\W
M  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/) #_#B(
M_PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ A #_
M (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -, _P#G /\
M] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_$!X _PT=
M /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (<
M_P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B /@ \ #W
M /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+
M&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^ (, _ "*
M /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X [ #M /H
MZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_
M"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X \@"% /$
MC #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A /< WP#_
M -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2#@#_$A4
M_P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*  .8#AP#D
M XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@ S@K_ ,P+
M_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_&!$ _Q89
M /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-@P#6#8H
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M Z$F_P.A)O\#H2;_ _\I  #_*   ]BT  .<P  #?+P  V2L$ -8B"@#.(Q8
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M"O8V  #F0   T4@  ,--  "Y3@  L4T  *E)  "D108 GT83 )I((P"623(
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M$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE3_\,94__#.Q!  #43
MPU0  +99  "L7   H%H  )=7  "15   BU4, (97&0"#6"< @%DT 'U9/P%Z
M64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!#V95C1%D5)H28E2I$V!4
MNA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-7U/_#>=$  #/4   OU@
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M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/  ##6@  M&,  *EI  ";:
MCV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH &=L- !D;#T!8FQ& E]K3@1=
M:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(03&>A$DMGLA))9\D226?K$DEF
M_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@  L6<  *9M  "7;   BFL
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M"CAX_PHX>/\*.'C_"KYD  "P;P  I7@  )9Y  "'>0  >WD  '!Z  !D?
M6(   %"#  !+A0H 2(84 $>'( !%B"L 1(@U $.(/@!!B4<!0(E/ 3Z(6 (\
MB&$#.HAL!#>(> 4UB(<&,XB8!S*'J@<PB, ',(?D!S"%^P@P@_\(,(+_"#"!
M_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@  =G\  &J   !>@P  4X<
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M :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G   JJP
M(:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.  JV7  )
MMFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-
M  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   AM0  &+@
M !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##4   Q%\
M ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_ ).4  "'
MF@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P   $,,   K&
M   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P  U%(  -1C
M  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;  ![H@
M;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX   #2
MUP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(  .A4  #H
M9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !NJP  7[(
M %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A    Y
M .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!  #Z50
M^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0  4KT  $3$
M   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L    [P   /$
M  #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_00  _U8
M /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P = /\ ( #_
M "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (< _P". /\
ME #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^ /T _0#_
M /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\ &@#_ !\
M_P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P") /\ D #_
M )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D \P#_ /(
M_P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_ !D _P E
M /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /< BP#V )$
M] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F
M /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4 _P @ /\
M+ #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J (P Z "3
M .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4 _P#4 /\
MTP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,: /\ )@#]
M #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (< V@". -@
ME0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_
M ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P''P#Q RL
MYP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2) ,@%D #&
M!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\ M W_ +0-
M_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C"2( V@DP
M -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/C0"Z$)4
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M O\F  #R*0  XS$  -(T  #(-   P#   +LI @"X(PX L28< *PH*P"H*C@
MI"M$ *$L3@"?+5< G2U? )LM9P&9+6X!F"YU 98N?0*4+H8"DRZ0 I$NF@./
M+J8#C2ZS XPNQ0.*+^$$AR_V!(4O_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI
M  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L IR\7 *(Q)@">,S0 FC1
M )@U2@"5-5, DS5; 9$U8@&/-6D"C35Q HPU>0.*-8(#B#6+!(8UE@2$-:(%
M@C6O!8$UP 9_-MP&?3;T!GLV_P5[-O\%>C;_!'HV_P1Z-?\$>C7_!/4M  #D
M-P  T#\  ,)#  "W1   K4   *<Z  "C-@8 G3<3 )DY(@"5.B\ DCP[ (\\
M1@",/$\!BCQ7 8@\7@*&/&4"A#QM X(\=02 /'T$?SR'!7T\D@9[.YX'>3NL
M!W<[O AV/-4(=#SQ"',\_P=R//\&<CS_!7(\_P5R._\%<CO_!?$R  #>/0
MR40  +Q(  "P20  ID8  )]!  ";/0$ E3T0 )$_'0"-02L BD(X (=#0@"$
M0TL!@D-3 8!#6P)^0F(#?$)I!'I"<05X0GH&=D&$!W1!CPAR09L(<$&I"6]!
MN0IM0= *;$'N"6M"_PAJ0O\':D'_!FI!_P9J0?\%:D'_!>TW  #60@  Q$D
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M#%A/_0M83_\)64__"%E._P=93O\'64[_!]]#  #'30  N%0  *Q9  "=5P
MD54  (A4  "!4   >U($ '=3$0!T5!X <54K &]6-@!L5D !:E9( 6A64 )F
M5E<#9%9>!&)59@5@56\'755X"%M4A I95)$+5U2@#%53L U44\4-4U/F#%-3
M_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4   M5@  *A;  "96@  C5@
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M"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",8P  @&,  '9C  !J8@
M8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J10%0:DP!3FI4 DQJ7 -*
M:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>"3YG]PD^9O\(/V7_!S]E
M_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P  >V<  '%G  !E:   7&H
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M [%J  "E=   E78  (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0
M-8@) #*)$0 QB1L ,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P F
MBWH!)(N+ 2.+G@$BB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR
M  "A?   CWL  (!Z  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$
M ":3#  DE!, (Y0< "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0
M&9>& !B7F0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9
M@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V>
M 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]
M  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0
M@X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /
MJP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "N
MAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y
M &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP
M ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P
MO)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?
M  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"
M  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,
M ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,
ML@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T    -$   #2
M 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+
M  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O
M,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .    #B
MY    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #X
MDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD
M !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O    \0
M /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P
M_YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\
M. #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P";
M /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\
M^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_
M $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H
MG0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_
M .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P
M_P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M
M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$
M_P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!#
M /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H
MW0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#,
M /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D
M2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"=
M ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\
MO #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3
M $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H
MH0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_
M /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4
MP -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K
M":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7
M  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y)
M +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8
MGA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T
M'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *49
M30"B&58 H!I= )X;90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO
M ) >OP"/']@ C"#Q 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@
MVBT  ,HP  "^+@  M2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7
M)%$ E219 ),E8 "2)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80G
MNP&#*-$!@"CN 7XI_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4
M ,$X  "T-@  JS$  *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P
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M!60\^@1D//\#8SO_ V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10
ME4,  (Y   ")/   A#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P
M05D!;D%@ FQ!9P)J07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!
M^05=0?\$74#_ UU _P-=0/\#74#_ ]\Y  #(0P  N4H  *E+  ";20  D$<
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M!$U-_P1.3/\#3DS_ \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30
M;$\  &A0"P!E414 8U(A &%3+ !?4S8 750_ %M41P!:5$X!6%16 59470)4
M5&8#4E-O U!3>P1.4X@%3%.7!DM3IP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1
M_P1)4/\#25#_ \I(  "Y4@  JE<  )A6  "*50  ?U0  '93  !L40  9U,
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M [Q5  "M7P  G&   (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H
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M 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@
MBFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G
M@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$
ME0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(
M '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X
M&HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /
MCZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W
M  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.
M  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL
M )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=
M@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E
M$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H
M  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C
M29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#
MLA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "U
MM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\
M #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^!@  OPP
M , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0
MQ\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS
M   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,    S0,  ,X)
M  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4
M -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4
MP@  #,8   /)    S    -    #5    V0   -H   #<    W@   .    #B
M!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_
M  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@
M -(   #7    W    .    #E    YP   .D   #K    [0   .\   #Q
M\P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_
MO@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/
M /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *,
M_P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I
M /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\
M5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F
M /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\
MW@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[
M %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8
MJ0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_
M /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0
MZ@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/
M *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*
M!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7
M -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@
MO0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_
M!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,,
M60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O
M *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P
M] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R
M %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!
MN0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0
M -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4
MI E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2
M#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA
M  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7
M )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD
MA!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S
M)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<
M60")'6  B!UG (8>;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D
M '<B^0!V(O\ =2+_ '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@
MH"H  )LF  "8(0$ E1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_
M)EP ?B9C 'PG:P![)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI
M]P%L*?\!:RG_ 6LI_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(
M )(M  ".*0  BR<, (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@
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M E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P
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M TM%[0-+1/\"2T3_ DM#_P),0O\"3$+_ LH_  "Y2   IDH  )5)  "'2
M?4<  '5%  !N0@  :4,  &5$"0!B11, 7T8> %U'* !<2#( 6D@[ %E)0P!7
M24H 5DE2 %1)60%326$!44EK 4])=@)-28("2TF1 TI)H0-(2;,#1TG* T9)
M[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3   HDP  )%,  "$2P  >4H
M '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!63"\ 54TX %--0 !234@
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M C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X5   ;50  &14  !85
M4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<-@!!7#X /UQ& #Y=3P ]
M75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W" C%<Y0(Q6_P",5K_ C%9
M_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P  :5<  &!8  !460  3EL
M $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y8CH .&-" #=C2P V8U0
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M :9F  "190  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O   P<P
M*78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5
M?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK
M  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I>P  (G\
M !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'4P +AV$
M"H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_ )5Q  "#
M;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0  &XD  !2,
M   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P  DUD  )-I
M  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW  !]=0
M<'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0   Z7   )
MFP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%   *!?  "@
M<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X?   :7P
M %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D    IP
M *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4  "O9@
MKWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA   88<  %.+
M  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R    M@   +<
M  "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  # 6@  P6X
M ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690  $N:   ]
MH   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q    ,4   #&
M    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53   UF   -AW
M  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J   UL
M*+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,   #6
MV    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$  .YG  #O
M@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   JO@  ',(
M !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F    Z
M .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5  #_;@
M_XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D _P E /\
M,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_ (L _P"1
M /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8 _P#V /\
M[P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @ /\ +0#_
M #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8 ]@", /4
MD@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G /\ Y0#_
M -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\ * #_ #4
M_P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"& .8 C0#D
M ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\ T@#_ ,X
M_P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S "X [P Z
M .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$ AP#/ (X
MS0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_ +X _P"]
M /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "< W0 S -D
M/@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "] (@ NP"0
M +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X _P"N /\
MK@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L ,0 . #!
M $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M (( K "* *H
MDP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P"> /\ G@#_
M /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0 ,0"Q #L
MK@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"% )P C@":
M )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\ CP#_ /T*
M  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E #0 H@ ^
M )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $B@".!)4
MC 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F
M%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X E@HX )0+
M00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"##I, @0^?
M ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0
MQB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R (D3/ "'
M$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08
MJ@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0*0  O"L
M *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<-P!\'4
M>AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I
M(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P  M#$  *,P
M  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S)3P <25#
M ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(II !@*;4
M7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34  )TT  "0
M,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M
M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0 7"^2 %HOH0%9+[(!6##(
M 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "].@  J#D  )<X  "*-P
M@#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q*P!D,C0 8S(] &$S1 !@
M,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360 50UGP%2-; !437& 5 U
MYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0  HSP  )(\  "%.P  >SH
M '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>-S$ 73@Z %LX00!:.4@
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M 3]!_P% 0?\!0$#_ ;]!  "J10  ED4  (9%  !Y1   ;T0  &="  !@/P
M6T$  %="  !40PT 4405 $]%'P!.12@ 3$8Q $M&.0!*1T$ 24=( $A'4 !&
M1U@ 14=A $-(; !"2'@!0$B' 3Y(EP$\2*D!.TB^ 3I(WP$Z1_@!.D;_ 3I%
M_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P  :T<  &-&  !;0P  5D4
M %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%2SX 0TM& $),30!!3%8
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M :]1  "840  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5   [6
M.%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I
M76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\ )%C_ *A5
M  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V70  ,& %
M "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D7  A9&D
M'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__ *%9  ",
M6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P  *F8  "1I
M"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT
M !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=  "%70
M=5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T  !YP 0 7
M<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU
M@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_80  <&$
M &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y   1? 0
M#7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G  !_>0
M?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P  :V8  &%F
M  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,A@( !HD*
M  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+<0  BX8
M (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P  %IM  !.
M;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@   )0&  "5
M#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:   F7T  )F4
M  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V  !&>@
M.W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$   "B!@
MH@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(  *B)  "H
MH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^AP  ,HT
M ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P    L00
M +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]  "ZEP
MNK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP  *IT  !^B
M   5IP  #:P   6P    M    +<   "[    O@   +\   #     P0   ,,!
M  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1B   T*0
M -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T  !:S   .
MN   !KP   #     PP   ,8   #+    S0   ,X   #0    T0   -0   #6
M    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>   ZY0  .NO
M  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["   $Q0
M ,H   #-    T0   -@   #;    WP   .    #B    Y    .8   #I
MZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(  /^=  #_
MM0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_ #L _P!'
M /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X DP#] )D
M^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_ .  _P#8
M /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8 _P!! /\
M3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O )0 [0";
M .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$ _P#, /\
MR #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [ /< 1@#S
M %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X W "5 -H
MG@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_
M /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .< 0 #B $H
MW0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/ ,0 F #"
M *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\ L #_ /\
M  #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+ $, QP!,
M ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +( D@"P )L
MKP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_ /\   #_
M    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T M0!& +(
M30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@ )8 GP"A
M )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\   #U
MYP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _ *, 1P"A
M $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$ D "< (X
MJ0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I#   U X
M ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8 00"4 $D
MD@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8 (( I0"
M +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0  Q14  +04
M  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(!$, A@5+
M (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*HP!U"K,
M<PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T  *D<  "=
M&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX ? Y& 'L.
M30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K$K( :1+'
M &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C  "4(0
MBQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9! '$62 !O
M%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;
MY !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",*   @R4
M 'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>1 !F'TL
M91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5
M(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0  ?"L  '8H
M  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?)D@ 729/
M %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\IW@!.*?<
M32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C   ' M  !K
M*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M
M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(+_8 1R__
M $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR  !F+P
M8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43)) % R4 !.
M,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S
M_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A,P  73(
M %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW3@!).%8
M1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_ #TW_P ]
M-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P  6#8  %0W
M  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ<
M $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[_P X._\
M.#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH  $\[  !,
M/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$ /4%: #Q!
M9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S/_\ -#[_
M +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I   !&004
M1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98 #9&8@ U
M1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#
M  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!1@$ /D<,
M #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+7P O2VL
M+4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_ *=&  "1
M1@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P  -TP) #5-
M$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H4&@ )U!W
M "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)  ",20
M>DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($ "U3#0 L
M5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4 'U9T !Y6
MA0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&30  =4T
M &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:"0 C6Q
M(EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP !5=@0 4
M794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40  <%$  &11
M  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :8PP &&01
M !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE?0 -99$
M#&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4  %]5  !6
M50  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4 $&T-  YN
M$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ ";HH  &V?
M  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9  !360
M2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*  5W$  !
M=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0  'B9  !W
ML   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-7P  0F(
M #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!#0  @1$
M ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23  "#J@
M@L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P  /&L  #%O
M   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0  C0X  (X1
M  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1H@  D;P
M )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8  "I[   @
M@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@  )P-  ">
M$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@  H;,  *#8
M  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*   7CP
M$)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&  "M"P
MKQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@  +3&  "S
M[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0GP  ":0
M  "I    K0   +    "T    MP   +@   "Y    NP   +P   "^ @  P @
M ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX  #*W0
MRO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L    +4   "Y
M    O0   ,$   #&    R    ,D   #+    S    ,X   #0    T@   -0%
M  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #EQ0  Y><
M .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4   #)
MS0   -(   #6    V@   -L   #>    X    .(   #D    YP   .D   #M
M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP  _<<  /WD
M /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\ 30#_ %<
M_P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"< /< I0#U
M *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\ R@#_ /\
M"@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9
M /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@ GP#F *D
MXP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_ /\  P#_
M    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L [ !4 .@
M6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/ *( S0"N
M ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\   #_
M_P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!- -$ 50#.
M %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P N0"G +<
MM0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_    _@
M /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P 3@"Z %4
MMP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@ *4 K0"C
M +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\    [@   .
M  #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H $\ I0!5
M *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4 IP"3 +<
MD0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP   ,D   "]
M    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D E@!/ )0
M50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"% +$ @P#$
M ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'  "L P
MI@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!) (< 4 "&
M %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P =@"^ '4
MW0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">#@  EPL
M ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P 2P!Z %$
M>0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H
M!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0  BQ(  (80
M  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P"DP ;PI3
M &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -V !>#O,
M70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H  'L7  !X
M$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D 9A%/ &01
M5@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_
M %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>  !O&P
M;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+ %P94@!:
M&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<
M_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H(0  9AX
M &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@3P!3(%<
M42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&
M(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@  7R0  %TB
M! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,)E0 2R=<
M $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H_P! )_\
M0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@  %<G  !4
M)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$ 12Q: $0L
M9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_
M +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L  !/+0D
M3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ]
M,FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS
M  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !),08 1S(/
M $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV7P W-FL
M-C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2
M-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@, 03<- #\X
M%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV
M "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X  "..0
M?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+ #H\$0 X
M/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E
MA  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*/   >#T
M &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!#P R0A8
M,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q "-%@@ B
M194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P  =$   &=
M  !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K2!( *D@:
M "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*?P ;2I(
M&DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,  &-#  !8
M0P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A  (DX6 "%/
M'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  44(\ $U"D
M !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'  !51P
M34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81 !E6&  7
M5B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP #5>@  M7
MM@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !12@  2DH
M $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>$P 07AH
M#EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;  )>L0 "
M7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@  1TX  #Y/
M   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &9Q4 !6<<
M  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !FK   9<<
M &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,  #E5   P
M6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(  &\8  !P
M'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP  ;\$  &_G
M  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=   J80
M(F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3  ![&0
M?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H  'OB  !Z
M^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C:P  &F\
M !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "($P  B1D
M (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8  "(]P
MB/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>   $WT   V!
M   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@  F!(  )H8
M  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":\   F?\
M )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P   21
ME0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P  *H1  "M
M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@  K/P  *S_
M %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B    I@
M *H   "N    L    +$   "S    M    +8   "X    N@0  +P*  "^$
MP1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\
M  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R    MP   +L
M  "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2"   U0X
M -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T $Z+  !
MD@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R    ,X   #1
M    U    -4   #8    V@   -T   #?    X@   .0   #G    ZP4  .\.
M  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\ "P#_  @
M_P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_
M &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H \@"W .\
MR0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_    _P
M /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /< 7 #T &,
M\@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P -T P #:
M -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_    _P   /\
M  #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A %P W@!C
M -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0 MP#! ,P
MP #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P   /H   #R
M  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8 Q !< ,(
M80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N ,$ K0#@
M *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@   #<
MT  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5 *X 6P"L
M &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@ F@#0 )D
M[P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%    NP %
M +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P 50": %H
MF !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#% (@ Y@"'
M /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S    J@   *,
M"@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"* %0 B0!:
M (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H VP!X /4
M> #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP   )8 !0"1
M  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\ ? !5 'H
M6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L .X :P#_
M &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"  "%  D
M@0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0 &X 5@!M
M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D 8 #\ &
M_P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y"0$ > ,+
M '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$4@!C!5D
M8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5
M"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$   ;0T% &T)
M#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;#58 60U>
M %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0_P!-$/\
M31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0  &00" !B
M#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U, 41-; % 3
M90!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%%?\ 117_
M +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7 @!:%0T
M5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8 $@:8@!'
M&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C
M  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3' L 41P2
M $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@7P! (6H
M/R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_ *HF  "4
M)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@< 2B(0 $@B
M%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z)F< .29U
M #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I  "/*@
M?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<- $(H% !!
M*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K
M@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "++0  >2X
M &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL$0 [+1D
M.BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P "PP@  J
M,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',   =C$  &@R
M  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V,A8 -3(>
M #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U?@ E-9
M(S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0  &4T  !:
M-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q, +S<; "XW
M(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB
M !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W  !7-P
M3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8 "@]'P F
M/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP &#^@ !8_
MM0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3.@  2SH
M $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"&P @0R,
M'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2> !%$LP 0
M1-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0  2#T  $(]
M   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 821X %TDF
M !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*L  *2LH
M"TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14   #]    Y
M00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D $% A  ]0
M*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "4,4  T_H
M  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$   U10
M+D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<  =8)  &
M6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\   %;E  !6
M^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P2@  *4T
M ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@'P  8"<
M & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B  !>^0
M7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40  (U0  !Q7
M   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0  :B$  &HI
M  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H]P  9_\
M &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T  !9@   0
M9   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L  '8C  !W
M+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0  <_\  '+_
M &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L   *<
M!',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;  "%)
MAB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\  (#_ %];
M  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !?@   ($
M  "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5&P  ER8
M )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_ %UA  !/
M80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@   )(   "6
M    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P  J1P  *HH
M  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H  !(;
M.G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,   "G
MJ@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(  , <  #
M+0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  ! >0  ,G\
M "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y    O
M +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42  #6(0
MUS0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0  *Y   !V8
M   2H   "J<   "N    M    +D   "^    P@   ,@   #+    S@   ,\
M  #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O$P  \"4
M /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P % /\ "P#_
M !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0 _P!J /\
M< #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I .0 YP#Y
M .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\  @#_  L
M_P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C .P :0#J
M &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0 SP#R ,T
M_P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_  8 ^0 /
M /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0 8P#1 &@
MSP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H +@ _0"W
M /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $ Y  , -X
M$P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G
M +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *, ]0"C /\
MH@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP ' ,$ #P"\
M !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H HP!@ *$
M9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1 /\ D #_
M )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L # "G !(
MI  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !: (\ 7P"-
M &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D ?P#_ '\
M_P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5  X D@ 5
M )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\ 60!^ &
M? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_ '  _P!P
M /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L @P 1 ($
M& !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P %H ;P!B
M &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &, _P!C /\
M9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P . '4 $P!R
M !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8 8P!= &(
M90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_
M ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L $ !I !8
M9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7
M &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0
M  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A!!$ 7@,9
M %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )7P!."6D
M30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9
M%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T 5PP4 %4,
M' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U
M $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9  "2&P
M@1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0 $X1& !,
M$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4 /A5R #P5
M@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-'@  >R
M &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7%0!%%QP
M1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO #4;?@ S
M&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@  =R,  &DD
M  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _'1D /ATA
M #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@?  M(8X
M+"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8  &4G  !;
M)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8 ."(> #8C
M)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H)8P )B6?
M "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J  !7*@
M3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P
M*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH (2J= !\J
ML@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4+   3"P
M $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL'P J+28
M*2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^; !HOL  8
M+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P  22\  $,O
M   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E,B, )#(J
M ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0SK@ 3,\@
M$S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(  $ Q   [
M,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R  'C<G !TX
M+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK
M ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT   X-
M,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC !8]*P 5
M/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$ "CWD  L]
M^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U-P  ,#<
M "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$)P /1"\
M#D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@  -#]@ $
M0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@  +3L  "<]
M   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (2BL !THT
M  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)]0  2/\
M $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4   "-"   =
M10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428  %$O  !1
M.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0  3_\  $__
M &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(   72P
M$DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI  !:,P
M6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\  %?_ &5%
M  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   24P  #E8
M  I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D+0  9#@
M &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_ %]*  !3
M2@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70  "&    )C
M    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@  <3$  ' ^
M  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/  !03@
M2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L   !O
M<@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@  ( U  "
M10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.4P  0E0
M #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]    @
M (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L  "2.P
MDDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@  .UT  "]A
M   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".    D0   ),
M  "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F,0  ID,
M *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD  "=N   ;
M=0  $7P   N#    B0   (X   "3    F    )T   "A    I    *4   "G
M    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0  O#<  +M,
M  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_   3A@
M"XX   &5    FP   *$   "F    JP   +    "S    MP   +<   "Z
MO    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L  -1   #3
M6   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -F0   Z
M  "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-    SP
M -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS  #N2P
M[V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X _P 5 /\
M'@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W
M /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .( _P#; /\
MRP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0 /\ &0#_
M ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H Y !P .(
M=@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#% /\ NP#_
M +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X
M[  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$
M '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4
M_P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B
M ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X
MJ@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3
M /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !, L0 < *\
M)0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N
M )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\
M@@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8
M "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G ((
M;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_
M .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$
MA  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q
M ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(
M  "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V !P =  C
M ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T
M8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J
M 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8
M)0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S
M %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0
MC0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!;
M "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P
M?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q
M '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ",
M40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!"
M XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4
M  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E
M $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H
M. R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>
M&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.
M* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"<
M "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'
M41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z
M$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5
MK@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\
M $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@
M,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A
M&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A
M   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL
M "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\,
M&Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \
M(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C
M,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E
M !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@
M-28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @
M*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H
M^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@
M "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3,
M&"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .
M+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK
M   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y
M !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\
M"S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C
M,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX
M/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_
M ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P
M&S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %
M/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR
M  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H
M !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$
M $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8
M-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"
M   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)
M  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P
M23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (
M3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !4
M4@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\
M #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92    5
M %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3
M7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!
M   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;    7@   &
M  !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8
M &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L
M2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@   &P   !N
M    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB
M  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P
M'%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P   !]
M?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+
M;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4
M  UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".    D0
M ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90
MH($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[
M    @0   (<   "-    D@   )8   ":    G0   )\   "A    I    *8
M  "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78
M +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".
ME    )H   "@    I0   *H   "N    L0   +(   "U    MP   +H   "\
M    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*
M  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A    IP
M *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X   #2
MU0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #K
MF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O
M /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (
M\0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P
M /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L
M,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"
M -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\
MH0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C .4 +0#>
M #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D
M@0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_
M /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\
MNP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"?
M (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<
M  #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P
M )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L
MB0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7
M    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L
M,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_
M '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_
MK    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W
M #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8
MA@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP
M (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P
M9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7
M )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\
M  !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L
M %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H
M2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J
M"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %
M+0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8
M $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0
M6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!&
M "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@
MIP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q
M $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL
M/00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O
M!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3
M  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN
M #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L
M)0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _
M%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /
M,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@
M !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0
M.!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H
M$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5
M^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L
M #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0
M(AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4
M&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=
M   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ
M !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\
M$1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G
M(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C
M00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_
M '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P
M(",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0
M*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B
M  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<
M !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48
M"BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=
M)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L
M   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).
M  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@
M3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0
M,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X
M6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\
M #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$
M"CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5
M/F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR
M   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %
M  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\
M $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R
M-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(
M!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM
M  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P
M*3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\   !1!
M4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8
M?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X
M !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;    70(
M %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P
M9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*
M   03@  "E(   -6    6@   %T   !@    8P   &4   !G    :0   &L!
M  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL
M '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )
M6@   5\   !C    :    &L   !O    <@   '4   !W    >0   'L   !]
M    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@
M  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED    :0
M &\   !T    >    'P   "!    A    (<   "(    BP   (X   "0
MDP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9
MM0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T    >P   ($
M  "&    BP   )    "4    EP   )D   "<    GP   *$   "D    IP
M *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@
MKL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@   )4   ":
M    GP   *0   "H    K    *T   "P    LP   +4   "X    NP   +\
M  ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X
M ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@   "N
MM    +@   "]    P    ,(   #%    R    ,L   #.    T0   -8   #;
M    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4
M /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X
M_P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J
M )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\
M  #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !
M .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$
MQP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z
M    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L
M0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5
M *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O
MYP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N
M $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0
MFP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0
M +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D
MDP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^
M *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<
M  "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X
M 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H
M:@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")
M    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P
M-P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E
M %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y
M<0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!<
M #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X
MM !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K    9
M &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$
M3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !"
M ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!
M  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R
M $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\
M. #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)
M!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L
M-  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#>
M "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#
M/PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S
M #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "<
M\@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X
M #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0
M*P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?
M!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0
M   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ
M "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P
M& S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K
M$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X0
M0@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_
M '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0
M)A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7
M%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5
M  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<
M " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@
M$1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>
M&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:
M   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1
M  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0
M31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5
M'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B
M6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$
M $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A   2(P(
M$"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@
M)V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD
M   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'
M  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,
M "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R
M)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O
M"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R
M   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0
M*2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0
M-0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   X
MA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H
M "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH
M #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @
M/YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M
M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!   0P<  $4+
M  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<
M $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6
M-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0  $X'  !/
M"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N
M  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0
M#$$   =$    2    $H   !-    4    %,   !5    5P   %@"  !;!@
M70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<
MS   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL
M  !/    4P   %8   !9    7    %\   !A    8P   &4   !G 0  :@4
M &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0
M:?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=
M    80   &4   !H    :P   &X   !Q    <P   '4   !X    >P   'X#
M  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<
M 'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@   !M
M<0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@   )(   "5
M 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z
M #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "     A
M (H   ".    D@   )4   "7    F@   )T   "@    HP   *<   "K
MKP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5
M   D6P  &&$   YI   %<0   'D   "!    B    (\   "4    F@   )\
M  "D    J    *D   "L    KP   +,   "U    N0   +T   #!    Q@
M ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <
M:0  $7$   =[    A    (T   "5    G0   *,   "I    KP   +0   "Y
M    O    +X   #"    Q0   ,@   #,    T    -0   #:    WP   .0
M  #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_
M_P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^
M %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .
MM0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@
M /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D
MX@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[
M ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<
M  #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!(
M +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4
MH #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&
M    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$
M1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$
M (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8   "I
MH0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"(
M $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ',
MWP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3    B@
M (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X
M<@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A
M /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^    >    ',
M  !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \
M &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D
M4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P   &,   !@
M    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %(
M/ !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\
M $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8   !3
M40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!%
M #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L
M_P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)    1P
M $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@
M.@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R
M /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P
M P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [
M #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\
M*@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T
M @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D
M/P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_
M 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0,
M+08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B
M 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,
M  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP%
M "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0
M&@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?
M$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-
M!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/
M !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0
M3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <
M#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X0
M70 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4
M $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8
M%A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )
M%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8
M   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8(
M !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,
M AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R
M&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;
M"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR
M   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0
M*1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )
M'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   A
MA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX
M "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT
M B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P
M)9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?
M   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.
M   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH
M "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <
M(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q
M#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S
M   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P
M%"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*   Y#0
M.A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   W
MVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H
M  XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!"@  0PX
M $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@
M/_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT
M   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P  3 L  $X.
M  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@
M $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H   (]
M0    $0   !'    20   $P   !/    40   %,   !5 0  6 8  %H+  !=
M#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_
M #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)    3
M %    !3    5@   %D   !;    70   &    !B    90   &@%  !K"P
M;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y
M   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6    6@   %X
M  !B    90   &@   !K    ;0   '    !S    =@   'D   !]!   @0L
M (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L
M/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P   &\   !T
M    >    'L   !^    @    (,   "&    B@   (T   "1    E@,  )L,
M  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$   E2
M&DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0   ")
MC0   )$   "3    E@   )D   "=    H    *0   "H    K    +(#  "W
M#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL
M  IB    :@   ',   ![    @@   (D   ".    E    )H   "?    I
M *8   "I    K0   +    "S    MP   +L   #     Q0   ,L   #1!
MU0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T
M    ?0   (<   "0    EP   )X   "D    JP   +$   "V    N@   +P
M  #     Q    ,@   #+    SP   -0   #:    X    .8   #K    \08
M / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T
M  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /<
M6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V
M ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D   #I
M[  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3
M %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X
M_P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;    W
M -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\
ML@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ",
M /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\    M@   +
M 0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!-
M )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\
M<P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F    )0   "1
M  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X
M2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_
M &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P   !Z  $
M>  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H
M $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0
M_P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F    90 $
M &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $,
M5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!'
M /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7    50 ! %0
M!P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$
M $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\
M/@#_ )0   !_    ;P   &,   !9    40   $T   !*    2    $< ! !'
M  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P
M1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_
M (@   !T    90   %@   !/    2    $,    _    /0   #P  @ \  <
M.P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P
M $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\
M  !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R  4 ,@ )
M #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8
M)P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E
M!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D
M"P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !.
M !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"
M40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B
M 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@
M5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P
M $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L
M' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2
M V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/
M   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD,
M !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$
M#0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R
M$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,
M#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ
M  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@
M*!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .
M#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0
MA   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0
M "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T
M"Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@
M$IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5
M   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/
M  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6@   %ID
M !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9
M%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:
M$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS
M   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P
M%18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$
M(!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >
MVP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<"
M !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$
M "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@
M(OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;
M   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3
M   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L
M "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +
M(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T  #81   V
M%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__
M #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE   &*
M BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .  !!$@
M01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH
M   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M    ,    #,
M   V    .    #L    ^    0    $(   !% @  1P8  $H*  !-#@  314
M $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M
M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@   #T   !
M    0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9
M  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P   L+@
M)RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D   !,
M3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP  &P2  !K
M'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(
M !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;    7P
M &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-  ""%@
M@"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)
M   +10   DL   !1    5@   %L   !@    90   &D   !N    <@   '8
M  !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<#@  FQH
M )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "
M5    %L   !A    :    &X   !S    >0   'X   "#    B    (P   "/
M    D@   )4   "9    G0   *$   "E    J@   +    "W!P  N!$  +4A
M  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<    9
M &T   !U    ?    (,   ")    CP   )4   ";    H    *,   "F
MJ0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H  -86  #2
M*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N    =P   '\
M  "(    D    )@   "?    I0   *T   "S    N    +H   "^    P@
M ,8   #*    S@   -,   #:    X    .<   #M    \P   /0.  #R'@
M[S8  .Q1  #H;@  Y)   -^Q                       ! P0%!@@)"@L-
M#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&
M1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z
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M________________________________________________
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M^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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MQVZLG\=NK)_';JR?QVZLG\?_GAX$_YTI"?^I,@[_MCH4^L)#'_#.2B[GW4]
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M;+2RO6RTLKW_FAL#_YDF"/^G+0K_M38/^<$_%^[.1B/DW$PRW>=/2<_H5E[
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M5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU39N@4
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
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M9DC_F'%6^Y-\8O2-AFWNAXYWZ("5@.1ZG(?@=:*,W7*HD=IOKY78;;>9U6O
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M8E#VRF)0]LIB4/;*8E#VRF)0]LIB4/;*8E#VRF+_HPL UK@& ,;$!P"[U D
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M?53#X7U4P^%]5,/A?53#X7U4P^%]5,/A?53#X7W_AQ,!_YP2 ?^N$0#:P@H
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M:EVD[VI=I.]J7:3O:EVD[VK_>1$!_XP. /^>#0#<K@@ TKL) ,S("0#'U@X
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M)CK_KR8Y_[HG./_*)SC_W"@X_]PH./_<*#C_W"@X_]PH./_<*#C_W"BUKP
MI[H  )K&  "-U   @>8! 'K_$ %P_Q@"9_\A!5__*0=8_S$*4O\Y#4W_00])
M_T@11?]/$T+_511 _UP5/?]B%CO_:1<Y_W 8-_]Y&37_@ADS_XP:,O^7&S#_
MH1LO_ZH<+_^U'"[_OQPN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQRIM0  FL(
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M7VZ,]U]NC/=?;HSW7VZ,]U__;!,!_WT/ ?^-$ #_FQ  ]*@/ .6U#0#5OQ
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M1T7AS$=%X.A'1=_V1D7>_T1%WO]$1=[_1$7>_T1%WO]$1=[_1$7>_T39EP
MQZ8  +BP  "LN0$ HL4" )C1!@"/ZPT B>X? H#N*P9X[30,<.T]$VCM1AEB
M[4X>7>U7(UGM8"=5[6@J4NUQ+4_M>2],[8,R2NZ--$?NF#5%[J4W0^^S.$+P
MQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA [/\X0.S_.$#L_SC+H   NJL
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M%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,  !ZV@
M;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O] "#/_10@P
M_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^ #1[_C X=_Y<.'/^A#AO_
MK \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !KXP  7_8
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M O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X:3C.<W-
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M47Y]_U%^??]1?GW_47Y]_U'_8Q0!_W(/ ?^!$ #_C1$ _)@2 .RA$P#?JA8
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M64^NQEE/KN184:[V5%.N_U!4K/]-5*S_352L_TU4K/]-5*S_352L_TW_?0
MWX\  ,Z=  ##J ( N; " +"Z @"HQ 4 H<P/ )O,(P*2RC,*B<@_%8'&21]Y
MQ%(H<L):,&O!83=FOV@\8;YP05R]>$58O(%)5+R+3%&[ED].NZ-13+NS4DJ[
MQE)*N^113+OV3DVZ_TM.N?])3KG_24ZY_TE.N?])3KG_24ZY_TGOA0  U)4
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M+CWH_"X]Y_\M/>?_+3WG_RT]Y_\M/>?_+3WG_RW%GP  M:D  *BQ  "<O
MD,<  (32 0!ZWP8 =/03 &WT( )F]"H$7_0T"%KU/0M4]44/3_5,$DSU511)
M]ET71O9E&$3V;AI!]G<</_>!'3WWC1\[]YD@.?BF(3CXM2(W^<@B-OGC(C;X
M\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@  J:X  )RY  "0Q   @\\
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M"A3_LPH4_[,*%/^S"A3_LPJ3NP  A,<  '73  !GX0  6.@  $[[  !(_P
M0?\* #O_$ $V_Q4!,?\< 2W_(@(I_R@")?\M B+_,@,?_S@#'/\] QK_0@,7
M_T@$%?].!!/_5001_UT%#_]G!0W_<@4,_WT%"O^)!@K_DP8)_YP&"?^<!@G_
MG 8)_YP&"?^<!@G_G ;_/RH"_S\P _]$, /_2#,$_TDY!O](0@C_1DT+_T5;
M#O]#:1'_07<3_T"%%?\_D1;_/IL8_SZD&/\]JQG_/;,:_SVZ&O\]PQK_/,P;
M_SS;&_\\YQO_// ;_SSX&_\]_QO_/?\;_SW_&_\]_QK_/?\9_SW_&?\]_QG_
M/?\9_SW_&?\]_QG_0"H"_T$N _]'+@/_2C$$_TPW!O]+0 C_2DL+_TA9#_]&
M9Q'_1'44_T."%O]"CQC_09D9_T&B&O] J1O_0+$;_S^X'/\_P!S_/\D=_S_6
M'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y _QO^0/\;
M_D#_&_Y _QO_0"H"_T,L _])+ /_32\$_T\U!O]0/@C_3DD,_TQ6#_]*9!+_
M2'(5_T=_&/]&BQG_198;_T2?'/]$IQW_0ZX>_T.U'_]"O1__0L8@_T+1(/]"
MXB'_0NTA_T+U(?]"_2']0O\A^T/_(/I#_Q_Y0_\>^4/_'OE#_Q[Y0_\>^4/_
M'OE#_Q[_02D"_T8J _],*0/_42P$_U,R!O]4/ C_5$<,_U%2#_]/8!/_36\7
M_TQ\&?]*B!S_29(>_TB;'_]'HR'_1ZLB_T:R(_]&NB/_1L,D_T7-)?]%WB7_
M1>HF_$7T)OE%_";V1?\F]4;_)/1&_R/S1_\A\T?_(?-'_R'S1_\A\T?_(?-'
M_R'_0B@"_TDG O]0)@/_52@$_U@O!?]:.0C_6D0,_U=/$/]57!3_4VH8_U%W
M&_]/@Q__3HXA_TV7(_],GR7_2Z<F_TJN)_]*MBG^2;XJ_4G)*OI(V2OW2.<L
M]$CR+/%(^RSO2?\J[4K_*.Q*_R?K2_\EZTS_)>M,_R7K3/\EZTS_)>M,_R7_
M0R@"_TTD O]4(P/_6B4#_UXL!?]@-@?_8$$+_UY,$/];5Q7_6689_U=R'O]5
M?B+^4XDE_%&3*/I0FRKY3Z,L]TZJ+O9-LB_T3+HP\TS$,O)+T3/N2^0TZDKP
M-.=+^C/E3?\PY$[_+>)/_ROA4/\IX5#_*>%0_RGA4/\IX5#_*>%0_RG_1B4"
M_U A O]8( +_7R$#_V0J!/]F,P?_9CT+_V5($/]B4Q7_8&$;_%UM(/A:>27U
M6(0I\U:-+?!4EC#N4IXS[5&E->M0K3?I3K4YYTZ_.^9-S#SC3. ]WTWN/-Q/
M^3G94?\UUE+_,M13_S#35/\MTU7_+=-5_RW35?\MTU7_+=-5_RW_2B,"_U0>
M O]<' +_9!\"_VDG!/]L, ;_;3H*_VQ$#_UJ3Q7X9UP<\V-H(N]@="CK77XN
MZ%J(,^57D3?C59DZX%.@/MY2J$#<4;%!V5"[0M90R$/34-Q$SU#L0\Q2^#_+
M5?\[R5?_-\A8_S3'6?\RQEG_,<99_S'&6?\QQEG_,<99_S'_32 "_U<; O]@
M&0+_:1T"_V\E _]R+07_=#<(_7-!#O9Q2Q3P;E@<ZFID).5E;BO@87DSW%Z"
M.-A<BSS36I0_T%B<0LY7HT3+5:Q&R56U1\=4P$G%5-!)PE/F2<!6]46^6?]
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M08]Q_T&/<?]!CW'_08]Q_T'_6Q0!_V@/ /]U#P#_@!$ _XD3 /*0%P#EEAP
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M65^-PUI>C>!88H_U4F20_TUFD/](9H__1V:/_T=FC_]'9H__1V:/_T?_; @
M_GP  -Z*  #0E@( R)\$ ,"G! "YK@, LK(4 *JQ* .AKS<,F:Q#%Y&H32&)
MI54J@J-<,GR@8SEWGFH^<IQQ1&V:>4AHF8%,9)>+4&"6E5-=EJ)56I6P5UF5
MP5=8E=Y66Y;S4%V7_TQ?E_]'8);_1F"6_T9@EO]&8);_1F"6_T;_< , ZX$
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M0TJU_T%+M?\^2[3_/4NT_SU+M/\]2[3_/4NT_SWB@P  S9(  ,&?  "TIP
MJJ\  *"X  "6P , C,H' (;-% "!S28">LPU"'/+00]LRDH79LE3'6'(6R-<
MQV(H6,9J+%3&<C!0Q7PS3<6&-DK$DCE'Q)\[1<2N/$3%P3Q#Q=\\1,3S.T3#
M_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "KK   H+0
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M&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5  !EW@
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M_Q#_-BT"_SLL O] + /_0R\#_T,U!/]"/@;_0$H(_SY7"_\\90W_.G,/_SB
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M4&YWQ%!M=^!/<'GU2')[_T-T?/\^=7W_.W5]_SMU??\[=7W_.W5]_SO_80H
M_V\" .A\  #9A@$ SXX$ ,B5!@##F@8 NYP6 +.<*@.JF3D+HI5%%)N13AV4
MCE<FCHM?+8F(9C.$AFTX@(1T/7N">T%W@(1%='^-2'!]ETMM?*-.:GRP3VA\
MP5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO@?\\;X'_/&^!_SS_9 @ _W(
M .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@)P*EG38)G9I#$Y:731R/DU4D
MB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+1VJ#E4IG@J%-9(*N3V*"OT]A
M@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0 ]G8  -R"
M  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*F5,BA)=;
M*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)O4Y<B=9-
M7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH  -6&  #)
MD0  P)D! +B? 0"PI0  J*D. **I(0&:J#$&DZ4^#XNC2!B$H%$@?IY9)WB<
M8"USFF<R;YAN-VJ6=3QFE7T_8I2'0U^2D49;DIU)69&K2E>1NTM6D=-+5Y+O
M1UJ2_4)<D_\^79/_.UV3_SM=D_\[79/_.UV3_SO_;@  X'X  ,Z+  #$E0
MNIT  +&C  "IJ0  H:X+ )NO'0&4KBX$C*P[#(6J1A5^J$X<>*96(W*D72IM
MHF0O::%K-&2?<SA@GGL\7)V%/UF<CT)5FYQ%4YNJ1U&;ND=0F]%'49ON1%.;
M_$!5F_\\5IO_.E:;_SI6F_\Z5IO_.E:;_SKQ=   V8,  ,B0  "^F@  LZ$
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M+4&\_RU!O/\M0;S_+4&\_RW.B@  OY@  +&@  "FJ   F[   )"X  "%OP
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M"B#\_ JBIP  E;$  (>[  !YQ@  ;,\  %_9  !2WP  2.@  $/_"  __Q
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M$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:298PYCV25/(QCGSZ)8JI
MAV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I_RV':?\MAVG_+8=I_RW_
M5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4: +Z$+0.V@3P)KWU($JAY
M4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZB&B2/(5GG#^"9J=!@&:T
M0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!;/\O@6S_+X%L_R__60L
M_V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'*P*QA3H(JH%&$:-^4!B=
M>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR//7]KF4!\:J5">6JQ1'=J
MPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_6P@ _V8
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M0&A[_3IJ>_\V:WS_,FM\_S)K?/\R:WS_,FM\_S+_80  ZF\  -EZ  #,A
MPXL  +N1 0"TE0$ K)<. *67(0&>EC$%EY,^#)"02!2*CE$;A(M9(7^)8"=[
MAV<K=X5N,'.$=31O@GTW:X&'.VB D3YE?YQ!8GZI0V!^N41??L]$8'_L0&*
M_#ID@/\V98'_,V:!_S)F@?\R9H'_,F:!_S+_9   Y7(  --^  #'AP  OH\
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M,%*6_S!2EO\P4I;_,%*6_S#F<@  T(   ,*,  "XE@  K9P  *.A  "9I@
MCJT  (BN$0"#KB(!?:TQ!'>L/0IRJD<0;*E/%F>H5QMCIUX?7Z9E)%ND;2=8
MI'4K5*-_+E&BB3%.H98T2Z&D-DFAM#9(H<@W2*#G-4F@^3)*G_\P2Y__+DN?
M_RU+G_\M2Y__+4N?_RW=>0  R88  +R2  "QF@  IJ   )RF  "1K   AK(
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M'#;$_QR^D0  L)L  *2C  "8J@  C+(  ("Y  !TP   :,<  %W-!0!3TPH
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M!![YF@4<^:L%&_K !1KZW@4:^?(%&O?]!1GV_P49]O\%&?;_!1GV_P6>I@
MD:\  (.Y  !UP@  9\L  %K3  !-V@  0M\  #CE   U^P< ,?\/ "[_%@ K
M_Q\ *?\F "7_+0 C_S0 (/\[ 1[_0P$;_TL!&?]3 1;_70(4_VH"$O]X A'_
MB (0_YH"$/^K P[_O@,._]4##O_M P[_\ ,.__ ##O_P P[_\ .3K@  A+@
M ';"  !GS   6M4  $S<   _X0  ->8  "WT   J_P( )O\+ "/_$0 @_Q<
M'?\= !G_(P 6_RD %/\O !+_-0 0_ST #O]% 0S_3@$*_U@!!_]E 07_= $#
M_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP  =\$  &C,
M  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P  &_\% !?_#  4_Q  $?\4
M  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0  _T<  /]2  #_7@  _VT
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M,Y-5RC.15>4SD5?W+9%9_RF16O\ED5O_(Y%;_R&16_\AD5O_(9%;_R'_3PL
M_U<" /]A @#J: $ WFT$ -AP" #5< L RW(; ,)Q+@*Z;ST&M&Q)#:YI5!.I
M9UT9I&1E':%B;2&=870EFE]\*)A>@RN578LMDEN4,)!;GC*-6J@TBUFU-8I9
MQC:(6>$VB%ST,(A=_RN)7O\HB5__)8E?_R.)7_\CB5__(XE?_R/_40D _UH
M /5D  #@;   UW$# -!T!@#-=0D Q'87 +QV*@&T=#H%KG%&#*=N41*B:UH8
MGFEB'9IG:2&697$EDV1X*)!B@"N-88@NBV"1,8A?FC.&7J4U@UZR-X)>PC>
M7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8 _UT  .=G
M  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<<%<8F&U?
M'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IBOCEY8M4Y
M>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V   .-J  #5
M<@  S'@! ,5[ P# ?04 N7X2 +%^)0&J?34$HWI!"IUW3!&7=%47DG)='(YP
M9""*;FLDAVQR*(1K>BN!:H(N?FF+,7MGE31X9Z V=F:L.'1FO#ES9M$Z<V?M
M-G1I_3!U:O\L=FO_*7=K_R=W:_\G=VO_)W=K_R?_5P  ]F,  -]M  #1=0
MR'L  ,%_ @"[@ , M($0 *R"(P&E@3($GGX_"9A[2A"2>5,6C79;&XET8B"%
M<FDD@7%P)WYO=RM[;G\N>&V(,75LDC1S:YXW<&JJ.6YJN3IM:LXZ;6OK-V]M
M_#%P;O\M<6[_*G%O_RAQ;_\H<6__*'%O_RC_60  ZV4  -MP  #->   Q'X
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M*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  # @P  MXD  *^.  "FD0
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M)$>:_R34=P  PH0  +:/  "KE@  H9P  ):@  "+I0  ?ZH  '2N!0!OKQ0
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M$C7#JQ,SP\ 3,\/@$S/!]1,RP/\4,K__%#&^_Q0QOO\4,;[_%#&^_Q2XD
MJYD  )^@  "3IP  AZX  'NT  !NNP  8\   %C% 0!-R@4 1,\, $/0%P!"
MT"4 0- R #_1/0$]T4<!.]%0 CG260,VTF,$--)N!3+2>@<PTH@(+M*8"2W3
MJ0DLT[X*+-/?"2O1\PHJS_X+*<[_#"G-_PTIS?\-*<W_#2G-_PVNF   HI\
M ):F  ")K@  ?+8  &^]  !CPP  5\@  $S-  !"T@, .=D) #7?$  TWQL
M,N G #'A,@ PX3T +N)' "WB4 $KXEH!*N-E BCC<0(FY'\#)>2/ R/EH00B
MY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@  F*4  (NN
M  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K[A@ *>XB
M "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?TD@(5]*4"
M%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T  '^V  !Q
MOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!, 'OT; !S]
M(@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*_Y,!"?^F
M 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_  !CR0
M5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3 !'_&0 /
M_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT  /^0  #_
MHP  _[0  /_&  #_U@  _]8  /_6  #_U@""M0  <[\  &3)  !6TP  1]L
M #K@   NY0  (^D  !KM   5_0  $O\  !#_ @ ._PD "_\-  C_$  $_Q,
M ?\8  #_'@  _R0  /\K  #_,P  _ST  /])  #_5@  _V8  /]X  #_B@
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M';!#V1ZM0^T=JT7\&JE%_QBH1O\6J$;_%:='_Q.G1_\3IT?_$Z='_Q/_1 X
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M*8-8_B2#6?\@A%K_'H1:_QR$6O\<A%K_'(1:_QS_3@$ _U<  .5?  #89@
MSFH  ,=L P##:P4 O&P2 +1M)0"M;#4#IVI"!Z%G30R<9581F&->%91B91B1
M8&P;CE]T'HQ>>R&)78,DAER,)H1;E2B!6J J?UJL+'U:NRU\6L\N>UOL*WQ<
M_"9\7?\B?5[_'WU>_QU]7O\=?5[_'7U>_QW_4   ]5D  .%C  #2:@  R6X
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M(FQJ_R!L:O\@;&K_(&QJ_R#_5P  Y&(  -)L  #&<P  O7@  +5[  "M?
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M(%=\_R#E9   SW   ,%Z  "V@P  K8D  *.,  "9C@  C8\  (:0#@"!D1T
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M($.7J"%"E[HB09?3(D&6[R!"E?X>0I7_'4.4_QQ#E/\<0Y3_'$.4_QS,=0
MO($  +&,  "FD@  FY<  )&;  "%GP  >:,  &JG  !EIPX 8Z@< &"H*P%=
MJ#8"6:= !%:G2093IE$)4*99#$VE8 Y*I6D11Z1R%$2D?19"HXD8/Z.7&CVC
MIQL\H[D<.Z/2&SNB[QL[H/X:.Y__&3R?_Q@\G_\8/)__&#R?_QC$?   MHD
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M!"7+[@0DR?P&(\C_!R/'_P<CQ_\'(\?_!R/'_P>IE@  GIT  )*C  "%JP
M>+(  &NX  !?O@  4L(  $?&   ]R@  -,\$ "O4"0 FV0\ )=D9 "7:)0 D
MVC  (]L[ "/;10 BW%  (=U; "#=:  >WG8 '=Z' 1S?F0$:WZP!&=_$ 1C>
MYP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G   E*,  (>K  !YLP  ;+H
M %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >Z X '>@5 !OI'@ 9Z2<
M&.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#NB@ .[YX #O"S  WPS0 ,
M[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO   7\0  %+*
M  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0^!X #ODE
M  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\M0  _-$
M /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT  $32   W
MV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0 !/\:  '_
M(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP  _[,  /_'
M  #_Y0  _^4  /_E  #_Y0!_M   <+T  &''  !3T   0]8  #;=   JX@
M'^8  !;J   0[0  #/H   G_   &_P   O\$  #_"0  _PT  /\0  #_%
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M!M4KYP;0*_4'S2S_!\LL_P?)+/\'R"S_!\<L_P;'+/\&QRS_!L<L_P;_-1(
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M%YE%_Q681O\3F$;_$9A&_Q"71O\0ET;_$)=&_Q#_0@4 _T<  /=/  #E4P
MW54! -=5!@#54@L RU,9 ,-4*P"\5#L!ME)(!+%14@>M4%P*J4YD#:9-; ^D
M3'01H4M[$Y]*@A6=2HH7FTF3&)E)G!J72*8;E4BR')1(P1V22-@=D$GO&X]*
M_AB/2_\6CDO_%(Y,_Q*.3/\2CDS_$HY,_Q+_10  _TL  .E3  #>6   TUL
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M&7=9_Q=W6?\6=UG_%G=9_Q;_3   Z58  -E?  #+90  P6@  +II  "T:
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M&6)H_QGL5P  V6(  ,=K  "\<@  LW<  *IY  "A>0  EW<! )!X$0"+>"$
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M(5%WIB)0=[<C3W?.(T]W["%0=_T>47?_&U)W_QE2=_\94G?_&5)W_QG>8@
MR&X  +MW  "P?P  IX0  )V'  "2AP  A(<  'V'"0!XB!8 =(@F '"(,@)L
MAST$:(9&!F6%3@EAA54,7H1<#UN#8Q)9@FL55H%T%U. ?AI0@(D<3G^6'DQ_
MI2!*?[8A27_,(4E^ZQ]*?OP<2W[_&DM^_QE,?O\83'[_&$Q^_QC59P  PW,
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M$S>=Z!(VF_H2-IK_$C:9_Q$WF?\1-YG_$3>9_Q&^>P  L8<  *6/  ";E
MD)@  (2<  !WH   :Z0  %^G  !2J@  3:L. $NK&@!*JR< 2*LS $:K/0%$
MJT8!0JM. D"K5@,^JU\%.ZMH!CFJ<P@WJH )-*J/"S*JGPPQJK ,,*K'##"I
MYPPOI_H-+Z;_#2^E_PTOI?\-+Z7_#2^E_PVVA   JHX  )Z4  "4F0  AYX
M 'NC  !OJ   8ZP  %>O  !+L@  0;4& #ZV$0 ]MAX .[8I #JW-  YMSX
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M !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]  !.P0
M0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,
MY3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y  #G
M_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!R@  -<X
M "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R(@  \BH
M /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E  #T]@
M]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP  *-@  ![=
M   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@  _!X  /PF
M  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_V   _^0
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M ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /T
M_P#_'R, _Q\A /\>(0#_&2, _Q,I /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S
M ?\#?0'_ X<!_P./ /\"E@#_ IP _P*B /\"J #_ J\ _P&V /\!O@#_ <D
M_P'; /\ Z@#\ /8 ^ #_ /<"_P#W _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_
M(A\ _R(< /\A' #_'A\ _Q@D /\5+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+
M>0'_"X(!_PN+ ?\+D@'_"ID!_PJ? /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4
M /<*YP#S"O0 \ K_ .\+_P#N#/\ [0S_ >T,_P'M#/\![0S_ >T,_P'_)1L
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M!K@L_P:V+/\%M2S_!;0L_P6T+/\%M"S_!;0L_P7_- P _S8% /\Y P#_/ @
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M#HA&_PV(1O\-B$;_#8A&_PW_0   \D<  .-/  #44P  RU4  ,14  # 4 0
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M$6Q8_Q'Q2P  WU8  ,Q>  # 9   MV<  *YH  "G9@  GV(& )AC% "29"0
MC6,R 8EB/0*$84<$@6!/!WU?5@EZ7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L
M6I 9:EJ<&VA9JAQF6KH=95K1'65:[AME6_X79EO_%69<_Q-G7/\29US_$F=<
M_Q+M3@  VED  ,AA  "\9P  LVH  *ML  "B:@  F6<" ))G$0"-9R$ B&<O
M 81F.P)_940$>V1-!GAC5 EU8EL+<F%A#7!A:0]M8' 2:U]Y%&E?@Q=F7HX9
M9%Z:&V)>J!QA7K@=7U[.'5]>[!M@7_T885__%6%?_Q-B7_\28E__$F)?_Q+J
M40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L  (UJ$ "':QX @VLL 'YK
M. )Z:D(#=FE*!G-H4@AP9UD*;69@#6ME9P]H9&X19F1W%&1C@19A8XP87V*8
M&EUBIAQ;8K8=6F+,'5IBZAQ;8_P87&/_%EQC_Q1=8_\376/_$UUC_Q/F50
MSU\  ,%H  "V;@  K'(  *1T  ":<P  CF\  (=O#0"";QL ?7 I 'EO-0%U
M;C\#<FU(!6YL4 =K;%<*:6M>#&9J90YD:6P186EU$U]H?Q9<:(H86F>6&EAG
MI!Q69[0=56?*'55GZ!M69_L85V?_%E=H_Q189_\36&?_$UAG_Q/A6   RV,
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M&$1ZY!A%>?@61GG_%$9X_Q)'>/\11WC_$4=X_Q'-90  O7   +%Y  "G@
MG(0  )*&  "&A@  =X8  &N&  !FAPT 8X<9 &"()P!>B#,!6X@\ EB'10-6
MATT$4X94!E"&6PA.A6,*2X1L#$F$=@]&@X$11(./$T*#G11 @JX5/X/"%3Z"
MXA4_@?<3/X'_$D" _Q% @/\00(#_$$" _Q#&:P  MW8  *Q_  "BA0  EXD
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M!RF@_P@IG_\(*9__""F?_PBQ@@  I8L  )J1  "0E@  @YH  ':?  !JH@
M7J8  %*I  !&JP  /*T  #6O#  SL!4 ,K A #&P*P OL#4 +K$^ "VQ2  L
ML5$ *[%; "FQ9P$GL70!)K&# 22QE (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M
M_P0?K/\$'ZS_!!^L_P2JBP  G9$  ).7  "'G   >J(  &VG  !@JP  5:\
M $FQ   ^M   ,[<  "JZ P DO T (KT5 "&](  AO2H (+TS !^^/0 >OD<
M';Y2 !R_7@ :OVP &;]\ !B_C@ 7P*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4
MNO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M   2K<  #ZZ
M   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .S3H #LU&
M  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+_P )R_\
M"<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L   #+#   H
MQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX  =LY  #<
M10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@  W_\  -__
M  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,   =T
M%-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K  #I-@
MZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8  /#V  #P
M]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2W   #.
M  7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T)P  ]S,
M /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?  #_WP!W
ML   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@   .D   #L
M    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0  _R,  /\O
M  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_N@#_%B,
M_Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_
M (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,< _P#6 /\
MYP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_&B  _QD>
M /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (,
M_P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W
M /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P _QP9 /\9
M&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_ 'X _P"&
M /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /  WP#N .X
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M /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.KP#@#K@
MW@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_ <H2_P'_
M)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\ ZA=: .86
M90#C%FX X!9W -X6?P#<%H< V1:. -86E0#4%IP TA>C - 7JP#.&+4 S!C!
M ,L8T@#'&N@!PQOX < ;_P&^'/\!O1S_ KP<_P*\&_\"O!O_ KP;_P+_*PP
M_RL% /\K P#_+0D _RP. /\I%0#W)B  [B,M .<A.@#A'T@ VQ]4 -4@7P#1
M(&@ SB!Q ,PA>0#*(8$!R"&( <8ACP'$(98!PR&> <$BI@&_(J\!O2*[ KPC
MR@*Y(^,"M23T K,D_P.Q)/\#KR3_ Z\D_P.N)/\#KB3_ ZXD_P/_+P8 _R\
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M"X\Z]PJ-.O\)C#O_"(P[_P>,._\'C#O_!XP[_P?_.   \3X  .-%  #420
MRTH  ,5'  #!000 NC\1 +-!(0"M0C$ J$,^ *1#20&@0E,"G4%; YM!8@28
M0&H%ED!Q!I0_> >2/W\(D#^("H\^D0N-/IL,BSZF#8D^LPV(/L0.AC_@#H0_
M] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/   ZT,  -Q*  #,3P  PU
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M#FQ/_PQL3_\+;$__"VQ/_PON10  W%   ,E7  "]7   M%X  *Q>  "D6P
MG%8$ )56$@"05R$ BU@O (=7.P&#5D0"?U9- WQ55 5Z5%L&=U1B"'53: ES
M4W +<5)X#6]2@@]M48T1:U&9$FE1IA1G4;859E'+%652Z11E4OL19E/_#V93
M_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P  L&(  *AB  "?7P  EEH
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M#5=>_PW>4P  R%T  +MD  "P:@  IFT  )UN  "3;0  A6<  'YG"0!X9Q4
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M$$ENFQ%';:L21FZ^$T5NW!)&;?011FW_#T=M_PY';/\-1VS_#4=L_PW,7P
MO&D  +!Q  "E=P  G'L  )%\  "&>P  =7@  &MW  !E=PP 87@7 %]X) !=
M>3  6GDZ 5AY0@)6>$H"4WA1!%%W6 5/=V '3'9H"$IV<@I(=7T,176*#D-U
MF0]"=:D00'6\$$!UV1! =/,/0'3_#D%S_PU!<_\,07/_#$%S_PS&9   MVX
M *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %> ( !5@"L
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M!BR2T08LD>\&*X__!BN._P8KC?\'*XW_!RN-_P>S>   IX(  )R(  "1C
MAY   'J3  !ME0  89<  %69  !)FP  /YP! #F=#@ WG1< -IXB #2>+  S
MGC4 ,IX^ #&>1P PGU  +I]: "V?9 $KGW$!*9Y_ B>>D (FGJ$"))ZU B.>
MS@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0  H(@  )6.  "+D@  ?Y8
M '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 IJ0\ **D8 ">J(@ FJBP
M):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VKBP ;JYT &JNQ !FKR@ 9
MJNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0  =9X  &BB
M  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7MR$ %K<J
M !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VYQ  -N.<
M#K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8  %ZK  !2
MKP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14 "<4>  C%
M*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@  QM(  ,7O
M  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T  !&N
M.KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6  #1'@
MTB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\  -;@  #6
M\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   YP0  +<0
M "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?%   X1P
M .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%  #IX@
MZ?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@  (,X  !;2
M   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0  [1$  .\8
M  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #ZP@  ^MH
M /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H   W?   %
MXP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D  /H.  #]
M$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP  _[D  /^\
M  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P /\ N #_
M ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\ ^@#_ /H
M_P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L M #Y +T
M^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_ /  _P#_
M%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P +@ [@##
M .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4 _P#_&A,
M_Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B /H ; #U
M '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0 X@"_ .
MS0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_'A  _QP-
M /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$9@#J!&\
MY@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[ - &R0#.
M!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P _R & /\<
M P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=#6D V0UQ
M -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00R #"$-\
MOA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,  /\C  #_
M) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6, R!9K ,46
M<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D MQFT +4:P@"T&M8 L!OM
M :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_*   _R<  /XJ  #O*@
MYR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@4P"\(5T N2%E +<B;0"U
M(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O :<CO &F),X!HR3H J E
M^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+   _RT  .TR  #B-   VC,
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M!GP[_P5\._\%?#O_!7P[_P7T-P  Y4   -)'  #%2@  O$L  +5)  "O0P
MJ3X+ *(_%P"=0"8 F$$T )1!/P"104D!CD%1 8M 60*)0& #AT!G X4_;02#
M/W4%@3]]!G\^AP=]/I$(>SZ<"7H^J0EX/K@*=S_-"G4_Z@IT0/P(=$#_!W1
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M"&!._PCC1P  S5   +Y7  "S6P  JET  *%=  "86@  C5,  (92# " 4Q@
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M"U19F@U26:H.45F\#E!9V Y06?(-45G_"U%9_PI16?\)45G_"%%9_PC440
MPEH  +1A  "J9@  H&@  )=I  ",9P  ?6   '5? P!O7Q  :U\< &A@* !F
M8#, 8V \ 6%@1 %?7TP"7%]3 UM?6@197V$%5UYI!E5><PA37GX)45V*"T]=
MF0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)3%W_"$Q=_PC/5   OEX
M +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I9 X 9609 &)D)0!@93
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M"CMPS0HZ;^P).V[^"#MN_P@[;?\'.VW_!SMM_P>_8@  L6L  *9S  "=>0
MDGL  (=\  ![?   ;7H  &!X  !6=P$ 4'<. $YX& !,>"0 2WDN $EY-P!(
M>4  1GE( 41Y3P%">5<"07E@ C]X:0,\>'0$.GB"!3AXD08W>*$'-7BS!S1X
MRP<T=^L'-';]!S1U_P<U=?\&-73_!C5T_P:Y:   K7$  *)Y  "8?@  C8
M (*!  !V@@  :8$  %N!  !1@0  2( * $6!$P!#@1X 0H(I $&",@! @CL
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M 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5  !AF
M59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M !ND-@ :
MI#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.( $:+X !&A
M_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8H0  3*0
M $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ*P -L34
M#;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O  6O_@ &
MKO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP  0:T  #6O
M   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@  OBL  +XV
M  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]]@  O?\
M +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8  "JX   @
MNP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(  ,LK  #-
M-0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP  SO@  ,[^
M  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["   5Q@
M#LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?  #>*
MX#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H  .7S  #E
M\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,T0  !-4
M  #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M&@  [R0
M /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??  #WWP!P
MK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP   .(   #E
M    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$   _!8  /\A
M  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_OP#_#1P
M_PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M /\ =P#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T _P#) /X
MW0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_$!D _PT7
M /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\ <@#_ 'L
M_P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@## /0 T@#S
M .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0 _P\2 /\+
M$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[ '8 ^0!]
M /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@ RP#G .$
MY0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$. /\-#0#_
M!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '  [0!X .L
M?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6 -D U #L
M -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/!0#_#@L
M_PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R -X >0#;
M (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -  Q0#H ,,
M]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_$P4 _Q$-
M /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%<P#*!7H
MR 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE +4+]P"S
M#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@  ]18% /81
M#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]#G0 NP][
M +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4]P"E%?\
MHQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$  -P9!0#;
M$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X K!EU *L9
M? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4 GAS? )H=\P&8'O\!EQ[_
M 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:+P  SRT  ,HG  #''P@
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M VTZ_P/J.0  U4(  ,1(  "Y2P  KTL  *=)  "?1   F#X! )$\$ ",/1T
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M!EY'F@=<1ZD(6TB["%I(U A:2/$'6DG_!EI)_P5:2/\%6DC_!%I(_P3;1
MQDT  +A3  "M5P  HUD  )I8  "15   ADX  'U+" !W2Q( <TP? '!,*P!M
M3#4 :TP^ &A,1@!F3$T!9$Q3 6),6@)A3&("7TQJ UY,<P1<2WX%6DN*!EA+
MF =73*<(5DRY"55,T0E43.\(5$W_!E5,_P953/\%54S_!55,_P752   PE$
M +57  "J6P  H%P  )=<  "-60  @5,  '=/! !Q3Q  ;E < &I0* !H4#(
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M"$99R@A%6>H(1EG]!D98_P9&6/\%1UC_!4=8_P7'4@  N%L  *MA  "A9@
MF&@  (YI  "#9P  <F   &A>  !A70D 7%T3 %I='@!772D 5EXS %1>.P!2
M7D, 45Y* 4]>4@%.7ED"3%YA DI>:@-(7G4$1EZ"!41=D 9#7J '05ZQ!T!>
MR = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@  M%\  *AF  ">:@  E6T
M (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!28R4 4&,O $YD. !-9$
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M RYP_P,N;_\#+F__ RYO_P.S9@  IV\  )UV  "3>@  B'P  'Y]  !R?0
M9'P  %=[  !,>@  0GD# #QY#@ Z>A< .7HA #AZ*@ W>S, -GL[ #1[1  S
M>TP ,GM5 #![7P O>VH!+7MW 2M[AP$J>Y@"*'NJ B=[OP(F>^$")GKW B9X
M_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P  A((  'B#  !LA   7X0
M %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  LA2T *X4U "J%/@ IA4<
M*(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&O $>AMX 'H3U 1Z"_P$>
M@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP  6(P  $R-
M  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >D4  '9%)
M !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2._P 4C?\
M%(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4  $67   Y
MF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC< $9Y! !">
M3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +FO\ "YG_
M  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@   PH0
M)J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX  *J1  !
MJE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\  *?_  "G
M_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   FJP  ':T
M !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X.0  N$8
M +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_  "V_P"/
MD@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@  $[@   V[
M   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@  R#H  ,E'
M  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(_0"%F0
M=Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,   /'
MR@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT  -TY  #>
M20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !YH0  :Z@
M %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3    V0
M -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK  #P.@
M\4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@  7K$  %"Y
M  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B    Y@   .D
M  #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_*0  _SH
M /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7 /\ %P#_
M !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L _P"# /\
MB@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\ .H ^P#X
M /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\ $P#_ !0
M_P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^ /\ A0#^
M (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q ., [P#S .X
M_P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_ !  _P 6
M /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0 ?P#S (8
M\0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M -\ ^P#>
M /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P _P 2 /\
M'0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E (  XP"&
M .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P ]@#* /\
MR@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P . /\ %@#W
M "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H T "  ,X
MAP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[ /X N0#_
M +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!$ #H !H
MXP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z +\ @0"]
M (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L JP7_ *H&
M_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #= Q( U ,@
M ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(>P"O"((
MK@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_ )P/_P";
M#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L QPL6 , -
M)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B$7T H1&%
M )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7_P".%_\
MCA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0 +(5'@"M
M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W< E!M_ )(<
MB "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H A"#_ 8,@_P&#(/\!@B#_
M 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P)0  K!T, *8>& "A("8
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M FTSG0)L,ZL":C2\ FDTU0-H-?$"9S7_ F<U_P)F-?\"9C7_ F8T_P+B-@
MS#\  +U$  "R1P  J$<  *!$  "8/P  D#D  (@T#0"#-1< ?S8D 'PW+P!Y
M-SD =SA" '0X20!R.%  <3A7 &\X7@!M.&4!;#AM 6HX=0%H.( "9SB, F4X
MF0-D.:@#8CFY V$ZT -@.NX#8#K_ U\Z_P)?.O\"7SK_ E\Z_P+=.P  QT,
M +E)  "N2P  I$P  )M*  "210  B3\  ($Z"0![.A0 =SL@ '0\*P!R/#4
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M!$]'QP1.1^<$3D?[!$Y'_P-.1_\#3T?_ T]'_P/,1@  NTX  *]4  "D5P
MFE@  )%7  "&5   >TX  '!*  !I2 T 94@6 &))(0!?22L 74DT %M)/ !9
M24, 5TE* %9)4@!52ED!5$IA 5)*:@%12G4"3TJ! TY*CP-,2Y\$2TNP!$I+
MQ01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20  N%$  *Q7  "A6P  F%P
M (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:32@ 6$TQ %9-.@!434$
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M SI8_P,[5_\#.U?_ SM7_P.\5   KEP  *-C  "99P  D&D  (5I  !Y9P
M:V(  &!@  !570  3EL, $M;% !)7!\ 1UPH $9=,0!%73D 0UU! $)=2 !!
M7E  0%Y8 #Y>80$\7FP!.UYX CE>AP(W7I<"-EZI S5>O0,T7]T#-%[U S5=
M_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;   C&X  (%N  !V;   9VD
M %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^8S4 /60] #QD10 [9$T
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M 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^  !#?@
M.'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W]( !Y_4@ =
M?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\ %GO_ !=[
M_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \B   ,H@
M "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*3  2BU@
M$8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_  Z&_P"?
M>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@  *I(  "&3
M   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (EU  !I=>
M  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2_P"8@@
MCH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT  !F>   2
MH   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@  *16  "D
M90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1B@  B8X
M 'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J   ,K
M!:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),  "R6P
MLFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D   ?Y4  '&:
M  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "N    +L
M  "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##3P  PV
M ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT  &6C  !7
MJ   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0   ,<   #(
M    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800  V%,  -EF
M  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL  !+L@
M/+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4   #6
MV0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,  .Y6  #O
M:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^O   +\
M "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F    Z
M .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&  #_6@
M_W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !< _P = /\
M* #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_ (L _P"1
M /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@ _P#W /\
M]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7 /\ ) #_
M #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8 ^@", /D
MD@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J /\ Z0#_
M .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\ 'P#_ "P
M_P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"' .P C0#J
M ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\ UP#_ -4
M_P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[ "8 ]P T
M /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P AP#: (T
MU@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_ ,, _P##
M /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\ Z@ M .8
M.@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#& (< Q ".
M ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +( _P"R /\
ML0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E -, ,@#.
M #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($ M "( +(
MD "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B /\ H@#_
M *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0 *@"_ #<
MNP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"# *0 BP"B
M )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\ E G_ )0)
M_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R!BX K@@Z
M *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,A@"6#)
ME R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_ (<1_P#V
M&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R< H1 S )T1
M/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")%(L AQ26
M (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O(0
MW2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM )$:. ".
M&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88 ?!Z1 'H>
MG@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H*   TC
M ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B,@"#(SP
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M 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2.   P$   +-%  "H2
MGD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT)0!I-2\ 9S4W &4V/P!C
M-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>" 5@XCP%6.)X!53BO E0Y
MPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/   O$0  *])  "D3   FDP
M )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C.BL 8#HT %XZ/ !=.D,
M6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\C0%0/9P!3SVL DX^P0)-
M/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4   EU$  (Y/
M  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7/D  53]&
M %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"O@)(0MX"
M2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50  (M3  "
M4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT 3T)# $]#
M2P!.0U( 341: $M$8P!*1&X!245Z 4=%B %&19@"14:I D1&O0)#1MP"0T;U
M D-&_P)#1O\!0T7_ 4-%_P'!1P  LD\  *94  "<5P  DE@  (A8  !^50
M<4\  &9*  !<1@4 5T8/ %1&& !11B( 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!%26P 1$EX 4))A@%!298!0$JG C]*NP(^2]@"/DKS CY*
M_P(^2?\!/TG_ 3])_P&]2@  KU(  *-8  "96P  D%T  (9<  ![60  ;5,
M &)/  !73 $ 44H- $Y*%0!,2Q\ 2DLH $E+, !'2S@ 1DP_ $5,1@!$3$X
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M 2Y6_P&R5P  I5\  )ME  "1:0  AVH  'QJ  !Q:   8V4  %AB  !-7P
M0UT" #Q;#0 Z7!0 .%P= #=<)@ U72X -%TV #-=/@ R748 ,5Y. #!>5P O
M7F( +5YN "Q??0 J7XX *5^@ "A?LP$G7\P )U_M 2=>_P$G7?\!*%W_ 2A<
M_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)9P  /V4
M #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE5  G95\
M)F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_ 2%C_P&I
M8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P  .FX  #!M
M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >;EL '6YG
M !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK_P"D:0
MFG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@  "MW   B
M=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8 $WAC !)X
M<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?<0  E7@
M (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"   <@@
M%(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=  F#;  (
M@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0  D'X  (:#
M  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5C@  #X\#
M  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/90  CW8
M (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4  (*)  !T
MC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@  "IL   *<
M"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7   G6X  )R!
M  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0  !JE
M7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@   "I!
MJ0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,  *QW  "K
MC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?G   4:
M $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U    M0,
M +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK  "]@0
MO9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0  1JH  #BM
M   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"    PP   ,0
M  #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2<P  THL
M -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,  "JV   =
MN0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@   -0   #6
M    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9   ZGP  .N5
M  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W    1Q
M"<@   #,    SP   -,   #9    W0   .    #A    XP   .4   #G
MZ@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH  /^#  #_
MFP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_ #0 _P!!
M /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\ DP#_ )D
M_P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I
M /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X _P \ /\
M2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V )0 ] ";
M /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@ /\
MV0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V /\ 0@#[
M $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X Y0"5 .,
MG #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_
M ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /  / #M $<
MZ0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/ ,T E@#+
M )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\ O #_ +P
M_P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#; $$ U@!+
M -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P D "Z )@
MN "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_ *L _P#_
M!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H PP!$ ,
M30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I )( IP"<
M *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L _P#_!P
M]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ] +  1@"M
M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T F0"7 )<
MH@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(
M -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *( /P"@ $@
MG0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62 (H&G@"(
M!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@
M  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3#$$ D Q)
M (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@
M>Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J  "X
M*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL A!-# ((4
M2P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT
M &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P,P
MIS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U
M'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z  92"P &0A
MQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J.0  H3@
M )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@
M:2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M %LHP0!;
M*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P  G#\  ),\
M  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C*4, 82I*
M & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3+MP
M4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0  (]!  "%
M/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O
M30!7+U0 5C!< %4P9 !3,6X 4C%Z %$QB !0,I< 3C*H $TSNP!---@ 3#3S
M $PT_P!,-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">20  E4D  (M'  "!0@
M=ST  &TW  !D,@D 8#(2 %TR' !:,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1
M-%$ 4#19 $\U80!--6P 3#9W $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X
M_P%&./\ 1CC_ $8W_P#!/@  LD4  *9*  "<30  DDT  (A+  !^1P  <T(
M &D]  !?-P8 6C80 %<W& !4-R( 4C<J % W,@!/.#D 33A  $PX1P!+.$X
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M 3A#_P"W20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,  !32
M2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/ #I'6  Y
M1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(
M_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !03@  1DH%
M $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,5@ S3&
M,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P
M4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50  0U$! #M/
M#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M4ET +%)I
M "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1_P"L50
MH%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@  #56"  Q
M51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H )5AG "18
M=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H6@  G6(
M )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%> P J70T
M*%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;
M8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8   F6@  )!N
M  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C9@@ 'V8/
M !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H;@ 2:'\
M$6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\  (QS  ""
M=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0  %G * !-P
M$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-
M  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y  !^?
M='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$  Q\#  *
M?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0  'R'  ![
MG   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y@P  ;(0
M %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)"@ !B0\
M (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!  "'E0
MAZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0  8XL  %:-
M  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@  E@P  )40
M  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5C@  E:0
M )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690  $R7   _
MF0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<  *,,  "C
M$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA   I9L  *2S
M  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@   SH@
M)J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %  "Q"P
ML@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY   +:I  "V
MP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   FJP  &JT
M !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #  @  P0@
M ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<  #+M0
MS,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0  $+@   >[
M    O@   ,$   #$    R    ,L   #+    S0   ,X   #0    T@   -4#
M  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #FI0  YKP
M .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0   #'
MRP   ,\   #4    V    -P   #=    WP   .$   #C    Y0   .@   #J
M    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0  _*H  /R[
M  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\ 20#_ %0
M_P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@"; /T HP#[
M *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\ W #_ -8
M_P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_ $\ _P!9
M /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M *4
M[ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_
M  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D \P!3 /
M7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#< )\ V0"I
M -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X _P#_
M_P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!- .  5@#<
M %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D Q "C ,$
MK0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_    _P
M /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H 3P#' %<
MQ !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"< *\ IP"M
M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_    _    /$
M  #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U %  LP!7
M +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\ H0"= *T
MF@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5
M!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H HP!1 *$
M5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP". *< C "V
M (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2  #%$0
MO0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!* ), 40"1
M %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *, ?@"Q 'T
MQ ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z'   L1D
M *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&2P"$!E$
M@@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO '$+P0!P
M#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@  J"0  * >
M  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X#DL =PY1
M '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82P !E$M\
M9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T  )@H  "0
M(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48 ;!5, &H6
M4P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS
M %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q  ")*P
M@24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?
M'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=( 4B+Q %(C
M_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#,@  >BT
M '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$
M52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+
M*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0  =3,  &PM
M  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5
M $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N_P!$+O\
M12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D  &<T  !>
M+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N
M6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_
M #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y  !:-
M4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 !
M,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV
M_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6.0  334)
M $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [.&
M.CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T
M0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P  2#H& $0Y
M#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V/%T -3UI
M #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P
MI$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 # #\^#0 \
M/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L ,$%G "Y"
M=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N2@  H5$
M )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#"@ V0Q$
M-$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D "E'<@ H
M1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P  GU4  )1:
M  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P20X +DD5
M "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,<  A3(
M($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(
M8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P )T\2 "90
M&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :4WT &5.0
M !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E  "%:
M>VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<. !Y7%  =
M5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH $EJ- !%:
MH0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  "";0  >&X
M &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@$  48!<
M$V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)  IAG0 )
M8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P  =74  &IT
M  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -:A( #&H9
M  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !JF   :JT
M &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L  &-[  !6
M>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\  '85  !V
M'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP  =*@  '/
M  !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"  !.@@
M08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1  ""%P
M@AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(  '^Z  !_
MW0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%BP  .8P
M "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/$@  D!@
M ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS  "-T
MC/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0  +I8  "*6
M   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0  GA$  )X7
M  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=Q@  G>D
M )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\  !>@   .
MH@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P  *T0  "N
M%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@  K]T  *_R
M  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK   %K@
M +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)  "^#@
MP!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@  ,7E  #%
M\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W    N@   +T
M  #     Q    ,8   #&    R    ,D   #+    S    ,X   #0!@  TPT
M -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/  #AY@!@
MH0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP   ,H   #/
M    TP   -8   #7    V@   -P   #?    X0   .,   #F    Z0$  .P+
M  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #XR0#_  T
M_P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9 /\ 8@#_
M &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *< ]P"Q /8
MO@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_  < _P $
M /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L 70#Y &0
M]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K .8 M@#D
M ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_    _P   /\
M  #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I %X Y@!E
M .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\ KP#- +X
MRP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P   /\   #^
M    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@ T !? ,X
M90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y +8 MP#(
M +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H   #Q
MZ  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X
M &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X I0"^ *(
MV "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A    U@
M ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D 6 "G %X
MI@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V )( R@"0
M .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0  Q    +T
M @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8 %@ E@!=
M )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (, P0"! .
M@ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L  *\#  "I
M  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$ B !7 (8
M70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T -0 <@#P
M '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0  "="@
MEP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1 'D 5P!X
M %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L &8(
M_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2%   C X!
M (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*4@!L"E@
M:@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;
M$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P  @A@  'L1
M!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A$%, 7Q%:
M %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5_P!2%O\
M4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$  '(:  !K
M$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6 %47
M7@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_
M $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC  !D' <
M7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+
M'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B
M_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>) ( 5R -
M %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C5P!$(V
M0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X
M-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@  424+ $TE
M$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^*%T /2EI
M #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U.@
MIT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L' $<I#P!%
M*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N
M<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0
M )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N#0 _+A,
M/2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D #$R<0 P
M,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00  HD@  )=,
M  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y,Q$ -S,8
M #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW;P K-W\
M*CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL  )1/  "+
M4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \ ,C@5 #$X
M'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/
M ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3  ")5@
M?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3 "L]&@ J
M/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H 'D&- !U"
MH  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&6P  ?5P
M ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#%@ D0QX
M(T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>* !='G@ 6
M1[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8   >F$  '!@
M  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =2AH '$HA
M !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-G  03;$
M#D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8  &UF  !C
M9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8 %%(= !-2
M)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )5*T "%3%
M  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML  !?:@
M4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8  U;(  ,
M6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@  %O   !:
MX@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9<   3&X
M $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D&P "9",
M &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[  !BW0
M8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@  1G4  #ET
M   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P  ;Q\  &\F
M  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !LU@  :_(
M &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX  #)^   F
M?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D  'PA  !\
M*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@  =^\  ';^
M  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'   =AP
M%(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:  "*(@
MBBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H  (7[  "$
M_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4D@  #9,
M  24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9&@  F2(
M )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W  "5_P"
MB0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@   Y\   "A
M    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0  J1D  *LC
M  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I^P!UCP
M9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L   "N
ML0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ   +T8  "_
M)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!JEP  6YP
M $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\    OP
M ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/  #5&
MV"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP  3Z4  $"J
M   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+    S@   -$
M  #1    U    -8   #9    VP   -X   #@    Y    .<&  #K#@  [QD
M / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P & /\ !P#_
M  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L /\
M<@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q ,L \ #H
M .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\   #_  0
M_P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F /  ; #O
M '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$ W0#= -L
M] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_    _P +
M /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X 9@#< &P
MV@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#- ,, ZP#
M /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y    \@ & .L
M#P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K
M ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X X "L /<
MJP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0   -8 # #/
M !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\ L !E *X
M:@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@": .X F0#_
M )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0 !@"]  \
MMP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!> )T 9 ";
M &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") ., B #Y (8
M_P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N  L J  2
M *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T 70"+ &,
MB@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R '@ _P!W
M /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4 FP . )8
M%0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!] %T >P!C
M 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H _ !J /\
M:@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  ) (H $ "%
M !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %< ;@!> &T
M90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_
M %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$"P!Y !(
M=0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19 &$$8 !?
M!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+
M_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N"0T :0@4
M &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5#60
M5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_
M)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0< 7PX0 %P/
M%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K
M $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P
MJS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1
M%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT 0QAG $$8
M= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U,   J#8
M )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9$ !*&A<
M2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y
M'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-   I#H  )D^
M  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#'Q0 01\;
M #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C;@ S)'X
M,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX  )9"  ",
M0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$ .R08 #DD
M'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L +"F-
M "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&  "*1P
M@$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5 #,H'  R
M*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D )RV+ "8N
MG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(2P  ?DP
M '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM&0 M+2
M*RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?
M,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P  ?%   '-/
M  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H,AX )C(D
M "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LWFP :-Z\
M&3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0  '%3  !F
M4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L (3@B " X
M*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4/*T $SW&
M !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8  !D5@
M6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX> !H^)0 9
M/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P #D+$  Y"
MYP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B6P  5E<
M $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%(@ 212D
M$44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^  A'X  )
M1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80  4UX  $=:
M   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -324 #$TN
M  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-VP !3?(
M 4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0  $)A   W
M7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(  U4J  )5
M-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U   5/$  %/]
M  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH   R9@
M)V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F  !?+P
M7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\  %O]  !;
M_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K;P  (&X
M !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I*@  :30
M &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\  !D_P"+
M<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0  &7@  !%W
M   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P  =BX  '4Z
M  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P_P"&>0
M?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,   J#   "
M@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8  (0R  "$
M/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""@   >H0
M &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/    D0
M )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H  "4-@
ME$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP  <(H  &&-
M  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<    G@   *
M  "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F*@  ICH
M *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$  %:5  !'
MF0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K    *X   "N
M    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@  N2X  +I
M  "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>   [H@
M+*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P   "\
MO@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2   -$R  #2
M1@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   OK   'Z\
M !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,    S@
M -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD  #M.
M[DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D _P / /\
M& #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y
M /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H ^ #I /\
MYP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P , /\ % #_
M "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T Z !S .<
M>0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0 /\ S@#_
M ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /< $ #S !H
M[P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L ,\ <@#-
M '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L N #_ +<
M_P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#? !4 V@ @
M -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H ; "X '(
MM@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_ *, _P"A
M /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$ P@ : +X
M) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E &L I !Q
M *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$ _P"0 /\
MC0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5 *P '@"H
M "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J )
M<0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_ /\ ?P#_
M 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P & "8 "(
ME0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D ($ :P!_
M ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\ < #_ '
M_P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"* !L AP D
M (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '( 9 !P &T
M;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0
M#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4 >@ > '8
M)0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q
M &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&%@
MMAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H
M "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L %4
M=P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_'0  L"(
M *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"&0!= R$
M6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG $L(<P!)
M"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL
M  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3"QL 40LB
M $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.< ! #G\
M/P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0
M,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8 2! = $80
M) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y$WP -Q2-
M #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W  ",.
M@C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09 #\4(  ]
M%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D ,!F* "\:
MG0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*/   @#P
M '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V&B,
M-1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ( "D?FP H
M'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00  ?4   '0^
M  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P'B  +QXF
M "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",CF0 B)*T
M(23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0  ')#  !G
M/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT *2(C "@C
M*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =**L &RG#
M !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'  !F1
M6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A ",H)P B
M*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D %BW! !8M
MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D20  6$0
M $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =+2P
M'"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2
M,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@  5DD  $U&
M  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q
M !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TWW0 --O8
M#C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\  $Q,  !"
M20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y
M-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (//  "3O_
M  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2   ^3@
M-$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K  M -  *
M0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X  4'\  )
M_P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z5   +U$
M "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(,0 "2#L
M $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[  !'_P"2
M6@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P  *ED  "!7
M   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@  4#@  %!#
M  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-_P"/80
MAF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$  !I?   2
M7@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,  %D_  !9
M3   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",:   @FT
M 'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H   -9P
M!V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z  !C1P
M8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P  ?W0  'AW
M  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '<@   '(
M  !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O0   ;U
M &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L  '-]  !E
M?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P   '\   !_
M    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0  ?4@  'U9
M  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#  !;A0
M388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T   "-
MC    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\  (U0  "-
M9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0C0  0H\
M #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";    FP
M )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&  "@60
MGW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@  -ID  ">;
M   9G   #YT   6?    H0   *,   "E    J    *D   "I    J0   *H
M  "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U30  M&0
M +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(  !JD   .
MI@  !*@   "K    K0   +    "T    M@   +@   "X    N0   +H   "\
M    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0   S58  ,YO
M  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N   $L0
M +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L   #-
MSP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@  .I@  #K
M>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_ "$ _P L
M /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0 >@#R (
M\0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_ -  _P#$
M /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P _0 G /D
M,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#? 'D W0"
M -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W /\
MKP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B .8 + #A
M #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y ,(
M@0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H /\ H@#_
M )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P )@#( #
MQ  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R *X >@"L
M (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\ E #_ )$
M_P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S "H L  S
M *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L <@"9 'L
MEP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_ (, _P#T
M    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ", G@ L )L
M- "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"' ', A0!]
M (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E
MT0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F (L +0"(
M #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T =@!V ',
M@0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5 P  PP<
M +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P )P!Z "X
M=P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P &4 >P!C
M (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0  N1   *P1
M  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L "@ :@ O
M &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D =0!7 ((
M50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@  *0:  "9
M&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "( 7@ I %T
M+P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !, 'T 2P"-
M $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB  "3(@
MB1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C %( *@!0
M #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD 00.) $ #
MF@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".*0  A"<
M 'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&) !'!BH
M10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N' #<+F0 U
M"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P  @"X  '<J
M  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^#"4 / TK
M #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0F  M$*L
M+!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30  '0Q  !J
M*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G #,1
M+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F%*D )17
M "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V  !G,0
M72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D "P4*@ K
M%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:< 'QF^ !X:
MX  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E-P  6S(
M %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89)P E&2T
M)!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9
M'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/   63<  $\S
M  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @'BL 'QXR
M !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,CV@ 4(_4
M%2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP  $TX  !$
M-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@ &B,P !DC
M.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_
M !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^  !#.@
M.C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2
M*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\ #2S_  TK
M_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"0   .3T
M "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N,P .+CT
M#2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\  @P_P"7
M2   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@  -4(  "L^
M   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *-3L "#5&
M  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U_P"430
MBE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@  "=$   >
M00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@  3Q#   \
M3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"14@  B%@
M ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+   :20
M$D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-   !#30
M0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6   AEX  'UA
M  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   540  #D\
M  E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+20  2U<
M $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0  'IG  !Q
M:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060  "E@   -7
M P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410  5%,  %1D
M  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N  !O<
M97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(   !B 0
M808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\  %Y?  !=
M<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K=@  774
M $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N    ; (
M &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:  !I;
M:(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P  5'P  $9\
M   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z    >0   'D!
M  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W90  =GP
M '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,  #R$   N
MA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP   (<   "'
M    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70  AG,  (:-
M  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.   CCP
M%H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8   "6
MEP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@  )F#  "9
MGP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6F   #9D
M  &;    G0   )\   "A    I    *4   "D    I0   *4   "F    IP
M *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV  "NDP
MKJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP   *4   "G
M    J@   *P   "P    L@   +0   "S    M    +4   "W    N    +D
M  "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&A0  QJ(
M ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$   "T
MMP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@   ,T   #/
M    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=   YI$  .6L
M  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\ - #_ #X
M_0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"! .D B0#H
M )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_ +
M_P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P #@ ZP!"
M .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$ @@#/ (L
MS0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_ *0 _P#_
M    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #( TP \ ,\
M1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y (0 MP".
M +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )< _P#_
M_P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U +D /0"V
M $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P H@"& *
MD@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\    \
M .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4 -@"C #X
MH !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^ (X B@"+
M )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M    W0   ,P
M  #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1 #< CP ]
M (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P @@!Z (\
M> "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0   +P   "Q
M    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #  ?P W 'T
M/0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J (@ : "7
M &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%  "E @
MG    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P &X -@!M
M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($ 6P"0 %D
MH0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";#@  D@L
M (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$ , !@ #8
M7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"* $T FP!,
M *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@  BA,  ($0
M  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4 #  4P V
M %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $, EP!! *D
M0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P  'H8  !R
M$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L 2  P $<
M-@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X *4 -@"Z
M #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@  !L&P
M9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K #X!,0 \
M 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:, +0:X "P&
MU  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H(@  7QT
M %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(+  S"#(
M,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW "0,TP C
M#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0  7"0  %,?
M  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K#2X *@TU
M "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0U  =$?(
M'1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H  % E  !(
M(   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H (Q$R "(1
M.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_
M !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK  !%)@
M/2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O !P5-P ;
M%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9
M_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#+   .B<
M #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CX
M%1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_  \=_P"9
M.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@  .2T  #$I
M   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1'SP $!]&
M ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA_P"7/@
MC$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0  "\P   G
M+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D #"1$  LE
M4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"50@  BD<
M (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV   D,0
M&RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"  8J3@ $
M*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@  B$L  ']/
M  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @.   %S0
M !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P3   ,5D
M #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE   'U4  !U
M5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@  %#L   XY
M!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20  -U<  #=G
M   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:  !R6P
M:5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,   M!!  $
M0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^
M=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P80  :&$
M %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9* P  20D
M $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@  !%<P
M18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P  9V@  %MF
M  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0  4@8  %$+
M  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.;P  3H4
M $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT  %1K  !'
M:0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,  %P(  !;
M#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P  5X$  %>9
M  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ   _<
M,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#  !F"
M9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL  &*4  !A
MK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V>   *7@
M !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S @  <P<
M ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".  !OJ
M;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@  'H$  !*!
M   *@0   ($   ""    @P   (,   "#    @@   ((   ""    @@   ((%
M  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_H0  ?KT
M 'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL   J+
MC    (T   "/    D0   )(   "1    D0   )$   "1    D0   )(   "2
M @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F   DK,  )'8
M  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7    F0
M )L   "=    GP   *    "@    H    *    "A    H@   *,   "D
MI0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@  *?'  "F
M[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C    I@   *@
M  "L    K@   *\   "O    L    +    "R    LP   +0   "V    MP
M +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W  "_V !3
MEP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP   +8   "[
M    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*    S    ,\
M  #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=P@#_
M_P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!# /4 2P#S
M %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T X "7 -T
MH@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_    _P
M /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .( 10#> $P
MVP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0 ,( FP#
M *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_    _P   /\
M  #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$ $8 P0!-
M +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T DP"J *$
MJ "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _    .X   #C
M    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $  K !& *H
M3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7 )D E "H
M )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P   #,
MP0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _ )< 10"5
M $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$ @@"@ (
ML@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[    L0
M *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8 /@"$ $0
M@@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8 &\ J0!M
M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K    HP   )L
M  "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T #T <@!"
M '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\ H@!> +8
M7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@   (X   "'
M    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #< 9  \ &,
M00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1 *X 4 #(
M $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"  !\
M=0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V %8 .P!5
M $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@ 1 "_ $,
MY !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S"   ;
M &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L -@!) #P
M2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X #D V0 X
M /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$   9 P  %T&
M  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ]
M #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\ S@ O .\
M+@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,  %<.  !0
M"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #( -  X #,
M/P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E .H )0'[
M "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$
M0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I
M!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)
M_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(
M #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D
M( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<
M+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03
M   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y'
M !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0
MCC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J
M%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(2
M40 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D
M ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'
M(!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -
M%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!
M  !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\
M !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH
M!QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U
M10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A
M!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G
M   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@
M:TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -
M) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F
M=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\
M &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H
M!2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0
M+(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3
M  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-
M   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<
M #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !5
M5P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z
M#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<
M   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27
M1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0
M0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _
ML0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX
M #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX
M $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP
M1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB
M   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40
M  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H
M $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7
M:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@
M$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM
M  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@
M!W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#
M;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F
M_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T
M  !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P
M 'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S
M@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
M    C    (T   "-    C    (P   ",    C    (P   "-    C00  (X,
M  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@
M6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9
MFP   )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B
M#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39
M #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@
M *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0
MN0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<
M   CH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L
M  "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$
M -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D
M6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"]
M ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_
M_    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #-
M %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0
MS0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z
M .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %,
MM !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "=
M .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8
M 0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1
M )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -,
MAP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K
M  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L
M4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K
M ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  (
ME  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X
M $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &,
M^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ '
M ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@
M9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4
M /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ',
M"@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!'
M %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\
M1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C
M  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L
M2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_
M #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @
M50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^
M $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$
M_P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  *
M $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8
M,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A
M'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $
M"P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+
M "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@
MD28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T
M  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "
M4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL
M (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D
M*04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7
M!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q
M  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP)
M !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH
M$ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V
M-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D.
M"@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G
M  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P
M:SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1
M$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03
M=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\
M & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D
M#!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=
M&(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"
M  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-
M  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<
M !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !5
M1   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?
M$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;
M   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420
M2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@
M)1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   F
ML   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP
M $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$
M "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP
M*\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-
M   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04
M   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H
M #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J
M3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \
M&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM
M   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50
M&5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%
M11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   _
M_P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL
M  M9   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@
M $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![
M:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<
M  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<
M<W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M
M;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G
M(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H
M %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@
M 'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&
M=R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2
M  !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D
M  "(    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P
M (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   Y
MB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
M    EP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA
M  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP
M'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F
MIP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T
M)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\
M  6A    HP   *8   "I    K    *\   "S    M0   +<   "V    MP
M +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@
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M_____________________________________________________P
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M]/7V]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________^X Q        "6',____________________________TEH"
M     %W,____________________________J#4          %S3________
M____________________?0T          %36________________________
M___N?44          $34___________________________\JF0O @  !"(W
M25C.____________________________Z:1K02@_8W^5I[K:____________
M___________________5LJRRS.3Z________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___ENY=W8LC_________________________________VYYG-@H  HS_____
M___________________________(?S\%     %[/____________________
M_________]F!.0       #RJ_____________________________YY,
M     ".0____________________________W&\:         !!]^?______
M____________________KT@           !O[O______________________
M____A!,           !DYO_________________________L40
M  !7WO________________________^X%0            !(UO__________
M______________]T%              XS_________________________FB
M6A,            CQ?_________________________?FUPL           -
MNO__________________________[[%]53DB$0<! A$BLO______________
M________________W[^EF9B:H*R]VO______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________X[Z=@'S[____________________
M____________\K>$5S . !VL_______________________________2BDP5
M      !R\____________________________]9_-@        !+R?______
M____________________^I$^           OJ_______________________
M____P%H            :E?__________________________C20
M   (A/_________________________G7@              =___________
M______________^T)0              :O________________________]]
M                6_3_______________________TK
M3.O______________________Z4                 /.'_____________
M_________S ,                +=G_____________________F8IA)P
M            )]?______________________^V^B54G            )=S_
M_________________________LJ==EU*/#(M+# Y1][_________________
M______________WFW=;2T-/9Y/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___OU+O6_________________________________^>XCVI++Q5O________
M_______________________DH6<T!P     \R?______________________
M_____]:".P         2E___________________________[84Q
M    ;___________________________ID(             4.'_________
M_______________L:0              -\G_______________________^S
M+P              (K;_______________________]Y
M$*?_______________________(T                 )G_____________
M_________ZD                  (S______________________T8
M             '______________________WP                   '3_
M____________________EP                   &K_________________
M____S@                   &/______________________RDB 0
M         &'______________________[FC@%<W%P           &C_____
M______________________K3KI2&?'5Q<')W@93_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________V[J=@FEIT_______________________________R)-E/1D
M   =GO___________________________]N.3!,         ;O__________
M________________VWPL            1=?_________________________
MBRH             (K3________________________"1
M Y?_______________________]] 0               '______________
M_________^<V                 &K______________________YT
M             %C______________________T8                  $?X
M____________________Z0                   #7I________________
M____E@                   "7;____________________O
M         !C.____________________ZP                    _"____
M_________________P                    JY____________________
M_R<                   JU_____________________W
M      VY_____________________^"<C'!50C,F&Q0/#0X2&B:_________
M____________________^>38TL[,R\S/UN#\________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z].\X___________
M_____________________]*IA65(+!(!A?__________________________
M__&K<3P/        3^#_________________________U7\U
M'[+________________________C=1T              (G_____________
M__________^0(P               &?______________________]5#
M             $CV_____________________XH                  "[=
M_____________________S@                  !?(________________
M____O@                    2V____________________G
M          "E____________________N@                    "3____
M________________W                     ""____________________
M_P                    !T_____________________Q,
M      !H_____________________T(                   !@________
M_____________WH                   !=_____________________]$
M                  !A______________________\D
M  !F_______________________)K)F)?79Q;&EG9F=K<'J,____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________XL6JD7EA
M=______________________________=IG=0+ P     ,<3_____________
M____________X)).$P           (_________________________2<!T
M             &#______________________^YO#P               #?B
M_____________________Y8<                 !3 ________________
M_____T                    "C____________________K@
M          ")____________________G@                    !R____
M________________O                     !?____________________
MV@                    !-____________________^@
M       [_____________________PX                    J^?______
M_____________S,                    ;Z?___________________UX
M                   /V____________________X\
M   &T/___________________]                      RO__________
M__________\K                    R/____________________^
M                R______________________W%@$%!0,!       !!@T8
MR________________________.OAV,_,S<_0TM37W.+J________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________':QO______________________________
M\<:CA&A-,A@ %:O__________________________[E\1A@          ''_
M_______________________7?"\              #OC________________
M_____]]D"0                RU_____________________W0#
M          "-____________________Q14                   !J____
M________________F0                    !+____________________
MM@                     P_?__________________UP
M       9Y___________________]@                     %T_______
M_____________PX                     P?___________________R\
M                    K____________________U(
M    GO___________________WD                     CO__________
M_________Z4                     @/___________________]@
M                =/____________________\V
M;?____________________]\                    :?______________
M_______7#0                  :/______________________<
M            8?_______________________U \1DY465UA9&AL<'9^B?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]6[HXMS6I7_________________
M__________B_CF1!(04      %+\_______________________WG588
M         !?!_____________________^5L%@                "-____
M_________________V,                   !>____________________
MG0                     U_/__________________H0
M       1V?__________________R@                      N_______
M____________[@                      H?___________________PP
M                    BO___________________RT
M    =O___________________TT                     9/__________
M_________V\                     4O___________________Y0
M                0/___________________[P
M,/___________________^H.                    (O______________
M______]$                    %?____________________^!
M            "_7____________________("P                   NS_
M____________________7@                   .7_________________
M____R1P                  -K______________________YT!
M      <.%\7________________________5N;S!Q\[5V^'F[?3[________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______XW\______________________________[,:EB&U4.R$' #+>____
M____________________UY)9*0            "@____________________
M__^)-@                !G_____________________V8
M       R]O__________________E0                     #R/______
M____________IP                      H/__________________UP
M                    ?/___________________P
M    7O___________________R4                     0___________
M_________T@                     +/___________________VH
M                &/___________________XL
M!?/__________________Z\                      .'_____________
M_____]4                      ,____________________\D
M             +[___________________]4                     *[_
M__________________^+                     )__________________
M___+#@                   )+_____________________5P
M         (;_____________________J@H                  'G_____
M_________________VT                  &;_____________________
M__=5                 $7_________________________:B,K-3]*56!J
M=7Z'D9S_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^C/MIV#:4ZY_________________________^RR@UPZ'0(
M      ![_______________________%;2D               ! ________
M_____________X,;                   'R___________________D@
M                    F/__________________I
M    :O__________________W0                      0?__________
M_________PX                     '?___________________SD
M                 .C__________________V
M ,[__________________X4                      +?_____________
M_____Z@                      */__________________\L
M             )#__________________^\6                     'W_
M__________________\^                     &S_________________
M__]I                     %K___________________^9
M         $G____________________2%@                   #G_____
M________________6                    "G_____________________
MH@                   !G_____________________]58
M      3______________________[LO                  #X________
M______________^K*0                #/________________________
MR4<     !Q,@+CY2:(3M________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________]-7)________
M____________________^M*PDG==0B@,  !*________________________
MQ7U%%P             1V/___________________\10
M    G___________________H@P                     :/__________
M________E                       -O__________________V@
M                !^S__________________Q4
M ,3__________________T@                      *+_____________
M_____W4                      (/__________________YT
M             &G__________________\,                      %+_
M_________________^</                     #[_________________
M__\S                     "O___________________]8
M         !C___________________^!                      7_____
M______________^L                      #____________________>
M(@                    #R____________________7
M      #?____________________GP                    #,________
M____________Z$H                   "W_____________________Z 6
M                  "<______________________]Z @
M  !W________________________>@L               5,____________
M_____________Z)7:'2 C9RKO-#G________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^WC___________________________2HWI8.BDC'!8.!@  G___________
M__________^L4@X                 :?__________________Y$,
M                -/__________________>0
M ./_________________S0                       ++_____________
M_____Q,                      (7__________________T\
M             %W__________________X,                      #K_
M_________________[(                      !S_________________
M_]L#                      +___________________\J
M          #[__________________]/                      #G____
M______________]T                      #4__________________^;
M                      # ___________________$!P
M      "M___________________P,P                    ":________
M____________9P                    "&____________________HP
M                  !R____________________XT0
M  !<_____________________Y$&                  !!____________
M_________^M?                   =_______________________*2P
M                ________________________RU<   P8)#$_3F!TBZ?'
M___________________________7Y_+_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KU,W'PKZZM[.PK:FH
MI?___________________]U^4S\P(QD1"0(          -O_____________
M____=@                       *?_________________N@
M             '7__________________P<                      $;_
M_________________TX                      !K_________________
M_XP                       #]_________________\$
M          #;__________________$9                      "^____
M______________]$                      "D__________________]K
M                      "-__________________^1
M      !Y__________________^W                      !F________
M___________>(0                    !3____________________2@
M                   _____________________=P
M   K____________________K H                    6____________
M________YT4                     _____________________XH
M                _____________________]9-
M_?____________________^G+@                  U?______________
M________F"H           88+45@X/_______________________ZAC=(&/
MG*N[S>+Z____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________GR[>IG96.B82 ?'AT<&QH99#_
M________________O&I(+1D*                 #'_________________
M_P                        /__________________T(
M          #<_________________XX                       "R____
M_____________\X                       "-__________________\I
M                      !K__________________]:
M      !.__________________^&                       T________
M__________^N                       >___________________4%P
M                   *___________________Z/0
M    ____________________90                      ____________
M________C@                      ____________________O!D
M                [___________________\4X
MV/___________________XL                     O_______________
M_____\Q#                    H?____________________^1&0
M            >O_____________________R= H                17___
M____________________Z'03'RPX15-B<H6;M-+U____________________
M_______7Z/3_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________OW
M\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$____
M_____________TLE"P                    "2_________________X@
M                      !F_________________]<
M       ]__________________\S                       8________
M__________]L                        __________________^=
M                    ___________________)#
M    ]O_________________Q-0                      W___________
M________6P                      R___________________@@
M                M___________________J08
MH___________________TR\                     C?______________
M_____UX                     =____________________Y,'
M            7O___________________\U#                    0/__
M__________________^'$                   '/__________________
M___87@                   /______________________OTX       X<
M+#Y2:H:ER/_______________________\)\C)JGML76Z/W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^[AU\_)P[ZZMK&M
MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4________
M_________]<%                        __________________\T
M                    ]O________________]V
M    TO________________^P                        LO__________
M_______A)                       EO__________________40
M                ?/__________________>0
M9O__________________H                       4?______________
M____QR,                     //__________________[DL
M            )____________________W0                     $/__
M_________________Z,6                     /__________________
M_]A,                     /____________________^(#P
M         /_____________________+4P                   /______
M________________I3@           D=-$YKC/______________________
M_YDY0U%?;GV.H+7+Y?_____________________________K^?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________KS+FLH9F1BX:!?'AT<&MH
M9F9H\?________________]A13(C& X&                GO__________
M______]^                        =?_________________#
M                4O_________________[-P
M,O__________________:@                      %O______________
M____E@                       /__________________OQL
M             /__________________YD(                      /__
M_________________VD                      /__________________
M_Y "                     /___________________[DL
M         /3__________________^A<                     -G_____
M______________^1&                    +S____________________*
M4P                   )W_____________________F"X
M$"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN____________
M_____________^>@JKG(V.G\____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________?7P
MZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N
M,?_________________2)1$#                     /______________
M____0@                       /__________________?0
M             /__________________L L                      /;_
M________________W3D                      -S_________________
M_V(                      ,7__________________XD
M         *___________________Z\B                     )G_____
M_____________]9(                     (+___________________]R
M                     &G___________________^A*
M     $[____________________37                    #/_________
M____________EBX              !4R4G?_____________________X'(3
M   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________^>#2R,"ZM;"L
MJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_
M________________D@                       *W_________________
MS!X                      (O_________________^U(
M         &W__________________X                       %'_____
M_____________ZD;                     #K__________________]!"
M                     "/___________________5H
M      S___________________^/%                     #_________
M__________^X/@                    #____________________E;0,
M                  #_____________________GS<              ! O
M4'3_____________________W7(4      87*D%:=92VVO______________
M_________[Q81%1D=8::K\CC_______________________________2S>'Q
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________\^_K[_?______________________[KFHG9:/BH:"?WMX
M=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_____
M_____________VD                       #__________________YL*
M                      #__________________\@Y
M      #___________________!C                      #_________
M__________^*#@                    #___________________^P-
M                  #____________________56P
M  #_____________________A1H                   /L____________
M________L4D              !@Y78'_____________________Y7L>
M   ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?______
M______________________^SGK3%U^O_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________Z
M[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A7
M5UE>97'__________________[\Q'Q80"@4               #_________
M_________^U6                      #H__________________^"!
M                  #,__________________^K+P
M  "S___________________25P                    ";____________
M_______W?!                    "%____________________HC<
M            !2N4____________________RV$"            #"Q0=I[1
M____________________]8TP       -(SM7=IF^Y?__________________
M_____\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G
M_____________________________________?______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________=SL6_
MO+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M0
M66:A__________________^G)@X' @                !6____________
M_______.4                      Z___________________T>0L
M               A____________________GS(                    .
M____________________Q%@                (,5J$________________
M____Z7\?           &)TMQFL+I_____________________Z=)      (7
M+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[___________
M__________________^N<H68K,+;]O______________________________
M____W^______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________O[*JIJ.A
MH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]
M____________________GBX&                    ________________
M____PU8                  !5!____________________YWL:
M      DT8(NT_____________________Y\_          0E2G&9PNO_____
M_________________\9F#P   !,J1&*#I\WU________________________
M_^N.-2L^46B!G;S>______________________________^^=G^4J<'<^?__
M________________________________TMCS________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8
MFY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I____
M_________________Z9! 0          !S9CC[KA____________________
M_\9E"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*F
MS/3___________________________^K4#9*87N6M-;Z________________
M_______________2AWR8L<OI____________________________________
MU,[M________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFR
MO-#M__________________________^=4T=)35%68'.*K];\____________
M______________^R5@ :-5!MBZ[2]______________________________-
M;SY?>YFWU_G________________________________NGX.FPN'_________
M____________________________X\[K____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________
M
M
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M,7B/.<2Z"V@9%5*;X.&V72/3:9J(GF/@LN$D^#:B6KE+CPPK>#^)*M^;2KV
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M/FV#S\=K'8#W[ >P0>#.V+&_\GVH8N4J[\J:EH6*21RD %\>FLD[[$%B>O\
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MVI#*E(/@I).LJ6@S2?4HB5Q(^H^!C%960[,K*?8P(/X'8S;UV5VKSU6)8A)
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MO[KY4JYPK03OM9AHPZ>X,!^(,LG^SWV>AQ90NNXC $;XVL6H3OX[LU3M[NC
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MP_\ 9M4_PL!&X]@^?UC\UG4?RZ]X?^S:I_A8"/N'S^L?FLZC^77O#_V;5/\
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M 1 1 1 1 1 1 1*H[V_T;LP_>K1W^-6G@21X_<WY&6N"1 1 1 1 1 1 1 1
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M1Q<LP.)6ON)3R_!>D446L29&1<JE$Z3BB-1FKF,C*@\/]N>G -A\=<.ZXJ[
M5:MH56/8X!'\]F#7BKOL""=^;J3S%B#*QQ%V"ZEZN9P#Q+H+ON6MT?7[<FM"
M>;^2O4+<HC8D$+R\O0#;8'?YEGV^_%S2=WHSICG;2>0EKQ3+)%4^X7,DEK;C
MSTNI0OAS&EI;W+\7%? NN/X]VYZ80<W@[AG7*QMNVEZM9BVD=.8K5>' ;QY5
M+['S/LJ_N_V":IOZ#QKQ1H#'?9=6TBO+K!V]4-9CE"5\-V5-_P#C['YW.J./
MF;>>;3]6ZU2.'2R,;1#R>.@BX<YI36'(><(B,U))!<3X<#X'\4?XM<3Z?ZNN
M]E7%N,PZM9IHIU2L ;;D#%[RQO$D;#?IMXGH_P (.%=1];0.UO@_)#;A*]3:
M[2K">NP+97=UKX;$GV[^ WG[8O9 M!V5MQ\J9SW!9BE)0ZQE6&6D!+*U$1FE
M3O!:CY2XFK@T1D1&?*+M7;]P(K+7JJ:]H5NX5TU;1LK&5&(WV+D$GS\%Z[=-
MY9M_L]<?.K6:2^@:]2 2EFDZUBY!< [ A=U WZ;>N1N?&;9Q_=GMPR?HBJM8
M,-);O(1-V5@JE4E2^'!*SN&H*$F1GRJ5S\A&1F2S(N(ZS3^U?LYU/E]$XOT;
M=P-AD9!PR"?)CEI0%()V.YV!\]IR.H]D?:5I7,<O@[6MDWW;&QQG @;^LHPG
MO8@[;CU=_(@'I-STN6XIDB25CN38]?)4GG2JENJVT2:.!*YB.#)?(T\IDKF(
M^' R/CP,=EAZMI>H@'3]2T_.! (.'F8^4""-P0:+'!!'4'PVZSBLW2-6TTD:
MCIFHZ>0=B,W"R<4@[[;$7U5G??IMX[])V$;":Z B B B B B B B B B B B
M B B B B B B B B B B B B<*424J4?'@DC4? N)\"+B? OUG^PA2[!$9VW
MV168[#<[*"3L/,[#H/. -SM[>D\IJSLD$UC(<;RW*\/PZOV_YUK5J1H!C=W5
MY1/F:I4>=Z=X]F&0N3,UQ-ZN9JX=+=Q\%O&6&:^PD6E8J34/SX_03%*;PL;/
MK]!Q,C-4UWZMP=K'&ND)C_:TV8.B+7DYFGY-C<K)G>@6/<+:E?&7)Q[,*QEN
MLJWO7T6>EZCCXP4C1-?T;A[5AD.*[6R->U+3M'P<O"5=U?'.I:K@*:KF2^W"
MNLSZ0U-%@/4\@[)CJ#A.%/9IF.BE*S%U$T)RO7_;_#ILDMIS]KBF'91B6/W<
M'4]2Z='Y.3*ZLSK&\QERZ1%I#10*M4F:9-:OI,C*:_$&7@Y)Q<;6--RN"1J;
MY-IJTC#T_C74[-)3.MR2#:E>A9E+UZL71:^6VBVES6SE::.ZR6Q<O'%]VDYF
M1Q'IN.:T5M2R-6T#2\S5Z<2C&YN[<:[AZ;J9TS:SO$MP'KO7FOI!L-MPWG76
MX7!],9-+B&/N9_FEYE"KIJCNIUKI] TZPC)W<?N=3:?)>TD2)^/Y(\AJ'I^W
M(CL2,CLGWU,I574]Q*B9_=%KL4BC+Q\4Z75J.HG,K6G)P+,NO)33M/-1.UF=
MG9-'I"4KTITFN_-R&K8XE67@UY'V.0[&NZS^(W:;@'#?O<?+MHIHR,J]K7"=
MWC:93D5U:@ZK8R9]N+AUJS90LKO=<VT&@J+2\LWDQJZGKYEG.?69$EF)!CN2
M7W#,S(N"6FU'\?7\0U^7DIB8U^59MR45/:VY"[\JDA=SL 6.R@GIN9GTU-?;
M72FW/:ZHN_0 L0-R?(#?<GR )E)]GN\]C<I1ZSR\RQ)G2B]T;S2;77%/96IO
MH/ )]4SD^#YW+DRV(90HN28G)8MWFG$$W!43["G5] M0R/5JT+!UC+=<9R,[
M&UK'?H-'U?2[FKU'3K;-R&;&4U,S=-^<[ CE)LV;_P :R])QU-ZBO!RM+N1D
M=]1P,Y6KIR4KK9]E;+HRL>LJS):M2V(Q5]A0?6_LHNH\'.MS*=!+O1_(],-'
M=#M(]5<=R+)<8U"K9+B<KU:_(7,9-B]<Q\>CV\)-.E=ABDZF;7CE@VIJ?W>D
M1U&D8^FO;8U-VI@T8G^)W '"60BH:LA-$XN*466=U>1?CZE5DYF&;DRZ:FQZ
M*\ADHNL>I3.ID8]F-BX*B_)MX*[0.(=PZWU6:EPG5IU^/179C\U5F,:FU"NP
MT67,^4:*;&QS3<9Z>1]Z&VM>%6><KU/A.5-%E9X#;QXV.9E)R,LW:@+M'L=K
M<*CXZ]F5W-55L2+J.5)16+,JBCOWD9YZI9<FINWVU4IB7$MW.?Z8V(0ECOW6
M!:U.=9DUHALP4T^T"K4'S4QUP;&1,HTM8@:,8/>+E4HSXF-I^3E,+*Q0M>II
M0VGO5D%NXR%SVR:*\'T>VTY5UM=%'>7,$GZZS>3MFNI6)Q*;5JCM59O J+''
MIE;7Y#.J7&,@MTT-(U;7<:F=IL:L+.W-R##J,EG5%J^[&G&F$;<":N/6VRY&
M3BM94EV+2]]I:ZH5&I-(R=?>RC(+C'RQ7HN'DZJXQ;;BF#4<A@*V1FM-?6M5
M%KET7(R1AUH]5JWKDG,73UKR,9D&1B\^>Z8*/E54UOFNF*CM>RUGJM;O1VZ4
MNFT/4J^U_P 3S7$L@RS+Z7&\FPK%\BM$69XU*=.XKJNAQ2/EEQ=Q\0C)Y<@R
MB#%53M,MJL9CD",KB6.,FFNG2Q?:$?.TL:HF1:K8]-NG]\]?\5O[T!-+P"37
M3WV=;51WG+]MO<B3)6JQ[]3K123I^J?PF_'Z=]C:CW0/\*&Y#9F>37?:*,>M
MKBBV@5$8UKCBP[()LQKI:(*MPN!6$@Z_#;>05 ]:9.S5TVH$TJ[$;N]E8Y6V
ML7'Z2WG*;B]V;QZOK(#KS";.7"Z=DUYE5-MV8,&I&;);5DT$+MRUG6;:J+L?
M3O2&VQO2LI,FCT.OO=\Q[5JQ>^M/(,9KZ4Q7S6<"BO3,W66)![[^&:=S_P 0
MREQMO277!%=C9:)2UN.M;O=6BHQ%Q4J2M*5H42DJ(E)4DR4E25%Q)23+B1D9
M&1D9&9&1\2%!!!((((.Q!Z$$>((\B)=!! ((((!!!W!!Z@@CH01X&<B),!$!
M$!$A8?RU=?0U7V<L)'F?N_7I\_F)@?SF3]1.?>#81YCX'\Q)T),!$!$!$!$\
MH=8&FH&O&H=CD,,K^CL,QTWB56NT WI]MMJG,QZER3ABS:(I=!!ON1,]V74*
M1 6K(2+*N=E;9*G1=@U";FBYM=U"RK.! 374"JO\$MLVZG#?_P /2BWFQ;!S
MK7MGK8!.I$!'<H,FNO0D%NGD+OICV6Y?)KM2,#NUE>^6;DWRZS@H=EPV2=@S
MF:NYQW==K+:M.OY]HOJ&Q1:6VCCSR++%ZG%J?%)T-BD>(B3%C9I)M9DRX1#;
M_P"O8EDQ$F')9CPVV8QV;'QM!S*ARY6JZ_DTYVP.]N*>(KM"_AEH(+/C8^#C
M=ZM'6I,NVS+5>^+.;CU+?EYF#;8/1,;A['OQV;JB93Z/D:LVJ#U@GI"Y35T=
M]ZKBG#..S=V]JOZ54<Q^QI:B?):-F1.K($N0R9&DVGI,5IYULTJ2E1&A:U)X
M*2DRX<#(CZA=O1:[[JU.ZI;8BGVJKLH/W@"8F.[68]-CC9GJK9A[&902/Q/N
M^ E ]]&;:L,:<Y;BT/1-Z=IXK-=#F5ZI%J+BD9M$61JOII*G3/R+>1^4"BKK
M%V15'')?2RSBG-8_F[S9"U+X^/DW3K[#[MOG/1 )$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$_%)K:Z:VMJ9 A2VG4FAQN3%8?0X@RX&E:'6U)
M4DRZC)1&1D+-N-CW*RW44VJW1ELJ1U8>Q@RD$>X[R_5DY-#*].1?2ZG=7JML
MK93[59&!!]X(FIL@VZZ#942SO]'=.+!U9<%2U8A21Y_#KZBL8D-B<DN)\>"9
M!%QX'PXD1ERFH=GG FJ[G/X/X<R'/0VG1\&N\#PV&1537>O_ /#8/;XSK=.[
M1N/M*Y1@<9<2XZ+X4_QG/MQ_OQ[K[*#[.M9Z=/":7NM@6V&U4IV#A5GBTE7%
M12,9RW)81MK^-+C,>996$%A39\%()F*VV2DD9H/KX\9F]@G9EE$M1HN5I=A.
MXLTO5M2H*MML&6NW)OH0KT*A:@H(!VG;8/\ :"[4<0!;];Q=5K'0UZIH^EWA
MAYJ]E.+CWV!AT8O:S$$^L)U[\R.=1$9:=;F=P6%MI/BS%=S"1=U[?!)DE+E>
MAVGBR&T&9&EMU"BX)(C,S^$,#_!6[!&W#O:5Q_HP'\M;ZQ9G8X]F^.&Q*G Z
M;!U/0;>)WFP_QQHSSOQ)V8]GFML1L]R:-7@Y+;G<D9#)FVULWFR$$D[^Z<]Y
MO>MC9^#.Z&@RF,UQ-N'G>!U9+=(B/@3DZMKW[!2E<$$?23U)(^91*29J-4?W
M/[:-- &F=I^!JE:;;5:]H6)NX&_1KL7&;();IN6R" 1OYG=_?/L1U(?^*=EF
MH:5:_P#-=H&OY9"[[=5HRLI,< =2.7']@V(V ^Z;[?WC9*.PPS1'4".US$2J
M6WN<:G/I2E1D9MS7)S1K7R\"Y6VD\RDIY"X\2N#.[>M-!.1H_!'$"(#UP\O,
MTRY]@=O5N.0O,2!X*J[D#;Q,MG _L_:EL,;6N.N'K'(W&=AX.IXZ;E01S4"A
MP!N3U9SL#U/29?G,:_X\E3F<;1\X0PWS=)(PK(*7)6U<A*,U,-*7$E+3\'B7
M-'2I1'U)-1DDZO\ $KCW3]SK?9-K@1=^:S1=0PM24@ [E%+56L.F^QK!(\!O
M(_PQ[/M1(70NU_0C8VW+5KFG9NEL-R-@[A;J5/B#M:0#U)V$X_/VTWJC).<:
M>:S8"9<W2.9#I_9-16>4E&:G))*2CHRY3_E$$M!D7$CY>)E3_CQPWB[_ ,<X
M?XRT';?F;4>'\E*E"[DEK=PH4;$\PW4@;@[=9([ .)LO<Z%Q%P5Q .G*NG<1
M8SVOOML%J*EN;J/5)!&_7KT/WR?L@&W6OP?(LDQK,X]_?5E:Z]5XJ<&RA65G
M8+,F8<<CDQ$1T-&^M#DE92#6B,AU:$K624G<U+M][.Z-#U'4M-UJK4,[$Q7L
MQM+[G)IR,F\^I37O94M80V,IL86;K6&8 D &C2_[/?:/D:[INF:GHMFGX&5D
MHF5JW?XMV-BXR[O=9LEK6,_=JRU#N^5K2BE@"2.W;1MRD;<3INS=W!TM5G%;
M83*S(**OD$A)FTHG8=E!A2)#TQ$.7$<1Q):WNBD,R&^E4DDJ/;=DO:15VB<-
MIG9?H>)K>/D78NH8%%H W0\]63138[7"FZIE_F+<KI8.8C8G3]K_ &9V=G'$
MKX.'Z;EZ%DXU.5I^?D5$G9P4NQK[JZTI-U-RG^4)S5O6W*"2!;$>K3R2 B B
M B B B B B B B B B B B B B B/Z B>8]AV/'&=3]QUOKWJ[B>B..LUD3,
MH^(4&C^#P:K(<HR/+L?L\.5JCK'J%*HZB_R[+J/$;BVJL6I2;<J<=>NK:<5E
M:/N1E1]=B:<E&EZO06[G.UC2-1T1*\,"G2M$P=6R<;*U6[3L=>5LG5-8MP-.
M3/U+(2EEP\>W!IQPF9E767LO(MR,W36V5\/2M5T[619DDWY^I96DUD:7C93N
MK+B:;IN0[YE6)C66G)S:=.R;;JEP$Q[)C;QLYU.T_P!1M.LOU:S3"LLJ=O.B
M^8:%:%5V,QKIA^PQS-+O&K"URG45NTALPVL@53X9C./-5M+W0@M-1Y]AV^XY
M.[58VXR;G&O:C>*WUSB/3^'M-S]@3I]./PZVHY([AF'?NVK:GGIG9G-56N.N
M%C8](M >UL&W%K!TK!Q[+%T;2=7U?7J4< 9ENI:I0^#C][R'N35H^G9>KXV*
MP/-DMJMMKIC=P$MZ-NH['_G>OFFM' K<OP)S4-W5=W4//Z[+H5ZC2_+ZUO#<
MKPO$L>575$>39L1-*ROJG,L%BJC*BGFF/M7$LHEE+3;0]2<.P96F6TY#4KCZ
M7K6-?EJ"<_#US6Z],Y^+=,LY@!KFF)I]ND:98]F.<;1-1R,6B_%6M*7V:WU&
MK4A9C\K95^B]S4MK656:3HVJ+G-P_ENZJ1I>L W9&J5TT]W;J#FVS'R:[,A;
MM_:R:"ZVY)M<PG;S@V:8Q?62ZW",&U<S34&_SC&K?*-/*N'&BYR>/7>$L3LA
MJ\PRN-$570[<IT-VH:L)-FU..?&CH<V>LC&US7*LC*I:C0;=5;4M1PL2UZ<N
MY*<A,G$P:7J-2)C67@/J 6RMKL>IL*DU#+;*QL#1A=H^EFFFTC5*,"S%T[)"
M56T861;1;4F3W>57>MPP.=/1*KJ'K?NT:]2$-;U,M>QM:@8MK1JW-T0S6+C>
M@VX?;V]HMK#7ZDZW;AM8-5CO6*ZTK\:S[$[_ %1ML[E17\4@V!T<*A7F$"JE
MTQ_!;KI##1+U]M&1EZ7Q1H^7;3Z+JNHT:WI#UT5&W%U>B@>DW:D0E3Y^/K>1
M1A)JM=UU]JX^.33:XL?';*2RK%R>%L_#I5<K1%LP<ZAV*X>3H]N5C6U8.(@%
MGHS:6JYN1IY2NNE[\VZFZA _I2:EU ['#O3SV/ETN7J9MABV62;:]+-MKE7%
MI-2(]5,K-,-1X^8P<P=L4PW'ZJ=-KXZX[] S36L4Y<HV46K,>(4B7LGO:S4L
MS4WK7O-3[1N">T#+QA8QKQ;N$;,;.?!QKV0OE5YV;B+C![JL8TXES9!+W4+C
M7:U<*NO$TO 2RPTZ-PAQEPEC9# +=E8O%F&-/-N12I*478E*491MKNN[Z_&>
M@U*N8<C$FM1.QF:WZJYE?:@9\UM3S%^'N(I-<,7TKSRAR74#27+:UW2]S2S*
ML1U%JLCPQ11I3-<X5]B&1U-3;NUETPT3];T9FZC PL:O"NTZ]JJ<XX]G'>)E
M592 ?^&<8:OIVN8^7@Y&UKX^KZ=F:5BU6#N^YR<._,H-ZK:0V9:UM]&;C]]9
MAG(PN$FIR,5F9TU+A:C(QNZOH+4UWZ5J./EWUVUM8+J7[G(K4VT)-TS=@>H%
M+J+HWF^B:M$]MI8-,QQO)X>@J<WTYQ>SPBHL)-O;Z7V6D-3%5I-J1C]X],F5
MU=D&3X[09!ARYC^34)=U.2 F_2+Z-3SLDY-N9@Y.!ET6X662]&JWG1,S2M*.
M3CW-E+HS:7?=BY56HZ1?Z8^-B/IEJ6XN2Y2Q?15D:<*QC8^/J7?UV49>.&JN
MTYK-5QLS.R*LZCT>_5%R,?']?3-2QS@7YC+;:5[OG?66E_8^-T>EDK!]0*;,
M]!).I.%9AN.-6+SW<[DZ:7VG^XF^:R6<RY,_)=J[I<KQ2SBQ&HKD2FG5UW7-
MO0Y;T)+R5LXN-B''P,;3N=+*<G@C3^#M6LL0NU+Z5J.;GX6J:?7S!<@6?Q++
MIR]/R7QZ[ *'7(#UC;89ERY>?J&7L]:#BY.*=,"<@LN#:-1HN3@:ENK"KO*L
M:K*IRL5K;*;^\0I978^^L[3L4^X2CTXUUTGTZS+0@\=U;T.P[2J'>Y(_GE?<
M5MU6YU89SD]Z]55>,6<&-52)5U8PL?J(=B]VC%BUZ7G>'2DB_4EE/\-1-C1H
M_&_9YQ'AAW9K;M,[/<?14Q<;*LY?_/ZI=H&(V58H>JA,S*-;6&FE+;==S#-?
M4;P+,K,T/C+ SU4D4KF\7V9Y=L4$;^BZ?3J5B5EPEF2^-4[UTFZPU^\6,1;2
M#C=!"NR@%<0Z6LBVI5;TB16E81X3+,SM!^6Q%E/0^V$.=K.28T=];/(IUEM9
MJ06=E/59E9-E'>=R]]KU=ZJK;W;6,R=XJ,Z*_*1S!&90V_*2-I@855F/AXM%
MI0VTXU--AK+%"]=:HQ0N%8J2NXY@#L>O63@QYE0$0$0$2%A_+5W]#4_92PD>
M9^ _-I@?SF3]1.?>#81YCX']).A)@(@(@(@(E>[O;;AEUDF5797^;5-1GUG6
MW6H&"5-K5-89FMO5,PX\:QMXLRBFWD)]Z/7P&+)..7]%'MFHC2+-F61N](QM
ML85( +J<?,MU#$HO'/7B9M]IR;;Z>7DL/-E$Y8IN>['7))M2E23%^][-83W=
MUN&NG7WUA>]R<)$LJ7'N[P6(0M%MF.MM:5WK0YK6T!4Y93(- ,*R+))M\_-R
M2!7W<BCG9=AM78PHV'YI88T3":&PR2 [62+%R57-Q(C!G5VU4S91H<*-<LV3
M$.*VS50QHL[P?:<F59GXZ6CFKQ<ZU!7=EXZKRD6VA5=DL-F.MZ^DUTIDLUS1
M8!96$ZUDXHP7LK)6RS #V6>AV$DJ:>:ZX%E5;N[NMI[WN;'K.[TI2E*4I(DI
M21)2DB(B2DBX$1$741$1<"(NHB%)))))W)ZDGQ)]I@    ;    >  Z ?=*I
M;V_T;LP_>K1W^-6G@2H>/W-^1EK@D0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$3Y.,,O$9.LM.D?49.-H61E^P^8C%+(C_P Z
M*W_J4-^8,J5W0[H[*?:K%3\B)YQ[YMKVH>MK.&L:28[A#*(,JRFY+)DG64-O
M+E.I0B'SV/:?3RXA)7(6M@W^J0HG30HSYB^=>W'LQXAXWJT>KA/3]$K6FW(O
MU*VWT; R[K&"BC?([DO;6OKL4+_SD,09])=A':EPYP-9K5G%^HZZ[7U8U.F5
M5>E9^)36A8W;8_?=W3:2*P'%?\B\H(\#4G1KL<&KT7+V2U2BTL#$%QS[9E4.
M:NLW460E]@VY%8Y6Q'N68TQT_0E*8=AFYR]-PX$H>2\%_P!G/B^C5P.**\*C
M2'0]Y;@:U97F4V!T*VXIQZG^V5#9R=ZC5%BH?8">O<:?VE.#K='8\*VY^1K*
M6#NJM0T1&P;JRCAJ\I<F]-Z6L[LN:K%N"[\F_A+S%M,U@PLS<TAW8:HU++1&
MF+1Y\<?.:AI'$S2A*+3IXC*2+@1DQ3H-76HE)/@1>XCLHXNT;UN$>U7B?#1-
MA5@Z[W6N8@4?Z=LL65H-MA]GB*=O,'K/"3VN<':V.7C#LEX6S';K;G</]YH.
M8S'Q).(*[;#N2WVF8P\ 0=R9B5CO\P-!=NTVD6LT",HN=ZM?F8E>2T)^,R2K
MEAFMPB+J:K&^11\>51'P$>D=O6A#[;$X2XRHK/K-C/=I&;:HW\ V]&[#PY<9
M0I/7F&TDXW]GW7R>YS>,."LBT>JF173K&!2QVVW(WNY5\^?*;FV_F$S3O)R[
M%3Z'5O;9JQB"VS/MBQHH",MIVD)(C-PGZTC>Z,RXK):VT%R%\+@KBDJAVPZO
MI1Y.+.S?BS2.7;O,G!H75\11YMSXN]G(!ZW,RKT\=CTE)[&-&U8<_"':9PEK
M(;I7C9][:/F.W79>[R?4YCL!RJS'<]-QUFPL4WM;:\L6B.UJ+"H)ZE$V=;E4
M2;0S6W#^-MY,MGH6E(/J43CR>!CH-*[:NS?56%:\148%Y.QQM5JNT^]6Z>JZ
MW(%1AOU#.")SNK=A_:9I"FQ^&[\_' +#)TFZG4*&4$C=#2_.X.W3EK)VED*'
M*L8RF/VWC614>01N4E&_2VL&T:(C,R+F7"?>)!\2,C)1D9*(R,B,C(O1<#5=
M,U2OO=-U'!U"K8'O,+*HRE /AN:;' ^!V(/0]9YMGZ3JFE6=SJ>FYVG6[D=W
MG8E^*Y(\=EOK0GV[C<$$$=#)X9\U\!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$A8?RU=_0U/V4L)'F?@/S,P/YS)^HG/O!L(\Q\
M#^:R="3 1 1 1 1 1 1 1*H[V_T;LP_>K1W^-6G@21X_<WY&6N"1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1.#
M(E$9*(C(^HR,B,C+]AD?48@@'Q /QZP"1U!V/M$Z+E6EVFN<M]'F> 89E2>4
MT)/(,:I[9QLCX];+TV&\ZPHN8S2ME:%I,S-*B/K&CU7A?AO7%Y-9T#1M4&VP
M.?IN'E,H_P"#W4NZ$;[@HRD'J"#-_I/%7$V@MSZ+Q#K6DGFYB-/U/-Q$8_\
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M_3='8;]-YW8;J:. B B B B B B B B B B B B B0L/Y:NOH:G[.6$CS/P
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M/?3>G'F6KTVUVHU>@5UV*U3AU9+!K#<CA@"KA3RML=CL!/J/(_M<7Y%%U%G
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M_P :M/ DCQ^YOR,M<$B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M_43GW@V$F3H1 1 1 1 1 1 1 1*H[V_T;LP_>K1W^-6G@21X_<WY&6N"1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1(6'\M77T-3]G+"1YGX#]?W_ !]TP/YS)^HG/O!L(\Q\#^8DZ$F B B
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M(@(@(@(@(D+#^6KOZ&I^REA(\S\!^;3 _G,GZB<^\&PCS'P/Z?U_VDZ$F B
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MJ&XZ],H]TC#UPY345,RQB*JS8GVKTJTDH<FR7756Y>'C]Q_(ST<"1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M&C:51=4P>JVG3L2JVMU_E:NQ*59&'DRD$>1E?&] =7X>J6H>JT+5_ ).0YE
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M[U:._P :M/ DCQ^YOR,M<$B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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ME9M3&K9LBRFCO<NZNIJL+&R\MZ,:W+P,*[4<S'P,<IZ1EV"C'5^<"W(L!%%
M*(_*^1;R45NX6E++%;(MIH%ER5+T&[(7I+N+RK&\4P' =8HK^6:)(UUH[?)Z
M+"J:BE8[VS$@R* YB<_F2$9)$L9::UZ4J'^1+LZ/.9A9E+*!+4SMLW'OP3Q.
MCUBV[A=\1,FFJZ@-G^G5YSXS:?9?;1CHKMIUZ?\ BM^F-LU.3RG!M7*FMIR:
MKFT3E++7KCY]=%Y4O5C-IQPFN&5W/>VL6HU#$R:QA5YC"JT5W"K*VQS^-O?=
M;N.H:_,\W!IYW$M](K6;L<*DIYE$GG4EO?HMTTEQYC2VTMTR(R2VI7!)VZU[
MQZTY@G.RKS,'94YB!S,*EL<A=]R*T=R!LBL=@<AP%YNH;EW\.8<VV_ASA=M_
M+FY=O]6W7;579(-X&H6ENA>HF-;;NBCZWN8O1QW,GGM1+*NTOMM1K6NQ# :C
MA"F2J^VU,S'*;VNI\0IHDF?!@$J7EEDN55UL.%=:W(Q\K5=2P-#T_+[FO.XI
MT/AF_4<?O$NLOU+4L>O,ITX6I7;7_#M&&=KFKY=E=5F!IF&]5:U:ADU6X69@
M7X6)AVZSJE?(F+H&K<1^@7=W<U6#H^F9&H9&5G>C/DT&@6T+I^(E5N17J6JW
MT48XRL5<EA^?>3NAU&VM[3[[$=-KH\XW%8'H7$LLESG)E';1L8M&J2/2P;^^
M-:^%OG6>YD['I\&QMPU%87,_NE:$517/M3'%&1?K&IYF%PS7Z!1J7$6#HF+?
M7RJ<;(X@U6G TG2<'J>;/[O*3+S;D##3-*QLO/.^3Z%3?C\,5UX6+I=G$]@R
M,BK3+M3U- P6H8VDX-FH\0:MEMS5]QI.#3CY0HKYZK,_+.)IM#T4OFY^G^@N
MA-!F.+:+Z58]J)DEEF&>U& 8K#S3*+AU3UG>92W31#OK&:XLS4IY^S5)49GP
MX)Y2(DD1)+H]:;";5M1_AJ"O3ER[ZL%1OUQ*7-6.[$[%K+:D2RQF]9K'9FW)
M)FHT=LRS3,*_4%:O.RJ1F9=+$'T;(S"<JW#3EZ"K#>XXM(  6JE% V$[[#^6
MKKZ&J^SEC638^9^ _'K^W3W[^<P/YS)^HG/O!L(\Q\#^8DZ$F B B B B B:
M+R7<!B.,9+:4#]-EEG7XS/I:K-LRJ8-0_B6#6>1$PJF@Y')E7D*Y4_*;EPWG
MSHJ2[:JF)D21<NUS,EIQ<XX](9 "*TMRK,'&NM.U65G5*C68E)7G<6+SI7WM
MJ58S7GT9+VR%:H+MZ%)(+V+B^G6TU@FVG Y[4],L#<J=T#1>W(COD=U39<*#
M2ALF\TJ2M*5I,E)4DE)41\24E1<2,C+J,C(R,C_60$$$@C8@D$'Q!'0@_"0"
M" 0=P0""/ @]0?OE4M[?Z-V8?O5H[_&K3P1*AX_<WY&6N"1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MV[^[\(W]P^?UCO#;G/+IU"]1VW?W?A(CO#;G/+IU"]1VW?W?A)W]P^?U\_\
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M4=MW]WX1]P^?UCO#;G/+IU"]1VW?W?A(CO#;G/+IU"]1VW?W?A)\O ?'KO\
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MK^NLZ$F B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B?C;L:]V8]7M3H;D^.A+K\%N2PN8PVOJ0X]&
M2LWFD*/J2M:$I5^HS >L"1U"GE8CJ W^TD= ?<>L'IL#T)&X!Z;@>)'M'4=1
M[9^P(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(D+#^6KKZ&JX_P#RY?\ P"1YG[OP_P"X/R^[ _G,GZB<^\&PCS'P
M/Z2="3 1 1 1 1 1 1 1*H:J27<VU\TVT7M7K"-AD_!,TSR[9@64^I=O)]1+
MJ:>I@=N5ST:4;5>Y9O6;K+<A"5.-QE+)24FE5&+6,B_6&=F7^&:;I]F-RD@I
MDZEFY%1RP/Y2^-5A,E?,&57R0Q7<+&38:,?354 _Q'4<G'R-U!'H^%@^E=R2
M>JC)NLK+<I5FKHM3?8DCL6U?,;G,M)6WKV3(GSL8S?4G 6[28\<B;:UV"YU?
M8Q4V$YXTIZ::_65T0I;Q$?32$./&9FX8R#8<G!T74654MU70]+U')1 %1<J_
M'5<ID4 !4NOKLR$0 "M;A6NZJ";;(N/J&M:>G,:M,UC+PZ&<EB<<K3ETIN>I
M&/7E+B!B69QC\[L79I8T6I<@(@(@(@(@(@(@(@(@(@(@(@(@(E'=1I:L/W(Z
M+N28.HF+PLBRBQK9^J+\^+:X5G,RSQ^T13Z2OT-7>S'J'MB8;-K"OKS':AEN
M3CQP($B6NQ5):KTKULO-Q^4(7TG.:K$NZMJ-^.]&39G57?:55V:?AT95XI[V
MK(R*BRFH)7R71J) PJ+]N;DU#3T:ZGQTRFRUJ.6VL\MEE>?D748+N$MHJ.8E
MCVK8B]W>(428"("("("("("("("("("("("(")H[<CJ!<:8:+9SF..]"F_A0
M(E?2R92%N1(%G?64.CAV<M*$K_FM8]8IGO&I/1FB.:5_!,Q8M2S(NT_ JL-+
MZIJ6%IHO'C2N7<$LL4[$+9W0=:F(.US5G9CZIOTM74N5E6U]]7@8.=J#TC<F
M_P!!Q;<E:2HV9EL>M5L"D$5%VW4 L-,Z#19FF6J=CI%D^/XQ:9):X+%SJ)JM
M21[-=_E+"K#M2ZB9K-O+&WL%VB+%],J/(B2XE/+;>4F%3UJ&$L)V*/5=3J-.
M/7Z(FEY6*AQJQRXMM&8EOHUM8/-9Z0AHN2];[<BQAM=WY+NBZ]A=4VG79%AR
M6U*K(YK6/-;3EXB4'(7IRU+C6):@QQ352$5!2U9"*YNN,69,!$!$!$!$!$!$
M!$!$!$!$!$!$!$I%KS>TQ:U8]BFKUG98MH_9:77LS%+]FVLJ*DF:JM7<<I$.
MUN*R3%5'N:S'&H\S%H,Q]+5BY*M>UVI+\<VRQD8%->8V&O4L:C3;='7<\QQ#
M7J?\2R,1=N2_*7,_AU610!9;3C+7:$%5]CB_8&5-***+,6[+U"O5!MORNB:;
M_"J[V WHQ+5MU7>TNB6Y2T(26J03;NUO)\DS'0C3[(<KE.V%O.JWR[IOI6B1
M:UT:?*C5-I)2XAM92+"M9BRGN9"3-QU1F7$QML].6ZHM6M5UN'@WY-*@!:<N
M_$IMR:E _E"7.X"^0Z>4U^/L/2JT<V4T9^?C8UA+,;,;'R[:L=RS;E^:I5]?
M<AQZVYWWE@!A3)@(@(@(@(@(@(@(@(@(@(@(@(FJ=<Z]=EH]J4RU9W-._'PO
M(K&/84-E(J;-B35U4JPCFQ.BFE]I"GXS:7DH4GI636T9DE9C5ZR[4Z7G9*,R
MV8N)DY-6Q/*;:L>UJ^\7P=%?E?D/0LJD[[;38:2B6ZE@T6*&KR,O%Q[ 0"37
M=D5HX4G^4LI*%AUY68#QFM-&J.%J!MDT5/-;2UF5[^F>*6F0&NXG0W+E:L>C
M...V]I'DLV+C;;BERW%)F-FZ\E+CRUDC@?2\05T5:MJ!952JBZSE7?DJJVY3
MWG*I YJPOJ$[A=V.Q)FDTNVVS#78EK+KKP7/5V4Y5X-8W\%LW52!L=E"C8;B
M3.VFGOZ?![ANQM;2TQF7FF1S--CNY,J9:Q=/W9*$T;,B7-6Y,?C.*1)D5:Y3
MKCZJIZ&M2S):2+%<V>B:<N4",],0C,)4(^[9%[XBW* H&2F V*N2"JNEP>JU
M5NKL49!6L9F><?IB&^L4*"63O$QZES6JYNHI;-%XK ]1@ILJ9Z;*W:Q L2N0
ML/Y:N_H:G[*6$CS/P'Z_UX?CY8'\YD_43GW@V$>8^!_,2="3 1 1 1 1 1 1
M 1-7Z@Z8L9O.Q^^@9#;X;EN+JGHILGHFJY^<S!MF$QK6L?BVT.= EPIS2&S6
MV_'6;,AEB2PIMYE"BM]WM998K,HOQVQ,E5.POQFL2WNRVW-6Z6UI95=65LK8
M'E8!CO46#5BME5N2Y,BEFW)IR*TLK6U5WY6WKMLKL2P,EE;LK+U!'8<"PBCT
MYQ.GPW'6G45=.T^3;DESIIDR5-EOV%C8SGS(CD3[*QE2ITQ\R(W9,AQ? B,B
M+(ML[PILB55U4T8U%-8(KHQL6E,?&HK!)(KIHJKK0$D[*"2229:12O>,SM9;
M==?DWVOMSW9&3<]]]K[ #>RVQVV "J"%4!5 ';Q;E<!$!$!$!$!$!$!$!$!$
M!$!$!$"#U!&^VX\?9[XFBZ_162O(8EMF&I&8Y]54F6NYKBV-9"U0MP,>N^CF
ML05-S*RJA6EI$J69[Y5<2VERVHCQ,24D;[#:RJQSW"TD@6Y-%&3CUY3[BT)E
MUM1>Q52*S<^-9;C=]R<XHNNK! L;>F]>^-R[FNC(MQ[;<9#]F6Q;:<BA 6W=
M:ER:*LDUA@K75HQZ*%F]!$J@(@(@(@(@(@(@(@(@(@(@(@(@(D+D>.TF74-M
MC.1UT:VHKV!(K;6MEHYX\R%*;-MYEQ/$C+BD^*5I-*VUDE:%)6E*BMVU)<G(
M^_1DL5E8J]=E3K95;6ZD,EE5BK96ZD%74$>$KKL>IQ8AV8<PZ@$%64JZ,IW#
M(Z,R.I!#*Q4@@F=-P+2;%-.WI4RG7=V=G*A1*L[C)[N;D-LQ30./:%+%GV"W
M'F*J%Q/H(B#X$?PW%.+^$,EKG974D;VV"Z]PH%F1<%*BZ]@!WEBJQ4'H "=A
MU,L"I%9" 0M59JHKW/=X]1(8UTH>B(2JD[;D\HW) $V8+4N0$0$0$0$0$0$0
M$0$0$0$0$0$0$36N=Z>R<]>BPYV99'58F<9R/=XG2%706,B)Q1GPL+HH:K]B
M,II1L/PH%A%C26C,GD*,^(I5$-C-<HO3:LUT6?Y*/6Q8NZKMWZOZH:JXO7Z@
MV4;MO47<(HJ8TV!K.:Y-C8R.J!50N&%+5D,R6U!;=W/K;*NW?Z^!"JH,2MKH
MS,*! CLQ(<2.@FV(T9A"6V66D)(B2AM"4I21?$1"Z[O8[66,6=V+,Q\22=R3
M]/ > Z2VB+6BH@"H@"J!Y ?UU/B3U/6?K%$J@(@(@(@(@(@(@(@(@(@(@(@(
MG3\_Q5_.,,R3$(]].QD\DJI5._=5L2MFSHD.>V<:<4:/;Q9M>IR1#<>CDM^,
MX;/2FZT274(46/E8R9E%F-:S"F]'JO5=@;:;:WKLKYMBR<P;?G39P0-B.LR,
M7(?$R*LFM5-M#BVDMN0EJ'FJL(!'-W;A7Y6W5MN5@5)$T+;[9K.PT-Q70RMU
MMU&QBJQ>-65J<HQZ'B$+);.EI4L(K*B<M= ]7E$93&:3)-B$V[8)2;<U;S:U
MH5G9M]N=GUZA8Q2U'-UB5]*[LG?=;W4[[,G0HBD5JRAPO,-YB8E:XF/?CH.=
M;N\5'?\ S**[BQM2MEY3]ISN#8=[%#$(Z]-MDZ-Z56>E5)8UMSJ?GVJ]E93D
M2W<CU!EULFT88992Q'KHK=17UD"/#822E)2W%2XM:S4XM7!/";+A9756*JT[
MLVLUB@FRYK6!+6LQ.Y4*%4#90-]AN23172:[+'[QV5EK5*CL*Z5K!&U:@#;G
MWW;<GJ!ML.DW"+$O2%A_+5W]#4_92PD>9^ _-I@?SF3]1.?>#81YCX']).A)
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(G3,TU%P+3F'$L,^S+&L-@V$A42#+R6X@T\>7*0V;RX\9V<\RAYY+
M25.*;;-2DH(U&1$7$4&RM76LNHL9'L5"0&*5\O>.!XE4YEYV\%YEW(W$J",4
M9PI**R*S;>JK6<W(I/@&?E;E'B>4[>!G6,=UWT@S.-+DX-J!CV?E 37N3(VG
M\I6=6,>/:3$0(<Q=7B;=O8]H*D+_ ):>44X<1AM^7+?8BQWWF[_=6_9[UNJV
MW+CK8RLM*VNAL46W,!50I0<W>7/76 1NXYEWM&Q +/64FNJVYD!#6,E._>"N
MH;V76 @JM-2O:[[(B,Y"S;0MRN B0F1Y'1XE2S\AR.RC5--6,F_-G2E*)MI'
M$DH0E"$K=??><4EF/&8;=D27UML,-..N(0JAW5.7?F+.Z55HB-99;;8>5*JJ
MJPUEMCD[*B*S,? >,K1&L)"[=%9V9F5$1$!9[++'*UUUHH+/98RHB@LS  F:
MXB;A-#YK>1.,ZK8*E6'QT2LPC2LBKH4[$FEN(9Y<IKYCS$['7VWUICOQ;B/#
MDQI/-'D--O(4@JWV2OOB]9H[[N%R$LKLQWM]8A*\BMFIM+!2R&MV5U',I*D&
M4)O8U:*E@LNI&172];UWFHH+.<T6*MJ[(P+!D#+OLP!Z3OV)9CB>>T43)\)R
M.ERS'9_2%!O,>LHEM52^B6;;O:TZ$Z]&>Z-9&E1MN*(E%P,7+*K:BHMK>LNH
M=0ZE2R$E0P! )',K#?PW!'E*$LKLYQ6ZOW;]V_*0>1^57Y6V\&Y75MCUV8'P
M,[(+<K@(G6*_,L;L\DN\0B6:%9+CS,*3:T[[$J)+:AV#1.PY\9,MAA%C7O<3
M9[H5RY4-N4V]#=?1+8>903[2M[$]9*KC181XUV\@L".O\R<Z,'K9@%M7=JRP
M4D'^S>NM_5:ZGOZM_"RH6/4Q5ANI9'0BRO?O*PU3.JK;4S]G"("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("(")"P_EJ[^AJ?LI82
M/,_ ?FTP/YS)^HG/O!L(\Q\#^8DZ$F B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B=,SI_&:C'[3*LF<K(,7&:F
MWF(NK/HFVZA#\)<>2^B0[_W<WFS2RI23)2R439<>;@>KUGII.J!=^\OT[,Q*
MU7<O:^344KQT ZLU]W=(M8ZV6<B@$["9>$"^7BH1NBY5&0P.W*O<%F:YB=@H
MJI:XLY("5ER2%WGF-!U"9PS8EH#G6$YI"QC*Z8M),(N;."S7.V;M>625C>68
ME/=F,.R(#<*L?G65BTE+3\1B.X\LVV3<4?3Y[#^\V@5NV^#GY.FKEJ".YNQ*
M=,"67V.I'V6-D4^C6-S!5>UJW//RS3ISMHW%+TJQRL9N)LC3R%+6UY65JF8^
M**:B!O=DTVUWT J6=41U#+N3!'KIE$S46Z0O<A=G4N;I6-/8$6$_01JIO2^[
MQ5^1*D16VJU23;KKDVZZ!?\ 2J*'+:):W5R%K)6MTNL68^EIEERV3C<4KG6N
MW=V!M.M8Z3<" !CMEK4EM?*H6^J]JZMT(VR=2N-=VIOC!%KQ*^&K\/E ='.9
M;6FJ*^^XOKQJ;;7O!.]34AK2.5@>K5&O&L><-X_B437Y.!XZSD>KE)5ZM7M3
M-NBN;2BS)UC!:NYGU$BKBNRYN++8G5K,]+4;)&C(HZ7W3(CC$%U^/I^5>JU9
MK</Z1E^A+0Y.7FK=>NKHF+ZQLR:TKQ5MPU4WH,DV55ECTKR"N/?J&.BM;15K
M65C67O:H.%BOIV-;B<]FP=<=LM\Y5S/\A7Q>ZMM'3>^NM;UU(D[66[:0F?0S
M]3<=<S*8[72ZF--M$8K92J5V7434]L5S4F^2F0U76*2=A3$QF'B3*93PRJQ6
M.(G%:=TE>#KS8%0M3(->0HJ1%6]#W=UE>$V0J75DBQ>]="%.\LKWG\ M-M@N
MM+:*N7<*S3WM#9%??V&I]GJKMR1C%ZV!-99*W\Y5NSO(]AJ;OOGT>M5?A5;#
MA4C-G7M4N+6[%TY!T^1C\UE4^YC/2&EQ[I*L?D(@.<S5DHXJB*6DD%I<D%^$
M<LA3E)D:CKIQ\93R][Z73BMC&MJ_M6&;W=AI8=&%;/42"QFXH)7B'1E)]'>G
M!TXV7L1]EW&I9M]K.K^HGHU-M5[\VP[IT+^J1.L5^K^0QM+]*Z2HU%R# J*J
MVLXU+TTM,4C-2HV9ZUT<"+76&!6S909O;UI >BQH)X@28LV8N;*-"3<BF;>^
MUFR^S6.(K\1!D9IU7$MT?!8<^/J&EY>1D#(RJST6U#:J467!]L&I?2;.6MF,
MT^EI0N!H]64XHQ&]-Q]9RP_=W:==57C/3SML5QR:KLC*0-N<JRM*TY^8 S.1
MZTZKXG<9%69GFN=4V9HR/;;D[.'4\&=<+9KLHAPDZI5%)65])-F6.-1;)4Z,
M_&CIDN0GD(CMODXII*[.V*<WN,6T68V/Q;Q!I[7W'F"Z3=I=%^EVY5C;(*:L
MFVQL:^WD0)638Q5&Y0:T:=7DY0%5]_"N#F;#:L_Q7&S[JLM*ZE)->39BI2<C
M&!8E["4 !#3XT6I>I%UIAJ)G<+7JTM[;'=P.7XMT-OD#&(4ECIU36[ZZ)B%8
MUN,V4##Y5W7L$]!R&TBE526N,9;[33Q.)Q QHT[AO(>IK&R],R\C4$#@Y#YV
M/?G!$I-A%3V5TMAW-I[O6V5794M9YF4'+L MSM=QA_T_H^1IZ8GJ.4QDS-/T
MZW)JMK7_ *@K5E^GXB9 1VQKL>UK1S+9R[\I<AM,HS'9CE<!O(T7N0XMEAY5
M^5*8K63NXLO'FWY+N0%6M-0725=,P'X[[33,5];K#[#39ND@L\5"G6M8J 48
MYT!;+@JE.2_TS"? 6RMRQKR$-M]5M?,S56=_4&*AB<.RXWZ9BV<JK<.(2E2B
MQ;%%87/JS/1K4(%^(:41J+@-K<?N+B S;"_(PYD0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$2%A_+5W]#4_92PD>9^ _68'\Y
MD_43GW@V$>8^!_,2="3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M=_0U/V4L)'F?@/S,P/YS)^HG/O!L(\Q\#^:R="3 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1(6'\M7?T-3]E+"1YGX#\S,#^<R?J)S[P;"/,? _F).A)@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(D+#^6KKZ&J^SEA(\S]WZ_+I^),P/YS)^HG/O!L(\Q\#^G
MTDZ$F B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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74\C;:4I22U=7+Q,SXF80!]_]>[:?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g374624g45v58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g45v58.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1=84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %SR^64@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))301$       0     @   D    )
M #A"24T$'@      !      X0DE-!!H      T$    &              ([
M   "L0    8 9P T #4 =@ U #@    !                          $
M             K$   ([                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ([     %)G:'1L;VYG   "L0    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M.P    !29VAT;&]N9P   K$    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MUAK-E<!\;M*M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                 /_B__])0T-?4%)/1DE,10 !";[,_OX>  B <$%$0D4"
M$   <')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                  $  /;6  $     TRU!1$)%
M                                           *9&5S8P   /P   !T
M8W!R=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;
M *(&03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %
MMR@  CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D
M("A35T]0*2!V,@
M                                                          !T
M97AT     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A9
M6B        "U6@  O&<  )(P;69T,@     $ PD   $
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M-]V =)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7>
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M2(BFO:<Y-Q.B_:0/(\*@8)@M"_&@'8@3  "$88  >V[+,7+];9G%MG,W7UC
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M'8  >O;%!J<P;3^_6Z/]7ORYP:$L4!:T89\40&>O=9Y9+XVK5IS3''BHX)-
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MKMB"#9;]FW6!>I2=ARF!!9)1<AN L) M7#6 A(Y410" :(R\*GB A(P)!J.
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MAIV;O:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  "
MX(  E76>8K3PACN;:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV
M% *0#(V'  " BX  C)RO-&X ?E>K>V\7;UVH W O7WFDP'%+3HRANW)H/$&?
M-W-W)\V=]W0D#2^@N'/%  ""?X  C"RN.79!?@:J>G:.;P"F[7;R7QJCE7=L
M3BN@@W?[.^B=]'B,)X2<F7CD#3J>XGC1  "!Q8  B[JM#7Y=?7.I6'W_;GRE
MPGV[7HNB:7VB3:>?5GVH.WF<QWW&)S.;5WW>#3^=-GX[  "!(8  BS"KZH9G
M?,^H.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  "
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M>KRE,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "
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M<*2Q<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "
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M9:7 K&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "
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M94J['X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "
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M'K6!6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30"
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MBS^-!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "
M (  F:2-[Y^"BH>,6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T
M%O^&LH^-  "  (  F1R-:*C,B?6+V*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&
MBYM)+^:%O9HI%KZ%X8]A  "  (  F+V-"+)6B82+>Z[Q>5:)W*LY:$Z(4J>0
M5I&'!J240]6&!*+V+X:%.)\=%FN%2(\H  "  (  D-B>X6C,@M><3&J-<]^:
M FPT8\27[VW%4H>6"V])/^R4AG"Q*TJ3Z'&S$&R6WG$O  "  'W0D$"=C7%C
M@DB;$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "
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M?IJ5SYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "
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M=3^CB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "
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M<L.?&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "
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M:.FL?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "
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M9[2HOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "
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M736V(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "
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MD#-_W8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "
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MC#E[8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "
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M@P^'4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "
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M>FF6F&59;$24XV=X7.&39&ER3$F2#VM-.C:1(&SU)=F1.&X!"SR3E6UT  "
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M=G*/J(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "
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M;:">S&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "
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M:H"8GI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "
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M83FGDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "
M (  ;*&HZG@(8*^F WA34_VC+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU
M  "4,'QC  "  (  ;"BGD']L8#BDKW]04X&AV7\K1>.?)G\$-S&<T'[T)IV;
M<'[R$I*<AG[C  "2Z(    "  (  :[VFAX;R7]FCI89W4R6@QX7D186>"X50
M-MB;JX3E)F^:*(35$I*; X2X  "1QH    "  (  :V2EMXY]7Y&BTHVO4M^?
MYXRR13J='HN[-H::O(L;)CN9)8M*$J69J(FA  "0VX    "  (  :R2E#Y80
M7U2B)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "
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M526Q&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "
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M5+NL+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "
M (  P1-G%5_MKM-I.6*TF^UK/F5@B")M)&?N<VEN^&II7;=PN6S11L=R16\0
M+,]S)G#="@1V*G$4OR!D)6K1K4MFBFR%FHYHOVXLANAJTF_+<D9LSW%@7*AN
ML7+K1<EP2713*^AP\75="6UT:'5KO4EAE76GJX9D('9.F0=F?7;SA7-HLW>E
M</AJTGA<6X%LT'D11,IN<'FO*P]NV7H*".ERW'HMNW=?2X!=J;AA]8 /ET-D
M;'_(@^YFP7^-;Y=I 7]I6E)K&']-0\]LOG\I*D)LY'[M"'9QLWZ&N<Q=58L$
MJ"!@%XG<E;)BIHBU@FEE#(>7;E)G8H:.635ID(6G0N=K.83-*8EK&80:"!1R
M68(_N'%;P)6SIM1>DI.[E'!A+9&U@3%CHH^V;2UF XW46#QH-XP=0AIIXXJ@
M*.5I?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG
M&I+ 07%HNY"O*&!H%X_*!WQS6840MHY9?ZL.I05<8J=\DIQ>_J.^?U]A=J (
M:VYCYYR95JUF+)F/0-9GR9<G)^QFXI4B!T1SN(3JM@I8U+6LI'Y;M;$_D@->
M1*RE?KI@L:@A:L]C':0#5A]E8*!^0$UF\)X?)VYER)E?!QAT X3,LS=N[%]'
MHIEP3V(QD0YQIV3I?FAR]F=W:K1T/VGM5>EU@6Q-/[QVI&YW)@)W6F_\!#)[
M"7$2L<)L+&FKH7MMSVN,D !O4&U0?6MPO6[_:<-R('"?50YS>'(R/OATH'.:
M)5=U#W1X ^%Y<G7)L#%IM7/TG\UK?G3?CGMM('6X>_9NK7:,:'IP,'=@4^UQ
MH7@N/?YRR7C<)(=RYGDF YEYZWI&KI)G@GX?GB9I9GXMC-IK(7XN>I5LQWXI
M9SAN:7XP4MEO[GX[/1QQ%WX\(])PX7X0 UMZ4WXKK1!EGXA'G+-GF(>+BVQI
M:8:Z>2YK((7A9A-LT8454==N;(1G/$MODH/'(S!O!H-3 R9ZK8&"J]9D&))]
MFX!F'Y#\BD%G^H]9> YIOXVO905K>HP:4/9M%HJO.Y1N.HF((J!M78D? OIZ
M^8(#JMQBW)RUFHED[)IRB4MFRY?^=Q]HE96%9"5J7),U4#9K_I$F.O]M$H^/
M(B]KZH[< M5[-X'JJB-A[*;MF<QC_J/IB(1EV:"H=E9GGYUB8V!I:IIA3X!K
M%)?1.FYL(986(<EJJI.0 K=[:H'6J:UA1;$?F49C5*U;A^AE(JE-=;%FW*5%
M8L5HHJ&D3OIJ2IZV.>MK2ISZ(4]IBI:% I][DX'%I:1W%5[#EGIWKV&ZAC1X
M7&1T=*=Y%&;[8?!YTVEG3@9ZFVNW.(M[9FV_'LM\.V[3  "  ')@I'AT>6B-
ME5IU5&J.A0%V)6QI<XMV]FXG8.YWRV_532)XHW%L-\-Y9G+''BAYV'-1  "
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MCSQLR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "
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MB %[('(!>.5[8G,G:'A[L'0W5OI\"'4Z1"]\<'8I+Y=\VW;8%<5]2':%  "
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M@S=T,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "
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M>OJ!Q7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "
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M=W1\8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "
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M;GB)6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "
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M9?&9]U]"63N88&&T2TZ6_&/[/ J5VF8'*N*5?6>>%BZ7A6?'  "3#6F_  "
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M8GR1UH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "
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M6::BCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "
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M5QF;&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "
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M34JL"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "
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M3!.E,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "
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MC-5QS%Q@?6=R\5^0;+QT&V*,6N%U1&5D1\%V9V@3,O)W:&I@&5YWS6M:  "
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MADQEWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "
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M@!!VF61 <9QW4F:;8?UX#VC341]XSVKK/MUYE6S3*I]Z1VY $(A[A6WV  "
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M>G5L>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "
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M<SE\5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "
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M;LYS^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "
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M9J&#"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "
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M8VI\8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "
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M6I:*O'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "
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M4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X!H2<2F$$  "#HVU)  "
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M3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,!SN-^'O1  "  (    "
M (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@
M  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$-I".AH<V*-R-?H<&&+>-
M<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0<H^C0L./%8[.-F^-D(W;
M*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (  4*:J851-1F*HF%;2.TVG
M#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "  '$N  "  (  3\:HE%LJ
M1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('  "=;&45  "  '7X  "
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M0W^=@WVB.*N;SWVP++>:-WV>'R:977V,#M&9Y7VU +"2"7[.  "  (    "
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MB>Y:(G)?>JY= W.':GA?MG2=60AB176G1G5D<7:D,F%EA7=V&BME.W>V  "
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MA.U0-Y\$=?=3DYQ$9@=6JYF95259B)=)0RQ;QI6-+\E<$Y3[&%E>9I!V  "
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M??)>M7EI;ZUA('G\8&!C67IU4!!E;'KF/D=G%WM1*M!G:'N=$C1J>GMO  "
M (  BA%9H(((?-)<:H(';J)>\H'?7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L
M$>9H]X$[  "  (  B1E7F8M/>^=:?8J>;<5=&(F\7I9??XC(3F1AKH?M//IC
M2X="*>EC)X;_$;-GL(9#  "  (  B%Q5]I2">S%8[9,G;1%;E9&.7>Q> H_J
M3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (  A]E4NIV9>JI7O9N?;():
M9YE675Y<TI<(345? Y46._I@CY/3*0E?[Y-H$21E[XN7  "  (  A3!QDE-
M>&IREE;S:J5SLUIX6Z5TV%W)2UYU]V#G.9=W#F.[)9EW^677"[IZQ&8"  "
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M<C=D.7^:9-QF&W^M5G!GT'^C1O1I5'^8-@9J7W^8(O=IRG^C"M]P&'_'  "
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M:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J'(A[!6CQ!)M^*6FR  "
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M9J%JOH3D6A9L"H213'AM)80B/;IN$(/$+6YN=8.7&IAMB(/>!)IX.(*#  "
M (  <9)GIXU&9@!I0XRQ67AJEHO-2^1KL(K./2ALDXH&+-QLWXFZ&BMK]HG,
M!)EX.H,<  "  (  <15F<96-981H&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IK
MA9!?&=!JM(Z(!&QXAX+]  "  (  ;,6"V5)[88*"S57G54B"]%DL1\N#.5P]
M.-:#H5\!)]F$>&$L$O2&NV&5  "#.F6N  "  'P#:Y9_A%I.8)!_P5TA5&:
M!U_01Q" 56)3.$. N620)W2!:V9$$M>"^V9?  "!"6IB  "  '\V:H1\4V(C
M7V]\RV1>4W9],F9\1BY]D&AN-XM]^&HG)NI^BFMG$I1_B6L_  "  &]Z  "
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M6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;$4MT:H;!  "  (    "
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M4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8"8:$9VX,  "  'A;  "
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M4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR"4Q[*H9)  "  (    "
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M1T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F BV(>'):  "  '\&  "
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M/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE  "1E%_D  "  '!Z  "
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M.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D  "&$'EG  "  (    "
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M@@)4;6/7<YE7N6909 ):SVBO4U9=I6KR06-?\6T0+=%@G6[:%;%CX&^*  "
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M>[)$RH^M;>)),(Y*7P%-)HSS3P-0E8O0/<M2W(KY*RU21XK&%"I=ZXF;  "
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M=A=7>6M":)5:=&T+6A1=,&ZZ2C]?H'!*.11A57&T)?E@R'*]#;AI>'+/  "
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M<4A*4Y3R9!].$9,V5?-16Y%Z1KI4"Y 7-C%53X]1(]]54(]D#.%J/(BU  "
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M:EY;;W&]7;5>"7+M4 )@5'0!02UB074 ,)IC.W76';AB^W8]!N=T57>$  "
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M909RDU&D6'ASS5552M%U!EC>.\UV+5P@*N=W0U[9%IUX,& 6 *=^YF):  "
M 'C:;P]LZU7<8[MN:ED35U]OW%PN2>EQ-E\A.PUR:F'0*E)S6F0#%D-T"637
M ,Y^I&<A  "  'R$;99HIUWW8E)J>&"15C9L(V,12-AMG65I.B9NW6>(*9IO
MGVDW%<=P?6FM .!^AFPJ  "  '^\;#5DM&878/AFQ&@25.)HG&GW1]YJ-FN]
M.49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (  :N-A(VY&7[AC9F^D4[ME
M9'#M1LIG%W(6.*-H;G,B*&UHPW/G%1MJR7/: 1-^+G<>  "  (  :<5> W:
M7LA@=G=04N=BEG?_1?1D7'B0-\UEHWD1)]EEJGEX%*YHFGEG 1)^,'OT  "
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M6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1#+1\K&(]  "  &I(  "
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M4TMFE7OS2!MH,WPZ.])I7WQB+C-IZ'R+'GII'7RL"]=OPGT]  "  (    "
M (  7.=B2H,R4J1D;8-!1WUF(8,'.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[
M  "  (    "  (  7&)@;8KL4B9BJHJE1O]D;HGU.LQEE8DM+4MEV(C,':AE
M)HDJ"UEM/H:J  "  (    "  (  6/.#7$Q@3JN#ED_=0X2$!%,^-PJ$FE9A
M*+R%@%D"%U:'B5I<!'&'U5NB  "  &DU  "  'X:5WA_3E-\381_U5:*0GF
M8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "  &WQ  "  (  5DA[6EJS
M3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O!(J MF56  "  ',D  "
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M1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P!%QXHH G  "  (    "
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M0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"  " JFK>  "  'KK  "
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M/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (    "
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M,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (    "
M (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[
M  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$
MQ713  "  'V8  "  (    "  (  .GR"NW<*,5V#SW=\)W:$97>N'"Z$EW>H
M#J.$27>2 FZ# GHK  "  (    "  (    "  (  .@V JGXG,.>!]GY/)PN"
MK'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "  (    "  (    #__P
M__\  /__  !M9G0R      0#"0   0                    $
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MK-J7FX?=IRJ"AH:;H8IM=X5ZF]!8H81BE=!$$H-SCVPP!8*-B%;4PHQJPJ;
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MA%[(_Y=FH/:V!Y2MG42BKY(;F;^.^H^]EFE[((V)DS-G48M_D!%3OHEMC,U
MBH==B6$N+H4TA:''[);8JF"T_I0BI=>AKI&2H7"."X\YG3%Z3(T)F0)FEXKX
ME,Y3-HCPD'1 ,(;OB],M_X38AL'&^Y9DL[^T().NKE:@UY$?J06-08[(H]%Y
MGHRAGJ=F"HJ3F6-2QHB"D^(_YX:/C@TMV(2,A[O&+I8#O1FS99-.ML2@(9#
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M"X$>CZ<N5H#.B!K*"H9UQ<VW X4\OL"C6800MWV/68,2L"5[8H)1J-1GC8'
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M4(7OA/(LQ81+@Q"_)Y&^FR:M=(^8F#&;/(V7E5&(BXO DHEUJ(H.C]=BQ8B
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M?/G&W(9'>N6U-(5^>Q^BIX3)>UJ/=(0I>Z5[S8.;? IH 8,A?(M47X*T?2!
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M@37%^7/3E2>S\'2PDO*A2W6.D+:.'G9WCGUZIG=[C$]G%'BDBC%3O7GAA_=
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MA1W$F6)PL""R=F3<JX&?LF<EII2,@&EWH81Y,VOXG'EE^&ZLEV)3'W&)DA-
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M-&QGIXB5P6WAHQR#U&]MGH)QOW$PF>5?N7,JE3E.('5)D%\\XG>EBS8LCWI
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M#6D,AQJ/TFL9ACQ^_VTJA5)MWF]?A&Y<CW''@YA+H'15@KH[%W<F@<\KI7I
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M?9UG='/$?=!9LW5(?@A+SG<#?DT^;WC@?IHQGWKY?O,F)7T]?U2-(FXAA4B
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MCR]FQ&.UC2=9,V=@BR%+JVM5B1P^R6]]AQ0R='/OA/4G:7A]@L:,?UA\FI6
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M>)XNNX#F>DXFQ8$@?!D@*H%L?>%E$W[U=_)<37\U>-93,W]/>:-)V7]8>F9
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M@%0  /__  #__P  __\  &UF=#$      P0A   !
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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M3H.!V%^+?]1KD'K1<)1WSW27=<YWF'/->9IRS7N;<<Q]FW#+?YQORX"=;\N
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MFJ^!PY*LA<B+J8K,A*>2SX"FG-" HZ7/@*&FSH"AILZ H:;.@*&FSH"AILZ
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M6=O=.V++Y3]WN]E(B:O.5YB@QF6DF,!QK).[>K.0N(&XC+6$NXBSAKZ%LHG
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M14K_JT55_+!&8?:V26OPO$YTY\)5>]_(88#1PVJ-Q+IPG;BR=:FMJWNSHZ6
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MK,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQO^@-1K_G4(N_Z)"//^J0$?_LCY1_;I
M6?/#1&#HSTYCW]Q99\_88'G SV:*LLAKFJ;"<*:;O':OD;A[MXFU@;R"LH?
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MK?^@,!3_HS8B_Z\P*/N\+2OHS2PHU> P,,?I.$2Y[#Y7K.E%9Y[G2W62X%.
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MLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"ZL_^2+0[_DCX>_YE%*_^?1#7_I$5
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M:-*2SVC2DO^"* G_@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/*
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M_Z%*0/^C4$K^HU54]J)<7>^@8F?HG&EPX99T>=J0?8+1B8:+RH*-D\5]E9G
M>9V>O':EH;ASK:2U<KBELG+#IJQTPZ:G=L.FHW?$I:%XQ*6A>,2EH7C$I:%X
MQ*6A>,2EH7C$I:%XQ*6A>,2EH7C$I?^()PG_B#@7_Y-!(O^;1"S_H$4U_Z-)
M/_^E3DC[IU11\Z9:6^NE8&3CHFAMW)US=M&5>H+)C8*+PH>*D[R"D9JW?9F?
MLGJAHZ]WJ::K=K.GJ7; J*1WPJBA><*GG7K#IYMZPZ:;>L.FFWK#IIMZPZ:;
M>L.FFWK#IIMZPZ:;>L.FFWK#IO^()PG_B3@7_Y5 (?^=0BO_HD0T_Z5(/?^H
M3$;XJE)/[ZM85^>K7V#@J&EIU*%P=<N9>('"DG^+NXN&E+6&CIJO@I6@JGZ=
MI*9[IJ>C>K"IH'F\JIUZP:F:?,&IF'W"J)9]PJ>6?<*GEGW"IY9]PJ>6?<*G
MEGW"IY9]PJ>6?<*GEGW"I_^))PG_B3@7_Y8_(?^>02K_HT(S_Z=&._ZK2T3U
MKE%,[+!75.2Q7ES;K6AFSZ5N=<6==8&\EGR+M9"#E*Z*BYNHAI*@HX*:I9Z
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MVX;)9=N&R67;ALEEVX;)9=N&R67;ALEEVX;)9=N&R67;AO]X) ;_>#40_WY
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MK&)9QJ1J9KR=<7*TEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV
MP9Z,@,F>BX#*G8J RYN*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+
MF_]_(@;_A3 /_Y4V%O^?.QW_I3TD_ZM!*O6P12_LM4PTX[I4.=BW64C+KV%8
MP:AH9K>A;W*OFW5\IY5\A*"1@XN:C8N1E(J3EH^'FYJ+A:6=B(2PGX:$OI^%
MA<F>A83)G86$RIR%A,N;A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;A83+F_^
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M>N1@NWOB7\=\X%_:?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^
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M[[@Q#N3#-PW9RCL6R\5&)[^_4#BSNEA'J;5?5)^P95^6K&MICJAR<8:E>'B
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M/C3_H3XS_ZH_,_^J/S/_JC\S_ZH_,_^J/S/_JC\S_ZH_,_^J/[&Z 0"CR
MEM8  (OT"0&#_Q8">?\@!F__* QG_S 27_\W%UC_/AM2_T0?3/]*(DC_4"1$
M_U4F0?]:)S[_7RD[_V0J.O]I*SC_;BPV_W0M-/]Z+C/_@2\Q_X@P,/^/,"[_
MEC$M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,J3"  "6SP  B-\
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M:*&'@6Z;@XATEX"0>))^F7R.?*)_BWJM@HAZNH.'>LN#AGO>@H5[WH&%>]^
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M44'OS%)![^520.WQ44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@,
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M)2S_I28K_Z\F*O^[)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@
MB\X  '[;  !U^0< :_\/ 6+_%@);_QX#5/\F!4[_+@9)_S4(1?\\"T'_0PT^
M_T@.._].$#C_4Q$U_U@2,_]>$S'_9!0N_VH5+/]R%BK_>A<G_X,8)?^.&23_
MF!HC_Z :(O^J&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<
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M&0#%L"L%NZTY#[*I1!NII4XGH*%6,IF=7CN2FF1#BY=K2H:4<E" DGE5>X^
M6G>-B5YRC))A;HJ<9&N)J&=IB;9H9XG(:&>)XV=HB?)F:8?S96J&\V1JAO-D
M:H;S9&J&\V1JAO-D:H;S9/]N$@'_?A  _XT0 />:#@#;IPH T[ + ,JT%@#
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M&&K74!]DUE@E7]5?*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y
M1-2_04/5V$!$T^Q 0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##
MI0  M:X  *FX  ">PP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C
M31M<XU4@5^-=)%3C9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X
M-S_ERS<_Y>0W/^/S-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP
MJK0  )Z^  "3R0( B-0& '_N#@!Y[1L!<>TG VKN,@AD[CL-7NY#$UCN2Q=3
M[E(:4.]9'DSO8"!)[V<C1^]O)43P=R=!\( I/_"**CWQE2P[\:$M.?*N+CCR
MOB\W\] O-_/G+S;Q\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL   G[L
M )+&  "&T $ >]T% '3W$0!M]QP!9O@F U_X+P9:^3@*5/E #E#Z1Q%,^DX4
M2/M5%D7[6QA"^V(:0/QH'#W\<!TZ_7@?./V"(#;]C2(T_I@C,OZD)#'_L24P
M_[\F+__/)B[_XR8N_^,F+O_C)B[_XR8N_^,F+O_C)JVM  "?MP  DL(  (;-
M  !YV@  </(( &C_$0!A_QH!6O\C U3_*P1/_S,&2O\["$;_0@M#_TD-0/]/
M#CW_51 Z_UL1./]A$S7_:!0S_V\5,/]X%B[_@A<L_XT9*O^9&BG_I!HH_Z\;
M)_^Z'";_QQPF_\<<)O_''";_QQPF_\<<)O_''*&T  "3OP  ALH  'C6  !L
MX@  8_P' %S_#P!5_Q8!3_\> DG_)@-$_RX$0/\T!3S_.P8Y_T$'-O]&"#/_
M3 @Q_U$)+O]7"BS_70HJ_V0+*/]L#"7_=0TC_W\.(?^*#R#_E1 >_Z 0'O^H
M$1W_L1$=_[$1'?^Q$1W_L1$=_[$1'?^Q$96\  "&QP  >=,  &O@  !>[0
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M5X=K_5:':_Y6AVO^5H=K_E:':_Y6AVO^5O]>%P'_;!(!_W@4 ?^#%P#YBQH
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M2$FTSDA)L^E(2+'V24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E
MPJ$  +:I  "KL0  H;H! )C#!0"0R1  BLD@ 8/)+P5[R#L-=,=%%&[&3AMH
MQ58A8\1=)U[#9"M:PFLO5L%R,U/!>S9/P(0Y3,"//$K FSY'P*@_1L"X0$7
MS4!%P.@_1+[V04.]_T)#O/]#0[S_0T.\_T-#O/]#0[S_0]:-  #&FP  N*4
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M(S3K]2,TZ_@C-.OX(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP
M==4! &GA!@!D\Q$ 7O,< 5GT)@)4]# $3_4X!DOU0 A']D<*1/9.#$'W50X_
M]UP///=C$3KX:A,W^',4-?A]%C/YB!<Q^908+_JA&2[ZKQHM^[X:+/O/&RO[
MYQLK^^L;*_OK&RO[ZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP  9]X
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M3%>0S$Q7D.=+5X_W2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@
MSXP  ,26 @"[G@( LJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YX
MI%@E<Z)>*VZA93!JGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9
MRDA1F.9(49?U2%&7_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$
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M-4&X_3= M_\W0+?_-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L
MD;@  (;  @![R < =,L2 '#,(@%KRS #9LL\!V'+10Q<RDX16,I6%53*71E1
MR60<3LEL'TO)=")(R'XD1<B()T/(E2A!R*(J/\BQ*S[)Q"L^R>$J/L?R*SW&
M_"T\Q?\N/,7_+CS%_RX\Q?\N/,7_+L23  "VGP  J:8  )VN  "2MP  AK\
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M$2?U\1$G]?$1)_7Q$:.H  "6L@  B+L  'O%  !OS@  8M<  %;>  !.\ <
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M9/\_@F3_/_]9#@#_9 L _VX* .IW" #;?0@ U((* ,R$$@##A20!NX,T!;.
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M1&5XS$5E>.=$97CW0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0
MV'P  ,N% @##C , NY$# +.4"0"LEA@ I98H IV4-@>6DD$.D(]*%8J-4AR$
MBUHB?XE@)WN'9RQWA6XP<X-U-&^"?3=L@88[:7^0/F9^FT%C?JA#87VV1&!]
MR41??>5#8'WV0F!]_T%A??] 87W_0&%]_T!A??] 87W_0/]G  #C=   TG\
M ,>( 0"^CP( MI4! *Z8!@"FFA4 GYHF IB9,P:1ES\,BY5(%(634!I_D5@@
M>H]?)7:-92IRBVPN;HIS,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:
MA.-"6H/T05N#_T!;@_] 6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,
M  "YDP  L)@  *>= @"@GQ( F9\C 9.>,06,G3P+A9M&$G^93AAZEU8>=99=
M(W"48RALDFHL:)%Q,&60>31ACH(W7HV,.EJ,ESU8C*0_5HNR0%2+Q4!4B^%
M5(KS/U6*_C]5B?\^58G_/E6)_SY5B?\^58G_/N]O  #6?   R(<  +V1  "T
MF   JIP  *"B  "9I!  DZ4@ 8RD+@.%HSD)?Z)##WF@3!9TGU,;;YU:(&J<
M825FFF@I8YEO+5^8=S!;EX T6):*-U65E3E2E:([4)2P/4^4PSU/E-\\3Y/R
M/$^2_3Q/DO\\3Y'_/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG
MHZ$  )BH  "0J@T BZL; (6K*@)^JC8&>*E!#'*H21)MIU$8::98'&2D7R%@
MHV8E7:)M*5FA=2Q6H7XO4Z"(,D^?DS5-GZ W2YZO.$J>P3A)GMTX29WP.$F<
M_#A)F_\Y29O_.4F;_SE)F_\Y29O_.=MZ  #(AP  O)(  +&:  "FH   G*8
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M)#B__R0XO_\D.+__)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0
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M!).N  "%MP  >,   &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q(
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M.7-FRSIR9N8Y<F?W.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90
MW6X  ,]V 0#'>P, P'\$ +F # "Q@AH JH(J J. -P6=?4(+EWM+$9)X5!>-
M=EL;B71B((5R:22!<7 G?F]W*WMN?RYX;8@Q=FR2-'-KG#9P:J@X;FJW.FUJ
MR3IL:N0Z;6OU.&UK_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P  V7$
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M.%UX_C=>>/\V7GC_-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0
MKHT  *2/  "=D1  EY(@ )&1+@.*D#D'A(Y##'^-3!)ZBU,7=8E:&W&(82!N
MAF@C:H5O)V>$=RMC@W\N8(*),5V!E#-;@*$V67^O-U=_P#A7?]HW5W_P-UA^
M_398?O\U6'[_-5A^_S58?O\U6'[_->EH  #4=   QGX  +N'  "RC0  J)$
M )Z4  "6E@X D9<< (N7*P*%EC<%?Y1!"GF321!TDE$5<)!8&6R/7QUHCF8A
M98QM)6&+="A>BGTL6XF'+UB(DC%5AY\S4X>M-5*'OC51A]8U48;N-5*%^S12
MA?\T4H7_,U*%_S-2A?\S4H7_,^-L  #.>0  P8,  +:+  "LD0  HI4  )>9
M  "/FPL BIT8 (2=)P%^G#0$>9L^"'.:1PUOF4\2:IA6%V:771MCE6,>7Y1J
M(ER3<B59DGLH59&%*U*1D"Y0D)TP3I"K,4R0O#),D-,R3(_M,DR.^C),C?\Q
M3(S_,4R,_S%,C/\Q3(S_,=QQ  #(?@  NX@  +&1  "FE@  G)H  )"?  "'
MH@8 @:,4 'RD(P%WI# #<J,[!FVB1 MHH4P/9*!4$V"?6A==GF$;69UH'E:=
M<"%3G'DD4)N#)TV:CBE*FILL2)JI+4>9NBU&FM M1ICK+4:7^2Y&EO\N1I;_
M+D:6_RY&EO\N1I;_+M%W  #!A   MHX  *J5  "@FP  E9\  (JD  !]J0
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M$JZ7  "AG@  E:4  (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X
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M 1/YD@$2^J("$?JS A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M
M<[T  &;&  !9S0  2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <
M_QP &?\B !?_*  5_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_
M?P$'_Y !!?^@ 03_K@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8
M %K/  !+U0  /]P  #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0
M$/\9  [_'@ -_R, "_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P
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M+(-6S"R"5^8L@5?W*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60
MXF   -5G  #,:@, QFP% ,!L#@"W;1T L&XL :IL.02E:D0(H&A.#9MF5Q&7
M9%X5E&)E&9%@;!R.7W,>BUY[(8E=@B2&7(LFA%N4*(%;GBI_6JHL?5JW+7Q:
MR2YZ6N,N>EOU+7I<_RQY7/\K>ES_*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0
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M+VEG_2UI9_\L:F?_*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>
MLWH  *MZ! "D>Q( GGPB )A\+P*2>CL%C'A%"H=W30Z#=542?W-<%GMR8AIX
M<&D==6]P(')N>"-O;8$F;6R+*6ILEBMH:Z$N9FNO+V1JOS!C:]@P8VOO+V1K
M_"UD:_\M96O_+&5K_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX
M *9^ 0"??Q  F8 ? ). +0*-?SD%B'U#"8-[2PU^>E,2>GA:%G9W81ES=6<<
M<'1N'VUS=B)J<G\F:'&)*&5PE"MB<* M8&^M+U]OO2]>;]0O7F_M+U]O^RU?
M;_\L8&__+&!O_RQ@;_\L8&__+.M>  #8:0  QW(  +QY  "S?P  JX(  *&"
M  "9@PX E(0= (Z$*P&(@S8$@X) "'Z 20QY?U$0=7U8%')\7QAN>V4;:WIL
M'FAY=")E>'TE8G>')V!VDBI==9XL6W6K+EITNR]9==$O673L+EET^BU:=/\L
M6G3_*UIT_RM:=/\K6G3_*^9A  #1;0  PW8  +E]  "O@P  IH8  )R&  "4
MB P CHD9 (F)* &#B30#?H<^!WF&1PMTA4\/<(16$VV"71=I@6,:9H!J'6-_
M<B!@?GHC77V$)EI\CRE8>YPK5GNI+%1[N2U3>\XM5'KJ+51Z^2Q4>?\K57G_
M*E5Y_RI5>?\J57G_*N%E  #,<0  OWH  +2"  "KAP  H8H  )6+  "-C0D
MAXX6 (*/) %]CS$">(X[!7.-1 EOC$P-:XI4$6>)6A5DB&$888=H&UZ&<!Y;
MA7@A6(2")%6$C292@YHI4(*G*D^"MRM.@LPK3H+H*TZ!^"I/@/\J3X#_*4^
M_RE/@/\I3X#_*=MJ  #'=0  NG\  +"'  "FC   G(\  (^1  "&DP4 @)02
M 'N5(0!WE2T!<I4X!&V40@=IDTH+99)1#F*16!)>D%\56X]F&%B.;1M5CG8>
M4HV (4^,BR--BY@E2XNE)TF+M2A(B\HH2(KG)TF)]RA)B/\G28?_)TF'_R=)
MA_\G28?_)]%O  #!>P  M80  *N,  "@D   E90  (F7  !^F@  =YL. '.<
M' !OG2D!:YPU F:</P5BFT<(7YI/"UR:5@]8F5P259AC%5.8:Q=0EW,:399]
M'4J5B1]'E94A196D(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D
M0Y#_),IU  "[@0  L(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!F
MI24 8Z4Q 5^D.P-;I$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@
MAAI"GY,<0)^B'3Z?LAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_
M(,)\  "UB   J9   )Z6  "3FP  AY\  'ND  !OJ   8ZP$ %^M$0!<K1\
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M!RO%J@@JQ;X(*L7:""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP
MD:(  (2I  !XKP  :[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  Q
MSR< ,- Q "_0.@ NT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4
MI@(AU;D"(=72 B#3ZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD
M 'FQ  !MN   8+X  %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP
M(M\E "'@+@ @X#< '^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6
MYJP!%>;  13GW0$3Y>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY
M  !AP   5,8  $C*   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T?
M !?N)@ 5[BT %.\U !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P
M"O6N  GVP@ )]MD "/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5
MR0  1\X  #O2   QV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\
M'0 -_2, #/TI  K^,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;
M  #_JP  _[L  /_.  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0
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M&II%T1N81>D;ED;X')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$
M\E   .%4 0#95@4 TU4) ,Q5$@##5B( O%<R ;=6/P*R5$H%K5-4"*I170NG
M4&0.I$YL$*)-<Q*?3'H4G4R!%IM+B1>92I$9ETJ9&I5)HQN32:X=DDF['I!)
MS!Z.2N4>C4KV'HM+_QZ+2_\=BDO_'8I+_QV*2_\=BDO_'?]%  #_30  Y50
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M)'57_2-U6/\B=5C_(758_R%U6/\A=5C_(?]-  #E5P  TU\  ,AD  "_9P
MMV@  +%G!P"I:!0 HVDD )YH,@&99ST$E&5'!Y!D3PJ,8E<-B&%>$(5?91.#
M7FP6@%US&'U=>AI[7(,=>5N,'W9;ER%T6J(C<EJO)'%:OR5P6M4E;UOM)6];
M_"-O6_\B;UO_(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P  LVP
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M(V%F_R)A9O\B86;_(NA8  #38P  Q&L  +EQ  "P=0  IW<  )YU  "6=@T
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M(-!G  # <@  M'L  *J"  "@A@  E8@  (>(  !\B@  =HP. '*-&@!NCB<
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M%#J:JQ4YFKT5.9K9%3F8[Q8YE_P6.);_%SB5_Q<XE?\7.)7_%[MZ  "OA0
MI(P  )B1  "-E0  @9H  '6=  !HH   6Z0  %:E# !3IA< 4:<C $^G+P!,
MIS@!2J=! 4BG20)&IU $0Z=8!4&G7P8_IF@(/:9R"CJF?0LXIHH--J69#C2E
MJ0\SI;L/,Z74#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC   G9(
M )*7  "&G   >:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"L3(
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M !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M  !HLP
M7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9 !79(@ 4
MV2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0 #>"X  S@
MT@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O   4,$
M $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$
M"^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #KO
MZ](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-
M   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@  /4>
M  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<
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M![@PW0>U,.X)LC#["K P_PNN,/\+KC#_"ZTP_PNM,/\+K3#_"_\S# #_-@8
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M%H9&_1:&1O\6A4?_%85'_Q6%1_\5A4?_%?\_  #L2   W4\  ,]3  #&50
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M&6M7_QEK5_\9:U?_&>M,  #85@  R%X  +QB  "S90  JV4  *-B  "<8@X
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M) "":S !?FHZ GII0P1V:$L&<V=2"'!G60IM9F -:V5F#VAD;A%F9'849&.
M%F)CBQA@8I<:7F*D'%QBLAU;8L4=6V+A'5MB]!Q;8O\;7&+_&EQB_QI<8O\:
M7&+_&N!5  #+7P  O6<  +)L  "I<   GV\  )1L  ",;0@ AFX3 ()O(0!]
M;RT!>6\X G5N00-R;4D%;FQ0!VMK5PII:UX,9FIE#F1I;!%A:7037VA^%EUG
MB1A;9Y4:66:B&U=FL!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_
M&MM9  #'8@  NFH  *]P  "F<P  FG,  (]P  "'<04 @7(1 'QS'@!X<RH
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M%TAXJQA&>+T91GC5&49W[QA'=OP81W;_&$=U_Q='=?\71W7_%\EE  "Z;P
MKG<  *1]  "8?P  BW\  'Y_  !S@0  ;(,) &B$$P!EA2  8H8L %^&-@%<
MAC\"685& U>%3@54A54'4H1<"4^#8PM-@VL-2X)T#TB"?Q%&@8P31(&:%4*
MJ19!@+H60(#2%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0  JGT
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M""Z?YP@MG?<)+9S_"BV;_PHMF_\*+9O_"J^   "CB0  EXX  (V3  !_E0
M<I@  &:<  !;H   3Z0  $6G   ^J0P /*H4 #JJ'P YJBD .*LR #>K.P U
MJT, -*Q+ #*L4P$QK%P!+ZQF BVL<0(KK'\#*JR. RBLG@0GK+ $)JS%!":K
MY ,EJ?4$):C_!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@  :Z(
M %^F  !3J@  2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ IMSH
M*+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<
MMO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL  %:P
M  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X
M !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX
M$,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX  !
MNP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1
M-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M
M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    TPP
M*L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*
MWS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75  #F
MYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS   ']
M !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0  ZB4
M .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #TR
M],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P   [@
M   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@  /8@
M  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L   _[
M /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_
M '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S /<
MNP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_
M /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X
M_P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!N #O
M <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<
M&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS
M /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<
MY@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_
M'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0
M=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X W@_,
M -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_(@\
M_R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06<@#B
M%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?) ,P8
MW@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L _R@,
M /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>;0#2'W4
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M!Y\P_PB>,?\(G3'_")PQ_PB<,?\(G#'_"/\P  #_-0  [S@  .(Z  #;.00
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M$'A&_P]X1O\/>$;_#_ _  #?20  S4\  ,%3  "X5   L5(  *M.!0"D3A$
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M$N!-  #+5@  O5T  +)A  "H8P  G6$  )5=  "-7@D AUX3 (-?( !_7RP
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M$U-BJA528KL546+2%5%A[1528?L44F'_$U-A_Q)38?\24V'_$M%6  # 7P
MLV8  *EK  "<:P  D&H  (5G  !]:0  =VH- '-K%P!O:R0 ;&PO &EL. %F
M:T$"8VM) V%K4 1>:E<&7&I=!UII90E8:6T+56AV#5-H@0]19XT13V>:$DYG
MJ11-9[D43&?/%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P  L&H
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M#CQZY@X\>?<./'C_#CQX_PX]=_\./7?_#KQH  "O<@  I'D  )9Z  "(>@
M?'H  '!\  !C?P  7((  %>$"P!3A10 488@ $^&*@!.AS0 3(<\ 4J'1 %(
MATL"1H=3 D2&6@-"AF($0(9L!CZ%=@<[A8,(.861"CB$H LVA+$+-H3&"S:#
MY LV@O8+-H'_##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P  =X
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M AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=  !-H0
M0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z !VQ0@ <
ML4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L $Z_Y !.N
M_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K   .[
M #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$
M#KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (
MO?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[
M   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8  LI
M  #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$
M ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$   5
MR   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT  #:
M/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(  -[B
M '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -T@
M!]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H,0
MZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[& '2J
M  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@   .$
M  #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX
M /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_
M#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\
M?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T \0#)
M .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D
M_PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W
M (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #& .<
MU@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4
M /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X
M[0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T T0#;
M .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2
M%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6!
M .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4
MS GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_
M%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-
M@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8 P!'U
M +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_'1(
M^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5?0#&
M%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR ;$:
M_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P [!T2
M .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?> "Y'WX
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M!8PQ_P6,,?\%C#'_!?\M  #J-0  W#H  ,X]  #&/   P#<" +LS#0"S-!D
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M"N5   #/20  P4\  +52  "K4@  H4\  )M*  "42@P CTL7 (M,) "'3"\
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M#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*  ##4P
MMED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q '!7.@!M
M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+652:#5A4
MIPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@  LUP
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M#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF  "-9@
M@F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI  55J1P%3
M:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,0F?%#$)G
MX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0  ?6D
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M=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4 /X!, 3V
M5 $\@%P".G]E CA_;P,V?WP$-'^*!#)_F@4Q?JH&,'Z]!C!^V@8P?? &,'O]
M!C![_P8P>O\&,'K_!K!L  "D=0  E'4  (9U  !Y=@  ;G<  &-Y  !7?0
M3X$  $>$  !"A@P /X<3 #V('0 \B"< .XDP #J).  XB4  -XE( #:)3P T
MB5@!,XEA 3&); $OB7@"+8F' BR)EP,JB*<#*8BZ RF(U ,IANX#*87\!"F$
M_P0IA/\$*83_!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0  28D
M $&,   YD 4 -9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ KE%(
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M ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   CK@
M&[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $
MMUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W (^1
M  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N   $[L
M  Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1   Q%
M ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !Y
MG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4   ;(
M    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0  -12
M  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !NI@
M8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M    #4
MUP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#  #G
M4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP  5;8
M $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A    XP
M .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W0P
M^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\
M' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"(
M /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K .8
MZ0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_
M "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /
MB0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .( WP#P
M -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X
M_P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E
M (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M -
M^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D
M /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8
MU@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#"
M /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&
M*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06(
M ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\
MM S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>
M"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.
MB@"Z#I$ N0Z8 +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_
M *<3_P"G$_\ IQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28
MR!(T ,030 "_%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6A0"N
M%HP K!:4 *L7G "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;
M_P&;&_\!FQO_ ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM
M +<=.@"S'D4 L!Y/ *T>5P"K'E\ J1]F *@?; "F'W, I1]Y *,?@ "B'X<
MH""/ )\@F "=(*( FR"L 9HAN0&8(<H!EB+D 90C]0&2(_\!D2/_ 9 C_P&0
M(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH L"4H *PF
M- "H)D  I2=) *(G4@"@)UH GB=A )PG9P";)VT F2=T )@G>P&6)X(!E2>+
M 9,GE &1*)X!D"BI 8XHM0*-*<8"BRG? HDJ\@*'*O\"ABK_ H8J_P*&*O\"
MABK_ O0H  #C,0  T38  ,4X  "\-@  MC   +(K"0"K+!0 IBTB *(N+P">
M+CH FRY$ )@O30"6+U4 E"Y< )(N8@"0+FD!CRYO 8TN=@&,+GX!BBZ& H@N
MCP*'+IH"A2^E X,OL@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_
M ^TO  #;-P  R3T  +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5-34
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M0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T @D W ']
M0 !]0$@ >T!/ 7E 5@%W/UT!=3]C G,_:@)Q/W(#<#]Z VX_A 1L/Y %:S^<
M!FD_J09H/[@'9T#,!V9 Z =F0/D&94#_!F5 _P9E0/\%94#_!=P^  #'1@
MN4L  *Q,  "@2@  ET<  )%#  "+0P@ AD,2 ()$'@!^1"D >T4T 'E%/0!V
M144 =$1, 7)$4P%P1%D!;D1@ FQ#9P)K0V\#:4-W!&=#@05F0XT&9$.9!F)#
MIP=A1+8(8$3*"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20  MDX
M *=/  ";30  DDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P24(
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M"5!0X0E04/0(45#_!U%/_P=13_\&44__!LE+  "Y4P  JU<  )Q6  "/50
MA50  'Q0  !U40  <%() &M3$@!H5!T 950G &)4,0!@5#D 7E1! %Q42 %:
M5$\!6516 5=470)65&4#5%1N!%)4> 515(0&3U21!TY4H A,5*\(3%3""4M4
MWPE,5/,(3%/_!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6   @5<
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M!CY@_P8^8/\&/F#_!KE9  "K80  FF$  (MA  !_80  =&$  &EA  !?8@
M660  %1F"0!19Q$ 3F<: $QH) !+:2T 26DV $AI/@!&:D4 16I, $-J5 %"
M:EP!0&EE CYI;P(\:7L#.VF)!#EIF 4X:*@%-VBZ!3=ITP4W:.X%-V?\!3AF
M_P4X9O\%.&;_!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:   4FH
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M J5Q  "3<0  @W$  '9Q  !L<@  8'4  %9X  !,?   0X   #N#   SA@
M+8D* "J*$0 IBQD )XLB ":+*@ EC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?
MC6L '8UY !R-B@ ;C9P &8VN !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW
M  ",=@  ?78  ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD   )9,"
M !^5#  =EA( ')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4F&0
M$YAS !&8A  0F)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%
M?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT  !>@
M P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J
M  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@
M<80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K   ,
MK@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A  "P
M<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@  :HX
M %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %N0,
M +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^90
MOG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH  %6?
M  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"    Q    ,4$
M  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60  SVH
M ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN  !!
MM   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T    -$   #2
M @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P  .1O
M  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   UO
M*,   !S$   2R   #,L   //    TP   -@   #<    WP   -\   #A
MXP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?  #V
M<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O
M /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U (X
M] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E
M /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\
M-P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H Z@"/
M .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\
MU@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W
M #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P
MD #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_
M ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D
MZ0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P C #+
M )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H
M_P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _
M -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X
MO "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M
M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$
M0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1
M *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\
MH W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X
M#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/
ME@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_
M /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4
MJ15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6
M&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=
M  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$
M )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@C0"*()<
MB2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;
M+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F
M1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0& *),!?BB>
M 7TIJP%[*;D!>BG- 7@JZ %W*_D!=BO_ 78K_P%U*_\!=2K_ >4L  #0-
MP3@  +,X  "H-0  HC$  )TM  "9*@X E"L8 ) L) "-+3  BBTZ (<M0P"%
M+4H @RU1 ($N6 " +EX ?BYD 'TN:P![+G,!>2Y[ 7@NA0%V+H\!="^; 7,O
MJ )Q+[8"<##) F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0  NSX
M *P]  "A.@  FC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!],T8
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M!%H_W019/_($63__ UD__P-9/_\#63__ \P_  "\1@  JT@  )Q'  "11@
MB$0  ()   !\/P  =T , '- %0!O02  ;$$J &I!,P!H03L 9D)# &1"2@!C
M05  84%7 &!"7@%>0F4!74)N EM"> ):0H0#6$*0 U="G@160ZT$54._!%1#
MV@140_$$5$/^ U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20  @T<
M 'U#  !V0P  <40* &U$$@!J11T 9T4G &1%, !B13@ 8$4_ %]%1P!=14T
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M!$9._P-'3O\#1T[_ [U,  "N4@  G%$  (U1  "!40  =U   &Y,  !G3@
M8D\  %U0#0!:4!0 5U$> %51)P!343  45(X %!2/P!.4D8 35)- $Q350!*
M4UT!25-E 4A3;P)&4WL"15.) T-3EP-"4Z<$05.X!$%3SP1!4^P$05+[ T)2
M_P-"4O\#0E'_ [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@  7%,
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M JY<  ";70  BET  'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!9@H
M/F<1 #QH&@ [:"( .6DK #AI,@ W:CH -FI! #5J20 T:E( ,VI; #%J90 P
M:G !+FI^ 2UJC@$L:I\!*VJP 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA
M  "58   A&   '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4 -F\.
M #1P%0 S<!X ,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I<FT
M)W)[ "9RBP D<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".
M9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@* "MY
M$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV
M !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0
M>6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*##0 @
MA!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&
M@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X
M &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5CPT
M$Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *
MD8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U
M  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@ "YP.
M  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@  G(0
M )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1
M@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,  "G
M$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H  *F.
M  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)C@
M/I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S#
MLQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"  "X
MEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G   -Z(
M "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_!@  P L
M ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)B@
MR9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[   "2U
M   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,    S0,  ,X(
M  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?   X)$
M ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P  !B_   0
MPP  ",<   #*    S0   -$   #5    V    -D   #;    W0   -\   #A
M!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X   /24
M  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_ $4
M_P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /  DP#N
M )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_ .$
M_P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$ ^P!,
M /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C )4
MX0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -  _P#0
M /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !' .T
M40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$ T0"7
M ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#" /\
MP@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\ 2P#;
M %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3 ,$
MF@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\ M #_
M /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#* $X
MQ@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0". +, E0"R
M )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_ /\&
M  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@ N0!1
M +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *< D0"E )H
MHP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q
M#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09* *H&
M4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9< F JA
M )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F%P
MUAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/3 "=
M#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&? (L1
MJ@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0  RB4
M +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2%DX
MD!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :IP!^
M&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP  + J
M  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD A1]0
M (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4BI !T(K(
M<R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(  *@P  ">
M+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0 ?"9+ 'HF
M4@!X)E@ =R9> '4F90!T)VP <B=T '$G?0!O*(@ ;BB4 &PHH0!K*:\!:BG
M 6DJVP%G*O$!9RO_ 68K_P%F*O\!9BK_ =0O  #"-@  KS8  *$U  "6-
MD#   (HM  "'*@8 @RD0 '\J&@!\*R4 >2LO '<L. !U+$  <RQ' '$L30!P
M+%0 ;BQ: &TL80!K+6@ :BUP &@M>@!G+H4 92Z1 60NG@%B+ZP!82^] 6$P
MU0%@,.\!7S#] 5\P_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.   B34
M (,R  !_, $ >R\. '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H,E
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M DX^_P%./?\!3CW_ < _  "N0P  G$,  (Y#  ""0@  >D   ',]  !M/
M:#T% &0]#@!A/A< 7CXA %P^*0!:/C$ 6#XY %<^0 !5/T8 5#]- %,_50!2
M0%P 4$!E $] ;P%.07H!34&' 4M!E@%*0:4"24*U DE"RP))0N@"24+Y DE!
M_P))0?\!24'_ ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H0   8T$!
M %]!#0!<010 64(= %=")@!50BX 4T(V %%"/0!/0D, 3T-+ $Y#4@!-1%H
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M ;--  ">3   C4P  '],  !T3   :DP  &!*  !92P  5$P  %!-!0!,3@X
M24\5 $=/'@!%3R8 1% N $)0-0!!4#T 0%%$ #]12P ^45, /5)< #Q29@ Z
M4G( .5)_ 3A2C@$W4IX!-E*O 352Q $U4N(!-E+U 391_P$V4/\!-U#_ :Y/
M  "93P  B4\  'M/  !P3P  9D\  %Q.  !43P  3U$  $I2 0!&4PP 0U02
M $%4&P! 52, /E4K #U6,@ \5CH .U9! #I620 Y5U$ .%=: #978P U5V\
M-%=\ 3-7C $Q5YP!,%>M 3!7P@$P5^ !,%;T 3%6_P$Q5?\!,57_ :A2  "5
M4@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@ /5H0 #M:
M%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O76P +EUZ
M "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5  "/50
M?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F - #1A$P R
M8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D )V1V "9D
MA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6   >ED
M &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI$  J:1<
M*6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =
M;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P  &E=
M  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A( (',:
M !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4=9
M$W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A  !;
M8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3 !5]
M&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH "WZ=
M  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6:
M3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)%  ,
MB1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6  "(
MJ0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<   1G0
M #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0  E!8
M )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.  "4H0
ME+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX  #6#
M   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(  * 7
M  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0  HJT
M *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0   D
ME0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T  *T1  "M
M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,  +*W
M  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <HP
M$Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,  "[$
MO!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K  #$
MO   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4L0  #;8
M  :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*"0  RPT
M ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;K@
MV[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@  !,(   #%
M    R0   ,T   #0    T@   -(   #5    U@   -D   #;    W@4  . *
M  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP  \*L
M /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X 5@#[
M %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@"; .@
MH@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\ W@#_
M /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P %H
M[0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H G0#8
M *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\
M" #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4 X !=
M -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#' *$
MQ0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\   #_
M    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7 ,L
M7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P MP"E
M +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_
M_0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P 60"Z
M %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A *<
MJP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V    Z@
M .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L %D
MJ@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H IP"8
M +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T  ,L*
M  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %, G@!9
M )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ", K$
MBP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2  "S
M$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*
M6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;  @ W
M '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F&0
MH14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<050"%
M$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04
MU0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0  EAX
M )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z%U8
M>1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I
M'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24  (@B
M  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8
M &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@).D
M8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H  !]
M)   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54 &4E
M6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N< 6"KX
M %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U*@
M<B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<
M*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W %(O
M_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P  :RX&
M &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L
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M ;,]  ">/@  C3X  '\^  !U/@  ;#T  &8Z  !@.0  6SH  %<Z" !3.Q
M43L8 $X[( !,.R@ 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"
M/W$ 03]^ $ _C0 _0)P /D"M 3U P $]0-T!/4#R 3U _P$^/_\!/C__ :Y
M  ":0   B4$  'Q!  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX 3#\5
M $D_'0!'0"4 1D L $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]0V\
M/$-\ #M#BP Z1)L .42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "6
M0P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP 1D,2 $1$
M&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP -T=Z
M #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "210
M@D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0 #])&  ]
M22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW #%,
MA@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2   ?D@
M '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W3AT
M-D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1A  J
M4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL  &U+
M  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D ,%4A
M "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D5Y(
M(U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.  !?
M3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P= "=<
M)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA
M !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;4@
M4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D(  >
M9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L %&6> !-E
ML0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@  3U<
M $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5;2$
M%&TI !1M,  3;3D $FY" !%N3  0;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +
M;<( "VS@  QK\P -:_T #6K_ ()9  !R60  9ED  %Q:  !46@  2EP  $%?
M   Y8P  ,68  "II   D;   '6\  !=R   2=0D #W</  YW%  .=QL #7<C
M  QW*@ +=S, "G<\  EW1P (=U( !W=?  5W;P $=X   W>4  %VIP  =KL
M 775  %TZP "=/8  G3\ 'M=  !M70  8EX  %E>  !.8   16,  #QG   S
M:P  *VX  "1R   >=0  %WD  !)\   -?P8 "8$,  6!$0 #@18  H$=  &!
M)   @2T  ((V  ""0   @DP  ()9  "":   @GD  (*-  "!H   @+0  (#+
M  !_YP  ?O(  '[Y '1B  !H8@  7F(  %-D  !)9P  /VL  #9P   M=
M)7@  !Y\   7@   $8,   V&   (B00  HL*  "+#@  BQ,  (P8  ",'P
MC28  (TO  "..0  CD0  (Y1  ".8   CG$  (Z%  ".F0  C:T  (S#  ",
MWP  B^X  (OV &YH  !D9P  6&D  $UL  !"<0  .'8  "][   F?P  'H0
M !:(   0C   #(\   :2    E0   )8'  "7#   EP\  )@3  "9&   FA\
M )LF  ";,   G#L  )Q(  "<5P  G&@  )Q[  "<D   FZ4  )NZ  ":T
MFN<  )KQ &IM  !>;P  47(  $9W   [?   ,8(  ">'   >C   %I$  !"5
M   *F0  !)P   "@    H@   *,!  "C!@  I L  *4.  "F$@  IQ<  *@>
M  "J)@  JS$  *L^  "L30  K%T  *QP  "LA0  K)L  *NO  "KPP  J]D
M *KH &1U  !7>0  2WX  #^$   TB@  *9   !^6   6FP  $)\   FC   !
MIP   *H   "N    L    +    "Q    L@,  +0(  "U#0  MA   +<5  "Y
M'0  NR8  +PS  "]00  O5(  +UD  "^>0  OI   +VD  "]MP  O<8  +W7
M %Q_  !0A0  1(L  #B2   LF0  (9\  !>D   0J0  ":X   "R    M@
M +D   "]    OP   +\   #     P0   ,,   #$!0  Q@H  ,<.  #)$P
MRQP  ,XF  #0-0  T44  -)7  #2:P  TX(  -.7  #3J0  TK@  -+$ %6,
M  !)DP  /9H  #"B   EJ   &JX  !&T   )N0   +T   #!    Q    ,@
M  #+    S0   ,T   #/    T    -(   #4    V    -H&  #=#   X!$
M .,:  #F)P  YS@  .A*  #I70  ZG(  .N(  #KFP  [*@  .RR /\ #0#_
M  L _P + /\ $ #_ !H _P F /\ ,@#_ #T _P!( /L 4@#X %H ]@!B /,
M:0#Q &\ \ !U .X >@#L '\ ZP"$ .D B@#H )  Y@"6 .0 G0#B *4 X0"O
M -\ NP#= ,L VP#F -D ]P#8 /\ V #_ -< _P#7 /\ U #_ /\ " #_  0
M_P $ /\ #0#_ !4 _@ A /H + #W #@ ] !# /  30#M %4 Z@!= .< 9 #D
M &H X@!P .  =0#> 'H W0!_ -L A0#9 (L U0"1 -, F0#1 *  SP"J ,T
MM0#+ ,0 R0#= ,@ \0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\   #_    _P
M /\ "@#X !$ \0 < .P )P#I #( Y@ ] .( 1P#= %  V0!8 -4 7P#2 &4
MT !J ,X < #, '4 R@!Z ,D ?P#' (4 Q0", ,, E #! )P OP"E +T L "[
M +T N@#0 +@ ZP"W /L M@#_ +8 _P"V /\ M@#_ /\   #_    _0   /,
M!0#I  X X0 6 -L (0#5 "T T0 W ,X 00#* $H QP!2 ,0 60#" %\ P !E
M +X :@"\ &\ NP!T +D >@"W (  M@"' +0 C@"R )< L "@ *X J@"M +<
MJP#( *D XP"H /4 IP#_ *< _P"G /\ I@#_ /\   #^    \0   .4   #7
M  H S0 1 ,< ' #" "8 OP Q +P .P"Z $0 MP!, +0 4P"R %D L0!? *\
M9 "M &D K !O *H = "I 'H IP"! *8 B0"D )$ H@"; *  I0"> +( G0#!
M )L V@": .\ F0#] )@ _P"8 /\ F #_ /T   #P    X0   -$   #&  0
MO0 - +< %0"S "  L  K *T -0"K #X J !& *8 30"D %0 HP!9 *$ 7P"@
M &0 G@!I )T ;@"; '4 F@![ )@ @P"6 (P E0"6 ), H0"1 *T CP"[ (T
MSP", .D BP#X (P _P", /\ C #_ /,"  #B!P  S <  +\$  "W    L0 (
M *L $ "G !D I  D *  +@"> #< G !  )H 1P"8 $X E@!4 )4 60"3 %X
MD@!D )  :0"/ &\ C0!V (L ?@"* (@ B "2 (8 G0"% *D @P"X ($ R@"
M .4 @ #U '\ _P!_ /\ ?P#_ .@-  #0$   OA   +$.  "H#0  HP@  * "
M# "< !, F  = )4 )P"2 #$ D  Y (X!00", 4@ B@). (D"5 "' ED A@)?
M (0#9 "# VL @0-R ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U '8'R !U".,
M=0GT '0*_P!S"O\ <PK_ -T5  #$%P  L1<  *46  "<$P  EA$  )0-! "3
M" T C@<5 (L)( "("2H A0HS (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,
M8 !X#&< =PQN '4-=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W
M &D0_P!I$/\ :1#_ - =  "Y'@  J!X  )L=  "2&P  BQD  (@5  "'$0<
MA0X0 ($/&@!^$"0 >Q M 'D0-@!W$3T =A%$ '012@!S$5  <1%6 ' 17 !N
M$F( ;1)J &L2<P!I$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7
M_P!@%_\ 8!?_ ,<B  "P(P  GR0  )(C  ")(@  @B   'X=  !\&0  >A4-
M '<5%0!T%A\ <18H &\7, !N%S@ ;!<_ &L710!I&$L :!A1 &886 !E&%X
M8QEF &(9;P!@&7D 7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8
M'O\ 6![_ +\G  "I*   F2@  (LH  "")P  >R4  '8C  !S(   <1P) &X<
M$0!K'!H :1TC &<=+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B
M %D@:P!8('8 5B&" %4AD !4(IX 4R*N %(CP !1(]T 423R %$D_P!1)/\
M42/_ +DK  "C+   DRP  (8M  !\+   ="H  &\H  !K)0  :2(% &8A#@!C
M(A8 82(? %\C)P!=(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E
M: !1)G, 3R9_ $XGC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_
M +,N  ">+P  CC   ($P  !W+P  ;RX  &HK  !E*@  8R<! %\G# !<)Q,
M6B<; %@H) !6*"L 52@R %,H.0!2*4  4"E& $\I30!.*50 32I< $PJ90!*
M*W  22M\ $@LBP!'+9H 1BVJ $4NO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ
M  ":,@  B3,  'PS  !R,P  :S$  &4O  !@+0  72P  %DL"0!6+!  5"P8
M %(L( !0+"@ 3BTO $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T
M0S!Z $(QB0!!,9@ 03*H $ RNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6
M-0  AC4  'DV  !N-0  9C4  &$R  !<,   5S   %0P!@!1, X 3C 5 $PQ
M'0!*,24 2#$L $<Q,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S8  _-&L /C5X
M #TUAP \-I8 .S:G #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_ *8V  "2-P
M@C@  '4X  !K.   8S<  %TV  !7,P  4S0  $\T P!+- P 2302 $8U&@!%
M-2( 0S4I $$U+P! -38 /S8] #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV #@Y
MA0 W.I4 -SJE #8ZN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X  "..0  ?CH
M '([  !H.P  7SH  %DY  !3-@  3C<  $HX  !&. H 1#D0 $$Y%P _.1\
M/CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SM3 #8\7  U/&< -#UT #,]@P S
M/I, ,CZD #$^M@ Q/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+/   >SP  &X]
M  !D/0  7#T  %4\  !..@  23L  $4\  !!/0< /CT. #P]%0 Z/AP .3XC
M #<^*@ V/S$ -3\X #0_0  S0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M0I$
M+4*B "Q"M0 K0LL +$+I "Q"^0 M0?\ +4'_ )D]  "'/@  =S\  &L_  !A
M0   63\  %(_  !)/@  1#\  $!    \000 .4(- #="$@ U0QD ,T,A #)#
M*  Q1"\ ,$0V "]$/0 N144 +45. "Q%6  K1F, *D9O "E&?@ H1H\ )T>A
M "9'LP F1\D )D;G "=&^  H1?\ *$7_ )5   ""00  <T(  &="  !>0@
M54(  $Y"  !%0@  /T0  #M%   W1@  -$<* #%($  O2!8 +DD> "Q))0 K
M22P *DDS "E*.@ H2D( )TI+ "9+50 E2V  )$MM "-+?  B2XT (4R? "%,
ML0 @3,< ($OF "%+]P B2O\ (DK_ )!#  !^1   ;T0  &1%  !:10  4D4
M $I&  !!1P  /$@  #=)   R2P  +DT' "M.#@ I3A, )T\: "9/(0 E3R@
M)$\P "-0-P B4#\ (5!( "!04@ ?45T 'E%J !U1>0 <48H &U&< !I1KP 9
M4<4 &5'D !I0]@ ;3_\ '$__ (I&  !Y1P  :T<  &!(  !62   3D@  $=)
M   ^2P  .4P  #-.   N4   *%," "14"P B51  (%46 !]6'@ >5B0 '58L
M !Q6,P ;5SL &E=$ !E73@ 85UD %UAF !58=0 46(< %%B: !-7K  25\(
M$E?A !-6]  45?\ %%7_ (1)  !T2@  9DL  %Q+  !32P  2TP  $1-   \
M3P  -5$  "]4   I5@  )%D  !Y;!P :70T &%T2 !==&0 67B  %5XG !1>
M+@ 37C< $EY  !%?2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:
M  U=\  -7/P #ES_ 'Y-  !N3@  8DX  %A/  !/3P  2%   $!2   X5
M,%<  "I:   D70  'U\  !EB 0 390D $68/ !!F%  /9AL #F<B  UG*0 -
M9S( #&<[  MG10 *9U  "6==  =G;  &9WT !6>0  1FHP "9K<  V7/  1E
MZ0 $9/4 !&3\ '=1  !I4@  75(  %12  !,4P  0U4  #M8   S6P  *UX
M "5A   ?9   &6<  !-J   /;08 "W ,  AP$0 '<!8 !7 =  1P)  #<"P
M G U  !P/P  <$H  '!7  !P90  <'8  '"*  !OG@  ;[(  &[(  !MY0
M;?(  &WY '!6  !C5@  658  /_B__])0T-?4%)/1DE,10 $"5%7  !'6
M/EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+  %X#P
M>1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#  !Z
MF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8   .6,
M #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "##0  @Q
M (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'D
MAJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT  "ER
M   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0  CPT  ) 0
M  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B   E9T
M )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_   9
MA   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<  )X+  "?
M#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0  *6I
M  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1D@
M"Y<   2<    H    *,   "F    J    *D   "J    K    *T$  "N"0
ML T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=  "X
ML0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@   Z<
M  "K    K@   +(   "V    N    +@   "Z    NP   +T   "^    P 4
M ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-I
MS;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8   "Z
M    O@   ,(   #&    R    ,@   #*    RP   ,T   #.    T    -(!
M  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@  YZ4
M .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U
M %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1 .$
MF0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_
M /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H %
MY0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#,
M )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\
M  #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2
M ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[ )8
MN0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_
M    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!- +P
M4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$ J@":
M *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W
MZ    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P 30"K
M %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5 )D
MGP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G    TP
M ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"< $X
MF@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L F@"*
M *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$  +0
M  "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!-
M (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!] *,
M>P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+  "=
M"   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!( (
M3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\ < "M
M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1$
MBPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T
M!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)
MO !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10
M 'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H
M:0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:
M$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L  '08
M  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+
M %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M(
M41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>  !I
M&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %88
M30!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK
M $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B(0
M8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-
M'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C
M^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0  62,
M %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT
M12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ]
M)_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8  %$F
M! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3
M #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\
M."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ  !)
M*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM
M60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__
M )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@
M02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S
M,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q
M  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4 /#(-
M #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F
M+3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_
M-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W
M$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ
M "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\.
M;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M
M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H "%
M=@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@  :3L
M %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G0A$
M)D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :
M184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_
M  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \ ($D4
M !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X(
M$TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="  !.
M0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0
M%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX #5&1
M  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+10
M1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8$P 0
M6!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,  58
MGP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2   04D
M #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@$  )8!4
M"& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?F@
M7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X  #50
M   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,  &@8
M  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE   :*D
M &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7   H
M6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4  !R
M&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y
M  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B9
M&V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]%0
M?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R  !^
MR@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P  %',
M  YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*$   BQ4
M (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-P0
MC=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$   B%
M    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#   F@\  )L3
M  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP  GLL
M )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4
MF    )P   "?    H0   *(   "D    I0   *<   "H!   J@D  *P-  "M
M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\  +'.
M $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D    J
M *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&  "^#
MP!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z
M   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S    MP   +P
M  "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/ P  T@H
M -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\  @#_
M    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T
M7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F
M -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_
M_P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9
M %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,(
MJP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_    _@
M /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#% %D
MPP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$ I0"O
M +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@   .(
M  #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9
M *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"? *P
MG@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L   #!
M  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3 )\
M6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8 C@"T
M (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P
MJ  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/
M %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O '\
MP !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B    FP %
M )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30"" %(
M@0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '( N@!Q
M -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@   (H
M" "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2
M ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F ,L
M90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\
M 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D
M4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D
M %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R# 0
M<0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>
M"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-
M]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0  9PX'
M &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$
M50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)
M$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0! %X1
M"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5
M $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\
M0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46!@!4
M%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2 $,8
M6@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_
M )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-&PP
M2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \
M'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C
M  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D 1!\/
M $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\
M-"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_
M*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0- #TD
M$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI
M "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@
M;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H$  U
M*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM
M=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX
M %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P+1,
M+BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C
M,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ
M  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7
M "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$
M'3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0
M-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W
M&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1
M !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !--@
M1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]&  <
M/1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/ !%
MH@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD
M #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L
M%$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%GP ,
M1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P  #H\
M   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>
M  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX
M!$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_   Q
M0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;  A1
M(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D  %&_
M  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M10
M)D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9'0
M624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ  !8
MU0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H3   (D\
M !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0  8B
M &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !ASP
M8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<  !9:
M   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB
M  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR   :^8
M &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D   ,
M9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y
M(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\  '?O
M %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %<P
M '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "('
MB24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H %)6
M  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]    @0   (4
M  "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7%0  F1T
M )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<  !
M8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0   )4   "8
M    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@  JA0  *T=
M  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y:P
M+G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4   "H
MJP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T  +\3  #"
M'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>   )X
M !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y    NP
M +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-  #6%
MUR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_    _P   /\
M"0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D
M .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L
MR #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X !0#W
M  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P
M8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#(
M +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E  L
MW0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X
M &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^ *4
MVP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8 Q  .
M +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F %P
MI !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4 S "4
M .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP + *L
M$0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!;
M ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"% .(
MA #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ ' )H #@"6
M !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6 (0
M6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -, =@#O
M '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L "P"( !
MA@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V
M %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H &D
M^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![  T >0 2
M '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8
M: !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X ] !=
M /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P / &T
M%0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8
M %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L
M5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B
M !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"
M7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_
M *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:!A(
M6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*
M"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4
M  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X 40T4
M $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$
M01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!
M&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1
M%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX .11I
M #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0
M;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _
M%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9
M<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(   :B(
M %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y&18
M-QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K
M'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE
M  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X:
M # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E(W\
M)".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0
M*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB
M'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/
M !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@
M1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D
M)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR- !DL
MGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+   0RP
M #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X
M'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4
M,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X  #LN
M   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B
M !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0-;
M#C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P   S
M,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X
M)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!
M  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q,@
M+#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -
M/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^
MUP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0  *3<
M ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '1"<
M!D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$T0
M1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L  " ]
M   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK
M  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@  2ND
M $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#   6
M1@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F  !3
M+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><  %'T
M %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   230
M#E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<*@
M7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"
M  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@  "ED
M  5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P  9RT
M &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&  !'
M1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8    F,   !F
M    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8  '0R
M  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%2@
M.TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\   !R
M=0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$
M-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4   -5,
M "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!    @P
M (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6+
MECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT  "1C
M   ::0  $F\   QU   $>P   (    "%    B0   (T   "1    DP   )0
M  "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I(P  J3$
M *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP   3
M>   #'\   .%    BP   )$   "6    FP   )\   "B    I    *4   "G
M    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&   OB8  +XX
M  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -B
M!8\   "6    G    *(   "G    K    +    "S    M@   +<   "Y
MNP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L  #4
M0   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X _P 5
M /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@
MV0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_
M /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2 .@
M&P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G
M ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N /H
MK #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T %@#*
M "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B *X
M9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /( G #_
M )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R !H
ML  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P 8 ":
M &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P
M_P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4 G0 >
M )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"* &
MB0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P _P!\
M /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$ BP 8 (D
M( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@
M '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N /\
M;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4 'L &P!Y
M "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L
M8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_
M +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L !T
M:P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!=
M &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!
M  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@ 8  ?
M %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$
M4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+
M"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8
M( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T 20!G
M $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "##P
M=!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!,
M 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%
M<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0
M &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T
M1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V
M#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8
M  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T?
M #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T
M+A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1
M&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41
M(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2,
M "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@
M1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4'0 M
M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF* "$9
MG  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(   1"
M #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"
M)ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;
M'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(  #LB
M   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T (1TD
M " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP
M%2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD   T
M(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB
M*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL $2;
M ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q)0
M+24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5
M*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJ
MUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*   *R<
M "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H
M$"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )
M+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H  "0J
M   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O
M  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^<
M!#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M   =
M+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X
M-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8  #?R
M %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :,P
M%34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^,0
M/SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR %HP
M  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.   $CL
M  \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0  1C8
M $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T  !*
M-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$   Q$
M   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(  $T]
M  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&.
M/3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+   "
M3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X  !7
M1   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/   .SL
M #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4    5P
M %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@
M84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\  #%
M   I0P  (48  !I*   33@  #E$   I5   $6    %L   !>    80   &,
M  !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@  ;D4
M &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'   C
M2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0   &\   !P
M    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-
M  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <50
M%%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X   !_
M@0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$  "1
M5P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@  #F@
M  =N    =    'D   !^    @@   (8   ")    C    (X   "0    D@
M )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E30
MI6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<   !W<   !^
M    A    (H   "/    E    )@   ";    G@   )\   "B    I    *8
M  "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P  NE@
M +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/
ME@   )L   "A    I@   *H   "N    L    +$   "T    M@   +@   "[
M    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X  -!E
M  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W "4
M\P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#.
M ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$
M_P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#? "  W@ I
M -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T
MMP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *, _P"=
M /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D +X
M+ "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &< I !M
M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\
MC@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@ )P"F
M "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )
M;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_
M .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2 "@
MCP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^
M &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L
M  "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ", ?P J
M 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N &D
M;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D
M    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D &X
M*@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M
M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5
MAP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A
M "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %,
M<P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")    >P,
M ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4
M50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!'
M 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H  &8*
M  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F
M $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^ '@
M/0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.  !7
M#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $(
M)@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4 -0"%
M #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0
M2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y
M R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@># "T'
ME0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%   1A0
M $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20
M,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E
M#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8  #T6
M   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG
M "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D
M'1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8   U
M%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00
M*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[
M !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R&@
M+QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =
M%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7
MT@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'   *QL
M "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P
M%QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .
M&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T  "4=
M   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ
M !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4
M#!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?   @
M'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC
M-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^, !R/Q
M &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >(0
M&B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (
M*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB
M  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)   &"4
M !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H
M 2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD  !-
M)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D  !$K
M   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"
M   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !**0
M/RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P   -
M,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^   Y
M2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+   /"P
M #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )-P(
M!3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@
M0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\  #(O
M   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %/@   $$$
M  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00  2$\
M $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q   K
M,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"  !*
M!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H  %%:
M  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G-0
M(3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$   !3 @
M5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;
M9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/   '#\
M !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=    7P
M & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I7P
M:'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD  !!-
M   *40  !%4   !:    70   &    !C    9@   &@   !J    :P   &T
M  !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60  >&T
M '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9   "
M7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P   'T   !_
M    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,  (I\
M  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G    ;0
M '(   !W    >P   '\   "#    A@   (@   "*    C0   (\   "1
ME    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P  "?
MBP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W    ?0   (,
M  "(    C0   )$   "5    F    )H   "<    GP   *$   "C    I@
M *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V?@
MM98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP   )8   ";
M    H    *0   "H    JP   *P   "O    L@   +0   "V    N0   +P
M  #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P  RXT
M ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L ,P#F
M #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U ,,
M?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_
M /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#, #8
MQ@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L
M '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,
M  #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W
M *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@
MEP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<   #=
M    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P )@
M-P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '  A0![
M (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #
MKP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4 , "#
M #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S ',
M@ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K    FP
M (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S #
M<0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B
M (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@   '\
M  !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O
M &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5 ($
M5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$   !I
M    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8
M+P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+
M $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>
M60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P *@!*
M "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X
MEP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@  4 8
M $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H
M0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T
M *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L  $0*
M  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4 -P J
M #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L *(
M+ "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-   [
M#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G "\
M+  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R
M "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V#P
M,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G
M!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&
MQ@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0  +A
M "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P
M( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6
M#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(  "@1
M   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR
M !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0
M$0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03   B
M$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01
M.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q
M &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?%0
M'!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /
M%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N %\6
M  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P  &18!
M !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P
M"QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.
M&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@! !48
M @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#
M  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+'
M01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,; @ 1
M' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")    C
M30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P  /B
M #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .( 0
M#2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G20
M*%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(  #(B
M   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -)0, "B8&
M  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@  +50
M "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D   I
M)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%  (N
M"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U   #-@
M   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H)@
M(R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T!P
M-0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<   Z
M;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*   (B<
M !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [!0  / @
M #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !":@
M08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL  !DM
M   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @  104  $8(
M  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9   2WL
M $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T   0
M-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$  $\$  !1
M!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,  %6-
M  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,0
M!T0   !'    2@   $T   !0    4P   %4   !7    60   %H   !< P
M7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%  !A
MGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@   $\
M  !3    5@   %D   !<    7P   &$   !D    90   &<   !I    ; $
M &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !RE0
M<*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P   %P   !@
M    9    &@   !K    ;@   '$   !S    =0   '<   !Z    ?    '\
M  ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP  @Z4
M (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L   !O
M=    'D   !]    @    (,   "%    AP   (H   ",    CP   )(   "6
M    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID  )FO
M "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""    A@
M (L   "/    DP   )4   "7    F@   )T   "@    HP   *8   "J
MK@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D ")4
M   86P  $&(   =J    <P   'L   ""    B0   )    "5    F@   )\
M  "C    I@   *@   "K    K@   +    "S    M@   +H   "]    P@
M ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P   #V
M    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D
M1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"-
M +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L
MZ    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P /@"Y
M $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"% *(
MDP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?    V0
M ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D #T
MH@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"-
M )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP   *X
M  "E    GP   )P "0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #< C  \
M (L 00") $8 B !+ (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )(
M> "C '< N0!V .  =0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D   "/
M    B0   (4 ! "$  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V 'D
M.P!W $  =@!$ '4 20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H : ";
M &< KP!F ,P 90#U &0 _P!A /\ 8 #_ +0   "@    D    (4   !]
M=P   ',   !P  @ ;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@ - !G
M #D 9@ ^ &4 0P!C $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3 %@
MI@!7 +\ 5P#J %< _P!6 /\ 5 #_ *$   ".    ?P   '4   !L    :
M &0   !A  0 8  + %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #,
M6  X %< /0!6 $, 50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+
M +4 2@#< $H ^@!* /\ 2@#_ )(   "     <@   &<   !?    6@   %<
M  !5  $ 4P ' %( # !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S
M $L . !* #T 20!# $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !  *X
M0 #+ #\ \@!  /\ 0 #_ (4   !T    9P   %T   !5    3P   $P   !*
M    2  $ $< "@!'  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$
M,P _ #@ /@ ^ #T 10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *< -@#
M #8 Z  V /X -@#_ 'P   !K    7@(  %0#  !- P  1P,  $,!  !!
M/P ! #X !P ]  L /0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #< +@ V
M #, -0 Z #0 00 S $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X "T
MW0 M /@ +@#_ ',!  !D!0  5P<  $T(  !&"   0 @  #L'   X!0  -P,
M #8 !  U  @ -  , #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N "\
M+0 V "P /0 K $4 *@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4 SP E
M /  )@#_ &T&  !>"0  4@L  $@,  ! #   .@L  #8+   R"@  , @  "X&
M @ N P8 +0 * "P #0 L !  *P 3 "H %P I !P *  @ "< )0 F "L )0 R
M "0 .0 C $( (@!+ "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP > .D
M'P#Z &@)  !9#   30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+   G
M"00 )@8( "8$"P E PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!
M-@ = 3\ ' %) !L!5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T
M &,,  !5#@  20\  $ 0   X$   ,A   "T/   I#@  )@X  ",-   B# ,
M( L& " )"0 ?!PP '@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7
M!CP %@9& !8&4@ 5!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.
M  !1#P  1A   #P1   U$0  +Q$  "H1   F$   (A   " /   =#@( ' T%
M !H-!P :"PH &0H- !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH
M$@M% !$+40 0#%\ #PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.
M$0  0Q(  #H3   R$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$ !8.
M!P 5#@D % T+ !,,#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&
M  T.40 ,#UX "P]M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@
M0!,  #<4   P%   *10  "44   A$P  '1(  !H2   7$0( %1$% !,0!P 2
M$ D $0\* ! .#  .#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!  D1
M30 ($EH !Q)J  82?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%   /A4
M #46   M%@  )Q8  "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D
M#Q$*  T1"P ,$@X "Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  052@ #
M%5@  A5G  $5>@  %8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<  #(7
M   K%P  )1<  "$6   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)
M  P4"@ *%0T "!80  86$P %%AD !!<?  ,7)P "&#   1@[   91P  &54
M !ED   9=P  &8P  !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9   I
M&0  (QD  !\8   ;%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7
M"@ '&0P !!H.  (;$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(  !UB
M   ==0  '8H  !R@   <M@  &]   !KK $P8  ! &@  -AL  "T;   F&P
M(1H  !T9   9&0  %Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #
M'0L  !\-   @$   (!0  "$:   A(@  (2H  "$U   B00  (D\  ")?   B
M<@  (8@  "&?   @M@  ']$  !_M $@:   ]'   ,QT  "L=   D'0  (!P
M !P;   8&@  %AD! !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H
M "0,   F#@  )A(  "88   G'P  )R<  "<R   G/@  )TL  "=<   G;@
M)H4  ":=   EM   )-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT  !L<
M   8&P  %!P  !$<   .'0  #1\   HA   &(@$  R0$   F!@  * @  "H+
M   K#0  +1   "T5   M'   +20  "XN   N.@  +D@  "U8   M:@  +8$
M "R:   KL@  *M   "GO $ @   V(0  +2$  "8A   A(   '1\  !H>   6
M'@  $A\   \A   -(@  "B0   8F   "*    "L"   M!   +P8  # )   R
M#   - X  #42   U&   -2   #4J   U-@  -4,  #53   T9@  -'P  #.6
M   RKP  ,<T  ##O #PC   R)   *B0  "0C   @(@  '"$  !<A   3(P
M$"4   TG   )*0  !2L   $N    ,    #(    T 0  -@0  #@&   Z"0
M/ T  #X0   ^%   /AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1   Z
MJP  .<D  #CM #<G   O)P  *"8  ",E   ?)   &24  !0F   0*   #2L
M  DN   %,    #,    U    .    #H    \    /@$  $ #  !"!P  1 H
M $8-  !)$0  21<  $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#I0
M0L,  $'H #0J   L*@  )R@  "(G   <*   %BH  !$M   -,   "3,   ,V
M    .0   #P    ^    00   $,   !&    2    $H   !, P  3@8  % *
M  !3#@  5!,  %0<  !3)P  4S0  %-#  !250  46H  %"#  !/G@  3;D
M $S@ # M   K+   )BL  !\L   8+@  $C(   TU   (.0   CT   !
M0P   $8   !)    3    $X   !1    4P   %4   !7    60$  %P&  !?
M"@  8@X  &,5  !C'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[   %G/
M "\P   J+P  (C   !HS   3-P  #CL   @_   !1    $@   !,    3P
M %(   !5    6    %L   !=    8    &(   !D    9@   &D   !M!0
M< L  '00  !T&   <R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS
M   E-0  '3@  !0\   .00  !T<   !,    40   %4   !9    70   &$
M  !E    :    &L   !M    ;P   '(   !T    =P   'H   !^    @@0
M (8+  "*$0  B1P  (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @
M/0  %D(   ](   (3@   %0   !:    8    &0   !I    ;@   '(   !V
M    >@   'T   "     @@   (4   "(    BP   (X   "2    E@   )L#
M  "@#   HA,  * A  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   92
M$4X   E5    7    &,   !J    <0   '8   ![    @    (8   "*
MC@   )$   "3    E@   )D   "<    H    *,   "G    JP   +    "V
M!   O T  +H7  "Y*   MSP  +12  "R:@  KX4  *V< !Q.   35   "UP
M  %D    ;    '0   !\    @P   (D   "/    E    )H   "?    H@
M *0   "G    J@   *X   "Q    M    +@   "\    P0   ,<   #-
MU 4  -@0  #5'@  TS$  -!(  #-7P  RW8  ,B.
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M[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;9RPD;Y\X-.>C-$&#<R0V2R[LPJ\:X3[3
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MAZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-3.T H5SM0*.LK3"FC
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MB::&T8:EA]*$I8K2@:6-TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]*
MI8_2@*6/TH"EC]* I8_2@*6/TH"EC]+LP0L,]<(2)/;!&D3WO2%JVK0IELV\
M**F[NT.SKK5AO*BQ<\&EKG_%H:V$QYNL@\F6JX/*D:J$RXZIA,R+J87-B*B&
MSH:HA\Z#J(G.@:>,SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/
M@*>-SX"GC<^ IXW/@*>-SX"GC<_?Q D+\L40(_/$%D/TP1QIWL(5C\' (ZRO
MN4RVIK1EO:*R=<"@L(##G:Z$Q9>MA,:3K83'CZR$R(RKA<F)JX;*AZN&RH6J
MB,J#JHG+@:J+RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,
MRX"JC,N JHS+@*J,RX"JC,O:Q0@*Z\D-(N[($D+OQA5HT-(*A[&^+ZZEN%2X
MG[5HO)VS=K^;L7_!F;"$PI2OA,.0KX7$C:Z%Q8JNAL:(K8;&AZV'QH6MB,>#
MK8G'@:V+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"L
MB\> K(O'@*R+QX"LB\?5Q@@)V<P*(.7/#4#8U0M?O=8+B*7$-*:<MUJXF;5K
MNY>T=[V6LW^^E;*%P)&QA<&.L87!B["&PHFPA\*(L(?#AK"(PX6OB<.#KXK$
M@J^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!
MKXO$@:^+Q(&OB\32R @'T\\*'=74"SW"V0MCJ]X0@YO.,YF4Q%.FD;YGKY"Z
M=+20MWVYD;6$O(ZSAKZ,LH:_BK*'P(BRB,"&L8C!A;&)P82QBL&"L8O!@;&,
MPH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"
M@+&,PH"QC,+.R@@&SM$*',;7"D&OZ@YAG>8<>)#:,HB+TDR4B<M?G(C&;J.(
MPWBHA<!\JX._?ZZ O8&P?[R#L7V\A+)\NX:S>[N'M'JZB+1YNHFU>+F+M7BY
MC+9XN8RV>+F,MGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,
MMGBYC+;)RP@&R-()(K/?"4*@_!5:D_ H:HOF.7>$WTF"@=A;BX#3:9%\T'&6
M><UVFG;+>IUTRGV><LE_H''(@:%PQX.B;\>%HV[&AJ-MQHBD;,6*I6S%BZ5L
MQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%
MBZ7$S@<*M]D')J/[#CV6_QY.C?HO6X;R/V> ZTYQ>^5;>7;@98!QW6R$;MIR
MB&O9=XMIUWJ-9]9^CF;5@(]EU(*09-2$D6/3AI%BTXF28=*+DV'2C)-ATHR3
M8=*,DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,DV'2C)/_
ML1@)_[$C'O^N,3K_J3Y9[:)+>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/
MCL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NI
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)
M_[$C'O^N,3K_J3Y9[:)+>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\
MC(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C
M'O^N,3K_J3Y9[:)+>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"
MNXF2Q+J&E,6Y@Y;&N8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N
M,3K_J3Y9[:)+>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2
MQ+J&E,6Y@Y;&N8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N,3K_
MJ3Y9[:)+>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&
ME,6Y@Y;&N8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*M'NI
MRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N,3K_J3Y9
M[:)+>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y
M@Y;&N8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[
MJ<JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N,3K_J3Y9[:)+
M>=F:7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&
MN8&9Q[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT
M>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N,3K_J3Y9[:)+>=F:
M7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9
MQ[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1<)_[(B'O^N,#K_J3U9[*-*>=B;6YC'
ME7*QQ9=[M<.8@[C!F8J[OY6+OKV1C,&[CH[#NHJ0Q;F'DL>XA)7)MX*8RK:
MF\NV?I[,M7VCS+-\I\VO?*C+KWRHRZ]\J,NO?*C+KWRHRZ]\J,NO?*C+KWRH
MRZ]\J,NO?*C+KWRHRZ]\J,O_LA<)_[(A'O^O+SK_JCQ9[*1)>MB;6IG&EG&R
MQ)AXM<*9@;G FXB\OI>*O[R4B\*ZD(W%N8R.Q[>(D<FVA93+M8.7S;2!FLZT
M?Y_/LWZDSZY]ILZK?:C,JWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS*M]
MJ,RK?:C,JWVHS*M]J,S_LA8)_[,A'O^P+CK_JSM9[*1(>M><69K&EV^RQ)EV
MML*;?[G G(>]O9J)P+N6BL.YDHO&MXZ-R;:*C\RTAY+.LX26T+*!FM&R@)_2
MKG^CTJI_I<^F?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF
M?Z?-IG^GS:9_I\W_LQ8)_[,@'O^P+3K_JSI9[*5'>M:<69K&F&VRQ)ITML*<
M?;F_G86]O9R(P;N8B<6XE(K(MI"+R[2,CLZSB)'1L865T["#FM2P@J#5JH&B
MTZ:!I="C@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-
MHX&GS:.!I\W_LQ4(_[0@'O^Q+3K_K#E9ZZ5&>]:<6)O&F6NRQ)QRML*=>[F_
MGX.^O)Z(PKJ:B,:WEHG*M9**S;..C-"QBH_3KX>4UJZ%FMBK@Y_7IH.BU**#
MI-"?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.F
MS9^#ILW_M!4(_[0?'O^Q+#K_K#E9ZZ9%>]6=6)O'FFFRQ)UPML*?>;J_H(*^
MO)^(PKF<B,>VF(C+M)2)S[&0B].OC([6K8F3V:R'F]NFAI[9HH6AU9Z%I-&<
MA:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%
MIL[_M!0(_[0?'?^Q+#K_K3A9ZZ9%>]6=5YS'FV>RQ)YNML*@=[J_H8"^NZ&(
MP[B>A\BUFH?-LI>(T;"3BM6MCXW9JXR3W:B*F]ZBB)[9GHBAU9N'I-&9AZ;.
MF8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'IL[_
MM!0(_[4>'?^R*SK_K3A:ZZ9$>]6=5YS'G&6RQ)]LM<*A=;J^HGZ_NZ.'Q+B@
MA\FTG8?.L9F(TZZ6B=BKDXS<J)"2X:..FM^>C)[:FHNAU9>*I-&6B:;.EHFF
MSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)IL[_M!0(
M_[4>'?^R*CK_K3=:ZZ=#?-6>59W'G6.RQ*!JM<*C<[J^I'R_NZ2%Q+>BA\JS
MGX?0L)V'U:R:B=NIF(S@I9>3YIZ4FM^9D9W:EH^@UI2-H]*3C*7/DXRESY.,
MI<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<__M1,(_[4>
M'?^S*CK_KC9:ZZ=#?-6?4YW'GF"RQ:)HM<*E<+J^IGJ_NZ:#Q;>EA\NSHH?1
MKZ"'UZJ>B=RDFXO@G9F.XYJ;F>"5EIS;DY.@UY&1H].0CZ7/D(^ESY"/I<^0
MCZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<__M1,(_[8='?^S
M*3K_KC9:ZZA"?-6@49W'GUZQQ:1DM<*G;;F^J7>_NZF!Q+:HB,NQI8?1JZ*'
MUZ6?B-N>G8C=EYN+X)*;D]^2G)S<CYB?UXZ5HM.-DZ30C9.DT(V3I-"-DZ30
MC9.DT(V3I-"-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-#_M1,(_[8='?^T*3K_
MKS5:ZJA!?-6B3IS'H5JQQ:9@M,*J:;F_K7.^NZY]Q+2JA\NMI8;1IZ*&U:"@
MAMB9GX;;DIV)W8V=CMV,GIC;C)Z?V(N:HM2*EZ31BI>DT8J7I-&*EZ31BI>D
MT8J7I-&*EZ31BI>DT8J7I-&*EZ31BI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:
MZJE ?=6D29S(I%6PQJI;L\.O8[? LVR]MJY\Q;"IA\RIIH;0HZ2%U)RBA-:5
MH878CY^'VHJ?B]N'GY+:B*&<UXB?H=2'G*31AYRDT8><I-&'G*31AYRDT8><
MI-&'G*31AYRDT8><I-&'G*31AYRDT8><I-'_MA((_[<;'?^U)SG_L#-:ZJH^
M?=:H1)O)J$^OQ[!3LL6X6;6YLVV_L:U]QJRJALNEIX7/GZ:$T9BDA-.2HX35
MC**&UXBABM>%H8[7@Z*6UH2DG]2$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$
MHJ/1A**CT82BH]&$HJ/1A**CT82BH]'_MQ$'_[@:'/^V)3G_L3%:ZJL\?M>L
M.YG*K42MR;E%KKVX6;BRLF_ K*Y^QJBKA<JAJ83-FZ>#SY6F@]"/I832BJ2&
MTX:CB-2#HXS4@:.1U("DF=. IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1
M@*:AT8"FH=& IJ'1@*:AT8"FH='_N! '_[D9'/^W)#G_LR]:Z:TY?MFT+Y;,
MN#*IPKU L+.V7;JLL7'!IZY^Q:2LA<B=JX/*EZF#S)*HA,Z-IX3/B:>&T(6F
MB-""IHO1@*:.T7ZFE-!]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:
MSWVGFL]]IYK/?:>:SWVGFL__N0\'_[H7'/^Y(CG_M2U:[+,P>MW 'Y#)PR&H
MM;I(M*NU8KRFLG/ HZ]^PZ"NA,:9K(/(E*N$R8^JA,J+JH7+B*F&S(6IB,V"
MJ(K-@*B-SGZHD<U\J9;-?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S7RI
MELU\J9;-?*F6S7RIELW\NPX'_+P5&_Z['SC_MRE:\+TD=-_3#H:YP2JJJKE/
MMJ2U9;R@LG2_GK%_PINOA,.6KH3%D:V$QHVMA<>*K(;(AZR'R86KB,F"JXK*
M@*N,RGZKC\I\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\
MJY+*?*N2RGRKDLKQO0P&^;X2&OJ^&S?\NB5:Y\X3:,C9"XFMPS*GH;A6N)VU
M:+N;LW6^F;)_P)BQA,&3L(7"CZ^%PXROAL2)KH;%AJZ'Q82NB,:#K8K&@:V+
MQG^MCL=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'
M?:V0QWVMD,??P @%]<(/&?;"%C;NR!50S=P,9K7:#XBBR3:@FKY6L)>W:KF5
MM7:\E+1^OI2SA+^0LH7 C;&&P8JQAL&(L8?"AK"(PH2PB<*#L(K#@;"+PX"O
MC<-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/
MPWZOC\/9P@<%Y,<+&._($#31V@M%NND.:*;>&(*8T3>5D<A3H8_"9:F.OG*N
MC;Q[LHRZ@;6)N(*WA[B$N(6WA;F#MH:Z@K:'NH&UB+N M8F[?K6*O'VTC+Q\
MM(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RT
MC;W4Q <$ULL)%=/4"R>]X@Q)J?0499GF)7B.W#F&B-1/D(;/8)>$S&V<@\EU
MH'_'>*)]QGND>L5]IGG$@*=WPX&H=L*#J77"A*ITP8:K<\&'JW+ B:QQOXNM
M<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZW/
MQ@<"T,T)$L#9"2RL]P](F_H>7(_O,6N&YT)V@.)0?G[=7X5[V6F*=]5NCW33
M<Y)QT7>4<-!ZEF[/?9=MSG^9;,V!F6O-@YIJS(6;:<R'G&C+B9UGRHR=9\J,
MG6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)W*R @!
MPM('$Z[F"2V=_Q5!D?\H4(?Z.5R!\TAF?.U4;G?H7G5QY&5Z;>%K?FK?<(%H
MWG6$9MQXA67;>X=CVGZ(8MJ!B6'9@XI@V86*8-B'BU[8BHQ>UHV-7M:-C5[6
MC8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8W$R@<#L=H$
M%9__#2B2_QTWB?\N0X+_/4Y\_4M7=_A67V_S765H\&)J9.UI;F'K;W%?Z7-S
M7>AW=5SG>W9;YGYW6N: >%GE@WE8Y85Z6.2(>E?DBWM6XXY\5N..?%;CCGQ6
MXXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGS_JAP%_ZHG%_^G
M-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4
MO;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAP%_ZHG%_^G-B__
MHD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$
MEK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAP%_ZHG%_^G-B__HD1*
M^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^
M@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAP%_ZHG%_^G-B__HD1*^IU2
M9>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG
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MTKHTH<S".:J[NE6UL+1JO:JP><.GK83'GZJ$RYBH@\V0IX30B:6&TH2DBM.
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MK!0"_ZT?#O^L*R3_L"\W^K\E0>31($7.Y!U;O>DB=*W:+(F?SD69E\9:I)/
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MWMY.=LW:5X>^T&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2
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MWG:6C]QTFY+:<:"5V&^EF-9MJYK5:[";U6JWG-1IOYW4:<F=S&O*G<9LR9W
M;<F=O6[)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9W_AQ(!_XDA!O^*
M-13_B$8E_XI2-?^.6D/_CV%1_HYH7O:+;VKOAWAUZ82!?N2 B(;@?(^,W7F4
MD=IVFI78<Y^9U7"EF]1NJI[3;;&?TFNXH-)KPJ'-;,>AQF['H<!NQZ&[;\>A
MN'#'H;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ'_B!$!_XHA!O^+-13_
MB48E_XU1-?^26$/_DEY1_I!E7O:.;&OOBW5VZ(=^@..$AHC>?XV/VWN3E-AX
MF9G5=9Z<TW*DG]%PJJ+0;K*CT&VZI,YLQ*7&;\2DOW#$I;IQQ*6U<<2ELG+$
MI+)RQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I+)RQ*3_B1$!_XLA!O^,-!3_BD8E
M_Y!/-/^45D/_E%M1_I-A7O:1:&ONCG!VZ(M[@.*'@XG=@XJ1V7Z1E]5ZEYS3
M=YV@T'2DH\]QJJ;.;[.GS6Z]J,=PPJB^<<&IN'+!J;1SP:FO=,*HK73"IZUT
MPJ>M=,*GK73"IZUTPJ>M=,*GK73"IZUTPJ?_BA$!_XPA!O^--!3_BT8F_Y-.
M-/^64T+_EUA0_I9>7O:49&KNDFQVYX]V@>&,@(K<AXB2V(*/F=-]E9_0>9RC
MSG6CI\QRJZK+<+2KR'"_K+]SOJRW=+ZMLG6^K*YVOZRJ=K^KJ'? JJAWP*JH
M=\"JJ'? JJAWP*JH=\"JJ'? JJAWP*K_BQ$!_XT@!O^.-!3_C44F_Y9-,_^9
M4$'_FE5/_YI:7?>88&GOE6AUZ))P@.&/>XK<BX23UH:,FM* DZ'.>YJFS'>B
MJLITJZ[(<KBOP'2\K[=UO+"P=KRPJW>\KZAXO:^E>;ZMHWF^K:-YOJVC>;ZM
MHWF^K:-YOJVC>;ZMHWF^K:-YOJW_BQ !_XX@!O^/-!3_CT0E_YA*,_^;34#_
MG5%._YU76_B<7&CPFF-TZ)=J?^*3=8K<CX"3UHJ)F]&$D*/-?IBIR7FBKL=U
MK;'$=+JSMW:YLZ]XN;.J>;JSIGJZLJ-[N[&@>[RPGWR]KI]\O:Z??+VNGWR]
MKI]\O:Z??+VNGWR]KI]\O:[_C! !_X\@!O^0-!3_DD,E_YI(,O^=2C__GTY-
M_Z!36OF@6&;QGU]RZIQE?>.8;XC<DWJ2UH^$F]"(C:/+@9:KQWNAL<5VL+6Z
M=[>VKWFWMJAZN+:C?+BTH'RYLYY]NK*<?KNQFWZ\L)M^O+";?KRPFWZ\L)M^
MO+";?KRPFWZ\L)M^O+#_C1 !_X\@!O^1-!3_E$,D_YM&,?^@2#[_HDM+_Z10
M6/JD563SI%IPZZ)A>^2?:87>FG.0UY5^F=".B*/*A9.LQ'V@_^+__TE#0U]0
M4D]&24Q%  4)M+UXL+FO>;6YIGNVN*%]M[:=?KBUFW^YM)E_NK.8@+JREX"[
ML9> N[&7@+NQEX"[L9> N[&7@+NQEX"[L9> N['_C1 !_Y @!O^1-!3_ET(D
M_YU#,/^B13W_I4A)_ZA,5?RI46'UJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+
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M<J6UNG>=M;EZF;:W?9:WMGZ3N;1_D;JR@)"[L8"0N[& D+NQ@)"[L8"0N[&
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MFEK%RIQ<O<F=7KC)GEZXR9Y>N,F>7KC)GEZXR9Y>N,F>7KC)GEZXR9[_F@P
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MW,R%4MK:A5+:VH52VMJ%4MK:A5+:VH52VMJ%4MK:A5+:VH7_H H _ZT3 =3
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M"87_(!)\_RP;<_\U(VK_/2IB_T0P7/]+-%?_4CA3_U@[3_]>/4S_8S]*_VA
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MRYJ==LN:G7;+FIUVRYJ==LN:G7;+FIUVRYK_@!$!_WX; _^ +PW_C#@8_Y=
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M@5/$WH%3Q-Z!4\3>@5/$WH%3Q-Z!4\3>@5/$WH'_D@P _Z - -NW!@#*PP<
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M@\Z6A(/0E(2"TI*$@=.0A('4CH2 UHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2
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MAF.=VX5CG=N%8YW;A6.=VX5CG=N%8YW;A6.=VX7_?A !_X<1 ?^:$0#_K10
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M?'*(XWIRA^1Y<H?D>7*'Y'ERA^1Y<H?D>7*'Y'G_;1,!_W83 ?^($@'_F!,
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M8)KH=&":Z'1@FNAT8)KH=&":Z'3_<A(!_X8, /N8"0#9J08 SK4' ,;!!P#
MSPD NML3 +':*06GV#<2G-1$(9+133"'SE4\?<M=1W3)95!LQVU79<5V7E[$
M@6-9PXYH5,.=:U'#KFQ/Q,AM3L+M;5"XZV]3L.MP5:OJ<%BFZW!9H^MP6:/K
M<%FCZW!9H^MP6:/K<%FCZW#_=P\!_XT( -Z@ @#/K@4 Q+D% +O%!@"UTPH
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M&Q__IAP=_[<='/_*'AS_YA\;__ ?&__P'QO_\!\;__ ?&__P'QO_\!^DM0
ME<(  (;/  !WW@  :_0  &+_ P!9_PL!4?\1 4K_%P)$_Q\#/_\F!#K_+04V
M_S0&,O\Z!R[_0 @K_T8(*/],"27_4@DB_UD*(/]B"QW_:PP:_W8-%_^$#A7_
MD@\4_Z 0$_^M$1/_NA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP
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M;7UY[FM]>?!I?7GP:7UY\&E]>?!I?7GP:7UY\&G_7Q@!_VL3 ?][$0'_B1,
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M:&F)\&AIB?!H:8GP:&F)\&C_9Q(!_WD, /^*"@#?F@0 TZ8' ,RQ" #'NP@
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M-#;XX34V]?DU-?/_-#?L_S8YY?\X.>7_.#GE_S@YY?\X.>7_.#GE_SC(G@
MMJD  *BR  ";O0  C\@  (/4  !YZ < <_P2 6O]'0)D_2<$7OXQ"%C^.PU3
M_T,13?]+%4G_4QA%_UH:0?]C'3[_;!\[_W8A-_^"(S3_D"4R_Y\G,/^P*"[_
MR"DM_^HJ+/__*BS__RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX
M )RY  ".Q0  @=$  '7>  !M^@D 9?\1 5[_&@)7_R,#4O\L!4S_- =(_SP*
M0_]$##__3 X\_U,0./];$C7_8Q0R_VP6+_]W%RS_A!DI_Y,:)_^B'"7_M!TD
M_\P>(__M'B+__1\B__\?(O__'R+__Q\B__\?(O__'R+__Q^LJP  G;8  (_"
M  " S@  <]P  &?I  !?_P8 6/\. %'_%0%+_QT"1O\F T'_+00\_S4%./\\
M!C3_0@<Q_TD(+O]0"2O_5PHH_U\*)?]I#"/_= T@_X(.'?^2#QO_HA :_[(1
M&?_($AC_Y1,7__H4%__Z%!?_^A07__H4%__Z%!?_^A2?LP  D+\  (#,  !R
MV@  9.0  %CU  !1_P$ 2O\+ $3_$ $^_Q<!.?\> C3_)0(P_RP#+/\R!"C_
M. 0E_SX%(O]$!1__2@4<_U$&&O]9!A?_8P<4_VX'$O]\"!#_C @/_YP(#O^L
M"0[_NPD-_],)#?_3"0W_TPD-_],)#?_3"0W_TPF1O   @<D  '+7  !DY
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M7(EL^UJ(;/Q8B&O\6(AK_%B(:_Q8B&O\6(AK_%C_5!H!_V(3 ?]O$ '_>Q(
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M6G5Y^UIU>?M:=7G[6G5Y^UK_71,!_VP- /]["P#VB D W),& -6="0#1I0H
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M1D?!ZD9$OO])1;G_2D>S_TM)K?],2JO_3$JK_TQ*J_],2JO_3$JK_TSI?P
MT9   ,*>  "UIP  JJ\  *"X  "6P0( C,L' (35#0" U1X!>=4N!7+4/ QL
MTT<49=)0&U_162%:T6(G5=!K+%'0=3!-SX$T2<^.-T;/G3E$T*X[0M#&.T/0
MZCI S?T^/LO_0$##_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@
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M'2KZ_QTJ]_\<*O?_'2KW_QTJ]_\=*O?_'2KW_QVSHP  I*L  )>V  ")P0
M>\L  &_6  !CWP  6_4& %7_$ !0_QD!2_\C D;_+ -"_S0$/O\\!3K_0P8W
M_TL'-/]3"#'_6PDN_V0**_]O#"C_? TF_XL.)/^<$"+_KA$A_\42(/_I$Q__
M_!,>__\3'O__$Q[__Q,>__\3'O__$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4
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MXE>!+=]5BS#<4Y0SV5&=-M50ICC33Z\ZT$^[.\Y.R3S+3^$]QT_R/L-/_T#
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M2)U;_T>;7/]&F5S_19E<_T697/]%F5S_19E<_T7_2QH!_U<3 ?]A$ #_:Q(
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M2H!K_TJ :_]*@&O_2H!K_TK_5!(!_V$, /]N"@#]> D Z((( -R)"0#8CPL
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MG30(III!$Y^63!V8DU4GD9!>+XN-93>%BFT]@(AU0WN%?DAV@XA,<H*34&Z
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M3U27W$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:
MY7D  -&'  #%D@  NYP  +&B  "IJ0  H;$" )NS%0"5LR@"CK(V"8:P0A)_
MKDP;>*Q4(W*J7"ILJ&0Q9Z=L-F*E=3M=I'] 6:.*0U6BET=1H:=)3Z&Z2DZB
MV4E.H/5)3I__25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\
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M,SO#_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP
MFJ\  (ZW  "#OP  >,<# &[/!P!EUPT 8]@= &#8+0);V#H$5]A&"5/84 U/
MV%D12]=B%4?7;!A$UW<;0=>$'C[8DR \V*,A.]FW(CK:U2(ZUO(C-]3_)S;2
M_RDTT?\K-LK_+3;*_RTVRO\M-LK_+3;*_RW%D   MIT  *BE  "<K0  C[8
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M"1G__PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X
M0^4  #[[ 0 Z_PP -O\3 #+_&P O_R, *_\J 2C_,0$D_S<!(?\_ A__1@(<
M_TX"&?]8 Q;_8P,3_W #$O^!!!'_DP00_Z<$#_^]!0[_X 4.__8%#O__!0[_
M_P4.__\%#O__!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,
M #+_   N_P< *O\. ";_$P C_QH '_\@ !O_)@ 8_RL!%?\R 1+_. $0_T !
M#O]( 0S_4@$)_UT"!O]K @3_?0("_Y " ?^C @#_M@( _\T# /_L P#_[ ,
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M+\!&_R^Z2/\OM4G_+K1)_RZT2?\NM$G_+K1)_R[_0!T!_TD6 ?]0$P'_5A0
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M.H];_SJ/6_\ZCUO_.H];_SK_3!( _U8- /]@"0#_: H ^F\, /-S#@#E=Q$
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M2&1[T$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0
M]VD  -UV  #-@   PX@  +N.  "TDP$ K9<) *>8&@"@F"P#F98Z"I*411*,
MDD\:AH]7(H"-7RA[BV<N=HEO,W*'=SAMA8$\:82+0&:"ET-B@:5&8(&V1UZ!
MS4=>@>]&7X'_1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T
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M/$R8_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP
MK)H  **?  "9I0  CJL  (6P"P"!L1L ?+$K G>P. =QKT,-:ZY-%&:M51EA
MK%T>7:ME(UFJ;B=5J7<K4:B"+TVGCS)*IYXU2*>O-D>GQC9&INDV1:3^-T6C
M_S=&H/\W2)S_-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X
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M(2_(_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP
M9L8  %O, @!0T@< 1]H, $;<& !%W"< 1-TU 4'=0 (_WDL#/=Y5!#K?7P8X
MWVD'-=]V"3/@A LQX)0,+^&F#2[AO XMXN .+=[X#RO=_Q(JW/\4*=K_%BC:
M_Q8HVO\6*-K_%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X
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M @?__P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P
M(/\$ !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2
M_U0  /]B 0#_<P$ _X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_
M\P&$MP  =,$  &7,  !6V   1]\  #GE   MZ@  (^X  !S]   8_P  %?\
M !'_!  /_PL #?\.  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P  _T$
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M)J=(_R:G2/\FITC_)J=(_R;_0!0 _T@. /]."P#_50X _UD1 /]<%@#T71\
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M.W1FS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400
M_UP  .)G  #2<   QW8  ,!Z  "Z?0( M'\, *V!'0"G@2X"H'\\")I]1P^5
M>E$6D'A:'(MV8B&'=&DF@W)Q*W]Q>B]\;X,R>&Z--75MF#AR;*4[<&NT/&YK
MR3QM:^D[;6S^.6UL_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\
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M.%Q[_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@
MMH8  *Z+  "EC@  FY$  )63$0"0E"(!BY,Q X62/0E_D4@/>H]1%G6-61MQ
MC& @;(IH)6B)<"EDAWDM88:#,5V%CS1:A)PV5X.L.%6#OSE5@^$X58+Y-U:"
M_S56@?\T6'__,UE]_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P  LHL
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M+$27_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP
M?J@  '"N  !JL X :+$= &6Q+ %AL3@#7;!#!EFP3 I5KU0.4J]=$4ZN915+
MKF\82*UY&T6MAAY"K)4@/ZRE(CZMN2,]K=@B/:OU(SRI_R4[I_\F.Z;_)CND
M_R8[I/\F.Z3_)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\
M &FT  !>N08 6[H4 %F[) !6NS$!4[L] U"[1P5-NU '2KI9"D>Z8@U$NFP0
M0;IW$SZYA!4\N9,7.;FC&#BYMQDWNM89-[CT&C6V_QPTM/\>,[/_'S.R_R S
MLO\@,[+_(#.R_R#!@P  M)$  *:8  ";G@  CZ4  (*K  !VL0  :[8  %^\
M  !4P0, 3,4- $O%&0!)QB@ 2,8U $7'0 %#QTH#0,=3!#['708[QV<(.<=S
M"C?'@ PTQY -,L>A#C'(M0\PR-,/,,;T$"[$_Q,MPO\5+,'_%BO _Q<KP/\7
M*\#_%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*
MR ( 0,T' #K2#@ YTAL .-,H #?3-0 VU$  --5+ 3/550$QUF "+]9L RW7
M>@0KV(L%*MB=!2C9L08GVLT&)]?O!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_
M#2/0_PVNE@  H)T  )2D  "&K   >;0  &R[  !@P@  5,8  $C+   ^T
M-=4$ "W="@ LX1, *^(? "GC*@ HY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@
MYWX"'NB0 AWII (;Z;P"&NKB AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC
M_P6CG0  EJ0  (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@  *M\
M "7N"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!
M$?>  1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9
MHP  BZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[
M!@ 9_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L
M  +_@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP
M?;4  &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0
M_P@ #O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_
M:0  _WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\
M &')  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P
M!/\&  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P
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M*X=4RRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P,
M_T\  .=8  #98   S60  ,9F 0#!9@0 NV8. +1I( "N:3$"J&@_!:-F2@J?
M950/FF-=%)=A91B38&T<D%YU'XY=?2*+7(8EB%N0*(5:FBJ#6:8L@%FT+7]9
MQRY]6>8M?%KZ+'M:_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(
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M+FEG_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@
MNW,  +-W  "K>0  I'@# )UZ% "8>R4!DWLT XYZ0 >)>$H-A'93$H!U6Q=\
M<V(;>')J'W5Q<B)R;WLF;VZ%*6QMD"QI;)PN9FRJ,&1LO#%C;-DP8VST+V-L
M_RUD;/\K9&O_*65J_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0  MW<
M *][  "G?0  GGT  )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W>6 :
M<W=H'F]V<"%L=7@E:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ_RQ>
M</\K7W#_*6!O_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N
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M*%1Z_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP
MB8T  (./" !^D!< >Y$G 7:1- -RD#\&;8])"VF.40]EC5D38HQ@%UZ+:!M;
MBG$>5XE[(52(AB11AY0G3X:B*4V&M"I+ALPJ2X7N*4R$_RE,@_\H3(/_)TV!
M_R9.@?\F3H'_)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0  A),
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M'#>?_QS$>   M84  *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L
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M B'/I0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE
MG)H  )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?
MU@H &]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3A
MF@ 3XK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$
M (2I  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4
M%.D. !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '
M\J  !?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR
M  !IN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*
M  OZ#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P
M /RD  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<
MQ   3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_
M"0  _PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-
M  #_I@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP
M/]8  #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_
M_P4  /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_
MC   _Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P
M /\+. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *(
M_P"H /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_&RD _QTF /\<)0#_&2< _Q,L /\.
M- #_"T !_PA. ?\%6P'_ V@!_P)T ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E
M /\!K #_ ;( _P&Z /\!Q #_ =$ _P#D /\ \0#_ /P _ '_ /P"_P#\ _\
M_ 3_ ?P%_P'\!?\!_ 7_ ?P%_P'_'R8 _R$B /\@(0#_'B, _Q@G /\3, #_
M$3P!_PY* ?\-5P'_"V,!_PIO ?\*>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*
MJ '_"J\!_PJW ?\*P #_"LP _PK@ /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_
M O0-_P+T#?\"] W_ O0-_P+_(B( _R0= /\D' #_(AT _QXB /\<+ #_&3@
M_Q9% ?\34@'_$EX!_Q!J ?\0=0'_$'\!_Q"( ?\0D '_$)<!_Q"> ?\0I0']
M$*P!_!"S ?H0O0'Y$<D!]1'= ?$1[0'N$?D![!+_ NL3_P+J$_\#Z1/_ ^D3
M_P/I$_\#Z1/_ ^D3_P/_)AT _R@8 /\H%@#_)A8 _R8= /\F* #_(S0 _R!
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M#+LL_PS_,1$ _S4, /\V!P#_.@L _SP0 /\[%0#X.1\ [S<K .<V.0#A-4<
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M%J% T!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8
M_S\  /E&  #E2P  W$X  ---! #12@D RDH4 ,)-)P"\3C<!MTY% K)-4 6O
M3%H(JTMC"JA*; VF270/I$E\$:%(A!.?1XP5G4>5%YM&GQB91JH9ET:X&I9&
MRAN31N8;D4?Y&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,
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M(G96_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@
MOV(  +=D  "Q8P  JV$( *1C%P"?9"@ FF4W I9D0P618TT(CF%5#(I@71"'
M7V43A%YL%H%==!E^7'T<?%N&'GE:D2!W6ITB=%FJ)')9NB5Q6=(E<%KP(V]:
M_R)O6O\@<%K_'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8
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M'V!F_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==
ME',  (UT#0")=AP A7<K 8%W. -\=D,&>'5,"71T5 UQ<UL1;G)C%&MQ:Q=H
M<',:96]\'6)NAR!?;90B76RB)%ILLB59;,<E6&SH)5EL_2-9:_\A6FO_'UMK
M_QY;:O\>6VK_'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0  C7<
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M'$E\_QS680  PFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T
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M#C:@I@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P
MKX,  *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#
MJA\ 0:LK $"K-P _K$$ /:Q* 3NL4P(YK%P#-ZQG!#6L<P4RK($&,*R1!RZL
MHP@MK+@)+*S9""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L
M )R1  "1E@  A9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14
M,[8A #*V+  QMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,D
MN;0#([G2 R.W] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67
M  "(G0  >Z,  &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4
M "+#'P APRH (,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X
M%\C+ !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]
MI0  <*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2
M$0 0TAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^
M  G9Y@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0
M9+0  %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &
MWQ$ !=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #G
MR   Y_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X
M $G#   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T
M .D1  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL
M]M   /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,
M   NT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+
M  #V#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(
M /_/  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   A
MW0  %N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_
M!@  _PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O
M  #_PP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$
M_P!/ /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_
M +  _P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+
M /\ 6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T
M_P"T /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y
M /\ ^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\
M4P#_ &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P
M /H N0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\
M\ #_ /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_
M"%L _P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&
MM0#P!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_
M >0+_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4
M_ YA /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F
M#[T Y0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3
M_P+_)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=;
M .P79@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L
MU!G* - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_
M*!  _RD+ /\H!@#_*PL _RL0 /\I%P#])B( ]",N .PA.P#F($D XB!5 -X@
M8 #:(6H UB%T -,A? '0(80!SR*, <TBDP'+(IL!R2*C <@CK +&([8"Q"/$
M L(DVP*^)>X#NR7^!+@E_P6V)?\%M27_!K4E_P:U)?\%M27_!;4E_P7_+ T
M_RT% /\N 0#_,04 _S$+ /TO$ #Q*Q@ YRDE -\H,P#8*$( T2I/ ,TK6@#)
M*V4!QRMN <0L=@+"+'X"P"R& [XLC@.]+)8#NRR>!+DLIP2X++$%MBR_!;4M
MT06Q+>H&KB[[!ZLN_PBI+O\(J"[_"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$
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M$HE"_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23
MR$X  ,!-  "[2@( MD<. +!)'0"K2RT IDP[ :),1P*>2U$$FTM:!IE*8@B6
M26H*E$EQ#))(>0Z/2((/C4>+$8M'E1*)1J 4AT:L%85&NQ:$1M$6@D?N%H!'
M_Q5_1_\4?T?_$G]'_Q%_1_\1?T?_$7]'_Q'_.P  [D,  -Q,  #,40  P50
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M%FI5_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8
MFUP  )5>$ "08!\ C&$N (AA.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S
M7'03<%M]%6Y:B!=K6I09:5FA&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59
M_Q5E6?\495G_%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P  E6$
M (]B#@"+9!P AV4K (-E-P%_94(#?&1+!GAC4PAU8UL+<V)B#G!A:A!M8'(3
M:V![%6A?AA=F7I$98UZ?&V%=KAQ@7<$<7UWA'%]=^!I?7?\87UW_%V!=_Q9@
M7?\58%W_%6!=_Q7K2@  U%8  ,->  "V90  K&D  *)I  "89P  CV4  (EF
M# "%:!D @6DH 'YJ-0%Z:3\#=FE)!7-H40AP9UD*;6=@#6MF9Q!H97 2961Y
M%6-D@Q=@8X\97F*=&UQBK!Q:8K\<66+?'%EB]QI:8O\96F'_%UMA_Q9;8?\5
M6V'_%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_
M;14 ?&XE 'AN,@%U;CT"<6Y&!&YM3P=K;%8):&Q>#&5K90]C:FT18&EV%%UI
M@19;:(T86&>;&E9GJAM59[T<5&?<'%1G]AI49O\856;_%U5E_Q969?\55F7_
M%59E_Q7B40  RET  +MF  "O;   IG$  )EP  ".;P  @VX  'UP!0!X<A(
M=7,A ')S+P%O<SH";'-$!&ER3 9F<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55
M;HL74VV9&5%MJ!I/;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J
M_Q7=50  Q6$  +=J  "L<0  HG4  )1T  ")=   ?',  '9U  !Q=Q  ;W@=
M &QY*P!I>3<!9GE  V-Y205@>%$'77=8"5MW8 Q8=F@.575Q$5)U?!-0=(@6
M3727%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q34
M6@  P&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_
M)@!B@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4
M%45[I!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P
MNVL  *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:
MARX 6(<X 56'0@)3ATH#4(=2!4Z&6@=+AF()285L"T:%=PU#A(,/0822$3^$
MHA(]A+43/(3/$SR"\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$
M *I[  "?@@  DH(  (6"  !Y@P  ;88  %^*  !8C0$ 5(X/ %*/&P!0CR<
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M R:DZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP
M?I4  '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P G
MKRT )K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQ
MYP$;K_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\
M &BB  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"
M%KPJ !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /
MO?L #[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL
M  !2L0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=
M  ?*)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T
M ,S_  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%
MN0  .;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6
M'@  V"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W
M  #?_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@
M+,8  "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P
MY1L  .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O
M^0  \/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']
M !75   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1
M /,7  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0
M__4  /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB
M   #Y@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-
M  #_$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$
M /_1  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_
M &4 _P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\
MN@#_ ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_
M /X _P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$
M_P!L /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\
M ,  ^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4
M_P#_%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G
M /\ <0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L
M\0#( .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_
M&!D _Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P
M; #X '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@##
M .0 U #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q,
M_QH0 /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N
M G  Z@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%
MT #3!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+
M /\:!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H
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M Z4F_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,
MWR\  -DK! #6(@H SB,6 ,8F)P# *#8 NRI$ +@K3P"U+%D LBQB ; L:@&N
M+7(!K"UZ JHM@0*I+8H"IRV2 Z4MFP.D+:4$HBVQ!* MP 2?+=@$G"[O!9DN
M_P:7+_\&EB__!I4N_P65+O\%E2[_!94N_P7_+   _RX  .HU  #=.0  T3D
M ,HV  #'+P8 P2T1 +HP(0"T,C$ L#0^ *PU2@"I-50!IS5= :0U90*B-6T"
MH#5T Y\U? 2=-80$FS6-!9HTEP:8-*$&EC2M!Y0UNPB3-= (D#7L"(XV_@B,
M-O\(BS;_"(LV_P>*-?\'BC7_!XHU_P?_+P  \C0  .(\  #200  QT(  ,!
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M"WA"_PMX0O\*>$'_"GA!_PKV-@  YD   -%(  ##30  N4X  +%-  "I20
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M#5]3_PWG1   SU   +]8  "S70  J%\  )Q=  "26P  BU@  (5:"@"!6Q8
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M$E)BHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P
MPUH  +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G
M;#0 9&P] 6)L1@)?:TX$76M6!5IJ70=8:F4)5FEN"U-I> U1:(0/3FB2$$QG
MH1)+9[(226?)$DEGZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15   OEX
M +%G  "F;0  EVP  (IK  !_:P  <VL  &UM  !H;@P 97 7 &)Q) !@<3
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M=0  C70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V
M.P!,@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#
M"S=]Y@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0
MAWD  'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#
MB#X 08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'
MY <PA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX
M '9_  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC<
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M 1.E_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G
M2*   #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -
MM38 #+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT
M_P (L_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P
M #6P   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL
M ,(V  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P
MP_\  ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ
M   ?O0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J
M  #1-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\
M -;_  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4
MQP  #<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C
M)P  Y3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_
M  #K_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP
M M@   #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0
M]"0  /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]
M] !QK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4
M  #H    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4
M /\A  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_
M"R  _P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\
M=@#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+
M /\ X0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T
M_PL: /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_
M 'H _P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8
MV0#U .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5
M /\(% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4
M^@!] /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I
M .8 Z #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,
M#P#_ Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X
M .T ?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .
MV #P -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_
M"PP _PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .
M>@#> (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M
M ,< ^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8
M_P\- /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-
M!'L RP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+
M_0"V#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,&
M /H0#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8
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M HXG_P*.)_\"CB?_ HXG_P+_)@  \BD  .,Q  #2-   R#0  , P  "[*0(
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M!6I!_P7M-P  UD(  ,1)  "W30  JTT  *!*  "81P  DT(  (Y##0")11H
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M"UU/H0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P
MQTT  +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O
M5C8 ;%9  6I62 %H5E "9E97 V167@1B568%8%5O!UU5> A;5(0*6521"U=4
MH Q54[ -5%/%#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU
M +58  "H6P  F5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C,
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M"T1BX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9
MC&,  (!C  !V8P  :F(  &-D  !?9@8 6V<1 %EH'0!7:2D 5FHS %1J/ !2
M:D4!4&I, 4YJ5 ),:EP#2FIE!$AI;P5&:7H'1&F("$)HF E :*D*/VB]"CYH
MW@D^9_<)/F;_"#]E_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I  "6:   AV<
M 'MG  !Q9P  96@  %QJ  !8; $ 5&X. %)O& !0;R0 3G N $UP. !+<4$
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M RE\_P,I>_\#*7O_ RE[_P.Q:@  I70  )5V  "%=0  >'4  &UU  !A=P
M5WH  $Q^  !#@0  .X4  #6("0 RB1$ ,8D; #"))0 OBB\ +HHX "V+00 L
MBTH *HM4 "F+7P HBVL )HMZ 22+BP$CBYX!(HNS 2&,S@$ABO$!((C_ B"&
M_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@  <WH  &9\  !;?P  4((
M $:&   \B@  -(T  "R1   FDPP ))03 ".4'  BE28 (94O ""5.  ?ED(
M'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2_P$6
MD?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((  %^$  !4B   28L  #^0
M   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)#
M !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +HN8 #*#^  V?_P -GO\
M#9W_  V=_P">A   DHD  (.(  !SB   98L  %B.  !,D@  09<  #>;   N
MG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;  6M)  $KBX  JXY  &N
M10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4  *WT  "M_P  K/\  *O_
M  "K_P"6BP  C)   'N0  !KD@  798  %":  !$GP  .:,  "^G   EJP
M'*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y'   NB4  +HO  "[.@
MO$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK  "[_@  N_\  +O_  "[
M_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0  ,+$  "6T   ;MP  $KH
M  R]   %OP   ,,   #$ @  Q0H  ,4.  #&%   QQL  ,@D  #*+@  S#H
M ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.]@  S?\  ,W_  #-_P"&
MF0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P  !F_   1P@  "L4   +)
M    S    -    #1    T@$  -,(  #5#0  UQ$  -H8  #<(0  WRP  .$Z
M  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@  Y?@  .7_  #E_P!ZH0
M:ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*   'S@   -$   #6
MW    -\   #@    X@   .0   #F P  Z D  .D.  #L%0  [AX  /$K  #T
M.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(
M $^Z  ! P0  ,<4  "+)   6S@  #=(   38    W0   .$   #D    Z
M .L   #M    [P   /$   #S    ]@   /@#  #Z"P  _1$  /\;  #_*0
M_SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6  #_U@#_!!P _P 9 /\
M&0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I /\ <@#_ 'H _P""
M /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_ +D _P#% /\ V0#^ .P
M_0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_
M !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!] /\
MA #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V
M /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_ !
M_P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L : #Y '  ]P!X /4 ?P#S
M (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y .< QP#E -X XP#P .(
M_@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1  _PD- /\!# #_  P _P 2
M /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L &L Z@!R .@ >0#F (
MY "& .( C #A ), WP": -T H0#; *H V "T -4 P #2 -, T #J ,X ^@#-
M /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP' /\# @#_  @ _P . /\
M%@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4 VP!L -< <P#4 'H T@"
M -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#" ,L P #E +X ]0"] /\
MO #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*  #_" $ _P0* /@ $ #I
M !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$
M@@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,< L@#@ +$!\@"O O\ K@/_
M *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R#0  Z@H  .D#"0#= !(
MU  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%: "W!F\ M09V +0'?0"R
M!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O? *0-] "B#O\ H [_ )\.
M_P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0  VQ8  -(0 @#/"0L R @6
M ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K$&H J1%Q *@1> "F$8
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M 7PH_P'U)   XRX  ,\U  #!.   M#8  *LQ  "E+   HB8& )XF$P"9*"$
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M!&H[H01H.[$%9SS%!64\Y05D//H$9#S_ V,[_P-C._\#8SO_ F,[_P+E-0
MS3\  +U&  "N1P  GT4  )5#  ".0   B3P  (0\"@" /10 ?3XB 'H_+@!X
M0#@ =4%" '-!2@!R05$!<$%9 6Y!8 )L06<":D%P VA!>0-G080$94&1!6-!
MGP5A0:X&8$'"!EY!X@9>0?D%74'_!%U _P-=0/\#74#_ UU _P/?.0  R$,
M +E*  "I2P  FTD  )!'  "(1   @T$  'Y!!@!Z0A$ =D,> '1%*@!Q134
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M!TU.V0=-3O4&34[_!4U-_P1-3?\$3DS_ TY,_P/.1   O$X  *Y4  "<4P
MCE(  (-1  !Z4   <DT  &Q/  !H4 L 95$5 &-2(0!A4RP 7U,V %U4/P!;
M5$< 6E1. 5A45@%65%T"5%1F U)3;P-04WL$3E.(!4Q3EP9+4Z<'25.Z!TA3
MU0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2   N5(  *I7  "85@  BE4
M ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;5RD 65@S %A8/ !6640
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M!#A@_P,X7_\#.5[_ SE>_P.\50  K5\  )Q@  "+7P  ?5\  ')?  !H7P
M76   %5B  !/9   2V8* $EG$@!':!T 16@G $1I,0!#:3D 0FI" $!J2@ _
M:E( /6I; 3QJ90$Z:G ".&I^ C9IC0,T:9\#,VFR S%IRP,Q:.T#,6?_ S%F
M_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P  >&,  &UC  !D9   664
M %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z<#0 .7$] #AQ10 W<4X
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M 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4=@  27D  #]]   W@0
M+X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.,  6CCD %8Y# !2/3P 3
MCUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ  ^+_P 0BO\ $(G_ !")
M_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@  0H(  #F&   OB@  )XX
M ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[  F:1@ (FE,
M!IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8_P $E_\ !9;_  66_P"9
M@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT  #&2   HE@  'YD  !B=
M   1H   #*,"  :E"@ !I1   *46  "F'P  IB@  *8R  "G/0  ITH  *=8
M  "G:   IWP  *>1  "FJ   IL,  *7I  "E_   I?\  *3_  "D_P"1AP
M@H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>   ?H@  %Z8  !"I   +
MK   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H  "T,@  M3\  +5-  "U
M70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\  +3_  "T_P"+CP  >HX
M &J1  !;E0  39H  $"?   UI   *J@  ""L   6L   #[0   FW   !N0
M +T   "^    O@8  +\,  # $   P18  ,(=  ##)P  Q3(  ,9   #&40
MQV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_  #'_P"#EP  <9H  &&>
M  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0  !L    ##    QP   ,D
M  #*    S    ,T#  #."0  T X  -(3  #4&P  V"4  -LR  #=0@  W50
M -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?_P!WGP  :*8  %FM  !*
MLP  .[@  "V[   ?OP  %,(   S&   #R0   ,P   #0    U0   -D   #:
M    W    -X   #@    X@4  .0+  #G$   ZA@  .TD  #P,@  \40  /)8
M  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !JJ   6Z\  $RW   ]O0
M+<$  !_&   3R@  "\X   #2    UP   -P   #@    Y0   .<   #I
MZP   .T   #O    \0   /,   #V!P  ^0X  /P6  #_(@  _S,  /]'  #_
M70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@ _P 6 /\ %0#_ !@ _P >
M /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H
M_P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T SP#[ .< ^@#X /D _P#Y
M /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_ !( _P 7 /\
M(P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X /T ?@#\ (4 ^@"+
M /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O .  [@#R .P _P#L /\
M[ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\ #0#_  T _P 3 /\ '@#_
M "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R /$ >0#O '\ [@"& .P
MC #J )( Z0"9 .< H #F *D Y "S .$ P #@ -, W@#K -P ^P#; /\ V@#_
M -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_  D _P / /\ & #[ "4
M^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .( <P#@ 'H W@"  -P A@#:
M (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8
M_P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0 _P + /0 $@#O !\ Z@ L
M .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #& (<
MQ0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +< \ "U /\ M@#_ +4 _P"U
M /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ # .@ #0#@ !< V0 D -$
M,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X N@!T +D >P"W (( M0")
M +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G /L I@#_ *8 _P"E /\
MI0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H !P#/ !$ R  < ,( *0"^
M #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O *L =0"I 'T J "$ *8
MC0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_
M )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"! L O  4 +<!(0"R RX
MK@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+<0"="W@ G N  )H,B0"9
M#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0
M_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0  L@L- *L-&0"G#B8 HP\S
M )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2$W, D!1\ (\4A0"-%8\
MBQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U
M&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4( * 4$P";%B$ EQ@M )09
M. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?@ ""'XL @!^7
M 'X@HP!](+( >R#% 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_ '0A_P#O(0
MVRL  ,<Q  "V,0  J2X  * J  ";)@  F"$! )4>$ "0(!L C2$H (DC,P"'
M)#T A21& (,E3@"!)E4 ?R9< 'XF8P!\)VL >R=S 'DG? !X*(< =BB3 '0H
MH %R**\!<2G! 6\IX %M*?<!;"G_ 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(
M , X  "N-P  H34  )@R  "2+0  CBD  (LG# "'*!< @RHC ( K+P!^+#D
M?"Q" 'HM2@!X+E$ =RY8 '4N8 !S+V< <B]O ' O>0%O+X,!;2^0 6LOG0%I
M+ZP!:#"^ 6<PVP%E,/4!9##_ 6,P_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]
M  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^
M '(T1@!P-$X ;S55 &TU7 !L-60 :C5L 6@U=0%G-8 !936, 6,UF@)A-JD"
M8#:[ E\VU@)=-O,"73;_ EPV_P%<-?\!7#7_ 5PT_P'<,P  Q3P  +1!  "B
M0   E3X  (L\  "$.0  ?S8  'LT! !W-1  =#<< '$X)P!O.3( ;3D[ &LZ
M0P!J.DL :#M2 &<[60!E.V$!8SMI 6([<@%@.WT!7CN* EP[EP);.Z<"63NX
M U@[T@-7._$"5CO_ E8[_P)6.O\!5CK_ 58Y_P'4-P  P$$  *]$  "=0P
MD$(  (5   !^/@  >3L  '0Z  !Q.@X ;3P8 &L]) !I/B\ 9S\X &4_0 !D
M0$@ 8D!/ &% 5P!?0%X!74!F 5Q ;P%:0'H"6$"' E9 E0)40*0#4T"V U)
MSP-10.\#4$#_XO__24-#7U!23T9)3$4 !@G_ E __P)0/_\"43[_ 5$^_P'/
M.P  O44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"
M(0!C0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6%
M E%$DP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P
MN4@  *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=
M1R@ 7$@R %I(.P!924, 5TE* %9)4@!425D!4TEA 5%):P%/278"34F" DM)
MD0-*2:$#2$FS T=)R@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P  MDP
M *),  "13   A$L  'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!83"4
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M C=7Q (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5
M>%0  &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"
M7#8 05P^ #]<1@ ^74\ /5U7 #M=80 Z76P!.%UY 39=B $T79D",UVK C%=
MP@(Q7.4",5O\ C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<
M &E7  !@6   5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C(
M.6(Z #AC0@ W8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J
M8^,!*F+[ 2I@_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;
M  !<7   45X  $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU
M "]J/0 N:D8 +6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N
M(VGY 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !7
M8   36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R
M-P E<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W
M !IP_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@
M2&D  #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9
M?#D &'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y
M_P 1>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W
M #ET   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$
M#H<[  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (
M@_\ "8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]
M   J@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S
M  "3/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\
M (__  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   B
MC0  &I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?
M-0  H$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_
M  "<_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@
M$IX   VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P
MKS<  *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M
M_P"!A   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P
M  2O    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL
M , X  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!Y
MC0  :)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
M    P0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K
M  #5.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0
M8)X  %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+
MSP   -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L
M*@  [3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T
M $FT   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X
M .,   #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'
M_RP  /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\
M$@#_ !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X
M /\ ?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .(
M^ #T /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_
M  \ _P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H
M>0#Y (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N
M .D _@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D
M_P 0 /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K
M 'H Z0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0
M^ #2 /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P -
M /P %@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0
MU0!Z -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_
M /\ OP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X
M$0#G !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S
M ,  >@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P
MK0#_ *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3
M !4 S  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +
M= "O 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_
M )X _P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \
MO0 9 +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A
M '4 GP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )
M_P"0 /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2
M *P '@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G
MDP-X )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#
M"_\ @PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%
M%@"=!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT
M (8.?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\
M=Q+_ '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3
M$!L CQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6
M> !Y%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_
M &T:_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8
MA!HB ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P
M('\ ;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A
M_P#@)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(>
M '@C*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L
M92B( &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8
M+   PS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J
M)0!M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$
M %POD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0
MO3H  *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F
M,2L 9#(T &,R/0!A,T0 8#-+ %\T4@!=-%H 7#1B %HT:P!9-74 5S6" %4U
MD %4-9\!4C6P 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T
M *,\  "2/   A3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@
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M 4!#P $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10
M>40  &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+
M1CD 2D=! $E'2 !(1U  1D=8 $5'80!#2&P 0DAX 4!(AP$^2)<!/$BI 3M(
MO@$Z2-\!.D?X 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<
M &M'  !C1@  6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8
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M "E5_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840
M3E(  $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N
M7$, +5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");
M_P C6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8
M $-8   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX
M)6-' "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;
M8/\ '&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>
M   W8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM"
M !IL3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\
M$VC_ !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R
M9P  *VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U
M1@ /=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_
M  QP_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P
M)'(  !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $
M?TL  G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![
M_P")9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P
M !:    0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,
M (M0  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P""
M;0  <VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",
M   +CP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'
M  "95@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=
M;W,  &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !
MG    *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I
M3   J5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L
M %E^  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP
M *X   "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0
MNE(  +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+
M  !#D   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X
M  "_    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0
M -!8  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [
MH0  +J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
M    T    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)
M  #I7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@
M)KD  !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@
MX@   .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^
M3P  _V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6
M /\ (@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (
M_P"& /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S
M /\ \P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\
M'0#_ "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "
M /( A@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\
MX@#_ -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_
M "0 _0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .(
M@ #@ (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_
M ,L _P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X
M[0 J .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#*
M (  R "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@
M_P"W /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C
M -( +@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H
MM0"! +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E
M /\ I0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X
M* "[ #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z
M *0 @@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\
MEP#_ )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K
M "P J  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4
M?0"4 (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_
M (@ _P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4
MFP P )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "'
M ($ A0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$
M_P#Q#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I
M (T",P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X
M>@F) '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H
M%@  T!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-
M+0" #38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&'
M &X1E !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@
MQB0  + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V
M%#$ =!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09
MD !C&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H
M *@I  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T
M:QTU &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:
M(IP 62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N
M  "2+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q
M &(E.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D
M42FJ % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",
M,@  @#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK
M-@!9+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H
M $DONP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0
M>S4  '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3
M,3H 4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,T
MN0!"--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@
M &TW  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@
M3#<_ $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ]
M.=, /#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ
M  !B.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\
M $8\1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$
M-SWR #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>
M/0  6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $%
M00! 0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P
M #) _P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0
M5#\  $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z
M148 .45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%
M_P N1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,
M $A#  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D,
M,TI, #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H
M2?\ *$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(
M   _2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!(
M "M04@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\
M(DW_ "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [
M3@  -5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "16
M3@ B5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_
M !Q2_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P
M,54  "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :
M754 &%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19
M_P"440  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL
M "5>   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195
M$&5=  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-
M50  >E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E
M   9:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7
M  9N90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@
M=%H  &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3
M<0  #G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X
M7@  >&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\
M &)>  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P
M"'X   * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P
MA&@  (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C
M  !29   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H
M  ", P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\
M ))S  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+
M;0  /W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
M    F@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I
M  "B@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0
M-WX  "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H
MJ0   *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U
M<P  M8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX
M ".4   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0
M +L   "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@
MRG\  ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE
M   1JP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P
M  #.    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\
M .:,  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +
MO    ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
M    Y    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ
M  #]EP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H
M_P V /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\
M (T ^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ .,
M_P#7 /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q
M /\ /0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (<
M[ ". .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#)
M /\ P@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /<
M-@#S $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "(
M -0 D #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\
MM@#_ +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A
M #L W !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\
MB0"] )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_
M *< _P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0
MQ  ^ ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J
M (L J "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L
M_P#_    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W
M *T 0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0
MF ". )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M    [P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T
M.@": $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0")
M (@ E0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @
MX D  ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"-
M #P BP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L
MD !Y )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ
M +D0  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8
M?P ^ 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N
M IH ; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7
M  ">%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X
M ',)0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D
M8@VI &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5
M'0  B1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0
M.P!I$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G
M %<4N@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P
M@2(  'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@
M%SX 7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;
MMP!.&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<
M '(F  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH
M5Q]! %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'
M(LT 1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ
M  !F*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^
M $\F10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L
M/RCM #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A
M+0  72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK
M0@!(+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK
M #HM_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0
M6"\  %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!"
M,4< 03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R
M_P U,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,
M % P  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40
M/#9, #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P
M-?\ ,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT
M  !'-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI*
M #4Z4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\
M*SG_ "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !"
M.@  /SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _
M4  N/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_
M "8]_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@
M.3\  #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H
M1%@ )T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!
M_P":/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4
M #!& P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4
M($IA !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"5
M0@  @$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+
M   F30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!=
M !=0:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10
M>T8  &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @
M4P, '%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7
M:  /5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH
M &=*  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60
M%5P' !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '
M7G, !5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).
M  !73@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#
M  QF"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT
M &>   !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !4
M4@  2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N
M"0  ;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y
M  !QCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@
M1E<  #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0
M> L  'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]
MB   ?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\
M #5C   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8
M (4+  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@
MBYD  (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN
M   D<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%
M  "5"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$
M )NK  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;
M@0  $H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E
M 0  IP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA
M  "NO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@
M#)@   .=    H@   *8   "J    K@   +    "Q    LP   +0   "V
MN    +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%
MKP  Q=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD
M  "N    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@
M ,T   #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0
MX;T  .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
M    Q    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(
M  #D    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L
M /C$  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_
M $@ _P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /<
MEP#U *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_
M ,( _P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $,
M_0!, /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D
M )H X@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +<
M_P#_    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !&
M .@ 3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ),
MR "= ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M    _P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X
M2 #* $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6
M +( H0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_
M_P   /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U
M $@ L@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\
MF@"= *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@
M .0   #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $(
MH !) )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP",
M *$ BP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T
M  "]    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !#
M (X 20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L
M? "J 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L
M 0  H@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (
M0P!^ $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E
M &X M@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#
MDPL  (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S
M $0 <0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &,
ML@!A ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$
M ( /  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T
M9P-& &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7
M!\8 5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86
M  !Q$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ"
M %X-2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@
M31#J $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I
M&@  9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %82
M10!4$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H
M $46_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P
M7QT  %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-
M&4@ 2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<
M_  ^'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(
M %8?  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4
M12!- $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W
M(O\ ."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C
M  !/(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5*
M #TF4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\
M,B;_ #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*
M)@  1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K
M4  V*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_
M "TJ_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P
M02L  #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q
M,%@ ,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N
M_P"<+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#
M #HQ"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8
M*C5A "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8
M,0  @S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U
M!@ R-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E?
M ",Y;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-
M?S8  &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L
M.PL *CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_
M:0 ;/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@
M &HY  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@
M)$(. ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 5
M1'< $T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]
M  !:/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@,
M !M)$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0
M#DJ'  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !6
M0   34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0
M#@ 24!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!
M  50E@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21
M2D0  $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +
M6!  "E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8
MD0  5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<
M $!'   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX
M %\2  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP
M7Z(  %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,
M   R3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</
M  !H$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT
M &FV  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M
M5@  )%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R
M$   =!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q
M  !TTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P
M'6,  !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#
M@1   ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#
MR0  @O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7
M  YU   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L
M )$/  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0
MD^H  )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
M    B0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(
M  "E#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T
M *?X  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6
MF@   )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X
M!0  N@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO
M  "\_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K
M +    "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*
MS0(  - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;
M\@!&@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(
M  #(    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@
M .8   #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_
M  8 _P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\
M50#_ %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F
M .X LP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_
M_P   /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T
M %< \0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D
MJP#5 +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P
M /\   #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %
MVP!7 -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "]
M +( NP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\
M  #U    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0
M +T 5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H
MI@"[ *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
M    T    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@
M3P"F %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R
M )( R0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'
MN@   +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4
M $\ D@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($
MO@"  .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J
M *    "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D
M@@!. ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R
M ,\ <0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$
M  "+  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !)
M ', 3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8
M9 #H &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M    >P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &<
M20!F $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A
M %@ ^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@
M;P8  &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!<
M $L 6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"
M] !. _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X
M &,+ P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@
M4PA/ %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%
M#/\ 10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1
M  !:#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY-
M $H.50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\
M/1#_ #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2
M$P  4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,4
M4@!!%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_
M #<5_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0
M2Q8& $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z
M&E@ .1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;
M_P"='P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P"
M $,<# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8
M,R!@ #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9
M(@  A"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA
M"0 [(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25>
M "LE:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0
M@"<  &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U
M)@X -"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J
M:0 D*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H
M &PK  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP
M+BP1 "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?
M+W8 '2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N
M  !;+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0
M "<Q%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0
M&#2& !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8
M,0  3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V
M$@ @-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$
M !$YF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-
M2S0  $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9
M/14 &#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^
ME0 +/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<
M $$W   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q(
M$4,8 !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $
M0Z4  D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ
M   X.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4
M  M*&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$
M $FY  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V
M/0  +SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1
M%P  41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U
M  !0V   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00
M*D,  "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P
M61D  %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8
MT0  6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H
M !Y-   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4
M &,;  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS
M8?(  &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5
M   260  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6
M  !P'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\
M &S_  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,
M9   !F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]
M%@  ?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_
M  !Z_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@
M '8   !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$
MD!8  )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",
M_P!560  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8
M  "+    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\
M *06  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.
M80  0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
M    H0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.
M  "\%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P
M.7   "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P
MLP   +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1
M#@  U!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8
M ".(   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@
M ,H   #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0
MZP\  .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\
M! #_  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!>
M /\ 90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,
MY@#@ ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M    _P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L
M7@#I &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#.
M ,D \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_    _P   /\   #_
M^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -  6 #-
M %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#! +(
MY "Q /T KP#_ *P _P"E /\ H #_ )P _P#_    _P   /L   #N    Y
M -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8
ML@!< +  80"N &< K !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T T0"<
M /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@   .<   #3    Q@   +T
M P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5
M )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@". )P C "M (H PP") .@
MB #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P   "\    L    *<   "A
M  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!. (D
M5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W
M '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H    G@   )8   "/  0
MBP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W
M %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M &D
M_P!I /\ :0#_ &D _P#2    N    *4   "7    C0   (8   "!    ?  (
M 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J $X
M: !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P ^P!<
M /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(  '@   !T    <  $ &T
M# !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/
M %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\
M40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*  !H!P  90,  &, !P!A
M  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$
M4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_
M $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9! H
M5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!(
M E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&
M_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D,
M $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30! "U4
M/PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=
M$P  AQ4  '87  !I&   7A@  %88  !0%P  314  $H3  !)$0  20X' $@-
M#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!>
M #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@
M@AD  '$;  !D'   61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2"P!
M$1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11< # 5
M:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P
M &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y%@X
M.!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H
M&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA
M  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T ,AP2
M # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W(
M(!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C  !9
M)   3R4  $<E  !!)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA
M%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'  &R2"
M !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6)P
M3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F$P D
M)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0I
ME  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0  22H
M $(I   [*0  -BD  #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?+!8
M'2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .
M+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP  #\L
M   Y+   -"L  "\K   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$:
M !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z(
M"#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN   V
M+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W
M'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U
M  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T,0
M+S   "LP   E,@  (#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]&0 *
M/2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]
MT   //   #S_   \_P!M,@  73,  % T  !&-   /C0  #<T   R,P  +3,
M "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "1!T
M $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#S0
M0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<  ",Y
M   >.P  &#T  !-    00@  #44!  A'!P #20P  $D/  !*$P  2QD  $L@
M  !+*   2S(  $L]  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\
M $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_   9
M00  $T0  !!'   ,20  "$P   )/!0  4 H  % -  !1$   4A4  %0;  !4
M(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_
M  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G0   ($,  !E&   320
M#TP   M/   &4@   %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>'0
M7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_  !:
M_P!61   2T,  $-"   \00  ,D(  "E%   A2   &DL  !-.   .4@  "E4
M  -9    6P   %X   !@    8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\
M &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E_P!1
M2   2$@  $%&   W1P  +$H  "--   ;40  $U4   Y9   (70   6$   !D
M    9P   &H   !L    ;@   '    !R!0  <PD  '4-  !W$0  >A@  'LA
M  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.30
M1TP  #M-   P3P  )E,  !Q8   37   #6$   9F    :@   &\   !R
M=@   'D   !\    ?0   '\   "!    @P(  (8'  "(#   BQ$  (X8  ".
M)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40  05,
M #15   I6@  'E\  !1E   -:@  !7    !V    >P   '\   "#    AP
M (H   "-    C@   )$   "3    E0   )@   ":!0  G0P  * 1  "C&@
MHR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P  "UA
M   A9P  %FX   YU   %>P   ($   "'    C0   )(   "6    F@   )T
M  "?    H0   *0   "F    J    *L   "N    L0,  +0+  "X$0  N1X
M +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O   8
M=P  #W\   :'    C@   )0   ":    H    *4   "J    K@   +$   "R
M    M0   +<   "Z    O    +\   ##    Q@   ,D   #."@  TA,  -(C
M  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1B0
M")$   ":    H0   *<   "M    LP   +D   "^    P@   ,4   #&
MR0   ,P   #.    T@   -4   #:    W@   .$   #E    Z@L  .L7  #J
M*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_    _P   /\  0#_  < _P -
M /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8
M^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\ ]P#=
M /\ S #_ +X _P"U /\ L #_ *T _P#_    _P   /\   #_    _P & /\
M#0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E
M .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\
MNP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T   #Z    ^    /  "0#L
M !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,,
M8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P J #_
M *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G    VP   -$ ! #*  T
MQP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H
M &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_ )$
M_P"+ /\ B #_ (8 _P#W    [    -X   #)    O    +0   "O  H JP 0
M *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H
MD0!A (\ : "- '$ BP![ (D B "' )< A0"H (, O@"! .0 @ #_ (  _P!\
M /\ >P#_ 'D _P#I    UP   ,$   "Q    I@   )T   "7  4 E  - )(
M$@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!:
M 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O /\
M;0#_ &P _P#:    OP   *P   ">    DP   (P   "%    @@ ) '\ #P!^
M !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P
M6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_
M &  _P#%    K0   )L   "-    @P   'P   !W    <@ % '  # !N !$
M;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!=
M %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4
M_P"V    GP   (T   !_    =0   &X   !I    9@ ! &, "0!A  X 8  3
M %\ &0!> "  70 F %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2 %@
M40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H _P"J
M 0  E 4  (('  !T"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0 %0
M%0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0 1P!=
M $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"
MB@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+
M !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T
M9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0  @PX
M '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$ A,
M0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T
M!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3
M  !?%   510  $X4  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6
M #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\
M*PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;
M%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.
M&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"
M ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@
M31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M
M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5
MD0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0  2AT
M $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD
M)Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5
M&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R   #\@
M   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P=
M " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J(
M$!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V
M(@  ,B$  "XA   J(   )R   "0?   B( ( (" * !XA#P =(10 '"$: !LB
M(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T
M  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+)   020  #HD   T)
M+R,  "LC   H(P  )",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4
M)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4G
MS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@  +28
M "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"(
M#BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   LR0
M+.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@  "<G
M   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F
M  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP  ,.H
M ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J   @
M*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B   W
M*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH  #;]
M   U_P!C+   5"X  $@O   ^+P  -BX  # N   K+0  )RT  "(M   =+P
M&#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^)@
M/B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]   [
M_P!>,   4#$  $0R   [,@  -#$  "XP   I+P  )#   !XR   9-   %#8
M ! Y   -.P  "CT   5 !0  00H  $(-  !#$   1!0  $4:  !&(@  1BL
M $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"_P!8
M-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T   U
M   )0@  !$4   !' P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4  $\O
M  !//   3TH  $]:  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3.0
M1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_   00@  #$4   =(   "
M2@   $T   !/    400  %('  !4"P  50X  %<1  !9%P  6A\  %DI  !9
M-@  640  %E4  !89P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0  0ST
M #P\   U.P  +#P  "0^   <00  %40  !!(   +2P  !4X   !1    5
M %<   !9    6P   %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F+@
M9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$  #H_
M   P0   )D,  !Y&   52@  $$X   I2   #5@   %H   !=    8    &,
M  !E    9P   &D   !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@  =C4
M '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J
M2   ($P  !=1   05@  "5H   %?    8P   &@   !K    ;P   '(   !U
M    =P   'D   ![    ?0   ( #  "#"   A@T  (D3  "*'0  BBL  (D\
M  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C4P
M&%@  !!>   )9    &D   !O    =    '@   !\    @0   (0   "'
MB    (L   ".    D    ),   "6    F0<  )T-  "A%   H"$  * Q  ">
M1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8   $6<
M  EM    =    'L   "!    A@   (L   "0    E    )<   "9    G
M )\   "A    I    *<   "J    K0   +$&  "U#0  N!8  +<F  "V.0
MM5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$  !YH   3<   "W@   "
M    AP   (X   "5    F@   )\   "D    J    *P   "M    L    +,
M  "U    N    +L   "_    PP   ,<   #+!0  T0X  -$;  #0+@  ST4
M ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3
MFP   *(   "H    K@   +0   "X    O0   ,    #"    Q0   ,@   #+
M    S@   -$   #6    VP   -\   #D    Z 8  .L1  #J(P  ZCH  .E4
M  #G<@  Y9,  ..S  #CU #_    _P   /\   #_  0 _P + /\ $ #_ !<
M_P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T
M ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +(
M_P"J /\ I0#_ *( _P#_    _P   /X   #\    _  # /X "P#_ !$ _P :
M /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L
MU !R -  >P#- (4 R@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0 _P"<
M /\ F #_ )4 _P#_    ^@   /0   #Q    \@   .H !0#G  X X@ 5 .$
M'@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K
M +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/ /\
MBP#_ (D _P#Y    [P   .<   #?    SP   ,@   #!  H OP 1 +P & "[
M "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C )T
M:@"; ', F0!^ )8 C "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_
M 'P _P#M    X    -$   "_    LP   *H   "F  4 H@ - *$ $P"@ !L
MGP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"&
M &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\
M_P#=    RP   +8   "G    G0   )0   ".  $ BP * (D $ "( !4 AP =
M (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S &,
M<0!N &\ >@!M (D ; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*
M    M    *$   "3    B0   ((   ![    >  % '8 # !U !$ =  8 ',
M'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F
M &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y
MH@   )    "#    >0   '$   !M    :0 ! &8 "0!E  X 9  3 &, &0!C
M "  80 F &  + !> #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@ %,
M; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J    E
M ((   !U    :P   &0   !@    70   %H !0!8  P 5P 0 %8 %0!6 !L
M50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@ 9@!&
M ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0   '@#
M  !J!   800  %H#  !5 0  4@   %   @!.  D 30 - $P $0!+ !< 2@ <
M $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X
M.P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)  !B
M"@  6 L  %$*  !,"   208  $<#  !&  8 1  + $, #P!" !, 00 8 $$
M'@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z
M #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<#@
M4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X
M "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H
MB0 I )T * "S "< T0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0  31$
M $41  ! $   / \  #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P
M, 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B
M!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3
M   [$P  -Q(  #01   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD *@L?
M "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P
M&0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6   X
M%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/
M(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S
M !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+&   0AD  #H9   T&
M,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =
M$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4
MR@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@  +1H
M "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0
M%A@K !48-  4&#T $AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )
M&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T  #4=   O'0  *AP  "8;
M   C&P  (1H  !X:   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI
M !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8
M!!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>   A
M'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB
M+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4  "#X
M   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J(0  )B   "(@   ?'P
M'!\  !D@   6(0  $B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F*@ &
M)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y   D
M_P!C(   5"(  $<C   ])   -"0  "XC   H(P  )"(  "$B   >(0  &B(
M !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P  +#
M "PZ   L10  +%,  "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I_P!?
M(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4  !0G
M   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP  #(V
M   R0@  ,D\  #)?   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:)P
M3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG   8*   %"H  !$L   .
M+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R   Y
M/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@  2"P
M #TL   T+   +2L  "@J   D*0  'BH  !DK   4+0  $2\   TQ   *-
M!S8   (X!   .@<  #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  ! .0
M0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\  #DO
M   R+P  +"T  "<L   @+0  &B\  !4Q   1,P  #38   DX   %.P   #T
M  !  0  000  $,'  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-   24(
M $E1  !)9   2'L  $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S   P
M,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X   -!    0P   $8   !(
M    2@   $P$  !.!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P  %1+
M  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O-
M)C4  !XW   7.@  $3T   Q!   '1    $@   !*    30   %    !3
M50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%  !@
M5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@  (3P
M !A    10P  #$<   9+    3P   %,   !6    60   %P   !?    80
M &,   !E    9P$  &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P3P
M;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8  !)*
M   ,3P  !%0   !8    70   &$   !E    :    &L   !N    <0   ',
M  !U    >    'L   !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@  @ET
M (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7   #
M70   &,   !H    ;0   '$   !V    >@   'X   "!    @P   (8   ")
M    BP   (X   "2    E0$  )D)  ">$   GAH  )TI  "</   FE(  )AL
M  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   560  #6    -G    ;@
M '0   !Z    @    (0   "*    C@   )(   "5    EP   )H   "=
MH    *,   "G    JP   *\   "T"0  N!   +<>  "U,   LT8  +%@  "O
M?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0  !7$   !Y    @0   (@
M  "/    E    )H   "?    I    *@   "I    K    *\   "S    M0
M +D   "]    P0   ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*<0
MR)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0   "-    E0   )T   "C
M    J0   *\   "T    N0   +P   "^    P@   ,4   #(    S    -
M  #4    V@   -\   #D    Z@   .X,  #M&@  ["\  .I)  #H90  YH8
M .2E  #BQ@#_    _P   /\   #\  $ _  ( /X #@#_ !0 _P = /\ )@#_
M #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T
M?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_
M )8 _P#_    ^P   /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W "H
M\@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#)
M (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H
M_P#Z    \0   .H   #G    YP   .0  0#@  L VP 1 -H &@#; ", T0 L
M ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '<
MK "# *D D0"F *$ HP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O
M    XP   -H   #3    Q@   +\   "Y  8 MP . +0 % "T !T LP E *X
M+0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X DP!Y
M )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@
MT    ,8   "V    J0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1
M "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P
M?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,    O@
M *L   "=    DP   (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !] "8
M>@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G
M (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0   )<
M  ")    ?@   '@   !S    ;P ! &T "0!L  X :P 3 &L &0!J "  :  F
M &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L
M5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8   !X
M    ;@   &<   !C    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A %@
M)@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0 20"%
M $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L
M8@   %L   !6    4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P (0!*
M "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T
MD@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3    ?@   &X   !A    6
M %$   !,    20   $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!  "(
M/P G #X +  ] #( .P X #H /P Y $< . !0 #< 6P U &@ - !X #, C  R
M *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <  $D&
M  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X -@ C
M #4 *  T "X ,P T #( .P P $, +P!, "X 5P M &0 + !S "L AP J )P
M*0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+   ]
M"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ? "X
M)  L "H *P P "H -P I #\ * !) "< 5  F &  ) !O ", @@ B )< (0"N
M "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.#@  10X  #T.   X#0
M,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "< (0 F
M "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H
MQ0 : .L &0#_ !H _P!U#   9 X  %4/  !*$   0!   #D0   S$   +P\
M "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0
M'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2
M!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$  "@1
M   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI
M !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.
M#0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4   M%   *!,  "43   B
M$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00
M,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T
M  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?%
M'1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .
M$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2
M_P!E$P  518  $@7   ]&   -!@  "T8   H&   (Q<  " 7   =%@  &A4
M !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#(
M"1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6_P!A
M%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<  !87
M @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX
M  (<1   '5$  !U@   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>&
M3QH  $(<   X'   +QT  "D<   C'   'QL  !P:   9&0  %QD! !09 @ 2
M&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U   A
M0   (4X  "%=   A;P  (88  "">   @N   ']X  ![X   >_P!:&P  2QT
M #\>   U'P  +1\  "<>   B'0  'AT  !L<   8&P  %1L  !(<   0'0(
M#A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F(   )B@  "8R   F/0
M)DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R   #PA
M   R(0  *R$  "4@   @'P  '1X  !H=   6'@  $QX  ! @   .(0  #","
M  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0  +"4  "PN   L.@  +$<
M "Q6   L:0  +(   "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D   O
M)   *",  ",B   ?(0  '"   !<@   3(0  $",   XD   +)@  ""@   0J
M!   + <  "X)   P#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,  #-2
M   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M)@
M)R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ   '+    R\    Q @
M,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.   [
M8   .G<  #F2   XL   -]L  #;\   U_P!'*0  .RH  #(J   K*0  )2<
M "$F   ;)P  %2@  !$J   .+   "B\   8Q   !-    #8    X    .P$
M #T$   _!P  00H  $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$6P
M0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ
M   7+   $2X   TQ   )-   !#<    Z    /    #\   !!    1    $8
M  !( P  2@<  $P+  !.#@  4!,  % <  !0)P  3S0  $]#  !/50  3FH
M $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ   2
M,P  #C<   DZ   "/0   $    !$    1P   $D   !,    3P   %$   !3
M    50$  %@&  !:"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,  %I^
M  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   ./0
M"$$   !%    20   $P   !0    4P   %8   !9    6P   %T   !@
M8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU  !H
ME   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P  %3\   Y$   '20   $T
M  !2    5@   %H   !>    8@   &4   !H    :P   &T   !P    <P
M '8   !Y    ?00  ($+  "%$0  A!T  ((L  " /@  ?E0  'YK  ![B@
M>JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL   =1    5P   %P   !B
M    9@   &L   !O    =    '@   ![    ?@   (    "#    A@   (H
M  "-    D0   )8#  ";#   G1,  )LA  ":,P  ETD  )1B  "3?P  D*
M ([%  ",\P Q1   )4@  !I-   04P  "%H   !A    :    &X   !T
M>0   '\   "$    B0   (T   "1    DP   )8   "9    G0   *    "D
M    J    *P   "R P  MPT  +<7  "U*   LCX  +!6  "L<P  JI0  *FT
M  "EY0 J3P  'E0  !);   *8@   &H   !S    >P   ((   ")    C@
M )0   ":    GP   *0   "F    J0   *T   "P    LP   +<   "[
MP    ,4   #+    T00  -4.  #3'0  T#(  ,U+  #*9@  QH<  ,*I  #!
MRP B6P  %F(   QK   !=    'T   "'    D    )<   ">    I    *L
M  "Q    M@   +H   "\    P    ,0   #(    RP   ,\   #4    V@
M .    #F    ZP   /$&  #P$P  [B<  .P_  #J6P  YWH  .2;  #@NP#_
M    ^P   /8   #S    ]  % /8 # #Z !$ _P 9 /\ (@#_ "P _P U /\
M/0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H [@!R .P >@#I (4 Y0"1
M .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6 /\ D #_ (P _P#Z
M\@   .P   #I    Z0   .P !0#R  P ^  2 /< &P#U "4 \  N .L -P#F
M #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J ,@ <@#% 'P P@"( +X
ME@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\ @P#_ (  _P#P    Y0
M -X   #:    VP   -P   #8  < T0 . -$ %0#2 !X RP G ,4 +P#  #<
MO0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P :0"I ', IP!_ *0 C0"A
M )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_ '0 _P#B    TP   ,H
M  #'    O    +8   "P  $ KP + *P $0"M !@ K0 @ *@ * "D "\ H  V
M )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/ &H C !U (H @P"( )0
MA@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@ _P#/    P0   +D   "M
M    H    )@   "4    D0 & )  #0"0 !( CP 9 (X (0"+ "@ B  O (8
M-0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &( =@!L '0 >0!R (D <0"=
M &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^    L0   *    "2
MB0   ((   !\    >@ ! '@ "0!W  X >  4 '< &@!T "$ <@ G '  +0!N
M #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D &$ < !? '\ 7@"3 %T
MJ0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P    GP   (T   !_    =
M &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C !L 80 A %\ )P!= "P
M7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %( : !0 '< 3P") $X GP!-
M +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0   'P   !N    90   %X
M  !9    5P   %4  0!4  < 4P - %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K
M $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!# '  0@"! $$ EP!  *\
M/P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\   !C    60   %$   !-
M    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$
M*P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D -P!Z #8 CP U *< -0#&
M #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8    3P   $@   !#
M/P   #T    \  ( /  ' #L #  [  \ .P 2 #H %P Y !P -P A #8 )@ U
M "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S "P B  L *  *P"[ "L
MZ@ K /\ *P#_ "P _P!_    ;    %T!  !1 @  2 ,  $ #   [ @  -P
M #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P !@ +P = "T (@ L "@
M*P N "H -0 I #T * !& "< 40 F %X )0!N "0 @@ C )D (P"S "( W@ B
M /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@  #H(   U!P  , 8  "T%
M   L P  *P # "H !P I  L *0 . "D $0 H !4 )P 9 "8 '@ E "0 )  J
M ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  < ), &P"L !L S0 ; /8
M&P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+   P"P  *PH  "@)   E
M"   ) <" ",$!@ C @D (@$, "( #P A !( (  6 !\ &P > "  '0 F !P
M+@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\ %0"F !0 PP 4 .X % #_
M !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L#0  )PT  ",,   A#
M'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$&  9!!X & 0C !<$*P 6
M!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B  \ O  / .4 #P#^ !
M_P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P  ) X  " .   =#@  &PT!
M !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4"1L $PDA !()*  2"3
M$0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'MP *!ML "@7V  H$_P!C
M#0  4PX  $80   [$0  ,A$  "L1   E$   (1   !T0   :#P  & \! !8.
M!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D $ P?  \,)P .#2\ #0TY
M  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  ##-(  @SQ  (+_P!?#@
M4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1   8$0  %1 " !00!0 2
M$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =  P0)  *$"P "1 V  @0
M00 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0   [S   ._P!<$   31(
M $ 3   V%   +10  "84   A$P  '!,  !D2   6$@  %!$# !(1!@ 1$0@
M$! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "
M$TL  !-:   3;   $X(  !*;   2M   $=<  !'U   1_P!8$@  210  #T5
M   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$ $Q($ !$2!P 0$@D #A()
M  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "%B<  !<P   7.P  %T@
M !=8   7:@  %H   !:9   5M   %=D  !3W   3_P!5%   1A8  #H7   P
M&   *!@  "(7   =%@  &18  !85   3% , $A,& ! 3!P /$P< #10'  L5
M"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0  !LM   ;.   &T8  !Q5
M   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1%@  0Q@  #<9   N&@
M)AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5!  -%@0 "Q<%  D9!@ &
M&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J   A-0  (4(  "%2   @
M9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0  /QL  #0<   K'   )!P
M !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +&@( "!P#  4=!  "'P8
M "$(   C"P  )0X  "81   F%@  )AX  "<G   G,@  )S\  "9.   F8
M)G<  "62   DKP  (]H  "+[   A_P!('0  /!X  #$?   H'@  (AX  !T<
M   9&P  %AH  !(:   0&P  #1P   L=   ('P  !"$   $C @  )00  "<&
M   I"0  + P  "X/   N$P  +AH  "XC   N+@  +CL  "Y*   M7   +7(
M "R.   KK   *M0  "G[   H_P!$(   ."$  "XA   F(0  ("   !P>   8
M'0  %!T  ! >   .'P  "R$   <C   #)0   "<    I    + $  "X#   P
M!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8  #9%   U5P  -6T  #2)
M   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D(P  'R$  !L@   6(
M$2$   XC   *)0  !B@   (J    +0   "\    R    -    #<    Y P
M.P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!    _4@  /F<  #V"   \
MH@  .L<  #GX   X_P Z*   ,"@  "DG   C)0  'R,  !@D   2)0  #B@
M  HJ   %+0   #     S    -@   #@    [    /@   $    !"    10(
M $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*3   26$  $A\  !'FP
M1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@  !0J   .+0  "C    0S
M    -P   #H    ]    0    $,   !&    2    $L   !-    4    %,!
M  !6!@  60L  %L0  !;&0  6B4  %DT  !81@  5UH  %5T  !4DP  4K4
M %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R   *-@   SH    _
M0@   $8   !)    3    $\   !2    50   %@   !:    70   &    !C
M    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(  &9J  !DB0  8:L  %_<
M  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "0@   $<   !,    4
M %0   !8    6P   %\   !B    90   &@   !K    ;@   '$   !U
M>0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA  !X?P  =I\  '/&  !P
M]P Q-@  )C@  !P[   20   "T4   )+    40   %8   !;    8    &4
M  !I    ;@   '(   !V    >0   'P   !^    @@   (4   ")    C@
M ),   "8!@  G X  )L:  "8*P  ED   ))9  "1<P  C94  (NU  "(Z  K
M/@  ($$  !5'   -30   E0   !;    80   &@   !N    <P   'D   !^
M    @P   (@   ",    CP   )(   "5    F0   )T   "A    I0   *H
M  "P    MP<  +@1  "U(0  LC4  *]-  "J:0  J(@  *:H  "BT0 C2
M&$X   Y4   $7    &0   !M    =0   'P   "#    B0   (\   "5
MFP   *    "C    I@   *D   "M    L0   +4   "Y    O@   ,0   #*
M    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P  ,*=  #!O0 <50  $5P
M  =E    ;@   '<   !_    B    )    "8    GP   *4   "M    LP
M +@   "Z    O@   ,(   #&    R@   ,X   #3    V@   .    #G
M[0   /,   #T#@  \AX  .\V  #L40  Z&X  .20  #?L0
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MZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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MYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^_O\
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M0B&^]D@ULO],1JG_456;]UU@CO!E:H7K;'%]YW%V=^1V>G/B>7UOX7Q_;-^
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M_YP?!/^:*0K_HC,0_ZT[%_^W1"/_P4PR^<E31?/-6EKLTF!PX-!FAL[(;)K
MOW&IM+AWM:FQ?+Z?K('%EZB&RI"DC,Z*HI71A:*ATH&<ILZ!FJ?,@9JGS(&:
MI\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,_YP>
M!/^;*0K_HS,0_Z\[%_^Y1"+]PTLQ]LQ21/#265GHVE]PV]5DALG,:IFZPV^H
MK;MTM**T>;V8KWW#D*R#R(FIB<R#IY'/?J:<T'VDILU\HJC+?**HRWRBJ,M\
MHJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+_YT>!/^;
M*0K_I3(/_[$[%O^\1"'ZQDLQ\]%10^O:5UGCWUUOT]MCA<+/:9>QQ&VGI+QP
MLIBU=+N.L7C"AJU]QH"K@LIZJ8K-=JB4SG:IH\QWJZC*=ZNHRG>KJ,IWJZC*
M=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*_YT>!/^<*0K_
MIS(/_[,[%O^^0R#URDLO[M900N;A5E?<Y%MNR]YC@[K1:)2IQVRCF[YNKI"X
M<;>&M'2]?K!XPG>N?,9RK(/);:N,RFVKF<ENK)_';JR?QVZLG\=NK)_';JR?
MQVZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_'_YX>!/^=*0G_J3(.
M_[8Z%/K"0Q_PSDHNY]U/0.+I4E?2Z%IMP>!B@+'49Y&ARFN>E,-NJ(F]<;"
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M7_"3:E_PDVI?\)-J_[<5 =;/"P#'ZA,"N?<I#:S_.1J>_SXFDO]$,(?_2SF
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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MB#(._Y,X%/^;01S_HDHG_Z14-/^B7T/_GVI1_9IT7_64?FSMCHAXYX>/@>*
ME8K=>YJ0VG>@EM9TIIK4<:R>TF^RH=!MN://;,.FQ6?#IL!IQZ' :<>AP&G'
MH<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>A_XT< _^*)PC_BC$-
M_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:?'#JE(5]XXN+B-V$DI'8
M?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O JK=MQ*6W;<2EMVW$I;=M
MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2E_XT; _^+)PC_C# -_Y@W
M$_^@0!O_IT@F_ZM2-/^K7$3_J694^J5P9/"?>7/GF(*!WX^(C=F(CY?2@96@
MSGN;I\IVH:W'<ZBQQ7"OM<%MM[>Y:[BULVZ]KK!PP:BP<,&HL'#!J+!PP:BP
M<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&H_XX; _^+)@C_CC -_YHV$O^B
M/QK_J4@F_ZY1-/^N6T3_K&15^:IN9>^E=W;EG7^%W)2%DM2,C)W.A)*GR7V8
MK\1XGK7"=:>YP72QN[APL[NQ;[:XK'&[L:ESOZNI<[^KJ7._JZESOZNI<[^K
MJ7._JZESOZNI<[^KJ7._JZESOZNI<[^K_XX; _^,)@C_D"\-_YLV$O^D/QK_
MJT<F_[%0-/^Q643\L&-5]JYL9^VJ=7CCH7R(V9B#EM&0B:/*AX^MQ8*7M,)_
MH+B^?*B[NWJPO;%TLKVI<K2[IG2YLZ-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^
MK:-VOJVC=KZMHW:^K:-VOJVC=KZM_X\; _^,)@?_D2X,_YTV$O^F/AK_K4<E
M_[-/-/^T6$3ZM&%6\[)J:.RO<WKAIGJ+UIV FLV4AJ?&C8VOOX>4M;J"G+FU
M?Z2\LGVLOJMYL;^C=K*]H'BXM9YYO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYY
MO:^>>;VOGGF]KYYYO:^>>;VO_X\; _^-)@?_DRX,_YXU$?^H/AG_KT8E_[9.
M,_ZW5T3WMV!6\+9H:>BS<'O>JG>-T)]\G<>7@Z>_D(JON(N1MK*&F+JM@Z"]
MJ8&IOZ5^L,"<>;&_FGNWMYA]N["8?;NPF'V[L)A]N["8?;NPF'V[L)A]N["8
M?;NPF'V[L)A]N["8?;NP_Y : _^-)@?_E"T,_Z U$?^I/AG_L48D_[A-,_R[
M5D3UNU]6[;MG:>.U;GW6K'./RJ-ZG<&;@*>XE(>PL8^.MJN*E;NFAYV^HH6E
MP)^$K\&6?K#!E'^VN). N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3@+NR
MDX"[LI. N[*3@+NR_Y : _^.)@?_E2T,_Z$U$?^K/1C_LT8D_[I-,_J^543S
MOUU6ZK]E:M^X:W[0KW&/Q:9XG+N??J>RF(6OJY.+MJ6.D[N?BYJ^FXFBP9B(
MK,*0@J_"CX.UN8^$NK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK./A+JSCX2Z
MLX^$NK./A+JS_Y : _^.)0?_EBP+_Z(U$/^L/1C_M44C_[Q,,OC!5$/PPUQ6
MY\-C:MJ[:7[,LG"/P*IVG+:B?*>MG(*OI9>)MIZ3D+N9CYB^E(V@P9&,J<*+
MB*["BHBTNHJ(N;2*B+FTBHBYM(J(N;2*B+FTBHBYM(J(N;2*B+FTBHBYM(J(
MN;2*B+FT_Y$: _^/)0?_F"P+_Z0T$/^N/1C_MT4C_[],,O;%4T/NR%M6X\9A
M:M2_:'['MFZ.NZUTG+&F>J:GH("OGYN&M9B7CKN3E96^CI*=P8J2I\*&CJ["
MA(VTNX6,N;2%C+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FTA8RYM(6,N;2%
MC+FT_Y$: _^/)0?_F2P+_Z8T#_^P/!?_N40B_,%+,?3)4D+KS5E5W\E@:L_"
M9GW"N6R-MK%RFZNK>*:BI7ZNF:"$M9*=B[J,FI.^AYB;P(27I<* EJ_"?Y*S
MO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU
M_Y(: _^0)0?_FRP*_Z<T#_^R/!;_NT0A^<5+,/'.44'GTEA4VLY>:<K&97R]
MO6N,L+9PFJ6P=J6<JGRMDZ:"M(RCB;F&H)"]@9Z9OWV>HL%[GJ_!>9FSO'J7
MN+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU_Y(9
M _^0)0?_G2L*_ZHS#O^U/!7\OT0@],A*+NW34#_CV%93T])=:,7*8WNWPFF+
MJKMOF)^V=*.5L7JLC:V LH6JA[=_IXZ[>J:7OG>FH+]TIJV_<Z&TNW2>N+5T
MGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU_Y,9 _^1
M) ?_GRL)_ZPS#?^X.Q3XPT,>[\U*+.?:3SW=WE51S=A;9[[/8GJPR&>)I,)M
MEYF\<J&/N'BIAK5^L'^RA;5YL(RX=*^5NW"OG[QNKZR\;:NUN6ZGN;1NI[FT
M;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT_Y09 _^2) ?_
MHBH(_[ R#/Z\.A+RQT(<Z--)*>'A3#O4XU-1QMU:9;?58'BISV:'G<EKE)'%
M<)Z'P7:F?[Y\K'B\A+%RNHNT;;F3MFJXG+AGMZ>X9[>WMFBRN[%HLKNQ:+*[
ML6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ_Y48 _^5(P;_I2D'
M_[0Q"OC!.A#KSD(8X-U')=7E2SO+YU%0O>-98Z_>7W2BV&6#EM-JCXK.;YE_
MR'.A=<1XIV[!?:MIOH2N9;V+L6&\D[)?O)VR7[RLL6*_OJUBO[ZM8K^^K6*_
MOJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM_Y88 _^9(07_JB@&_[DP
M"/#(. WAV$ 3U.-%)LKK2SO![$]/L^A78*;E7V^:XF9\CMQLAH35<8]ZT'65
M<\UZFVS*?Y]GQX2B8\:*I%_$D:9<Q)FG6L.DIUK$L*=:Q+"G6L2PIUK$L*=:
MQ+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G_Y@7 O^>( 3_KR8%^, N!N;0
M,PC5X3P4R>I%*+_R2CNU\4Y,J>]66YWM7VB2ZF=SA^-M?'[><H)VVGB(<-=]
MC&O4@I!FTH>28]&,E5_/DI9<SIF86<ZBF5C-JYI8S:N:6,VKFEC-JYI8S:N:
M6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:_YH7 O^E'@/_MR,#[<DF ];>*0;)
MZ3L7OO-$*;/X23JH]TU(G_95593U7V")\6AH@.QO<'CH=75RY7IY;>)_?6G@
MA(!EWXF"8MV.A%_<DX9=VYF'6MJAB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FH
MB5C9J(E8V:B)6-FHB5C9J(E8V:B)_YP6 O^M&P+VP1T!V]H3 <GH*0F]\SL9
MLOU#**;^1S:<_4Q#D_U538K]7U:!^6E=>?5P8G/R=F=N\'QJ:NZ!;6?LAF]D
MZXMQ8>J/<E_IE'1=Z)EU6N>@=UCFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CF
MIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL RN<3 KSS*0NQ_3L9I/]
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M8-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'_X,< _^
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M _^') ;_E"D)_Z$P#/^K.1+_M$$<_+M(*/3#3CCKQU9*X,->7=&\96_$LVN
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MS)E9S,R96<S,F5G,S)E9S,R9_Y(6 O^=' /_KR "]L E N+3) /0XS(,Q>Q
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M)CO_GB8[_YXF._^>)CO_GB8[_YXF._^>)CO_GB8[_YXFJ\$  )W0  "/X0
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M1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'T:X  +^Y P"RQ0,
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M:D[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9T[/\&=.S_!G_X\+ .FD! #1M 8
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M=O\@!6S_* ED_S -7?\X$%?_0!-1_T<63?].&$K_5AE'_UP:1/]C'$+_:1U
M_W >/_]X'CW_@!\[_X@@.O^1(3C_FR(W_Z0B-O^M(S7_N",U_[DC-?^Y(S7_
MN2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@  A.$  'W_#0%R_Q,":/\;
M!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]_U03._]:%#G_7Q0W_V45
M-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_IQDJ_Z<9*O^G&2K_IQDJ
M_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<  &[_"@%C_Q "6O\5 U+_
M'01+_R0&1O\L"$'_,PD\_SH*.?] "S7_10PR_TH-,/]0#2[_5 XL_UD.*O]>
M#RC_9 \F_VH/)?]Q$"/_>! B_X 1(/^($1__D1$?_Y$1'_^1$1__D1$?_Y$1
M'_^1$1__D1$?_Y$1_UPB _]7+07_6#,'_U\V"?]C/0W_9482_V90%_]E7AS_
M9&XB_V%\)_]?BBO_7I8N_URA,?];JC/_6K(U_UFZ-O]8PS?_6,TY_U?8.?]6
MX#K_5>8[_U3L//]3\3S\4O4]^%+Y/?51_3WS4?\]\U'_/?-1_SWS4?\]\U'_
M/?-1_SWS4?\]_UPB _]7+ 7_6C('_V$U"?]E/ W_9T42_VA/%_]H7!W_9FTB
M_V-[*/]AB"S_7Y0O_UZ?,O]=J37_6[$W_UJY./]:P3K_6<L[_UC5//]7WSW_
M5N8^_U7K/OU4\#_Y4_4_]E+Y0/-2_4#P4O\^\%+_/O!2_S[P4O\^\%+_/O!2
M_S[P4O\^_UTA _]8+ 7_7# '_V0S"?]H.@W_:T,2_VQ.%_]L6AW_:FHD_V=X
M*?]DA2[_8I$R_V&<-O]?ICC_7JXZ_UVV//]<OC[_6\@__UK20?]9W4+_5^5#
M_5;J1/E5\$3U5/5%\53Z1>Y4_D3L5/]"[%3_0NQ4_T+L5/]"[%3_0NQ4_T+L
M5/]"_UXA _]9+ 7_7RX&_V8R"?]L. S_;T$1_V],%_]Q5Q[_;F<E_VMU*_]H
M@C#_98XU_V29.?]BHSS_8*L^_U^S0?]>NT+_7<1$_US.1O]:W$?^6>1(^E?J
M2?56\$KP5?9*[57Z2NE6_D?G5O]%YU;_1>=6_T7G5O]%YU;_1>=6_T7G5O]%
M_UXA _]9*P7_8BT&_VHP"/]O-@S_<D 1_W1*&/]U51[_<F0F_V]R+?]L?S/_
M:8LX_V:6//]EH$#_8ZA#_V&P1O]@N$C_7L%*_UW+2_]<VDWZ6N-.]5GJ3_!7
M\5#K5O91YU?[3N18_TOA6?])X5G_2>%9_TGA6?])X5G_2>%9_TGA6?])_U\@
M _]:*P7_92L&_VTN"/]S-0S_=SX1_WA(%_]Y4A__=V G_W1N+O]P>S7_;8<[
M_VJ20?]GFT7_9:1)_F.L3/UAM$[[8+Q1^E[&4_E=U%7U6^-6[UKJ6.E8\EGE
M6?=6X%K[4]M;_T_76_]-UUO_3==;_TW76_]-UUO_3==;_TW76_]-_V @ _]=
M*07_:"D&_W$K!_]X,PO_?#P0_WU&%_]^4!__?5TH_WEJ,/]U=CC_<8(__&V-
M1?IJETOX9Y]/]F6G4_1BKU;S8+A9\5_!7/!=S5[M7.!@Z%KL8>%:\F#:6_9;
MTUSZ5\]=_5/,7O]1S%[_4<Q>_U',7O]1S%[_4<Q>_U',7O]1_V$? _]@)P3_
M:R8%_W4I!_]\,0K_@3H0_X-$%_^$31__@UDH_W]F,OQZ<COX=7Y#]7&(2_)M
MDE'O:9I6[6:B6^ICJE_H8+)CYEZ\9N1<R&GA6]IKW5KJ:]-<\&;-7O5AR%_Y
M7,1@_%C!8?Y5P6'^5<%A_E7!8?Y5P6'^5<%A_E7!8?Y5_V(? _]C)03_;R0%
M_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6 ;CWP>GE'['6#4.EPC%CE
M:Y5>X6:=9-YCI&G;8*UMUU^W;]1>PW#17M)QS5WG<<=?[FO"8?)FOF+V8;IC
M^5RW8_Q8MV/\6+=C_%BW8_Q8MV/\6+=C_%BW8_Q8_V,? _]F(P3_<B($_WTG
M!O^%+@G_BC<._XU %?^/21[ZCU,H](Q?-.Z&:C_I?W1+XWA^5=YRAE[8;8]E
MTVJ8:L]GH&W,9:APR6.Q<\9BO'3$8<EUP6'@=KQCZG&W9.]JM&7S9;!F]F"N
M9_E<KF?Y7*YG^5RN9_E<KF?Y7*YG^5RN9_E<_V,> _]H(03_=2 $_X$E!?^)
M+0C_CS4,_Y(^%/R41QWUED\H[I%;-.>+9D'@A&].V7UY6-%W@F#,<XIGQV^3
M;,1LFW# ::-SO6>L=KIFMGBX9<)YMF75>;)FYG:N:.QOJFGP::AI]&.F:O=?
MIFKW7Z9J]U^F:O=?IFKW7Z9J]U^F:O=?_V0> _]K( /_>!X$_X0D!?^-+ ?_
MDS0+_Y<\$OB911OPFTTGZ)=9-.&08D+7B6Q.SH-U6,A]?F'#>(9HOG2.;;EP
MEG*V;IYULFRG>*]JL7NM:;U\JFG-?:AJXWJE;.ERHFSM;*!M\F:>;O5BGF[U
M8IYN]6*>;O5BGF[U8IYN]6*>;O5B_V4= O]M'@/_>QT#_X<C!/^0*@;_ES(*
M_9P[$/2?0QGLH4LEXYQ6,]J68$'/CFE.QXAR6,"">F&Z?8)HM7F*;K%UDG.L
M<IIWJ7"C>J9NK'VC;;A^H6W'?Y]NX'Z<<.=UFG#K;YEQ\&B7<?-DEW'S9)=Q
M\V27<?-DEW'S9)=Q\V27<?-D_V4= O]O'0/_?AP#_XHB!/^3*07_FS$)^: Y
M#_"C01CGIDDCWJ%4,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9X
MH'2?>YUSJ'Z:<;2 F''"@99RV(&5=.5XDW3J<9)U[VN1=?)FD77R9I%U\F:1
M=?)FD77R9I%U\F:1=?)F_V8= O]Q&P/_@!L#_XPA _^6* 7_GB\(]J0W#>RH
M/Q7CJT@@V*92,,R>7$##EV5-NY%M5[.+=&&MAGQHIX*#;J)^BW2=>Y-XF7F<
M?)5WI7^2=K"!D'6^@HYVT8*.>.-ZC7CH<XQX[6R+>/%HBWCQ:(MX\6B+>/%H
MBWCQ:(MX\6B+>/%H_V<< O]S&@+_@AH"_X\@ _^9)@3^HBX&\Z@U"^FM/1/?
MKT8>TJE1+\>B6C^^FV-,M95J5ZZ/<F"GBWEHH8>!;IR#B'27@)!XDGV9?(Y\
MHH"+>JV"B'J[@X=ZS8.'?.)\AWSG=89\[&Z&?/!IAGSP:89\\&F&?/!IAGSP
M:89\\&F&?/!I_V<< O]U&0+_A1D"_Y(? O^<)0/[I2P%\*PT">:R.Q#;LT0=
MS:U/+L.F63ZYGV%+L)EH5JB4<%^ACW=GFXM^;I:(AG.0A8YXC(*6?(B H("$
M?ZN"@7^X@W]_RH2!@>%]@8'F=H& ZV^ @.]J@(#O:H" [VJ @.]J@(#O:H"
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M<URG[&Y=I.]J7:3O:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T
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M3TCA_$](X?Q/2.'\3TCA_$](X?Q/X9D  ,VI  "^LP( L[X# *C+!0"?V@D
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M;6V.\6=NC/9@;HSW7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1
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M6E:M^UI6K?M:5JW[6E:M^UI6K?M:_WX) /*1 @#6H0( RJT% ,"W!0"XP@4
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M1=[_1$7>_T1%WO]$V9<  ,>F  "XL   K+D! *+% @"8T08 C^L- (GN'P*
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M@ T>_XP.'?^7#AS_H0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P
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M4\U8NE3+6,95R5?:5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/]
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M87Y^^EI^??Y5?GW_47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1
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M4F>1_U)GD?]29Y'_4F>1_U)GD?]2_VX. /]_"0#QC@4 V9L% ,^F!P#)KP<
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MIB$X^+4B-_G((C;YXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8
M *FN  "<N0  D,0  (//  !WVP  ;_8* &?_$P%@_QT"6O\G U3_, 5/_S@(
M2O] "D;_2 Q#_T\.0/]6#SW_7A [_V42./]N$S;_=Q0T_X(5,O^/%C#_FQ<O
M_ZD7+O^W&"W_R!@L_^$8+/_O&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL  )ZU
M  "0P0  @LP  '79  !IY   8?\) %O_$0!4_QD!3O\B DG_*P1$_S(%0/\Z
M!CS_00<Y_T<(-O]."3/_5 HQ_UL++O]B#"S_:PPI_W4-)_^ #B7_C0XD_YH/
M(_^F$"+_LQ A_\$0(?_0$"'_T! A_] 0(?_0$"'_T! A_] 0G[(  )&^  "#
MR@  ==8  &?B  !;\0  5/\& $[_#@!(_Q0!0O\< CW_) (Y_RL#-?\R!#'_
M. 0N_SX%*_]#!2C_208E_T\&(_]6!R'_70<>_V4('/]O"!G_>@D7_X<)%O^4
M"17_GPH4_ZH*%/^S"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP
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M4X]N_TR0</]'CW'_0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\
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M1W> _T9W@/]&=X#_1G> _T9W@/]&_V0/ /]R"0#_?P@ Y8P% -B6!P#1G@D
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MKCQ$Q<$\0\7?/$3$\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L
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M&C'UXAHQ]/$9,?'^&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@
MB\   '[*  !QU0  9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^
M_D@'._Y/"3C_5PHV_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_
MQQ$G_^$1)O_R$2;_]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD
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M0*->_SNC7_\WHV#_,Z-A_S&C8?\QHV'_,:-A_S&C8?\Q_U,5 ?]=$ #_: \
M_W 2 /]W%@#[?!P![G\D >2 +0/:?SL(SWI)$L=U5!O!<5\DNVUH*[9J<#&R
M9WDVKV6 .JMCB#VH89! IF"80Z->H46@7JM'GEVW2)Q=QDF:7-])FE_R1)IB
M_SZ:8_\YFV7_-IME_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX _W00
M /][$@#U@1< Z(0> -Z')P'1A#<'R']&$<![41NY=ELCM')E*Z]O;3&J;'4V
MIVI\.J-HA#Z@9HQ!G6241)ICG4>78J=)E6&R2Y-AP4R18=A,D6/O1Y)E_4&2
M9_\\DVG_.)-J_S63:O\UDVK_-9-J_S63:O\U_U<1 ?]C#0#_;@P _W<. /]_
M#P#PA1$ XXD6 -:+(P'+B#4&PH1#$+J 3QJS>UDCK7=B*JAT:C&C<7$VGVYY
M.YQL@3^8:HA"E6F119)GFDB/9J-*C66O3(IEO4V)9=%.B6?L2HII^T.+:_\^
MC&W_.HQN_S>,;O\WC&[_-XQN_S>,;O\W_UD0 /]E"P#_<0L _WH+ /&"# #H
MB0T W8X. ,^/( '&C3(&O8E!#[6$31FN@%8BIWQ?*J)X9S"==6\VF7-V.I5Q
M?3^2;X5"CFV.1HMLEDF(:J!+A6JL38-IND^!:<Q/@6KH3(-M^46$;_\_A7#_
M.X9Q_SB&<?\XAG'_.(9Q_SB&<?\X_UL/ /]G" #_<P@ \WT( -Z&!P#9C D
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MJD=1F[I'4)O11U&;[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70
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M,4&^[C!!O?TO0;S_+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH
MIJ@  )NP  "0N   A;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5
MSU,04<];%$[/8QA+SFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-
M[R4[S/LE.\O_)3O*_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X
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M"B#\_ H@_/P*(/S\"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0
M4M\  $CH  !#_P@ /_\0 #O_&0 W_R$ -/\I 3#_, $M_S<"*O\^ B?_1 (E
M_TL#(O]3 R#_7 ,=_V8$&_]R!!G_@ 47_X\%%O^?!A7_KP84_\ &%/_6!A/_
MZ083_^D&$__I!A/_Z083_^D&EZ\  (BZ  !ZQ0  ;,\  %[:  !0X   1.8
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M*,!+_R6_3/\BODW_(+U-_Q^]3?\>O4W_'KU-_QZ]3?\>_T<8 ?]/$P'_5A$
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M+99@_RJ68/\JEF#_*I9@_RJ68/\J_U(/ /]<"@#_9@D _VX* /9T# #O> X
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M!Z"*0@Z:ADP6DX-5'8Z!722)?F0IA7QK+8%Z<C)]>'DU>G>".79VBSQS=95
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MJ4-@?KE$7W[/1&!_[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0
M .5R  #3?@  QX<  +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82
MA91/&7^15Q]ZCUXE=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:
MA;="687,0EJ%ZC]<AOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V
M  #-@@  PHP  +F3  "PF0  J)T  )^@"0"9H1H DZ K XR?. B%G4,0?YI,
M%WF85!UTEUPB<)5C)VN3:BQGDG$P9)%Y,V"/@C=<CHTZ68V9/5>-IC]4C;9
M4XW+0%2-Z3U6C?HY5XW_-5F._S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(
MAP  O9   +28  "JG0  H:$  )>F! "1IQ4 C*<G H6F-09_I$ ->:)*%'.@
M4AINGUD?:9U@)&6<9RAAFV\L7IIW,%J8@#-6EXLV4Y>7.5&6I3M/EK0\3I;)
M/$Z6Z#I/EODV49;_,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C
MN)8  *V<  "CH0  F:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9G
MJ%<;8Z=>'U^F921;I&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@
MYS5)H/DR2I__,$N?_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H
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M'#;$_QPVQ/\<-L3_'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0
M=,   &C'  !=S04 4],* $_7$@!-V"( 2]@P $G8/ )&V$8#1-E/!$'96 8_
MV6$(/-EK"CK9=@PWV8(.-=J0#S3:H! RVK$1,=O'$3':YQ$PV/82,-;_$R_4
M_Q,OU/\3+]3_$R_4_Q,OU/\3LYH  *:A  ":J0  C;$  ("Z  !TP0  :,D
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M P[_\ ,.__ #DZX  (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]
M*O\" ";_"P C_Q$ (/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,
M_TX!"O]8 0?_90$%_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_
MR@$ _\H!AK<  '?!  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\
M !O_!0 7_PP %/\0 !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST
M /]'  #_4@  _UX  /]M  #_?@$ _XX! /^; 0#_J0$ _ZL! /^K 0#_JP$
M_ZL!_RHM ?\N*P'_,"L!_S N O\N-0+_*3T#_R5)!/\C5P3_(60%_Q]R!O\=
M?P;_'8H&_QV4!O\=G ?_'*,'_QRJ!_\<L0?_'+@&_QR_!O\<R0;_'-8&_QWE
M!O\=[P;_'?D%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%
M_RPK ?\P* '_,R@!_S,K O\Q,0+_+3H#_RM'!/\H5 7_)F$%_R1O!O\B? ?_
M(H<'_R*1!_\AF0?_(:$(_R&G"/\AK@C_(;4(_R&\"/\AQ@?_(=$'_R'B!_\B
M[0?_(O<'_R+_!OTB_P;\(O\&_"+_!OPB_P;[(O\&^R+_!OLB_P;[(O\&_RXH
M ?\S)0'_-B4!_S<G ?\U+0+_-#@#_S)$!/\O407_+%X&_RIK!_\I=P?_*(,(
M_R>-"/\GE@G_)YT)_R>D"?\GJPG_)[()_R>Y"?\GP@G_)\T)_R?>"?\GZPG\
M)_8(^2C^"/<H_PCV*/\(]2C_"/4H_PCU*/\(]2C_"/4H_PCU*/\(_S(E ?\W
M(@'_.B$!_SLC ?\[*0+_.S0"_SE !/\V307_-%H&_S%F!_\P<PC_+G\)_RZ)
M"O\ND@K_+9D+_RVA"_\MIPO_+:X+_RVU#/\MO@S^+<D,^RW9#/@MZ OT+O0+
M\2[^"^\N_PON+O\+[2[_"^PN_PKL+O\*["[_"NPN_PKL+O\*_S4B ?\['@'_
M/QT!_T ? ?]")@'_0C$"_T \ _\^2 7_.U4&_SEB"/\W;@K_-GD+_S6$#/TT
MC0W\-)4-^C2<#ODSHP[W,ZH/]C.R#_4SN@_S,\4/\C/2#^XSY0_J-/(/YS3]
M#^4T_P_D-/\.XC7_#N(U_PWA-?\-X37_#>$U_PWA-?\-_SD> ?\_&@'_0Q@!
M_T8: ?])(P'_22T"_T@X _]%1 7_0U '_T!="?L^:0OX/70-]3Q_#O,[B _Q
M.Y 0[SJ8$>TZGQ+L.:83ZCFN$^DYMA3G.<$4YCG.%>(YXQ7>.?$5VSK\%-@Z
M_Q/5._\2TSO_$M([_Q'2._\0TCO_$-([_Q#2._\0_ST; ?]#%@#_2!0 _TP7
M ?]/'P'_4"@!_T\S O]-/P3[2DH&]4=7"?%&9 SM1&\.Z4-Y$>="@Q/D08L4
MXD"3%N _FQ??/Z(8W3ZJ&=L^LQK8/KT:UC[*&](^WQO./N\;RS_[&LE _QC'
M0/\7QD'_%<5!_Q3$0?\4Q$'_%,1!_Q3$0?\4_T$7 /]'$@#_3!  _U(4 /]6
M&P#_5R0!_U8N OA4.0/Q444&ZT]2">9-7@SA2VD0W4ET$]E(?1;51H88TD6.
M&M!%EAS.1)T=S$2E'LI#K1_(0[8@QD/#(<5#TR'!0^DAOD3W'[Q%_QVZ1O\;
MN4?_&;A'_QBX1_\7N$?_%[A'_Q>X1_\7_T04 /]+$ #_40X _U<1 /];%@#_
M71X ^5TH >];,P+G63\$X%=-"-I460W34F02SE!N%LI.=QG'3( <Q4N('L)*
MD"# 2I<AODF?([Q(IR2Z2+ EN$B\)K=(RR>T1^,GLDGS);!*_R*N2_\?KDS_
M':U,_QNM3?\:K4W_&JU-_QJM3?\:_T<1 /]/#0#_5@P _UP. /]@$@#]8A@
M\&,A .9B+ '>8#H#U%Y(!\U;5 W'6%\3PU9I%[]4<AN\4GH>N5&"(;90BB.T
M3Y$ELDZ9)[!-HBBN3:LJK$RV*ZI,Q"RH3-LLIDWO*J1/_2:D4/\CHU'_(*-2
M_QZB4O\=HE+_':)2_QVB4O\=_TH/ /]2"@#_6@D _V + /]E#@#U9Q$ Z&@8
M -UG) #29C4"RF1$!\-A4 V]7EL3N5QD&+5:;1RQ6'4@KE=](ZQ5A"6I5(PH
MIU.4*J52G2RC4J8MH5&Q+Y]1OC"=4=$PFU'J+YI3^BJ:5?\FF5;_(YE6_R&9
M5_\?F5?_'YE7_Q^95_\?_TT- /]5!@#_704 ^V0' .]I"0#I:PP X6P0 --M
M'@#);#$"PFI ![MG3 VU9%<3L&%@&:Q?:1VH77$AI5QX)*):@">@68<JG5B0
M+)M7F"Z95J(PEE6L,I15N3.35<HSD57E,Y%7]RV16?\ID5K_)9%;_R.16_\A
MD5O_(9%;_R&16_\A_T\+ /]7 @#_80( ZF@! -YM! #8< @ U7 + ,MR&P#"
M<2X"NF\]!K1L20VN:503J6==&:1D91VA8FTAG6%T)9I??"B87H,KE5V++9);
ME#"06YXRC5JH-(M9M36*6<8VB%GA-HA<]#"(7?\KB5[_*(E?_R6)7_\CB5__
M(XE?_R.)7_\C_U$) /]:  #U9   X&P  -=Q P#0= 8 S74) ,1V%P"\=BH!
MM'0Z!:YQ1@RG;E$2HFM:&)YI8AV:9VDAEF5Q)9-D>"B08H KC6&(+HM@D3&(
M7YHSAEZE-8->LC>"7L(W@%[<.(!?\C.!8?\M@F+_*8)C_R:"9/\E@F3_)8)D
M_R6"9/\E_U,& /]=  #G9P  VV\  -!T @#*> 4 QGD' +YZ%0"V>B@!KW@W
M!:AV1 NB<TX2G'!7&)AM7QV4:V<AD&IN)8UH=2B*9WTKAV6%+H1DCC&!8Y<T
M?V*B-GQBKSAZ8KXY>6+5.7EC[S1Z9?XO>V;_*WQG_RA\9_\F?&?_)GQG_R9\
M9_\F_U4# /]@  #C:@  U7(  ,QX 0#%>P, P'T% +E^$@"Q?B4!JGTU!*-Z
M00J==TP1EW15%Y)R71R.<&0@BFYK)(=L<BB$:WHK@6J"+GYIBS%[9Y4T>&>@
M-G9FK#AT9KPY<V;1.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G
M_U<  /9C  #?;0  T74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8
M>TH0DGE3%HUV6QN)=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!J
MJCEN:KDZ;6K..FUKZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD
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M.5QZY3=>>_@R7WO_+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@
MP(,  +>)  "OC@  II$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9U
MBEH;<8AA'VV':"-JAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U:
MXS98@?<Q68'_+5N"_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<
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M)T>:_R5'FO\D1YK_)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H
MBZ4  '^J  !TK@4 ;Z\4 &RO) !HKS("9*X]!5^M1@E;K$\-6*Q6$52K7A11
MJF873JIN&DNI>!U(J8,@1:B/(D.HG21!J*TE0*C )3^HWR4_IO0C0*7_(D"E
M_R% I/\@0*3_($"D_R! I/\@RGX  +N+  "OE0  I)L  )FA  ".I@  @JP
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M#2G-_PTIS?\-KI@  **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0
M0M(# #G9"0 UWQ  --\; #+@)P QX3( ,.$] "[B1P MXE !*^): 2KC90(H
MXW$")N1_ R7DCP,CY:$$(N6T!"'ES00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@
M_P4?X/\%I)X  )BE  "+K@  ?;8  '"^  !CQ@  5LL  $O0  ! U0  -MP
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M7   _VL  /]]  #_D   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4
M '._  !DR0  5M,  $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P(
M#O\)  O_#0 (_Q  !/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20
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M#,TT_PO,-/\+S#3_"\PT_PO,-/\+_SD6 /\^$@#_01  _T43 /](&P#_2"0
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MK"Q]6KLM?%K/+GM;["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U
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M,&AFY"]J:/<I:VG_)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;
MQG,  +UX  "U>P  K7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_
M<UL6>W)B&7AP:1UU;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)K
MX2]D;/8J9FW_)F9M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8
M +E\  "Q?P  J8   *" !P"9@1< E($H 8Z -0.(?D$(@WQ*#7YZ4A%Z>%D5
M=G=@&7-V9QQP=&X?;7-V(VIR?R9G<8DI9'&5*V)PH2U@<+ O7G#"+UUPWR]?
M<?4J8''_)F%R_R-B<O\@8G+_(&)R_R!B<O\@[UP  -QI  #*<@  OGH  +6
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M)59\_R)7?/\@5WS_(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC
MF8X  (V/  "&D X @9$= 'V0+ %XCS@$<XY""&Z-2PQJC%,09XI:%&.)81=@
MB&@;78=P'EJ&>2%6A8,D5(6/)E&$G"A/A*HJ382\*DV$URI-@_$G3X/_)%"#
M_R)0@_\?4(/_'U"#_Q]0@_\?WFD  ,EU  "\@   LH@  *B-  "=D0  DY,
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M&#R?_Q@\G_\8Q'P  +:)  "JD@  GY<  )6<  ")H0  ?:8  '&J  !DK@
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MAP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P
M )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9   AW@4
M'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG !#N=P 0
M[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK
M  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8[ ( %O<+
M !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "_G<
M /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT  !N
MO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&  W_
M#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(  /]U
M  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]  !AQP
M4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\   +_!
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MLAR42,$=DDC8'9!)[QN/2OX8CTO_%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4
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M)'96Y"1V5_<?=UC_&W=9_QEW6?\7=UG_%G=9_Q9W6?\6_TP  .E6  #97P
MRV4  ,%H  "Z:0  M&@  *UG#0"F:!P H&@M 9IG.@.5944&D&-."HQB5PV)
M85X0AE]E$X->;!: 77,8?EQ[&GM<@QUY6XT?=EJ8(71:I"-R6K(D<5K$)6]:
MX25P6_8@<5S_''%=_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@  QV@
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M'F%H_QQB:/\:8FC_&6)H_QEB:/\9[%<  -EB  #':P  O'(  +-W  "J>0
MH7D  )=W 0"0>!$ BW@A (9X+P&!=SL$?'5%!WAT30IT<E4.<7%<$6YP8Q1K
M;VH6:&YQ&69N>AQC;80>8&R/(5YLG"-<:ZHE6FN[)EELTR9:;.\C6VS_'UQM
M_QQ=;?\:76W_&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F?@  G7X
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M&$Q^_QA,?O\8U6<  ,-S  "V?   K(0  **)  "8BP  C8T  'R-  !UC@0
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MCPLRJI\,,:JP##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0
M *J.  ">E   E)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^MA$
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M !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#J
M=;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H% !#B"P 0
MXQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5  3F
MJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0  :;D
M %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )\PX
M!_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"  #RF
M\ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(  $[)
M  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0  _ @  /L-
M  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_@@  _Y@
M /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T  $#2   R
MV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P   /\$  #_
M"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P  _X   /^5
M  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0+0#_"C8
M_P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@ /\ I@#_
M *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\ _0#_ /T
M_P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_#C( _PQ
M /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"H@#_ J@
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M >$2_P'A$O\!_RD6 /\J$P#_*1( _R<3 /\H' #_)R< _R,S /\@/P#_'4P
M_QM8 ?P99 'X&6X!]AAX ?,8@0'Q&(D![QB0 >X8EP'L&)X!ZABD >D8K 'G
M&+0!YAB_ >08S0'@&>,!W!KQ =@:_@+4&_\"TAO_ M$;_P+0&_\"T!O_ M ;
M_P+0&_\"_RT2 /\N#P#_+@T _R\0 /\O%P#_+B$ _RPM /\I.0#Y)D8 ]"13
M >\B7@'K(FD!Z"%S >8A? 'C(80!X2&, > ADP'>(9H!W"&A =HAJ0'8(;$"
MU2&\ M,BR0+0(M\"S"/P \@C_0/&)/\#Q"3_ \,D_P/")/\#P23_ \$D_P/!
M)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\ YRQ, .(K
M6 '=*V,!V2IM =4J=@+2*G\"T"J& LXJC@/,*I4#RBJ< \DJHP3'*JP$Q2JV
M!,,JPP7"*M4%OBOK!;HK^0:X+/\&MBS_!;4L_P6T+/\%M"S_!;0L_P6T+/\%
M_S0, /\V!0#_.0, _SP( /\\#0#].Q, \3@= .@U*0#@-#< V3-& -$T4@'-
M,UT!R3-G L8S< /$,G@$P3* !+\RAP6^,H\&O#*6!KHQG@>X,:8'MS&P"+4R
MO BS,LP)L3+E":TS]0FK,_\)JC/_"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<'
M /\Z  #_/@  ^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30' /%@"
MO#MA [D[:@6V.G(&M#IZ![(Y@0BP.8@)KSF0"JTXF JK.*$+J3BJ#*@XM@VF
M.,4-I#C>#J$Y\0V?.O\,GCK_"YTZ_PJ<.O\)G#K_"9PZ_PF<.O\)_SL" /\^
M  #W1   YD<  -]( 0#:1@8 V4 + ,U"&0#%1"L OD0[ +E$2 &U0U,#L4)<
M!*Y"90:K06P'J4!T":9 >PJD/X,+HS^*#:$^DPZ?/IP/G3ZE$)L^L1&:/K\1
MF#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST  /]#  #I
M20  WDX  --/  #-3@, RDD( ,))% "[2B8 M4LV *]+0P*K2DX#ITE7!:1(
M8 >A1V<)GD9O"IQ&=@R:17T.F$6%#Y9$CA"41)<2DD.A$Y!#K!2/0[H5C4/-
M%8M$Z!6*1?H2B4;_$(E&_PZ(1O\-B$;_#8A&_PV(1O\-_T   /)'  #C3P
MU%,  ,M5  #$5   P% $ +E/$0"R4"( K%$R *=1/P*B4$H#GD]3!9M.7 B8
M36,*E4QJ#)-+<0V12GD/CDJ $8Q)B1**29(4B$B<%89(J!:%2+47@TC'&(%(
MY!B!2O<5@$K_$H!+_Q" 2_\/@$O_#H!+_PZ 2_\._T,  .Q+  #=4P  SE@
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M%VM8_Q1L6/\2;%C_$6Q8_Q%L6/\1\4L  -]6  #,7@  P&0  +=G  "N:
MIV8  )]B!@"88Q0 DF0D (UC,@&)8CT"A&%'!(%@3P=]7U8)>EY="W==9 UU
M7&L0<UQS$G!;>Q1N6X47;%J0&6I:G!MH6:H<9EJZ'65:T1UE6NX;95O^%V9;
M_Q5F7/\39US_$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K;   HFH
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M$UAG_Q-89_\3X5@  ,MC  "]:P  LG(  *EV  "@>   EG<  (AS  "!<PL
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M<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P( ;G\1 &N
M'@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/>W@13'N#
M%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X_Q%'>/\1
MS64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<- &.'&0!@
MB"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/1H.!$42#
MCQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q! @/\0QFL
M +=V  "L?P  HH4  )>)  ",BP  @8T  '..  !ECP  78\) %J0% !8D"$
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M!BNDO08JI-X&*J+U!RFA_P<IH/\(*9__""F?_P@IG_\(L8(  *6+  ":D0
MD)8  (.:  !VGP  :J(  %ZF  !2J0  1JL  #RM   UKPP ,[ 5 #*P(0 Q
ML"L +[ U "ZQ/@ ML4@ ++%1 "NQ6P IL6<!)[%T 2:Q@P$DL90"([&F B*R
MNP(ALML"(:_S R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP  AYP
M 'JB  !MIP  8*L  %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 AO2
M(;TJ ""],P ?OCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !; M@ 4
MP-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0  &^J
M  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!( $<P;
M !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (SL8
M",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S  !7
MN0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2  7:
M&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,  -_.
M  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*P@
M/<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-  #D$@
MY1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W  #O
MT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@  +\X
M "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N"P  \!
M /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^M@
M_LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU   (MH  !?>
M   0X@  ">8   #I    [    /    #V    ]@   /<   #X    ^@<  /L-
M  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP  _ZX
M /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_
M %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N /\
MM0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\ ^P#_
M /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_ %@
M_P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L0#]
M +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_ /,
M_P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_ E, _P!?
M /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@ K@#U +4
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M /\4.P#_$DD _!!5 /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID
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M ZXD_P.N)/\#_R\& /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S(
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MI@V)/K,-B#[$#H8_X Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP
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M%&Q-SA1L3>L3;$[]$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P
MO5P  +1>  "L7@  I%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\
M550%>E1;!G=48@AU4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691
MRQ5E4ND495+[$693_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\
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M$E9>_Q!77O\.5U[_#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@
MDVT  (5G  !^9PD >&<5 '1G(P!Q:"\ ;F<Y 6MG0@)H9DH#9692!6-E6 9@
M95\(7F1G"EQD;PQ:8WD.6&.$$%5BD1)38I\34F*N%5%BPA508N$546+V$E%B
M_Q!28O\.4F+_#5)B_PU28O\-V58  ,1@  "W:   K&X  *-Q  ":<P  CW$
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M#$%S_PQ!<_\,QF0  +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P
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M?P(GGI ")IZA B2>M0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($
M *"(  "5C@  BY(  '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4
M*:D/ "BI&  GJB( )JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =
MJXL &ZN= !JKL0 9J\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/
M  "/E   @YD  '6>  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4&
M !FW#P 8MQ< %[<A !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8,
M#[F7  ZYK  -N<0 #;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&
MFP  >:   &NF  !>JP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##
M!@ +Q@X "L45  G%'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+
M  #&H   Q;8  ,;2  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP
M;:D  &"O  !3M   1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !
MT H  - 0  #0%@  T1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6
MD@  UJ<  -:_  #6X   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(
M %2Y  !&O0  .<$  "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,
M -T*  #>#P  WQ0  .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0
MZ9@  .FM  #IQ0  Z>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"
M   YQ@  +,H  "#.   6T@  #]8   C;    WP   .,   #E    YP   .@!
M  #J!P  ZPT  .T1  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0
M /J;  #ZKP  ^L(  /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   K
MT   ']0  !3:   -WP  !>,   #F    Z0   .T   #O    \0   /,   #U
M    ]@(  /@)  #Z#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%
M  #_F@  _ZL  /^Y  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #
M_P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_
M *0 _P"J /\ L #_ +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L
M_P#Z /\ ^@#_ /H _P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z
M /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *
M_0"F /P K #[ +0 ^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P
M /\ \ #_ /  _P#P /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\
M0P#_ %  _P!< /\ 9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B
M /, J #Q +  \ "X .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\
MY0#_ .4 _P#E /\ _QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_
M $L _P!7 /X 8@#Z &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .<
MI #F *P Y "T .( OP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_
M -4"_P#5 O\ _QX0 /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4
M^ 91 /0$7 #N!&8 Z@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8
M!:@ U06Q -(%NP#0!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,
M_P#%#/\ _R$, /\@!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y*
M .4-5@#A#6  W0UI -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4
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MKP&G([P!IB3. :,DZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP
M /\M  #M,@  XC0  -HS  #3+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX
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M"($YTPA_.NX(?3K^!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P
MQ4H  +Q+  "U20  KT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+
M0%D"B4!@ X= 9P.%/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_
MS0IU/^H*=$#\"'1 _P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\
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M#&!._PI@3O\)8$[_"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70
MF%H  (U3  "&4@P @%,8 'Q3)0!Y5#$ =50\ '-31 %P4TP";5)3 FM260-I
M4F $9U%H!F51< =C47D(85&$"F!0D0Q>4)X-7%"M#EM1P Y:4=X/6E'U#%I2
M_PI;4O\)6U'_"%M1_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X
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M"4Q=_PA,7?\(SU0  +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9
M:60. &5D&0!B9"4 8&4P %YE.@!<94(!6F5* EAD40)69%@#5&1?!%)D9P50
M8W$'3F-["4QCB I*8Y<+2&.F#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B
M_PA'8O\(RE@  +IB  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+
M %]I%0!<:B$ 6FHM %AK-@!6:S\!56M' 5-J3@)1:E4#3VI=!$UJ905*:6X&
M2&EY!T9IA@E$:94*0VBE"T%IMPQ :<\,0&CN"T%H_PI!9_\)06?_"$)G_PA"
M9_\(Q5T  +9F  "J;0  H',  )9V  "+=P  @'8  '!R  !E<0  7' ' %AP
M$0!6<!T 5'$H %)Q,P!0<3P 3W)$ 4UQ2P%+<5,"27%: T=Q8@1%<&P%0W!W
M!D%PA <_<),(/6^C"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'
MOV(  +%K  "F<P  G7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.
M>!@ 3'@D $MY+@!)>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX
M@@4X>)$&-WBA!S5XLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@
M *UQ  "B>0  F'X  (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1,
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M 1V8K $<F,,!')?E 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP
MAX\  'J2  !ME0  89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >
MHQH ':0D !RD+0 ;I#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*E
MJ  1I;\ $*3B !&B^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4
M '&:  !DG@  6*$  $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1
M$+$8  ZQ(@ .L2L #;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $
ML+4 !+#0  2P[P %K_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B
M  !:IP  3JL  $&M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2
M  &]&0  OB(  +XK  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH
M +["  "]Y   O?8  +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/
ML   0K,  #6V   JN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)
M$@  RAD  ,LB  #+*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S
M  #/S@  S^L  ,[X  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0
M-;P  "F_   >P@  %<8   [)   (S    -    #3    U0   -8&  #8#
MV1$  -L6  #<'P  WB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #D
MN@  Y=0  .7J  #E\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8
M !S)   3S0  #-$   35    V@   -X   #A    X@   .0   #E P  YPD
M .D.  #K$@  [1H  .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0
M][P  /?.  #WWP  ]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5
M   *VP   -\   #B    Y0   .D   #L    [0   /    #Q    \P   /4$
M  #W"@  ^A   /P6  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@
M /^V  #_OP  _[\ _PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_
M %8 _P!C /\ ;0#_ '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\
MK #_ +0 _P"] /\ R0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_
M /H _P#Z /\ _Q 9 /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %(
M_P!> /\ :0#_ '( _P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y
M *\ ^ "X /8 PP#T -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X
M_P#N /\ _Q(4 /\/$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9
M /\ 9 #] &T ^P!V /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H
M[ "S .H O0#H ,L YP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@
M /\ _Q00 /\1#@#_#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4
M7@#R &@ \ !P .T > #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N
M -P N #: ,4 U@#9 -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\
M_Q<, /\4" #_#P4 _PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F
M &( XP!J .  <@#> 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L
MLP#) +\ Q@#0 ,4 Z ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL&
M /\7  #_%   _Q,% /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L
MT@1D ,\%; #,!7, R@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[
M![P N0C- +@*Y0"U"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;
M  #_&P  ^AH  /46!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y>
M ,$.9@"_#FT O0YT +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H
MK1'* *H2Y0"G%/< I17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P
M(P  YB0  . A  #<&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,8
M8 "P&&< KAAN *P9=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS%
M )X<WP":'?,!F![_ 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0
MVB\  ,\M  #*)P  QQ\( ,$<$P"Z'B( M!\Q *\@/0"K(4@ J")2 *8B6@"C
M(V( H2-I * C;P">(W< G"-^ )LCA@"9)(\!ER29 98DHP&4)+ !DB6_ 9$E
MU@&.)N\!C"?_ HLG_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@  S3@
M ,0W  "^,@  NBL" +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8*UP
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M!6X[_P1M._\$;3O_ VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20
MGT0  )@^ 0"1/!  C#T= (@^*@"$/S4 @3\_ 'X_2 !\/T\!>C]6 7@_70%V
M/F0"=#YK G(^<P-P/GP#;SZ'!&T^DP5K/J &:CZN!FD_P =G/]X'9S_U!F9
M_P5F0/\$9D#_!&8__P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P  F4H
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M!55,_P553/\%U4@  ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0
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M@@5$79 &0UZ@!T%>L0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8
M +1?  "H9@  GFH  )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL
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M R]RK ,N<L$#+G+C RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@
MDWH  (A\  !^?0  <GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X
M>BH -WLS #9[.P T>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[
MJ@(G>[\")GOA B9Z]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\
M (2"  !X@P  ;(0  %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0
M+(4M "N%-0 JA3X *85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>
MAKP!'H;> !Z$]0$>@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(
M  !QB@  98L  %B,  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E
M ""1+@ ?D38 'I%  !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D
M$Y'8 !./]  4CO\ %(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !I
MD0  79,  %"5  !%EP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=
M)  2G2T $9XW !&>00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,
M  F<[  *F_X "YK_  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0
M5)P  $B?   \H   ,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &
MJB0 !:HN  2J.  "JD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "H
MY   J/8  *?_  "G_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8
M #VH   QJ@  )JL  !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT
M +<E  "W+P  N#D  +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP
MMN\  +;\  "V_P  MO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q
M   FLP  '+8  !.X   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<
M  #%)   QBX  ,@Z  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0
M ,CT  #(_0  R/T A9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :
MO0  $<    O#   #QP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5
M&0  UR(  -HM  #=.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F
M  #?]   W_0 >:$  &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R
M"<P   #/    TP   -D   #<    W0   -\   #A    X@4  .0+  #F$
MZ!8  .H@  #M*P  \#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #S
MX0  \^$ ;:H  %ZQ  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H
M  #>    X@   .8   #I    Z@   .P   #N    \    /(   #T!@  ]@P
M /D2  #\'   _RD  /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0
M_\$ _P<9 /\!%P#_ !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\
M:@#_ ', _P![ /\ @P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X
M /\ Q #^ -4 _ #J /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\
M_PL5 /\%$P#_ !, _P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_
M &X _P!V /\ ?@#_ (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0
MO@#S ,P \0#C .\ \P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1
M /\)$ #_  \ _P 0 /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D
M^ !Q /8 >0#T '\ \P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E
M ,4 XP#: .$ [0#? /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,
M"P#_ PD _P , /\ $@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K
M .D <P#G 'H Y0"  ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X
MT #. ,X Y@#, /8 R@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_
M!P  _P4( /\ #@#_ !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D
M;0#5 ', T@!Z -  @ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #'
M +T WP"\ /$ NP#^ +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0
M_PP  /\'"0#X 1  Z  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#%
M &T PP!T ,$ >@"_ ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\
MV "N NT K /[ *L%_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$
M .8.  #E!@@ W0,2 -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V<
MM0=N +,'=0"Q"'L KPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A
M#>T GP[^ )T._P"<#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:
M  #0$P( S@P+ ,<+%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H
M *81;P"D$78 HA%] *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P
MDA;] ) 7_P"/%_\ CA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!
M(0  O1D% +D2$ "R%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D:
M:0"7&W  E1MW )0;?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z
M (0@_P&#(/\!@R#_ 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0
ML"4  *P=# "F'A@ H2 F )PA,@"9(CT E2)' ),C3P"1(U8 CR-= (TD9 "+
M)&L B21R (@D>@"&)(, A"6- (,EF &!):0!@":R 7XFQ0%])^(!>R?W 7DH
M_P%X*/\!>"C_ 7@H_P%X*/\![RL  -TS  #*.0  OCL  +0Z  "M-@  IB\
M *$H!P";)Q, EB@@ )$I+0".*C@ BRM" (@K2@"&*U( A"M8 ((L7P" +&8
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M E\Z_P)?.O\"W3L  ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D
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M@0-.2H\#3$N?!$M+L 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D
M +A1  "L5P  H5L  )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X
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M SQ8J@,[6;\#.EG@ SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P
MF6<  )!I  "%:0  >6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&
M73$ 15TY $-=00!"74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>
MJ0,U7KT#-%_= S1>]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP
M (QN  "!;@  =FP  &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT
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M !]T\0 ?<_\!'W+_ 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P
M9W\  %I_  !-?@  0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A
M?C8 (7X_ !]_2  >?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^
M[P 6?/\ %GO_ !9[_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<
M %2'  !(B   /(@  #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX
M%8HW !2*00 3BDP $HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -
MA_P #H?_  Z&_P .AO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0
M  !!D@  -)(  "J2   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O
M  J7.0 )ET0 ")=0  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0
M )/_  &2_P !DO\ F((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   X
MFP  +)P  "*=   9G@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C
M,0  I#P  *1(  "D5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[
M  "@_P  H/\ D8H  (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI
M(Z8  !FH   1J@  #*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*
ML3(  +(^  "R3   LEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O
M_P  K_\ C)   '^5  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+
M !"S   *M0   K@   "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<
M ,$R  #"0   PT\  ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@
MP?X @9<  '.=  !EHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^
M    P0   ,4   #'    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F
M  #6,@  V$$  -A3  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0
M=I\  &>F  !9K   2[(  #RW   NN@  (;T  !7    -Q   !<<   #*
MS@   -(   #5    U@   -D   #;    W0   -\'  #A#   XQ$  .89  #I
M)   [#(  .U#  #N5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@
M %NO  !,M@  /KP  "_    @Q   %,@   S,   "T    -0   #9    W@
M .(   #E    Y@   .@   #I    [    .X   #P @  \@D  /4/  #X%P
M_",  /\S  #_1@  _UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\
M% #_ !0 _P 7 /\ '0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W
M /\ ?@#_ (4 _P"+ /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X
M^P#F /D ]@#X /\ ]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_
M !  _P 1 /\ %P#_ "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\
M>0#] (  _ "& /H C #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#>
M .T \ #K /X Z@#_ .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L
M_P , /\ $P#_ !\ _P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q
M 'H [P"! .X AP#L (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T
MZ0#: /D V0#_ -< _P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P )
M /\ $ #_ !D ^P F /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0
MX ![ -X @0#< (< V@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #&
M /, Q0#_ ,, _P## /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\
M"P#S !( [@ ? .H +0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T
M ,H >P#( ($ Q@"' ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P
MLP#[ +, _P"R /\ L@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G
M  T X  8 -H )0#3 #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H
M= "X 'L M@"! +0 B "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W
M *0 _P"C /\ H@#_ *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8
MT  1 ,D '0#$ "H OP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I
M '4 J ![ *8 @P"D (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(
M_P"5"?\ E G_ )0)_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <*
M +T#% "W!"$ L@8N *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\
MFPMV )D,?@"7#(8 E@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"(
M$?\ AQ'_ (<1_P"'$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-
M#@"J#AD I0\G *$0,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P
M (P3> "+$X$ B12+ (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\
M?!G_ 'L9_P![&?\ [R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">
M%A, F1<A )09+0"1&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <
M<P!_'7P ?1V& 'P>D0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_
M '$A_P!Q(?\ Z"@  -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A
MC2 ; (DA)P"&(C( @R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T
M)7< <R6! '$FC0!O)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H
M_P%H*/\!X2X  ,LV  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6
M '\H(@!\*2T >2HW '<J/P!U*D< <RM. '$K5 !P*UL ;BMB &PK:@!K+'(
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M@@%8.(\!5CB> 54XKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P
M +Q$  "O20  I$P  )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2(
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M D5&J0)$1KT"0T;< D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5
MG%<  ))8  "(6   ?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.
M1C, 3$<Z $M'00!*1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*
MIP(_2KL"/DO8 CY*\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L
M )!=  "&7   >UD  &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S
M1TLX $9,/P!%3$8 1$Q. $--5@!"35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y
M3[D".4_4 CE/\@$Y3O\!.4[_ 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA
M  "#80  >%X  &E8  !?5@  5%(  $Q/"P!)3Q( 1U < $50)0!#4"T 0E U
M $%1/ ! 440 /U%, #Y25  \4ET .U)G #I2<P X4X(!-U.2 353I $T4[<!
M,U31 3-3\0$T4_\!-%+_ 312_P$T4O\!ME(  *E:  ">8   E&0  (MF  "
M90  =&,  &9>  !<7   45@  $=5!P!"51  0%48 #]6(0 ]5BH /%8R #M6
M.0 Z5T$ .5=) #A740 W6%H -5AE #18<0 R6( !,5B0 2]9H@$N6;4!+5G/
M 2U9[P$N6/\!+E?_ 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@
M<6@  &-E  !88@  35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S
M73X ,EU& #%>3@ P7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?
M[0$G7O\!)UW_ 2A=_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX
M &!K  !4:0  26<  #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D
M*V5" "IE2@ H950 )V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @
M9?X (&3_ "!C_P$A8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR
M  !/<0  1&\  #IN   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT]
M "%N1@ @;E  'FY; !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P
M&&S_ !AK_P 8:_\ I&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*
M>0  /W@  #5X   K=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X
M0  5>$H %'A6 !-X8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_
M !!U_P 0=/\ GW$  )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@
M.((  "Z"   D@@  '((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -
M@T0 #(-0  N#70 )@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9_
M_P &?_\ FGD  )!^  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P
M ":,   =C0  %8X   ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T
M )!)  "/5@  CV4  (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P
MB_\ E(   (N%  ""B0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7
M   5F   #YH   J;   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U
M  "=3@  G5P  )UN  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\
MCH@  (:,  !XD   :I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .
MI   "*8   "H    J00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L
M1   K%,  *QC  "L=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X
M 'N3  !MEP  7YP  %&@  !$I   -J8  "JH   >J0  %*L   VN   &L
M +(   "U    M0   +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.
MO4<  +U8  "]:P  O8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";
M  !BH   4Z4  $:J   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\
M  #"    P@   ,,   #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H
M -%+  #17@  TG,  -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6
MJ0  1Z\  #FS   JM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/
M    T    -(   #4    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\
M  #I3P  Z60  .I\  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP
M.[D  "N\   =P   $<0   G(    S    ,\   #3    V0   -T   #@
MX0   .,   #E    YP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]
M/@  _E,  /YJ  #_@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3
M /\ &0#_ "8 _P T /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($
M_P"' /\ C0#_ ), _P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W
M /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P . /\
M% #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0""
M /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P
MYP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_
M !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H
M@@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_
M -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z !8
M]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4
M (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^ +X
M_P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$ Z  <
M ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L
MOP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P _P"K
M /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5 ,\
M(@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![
M *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"< /\
MG #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[
M "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U )\
M? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\ C0'_
M (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N !X
MJ@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0
M!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,
M_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC
M )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"##GH
M@@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T
M$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1
M)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^
M '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\
MX"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^
M&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>
MA0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP
M ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B<
M<2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?
M)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY
M  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L
M &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L
M5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M
M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N
M,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7
M $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I1@
MGDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S+0!6
M,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5 $@W
MI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@  G$T
M ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S(
M3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"
M/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5   (]1
M  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV
M $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y H@ ]0+4!
M/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0  (U5  "#
M5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P 1$ S $-
M.@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X1;,!-T7+
M 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9  " 6
M=E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q #Y%.  ]
M13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$ ,DG) #%)
MZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70  <UH
M &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST
M-TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L
M3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\  &);
M  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!"
M #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P
M)U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A  !5
M7@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E7
M1P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_
M "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !190
M1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @
M7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>
M_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;   06L
M #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@
M%F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 1
M9?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,  #%R
M   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.
M  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\
MFV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\   A
M?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\
M50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<
M (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :AP
M$H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(3@
MB%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#
M  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP  #90
M  :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@  EE4
M )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*  !U
MC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*    "B
M    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL  *9;
M  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !JE0
M7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O
ML    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0  "W
M8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0  4*(
M $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\    O0
M +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+50
MS&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P
M   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+    RP   ,T
M  #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2   Y5P
M .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :
MO   #\    7$    QP   ,L   #/    U    -@   #<    W0   -\   #A
M    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC
M  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_ ",
M_P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_
M (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /(
M_P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X _P K
M /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T (D
M\@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .( _P#@
M /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E /T
M,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (, X@")
M .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#* /\
MR #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T + #J
M #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H
MB0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_
M +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5 #$
MT@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V
M (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0
M_P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H OP U
M +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E (0
MHP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5
M /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N *L
M. "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T E "&
M )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\
M] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X ,0":
M #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"  (0
MBP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,
M -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"- S,
MBP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V
M"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC
M  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU
M 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\
M:1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U
M+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4
M. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9
M %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0
MI#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E
M'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@
MI@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P
M )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8
M6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,
M)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))
M  ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y
M %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;,
M12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%
M0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM
M/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+(
M #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#2
M>$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DW
MZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3   =4@
M &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT
M/C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T
M._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT  &=(
M  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H
M,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,  !9
M20  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_
M "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !73@
M34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L
M14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'
M_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550  2U$
M $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F2TP
M)4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @
M2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5
M   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D 'E)3
M !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\
MHUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<   N
M6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !59
M6P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\
M )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I8P
M(&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA6  -
M868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8  ))M
M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D;   &VL
M !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$
M FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US  "$
M=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78   ]V
M @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P  '5L
M  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  " ?@
M=H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"   "
M@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E  "!
M>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A   ;H8
M &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */    D ,
M (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/<
MCX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0
M  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0   )T#
M  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@  GWL
M )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9   ]
MG   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@   *H   "K
M 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(
M  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   QI@
M(Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@   "Y
MN@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&
ME   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP  %K$
M  VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)    RP
M ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #AA0
MX9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P   &_
M    PP   ,<   #*    SP   -,   #6    UP   -H   #<    WP   .$
M  #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=   ^(\
M /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\ .0#_
M $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P
MEP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_
M -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\
M_P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T D0#L
M )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4
M_P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D \P!%
M .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8 )(
MU0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U
M /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^ -T
M2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P P "4
M +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\
M_P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8 00#"
M $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"- *L
MEP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\ _P
M /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $,
MK@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H D "8
M )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"
M  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P G@!$
M )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@") )4
MAP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*
M$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X
M10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"<
M '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0
MLQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^
M $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#
MI@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,
M *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\
M< E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?
M#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI
M  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!
M &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0
M5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",
M+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L6
M0@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO'
M $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'-
M?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1
M'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,B
MY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@  >34
M &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D
M2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]
M*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL  &PV
M  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$
M $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@
M-RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[  !?
M-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL
M2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_
M #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;.P
M4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T
M,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT
M_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80   3CP
M $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P
M+C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I
M./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(  $(]
M   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4
M "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C//\
MJ$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$   V
M0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ")
M70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T
M )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S1P
M*D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&6@ ;
M1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(  )=8
M  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O3@  )DL&
M "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 43&4
M$TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=  "+
M8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0! !I2
M"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V( #51R
M  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(:
M?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;!0 0
M6@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM  -;
M@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@  >W
M ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,90H
M!V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I  !D>P
M9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<  &UX
M  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &<0@  ' -
M  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0  ;HH
M &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^  !8
M?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04  'P+  !\
M#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0  'J:
M  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/A@
M0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&  ")#
MB0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P  (B4  "'
MJP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP  .)$
M "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7!0  EPL
M )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8HP
ME[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H  !^;
M   4G   #)X   .?    H0   *,   "E    I0   *4   "E    I@(  *<(
M  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@  JK,
M *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E   +
MIP   :D   "K    K@   +$   "R    L@   +,   "T    M0   +8   "X
M!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8  ,#!
M  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP    LP
M +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<   #)
MRP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP  #<
MR0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[    OP   ,,
M  #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>    X
M .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #TM@
M],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!, /\
M50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B
M /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$ /\
M_P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H 4 #W
M %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"< .,
MI@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\ _P
M /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F %(
MXP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P GP#)
M *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P   /\
M  #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P S !3
M ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U *,
MLP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\   #U
M    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !- +8
M5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P H "I
M )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E
MV0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!& *0 30"B
M %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B (T
ML "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1    Q0
M +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2 $P
MD0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\
M +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P  *X(
M  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8 @@!,
M (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N +0
M; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02  "<
M#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!& ',
M3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\ 8 #$
M %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3%P
MBQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#1@!F
M TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)
MX0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0  @QL
M 'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;#$<
M6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+
M$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20  '0>
M  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4( 4!%(
M $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#%O@
M0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F  !F
M(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<7
M3 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_
M #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A)P
M62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <2  ^
M'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A
M_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0  5"@
M $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X(DT
M-R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F_P P
M)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X  $@H
M 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH ,2=4
M # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K*O\
MK#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N   \
M*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL
M70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\ J3\
M )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X+P8
M,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P6P D
M,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,  )I)
M  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V-@( +C(,
M "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?-F4
M'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-  ".
M40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0  *CD) "4W
M#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR
M !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+50
M@E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^#0 =
M/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P !%!
M@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@  @%T
M '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%"0 71 \
M%404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'?P +
M1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(  '-C
M  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  13 P #TP1
M  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "3H\
M 4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I  !H
M:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.  =5
M$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P  58L  %6@
M  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C;@
M5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -  !?$0
M7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<  !=
ML@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !==   3W,
M $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J#P  :A0
M &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8  !GK@
M9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H  #MZ
M   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0  =A   '85
M  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !SJ@  <L0
M ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$   E
M@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT  (,0  "#
M%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T  '_C
M  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;C0
M$8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,  "2$
MDQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8  )#8  "/
M\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1F   "9D
M  ";    G    )X   "@    H    *    "@    H0   *$$  "B"0  HPX
M *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "CZP
MHOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP   *4   "G
M    J0   *P   "N    K@   *X   "O    L    +$   "R    LP8  +4-
M  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@  N?(
M9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$   "T
MN    +L   "\    O    +X   "_    P    ,(   #$    Q@   ,@#  #+
M"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.( 6YT
M $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"    QP
M ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\   #B
MY@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P # /\
M 0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D _P!@
M /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N +,
M[ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\   #_
M    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !; .X
M80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P V "[
M -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_
M_P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D 6P#6
M &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R +X
MQ0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^    ]0
M .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#  %L
MO@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J *D NP"H
M -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0   -@
M  #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0 J@!:
M *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6 ,<
MDP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP   ,8   "\
M  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3 )<
M60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P @@#<
M ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8   "N
MIP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (< 4@"&
M %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#, '$
M[0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A    FP #
M )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W %(
M=@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90## &0 Y !C
M /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,  (D
M!P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P :0!2
M &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8 /0
M6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)  !W
M 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!, %P
M4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/  307_
M $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N#0(
M9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0
M!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_ $,-
M_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F%   7P\%
M %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&#5$
M10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \
M$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618  %$1
M" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT /1)6
M #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T%O\
MKRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8! !&
M% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3 #47
M7@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\ K#(
M )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  ! &@H
M/!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M
M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38  )T\
M  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [( < -AX.
M #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G(F4
M)B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_  "/
M0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,, "XB
M$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R
M !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-1P
M@TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G#P G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL
M@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P  @DT
M 'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A+!(
M("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q?P 3
M,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$  '92
M  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A  &S(5
M !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /-I$
M#C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56  !J
M50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2 !0X
M&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT "3RB
M  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H6@
M7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0  X_%0 .
M/QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?  !!
MM   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8   75X
M %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '1QD
M!D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(L0
M1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660  $Q@
M  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8  % =
M  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/K@  3LD
M $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G   Z
M9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9  !9
M(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4  %;I
M  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S;0
M*&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05  !D'
M9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F  !?
M^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@  ('0
M !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P%P  <!X
M ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J^
M:?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P  %WX   ]^
M   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<  'X@
M  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0  =_\
M@'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*
MBP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$  (T7  ".
M(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\ >X4
M &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6    F
M )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0  "?%P
MH"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P  &&/
M  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C    I0   *@
M  "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R#P  LQ@
M +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67  !'
MFP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M    +8   "X
M    N    +D   "Z    O    +T   "_    P    ,,   #%!P  R0\  ,H:
M  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   ZI0
M+*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8   #(
MR    ,H   #+    S0   ,\   #2    U0   -D   #=    X04  .8/  #G
M'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_    _P &
M /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X &@
M]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4 V #D
M /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_    _P   /\
M"0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H
M ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#) .D
MR #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P   /@ !0#R
M  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B ,H
M9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T LP#W
M +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8   #?  L
MU@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4 80"S
M &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N )T
M_P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'  8 P  /
M +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@ %\
MG@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B (L ^@")
M /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $ K@ + *D
M$@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D C0!>
M (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X /\
M=P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  & )H #@"5
M !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8 'L
M7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T : #_
M &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T "@"( !
M@P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T 6 !K
M %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_ %L
M_P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![  T =P 2
M ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!? %D
M70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0
M /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P . &<
M% !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0 4@!<
M %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!% /\
MN!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800* %T $ !9
M !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7 $8!
M80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\ LB(
M *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/!1$
M3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)70 [
M"F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<  * L
M  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T 0PP2
M $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S#F8
M,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2
M-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q / #D0
M%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F, *A-Q
M "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/.0
MA3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3$0 Q
M%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO ",8
M@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0  @SX
M 'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J&!0
M*1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=?@ <
M'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(  '="
M  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1( (QT7
M "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6(H\
M%2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&  !L
M1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5 !PB
M&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT $2>B
M ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J20
M8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G&  6
M)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?  PL
MM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@  7DL
M %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2+1P
M$2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8QL0 &
M,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75   %),
M  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD #3,@
M  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP  -L@
M #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2  !'
M3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>  4[
M)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K   .\4  #OG
M   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"5
M-U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#(P
M0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F  !!
M^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@  ,E@
M "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+'P  2R@
M $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(^
M1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\  "%=
M   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P  5",  %0M
M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0^   3_\
MB&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF   1
M9   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH  !>
M,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\ A&X
M 'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O   ,;@
M!&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J+0
M:CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4  'IY
M  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@   'H
M  !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0  >#(
M '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6   !G
M@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@   (<   "(
M    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('   B"D  (@X
M  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<B
M38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4   "6
ME@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\  )HM  ":
M/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D   09,
M #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E    I
M *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA  "N,P
MKD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P  ":?
M   7H0  #:,   "E    IP   *H   "L    L    +(   "T    LP   +0
M  "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%)0  QCD
M ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH   -
MJP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP   ,4   #&
M    R    ,H   #-    SP   -(   #6    VP   . ,  #A&   XRL  .1!
M  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_ !(
M_P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /  ;P#O
M '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_ -D
M_P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_  \ _  8
M /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9 &X
MU@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,  _P"[
M /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P Z  3 .,
M'@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &< OP!M
M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I /\
MH0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0 ,D & #%
M "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F *D
M;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\ D@#_
M (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +, $P"O !P
MK  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8 9@"4
M &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X
M_P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ "> !< F@ ?
M )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P"" &4
M@ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '  _P!N
M /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !( B@ 9 (<
M(0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\ <0!G
M &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A /\
MS0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4 '@ &P!U
M ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@ &$
M:0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\ P0P
M +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H !T
M9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2
M &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(  *H6
M  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@ 6@ >
M %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!' &D
M1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>  "8
M'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9 $X
M'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R
M #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4)@
MB28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0 &@!"
M "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%
M?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+   ABT
M 'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL
M. <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+?  H
M#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(  'DQ
M  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8 +PP<
M "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @$(X
M'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V  !M
M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8 "<0
M'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL &!2@
M !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K.
M830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB> !(8
MLP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0  7SD
M %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=L0 -
M'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX  %,Z
M  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L %!TB
M !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )(L<
M"2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_  !)
M.P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@  \B
M)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0 !";E
M  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'00
M/SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH)0 *
M*2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC   K
M]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P  /D0
M #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #+RL
M C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P]0
M+_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30  .DD  "]%
M   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(   -BD  #8R
M   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U]0  -?\
MC5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+   @
M2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO   ^
M.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0  ._\ BE<
M ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;4
M$DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&-P
M1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T  ']B
M  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   55P  #E8
M  =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@  3S\
M $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI  !T
M;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08   "5\   !>
M    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0  63H  %E(
M  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S<P
M:',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H   !I
M:0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#  !D
M4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0  7WD
M %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V    =0
M '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([  !Q3
M<5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\  $>
M   Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#    @P   ((
M  ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P  @58
M (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)   N
MB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0   )$   "1
M    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.   E$P  )-B
M  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   AE
M%)4   J6    EP   )D   ";    G0   )\   "@    H    *    "@
MH0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4   *E6  "I
M;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0  "I\
M  "A    HP   *8   "H    K    *X   "O    KP   +    "P    L@
M +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)  # 8@
MP'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H   "M
M    L    +,   "V    NP   +T   #     OP   ,$   #"    Q    ,8
M  #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?4P  X&X
M -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9 /\ ) #_
M "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U .8
M? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_
M *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O "D
MZ@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P =0#*
M 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_ *(
M_P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7 ", T  N
M ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T '4
ML0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4 _P"1
M /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G +4
M, "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X G@!V
M )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"# /\
M^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A *( *0">
M #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O (D
M> "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\ Y@
M -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )  (P", "L
MB@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '< <0!U
M 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP   ,,
M  "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!] "0 >@ K
M '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F '0
M9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"  "I
M @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X :P E &D
M*P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X 5@![
M %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@#0
ME0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T )0!;
M "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@
MA !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0  CA,
M (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/ "4
M3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X ?@ \
M )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P  '\9
M  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "  1  F
M $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R (P
M,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA  !Q
M'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A #D
M)@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J (@ * "<
M "< L  F ,D )0#J "4!^P E ?\ HB,  )8H  "+*@  @2H  '<H  !M)0
M9"   %L;  !2%0  2Q   $,, @ ]!PD .0,. #8!$@ S 1< ,0$< # !(@ O
M B< +0(M "P#-  J SL *01# "@$30 F!5@ )05E ",&=  B!H8 ( :: !\'
MK@ >!\8 '0?G !T(^  ="?\ GR@  ),M  "(+P  ?B\  '0N  !J*P  828
M %@A  !/'   1Q<  #\2   X#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G"",
M)0@I "0),  C"3< (0I  " *2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6
M#,8 %0WF !4-^0 6#?\ G"T  ) Q  "&-   ?#0  '(S  !H,0  7RP  %4G
M  !,(P  1!T  #P8   T$P  +1 & "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE
M !T-+  ;#30 &@X] !D.1P 7#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8
M$!#H ! 0^P 1$/\ F3$  (XU  "$.   >CD  ' X  !G-@  73(  %,M  !*
M*   0B0  #D?   Q&@  *A4! ",1!P =$ T &P\0 !D/%0 8$!L %Q A !80
M*0 5$#$ %!$Z !,110 2$E$ $1)? ! 2;P .$X( #A.6  T3JP +$\( "Q3C
M  P4^@ -$_\ ES4  (PY  ""/   >#T  &\]  !E.@  6S<  %(R  !)+@
M0"H  #<E   O(0  *!P  " 8 P 9% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1
M%"X $!0X  \50@ .%D\ #19<  P7;  +%W\ "1B3  @8J  &&+\ !QC@  <8
M]0 )&/\ E3@  (H]  " 0   =T$  &U!  !D/P  6CP  % X  !',P  /C
M #8K   N)P  )R,  !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -&2P
M#!HU  L:0  *&TP "1M:  <<:0 %''P !!V1  (=I@ !';P  AS=  (<\@ #
M'/\ DSP  (A!  !_1   =44  &Q%  !C1   64$  $\]  !&.0  /C8  #4R
M   N+@  )2H  !TE   4(00 #QT+  T=$  ,'10 "QT:  H>(@ ('BH !Q\S
M  8@/@ $($H  R%7  $A9P  (7D  "&.   AI   (;H  "';   A\@  (/X
MD$   (9%  !]2   =$H  &M*  !B20  6$8  $Y"  !%/P  /3P  #4Y   K
M-   (B\  !DK   2* 0 #20*  DC#@ &(Q( !2,9  0D(  ")"@  24Q   E
M/   )4@  "95   F90  )G<  ":,   FH@  )KD  ";9   E\@  )?X CD4
M (1)  ![30  <T\  &I/  !@3@  5TL  $U(  !$10  /$(  #$]   G.0
M'C4  !4R   /+@, "BP*  4K#@ !*A$  "H6   J'@  *B8  "LO   K.0
M*T4  "Q3   L8@  +'4  "R*   KH   *[<  "O6   J\@  *O\ C$D  ().
M  !Z4@  <50  &A4  !?4P  5E$  $Q.  !#2P  -T<  "U#   C/P  &CP
M !(X   ,-@, !C,)   R#0  ,A   #$4   Q&P  ,2,  #$L   R-P  ,D,
M #)0   R8   ,G(  #*'   QG@  ,;4  ##4   P\@  +_\ B4\  (!4  !X
M5P  ;UD  &99  !>60  55<  $E3   ^3P  ,DP  "A(   >10  %4(   Y
M   (/0(  3P(   [#   .@\  #D2   Y&   .2   #DI   Y-   .4   #E.
M   Y70  .6\  #B%   XG   -[,  #?2   V\@  -?\ AU4  ']:  !V70
M;5\  &5?  !=7P  4EP  $18   X50  +5(  ")/   83   $$H   I(   #
M1@$  $4&  !$"@  0PT  $(0  !!%0  01T  $$F  !!,0  03T  $%*  !!
M6@  06P  $"!   _F0  /[$  #[0   ]\@  //\ A%P  'Q@  !S8P  ;&4
M &1F  !99   2V$  #Y>   R6P  )ED  !Q6   25   #%(   11    3P
M $X#  !-"   3 P  $L.  !+$@  2AD  $HB  !*+   2CD  $I'  !*5@
M26@  $E^  !(E@  1Z\  $;-  !%\0  1/\ @6,  'EG  !R:@  :VP  &!K
M  !2:0  1&8  #=D   J8@  'V   !5>   -70  !EL   !:    60   %@
M  !7!   5@@  %8,  !5$   5!0  %0=  !4)P  5#0  %1"  !34@  4V0
M %)Y  !2D@  4:L  %#*  !/[P  3O\ ?FH  '=N  !P<0  9G$  %AP  !*
M;P  /&T  "]L   B:@  %VD   YG   &9@   &4   !E    90   &,   !B
M    8@0  &$(  !A#0  8!   & 7  !@(0  7RX  %\\  !?30  7EX  %YT
M  !=C0  7*<  %O%  !:[0  6?\ >W(  '5V  !K=P  778  $]V  !!=0
M,W4  "9T   9<P  $'(   =Q    <0   '$   !Q    <0   &\   !O
M;@   &X"  !N"   ;0P  &T1  !M&@  ;28  &PU  !L1@  :U@  &MM  !J
MA@  ::$  &B^  !GZ   9OX >7H  '!\  !A?   4WT  $1]   V?@  *'X
M !M]   0?0  !WT   !]    ?0   'X   !_    ?@   'T   !]    ?
M 'P   !\    ? 8  'P,  !\$@  ?!T  'PL  !\/   ?$\  'ME  ![?@
M>IH  'FV  !XWP  =_H <X   &6!  !6@P  2(0  #F&   KAP  '8<  !&'
M   'B    (@   ")    B@   (P   "-    C0   (P   ",    C    (P
M  ",    C0   (T$  ".#   CA,  (\A  ".,@  CD8  (Y;  "-=   C9
M (RM  "+S@  BO, :(8  %J(  !+BP  /(T  "V/   >D   $9$   >2
MDP   )4   "7    F0   )L   "<    FP   )L   "<    G    )T   ">
M    G@   )\   "A P  H@P  *(6  "C)@  HSH  *-/  "C:   HH8  **B
M  "BP   H>@ 7(T  $V0   _DP  ,)8  "&9   2F@  !YL   "=    H
M *(   "D    J    *H   "K    J@   *L   "L    K0   *X   "O
ML0   +(   "T    MP$  +D-  "Y&@  NBT  +I#  "Z6P  NG<  +N4  "[
ML0  N=( 4)4  $&8   RG   (Z   !.B   (I    *<   "J    K    *\
M  "R    MP   +D   "[    N@   +P   "]    OP   ,    #"    Q
M ,8   #)    S0   -(!  #4#P  U1\  -<U  #830  V&D  ->&  #7HP
MUKT _P   /\   #_    _P   /\  P#_  T _P 5 /\ ( #\ "L ^  U /0
M/P#P $< [@!. .L 5 #I %H YP!? .4 9 #C &H X0!P -\ =@#= 'X VP"'
M -@ D0#3 )T SP"K ,T O0#+ .  R0#[ ,< _P"] /\ L0#_ *D _P"C /\
M_P   /\   #_    _P   /P   #V  L \0 1 .T &P#I "4 Y  P -\ .0#:
M $$ U0!( -$ 3@#/ %0 S0!9 ,L 7@#) &, QP!I ,4 ;P## '< P !_ +X
MB@"[ )4 N "C +8 M "T ,T L@#R +  _P"L /\ HP#_ )P _P"7 /\ _P
M /\   #Z    \0   .@   #@  8 V0 . -( %@#. !\ R  I ,0 ,@#  #H
MO0!! +H 2 "X $T M@!3 +0 6 "R %T L !B *X :0"L &\ J@!X *@ @@"F
M (X I "; *$ JP"? ,  G0#F )L _P": /\ E #_ (X _P"* /\ _P   /8
M  #H    W    ,X   #&  $ OP + +H $0"V !H L@ B *X *P"J #0 J  [
M *4 00"C $< H0!, )\ 40"> %8 G !< )H 8@"9 &@ EP!P )4 >@"2 (8
MD "3 (T H@"+ +4 B0#3 (< ]P"& /\ A #_ '\ _P!\ /\ \@   .,   #2
M    Q0   +H   "Q    JP ' *4 #@"A !0 G@ < )H )0"7 "T E  T )(
M.@"0 $  C@!% (T 2@"+ %  B0!5 (@ 6P"& &$ A !I (( <@!_ 'T ?0"+
M 'L F@!X *L =@#$ '0 ZP!S /\ <P#_ '  _P!N /\ WP   ,P   "_
MM    *L   "A    F@ " )0 "P"0 !  C  7 (@ '@"% "8 @P M ($ ,P!_
M #D ?0 _ 'L 1 !Y $D > !. '8 5 !T %H <P!B '  :P!N '4 ; "# &H
MD@!H *, 9@"X &0 W@!C /L 8@#_ &( _P!@ /\ S    +P   "O    I0
M )T   "4    C    (8 !P"!  T ?  2 '@ &0!U !\ <P F '$ +0!O #(
M;0 X &L /0!J $( : !( &< 3@!E %0 8P!; &$ 9 !? &X 70![ %L B@!9
M )L 5P"O %8 RP!5 /( 5 #_ %0 _P!4 /\ O@   +    "D    F0   )
M  "(    @0   'D  @!S  H ;P / &L % !G !H 90 @ &, )@!A "P 7P R
M %X -P!< #P 6P!" %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T $X @P!, )4
M2@"H $D P !( .@ 1P#_ $< _P!' /\ M D  *8+  ";#   D H  (8%  !^
M    =@   &\   !H  4 8P , %\ $ !; !4 6  : %8 (0!4 "8 4P L %$
M,0!0 #8 3@ \ $T 0@!+ $@ 20!0 $@ 6 !& &( 1 !N $( ?0!  (X /P"B
M #T N  ] -T / #X #P _P \ /\ K!   )\2  "4$@  B1$  '\/  !V#
M;@4  &8   !@  $ 60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$ 2  F $8 *P!%
M #$ 0P V $( / !  $, /@!+ #T 4P [ %T .0!I #< >  V (D - "< #,
ML0 R ,X ,@#Q #$ _P Q /\ IA8  )H9  ".&@  A!H  'H6  !P$@  : X
M %\*  !8 P  40 $ $P "@!(  X 1  2 $$ %@ _ !L /0 A #P )@ Z "P
M.0 Q #< -P V #X - !& #, 3P Q %D +P!E "X <P L (4 *P"8 "H K0 I
M ,8 * #J "@ _@ H /\ H1P  )4@  "*(0  ?R$  '4?  !L&@  8Q8  %H1
M  !2#0  2P<  $0 !@!   L /  / #@ $@ V !< -  < #, (0 Q "< ,  L
M "X ,P M #H *P!" "H 2P H %4 )@!A "4 <  D ($ (@"5 "$ J0 @ ,$
M( #D !\ ^0 ? /\ G2(  )$F  "&*   ?"<  '(E  !I(@  7QT  %<8  !.
M$P  1@X  #\+   X!0< -  , #$ $  N !, +  8 "H '0 I "( )P H "8
M+@ D #8 (P ^ "( 1P @ %( 'P!> !T ;0 < 'X &@"2 !D IP 8 +T %P#?
M !<!]0 7 O\ FB<  (XK  "$+0  >2T  ' K  !F*   720  %0?  !+&@
M0Q0  #L0   T#0( +0D) "D%#0 F Q  ) $3 "("&0 A AX ( (D !X#*@ =
M S( &P0Z !H%1  9!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1![L $ ?; ! (
M\@ 0"?\ ERL  (PO  "!,0  =S(  &XQ  !D+@  6RH  %$E  !)(   0!L
M #@6   Q$@  *0X$ ",,"0 ?"0T '0<0 !L'%0 9"!H & @@ !<))P 6"2X
M%0HW !,*00 2"TT $0M: ! +:0 .#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,
M#?\ E2\  (HS  !_-@  =C8  &PU  !C,P  62\  % K  !')@  /B$  #8=
M   N&   )Q,  " 0!0 9#@H %0P. !0,$0 3#!8 $@P< !$-(P 0#2L #PTT
M  X./P -#DH # ]8  L/9P *$'D "!"-  <0H@ &$+@ !1#4  40[P &$/\
MDC,  (@W  !^.@  =#L  &LZ  !A.   6#4  $XP  !%+   /2<  #4C   M
M'P  )AH  !X6 0 7$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1
M/  ($D@ !Q)5  8390 $$W8  Q.+  $4H   $[8  !/1   3[@  $_L D#8
M (8[  !\/@  <S\  &H_  !@/0  5SD  $TV  !$,0  /"X  #0J   L)@
M)2(  !X>   6&@( $!4)  P3#@ *$Q( "107  @4'P '%28 !A4O  06.@ #
M%D8  1=3   78@  &'0  !B)   8GP  &+4  !?0   7[0  %_L CCH  (0_
M  ![0@  <D,  &A#  !?0@  5C\  $P[  !#-P  .S0  #,P   L+   )"D
M !LD   3'P( #1L)  D9#0 &&1$ !!D6  (9'0 !&B0  !HM   ;.   &T0
M !Q1   <8   '7(  !V'   <G0  '+,  !S.   ;[0  &_P C#X  ()#  !Y
M1@  <$@  &A(  !>1@  540  $M   !#/0  .SH  #,W   J,@  ("T  !<I
M   0)0( "R()  4@#0 !'Q   !\4   ?&P  ("(  " K   A-@  (4$  "%/
M   A7@  (G   "*%   AFP  (;(  "'-   @[0  '_P BD,  (!(  !X2P
M;TP  &9-  !=2P  5$D  $I&  !"0P  .D   "\[   E-P  '#,  !,O   -
M+ ( !RD(  $G#   )@X  "42   F&0  )B$  "8I   F,P  )S\  "=-   G
M7   )VT  ">"   GF0  )K   "7,   E[@  )/T B$@  '],  !V4   ;E$
M &52  !<40  4T\  $I,  !!20  -40  "M    A/   %SD  ! V   *,@$
M S '   O"P  +@X  "T1   M%@  +1X  "TG   M,0  +3T  "U*   M60
M+6L  "V    LEP  +*\  "O+   J[@  *OX A4T  'U2  !U50  ;%<  &-7
M  !;5@  4U4  $=1   [30  ,$D  "5&   <0P  $S\   T]   &.@   #@%
M   W"0  -@T  #4/   T%   -!L  #0D   T+@  -#H  #1'   T5P  -&@
M #1]   SE0  ,JT  #'*   Q[@  ,/\ @U,  'M8  !S6P  :ET  &)=  !;
M70  3UH  $)6   V4@  *D\  "!,   620  #D<   A$    0@   $$#   _
M!P  /@L  #T.   ]$0  /!@  #PA   \*P  /#<  #Q$   \4P  /&4  #MZ
M   ZD@  .JL  #G(   X[0  -_\ @5H  'E>  !Q80  :6,  &)D  !78@
M25X  #Q;   O6   )%4  !E3   040  "D\   %-    3    $H   !)!
M2 @  $<,  !&#P  1A0  $4<  !%)P  13,  $5   !%4   1&$  $1V  !#
MCP  0J@  $'&  ! [   /_\ ?F$  '9E  !O:   :&H  %UI  !/9@  0F0
M #1A   H7P  '5T  !);   +60   E@   !6    5@   %0   !3    4@0
M %$)  !0#0  4!   $\8  !/(@  3RX  $\\  !/2P  3ET  $YR  !-BP
M3*4  $O"  !)Z@  2/\ >VD  '1L  !N;P  9&\  %5M  !';   .6H  "QI
M   @9P  %&4   UD   #8@   &(   !A    8    %\   !>    70   %P$
M  !<"0  6PT  %L2  !;'   6B@  %HV  !:1@  65@  %EM  !8A0  5Z
M %:]  !5Z   4_X >7   '-T  !I=0  6W0  $QS   ^<P  ,'(  "-Q   6
M;P  #6X   1M    ;0   &T   !M    ;    &L   !J    :0   &D   !I
M P  : D  &@.  !H%0  9R$  &<O  !G/P  9E(  &9F  !E?P  9)H  &.W
M  !BX0  8?P =W@  &UZ  !?>@  4'H  $)Z   S>P  )7L  !AZ   .>0
M!'D   !Y    >0   'H   !Z    >@   '@   !X    =P   '<   !W
M=P$  '<(  !W#@  =Q@  '<F  !V-@  =DD  '5?  !U=P  =),  '.O  !R
MTP  <?< <7X  &-_  !4@   18(  #:#   HA   &H0   Z#   $A    (0
M  "%    A@   (@   ")    B    (<   "'    AP   (<   "'    B
M (@   "(!P  B1   (D<  ")+   B#\  (A5  "(;0  AXD  (:G  "%QP
MA.\ 9H0  %>&  !(B   .8H  "J,   ;C0  #XT   2.    D    )$   "3
M    E0   )<   "8    E@   )<   "7    EP   )@   "8    F0   )H
M  ";    G0<  )T1  "=(0  G3,  )U)  "<8@  G'\  )R<  "<N0  F^(
M6HL  $N.   \D0  +9,  !Z5   0E@  !)@   ":    G    )X   "A
MI    *8   "G    I@   *<   "G    J    *D   "J    K    *T   "O
M    L0   +,)  "S%0  M"<  +0]  "U50  M7   +2.  "TK   M,P 39(
M #^6   OF@  ()T  !&?   %H0   *,   "F    J0   *P   "O    LP
M +4   "W    M@   +<   "X    N@   +L   "]    OP   ,$   #$
MQP   ,L   #-#   SAH  ,\O  #/2   T&(  -"   #0G0  T+@
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MY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P$A   !
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M________[%$             5][_________________________N!4
M        2-;_________________________=!0             .,______
M___________________YHEH3            (\7_____________________
M____WYM<+           #;K__________________________^^Q?54Y(A$'
M 0(1(K+______________________________]^_I9F8FJ"LO=K_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^.^G8!\
M^_________________________________*WA%<P#@ =K/______________
M________________THI,%0      <O/____________________________6
M?S8         2\G___________________________J1/@          +ZO_
M_________________________\!:            &I7_________________
M_________XTD            "(3_________________________YUX
M         '?_________________________M"4              &K_____
M____________________?0               %OT____________________
M___]*P               $SK______________________^E
M     #SA______________________\P#                "W9________
M_____________YF*82<              "?7_______________________M
MOHE5)P           "7<__________________________[*G79=2CPR+2PP
M.4?>_______________________________]YMW6TM#3V>3_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________[]2[UO______________________________
M___GN(]J2R\5;_______________________________Y*%G- <     /,G_
M___________________________6@CL         $I?_________________
M_________^V%,0           &___________________________Z9"
M         %#A________________________[&D              #?)____
M____________________LR\              "*V____________________
M____>0               !"G_______________________R-
M      "9______________________^I                  ",________
M______________]&                  !______________________]\
M                  !T_____________________Y<
M  !J_____________________\X                   !C____________
M__________\I(@$               !A______________________^YHX!7
M-Q<           !H___________________________ZTZZ4AGQU<7!R=X&4
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________]NZG8)I:=/_________________
M_____________\B393T9    '9[____________________________;CDP3
M         &[__________________________]M\+            $77____
M_____________________XLJ             "*T____________________
M____PD0               .7________________________?0$
M      !________________________G-@                !J________
M______________^=                  !8______________________]&
M                  !'^/___________________^D
M   UZ?___________________Y8                    EV___________
M_________[P                    8SO___________________^L
M               /PO____________________\                    *
MN?____________________\G                   *M?______________
M______]P                   -N?_____________________@G(QP54(S
M)AL4#PT.$AHFO_____________________________GDV-+.S,O,S];@_/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^O3O./________________________________2J85E2"P2 87_____
M_______________________QJW$\#P       $_@____________________
M_____]5_-0           !^R________________________XW4=
M      ")________________________D",               !G________
M_______________50P                !(]O____________________^*
M                   NW?____________________\X
M   7R/___________________[X                    $MO__________
M_________YP                     I?___________________[H
M                D____________________]P
M@O____________________\                     =/______________
M______\3                    :/____________________]"
M            8/____________________]Z                    7?__
M___________________1                    8?__________________
M____)                   9O______________________R:R9B7UV<6QI
M9V9G:W!ZC/__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^+%JI%Y87?_____________________________W:9W4"P,
M     #'$_________________________^"23A,           "/________
M________________TG =              !@_______________________N
M;P\                WXO____________________^6'
M   4P/____________________]                     H___________
M_________ZX                     B?___________________YX
M                <O___________________[P
M7____________________]H                     3?______________
M______H                     ._____________________\.
M            *OG___________________\S                    &^G_
M__________________]>                    #]O_________________
M__^/                    !M#____________________0
M         ,K_____________________*P                   ,C_____
M________________@                    ,O_____________________
M]Q8!!04# 0       08-&,O_______________________SKX=C/S,W/T-+4
MU]SBZO______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________QVL;_________
M______________________'&HX1H33(8 !6K________________________
M__^Y?$88          !Q________________________UWPO
M   [X______________________?9 D                ,M?__________
M__________]T P                  C?___________________\45
M                :O___________________YD
M2____________________[8                     ,/W_____________
M_____]<                     &>?___________________8
M            !=/___________________\.                     ,'_
M__________________\O                     *__________________
M__]2                     )[___________________]Y
M         ([___________________^E                     (#_____
M_______________8                     '3_____________________
M-@                   &W_____________________?
M     &G_____________________UPT                  &C_________
M_____________W                   &'_______________________]0
M/$9.5%E=861H;'!V?HG_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^_5NZ.+
M<UJ5___________________________XOXYD02$%      !2_/__________
M____________]YU6&              7P?_____________________E;!8
M                C?____________________]C
M7O___________________YT                     -?S_____________
M_____Z$                     $=G__________________\H
M             +O__________________^X                      *'_
M__________________\,                     (K_________________
M__\M                     ';___________________]-
M         &3___________________]O                     %+_____
M______________^4                     $#___________________^\
M                     ##____________________J#@
M     "+_____________________1                    !7_________
M____________@0                    OU____________________R L
M                  +L_____________________UX
M  #E_____________________\D<                  #:____________
M__________^= 0             '#A?%________________________U;F\
MP<?.U=OAYNWT^_______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________^-_/____________________________
M_^S&I8AM5#LA!P RWO_______________________]>262D
MH/______________________B38                 9_______________
M______]F                    ,O;__________________Y4
M             \C__________________Z<                      *#_
M_________________]<                      'S_________________
M__\                      %[___________________\E
M         $/___________________](                     "S_____
M______________]J                     !C___________________^+
M                      7S__________________^O
M      #A___________________5                      #/________
M____________)                     "^____________________5
M                  "N____________________BP
M  "?____________________RPX                   "2____________
M_________U<                   "&_____________________ZH*
M              !Y______________________]M                  !F
M_______________________W50                !%________________
M_________VHC*S4_2E5@:G5^AY&<________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________HS[:=@VE.N?______________
M___________LLH-<.AT"        >_______________________Q6TI
M            0/____________________^#&P                  !\O_
M_________________Y(                      )C_________________
M_Z0                      &K__________________]T
M         $'___________________\.                     !W_____
M______________\Y                      #H__________________]@
M                      #.__________________^%
M      "W__________________^H                      "C________
M___________+                      "0___________________O%@
M                  !]____________________/@
M  !L____________________:0                    !:____________
M________F0                    !)____________________TA8
M               Y_____________________U@                    I
M_____________________Z(                    9________________
M______56                   $______________________^[+P
M            ^/______________________JRD                 S___
M_____________________\E'      <3("X^4FB$[?__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________35R?____________________________K2L))W74(H#   2O__
M_____________________\5]11<             $=C_________________
M___$4                    )___________________Z(,
M         &C__________________Y0                      #;_____
M_____________]H                       ?L__________________\5
M                      #$__________________](
M      "B__________________]U                      "#________
M__________^=                      !I___________________#
M                  !2___________________G#P
M   ^____________________,P                     K____________
M________6                      8____________________@0
M               %____________________K
M____________________WB(                     \O______________
M_____UP                     W____________________Y\
M            S/___________________^A*                    M___
M__________________^@%@                  G/__________________
M____>@(                 =________________________WH+
M       %3/________________________^B5VAT@(V<J[S0Y___________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________MX___________________________TJ-Z6#HI
M(QP6#@8  )______________________K%(.                 &G_____
M_____________^1#                     #3__________________WD
M                      #C_________________\T
M      "R__________________\3                      "%________
M__________]/                      !=__________________^#
M                   Z__________________^R
M   <___________________; P                     "____________
M________*@                      ^___________________3P
M                Y___________________=
MU/__________________FP                      P/______________
M____Q <                     K?__________________\#,
M            FO___________________V<                     AO__
M_________________Z,                     <O__________________
M_^-$                    7/____________________^1!@
M        0?_____________________K7P                  '?______
M________________RDL                  /______________________
M_\M7   ,&"0Q/TY@=(NGQ___________________________U^?R________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9$0D"
M      #;_________________W8                       "G________
M_________[H                       !U__________________\'
M                  !&__________________].
M   :__________________^,                        _?__________
M_______!                        V__________________Q&0
M                OO__________________1
MI/__________________:P                      C?______________
M____D0                      >?__________________MP
M            9O__________________WB$                     4___
M_________________TH                     /___________________
M_W<                     *____________________ZP*
M        %O___________________^=%                     /______
M______________^*                     /_____________________6
M30                   /W_____________________IRX
M     -7______________________Y@J           &&"U%8.#_________
M______________^H8W2!CYRKN\WB^O______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________Y\NW
MJ9V5CHF$@'QX='!L:&60_________________[QJ2"T9"@
M   Q__________________\                        #____________
M______]"                        W/________________^.
M                LO_________________.
MC?__________________*0                      :_______________
M____6@                      3O__________________A@
M            -/__________________K@                      'O__
M________________U!<                     "O__________________
M^CT                      /___________________V4
M         /___________________XX                      /______
M_____________[P9                     .____________________%.
M                     -C___________________^+
M     +_____________________,0P                   *'_________
M____________D1D                  'K_____________________\G0*
M                $5_______________________^AT$Q\L.$538G*%F[32
M]?__________________________U^CT____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________[]_/Q[NSKZ^SQ___________________9LIF'>6UD
M75912T9!/#@R+2@CQ/________________]+)0L
MDO________________^(                        9O______________
M___7                        /?__________________,P
M            &/__________________;                        /__
M________________G0                       /__________________
MR0P                      /;_________________\34
M         -___________________UL                      ,O_____
M_____________X(                      +?__________________ZD&
M                     */__________________],O
M     (W___________________]>                     '?_________
M__________^3!P                   %[____________________-0P
M                 $#_____________________AQ
M !S_____________________V%X                   #_____________
M_________[].       .'"P^4FJ&I<C________________________"?(R:
MI[;%UNC]____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______NX=?/R<.^NK:QK:FGIJ:GKO________________^^AFU;3$ W+R@B
M'!80"P0     %/_________________7!0                       /__
M________________-                        /;_________________
M=@                       -+_________________L
M         ++_________________X20                      );_____
M_____________U$                      'S__________________WD
M                     &;__________________Z
M     %'__________________\<C                     #S_________
M_________^Y+                     "?___________________]T
M                 !#___________________^C%@
M  #____________________83                     #_____________
M________B \                   #_____________________RU,
M              #______________________Z4X           )'31.:XS_
M______________________^9.4-17VY]CJ"UR^7_____________________
M________Z_G_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MZ\RYK*&9D8N&@7QX='!K:&9F:/'_________________844R(Q@.!@
M         )[_________________?@                       '7_____
M____________PP                       %+_________________^S<
M                     #+__________________VH
M     !;__________________Y8                       #_________
M_________[\;                      #__________________^9"
M                  #___________________]I
M  #___________________^0 @                    #_____________
M______^Y+                     #T___________________H7
M              #9____________________D1@                   "\
M____________________RE,                   "=________________
M_____Y@N             ! I1F;$_____________________^Y_'0P:*#=&
M5VE^E:_,[O_________________________GH*JYR-CI_/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________WU\.OFXM_;V-32T=#2U^#_________________SIZ*
M?'%I85M644Q(0SXZ-C(O+C'_________________TB41 P
M      #__________________T(                       #_________
M_________WT                       #__________________[ +
M                  #V_________________]TY
M  #<__________________]B                      #%____________
M______^)                      "O__________________^O(@
M              "9___________________62                     ""
M____________________<@                    !I________________
M____H2@                   !.____________________TUP
M           S_____________________Y8N               5,E)W____
M_________________^!R$P   0\?+T)8<(NHR.S_____________________
M___*;VY^CIZPP]CO____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________G@TLC NK6PK*BEHI^=FYN<H*?__________________X)D5DM#
M/#8P*R<B'1@3#@D$  #4_________________Y(
M  "M_________________\P>                      "+____________
M______M2                      !M__________________^
M              !1__________________^I&P                     Z
M___________________00@                     C________________
M___U:                      ,____________________CQ0
M            ____________________N#X                     ____
M________________Y6T#                    ____________________
M_Y\W               0+U!T_____________________]UR%      &%RI!
M6G64MMK_______________________^\6$149'6&FJ_(X_______________
M________________TLWA\?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________/OZ^_W_________________
M_____^ZYJ)V6CXJ&@G][>'9T<G-U>'^0_________________^M/.C H(1L5
M$ L' @         C__________________]I
M__________________^;"@                      ________________
M___(.0                      ___________________P8P
M            ____________________B@X                     ____
M________________L#0                     ____________________
MU5L                     _____________________X4:
M       #[/___________________[%)               8.5V!________
M_____________^5['@      #"$X4F^/L]G_______________________^[
M6"DY25IL@)>PS>W_____________________________LYZTQ=?K________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________^N_GX=S9UM32T-#0T=/9X.OW________________
M__^XBGYW<6QH9&%>6UE85U=97F5Q__________________^_,1\6$ H%
M            ___________________M5@                      Z/__
M________________@@0                     S/__________________
MJR\                     L___________________TE<
M        F___________________]WP0                    A?______
M_____________Z(W                  4KE/___________________\MA
M @            PL4':>T?____________________6-,       #2,[5W:9
MON7________________________#8Q@J.TQ?=(VGQN?_________________
M____________J'^6J+O0Y_____________________________________W_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________W<[%O[RYMK2SL;*RM;G R=7C____________________
MEVQD7EE544],2DA'1DA+4%EFH?__________________IR8.!P(
M        5O__________________SE                      .O______
M____________]'D+                    (?___________________Y\R
M                    #O___________________\18
M"#%:A/___________________^E_'P          !B=+<9K"Z?__________
M__________^G20     "%R]*:(JNU?S________________________3=1XF
M.$I>=8^KR^______________________________KG*%F*S"V_;_________
M_________________________]_O________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________[^RJJ:CH:"?GZ&CIJRTP,W=[/___________________XI:
M4T]+2$9$0T)!0D-'3EEI??___________________YXN!@
M     /___________________\-6                   50?__________
M_________^=[&@             )-&"+M/____________________^?/P
M       $)4IQF<+K_______________________&9@\    3*D1B@Z?-]?__
M_______________________KCC4K/E%H@9V\WO______________________
M________OG9_E*G!W/G__________________________________]+8\___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________]O+P[^_O\?/X_?__________________
M__________BPGYJ7EI:6F)N?I*RVPM'A[O____________________Z.4$I'
M141$1$5&1TM16FB#J?____________________^F00$           <V8X^Z
MX?_____________________&90H       0G3'.<Q.S_________________
M_______EB"\  !,J1&*"ILST____________________________JU V2F%[
MEK36^O______________________________TH=\F+'+Z?______________
M_____________________]3.[?__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________[>7CX^3FZ.WQ^?______________________
M_______]L922DI69G:.ILKS0[?__________________________G5-'24U1
M5F!SBJ_6_/__________________________LE8 &C50;8NNTO?_________
M____________________S6\^7WN9M]?Y____________________________
M____[I^#IL+A_____________________________________^/.Z_______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________P
M
M
M                                    ________________________
M____________________________________________________________
M____________________________________________________________
M__________________________\     _^% MVAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#
M96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B
M93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-RXR+6,P,# @
M-SDN,6(V-6$W.2P@,C R,B\P-B\Q,RTQ-SHT-CHQ-" @(" @(" @(CX*(" @
M/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R
M+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS
M=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H
M;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N
M8V]M+V5X:68O,2XP+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S
M;V9TPJX@5V]R9" R,#$Y/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^36EC<F]S;V9TPJX@5V]R9" R,#$Y/"]X;7 Z0W)E871O
M<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(R+3$Q+3(V5# R
M.C R.C(T*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,C(M,3$M,C94,#0Z,3DZ-3(K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(R+3$Q+3(V
M5# T.C$Y.C4R*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \
M>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z.#(Q-&$X
M8S,M8C5E,"UE8C1C+6)F,&8M-#<P-S8V8S Q-&5F/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C,U.#9B
M,SAD+61D8F4M9F8T8BTX.3$V+64W.3EE.61A9C$Y,CPO>&UP34TZ26YS=&%N
M8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$-#!&-C4T1D$U-CPO>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S0S8F)F-#<M8C=B
M8BUF-#0Y+6%A.6(M-C8W,F5D,#$U-C%A/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3$Q+3(V5# T.C$V
M.C,W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$Y.3$S-# T+3)C93$M8C4T9BUA-S4W
M+30P8V8Q,C<W,S0P83PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,BTQ,2TR-E0P-#HQ.3HU,BLP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,U
M.#9B,SAD+61D8F4M9F8T8BTX.3$V+64W.3EE.61A9C$Y,CPO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ
M,2TR-E0P-#HQ.3HU,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S
M+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,3DY,3,T,#0M,F-E,2UB-31F
M+6$W-3<M-#!C9C$R-S<S-#!A/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&
M1BU!,$$P+39$-#!&-C4T1D$U-CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$
M+3A%,SDM-#%&1BU!,$$P+39$-#!&-C4T1D$U-CPO<W12968Z;W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^4W1E<&AE;B!-83PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @
M(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T
M960@*%-73U I('8R/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @
M/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @
M(" @/'1I9F8Z6%)E<V]L=71I;VX^,3 X-S@Y,"\Q,# P,#PO=&EF9CI84F5S
M;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^,3 X-S@Y,"\Q
M,# P,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU
M=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(" @(" @(" @/&5X
M:68Z0V]L;W)3<&%C93XV-34S-3PO97AI9CI#;VQO<E-P86-E/@H@(" @(" @
M(" \97AI9CI0:7AE;%A$:6UE;G-I;VX^-C@Y/"]E>&EF.E!I>&5L6$1I;65N
M<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/C4W,3PO97AI
M9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!^ )@
M P$1  (1 0,1 ?_$ !X  0 " @,! 0$            %" 8' 00) @,*_\0
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M?LC%BQFI,B*TW*BN.['+=1JFOZV-[],OLZ8.-?4&L3-7%ZF_;N6V*0"<A<3
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MQ7?^%=V+;#QNQ/UE"U55EVKKKK-SFVTHBJ;;=A7W+"H!>SA76G-MVX(B[[*
M+A")7 1/E:4K2I"TI6A:32M"R)25)41DI*DF1DI*B,R,C(R,C,C+@'M[2" 0
M00"""""-P0?!!!\$$>"#[S6F1:*Z.Y;TGMHTJTZR!;O,:W;?"\<GR#-2C4I1
M2)-<X^E:E&9J6AQ*C,U<3[I\<VG4M1Q]NQG9E('TKR;D7\BH< C\"-IH\WI?
MIO4>7Q_3^BYA;?=LG3,*YSN=R>;TEP2?J&!\GSYE>\G['ALORTG56F@&$LON
MF9]:JFI]0\V9D1&;95\YAA)\"(N!LF1>$B(^Z-O1U?U)C[=O5LD@#;:PI8-O
MQYJ3_P!9X[.]&?3'4=S?TAI:.3OSQUNQF!(V\"FU$]O_ *9J:3V+#;K"(UX'
MDFM6F3Y<O0GA6JN35D6/R%P1T4)N0EM/(1$2?==PB(BX$-@.NM8?QETZ9G#Z
MC*P*+"3]26X[G^_PV\Z_H#T75YTG-ZHT-O\ +^R^H,^A$V VXUK8 -MAMYG2
M[0O6C%^+FF6^W<!1K(_XJ)E)T>7PD()7$FUJLXCLQU)IXH6:W^=1$1DHCXB?
M\5:;?XS>EM)M!]VH[N.^^WN.VP4>?/MMY]CL);_W2=3X)#:'ZL=7XO$_+7G_
M  FHU;#V#&^LV, /&Y??;Z^^_P!MZ,=DOQ/BK&]UND.>-IX&B+GVE\NN==0E
M/'HW;"JD3S0M:TI0;[4,N5#BU$WS(2E<G4NBLCQ=H.HXA\_/B9RN 2?HE@3P
M 20"Q\@#?:2.F?7'3_\ R/J!TYJRCV35]!LI9@!OLUN.]Q!) 4LJ @,2%.P!
M[1YAV4W$"-%CH[MIU8:21?QV)ZA7.-3W2)24$:6<HB8Y!;6HE]*XA2UH2EIU
M#;JE&UTE/P_0N1Y34=:P#_Z;\.N]!XW]Z&N8[$;;^-]P=O?:X=2]?--\7=-=
M#]0C;^+3]8R<&UMCMN%SZ\*I20>14E@ K!6)*[_)[QMV>*)).HW8\=75<G=?
MEZ:YEANH)$1<.),UV.2;=U\^4G%%R33XJ)MLBXN$HG^'= R/.'U?I_GV7-QL
MG$_^Y[EK"_3_ "G;R2?$@^I7J'IX UKT:ZC)'\=FAZGIFL ;#SPIPGR6??9B
M-K??BON09U%=E*THHEDQJ9H9NGTJ?1QZRYEVCLM,!A22]V730;:1/7R'RDKC
M5H,N=' CXJY*O\#9]HWPM4T+/4_P_#ZBO(_;P]:IY_\ >?8[[>-[?^_OI[$/
M#7.E.ONGW7?N-J735@J3;^+YJLA[B%\;_P##@_,NP/G;8F/=DWV/Y"III.N=
M;027.!*CYCBN=X=T*S-!<CLS(\8KJWB1K3Q4U.=;_G'S\$+Y<.[HGJ>G<_LM
M[A]#C7XN3R'D[A:;W?Z'P5!_#R-]SA^NGI9FD*.JZ<.P^#7J>GZMII4^/#69
MN!33]1N5M91Y\^#M8+%MS6W3-S;1B&NFDN2..&DDLTVH&+SW^91<20IB/9K>
M;<[O VG&TN)/B2DD9&0U-^B:QB[_ !&EZA2!ON;,2]!X^NY0 C\0=C])['!Z
MZZ+U/;]G=5].YI.VRXVL8%K;GV!1+RRM_P#20&'U$W#%MJJ:23A6=?+)1$:3
MC3([Y*(_ 9&TXOCQ_9P\(US5NO\ $CK_ .Y2/^X$])7D8]O_ "KZ;-_;MVH^
M_P#]K&1F6Y?B^!X[:Y;FE_58QC-)%<FVUY=3&8%= C-%Q4X_(?4E">/<2V@C
M4XZXI+32%N+2DZ\?'ORKJ\?&JLOOM8+754I=W8^P"@$_F?8>Y($L:CJ.!I.%
MD:CJ>7CX.#BUFW(RLJU:::D'NSNY &_LH&[,Q"J"Q ,'IGJGIYK)B5?G6F&6
MU&:8G:$LHEQ3OK<:-QI1H>C28[[;,R!,861HD09\:-,CK+E>80KN"[FX.9IV
M0^+G8]F-D)MRJM78['V8$$JRGZ,I*GZ$S%T/7]&ZET^G5="U'&U/3[]^WDXS
MEEY*=F2Q&"VTVJ?#U7(EB'PR S/QB3;P$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$2!@^,%]\EI?NV 1!>,Z_F%O\ $'0B3P1 1 1 1 1 1 1 1*<[8_?K
M[(G],;"/R_-BP??_ *_H/Y;23[+^7\S+C!(@(@(@(@(@(@(@(@(@(@R(R,C(
MC(RX&1]TC(_"1E^TC")KS(=(M*<M)PLITSP#(^EXFM5WA^/6CAF?'BKI)M>\
MX2^Z9DM*B61GQ)1'W1ETZAGX^W8S<NG;V[61=6/T5P-OP]IILSISI_4=_C]#
MTC-Y>YRM-P[V^V_*VEF!^Q!!'T,KYD_8_-FF7&XNYV^X%TSAF?35L.93.(49
M*+F053-AMI,N8^!=&:2/@?+W"X;>CJWJ/'V%>KY>P\;.RV#;['N*Q\_7SO[_
M ',\=G^CWIGJ1)RNCM(YG_/179C,#L1N/A[:U]B?=2/P\#;5#_8M=KT1*U84
MK53360?'HG<%U5S&C:8/W/ VXK-D;!FDTD:>8CX&:C[IF,\=<ZXWC)^ S1ON
M1E8&-:6]_=BF^Q!(/X>)YY_03H.O<Z6=?T1_\ITK7]2QE4^-B*Q>5\;?;ZF5
M&WC]CDU79T;F/:2:R:UZTM4%O7WUCH[J'EQ7D2^K*_IS?742I)QILNX@$XS,
MC09TR4W,*'T<:.J<MM2O3=*=:Z;5K%#ZII.EXBL&K7,QJ#3P9N.RV\"56M]F
M5G51Q+ N> 8'P'J'Z,Z]1H!NT'J+J?JVK!RZ,R_I;6]2^*JS<>@N7^'L<UVV
M9%.Z6UTVVV);VRJUFQAOJW8=M(WS8WB>5ZH:=9[4[;X6?2X$BJT_SK%?;0>1
MPX++AM95;49SV_:S)=<44&-'DQ46$N%TLB1%:CI@KE;7KKJCI'4=36BW37U%
M<<.'R,/([':9C\U26<"+?_6_;;MH_A23R TWIET%ZH58^J=1Z!J6-T)CZU;2
M^-HNJZ?\<<VNE6XZEDX@NXX%MC'M+4:Q997R=D""IGOC["]EBQXC4QE^U'4)
M#7)[BRA95B<N224<%&EJNQYZ*AQ:UFI25S6FTI:(T+XK-L>)[O05W@XVO89.
M^Q1J,A5._P!2]P;8#[*Q)/GVG3_A?]H3#!*:CZ?:P%V^6^K4-/MLV78["G#:
MH,S'<[VHH"^".7$?1:P=E$HCZ.VVBZ-9QT:S0I["-8:BCZ="32A+B"S+(H/(
M:^5;I\S39<BT))I"T*0J/V?T/:?DZ@U+%W'MDZ=9;Q)W\'X:EM]O \?8^3N)
M/^(_7G$V&1Z==,ZKL2"VE]2XV+S ( (_:6;5L3Y8_*/! "@CC..W5W747*G-
M.QRZS-I27,]*PG-,;S8S2:UG_$P*6ME+4I+*#/D*:M:W>5'!'2H$_P"&M!M\
MXW6.F[G?9<G&OQO(^[VNH )^O'8#SYD#U0]0<0#]J>BW4R[>6?2]3PM4.VY_
MAJQJ;"2%'L+22=ALO("?;?9,:&J+ES_:AO'P5U*>+RIVC3TN)'4E',X3KR[>
MOE$23-"4J3 4:N<C4ELNZ(/15MA_X37^G,H'^'AJ05S^2BMU^^_S^-OJ?$E?
M7/#QQMK'I]ZE:2P'SF[IE[*T('S!F.159X) !%/G?<A1)^O[*=L^>6IJ^R;4
M/"W4*4AQK*-&]4$+;=0:4J:6='B]XE*R6:VSXJY$K:<):TER&NR_0W4( -5&
M)D@[$&C4<$^^_MW;ZB?R ).XVW\[9E/KYZ;L=LO.UG3&!(*Y_36N@A@0.)^%
MP,H [DCWV!!Y$#8G9%+V0W9/>N(:B;C].83CBD)2G(IT[$C2:W":2;AY3 IB
M902S]TXZ:&T((W5J2T1K+$LZ0ZFJ!9M&S6 !)-*+?[#?QV&LW.WT&Y/@#R1-
MWC>LGI?ELJU]:Z+4S$ #,MNT_P!VX@DY].,% /NS;*H^9B%\S<-)N3V\Y+T?
MM>USTCN^E_P7L5J)B<XW/<*<]P4:V<-7N$J6?+QX)2:O 1C6VZ-J]._>TO4*
M]O?GAY"[>=O.]8^OB>DQ>MNC<[C\'U5T[E<OX?A]9T^W?P6\<,AOH"?R\S9<
M3+<5GDE4')L?F)6DE).+<UT@E),B,E)-J2LC29&1\2[G R/]HPVQ[T_BHN7_
M -U;C_NH^QF\KU'3[@#5G8=@(!!KR:7!!\@CBY^\G4.-NI);:T.(/CP4A25I
M/AX>"DF9'P_;W19((\$;'[&9896&ZD,/N""/U'B?828"("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M) P?&"^^2TOW; (@O&=?S"W^(.A$G@B B B B B B B B4YVQ^_7V1/Z8V$?
ME^;%@_E)/LOY?S,N,$B B B B B B B B B B B B B B B B B B B B1MC
M34]NDD6U36V:"(B)%C!BS4D1'S$1)DM.D1$KW1%P[A]WPBM+;*SO78]9^Z.R
MG_\ 21+%V+C9 VR,>B\?:ZFNT?HZM-:76@&AN1(6W=Z/Z:6)+2I"UOX3CI/*
M2I*D&DY#=>A_ARK41<'/<\QFG@?=&;5JVJ4D&K4<U-B" ,F[;<$'^$N1]!]/
MH)H\GI#I3,!&5TWH=VX();2\+D001L76D-ML3]?K--WVP'9KDG2JM=O6GBW7
M241OQ:QZ"Z@U)2DU-G#DLI0KE21$9(X%X2+B9F-C5U9U'3MV]7S !MX-@8>-
MR-^0/WGFLOTA]-<[D;^CM'+,""]=#4L-P 2IK=0#L!])JJ9V*_9PZI:ZG"LG
MQ-2S4?-B&>9/CYI-3A.*Y>I3D\",R)!D?$C;(D^ 9Z]==1#;N9-&1M__ %&+
M1=OXV\\D_P!?S]YH+?0+TU8DX^EYVG$[^=-U;/P]MVY'_E6CW( (]B!L9!.=
MC'PJ OGP[<-N=PTTJ0MI$+52VM6F5MDHTJ0Q='-9/^-,G3);:B4:>59*09I.
MZ.MLEQMDZ1HF3[[\L"JLG?[FH(?;QX(^_@S$_P!Q>ET'?3>LNN]-V(*BK7[[
MU4KN1LF2+4/S;-Y4[[;'<$@_2-C6X.A22,)[(%KS7LH)1(8RBFQ?)VE<$$ED
MGB0BI6LF^+AKX.)-9FV9&@T&:QZHTBW_ ,STEI+'QYHMOH/_ -6W\8W/CZ;>
M/8[P/2KK'$ &E^L'5M*C?9,_&P,]3X 7D ,?< <MP.))*^01N>P6@79%<;,U
M8SO6P#*TI(C0QG6B+452B-1)4V]*@W]T:C)I"5$^W&;-3KCI$TV7*LZ?VMT?
M=_S^FLNCSY.+J9.WVXJU-7U)\%CX \GV%S_"/K/A;? ^I^CZ@![+JO2RUG;P
M.+659>63LHWYA 2['Y0/(^BB=E;QS@X4_9[J(RA22Z%V;J'C4]TBZ1Q1K9:Q
M2)":0HDH82:+12^=:%FA*2<<2Y=!W#;CU#AG8^0F)>HW\>"<DL=O?R@&V_D^
M!';_ -H'")/=]-]:0$;*UFLX-S_Q$[JN!74H(V3<7$[D'8#=A^#NMW9,,>2:
M[K9AI;F3;1%TKV"ZWTU7S\J"-:V8N23'IRB<6K@TVB,\ZGHW"6DR4A8J_9G1
M5QVJZDSL??V&5IEK[>?')J5"CP/)Y >1MY\2ANJ?7+#&^3Z9:!J:@?,VE=4X
MN/[ ;E4S;7M(8GP%K9AQ;<;$-/Q[>'<S2J).:=CFUYB\A\'7,&R2FU!2:26E
MOI&TP*.M2KBHG5&V;Q\C:6U](MMPW$3_ (8T6T;XW6.E-O[#*ILQ#[;['E:Y
M^H'\/GSX!&QI_P!ZG7.+XU/T6ZMKV.S'2L[&U@;;A>0%6)1OYY'8,=@%.Y5N
M0J/NW[*+J8QC&.87I5I+JMH!F652[)BYRG6O%*ZC?K*^&B,IE&$,LVUHU;6<
MOIW#?D368)U_0$AAF4;IR&?6='^G>%J&HM\?JNF:AC5\"E>!DM8KDEN7>W2I
M@ %'!$+<RWDKML?"];^N&N9%&GZ+H&@Z]T5J.I6WIDZGU9I]&(U%-0K*KI-8
MR<A<K)MYD$VK3VN.RJ_+FN:[6NRVXA-TY?@[F(>1P<UQ>T.C/,<)PV\R?',S
MBM1VUMV2DT<:6NNNV5GT-O"0R<5*G(TEI39//,Q]?U-Z<Y.'JEE6BW8U^,P9
M^U;ETU/0>1'$-8ZAZF'E&)# AE8#B"<[HG_:#TY=*R,7KE<M=4TS+.%^U-'T
M[*U' U2M45EO_P"$2PTY:$\,JD+P5BC J69$M%'[*KLL6R;LS/<SJ5=(;:6;
M#1S5OI%D24J)Q"H.&36#0KB:22;Q.D:%&IM*30I?G6Z$ZE!V7$QK/&^]>I:?
MM^7S9*G[?38[@ D[B>W3_: ],"G*W5]3QB20%NZ:ZA+$ #Y@:=-N38DD %PV
MX/R[$$RS790MD+C+3ZM9'(J7B6;;<_ -2:^09(6I"C5&FXBQ(1W4\2YVT\R3
M2M/%"DJ.V>A^IP2O[.#%=M^&7AN/(W'S)D,I_P!#^'O,E?7CTL9%<]3&L,"0
MMVD:Y2^RG8[UVZ:KC[C=1N"&&X(,F$]DJV0&VTXO<!BC'2MH=2W)AY!%?2EQ
M)+23K$BG;>:61'P6VXA+C:R-"TI4DR*W_@OJ?<@:3>=B1\KTD$C[$6$'\"/?
MZ3)'K?Z6D*3U?@+R56 >O+K;9@"-T?'5U.Q\JR@@[@@$$3(VNR![+7EM(3N3
MTJ2ITT)2;N3Q&4IYS(B-Q;IH0TDC,N=;JD)07$UFDB,RLGI+J0 G]C9_CSXH
M8[^_M]_8^/<^PW,S5]8?3%BH'6V@#EQV+9R*!RVVW9M@H\C<D@ ;D[ &9&QO
M:V@2GFX\?<SH@^\\HD---:D8LM;BC\"4)*R,U&?["(63TUU" 2=$U0 #<DX6
M0 ![;DE-MM_$S4]4?3BQE1.N>EG9CLJKK6 2Q^P N\S(XFZS;//>*/"U[TDD
MOJ2:B:9SS'%K-*?YQDE-@9\"_:?[!9;0=:0;MI6>HWVW.+=MN?\ \LS:O4#H
M>YN%75O3UC[$\5U;")V'N=N]])D<#7S1"T6MJNU<TYFN(22UHC9C0NJ2@SY2
M4HDSC,B-1\.)_M[GA%E])U.L OI^8H)V!;'M&Y]]OX?>9M75_2UY*T]1:+80
M.1":EB,0-]MR!;[;^-YDD+4S3FRZ3J&>X=,Z+EZ7J^2T[O1\W'EY^68?+S<#
MX<?#P,66PLQ-N>)DKO[;TV#?_P#3,VG7=%OY=G5]-MX[<N&=C-MOOMOM9XWV
M/Z&2C>88D\1J:RG''4D? U-W=8LB/X#-,HRX_P! MG'R![T7#\ZG'_=9D+J.
MGL-US\)A]URJ"/U%AG<;R"A=22VKNH=0?$B6W90EI,R/@9$I+QD? ^X?=[A]
MP4]F[_Y5G_V-_27!F8A&XRL8@^Q%]1'ZAIVTV$!:26B=#6A1<4J3)94E1?"2
MB69&7])&*2C@[%6!]MBI!W^WM+@OI(!%U1!]B+$(/Y$&=LC)1$I)D9&7$C(R
M,C(_ 9&7<,C^$A3+H((W!W!\@CV(^\Y"(")I+7'<)I;MXQZNR34[(H=-$MKF
MNI*V(J?3QK";(L);,5<B,Q;VE4V]#K$/=>M7FGU+B0&GGR:=-!-JV>EZ1G:Q
M<]&#2UK5UO:[!+&1%12P#&M+"&<CB@(V+$ D#R/+]5=8Z#T;ATYNNYM>-7D9
M-.+16;L9+[7NL5"]:9%^.'KH#&W(96)KJ5F"L1Q.W:JUK;RM@W%/.B6=791F
MID"P@R&I<.7&>22VGX\EA;C+S2TGQ2MM:DG^PS&OLK>IVKL5D=&*NCJ596!V
M(92 01]B 9Z+'R*,NBK)QKJ[\>^M;:;J76RJRMQNKI8A9&4CV*DC\9("B7H"
M("("("("("("("("("("("("("("(") P?&"^^2TOW; (@O&=?S"U^(.A$G@
MB B B B B B B B4PVWS(=?K'V1>9/E1H41C>)A"GI4M]J-'93_[/W8L7,Z^
M\M#3:>)D7%:B+B9%QXF(^_Y_R'Z^?^OB2?9?R_F9:7V]81\<<5_K#4?\8)D1
M[>L(^..*_P!8:C_C B/;UA'QQQ7^L-1_Q@1'MZPCXXXK_6&H_P","(]O6$?'
M'%?ZPU'_ !@1'MZPCXXXK_6&H_XP(CV]81\<<5_K#4?\8$24*^HS(C*YJ3(R
M(R,K&&9&1]TC(R>X&1EX#")S[/4?EFJ](P_]\$1[/4?EFJ](P_\ ?!$>SM'Y
M9JO2,3_?!$>SM'Y9JO2,3_?!$>SM)Y9JO2,3_?!$>SM'Y9JO2,3_ 'P1'L[1
M^6:KTC$_WP1'L]1^6:KX?\8P_!\/^&")RF\I%J2A%Q5+6I1)2E-A$4I2E'P2
ME*2>,S49F1$1$9F9\"[H1)0(@(@(@(@(@(@(@(@(@(@(@(@(FAMQ.W;3G<OI
MW8:?ZB4L*P94EZ306SS#BY^-71LJ:8N*M^/(B2F)#1*X.)8EL=8:YFG%\I]S
M:Z/K&;HF:F9A6O6X(%B*VRW5@AC6X(92-QN-U.Q\CS/)]9=&Z+UOH]NDZQBU
M7#YK,/(96-V#E<2J96.];UV(Z;^0EB<UW4G8S*-*M&]/-&]/:/3/!,7IZ7%J
M1E/)7QH39,S+!:4'-MIA/=,Y*L9[R>FDRY+KTA:N5*G5);016,_4LS4LRW.R
M[[+<BT^79CNJ_P"6M=M@J*/ 50!^'DS.T#IK1NFM'Q=#TG QL; Q5&U*5#C9
M<0.[D6\N;677,.3V6,[D[ L=A,SE8KB\U*43<;H9:$*-2$2J>OD)0HRX&I*7
M8ZR2HR[AF1$?#N<> QUR+U)*WW*2-B5L<$C[$AAXFSLT_ M %N%B6 '<"S&I
M< ^VX#(0#M]9#R=--.)IH.9I_A,LVR439R<4HGS02N!J)!NP%FDE&1<Q)X<>
M!<? 0K7-S%WXY>2N_OQOM&^WMOL_F8UFAZ);MW='TNSCOMW-/Q'VW]]N5)VW
MV&^WOM(>3HGHS,63DS233&4X2223DG L5?622XF226[4J422,SX%QX%Q/X1=
M74]24;+J&<H^RY=X'Z"P3&?I?IFT\K.G="L8#8%](T]R!]MVQR=O)\2#D[;M
MODMY3\C1'2IQU?#F5[0L91QY2))>Y;K4H+@1$7<27PGW>Z+@UG5U&PU//V__
M ,N\_C]7)_O:8EG1'1UC%WZ6T!F.VY_9."/;P/ I '@?0"0#^T?;#(=<>>T%
MTK6XZHU+5[3:9/%1]PSY414I3_H21%_0+PZ@UM0 -5S@!_\ W%G_ /U,5O3O
MH1V+-TCT^68[D_LO%&Y_TK F/.['-H3W2=+MUTK5TO/TG>O"+FZ3CS_S2+AQ
MXGX.'#CW. NCJ?J%=MM8SQMMM^_?QM[?68+>E7IPW+ET7T^>6_+_ ,/J&^_O
M[ ?])C[_ &/390^RXR>VW3%HG$&@UL4ALNHX_P#6;<0^2FUEX4J2?$C[I"\.
MK^I00?VSG$C[V[@_GX\B8C^CGI>Z,AZ)T)0P()3%*,-_JK*X((^A!\3')G8T
M-D4R.J.K03$XZ5&DS=AG.BR"Y5<Q$EYJ42TI/P*(CX&DS(^X8O+UIU.K<AJV
M0??PW%EW(VWV*^\PK/0[TMM0H>DL!0=OFK-R.-COL&6P$#[@>X\2(<[%[LM.
M-U6+I6]5M=*3RO8C*<DK5+62%(X+5%LFS4@R5Q4D^XI24&?=07"Y_C?J0MR;
M/#G;;]Y119_T=#_I]IC-Z#^F!3MIT^U"\N9^'S\ZDD[%?)KO&XV/L?J ?H)U
M'^Q<[1G&F6&,=U K66%.*0U4ZL:@5K:E.FE2C6B)>MI6?,GB7,7<-2S+NJ/C
M4O7/4()9KL2PG;S9@8C^V^VV]7X_]OL);;T%].2JHF%K%")RV7'ZAUBE?F()
MW5,L ^1N/'N2?K.M([%_MP,FD5]YKE4QVFB;3%AZX:B*9+@I1DI*9-V\;?<4
M2>5LTHX)(^7B9F=0ZXUGR7JTMV)WY-I>'O[ >=JAO[?7W^LM6>@W1)*]G*ZJ
MQT4 "NKJG62NX)\CGE-MX('$;+XWVW),Z<CL9&E*WDN0=9=SE8PV39-1(NN&
M8N,MFV1$1I.5-?<X&9$9H-9H+P)22>X*EZVS@NSZ;H=I\[LVF8X)W.Y\*H&_
MX[;GZG>4OZ%]/EPU?4O75"CCQKKZJU(HO';VYVN?<;[;[?0#;Q/A78VJ!$KK
M43<_NOA\CA.,LMZJO/-L\/YJ4G)KWEK(OV&ZIPS_ &\0_P 9VE>+:'H+;^Y.
M  3^CC;_ $VE)]$L,6=RKKOU!JV;=47J!V5?P_>4N3_^8F?DWV.JXC/JDPM[
M&\",X1K-DO;UC3S;/-S<$\'L46I:4D9%[M1J,B_G\3XB3UA65XMTUT\PV /_
M  MXWV^OC( !_(;?A('HQDHYLJ]4/4=&\E0=6P75=]]@ VGDD#\22=AN=]R?
M-7?3L$W'X[=X=G%)E&H6[/'RK5XF^C+9<69EN'65E8]' =8@-.QXLJGMW);+
M4^?&BH=@O1U/35IBK95'Z)T+UQH&.V75EZ=@:4[*UBK4K)1<HJ(?9CRXV)Q.
MR.6Y(Y%6S@[\=]2/2OK#2,[3]8JNU;U*PCB/IC+J3UV:CI61?;PH>NH.M5F-
ME&Q4ONKJ#TE"SD(5*VXVY; =VF!:*8CC[V\7.M(+EN//FNZ<8S6U^58IA?LI
M8O3FZ2'-F63:YCL9MSI9BX3S,)JPE2X\-R3$9:E2/(:UU=T_F:KE9"]-8>;4
MSA5R;;+*+KPBA>X5"$@';BO/=RBJ7V8E1[KH[TB]0M+Z:T_$/J/JO3&0%R+C
MH>GTTZAIVE_$WO<N)5;?>&M[2MO8:W6M;;+$K:Q%6Q]U)VB[UX<=;=;V0[)E
M/N.)4;MWI%4VS:4D1D:6T)R^&ZCCQ_8_R\2(S29C5_X@Z:8@OTA1L 1M7J%M
M6Y^A)^'8>/R^_P!?,])_NY]4*T84>LN>7)!WRNG,?(4#V( &HUL/_OVW^DY5
MMI[(57QT-5>_F@LE&XM3BKK0.N96A*B+@2)",PM''"XEP)M2&DH+B9*49F0?
MMKI%V)?I.VL;>.UJS,/]0<5/UW\_]2/0_K)0@7']7,/(/(DG*Z2I0@$>-G&H
MWEMB/8A=M_<SA[1?LGL%J/'J]XVCEDVA*ND>M]$(,:21FLU)+G0U:JD<249<
M[BVC024I)*B\ :ET0Q8V=.:BA.VPKU-F7_J:P/\ 1?/GV,'IGUWJ5$H]2>FK
M0 >39/2U2/OOXV*KD%]]_)8J1L  1YA_3OLK+!M-PMP6V*Q;0RVER5/P&[K9
M#KJ2X+6J/$QJ>PGGX<QFVZA/,HR2TA)$0#,Z$.Y;2=;0DDA4RZG4?8!FN5MA
M[;D$_?>'T;_:!3BM?6/0MX"@-9;I&50[,  243!N0;^_A@-SX4"?;F/=EK9E
M)ZOG.RR=$;4VKC,1J=!=D)3RFXAUF+I_*)DEF2DF;,I2N4^9)H5P)(7= %?F
MQ>I48_\ I."X'X@MEKOM]-U\_60</_:)6SY-5],+:U(([BZ[4S@>X9:])L";
M^Q*N3MY&Q]B9_9:8LKBO'MF%DPRZHC2G(-2VH\M">)<4J.IART(<\*.9,=TN
M*>=*/=$0IT RC:[J1"1YWIPB5/\ _L93M_J/Q,K%O^T-6^YP_3*]5;V&7K:I
M8H.QV)QZK "/(WX-[;A3N)\M9]V5]AQQ<O0?:?/8;0YRLUV?9;$D/K27\7T3
MTVY=:22S+N$\VWQ(R)2VNZ9#B=!$#CJNOJ2?)?$QV 'XA:P?SV)_#>0NK_[0
M2LQLZ2]/K4"MLM.KZC6[L!\O%K<IE )_]2K]-ROG;AC6+LHL9#[L_9_HQ9DA
MKBS%JM9JB!)<<(^/*3ECD+T97,GN))QR.DE=U3O#N =/Z'8@+U!J=>Y\M9IS
MNH'W(2D-X]SL&.WL)"=2^O*!VN]-^F+]EW2O'ZFQZK&(^@:_,:O<CP.3( ?)
M;:<M[ANR1067GK;8)C<U)*;2TFGW!Z>DZ1*,TJ-<=-K:/.D9FDR4A#9-I)2E
M\2/BD=(Z,<@5]67I]^YI&61^O;K \?0[[G]('67K94K-D>D.%:/ 48_6.C<@
M3[\D&1D,PWV\J!Q ).X/C[+=COGKXY+MNQQW\QU;II0JFU\PI:4HY>)$Y':Q
M^T>3P,E<736A!F:4$GF\+]@=+.=J^LJE &Y[FDY0W/UV)NK'Y ;GZ_E/^\+U
M7I3?)]%<RPEME.+U?I;;#;<<D7#O8>Q^;<#R!MO/T7O0W70V6%6?8X=7T2'C
M=XM5&I.+7;+9-J21<TB/C[*T&M"T*(GH[)&KI$MFZEI2Q Z;T!B>/66G[#;R
M^%?63X^@-Q^Q]B?IOL3M*O\ >=Z@5JAO]%>I%=N6ZX^M8&4B[;;;O7AJPW!'
M\5:[GD%Y!29^KF^G7.(EE$[L>.Z$I2V4N.MUC%);16UF:DJ0B9')"5\JDGPZ
M1EATTFE9LI):>,#I?2VW*=7Z(5WV!<VUL1]RC'<>_P!"1OXW\&5-ZK]5UA1;
MZ-==]PJ&84+BY%8)WW"V(!OL0?XUK;V/'8C?]'NR$9-"?3&L]C>\>$^1-*?;
M]H>..*:2X1*,T$K*FNE(B,S1S&UTG N/1\>Y Z1I8<DZGZ<<>0",J_SMO[_\
M.=O^OO\ 4R7]8LZI@E_I5ZEU/LI=?V1A,5Y $_\ X@-]@?&_'?["<GV2G%6I
M?4YFU/>I <2YT;RY.D&*FW',O";J8VIDA\TE^WHF7%_ @!T7D%>2:[TV_C<!
M=0O!._L!RPE )_$C\=H_WX:>MAJM]/O5"DAN+E^F\ JA^I(37'?8?@A/V$\K
M]:.RP;A/X<KC*-/XD?"M--.+DZB+I%FU<W R'+8+A,HFR\Y;;=>EUEO/21OT
MT2#)<9JTN--M+FN$]*F],T7TRTB_IZV[+RZ;LVU%<Y5%W):F/(@8V^RM6O\
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M[]?9$_IC81^7YL6#[_\ 3]!)/LOY?S,N,$B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MO6+U=D>HJ;+#'EZ4YVQ^_7V1/Z8V$?E^;%@^_P#T_0?SWDGV7\OYF7&"1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M("("("("("("("("("("("("("("("("("("("("("("("("("("("("(")
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MU!IN1IN=3Y[=Z$)?420N1C7#>K)QWV/"ZEG0D%20ZLHSH;R:& B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M("("("("("("("(") P?&"^^2TOW; (@O&=?S"W^(.A$G@B B B B B B B
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M!CC@%8OQ"Y(8JP9]K,9@%MMEH]KAI[KACI7^#VY/NQ^5FZH)J2B9!CL[ND[
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MMN]G&L.Q)%:#91E0MRN B B B4YVQ^_7V1/Z8V$?E^;%@DGV7\OYF7&"1 1
M1 1 1 1 1 1 1 1 1 1 1 1/,#LH1RI6F.&T-/@DC)KR\R1PT7\.@D6LS':R
MKC=8E-1YL1EUZ"]:/OQV"0LNBD1$3N!$XV1CYE_VG#;;TQH^#AZ%9J>=FZB^
MV?3@69=VG8V+5W;4JNJ1WILRG>NL*=ELI&1M\P!GU'_LM"FKJG6=0S=>JTO
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MPF1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M]/R^ID^R_E_,RXPF1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M_+\V+"/O^?\ (?W]9)]E_+^9EQA,B B B B B B B B B B B B B B B B
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M/!$!$!$!$!$!$!$!$ISMC]^OLB?TQL(_+\V+!)/LOY?S,N,$B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M.OYA;_$'0B3P1 1 1 1/QD1H\MER-+89E1WDFAZ/(:0\RZ@_"AQIQ*FUI/\
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MFP<-F8DLS8U)9B3N224)))\DGR3,U=2U%%"IGYJJH"JJY5ZJJ@;  "P  #P
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MDJ"BH*+(N(RG'%,6;K2YK*G%FV^DUJ,P^48X'@8?+X0#P,7FH1_AP/\ D<E
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M0$0$0$0$0$2G.V/WZ^R)_3&PC\OS8L('U_/^0_OS_P!MI)]E_+^9EQA,B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M^4YVQ^_7V1/Z8V$?E^;%@^__ %_0?RVDGV7\OYF7&"1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M]?.X#]4 D<C^'Z#^D=H/M>^)^<?7SN _5 (Y'\/T']([0?:]\3\X^OG<!^J
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M<E;NSJS':@LRY 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MV5TH[JKLP&TA:ER B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B0,'Q@OODM+]VP"(+QG7\PM?B#H1)X(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(D#!\8+[Y+2_=L B"\9U_,+?X@Z$2>"("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"(") P?&"^^2TOW; (@O&=?S"U^(.A$G@B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M0,'Q@OODM+]VP"(+QG7\PM_B#H1)X(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(D#!\
M8+[Y+2_=L B"\9U_,+7X@Z$2>"("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("(") P?&"^^
M2TOW; (GW-K)CM@FP@V*(3O4RA.(=A)F(6VE]3Z5%QD,&A1*49'_ #B,N'@"
M)\=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2
MR#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]
M%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I
M]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$
M=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#
MR]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]
M"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8
M!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2
MR#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]
M%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I
M]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$
M=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#
MR]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]
M"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8
M!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2
MR#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]
M%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I]8!$=2R#R]%]"I
M]8!$=2R#R]%]"I]8!$_:MK9,23.ERYR9LB:F*A2D14Q$-HB)>)!$@GG^8U=.
+HU*-1> B(@B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g374624g46h52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g46h52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &H AX# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            8'!0@#! D" 0K_Q !2$  !! ("  $)! 8'
M!04&! <% @,$!@$'  @1"1(3%!475973%B%6E"(Q4U32U",V06&6M-4R4723
MM20U<7-U&#-"=H&S)31B@B9C<H6AP='_Q  = 0$  04! 0$
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M=7]9OTSL=)'ZOXFMEO1Q;VX5)6G#;CG2HBL#Y2DQ3W74 L(*@0@>LQDS_O\
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MN]&P]>]&T%B-XG=D[KKB$Q&166*!97B#.\6[/2#4FQ.N_4C6&HM@BPTF[ZY
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M2G('QXZ9<^1YJ?3S)&')#OFX](XKPQR^2624@RR/(54*ID=G*J/<H+$\*/D
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M:[6K-)&S>IS12O(TT(9XM0=C-^#6O(D1DB9EGA;N7L99 C+W=_Y2_E '\L,
M #[]\;5OJTF:3U@.Z,.:ZNA#L<>J209,R L20)'7YBE$-B6/88R +MF)XB'7
M:8)EDHPTJ2G1RIR?7J>^<$D3<.:O@JNBK0W>IX-Y!L:2=.5[AGBAGKF>/80W
M8]=6UTLDE4QRO8NS)$\L4:-%!'9N+!+% Z"<T[,E9H&C<V&3M)#=IC*&1Y
M_([44D D@L50D%@<I$7V@[&6SN]OOJ%5ANE([&GM34#;0BXV ->DO62+?Y;L
M2+62(\=:WD!7Q3K#R'[!&68;FMI:D-@(BG51&=W+TQT]4Z(T/5UJ3<L^XVVP
MU$U.":CVUGUZ([6HI)*H,ZS!U*UV$)C/*FPX =L(LV'NSU%$/$,4<H=EDY82
M<\*0'('''FWGS[^T>[-9=B^5>V,(Z@[Q[#U;4E+%[#ZP=J)?4K<.MK"<.6BF
MF[Q!O-4I$NR:WV<%:K,B;6&W+7"*M(+TIHHZA,D?(C0<L1")7IM;Z*M=-U?H
M^GK>WNRZ[J?I1.KM/LJT$%:Y#1DHW+R5MEK)FLJEHBG)"W@WFA4E)%DD[GCA
MC2;204Y["Q(LE6T:LT;,SH7$B(6CD 0E?;#>: _(0. 6]K82;'& H21>"F+.
MU =RX["BSJV!GD\(<4PA##\NU$!4%QST33KJI)F0RCTDA#3ZO-C<\7<P-,?#
M6:&N7' =DLS1Q\CDEE2K'*X') [858\*2OY6;D=P7S(9N/D!52?\W+D#_6W_
M /&:JH[>0:'G$/L]JZ\=;G6LX;>O1Q#%^T#(SC[ES6MX4EN:"J(CQ\4LR=UB
M-/DI"D+]&'RCT:W.I/24E_V^F=G2ZC!Y*T8.ZAOU\N1&='=*3W)N/,II)MS$
MH]\W/($7UL)Y68GKG](P\2N?Y?'0%47^6<0G_P"[G<V!<^V%G.CR'5X%UFL.
MJ)-:$$HE]VEL*YJ7;RI1<R2Z]3(VL*]:ASU4@B_926S90I%F%"LDBU"%I%P(
MI0I9KZ?2E:"2/J>?J6OM4LS1/0U>OI\5(H@BA;C;.Q5D%MY?%Y@BB=(HDC+R
MF61X84CVV8&L*S1%00\KN2['D^P(@P[ ./:)!)YX' !/9Z8;GV;O_23.T=H
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MFG[?-UJ0&%8#T@9((CVXDR7J.F[&XZ<;6]0Z3JS7ZF26<K<A@V4\5VG%7L,
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M'F?</,YY[]2>R=Q[14_3>QM'=M:WN4C$L%6SVOTG<*+0*A=Z%$)#I(NW!JP
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M<8QQC((=_KU0?^&M_P#D1O/'.L?\,/H8_P"P>D__ -'T.;NC_>7>_P"GJO\
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MP_W+'L._?CP?_@R/_K?'P1],W^6/2?[JZ7_-N/7=%^H['UP_W+'L._?CP?\
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MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC()LO^I9;_ ,\-_P!=&<\;]/\
M_@GZD_[9TI_[QZ?S=]._WXJ_Z%S_ (*SD[Y[)FDQQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R";+_ *EEO_/#?]=&<\;]/_\
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M!Y7X!DD(Y8\ !455$\][E'^(R?ET[Z//9OC(^B?]=7_J3:?=LT?P5W7S>/\
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M !&3\NG?1X^,CZ)_UU?^I-I]VQ\%=U\WC_>(?MX][E'^(R?ET[Z/'QD?1/\
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MD>61Y97>261VDDDD8O)([DL[N[$LSLQ+,S$EB2223GI          '  'D
M/( #R 'NSYY9E<<8QQC'&,AEWV/KS60R,:V1?*9KX/,FM#(A:[V@'4QDHD\A
MQQD?&GGIT"*_-=;:=<:B-.J?<0VXI+>4H5G$ZAK-EM97@UFOO;*=(S*\-"I8
MN2I$I :1XZ\<CK&I8 N0%!(!/)&8Y)8H@&EDCB4G@-(ZH"?S L0"?Y/?G;J=
MXI=]'OEJ-;ZO=!<62W"DDJF?$V(?'F/#H!=J(_,#RYD=J2Z)*BRC;#CB75CB
M4":E&8TR.ZY9<H7M?(L.PI6Z,S(9%BN5IJTC(LLD#.L<R(Q030S0E@"!+%)&
M3WHP%4DCD'=&Z2*#P2C*X!X#<<J2.>UE;C\Q!]Q&2CD3+\<8QQC'&,<8QQC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8R,VRZTVA"5G[U;:S2P3:UMN&K8>%UT2A
MQN+)G.-K(F)4.&E:(4*9,6C+V%)BQ),A6,,L.K1*IT;NPF%>A3M7K! (@IUY
MK4Q!=(P1% CN09)$0$+YNZ*/:90;'DCB7ND=(U]W<[*B\\$\<L0/<"?\P)]P
MSMUNS5RY 1%JJ%@"6NKGX+!0%9*V5@' )L9*1AR*1$&!<B4.)09+><+8EPY#
MT=Y&<*;<4G/CRRU5M4;$U.[6GIVZTC16*MJ&2O8@E0\/%-!*J2Q2*?)D=593
MY$#*HZ2*KQLKHP!5T8,K ^XJP)!!^0@D9F^8,NQQC'&,<8R(1=@T*=<9FNX5
MWJ$S8 X2X?(46+90TBXP 34F%#=-3*PU-6;BB6YA(=%<)/P40T22$)A3V'93
M"')CZ[8)239/0N)KI)A6CV#U9UI26"LCB!+100/,4BE<1+(7*QR,%X1B+!+$
M9#$)(S*%+&,.ID"@@%B@/<%!(!)'') ^49+^0\OQQC'&,<8R%7W9.NM5 56G
M:%^I6MZPB2U#78[[:@5/ IF/X6IB*HO89XX>F2\EIQ33&9&'7,-KRA"L(5X3
MM=J]GM[ J:G77MI;*EQ5UU2Q=L%%(#.(:T<LA520"W;P"1R?,9CDEBA7OFEC
MB3GCND=8UY/N'<Q Y_DYS/ + !M8499*N;$62NFHC4\.> $H1@*6@/X\YB:,
M*#GI,&?$>3^DU)BONLN8^]"\XY'L5K%.>6K;@FJV8',<]>Q$\$\,B^31RPRJ
MLD;J?(JZAA\HRY65U#HRNK %64AE8'W$,"00?D(/&9?F'+L<8QQC'&,<8R*9
MOE'Q<$:\S<JIB_N"'[ W1LV(1BX. 8KL5B2;16?7/;2A$=Z="9?))A9AM.S(
MK;CR5R&L+F?@^_ZD=EZC<_!PF6L=AZM-ZD+#AV2N;79X F98Y&6(R>(P1R%(
M5N+/$C[_  O$3Q"I81]R]Y4<<MV<]W:.1R>.!R/SY*^0\OQQC'&,<8QQC'&,
MR PH0#362 R4[$EL*QE#K2O#QQXXRIMQ.?%#K2_#P<:<2IM:?N4G..;C0]0;
MGIC:5MSH=A8UNQJ,&BL5W[2R\@O#-&>8[%>4 +-7F22&9/9D1AY9@LUH+<30
M68DEB<<%7'/!^1E/O5A[U92&4^8(S<>CVMFW!&Y_FI:FL*]6)1TYSYK4I*<*
M](WC.<J]!(1E+K7CG/F^*V<J6II2L_IWZ*/2)6])/2L&W[(ZVUJ2>H[NC&3V
M07T17$T <E_5+D3+8K]Q<Q\R5FDEDKR.?)-SK'U5QH.2\+CQ*\A][1DD<-QY
M=Z,"K<<<\!^ & R8\]-S4XXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,9H[<YCLZV6&0[G.59+S64^.?'*68KZXK"?_ -C#+:?_ *<_)OTH[*QMO2+U
MK=LL6D/4FUJIW'DK6UUJ37TXSS^BJ58(^/< O \@,]FT\2P:NA&O''JL+GCW
M%Y4$KG_6[L?Y><C/.#S98XQCC&.,8XQGF?W+TEV(.;VTMV?ZEV/6%KW)UUIM
MV '.O.W)ST*NWS7NW)4'$N=7["/6]-UO>R$FAS15=M$Z"D*<R/D#B1-@2%,C
M2_J71&]Z:K]/[WI3K&KMJFDZFO:^Q!U+IHUDM:[9:59"D=FM*%CVFOC38I-:
MJ1R>L5_$66*)IIX)8=5>KVFLU[=)H7GK1R*U:8\+)%,1R58><4A\-@KD -P0
M6[596KKKUO6=N74W<XWU1T]&ZY=X*M;?:FZNO6Y@;16MQ=_1Z1#B!I$^54S%
M5A'0VU@-6'#(6QA10;[56.8M4\0XCTN3.RZEZ>31[GH>OU?NVZFZ"MTA%H^I
M-'.8K+]-M?D:=(EN07)*\^GL6Y9GU<T,W@B5J<4RDCP,5:P9X+[4H!5OH_,]
M:=>Y18$8 Y*% PF5 HD!')'>5\^6O#K=VPL/:83UX,ZWG!(3!S4M@OW8N"<J
M\U9:@6V"37KP9K5T:BP#Y%:LCFU >R8CB9_M9N0"U3:(Z?59),.63H.I^CZ_
M24_4D&T2Q(U?<5M=TU)7M1B'8TY(OPG+M1*:TJVJHU$^K8>%X++8W%1_;2*>
M',]6Z]P56A*@-"\MH,A+1N#X2Q=O<I1S,LH\^05A?W$J<TU)=\>W SIY=^WC
M\G0\IO47:TOI*P:TBZZNP]C8-2A]I1/7E$Z';I&TB\FB&,0#L8TQGV#<F&2
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MD 5B9?G2%4U_4U_6Z+<].P0TFUV_DH2[02PR/8G?5RRSZXI.LR-!ZK+/,ZB
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MU<?7?"]5[0[*C[CVDA^VN1"2]HPB=3,0+E6"8J"/E5J= (T2F2(0X>K "/\
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M8QQC'&,<8QQC'&,@FR_ZEEO_ #PW_71G/&_3_P#X)^I/^V=*?^\>G\W?3O\
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M$\$\"P.:[,F8H@="B9@,>4+#AT^SDWPM<AS9C$:4=+Q@Q:QR!@AAYQ#A">P
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MUU2]7W\]MEBZF39SRP2LUZM;-R*5&E2?11+ :XI>&CY8CF>KLWL2R0VJ\UD
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M]H Y=3Y#CW8,<98.40NOY+E5+#_,Q'(_U'/R12J;+.-V>54JS)LC2V'6K#(
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M_-\Q"<8PO=NR0BM);M25PW<*[V)6A#<ENX1,YC#=S,>0O/))YY)RHCC#=P1
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MXKOI,_2]-?6MG^KL?"_4_P 6W]"G]+CW,7#]H'_.O?RG'Q7?29^EZ:^M;/\
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M74JNW@1_;5!&MF,HR22Q>8"OV,PFB'N!+H.SD):VI@=[]518;Q8#+[DIKQ'
M9,A6$1V7$_=+)-^"<YDN(SXL1%_=&3GTCZ<R<I;C?2?\&CH_TR?@Z+K?TO\
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M\RJ?NT/V,?: ]\;+_,IOUN/AEU?^U74GUYM/O6/4*/S*I^[0_8Q]H#WQLO\
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M'[&?2+'86U86@Z90I.?'"DDYJ58S_=G#^,XYDBZWZTA=9(>KNIXI%/*O'O\
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M=7OMX^%>Y_2P_01_S8]T%)_<YOS"1_%Q\6KT5?JS:?75[[>/A7N?TL/T$?\
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M-V$B[+A5\3%;C,/2&7WHOKTJWJC'X#5^XQ-K*=^Q),Z!(#:\@I?M0<%RJ1J
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M54-);DMVL:+=K1!N%2J<.OU.R0-.%'C8\Q<!>M46<>2A#ZA=<,EF9M5)CB<
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MW9C:*U?UZ,X:K-81B9(BTL+2<.4)4 1V[^3YJ>PG[))L&Q;%&EFM5:/UN)G
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M..?35--))#+7K0U:\BVJD=J"W#5A$2Q6:TCA2K]J.QCD21)$#PO&P5EH&E]
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MI;!EDF"R=O7_ '0[![C?ZX4^H&].U2Q[?V/V[UH?LY*DEKO#AO=?8Q>943\
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M@:OS,G=Q, '@C-@>%9B&OBM,]6UZN(I'[I1-X$X@?U5D4,).7&4=8;$K2G[
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M&+(G#BDAEZ9=C3X1U:_@H8;*ZNO+ J*D;Q6*]:.1510JH1W%D90/"D573M9
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M9UVZ/2F3+UC9I]7:L,B5B=(.MU\2@R_-2WZ),QXHF)B<[*PU_1XD+?4[AO\
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MY@,9)BS33K>&73$N.]%6S(*.-8PTX0>0N6MO&$*>RG'AP)I5(999%95"*0[
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M0]M61Q$*\@Y:06:Q*)XA[;P]9C_?_3L_=YOC_2H^[SO#S?']+[O.\<>;_O\
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M1Q\QN):[-$+3PV#;3Y.'-A"Y40":=]I1XDUIO(YUE:<2'HC,B56IRVELO$4
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M:<-X4K&5Y4MQM"<)\?%;B$X\<J3C.OX)]P)X]^;\LHXY8#GW<D#GS \OS^9
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M](FRIXZOQ\XZVTJ11T%DE(>K/KV[X!83OA@E$L\=F!@8'*<R+!-!VRRAP)U
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MAN=$WIJVRBAU-)&L]'ZK5U_.DH3>U'E,USV3[#!)E"W%'C,(F'']S[[Y%Z9
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2,4?B.S(@#<G<WFHSK,<8S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g374624g47j55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g47j55.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1<(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %NR^6&@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              7<   (O    !@!G #0 -P!J #4 -0
M  $                          0             "+P   7<
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7<     4F=H
M=&QO;F<   (O    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %W     %)G:'1L;VYG   "+P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     #)0    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /4FM!$F>3W/BGV#S^\I,X^9_*A?:OU[[)M_P?J[Y'[VS;L24OD6
M"BL/VN?+FM@$S[G!G_?D+$RVY+7N-;ZPP F2=9'YOW?]M[%;4+?YM_\ 5/Y$
ME*T_==]_^U+3P=]_^U368[]IY3<W[-8QC"YU>,73J6CT[)VC<QOK!S-__7$V
M1(H &1/E_P!TD5U-.AIX.^__ &J!MI;])T?%WGZ?[W[_ +$"O"R',:,G)<YP
M W"OVM)CW?3]1_\ F[$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_XO__24-#7U!23T9)3$4  0F^S/[^
M'@ (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,
M     $%$0D4                    !  #VU@ !     -,M041"10
M                                                        "F1E
M<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B
M!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT
M  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@
M5V5B($-O871E9" H4U=/4"D@=C(
M
M            =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US
M+"!);F,N  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
M                 0                    $   $   (   (D!!T%V@=I
M"-D*-@N%#,<-_P\Q$%X1BQ*W$^(5"Q8R%U<8>1F8&K4;TASO'B4?62"'(;(B
MVB/_)2,F1"=F*(8IIRK'*^@M""XH+T@P:3&),J8SPC3>-?LW&#@U.5$Z;3N)
M/*4]PC[>/_A!$4(I0T)$7$5U1H]'J4C#2=U*]TP232Q.0T]94&]1AE*<4[)4
MR57?5O98#5DC6CI;45QF77A>BE^;8*UAOF+/8^!D\68"9Q)H(VDS:D)K4FQ>
M;6=N<6]Z<(-QC'*4<YQTHW6J=K%WMWB]><-ZR'O-?,Y]S7[,?\N R8''@L6#
MPH2_A;N&MX>SB*Z)J8JDBYZ,F(V1CH:/>Y!PD6226)-,E$"5,Y8FEQF8#)C_
MF?*:Y)O6G,B=NYZMGY^@CJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N
M?:]KL%FQ1[(VLR2T$K4 M>VVVK?(N+6YH[J0NWZ\:[U9OD>_-< BP1#!_L+L
MP]K$Q\6UQJ/'D<A^R6S*6<M$S"[-&,X!SNO/U="^T:?2D--YU&'52=8QUQC8
M -CFV<W:LMN8W'W=8MY'WRS@$.#TX=CBN^.>Y'OE5^8SYP[GZ.C!Z9KJ<>M(
M[!WL\.W#[I;O=O!5\3/R#_+J\\/TG/5S]DGW'O?S^,;YE?IA^RG[Z_RG_5S^
M"_ZT_UK__P   >@#IP4L!H0'OPCG"@0+%@P<#1X.' \9$!<1%!(0$PL4!!3\
M%?,6YA?8&,P9UAK>&^$<X1W?'ML?UB#1(<LBQ".^)+@ELR:N)ZHHIBFB*J K
MGBR=+9HNE2^1,(TQB3*&,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU ?T&"
M0H5#B42-19)&F$>:2)M)G4J?2Z-,IDVJ3J]/M%"Z4<!2QU/.5-55UU;95]M8
MWEG@6N-;YUSJ7>U>\5_U8/AA_&, 9 -E 67_9OQG^FCX:?5J\VOP;.YMZV[H
M;^5PX7'><MISUG3-=<-VN7>O>*5YFWJ0>X5\>GUO?F1_6(!-@4&"-8,IA!R%
M$(7^ANV'VXC*B;B*IHN5C(.-<8Y@CTZ0/9$LDAN3"I/ZE.F5V9;)E[J8IYF3
MFH";;9Q:G4B>-I\EH!2A!*'UHN:CV*3*I;VFL:>FJ)NID:J'JW^L=ZUOKF>O
M8+!:L52R3[-,M$FU1K9%MT2X1;E&NDB[2KQ.O5*^5[]=P&/!:L)RPWO$A,6*
MQI#'ELB=R:7*K<NVS+_-R,[2S]S0YM'QTOO4!M42UA[7*M@WV43:4=M>W&O=
M>=Z&WY3@G.&BXJCCK>2RY;;FNN>]Z,#IP^K4Z^7L]>X$[Q+P(/$L\CCS0_1.
M]5GV8_=J^&[Y;_IL^V3\5OU$_B__%___   "!0/8!6@&Q@@&"3(*4@ME#'(-
M> YZ#WH0>A%Y$G43<!1H%5X64A=%&#<9*1HT&ST<0!T_'CH?-" L(2,B&2,/
M) 0D^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y
M"SH .O8[[3SC/=L^TS_+0,1!O4*W0[)$K$6F1J%'G$B7291*D$N.3(M-BDZ)
M3XA0B%&)4HA3B%2(58A6B5>*6(M9C5J/6Y%<DUV67IA?FV"=89]BH&.A9*-E
MI&:F9Z=HJ&FI:JIKJFRK;:MNJV^K<*EQJ'*E<Z-TH'6==IEWE7B1>8QZAWN"
M?'Q]=GYO?VF 88%:@E&#2(0^A36&*X<AB!>)#(H"BO>+[8SBC=B.S8_#D+F1
MKY*EDYR4DI6)EH"7>)APF6J:8YM>G%F=59Y2GU"@3Z%/HE"C4J15I5FF7Z=F
MJ&ZI>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/
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MG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ.
M8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*J?Z)C8B]
MI>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"  *L2K6J3
MYYFJJ3>1FH?,I3"/A'50H6B-O6(2G?R,44WHFNB+.#A!F&J*HA[*E]>+LP
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M:8QBLF&7IGM[K::5-&H&J223&%?MI/"1743AH3^0-3 ^GE*0*A<^GC:.N
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M&((?O])XRW(6NGQXN6&CM6EXZE!QL*=Y4SX+K'-YY"FFJ99Z:@]FJUE["P
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M8H!"N[6=-W!-MD":<U_/L0F8+$ZNK":6<3R5I]"5LBC"I):5O! KI..*[@
MC#B  (]FP-6HE'_\NRJDT' 6M:JAAU^BL&^>WTZ)JY.=!SQ]ISJ<K"BXH^":
M;A!.I :+!@  C!F  (\FP%&P]7_,NJ&LDV_VM1^HRU^-K^.EV$YWJPFD&CQO
MIKRB_RBSHU.;A1!LHT2+&P  B_^  ([4O_"YR7^NNBVTFV_MM)NP+5^'KU&L
M^DY[JG"K7#R IB"G]2C<HLB;H!"PHKB+2   B^N  (2TT)]X\W77REEX@V:N
MQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F  (1BSY^
M;G6;R7Y_9V9PPXQ^K5;.O=9^1$9QN'1^*339L\Q^4"#VL/Y^GPAGL.I_YP
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MSW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6VPJ1JA^')0
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M@EUZ2U5@@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F
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MB)(_I.2$A8%LH6:#I&^RGC&"_ET?FSR"B$EYF*."1#0LEK*"*QIMEQF"Q@
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M-([FH:2N$'WTGB.J%6Q(FMJF>EGUE^"CE$:^E4RB#C(1DRZ?=!DFDQ"1 0
MB N  )ZJI/F[WHY]H52W(7V$G="RBVO7FH.N>EF0EX:K@T9LE.^I0C'.DMBA
MK!CWDK60X0  A["  )7QM0ASQ(9]L+AT-W:0K*)TPF7OJ,5U;%1GI2MV,4&B
MH@AW RSPG_AWK!)NHAQWK   B7Z  )55M")\ 88?K\5[M'8TJYY[D&6.I[)[
MEE/[I!%[R$$XH.E\&BR/GLE\:1)4H)U\KP  B,2  )35LQF$+(6,KL.#-'6P
MJI."963\IJF!V%-OHP>!?T"]G^"!6RPOG;2!9Q(_GS^""0  B"&  )1.LA^,
M4X3LK<^*PG3[J:2)8&19I;&(/U+6HAB':$ ]GO*&V"O2G+J&P1(KG@:&R@
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M;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&F>:,,
MA>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V1B12J"MV
MMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/K&YZ[CA?
MJ-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^
MM4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!M_6)&VGG
MLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J2
M8'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*H[F'H@
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M_6V9Q;9S-U]8P']SFE!SNX)T)T">MM]TRR]%LR%U9!L&L?AU:P-OL$UWB0
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MY&U4P)J5D%[WNQ^3CE #M=61]D!/L.Z0["]AK-*1 1P5JJ:0"P7DI^&#^P
M@QV  'L7Q82?=6U'O^J<LU[WNF":1U *M0R89D!;L"6772]YK "7>1Q+J:.3
M(08[ILZ$-P  @QV  'KVQ0:G,&T_OUNC_5[\N<&A+% 6M&&?%$!GKW6>62^-
MJU:<TQQXJ."30 :'I>N$:@  @QR  'K<Q)VO/FT^ON&KDU\)N3BH6U JL\RF
M,T"%KM>DSB^YJK"@11RSJ#&39P;(I4:$E@  @QR  .8?=G!S&- ;=TMS\;F
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M")B.F'-P08>EECQQ:76PE#QRC&*UDFASMTZ2D-5TYSC4C\)U]!ZCD(9VA
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MQI0-DR^:48,*D0Z7WG$DCQJ5AEYWC5J3:$K*B]^1KC68BL60QQPCBO*/D0
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M+HJTH*1WA7K#G<%WZ6GDFQ%X7E?\F)MXYT3=EH)Y>B_JE2IY[16FEM1YW
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MCX<8G"B?SW<5F42=#68YEHJ:=%2=E!6804'_D?R6R2VTD&V6A11AD3B-R
M@4N  )7.GK&KEX:=F[VH3G:2F-*D^66VE@ZAUU0>DY6?44&'D8*>$"U8C^F;
MX!0YD(2-K   @."  )5UGF*T\(8[FVNQ*78BF'BM1F5!E:JIKE.TDRJG#D$O
MD1*E.BT.CWV>=A0"D R-AP  @(N  (R<KS1N 'Y7JWMO%V]=J -P+U]YI,!Q
M2TZ,H;MR:#Q!GS=S=R?-G?=T) TOH+ASQ0  @G^  (PLKCEV07X&JGIVCF\
MINUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6  (NZK0U^
M77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_G39^.P
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MIWL%I8JDO6OGH>2ASEOXGF*?(TM*FSF=.3F*F)F<K"7SELN9<@U*ESF(_
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MDG$%LG&#L&+&KCV"\5/*JCB"9D/)II:"%#)RHZ2!\!ZDHF*"%@:VH7^!Y
M@ "  'Y,M;^,.'"DL7**X6);K3Z)L%-5J3>(K4-TI8:'\#(QHI.'GAZ0H32(
M*P;QG_J$L0  @ "  'WPM/Z4!G!/L*V20&((K'&0EU,"J&*/)D,EI*J.$C'^
MH9V-M1Z!H".-X <AGJ.$T@  @ "  'V?M&F;YG +L!*9MF'&J\F7F5*^IZ^5
MQ$+BH_:4@C'2H-Z4>AY^GRZ2IP=.G7B$\0  @ "  'UJL^FCY6_8KXZA4&&0
MJSV>S5*&IQN<J4*LHUR;<#&<H$J:XAYFGGR4C0=YG':%#@  @ "  'TVLYNL
M1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@F\6%*
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M"V5?O >(R%? MT6'MDEULJB&VCI1KG.&42F>JT>&217MJJ^&D &1I%6!#P
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M6IFDA@^%MXB0A3Z% ':+A(:$4V-Y@^V#PT]<@WF#23FF@SB"XQ_&@YB"N
M@F^  *BEA<./VYB8A.".BH>#A!>-(G5B@V>+MF)O@M:*9$YK@G6)2CCA@C*(
M;A\R@F:(>P  @2Z  *>KA->9?I>6@_J7?H:!@S"57'1O@H"3,V&,@?&1,$VJ
M@8:/>#A%@46.4AZU@5B-W0  @""  *;BA!RC,I;(@T6@B(6M@G:=K'.9@<*:
MRF#$@3>8)DT @,V5\C?'@':4NAY1@&R25P  @ "  *9*@X^M")8C@KZINH3X
M@>>F)G+A@2:BC& 2@)>?5DQ3@#F<V3<W?]^;M1WX?Z>41   @ "  *7C@RVW
M&I6D@F"S,X1>@7RNZW(\@*FJH%]\@!"F[TO7?Z^D>C;-?UBA>1V>?PV4!P
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M+(P C>*,$'OXC%Z*Z6L(BO:)OUDMB;6(LD8<B+Z'W#%9B!>'4!>PB,:'6
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MS(+7G$QJC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P
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M1W\7EGB1RW !E#R00& *DA^.ND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0
M@ "  (S&F!B;]WZ:E<^9^&^"DXF7U%]ZD6"5N4Z>CW63\3REC>*2S2C/C-B2
MQ0]IC9V*:P  @ "  (Q5EYFDOWXBE5*B0V\ DP.?DU[VD,V<\4X=CMR:U#PF
MC4^9W"AKC#B8&@]+C*R*5P  @ "  (P!ESVMQ'W#E/2JW&Z1DIJGJ%Z"D%:D
MD4VTCENB43O/C,:@]2@?BZ^;(0\<B_F*-P  @ "  (.)J1-H-W8\I?9IX&@5
MHQYK>%CBH'AL_DB+G@YN<C:RG#5OMR)>F^-P6@A8G:]P(   @ "  (,2I_)P
M9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0
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MAW+WGYF6SF2XG*B5 E6=F=J3346FEU&1\C1WE3R16R$5E!Z0Z CBDPZ& @
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MZ&E@K=AW&UP"JD=W8$V@INMWPSXHH^QX+2T0H<=XA!CNH>EX5 )>G?EZ6
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M F>QJ2V;.UHRI8:95DO8H@:7HSR4GNR6M2OKG).6=AB[F\:0N0.)EE."9
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M:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V   FVA_H0
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MZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#   E[*
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M8*T$=8)GOIIL=G%I[X:^=UIK_7(/>$)M^UQ:>2QO[D53>@]QNRL#>M]S&0>
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MT5^XA MLRDOQ@_)NK#:!A"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G@T5O"8*
M@NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !ZN:"+@=EV
MU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+
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M\XRV>]RC57R.>Z>@:VMW>WF=<EF)>W&:R4:/>X.8PS(?>VV7^1D@>L20_0
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M^X0+B+)^)'3RA\%^-63JAN)^.U.IABY^1T$NA:E^52S+A79^5!*YAJ!^!@
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M]X"7A&6H5W%C@V*E16$_@F*B(5!8@9>?F#Y6@0J>92J;@(Z;-1%Q@$6+RP
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M67<JD+&$!VCXCQB#H5G&C9J#,4FHC$&"R3@%BU&"AR0XBOZ"9PKMBO&![@
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M<&X3H"9DE6"KG>YFH%(@F^=HBD)8FAYJ3C#BF/YKPQR!F<%L/P/?F*%LO@
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MWVKZF7.).%V3ES"(=4\ZE0F'K3_BDR*'!R\9D;F&L1N/D9V'%@2HCG:#)@
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M/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@  ERUS:0
M@ "  &T7JH%PLV$YIY-Q<U28I+1R-T;>H@-S 3?MG[ESNB<;GG)T+A*2H!-S
MF   E:!X,   @ "  &RAJ.IX"&"OI@-X4U/]HRQXG$9JH'IX[S>)GC-Y02;=
MG-QY;!*7GC)X]0  E#!\8P  @ "  &PHIY!_;& XI*]_4%.!H=E_*T7CGR9_
M!#<QG-!^]":=FW!^\A*2G(9^XP  DNB     @ "  &N]IH>&\E_9HZ6&=U,E
MH,>%Y$6%G@N%4#;8FZN$Y29OFBB$U1*2FP.$N   D<:     @ "  &MDI;>.
M?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0  D-N
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M[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0  D.%[@
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M1E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R
M@ "  %_!K]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*'
M)@  C "     @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW
M<+ELT4;'<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)O
MRW)&;,]Q8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'
M9GUV\X5S:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN
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MPY9Z=Z]ANH8T>%QD='2G>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP
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M5I @;>^./G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P
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MF(E&?3EII'H!?61KAVF1?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP
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MB8/;=0R4(W2W=7V2?&21=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@
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M4WP=@Z1PHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P
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MU7?G?/N91&FP?+>77UIY?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@
M@ "  (2X?'^CL7=T?&"AK&DO?!.?.%GV>[R<L4G6>X>:K#AV>VN9X"4F>PR7
M(PR*>U^(>@  @ "  'Y#D?E=9G':D)%@&F1ICW%BIE6ZCH-E!T6^C<-G.30?
MC7)I&Q_2CE9J%P9.CIEJ%   @ !\RWU[C^AEJ'$JCK!GH&.RC9EI?U49C*1K
M0T4VB]QLY3.UBWUN11^.C"=NX 9JB_9N\   @ !_WGRNC==MT7 ZC,5O(V+D
MB[QP8E1.BM!QCD2+B@URHS,NB:ESAA\VBB-SS 9WB9]T*P  @ "  'O)B^UU
MZ6]$BNYVJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP
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M36Q2A;Z=RU[JA+B;QE""@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P
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MD&,7DPQ[XE9QD8)\'4C0D E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@
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ML%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@  C91MT@
M@ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5JB@Q/GOII
M_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0
MFL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S
M]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>
MFSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR
M5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2
M@ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%
M#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+
MDWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%EVR4[SV]E2B3
MK"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:9$X:KU)<C4)D
MK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0  @ "  %APL&=A
M?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40  AZ!VL@
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M+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@  @JV
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M?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@.
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M#H=G9Z9_/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\
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ML8$G>5)<"7*W>>%?*&+^>H1B$U(!>S%DU#^=>^]G7BL\?,5I6Q#>?E!I8
M@ !V"8U2=>%ANH 0=IED0'&<=U)FFV']> ]HTU$?>,]JZS[=>95LTRJ?>D=N
M0!"(>X5M]@  @ !Z'XP=<QMJM7Z]= EL>7![=.-N'6#E=;MOHE R=H]Q$CX:
M=UUR72H+=^US11 ]>1!RRP  @ !]M8K5<)-SLGUK<:ATP&\I<J%UK5_H<XUV
MAT]/='IW2SUG=4]W^RF.=;UX:1 #=NQW\   @ "  (F3;FM\KGQ0;YE]%FX+
M<*E]5UZX<:5]>DY=<IY]FCR*<WU]NBC=<\9]PP^A=25]G@  @ "  (B);*2%
MMGM';>.%>FT.;O^%#%W'< F$@DU_<0>#_SOC<=N#F2A;<?^#90]:<Z&"^@
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MXG1H?LIC7V;4?NUEM5@7?QYGYT@+?V!I\C9P?\IKN2)G@(1LR0C?@>ELF@
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M:F]F=1"*WF(,=8F*$%.E=?&)*$0T=EB(73-<=J"'V2!*=CN(#PAR>-B%50
M@ "  'LQ<U*3\&[.<_N2X&%S='.1?U,3=-60!$.C=3F.S#++=7J.*Q_<=.".
M#0AC=\Z%JP  @ "  'J^<GB<?&Y7<R>:_6#S<YN9$%*3<_*7#D,U=$F5@3)T
M='J5$A^!<[:2U@@L=PJ%A@  @ "  '5.BK=7VFF B?M:\%RRB7Q=WDZDB2=@
MFS\TB/YC&RWSB4IE*1E_BOEE\P'UBA1G&   @ !\7W18B!M?YVBSAYEB4UOH
MARYDGDWXAMEFQ3ZIAJMHN2V.AN)J2QE/B#!JNP(LAVQK^@  @ !_@W-JA9%G
MYV>LA3YILUL+A.EK9DTCA*%L^3WXA'AN9"T'A*%O?1D A9EOH ).A1-Q-@
M@ "  ')P@S]OWV:A@PAQ&5GV@L=R.$Q*@HQS/CTT@G!T(RQM@HYTRAB<@S9T
ML@)=@PIVS0  @ "  '%]@4)WX&6Y@1UXD5D.@.IY(DM=@+=YF#R9@)-Y_"OH
M@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6 )TJU?R&
M##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A?CJ'QE?/
M?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "  &]I?2:0
M)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*??6J!Q@
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MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@  @KQXF@
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M&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P  @ "
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M@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@  @ !_+@
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M349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?   @ !Q+@
M@ "  $_&J)1;*D7$ILQ=-SJ_I1Y?,BZ%H\%@]R!;HVUB*P['I;)B!P  G6QE
M%0  @ !U^   @ "  $\]IE-A[T4MI)9CCCI!HNME&"X1H7YF>2 3H0=G5@[1
MHN%G"@  FMYI[@  @ !Z/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL
M !_ GK]LD0[&H#]L*   F'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDS
MGL5Q$2TKG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7H&IV
M8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "
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M68N>74-I9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ9Y%RSP
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M&H5[46V61':(5,6426:15]N24E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0
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M;G]386APUW#^8ZMR)6&A9<9S6%#^9\-T>#\;:6-U@"MQ:>MV11*2;$=V#
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MF7JJ5[V;GVR"6F>95EU>7-*7"$U%7P.5%COZ8(^3TRD)7^^3:!$D9>^+EP
M@ "  (4P<9)30'AJ<I96\VJE<[-:>%NE=-A=R4M>=?=@YSF7=PYCNR69=_EE
MUPNZ>L1F @  @ !UPH/';=)<#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA
M=")I)"4+=,AJM@N-=_=JJ@  @ !YX8)P:EUDW772; %G%VA8;8-I,EF-;NYK
M*4F8<$!L_S@C<5YNGB2"<;QOL@ME=8)OB@  @ !]@($.9S-ML'1P:0QO-V<
M:K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "  '^Z9')V
M@'-(9G-W8V7<:#YX(E=@:=UXP4?/:UIY5#:D;'AYTR-M;#EZ%0L*<9MZ90
M@ "  'Z@8AU_67(W9#E_FF3<9AM_K59P9]!_HT;T:51_F#8&:E]_F"+W:<I_
MHPK?<!A_QP  @ "  'V\8"B()G%>8EJ'RF0/9$R'-%6N9@V&AD8]9YB%ZS5P
M:).%@B*D9Z2%B@K+;L^$0P  @ "  'T*7I&0Y7"S8-2/]F-D8M".NU4,9)2-
M:T6?9AZ,4#349PJ+I2(N9=B+Z0JS;>J'/   @ "  'R+75>9DG R7ZB8(&+;
M8:662E2$8V24844I9.62UC1X9;Z2&R')9&*140IK;F2'"P  @ "  'C]>>Y2
M_FT$>F)6CV ->P!9]E'7>[!=*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0
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MGF=O;(]]$UK:;<]]6DTR;N)]?CYJ;\Y]G"X <%)]O1KA;XA]P@28>#Q^@@
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M3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@
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MLUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "
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M8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP  @ !S9
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MRU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP  @ "
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M0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI   @ ![/
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M,T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![   @ "
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MZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "
M@ "  $3%E9-OOCM*E0IPIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y
M9P  @ "     @ "  $0[D\)VG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"
MC])XFP  A+)]R@  @ "     @ "  $/)DD%]D#IMD?9][3 RD4]]^"3#D(A]
MVA="D'-]R A2C?!^>   @T6     @ "     @ "  $. D02$QCHED,Z$]"_Q
MD#*$LR29CUF$91=*CP6$APB%C%F#6   @G&     @ "     @ "  )[[4]5-
MU8_(5PA2'8 $6B)64&]<72Q:8UVE8!E>44J_8K5B$39Q9&-E@1Y?8Y9G] %[
M?8!K&9S13H58"(X44BY;;WZ$5;)>OFX(61%A\EQO7$-E!DFK7P=G]C6 8)AJ
MGQVM8#)L=@&+?61OSYK:2:QB/HP[3<!DN7SO49QG(FR*54%I>UL@6*AKODB-
M6XIMZ#2:7/-OVAT.74IQ) &:?4MTXICH13QL9(IK2;-M^7LR3=1OB&L?4;EQ
M#5G:559RA4=^6$YS\#/(685U-!Q_6MIV!@&F?39YBY<*039V>(C+1@IW.'F^
M2GEW]6F]3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F
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MF8/56+M:_G4M6[9>2F5_7HUA=E2C83%D>$* 8VIG2BZY9%UIMQ9.9F!JV@
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MGGQ^1P:'#6Z72T2&;5^>3QZ%S4^44GZ%0SY85-2$WRN;5$R$Q!157:*$^@
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M1G>T6UMBWVHM7AQE8UM<8*-GQ4MI8NAJ SH+9*%L#2:Y9))MF0X3:X=MQ0
M@ !ZBX*[5#!I:7875WEK0FB56G1M"UH473!NNDH_7Z!P2CD4855QM"7Y8,AR
MO0VX:7ARSP  @ !^(X$R4&MRB'2J4_1SJF=!5RETN5C46@]ULDE<7)]VG3A,
M7DMW<25G78-X"0U^:3%X.@  @ "  '_K32%[IW. 4.%\%V8V5$=\;U??5U9\
MM4A[6?9\^3>R6Y!]0R3V6LQ]B0U2:7Q^"0  @ "  '[A2DV$M'*.3CR$>&5;
M4<J$&5<85/B#L$? 5Z6#63<962:#*22F6)&#1 T\::&#$P  @ "  'X31_6-
MI7'23 J,PV2J3[:+LE9W4OB*G$<G5:J)N#:$5PJ)*R0W5L*)8@TE:<B'-@
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MTVN:7MIIOE[D841KEU$[8W)M6$(794MNZS%M9F5P11Y89=YQ 0<.=!-QS@
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MFF<M4>V1HEJP5/602TTO5X*.XCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0
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M1E^X8V9OI%.[961P[4;*9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@
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M6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>   @ !EG0
M@ ![M&-%=<)4WUBH=L%8 DS]=[I;!4 J>*1=V#'(>8)@4R$<>F=B$0RT?*QB
M/0  @ !J2   @ !^]&'Q<:=<@U==<NY?%TON=!)AD#\O=0]CUS#Z=>9ET""!
M=GAG'@Q\>4%G&@  @ !O5@  @ "  &"P;=5D,E8;;U%F-$JP<)=H'3XW<:QI
MWS ><GYK61_5<K-L/PPP=EAL(   @ !TT0  @ "  %^$:EQKZ%4#; 1M7TFD
M;6ENO#TL;HMO\R]X;T]P^1]+;QUQB O^<]!Q;@  @ !YL@  @ "  %YV9T9S
MLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P  @ !]TP
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M?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@  @ !M\0
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M"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P  @ "
M@ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>**
M)P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00
M;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]4
M1!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94BS>U
MBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%A?I8
M9T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !VB
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M;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "
M@ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "
M    @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2
MF;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!6
M9A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>
MDCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;
M_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6
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M)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "
M@ "     __\  /__  #__P  ;69T,@     $ PD   $
M   !                     0   0   @   B0$'07:!VD(V0HV"X4,QPW_
M#S$07A&+$K<3XA4+%C(75QAY&9@:M1O2'.\>)1]9((<ALB+:(_\E(R9$)V8H
MABFG*L<KZ"T(+B@O2#!I,8DRIC/"--XU^S<8.#4Y43IM.XD\I3W"/MX_^$$1
M0BE#0D1<175&CT>I2,-)W4KW3!)-+$Y#3UE0;U&&4IQ3LE3)5=]6]E@-62-:
M.EM17&9=>%Z*7YM@K6&^8L]CX&3Q9@)G$F@C:3-J0FM2;%YM9VYQ;WIP@W&,
M<I1SG'2C=:IVL7>W>+UYPWK(>\U\SGW-?LQ_RX#)@<>"Q8/"A+^%NX:WA[.(
MKHFIBJ2+GHR8C9&.AH][D'"19))8DTR40)4SEB:7&9@,F/^9\IKDF]:<R)V[
MGJV?GZ".H7RB:J-7I$6E,Z8@IPZG_*CJJ=>JQ:NSK*&MCZY]KVNP6;%'LC:S
M)+02M0"U[;;:M\BXM;FCNI"[?KQKO5F^1[\UP"+!$,'^PNS#VL3'Q;7&H\>1
MR'[);,I9RT3,+LT8S@'.Z\_5T+[1I]*0TWG48=5)UC'7&-@ V.;9S=JRVYC<
M?=UBWD??+. 0X/3AV.*[XY[D>^57YC/G#N?HZ,'IFNIQZTCL'>SP[</NEN]V
M\%7Q,_(/\NKSP_2<]7/V2?<>]_/XQOF5^F'[*?OK_*?]7/X+_K3_6O__   !
MZ .G!2P&A >_".<*! L6#!P-'@X<#QD0%Q$4$A 3"Q0$%/P5\Q;F%]@8S!G6
M&MX;X1SA'=\>VQ_6(-$ARR+$([XDN"6S)JXGJBBF*:(JH"N>+)TMFBZ5+Y$P
MC3&),H8S@S2!-7\V?S=_.( Y@CI_.WX\?#U\/GP_?4!_08)"A4.)1(U%DD:8
M1YI(FTF=2I]+HTRF3:I.KT^T4+I1P%+'4\Y4U5775ME7VUC>6>!:XUOG7.I=
M[5[Q7_5@^&'\8P!D V4!9?]F_&?Z:/AI]6KS:_!L[FWK;NAOY7#A<=YRVG/6
M=,UUPW:Y=Z]XI7F;>I![A7QZ?6]^9']8@$V!08(U@RF$'(40A?Z&[8?;B,J)
MN(JFBY6,@XUQCF"/3I ]D2R2&Y,*D_J4Z979ELF7NIBGF9.:@)MMG%J=2)XV
MGR6@%*$$H?6BYJ/8I,JEO::QIZ:HFZF1JH>K?ZQWK6^N9Z]@L%JQ5+)/LTRT
M2;5&MD6W1+A%N4:Z2+M*O$Z]4KY7OUW 8\%JPG+#>\2$Q8K&D,>6R)W)I<JM
MR[;,O\W(SM+/W-#FT?'2^]0&U1+6'M<JV#?91-I1VU[<:]UYWH;?E."<X:+B
MJ..MY++EMN:ZY[WHP.G#ZM3KY>SU[@3O$O @\2SR./-#]$[U6?9C]VKX;OEO
M^FS[9/Q6_43^+_\7__\   (% ]@%: ;&" 8),@I2"V4,<@UX#GH/>A!Z$7D2
M=1-P%&@57A92%T48-QDI&C0;/1Q '3\>.A\T("PA(R(9(P\D!"3Y)>XFXR?8
M*,PIP2JV*ZLLGRV3+H<O?#!P,60R63---$$U-C8K-R$X%CD+.@ Z]COM/.,]
MVS[3/\M Q$&]0K=#LD2L1:9&H4><2)=)E$J02XY,BTV*3HE/B%"(48E2B%.(
M5(A5B%:)5XI8BUF-6H];D5R3799>F%^;8)UAGV*@8Z%DHV6D9J9GIVBH::EJ
MJFNJ;*MMJVZK;ZMPJ7&H<J5SHW2@=9UVF7>5>)%YC'J'>X)\?'UV?F]_:8!A
M@5J"48-(A#Z%-88KAR&(%XD,B@**]XOMC.*-V([-C\.0N9&ODJ63G)22E8F6
M@)=XF'"9:IICFUZ<69U5GE*?4*!/H4^B4*-2I%6E6:9?IV:H;JEXJH*KCJR<
MK:NNNZ_,L-^Q\[,)M""U.+91MVRXA[FDNL*[X;T!OB&_0\!EP8?"JL/.Q/'&
M%<<YR%[)@LJFR\K,[<X0SS+05-%TTI33LM3/U>O7!M@>V3;:3-MAW'3=A]Z8
MWZ?@L^&^XL?CS>31Y=+FT.?,Z,3INNJLZYOLA^UO[ECO7/!;\5;R3/,]]"KU
M$O7V]M;WL_B-^6+Z+_KT^['\9OT1_;/^3?[A_W'__P   =D#C04)!E0'?PB6
M":$*I N?#),-@@YP#U\03!$W$B$3"1/P%-85NQ:?%X,8@1E]&G0;9AQ5'4$>
M+!\7(  @ZB'3(KTCIB20)7HF9"=.*#DI)2H0*OTKZBS7+<0NL2^>,(PQ>3)G
M,U4T1#4R-B(W$3@!./$YXCK3.\0\M3VF/I@_BD!]06]"8D-51$E%/$8P1R-(
M%TD+2?]*\TOH3-Q-T$[%3[E0K5&A4I53B%1Z56U67U=16$-9-5HF6QA<"5SZ
M7>M>W%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR
M5G- ="EU$G7[=N1WS7BV>9YZAGMN?%9]/GXE?PU_](#;@<*"J(.-A'*%5X8[
MAR"(!8CJB<^*LXN8C'V-8HY'CRV0$I#XD=Z2Q).JE)&5>)9@ET>8+YD8F@&:
MZIO4G+^=JIZ6GX.@<:%?HD^C/Z0PI2*F%:<(I_VH\ZGJJN*KVZS5K="NRZ_'
ML,2QPK+!L\&TPK7%MLBWS;C3N=NZX[OMO/B^!+\1P"#!,,) PU+$9L5ZQH_'
MILB^R=;*\<P,S2K.1\]CT(#1G]*_T^#5 ]8GUTS8<]F;VL3;[]T:WD;?<^"A
MX<_C N1-Y9GFY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^
MN____P"  (  YD]_SG]8S9E_J'[-M-I_F7YYG!1_HWYE@TQ_QGZ%:H5__G[
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MT!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2 KXXZ,KF
MP8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY57J> 5)?1
M2&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N
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M68L\C0R!W(FG>9^!?X@V9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A
ML4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6:
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M.*2 MH9O*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B
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ME$A_WX @A5-_KH #==Q_AW_B9=I_>G_+5<=_AG^^1@5_IG^U-J9_\7^L*&N
M7G^@H7]^PHCODTM^EH@OA%E^<X=)=,Q^789*9/I^9(5-50E^DH1817U^SX-9
M-E]_-8)'*&M_OX$8H)9]LI&SDEQ]D9 Q@W%]=8YV<_1]:HR79#E]?HJQ5'9]
MMXC'119^#X;1-BA^DX2Q*&M_.()EG]E\V9I2D9Y\PI@,@K5\IY5V<SY\H)*Q
M8Y5\PH_@4_5]"HT!1,5]:XH+-?Y^"8;B*&M^QX.&GTI\-*+(D09\))^[@A1\
M!IQ#<J)[_)B,8P-\))3(4W-\@)#R1&I\\8T -=A]F(C4*&M^:X1[GNA[P*L,
MD)%[LZ<T@8Y[C:+1<AI[>9X>8HU[H9E?4Q=\!)2.1!Y\AX^>-:=]0HIY*&M^
M(85%F)V.,63IBZF,KF=L?=V+:&G0;SJ*06PH8!V)'&Z14-Z'^7$@0?J&UW/9
M,W*%R7;F)?^$U7IAE^B,:FUYBO"+(6\:?1")\G"N;G^(TW)%7WJ'O'/O4%F&
MKW6Y09B%J'>A,T:$N'G%)B&#X'PPEQ>*M'7?B?6)DG:Y?#&(='>*;::':WA?
M7L.&:WE&3\N%>GI$03:$D7M5,QV#P7R')CZ#!WW=EB*)(WX:B/F($'Y'>R:'
M#'Y?;-F&$'YQ7A*%+GZ/3TJ$6WZX0.:#D7[J,OV"XW\E)EB"27]FE36'RX97
MB!"&R(72>D>%TH4K; *$Y81N77R$#(.Q3MN#5H,#0)Z"JX)0,N""'X&3)FZ!
MIH#(E&N&R8Z/AV.%T8U:>:"$WHOL:TF#]HI67,^#*8B\3EJ"?(<I0$>!ZH6.
M,KF!>8/4)H"!'(( D\>%^Y:?AK>%#92V>/6$&9)Z:J:#,Y *7#>"<8V33>.!
MT(L80 B!0XB0,J" [(7=)H^ J8,,DT>%7YZ!AC*$>9OB>&B#@9C3:A^"DY5^
M6[F!U)(A36Z!1HZ\/[B QHM*,HJ >(>I)IR 2X/ODNR$[Z8ZA<F$#J+E=^^#
M#9[W::6"$YJO6U.!3Y9D32. QY(4/X. 68VU,FV 'HDM)J:  (2IC"B7 V2M
M@!Z4T&<@<UF2U&F#9=^0Z&OC6 2.ZVY72AF,X7#V/*"*S7/ +YR(O';?(\R&
MMWICBXZ5>&S"?Y&3;FY@<L&1=V_]95F/AW&F5Y*-CW-G2<*+EW5,/&>)F'=3
M+Y6'H7F9) Z%M7PABN:3VG2D?L21\'6)<A"0!G9O9*R.)7=A5P6,0'AK25J*
M87F0/"F(?7K-+XV&HWPR)$B$TWV[BAZ25WQ=?>F0?'R><2>.IWS58_:,U'T2
M5FF+"WU>2.J)1GV\.^>'?GXF+X"%PGZE)'F$#G\QB561%H0"?2F/1X.E<&N-
M>X,Q8S>+M8*Q5>>)\H(S2(6(28''.ZV&FX%8+W>$^H#L)*2#98!^B*V0#XNJ
M?(*.3HJI;\B,B8E]8J2*PX@R56:)"8;D2#N'8X6?.X&%SH1:+VV$38,#),B"
MUH&BB"6/1Y,M? R-DI&,;U2+QX^>8B>)^XV!5.N(2HMB1]J&M(E%.U6%(X<C
M+V2#NH3D).6"8(*=A[F.LYI^>YZ- 9@X;N&+,96%8;J)7I*15(6'KX^:1WR&
M)XRA.QF$HHFE+UV#0H:))/V" (-OAVB.1J&>>T:,E9ZR;G^*O)LR85F(WY==
M5#2'+).'1T*%J8^Q.O&$,XO8+TV"YX?J)1"!LX0;@$*@#&1;=/:=.&:_:22:
M@FDA7,N7PFN-4"V4W6X50Y21VW#+-X".OW.K+ .+E7;>(=B(;GID?[J>NFO]
M=)";]&V9:+V9,F]!7':69'#_3^N3?W+<0VJ0BG3B-W.-@'<*+"2*;7ES(CB'
M7WP2?S:=,G-C<_&:@W13:#J7QW5.6_B5 G9A3XF2+'>10RN/37CC-UN,6WI.
M+#Z)8WOE(HR&<GV<?IZ;M7J;<TF9$WKS9X>6:'M,6W"3L'NU3Q>0\GPT0N".
M*WS)-SN+4WUO+$^(>'XP(M6%I'[_?@2:=H'!<K&7X(&(9N^5/8%"6MR2C8#V
M3K./V8"[0I:-*H"0-QJ*:8!J+%R'J8!0(Q*$]8 [?7V9?HC=<C26\8@29GB4
M3X<B6FB1H(8?3DV.\(4>0F6,0(0H-P>)EX,X+&F&]8)!(T:$88%.?1*8KH_.
M<<>6*HYL9@N3B8S-6@"0VXL,3?6.,HE(0BV+C(>&-P*(WX7'+'F&68/](W"#
MYX(Y?+V8'9:5<9>5GI2H9=N2[Y).6<:0*H^U3;J-?8TB0>Z*[8J8-MB(58@5
M+("%VX6!(Y*#A(+]?'R7M)TH<5>5+)JF9962<Y>,67^/II0A38&,]I"^0<>*
M:HUE-L.'XHH7+(&%?8;#(ZZ#-8.==.NI4&/H:D^EXV8]7V"B<FBA5!^>T&L>
M2+F:[FV^/6^6V7"0,KZ2GW.,*,".2';9("*)^'IB='6H-6LC:A"DN&RZ7RVA
M)&YN4_^=:G!$2*F9@W)"/725>71N,MV13W:]*0>-#GE,()Z(VWP#=!6FO'(4
M:9^C27,-7MF?M70<4[&;_7532'28(W:M/5^4+G@P,NN0&GG.*4*+]GN;(0J'
MXGU^<ZRE/'C1:2>AU'D_7E>>3'FY4U::HGI/2"V6W'L%/3J2_GO6,NZ/!'R\
M*7"*_7W!(6>'"W[3<T"C]G]\:,"@EW]G7?"=%G]/4NV9<G\Z1^Z5MG]!/121
M[W]>,NR.#G^%*9:*)'^^(;6&57__<N&B^X8>:&Z?H(6%7:.<'83/4J.8>80.
M1Z^4PH-://B0_X*X,NR-,X(@*;2):(&.(?>%O($$<I*B-XR/:"^>VXMU76J;
M4HH<4FB7JHBF1W:3^H<Z/-F00879,O2,=H2#*=*(QH,J(BV%/8'A<EFAF9+%
M9_N>/)$B73*:KX\D4C&7 HSV1T235(K//*F/JXBO,N6+Y(:A*?"(/X20(EF$
MUX*9<BNA,)C59_V=R):]72^:)I0$4AR68)#\1SN2IHX,/+2/ XLT,O:+7HAU
M*@2'VH6Y(GR$A8,O:@FRUV-J7_RNZ&6I5>&JN6@-2["F)&J;08"A*VU8-XF;
MZ'!-+CV6='-K);V0V7;3'J"+7'I@:9BQ\FI 7]>MTFO+5=:I:6V)2[JDL6]X
M09R?KG&;-[F:='/S+H65#W9P)BB/C7DH'S:*,'OU:5NPA'#"7Y.L8/_B__])
M0T-?4%)/1DE,10 ""7&[5:RG\G+;2YFC-70W09*>/'7!-\N9%7=Z+KB3QWE1
M)H*.8WM6'[>)*WUD:22N^7<(7T^JVW>#55^F=G@:2VNAR'C?07:<X7G0-\V7
MTGKC+MV2GWP.)LR-7'U;(">(2WZJ:.JMHGTY7QRIBWU!52VE*7U42S2@@7UW
M062;J'W$-\Z6L'XN+OR1EWZG)PN,=G\V((6'C7_*:+>LF8-C7P"H>H+Y51>D
M%8)[2QZ?;X'^04^:GX&7-]25L(%,+QF0L($3)T&+L(#F(-.&[H#":(ZKRHE;
M7O&GGHA^50ZC,(=J2Q*>BX9%04.9Q(4Q-]>4XH0Q+S>/Z8-$)W*+"8)B(12&
M:X&3:&ZK+X\;7N^F\(W)50^B=8P;2PV=RHI%03B9"(B!-\V4.8;0+T&/3X4W
M)YB*?X.K(4B& 8)!:%JJOI2A7O:F8I+951>AV)"(2P^=)XW]03R89XN#-]N3
MHXDD+TR.S8;?)ZJ*%(2V(7*%K8+-PL]H#F#@L4IJ3F._GU%L>6:,C,)NF6E-
M><-PPVP39I9S"&[P4Y]U<G'R0.AX('4\+PA[+'D"P.YE16M_K]-GR&U%G@9J
M*F\'BY]L@'#,>+QNXW*:9:YQ9'1_4MAT"G9\0%5V]7BQ+L%Z/7LYOREBV'8$
MKB)EAG:WG)5H&'=LBD5JFW@V=X]M,'D09+%OYGG\4A%RQ'KW/\QUYWP1+H%Y
M97U3O6E@L(!9K&IC@X .FNIF-G_,B-UHXW^6=E)KJ7]Y8ZYND']G44YQH7]9
M/TMT^']3+DIXI7],N\]>V8J,JN9AR8E9F7%DFX@EAW9G9H;T=2]J3X7.8KQM
M9H2[4)MPI8.=/MET*()O+AIW_H$<NH%=7I2KJ:E@8Y*7F$-C2)!LAE9F*XX[
M="EI,(P/8>AL9(GG3_YOS(>U/G1S=X5;+?)W;H*_N7=<+9ZFJ*Y?09NNETUB
M,)B)A6ME(Y53<U-H09(A83=KD8[G3WQO%(N2/B-RX8@++=!V]H0PN+%;1*AN
MI_!>8:2,EHMA4Z!HA*ID3)PE<IMG>Y?G8)AJY9.?3P=N@H\M/=QR9HIV+;5V
MDH5MN#-:I+'JIW!=PJT+E?M@KJ?<A!)CI**-<@UFV)U#8"!J4I?K3I]N I)B
M/9%Q_HR.+9]V0H9WM7YOKF!>I:-Q)F-CE19RG69"@\=T&&D+<?5UHVO:7_1W
M26[%3C%Y$7'8/+A[%G4X+"U]<'D7M!AM$VIYI)1NSFQPE!EP=&Y2@MYR&' O
M<1]SSW(57SMUJ'0439YWIW8R/%1YZ7B)+ 1\?GLVLIEJOW1NHOQLIG5FDJUN
M='94@8EP17=&;_QR*WA&7DIT.'E:3.)V:WI_.]MXX'O%*^![IGTVL0QHKWXT
MH6QJMGY&D2ALIGY,@$9NF7Y1;M]PL'YE765RZGZ&3#IU37ZM.W-W]'[?*\!Z
MYG\4KYMFZH?AH UI#(<:C])K&88\?O]M*H52;=YO7X1N7(]QQX.82Z!T58*Z
M.Q=W)H'/*Z5Z0(#)KF]E?I%_GNIGLH_@CKQIT8X8??AK^8PZ;/!N2(I;6]5P
MRHA^2QES@(:9.L9V=X2/*XYYLH)1K8%D6)KYG@%FFIA_C==HPI7'?1]J^9+P
M;"QM89 66S=O_HTT2JQRRHHZ.H9UXX<3*WMY.X.HK-!C>*1 G4]EP*#GC1UG
M[)TY?&AJ*)E@:X!LH)6%6J%O6)&?2D)R/8V8.DYU:8E4*VMXV83.K%]BWJT_
MG-!E)JC^C(UG2J12>])I@Y]R:OAL IJ36C1NQY6G2>-QPI"4.@IU!XM!*U]X
MBH7#J(=WB& &FBYX,&,;BOAX[V8#>N)YPFC1:C]ZIFNG66U[HVZ>2.5\O7'
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M,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L:
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M<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F [H4!(^^
MHX*C?G^& 9L4<V6%(ICD9Y^$%Y826W6# Y+F3T^"'(_!0U>!<8RE. . X(F/
M+5. B(9F) 6 48-5>#.99E\I;;^7,F((8L&5(63I5SJ3!6?62V^0Q&K>/Z^.
M;&X7-'V,"'%]*>F)JG4](*J':'E0=XZ7N&:?;4:5I6C%8DZ3D&KW5N*1;6T\
M2S*/,V^?/Y",\7(L-'Z*IW3?*A>(:7?:(1*&1GL-=O>5X6WA;)F3[V]E8<*1
MZW#P5F"/UG*12M.-LW1*/UB+CG8H-'*)97@C*CR'2GI3(6V%2'RD=DZ4('3Y
M:^*2077I80*05';85=*.5G?32F&,47C@/Q**2WH'-%F(1'M#*E6&3'RC(;N$
M;7X3=::2IWP :T"0V7QA8&6.^7RS53N-!WS]2?^+%'U7/LV)+WW$-#R'1GX]
M*F:%;G[((?Z#L7]:=1.1?H+\:KF/OH+/7^F-XX)[5,6+]H(029F*#H&J/J*(
M+X%5-"N&9($+*G6$KH# (C6#%(!W=)N0AHG*:D..U(D+7W>,_8@,5%F+%(;G
M23V)-H7#/F>'9X2J-"N%GX.;*HB$"8*!(F."DH%J=#R/T9!L:@B.*8\H7S^,
M2HUT5!Z*3XM]20F(;XF2/BV&MX>V- .%!H7I*I2#@80+(HB"*((U<_*/29;6
M:<&-GI4(7O6+N9*:4]F)N8_72-.'V(TB/@N&)8I_,_:$AH?L*IN#&852(J:!
MTX+;;4*B;UZP8WB?I&& 65J<UF1C3N:9VF=B1$R6HFJ'.=&306WB+_6/R7%I
M)L^,2W5"'P>(\GE4;*F@_&6]8QR>-&?B60^;4&HC3K:81&R#1#:5#&\*.=B1
MO''!,!R.6W2>)Q^*^W>^'XB'PGL";#&?.FR-8IF<A6X=6*R9K&_"3EZ6J7&)
M0_Z3A7-P.<603W6!,#&-#'>Q)V&)SWH4'_>&N7R*:[6=?',P8A&:V'0Y6!V8
M$75,3?R5(G9W0[22&7>^.:*/ 7DC,#F+WGJ@)Y6(Q7Q!(%>%U7WJ:SB< 'G#
M89R9;'I*5ZV6KWK,38V3RWM00W:0TWON.7Z-VGRE,#F*U7UJ)[V'WGY%(*F%
M$W\B:LJ:UH!+83V83(!25UB5DH Z34"2LH 40S:/Q'_\.6B,TW_\,#R)ZX (
M)]Z'%H ;(.V$<( P:FV9Z8:D8/.79H8L5Q>4JH5T30&1R82>0OF.Y8/3.4:,
M X,9,$>)(8)N)_Z&:X&_(26#Z8$5:B>9*HR_8+*6K(O#5M:3\(II3,:1#8C?
M0L>.+8=>.16+787K,#>(A(2.*!Z%W8,K(5*#?('4:>^8HI*R8*>6(I%)5LN3
M68\[3+*08(S<0L6-=8J9.2J*K8AS,%"'](9G*#:%;X1:(7:#)8)P8JRKREX:
M67VH<V#74#>DXV.]1M&@\6;0/6F<I6H9-#B8'6V=*[63=W%-(_J.QW5%'96*
M5'E58A6JD&3!62^G(F;A4 2C9VDP1KV?7&NO/7&;"FYB-%^6CG%+*_R1^W1:
M)&B-:'>C'BV)%GKX8;VHWFLD6-2E=&R\3\6AP&YX1HN=N'!J/5V9=W*'-&V5
M$W35+#&0G'= ),6,+'G9'K"( GQS87"G&G%66'VCO')S3VF@%7.I1E.<(W4)
M/3N7^G:2-&V3M7@]+%>/7WH!)1&+%7OF'R"'%7W%82.EDG=X6#BB07@A3RF>
MHGC31A.:N7F4/266I7I^-&R2?7N&+':.1WR=)5&*(WW*'W^&2W[O8-VD77V2
M6 JA#GW*3P:=<7WM1?29C7X0/0V5A'Y*-'61:7ZD+)6-47\.)8B)4G^"'\^%
MHW_P8*.C9H-Z5^J@%8-!3O"<=8+11>"8E()///N4EH'A-'60BX&)++2,?H%%
M);F(HH$&(!"%&(#*8':BJ(DJ5]B?3XB 3N6;J(=X1=:7Q(9*/.Z3S(4O-&B/
MUX0J++R+VX,^)>"($8)7($2$J(%_8%FB&(ZD5].>KXV'3N*:_XOA1=.7%XH
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M]GPC31YNQGS%/'ERZ7V"+0!W8WY;L$%7JX/$H)=;18-$D&!>O(+!?Y]B+X)
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MSWA!A?E^T&*X>JE^Z&5I;H=_#F@+8<E_06JN5)]_@FUC1V9_VG ].J: 2G-
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MB6;&44R,)&F21G2*KFQ].[&).6^7,8:'R'+9*!2&<'9E( F%/GHC;O:-_FB
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M8IJ%[(G$6+Z% 8BJ3I2#](=51'6#!H83.HJ"283G,4N!GH/2*,.!*H*K(9F
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M?8+&C']8?)J5@%E;^9@W<Y!?695V9DIBTI*&6-!FDH^;2V1JHHRR/HIN[(G
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M6[M]RW[24K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?)P1_B7_<()V
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MV'O2,]5U2WS8*I!XYGWR(K5\8'\/<%-@:W[29L5CG'\97,=FN7\U4F5IX']
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M3)1[N'> 14)\>WAT/=E]#'EN-GM]EWJ#+VM^,GNR*0A^UGSN(T1_JGXA'K"
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M"7H^3'B+$6'01>J*?&2D/S&)KV>/.'N(K&J?,<F'B6W@*V6&;W%&):^%:G3
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M(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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ML[MMLZNU>+NEL8#!GZZ$QIBKA,J0J(3.B*:&T8*DC-. I)+3@*22TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"D
MDM/_I3<J_Z%$0?^E15'^K$)?];0_;.V\/GCGQT"!X-9&A\G-49JXPF"JK+IM
MM:6U>+R@L8#!FZZ$Q96LA,B.JH3+AZB&SH*GB\]_IH_0?Z:/T'^FC]!_IH_0
M?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]#_
MI38J_Z)#0?^G0U#_KC]=][<\:?#".W/FT#]YT]D_BK[+49VOP&&LI;ENMJ"U
M>;R<LH' F*^$PY*NA,:,K(7(AZJ'RH*IBLQ_J8[-?ZF.S7^ICLU_J8[-?ZF.
MS7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLW_IC8J
M_Z)"0?^I0$__LCM;^;TX9>S+.&W<W#5XQ]8^CK/)4J"GP&.MG[EPMIJU>KR8
MLH&_E+&%PH^OA<2+KH;%AJV'QX*LBLA_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^K
MC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<G_IS4J_Z-"
M0?^L/$W_MS97\L4S7^'6-F/-XS%\NM,_D:G(5*&?P&6MF;IRM9:V>[J4LX*^
MDK*%P(VQAL&)L(?#AJ^(Q(*NBL6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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M-6R,Y41ZA-Y3@X#98HI\U6R/>-)QDW70=95SSWB7<<YZF'#-?)EOS7Z:;LR
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M047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ# <*R9NGFTE+:
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MOKY]HK^]>JC O'FOP;1YL,&P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M9UU:^&M?6/=N8%?W<6%6]G1A5?9V8E3U=V-3]7EC4_1\9%+T?F11](!E4?2
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MM'R5N;1\E;FT?)6YM'R5N;3_E2P._Y4]'O^@/2?_J#LP_[ \-_VX/SSQP41
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M8_\Z)%S_0BA6_TDL4?]/+T[_53%+_UHS2/]>-4;_8C9$_V8W0_]I.$'_;#A
M_W Y/_]S.C[_=SH]_WL[//]^/#K_@SPZ_X8].O^&/3K_ACTZ_X8].O^&/3K_
MACTZ_X8].O^&/3K_ACW_=20&_W8U$/]W0QS_@$HG_X52,_^&63[_A6!(_X%H
M4O]\;UK\=WEB]W.#:/1OC&[Q;)-R[VJ:=>UGH'CL9:5ZZV2J?.IBKWWI8;5^
MZ&"[?^A?PX#G7\N!YE[5@>!@VX'78MZ!U&/?@=1CWX'48]^!U&/?@=1CWX'4
M8]^!U&/?@=1CWX'_=20&_W8U$/]W0QS_@$HG_X52,_^&63[_A6!(_X%H4O]\
M;UK\=WEB]W.#:/1OC&[Q;)-R[VJ:=>UGH'CL9:5ZZV2J?.IBKWWI8;5^Z&"[
M?^A?PX#G7\N!YE[5@>!@VX'78MZ!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!
MU&/?@=1CWX'_=20&_W8U$/]W0QS_@$HG_X52,_^&63[_A6!(_X%H4O]\;UK\
M=WEB]W.#:/1OC&[Q;)-R[VJ:=>UGH'CL9:5ZZV2J?.IBKWWI8;5^Z&"[?^A?
MPX#G7\N!YE[5@>!@VX'78MZ!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?
M@=1CWX'_=B0&_W<U$/]Y0AS_@DDG_X=1,O^(6#W_AU](_X-F4?]^;EK[>7=B
M]W6":?1QBF[Q;9)S[FN9=NQHGWGK9J1[ZF2J?>ECKW_H8K6 YV&\@>=@Q(+F
M7\Z"XU_7@]QAVX/28]V#SV3=@\]DW8//9-V#SV3=@\]DW8//9-V#SV3=@\]D
MW8/_=R0&_W@U$/]\01S_A4@G_XI/,O^,5CW_BUU'_X=D4?^";%K[?'1B]WA_
M:?-TB&_P<)!T[6R7>.MJGGOI9Z1^Z&:J@.=DL(+F8K:#Y6&^A.5@QX7E8-.%
MW6+9A=-DW(7,9=N&R67;ALEEVX;)9=N&R67;ALEEVX;)9=N&R67;ALEEVX;_
M>"0&_W@U$/]^0!O_B$<F_XU.,?^/53S_CEM&_XMB4/^&:5G\@'%B]WM[:?-V
MA7#O<HYU[&Z5>>IKG'WH::. YV:I@N5EL(3D8[>%Y&+ A^-ARX??8M6'U63:
MA\UEV8C&9]F)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G$9]B)Q&?8B<1GV(G_>2,&
M_WDT$/^ /QO_BD8F_Y!-,/^24SO_D5I%_X]@3_^*9UG\A&YA]WYX:?)Y@G#O
M=(MVZW"3>^EMFW_G:J*"Y6>IA.1EL(;C9+F(XF+#B>)BT(K89-B*SF;8BL=G
MUXO :-:,OFG6C+YIUHR^:=:,OFG6C+YIUHR^:=:,OFG6C+YIUHS_>2,&_WHT
M$/^#/AO_C44E_Y-,+_^543K_E%=$_Y)=3O^.95C\B&MA]X)T:?)\?W#N=XAV
MZW.1?.AOF8#F:Z&$Y&BIA^)FL8GA9+N+X&/'C-QCU(S/9M:,QVC5C<!IU(ZZ
M:M2.N&O4CKAKU(ZX:]2.N&O4CKAKU(ZX:]2.N&O4CKAKU([_>B,&_WLT$/^%
M/1K_CT0D_Y9*+O^73CC_EU1"_Y5:3/^285;\CFE?]H=P:/*!>G#M>X5WZG:.
M?.9QEX'C;9^&X&JHB=UGL(S:9KN-UF7'CM%FU(_':-./OVK3D+EKTI&S;-*1
MLFW2D;)MTI&R;=*1LFW2D;)MTI&R;=*1LFW2D;)MTI'_>R,&_WPT$?^(/!K_
MDD,D_YA(+?^:3#?_FE)!_YE82OR77U3VDV9=\(UN9NN'=V_F@(%VX7N+?=QU
MDX/7<9R'TFZDB\]KK([,:;61R6C DL=HSY._:]&3N&S0D[)MT)2M;]"3JV_1
MDZMOT9.K;]&3JV_1DZMOT9.K;]&3JV_1DZMOT9/_?",&_WTT$?^*.QG_E$$C
M_YI&+/^<2S7_G5 __YU62/B;75'QF&-;ZY-K9.2-=6W>AGYUV("'?-%ZCX/,
M=I>)QW*?C<1OIY' ;;"3OFR[E;MKR):V;<^6L&_.EJMPSY:F<<^5I7+/E:5R
MSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5RSY7_?",&_WTT$?^,.AG_ET B_YQ%
M*_^?233_H$X\^Z%41?2@6D[LG6%8Y9EI8=Z3<VK5C'MTSH6#?<A_BX3">I.*
MOG:;C[ISHY.V<:N6LV^VF+%OPIBM<,V8J'+-F*1SS9B@=,Z7GW3.EY]TSI>?
M=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI?_?2,&_W\S$?^..1C_F3\A_YY#*?^A
M1S+_HTPZ^*520_"D6$OHHU]4X9]H7=>8<&C.D7ATQHJ ?<"$B(6Z?X^+M7N7
MD+%WGY2M=:>7JG.QF:=SO9NE<\N;H'7+FIUVS)J:=\V9F7?-F)EWS9B9=\V8
MF7?-F)EWS9B9=\V8F7?-F)EWS9C_?B(&_X R$/^0.!C_FS\@_Z!"*/^D1C#^
MIDLX]*A00.RI5T?DJ5U0W*5F6M"=;FC'E75SOXY]?;F)A(6S@XR,K7^3D:E\
MFY6D>:29H7>MFYYWN9R<=\B<F7C*G)=YRYN5>LR:E'K,F91ZS)F4>LR9E'K,
MF91ZS)F4>LR9E'K,F91ZS)G_?B(&_X(R$/^2-Q?_G#T?_Z% )_^F1"[[J4DU
M\:Q//.FN54/AKUU+U:AD6<NA:V?"F7-SN9-Z?;*-@86LB(F,IH20D:& F):=
M?:":F7RJG)9[MIV4>\2>DGS*G9%]RIR/?<N;CWW,FH]]S)J/?<R:CWW,FH]]
MS)J/?<R:CWW,FH]]S)K_?R(&_X0Q$/^3-A?_GCP>_Z,_)?^H0BSXK4<R[[!-
M.>:T5#_=LUM)T*QB6<:D:F:\G7%RM)=W?*R1?H6FC(:,H(B-D9J%E9:6@IZ:
MDH"GG8]_LIZ-@,&>C(#)GHN RIV*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*
M@,N;BH#+FXJ RYO_?R(&_X4P#_^5-A;_GSL=_Z4])/^K02KUL$4O[+5,-..Z
M5#G8MUE(RZ]A6,&H:&:WH6]RKYMU?*>5?(2@D8.+FHV+D92*DY:/AYN:BX6E
MG8B$L)^&A+Z?A87)GH6$R9V%A,J<A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;
MA83+FX6$RYO_@"(&_X<O#_^7-1;_H#H<_Z<\(OZM/R?SLT0LZ;I+,.&_4C73
MNEA'Q[-?5[RL9F6RI6UQJ9]S>Z&:>H2:EH&+E)*(D8Z/D):)C)F:A(JBG8&*
MK9]_BKN??HK(GG^)R9V B,J<@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;@(C+
MFX"(RYO_@2(&_XDN#_^9-17_HC@;_ZDZ(/NP/23PN$(HYK]**MW#3S3.O59&
MPK9>5K>P962MJ6MPI*1Q>IR?>(.4FWZ*CI>&D(B5CI6"DI:9?I"@G'J/JYYX
MC[B?=Y#)GGF.RIUZC,N;>XS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;>XS+FWN,
MRYO_@2(&_XLM#O^;-!3_I#<9_ZPX'OBT.B'MO4 CY,9)(]?'3#/)P55%O;I<
M5;*T8V.HKFEOGZEO>9:E=H*.H7R)AYV#CX&;BY1\F)28=Y>=FW.6J)UQEK6>
M<);&G7*4RIQTDLN;=9'+FG61RYIUD<N:=9'+FG61RYIUD<N:=9'+FG61RYK_
M@B(&_XTL#?^=-!/_IC08_Z\U&_2X-QSIPSX<X,U%']'+2S+$Q51#N+];4ZVY
M86&BM&AMF:]N=Y"K=("(IWJ'@:2!C7NBB9)UH)&6<)Z;F6V=IIMJG;.<:9[#
MG&N<RYMNF,R:;Y?,F6^7S)EOE\R9;Y?,F6^7S)EOE\R9;Y?,F6^7S)G_@R$&
M_Y K#?^@,Q'_J3(5_;,Q%_"^-!?ERSL5VM0_'<O/23"^R5)"LL194:>_8%^<
MNF9KDK9L=8FR<GZ!KWB%>JQ_BW2JAY!OJ(^3:J>9EF>FI)ADIK&98Z?!F62E
MS9AGH,V8:)_-EVB?S9=HG\V7:)_-EVB?S9=HG\V7:)_-EVB?S9?_A"$&_Y,I
M"_^B, __K2X2^+@L$NO&+Q#@U3@+TMH]',742"ZXSU! K,I83Z#%7EV5P61H
MB[UJ<H.Z<'I[MW:!=+5]AVZSA8MHLHZ/9+&8DF&PHY1>L+"57;&_E5VQT)1@
MJM"48:C0E&&HT)1AJ-"48:C0E&&HT)1AJ-"48:C0E&&HT)3_AB$&_Y<H"O^F
M+ W_L2@.\L F#./0* ?4WS(+R=\^&;W;1RRQUD\]I-%63)G-7%F.R6)EA,9H
M;GO$;W9TP75\;<!\@FB^A(9CO8V)7[R7C%N\HHY9O*^/6+V^CE>^U(Y9MM./
M6K33D%JTTY!:M-.06K33D%JTTY!:M-.06K33D%JTTY#_B"$&_YPG"/^J)PK\
MN"$)Z<H;!=7>( 3)Y3 /ON,]';3A1BRHWDXZG-I52)'66U6&TV%@?-!G:73.
M;G!MS75V9\M\>V++A'Y>RHV"6LJ7A%?*HX95RJ^&5,N^AE/,U894Q-F(5<'9
MB57!V8E5P=F)5<'9B57!V8E5P=F)5<'9B57!V8G_C1T%_Z(E!O^P'P7RPA0#
MV=L. <GF( >]Z"\4LN<Z(J?E0S&;XTH^D.%02H;?5U1\WEY==-UE9&S;;&IF
MVW1O8=I\<US9A'99V8YY5=F8>U/:HWQ1VK!]4-N^?5#<TWQ0U.!^4=#@?U'0
MX']1T.!_4=#@?U'0X']1T.!_4=#@?U'0X'__E1H#_ZD? _NZ$@+4S0L R>8/
M KSM( NP[2X9I>PY)YKK0C6/ZDE!A>E02WOH5U-RZ%U::N=C8&3G:F5?YW)I
M6^=Z;%?G@FY3YXMQ4.>5<D[HGW1,Z*IU2^BU=DKGPW9*Z-UV2^3@=4ODX'5+
MY.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'7_G18!_[$2 =/#"0#'T0H N_(1!*_S
M(0^C\RX=F?,Y*H[S0C:$\TI!>_-227+S5U!I\UQ68_-C6EWS:5Y9\W!A5?-W
M8U+S?V9/\H=G3?"/:4OOF&M*[Z!L2>ZI;4CNLVU'[<!N1NW';D;MQVY&[<=N
M1NW';D;MQVY&[<=N1NW';D;MQV[_IP\ T[H' ,7'!P"ZU@D K?H3!J+Z(A*7
M^B\?C?LZ*X/\0S5Z_4P^<?U116C]5DMA_EM/7/YB4U?^:%94_6]84?MU6D[Z
M?%Q,^8-=2OB*7TCWD6!']IEA1O:@8D7UIV-$]+%D0_2U9$/TM61#]+5D0_2U
M9$/TM61#]+5D0_2U9$/TM636L@0 Q+X& +?,!@"LW D!H/\6")7_)12+_S(?
M@O\\*7G_13)O_THY9_]//U__54-:_UM'5?]A2E+_9TQ/_VQ.3?]R3TO_>%%)
M_WY21_^$4T7_BU1#_Y%50OZ85D']GE= _:980/RI6$#\J5A _*E80/RI6$#\
MJ5A _*E80/RI6$#\J5C&N 0 ML0$ *K3!0">\@T"E/\:"8K_*!.!_S0==_\\
M)6W_0BQE_T<R7?]--E?_4SI3_UD]3_]?/TS_9$%*_VE#2/]N1$;_<T5$_WE&
M0O]^1T'_A$@__XI)/O^02CW_E4L\_YQ,//^?3#S_GTP\_Y],//^?3#S_GTP\
M_Y],//^?3#S_GTRWO , J<L" )S; P"2_Q "B?\="(#_*A!U_S$8:_\X'V+_
M/B1;_T0I5/]*+%#_42],_U<R2?]<,T;_8#5$_V4V0O]I-T'_;C@__W,Y/?]W
M.CS_?#L[_X(\.?^'/3C_C#TW_Y,^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^
M-O^5/C;_E3ZJQ   G-(  (_G @"&_Q$"?/\;!7'_) MH_RL17_\R%U?_.1M1
M_S\>3/]&(4C_32-%_U(E0O]7)T#_6R@^_U\I//]C*CK_9RLY_VLL-_]O+#;_
M="TU_W@N-/]]+C+_@B\Q_X@P,?^*,#'_BC Q_XHP,?^*,#'_BC Q_XHP,?^*
M,#'_BC#_:B0$_VDR"O]L/A3_=D8>_WM-*?]\53/_>ET]_W9F1O]Q;DW_;7E4
M_VJ$6OYFC5_[8Y5B^6&<9?A?HFCW7JAJ]ERM:_5;LVST6KEN\UG!;O-8R6_R
M6-1P[UC@<.E9Y'#C6N9PW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH<-Q=
MZ'#_:B0$_VDR"O]L/A3_=D8>_WM-*?]\53/_>ET]_W9F1O]Q;DW_;7E4_VJ$
M6OYFC5_[8Y5B^6&<9?A?HFCW7JAJ]ERM:_5;LVST6KEN\UG!;O-8R6_R6-1P
M[UC@<.E9Y'#C6N9PW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#_
M:B,$_VDQ"O]N/A3_=T4>_WQ-*/]^5#/_?%P\_WED1?]S;4[_;WA5_VN"6OUH
MBU_[991C^6*;9O=@H6GV7J=K]5VM;/1<LV[S6KIO\EG!</)9RG'Q6-AQ[%GA
M<>9:Y''@7.=QV%WH<=A>Z''87NAQV%[H<=A>Z''87NAQV%[H<=A>Z''_:R,$
M_VHQ"O]Q/!3_>D,=_X!+*/^!4S+_@%H\_WQB1?]W:D[_<715_VY_6_UJB6#Z
M9I)D^&29:/9AH&OU7Z=M\UZM;_)<LW#R6[IQ\5K#<O!9S7/N6=USZ%KB=.%<
MY7/97N9ST%_G=-!?YW307^=TT%_G=-!?YW307^=TT%_G=-!?YW3_;",$_VLQ
M"O]S.Q3_?4(=_X)*)_^$43+_@UD[_X!@1?][:$W_='%5_W!\6_QLAV'Y:)!F
M]V68:?5CGVSS8:9O\E^L<?%=LW+P7+MT[UO%=>]:T'7J6M]VXESB=MM?Y771
M8.9VRF'E=\IAY7?*8>5WRF'E=\IAY7?*8>5WRF'E=\IAY7?_;2($_VPQ"_]V
M.A3_@$$=_X5()_^(3S'_AU<[_X1>1/]_9DW_>&Y5_W-Y7/QNA&+Y:HUG]F>6
M:_1DGF[R8J5Q\6"L<^]>M'7N7;QV[EO'=^U;UGCE7.!XW%_C>-)@Y'C+8>1Y
MQ&/C>L1CXWK$8^-ZQ&/C>L1CXWK$8^-ZQ&/C>L1CXWK_;B($_VTQ"_]X.!/_
M@S\<_XE')O^+3C#_BU4Y_XA<0_^#8TS_?6M4_W9U7/QR@&+X;8IG]6F4;/-F
MG'#Q8Z1S[V&L=>Y?M'?M7;YY[%S+>NA<W'K>7^%ZTF'C>\IBXGS$8^)]OF7A
M?;UEX7V]9>%]O67A?;UEX7V]9>%]O67A?;UEX7W_;B($_VXP"_][-Q/_ACX<
M_XQ%)?^/3"[_CU,X_XU:0?^(84O_@VE3^GQQ6_=V?&+S<8=H\&V0;>UIF7'J
M9J%UZ&.I>.9ALGKD8+M[XE_'?.!?VGW48N%]RF/@?L-DX'^]9M^ MV??@+=G
MWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX#_;R$$_V\P"_]^-A+_B3P;_Y!$
M)/^33"W_DU(V_Y)90/^.8$GYB&92]()N6N]\>6'K=X-HYW*,;N1ME7/@:IUW
MW6>F>MIEKGS68[A^TV+#@-%BTX'*9-^!P67>@KMGW8*U:-V#L&G=@[!IW8.P
M:=V#L&G=@[!IW8.P:=V#L&G=@[!IW8/_<"$$_W(O"_^!-!+_C#L:_Y-#(O^7
M2RO_EU$T_Y97/?J374;SCF1/[HAK6.B"=6#C?']HWG>);MERD733;IEYT&NA
M?<QHJ8#)9K*"QV6]@\5ERX3!9MR$N6C;A;-IVX6N:]N%J6S;A:ELVX6I;-N%
MJ6S;A:ELVX6I;-N%J6S;A:ELVX7_<2$$_W0N"O^$,Q'_CSH9_Y9#(?^:22G_
MFDXR_)I4._686T3NE&)-YX]I5>&)<U[;@GQFTWR%;\UWC77)<I5ZQ6^=?\%L
MI8*^:JV%NVFXA[EIQ(BW:=B(L&O9B*MLV8BG;=F(HV_:AZ-OVH>C;]J'HV_:
MAZ-OVH>C;]J'HV_:AZ-OVH?_<2 $_W8L"O^&,A'_DCH8_YE"(/^<1R?_GDPO
M^)Y2./"=6$#IFE])XI5G4MJ/<%S1AWAFRH&!;\5\B7; =Y!\NW28@+=QH(2T
M;ZF'L6VSB:YLOXJL;,^+J&[7BZ1OV(J@<-B*G7'9B9UQV8F=<=F)G7'9B9UQ
MV8F=<=F)G7'9B9UQV8G_<B $_W@K"O^(,!#_E#D7_YM!'O^?127]H4HM]*)0
M-.RB5CSDH%Q%W)ME3]*3;5S*C'5FPX9];[V!A7:W?(U]LWB4@:YUG(:K<Z6)
MIW&NBZ5PNHVC<,F-H''5C9QSUHR:=-:+EW38BI=TV(J7=-B*EW38BI=TV(J7
M=-B*EW38BI=TV(K_<R $_WHJ"?^++P__ECD6_YT_'/^A0R/ZI$@J\:9.,>BG
M5#CAIUQ U9]B3LN8:UO#D7)FO(MZ;[:%@G>P@8E]JWV1@J9YF8:B=Z&*GW6K
MC9QTMHZ:=,6/F'74CI5VU8V3=]6-DG?6BY)WUHN2=]:+DG?6BY)WUHN2=]:+
MDG?6BY)WUHO_<R $_WPI"?^-+P__F#@5_Y\]&_^D02'WJ$8G[:M,+>6M4C/<
MJED_T*-A3<:<:5J^E7!EMH]W;Z^*?W:IA89]I(&.@I]^EH>;>YZ+EWFHCI1X
MLX^2>,&0D'G3D(]ZU(^.>M6-C'O6C(Q[UHR,>]:,C'O6C(Q[UHR,>]:,C'O6
MC(Q[UHS_=!\$_WXH"?^.+@[_FS@4_Z$\&?^G/Q_TJT0DZJ]**>*S42[6KE<^
MRZ=?3<&@9UJYF6YEL9-U;JJ.?':CBH-]GH:+@IF#DX>4@)N+D'ZECHU]L)"*
M?;V1B7[0D8A^TX^(?M2.AW[5C8=^U8V'?M6-AW[5C8=^U8V'?M6-AW[5C8=^
MU8W_=!\$_X G"/^0+@[_G3<3_Z,Z&/RI/1SQKT(@Y[1()-^W3BS1L54]QZI>
M3+VC95FTG6QDJY=S;J23>G:>CH%\F(N(@I*'D(>.A9F+B8.BCH:"K9"#@KN1
M@H+,D8*"TY""@M2/@H'5C8*!U8V"@=6-@H'5C8*!U8V"@=6-@H'5C8*!U8W_
M=1\$_X(F"/^2+0W_GS82_Z4X%OFL.QKNLS\=Y;E&']J[2RO-M%0\PJY<2[BG
M8UBOH6ICIIQQ;9^7=W68DWY\DI"&@HR-CH>'BI:+@XB@CG^'JY!]A[B1>X?)
MD7R'TY!\AM2/?875C7V%U8U]A=6-?875C7V%U8U]A=6-?875C7V%U8W_=1\$
M_X0E"/^4+0S_H#40_Z@V%/:O.!?KMST8XK]%&=6^22K(N%,[O;%;2K.K8E>J
MIFABH:%O;)F<=722F'Q[C)6#@8:2BX:!D)2+?(Z>CGF-J)!VC+61=(W&D76-
MTY!VB]2/>(G5C7B)U8UXB=6->(G5C7B)U8UXB=6->(G5C7B)U8W_=AX#_X8D
M!_^7+ O_HC(/_ZLS$?*S-1/HO#H3WL4_%]#!2"G$NU$YN;592*ZP8%6EJF=A
MG*9M:Y2B='.-GGIZAIN!@("8B85[EI*)=I2;C7*3IH]OD[.0;I/#D&Z3TX]P
MD=2.<H[5C7*.U8URCM6-<H[5C7*.U8URCM6-<H[5C7*.U8W_=QX#_XDB!_^9
M+ K_I3 -_*XO#N^X,0[DPS<-V<H[%LO%1B>_OU XL[I81ZFU7U2?L&5?EJQK
M:8ZH<G&&I7AX@*)_?GJ?AX-TG8^(;YN9BVR:I(UIFK".9YO CF>;U8YIF-6-
M;)36C&R4UHQLE-:,;)36C&R4UHQLE-:,;)36C&R4UHS_>!X#_XPA!O^=*PC_
MJ"P*^+,J"^J_*PG@S#(&T<XY%<7)126YQ$XVKK]61:.[75*9MF-=D+)I9X>O
M<&^ K'9V>:E]?'.GA(%NI8V%::27B&6CHHICHZZ,8:.^C&"DTHMCH->+99S8
MBF6<V(IEG-B*99S8BF6<V(IEG-B*99S8BF6<V(K_>AT#_X\@!?^@*0?_K"<'
M\K@D!N7') 39U2<%R],W$[_.0R.SRDPTI\540IS!6T^2O6):B;IH9(&W;FQY
MM'1R<[)[>&VP@WUHKXN!8ZZ5A%^MH(9=K:V'6ZV\AUJNT(=<JMJ'7Z7:AU^E
MVH=?I=J'7Z7:AU^EVH=?I=J'7Z7:AU^EVH?_?AH#_Y0?!/^E)@7]L2 $[,$:
M ]_3%P'0W"4$Q-DU$+C502&LT$LQH,Q2/Y7)64R+Q6!7@L-F8'K ;&=SOG-M
M;+QZ<V>[@G=BNHI[7KF4?EJXGX!8N*R!5KF[@56ZSX%6MMZ"6+#=@EBOW8)8
MK]V"6*_=@EBOW8)8K]V"6*_=@EBOW8+_A!<"_YD< O^J'P/UN14"WLT, -#?
M$@#%X"8%N]\V#K#=0!VDV4DMF-51.XW16$B#SUY2>\QE6G/+:V%LR7)G9LAY
M;&''@7!=QHIT6<:4=E;%GWA3QJQY4L:[>E''SWE1Q.-Z4[SB?%.\XGQ3O.)\
M4[SB?%.\XGQ3O.)\4[SB?%.\XGS_BA0!_Y\8 ?^P% '8PPH SM$* ,3E% &Y
MY"8(KN0T$Z3B/R"9X$<MC]Y/.87<5D1[VEU,<]ED5&S7:UIFUG)?8=5Y9%S4
M@F=8U(MJ5=25;5+4H&Y0U*UO3M6\<$W6T&]-U>AP3LSI<D[,Z7).S.ER3LSI
M<D[,Z7).S.ER3LSI<D[,Z7+_DA$!_Z<1 -BY"0#+Q@@ PM4* +?J%@.LZB<,
MHNDT&)CH/B2-YT<P@^9..GKE5$-QY%I*:>1A4&3C:%5?XW!96N-X7%;C@%]3
MXXEB4..39$WDG65+Y*EG2N6V9TGEQF=(YM]G2N#L9TK?[&=*W^QG2M_L9TK?
M[&=*W^QG2M_L9TK?[&?_G T V[$& ,J]!P"_R@< M=H* *KO&06@\"@/EO U
M&XSP/R:"\$<Q>?!..7#O5$!H[UI&8>]@2UWO9T]8[VY25.]U55'P?5=.\(59
M2_"/6TCQF5Q&\:->1/*O7T/RNU]"\\Q@0?/G8$'SZ&!!\^A@0?/H8$'SZ&!!
M\^A@0?/H8$'SZ&#>IP( R[8% +W!!0"RSP< I^H- 9WW' >4^"L2BO@V'('Y
M0"9X^D@O;_I--F?Z4SQ@^EA 6_M?1%;[94=2^VQ)3_QR2TO\>4U(_(%/1?V*
M44/]DU)!_IQ3/_ZF5#W_L54]_KQ6//[-5CS^SE8\_LY6//[.5CS^SE8\_LY6
M//[.5CS^SE;.L ( O;H$ +''! "EU@< F_T0 I'_( F(_RT2@/\Y&W;_/R-M
M_T4J9?]+,%[_4358_U<X4_]=.T__8SY,_VA 2?]N04;_=4-#_WQ$0/^$1CW_
MC$<\_Y1(._^=23K_I4HY_ZU+./^Y2SC_N4LX_[E+./^Y2SC_N4LX_[E+./^Y
M2SC_N4N^M0( L, " *3. P"7W@4 C_\4 H;_(PA]_RX0<_\U&&K_/!YB_T(D
M6_](*%7_3BQ0_U0O3/]:,4C_7S-%_V0U0O]J-C__<#<]_W8Y._]\.CG_@SLX
M_XL\-O^3/37_FCXT_Z$^,_^J/S/_JC\S_ZH_,_^J/S/_JC\S_ZH_,_^J/S/_
MJC^QN@$ H\@  );6  "+] D!@_\6 GG_( 9O_R@,9_\P$E__-Q=8_SX;4O]$
M'TS_2B)(_U D1/]5)D'_6B<^_U\I._]D*CK_:2LX_VXL-O]T+33_>BXS_X$O
M,?^(,##_CS N_Y8Q+?^>,BW_GC(M_YXR+?^>,BW_GC(M_YXR+?^>,BW_GC*D
MP@  EL\  (C?  " _PP!=?\2 FK_& -B_R$'6O\I"U/_,0]-_S@22/\^%4/_
M1!<__TH9//]/&CG_4QLW_U@<-?]<'3/_81XQ_V4?,/]J("[_<" M_W8A*_]\
M(BK_@B,H_X@C)_^0)"?_D"0G_Y D)_^0)"?_D"0G_Y D)_^0)"?_D"3_8"4$
M_ULP!O]A.@W_:D$6_V]*'_]Q4BG_;ULR_VMD.O]G;D'_9'I'_V"$3/]=CE#_
M6I93_UB>5O]7I5C_5:M:_U2Q6_]3MUS_4KY=_E''7OQ1T5_[4.!?^%#I7_-1
M[5_N4_!?Z%3Q7^16\E_D5O)?Y%;R7^16\E_D5O)?Y%;R7^16\E__8"4$_ULP
M!O]B.0W_;$ 6_W%)'_]R42G_<5HR_VUC.O]H;4'_97A'_V&#3?]>C5'_6Y94
M_UF=5_]7I%G_5JI;_U6Q7/]4MUW^4[]>_5+'7_Q1TV#Z4.)@]E'I8/%2[F#K
M5.]@Y5;Q8.%7\F#A5_)@X5?R8.%7\F#A5_)@X5?R8.%7\F#_824$_UPP!O]E
M. W_;C\5_W1''_]U4"C_=%@Q_W!A.O]K:D'_9W9(_V.!3?]@BU+_7915_UJ<
M6/]8HUK_5ZI<_E:P7OU4MU_]4[]@_%/)8?I2UF+X4>1B\U+J8NU4[F+F5N]B
MX%CP8MM8\6/;6/%CVUCQ8]M8\6/;6/%CVUCQ8]M8\6/_8B4$_UTO!O]G-@W_
M<3X5_W=&'O]X3BC_=U8Q_W1?.O]N:$'_:G-(_V9^3O]BB5/_7Y)6_UR;6O]:
MHES^6*E>_5>P8/Q5MV'[5,!B^U/*8_E3VF3U4N9D[U3K9.A6[F3A6.]DV5GP
M9=-:\&;36O!FTUKP9M-:\&;36O!FTUKP9M-:\&;_8B0$_UXO!O]J-0W_=#P5
M_WI$'O]\3"?_>U0P_W=<.?]R94'_;&](_VA[3O]DAE/_8)!8_UV96_Y;H5[]
M6:A@_%BP8OM6N&/Z5<%D^53-9?=3WF;R5.=FZE;K9N)9[F;:6NYGT5OO:,Q<
M\&C,7/!HS%SP:,Q<\&C,7/!HS%SP:,Q<\&C_8R0$_U\N!O]M,PS_=SH4_WU"
M'?^ 2B;_?U(P_WQ;./]W8T'_<&Q(_VQW3_]G@E3_8XU9_6"67/Q=GU_Z6Z=B
M^%FN9/=8MF;U5\!G]%;+:/%5W6CM5NEIXUGL:-I;[6G07.YJR5WN:\5>[FO%
M7NYKQ5[N:\5>[FO%7NYKQ5[N:\5>[FO_9",$_V$M!O]P,@S_>S@4_X% '/^$
M227_A%$N_X%9-_]\84#_=FE(_W!S3_ML?U7X:(E:]F227O-AFV'Q7Z-D\%VK
M9NY;LVCL6KQJZEG':^A9V&OD6>AKVEOK;,]=[6W(7NQNPE_L;KY@[&^^8.QO
MOF#L;[Y@[&^^8.QOOF#L;[Y@[&__92,$_V0K!O]S, S_?C83_X4_&_^)2"3_
MB4\M_X97-O^"7C[\?&9&^'9P3O1Q>U7P;85:[6F.7^IEEV/H8I]FYF"G:>->
MKVOA7;ELX%S$;=Y<TV[97>9NSE[K;\9?ZG&_8>IQNF+I<K9CZ7*V8^ERMF/I
M<K9CZ7*V8^ERMF/I<K9CZ7+_9B,$_V<I!O]W+@O_@C42_XD^&O^-1R+_C4XK
M_XQ5,_R(7#SV@V1%\7QL3>QW=U3H<H%:Y&Z*8.%JDV3=9IMHVF2C:]9BK&[3
M8+5PT%^_<<Y?S7++7^)SQ&'H<[UBZ'2W9.=TLF7G=*]FYW2O9N=TKV;G=*]F
MYW2O9N=TKV;G=*]FYW3_9R($_VHG!?]Z+ K_AC01_XT]&?^112#_DDTH_9%3
M,?:.6CKPB6%"ZH-I2^5^=%/@>'U:VG.&8-1NCV;0:Y=JS&B?;LEFIW''9*]S
MQ&.Y=<)BQG; 8MIWNF3F=[-EY7>N9N5WJFCE=ZAHYG>H:.9WJ&CF=ZAHYG>H
M:.9WJ&CF=ZAHYG?_9R($_VTF!?]]*@K_B300_Y$\%_^51![_ETLF^)92+O&4
M6#;JD%X_Y(IG2-V$<5#5?7E:SWB"8<ISBF?&;Y)LPFR:<+]JHG.\:*IVN6>T
M>+9FP'FT9M!ZL6?C>JMHXWJG:N-ZHVOD>:%KY'FA:^1YH6OD>:%KY'FA:^1Y
MH6OD>:%KY'G_:"$$_V\D!?^ *0G_C#,/_Y0[%O^90QS]FTDC])M/*NR953/E
MEEP[WI%E1=2);5#,@W9:QWU^8<%XAFB]=(YMN'&6<K5NG76Q;*9XKFNO>ZQJ
MNWRJ:<I]J&KA?:-LXGR?;>)\G&[B>YINXWN:;N-[FF[C>YINXWN:;N-[FF[C
M>YINXWO_:2$#_W$C!?^"* G_CS(._Y<[%/^<0AKYGD8@\)],)^B?4B[@G5HV
MUI5A1,V.:D_&B')9OX)Z8KE]@FBT>8INL':2<ZQSFG>H<*)ZI6^K?:)NMGZ@
M;<5_GF[;?YMOX'Z8<.%^EG'A?91QXGR4<>)\E''B?)1QXGR4<>)\E''B?)1Q
MXGS_:2$#_W0B!/^%* C_D3$-_YHZ$O^?/Q?UHD0=[*1*(^2D4"G;H5<USYI?
M0\>3:$^_C'!9N(=W8;*"?VBM?H9NJ7J.<Z1WEGB@=9Y[G7.H?IIRLX"7<<"!
MEG+3@9-SWX"1=.!_D'3@?H]TX7V/=.%]CW3A?8]TX7V/=.%]CW3A?8]TX7W_
M:B$#_W8@!/^')P?_E# ,_YTY$?VB/17RI4$:Z:A''^"J3274I%0TRIU=0L&7
M94ZZD6U8LHMU8:R&?&BG@H-NHG^+=)U\DWB9>9M\E7>E?Y)VKX&0=KV"CG;.
M@HUWWH&+=]^ BGC@?XIXX'Z*>.!^BGC@?HIXX'Z*>.!^BGC@?HIXX'[_:B #
M_W@?!/^))@?_EC +_Y\W#_JD.A/OJ3\7YJU%&MRN2B3/J%,SQJ%<0;V;9$VT
ME6M8K8]R8*>+>6BAAX%NFX.(=)> D'B2?IE\CGRB?XMZK8*(>KJ#AWK+@X9[
MWH*%>]Z!A7O?@(5[X'^%>^!_A7O@?X5[X'^%>^!_A7O@?X5[X'__:R #_WH>
M!/^+)@;_F"\*_Z$U#?>G.!#LK3P3X[)"%M>Q1R/+JU(RP:5:0+B?8DRPF6E7
MJ)1P8*&/=V>;BWYNEHB&<Y&%CGB,@I9\B("?@(1_JH*!?[>#@'_(A'^ W8-_
M?]Z!?W_?@(!^X'^ ?N!_@'[@?X!^X'^ ?N!_@'[@?X!^X'__;" #_WP< _^-
M)0;_FBX)_Z,S"_2J- WIL3D/W[<_$M*T1B+'KE QO:A9/[.B8$NKG6=6HYAN
M7YR4=6>6D'QMD(V#<XN*BWB&B)1\@8:=@'Z$J()[A+6#>83%A'B%W8-YA-Z!
M>H/?@'J"X']Z@N!_>H+@?WJ"X']Z@N!_>H+@?WJ"X'__;1\#_WX; _^/) 7_
MG2P'_J8P"?"N,0OEMC4+V[PY$<ZW12##LD\PN*Q7/J^G7TJFH655GIUL7I>9
M<V:0E7ILBI*!<H60B7> C9%\>XN;?W>*I8)TB;*#<HG"@W**VH-SB=Z!=(??
M@'6&X']UAN!_=8;@?W6&X']UAN!_=8;@?W6&X'__;QX#_X ; _^2(P3_H"L&
M^JDL!^VR+ ?BO#$'U< V$,F[0Q^^MDTNM+!6/*JK74FAIF14F:)J79&><66*
MFWAKA)A_<7^6AG9YDX]Z=9&8?G&0HX%ND*^";)"_@VN1U8)MC]Z!;XW?@'"+
MX']PB^!_<(O@?W"+X']PB^!_<(O@?W"+X'__<1P#_X,9 O^5(0/_HRD%]JTG
M!>BW)@3>PRH#T,,U#L2_01VYNDPMKK54.Z6P6T>;K&)2DZAI6XNE;V.%HG9J
M?I]\;WB<A'1SFHQY;YF6?&N7H7]HEZV 9I>\@668T8!FEM]_:)/@?FJ1X7YJ
MD>%^:I'A?FJ1X7YJD>%^:I'A?FJ1X7[_=1H"_X<8 O^8( /_IB4#\K(@ ^2^
M'@+7R2("RL<S#;[#0!RSOTHKJ;I3.9^V6D66LF%0C:]G686L;6!^J71G>*9Z
M;7*D@G)MHHIV:*&4>62@GWQAGZM^7Z"Z?E^@SGY?G^%]8IOA?6.8XGQCF.)\
M8YCB?&.8XGQCF.)\8YCB?&.8XGS_>!@"_XL7 ?^='0+]JQX"[+@7 =[($0#/
MS1\"Q,PP"[C(/AFMQ4@HH\%1-IB]6$*/N5]-AK9E5G^S:UUXL7)D<J]Y:6RM
M@&YGK(ER8JJ2=5^IG7A<J:IZ6JFY>EFJS'I8J>1Z6Z3D>EVAY'E=H>1Y7:'D
M>5VAY'E=H>1Y7:'D>5VAY'G_?14"_Y 4 ?^A& 'VL10 V<$+ -+/"P#(TAP!
MO-$N";'..Q>FRT8EG,A/,Y'$5C^(P5U)@+]C4GB\:EEQNG!?:[EW9&:W?VEA
MMH=M7;61<%FUG')6M*ET5+2X=%.URW13M>1T5+#G=5:LYW56K.=U5JSG=5:L
MYW56K.=U5JSG=5:LYW7_@Q(!_Y81 /^H$0#9N H SL0) ,?2"@"_V1D!M-@K
M!ZG6.12?TT0BE-!-+XK-5#N!REM$>,AB37'':5-KQ6]99<1V7F##?F)<PH=F
M6,&1:%7!G&M2P:AL4,&W;4_"RFU/PN1L3[WL;E"Y[&]0N>QO4+GL;U"Y[&]0
MN>QO4+GL;U"Y[&__B1 !_YT. -JO" #-NP@ Q,<' +S6"P"SWQH!JM\K!Z#>
M.1*6W4,>C-I+*H+84S5YU5H_<=-A1FK2:$QET6]28-!V5EO0?EI7SX==4\^1
M7U#/G&%.SZEC3,^X8TO0RV-,T.5B2L[R94O(\F9+R/)F2\CR9DO(\F9+R/)F
M2\CR9DO(\F;_D@T WJ8$ ,ZT!@#"OP8 N<P( +#=# "GY1T#GN4M"Y3E.1:*
MY$(@@>-**G?B4#-OX5@[:>!?06/@9D9>WVY*6M]U3E;??5%2WX933]^05DW?
MFU=+X*=82>"U64CAQEE(X=]91]_P64;<]5M&W/5;1MSU6T;<]5M&W/5;1MSU
M6T;<]5OMG 0 T:T$ ,*X!0"WPP4 K=$( *3M$ &;[2 %DNTN#HGL.AB [$,A
M=NQ**F[L4#%FZU8W8.M</%OK9$!7ZVM#4^MR1E#K>DE-[(-+2NR,34CLEDY%
M[:%00^VN44+NO%%![\Q20>_E4D#M\5% [?%10.WQ44#M\5% [?%10.WQ44#M
M\5'4I0  Q+(# +:\ P"KR04 H-@( )?T$P&/]20'A_4Q#W[V.QAT]D(@;/9(
M)V7V3RU>]U4Q6?=;-57W8CA1]V@[3?AO/4KX=C]'^'Y!1/F'0T+YD45 ^IM&
M/OJF1SS[L4@[^[Y).OS/23G\XTDY_.-).?SC23G\XTDY_.-).?SC23G\XTG'
MK0  M[<" *K# @">T 0 D^,) (S]& *$_B<'>_\Q#W+_.!9I_T <8O]&(ES_
M3296_U,J4O]9+4[_7S!*_V4R1_]K-$3_<35!_WDW/_^!.#S_BCHZ_Y,[./^=
M/#;_ISTU_[$^-/^^/C/_RC\S_\H_,__*/S/_RC\S_\H_,__*/S/_RC^XL@
MJKT  )W*  "1V ( B/L- 7__&0)V_R0&;O\M#&;_-1)?_SP76/]#&U/_21Y.
M_T\A2O]5)$;_6R9#_V G0/]F*3[_:RH[_W(K.?]Y+3;_@2XT_XHO,?^4,##_
MG#$N_Z4R+?^O,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS.KN   GL4
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M6S/Y=F0Z]7!N0?%L>4CM:(--ZF2,4>=AE57E7YU8XUVE6N%;K5S>6K9>W%G
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M<.ERCG'J<8UQZW",<>MPC''K<(QQZW",<>MPC''K<(QQZW#_8R #_W(; _^
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M6DC%^UI(Q?M:2,7[6DC%^UKWD00 U*(" ,>O! "ZN0, L,0% *?0"0"?X1
MF.$A X_@, F&X#L2?=]$&W7>321NW54K9]Q<,F+;9#==VVL[6=IR/U7:>D-2
MVH-%3MJ-2$S:F$I)VJ5+2-NS3$?<Q$Q&W-Y,1MKM3$38^4]#V/M/0]C[3T/8
M^T]#V/M/0]C[3T/8^T_;F@  RJD" +NS @"PO0, I<D% )O6"0"4Z!0!C.DE
M!(3H,PM[Z#P4<^A$&VOH2R)DYU(H7N=9+5GG8#)5YV@U4N=O.$_G=SM,YX ]
M2>>)/T?HE$%$Z)]"0NFL0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$-
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M9F^"\F5P@?-D<('S9'"!\V1P@?-D<('S9'"!\V3_:Q0!_WL2 ?^*$@#_EA(
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M7U><]U]7G/=?5YSW7U><]U__>@P _8L) -J;! #.IP8 Q+ & +RY! "UP0X
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M1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D CMH2 (C;) *
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M(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0
MG[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$3_\S!DK_.PA&
M_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N_X(7+/^-&2K_
MF1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRAM   D[\
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MX4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'P%'_1\!1_T?
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M6GQR_%E\<OQ7?'+]5WQR_5=\<OU7?'+]5WQR_5?_8A0!_W$1 ?]]$0#_B!(
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M5V>#_%=G@_Q79X/\5V>#_%?_; X _WL, /*)"0#9E08 SYX( ,FF" #!JQ
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M-4+.N#9!S\TU0<[H-4#-]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@
MO*(  *^J  "CLP  F+P  (W& P""SP< >-D+ '/>& !NWB8":-XS!6+>/@I=
MWD@/6=Y0%%7>6!=1WF ;3MYG'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF*C[?
MM2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP  L:<
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M+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  "
MR0  =-,  &?>  !>\@@ 6?X1 %/_&@%._R,"2?\K T7_,P1!_SH%/O]!!CO_
M1P<X_TX(-?]4"3/_6@DQ_V$*+_]I"RS_<@PJ_WT-*/^(#B;_E0\E_Z$0)/^N
M$2/_NA(B_\H2(O_0$B+_T!(B_] 2(O_0$B+_T!*<L@  CKP  (''  !ST0
M9]T  %GC  !3_08 3?\. $C_%@!#_QX!/_\F CK_+0(W_S,#,_\Y S#_/P0N
M_T0$*_]*!2G_4 4G_U8&)/]=!B+_90<@_VX''?]Y"!O_A0@:_Y()&?^>"1C_
MJ D7_[,)%_^W"1?_MPD7_[<)%_^W"1?_MPF0N@  @L4  '30  !GW   6.,
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M2XUC_TJ,9/])BV3_28MD_TF+9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_>A(
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M3'1S_TQT<_],='/_3'1S_TS_8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$
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M0DVCM$-,H\A#3*/D0TNA]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0
MSXL  ,*6  "WGP  K:8  *.M  "9M0  D+D. (NZ'@&$NBT#?;DY"7>X0Q!Q
MMDP7:[53'6:T6B)BLV$F7K)H*UJQ;RY6L'<R4["!-4^OBSA,KY<Z2JZD/$BN
MLSU'KL<]1Z[C/$:M\SU&J_X^1:O_/T6K_S]%J_\_1:O_/T6K_S_:@P  QY$
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M(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0  )^L  "3M0
MA[X  'O&  !PS@, 9=8' %WC#@!:XQL 5N,G 5+D,@).Y#P$2N1$!D?E30A%
MY54*0N5<#$#E9 X^YFP0.^9V$CGF@!0WYXP5->>9%C3GJ!<RZ+@8,NC,&#'H
MY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(O0  >\8
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M!1'_O 41_[P%$?^\!1'_O 6,N   ?<(  &_,  !BV   5-\  $?E   ^\0
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M.:-3_SFB4_\YH53_.*%4_SBA5/\XH53_.*%4_SC_3Q0!_UD0 /]C$@#_:A0
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M$0#9?1@ SGTJ L5[.0:^=T4.MW10%;%P61RM;6(BJ&II)Z5H<2RA9G@OGF2
M,YMBAS:888\XEF"8.Y-?H3V17JL_CUZX0(U>R$&+7N%!BE_S0(E?_S^)8/\^
MB&#_/HA@_SV(8/\]B&#_/8A@_SW_5P\ _V(, /]L# #X= P Z7H, -Y^# #2
M@14 R($G <!_-@:X?$(-LGA-%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1G
MA#:198PYCF25/(QCGCZ)8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_
M/X)D_S^"9/\_@F3_/X)D_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!(
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M/7EPED!V;Z%"=&ZN1')NO45P;M%%<&_K1'!O^D-Q;_]!<6__0'%P_T!Q</]
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M05N$M$):A,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@
MWG@  ,V#  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_
MF4X8>I=6'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+
MLD!4B\5 5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP
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M,D2H[S)#I_LS0Z;_,T.E_S1#I?\T0Z7_-$.E_S30@0  P8X  +68  "IGP
MGJ4  ).L  "(L@  ?+D" ':Z$0!RNR$ ;KLN FB[.@9DND,*7[I,#ENY4Q)7
MN%H65+AA&5&W:1Q.MW$?2[9Z(DBVA"5%MI G0[6=*4&UK"I MKXJ/[;8*C^T
M[BH^L_HL/;+_+3VQ_RT]L?\M/;'_+3VQ_RW'B0  N94  *R=  "AI   EJL
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M#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$  &K)  !>SP
M4]4! $G<!@!%Z0\ 0ND9 $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M50,O
M[ET$+>YE!2ON< 4I[WL&*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O
M]0@B[_4((N_U""+O]0B>I@  D:\  (2X  !WP0  :LD  %W0  !1UP  1MT
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M(\!!_R2^0?\DO4'_);U!_R6]0?\EO4'_);U!_R7_0A@!_TD3 /]0% #_5AD
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M,)14_S"45/\PE%3_,)14_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8
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M.&EOM3IH;\<Z9V_B.F=O]#AH;_\W:&__-FAO_S9H;_\V:&__-FAO_S;_7@
MY&H  --T  #(?   OX$! +>% 0"OAP< J(D5 *&))0&;B#,$E(8^"8Z$1P^)
M@5 5A']7&G]^7AY[?&4B>'IL)G1Y<RIQ>'LM;G>$,&MVCC-H=9DV9G2E.&1S
MLSEB<\0Z8G/@.F)S\SAC<_\W8W/_-F-S_S9C<_\V8W/_-F-S_S;_80  X&T
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M-5&&[C52A?LT4H7_-%*%_S-2A?\S4H7_,U*%_S/C;   SGD  ,&#  "VBP
MK)$  **5  "7F0  CYL+ (J=& "$G2<!?IPT!'F;/@ASFD<-;YE/$FJ85A=F
MEUT;8Y5C'E^4:B)<DW(E69)[*%61A2M2D9 N4)"=,$Z0JS%,D+PR3)#3,DR/
M[3),COHR3(W_,4R,_S%,C/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0  II8
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M(CJL_R,ZK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8  (2L  !YL0
M;;<  &&\!0!=O1( 6KX@ %B^+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$
MOF@.0;UQ$3^]?!,\O8@5.KV5%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y
M_QLTN?\;-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0  8[X
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M QOI^0.:I   C:P  '^U  !RO0  9<4  %G+  !,T   0=4  #C<   OX0(
M+?$- "OQ$P H\AP )O(D "3S*P B]#( (?0Y !_U00 =]4D &_91 !GW6@$7
M]V4!%?AR 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[
MZ0*/JP  @;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X*
M "'_$  ?_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8
M"_]B  G_;P (_W\!!_^0 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#
MM   =;T  &?&  !:SP  2]4  #_<   SX0  *>4  "'L   >_0  &O\% !?_
M#  5_Q  $O\4 !#_&0 ._QX #?\C  O_*  (_RX !O\U  /_/0  _T8  /]1
M  #_70  _VL  /][  #_BP  _YD  /^E  #_K   _ZP  /^L  #_K #_)RP!
M_RHJ ?\K*@'_*BX!_R8T O\E/P+_(TL#_R%8 _\@9 3_'G $_QU[!/\=A07_
M'8X%_QV6!?\=G ;_':(&_QRH!O\<K@?_'+0'_QR[!_\<PP?_',X'_QW?!_\=
MZP?\'?4'^1W^!O<>_P?W'?\(]AW_"?8=_PGV'?\)]AW_"?8=_PG_*2H!_RPG
M ?\N)P'_+2H!_RPR ?\K/0+_*4D#_R=5 _\E803_(VT$_R)X!?\B@@7_(8L&
M_R&3!O\AF@?_(: '_R&E!_\AJPC_(;$(_R&X"/\AP0C_(<L(_"'<"/DAZ0CV
M(?0(\R+]!_(B_PGQ(O\*\2'_"_ A_POP(?\+\"'_"_ A_PO_+"8!_S D ?\Q
M(P'_,28!_S(O ?\Q.@+_+T8#_RU2 _\K7@3_*6D%_RAU!?\G?P;_)X@'_R:0
M!_\FE@C_)IT(_B:C"?TFJ0G\)J\)^R:V"?HFO@GX)L@)]B;9"?(FZ GO)_,)
M[2?]"NLF_POJ)O\-Z2;_#>@F_P[H)O\.Z";_#N@F_P[_+R,!_S,@ ?\U'P'_
M-R,!_S@L ?\X-P+_-D("_S1. _\R6@3_,&4%_RYP!OXM>P?\+80(^BR,"?@L
MDPGW+)D*]BN@"O0KI@KS*ZP+\BNS"_$KNPOO*\8+[BS4"^HLY@OF+/(+Y"S\
M#>(L_P_A+/\0X"S_$-\L_Q'?+/\1WRS_$=\L_Q'_,Q\!_S<; ?\Z&@'_/2 !
M_S\H ?\_,@'_/3X"_SM) _\Y503[-V$&]S5L!_4T=@CR,W\)\#*'"N\RCPOM
M,I8+[#&<#.HQH@SI,:D,Z#&P#>8QN0WE,<,-XS+1#=\RY0S<,O$/V#'\$=4Q
M_Q+2,?\3T3'_%- Q_Q30,?\4T#'_%- Q_Q3_-QL!_SL7 /\_%@#_0QP _T8D
M ?]&+@'_1#D"_$)$ _8_4 3Q/5P&[3QG!^H[<0GH.GH*Y3F#"^,XBPSB.)(-
MX#>9#=\WGP[=-Z8.VS>M#]DVMA#7-L$0U3;.$-$WXQ'--_$3RC?[%<@W_Q;&
M-_\7Q3?_&,0W_QC$-_\8Q#?_&,0W_QC_.Q< _T 3 /]%$P#_21@ _TP@ /],
M*0'Z2S,!\D@^ NQ&2@3G1%8&XT-B"-]!; K<0'4,V3]^#=4^A@_3/8T0T3V4
M$<\\FQ+-/*(3S#RI%,H[L13(.[L5QSO(%L4\W!;!/.T7OCSY&;L\_QJZ//\;
MN3S_&[@\_QNX//\;N#S_&[@\_QO_/A0 _T00 /]*$0#_3Q0 _U$; /M2(P#Q
M42T!Z4\X >)-10/<2U$%UDE<"-%'9@O.1G .RT5X$,A$@!+&0X<4Q$*.%<-"
ME1;!09P7OT&D&+U K!F\0+8:ND#"&KA TANU0>@;LD'V';!!_QZN0?\>K4'_
M'JQ!_QZL0?\>K$'_'JQ!_Q[_0A$ _T<- /]/#@#_4Q$ _U85 /-7' #H5B4
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M+79>M2YU7L8O=%[A+W1?\RYT7_\L=&#_*W1@_RMT8/\K=&#_*W1@_RO_4P
MZ%X  -EG  #+;0  PW$! +MS @"U<PD K747 *=U)P&A=#0#FW(_!Y5P20N1
M;E(0C&Q9%(EJ8!B%:6<;@FAN'G]F=2%]97TD>F2%)G=DCREU8YHK<F*E+7!B
MLR]O8L0O;F+>+VYC\BYN8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50  Y6
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M8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  #
M=@  MWL  *]^  "F?@$ GW\0 )F 'P"3@"T"C7\Y!8A]0PF#>TL-?GI3$GIX
M6A9V=V$9<W5G''!T;A]M<W8B:G)_)FAQB2AE<)0K8G"@+6!OK2]?;[TO7F_4
M+UYO[2]?;_LM7V__+&!O_RQ@;_\L8&__+&!O_RSK7@  V&D  ,=R  "\>0
MLW\  *N"  "A@@  F8,. )2$'0".A"L!B(,V!(."0 A^@$D,>7]1$'5]6!1R
M?%\8;GME&VMZ;!YH>70B97A])6)WAR=@=I(J776>+%MUJRY:=+LO6771+UET
M["Y9=/HM6G3_+%IT_RM:=/\K6G3_*UIT_ROF80  T6T  ,-V  "Y?0  KX,
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M)TF'_R=)A_\G28?_)TF'_R?1;P  P7L  +6$  "KC   H)   )64  ")EP
M?IH  '>;#@!SG!P ;YTI 6N<-0)FG#\%8IM'"%^:3PM<FE8/6)E<$E688Q53
MF&L74)=S&DV6?1U*E8D?1Y65(465I"-$E+,C0Y3((T.4Y2-#DO4D0Y'_)$.0
M_R1#D/\D0Y#_)$.0_R3*=0  NX$  +"+  "DD0  FI4  (^9  "#G0  =*(
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M$S"S_Q.RC@  I94  )J;  ".H@  @J@  '6M  !ILP  7K<  %.[  !'P 4
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M !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@
MB:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <
M[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS
M>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(
M &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T
M$OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@
M_W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#
M  !6RP  2-$  #K6   OW0  )>$  !SE   4Z0  $?<   __ 0 -_PD "_\-
M  C_$  &_Q0  _\8  #_'@  _R,  /\J  #_,@  _SP  /]'  #_5   _V,
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M2D@"Q$A3!,!'70>\1F8)ND1N"[=#=@VU0WT.LT*$$+%!BQ&P09(2KD":$ZQ
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M'XA.MR"'3L@AA4[B(81/\R"#3_\@@T__'X)0_Q^"4/\>@E#_'H)0_Q[_1P
M\U$  -]8  #170  R6 " ,-@! "]7@T M6 : *YA*@"I8#<"I%Y#!)]=30B;
M6U4+F%E=#I589!&25VL3CU9R%HU5>1B+5($:B%.)'(93DAZ$4IP?@E*G(8!2
MM")_4L0C?5+>(WQ3\2)\4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@  Z50
M -I<  #,80  PV0  +QD @"V8PH KV07 *EE)P"C9#0"GF- !)EA2@>57U(+
MD5Y:#HY=81&+6V@3B5IO%H99=AB$6'T:@5B&'']7CQY]5ID@>U:D(GE6L2-W
M5L$D=E;:)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30  Y5<  --?
M  #(9   OV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>09$\*C&)7
M#8AA7A"%7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):KR1Q6K\E
M<%K5)6];[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$
M9P  NVL  +-L  "L:@0 I&L2 )YL(0"9;"\!E&LZ X]I1 :*:$T)AF95#8-E
M7!" 9&(3?6)I%7IB<!AX87@:=6" '7-?BA]P7Y0A;EZ@(VQ>K25K7KPF:E[1
M)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T  ,ME  # :P
MMVX  *]O  "G;@$ H&\0 )IP'P"4<"P!CV\X XIM0@:&;$L)@FI2#'YI60][
M:& 2=V9F%'5F;A=R974:<&1^'6UCB!]K8Y(B:6*>)&=BJR5E8KHF9&+/)F1B
MZB9E8OHD96/_(V5C_R)E8_\B96/_(F5C_R+K50  V&   ,AH  "\;@  LW$
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M(U9O_R)7;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@
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M&S^+_QO"<P  M7X  *J'  "?C   E)   (B3  ![E0  ;)D  &6;! !@G!
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M!R^QE@@NLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP
MH)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P W
MO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_
MD0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@
M (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!,
M)\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;
MS9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F
M  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0
M !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$
M#N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !J
MM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G
M$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4
M  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@
M4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %
M]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #V
ME0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T
M #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"   _PT
M /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@
M_Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2< _Q$N /\0
M.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_"IL!_PF@
M ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)_P#R"O\
M\0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L /\5-P#_
M$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.
MHP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__
M >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D
M_Q=, ?\56 '_%&,!_Q-N ?\3=P'^$X !_!.( ?H2C@'Y$I4!^!*: ?82H 'U
M$J8!]!*L ?,2LP'Q$KP!\!+' >T2V 'I$^@!YA/U >04_P'B%/\"X17_ N$5
M_P+@%?\"X!7_ N 5_P+_)1L _R87 /\D%@#_)1P _R8E /\D, #_(3L _Q](
M /\=5 ']&U\!^1II ?<:<P'T&7P!\AF$ ?$9BP'O&9$![AF7 >P9G0'K&:,!
MZ1FJ >@9L0'G&;H!Y1G% >,9U0'?&N@!W!OU M@;_P+5'/\#U!S_ ],<_P32
M'/\$TAS_!-(<_P3_*1< _RH3 /\I$@#_+!@ _RPA /\L*P#_*3< _2=# /<E
M3P'S(UH![R)D >PA;@'I(7<!YR%_ >4AA@'D(8T!XB"4 >$@F@'?(* !WB"G
M =PAKP':(;@"V"'# M4ATP+1(N<"S2+T \HC_P3((_\%QR/_!L8C_P;&(_\&
MQB/_!L8C_P;_+!( _RX/ /\P$ #_,Q0 _S,; /\R)0#Z,#  \BX\ .PL20#G
M*E4!XRI? > I:0'=*7(!VBAZ =<H@@+5*(D"TRB0 M$HE@//*)P#SBBC \PH
MJP/**+,#R2B^!,<HS 3%*>($P2KQ!KXJ_@>\*O\(NBK_"+HJ_PBY*O\)N2K_
M";DJ_PG_, \ _S(+ /\V#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\
MU3%: = Q9 +-,&T"RS!U \DP? /'+X,$Q2^*!,0OD07"+Y<%P2^>!K\OI@:]
M+Z\&O"^Y![HOQP>X,-T'M3#N";(P^PJP,/\+KC#_"ZXP_PNM,/\+K3#_"ZTP
M_PO_,PP _S8& /\\"0#_/@P _3T0 .\\%0#D.1\ VSDM -(Z/ #-.DD!R#E4
M <0Y7@+!.&<#OS=O!+TW=@6[-GT&N3:$![<VBP>V-9((M#6:";,UH0FQ-:H*
MKS6T"ZXUP0NL-=0+J3;J#*8V^ VE-O\.HS?_#J(W_PZB-_\.HC?_#J(W_P[_
M-P< _SL" /]  P#R0@4 Z4() .4_#@#8/A8 SD G ,=!-@#"040!O4%/ KE
M60.V/V$$M#YI!K$]<0>O/7@(KCQ_":P\A@JJ.XT+J3N5#*<[G0VE.Z8-HSJP
M#J([O ^@.\T/GCOF$)L\]1&://\1F3S_$9@\_Q&8//\1F#S_$9@\_Q'_.@$
M_T   .]%  #A2   V4@% --&"0#,11( Q$<B +U(,0"X2#\!LT=* K!&5 2L
M15T%JD1D!Z=#; BE0G,*HT)Z"Z%!@0R@08@-GD"0#YQ F!":0*$1F$"L$I=
MN!*50,@3DT#A$Y%!\Q200?\4CT'_%(Y"_Q..0O\3CD+_$XY"_Q/_/   ^40
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M&G=.ZQIW3_H9=D__&79/_QAV3_\7=D__%W9/_Q?X1@  XE   -!7  #$7
MNUX  +1=  "N6@8 IEL3 *!<(@";7"\ EUL[ I):10./64T&BUA5"(A77 J&
M5F,,@U5J#H%4<1!^5'@2?%. %'I2B19X4I08=E*?&712JQIR4KH;<5+-''!2
MZ!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  # 7P  MV(
M *]A  "H7@( H5\0 )M@'@"68"P D6 X 8U>0@.)74L%A5Q2!X);60J 6F ,
M?5EG#GM8;A!X6'42=E=]%'17AQ9R5I$8;U:<&FY6J1ML5K@<:U;+'6I6YAQJ
M5_<;:E?_&FI7_QEK5_\9:U?_&6M7_QGK3   V%8  ,A>  "\8@  LV4  *ME
M  "C8@  G&(. )9C' "19"D C&,U 8AB/P.$84@%@&!0!WU?5PEZ7ET+=UUD
M#75<:Q!S7'(2<%M[%&Y;A!=L6H\8:EJ:&FA:IQQF6K8=95K('65:Y!UE6O8<
M95K_&V5:_QIE6O\995K_&65:_QGH3P  TUD  ,1A  "Y9@  L&@  *=I  ">
M90  EV8- )%G&0",:"< AV<R 8-F/0)_948$>V1-!GAC5 EU8EL+<F%A#7!A
M:0]M8' 2:U]Y%&E?@A9G7HT995Z8&F->I1QA7K0=8%[''6!>XQU@7O4<8%[_
M&V!>_QIA7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P  *-L  "9:0
MDFH+ (QJ%@"':R0 @FLP 7YJ.@)Z:4,$=FA+!G-G4@AP9UD*;69@#6ME9@]H
M9&X19F1V%&1C@!9B8XL88&*7&EYBI!Q<8K(=6V+%'5MBX1U;8O0<6V+_&UQB
M_QI<8O\:7&+_&EQB_QK@50  RU\  +UG  "R;   J7   )]O  "4;   C&T(
M (9N$P"";R$ ?6\M 7EO. )U;D$#<FU)!6YL4 =K:U<*:6M>#&9J90YD:6P1
M86ET$U]H?A9=9XD86V>5&EEFHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI7
M9O\:5V;_&E=F_QK;60  QV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R
M$0!\<QX >',J '1S-0%P<S\#;7)'!6IQ3@=G<54)9'!<"V)O8PY?;VH076YR
M$EIM?!58;8875FR3&51LH!M2:Z\<46O!'%%KW!Q1:_$;4FO^&E)J_QI2:O\9
M4FK_&5)J_QG47   PV8  +9N  "L=   HG<  )9V  ")=0  @78! 'IW#P!V
M>!L <GDG &]Y,@%K>#P":'A$!&5W3 9B=U,(7W9:"EUU80Q:=6@/6'1P$55S
M>1-3<X0647*0&$]RGAE-<:T:3'&_&TMQV1M,<? :3'#]&DUP_QE-;_\936__
M&4UO_QG.8   OFH  +)R  "H>   G7L  )!Z  "$>@  >GL  '1\# !O?A<
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M#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0
MKWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P 5)86 %*6(@!0
MERT 39<V $N7/P%)ET<"1Y=. T66501#EET%099E!CZ5;P@\E7H).I6'"SB5
ME0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U>   JH(
M )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?&P!&H"8
M1* P $.A.@!!H4(!/Z%) 3VA40([H5D".:%A S>@:P0UH'8%,Z"#!C&@D@<P
MH*((+J"S""Z@R0@NG^<(+9WW"2V<_PHMF_\*+9O_"BV;_PJO@   HXD  )>.
M  "-DP  ?Y4  '*8  !FG   6Z   $^D  !%IP  /JD, #RJ%  ZJA\ .:HI
M #BK,@ WJSL -:M# #2L2P RK%,!,:Q< 2^L9@(MK'$"*ZQ_ RJLC@,HK)X$
M)ZRP!":LQ00FJ^0#):GU!"6H_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$
MF0  >)X  &NB  !?I@  4ZH  $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV
M*0 JMC( *;<Z "BW0P GMTP )KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK
M 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0
M;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;
MPR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'
MN0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\
M %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D
M#=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #
MU<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]
M   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8
M  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X
M .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   S
MR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H
M%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M
M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0
M'=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@
M\Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_
MI@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1
M /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8
M^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M
M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%
M60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J
M /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\
MY@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_
M"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)
MK@#K";8 Z G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_
M =L-_P'_'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L
M]1!F /,0;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A
M#[0 X ^^ -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3
M_P'_(A( _R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@
M .<6:@#D%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$
MT!>[ ,X7R0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_
M)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>
M90#5'FT TA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W
M <$@Q ' (=8!O"+J KDB^ .V(O\#M2/_ [0C_P2S(_\$LR/_!+,C_P3_*0L
M_RH% /\N" #_+PP _RT0 /,K%P#H*"( X"8O -DF/0#2)TH S2=5 ,HH7P#'
M*&@!Q2AO <,G=P'!)WX!OR>$ ;XGBP*\)Y("NR>9 KDGH *W)ZD#MBBS [0H
MOP.S*,\#L"GF!*TI]@2K*O\%J2K_!J@J_P:H*O\&J"K_!J@J_P;_+04 _S
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M#(P\[ V*//L-B3S_#8D\_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20
MQ4D  +]& @"Z0PP LT09 *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@66
M0FD&E$%P!Y)!=@B00'X)CD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!
MZ0^!0?D/@$'_#X!"_PZ 0O\.@$+_#H!"_P[Z.P  Y40  --+  #'3@  OD\
M +A,  "R20D JTD5 *5+(P"@2S$ G$L] 9A*1P*524\#DDE7!)!(7@6.1V4&
MBT=K!XE&<@F(1GD*AD6""X1%B@V"190.@$2?#WY$JQ!\1;D1>T7+$7I%YA%Y
M1O<1>$;_$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P  N%0  +%2
M  "K3@4 I$X1 )Y/( "94"T E5 Y 9)/0P&.3DP#BTU3!(E-6@6&3&$&A$MH
M"()+;@F 2G8+?DI^#'Q)APYZ29$/>$F<$'9)J!)T2;82<TG($W)*XQ-Q2O42
M<4K_$7%+_Q%Q2_\0<4O_$'%+_Q#L0P  V4P  ,A3  "]5P  M%@  *Q7  "E
M4@$ GE,/ )A4' "35"D CU0U (M30 &(4T@"A5)0!()15P5_4%X&?5!D"'M/
M:PEY3W(+=TY[#75.A YS38X0<4V9$6]-I1-M3;,4;$W%%&M.X11K3O03:T[_
M$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P  *9:  "?5@
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M$E==_Q+64P  Q%P  +=C  "L:   H&@  )5G  "*8P  @V4" 'UF#P!X9AH
M=&<G '%G,@!N9SL!:V9# FAF2P-E95(%8V59!F%D7PA>9&<*7&-O#%IC> Y8
M8X,05F*/$E1BG!-38JH54F*[%5%BTA518>T54F'[%%)A_Q-38?\24V'_$E-A
M_Q+15@  P%\  +-F  "I:P  G&L  )!J  "%9P  ?6D  '=J#0!S:Q< ;VLD
M &QL+P!I;#@!9FM! F-K20-A:U $7FI7!EQJ70=::64)6&EM"U5H=@U3:($/
M46>-$4]GFA).9ZD436>Y%$QGSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,
M6@  O&,  +!J  "E;P  F&X  (QM  " ;   =VT  '%N"P!M;Q0 :7 A &9Q
M+ !D<38!87$^ 5YQ1@)<<$T#67!4!5=P6P95;V((4V]J"E!N<PQ.;GX.3&V*
M$$IMF!%);*<22&RX$T=LS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@
MN&<  *QN  "A<@  DW(  (=Q  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>
M=S, 6W@\ 5EW0P)6=TL#5'=2!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5S
ME@]#<Z400G.V$4%SRQ%"<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP
M *AS  ";=@  CG4  (%V  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\
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M!R^.PP<OCN$'+XST""^+_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A
M?84  '"'  !EB@  6HX  $^2  !&E0  09@, #Z8%  ]F1\ .YDH #J:,0 Y
MFCH -YI" #::2@ UFE(!,YI: 3&:9 $OFF\"+9I[ BR:B@,JFIH#*9JL!"B:
MP 0GF=X#)Y?R!">6_04GE?\%)Y7_!2>5_P6I?@  GH4  )*)  "$B@  =HP
M &J/  !>DP  5)<  $F;  ! GP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ MI#(
M+*4Z "NE0P JI4L *:54 "BE7@ FI6D ):5V 2.EA0$BI98!(*:H 1^ENP$>
MI=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8
M  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q
M !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX
M$['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0
MJ   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]
M+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?
M  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP
M/+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $
MRBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,
MX@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X
M ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(
M -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R
MWMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+
M   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>
M  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(
M .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +
MVP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R
M&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO
M  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4
M_P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S
M +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H
M_P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K
M /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +(
MZ@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_
M%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8
M;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X
M -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!,
M_Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I
M!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&
MP #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD,
M /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T
MVPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&
M#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?
M" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O
M ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L
MMQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\
M) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?
M<0"Z'W@ N1]^ +<?A0"V'XP M!^3 +,?F@&Q(*,!L""L :X@MP&L(<8!JR'=
M :<B[P*E(OT"HR/_ J(C_P*B(_\"H2/_ J$C_P+_)0  _R@  /(J  #E*P
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M"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&  "I000
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M"V!-_PO<1P  QU   +E6  "N60  HE@  )A6  "040  B5(& (-3$0!_4QT
M>U0I 'A4- !U5#T!<E-% 7!33 )M4E,":U)9 VE28 1G46<&95%O!V-1> AB
M48,*8%&/"UY0FPU=4*D.6U&Y#EM1S@]:4>H.6U'Z#5M1_PQ;4?\,6U'_"UM1
M_PO62@  PU,  +99  "K7   GEH  )-9  "+5   A%8# 'Y6$ !Z5QH =E<F
M '-8,0!P5SH ;5=" 6I720)H5E "9E97 V167@1B564%8%5M!UY5=@A=58$*
M6U6-"UE4F@U85*<.5E6X#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS1
M30  P%8  +-<  "G7@  FET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;
M+@!K6S< :%M  65;1P%C6DX"85I5 U]:7 1=6F,%7%IK!EI9= A867\*5EF+
M"U19F U36*8.4EFV#E%9R@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40
MO%D  +!?  "C80  EF   (M?  "!6P  >5T  '-># !O7A4 :U\@ &A?*P!F
M8#4 8V ] 6%?10%?7TP"75]3 UM?6@197F$%5UYI!E5><@A37GT)45V)"U!=
ME@Q.7:0-35VT#DQ=R Y,7>8.35WW#4U<_PQ-7/\,3ES_#$Y<_PS)5   N5P
M *UC  "?8P  DF,  (=B  !\8   =&$  &YB"0!I8Q( 9F,= &-D* !A9#(
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M"CUNP@H\;N */6WT"CUL_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0
MA&T  'AM  !L;@  87   %MR  !6= H 4G42 %!V'0!.=R< 3'<Q $MX.0!)
M>$$ 2'A) 49X4 %$=U<"0G=? T!W: ,^=W,$/'9_!CIVC0<Y=IP(-W6M"#=U
MP @V==X(-W3R"#=S_@@W<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0  ?G$
M '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T
M08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P
M?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW
M  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E
M #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#
M*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=
M@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V3
M00 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L
M 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0
M38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ A
MGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<
M]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@
M #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD
M$ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -
MJ/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G
M   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y
M  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$
M +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   C
MM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##
M.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N
M  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP
M$<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0
MTC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8
MW0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP
M  +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH
M .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!P
MJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=
M    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G
M  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL
M_P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#]
M 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X
MPP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5
M /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '<
M\P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C
M ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&
M$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y
M .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@
MT@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_
M"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T
M>P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7
M ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X
M_PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,
M!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)
MZ0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$.
M /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7<
MOPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K
M$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40
M#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X
M +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O<
MG1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*
M%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?
M>0"C'X  HA^' * @CP"?()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_
M 9$C_P&0(_\!D"/_ 9 C_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T
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M!6P\_P7B.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$
MA4 M () -P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N
M/X0$;#^0!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65
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M!EY(EP==2*4(6TBT"%M(QPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110
MOTP  +)2  "C40  EU   (U.  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M
M338 :DP_ &A,1@!F3$T!9$Q3 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,
ME0=73*,(5DRR"%5,Q@E53.()54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%
M *]5  "@5   DU,  (E1  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#,
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M"$=8P A'6-T(1UCR"$=7_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P
MAUL  'U:  !R6   :UD  &5: P!@6PX 75P7 %I<(0!872L 5ETT %1>/ !3
M7D0 45Y+ 5!>4@%.7ED"3%YA DM=:@-)770$1UV !45=C09$79P'0UVL!T)=
MO@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?  "07@  @UX
M 'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.8T$
M3&-( $MC3P%)8U8!1V-> D5C9P)$8W$#0F-]!$!BBP4_8IH&/F*J!CUBO <\
M8M8'/6'O!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+80  ?V$  '1A
M  !I80  7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI-@!(:3X 1FI%
M $5J3 !#:E0!0FI< 4!I90(^:6\"/&E[ SMIB00Y:9@%.&BH!3=HN@4W:=,%
M-VCN!3=G_ 4X9O\%.&;_!3AF_P6T7@  IV4  )5E  "&9   >F4  &]E  !D
M9@  66@  %)J  !-; 0 26X. $=N%@!%;R  1' I $)P,@!!<#H 0'%" #]Q
M20 ]<5$ /'%9 3IQ8@$X<6P"-G!X C5PA@,S<)4#,G"F!#%PN 0P<- $,6_L
M!#%N^P0Q;?\$,6S_!#%L_P2O9   H6D  (]H  "!:   =6D  &MI  !@:P
M56X  $UQ  !&<P  0G4+ #]V$@ ]=QP /'<E #IX+0 Y>#4 .'D] #=Y10 V
M>4T -7E5 #-Y7@ Q>6@!,'ET 2YY@P(M>9("*WBC BIXM0(J>,P"*G?J BIV
M^0,J=?\#*G3_ RIT_P.J:@  FFT  (EL  !\;0  <&T  &9N  !;<0  4'4
M $AX  !!>P  .GX% #9_#@ T@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M@D@
M+()0 "N"6@ J@F0 *()P ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B
M?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.
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M !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP
M)IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +
MI%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A
M^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4
M !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<
M +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'
MB0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T
M   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(
M  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@
M<)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "
MP@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.
M20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$
M %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@
M -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/
MXTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R
M  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\
M  #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP
M /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_
M !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@
M@P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A
M .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4
M_P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M
M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H
M[ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P :
M /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (
MX "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#)
M /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P
M( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "
M ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /(
MNP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F
M "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$
M@0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[
M *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT
MT@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S
M!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-
M_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB
M , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX
MIP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5
M%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03
M*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>
M )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\
MB1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D
M'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@
MA ",((T BB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_
M 7\D_P'L)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H
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M FPTF )J-:4":36S V@UQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P
MQ#X  +5"  "F00  FS\  ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W
M.3H =3E" ',Y20!Q.5  <#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0Y
ME0-C.J(#8CJQ V$ZPP-@.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(
M +!%  "A1   E4,  (U   "'/0  @CL" 'T[#@!Y/!@ =3TC ',]+0!P/38
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M!%!'O01/1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53
MB4L  ']*  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9
M240 5TE* %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+
MO 1*2],%2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X
M 'M-  !S20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$
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M SQ7^@,]5O\#/5;_ SU6_P.V4P  I5<  )17  "%5@  >58  &]6  !E50
M7%8  %=8  !260< 3EH0 $Q:& !*6R$ 2%PJ $=<,@!%7#H 1%U! $-=2 !"
M75  0%U8 #]=80$]76L!/%UV CI=A (Y79,".%VC S==M0,V7<L#-ESH S=<
M^0,W6_\#.%O_ SA:_P.R5P  H%H  (]9  "!60  =5D  &M9  !@6@  5EL
M %%=  !,7@( 2& - $5@% !$81X 0F(F $!B+@ _8C8 /F,^ #UC10 \8TT
M.V-5 #EC7@ X8V@!-F-T 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q
M8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB
M  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2
M #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"
M*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  !
M:P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR
M5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_
M 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@
M-'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A
M>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW
M_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT
M ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8
M%H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1
M;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*
M   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<
M  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P
M>W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3
MEP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=
M8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD
M &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP
M":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60
MJ6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$
M  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(
M  "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T
M +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.
ME@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^
M    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB
M  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I
M.JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*
MS    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?
M9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@
M "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9    VP
M -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6
M\VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\
M+ #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@")
M /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L
MX@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_
M #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8
MB@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_
M -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\
M]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5
M (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,(
M_P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V
M ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8
MQ0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T
M /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O -$
M.P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"'
M +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G /\
MI@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_
M #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@"" *D
MB0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_
M )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#<
ML 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";
M"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T.
M_P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[
M *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H
MCQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M
M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86
M/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0
M ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@
MT"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")
M'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<A
MEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#
M +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT
M?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L
M**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V
M  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q
M ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!
M8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";
M.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ
M0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J
M 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0
MBSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C
M-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6.9D!53FH E0Y
MN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20   AC\
M 'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=.T,
M6SM* %H[4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^MP).
M/LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I
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M D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@
M8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])
M]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<
M %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X
M0TU6 $)-7P!!36@ 0$UT 3Y-@0$]39 !/$V@ 3M.L0(Z3L8".D[D CM-]@([
M3?\!.TS_ 3Q,_P&S30  GDP  (U,  !_3   =$P  &I,  !@2@  64L  %1,
M  !0304 3$X. $E/%0!'3QX 14\F $10+@!"4#4 05 ] $!11  _44L /E%3
M #U27  \4F8 .E)R #E2?P$X4HX!-U*> 392KP$U4L0!-5+B 392]0$V4?\!
M-E#_ 3=0_P&N3P  F4\  (E/  ![3P  <$\  &9/  !<3@  5$\  $]1  !*
M4@$ 1E,, $-4$@!!5!L 0%4C #Y5*P ]5C( /%8Z #M600 Z5DD .5=1 #A7
M6@ V5V, -5=O #17? $S5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q5O\!,57_
M 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P
M0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P
M76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:
M_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$
M #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T
M*&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<
M6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H
M"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE
M !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57
M@UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C
M<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U
M;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6
M &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <>P<
M%WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -
M?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE
M  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A   $(<(
M  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$
M 8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;
M;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3
M#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z
M  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4=0
M27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0
MGPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "C
MA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4
M #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!   JPH
M *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0
MLHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9
M   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(  +D(
M  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((
M ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =
MK0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<   #)
M!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*
M  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5NP
M#;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8   #9
MVP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z  #O
MCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!!
M /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\
MZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#=
M /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@
M2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0
M -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\
MRP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G
M $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L
MD@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_
M +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $<
MT@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z
M )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T
M_P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!*
M +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M (\
MJP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_
M    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !# +$
M3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3
M )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0
MZ@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B
M $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !
MF0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0
M ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4<
ME0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"#
M#*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=
M  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!(
M (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J
M=Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E
M(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X7
M2@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK
M &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@
MDR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R
M'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(C
MN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T
M (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4<
M:"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:
M*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O
M  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I*
M %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\<
M4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S
M,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O
M30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C
M 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-
M:3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1
M-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X
M]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8
M & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X
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M 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@(
M24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y
M1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&
M_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P  1$<*
M $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\
M,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A
M1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-
M#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G
M "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@
MB4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53#  S
M5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97
M<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X
M '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\
M*EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >
M7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1
M  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1
M "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H
M%66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@
M5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P. !AL
M$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'
M  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@
M5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .
M=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -W
ME  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F
M $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$
M X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0
M@:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K
M   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3
M  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID
M (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O
M>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</  "8
M$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)   )NE
M  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP
M'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E#@
MIA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "K
MKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL
M !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T"   M0T
M +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I
MO;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D   FN
M    L@   +8   "Y    O0   +\   "_    P    ,$   ##    Q 4  ,8*
M  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD
M -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]
MP0   ,0   #(    RP   ,T   #-    SP   -    #2    U    -@   #:
M!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH
M  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %(
M^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D
M )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0
M_P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5
M .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D
MT0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_
M    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D
M6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"<
M +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_
M_P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$
M %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +
MH "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_    _@
M /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %,
ML@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@
M *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \    .$
M  #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4
M *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$
MD0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_
M!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8
M5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I
M (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@
MJ T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@")
M E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&
MM0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,
M )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\
M?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L
M#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9
M  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0
M '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8
M8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^
M'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@8
M40!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@
M %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P
M<R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>
M'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D
M\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4
M &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%
M5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!*
M*?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G
M 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4
M $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX
M12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9
M+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N
M60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_
M $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8
M43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P!
M,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV
M_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0,
M $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X
M.CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B
M.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y
M$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG
M #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P
MBSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \
M/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!
M<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX
M '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A(
M-4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I
M1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"
M  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6
M "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP
M(DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D
M10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/
M&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&*
M !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2
M5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?
M5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18
MF@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL
M $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 771D
M%EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -
M7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0
M  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;
M  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,
M F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [
M6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P
M'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R
M  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4
M! E15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$
M  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\
M 'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,
M7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  ""
M"   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H
M  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9
M/&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!
MC@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5
M<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70
M "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (
M )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:
MIGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'
M   9C0  $9(   N7   $G    *    "C    I@   *@   "I    J@   *P
M  "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$
M +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2
MG0  #*(   .G    JP   *X   "R    M@   +@   "X    N@   +L   "]
M    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ
M  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K
M [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-
MS@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F
M@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X
M /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4
MY "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1
M /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /
M/@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"%
M -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\
MOP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #;
M $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\
MA@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_
M +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P
MP@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M
M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$
M_P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _
M *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> ((
MG "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W
M    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *
M0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"%
M (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L
MTP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1
M $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (
MB@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L
M +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L
M@P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S
M )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82
M  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\
M '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")
M9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0
M&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,
M/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^<
M %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@
M?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C
M$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5
MJ0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(
M ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL
M61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*
M'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE
M  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T]
M % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8
M0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@
M)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB
M0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?*
M #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P
M6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!
M)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<L
MY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL
M % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T
M.RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S
M,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM
M  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!&
M #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8
M+S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !"
M,@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U
M3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_
M "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@
M.C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J
M.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[
M_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L
M #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U
M(T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P")
M.0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!
M!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459
M !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/
M<ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D
M1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+
M8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T
M &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308
M&T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /
M4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$
M  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8)
M !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@
M!UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !0
M2   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@
M#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S
M  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3
M14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #
M9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I
M@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$
M #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T
M '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0
M<XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<
M   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.
M  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8
M ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C
M:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")
M#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5
M  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P
M%'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#  "7"
MF P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?
MH@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L
M  :0    E    )@   "<    GP   *$   "B    I    *4   "G    J 0
M *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF
ML:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?
M    I    *@   "L    KP   +$   "Q    LP   +4   "V    N    +H
M  "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\
M ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O
MLP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-
M    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B
M  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@
M\P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #<
M ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$
M_P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+
M .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X
MQ@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_
M    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H
M30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0
M +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_
M_0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U
M $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *,
ME "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@
M -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@
MH@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2
M )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<
M  "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !(
M )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0
M@@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J
M    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4
M1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"<
M '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@
MDP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W
M $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@
MI@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T
M ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $(
M:P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!<
M [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81
M  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=#
M &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[,
M4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J
M%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-
M10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'(
M $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@
M7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/
M$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7
MXP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P
M %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T,
M1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 [
M'?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>
M  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU'
M #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?,
M-B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)
M(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B
M3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_
M #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)
M020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q
M)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI
M_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@"
M #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$
M*RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"*
M*P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L
M"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9
M "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0
M=2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M
M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U
M8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(
M &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L
M)3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9
M.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U
M  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P.
M !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP
M$T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2
M.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#
M$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y
M  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P
M1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 1
M2A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+
MAP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X
M #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41
M"E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0
M498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"
M   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2
M  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69
M %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O
M20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A
M%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@
M  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4
M(U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0
M:Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !L
ML   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P
M !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$
M '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@
M>,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K
M   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01
M  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D
M (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "
M?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5
M$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'
M  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C
M )$   "5    F    )H   ";    G0   )\   "@    H@   *0%  "F"@
MJ X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "K
MRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$
M  "E    J    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<
M +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^
M<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0   +(   "V
M    N0   +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%
M  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_
M_P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J
M %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\
MH0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P
M /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %,
MT0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[
M *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@
M  #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3
M +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *
MJ "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7
M    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D
M4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F
M )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!
MMP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7
M %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (<
MKP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@
M )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P
MAP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W
M +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )
M @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+
M '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0
M:@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_
M  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P
M2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@##
M %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!
M<0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@
M $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0
MV@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD#
M &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4<
M5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*
M!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-
M!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E*
M $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X
M0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4
M#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.
M3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+]
M #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P,
M3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \
M$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06
M_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118'
M $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$
M-!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*
M'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:
M#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9
M "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(
M=",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U
M'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B
M8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24
M &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T
M+B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A
M)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I
M  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0
M "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL
M&RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3
M+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L
M$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y
M !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@
M2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;
M,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$U
MB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13
M #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q,
M%#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,
M.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS
M   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5
M  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0
M!#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T
M-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$
M&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D
M  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.
M*SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@
M2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+
MM0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX
M ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@
M %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0
M4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'
M   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:
M  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4
M %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   2
M4P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F
M'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>
M  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7
M"&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P
M<QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P
M[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L
M  !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8
M (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*
M3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]
M    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06
M  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50
M.5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-
MD0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H
M%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,
M "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@
M *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)  "[$
MOA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X
M   6@   #8@   6/    E@   )P   "B    IP   *P   "P    LP   +8
M  "W    N0   +L   "]    OP   ,(   #%    R    ,H   #."   TA
M -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_
M  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$
M7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W
M ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $
M\P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#&
M %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +
MP@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 '
M -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@
ML0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0">
M -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H
M# "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7
M )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8
MC #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A
M  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T
M50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #<
M 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P
MC0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\
M %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X
M[0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ .
M 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\
M;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A
M /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\
M$ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/
M &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$
M5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C
M !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8
M40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z
M $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X
M6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+
M %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $,
M_P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0
M $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$
M0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".
M$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D(
M$0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8
M #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P
M=Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@!
M#1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/
M8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD
M &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!
M.! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J
M%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =
M  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02
M # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H
M(QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3
M(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8
M%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW
M !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@
M2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C
M'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@B
MAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124
M #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14
M'2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2
M)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF
M   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8
M !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8
M#BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T
M*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L
M'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E
M  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@
M+2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -
M,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (S
MM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP
M "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T
M!S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP
M.,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P
M   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA
M   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<
M #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;
M-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%
M)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C
M  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/
M$C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(
M3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*
M\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8
M  M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,
M %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+
M/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51
M    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F
M  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0
M/S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;
M7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O
M*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,
M #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P
M &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@
M?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],
M   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P
M  !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4
M )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >
M7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".
M    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I
M  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0
M#W    =W    ?@   (0   "*    CP   )0   "8    FP   )X   "?
MH@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[
M,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8
M  "(    CP   )8   ";    H0   *8   "J    K@   +    "Q    M
M +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0
MTC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P
M$0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C
M -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H
MN0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B
M !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P
M8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y
M *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !(
MPP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G
M &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0
M_P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6
M *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H
MDP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$
M /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0
M&0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!:
M ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\
M= #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "!
M !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$
M6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_
M &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8
M<  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C
M %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H
M_P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8
M &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8
M5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<
M    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %<
M&0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!:
M $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!
M@ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!-
M !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$
M7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P
M &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8
M1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X
M &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00
M  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8
M #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8
M+P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4
M%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(
M&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS
M "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P
M2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M
M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0
MA  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D
M #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@
M)A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9
M%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;
M   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,:
M !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&),
M$QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T
M'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8
M'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE
M  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P
M+1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4
M'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@
MM0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B
M "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\
M#R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &
M),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A
M   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C
M  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4
M 2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?
M(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L
M*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@
M   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@
M&2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0
M,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q
M\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP
M !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H
M #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1
M*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S
M   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O
M  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@
M0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )
M/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(
M-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(
M #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1
M $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,
M4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U
M   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\
M  !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738
M %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K
M.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<
M    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\
M  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0
M'40  !9)   030  "E$   15    6@   %T   !@    8P   &8   !H
M:@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y
M10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX
M !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W    >0
M 'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P
MC4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA
M   !9P   &T   !R    =P   'L   !_    @P   (8   "(    B@   (T
M  "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0
M *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P
M=P   'T   "#    B    (T   "1    E0   )@   ":    G    )\   "A
M    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.
M  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0
M (\   "6    FP   *    "D    J    *L   "L    KP   +(   "T
MM@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/
M6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @
M /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@
MR0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E
M /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8
M) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G
M +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\
MD@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W
M "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X
M9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_
M (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "(
MGP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"(
M &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8
M_P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C
M (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$
M=@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#
M    JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '<
M) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C
M &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L
MF0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G
M "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@
M9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP
M 'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\
M60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+
M &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '
M  !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @
M $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@
M0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=
M!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $,
M( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q
M #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#
M3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z
M "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X
M?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X
M $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T
M,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F
M 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1
M   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,>
M "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL
M'@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U
M$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)
M(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R>
M !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%
M+1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =
M#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0
MLP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4
M "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$
M%A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -
M$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06
M   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F
M !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$
M"!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?
M&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8
M*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:
M  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0
M&AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P (
M'2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =
M[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L
M !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP
M 2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5
M'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>
M   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R
M   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(
M12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /
M(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M
M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020
M #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*
M"BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@
M,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G
M   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !
M  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX
M #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K
M*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y
M @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'
M  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P
M)2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!
M0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,
M40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\
M !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*    3
M $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P
M5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X
M   1/   #$    =$    1P   $H   !-    4    %,   !5    5P   %D
M  !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<
M &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,
M1@  !DH   !/    4P   %8   !9    7    %\   !A    9    &4   !G
M    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C
M  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@
M %<   !<    8    &0   !H    :P   &X   !Q    <P   '4   !W
M>@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&
M<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8
M  !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*    C
M (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P
MFH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]
M    @@   (8   "+    CP   ),   "5    EP   )H   "=    H    *,
M  "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0
M +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0
ME0   )H   "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z
M    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!
M  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X
MX@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^
M '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\
M_P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P
M ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$
MIP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H
M    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D
M,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R
M )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9
MS0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1
M #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X
M=0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0
M *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L
M?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L
M 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )
M  "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J
M &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ',
M6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U
M    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P
M*@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![
M $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G
M7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !.
M "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $(
MA@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50
M $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0
M0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W
M ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#
M  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D
M #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X
M+0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [
M!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #
M)  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"=
M "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P
M,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G
M "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X
MK@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T
M "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "(
M(  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8
M ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.
M   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E
M !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P
M$@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @
M#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0*
M*0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2
M  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$
M&A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /
M#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.
MZ !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$"
M !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T
M"Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5
M$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2
M!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S
M  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%
M1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1
M$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8
M.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@
M #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8
M#A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.
M'40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;
M   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%
M  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$
M ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K
M'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?
M!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+
M   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P
M(QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!
M)@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M
M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2
M !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00
M "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P
M-&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA
M   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$
M   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$
M #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4
M)@  $"@   TK   )+@  !3     S    -0   #@    Z    /    #X!  !
M P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q
M  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0
M#3    DS   #-@   #D    \    /@   $$   !#    1@   $@   !*
M3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0
M@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D
M  (]    0    $,   !&    20   $P   !.    40   %,   !5    5P
M %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P
M7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(
M    3    $\   !2    50   %@   !;    70   &    !B    9    &8
M  !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L
M &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5
M60   %T   !A    90   &@   !K    ;0   &\   !R    =    '<   !Z
M    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;
M  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0
M &X   !R    =@   'H   !]    @    ((   "%    B    (L   ".
MD@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5
MIP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V    >P   (
M  "&    B@   (X   "1    DP   )8   "9    G    *    "C    IP
M *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <
M3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP   )0   ":
M    GP   *(   "D    IP   *H   "N    L0   +0   "X    O    ,$
M  #'    S0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
M                 0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ
M*RTN+S R,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C
M969G:6IK;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=
MGI^AHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76
MU]G:V]W>W^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________
M____________________________________                      $#
M! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\
M/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U
M=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VO
ML+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?H
MZ>OL[>[P\?+T]?;W^?K[_/[_____________________________________
M_________________P                     ! P0%!@@)"@L-#@\1$A,4
M%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.
M3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'
MB(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!
MPL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ
M^_S^______________________________________________________\
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MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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M@K&+PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"]\ 0%?C %C'YO2!3ZK<H?,RH
M1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0
MUJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&
MI5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(
MD]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VT
MPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BM
MAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-P
MNKZB?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB
M?[^\H(C#N9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\
MH(C#N9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#
MN9N(QK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(
MQK>8B,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8
MB,JUE8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
M]\ 0%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JU
ME8G-LY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0
M%?C %C'YO2!3ZK<H?,RH1*K&I5VTPJ-PNKZB?[^\H(C#N9N(QK>8B,JUE8G-
MLY**T+&/B]*PC(W4KXJ0UJZ(D]BMAIC9K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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MP(JL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MB9#.LX>2T+*$E=*Q@IG3L8&>U*Z HM2L@*/2K("CTJR H]*L@*/2K("CTJR
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MUI.2H-:3DJ#6_;L1#?V\&2;^N21&]K0N:MRK.I+'H%RQQ*%HML&E<;J^IWK
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MB:N&RH>KALJ%JHC*@ZJ)RX&JB\N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R
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M[))I>N&1<XK8CWR8T(Z$I,J.C*W&C9"TQ(J3M\.&E;C"A)BYP8&;NL%_G;O
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MO+R;B,*YE8K'M8V-SK"&EM2I@J#6H8*DT)V"J,N:@ZK(F8.MQ9>$K\*6A+#
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M\[8Y<.J_-WWCRC6'U-$WE;["2ZFPN6"UJ+1PO:.P?L*=K83'DJJ$RXBGALZ
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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MM+J*B[2ZBHNTNHJ+M+J*B[2Z_YP0 ?^A)@K_H#8<_YY",?^E0#[_JT!,_[%
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M;,R:_X82 ?^((0;_B#44_X9&)?^'4S7_BUM#_XQB4?Z*:E[VAW%J\(1Z=.J
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M2CO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+MKH" *;*  "8W
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M9T7NYV=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0
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M2X#48%=VT6AA;<]P:67->G!>S(9U6,R5>53,IGM1S;Q\4,SB?%/!X']5M]^
M6+'>@5JKWH%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_
MH@T V[4( ,[!" #&T D OND2 K3I)0JJZ#,7H.8^)9;E1S*+XTX_@.%527;@
M75-MWF9;9=UO85[=>F=8W(9K4]R5;U#=IG%-WKMR3=_A<4[1YW10QN9W4K[D
M>%.XY'E5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z_X,. ?^6"P#=JP0
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MYW68;N=UF&[G=9ANYW68;N=U_V<6 ?]D( /_<!X#_WXB!?^++ G_DS<0_YA
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M@(#;A8" W8. ?]Z!@'[@?X!]X7V ?>-[@'SD>H!\Y'J ?.1Z@'SD>H!\Y'J
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M>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X
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M8$N]]F!+O?9@2[WV8$N]]F!+O?9@_XD  -F>  #'K $ N;8" *[! P"ES@8
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M;W*#[6US@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X
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M9%R7\V1<E_-D7)?S9%R7\V1<E_-D_W - /^$! #=E@  SJ,# ,2N! "[MP0
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MD@\;_Z(0&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,
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M8']S^%Y^<_E<?G+Z6GYR^UE^<OM9?G+[67YR^UE^<OM9_U@7 ?]G$ '_=0X
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M6FN!^UIK@?M::X'[6FN!^UIK@?M:_V(0 /]R!P#X@@, VX\" ,^:!0#)HP8
MPZP& +VR$ "ULB0"K+ U"Z.M0A>;JDPCDJ95+HJC73B#H&5 ?9UL1W:;=$UP
MF7U3:Y:(6&:5E%QBE*%?7Y.R8%V3R6!=D^U?7I#X7F&,^5QCBOI;9(?[6F6&
M^UEEAOM998;[666&^UEEAOM9_V8- /]W P#CAP  TY,! ,J>! #"IP0 NZ\$
M +6V#0"NMR$"I;8R"9VS/Q64L$H@C*U3*X2J6S1]J&,\=J5J0W"C<DIJH7M/
M9:"&5&">D5A;G9];6)VP75:=QUU6G>M<5YKZ6UJ5^EI<D?M97H[\6%^-_%=?
MC?Q77XW\5U^-_%=?C?Q7_VH* /]\  #<C   S9@  ,.C P"ZJ@( L[,! *R\
M"@"FO1T!GKPO!I:Z/!&-N$<<A;50)WVS63!VL6 X;Z]H/VFM<$5CJWE*7JJ$
M3UJID%)5J)Y54J>O5U&HQE=0I^I74*7\5U.?_5=5FOU65Y;^5EB5_E58E?Y5
M6)7^55B5_E58E?Y5_V\$ .:"  #2D0  QIT  +NF 0"RK@  JK<! *+"!0"<
MQ!@ E<,J!(W".0V%P$08?;Y.(76\5BINNEXR:+EF.&*W;CY=MGA#6+6"1U2T
MCTM0M)U.3;.N4$NTQ5!+L^I02K'_44RK_U).I?]24*'_4E&>_U%1GO]149[_
M45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P" )C&!@"1S!(
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MMB8U\=(F-._S)C3L_R8RZ_\H,N?_*S/D_RPSY/\L,^3_+#/D_RPSY/\LP9P
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M"13_PPD3_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$  (N]  !\R
M;=0  %_@  !1Y@  1_4  $'_   \_PD -_\0 #+_%0$N_QT!*O\C 2;_*0$B
M_R\"'_\U AS_.P(9_T(#%O]) Q/_40,1_UH##_]F! W_= 0+_X4$"O^6!0G_
MJ 4(_[D%!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP  7^
M %#G  !"[0  .O\  #7_   O_P( *O\* ";_#P B_Q0 'O\: 1K_'P$6_R,!
M$_\H 1#_+0$._S,!#/\Y @K_00('_TD" _]3 @#_7@( _VP" /]\ P#_C0,
M_YT# /^L P#_M0, _[4# /^U P#_M0, _[4#_SDG O\S,@+_-30#_S@V _\X
M.P3_-D,%_S-.!_\Q6PG_+V@-_RUV$?\KA!3_*9$6_RF;&/\HI!G_**T:_RBU
M&_\GOAS_)\@<_R?4'?\GY!W_)^\>_R?Y'O\G_Q[_)_\>_R?_'?\H_QW_*_\>
M_RW_'_PO_Q_\+_\?_"__'_PO_Q_\+_\?_SHG O\T,0+_.#$#_SLT _\[.03_
M.D$%_S=+!_\U6 K_,V4._S%S$O\O@17_+8X7_RV8&?\LH1O_+*H<_RNR'?\K
MNQ[_*\0?_RO0'_\JX2#_*NT@_RKW(/\J_R#_*_\@_RO_'_\L_Q__+_\A_#'_
M(O<S_R+W,_\B]S/_(O<S_R+W,_\B_SLF O\U, +_.R\"_SXQ _\_-@3_/CT%
M_SQ(!_\[50O_.6(/_S=O$_\U?1?_,XH9_S*5&_\QGAW_,*<>_S"O'_\PMR#_
M+\ A_R_+(O\OW"+_+^HC_R_U(_\O_B/_+_\B_S#_(O\P_R/[,_\E]37_)? W
M_R;P-_\F\#?_)O W_R;P-_\F_SPF O\Y+0+_/RP"_T,M _]$,@3_0SD%_T-%
M!_]"4@O_0%\0_SYK%?\[>!C_.84;_S>0'O\WFB#_-J,A_S6K(O\ULR/_-+PD
M_S3&)?\TU"7_-.8F_S3Q)O\T^R;_-?\E_C7_)OHV_RCS./\I[#K_*>8\_RKF
M//\JYCS_*N8\_RKF//\J_STE O\]*@+_0R@"_T<I _])+03_2C8%_TI!!_])
M30S_1UH1_T5G%O]"=!K_0( =_SZ,(/\]E2+_/)XD_SNF)O\[KB?_.K<H_SK!
M*/\ZS2G_.N$I_CKN*?LZ^2GW._\I]CK_*_ [_RWH/?\NX3__+MM!_R[;0?\N
MVT'_+MM!_R[;0?\N_SXE O]!)@+_2"0"_TPE O]/*0/_4C,%_U$^!_]120S_
M3U82_TQB%_]*;QS_1WL@_T6&(_]#D27_0IHG_T&B*?]!JBK]0+(K_$"\+/L_
MR"WX/]LM]$#K+?! ]RWM0/\OZS__,>1!_S+;0_\ST43_,\M&_S/+1O\SRT;_
M,\M&_S/+1O\S_T D O]%(P+_3" "_U(A O]6)@/_62\$_UDZ!_]91@S_5E$2
M_U1=&/]1:AW^3G4A_$R!)?E*BRCW294K]4>=+/-'IB[R1JXO\$6X,.]%Q#'M
M1=,QZ$;H,>5&]C+B1?\UWT3_-M-'_S?*2/\XQ$K_.+]+_S>_2_\WOTO_-[]+
M_S>_2_\W_T$C ?])'P'_41P!_U<< O]<(P+_8"P#_V V!O]@00O_7DT1_5M8
M&/A89!WT57 C\5-\)^Y0ABOK3Y NZ4V9,.=,H3+E3*HSXTNT-.)+P#7@2\\U
MVTOF-M5*]#C12O\ZSDK_/,1,_SR]3?\\N$__/+1/_SNT3_\[M$__.[1/_SNT
M3_\[_T(B ?],' '_51@!_UP9 ?]C( +_9B@#_V@R!?]H/0GZ9D@0]&-3%^Y@
M7QWJ76LCYEIV*.)7@2W?58LPW%.4,]E1G3;54*8XTT^O.M!/NSO.3LD\RT_A
M/<=/\C[#3_] P$__0;=1_T&Q4O] K5/_0*I4_S^J5/\_JE3_/ZI4_S^J5/\_
M_T8? ?]0&0'_614!_V(7 ?]H'0'_;"0"_V\N _EO. ?Q;D0.ZVM.%>5H6QS?
M9&<CVF!Q*M1=>R_06X4TS%B..,E7ESO'5: ]Q%2I/\)3M$&_4\)"O5/60[E3
M[42V4_U%LU3_1:Q6_T2G5_]$I%C_0Z%8_T*A6/]"H5C_0J%8_T*A6/]"_T@=
M ?]3%@'_71(!_V84 ?]M&0'_<B$!^W4I O)V,P7I=CX+XG-*$MMO5QK2:V(C
MS6=L*\AD=C'$87\WP%Z).[U<DCZZ6YI!MUFD1+58KD:R5[M'L%?-2*U8Z$BJ
M6/I)IUG_2*%:_TB=6_]'FUS_1IE<_T697/]%F5S_19E<_T697/]%_TL: ?]7
M$P'_81  _VL2 /]R%@#_>!P!]7LD >M]+0/B?CD'V7M&$-!V4QK)<5XDPVUH
M++YJ<3.Z9WLXMF2#/;)BC$&O8)5%K%Z?1ZE=J4JF7+9+I%S'3*)<XDV?7?=,
MG%[_3)A?_TJ58/])DV#_2)%@_T>18/]'D6#_1Y%@_T>18/]'_TX8 ?]:$0'_
M9 X _V\0 /]V$P#\?1< [X$> >2$)P+;A#0%T(%##\A\3QG!>%HCNW-D++5P
M;3.Q;'8ZK6I_/ZEGB$.E99%'HF.;2I]BI4V<8;%/F6#!4)=@W%"58?-/DV+_
M3I!C_TR.9/]+C&3_2HMD_TB+9/](BV3_2(MD_TB+9/](_U 6 ?]<$ #_: T
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M379Q_TQV<?],=G'_3'9Q_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(! #/D 8
MRI8( ,2:$@"\FR8"M)@W":R51!2DD4X?G8Y7*):*8#&0AV@XBX1P/X:">$2!
M?X%)?7V+37A[EE%T>J)4<7FQ5F]YQ59N>N95;GK\4V]Y_U%P=_]/<7;_37%U
M_TQQ=?],<77_3'%U_TQQ=?],_UL. /]I! #V=P  W8(  -"+ P#)DP4 Q)D&
M +Z>$ "VGR0"KITT"*::01.?EDP=F)-5)Y&07B^+C64WA8IM/8"(=4-[A7Y(
M=H.(3'*"DU!N@*!3:W^N56A_PE9G?^-5:(#Z4VE^_U%J?/]/:WO_36QY_TQL
M>?],;'G_3&QY_TQL>?],_UX, /]L 0#F>@  UH8  ,N/ @#$EP0 OIT$ +BB
M#@"QHR$!J:(R!Z&?/Q&9G$H;DIE3)8N67"V%DV,U?Y%K.WJ.<T%UC'Q&<(J%
M2VN(D4]GAYU29(:L5&*&OU5AAN%488;Y4F.$_U!E@?]/9G__36=^_TQG?O],
M9W[_3&=^_TQG?O],_V$* /]O  #@?@  T(D  ,:3 0"_FP, N*$" +&F"P"J
MJ!X!HZ<O!9NE/0^4HD@9C)]1(H6<62M_FF$R>9AI.725<3]ODWE$:I*#2&60
MCDQACYM/7HZJ4EN.O5):CMY26XWX4%R+_T]>B/].8(7_3&&#_TMA@_]+88/_
M2V&#_TMA@_]+_V0% /5T  #:@@  RXX  ,&7  "XG@$ L:4  *FK!P"CK1H
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MN#I$NM<Y0[CU.T*V_SU"L_\^1*[_/D6I_SY%J?\^1:G_/D6I_SY%J?\^X'T
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M&3'E_ADOY/\<+N3_'BWB_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP
MD+0  (.]  !WQ@  :\\  %_6  !4W@0 4? 0 $WP&P!*\"8!1O$P D+R.@,^
M\D,$._-+!3CS5 <V]%T(,_1H"3#U= LN]8$,+/:1#BKVH@\H][<0)_C6$2?V
M]!$F\_\1)O'_$27Q_Q,E\?\3)?'_$R7Q_Q,E\?\3K:$  *"I  "2LP  A+P
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M P#_[ , _^P# /_L P#_[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0
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M.*Q0_SBG4?\WHU+_-J!3_S6?4_\UGU/_-9]3_S6?4_\U_T87 ?]0$0#_6 T
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M/H)C_SV"8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4? <
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M/VUR_S]M<O\__UD' /]E  #B<@  T7P  ,>$  # B@( N8\" +.2# "LE!T
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MLD%2DLE"4I'K05*0_T!2C_\_58O_/E:(_SU7A_\]5X?_/5>'_SU7A_\]^6<
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M+4"P_B\_K_\Q/JW_,D"H_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@
MJ)T  )VC  "2J@  A[$  'RW  !PO@, :,(. &;#'0!CPRT!7L,Y!%K#1 A6
MPDX,4L)7$$_!7Q1+P6D72,%S&D7 ?AU"P(P@/\";(CW K2,\P<0C/,#I(SJ^
M_B8XO/\H-[O_*3BX_RHXMO\K.+;_*SBV_RLXMO\KR84  +F3  "LG   H*(
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M""#K_PH?ZO\+'^K_"Q_J_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@
M6-   $S6  !!W0  ..0  #7V#  S]Q0 ,/<> "[X)P K^3  */DX 2;Z0 $C
M^TD!(?M2 1[\70(<_6D"&OUY QC^BP,7_YX#%?^S!!3_TP04_O0$$_S_ Q/Z
M_P,3^?\#$_G_ Q/Y_P,3^?\#G:4  (^N  " N   <L(  &3+  !6TP  2=H
M #[?   TY   +O0  "O_"@ H_Q  )?\7 "+_'P ?_R8 '/\M !G_-  7_SP
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M',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?] %0#_11$
M_TH3 /].&0#_4"(!_U L ?U.-P+V2T,$\$E0!^M(70KG1FD-XT5T$.!$?A/=
M0X<5VT*0%]A!F!C50* 9TT"I&]% LAS/0+T=S4#,'<I!Y![&0/0@PD#_(K]
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M+992_RR44O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX& .]B!P#G90H
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M,7EB_S%Y8O\Q_T\' /]9  #F9   UVP  ,QS  #$=P( OWD$ +EZ#@"R?"
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ML#MA=L0\87;E.V%V^SEB=O\W8W7_-6-S_S1D<O\S9'+_,V1R_S-D<O\S_U@
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M-4^+]S1/BO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P
MMH@  *R0  "BE   F)@  (R<  "$GPH @* 9 'RA*0%WH#8%<I]!"FV>2P]H
MG5,49)Q;&6";8QU<FFLA6)ET)568?BE1EXHL3I:8+DN6J#!*EKPQ29;<,$F4
M]C!)D_\P29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0  L8\
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M'C.S_Q\SLO\@,[+_(#.R_R SLO\@P8,  +21  "FF   FYX  (^E  ""JP
M=K$  &NV  !?O   5,$# $S%#0!+Q1D 2<8H $C&-0!%QT !0\=* T#'4P0^
MQUT&.\=G"#G'<PHWQX ,-,>0#3+'H0XQR+4/,,C3#S#&]! NQ/\3+<+_%2S!
M_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L  !XL@  :[D
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M 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@
M)N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )
M_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #_
M_P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H
M !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST
M /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@
M__H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_
M   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V
M  #_0P  _U,  /]E  #_>@  _Y$  /^F  #_N   _\\  /_/  #_SP  _\\
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M!?$<_P;P'/\'[QW_".\=_PGO'/\)[AS_">X<_PGN'/\)_RHB ?\N'0#_,!L
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M&;4Z_QBR._\8L3O_&+$[_QBQ._\8_SD2 /\_#0#_0PD _T@, /]+$ #_3!4
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M(XA2_R.(4O\C_T4' /]+  #P50  WUL  --@  #,80, R&$& ,-A$0"[9"0
MM60T J]C0@6J84X*I5]7#Z%=8!2>7&@8FUMP&YA9>!Z56($ADU>*))!6DR:.
M59XHBU6I*HE4MRN'5,LKA57I*X15_"J#5O\H@U;_)X)6_R6!5O\D@5;_)(%6
M_R2!5O\D_T<# /]/  #G6   V6   ,UD  #&9@$ P68$ +MF#@"T:2  KFDQ
M JAH/P6C9DH*GV54#YIC71278648DV!M')!>=1^.77TBBUR&)8A;D"B%6IHJ
M@UFF+(!9M"U_6<<N?5GF+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z
M6O\E_TD  /M2  #C7   TF,  ,=H  # :P  NFL" +5K#0"N;1T J&XN :-M
M/ 6=:T@*F6I1#Y1H6A209F(8C65J'(IC<B"'8GHCA&&#)H%@C"E^7Y<K>UZC
M+7E>L2]W7<0O=5[B+W5>^2UU7_\K=5__*75?_RAU7O\F=5[_)G5>_R9U7O\F
M_TL  /!5  #>7P  S6<  ,-L  "[;P  M7   *]O"@"H<1H HW(K 9UR.028
M<$4)DVY/#H]M6!2+:V 8AVEG'(1H;R"!9W<C?6: )GIDBBEW8Y0L=6.A+G)B
MKR]P8L$P;V+?,&YC]RYO8_\L;V/_*F]C_RAO8O\G;V+_)V]B_R=O8O\G_TT
M .M8  #98P  R6H  +]P  "W<P  L'0  *ET!P"C=A< GG<H 9AV-P23=4((
MCG-,#HEQ51.%<%T8@6YE''YM;!][;'0C>&I])G1IAREQ:)(L;F>>+FQGK#!J
M9[XQ:6?<,&EG]2YI9_\L:6?_*FIG_REJ9O\H:F;_)VIF_R=J9O\G_U   .=;
M  #39@  Q6X  +MS  "S=P  JWD  *1X P"=>A0 F'LE 9-[- ..>D 'B7A*
M#81V4Q* =5L7?'-B&WAR:A]U<7(B<F][)F]NA2EL;9 L:6R<+F9LJC!D;+PQ
M8VS9,&-L]"]C;/\M9&S_*V1K_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.
M:0  P7$  +=W  "O>P  IWT  )Y]  "8?A$ DX B (Z ,0*)?SX&A'U(#']\
M41%[>ED6=WE@&G-W:!YO=G A;'5X)6ET@BAF<XXK8W*:+F!QJ"]><;HP77'4
M,%UQ\BY><?\L7G#_*U]P_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0
MO74  +-[  "K@   HH(  )B!  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U
M@%84<7]>&&Y]9AQJ?&T@9WMV(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W
M\2Y8=O\L6';_*EEU_RE:=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H
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M)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH  )^/  "5DP
MBI8  'Z:  !PG0  :Y\. &B?' !FH"H!8J W E^?005;GTH(6)Y2"U2>6@Y1
MG6(23IQK%4N<=1A(FX$:19N/'4*:GQ] FK @/YK((#^9ZQ\_F/\@/I;_(3Z5
M_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".F   @YT
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MM   3K<  $.\!0! O1$ /[T> #Z^*P \OC8 .[]! #F_2P$WOU0"-<!? C/
M:@0QP'<%+\"&!BW EP<KP*H(*L'"""K YP<IO?T**+S_#">Z_PTGN?\.)[G_
M#B>Y_PXGN?\.LHP  *64  "9F@  C:$  '^G  !RK0  9K,  %JX  !/NP
M1+\  #K$ @ PR0@ +LH1 "W*'0 LRRD *\LU "O,0  JS4H *,U6 "?.80 F
MSF\!),Y_ 2//D0(ASZ4"(-"] B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)
M_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[   !#PP  .<<
M "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7WV(
M%N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1
MV_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35
M   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B
M  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\
ME:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2
MY   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\
M80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D
M 'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0
M"/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30
M_U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\
M  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\
M  #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH
M /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_
M&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\
ME '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#]
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4
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M!=P<_P7<'/\%VQS_!=L<_P7;'/\%_RH9 /\M$P#_+1$ _RT1 /\N&0#_+2(
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M$J([_Q*B._\2_S@* /\\  #_00  ]44  .9& @#A10< XT(- -5#&0#,12P
MQD<\ <%'20*\1E4$N45?!K5$: FS0W$+L$-Y#:Y"@0^L0HD0JD&1$JA!FA.G
M0*04I4"O%:- O!:A0- 6GD'J%YQ!_!>:0?\7F$'_%YA!_Q:70?\5ET'_%9=!
M_Q670?\5_SL& /\_  #Y1@  Y4L  -Q.  #3300 T4H) ,I*% #"32< O$XW
M ;=.10*R35 %KTQ:"*M+8PJH2FP-IDET#Z1)?!&A2(03GT>,%9U'E1>;1I\8
MF4:J&9=&N!J61LH;DT;F&Y%'^1N/1_\:CD?_&8Y'_QB-1_\8C4?_%XU'_Q>-
M1_\7_SX" /]#  #K2P  W5$  -%4  #*5 $ QE(% ,%1$0"Y4R( LU4S :Y4
M00*J5$P%IE-6"*)17PR?4&</G4]O$9I.=Q283G\6EDV(&)-,D1F13)L;CTNF
M'8U+LQZ+2\4>B4OB'H=,]QZ&3/\=A4S_'(5-_QJ%3/\9A4S_&85,_QF%3/\9
M_T   /Q'  #E4   U58  ,I9  #"6@  O5@# +A7#@"Q61X K%HO :=:/0*B
M64D%GEA3"9M76PR75F00E55K$I)4<Q6/4WL7C5*$&HM1C1R(49<>AE"C'X10
ML"""4,$A@%#=(7Y1]"!]4?\??5'_'7U1_QQ]4?\;?5'_&GU1_QI]4?\:_T(
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M)FE>[B1I7O\B:E[_(&I>_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P
MP64  +=J  "O;   IVP  )]J 0"9:Q$ E&TB )!N,0&+;3T$AVQ'!X-K4 M_
M:E@/?&A@$WAG9Q9V9V\9<V9X''!E@1YM9(PA:F.8(VABIB5F8K8F9&+,)F1B
M["5D8O\C9&+_(65B_Q]E8O\>96+_'65B_QUE8O\=\DP  -]8  #*8@  O6D
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M(%1P_Q]5</\>56__'55O_QU5;_\=Y5<  ,UD  "^;0  LG4  *A[  "??@
MDWT  (=]  " ?P< ?( 5 'B!) !U@C(!<8$]!&V 1@=I@$\*9G]6#6-^7A%@
M?68477QN%UI[=QI7>H(=5'J/'U%YG2%/>:XB3GG#(DUXY2)-=_LA3G?_'TYV
M_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6   ":@@  CH(
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M%SJ._Q<ZCO\7Q6X  +9[  "JA0  GHL  )2/  "(D@  >Y0  &Z7  !BFP
M5YX  %*@#@!1H!L 3Z$H $VA- !+H3X!2:%' D>A4 -$H5@%0J%A!S^@:PD]
MH'<+.J"%#3B@E XVH*8/-:"[$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9
M_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP  &>?  !;H@  3Z8
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MA0 9QYD &,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$
M )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,   "K$   BR
M&<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,
MUHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?
M  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8
M  S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L
M .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !T
MKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$   +E
M    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^
M  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN
M6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U
M]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_
M@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L
M #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_    _P
M /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_:0
M_X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&
M+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"=
M /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_
M #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\
MH #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_
M /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP
M_P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_
M *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\
M_P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT
M /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\
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M \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B /0C+@#L(3L
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MM Z;.\4.F3O@#I8[] ^4//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1//\-_S4
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M&'E,ZQAX3/X7=TS_%7=,_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54
MQE8  +Q8  "T60  K58  *=3!P"A5!4 G%8E )A7- &45T "D%=*!(U64P:*
M55L)AU1C"X14:@Z"4W(0@%)Z$GU2@Q1[48X6>%"9&'90IAET4+4:<U#)&G%0
MZ!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4   .1+  #/5   P5H
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M&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@  MF4  *QI  "B:0
MF&<  (]E  ")9@P A6@9 (%I* !^:C4!>FD_ W9I205S:%$(<&=9"FUG8 UK
M9F<0:&5P$F5D>15C9(,78&./&5YBG1M<8JP<6F*_'%EBWQQ98O<:6F+_&5IA
M_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@  *EM  ">;0  DVL
M (EI  "#:PD ?VT5 'QN)0!X;C(!=6X] G%N1@1N;4\':VQ6"6AL7@QE:V4/
M8VIM$6!I=A1=:8$66VB-&%AGFQI69ZH;56>]'%1GW!Q49_8:5&;_&%5F_Q=5
M9?\65F7_%59E_Q569?\5XE$  ,I=  "[9@  KVP  *9Q  "9<   CF\  (-N
M  !]< 4 >'(2 '5S(0!R<R\!;W,Z FQS1 1I<DP&9G)4"&-Q6PM@<&,-77!K
M$%MO=!-8;G\556Z+%U-MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K_Q=0:O\6
M4&K_%5!J_Q50:O\5W54  ,5A  "W:@  K'$  *)U  "4=   B70  'QS  !V
M=0  <7<0 &]X'0!L>2L :7DW 69Y0 -C>4D%8'A1!UUW6 E;=V ,6'9H#E5U
M<1%2=7P34'2(%DUTEQ=+<Z8827.Y&4ASU1E)<O,827'_%TIQ_Q9*</\52W#_
M%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@  '=Y  !O?
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M#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z
M"SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/
MOFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'
MF!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,WFF\%-9E]!C.9
MC <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2_PLMDO\+MG4
M *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T  $"@   ZH@T
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M  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP
M>:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +
MR@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,
MJP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH
M &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !U D
M -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP
MW[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z
M  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $  .$)
M  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(
M /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   W
MR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P   #N
M!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F
M  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   JT@
M'=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8   #X
M^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_
MI@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^
M /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4
M_P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^
M /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\
M2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G
M /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\
M]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_
M %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4
MJ@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_
M .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L
M_P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I
M *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T
M_P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1
M /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L
MVP2T -@%P #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+
M"_\ _Q\0 /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,
M5@#E#&$ X@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD S0ZS
M ,L.OP#*#]  QA'I ,(2^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3_P&[$_\!
M_R(, /\A! #_(   _R$% /\?# #_'!$ ]A@< .P5* #E$S8 WQ)# -D33P#3
M%%H T!5D ,T6;0#+%G4 R1=] ,<7A0#%&(P Q!B4 ,(9G # &:4 OAFO +T:
MNP"[&LL N!OE ;0<]@&R'?\"L!W_ J\=_P*N'?\"KAW_ JX=_P*N'?\"_R8&
M /\E  #_)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4
MP2%? +\B: "\(G  NB-X +DC?P&W(X<!M2./ ;0DEP&R)* !L22J J\DM@*M
M)<8"JR7? J@F\P.E)O\#HR;_ Z(F_P2A)O\#H2;_ Z$F_P.A)O\#_RD  /\H
M  #V+0  YS   -\O  #9*P0 UB(* ,XC%@#&)B< P"@V +LJ1 "X*T\ M2Q9
M +(L8@&P+&H!KBUR :PM>@*J+8$"J2V* J<MD@.E+9L#I"VE!*(ML02@+< $
MGRW8!)PN[P69+O\&ER__!I8O_P:5+O\%E2[_!94N_P65+O\%_RP  /\N  #J
M-0  W3D  -$Y  #*-@  QR\& ,$M$0"Z,"$ M#(Q + T/@"L-4H J354 :<U
M70&D-64"HC5M J U= .?-7P$G36$!)LUC06:-)<&F#2A!I8TK0>4-;L(DS70
M") U[ B.-OX(C#;_"(LV_PB+-O\'BC7_!XHU_P>*-?\'_R\  /(T  #B/
MTD$  ,="  # 0   NSH! +8V#@"P.1P JCLL *8\.@"C/48 GSU0 9T]60*:
M/6$#F#UH!)8\< 64/'<&DCR !Y$\B >/.Y((C3N="8L[J0J).[<+B#O*"X4\
MZ N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ  #:0P  RD<
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M#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4  +!8  "E5@
MG%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\5%,$>E-:!GA38@AU
M4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50V!-D4/,29%#_$&10
M_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@6@  EU<
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M#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39   B6,  ']A  !Y8@,
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MC0Q!=9T./W6N#CYUQ0X]=>@./G/]#3YR_PT^<?\,/W'_##]P_PP_</\,Q5X
M +5I  "I<0  G'4  (UT  " =   =70  &EV  !>>0  6'P! %1]#@!2?AH
M47\F $]_,0!-@#L 3(!# 4J 2P)(?U0"1G]<!$-_905!?W &/WY\"#Q^B@DZ
M?IH*.7ZL"S=^PPLW?>8+-WO\"S=Z_PLW>?\*.'C_"CAX_PHX>/\*OF0  +!O
M  "E>   EGD  (=Y  ![>0  <'H  &1\  !8@   4(,  $N%"@!(AA0 1X<@
M $6(*P!$B#4 0X@^ $&)1P% B4\!/HA8 CR(80,ZB&P$-XAX!36(AP8SB)@'
M,H>J!S"(P <PA^0',(7["#"#_P@P@O\(,('_"#"!_P@P@?\(MVL  *IV  "@
M?P  D'X  ()^  !V?P  :H   %Z#  !3AP  2HL  $&. @ ]D X .Y 8 #J1
M(P YD2T .)(W #>20  VDDD -)-2 #.37 $QDV<!+Y-T BV2@P,KDI0#*I*G
M RB2O00HDN$#)Y#Z!">._P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0
MBH0  'V$  !OA0  8X@  %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ L
MG"0 *YPN "J=.  IG4$ *)U+ ">>50 FGF$ )9YN ".>?@$BGI !()ZC 1^>
MN0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%  "3BP  A8H
M '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8) !^G$0 >IQH
M':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD %*J> !.KM  2
MJ], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5
M  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1  #K47
M  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4
M!K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7
MI   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1  '!
M&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:
M  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0
M0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-$0
MSA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6
MZ0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T
M "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<"P  W1
M -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@
MZ^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+
M   2SP  "],   +8    W0   .$   #D    Y0   .<   #I    ZP<  .T-
M  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(
M /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (
MW0   .$   #E    Z    .P   #O    \0   /,   #U    ]P   /D!  #[
M"   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*
M  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8
M_P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_
M +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D
M_P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!>
M /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +
M^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S
M /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\
M8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T
M .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\
M_Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T
M &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\
MN@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40
M /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$
MY0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#,
M ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5
M!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D
M -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$
MO0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_
M%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-
M9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5
M *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@
MZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T
M&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>
MZ@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H
M -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0
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M!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P  PD,  +=$  "M0
MISH  *,V!@"=-Q, F3DB )4Z+P"2/#L CSQ& (P\3P&*/%<!B#Q> H8\90*$
M/&T#@CQU!( \?01_/(<%?3R2!GL[G@=Y.ZP'=SN\"'8\U0AT//$(<SS_!W(\
M_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@  +!)  "F1@  GT$
M )L] 0"5/1  D3\= (U!*P"*0C@ AT-" (1#2P&"0U,!@$-; GY"8@-\0FD$
M>D)Q!7A">@9V080'=$&/"')!FPAP0:D);T&Y"FU!T IL0>X):T+_"&I"_P=J
M0?\&:D'_!FI!_P5J0?\%[3<  -9"  #$20  MTT  *M-  "@2@  F$<  )-"
M  ".0PT B44: (9&* "#1S0 @$@_ 'Y(2 %[2% ">4A7 G=(7P-U2&8$<T=N
M!7%'=@9O1X ';4:,"6M&F II1J8+9T:V"V9&S ME1NP+9$?_"61&_PAD1O\'
M9$;_!F1%_P9D1?\&Z#L  -!&  "_30  LU$  *51  ":3@  DDL  (U'  "'
M2 L @TH6 ']+) !]3#$ >DT\ '=-10%U34T"<TU5 G%-7 -O36,$;4QK!6M,
M<P=I2WT(9DN)"61+E@IB2Z0+84NT#%]+R@Q>2^H+7DO^"EY+_PE>2O\(7DK_
M!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@  C5   (=,  "!30@
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MC0I-79P+2UVL#$I=P0Q)7>,,25SZ"DE;_PE*6_\(2EK_"$I:_P=*6O\'SDX
M +Q8  "N8   GV$  )%@  "%7P  >U\  '!=  !J7P  96$* &)B% !@8R$
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M"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0
MD6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A, 1W<? $9W*0!%
M>#, 0W@\ $)X1 !!>$T!/WA5 3UX7@([>&@".7AT S=X@@0U>),%,W>D!3)W
MN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0  BW
M 'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [@"T
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M !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A
M5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2
MH2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@
M_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(
M $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20
M!*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]
MK?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC
M   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P  +HE
M  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X
M +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   E
MM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #(
M)   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_
M  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP
M$<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:&
MW"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E
M_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@  !\X
M  #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I#@  [!4
M .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P
M^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T   #A
M    Y    .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L  /T1
M  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8
M_P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_
M '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\
MQ0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8
M /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T
M ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&
M$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P
M /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,<
MY0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_
M 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H
M<@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3
M -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P(
M_P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7
M ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,
MY0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@!
M /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X
MQ !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q
M ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*
M  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O
M +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0
MH@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2
M$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1
M<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_
M )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0
MOA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";
M'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_ 8@@
M_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC   +XN  "U*   L"(
M *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0)FX
MCB9V (TF?P"+)H@!BB>3 8@GG@&&)ZL!A">[ 8,HT0& *.X!?BG_ 7TI_P%\
M*/\!?"C_ 7PH_P%\*/\!]20  .,N  #/-0  P3@  +0V  "K,0  I2P  *(F
M!@">)A, F2@A )4J+@"2*SD CRQ$ (TM3 "++50 B2Y< (<N8P"&+FH!A"YR
M 8(N>@&!+X0!?R^/ GTOF@)[+Z<">B^W G@OS )V,.H"=3#^ G,P_P)S,/\"
M<R__ G,O_P)S+_\"\"H  -PU  #'.P  NC\  *P\  "B.   G#,  )@O  "5
M+A  D# < (PR*0"),S4 AC0_ (0U20""-5$ @#58 'XU7P%]-68!>S9N 7DU
M=@)X-8 "=C6+ W0UEP-R-J0#<#:T!&\VR 1M-N<$;#;\ VLV_P-K-O\":C;_
M FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@  E3H  ) V  ",-0T
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MC 572IH&54JJ!U1*O0=32MP'4DKV!E)*_P522?\$4DG_ U)(_P-32/\#U$$
M ,!+  "R40  H%   ))/  "'3@  ?DP  'A(  !R2@  ;DL- &M-& !H3B0
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M!D17N 9#6-(&0U?R!D-6_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@
ME%D  (98  ![6   <5<  &96  !A6   75D$ %E:$ !76QL 55PF %-=, !2
M73D 45Y! $]>20!-7E$!3%Y8 4I>80)(76L#1EUV T1=@P1"79(%0%VC!C]=
MM@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5   +%:  "A70  D%P
M ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081< 3F(B $UB+ !,8S4
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M BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P
M7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O
M>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!(GGI 2)W
M_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E;   6FX
M %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"+P C@S@
M(H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F !B!_0 9
M@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8  $EY
M   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY
M !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\
M$(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"   Y
MA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:
M.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_
M  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@
M*)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F,@
MIST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D
M_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(
M !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*   M#(
M +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P
MM/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T
M   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R
M  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\
M@Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;
MPP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;
M,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\
M &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,    T
M -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M)
M\#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO
M  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X    .4
M  #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@  _R(
M /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_
M !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\
M?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G
M /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$
M_P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #]
M 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X
M\@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P -
M /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D
M[P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#<
M /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\
M#P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z
M -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8
MQ@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T
M !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H
M>@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_
M +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H  T
MX  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y
M 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[ *8
M_P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1
M ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4
MJ0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8
M"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P
M% "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX
M )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\
MBQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K
M#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4
M? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_
M '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!,
MFQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#
M'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A
M_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ;
M (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP
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MC %C-9H"83:I F VNP)?-M8"73;S ETV_P)<-O\!7#7_ 5PU_P%<-/\!W#,
M ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0 =S40 '0W' !Q."<
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M E$^_P%1/O\!SSL  +U%  "J1P  F48  (M%  "!1   >4(  '0^  !O/P
M:T , &=!%0!E0B$ 8T,K &%#-0!?1#X 7D1% %U%30!;150 645< 5A%9 %6
M16T!5$5X E)%A0)11),#3T2C TU%M -,1<P#2T7M TM$_P)+1/\"2T/_ DQ"
M_P),0O\"RC\  +E(  "F2@  E4D  (=(  !]1P  =44  &Y"  !I0P  940)
M &)%$P!?1AX 74<H %Q(,@!:2#L 64E# %=)2@!625( 5$E9 5-)80%126L!
M3TEV DU)@@)+29$#2DFA TA)LP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'
M1O\"QD,  +9,  "B3   D4P  (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*
M$ !:2QL 6$PE %9,+P!533@ 4TU  %)-2 !13D\ 3TY7 $Y.7P%,3FD!2DYS
M DA-@ )&38\#14V? T--L0-"3<@#04WJ T%,_P)!3/\"0DO_ D)*_P)"2O\"
MPD<  +-/  ">3P  C4X  (!.  !U30  ;$P  &-*  !>3   6DT" %9.#@!4
M3Q@ 4E B %%1+ !/434 3E(] $U210!,4DT 2E)4 $E270%'4F8!15)Q 4-2
M?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/_P(]3O\"ODL
M *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(  %%3# !.5!0
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M 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7
M>UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S
M:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1K
MIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\
M &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X
M*'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :
M<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D
M  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L?
M !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4
M#WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7
M:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"'
M'P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)
M  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@
M1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "
MDB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1
MY0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X
M #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH
M )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@
MG?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1
M   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9
M  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\
M *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :
MI   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[
M&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y
M  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP
M"[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P
MSA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9
M^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4
M  #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T
M .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[
M\/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6
M    W    .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*
M  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$
M_P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_
M &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P
MN0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1
M /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &,
M_@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M
M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\
M"@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F
M .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D
MV@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_
M    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X
M9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#"
M ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_
M_P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#&
M &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$
MS@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@
M .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$
MM !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A
M ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4
M  #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B
M *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P
MD@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[
M!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!
M8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP
M (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@
MJ T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+
M#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2
M_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<
M )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6
M?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M
M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<
M  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C
M ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\
M9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""
M( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG
M: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_
M %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* ,
M=B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A
M+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N
M_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX-
M &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L
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M?0%*/XL!2#^; 4<_K %%/\$!1#_C 40^^P%$/O\!1#W_ 40]_P%%//\!PSX
M *]#  ":0@  BD(  'U!  !S0   :S\  &4\  !@/   7#X$ %D^#P!7/Q@
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M 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@
M?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!
M3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1
MI0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT
M &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52<
M.54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J
M5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0
M  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK
M #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4
M(EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<
M5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB
M+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63.
M !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96
M4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =
M:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K
M[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX
M $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D
M$74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *
M<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH
M   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J
M  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<
M 'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L
M=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "+
M+   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_
M  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@
M'80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)
MF"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5
M_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(
M  Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0
M *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P
MI?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D
M    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D
M  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\
M;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T
MMP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-
M)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\
M %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@
M ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/  #C%P
MYB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D
M  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L
M  #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18
M /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_
M  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\
M<P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#:
M /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H
M_P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W
M '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4
MZ0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $
M /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X
MY@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#.
M /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T
M"P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M
M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T
MN0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E
M  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L
M;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X
M *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H
MR  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H
M &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8
M_P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  .
M +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &<
MF !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"(
M /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8
M$ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I
M (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\
M>P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7
M !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(
M; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_
M &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X
MB0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S
M$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43
M_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2
M 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T
M:!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<
M&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:
M& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S
M %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\
MS2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G
M(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H
M? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#
M + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P
M7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.
M+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU
M  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B
M %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4
M1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3
M.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U
M* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3
M $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P
M?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*
M.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]
MHP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X
M &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH
M0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T
M0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!
M  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O
M #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K,
M+4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?
M0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)
M-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO*
M "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@
M5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O
M3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0
MZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H
M $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53,
M)E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :
M5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/
M   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW
M !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X
M$UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X
M5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E
M.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_
M  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7
M+%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *
M;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J
M_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<
M !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<
M 'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P
M=/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT
M   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[
M  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\
M=V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,
M@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2
M/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L
M &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0
M )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0
MHT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R
M  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0
M  "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D
M +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)
M@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W
M    N    +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]
M  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0
M,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(
MR0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C
M0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D
M !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP
M -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@
M^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\
M$P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z
M /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X
M[P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_
M !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$
M>@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_
M -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0
M_0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #<
M 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0
M_P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP :
M .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ',
MPP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P
M /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T
M'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S
M *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\
MGP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U
M ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T
M<P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_
M (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T
MH@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"-
M '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (
M_P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A
M )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '
M?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S
M /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8
M) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U
M '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\
MWQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y
M!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,
M?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P
M +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B(
M;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<
M$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B
M  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G
M &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4
M4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6
M)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>
M*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1
M $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P
M@BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3
M)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,H
MH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\
M '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP
M2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \
M+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR
M  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q
M $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\
M-3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@
M-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U
M-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?%
M "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P
M5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y
M.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[
MY@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH
M $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C<
M,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D
M/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]
M  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\
M "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L
M'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^
M00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)
M00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_
M !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10
M-4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <
M4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--
M_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P
M "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T(
M$E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .
M4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94
M   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(
M  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\
M@4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;
M70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G
M3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(
M &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490
M$&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2
M<58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57
M  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(
M  1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X
M 'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !7
M7   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""
M    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6
M  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@
M1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0
MD@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<
M7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$
M #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0
M *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5
MKVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%
M   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,
M  "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X
M ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4
MG0  #:,   .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&
M    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H
M  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP
M!;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@   #:
MW0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X
M<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F
M /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($
M^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#=
M /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\
M+ #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@""
M .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\
MP0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T
M #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -
M@@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_
M *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L
MVP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X
M (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$
M_P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O
M +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L
MHP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2
M /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@
M,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!]
M )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\
M^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5
M #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($
M@0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0
M -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X
MA  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R
M (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,
M  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P
M '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0
M90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B
M$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!
M,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/
M %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&
MBA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B
M##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.
MGP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX
M '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$
M6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'
M%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B
M  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T
M $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP
M/QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C
M)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?
M-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+
M #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0
M6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!
M)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$G
MX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L
M % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD
M.RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L
M+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN
M  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^
M #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/<
M)R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$
M,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T
M0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_
M ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -
M.C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H
M.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX
M_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@
M #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8
M(#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8
M//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^
M   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1-
M !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\
MB3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E
M1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*
M5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX
M '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20
M'$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *
M45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#
M  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$
M !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H
M %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !9
M2   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U;
M @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C
M  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53
M3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "
M9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J
M;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\
M #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,
M ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:
M=GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8
M   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#
M  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74
M (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G
M9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "-
M 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&
M  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=
M%7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L   "=
MGP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "H
MF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH
M  >0    E@   )H   "?    HP   *<   "J    JP   *T   "O    L0
M +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP
MOJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B
M    IP   *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8
M  #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH
M -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T
MN0   +X   #"    R    ,L   #.    SP   -(   #4    U@   -H   #=
M    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E
M  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D
M_P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U
M )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\
M_P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^
M /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L
MWP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P
M /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .<
M0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"-
M ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\
M_P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#(
M $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T
MD "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P
M /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L
MK0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8
M )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P
M  #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \
M )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P
MA ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"
M    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (<
M/0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4
M '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P
MH@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X
M #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &<
MG0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @
M (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@
M:@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!;
M *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.
M  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y
M %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *<
M4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L
M$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'
M.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ
M $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P
M7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.
M#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0
MW  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L
M %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL
M11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U
M%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >
M  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_
M #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/,
M+QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !(
M(   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?
M1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_
M "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)
M0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P
M)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D
M_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28
M #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4<
M*2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A
M*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J
M   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/
M ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\
MC"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M
M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS
M5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX
M '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-
M)34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5
M.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R
M  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H"
M !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\
M#SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=
M-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!
M!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J
M  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@
M3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /
M20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*
M=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX
M $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD
M!U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@
M48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!
M   Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,
M  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$
M %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U
M10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@
M#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3
M  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3
M)T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@
M:PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !O
MIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@
M !A<   18   #&0   9H    :P   &\   !R    =    '4   !W!   > D
M 'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H
M?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H
M   +;0   W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'
M  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0
M ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "
M?0   ((   "&    BP   (X   "1    DP   )4   "7    F0   )L   "=
M!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0
M  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@
M ),   "8    G0   *$   "D    I0   *<   "I    JP   *T   "P
ML@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "W
MZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8
M  "K    L    +,   "W    MP   +H   "\    OP   ,$   #$    QP
M ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP
MTO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]
M    P@   ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\
M  #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@
M_P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_
M %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X
MH@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P
M /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H
M\@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1
M *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\
M  #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+
M -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\
MMP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[
M    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H
M2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E
M )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G
MTP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A
M $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P
MK0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O
M +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $,
MC !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y
M +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X
M  "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !#
M 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\
M:0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&
M    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P
M0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^
M %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X
M=    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!?
M $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$
MU@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <
M &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\
M5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !'
M .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,
M  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %!
M $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H
M/07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1
M#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*
M10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W]
M #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P
M21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [
M$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1
M_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4
M $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@
M,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I
M%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8
M   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/
M "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\
MC1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U
M' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?
M5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2
M '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $
M+B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?
M)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D
M  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24'
M "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\
M&"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?
M*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K
M#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL
M !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P
M4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :
M,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS
M>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\
M $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P
M$C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %
M.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q
M   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.
M  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8
M #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W
M-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$
M$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28
M  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@
M,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P
M2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*
MK   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H
M "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41
M %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J
M4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#
M   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1
M  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$
M %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   3
M3@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H
M$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G
M  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60
M"%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0
M=Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T
M_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H
M  !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P
M (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P
MA?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_
M    @P   (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,
M  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\
M1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2
ME@   )H   "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T
M"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0
M #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@
M *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8   #)
MS@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX
M   =@   $8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(
M  #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0
M .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_
M  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\
M6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\
M ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_
M_P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H
M %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4
MR0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@
M /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %(
MR !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L
M .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L
M  #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1
M *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P
ME0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T
M    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8
M3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D
M (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=
MEP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "!
M $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\
M]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0
M (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@
M;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A
M /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '(
M!0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!(
M &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L
M5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C
M  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4
M20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_
M $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4
M5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!*
M $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $
M_P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P((
M $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@
M0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W
M /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'
M"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05.
M #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\
MD1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@!
M"@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,
M5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(
M '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@
M. X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H
M$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7
M  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+
M #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\
M(!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?
M'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6
M#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK
M !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P
M4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D
M'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?
M>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(
M $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\
M'2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .
M(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D
M   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81
M !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(<
M"2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W
M)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L
M%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8
M   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0
M+R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,
M,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   Q
MK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L
M "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0
M S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0
M-L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M
M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7
M   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,
M #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >
M,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%
M&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H
M  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.
M%#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0
M3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+
M_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(
M  Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<
M %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0
M5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.
M    40   %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8
M  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\
M24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:
M70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W
M&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8
M $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P
M &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P
MBAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,
M   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($
M  "$    AP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10
M * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F
M6@  &V   !%G   );0   '0   ![    @0   (8   "+    D    )0   "7
M    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6
M  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:
M$W    MX    @    (<   ".    E0   )H   "?    I    *@   "L
MK0   +    "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1
M&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$
M  &+    DP   )L   "B    J    *X   "T    N    +T   #     P@
M ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0
MZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\
M"P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A
M /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /<
MU@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^
M  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\
M7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_
M +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4
MYP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "]
M %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\
M_P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 *
M +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8
MH0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"&
M /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *(
M#0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5
M (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\
M<@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@")
M !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8
M5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_
M &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P
M=0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E
M %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@
M_P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 .
M &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\
M5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!-
M /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4 6  , %<
M$ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2
M $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\
MG@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!,
M !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\
M5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,
M ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \
M0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V
M %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,
M  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0
M #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H
M+0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C
M$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%
M$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E
M "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@
M4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M
M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-
M=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8
M $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$
M)@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5
M$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9
M   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4
M " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(<
M$!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W
M&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7
M%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8
M  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0
M+QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4
M'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=
MJ@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\
M "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@
M#B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ
M(<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@
M   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<
M  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\
M "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A
M(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K
M'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD
M   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)
M&R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'
M,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O
M^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@
M !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."
M #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_
M-?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O
M   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D
M  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\
M4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   )
M.   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !*
M*   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,
M #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00
M $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@
M5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW
M   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T
M  !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<
M &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T
M.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<
M    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M
M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P
M)$(  !I&   22@  #$\   14    6    %T   !A    90   &@   !K
M;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%
M-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P
M !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^    @0
M (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0
MG#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@
M   #9P   &X   !T    >@   (    "$    B@   (X   "2    E0   )<
M  ":    G0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3
M +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q
M>0   ($   "(    CP   )0   ":    GP   *0   "H    J0   *P   "O
M    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [
M  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0
M )4   "=    HP   *D   "O    M    +D   "\    O@   ,(   #%
MR    ,P   #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J
M20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4
M /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@
M\@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H
M /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T
M%@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G
M ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\
MD@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#:
M !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +,
M9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_
M (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0
MM  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7
M &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ',
M_P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6
M )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X
M@ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E
M /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\
M& "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !>
M &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\
MO0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K
M !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H
M80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0
M )@   "&    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4
M6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+
M &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D
M  !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6
M $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &
M/P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N
M    80   %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $,
M%P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H
M #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0
M60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y
M !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P
M<P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL
M $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4
M,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C
M (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.
M   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7
M "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\
M&P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y
M$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&
M&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1
M !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@
M,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <
M#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-
MIP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10
M "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH
M%@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 (
M$+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85
M   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,>
M !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L
M A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @
M%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7
M(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=
M   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&
M&Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P '
M'"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :
M]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D
M !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,
M "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^
M'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;
M   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H
M   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\
M51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0
M(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L
M+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(
M $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)
M"R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@
M,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F
M   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP
M  ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$
M #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R
M*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V
M    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y
M  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0
M*2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _
M00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/
M0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X
M " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)    3
M $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/
M7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV
M   3.0  #CT   A!    10   $D   !,    4    %,   !6    60   %L
M  !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48
M &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .
M1   !TD   !-    4@   %8   !:    7@   &(   !E    :    &L   !M
M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4
M  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '40
M %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X   "
M@P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "4
M8@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80   &@
M  !N    =    'D   !_    A    (D   "-    D0   ),   "6    F0
M )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P5@
MK',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L   ""
M    B0   (X   "4    F@   )\   "D    I@   *D   "M    L    +,
M  "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P  RF8
M ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7
MG@   *0   "K    L0   +8   "Z    O    ,    #$    R    ,L   #/
M    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z
M  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "(
M_P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L
M 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )
M_P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E
M /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '(
MQ0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"
M /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L
M)P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S
M *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\
MX@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H
M "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P
M=0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP
M ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\ &0". "$
MBP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T
M 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$
M  "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H =  A
M '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '
M7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-
M    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ; &$
M(0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W
M $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\
M;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1
M "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $(
M@0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O    8P
M %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P
M1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #< >@ V
M (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6    $\
M  !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !< .0 <
M #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@
M+ "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#  !
M P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\
M'0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9
M ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z"
M-0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F
M !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L
MK  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L
M "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L
M'@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4
M ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-
M   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00>
M !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P
M#P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.   @
M#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)
M(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;
M  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =$
M&@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /
M#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,
M\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$
M !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0
M"A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .\P
M#O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(  !01
M P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I
M  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0  $?\
M6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1
M$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7
M,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\ 510
M $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P<
M#Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;+0
M&S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8
M   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$
M  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@  (34
M "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T
M'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @<
M P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_
M   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P
M*!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A   !
M(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[   N
M2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$
M " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G    *0
M "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V10
M-5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",  !\A
M   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O    ,@   #0
M   W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(
M #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C   8
M)   $B4   XH   **@  !2T    P    ,P   #8    X    .P   #X   !
M    0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA
M  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@
M#BT   HP   $,P   #<    Z    /0   $    !#    1@   $@   !+
M30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5
M=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8
M  ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8    6@
M %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@
M9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(   !'
M    3    %    !4    6    %L   !?    8@   &4   !H    :P   &X
M  !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\
M ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6
M6P   &    !E    :0   &X   !R    =@   'D   !\    ?@   ((   "%
M    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,  (V5
M  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H    ;@
M ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D   "=
MH0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "F
MJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\    @P   (D
M  "/    E0   )L   "@    HP   *8   "I    K0   +$   "U    N0
M +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"G0
MP;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F    )\   "E
M    K0   +,   "X    N@   +X   #"    Q@   ,H   #.    TP   -H
M  #@    YP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M_________________________________________P
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M[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#IL5GPZ;
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MBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NRDX"[LI.
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M-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1_WPQ4/^
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MC"(&_YTG!_^J+@G_MC8.]\$^%NW,1B#DV$LNV=Q01,G46%B[S5YKKL9E>J+
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M*3S_L"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"EQ@
ME]4  (OO! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_3Q=%
M_U880O]<&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7'C+_
MH!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@  B=X
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M34GXX$U(]_--2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T3=JC  #'L0(
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M:D_%[6A0P/-D4;WU85&]]6%1O?5A4;WU85&]]6%1O?5A4;WU8?^&"@#PF@0
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M-3__[S4__^\U/__O-3__[S4__^\U/__O-<2J  "SLP  I[\  )K+  "/V@(
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M<%^?ZVMAG?)E8IKV8&*9]UYBF?=>8IGW7F*9]UYBF?=>8IGW7O]S$ '_A0P
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M3DK*_TU*RO]-2LK_34K*_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP,
MH\L& )O9"@"4Y1H!C>4K!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97
MX'(Z4]][/5#?A4!-WX]#2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>
M_T1%WO]$1=[_1$7>_T1%WO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$&
M (_K#0")[A\"@.XK!GCM- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M
M3^UY+TSM@S)*[HTT1^Z8-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA
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M:6^&ZV-RA_E<<X;]5G.%_U)SA?]2<X7_4G.%_U)SA?]2<X7_4O]H$0'_> T
M_X8- /:3# #>H D UJD* -*R#0#'LB("O:\S"K.K01>JITPDH:)5,)F>73J2
MFF1"BY=K2864<E" DGE5>X^!6G:-B5YRC))B;HJ=96N)J6=HB;AH9XG+:&F+
MZ6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K$ '_>PL _XH*
M .*8!@#6HP@ T*P) ,NU"P#!MA\!N+0Q":ZP/Q:DK$HBG*A3+I2D6SB,H&)
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M5%NA_U!;H?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00
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M.4/8_SE#V/\Y0]C_.="6  #!HP  LJP  *>U  "<P   D<H# (?6!P" Z1$
M>>D@ G+I+ 5KZ38*9.D_#U[I2!19Z5$95>A:'%'I8B!.Z6LC2^ET)4CI?2=&
MZ8@J0^F3*T'JH"U ZJ\N/NO +CWLVRX]ZN\N/>C\+CWG_RT]Y_\M/>?_+3WG
M_RT]Y_\M/>?_+<6?  "UJ0  J+$  )R\  "0QP  A-(! 'K?!@!T]!, ;?0@
M F;T*@1?]#0(6O4]"U3U10]/]4P23/55%$GV71=&]F481/9N&D'V=QP_]X$=
M/?>-'SOWF2 Y^*8A./BU(C?YR"(V^>,B-OCS(C;W_"(V]_PB-O?\(C;W_"(V
M]_PB-O?\(K>F  "IK@  G+D  )#$  "#SP  =]L  &_V"@!G_Q,!8/\= EK_
M)P-4_S %3_\X"$K_0 I&_T@,0_]/#D#_5@\]_UX0._]E$CC_;A,V_W<4-/^"
M%3+_CQ8P_YL7+_^I%R[_MQ@M_\@8+/_A&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8
M+/_O&*NK  ">M0  D,$  (+,  !UV0  :>0  &'_"0!;_Q$ 5/\9 4[_(@))
M_RL$1/\R!4#_.@8\_T$'.?]'"#;_3@DS_U0*,?];"R[_8@PL_VL,*?]U#2?_
M@ XE_XT.)/^:#R/_IA B_[,0(?_!$"'_T! A_] 0(?_0$"'_T! A_] 0(?_0
M$)^R  "1O@  @\H  '76  !GX@  6_$  %3_!@!._PX 2/\4 4+_' (]_R0"
M.?\K S7_,@0Q_S@$+O\^!2O_0P4H_TD&)?]/!B/_5@<A_UT''O]E"!S_;P@9
M_WH)%_^'"1;_E D5_Y\*%/^J"A3_LPH4_[,*%/^S"A3_LPH4_[,*%/^S"I.[
M  "$QP  ==,  &?A  !8Z   3OL  $C_  !!_PH ._\0 3;_%0$Q_QP!+?\B
M BG_* (E_RT"(O\R Q__. ,<_ST#&O]" Q?_2 05_TX$$_]5!!'_704/_V<%
M#?]R!0S_?04*_XD&"O^3!@G_G 8)_YP&"?^<!@G_G 8)_YP&"?^<!O\_*@+_
M/S #_T0P _](,P3_23D&_TA""/]&30O_15L._T-I$?]!=Q/_0(45_S^1%O\^
MFQC_/J08_SVK&?\]LQK_/;H:_SW#&O\\S!O_/-L;_SSG&_\\\!O_//@;_SW_
M&_\]_QO_/?\;_SW_&O\]_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?] *@+_02X#
M_T<N _]*,03_3#<&_TM "/]*2PO_2%D/_T9G$?]$=13_0X(6_T*/&/]!F1G_
M0:(:_T"I&_] L1O_/[@<_S_ '/\_R1W_/]8=_S_E'?\_[QW_/_<>_S_^'?\_
M_QW_/_\=_T#_'/Y _QO^0/\;_D#_&_Y _QO^0/\;_D#_&_] *@+_0RP#_TDL
M _]-+P3_3S4&_U ^"/].20S_3%8/_TID$O](<A7_1W\8_T:+&?]%EAO_1)\<
M_T2G'?]#KA[_0[4?_T*]'_]"QB#_0M$@_T+B(?]"[2'_0O4A_T+](?U"_R'[
M0_\@^D/_'_E#_Q[Y0_\>^4/_'OE#_Q[Y0_\>^4/_'O]!*0+_1BH#_TPI _]1
M+ 3_4S(&_U0\"/]41PS_45(/_T]@$_]-;Q?_3'P9_TJ('/])DA[_2)L?_T>C
M(?]'JR+_1K(C_T:Z(_]&PR3_1<TE_T7>)?]%ZB;\1?0F^47\)O9%_R;U1O\D
M]$;_(_-'_R'S1_\A\T?_(?-'_R'S1_\A\T?_(?]"* +_22<"_U F _]5* 3_
M6"\%_UHY"/]:1 S_5T\0_U5<%/]3:AC_47<;_T^#'_].CB'_39<C_TR?)?]+
MIR;_2JXG_TJV*?Y)OBK]2<DJ^DC9*_=(YRST2/(L\4C[+.])_RKM2O\H[$K_
M)^M+_R7K3/\EZTS_)>M,_R7K3/\EZTS_)?]#* +_320"_U0C _]:)0/_7BP%
M_V V!_]@00O_7DP0_UM7%?]99AG_5W(>_U5^(OY3B27\49,H^E";*OE/HRSW
M3JHN]DVR+_1,NC#S3,0R\DO1,^Y+Y#3J2O TYTOZ,^5-_S#D3O\MXD__*^%0
M_RGA4/\IX5#_*>%0_RGA4/\IX5#_*?]&)0+_4"$"_U@@ O]?(0/_9"H$_V8S
M!_]F/0O_94@0_V)3%?]@81O\76T@^%IY)?58A"GS5HTM\%26,.Y2GC/M4:4U
MZU"M-^E.M3GG3K\[YDW,/.-,X#W?3>X\W$_Y.=E1_S764O\RU%/_,--4_RW3
M5?\MTU7_+=-5_RW35?\MTU7_+?]*(P+_5!X"_UP< O]D'P+_:2<$_VPP!O]M
M.@K_;$0/_6I/%?AG7!SS8V@B[V!T*.M=?B[H6H@SY5>1-^-5F3K@4Z ^WE*H
M0-Q1L4'94+M"UE#(0]-0W$3/4.Q#S%+X/\M5_SO)5_\WR%C_-,=9_S+&6?\Q
MQEG_,<99_S'&6?\QQEG_,?]-( +_5QL"_V 9 O]I'0+_;R4#_W(M!?]T-PC]
M<T$.]G%+%/!N6!SJ:F0DY65N*^!A>3/<7H(XV%R+/--:E#_06)Q"SE>C1,M5
MK$;)5;5'QU3 2<54T$G"4^9)P%;U1;Y9_T"]6_\\O%S_.;M=_S6Z7?\UNEW_
M-;I=_S6Z7?\UNEW_-?]0'@+_6QD!_V06 ?]M&P+_="("_W@J!/]Z,P?V>CT,
M[WA'$^=U5!OA<%\EVFMJ+=-G=#3.9'TZRF&&/\=?CD+$799%P5N>2+]:IDJ\
M6:],NEBZ3;A8R$ZV6-].M%GP2[-<_46R7_] LF#_/+!A_SFP8?\XL&'_.+!A
M_SBP8?\XL&'_./]2&P'_7A8!_V@4 ?]R&0'_>1\"_WXG _F , 7P@3D*YX!#
M$>!\4!K6=ULDSW)F+LEM;S7$:G@[P&>!0+QDB42Y8I%(MF"92K-?H4VQ7:I/
MKERT4:Q<P5*J7-12J%WK4*A@^DFH8_]$J&3_0*9E_SRF9?\[IF7_.Z9E_SNF
M9?\[IF7_._]5&0'_810!_VP2 ?]V%P'_?1P!_X,C O2&+ 3JB#4'X8= #M:"
M3!G-?5@DQG=B+<!S:S6[;W0\MVQ\0;-IA$:O9XQ)K&643*ECG$^F8J51I&&O
M4Z)@O%6@8,U5GF#F5)YD]TV?9_]'GVG_0YYI_S^=:?\]G6G_/9UI_SV=:?\]
MG6G_/?]7%P'_8Q(!_V\1 ?]Y% '_@1D!^X<@ >^,)P+DCC %VHT]#,^'2AC'
M@E4COWU?+;EX:#6S=' \KW%X0JMN@$:G;(A*I&F03J!HF%&=9J%3FV6K59AD
MN%>69,A8E&3A6)5H]%"6:_]*EVS_199M_T&6;?] EFW_0)9M_T"6;?] EFW_
M0/]9%0'_9A !_W(0 /]]$@#_A18 ]HP; >J1(@'?E"L#TY$Z"\F,1Q? AU,B
MN8)<++)]936M>6T\J'5U0J-S?4>@<(1+G&Z,3IELE5*5:YY4DFFH5Y!IM%F.
M:,-9C&C<6HUL\E./;O],D'#_1X]Q_T./<?]!CW'_08]Q_T&/<?]!CW'_0?];
M% '_: \ _W4/ /^ $0#_B1, \I 7 .66' #9F28"S94X"L2011:[BU$ALX9:
M+*V"8S2G?FL[H7IR09UW>D:9=8%+E7.)3Y)QD5*.;YM5BVZE6(AML%J&;+];
MA&W56X9O[U6(<OU.B73_28ET_T2(=/]#B'3_0XAT_T.(=/]#B'3_0_]=$@'_
M:PX _W@. /^##P#]C!  [902 .":%0#3G"0"R)DV";^40Q6VCT\@KHI8*Z>&
M83.A@F@[G']P09=\=T:3>7Y+CW>&3XMUCU*(<YA6A'*B6(%QKEI_<;Q<?7'0
M7']S[%:!=OM/@WC_2H-X_T6">/]$@GC_1()X_T2">/]$@GC_1/]?$0'_;0P
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M36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0 Y8<  -:2 P#-G 4
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M0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP  J;(  *"[ @"7Q D
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M"AW_HPH<_[$*&__ "QK_U@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O
M?L<  '#2  !CW@  5>0  $OU  !&_P4 0/\. #O_%  W_QL!,_\C 2__*0(K
M_S "*/\U B7_.P,B_T$#'_]' QW_3@,:_U4$&/]>!!7_: 43_W0%$?^"!1#_
MD 80_YT&#_^I!@[_M08._[H&#O^Z!@[_N@8._[H&#O^Z!HZZ  !_Q0  <-$
M &+>  !4Y0  1NL  #_^   Y_P  -/\) "__#@ K_Q0 )_\: 2/_(0$?_R4!
M'/\J 1G_+P$6_S0"%/\Z A'_0 (0_T8"#O]. @S_5@()_V #!_]L P3_> ,#
M_X8# O^1 P'_G0,!_Z$# ?^A P'_H0,!_Z$# ?^A _\V+0+_.2X"_SXN _]
M,@/_0#@$_SY!!O\\3 C_.EH*_SAH#/\V=@[_-8,/_S2/$/\SF1'_,Z$1_S.I
M$O\RL!+_,K<2_S*_$O\RR!/_,M,3_S+C$_\R[1/_,O82_S/^$O\S_Q+_,_\2
M_S/_$?\S_Q'_,_\0_S/_$/\S_Q#_,_\0_S/_$/\V+0+_.RP"_T L _]#+P/_
M0S4$_T(^!O] 2@C_/E<+_SQE#?\Z<P__.( 0_S>,$?\WEA+_-I\3_S:G$_\V
MKA3_-K44_S:\%/\UQ17_-= 5_S7@%?\VZQ7_-O05_S;]%/\V_Q3_-O\4_C?_
M$_XV_Q/]-O\2_3;_$OTV_Q+]-O\2_3;_$O\W+ +_/BH"_T,J O]&+0/_1S($
M_T8\!O]%2 C_0U4+_T%B#?\_<!#_/7T1_SR)$_\[DQ3_.YP5_SJD%O\ZJQ;_
M.K(7_SJY%_\YPA?_.<P7_SG=&/\YZ1C_.?,8_SK[&/PZ_Q?Z.O\7^3K_%O@Z
M_Q;X.O\5^#K_%?@Z_Q7X.O\5^#K_%?\Y*P+_02<"_T8G O]**0/_2R\$_TPY
M!O]+10C_2%$+_T9>#O]$;!'_0GD3_T&%%?] CQ?_0)@8_S^@&/\_IQG_/JX:
M_SZV&O\^OAO_/L@;_SW6'/X]YAS[/O$<^#[Z'/4^_QSS/O\:\C__&?$__QGQ
M/_\8\3__&/$__QCQ/_\8\3__&/\]* +_120"_THC O].)0/_42P$_U(V!O]1
M00C_3TT,_TQ:#_]*9Q+_2'05_T> %_]&BQG_190;_T2<'/]#I!W^0ZL>_4*R
M'_Q"NB#Z0L0@^4+0(?9!XB'R0NXB[T+Y(NU"_R#K0_\?ZD/_'>E$_QSH1/\;
MZ$3_&^A$_QOH1/\;Z$3_&_] )0+_2"$"_T\@ O]3(0+_5RD#_UDS!?]8/@C_
M5DD,_U)5$/]18Q3_3V\7_DU[&OM+AAWY2H\?]TF8(?9(GR+T1Z8D\T>N)?%&
MMB;P1K\G[T7+*.Q%WBGH1>PIY4;X*.)'_R;A2/\DWTG_(MY)_R#=2?\?W4G_
M']U)_Q_=2?\?W4G_'_]#(@+_3!X!_U,< O]9'@+_728#_U\P!/]?.@?_744+
M_UI0$/U87A7X56H9]5-V'?)1@"'O3XHD[4V3)NM,FBGI2Z(KYTJI+.5)L2[D
M2+LOXDC',>!(V3'<2.HQV$GV+M1+_RO23/\IT$W_)L]._R7.3O\CSD[_(\Y.
M_R/.3O\CSD[_(_]''P'_4!H!_U<8 ?]>' '_8R,"_V8L!/]F-@;_9$$*^F),
M#_1?617O7&4;ZUEP(.=6>R7D5(0IX5&-+=Y0E3#<3YTRV4ZE,]9-K3733;<V
MT4S"-\],T3C,3.8XR4WT-<=/_S'%4?\NQ%+_*\-3_RG"4_\GPE/_)\)3_R?"
M4_\GPE/_)_]*' '_5!<!_UP5 ?]C&0'_:2 "_VPI _]M,@7Y;#T)\FE'#NMF
M5!7E8V <X%]K(MM<=2C667\MTE>(,,]5D#/,5)@VRE.@.,=2ISK%4; [PU"[
M/,%0R3V_4-\]O%'P.[I3_#>Y5?\SN%?_+[=8_RVW6/\KMUC_*[=8_RNW6/\K
MMUC_*_]-&@'_5Q0!_V 2 ?]H%P'_;AT!_W(E OMS+@/R<S@'Z7%##>)N4!3;
M:5P<TV5F),YB<"K)7WHOQER",\-;BC; 69(YO5B:.[M6HCZX5:L_ME6U0;14
MPD*R5-1"L%7J0:Y7^3RN6?\WK5O_,ZU<_S"M7?\NK5W_+JU=_RZM7?\NK5W_
M+O]0%P'_6A(!_V00 /]M% #_<QH!_W<A ?1Y*0+J>C,%XG@_"MET3!//<%@<
MR6MB),1H;"N_974PNV)]-;A@A3BU7HT\LER5/J];G4&M6J9#JUFO1*E9O$6G
M6,Q&I%CE1J1;]D"C7O\[HU__-Z-@_S.C8?\QHV'_,:-A_S&C8?\QHV'_,?]3
M%0'_71  _V@/ /]P$@#_=Q8 ^WP< >Y_) 'D@"T#VG\[",]Z21+'=50;P7%?
M)+MM:"NV:G QLF=Y-J]E@#JK8X@]J&&00*9@F$.C7J%%H%ZK1YY=MTB<7<9)
MFES?29I?\D2:8O\^FF/_.9ME_S:;9?\SFV7_,YME_S.;9?\SFV7_,_]5$P'_
M8 X _VL. /]T$ #_>Q( ]8$7 .B$'@#>AR<!T80W!\A_1A' >U$;N79;([1R
M92NO;VTQJFQU-J=J?#JC:(0^H&:,09UDE$2:8YU'EV*G295ALDN38<%,D6'8
M3)%C[T>29?U!DF?_/)-I_SB3:O\UDVK_-9-J_S63:O\UDVK_-?]7$0'_8PT
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M0GIX_SY[>?\Z>WG_.GMY_SI[>?\Z>WG_.O]?# #_; 0 ]7D" -Z# @#3BP4
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M/&.,_SQCC/\\8XS_//]J  #F>@  U88  ,F1  # F0$ N)\! +"E  "HJ0X
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M&C;AS1HVW^P:-=[Y&C3=_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI
MGJL  )*U  "%O@  ><<  &W/  !BU@, 6.$( %7J$P!1ZR  3>LK 4GK-0)%
M[#X$0NQ'!3_L3P<][5@).NU@"CCM:@PV[G0-,^Z #C+NC@\P[YT0+N^M$2WP
MP!$M\-X1+.[Q$2SL_A$LZ_\0+.O_$"SK_Q LZ_\0+.O_$*VB  "@J0  D[,
M (:]  !YQ@  ;,\  &#8  !5W@  3O,* $KW$P!&^!T 0_@G 3_X, ([^3@"
M./E  S7Z1P0S^D\%,/M7!2[[7P8K_&D'*?QT""?\@@DE_9 ))/V@"B/^L HB
M_L0+(?_@"R']\@H@_/P*(/S\"B#\_ H@_/P*(/S\"J*G  "5L0  A[L  'G&
M  !LSP  7]D  %+?  !(Z   0_\( #__$  [_QD -_\A #3_*0$P_S !+?\W
M BK_/@(G_T0")?]+ R+_4P,@_UP#'?]F!!O_<@09_X %%_^/!1;_GP85_Z\&
M%/_ !A3_U@83_^D&$__I!A/_Z083_^D&$__I!I>O  "(N@  >L4  &S/  !>
MV@  4.   $3F   \]0  -_\$ #/_#0 O_Q, *_\: "C_(0 E_R<!(?\M 1[_
M,@$;_S@!&?\_ 1;_1@(4_TT"$?]6 A#_8 (._VP"#/][ PO_BP,*_YH#"O^H
M PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@
M0N<  #;L   Q_P  +/\  "?_!P C_PX (/\2 !S_&  8_QT %?\A !+_)@ 0
M_RP!#O\Q 0W_-P$*_SX!"/]& 07_3P$!_UD! /]F 0#_= $ _X(" /^0 @#_
MG ( _Z8" /^F @#_I@( _Z8" /^F O\N+P+_,RP"_S<M O\X, +_-S8#_S0_
M!/\Q2P;_+U@'_RQF"/\J= G_*8$*_RB-"_\HEPO_*)\+_RBF#/\GK0S_)[0,
M_R>[#/\GQ S_)\X,_RC>"_\HZ0O_*/,+_RC["_\H_PK_*?\*_RG_"O\I_PK_
M*/\*_RC_"O\H_PK_*/\*_RC_"O\P+0+_-BH"_SDJ O\[+@+_.C0#_S@\!/\V
M20;_,U8'_S%C"?\O<0K_+7X+_RV*#/\LE S_+)P-_RRD#?\LJPW_++$-_RRY
M#?\KP0W_+,L-_RS:#?\LYPW_+/$-_RSZ#?\L_PS^+?\,_2W_#/TM_PS]+/\+
M_2S_"_TL_PO]+/\+_2S_"_\R*P'_.2@"_STH O\_*@+_/C #_STZ!/\\1@;_
M.5,(_S=@"?\U;0O_,WH,_S*&#?\QD [_,9D._S&A#_\QJ __,*X/_S"U#_\P
MO1#_,,<0_S#4$/\PY!#_,>\0_C'Y#_LQ_P_Y,?\/^#'_#O<Q_P[W,?\.]C'_
M#O8Q_P[V,?\.]C'_#O\U* '_/"4!_T D O]#)P+_0RP#_T0W!/]"0P;_0$\(
M_SU<"O\[:0S_.78-_SB"#_\WC!#_-Y41_S:=$?\VI!+_-JL2_S:R$_\UNA/_
M-<,3_S7/$_PUX1/Y-NT3]C;W$_,V_Q/Q-O\2\#;_$O W_Q'O-_\1[S?_$.\W
M_Q#O-_\0[S?_$/\Y)0'_0"$!_T4@ ?]'(@+_22D"_THT!/])/P7_1DL(_T18
M"O]"90W_0'$/_SY]$?\]AQ+_/9$4_CR9%?T\H!7\.Z<6^CNN%_D[MA?X.[\7
M]CO*&/0[W!CP.^H8[3OV&.H[_Q?H//\7YSS_%N8]_Q7E/?\4Y3W_%.4]_Q3E
M/?\4Y3W_%/\](@'_1!X!_TD< ?]-'@'_4"8"_U$P _]0.P7_3D8(_TM3"_](
M8 [_1FP1^T5X$_A$@A7V0XP7]$*4&/-!G!GQ0:,;[T"J&^Y LASM/[L=ZS_&
M'ND_U1[E/^@?XD#T'M] _AW=0?\;VT+_&ME"_QC80O\7V$+_%]A"_Q?80O\7
MV$+_%_] 'P'_2!H!_TX8 ?]2&P'_5B,"_U@L _]7-P3_54('_U)-"_E06@[U
M36<2\4QR%NY*?1CK2(8;Z4>/'>=&EQ_E19X@XT2F(N%$KB/@0[<DWD/")=Q#
MT";70^4FTT3S)-!%_B+-1O\@S$?_'LI'_QS)2/\;R4C_&\E(_QO)2/\;R4C_
M&_]$&P'_3!8!_U(4 ?]8& '_71\!_U\H O]>,@/]73T&]EI)"O!750_J56(3
MYE)M&.)0=QS?3H$?W$R*(ME+DB352IHFTTFA*-%)J2G/2+(JS4B\*\M(R2S(
M2-\LQ4CO*\)*_"C 2_\EOTS_(KY-_R"]3?\?O4W_'KU-_QZ]3?\>O4W_'O]'
M& '_3Q,!_U81 /]>%0#_8AP!_V4D ?YE+0+T9#@%[6%#">9?40[@7%T4VEAH
M&M16<A[05'LBS%*$)LI0C"C'3Y0JQ4Z;+,-.HR[!3:POOTRV,+U,PC&[3-,R
MN$SI,;9.^"VT4/\JLU'_)[-2_R2R4O\BLE+_(K)2_R*R4O\BLE+_(O]*%0'_
M4Q$ _UL/ /]B$@#_:!< _VH? ?9K* 'L:S(#Y&D^!]QF3 W38E@4S5]C&\A<
M;2#$6G8DP5A^*+Y6ABN[58XNN5.6,+92GC*T4J8SLE&P-;!1O#:N4,LWK%#C
M-ZI2]#.I5/\NJ%;_*ZA7_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X
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M-8=G_S&':/\NAVG_+8=I_RV':?\MAVG_+?]7# #_800 _FP# .1U 0#;>P4
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M,7%X_S%Q>/\Q<7C_,?]? @#W;   WG<  -"!  #'B $ P(T# +F1 P"RDQ$
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M+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0
MM9@  *F?  ">I0  DZP  (BR  !]N   <;X& &Z_%0!JOR8!9K\S V&^/P==
MOD@+6;U1#U6]61-1O& 73KQH&DN[<1U(NWL?1;J'(D*ZE"1 NJ(F/KJS)CVZ
MR"8]NN@F/;CY)3VW_R0]MO\C/;;_(SVV_R,]MO\C/;;_(\>(  "YE0  K)T
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M,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  "
MN@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG
M1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP
M"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@
M:,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L
M]4<!*?9/ B?V5P(E]V$#(_=L R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY
M\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,
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M&\L_^QK)0/\8QT#_%\9!_Q7%0?\4Q$'_%,1!_Q3$0?\4Q$'_%/]!%P#_1Q(
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M)IE6_R.95O\AF5?_'YE7_Q^95_\?F5?_'_]-#0#_508 _UT% /MD!P#O:0D
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M"0#$=A< O'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@HD&*
M*XUAB"Z+8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"8_\F
M@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y!P"^
M>A4 MGHH :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]*X=E
MA2Z$9(XQ@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H?&?_
M)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y?A(
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M-%&(PS50B.(T4HCV,%.(_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>
MPH,  +>,  "MD@  HY8  )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QN
MFTT1:9E5%F687!IAEV,>7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2
MPC%*D> Q3)'U+4V1_RI.D/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D
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M'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP  IYH  )R@  "1IP
MA:T  'FS  !MN   8KT! %;"!P!3PQ0 4L,C %#$, %-Q#L"2L1% T?$3@5%
MQ%<'0L-?"4##: L]PW(-.\-^#SC#C!$VPYL2-<.K$S/#P!,SP^ 3,\'U$S+
M_Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@  >[0
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M A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@
M,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1
M_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_
M]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8
M !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL
M _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@
M_]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT  !7]
M   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL  /\S
M  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_L0  _[$
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M)@'_+B,!_R\B ?\O)0'_+"L!_RHU O\G00+_)$X#_R); _\@: 3_'G0$_QV
M!/\=B@3_'9(%_QV:!?\=H07_':<%_QVM!?\=M 3_';T$_QW'!/\=U 3^'>8$
M^QWR!/<>^P/U'O\$]![_!/,>_P3S'O\$\A[_!/(>_P3R'O\$\A[_!/\N(@'_
M,A\!_S0> ?\S( '_,B8!_S(R ?\O/@+_+$H#_RI7 _\G9 3_)G %_R5[!?\D
MA07_)(X&_R26!O\DG0;_)*,&_R2J!OTDL0;\)+D&^R3#!ODDSP;V).,&\B3P
M!>XE^@7M)?\&ZR7_!NHE_P;I)?\&Z27_!NDE_P;I)?\&Z27_!O\R'@'_-AL
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M3A8 _T\? /U.*0'T3#0![$A! N9'3@3@15L&VT1F"=9"< S207D.ST""$,U
MBA'*/Y$3R3^9%,<^H!7%/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W/_\6M4#_
M%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1#0#_4Q$
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M&HM6_QJ+5O\:BU;_&O],! #_4P  [%P  -]B  #49@$ SF@% ,MG" #"9Q8
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M+UYPPB]=<-\O7W'U*F!Q_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0
MRG(  +YZ  "U@   K80  *2%  ":A0, E(44 (Z&)0&)A#,#@X,^!WZ!2 MY
M?U 0=7Y7%'%]7AAN>V4;:WIL'FAY=")E>'TE8G>'*%]VDRI<=I\L6G6N+EEU
MP"Y8==TN67;S*EMV_R9<=_\C7'?_(%QW_R!<=_\@7'?_(.I@  #5;   Q78
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M)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4  *R-  "BD@
MEY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1AGD4'79U-"EJ<5 U7
MFUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B09;O($*5
M_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";EP  D9L
M (6?  !YHP  :J<  &6G#@!CJ!P 8*@K 5VH-@)9IT $5J=)!E.F40E0IED,
M3:5@#DJE:1%'I'(41*1]%D*CB1@_HY<:/:.G&SRCN1P[H](;.Z+O&SN@_AH[
MG_\9/)__&#R?_Q@\G_\8/)__&,1\  "VB0  JI(  )^7  "5G   B:$  'VF
M  !QJ@  9*X  %JQ" !7L10 5;(C %.R, %0LCL"3;)$ TNQ305(L54'1;%=
M"4.Q90M L&\-/K!Z#SNPAQ$YKY83-Z^F%#:ON!0UL-$4-:[O%#2M_A0TK/\4
M-*O_%#2K_Q0TJ_\4-*O_%+N%  "OD   HY<  )B=  ",HP  @*@  '2M  !H
ML@  7+8  %"Z 0!)O T 2+P9 $:])P!%O3, 0[T] 4&]1P$_O5 "/;U8 SJ]
M804XO6L&-KUW"#2]A DRO9,*,+VD"R^]MPPNOM ++KSN#"VZ_@TLN?\-++C_
M#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K   &JU  !>N@
M4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT< ,<M1 3#+6P$N
MS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)_ 8CR/\'(\?_!R/'
M_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2P@  1\8
M #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<4  AW5L
M(-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7
MVO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3
M   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ:
M !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\
M#.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =
MX0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\
M5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S]
M (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@
M$/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10
M_U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T
M  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M   ,^@  "?\
M  ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I  #_-   _T
M /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D  /^Y /\@*0'_
M(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*;0+_"7D"_PF$ O\)
MC@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC( ?\(U@'_".8!_PCQ
M ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!_PG_ ?\C)@'_)20
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M!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!( _S81 /\W$P#_.1L
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M#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8 ZD\+ .-,$ #63!X
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M)6M>P29I7MXF:E_T(6M@_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7
MSV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY !89L20B"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D9F*N)65B
MOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P  RV@
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M(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0  OW,  +1Z  "K?P
MHH(  )B#  "+@0  A($- '^"&@![@BD!=H$V G*!0 5N?TD(:GY0"V=]5PYD
M?%X187MF%%YZ;1=;>G8967F '%9XBQ]3>)@A47>F(E!WMR-/=\XC3W?L(5!W
M_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<  +!_  "GA   G8<
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M%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8  '^9  !SG
M9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*H%,%2*!:!T6?8PE#
MGVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_$3>9
M_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P  '>@  !KI   7Z<
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M!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L   #C#   OQP
M)LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3
MUGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:
M  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4
M !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT
M!N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%
MJ0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\   WC
M   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M
M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@
M:KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S   #
M_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^
M;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0
M $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_    _P
M /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6
M_VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5
M)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P":
M /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_
M$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"
MG #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X /\ ]P+_
M /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>'P#_&"0
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M \$D_P/!)/\#P23_ _\P#P#_,@L _S,( /\V#0#_-A( _S4: /TR)0#T,#(
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M0ZP4CT.Z%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]
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M&7I-PQIY3=\:>$[T%WA/_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P
MUE<  ,A<  "_7P  MU\  +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,
M6%4(B5=<"H968PR#56H.@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1
MP!MQ4=L<<5+R&7%3_Q5Q5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L
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M&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0  +EJ  "P;@
MIW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V:4H&<VA2"'!G60IM
M9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MBMAU:8LP=6F+J'%MC
M_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L<@  I'0
M )IS  ".;P  AV\- ()O&P!]<"D >6\U 75N/P-R;4@%;FQ0!VML5PII:UX,
M9FIE#F1I;!%A:7437VA_%EQHBAA:9Y8:6&>D'%9GM!U59\H=56?H&U9G^QA7
M9_\65VC_%%AG_Q-89_\36&?_$^%8  #+8P  O6L  +)R  "I=@  H'@  )9W
M  "(<P  @7,+ 'QT%P!X="8 ='0R 7!S/0)M<T8$:G).!V=Q50ED<%P+87!C
M#E]O:A!<;G,26FY\%5=MB!=5;)094VRC&U%LLQQ0;,@<3VSG&U%L^AA1;/\5
M4FS_%%)L_Q-2;/\34FS_$]Q<  #'9P  N6\  *]V  "E>P  G'P  )%\  ""
M>   >GD' '5Y% !R>B, ;GHO 6MY.@)H>4,#9'A+!6%W4@A?=UD*7'9@#%EU
M: ]7=' 15'1Z$U)SAA9/<Y,837*A&4QRL1I*<L8:2G+E&DMR^1=,<O\53'+_
M$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$  (R!  !Z?@
M<W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\9@U1
M?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_$D=X
M_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&  !WA@  :X8
M &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;"$Z%8PI+A&P,
M281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q!
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M"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J   $ZB  !%I D
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M !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F
MBIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3
MRPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.
MEP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4
M '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4
M"-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B
MWYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U
M  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0   .,'
M  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP
M .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+
MQ@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L   #M
M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-
M  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \SP
M+M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W
M^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_
MC0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S
M /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *(
M_P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[
M /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\
M/0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D
M /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\
M\P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_
M!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H
MIP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\ Z0'_
M .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT _Q,H /\0- #_#4$
M_PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O
M!JH [0:R /_B__])0T-?4%)/1DE,10 (">H&NP#H!L@ Y@;< .0&[ #B"/H
MX K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_
M'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.
MBP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_
M ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1,
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M!I8T_P66-/\%EC3_!?\U  #_.   ZCX  -]"  #50@  SS\# ,TX" #%.!4
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M"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93) "14S(
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M%&%5M!5@5<@67U7G%6!6^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@
MP5X  +9C  "M9@  I&8  )MD  "07@  B5X. (1?&P" 7RD ?%\U 7A?/P)T
M7D<#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I]#V):B!%?69037EFB%%Q9
MLA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/  #-60  OF$
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M%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@
MEG<  (IV  !Y<0  <7$  &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ30-9
M<50%5W!;!E1P8PA2;VL*4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<$D9M
M]!%&;?\/1VW_#D=L_PU';/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P  D7P
M (9[  !U>   :W<  &5W# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3>%$$
M47=8!4]W8 =,=F@(2G9R"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T\P]
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M"3.#_PDS@_\),X/_";EP  "M>@  HH(  )>'  "-B@  @8P  '6.  !HCP
M6I   $^1  !'D@H 1)(3 $.3'P!!DRH 0),T #^3/0 ]DT4 .Y-- 3J35@$X
MDU\"-I-I S23=0,RDH,$,)*3!2Z2I 8MDK<&+)+1!BR1[P8KC_\&*X[_!BN-
M_P<KC?\'*XW_![-X  "G@@  G(@  )&,  "'D   >I,  &V5  !AEP  59D
M $F;   _G $ .9T. #>=%P VGB( -)XL #.>-0 RGCX ,9Y' #"?4  NGUH
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M )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@
M';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #
MQF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66
M  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<
M  [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@
M -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^
MI   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75
M    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9
M  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0
M8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C
MY0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X
M6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX
M $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P
M /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P
M_UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$
M(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2
M /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L
M^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_
M "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\
ME #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_
M /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T
M_P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W
M )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8
M_P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD
M /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$
MZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6
M /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.
M*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23
M -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\
MQ0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V
M$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.
ME@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_
M ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B<
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M!/PS  #K.@  W$$  ,U$  ##1   O4$  +@[ 0"R-PX JS@< *4Y*P"A.C@
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M"W!#M0QN1,D,;43G#&U%^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820
MQU   +M4  "Q50  J50  *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_
M2TH!?$I2 GE*6 -W2E\$=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(
ML@UG2,4-9DGD#69)^ MF2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,
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M#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C90
MFF4  )!C  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;3@)A
M6E4#7UI<!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8#E!9
M\@U16?\+45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:   EVD
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M"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@
M97$  %QP!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'
M<6($17!L!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM
M_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@
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M ZUV  "C@   EX4  (V)  ""C   =HX  &F0  !<D@  4),  $24   ZE0
M,98( "V7$0 LEQH *Y<D "J7+0 IES8 *)@_ ">82  FF%( )9A< ".8:  B
MF'< ()B' !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_
M  "<A@  D8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$
M "&C"@ ?HQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7
M%*6! !.EE  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5
MC   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN
M   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X
M  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP
M@I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -
MO , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_
M@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*
M &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP
M ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@
MSX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO
M  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4
M  #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<
M .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#
MO@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D
M    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\
M  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP
M)\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T   #P
M\0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_
M@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N
M /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H
M_P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y
M /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\
M-P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"<
M /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\
M[P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_
M $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$
MG0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_
M .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H
M_P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C
M )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X
M_P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !!
M .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H
MSP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_
M _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #
M1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:=
M +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\
MKP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+
M#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0
MHP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_
M /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0
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M H8LN@*%+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P
MTCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^ )(S2 "0
M,U  C3-8 (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#?3.G WPS
MM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0  RD,
M +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'.4P
MA#E3 8(Y6@& .6$!?CEH GPY;P)Z.7<">3F  W<YBP1U.98$=#FC!7(YL05Q
M.<0&;SKB!FXZ]P5N._\$;3O_!&T[_P-M.O\#;3K_ ^HY  #50@  Q$@  +E+
M  "O2P  ITD  )]$  "8/@$ D3P0 (P]'0"(/BH A#\U ($_/P!^/T@ ?#]/
M 7H_5@%X/UT!=CYD G0^:P)R/G,#<#Y\ V\^AP1M/I,%:SZ@!FH^K@9I/\ '
M9S_>!V<_]09F0/\%9D#_!&9 _P1F/_\$9C__!.4]  #/1@  OTP  +1/  "J
M4   HD\  )E*  "11   BD$- (1"&0" 0R8 ?40R 'I$/ !W1$0 =41, 7)$
M4P%P0UD!;T-@ FU#9P)K0V\#:4-Y!&A#@P5F0X\&9$.=!V-#JP=A0[T(8$39
M"&!$\P=@1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU   +!3  "G50
MGE,  )5/  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$ ;DA) 6Q(4 %J
M2%8!:$A= F9'9 )E1VP#8T=V!&%'@ 5@1XT&7D>:!UQ'J0A;2+L(6DC4"%I(
M\0=:2?\&6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60  FE@
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M!DM4_P5+5/\%2U3_!<Q.  "[5P  KEX  *1B  ":9   D60  (9B  !W6P
M;5@  &98# !B6!8 7U@B %U9+ !;638 65D^ %=91@!664T!5%E4 5)96P)1
M66,#3UEL TU9=P1+6(0%25B2!TA8H@='6;,(1EG*"$59Z@A&6?T&1EC_!D98
M_P5'6/\%1UC_!<=2  "X6P  JV$  *%F  "8:   CFD  (-G  !R8   :%X
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M!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',  %%Q  !(< H
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M "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0
MDX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  C
MD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2
MD  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@
M (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P
M%9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +
MG9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2
M  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-
M  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4
M *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !C
MG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V
M#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@
M  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP
M2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P
MPQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(
MJ@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4
M #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D
M -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G
MW[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!
M   9Q0  $,@   G,    SP   -,   #9    W    -T   #?    X0   .(%
M  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(
M /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .
MT   !M4   #:    W@   .(   #F    Z0   .H   #L    [@   /    #R
M    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C
M  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $<
M_P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_
M *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8
M_P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/
M /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *,
M]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L
M /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\
M50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F
M .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\
MW0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R
M %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D
MJ0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_
M /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0
MX != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$
M *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4
M  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7
M ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@
MLP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_
M$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&
M6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP
M *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0
MZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L
M$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3
MO "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@
M - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50
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M G$N] )P+_\";R__ F\O_P%N+_\!;B__ >@Q  #3.@  PS\  +=!  "N00
MICX  )XX  "7,0$ D2X0 (PO' "(,"@ A#$S ($R/0!_,D8 ?3)- 'LR5 !Y
M,EL =S)A '4R:0%T,G !<C)Y 7 SA %O,Y ";3.= FPSJP)J-+P":335 V@U
M\0)G-?\"9S7_ F8U_P)F-?\"9C3_ N(V  #,/P  O40  +)'  "H1P  H$0
M )@_  "0.0  B#0- (,U%P!_-B0 ?#<O 'DW.0!W.$( =#A) '(X4 !Q.%<
M;SA> &TX90%L.&T!:CAU 6@X@ )G.(P"93B9 V0YJ -B.;D#83K0 V Z[@-@
M.O\#7SK_ E\Z_P)?.O\"7SK_ MT[  #'0P  N4D  *Y+  "D3   FTH  ))%
M  ")/P  @3H) 'LZ% !W.R  =#PK '(\-0!O/3X ;3U& &L]30!I/5, :#U:
M &8]80%D/6D!8SUR 6$]?0)@/8D"7CV6 UT^I0-;/K8$6C[,!%H_[ 19/_X#
M63__ UD__P)9/_\"63[_ M8_  ##1P  M4P  *I0  "@4   ET\  (Y+  "$
M10  >D & '4_$0!Q0!P ;4 H &M!,@!I03L 9T%" &5!20!C05  84%7 &!!
M7@%>068!74)O EM">@):0H8#6$*4 U="HP150[,$5$/)!%1#Z0130_T#4T/_
M U1#_P-40_\"5$/_ M!"  "_2@  LE   *=3  "=5   E%,  (I0  !_2@
M=44" &Y##@!K1!D 9T4D &5%+@!B13< 844_ %]%1@!=14T 6T54 %I&6P%9
M1F,!5T9L E9&=P)41H,#4T:1 U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'
M_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94  ![3@  <$H
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M \!0  "R6   IEX  )QB  "290  B&4  'UB  !N7   8UD  %E6 P!45@X
M4588 $]6(@!-5RP 3%<T $I7/ !)6$0 2%A+ $=84P!%6%L!1%AD 4)8;@%
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M 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@
MG&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y
M:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2IL
MDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,
M (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH
M+W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A
M=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\
M  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T<
M "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\
M%G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![
MA   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)
M'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO
M  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP
M98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,
MEQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5
MO@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794
M %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<
M *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@
MH=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A
M   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8
M  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8
M +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   M
MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^
M%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7
M  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@
M%KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P
MSA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9
MX0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0
M  7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P
M .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@
M[]T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4
M    V0   -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()
M  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\
M /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_
M &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\
MM #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_
M /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$
M_P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R
M +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'
M#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E
M /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +,
MX0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_
M 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .<
M9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X
M ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P
M_P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1
M &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D
MP "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,
M /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$
MO@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H
M ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-
M  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B
M *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8
MF07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,
M%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *
M8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B
M (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@
MN1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1
M$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8
M] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<
M *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X
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M 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-
M@"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D
M,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT
M_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   "".P  >34$
M ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V,
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M/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T 4$!F $]
M< %.0'P!3$&* 4M!F@)*0:L"24*^ DA"W@)(0O8"2$+_ DA"_P%(0?\!2$'_
M <5$  "U2P  J5   )Y4  "55   BU,  (!0  !U2@  :D8  &%"" !<01$
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M 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@
MH5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%
M4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G, .%." 3=3
MD@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@  GF
M )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5&  _5B$
M/58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8D $O
M6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I
M  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF
M #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z
M*%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#
M;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD
M*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q
M !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0
M=74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D
M;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9O
MQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L
M &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8
M&7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .
M=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"
M  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G
M  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L
M!('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)
MBP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/
M*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN
M  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0
M-)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@
MG2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9
M^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\
M !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(
M *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]
MJ?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K
M   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA
M  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<
M +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #
MN0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,
M(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V
M '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@
M ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P
MY!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F
M  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D
M  #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(
M /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_
M !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\
M<P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#)
M /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T
M_P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\
M '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L
MU0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P &
M /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\
M[0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7
M .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\
M! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O
M -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@
MP #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T
M  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8
M;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G
M *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G
MWP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S
M &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X
M\@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ %
M ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@
MH@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/
M /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H"
M"@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I
M ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P
M@0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H
M"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-
M:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_
M '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P,
ME@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y
M%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;
M_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<,
M (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6<
M;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A
M(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@
M$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K
M &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\
M62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N
M)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK
M<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_
M ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14
M9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2
M,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z
M  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(<
M %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G<
M2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R
M10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W
M(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N#
M $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20
MHTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-
M.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_
MD0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$
M )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0
M1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y
M1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18
M  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X
M,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(
M70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*
M+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO
M "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@
M>V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S
M4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93
MQ0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8
M &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\
M*U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?
M6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK
M  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR
M ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.(
M%U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8
M;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG
M-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W
M !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@
M1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0
M<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO
M_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T
M #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#(
M!'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@
M>?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'
M   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV
M  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\
M (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :
MD@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6
M.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_
M (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0
M#)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P
MICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-
M  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L
M  "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS
M +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !M
MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z
M    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR
M  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0
M4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(
MRP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C
M-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K
M #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W
M -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0
M^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\
M$ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\
M /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /
M] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_
M !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /<
M?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z
M ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X
M_P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F
M 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P
M_P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3
M /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8
MS@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W
M /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$
M&0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V
M +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\
MI0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#'
M !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D
M=0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_
M )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !<
MLP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8
M '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8
M_P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ;
M *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '
MB !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X
M!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4
M'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR
M 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\
M;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$
M#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0
M=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_
M -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP
M=A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B
M%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ
M  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB
M &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD
M6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X
M-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A
M)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6#
M $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P
MIS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7
M)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@K
MD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,
M )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"<
M3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!
M,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)
M  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP
M.S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*
M3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U
M+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM
M #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@
M?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_
MP@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4
M '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I
M1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7
M  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V
M "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.
M)$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?
M6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*
M.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV
M !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@
M4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A
M44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2
M_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$
M $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P
M&%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 1
M6/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF
M   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%
M  ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\
M"U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M
M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K
M1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_
M )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P
M'78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00
M=4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U
M  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$
M !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<
M ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$
M@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.
M   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-
M  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B
M<HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";
MG0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@
M5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(
M %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@
M *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2
ML5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?
M   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<
M  "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX
M ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   R
MK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(
M    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4
M  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0
M%[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:
MW    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W
M7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ?
M /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0
M_@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P
M /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\
M)P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$
M .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\
MV0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y
M "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T
MA #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_
M +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@
MY  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$
M (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +
M_P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M
M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T
MKP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P">
M /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +<
M,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^
M )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\
MC0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D
M #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T
M@ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_
M .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P
MDP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!]
M (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1
M  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O
M (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\
M;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$
M(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(
M, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR'
M &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*
MKRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I
M#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2
MD@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(
M )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T
M714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.
M&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX
M  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP
M %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P
M12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-
M/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA
M,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K
M #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@
M@#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$
M)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<L
MOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40
M '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S,
M/2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q
M,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%
M  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L
M+#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B
M10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T
M/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT
M "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20
M5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K
M.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]
M_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP
M $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\
M)#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =
M0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.
M   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5%
M !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\
M%T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14   Y
M40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,
M3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_
M )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U6
M*U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /
M4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=
M  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8   )EX
M !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$
M!EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".
M:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF
M   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:
M  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0
M@'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -
M<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O
M9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L
M '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &?0
M 'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@
M>V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#
M  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@   (H
M  ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@
M (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3
MC0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@   "7
M    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES
M  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(E@
M.ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E
MI0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K
M@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP  +:(
M ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S    M
M +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@
MP(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M
M   +L    +,   "U    N    +P   "_    P0   ,$   ##    Q    ,8
M  #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9   VWX
M -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX
MNP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@   -D   #;
M    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(
M  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0
M_P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y
M )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -(
M_P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [
M /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P
MYP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"]
M /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U .X
M0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "-
M ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\
MK0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3
M $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D
MC@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_
M /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T
MNP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E
M )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T
M  #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^
M *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4 (H
MD0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C
M    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W )<
M/P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/
M '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#
MPPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"&
M $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$
ME0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8
M *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D
M=P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C
M )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?
M  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z
M &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP
M5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4
M)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+
M.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL
M $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0
MABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3
M$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04
MO@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$
M '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C<
M218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [
M&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R
M  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ
M $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8
M-2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G
M,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA
M/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R
M "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.
M6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S
M)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK
M_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@
M $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E
M+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY
M  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]&
M "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\
M(3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _
M.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U
M30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_
M *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]00
M,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :
M.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+
M  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,
M "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%,
M$T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "3
M5@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(
M   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>
M  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P
MAV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0   7
M3@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.
M:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8
M 'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   25P$
M#58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !690
M57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N
M  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80  "6 (
M  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(
M %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J
M=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&  !K
M"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"
M  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P
M57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W"
M=@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !T
MD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((
M #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P  @P@
M (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""C
M@:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-
M   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2    D@$  )('
M  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP
M )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <
MEP  $9@   F9    FP   )P   ">    H    *    "@    H    *$   "A
M!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L
M  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1H0
M"*,   "E    IP   *D   "L    K@   *X   "N    KP   +    "Q
ML@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "Y
MNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K    *\
M  "Q    M    +@   "[    O    +P   "^    OP   ,    #"    Q
M ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5JP
MU<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L   "^
M    P@   ,<   #*    S    ,P   #.    T    -(   #5    V    -L
M  #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(
M /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_
M %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /(
MG0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_
M /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L
M\@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#=
M *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\
M  #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !-
M -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H
MPP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_
M    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4
M3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@">
M *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[
M\    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N
M $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D
MHP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K    W0
M ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@
MFP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "&
M *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X
M  "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!'
M (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *,
M=0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H
M!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L
M1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N
M &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$
ME0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L
M $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D
MO !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10
M (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $
M7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !.
M M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8
M  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9!
M %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]
M1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N
M&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-
M0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q
M #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P
M81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@!
M$44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06
M_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0
M %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D(
M-Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N
M&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H  % E
M  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M'
M "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\
M*"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$
M)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA
M3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_
M *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+
M."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C
M)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^
M  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T
M "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0
M'2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "5
M1P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0  "HO
M!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!>
M !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P
MB4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V P ?
M,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U
M:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,
M 'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <.@@
M%C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +
M.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;
M  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@, $D +
M ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $078
M T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P
M8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(  M'
M#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&
M  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@
M968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51#0 !
M4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#  !/
MF   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L
M %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P  6@\
M %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8E
M5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP
M   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T  &41
M  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<
M &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W   X
M=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.  !P
M$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\
M  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O@
M(G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^#0
M?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !Y
MV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D
M  ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ","   C0T
M (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*S0
MB>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5
M    E@   )@   ":    FP   )L   ";    FP   )L   "<    G04  )T+
M  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@
M )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A
MHP   *4   "H    J0   *D   "I    J@   *L   "L    K0   *X!  "P
M"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P
M &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M    L
M +0   "V    N    +@   "Y    N@   +P   "]    OP   ,    ##
MQ0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;
M  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@   ,,
M  #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9    W0
M .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_
M    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L
M6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M
M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_
M_P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H
M %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\
MM #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P
M /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8
MS@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V
M +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\
M  #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6
M +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0
MH #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/
M    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *,
M50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_
M (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_
MM0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0
M %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L
MSP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O    J
M *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"  $T
M?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J
M .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP   )0
M  "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !,
M &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!= -P
M7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""
M  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!& &(
M3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O
M %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@
M<0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5
M $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8
M^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$   : L
M &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@
M20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \
M!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(  %H-
M P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+
M #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\
M- W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04  !,
M#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.
M4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_
M *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@
M0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M
M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q
M  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<%
M #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0
M)A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8
M.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9
M"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q>
M !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0
MBT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G
M'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA
M:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40
M ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C(@L
M("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3
M)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*
M  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<.
M !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W<
M#BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S
M3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L
M$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(
M  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5
M9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .
M,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   V
MF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60  95@
M %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$
M"#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP
M/*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<
M  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5
M  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E   0JH
M $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)
M70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+
M&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G
M  !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#9
M-V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5%0
M5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0
MX@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D
M "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<
M %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:WP
M6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(  !UP
M   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9
M  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4
M &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z   -
M>@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3  !X
M&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_
M 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #A0
M (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.  "($P
MB!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$
M  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@   ),
M  "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8#0  F1,
M )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*  !?
MC0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$   "D
M    I0   *0   "E    I0   *8   "G    J    *D   "J!   K P  *X3
M  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0
M1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +    "R
MM    +,   "T    M0   +<   "X    N0   +L   "]    OP$  ,,+  #%
M%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(
M "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!    Q
M ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@#
MX1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P   /\
M 0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C
M /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T
MW #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\   #_
M  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X != -X
M8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C
M ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S  $
M[0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#"
M &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0 *L
M\@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@    U0 (
M ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L
MK !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6
M /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP # +D
M#0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!:
M )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8
M@@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *< "0"B
M !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3 (8
M60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_
M '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3  P
MC@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T
M %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$
M_P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @ @0 .
M 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %(
M9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4 _P!4
M /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 + '
M$ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3
M %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\
M20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A
M !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L
M5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_
M +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X
M4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _
M %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@
M  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/
M $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8
M-01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";
M*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'
M$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I>
M "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P
MC3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S
M#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/
M:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8
M ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X
M*A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;
M$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[
M  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8
M%!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S
M/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'
M  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P
M:$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5
M'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LB
MF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8
M %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1(1,
M$"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $
M)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(
M  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6
M  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD
M "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/
M2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5  8O
M&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_
M   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.4
M14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V&0
M-B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]   V
MX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(
M #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT
M #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \W@
M._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5
M   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B
M  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W   0O4
M $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?
M6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/
M)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_
M (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   88@
M$&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9(@
M62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L
M  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H
M  !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'   92<
M &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W
M=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4   !U
M    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B   '(L
M  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@
M9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#
M@P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C  ""
M,@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684
M $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1    D@
M )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09  "4)P
ME#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0
M   PD@  (90  !25   *E@   )<   "9    FP   )T   "?    H    *
M  "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H'   J"T
M *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9   C
MG   %)T   J?    H0   *,   "F    J    *P   "N    KP   *\   "P
M    L    +(   "S    M    +8   "W    N@   +T'  "_$   OQ\  , S
M  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0
M"Z<   "J    K0   +    "S    M@   +L   "]    P    +\   #!
MP@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE  #>
M.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  < _P 0
M /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D
MZ0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/
M /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P - /<
M%0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I
M ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\
MM #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$ $0#<
M !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@
M: "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_
M )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#! !4
MO0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A
M &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L
M_P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L !$ J  8
M *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &
MC0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W
M /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3 ),
M&P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@
M 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\
M9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0 (, %@!_
M !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H
M80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_
M ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q !@
M;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!:
M &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*
M  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9
M %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X
M3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E
M%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0
M&@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C
M #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P
MDQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H %0!'
M !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8
M:P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0
M (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8
M/  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K
M '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J
M  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7
M #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0
M(@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T
M+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'
M%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R%
M !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P
M:#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A
M#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0
MF  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8
M %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4
M&! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -
M$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW
M  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8
M !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@
M!AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0
M.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8
M'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\
M  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !//0
M1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *
M'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   A
MVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\
M #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"
M B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   FV0
M)?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"
M   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF
M   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(
M "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='   M
M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q
M+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__
M (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H2
M'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0
M.30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5
M  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P  &$P
M !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@  03$
M $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\
M8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2
M   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY
M  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P
M<FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;
M6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T  !4
M0@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$
M &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E    90
M &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?/
M7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV
M  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0   '$
M  !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8
M &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$
M?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X   !]
M    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/
M  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@
M*X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T   ",
MC    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".
M6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP  'I
M !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";    G
M )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C3P
MHV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;
M    G0   *    "B    I    *@   "J    JP   *H   "K    K    *T
M  "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL
M +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G
MJ@   *P   "O    L@   +<   "Y    NP   +H   "\    O0   +\   #
M    P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI
M  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_ "
M_  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #?
M '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$
M_P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L Z0 E
M .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\
MPP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"<
M /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@
M*0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O
M *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\
MB@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N
M "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )<
M< "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_
M /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ": "4
MEP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0""
M '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\
M  #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X A0 F
M (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L
M;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\
M    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ? ',
M)@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N
M %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P
MI    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C
M "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %
M= !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP
M ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6 "$
M5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!"
M 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1
M  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A
M $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@
M-@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z
M%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T
M(0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "%
M "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U'P
M;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S
M "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "(
ME0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(
M %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T
M*0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9
M *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD
M  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(>
M " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4
M$0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1
M)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@(
M(  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[
M  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P
M1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1
M#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40
MU  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P
M #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"
M#! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0
M$^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN
M   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F
M  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T   %^T
M !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S
M,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :
M+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T  !O\
M (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S-P
M*C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @*P
M(38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#
M  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P  )3<
M !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,
M "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_
M3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y
M   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$  "T]
M   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@
M=54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_   -
M/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z   T
M1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL
M &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (1
M $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \1
M/%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC
M  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30   $P
M  !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0   15
M $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=
M:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8   !4
M    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=
M  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0
M1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &    !?
M7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9
M;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,
M #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K    :@
M &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@
M97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[
M   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X    >    '<
M  !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<
M '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$   .
M@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP   (<   "'
M    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T  (>)
M  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $C@
M )    "1    DP   )4   "7    F    )8   "7    EP   )<   "8
MF    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<
MG   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@   )P
M  ">    H0   *0   "F    IP   *8   "G    IP   *@   "I    J@
M *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@
MM*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D   "L
M    KP   +,   "U    MP   +8   "W    N    +H   "[    O0   +\
M  #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T
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M______________________________________________\
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MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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M__________^H-0          7-/___________________________]]#0
M        5-;__________________________^Y]10          1-3_____
M______________________RJ9"\"   $(C=)6,[_____________________
M_______II&M!*#]C?Y6GNMK______________________________]6RK++,
MY/K_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^6[EW=BR/______________
M___________________;GF<V"@ "C/______________________________
M_\A_/P4     7L______________________________V8$Y        /*K_
M____________________________GDP         (Y#_________________
M___________<;QH         $'WY__________________________^O2
M         &_N__________________________^$$P           &3F____
M_____________________^Q1             %?>____________________
M_____[@5             $C6_________________________W04
M     #C/________________________^:):$P           "/%________
M_________________]^;7"P           VZ________________________
M___OL7U5.2(1!P$"$2*R_______________________________?OZ69F)J@
MK+W:________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______COIV ?/O________________________________RMX17, X ':S_
M_____________________________]**3!4      '+S________________
M____________UG\V         $O)___________________________ZD3X
M         "^K___________________________ 6@           !J5____
M______________________^-)             B$____________________
M_____^=>              !W_________________________[0E
M      !J_________________________WT               !;]/______
M_________________2L               !,Z_______________________
MI0                 \X?______________________, P
M   MV?____________________^9BF$G               GU___________
M____________[;Z)52<            EW/_________________________^
MRIUV74H\,BTL,#E'WO_______________________________>;=UM+0T]GD
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^_4N];_________________
M________________Y[B/:DLO%6_______________________________^2A
M9S0'     #S)____________________________UH([         !*7____
M_______________________MA3$           !O____________________
M______^F0@            !0X?_______________________^QI
M       WR?_______________________[,O               BMO______
M_________________WD                0I_______________________
M\C0                 F?______________________J0
M    C/______________________1@                  ?___________
M___________?                    =/____________________^7
M                :O_____________________.
M8_______________________*2(!                8?______________
M________N:. 5S<7            :/__________________________^M.N
ME(9\=7%P<G>!E/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________;NIV":6G3____
M___________________________(DV4]&0   !V>____________________
M________VXY,$P        !N___________________________;?"P
M      !%U_________________________^+*@             BM/______
M_________________\)$               #E_______________________
M_WT!                ?_______________________YS8
M    :O______________________G0                  6/__________
M____________1@                  1_C____________________I
M                ->G___________________^6
M)=O___________________^\                    &,[_____________
M_______K                    #\+_____________________
M            "KG_____________________)P                  "K7_
M____________________<                   #;G_________________
M____X)R,<%5",R8;% \-#A(:)K_____________________________YY-C2
MSLS+S,_6X/S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________KT[SC________________________________TJF%
M94@L$@&%____________________________\:MQ/ \       !/X/______
M___________________5?S4            ?LO______________________
M_^-U'0              B?_______________________Y C
M    9_______________________U4,                 2/;_________
M____________B@                  +MW_____________________.
M                %\C___________________^^
M!+;___________________^<                     *7_____________
M______^Z                     )/____________________<
M             (+_____________________                     '3_
M____________________$P                   &C_________________
M____0@                   &#_____________________>@
M         %W_____________________T0                   &'_____
M_________________R0                  &;_____________________
M_\FLF8E]=G%L:6=F9VMP>HS_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________BQ:J1>6%W________________________
M_____]VF=U L#      QQ/_________________________@DDX3
M    C________________________])P'0              8/__________
M____________[F\/                -^+_____________________EAP
M                %,#_____________________0
M */___________________^N                     (G_____________
M______^>                     '+___________________^\
M             %_____________________:                     $W_
M___________________Z                     #O_________________
M____#@                   "KY____________________,P
M         !OI____________________7@                    _;____
M________________CP                    ;0____________________
MT                     #*_____________________RL
M      #(_____________________X                    #+________
M______________<6 04% P$       $&#1C+_______________________\
MZ^'8S\S-S]#2U-?<XNK_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M\=K&_______________________________QQJ.$:$TR&  5J___________
M________________N7Q&&           <?_______________________]=\
M+P              .^/_____________________WV0)
M#+7_____________________= ,                  (W_____________
M_______%%0                   &K___________________^9
M             $O___________________^V                     ##]
M___________________7                     !GG________________
M___V                      73____________________#@
M          #!____________________+P                    "O____
M________________4@                    ">____________________
M>0                    ".____________________I0
M      " ____________________V                     !T________
M_____________S8                   !M_____________________WP
M                  !I_____________________]<-
M  !H______________________]P                  !A____________
M____________4#Q&3E1976%D:&QP=GZ)____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU;NCBW-:E?__________________________^+^.9$$A!0
M4OS_______________________>=5A@             %\'_____________
M________Y6P6                 (W_____________________8P
M             %[___________________^=                     #7\
M__________________^A                     !'9________________
M___*                      "[___________________N
M          "A____________________#                     "*____
M________________+0                    !V____________________
M30                    !D____________________;P
M      !2____________________E                     ! ________
M____________O                      P____________________Z@X
M                   B_____________________T0
M   5_____________________X$                    +]?__________
M_________\@+                   "[/____________________]>
M                Y?_____________________)'
MVO______________________G0$             !PX7Q?______________
M_________]6YO,''SM7;X>;M]/O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________C?S_______________
M_______________LQJ6(;50[(0< ,M[________________________7DEDI
M             *#______________________XDV                 &?_
M____________________9@                   #+V________________
M__^5                      /(__________________^G
M          "@___________________7                      !\____
M________________                      !>____________________
M)0                    !#____________________2
M       L____________________:@                     8________
M____________BP                     %\___________________KP
M                    X?__________________U0
M    S____________________R0                     OO__________
M_________U0                     KO___________________XL
M                G____________________\L.
MDO____________________]7                    AO______________
M______^J"@                  >?______________________;0
M            9O______________________]U4                 1?__
M______________________]J(RLU/TI58&IU?H>1G/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z,^VG8-I3KG_
M________________________[+*#7#H= @       'O_________________
M_____\5M*0               $#_____________________@QL
M          ?+__________________^2                      "8____
M______________^D                      !J___________________=
M                      !!____________________#@
M       =____________________.0                      Z/______
M____________8                       SO__________________A0
M                    M___________________J
M    H___________________RP                      D/__________
M________[Q8                     ??___________________SX
M                ;/___________________VD
M6O___________________YD                     2?______________
M_____](6                    .?____________________]8
M            *?____________________^B                    &?__
M___________________U5@                  !/__________________
M____NR\                  /C______________________ZLI
M         ,_________________________)1P     '$R N/E)HA.W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________TU<G____________________________ZTK"2
M=UU"* P  $K________________________%?447             !'8____
M________________Q%                    "?__________________^B
M#                     !H__________________^4
M       V___________________:                       '[/______
M____________%0                      Q/__________________2
M                    HO__________________=0
M    @___________________G0                      :?__________
M________PP                      4O__________________YP\
M                /O___________________S,
M*____________________U@                     &/______________
M_____X$                     !?___________________ZP
M             /___________________]XB                     /+_
M__________________]<                     -__________________
M__^?                     ,S____________________H2@
M         +?_____________________H!8                  )S_____
M_________________WH"                 '?_____________________
M__]Z"P              !4S_________________________HE=H=("-G*N\
MT.?_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[>/_____________________
M_____]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M      !I___________________D0P                     T________
M__________]Y                        X__________________-
M                    LO__________________$P
M    A?__________________3P                      7?__________
M________@P                      .O__________________L@
M                '/__________________VP,
M O___________________RH                      /O_____________
M_____T\                      .?__________________W0
M             -3__________________YL                      ,#_
M_________________\0'                     *W_________________
M__ S                     )K___________________]G
M         (;___________________^C                     '+_____
M_______________C1                    %S_____________________
MD08                  $'_____________________ZU\
M     !W______________________\I+                  #_________
M_______________+5P  #!@D,3].8'2+I\?_________________________
M_]?G\O______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O4S<?"OKJWL["MJ:BE____________________W7Y3
M/S C&1$) @          V_________________]V
M    I_________________^Z                        =?__________
M________!P                      1O__________________3@
M                &O__________________C
M /W_________________P0                       -O_____________
M____\1D                      +[__________________T0
M             *3__________________VL                      (W_
M_________________Y$                      'G_________________
M_[<                      &;__________________]XA
M         %/___________________]*                     #______
M______________]W                     "O___________________^L
M"@                   !;____________________G10
M      #_____________________B@                    #_________
M____________UDT                   #]_____________________Z<N
M                  #5______________________^8*@          !A@M
M16#@________________________J&-T@8^<J[O-XOK_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M                ,?__________________
M ___________________0@                       -S_____________
M____C@                       ++_________________S@
M             (W__________________RD                      &O_
M_________________UH                      $[_________________
M_X8                      #3__________________ZX
M         ![__________________]07                      K_____
M______________H]                      #___________________]E
M                      #___________________^.
M      #___________________^\&0                    #O________
M___________Q3@                    #8____________________BP
M                  "_____________________S$,
M  "A_____________________Y$9                  !Z____________
M__________)T"@               !%?_______________________H=!,?
M+#A%4V)RA9NTTO7__________________________]?H]/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^_?S\>[LZ^OL\?______________
M____V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M             )+_________________B                        &;_
M________________UP                       #W_________________
M_S,                      !C__________________VP
M          #__________________YT                       #_____
M_____________\D,                      #V__________________$U
M                      #?__________________];
M      #+__________________^"                      "W________
M__________^I!@                    "C___________________3+P
M                  "-____________________7@
M  !W____________________DP<                   !>____________
M________S4,                   ! _____________________X<0
M               <_____________________]A>
M______________________^_3@      #APL/E)JAJ7(________________
M________PGR,FJ>VQ=;H_?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________[N'7S\G#OKJVL:VIIZ:FIZ[_________________
MOH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M          #__________________S0                       #V____
M_____________W8                       #2_________________[
M                      "R_________________^$D
M      "6__________________]1                      !\________
M__________]Y                      !F__________________^@
M                  !1___________________'(P
M   \___________________N2P                     G____________
M________=                      0____________________HQ8
M                ____________________V$P
M_____________________X@/                    ________________
M_____\M3                    ______________________^E.
M    "1TT3FN,________________________F3E#45]N?8Z@M<OE________
M_____________________^OY____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%
M,B,8#@8               ">_________________WX
M      !U_________________\,                       !2________
M__________LW                       R__________________]J
M                   6__________________^6
M    __________________^_&P                      ____________
M_______F0@                      ____________________:0
M                ____________________D (
M____________________N2P                     ]/______________
M____Z%P                     V?___________________Y$8
M            O/___________________\I3                    G?__
M__________________^8+@             0*49FQ/__________________
M___N?QT,&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________]]?#KYN+?V]C4TM'0TM?@________
M_________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M                    __________________]"
M    __________________]]                        ____________
M______^P"P                      ]O_________________=.0
M                W/__________________8@
MQ?__________________B0                      K_______________
M____KR(                     F?__________________UD@
M            @O___________________W(                     :?__
M_________________Z$H                    3O__________________
M_]-<                    ,_____________________^6+@
M    %3)2=______________________@<A,   $/'R]"6'"+J,CL________
M________________RF]N?HZ>L,/8[_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________YX-+(P+JUL*RHI:*?G9N;G*"G____________
M______^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                K?_________________,'@
MB__________________[4@                      ;?______________
M____@                       4?__________________J1L
M            .O__________________T$(                     (___
M________________]6@                     #/__________________
M_X\4                     /___________________[@^
M         /___________________^5M P                   /______
M______________^?-P              $"]0=/_____________________=
M<A0     !A<J05IUE+;:________________________O%A$5&1UAIJOR./_
M_____________________________]+-X?'_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________S[^OO]____
M___________________NN:B=EH^*AH)_>WAV=')S=7A_D/______________
M___K3SHP*"$;%1 +!P(         (___________________:0
M             /__________________FPH                      /__
M________________R#D                      /__________________
M\&,                      /___________________XH.
M         /___________________[ T                     /______
M_____________]5;                     /____________________^%
M&@                   ^S___________________^Q20
M&#E=@?_____________________E>QX       PA.%)OC[/9____________
M____________NU@I.4E:;("7L,WM_____________________________[.>
MM,77Z_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________KOY^'<V=;4TM#0T-'3V>#K]___
M________________N(I^=W%L:&1A7EM96%=765YE<?__________________
MOS$?%A *!0               /__________________[58
M         .C__________________X($                     ,S_____
M_____________ZLO                     +/__________________])7
M                     )O___________________=\$
M     (7___________________^B-P                 %*Y3_________
M___________+80(            ,+%!VGM'____________________UC3
M      TC.U=VF;[E________________________PV,8*CM,7W2-I\;G____
M_________________________ZA_EJB[T.?_________________________
M___________]________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________]W.Q;^\N;:TL[&RLK6YP,G5X_______
M_____________Y=L9%Y955%/3$I(1T9(2U!99J'__________________Z<F
M#@<"                 %;__________________\Y0
M     #K___________________1Y"P                   "'_________
M__________^?,@                    [____________________$6
M              @Q6H3____________________I?Q\           8G2W&:
MPNG_____________________ITD      A<O2FB*KM7\________________
M________TW4>)CA*7G6/J\OO_____________________________ZYRA9BL
MPMOV___________________________________?[___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_________
M__________^*6E-/2TA&1$-"04)#1TY9:7W___________________^>+@8
M                  #____________________#5@
M%4'____________________G>QH             "31@B[3_____________
M________GS\         !"5*<9G"Z_______________________QF8/
M$RI$8H.GS?7_________________________ZXXU*SY1:(&=O-[_________
M_____________________[YV?Y2IP=SY____________________________
M_______2V//_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________;R\._O[_'S^/W_____
M_______________________XL)^:EY:6EIB;GZ2LML+1X>[_____________
M_______^CE!*1T5$1$1%1D=+45IH@ZG_____________________ID$!
M       '-F./NN'_____________________QF4*       $)TQSG,3L____
M____________________Y8@O   3*D1B@J;,]/______________________
M_____ZM0-DIA>Y:TUOK______________________________]*'?)BQR^G_
M___________________________________4SNW_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^WEX^/DYNCM\?G_________
M_____________________;&4DI*5F9VCJ;*\T.W_____________________
M_____YU31TE-459@<XJOUOS__________________________[)6 !HU4&V+
MKM+W_____________________________\UO/E][F;?7^?______________
M_________________^Z?@Z;"X?__________________________________
M___CSNO_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________\
M
M
M                                                 /__________
M____________________________________________________________
M____________________________________________________________
M________________________________________     /_A0+5H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#<N,BUC,# P(#<Y+C%B-C5A-SDL(#(P,C(O,#8O,3,M,3<Z-#8Z,30@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL
M;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO<&1F.E!R;V1U8V5R/@H@(" @
M(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M,BTQ,2TR-E0P,CHP,CHR-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(R+3$Q+3(V5# T.C$Q.C U*S U.C,P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R,BTQ,2TR-E0P-#HQ,3HP-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.F1A93 V,30U+30R-S$M-3<T."TY9#0Y+6,Q839B,F4R.#EF83PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#HX8S4Q,F5D.2UC-60R+30Y-#<M.#$S8RTT.#-D-#EE9#=E.34\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#I!.4$V,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!
M-38\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)E
M83<U.#<T+68U-F8M9C,T,RTY.30V+3!E,C%B.6(S-V(Y-3PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ
M,2TR-E0P-#HQ,#HU,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S
M+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#IF,C<R9C4T,2TV-CDT
M+60P-#@M.#9E-RUA8C W9F(V9CEC,C<\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,3$M,C94,#0Z,3$Z
M,#4K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HX8S4Q,F5D.2UC-60R+30Y-#<M.#$S8RTT.#-D-#EE9#=E.34\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C(M,3$M,C94,#0Z,3$Z,#4K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.F8R-S)F-30Q
M+38V.30M9# T."TX-F4W+6%B,#=F8C9F.6,R-SPO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^=75I9#I!.4$V,#)%
M1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I
M9#I!.4$V,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/E-T97!H96X@36$\+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T
M;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T
M/@H@(" @(" @(" \=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T
M:6]N/@H@(" @(" @(" \=&EF9CI84F5S;VQU=&EO;CXY-C R,S O,3 P,# \
M+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N
M/CDV,#(S,"\Q,# P,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @/'1I
M9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(" @
M(" @(" @/&5X:68Z0V]L;W)3<&%C93XV-34S-3PO97AI9CI#;VQO<E-P86-E
M/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I;VX^-34Y/"]E>&EF.E!I
M>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N
M/C,W-3PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(" @(#QP:&]T;W-H
M;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @
M(#QP:&]T;W-H;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I
M('8R/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" %W B\# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$           8( 0<)
M!00# @K_Q !8$   !@(  0<&" H&!P8%!0   @,$!08!!P@1$A05%E;6$U5V
ME)66(3$U-E%4D=0)(D%A@;6VM]7P%R-QH<'A)"8R1(6Q\1@E,S1FT4)&4F+&
M4X2FM,7_Q  = 0$  04! 0$             ! (#!08' 0@)_\0 0Q$  @("
M 0,# P$$" 0$!04! @,!!  %!A$2$P<4(14B,2,D,C-!"!9187)TLK0E-$)Q
M%T-2D4149)*A4X&QT=+P_]H # ,!  (1 Q$ /P#_ 'MR<G(-Y%A&1K!D\7>L
MY)\<[Z27C4D48U>*;F*4S>*E#JJ*GE4\E+E-$I2I'SDYLFQ@,9^72;9YDKOO
M1)>$ QCI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,E=]Z)+P@&,=)MGF2N^
M]$EX0#&.DVSS+7?>B2_1_P#*'\_G#&9Z3;/,M=]YY+P@&,QTFV>9*[[T27A
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MEKOO1)>$ QCI-L\R5WWHDO" 8QTFV>9:[[T27Q^Z']_]P8QTFV>9*[[T27A
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M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C(["?*5O\
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MBC7!@"Q,2\8S'1N&>I^^X-2MT-13TUA5RU%MI[&M;:Z&0H%0 LJWZ?Z4"$3
M&)]I$9#,=Y1/UZBT%4-+N9MS5Y:U/^OD&2#U">D8]RU+A@HNHW52;QT3%IY<
M%Z2L3"SC#@Z::BA$,I%67PK*],_1KC7I6[;.X]LN17/K*JJK:MQ>IOKC%,W&
MEBD4==KERZ/.T?*\7& $8)E0M=#+'-?4;=<[707MZ>GK_3C>:&:ZK94V?<"L
M6 ;;5VX?CGQ!,K5*Q(A$F0<@OLU[Q,Z/;W>F**4+75>?WU>>CW1IACF+K4V5
MH4CG#]9Q+9<Q)99!=,V&J\9+.W3-3I!7Q6IWS!DLAB/7?A>UY1PF[1XCQ72[
MKD=ZW51-JS7T2=C1H$V7W;6OV.V\,5K3?&-1C$6DV"JV[4 4]Q1,STNW^MTG
M**5SD.^VNKT]!5BP"*EG<12N7(3->M7V%+5D7O*H"X[ (LUWU8LUJS#7!K68
M4_USPD;5->:NO=:E(P4$PD\/S6*&MM00G*V];-G.8^;A'+9[-NFTFR<F3\BJ
MUCU%S)J+(%6:%6.Z2^9_2;T5]7N-\NJ3N-1N]#QO8BRIOK>DYU4TUH*T):==
MT-X[O#NV"19\<C7*N]3@-J3\ MFRGM7J'ZB^G&_X^WV5S4[C=Z]JKFF3MN)N
MVB1M"P(9 #N]3[:N1IDX]P#4M44 P99(>%EAM[:<G:MJ2^.4=Z;<DJZM77$=
M.PEFE#V5S--)0^8U6-1EV)H.1A$'_3$&CF099.LS:Y<K*](2,9(GT=SC7\@]
M,^)[WF6E]3.?$_1TYM5:>T'C/(Z[+9L76HK/ZIQNQ:!$VWA-IY/8:4S+EDOP
M!TXMH_HGJ'MZ/$=WPGBI4=XPJ5YNN=R'06)I$!MO=C=5OZ@0R:JB!*U J&%U
M4??#C@N8D!'3:MIICJHVV>H=FB+#'JU^QUDQ"NF:Z_/C56#MH:(GDY.$DVCQ
M:/EHO,))Y=,ECX08N7!$4C_$GHIZL\FX!SBSL*DU]U/,!9JMW2WWU6]3V=J_
M:&Q5V%T=:V=D=ZOLIAP["LJY?2#[DIJW2>RI8^C/5_TFX[S[BFKI-L;'C3>%
MV4[;C^SXO.IH7]57I5#JVM;5^IT[&M^E7-9)5K&LL#7H6(34AKZOMU64=DB[
M7W; D3/<>'R3=,4#%3?S-%MT+855LY,;)EXZJ8QUQE+">.4I'+POXV,8561Y
MY<8_07^MGJ+K9$=SZ8LV*A$B;<X;RC5;09B(ZQ(:_?!QJY)S\QXED^?B)$RD
MH"/E[Z%P^X,EKN:Q3.2$5UN1Z+84B^9Z3)6].6]K0,1]W>SPQ'68(8B.Z:1V
M[CSV=FSO;51JU$2%#AUC*0M$6<M"3-XB$D$NEFF+"9LY3K=A=*Y>$AFL4N[B
MHEPDQ--+31%'K-+D^T_I&4*WJYQ'BS5;'C7%1F=5SN>3ZVM1V6IW6Q:U"&L%
M=JY[>AH/V"U;9#PFTI^R6:@A-1\;#7]*=^[TQYAR[7?1^4[Q?_%> T^,;1^P
MI<@T6M0IUE/NF4JL%MN0%]1JZ]*DN12?7U32L6(?=K9TZUKL& VK0ZKL6KIR
MZ,#;HAO,1S>?B'L#--4EN<11I)Q,@FDY9O&KA-5NL7&%6RIDLKL7+QDJW=+?
M6%A,UW&F6H= 3$BZJ]=FLY9C!K<AZB);4M60L68ST("B9B)ZQ'%M3LT[C75-
MFA-VLNVKO]ML:;Z%^LP2);JURG9!;J]FNX&)<LQZ083($82)E.!9S(X#& Q@
M,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#&1Z%^4K=
MZ0MOT_ZIUC_I^@,9AS\[(3T=M'ZRJ'Y/Y_O#&2(,8#& QFF^(.<-7-+;'F,4
MV#V DUK+TCNIVAPDUJ\G'NN8TD#V9=9G(%)7(]DNO)3O,8NELQ;-T5!$ZV28
M$*\,,77KD-7MM[#64Y;=(AJ5)MWZU<+M@@B3%=1C ?WA(DL@%OD5 2T)522!
MIM";,G7JWK2U4@\ERVRK2L60HU%]>AV;Y*BD@)@H)KP&5LB9 J*</D(_+Q!4
MVT2E>X"$)$]6?4XLIPZ7:?LVPVT#!U=V2%CRQ<Q&1D<S@V32/:QKN38D5E2M
M$(V+R?,5Y0J6<KG/=O9([?DO5&;"T0 ,JL7(V^G V6V%/E6#/.QLJ 858N>)
M]B?.M,EAG]"^BB,5)54M&JO#3F32AM#9LD:41]K;4L+N[S(I"FS8RN/U63G4
M\0,GX#& Q@,8#& Q@,9"[[\A,O3+7/[PJN)%7^(7^7M_[1V5#^9_PG_H+)H(
M^4X#& QD1OUK;4:EV:VN^;E.!AWCY-,WQ.'A4\IQ[/'XQ>4[U\HV:)XYQ>4Z
MQ<<N.7E&M<QY$CB7%M]R2Q$$&HUMFVM4_P#Q%J [*54?F.IV[AHK!'6.IM&.
ML=<S7'=.W?[W5:9,S!;"ZE!G'_E(DNZR^?B>@UZXM<4])Z"N9Z3E(?P>%2<N
MJ'?M^S63.)O?=V?2D2\.JLJ937--7>UNFK(X733,BULCXEGV"BDG@J/-NN,X
M+DV,G-,XIQQ_#.%\4XG;DBVM#6SM.3,/M\CN7\E<>]Y&33$BAI5;UV=:#)GK
MX:*QB!$1$=*K;E?,^4\V]04P/T_D>[G5\4A;38E?!.( 7'N+%6@P E)VB:MO
MD4JB.V&;LY[C*28?0P9G,W@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8
M#& Q@,9CDQ]&/LP/.D?V1_[1C&<<N,XQGDSG&<8SCX\<OY?T!,=8F/[8Z8C\
MQ_/.>TOP).9B6E)=UMQ11S*R+V2<*+4CRJYW#YRJZ6.JL6W)%45.HJ8RBA4D
ML*'SDV$R8S@F/BG9_P!#]^UV6PV=CU+-EC8WK=]YNXGY&FZV]EAI-9')5PQA
M&PI,X6$$4R4 ,3VQ]+4?Z0ZJ%*I13PH 33JHJJ!?()!8KKJ!0" 3I#D @0B!
M&3.1B(B2+IUF<,N'[;FI(]D]TEM/,HY;HI*3=%OK8V*A8'9<$Z8XAE6F7CBL
MJO,IG6.@<C]R\=*%1-8XEF7E)VG0^D>TX9IM:CAG.=GK=M1J+7=3LZT[3AV_
MM!UEEBYQUMDK6E=;+M%US1;5#0 ?*U%ZR36.Y7N?4!?(-G=L;[B^NV>LM6".
MN%5\:SDVH070851WJJ_M=HNN,$::6ZUK%L:<K&_1K0L%?M5N,."8S[6A;UJ<
M[I2_+)',BSL+8RL%+X0YA7#F"EVAW;269(G52(X?P+NP0C)0_DGDXFIC)1G#
MY[M^+#V^I?&GZ"F+/"/--"3N0\&L'/2%E9NUT#M>.,LS,^&IR'75)[1,ILD(
M]TX:KI]+R1\5N&;P+FV)16"X;R %:+F2E+[?.52FYQZWD=>I)@%C8<<V&PJP
MPU@/WG Y;Z-DXZ89-Y*)?LI2.=IX5:OH]T@\9N$S?#A1!RW.HBJ3/Y#$.;'Y
MQT>C?H[.JF]K;E784K 0RO;I6%6JS@G\&IZ#-3!G^T2F,UZU4M47LJW:SZEE
M)2#:]E+$/44?D6*:(F$_W$,3GW"7D? 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,CT+\I6[TA;?LG6/Y_)_CEC#GYV0OH[9_UE4/
MY^+_ #8R0AC 8P&,KKQ:0:=CX==J1"BE03Z37B'2S?I92$IBCAK),7;5O9)%
M,V,(Q3EP@DW=)+%5:NB*Y:.T%VZZJ1X=L9EFK(5UFDK?:!HIN#)UW2&XI?I,
M5 G+X.)D?;@MC7]?%7'W!J(9-8H@;T25H!/3[Q1LIR 65@[3WE&Q363 ()8G
M)^Y.8&M R\I[5SE*N'".1B^)*(JB^O/P?=0L]8A)26G"<,Z$S';.8QLQ6W&&
M!'W6E+JK5]!.RR$>O*1S:0DY%F=W"R#J*1:J$?HYJG/>O<M [GC16=K6^*8F
MI[U>XU!LKVH@H[O![9X0Y:34BXHZC+"'G[=^'LQ(GI9,:9>X>-M+&P4-FN>L
MV0K=1G[H%[^Z"!;&0;]=-MZ@<L":OJ^(.3\!C 8P&,!C 8P&,A=]^0F7IEKG
M]X57$BK_ !"_R]O_ &CLJ'\S_A/_ $%DT$?*<!C 8SGI^$$M4U(5"C:&ICX[
M.Z[PM\/48Y9NLHBY8)2KY*,)+8\F7)CDKZ3B3O"F"<IBMJ.\.;),%P;/.N1I
M7R;G?I_PE@D[5UKS_4?F"A@B">.\))5G64K@2,K.KO.5NT^OD&3T*5G'Q/;!
M9"_?L\;]/^9\@HN&MOMTFKZ;<-=Y!4]?(^;R=&YLJ)=8/W7'.-!N-X<+B2A%
M8SZ2 ,(+T4^JPM%J=9I5;:%85^HP$16H-D3DYK2)@V#>-CV^,XP7&?)-6R1,
MFYN,FSC)LXY<Y'2GO99>ZPXN]KVL<TI_ZF-.3.?_ -R*9S!:W7U=5KZ.KI+A
M-/74ZU&JJ.GZ=>JD$)#XZ1,BL!B9C\S\Y(Q:R;@,8#& Q@,8#& Q@,8#& Q@
M,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#&0^]:_I&S:X\J6P:M"6^N/C)*+Q,Z
MP0?-L.&YO*-7K;RI<J,I%DMC"["19J(/F#DI'+-P@N0BA;J7NKG)I82RD#67
M3\&M@R+%,&>HL4P9D&*8)+8$R)B0S,9!V.LH;:M[38U$VT>1;@!H]95824,1
M90R.C*]JNR!;7LI-;T-$6I8#!$HH38^%3>&D7J]JX1ME/I"-PIET_P!-[.GW
M*S=XFBFKE-I6K\Z9RJRRO+DA$FNQXVT+KYSY(EQ@&^<J$T"YZ8\7=:?M.*7M
MCZ6<AL%+6['AZ4-XQL[,S]K.1<$M3&EMC'<?5VHC46A@N[JTA@9FARKG>F0N
MK8BCZJ<=0,+'C_.;;D<HU]8 F/%QGU$KK;MELGH)>#E"MZ%@X@2OTP*3'T=<
M<>C-*V(ZKW]0[-J;9Q$S&S#3$0JR?23<BSI#$E#Q:+J59VV,.5@Y<GEM;S]W
M9)I%R=TC&9(J@C!M[OGW!T^XY]QA>\XTLNV?47TX"WN]*H9@2@]_QD@+DW'3
M6N1FTTZURIYS@*QDN8+,AIMMP#FU_P"C\:W5SBO,B$CCTW]2 K:'?O[9=$SQ
M[> YG&>4H9X6,1.KV!N76'ON0EO<N+[5RTURWQJ4O5YN-G8U;!<E=1CM)T0A
MC8Y?)+E3-E1LX+R9PHV<$2<)'P8BJ9#E,7&WZ/D.BY-17L^/[:AN*+8B1LT+
M*[ #,QU\;8 I-#A^8-#Q6Y91(F E$Q%6TU&TTMHZ6VH6M=:"9B4VTFDIB)Z=
MRY*(%JY^)%JR-9Q,$)3$Q,^^,SF.P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!
MC 8P&,!C 8P&,!C 8R.PGRE;_2)M^R=7^/\ GXN0,8=?.V$]';1^LZ@&,D08
MP&,!C--\0#BK,]1VYY<'5D9Q#)**>H.*=&DFK86P,YR,=5,E:A56<BVFIU:T
M)1",7$/F#R.DWAT64@V59KKDS&LFP)K&CSS:B[5]F-90.:5DG"(1*VQ*Y3VR
M<V3.0\-:'/%R#4+URJD21V!GQ>$]?M%W)<9+4.N9K;0;$R,(E@]E$K!P2Q-D
M$,2"V%T N?\ PN6FIR6UM=5BMT?B58\^9W9L&UWC<U K%2+<=HJ$6K]HF9F5
MC5E#/G\024?55K7X<L<TKA4FS-:,>%3PZB<M46 J;X/;HITN)5*>MK>8S(M?
ML-UI]DZVN3[G7+6SM)K["Q?:PUD,MB)3+D@[%W9+O0VP-EMRWR9#+-CPP*P)
M'&]Y7HTI^872IU*2S"I32J);,P^#@0?YNL@A9*P&,!C 8P&,!C 8R%WWY"9>
MF6N?WA5<2*O\0O\ +V_]H[*A_,_X3_T%DT$?*<!C 8SF]K<O]._')>]BG-TN
MF<.M>[,UH^%BK-%KW;4GL,FNWYI3$\O!U-I:I+&.<4W0=J,%<<N,X'/?3K_B
MUKG_ *@G/>/)MZ/"^,LGH8CP_@;&HOV:CHGH53>\PL;!W2(F)G3C\_F,D<TB
M9Y#PSAH]8K<$X\?+]\ D':?..?*E>LKV52,L7>XYPNK(E$E'57*%EV].V<Z0
MCH61\!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&
M,!C 8S7&T-0:QW36EJCM2D5Z\5]7)E$V4ZP3<J,7&2Y)A]$OR^3D(623+G.$
M).)=,I!OG/*BY3S\(F4MA=UKHL4;+JK8^))1R,&/_I8$]0:$_P P8)!/\QG,
M+O>.:+D](M=O]53VM,IZPJVD3)1_R;7;'1U9X_\ 2^NQ3@GY$XSGQ9.$7>^C
MI-U:^&N]2&R($BAG']&]_MCFO;+CVY3&6ZMINYCI/F5E:'4PW:M:_N*$G6C6
M-;=%1L[8RN3C4MYZ=>G_ "N\>Z!%[TWYFR)Z\T]/Y'53=810?=R#1)&-;MU&
M<05F6UV-?$=G0(^8AZW>>J_ *T4-'LZ?JIPE9=T<!]2WLN[&@CH42GBW,FR=
MZD8B7CJ)V)&JL(AVV>L=)F6H>-YQ*SG]'VPJ_,-=@L$\9EZ)/P9=?[G8$)DZ
M>7B.NY-T>)V#&KG34<MIK5L_-('B\)O%HIJ<^6Y-9V$>K?IZN+')='7]3N(C
M^[S?T_2(;9*HZ1)[?B),+R-@B_5C4V18 #,AKV3UB-MXWS'TK]1+7TK4[.[Z
M9<YZ?K>GWJ',U9)DS/QJ-[(PNU5*!F4.8+UM&1)EI43TB]-/V%3;XW47JT\R
MDE6V.1_'<XS:8BSX/E,R4K#NRHR4<H54IDLX=M4L&.4V$S'QCESG>,<VXMS%
M#'<>W%6^Q'6+E'J5?::\Q+L)>PU=D4WZ)BR)#I9KK@BC[",>DSEMWQK><=:*
M]OKK%0&S^SVND-HVQZ=T'4O)EE2T,A,'U2XY@9CN@9^,F8VK,%@,8#& Q@,8
M#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,9'83Y2M_I$V_9.KAC#KYV0GH[:
M/UE4 QDB#& Q@,94#B(?;ZGW4UK:F<.]2VIKB:K,<K(V&;W.YUM(%E7+U_Y1
ME&I,ZK)2#&2@E8Z.E6,U'RK=VT<N&3MFJ@Z0Y4HWB*Q#HL#X!1<2=-J7F+R\
M"JME=N"" )!+MRY,+[C%@(ZL[E/)621,40IBCAI-393:2U(DKQM%E=U=@')@
M^O:J.[#[H'N@WJD(@!8RO^@-9;03WQ5+W9M-M*E7X6*FH->0B^**P[DA(J=-
M5C13B</37<=&,FMSLK=@P86:VNW+YY(F+E1ZP4E)%662RU9@1]7<1B/U&E89
M6[:PRL?<[[6;&SKZ#8*!IT'V9L[1E5*R%EI'<#D )HL8JTLB+5)$)/V-U96I
M)T@V91I]E0J7;H=.MNS4KM#5599(S7I/A0 2JR!K]/Q"R9@,8#& Q@,8#& Q
MD+OOR$R],M<_O"JXD5?XA?Y>W_M'94/YG_"?^@LF@CY3@,9J/>VPFVK=37:Z
M+NTV*L9"N4X]RJ?"94))Z7+1FYSG.2YRFP45ZQ<\W.#%:-'"F,XP3.<:/ZC;
MZWQ[A^WMZL29O+@(TG'4+Z2Y_(=[85J=."0F8EA!>MJL& SW2E+9C]WKFR<2
MUU39;ZD&R8M&HI0_;;NRZ>U%?2ZA#-CLVN.8D5K]I68OO+[8-@=?SFGN!W7#
MJ@Z KTK,M%V=MVJ^>[;M2#U,J<@S<W%-JK7(20+A),Y7M5HK.J51RFIE8Q%X
M13&%CEY,C;=7HZG%-)H>(T"!E/BFFHZ%;ER9!;L4E]=GL(DYZS.TVS+^R.>@
M=2MS/C#]V-!T]^WOSW/,MDMRMESK>;#EME%D%!8IU=F8CH=4\4C PS1\;KZ?
M2E$DTNNOF2:TIDRMZ)>9K 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&
M,!C 8P&,!C 8P&,!C 8P&,!C 8S4VWM%ZFWQ7>S&UZ1#6Z.2,9:-<NTCMIR!
M>9R3.)&M6-@HUG:Y)DRF3)7\+(,77(7R9E#)9,0T_7[2_JG>>A:;7.8Z&(S!
M*:/S]CTG!*<$]9^QH&/\^G7YS7>1\3X]RVG['D&JJ[%0S)H8P9"W3;\='T;J
M27;I/CI'1U5RF=([9*1F8FBUSX=>('4#EK,T24><4%&BC8Z/!VV>;4CB>IC%
M)/!"=A]W,.K8[8:+1,RN48/9S(S[*"#=DTG5UE>>3 \FX#Z:^HCPO;K5%Q'E
MBNA4^9<68_5W5/@8 6-;2(+:NT8B "3MT8F2,J/Q&8S2;[UB]*US6XUN)]3>
M$S\6>%<Q.M9VB:T3W$O7[&V,4=G\]2[-@JM?(1!*]F4E,Q/-.<5+NSR;RIQ$
MF\NUH@T3+6'3VR88FI>)>I-T2Y.ME:JRF$H&^LVC4A5U)BN.<MG)E2_]Y+**
MD*-$V6C]9?3<(L-73]6N(QV^+8TF5=9RM"!Z1,"Y41I-\Q:XDH6^-+LK+H(>
MQAE$QT3C7/O2+U,L,UU5]WTTYHH9FYQK>5[/M@;T(B(Z5B9VE!,E^]9HGN-6
MA?;,."(F,N!3]K4JZ.5(N.D5(VR-N=A_4+$V5@K7'G3Q@RA'$*_PFX5*F4Q3
M'<,<NV>,&QR.,YY<8R7&?47BO*GLUU*\RAO:_=%SC.[KLU'(J1@,$8NU5R <
MP0&8(GU)LU>DQT?/STS&[X?O=$H;=FL%K5MZ37W6L<&QT]D2GM&5WZTFH)(H
MF(58\#^L3U5'QUV,-XS6,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MR.PGRE;_ $B;?LG5_P"?R?XAC#KYV0GH[:/UE4 QDB#& Q@,97[BJKUIM?#U
MM6O4N/G9BRRE7<-XV%K<L6#F9S/2&ZCJ$:2F5$,M"R[,CB.='(X;*G:.5TTG
M*"ARJEAW%PV=?!U??('=:,[E*60I=ND&WIS<0]A2(KKG6\GN&&4 I4&UD,!9
M*.54;XBLG%CV;8UNV&M;%,V&5;9ZNX%.RA$1,MLHM$EM5<=.ZP*A[@Z]PT(H
M=8W%I^W56RZ8_!MR^LD&#24CKDQKW$-IHB=VBEXM1M%Q\RV/;S-)!S&3!V\V
MWG9))[,-S,E6+5<J$Q(&&5BRT2O03I95L4C!=7QP*E[&+VO>B^"@&10:J5>]
M2(:XQ+QV'ZDS%94%BIK#*J4P$!9JVUM)\L)C3J31OHL4RL',.<IMM]*U(/DE
M2=(&]D-$"'II&7Q./UC%;#V:BUUSDM6CI^WLIIV1%"J.W#)!>0C';I7.,'58
M.E3,<<W!CN5RE(@0ZBJ9#6MA-:F]P*L>Y0%B$5GK4SON2;(57A%<1)YMLF0"
MFL &\S,5"!,GI,NN+K'2)3*F]&D:B:HX0">\V$RP!>WE25 3&V8.*\+ G=\)
MCNRMAN.K7F);+=/4'%.XJN%.:;9:'#GL8]"PA@W-R]Z9F,+/998QG"GERUTW
M*EG!RESC..6E8]8ZV2#7S_*+Y0CK_9W3'D!43TGK+B7 =)\G9$3T\841$37F
M+W7IU]E/FB.LQ$Q!3V"SIUCY43(/K'CD^X>MN:O::[=8&,M%3F&$_7YAN5U&
MRT:N5PT=(Y,8ALE.7D,15)0IT7""I4UVRZ:B#A))9,Z9:W)8@Y6T>TNT#CI(
MD)K: L4U9A) U35D#$M61+:LQ8LB A*:%M!HR03,Q!&LH(2 UL49+:IJS@6*
M<I@DMJF"+%,$EL$3&1CWA:RYE+N+&1ML!<^%*8KE^N5;CY7B-I=*LE6@I)K'
M5ZV0T^VEGS@ED*BPZZ?X;GA4D&[$DPA#*MWCW$C&/E3-E6U>IB"Y+60V/.BQ
MH.5M\#?E*7Z[0W[";"UCVB;I:Y9]UCSBDZM=M4:[A8QM-^)G1[ US*6U;G''
M0Y72',"SROC^O;7-A01!7*O:L08U_ ;H:2[#'(F$QK7<T_=K;>.*ETRV#;Z*
MRX:-2UBPZ^8UBT2U;CG-WDJ]8KN^L]P81KEHQN<(=&)BZ]FO6E*7KZ3)*452
M8I/WF7:./]T='47N0"(V+*.4%K$U'Q+JDZW5T]!8M42JS,*-^X;N; 3;[/?5
MP&I%&Q7,)-F0765>VNDT1^15?8ZM=NW807AM^YVVYVNGJ-KVAB&*C4AIRM C
MN*K8?;GWZ+2!6D;SZXL;NXZ\HEN?H$;/K33:Q8GC9,IB)MW4U"LI)PB0AC&,
M0B2KDY"E,8QBE+C&<YSCE&=VU5=':[.DHI)5/87*JB*8(B77L,4$E,1$24B$
M=TQ$1,]>D1F!U%IE[5:VZZ!AMNA3LM@(F ACZZVGVQ,S,#W%/;$S,Q'2)F?S
MGY[#.9*NMU"(J.#IV[7AR((Y2PJN8FP*P8J*65U44,**9Q@A,K+))8,;&5%4
MR<I\1ZO\0O\ +V_]H[,D/YG_  G_ *"SUNNY'NC8O6*MXF_GD_L$?*<_A6P/
M4$E%UZM/(HHIG5665=U--))),N3J***'LY2$33)C)CG-G!2EQDV<\F,Y#/)F
M(B9F8B(B9F9GI$1'S,S,_$1$?F<X][RV=_VA[XE59J9?Q>G)*VU%B]@72Z!6
M;NJ1LRW1LAWB*ZR,<W>6J!=V"-<.W:G1X]G+HHO5W#:-(MGX%UWKI7Y!_2#X
M_?W%JZ7 M3R$5<=UJWP=)6[J4=CK..<FL)_37)1O+X;1C1_5K5)2'>^:*I+Z
M<Y'Z0V%>B.^T^N735R;=:A0\BNO5(O=QRWL===Y5QY1]#*)L\<J6]6H3B5';
M8;)%0V&1'84DR_(0I"5"PE(0I2D*5>JX+@I<8P7!<8LW)C&,8QC&,8Y,8Y/B
MP/OKKU^?SU^>O]O7/F.(@8B(CI$1$1$?$1$1TB.D?'XS^^NY'NE8O6*MXE#/
M<QUW(]T;%ZQ5OA__ )-_S#&.NY'NC8O6*M]OSF_S_,&,==R/=&Q>L57Q,&,=
M=R/=&Q>L5;Q,&,==R/=&Q>L57Q,&,==R/=&Q>L5;Q-^G_/X QCKN1[HV+UBJ
M^)@QCKN1[HV+UBJ^)@QCKN1[HV+UBK>)@QCKN1[HV+UBJ^)@QCKN1[HV+UBK
M>)OR?] QCKN1[HV+UBJ^)@QF>NY'NE8O6*MXE#&8Z[D>Z-B]8JOB8,8Z[D>Z
M-B]8JOB8,8Z[D>Z-B]8JOB8,8Z[D>Z-B]8JOB8,8Z[D>Z-B]8JOB8,8Z[D>Z
M-B]8JOB8,8Z[D>Z-B]8JWB8,8Z[D>Z-B]8JOB8,8Z[D>Z-B]8JOB8,8Z[D>Z
M-B]8JWV?.;_+\X8QUW(]T;%ZQ5?$P8QUW(]T;%ZQ5?$P8QUW(]T;%ZQ5?$P8
MQUW(]T;%ZQ5?$P8QUW(]T;%ZQ5O$P8QUW(]T;%ZQ5?$P8QUW(]T;%ZQ5?$P8
MS2>X](ZPWRQ9-]E:@E963ASX7K5NCWT! 7FI/"J%72>U:YPEL8V.#62<D2<F
M392!&CI9!+#ULZ2+Y/.2UVWV&J,BI6"6#/AU<X%M6P/28D7UFP:6Q(S(]2"2
MB)GM(9^<U?DW#.-\N4H-YK5V'UI[J.Q0;*>UUS(GN%M#9U33=JD)P+.U3A69
M"/E QCIE2I_7?$QK+G-)NH2'&5IV-Y%HWM;)56I\4]&8(&P?"4%=X:73BMH*
M-2>7=FS)*52T2;@Y&A'SGX"GQO*.&>FOJ4A2>3:.IK=HN8]ML$BX*Z&Q,F+:
MEZJQ6XT92R8^:-DZXQU(UR,S$XG0[[UD])VO;H-Q8Y[QF!F6:ZZU".6*KQ':
M23AZ2T?*^U<24_4E4KS9Z+!YE ]9OI;B'=WM=\PTO9Y/8ZM?542M.F]T'B:-
MNZCY0R4J[1\E(2*-D+E-90K9-W8ZZ[CC\WFMYQT;E..8W^$>KOIS(,TFV5S[
MC<Q!(U7*[0CM91$24*TG-Z26U;[3ZP(+W]<R6 CY+D%)%/5N->IGI)ZGPY#
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M:"UK&  !B/B! 8@1B/Q$1&1.^_(3+TRUS^\*KB[5_B%_E[?^T=EX?S/^$_\
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MQ$Q,3$QUS^Q7E. Q@,8#& Q@,8#& Q@,8#& Q@,8#&1V$^4K?Z1-N3W3J_\
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M:"S& CM&'5]8ELP4DR".0.1@!$;+CJ&:;@,8#& Q@,8#& Q@,8#& Q@,8#&
MQ@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#&5OW'P
MJZFW-+,[A),IFD;3AT,(U[<>LYAQ2MG0928R5%).QQ>,=<1Z13'*6%LK6:A>
M:JMCJ_!E#&&9UV]OZU95P)=JBR>KM=>7%FBV9_,RD_X9STC]5!*;UB/O^.F:
M3R7T_P"/<FL*V3E6=5OZP=E/DNCLGK-Y5B/W1&XB.EE(_,16O+M5NA%^CUF9
MS0\A9>*+1#5[";KHR?&#I/*9$L[!US7(MKN6%C<?[9;[IQ0R<'?$43'03ZTU
M\Z1E3HM7,B[K"RRQ4D;VPTW$>6U'46IIT9MA*[6EW@!=T5R)Z3V+LO!L)$IB
M9\5]9*@I$1>,#UG 5.0^IWIU:"QLDVN:::J0G6Y-Q9<4.8:T1B>I;'1)8M6R
M@(Z#-G2N"R0B;642D^T9UJ61UWLJ />>$;<S(T.58V)&D/%'DW58U^8ZV5HN
M<I,PHPMNO)59P0YED2XB7)4TRF1CE6N4\&X?L_1_?\'LFS@&\O</(B-T<6W
MMWO!KO?/D/V=-CXL:J',(9.UH]@*@'],:LC'9'=^->L'$_4;7!8VJ=?RY$=J
MF;S5F&IY=KS'[(5L>J1)SDB)0-3=4(:4]3EOS!SME+<3VK*)L=P5-[1SY.1
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M>TD,$(F>LK+YB>=;WTVT^RV!;[26;O$.4="GZ]QXPK':*9[NS<:\P/7;E!%
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M=SK;%*61U0TQAE6R/3KWU;:B95LA,3!02&LCMF)Z])C)@-GS"8#& Q@,8#&
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MJ48O:2IQ4QB46AV4BO*YFU#-LO4:H4[375UE%L*"=AL]EXT+=?KU=E1III[
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M6:35!HV18I(H,DD$4VB+9,B+=)L5,N$$T$DRE(DD1/!2IID*4I"8P4I<8QC
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MSA-!!)%/!LY,;!$B%(7G9S\.<\A<<N<_'GX1M5=(5T)0N)A:%+2$3/68!8"
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MZ2GN_'Q^>OX^/[,CJ$!4H5S,K%8"$S,S,A Q S,S\S,CTZS/SU_/SGTBC+F
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M5$\KL'K1XDDJIE%;'+DA\8WS#'EK0OW("<+ELF$2#!\;T^5<2:HL(DT$R!9
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M7*MPU'<MICD:-<>5POR-T,>7*0J95N1,N/*E3)C!$\*?[>"%Q@I,9YI<8QC
M]9^^?V]GWE]O69[?F?MZS\SV_CK/S/3K.6E1T4N.[OZ+".^!@8+[8^[MCX'N
M_/;'Q'7I'QGT"C+F Q@,8#&0N^_(3+TRUS^\*KB15_B%_E[?^T=E0_F?\)_Z
M"R:"/E.<O="9S:.)+;-Q<DR=::XNMT1J)S%45(XA](Z:HVJ&1_**F4QGH,VO
M*MR8*LHFV52PBW1:'PX00TWU2GNY_P#T?=1$=RZNNY=R!JYB)&&?0[:P9(?
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MS VD<=BVP&N;K&M\LZX^'J@D-"^<(2^C:IUJFL:-&:4C;0+5<E"P8ZVK6J;
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M>[Y7R:SUF8?O]NP>I270"OV)"(*>DR(AVB/Q'08B(B(B(R>C<<UW 8P&,!C
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MG^%L^L_@[OC_ /T>)'XOA_/\?Q?V<F?CY?@VOKZ?_P#IY?\ ^^F__O.1]O\
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MP"U5UX>7_C-2Y0=_6$U, _<V':MU2MI5,JF;->ULV=TK:VI,BD;$3"QM!@_
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MO)42*KE;D<LUI)W5YAU Q+7&(F=DZ_.IO7<=)8S*JK8%_C#75!JVV<HV.H<
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M[=LE>-C&]DM,V$"E)AC"DVD"5BI<M:4RQS( !@W.-CF3'<QAG,E-/:,$PA
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M]N QCEQ]./MP&,<N/IQ]N QCEQ]./MP&,<N/IQ]N QCEQ]./MP&,<N/IQ]N
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M.P':ZYE=Q,BH'6R5RO<A]A9+2ZH](.-;D1YE\TYL*H,^!ZF46@638T+P_6F
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M6U))>R\YJ/)LZ6N2ZZWL^FVA7T.PU&Q(X"1&TH*FO8ZDNJ3O$N&7=B:"-J+
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MC 8P&,!C(["?*5O](FW[)U?^?R_X!C#GYV0GH[:/A_XE4/Y_0&,D08P&,!C
M8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8RF?%!L7B,U1 V_8=%D]/,Z-76U*:QD3;J%<+799R9L%C3A)I5>5A-J4F
M/AHV,2?QJ[!'J64<OEBNTU7#9/*2A?*8FZ]KZ3S$2VO(Z&GK>-<_L]&]&O0-
MUQ$TH>\;KKT>V *X^!")ET$TBBI\B%:[84)3&NX_M=N^3..CK6LK;*]--0P$
M2I;*U2L,V")LBRP90HX5*\DBVQ+#0)RJU'B W#1X2PW&_1+#5I]9U!S6%-DM
M2L$.M*O/5.W2>X9"+9H2;DI).=B+%$829JQJI9N&4.N1:XDT-<M( <W4HW-J
MU5-HLJEK:FO*P&S:T%5SI^V ;;5I;9@6VJ(!UN*<50[+_(I+;)D(T"G35AM0
M$B]&UO;5RHH@,L<%@+:54U>3V_4$W+Q0-=E9=U/],^-7AED739K&[-2DTWEG
MD:4TE(VJ7B1KKFX1C0SU6KH6AE6EZXK8'K8ICP<024R_L9BY2K[>36QY,4*[
MGK2Q2VG%JB[8U A+?/<J5FDFP=.M(18ML00P3:]=3+"T-KV25%>RAK+C^E9E
ME5@@2=*RJI=\A@(4FO[/$=UDEXZE4S.51=L&NE%A-JO-B'T[:TR)+BGT@XJC
M>X-K1,NV#JS3--1AF>OMCN[YVIKI%%9^#4UDVJ2NQD'\(V14>RR*]63ZNCR]
M8.\HLLE<9\:0J&L9$!*MT';1#U&+Z\ZVN[V[[S;"98A%1%F1K.>]BUJLFM#"
M%K  O0B6'97$2#*EBO4<#HFN?NK5==NK74+_ !E9=9K-%]==>&FY4,-<$*FR
M$]8W=CL76F;QJ.TUY\VG8)X_J-G?Q,A.P.'*95DTEI.!0EZK*N4VCQ%1"1B<
MR\'()+(KM%7#-PF?F6MO%K6U[+.U4.KUPNP)S#5/K>(+<>)R&2$C;J3^S6ED
MY0>5=CQ65C*6>4VHLE'7RR'D=7,8@D.4]9F@Q:MRN\#KV!F'(8"V3V$J2410
MP:,:TXLMQ*.N%J1V&^TW;8'B9/*1V(;7E;L]0MM D(V,?R#F57Z[V-L%G:JS
M&*QYV$^\PUJ[B(770,=-8QLH8R4*K#L;.M:1A*^,QR4+\L :M=05*ETZ]]1!
MU0-I5OQ:ZT-F1LO0X92(CW18MRZM6L6QZ'%3E;.+LK0HR99+ZQ:U"KM=T-&
MA95?=6:Y(;()<L1?,_>5JZ]Q4:&L\PM!Q=]32=EAYNPL'4W7K968.QP-:RIB
M?FZ99K)!1-<O,3#814/(R-/E9QHT2+E998J6<'S!(H"G:O'U6BE41?MBP27:
MKT;7_*W'4#@;P5;,](KV)KPIY&L5&9,7!2I HM(IQ'?8LW&ZY$+F&J9L$3T?
M1&PJ3K^\3,%#:LMAZY6V"7$J;V0*^\:VI*?1,WB*97ZUIFFZ)"IQ#766S(>2
M+C8<NM&5R5=,YBF-I%"(D4FCY[%/$HYSF?*DR:0*<B\F8=%[=\38NZVB:S ]
MAM6ZHYD2(Z=BG7K7M@E]<(*P-^K1MI>&L)07'D?3L4A%VS4L>515-I;6U1AK
M=66SB?*L46TLAH465[9%[9E&W;7[:=HMC:2.C6$PY5XRME%R+>7C6$JU3?(M
MI%HW>MTI2+DH2231<I%63(_AYEHPEHMV4A\%<,)-DT?-%<&0=-D5B'3+ZU9)
M8Q1RN269 4J:IZY(9F)E;DFQ+0F8^UBC-9QT("(9B9] X8 F,' E$%$&LU'$
M3_ZEL$&!/]HF(E'\XC/M-SN;GFYQ@W)GFY-C)BX-R?!G)<&+DV,9^'.,&+G.
M/@P;'QBT7=(SVS$%TGMDADAB?Y3(P0R41/YB"&9_'6/SE?\ W_\ ^_\ YSG]
M3-E<8%]E-^1]:L?#LX?Z7V.O28R"E-4[&B$[LBC7X2RIG<6E#>$P6JNG#69Z
MNPL6J61NB[;X=G1.@MELC;6QD:2AN"1-L[#]TE]-#1K,F-)M+6L:55C@>!-M
M35EZ4/\ &M<L%#+4P,V9NV!2.YM:L6%62%#574VG![J5?6*K+*5O4N:\L&K(
M@MSE2!/'N:NNJ>U$[%UKQD:ZMNGJ9LVX-IBGS=FEI^INJ!$0=DV+:D+E3W3Q
MG;8J'@Z'!SUAGF$09@X?K2C.%\@UB3(OI'H:9L\DJW-194VU+$V:6QU"]]4L
M>)@P&I,5RRU=GM[*:JSFC4<^P2DS8D $NYJPF,F+/?L*]I:TVM5M2TEP1:$K
M/8]/(A%4BD9L.M5NEI=9'F:(0^(EH5FNR;&XK="&C:_,,KWF:BK+ /[0QD*U
M6+C:&K&OQCOJY[*69:NUZ4+36R$I@T1RV[,(96935AT2J2:2C4GHUVE<BC Q
M[@BU8!,FN*S&;MI)TZU79**36;(P/V0+L$=@ -JX)0$<4D]85BM') L#N@8&
MM@V@G6BH]B3*1#%P%ZX+"&7VFB%TUO2=DE"T)+VGO$9IR/OK;6SRVJH6=W/H
M5-%0U;MAJMFW.F>)!O3U+\2"-1$+>LR.FX3JR]D3GS)JHYQ'?UJ>#6JD3=F1
MK1Y"\=YJQ+HHK*M81AL64A;V3>71-;0MG4AXUS2\6R,I; 7;$Q5&#?\ :/=4
M$Y&)9->;\A%+WD+[RI1;\BIK%;A(O%J25)BY4GYVYK_88N>UMJ>B/V\1>]M2
MLP@VL+EFVDBU"HU6,S,6^TMXMWRM)*4;-SL8B":ODUHW$W,L'4DW>,6KABZI
MKC-J\=>#E:*.O;N-BP(@FS67;J:^I33)"8+=L-A>0$L,2A5!&Q<N)L*0!UM,
M:U2;4@#6ONUM712R60H[MJO<NDVSXB6R:U37ZW86B6IJF6;"JM.'5QLG:1HO
M2/$P1K9MD:^W9L8DI:V_$/8-4T:28T&2B(%) D+!/*U RDK"1DK7*_+RIW#\
M\62X6)!]8WJ;PL1Y9%(C!I=IC&QUFFFN/38V:.^9<()D ?8T^[WE>R5.+/5)
M'7UU!-N=<D[-JK3)#+4V9;%NS:MQ-&]LUL,SJ4QX^:I,1.PNONM?K2KNMC7
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DTZ?89%5,L5DRCR%*2/9,&Q$R-F#<I<%;\_)L'.<YLF^!C/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g374624g47l56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g47l56.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1K24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &K:^:#@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B
M:F,    !        4D="0P    ,     4F0@(&1O=6) ;^            !'
M<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%5N
M=$8C4FQT                0FQD(%5N=$8C4FQT                4G-L
M=%5N=$8C4'AL0%C\F\         *=F5C=&]R1&%T86)O;VP!     %!G4'-E
M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              5(   )Y    !@!G #0 -P!L #4 -@
M  $                          0             ">0   5(
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5(     4F=H
M=&QO;F<   )Y    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %2     %)G:'1L;VYG   ">0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     $%T    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /0W,LZE9D4OMLQF46;:S0XUV$;?=ZGT_9N_FOWT3&J<Z_,'K6^V
M\;?=( -5#]K0_=M9N=]%5:\?%S,CJF/:YWIBZO<6VN!!%;'QO:[V;7_X)6L2
MEGVC-U=_2 ?IN[TX_P#*240V/1M[7O\ F&?^DTMF2.+6G^LR?^I>Q2]!GB__
M #W_ /DDO09XO_SW?^2213&,L<.K=_9<W_OSU&VS.;637378\1#386@Z^[W>
MD_\ -1/09XO_ ,]__DDO09XO_P ]W_DDK57B6.[*_P!&S_//_I)+=E?Z.O\
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M:TO_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    _^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0  !P<G1R0TU9
M2TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M     0  ]M8  0    #3+4%$0D4
M                              ID97-C    _    '1C<')T   !<
M "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "C
MN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT
M  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                             '1E>'0     0V]P
M>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:
M  "\9P  DC!M9G0R      0#"0   0                    $
M           !   !   "   ") 0=!=H':0C9"C8+A0S'#?\/,1!>$8L2MQ/B
M%0L6,A=7&'D9F!JU&](<[QXE'UD@AR&R(MHC_R4C)D0G9BB&*:<JQROH+0@N
M*"](,&DQB3*F,\(TWC7[-Q@X-3E1.FT[B3RE/<(^WC_X01%"*4-"1%Q%=4:/
M1ZE(PTG=2O=,$DTL3D-/65!O4892G%.R5,E5WU;V6 U9(UHZ6U%<9EUX7HI?
MFV"M8;YBSV/@9/%F F<2:"-I,VI":U)L7FUG;G%O>G"#<8QRE'.<=*-UJG:Q
M=[=XO7G#>LA[S7S.?<U^S'_+@,F!QX+%@\*$OX6[AK>'LXBNB:F*I(N>C)B-
MD8Z&CWN0<)%DDEB33)1 E3.6)I<9F R8_YGRFN2;UIS(G;N>K9^?H(ZA?*)J
MHU>D1:4SIB"G#J?\J.JIUZK%J[.LH:V/KGVO:[!9L4>R-K,DM!*U +7MMMJW
MR+BUN:.ZD+M^O&N]6;Y'OS7 (L$0P?["[,/:Q,?%M<:CQY'(?LELREG+1,PN
MS1C. <[KS]70OM&GTI#3>=1AU4G6,=<8V #8YMG-VK+;F-Q]W6+>1]\LX!#@
M].'8XKOCGN1[Y5?F,^<.Y^CHP>F:ZG'K2.P=[/#MP^Z6[W;P5?$S\@_RZO/#
M])SU<_9)]Q[W\_C&^97Z8?LI^^O\I_U<_@O^M/]:__\   'H Z<%+ :$![\(
MYPH$"Q8,' T>#AP/&1 7$102$!,+% 04_!7S%N87V!C,&=8:WAOA'.$=WQ[;
M']8@T2'+(L0COB2X);,FKB>J**8IHBJ@*YXLG2V:+I4OD3"-,8DRAC.#-($U
M?S9_-W\X@#F".G\[?CQ\/7P^?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC
M3*9-JDZO3[10NE' 4L=3SE355==6V5?;6-Y9X%KC6^=<ZEWM7O%?]6#X8?QC
M &0#90%E_V;\9_IH^&GU:O-K\&SN;>MNZ&_E<.%QWG+:<]9TS77#=KEWKWBE
M>9MZD'N%?'I];WYD?UB 38%!@C6#*80<A1"%_H;MA]N(RHFXBJ:+E8R#C7&.
M8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ FVV<6IU(GC:?): 4H02A]:+F
MH]BDRJ6]IK&GIJB;J9&JAZM_K'>M;ZYGKV"P6K%4LD^S3+1)M4:V1;=$N$6Y
M1KI(NTJ\3KU2OE>_7<!CP6K"<L-[Q(3%BL:0QY;(G<FERJW+MLR_S<C.TL_<
MT.;1\=+[U ;5$M8>URK8-]E$VE';7MQKW7G>AM^4X)SAHN*HXZWDLN6VYKKG
MO>C Z</JU.OE[/7N!.\2\"#Q+/(X\T/T3O59]F/W:OAN^6_Z;/MD_%;]1/XO
M_Q?__P   @4#V 5H!L8(!@DR"E(+90QR#7@.>@]Z$'H1>1)U$W 4:!5>%E(7
M11@W&2D:-!L]'$ =/QXZ'S0@+"$C(ADC#R0$)/DE[B;C)]@HS"G!*K8KJRR?
M+9,NAR]\,' Q9#)9,TTT034V-BLW(3@6.0LZ #KV.^T\XSW;/M,_RT#$0;U"
MMT.R1*Q%ID:A1YQ(ETF42I!+CDR+38I.B4^(4(A1B5*(4XA4B%6(5HE7BEB+
M68U:CUN17)-=EEZ87YM@G6&?8J!CH62C9:1FIF>G:*AIJ6JJ:ZILJVVK;JMO
MJW"I<:ARI7.C=*!UG7:9=Y5XD7F,>H=[@GQ\?79^;W]I@&&!6H)1@TB$/H4U
MABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9: EWB8<)EJFF.;
M7IQ9G56>4I]0H$^A3Z)0HU*D5:59IE^G9JANJ7BJ@JN.K)RMJZZ[K\RPW['S
MLPFT(+4XME&W;+B'N:2ZPKOAO0&^(;]#P&7!A\*JP\[$\<85QSG(7LF"RJ;+
MRLSMSA#/,M!4T732E-.RU,_5Z]<&V![9-MI,VV'<=-V'WIC?I^"SX;[BQ^/-
MY-'ETN;0Y\SHQ.FZZJSKF^R'[6_N6.]<\%OQ5O),\SWT*O42]?;VUO>S^(WY
M8OHO^O3[L?QF_1']L_Y-_N'_<?__   !V0.-!0D&5 =_")8)H0JD"Y\,DPV"
M#G /7Q!,$3<2(1,)$_ 4UA6[%I\7@QB!&7T:=!MF'%4=01XL'Q<@ "#J(=,B
MO2.F)) E>B9D)TXH.2DE*A J_2OJ+-<MQ"ZQ+YXPC#%Y,F<S531$-3(V(C<1
M. $X\3GB.M,[Q#RU/:8^F#^*0'U!;T)B0U5$244\1C!'(T@720M)_TKS2^A,
MW$W03L5/N5"M4:%2E5.(5'I5;59?5U%80UDU6B9;&%P)7/I=ZU[<7\Q@O6&L
M8IMCB61X969F5&=":#!I'FH+:OAKY6S2;;YNJF^6<()Q;')6<T!T*742=?MV
MY'?->+9YGGJ&>VY\5GT^?B5_#7_T@-N!PH*H@XV$<H57ACN'((@%B.J)SXJS
MBYB,?8UBCD>/+9 2D/B1WI+$DZJ4D95XEF"71Y@OF1B: 9KJF]2<OYVJGI:?
M@Z!QH5^B3Z,_I#"E(J85IPBG_:CSJ>JJXJO;K-6MT*[+K\>PQ+'"LL&SP;3"
MM<6VR+?-N-.YV[KCN^V\^+X$OQ' (,$PPD##4L1FQ7K&C\>FR+[)ULKQS S-
M*LY'SV/0@-&?TK_3X-4#UB?73-ASV9O:Q-OOW1K>1M]SX*'AS^,"Y$WEF>;G
MZ#;IANK8["OM@.[7\#'QD/+O]$WUJO<$^%KYJ_KV_#K]>_Z[____ (  @ #E
MM'_-?U3,/W^E?L.RC'^4?FF8?W^>?DQ]XW_!?F-B07_^?I)$88!_?P4?9('^
M@!S\N'YTBWGD#WY7B;+*VWY/B!2Q/GY<AK27+WZ"A9M\DWZ^A+I@Z7\/@_1#
M '^6@W@=HH#D@]_ZHWTEEPCB2'T<E#')6'TED7JOSGU+CQZ5UGV&C0U[3GW7
MBSQ?M'XWB8E!RW[ B"T<!'_/B!'XOWP7HK#@@GP7GLG'LGPKFQ2N17Q;EZ.4
M<WRKE*9Z#GT,D>9>E7UWCT] MGW_C2T:C'[$B\GW"7M'KG7>VGM$J7K&&WM=
MI,2LTGN6H&:3$'OJG%IXVGQ;F+M=B'S/E4T_N7U2DHL9/'W&CO#UA7JJNEW=
M67J?M$C$IWJSKHNK?'KPJ3V1XGM,I$YWLGO G[I<BWP]FX\^TWR\F'88%WS;
MD$GT.'HOQG+<#7H;OSO#8GHGN'.J37IDLC:0WWK)K'%VTGM$IQ!;KGO HC ^
M#'P[GP\7''P'CZ#S'7G1TLC:\7FTRF'"27FXPHVI/WGPNV&/YWI9M,YV!GK=
MKL9;!GM>J8<]8WO0I-,627M2CQ'R*GF,WX39_7EFU=/!57E@S.ZH5GF4Q.*/
M$WG^O9)U2WJ&MP=::7L,L=P\VGMZJ245GGK(CIWM[8D3?BO6?H@ ?;&^S8<%
M?5>FM88P?3..&H6$?4ATT(3\?8Q::X2;?>@]CH2??HL8BX9Z@ 'KR8>NB0C5
M (:CAWV]C86YAB&E?H3XA0.,T(1DA"IS?8/T@XA9#X.H@P<\.8.X@N 6^85W
MA /I^X9PD_C34X5WD76\$(2<CQFD%(/UC1.+B8-UBU9R58,7B=57_X+8B'P[
M+(+KAY05B(1[AZCH4H5SGOC1LH2#FX&Z?X.RF#NBH8,.E3J*.(*@DJ%Q*8)0
MD$-6]X(;CAPZ-((NC)84.(.)BLGFR(2JJAC0,H.[I:VY!H+QH8*A/X)5G:2(
M[H'CFA)P"X&CEN=6 H%UD_\Y4X&&D@P3%8*:C.?E8X0,M6+.UH,=L .WM8)2
MJNJ@!8&YIBZ'U8%.H<9N_8$)G;Q5'X#CFC,XB8#SF#@2'X&\C$'D+X.+P-K-
MK(*<NH*VDH'.M'J>]($VKM^&Z(#3J;!N,8"3I.U47(!EH-@WW8!TGE@15($#
MB[?C*8,DS)7,KX(VQ3NUF(%EOD.> X#*M\N&"8!IL=UM=X SK(U3QH (J%8W
M38 *HUP0KH!LBT?B3H+0V+O+VH'FT$ZTQ($3R&&=-8!TP12%3H 2NGILU7_?
MM,U3/'^ZL$@VT7^\I1 0*G_TBN[=/))A?)C':Y!Z?$.Q5HZR?!":QXT:?!&#
MEXNW?$EKGHJ"?+%2=8F(?3(VCHDG?@$1,HO6?][;1I$MALO&!8]"A82P*HV#
MA&^9LHO\@Y""@XJM@O)JC(F-@HA17HBC@D U>HA)@F 0!(J8@X;9LY  D23$
MG8XBCNVN_8QCC-^8@(KQBR:!58FSB;)I:HBFB'Q02H?+AW8T=H=YAP4.^HE6
MAKO81X\(FY+#+HTRF'NM@8N&E9>7'HH3DOV %XCHD+YH4X?FCKQ/6X<3C/\S
MG8;"C!T.%(@HB836Z8Y*IA7!T8QXHB:L)(K4GG.5THEHFPI^YH@RE^IG2X<^
ME2U.?89ODLPRV88<D<$-3H<EB/_5IXVQL,? FXOBK "J]HH^IW>4M(C6HT%]
MXH>DGUQF6(:GF]I-M87=F/DR+(6*E_(,J(9+B(_4D(TSNZ6_DHMGM@6I\HG"
ML*:3OHA;JZ1]"H<PIPAEGH8VHN=-#(5?GZ\QG84+G3\,'H67B#'3HXS+QL>^
MLXL#P$FI%HE>NA22YX?TM$E\0H;,KP1D]H7<JG=,AX4%IV4Q)(2BH3H+KH4$
MA^;2X(QRTE>]^XJPRO&H78D-P^&2,8>CO5-[G89ZMWQD:86+LL=,#82]KF<P
MMX1<H/ +582.AZG,^YOR>UNXDYE'>R&C]I:X>PF.WI1@>R9Y%9)%>WAB:9!E
M>_E*<H[:?),O8XXU?7X*?I ??\#+.IKBA/VW9I@C@^>C 969@OR-^I--@DMX
M*Y%#@=AA?(]U@9I)?HWW@8$N>8U7@>,)SXZ;@PC)TYG?CJVV')<EC,*AY928
MBOB,X9);B8EW(9!>B%1@@XZ>AUY(F(TJAJ MIXR,AIT)-8U'A>C(J)CGF(ZT
MXY8]E<Z@IY.]DS2+NY%RD.UV X^&CO]??XW2C5)'L8QFB_LLWHO,B\T(KXP?
MA=_'?)@LHH:SQI6$GOJ?>Y,+FZR*A)#2F*IT[([9E?1>CXTQDZ!&[HO%D<0L
M.XLGD;X(/(LAA9'&7Y>;K*6RLI3UJ%F>;))^I$J)A)!*H(UT 8Y3G2-=N(R=
MFB=&08LTE_<KKHJ4ESL'VXI,A5#%9I<FMNRQR92 L=Z=B9((K0Z(JH_5J)IS
M0(WEI(]=$XPPH1-%L8JTGM,K.HH2F\@'BXF;A1K$DI;#P7BQ!Y0>NZ6<R9&G
MMA:'[H]RL.YRCXV%K%5<?8O:J)E%/HI<ID$JV8FHG/D'2HD+A.[#XI9NS'FP
M9Y/*Q=B<*)%6OX6'3H\CN;-Q_HTVM*I< XN-L1-$U8H:K$(J?(EIG+H'%HB9
MA,N]/Z70>GJJ'*)H>DV6T9\<>D6#%)P(>G)NG9DX>M19+):R>V1"4Y2B? HG
M\Y/S?/T$JI-_?Z:[LZ3B@Y2I*J%:@IR6%9X*@=""8)K]@3YMVY@Z@.M88Y7"
M@,Y!@I.\@-LG-),+@74$:)(#@IJZB*/KC,*H%Z!HBP&5))T5B6Z!:YH7B"EL
M\9==AR=7BI3OAF9 O)+NA>@FCI(XAEL$+Y"T@M2Y?*,;E?6F_9^CDWJ3_YQ9
MD3F 7YE.CS-K]9:=C9%6K90TC#%  I(TBSDE^9%WB]D#_8^2@K*XEJ)5GVBF
M"I[IG#.2_INJF3]_5IBFEHMK!)78E"Y5V9-\DC\_4I%^D.PE;I"_D58#TXZ9
M@I:WHZ'(J0*E-9Y5I162+IL1H6M^@I@1GAEJ.956FR)5(I+KF*P^PY#LES\E
M 9 GE@L#KXW(@GVVRZ%7LKVD;9WAKAZ1;)J=J<9]RI>@I=%IEI3KHE)4EI*
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MVGX@JB2N[7W5I;V82WVQH8^!%7VPG:EI,GW+FAM0.'WYEPLT7GXRE5\.>WZ
MB<K8\WWSN>K#R'V.M(&MVGT^KS&7/'T8JB" (WT>I6]H87T_H2=/?'UGG8PS
MN'V9FV8-V'W#B5S8$'V%Q5G"ZWT?OPZL\GS(N->64'R9LN-_1'R@K6UGG7S+
MJ)5.VGSWI-DS+'T;H%@-4WTHB0+79'TUT1?"/'S0R>>L,'QNPL:5@GPTN_=^
MA'PXM<UF]WQEL)=.5'R7K)8RNGRWHDP,Z'RMB+K1P8U1=I*]M8OK=P:I XJI
M=WZ3?HF.> E],8B7>+)F!8?%>7I-GH<H>DDR.(<E>S$,UHDD?'G0/(OQ@,>\
M?(J9@#ZGVHEC?\Z2:(A5?WY\'X=N?U=D^X:N?U%,E(8>?UPQ-88:?Y@+[(>+
M@%K.XHJIBQN[(8E?B9RFK(@KB#>1+X<PAPUZ\H98AA-CXH6IA49+CX4FA)8P
M1(4AA$0+'H8D@\+-?HF/E76YL8A)DQ>E)H<ED-J/S88NCL]YL85LC0MBQX3,
MBW9*G(11BA4O;H1&B5D*:X3LAK?,)HBPG]JX5X=LG*NCSH9.F9Z.@85=EL)X
MA(28E!YAPH0(D=%)P(.3C] NKX-^CO$)TH/AAJ3*]H@ JFBW+X:]IFJBJH6>
MHHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48, ADS)^8=RM1FV
M-X8QL$ZAL84/JY>,=80@IQIVIX-FHO=@%X+2GT=(58)8G'4M>X(XFDD(YH)&
MA@3)+(<#O_^U;87%NF>@WX2?M-Z+H8.IKY)UWH+OJL)?9X)FIJ1'QX'MH_DM
M!(&ZGG (CX&NA<G(D8:NRSVTS85TQ-B@+X1)OGJ*ZH-+N&AU-8*.LP!>U8(&
MKK5'2H&3JM8LEX%>GB8(2H$UA9O"!Y:]=82O692*=@N<#9*#=I>'\)"N=S9R
M^(\'=_-=!HV4>,M%N8QR>:8K XQ.>HP&J8S_?)S O)5]?RRN4Y-0?LN;%)%3
M?GZ' 8^(?E-R"8WM?D]<'(R(?FU$SHMO?IDJ)XM#?OH&+(ML@!>_CI17B-BM
M&)(TAYV9^Y VAG6%Y(YXA8EP_XSJA,9;*(N2A"]#\8J!@[HI8XI-@[D%OHH*
M@R:^;Y-!DJ>KY)$HD)F8N8\WCJ&$R(UPC.-OZXOTBV9:,(JHBAQ#&8F>B1$H
MJHEEB.<%7XC7@Z&]1Y)GG(6JSY!.F;*7F8YAEP.#E8RJE(5NV8LHDD%90(GK
MD%)"4XCDCL<H"(B@CLH%#8?0@VJ\/)&_IH:IQ8^IHOB6D(V\GX>"EXP'G$IM
M\(J'F5%8;8E EKM!IX@\E-\G?(?PE#L$R(;S@SR[6Y$YL*>HZ8\EK%^5M(TU
MJ"R!P(M^I#1M+(H$H)A7QHB]G8-!&8>IFY4G"X=5F+X$CX8\@Q6ZI)#/NP&H
M-HZ]M@"4^8S*L0^!!(L.K%YL>8F4J#!7*(A7I-= G8= HMPFJH;6FB0$8(6F
M@O:Z&I!\Q;JGIXYMP .46XQXNE* 8(JVM/)KXHDWL$Y6IX?[K1) +8;LJ,0F
M2(:!F>($.X4O@MVRPZ!Z=,.A2)V(=4Z//)K'=>)\:)@]=HQHL97I=U-3Z)/:
M>#(]H9)%>0PC9Y))>=0!2I!9?+JQL)]@?>:@?9QK?9B.?)FL?6-[JI<D?5%G
M[)38?693))+2?9T\VY% ?>$BN9$S?E0!+([,?]VPNYY&APZ?>9M<A?2-CYB;
MA/EZMI8@A#-G!9/=@YQ24)'A@S$\'9!3@NXB'I U@SL!$8UO@+FOO)U3D#&>
M:)IMCF",;I>TC+9YMY4PBS-F$Y+ZB?I1?I$%B/,[;H]XB#DAE8]*B+, ^HQ
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M'YL\@HA)>9BC@D0T+):R@BL:;9<9@L8  (M@@ "AL*>5CB^18Z/VC(. ?:"
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MI \CPJ!@F"T+\: =B!,  (1A@ ![;LLQ<OUMF<6V<S=?6,!_<YI0<[N"="=
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MBJP;WZO0BS %@:DD@[D  (,>@ ![.<8EE^1M5,":E9!>][L?DXY0 [75D?9
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MX;7 ;FECL;&];W%4JZWI<(!$F:I@<8TS :>3<G@>NZ;1<L$%O:<_<VT  (
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M3["MDD!B"*QQD)=3 JABCR9#):2JCA(Q_J&=C;4>@: CC> '(9ZCA-(  (
M@ !]G[1IF^9P"[ 2F;9AQJO)EYE2OJ>OE<1"XJ/VE((QTJ#>E'H>?I\NDJ<'
M3IUXA/$  (  @ !]:K/IH^5OV*^.H5!AD*L]GLU2AJ<;G*E"K*-<FW QG*!*
MFN(>9IY\E(T'>9QVA0X  (  @ !]-K.;K$=OT*\KJ59AA*K!IEU29*:"H^M"
MD**MHL,QE)^/G_,>=IW)E)D'H)O%A2@  (  @ !RK\5(;-YEI<"L;;18';PY
M;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (  @ !RHL1W='!E
MP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L #ZGI>.<  (
M@ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR>S@5;JW>>P0
MHZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ9J^M@)8IG*R*
M@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%A[9)=;*HAMHZ
M4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE2KL?C\M7LK9.
MCE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (  @ !R,+]0F--E
M/[IBEN!7KK5_E0I)8[#/DXTZ/ZR0DL(IMJDXDP<68*@MCR$"1Z&T@8H  (
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MAXQ:G3!Z>8K-FK5I>HE>F#U7K8@AE@I$U8<<E%LP7H97D_06_X:RCXT  (
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M=9FZ>A)R?9=M>DUB8)53>I51/9-J>ND^RY'A>T J69$<>W$0!I,O>R4  (
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M(I52HD-O ),#GY->]I#-G/%.'8[<FM0\)HU/F=PH:XPXF!H/2XRLBE<  (
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MD*(Z@ !F7Y].?[973IR,?X)'')H8?VDUBY@I?U\AH9=U?U@(KI>+?Y,  (
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M?9ZWINQD+INFI#)4^IBMH:5% I8-H"TSV9/\GGP@F9+8E@H(XY$[A@(  (
M@ !VM+/!9W]I]; X:0A<@*SE:HQ.&*F\; (^AZ;B;5PM/:3K;FL8N:67;FP!
MB:*J< (  (  @ !V6K+0;U)IRJ\H<!U<5ZNF</E-^:A4<=T^<*5><KPM.J-)
M<VH8XZ.G<T8!_J W=6$  (  @ !V#+%\=NAI8*W8=QM< JI'=V!-H*;K=\,^
M**/L>"TM$*''>(08[J'I>%0"7IWY>E@  (  @ !UK+ =?EUHZ:Q]?A9;=ZCS
M?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (  @ !U1*[TA>%H
M?ZM8A2Y;!:?/A(=,MZ1M@_,]<J%D@X\LD)\R@VL8V9[W@[\"[9H[@?L  (
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MSKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,  )\$<[   (
M@ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8
M )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT4:V0=GPCD:N(
M=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=>^E"\J]W>]XT
M+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=-;8C@MI05K(5
M@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (  @ !I3KD\BKM=
M'K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@  )F0@    (
M@ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8RCD40(J99BND
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M)'Y]B,]_!WY0A_]MY'XKAQU;UGX>ADI(D7XRA9DSLGY"A0T:.7Y9A0P  (
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M\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3R(R;;Q0  (
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M5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$B@ KTH+]B9X2'X-GB#H  (
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MSY4?;0)KF9-I;F=<19';;[]+O)![<08YOH^!<B<E>(]V<L@++I$8<D4  (
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M\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W%(E"CI@CGHBRCL8*QH@=ATD  (
M@ ""L8_6G<YU=HY"G 5G.HR7F>]8!(KVE\Q'ZHF3EAHVCXB,E6LC-(?IE!4*
MMH<0ASX  (  @ ""6H]DIH1U%HW.I%MFRXP7H<=7D8IGGR]'A(CWG5(V/(?E
MG' B[H<YEYX*E89&AR@  (  @ !ZD**E8G!N$Z F9)5@JYWN9J!2()OG:(I"
M6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (  ?]!Y_*%!:GMMH)[,:^)@-)Q_
M;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (  @ !Y:Y^B<EAL
M[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$4I/%=TT  (
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M2Y@&F(-<W96NELM.<Y-AE0P_'I%ED]8N8X_[D](;,(^,D3T$U8P<@T4  (
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MKZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4  )0P?&,  (
M@ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP?O(2DIR&?N,
M )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 VV)NKA.4F;YHH
MA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_GC+)%.IT>B[LV
MAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?5*(FE/52G)\S
MDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (  @ !J\*2AG>-?
M5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X "X^*@ @  (
M@ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$9[@(7*ZD9VL
M )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8MY:N?;&0<\*L*
M;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R<$4\0ZQ1<0<M
MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5);$:=AE(_:W0
M=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (  @ !@:++U?-)4
MZ:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D  ([!@    (
M@ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00@J *)Z/,@CD
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M G,?<VZ#Y'0.='1R:'3X=69?['7@=E-,1G;'=S8W$7>%=^T=G7>2> <  (
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MBFOCH%=^6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;.F\UD7H  (
M@ "=5&GQK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*G0,S5F__FW@:
MQ&Y'DAD  (  @ "84'^77EJ*27]P849[&']X8_AJEG^>9G98V'_7:-5%QH N
M:PTPY8"^;-X6M8(];30  (  =ER74WT;9YB)1GTY::1Z 7UD:X=ID7V<;4U7
M[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (  >F>6.7K7<+Z( 7L@<@%XY7MB
M<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (  ??.5!7C$>>>&
MO'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K >]PO"7L;? H59GL=>Z8  (
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MNG./I8IS?7/THI-C5711GX]24W3&G/U ,W4YFVHL;'4SF8P3BW2TC3<  (
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M_8 ;@*-KPG_?@)9<BW^F@&Y,9W][@$DZJ']]@"TFW'^.@! -4G_^?^@  (
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MVI"18!ID:8]Q8J95NHZ#90=%OHW#9SDT'XUR:1L?THY6:A<&3HZ9:A0  (
M?,M]>X_H9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M];D4?CHPG;N &
M:HOV;O   (  ?]Y\KHW7;=%P.HS%;R-BY(N\<&)43HK0<8Y$BXH-<J,S+HFI
M<X8?-HHC<\P&=XF?="L  (  @ ![R8OM=>EO1(KN=JIAWHGY=U13A8D3=_%#
MUXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (  @ !ZZ8I*?@5N>(E8?D1A&8AK
M?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (  @ !Z(HCZAD1M
MN8@6A?M@7H<JA8=2"X9"A/A"NH5\A'$Q\H3WA" >;H3YA#L&D80\@ML  (
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M9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0 +Y"^;K8  (
M@ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"<<H6%9+<<84
M<XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(ZF9!;=J@IY8_!
M=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"?!U(T) )?$,Z
M$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB?)'6@SY5W)!(
M@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (  @ !MK))/BR=A
M]9#5BJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=B%$5=8OCB 0! X??@*\  (
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M#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8  (I[=Z(  (
M@ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>=,,,CIH9=%4
M (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PPM)>I>B<@39<M
M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX@$@^?)?S@!HP
M599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7&9L8AWE+))CP
MAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (  @ !AU9Q>CRM6
MS)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H  (4A@    (
M@ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);D>\,OY'LB)\
M (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG+*GC8B,5DZMA
M8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ9+DU?ZDN9CHG
M.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-2JP+:9!!T*F)
M:K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (  @ !7KJRG;SI,
MWZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP  (5!?HH  (
M@ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)==RD$PI\&>.$
M (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\FDJ!T?3,6&Z"7
M?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U@\<T0:$"@VPF
M=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,$Z4RBOU JJ*#
MBF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (  @ !68J<TDGY,
M#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD  (& @    (
M@ "U)F%36;*C_F/170.2-F8O8#=_AFAQ8TQKWFJ?9D97*&RN:25!*FYB:\\G
MZV[:;=T&N72C;L6S*EW.9&&B<6":9JR0U&,V:.9^2V6N:Q!JNF@-;2A6'FI
M;RY -6O\<08G&&P2<EX&8W4U<T&Q3EJQ;P&@JEVS<$J/36"#<8Q\UF,F<LYI
M;F6L= U4^V?^=4,_/FF[=E8F46EE=PH&%W6U>"*O=%?E>8&>W5L6>=R-C%X)
M>CE[66#2>I=H%&-_>P%3U&7J>VL^3F>H>\0EEV;=>^L%U78D?)JMOE5X@_*=
M1EC.@W6,!%OC@O9YWE[%@GEFXF&,@@A2R&01@:\]=F7*@5@D\F2$@1$%G7:#
M@&VL4E-VCF:;]U;IC1B*S%H4B\!XN%T-BFIESE_DB2A1YV)PB H\OF0EAQDD
M8F)UAIT%;G;3@Z:K+5'/F-6:ZE58EK:)T%B1E(-WREN8DEED[UZ D%11)&$4
MCH4\*6*XC0PC\&#(C*(%1G<6@Y&J4%"$HS::'E0;H$.)"E=:G3=W#%IDFCMD
M-UU4EX!0>%_QE1X[G&&*DU8CCE]LD>P%)G=,@WNIP4^8K769DE,TJ:"(>%9L
MI;EV>5EPH?ACL%Q>GIE0!%[ZF\4[*&!_F@4C(EY%EAX%#7=W@VJH%VC;64F8
M8VJI7*^'SVQK7^9V)6X?8O!C96_*9=Q/?W%?:*<Z(G*O:RH@Z'+Q;,P!3'W/
M;O.F@66(8W>7-&>E9>2&O6F::#%U+6MV:F-B@&U";'U.LV[Q;G\Y=' ^<$4@
M6W "<4P!+GX!<\>DWF*(;8Z5?V39;PZ%-V;[<'ASN&C_<=1A.&KO<R9-EFRX
M=&DX@6W]=7P?G6TN=?D!%'XM>&6C-%_7=XB3U6)0>#"#EF24>,=R7V:X>5%?
M_FC->=Q,C&JJ>F,WJVOF>L\>^FJ=>N$ _7Y4?&:AJ%U_@7V28& 9@5V"+6)\
M@29P_F2X@.)>Z&;A@*1+EVC4@'<VZ&H#@$L>:VAT@!T ZGYU?]2@8UN0BWN1
M*UY"BI:!"6"XB9)OZ6,)B(-=YF5 AX)*R6<UAJ,V0VA8A?@=[F:KA=H V7Z1
M@).?7UGYE720,ER\D\R &E\^D?MO!F&;D"1=$6/BCF]*$V7<C/,UOV;EB^$=
MCV4SBXP S'ZH@(J>G5B[GV&/<UN(G/=_65X-FEMN2F!LE[]<6F*XE6%):&2Y
MDVDU-V6RDC<=.F0$D#8 P7ZZ@(*>'5?8J3:.ZEJEI@Q^PUTCHJ=MLE][GTY;
MT&'$G%A(]6/"F@<TPV2BF.4<RV,-DW@ N'[)@'R;-G"R6/>,U7',7&!]9W+Q
M7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (  <AV9X6V'8HV+
MHV[N90]\,7!!9VEKHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8TG3);]P  (
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M961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6G6LCB<<  (
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MO70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40/7D0<LL  (
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MS6M8ED1KE6Q\E(%<76V)DJE,(VZ.D0\ZJF];C_8G@&\GC^P/ '%0BB4  (
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M#GH-<O=DEGIH= 56+GJ[=/=&6WL@==,U%WN'=H@A='O4=M (LGUP=PL  (
M@ !]@'>)>DMP^7@+>MQCC'AY>TE5+'C:>YE%M'D_>^$TBWFI?!LA&7G ?" (
MJGNA?)8  (  @ !\CW77@MYP+'9K@M]BS7;A@JU47W=&@EQ$Y7>L@A S\G@"
M@=\@GW?C@=4(@WH?@5P  (  @ ![RW1QBVIO9G40BMYB#'6)BA!3I77QB2A$
M-'98B%TS7':@A]D@2G8[B \(<GC8A54  (  @ ![,7-2D_!NSG/[DN!A<W1S
MD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (  @ !ZOG)XG'QN
M5W,GFOU@\W.;F1!2DW/REPY#-71)E8$R='1ZE1(?@7.VDM8(+'<*A88  (
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MN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,";H%$>\   (
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MT)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<  (@):9H  (
M?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<:%L/:9%M9_H
M (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STTC8R1;)4CXHS"
M;6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)<"I"98L%<3PS
M[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:EHJ\=A5.FXGQ
M=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (  @ !D]XGB?/!9
M[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4  ( ;@    (
M@ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<
M (  @    (  @ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&
MB@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08Q
MXX-SD&XB H+MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]20IU96)]&P)P(
M6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1
MK)M97U5&-YGT87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,  ((0<C$  (
M@ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0
M ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S
M;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J
M I&K=2T9E)(<=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N
M>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.
MEI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.   (  @    (
M@ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D
M (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(
MC*$'<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@
MAJ797/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>
M7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (  @ !//:938>]%
M+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (
M@ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL
M (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9
M<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?
M6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/
M?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#
M2IQSA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (
M@ !,\9TIBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8
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M=5==>U]Y25IJ>[UI'ET^? I8 E_J?%9%CF(H?*0QK6,;?.49L&-$?.X  (
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MGFM,5R]T\VSP6LQE&VZ07C=4$' C87A!K'&89( M=7*E9PD3T7/&9\<  (
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MTEQJ@@=NHE[R@=]?96%&@:!/)V-G@60]G64+@3LJ364D@2P1YFCW@3L  (
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M-V\P7P-I@7"$8<Y:I7'-9'-*@G,&9NTXX70B:20E"W3(:K8+C7?W:JH  (
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M7F):A\ID#V1,AS15KF8-AH9&/6>8A>LU<&B3A8(BI&>DA8H*RV[/A$,  (
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ML'079=1=_'4)9_-/_'7J:>M N7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (
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M &E#C+%9>&J6B\U+Y&NPBLX]*&R3B@8LW&S?B;H:*VOVB<P$F7@Z@QP  (
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M3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (
M@ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X
M (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?
M>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PT
MZ74Y@6,D]W4O@601J77:@8D  (  @    (  @ !F$G%)B9I;-')-B55/8G,!
MB+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @    (  @ !EF' 6D89:
MOG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO   (  @    (
M@ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD
M (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY
M8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N
M!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q
M:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU2
M3H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (
M@ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D
M (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD
M?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK
M;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_
MC&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @    (  @ !4I9;<4#U*
MC)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (
M@ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD
M (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D
M98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C
M5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW
M;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&
MF8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H  (  @    (
M@ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<
M (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48
M@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A
M[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G
M4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]
M^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X  (  =5$  (
M@ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$
M (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,
M9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7
M^Y9,;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;
M<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZ
MSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (
M@ !#R9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@
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M9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (  =V*-RDR3:NN
M1U!S;*=Q]50!;E9BM%=2;_)2*5I9<7A :ERO<N<M$UT*=!@5.&&X=',  (
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M'$,,F!9M5D>*E?5>ADN2D_).H$\*DD4]@E%%D1TJX5"MD1,3WUYIC4   (
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MJE/T<ZIG05<I=+E8U%H/=;))7%R?=ITX3%Y+=W$E9UV#> D-?FDQ>#H  (
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M!FL-4?QBNFRW5=)486Y868-$QF_=7/LSCW$K8!,?U'&L8CD',W>V8Q   (
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M0EAI><=<L%LK>DY/$5V6>KQ 5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (
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MNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:9 ,60W0)9-< SGZD9R$  (
M?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T
MX'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1
M;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D<.U&RF<7<A8X
MHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>R&!V=U!2YV*6
M=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (  @ !HW%M+?JM=
M[5WC?O12&V ??PQ%-F'R?PLW&V,K?Q,G1V+>?R\4<6:[?V8!)'X3?_H  (
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M77+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (
M@ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"
M (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=
M<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(N
MSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S
M?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2
MI&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (
M@ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH
M (  @    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)
M6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH
M$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)
M7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+
M,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (
M@ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,
M (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'
M<],$8GE#==\  (  @    (  @ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LD
MH7&;>9\4HG(F>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W
M?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @    (  @ !1)6H_AO)'
M;VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL  (  @    (
M@ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0
M (  ;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T5
M6]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<
MW(?48(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C
M8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_
M)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (
M@ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4
M (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV
M=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9
M^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@
M@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LW
MLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (
M@  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$
M (  =0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/
M7BX  (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/
M_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM
M970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TR
MIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (
M@  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@
M (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,"
M>BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.
MD8)<?BX"B8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF
M=#(     ! ,)   !                     0                    $
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MO]/@U0/6)]=,V'/9F]K$V^_=&MY&WW/@H>'/XP+D3>69YN?H-NF&ZMCL*^V
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MHWUZK%._GDA[@T1&F-]\AC5*DQQ]YR=_C-E_MJ'DMRV!C9)WL>B L(+6K+R
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M@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F .5YS@/Z &4AU@16 'S+@@5J
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MM/^!QW&IKX2!#&/IJ@* FE8FI&. 74B4GIR 33N8F)6 5"]PDC^ C"3-BYV
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MJ]Q[7D*+I-Q\'3;CG8=] "P:E<E^*B+7C<!_AX$0Q&"!L'2'OCN P6?PM^R
M#5M*L6U_L4[#JK9_D$*)H[Y_I3;^G'1_UBQ@E,V .R-5C.J Q8$/PT2(-W1P
MO2"&NF?&MM*%=%LIL%"$=$ZLJ:*#M$*%HK>#%3<6FWV"BBR>D_"")2/ C#.!
MWX#[PE..KW1;O"J,HV>PM=>*SUL,KU:)+4Z@J*:'N4*)H<V&93<OFJ2%&"S6
MDS"#YB0<BYB"UH#<P925'W1+NV"2?F>JM020"5L-KH&-PDZ@I]:+F$*4H/R)
M@S=*F>:'=2T'DHR%>R1HBQ:#JH"]P/F;8G1 NKJ8(V>JM%.5!5L3K<Z2$$ZI
MIRN/-4*DH%J,9#=EF4.)ERTSD@&&W22GBJR$7("?P'ZA<G0YNC.=C&>OL\*9
MNUL<K366#DZSII>2@4*RG]>.^C=\F,J+>2U8D9"(#B3:BE6$[X"'P!FG4'0X
MN<"BLV>ZLT2>'ELMK+*9M$[)IA65<D+/GUV1/3>:F&.-$RUXD3V)""4"BA&%
M9>:W=K%S:-%5=Y-T2[N&>'!U-*4Z>4AV*HZA>B1W.7?O>P]X96%/? ]YJDK/
M?3U[*#2O?KM\_^2U=-=^<\^S=>%^*[H/=N!]^J/M=]M]YXUP>-M]]';:>>I^
M&F!3>PY^2DGW?%]^EC0&??M^_.+E<TV)BLWQ=&F(&KB%=7^&Q*)]=I6%J(PK
M=[.$KW6_>.*#RU]D>B:"XDDT>Y6!]3-P?4R Y.$H<?R4C<PS<R.2"+;4=$:/
MI:#]=7&-:XK8=JR+:G2@=_>)<UY]>5>':4B >N&%/#+L?*^"LM^4<.B?>LJF
M<A.;\[5+<T&8B)^,='B50HF/=<22%W.+=RJ/"EVB>**+U4?;>D.(7S)Z?"2$
M7MY!<!.J5<E9<3^EU[0"<FZA89Y.<ZR=!HAP=028P'*'=G>4?%S7> :0&$=&
M>;R+5C(9>ZV%X]TK;VVU&<A*<)BOI;+O<<*J()U!<P*DJ8=_=&6?1W&[=>:9
MU5PG=X&4)4;(>4J.%3')>T>'.]Q2;O._NL=V<!NY3;(1<3ZRMIQ<<GFL&8:D
M<^&ECG$#=7">\EN:=QB8 $9<>.N0E#&&>O.(9MNS;J7*(\;:;\;"LK%A<-V[
M IN<<@ZS.X7J<W6K?G!@=0JCIUL3=KV;=T7W>)R2QC%1>J^)8=<@?Q5R&L.:
M?QES.:^ ?RAT3IK)?T!U:(6J?V1VEW!B?Y9WY5LS?]AY3D8>@#YZ]3%^@-Y\
M_=6C?69\F<)R?8M\FJYH?;-\HYFX?>)\P82>?AY\^V]I?FU]3UI1?M%]LD5F
M?UU^-S$ @"%^Y-0C>_.'%,#7?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""
MPEEQ??&"&$2X?IB!<#"1?W6 M-*>>K*1=+]$>N^/::M@>S6-;I;U>XR+C((N
M? &)U&U5?(F()5B??26&9D0=?>>$BS O?MR"9]$N>:B;QKW=>>J8S:G^>CF5
MW96B>IV2_($%>QV0+6Q;>\"-=%?=?'.*ET.0?4R'@2_:?E6#]\_Y>-FF$KRL
M>1VB,*C2>6V>0I2#>=B:6H ">F26?6MW>Q"2G%<M>]F.GD,3?,B*22^2?>*%
M8<[]>#6P3+NS>'JK?:?7>,>FC)..>32AE'\G><N<IFK!>H27I5:8>U:2;4*K
M?%>,V2]7?8&&G\XY=[RZ:+KO> "TJJ<(>$>NKI*\>*^HFWYA>4NBCFH9>A.<
M;588>O&6!$)2>_J/*2\F?3"'L<VO=VK$7KI<=ZR]IJ9?=^BVE)((>$6O6GVY
M>."H)&F)>:^@UE6D>IJ9/$'_>["1+B[_?.^(E<@)A])Q!;8ZANAR1J.WAA]S
M=I!VA6]TIWS!A,YU\&C?A#MW7%4E@[%XZD&'@T-ZO"Y[@OE\^<;<AD=ZY;4T
MA7Y['Z*GA,E[6H]TA"E[I7O-@YM\"F@!@R%\BU1?@K1]($#N@F9]W"XG@CI^
MR\6SA.&$RK0 A"V$ J&B@X&#0HY:@O6"GGK%@GF"&F<;@A>!K%.?@<J!1$!A
M@9V YBW>@8Z @\1:@Z6.CK*9@O2,Y* B@EF+/(T,@=R)IWF?@7^(-F8G@3B&
MSE+B@0.%7C_>@.Z#V"V=@/:"'L,.@J280+%.@?:5OI[@@663-HO;@/*0L'B5
M@)Z.-F5+@'&+TU([@%&)4C]M@%.&H"UF@'&#E<'U@=NA]; [@3*>FYW2@**;
M)(K;@#27I'>P?^F4*62(?\"0KE&I?[>-&S\)?\Z).BTW?_^$Y,$2@3VKFZ]9
M@)BG8ISM@ 2B]HGY?Y>><7;G?U>9\F/E?SJ595$N?S.0K3ZW?UZ+G2T0?Z"&
M"<!D@,:U*JZF@"6P#9PM?XNJH8DV?Q:E"78R?MF?>&-'?LR9UU"X?M*4 #YP
M?P*-PBSP?U&'!+_M@'2^H:X>?]6XF)N*?S&R&HB)?J^K7W66?F^DKV+*?FF=
M\E!;?GV6_#XR?KN/G2S7?Q*'U;EWD*YP1JD2CN9QDI?XC4QRT(8>B]1T$7/1
MBFEU;F%:B0=V\D\9AZ5XFST#AE!ZCRNFA0=\\[A^CT1YE:@LC9QYZI<%C!1Z
M0X4WBJ=ZKG+WB4I[-F"5A_Q[W4YLAK!\FCR)A75]B"M^A$-^LK=ZC?F"RZ<$
MC&."/Y7[BN&!MH0LB86!2W(+B#N ^5_-AP2 ODW,A=" C#P=A*Z :BM:@Y.
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MCR]ZA%E!C/Y[2TB4BL)\+#A(B(1]0BD'AC5^F:G#ET.!+)I_E-B OHJRDH*
M7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^ )ZC5EBN)M)F
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MEJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#C-V D3\-BF& :#&UA^" 3"6YA52
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M<(*#_IGI<=V#7H?;<SV"P750=+J".V*P=E.!O%!0> N!/#Y!>?N MBT=?#"
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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MC[Z"SU_IC>.">U3%B_:"$$F9B@Z!JCZBB"^!530KAF2!"RIUA*Z P"(U@Q2
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MD--[[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9*
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M[S5I?X1_]2M5?]U__"*U@$V  W:G?FB'(FQA?G.&M&&-?EN& %90?CR%(DL
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ME\]^)TC\E1U^44#9DB%^<3C?CPQ^J3%"B_I^^RI<B/A_8"0BACY_PA\F@]F
M%EBUF2^#>E#GEN>#6TC>E#B"[D#%D3V"93C0CC&!]3$PBSB!GBI?B$N!7R1*
MA:6!&A];@V. T5B+F&^(]5#-EBF(84C)DWZ'4T"YD(6&&3C6C7J$_#%%BHV#
M_2ITA[:#%21CA2R"-!^%@P2!::Q_7.-5*YTR7_U9)HV%8Q%=%7U,9C!@^VR?
M:71DYUO$;.IH[TL[<)5M*#L0=)EQNRP'>/IVY:J+6.U?89NP7&]B8(PS7]]E
M5WPG8U=H3&N<9O1K25KH:L9N84J,;M!QHCJE<S1U-"OW=_)Y/JB]56=I@)G]
M63YK@(K$7/]M?GK18,-O@VIX9*]QEEG\:-5SP4G>;3=V##I <?5XEBOJ=P=[
M=J;R4CUS<YA+5F-T@HDF6F1UE'F 7FQVJVE38J9WTED49QMY#4DZ:\YZ73GE
M<-Y[V2O>=C=]B*5"3W=]0I;+4^!];H?%6")]F7@T7&1]Q&A;8-Q]^%A)99M^
M/DBK:I9^CCF6;^Q^]"O3=8-_;J/432"&\96+4<*&/8:O5CB%?W<]6K&$NV=]
M7UV#^U>H9%&#14@X:8V"DCE4;R"!W2O*=.F!(J*I2RF0<Y2)3_N.UX7/5)N-
M*G9Z64"+=6;-7AZ)Q%<:8T.($4?>:*V&5CDB;G2$ARO#=&F"H:'$29>9L)/"
M3HZ7)(4A4TV4@G7B6!"1VF9$71./-U:?8F6,C4>$9_N)SSCY;>:&ZRN]= "#
MZ:$K2'"B@9,W37N>]X2@4DN;7'5P5R&7Q67G7#N4.%988:J0G4=$9V*,Y#C*
M;7*(^BNY<ZN$^Z#58_-5-9+49FE9.H1):.==)W49:WAA!F5Q;BQD[E6B<1!H
M^48O="AM-S<K=Y5QUBE;>UAW"I\K8#!>Y9&C8P]A^X-%9>!E G0\:+QH F2T
M:[UK"E4*;O5N,47#<F5Q@C;S=B]U*BEC>DMY29V*7,YH>9 !8 !JI8';8QML
MQW+N9D%NYV.;:8]Q$U0J;1ES6D4A<-UUPC:>=/AX:REJ>5M[99OJ6<1QY8YO
M73US-(!=8)=T>G' 8_UUNV*69YAW!U-?:VUX:$27;WYYX398<^5[ABEO>(E]
M6YIH5QM[-8T/6M![KW\77F=\&7"-8@5\>6&X9=M\WU*J:?A]6$0=;DY]W#8=
M<O9^=BET=]-_)9DH5-^$:HOM6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"
M&$.Z;4F!IC7K<BN!-"EY=SB OI@F4P&-<(L"5P^,/'T_6ON*XF[E7O>)=& ^
M8S"("%&59ZZ&G4-N;&R%,#7'<8"#LRE\=K>"(Y=B4866,8I-5;"4(GR56;>1
MWFY-7="/@U^S8BR-+%$:9M:*TT,;:[V(<#6G</.%[BE_=DV#59;=4&J>CXG*
M5*>;HWP26+V8<VW37.>5*E]/85J1ZE#09B&.ID+9:RF+3S5Z<(.'U"F!=?F$
M4I5;:S555HB4;0195GLG;NI=/6T$<.=A%EYG<P-D^T^I=4QI!T%3=\1M23-V
M>HUQ\2;9?:)W*Y/F9Z->:H=B:==AD'H(; EDHVP.;DQGL%V9<+%JR4\(<TEN
M!$#C=A-Q:S-&>2]U)R;X?(UY49*!9&%G>(8)9NIIQGC^:6%L!VL7:^1N0ES3
M;HUPBDYU<7!R[D"(=(AU=#,C=_)X/"<3>YA[4Y$'871P882?9$!QXW>49O1S
M5VGY:;1TPEO<;*AV-4VW;]-WOT )<S1Y8C+K=N-[,2<J>L%]+H^M7NEY+H-;
M8>IYZW9F9-5ZD&CC9\Q[)5L8:O=[P$T9;F=\;#^D<@E])C+#=?5]^"<^>@A^
MWHZ/7,:!Y()27_*!VW5W8PF!K&@)9C&!9UI9:8R!(DR9;2N Z3]2<0: N3*@
M=2F BR=/>6N 78VI6OZ*:8%[7DV)F'2Q88:(D6=79-2';5FZ:%V&24PA;"B%
M*3\4<"J$##**='V"XB==>.B!JXSY69"2K(#47/J1$G008$R/+V;$8[6-)UDS
M9V"+(4NK:U6)'#[);WV'%#)T<^^$]2=I>'V"QHQ_6'R:E8!96_F8-W.07UF5
M=F9*8M*2AEC09I*/FTMD:J*,LCZ*;NR)P#)+<X*&MB=R>">#L8H'<K95@'Y,
M<]Y9<7'G=2E=3V30=HYA(U=&> ME"$FF>:QI&3QZ>W5M82_7?85R$22!?]1W
M1XBY;T]>!7TU<-EA+W#E<FQD2F/U= YG8E:6=<UJBDDC=[=MUSPG><MQ4B_"
M?"9U(B2W?K5Y5H=];#1F>WOP;@YHXV_>;]YK/V,'<;YMEU7:<[YO_4B;=>YR
M@CO8>$IU*B^O>NQX$R3F?;A[0(8V:6)NXWJP:WUPC6ZN;8AR)V(T;YYSOE4L
M<=]U6D@E=%%W#CN:=O%XW2^D>=5ZVB4/?-Q] H3]9O5W,7FD:4)X)6VM:W]X
M_V$O;<9YR51P<#QZF4>+<O![?#LY=<Q\;B^$>.A]>B4R?!U^F8/Z9.I_9WBN
M9UY_I&S,:<)_MV!D;#=_LE/#;ME_KD<<<;=_MSKV=,I_RR]P>!M_Y25/>WV
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M;9.$16-\;UJ#V5@J<2R#2TRO<RF"P$%/=5R"0#:-=[*!R"QB>DB!3".>?.&
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M6V9Z2U-]83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D"
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M=@A^A22">F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!:
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M<@=_QTQG<]%_QD09=7-_LCO'=QQ_NS.F>.Q_W2Q">L& %"6/?+R 0" /?J2
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M>/:"%T2@>A^!OSUQ>NV!6#95>Z.!&B]H?'R ^"DG?6. Z".*?GZ SA\(?YB
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M  #__P  ;69T,0     #!"$   $                    !
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M_Z,X*O^@14#_H$Q4^Z1+8_&H2W/FJTR#W:U0D=2L6)[,JF*IQZILL<2J=K;
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M14#_H4I3^Z9(8O*K2''HKTB W[-*CM:U49K0MEJDS+AEJ\J]<:[!N7NVM[*
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MD*B$SHBFAM&"I(S3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
MH\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B
M_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\?^2%A(;@
M@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O H\UL
MQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B_XTM
M#O^-/AW_C$PN_Y13._^55D?_EEM4_95A8/:2:&OOCW!UZ8MZ?^2'@X??@HJ-
MW'Z0DMEZEI?6=YN:U72@G=-RI9_2<*FAT6ZNHM!MM*/0;+JDT&S"I,INQ*3$
M;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2D_XXM#O^.
M/AW_CDLN_Y51.O^85$?_F%A3_IA>7_:59&KODFQUZ8YV?N2*@(??A8>.VX".
ME-A\E)C5>9J<TW:?G]%SI*+0<:JDSV^OI<YNMJ;.;;VGRF["I\-PPJ>]<<*G
MO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*G_X\M#O^./A[_
MD$HM_Y=/.O^944;_FU92_II;7O>886GPE6ATZI%Q?N2.?(;?B82.VX.+E-=_
MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M;%>D[6Q:G^UL6I[M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL_WP0 ?^.$ #VG@T
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
M@L\' 'C9"P!SWA@ ;MXF FC>,P5BWCX*7=Y(#UG>4!15WE@74=Y@&T[>9QY+
MW6\@2-YX(T;>@25#WHPG0=Z8*3_>IBH^W[4J/>#(*CW?XRH\W?$K.]S[+3K<
M_2XZW/TN.MS]+CK<_2XZW/TNP)\  +&G  "DL   F+H  (W#  "!S0( =M<'
M &[H#P!IZ!L!8^@G E[I,@58Z3L(5.E$#$_J3 ],ZE,22>I;%4;J8A=$ZVH9
M0>MR&S_K>QT\ZX8>.NR1(#CLGB$W[:PB-NV[(S7NSR,T[N8C-.OU(S3K^",T
MZ_@C-.OX(S3K^",TZ_@CLZ4  *:M  "9MP  C<$  (#+  !UU0$ :>$& &3S
M$0!>\QP!6?0F E3T, 1/]3@&2_5 "$?V1PI$]DX,0?=5#C_W7 \\]V,1.OAJ
M$S?X<Q0U^'T6,_F(%S'YE!@O^J$9+OJO&BW[OAHL^\\;*_OG&RO[ZQLK^^L;
M*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@  7O(( %G^$0!3
M_QH!3O\C DG_*P-%_S,$0?\Z!3[_008[_T<'./]."#7_5 DS_UH),?]A"B__
M:0LL_W(,*O]]#2C_B XF_Y4/)?^A$"3_KA$C_[H2(O_*$B+_T!(B_] 2(O_0
M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
M<KLA &Z[+@)HNSH&9+I#"E^Z3 Y;N5,25[A:%E2X81E1MVD<3K=Q'TNV>B)(
MMH0E1;:0)T.UG2E!M:PJ0+:^*C^VV"H_M.XJ/K/Z+#VR_RT]L?\M/;'_+3VQ
M_RT]L?\MQXD  +F5  "LG0  H:0  ):K  "*L@  ?[@  '._ P!JQ P 9\4:
M &/%* %?Q34#6\4_!5?%2 E4Q% ,4,18#TW$7Q)*PV852,-N%T7#>!I"PX(<
M0,..'C[#G!\\PZL@.\.\(3K#U2$[PNXA.<#Y(CB__R0XO_\D.+__)#B__R0X
MO_\DO9$  +";  "DH@  F*H  (RQ  " N0  =;\  &K&! !>S @ 6<\2 %?0
M(0!5T"X!4= Y D[00P1+T$P&2=!3"$;06PM#T&,-0=!K#S[0=1$\T8 3.M&,
M%#C1FA8VT:D7-=&[%S32TA<UT.P6-,_W&#/._QHSSO\:,\[_&C/._QHSSO\:
MLYD  *:A  ":J0  CK$  (&Y  !UP   :L<  %[- P!4U @ 3-T- $K=& !(
MWB8 1MXR 43?/ )"WT4#/]]-!#W@504[X%T&.>!F"#?@;PDUX7H*,^&&##'A
ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
M +.2  "GF0  G)\  )"F  "$K   >;$  &VW  !AO 4 7;T2 %J^( !8OBT!
M5+XX E&^0@1.ODH&3+Y2"$F^60I&OF ,1+YH#D&]<1$_O7P3/+V(%3J]E18X
MO:07-[VU&#:]RA@WO.<7-;OV&36Z_QHTN?\;-+G_&S2Y_QLTN?\;N(\  *J8
M  "?GP  DZ8  (>L  ![LP  ;[D  &.^  !8Q 0 4,@, $W(%P!,R24 2LHQ
M $?*.P%%RD0"0\I, T'*5 0^REP&/,ID!SK+;@DXRW@*-LN%##3+D@TRRZ(.
M,<NR#S#,QP\PR^4.+\GU#R[(_1$NQ_\2+L?_$B['_Q(NQ_\2KI<  *&>  "5
MI0  B:T  'RT  !PNP  9,$  %G&  !.RP, 1= ( #[5#@ ]U1H /-8F #O7
M,0 YV#L .-E% 3;930$UV58",]I> C':: ,PVW,$+MM_!2S;C04JW)T&*=RM
M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
MXE\# -IB!@#48PD S6,2 ,1E(P"\93("MF- !;%A2PFL7E0.J%Q=$J5;91:A
M66P8GUAS&YQ6>AZ:58(@F%2*(I54DB234YLFD5*E)X]2L"F-4KXJC%+0*HI3
MZ2J)4_DIB%3_*8=4_RB'5/\HAU3_*(=4_RB'5/\H_TP% /]6 0#I70  W&,"
M -%G!0#,: < QF@0 +UJ( "V:2\!L&@\!*IE1PFE8U$-H6%:$IU?81::7FD9
MEUQP')5;=QZ26GXAD%F&(XU8CB6+5Y<GB5>A*896K2N%5KHL@U;,+()7YBR!
M5_<K@%C_*H!8_RJ 6/\I@%C_*8!8_RF 6/\I_T\" /U9  #B8   U6<  ,QJ
M P#&; 4 P&P. +=M'0"P;BP!JFPY!*5J1 B@:$X-FV97$9=D7A648F49D6!L
M'(Y?<QZ+7GLAB5V")(9<BR:$6Y0H@5N>*G]:JBQ]6K<M?%K)+GI:XRYZ6_4M
M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M(FI?_R)J7_\B\%(  -U=  #+90  P&L  +=N  "O;P  IVX! *!O$ ":<!\
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MF")8<*8D5G"U)55PR"55<.4E57#V)%9O_R-6;_\B5V__(E=O_R)7;_\BWU\
M ,II  "\<@  LG@  *E]  "??P  DGX  (I_!P"$@!, @($A 'N!+@%W@#D#
M<H!"!6Y_2@AK?E$+:'U8#F1\7Q%B>V847WIM%UQY=1E9>'\<5WB*'E1WEB%2
M=J0B47:S(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T_R%1=/\AV&,  ,5M
M  "X=@  KGT  *6"  ":@P  C8,  (2$ P!]A1  >88> '6'*P%QAS8";88_
M!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:47^('$]^E!]-?J(@
M2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T
M>P  JH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.)P!JCC(!9HT\ V.-
M1 5@C$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%&DJ&DAQ(AJ =1H:O
M'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT  +IX  "O@0
MI8<  )J+  "/C0  @8X  '21  !NDPH :905 &:5(@!CE2X!8)4X ER50019
ME$D&5I10"%235PI1DUX,3I)F#TR2;A%)D7@41I"#%D20D!A"CYX90(^M&C^/
MP!H_C]P:/XWQ&C^,_1L_B_\;/XO_&S^+_QL_B_\;PG,  +5^  "JAP  GXP
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M"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ
M9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  Q
MODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,CO\L#([[H R.\
M]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K  !GL   6[4
M $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP "3*.0 CRD(
M(LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4 &,WD !C,] $8
MROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<N0  4+T  $3!
M   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H]
M !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO<
M#-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   N
MS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ
M.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO
M  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@
M&]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@
M]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #X
MT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<   8X   $>0
M  SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:  #_(0  _RD
M /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT  /^S  #_LP
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M LTB] /*(_\$R"/_!<<C_P;&(_\&QB/_!L8C_P;&(_\&_RP2 /\N#P#_,!
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M$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10  X4@  -E(!0#31@D
MS$42 ,1'(@"]2#$ N$@_ ;-'2@*P1E0$K$5=!:I$9 >G0VP(I4)S"J-">@NA
M08$,H$&(#9Y D ^<0)@0FD"A$9A K!*70+@2E4#($Y- X1.10?,4D$'_%(]!
M_Q2.0O\3CD+_$XY"_Q..0O\3_SP  /E$  #D2@  V$X  ,Y/ @#)308 PTL/
M +M-'0"U3BT KTXZ :M-1@*G3$\$I$M8!J%*8 B>26<)G$AN"YI'=0V81GP.
MED:##Y1%BQ&21902D$6=$XY%J!2,1;05BT7$%HI%W!:(1O 6AD;]%H9&_Q:%
M1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P  SU,  ,95  # 4P, NU$, +-2
M&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B63F,*E$UJ#)%,<0Z/2W@/C4M_
M$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*UAE_2NT8?DO\&'Y+_Q=]2_\7
M?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@  ,!9  "Z6 $ M%8) *Q7%@"F
M6"4 H5@R 9U7/@*85D@$E551!I)46 B/4E\*C%)F#(I1;0Z(4'00A4][$H-/
MA!.!3HT5?TZ7%WU.H1A[3:X9>DZ]&GA.T1IW3NL:=T_Z&79/_QEV3_\8=D__
M%W9/_Q=V3_\7^$8  .)0  #05P  Q%P  +M>  "T70  KEH& *9;$P"@7"(
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MF!IC7J4<85ZT'6!>QQU@7N,=8%[U'&!>_QM@7O\:85[_&F%>_QIA7O\:Y%(
M ,]<  # 9   MFD  *QL  "C;   F6D  ))J"P",:A8 AVLD ()K, %^:CH"
M>FE#!'9H2P9S9U((<&=9"FUF8 UK968/:&1N$69D=A1D8X 68F.+&&!BEQI>
M8J0<7&*R'5MBQ1U;8N$=6V+T'%MB_QM<8O\:7&+_&EQB_QI<8O\:X%4  ,M?
M  "]9P  LFP  *EP  "?;P  E&P  (QM" "&;A, @F\A 'UO+0%Y;S@"=6Y!
M W)M205N;% ':VM7"FEK7@QF:F4.9&EL$6%I=!-?:'X676>)&%MGE1I99J(;
M5V:P'%9FPQU69M\=5F;S'%=F_QM79O\:5V;_&E=F_QI79O\:VUD  ,=B  "Z
M:@  KW   *9S  ":<P  CW   (=Q!0"!<A$ ?',> 'AS*@!T<S4!<',_ VUR
M1P5J<4X'9W%5"61P7 MB;V,.7V]J$%UN<A):;7P56&V&%U9LDQE4;* ;4FNO
M'%%KP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P  ,-F  "V;@
MK'0  *)W  "6=@  B74  (%V 0!Z=P\ =G@; ')Y)P!O>3(!:W@\ FAX1 1E
M=TP&8G=3"%]V6@I==6$,6G5H#UAT<!%5<WD34W.$%E%RD!A/<IX937&M&DQQ
MOQM+<=D;3''P&DQP_1I-</\936__&4UO_QE-;_\9SF   +YJ  "R<@  J'@
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M$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<  (R(  !_B0
M<XP  &60  !<DP  5Y4, %26%@!2EB( 4)<M $V7-@!+ES\!29=' D>73@-%
MEE4$0Y9=!4&6908^E6\(/)5Z"3J5APLXE94,-I2E#364M@XTE,P--)/I#322
M^ XTD/\/-)#_#S20_P\TD/\/M7@  *J"  ">B   DXT  (:.  !YD   ;9,
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M ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@
M-;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6
MQ54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##
M_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$
M "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD
M"=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !
MU?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.
M   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'
M  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN<
M@Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +
MW0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O
M10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT
M &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@
M .H   #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0
M_4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5
M(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"#
M /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$
M\@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_
M%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#
MAP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C
M .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@
M_Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W
M"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*
M\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9
M /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8
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M [4C_P.T(_\$LR/_!+,C_P2S(_\$_RD+ /\J!0#_+@@ _R\, /\M$ #S*Q<
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M#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,, +-$&0"M12<
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MF1%O3:43;4VS%&Q-Q11K3N$4:T[T$VM._Q)K3O\2:T[_$6M._Q%K3O\1Z$8
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M%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%   ,=9  "Z8
MKV0  *1E  "99   D&   (AA!@""8A$ ?F,= 'IC*@!V8S0!<V(] 6]B1@)L
M84T$:F%4!6=@6@=E8&$(8U]I"F%?<0Q?7GH.75Z%$%M>D1)979X46%VL%5==
MO1967=465EWN%5==_!177?\35UW_$E==_Q)77?\2UE,  ,1<  "W8P  K&@
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M$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(  )-R  "'<0
M>G$  '%R  !K= < 9G41 &-V'0!@=R@ 7G<S %MX/ %9=T,"5G=+ U1W4@12
M=ED%4'9@!TYU: A+=7$*271\#$=TB Y%<Y8/0W.E$$)SMA%!<\L10G+H$4)R
M^!%"<?\00W#_$$-P_Q!#</\0P6,  +-L  "H<P  FW8  (YU  "!=@  =78
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M""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H  %J.  !/D@
M1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ VFDH -9I2 3.:6@$Q
MFF0!+YIO BV:>P(LFHH#*IJ: RF:K 0HFL $)YG> R>7\@0GEOT%)Y7_!2>5
M_P4GE?\%J7X  )Z%  "2B0  A(H  ':,  !JCP  7I,  %27  !)FP  0)\
M #>B!  RHPX ,:,7 #"D(0 NI"H +:0R "RE.@ KI4, *J5+ "FE5  HI5X
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M90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0
M (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0
M$<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60
MRV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA
M  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX
M  32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H
M -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !D
ML   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>
M    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:
M  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0
M2\   #W%   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H
MZ0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\
M6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@
M /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P
M^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M
M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#
M)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/
M /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4
MXP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_
M""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H
MD0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#]
M -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@
M_PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?
M!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,
M_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N
M /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\
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M J$C_P*A(_\"_R4  /\H  #R*@  Y2L  -\H!0#<(0L TB$4 ,DD) ##)3(
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MG >!.J@(@#JU"7X[Q@E].^$)>SSS"7L\_PEZ//\(>CS_"'H\_PAZ//\([C<
M -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!$0"=0AX F$,K )5#-P"10T$
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M#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0  ,M-  "]4@
MLE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @ (%0+ !^4#< >U!  7A02 %U
M3T\"<TY5 W%.7 1O3F,%;4UJ!FM-<@=I37L(9TV%"F5-D0MD3)T,8DVK#6%-
MNPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@3?\+W$<  ,=0  "Y5@  KED
M *)8  "85@  D%$  (E2!@"#4Q$ ?U,= 'M4*0!X5#0 =50] 7)310%P4TP"
M;5)3 FM260-I4F $9U%G!F51;P=C47@(8E&#"F!1CPM>4)L-75"I#EM1N0Y;
M4<X/6E'J#EM1^@U;4?\,6U'_#%M1_PM;4?\+UDH  ,-3  "V60  JUP  )Y:
M  "360  BU0  (16 P!^5A  >E<: '97)@!S6#$ <%<Z &U70@%J5TD":%90
M F965P-D5EX$8E5E!6!5;0=>578(756!"EM5C0M95)H-6%2G#E95N ]65<P/
M5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T  ,!6  "S7   IUX  )I=  "/
M7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX :ULW &A;0 %E6T<!8UI. F%:
M50-?6EP$75IC!5Q::P9:670(6%E_"E99BPM469@-4UBF#E)9M@Y16<H/45GG
M#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$  )9@  "+7P
M@5L  'E=  !S7@P ;UX5 &M?( !H7RL 9F U &-@/0%A7T4!7U], EU?4P-;
M7UH$65YA!5=>:0957G((4UY]"5%=B0M0798,3EVD#4U=M Y,7<@.3%WF#DU=
M]PU-7/\,35S_#$Y<_PQ.7/\,R50  +E<  "M8P  GV,  ))C  "'8@  ?&
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M"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0  ;&X  &%P  !;<@
M5G0* %)U$@!0=AT 3G<G $QW,0!+>#D 27A! $AX20%&>% !1'=7 D)W7P-
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M<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/_P(@C_\"I'P
M )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8  #*9   JG D
M*)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4 'I]@ !R?;0 ;
MGWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&
M  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+
M !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0
M#JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !Z
MC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U
M"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[
M  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP
M99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #
MP0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%
M@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D
M %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <
M ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P
MUH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X
M   XO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%
M  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<
M .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    L
MQ   (,@  !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G
M 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ
M  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #(
M_P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V
M )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@
M_P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [
M /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0
M[ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#=
M /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\
M0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6
M .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\
MS0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O
M $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -(
MF #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_
M , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T(
MWP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$
M!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,
M_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q'
M ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@
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MH@";(*P!FB&Y 9@AR@&6(N0!E"/U 9(C_P&1(_\!D"/_ 9 C_P&0(_\!_R(
M .LI  #=+@  SR\  ,<M  #!)P, O2(- +8C&@"P)2@ K"8T *@F0 "E)TD
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M!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@
MN$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL ASM$ (0[3 ""
M.U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R.IX%<3JK!6\[
MNP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"  "^1P  L4@
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M"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$  )=0  "-3@
MADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H3$8 9DQ- 61,4P%B
M3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'5TRC"%9,L@A53,8)54SB"55,
M]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O50  H%0  )-3  ")40  @4T
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M!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@  <E@  &M9  !E6@,
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M> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L_P0Q;/\$KV0
M *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,  $)U"P _=A(
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M !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@
M<G<  &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <
MEAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8
ME@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX
M %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ(
M$*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $
MHZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,
M  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2
M  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<
M *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%
MG0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z
M$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?
M  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP
M,J\  "BT   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@
MQQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/
MI@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H
M !V]   3P   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P
M -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF
MY:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(
M   ,RP   \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(
M  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD
M /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_
M %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$
MG@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_
M .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\
M^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E
M *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@
M_P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5
M .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P
MU0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#(
M /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$
M60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@
M ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\
M_PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#.
M %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D
MI "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q
M /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8
MO@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K
M!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2
M  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7
M + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D
MGQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@
M'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *06
M60"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88FP"4&*8 DQFR
M )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T  .0E  #3*0
MQRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0 FQY, )D>5 "7
M'UL E1]A )0?9P"2'VT D1]T (\@? ".((0 C""- (H@EP")(:( AR&N (8B
MO0"%(M$!@B/K 8$D^P& )/\!?R3_ 7\D_P%_)/\!["4  -LM  #),0  O#$
M +$N  "K*0  IR0% *,C$0">)!T FB4J )8F-0"3)C\ D29' (\F3P"-)E8
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M V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$  )L_  "3/
MC3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D <3E0 ' Y5P!N
M.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#8SJB V(ZL0-A.L,#8#O@!%\[
M\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P10  H40  )5#  "-0   AST
M (([ @!].PX >3P8 '4](P!S/2T <#TV &X]/P!L/48 :SU- &D]4P!G/5H
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M T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@  >$8  '%'  !L1P<
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M>0) 6(8"/EB5 SU8I0,\6+<$/%C-!#Q7Z@,\5_H#/5;_ SU6_P,]5O\#ME,
M *57  "45P  A58  'E6  !O5@  954  %Q6  !76   4ED' $Y:$ !,6A@
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M 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$  )5@  "$8
M=V   &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX -' 5 #-P'@ R
M<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G<GL )G*+ "1R
MG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD  !_9   <F0
M &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1 "IY&  I>B$
M)WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8 '7R& !Q[F  ;
M>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J
M  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B
M !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8
M$86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3
M<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0
M(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S
M  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0
M0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ '
MG"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";
MOP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P
M #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P
M *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0
MJ,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>
M   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;
M  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X
M +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9
MKP  $;,   NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##
M&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!
M  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O
M"K\   '!    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$
MTQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@
MO@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H
M  #-    T0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X
M .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@
M]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X
M8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F
M .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\
M_P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q
M &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X
MJ@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P -
M /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &(
MX@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+
M *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\
M 0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C
M ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L
MNP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_
M    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$
M9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R
M *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P
MZ    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R
M &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *
MNP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\
M ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\
MI0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3
M"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5
M  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@
M )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL
MAA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K
M&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P7
M80"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB
M 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P
MG1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 "
M'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D
M\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W,@  J#   )XN  "7*@  DR<
M ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX
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M 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<  '@T  !T- L
M<#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E, 7C=: %TW8@!<
M-VH 6CAT 5DX?P%7.(P!5CF9 54YJ )4.;D"4SK/ E,ZZP)3.OL!4SK_ 5,Y
M_P%3.?\!Q#P  +)!  "@0   DD   (8_  !^/0  >#H  ',X  !N.0@ :CD1
M &<Y&@!D.B0 8CHL & Z- !>.CP 73M# %L[2@!:.U  6#M7 %<[7P!6/&<
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M> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%_P)%1?\!ND8
M *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+ %9%$@!41AL
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M 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\  )E/  ")3P
M>T\  '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!( 050; $!5(P ^
M52L /58R #Q6.@ [5D$ .E9) #E740 X5UH -E=C #57;P T5WP!,U>, 3%7
MG $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52  "$4@  =U(
M &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A  .UH7 #E;(  X6R<
M-UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N77H +%V) "M=F@$J
M7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6
M  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K
M "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D
M(V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:
M6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J
M+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ
M !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@
M3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  =
M=#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%T
MSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<
M #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH
M$GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *
M?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES
M   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK
M  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H
M (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J
M@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5
M+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F
M  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0
M&Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0
MHBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "A
MZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X
M  ZA   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0
M + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX
ML>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N
M    L@   +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C
M  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H
M98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\
MOP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2
M(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8
M %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0
M -    #2    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@
MZ"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\
M#@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M
M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +,
MXP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_
M  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D
M;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z
M -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4
M_P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8
M '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$
MPP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 '
M /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H
MQ0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q
M ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! .,
M# #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J
M +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@
MH@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)
M  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *<
M:@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#<
M )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H
MM@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ":
M &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&
M[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8-
M *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4
MC0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\
M#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-
M#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G
M ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT
M<1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-
M%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88
M:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_
M &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q
M?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K
M(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D
M_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5
M ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD
M829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8
M*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI
M&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO
M %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\
MP38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B
M+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R
M=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD
M *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX
M6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+
M-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\
M  "1/   @SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C
M %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X
M13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-
M/@  ?SX  '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[
M* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$/EP 0SYF $(_<0!!/WX 0#^-
M #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD   )I   ")00
M?$$  '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4 23\= $= )0!&
M0"P 1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \0WP .T.+ #I$
MFP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#  "&0P  >$,
M &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0: $)$(@!!1"H
M/T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH -DB) #5(F0 T
M2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&
M  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN
M #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@
M+DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=
M2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/
M,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y
M "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3
M44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L
M5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7
MSP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35
M $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#,
M)%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;
M7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7
M   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V
M !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.<
M$V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V
M7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M
M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS
M  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@
M*FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *
M=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T
M]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(
M !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8
M ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@
M?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>
M   1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY
M  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8
M;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,
MCP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<
M.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT
M %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G
M *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0
MJSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y
M  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X
M  "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,
M +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$
MBP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_
M    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U
M  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@
M,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-
MS0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G
M.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0
M /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4
M[@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#;
M .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\
M%0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U
M -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T
MR #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q
M !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P
M=0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K
M +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8
MVP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[
M '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@
M]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP <
M ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\
MJ@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9
M /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +,
M( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N
M )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@
MC #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D
M "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\
M;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_
M '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T
ME0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"!
M W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*
M_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@
M (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X
M=0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I
M$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0
M) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S
M &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\
MQR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q
M%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9
M>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<
M *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2,
M9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6
M(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L
M  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G
M %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\
M3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".
M,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H
M*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+
M $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P
M?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.
M+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$Q
MF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38
M &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P
M1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [
M-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX
M  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O
M $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4
M-CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?
M.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ
M-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV
M #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0
M53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U
M/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"
MRP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\
M $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8
M+T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F
M1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"
M   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ
M "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8
M(4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \
M2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0
M/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V
M !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3
M,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :
M5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15
M_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0
M "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D
M$5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .
M7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=
M   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%
M  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P
M=U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   9
M9P  $VH   ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P
M2@  <%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8
M &-6  !95@  _^+__TE#0U]04D]&24Q%  0)45<  $=8   ^6P  -E\  "YB
M   F9@  'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?
M  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(
M 'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @
M<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&
M(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73
M  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P
M$H    V#   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0
MDR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3
MX@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T
M  :1    E    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@
M *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0
MI.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@
M    HP   *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7
M  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]
M5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N
ML@   +8   "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&
M%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,
M $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@
M ,8   #(    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@
MW14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\
M!0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C
M .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H
MV@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_
M  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\
M9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P
M ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_
M^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#)
M &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8
MMP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ "
M .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\
MMP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D
M ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L
M" ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!>
M *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H
ME #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S
M  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )<
M70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#'
M (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  <
MH  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ")
M %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D
MW0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 *
M )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@
M? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M
M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%
M# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059
M ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P
M8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\
M"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-
M7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61']
M %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D
M;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<
M$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7
M_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4.
M &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P
M4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*
M'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;
M$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A
M $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\
MIB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2
M(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D
M:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH
M (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1,
M2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \
M*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN
M  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7
M $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G
M-B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W
M,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN
M'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-]
M # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-
M:#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V
M,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LW
MBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<
M %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T
M+S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E
M/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z
M  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA
M "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D
M'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-
M/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#
M)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I
M !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P
M1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <
M22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+
MO  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(
M #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4
M%% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,
M4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(
M   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H
M  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H
M!5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K
M4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@
M*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B
M  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@
M(%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@
M:2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F
M[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(
M !1E   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@
M ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP
M</0 85,  %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O
M   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J
M  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$
M7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #
M?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/
M+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T
M $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0
M )    "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P
MH"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H
M   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\
M  "A    H@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,
M +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U
M>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q
M    L0   +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F
M  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0
M(I   !>8   /GP  !Z4   "J    KP   +,   "W    O    +\   #!
MP@   ,0   #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=
M*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P ,
M /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D
MYP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/
M -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L
M$ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I
M -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T
MO #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D
M !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\
M:0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A
M *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$
MQP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L
M &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L
M[@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4
M +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &(
MFP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+
M /D B@#_ (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *
M& "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A
M (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /(
M?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0
M !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X
M8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[
M '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8
M@0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q
M &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4
M_P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8
M '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\
M90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;
M!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$
M&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC
M %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\
MK14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A
M#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.
M:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D
M )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@
M5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(
M%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@
M  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8<
M $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7
M/QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X
M)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;
M( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][
M #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P
M:"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _
M(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(E
MB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H
M %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\
M-R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L
M*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM
M  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C
M # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9<
M)BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.
M+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM
M)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G
M "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0
M13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E
M,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LV
MN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,
M #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@
M'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5
M.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV
M   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM
M !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X
M$3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q
M.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$
M,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E
M  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@
M*$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -
M2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*
M\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4
M !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43(
M!%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@
M4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-
M   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV
M  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8
M8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   1
M6   #5H   E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B
M.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@
M %))  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8
M"&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-
M;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-
M  !(3   /DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X
M  !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD
M 'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"
M4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\
M    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^
M  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@
M,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*
MC    (T   "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";
M1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH
M "%Q   7=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP
M )T   "?    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0
MK4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_
M   0A@  "8T   "3    F    )T   "A    I0   *@   "K    JP   *X
M  "O    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD
M ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *
MEP   )T   "C    J    *T   "R    M@   +D   "[    O    +X   #
M    P@   ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)
M  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D
M_@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#>
M ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8
M_P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ?
M .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T
MQP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T
M /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -(
M) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M
M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\
MHP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y
M "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$
M; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_
M ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "(
MHP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0
M &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0
M_P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E
M )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &<
M@ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U
M /\ T    +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ ((
M)P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I
M '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\
MP    *P   "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T
M "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4
M; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <
M * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ",
M:  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !:
M '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.
M  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E
M %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\
M3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^
M%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4'
M)P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ
M $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&
M;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,
M#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0
MB  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT
M %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20
M1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V
M%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@
M  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G
M #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0
M+ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/
M(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:
M*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D
M "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0
M1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N
M'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(D
MM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<
M #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH
M)R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =
M*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH
M   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N
M "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D
M&"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T
M*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM
M,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E
M !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0
M+"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6
M,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T
M]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$
M "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38
M$#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,
M./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V
M   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\
M  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O<
M:3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :
M/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%
M0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8
M %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@
M$D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@
M3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([
M  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL
M  M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4
M %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%
M/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95
M @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-
M  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@
M/$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>
M8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G
M50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<
M "]*   F30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@
M &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@
M<U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2
M   @5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<
M  !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8
M (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   9
M8@  $F<   QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(
M    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@
M  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P
M#'4   1[    @    (4   ")    C0   )$   "3    E    )8   "8
MF@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H
M;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4
M  "+    D0   )8   ";    GP   *(   "D    I0   *<   "I    JP
M *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80
MO'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<
M    H@   *<   "L    L    +,   "V    MP   +D   "[    O0   +\
M  #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX
M -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V
M #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -,
M>0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_
M +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X
MWP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"]
M 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D
M_P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R
M ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ',
MJ0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9
M /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T
M- "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T
M )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\
M[0   -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7
M #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4
M=@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0
M ,$   "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\
MA0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U
M 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\
M  "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P
M '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0
M9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1
M    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D
M, !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z
M %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P
M>@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!=
M #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\
MA !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T
M &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L
M4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !%
M )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1
M  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L
M $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX
M/ >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4
M%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)
M+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V?
M #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&
M2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y
M#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1
ML@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH
M $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T
M,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E
M%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<
M   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P
M "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0
M'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W
M'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:
M-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@
M !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(
M,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >
M'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A
M\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(
M "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@
M&"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2
M)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D
M   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^
M !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L
M;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >
M*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN
M1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<
M %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0
M&"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ )
M,TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L
M  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(
M !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H
M #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(
M+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y
M P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3
M   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@
M/#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (
M00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&
M70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34
M #,T   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8
M $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6
M36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W
M   J.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(
M  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,
M %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F
M/P  'T(  !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;
M"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P
M  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@
M&DH  !-.   .40  "E4   18    6P   %X   !A    8P   &0!  !E!
M9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M
M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0
M  Y8   (7    F    !D    9P   &L   !M    ;P   '    !R    = (
M '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P
M?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E
M    :@   &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4
M  "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8
M (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T
M>0   'X   ""    A@   (D   ",    C@   )    "2    E    )8   "8
M    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4
M  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@
M (\   "4    F    )L   ">    GP   *(   "D    I@   *@   "K
MK0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "W
MH0  M[, ,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$
M  "F    J@   *X   "P    L0   +0   "V    N    +L   "]    P
M ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@
MS*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D
M0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R ""
M ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\
M_P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#,
M $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +(
MA0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0
M /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P
MLP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0">
M (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8
M  #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \
M )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($
MB@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z
M    K    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L
M/ ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"&
M '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F
MF@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z
M #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D
MC0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@
M ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4
M:@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!;
M )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',
M  !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U
M %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$
M3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B
M 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %(
M- !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"=
M $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0
M50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !(
M #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P
MJP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P
M $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$
M/@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S
M +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.
M  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R
M #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H
M*P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \
M$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*
M-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2
M ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P
M-1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H
M#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0
M[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4
M "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D
M(1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8
M$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6
M   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_
M !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H
M;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D
M&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:
M1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L
M %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P
M'1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0
M'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?
M  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2
M !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T
M"R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)
M(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D
M P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5
M  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0
M/24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /
M*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N
M8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<
M #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@<
M"3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70
M,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J
M   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+
M  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D
M #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J
M*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \
M#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X
M   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@
M(B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P
M1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'
MB@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0
M !DV   3.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L
M $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A
M3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^
M   000  #$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+
M  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<
M %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +
M2@  !4X   !1    5    %<   !:    7    %T   !?    8 0  &('  !D
M"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H
M  !EP@  9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50
M %H   !=    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@
M= H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !U
MMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<
M  !K    ;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,
M (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0
MA\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![
M    ?P   (,   "&    B    (H   "-    CP   )$   "4    EP   )H!
M  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;<
M,%   "55   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-
MD0   )4   "8    F@   )P   "?    H0   *,   "F    J0   *P   "P
M    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L
M !YB   4:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I
M *@   "K    K    *\   "R    M    +8   "Y    O    ,    #$
MR    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\
M  #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!)
M -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )(
MNP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R
M    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\
M20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7
M *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C
MTP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H
M $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ),
MG@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N
M *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $(
MD@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_
M *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D
M  "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !
M '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\
M;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "
M    ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X
M/P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J
M %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q
M;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@
M #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %(
MN !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8
M %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@
M4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!'
M ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,
M 0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X
M $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,,
M/0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)
M  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X
M.@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #=
M #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$
M/P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T
M #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P
M[@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D#
M #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@
M+ !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E
M /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +
M!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04]
M "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?,
M;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J
M#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+
M1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1
M %H2  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0
M(PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7
M#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4
M  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$&
M !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX
M$1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)
M&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2
M!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97
M  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@
M/1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3
M%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:
M80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP
M #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P<
M#AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "
M'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >
M   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+
M  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL
M "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H
M(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E
M#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[
M   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0
M(B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0
M*P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   L
MC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(
M !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X
M #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@
M,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE
M   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.
M   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X
M #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3
M*P  $"X   TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!
M$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R
M   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@
M#34   @X   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@
M3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(
MR@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T
M  )     0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X
M %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@
M4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*
M    30   %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.
M  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP
M-3<  # U   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6
M60   %P   !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T
M#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H
M "L[   B/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :
M &L   !N    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@
MB@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$
M   <20  $TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T
M  "     @P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D
M *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   5
M5   #EL   5B    :0   '    !W    ?0   ((   "&    BP   (\   "3
M    E0   )<   ":    G0   *    "C    I@   *H   "N    L@   +<*
M  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@
M!VH   !S    >P   ((   ")    D    )4   ":    GP   *,   "F
MJ    *L   "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3
M"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0
M /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\
MS@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q
M ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\
M  #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!.
M +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8
MFP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X
M  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X
M3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#%
M (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?
MG  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"(
M $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8
MX !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $
M (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0
M=0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E
M /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '
M" !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!#
M &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H
M5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@
M  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8
M0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z
M $H _P!* /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  <
M4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!)
M $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $
M_P!  /\ A0   '0   !G    70   %4   !/    3    $H   !(  0 1P *
M $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X
M/0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V
M /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T
M"P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !!
M #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\
M<P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T
M  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L
M10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08
M %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H
M+  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B
M $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,
M  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+
M "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D
M&P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)
M#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'
M#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92
M !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$
M/!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9
M"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,
M7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,
M #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L
M$PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +
M#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4
M   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,
M  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH
M!A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G
M%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2
M#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z
M   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P
M(18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (
M%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9
MC   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@
M !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X
M AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@
M'*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9
M   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0
M   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\
M ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6
M&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F
M$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T
M   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'
M$1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$
M+14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   J
MT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$
M  TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(
M #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0
M,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI
M   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4
M   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T
M-R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P
M,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)
M%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H
M "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /
M #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P
M5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL
M   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D
M  !,    3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4
M &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B
M,   &C,  !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8
M    6P   %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08
M  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.
M%#P   Y!   '1P   $P   !1    50   %D   !=    80   &4   !H
M:P   &T   !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")
M'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@
M  A.    5    %H   !@    9    &D   !N    <@   '8   !Z    ?0
M (    ""    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P
MH"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<
M    8P   &H   !Q    =@   'L   "     A@   (H   ".    D0   ),
M  "6    F0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<
M +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L
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M__________________________________________________\
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M]O?X^?K[_/W^_VUF=#$      P0A   !                     0
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MT]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\
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M@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MGH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W.;%"Q/QQA$O\L074NK
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
MG=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT?^X% [_N!TG_[4I1O>P-6G>J$&0QYQAL<2<<;;"FWZY
MOYV&O;V:B<&[EXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N
M@*+4K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR
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M@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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MCK.&OHRRAK^*LH? B+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"@+&,PH"QC,*
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MRO&]# ;YOA(:^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:XG;5HNYNS=;Z9LG_
MF+&$P9.PA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!K8O&?ZV.QWVMD,=]
MK9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0Q]_
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MD(S%N(R/R+:'DLNT@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_J<FA@*S&H8"LQJ&
MK,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQO^M& 7_K2,6_ZLQ
M+_^F/TOXH$UGYYU5@=F<7)?*F6BLQ9IRM,.<>KC G(.[OIR)O[N7B<.YDXO'
MMXZ-R[2)D,ZRA);1L8&=TZR HM.G@*70I("GS:"!J<J>@:O&GH&KQIZ!J\:>
M@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQO^M& 7_K2(6_ZLQ+_^G
M/TOXH4QGYYY3@=F=69?*FV6LQ9QOM,.=>+C GH&\O9Z(P+N:B,2XE8G)M9"+
MS;*+C]&PAI75KH2>UZ>"H=2C@J31GX*GS9R#J<J:@ZO'FH.KQYJ#J\>:@ZO'
MFH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQ_^M%P7_KB(6_ZLP+_^G/DOX
MH4MHYY]1@=F?5I?*G&*LQ9ULM,.?=;C H'Z\O:"'P;J=B,:WF(C+LY.)S[".
MC=2MB939J(:=VJ*%H=6>A:31FX6FSIF%J<J7A:O'EX6KQY>%J\>7A:O'EX6K
MQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6KQ_^N%P3_KB(6_ZPP+_^G/DOXHDMH
MZ*%/@=F@4Y?*GE^LQI]IM,.A<KC HGR\O:*$P;F@A\>UG(?-LI>(TJZ3B]BJ
MCI/?HHN<W)R)H-:9B*/2EXBFSI6(J<J4B*O'E(BKQY2(J\>4B*O'E(BKQY2(
MJ\>4B*O'E(BKQY2(J\>4B*O'E(BKQ_^N%P3_KB$6_ZPO+_^H/4OXHDIHZ*)-
M@-FB4)?+H%RLQJ%EL\.D;K? I7B\O*6"PKBDA\BTH(?.L)V(U:N9BMVEEY/F
MFY&;W9:/H->4C:/3DHRFSY&+J,N0BJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0
MBJO(D(JKR)"*J\B0BJO(D(JKR/^N%@3_KR$6_ZTO+_^H/$OWHDEHZ*1*@-FD
M39;+HEBKQJ1AL\2G:K? J72\O*E^PKBHA\BSIH?/K**'UZ2=B=V:FHWAE9J;
MWI&5G]B/DZ+3CI"ET(Z/J,R-CJK)C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)
MC8ZJR8V.JLF-CJK)C8ZJR?^O%@3_KR$6_ZTN+_^I/$OWHTEIZ*9(?]JG2)7,
MI5.JQZA<LL2L9+;!KFZ[O:]XP+:LA,FNIX?0IJ.&U9V@AMF3G8G=C9V4W8V=
MG]B+F:'4BY:DT(J3I\V*D:G)BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&I
MR8J1J<F*D:G)BI&IR?^O%03_L" 6_ZXN+_^I.TOWI$=IZ:A$?MNK0Y3-J4RI
MR*U4L,:S7+/"MV:YM[!WPK"KA,FIIX;/H:2$TY>BA-:.H(?9B)^/VH>AFMB'
MH*'4AYNDT8>8ILZ'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5
MJ<J'E:G*AY6IRO^P%03_L" 5_ZXM+_^J.DOXID1HZJM ?=RO/)+/KT*FRK5)
MK<:\4K&YM6>[L+!XPZNLA,FDJ83-G*:#T).DA-.+HX;5A:*,UH*BE-:#I)W4
M@Z*DT8.>ILZ$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$
MFJC+A)JHR_^P% 3_L1\5_Z\L+O^K.4OXJ4!GZZ\[>]ZV,X_2NC2AS,(YJKNZ
M5;6PM&J]JK!YPZ>MA,>?JH3+F*B#S9"GA-")I8;2A*2*TX"DD--_I9?2?Z:@
MT'^EILZ H*C+@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+
M@*"HR_^Q$P3_LAX5_[ K+O^L-TSZK#ME[;4T>.*_*8G8S""8OK\]KK"X6;BI
MLVR^I;!ZPJ*NA,6;K(/(E*J$RHZIA,R(J(;.@Z>)SX"GC<]^IY//?*B:SGRI
MHLU\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>H
MR_^R$@3_LQT5_[$I+O^M-DS\L35B\;TJ<N;-'X#(S"&;L;Q%LJBW7KFCLV^^
MH+%[P9ZOA,.7KH3&D:R$QXRKA<F'JH?*@ZJ)RX"JC,Q]J9#,?*J5RWJJG,IY
MJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRO^S
M$03_M!L4_[,F+O^O,TS]N2M=Z\H?:=+?$7^YS"><I[U,L:"W8KF=M'&]F[)\
MOYJQA,&4L(3#CZ^%Q8JNAL:&K8?'@ZR)QX"LB\A^K([(?*R2R'NLE\AYK9['
M>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['>:V>Q_^U$ /_
MMAD4_[4D+?^T+$GRQ1]4UMT28L'?$X&LS2Z:G\!/JYJX9;>7M7*[EK1\O96R
M@[^1L87!C;&&PHFPA\.&KXC#@Z^)Q(&OB\1_KHW%?:Z0Q7NNE,5ZKYG$>J^9
MQ'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q/^W#@/_N!83
M_[<@+?F_'T'<V1%$Q.L29K'?&(&@T#.5E\90HY/ 8ZV1NW&SD;A[N)"V@KN.
MM(6]B[.&OXBRA\"&LHG A+&*P8*QB\& L8W!?K&/PGRQDL)[L97!>[&5P7NQ
ME<%[L97!>[&5P7NQE<%[L97!>[&5P7NQE<%[L97!>[&5P?2Z"P/]NQ(2_KL;
M+.70#S+(Z0]*M/(59Z+B(GV6UC>-C\Y/F(S(8:"*Q&ZFBL%XJH>_?:V$OH"P
M@;R"L7^[A+-]NX6T>[J'M7JYB;5YN8NV=[F-MG:XC[=TN).W=+B3MW2XD[=T
MN).W=+B3MW2XD[=TN).W=+B3MW2XD[=TN).W=+B3M]R^!@+XP X1[L@.(LO;
M"RZV^!%,I?4=8Y?H+'6-WSV!A]A0BX/38)*"SVR7?\USFWS+=YUYR7J@=\A]
MH77'?Z-SQH*D<L6$I7#%AJ5OQ(BF;L2*IVW#C:=KPY"H:\.0J&O#D*AKPY"H
M:\.0J&O#D*AKPY"H:\.0J&O#D*AKPY"H:\.0J-? !@';Q@@.R],*%;CH##*F
M_Q5*F/HF7(WP-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4
M>Y!ITWZ19]. DF;2@Y-ETH649-&'E&/0BI5BT(Z68M".EF+0CI9BT(Z68M".
MEF+0CI9BT(Z68M".EF+0CI9BT(Z68M".EM'"!@'-RPD%NMH'&:C^#C&9_QU#
MCO\O487Z/UQ^]$UD>?!8:G/L7V]MZF-S:>=I=F?E;GEEY')[8^-V?6+B>7Y@
MX7Q_7^!^@%[?@8%=WX."7-Z&@UO=B81:W8V%6MV-A5K=C85:W8V%6MV-A5K=
MC85:W8V%6MV-A5K=C85:W8V%6MV-A<O$!@"[T08'J><&&IK_$RN._R0YA?\V
M1'[_1$UY_U%5<?M76VOW76!E]&)D8O)H9U_P;6I=[W%L6^UU;5KM>&]9['MP
M6.M^<5?J@7)6ZH1R5>F'<U3IBG13Z(YU4^B.=5/HCG53Z(YU4^B.=5/HCG53
MZ(YU4^B.=5/HCG53Z(YU4^B.=;S)!0"KVP$(FO\+%H__&2.%_RLM?O\Y-WC_
M1D!P_TY':?]436+_6E)>_F%66OQF65C[:UM5^7!=5/AT7E+W>%]1]WM@4/9^
M84_U@6)/]81C3O2'9$WTBV5,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F
M3/.09DSSD&9,\Y!F3/.09O^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GB
MCW6)V8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[
MI+O >J>[P'FJO,!XKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN[QXM+N\>+2[O'BTN_^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)
MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
M>J>[P'FJO,!XKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QX
MM+N\>+2[O'BTN_^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^
ME]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[
MP'FJO,!XKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\
M>+2[O'BTN_^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-
MAZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJ
MO,!XKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[
MO'BTN_^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,
MC(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!X
MKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN_^A& /_HRL0_Z Z)?^<2#S_EU93^)-C:.R2:7KAD7.*V(]\F-".A*3*CHRM
MQHV0M,2*D[?#AI6XPH28N<&!F[K!?YV[P'V@O,![I+S >J>]P'FLO<!XL+V]
M>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO/^A
M& /_HRH0_Z$Y)?^=2#W_F%54]Y1A:>N49GO@DF^,UI%XFLZ0@J;(CXFPQ(^/
MML.+D;?"B)2YP827NL""FKS ?YV]OWV@OK][I+Z^>JB_OGBMO[UXL;ZX>+*^
MM'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO?^B& /_
MI"D0_Z$X)?^=1SW_F554]Y9>:>N58WO@E&R-U9)UG,V1?ZC'D8>RQ)&.ML.-
MD+C!B9.ZP(:6O+^"F;V_?YR^OGV@O[U[I<"]>:K O7BPP+AYL,"T>;&_KWJR
MO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO?^C& /_I"D0
M_Z(X)?^>1CW_F515]Y=<:>N78'S?EFF-U9-RG<R2?*K%DH6TQ)*,ML*/C[G!
MBY*[P(>5O;Z#F+^]@)S O7V@P;Q[I<*\>:O"N7FOPK1YK\&P>K# K'NROJQ[
MLKZL>[*^K'NROJQ[LKZL>[*^K'NROJQ[LKZL>[*^K'NROO^C& +_I2@0_Z(W
M)?^?1CW_FE-5]YE::>N97GS?EV6.U)5OG<N4>:O%DX*TQ)2*M\*1CKG C)"\
MOXB3OKV$E\"\@)O"NWV@P[M[IL2Z>JW%M'JNQ*]ZK\*L>[# J'RQOZA\L;^H
M?+&_J'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&_J'RQO_^D& +_I2@0_Z,V)?^?
M13W_FE-5]YI7:>N;6WS?F6*.U)=KGLN5=JS%E("TPY6(M\&3C;K CH^]OHF2
MP+R%E<*[@9K$N7V@QKE[J,>T>JO'KWNMQ:M[KL.G?*_!I'VQOZ1]L;^D?;&_
MI'VQOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_I'VQO_^D& +_IB<0_Z,V)?^@1#W_
MFU)6]YQ5:>N<6'S?FUZ.U)EGGLJ7<ZS%EGRTPY>%M\&6B[N_D8V^O8N0P;N&
ME,2Y@9G'MWZ@R;9\J<JN>ZK(JGRLQJ9]K<2C?J_!H'ZQOZ!^L;^@?K&_H'ZQ
MOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQO_^E& +_IB8/_Z0U)?^@1#W_G%%6
M]YY3:>N>57O?GEJ-U)MDGLJ9;ZS%F'FTPYF"N,&9BKN^E(R_O(Z.P[F(DL>W
M@IC+M7ZAS:]\I\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=@+&_G8"QOYV
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MUJ&"I-"=@JC+FH.JR)F#K<67A*_"EH2PP):$L,"6A+# EH2PP):$L,"6A+#
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ML+E@M:BT<+VCL'["G:V$QY*JA,N(IX;.@*:-T'VGF-!]J*3.?J2HRW^?JLF
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M)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!=JJ)OGVOA;R
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MMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAWP*JH=\"JJ'?
MJJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE00?^:54__FEI=
M]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*JRG2KKLARN*_
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M:_-KDW#P:9ES[F>?=^QEI7GK9*I[ZF*O?>EAM7[H8+U_Z%_%@.A>T('B7]J
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MZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/P.IP3\#J<$_
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M&A[_G!L>_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@
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MA^1Y<H?D>7*'Y'ERA^1Y<H?D>?]M$P'_=A,!_X@2 ?^8$P#_IQD![[,6 >+
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M=V:2YG=FDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD S[X) ,O,"0#$TQ<
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M."[_[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0
MHKT  )3*  "'V   ??,' ';_$@%M_QH#9?\D!5[_+0I8_S8/4O\]$TS_119(
M_TP90_]3&S__6AX\_V$@./]I(37_<B,Q_WTE+O^*)BO_F2@I_Z<I)_^Y*R;_
MTBPE_^\L)/__+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8
M (;3  !YX0  <?\( &?_#P%?_Q4"5_\> U'_)@5+_RX'1O\V"D'_/0P]_T0.
M.?]+$#;_41(R_U@3+_]?%2S_9Q8I_W$7)O]\&"/_B1H@_Y@;'_^F'!W_MQT<
M_\H>'/_F'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5P@  AL\  '?>
M  !K]   8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_- 8R_SH'+O]
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M:72 \&ET@/!I=(#P:?]A%P'_<1 !_X(. /^0#@#UG0T XZD, -FU# #/N1H
MQ;@N![NT/16QL$DCIZM2,9ZG6SZ6HV-(CI]J48:;<EE_F'I@>)6$9G*3CVQM
MD9QO:9"J<F:0OG-ED>%R:([K<&J*[&YLB.UL;8;O:VZ$\&ENA/!I;H3P:6Z$
M\&ENA/!I;H3P:?]C%0'_=0X!_X8- /B4"P#<H@@ U*T) ,^X"@#)O1< O[PK
M!K6Y.Q.KMD<AH;%0+YBM63N/JF%&AZ9H3W^C<%=XH'A><IZ!9&N;C&EFFIEM
M8IFH;U^9O'!>F=]O8);L;F.1[6UFCNYK9XOO:FF)\&AIB?!H:8GP:&F)\&AI
MB?!H:8GP:/]G$@'_>0P _XH* -^:! #3I@< S+$( ,>[" #!PA, N,(H!*Z_
M.!"EO$0>F[A.+)&U5SB(L5Y"@*YF2WBK;5-QJ79::Z=_8&6EBF1@HY=H6Z.F
M:UFCNFQ8H]QK6:#N:UR:[VI?EO!I89+Q:&./\69CC_%F8X_Q9F./\69CC_%F
M8X_Q9O]K$ '_?@D \9 $ -:> P#,J@8 Q+0& +Z^!0"XR!  L,@D Z?&-0V=
MPT(;D\!,*(J]5#.!NEP^>;=D1G&U:TYKLW149+%^6E^PB5]:KY9B5JZE95.N
MN692K]ME4JOR9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S
M9/]P#0#_A 0 W98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6
MB\A)(X+&4BYZPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-
MO-M=2[GW7TZQ]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W
M" #KC   TYL  ,:H @"[L0( LKL" *K'!@"BTPH G=8: 976+ :,U#H1@])&
M'7K03R=RSE@Q:LU@.&3+:#]>RG)%6,I\253)B$U/R9513,FE4TK)N51)RMQ3
M1\CW54C _%A*N/M93++[6DZM^EI.K?I:3JWZ6DZM^EI.K?I:3JWZ6O]_  #<
MDP  RJ(  +RL 0"QM0  J, # )_+!@"6V0L D> ; 8K?+ :"WSD.>=Y#%W'=
M32!JW%8H8]M?+UW:9S58V7$Z4]E[/D_9B$)+V99%2-FF1T;:NDA%V]M'1-CT
M24+3_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP
MOZ<  +*P  "GNP  G,8# )/1!@"+Z@X A>@? G[H+09VZ#@.;NA!%F;G2AU?
MYU(C6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z0^B@/$#ILCX_ZLL^/NCO/CWF
M_S\]X/]"/]?_1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P
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M'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW
M9^D  %__!@!8_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X_SP&-/]"!S'_20@N
M_U )*_]7"BC_7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_LA$9_\@2&/_E$Q?_
M^A07__H4%__Z%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4
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M67YR^UE^<OM9?G+[6?]8%P'_9Q !_W4. /^!#@#_C X \940 ..=$0#6HQL
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M5U"E_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@
MTI$  ,:=  "[I@$ LJX  *JW 0"BP@4 G,08 )7#*@2-PCD-A<!$&'V^3B%U
MO%8J;KI>,FBY9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+M,502[/J4$JQ
M_U%,J_]23J7_4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<
M +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C
M9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%
MN?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G
M  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9
M(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_]
M0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@
MM   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@
M7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_
M-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP
MB<4  '[/ @!TV@8 ;NL1 &CK'@%BZRH#7>PU!E?L/PM2[$@/3>Q1$TKM6A9&
M[6,90^UM'$#M>!X][H4A.NZ3(SCOHR0V\+8F-?'2)C3O\R8T[/\F,NO_*#+G
M_RLSY/\L,^3_+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T
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M"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8  $?U  !!_P
M//\) #?_$  R_Q4!+O\= 2K_(P$F_RD!(O\O A__-0(<_SL"&?]" Q;_20,3
M_U$#$?]: P__9@0-_W0$"_^%! K_E@4)_Z@%"/^Y!0?_T 4'_^,%!__C!0?_
MXP4'_^,%!__C!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\"
M "K_"@ F_P\ (O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"
M!_]) @/_4P( _UX" /]L @#_? , _XT# /^= P#_K , _[4# /^U P#_M0,
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MBFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_38!K_TR :_]*@&O_2H!K_TJ
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M5&&&^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P
MX'X  -")  #&DP$ OYL# +BA @"QI@L JJ@> :.G+P6;I3T/E*)(&8R?42*%
MG%DK?YIA,GF8:3ETE7$_;Y-Y1&J2@TAED(Y,88^;3UZ.JE);CKU26H[>4EN-
M^%!<B_]/7HC_3F"%_TQA@_]+88/_2V&#_TMA@_]+88/_2_]D!0#U=   VH(
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M1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,  +>=  "LI
MHJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\88[Y7'EZ]7R-9
MO&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"MO\]0K/_/D2N
M_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB  "CJ0  F+$
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M("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8  &O/  !?U@
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M XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\  "'_   =_P@
M&O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<! /]  0#_2@$
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M+?\:^2W_'/,O_QSM,?\=ZC+_'>HR_QWJ,O\=ZC+_'?\S*0'_."8!_STD ?]
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M27%P]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_/O]6"@#_8@
MYF\  -=Y  #,@0$ Q8<# +^+! "YC@X LI @ :N/,06DC#\-G8I*%I:'4QZ1
MA%PEBX%D+(9_:S&"?7,V?GM\.WIYAC]V=Y!"<G:<16]UJ4AL=;I):W7426MU
M\D=K=?]%;'7_0VUS_T%M<O\_;7+_/VUR_S]M<O\_;7+_/_]9!P#_90  XG(
M -%\  #'A   P(H" +F/ @"SD@P K)0= *:3+P2>D3P+F(](%)&,41R+B5HD
MAH=B*H&%:3!\@G$U>(%Z.G1_@SYP?8Y";'R:16E[IT=F>KA(9'O02&1[\$=E
M>_]$9GK_0V=X_T%H=O\_:';_/VAV_S]H=O\_:';_/_];! #W:0  W78  ,V
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M05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX  ,.(  "YD0
ML)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ% #8"?2A5YG5,<=)M:(V^98BAJ
MF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!4I+)0E*1ZT%2D/] 4H__/U6+
M_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #==@  R8,  +V-  "SE0  J9L
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M,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH  (>Q  !\MP
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M"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T  #CD   U]@P
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M 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0
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M+?\6X"[_%N N_Q;@+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_0"(!_T$K ?]
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M.8)>\#B!7_\V@%__-(!?_S-_7_\Q?E__,'Y?_S!^7_\P?E__,/]-"0#_5@
M[F$  -UI  #1;P  RG,# ,5U!@# =A  N'@C +%X,P.K=D$)I7-,$)]P5A>;
M;E\=EFQG(I-J;R>/:'<KC&=_+XEEB#*%9)(U@F.=-X!BJCE]8KDZ>V+/.WIB
M[CEZ8_\X>F/_-GEC_S1Y8_\R>6+_,7EB_S%Y8O\Q>6+_,?]/!P#_60  YF0
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M-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X  ,EV  "_?0
MMX(  +"%  "HAP8 HHD7 )R**0&6B3<&D(=##(N%31.%@E49@(!='WQ_921X
M?6TI='MU+7!Z?C%M>8@T:7>4-V9VH3IC=K [87;$/&%VY3MA=OLY8G;_-V-U
M_S5C<_\T9'+_,V1R_S-D<O\S9'+_,_]8  #F9@  TG$  ,5Z  "[@0  LH<
M *N*  "BC ( G(X4 )>/)@&1CC0%BXQ "X6*2A& B%,8>X9;'7:%8R)R@VHG
M;H)R*VJ >R]G?X8S8WZ1-F!]GCE=?*XZ6WS!.UM\XSI;?/HX7'O_-UU[_S5>
M>?\T7W?_,U]W_S-?=_\S7W?_,_Y<  #A:@  S74  ,!^  "VA@  KHL  *6.
M  ";D0  E9,1 )"4(@&+DS$#A9(]"7^12 ]ZCU$6=8U9&W&,8"!LBF@E:(EP
M*62'>2UAAH,Q786/-%J$G#97@ZPX58._.56#X3A5@ODW5H+_-5:!_S18?_\S
M67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP  J)   )^3  "4
ME@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUFDF4A8I%M)EZ/
M=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")_S)1AO\Q4H3_
M,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0  )B8  ",G
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M(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P  %3! P!,Q0T
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M AOIO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC_P48X_\%&./_!:.=  "6I
MB*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP  )>X) "/P$0 A
M\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1]X !$/B4 0_Y
MJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC  "+K   ?+4
M &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L& !G_#@ 7_Q,
M%/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP  O^   '_E@
M_ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(
M  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1
M  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4
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M)9E+\"663/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20
M_U$  .97  #=6P$ U5P% -);"0#+7!0 PUXH +Q>. *V748&L5M1"JU96P^I
M6&03IE9L%Z-5=!J@5'T=GE.%'YM2CB*949<DEU"A)I50K2>24+PHD5#0*(Y0
M["B-4?XGBU'_)HM1_R6*4O\DB5+_(XA2_R.(4O\CB%+_(_]%!P#_2P  \%4
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M*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\  ,UG  ##;
MNV\  +5P  "O;PH J'$: *-R*P&=<CD$F'!%"9-N3PZ/;5@4BVM@&(=I9QR$
M:&\@@6=W(WUF@"9Z9(HI=V.4+'5CH2YR8J\O<&+!,&]BWS!N8_<N;V/_+&]C
M_RIO8_\H;V+_)V]B_R=O8O\G;V+_)_]-  #K6   V6,  ,EJ  "_<   MW,
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M*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX   **"  "8@0
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M)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T  &N?#@!HGQP
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M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@
MH94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^
MOBL /+XV #N_00 YOTL!-[]4 C7 7P(SP&H$,<!W!2_ A@8MP)<'*\"J""K!
MP@@JP.<'*;W]"BB\_PPGNO\-)[G_#B>Y_PXGN?\.)[G_#K*,  "EE   F9H
M (VA  !_IP  <JT  &:S  !:N   3[L  $2_   ZQ ( ,,D( "[*$0 MRAT
M+,LI "O+-0 KS$  *LU* "C-5@ GSF$ )LYO 23.?P$CSY$"(<^E B#0O0(@
MS^0"'\WZ Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4  "<F@  D*$  (*H
M  !TKP  9[8  %N\  !.P   0\,  #G'   OS   )] $ !_6"@ ;VA  &]L:
M !K;)@ :W#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4 %.&: !/BL0 2X\\
M$N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !H
MN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K
M'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D
M  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@
M3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '
M^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\
MZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$
M #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(
M /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@
M_^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _U@  ,=T  "7B
M   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_!0  _PH  /\.
M  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,  #_I   _[D
M /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#  _PLX ?\#1 '_
M %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_ *@ _P"O /\
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M"[<T\PVT-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_#_\U#@#_. <
M_SP" /] !@#_00L ^D$/ .T_%@#C/"( VCTQ -(^00#,/D\"R#Y: \0]9 7!
M/6X'OSQV"+P\?@JZ.X<+N#N/#+<[EPVU.I\.LSJI#[$ZM!"O.L(1KCK9$:H[
M[Q*G._\3I3O_%*0[_Q.C._\3HCO_$Z([_Q*B._\2HCO_$O\X"@#_/   _T$
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M'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5   -56  #*60
MPEH  +U8 P"X5PX L5D> *Q:+P&G6CT"HEE)!9Y84PF;5UL,EU9D$)55:Q*2
M5',5CU-[%XU2A!J+48T<B%&7'H90HQ^$4+ @@E#!(8!0W2%^4?0@?5'_'WU1
M_QU]4?\<?5'_&WU1_QI]4?\:?5'_&O]"  #P2@  WU0  ,Y:  #$7@  O%\
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M'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP  *=L  "?:@$
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M'>57  #-9   OFT  +)U  "H>P  GWX  )-]  "'?0  @'\' 'R %0!X@20
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M&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=
MKWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0 7)<C %J8+P!7
MF#H!5)A$ U*73 5/EU0'3)=<"4F690Q'EF\.1)5Z$4&5B!,_E)<5/92H%CN4
MO18[E-\6.I+X%SJ0_Q<ZC_\7.H[_%SJ._Q<ZCO\7.H[_%\5N  "V>P  JH4
M )Z+  "4CP  B)(  'N4  !NEP  8IL  %>>  !2H X 4: ; $^A* !-H30
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M!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<  (B=  ![HP
M;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0 (L,? "'#*@ @
MQ#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7R,L %\;Q 1?$
M_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE  !PJP  8K$
M %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1 !#2&@ 0TR4
M#],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X "=GF  K6_@ +
MU/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_
M   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D
M  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\
M .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   P
MRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K
M(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_
M  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@
M&=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%
M^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_
M^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8
M  CJ    [0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q
M /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0
M_]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\
M:0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#
M /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_
M '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X
MR #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_
M /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L
M_P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U
M -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>
M'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q
M /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X
MZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_
M(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.
M=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/O0#E#\P X0_C
M -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_ O\E$P#_)1
M_R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL [!=F .D7< #F
M%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z< V1BQ -88NP#4&<H T!KA <P;
M\P')'/\"QAS_ L0<_P/#'/\#PQS_ \,<_P/#'/\#PQS_ _\H$ #_*0L _R@&
M /\K"P#_*Q  _RD7 /TF(@#T(RX ["$[ .8@20#B(%4 WB!@ -HA:@#6(70
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M#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH  .4^  #<0
MU#T$ -(W"0#+.!4 PSHF +T]-@"X/D0!M#Y0 ;$]6@.N/6,$K#UK!:D\<P:G
M/'L(ICR#":0[BPJB.Y0+H#N=#)X[J V=.[0.FSO%#ID[X Z6._0/E#S_#Y(\
M_P^2//\.D3S_#9$\_PV1//\-D3S_#?\U  #_.0  ZD$  -U&  #01P  R48
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M$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D  *U6  "G4P<
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M%>M*  #45@  PUX  +9E  "L:0  HFD  )AG  "/90  B68, (5H&0"!:2@
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M&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_%=U5  #%80
MMVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T ;'DK &EY-P%F
M>4 #8WE)!6!X40===U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-=)<72W.F&$ES
MN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:  # 9@  LV\
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M#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(  )F'  ",B
M?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L 0YDV $&:0 !
MFD@!/II1 CR:6@(ZFF0#-YIO!369?08SF8P',9F=""^9L @NF<H(+ICM""Z6
M_PHME/\*+9/_"RV2_PLMDO\++9+_"[9U  "J@0  GH@  ).-  "&C@  >(\
M &N2  !?E0  5)D  $F=  ! H   .J(- #BC%P WHR( -J0M #6D-P TI$$
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M 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M
M.K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &
MRSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*
M_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\
M "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$
M -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P
MW_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-
M   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO
M  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\
M /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   '
MW@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X
M*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U
M '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0
M .P   #P    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P
M_R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/
M) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z
M /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -,
M_P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_
M$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\
M?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B
M /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH
M_Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^
M (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X
M[ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3
M /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X
M\@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A
M /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2
M#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*
M .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@
MS@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_
M&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-
M@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81Z0#"$OD OQ/_
M +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R   /\A!0#_'PP
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M!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$   +LZ 0"V-@X
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M#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 . (Q2' ")5"L
MA50W ()40@%_5$L#?%13!'I36@9X4V((=5)I"7-2<0MQ47H-;E&$#VQ0D!!J
M4)P2:%"K$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE3_\,94__#.Q!
M  #43   PU0  +99  "L7   H%H  )=7  "15   BU4, (97&0"#6"< @%DT
M 'U9/P%Z64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!#V95C1%D5)H2
M8E2I$V!4NA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-7U/_#>=$  #/
M4   OU@  +-=  "H7P  G%T  ));  "+6   A5H* (%;%@!]7"0 >ETQ '==
M/ %T748"<5U.!&]<505L7%T':EQD"6A;; ME6G4-8UI_#V%9BQ%>69@27%BG
M%%M8N!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_#>-(  #+4P
MNUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$ =6(N ')B.0%O
M8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%979825UVE$U5=
MMA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,  #'5@  N%\
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M$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P  *%Q  "2<
MA6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8 57@_ 5-X2 )1
M>$\#3W=7!$QW7P5*=V@'2'9S"45V?PM#=8T,076=#C]UK@X^=<4./77H#CYS
M_0T^<O\-/G'_##]Q_PP_</\,/W#_#,5>  "U:0  J7$  )QU  "-=   @'0
M '5T  !I=@  7GD  %A\ 0!4?0X 4GX: %%_)@!/?S$ 38 [ $R 0P%*@$L"
M2']4 D9_7 1#?V4%07]P!C]^? @\?HH).GZ:"CE^K LW?L,+-WWF"S=[_ LW
M>O\+-WG_"CAX_PHX>/\*.'C_"KYD  "P;P  I7@  )9Y  "'>0  >WD  '!Z
M  !D?   6(   %"#  !+A0H 2(84 $>'( !%B"L 1(@U $.(/@!!B4<!0(E/
M 3Z(6 (\B&$#.HAL!#>(> 4UB(<&,XB8!S*'J@<PB, ',(?D!S"%^P@P@_\(
M,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@  =G\  &J   !>
M@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P WDD  -I)) #23
M4@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0^@0GCO\%)XW_
M!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4  &.(  !8BP
M38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@ *9U! "B=2P G
MGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!'I[= 1Z<^ (>FO\"'IG_ QZ7
M_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*  !UBP  :(X  %N1  !0E0  1ID
M #N=   RH   *J,  "*F"0 ?IQ$ 'J<: !VH)  <J"T &Z@W !JI00 9J4P
M&*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3 !*H]0 3I_\!$Z7_ 1.E_P$3
MI/\!$Z3_ :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G
M   JJP  (:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.
M  JV7  )MFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\
M";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   A
MM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##
M4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_
M ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P
M$,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P
MU%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;
M  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX
M  #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(
M .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !N
MJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A
M    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!
M  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0
M4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L
M[P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_
M00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P =
M /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (<
M_P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^
M /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\
M&@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P")
M /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D
M\P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_
M !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /<
MBP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_
M .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4
M_P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J
M (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4
M_P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,:
M /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (<
MV@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$
M ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P'
M'P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2)
M ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\
MM W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C
M"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/
MC0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5_P"G%?\ IQ7_
M *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4% -X.#0#3#A@
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M!/4M  #D-P  T#\  ,)#  "W1   K4   *<Z  "C-@8 G3<3 )DY(@"5.B\
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M"V=&M@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_!N@[  #01@
MOTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0 ?4PQ 'I-/ !W
M344!=4U- G--50)Q35P#;TUC!&U,:P5K3',':4M]"&9+B0ED2Y8*8DND"V%+
MM Q?2\H,7DOJ"UY+_@I>2_\)7DK_"%Y*_P=>2O\'7DK_!^,_  #+20  O%$
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M#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP  *->  "570
MB5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH 8%]# 5Y?2P)<
M7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*7<$,25WC#$E<
M^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A  "18   A5\
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M!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL  &QL  !A;@
M5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0 07A- 3]X50$]
M>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q=/\%,7/_!3%R
M_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q  !<<P  47<
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M :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP
M)9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .
MHVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$
M  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4
M !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$
M *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",
MD   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT
M   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG
M  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F
M<YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_
MPP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-
M;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8
M %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T
M -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70
MY'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV
M   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .
M  #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$
M /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   Q
MQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O
M    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F
M  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "(
M_P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_
M )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L
M_P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F
M /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )
M_ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O
M /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\
M+@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2
M .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\
MX0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\
M #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$
MDP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_
M ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\
M[  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#,
M )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P
M_P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U
M -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )
MO "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M
M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@"
M.@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5
M *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\
MGP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W
M#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2
MFP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_
M /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@
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M GHOMP)X+\P"=C#J G4P_@)S,/\"<S#_ G,O_P)S+_\"<R__ O J  #<-0
MQSL  +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD B3,U (8T/P"$
M-4D @C51 ( U6 !^-5\!?35F 7LV;@%Y-78">#6  G8UBP-T-9<#<C:D W V
MM 1O-L@$;3;G!&PV_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP  #3.@  PD$
M +-#  "E00  FSX  )4Z  "0-@  C#4- (@W& "$."4 @3HQ '\[/ !\.T4
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M!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X  *1.  "63
MBTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J2SP :$M$ &9+3 %D
M2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%5TJ:!E5*J@=42KT'4TK<!U)*
M]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  # 2P  LE$  *!0  "23P  ATX
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M!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@  '%7  !F5@
M85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/7DD 35Y1 4Q>6 %*
M7F$"2%UK T9==@-$78,$0EV2!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:
M_P,^6?\#/UG_ \%0  "Q6@  H5T  )!<  ""6P  =EL  &U;  !A6P  6UT
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M K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=
M-W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H
M>G8 )GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH
M  "=;@  BFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\"
M "F!#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$
M'(2" !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5
M<P  A'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+
M!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][
M !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0
M?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2
MF 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:
MA@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX
M &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP(
M!J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?
MIY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(
M  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&
M  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88
M +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-
MF@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^
M!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1
M  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0
M.*X  "RS   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,
MS0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>
MG   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L
M !^_   4P@  #,8   /)    S    -    #5    V0   -H   #<    W@
M .    #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@
M]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*
M   +S@   -(   #7    W    .    #E    YP   .D   #K    [0   .\
M  #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$
M /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_
M $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\
MG #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_
M .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X
M_P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W
M )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4
M_P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!%
M /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D
MYP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4
M /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /(
M2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U ";
M -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\
MQP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#=
M $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$
MG@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_
M /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $<
MQ@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P
M *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-
M  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!*
M +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *
MH0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W
M$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(
M30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ
M )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@
MW2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":
M$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6
MM0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD
M , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL
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M 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT  *@\  ":.@
MD3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX <C1& ' T3@!O
M-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$VJ0)@-KL"7S;6 ETV
M\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)   "5/@  BSP
M (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI# &HZ2P!H.U(
M9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#6#O2 U<[\0)6
M._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "00@  A4   'X^
M  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7
M %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#4D#/ U% [P-00/_B
M__])0T-?4%)/1DE,10 &"?\"4#__ E __P)1/O\!43[_ <\[  "]10  JD<
M )E&  "+10  @40  'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4
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M T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\  (U.  " 3@
M=4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P 3U$U $Y2/0!-
M4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^4J\#/5+& SQ2
MZ0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1  !\40  <5
M &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R $A6.@!'5T(
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M 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L  %Q<  !17@
M26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34 +VH] "YJ1@ M
M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C:?D!(V?_ 2-F
M_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@  !-8P  1&8
M #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W "5R0  D<DH
M(G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?< &G#_ !MO_P ;
M;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O
M   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ.
M !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\
M$G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I
M>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'
M4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_
M )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0
M&XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P
MDUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW
M  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0
M  Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%
M *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X
M?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D
M    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4
M  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA
M88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R
MM@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  #
M6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690
M $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q
M ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53
MUF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J
M   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,
M  #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$
M .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   J
MO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F
M    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5
M  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D
M_P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_
M (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8
M_P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @
M /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8
M]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G
M /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\
M* #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"&
M .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\
MT@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S
M "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$
MAP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_
M +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "<
MW0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "]
M (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X
M_P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L
M ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M ((
MK "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P">
M /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0
M,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"%
M )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\
MCP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E
M #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $
MB@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_
M /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X
ME@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"#
M#I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7
M  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R
M (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\
M=AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0
M*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<
M-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8
M &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P
MM#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S
M)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(I
MI !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34
M )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@
M:BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0 7"^2 %HOH0%9
M+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "].@  J#D  )<X
M  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q*P!D,C0 8S(]
M &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360 50UGP%2-; !
M437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0  HSP  )(\  "%
M.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>-S$ 73@Z %LX
M00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZG0%,.JX!2SK#
M 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\  (X_  "!/@
M=ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X 5STW %8]/@!4
M/D8 4SY- %(^50!1/ET 3S]F $T_< !,/WT!2C^+ 4@_FP%'/ZP!13_! 40_
MXP%$/OL!1#[_ 40]_P%$/?\!13S_ <,^  "O0P  FD(  (I"  !]00  <T
M &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5 (@!302L 4D$T %!"/ !/0D,
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M 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H  %])  !52
M4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L /E!# #Q12@ [
M45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O4/8!+T__ 3!.
M_P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-  !130  2T\
M $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_ #961P U5E
M,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4 *57_ "I4_P$J
M4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5
M   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6
M "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\
M)%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V
M70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D
M7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__
M *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P
M*F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7
M;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=
M  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T
M !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\
M#75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_
M80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y
M   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G
M  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P
M:V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,
MA@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+
M<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P
M %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@
M )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:
MF7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V
M  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$
M  "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(
M *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^
MAP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P
M    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]
M  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP
M*IT  !^B   5IP  #:P   6P    M    +<   "[    O@   +\   #
MP0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1
MB   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T
M !:S   .N   !KP   #     PP   ,8   #+    S0   ,X   #0    T0
M -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>
MZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["
M   $Q0   ,H   #-    T0   -@   #;    WP   .    #B    Y    .8
M  #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(
M /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_
M #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X
MDP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_
M .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8
M_P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O
M )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$
M_P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [
M /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X
MW "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_
M /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .<
M0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/
M ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\
ML #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+
M $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +(
MD@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_
M /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T
MM0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@
M )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\
M  #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _
M *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$
MD "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I
M#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8
M00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8
M (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0
MQ14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(
M!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*
MHP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T
M *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX
M? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K
M$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C
M  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9!
M '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\
M8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",
M*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>
M1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+
M %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0
M?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?
M)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\I
MW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C
M ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0
M5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(
M+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR
M  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43))
M % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0
M0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A
M,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW
M3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_
M #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P
M6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$
M/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[
M_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH
M $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$
M/4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S
M/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I
M  !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98
M #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\
M+D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!
M1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+
M7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_
M *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P
M-TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H
M4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)
M  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($
M "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4
M'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&
M30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:
M"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP
M !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40
M<%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :
M8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE
M?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4
M %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4
M$&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ "
M;HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9
M  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*
M  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0
M 'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-
M7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!
M#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23
M  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P
M/&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0
MC0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1
MH@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8
M "I[   @@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@
M )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@
MH;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*
M   7CP  $)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&
M  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@
M +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0
MGP  ":0   "I    K0   +    "T    MP   +@   "Y    NP   +P   "^
M @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX
M  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L
M +4   "Y    O0   ,$   #&    R    ,D   #+    S    ,X   #0
MT@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #E
MQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4
M  #)    S0   -(   #6    V@   -L   #>    X    .(   #D    YP
M .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP
M_<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\
M30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"<
M /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\
MR@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^
M %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@
MGP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_
M /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L
M[ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/
M *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\
M  #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!-
M -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P
MN0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_
M    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P
M3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@
M *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\
M[@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H
M $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4
MIP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP
M ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D
ME@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"%
M +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'
M  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!)
M (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P
M=@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">
M#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P
M2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[
M &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0
MBQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P
M"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -
MV !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H
M 'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D
M9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5
M%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>
M  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+
M %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$
M3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H
M(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@
M3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_
M $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@
M7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,
M)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H
M_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@
M %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$
M12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z
M+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L
M  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7
M #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\
M-3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !)
M,08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV
M7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_
M *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@,
M03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R
M.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X
M  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+
M #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8
M*T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*
M/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!
M#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q
M "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P
M=$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K
M2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*
M?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,
M &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A
M(DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  4
M4(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'
M  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81
M !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP
M#5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !1
M2@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>
M$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;
M  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@
M1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &
M9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !F
MK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,
M #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(
M &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP
M;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=
M   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3
M  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H
M 'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C
M:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "(
M$P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8
M  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>
M$WT   V!   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@
MF!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":
M\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P
M  21    E0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P
M *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@
MK/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B
M    I@   *H   "N    L    +$   "S    M    +8   "X    N@0  +P*
M  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(
M ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R
MMP   +L   "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2
M"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T
M $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R
M ,X   #1    U    -4   #8    V@   -T   #?    X@   .0   #G
MZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\
M"P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!:
M /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H
M\@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_
M    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /<
M7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P
M -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_
M_P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A
M %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0
MMP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P
M /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8
MQ !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N
M ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@
M  #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5
M *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@
MF@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%
M    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P
M50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#%
M (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S
MJ@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"*
M %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H
MVP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP
M )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\
M? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L
M .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"
M  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0
M &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D
M8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y
M"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$
M4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[
M %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$
M;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;
M#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0
M_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0
M &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U,
M41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%
M%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7
M @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8
M $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\
M/AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3
M' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@
M7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_
M *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@<
M2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z
M)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I
M  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<-
M $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4
M,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "+
M+0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL
M$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P
M "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',
M=C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V
M,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U
M?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0
M &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q,
M+S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @
M.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W
M  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8
M "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP
M&#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3
M.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"
M&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2>
M !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0
M2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 8
M21X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*
ML  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14
M #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D
M$% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "
M4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$
M   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<
M  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\
M %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P
M2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@
M'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B
M  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40
M(U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0
M:B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H
M]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T
M !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L
M '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0
M<_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L
M   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;
M  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\
M (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !
M?@   ($   "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5
M&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_
M %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@
M )(   "6    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P
MJ1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H
M  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,
M  "G    J@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(
M , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  !
M>0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y
M    O    +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42
M  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0
M*Y   !V8   2H   "J<   "N    M    +D   "^    P@   ,@   #+
MS@   ,\   #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O
M$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P %
M /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0
M_P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I
M .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\
M @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C
M .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0
MSP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_
M  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0
M8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H
M +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $
MY  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y
M &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *,
M]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP '
M ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H
MHP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1
M /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L
M# "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !:
M (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D
M?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5
M  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\
M60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_
M '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L
M@P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P
M %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &,
M_P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P .
M '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8
M8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8
M /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L
M$ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9
M %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\
M3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A
M!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )
M7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_
M + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T
M5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'
M#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9
M  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0
M $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4
M/A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-
M'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7
M%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO
M #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@
M=R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _
M'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@
M?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8
M &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8
M."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H
M)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J
M  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<;
M #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH
M(2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4
M+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL
M'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^;
M !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P
M22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E
M,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0S
MK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(
M $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R
M'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 .
M.,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT
M   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC
M !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$
M"CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U
M-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$
M)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@
M  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@
M+3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (
M2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)
M]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4
M "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428
M %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0
M3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(
M   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI
M  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\
M %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   2
M4P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D
M+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_
M %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70
M"&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@
M<3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/
M  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L
M  !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@
M ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.
M4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]
M    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L
M  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@
M.UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".
MD0   ),   "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F
M,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD
M "=N   ;=0  $7P   N#    B0   (X   "3    F    )T   "A    I
M *4   "G    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0
MO#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_
M   3A@  "XX   &5    FP   *$   "F    JP   +    "S    MP   +<
M  "Z    O    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L
M -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -
MF0   Z    "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-
M    SP   -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS
M  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X
M_P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[
M '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .(
M_P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0
M /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H
MY !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#%
M /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$
M$P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H
M ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\
MK #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/
M !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X
M9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_
M )8 _P"3 /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !,
ML0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8
M &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (<
M_P"% /\ @@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6
M )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &
MA !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W
M /\ =0#_ .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (<
M&0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A
M '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\
M:0#_ -(   "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V
M !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4
M8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_
M ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !<
M:  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8
M &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'
M  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 :
M %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0
M30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5
M#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %,
M' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M
M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@
M?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+
M"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+
M>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<
M &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H
M0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R
M$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<
M  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(>
M #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@
M*A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6
M'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48
M(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9
M "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@
M2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N
M'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?
MJP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4
M $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B,
M)R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6
M),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG
M   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G
M "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<
M$2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V
M*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM
M*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?
M  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P
M+RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4
M,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R
M]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X
M "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P
M#C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #
M-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R
M   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ
M  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\
M #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =
M.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$
M-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_
M &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0
M$T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@
M2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z
M  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<
M  Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<
M %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !/
M/P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92
M    5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]
M  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P
M0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;
M7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K
M10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048
M #='   L2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@
M &P   !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0
M>DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/
M   F4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P
M  !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40
M (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >
M7P  %&4   UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".
M    D0   ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.
M  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@
M#G4   5[    @0   (<   "-    D@   )8   ":    G0   )\   "A
MI    *8   "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W
M6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<
M  ".    E    )H   "@    I0   *H   "N    L0   +(   "U    MP
M +H   "\    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P
MSFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A
M    IP   *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X
M  #2    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX
M .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_
M "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8
M> #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_
M +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\
M_P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#:
M '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@
M_P"D /\ H0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C
M .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '
MO !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6
M /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,(
M)@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P
M *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\
MA@#_ /<   #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G
M "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T
M<0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_
M .D   #7    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "(
MC@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X
M ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H
M  "_    K    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D
M 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P
M9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M
M    FP   (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L
M)0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R
M %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?
MC0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( !=
M "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X
M>@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<
M '0(  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "(
M40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!#
M (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-
M  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C
M $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z ((
M.0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;
M$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #
M)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2
M # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%
M3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X
M"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,
MI0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<
M $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4
M,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?
M$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :
M   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I
M "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L
M&!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W
M'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08
M+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG;
M !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P
M,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >
M'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>
M]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$
M "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\
M%R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,
M(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C
M   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U
M !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX
M"";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B
M)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM
M.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_
M &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*
M&RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %
M,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I
M  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX
M !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X
M #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4
M+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U
M   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&
M   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0
M1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   *
M/0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&
M3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034
M #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10
M $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@
M3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X
M   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\
M  !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650
M %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L
M/   )#X  !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;
M    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@
M  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P
M'D8  !5*   03@  "E(   -6    6@   %T   !@    8P   &4   !G
M:0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T
M;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$
M !!6   )6@   5\   !C    :    &L   !O    <@   '4   !W    >0
M 'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@
MA8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED
M    :0   &\   !T    >    'P   "!    A    (<   "(    BP   (X
M  "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8
M )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T
M>P   ($   "&    BP   )    "4    EP   )D   "<    GP   *$   "D
M    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)
M  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@
M )4   ":    GP   *0   "H    K    *T   "P    LP   +4   "X
MNP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)
MG@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@
M  "N    M    +@   "]    P    ,(   #%    R    ,L   #.    T0
M -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP
MX[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\
M-0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$
M .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\
MH@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T
M #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T
MA0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_
M /\   #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$
MT  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q
M (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D
M  #O    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R
M +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X
ME@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@
M    T0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@
M,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@""
M (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+
MM@   *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + ""
M #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T
MB0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0
M ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P
M;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ !=
M )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,
M  !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L
M %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H
M3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K
M    9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %(
M+ !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7
M $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!
M6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!'
M "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D
MI@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H
M $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D
M/0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P
M +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-
M  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K
M #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +,
M)P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \
M#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&
M+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+
M !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@
M-!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G
M##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,
MZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0
M "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$
M(! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2
M$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6
M   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V
M !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X
M#A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D
M&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08
M/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_
M &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@
M'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .
M'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:
M  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T
M !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$
M"2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7
M'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A
M   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)
M  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@
M1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0
M)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L
M4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8
M #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P(
M"RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P
M,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I
M   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%
M  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L
M #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M
M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z
M!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I
M  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0
M)RP  " M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!
M0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(
M>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$
M !PS   6-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0
M $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=
M4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z
M   1/0  #$$   =$    2    $H   !-    4    %,   !5    5P   %@"
M  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD
M %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,
M1P  !DL   !/    4P   %8   !9    7    %\   !A    8P   &4   !G
M 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?
M  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5
M %@   !=    80   &4   !H    :P   &X   !Q    <P   '4   !X
M>P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^
MM@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@
M  !M    <0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@
M )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@
MDM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "
M    A    (H   ".    D@   )4   "7    F@   )T   "@    HP   *<
M  "K    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$
M *GN #%5   D6P  &&$   YI   %<0   'D   "!    B    (\   "4
MF@   )\   "D    J    *D   "L    KP   +,   "U    N0   +T   #!
M    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/>
M "EB   <:0  $7$   =[    A    (T   "5    G0   *,   "I    KP
M +0   "Y    O    +X   #"    Q0   ,@   #,    T    -0   #:
MWP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\
M  #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!"
M /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4
MY "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[
M    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D
M0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@":
M +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q
MZ@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#"
M $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8
MH0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@
M -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L
MI !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP",
M *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8
M  "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z
M (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *
M=0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3
M    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4
M. !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K
M &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^
M>    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C
M #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %,
MNP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P
M &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$
M4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!&
M -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8
M  !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q
M $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,<
M.P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)
M    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T
M,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G
M #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P
M/@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S
M #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D
M^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@
M #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #
M*@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A
M /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+
M   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T
M ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\
M&@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G
M#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'
M.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_
M '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$
M(@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6
M#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0
M  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$#
M !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0
M$!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8
M%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2
M!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+
M  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@
M2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4
M%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  48
M5  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H
M #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4
M$!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40
M'6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<
M   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'
M  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T
M "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M
M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB
M"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L
M   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0
M)2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0
M* L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L
M@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(
M !\A   <(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D
M # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P
M,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC
M   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*
M   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(
M #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5
M*   $2H   XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!
M"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K
M  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@
M#3$   DT   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P
M3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*
MR@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H
M  (]    0    $0   !'    20   $P   !/    40   %,   !5 0  6 8
M %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P
M5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)
M    3    %    !3    5@   %D   !;    70   &    !B    90   &@%
M  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D
M &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6
M6@   %X   !B    90   &@   !K    ;0   '    !S    =@   'D   !]
M!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7]
M #@]   L/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P
M &\   !T    >    'L   !^    @    (,   "&    B@   (T   "1
ME@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$
M   E2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0
M  ")    C0   )$   "3    E@   )D   "=    H    *0   "H    K
M +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >
M5   $EL   IB    :@   ',   ![    @@   (D   ".    E    )H   "?
M    I    *8   "I    K0   +    "S    MP   +L   #     Q0   ,L
M  #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@
M#&L   %T    ?0   (<   "0    EP   )X   "D    JP   +$   "V
MN@   +P   #     Q    ,@   #+    SP   -0   #:    X    .8   #K
M    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@
M /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P
M^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8
M ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D
M  #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+
M -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\
MM #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;
M    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +<
M20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5
M )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\
MM@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9
M $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" ((
M\ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F
M )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $
M@ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L
M /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P
M  !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^
M &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /<
M5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F
M    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D
M/0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_
M $D _P!' /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7
M50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!*
M #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X
M_P ] /\ /@#_ )0   !_    ;P   &,   !9    40   $T   !*    2
M $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #<
M/0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T
M /\ -0#_ (@   !T    90   %@   !/    2    $,    _    /0   #P
M @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y
M #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\
M+ #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R
M  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D
M/0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_
M '<   !E!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  ,
M*@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A
M $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %
M  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0&
M ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\
M&0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;
M"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T(
M"  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1'
M !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0
M20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8
M"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)
M4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A
M #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D
M$PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )
M#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2
M   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \*
M ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T
M Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M
M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1
M"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L
M   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@
M)!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )
M% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6
M@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<
M !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P
M QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0
M&Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8
M   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-
M   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4
M !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7
M&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E
M#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O
M   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@
M$AH  ! ;   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#
M+@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   J
MU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X
M  X?   +(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T
M #81   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP
M,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE
M   &*    BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .
M  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@
M #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M
M,    #,    V    .    #L    ^    0    $(   !% @  1P8  $H*  !-
M#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_
M #8L   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@
M #T   !     0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P
M6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P
M   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D
M  !,    3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP
M &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L
M,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;
M    7P   &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-
M  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.
M'#L  !)    +10   DL   !1    5@   %L   !@    90   &D   !N
M<@   '8   !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<
M#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<
M  U-   "5    %L   !A    :    &X   !S    >0   'X   "#    B
M (P   "/    D@   )4   "9    G0   *$   "E    J@   +    "W!P
MN!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<
M    9    &T   !U    ?    (,   ")    CP   )4   ";    H    *,
M  "F    J0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H
M -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N
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M_O______________________________________________________
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M\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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MUG2FFM1QK)[2;[*AT&VYH\]LPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ'
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M?[:XDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI.
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MJZMXIJ*E?JZ9H(2UDIV+NHR:D[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6
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M-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC6WQ ,
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MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
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M6E3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5OPKP@
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MB723V(G_?!@"_X0< _^5'P/_HR4$_Z\L!O>Z,PGLQ#L/XLY"&-/.2"S&QU)
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M:$WHZ&A-Z.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&C_F0L W:X$ ,R\!@#!R0<
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M=5BRYW18LN=T6++G=%BRYW18LN=T6++G=%BRYW3_@!(!_Y00 /^F#P#CN L
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M, U=_S@05_] $U'_1Q9-_TX82O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
M )FQ  "/N0  A, # 'O&#0!XQAX <\8N VW%.@AGQ$4.8L-.$UW#5AA9PEX=
M5<%F(5'!;B1.P'<H2\"!*TB_C"U%OYHO0[^H,4&_NC%!P-(Q0;[N,$&]_2]!
MO/\N0;S_+4&\_RU!O/\M0;S_+4&\_RW.B@  OY@  +&@  "FJ   F[   )"X
M  "%OP  >L<$ &_/"0!KT14 9]$F 6/1- 1>T$ (6=!*#%7/4Q!1SUL43L]C
M&$O.:QM(SG4>1<Y_($+.C") SIDD/LZH)CS.NB8\S]0F/,WO)3O,^R4[R_\E
M.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@  D;8  (6_  !Y
MQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)WU<,1M]?#T/?
M:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>^1HTW?\;--S_
M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0  ?YP  '6>!0!PGQ,
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M$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K_Q0TJ_\4-*O_%#2K_Q2[A0
MKY   *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$ 2;P- $B\&0!&
MO2< 1;TS $.]/0%!O4<!/[U0 CV]6 ,ZO6$%.+UK!C:]=P@TO80),KV3"C"]
MI LOO;<,+K[0"RZ\[@PMNOX-++G_#2RX_PXLN/\.++C_#BRX_PZSCP  II<
M )N=  "/HP  @ZH  ':P  !JM0  7KH  %*^  !'P@$ /<<& #C)$  WR1L
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M  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO
M7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0
M^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\
MM0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT
M $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0
M!/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP
M_[,  /_'  #_Y0  _^4  /_E  #_Y0!_M   <+T  &''  !3T   0]8  #;=
M   JX@  '^8  !;J   0[0  #/H   G_   &_P   O\$  #_"0  _PT  /\0
M  #_%   _QH  /\A  #_*0  _S0  /]   #_3@  _UX  /]R  #_AP  _YH
M /^J  #_N0  _[D  /^Y  #_N0#_("D!_R(G ?\B)P'_'RH!_QDP ?\2.0'_
M$$4!_PU3 ?\,8 '_"FT"_PEY O\)A +_"8X!_PF6 ?\)G0'_":,!_PFI ?\)
ML '_"+<!_PB^ ?\(R '_"-8!_PCF ?\(\0'_"/L _PC_ /\(_P#_"?\!_PG_
M ?\)_P'_"?\!_PG_ ?\)_P'_(R8!_R4D /\E) #_(R<!_QTL ?\8-0'_%4(!
M_Q)0 ?\070+_#FH"_PYV O\.@ +_#HH"_PZ2 O\.F@+_#J "_PZF ?\-K0'_
M#;,!_PV[ ?\-Q0'_#=$!_PWC ?\-[P'^#?H!^@W_ ?D._P'Y#O\!^0[_ ?@.
M_P'X#O\!^ [_ ?@._P'_)B, _R@@ /\H( #_)B( _R(H ?\@,@'_'#\!_QE,
M ?\760+_%64"_Q-Q O\3? +_$X8"_Q.. O\2E@+_$IT"_Q*C O\2J0+_$K "
M_Q*W O\2P0+_$LP!_1+? ?D3[0'U$_@!\Q/_ ?(3_P'Q$_\"\!3_ O 4_P+P
M%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT _RDD /\H+P'_)3L!_R)( ?\?
M5 +_'6$"_QMM O\:=P+_&H$"_QJ* O\:D@+_&ID"_1J? OP:I@+[&JP"^1JT
M O@:O0+V&L@"\QK; N\:Z@+L&_<"Z1O_ N@;_P/G'/\#YAS_ ^4<_P/E&_\#
MY1O_ ^4;_P/_+1L _S 7 /\Q%0#_,!8 _S$@ /\P*@#_+C8!_RM# ?\H3P+_
M)EP"_R1G OPC<@/Y(WP#]R*% _4BC0/S(I4#\B*; _ BH@/O(JD#[2*Q ^PB
MN0/J(L4#Z"+5 ^0CZ0/@(_8$WB/_!-LD_P39)/\$V"3_!-<D_P36)/\$UB3_
M!-8D_P3_,18 _S02 /\V$0#_-Q, _SD; /\X)0#_-C$!_S,] ?TQ2@'X+E8"
M]"UB _ L;0/M*W<#ZBN !.@JB 3F*I $Y2J7!.,JG@7A*J4%X"JM!=XJM@7<
M*L(%VBK2!M4KYP;0*_4'S2S_!\LL_P?)+/\'R"S_!\<L_P;'+/\&QRS_!L<L
M_P;_-1( _SD. /\Z#0#_/A  _T 6 /\_( #_/2H ^3LW ?(X1 'L-E$"YS5<
M ^,T9P/@,W($W3-[!=HR@P;6,HL&U#*3!](QF@C0,:$(SC&I"<PQL@G+,;P*
MR3'*"L8RX0O",O$+OS/^"[TS_PJ[,_\*NC/_";HS_PFZ,_\)NC/_";HS_PG_
M.1  _ST+ /] "0#_1 T _T81 /]%&0#W1", [D$O .8_/ '@/DH!VCU7 M,\
M8@3/.VP&S#IU!\DZ?0G'.84*Q3F,"\,XE S!.)L-P#BC#;XXK Z\.+8/NCC#
M#[DXUQ"U..P0LCG[#[ Z_PZO.O\-KCK_#*TZ_PNM.O\+K3K_"ZTZ_PO_/ T
M_T & /]%! #_20D _TL- /E*$0#M21H XT8F -I&-@#11D4!RT51 \9$7 7"
M0F8(OT)O"KQ!=PNZ0'\-N#^&#K8_CA"T/I41LCZ=$K ^IA.O/K 4K3Z]%*L^
MS16I/N85IC_W$Z1 _Q*C0/\0HD#_#Z) _PZB0?\.HD'_#J)!_P[_/PD _T0
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M'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\  .17  #570
MS&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY  Z%<2P>=6E0*F5E<#I989!&3
M5FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?@U&J(8%1N")_4<LB?E+G(7Y3
M^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_2@  [E(  -Y;  #/80  QF0
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M&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P  N6\  +%Q  "J<0
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M&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P  BX$  (2!#0!_@AH
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M&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_%T6%_Q?-;0
MO7@  +&"  "GB@  G(X  )*0  "&DP  >94  &R7  !FEPX 8Y@; &&8*0!>
MF#4!6I<^ U>71P55ED\'4I96"4^57@Q,E&8.2I1O$$>3>1-$DX450I*3%T"2
MHA@^DK,9/9+)&3V1Z1@]D/H7/H__%CZ/_Q4^C_\5/H__%3Z/_Q7%<P  MW\
M *R)  "ACP  EI,  (N6  !_F0  <YP  &2?  !<H D 6: 4 %>A(@!5H2\
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M!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0  )>:  "+H
M?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ( +,,> "O#*0 J
MQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?QJL!'L?! 1[&
MY $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA  "!IP  <ZX
M &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1 !K2&@ 9TB4
M&-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0 $-F[ !#9W@ 0
MU?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]
M  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C
M  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8
M .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!
MR@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R
M(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E
M  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP
M*-@  ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@
M_!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_
MV   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9   FW@  &^(
M !+F   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)  #_#@  _Q(
M /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4  /^F  #_LP
M_[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\
M7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y
M /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\
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M ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0H0'W$*@!]A"O ?00MP#S$,(
M\1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_ >(2_P'A$O\!X1+_ >$2_P'_
M*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S, _R _ /\=3 #_&U@!_!ED ?@9
M;@'V&'@!\QB! ?$8B0'O&) ![AB7 >P8G@'J&*0!Z1BL ><8M 'F&+\!Y!C-
M > 9XP'<&O$!V!K^ M0;_P+2&_\"T1O_ M ;_P+0&_\"T!O_ M ;_P+_+1(
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M#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX  /=$  #F1P
MWT@! -I&!@#90 L S4(9 ,5$*P"^1#L N41( ;5#4P.Q0EP$KD)E!JM!; >I
M0'0)ID!["J0_@PNC/XH-H3Z3#I\^G ^=/J40FSZQ$9H^OQ&8/M02EC_M$90_
M_ ^30/\.DD#_#))!_PN20?\+DD'_"Y)!_PO_/0  _T,  .E)  #>3@  TT\
M ,U. P#*20@ PDD4 +M*)@"U2S8 KTM# JM*3@.G25<%I$A@!Z%'9PF>1F\*
MG$9V#)I%?0Z8184/ED2.$)1$EQ*20Z$3D$.L%(]#NA6-0\T5BT3H%8I%^A*)
M1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0   \D<  .-/  #44P  RU4  ,14
M  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>3U,%FTY<")A-8PJ53&H,DTMQ
M#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(M1>#2,<8@4CD&(%*]Q6 2O\2
M@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L  -U3  #.6   Q%H  +U:  "X
M5P$ L50. *I6'@"E5BX GU8[ 9M51@.75% %DU-8")!27PJ-468,BU!M#HA/
M=!"&3WP2A$Z%$X).CA6 39D7?DVD&'Q-LAEZ3<,:>4W?&GA.]!=X3_\4>$__
M$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7   OU\  +=?  "Q7
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M$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L  (UJ$ "':QX
M@VLL 'YK. )Z:D(#=FE*!G-H4@AP9UD*;69@#6ME9P]H9&X19F1W%&1C@19A
M8XP87V*8&EUBIAQ;8K8=6F+,'5IBZAQ;8_P87&/_%EQC_Q1=8_\376/_$UUC
M_Q/F50  SU\  ,%H  "V;@  K'(  *1T  ":<P  CF\  (=O#0"";QL ?7 I
M 'EO-0%U;C\#<FU(!6YL4 =K;%<*:6M>#&9J90YD:6P186EU$U]H?Q9<:(H8
M6F>6&EAGI!Q69[0=56?*'55GZ!M69_L85V?_%E=H_Q189_\36&?_$UAG_Q/A
M6   RV,  +UK  "R<@  J78  *!X  "6=P  B',  (%S"P!\=!< >'0F '1T
M,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?;VH07&YS$EIN?!57;8@756R4
M&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L_Q12;/\34FS_$U)L_Q/<7
MQV<  +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10 <GHC &YZ+P%K
M>3H":'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/5W1P$51T>A-2<X863W.3&$UR
MH1E,<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--<O\237+_$DUR_Q+48   PFL
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M$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT  *>&  "<B@
MD8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,FB< 2IHR $B:/ %&
MFD0!1)I, D*:5 - F5P$/IEF!3N9< <YF'P(-YB*"C68F@LSF*L+,IB_##*8
MWPLQEO4+,97_"S&4_PLQD_\+,9/_"S&3_PNX>@  K(4  *&+  "6D   BY0
M '^7  !RFP  9IT  %J@  !.H@  1:0) $*D$P! I!\ /Z0J #ZE-  \I3X
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M 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M
M2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .
MS3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+
M_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L
M #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX
M =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@
MW_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,
M   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K
M  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8
M /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2
MW   #.    7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T
M)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?
M  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@
M .D   #L    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0
M_R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_
MN@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T
M /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,<
M_P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_
M&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\
M>@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0
M /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P
M_QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_
M 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /
MWP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!_P#_(!< _Q\4
M /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF /\(< #^!WD
M_ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__24-#7U!23T9)
M3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
MK!EU *L9? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4 GAS? )H=\P&8
M'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:+P  SRT  ,HG
M  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H(E( IB): *,C8@"A(VD H"-O
M )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90DL &2);\!D276 8XF[P&,)_\"
MBR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.   Q#<  +XR  "Z
M*P( M24. *XG'0"H*2L I"HX * J0P"=*TP FBM5 )@K7 "6*V, E"MJ 9(K
M<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&++H"A2W. X,NZ@.!+OP#@"[_
M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
MJ2\+ *,O%P">,28 F3(S )8R/@"2,T@ D#-0 (TS6 "+,UX!B3-E 8<S; &&
M,W,!A#-\ H(SA0* ,X\#?S.: WTSIP-\,[4$>C/)!'DTY@1W-?D$=C7_ W4U
M_P-U-?\#=37_ W4U_P/P,P  W3T  ,I#  "^10  M48  *U#  "F/0  H#8&
M )DV$P"4."$ D#DN (PY.0").4, ASE, (0Y4P&".5H!@#EA 7XY: )\.6\"
M>CEW GDY@ -W.8L$=3F6!'0YHP5R.;$%<3G$!F\ZX@9N.O<%;CO_!&T[_P1M
M._\#;3K_ VTZ_P/J.0  U4(  ,1(  "Y2P  KTL  *=)  "?1   F#X! )$\
M$ ",/1T B#XJ (0_-0"!/S\ ?C]( 'P_3P%Z/U8!>#]= 78^9 )T/FL"<CYS
M W ^? -O/H<$;3Z3!6L^H 9J/JX&:3_ !V<_W@=G/_4&9D#_!69 _P1F0/\$
M9C__!&8__P3E/0  ST8  +],  "T3P  JE   *)/  "92@  D40  (I!#0"$
M0AD @$,F 'U$,@!Z1#P =T1$ '5$3 %R1%,!<$-9 6]#8 )M0V<":T-O VE#
M>01H0X,%9D./!F1#G0=C0ZL'84.]"&!$V0A@1/,'8$3_!E]$_P5?1/\$8$3_
M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_
M /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X
M_P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V
M )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8
M_P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V
M /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X
MY0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/
M /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /
M/ #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/
M ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\
MO #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#;
M $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P
MD "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_
M *L _P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H
MPP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I
M )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L
M_P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ]
M +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T
MF0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y
M#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *(
M/P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62
M (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0
MX!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3
M#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/
MFP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8
M ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL
MA!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q
M%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ
M  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^
M '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z
M92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J
M.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC
M00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M
M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P
MG#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C
M*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0N
MO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0
M (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T
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M 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$  (50  ![3
M;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&
M/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$ /D"B #U M0$\0<X!/$'N 3Q!
M_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "75   C54  (-4  !X40  ;$L
M &%'  !60@  3T , $P_$P!)0!P 1T D $9 + !$0#, 0T Z $)!0@!!04D
M0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@ #A%LP$W1<L!-T7L 3=%_P$W
M1/\!.$3_ 3A#_P"W20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,
M  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/
M #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\
M,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !0
M3@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,
M5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_
M "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50
M0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M
M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1
M_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@
M #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H
M)5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H
M6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%>
M P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C
M !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8
MF6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C
M9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H
M;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\
M (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0
M%G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +
M<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y
M  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$
M  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0
M 'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y
M@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)
M"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!
M  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0
M8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@
ME@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5
MC@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690
M $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<
M *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA
MI9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@
M   SH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %
M  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY
M +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   F
MJP  &JT  !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #
M @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<
M  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0
M$+@   >[    O@   ,$   #$    R    ,L   #+    S0   ,X   #0
MT@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #F
MI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0
M  #'    RP   ,\   #4    V    -P   #=    WP   .$   #C    Y0
M .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0
M_*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\
M20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@";
M /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\
MW #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_
M $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\
MG0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_
M ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D
M\P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#<
M )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X
M_P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!-
M .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D
MQ "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_
M    _P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H
M3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"<
M *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_
M_    /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U
M %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\
MH0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4
M .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H
MHP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP".
M *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2
M  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!*
M ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *,
M?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z
M'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&
M2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO
M '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@
MJ"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X
M#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82
MP !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T
M )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48
M;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<
M&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q
M  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU(
M & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=(
M4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#
M,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C
M2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN
M $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0
M=3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0
M*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N
M_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D
M &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H
M2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _
M,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y
M  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/
M $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\
M.C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6
M.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW
M50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_
M #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P
M2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V
M/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^
M_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 #
M #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L
M,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N
M2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#
M"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D
M "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P
MGU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P
M20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,
M<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H
M ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P
M)T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :
M4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E
M  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<.
M !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH
M$EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  ""
M;0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@
M$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)
M  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P
M=74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -
M:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !J
MF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L
M &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\
M '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP
M=*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"
M  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1
M  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(
M '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%
MBP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/
M$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS
M  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0
M+I8  "*6   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0
MGA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=
MQ@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\
M !>@   .H@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P
M *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@
MK]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK
M   %K@   +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)
M  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@
M ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W
MN@   +T   #     Q    ,8   #&    R    ,D   #+    S    ,X   #0
M!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/
M  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP
M ,H   #/    TP   -8   #7    V@   -P   #?    X0   .,   #F
MZ0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #X
MR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9
M /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *<
M]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_
M  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L
M70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K
M .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_
M_P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I
M %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\
MKP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P
M /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@
MT !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y
M +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H
M  #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9
M +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X
MI0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A
M    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D
M6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V
M )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0
MQ    +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8
M %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (,
MP0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L
M *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$
MB !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T
M -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0
M  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1
M 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X
M9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2
M%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*
M4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M
M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P
M@A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A
M$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5
M_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$
M '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\
M5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*
M'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC
M  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2
M $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\
M0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>
M) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C
M5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_
M #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@
M424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^
M*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L
M_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L'
M $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L
M."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q
M/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N
M#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D
M #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00
MHD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y
M,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW
M;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL
M )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \
M,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E
M/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3
M  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3
M "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H
M'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&
M6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#
M%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>*
M !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8
M>F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =
M2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-
MG  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8
M &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8
M%%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )
M5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML
M  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8
M  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@
M %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9
M<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D
M&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[
M  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@
M1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P
M;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !L
MU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX
M #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D
M 'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@
M=^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'
M   =AP  %(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:
M  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H
M (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4
MD@  #9,   24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9
M&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W
M  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@
M Y\   "A    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0
MJ1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I
M^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L
M  "N    L0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ
M +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!J
MEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\
M    OP   ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/
M  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP
M3Z4  $"J   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+
MS@   -$   #1    U    -8   #9    VP   -X   #@    Y    .<&  #K
M#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P &
M /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4
M_P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q
M ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\
M  #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F
M /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$
MW0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_
M    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X
M9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#-
M ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y
M\@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #%
M &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X
MX "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0
M -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\
ML !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@":
M .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0
M!@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!>
M )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") .,
MB #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N
M  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T
M70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R
M '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4
MFP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!]
M %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H
M_ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  )
M (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %<
M;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !>
M O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$
M"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19
M &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\
M5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N
M"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-
M7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_
M $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0<
M7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,
M$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6
M_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0-
M %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT
M0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U
M,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9
M$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD
M #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-
MI#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#
M'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C
M;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX
M )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$
M.R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N
M*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&
M  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5
M #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D
M)RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(
M2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM
M&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*)
M "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P
M?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H
M,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LW
MFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0
M '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L
M(3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4
M/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8
M  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX>
M !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P
M#D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B
M6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%
M(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^
M  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80
M4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -
M324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-
MVP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0
M $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(
M U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U
M5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH
M   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F
M  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\
M %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K
M;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I
M*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\
M  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0
M&7@  !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P
M=BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P
M_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,
M  J#   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8
M (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""
M@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/
M    D0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H
M  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP
M<(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<
MG@   *    "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F
M*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$
M %:5  !'F0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K
M *X   "N    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@
MN2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>
M   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P
M  "\    O@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2
M -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   O
MK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,
M    S@   -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD
M  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D
M_P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z
M ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H
M^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P ,
M /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T
MZ !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0
M /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /<
M$ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L
M ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L
MN #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#?
M !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H
M; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_
M *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$
MP@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E
M &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$
M_P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5
M *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0
MD@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_
M /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P
M& "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D
M ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\
M< #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"*
M !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '(
M9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_
M &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4
M>@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D
M &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %<
M_P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7
M &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &(
M5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_
M'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"
M&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG
M $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)
MJBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3
M"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.
M< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\
M )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8
M2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y
M$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W
M  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09
M #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D
M,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*
M/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9
M'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ(
M "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00
M?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P
M'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",C
MF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0
M ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT
M*2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =
M**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'
M  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A
M ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D
M%BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D
M20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM
M)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_
M !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@
M5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7
M,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TW
MW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\
M $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28
M$3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (
M//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2
M   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K
M  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X
M 4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z
M5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(
M,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[
M  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P
M*ED  "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@
M4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-
M_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$
M !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,
M %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",
M:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H
M   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z
M  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P
M?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '
M<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O
M0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L
M '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P
M '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0
M?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#
M  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T
M  "-    C    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\
M (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0
MC0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";
M    FP   )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&
M  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@
M-ID  ">;   9G   #YT   6?    H0   *,   "E    J    *D   "I
MJ0   *H   "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U
M30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(
M !JD   .I@  !*@   "K    K0   +    "T    M@   +@   "X    N0
M +H   "\    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0
MS58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N
M   $L0   +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L
M  #-    SP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@
M .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_
M "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0
M>@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_
M -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P
M_0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#?
M 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$
M_P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B
M .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ',
MQ !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H
M /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P
M)@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R
M *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\
ME #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S
M "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L
M<@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_
M (, _P#T    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ",
MG@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"'
M ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4
M_P#E    T0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F
M (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T
M=@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5
M P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P
M)P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P
M &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0
MN1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L
M "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D
M=0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@
M *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "(
M7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !,
M 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB
M  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C
M %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD
M00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".
M*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&
M) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N'
M #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P
M@"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^
M#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0
MF  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30
M '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$
M-! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F
M%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V
M  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D
M "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:<
M'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E
M-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89
M)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\
M !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/
M63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @
M'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,C
MV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP
M $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@
M&B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0
M*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^
M  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M
M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\
M#2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"
M0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N
M,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\
M  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@
M-4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *
M-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U
M_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@
M "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@
M 3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"1
M4@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+
M   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-
M  !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6
MAEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   5
M40  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+
M20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0
M 'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060
M"E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410
M5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N
M  !O<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(
M  !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\
M %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K
M=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N
M    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:
M  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P
M5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z
M>0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W
M90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,
M #R$   NA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP
M (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70
MAG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.
M   CCP  %H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8
M  "6    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@
M )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6
MF   #9D   &;    G0   )\   "A    I    *4   "D    I0   *4   "F
M    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV
M  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP
M *4   "G    J@   *P   "P    L@   +0   "S    M    +4   "W
MN    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&
MA0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$
M  "T    MP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@
M ,T   #/    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=
MYI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\
M- #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"!
M .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\
MM0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P
M #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$
M@@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_
M *0 _P#_    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #(
MTP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y
M (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )<
M_P#_    _P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U
M +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P
MH@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\
M    \    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4
M-@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^
M (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M
MW0   ,P   #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1
M #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P
M@@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0
M +P   "Q    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #
M?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J
M (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%
M  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P
M &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($
M6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";
M#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$
M, !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"*
M $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@
MBA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4
M #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $,
MEP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P
M 'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L
M2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X
M *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@
M  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K
M #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:,
M+0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H
M(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(
M+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW
M "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0
M7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K
M#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0
MU  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H
M % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H
M(Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6
M%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK
M  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O
M !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\
M$AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#
M+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9
M-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_
M  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@
M.2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1
M'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA
M_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0
M "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D
M#"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"5
M0@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV
M   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"
M  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@
MB$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @
M.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P
M3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE
M 'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@
M%#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20
M-U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:
M  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,
M  M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0
M #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P
M80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9*
M P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@
M  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P
M9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0
M4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.
M;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT
M %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,
M %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P
M5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ
M   _<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#
M  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL
M &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V
M>   *7@  !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S
M @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".
M  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@
M'H$  !*!   *@0   ($   ""    @P   (,   "#    @@   ((   ""
M@@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_
MH0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL
M  J+    C    (T   "/    D0   )(   "1    D0   )$   "1    D0
M )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F
MDK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7
M    F0   )L   "=    GP   *    "@    H    *    "A    H@   *,
M  "D    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@
M *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C
MI@   *@   "L    K@   *\   "O    L    +    "R    LP   +0   "V
M    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W
M  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP
M +8   "[    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*
MS    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=
MP@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!#
M /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T
MX "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_
M    _P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .(
M10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0
M ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_
M_P   /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$
M $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T
MDP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _
M .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $
MK !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7
M )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P
M  #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _
M )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$
M@@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[
M    L0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8
M/@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8
M &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K
MHP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T
M #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\
MH@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@
M (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #<
M9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1
M *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"
M  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V
M %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@
M1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S
M"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L
M-@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X
M #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$
M9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _
M #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\
MS@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,
M %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #(
M-  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E
M .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5
M  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T
M "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^<
M'0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'
M%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)
M-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY
M !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0
M/!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :
M#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0
M_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\
M #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H
M$Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7
M-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A
M   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"
M  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.
MBCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G
M(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;
M3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$
M ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@
M'24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #
M(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(
M  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L
M !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4
M "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S
M3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N
M P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB
M   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5
M:%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &
M,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R
M<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED
M %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @
M #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P
M.(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?
M  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*
M  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($
M #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+
M80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,
M#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6
M  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@
M-V0  "IB   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"
M5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1
MJP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP
M ")J   7:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@
M &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP
M6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES
M   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(
M  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X
M &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '
M?0   'T   !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\
M!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?
M  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B
M (D   "*    C    (T   "-    C    (P   ",    C    (P   "-
MC00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*
M\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<
M  "9    FP   )P   ";    FP   )P   "<    G0   )X   ">    GP
M *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<
MC0  39   #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H
M    J@   *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0
M  "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0
M09@  #*<   CH   $Z(   BD    IP   *H   "L    KP   +(   "W
MN0   +L   "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-
M    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P
M /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X
MZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/
M *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\
M  #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!.
M ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *,
MM@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q
M    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@
M30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K
M )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<
MS@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A
M $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L
MM0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@
M +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4
MC0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V
M ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$
M  ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$
M 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@
M9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",
M    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H
M0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+
M %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!
M>0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !;
M $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@
MZ !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P
M &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P
M30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \
M /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &
M 0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \
M $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$
M,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1
M  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8
M/@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^
M "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P
M1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K
M $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\
M_P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL
M #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X
M(@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":
M)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0-
M @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$
M !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P
MC"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I
M#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+
M30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,
M '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P
M(! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,
M#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ
M  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8!
M !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4
M!A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S
M/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8:
M @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B
M   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P
M:$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -
M&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =
M<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@
M %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D
M!2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<
M(H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+
M  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,
M   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(
M ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !3
M3P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N
M#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7
M   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350
M1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0
M-0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   R
MK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8
M #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X
M #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP
M.<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8
M   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/
M  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8
M $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =
M70  $EL   M9   "6    %8   !6    5    %,   !2!   40D  % -  !0
M$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ
M  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490
M#60   -B    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0
M6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3
M_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T
M  !M    ;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X
M &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W
M>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y
M    >@   'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.
M  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@
M8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&
MB    (D   "(    AP   (<   "'    AP   (<   "(    B    (@'  ")
M$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8
M $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP
M )@   "6    EP   )<   "7    F    )@   "9    F@   )L   "=!P
MG1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1
M   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<
M  "F    IP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD
M +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @
MG0  $9\   6A    HP   *8   "I    K    *\   "S    M0   +<   "V
M    MP   +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,
M  #.&@  SR\  ,](  #08@  T(   -"=  #0N
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ME)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM
M[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
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M_____\]T-0L    *4J?______________________________Y8T
M3Z?_____________________________]FD=   )# 8)4K'_____________
M________________RSL.$S5,6TU,7L/_____________________________
MJ6 V8(:?MJRIN-G_____________________________X)>-ON7_________
M_____________________________^WY____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KV<J\Q___________
M________________________SYJ!;5I&B.K_________________________
M_______$?#XF$   5+#______________________________^"#/
M+H?M_____________________________ZQ3$       %VW6____________
M________________^X Q        "6',____________________________
MTEH"         %W,____________________________J#4          %S3
M____________________________?0T          %36________________
M___________N?44          $34___________________________\JF0O
M @  !"(W25C.____________________________Z:1K02@_8W^5I[K:____
M___________________________5LJRRS.3Z________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________ENY=W8LC_________________________________VYYG-@H
M HS________________________________(?S\%     %[/____________
M_________________]F!.0       #RJ____________________________
M_YY,         ".0____________________________W&\:         !!]
M^?__________________________KT@           !O[O______________
M____________A!,           !DYO_________________________L40
M          !7WO________________________^X%0            !(UO__
M______________________]T%              XS___________________
M______FB6A,            CQ?_________________________?FUPL
M       -NO__________________________[[%]53DB$0<! A$BLO______
M________________________W[^EF9B:H*R]VO______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________X[Z=@'S[____________
M____________________\K>$5S . !VL____________________________
M___2BDP5      !R\____________________________]9_-@        !+
MR?__________________________^I$^           OJ_______________
M____________P%H            :E?__________________________C20
M           (A/_________________________G7@              =___
M______________________^T)0              :O__________________
M______]]                6_3_______________________TK
M        3.O______________________Z4                 /.'_____
M_________________S ,                +=G_____________________
MF8IA)P              )]?______________________^V^B54G
M    )=S__________________________LJ==EU*/#(M+# Y1][_________
M______________________WFW=;2T-/9Y/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________OU+O6_________________________________^>XCVI++Q5O
M_______________________________DH6<T!P     \R?______________
M_____________]:".P         2E___________________________[84Q
M            ;___________________________ID(             4.'_
M_______________________L:0              -\G_________________
M______^S+P              (K;_______________________]Y
M        $*?_______________________(T                 )G_____
M_________________ZD                  (S_____________________
M_T8                  '______________________WP
M     '3_____________________EP                   &K_________
M____________S@                   &/______________________RDB
M 0               &'______________________[FC@%<W%P
M &C___________________________K3KI2&?'5Q<')W@93_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________V[J=@FEIT_______________________________
MR)-E/1D    =GO___________________________]N.3!,         ;O__
M________________________VWPL            1=?_________________
M________BRH             (K3________________________"1
M         Y?_______________________]] 0               '______
M_________________^<V                 &K_____________________
M_YT                  %C______________________T8
M     $?X____________________Z0                   #7I________
M____________E@                   "7;____________________O
M                 !C.____________________ZP
M  _"_____________________P                    JY____________
M_________R<                   JU_____________________W
M              VY_____________________^"<C'!50C,F&Q0/#0X2&B:_
M____________________________^>38TL[,R\S/UN#\________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z].\X___
M_____________________________]*IA65(+!(!A?__________________
M__________&K<3P/        3^#_________________________U7\U
M        '[+________________________C=1T              (G_____
M__________________^0(P               &?_____________________
M_]5#                 $CV_____________________XH
M     "[=_____________________S@                  !?(________
M____________O@                    2V____________________G
M                  "E____________________N@
M  "3____________________W                     ""____________
M_________P                    !T_____________________Q,
M              !H_____________________T(                   !@
M_____________________WH                   !=________________
M_____]$                   !A______________________\D
M          !F_______________________)K)F)?79Q;&EG9F=K<'J,____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MXL6JD7EA=______________________________=IG=0+ P     ,<3_____
M____________________X)).$P           (______________________
M___2<!T              &#______________________^YO#P
M     #?B_____________________Y8<                 !3 ________
M_____________T                    "C____________________K@
M                  ")____________________G@
M  !R____________________O                     !?____________
M________V@                    !-____________________^@
M               [_____________________PX                    J
M^?___________________S,                    ;Z?______________
M_____UX                    /V____________________X\
M           &T/___________________]                      RO__
M__________________\K                    R/__________________
M__^                     R______________________W%@$%!0,!
M   !!@T8R________________________.OAV,_,S<_0TM37W.+J________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________':QO______________________
M________\<:CA&A-,A@ %:O__________________________[E\1A@
M     ''________________________7?"\              #OC________
M_____________]]D"0                RU_____________________W0#
M                  "-____________________Q14
M  !J____________________F0                    !+____________
M________M@                     P_?__________________UP
M               9Y___________________]@                     %
MT____________________PX                     P?______________
M_____R\                     K____________________U(
M            GO___________________WD                     CO__
M_________________Z4                     @/__________________
M_]@                     =/____________________\V
M        ;?____________________]\                    :?______
M_______________7#0                  :/______________________
M<                   8?_______________________U \1DY465UA9&AL
M<'9^B?______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________[]6[HXMS6I7_________
M__________________B_CF1!(04      %+\_______________________W
MG588             !?!_____________________^5L%@
M  "-_____________________V,                   !>____________
M________G0                     U_/__________________H0
M               1V?__________________R@
MN___________________[@                      H?______________
M_____PP                     BO___________________RT
M            =O___________________TT                     9/__
M_________________V\                     4O__________________
M_Y0                     0/___________________[P
M        ,/___________________^H.                    (O______
M______________]$                    %?____________________^!
M                    "_7____________________("P
M     NS_____________________7@                   .7_________
M____________R1P                  -K______________________YT!
M              <.%\7________________________5N;S!Q\[5V^'F[?3[
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________XW\______________________________[,:EB&U4.R$'
M #+>________________________UY)9*0            "@____________
M__________^)-@                !G_____________________V8
M               R]O__________________E0                     #
MR/__________________IP                      H/______________
M____UP                      ?/___________________P
M            7O___________________R4                     0___
M_________________T@                     +/__________________
M_VH                     &/___________________XL
M        !?/__________________Z\                      .'_____
M_____________]4                      ,____________________\D
M                     +[___________________]4
M     *[___________________^+                     )__________
M___________+#@                   )+_____________________5P
M                 (;_____________________J@H
M 'G______________________VT                  &;_____________
M__________=5                 $7_________________________:B,K
M-3]*56!J=7Z'D9S_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^C/MIV#:4ZY_________________________^RR
M@UPZ'0(       ![_______________________%;2D               !
M_____________________X,;                   'R_______________
M____D@                      F/__________________I
M            :O__________________W0                      0?__
M_________________PX                     '?__________________
M_SD                      .C__________________V
M         ,[__________________X4                      +?_____
M_____________Z@                      */__________________\L
M                     )#__________________^\6
M     'W___________________\^                     &S_________
M__________]I                     %K___________________^9
M                 $G____________________2%@
M #G_____________________6                    "G_____________
M________H@                   !G_____________________]58
M              3______________________[LO                  #X
M______________________^K*0                #/________________
M________R4<     !Q,@+CY2:(3M________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________]-7)
M____________________________^M*PDG==0B@,  !*________________
M________Q7U%%P             1V/___________________\10
M            G___________________H@P                     :/__
M________________E                       -O__________________
MV@                      !^S__________________Q4
M         ,3__________________T@                      *+_____
M_____________W4                      (/__________________YT
M                     &G__________________\,
M     %+__________________^</                     #[_________
M__________\S                     "O___________________]8
M                 !C___________________^!
M  7___________________^L                      #_____________
M_______>(@                    #R____________________7
M              #?____________________GP                    #,
M____________________Z$H                   "W________________
M_____Z 6                  "<______________________]Z @
M          !W________________________>@L               5,____
M_____________________Z)7:'2 C9RKO-#G________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^WC___________________________2HWI8.BDC'!8.!@  G___
M__________________^L4@X                 :?__________________
MY$,                     -/__________________>0
M         ./_________________S0                       ++_____
M_____________Q,                      (7__________________T\
M                     %W__________________X,
M     #K__________________[(                      !S_________
M_________]L#                      +___________________\J
M                  #[__________________]/
M  #G__________________]T                      #4____________
M______^;                      # ___________________$!P
M              "M___________________P,P                    ":
M____________________9P                    "&________________
M____HP                    !R____________________XT0
M          !<_____________________Y$&                  !!____
M_________________^M?                   =____________________
M___*2P                  ________________________RU<   P8)#$_
M3F!TBZ?'___________________________7Y_+_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________KU,W'PKZZ
MM[.PK:FHI?___________________]U^4S\P(QD1"0(          -O_____
M____________=@                       *?_________________N@
M                     '7__________________P<
M     $;__________________TX                      !K_________
M_________XP                       #]_________________\$
M                  #;__________________$9
M  "^__________________]$                      "D____________
M______]K                      "-__________________^1
M              !Y__________________^W                      !F
M___________________>(0                    !3________________
M____2@                     _____________________=P
M           K____________________K H                    6____
M________________YT4                     ____________________
M_XH                     _____________________]9-
M        _?____________________^G+@                  U?______
M________________F"H           88+45@X/______________________
M_ZAC=(&/G*N[S>+Z____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________GR[>IG96.B82 ?'AT
M<&QH99#_________________O&I(+1D*                 #'_________
M_________P                        /__________________T(
M                  #<_________________XX
M  "R_________________\X                       "-____________
M______\I                      !K__________________]:
M              !.__________________^&                       T
M__________________^N                       >________________
M___4%P                     *___________________Z/0
M            ____________________90                      ____
M________________C@                      ____________________
MO!D                     [___________________\4X
M        V/___________________XL                     O_______
M_____________\Q#                    H?____________________^1
M&0                  >O_____________________R= H
M   17_______________________Z'03'RPX15-B<H6;M-+U____________
M_______________7Z/3_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______OW\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M
M*"/$_________________TLE"P                    "2____________
M_____X@                       !F_________________]<
M               ]__________________\S                       8
M__________________]L                        ________________
M__^=                        ___________________)#
M            ]O_________________Q-0                      W___
M________________6P                      R___________________
M@@                      M___________________J08
M        H___________________TR\                     C?______
M_____________UX                     =____________________Y,'
M                    7O___________________\U#
M    0/____________________^'$                   '/__________
M___________87@                   /______________________OTX
M      X<+#Y2:H:ER/_______________________\)\C)JGML76Z/W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^[AU\_)
MP[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4
M_________________]<%                        ________________
M__\T                        ]O________________]V
M            TO________________^P                        LO__
M_______________A)                       EO__________________
M40                      ?/__________________>0
M        9O__________________H                       4?______
M____________QR,                     //__________________[DL
M                    )____________________W0
M    $/___________________Z,6                     /__________
M_________]A,                     /____________________^(#P
M                 /_____________________+4P
M /______________________I3@           D=-$YKC/______________
M_________YDY0U%?;GV.H+7+Y?_____________________________K^?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________KS+FLH9F1BX:!
M?'AT<&MH9F9H\?________________]A13(C& X&                GO__
M______________]^                        =?_________________#
M                        4O_________________[-P
M        ,O__________________:@                      %O______
M____________E@                       /__________________OQL
M                     /__________________YD(
M     /___________________VD                      /__________
M_________Y "                     /___________________[DL
M                 /3__________________^A<
M -G___________________^1&                    +S_____________
M_______*4P                   )W_____________________F"X
M        $"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN____
M_____________________^>@JKG(V.G\____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#
M/CHV,B\N,?_________________2)1$#                     /______
M____________0@                       /__________________?0
M                     /__________________L L
M     /;_________________W3D                      -S_________
M_________V(                      ,7__________________XD
M                 *___________________Z\B
M )G__________________]9(                     (+_____________
M______]R                     &G___________________^A*
M             $[____________________37                    #/_
M____________________EBX              !4R4G?_________________
M____X'(3   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##
MV.__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________^>#2
MR,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,.
M"00  -3_________________D@                       *W_________
M________S!X                      (O_________________^U(
M                 &W__________________X
M %'__________________ZD;                     #K_____________
M_____]!"                     "/___________________5H
M              S___________________^/%                     #_
M__________________^X/@                    #_________________
M___E;0,                   #_____________________GS<
M     ! O4'3_____________________W7(4      87*D%:=92VVO______
M_________________[Q81%1D=8::K\CC____________________________
M___2S>'Q____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________\^_K[_?______________________[KFHG9:/
MBH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"
M "/__________________VD                       #_____________
M_____YL*                      #__________________\@Y
M              #___________________!C                      #_
M__________________^*#@                    #_________________
M__^P-                     #____________________56P
M          #_____________________A1H                   /L____
M________________L4D              !@Y78'_____________________
MY7L>       ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-
M[?____________________________^SGK3%U^O_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______Z[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD
M85Y;65A75UE>97'__________________[\Q'Q80"@4               #_
M_________________^U6                      #H________________
M__^"!                     #,__________________^K+P
M          "S___________________25P                    ";____
M_______________W?!                    "%____________________
MHC<                 !2N4____________________RV$"
M#"Q0=I[1____________________]8TP       -(SM7=IF^Y?__________
M_____________\-C&"H[3%]TC:?&Y_____________________________^H
M?Y:HN]#G_____________________________________?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___=SL6_O+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*
M2$=&2$M066:A__________________^G)@X' @                !6____
M_______________.4                      Z___________________T
M>0L                    A____________________GS(
M       .____________________Q%@                (,5J$________
M____________Z7\?           &)TMQFL+I_____________________Z=)
M      (7+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[___
M__________________________^N<H68K,+;]O______________________
M____________W^______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MO[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"
M0T=.66E]____________________GBX&                    ________
M____________PU8                  !5!____________________YWL:
M              DT8(NT_____________________Y\_          0E2G&9
MPNO______________________\9F#P   !,J1&*#I\WU________________
M_________^N.-2L^46B!G;S>______________________________^^=G^4
MJ<'<^?__________________________________TMCS________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________V\O#O[^_Q\_C]____________________________^+"?
MFI>6EI:8FY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%:
M:(.I_____________________Z9! 0          !S9CC[KA____________
M_________\9E"@      !"=,<YS$[/_______________________^6(+P
M$RI$8H*FS/3___________________________^K4#9*87N6M-;Z________
M_______________________2AWR8L<OI____________________________
M________U,[M________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MY>/CY.;H[?'Y______________________________VQE)*2
ME9F=HZFRO-#M__________________________^=4T=)35%68'.*K];\____
M______________________^R5@ :-5!MBZ[2]_______________________
M_______-;SY?>YFWU_G________________________________NGX.FPN'_
M____________________________________X\[K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________
M
M
M                      #_____________________________________
M____________________________________________________________
M____________________________________________________________
M_____________P    #_X4"U:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M8S P," W.2XQ8C8U83<Y
M+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @(" B/@H@(" \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA
M9&]B92YC;VTO=&EF9B\Q+C O(@H@(" @(" @(" @("!X;6QN<SIE>&EF/2)H
M='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!7;W)D
M(#(P,3D\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y-:6-R;W-O9G3"KB!7;W)D(#(P,3D\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,3$M,C94,#(Z,#(Z,C0K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,BTQ,2TR-E0P-#HQ,SHS-BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C(M,3$M,C94,#0Z,3,Z,S8K
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#ID.#=E9#<R-BTT83)D+69C
M-#(M.39C.2TR-6-D-38Q.&0R,S(\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z8C@R8F,V,#4M.&(V92TV
M,#0R+6)A.64M-64Y939B-S@T,C8X/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z03E!-C R140M
M.$4S.2TT,49&+4$P03 M-D0T,$8V-31&034V/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HU-F$U9F$X."UB9#8Y+3%E-#@M86)C
M-2TS,6(T-S(S-# Q-C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,3$M,C94,#0Z,3(Z,3DK,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z.6)A8C,Q8F8M,V)F,RUE,S1F+3AC9F,M9C<P,#$U8V9F
M,3 U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(R+3$Q+3(V5# T.C$S.C,V*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8C@R8F,V,#4M.&(V
M92TV,#0R+6)A.64M-64Y939B-S@T,C8X/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3$Q+3(V5# T.C$S
M.C,V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HY8F%B,S%B9BTS8F8S+64S-&8M.&-F8RUF-S P
M,35C9F8Q,#4\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/G5U:60Z03E!-C R140M.$4S.2TT,49&+4$P03 M-D0T
M,$8V-31&034V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z03E!-C R140M.$4S.2TT,49&
M+4$P03 M-D0T,$8V-31&034V/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QD8SIC
M<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y3=&5P:&5N($UA/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'1I9F8Z3W)I
M96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z
M6%)E<V]L=71I;VX^.3DY-#<P+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@
M(" @(" @(" \=&EF9CI94F5S;VQU=&EO;CXY.3DT-S O,3 P,# \+W1I9F8Z
M65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\
M+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A
M8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX
M96Q81&EM96YS:6]N/C8S,SPO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @
M(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXS,S@\+V5X:68Z4&EX96Q91&EM
M96YS:6]N/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T
M;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I
M;&4^52Y3+B!796(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R
M;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^
M"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!10)@ P$1  (1 0,1 ?_$
M !\  0 !!0$! 0$!           ( 04&!PD$ P(*"__$ '<0   & @$!! 0&
M!P\($@X)!0$" P0%!@ '"!$)$A,A%!4Q0187&5%AEQ@B5G&5U-<C-SA76%EW
M>(&1EJ&QMK<D)S(VE,'5\"4F*"DS-3E"1D=)9X.3I]/6X31#4E1D971VAZ;'
MT>/Q1$5(4U5C=86T9H2UP\7_Q  = 0$  @,! 0$!             00" P4&
M!P@)_\0 =!$  @(! @0"! 8)# D."@,1 @,!! 4 $082$R$4,0<505$(%A<B
M87$C,E56@9&4TO 8)"545Y.5H;'1T]4S-#4V0E.2P>$F)S=$14928F6$EM36
M\4-'<G."A::RM+5D=G>DMF-F='6#HJ6SQ,7&XX:CY/_:  P# 0 "$0,1 #\
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M\LV<71<0]28D^4F((ADY$9.1F)+:-]]HUB9^+''ON]QMJJL11//H2 3>UTA
M,'=,5,D$\CBIE,']D0@%*8?MA 3>>;?7&3F=RNN9/G,MF'3,^>\RV#F?P^?M
MU6'@_A@ A:<+2JKC?E"F!4A'?S@8J$F!B=^\#M$SWF-]6'[$'2J"Y7$2VV#
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M]B;2_P!,CD+]?.Q_[TUCU]8_:6(]W]RJ?]'_ !^??3X@8_[O<9_]+<U]._\
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M( ,,PMU<[05-T_\ T:_3L1/?;:)2\^\><QYQ'GMK97XUPCPZA!F*8\TC,9+
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M@R*AX ._6 IK"J"GA%$O=$8[_1^GZ?IOV:\J*&_@8P@+O=5C(EL:AK"9).S
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MQ@::]B:O(/UXV!9AIL*U\ U3NU$Y:[#.!L[T0XHMFR1H4&!J&+[PRJO55BV
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MW X[3[M<NWP_@+X\M["8BX,E!2-O&TK R0QL);.2<20QO$3MO$>4ZUJCQ=G
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MM44Q]F\NO62+4GC>+WBTV2B&Y+ASA7,9^M42;!@7UCL8HZF4M5!N'CC)==R
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M8"5: X4Z(W1B\BTRN+5)XBX<XNA!'/.7$'#B,(E4R_EF(P^0GAS$%?QT)\9
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MG&\3&X&,&!1OYB8$)B4=B$H*)F)B=/*2&?M@-BC'V@Q1DMJRCS$UL$EL"=B
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MQ&TS.\S';>??/OGZ?/7U111;I)H-TDD$$B@1)%%,J229 ]A4TR 4A"A[BE
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MB'48V8(4K5!<YN..10CSG,#$SJQ6A?5$WGTZZOLCF<IE A'D,BL284M+90B
MD9$<0 $6T3ISC]#W+5D//T#94Q)S*,.[93T)>)OOECGI+:4'<M76DHY<+ <8
M"PG=M6+598JY(UXQ;HIBBW*.73-3$K .QTVGC0,QD7WJR8@Z60=O BRU95+(
MM0B)6IBA&9@CVFL4FRP5B1D?6"HOL0)"P:+]^G8IC*4)0JND13%6.[7@+K+(
M&3F-2? 0$.H#U ?,!#V"'SYHU.F--1ZY<?H4N3G[7K=']&]E^]C2/./T_FUL
M+4?YU&L?V/*7_-N-^_C2?.?T_GUL/&FF--,::8TTQIIC33&FF--,::8TTQII
MC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,
M::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC
M33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TUH'DK-:_BM72K;
M8=2M=]C9M9O$QE.H326=WJ=FEC"JQ0J P+V-FF4VV,D9ZVDXN18/8T&YWB+I
M$R/?"I9@6'61 /.PYI17FL9J<HEJ8UKH>!!*5KK@TG')P$IA@'! 1#-JM)K%
M]CJ*6A"QFR5@08@@:T$*2:6"8.)[VJ2E4@4DXPY=BB)B$_$O7VFC[-4-+4+F
M/5[Y$QRTA3X+E;L#8MJKOJUN=,CA]3HV<M$M69*2C0,F560DFLA8(]-4>Z_(
M"QA/UZY$%>PQ+*YV A<6BD \<I39(08$2$"E+3YE$ZJ*I,HE1E(_-US;,";4
MI8#1K-)AH "**AL5RD2VQ!29D,2+0KVC8$;0P0@QB8ZK93U8TQIJ/7+C]"ER
M<_:];H_HWLOS8TCSC]/Y-;"U'^=1K']CRE_S;C?GQI/G/Z?RZV'C33&FF--,
M::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC
M33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC3
M3&FF--,::B?S$EM81^K$6.YZLO/ZQFIYDQMTLB_FXL:;&I).'XV4DC7$E)MJ
MY04:$:,3,56GB/G;=%P\;ME%5 I62K18I^)F5")6')LB10Q5E-5QH4N!B(DK
M+>5!]0P#HFR9AI0*66T18A%QE;E80!7!E4HB1L)?<KH=O!;Q/AEL*WV&2CH_
M-)<_9!TGP]=\&F=I.CQOLTC:KQ::P28=.[!.WNS3C*N(IMEO1A>7%99".1(9
MRB11O''$RBH""AU"$ V=G]<"N[4"!Z55BVW# 1CJ&330HC9,0UD<X'(#.P1]
MO(P4ZYA] 7UB84]5D/75&9*1$1$&/A8Q\P?FR$D4_.F-AWF.VIE[JV_3M":L
MNVW[\L_2JM%AE9>22B6"TK,R*@JI-(Z&@XIL N)2<G)-RSB(:-;@*S^3>M6J
M0=]4N<BY;BHH3Z3K#6O15K5JZR:^Q9LM%*4K 8DIDC*",MIA:A-I?- M=.C3
M.]8A &M0BFS9>]Q<B:U2G7;;N67'_@JK54.>R?8"YV[Z@EK[M,ZIL$M(>QNM
MG80LNG6'FQGZ%P;F?:E8;!V)/:QH#>QP$M78*86L[RSUF;:W*K+MXE]1S1CU
M)=:7523*OUUTS*TFN;%0FR-"M3R"3BS0OYC(4'9)./HO7.[T35"OM>(%1+[]
M1)5EEXB45&0:Z+;Q+8J%SFWS6M#-:TO'</)Q3LG9M)+F*N\0RR#JU8ZJ[:5M
M<NW 2N3EURX_0I<G/=_F>MT?T;V7*>ICSCV=];"U'YZHUC^Q[2_YMQN-)[S/
MUSK86-1IC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC
M33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC3
M3&FF--,::8TTQIIC33&FF--62RM7+VOS35DU9O7J\8]39-9!%)PR7>&;J V3
M<HK]$5$C+=P#D5$J9@$0.8I1$0K6Q:59T(@2=(3TX*!F.;V3$'\WFCS#F^;S
M1&_;?6U$A#E]29A?/$',20_-F>^\C$E [?;<L27+ORQ,[:Y_<3XW9D9L5U&S
ML9R*>1\;77@76?WC3=85.G1UK55;E;0>FS5%@PEG\,@0JJ/?CP>U,(5!D8\D
MYG1<B/32:65+; ^:B20%([A,C-6&09%9.\N-@A,!RF4L  \81Q1'PL06JUF#
MBVK>!EA%8)P5=BQZ$<L17E+)W$B.=Q 0F;?3B"O"MDR$3.W)JBN;NUS8=:VA
MQ)L(R=]5NF\O"+MV\W 3M>F8^R5BR0JSML]9$EZY8XF+FXWT]B^8&>L$"/F+
MQH99LK08#).LY%AM2U3M(N5+2(5+4/0?-!0#UN0P&!+$/2]34OKN:EJR!A1J
MY6L36)T],&JLT[^/M(830"Q2R=)^/NH(T,2]<.J67+ZB&J<N2ABF P1*(C5S
MLY]6UZQ5^T_&%M&4F3S2%FV\X>*T-H3D+98Z]S&SH*9V>A#4:+1C3P%ZL$U.
M1L=K$FOH4R4BX@WL:[KPDB2VZK0I,3X5(*IU%)FAC9-S:5#(I5:5ZYKPYK+$
MY)OC'L<;K#:YNBNWP\'2I%7UV7V+E=J;+S:Q_BTMLD*^J>/O4</B[6,Z<!%:
M*K,9@,11ZPUXOBJJ; N18MW76,BY]:2K&RN.N];3-6C<,(_J7'W<9X]AKW>6
MW]8UN0%&C6"1*%GJNO[I6ZY;B&62*BJ2S1DJ59@96.5 [%91N;3K")V_3])C
M\&VI1:B_.HUA^QY2OYMQF-1K8>--,::8TTQIIC33&FF--,::8TTQIIC33&FF
M--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQ
MIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF-
M-,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIJPVI\XC*S8)%HX;-'
M3"%DWC=T\#JU;+-F:RR:[@!$H"BD8@** )B@)2B F*'40J7V&FG9:M@*,%$0
ML9]H&T=RG>8CYL;S&_;FVW[;ZWU5PVRA4B1PQH!R#]L?,41 Q/LYIG;>(F8B
M=XB9VC7.KAKM;DYL>SU@]Y96B5U@77,H]FMC6Z*J<#'72W/9T7-><:Z95_PW
M3Z(2A%CIO'QP<QPM$68%<G?^DG4ZPKCI6V/7%7:OC@IU&\_C_$<S9LV; Q/3
M76?4FLS:1B9MF70F$1 ZJW61XWDI\K%1D\H+R5S35514I"4)6PXDSM)R2[BB
M@B@HKC$M 3*-NF>5-9Z8TU'KEQ^A1Y.?M>MT?T;V7&FMA:B_.HUA^QY2OYMQ
MF--;#QIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC
M33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC3
M3&FF--,::8TTQIIC33&FF--8[;TB+U2R(*,E))-:"E4CQZ2ATE7Q%&*Y#-$U
M$A!4AW!3"D4Z?YH43 ).I@ ,I9$8.C;"5RZ"08RN)*)*"C:>X?.VB)YIY?G;
M1,1WU8J'(6JYB7(0.64%,1.TB43'8OF^<;?.[=^_;7&[L[M7:TUSN1\VJ,K7
M[!9%*5(J3L34)+<#MOJMLX=-E&M5M/Q@2TC"&E3F_J8I62#"4]+;N'!6Q(PZ
M73MU>V/O"ILV4+#'H]8QR>'O&LB^Q5H/=\&H8AT[',"DA!\"Z-M4;^[,FFRX
M94YUG)-BJ6\.3+BZC7.%<PJ!892(S(=*3WFN1C/-/;/*.MVF--1[Y<?H4N3G
M[7K='T?[6]EQJ8\X^OZM;"U'^=1K']CVE_S;C<:3YS]<ZV%C4:8TTQIIC33&
MFF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8T
MTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&F
MF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TT
MQIIC36/VP6H5BPB^?+1C+U+)^ER+=-=9PQ;^AK>,Z02:D4<JJH)]Y1--N0ZY
MS% J)14$H93R$+*E9%K"2LE$),$3,AB>V_(N),HF9B)$/G%$S$3$SOK?6DHL
M)D!@BA@2(R0A$S$QMN9_,';SYC^8.VY?-B=<G^%[UN_Y'R#".V%1@KU%U2WJ
M<+4=>::W11?A6I(NT;&6:V9<-G-4XM[?8Z.=HR+BF1ZHS<027-*R(%;2#9$G
M8KRQM?,VG;$\[%.D=6NU08NA.-B$,913_9;#8(EX]KQ(@K*7%-DL>MC(IW5]
M*SBJZR@0'UCD):40Z[;"^4PH;+%2:TTR)3K=5A3 7V<]BKLGE#71_D!(N(S3
M.Q5F6T*II:1<UI[%16TKN825BER\UW(B+F)(262GK#X;]ZW19E;6:%=F?K-0
M:/DG(I=>+D-YKP/B%UQE]>6RQS:\.JJ>#[M4+-=J+%5EJDJP@;==D/I]2;:H
M(TQ$]+'C)6AD:S;1 JRT5I4MY :JSF!8)#DV$O34,1M6$/427(2Q3N59D0\8
MHO=6V&-ZTE !=M@5I^,=K1OH"M_'#LN]0O)&2=;YO57WI94WM]=3-JVS3@U7
M$TV]5U6Z'GE:-1[@VL,;()(MB6!/T%08;F8$DF-HQP,9/!W4*2>!X7L<-S;N
MWW@*:8>M:65.S3N7S57OS=Q6.1<KT;&89CK=6PNNKAZ'*M5;FX\7N5E*MAT5
M;V:KC@&<*5$6&$PEQ;99R"!PZ;EJA=:.075G)5,<C('T.[0':UVHO'G>%?K7
M&_=FXHNQ\?=Q%EKMK:7X^Q]8H@*TB?9'4M;;;&]]77!T1NW4/++!2JG<%!CT
M%4T"+2@H1JW-UC$;S'?;O'O_ (MHG4KM1_G4:Q]_];VE_P VXW&D^<^WO.M)
MV+G/Q"J5AGJI9>06MX6R5B9E*]8(9],BD^B9N%?+QLK&/$O 'PW3!^V7:N$^
MH]Q9(Y>H].N=Q/#/$#U*>G$7FI<L'*8""D&*8,$M@S':1,2B1GRF)C7@;GI2
M]'6/MVJ%[C/AZK=HV7T[E5^20MU:U6::7H<!%N#5- UF$]Q(9B?+5F^4(X3_
M *I75OX=^GIY_F'EYYL^*G$GW%R'Y.>JWRN^C#R^/?#/?_E2O[?_ $M/E".%
M'ZI75WX<'\7R?BGQ+]Q,C[O[7/S]WEI\KOHP^_OAGSV_NI7\_=]MYZ?*$<*/
MU2NK?PZ/WO\ O?YPZ??Q\4^)?N)D?R<_YM3\KOHQ^_KAK^%*_P"=I\H1PH_5
M*ZM'W^4Z(_R(8GA3B2//"9&/KKG_ #:CY7?1A]_?#/?_ )4K_G:?*$<*/U2N
MK?/R#K.B'\J&1\5.))\L)D)_YN?\VGRO>C#[^^&?X4K_ )VGRA'"?]4KJW\.
MC^+X^*G$GW$R'Y.?\VD^EWT81Y\=\,Q]>4K_ )VJ?*$\)_U2NK?PZ/XOCXJ<
M2?<7(?DYZ?*[Z,)\N.^&9_\ 6E?\[5?E".%'ZI75OLZ_Z>C[/^(Q\5.)/N+D
M/R<]3\KOHP\OCWPSO_\ G2O[?_2^G5/E">$_ZI75OX='\7Q\5.)/N+D/R<]1
M\KWHPCSX[X9_A2O^=],?CT^4)X3_ *I75OX='\7Q\5.)/N+D/R<]/E=]&'W]
M\,_PI7_.U7Y0CA1^J5U;^'1Z?-[? Z8^*G$GW%R'Y.>GRO>C#[^^&?X4K_G:
M?*$<*/9]DKJWJ/N]>CU__CX^*G$GW%R'Y.>GRO>C#[^^&?X4K_G:I\H3PG_5
M+:M^?_3T0_\ ]&/BIQ)]Q<A^3GI\KWHO^_OAG^%*WYVGRA'"?]4KJW\.C^+X
M^*G$GW%R'Y.>GRN^C#[^^&?X4K_G:J':$<*!]G)75OX='_F,GXJ<2?<3(_DY
M_P VD^EWT81Y\=\,Q]>4K_G:?*$<)Q]G)75H_P#[Z/XOCXI\2_<3(^_^US\O
M?Y:GY7?1C]_7#7O_ +J5_+W_ &VJ?*$\)_U2NK?PZ/XOCXI\2_<3(_DY_P V
MH^5WT8??WPS_  I7_.U7Y0?A1^J5U;^'1^__ /<9'Q4XD^XN0_)ST^5WT8??
MWPS_  I7_.^B=4^4)X3_ *I75OX='\7Q\5.)/N+D/R<]/E=]&&^WQ[X9W]WK
M2OO_ .]I\H3PG_5*ZM_#H_B^3\5.))\L)D9_YN?\VGRN^C"=]N.^&9V\_P!E
M*_;Z_G:K\H1PG_5*ZM_#H_B^/BIQ)/EA,C/_ #<_YM/E=]&'W]\,_P *5_SO
MIC3Y0CA/Y_YI75OE[?\ )T??_P !CXJ<2?<3(_DY_P VGRN^C#[^^&?X4K_G
M:I\H3PG_ %2NK?/_ ,>C_P QD?%3B2//"9#\G/\ FU/RN^C'S^/7#6WO]:5_
MSM5^4(X4?JE=6^WI_IZ/M^;_ +'Q\5.)/N+D/R<]1\KOHP^_OAGMY_LI7[?_
M *VGRA'"C]4KJW\/?/\ \![?H]N/BIQ)]Q<A^3GI\KOHP^_OAG^%*_YV@=H1
MPH'V<E=6_A[_ .![?H]N/BIQ)]Q,AW\OUN?\VGRN^C#[^^&?X4K_ )VGRA'"
M?]4KJWS_ /'H_1_X/](8^*G$GW%R'Y.>GRO>C#[^^&>W:?V4K]I]WVVGRA'"
M?]4KJW\.C]__ +W^;S^]CXJ<2?<7(?DYZ?*]Z,/O[X9_A2O^=I\H1PG_ %2N
MK?W)T1_<\D/;]&/BIQ)]Q<A^3GI\KOHPVW^/?#.WO]:5]O\ WM/E".%'G_FE
M=6^7M_R='\7Q\5.)/N+D/R<]/E=]&'W]\,_PI7_.U3Y0GA/^J5U;^'1_%\?%
M3B3[BY#\G/3Y7O1A]_?#/\*5_P [3Y0GA/\ JE=6_AT?^8R?BIQ)]Q,C^3G_
M #:?*[Z,/O[X9]_]U*_E[_MM/E".$_ZI75OX='\7R/BIQ)]Q<A^3GI\KOHPG
MRX[X9G_UI7_.U7Y0CA1^J5U;\_\ IZ/XO](8^*G$GW$R'Y.?\VGRO>C#[^^&
M?X4K_G:!VA'"<?9R5U;^'1_YC'Q4XD^XN0_)ST^5[T8??WPS_"E?\[3Y0CA1
MUZ?9*ZMZ_P#ZZ/\ S&/BIQ)]Q<A^3GI\KOHP^_OAG^%*_P"=I\H1PGZ=?LE=
M6]/G]>C^+X^*G$GW%R'Y.>GRN^C#[^^&?X4K_G:?*$<)_P!4KJWV=?\ 3T?9
M_P 1CXJ<2?<7(?DYZ?*[Z,/O[X9_A2O^=I\H1PH_5*ZM_#H_-U_^X^;]_P!V
M/BIQ)]Q<A^3GI\KWHP^_OAG^%*_YVJ?*$\)_U2NK?F_T]'_F,?%3B3[BY#\G
M/3Y7O1A]_?#/\*5_SM5^4(X4"'7[)75O3S_^O?F]O_:,?%3B3R]29#?W>'/^
M;3Y7O1A]_?#/\*5_SM/E".%'ZI75OS_Z>C][_O?)^*?$OGZDR.WO\.?\VI^5
MWT8_?UPU_"E?\[3Y0CA/^J6U;^'?_@?O?/[LCXJ<2?<3(?DY_P VH^5WT8??
MWPS_  I7_.U3Y0GA./\ ]I;5OS_Z>C_S&/BIQ)]Q<A^3GI\KOHP^_OAG^%*_
MYVJ_*$<*/U2NK?+_ ,>C[_\ ^WQ\5.)/N)D/R<_YM/E=]&&^WQ[X9W]WK2OO
M_P"]I\H1PG_5*ZM_#H]/9U]O@=/9CXJ<2?<7(?DYZGY7?1C]_7#7O_NI7\O?
M]MH':$<*!Z].2NK?+_Q[_P# Q\5.)/N+D/R<]1\KOHP^_OAG^%*_YVGRA'"C
MIU^R5U;T^?UZ/_,9/Q4XD^XF1_)S_FT^5WT8??WPS_"E?\[3Y0CA/^J5U;^'
M1_%\CXJ<2?<3(?DY_P VGRN^C#[^^&?X4K_G:I\H3PG_ %2NK?PZ/XOD_%3B
M3[B9'\G/^;3Y7O1AOM\>^&=_=ZTK[_\ O:_7R@_"@/\ [2NK?F_T]_\ @9'Q
M4XD\_4F0V]_AS_FT^5[T8??WPS_"E?\ .U^?E".$_P"J5U;Y^S_)T?Q?'Q4X
MD^XF0_)S_FT^5[T8??WPS_"E?\[7K8\^^&4F^9QL?R-UD[?R#INQ9-$)L3K.
M7;I8B#9NB0$.IU5EE")IE#^R,8 ]^0?"W$2Q(SPU\! 9,B*N<0(C$R13,^41
M$3,S[HUM3Z5_1K8:I".-^'&N>P$I4O)((VM:<+6L!@MR,S*!$8[R4Q$=]2Z3
M4(LFFJF8#IJD*HF</88AR@8A@^@Q1 0^@<X$QM,Q/G':=?0(F)B)B=XF(F)]
M\3WB=?O&ITQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC35DLKQE'UZ=?
MR3,9".91$B[?,"I$6,\:-VBJKAL5%4034%=(ATP(H($,)NAA O40JW6+54L,
M<KK*!1$:OF_/B/\ !^?(C&\_X13$#]M,QMOK?6 VV$K6< QC  #F9B!(BB(F
M=HF?;Y1$S/EM.^N97##9NO[GL-G'T?B<31L,M7['982SAMC5%K"3+,KL%'JB
M]-UYL6W2D5+RS=-GZ:^LT3'/6K5HWB/2"E;$9)=1(NE%J&-A95J6/KPB)*Q$
MU_$O:"0LKAE>%+>QE@Y!V]E[2>75*99-2Y(C> )&7D5W(2RQ/V&1>@ K&9);
M*WSS@J$K'IS"%A P*HG:>J&5=;-,::CURX\N*7)S]KUNC^C>RXT\M;"U%YZH
MUC^QY2OYMQN-//7\-7,,?\UQRE\Q\N1F[O(1]X;-LW0.@>[V#](=?>&?JOAW
MO@,#YQ^P^,]N_>**8CS[1,[;1W^KRU_(CTE[?*+Q_M,[_';BKM$S/EG+_>?+
M;MV[>SRWVG4<>G\8=0Z= ]OG]MY^0![?[_EG9CW;3OM,1VCW^4SY3'O[1$]_
M.=M>(C;Z=_9MVG?S[^S:/Q]M]XC:-5]WN !Z=>G0/=U#J'4/8/7Z! ?+V!D;
M;?@F-_+:-_;OW]WNVC?;O'F[S[?+EVG?R_T^V?JF=5 ?9T]_7]T>OM'KY_?'
MH'L'V].@(^K>9CV[^7OCZX[1^F\;S,[Q&^\>[M/T1M[-HV\^\1/TZH'>'V#[
MQ]H]!Z].GOZCU /,?XNF9;;SY1VV]T_Q]I]GMB?JVVU.TSV[;_3Y^[V]_IF(
MWU^@$ 'H(_0'D(>73IUZ_?\ ?U]W[V,;SO/:9CZYW]G;Z)C?VS]$1IOMOY>Z
M/.=_*)[^Z8W^KV;:H(AT_P"L>H^74>OF/E[^O7^41&/H\XG;?;;S[3/E[H[1
M^';VQIO,=O/:9_BC;Z_+ZMO9]%!\P#Z//J'EU]GGU_?ZC[?+S .GEEWWCW[=
MI]T3[]_*=_/S]T>Z4SW[;Q[?/W_3]/M_CVVT\A#W] \O(/,?(?/IU^<.OL]P
M![AR)G>-_*8\]O*)]\S[=]MHV^COWTF=QVV[1,?5]?G[]_9M_%IU\P$/H]GE
MT#S#S]O0/(.O4!]O01Z= R)V[SM[NWN[>^.T1[8]_;V3W3Y1O&WMWB(F(CZ/
M=O,QV[>S?>>\T'W].@^0CUZ^?G[>H^P>GT>X??YY,[1$;;[S$3V[;1Y;]O?]
M.^TS/X4_@V[]^\1&_P!7MV]G?^75?:'3V]  ?XO+[_MZ  =.H]1'VXGM[_+V
M^[;N,3]'EY>?LB8[S^&/*-O/RB-Y\N\?5VWW[1VC:HB'4>@AU]H"/LZ^\ Z^
M7NZ@/7Y@]F1/GY=_=]&WL]^T^4[^6VW:.R9V\X[^6WT3O[8\O/:(W\N^VJ&
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M4 YS*>"0QP]Q9XGPE6S%5]T!9*:SC. 82DA<I6;]2'-$9%;+-.JYR084&R(
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M>H=?+V^_YYGVQ]'EO/:(]LS&\=X\XCS[>W2=X]LQ]&W;;W[;[=]^\>_SGWU
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MV]L=L@CW]X[^?>)CSU_H-1'^E,9_^GLO_P",EGY+/[<O_*+^6=?V/3_8E?\
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M6G:DV5BM4P:Z+U^SC*7;R7.NPT9-6".C(]^6KDJQV+9LV'PD8P4"F>@T1(0
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MA3&,(  CE!K5H6QSC%:E 3&,.8$ 6$21F13V@1&)F9GM$1K8 &PP6L"-AD(
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MT!,#U.@G(,\;FD6[A5:N/X0N\05[,L:<S;J9G#8TE6@YAVK0K*P8 B2L67;
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M=^T*7Y*C^CUS_P"T5KT!&:QTHYC8.'CW/V6G'9/TAE&,FJX)GN7VY 50034
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M! 4\J+"^@V=N:8VB8\/P;E<4GTT^E2P_*5T(;@."Q184VFV2>.*R@!"2;82
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MN44-4N-S8LH,(D9B=9,^"UZ+EE(L1Q"LQ!CB$\N0%"TQ!-:0E6B16J"&6'M
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MFECXP1</#AQM>LW3D9<NU%V&SC?5G1A9',HF(R4D,1#?G;].(JQSZQ1G-#M
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MC//4QS4'DOIV_*S-A?7!5=JY&)E:VM R$[!J-(F4!>>C5U E64:J6/;.W)2
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MO?C+;6\3ONW1L-.36S7^OYVH6-M$->.@%:PU3GZ3(/QBUG+E\=:TN%T9,AF
MD?:\LD,A3XRJHEE?XR)X8*B;"ZS,;=X?S5^Y%B61TX.8JWQ;7)8*D;--*S$A
M/K+RQ-T<>CAU5E8V_4?$MG*N$1A(7\=:X>/#7*LC,LZ+<CUX5:ZGB "M27R<
MWB2!.54?3.]>-U'Y"ALO46HJY#;8X]Z6T=K^LZBV+8=B6"U[1IU3EJ4HHXK2
MVHJ&@5*>4GP>JR82"YXZ.@B*2!C(G%9GT,W95F4Y/'U@)>0X@X^R.?QU4H7%
M:O0R:<1+UV+1& ('&)PIV#?*A08M(BA1+^R\W!*C#AP[8LL!M;ACA:OB\K=,
M60=RQ5?9-312H'M9.0L6QKC6'JOZCB@.I';78;2=/D]?:?U?19I<CJ7J-"JM
M=E%TQ$R:C^(A6;)V*9C&.)DP71.5,PF-U( #U\\W9BTJ[E<A:3O*7VWL41=B
M,"87*91VV)D;&4>PBF-4\<IB:5<&K%3>238D)B0033)LH"8[2")/I#,=I$(F
M.TZV?G-U=TQIIC33&FF--,::8TTQIKGIVD7YU6E/VV_'3^>0^S_'R#J/NSU_
M!G]OY/?[W\Q_\-]/_?[N^OC/IO\ [W^%O_M&X*]F_P#NG/Z;^_\ %KH7GD-?
M9M,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIK2'(ACNY_J>S(\>[
MWKS7&S2MTU8>U[0K#VUU*/034*9\+N/93L$+=R9H"H,I!TK(,6;GPUGD4^;E
M.B-2UUXA)*<*E"X9M]@A[*^TP056NYZZ7\TC(D]+EEM($(\W4&U4FOSG%A+'
M22R%$ 4\HO\ \ G+#E:Y7:8-:G)9M/,)S(\A0 X-51T3;=DN&Y=H[\V[OQ9"
MP1$?:[C<(V=U"-) L8NX;TF"U81OHBO*>LP<';HQ$>UO0,O"2LBZX]"AU*_A
M@JVXH()4/36*\=WJMOM6NTWPD^(L[B6QD76#%2&-B9&87#(DM4;L&5NA%EHL
ME*3Z 4Q!-)5LU;7HE2A%^W3A(H++2=N8@Y67),S/379CRRQVO;G(T^31A[/'
M5R5D(627HDWL\C1\R:*NDU"Z[K4_5K!=%S D)&U;A;!%2<JX.DT9NBKJ$*;E
MWF-36-J9GG62SD1K,MFQ<,'JJ6E3%G+&+Y@!D$0I(H<:V !+*]24MUI*60/*
MXNB,G:526#&Q(*8ZT\&)2E32!CB9 C*A,98K?JAR6H/:%;EN".KI)-'7SAA7
MZKJ&1WK'K:ZOM9L%OG=M[DNVESPU&AYJU'D=53^O9:ARDE<*I9F6QG*4NX)3
M2R[<&HVAQV45P;>J$8C&.RD\.8^BNM;7<:G(9WA:KQ$64*\*4HNX%9W:Z*C0
MJU&VJD7+C"K-IS2=ILH95QEMYG,VZMGC^Q\ZLU7-B^"\A175KLI,F&IOY?'Y
M!33;-E@T7@N(JVU6@-<LNT!WK7=7\>MX5.7I.Z[*]N''W<1&,KK;1^TMF5B(
M%>D3\:4ULM-'J\W U(A%5BN5CV%_'E1CR*R*@E9HJ+%HZPB-Y]W\OX(\Y_!J
M5NH_SJ-8_L>4OV^W^UN-]N-1/G/^?S_#K^?_ (2<$-];@XO:LV/3>?>]=,UN
MR-[4I&:UIZUS+7*R6-O-GAG*<:6+VU6V %DWL<YFG/H\(Q 7DDX\0JZOB.5_
MLG$W%.)QV<OT[/">+R+TS7AEVS%:7OYZJ&#)]3'O/[&!BH=VE\Q8[<L;#'XB
M]%?HDXOXEX"P&;QOI@XLX9HWEY"48/&EE(I4.AEK]8X3X?B.BJ.NU)VF].JG
M=KV<W.7,PY5_)C<H?UTKDU\__9&P_P"]O;^+V?-YYPOCM@MYGXBX3\5/:/P>
MJMOQ[Z^@_(/Q[W_U_N.O\O-=O_:[;45==<$-]SW*[D?K./Y][U@+/0:EIF4L
M&T6*US^$VPFMLAYIU$14^9';320,UJ"319K$^FSLNF"3Q4&S>.)WDU.[<XIQ
M*<#AKI\)XIR+5C(K31.*TIJ%7:N&,5!8\@YK$E!'R*5.XQS$?:8^?83T1\7W
M/2%QM@D^F'BVG?PV.X8?<SRBR?CLRO(UK3:U>YR<1J=*\:*R57ZUNS'*T^F"
M([%*GY,;E#^NE<FO?T_-]A_N>?Q[]1Z?O#Y9POCM@OO%PG^32G_^4]_\^OH,
M>@?CZ/\ Q_<=?Y69_P _%L_CG>9]LSI\F+RA_72N3?\ =&P_R[8^.V"^\7"?
M7M4_JO4?(/Q[&_\ K_<=]_>>9G;_ -K?T[^4ZK\F-RA_72N37_'["Z_T[?Q?
M]?6/CM@OO&POXJ?]4ZF/0/Q[&W^O[QW/GON>9[_^UO;3Y,;E#U_U4GDS[_\
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M%PGXJGT_\E?IM&I^0?CWV>G[COW?;YF?Y>+?/ZMM/DQN4/7K\J5R:_X_8?\
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MCIY3Y"!M5:K,&\#UY7&+.%F'Z8/%&2P*@FGG:*$KXJIUW+B$6[N$P./!?SJ
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M0\G'DF9Y'-I3X7,& I1[9HN9F@=F=RIT:I%5*DF(#G5EB6PV602S54H)J"L
MA3&*B%6F-*)Y^HP1ZTS([$;"^=,]M43AHN"5P!+:ZPRT1D7.$$,$F$C'S>7J
M<PD,S$ &W+'>9U.S*NMVF--1ZY<?H4N3G[7K='M]GYV]E]N-(\X_S^7X=;"U
M'^=1K']CRE^SV?VMQOLQI/G/^;R_!KFMV9O(70-)X/Z,K%SWCI^I66*9WLLG
M7K/LREP,Y&F=;0N[YL5_$RLTT?LQ<,G39XW!PW2%9JX0<)@9%5,YOH'&V(RU
MKB?*6*V+R-A#)J<CD4K+5'RT*H%R,6H@+E,2$N69V*)B>\3K\Z>@KC/@_%^B
MGA.AD^*^&L=>KKR\/I7L[BZ=M$MS^5<N'5K%I;E2Q1@P(,(YEF)CN)1,S2;<
MB>&S.36FV>].,K69<]_TB7;;-U8A)N/$Z>)XS]*;*[5\0 #O]]4W>Z!WNO3/
M->I^(X5T/5>;A$3'V'P-_I1,3,Q]CZ7)O$S,Q\WM,S/GKZC'&OHSBS-V.+>!
M8N%$\UN,]P_%DHF(&=[$6^K,2,0,[G.\1$3VB-<^8/;6D[-S"YP*(<F]6ZZB
M;MKWC.SJ.SD;?IZ;CU9&N1DVO*_!P+^6Q4:PO8M8J+200<1DKZJ4=)JF2;/0
M;+$]!E<+F6\*\,(30R:[-7(99[EJQ[6/ "<F0%@$@S2+AYH@X@#D=Y4<=YU\
MVX3XXX-J>E_TG9&SQ+PS..OX+A"M3M/S]%%*VY>,R2'^%MA=4NRRBQJS<E;3
M 3@%6@)9DLI6:KV_JZC2[Y_>NTGH6YXYRP]$:0-MM?%&KL8QUXR2@239WK2M
M4R56< D0[<$'KYRQ\-8Y_1O%*FH3S\8/-0IBRX?RA,(UD+YH9"#6(PR#6(0$
M*(6R8$1&!&,J&%D$$<%]0^4'@&2"1X[X0$1@HD!XEP<B<;;1O,W)(>7;>.21
M]T[QVT96?@XCL*8V5,<HM<W*<DSOCL(R]\G*_;ZG4 DV7J^32HM4F[BZA*BC
M(,A%N\2A6C8JZ9C%. ]XW70'#N:&I9J%@LHU=M;46&NQ=MMAE=TD3*LV#1+8
MK%)=T04!L(QMRC$1O9Z2.!&-0WX]\(*FO*6+6CB;"I3UZ\[IM$D+L 5I<[R-
MB1ZD3)3!=YU8]-E[//0\W9;%KW?FFVTO9&",&#N;Y%5:Q&K-6:NWL@RIM)+,
M6]T6H4YA(23]^QK<$#.+:O':ZZ2 '/U#:6&XB.BS'EB\U*W<LO?%"[%VP:T1
M50RQ<A,6''5KC":A&<S7"-E<N\[X-](G #;2[9\;<%P2>M*4CQ'@PJJ.RP'6
MVKJQ<A(-N,6LKC!""L])?5DH6.V/[0JG9J;?K-!JETW3I):*UQ(RDC!J1/(>
MK0DB^&Q>(:W,+/)QMO;O+-%79591Q<XV95=M;*X.*\HFNI]MF*\#G%9.GEE8
M+)KM4*R*=8 Q5J*JZ=2S0NTZOA>AT2KTK>+Q]JHLAD4/IH:/SPB=3/I&X#FK
M:JEQYPC(6[)W6NGBC#>)&ZU%VHRXFSX[K)LLJ9*_4)RR$IK6WHB86<CK8^U;
M;P*W,.OOAUOO1CL=86-M::?ZLWS2X86+]NT,P%LX]6VI#T^(=LC"T?1+KQ&+
MUOT271.0.F83P[FCMS=9@\HYYT\C0;U<9;8MU7*JA-Y3EDF0:+@B)^?$\I1S
M#L7?6(^D+@%=.: <<<'JK]6C87"^)<*!I=C62RDU#!NP:324S DN1GEF1GYL
MS&L.TXS[//1=C<6>B<A=4F>E:RL;7&5FY+5VUPNOX2<>HR,Q7=<0\[<7C&CU
MZ2>-FB[R'KZ3-DL9FT R0E;(E)87B.(UUF5O5.99#XJ+>]N.N-M658\&A12^
MR:9:U5.'N\.LBD5RYDCW.=8.X_\ 1ZZP-B>-N#%],GL!".),(FJ#K7+XFR-9
M=T4Q9L=,(:^ ZAP.TEMOO(&=Y%\.K.T]!L6_.-\RT 3"5&1VSK5R5(QRB0QT
M3*6$3H*"41+XB)B'Z"(=[IFB>'LW)1,X/+<PS'+/JVY!1W@HVF$[QO(C,Q$[
M3M&^\:VCZ1> A@H'CKA"!*/G1\9L+RE'>/G1XW:8C>=MXG:?+:=6NW;UX;W>
MK.*9/\BM#JUUT$<1=BTW=0V/B(Q;ML\:MC+-K.FJ+8%6B!5D!.*:Z)3(J@9,
MYBCE."SQ/39/"Y8VILC:&2QMLA)PR4B3 E'*<012<"42// E$;C$QBKTA\ H
M62D\<\(*$JYUHY.)\,) DPZ1@!1>YAYE3*YF)WD"(9G8IUK^[7#A'L.VP%IM
M/*?7;]C7FS!NWU^GR>K[754BK%/T92+D)[7#>XDJTY)QSYNV79OI&/771,W1
M INZF4H37P>?KVF7 PV798,X8LWXVX_PKA#DBQ3%B2BK8B)*8<F!.#,CB8.=
M]0STA>C]E4*?QWX-4@ :HQ3Q+A538KM"5-JVC"[!6*IKF5DALDN0GED9CMK,
M)[<'"6SS3N>L.^^/DP^=T]_11(_W/K]PS:UJ75.M,LV#)2RBV9*3/5NE+.FZ
M9'#]NPCVZZAD6:)"Z'<-9A]>]5;@\L2LB"U7(G'7.9JE0SIID^CS"H":QD+&
M8'JE+9B3@9C>OTE<"I.FQ?'?!ZSHO.U6(>)<(/(]@K#K=KOSB!:^113OTP:\
M0V%S(+5.F2]GSH'7%JUAJ[D5JFOP%Q.Z/,RA^2U<?6X/'BDH)D6/MKRXJSD:
MG P[=K&5LC1VD6"9M&R$<"!$2 &^]A.(<A3&C:Q.:)0P^3,:-Y=A[;38;;LV
M'@J&NM6SB)LV&%+71&S"F(B-:$^D+T?(NLOKXVX,ZS)7$"7$>#-"E)EI)KH1
M-V5IK)-[32A8BM9L,A&)*9UKVQZU[.>TZKU+J&4Y50A:WI&Y(7_7TPPYDIQ]
MXC;4U.^,UE'MW:7Q.Q2IVP23Y-!-\^6232<JI 7N&$,V>I^(/6V,S,87*#=Q
M55E*M XNT-<ZSDIKN5:JPB$VH>A(I=U@/J+)@EOU"WD/2%P"%/)42XZX197R
MMD;5SK\3X9K":NS-Q<+:R[)J!5GD<L F( E*D=H6.L;N7'_LJ[W>'-_L.[]:
M'EW%^4VLE',.5D?%UF/VDZKKJKR.QXJM,+TA#QMVF(QV<TS86K5.0E)!)O(O
M%57:)5<I*X7S"4FA.%S*QZ&8JUC&C>AN/J9VPRWE:F-9TN:C5MVFMM,17D%P
M]K&0,$9;[V>DO@5I,)W'/!S>O7Q->T+.),(0WAPG@PQ3;HS=VM6*=>C6I)>W
MF8-$)JP72*1UB$%Q/[*.$;,V)N1T)/1T;05=:Q,;:>:JUCCHBKGG1LZ*<4TE
M-@KI,)-A8N[,QLNV D@PD$TG+9=-1,HA=G$<1\IB.)S"S(\4U;EXZXNQ6;A*
MTT\6VJX4PRN=2F15%DN1GPQDJ=P*8UJ'TB< #'+\=N#"43,DUJ3XCP9HL%F'
M%8R<6$S=D'#<LD5AXLB8)TRR8YM;N2J_9_?"32]OD>6T/8;)H>0F9.CR]EYE
M)SKMTZGV 1,I\,#R-\7^&*3B**2,\"?!XDFQ33;$*"9 +F X+.!;L7(P.2ZM
MK$6,'866)M%7;C[;ALV@.N2)43;%D$V&O(98;D(.2W4&V@^/?1ZRH%(N.N$9
M2O*ULRJ8XIP\-5>IJ97K$IT7NH"D5WV:ZTB4+%-JTOEV>S>T--8]F@SI]_UR
M'(+7+G6^P <BIKI[RJBW5&I"CJ8"PJ.-75E6[C&:X<$G2)R[=>JH1RC9^BBX
M0%,Z28ET?%S.Q3HT_5.<WQC:;,?=FE?G)THQQJ*BJOD)5XI::?ATBA4,Y5@D
M CYH[:MEZ2^ SN6KA<<<%R5^;YWT?&+!33OLRB7(R#KE7QG1L-N+LVO$,8,R
MPK=DBW)Q3.=:';=G=QS^,1;7&^].FEMLR3>8V-8K=R.K5TLEOD6T2W@TG<S-
M6.XOWKI7U<V21.8RGYH;OG-U,<PCM=@<V['3B9P.15CY.XR:J<394N6WI*;;
M2@*\23'$9$93,S)%,^<ZTCZ0^ HM(N_'OA([5>M7J)>?%.'-@UZK3;77S3>F
M9A4G A,]X6"PB>4(UH>F:YX9E;:VK6Q^5&GI>K\;MCSMSXZKU3DY#U55G&6)
MJ\:JP]_@HNWMXFSFC&,K+5\AWHN6<A#/G"*C)OZ2N0^T,/Q"PPNW,+D[.2/!
MV>&<A+L7;=2R.*>"UL-U1J)4#[()K39&!.(=3K-68])8AG:](GH_85M%7CGA
M"MC[F1JYV%HXEP=9U/*(;+>E6:BX!>"2WG;6B2@Q&RY3.>9)A[+J5([.VC4^
MPZ_J_*.L15)F3HA#U='F W&%UTU0E2S*4;JMB:]BAKR*+()H*^K:T5DT\-JU
M0\+P&Z:9=+<!Q ZM7KOQ6<<5>3Y;;J5YEY@%CVXR$ON&F7/0NF]@*4TB%9'U
M1V9$%K./23P%%]V0'C;@H6V"ACD!Q#@AIF_Q V669J#<A$67/&3>Z @VR;(*
M9@RC7UAJ1V;L$;618_D-K4K+4[QG)UJ(7Y20KF&>S#!W)R+>:M$6M=#-++,!
M)R\A**2$JFNY4D'!G1SBH4HEL1B>(AO!D(PF3%ZJ@4JXQBK4(JUUU%45#51T
M.F@E5$K0LEC$BO<8[%.]=OI!X ?5;4;QWPB:W6&V;!SQ1A>N\W.A[0>[QO48
MHVB)$LID=P';;;5XY PO9V<EWSB2V9R'U<61=Z\L>JWSZG\G(&E.G]%MCE!U
M-P3Y:N7-B=T@Z,B=,AUA,H@W>/T4C%3>+@;G3PKEY.V?J3,Q-[U7-F(H7H%A
M86V^[CCVA.T'7L6'%!QW(3D)F1B(BZCTH<#USHL5QUP9U,:^]8ID7$6",DLR
M-5%6WM)7)F18%:HV!GL-BK6>,0Q0%&DT.-?9?)ELOIG*5I-+VI;43N0>SW-Y
MU,/FK[1BJ!]9R,2Z?;"55BI"OIH&:%=M!35=LW+UJY,HDZ6*:_.'X@EQ6/4N
M4AQ9W)<1D<8RWN65S&(;@,JTOL/=61PQJQURO/V)U:G060[4T<G.'CST>!V#
MC?@\ ]1IX=A0\3X85CB:N4G,T:XA%Z(B<?E"L7*#?MZK[ETE$/BG<UKD>*?9
M7R#9%DGR@;Q+!O5+;2$8^"YQOH9DG6+S9UKA:(HK9CL1)+P)2PKB_6ZE$P&2
M;D 0(@F!:_Q>SDJ-,X;+DLZV!J$)8^X4=#AD0#"KC=,[12A8<DQWF1CFF=M7
MC])? K/MN.>#2+QN2R'/\8\'SS:RZ(K9!DE%S>8L)YUD'VL"UT#$=0]]\['A
M> .TJAI>EV7E=6FT;H.5BYO74A7.7S.N6%M,0L2>#C)*;GXF\MI.Q/6<4LY9
MI+RZ[DX)/'@"(^DJ][=8PO$-G*LS3,/F!O-K9"J9JQUQ2NEE%=&],)!,+%CQ
MVDF0,'!Q!#,%$3JM3](/H^H8EF$3QMP:5!LTN<'\281[9C'.\147#F798*U.
M$&0L2@9E*=XGI!MHH>*?92JU*&I3SD77Y*%A(#8=5;C)\T#OY%U7-H3\;:K5
M"R4FXOYWDA''LT4VGXMNX5,6(ECNGC'PE7*PFA&#SU5E1B,'DU32J\*5*L!B
M[4 M7 ]^UD.%B@>ARRW#G;?6JMF),:$C2F9K@ 1(^D3@(9LS\>^$B*UDLYE7
M$?%&&,IN<2TE4LZ0R5Z>1>4!0V+:AV!MTF7)CKL,RR"P:![-&R2-TE'W+,&S
MO8%XJ.Q;0,5SC>1:3ZUT5JFSJ[]-%EL))-JG%HI)^$U;@FW,<A5#D$X=<PK8
M#.U64C1A<O$T,M?SE49QUPP#)9.8\:Z0),P0M 05TBB5BE2E", L8B&>D'T?
M,5:4SC;@PANX2GP\\BXDPG.6*H,EM5 G-W<"6TVGUAF&$3WR13U3WD7MVP\%
M=V0%1AKER;UHUD:&\3D*?>*GR:KU0V/7GP,0C7CN-O<#<6=B;KR['O-9HQ7O
M252.<KT%0-Y0?#^<.[&0C"953^2PDH3C;BD-JVB WTG(!,*;3,EJ*:QC*X):
MYB(D8G6:_2-P$NH=&>.>#VUS*LV1?Q-A7%#Z<GX:U!LND4650QHB_?J<K6C,
MS!EOK[X)]G<A?]([&BN3=*KDUQ^AY6$UU&UOEG&P=63:6)X5]:EK'5V%W1A[
M3(6]=- +9(3;9V[L";=NG(JKE1)TW(PF>KW[.05@LEUK6(7@946)LG51ATA7
MBO0J52KRFK7K%3I.K D!A+Z--R]CKKF-3?2#Z/W8]6-9QWPAT0SC.(S</%&%
M&Y9S+1L@V[:MQ>A]EIA>R2SZIE$AE,D,Q^O7\WIW=6NSGW_-6JPWWD1K-O,7
M;7Y=8V9]4.4,)3%92HDD0DT62_P?NC(HN6[KO^CO@#TI!%9=%-0J:QP&E'"V
M8B+,#A,R,7+^*R3X&A>B#N86730;_8NW3BPP6!&PN"8%D% QJU\I? L36GX\
M\&25.ODJB)GB/!R0U\N*1O*+>Y\X63748<V_38'.'*6\ZT_'\;NS C74W*H<
MI6A[),S-7L*%Q<\WG3BXUJ<J$*>MPLI3K*IL(92K/"5TXP+Q6(7;>GQ %8.P
M50*4@7IQ'$?V.1Q.8!B[.4M=8,=<!S#S1K;E%-:*8-M:]84NS8KG,J.R ND>
MI$3K1'I"]'W2&O/&O!9UPJT::ZY\1X0D+3C2F<?*US=Y0;2@C"LV(ABEL8L2
M@3*)]?.N8T]N/B0&@-)\A^-MBF7%YU+(NW>Q^6-?K#PU>I.PX"\S\JXO#/X9
MV%_:9$L"9N@Y.W0<JR$D>44E$E&OA.*S<!Q [-\-7CP>535Q.?QV3M>#Q]RJ
MU-7'+9"U4%JKB(-WZ:U3U%0F(ZFYR/(5K'^DCT>4J.>1''?"+'Y'AGB+#U/$
M<286V!VL_C;.+AUPFY'F)"!O,MLB19-B$15V7UNNJ[R>F^S*L]*A:I9=_P"O
MG3IE9)FZRMD5Y<L7UZL%EL]:7JD\:V7U2YHV&W-5J\Z/ D3F%3(A&-VB*3=
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M*R%4;VA.*?)\R2(.CR%QDFDO.V%ZLC?2'>V9Q(1\>X1GU1&2;&CV0(+D*@0
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M*TZV)LM/B?"RL,2I729RK\;//9E"PJ(9N'1 R=S'*X671@.5W%DH  <E- %
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M/8ZD@WD@R0!R\8M-U[;</6C<Q>^5=RV1V>==NB8@]X%52$()1 >]TQ/'W%L
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M]G1V7FK(B,G;_JR)K$5,SD/6XEW)[?W,@22G9UP5I$1C+KLCO.73U<Y2()I
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M,1Q!Q/)"7_!F/74R,]_+M.O&AV879INE'J3;4\ Y5C&PO9%-#=NV5E(]F B
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M&O93?H N/OGU_J+87T>W;5]SU_'O]]F7V_X5.?QX^I/T:^+_  >^_H>X-_\
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M$36*V28@ANFMEE3)*(::5P"H%HSSK".0)()AJXF"):P89F6UDBZ*XMB?UL)
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M&S?/X!JCR-UAL)CHZ3Y*[7LRPG,:B" H:0%%RJU58% +60"_2CGN+.2 $"C
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M <M-1IA:5B JB-E=H@N_S1*;!\+VL"31F2'*Y!L6!J9E^TP0,HK:  QT%<*
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M1V/II]IL#FQD+>8/K<*<7\-GDPADVD,O<0Y3*X2Z#"*',(JEE""$95%1I,@
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M"HJZ(-< \C8L95D<A3"0,34:<=1H7+#2;N,+M(FS9FY1Y3FE315O-?(7NE6
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M+<AB8B(VB8C:(CRB-0<[2+\ZK2G[;?CI_/(?\?=^]USUW!O]O9/_ .K^8_\
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MQ:&6F,B!?9$6*N0KVU<Z"778<6@A+ICA1S=U)>^1UFF:OQ"V_5N0MMV[+O\
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M-W[1^/Z->5_QB[4.*9N9&3[0ZFQL>S2.X>/G]'AFC)JW3#O'6<NG%531013
M!$ZJJA"%#J(F  Q/$' <;;\)MB9(1C>V?SB*=H&-['>2F8@8CO,S$1O,ZR'T
M=_"$,H$/3!1(IGL(X5)%/T1$8V9GW]N^OHVXM]J4\;HNVG:$U-TU<I)KMW+:
MAQ*[==!4H'26062J9TU4E""!DU"&,0Y3 8HB @.26=X'"9$N$7B0S,$)63B8
MF)VD9&7Q,3$Q,3$]]]8QZ/OA S';TQX^?IC#5Y\MXF/[F^_S^F->26XU]IY
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MCPS-FT03#JHNY=.:JF@@BF "8ZBIR$*'F8W3(GB#@2-M^$VQN4#&]LOG$4Q
MC&]CO,S,",1WF9VC>=2/H[^$(<P(>F"B1S,[".%21%[=H&,;,]H]V^OVUXN]
MJ2^;-WC+M"JD\9ND4G#5VUHD0X;N6ZQ 427;KI50Z2R*I#%.DJF8Q#D,!BF,
M40$<BSO PE(EP@\"&9@Q*R<%!1.TC(R^)&8G>)B>\>WOK'Y/OA SY>F*A,=X
M_N.B>\=ICMC8\IB?P]IU]_L4^U2_7 :S][XOHS_HE_C\^1.?X$]G"3H_YV<[
M_P#^_4_)]\(+]V''_5ZF1_5WX=5'BGVJ7N[0&LA_Z/HP?W?[4LCU]P+]Z;OR
MHO\ K&H^3WX07[L5#^!D=_\ ]FZ?8I]JE^N UGV_I?1GF'S?VH_X_3DQG^!?
M;PDZ?^='_FL:?)[\(+]V*A_ R/ZMU;9?C7VG<!'.9>=[1:CPD2R)XKR4EZ9!
MQL<T2$P% [IZ\JZ#9 @F,4H'55(7O& .O40Q&?X$DUA'"3I-K02I<6SDFM:4
M M2QZ\D;6'," #N1E,"(S,[:R'T=_"$*9@?3!1*8@CV'"IF1$(DC*8C&[\HC
M$R13V$8F9F(C?5P+Q5[5 Y2F+V@=8,4P 8IBZ_BQ*8I@Z@8HA4A 0$! 0, B
M @/4/GQZ^X%C>)X2=O$^VT<;;>R8Z_X_;K&/1]\(&8B8],5"8F(F)]3UYB8F
M-XF-L;[?..\QM[]?K[%/M4NO^J UG[WQ?QG[W]J.1Z^X%^]-WY4?_6-/D]^$
M%^[%0_@9']6ZML;QL[3J9!Z,/VBU'E0C7Z\5(C&TR#?!'RC4J9W,:]%K5U0:
MOVY%D3.&:_AN$BJIF.F0%"",QG^!26ML<).);1,E,BT<@T08Q!$LXL2)P#TM
M44C,Q#5L7.Q 40^3[X0,&Q<^F+']11"#5SAT<ZC)2W"+!]6\P$:6J<(E$3*F
M@<1RF!3<?L4NU2_7 JS]7T9_T2QZ_P"!?O2=[/\ ;1_A_P!L>W^;\,_)[\('
M]V*AY?<>OY^_^YG\6K5.<<.TVK$4]GK)VC5#K\'&('<R4S.4^!B8J/;)AU.X
M>R+^L-VC1 @>9U5UDTRA[3%]N8'Q%P$N(EG"IA!$(1)W)&",YV (DK,;D4SL
M(Q.Y3M$1,^>0>COX0AS(AZ7Z1E$24P.%24P(QN4S XW>!B.\E[([S,:L+#3?
M:'2LM$0,7VGVI9*<GX<+#!0T?#U!Y+3<!T(/KV)CF\ J[D8<043'UFS169=#
MDZ+_ &P".Z,WP1SO7\3[,LJ0$VE^(9!UH9,0N; ]?F3SS.P]2!@MXY=YUKC@
M#T_RM+OEDQQ)L$05VQB*_3>81,F*61CN5I!$3)"N9D8C>8C;61NN-/:>L7;!
M@^[16DLWTHHHC&,G5+@V[N162(951)BW6JQ%G:B:9144(W(H8J91,8 * CF$
M9_@0BY!X2<1P!,D(ME)],8^<?+#]X -XDBVY8]LZRGT>_""$>H7IBH0$$ 24
MX9$#SG/* 24XW:",NPCON4]AC?5Q^Q3[5+K_ *H#6>G['T9_+\$O;^YT^C'K
M_@3[TG?E9_3[K$?1^D]H^3WX07[L5#\.&1_FQL=_XOHT'BGVJ7N[0&L>SWZ_
MC/\ HE^Z(_>\O;U>O^!?O2=^5EM_^_\ +;Z=_I][Y/OA!;?[,6/^OU.CZ-H_
MN;M[]YU:HWC?VG$RB[<0_:,T66;L'CF/?.(VG0+Y%F_9]/3&+M5K6%2-WC7O
MD]);+&(LAU+XJ9>\'6/C!P'TENGA-W28!-6[Q90MBA,UDP#E\@2Q-; DQF1@
MUF,SN)1"/1]\(&38J/3%CY:ID+8N,.B6+80 P5L#U=) 9+:I@B404@8%$2)C
M,_6*XT]I[.,4).%[1.DS$:Y\3T>1BZ7"/V+@$E#HJ^ [:599NKX:R:B2G<4-
MW%"'3-W3E$ S+.<#!L)\(6!*8$MBM,&9$X@P+:7_ &I!,$,^1#,%$[3$ZGY/
MOA ;E'RPX^9$B$H]3HW$A[2,_L;V(9WB8F-X\I[Z^K/C%VH<BFHM']H=3GR2
M+EPT659T>&=)INVBQD'350Z%4.1-RU7(=!PB80415(9-4A3E$H81G^!9$#CA
M-T@P!8LHM%(L6?<# H?L8%'<2&=BCO$Z?)]\(&",9],5"" I$A]3HY@+;?E*
M/5N\3&\3M,1.VWOUZOL4^U2_7 :S]7T9_P!$OW_XNF3Z_P"!?O2='U6R_P [
MY]FH^3WX07[L5#^!D?U;I]BEVJ?ZX%6?J^C/^B6/7_ OWI._*CW_ /B/\WX-
M3\GOP@=O]F*AO[_4Z/ZM_3?5?L4^U2\O\\!K/U?1GG_ZI!]_VX]?\"_>D[S_
M &T?XO[//Z?QOD]^$%^[%0_@='T?\F_7^/5/L4^U2_7 :S]7T9^__:E_[L3G
M^!/O2='_ #L_\[Y_S:3Z/OA ^STPT(_]3H_JW].WT[U^Q3[5+W]H#6?J^C//
M_P!4?9_']./7_ OWI._*C_ZQJ/D]^$%^[%0_@9']6ZI]BGVJ7ZX#6?J^C/W?
M]B./7_ OWI._*C]W_P"41]?^C3Y/?A!?NQ4/X&1_5NJ_8I]JEU_U0&L_>^+Z
M,_=_V)8]?<"_>F[Z?UT7O_\ /^[^/4_)]\('V^F*A_ Z(G_Y;,?Q:?8I]JE^
MN UGV_I?1GL\_+^U'[W[V(S_  )'GPDZ?^=G'_\ $:CY/?A!?NQ4/X&1]/\
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M3&FF--,::8TTQIIC33&FF--,::YZ=I%^=5I3V_HM^.OL_P#/(?XOGSU_!O\
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M5,PM:TFR5H#RX) &&\?#RFP^2&"E@J[1,G&_;6<6VB!FK32/(]LV.8YS-F]
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M9_N5A_;Y=_7^W?V>_;3Y;WC3^D]R;_@10>GE[1_/0\_W,GY,LU]T,)^56_\
MJ/\ 'Y?3YZF?A5<"Q$3/#7'>T_\ )6'V_'Z_VU4>V\XTA_M/<F_9U_M(H/NZ
M#^FA]/M]GTXGT99K[HX3RW_MFWV_^X?/Z-3^JHX&^]KCORB?[E8?RGV_W?\
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M_5#NO\M^-.WZ3_HT]4]H']W_  Y^J'=?Y;\::IZI[03[O^''T_UH-V?EP_\
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M$_3 X<?5!NS\N&--5]4]H'[[_P .?J@W6'_MP'&I[>V)_'M_FG3U3V@?W?\
M#GZH=U_EOQJ.WL_EW_S1IZI[0/[O^'/7]B#=?\GQX?W\::>J>T#Z?V_\..O[
M$&Z^G[WQX?W\::IZI[03],#AQ]4&[/RX8TT]4]H)^F!PX^J#=GY<,::KZI[0
M/[O^'/T_UH-U_EP\OX\::>J>T#^[_AS]4&Z_RX8TT]4]H']W_#GZH=U_EOQI
MIZI[0/[O^'/U0[K_ "WXT[?I/X_9_P!WTZ>J>T#^[_AS]4&Z_P!W_;P_Q^G&
MG;])_P!&J>J>T$^[_AQ]4&[/RX??_P ?:TU7U3V@?W?\.?JAW7^6_&FGJGM
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M@?W?\.?J@W7[/KP_C_BQIV_2?9^+^/\ BU3U3V@GZ8'#CZH-V?EPQIJOJGM
M_N_X<_5#NO\ +?C3M[?Y?]$Z>J>T#^[_ (<_5#NO\M^-3V]T_C_T:IZI[03[
MO^''U0;L_+AC4:>J>T$_3 X<?5!NS\N&--5]4]H']W_#GZH=U_EOQIV_2?\
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C-,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g374624g64p61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g64p61.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X=F@:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M8S P," W.2XQ
M8C8U83<Y+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C
M.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A
M=6QT(CYG-C1P-C$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @
M(&<V-' V,2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!$96QT828C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C8M3F]V+3(P,C(@,#0Z-#(Z
M,34F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C4M3F]V+3(P,C(@,3DZ
M,3(Z,34F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,C8N-2XR)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#(@0TU92R!B;&%C:R!O
M8FIE8W1S(&-H86YG960@=&\@9W)A>7-C86QE+B8C>$$[)B-X03OB@*(@.#8@
M0TU92R!B;&%C:R!C:&%R86-T97)S(&-H86YG960@=&\@9W)A>7-C86QE+B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE<RU";VQD)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U
M;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF
M(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S8T
M<#8Q+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E;'1A)B-X03M,
M;V-A;"!4:6UE.B @(" @(" @(" @(" R-BU.;W8M,C R,B P-3HP,CHP-28C
M>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R-2U.;W8M,C R,B Q.3HS,CHP
M-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R
M871O<B!697)S:6]N.B @(" R-BXU+C(F(WA!.T=R87!H:6,@='EP93H@(" @
M(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K
M(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E
M(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @5&EM97,M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O
M;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<V-' V,2YA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,C8M3F]V+3(P,C(@,#4Z,#4Z-# F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,C4M3F]V+3(P,C(@,3DZ,S4Z-# F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,C8N-2XR)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE
M87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R
M;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @(%1I;65S+4)O
M;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @
M(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C(M,3$M,C94,#4Z,#4Z-#4K
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(R+3$Q+3(V5# U.C U.C0U*S U.C,P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,3$M,C94,#4Z,#4Z
M-#4K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T
M;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R(#(V+C4@*%=I;F1O=W,I/"]X;7 Z
M0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FAE:6=H=#XQ,3(\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M
M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W
M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!8T%%04%W15(F(WA!
M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'
M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1
M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q
M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L
M<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!
M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%
M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!-V0U9B].
M16$X8FQD4#!M4G!,5D$F(WA!.S=).'%Q5S5'9T-N:GAR+W)%041C;6=/6D]4
M5&-(375S,"]A47I8=WA/>4Y0;F)79VMZ+S1C;4M7-D=78VDW=%<T27!C16M"
M>61J17<F(WA!.RMJ22M#4#4S,W1V-75F.$%-3S-N2#EB1R]0,VY0>E1P9'IP
M=7!2864Y:D9A>GE23WIZ4GEX6$MY2W)C0W%(;%%Q=%%30E0R3UA934TF(WA!
M.UI73'1W=&9R375->&M),$%E.%55.6XO3E121CAR4C8O0D4P-#E624QI>D1!
M4U)33W)':E8W9D1S92M61%13-'5&>6HR;FHX3'A"=C4F(WA!.V11-U)F>DEF
M5CE0=611='1+6DQA,5-2:3!S-DM834E6;E9&05DQ<$EV,G%$9G)81V5N-%12
M2S1.9C1S5$E2,DAM14(U,C@U-FMM:&$F(WA!.W9:>C91.79X:F5%,TEU;T=O
M5SE-0U)51&5O>2]V-#EW=3-,96U4=S1H>$$R,6$S5U-'3U%-4TYU9&HU.#<V
M:%,O3$PX>E8Q5EDY1S$F(WA!.VU13'%A:FIB6$QB0V-$.6QV*TQ0*TIF4'%D
M4G K2&-C;4A:=F%8:65I9C$O9BLQ25A0-7IF;S8P,4,S,4$S5G1D5S8S46%-
M=W%54C F(WA!.TUG1&E622]I-&<O6G(K<DQF,TYK14]*+V@S0TI#5F=I*VXV
M44=T56(X-3E/=%!R:W0O-FQU<U)M;6MJ93-):C1Q>G-J8V=T5U954#(F(WA!
M.V%G.6EC62M#5%9,;$]U:$AI2C)Q+W=#2&(X951*4$]F-6UP;VUI,G1P6G5*
M.65U8F5.,UDP2W<X,$(U=4]N23%Q<2]39'5T3TA4.%(F(WA!.W,O4S4R=3=3
M1TM!03-M4CAK=#AP+VTW-68P+WDO85=M<&TW;78T=S5U2E%G9FMZ>4TY95)C
M12]A>6584WE-:5)Y84Y,,G9I:FI!;50F(WA!.WAD53,O=T-6,V549CDY,VXO
M27!0*V$X<B]*>CAM+SA!;&Y"-2]*,R]!0W4W>6(O=G4X+S5&2B]Z6&HK5&XU
M3"]!0WIG."]K-R]L9#,F(WA!.VLS+V9D-2]Y2U0O;79(.&Y0>5@K5V-(;CAN
M9CAR=3AM+W=#*S=Z+VM5;B].95 U3V9K=CAS-%!0-4\O-5AD-4XO=T(Y,VXO
M27!0.$$F(WA!.VUV2#AN4'E8*U=C2&XX;F8X<G4X;2\W-W90.$%K56XO0418
M:BM4;C5,+TQ/1'HK5'8K5C-E5&8Y.3-N+T%#2U0O;79(.&Y0>5@K5V,F(WA!
M.TAN.&YF.')U.&TO-S=V4"M24V8X,30O:S4K4R]Y>F<X+VLW+T%*6&0U3B\S
M,V5F.&EK+S5R>"]*>CAL+VQN0C4O2C,O04-U-WEB+W8F(WA!.W4X+S5&2B]Z
M6&HK5&XU3"]!0WIG."]K-R]L9#-K,R]F9#4O>4M4+VUV2#AN4'E8*U=C2&XX
M;F8X<G4X;2]W0RLW>B]K56XO3F50-4\F(WA!.V9K=CAS-%!0-4\O-5AD-4XO
M=T(Y,VXO27!0.$%M=D@X;E!Y6"M78TAN.&YF.')U.&TO-S=V4#A!:U5N+T%$
M6&HK5&XU3"],3T1Z*U0F(WA!.W8K5C-E5&8Y.3-N+T%#2U0O;79(.&Y0>5@K
M5V-(;CAN9CAR=3AM+S<W=E K4E-F.#$T+VLU*U,O>7IG."]K-R]!2EAD-4XO
M,S-E9C@F(WA!.VEK+S5R>"]*>CAL+VQN0C4O2C,O04-U-WEB+W9U."\U1DHO
M>EAJ*U1N-4PO04-Z9S@O:S<O;&0S:S,O9F0U+WE+5"]M=D@X;E!Y6"LF(WA!
M.U=C2&XX;4LV-RMB<7(U<'1.53!8,5=S5F=%3C=A5&=)2DM/>F)53%5)1&).
M+T1,-&%8,&M3-75$;C=807EI55!P<F-05V1",3=49&0F(WA!.S R3%5.4&PY
M4T-46FQ/>DEW-F\T-TU-=UIW35129"]G>GAY>$5O;EHT>' O:RLS6%-,4TLK
M.'0V;S)P0GDY,6-2=U-/<%535E9/4'(F(WA!.W=G:&M8:6%!2#1Q:'1Q2%E3
M>D=Z56A8-#AN;DUE:4A!0DQ(4&DV;C0O=T)99% W5FQZ-4UT<$AU+U0X=C9Z
M178Q9%)9*VQ">"]W0DHF(WA!.T%E=G%I4U-F-$0X1F5,5C8P07=J361V5D9%
M.41%,U=/63(R.2LO3WED=51T9'1V3#)N47IX6%=K86YP.6YC54]N,CEW<VE2
M3$MJ9WDF(WA!.U-+1%!*.&)1;FAV>49A2%E':7-$23AI0V9X-4QN:&EG0TI2
M;D=*-4$X<C<O04MJ=E=Y;'!0-6-A>"MG1C%A-G0W:5),<5)6:3 K1E<F(WA!
M.V%1>&Q72WI32TM(:4@T-V1A5CES6C9G8U9"1VXW3FXT9D9)2&8K2#E*4E8Q
M-55T1W5N34AL5%9&=%I8:D)8,'!6:VEJ5UAK>E)K>E,F(WA!.V=S.%(T1EAR
M=4]12S%O04UP<C9H*U!G>FQO-#-T:6Y7,S,O,6HP,B]5;WHK6&)7>#!3.%8Y
M1C%I1F53>79D5%)(:4DT-#0R2WEH2EDF(WA!.S1Y=G%#540T86=-1S562$5K
M6D-:1&5,139A34UC=E)K<FYF:TLU*V]$=CA!;GI1,F=E5$DO3E!M854V17-T
M;F]%3$EZ6$UL96-9-&<F(WA!.VQ"57174W1F,FI4<C!Y53@S0D@Q8GEA<T=J
M1V9,94\T-'@Q+TA6:E=H>F%01&9C.5=G831T4%1K2'!O1THY47%21V%,2D%A
M0G%%+T@F(WA!.VPP>$EJ6G=D4$Q'2F5S5U!X-6@R=5,V3DQQ1%-A4$)*8C)*
M4D]-37@U3W)H44@K3&LQ8715,3(K47AG2E8V=6%.4DQ'6EAJ0D5F3D8F(WA!
M.RMA4$QE<F%.8WA09D%Y4EAQ3%!B6&4U5U)706)R+TUT9'@O1$DT<V=K3G5J
M9').3%!&2S5B9SE5<%<R=5A537-4<W V14M337-S3TTF(WA!.TUC:GE"8BMP
M,V8X079I5"]!249V-EE/24PT574T=2MP,V8X079I5"]!249V-EDX45AW<&1X
M9#E4=2\X069%;B]!04QF,'@T9W9H4S<F(WA!.VDW-FYD+S<T:R\T1G8V63A1
M6'=P9'AD.51U+SDX4V8X0S,Y365)3#15=31U*W S9BLK2E K0F(K;5!%1CA+
M6&-89E4W=B]F16XO070F(WA!.R]42&E#*T9,=4MC-D1F,BMN,CDS0F9A1TY3
M1C!984Y)3T1X<$=73'%J.$=:5$E'<%932V9Q<GE#-G%63U9P-6-!26QJ-')R
M-&9:,5(F(WA!.SDQ<EAL*S9705-E575$>#(U9VMK:&YK:4Q.46-:445J0SAW
M86XT9S%E*U)%2D0K2G9N;'AY-31E;&)%:C0X;%<Q,79Y,UI7;'!,8F4F(WA!
M.U9053%324UT>3$P.&LY=34Y2&=R96Q)1T)R265:04-K56]',S)":$EN95=Y
M635C8U%#35AR-C-:2'E0>C9E.5)G,69Y-4A'16)Y:'HF(WA!.T%-5$9J8WHX
M:3A:*TTQ2W0X3'%A8U)T,S,R;U1'6#@U:DA,:D@K4BLP+W%9+V9X>EA..6-8
M159M,79&3DLX:V1U<6YJ1W)-4T5&074F(WA!.WEG,#9:8D5G0W)C3$I#57!%
M:4I!2C5+2#%/-R]!3CA39CA#,SE-4$5'2&A3-VDW-FYD+S<T:R\T1G8V63A1
M6'=P9'AD.51U+SDX4V8F(WA!.SA#,SE-94E,-%5U-'4K<#-F*RM*4"M"8BMM
M4$5&.$M88UAF53=V.$$S>$HO=TQF,'@T9W9H4S=I-S9N9"]W0RM*4#A!9U<O
M<&IX0F8F(WA!.T-L,T8S,4\W+W=".%-F.$%!="]42&E#*T9,=4MY4TM333!K
M4FM*,T%9169R=V=S6E))-799+WE:.' V,UER2G).,4TY=%HS855H<V8F(WA!
M.SDK:G%S<F<Y05 R934K6%A8-G9,13="-EAS9E-49T]/4F](<"ML-FYM0S<Q
M,DMP5')0;&Y43EEV=%!U<CE05UA4;6532T)T,%HS-# F(WA!.TQJ=G@T.4UN
M1$E99V=D5VI,<#0U0T1,9FA48DE.-W-6465S85I&<6UL,U=N4W5Y4EAC8E)3
M3W1/459T:E-V9DI1;'=M,G9,:D4T;4HF(WA!.S5&5'-B2%(O3"ML4C(Q=7-D
M;EE1555&:E%666AA<W@V;&U0531:4TUJ6C5O:$-'2TY$84E9<BM91FAP,7-T
M:3!D=D1#<$5X8W%I<4LF(WA!.T1H,6]",'A%:C-P3T]08T9$>499-F9C6&1Z
M-G1V1DUN<$M6-4ER1&1U;W%-5$DY-FI(2'5$34YC.'8V6')E;'EA8F9W:#=D
M>#A&2T(F(WA!.V\R06]R268R4W8X06YT:D-::6)$2$YG:FMJ=WE'>6XU5C!2
M=$0P1S$P<'!236)53V]L07!Y0FM:;$Y/>&\R*T]39D9);$=M=RM(:D4F(WA!
M.T\U3F-G,W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W-:,6YY4%EA>C5O=$Y9,4=K,79:44-/2S F(WA!.TDR95%/>F-N
M.%9&96YF=G0Q=6AM35EK1'$T96)2>'E:0D]7+T-/5$IU;55U63=&6%EQ-T98
M>FPU3S!,>DHU<'5R:3-S.51A0C=D0DDF(WA!.WAM;&QO45148FIY>F(U<'AH
M>D1X,FEW-6,U245Y2SAY>7(O;%0O;F8O<2M29CAJ8FHO;6Y+4'I54#5R<U U
M2WHO=T-Q9F4W+T%*52\F(WA!.S4S+S9V:U@O04-.=5 K86-F>E50-7$O>59N
M+S%4-S!,<68U4BMD-#=+4G8P:VPW=7$O5E5K;4IF:W=8.7-"84-T5%A*4C%5
M3#55,34F(WA!.V5Y<R]$.69&-6)P<C4S.'(V;D8U4S!84TQM+TYZ95%E;U=M
M979(8FA33W1/4E9A-T4W-V9D:E)Z050T9TAA5#!5<&%F=VI,,60V6F8F(WA!
M.VQ,<#<R0WI7>GEE;S9X,5DY9U,Y84PW6EAL;GA3='ED2F=/3$=)13-4,&)+
M;DED:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U8F(WA!.V1I<G-69&ER
M<U9D:7)S5F1I<G-65W9,1VA13W=5>4YX44AU,4-A1#9!8U9867$W1EA9<3=&
M6&DS-41F.&1J5E K6610*THU<V1B>40F(WA!.WIF65 Q4SEW93 U<FYP2%EQ
M-T971R]M2B]W0DLO=T0U-V8X04=M14MW-"MF3$AY878Q,CED631R:VU%33!C
M<V=Q:5!-,6931$5!4G@F(WA!.TUX2C)!1TM%.3!Z.#%*9%5T9G)6:DA$3$%*
M2DEI4VMQ15-1=5DU1DMU5EE&6%5J8UDP;$8O=T1+=TY4+T%/5V5$+V@O*V%S
M859*+TTF(WA!.U U,C)8;#!7-V%W66)96%1&3&-I2S1K-4U#;S1J,&<O>&9'
M2T1V=C1(1VQ2,FYF;6IC86IA:39T25EM:$QY4C%E3V%.=554=$<T2U,F(WA!
M.V-71DA1:G!J4V]R+T%*5T)Q9CA!>7IW9CA0.$$X,5DP<51A,RMD.6AO;#5A
M,F5Q3D1B,TXY6#9P2#96=R]Q1F5Q<55$070P2$AR56HF(WA!.WA'3DMM1VXO
M04IO>F%H8FTT<VQT-31"2DI&-FDX*U!/1GI'-$)R=E(Q27)J4V]N+T%*5T)Q
M9CA!>7IW9CA0.$$X,5DP<51A,RMD.6@F(WA!.V]L-6$R97%.1&(S3CE8-G!(
M-E9W+W%&97%Q541!=#!(2')5:GA'3DMI=$0O041B1W5A6$1Q;6QR0F-71GAY
M.4=B:$MN3&<U:F(T6D\F(WA!.TQ#:DM2=4UA5D@O.')!,5 O;&YG+W=#2"]W
M0V%S859*9&,O4$=W,$LV=')45E=I=#=I.41F5DEX1&-31U5R,5905$0Q8G1X
M-FMK1'$F(WA!.U)J4V]N4W9Z9U16:5)93$9-0D)"9$)J1D]I;4<U1$Y%-G,O
M14YY0TAP,#<P>'!5>"]W0U9G86XO04US.$@O1"]!4$Y73DML;78O;D@F(WA!
M.T0U9G-0<BMR*VIB5V9-4FUB,#5P04=+;&=$-F9-:79(879F8G%2:E-O9E1V
M>C P=E5B*U!4-T]A,VMV<$8U<F)&2C!K-&U.6E%3<C@F(WA!.U-+>'5'1F8T
M2$=L5'8O;%E'<"\X<SA(+T%!+R]!1%9J4W)*9GI%,4=+2C58=#1U0TM78FES
M:D=G1E125DI**U%X<%=-,B\X07IK8C4F(WA!.V-U8F5/-70W:4M7,VQL*W)P
M2VQV9'-P;4YA4E9#9F)B:CA+.51T5'%+=$MY3S O374W=DQ31S=T;S=E5S)U
M23%L9VQ8;E)K8T)L668F(WA!.T8P24].2W)F.')!,5 O;&YG+S1F+VUR1VQ9
M:#5P+T]N47AE2%)D4750<3)O5VXK;'1(1&(S5'5Q4G@X>31+230T:%AR561X
M5'%$:E,F(WA!.W919DI(;FY44$U59'IB4C-#4S,K;E1.83-94W105FI65UEF
M-GEH>'E!+W)22W O9EA%.%)T-#1&47E816YP9W98:4M2=DI88B]5<&DF(WA!
M.T%X:U-+<$18=#=E,DYP3&58='A:5W1P07!E831M9&\T,%5D5UHR2592.#A/
M>5!6-4M597)Y4S)K1C5(939E.7!D37-D=&-R2U1(23<F(WA!.W1X4E5C2&EX
M6G1G0C%/3WDK<GE93#5.,$-Z.&PK<'%T>#5H,'1R4%5,65!"4$Q-<U5446@P
M2'%O-6)I>6-P54A)1VQ72&E->4TK8U0F(WA!.TA*,75G-U!L<'E464YS+RMU
M6"\Q;U=N<C)8,71O>DUT=GIB,41%0T9,:$LX=5!)9U8V6FHW3WDY6&MQ9E=.
M5&EU8F%/9%E42&-31TTF(WA!.VQ/9DE5:F53=2\X07%9,$5745)A4'E,67<O
M.$%-1D]8,41E;%!7+S0P>E<Y;SEP9FQU2# X6$9F5W5695(W,TXP96HX83DV
M<&I.:C4F(WA!.TYS9DUJ;4,X:F=L5S)P3D=,:49:9T=.5C5+1S9':D56>5!:
M+V%N-6U22$1W,34S*V=-=%AO9D)!3C-F:VYD<BM7361P0TE,4V5',V<F(WA!
M.U=P5TM+14EG<6%M:7%133)T=4%R9CAQ.6XO-6)6+S5&;B]M<D<Q56)J.'-9
M-VYH.5EN:&TY3G5C9G%1.'5,54EQ2VLP3D1J849T:BLF(WA!.U9T=EE7-C(Q
M:DI"85=Y:VQ924E"1V=,1W!)5E-"=515-#)L168X<3EN+S5B5B\U1FXO;7)'
M,55:+W=!<TEP,VIK;FUH;&5),6E:-%$F(WA!.WA5:&QF-%-4=#A32S-Z03A-
M8E94<U!Y>',W2T57,FYZ,C%T04-714YV0W-A5EDQ63A52493975217=E4E-9
M:TER+VQ8<R\X07DR<B\F(WA!.T%-:7HO=T$Q6DLP2TTO-5E26$1O.#@P37)X
M8GAS.$E9<653=CA*2C(K2D9B-6=E1TYQ-C O3$-+>70Q=')/84<R=#!R=VAH
M:$5A3'DF(WA!.TI9,%9304MK:S0R<70O>7(R9CA!-6)6+S5&;B]!2G%X=%9'
M9CAS27)H:V4T;6=M85 K-V%314U6*TI8*T5K;6YX27 K64AH:F%Q1F@F(WA!
M.RM55VTV93=V<#8R;&TX:7!(23!&<W-26DEX4D9*4VQ1;S)!-UDR<4XO=T-6
M97HO.'1Q+SAI>B]Z5FIA<59X*U=I,TUF<%A&>$9.15,F(WA!.T=-8VM82F%Q
M86<P2DDR27)J84501"M55VUW6%IV249T27)X:5,Q>6QS:7E%;%%P<30K3#=)
M02M73G%J9BM697HO=T1,878X07E,4"\F(WA!.T%$5FIA6&8X<3EN+T%/5S%F
M*U):+W=#87-B5DLW;CAM=$%L5TU8349H27-22FA%;'!'47!+2VA+.'5N=TEQ
M-V1G0C)W1U%(3E%#57@F(WA!.VDO3'!K:5))<GE.66Q!5D933VEG1%E!04=L
M0FE*5W!#+W=$-58W4"]!371Q+W=$27,O.$%.5T<Q4U!Z4"M81VYP8D-3.'0W
M8E5M=6XF(WA!.U,R84M3,U9Y-"M*,54X=5A)0FAS4$A',$UT.&TK4SE-.'4R
M.'-K1G)$0F588G1.9$="1E%'4C9C:65)2$IJ46-M-FY&2V-8+T%0=E8F(WA!
M.W S+TU1,R]54$QH2$ES2F-X-R\P1FI8-6YJ>EA,;W-.;&]/:' U9W0W,E)O
M3EIS1W5"84\Q;S!B5D5D=UHW8WAS>E57;S5B13=E35<F(WA!.V)Y=E4O=T%V
M8BLY,653-&PO2C5:<EDK<$Q+-V591D4X.7A+,$DY475*,4,O1$=Z4'E6:3=5
M3E903&MP4G(O;#ED>F%60F)4+T%*53@F(WA!.W)A,&@Y87HP>B]%3$%X,TUS
M.'$S04UW;31S6DEF5&9L>#,K>5-A1&EO5&YY5C5/,7IY=DQ(96%:-4YH<W12
M9E0W0T=E6F)X<%96<'(F(WA!.W1(,4LR4T]A.6U"5D9,>7AV56(W9DA7:%9E
M<#,O=T1V5G S+T%$14XO=T)1.'532$ES2F-X-R\P1D=:1FUX2'HY+W@T9C@Y
M9BM.334F(WA!.VXR:2]Y9CA!;F8W,3-862\X6'<O4V\K42]W1&5Y-B\T>&HO
M:5=697HS.35,,TYN82]W0D5F97I43W)D0S=&6%EQ-T9867$W1E="*U4F(WA!
M.VA08F%G3'%A,G5&=#-I4$-1451-1'EO4E1I<#9J3V$W23=/>EES,7IJ46\Y
M4BMT,T=V,3),2FIQ2G9F=5 V;5EF<&$Q+VMU4"MK830F(WA!.R]W0W%E9%!W
M;#!N1U!0-48S-E=T9C5,:B]P1W50*W%E4$-6-'@U+TEU+U,Q<B]*8V8Y23%X
M+S%4>#13=D=04#5&,S97=&8U3&HO<$<F(WA!.W50.$%Q;FIW;&5-969Y3'8P
M=&$O>5A(+T%%:EA(+U902&A+.%DX+VM89G!A,2]K=5 K:V$T+S9P-#A*6&I(
M;CAI-SE,5W8X04IC9CDF(WA!.TDQ>"\Q5'@T4W9'4% U1C,V5W1F-4QJ+T%+
M4G)J+W%N:G=L94UE9GE,=C!T82]Y6$@O4TYC9CA!5E!(:$LX63@O:UAF<&$Q
M+VMU4"LF(WA!.VMA-"\V<#0X2EAJ2&XX:3<Y3%=V.&QX+S!J6$@O5E!(:$LX
M63@O:U5G.#-34&97.75L<&(S37))-4Q!5S@T;T-09$)M;#=A,&U43$<F(WA!
M.TEG3&\Y-&1L,F)Q<V5/4C1J6'=0-FLS.'-6+U%6<T-#<DQZ4FQ91E=$3$EY
M<T-$43=%6FUD;C1P63A%67E&4T12<7-S8VU1>6IY2V$F(WA!.UIM3T\P>4EX
M57-O2E$X:TI(43!)<5!O3TMT2DEK:3AK64UT4TMG,49184A)>&M#3$-416IM
M:&(O05 S<3 W+VU)8B]Q2&QY=V-I,7DF(WA!.S5J,R]!2T-J36EZ651&-3<X
M>E U,"]1<BM5<G!.1%=A84=46"M5<%%,1T573U%1*V@X4WE3>7%G-'9S07IN
M-$5,67%G3DHO3EA8<FHF(WA!.S%7,4AY5'$Y;DA$671E<VM513@P<G5':E9B
M94Y79VAJ85)G>E!X.5%%2T)58VEY;W%Z:E).54]Q-E9B-F=B3S4P+S9Y=DU7
M9#='27(F(WA!.VA"56=E<$='8FE30E=H3F9':#)X5G4O+T%.-G1/+S5I1R\V
M:#5C:T]265,U:C,O;TM->4Q.:5!N-R]J=R]W0V5V+T=M8WHW4F8U4"\F(WA!
M.T%$=CDV-W)S9BM,-&9P569)9CA!=EID9CA9>"]X3$MV6C<K.&PW;7IT9C9)
M*SEM;617-D8R2W5X5C)+=7A6,DMO4%)F*T]0668X=S@F(WA!.U@O14)K<&-Y
M=W@O4U!C:DUI>F1I<D=03G8U;"M44$M6-4)A95E,.%=4,T5%;'EJ1E=K;VM4
M2W1#<UE:*U1&>GA!6&9I,VAI<D%F>D(F(WA!.S@V+VQ:<FLY;3$U<CDY;SDW
M8D<X<SE-,4='0S1623=V;$1U5D59;41*2D=T1U%P54LV;'5,9D5Q;&)49FPY
M2&$R,FY8;FYV>E1.2'$F(WA!.TU7;E-7,7IC>71-='<P,3%*3F)Y>&DT9VQA
M0GA,8F1315!&5G!7<'%Q;S)&>BM496UW<&1Z964O348Q85=S;'A+23<U6C5)
M,6YU-#4F(WA!.S1:<$AJ87E8.38S-WID="M8*W5E4W%(:3!0.$%+=E-:3#-Y
M0T(U:7-O<C-53%=#-#%&>&%T1F,S33AQ>5=O4V-Q-4%%5$TS=W%T63(F(WA!
M.UE05FEO=W%Y2#AV4%!0-5@V23EL;UAL8E@Y4S%W,WIZ2F(V5S%R1$175DE$
M3UI3>E=T:5-Z3$5Q3#A:-4UW<4]R04MN=6IF;G@U5C$F(WA!.U153DUS53 W
M53=79E9R:4\R<S%U27)D5U!Q."M-<E),3SAQ>$@P:CA:5"M.1EAP3TMU>%8R
M2W903'989%=T8C8X9V=U1VII4S5N-&\F(WA!.T%U,5I72C9J>$]C;C)P,FAM
M>#9I55EY<4ER+V-H,W9:*VMX5'=G>49N9CA!,U)5=CA4-C<O=T%T8F9C=CE-
M=U U5C%0.#@O635V-40F(WA!.T0O3F0O:6989BM7='9U6"MM4#A!2W5P+VYN
M-T8O25EF-7%,.',V>'%-5V]I1D9A-&IU6$IL:DA9;G$T-T0S>DDW2S%U5T]8
M:$AQ16HF(WA!.W50,'1/=C P1&IS*VMX+T9-=C%35TM'5W=L;&19-&MU0UAK
M8VA654=#54-P3W<S24=D<DAQ.'A-,5AV+T%%1F0K;71(+W=#5RLS+S4F(WA!
M.T=P+UA(:%!C=FE2-W=W;GIL-61V3F(Q=$Y7,&IZ-4QO3'=7.%56=&%W4V5P
M8F5T2$LX:E1444=D27!U4T]%-'-T3G0K46]!.$HW;#@F(WA!.U-0945(8V%$
M-39K;5,T5#@P64DU-#!L:E%$5#=4,&5-<')Y8454:%AD84QW6G$P<"]L4'EE
M13EY*TI(=D0P16%Z<$%!0G8W8VYU9E8F(WA!.U0K=5!#935F16HS:%%N,4-W
M=6(S5#!T-VU+6GA/>D99,U9J5#9V2TLP0E!J:$%)0EEM64I&2'(K9W!P:T<Q
M:5!N-R]J=R\U-B]W1$<F(WA!.VUC>C=29C50+T\O,W)U=7@O=T-,-&9P569)
M9BLY;#$O>&I(+T%"3$MV6C<K.&PW;7IT9C9)*SEM;617-D8R2W5X5C)+=7A6
M,DMS43 F(WA!.T](>F0Y6'0R95IJ66U&4%)21&)H=W9%8TML;VHR>DAW>'II
M9C=W=TDX9U=5>FI-0C19:U!E62]Q5$,W;3%E,'1:<G%:<G-X45)T3$DF(WA!
M.TDO<3AR.%5"63A9-#1'9'I18DMO2E!96FUB9FDS2'%8;CEN-FU,-F8K82]L
M2R]H.5=$>DEI2U5$<71X3F$R-W-#>DI256YG:F1M-4PF(WA!.U%Q0GE"<%5B
M:7)S=%,X+W,O56DW6#AW+TQD,4A$2D0U;7132C%2-#!A*S U2DM30E-L63-J
M5C%*.5)D:4LW:DAB.%=T4S@O<R]5<%$F(WA!.V5D+TQ6<&8R96=71W%O.3-C
M;5IB6%0Y4&4P;F]907IY<59T;TA%6BM"-D)Q1FE#0E5G-#=,5790-U Q2W%F
M;49O5%-2>'EA-G1T2DXF(WA!.V%W,S!A6%4Y<&)%,CEY:GE23E-E1T]H2U)S
M>%4O16\S24%P:G0K3%=P968R9G%21GHU,#!E,6MI:G5V359R0DI.1UIO56QV
M.4Y2;FDF(WA!.T)91C%$24MR5D=&4G1S9D1(8CA7=%,X+W,O56@O=T1L64]I
M9F]B.4TO<'=F54]%56AB,7)8,5%*-&9R15-M1#!05T1V1#A947!Y-#<F(WA!
M.S!X,E=P968R9G%D869M2#5F=2M8;V59;U-%:5=D>3$Q66]&4C0S;&]X94IE
M3$Q(13=U:"M*5D9704=/>3%,>BMZ.5-K=C5L*UA*22\F(WA!.U5H,3A80SA,
M<5%E:$QB5$5R6DE:6C9#3T)J.$U9-6=D5U@T;'%-9&QQ6&XY;C9L,&XU:BM8
M;W(Q8DMB6#%H=5=U2DQ4:$Q084E"4$,F(WA!.W%T26A:;U%O-"MO<3%*<'E0
M2#=7,D]Y,4QZ*WHY4W10-3<P5T=Z:G90,"]&3&)Z4VE#0G)E-G-:,FML25)V
M5&I31THR9"M-<4YX544F(WA!.SA31#!X,E=P968R9G%1<S-N,U0W<3!3-3!V
M>E1P+W!66#%*2F(W5'E"-F=9;T120599.$<R4&=F1$UB541)45!$35%F3S(W
M1'=G*W8F(WA!.VE0=7(Y4W!9*V)02TU7;5A%.7IC-EAQ53%P1$QF86A00F-7
M,7I*-DY223AX4T5-+T%#5F1W=$M%6EA(4U%K3'EX:$MF53A0-C)Z.'@F(WA!
M.T]/,$1)4CDO-FQE,#@U95-,>2]G,"LP:3 K-'9B;5@P3&4S:6%*,FMB,$)C
M.&M#<6%X*VEY<TI2.$<T2$MP07E8-4A4+W=!>4@K;$,F(WA!.R]M.#-F3"]4
M36<K<%(O.$%6:G0O*U-0+T%$5&<O239F*UI$+T%%;U@X,VTW-68V6E0P93%4
M5')R,&UT4%-K=7DW971Y5G1L*TQG04\F(WA!.V=!>4]L,$=00EIJ>DHO03EZ
M3%!R2C530DQK;FU:5%,W1EA9<3=&6%EQ-T9867%X2'HY+W@T9CA!4%@O:E1/
M6CEO=CA!2B\U,RLY9#$F(WA!.S)0.$%X9D0Y2VHU1"]W0C=,<B]J1U X06E7
M5F5Z,SDU3#-.;F$O,%(Y-TY--G0P3'-69&ER<U9D:7)S5E-F4CE:,&1D2W-O
M,G9R9%HF(WA!.T5G:41)6E5"0D-!1456>5(S2G!R:$E#271&4V%T;V-K8E)Y
M6&QS.&)G<39.3$=1461I0T-E;5!#9350:5(W=W@V-3AP+VQ68U%25S@F(WA!
M.VUM-D]S34)1>%)X2D)%04DU4D]Q9G4K3EDO5DA);V9H63E18V5%.7DK2DAV
M0RM0>7HK5FQU>7I7,FMA1DA01E)O6%,S<S%:5U=H57$F(WA!.U%O;U)X1E!L
M:G=N=5AX23DT64(U84AM1#!B;E5034AK+W=!<U(V=4QM,70W13)-9&E*0F%Y
M>4@V+TQ+.&PP,W<K:35#0E@U1GEA;U8F(WA!.S9V0U8X4U!E14<X5W S;FQU
M.$=P*U$Y069Z1W1P1$1P,%9U,6IB=RMK06M5,$@Q<4\V85)60U-':6-O=U5$
M<E9H.7 T5#-,-&ME.$HF(WA!.W1F6$4R;S).,#@S-6,V070Y8C(V1%1"8S-E
M;5AA="]P4E)R9&A32# V47E03G,O2&5N,FE2:G=N=5AX23DT43)J86AR<5-4
M5SDS*U@F(WA!.TAL,D\Q;G52>&%+.3 V0EDW5E97,VDY4E9&>C9Z>'=Y>4Q5
M0D)W0D%58W5/4$-E-69%:C-H1EA7;TYP;7$S43!J.'(Y1FYT>DY,04PF(WA!
M.RM(54Y*=#-M=#(U4DY+>4UG64-322]92C9%9RLW=VYU6'A).311,'5Q-C!L
M.39I9FQP;U5K13E*8G%16#)M0U=L-6)#2S=I2E R,T(F(WA!.UIL95-L2D5(
M2&IV>7@T5#-,-&ME.$M6.65.<4]L86)Q5VYF;'1O3'EZ575R*WAV<$Q"2C%L
M9#56;&I1>7)!56MP1$<S<7-P<GI(=VXF(WA!.VE4:G=N=5AX23DT4G1V2F5,
M-6-#2C5&,% Y25=&,R]U36AV3"MZ;4E33TAJ1&1T26986C5L5T-+26QP43<W
M17-G-E!#935F16HS:$4F(WA!.RM6;SE0,5<P;3!J>E8U2S!8461,;E-B:CE8
M=7)"9V=29TQE34,S8FM(-#-5+T=60W9%9VM"4RMW27)M:U1I97),669,9C57
M4D)$1G F(WA!.VUI07!&.5A2+U)T4S-P1F5"5&M14U9+-T56-EEI2DLK2DAV
M5G)04F9Y,G-R=4\Y<W)$4G)7.&DT:4LU:&ET6356-$HV86-854)H>%0F(WA!
M.S12-$1B1'=N=5(T:V4X2GHK;71(+W=#5RLS+S5'<"]82&A08W9I4C=W;TYF
M5U8Q<6QM3&$T:FY+0U5U23-6-D1I0E4X4V-.14%O-&<F(WA!.UI#:6UE46)(
M67$W1EA9<3=&6%EQ-T9722MF=BM01"]N<B]X<&Y-*S!8*U0O04TW+T%(<G5U
M>"\T=F@K;%(X:"\W,EA8+T=-9CA3>7(F(WA!.S)E+W9*935S-U@K:5!V6G!N
M5G5H9&ER<U9D:7)S5F1I<54V6#5:<TY.=69R145K<D]62U5C<5)1,#A&2&AM
M<S!N6E=00E!J:5I86%<F(WA!.W8Q3V)Q3F903$AH24-B6G,S0V1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U911W(V3F$V<$A(2&---FE-;&PY36='<$9.-FAS
M=W1:;UDF(WA!.V%G05-*1F1Z:S9B5E-W:VU.8F]I=W-O<DLP:G19:7I2>$%H
M4S%#9'E4=E%$>'DO5#1":6=)4C5"<7I:5&MK6DAM5F9,;70R2W5X5C(F(WA!
M.TMU>%8R2W5X5C)+=7A6,DMS4C@O9CAE2"]06"]!23!Z;69A3"]*+S4S*SED
M,3)0+T%"9D0Y2V@U1F1&=3=R:W=8.3)/<' K,6Q0<R\F(WA!.TE#8W(W;3-T
M645X:C<R6F5V1"]V>&9V1V14-&ME.$]I-$0S3SEE2"]!2#1V,VI(>$DY-%AG
M4&,W,31F.2M,.31X.%-0948T1#-/.64F(WA!.T@O9FDO94UF16HS:&5!.7IV
M6&@O,S1V,VI(>$DY-%AG4&,W,31F.$%F:2]E369%:C-H94$Y>G98:"\S-'8S
M:DAX23DT6&=08S<Q-&8F(WA!.SDK3#DT>#A34&5&-$0S3SEE2"]F:2]E369%
M:C-H94$Y>G98:"]W0BM,.31X.%-0948T1#-/.65(+V9I+V5-9D5J,VAE03EZ
M=EAH+S,F(WA!.S1V,VI(>$DY-%AG4&,W,31F.2M,.31X.%-0948T1#-/.65(
M+T%(-'8S:DAX23DT6&=08S<Q-&8Y*TPY-'@X4U!E1C1$,T\Y94@O9FDF(WA!
M.R]E369%:C-H94$Y>G98:"\S-'8S:DAX23DT6&=08S<Q-&8X069I+V5-9D5J
M,VAE03EZ=EAH+S,T=C-J2'A).3189U!C-S$T9CDK3#DF(WA!.S1X.%-0948T
M1#-/.65(+V9I+V5-9D5J,VAE03EY0S%F5FMS3$DS2V-:94Q+1U-U-55S06%:
M:38S5T1$:C1X4F]H=C R;D]39D-D:U0F(WA!.UI8='1E,GE81G4O3TXO=D(W
M9VIS4FPK1%!$3$%3:6)"87-U2U=/6$1,;7(U8S%U>%8R2W5X5C)+=7A6,DMS
M4C@O9CA!2&@O>C$O-# F(WA!.WIM9F%,+THO-3,K.60Q,E O1CA0,'-C,#90
M5&YL8U@P:E)2:%%52U9Q5S5!2&]R+T%,3E1M:3 P8U)*.%%K1'DY+W504S-A
M-35403DF(WA!.T%S+VIZ0WDY4S!38VDQ8WE1.%8K2G5V2V<U9%%U,65M,E%Z
M>&=*96<S2#A8,TUS4FM2-FA254UP8D5:<'EA57AK+U-$>6]!05EV4W F(WA!
M.W5E-$Y1,EI7;4=%,S1P:T\V=C=':DUC9W)G<C1Q5C9L<6QW5G1836M.1F]X
M<C$T:FPQ5E R<3ES<GIX9TI603-(.%@P2%AY6C1J27@F(WA!.SE1;R]J>DMH
M;$Q9:F)&3DIA1UDS<GEP374X26IP4G1I84=O3D]L2RLK6F5N:F=-5#1H:TID
M2S8O6BM,8V9+8V])-$%+-C)O,VMD<D@F(WA!.TYX='!F5VDT<BLX;U9Q,T5C
M=&E"*S%L5V5-27EQ0C1H43,K+S=7>D9+4DAQ1D91>6QS4G1I;6MT1$MB,355
M;5AE15(P;S)X3D165%0F(WA!.W!3=G9M6' T-$1%*TE:0UA3=C=0>&)J-51L
M0DA!0EA7,4Q517-K=35&<UI':W125# S9EIJ.$ER6%IE.64R5C9M3TU427AK
M;4A3+W<F(WA!.T=E17I-4GAI<$EF2T<Q1S)#85$P57!V;FQ35F0T4DA3:F)%
M:T=Q=%1P4W9V;5AP-#1$12M)6D$Y2S8O6BM,8V9-8V])-$%+-C(Q9G<F(WA!
M.S9B1W$O535J2U,X9TYA+UE"2'!N9$4S27)88S0V:4=)1#DS2SEZ.'5N44IW
M>7E(-FA7=RMF6'%52&U),V]N5#$P.7)I;"LP:5%C5#@F(WA!.U563U%98FIQ
M1#$V6FMA65EJ3#DT4TDK5%1M37A(,%9F;6E,<4120F%'4S)U6D=U82]$0W=.
M04]21S=C5D@R85IF;'@V8U%U16IX9#,F(WA!.W@W-C=M=DA03GA6241H-R]!
M365A6%IG3U4R=DAK3U%*5W9X06)';G0Q=VER,U%5,RMR959Z2317-FU%65=Q
M32MX3%9P>&]S8F)B5G(F(WA!.S=J8G)M,#A,4C)A;$MQ-CDO=T1P5#@O4&QZ
M8TQJ,49$,&DO>#5P5DU):$Y)25=,4D)I23));U-T9&E2.',Q=5%216IW+U1E
M>FU2=6@F(WA!.V9.6FM'4UI755=G4&)P.6)M;6IU0S%*05!S0F$O83)2>C W
M94]B1$)$5$=)-'I)4W9F=7(O4VXK,7A-<W-W:V5%07@K,S=W:3E(=DHF(WA!
M.TQ(54QA4%1(83=&=VDO5V]+1E)Z2E!)0V](,E(K,6U4;W,U>%I9:D-E4&E!
M-&@U+W,W,FY5-&AK:$DU4%12,E!L*S-U6CEN6G9.=7@F(WA!.U8R2W5X5C)+
M=7A6,DMO3%5T2'-.4CE0-C)H9C!U6$-J1F%C<58V9DQ-5%9A3$AN<FI&,#5'
M1%5Z>%AW.55&+V<O478Y.'0O=V)F,7HF(WA!.T4O:UA49'@K6F(O-5-Z9"\R
M3R]W9F]8*RM7+S1.=C8T+W=!:39B=5!Z2R]Y;&TW+T%,2&8T4#!,+V9,9CA'
M,SEC9C5&,#-C9FU6+VPF(WA!.TQ.,R]!1T\O=V9O6"LK5R\T3G8V-"]Y3'!U
M-"]-<B]+5V)V*W@S*T0Y0R\S>3,O0G0O6$@K4F1.,T@U;&8U4WID+S)/+W=!
M2#9&+W8F(WA!.VQV.$%G,B]R:B])=6TW:CAY=CA!2U=B=BMX,RM$.4,O,WDS
M+T%!8F8Q>"]K6%1D>"M:6"M5<S-F.6IV.$@V1B]V;'8K1&(K=5 X:38F(WA!
M.V)U4'I++WEL;3<O<V0O9R]1=CA!9DQF.$<S.6-F-48P,V-F;58O;$Q.,R]9
M-R]"*VAF-S5B+V<R+W)J+T%#3'!U-"]-<B]+5V)V.$$F(WA!.W-D+V<O478Y
M.'0O=V)F,7@O:UA49'@K6E@K57,S9CA!63<O0BMH9C<U8B]G,B]R:B])=6TW
M:CAY=CAP6G4O-TAF-% P3"]F3&8X1S,F(WA!.SEC9C5&,#-C9FU6+VQ,3C,O
M63<O04%F;U@K*U<O=T-$8BMU4#AI-F)U4'I++W=!<%IU+S=(9C10,$PO9DQF
M.$%"="]82"M29$XS2#4F(WA!.VQF-5-Z9"\R3R]W9F]8*RM7+S1.=C8T+WE,
M<'4T+TUR+TM78G8K>#,K1#E#+W=".'0O=V)F,7@O:UA49'@K6E@K57,S9CEJ
M=CA(-D8F(WA!.R]V;'8K1&(K=5 X04EU;3=J.'EV.'!:=2]W0W@S*T0Y0R\S
M>3,O0G0O6$@K4F1.,T@U;&8U4WID+W=":G8X2#9&+W9L=BM$8BMU4#@F(WA!
M.VDV8G50>DLO>6QM-R]S9"]G+U%V.3AT+W=B9C%X+VM85&1X*UI8*U5S,V8Y
M:G8X04(K:&8W-6(O04E.=C8T+WE,<'4T+TUR+T%#;&TF(WA!.S<O<U%/<RM6
M3$=/>$IS24=.,%=654A*:C%903E45'!M2G)U>#AC8V8W<4HT-TA6>4Y,,FI-
M>CE:.4MA841O34=L=V1N=6Y(-S)8+VHF(WA!.U9F8DYH,F8R9DA4>#<U;FU8
M13%E<D]9+S!8+R\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+WAM<#I4:'5M8FYA:6QS/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C8P-30U83DT+30X8F(M.#DT-"UA9#,X+3 U-F(Y8CDS-F-C,3PO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^
M>&UP+F1I9#HV,#4T-6$Y-"TT.&)B+3@Y-#0M860S."TP-39B.6(Y,S9C8S$\
M+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#
M.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^
M"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/G5U:60Z
M-C%D831F8S,M-S9B9"TT86$P+6%B.38M,F,Q-6-D-#!D,39E/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.C9B,V9B,C<Y+65A-30M8S@T82TX,V4U+3 P8SDP830S-C%B93PO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X
M/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S
M<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM
M<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D9!-D-$0T%$,$$V1$5$,3$X-#4V03-%,$)%,48R,C,Q/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3$Q
M+3(V5# T.C V.C,Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV,#4T-6$Y-"TT.&)B
M+3@Y-#0M860S."TP-39B.6(Y,S9C8S$\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,3$M,C94,#4Z,#4Z
M-#4K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(V+C4@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P
M4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @
M(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU
M<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(" @
M(#QX;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE
M5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E
M<SX*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C@N-3 P,# P/"]S
M=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XQ-"XP,# P,# \+W-T1&EM
M.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/DEN8VAE<SPO<W1$:6TZ=6YI
M=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX
M;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1I;65S+4)O;&0\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y4:6UE<SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT
M5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^
M,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/E1)0E]?7U\N
M4$9".R!424)?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @
M(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA
M;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G
M96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA
M=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M
M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z
M9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^
M"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y7
M:&ET93PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#35E+(%)E9#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ
M,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+
M(%EE;&QO=SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0TU92R!'<F5E;CPO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO
M=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+($-Y86X\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D--64L@0FQU93PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+
M($UA9V5N=&$\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],34@33TQ,# @63TY
M,"!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ-2XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXQ,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TY,"!9/3@U
M($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XY,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].# @63TY-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^.# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/34P(%D],3 P($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3,U(%D].#4@2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,U
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^.#4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/34@33TP(%D].3 @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXU+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P
M/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,],C @33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,]-3 @33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-S4@33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M.#4@33TQ,"!9/3$P,"!+/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#
M/3DP($T],S @63TY-2!+/3,P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXY,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XS,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/CDU+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C,P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M-S4@33TP(%D]-S4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXW-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-S4N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@P($T]
M,3 @63TT-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C@P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-#4N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3<P($T],34@
M63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,34N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-2!-/34P(%D],"!+
M/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],3 P($T].34@63TU($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/CDU+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],3 P($T],3 P(%D],C4@2STR-3PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C(U+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TQ,# @63TP($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-S4N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TQ,# @63TP($L],#PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],S4@33TQ,# @63TS-2!+/3$P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXS-2XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXS-2XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3$P($T],3 P(%D]-3 @2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,"XP,# P,# \+WAM<$<Z
M8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT
M83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXU,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3DU(%D],C @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDU
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3(U($T],C4@63TT,"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C(U+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C(U+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^-# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/30P($T]-#4@63TU,"!+/34\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C0P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C0U+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^-3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-2XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/34P($T]-3 @63TV,"!+/3(U/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C8P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,]-34@33TV,"!9/38U($L]-# \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C4U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C8P+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^-C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-# N,# P,# P/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^0STR-2!-/30P(%D]-C4@2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XT,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C8U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STS,"!-/34P(%D]-S4@2STQ,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^,S N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXW-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,"XP,# P,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3,U($T]-C @63TX,"!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXS-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XV,"XP,# P,# \+WAM<$<Z
M;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L
M;&]W/C@P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C(U+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-# @33TV-2!9/3DP($L],S4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C0P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C8U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^.3 N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^,S4N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STT,"!-/3<P(%D],3 P($L]-3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C0P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<P+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C4P+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-3 @33TW,"!9/3@P($L]-S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<P+C P,# P,#PO>&UP1SIM
M86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL
M;W<^.# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQA8VL^-S N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z
M0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U
M<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X
M;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A
M;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],"!9/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3 @63TP($L].3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^.#DN.3DY-# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9
M/3 @2STX,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;&%C:SXW.2XY.3@X,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3<P
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C8Y
M+CDY.3<P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-C \+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3DN.3DY,3 P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STU,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z
M8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A
M=&-H3F%M93Y#/3 @33TP(%D],"!+/30P/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C,Y+CDY.30P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,],"!-/3 @63TP($L],S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,CDN.3DX.# P/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]
M,"!9/3 @2STR,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXQ.2XY.3DW,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+
M/3$P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K
M/CDN.3DY,3 P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STU/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C0N.3DX.# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y"
M<FEG:'1S/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,# @63TQ,# @2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3<U(%D],3 P($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XW
M-2XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3$P(%D].34@2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,],3 P($T].3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D,]-C @33TY,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8WEA;CXV,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XY,"XP,# P,# \+WAM
M<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M>65L;&]W/C N,# S,3 P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,#,Q,# \+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP
M1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P
M<SX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q
M-BXP-SPO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!"P)F P$1  (1 0,1
M ?_$ !\  0 " @,! 0$!           '" 8)! 4* P(!"__$ %X0   & @$
M! D&" @("P<%  (#! 4&!P !" D3&%<1$A07&966U=85(5-6F-06-#58=).S
MUR(C,75XE+2W-C<X5'>7MM,*)"4R,SE!47)SLB9A8W%VM;@G0D-$8O_$ !T!
M 0  !P$!               ! @0%!@<( PG_Q !H$0  !0(!!08."0\*! 0%
M!0   0(#! 4&$0<2$R$Q%T%15I73%!46&%)55V&1EJ'1U-4((C54<8&2E-8C
M,C,T4W1UDY>QL[2UTO D-C="<W9WLK;!)D1RX24G8O$X1D>BMT-G@X2F_]H
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M1B-T3<+1O/Q(,F,\;*,7'U/M,1DOR%DT(^]/#RJWXO@J2A]^.'0P?\AV-_"
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M+!K6ARKF7P:^# #;M2?24O.^(5W\3+R6N#VF=*@EL<IF=FZ/7N3<J$S'$MD
MDHPZ,4*F@W00I8N\CZPYF'U+,X"$RB1*&37U3LMOJAIE?I:4-*;J,=ZI12P0
MA:2=(URV-B4N%K4^UJ)S6XCZIG)=Z5M3+M*/)I=F3B[G7I:)%LU*#:]75GO/
MLN'$6F/1IYD2EN1U8$W3Y1XJC'FQ7C.,;2XU6(CS%=8;2T9IU#!6]S11R*WG
M%C3GU]4+XZ_ O7<<TZ.;Y#RVQ*G7+X;^#:1P@XS7406F0[ ]GZ6#2D)0WZ1;
MK<BI/U%4I:%//TM\B::)#S72O39B&I!K4I").F4B5@W]49Q:+-SC4->TS*?(
MI=JP+89I#4AJ%3KMIZE2YBWH,PKNZ"Z(D2Z6F.VV\]2S@MO4DU2#*-,PE+)T
MT(;*49'TA2EYVC(05"V(F@G<](<HZ]2DJ9,LF:YXZL<A5-DG#(X@J<W4]JD;
M"@>6R7Z=$]C)UJ1&X%30I\"X/+I0LVBEK.-506IP^A30\TP<9QAR(VZREQC0
MR$H;2XRZMIR-F*AJ0I:#C&T:&D9#.RUKE:-#-LL-1DG5TR(4JHIJD6?'J\B)
M,<8J!3J8Z_(7'G0V94>I=$(K;;K;3R:HF43\F1P3^D$?%CX_/JNO"A"DZ:M%
M#JR)I;M)&D$C@4^J2?.CU%VDF,>,S$S)=3D:2NB)<K>UB8M4NV6\*$R=E0M4
M2M%DFFFBF']05-2ATX^<^MB7$J$1#3[AO?551DU%]3:TI:2K!!&V2C<6YXN9
M:9;LJ9+=HB3Z/10ER(J*EHH+,ZCUBW*S(E4^.FGXQ451ZV(*)#3SDMULG'LV
M2MM$5F-V;+TC4BCBAK7,]7LWES*X(7%OVZ212XH>M1<IW;E-H*M$6R(A']:_
MNYT4V:0J2'%,Q1*X@PMS!HS)'+.9>2XAR<[F.H4A>8RE"\%4)%"]JHW%$6#3
M92,%)41N&:%$:-0J(F7&;!7'=C6]%TL5]I]GHB>M]K.:R@R<H.#C11&C7C,D
MKIV<A;2T1DI>0I,@LX9;P;Y<UY5?+*57_9)KRQ0R.TI*6..1U0YDRB0G 2ZC
MK?$H$PJ$S3&T*LT)9(&ED)+:69M:69(48XF$I&Y>Z"I[HM^9/H$>DPB;=DO5
M-AUYXD&PR1JTRY$MXE./K21F9N.F;CBW'%&2"-2T-BY9)<I5%H&4>H7E7ER8
M=*A6K48D&$N0BH35$WT$U3J/#6B-!:=41)*/$0F-%8CQ6TJ>-+3#T@ZN<ON7
MUG<Q;.4SR>*1-S"W"5(H% D2HTUAA+"<:$6DJ70@E:7O*_11!T@D!Q!2MW5E
M%!"4C:T;6UM]]MZWH-NP4Q(J<]U>:J7+4DB=DND7URM9YC:<3)IHC-+:3/6I
M:EK7KW*9E,K^4ZOKJ]76;$)@W&J/1FG%*B4J(I1'F(Q))/2WB2A4R8I"7)#B
M4D26H[4>.S5#+\-<A@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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MA--/.OH4EYYEEHFEMK6M3\EJ(E2$9Y&M"'WFTNJ1G:,CQ46HQZT.S;@K\V5
MAP'V7H4*=.E+FL2H[$=N#2Y596T^]T.M$=^1 AR'8;;^B*2:22VK%2<8;RXC
M%@P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 <E$M6-JQ(XMRM2@
M<$"DA:A7(CS4JQ$L2F@/2JTBH@99Z92F/+ <0>2,!I)H &%C",.MZE4E*TJ0
MM*5H6DTK0HB4E25$9*2I)D9*2HC,C(R,C(S(RP'HTZZPZV^PXXR\RXAUEYI:
MFW6G6U$MMQMQ!DMMQM9$I"TF2DJ(E),C(C'K%Z,3I.D5_(6BA[W=TK?=[<E
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MZ7D-C\<9$OFC@<=<4NCY0Y;&&]H:B1& 9FMP4-CW)8FMG+*ZL2Q:YQ5*%/Y
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M,HU9FV_29#+%3:HL^J042/:L2Y$%<?"$X[B11^B4.K0V^HE(;>)O2DEHUK1
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MKZ&IO;X[W!C=,MGLI_S0N=#K4<JW!;?+"_0@]"1S:^AJ;V^.]P8W3+9[*?\
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M4_$S(OM0M_\ _E$J_8IY54)4LTVW@E)J/"L+QP21F>'\BVX$-16; '-8V_\
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MFGX[[4#-6VXA1$9&1EJ/6E23)23-)D9[ULU:.N0P 8 , & # !@ P 8 , &
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MC[;:$.RCC(-MA4A:2)3JF6S-MM2S4I+9)01YB4D7;YYBI# !@ P 8 , & #
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M:&6([#*";:99:;)*&VVT)2E"$D24I(B(B(AVF>8J P 8 , & # !@ P 8 ,
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M+;]K2.EU0K;4N9,JR6VW)$:%'<0PW'A:9+C;;TEU;INR,PW6&V4$PI"W=(W
M?&KD382BQ&6&RY]72EDE"@QO -U'I6X-;@(@TU(J2K1!\I&08<6!,I3'FF$
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M\>/::R/W5XW5*![RK'XB%Z>'6?Y1>W]E?/J[]'P] WRR[R^/'M-9'[J\;JE
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M<\!.& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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M+@/R><.WY47U9L;U7&OBO&A7WO"&>7 ?D\X=ORHOJS8WJN-?%>-"OO>$,\N
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M\WP#<HD5I5Z5,N0J2%B)802J2*TQH#TRI,H+":0H3G%B$6<2<4,)A1A8A &
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MJ*)J&1)6=F7P>77-"*PL9Y<MK0GPEGGZ_P"16:7D[3J4Z42%+(AMS*Y:6BT
MC;ZC7A$(M">F52+4:<#+# U$1XEC@1[^TOXWA.A)*SBUXDDS(B+'$R+'#P>8
M1A0W*&<W,MG$=+C<62S6O[#L9@<HX(3NU$/<'8HS&7ZMIFA<EBM>H9R+'*G<
M*=$P5S.N\B9G!["$A0NCX@.,J%J5O%J-6.!8:BPPUYQ_78EAWO"(J02<#Q/
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M"  ECP^NCD[KA%%DD;6+C]D$$$[ 2"8B))$1;"$IF9GB>WS:B\@RW(B 8 ,
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M^OXI6<&0F-\5AS22T-"<\\2I4,L S#U*U<J'H(E3BY+3U+BXJMA!Y2N5*#M
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MXZIIGO&@\@4GT0-RNB\8LHWY2+T]<AV**\[U^6/VM>0'Q[CJFF>\:#R!2?1
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M.TRM!M=#1(QDHS<42L\UD9$6!$>)G;_.FAI(, & # !@ P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@ P 8 , & # #6E8O-"QX?/9E%6Z-PA0@CDE>6
M5&>M1OPU9R9M7GI235(R'].2(\8"@B,V4047L>]^*6'7@UK@V^/947S;%XW1
M;L*A6F_#H=>JE*C/2HU85)=8@S'H[3CZFJRRTIU2&R4X;;3:#49YJ$E@1=5V
MOD)M>N6Y0ZQ*JM?:D52E09S[;#U.2RAV5'0\M#1.4YQ9-I4LR22W%JP(L5&>
ML2%QWY13BWK!W$I QQ1O;],3DZ>4,R9W*6=>B-1@+!XZUY7$]4+2@>QZZCQ]
M[T'Q1AUK>MYKD2]D'=F4R]3MNM4FW84,J//J.FI;%2;E::*Y%0VC.EU.6UHU
M$^HUEHLXS)."DZ\<:RFY(J!95M=.J;4*Q)D],8D313G82V-&^A]2U81X,=S/
M(VDYIZ3-P,\4GJPO7G7HYY# !@ P 8 5KN*A$]R6#7CG(#@@AL10/1KPB+-$
M!8]*UBML,1-)>P;T-.B-"D.,<E81!.T1H*9)XIRG:I'.A9H)6&T\,#X,,=?P
MZRPWN$2FG$RQV%C\>P6,2)$J!*F0H4Q"-$C()2I$B8H!"9,F3EA*(3D$EA"6
M4224 )918 A   =!#K6M:UD@F'(P 8 , *>\K_\ "OAC_3"BW]RUZ9D5 ^U[
MD_NZ_P#M*EC6>43W1R7?XF4__2MW"X68Z-F"G7/[DK(>'O$.Z.2L7C;-,7BI
MF5F?"8L_*%Z)M>R7"5,,>4I#%[;L2M": AY&J(4%IU>NM3A)&F$$W8RPB18F
M1<(K7".E.K)'4-KW?=34JCU15_=UPUI$;C@S4^2"#V= Z7:6]=,+8+;U*?3E
M""6A[_"F%'0=Q<'Z32"10IV# M3#1X4J,(YIXD6TS(CPX,=A?&6!_'@8D.4]
M*9Q(A,BGT9EC_-F-?7R^VF-:>J@;V<W2*4TO+*CA4TB,06H@JBWV0[D-\5&B
M9$X-$(WD<U1%IEWE#>]D-@0S3PQ^#?X<?,>/!OC J?Z4^HGY)+V^Z2Q5O,8G
M>MN5:X-") O<$\?B,-Y:D</J\G4Y,ZY45&O.%:;O'8^8@1+G],QN2IZ<%3A^
M"$:>I.C")I/>UZB/@_JYQ^ M_P"/?(9;#.E:XG3J00Z-LRJS2'">NM6-,9-=
M*W>D#<M,N:Q;*I^O59CB8(25(@>[9J6:5]I2I,*V0\("'0PO434AD009I_#M
MV=XB,_(9'\?#J&)0?I7Z!*J6IYY<*U;&U]A49+KY6.T/C$K=H(EA,"(9=2B0
M(C'MO:9NEC^GV4Q2#L3I(8FU)9%8+^GAC*I<'M"[IVX!I/$\->LB[^O9LX<#
M\&O#$A][$Z46K4\IJF%4PWK+"DLEO^@JCM%(X-3BW-E9LMW7O8% )%K@_ICC
M6U1(ARNJK'710IG%(8Y*&2):?$[T5'99"WU^!FGOD9:C,OB+'R8ECOXGAMQP
ML/,.4;M#N8K#QI60(+A%G7B/<G)P<P85SS()HI6519%0P8R%-=>MT<$8N/<T
MUDJEZ UM>G9U=EZ)&UI&=,:9XZH(88D9X[#(L/A(]>./>_[CAQ3E@YR[EK".
M/2>O%3'$YUPY.Y6M<GE!C]'K!0FF6'!X4G@DKK)\C36KACJW)Y4H5/*=R=EC
MPE<T^VE>TM"E"J">$<WVIJX%$G#XC/;\0NC@2BGG+?\ *W$;^F'6O^Q-G9D5
MO_8[A_N[,_6X UGE(^V<F_\ B90OV57Q</,=&S P 8 , /..K_&U7Z0=^T%G
MPWE_;<K[X>_2*'U#8^P,_P!DW_D2./E./4;-N 'Y"LK^=HW_ &-VSOGV&/N3
M?OX1H7ZM4AR=[)'W1M7[RJGZ>&-A6=KCF@, & # !@ P 8 , & # !@ P 8
M, & 'G*7_CRW]+4_MAY\.)OVY+^^7_TJQ]08OVM'_L&?T:1?S@#_ (0V1_,T
M?_MSCG9?L,O=J^OP71?UN<.</9(^YMK??U3_ %>*-G.=^#DT, & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # #0E>/^.2TO_KV4
M_P#WE7GQRRM_THY0O[XW#^U)(^C&3[^8UH_W=I'ZDR)MX0_XZQ?_ $>_?VAK
MS;'L3/Z5E?W8K'Z>GC LOW\PB_#=._1RQN SZ:CB0, & # !@ P 8 , & #
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M:>5F6]0W$+IEJ5ZKQ7FYM-;Z)(TR8C1*;)24K1G$K$CP&VG,M&2A@ P 8 ,
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MV-VSOGV&/N3?OX1H7ZM4AR=[)'W1M7[RJGZ>&-A6=KCF@, & # !@ P 8 ,
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MHACV2$)!D^ # "GG+?\ *W$;^F'6O^Q-G9D5O_8[A_N[,_6X UGE(^V<F_\
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M.;K= E6(ET4%+/2PKJ1/T":)@IR-$2D.M/A.B2M%K@Z+!XKJ5K7W*#RS1?6
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MY]AC[DW[^$:%^K5(<G>R1]T;5^\JI^GAC85G:XYH# !@ P 8 , & # !@ P
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M [4)2K1<CQG:K48M+B+>1#NJ3)-M4R8PA1LL.J22\[,,B,7=S&!M8, (#O\
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MXI6=ZK#S%<G_ ,^.;?ZBJ#^#L=-:'Q7B\J5;TD.I&_NZS5O%*SO58>8KD_\
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M$L*DKFT65-:G>Y@1$X\ED,I:&?Y";X*@:VQM![7.U?6Z]N/?PQP+'@V$?QB
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MD$EZ\ "B2PE%@UO>][T L&@A#K>][WX-:UKP[WO^7> 'TP 8 , & # !@ P
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M#'W)OW\(T+]6J0Y.]DC[HVK]Y53]/#&PK.UQS0& # !@ P 8 , & # !@ P
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M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M, & # !@ P 8 , & 'G'5_C:K](._:"SX;R_MN5]\/?I%#ZAL?8&?[)O_(D<
M?*<>HV;< /R%97\[1O\ L;MG?/L,?<F_?PC0OU:I#D[V2/NC:OWE5/T\,;"L
M[7'- 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
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MC''EQSQ(RQ4S)949Z*5%=P(GH[Q$9H61$9&2FW$H=0XVG,LR@6,, & # !@
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M%"9G1URE*<0E@EX+4ZRRU(>8+$B(Y+$=]E]^,1]$,LNMNNMH0HE'C^647,,
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M& # !@!W37'7M[2NRUJ;5*Y*PHOE%Y/("$1;:@V/J_+%>]BUU2?K/%*V;O\
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MWP]^D4/J&Q]@9_LF_P#(D<?*<>HEVAY,Q0VV8=*)*X!;&1F6+5*Y7M*N6"
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MFFY*R=-;:&%)7%9A$TS&6V=?,TN-F!@ P 8 ?4@XY,<2H3FC)/3FEG$'%"V
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M#D-2E*4:E&:E*,U*4HS-2E&>)F9GK,S/69GK,]9C]9,(!@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # "J_,S_$/(/YXC7_WA-G._LI/Z'ZS^%*%^TF1N#(7
M_2)3?O&J_J3HJOQ>XO#EHT%BV*@$7%BQ 51V.JB]A')1AWH13BXE"UH06 (M
M:$G3BUK;SO6ACU\EZUIQYY]C[['U5R*AWO>\-2+>0I$BB420@TJKJDF2FYTY
MM1$::.DR)3+*B(ZH9$I1=+\"F[=RN97$T=,FV+8DDJK*)3-3J;*B--,298+B
MQ5IU'4#+$G74GA"+%*3Z+Q.-M.  !8 %E@"666$(   '00  '6@A  (=:"$(
M0ZUH(=:UK6M:UK6M:SZ&)2E"4H0E*$(224(21)2E*2(DI2DB(DI21$1$1$1$
M1$18#D-2E*4:E&:E*,U*4HS-2E&>)F9GK,S/69GK,]9C]9,(!@ P 8 , & #
M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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)K,?K)A , /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g374624g75s68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g374624g75s68.jpg
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M-F%Q)E5S\*&QL__$ !X! 0  !P$! 0             ! @,$!08'" D*_\0
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M>$?](E_N_,?S^PW^8WRN-=@_\>-_^KDO_>O<T%[_ &KO\8?]I:]Q6[][X/\
M(XO]P%6CE.KRG%*<4IQ2NP_@5?Y0^^_Z&VZ_ZYU_S?-GO[ZW+[@W#^\BUXEZ
M.W^#;9Q_3E@/\PQ+7'CFAU[:J6%8Z8;LN8X$2K,.N%6CM-K]^;CL',)G0*M:
ME6R-7B,Z&]$;>5DH6I1X$W%')(2HI5N W/:B1"HV7*SC.'KC(%HV49-'8[4I
M$1W(A9?WZ,F0J**NLX[K2"&I1<04-!0P(N/W;;E@.QR;A%NLBY0SM]\N6'2<
M<@*L>1=[0EF=N4:.^#I-BD6'?[=<">E+&9=AE(*.;ST.4PUH.1K?8D-<QN70
MKI%<'%F )!N15CC"X!R4H>B*&F)=@I5%+25EA:&!S^$3'E$AZ6V59F1L.8M8
M<L=6J+('2:-EFPZFEPM&ELLQX&6\#(%R)=89)V29]$;Q1AIX6"9Q%8G1DPW+
MC&)N[0'!D6]E)).SF%&0J.PVAARU<E-J3 )%DJ1HC#NFW%*=;@<-PB:JMD$#
MV2*0[T\H#)CX;1=<7,U MR5+BLL((JAI5+3!4O$E45.9&&LM8RODKD:0T*FZ
MP\V"'NU)QHP%#RU:%(A1$/3QTYYY<<LJN8E[LL]\8T&[VN;).*LX(\2?$DOG
M"%U&"F"TRZ;A14?(65D(*M(Z2-J>M4&KU>M<G=?M4R28E@9\2^T]F[5Z6 ,Q
M3##HA9^P5:0U,S'SAR"0@V&K'1TB-(;2E_$-LD.>G!YPXC+J28CL5(Y.*V0R
MF$D-$TX+B*VKCK*H67$2%UEP%14R72A@I 0D5AA_$UOQ&=]:A,W&.]AV]G8;
MDS<8+T)P9HVVVW=HV-ZFB1&D6R[V^4V\T2JVKY1901YT>5%9ZE^"P_R3>$[_
M *!^V/[-67FY8+_<6+_YMS?[EZO)/1<_9ET)_P#^Q&#/TK:ZX[\T.O;%.*4X
MI3BE.*5V(\']_($\+9_-GH/^MMN\WS"_V,XX_D=M_MSZ\2]$?_O&=!I_.K:-
M^98+KCOS0Z]M4XI3BE.*4XI7:+J[_F<?"+_SD:5_MMK/G0K+]@6*OY5"_OHE
M>%]K7^^[T,?\U\>?H#%5<7><]KW13BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*5*CK'K;7VP(&_BVP_16!^KM/B-A#"!&=9X0F'/?
MWIIG7$_USBH#C!Z2/56]AG7F6AHJ9+:-10\KR'8,>?!FYNRQ(DH;F<M!0(<
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MERU*N6:JJKESJJJO&JT:%"A(8PXD6()Z-8QH[3"'NP%IO6C0 A;MH1;#//0
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M^[73QF/]$KX@>V0[=_![9=Y Q/ZY4^3]=*/IQV/^W&O?A/QU,L.^[73QF/\
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M<*4K.,>+&59S\^<26S/#Q$1*]=,R527_ %F/SJN:_P#\3NUU-G_2.;=6&6F
MP_LO4&6FVA4K#B9246Q0!4E3&*(I*B)FJ(B9\R(G"J?Y/UTH^G'8_P"W&O?A
M/R'4RP[[M=/&8_T2JGMD.W?P>V7>0,3^N5/D_72CZ<=C_MQKWX3\=3+#ONUT
M\9C_ $2GMD.W?P>V7>0,3^N5/D_72CZ<=C_MQKWX3\=3+#ONUT\9C_1*>V0[
M=_![9=Y Q/ZY4^3]=*/IQV/^W&O?A/QU,L.^[73QF/\ 1*>V0[=_![9=Y Q/
MZY5([K)X)KK7U1N-MN^M[/N,F7N>MK/JTJS<+-42<!FNVR2(E$I,%D30@+[1
M=IP+$Q#DOR9,1I"W\/07\K0IK*VC!5HLLAZ3#<G$X_$>AFC[S)BC3R@1J*!'
M;5#16QTJJJB<<Q7/AR_:OT9&U+;%9++8<46C \.'8L4VG%\-RQVJ]19)W.SL
MSF8K4@YN([BT<(PGO*^T#+3QD+:A(;020XX_)^NE'TX['_;C7OPGYBNIEAWW
M:Z>,Q_HE=0]LAV[^#VR[R!B?URI\GZZ4?3CL?]N->_"?CJ98=]VNGC,?Z)3V
MR';OX/;+O(&)_7*GR?KI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;(=N_@]LN\@8
MG]<J?)^NE'TX['_;C7OPGXZF6'?=KIXS'^B4]LAV[^#VR[R!B?URI\GZZ4?3
MCL?]N->_"?CJ98=]VNGC,?Z)3VR';OX/;+O(&)_7*I':%\$UUKZ[5_>5;HUG
MW'/@=@=46#3MU<LUFJ,^5!JUDA38$^76W!U"$-03;;,]Y46609+0FW,-J='/
M)2I"LK;<%6BU-7%J,[.4;G"=@2-Z\R:BRZ)"1-*,<$%Q$)=)$ABB\XK7,-HG
M1D;4]IERV?W2_P!HP/&D;-\8VW'%A&TVJ]1V9%WM4AB1&9N@RL1SCD0"<C@C
MS,5R$^0J2!)!50ACC\GZZ4?3CL?]N->_"?F*ZF6'?=KIXS'^B5T_VR';OX/;
M+O(&)_7*GR?KI1]..Q_VXU[\)^.IEAWW:Z>,Q_HE/;(=N_@]LN\@8G]<J?)^
MNE'TX['_ &XU[\)^.IEAWW:Z>,Q_HE/;(=N_@]LN\@8G]<J?)^NE'TX['_;C
M7OPGXZF6'?=KIXS'^B4]LAV[^#VR[R!B?URI\GZZ4?3CL?\ ;C7OPGXZF6'?
M=KIXS'^B4]LAV[^#VR[R!B?URJ1VHO!-=:]+:D[":8J=GW'+JG94'4@%^EG;
M-499T?"IDBQ212ZM+A4(;"'R7G+,0Q.63&F6W4-Q<,-1LMNJ>RL'!5HM\*Z0
M&')RL79MAJ4KCS).",=75#<DD<1!5WQZE(3SX9(F2Y\OQIT9&U+'>,]FN.;Q
M:,#L7C99/O-QPZQ;K5>V;?*?OK5L:F#=V9&(Y4B2T VJ,L<8DJ 0*;RN&ZA
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M6E9SX_%A+BDX0KQ^+/B\6<^/Q9\7\7,?DN6>2Y=W)<OEKH2.M$9-BXV3@_7
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M,8RI:L)0G&<^+QJ4K.$IQ_&I6<8QX\YQCBE>?'C/C\6<9\6?%G_[9_\ +/\
MY9^?'%*\94G&4IRK&%*\?DISG&,J\GY\^3C^//BQ\^?%_%_IXI7GBE>,J2G'
MC5G"<>/&/'G.,8\:LX2G'CS_ *5*SA.,?QYSG&,?/GBE/'CYOGQ\_P#%\_\
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M<K/E^/R'%U%=84E-1524E55447G)PM2HI9+P($5%_P"5>USX]FU7UF($0)+
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M-K_[5QTI8;[SP_P"_6IU<]KOA_B'QH/FJ?D0=2_<+0/S:_\ M7'2EAOO/#_
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M:I^1!U+]PM _-K_[5QTI8;[SP_P"_6IU<]KOA_B'QH/FJ?D0=2_<+0/S:_\
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M&'JA&F*4,KQD7:ZQ%GD7<2!DF4TJ882M4H8O)$';,.#)3D)]O#3,8; 7!?\
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M2@5P(I3XSXDV02Y$=QN4T6X,9D"%(N485('7(+3K^Z06'MW^)>KKR/KIBU$
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M8DL1+CRDI=]=Y::2PZVAUR6\BM6%YB"VA<QZ.#*R&F%L0)+C=$K9<0)0.%)
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MDFMT!D+)@:AC7,QGL3OO4L&Q#KK?MF6ND/:U;!ZPJ($];#)"I.UW<UN!5,A
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M&-L^+EDM ,Q0[UCU=O#9@(P9H69E:GRZBRSH6RU<@61;Q3>;E:-=@F%Y;LA
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M_$K]=CMEF9. :6,/1D3EH$MPLAY,EYD<I;)A\Y)3/:0D=%6_5Y9$35NV%!2
M@)1;:1#1=WEFFI="#H)50<]:N*A?6HJXM,&XL>5A)]];F-,2V9<=MZXW-PH9
MM<N5S0Z3 K,)_EK30')$7(3<!M8YDLET6Z1G:.I\6E1>30O2 4B:/).@WZU4
MYCL>;!NM3.DDH*/K3.(P[4! E1<N'/>Q&KR[$1BCV2(UYQI4$E0]ZIK'56U(
M25M6F25"%]IPNS5=1"\TV8$)+DTKA(*&*JE5CPGC!;2D-O$.[GML28HSFKI>
M&0<8?L=X@156*VFXC/VFX7")+9?CM[VXC;8SLDXTD!)/<,VOJQ.13]@I<L_*
M@0M>#G?6(.MSD.1*4QJN%+;8?DRO26V#(NFV\5)@RU3HGHUGBN,(B+8*(* E
MQ.P5QA7%$8PKJ;:+-&$B"2(JKFB&##P**ZDR=14TJA(<DO"&+BY6W;KZS;69
M#^(Y(\FGW-@A>OCF+7V2<;:9W1G!EWJS2VGV4CO;RU/"XKPN1%BZ+F6%$D#,
M&)90W,+V?)XLY'A0!T!;8^ ]%!LP!XYMB) \PX8L:I,:+'9B);D06XZ?)94E
M-@3F;9#DB$;N\-4$1'(15&T$11!')3<S1$1,E'+FK?F+:35Q8E*XI,0[5['P
MP<?D29 G)D ]/.1)DDX[(W@PK8C3KKAO*3<@G%S-%+26U/\ Z->_VBHO]NJW
MS 8A_>B3_&0_SZ-6[X8_?=/N;??T%<JK.:S6/IQ2MD4;8;M)!;$#,#G92]@5
MF)6G)[)-0]X0S$/BK&B7'2B'(5(?7-#0V5I4ZPCT1<IO'^-=:>CWT2:L1F<T
M@*2S8XQU-'-"M(+[4C4F0%J539!%3,4T*:<ZH0ZS?L.!?)^')KDD6AP]='KF
M,<XJ2&YAO6^7;59<4GFT; 6)KQHJ":[Y&B5% "!S8-7W[^#U5G )-123*&1Q
MB!8;*FQ31Y,^X5N &X-%";[,)TBX6@R #(V/+040AJ!(?>B,0RCTHA*O8]YW
M$<V2C;QQYMYM]_?F#CRNRF92.F2"KBN@3*-B>\R0")0$'%(RUVZ[/?9&[1[@
MU>%BQ84F'(MUL6VL2(MO&+9KA9CBQ@-\8XQ)#=P<E.,K%53D-MB\;\4&H[5)
M=-[/W:MV:OD:O#2]8IE**.G<3([19\S3D7.,DR<P*$"1YLD3@727$ERDP1KS
MK@T=.GN$IJI[TZ65>%EL2&3CAF^41Q7M0HZ3L5)8HZ]NFFFWG' ED)'H;55;
M;,]X>M3K63 (6.YVNXQKJ\H6UF]Q0@*RX<0(5Y*RNK"@K+F3)$&-%?LK3K32
MOR6P&3(8CC&82.#&##[XU#UD;ULZ'6^R;N=>N3I=!)+#K$BNC#8AB$W#4/?0
MIF1$L!!3SJY'EID)AN(3AMEYB5:!,0;>[ 5K-'9;$I74/)1)AMYI 0="HJ$+
MYYJI9H2"J)DBH6>DX?-[%$'$P31;.#9;C90AE%5P#;N,J#+<?)Y)+9(;;UOC
MH (WI5M7A5=1@XUN$7V6:&WNXW]6OH#QFV7./;_.H-N,21Z/5A@:0K^)RA#[
MSP:9DR].0W'2/?3+BP<$'2L1E<5W)MWY F2IO(@5Z3*&3FCJH0)NW6W&->Z5
M5:-75-$'=KJ $<5T$45TR7LQ.38;-AY,1/A"M%D<LV@H(FU(7E4*5'N"L),;
M )K*0@CD3BR 5EY]8X1'31T;8,[#J#6>/=A5,BC[9^!,BHSB,<W)7!DRL5%B
MECK!&"3(,L;#F1Q<9B5/AK:EPR!-AIUI,""J4/E2-WQ6I"2VHHMR>1E%-Q'2
M4"+DHQ ?%H@)L"1L!)P50Q<<%%3=AJ KJ5LX2;:W+'+O;TBT)?&[Q'C.061?
M::]F'+U(MSLYE]J4\R<IUQJ.\ALO1XQF)K(?1J0UAK.S*_'V-8+TQKT:Q /P
M#K*:RT3RN,"*'QST209K\J6,EM0WX4Q]X@+C2AL^..4YYF,E'F(CL:T2>PDY
M^8D)L0>!Y$CHYV++C[:B3K!$V0B0&2N-B39BVJZ11-(J.:/"]Q<PU;K"YB*2
MX_;Y$ UNAQ<G9\6WR >;A7%IF4T;S;[381Y;C4F.Y($=;BEK>%W91+L_()$W
MBCE+:;>?*[!+N(Q87G$YD;%U*+U(61A;HI;N6X8T6@M RXXX[Z>ZMJ4Y)9QC
M.;]S$"N.*XL5$57)KJIOU5-4ZV-VUU,U:5<A!M'0S55UJJ$I#6LQMEC<:*$4
M;V9 $3#T,56W *[O#F+Y6+XBJ@2Q#4]*E%$D:1$=P"$R+1KDF$;#W3B_UR>&
M<JS(B>:LU?MYLC&+N2(CYH%4W*DKU<+='MJ&P)\1?IKL1PC.5'F^5B-(1#RW
M$:M)MU29'-I8Z-&[(8DNN"ZJB3K,98R[MM03=@8KK45,])YH*H&0IG,.8(7#
MUS8G#=CF,0K7<;-!C.PQ;>;@S[N-X1)$L9!))D1WA1@'ACL(XQEO&U>U.EYG
M[R+3"FJ)34,C&%:N&4P>BO8L4I8H^[2BKQ6 0EQDPFHT6=)=?<9?>3&DJ;9P
MWAG*%(4I8[NZ3EM)!,6[<W$!&-^2MO+$<5P#,4%!$R55%5TEDF67-Q1\"0V(
MN+6C>C.R\52KW)*X^QK0R[>-\B!$D1F75?-UUAH $VP5UI"-3UHJ$B"G[OFS
MZA8*ED/*B-$[5=;*+F#K07&>AHO[0QBP!SL(;B)%M8_#8B$X.3.3%Q'?2^F4
MW/@2'1ZAW8SC/1E;(4<DRY#9!(<;T\M1L7VG@;TC(#)H%;0M.DM6I#;)6ZA'
MP(Q'O-OO"36GCBVJQVR4S)M4.5OBP\<ERW3(#\I7G;3(59;XR285U7 4%9*/
M(;&0EHI.WS&OI50(5J&A$RNX.Q#48G(01!7 '87V%DZ\9#*ALH6)EQF,1I+#
MLJ4I2_-S8ZHLN-'=:IQ+F[!**<<<C8WPNBX2.,RF7U'>,.M:$16C$=)"I%FN
M1BHD(JEY?,&P\1-7F/<WU)FY<@=@NQ6RC3[-.MS;@Q;C"FH^:I+9<<5ULQ::
M1$U,N(ZRXX!7EW<HZ6&J8LG26B>:=>+E?1Z9!]YL80*7"4$E2(!J#'&,S)(B
M)FOCT)8@EADN1A4SSDU"7VT1ZJW4":BMN1$<Y)+E3&\WE1LW)1LD0/ +:$30
M[@$R!ULB[+,TS1$LAP5)9FW>7%OA1?9JQ6;#\DF[>!2H\6S,S66Y$%]R6;+4
MQY+A()7'X<IEM49TL*H$3ET ]BSHJR-V4@$@'I)4M?3-[C3\#,MW&5L.*L<=
MCXE*!O$:^+>%^9'NCA4SS+C#.,MJCK<<RJHS?'FWT?-H'B==F.S1-&\I13A4
M'AU;E38;)O)M6VBTJB<-.:U:W#9M F6PK9'G/P&HD2P0K Y&Y4A65K#KR28#
MJM)/"-<982]<D9,MC6+CBZD<011(\/9:4ZZIAM;3"G%Y9:==2\XVUE6<MMN/
M):82ZM"/$E;J664N*QE>&F\9\C&$7+-<D5$S7)%7-43M(JHB(JHG.J(F?/DG
M-71P0T $<(3<010R 5 "-$340@IN* J6:B*N&HHJ(IDJ:E]?(5-3BE.*4XI3
MBE>,YPG&5*SC"<8SG.<YQC&,8QX\YSG/S8QC'SYSGYL8XHB*JY(F:KP1$YU7
MN5+GJ=TYLW9^5#N5H65J'7R/(\I9F*M\;9=NJ8<\ET31Y*?-RA%*4M*F#&P&
M,HE$T>='49SSRWK0&V?#6%I%_(94K>1;*)?[05)M^YY+Q;BDBH347-,G9B=D
MXF;<14)2D,\?VN;9[7LN:>LMJ2+>-H;C>20G1;E6S!Z&.82[ZTNIJ9?$14<A
MX><0FHJZ)-^'0@6J;]"%5JE:HU<"U"G A=9J]='QQ0,"%ALCQ8L?%1Y#$6'$
MCH0TTVG'C4KQ)\IQQ2W7%+=6M:NUQX[$1AJ-%9;8CL +;++0H#;8"F2"(BB(
MB)^5<U7-55:^=]VNUSOMRFWB\SY5TNMRD.2Y]PFO'(E2Y+JZG'7GG%(S)5X)
MFN0BB"*((HB9!RM6/IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2N?DWPB^DB]=V>_K8
M?9=AW#6M8N=GFU*'#89CJ&52B:^O4:PDCH]XZQ!I9)G:VO!\L\-A'B==DFB#
MAJN1L5FP('JCEEQ7F7M_MV_D_JK#P'A-]13R%>%DZ;=HATQ77<JI &NF+?LB
M9LB*PP9(4BK5>M"B(ZSMHIR9EPAD8-E07(P([ N-6UV%UP5'4R5<^XG;7A^R
MUM#V@&@LF<!%0-E+,1K5=ZJ7@Q->%"Y*L2=97+-)V,8LPP*LD6!@J/DA4[=8
M"$R$VY'UKL*D["C1Y51,2"D%32O]7Q9Y\V6?[<%JAH7>ZHVVE;AV.4HMI%U"
M@=A-#:'I;0Y8\O:+^YV4UOU5MVI#T@+*D"(58<L=E[55.L/B9AF7@)"BI.'I
MXWSA0<%4RYOC15^3/_*L"(>%%T2W7X%V" +Y)U] ,EQMVLQ>N3 F0: ?3*^=
MV"0@ )0T1FG;H,U?4(BR( GBL!V%3"D>/:)=@'#*Y8%1TKGEP^+BG_-I^]Q[
MM4<COQU U\>W-M8V O5-MHT#,B;*)%@\)9,V#T63WD*+PAD:+;R0LD[0I.L=
MJ.I&A\-E3R'HZZW%LLDFRTA4,EX)W5X??1/_ !^W/O6M=VM26RZ5ND0*_L6.
M1N=]W-KFDDB=;&P@MOMO7S:P_3NW(5>FK/K>F.5*QR3!=;2XK$XK2:7>[>#B
M$@M3*R&5%14_)GEVLTS3_P ]SF7C6);'\(CUVUA;K=2"R+F8M%+G/0"0^K@Q
M!3+ZX-<W':"RHLIRP0XL=08;HS8OK""7?%%?/1!BH8^7%.C94A3)?V^]W/MI
M551^]=!V'>=H0JK7S9C5>L]*6/;*]BC8\X@7M<^A;2VEJC8U4K6O8HY=BDR:
MI9]46 /'<>\R3LAQI^&&".CDC#!E145.';_SR5%SYLES[M4U:\(?UXO<O$&D
M1=@7J5-*SJO7WZ?3?PI 7"["=7Q-U%-?U.\AB,Z@F[G&U.2:O(X(Q:<+M8G!
M&+27;*8$F!<%3)?V_K^TJ]W[^6:59;-X3+K!6)LT?)>O)%<0*9MDI8JI-O,9
MUX!);@#3]A8S**0U/5CTK06X$1(J6U6F<S27UPZT\D[5,'E,E_P^_P!S^KXN
M//5E5X3+2XZQ[%=L@PH*UA4A>KRM.OT9Z&0G7H=?%[TP9L4.I*7#)0JY78>D
M#!"+Z(\6LYH9.3,168B4(9=5'3S=W-4R^-,N&?-VZW'0.ZNI]DW:ET0/7MBC
MS>QL[%<U[(L5;&"QUR@:CM(RI[,* )2S[SDB#3#9&'@OAUB/,5&PB= B36'8
M:Y"H*BY9_:S^+/BF=8:?\(QU_KTU3$D9M:2,Q8KZ :M,?79%BI$&-7W)=!OU
MA"6$K)&P;$%K%HBDQY-JO+*6!M W,M )<4Q6'CJF2_%S9_U?YI\7Q\%K7*O"
MCZ>'D+T5-5&Z9UB&$URS4&[UN''L4Z^4N=I796_;'>'*QAX?. @!&M=56VQB
MH2GR5F/P8#45D#%LI,76I2F2YY?MSY??X\/M_%QJ^63PG?7P*4&-CU'3 5RO
M&[J3F-BB+!:31([UZ%5>WU 5B"_#.#+;8M9WP;#BG3-2,18E9F$7AJTS@<<J
MII7N?MP_S3ASUD GPC>CB1F<-DA+\#'0+#1:1(L!R#6( F)?[O<=VT)%/)RE
M6M<89,%VW0]NK22DB3D)9K+-K5<I9"QF;1689I4=*_;Y^;/M)GW.XN?]>62U
M/[BI:<4JEG0812%,&$X<4B-(Q9$$@/G1V9<*="ELKCRX<R)(0XQ*BRF''&)$
M=]M;+S*UMN(4A2DY4K493KCU[-P:(+,Z*TZ5%ZN%CP>M!I'6=+F#]>!1!2M&
MQ0>CPI 5R+5!8PS3*@5'CP34")"(U:NS8S+4@,.<CJCFO'BO'G^/[?RK5;4=
M!Z*U_.BE*'I;4M))P14L%"(U'7-/K<Z&$G@J/5IP:++#!H4B.*FUG66MJ[+'
M,N(B206O:.(>96/J8&/ 5#->[^W[*M6@GUDZW&HPZ&8Z_:2*Q [;3(B,1U51
M9C EI@;3P[#0QJ0"<0/;9$:]H(MI$3#*6QU'J$)&,1JT&:A*CFO=7Y:MB.I7
M59N$P-;ZT: ;@1I$27'AHT[KQ$:/+'MUEF!*9937<(:DPF:53FHCZ,)=CM5.
MLMLK0@$+3%4S7NK\O[=U?EK6P7P?_4P)=;7<F=+Z^F1K8/K@R31R%"H#]!%P
MZF.H@VNQ10!NIL.X'@TZUI\ZO!B9 F"JA<8X7J8L$1G3I$A3-?Z_R\_[?+6V
MW^L76N3F0J3UYT;(5*?FR92G]34)W,F22)6TR1D2,N %9>?(&+]>BLUUSRG)
M1*ZVV<^IR58S#LQ3->ZM4WY*W6'U<X)_)ST3D8Z)? NP,ZDH.8CH237+'3I(
MAQC(#S:QLBI7&W5=^$M.8[U>M-C#.-J''"<:4IFO=7Y:WG%BQ8,6-!@QH\.%
M#CLQ8<.*RW'BQ8L=M+,>-&CLI0TQ'8:0AIEEI"6VFTI0A*4IQC"H5[^*5Q$\
M(M_EX#_S;5_^OK5S1L1_O@'\F;_MNU[LZ&K[ )W\Z+C^CK/4"N8"O0E78!*:
M@G0LU]QAIB&6'2GG90]!:*TU'F,NN.213BD-DV$(1E3P]Q:$3&\*C*4E+F<X
MG;5!<;)51$$Q554=:(B$BJJAPUHG;'_B3AVZL[BT<BWSF&Q<-QZ'): &9!0W
M2-Q@P$6I8H117"(D0) BI,$J.HBJ.52.7<-/3+!5[),2_@A&-"'[1'=7;YT.
M /27'$Y'X $T3!QE28F&33;[=T02ELL&F( N9*P(AD$Y)7H1.-.KGJ0P5U,W
MR01UB2\G-" ^QR-%1]"5$-! B0$5.8C9<:LVV[6ME06,[!F-VIP$LT=Z1(6'
M)BM],,4F9,%">4X)-E9%BL&Y!<D2V6EFOQE_  WH(+BNO9BYD$H[U4<,D,1+
M8AQ38RPTHB7D0&LD5*&EY<%FSM+<A25Q\98\B&_'9E1XSD6W+<WNURS)%94S
MR>S30XR1D/99@9"CJ=BN7#)%1%1"FN$':).6Y CN[C.!=QA1E>LZBA2K=?(T
M-N221M,J&R^=J,1>:%S)Q5>!QQIQT<=ANZ-RF3B<GSK:JXVF*K,6WM%L6*56
MWV)DB7*:*O"W,#[@RS-',,"F8LP!/RY.D-S8:@;](>09%JX_4TTJJ/H>\5I4
M)55"4%TO)J%-""0%F2HH[M<D\&/LVMPN@AN1*ZF^LQPUMK5S!QAMEDH@2Q61
M9C-B2;DPW6+A'06&S8?Y<W[@=]I;5,I].,1HDQAX>='VM\A#)R&16,VMNSAI
M(YL?F'*03E^@Q@KQV'*F2!8(D:B-#)GI.6'02&-PPR:(2*+@O*2&J!]61T%'
M3I)"72@*8J2BV1H@%GDLEPP[?#O=YO<)UYAQN5 DVAN,_%:.9_\ 2"M,YJ24
MC?-+%:Y0[.;@/-,MRY\6$Z<IA6T<"_R377AQO$/ Z3(@L3)B!R)#ERRL8.GD
M"<ES+&6B#"%RH[#PY#.9")*%+BX4\A]Q4AR15)RVJB#I510BTYJ]F(D1+PR)
M$S1%%$S14S'BB\57'MP-I DK_*FVY#C#!22;&R:94J-&B- CFN,X0LN.!*(T
M;)HD%[(";1&Q;T7=) F00%J%Y96ZW6:XP;D1O)]&DGV14=!-YM2/\!Y["\(9
M(2T>4F<4:G3DNR$R<27L>^H*0:,L]TTCBIS*X@(AJB]M<_KBXZCU%FN>:[_8
MFYC<:6DM'! KK<W(#;V>]:MQS'5B@2%V0 HZCC,EI6/$./'4&U:5L,/Y1K-5
M6"]73-TFZWJ\>=C5B=;[558,0],%.FX@R1%L0PDS(DB6"0=Z>SE<%+;D=HI!
M<4AS.4R$9QC/+>3;2O#7L:#PQRE.QQ%XFU>%M0D-.HJMHXTIHJMZ51'!7CGG
MPJVG8I9P3;KIBF1 =NC%GM-V?>@,RQ@NRFW;=*C&VW+.-,".>E]2%PHKXHHI
MFV2+4Z_93;:^L;KK[CK+\:^5^IS<>_D+R2_Z5KSWUV6$?@VQ'Y]VSU(I[*;;
M7UC==?<=9?C7QU.;CW\A>27_ $K3KLL(_!MB/S[MGJ13V4VVOK&ZZ^XZR_&O
MCJ<W'OY"\DO^E:==EA'X-L1^?=L]2*>RFVU]8W77W'67XU\=3FX]_(7DE_TK
M3KLL(_!MB/S[MGJ13V4VVOK&ZZ^XZR_&OCJ<W'OY"\DO^E:==EA'X-L1^?=L
M]2*>RFVU]8W77W'67XU\=3FX]_(7DE_TK3KLL(_!MB/S[MGJ13V4VVOK&ZZ^
MXZR_&OCJ<W'OY"\DO^E:==EA'X-L1^?=L]2*>RFVU]8W77W'67XU\=3FX]_(
M7DE_TK3KLL(_!MB/S[MGJ13V4VVOK&ZZ^XZR_&OCJ<W'OY"\DO\ I6G7981^
M#;$?GW;/4BGLIMM?6-UU]QUE^-?'4YN/?R%Y)?\ 2M.NRPC\&V(_/NV>I%/9
M3;:^L;KK[CK+\:^.IS<>_D+R2_Z5IUV6$?@VQ'Y]VSU(I[*;;7UC==?<=9?C
M7QU.;CW\A>27_2M.NRPC\&V(_/NV>I%/93;:^L;KK[CK+\:^.IS<>_D+R2_Z
M5IUV6$?@VQ'Y]VSU(I[*;;7UC==?<=9?C7QU.;CW\A>27_2M.NRPC\&V(_/N
MV>I%/93;:^L;KK[CK+\:^.IS<>_D+R2_Z5IUV6$?@VQ'Y]VSU(I[*;;7UC==
M?<=9?C7QU.;CW\A>27_2M.NRPC\&V(_/NV>I%/93;:^L;KK[CK+\:^.IS<>_
MD+R2_P"E:==EA'X-L1^?=L]2*>RFVU]8W77W'67XU\=3FX]_(7DE_P!*TZ[+
M"/P;8C\^[9ZD4]E-MKZQNNON.LOQKXZG-Q[^0O)+_I6G7981^#;$?GW;/4BG
MLIMM?6-UU]QUE^-?'4YN/?R%Y)?]*TZ[+"/P;8C\^[9ZD4]E-MKZQNNON.LO
MQKXZG-Q[^0O)+_I6G7981^#;$?GW;/4BGLIMM?6-UU]QUE^-?'4YN/?R%Y)?
M]*TZ[+"/P;8C\^[9ZD5L#67@KF(%O'%=X;3#;/I0M7IBM?5N@$:0-LQ%MQM4
M2-<2,^^6^25JS/DN.S:U"9&-'7?,13,V6#P1"E+VW[.Q;E-NW:X-7"*VNOD3
M$(XK;YHJ**2C.7))R./.3 (VCJY"Z9-:VG->Q1T5SDBSR8F!L*3<+7N4FY3$
M-RQ#&ODFV1R$D=<LT:/8+.W$NIYB#-S?.4< -X["89G+'FQ>N46+%@Q8T*%&
M8APX;#,6)$BLMQXL6+';2RQ&C1V4H:888:0AIEEI"6VFTI0A*4IQC'2Q$0$0
M 4$11!$11!$1%,D$43)$1$1$1$1$1$R2O(+KKK[KC[[CCSSSANO/.F3CKKKA
M*;CCCAJIN..&JD9DJD1*I$JJJK7OY&J=.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI4=X/4+J>,1&;'=8^OL%N&R0C16XFF]=QT1HQ8 *JI2*PAJNH2U&)5@$#KT^
M.C&&980*(%R&W(0V$PPJ.:KSJJU72NJW6";Z3Z9UQT/)]-<ANS,OZBU^XJ4X
M/FB24%R2I5?RI]<,@!!SHJG<JRQ+#"I#64NCXBVE,U[J_+67F]+Z>LLZ 3L6
MJ=;GB0JT)O L@9H]9)S1US0"@5=%M@RIHQ]^+94UH4+KZ3C"T$\!!H\7B3Z#
M#C,-JA6N3_4CKZ6US(U0$UE3]=T2=L34.T2H#6=4JE,'FK9H^WZYN.OI!J ,
M!8'%(HZ3J:@@9$>9"=S)J%=@59+K(>/'C,JCFO=5>&7'CPX_YK63SNMG74H,
MDA2>@]*D0TR2B9+$SM64:6,E2V];/Z:1*DP) )R*_)1J"3)U2E]UI;J=;2'Z
M-A>*PZX+4IFO=7]ES_KX_;XU:#O4SJQ9\/XLG6K01[TIXQ(E>N-/:](YDR+#
M^%/K]^0J77G<O.G/PXNN3#CF5+)JM]G5-R]D\5S+4S7NKW.=>;N?D2LG$Z0U
MK7CM:+UNL!JT/IY"WV*N5&M@:X!J(N[WV4<DW'8D44*#1'FKQ8TVFV1S9M$U
M/KA%KL,HI&F$R3L_"H58YO5SK.2-&+&2Z\:-(V"PSBY,\<GZGH<TN:)'VK(P
M=(%2,D"[+(33;%RM[)>5*>=?)-6JR-S''D'"F)2HYKW5_;_TGR5=@77O0E7<
MM+M:TEJ2O.W@'-K%S<!ZXIXE=LK1)<APE7K(J 'CY-@R#LN4[.$D<R8$QZ5)
M=D1W''W5+5"K+(ZK]8Y;I%^7UUT;*?+R DPL_)U11)#Y296GF7Z],)// 5N3
MI@1Z-&=%RI2G9$%<=A4=QO++7DJCFO=7Y:N!+K9UU-+GN&=":7+K*+.N$E%=
M74@BJ>NT-&&+,J9F8#>S(_")FQ6!L[AWRL%T'C6"&)&"L_TA3->ZM6&=U#ZH
MDU$5DNLO7^>LO,E$"JYNG=>REDYTW-DS+ESU/5Y:IDB2JY6Y;[TC+BW%VBPK
M4K*S)!4A3->ZORUF8#2^O*I9@=BK%>%UV/5J_80%4JH +7P=0JRKC8<V:['
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MA(*DJ *)RJ]N?X1SWL5+[I]=?N_S4.J!B?WXSXG%^:KTWUEG0_>#%U\Z+_\
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M'*W8:G;J>\*GS']E!7PEEEP8.PZ_2K+316M[4SL.W;,5!%X99)GVE^^B_?\
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MAZ5 LDHYW))4*9A!VY155V$D6*^0WN+E:7X;=V!R;$_^NV^;)M+S/+V69=7
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M^$UZ,IUP'1@_!'@7Q6X?]P*?D\?P>O\ UA.\/]Z/^F#CI:P)W^N/X37HRG7
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MKM/U>T'?-@Q+D/WEM^JT*S*UG.#H+U\'(VRUJ:XR89-;UKA12HRP#[9#%O$
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MA2 %9;/(7-;ILMMUA;WA?:@C%Y@V9B\$"W7%4RP7 \6D],BMN/X:/#S1+.Q
M&B/N+?=!9?DC<I4177(7)H,>Y2Y:05["%1^_]A]?:QI5PAL8V,ZZ=>M..#J_
M7[(F?*V#3:A"J9<*+&D@\ F44X682D:_!AOMD&I,?T?.9"G([6!NLEJ0Y!&-
MKD&,"!"%IIMPG'93;2-*RTVH";A$:9#I%4)%SSX+EUK ULF6"W8LDWT6+-&=
MQ?B[$QRYLR&$6)9)]P<GM3YDIJ0ZQ%;;CFJOHZX)M$!"J+F"E]M?@D>H^_.H
M?6QBG[[V63L1BPRHY\/JQ;\,F!TW'DH??F@QQM*7Y4LJ7D24S;'"@3UU4>39
M7ZE9ES))<\9ZY@JR7*RVTV[C(+.0XCS-M0D<9M@DBJ30.\5)QQ5UO V21FS1
M49%55QUSYR]$GM*P=M*QJW.PC9V6VK7'.WSL6FT[%GXP=;( 9FR(>8MM18C;
M>XMS\EGV5DQB$I[H $:'%ZH\W*O.M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE/\ _/\ _?\ [\4KD;&\*[19%)C2,Z^V*Q;'
MZX$)).NU:F9I#A<Q6P=V]4MB&=T/VI#K%5+O/OJ=?Q ;G"YT=@O-4H<T25,@
MJO-ESY?XY_:_+\55!SPINI1==V4?V9KFZPJ-7];F+1,JT&/0SML*U\58.Y0^
MTR66,;+C)L'CH_4FS'B%3#AEE:W'GK+$")*HLG;#5%-*KDB<<\ORZ?BX<2YU
M_(O/NKKSW0U+<[D*ZY4K5ETI1*H&-BT&"%@#ZN[2*73M0[:[&Z'K9%^:+L.<
M"PIPOU:N(T.#'#)<P"N=5(,R*R(*PBZE%3MYIS(OV\T15^^F?&HK)\)CNZM0
MJWL"Y:%C'=+R]K=@]?6*UTN.L,=4YU]8[PS["$I(J^7<2-M9Q=9ZK5.Y33ZR
MPVJ0&[H9ID9TG9!K+S2HZ4[N2Y(J(OQY<ZHGQ]SN+S5(.=X4OKJ.*V0>_7]J
MO0JH:I(TW9AE=KANJ015]OF\M:A[;+/!;@0A0:W$NO7Z[5HX_/7%(!;20JM#
MGCF=C%Y%.'*ETKEG]OXN9$7M_$J?;[7"LNM?<QXYUF =A-0"  )VR6.LP:Q4
M]_$(=-D7F&>C0S(T2 (@+"4$C9EKK4YD^-M<XG/!U.M,EKC9A3X4"5:94RXY
M<?O)G^1<J_6W^T.NE[K8ZR6_15SV?,<V'HF%4_5;FL98PAL8E6MM=AZO8<0K
MI?:GD3%UA%ZZ.VL=9,K=+Q;O$"* #,3X0LE)4RX9Y]WN_$G^/VLOCX5'L?X5
MNFGZ5I"37*N5F778X'JW=3CQ$4%BT[\$=TVOIZ%V!$&.!-D66?6KS31'<2C3
MX=3M,Q]Z/+B25SY$^MR@%EL:HZ>?XL_R9_Y5N.[^$6UW5-4:JWDBF;(S2+S)
MW>T:J<NK@(NS@CVD05TFV$ 5!F-@5^-4+8@E3IJ'@-A<?)P,-O!++ JAY+S$
M-3+CEFF>:(G/EQ[?,N:?^TSKT;I\(*.HVB1^UJ5K:QS#%CE]NJL,$7.161\>
MJ7?J53=\$K5%MR UMFME1A&Y:,*@('X)&I[L\1/P7CRFI*8HV8IIXY9IVN[S
M+E_FG<K,M)=^=;;KV@WI051MH!]DC6G4W6(5"UC(&FNH*;C"0I10T'N1R*^-
M/D]&7-L,Z(<+R&\3:RR89&RB4QH:J"IEQX?%^3M<Z<_;1,^U6I#_ 'OV0-OT
M>I1-9A9C"]M=O-9O,!,DK,6Q%Z[4 %:ZQ8$*DE*A&3@],+Y59X*F5^KX:<0Q
M<E]YO)-]453+M_\ "B_*J</RUD4#NY9+!H'KAM*OP:'&O.RF.M96_P!'N4*[
MTL:1A;J T^WVX3I^T6)@<!L<JAT,]:+Q+/PB]O@0X]&76"HIHQ8VY()4,N*I
MSY9\W'F^US9K6K=(>$3V+N.)J4FJJ:DJ>;O:M((,UJR6LF&+R:3NWK!IKL1/
MEUHK/?1!8+Z6>V^-JMMD$!\Z)=ISU,'"A]0L.Q @B,J*IEGS\$Y_OJG'[>7#
M_+-:G9U@VW:]RZY,V"\!88"U5S:>V]=DX$$27!L/1*%L$_7*V:]6%IYM,55G
MJ<,#9LMB;1;0N,%TX@6&7C#C$14%3)?ZOVX?+VZD7Q4*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4KX//X2Y_G!*7_1@UU_S!VYSD6.OWY:_D#']])KZ0="
M5_!C</YX77]%V.OGJYIE>H*S2DT4S>I)] K,:/"JE4-W6RE)JW$0Q%>!-LI?
MDO>9:>?<?GDI@P")C--*S+-F!D1QR,P^[*8JLLF\IZ<D1ILWG"7/(0#+->"*
MJJI*("G;(A3-$7-,?<;E'MH1E>0S<FS8]OB,MH*N/RI)%I =1"(BVT#TEXR)
M-$=AXT0R$0*?8KHCV!K]_P :G [8A@YHZ]T\BB7#3MJNU5NWI-46NT^["B3U
M1'#I3XF7M:+&&VV,I#X-]1&$F9"=*#4D\R-HF@\D<)* HO-EF/*0;1Q"9!MX
M25L15060B"XB]@NH=2*0ZN9/[2,,2K8MZDV0Y+;MMGM*#BV25,6"L>XRI]O?
M:&:Z\V+P68C>@FBC)'=.;MQ&7=SBDFE>$<%0Q0QZU;RAC8R T0'#9W<ZD:T,
MS,HZ:P0%-1KWF'^"DPFYJYBJ6*)C-8)DI^M(H E)F%:>U*IJS?1015R6@II0
M$27P0<VD;(41[+=J7)T;-.P(B80"52:SO0N.RAYQ]X86'''35]R0X6'45TGM
M%QY8V\I6W6LUMH;P4V*?^N,M-7<Y+0-LSU"VJU?X05;3Q%XIN+"[171%:((E
M[A0T5(56S$Z=<AU=.#9-W068"226Y*A<IH4O%8ACEWINTE(L1J=/(8EY/>N)
M*4G-P!;+.4B$K;A-.B!"KVI 4I3;BB2(([[62)J):J^S.RY%%I&+"J0Y3\MI
M0L*DPW-B-3X#LJ,\%N5@Y -6&= !]@R<=2W+#9,U;;:6XZ\UYWJV+?P56SLK
M:X"7+O6OM<EK,;VK99K5%+F;*"A4URS,!3Y>R!QPVR;""YA2D#,LC"UH:0RI
MB<2<2Y,PQ=WGA;61(!5=99-PI!EN2)P$:UZ#)P41Q\,ERR$G4YE*J5UNVS>U
M6R3-2T664 6VYW5B''LL1LKDQ'B27)Z1"D16(C[KL6UR-X!/:GF89*J$VTF5
MB+:U[LV+7!I-VM^SW:7/@U>?^"5MV69)CK%APU7<B6"8>0?GB@3@%S8@NP*_
M#C !H<DTIYE6",K+2Y2CW8V#WSLA6B%M=TZ^1(YV8:4(5,A!05X3^JZ,M7#L
MERJY9O&SR)=8RV^#9QGMN3&N70K0PR[$RCRD?)I\8K;TE)*6IZ*BV[E).K'T
ME]2#-(X; TKL#6 M@G<PRPZ\76X:Z+#9&<X) +K1XM<)F@A5G"<M8\Z'MU>+
M"24-^6++Q)K^($Q]X:1;C6#T1^.*$Z&GZJZP0K]<#K2 1 7:X@X!B0JHD*KI
M55$D3;+9B"V7A\V8#Z/I['P+JP\*?495ON)RV8\ADL]68R(,IA]EP6WF#;'>
MMB+K2EJCEM6;K8.JJU8KGL&LU*H@R]FM%EF/!*]70 Z67-FS!*#*B#Q8D6/9
MD3B!";*=;CQ(<1AZ1(><0TTVM:L)S:S&7I#"LQV79#QNQT;98;-UUQ4D-+I;
M;;0C,LD5<A%5R1>%7D&X6^U/E<+I/A6RWQ8L]V7<+C*8A08C7(9 J]*ER3;8
MCM"I(A..N" YIFM39]G=WO\ J=]F/N.V9^['*OL;>>\5]\D3_F*PG5&V9_"?
MLV\^\,>DZ>SN[W_4[[,?<=LS]V./8V\]XK[Y(G_,4ZHVS/X3]FWGWACTG3V=
MW>_ZG?9C[CMF?NQQ[&WGO%??)$_YBG5&V9_"?LV\^\,>DZ>SN[W_ %.^S'W'
M;,_=CCV-O/>*^^2)_P Q3JC;,_A/V;>?>&/2=/9W=[_J=]F/N.V9^[''L;>>
M\5]\D3_F*=4;9G\)^S;S[PQZ3I[.[O?]3OLQ]QVS/W8X]C;SWBOODB?\Q3JC
M;,_A/V;>?>&/2=/9W=[_ *G?9C[CMF?NQQ[&WGO%??)$_P"8IU1MF?PG[-O/
MO#'I.GL[N]_U.^S'W';,_=CCV-O/>*^^2)_S%.J-LS^$_9MY]X8])T]G=WO^
MIWV8^X[9G[L<>QMY[Q7WR1/^8IU1MF?PG[-O/O#'I.GL[N]_U.^S'W';,_=C
MCV-O/>*^^2)_S%.J-LS^$_9MY]X8])U<PG@V>^ITP+"Q^HG8>'(+$(8YB48U
M'>@8F,]-?;CMO$C1D' $"8+:W,+E$BLZ$.A,X7)FRX\9MQY$1M5[,A +#>U,
MR0 1RV2V0U$J(.MYUH&F@S7LG'#$ ',B5$1:I/[3=ET5AZ3(VG[/48CM./O<
MFQ?8KA)5IH"<-(\&#-D39CZB*HS%BL.R'W%%IILC)$K[)O!@^"=UUT8K<*^W
M=L3?.RAH=Y)BV8:Q*#4!B:QY$RMT+TEI#B75-.+AF;6XTP1+-9>AP6A@B1*B
M3NNX5P>S94&?.5N5>' 5%<1-3$$#3LF(:$B+J5%TO221''<E$=VVJ@7SKV[]
M$-=-I[[F',.I)LNS^)(0VH1%N[AB-]@LV;G?B;)14!)-[!M(&46$JBZZLF8(
M/M=A>;O7F>G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*?Q_Q\4K6WXFM/\ FL,?BIUMYA/D>2S^ M7\TGS<9,-'B;]5^1CR
M(B4Q4>+'^#&2EC'B:QA/%,U[OQ_?[M?@AI;3A9+Z"NIM9DT29$B9)00HE6F)
MD2Y<LY/ERGTR13F'9$J=9[+-D/N84Z]+L)R2XI3Q:>N0IFO=_;]D2KV/UWK\
M25BGA5%IPPY!=.O0C(^L!(16&]:)#<NRO12,:"W,CNV*4TU).N,O(67D--O$
M,R'$)5A2O6O6NNG!#%?<H-*< Q9I,E%"+JH)8B,1-L$8IF>P-5 S"9FEXQ<M
M')RFV4OSV"A%F4XZW-DI=4JV0=.:A&$/6PW5>MQY7!&.7P3@T>L1"'K:)+E3
MXI3TQ@6W)]8QITZ;-CS?.>DLRYDJ2VZEZ0ZM:F:]W]OV1/DKVR=0ZGF A56E
MZPUY*K (A(+A*Y)I5:?!!RLMZ1)E$Q0AT8H>/(29$R7(D38D=F2\]*D.N.J<
M?=4I4<U[JU>IU&I1,VW925/JQ"QL^@89/SJ^)EFVL"FB[ O#961$<G(]6LV
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MBN,"V1S#:8^R<[,%W_\ LPW8)NF=*-H3)B"CN]) !1V%;$D5&]T&[04%*E7
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0%*<4IQ2G%*<4IQ2G%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628760953536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Company/DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756421152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,483,000<span></span>
</td>
<td class="nump">$ 4,338,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,839,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">17,474,000<span></span>
</td>
<td class="nump">14,268,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,126,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">933,000<span></span>
</td>
<td class="nump">2,562,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,145,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">10,583,000<span></span>
</td>
<td class="nump">1,835,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,314,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">31,473,000<span></span>
</td>
<td class="nump">23,003,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,424,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">846,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,271,000<span></span>
</td>
<td class="nump">1,303,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,675,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">41,617,000<span></span>
</td>
<td class="nump">38,802,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,540,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,481,000<span></span>
</td>
<td class="nump">13,481,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,481,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term deposit</a></td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">538,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,777,000<span></span>
</td>
<td class="nump">77,932,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81,504,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,684,000<span></span>
</td>
<td class="nump">4,284,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,120,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">1,426,000<span></span>
</td>
<td class="nump">3,733,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,754,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">23,862,000<span></span>
</td>
<td class="nump">10,621,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,622,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred consideration</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,950,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,888,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">166,145,000<span></span>
</td>
<td class="nump">92,724,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,664,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyNotePayableCurrent', window );">Related party note payable</a></td>
<td class="nump">47,108,000<span></span>
</td>
<td class="nump">19,608,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,008,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">717,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">424,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">251,075,000<span></span>
</td>
<td class="nump">169,420,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">78,480,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred consideration</a></td>
<td class="nump">3,517,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92,255,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyNotePayableNoncurrent', window );">Related party note payable, net</a></td>
<td class="nump">62,717,000<span></span>
</td>
<td class="nump">23,503,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,403,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeLiabilityNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">863,000<span></span>
</td>
<td class="nump">1,148,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,649,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">318,172,000<span></span>
</td>
<td class="nump">301,808,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">223,187,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">128,615,000<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">122,423,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(358,030,000)<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(229,395,000)<span></span>
</td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">88,777,000<span></span>
</td>
<td class="nump">77,932,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81,504,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">130,788<span></span>
</td>
<td class="nump">4,536<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">34,961<span></span>
</td>
<td class="nump">507,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">165,749<span></span>
</td>
<td class="nump">512,457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">139,410,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">101,458,835<span></span>
</td>
<td class="nump">139,923,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">199,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">809,292<span></span>
</td>
<td class="nump">208,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">809,292<span></span>
</td>
<td class="nump">208,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdvancesFromRelatedParty', window );">Advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Promissory note &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes &#8212; related party, net of discount</a></td>
<td class="nump">2,035,000<span></span>
</td>
<td class="nump">483,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion option liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Simple promissory notes</a></td>
<td class="nump">2,971,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent', window );">Mandatorily redeemable ordinary shares liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">5,190,000<span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,168,759<span></span>
</td>
<td class="nump">9,240,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,655<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(12,003,355)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September 30, 2022 and December 31, 2021, respectively, at redemption value of $10.41 and $10.00, respectively, per share</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">139,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(12,003,010)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 101,458,835<span></span>
</td>
<td class="nump">$ 139,923,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 199,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdvancesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdvancesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyNotePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party note payable, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyNotePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyNotePayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party note payable, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyNotePayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628754679952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture', window );">Ordinary shares redemption subjected to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesSubjectToPossibleRedemption', window );">Subject to possible redemption shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,726,395<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Ordinary shares subject to possible redemption per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.41<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubjectToPossibleRedemptionPerShares', window );">Subject to possible redemption per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesCapitalization', window );">Shares capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture', window );">Ordinary shares redemption subjected to forfeiture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption subjected to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesRedemptionSubjectedToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SubjectToPossibleRedemptionPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subject To possible redemption per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SubjectToPossibleRedemptionPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756925856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,115,000<span></span>
</td>
<td class="nump">$ 23,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 31,317,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 23,560,000<span></span>
</td>
<td class="nump">$ 21,033,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,284,000<span></span>
</td>
<td class="nump">2,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,634,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,149,000<span></span>
</td>
<td class="nump">5,802,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,457,000<span></span>
</td>
<td class="nump">7,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,201,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,961,000<span></span>
</td>
<td class="nump">10,216,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquiredinprocessresearchAndDevelopment', window );">Acquired&#160;in-process&#160;research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,371,000<span></span>
</td>
<td class="nump">36,092,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,582,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,970,000<span></span>
</td>
<td class="nump">64,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896,000<span></span>
</td>
<td class="nump">2,803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,738,000<span></span>
</td>
<td class="nump">3,713,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,008,000<span></span>
</td>
<td class="nump">48,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,155,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,818,000<span></span>
</td>
<td class="nump">159,728,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,893,000)<span></span>
</td>
<td class="num">(25,421,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(35,838,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(35,258,000)<span></span>
</td>
<td class="num">(138,695,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_GainLossOnDerivative', window );">Gain on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,300,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">23,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_GainLossOnExtinguishmentOfDebtt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,634,000)<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,463,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScilexPharmaNotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,596,000)<span></span>
</td>
<td class="num">(8,617,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,764,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,116,000)<span></span>
</td>
<td class="num">(16,889,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(460,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">(Gain) loss on foreign currency exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,377,000)<span></span>
</td>
<td class="nump">21,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,581,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,314,000<span></span>
</td>
<td class="nump">39,897,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,516,000)<span></span>
</td>
<td class="num">(46,449,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(88,419,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(47,572,000)<span></span>
</td>
<td class="num">(178,592,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,400)<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(53,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,480,000)<span></span>
</td>
<td class="num">$ (46,459,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (88,424,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (47,519,000)<span></span>
</td>
<td class="num">$ (178,594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">$ 657,746<span></span>
</td>
<td class="nump">$ 283,346<span></span>
</td>
<td class="nump">$ 2,412,297<span></span>
</td>
<td class="nump">$ 620,642<span></span>
</td>
<td class="nump">$ 6,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,005,498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(657,746)<span></span>
</td>
<td class="num">(283,346)<span></span>
</td>
<td class="num">(2,412,297)<span></span>
</td>
<td class="num">(620,642)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,005,498)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,377,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">68,400<span></span>
</td>
<td class="num">(1,162,800)<span></span>
</td>
<td class="nump">2,188,800<span></span>
</td>
<td class="nump">2,872,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,377,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Loss on initial issuance of private warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,599,200)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,599,200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsAllocatedToWarrantLiabilities', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,212)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(30,212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of conversion option liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities', window );">Interest on mandatorily redeemable ordinary shares liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Income earned on investments held in Trust Account</a></td>
<td class="nump">459,114<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">664,973<span></span>
</td>
<td class="nump">28,006<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,155)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,901)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,826)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total other (income) expense</a></td>
<td class="nump">526,359<span></span>
</td>
<td class="num">(1,161,006)<span></span>
</td>
<td class="nump">3,035,813<span></span>
</td>
<td class="nump">271,394<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,788,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (131,387)<span></span>
</td>
<td class="num">$ (1,444,352)<span></span>
</td>
<td class="nump">$ 623,516<span></span>
</td>
<td class="num">$ (349,248)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 783,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,820,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,834,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquiredinprocessresearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired&#160;in-process&#160;research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquiredinprocessresearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_GainLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_GainLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_GainLossOnExtinguishmentOfDebtt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on extinguishment of debtt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_GainLossOnExtinguishmentOfDebtt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScilexPharmaNotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Scilex Pharma Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScilexPharmaNotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsAllocatedToWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs allocated to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsAllocatedToWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distributions during the period on mandatorily redeemable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=118255708&amp;loc=d3e21951-110878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributionsOnMandatorilyRedeemableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756204752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture', window );">Ordinary shares redemption subjected to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">16,834,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption subjected to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesRedemptionSubjectedToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628755299008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Vickers Vantage [Member]</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th">
<div>Ordinary Shares </div>
<div>Vickers Vantage [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Vickers Vantage [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Vickers Vantage [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 35,464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38,013,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(178,594,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178,594,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued related to Semnur Acquisition , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued related to Semnur Acquisition</a></td>
<td class="nump">54,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,586,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Distribution to Sorrento</a></td>
<td class="num">(5,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (90,009,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,607,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,519,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,519,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Distribution to Sorrento</a></td>
<td class="num">(9,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 5,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options excercised</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation of shares held in escrow related to Semnur Acquisition , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Feb. 20, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Feb. 20, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Distribution to Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Distribution to Sorrento , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Cancellation of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Cancellation of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of ordinary shares to Sponsor (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,499,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,474,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,853<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,151,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,152,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,459,000)<span></span>
</td>
<td class="num">(349,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,459,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition', window );">Adjustment to shares issued in Semnur Acquisition</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(183,365,000)<span></span>
</td>
<td class="num">(9,829,785)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">127,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(310,585,000)<span></span>
</td>
<td class="num">(9,830,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,499,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,474,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,424,000)<span></span>
</td>
<td class="nump">783,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(88,424,000)<span></span>
</td>
<td class="nump">783,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 5,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition', window );">Adjustment to shares issued in Semnur Acquisition</a></td>
<td class="nump">$ 409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,151,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,152,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,385,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,385,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,444,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,444,352)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(183,365,000)<span></span>
</td>
<td class="num">(9,829,785)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">127,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(310,585,000)<span></span>
</td>
<td class="num">(9,830,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,035,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,035,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(806,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(806,222)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,666)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,480,000)<span></span>
</td>
<td class="nump">623,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,480,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">4,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options excercised</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount', window );">Aardvark SP-104 license transfer from Sorrento, net of discount</a></td>
<td class="num">(4,127,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,127,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization', window );">Aardvark SP-104 discount amortization</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">(229,395,000)<span></span>
</td>
<td class="num">(12,003,010)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,615,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(358,030,000)<span></span>
</td>
<td class="num">(12,003,355)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,566,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,666)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue', window );">Mandatorily redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,595,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,595,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,125<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,764,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,765,076)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,106,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,106,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,387)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">$ (229,395,000)<span></span>
</td>
<td class="num">$ (12,003,010)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 128,615,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (358,030,000)<span></span>
</td>
<td class="num">$ (12,003,355)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,566,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital discount amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital net of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of net shares reclassified to mandatorily redeemable capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750280768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,480,000)<span></span>
</td>
<td class="num">$ (46,459,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88,424,000)<span></span>
</td>
<td class="num">$ (47,519,000)<span></span>
</td>
<td class="num">$ (178,594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,926,000<span></span>
</td>
<td class="nump">2,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,779,000<span></span>
</td>
<td class="nump">3,777,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">3,108,000<span></span>
</td>
<td class="nump">5,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,909,000<span></span>
</td>
<td class="nump">10,664,000<span></span>
</td>
<td class="nump">15,033,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</a></td>
<td class="num">(21,190,000)<span></span>
</td>
<td class="num">(11,813,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,487,000)<span></span>
</td>
<td class="num">(10,866,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="num">(28,634,000)<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashOperatingLeaseCosts', window );">Non-cash operating lease cost</a></td>
<td class="nump">351,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">528,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,027,000<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,822,000<span></span>
</td>
<td class="nump">5,395,000<span></span>
</td>
<td class="nump">4,330,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative liability</a></td>
<td class="num">(5,300,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">23,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseInNotesPayableOne', window );">Scilex Pharma Notes principal increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Semnur-related IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,629,000<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,417,000)<span></span>
</td>
<td class="nump">2,379,000<span></span>
</td>
<td class="num">(1,116,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables, net</a></td>
<td class="num">(3,206,000)<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,142,000)<span></span>
</td>
<td class="num">(598,000)<span></span>
</td>
<td class="num">(12,356,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(3,478,000)<span></span>
</td>
<td class="num">(1,647,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479,000<span></span>
</td>
<td class="num">(1,035,000)<span></span>
</td>
<td class="num">(1,307,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Long-term deposits</a></td>
<td class="nump">385,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,580,000<span></span>
</td>
<td class="num">(88,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">2,967,000<span></span>
</td>
<td class="num">(2,784,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,836,000)<span></span>
</td>
<td class="num">(4,062,000)<span></span>
</td>
<td class="nump">4,271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase (Decrease) in Employee Related Liabilities</a></td>
<td class="num">(2,307,000)<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="nump">1,247,000<span></span>
</td>
<td class="nump">1,131,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">12,403,000<span></span>
</td>
<td class="num">(522,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">2,051,000<span></span>
</td>
<td class="nump">3,689,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase (Decrease) in Other Current Liabilities</a></td>
<td class="num">(255,000)<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(604,000)<span></span>
</td>
<td class="num">(147,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">21,521,000<span></span>
</td>
<td class="nump">13,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,210,000<span></span>
</td>
<td class="nump">5,105,000<span></span>
</td>
<td class="nump">1,854,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(20,533,000)<span></span>
</td>
<td class="num">(22,707,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,664,000)<span></span>
</td>
<td class="num">(31,461,000)<span></span>
</td>
<td class="num">(60,421,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(584,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisition consideration paid in cash for Romeg intangible asset acquisition</a></td>
<td class="num">(2,060,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Semnur, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,040,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(2,067,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(17,624,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of principal on the Scilex Pharma Notes</a></td>
<td class="num">(84,808,000)<span></span>
</td>
<td class="num">(32,376,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,387,000)<span></span>
</td>
<td class="num">(58,927,000)<span></span>
</td>
<td class="num">(2,334,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayment on other loans</a></td>
<td class="num">(18,800,000)<span></span>
</td>
<td class="num">(36,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,832,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from other loans</a></td>
<td class="nump">9,857,000<span></span>
</td>
<td class="nump">34,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,832,000<span></span>
</td>
<td class="nump">11,007,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party payable</a></td>
<td class="nump">51,900,000<span></span>
</td>
<td class="nump">45,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,850,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from related party note payable</a></td>
<td class="nump">62,500,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="nump">21,628,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Repayment of related party note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,518,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,745,000<span></span>
</td>
<td class="nump">22,073,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163,000<span></span>
</td>
<td class="num">(19,170,000)<span></span>
</td>
<td class="nump">15,776,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,855,000)<span></span>
</td>
<td class="num">(634,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(501,000)<span></span>
</td>
<td class="num">(50,656,000)<span></span>
</td>
<td class="num">(62,269,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">55,495,000<span></span>
</td>
<td class="nump">117,764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="nump">4,205,000<span></span>
</td>
<td class="nump">$ 4,839,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">55,495,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Deferred consideration for Romeg intangible asset acquisition</a></td>
<td class="nump">3,650,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Non-cash&#160;consideration in Semnur acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,591,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherLoanForgiveness', window );">Other loan forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PromissoryNoteIssuedNetOfDiscount', window );">Promissory Note issued to Sorrento in exchange for the&#160;SP-104&#160;license, net of discount</a></td>
<td class="nump">4,162,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashFairValueAdjustmentToDerivativeLiability', window );">Fair value adjustment to derivative liability in troubled debt restructuring</a></td>
<td class="nump">30,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashRightOfUseAsset', window );">Live Action&#160;right-of-use&#160;asset in Palo Alto</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable', window );">Semnur acquisition costs incurred but not paid in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">601,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashDistributionToAcquiree', window );">Non-cash distribution to Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashIncreaseInPrincipal', window );">Scilex Pharma Notes principal increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">10,295,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 45,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">623,516<span></span>
</td>
<td class="num">(349,248)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="nump">783,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor', window );">Formation cost paid through advances from affiliate of Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity', window );">Income earned on investments held in Trust Account</a></td>
<td class="num">(664,973)<span></span>
</td>
<td class="num">(28,006)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities', window );">Interest on mandatorily redeemable ordinary shares liability</a></td>
<td class="num">(192,049)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(2,188,800)<span></span>
</td>
<td class="num">(2,872,800)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,377,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LossOnInitialIssuanceOfWarrantLiability', window );">Loss on initial issuance of private warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,599,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,599,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConversionOptionLiability', window );">Change in fair value of conversion option liability</a></td>
<td class="num">(6,892)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">16,901<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionsCostsAllocatedToPrivateWarrants', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(126,252)<span></span>
</td>
<td class="num">(116,536)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">600,588<span></span>
</td>
<td class="nump">43,569<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">208,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(1,937,961)<span></span>
</td>
<td class="num">(693,609)<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
<td class="num">(801,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InvestmentOfCashInTrustAccounts', window );">Investment of cash in Trust Account</a></td>
<td class="num">(3,041,666)<span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDecommissioningFund', window );">Cash withdrawn from Trust Account in connection with redemption</a></td>
<td class="nump">41,824,292<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="nump">38,782,626<span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from other loans</a></td>
<td class="nump">1,535,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of Units, net of underwriting discounts paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of Private Placement Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,130,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of advances from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSimplePromissoryNoteRelatedParty', window );">Proceeds from simple promissory note &#8211; related party</a></td>
<td class="nump">2,971,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfPromissoryNoteRelatedParty', window );">Repayment of promissory note &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromPromissoryNoteRelatedParty', window );">Proceeds from promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Repayment of promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(416,260)<span></span>
</td>
<td class="num">(118,213)<span></span>
</td>
<td class="num">(416,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfOtherEquity', window );">Redemption of ordinary shares</a></td>
<td class="num">(41,824,292)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(37,317,625)<span></span>
</td>
<td class="nump">140,158,740<span></span>
</td>
<td class="nump">31,787<span></span>
</td>
<td class="nump">140,658,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(472,960)<span></span>
</td>
<td class="nump">85,131<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="nump">477,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">507,921<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">34,961<span></span>
</td>
<td class="nump">115,642<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="nump">507,921<span></span>
</td>
<td class="nump">$ 30,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,190,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OfferingCostIncludedInAccruedOfferingCost', window );">Offering costs included in accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,760<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Offering costs paid through promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquistion costs incurred but not paid included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConversionOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in fair value of conversion option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConversionOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Underwriting Fees means the amount of deferred underwriting fees held in the Trust Account in connection with SPAC's initial public offering payable to the underwriters upon consummation of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Formation cost paid through advances from affiliate of Sponsor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseInNotesPayableOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in notes payable one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseInNotesPayableOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvestmentOfCashInTrustAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment of cash in Trust Account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvestmentOfCashInTrustAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LossOnInitialIssuanceOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LossOnInitialIssuanceOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashDistributionToAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash distribution to acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashDistributionToAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashFairValueAdjustmentToDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash fair value adjustment to derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashFairValueAdjustmentToDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashIncreaseInPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash increase in principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashIncreaseInPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OfferingCostIncludedInAccruedOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering cost included in accrued offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OfferingCostIncludedInAccruedOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from promissory note related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromSimplePromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from simple promissory note &#8211; related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromSimplePromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PromissoryNoteIssuedNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note issued net of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PromissoryNoteIssuedNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of promissory note &#8211; related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionsCostsAllocatedToPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs allocated to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionsCostsAllocatedToPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distributions during the period on mandatorily redeemable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=118255708&amp;loc=d3e21951-110878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributionsOnMandatorilyRedeemableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to reacquire equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDecommissioningFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of assets held in a decommissioning trust fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDecommissioningFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758782336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description of Organization and Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#8220;Sorrento&#8221;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10&#160;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> naltrexone hydrochloride delayed-release capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-104&#8221;),</div> a novel formulation for the treatment of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fibromyalgia. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $</div>16.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly-owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger of Semnur&#8221;), with Semnur surviving as the Company&#8217;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and the commercialization of ZTlido.</div></div><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;BCA&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company, and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#8220;Legacy Scilex&#8221;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $</div>12.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $</div>290.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;</div>11<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill or other intangible assets recorded.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had capitalized $</div>7.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of costs incurred in relation to the Business Combination. There were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capitalized costs in relation to the Business Combination as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#8217;s </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fiscal year, or any subsequent period.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there have been </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> beginning on page </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> thereof.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div></div> <span></span>
</td>
<td class="text"> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; and together with its wholly owned subsidiaries, <div style="display:inline;">the</div> &#8220;Company&#8221;) was incorporated in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> Delaware in February&#160;2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;). The Company is a commercial-stage, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> pain management company focused on the development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October&#160;2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company is currently developing two product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase&#160;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;),</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $16.5&#160;million <div style="letter-spacing: 0px; top: 0px;;display:inline;">in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger&#8221;), with Semnur surviving as the Company&#8217;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company. Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding.</div> </div></div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP-103</div> and the commercialization of ZTlido. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description of Organization and Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one wholly owned subsidiary which was formed on February&#160;2, 2022, Vantage Merger Sub Inc., a Delaware corporation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through September&#160;30, 2022 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of&#160;13,800,000&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of&#160;1,800,000&#160;Units, at $10.00&#160;per Unit, generating gross proceeds of $138,000,000&#160;which is described in Note 3. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&#160;6,840,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $0.75&#160;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $5,130,000, which is described in Note 4. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $8,149,473, consisting of $2,400,000&#160;in cash underwriting fees, $5,190,000&#160;in deferred underwriting fees, and $559,473&#160;of other offering costs </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000&#160;($10.10&#160;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S.&#160;Treasuries and meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. On July&#160;11, 2022, the Company extended the period of time to </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">consummate a Business Combination to August&#160;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business Combination to November&#160;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $3,365,554 into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans as of the date of this filing. The Company will have until November&#160;11, 2022 to consummate a Business Combination. As a result, an aggregate of $101,293,086&#160;as of September&#160;30, 2022 is held in the Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&#160;The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $10.38&#160;per Public Share as of the date of this filing), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001&#160;and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of&#160;20% of the Public Shares without the Company&#8217;s prior written consent. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem&#160;100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem&#160;100% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000&#160;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.38&#160;per share). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trust Account to below (1) $10.10&#160;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#8220;Meeting&#8221;), to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (the &#8220;Extension Amendment&#8221;) to (i)&#160;extend the date by which the Company has to consummate an initial business combination from July&#160;11, 2022 (the &#8220;Original Termination Date&#8221;) to August&#160;11, 2022 (the &#8220;Extended Date&#8221;) and (ii)&#160;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the Extended Date, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023 or a total of up to nine months after the Original Termination Date (the &#8220;Extension Proposal&#8221;). The Company&#8217;s shareholders approved the Extension Amendment at the Meeting. On July&#160;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deposited an aggregate of $1,295,556&#160;into the Trust Account to extend the date to consummate a business combination to November&#160;11, 2022 (the &#8220;Combination Period&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern and Liquidity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the Company had $34,961&#160;in its operating bank accounts, and working capital deficit of $643,543. As of September&#160;30, 2022, approximately $696,000&#160;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Codification Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> &#8220;Presentation of Financial Statements &#8211; Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through November&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of 13,800,000&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,800,000&#160;Units, at $10.00 per Unit, generating gross proceeds of $138,000,000 which is described in Note 3. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 6,840,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $0.75 per Private Placement Warrant in a private placement to Vickers Venture Fund&#160;VI Pte Ltd and Vickers Venture Fund&#160;VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $5,130,000, which is described in Note 4. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $8,149,473, consisting of $2,400,000 in cash underwriting fees, $5,190,000 in deferred underwriting fees, and $559,473 of other offering costs. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below)&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (initially anticipated to be $10.10 per Public Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company&#8217;s prior written consent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. In connection with the extension, the Sponsors deposited $1,035,000 into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loan. The Company will have until April&#160;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&#160;11, 2022, the Company may extend the period of time to consummate a Business Combination by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination (the &#8220;Combination Period&#8221;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)&#160;$10.10 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern and Liquidity </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $507,921 in its operating bank accounts, and working capital of $303,753. As of December&#160;31, 2021, approximately $31,000 of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through July&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758564848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant Accounting Policies </div></div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. As of December&#160;31, 2021 and 2020, the Company&#8217;s inventory was primarily comprised of finished goods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and services that will be used </div></div></div> <div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>   <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 730, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development</div></div>. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#8217;s deferred tax assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition&#160;</div> </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#8217;s revenue and accounts receivable result from a sole customer. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For product sales, the Company records <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div> sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#8217;s consolidated balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrators. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Customer Concentration Risk </div></div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">During the fiscal years ended December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, 2020 and 2019, sales to the Company&#8217;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts </div></div> for stock-based compensation in accordance with FASB ASC Topic 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Compensation</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of determining </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#8217;s consolidated statement of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div> are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-opioid<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October</div></div>&#160;2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</div></div>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal&#160;years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.</div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div>2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments Held in Trust Account </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; deficit section of the Company&#8217;s condensed consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,380,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,824,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,737,378</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,293,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,444,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,176,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,862,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,675,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed consolidated financial statements. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, <div style="letter-spacing: 0px; top: 0px;;display:inline;">accounting </div>standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2&#160;&#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; (deficit) equity section of the Company&#8217;s balance sheets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,820,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,834,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for fiscal&#160;years beginning after December&#160;15, 2023, </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628760855168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernAbstract', window );"><strong>Liquidity And Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year after the date the financial statements are issued.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s negative working capital was $</div>219.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, including cash and cash equivalents of approximately $</div>2.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had operating losses of $</div>30.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and cash flows used for operations of $</div>20.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company had an accumulated deficit of approximately $</div>358.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In </div>August 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div>41.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. Pursuant to Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, a principal balance of $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was forgiven by the Scilex Pharma Note Purchasers (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> upon the Company&#8217;s exercise of the Early Paydown Provision. The Company funded the principal payments with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-on</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> hand and $</div>34.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received from Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento and Scilex entered into a Funding Commitment Letter (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company, Sorrento shall fund </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more loans to the Company in the amount to achieve $</div>5,000,001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets immediately following the effective time of the Business Combination. Such related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $</div>10,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $</div>310,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company did not draw funds from the Funding Commitment Letter at the effective time of the Business Combination.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (see Note 3). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of the acquired licenses. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are issued. </div></div></div><span></span>
</td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern at least one year after the date the financial statements are issued. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, the Company&#8217;s negative working capital was $146.4&#160;million, including cash and cash equivalents of approximately $4.3&#160;million. During the year ended December&#160;31, 2021, the Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>had operating losses of $35.8&#160;million and negative cash flows from operations of $28.7&#160;million. The Company had an accumulated deficit of approximately $352.6&#160;million as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018, Scilex Pharma issued $224.0&#160;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $140.0&#160;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum unrestricted cash balance of $4.0&#160;million at the end of each month. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">2020, Scilex Pharma repurchased an aggregate of $65.0&#160;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $45.0&#160;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the purpose of consummating the repurchase of an aggregate of $45.0&#160;million of principal amount. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021 and <div style="letter-spacing: 0px; top: 0px;;display:inline;">April&#160;</div>2021, Scilex Pharma effected specified principal repurchases totaling $40.0&#160;million of the principal amount of the Scilex Pharma Notes. On December&#160;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $28.0&#160;million. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2022, Scilex Pharma drew down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#8217;s obligation to repurchase $20.0&#160;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash balance of $10.0&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div></div>18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least </div></div>twelve&#160;months from the issuance of these consolidated financial statements through debt and equity financing. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going Concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758469536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProposedPublicOfferingTextBlock', window );">PUBLIC OFFERING</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to&#160;13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&#160;1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3&#160;&#8212;&#160;PUBLIC OFFERING </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to 13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of 1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProposedPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProposedPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758538336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&#160;6,840,000 Private Placement Warrants at a price of $0.75&#160;per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50&#160;per share, subject to adjustment (see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4&#160;&#8212;&#160;PRIVATE PLACEMENT </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of 6,840,000 Private Placement Warrants at a price of $0.75 per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50 per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756175504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Semnur Acquisition</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $</div>70.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock </div>(47,039,315<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately </div>58<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the holders of Semnur equity (the &#8220;Semnur Equityholders&#8221;) up to $</div>280.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>payment upon the achievement of $</div>100.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div>250.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>50.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div>500.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, and </div>(4)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>150.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div>750.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div>0.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liabilities. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months following the closing of the Merger, </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $</div>5.55<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div>9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div>82.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately </div>99.97<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div>75.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was expensed as a component of acquired </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> research and development during the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;DBR-LDN&#8221;)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets&#8221;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in </div>April 2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> pursuant to an asset purchase agreement</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition&#8221;). </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div>5.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;</div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note&#8221;). Upon issuance of the note, the Company recorded a related party note payable liability of $</div>4.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note matures </div>seven years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div>2.66<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note is payable in cash, shares of the Company&#8217;s common stock or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">penalty. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $</div>3,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $</div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Derivatives and Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#8217;s accounting policy for contingent consideration in an asset acquisition. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized at September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">,&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder and chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Aardvark.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GLOPERBA License Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with the right to sublicense, under the patents and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> specified therein (with such license to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> being exclusive for the limited purposes specified therein) to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States of America (including its territories) (the &#8220;Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States in 2020. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for the license under the Romeg License Agreement, the Company paid Romeg an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> license fee of $</div>2.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $</div>13.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, (b)&#160;certain royalties in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digit to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-double</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $</div>7.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million commencing on the first year anniversary of the</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effective date of the Romeg License Agreement and ending on the later of (i)&#160;expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the effective date of the Romeg License Agreement. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $</div>5.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is comprised of the upfront license fee of $</div>2.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a deferred consideration of $</div>3.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent s</div>ale<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">s milestones and sales volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and will not be recognized until the contingencies are realized. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized as a liability or included in the fair value of the asset as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company determined the useful life of the intangible asset to be approximately </div>15 years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, which approximates the life of the licensed patents covering the Initial Licensed Product.</div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur Acquisition </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $15.0&#160;million, and (b)&#160;$55.0&#160;million of shares of the Company&#8217;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately 58% of the Company&#8217;s issued and outstanding capital stock. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of a Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (2)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (3)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (4)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;7, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&#160;the </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div>0.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued liabilities.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2019, the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>following the closing of the Merger, </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price of one share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b)&#160;$</div>5.55<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div>9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;">common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;31, 2020, Sorrento held approximately 82.3% of the outstanding common stock of the Company. On January&#160;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately 99.97% of the outstanding common stock of the <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div>75.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million was expensed as a component of acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development during the year ended December&#160;31, 2019. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628755288896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">15.0</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">55.0</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">47,039,315</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">352,972</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">1.16</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">58</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">. Following the completion of the Share Exchange and as of December&#160;</div>31<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">82.3</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14.7</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34,889,868</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34,889,868</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99.97</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company purchased approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.0</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.8</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who served on the Company&#8217;s board of directors from March 2019 through September 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single</div> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div> Through September&#160;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&#160;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $<div style="letter-spacing: 0px; top: 0px;;display:inline;">3.2</div>&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to the Company in the amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.4</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the note payable. The outstanding principal balance of the note on September&#160;30, 2022 and December&#160;31, 2021 was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">47.1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19.6</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.8</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.9</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. During the nine months ended September&#160;30, 2022, the proceeds from the note payable were used to finance the operations of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note i</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">n the amount of approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under </div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24,117,608</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.7</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.1</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4.9</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.1</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">23.5</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">35.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in February 2022 to fund the payment of Scilex Pharma Notes in February 2022 totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 6. The $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">35.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February 2022 is due no earlier than February 2030 and was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional funding received from Sorrento is due on demand and recorded under the related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022, related party payables due to Sorrento included $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">48.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">100.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for litigation fees (see Note 8). As of December&#160;31, 2021, related party payables due to Sorrento consisted of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">35.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">51.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 8).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;May&#160;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures </div>seven years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.66</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. As of September&#160;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4.2</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt Exchange Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i)&#160;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">27.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Debt Exchange Agreement effective</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as of immediately prior to, and contingent upon, the closing of the</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Business Combination, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento has elected to contribute the Outstanding Indebtedness</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the Company in exchange for the issuance by the Company to</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento of that number of shares of preferred stock, par value $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.0001</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) </div><br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">tha</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">t is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Aggregate Outstanding Amount divided by (ii) $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11.00</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">310,000,000</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of September&#160;30, 2022, the Aggregate Outstanding Amount was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">276.8</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, pursuant to the terms of the Debt Exchange Agreement, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">290.6</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, was contributed by Sorrento to the Company in exchange for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,057,097</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s preferred stock. At the Effective Time, such shares were then exchanged for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,057,097</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex preferred stock and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,905,710</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex common stock.</div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b)&#160;$</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div>47,039,315<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div>58<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;31, 2019. Following the completion of the Semnur Share Exchange and as of December&#160;31, 2020, Sorrento held approximately </div>82.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, 2020 and 2019, the Company purchased approximately $</div>5.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>1.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>8.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations. As of December&#160;31, 2020, approximately </div>14.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;13, 2021, </div>34,889,868<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;13, 2021. On January&#160;29, 2021, Sorrento acquired </div>34,889,868<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div>99.97<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who has served on the Company&#8217;s board of directors since March&#160;2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> To date, the Company has made no royalty payments pursuant to the Assignment Agreement.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the&#160;years ended December&#160;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>2.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>0.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div>16.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The note is interest bearing at the lesser of (a)&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&#160;31, 2021 and 2020 was $</div>19.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>13.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the note payable of $</div>3.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>2.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $</div>21.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). Scilex Pharma may borrow up to an aggregate of $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a)&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div>24,117,608<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div>21.7<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $</div>8.1<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>10.3<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the promissory note of $</div>3.1<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>1.0<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div>23.5<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>15.4<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div>17.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, in February&#160;2021 and April&#160;2021, respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February&#160;2021 and April&#160;2021, totaling $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 8. The $</div>37.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February&#160;2021 and April 2021 is due on demand to Sorrento and was recorded under the related party payables in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021, related party payables due to Sorrento included $</div>35.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div>51.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div>6.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 11). As of December&#160;31, 2020, related party payables due to Sorrento consisted of $</div>13.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements and $</div>13.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes.</div><br/></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of&#160;3,593,750&#160;ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share capitalization of 0.2&#160;shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of&#160;0.2&#160;shares for each share outstanding, resulting in&#160;3,450,000&#160;ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&#160;450,000&#160;shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, approximately&#160;20% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000&#160;to fund expenses in connection with the Initial Public Offering. The advances were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note &#8212; Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000&#160;was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes.&#160;The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.&#160;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000&#160;(the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $500,000&#160;of the Convertible Promissory Notes may be converted into warrants at a price of $0.75&#160;per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000&#160;and $500,000, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended September&#160;30, 2022, the Company recorded $1,155&#160;and $16,901&#160;of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at September&#160;30, 2022 and December&#160;31, 2021 amounted to $0 and $16,901, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $1,500,000&#160;(the &#8220;Simple Promissory Notes&#8221;). The Simple Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On April&#160;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $2,971,667&#160;and $0, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&#160;In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension., </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75&#160;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. The Sponsors deposited $1,035,000&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to August&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to&#160;September&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;9, 2022, the Company extended the period of time to consummate a Business Combination to October&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of 3,593,750 ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August&#160;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, the Company effected a share capitalization of 0.2 shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, approximately 20% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&#160;months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000 to fund expenses in connection with the Initial Public Offering. The advances are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. As of December&#160;31, 2021 and 2020, there was $0 and $30,000 advances outstanding, respectively. The outstanding amount of $30,000 was repaid on February&#160;26, 2021. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the Working Capital Loans. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered into two convertible promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000 (the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&#160;be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $500,000 of the Convertible Promissory Notes may be converted into warrants at a price of $0.75 per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. As of December&#160;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $500,000. Subsequent to December&#160;31, 2021, on January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&#160;loan&#160;the Company up to an aggregate principal amount of $500,000. Subsequent to December&#160;31, 2021, the&#160;principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000 (see Note 11). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&#160;2022, the Company&#8217;s expected Business Combination date. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, the Company recorded $1,826 of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&#160;31, 2021&#160;amounted to $16,901. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case). Any such deposits would be made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant insider&#8217;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $0.75 per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated, to fund the Trust Account to extend the time for the Company to complete a Business Combination. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758714384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Fair value measurements at September&#160;30, 2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Balance</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level&#160;1)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">2,483</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><span style="-sec-ix-hidden:hidden61009247">2.4</span>83</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 0pt; line-height: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">2,483</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"><span style="-sec-ix-hidden:hidden61003888">2.4</span>83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;">Balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative liabilities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded a gain of $</div>5.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>0.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on derivative liabilities for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $</div>30.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million immediately after the entry into Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> associated with the Scilex Pharma Notes on June&#160;</div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was accounted</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4. Significant Level&#160;3 assumptions used in the measurement included a </div>6.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast and an effective debt yield of </div>21.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% as of June&#160;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> remaining derivative liabilities as of September&#160;30, 2022.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>value</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value measurement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs&#160;(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">in&#160;Active</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative liabilities </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded a loss of $</div>0.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, a gain of $</div>0.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss of $</div>23.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on derivative liabilities for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded features as further described in Note </div>8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model. This involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div>6.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast and an effective debt yield of </div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast, an effective debt yield of </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and an estimated probability of </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included an </div>8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast, an effective debt yield of </div>19.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and estimated probabilities of </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>55<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring prior to October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. FAIR VALUE MEASUREMENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;1:</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></div></td></tr></table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;2:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;3:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, assets held in the Trust Account were comprised of $101,293,086&#160;and $139,410,739, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through September&#160;30, 2022, the Company did not withdraw any interest earned on the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at September&#160;30, 2022 and December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,293,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability &#8211; Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Private Placement Warrants were accounted for as liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and are presented within warrant liabilities on our accompanying September&#160;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&#160;30, 2022 and 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,104,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,625,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,693,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of September&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,856,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,504,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,762,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,530,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,231,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;10, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;27, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022 and September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9&#160;&#8212;&#160;FAIR VALUE MEASUREMENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 96%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 89%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;1:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"/>
<td colspan="2" style="height: 6pt; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;2:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"/>
<td colspan="2" style="height: 6pt; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;3:</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</td></tr></table><div style="clear:both;max-height:0pt;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, assets held in the Trust Account were comprised of $139,410,739 in money market funds which are invested primarily in U.S. Treasury Securities. Through December&#160;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&#160;31, 2020, there were no assets in the Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability&#160;&#8212;&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the year ended December&#160;31, 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in&#160;years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,377,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;20,<br/>2021<br/>(Initial<br/>Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628839909520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers&#160;&amp; equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, <div style="letter-spacing: 0px; top: 0px;;display:inline;">net</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense<div style="display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div>39<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, $</div>40<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and $</div>40<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628761918064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had recorded goodwill of $</div>13.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. The conclusion has not changed as of September&#160;30, 2022 and </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the nine months ended September&#160;30, 2022 and 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div>A summary of the Company&#8217;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):</div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/>amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/>amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired licenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>31.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/>amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/>amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $</div>5.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was assigned to acquired licenses with an amortization period of approximately </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the weighted average remaining life for identifiable intangible assets was </div></div>10.6<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">years. Aggregate amortization expense was $</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2.9</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2.8</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2022 and 2021, respectively. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">15-year</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">5-year</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> period.</div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in thousands):</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amount</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining three months)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had recorded goodwill of $</div>13.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div>A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the weighted average remaining life for identifiable intangible assets is </div>10.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Aggregate amortization expense was $</div>3.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment charges related to intangible assets were recorded during the&#160;years ended </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628760851408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;2018 Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the 2018 Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div>2026<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div>224.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div>140.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which resulted in a $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million increase in the principal amount of the Scilex Pharma Notes, effective <div style="letter-spacing: 0px; top: 0px;;display:inline;">February&#160;15, 2022</div>. As a result, the Company recorded the increase of $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in principal and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> expense at December&#160;31, 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&#160;4 to Indenture (the &#8220;Amendment No.&#160;4&#8221;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;4, (1)&#160;on </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> June&#160;3, 2022, Scilex Pharma repurchased approximately $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&#160;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $28.0&#160;million of the aggregate principal amount of the Scilex Pharma Notes (the &#8220;Early Paydown Provision&#8221;), (3) the minimum </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cash</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirement under the Indenture was reduced to $<div style="letter-spacing: 0px; top: 0px;;display:inline;">5.0</div>&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&#160;the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento on October&#160;5, 2018 was increased from up to $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to up to $</div>50.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company funded the repurchase with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cash-on-hand</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received from Sorrento on June&#160;2, 2022, which was recorded under the current related party notes payable in the Company&#8217;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&#160;4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&#160;4, and accordingly, </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> gain was recognized in the quarter ended June&#160;30, 2022. Due to a decrease of $</div>30.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&#160;4, the carrying value of the Scilex Notes was increased by $</div>30.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div>1.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>39.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. Pursuant to Amendment No.&#160;4, $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The C<div style="display:inline;">o</div>mpany recorded a gain on debt extinguishment of $</div>33.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as a result of the extinguishment. There are </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> derivative liabilities as of September&#160;30, 2022.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Notes consisted of the following (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">September&#160;30,&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;">December&#160;31,&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made principal payments of $</div>106.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>44.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the nine months ended September&#160;30, 2022 and 2021, respectively. The imputed effective interest rate at December&#160;31, 2021 was </div>7.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&#160;30, 2022 and 2021 was approximately $</div>3.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>5.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. The Company recorded a gain on debt extinguishment of $</div>28.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss on debt extinguishment of $</div>14.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in connection with its repayments of principal made during the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&#160;18, 2019, the Company entered into a note payable with Sorrento (see Note 10). On February&#160;14, 2022, Sorrento paid to Scilex Pharma $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan (see Note 10). On May&#160;12, 2022, the Company issued Sorrento a promissory note of $</div>5.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in exchange for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (see Note 3).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $10.0&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;1, 2024; unless the Credit Agreement is earlier terminated. As of December&#160;31, 2021, the outstanding </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">balance was $8.8&#160;million. On February&#160;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March 18, 2022. Upon termination, all principal balances and interest accrued were settled. </div></div> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;</div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements, on September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div>2026<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div>224.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div>140.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bank </div></div></div><div style="clear: both; max-height: 0px;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net proceeds of the Offering were approximately $</div>89.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, after deducting the Offering expenses payable by Scilex Pharma and funding a segregated reserve account with $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Reserve Account&#8221;) and a segregated collateral account with $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Collateral Account&#8221;) pursuant to the terms of the Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#8217;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with respect to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or a similar product with a concentration of not less than </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% (the &#8220;Marketing Approval Letter&#8221;) on or prior to July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Funds in the Collateral Account were to be released to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On each February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, May&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, August&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and November&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, beginning with February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the holders of the Scilex Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed&#160;percentage, ranging from </div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>20<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex Pharma did not receive the Marketing Approval Letter by March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the&#160;percentage of net sales payable was increased to be in the range of </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. If actual cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div>218.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately $</div>10.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div>30.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div>218.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the Indenture, the aggregate principal amount due under the Scilex Pharma Notes was to be increased by $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than approximately $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not equal or exceed the $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million threshold for such period, the Company recorded the increase of $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If actual cumulative net sales of ZTlido for the period from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div>290.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on </div>November 15, 2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by between approximately $</div>2.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div>84.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the principal increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> is less than approximately $</div>290.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The final maturity date of the Scilex Pharma Notes is </div>August 15, 2026<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Scilex Pharma Notes may be redeemed in whole at any time upon </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; written notice at Scilex Pharma&#8217;s option prior to August&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2026<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a redemption price equal to 100% of the then-outstanding principal amount of the Scilex Pharma Notes. In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#8217;s Scilex Pharma Note at a repurchase price in cash equal to 101% of the then-outstanding principal amount </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thereof. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The 2018 Purchase&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreements include the terms and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">type. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become due and payable.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger, amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#8220;Collateral Agreement&#8221;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or modifications of such product made, developed or licensed (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensed)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by Scilex Pharma or any of its affiliates or licensees (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensees)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (including </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (the &#8220;Letter of Credit&#8221;), which provides that, in the event that </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma did not hold at least $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in unrestricted cash as of the end of any calendar month during the term of the Scilex Pharma Notes, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than a specified sales threshold for such period, or </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento would be required to pay to Scilex Pharma, $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&#160;the repayment of the Scilex Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exchange by the Company that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes.</div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On December&#160;14, 2020, Scilex,</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex Note Purchasers entered into a Consent Under and Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Indenture and Letter of Credit (&#8220;Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8221;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit. </div></div></div><div style="font-size: 8pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders agreed to release all of the aggregate $</div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in restricted funds held in the Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $</div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount of the Scilex Pharma Notes from the Holders on a pro&#160;rata basis at a purchase price equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof (such repurchase, the &#8220;Scilex Repurchase&#8221;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&#160;Sorrento&#8217;s obligations under the Indenture to repurchase $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&#160;Scilex Pharma&#8217;s obligation to repurchase $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing Approval Letter on or prior to</div> July 1, 2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, be equal to at least $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate, provided that if Scilex Pharma did not effectuate (i)&#160;the December Optional Repurchase (as defined below) and (ii)&#160;at least one of either (x)&#160;the February Optional Repurchase (as defined below) or (y)&#160;the April Optional Repurchase (as defined below), then, commencing with the month ending April&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and for each month thereafter, such amount would have been required to be at least $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will be required to draw on the Letter of Credit.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also provided Scilex Pharma with the option, in its sole and absolute discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis on each of December&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;December Optional Repurchase&#8221;), February&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;February Optional Repurchase&#8221;) and April&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;April Optional Repurchase&#8221;), in each case in an aggregate amount equal to the lesser of $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by $</div>60.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and resulted in the minimum unrestricted requirement remaining at $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> further provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis in an aggregate amount equal to the lesser of $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on, Scilex Pharma is required to have minimum cash of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at all times thereafter. In February&#160;</div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the principal amount of the Scilex Pharma Notes and became subject to a minimum cash requirement of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders also consented to Scilex Pharma incurring up to $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below).</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounted for Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as a debt modification under ASC Topic </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as modified terms were not substantially different than the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-modified</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> terms. The execution of Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> resulted</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>in an additional derivative liability of $</div>2.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which pertains to a $</div>9.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $</div>6.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million reduction to the debt discount on the Scilex Pharma Notes.</div><br/></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow method under the income approach, which involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and the discounted rate of return reflective of the Company&#8217;s credit </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risk. </div></div></div><div style="font-size: 8pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Pharma Notes are as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden61004186">92,25</span>8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum future payments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made principal payments of $</div>45.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>69.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>2.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the fiscal&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and debt issuance costs, which are presented as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a&#160;percentage of net sales of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was </div>7.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>9.15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, respectively. The amount of debt discount and debt issuance costs included in interest expense for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was approximately $</div>7.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>10.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note </div>5)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> this assessment each reporting period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the holders of at least </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes of the Scilex Pharma Notes, an event of default includes, among other things, (i)&#160;Scilex Pharma&#8217;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&#160;Scilex Pharma&#8217;s breach of its representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&#160;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma. The Company is in compliance with event of default clauses.</div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma issued to Sorrento a promissory note (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a note payable with Sorrento (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund&#160;I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus </div>1.75<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2024<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">; unless the Credit Agreement is earlier terminated. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the outstanding balance was $</div>8.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>9.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company notified CNH that it was terminating the Credit Agreement, effective </div>March 18, 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Upon termination, all principal balances and interest accrued were </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">settled.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Paycheck Protection Program </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May&#160;</div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received the proceeds from a loan in the amount of $</div>1.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;PPP Loan&#8221;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The PPP Loan matures on </div>May 05, 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and bears interest at a rate of </div>1.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% per annum. The PPP Loan is evidenced by a promissory note dated May </div>03<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Note&#8221;), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warranties.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $</div>100,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, prorated annually. Not more than </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the forgiven amount may be for </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payroll</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $</div>100,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or less annually are reduced by more than </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a gain on debt extinguishment of $</div>1.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758571184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. WARRANTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,900,000&#160;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $<div style="display:inline;">0.01 </div>per warrant; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than <div style="display:inline;">30 </div>days&#8217; prior written notice of redemption to each warrant holder; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $<div style="display:inline;">18.00&#160;</div>per share (subject to adjustment) for any <div style="display:inline;">20 </div>trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $<div style="display:inline;">9.20 </div>per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <div style="display:inline;">60</div>% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the <div style="display:inline;">20 </div>trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $<div style="display:inline;">9.20 </div>per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <div style="display:inline;">115</div>% of the higher of the Market Value and the Newly Issued Price, the $<div style="display:inline;">18.00 </div>per share redemption trigger price will be adjusted (to the nearest cent) to be equal to <div style="display:inline;">180</div>% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,840,000&#160;Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8&#160;&#8212;&#160;WARRANTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, there were 6,900,000 and 0 Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90&#160;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; </div></div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></td></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021 and 2020, there were 6,840,000 and 0 Private Placement Warrants outstanding, respectively. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Line item]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758785472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' DEFICIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Equity </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of authorized shares of preferred stock of Scilex Holding is </div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares were issued and outstanding at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The total number of authorized shares of common stock of Scilex Holding is </div>350,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div>197,266,338<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares were issued and outstanding at&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020. </div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' DEFICIT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#8212;</div></div>&#160;The Company is authorized to issue&#160;1,000,000&#160;preference shares with a par value of $0.0001&#160;per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;no&#160;preference shares issued or outstanding. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div>&#160;&#8212; The Company is authorized to issue&#160;200,000,000&#160;ordinary shares with a par value of $0.0001&#160;per share. Holders of ordinary shares are entitled to one vote for each share. At September&#160;30, 2022, there were&#160;3,450,000&#160;shares of ordinary shares issued and outstanding, excluding&#160;9,726,395&#160;ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2021, there were&#160;3,450,000&#160;shares of ordinary shares issued and outstanding, excluding&#160;13,800,000&#160;ordinary shares subject to possible redemption which are presented as temporary equity. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7&#160;&#8212;&#160;SHAREHOLDERS&#8217; EQUITY </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December&#160;31, 2021 and 2020, there were no preference shares issued or outstanding. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were 3,450,000 shares of ordinary shares issued and outstanding, excluding 13,800,000 ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2020, there were 3,450,000 ordinary shares issued or outstanding. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628761892736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansAbstract', window );"><strong>Compensation And Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Incentive and Employee Benefit Plans</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In June </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). The Scilex Pharma 2017 Plan reserved </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">24.0</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div>Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> acquire common stock of Scilex </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;7, 2019. As of December&#160;31, 2019, 30.0&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. On December&#160;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional </div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the 2019 Stock Option Plan. As of December&#160;31, 2020, </div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. </div>Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, options to purchase </div>25,159,760<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div>24,054,760<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase </div>1,105,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. As of September&#160;30, 2022, </div>20,945,240<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>4.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">T</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">he total unrecognized compensation costs related to unvested employee and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> stock option grants as of September&#160;30, 2022 was $</div>3.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div>1.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $</div>0.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>0.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the nine months ended September&#160;30, 2022 and 2021, respectively.</div><br/></div> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June&#160;</div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan (the &#8220;Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan&#8221;). The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan reserved </div>24.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div>Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan was amended and restated on July&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the Merger Closing, the Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors of the Company adopted the Scilex Holding Company </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan (the &#8220;</div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan&#8221;) on May&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>30.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. On December&#160;</div>21<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the board of directors approved an amendment to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan to reserve an additional </div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. </div>Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, options to purchase </div>28,163,510<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div>26,743,510<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan and options to purchase </div>1,420,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>18,256,490<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div>5.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>5.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>4.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total unrecognized compensation costs related to unvested employee and nonemployee stock option grants as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div>8.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div>1.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Valuation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below:</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$0.83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$0.87</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">90.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">89.00%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>104.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">0.53%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">1.63%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>2.50%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.60</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.76<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>6.08</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#8217;s common stock.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected stock-price volatility</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bonds with maturities similar to those of the expected term of the award being valued.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term of options</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Holding issued stock options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">March&#160;17 and March&#160;31, 2019 Valuations </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performed on March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the Company&#8217;s common stock was estimated using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#8220;OPM&#8221;) to allocate the concluded equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#8217;s common stock of $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">May&#160;31, 2019 Valuation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on May&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the Company&#8217;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;), which estimates the value by<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of May&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December&#160;31, 2019 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on December&#160;31, 2019, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $1.16 per share as of December&#160;31, 2019. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">July&#160;31, 2020 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on July&#160;31, 2020, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $1.16 per share as of July&#160;31, 2020. </div></div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>average<br/>exercise&#160;price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(838</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,641</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.68</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">915</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a defined contribution </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan totaling $</div>0.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompensationAndEmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation and employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompensationAndEmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756924656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with two parties (the &#8220;Developers&#8221;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">between </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>35<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div>October 2, 2028<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div>ten years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">one-year</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the Developers terminate it upon </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6-month</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div>180<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;31, 2023, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, the Company&#8217;s net profits for ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Distribution Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div>three years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to distributors.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until June&#160;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with </div>90<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days&#8217; notice. Scilex Pharma paid an implementation fee of $</div>59.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div>63.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div>65.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">services. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div>0.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>1.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the nine months ended September&#160;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#8220;Sanofi- Aventis&#160;&amp; Hisamitsu Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement. The case was tried from September <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-14,</div> 2022. Post-trial briefing is underway and closing arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;Aveva Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 14%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating cash flows from operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ROU assets obtained in exchange for new operating lease</div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;">liabilities</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>June 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a new </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is </div>26<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months and the Company expects to exercise the extension option at the end of the lease.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (Remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2013<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> parties (the &#8220;Developers&#8221;), </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>35<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> aggregate royalty payments. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 2, 2028</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">ten</div> years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the Developers terminate it upon </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div>180<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days after notice requesting to cure; </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of </div>four<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b)&#160;after </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days of good-faith discussion; </div>(4)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or </div>(5)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma or either </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of the Developers are bankrupt or make assignment for the benefit of creditors.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Up to the date the financial statements were issued, Scilex&#8217;s net profits for ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> have not exceeded </div>five<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within </div>three<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Developers to provide commercial supply of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Distribution Agreement</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August&#160;</div>2015<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">three</div> years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year each, unless written notice of termination is given by either party at least </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to early </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in </div>April 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma began directly selling and transferring title to distributors.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January&#160;</div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September&#160;</div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will remain in effect until June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and may be extended for additional periods of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year upon the mutual agreement of both parties. Either party may terminate the work order with </div>90<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; notice. Scilex Pharma paid an implementation fee of $</div>59.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div>63.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div>65.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing services.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div>1.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>10.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>25.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more lawsuits. Other than the following </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lawsuits, the Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> manufacturers of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (OTC) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax Pharmaceuticals, Inc., a company now headed by Mr.&#160;Mack,</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">alleging</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, among other things, breach by Mr.&#160;Mack of his </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> agreement with the Company and his fiduciary duties to the Company, and tortious interference by Virpax with that </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> agreement. Both lawsuits are ongoing.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases administrative and research and development facilities under various </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s leases have remaining lease terms of approximately </div>2.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div>2.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. The term of the Company&#8217;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company has </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> finance leases.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease expense were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. </div></div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(654</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"/></tr></table><div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">Operating</div> lease expense totaled approximately $</div>0.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>1.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>0.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.&#160;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Merger Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) by and among Scilex Holding Company (&#8220;Scilex&#8221;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (&#8220;Sorrento&#8221;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#8220;Merger Sub&#8221;). Parent and Merger Sub are sometimes referred to collectively as the &#8220;Parent Parties.&#8221; Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies Law (the &#8220;Domestication&#8221;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the &#8220;Merger&#8221;). Upon the closing of the Merger (the &#8220;Closing&#8221;), it is anticipated that VCKA will change its name to &#8220;Scilex Holding Company&#8221;. The board of directors of VCKA has (i)&#160;approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&#160;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On September&#160;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&#160;1 to the Merger Agreement (the &#8220;Amendment&#8221;). The Amendment amends the Merger Agreement to, among other things, provide that: (i)&#160;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&#160;388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&#160;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of Domesticated Parent Common Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#8217;s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of whom will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&#160;at the Effective Time, by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-tenth</div> of one Domesticated Parent Common Share; (v)&#160;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the Merger Agreement; (vi)&#160;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on the Stock Exchange; (vii)&#160;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii)&#160;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from Nasdaq of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with Nasdaq&#8217;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix)&#160;extend the Outside Date to November&#160;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of preferred stock set forth therein from&#160;20,000,000&#160;to&#160;45,000,000&#160;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from&#160;750,000,000&#160;to&#160;785,000,000&#160;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of certain other customary closing conditions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Consideration </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#8220;Merger Consideration&#8221;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#8220;Closing Date&#8221;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#8220;VCKA Common Stock&#8221;).&#160;The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a)&#160;one&#160;share of Series A Preferred Stock of Vickers (following the Domestication), par value $0.0001&#160;per share (the &#8220;New Scilex Series A Preferred Stock&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(b)&#160;one-tenth</div> of one share of New Scilex Common Stock, and (iii)&#160;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued shares of New Scilex Common Stock with an aggregate value equal to $1.5&#160;billion, subject to adjustments for certain debt obligations of Scilex (the &#8220;Merger Consideration&#8221;).&#160;The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#8220;Preferred Consideration&#8221;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#8217;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Representations and Warranties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;capital structure; (vi)&#160;organizational documents; (vii)&#160;assumed names; (viii)&#160;subsidiaries; (ix) financial statements; (x)&#160;absence of certain changes; (xi)&#160;properties and title to assets; (xii)&#160;litigation; (xiii) contracts; (xiv)&#160;licenses and permits; (xv)&#160;compliance with laws; (xvi)&#160;intellectual property; (xvii)&#160;customers and suppliers; (xviii)&#160;employees and employee benefits; (xix)&#160;employment matters; (xx)&#160;withholding; (xxi) real property; (xxii)&#160;tax matters; (xxiii)&#160;environmental laws; (xiv)&#160;finders&#8217; fees; (xv)&#160;directors and officers; (xvi)&#160;certain business practices; (xvii)&#160;international trade matters and anti-bribery compliance; (xviii)&#160;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&#160;insurance; (xxxi)&#160;related party transactions; (xxxii)&#160;privacy and data security and (xxxiii)&#160;exclusivity of representations and warranties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of the Parent Parties with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;finders&#8217; fees; (vi)&#160;issuance of shares; (vii)&#160;capitalization; (viii) information supplied; (ix)&#160;amount in the trust account; (x)&#160;listing of VCKA securities; (xi)&#160;that VCKA is a reporting company; (xii)&#160;no market manipulation; (xiii)&#160;board approval; (xiv)&#160;SEC documents and financial statements; (xv)&#160;absence of changes; (xvi)&#160;litigation; (xvii) compliance with laws; (xviii)&#160;money laundering laws; (xix)&#160;OFAC; (xx) that VCKA is not an investment company; (xxi)&#160;tax matters; (xxii)&#160;contracts; (xxiii) investigation; and (xiv)&#160;exclusivity of representations and warranties. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All representations and warranties by all parties shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Covenants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (the &#8220;Registration Statement&#8221;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party&#8217;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conduct between Signing and Closing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of VCKA, Merger Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conditions to Closing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the Merger is conditioned upon, among other things, (i)&#160;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&#160;the Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); (iii) approval by VCKA&#8217;s shareholders of the Merger and related transactions; (iv)&#160;approval by Scilex&#8217;s stockholders of the Merger and related transactions; and (v)&#160;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&#160;Scilex having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#8217;s ability to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Company Material Adverse Effect; (iv)&#160;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&#160;Scilex providing VCKA a certificate from the secretary which has attached true and complete copies of (a)&#160;Scilex&#8217;s organizational documents, (b)&#160;Scilex&#8217;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&#160;Scilex&#8217;s stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&#160;certified certificate of good standing; (vi)&#160;Scilex shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi)&#160;Sorrento shall have executed the Registration Rights Agreement (as defined below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Solely with respect to Scilex, the consummation of the Merger is conditioned upon, among other things: (i)&#160;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&#160;each of the Parent Parties providing Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v)&#160;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); (vi)&#160;each of VCKA the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&#160;the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&#160;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&#160;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;3a51-1(g)(1)&#160;of</div> the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&#160;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Scilex, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&#160;12, 2022 (the &#8220;Debt Exchange Agreement&#8221;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $5,000,001&#160;in net tangible assets (as determined in accordance with Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3a51-1(g)(1)</div> of the United States Securities and Exchange Act of 1934) (the &#8220;Net Tangible Assets Condition&#8221;). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement may be terminated as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">i.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By the mutual consent of VCKA and Scilex; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">ii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&#160;the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">iii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&#160;the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">iv.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either VCKA or Scilex </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">a.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on or after November&#160;11, 2022 (the &#8220;Outside Date&#8221;), if the Merger shall not have been consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section&#160;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to such party&#8217;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">b.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions shall have become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">v.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">vi.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;), provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">vii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, in the event that Scilex&#8217;s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on or before March&#160;31, 2022 and remain undelivered prior to the termination of the Merger Agreement </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&#160;17, 2022 (the &#8220;Sponsor Support Agreement&#8221;) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers and Scilex entered into Amendment No.&#160;1 to the Original Support Agreement with the Vickers Shareholders (the &#8220;Support Agreement Amendment&#8221;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (75%) of the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&#160;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (40%) of all Parent Warrants held by such Vickers Shareholder immediately prior to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Company Stockholder Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March&#160;17, 2022 (the &#8220;Company Stockholder Support Agreements&#8221;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the &#8220;Stockholder Agreement&#8221;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $0.0001&#160;per share (&#8220;New Scilex Series A Preferred Stock&#8221;), among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of (i)&#160;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#8220;New Scilex Board&#8221;) at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the New Scilex Board, or (ii)&#160;the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each Stockholder Designee to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common Stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement Amendment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#8220;Maxim&#8221;) entered into an amendment (the &#8220;UWA Amendment&#8221;) of the underwriting agreement between VCKA and Maxim dated January&#160;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&#160;(as defined in the UWA Amendment) as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#8217;s shareholders, the balance in the trust account is $25,000,000&#160;or less, then the Deferred Underwriting Commission will be payable as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(A)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(B)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the remaining&#160;50% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the effective date of a Business Combination. </div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA Amendment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreements to be Executed at Closing </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758576368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10&#160;&#8212;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 1 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company previously accounted for its outstanding Private Placement Warrants (the &#8220;Warrants&#8221;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies titled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#8220;SPACs&#8221;)&#8221; (the &#8220;SEC Statement&#8221;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In further consideration of the SEC Statement, the Company&#8217;s management further evaluated the Warrants under Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Contracts in Entity&#8217;s Own Equity. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s ordinary shares. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15,</div></div> a warrant is not indexed to the issuer&#8217;s ordinary shares if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that the Company&#8217;s Private Placement Warrants are not indexed to the Company&#8217;s ordinary shares in the manner contemplated by ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> because the holder of the instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on equity shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 2 </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition, in connection with the preparation of the Company&#8217;s financial statements as of September&#160;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&#160;30, 2021 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q/A,</div> filed with the SEC on December&#160;8, 2021, includes the restatement of the unaudited March&#160;31, 2021 and June&#160;30, 2021 financial information. Included in the table below is the restatement </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">of the audited IPO Balance Sheet as of January&#160;11, 2021 originally filed on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed with the SEC on January&#160;15, 2021. In accordance with ASC 480, paragraph <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99,</div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $10.10 per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the ordinary shares subject </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to possible redemption with the offset recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available), accumulated deficit and ordinary shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the change in presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, ordinary shares share pro&#160;rata in the income (loss) of the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of these adjustments to the financial statement, as previously reported, is presented below. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet as of January&#160;11, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,345,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,074,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,999,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,006,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,629,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,635,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,629,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,474,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI https://asc.fasb.org/extlink&amp;oid=126898705&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628761960048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#8217;s ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company&#8217;s deferred tax assets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s income tax (benefit) expense of $</div>(36.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) thousand and $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand reflect effective tax rates of </div>0.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>0.02<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the expected statutory federal tax rate of </div>21.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and the </div>0.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% effective tax rate for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was primarily attributable to income tax expense associated with changes in a valuation </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">allowance. </div></div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense limitations</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,753</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,285</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); width: 73%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,939</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,412</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(56,643</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43,514</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,296</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,898</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0);">(1,975</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(2,486</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">(319</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;">(412</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Liabilities</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,296</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,898</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $</div>56.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>43.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million against its deferred tax assets as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively. Realization of the deferred tax assets will <div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">e </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">primarily<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s benefit from income taxes are as follows for the year ended December 31: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal Income Tax Rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal tax benefit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and interest limitation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to provision adjustments and carryback</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Tax Benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had net operating loss carryforwards of approximately $</div>167.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal and $</div>81.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in </div>2034<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for state and </div>2035<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for federal, except for $</div>154.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the federal net operating losses that have an indefinite carryforward period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the&#160;years ended December&#160;31, 2021, 2020, and 2019, there was no impact of such limitations on the Company&#8217;s income tax provision.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also has research and development and orphan drug credits of approximately $</div>2.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in </div>2035<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the Company&#8217;s tax&#160;years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the accounting guidance for uncertainty in income taxes pursuant to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC-740-10.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#8220;more likely than not&#8221; to be sustained upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a </div>50<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% likelihood of being sustained.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unrecognized tax benefits balances as of December&#160;31, 2021, 2020 and 2019 and the related increases and decreases to the balances were immaterial.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> interest and penalties have been recognized as of and for the periods ended December&#160;31, 2021, 2020 and 2019.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that no material amount of liabilities for uncertain tax positions will expire within 12&#160;months of December&#160;31, 2021.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628762089184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the nine months ended September&#160;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&#160;30, 2022 and 2021 were </div>25.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and </div>30.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(178,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share&#160;</div><div style="font-size: 10pt; line-height: 107%; font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the&#160;years ended December&#160;31, 2021, 2020, and 2019 of </div>28.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div>30.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and </div>25.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757473488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of September&#160;30, 2022, and the nine months then ended, through November&#160;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through November&#160;30, 2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Commitment Letter </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;October&#160;17, 2022, Sorrento and the Company entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined company to have $</div>5,000,001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets as of immediately following the effective time of the Business Combination (the &#8220;Effective Time&#8221;) under the BCA (the &#8220;Net Tangible Assets Condition&#8221;)), Sorrento agreed to fund one or more loans to the Company in the amount set forth in such written request (a &#8220;Loan Request&#8221;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment to Amended and Restated Certificate of Incorporation</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from </div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div>45,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $</div>0.0001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share, of Legacy </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sorrento Absorbed Liabilities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October </div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">and November 2022, Sorrento entered into agreements with certain of the Company&#8217;s third party professional service providers to assume $</div>11.9<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million of liabilities accrued by the Company, of which $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million and $</div>1.9<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&#160;10, 2022 under the terms of the Debt Exchange </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Agreement (see </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Note 10).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">Committed Equity Financing</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;YA II&#8221;). Pursuant to the Yorkville Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $</div>500,000,000<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to YA II&#8217;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the </div><div style="font-size: 10pt; text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to YA II (each, an &#8220;Advance Notice&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">While</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;there is no mandatory minimum amount for any Advance, an Advance may be for a number of shares of New Scilex common stock not to exceed </div>200<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the </div><span style="-sec-ix-hidden:hidden61004144">five</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> trading days immediately preceding the date of the Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to an Advance will be purchased at a price equal to </div>98<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% of the lowest daily VWAP (as defined below) during the </div><span style="-sec-ix-hidden:hidden61004145">two</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> consecutive trading days commencing on the date of delivery of an Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the New Scilex common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Advance.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">As</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;consideration for YA II&#8217;s commitment to purchase shares of New Scilex common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued </div>250,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> shares of New Scilex common stock to YA II.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following events were identified subsequent to the balance sheet date. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SPAC Transaction </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#8220;Merger Agreement&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of Vickers (&#8220;Merger Sub&#8221;). Pursuant to the terms of the Merger Agreement, (i)&#160;Merger </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sub will </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">merge with and into the Company</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">, with the Company surviving the merger (&#8220;combined company&#8221;) and (ii)&#160;become a wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>owned subsidiary of Vickers (collectively, the &#8220;SPAC Transaction&#8221;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Pharma Note </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February&#160;2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at a purchase price in cash equal</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>to 100% of the principal amount. In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $10.0&#160;million at all times going </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">forward. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million sales threshold for such period.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances on Related Party Note Payable </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2022, Sorrento made advances to the Company in the amount of $</div>23.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million under the related party note payable entered into on March&#160;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payable. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition from Sorrento </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On May&#160;12, 2022</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(DBR-LDN)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets&#8221;) and the Company is currently analyzing the accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div>5.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;2022 Promissory Note&#8221;). The 2022 Promissory Note matures </div>seven years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div>2.66<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#8220;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration Shares&#8221;) or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within </div>60<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days of the issuance of such Consideration Shares.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i)&#160;$</div>3,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Aardvark Asset Purchase Agreement) (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii)&#160;$</div>20,000,000<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with its acquisition of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets, the Company has agreed that if it issues any shares of the Company&#8217;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within </div>60<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>days following the date on which any such shares are issued.</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder, chief executive officer and a member of the board of directors of Aardvark.</div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10. SUBSEQUENT EVENTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment of certain outstanding loans (the &#8220;Company Obligations&#8221;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt Contribution Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in exchange for the issuance of that number of shares of shares of common stock, par value $0.0001&#160;per share, of the Company, determined by dividing the Company Obligations by $10.00&#160;(the &#8220;Contribution Shares&#8221;) to the Sponsors immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Debt Exchange Agreement, on October&#160;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set forth in such written request. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#8220;Warrant Transfer Agreement&#8221;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">On October&#160;17, 2022, the Company entered into a Letter Agreement with Sorrento and the Sponsors (the &#8220;Letter Agreement&#8221;) to provide that certain shares held by the Sponsors will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> restrictions only in an amount necessary to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&#160;1,500,000&#160;shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the Company&#8217;s shareholders ahead of the extraordinary general meeting of the Company&#8217;s shareholders on November&#160;9, 2022. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11&#160;&#8212;&#160;SUBSEQUENT EVENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;27, 2022, the Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $500,000. The aggregate principal balance of the Convertible Promissory Notes amounted to $2,035,000. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750293936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#8217;s </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fiscal year, or any subsequent period.</div></div><span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there have been </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> beginning on page </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> thereof.</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;BCA&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company, and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#8220;Legacy Scilex&#8221;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $</div>12.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $</div>290.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;</div>11<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill or other intangible assets recorded.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had capitalized $</div>7.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of costs incurred in relation to the Business Combination. There were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capitalized costs in relation to the Business Combination as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. As of December&#160;31, 2021 and 2020, the Company&#8217;s inventory was primarily comprised of finished goods. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#8217;s deferred tax assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and services that will be used </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 730, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development</div></div>. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Ordinary Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RebatesPolicyTextBlock', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ServiceFeesPolicyTextBlock', window );">Service Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesReturnsPolicyTextBlock', window );">Product Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CoPaymentAssistancePolicyTextBlock', window );">Co-Payment Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrators. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Customer Concentration Risk </div></div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">During the fiscal years ended December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, 2020 and 2019, sales to the Company&#8217;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div> are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-opioid<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <br/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October</div></div>&#160;2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</div></div>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal&#160;years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.</div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div>2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition&#160;</div> </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#8217;s revenue and accounts receivable result from a sole customer. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For product sales, the Company records <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div> sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#8217;s consolidated balance sheet. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts </div></div> for stock-based compensation in accordance with FASB ASC Topic 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Compensation</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of determining </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#8217;s consolidated statement of operations. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments Held in Trust Account</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments Held in Trust Account </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; deficit section of the Company&#8217;s condensed consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,380,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,824,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,737,378</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,293,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; (deficit) equity section of the Company&#8217;s balance sheets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Ordinary Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,444,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,176,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,862,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,675,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,820,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,834,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed consolidated financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, <div style="letter-spacing: 0px; top: 0px;;display:inline;">accounting </div>standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for fiscal&#160;years beginning after December&#160;15, 2023, </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CoPaymentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co payment assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CoPaymentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RebatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RebatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SalesReturnsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SalesReturnsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ServiceFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ServiceFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628747536736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(178,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share&#160;</div><div style="font-size: 10pt; line-height: 107%; font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,380,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,824,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,737,378</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,293,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,444,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,176,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,862,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,675,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table><span></span>
</td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,820,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,834,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756429984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valued using the compound option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$0.83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$0.87</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">90.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">89.00%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>104.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">0.53%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">1.63%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>2.50%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.60</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.76<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>6.08</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Fair value measurements at September&#160;30, 2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Balance</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level&#160;1)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">2,483</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><span style="-sec-ix-hidden:hidden61009247">2.4</span>83</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 0pt; line-height: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;"><div style="line-height: 0pt; font-size: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size:0pt;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">2,483</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"><span style="-sec-ix-hidden:hidden61003888">2.4</span>83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;">Balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs&#160;(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">in&#160;Active</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Observable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs&#160;(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>value</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value measurement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value hierarchy of the valuation inputs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,293,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability &#8211; Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability&#160;&#8212;&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of quantitative information regarding Level 3 fair value measurements</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in&#160;years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of changes in the fair value of warrant liabilities</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,104,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,625,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,693,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of September&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,856,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,504,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,762,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,530,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,231,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;10, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;27, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022 and September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,377,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valued using the compound option pricing model</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;20,<br/>2021<br/>(Initial<br/>Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of change in the fair value of conversion option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13572-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13587-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628762215536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers&#160;&amp; equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, <div style="letter-spacing: 0px; top: 0px;;display:inline;">net</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756987776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of the Company's Identifiable Intangible Assets</a></td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/>amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/>amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired licenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>31.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/>amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/>amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Estimated Future Amortization Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in thousands):</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amount</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining three months)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628760886768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Borrowings of the Scilex Pharma Notes</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Notes consisted of the following (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 16%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">September&#160;30,&#160;2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;">December&#160;31,&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Pharma Notes are as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><span style="-sec-ix-hidden:hidden61004186">92,25</span>8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock', window );">Summary of Future Minimum Payments Under the Scilex Pharma Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum future payments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum payments of long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628755127152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansAbstract', window );"><strong>Compensation And Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary Of Share Based Payment Award Options Issued To Employees And Nonemployees Valuation Assumptions</a></td>
<td class="text">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$0.83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$0.87</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">90.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">89.00%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>104.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">0.53%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">1.63%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>2.50%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.60</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.76<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>6.08</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary Of The Options Outstanding</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>average<br/>exercise&#160;price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(838</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,641</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.68</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">915</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompensationAndEmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation and employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompensationAndEmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756172288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease expense were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. </div></div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Quantitative Information Related To Leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 14%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating cash flows from operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ROU assets obtained in exchange for new operating lease</div><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;">liabilities</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(654</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (Remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental quantitative information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628755127152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of impact of these adjustments to the financial statement, as previously reported</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of these adjustments to the financial statement, as previously reported, is presented below. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet as of January&#160;11, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,345,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,074,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,999,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,006,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,629,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,635,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,629,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,474,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758554336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit)</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense limitations</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,714</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,732</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">404</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,753</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,285</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); width: 73%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,939</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,412</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(56,643</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43,514</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,296</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,898</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0);">(1,975</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(2,486</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">(319</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;">(412</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Liabilities</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,296</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,898</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s benefit from income taxes are as follows for the year ended December 31: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal Income Tax Rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal tax benefit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and interest limitation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to provision adjustments and carryback</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Tax Benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758339760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of reconciliation of basic and diluted loss per share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(47,519</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(178,594</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share&#160;</div><div style="font-size: 10pt; line-height: 107%; font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628748051392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 18, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Company place of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds', window );">Gross proceeds</a></td>
<td class="nump">$ 138,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Sale of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,149,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Cash underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingFees', window );">Deferred underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestBearingDepositLiabilities', window );">Non-interest-bearing loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,365,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Deposited trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="nump">$ 139,410,739<span></span>
</td>
<td class="nump">$ 1,295,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SaleOfStockDescriptionOfTransactions', window );">Sale of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.<span></span>
</td>
<td class="text">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below)(less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerPublicShare', window );">Anticipated public share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Net tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfPublicShares', window );">Percentage of public shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_BusinessCombinationRedeemPercentage', window );">Business combination redeem percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DepositIntoTheTrustAccountPerShare', window );">Deposit into the trust account per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LesserPublicPerShare', window );">Lesser public per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquiredReceivablesDescription', window );">Business combination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Opening bank account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease', window );">Deposit interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsOfInitialPublicOffering', window );">Proceeds of initial public offering</a></td>
<td class="nump">$ 138,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Transactioncostsamount', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,149,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Otherofferingcosts', window );">OtherOfferingCosts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Numberofbusinessdays', window );">Number of business days | Day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetTangibleAssets', window );">Net tangible assets (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Depositintotrustaccount', window );">Deposit into trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Interestexpenses', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,961<span></span>
</td>
<td class="nump">507,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units amount</a></td>
<td class="nump">$ 139,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Numberofshares', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Saleofwarrants', window );">Sale of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerPublicShare', window );">Anticipated public share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Numberofshares', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Depositintotrustaccount', window );">Deposit into trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_PrivatePlacementWarrantMember', window );">Private Placement Warrant [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Grossproceedsofwarrants', window );">Gross proceeds of amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Redeem percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Contribution And Loan Agreement [Member] | Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business combination equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember', window );">Vantage Merger Sub Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Gross proceeds from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember', window );">Vantage Merger Sub Inc [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity interest from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_SponsorMember', window );">Sponsor [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_BusinessCombinationRedeemPercentage', window );">Business combination redeem percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_BusinessCombinationRedeemPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination redeem percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_BusinessCombinationRedeemPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DepositIntoTheTrustAccountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit into the trust account per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DepositIntoTheTrustAccountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Depositintotrustaccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit Into Trust Account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Depositintotrustaccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Grossproceedsofwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Grossproceedsofwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Interestexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Interestexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LesserPublicPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lesser public per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LesserPublicPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Numberofbusinessdays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Numberofbusinessdays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Numberofshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Numberofshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Otherofferingcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OtherOfferingCosts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Otherofferingcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfPublicShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of public shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfPublicShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerPublicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerPublicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Of Initial Public Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SaleOfStockDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock description of transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SaleOfStockDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Saleofwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Saleofwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Transactioncostsamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Transactioncostsamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquiredReceivablesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of receivable acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquiredReceivablesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 805<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505872&amp;loc=d3e30785-158569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in interest income on deposit with financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(iii)<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(i)<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(ii)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestBearingDepositLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of all domestic and foreign noninterest-bearing deposits liabilities held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestBearingDepositLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of offering costs allocated to the other unit holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_ReorganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_ReorganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_ContributionAndLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_ContributionAndLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750173600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses on accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Sole Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsNet', window );">Offering costs amount</a></td>
<td class="nump">$ 8,119,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,119,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of ordinary shares (in Shares)</a></td>
<td class="nump">13,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,740,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal depository insurance coverage</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Foundershares', window );">Founder shares (in Shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsNet', window );">Offering costs amount</a></td>
<td class="nump">$ 30,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Foundershares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Founder Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Foundershares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sclx_SoleDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sclx_SoleDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757170592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled - Vickers Vantage [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LessAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesIssuanceCost', window );">Ordinary shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,119,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PlusAbstract', window );"><strong>Plus:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccretionOfCarryingValueToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">$ 3,737,378<span></span>
</td>
<td class="nump">9,499,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,499,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesSubjectToPossibleRedemption', window );">Ordinary shares subject to possible redemption</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">$ 139,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LessAbstract0', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Mandatorily redeemable ordinary shares</a></td>
<td class="num">$ (41,824,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccretionOfCarryingValueToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccretionOfCarryingValueToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LessAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LessAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PlusAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PlusAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in temporary equity from changes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757196400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net income (loss) per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Allocation of net income (loss)</a></td>
<td class="num">$ (131,387)<span></span>
</td>
<td class="num">$ (1,444,352)<span></span>
</td>
<td class="nump">$ 623,516<span></span>
</td>
<td class="num">$ (349,248)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 783,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic and diluted weighted average ordinary shares outstanding</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net income (loss) per ordinary share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,820,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,834,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per ordinary share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750493888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Basic and diluted weighted average ordinary shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net income (loss) per ordinary share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Basic and diluted weighted average ordinary shares outstanding (in Shares)</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">16,834,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net income (loss) per ordinary share (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756786624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetWorkingCapital', window );">Net working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">$ 4,839,000<span></span>
</td>
<td class="nump">$ 10,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,893,000<span></span>
</td>
<td class="nump">$ 25,421,000<span></span>
</td>
<td class="nump">35,838,000<span></span>
</td>
<td class="nump">35,258,000<span></span>
</td>
<td class="nump">138,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flow from operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,533,000<span></span>
</td>
<td class="nump">$ 22,707,000<span></span>
</td>
<td class="nump">28,664,000<span></span>
</td>
<td class="nump">31,461,000<span></span>
</td>
<td class="nump">60,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,550,000<span></span>
</td>
<td class="nump">264,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt Instrument, Annual Principal Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="nump">$ 69,800,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember', window );">Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember', window );">Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt Instrument, Annual Principal Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt instrument, decrease, forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from senior secured notes</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumUnrestrictedCashBalance', window );">Minimum unrestricted cash balance</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt', window );">Restricted funds releasable for future repurchase of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member] | Cumulative Sales Related Contingency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member] | Letter Of Credit Drawn Down [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumUnrestrictedCashBalance', window );">Minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentRepurchaseObligation', window );">Debt instrument repurchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregateOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate outstanding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregateOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentRepurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Repurchase Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentRepurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum unrestricted cash balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted funds relesable for future repurchase of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinimumNetWorthRequiredForCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum net worth required for mortgage banking as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinimumNetWorthRequiredForCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_CumulativeSalesRelatedContingencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_CumulativeSalesRelatedContingencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_LetterOfCreditDrawnDownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_LetterOfCreditDrawnDownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750291344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering (Details) - Vickers Vantage [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasePricePerShare', window );">Purchase price per unit (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued related to Semnur Acquisition , shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).<span></span>
</td>
<td class="text">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSaleUnits', window );">Number of sale units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued related to Semnur Acquisition , shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSaleUnits', window );">Number of sale units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSaleUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sale units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSaleUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750037984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement (Details) - Vickers Vantage [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Ordinary share, per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628657862720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Sep. 09, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Oct. 08, 2020</div></th>
<th class="th"><div>Jul. 16, 2020</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
<th class="th"><div>Oct. 02, 2018</div></th>
<th class="th"><div>Sep. 11, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Apr. 11, 2022</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Jan. 13, 2021</div></th>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,423,000<span></span>
</td>
<td class="nump">$ 128,654,000<span></span>
</td>
<td class="nump">$ 122,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,000<span></span>
</td>
<td class="nump">$ 5,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,909,000<span></span>
</td>
<td class="nump">10,664,000<span></span>
</td>
<td class="nump">15,033,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToAcquireInventory', window );">Payment to acquire inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesAcquired', window );">Number of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,117,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,664,000<span></span>
</td>
<td class="nump">92,724,000<span></span>
</td>
<td class="nump">26,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Advances outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from Issuance of Medium-term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="nump">21,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodAxis=sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember', window );">Due On Or After February Two Thousand And Thirty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from Issuance of Medium-term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Ordinary shares, subject to forfeiture (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares', window );">Per share calculation of Outstanding Amount In Exchange of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LimitationOfOutstandingAmountInExchangeOfShares', window );">Limitation of Outstanding Amount In Exchange of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 290.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member] | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member] | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">2,905,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember', window );">Two Thousand And Twenty Two Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember', window );">Two Thousand And Twenty Two Promissory Note [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InvesteeAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ItochuMember', window );">Itochu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfCapitalSharesOutstanding', window );">Percentage of capital shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesOutstanding', window );">Capital stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,889,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesAcquired', window );">Number of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,889,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Related Party transaction, selling, general and administrative expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSimpleInterest', window );">Percentage of simple interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Related party note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapitalRequirements', window );">Working capital requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfOutstandingAmountIndebtedness', window );">Percentage of Outstanding Amount Indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquistion consideration transferred equity interest issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period shares purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,039,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock shares subscribed but not issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AssetAcquisitionPricePerShare', window );">Asset acquisition price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfOwnershipInterest', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Two Thousand And Twenty Two Promissory Note [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteRelatedPartyMember', window );">Promissory Note - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationControlObtainedDescription', window );">Business combination, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsExercisePrice', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,971,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Description of related party extension loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DepositedInTrustAccount', window );">Trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerWarrants', window );">Price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,410,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,295,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaidAmount', window );">Repaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Shareholder issued and outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Fund expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,593,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CapitalizationOfShareOutstanding', window );">Capitalization of share outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Ordinary shares, subject to forfeiture (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesIssuedAndOutstanding', window );">Ordinary shares issued and outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Promissory Note - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Promissory Note - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesAcquired', window );">Number of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,117,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSimpleInterest', window );">Percentage of simple interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Promissory Note - Related Party [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Principal Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AssetAcquisitionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AssetAcquisitionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CapitalizationOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization of share outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CapitalizationOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DepositedInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposited in trust account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DepositedInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LimitationOfOutstandingAmountInExchangeOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Limitation of Outstanding Amount In Exchange of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LimitationOfOutstandingAmountInExchangeOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToAcquireInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to acquire inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToAcquireInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share calculation of Outstanding Amount In Exchange of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfCapitalSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfCapitalSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfOutstandingAmountIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding amount indebtedness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfOutstandingAmountIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSimpleInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of simple interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSimpleInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repaid Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapitalRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapitalRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_aggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_aggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationControlObtainedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of how the entity obtained control of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationControlObtainedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123395306&amp;loc=d3e36975-112693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919370-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128295416&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodAxis=sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodAxis=sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ItochuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ItochuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_ReorganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_ReorganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_SenmurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sclx_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sclx_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=sclx_ConvertiblePromisoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=sclx_ConvertiblePromisoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628746282384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SellingGeneralAndAdministrativeExpenses', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PaloAltoAadministrativeFacilityMember', window );">Palo Alto Aadministrative Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementExpirationDate', window );">Agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementExpirationTerm', window );">Agreement expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm', window );">Agreement automatic renewal period on expiration of initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal', window );">Notice of termination period for cancellation of automatic renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement', window );">Termination of aggrement notice period for a request to cure material breach of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ThresholdMinimumPercentageOfSales', window );">Threshold minimum percentage of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember', window );">Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementExpirationTerm', window );">Agreement expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfAnnualAdjustmentToFees', window );">Percentage of annual adjustment to fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember', window );">Project Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoticePeriodForTerminationOfWorkOrder', window );">Notice period for termination of work order</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkOrderImplementationFee', window );">Work order implementation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Leases remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfAggregateRoyalityPayments', window );">Percentage of aggregate royality payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDistributionFeeReceivedOverThePeriod', window );">Percentage of distribution fee received over the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Project Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesOperationsServicesMonthlyFee', window );">Sales operations services monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Leases remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfAggregateRoyalityPayments', window );">Percentage of aggregate royality payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDistributionFeeReceivedOverThePeriod', window );">Percentage of distribution fee received over the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Project Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesOperationsServicesMonthlyFee', window );">Sales operations services monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Underwriting agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MergerConsiderationDescription', window );">Merger consideration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#8220;Merger Consideration&#8221;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#8220;Closing Date&#8221;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#8220;VCKA Common Stock&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockAggregateValue', window );">Common stock aggregate value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetTangibleAssets', window );">Net tangible assets (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePercentage', window );">Aggregate percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsPercentage', window );">Warrants percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_BalanceInTheTrustAccount', window );">Balance in the trust account (in Dollars)</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingCommission', window );">Deferred underwriting commission percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingCommissionPayable', window );">Underwriting commission payable percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredUnitsAuthorized', window );">Stock authority to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredUnitsAuthorized', window );">Stock authority to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred Stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Series A preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationReasonForBusinessCombination', window );">Business combination, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#8220;Preferred Consideration&#8221;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#8217;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Scilex Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred Stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement automatic renewal period on expiration of initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_BalanceInTheTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance in the trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_BalanceInTheTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock with an aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Underwriting Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingCommissionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Underwriting Commission Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingCommissionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MergerConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger consideration description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MergerConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice of termination period for cancellation of automatic renewal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NoticePeriodForTerminationOfWorkOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of work order.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NoticePeriodForTerminationOfWorkOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfAggregateRoyalityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate royality payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfAggregateRoyalityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfAnnualAdjustmentToFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual adjustment to fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfAnnualAdjustmentToFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfDistributionFeeReceivedOverThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of distribution fee received over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfDistributionFeeReceivedOverThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SalesOperationsServicesMonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales operations services monthly fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SalesOperationsServicesMonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SellingGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SellingGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of agreement notice period for a request to cure material breach of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ThresholdMinimumPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold minimum percentage of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ThresholdMinimumPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkOrderImplementationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work order implementation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkOrderImplementationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationReasonForBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationReasonForBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of preferred units authorized to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PaloAltoAadministrativeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PaloAltoAadministrativeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_ScilexCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_ScilexCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628747526848">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 904<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757167584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (Remaining three months)</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">$ 674,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">1,964,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(316,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities as of December&#160;31, 2021</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="nump">$ 1,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750200432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Operating Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingCashFlowsFromOperatingLeases', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="num">$ (654)<span></span>
</td>
<td class="num">$ (833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate&#160;&#8212;&#160;operating leases</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingCashFlowsFromOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows from operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingCashFlowsFromOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628657715520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Deficit (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesSubjectToPossibleRedemption', window );">Ordinary shares subject to possible redemption</a></td>
<td class="nump">9,726,395<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757955552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Vicker's Vantage - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicWarrantsRedemptionDescription', window );">Public warrants redemption, description</a></td>
<td class="text">The Company may redeem the Public Warrants:  &#160;


&#160;
&#8226;
&#160;
in whole and not in part;   &#160;


&#160;
&#8226;
&#160;
at a price of $0.01 per warrant;   &#160;


&#160;
&#8226;
&#160;
at any time while the warrants become exercisable;   &#160;


&#160;
&#8226;
&#160;
upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder;   &#160;


&#160;
&#8226;
&#160;
if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and   &#160;


&#160;
&#8226;
&#160;
if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.  <span></span>
</td>
<td class="text">The Company may redeem the Public Warrants: &#160;


&#160;
&#8226;
&#160;
in whole and not in part; &#160;


&#160;
&#8226;
&#160;
at a price of $0.01 per warrant; &#160;


&#160;
&#8226;
&#160;
at any time while the warrants become exercisable; &#160;


&#160;
&#8226;
&#160;
upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder;


&#160;
&#8226;
&#160;
if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and &#160;


&#160;
&#8226;
&#160;
if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CapitalRaisingDescription', window );">Capital raising, description</a></td>
<td class="text">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. <span></span>
</td>
<td class="text">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Public Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsOutstandingShares', window );">Warrants outstanding shares</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsOutstandingShares', window );">Warrants outstanding shares</a></td>
<td class="nump">6,840,000<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CapitalRaisingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CapitalRaisingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicWarrantsRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicWarrantsRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628749906944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member] | Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease</a></td>
<td class="nump">$ 30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputRiskadjustedNetSalesForecastMember', window );">Measurement Input, RiskAdjusted Net Sales Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEffectiveDebtYieldMember', window );">Measurement Input, Effective Debt Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member', window );">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before March 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member', window );">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before July 1, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Assets Held-in-trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,410,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,295,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets held in the trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,410,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsHighestAndBestUseDescription', window );">Initial measurement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be  equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period.  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,162,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,351,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsHighestAndBestUseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reasons that a nonfinancial asset is being used in a manner that differs from its highest and best use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsHighestAndBestUseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputRiskadjustedNetSalesForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputRiskadjustedNetSalesForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEffectiveDebtYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEffectiveDebtYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628755048304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs - Vicker's Vantage - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeSecuritiesUSTreasury', window );">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">139,410,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Warrant Liability &#8211; Private Placement Warrants</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeSecuritiesUSTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeSecuritiesUSTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628746330384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: - USD ($)<br></strong></div></th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="nump">1,231,200<span></span>
</td>
<td class="nump">$ 3,762,000<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="nump">4,856,400<span></span>
</td>
<td class="nump">$ 3,693,600<span></span>
</td>
<td class="nump">$ 3,625,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,762,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InitialMeasurementOne', window );">Initial measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in valuation inputs or other assumptions</a></td>
<td class="num">(68,400)<span></span>
</td>
<td class="num">(2,530,800)<span></span>
</td>
<td class="nump">410,400<span></span>
</td>
<td class="num">(1,504,800)<span></span>
</td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">68,400<span></span>
</td>
<td class="num">(4,104,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,377,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">1,231,200<span></span>
</td>
<td class="nump">3,762,000<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="nump">$ 4,856,400<span></span>
</td>
<td class="nump">$ 3,693,600<span></span>
</td>
<td class="nump">3,625,200<span></span>
</td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_ConversionOptionLiabilityMember', window );">Conversion Option Liability [Member] | Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,788<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76,788<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InitialMeasurementOne', window );">Initial measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in valuation inputs or other assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,788)<span></span>
</td>
<td class="num">(11,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,788<span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInValuationInputsOrOtherAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation inputs or other assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInValuationInputsOrOtherAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InitialMeasurementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InitialMeasurementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_ConversionOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_ConversionOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628657699520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_UnderlyingWarrantValue', window );">Underlying warrant value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.0103<span></span>
</td>
<td class="nump">$ 0.0281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_HoldingPeriod', window );">Holding period</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="nump">1.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_HoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Holding period return is the total return received from holding an asset or portfolio of assets over a period of time, generally expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_HoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_UnderlyingWarrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying warrant value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_UnderlyingWarrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628755033584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,483,000<span></span>
</td>
<td class="nump">$ 4,338,000<span></span>
</td>
<td class="nump">$ 4,839,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 2,483,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758381952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs - Derivative Financial Instruments, Liabilities [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Re-measurement&#160;of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">23,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value measurement</a></td>
<td class="num">$ (35,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628749925328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1', window );">Risk-free rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfWarrantsinDollars', window );">Fair value of warrants</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueMeasurementStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueMeasurementStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfWarrantsinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfWarrantsinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756904272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability - Vicker's Vantage<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems', window );"><strong>Schedule Of Change In The Fair Value Of Conversion Option Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Initial measurement</a></td>
<td class="nump">18,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue', window );">Change in fair value</a></td>
<td class="num">(11,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, ending balance</a></td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of change in the fair value of conversion option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128311188&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757302816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Property and equipment consisted - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758339888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross', window );">Depreciation</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919398-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123405975&amp;loc=d3e41551-112718<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123422147&amp;loc=d3e41457-112716<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628747842912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 60,781<span></span>
</td>
<td class="nump">$ 55,070<span></span>
</td>
<td class="nump">$ 55,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">19,164<span></span>
</td>
<td class="nump">16,268<span></span>
</td>
<td class="nump">12,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">41,617<span></span>
</td>
<td class="nump">38,802<span></span>
</td>
<td class="nump">42,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,871<span></span>
</td>
<td class="nump">11,239<span></span>
</td>
<td class="nump">9,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">19,759<span></span>
</td>
<td class="nump">21,391<span></span>
</td>
<td class="nump">23,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">5,851<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">16,089<span></span>
</td>
<td class="nump">17,186<span></span>
</td>
<td class="nump">18,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">5,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628748008880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (Remaining three months)</a></td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,106<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">3,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">Thereafter</a></td>
<td class="nump">24,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 41,617<span></span>
</td>
<td class="nump">$ 38,802<span></span>
</td>
<td class="nump">$ 42,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets amortization expense after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628746252272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,481,000<span></span>
</td>
<td class="nump">$ 13,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,896,000<span></span>
</td>
<td class="nump">$ 2,803,000<span></span>
</td>
<td class="nump">3,738,000<span></span>
</td>
<td class="nump">3,738,000<span></span>
</td>
<td class="nump">$ 3,713,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite lived intangible assets, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite lived intangible assets, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled Workforce [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite lived intangible assets acquired</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets, weighted average useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628661593360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 02, 2022</div></th>
<th class="th"><div>Feb. 16, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
<th class="th"><div>Feb. 15, 2019</div></th>
<th class="th"><div>Sep. 07, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 03, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt instrument, annual principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="nump">69,800,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,634,000<span></span>
</td>
<td class="num">$ (12,463,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,463,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,900,000<span></span>
</td>
<td class="nump">45,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,850,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmendmentAxis=sclx_AmendmentNoFourMember', window );">Amendment No Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Debt instrument, collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gains (Losses) on Restructuring of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmendmentAxis=sclx_AmendmentNoFourMember', window );">Amendment No Four [Member] | Sorrento [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member] | Coronavirus Aid, Relief, and Economic Security Act [Member] | Non Payroll Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaximumCompensationCostToBeAvailableProratedBasis', window );">Maximum compensation cost to be available, prorated basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLoanForgivenessUnderTheAct', window );">Percentage of loan forgiveness under the act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member] | Coronavirus Aid, Relief, and Economic Security Act [Member] | Payroll Costs Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLoanForgivenessUnderTheAct', window );">Percentage of loan forgiveness under the act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumPayrollCostToBeAvailable', window );">Minimum payroll cost to be available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes', window );">Minimum cash requirements to repurchase of Notes</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfThePrincipalAmountOfTheNotes', window );">Percentage of the principal amount of the Notes</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_AccountsReceivableRevolvingLoanFacilityMember', window );">Accounts receivable revolving loan facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LineOfCreditFacilityindebtednessAmount', window );">Line of credit facility, indebtedness amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementAxis=sclx_IndebentureMember', window );">Indebenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis', window );">Percentage of the principal amount from Holders on pro rata basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=sclx_IfLetterOfCreditIsDrawnMember', window );">If Letter Of Credit Is Drawn [Member] | Indebenture [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=sclx_MarketingApprovalLetterMember', window );">Marketing Approval Letter [Member] | Indebenture [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes', window );">Minimum cash requirements to repurchase of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Indebenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes', window );">Minimum cash requirements to repurchase of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Indebenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToDepositIntoASeggregateReserveFund', window );">Payment to deposit into a seggregate reserve fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToDepositIntoASegregatedCollateralAccount', window );">Payment to deposit into a segregated collateral account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfConcentrationOnASimilarProduct', window );">Percentage of concentration on a similar product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage', window );">Percentage of quarterly payments of the principal Notes equal to a fixed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetSalesPayable', window );">Percentage of net sales payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Maximum [Member] | Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Maximum [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage', window );">Percentage of quarterly payments of the principal Notes equal to a fixed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetSalesPayable', window );">Percentage of net sales payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Minimum [Member] | Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Minimum [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentredemptionPeriod', window );">Debt instrument,redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfThePrincipalAmountOfTheNotes', window );">Percentage of the principal amount of the Notes</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes', window );">Minimum unrestricted cash requirements to repurchase of Notes</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes', window );">Amount distribution to acquire related contingent accelerated repayment notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt related commitment Fees and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt instrument, increase (decrease), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | 2018 Purchase Agreements and Indenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Amendment No Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased', window );">Debt instrument, percentage of principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt instrument, decrease, forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Subordinated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | December Optional Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | February Optional Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | April Optional Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LineOfCreditFacilityindebtednessAmount', window );">Line of credit facility, indebtedness amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentTerminationDate', window );">Debt instrument, termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Maximum [Member] | Amendment No Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseDate', window );">Debt instrument, repurchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount distribution to acquire related contingent accelerated repayment notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of principal amount repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentredemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument,redemption period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentredemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LineOfCreditFacilityindebtednessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility ,indebtedness amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LineOfCreditFacilityindebtednessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaximumCompensationCostToBeAvailableProratedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum compensation cost to be available, prorated basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaximumCompensationCostToBeAvailableProratedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash requirements to repurchase of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumCashRequirementsToRepurchaseOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumPayrollCostToBeAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum payroll cost to be available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumPayrollCostToBeAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum unrestricted cash requirements to repurchase of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToDepositIntoASeggregateReserveFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to deposit into a seggregate reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToDepositIntoASeggregateReserveFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToDepositIntoASegregatedCollateralAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to deposit into a segregated collateral account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToDepositIntoASegregatedCollateralAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfConcentrationOnASimilarProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of concentration on a similar product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfConcentrationOnASimilarProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfLoanForgivenessUnderTheAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of loan forgiveness under the act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfLoanForgivenessUnderTheAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfNetSalesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfNetSalesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of quarterly payments of the principal notes equal to a fixed percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the principal amount from Holders on pro rata basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfThePrincipalAmountOfTheNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the principal amount of the notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfThePrincipalAmountOfTheNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was repurchased, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmendmentAxis=sclx_AmendmentNoFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmendmentAxis=sclx_AmendmentNoFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventTypeAxis=sclx_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventTypeAxis=sclx_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ClassificationOfCostAxis=sclx_NonPayrollCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ClassificationOfCostAxis=sclx_NonPayrollCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ClassificationOfCostAxis=sclx_PayrollCostsBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ClassificationOfCostAxis=sclx_PayrollCostsBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_AccountsReceivableRevolvingLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_AccountsReceivableRevolvingLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_IndebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_IndebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sclx_IfLetterOfCreditIsDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sclx_IfLetterOfCreditIsDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sclx_MarketingApprovalLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sclx_MarketingApprovalLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StatementAxis=sclx_DecemberOptionalRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StatementAxis=sclx_DecemberOptionalRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StatementAxis=sclx_FebruaryOptionalRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StatementAxis=sclx_FebruaryOptionalRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StatementAxis=sclx_AprilOptionalRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StatementAxis=sclx_AprilOptionalRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628661579280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - Summary of borrowings of the scilex pharma notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (37,950)<span></span>
</td>
<td class="num">$ (15,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037<span></span>
</td>
<td class="nump">92,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember', window );">Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">133,997<span></span>
</td>
<td class="nump">151,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,597)<span></span>
</td>
<td class="num">(51,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_UnamortizedDebtDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,228)<span></span>
</td>
<td class="num">(3,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">101,172<span></span>
</td>
<td class="nump">97,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,135)<span></span>
</td>
<td class="num">(4,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037<span></span>
</td>
<td class="nump">92,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 115,400<span></span>
</td>
<td class="nump">$ 122,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_UnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unamortized debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_UnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758779984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details)  - Summary of future minimum payments under the scilex pharma notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems', window );"><strong>Schedule Of Future minimum payments Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtfutureMinimumPaymentYearOne', window );">2022</a></td>
<td class="nump">$ 29,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearTwo', window );">2023</a></td>
<td class="nump">12,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearThree', window );">2024</a></td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearFour', window );">2025</a></td>
<td class="nump">14,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearFive', window );">2026</a></td>
<td class="nump">64,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPayment', window );">Total minimum future payments</a></td>
<td class="nump">$ 133,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtfutureMinimumPaymentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt,&#160;Future minimum payment , year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtfutureMinimumPaymentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum payments of long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628756624560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 17, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,159,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163,000<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,781,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant', window );">Fair value per share of common stock on date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Payment to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=sclx_FourHundredAndOneKPlanMember', window );">401(k) Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan matching contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=sclx_OperatingExpensesMember', window );">Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_ScilexPharmaTwoThousandSeventeenPlanMember', window );">Scilex Pharma 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under plan</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation arrangement,vesting rights</a></td>
<td class="text">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember', window );">2019 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation arrangement,vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.<span></span>
</td>
<td class="text">20,945,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18,256,490<span></span>
</td>
<td class="text">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,054,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,743,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember', window );">Amendment to 2019 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompensationAndEmployeeBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation and employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompensationAndEmployeeBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=sclx_FourHundredAndOneKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=sclx_FourHundredAndOneKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=sclx_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=sclx_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_ScilexPharmaTwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_ScilexPharmaTwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750080256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 17, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock-price volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock-price volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock-price volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant', window );">Fair value per share of common stock on date of grant</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628749877280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment Arrangement, Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning, Options</a></td>
<td class="nump">28,163,000<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,411,000<span></span>
</td>
<td class="nump">4,781,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,194,000<span></span>
</td>
<td class="nump">21,468,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Cancelled, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,641,000)<span></span>
</td>
<td class="num">(745,000)<span></span>
</td>
<td class="num">(838,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending, Options</a></td>
<td class="nump">25,159,760<span></span>
</td>
<td class="nump">28,163,000<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,411,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning, Weighted average exercise price</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,183<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628745634016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichShareTransferIsRestricted', window );">Period during which share transfer is restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichTheSharesMayBeExchanged', window );">Period during which the shares may be exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In process research and development costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=sclx_AsRestatedMember', window );">As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InvesteeAxis=sclx_SorrentoMember', window );">Sorrento [Member] | 2022 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquistion consideration transferred equity interest issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period shares purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,039,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock shares subscribed but not issued</a></td>
<td class="nump">352,972<span></span>
</td>
<td class="nump">352,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AssetAcquisitionPricePerShare', window );">Asset acquisition price per share</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfOwnershipInterest', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer', window );">Percentage of shares issued subject to restriction of transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichShareTransferIsRestricted', window );">Period during which share transfer is restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichTheSharesMayBeExchanged', window );">Period during which the shares may be exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockValueToBeExchanged', window );">Common stock value to be exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares', window );">Number of days for determining the weighted volume averge price of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerShareForDeterminingTheExchangeOfShares', window );">Price per share for determining the exchange of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentMadeInSurrenderingTheShares', window );">Payment made in surrendering the shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In process research and development costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentMadeInSurrenderingTheShares', window );">Payment made in surrendering the shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Regulatory Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember', window );">Aardvark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember', window );">Aardvark [Member] | Reveue Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember', window );">Aardvark [Member] | Approval Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_RomegLicenseAgreementMember', window );">Romeg License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_UpfrontlicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue', window );">Acquired Finite-Lived Intangible Asset, Residual Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredConsideration', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AssetAcquisitionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AssetAcquisitionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockValueToBeExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value to be exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockValueToBeExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>milestone payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days for determining the weighted volume average price for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentMadeInSurrenderingTheShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made in surrendering the shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentMadeInSurrenderingTheShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares issued subject to restriction of transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodDuringWhichShareTransferIsRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which share transfer is restricted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodDuringWhichShareTransferIsRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodDuringWhichTheSharesMayBeExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which the shares may be exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodDuringWhichTheSharesMayBeExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerShareForDeterminingTheExchangeOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share for determining the exchange of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerShareForDeterminingTheExchangeOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RevenueToBeEarnedByTheAcquireeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue to be earned by the acquiree value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RevenueToBeEarnedByTheAcquireeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_UpfrontlicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>up-front&#160;license fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_UpfrontlicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=sclx_AsRestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=sclx_AsRestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_SenmurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestoneAxis=sclx_RegulatoryBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestoneAxis=sclx_RegulatoryBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestoneAxis=sclx_ReveueBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestoneAxis=sclx_ReveueBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestoneAxis=sclx_ApprovalBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestoneAxis=sclx_ApprovalBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_RomegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_RomegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628750033456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - Vicker's Vantage<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Ordinary per share | $ / shares</a></td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Net tangible assets | $</a></td>
<td class="nump">$ 5,000,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628745922304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">318,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,808,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,187,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="nump">128,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(358,030,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="num">(229,395,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (183,365,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,009,000)<span></span>
</td>
<td class="nump">$ 35,464,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">12,168,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,240,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(12,003,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="num">$ (12,003,010)<span></span>
</td>
<td class="num">$ (10,764,731)<span></span>
</td>
<td class="num">$ (10,538,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,697,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (9,829,785)<span></span>
</td>
<td class="num">$ (8,385,433)<span></span>
</td>
<td class="num">$ (8,151,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,999,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,006,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Adjustments Restatement 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,729,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,629,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,629,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Adjustments Restatement 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,110,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,635,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,474,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,110,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,074,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,110,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,110,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=sclx_AdjustmentsRestatement2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=sclx_AdjustmentsRestatement2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=sclx_AsRestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=sclx_AsRestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628747830432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (36,400)<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (53,000)<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rates</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,643,000<span></span>
</td>
<td class="nump">$ 43,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition', window );">Minimum threshold percentage for recognition of uncertain income tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforward expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Indefinite Carryforward Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforward expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum threshold percentage for recognition of uncertain income tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sclx_IndefiniteCarryforwardPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sclx_IndefiniteCarryforwardPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628746256560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of components of income tax expense (benefit) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (36,400)<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (53,000)<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628746291072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsInterestExpenseLimitations', window );">Interest expense limitations</a></td>
<td class="nump">$ 12,205<span></span>
</td>
<td class="nump">$ 8,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">39,714<span></span>
</td>
<td class="nump">31,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">58,939<span></span>
</td>
<td class="nump">46,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(56,643)<span></span>
</td>
<td class="num">(43,514)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(2,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease&#160;right-of-use&#160;assets</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">$ (2,296)<span></span>
</td>
<td class="num">$ (2,898)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsInterestExpenseLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets interest expense limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsInterestExpenseLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628757306432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of effective income tax rate reconciliation<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Federal Income Tax Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation', window );">Debt discount and interest limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.10%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">In-process&#160;research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback', window );">Return to provision adjustments and carryback</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="num">(11.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.80%)<span></span>
</td>
<td class="num">(13.20%)<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Benefit</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation debt discount and interest limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return to provision adjustments and carryback.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628761918064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628758248656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,480,000)<span></span>
</td>
<td class="num">$ (46,459,000)<span></span>
</td>
<td class="num">$ (88,424,000)<span></span>
</td>
<td class="num">$ (47,519,000)<span></span>
</td>
<td class="num">$ (178,594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Denominator for Basic Loss Per Share</a></td>
<td class="nump">197,550,000<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">197,315,000<span></span>
</td>
<td class="nump">187,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Effect of Dilutive Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</a></td>
<td class="nump">$ 197,550,000<span></span>
</td>
<td class="nump">$ 197,266,000<span></span>
</td>
<td class="nump">$ 197,266,000<span></span>
</td>
<td class="nump">$ 197,315,000<span></span>
</td>
<td class="nump">$ 187,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss Per Share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilutive Loss Per Share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140628658450000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Apr. 11, 2022</div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember', window );">Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Two Thousand And Twenty Two Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Subordinated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Contribution per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SponsorLoan', window );">Sponsor loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement', window );">Minimum time declared to file with sec regarding resale registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Standby Equity Purchase Agreement [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock shares subscribed but not issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares', window );">Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance', window );">Maximum Percentage Of Volume Weighted Average Price Of Shares Measured On A Daily Basis That Is Eligible To Be Received As Advance</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares', window );">Number Of Threshold Trading Days Prior To Date Of Notice To The Shareholders For Determining The Volume Weighted Average Price Of Shares</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased', window );">Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares', window );">Number Of Consecutive Trading Days For Determining The Volume Weighted Average Price Of Shares</a></td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Aardvark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Two Thousand And Twenty Two Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement', window );">Minimum time declared to file with sec regarding resale registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scilex Pharma Note [Member] | Subordinated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan', window );">Percentage of purchase price in cash equal is to principal amount of the loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesThresholdLimit', window );">Sales threshold limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scilex Pharma Note [Member] | Subordinated Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Sponsors deposited (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Contribution per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesLimits', window );">Number of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantExercisePrice', window );">Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdditionalPrincipalAmount', window );">Additional principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConvertiblePromissoryNote', window );">Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Agreement With Certain Of The Third Party Professional Service Providers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in a non cash transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Agreement With Certain Of The Third Party Professional Service Providers [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in a non cash transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Agreement With Certain Of The Third Party Professional Service Providers [Member] | Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in a non cash transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdditionalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdditionalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregateOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate outstanding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregateOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of volume weighted average price of shares measured on a daily basis that is eligible to be received as advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum time declared to file with sec regarding resale registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the volume weighted average price of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSharesLimits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares limits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSharesLimits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of threshold trading days prior to date of notice to the shareholders for determining the volume weighted average price of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of daily volume weighted average price of shares at which the shares are eligible to be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price in cash equal is to principal amount of the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after registration when the request could be made to the investee to purchase the shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SalesThresholdLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales threshold limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SalesThresholdLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SponsorLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsor loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SponsorLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919106-209958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinimumNetWorthRequiredForCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum net worth required for mortgage banking as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinimumNetWorthRequiredForCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>d374624ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sclx="http://www.vickersvantagecorp.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sclx-20220930.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="PAsOn03_17_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-03-17</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="P03_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_02_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ScilexCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ApprovalBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:StatementAxis">sclx:DecemberOptionalRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:StatementAxis">sclx:FebruaryOptionalRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:StatementAxis">sclx:AprilOptionalRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:AccountsReceivableRevolvingLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:CumulativeSalesRelatedContingencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sclx:IndefiniteCarryforwardPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:FundingCommitmentLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:FundingCommitmentLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:SoleDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis">sclx:NonPayrollCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventTypeAxis">sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis">sclx:PayrollCostsBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventTypeAxis">sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="PAsOn11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-17</instant>
        </period>
    </context>
    <context id="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-09-11</endDate>
        </period>
    </context>
    <context id="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AsRestatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AdjustmentsRestatement2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-18</instant>
        </period>
    </context>
    <context id="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-11</instant>
        </period>
    </context>
    <context id="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-10</instant>
        </period>
    </context>
    <context id="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-10</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-05</startDate>
            <endDate>2021-01-14</endDate>
        </period>
    </context>
    <context id="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-16</instant>
        </period>
    </context>
    <context id="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-16</endDate>
        </period>
    </context>
    <context id="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <context id="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-03</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:AmendmentToTwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:SoleDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:SoleDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:ReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:ContributionAndLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:ReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:RegulatoryBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:LetterOfCreditDrawnDownMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AsRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AsRestatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-07</startDate>
            <endDate>2019-08-07</endDate>
        </period>
    </context>
    <context id="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-22</startDate>
            <endDate>2018-10-22</endDate>
        </period>
    </context>
    <context id="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-28</instant>
        </period>
    </context>
    <context id="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-07</instant>
        </period>
    </context>
    <context id="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-02</startDate>
            <endDate>2018-10-02</endDate>
        </period>
    </context>
    <context id="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2018-09-07</endDate>
        </period>
    </context>
    <context id="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-28</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-28</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:PaloAltoAadministrativeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sclx:IfLetterOfCreditIsDrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sclx:MarketingApprovalLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-16</endDate>
        </period>
    </context>
    <context id="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-03</instant>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P11_11_2022To11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-11</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PeriodAxis">sclx:DueOnOrAfterFebruaryTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-06</instant>
        </period>
    </context>
    <context id="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-10</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To09_30_2022">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P01_01_2022To09_30_2022" id="hidden61004188">Scilex Holding Company/DE</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To09_30_2022">0001820190</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To09_30_2022">S-1</dei:DocumentType>
    <dei:EntityFilerCategory contextRef="P01_01_2022To09_30_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To09_30_2022">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To09_30_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To09_30_2022">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="0"
      id="hidden61009247"
      unitRef="Unit_USD">2483</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      id="hidden61003888"
      unitRef="Unit_USD">2483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="hidden61004186"
      unitRef="Unit_USD">92255000</us-gaap:LongTermDebtNoncurrent>
    <sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      id="hidden61004144">P5D</sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares>
    <sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      id="hidden61004145">P2D</sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4536</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">512457</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">168973</us-gaap:DeferredCosts>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">199484</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25760</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sclx:AdvancesFromRelatedParty
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:AdvancesFromRelatedParty>
    <sclx:AdvancesFromRelatedParty
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</sclx:AdvancesFromRelatedParty>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">180760</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">483099</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9240295</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">180760</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:SubjectToPossibleRedemptionPerShares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.1</sclx:SubjectToPossibleRedemptionPerShares>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_61002555"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_61002556"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18724</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">199484</us-gaap:LiabilitiesAndStockholdersEquity>
    <sclx:OrdinarySharesRedemptionSubjectedToForfeiture
      contextRef="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">450000</sclx:OrdinarySharesRedemptionSubjectedToForfeiture>
    <sclx:SharesCapitalization
      contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.2</sclx:SharesCapitalization>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesRedemptionSubjectedToForfeiture
      contextRef="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</sclx:OrdinarySharesRedemptionSubjectedToForfeiture>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1005498</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6276</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1005498</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:OperatingIncomeLoss>
    <sclx:ChangeInFairValueOfWarrantLiability
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4377600</sclx:ChangeInFairValueOfWarrantLiability>
    <sclx:ChangeInFairValueOfWarrantLiability
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2599200</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">11835</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1826</us-gaap:InterestExpense>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30739</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1788935</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_61003170"
      unitRef="Unit_shares">16820548</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_61003171"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16834110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <sclx:OrdinarySharesRedemptionSubjectedToForfeiture
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">450000</sclx:OrdinarySharesRedemptionSubjectedToForfeiture>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">-1</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3450000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">345</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">24655</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18724</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9474606</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30739</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4377600</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2599200</sclx:LossOnInitialIssuanceOfWarrantLiability>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-11835</sclx:ChangeInFairValueOfConversionOptionLiability>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1826</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionsCostsAllocatedToPrivateWarrants>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4536</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-801330</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1276</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:InvestmentOfCashInTrustAccounts>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-139380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">135600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">55000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ProceedsFromPromissoryNoteRelatedParty
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ProceedsFromPromissoryNoteRelatedParty
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</sclx:ProceedsFromPromissoryNoteRelatedParty>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-125000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">416260</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">118213</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">140658740</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">31787</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">477410</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFeePayable>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OfferingCostIncludedInAccruedOfferingCost
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OfferingCostIncludedInAccruedOfferingCost
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25760</sclx:OfferingCostIncludedInAccruedOfferingCost>
    <us-gaap:NotesIssued1
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NotesIssued1
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:NotesIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1&#160;&#x2014;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vickers Vantage Corp. I (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#x201c;Business Combination&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through December&#160;31, 2021 relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of 13,800,000&#160;Units (the &#x201c;Units&#x201d; and, with respect to the ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,800,000&#160;Units, at $10.00 per Unit, generating gross proceeds of $138,000,000 which is described in Note 3. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 6,840,000 warrants (the &#x201c;Private Placement Warrants&#x201d;) at a price of $0.75 per Private Placement Warrant in a private placement to Vickers Venture Fund&#160;VI Pte Ltd and Vickers Venture Fund&#160;VI (Plan) Pte Ltd, (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $5,130,000, which is described in Note 4. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $8,149,473, consisting of $2,400,000 in cash underwriting fees, $5,190,000 in deferred underwriting fees, and $559,473 of other offering costs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#x201c;Trust Account&#x201d;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&#160;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#x2019;s shareholders, as described below. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below)&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will provide the holders of the public shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (initially anticipated to be $10.10 per Public Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#x2019;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company&#x2019;s prior written consent. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Company&#x2019;s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-initial&lt;/div&gt; business combination activity, unless the Company provides the Public &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. In connection with the extension, the Sponsors deposited $1,035,000 into the trust account in the form of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing loan. The Company will have until April&#160;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&#160;11, 2022, the Company may extend the period of time to consummate a Business Combination by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination (the &#x201c;Combination Period&#x201d;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#x2019;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)&#160;$10.10 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#x2019;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Going Concern and Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had $507,921 in its operating bank accounts, and working capital of $303,753. As of December&#160;31, 2021, approximately $31,000 of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#x2019;s tax obligations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of the above, in connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#x2019;s Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2014-15,&lt;/div&gt; &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern,&#x201d; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern through July&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <sclx:Numberofshares
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:Numberofshares>
    <sclx:Numberofshares
      contextRef="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1800000</sclx:Numberofshares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <sclx:ProceedsOfInitialPublicOffering
      contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</sclx:ProceedsOfInitialPublicOffering>
    <sclx:Saleofwarrants
      contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:Saleofwarrants>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <sclx:Grossproceedsofwarrants
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</sclx:Grossproceedsofwarrants>
    <sclx:Transactioncostsamount
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8149473</sclx:Transactioncostsamount>
    <us-gaap:OtherUnderwritingExpense
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2400000</us-gaap:OtherUnderwritingExpense>
    <sclx:DeferredUnderwritingFees
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFees>
    <sclx:Otherofferingcosts
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">559473</sclx:Otherofferingcosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</us-gaap:SaleOfStockPricePerShare>
    <sclx:SaleOfStockDescriptionOfTransactions contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below)(less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination.</sclx:SaleOfStockDescriptionOfTransactions>
    <sclx:Numberofbusinessdays
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_Day">2</sclx:Numberofbusinessdays>
    <sclx:PricePerPublicShare
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</sclx:PricePerPublicShare>
    <sclx:NetTangibleAssets
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</sclx:NetTangibleAssets>
    <sclx:PercentageOfPublicShares
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</sclx:PercentageOfPublicShares>
    <sclx:BusinessCombinationRedeemPercentage
      contextRef="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:BusinessCombinationRedeemPercentage>
    <sclx:Depositintotrustaccount
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:Depositintotrustaccount>
    <sclx:Depositintotrustaccount
      contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:Depositintotrustaccount>
    <sclx:PricePerPublicShare
      contextRef="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.075</sclx:PricePerPublicShare>
    <sclx:BusinessCombinationRedeemPercentage
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:BusinessCombinationRedeemPercentage>
    <sclx:Interestexpenses
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">50000</sclx:Interestexpenses>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:Cash>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">303753</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">31000</us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2&#160;&#x2014;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; (deficit) equity section of the Company&#x2019;s balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period&lt;br/&gt;from&#160;February&#160;21,&lt;br/&gt;2020 (Inception)&lt;br/&gt;Through&lt;br/&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,820,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,834,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective for fiscal&#160;years beginning after December&#160;15, 2023, &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</us-gaap:OtherDeferredCostsNet>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</us-gaap:OtherDeferredCostsNet>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; (deficit) equity section of the Company&#x2019;s balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <sclx:GrossProceeds
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</sclx:GrossProceeds>
    <sclx:OrdinarySharesIssuanceCost
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</sclx:OrdinarySharesIssuanceCost>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <sclx:SharesSubjectToPossibleRedemption
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:SharesSubjectToPossibleRedemption>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period&lt;br/&gt;from&#160;February&#160;21,&lt;br/&gt;2020 (Inception)&lt;br/&gt;Through&lt;br/&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,820,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,834,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ExcessStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13740000</us-gaap:ExcessStockSharesIssued>
    <sclx:Foundershares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">450000</sclx:Foundershares>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period&lt;br/&gt;from&#160;February&#160;21,&lt;br/&gt;2020 (Inception)&lt;br/&gt;Through&lt;br/&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,820,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,834,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16820548</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16834110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective for fiscal&#160;years beginning after December&#160;15, 2023, &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sclx:ProposedPublicOfferingTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3&#160;&#x2014;&#160;PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Pursuant to the Initial Public Offering, the Company sold to 13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of 1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). &lt;/div&gt;</sclx:ProposedPublicOfferingTextBlock>
    <sclx:NumberOfSaleUnits
      contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:NumberOfSaleUnits>
    <sclx:NumberOfSaleUnits
      contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1800000</sclx:NumberOfSaleUnits>
    <sclx:PurchasePricePerShare
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</sclx:PurchasePricePerShare>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</us-gaap:SaleOfStockDescriptionOfTransaction>
    <sclx:PrivatePlacementTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4&#160;&#x2014;&#160;PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of 6,840,000 Private Placement Warrants at a price of $0.75 per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50 per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. &lt;/div&gt;&lt;/div&gt;</sclx:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5&#160;&#x2014;&#160;RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an aggregate of 3,593,750 ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August&#160;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, the Company effected a share capitalization of 0.2 shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (the &#x201c;Founder Shares&#x201d;). All share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised, so that the number of Founder Shares will equal, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, approximately 20% of the Company&#x2019;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#x2019; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&#160;months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances from Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000 to fund expenses in connection with the Initial Public Offering. The advances are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon demand. As of December&#160;31, 2021 and 2020, there was $0 and $30,000 advances outstanding, respectively. The outstanding amount of $30,000 was repaid on February&#160;26, 2021. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note&#160;&#x2014;&#160;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#x201c;Promissory Note&#x201d;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the Working Capital Loans. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;20, 2021, the Company entered into two convertible promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000 (the &#x201c;Convertible Promissory Notes&#x201d;). The Convertible Promissory Notes are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&#160;be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $500,000 of the Convertible Promissory Notes may be converted into warrants at a price of $0.75 per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. As of December&#160;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $500,000. Subsequent to December&#160;31, 2021, on January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&#160;loan&#160;the Company up to an aggregate principal amount of $500,000. Subsequent to December&#160;31, 2021, the&#160;principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000 (see Note 11). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The debt discount is being amortized to interest expense as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&#160;2022, the Company&#x2019;s expected Business Combination date. &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, the Company recorded $1,826 of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&#160;31, 2021&#160;amounted to $16,901. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Extension Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case). Any such deposits would be made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant insider&#x2019;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $0.75 per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated, to fund the Trust Account to extend the time for the Company to complete a Business Combination. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3593750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:aggregatePurchasePrice
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</sclx:aggregatePurchasePrice>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1437500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <sclx:OrdinarySharesIssuedAndOutstanding
      contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</sclx:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">450000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DueToAffiliateCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:DueToAffiliateCurrent>
    <sclx:RepaidAmount
      contextRef="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</sclx:RepaidAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:RepaymentsOfDebt>
    <us-gaap:BusinessCombinationControlObtainedDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</us-gaap:BusinessCombinationControlObtainedDescription>
    <sclx:AggregatePrincipalAmount
      contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:AggregatePrincipalAmount>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:ConvertibleDebt>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:aggregatePurchasePrice>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:AdditionalPaidInCapital>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:aggregatePurchasePrice>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</sclx:aggregatePurchasePrice>
    <us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1826</us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case).</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <sclx:PricePerWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:PricePerWarrants>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:AssetsHeldInTrust>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6&#160;&#x2014;&#160;COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration and Shareholder Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentsDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.</us-gaap:OtherCommitmentsDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7&#160;&#x2014;&#160;SHAREHOLDERS&#x2019; EQUITY &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&#x2014;&#160;The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. At December&#160;31, 2021 and 2020, there were no preference shares issued or outstanding. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&#x2014;&#160;The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were 3,450,000 shares of ordinary shares issued and outstanding, excluding 13,800,000 ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2020, there were 3,450,000 ordinary shares issued or outstanding. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:WarrantsTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8&#160;&#x2014;&#160;WARRANTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, there were 6,900,000 and 0 Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90&#160;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may redeem the Public Warrants: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at any time while the warrants become exercisable; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30&#160;days&#x2019; prior written notice of redemption to each warrant holder; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; trading period referred to above and continuing each day thereafter until the date of redemption. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021 and 2020, there were 6,840,000 and 0 Private Placement Warrants outstanding, respectively. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#x2019;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. &lt;/div&gt;&lt;/div&gt;</sclx:WarrantsTextBlock>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6900000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</sclx:WarrantsOutstandingShares>
    <sclx:PublicWarrantsRedemptionDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The Company may redeem the Public Warrants: &#160;


&#160;
&#x2022;
&#160;
in whole and not in part; &#160;


&#160;
&#x2022;
&#160;
at a price of $0.01 per warrant; &#160;


&#160;
&#x2022;
&#160;
at any time while the warrants become exercisable; &#160;


&#160;
&#x2022;
&#160;
upon not less than 30&#160;days&#x2019; prior written notice of redemption to each warrant holder;


&#160;
&#x2022;
&#160;
if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and &#160;


&#160;
&#x2022;
&#160;
if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. </sclx:PublicWarrantsRedemptionDescription>
    <sclx:CapitalRaisingDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </sclx:CapitalRaisingDescription>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</sclx:WarrantsOutstandingShares>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9&#160;&#x2014;&#160;FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 96%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 9%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 89%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-size: 0px;"/&gt;
&lt;td colspan="2" style="height: 6pt; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-size: 0px;"/&gt;
&lt;td colspan="2" style="height: 6pt; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, assets held in the Trust Account were comprised of $139,410,739 in money market funds which are invested primarily in U.S. Treasury Securities. Through December&#160;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&#160;31, 2020, there were no assets in the Trust Account. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account&#160;&#x2014;&#160;U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&#160;&#x2014;&#160;Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluated&lt;/div&gt; each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers between Levels 1, 2 or 3 during the year ended December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides quantitative information regarding Level&#160;3 fair value measurements: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,377,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Option Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;20,&lt;br/&gt;2021&lt;br/&gt;(Initial&lt;br/&gt;Measurement)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the change in the fair value of conversion option liability: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrust>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account&#160;&#x2014;&#160;U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&#160;&#x2014;&#160;Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:FairValueMeasurementsHighestAndBestUseDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </us-gaap:FairValueMeasurementsHighestAndBestUseDescription>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.04</us-gaap:SharePrice>
    <sclx:FairValueMeasurementStrikePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</sclx:FairValueMeasurementStrikePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <sclx:FairValueOfWarrantsinDollars
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.49</sclx:FairValueOfWarrantsinDollars>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,377,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</sclx:InitialMeasurementOne>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4377600</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;20,&lt;br/&gt;2021&lt;br/&gt;(Initial&lt;br/&gt;Measurement)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sclx:UnderlyingWarrantValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0103</sclx:UnderlyingWarrantValue>
    <sclx:UnderlyingWarrantValue
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0281</sclx:UnderlyingWarrantValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <sclx:HoldingPeriod
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.28</sclx:HoldingPeriod>
    <sclx:HoldingPeriod
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.31</sclx:HoldingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18727</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-11835</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 10&#160;&#x2014;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restatement 1 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company previously accounted for its outstanding Private Placement Warrants (the &#x201c;Warrants&#x201d;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies titled &#x201c;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#x201c;SPACs&#x201d;)&#x201d; (the &#x201c;SEC Statement&#x201d;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In further consideration of the SEC Statement, the Company&#x2019;s management further evaluated the Warrants under Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40,&lt;/div&gt; Contracts in Entity&#x2019;s Own Equity. ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;815-40-15&lt;/div&gt;&lt;/div&gt; addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#x2019;s ordinary shares. Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;815-40-15,&lt;/div&gt;&lt;/div&gt; a warrant is not indexed to the issuer&#x2019;s ordinary shares if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#x2019;s evaluation, the Company&#x2019;s audit committee, in consultation with management, concluded that the Company&#x2019;s Private Placement Warrants are not indexed to the Company&#x2019;s ordinary shares in the manner contemplated by ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;815-40-15&lt;/div&gt;&lt;/div&gt; because the holder of the instrument is not an input into the pricing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; option on equity shares. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restatement 2 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In addition, in connection with the preparation of the Company&#x2019;s financial statements as of September&#160;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&#160;30, 2021 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q/A,&lt;/div&gt; filed with the SEC on December&#160;8, 2021, includes the restatement of the unaudited March&#160;31, 2021 and June&#160;30, 2021 financial information. Included in the table below is the restatement &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;of the audited IPO Balance Sheet as of January&#160;11, 2021 originally filed on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8-K&lt;/div&gt; filed with the SEC on January&#160;15, 2021. In accordance with ASC 480, paragraph &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-S99,&lt;/div&gt; redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $10.10 per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the ordinary shares subject &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;to possible redemption with the offset recorded to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital (to the extent available), accumulated deficit and ordinary shares. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the change in presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, ordinary shares share pro&#160;rata in the income (loss) of the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The impact of these adjustments to the financial statement, as previously reported, is presented below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As Previously&lt;br/&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance sheet as of January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,345,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,074,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129,999,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,006,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,629,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,635,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,629,412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,474,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Shareholders&#x2019; Equity (Deficit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:IntangibleAssetsCurrent>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The impact of these adjustments to the financial statement, as previously reported, is presented below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As Previously&lt;br/&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance sheet as of January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,345,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,074,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129,999,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,006,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,629,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,635,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,629,412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,474,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Shareholders&#x2019; Equity (Deficit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</us-gaap:DerivativeLiabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5345000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13074200</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">129999029</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7729200</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">17110171</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">438</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">76</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-169</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5006060</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2629336</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7635396</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6490</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2629412</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9474606</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12110508</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-17110171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12110163</us-gaap:StockholdersEquity>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 11&#160;&#x2014;&#160;SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;27, 2022, the Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $500,000. The aggregate principal balance of the Convertible Promissory Notes amounted to $2,035,000. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <sclx:SponsorLoan
      contextRef="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:SponsorLoan>
    <sclx:WarrantExercisePrice
      contextRef="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:WarrantExercisePrice>
    <sclx:AdditionalPrincipalAmount
      contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:AdditionalPrincipalAmount>
    <sclx:ConvertiblePromissoryNote
      contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</sclx:ConvertiblePromissoryNote>
    <us-gaap:Cash
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">34961</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">130788</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4536</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">165749</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">512457</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101458835</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">809292</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">809292</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">483099</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLongTermNotesPayable
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2971667</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:OtherLongTermNotesPayable
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12168759</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9240295</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">9726395</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.41</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003355</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101458835</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">657746</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">283346</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2412297</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">620642</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-657746</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-283346</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2412297</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-620642</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-68400</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2188800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2872800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2599200</us-gaap:GainLossOnSaleOfDerivatives>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">192049</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:InterestExpense
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1155</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">459114</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1794</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">664973</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28006</us-gaap:InterestIncomeOther>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">526359</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1161006</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3035813</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">271394</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">623516</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-349248</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-806222</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-806222</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10538666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10538321</us-gaap:StockholdersEquity>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-192049</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-192049</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1595486</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1595486</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1561125</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1561125</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10765076</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10764731</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1106892</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1106892</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003010</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18724</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24665</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9474606</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1328853</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1328853</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8152029</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8151684</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-233749</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-233749</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8385778</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8385433</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9830130</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9829785</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">623516</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-349248</us-gaap:NetIncomeLoss>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">664973</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28006</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">192049</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2188800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2872800</us-gaap:FairValueAdjustmentOfWarrants>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:LossOnInitialIssuanceOfWarrantLiability>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2599200</sclx:LossOnInitialIssuanceOfWarrantLiability>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6892</sclx:ChangeInFairValueOfConversionOptionLiability>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueOfConversionOptionLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionsCostsAllocatedToPrivateWarrants>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionsCostsAllocatedToPrivateWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">126252</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">116536</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">600588</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">43569</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1937961</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-693609</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3041666</sclx:InvestmentOfCashInTrustAccounts>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:InvestmentOfCashInTrustAccounts>
    <us-gaap:ProceedsFromDecommissioningFund
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">41824292</us-gaap:ProceedsFromDecommissioningFund>
    <us-gaap:ProceedsFromDecommissioningFund
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromDecommissioningFund>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">38782626</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-139380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">135600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">55000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1535000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <sclx:ProceedsFromSimplePromissoryNoteRelatedParty
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2971667</sclx:ProceedsFromSimplePromissoryNoteRelatedParty>
    <sclx:ProceedsFromSimplePromissoryNoteRelatedParty
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:ProceedsFromSimplePromissoryNoteRelatedParty>
    <sclx:RepaymentOfPromissoryNoteRelatedParty
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:RepaymentOfPromissoryNoteRelatedParty>
    <sclx:RepaymentOfPromissoryNoteRelatedParty
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</sclx:RepaymentOfPromissoryNoteRelatedParty>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">416260</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">41824292</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-37317625</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">140158740</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-472960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">85131</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">34961</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">115642</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:DeferredUnderwritingFeePayable>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFeePayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vickers Vantage Corp. I (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#x201c;Business Combination&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has one wholly owned subsidiary which was formed on February&#160;2, 2022, Vantage Merger Sub Inc., a Delaware corporation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through September&#160;30, 2022 relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of&#160;13,800,000&#160;Units (the &#x201c;Units&#x201d; and, with respect to the ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), which includes the full exercise by the underwriter of its over-allotment option in the amount of&#160;1,800,000&#160;Units, at $10.00&#160;per Unit, generating gross proceeds of $138,000,000&#160;which is described in Note 3. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&#160;6,840,000 warrants (the &#x201c;Private Placement Warrants&#x201d;) at a price of $0.75&#160;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $5,130,000, which is described in Note 4. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $8,149,473, consisting of $2,400,000&#160;in cash underwriting fees, $5,190,000&#160;in deferred underwriting fees, and $559,473&#160;of other offering costs &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000&#160;($10.10&#160;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#x201c;Trust Account&#x201d;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S.&#160;Treasuries and meeting certain conditions under Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#x2019;s shareholders, as described below. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. On July&#160;11, 2022, the Company extended the period of time to &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;consummate a Business Combination to August&#160;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after, upon five days&#x2019; advance notice prior to the applicable deadlines, until January&#160;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business Combination to November&#160;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $3,365,554 into the trust account in the form of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans as of the date of this filing. The Company will have until November&#160;11, 2022 to consummate a Business Combination. As a result, an aggregate of $101,293,086&#160;as of September&#160;30, 2022 is held in the Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&#160;The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will provide the holders of the public shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $10.38&#160;per Public Share as of the date of this filing), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001&#160;and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#x2019;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of&#160;20% of the Public Shares without the Company&#x2019;s prior written consent. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Company&#x2019;s initial Business Combination or to redeem&#160;100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-initial&lt;/div&gt; business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the Company has not completed a Business Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem&#160;100% of the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000&#160;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.38&#160;per share). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#x2019;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trust Account to below (1) $10.10&#160;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#x2019;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#x201c;Meeting&#x201d;), to amend the Company&#x2019;s Amended and Restated Memorandum and Articles of Association (the &#x201c;Extension Amendment&#x201d;) to (i)&#160;extend the date by which the Company has to consummate an initial business combination from July&#160;11, 2022 (the &#x201c;Original Termination Date&#x201d;) to August&#160;11, 2022 (the &#x201c;Extended Date&#x201d;) and (ii)&#160;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the Extended Date, upon five days&#x2019; advance notice prior to the applicable deadlines, until January&#160;11, 2023 or a total of up to nine months after the Original Termination Date (the &#x201c;Extension Proposal&#x201d;). The Company&#x2019;s shareholders approved the Extension Amendment at the Meeting. On July&#160;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has deposited an aggregate of $1,295,556&#160;into the Trust Account to extend the date to consummate a business combination to November&#160;11, 2022 (the &#x201c;Combination Period&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern and Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, the Company had $34,961&#160;in its operating bank accounts, and working capital deficit of $643,543. As of September&#160;30, 2022, approximately $696,000&#160;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#x2019;s tax obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;As a result of the above, in connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#x2019;s Accounting Standards Codification Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; &#x201c;Presentation of Financial Statements &#x2013; Going Concern,&#x201d; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern through November&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssued
      contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1800000</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds
      contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6840000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8149473</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:OtherUnderwritingExpense
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2400000</us-gaap:OtherUnderwritingExpense>
    <sclx:DeferredUnderwritingFees
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFees>
    <us-gaap:OtherOwnershipInterestsOfferingCosts
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">559473</us-gaap:OtherOwnershipInterestsOfferingCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:NoninterestBearingDepositLiabilities
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3365554</us-gaap:NoninterestBearingDepositLiabilities>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:AssetsHeldInTrust>
    <sclx:SaleOfStockDescriptionOfTransactions contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination.</sclx:SaleOfStockDescriptionOfTransactions>
    <sclx:PricePerPublicShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.38</sclx:PricePerPublicShare>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:OtherIntangibleAssetsNet>
    <sclx:PercentageOfPublicShares
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</sclx:PercentageOfPublicShares>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <sclx:BusinessCombinationRedeemPercentage
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:BusinessCombinationRedeemPercentage>
    <us-gaap:OtherExpenses
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">50000</us-gaap:OtherExpenses>
    <sclx:DepositIntoTheTrustAccountPerShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.38</sclx:DepositIntoTheTrustAccountPerShare>
    <sclx:LesserPublicPerShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</sclx:LesserPublicPerShare>
    <us-gaap:BusinessCombinationAcquiredReceivablesDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.</us-gaap:BusinessCombinationAcquiredReceivablesDescription>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1295556</us-gaap:AssetsHeldInTrust>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">34961</us-gaap:RestrictedCashCurrent>
    <sclx:WorkingCapital
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">643543</sclx:WorkingCapital>
    <us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">696000</us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-K&lt;/div&gt; as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; deficit section of the Company&#x2019;s condensed consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;139,380,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatorily redeemable ordinary shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41,824,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,737,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,293,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,444,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,176,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,862,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,675,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt &#x2014; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;accounting &lt;/div&gt;standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-K&lt;/div&gt; as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. &lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</us-gaap:OtherDeferredCostsNet>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</us-gaap:OtherDeferredCostsNet>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; deficit section of the Company&#x2019;s condensed consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;139,380,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatorily redeemable ordinary shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41,824,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,737,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,293,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;139,380,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatorily redeemable ordinary shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41,824,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,737,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,293,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <sclx:GrossProceeds
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</sclx:GrossProceeds>
    <sclx:OrdinarySharesIssuanceCost
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</sclx:OrdinarySharesIssuanceCost>
    <sclx:AccretionOfCarryingValueToRedemptionValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</sclx:AccretionOfCarryingValueToRedemptionValue>
    <sclx:SharesSubjectToPossibleRedemption
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:SharesSubjectToPossibleRedemption>
    <us-gaap:TemporaryEquityOtherChanges
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-41824292</us-gaap:TemporaryEquityOtherChanges>
    <sclx:AccretionOfCarryingValueToRedemptionValue
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3737378</sclx:AccretionOfCarryingValueToRedemptionValue>
    <sclx:SharesSubjectToPossibleRedemption
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</sclx:SharesSubjectToPossibleRedemption>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,444,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,176,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,862,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,675,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ExcessStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13740000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,444,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,176,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,862,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,675,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">623516</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-349248</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt &#x2014; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;accounting &lt;/div&gt;standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sclx:ProposedPublicOfferingTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3. PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Pursuant to the Initial Public Offering, the Company sold to&#160;13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&#160;1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). &lt;/div&gt;</sclx:ProposedPublicOfferingTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1800000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <sclx:PurchasePricePerShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</sclx:PurchasePricePerShare>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</us-gaap:SaleOfStockDescriptionOfTransaction>
    <sclx:PrivatePlacementTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&#160;6,840,000 Private Placement Warrants at a price of $0.75&#160;per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50&#160;per share, subject to adjustment (see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. &lt;/div&gt;&lt;/div&gt;</sclx:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an aggregate of&#160;3,593,750&#160;ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share capitalization of 0.2&#160;shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of&#160;0.2&#160;shares for each share outstanding, resulting in&#160;3,450,000&#160;ordinary shares issued and outstanding (the &#x201c;Founder Shares&#x201d;). All share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&#160;450,000&#160;shares that were subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised, so that the number of Founder Shares will equal, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, approximately&#160;20% of the Company&#x2019;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#x2019; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances from Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000&#160;to fund expenses in connection with the Initial Public Offering. The advances were &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note &#x2014; Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#x201c;Promissory Note&#x201d;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000&#160;was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). Such Working Capital Loans would be evidenced by promissory notes.&#160;The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.&#160;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000&#160;(the &#x201c;Convertible Promissory Notes&#x201d;). The Convertible Promissory Notes are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $500,000&#160;of the Convertible Promissory Notes may be converted into warrants at a price of $0.75&#160;per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000&#160;and $500,000, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The debt discount is being amortized to interest expense as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge over the term of the Convertible Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended September&#160;30, 2022, the Company recorded $1,155&#160;and $16,901&#160;of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at September&#160;30, 2022 and December&#160;31, 2021 amounted to $0 and $16,901, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $1,500,000&#160;(the &#x201c;Simple Promissory Notes&#x201d;). The Simple Promissory Notes are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon Business Combination. If a Business Combination is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On April&#160;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $2,971,667&#160;and $0, respectively. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Extension Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&#160;In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension., &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75&#160;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. The Sponsors deposited $1,035,000&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to August&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to&#160;September&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;9, 2022, the Company extended the period of time to consummate a Business Combination to October&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3593750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1437500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <sclx:OrdinarySharesIssuedAndOutstanding
      contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</sclx:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">450000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:RepaymentsOfDebt>
    <us-gaap:BusinessCombinationControlObtainedDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</us-gaap:BusinessCombinationControlObtainedDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:ConvertibleDebt>
    <sclx:WarrantsExercisePrice
      contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:WarrantsExercisePrice>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</sclx:aggregatePurchasePrice>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:aggregatePurchasePrice>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1155</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2971667</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <sclx:DepositedInTrustAccount
      contextRef="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:DepositedInTrustAccount>
    <sclx:WarrantsExercisePrice
      contextRef="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:WarrantsExercisePrice>
    <sclx:DepositedInTrustAccount
      contextRef="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration and Shareholder Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.&#160;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination Merger Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;17, 2022, the Company entered into an agreement and plan of merger (the &#x201c;Merger Agreement&#x201d;) by and among Scilex Holding Company (&#x201c;Scilex&#x201d;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (&#x201c;Sorrento&#x201d;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#x201c;Merger Sub&#x201d;). Parent and Merger Sub are sometimes referred to collectively as the &#x201c;Parent Parties.&#x201d; Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies Law (the &#x201c;Domestication&#x201d;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the &#x201c;Merger&#x201d;). Upon the closing of the Merger (the &#x201c;Closing&#x201d;), it is anticipated that VCKA will change its name to &#x201c;Scilex Holding Company&#x201d;. The board of directors of VCKA has (i)&#160;approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&#160;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On September&#160;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&#160;1 to the Merger Agreement (the &#x201c;Amendment&#x201d;). The Amendment amends the Merger Agreement to, among other things, provide that: (i)&#160;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&#160;388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&#160;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of Domesticated Parent Common Share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#x2019;s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of whom will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&#160;at the Effective Time, by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-tenth&lt;/div&gt; of one Domesticated Parent Common Share; (v)&#160;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the Merger Agreement; (vi)&#160;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on the Stock Exchange; (vii)&#160;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii)&#160;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from Nasdaq of &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compliance&lt;/div&gt; with Nasdaq&#x2019;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix)&#160;extend the Outside Date to November&#160;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of preferred stock set forth therein from&#160;20,000,000&#160;to&#160;45,000,000&#160;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from&#160;750,000,000&#160;to&#160;785,000,000&#160;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of certain other customary closing conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Merger Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The total consideration to be paid to the holders of Scilex common stock at Closing (the &#x201c;Merger Consideration&#x201d;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#x201c;Closing Date&#x201d;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#x201c;VCKA Common Stock&#x201d;).&#160;The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a)&#160;one&#160;share of Series A Preferred Stock of Vickers (following the Domestication), par value $0.0001&#160;per share (the &#x201c;New Scilex Series A Preferred Stock&#x201d;), and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b)&#160;one-tenth&lt;/div&gt; of one share of New Scilex Common Stock, and (iii)&#160;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued shares of New Scilex Common Stock with an aggregate value equal to $1.5&#160;billion, subject to adjustments for certain debt obligations of Scilex (the &#x201c;Merger Consideration&#x201d;).&#160;The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#x201c;Preferred Consideration&#x201d;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#x2019;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Representations and Warranties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv)&#160;non-contravention;&lt;/div&gt; (v)&#160;capital structure; (vi)&#160;organizational documents; (vii)&#160;assumed names; (viii)&#160;subsidiaries; (ix) financial statements; (x)&#160;absence of certain changes; (xi)&#160;properties and title to assets; (xii)&#160;litigation; (xiii) contracts; (xiv)&#160;licenses and permits; (xv)&#160;compliance with laws; (xvi)&#160;intellectual property; (xvii)&#160;customers and suppliers; (xviii)&#160;employees and employee benefits; (xix)&#160;employment matters; (xx)&#160;withholding; (xxi) real property; (xxii)&#160;tax matters; (xxiii)&#160;environmental laws; (xiv)&#160;finders&#x2019; fees; (xv)&#160;directors and officers; (xvi)&#160;certain business practices; (xvii)&#160;international trade matters and anti-bribery compliance; (xviii)&#160;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&#160;insurance; (xxxi)&#160;related party transactions; (xxxii)&#160;privacy and data security and (xxxiii)&#160;exclusivity of representations and warranties. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Merger Agreement contains customary representations and warranties of the Parent Parties with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv)&#160;non-contravention;&lt;/div&gt; (v)&#160;finders&#x2019; fees; (vi)&#160;issuance of shares; (vii)&#160;capitalization; (viii) information supplied; (ix)&#160;amount in the trust account; (x)&#160;listing of VCKA securities; (xi)&#160;that VCKA is a reporting company; (xii)&#160;no market manipulation; (xiii)&#160;board approval; (xiv)&#160;SEC documents and financial statements; (xv)&#160;absence of changes; (xvi)&#160;litigation; (xvii) compliance with laws; (xviii)&#160;money laundering laws; (xix)&#160;OFAC; (xx) that VCKA is not an investment company; (xxi)&#160;tax matters; (xxii)&#160;contracts; (xxiii) investigation; and (xiv)&#160;exclusivity of representations and warranties. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All representations and warranties by all parties shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Covenants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4&lt;/div&gt; (the &#x201c;Registration Statement&#x201d;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party&#x2019;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conduct between Signing and Closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each of VCKA, Merger Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conditions to Closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consummation of the Merger is conditioned upon, among other things, (i)&#160;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&#160;the Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;); (iii) approval by VCKA&#x2019;s shareholders of the Merger and related transactions; (iv)&#160;approval by Scilex&#x2019;s stockholders of the Merger and related transactions; and (v)&#160;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&#160;Scilex having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#x2019;s ability to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Company Material Adverse Effect; (iv)&#160;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&#160;Scilex providing VCKA a certificate from the secretary which has attached true and complete copies of (a)&#160;Scilex&#x2019;s organizational documents, (b)&#160;Scilex&#x2019;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&#160;Scilex&#x2019;s stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&#160;certified certificate of good standing; (vi)&#160;Scilex shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi)&#160;Sorrento shall have executed the Registration Rights Agreement (as defined below). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Solely with respect to Scilex, the consummation of the Merger is conditioned upon, among other things: (i)&#160;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&#160;each of the Parent Parties providing Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v)&#160;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;); (vi)&#160;each of VCKA the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&#160;the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&#160;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&#160;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&#160;3a51-1(g)(1)&#160;of&lt;/div&gt; the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&#160;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Scilex, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&#160;12, 2022 (the &#x201c;Debt Exchange Agreement&#x201d;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $5,000,001&#160;in net tangible assets (as determined in accordance with Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3a51-1(g)(1)&lt;/div&gt; of the United States Securities and Exchange Act of 1934) (the &#x201c;Net Tangible Assets Condition&#x201d;). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Termination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement may be terminated as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;i.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;By the mutual consent of VCKA and Scilex; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;ii.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&#160;the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;iii.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&#160;the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;iv.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by either VCKA or Scilex &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;a.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on or after November&#160;11, 2022 (the &#x201c;Outside Date&#x201d;), if the Merger shall not have been consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section&#160;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to such party&#x2019;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;b.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions shall have become final and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-appealable;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;v.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;vi.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;vii.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by VCKA, in the event that Scilex&#x2019;s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on or before March&#160;31, 2022 and remain undelivered prior to the termination of the Merger Agreement &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&#160;17, 2022 (the &#x201c;Sponsor Support Agreement&#x201d;) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;12, 2022, Vickers and Scilex entered into Amendment No.&#160;1 to the Original Support Agreement with the Vickers Shareholders (the &#x201c;Support Agreement Amendment&#x201d;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (75%) of the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&#160;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (40%) of all Parent Warrants held by such Vickers Shareholder immediately prior to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Company Stockholder Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March&#160;17, 2022 (the &#x201c;Company Stockholder Support Agreements&#x201d;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the &#x201c;Stockholder Agreement&#x201d;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $0.0001&#160;per share (&#x201c;New Scilex Series A Preferred Stock&#x201d;), among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a &#x201c;Stockholder Designee&#x201d; and collectively, the &#x201c;Stockholder Designees&#x201d;), regardless of (i)&#160;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#x201c;New Scilex Board&#x201d;) at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the New Scilex Board, or (ii)&#160;the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each Stockholder Designee to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common Stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement Amendment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#x201c;Maxim&#x201d;) entered into an amendment (the &#x201c;UWA Amendment&#x201d;) of the underwriting agreement between VCKA and Maxim dated January&#160;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&#160;(as defined in the UWA Amendment) as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#x2019;s shareholders, the balance in the trust account is $25,000,000&#160;or less, then the Deferred Underwriting Commission will be payable as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(A)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(B)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;the remaining&#160;50% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; anniversary of the effective date of a Business Combination. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA Amendment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Agreements to be Executed at Closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the &#x201c;Registration Rights Agreement&#x201d;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#x2019;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. &lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentsDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.</us-gaap:OtherCommitmentsDescription>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredUnitsAuthorized
      contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">750000000</us-gaap:PreferredUnitsAuthorized>
    <us-gaap:PreferredUnitsAuthorized
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">785000000</us-gaap:PreferredUnitsAuthorized>
    <sclx:MergerConsiderationDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#x201c;Merger Consideration&#x201d;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#x201c;Closing Date&#x201d;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#x201c;VCKA Common Stock&#x201d;).</sclx:MergerConsiderationDescription>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:SharesIssuedPricePerShare>
    <sclx:CommonStockAggregateValue
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="-8"
      unitRef="Unit_USD">1500000000</sclx:CommonStockAggregateValue>
    <us-gaap:BusinessCombinationReasonForBusinessCombination contextRef="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#x201c;Preferred Consideration&#x201d;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#x2019;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.</us-gaap:BusinessCombinationReasonForBusinessCombination>
    <sclx:NetTangibleAssets
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</sclx:NetTangibleAssets>
    <sclx:AggregatePercentage
      contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</sclx:AggregatePercentage>
    <sclx:WarrantsPercentage
      contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</sclx:WarrantsPercentage>
    <us-gaap:PreferredStockNoParValue
      contextRef="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockNoParValue>
    <sclx:BalanceInTheTrustAccount
      contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000000</sclx:BalanceInTheTrustAccount>
    <sclx:DeferredUnderwritingCommission
      contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</sclx:DeferredUnderwritingCommission>
    <sclx:DeferredUnderwritingCommissionPayable
      contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</sclx:DeferredUnderwritingCommissionPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7. SHAREHOLDERS&#x2019; DEFICIT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt;&#160;The Company is authorized to issue&#160;1,000,000&#160;preference shares with a par value of $0.0001&#160;per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;no&#160;preference shares issued or outstanding. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&#x2014; The Company is authorized to issue&#160;200,000,000&#160;ordinary shares with a par value of $0.0001&#160;per share. Holders of ordinary shares are entitled to one vote for each share. At September&#160;30, 2022, there were&#160;3,450,000&#160;shares of ordinary shares issued and outstanding, excluding&#160;9,726,395&#160;ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2021, there were&#160;3,450,000&#160;shares of ordinary shares issued and outstanding, excluding&#160;13,800,000&#160;ordinary shares subject to possible redemption which are presented as temporary equity. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">9726395</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:WarrantsTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8. WARRANTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,900,000&#160;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may redeem the Public Warrants: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $&lt;div style="display:inline;"&gt;0.01 &lt;/div&gt;per warrant; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at any time while the warrants become exercisable; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than &lt;div style="display:inline;"&gt;30 &lt;/div&gt;days&#x2019; prior written notice of redemption to each warrant holder; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $&lt;div style="display:inline;"&gt;18.00&#160;&lt;/div&gt;per share (subject to adjustment) for any &lt;div style="display:inline;"&gt;20 &lt;/div&gt;trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;30&lt;/div&gt;-trading&lt;/div&gt; day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;30&lt;/div&gt;-day&lt;/div&gt; trading period referred to above and continuing each day thereafter until the date of redemption. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $&lt;div style="display:inline;"&gt;9.20 &lt;/div&gt;per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than &lt;div style="display:inline;"&gt;60&lt;/div&gt;% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the &lt;div style="display:inline;"&gt;20 &lt;/div&gt;trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $&lt;div style="display:inline;"&gt;9.20 &lt;/div&gt;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to &lt;div style="display:inline;"&gt;115&lt;/div&gt;% of the higher of the Market Value and the Newly Issued Price, the $&lt;div style="display:inline;"&gt;18.00 &lt;/div&gt;per share redemption trigger price will be adjusted (to the nearest cent) to be equal to &lt;div style="display:inline;"&gt;180&lt;/div&gt;% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,840,000&#160;Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#x2019;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. &lt;/div&gt;&lt;/div&gt; </sclx:WarrantsTextBlock>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6900000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6900000</sclx:WarrantsOutstandingShares>
    <sclx:PublicWarrantsRedemptionDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The Company may redeem the Public Warrants:  &#160;


&#160;
&#x2022;
&#160;
in whole and not in part;   &#160;


&#160;
&#x2022;
&#160;
at a price of $0.01 per warrant;   &#160;


&#160;
&#x2022;
&#160;
at any time while the warrants become exercisable;   &#160;


&#160;
&#x2022;
&#160;
upon not less than 30 days&#x2019; prior written notice of redemption to each warrant holder;   &#160;


&#160;
&#x2022;
&#160;
if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and   &#160;


&#160;
&#x2022;
&#160;
if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.  </sclx:PublicWarrantsRedemptionDescription>
    <sclx:CapitalRaisingDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </sclx:CapitalRaisingDescription>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:WarrantsOutstandingShares>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: top;;text-align:left;"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: top;;text-align:left;"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: top;;text-align:left;"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, assets held in the Trust Account were comprised of $101,293,086&#160;and $139,410,739, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through September&#160;30, 2022, the Company did not withdraw any interest earned on the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at September&#160;30, 2022 and December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account &#x2013; U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,293,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability &#x2013; Private Placement Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Private Placement Warrants were accounted for as liabilities in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40&lt;/div&gt; and are presented within warrant liabilities on our accompanying September&#160;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;equivalent to their remaining contractual term. Inputs are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluated&lt;/div&gt; each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&#160;30, 2022 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides quantitative information regarding Level&#160;3 fair value measurements: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,104,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,625,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,693,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of September&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,856,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,504,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,762,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,530,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,231,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Option Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the change in the fair value of conversion option liability: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Option&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;10, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;27, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022 and September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account &#x2013; U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,293,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability &#x2013; Private Placement Warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:FairValueMeasurementsHighestAndBestUseDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be  equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period.  </us-gaap:FairValueMeasurementsHighestAndBestUseDescription>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.33</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.04</us-gaap:SharePrice>
    <sclx:FairValueMeasurementStrikePrice
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</sclx:FairValueMeasurementStrikePrice>
    <sclx:FairValueMeasurementStrikePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</sclx:FairValueMeasurementStrikePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0403</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <sclx:FairValueOfWarrantsinDollars
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.17</sclx:FairValueOfWarrantsinDollars>
    <sclx:FairValueOfWarrantsinDollars
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.49</sclx:FairValueOfWarrantsinDollars>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,104,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,625,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,693,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of September&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,856,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,504,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,762,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,530,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,231,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Option&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;10, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;27, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022 and September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</sclx:InitialMeasurementOne>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4104000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3625200</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">68400</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3693600</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4856400</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1504800</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">410400</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3762000</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2530800</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1231200</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-68400</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sclx:UnderlyingWarrantValue
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0</sclx:UnderlyingWarrantValue>
    <sclx:UnderlyingWarrantValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0103</sclx:UnderlyingWarrantValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <sclx:HoldingPeriod
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.5</sclx:HoldingPeriod>
    <sclx:HoldingPeriod
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.28</sclx:HoldingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18727</sclx:InitialMeasurementOne>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-11835</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:DerivativeLiabilities>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">69896</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">76788</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-76788</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 10. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#x201c;Debt Contribution Agreement&#x201d;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment of certain outstanding loans (the &#x201c;Company Obligations&#x201d;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt Contribution Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in exchange for the issuance of that number of shares of shares of common stock, par value $0.0001&#160;per share, of the Company, determined by dividing the Company Obligations by $10.00&#160;(the &#x201c;Contribution Shares&#x201d;) to the Sponsors immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Debt Exchange Agreement, on October&#160;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#x201c;Funding Commitment Letter&#x201d;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set forth in such written request. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#x201c;Warrant Transfer Agreement&#x201d;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;On October&#160;17, 2022, the Company entered into a Letter Agreement with Sorrento and the Sponsors (the &#x201c;Letter Agreement&#x201d;) to provide that certain shares held by the Sponsors will be released from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; restrictions only in an amount necessary to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&#160;1,500,000&#160;shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the Company&#x2019;s shareholders ahead of the extraordinary general meeting of the Company&#x2019;s shareholders on November&#160;9, 2022. &lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LeaseDepositLiability
      contextRef="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</us-gaap:LeaseDepositLiability>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockNoParValue>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <sclx:NumberOfSharesLimits
      contextRef="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1500000</sclx:NumberOfSharesLimits>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14268000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13126000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2562000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1145000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1835000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3314000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23003000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22424000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">846000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1675000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">42540000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">538000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">538000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">81504000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4284000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8120000</us-gaap:AccountsPayableCurrent>
    <sclx:AccruedPayroll
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3733000</sclx:AccruedPayroll>
    <sclx:AccruedPayroll
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3754000</sclx:AccruedPayroll>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10622000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37950000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15888000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">92724000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26664000</us-gaap:DueToRelatedPartiesCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19608000</sclx:RelatedPartyNotePayableCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13008000</sclx:RelatedPartyNotePayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">424000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">169420000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">78480000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">92255000</us-gaap:LongTermDebtNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23503000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15403000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</sclx:DerivativeLiabilityNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35400000</sclx:DerivativeLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1649000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">301808000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">223187000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">122423000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-264126000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">81504000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31317000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23560000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">21033000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3634000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2149000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5802000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9961000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10216000</us-gaap:ResearchAndDevelopmentExpense>
    <sclx:AcquiredinprocessresearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquiredinprocessresearchAndDevelopment>
    <sclx:AcquiredinprocessresearchAndDevelopment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquiredinprocessresearchAndDevelopment>
    <sclx:AcquiredinprocessresearchAndDevelopment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">75301000</sclx:AcquiredinprocessresearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50582000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">42970000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">64696000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3713000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67155000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">58818000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">159728000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-35838000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-35258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-138695000</us-gaap:OperatingIncomeLoss>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">300000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-800000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">23300000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12463000</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000000</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:ScilexPharmaNotesPrincipalIncrease>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11764000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13116000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16889000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">460000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">168000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">52581000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12314000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">39897000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47572000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197315</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">187524</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">187524</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">150270000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">73462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-38013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">35464000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">47040000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">54586000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54591000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-5800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197310000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">126578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-216607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-90009000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">56000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-9600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-9600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">122423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-264126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5822000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5822000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3779000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3777000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3750000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7909000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10664000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15033000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <sclx:IncreaseInNotesPayableOne
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000000</sclx:IncreaseInNotesPayableOne>
    <sclx:IncreaseInNotesPayableOne
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:IncreaseInNotesPayableOne>
    <sclx:IncreaseInNotesPayableOne
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:IncreaseInNotesPayableOne>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12487000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10866000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">372000</sclx:NonCashOperatingLeaseCosts>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">825000</sclx:NonCashOperatingLeaseCosts>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">528000</sclx:NonCashOperatingLeaseCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5822000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5395000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4330000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-23300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">75301000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1142000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">598000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">12356000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1417000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2379000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1116000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1479000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1035000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1307000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2580000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-88000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3836000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-4062000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4271000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-21000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1247000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1131000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2051000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3689000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-80000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-604000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-147000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18210000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5105000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1854000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-28664000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-31461000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-60421000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">584000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">17040000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-25000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-17624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33387000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">58927000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2334000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">48832000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47832000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11007000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47850000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18400000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14700000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10300000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">21628000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3518000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-19170000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-50656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-62269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">117764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54591000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable>
    <sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable>
    <sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">601000</sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1536000</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:OtherLoanForgiveness>
    <sclx:NonCashDistributionToAcquiree
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashDistributionToAcquiree>
    <sclx:NonCashDistributionToAcquiree
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9600000</sclx:NonCashDistributionToAcquiree>
    <sclx:NonCashDistributionToAcquiree
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5800000</sclx:NonCashDistributionToAcquiree>
    <sclx:NonCashIncreaseInPrincipal
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000000</sclx:NonCashIncreaseInPrincipal>
    <sclx:NonCashIncreaseInPrincipal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashIncreaseInPrincipal>
    <sclx:NonCashIncreaseInPrincipal
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashIncreaseInPrincipal>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10295000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">45200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021"> &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company (&#x201c;Scilex Holding&#x201d; and together with its wholly owned subsidiaries, &lt;div style="display:inline;"&gt;the&lt;/div&gt; &#x201c;Company&#x201d;) was incorporated in &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; Delaware in February&#160;2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;). The Company is a commercial-stage, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; pain management company focused on the development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October&#160;2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-hour&lt;/div&gt; administration period. The Company is currently developing two product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; (10 mg, dexamethasone sodium phosphate viscous gel), a Phase&#160;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-102&#x201d;),&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; for the treatment of acute low back pain. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;) pursuant to which the Company acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#x2019;s common stock (the &#x201c;Contribution&#x201d;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $16.5&#160;million &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#x2019;s prior wholly owned subsidiary (&#x201c;Merger Sub&#x201d;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x2019; Representative&#x201d;), and Sorrento, for limited purposes (the &#x201c;Merger Agreement&#x201d;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#x201c;Merger&#x201d;), with Semnur surviving as the Company&#x2019;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company. Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since inception, the Company had devoted substantially all of its efforts to the product development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;SP&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;-102&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; and the commercialization of ZTlido. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="P02_01_2019To02_28_2019">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <sclx:LiquidityAndGoingConcernTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern at least one year after the date the financial statements are issued. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31, 2021, the Company&#x2019;s negative working capital was $146.4&#160;million, including cash and cash equivalents of approximately $4.3&#160;million. During the year ended December&#160;31, 2021, the Company&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;had operating losses of $35.8&#160;million and negative cash flows from operations of $28.7&#160;million. The Company had an accumulated deficit of approximately $352.6&#160;million as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018, Scilex Pharma issued $224.0&#160;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $140.0&#160;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum unrestricted cash balance of $4.0&#160;million at the end of each month. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;2020, Scilex Pharma repurchased an aggregate of $65.0&#160;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $45.0&#160;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the purpose of consummating the repurchase of an aggregate of $45.0&#160;million of principal amount. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2021 and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;April&#160;&lt;/div&gt;2021, Scilex Pharma effected specified principal repurchases totaling $40.0&#160;million of the principal amount of the Scilex Pharma Notes. On December&#160;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $28.0&#160;million. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2022, Scilex Pharma drew down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#x2019;s obligation to repurchase $20.0&#160;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash balance of $10.0&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;&lt;/div&gt;&lt;/div&gt;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#x2019;s primary product candidate in development, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; as well in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; will be in excess of the Company&#x2019;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least &lt;/div&gt;&lt;/div&gt;twelve&#160;months from the issuance of these consolidated financial statements through debt and equity financing. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#x2019;s marketing of ZTlido. Should the Company&#x2019;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#x2019;s business plan, due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued. &lt;/div&gt; </sclx:LiquidityAndGoingConcernTextBlock>
    <sclx:NetWorkingCapital
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">146400000</sclx:NetWorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">4300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-35800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-28700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-352600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">224000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">140000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <sclx:MinimumUnrestrictedCashBalance
      contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:MinimumUnrestrictedCashBalance>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">65000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:RestrictedFundsRelesableForFutureRepurchaseOfDebt
      contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000</sclx:RestrictedFundsRelesableForFutureRepurchaseOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:DebtInstrumentRepurchaseObligation
      contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</sclx:DebtInstrumentRepurchaseObligation>
    <sclx:MinimumUnrestrictedCashBalance
      contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumUnrestrictedCashBalance>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-hand&lt;/div&gt; inventory. As of December&#160;31, 2021 and 2020, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and services that will be used &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 730, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The provisions of the FASB ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#x2019;s deferred tax assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#x2019;s revenue and accounts receivable result from a sole customer. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For product sales, the Company records &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt; sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net&lt;/div&gt;&lt;/div&gt; adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;administrators. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;During the fiscal years ended December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31, 2021, 2020 and 2019, sales to the Company&#x2019;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts &lt;/div&gt;&lt;/div&gt; for stock-based compensation in accordance with FASB ASC Topic 718,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Compensation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Compensation &lt;/div&gt;&lt;/div&gt;which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt; vesting period. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For purposes of determining &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#x2019;s consolidated statement of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt; are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-opioid&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October&lt;/div&gt;&lt;/div&gt;&#160;2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; is effective for fiscal&#160;years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December &lt;/div&gt;&lt;/div&gt;2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-hand&lt;/div&gt; inventory. As of December&#160;31, 2021 and 2020, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and services that will be used &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 730, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The provisions of the FASB ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#x2019;s deferred tax assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#x2019;s revenue and accounts receivable result from a sole customer. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For product sales, the Company records &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt; sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net&lt;/div&gt;&lt;/div&gt; adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sclx:RebatesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:RebatesPolicyTextBlock>
    <sclx:ServiceFeesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:ServiceFeesPolicyTextBlock>
    <sclx:SalesReturnsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:SalesReturnsPolicyTextBlock>
    <sclx:CoPaymentAssistancePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;administrators. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:CoPaymentAssistancePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;During the fiscal years ended December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31, 2021, 2020 and 2019, sales to the Company&#x2019;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts &lt;/div&gt;&lt;/div&gt; for stock-based compensation in accordance with FASB ASC Topic 718,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Compensation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Compensation &lt;/div&gt;&lt;/div&gt;which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt; vesting period. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For purposes of determining &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#x2019;s consolidated statement of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt; are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-opioid&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;br/&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October&lt;/div&gt;&lt;/div&gt;&#160;2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; is effective for fiscal&#160;years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December &lt;/div&gt;&lt;/div&gt;2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Semnur Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#x2019;s capital stock and options to purchase Semnur&#x2019;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $15.0&#160;million, and (b)&#160;$55.0&#160;million of shares of the Company&#x2019;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#x201c;Stock Consideration&#x201d;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately 58% of the Company&#x2019;s issued and outstanding capital stock. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#x201c;NDA&#x201d;) of a Semnur product by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (2)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (3)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (4)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;7, 2019, the Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#x2019;s first bona fide equity financing with one or more third-party financing sources on an arms&#x2019; length basis with gross proceeds to the Company of at least $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&#160;the &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share. The amendment resulted in a reclassification of $&lt;/div&gt;0.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million from additional &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capital to accrued liabilities.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2019, the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#x201c;Exchange Agreement&#x201d;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;months&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;following the closing of the Merger, &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period commencing the date that is the &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; month anniversary of the Closing (the &#x201c;Share Exchange&#x201d;), the Stock Consideration for shares of Sorrento&#x2019;s common stock with a value of $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million based on a price per share of Sorrento&#x2019;s common stock equal to the greater of (a)&#160;the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; trailing volume weighted average price of one share of Sorrento&#x2019;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b)&#160;$&lt;/div&gt;5.55&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#x201c;Exchange Price&#x201d;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, on October&#160;&lt;/div&gt;9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento paid $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cash to the Semnur Equityholders in lieu of issuing $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of Sorrento&#x2019;s&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;31, 2020, Sorrento held approximately 82.3% of the outstanding common stock of the Company. On January&#160;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately 99.97% of the outstanding common stock of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; As a result, approximately $&lt;/div&gt;75.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million was expensed as a component of acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development during the year ended December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recorded as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; since the related regulatory approval milestones are not deemed probable until they actually occur.&lt;/div&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">70000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">280000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">250000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">500000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">150000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">750000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer>
    <sclx:PeriodDuringWhichTheSharesMayBeExchanged contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P60D</sclx:PeriodDuringWhichTheSharesMayBeExchanged>
    <sclx:PeriodDuringWhichShareTransferIsRestricted contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P18M</sclx:PeriodDuringWhichShareTransferIsRestricted>
    <sclx:CommonStockValueToBeExchanged
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:CommonStockValueToBeExchanged>
    <sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P30D</sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares>
    <sclx:PricePerShareForDeterminingTheExchangeOfShares
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.55</sclx:PricePerShareForDeterminingTheExchangeOfShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">75300000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&#160;Active&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unobservable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inputs&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recorded a loss of $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, a gain of $&lt;/div&gt;0.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and a loss of $&lt;/div&gt;23.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million on derivative liabilities for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded features as further described in Note &lt;/div&gt;8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model. This involves significant Level&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; inputs and assumptions.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included a &lt;/div&gt;6.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk-adjusted net sales forecast and an effective debt yield of &lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included a &lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk-adjusted net sales forecast, an effective debt yield of &lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and an estimated probability of &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of not obtaining marketing approval before March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included an &lt;/div&gt;8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk adjusted net sales forecast, an effective debt yield of &lt;/div&gt;19.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and estimated probabilities of &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;55&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of not obtaining marketing approval before March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and July&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring prior to October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;in&#160;Active&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Markets&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Observable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inputs&#160;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unobservable&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inputs&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Level&#160;3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2020To12_31_2020"
      decimals="1"
      unitRef="Unit_USD">0.8</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">23300000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">6.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">15</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">15</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">19.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">55</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">10100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">23300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">33400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&#160;&amp;amp; equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for each of the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was $&lt;/div&gt;39&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand, $&lt;/div&gt;40&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand and $&lt;/div&gt;40&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&#160;&amp;amp; equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">691000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">932000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">934000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">127000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">846000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">39</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">40</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">40</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had recorded goodwill of $&lt;/div&gt;13.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Based upon the results of the qualitative testing, the Company concluded that it is &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; that the fair value of the Company&#x2019;s goodwill was in excess of the carrying value and therefore performing the first step of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; impairment test was unnecessary. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill impairment was recognized for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. &lt;/div&gt;A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the weighted average remaining life for identifiable intangible assets is &lt;/div&gt;10.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years. Aggregate amortization expense was $&lt;/div&gt;3.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for each of the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Patent rights and acquired technology are amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period. Assembled workforce is amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-year&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; impairment charges related to intangible assets were recorded during the&#160;years ended &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2021To12_31_2021">A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11239000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17186000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">275000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16268000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9064000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">23566000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3291000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18649000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">325000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12530000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">42540000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis">P10Y7M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3663000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3638000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3638000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20387000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2018 Purchase Agreements and Indenture &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#x201c;&lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Purchase Agreements&#x201d;) with certain investors (collectively, the &#x201c;Scilex Pharma Note Purchasers&#x201d;). Pursuant to the &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Purchase Agreements, on September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due &lt;/div&gt;2026&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in an aggregate principal amount of $&lt;/div&gt;224.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Scilex Pharma Notes&#x201d;) for an aggregate purchase price of $&lt;/div&gt;140.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Offering&#x201d;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#x201c;Indenture&#x201d;) with Scilex Pharma, as issuer, U.S. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bank &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;National&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Association, a national banking association, as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Collateral Agent&#x201d;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#x201c;Guarantee&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net proceeds of the Offering were approximately $&lt;/div&gt;89.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, after deducting the Offering expenses payable by Scilex Pharma and funding a segregated reserve account with $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Reserve Account&#x201d;) and a segregated collateral account with $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Collateral Account&#x201d;) pursuant to the terms of the Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#x2019;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with respect to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or a similar product with a concentration of not less than &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% (the &#x201c;Marketing Approval Letter&#x201d;) on or prior to July&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Funds in the Collateral Account were to be released to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On each February&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, May&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, August&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and November&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, beginning with February&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the holders of the Scilex Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed&#160;percentage, ranging from &lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;20&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex Pharma did not receive the Marketing Approval Letter by March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the&#160;percentage of net sales payable was increased to be in the range of &lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. If actual cumulative net sales of ZTlido from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; are less than approximately $&lt;/div&gt;218.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately $&lt;/div&gt;10.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and approximately $&lt;/div&gt;30.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; are less than approximately $&lt;/div&gt;218.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the Indenture, the aggregate principal amount due under the Scilex Pharma Notes was to be increased by $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million on February&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; if actual cumulative net sales of ZTlido from September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; were less than approximately $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; did not equal or exceed the $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million threshold for such period, the Company recorded the increase of $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If actual cumulative net sales of ZTlido for the period from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; are less than approximately $&lt;/div&gt;290.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on &lt;/div&gt;November 15, 2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; by between approximately $&lt;/div&gt;2.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and approximately $&lt;/div&gt;84.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, with the amount of the principal increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; is less than approximately $&lt;/div&gt;290.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The final maturity date of the Scilex Pharma Notes is &lt;/div&gt;August 15, 2026&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Scilex Pharma Notes may be redeemed in whole at any time upon &lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days&#x2019; written notice at Scilex Pharma&#x2019;s option prior to August&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2026&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a redemption price equal to 100% of the then-outstanding principal amount of the Scilex Pharma Notes. In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#x2019;s Scilex Pharma Note at a repurchase price in cash equal to 101% of the then-outstanding principal amount &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thereof. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The 2018 Purchase&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agreements include the terms and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;type. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% in principal amount of the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become due and payable.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger, amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#x201c;Collateral Agreement&#x201d;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or modifications of such product made, developed or licensed (or &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-licensed)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; by Scilex Pharma or any of its affiliates or licensees (or &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-licensees)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (including &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (the &#x201c;Letter of Credit&#x201d;), which provides that, in the event that &lt;/div&gt;(1)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Scilex Pharma did not hold at least $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in unrestricted cash as of the end of any calendar month during the term of the Scilex Pharma Notes, &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;actual cumulative net sales of ZTlido from September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; were less than a specified sales threshold for such period, or &lt;/div&gt;(3)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento would be required to pay to Scilex Pharma, $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&#160;the repayment of the Scilex Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exchange by the Company that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On December&#160;14, 2020, Scilex,&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex Note Purchasers entered into a Consent Under and Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to Indenture and Letter of Credit (&#x201c;Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201d;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Holders agreed to release all of the aggregate $&lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in restricted funds held in the Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $&lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount of the Scilex Pharma Notes from the Holders on a pro&#160;rata basis at a purchase price equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the principal amount thereof (such repurchase, the &#x201c;Scilex Repurchase&#x201d;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&#160;Sorrento&#x2019;s obligations under the Indenture to repurchase $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&#160;Scilex Pharma&#x2019;s obligation to repurchase $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing Approval Letter on or prior to&lt;/div&gt; July 1, 2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. On December&#160;&lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, be equal to at least $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the aggregate, provided that if Scilex Pharma did not effectuate (i)&#160;the December Optional Repurchase (as defined below) and (ii)&#160;at least one of either (x)&#160;the February Optional Repurchase (as defined below) or (y)&#160;the April Optional Repurchase (as defined below), then, commencing with the month ending April&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and for each month thereafter, such amount would have been required to be at least $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will be required to draw on the Letter of Credit.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; also provided Scilex Pharma with the option, in its sole and absolute discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis on each of December&#160;&lt;/div&gt;16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;December Optional Repurchase&#x201d;), February&#160;&lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;February Optional Repurchase&#x201d;) and April&#160;&lt;/div&gt;13&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;April Optional Repurchase&#x201d;), in each case in an aggregate amount equal to the lesser of $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by $&lt;/div&gt;60.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and resulted in the minimum unrestricted requirement remaining at $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; further provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis in an aggregate amount equal to the lesser of $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on, Scilex Pharma is required to have minimum cash of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million at all times thereafter. In February&#160;&lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of the principal amount of the Scilex Pharma Notes and became subject to a minimum cash requirement of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Holders also consented to Scilex Pharma incurring up to $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounted for Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; as a debt modification under ASC Topic &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-50&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; as modified terms were not substantially different than the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-modified&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; terms. The execution of Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; resulted&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;in an additional derivative liability of $&lt;/div&gt;2.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which pertains to a $&lt;/div&gt;9.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $&lt;/div&gt;6.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million reduction to the debt discount on the Scilex Pharma Notes.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow method under the income approach, which involves significant Level&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and the discounted rate of return reflective of the Company&#x2019;s credit &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;risk. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Pharma Notes are as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;97,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden61004186"&gt;92,25&lt;/span&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum future payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company made principal payments of $&lt;/div&gt;45.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;69.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;2.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million during the fiscal&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt discount and debt issuance costs, which are presented as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a&#160;percentage of net sales of ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was &lt;/div&gt;7.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;9.15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%, respectively. The amount of debt discount and debt issuance costs included in interest expense for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was approximately $&lt;/div&gt;7.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;10.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note &lt;/div&gt;5)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; this assessment each reporting period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the holders of at least &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes of the Scilex Pharma Notes, an event of default includes, among other things, (i)&#160;Scilex Pharma&#x2019;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&#160;Scilex Pharma&#x2019;s breach of its representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&#160;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma. The Company is in compliance with event of default clauses.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Notes Payable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;&lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma issued to Sorrento a promissory note (see Note &lt;/div&gt;13)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. On March&#160;&lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a note payable with Sorrento (see Note &lt;/div&gt;13)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2020 Revolving Credit Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;&lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into the Credit and Security Agreement (the &#x201c;Credit Agreement&#x201d;) with CNH Finance Fund&#160;I, L.P. (&#x201c;CNH&#x201d;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus &lt;/div&gt;1.75&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2024&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;; unless the Credit Agreement is earlier terminated. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the outstanding balance was $&lt;/div&gt;8.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;9.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. On February&#160;&lt;/div&gt;16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company notified CNH that it was terminating the Credit Agreement, effective &lt;/div&gt;March 18, 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Upon termination, all principal balances and interest accrued were &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;settled.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Paycheck Protection Program &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May&#160;&lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company received the proceeds from a loan in the amount of $&lt;/div&gt;1.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;PPP Loan&#x201d;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). The PPP Loan matures on &lt;/div&gt;May 05, 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and bears interest at a rate of &lt;/div&gt;1.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% per annum. The PPP Loan is evidenced by a promissory note dated May &lt;/div&gt;03&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Note&#x201d;), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;warranties.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $&lt;/div&gt;100,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, prorated annually. Not more than &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the forgiven amount may be for &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-payroll&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $&lt;/div&gt;100,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or less annually are reduced by more than &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May&#160;&lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a gain on debt extinguishment of $&lt;/div&gt;1.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentTerm contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">P2026Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">224000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">140000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">89300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <sclx:PaymentToDepositIntoASeggregateReserveFund
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</sclx:PaymentToDepositIntoASeggregateReserveFund>
    <sclx:PaymentToDepositIntoASegregatedCollateralAccount
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</sclx:PaymentToDepositIntoASegregatedCollateralAccount>
    <sclx:PercentageOfConcentrationOnASimilarProduct
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</sclx:PercentageOfConcentrationOnASimilarProduct>
    <sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage
      contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage>
    <sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage
      contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage>
    <sclx:PercentageOfNetSalesPayable
      contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</sclx:PercentageOfNetSalesPayable>
    <sclx:PercentageOfNetSalesPayable
      contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfNetSalesPayable>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">218100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10100000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30600000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">218100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">481000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">290700000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">2023-11-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">2600000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">84800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2026-08-15</us-gaap:DebtInstrumentMaturityDate>
    <sclx:DebtInstrumentredemptionPeriod contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">P30D</sclx:DebtInstrumentredemptionPeriod>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:PercentageOfThePrincipalAmountFromHoldersOnProRataBasis
      contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfThePrincipalAmountFromHoldersOnProRataBasis>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis">2023-07-01</us-gaap:DebtInstrumentMaturityDate>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:PercentageOfThePrincipalAmountOfTheNotes
      contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfThePrincipalAmountOfTheNotes>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes
      contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:PercentageOfThePrincipalAmountOfTheNotes
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfThePrincipalAmountOfTheNotes>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RepaymentsOfDebt>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <sclx:LineOfCreditFacilityindebtednessAmount
      contextRef="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:LineOfCreditFacilityindebtednessAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:DerivativeLiabilities>
    <sclx:AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes
      contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">9600000</sclx:AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">6800000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Pharma Notes are as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;97,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden61004186"&gt;92,25&lt;/span&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">133997000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">151872000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">30597000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">51022000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2228000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3711000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">101172000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">97139000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">29135000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4881000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">115400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">122300000</us-gaap:LongTermDebtFairValue>
    <sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 4pt; margin-bottom: 6pt; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 4pt; margin-bottom: 6pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 4pt; margin-bottom: 6pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum future payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock>
    <sclx:LongtermDebtfutureMinimumPaymentYearOne
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">29135000</sclx:LongtermDebtfutureMinimumPaymentYearOne>
    <sclx:LongtermDebtFutureMinimumPaymentYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12005000</sclx:LongtermDebtFutureMinimumPaymentYearTwo>
    <sclx:LongtermDebtFutureMinimumPaymentYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13637000</sclx:LongtermDebtFutureMinimumPaymentYearThree>
    <sclx:LongtermDebtFutureMinimumPaymentYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14746000</sclx:LongtermDebtFutureMinimumPaymentYearFour>
    <sclx:LongtermDebtFutureMinimumPaymentYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">64474000</sclx:LongtermDebtFutureMinimumPaymentYearFive>
    <sclx:LongtermDebtFutureMinimumPayment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">133997000</sclx:LongtermDebtFutureMinimumPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">45900000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">69800000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">2300000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.077</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0915</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">7900000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10700000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <sclx:LineOfCreditFacilityindebtednessAmount
      contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:LineOfCreditFacilityindebtednessAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">8800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">9500000</us-gaap:LongTermDebt>
    <sclx:DebtInstrumentTerminationDate contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2022-03-18</sclx:DebtInstrumentTerminationDate>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">2022-05-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <sclx:MaximumCompensationCostToBeAvailableProratedBasis
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      unitRef="Unit_USD">100000</sclx:MaximumCompensationCostToBeAvailableProratedBasis>
    <sclx:PercentageOfLoanForgivenessUnderTheAct
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfLoanForgivenessUnderTheAct>
    <sclx:MinimumPayrollCostToBeAvailable
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis"
      decimals="0"
      unitRef="Unit_USD">100000</sclx:MinimumPayrollCostToBeAvailable>
    <sclx:PercentageOfLoanForgivenessUnderTheAct
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfLoanForgivenessUnderTheAct>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total number of authorized shares of preferred stock of Scilex Holding is &lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, of which &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;shares were issued and outstanding at December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The total number of authorized shares of common stock of Scilex Holding is &lt;/div&gt;350,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, of which &lt;/div&gt;197,266,338&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares were issued and outstanding at&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive and Employee Benefit Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2017 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June&#160;&lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Equity Incentive Plan (the &#x201c;Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan&#x201d;). The Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan reserved &lt;/div&gt;24.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of Scilex Pharma common stock. &lt;/div&gt;Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; The Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan was amended and restated on July&#160;&lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the Merger Closing, the Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Equity Incentive Plan was terminated, and each option to purchase Scilex Pharma&#x2019;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The board of directors of the Company adopted the Scilex Holding Company &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan (the &#x201c;&lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan&#x201d;) on May&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan was approved by the Company&#x2019;s stockholders on June&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;30.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock of the Company were reserved for issuance pursuant to the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan. On December&#160;&lt;/div&gt;21&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the board of directors approved an amendment to the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan to reserve an additional &lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock for issuance under the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock of the Company were reserved for issuance pursuant to the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan. &lt;/div&gt;Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, options to purchase &lt;/div&gt;28,163,510&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase &lt;/div&gt;26,743,510&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding under the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan and options to purchase &lt;/div&gt;1,420,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;18,256,490&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock were reserved for awards available for future issuance under the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation recorded within operating expenses was $&lt;/div&gt;5.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;5.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;4.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total unrecognized compensation costs related to unvested employee and nonemployee stock option grants as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was $&lt;/div&gt;8.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and the weighted average period over which these grants are expected to vest is &lt;/div&gt;1.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Option Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$0.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#160;$0.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock-price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;89.00%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;104.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;0.53%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;1.63%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;2.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.76&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;6.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value per share of common stock on date of grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#x2019;s common stock.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected stock-price volatility&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;zero-coupon&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; bonds with maturities similar to those of the expected term of the award being valued.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected term of options&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Holding issued stock options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;March&#160;17 and March&#160;31, 2019 Valuations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;performed on March&#160;&lt;/div&gt;17&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the fair value of the Company&#x2019;s common stock was estimated using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#x201c;OPM&#x201d;) to allocate the concluded equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#x2019;s common stock of $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share as of March&#160;&lt;/div&gt;17&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;May&#160;31, 2019 Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation performed on May&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the fair value of the Company&#x2019;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#x201c;PWERM&#x201d;), which estimates the value by&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#x2019;s best estimates at the time) each scenario&#x2019;s common stock value to arrive at the Company&#x2019;s concluded common stock value. This valuation resulted in a valuation of the Company&#x2019;s common stock of $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share as of May&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;December&#160;31, 2019 Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation performed on December&#160;31, 2019, the fair value of the Company&#x2019;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#x2019;s best estimates at the time) each scenario&#x2019;s common stock value to arrive at the Company&#x2019;s concluded common stock value. This valuation resulted in a valuation of the Company&#x2019;s common stock of $1.16 per share as of December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;July&#160;31, 2020 Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation performed on July&#160;31, 2020, the fair value of the Company&#x2019;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#x2019;s best estimates at the time) each scenario&#x2019;s common stock value to arrive at the Company&#x2019;s concluded common stock value. This valuation resulted in a valuation of the Company&#x2019;s common stock of $1.16 per share as of July&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(838&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,641&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.68&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;915&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,177&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.11&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains a defined contribution &lt;/div&gt;401&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the &lt;/div&gt;401&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(k) plan totaling $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for each of the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">24000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">30000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">15000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">45000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">28163510</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">26743510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1420000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">18,256,490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">8800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021">The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$0.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#160;$0.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock-price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;89.00%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;104.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;0.53%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;1.63%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;2.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.76&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;6.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value per share of common stock on date of grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.83</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.87</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn03_17_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn05_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn07_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(838&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,641&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.68&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;915&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,177&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.11&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">4781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">1291000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">21468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">838000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">25411000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">6194000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">56000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">30804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2172000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">2641000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">28163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">915000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">17177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2013&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; parties (the &#x201c;Developers&#x201d;), &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of which is ITOCHU CHEMICAL FRONTIER Corporation (&#x201c;Itochu&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;35&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; aggregate royalty payments. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;October 2, 2028&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the date that is &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten&lt;/div&gt; years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; renewal periods unless Scilex Pharma or the Developers terminate it upon &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6-month&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if &lt;/div&gt;(1)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within &lt;/div&gt;180&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days after notice requesting to cure; &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; &lt;/div&gt;(3)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma&#x2019;s total net profits of the Products are equal to or less than &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of Scilex Pharma&#x2019;s net sales of the Products for a period of &lt;/div&gt;four&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more consecutive quarters, or (b)&#160;the Products&#x2019; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b)&#160;after &lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days of good-faith discussion; &lt;/div&gt;(4)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or &lt;/div&gt;(5)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Scilex Pharma or either &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of the Developers are bankrupt or make assignment for the benefit of creditors.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Up to the date the financial statements were issued, Scilex&#x2019;s net profits for ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; have not exceeded &lt;/div&gt;five&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#x201c;Refusal to File&#x201d; for any of the Products&#x2019; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-file.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within &lt;/div&gt;three&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;&lt;/div&gt;16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Developers to provide commercial supply of ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Exclusive Distribution Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August&#160;&lt;/div&gt;2015&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) to appoint an exclusive third-party logistics distribution provider (the &#x201c;Distributor&#x201d;) and as an authorized distributor of record of ZTlido (&#x201c;Product&#x201d;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a &lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% annual adjustment. The Distribution Agreement has an initial term of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;three&lt;/div&gt; years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following the first shipment of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Product to a commercial customer and shall automatically renew for additional terms of &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; year each, unless written notice of termination is given by either party at least &lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all product recalls, except in the event where the recalls arise from the Distributor&#x2019;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#x2019;s facility, including all costs, expenses and risk of loss associated with such delivery. From late &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to early &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between &lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% which was recorded as a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; sales adjustment. Beginning in &lt;/div&gt;April 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma began directly selling and transferring title to distributors.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales Operations Services &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January&#160;&lt;/div&gt;2016&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September&#160;&lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Project Agreement&#x201d;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will remain in effect until June&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and may be extended for additional periods of &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; year upon the mutual agreement of both parties. Either party may terminate the work order with &lt;/div&gt;90&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days&#x2019; notice. Scilex Pharma paid an implementation fee of $&lt;/div&gt;59.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand and will pay fixed monthly fees of $&lt;/div&gt;63.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand to $&lt;/div&gt;65.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand for ongoing services.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized an expense of $&lt;/div&gt;1.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;10.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;25.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million within selling, general and administrative expenses for services performed for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, including implementation fees, fixed monthly fees and pass-through costs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company may be named as a defendant in &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more lawsuits. Other than the following &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; lawsuits, the Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; manufacturers of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (OTC) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March&#160;&lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax Pharmaceuticals, Inc., a company now headed by Mr.&#160;Mack,&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;alleging&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, among other things, breach by Mr.&#160;Mack of his &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement with the Company and his fiduciary duties to the Company, and tortious interference by Virpax with that &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement. Both lawsuits are ongoing.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases administrative and research and development facilities under various &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company&#x2019;s leases have remaining lease terms of approximately &lt;/div&gt;2.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to &lt;/div&gt;2.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years. The term of the Company&#x2019;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from &lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years. Many of the Company&#x2019;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company has &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; finance leases.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease expense were as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term in&#160;years&#160;&#x2014;&#160;operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&#160;&#x2014;&#160;operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;Operating&lt;/div&gt; lease expense totaled approximately $&lt;/div&gt;0.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;1.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;0.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.35</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:AgreementExpirationDate contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">2028-10-02</sclx:AgreementExpirationDate>
    <sclx:AgreementExpirationTerm contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P10Y</sclx:AgreementExpirationTerm>
    <sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P1Y</sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm>
    <sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P6M</sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal>
    <sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P180D</sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement>
    <sclx:ThresholdMinimumPercentageOfSales
      contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</sclx:ThresholdMinimumPercentageOfSales>
    <sclx:PercentageOfAnnualAdjustmentToFees
      contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</sclx:PercentageOfAnnualAdjustmentToFees>
    <sclx:AgreementExpirationTerm contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">P3Y</sclx:AgreementExpirationTerm>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:NoticePeriodForTerminationOfWorkOrder contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis">P90D</sclx:NoticePeriodForTerminationOfWorkOrder>
    <sclx:WorkOrderImplementationFee
      contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">59000</sclx:WorkOrderImplementationFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">63700</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">65800</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1900000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">10500000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">25300000</sclx:SellingGeneralAndAdministrativeExpenses>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis">P2Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis">P2Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease expense were as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="Fact_61002970"
      unitRef="Unit_USD">623000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      id="Fact_61002969"
      unitRef="Unit_USD">904000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      id="Fact_61002968"
      unitRef="Unit_USD">776000</us-gaap:OperatingLeaseCost>
    <sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term in&#160;years&#160;&#x2014;&#160;operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&#160;&#x2014;&#160;operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-654</sclx:OperatingCashFlowsFromOperatingLeases>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-833</sclx:OperatingCashFlowsFromOperatingLeases>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P3Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">674000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">596000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1964000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">316000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1648000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense limitations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,753&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,412&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(56,643&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43,514&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,296&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,898&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Tax Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(2,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;(319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"&gt;(412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $&lt;/div&gt;56.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;43.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million against its deferred tax assets as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively. Realization of the deferred tax assets will &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;e &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;primarily&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;dependent upon the Company&#x2019;s ability to generate sufficient taxable income prior to the expiration of its net operating losses.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s benefit from income taxes are as follows for the year ended December 31: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory Federal Income Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt discount and interest limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Return to provision adjustments and carryback&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Tax Benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had net operating loss carryforwards of approximately $&lt;/div&gt;167.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for federal and $&lt;/div&gt;81.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in &lt;/div&gt;2034&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; for state and &lt;/div&gt;2035&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; for federal, except for $&lt;/div&gt;154.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of the federal net operating losses that have an indefinite carryforward period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#x2019;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the&#160;years ended December&#160;31, 2021, 2020, and 2019, there was no impact of such limitations on the Company&#x2019;s income tax provision.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company also has research and development and orphan drug credits of approximately $&lt;/div&gt;2.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in &lt;/div&gt;2035&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the Company&#x2019;s tax&#160;years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies the accounting guidance for uncertainty in income taxes pursuant to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC-740-10.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#x201c;more likely than not&#x201d; to be sustained upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a &lt;/div&gt;50&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% likelihood of being sustained.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The unrecognized tax benefits balances as of December&#160;31, 2021, 2020 and 2019 and the related increases and decreases to the balances were immaterial.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; interest and penalties have been recognized as of and for the periods ended December&#160;31, 2021, 2020 and 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that no material amount of liabilities for uncertain tax positions will expire within 12&#160;months of December&#160;31, 2021.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense limitations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,753&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0); width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,412&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(56,643&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43,514&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,296&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,898&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Tax Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(2,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;(319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 0.75pt solid black;;text-align:right;"&gt;(412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <sclx:DeferredTaxAssetsInterestExpenseLimitations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12205000</sclx:DeferredTaxAssetsInterestExpenseLimitations>
    <sclx:DeferredTaxAssetsInterestExpenseLimitations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8225000</sclx:DeferredTaxAssetsInterestExpenseLimitations>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1630000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1623000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39714000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">31732000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3233000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2037000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">404000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">510000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1753000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2285000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">58939000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46412000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">56643000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43514000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2296000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2898000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1975000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2486000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">319000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">412000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2296000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2898000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">56600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">43500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s benefit from income taxes are as follows for the year ended December 31: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory Federal Income Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt discount and interest limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Return to provision adjustments and carryback&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Tax Benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.101</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.017</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.11</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.027</sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback>
    <sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.112</sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback>
    <sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0</sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.148</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.132</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.142</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">167500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">81700000</us-gaap:OperatingLossCarryforwards>
    <sclx:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2034</sclx:OperatingLossCarryforwardsExpirationYear>
    <sclx:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2035</sclx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">154800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</us-gaap:TaxCreditCarryforwardAmount>
    <sclx:TaxCreditCarryforwardExpirationYear contextRef="P01_01_2021To12_31_2021">2035</sclx:TaxCreditCarryforwardExpirationYear>
    <sclx:MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.50</sclx:MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#x2019;s board of directors, was Semnur&#x2019;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and (b)&#160;$&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of the Company&#x2019;s common stock (&lt;/div&gt;47,039,315&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issued and &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issuable, valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately &lt;/div&gt;58&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding capital stock as of December&#160;31, 2019. Following the completion of the Semnur Share Exchange and as of December&#160;31, 2020, Sorrento held approximately &lt;/div&gt;82.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, 2020 and 2019, the Company purchased approximately $&lt;/div&gt;5.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;1.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;8.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#x2019;s statement of operations. As of December&#160;31, 2020, approximately &lt;/div&gt;14.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding capital stock of the Company was held by Itochu. On January&#160;13, 2021, &lt;/div&gt;34,889,868&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-related&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;13, 2021. On January&#160;29, 2021, Sorrento acquired &lt;/div&gt;34,889,868&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;99.97&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#x201c;Assignment Agreement&#x201d;), with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who has served on the Company&#x2019;s board of directors since March&#160;2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-single&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; To date, the Company has made no royalty payments pursuant to the Assignment Agreement.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;1, 2017, a Transition Services Agreement (&#x201c;TSA&#x201d;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#x2019;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the&#160;years ended December&#160;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;2.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;0.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $&lt;/div&gt;16.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The note is interest bearing at the lesser of (a)&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&#160;31, 2021 and 2020 was $&lt;/div&gt;19.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;13.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under the current related party note&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; payable in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/div&gt;3.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;2.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $&lt;/div&gt;21.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#x201c;Intercompany Note&#x201d;). Scilex Pharma may borrow up to an aggregate of $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a)&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maximum &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company &lt;/div&gt;24,117,608&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock in exchange for the repayment of $&lt;/div&gt;21.7&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of indebtedness under this promissory note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $&lt;/div&gt;8.1&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;10.3&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, under the promissory note. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the promissory note of $&lt;/div&gt;3.1&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1.0&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, Scilex Pharma&#x2019;s outstanding principal balance under the promissory note was $&lt;/div&gt;23.5&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;15.4&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received $&lt;/div&gt;17.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, in February&#160;2021 and April&#160;2021, respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February&#160;2021 and April&#160;2021, totaling $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, as described in Note 8. The $&lt;/div&gt;37.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received in February&#160;2021 and April 2021 is due on demand to Sorrento and was recorded under the related party payables in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2021, related party payables due to Sorrento included $&lt;/div&gt;35.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements, $&lt;/div&gt;51.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes, and $&lt;/div&gt;6.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to pay litigation fees (see Note 11). As of December&#160;31, 2020, related party payables due to Sorrento consisted of $&lt;/div&gt;13.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements and $&lt;/div&gt;13.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">5700000</sclx:PaymentToAcquireInventory>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1000000</sclx:PaymentToAcquireInventory>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">8400000</sclx:PaymentToAcquireInventory>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.147</sclx:PercentageOfSharesOutstanding>
    <sclx:NumberOfSharesOutstanding
      contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesOutstanding>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesAcquired>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2300000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19600000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</us-gaap:NotesPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2600000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn10_02_2018"
      decimals="0"
      unitRef="Unit_shares">24117608</sclx:NumberOfSharesAcquired>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:RepaymentsOfDebt>
    <sclx:AccruedInterest
      contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">8100000</sclx:AccruedInterest>
    <sclx:AccruedInterest
      contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">10300000</sclx:AccruedInterest>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">15400000</us-gaap:LongTermNotesPayable>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">17300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">37300000</us-gaap:DueToRelatedPartiesCurrent>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">35700000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">51000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LegalFees
      contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">6000000</us-gaap:LegalFees>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">13700000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the&#160;years ended December&#160;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(178,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjusted for Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the&#160;years ended December&#160;31, 2021, 2020, and 2019 of &lt;/div&gt;28.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, &lt;/div&gt;30.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and &lt;/div&gt;25.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(47,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(178,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Adjusted for Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">197315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">187524000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-2"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-2"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-2"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">197315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">187524000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_shares">28200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_shares">30800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_shares">25400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following events were identified subsequent to the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SPAC Transaction &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#x201c;Merger Agreement&#x201d;) with Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of Vickers (&#x201c;Merger Sub&#x201d;). Pursuant to the terms of the Merger Agreement, (i)&#160;Merger &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sub will &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;merge with and into the Company&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;, with the Company surviving the merger (&#x201c;combined company&#x201d;) and (ii)&#160;become a wholly&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;owned subsidiary of Vickers (collectively, the &#x201c;SPAC Transaction&#x201d;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Pharma Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February&#160;2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million at a purchase price in cash equal&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;to 100% of the principal amount. In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $10.0&#160;million at all times going &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;forward. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million sales threshold for such period.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances on Related Party Note Payable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;30, 2022, Sorrento made advances to the Company in the amount of $&lt;/div&gt;23.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million under the related party note payable entered into on March&#160;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;payable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition from Sorrento &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On May&#160;12, 2022&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#x2019;s Delayed Burst Release Low Dose Naltrexone &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(DBR-LDN)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets&#x201d;) and the Company is currently analyzing the accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) in April 2021 pursuant to an asset purchase agreement (the &#x201c;Aardvark Asset Purchase Agreement&#x201d;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Acquisition&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Acquisition, the Company issued a promissory note in the aggregate principal amount of $&lt;/div&gt;5.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to Sorrento (the &#x201c;2022 Promissory Note&#x201d;). The 2022 Promissory Note matures &lt;/div&gt;seven years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/div&gt;2.66&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#x201c;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consideration Shares&#x201d;) or any combination thereof, at the Company&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within &lt;/div&gt;60&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; days of the issuance of such Consideration Shares.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i)&#160;$&lt;/div&gt;3,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Aardvark Asset Purchase Agreement) (which amount may be paid in shares of the Company&#x2019;s common stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii)&#160;$&lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the LDN Formulation (the &#x201c;Commercial Product&#x201d;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with its acquisition of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets, the Company has agreed that if it issues any shares of the Company&#x2019;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within &lt;/div&gt;60&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;days following the date on which any such shares are issued.&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tien-Li&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Lee, MD, a member of the board of directors of the Company, is the founder, chief executive officer and a member of the board of directors of Aardvark.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <sclx:PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan>
    <us-gaap:RestrictedCash
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:SalesThresholdLimit
      contextRef="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">481000000</sclx:SalesThresholdLimit>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">23000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P60D</sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">20000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement contextRef="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P60D</sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">17474000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14268000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">933000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2562000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">10583000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1835000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">31473000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23003000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">782000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1271000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41617000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">153000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">538000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">88777000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">11684000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4284000</us-gaap:AccountsPayableCurrent>
    <sclx:AccruedPayroll
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1426000</sclx:AccruedPayroll>
    <sclx:AccruedPayroll
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3733000</sclx:AccruedPayroll>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">23862000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">133000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37950000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">166145000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">92724000</us-gaap:DueToRelatedPartiesCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">47108000</sclx:RelatedPartyNotePayableCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19608000</sclx:RelatedPartyNotePayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">717000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">251075000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">169420000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3517000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">62717000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23503000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:DerivativeLiabilityNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</sclx:DerivativeLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">863000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">318172000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">301808000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">197566338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">197566338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">128615000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-358030000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-229395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">88777000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">26115000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">23054000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6284000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2549000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6457000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">7031000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41371000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">36092000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2896000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2803000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">57008000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">48475000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-30893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-25421000</us-gaap:OperatingIncomeLoss>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5300000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-100000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-28634000</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">12463000</sclx:GainLossOnExtinguishmentOfDebtt>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">8596000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">8617000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-39000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-25377000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">21028000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5516000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46449000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-36000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">197550</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">197550</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4127000</sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount>
    <sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-4127000</sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount>
    <sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-35000</sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization>
    <sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-35000</sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4027000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4027000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197566000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-358030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-229395000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">122423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-264126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">127200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-310585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-183365000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2926000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2832000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3108000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">5904000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21190000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11813000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">28634000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">351000</sclx:NonCashOperatingLeaseCosts>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">276000</sclx:NonCashOperatingLeaseCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4027000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4368000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3206000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-517000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1629000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-186000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3478000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1647000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">385000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2967000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2784000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-2307000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">12403000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-522000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-255000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21521000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">13765000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-20533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-22707000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2060000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-2067000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">84808000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">32376000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">18800000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">36900000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">9857000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">34799000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">51900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">45050000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">62500000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11500000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">20745000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">22073000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1855000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4205000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3650000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1536000</sclx:OtherLoanForgiveness>
    <sclx:PromissoryNoteIssuedNetOfDiscount
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4162000</sclx:PromissoryNoteIssuedNetOfDiscount>
    <sclx:PromissoryNoteIssuedNetOfDiscount
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:PromissoryNoteIssuedNetOfDiscount>
    <sclx:NonCashFairValueAdjustmentToDerivativeLiability
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">30400000</sclx:NonCashFairValueAdjustmentToDerivativeLiability>
    <sclx:NonCashFairValueAdjustmentToDerivativeLiability
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashFairValueAdjustmentToDerivativeLiability>
    <sclx:NonCashRightOfUseAsset
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">320000</sclx:NonCashRightOfUseAsset>
    <sclx:NonCashRightOfUseAsset
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashRightOfUseAsset>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company (&#x201c;Scilex Holding&#x201d; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#x201c;Sorrento&#x201d;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-hour&lt;/div&gt; administration period. The Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt; prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; (10&#160;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-102&#x201d;&lt;/div&gt; or &#x201c;SEMDEXA&#x201d;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; for the treatment of acute low back pain, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; (4.5 mg, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-dose&lt;/div&gt; naltrexone hydrochloride delayed-release capsules) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-104&#x201d;),&lt;/div&gt; a novel formulation for the treatment of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fibromyalgia. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;) pursuant to which the Company acquired &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#x2019;s common stock (the &#x201c;Contribution&#x201d;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $&lt;/div&gt;16.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#x2019;s prior wholly-owned subsidiary (&#x201c;Merger Sub&#x201d;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x2019; Representative&#x201d;), and Sorrento, for limited purposes (the &#x201c;Merger Agreement&#x201d;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#x201c;Merger of Semnur&#x201d;), with Semnur surviving as the Company&#x2019;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since inception, the Company had devoted substantially all of its efforts to the product development of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and the commercialization of ZTlido.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/&gt;&lt;div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#x201c;BCA&#x201d;) with Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a special purpose acquisition&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company, and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#x201c;Vickers Merger Sub&#x201d;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#x201c;Legacy Scilex&#x201d;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#x201c;Business Combination&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $&lt;/div&gt;12.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $&lt;/div&gt;290.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#x201c;Scilex Holding Company&#x201d; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November&#160;&lt;/div&gt;11&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#x201c;New Scilex.&#x201d;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill or other intangible assets recorded.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had capitalized $&lt;/div&gt;7.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of costs incurred in relation to the Business Combination. There were &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capitalized costs in relation to the Business Combination as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#x2019;s &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; fiscal year, or any subsequent period.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, there have been &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; beginning on page &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;F-48&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; thereof.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#x201c;BCA&#x201d;) with Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a special purpose acquisition&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company, and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#x201c;Vickers Merger Sub&#x201d;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#x201c;Legacy Scilex&#x201d;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#x201c;Business Combination&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $&lt;/div&gt;12.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $&lt;/div&gt;290.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#x201c;Scilex Holding Company&#x201d; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November&#160;&lt;/div&gt;11&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#x201c;New Scilex.&#x201d;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill or other intangible assets recorded.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had capitalized $&lt;/div&gt;7.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of costs incurred in relation to the Business Combination. There were &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capitalized costs in relation to the Business Combination as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; </us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">290600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">7300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#x2019;s &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; fiscal year, or any subsequent period.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, there have been &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; beginning on page &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;F-48&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; thereof.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <sclx:LiquidityAndGoingConcernTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern for at least &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; year after the date the financial statements are issued.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company&#x2019;s negative working capital was $&lt;/div&gt;219.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, including cash and cash equivalents of approximately $&lt;/div&gt;2.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had operating losses of $&lt;/div&gt;30.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and cash flows used for operations of $&lt;/div&gt;20.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company had an accumulated deficit of approximately $&lt;/div&gt;358.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million as of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;September 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. In &lt;/div&gt;August 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;September 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $&lt;/div&gt;41.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. Pursuant to Amendment &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&#160;&lt;/div&gt;4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, a principal balance of $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was forgiven by the Scilex Pharma Note Purchasers (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; upon the Company&#x2019;s exercise of the Early Paydown Provision. The Company funded the principal payments with &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-on&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; hand and $&lt;/div&gt;34.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received from Sorrento on September&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;&lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;&lt;/div&gt;17&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento and Scilex entered into a Funding Commitment Letter (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company, Sorrento shall fund &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more loans to the Company in the amount to achieve $&lt;/div&gt;5,000,001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in net tangible assets immediately following the effective time of the Business Combination. Such related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $&lt;/div&gt;10,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $&lt;/div&gt;310,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company did not draw funds from the Funding Commitment Letter at the effective time of the Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#x2019;s primary product candidate in development, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; as well in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; will be in excess of the Company&#x2019;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Assets (see Note 3). &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of the acquired licenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#x2019;s marketing of ZTlido. Should the Company&#x2019;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#x2019;s business plan, due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104,&lt;/div&gt; and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are issued. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:LiquidityAndGoingConcernTextBlock>
    <sclx:NetWorkingCapital
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">219600000</sclx:NetWorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-30900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-20500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-358000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">34000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:MinimumNetWorthRequiredForCompliance
      contextRef="PAsOn10_17_2022"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:MinimumNetWorthRequiredForCompliance>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <sclx:AggregateOutstandingAmount
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_USD">310000000</sclx:AggregateOutstandingAmount>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Semnur Acquisition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;&lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#x2019;s capital stock and options to purchase Semnur&#x2019;s common stock, upfront consideration with a value of $&lt;/div&gt;70.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and (b) $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of the Company&#x2019;s common stock &lt;/div&gt;(47,039,315&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issued and &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issuable, valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share) (the &#x201c;Stock Consideration&#x201d;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately &lt;/div&gt;58&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding capital &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x201d;) up to $&lt;/div&gt;280.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#x201c;NDA&#x201d;) of&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Semnur product by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: &lt;/div&gt;(1)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;payment upon the achievement of $&lt;/div&gt;100.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur product, &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment upon the achievement of $&lt;/div&gt;250.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur product, &lt;/div&gt;(3)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;50.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment upon the achievement of $&lt;/div&gt;500.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur product, and &lt;/div&gt;(4)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;150.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment upon the achievement of $&lt;/div&gt;750.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#x2019;s first bona fide equity financing with &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more third-party financing sources on an arms&#x2019; length basis with gross proceeds to the Company of at least $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: &lt;/div&gt;(1)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share. The amendment resulted in a reclassification of $&lt;/div&gt;0.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million from additional &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capital to accrued &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;March 2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#x201c;Exchange Agreement&#x201d;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months following the closing of the Merger, &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period commencing the date that is the &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; month anniversary of the Closing (the &#x201c;Share Exchange&#x201d;), the Stock Consideration for shares of Sorrento&#x2019;s common stock with a value of $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million based on a price per share of Sorrento&#x2019;s common stock equal to the greater of (a)&#160;the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; trailing volume weighted average price of &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; share of Sorrento&#x2019;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $&lt;/div&gt;5.55&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#x201c;Exchange Price&#x201d;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, on October&#160;&lt;/div&gt;9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento paid $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cash to the Semnur Equityholders in lieu of issuing $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of Sorrento&#x2019;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento held approximately &lt;/div&gt;82.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company. On January&#160;&lt;/div&gt;29&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;99.97&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;March 2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; As a result, approximately $&lt;/div&gt;75.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was expensed as a component of acquired &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development during the year ended &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recorded as of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; since the related regulatory approval milestones are not deemed probable until they actually occur.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;&lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#x2019;s Delayed Burst Release Low Dose Naltrexone &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;DBR-LDN&#x201d;)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets&#x201d;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) in &lt;/div&gt;April 2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; pursuant to an asset purchase agreement&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(the &#x201c;Aardvark Asset Purchase Agreement&#x201d;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Acquisition, the Company issued a promissory note in the aggregate principal amount of $&lt;/div&gt;5.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to Sorrento (the &#x201c;&lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Promissory Note&#x201d;). Upon issuance of the note, the Company recorded a related party note payable liability of $&lt;/div&gt;4.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Promissory Note matures &lt;/div&gt;seven years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/div&gt;2.66&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Promissory Note is payable in cash, shares of the Company&#x2019;s common stock or any combination thereof, at the Company&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;penalty. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $&lt;/div&gt;3,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, upon initial approval by the FDA of a new drug application for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets (which amount may be paid in shares of the Company&#x2019;s common stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii) $&lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic &lt;/div&gt;815&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Derivatives and Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#x2019;s accounting policy for contingent consideration in an asset acquisition. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recognized at September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tien-Li&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Lee, MD, a member of the board of directors of the Company, is the founder and chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of &lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aardvark.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GLOPERBA License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;&lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a license agreement (the &#x201c;Romeg License Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with the right to sublicense, under the patents and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; specified therein (with such license to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; being exclusive for the limited purposes specified therein) to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d; or &#x201c;GLOPERBA&#x201d;) in the United States of America (including its territories) (the &#x201c;Territory&#x201d;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States in 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for the license under the Romeg License Agreement, the Company paid Romeg an &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; license fee of $&lt;/div&gt;2.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $&lt;/div&gt;13.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, (b)&#160;certain royalties in the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; digit to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-double&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $&lt;/div&gt;7.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million commencing on the first year anniversary of the&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;effective date of the Romeg License Agreement and ending on the later of (i)&#160;expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the effective date of the Romeg License Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $&lt;/div&gt;5.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which is comprised of the upfront license fee of $&lt;/div&gt;2.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and a deferred consideration of $&lt;/div&gt;3.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent s&lt;/div&gt;ale&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;s milestones and sales volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic &lt;/div&gt;815&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and will not be recognized until the contingencies are realized. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recognized as a liability or included in the fair value of the asset as of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company determined the useful life of the intangible asset to be approximately &lt;/div&gt;15 years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, which approximates the life of the licensed patents covering the Initial Licensed Product.&lt;/div&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">70000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">280000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">250000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">500000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">150000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">750000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer>
    <sclx:PeriodDuringWhichTheSharesMayBeExchanged contextRef="P03_01_2019To03_31_2019">P60D</sclx:PeriodDuringWhichTheSharesMayBeExchanged>
    <sclx:PeriodDuringWhichShareTransferIsRestricted contextRef="P03_01_2019To03_31_2019">P18M</sclx:PeriodDuringWhichShareTransferIsRestricted>
    <sclx:CommonStockValueToBeExchanged
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:CommonStockValueToBeExchanged>
    <sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P30D</sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares>
    <sclx:PricePerShareForDeterminingTheExchangeOfShares
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.55</sclx:PricePerShareForDeterminingTheExchangeOfShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">75300000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4100000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentTerm contextRef="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis"
      decimals="0"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis"
      decimals="0"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:UpfrontlicenseFee
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</sclx:UpfrontlicenseFee>
    <sclx:MilestonePayment
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</sclx:MilestonePayment>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">7100000</us-gaap:RoyaltyExpense>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue
      contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">5700000</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <sclx:UpfrontlicenseFee
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</sclx:UpfrontlicenseFee>
    <sclx:DeferredConsideration
      contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">3700000</sclx:DeferredConsideration>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Fair value measurements at September&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;2,483&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden61009247"&gt;2.4&lt;/span&gt;83&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;2,483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden61003888"&gt;2.4&lt;/span&gt;83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;(Level&#160;1)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Company&#x2019;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recorded a gain of $&lt;/div&gt;5.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;0.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million on derivative liabilities for the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $&lt;/div&gt;30.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million immediately after the entry into Amendment &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&#160;&lt;/div&gt;4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; associated with the Scilex Pharma Notes on June&#160;&lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Amendment &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&#160;&lt;/div&gt;4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was accounted&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4. Significant Level&#160;3 assumptions used in the measurement included a &lt;/div&gt;6.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk adjusted net sales forecast and an effective debt yield of &lt;/div&gt;21.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% as of June&#160;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; remaining derivative liabilities as of September&#160;30, 2022.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Fair&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Fair value measurements at September&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;2,483&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden61009247"&gt;2.4&lt;/span&gt;83&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&lt;div style="line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt; font-size: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt;"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size:0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;2,483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&lt;span style="-sec-ix-hidden:hidden61003888"&gt;2.4&lt;/span&gt;83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;(Level&#160;1)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2022To09_30_2022"
      decimals="1"
      unitRef="Unit_USD">5.3</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2021To09_30_2021"
      decimals="1"
      unitRef="Unit_USD">0.1</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">6.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">21.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Fair&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at September&#160;30, 2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-35700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company had recorded goodwill of $&lt;/div&gt;13.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; that the fair value of the Company&#x2019;s goodwill was in excess of the carrying value and therefore performing the first step of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; impairment test was unnecessary. The conclusion has not changed as of September&#160;30, 2022 and &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill impairment was recognized for the nine months ended September&#160;30, 2022 and 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. &lt;/div&gt;A summary of the Company&#x2019;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;ended&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;September&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;30,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt;amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt;amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,871&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired licenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;31.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt;amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt;amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $&lt;/div&gt;5.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was assigned to acquired licenses with an amortization period of approximately &lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;years. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, the weighted average remaining life for identifiable intangible assets was &lt;/div&gt;&lt;/div&gt;10.6&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;years. Aggregate amortization expense was $&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.9&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and $&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.8&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the nine months ended September&#160;30,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 and 2021, respectively. Patent rights and acquired technology are amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; period. Assembled workforce is amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-year&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt; period.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (remaining three months)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2022To09_30_2022">A summary of the Company&#x2019;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands): &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;ended&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;September&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;30,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt;amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt;amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,871&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired licenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;31.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt;amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt;amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">12871000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">19759000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5851000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">16089000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">92000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5619000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">19164000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41617000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11239000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17186000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">275000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16268000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">5700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis">P10Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">2900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (remaining three months)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1027000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4106000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4031000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <sclx:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">24441000</sclx:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41617000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2018 Purchase Agreements and Indenture &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#x201c;2018 Purchase Agreements&#x201d;) with certain investors (collectively, the &#x201c;Scilex Pharma Note Purchasers&#x201d;). Pursuant to the 2018 Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due &lt;/div&gt;2026&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in an aggregate principal amount of $&lt;/div&gt;224.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Scilex Pharma Notes&#x201d;) for an aggregate purchase price of $&lt;/div&gt;140.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Offering&#x201d;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#x201c;Indenture&#x201d;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Collateral Agent&#x201d;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#x201c;Guarantee&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which resulted in a $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million increase in the principal amount of the Scilex Pharma Notes, effective &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;February&#160;15, 2022&lt;/div&gt;. As a result, the Company recorded the increase of $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in principal and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; expense at December&#160;31, 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&#160;4 to Indenture (the &#x201c;Amendment No.&#160;4&#x201d;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;4, (1)&#160;on &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; June&#160;3, 2022, Scilex Pharma repurchased approximately $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&#160;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $28.0&#160;million of the aggregate principal amount of the Scilex Pharma Notes (the &#x201c;Early Paydown Provision&#x201d;), (3) the minimum &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;requirement under the Indenture was reduced to $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0&lt;/div&gt;&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&#160;the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sorrento on October&#160;5, 2018 was increased from up to $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to up to $&lt;/div&gt;50.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company funded the repurchase with &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-on-hand&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received from Sorrento on June&#160;2, 2022, which was recorded under the current related party notes payable in the Company&#x2019;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&#160;4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&#160;4, and accordingly, &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; gain was recognized in the quarter ended June&#160;30, 2022. Due to a decrease of $&lt;/div&gt;30.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&#160;4, the carrying value of the Scilex Notes was increased by $&lt;/div&gt;30.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $&lt;/div&gt;1.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;39.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. Pursuant to Amendment No.&#160;4, $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The C&lt;div style="display:inline;"&gt;o&lt;/div&gt;mpany recorded a gain on debt extinguishment of $&lt;/div&gt;33.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million as a result of the extinguishment. There are &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; derivative liabilities as of September&#160;30, 2022.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Notes consisted of the following (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;September&#160;30,&#160;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;December&#160;31,&#160;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company made principal payments of $&lt;/div&gt;106.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;44.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million during the nine months ended September&#160;30, 2022 and 2021, respectively. The imputed effective interest rate at December&#160;31, 2021 was &lt;/div&gt;7.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&#160;30, 2022 and 2021 was approximately $&lt;/div&gt;3.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;5.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. The Company recorded a gain on debt extinguishment of $&lt;/div&gt;28.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and a loss on debt extinguishment of $&lt;/div&gt;14.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in connection with its repayments of principal made during the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Notes Payable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&#160;18, 2019, the Company entered into a note payable with Sorrento (see Note 10). On February&#160;14, 2022, Sorrento paid to Scilex Pharma $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan (see Note 10). On May&#160;12, 2022, the Company issued Sorrento a promissory note of $&lt;/div&gt;5.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in exchange for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets (see Note 3).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2020 Revolving Credit Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#x201c;Credit Agreement&#x201d;) with CNH Finance Fund I, L.P. (&#x201c;CNH&#x201d;) which provides Scilex Pharma with the ability to incur&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $10.0&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;1, 2024; unless the Credit Agreement is earlier terminated. As of December&#160;31, 2021, the outstanding &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;balance was $8.8&#160;million. On February&#160;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March 18, 2022. Upon termination, all principal balances and interest accrued were settled. &lt;/div&gt;&lt;/div&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentTerm contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">P2026Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">224000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">140000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">481000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RestrictedCash
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:DebtInstrumentRepurchaseAmount>
    <sclx:DebtInstrumentPercentageOfPrincipalAmountRepurchased
      contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:DebtInstrumentPercentageOfPrincipalAmountRepurchased>
    <us-gaap:DebtInstrumentRepurchaseDate contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2022-09-30</us-gaap:DebtInstrumentRepurchaseDate>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30400000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RepaymentsOfDebt
      contextRef="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">39700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">33400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Notes consisted of the following (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 16%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;September&#160;30,&#160;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;"&gt;December&#160;31,&#160;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">133997000</us-gaap:DebtInstrumentCarryingAmount>
    <sclx:UnamortizedDebtDiscount
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:UnamortizedDebtDiscount>
    <sclx:UnamortizedDebtDiscount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">-30597000</sclx:UnamortizedDebtDiscount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2228000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">101172000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">29135000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">115400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">106000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">44200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.077</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">5900000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">28600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">14000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:LineOfCreditFacilityindebtednessAmount
      contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:LineOfCreditFacilityindebtednessAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">8800000</us-gaap:LongTermDebt>
    <sclx:DebtInstrumentTerminationDate contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2022-03-18</sclx:DebtInstrumentTerminationDate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive and Employee Benefit Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2017 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In June &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;). The Scilex Pharma 2017 Plan reserved &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24.0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of Scilex Pharma common stock. &lt;/div&gt;Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#x2019;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;to&lt;/div&gt; acquire common stock of Scilex &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The board of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by the Company&#x2019;s stockholders on June&#160;7, 2019. As of December&#160;31, 2019, 30.0&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. On December&#160;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional &lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock for issuance under the 2019 Stock Option Plan. As of December&#160;31, 2020, &lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. &lt;/div&gt;Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, options to purchase &lt;/div&gt;25,159,760&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase &lt;/div&gt;24,054,760&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase &lt;/div&gt;1,105,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. As of September&#160;30, 2022, &lt;/div&gt;20,945,240&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation recorded within operating expenses was $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;4.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;T&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;he total unrecognized compensation costs related to unvested employee and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; stock option grants as of September&#160;30, 2022 was $&lt;/div&gt;3.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and the weighted average period over which these grants are expected to vest is &lt;/div&gt;1.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; years.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;0.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for each of the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">24000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">30000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">15000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">45000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_shares">25159760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">24054760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1105000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">20,945,240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To09_30_2022">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PaymentsToEmployees
      contextRef="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:PaymentsToEmployees>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with two parties (the &#x201c;Developers&#x201d;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#x201c;Itochu&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;between &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;35&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until &lt;/div&gt;October 2, 2028&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the date that is &lt;/div&gt;ten years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; renewal periods unless Scilex Pharma or the Developers terminate it upon &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6-month&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within &lt;/div&gt;180&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;31, 2023, Scilex Pharma&#x2019;s total net profits of the Products are equal to or less than &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of Scilex Pharma&#x2019;s net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#x2019; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, the Company&#x2019;s net profits for ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#x201c;Refusal to File&#x201d; for any of the Products&#x2019; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-file.&lt;/div&gt; The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the two Developers to provide commercial supply of ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Exclusive Distribution Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) to appoint an exclusive third-party logistics distribution provider (the &#x201c;Distributor&#x201d;) and as an authorized distributor of record of ZTlido (&#x201c;Product&#x201d;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a &lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% annual adjustment. The Distribution Agreement has an initial term of &lt;/div&gt;three years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following the first shipment of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#x2019;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#x2019;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between &lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% which was recorded as a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to distributors.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales Operations Services &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#x201c;Project Agreement&#x201d;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until June&#160;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with &lt;/div&gt;90&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; days&#x2019; notice. Scilex Pharma paid an implementation fee of $&lt;/div&gt;59.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand and will pay fixed monthly fees of $&lt;/div&gt;63.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand to $&lt;/div&gt;65.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand for ongoing &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;services. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized an expense of $&lt;/div&gt;0.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million within selling, general and administrative expenses for services performed for the nine months ended September&#160;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and pass-through costs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#x201c;Sanofi- Aventis&#160;&amp;amp; Hisamitsu Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Former Employee Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement (the &#x201c;Former Employee Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement. The case was tried from September &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-14,&lt;/div&gt; 2022. Post-trial briefing is underway and closing arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#x201c;Aveva&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;Aveva Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-month&lt;/div&gt; stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&#160;September&#160;30,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;ROU assets obtained in exchange for new operating lease&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"&gt;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;June 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a new &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is &lt;/div&gt;26&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months and the Company expects to exercise the extension option at the end of the lease.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (Remaining three months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.35</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:AgreementExpirationDate contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">2028-10-02</sclx:AgreementExpirationDate>
    <sclx:AgreementExpirationTerm contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P10Y</sclx:AgreementExpirationTerm>
    <sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P1Y</sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm>
    <sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P6M</sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal>
    <sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P180D</sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement>
    <sclx:ThresholdMinimumPercentageOfSales
      contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</sclx:ThresholdMinimumPercentageOfSales>
    <sclx:PercentageOfAnnualAdjustmentToFees
      contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</sclx:PercentageOfAnnualAdjustmentToFees>
    <sclx:AgreementExpirationTerm contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">P3Y</sclx:AgreementExpirationTerm>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:NoticePeriodForTerminationOfWorkOrder contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis">P90D</sclx:NoticePeriodForTerminationOfWorkOrder>
    <sclx:WorkOrderImplementationFee
      contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">59000</sclx:WorkOrderImplementationFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">63700</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">65800</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">500000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">1600000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&#160;September&#160;30,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;ROU assets obtained in exchange for new operating lease&lt;/div&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; line-height: normal;"&gt;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_USD">531</sclx:OperatingCashFlowsFromOperatingLeases>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">489</sclx:OperatingCashFlowsFromOperatingLeases>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_USD">320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn09_30_2022">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn09_30_2021">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P26M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (Remaining three months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">215</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">872</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">703</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">1790</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">210</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">1580</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#x2019;s ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company&#x2019;s deferred tax assets.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s income tax (benefit) expense of $&lt;/div&gt;(36.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) thousand and $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand reflect effective tax rates of &lt;/div&gt;0.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;0.02&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% for the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The difference between the expected statutory federal tax rate of &lt;/div&gt;21.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and the &lt;/div&gt;0.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% effective tax rate for the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was primarily attributable to income tax expense associated with changes in a valuation &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;allowance. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-2"
      unitRef="Unit_USD">-36400</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To09_30_2021"
      decimals="-2"
      unitRef="Unit_USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To09_30_2021"
      decimals="4"
      unitRef="Unit_pure">0.0002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#x2019;s board of directors, was Semnur&#x2019;s Chief Executive &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15.0&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and (b) $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55.0&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of the Company&#x2019;s common stock (&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;47,039,315&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issued and &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;352,972&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issuable, valued at $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.16&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;58&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding capital stock as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Following the completion of the Share Exchange and as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento held approximately &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;82.3&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, approximately &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.7&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding capital stock of the Company was held by Itochu. On January&#160;&lt;/div&gt;13&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,889,868&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-related&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;&lt;/div&gt;13&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. On January&#160;&lt;/div&gt;29&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento acquired &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,889,868&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;99.97&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company. During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company purchased approximately $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.8&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#x2019;s statement of operations.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#x201c;Assignment Agreement&#x201d;), with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who served on the Company&#x2019;s board of directors from March 2019 through September 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-single&lt;/div&gt; digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt; Through September&#160;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;1, 2017, a Transition Services Agreement (&#x201c;TSA&#x201d;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#x2019;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&#160;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.2&lt;/div&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to the Company in the amount of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.4&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, under the note payable. The outstanding principal balance of the note on September&#160;30, 2022 and December&#160;31, 2021 was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;47.1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.6&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under the current related party note payable in the Company&#x2019;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.8&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.9&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. During the nine months ended September&#160;30, 2022, the proceeds from the note payable were used to finance the operations of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note i&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;n the amount of approximately $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the maximum interest rate permitted under &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,117,608&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock in exchange for the repayment of $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of indebtedness under this promissory note. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, under the promissory note. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.9&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, Scilex Pharma&#x2019;s outstanding principal balance under the promissory note was $&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23.5&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in February 2022 to fund the payment of Scilex Pharma Notes in February 2022 totaling $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, as described in Note 6. The $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received in February 2022 is due no earlier than February 2030 and was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional funding received from Sorrento is due on demand and recorded under the related party payable in the Company&#x2019;s consolidated balance sheets. As of September&#160;30, 2022, related party payables due to Sorrento included $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;48.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements, $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;100.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes, and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for litigation fees (see Note 8). As of December&#160;31, 2021, related party payables due to Sorrento consisted of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements, $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;51.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes, and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to pay litigation fees (see Note 8).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;May&#160;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures &lt;/div&gt;seven years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.66&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. As of September&#160;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.2&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt Exchange Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#x201c;Debt Exchange Agreement&#x201d;) with Sorrento, pursuant to which (i)&#160;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#x201c;Aggregate Outstanding Amount&#x201d; or &#x201c;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(ii)&#160;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the terms of the Debt Exchange Agreement effective&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as of immediately prior to, and contingent upon, the closing of the&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Business Combination, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sorrento has elected to contribute the Outstanding Indebtedness&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to the Company in exchange for the issuance by the Company to&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Sorrento of that number of shares of preferred stock, par value $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.0001&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#x201c;Exchange Shares&#x201d; and such transaction, the &#x201c;Debt Contribution&#x201d;) &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;tha&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;t is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Aggregate Outstanding Amount divided by (ii) $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11.00&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;310,000,000&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. As of September&#160;30, 2022, the Aggregate Outstanding Amount was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;276.8&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;November&#160;10, 2022, pursuant to the terms of the Debt Exchange Agreement, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;290.6&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, was contributed by Sorrento to the Company in exchange for &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,057,097&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s preferred stock. At the Effective Time, such shares were then exchanged for &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,057,097&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of New Scilex preferred stock and &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,905,710&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of New Scilex common stock.&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PercentageOfCapitalSharesOutstanding
      contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.147</sclx:PercentageOfCapitalSharesOutstanding>
    <sclx:NumberOfSharesOutstanding
      contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesOutstanding>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesAcquired>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:PaymentToAcquireInventory>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">4800000</sclx:PaymentToAcquireInventory>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">27500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3400000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">47100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19600000</us-gaap:NotesPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">6800000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">24117608</sclx:NumberOfSharesAcquired>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:RepaymentsOfDebt>
    <sclx:AccruedInterest
      contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_USD">0</sclx:AccruedInterest>
    <sclx:AccruedInterest
      contextRef="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">8100000</sclx:AccruedInterest>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">4900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:LongTermNotesPayable>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">48700000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LegalFees
      contextRef="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">17500000</us-gaap:LegalFees>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">35700000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">51000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LegalFees
      contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">6000000</us-gaap:LegalFees>
    <us-gaap:DebtInstrumentTerm contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4200000</us-gaap:LongTermNotesPayable>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_USD">27.5</us-gaap:RepaymentsOfDebt>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <sclx:PercentageOfOutstandingAmountIndebtedness
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfOutstandingAmountIndebtedness>
    <sclx:PerShareCalculationOfOutstandingAmountInExchangeOfShares
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</sclx:PerShareCalculationOfOutstandingAmountInExchangeOfShares>
    <sclx:LimitationOfOutstandingAmountInExchangeOfShares
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">310000000</sclx:LimitationOfOutstandingAmountInExchangeOfShares>
    <us-gaap:LongTermDebt
      contextRef="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="1"
      unitRef="Unit_USD">276.8</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="1"
      unitRef="Unit_USD">290.6</us-gaap:LongTermDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">29057097</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">29057097</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">2905710</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the nine months ended September&#160;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt;September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(46,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share &#x2014; Adjusted for Dilutive Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&#160;30, 2022 and 2021 were &lt;/div&gt;25.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and &lt;/div&gt;30.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt;September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(46,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share &#x2014; Adjusted for Dilutive Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">197550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">197550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_shares">25200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_shares">30300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of September&#160;30, 2022, and the nine months then ended, through November&#160;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through November&#160;30, 2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Funding Commitment Letter &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;October&#160;17, 2022, Sorrento and the Company entered into a letter agreement (the &#x201c;Funding Commitment Letter&#x201d;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined company to have $&lt;/div&gt;5,000,001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in net tangible assets as of immediately following the effective time of the Business Combination (the &#x201c;Effective Time&#x201d;) under the BCA (the &#x201c;Net Tangible Assets Condition&#x201d;)), Sorrento agreed to fund one or more loans to the Company in the amount set forth in such written request (a &#x201c;Loan Request&#x201d;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;included in &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amendment to Amended and Restated Certificate of Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;November&#160;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from &lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to &lt;/div&gt;45,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $&lt;/div&gt;0.0001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share, of Legacy &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sorrento Absorbed Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;and November 2022, Sorrento entered into agreements with certain of the Company&#x2019;s third party professional service providers to assume $&lt;/div&gt;11.9&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;million of liabilities accrued by the Company, of which $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1.9&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&#160;10, 2022 under the terms of the Debt Exchange &lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agreement (see &lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 10).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;Committed Equity Financing&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#x201c;Yorkville Purchase Agreement&#x201d;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#x201c;YA II&#x201d;). Pursuant to the Yorkville Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $&lt;/div&gt;500,000,000&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to YA II&#x2019;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, an &#x201c;Advance&#x201d;) by delivering written notice to YA II (each, an &#x201c;Advance Notice&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;While&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;there is no mandatory minimum amount for any Advance, an Advance may be for a number of shares of New Scilex common stock not to exceed &lt;/div&gt;200&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the &lt;/div&gt;&lt;span style="-sec-ix-hidden:hidden61004144"&gt;five&lt;/span&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; trading days immediately preceding the date of the Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to an Advance will be purchased at a price equal to &lt;/div&gt;98&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;% of the lowest daily VWAP (as defined below) during the &lt;/div&gt;&lt;span style="-sec-ix-hidden:hidden61004145"&gt;two&lt;/span&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; consecutive trading days commencing on the date of delivery of an Advance Notice. &#x201c;VWAP&#x201d; means, for any trading day, the daily volume weighted average price of the New Scilex common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Advance.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;consideration for YA II&#x2019;s commitment to purchase shares of New Scilex common stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued &lt;/div&gt;250,000&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; shares of New Scilex common stock to YA II.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:MinimumNetWorthRequiredForCompliance
      contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:MinimumNetWorthRequiredForCompliance>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <sclx:AggregateOutstandingAmount
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">310000000</sclx:AggregateOutstandingAmount>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11900000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="PAsOn11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="0"
      unitRef="Unit_USD">500000000</us-gaap:CommonStockSharesSubscriptions>
    <sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares contextRef="P11_11_2022To11_11_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">P36M</sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares>
    <sclx:MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="2"
      unitRef="Unit_pure">2</sclx:MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance>
    <sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="2"
      unitRef="Unit_pure">0.98</sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="0"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_61002555"
          xlink:label="Fact_61002555"
          xlink:type="locator"/>
        <link:footnote id="FN_208988" xlink:label="FN_208988" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#x2019; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61002555"
          xlink:to="FN_208988"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_61002556"
          xlink:label="Fact_61002556"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61002556"
          xlink:to="FN_208988"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_61002968"
          xlink:label="Fact_61002968"
          xlink:type="locator"/>
        <link:footnote id="FN_208990" xlink:label="FN_208990" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61002968"
          xlink:to="FN_208990"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_61002969"
          xlink:label="Fact_61002969"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61002969"
          xlink:to="FN_208990"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_61002970"
          xlink:label="Fact_61002970"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61002970"
          xlink:to="FN_208990"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_61003170"
          xlink:label="Fact_61003170"
          xlink:type="locator"/>
        <link:footnote id="FN_208989" xlink:label="FN_208989" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61003170"
          xlink:to="FN_208989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_61003171"
          xlink:label="Fact_61003171"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_61003171"
          xlink:to="FN_208989"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPG/;_.^@A<'[G1>< C0O0&;FC'Q#!YT?CDKG1>@VU+)VDAW=QN%)9%OR@I^
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MX^,$YXF'&R.XA*>[N#U.8LM)!#F]G4S,"BA A)UHX'-?Z'-2Z@:CM+:D=KI
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MB_;E7&?@30N O\\,#&[WQCY@^W-%-_\!4$L#!!0    ( ): ?E4\250NA08
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M*Y_F*-\(NBN>/GB@0M"T>+DE>$58#I#?KRD5+V_R!/4S-=-_ 5!+ P04
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MK0%C $ALQO:!/07PG0)X4Y(=4$ [QN8+:UI4<MA-\IDEOJW5V%S=0)K@F)K
M) LQR4:89&-,L@B3;())%B.1]73L['3L&$>R.ZE>M68PC&9&@G.5BTD6;LG<
MO8O;I;X^1HUT''5XH(]EF)6+]*#,97KE)D#E"%"Y6,<YOIP,#PUD[DX KE$
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MMO%+V"Q0SU3/-&">Y^HO7$#-J,9BZTMU[^T=9J__B%3-Z=5,3^AU?>V^VQT
MNR+$57?LA[,ND"%,?%\#CB"@[^F,8W/SSY&''O& /#!M_QB+K2^/SL]G9C__
MAS;O*,W3.E7ILE6U2?)I(Y%UDX,OS*/:T9S?N^.0\#AD!$"NJ!.H>^5#1;S
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M:+)FA2\=G)4<A-[A4[DR- <RJBQ]( NFY0<ABA&+$Y4?A#Z0$465E8?H@^Y
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MKMO_-U[VMN:5L=S53;G9/\QKL,F+[K_IMWU#'#W <? #UOX!:_B <^(!>_^
M/7S ._& LW_ .?<!=_^ >VZ5O/T#WKD/^/L'_):LKG5;:J*T26\^5N6+40EK
MCB9^:/EMG^:,Y(7HBG=-Q?\UY\\U-[\7Z6Z5-]G*F)?%BG>Q[J>Z7.>K5/SY
MKN'_X7VOJ8WRP9BG]9,1\_Y;&S/C][O(^.M_?/_QNN$5$7#7RWVA/W>%6B<*
M#8U?RZ)YJHT%+W(%GH_TSS-S#& Q F!I *YY$Q[:T7IKQY\M+>)=MOW1L,T?
M#,NT+%"A^?F/,]0@^L>C;,D?9^WC)FJ.\Q]'I<?_7NG)V8^S4$.%?>C2=HMG
MG\#[;9M5:9,7C]T\ES=Y5J,^VJ$X&$4L 1_J;;K,/EWQ.;[.JN?LZN:[OS#/
M_ G12PD648(M*,%B2K"$"*S729Q#)W%TZ#=_YZO\NJQAQ^B>=-LGQ5+^?#-S
MG<#D__MX_7Q,.C!T/,<-%<M(6YFIC()B@\"Q'*78&%70=YE:P018,C]PPQYH
MKZ7=0TN[VN'X>?4_?!GK5I"FY-N795DL\W5F%'L*Q%_%STNQMNS$ L1W6$8)
M1O$'Q)9+.8PIP2)*L 4E6$P)EA"!]3J7=^A<GG881QD'7>9IMZTM5D:Z*:LF
M_]_V#ZBW='#>43^W0LM3AS:P"VQ+'=C:ZDWE6"W4]GUUL,;0SE<'-;)SS9,C
MVC\TNJ]M],]';2PVA:OLOC'RNMZEQ3(SEF7-1[K@HOW[*J^7Y:YH$!F^6C]F
M!BH9JAV?8]7I+M)6>RH9:J&<"D"&:L=,SU-KEP!#U[3MDW0$!SH"+1VWZ:N8
M70U.1O.4&7=B<OUFW#ZEW%,S_EXV&6>C::K\?B?V\WRR39?+*A,_YT63\99H
M^*2\3O?_*"!&B0N45YE9K%U6AM0!2\8"9JOD:5]R*GFH6,L)U#$2(TLS\-0I
M(5$M3Q 7'H@+M<3]-4GSXOMN#>3DM:V>?1-KWBZOGP2G/XB%$1$0 @("SU9[
MW5RUY WA@?;7UG5J^Y];:JP:#IM=9]%K=F9*G]?4;_[*8M;N-N0F8YVE=3=W
M07?65&<JEZF-#>PL7^U*D;Y^4QL;U<Y7UZH8V 66JW9T8.=:P<EYBAUI#4S;
M[G=-N?QS)I2C%6_JS38KZI,+]1[JN!*.::D#>(X,;4]=12)]Y28WNEJL&UBH
MU8&A':)F1R]BGUZNF27;W=*VNYAGNAFFRI]3H?T9ZSR]S]=Y\PK;WE*G%[>M
MB=+XP)(!PTA?P\F-KQ:+JA>CZ@7 , &&ECV [#>^5".8UH^]0>OQMLJY#[1-
MUWP)YFLQ'Q"0!E*%@A0M(D5;[-'ZVVT3,JI:*ESJ3/HD2K6 Z>6"NVQ3[*K9
MVS[IR^W7[]+-]J<(TD;I[,])T2)2M,4>34-&/&Z2 !.?SS;L]-B3T@/3:P_S
MI[1XY.--3']23ZCK;.^AO,V"I[0%1BHND*)%I&@+4K28%"VA0NMW(BDQ,+W&
M\*5XYEOQLL)+I>IC,\]2W<0Y,@S0UI!440"ESIC#@!\$+"T;B \)A&3,.SU<
MI:[ 1H2%9>MQUD(DS/A.Y7Z=U2==(*;ZTS/;,H&6 RQ=T 21OG:3FQ[4CS$'
M[1"!I1NJ.]@$0EJVJVE[*2*P$16ARK9ION(.J-B69]W\6#9/604;'[C-MN,#
M[099,L]!S4^J (!RF8/$-%A!TT8;=&1IF_[IUI=* --+ ;^4Q>.LR:H-WZ-O
MRSIOX,$$4WUA.U K.@=V2F.3NOOC!<; Q'+!H4H"#&?!:>_3DEZ_I??Z#[/+
M-GT54PMJ80LX\*$'O$Y@.+/\ (B2^EI-;6E4KAW8ZJP7(TO']-3Y)P&6CN6?
MWG]9TN&W] [_E[UW8_PURKJ?OA=[L<5FNRY?L\SXNM]/_R+W89 5U3.>68.!
MMZ=%M6S;1B&%5 N ]5/EH1C8,0M,A0DR9+:&$2D%6'HI@ ^":I?):1XVM^H,
M\VJ:JGHW!Y8S%X@@D;Y6D]M;+=9!TCRPLTR@VR7 T/:"\'1[2^_?TGO_)T;
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MS<=M^IC]FE9\%U\;Z^R!%V7^*"(*VT3:;[\TY?;3%=_;WI=-4V[:'Y^RE*]
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MDQ61#? MX'+15&K66HY\58HBNEA44H+=;9A;+'V(D6 QX)Q45L3?^!,L?=W
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MA_"F>_S9DY58R-<"N_YK<"WG\"JVMNZQ#C<_FG*%2T:SLFG*G/Y<2@'LAP_
M_7D)88C^@1N@WB3PGOT?4$L#!!0    ( ): ?E73-A9PGB<  -JG   8
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M-E<@K0K-/!@LV#S-KAI<NT%/HP]:I<"B^2KN$L%Y.>*WX1Y6QAI8I\K:!)P
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MA4WQJ54M^6F=D6Z;H=-0&*3%DDR"CN9@K DD1W7.<E:I18U)?'MM10^TO]G
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M2BD6^;,)P5>1\S!ZIS@;3#LNLS(%<W>5B?VWUM/(?[-9 HNC_(9$HBTCX21
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MS/'! M%2R<8=[A_:?5/51,$^##Y>YWK%>\?PE_!X$)=IQSDH<M:0Q E[J'[
M;3IT/8S.DKK'&+I77J\\<9)<:6>O.-X+)X]M2E3.1&]UDG&0!#N?U=CZ=5DR
M>G/#E BEAWXP-[=R(^:ERAD-LXIF^#4ZNN"*S1$@9;/@N$>(3T;>095,-V)V
M\S5VYF"*S%!UM#_>G>SMCJQ,&,:5Y=5;&(56O9T5$(]&"<-+ @QXB"O' ;7%
MW#%NQ-2YW(-VI;$;W>R2JNU*<!4,L$"X42C+PG.29'3Q=*J3G R;P]*Z/+R$
M\H2)I0#1#>FQ,%?FD%2OI&T8'[@GX)C-$G$K4G X:O=""G)&A(VJ0XB?:\2
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M&@$4(4HU7L9-0O9/!L)ZQVX0E#+VE*.@O/"4!J)NV!33Z?DQ14J<<P]4>?T
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MMF%#ZJR3UKGH^IHRNL&BF8(H!-PQ^@T0;Z^SAY2SS!D.7[$++A&RL8[:UZ(
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MO #/EPYV;2Z80?<Z\OS?4$L#!!0    ( ): ?E6N]^?<$0,  "P)   9
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M :;6X0,8GJ(:NYYF,^%"QPHF$(:T4UK!,[0GPZGJFM0SG*:&(,EFVNJ'-/)
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M79HWEOPIU+=< 7T0S&L,&A8$X@;E)T2'*FJ;2A$-CC54O$*DK.%.@O5OF>G
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MB AMM@H-L0+_8#8 KY/E)9IV_0P LYD2OU=H:' E-6=;C+IK<R3<Q'H$O"L
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M)02LG<M4?(%KXY"+:5:,$]F6'FSF.RGB-<*XW':_!;H\!=)%813Y)018<]7
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M6NK[W%./B8:C\\Q4EU^ZGS3NPG.*?O\TF.6T1&N/;"!\_7E ,*9X3,Y75TK
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M,[2Z7<QHD03;N6@[ XLP"KTD\G$1A-YH&-!B[ WC<6>RZ2:&Q3T>^"SV1G'
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MK%#=*5B#I,S&E )H5+)TZ>DKNT_F.X Z@ M,C)^: G2P)U1/D+WM1]:%%&]
M#.%&?R,BQ->O4)O0YG\I3\4Y+C4LBSHOQHJF52>D 6"=]4868&D,:1?28D _
M*1 ;4!(9*@AE1<>S7S.Q2@FHNV,0Q+JA W,BCJ<GB'U"W]DPGX>G*C=P2G<:
MG#0PF\3C\^GIN:=.2^?[+0Q\ US6J@:HD0<&%7XMII/)$_=Z;QI+-0#\[&3/
MSKW"6\&$\3JI+()MT1Q \& A(D@/$,@(*IRJJ,%]1C3"X<T5" ,56'S.]2$A
M$6/L.&!"H,F&_6<VJ78""-T %0">3;F3>;US*K7B,V\V\#))G<Y61M"QA55Q
M\B5*3IP@ R\(-K-4XO'L\G3R\(,<PDC((>\D0G\M=UFY+<2U*6\UQAA:D^;X
MC ]P5/X,V0-;4AZ +58^C\5S@-US/,#_:UJ7B/GG;&O3 *=U,Q9"S282(?BE
M\Q/;HY9MQ0(!R2RA>&2S;P$P/P4-NT*4XG_MK 9T"B#;KAF"&(LK-AAX7RD(
M\$@I@L6%P^!13F)] U2QLW8]$ 08<=Z4L- B?J<7KRHP- MP''1&X^8R)]N,
M(A)P3A58JD0BT\E)O%D8EN9-YE@'9^X*Q2VIFQI4)RP/E(3^(,HK S3<H%G/
M5)RF2"[$5(W9E)6J>*5%0R<)FP02Q%=@#CK[15YNJWWD14IYI9?L)TG>=RJ-
MV>$JMS)O]FI[NQWF5WX--@7JC-3!P$[9[,:-H%Y=HJ^X1$_2'=:RT'^PC8>#
M+<L*\D>L4+7L#TXS@,8VDK(68.0<V2D64IO!?? &WH*!<<O&#QE%Y!$-PGTO
M8BQ"(^: R6)]W\HQ)M6 S,"25";5E>6+$6;'+2\:]"K4'5)"H^&81XZ'5KQJ
MEJ@P27/O67PMLU P.=$(RVVER:J#%$U=UC+'A^TI1 R<($UO7)3@'DWZ.)2?
M?8E9C),TG( 5RX4[S?T^?D?C]QFDBW"FT!B=EN=%V>Z];[2V4^!6:0A,CQYY
MUA)BKN5<Y^ ^(H.Q4]?3?F#!@/@KMQC9&*1#E%6Z0D%@GR[ $:;WQ3&Q1ME4
ML._JY)M' [JU9[T_NO8G\)C4T73V"CY-S\Z2ER\O'OU6P+F8FGB7A)<31/[=
M8YC[^<L+<=)_%^UV$J5I60'%^1&S9#:[A %O8JYSSZ>3:3*]F#UZ8P7Z!B<%
MM+?C7R;3L^<PP<\8"T)GJ/?.Q2R9G%T\>E?59(-EH;B(]@E>X?ED\NCC 1P3
M2:%8@64LR_$XP#0"/<VA819O \> HQ'[7<9!,/1ZTR#$K0OKC5Q#]OV /TJ\
M\83'MZ9'?&!DR0P<BW9*+#2GG?.+VNG!NV*M%UO APF.\!B\BI>L21#-"'[,
M:OU3D>#0@2]ZR.LP*[!38?,Q9*7H&O55>.8M)1!A?*FC_F#-E&LR4YBWKZV9
M\FO/-CLHI@ (7VOTC-CLZ9HN,.L_),A&@=/!I"\[6BIV^&@&9S=Q3-"MU)]W
M* ;R%9WUH8W!VMY.#+=E,;4'35V24'>@/XIE2_PWUT^GDW-T)F.#\ S6A@4G
M<):W97Z+9&'#-N]EBH)^AZ!Y9K6XF73/,D(\@6YC/Z39P:S%B7R@/ Z"\IO^
M8>Q;O_GE!_$>\(:\_K[!9$,B?CZ]/A7';O@O/[0CR+;>H#F2 2G&(-)TY.O,
M>5\8'"T -(HPS^%@"HS_-#8XX S:REKV1$/&(XG.<.%0-!*_P%.93@)ORRES
M6A?.DH/FN08YY9]MP,A>TN]![!A@14P,,#N[*8-@G=I(1R_<UD5YT@I-<AQA
MZX;":1K$7CD6N@P,+G2-6;)O"'D%D+\/WN#H?V(T^*8VF!'_J6P,!C9 :X-E
M_H%&Y4TEIJ<7ST'^7\&;T8E89+'#%:Y*L,X5!9QM%-IY2&@4D>\E"^9I(MOS
M5W"\-LK7QP*PF5!@V&I$&:"+N97B>X"WGKY*>F:G\[I0=3R^/+V,@E:M>'DQ
MQ.(8+*1P(QXSN6( &D[D('$"NW]VK9(-12.:8;]AU,!/0)D+0$M[DA9@ICU/
M GSZ&5N7("[J'+$PE.3\$PG%R\](*";BR^42_U_D$>]/(?:V_%?V\*_LX5_9
MPS^7/42RP2P2& B8QO/JT!$82[P1HQ_PN,!P3\:Q6RN-_5#K;+1A.B"_OJS"
MT"+1 R#*LD$FK&QT!@>3WS K?+"O7O&K$:U$<X:$<_^T(25U9MYTR&4X;7=*
MMEGEXEH=,!FO,,$<396<HT\]:YI"W&1K;6H7&K$\002!L98%" K3ACQ!0H/2
M3%&8#)$#1V+C9$!9+#3JPZ5?"N<&M\A\4G2J=/S@9(N<\Y@^C_7^[17CT/I
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MKIZ)FF@=9KC]6O1;'7S1OEI?MI,62*YTI=)/V#>WMJ0''Y=&KC%^S T>ZM@
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M)H,?CGJ!Q-87WI3\*_6Q\=[,^>-,23B*7L#SB3&^OJ -FO_G</Y?4$L#!!0
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M!!D7Q3][*<]A"]#M[@"$)2#\#7 <[ !T2D#'"2TB<[(NF&'#OI)K4-:;V.S
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M?.@T"PD8$3C[$B7B3?LD=Y+G])%(C+EU9"36LYFBP^UJ2)0 27S)U("S>0[
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MR3@SBBVE5OFB'V2T;?CR$T",.R;?>-3C_LC2\Y3( X$,X\17?/B;X$/%-;9
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M\ .\RHN$=YLA:1"$@'IP'?\M;,ZC:0I,U=9I#ABA<&?JO?&^:EN"4F<ZT&B
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MR@SFOAGPF!RN%GEF,C/('N!Q(-<&SGK,9V4NBH3&:,-K$2SIW'MFG^D%- Z
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MY=Y"7NXU2;GA=OZ$A-RMR;BWG(@K.C<'&X#84;.DK!R8.Q6?AT/,<7)&DAH
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M%=^%<K9^ZDC_FOC\A-NC.-4F0&@_< 1J\;R67 WR'\(^,8D+OZ)PR2"D!JJ
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M3VU17>UOY<Q\HMOEQ@.VZ:=Q9K90_DC>/+#E/YM/RW9^*YMF%9%YL_IV8?G
M(/G#./;N$PG##KLI]F[$<TGEN)M\,F[HXACXKV#-$D>FDY'*$W9]# )30E'4
M)A3K L*NA%NU5N53P=?.V^:UV@=;M=KPX4"G1=YA \-S"(HW8EX:\_TU[$N(
MS@?E,XL=Y]2XV.2A!%WI^..CLSNB^S<)+&Q&];TQ8=Q3H07-F\_EYGE_4FDN
MKU$ <N+$('=_@9^BT'A3T+)+XP*;SFM)[MR2DR>;'X 19S, &'DCDGN$TPMS
M81R4+F&4%ACWT2$JD5-HRS4J/S&8BDAI;$JYVQB4]CQ<8ET_;E>F4PA$)# ,
M:]=&C5<92?,;,AIEH]KME$X>]0-!,&6UN2H]'+35:Y!AJQPY> 4%=>=!7SC+
M'O9<Y=A6<2__J,T?YYQ"([[SR-TY"E&#V;1V&[IW(O'-"=XI]G9IL0"/BJ6X
M HT9]J[@V#OL]W1L3B8'D[WY_MYDWRN7O083_?<&D4_)13[[K=[*N)/-12]&
M_:+$"*K-*.;E*3PC@MU,%.GUEY^V >?JY^^-N.R=F&#DCQF*E8<16%\1OD/R
M$_H*LC4N>N8DZ.][->\#I]J@0U.: 3A?=!94QCRYDX^3;]C1(@TG5,'=3"YX
M>B>'I\5!03Z^H(:SK]H@^0Y9G5@-AR[;Q34.:NGJVU=@M&%QX+ADAD%M0%BA
M2SC?FKVUY%;S<U^[^E[0%JH,"T.W:2>,6R2@Z.5DOI6OJ+*A,UJP*FI<[*C?
M,7-MY5S+)_2U&RX5E+3H7;#&:8>UOY%RIT!)O!9F+/J=,\\7P'(AXAXMKJT@
M$3/VU7.G[PF2[ O\ZDW78JB>6>^F=> :B.KKU9D3]B1'R^]:0W$_H"OX0.@(
MN]B"8B@^1Y;8 I]%3X_RW;-9&(0 =L&8M0_%$"@#[-B"3EIH*--'HH3@AS3%
M1*7\]1/):D"/OB42&YCY,[G]M<B-<>;&!/>;J O182MM"3O^"U+7Y3CHS*@H
MS=N]8\:)Q%T($*_1-4T:QF1 PP@A&:@5D9+OZ2IT4/N4P"CI(9RPG[U!3 #T
M&>W)X'-3;V1NN^P-EWLQVL0&]Q"G6.A2&ZQYVRH#R##RE#C87CMOHO A5:R)
MR?%X/-G+]A%MMT4&(Z;E6P!P-T!^(\(L(K=X(E7'-BYE:M'V'A!/0KT]T.2S
M@#SWJ4E@UEF7M4,[\0Y+A_C8SG&8#4@$( @O1Q']:WDH]F*_,QVKX/C+QMT&
MPFKHQ2XD!:+$UJ[6T*4^O7,9R$0GC)3 O5GIFF%KZY%?$=G2]&1Q3UR ?8D\
MZY7E-LDW"_^*]XW?A2$C<;ML+F<_5UU=LK&WJIH64Y:SD>]!0I),7WC!,.$A
M'/'W@\3<( X-0/+JN.)^F(#U*9[KK< 98FGN78#2;&T6)F^P:(DS![?$6=FS
MZ:HAO%]$4#!P2N'^G'E'!=;\MM HPOK\/'@G6,1/*?U&8,/8XZ1[""K%IUX1
M49BWH/#>ZMWQ-25E18G#\+.\="!O/%ML LY(%'P9&U=A0]Y Q/HP%RA-U*=[
MZ$U1Z-2@SAH(-FH9X%Z>0!<8"?8!UQQ+16&,7&AWK#*1,86\4<C!=:*M -O&
MSB^PG2_*XFZ%+LO@E_.J](WAG"M*HF';9]0BN" 3WO7>['$%#HG$[@E]=ON^
MV!$1UQW&"+AMJ$MD'WI3'?4VD\75K>-#_MAR%55 S:@BXL<-N]Z<EU5+;^;H
M)TZ_T<IN+@J7EVO(RPRX HOI;!GU0D81XIV)O3E;>B,6ORF.YJBQ/[?(-X0$
MI>[IK@B-9^:RJF_(BJ\K"?K4,J W0&[$3C<OT^&53GT10CVZU8VQ6PJ(=CP8
MEA3MV-1-BHN TX^NRR<7#^=&JX E*SH&^V,B9UD?$.O6]ZCL/3SYPNE?0^40
MPB;ZF"4^9*J?"9*M>9,]>HF]_M(Y#.X1U ].M>88(ONC?^[*?O_=H+<"(;ZF
M50ZHRH*2*M>#D6>J-[RB=[ES$DC9JS'2G!1\P32U#]0W#J<J"'RRREN8!$T9
MDB@#&"7'!GXZ U,$>Q6[<@?9GNO/X!*N4>E;^[MY<,AW@_/TQU -]G2]??E!
M3'%80E5>E!2*+\7KS>U3YEW%@;1QQ:-8[DY45G%9T"BH.$NY3Y!4PHQ=OL1%
M('A_3R&PS1^M//=F^[F6^=]HFN EH9NBP&UT@+?+>:+0S3!#S]L;L7-5K5ME
MY\V?P<][5Q+"KL>J'7 BUCST?%"8WBL;'WQ\I/':+.C:,92ES>\GY5HP8&UN
M0_UK:+A_A1><2H];:E^N*:3Y544T6](TA](YG+$^ A6^5?]-X'T9<3<4"9VR
MZTU#H>+YPM>=46AAE-B"PW.<S1I'4K_12.JS,)(:G&R/7[QAAN[W&>W NI=&
ML:/-=Q*(7Q$T,#"@/6X@2Q:;^,JN%I:@Q54L Z.IG(@;7A8N 'FS0VW>((WQ
MKX!!@:!&(UK.H;:*LLCZ7M12[(N/T3[(@'(+H\MBNG:6'@6,;<>]+FCZ_?A>
MQ,[J[RP.EE&W?,#H2X,28(TM"4,_08:)ZVWG.S<[W*#NS-P>U;5I]BD17@(N
MB3LX<[V_F_BU8@V^<GC+DX03P9?^W2'^);Z<IXU'$@,W""^7%M/U0;'1LHQV
MP-/!)X^]+$0BZ#,6\AA$(,:>IKHIM6R>KF$%#M_2@-6F35KG4^^5&.1NXS[-
M4WG#YDOP/'UC)Z:5:QOE+E/CY,-'0[W4N3O .J3D )<O.'A/T?+N-4N]5PB0
MI-(#X'/HR6!E13#:H4U*7==::[<BDFCI@S*&P!*_-V, D0(<X,/)^RY$DU"4
M4JU1(A(:3M6#8#-);%PL3TL]S3#7-JK-NL2A7G:@7AQ-Y?X0O\L-A,8H:&%,
MK]71/P2K=M$;LUSIZR2I_PX6TAX(S90PKJ]7+_T1.:\&H8[F$>:U^#5"96=K
MRR>O[@_T!'(![%?F8[Y,OJNK;C7"QNFCC>#:I3MEU$ J2IS1+E K;O!428,G
MWQP'5W%LW?:;$'D??B"I?OCI;-.>W-A*U"1ILY4+'X]5U%Z[.$;Z:!6/Y_+2
MU@H+;?%@W"G*]_EXIJ@2 3]TOVTZ1Z.E]L-< WQ1]I8\H\TV8T,];/Q;'M5<
M)/S:<'3L**'@BY^:@E(J9,M<G"!O_D!!?^_HQ'4)J/C5N&(BW@@J_3+[,-]B
M[VP_.3G\XL80[L\%N"2WK6]?<FPV.@8I2'?VOM'$4^W:>BMKY_J:".XO;/"E
M+C@(7QGY6JQR[T D=5)?P\T34,8XLEQOZMBXRHD4,4\RPOQ>E)>6WU 5MFR4
MMF.#:<?;F^,TFAD3J@?L@_8M'\M6F-0&:H_#=CPLVY^[-,8VJK(:K+25>(N^
MU\*PGW_0B^/S<%04TLU$$..-B7'^SI(S.+LN/3O@0SN?])KSE:;+![W=E.7[
M>E!^JQP7LC*SKWV?1;KR86DGL71]AUC?D-I(7A2=1)HPKK6J/^?>%BV]UUJ\
M3(3 ]"<'$5BEWIQRP*A&598_N%<QJJ]%] A?"9DQYKCV _V8//9@6 !;IW@'
M0GF=[$T>'>Y+U&2H[G+W'8:Z<?R65T(AUWV2:S$P0;;( =TS8:A+R2?DBGT%
M#EI(86&&+S5N\F5>F+@3D*2_\=M2)"U=4RU[K>(CTT:21"-%T'6R:"GU?M?E
MX_UA]\)1V(33;51:XJ]9_NV&(:$EUYL)MPR>#G2:ZW;#[4:) J=V5YKO.!EJ
MT?NKN]ZZMMF?F]]^;G[[N?GMY^:WGYO?_CV;WP[U6K_?+*QMGYG6?/TE2>MS
MBV_7I%6^NCNY&WR+75:_NGLV>7)V=/<^C/2/?_WE"E@\F,=S;&I1V!D,/1P_
M/+G+I*)_M-4*I\3W#((F1Q_IW50U/@"_SRI0[N4/7 !?,4C;^_K_ 5!+ P04
M    " "6@'Y5I;1!^P (  !F$P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6RU6%%/XT@2?N=7M+*KO2 98B<AP P@A9#1<<<,.<+,ZG2ZAX[=27K'
M=GN[VP3^_7W5;3L.!$XZZ1X@;KNKZJNJKZK:OM@H_=.LA;#L.4MS<]E96UM\
MZO5,O!89-\>J$#F>+)7.N,52KWJFT((G3BA+>_TP'/4R+O/.U86[-]-7%ZJT
MJ<S%3#-39AG7+]<B59O+3M2I;SS(U=K2C=[51<%78B[L]V*FL>HU6A*9B=Q(
ME3,MEI>=<?3I^H3VNPT_I-B8UC4C3Q9*_:3%;7+9"0F02$5L20/'SY.8B#0E
M18#Q9Z6STY@DP?9UK?V+\QV^++@1$Y7^+A.[ONR<=5@BEKQ,[8/:_%54_CB
ML4J-^\\V?N_)L,/BTEB55<) D,G<__+G*@XM@;/P'8%^)=!WN+TAA_*&6WYU
MH=6&:=H-;73A7'72 "=S2LK<:CR5D+-7#\)8;@7";)E:LID63U*5)GUAM\:4
M(F%?9,[S6/*4S>N-YJ)G89H4].+*S+4WTW_'3-1G7U5NUX9-\T0DNPIZP-P
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MR -57\SJCI&EN]LLI*&;DFMF=)=%90UH?BDIC4W'+M#=CN=_ U!+ P04
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M537BS1W^MR]/&H"EAR>9!W'A0)SN ?&3>&^J9FG%FRI7^<#^R\/[IZ<' )R
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MOC=T1J4R92VB%GUO9:/M?,//B9F$#V23.Y/P<KRX/.]QWKKEIIQ!B\D>W(D
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MNRQCXSHFI/[QGB3TB\Z^48GS!0Z([.T2A>U8O(L)IG\>-E&62E2XUGG8Y(\
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MONL*]X8ECWB6@;#@;3Y*)>T^!HBSBH@RL%=G>56 :B9H(8+R<*RE8"0//)V
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M\PB>AW,9;4Y&X$\NSZ2AT)*7PLR!T<K8V6S2[OI-1Z+)YN3SXSH(2;IV#ND
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M1U?JG-P+H-1AC:X9QT'5U9>X=JB8;0,H.^7#B8<JF*C<C3"?HYJ*:GZ>HM/
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MS81D]=/61RBGO%G,F*_KZ+72+QT]S'JD<H]70%O_;8J\ 6X*G(KM0,P'YOG
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MZX]?OW)"^TU;//:D;"LZ?A,=OTO[> K4E10IP_! D2,#***7C,0TC8N4&CZ
M;U#./"8T3TC"TT*SA.1 @SR/1<;(82H4!&W%)!$RX3F&6RVI9&VAZ[2GW=M;
ML&<N4F!%3)?&4B&*@:' M'IIS)4L%GG,4]YA,5IIC#2VH; 1S3'565D##&N
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M:Y&9X9+1A$E< -_G0NAZ@ALTE[+C_P!02P,$%     @ EH!^54N8>:<*"0
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M!1>X4*#KLF3J?8Z%W$R\T-MM//)U;NR&/QU7;(U/:'Y4"T4KOT7)>(E"<RE
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MK/G4["W%?,HKE;$"EH+(*L^I>+Z!C.]GEF<=-KZP[4[I#6<^+>D65J >RJ7
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ME.Y==ZQ@>963)7W&[S@^P /V;/$])=U[X_?VM_]@K DD;P(I#X%4?8'89D[
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MPXS^ : T&^CY1@A]F)@ [7^*V=]02P,$%     @ EH!^5<%**;\]!0  ' T
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M_ 3LJI(-;2XZ+IMOIW4G;ZM.>F]TT@?W1- 8F)09RC3ZI%O??T\_[=:[SGN
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MG)-"76X0S!"5 :)^10A_O9$)FE]-QO\!4$L#!!0    ( ): ?E6GTG*\I@L
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MH+*#>#XCA*\OY #E,9'S%U!+ P04    " "7@'Y5'\@Y<>!@  "J=0@ &0
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MKF2WB[DQGFQ>!TO=O,A3K"NH9J*:A6I55+-1S4$U%]5JJ%9'M0:J>:CFHUJ
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MR]59KL%R'LOY+!>P7,AR399KL5S$<O&&V[T+?C'U?9/H=3LLUV6Y'LOU66[
M<LKK^^D;&>O!B1?<>,&1%UQYP9D7W'G!H1=<>L&I%]QZP;$77'O!N1?<>\'!
M%U?\@XVLN+.199Y3G?6^R<ID_#V9SD>WC\F[]U!FOF<R^Y*GKVTD9[*<Q7)5
MEK-9SF$YE^5J+%=GN0;+>2SGLUS <B'+-5FNQ7(1R\4LUV:Y#LMU6:['<GV6
M&["<\D:%3RQWJ </ H(G <&C@.!90/ P('@:$#P.")X'! \$@B<"P2.!X)E
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MRR7/GWK!\SOW WSUO4F[>V_77;N(KUU:=^TGOF\\GU-9]S-_XONNON#KK+W
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MT5IR=NW*ZL=6+K/N$* J,93F06D^E!9 :2&41J$T!J5Q%,UT":TEN].7V2%
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MS>RR,;3K;4-+[N0PLTTVF,O3J3LY'5Z.FYPKOQ8S6;)X)#>M.E>HYTS,5(;
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MH&F36@V5=;N8=F&2 UA-XLPVT/[[V4Z:!1*@JW8#MG/>X^<]3FP/MY0]\A6
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M*^LF6I2V5YL+39V?':ZH^T=I#.C[0@C]-#$;U/]/C/\%4$L#!!0    ( )>
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M:P?DH7*FXI3.Y)BSP\+J9 6F85K6:=[2+<P8UD0[35I0BV*H- ^5YK^$!K\
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M-:,+EI<-Q._++..[B]+ _D#T]#]02P,$%     @ EX!^5<200;HE!   0!8
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MK5*UOFT?GO;!26X::X"9[21[__VS@4)H'(^\>E\:#/<<? _7UZ>>[1G_(38
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M&+HL<Y=DB2.RCFBC1K21M202X*JP]0YXV%9-^HV.OMK3[W\<$0W'07!< *;
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M7(X5!Z^.AJN!9$5Y6+I@4K*LO-P 60'7 >KYFC'Y.-#GK\T!??P?4$L#!!0
M   ( )> ?E5Q*6WXH0,  'H-   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;*U7VV[;.!#]%4(MBA9HHIMO36T!L>5@ ]1 D&RZ#T4?:&EL$:5(EZ3L
M[M\O2<FJ'"EJLO"++5)S#F?.C(;D],#%#YD!*/0KITS.G$RIW97KRB2#',M+
MO@.FWVRXR+'20[%UY4X 3BTHIV[@>2,WQX0YT=3.W8EHR@M%"8,[@621YUC\
M.P?*#S/'=XX3]V2;*3/A1M,=WL(#J,?=G= CMV9)20Y,$LZ0@,W,N?:OEA-C
M;PV^$CC(QC,RD:PY_V$&M^G,\8Q#0"%1A@'KOSTL@%)#I-WX67$Z]9(&V'P^
MLM_8V'4L:RQAP>D_)%79S)DX*(4-+JBZYX>_H(IG:/@23J7]18?*UG-04DC%
M\PJL/<@)*__QKTJ'!D#S= .""A \!8R> 805('P*&#P#&%2 P4L!PPI@0W?+
MV*UP,58XF@I^0,)8:S;S8-6W:*T78:9.'I30;XG&J>@&$X&^8EH 6@&6A0!=
M!$JB]S$H3*C\@"Y0#(+LL4DHH@2O"26*@$1Y:9\BK-#&T.PM32$)VR))MHQL
M2(*90@7C:PEBC]<4$&&[0O.?L-X0AEE",$6W3"I16!<^HB^-Q;ZM(%^#^*Z!
MCP\Q>O_V WJKN=#?&2\D9JF<NDK+88)RDRKT>1EZ\$SHG]"*,Y5)M&0II!WX
M13_>#WH(7)V'.AG!,1GSH)?Q 7:7*/0^HL +@BZ'^N$Q)!KN6[C? 8]?#O<Z
MX,L7P_U//6*$=66&EB_\8V6>5L+J6':ZS=Q#4@AAZFV.)=$E\]@LM5M3:L:&
MZ^+2E6L[T[<O>AUTJR"7W[MJIG1JT.V4Z=I7<H<3F#FZ+9N5P(G>O?%'WN>N
M?)V3+#XGV?),9">9'=29'?2Q1W/8$L;*K%']X4-7'DJ*H:4PF]T^"H=C3]?E
MOBEPE]7@J57<816VK):]3O]/28:U),->2:[3E)CR[&QCO=#7EN0YR>*2;-00
M-IBT=!VVU/<]OV%U(MBH%FS4*]@]7.2_]ZO20[YI[$-=0O92OE;(42OVL%5X
M;9N+MCYMHR ,G]-G7.LS[M5GD6&V-;MM<VMN*-8ES[B5J(NN;ZYWX==6T#G)
MEF<B.Q%\4@L^Z15<GP'^T-%Z\:^MOLE+VF/<9=5N?!U6)^VQU,-M'#)S$%M[
MNI<HX053Y1&GGJTO$-?VW/QD?J$O%N4]X#=->2M98:%W!HDH;#2E=SG6/HGR
MI%\.%-_9H^R:*WTPMH^9OAR!, ;Z_89S=1R8!>KK5O0?4$L#!!0    ( )>
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M104'B>G8NPPN)@-K[PR>*&[4P1IL)DLAGNUFGHR]CB6$#&-M$8CY6^,4&;-
MAL;/+:97A[2.A^L=^K7+W>2R) JG@GVCB<[&WM"#!%-2,OT@-E]PFT_/XL6"
M*?<+FZUMQX.X5%KD6V?#(*>\^B<O6QT.',+P#8=PZQ ZWE4@QW)&-(E&4FQ
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M_?=WB\5J_X?- +\OJG]N/^:G_P=02P,$%     @ EX!^57=8-2#& P  Y@\
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M"#QKH.XO&)-O)UD'U=;:V?]02P,$%     @ EX!^50MC0K3L!   E!<  !D
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M35&:70DFVQZYMVB_9>T1N-<>: :.:B&J1:@6HUJ":@+5)*HI2K,*:6PR\/$
M7GN,T>@;U4)4BU M1K4$U02J2513E&87B(G'Q^YX_$UK#[?=NU8.;]-]9.V!
M]ANA6HQJ":H)5).HIBC-K@,3IX_=<?K;UAYNO'<A'-[).Q@?J00T($>U&-42
M5!.H)E%-49I="28@'[NW<[]E[3%TKCW<'?>N$C1(1[4(U6)42U!-H)I$-45I
M=B&9('T\HM<>:'J.:B&J1:@6HUJ":@+5)*HI2K,+Q"3LXW_C;<;==N]:&1],
MN8[-N-" '-5B5$M03:":1#5%:78=F(!\[+[-^1O7'FA8WFI=A7!0"6@2CFHQ
MJB6H)E!-HIJB-+L23!(^=B?A;UE[C-QK#S0F1[40U2)4BU$M036!:A+5%*79
MA62B]/$%O?9 XW-4"U$M0K48U1)4$Z@F44U1FET@)F$?NQ/VMZT]T!!]?/SC
MK0^F7&A"CFHQJB6H)E!-HIJB-*L0)B8AG[AWB;]M\>'&^U;"Y'!K]_1(): =
M1Z@6HUJ":@+5)*HI2K,KP43ADQ-1>%K,[]/BEW,=X39Z#WAT:SBJ1:@6HUJ"
M:@+5)*HI2K-KPL3BDP!>1TS0*!S50E2+4"U&M035!*I)5%.49A>(2<LGK__H
MZ][K"+?=NU;00!S5HE;;7^.\_#15M,,$U02J2513E&87@$FY)\Z0\'#6=/JB
M;6<IH-$WJH6H%J%:C&H)J@E4DZBF*,VN&A-]3\;TO K-NU$M1+4(U6)42U!-
MH)I$-45I=H&83'SBSL3?-J]"(W%4"U$MFAS&]=WOF8_1?A-4$Z@F44U1FET'
M)A&?G-@;WC&]^KQ>%_E]NN@WP4(#<%0+42U"M1C5$E03J"9135&:73<F )_0
M ?@$#<!1+42U"-5B5$M03:":1#5%:7:!F !\\F\,P-UV[UI!=Y&C6C0Y#.>'
MW?,K-/Y&-8%J$M44I5EE,#7Q]_1$_)TO]:WW6S9K/IC2^WQ;:+V]:;IK*N4F
M^XY^5 M1+4*U&-425!.H)E%-49I=(B87G_KP5&J*AN2H%J):A&HQJB6H)E!-
MHIJB-+M 3$@^=>\=?]-4RFWWKA4T+T>U:'JXK?WE) KM,$$U@6H2U12EV05@
M0O"I.P3_?7U3U$/^>1H5Z\XW"[J5WD,=C;M1+9H>QMU!YZH![39!-8%J$M44
MI=D#WH3>4W?H;2ZYKG<?LM0YW-%(&]5"5(M:S7H'>_<J&>TW036!:A+5%*79
MX]W$U5/W3NT?^6.ZJ!Z?1GOG9X:YB=[#'0VH42V:'FX6G_J=HQW-GE%-H)I$
M-45I]F@WV?/T1/:\V_8P]^)LE57Z+[]E]_4W<E6EJ]OL>J&][83_7?-A]ME\
MDRZ\OQW;'N'NJ'=-H$$TJD73CGWCT\Z:0'-H5!.H)E%-49I=$R:'GKISZ%#?
MZ**IB=,+6C1H1K40U:+IX0>.#[O'/)HAHYI -8EJBM+L,6\RY*G[?N2[EW]O
ML7WYS\S+?[I[^?^]U#>;1?WKF^[7?C1/1K40U:(3?T9_[#WJM.B:-,;H@22H
M)E!-HIJBM%UEG)=W6E=A6J57'Y>ZN-5?]6)1UB_UFU7--]=!GW_J%?JFKAS_
MP^?@[/S@Y['_0?C-S\\-<_5QG=[J;VEQFZU*;Z%O:G+POIGB%=GMW?,W5;[^
M=.:?>==Y5>7+[9=W.JU/-,T#ZM_?Y'GU]$W3P4->_-H>]M6_ %!+ P04
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MCE9<H%J(:A&EM?O#LX^&EH=(AV7$Y-C@5L%^HC3[D=+L9TJC>5)4\U#-1[7
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M28N/Y#/Y]D#)AU\_7HRE:J6T'4<-\:HF.@>(9^26YW)9D""/(=;X4[._[1@
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M%LV$?9/',$_R1$)_GKX#D? WIFO4:A,JC:+2 E1:B$7KOP1=)<H^>X_I&K7
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M)<^JCTM@*C4K#=3W<\[EZT790'N&=_8_4$L#!!0    ( )> ?E7R[0[&DP,
M )$2   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;*U876_:,!3]*U8V
M39VT-A] 6AA$*J31^E"I&OMX=LD%HB9Q9IO"_OUL)Z0!C($I+Q [YQQ?GVNN
ML8=K0E_9$H"C39;F;&0M.2\&MLUF2\@PNR$%Y.+-G- ,<]&D"YL5%'"L2%EJ
M>X[CVQE.<BL8JKYG&@S)BJ=)#L\4L5668?IW#"E9CRS7VG9\3Q9++COL8%C@
M!4R!_RR>J6C9M4J<9)"SA.2(PGQDW;N#R%4$A?B5P)HUGI&<R@LAK[+Q&(\L
M1T8$*<RXE,#BZPTFD*922<3QIQ*UZC$EL?F\58_4Y,5D7C"#"4E_)S%?CJP[
M"\4PQZN4?R?K;U!-J"?U9B1EZA.M*ZQCH=F*<9)59!%!EN3E-]Y41C0(0D=/
M\"J"MT_H'B%T*D)GG^ ?(70K0O?<$7H5H7<NP:\(OO*^-$LY'6*.@R$E:T0E
M6JC)!Y4NQ18&)[E<65-.Q=M$\'CPF,](!N@'W@!#5R%PG*3L,[I&4[&&XU4*
MB,R1@!0DAYPSV4I*"L<;!!NQPAF@JQ?(89YP2?PY#='5Q\]#FXOPY"#VK IE
M7(;B'0FECYY(SI<,/>0QQ!I^:.:[GD' %K[4YGA;<\:>47$*Q0WJ.%^0YWB>
M)J#)^717-Q\S/829H+M'Z0_GTQT-/3J;[O8-7G;JA=91>ITC>I,5I6(%;9?,
M0+<^2H6N7D'6V $K\ Q&EBBB#.@;6,&G#Z[O?-7EIDVQL$VQAS;%HI;$=G+:
MK7/:-:D'$<1 <:I+I9%X:2K;% M+L9X2D_ON6R!^'6_-_)Q$1";$CI.]VLF>
MT<DIQQQT/AIIE_K8IEA8BOD-#WJ.LV_E(>BZUSF 18<PKPG:L=2O+?6-EFX+
MCFF[TCEN5+W4\3;%0O\<QP]!6L</8<<=OZT=OS66^!#F(#S7;=WCVS9=;5,L
M;%/LH4VQJ"6QG5S>U;F\^]_2;B1>FLHVQ<*[@T6]_^LXB8A,B!TG^[63_?\K
M[4;:I3ZV*1;V3_IX$A&9$#L^NL[[4<4Q.KFM+Q>7=+/NI5:WJA96:B:S3T,B
M(V37[L;)T#7:_8-P?0&H>,V_/]<=O[N_QTPT.-<YV(I"#4RSK^D&U6UL&IQF
M9[,;)^8,Z$+=;3!QT%WEO#S3U+WU_<F]NC78ZQ^[@XFKZ0_E?8LZH;_+EY<U
M3Y@NDIRA%.9B*.?F5H1*R_N/LL%)H<[K+X2+T[]Z7 (6Y5@"Q/LY(7S;D /4
MMU#!/U!+ P04    " "7@'Y5Q@\%,-D#  #]#0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970W-RYX;6RMEVUOVS80Q[\*H15#"\R12#U8RFP#:8)A!;HMJ-ON
M-2V?;2*4Z)%T[.[3CY04V98H+2_RQA:EN[]^=R3OJ-E1R">U ]#H5/!2S;V=
MUOM;WU?Y#@JJ;L0>2O-D(V1!M1G*K:_V$NBZ<BJX3X(@\0O*2F\QJ^X]RL5,
M'#1G)3Q*I Y%0>6/C\#%<>YA[^7&%[;=:7O#7\SV= M+T-_VC]*,_%9ES0HH
M%1,EDK"9>W?X]AXGUJ&R^,[@J"ZND0UE)<23'7Q:S[W $@&'7%L):OZ>X1XX
MMTJ&XY]&U&O?:1TOKU_4?ZN"-\&LJ()[P?]F:[V;>ZF'UK"A!ZZ_B./OT 04
M6[U<<%7]HF-C&W@H/R@MBL;9$!2LK/_IJ4G$A0..!AQ(XT!>ZQ V#F$5:$U6
MA?5 -5W,I#@B::V-FKVH<E-YFVA8::=QJ:5YRHR?7GPJ<U$ ^DI/H-#[!]"4
M<?4!3=#2+)CU@0,2&YL6D!+62-,3HDJ!5HB6:\0973'.-#.^$_1M^8#>O_N
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M"7447TPSKG_1OHCMR>!XRP7-2[ <09Z2XA^_ET(< 22/&1"4@. <T*X!M$I
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M?4>GG3<K%_7FO^+[]KE'[\1L73?E<CNX?07+8O7X_^S/[7=B9\#DY(4!T^V
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MJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ)92VC"$^IZ
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( )> ?E4<XH5VK@4  "(U   /
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M<',O87!P+GAM;%!+ 0(4 Q0    ( ): ?E7-8\D/[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " "6@'Y5/$E4+H4&  !?,P  &
M    @(&'&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MEH!^53(A\,BA#0  DV@  !@              ("!0A\  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ): ?E6X65H11 0  , 5   8
M          " @1DM  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " "6@'Y5]:<#-D02  !(S0  &               @(&3,0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ EH!^52!!\,[2%0  IJX
M !@              ("!#40  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+
M 0(4 Q0    ( ): ?E6>M>60E1\  /BB   8              " @15:  !X
M;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "6@'Y5TS86<)XG
M  #:IP  &               @('@>0  >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL4$L! A0#%     @ EH!^5;.'&7>'"0  FAP  !D              ("!
MM*$  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "6@'Y5
MKO?GW!$#   L"0  &0              @(%RJP  >&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ): ?E4/6#9=X@,  .@-   9
M      " @;JN  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ EH!^56"IS04N$0  X$8  !D              ("!T[(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "6@'Y5Q(9/:&<6   J<P
M&0              @($XQ   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( ): ?E4G2DP@ !   !Y-   9              " @=;:  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ EH!^5<2([8'L
M @  G@8  !D              ("!#>L  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " "6@'Y5E0DM-]8&  !:%P  &0
M@($P[@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ):
M?E6MI*FQ2AX  *ES   9              " @3WU  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ EH!^5<9/_BE>"@  \S   !D
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M=#(S+GAM;%!+ 0(4 Q0    ( ): ?E4V5P5Y80H  +@=   9
M  " @=-E 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MEH!^59+/PG6%!   *0\  !D              ("!:W ! 'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " "6@'Y5^T_L;AH5   )1   &0
M            @($G=0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( ): ?E7C9@'!2#   ,O?   9              " @7B* 0!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ EH!^55DS)[7;!0
MH!4  !D              ("!][H! 'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " "6@'Y52YAYIPH)  "G)0  &0              @($)
MP0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ): ?E7Z
M#'NXP@(  "D&   9              " @4K* 0!X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ EH!^53\7__)C!   W T  !D
M     ("!0\T! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M" "6@'Y5FTGU9/4#  #S"@  &0              @('=T0$ >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ): ?E6_L]C4=00  )H*   9
M              " @0G6 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L!
M A0#%     @ EH!^517?=Q>Z!   N X  !D              ("!M=H! 'AL
M+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "6@'Y59^( <)T#
M  !?"   &0              @(&FWP$ >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;%!+ 0(4 Q0    ( ): ?E7!2BF_/04  !P-   9              "
M@7KC 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ EH!^
M50<B>4Z' P  7@H  !D              ("![N@! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " "6@'Y5BS(6I1L5  !8%0$ &0
M        @(&L[ $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( ): ?E5&_%@'=@0  ,$9   9              " @?X! @!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ EH!^5?O>BYRI P  <0T
M !D              ("!JP8" 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " "6@'Y5YTM065L&   R*@  &0              @(&+"@(
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ): ?E7_[/^=
M< 0  $$9   9              " @1T1 @!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ EH!^5:?2<KRF"P  MI(  !D
M ("!Q!4" 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "6
M@'Y5UI6?0/ #   5$   &0              @(&A(0( >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ): ?E4E8 =!F@,  #(2   9
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M970T.2YX;6Q02P$"% ,4    " "7@'Y56L[;+*H#  !;#   &0
M    @(%(I@( >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M )> ?E5\YZYRD 0  +$<   9              " @2FJ @!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ EX!^5:HP1CA8!P  ;B,  !D
M             ("!\*X" 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " "7@'Y5SS!]?P0*  #52@  &0              @(%_M@( >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( )> ?E6F0E\7?@,
M "\,   9              " @;K  @!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ EX!^5<) /U"O!@  '#T  !D              ("!
M;\0" 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "7@'Y5
MQ)!!NB4$  ! %@  &0              @(%5RP( >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( )> ?E79IIX;\ ,  *P7   9
M      " @;'/ @!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ EX!^57$I;?BA P  >@T  !D              ("!V-," 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "7@'Y5GXN2:Y$#   1#@
M&0              @(&PUP( >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    ( )> ?E54:'4 P (  - &   9              " @7C; @!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ EX!^56+RW''J
M P  SA8  !D              ("!;]X" 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    " "7@'Y5.2]U>2<"  #1!0  &0
M@(&0X@( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( )>
M?E4X_YI#O 0  )D<   9              " @>[D @!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ EX!^53%5@T=1 P  ZPT  !D
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M=#8X+GAM;%!+ 0(4 Q0    ( )> ?E43+(GS0@H  'UX   9
M  " @>(W P!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @
MEX!^5?F$X;V[!0  9BL  !D              ("!6T(# 'AL+W=O<FMS:&5E
M=',O<VAE970W,"YX;6Q02P$"% ,4    " "7@'Y5"V-"M.P$  "4%P  &0
M            @(%-2 , >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4
M Q0    ( )> ?E42-YCAX!   #7P   9              " @7!- P!X;"]W
M;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ EX!^5:;%IA%2 @
M\ 0  !D              ("!AUX# 'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6Q02P$"% ,4    " "7@'Y5'W=D4GP0  !"Y   &0              @($0
M80, >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( )> ?E5)
MM.ONT 4  ,\K   9              " @<-Q P!X;"]W;W)K<VAE971S+W-H
M965T-S4N>&UL4$L! A0#%     @ EX!^5?+M#L:3 P  D1(  !D
M     ("!RG<# 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )> ?E6(XQE^,"0  '2X @ 9              "
M@0Z+ P!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ EX!^
M5570$1-6 P  SA4   T              ( !=:\# 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " "7@'Y5EXJ[',     3 @  "P              @ 'VL@,
M7W)E;',O+G)E;'-02P$"% ,4    " "7@'Y5'.*%=JX%   B-0  #P
M        @ '?LP, >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ EX!^5:N<
M,4MN @  VB\  !H              ( !NKD# 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ EX!^543DWU@> @  ERX  !,
M     ( !8+P# %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %D 60!F&
&K[X#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>517</ContextCount>
  <ElementCount>606</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>121</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Unaudited Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Description of Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>Description of Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Public Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PublicOffering</Role>
      <ShortName>Public Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Private Placement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PrivatePlacement</Role>
      <ShortName>Private Placement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Shareholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/ShareholdersDeficit</Role>
      <ShortName>Shareholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Stock Incentive and Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Property and Equipment  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Debt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Description of Organization and Business Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails</Role>
      <ShortName>Description of Organization and Business Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Liquidity and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails</Role>
      <ShortName>Liquidity and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PublicOfferingDetails</Role>
      <ShortName>Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PublicOffering</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Private Placement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PrivatePlacementDetails</Role>
      <ShortName>Private Placement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PrivatePlacement</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Shareholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails</Role>
      <ShortName>Shareholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/ShareholdersDeficit</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Warrants</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue</Role>
      <ShortName>Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs</Role>
      <ShortName>Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Property and Equipment (Details) - Property and equipment consisted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted</Role>
      <ShortName>Property and Equipment (Details) - Property and equipment consisted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense</Role>
      <ShortName>Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Debt (Details) - Summary of borrowings of the scilex pharma notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes</Role>
      <ShortName>Debt (Details) - Summary of borrowings of the scilex pharma notes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Debt (Details)  - Summary of future minimum payments under the scilex pharma notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes</Role>
      <ShortName>Debt (Details)  - Summary of future minimum payments under the scilex pharma notes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Stock Incentive and Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/AcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Acquisitions</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit</Role>
      <ShortName>Income Taxes (Details) - Schedule of components of income tax expense (benefit)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation</Role>
      <ShortName>Income Taxes (Details) - Schedule of effective income tax rate reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LossPerShareTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare</Role>
      <ShortName>Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LossPerShareTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="d374624ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares, sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares, us-gaap:AssetsFairValueDisclosure, us-gaap:CashAndCashEquivalentsFairValueDisclosure, us-gaap:LongTermDebtNoncurrent -  d374624ds1.htm 16922</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" original="d374624ds1.htm">d374624ds1.htm</File>
    <File>d374624dex231.htm</File>
    <File>d374624dex232.htm</File>
    <File>d374624dex233.htm</File>
    <File>d374624dex51.htm</File>
    <File>d374624dexfilingfees.htm</File>
    <File>sclx-20220930.xsd</File>
    <File>sclx-20220930_cal.xml</File>
    <File>sclx-20220930_def.xml</File>
    <File>sclx-20220930_lab.xml</File>
    <File>sclx-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g374624g24p49.jpg</File>
    <File>g374624g24q49.jpg</File>
    <File>g374624g37g45.jpg</File>
    <File>g374624g37x44.jpg</File>
    <File>g374624g38a43.jpg</File>
    <File>g374624g42n54.jpg</File>
    <File>g374624g42x62.jpg</File>
    <File>g374624g43v59.jpg</File>
    <File>g374624g45m57.jpg</File>
    <File>g374624g45v58.jpg</File>
    <File>g374624g46h52.jpg</File>
    <File>g374624g47j55.jpg</File>
    <File>g374624g47l56.jpg</File>
    <File>g374624g64p61.jpg</File>
    <File>g374624g75s68.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1934">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d374624ds1.htm": {
   "axisCustom": 10,
   "axisStandard": 36,
   "contextCount": 517,
   "dts": {
    "calculationLink": {
     "local": [
      "sclx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sclx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d374624ds1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sclx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sclx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sclx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 935,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://www.vickersvantagecorp.com/20220930": 2,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 8
   },
   "keyCustom": 188,
   "keyStandard": 418,
   "memberCustom": 70,
   "memberStandard": 45,
   "nsprefix": "sclx",
   "nsuri": "http://www.vickersvantagecorp.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.vickersvantagecorp.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:LiquidityAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Liquidity and Going Concern",
     "role": "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern",
     "shortName": "Liquidity and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:LiquidityAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:ProposedPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Public Offering",
     "role": "http://www.vickersvantagecorp.com/role/PublicOffering",
     "shortName": "Public Offering",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:ProposedPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Private Placement",
     "role": "http://www.vickersvantagecorp.com/role/PrivatePlacement",
     "shortName": "Private Placement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Acquisitions",
     "role": "http://www.vickersvantagecorp.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Related Party Transactions",
     "role": "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Fair Value Measurements",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Property and Equipment",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Debt",
     "role": "http://www.vickersvantagecorp.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Warrants",
     "role": "http://www.vickersvantagecorp.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Shareholders' Deficit",
     "role": "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
     "shortName": "Shareholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Stock Incentive and Employee Benefit Plans",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans",
     "shortName": "Stock Incentive and Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Commitments and Contingencies",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Restatement of Previously Issued Financial Statements",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
     "shortName": "Restatement of Previously Issued Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Income Taxes",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Loss Per Share",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Subsequent Events",
     "role": "http://www.vickersvantagecorp.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Property and Equipment  (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment  (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Debt (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables",
     "shortName": "Stock Incentive and Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
     "shortName": "Restatement of Previously Issued Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Loss Per Share (Tables)",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P02_01_2019To02_28_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Description of Organization and Business Operations (Details)",
     "role": "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
     "shortName": "Description of Organization and Business Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P02_01_2019To02_28_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "us-gaap:ProvisionForDoubtfulAccounts",
       "div",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "us-gaap:ProvisionForDoubtfulAccounts",
       "div",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Unaudited Condensed Consolidated Statements of Operations",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:GrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:GrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TemporaryEquityNetIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "sclx:LiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:NetWorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Liquidity and Going Concern (Details)",
     "role": "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
     "shortName": "Liquidity and Going Concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "sclx:LiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:NetWorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "sclx:ProposedPublicOfferingTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sclx:PurchasePricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Public Offering (Details)",
     "role": "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
     "shortName": "Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "sclx:ProposedPublicOfferingTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sclx:PurchasePricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Private Placement (Details)",
     "role": "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
     "shortName": "Private Placement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "sclx:PrivatePlacementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "lang": null,
      "name": "sclx:PaymentToAcquireInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "lang": null,
      "name": "sclx:SellingGeneralAndAdministrativeExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Detail)",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail",
     "shortName": "Commitments and Contingencies - Summary of Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail",
     "shortName": "Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Shareholders' Deficit (Details)",
     "role": "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
     "shortName": "Shareholders' Deficit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "sclx:WarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PublicWarrantsRedemptionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Warrants (Details)",
     "role": "http://www.vickersvantagecorp.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "sclx:WarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PublicWarrantsRedemptionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To09_30_2021",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLossOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To09_30_2021",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLossOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
     "shortName": "Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestIncomeSecuritiesUSTreasury",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
     "shortName": "Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "sclx:InitialMeasurementOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
     "shortName": "Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "4",
      "lang": null,
      "name": "sclx:UnderlyingWarrantValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
     "shortName": "Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs",
     "shortName": "Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
     "shortName": "Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "shortName": "Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
     "shortName": "Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Property and Equipment (Details) - Property and equipment consisted",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted",
     "shortName": "Property and Equipment (Details) - Property and equipment consisted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense",
     "shortName": "Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Goodwill and Intangible Assets (Details)",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Debt (Details)",
     "role": "http://www.vickersvantagecorp.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Debt (Details) - Summary of borrowings of the scilex pharma notes",
     "role": "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
     "shortName": "Debt (Details) - Summary of borrowings of the scilex pharma notes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:LongtermDebtfutureMinimumPaymentYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Debt (Details)  - Summary of future minimum payments under the scilex pharma notes",
     "role": "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes",
     "shortName": "Debt (Details)  - Summary of future minimum payments under the scilex pharma notes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:LongtermDebtfutureMinimumPaymentYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Stock Incentive and Employee Benefit Plans (Details)",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails",
     "shortName": "Stock Incentive and Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
     "shortName": "Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding",
     "shortName": "Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P03_01_2019To03_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PeriodDuringWhichShareTransferIsRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Acquisitions (Details)",
     "role": "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
     "shortName": "Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P03_01_2019To03_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PeriodDuringWhichShareTransferIsRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockRedemptionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Restatement of Previously Issued Financial Statements (Details)",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
     "shortName": "Restatement of Previously Issued Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockRedemptionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
     "shortName": "Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Income Taxes (Details)",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "sclx:TaxCreditCarryforwardExpirationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit",
     "shortName": "Income Taxes (Details) - Schedule of components of income tax expense (benefit)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:DeferredTaxAssetsInterestExpenseLimitations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:DeferredTaxAssetsInterestExpenseLimitations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate reconciliation",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation",
     "shortName": "Income Taxes (Details) - Schedule of effective income tax rate reconciliation",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Loss Per Share (Details)",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShareDetails",
     "shortName": "Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Description of Organization and Business Operations",
     "role": "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
     "shortName": "Description of Organization and Business Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
     "shortName": "Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "sclx:SponsorLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d374624ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 121,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
      "http://www.vickersvantagecorp.com/role/Warrants",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Company place of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
      "http://www.vickersvantagecorp.com/role/Warrants",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_AardvarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aardvark.",
        "label": "Aardvark [Member]"
       }
      }
     },
     "localname": "AardvarkMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AccountsReceivableRevolvingLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable revolving loan facility.",
        "label": "Accounts receivable revolving loan facility [Member]"
       }
      }
     },
     "localname": "AccountsReceivableRevolvingLoanFacilityMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AccretionOfCarryingValueToRedemptionValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Of Carrying Value To Redemption Value",
        "terseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "AccretionOfCarryingValueToRedemptionValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest.",
        "label": "Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AccruedPayroll": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll",
        "label": "Accrued payroll",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedPayroll",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AcquiredinprocessresearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired\u00a0in-process\u00a0research and development",
        "label": "Acquiredinprocessresearch and development",
        "terseLabel": "Acquired\u00a0in-process\u00a0research and development"
       }
      }
     },
     "localname": "AcquiredinprocessresearchAndDevelopment",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquistion costs incurred but not paid included in accounts payable.",
        "label": "Acquistion Costs Incurred But Not Paid Included In Accounts Payable",
        "terseLabel": "Semnur acquisition costs incurred but not paid in accounts payable"
       }
      }
     },
     "localname": "AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdditionalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional principal amount.",
        "label": "Additional Principal Amount",
        "terseLabel": "Additional principal amount"
       }
      }
     },
     "localname": "AdditionalPrincipalAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsRestatement2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments restatement 2.",
        "label": "Adjustments Restatement 2 [Member]",
        "terseLabel": "Adjustments Restatement 2 [Member]"
       }
      }
     },
     "localname": "AdjustmentsRestatement2Member",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital discount amortization.",
        "label": "Adjustments To Additional Paid In Capital Discount Amortization",
        "terseLabel": "Aardvark SP-104 discount amortization"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDiscountAmortization",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital net of discount.",
        "label": "Adjustments To Additional Paid In Capital Net Of Discount",
        "terseLabel": "Aardvark SP-104 license transfer from Sorrento, net of discount"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalNetOfDiscount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition",
        "label": "Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition",
        "terseLabel": "Adjustment to shares issued in Semnur Acquisition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdvancesFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 35.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances from related party.",
        "label": "Advances From Related Party",
        "terseLabel": "Advances from related party"
       }
      }
     },
     "localname": "AdvancesFromRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AggregateOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate outstanding amount.",
        "label": "Aggregate Outstanding Amount",
        "terseLabel": "Aggregate Outstanding Amount"
       }
      }
     },
     "localname": "AggregateOutstandingAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AggregatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Percentage.",
        "label": "Aggregate Percentage",
        "terseLabel": "Aggregate percentage"
       }
      }
     },
     "localname": "AggregatePercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_AggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Principal Amount.",
        "label": "Aggregate Principal Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "AggregatePrincipalAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement automatic renewal period on expiration of initial term.",
        "label": "Agreement Automatic Renewal Period On Expiration Of Initial Term",
        "terseLabel": "Agreement automatic renewal period on expiration of initial term"
       }
      }
     },
     "localname": "AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AgreementExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration date.",
        "label": "Agreement Expiration Date",
        "terseLabel": "Agreement expiration date"
       }
      }
     },
     "localname": "AgreementExpirationDate",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "sclx_AgreementExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration term.",
        "label": "Agreement Expiration Term",
        "terseLabel": "Agreement expiration term"
       }
      }
     },
     "localname": "AgreementExpirationTerm",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with certain of the third party professional service providers.",
        "label": "Agreement With Certain Of The Third Party Professional Service Providers [Member]"
       }
      }
     },
     "localname": "AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmendmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment.",
        "label": "Amendment [Axis]"
       }
      }
     },
     "localname": "AmendmentAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_AmendmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment.",
        "label": "Amendment [Domain]"
       }
      }
     },
     "localname": "AmendmentDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmendmentNoFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment no four.",
        "label": "Amendment No Four [Member]"
       }
      }
     },
     "localname": "AmendmentNoFourMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to two thousand nineteen stock option plan.",
        "label": "Amendment to two thousand nineteen Stock Option Plan [Member]",
        "terseLabel": "Amendment to 2019 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "AmendmentToTwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount distribution to acquire related contingent accelerated repayment notes.",
        "label": "Amount Distribution To Acquire Related Contingent Accelerated Repayment Notes",
        "terseLabel": "Amount distribution to acquire related contingent accelerated repayment notes"
       }
      }
     },
     "localname": "AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ApprovalBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approval Based Milestone [Member]"
       }
      }
     },
     "localname": "ApprovalBasedMilestoneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AprilOptionalRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April optional repurchase.",
        "label": "April Optional Repurchase [Member]"
       }
      }
     },
     "localname": "AprilOptionalRepurchaseMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AsRestatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As restated.",
        "label": "As Restated [Member]",
        "terseLabel": "As Restated [Member]"
       }
      }
     },
     "localname": "AsRestatedMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AssetAcquisitionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition price per share.",
        "label": "Asset Acquisition Price Per Share",
        "terseLabel": "Asset acquisition price per share"
       }
      }
     },
     "localname": "AssetAcquisitionPricePerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_BalanceInTheTrustAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance in the trust account.",
        "label": "Balance In The Trust Account",
        "terseLabel": "Balance in the trust account (in Dollars)"
       }
      }
     },
     "localname": "BalanceInTheTrustAccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_BusinessCombinationRedeemPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination redeem percentage.",
        "label": "Business Combination Redeem Percentage",
        "terseLabel": "Business combination redeem percentage"
       }
      }
     },
     "localname": "BusinessCombinationRedeemPercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_CapitalRaisingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Raising Description",
        "terseLabel": "Capital raising, description"
       }
      }
     },
     "localname": "CapitalRaisingDescription",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CapitalizationOfShareOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization of share outstanding.",
        "label": "Capitalization Of Share Outstanding",
        "terseLabel": "Capitalization of share outstanding (in Shares)"
       }
      }
     },
     "localname": "CapitalizationOfShareOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_ChangeInFairValueOfConversionOptionLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in fair value of conversion option liability.",
        "label": "Change In Fair Value Of Conversion Option Liability",
        "terseLabel": "Change in fair value of conversion option liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfConversionOptionLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ChangeInFairValueOfWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of warrant liability.",
        "label": "Change In Fair Value Of Warrant Liability",
        "negatedLabel": "Change in fair value of warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ChangeInValuationInputsOrOtherAssumptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in valuation inputs or other assumptions.",
        "label": "Change In Valuation Inputs Or Other Assumptions",
        "terseLabel": "Change in valuation inputs or other assumptions"
       }
      }
     },
     "localname": "ChangeInValuationInputsOrOtherAssumptions",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ClassificationOfCostAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of cost.",
        "label": "Classification of cost [Axis]"
       }
      }
     },
     "localname": "ClassificationOfCostAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ClassificationOfCostDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of cost.",
        "label": "Classification of cost [Domain]"
       }
      }
     },
     "localname": "ClassificationOfCostDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_CoPaymentAssistancePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co payment assistance.",
        "label": "Co Payment Assistance [Policy Text Block]",
        "terseLabel": "Co-Payment Assistance"
       }
      }
     },
     "localname": "CoPaymentAssistancePolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommonStockAggregateValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock with an aggregate value.",
        "label": "Common Stock Aggregate Value",
        "terseLabel": "Common stock aggregate value (in Dollars)"
       }
      }
     },
     "localname": "CommonStockAggregateValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CommonStockValueToBeExchanged": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock value to be exchanged.",
        "label": "Common Stock Value To Be Exchanged",
        "terseLabel": "Common stock value to be exchanged"
       }
      }
     },
     "localname": "CommonStockValueToBeExchanged",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CompensationAndEmployeeBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation and employee benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Abstract]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_CompensationAndEmployeeBenefitPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation and employee benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Line Items]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CompensationAndEmployeeBenefitPlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation and employee benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Table]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ContributionAndLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution and loan agreement.",
        "label": "Contribution And Loan Agreement [Member]"
       }
      }
     },
     "localname": "ContributionAndLoanAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ConversionOptionLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Option Liability Member",
        "terseLabel": "Conversion Option Liability [Member]"
       }
      }
     },
     "localname": "ConversionOptionLiabilityMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ConvertiblePromisoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promisory Note Member",
        "terseLabel": "Convertible Promissory Note [Member]"
       }
      }
     },
     "localname": "ConvertiblePromisoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ConvertiblePromissoryNote": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note.",
        "label": "Convertible Promissory Note"
       }
      }
     },
     "localname": "ConvertiblePromissoryNote",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CoronavirusAidReliefAndEconomicSecurityActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus aid, relief, and economic security act.",
        "label": "Coronavirus Aid, Relief, and Economic Security Act [Member]"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_CumulativeSalesRelatedContingencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative sales related contingency.",
        "label": "Cumulative Sales Related Contingency [Member]"
       }
      }
     },
     "localname": "CumulativeSalesRelatedContingencyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DebtExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt exchange agreement.",
        "label": "Debt Exchange Agreement [Member]"
       }
      }
     },
     "localname": "DebtExchangeAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, percentage of principal amount repurchased.",
        "label": "Debt Instrument, Percentage of Principal Amount Repurchased",
        "terseLabel": "Debt instrument, percentage of principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfPrincipalAmountRepurchased",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DebtInstrumentRepurchaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Repurchase Obligation",
        "label": "Debt Instrument Repurchase Obligation",
        "terseLabel": "Debt instrument repurchase obligation"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseObligation",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DebtInstrumentTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, termination date.",
        "label": "Debt Instrument, termination Date",
        "terseLabel": "Debt instrument, termination date"
       }
      }
     },
     "localname": "DebtInstrumentTerminationDate",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "sclx_DebtInstrumentredemptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument,redemption period.",
        "label": "Debt Instrument,Redemption period",
        "terseLabel": "Debt instrument,redemption period"
       }
      }
     },
     "localname": "DebtInstrumentredemptionPeriod",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_DecemberOptionalRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December optional repurchase.",
        "label": "December Optional Repurchase [Member]"
       }
      }
     },
     "localname": "DecemberOptionalRepurchaseMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DeferredConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "deferred consideration",
        "label": "Deferred Consideration",
        "terseLabel": "Deferred consideration"
       }
      }
     },
     "localname": "DeferredConsideration",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsInterestExpenseLimitations": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets interest expense limitations.",
        "label": "Deferred Tax Assets Interest expense limitations",
        "terseLabel": "Interest expense limitations"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpenseLimitations",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredUnderwritingCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Underwriting Commission.",
        "label": "Deferred Underwriting Commission",
        "terseLabel": "Deferred underwriting commission percentage"
       }
      }
     },
     "localname": "DeferredUnderwritingCommission",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DeferredUnderwritingCommissionPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Underwriting Commission Payable.",
        "label": "Deferred Underwriting Commission Payable",
        "terseLabel": "Underwriting commission payable percentage"
       }
      }
     },
     "localname": "DeferredUnderwritingCommissionPayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Underwriting Fees means the amount of deferred underwriting fees held in the Trust Account in connection with SPAC's initial public offering payable to the underwriters upon consummation of a business combination.",
        "label": "Deferred Underwriting Fee Payable",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingFeePayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredUnderwritingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fees.",
        "label": "Deferred Underwriting Fees",
        "terseLabel": "Deferred underwriting fees"
       }
      }
     },
     "localname": "DeferredUnderwritingFees",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator Abstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DepositIntoTheTrustAccountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit into the trust account per share.",
        "label": "Deposit Into The Trust Account Per Share",
        "terseLabel": "Deposit into the trust account per share (in Dollars per share)"
       }
      }
     },
     "localname": "DepositIntoTheTrustAccountPerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_DepositedInTrustAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposited in trust account",
        "label": "Deposited In Trust Account",
        "terseLabel": "Trust account"
       }
      }
     },
     "localname": "DepositedInTrustAccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Depositintotrustaccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit Into Trust Account.",
        "label": "DepositIntoTrustAccount",
        "terseLabel": "Deposit into trust account"
       }
      }
     },
     "localname": "Depositintotrustaccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DerivativeLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability, noncurrent.",
        "label": "Derivative Liability Noncurrent",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityNoncurrent",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfOrganizationAndBusinessOperationsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Line Items]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Table]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations [Table]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due on or after february two thousand and thirty.",
        "label": "Due On Or After February Two Thousand And Thirty [Member]"
       }
      }
     },
     "localname": "DueOnOrAfterFebruaryTwoThousandAndThirtyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation debt discount and interest limitation.",
        "label": "Effective Income Tax Rate Reconciliation Debt Discount and Interest Limitation",
        "terseLabel": "Debt discount and interest limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation return to provision adjustments and carryback.",
        "label": "Effective Income Tax Rate Reconciliation Return to Provision Adjustments and Carryback",
        "terseLabel": "Return to provision adjustments and carryback"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_EventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event.",
        "label": "Event [Axis]"
       }
      }
     },
     "localname": "EventAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_EventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event.",
        "label": "Event [Domain]"
       }
      }
     },
     "localname": "EventDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_EventTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event type.",
        "label": "Event Type [Axis]"
       }
      }
     },
     "localname": "EventTypeAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_EventTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event type.",
        "label": "Event Type [Domain]"
       }
      }
     },
     "localname": "EventTypeDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ExclusiveDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive distribution agreement.",
        "label": "Exclusive Distribution Agreement [Member]"
       }
      }
     },
     "localname": "ExclusiveDistributionAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FairValueMeasurementStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strike price.",
        "label": "Fair Value Measurement Strike Price",
        "terseLabel": "Strike price"
       }
      }
     },
     "localname": "FairValueMeasurementStrikePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueOfWarrantsinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrantsin Dollars",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrantsinDollars",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_FebruaryOptionalRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February optional repurchase.",
        "label": "February Optional Repurchase [Member]"
       }
      }
     },
     "localname": "FebruaryOptionalRepurchaseMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 8.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets amortization expense after year four.",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 52.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formation cost paid through advances from affiliate of Sponsor.",
        "label": "Formation Cost Paid Through Advances From Affiliate Of Sponsor",
        "terseLabel": "Formation cost paid through advances from affiliate of Sponsor"
       }
      }
     },
     "localname": "FormationCostPaidThroughAdvancesFromAffiliateOfSponsor",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FounderSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares Member",
        "terseLabel": "Founder Shares [Member]"
       }
      }
     },
     "localname": "FounderSharesMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_Foundershares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder Shares.",
        "label": "FounderShares",
        "terseLabel": "Founder shares (in Shares)"
       }
      }
     },
     "localname": "Foundershares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_FourHundredAndOneKPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four hundred and one (k) Plan .",
        "label": "Four hundred and one (k) Plan [Member]",
        "terseLabel": "401(k) Plan [Member]"
       }
      }
     },
     "localname": "FourHundredAndOneKPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FundingCommitmentLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding commitment letter.",
        "label": "Funding Commitment Letter [Member]"
       }
      }
     },
     "localname": "FundingCommitmentLetterMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_GainLossOnDerivative": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 15.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on derivative.",
        "label": "Gain (Loss) on Derivative",
        "verboseLabel": "Gain on derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivative",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_GainLossOnExtinguishmentOfDebtt": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 16.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on extinguishment of debtt.",
        "label": "Gain (Loss) on Extinguishment of Debtt",
        "terseLabel": "(Gain) loss on debt extinguishment, net"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtt",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_GrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Grossproceedsofwarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds Of Warrants.",
        "label": "GrossProceedsOfWarrants",
        "terseLabel": "Gross proceeds of amount"
       }
      }
     },
     "localname": "Grossproceedsofwarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_HoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Holding period return is the total return received from holding an asset or portfolio of assets over a period of time, generally expressed as a percentage.",
        "label": "Holding Period",
        "terseLabel": "Holding period"
       }
      }
     },
     "localname": "HoldingPeriod",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_IfLetterOfCreditIsDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "If Letter Of Credit Is Drawn [Member]"
       }
      }
     },
     "localname": "IfLetterOfCreditIsDrawnMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_IncreaseInNotesPayableOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 43.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in notes payable one.",
        "label": "Increase In Notes Payable One",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "IncreaseInNotesPayableOne",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IndebentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indebenture.",
        "label": "Indebenture [Member]"
       }
      }
     },
     "localname": "IndebentureMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_IndefiniteCarryforwardPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "indefinite carryforward period.",
        "label": "Indefinite Carryforward Period [Member]"
       }
      }
     },
     "localname": "IndefiniteCarryforwardPeriodMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InitialMeasurementOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Measurement One",
        "terseLabel": "Initial measurement"
       }
      }
     },
     "localname": "InitialMeasurementOne",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Interestexpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expenses.",
        "label": "InterestExpenses",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "Interestexpenses",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_InvesteeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Axis]"
       }
      }
     },
     "localname": "InvesteeAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_InvesteeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Domain]"
       }
      }
     },
     "localname": "InvesteeDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InvestmentOfCashInTrustAccounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment of cash in Trust Account.",
        "label": "Investment Of Cash In Trust Accounts",
        "negatedLabel": "Investment of cash in Trust Account"
       }
      }
     },
     "localname": "InvestmentOfCashInTrustAccounts",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ItochuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Itochu.",
        "label": "Itochu [Member]"
       }
      }
     },
     "localname": "ItochuMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Abstract",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LessAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LessAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Abstract0",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LessAbstract0",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LesserPublicPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lesser public per share",
        "label": "Lesser Public Per Share",
        "terseLabel": "Lesser public per share (in Dollars per share)"
       }
      }
     },
     "localname": "LesserPublicPerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_LetterOfCreditDrawnDownMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit drawn down.",
        "label": "Letter Of Credit Drawn Down [Member]"
       }
      }
     },
     "localname": "LetterOfCreditDrawnDownMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LimitationOfOutstandingAmountInExchangeOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limitation of Outstanding Amount In Exchange of Shares",
        "label": "Limitation of Outstanding Amount In Exchange of Shares",
        "terseLabel": "Limitation of Outstanding Amount In Exchange of Shares"
       }
      }
     },
     "localname": "LimitationOfOutstandingAmountInExchangeOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LineOfCreditFacilityindebtednessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility ,indebtedness amount.",
        "label": "Line of Credit Facility ,indebtedness Amount",
        "terseLabel": "Line of credit facility, indebtedness amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityindebtednessAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LiquidityAndGoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going Concern.",
        "label": "Liquidity And Going Concern [Abstract]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern [Line Items]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern [Table]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern [Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_LongtermDebtFutureMinimumPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment.",
        "label": "LongTerm Debt, Future Minimum Payment",
        "totalLabel": "Total minimum future payments"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPayment",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 5.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year five.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearFive",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 4.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year four.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearFour",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 3.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year three.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearThree",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 2.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year two.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearTwo",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtfutureMinimumPaymentYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 1.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt,\u00a0Future minimum payment , year one.",
        "label": "LongTerm Debt,Future minimum payment , year one",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongtermDebtfutureMinimumPaymentYearOne",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LossOnInitialIssuanceOfWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss On Initial Issuance Of Warrant Liability",
        "terseLabel": "Loss on initial issuance of private warrants"
       }
      }
     },
     "localname": "LossOnInitialIssuanceOfWarrantLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MarketingApprovalLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing approval letter.",
        "label": "Marketing Approval Letter [Member]"
       }
      }
     },
     "localname": "MarketingApprovalLetterMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MaximumCompensationCostToBeAvailableProratedBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum compensation cost to be available, prorated basis.",
        "label": "Maximum Compensation Cost To Be Available, Prorated Basis",
        "terseLabel": "Maximum compensation cost to be available, prorated basis"
       }
      }
     },
     "localname": "MaximumCompensationCostToBeAvailableProratedBasis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of volume weighted average price of shares measured on a daily basis that is eligible to be received as advance.",
        "label": "Maximum Percentage Of Volume Weighted Average Price Of Shares Measured On A Daily Basis That Is Eligible To Be Received As Advance"
       }
      }
     },
     "localname": "MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_MeasurementInputEffectiveDebtYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, effective debt yield .",
        "label": "Measurement Input, Effective Debt Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputEffectiveDebtYieldMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, estimated probability of not obtaining marketing approval before july 1, 2023 .",
        "label": "Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before July 1, 2023 [Member]"
       }
      }
     },
     "localname": "MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, estimated probability of not obtaining marketing approval before march 31, 2021 .",
        "label": "Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before March 31, 2021 [Member]"
       }
      }
     },
     "localname": "MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MeasurementInputRiskadjustedNetSalesForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, risk-adjusted net sales forecast .",
        "label": "Measurement Input, RiskAdjusted Net Sales Forecast [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskadjustedNetSalesForecastMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MergerConsiderationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger consideration description.",
        "label": "Merger Consideration Description",
        "terseLabel": "Merger consideration description"
       }
      }
     },
     "localname": "MergerConsiderationDescription",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "milestone payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumCashRequirementsToRepurchaseOfNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash requirements to repurchase of notes.",
        "label": "Minimum Cash Requirements To Repurchase Of Notes",
        "terseLabel": "Minimum cash requirements to repurchase of Notes"
       }
      }
     },
     "localname": "MinimumCashRequirementsToRepurchaseOfNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumPayrollCostToBeAvailable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum payroll cost to be available.",
        "label": "Minimum payroll cost to be available",
        "terseLabel": "Minimum payroll cost to be available"
       }
      }
     },
     "localname": "MinimumPayrollCostToBeAvailable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum threshold percentage for recognition of uncertain income tax position.",
        "label": "Minimum Threshold Percentage for Recognition of Uncertain Income Tax Position",
        "terseLabel": "Minimum threshold percentage for recognition of uncertain income tax position"
       }
      }
     },
     "localname": "MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum time declared to file with sec regarding resale registration statement.",
        "label": "Minimum Time Declared To File With SEC Regarding Resale Registration Statement",
        "terseLabel": "Minimum time declared to file with sec regarding resale registration statement"
       }
      }
     },
     "localname": "MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_MinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum unrestricted cash balance.",
        "label": "Minimum Unrestricted Cash Balance",
        "terseLabel": "Minimum unrestricted cash balance"
       }
      }
     },
     "localname": "MinimumUnrestrictedCashBalance",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum unrestricted cash requirements to repurchase of notes.",
        "label": "Minimum Unrestricted Cash Requirements To Repurchase Of Notes",
        "terseLabel": "Minimum unrestricted cash requirements to repurchase of Notes"
       }
      }
     },
     "localname": "MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NetTangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net tangible assets.",
        "label": "Net Tangible Assets",
        "terseLabel": "Net tangible assets (in Dollars)"
       }
      }
     },
     "localname": "NetTangibleAssets",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NetWorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net working capital.",
        "label": "Net Working Capital",
        "terseLabel": "Net working capital"
       }
      }
     },
     "localname": "NetWorkingCapital",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashDistributionToAcquiree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash distribution to acquiree.",
        "label": "Non Cash Distribution To Acquiree",
        "terseLabel": "Non-cash distribution to Sorrento"
       }
      }
     },
     "localname": "NonCashDistributionToAcquiree",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashFairValueAdjustmentToDerivativeLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash fair value adjustment to derivative liability.",
        "label": "Non Cash Fair Value Adjustment To Derivative Liability",
        "terseLabel": "Fair value adjustment to derivative liability in troubled debt restructuring"
       }
      }
     },
     "localname": "NonCashFairValueAdjustmentToDerivativeLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashIncreaseInPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash increase in principal.",
        "label": "Non Cash Increase In Principal",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "NonCashIncreaseInPrincipal",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashOperatingLeaseCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 46.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash operating lease costs.",
        "label": "Non Cash Operating Lease Costs",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashOperatingLeaseCosts",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash right of use asset.",
        "label": "Non Cash Right Of Use Asset",
        "terseLabel": "Live Action\u00a0right-of-use\u00a0asset in Palo Alto"
       }
      }
     },
     "localname": "NonCashRightOfUseAsset",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonPayrollCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-payroll costs.",
        "label": "Non Payroll Costs [Member]"
       }
      }
     },
     "localname": "NonPayrollCostsMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice of termination period for cancellation of automatic renewal.",
        "label": "Notice of Termination Period for Cancellation of Automatic Renewal",
        "terseLabel": "Notice of termination period for cancellation of automatic renewal"
       }
      }
     },
     "localname": "NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NoticePeriodForTerminationOfWorkOrder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period for termination of work order.",
        "label": "Notice Period for Termination of Work Order",
        "terseLabel": "Notice period for termination of work order"
       }
      }
     },
     "localname": "NoticePeriodForTerminationOfWorkOrder",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days for determining the volume weighted average price of shares.",
        "label": "Number Of Consecutive Trading Days For Determining The Volume Weighted Average Price Of Shares"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for determining the weighted volume average price for shares.",
        "label": "Number Of Days For Determining The Weighted Volume Average Price For Shares",
        "terseLabel": "Number of days for determining the weighted volume averge price of shares"
       }
      }
     },
     "localname": "NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NumberOfSaleUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of sale units",
        "label": "Number Of Sale Units",
        "terseLabel": "Number of sale units"
       }
      }
     },
     "localname": "NumberOfSaleUnits",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares acquired.",
        "label": "Number Of Shares Acquired",
        "terseLabel": "Number of shares acquired"
       }
      }
     },
     "localname": "NumberOfSharesAcquired",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfSharesLimits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares limits.",
        "label": "Number Of Shares Limits",
        "terseLabel": "Number of shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfSharesLimits",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares outstanding.",
        "label": "Number Of Shares Outstanding",
        "terseLabel": "Capital stock, shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of threshold trading days prior to date of notice to the shareholders for determining the volume weighted average price of shares.",
        "label": "Number Of Threshold Trading Days Prior To Date Of Notice To The Shareholders For Determining The Volume Weighted Average Price Of Shares"
       }
      }
     },
     "localname": "NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_Numberofbusinessdays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Days.",
        "label": "NumberOfBusinessDays",
        "terseLabel": "Number of business days"
       }
      }
     },
     "localname": "Numberofbusinessdays",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sclx_Numberofshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares.",
        "label": "NumberOfShares",
        "terseLabel": "Number of shares (in Shares)"
       }
      }
     },
     "localname": "Numberofshares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_OfferingCostIncludedInAccruedOfferingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering cost included in accrued offering cost.",
        "label": "Offering Cost Included In Accrued Offering Cost",
        "terseLabel": "Offering costs included in accrued offering costs"
       }
      }
     },
     "localname": "OfferingCostIncludedInAccruedOfferingCost",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OperatingCashFlowsFromOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating cash flows from operating leases.",
        "label": "Operating Cash Flows From Operating Leases",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingCashFlowsFromOperatingLeases",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OperatingExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating expenses.",
        "label": "Operating Expenses [Member]"
       }
      }
     },
     "localname": "OperatingExpensesMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforward expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_OrdinarySharesIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Ordinary Shares Issuance Cost",
        "negatedLabel": "Ordinary shares issuance costs"
       }
      }
     },
     "localname": "OrdinarySharesIssuanceCost",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OrdinarySharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares issued and outstanding.",
        "label": "Ordinary Shares Issued And Outstanding",
        "terseLabel": "Ordinary shares issued and outstanding (in Shares)"
       }
      }
     },
     "localname": "OrdinarySharesIssuedAndOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OrdinarySharesRedemptionSubjectedToForfeiture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption subjected to forfeiture.",
        "label": "Ordinary Shares Redemption Subjected To Forfeiture",
        "terseLabel": "Ordinary shares redemption subjected to forfeiture"
       }
      }
     },
     "localname": "OrdinarySharesRedemptionSubjectedToForfeiture",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OrdinarySharesSubjectToPossibleRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares Subject To Possible Redemption",
        "terseLabel": "Subject to possible redemption shares",
        "verboseLabel": "Ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "OrdinarySharesSubjectToPossibleRedemption",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OtherLoanForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other loan forgiveness.",
        "label": "Other Loan Forgiveness",
        "terseLabel": "Other loan forgiveness"
       }
      }
     },
     "localname": "OtherLoanForgiveness",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Otherofferingcosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OtherOfferingCosts.",
        "label": "OtherOfferingCosts"
       }
      }
     },
     "localname": "Otherofferingcosts",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaloAltoAadministrativeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palo Alto Aadministrative Facility",
        "label": "Palo Alto Aadministrative Facility [Member]"
       }
      }
     },
     "localname": "PaloAltoAadministrativeFacilityMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program.",
        "label": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PaymentMadeInSurrenderingTheShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made in surrendering the shares.",
        "label": "Payment Made In Surrendering The Shares",
        "terseLabel": "Payment made in surrendering the shares"
       }
      }
     },
     "localname": "PaymentMadeInSurrenderingTheShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentToAcquireInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to acquire inventory.",
        "label": "Payment To Acquire Inventory",
        "terseLabel": "Payment to acquire inventory"
       }
      }
     },
     "localname": "PaymentToAcquireInventory",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentToDepositIntoASeggregateReserveFund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to deposit into a seggregate reserve fund.",
        "label": "Payment To Deposit Into A Seggregate Reserve Fund",
        "terseLabel": "Payment to deposit into a seggregate reserve fund"
       }
      }
     },
     "localname": "PaymentToDepositIntoASeggregateReserveFund",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentToDepositIntoASegregatedCollateralAccount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to deposit into a segregated collateral account.",
        "label": "Payment To Deposit Into A Segregated Collateral Account",
        "terseLabel": "Payment to deposit into a segregated collateral account"
       }
      }
     },
     "localname": "PaymentToDepositIntoASegregatedCollateralAccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PayrollCostsBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll costs basis.",
        "label": "Payroll Costs Basis [Member]"
       }
      }
     },
     "localname": "PayrollCostsBasisMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share calculation of Outstanding Amount In Exchange of Shares",
        "label": "Per share calculation of Outstanding Amount In Exchange of Shares",
        "terseLabel": "Per share calculation of Outstanding Amount In Exchange of Shares"
       }
      }
     },
     "localname": "PerShareCalculationOfOutstandingAmountInExchangeOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PercentageOfAggregateRoyalityPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate royality payments.",
        "label": "Percentage of Aggregate Royality Payments",
        "terseLabel": "Percentage of aggregate royality payments"
       }
      }
     },
     "localname": "PercentageOfAggregateRoyalityPayments",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfAnnualAdjustmentToFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual adjustment to fees.",
        "label": "Percentage Of Annual Adjustment To Fees",
        "terseLabel": "Percentage of annual adjustment to fees"
       }
      }
     },
     "localname": "PercentageOfAnnualAdjustmentToFees",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfCapitalSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of capital shares outstanding.",
        "label": "Percentage Of Capital Shares Outstanding",
        "terseLabel": "Percentage of capital shares outstanding"
       }
      }
     },
     "localname": "PercentageOfCapitalSharesOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfConcentrationOnASimilarProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of concentration on a similar product.",
        "label": "Percentage of concentration on a similar product",
        "terseLabel": "Percentage of concentration on a similar product"
       }
      }
     },
     "localname": "PercentageOfConcentrationOnASimilarProduct",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of daily volume weighted average price of shares at which the shares are eligible to be purchased.",
        "label": "Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased"
       }
      }
     },
     "localname": "PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfDistributionFeeReceivedOverThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of distribution fee received over the period.",
        "label": "Percentage Of Distribution Fee Received Over The Period",
        "terseLabel": "Percentage of distribution fee received over the period"
       }
      }
     },
     "localname": "PercentageOfDistributionFeeReceivedOverThePeriod",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfLoanForgivenessUnderTheAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of loan forgiveness under the act.",
        "label": "Percentage Of Loan Forgiveness Under The Act",
        "terseLabel": "Percentage of loan forgiveness under the act"
       }
      }
     },
     "localname": "PercentageOfLoanForgivenessUnderTheAct",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfNetSalesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales payable.",
        "label": "Percentage Of Net Sales Payable",
        "terseLabel": "Percentage of net sales payable"
       }
      }
     },
     "localname": "PercentageOfNetSalesPayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfOutstandingAmountIndebtedness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding amount indebtedness",
        "label": "Percentage of Outstanding Amount Indebtedness",
        "terseLabel": "Percentage of Outstanding Amount Indebtedness"
       }
      }
     },
     "localname": "PercentageOfOutstandingAmountIndebtedness",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfOwnershipInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership interest.",
        "label": "Percentage Of Ownership Interest",
        "terseLabel": "Percentage of ownership interest"
       }
      }
     },
     "localname": "PercentageOfOwnershipInterest",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfPublicShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of public shares.",
        "label": "Percentage Of Public Shares",
        "terseLabel": "Percentage of public shares"
       }
      }
     },
     "localname": "PercentageOfPublicShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of purchase price in cash equal is to principal amount of the loan.",
        "label": "Percentage Of Purchase Price In Cash Equal Is To Principal Amount Of The Loan",
        "terseLabel": "Percentage of purchase price in cash equal is to principal amount of the loan"
       }
      }
     },
     "localname": "PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of quarterly payments of the principal notes equal to a fixed percentage.",
        "label": "Percentage Of Quarterly Payments Of The Principal Notes Equal To A Fixed Percentage",
        "terseLabel": "Percentage of quarterly payments of the principal Notes equal to a fixed percentage"
       }
      }
     },
     "localname": "PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares issued subject to restriction of transfer.",
        "label": "Percentage Of Shares Issued Subject To Restriction Of Transfer",
        "terseLabel": "Percentage of shares issued subject to restriction of transfer"
       }
      }
     },
     "localname": "PercentageOfSharesIssuedSubjectToRestrictionOfTransfer",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares outstanding.",
        "label": "Percentage Of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfSimpleInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of simple interest.",
        "label": "Percentage Of Simple Interest",
        "terseLabel": "Percentage of simple interest"
       }
      }
     },
     "localname": "PercentageOfSimpleInterest",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the principal amount from Holders on pro rata basis.",
        "label": "Percentage Of The Principal Amount From Holders On Pro Rata Basis",
        "terseLabel": "Percentage of the principal amount from Holders on pro rata basis"
       }
      }
     },
     "localname": "PercentageOfThePrincipalAmountFromHoldersOnProRataBasis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfThePrincipalAmountOfTheNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the principal amount of the notes.",
        "label": "Percentage Of The Principal Amount Of The Notes",
        "terseLabel": "Percentage of the principal amount of the Notes"
       }
      }
     },
     "localname": "PercentageOfThePrincipalAmountOfTheNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period after registration when the request could be made to the investee to purchase the shares.",
        "label": "Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares"
       }
      }
     },
     "localname": "PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period.",
        "label": "Period [Axis]"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period.",
        "label": "Period [Domain]"
       }
      }
     },
     "localname": "PeriodDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PeriodDuringWhichShareTransferIsRestricted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which share transfer is restricted.",
        "label": "Period During Which Share Transfer Is Restricted",
        "terseLabel": "Period during which share transfer is restricted"
       }
      }
     },
     "localname": "PeriodDuringWhichShareTransferIsRestricted",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_PeriodDuringWhichTheSharesMayBeExchanged": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which the shares may be exchanged.",
        "label": "Period During Which The Shares May Be Exchanged",
        "terseLabel": "Period during which the shares may be exchanged"
       }
      }
     },
     "localname": "PeriodDuringWhichTheSharesMayBeExchanged",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_PlusAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus Abstract",
        "terseLabel": "Plus:"
       }
      }
     },
     "localname": "PlusAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PricePerPublicShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Per Public Share",
        "terseLabel": "Anticipated public share (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerPublicShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PricePerShareForDeterminingTheExchangeOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share for determining the exchange of shares.",
        "label": "Price Per Share For Determining The Exchange Of Shares",
        "terseLabel": "Price per share for determining the exchange of shares"
       }
      }
     },
     "localname": "PricePerShareForDeterminingTheExchangeOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PricePerWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per warrant.",
        "label": "Price Per Warrants",
        "terseLabel": "Price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerWarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PrivatePlacementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement (Details) [Line Items]"
       }
      }
     },
     "localname": "PrivatePlacementDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement (Details) [Table]"
       }
      }
     },
     "localname": "PrivatePlacementDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for private placement.",
        "label": "Private Placement Text Block",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PrivatePlacementWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Warrant [Member].",
        "label": "Private Placement Warrant Member",
        "terseLabel": "Private Placement Warrant [Member]"
       }
      }
     },
     "localname": "PrivatePlacementWarrantMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProceedsFromPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from promissory note related party.",
        "label": "Proceeds From Promissory Note Related Party",
        "terseLabel": "Proceeds from promissory note \u2013 related party"
       }
      }
     },
     "localname": "ProceedsFromPromissoryNoteRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsFromSimplePromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from simple promissory note \u2013 related party.",
        "label": "Proceeds From Simple Promissory Note Related Party",
        "terseLabel": "Proceeds from simple promissory note \u2013 related party"
       }
      }
     },
     "localname": "ProceedsFromSimplePromissoryNoteRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Of Initial Public Offering.",
        "label": "Proceeds Of Initial Public Offering",
        "terseLabel": "Proceeds of initial public offering"
       }
      }
     },
     "localname": "ProceedsOfInitialPublicOffering",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProductDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development agreement.",
        "label": "Product Development Agreement [Member]"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProjectAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project agreement.",
        "label": "Project Agreement [Member]",
        "terseLabel": "Project Agreement [Member]"
       }
      }
     },
     "localname": "ProjectAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PromissoryNoteIssuedNetOfDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note issued net of discount.",
        "label": "Promissory Note Issued Net Of Discount",
        "terseLabel": "Promissory Note issued to Sorrento in exchange for the\u00a0SP-104\u00a0license, net of discount"
       }
      }
     },
     "localname": "PromissoryNoteIssuedNetOfDiscount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note.",
        "label": "Promissory Note [Member]"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PromissoryNoteRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Related Party Member",
        "terseLabel": "Promissory Note - Related Party [Member]"
       }
      }
     },
     "localname": "PromissoryNoteRelatedPartyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProposedPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Abstract]"
       }
      }
     },
     "localname": "ProposedPublicOfferingAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ProposedPublicOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proposed Public Offering Text Block",
        "terseLabel": "PUBLIC OFFERING"
       }
      }
     },
     "localname": "ProposedPublicOfferingTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PublicOfferingDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering (Details) [Line Items]"
       }
      }
     },
     "localname": "PublicOfferingDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PublicOfferingDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering (Details) [Table]"
       }
      }
     },
     "localname": "PublicOfferingDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PublicWarrantsRedemptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Redemption Description",
        "terseLabel": "Public warrants redemption, description"
       }
      }
     },
     "localname": "PublicWarrantsRedemptionDescription",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price Per Share",
        "terseLabel": "Purchase price per unit (in Dollars per share)"
       }
      }
     },
     "localname": "PurchasePricePerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_RebatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates [Policy Text Block]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "RebatesPolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_RegulatoryBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Based Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryBasedMilestoneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RelatedPartyNotePayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party note payable, current.",
        "label": "Related Party Note Payable Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "RelatedPartyNotePayableCurrent",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyNotePayableNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party note payable, non current.",
        "label": "Related Party Note Payable Noncurrent",
        "terseLabel": "Related party note payable, net"
       }
      }
     },
     "localname": "RelatedPartyNotePayableNoncurrent",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]",
        "verboseLabel": "Related Party Transactions [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]",
        "verboseLabel": "Related Party Transactions [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ReorganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reorganization.",
        "label": "Reorganization [Member]"
       }
      }
     },
     "localname": "ReorganizationMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RepaidAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repaid Amount.",
        "label": "Repaid Amount",
        "terseLabel": "Repaid amount"
       }
      }
     },
     "localname": "RepaidAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RepaymentOfPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of promissory note \u2013 related party.",
        "label": "Repayment Of Promissory Note Related Party",
        "negatedLabel": "Repayment of promissory note \u2013 related party"
       }
      }
     },
     "localname": "RepaymentOfPromissoryNoteRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted funds relesable for future repurchase of debt.",
        "label": "Restricted Funds Relesable For Future Repurchase Of Debt",
        "terseLabel": "Restricted funds releasable for future repurchase of debt"
       }
      }
     },
     "localname": "RestrictedFundsRelesableForFutureRepurchaseOfDebt",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RevenueToBeEarnedByTheAcquireeValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to be earned by the acquiree value.",
        "label": "Revenue To Be Earned By The Acquiree Value",
        "terseLabel": "Revenue to be earned by the acquiree value"
       }
      }
     },
     "localname": "RevenueToBeEarnedByTheAcquireeValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ReveueBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reveue Based Milestone [Member]"
       }
      }
     },
     "localname": "ReveueBasedMilestoneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RomegLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Romeg License Agreement",
        "label": "Romeg License Agreement [Member]"
       }
      }
     },
     "localname": "RomegLicenseAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SaleOfStockDescriptionOfTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock description of transaction.",
        "label": "Sale Of Stock Description Of Transactions",
        "terseLabel": "Sale of stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransactions",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_Saleofwarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Warrants.",
        "label": "SaleOfWarrants",
        "terseLabel": "Sale of warrants (in Shares)"
       }
      }
     },
     "localname": "Saleofwarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SalesOperationsServicesMonthlyFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales operations services monthly fee.",
        "label": "Sales Operations Services Monthly Fee",
        "terseLabel": "Sales operations services monthly fee"
       }
      }
     },
     "localname": "SalesOperationsServicesMonthlyFee",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SalesReturnsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales returns.",
        "label": "Sales Returns [Policy Text Block]",
        "terseLabel": "Product Returns"
       }
      }
     },
     "localname": "SalesReturnsPolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_SalesThresholdLimit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales threshold limit.",
        "label": "Sales Threshold Limit",
        "terseLabel": "Sales threshold limit"
       }
      }
     },
     "localname": "SalesThresholdLimit",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of change in the fair value of conversion option liability.",
        "label": "Schedule Of Change In The Fair Value Of Conversion Option Liability [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of change in the fair value of conversion option liability.",
        "label": "Schedule Of Change In The Fair Value Of Conversion Option Liability [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of change in the fair value of conversion option liability.",
        "label": "Schedule Of Change In The Fair Value Of Conversion Option Liability [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities And Conversion Option Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Hierarchy Of The Valuation Inputs Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments of long term debt.",
        "label": "Schedule Of Future minimum payments Of Long Term Debt [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments of long term debt.",
        "label": "Schedule Of Future minimum payments Of Long Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments of long term debt.",
        "label": "Schedule Of Future minimum payments Of Long Term Debt [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Payments Under the Scilex Pharma Notes"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Ordinary Shares Reflected In Condensed Consolidated Balance Sheets Are Reconciled Abstract"
       }
      }
     },
     "localname": "ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Quantitative Information Regarding Level3 Fair Value Measurements Abstract"
       }
      }
     },
     "localname": "ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reflects The Calculation Of Basic And Diluted Net Income Loss Per Ordinary Share Abstract"
       }
      }
     },
     "localname": "ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental quantitative information related to leases.",
        "label": "Schedule Of Supplemental Quantitative Information Related To Leases [Table Text Block]",
        "terseLabel": "Summary of Supplemental Quantitative Information Related To Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Valued Using The Compound Option Pricing Model Abstract"
       }
      }
     },
     "localname": "ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScilexCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scilex Common Stock Member",
        "terseLabel": "Scilex Common Stock [Member]"
       }
      }
     },
     "localname": "ScilexCommonStockMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma.",
        "label": "Scilex Pharma [Member]"
       }
      }
     },
     "localname": "ScilexPharmaMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma note.",
        "label": "Scilex Pharma Note [Member]"
       }
      }
     },
     "localname": "ScilexPharmaNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma notes.",
        "label": "Scilex Pharma Notes [Member]"
       }
      }
     },
     "localname": "ScilexPharmaNotesMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNotesPrincipalIncrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 17.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex Pharma Notes principal increase",
        "label": "Scilex Pharma Notes principal increase",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "ScilexPharmaNotesPrincipalIncrease",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ScilexPharmaTwoThousandSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma two thousand seventeen plan.",
        "label": "Scilex Pharma two thousand seventeen Plan [Member]",
        "terseLabel": "Scilex Pharma 2017 Plan [Member]"
       }
      }
     },
     "localname": "ScilexPharmaTwoThousandSeventeenPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SellingGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, general and administrative expense.",
        "label": "Selling, General And Administrative Expenses",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured notes due two thousand and twenty six.",
        "label": "Senior Secured Notes Due Two Thousand And Twenty Six [Member]"
       }
      }
     },
     "localname": "SeniorSecuredNotesDueTwoThousandAndTwentySixMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SenmurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senmur [Member]"
       }
      }
     },
     "localname": "SenmurMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ServiceFeesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service fees.",
        "label": "Service Fees [Policy Text Block]",
        "terseLabel": "Service Fees"
       }
      }
     },
     "localname": "ServiceFeesPolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Per Share Of Common Stock On Date Of Grant",
        "terseLabel": "Fair value per share of common stock on date of grant",
        "verboseLabel": "Fair value per share of common stock on date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "ShareBased Compensation Arrangement by ShareBased Payment Award, Option, Outstanding, Number",
        "terseLabel": "Share based compensation arrangement,Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SharesCapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares capitalization.",
        "label": "Shares Capitalization",
        "terseLabel": "Shares capitalization"
       }
      }
     },
     "localname": "SharesCapitalization",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_SharesSubjectToPossibleRedemption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares subject to possible redemption.",
        "label": "Shares Subject To Possible Redemption",
        "terseLabel": "Ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "SharesSubjectToPossibleRedemption",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SoleDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sole distributor.",
        "label": "Sole Distributor [Member]"
       }
      }
     },
     "localname": "SoleDistributorMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SorrentoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento.",
        "label": "Sorrento [Member]"
       }
      }
     },
     "localname": "SorrentoMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SponsorLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor loan.",
        "label": "Sponsor Loan",
        "terseLabel": "Sponsor loan"
       }
      }
     },
     "localname": "SponsorLoan",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor Member.",
        "label": "Sponsor [Member]"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_StandbyEquityPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby equity purchase agreement.",
        "label": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StandbyEquityPurchaseAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_StatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement .",
        "label": "Statement [Axis]"
       }
      }
     },
     "localname": "StatementAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_StatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement.",
        "label": "Statement [Domain]"
       }
      }
     },
     "localname": "StatementDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SubjectToPossibleRedemptionPerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subject To possible redemption per shares.",
        "label": "Subject To Possible Redemption Per Shares",
        "terseLabel": "Subject to possible redemption per shares (in Dollars per share)"
       }
      }
     },
     "localname": "SubjectToPossibleRedemptionPerShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward, expiration year.",
        "label": "Tax Credit Carryforward, Expiration Year",
        "terseLabel": "Tax credit carryforward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of agreement notice period for a request to cure material breach of the agreement.",
        "label": "Termination Of Agreement Notice Period For a Request To Cure Material Breach Of The Agreement",
        "terseLabel": "Termination of aggrement notice period for a request to cure material breach of the agreement"
       }
      }
     },
     "localname": "TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_ThresholdMinimumPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold minimum percentage of sales.",
        "label": "Threshold Minimum Percentage Of Sales",
        "terseLabel": "Threshold minimum percentage of sales"
       }
      }
     },
     "localname": "ThresholdMinimumPercentageOfSales",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Four [Member]",
        "terseLabel": "Tranche 4 [Member]"
       }
      }
     },
     "localname": "TrancheFourMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche 1 [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche 3 [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche 2 [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TransactionCostsAllocatedToWarrantLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs allocated to warrant liabilities.",
        "label": "Transaction Costs Allocated To Warrant Liabilities",
        "negatedLabel": "Transaction costs allocated to warrant liabilities"
       }
      }
     },
     "localname": "TransactionCostsAllocatedToWarrantLiabilities",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Transactioncostsamount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Amount.",
        "label": "TransactionCostsAmount",
        "terseLabel": "Transaction costs amount"
       }
      }
     },
     "localname": "Transactioncostsamount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TransactionsCostsAllocatedToPrivateWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 42.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs allocated to warrant liabilities.",
        "label": "Transactions Costs Allocated To Private Warrants",
        "terseLabel": "Transaction costs allocated to warrant liabilities"
       }
      }
     },
     "localname": "TransactionsCostsAllocatedToPrivateWarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen purchase agreements and indenture.",
        "label": "Two Thousand and Eighteen Purchase Agreements and Indenture [Member]",
        "terseLabel": "2018 Purchase Agreements and Indenture [Member]"
       }
      }
     },
     "localname": "TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandAndEighteenPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Eighteen Purchase Agreements [Member]",
        "terseLabel": "2018 Purchase Agreements [Member]"
       }
      }
     },
     "localname": "TwoThousandAndEighteenPurchaseAgreementsMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandAndTwentyTwoPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty two promissory note.",
        "label": "Two Thousand And Twenty Two Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyTwoPromissoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock option Plan .",
        "label": "Two thousand nineteen Stock Option Plan [Member]",
        "terseLabel": "2019 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandTwentyTwoPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Promissory Note [Member]",
        "terseLabel": "2022 Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoPromissoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_UnamortizedDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unamortized debt discount.",
        "label": "Unamortized Debt Discount",
        "terseLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "UnamortizedDebtDiscount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_UnderlyingWarrantValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underlying warrant value",
        "label": "Underlying Warrant Value",
        "terseLabel": "Underlying warrant value"
       }
      }
     },
     "localname": "UnderlyingWarrantValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_UpfrontlicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "up-front\u00a0license fee",
        "label": "Upfront License Fee"
       }
      }
     },
     "localname": "UpfrontlicenseFee",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_VantageMergerSubIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vantage merger sub inc.",
        "label": "Vantage Merger Sub Inc [Member]"
       }
      }
     },
     "localname": "VantageMergerSubIncMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_VickersVantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vickers vantage .",
        "label": "Vickers Vantage [Member]",
        "terseLabel": "Vicker's Vantage"
       }
      }
     },
     "localname": "VickersVantageMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
      "http://www.vickersvantagecorp.com/role/Warrants",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_WarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercise price.",
        "label": "Warrant Exercise Price"
       }
      }
     },
     "localname": "WarrantExercisePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_WarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Abstract"
       }
      }
     },
     "localname": "WarrantsAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Line Items]"
       }
      }
     },
     "localname": "WarrantsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "localname": "WarrantsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price",
        "label": "Warrants Exercise Price",
        "terseLabel": "Warrant price per share (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantsExercisePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_WarrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Line item]",
        "label": "Warrants [Line Items]"
       }
      }
     },
     "localname": "WarrantsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Warrants"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants outstanding shares.",
        "label": "Warrants Outstanding Shares",
        "terseLabel": "Warrants outstanding shares"
       }
      }
     },
     "localname": "WarrantsOutstandingShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_WarrantsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Percentage.",
        "label": "Warrants Percentage",
        "terseLabel": "Warrants percentage"
       }
      }
     },
     "localname": "WarrantsPercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_WarrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Table]"
       }
      }
     },
     "localname": "WarrantsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Warrants"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Text Block",
        "terseLabel": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_WorkOrderImplementationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work order implementation fee.",
        "label": "Work Order Implementation Fee",
        "terseLabel": "Work order implementation fee"
       }
      }
     },
     "localname": "WorkOrderImplementationFee",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_WorkingCapitalRequirements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital requirements.",
        "label": "Working Capital Requirements",
        "terseLabel": "Working capital requirements"
       }
      }
     },
     "localname": "WorkingCapitalRequirements",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_YorkvilleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yorkville.",
        "label": "Yorkville [Member]"
       }
      }
     },
     "localname": "YorkvilleMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_aggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "aggregate purchase price.",
        "label": "aggregate Purchase Price",
        "terseLabel": "Aggregate purchase price value"
       }
      }
     },
     "localname": "aggregatePurchasePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r200",
      "r362",
      "r363",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r282",
      "r328",
      "r433",
      "r440",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r713",
      "r715",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r282",
      "r328",
      "r433",
      "r440",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r713",
      "r715",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r200",
      "r362",
      "r363",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r253",
      "r259",
      "r260",
      "r261",
      "r262",
      "r282",
      "r328",
      "r388",
      "r433",
      "r440",
      "r472",
      "r473",
      "r474",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r713",
      "r715",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r253",
      "r259",
      "r260",
      "r261",
      "r262",
      "r282",
      "r328",
      "r388",
      "r433",
      "r440",
      "r472",
      "r473",
      "r474",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r713",
      "r715",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r127",
      "r129",
      "r130",
      "r132",
      "r133",
      "r156",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Adjustments Restatement 1 [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r156",
      "r214",
      "r215",
      "r511",
      "r561",
      "r562",
      "r563",
      "r564",
      "r608",
      "r628",
      "r629",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r156",
      "r214",
      "r215",
      "r511",
      "r561",
      "r562",
      "r563",
      "r564",
      "r608",
      "r628",
      "r629",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r1",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r132",
      "r133",
      "r156",
      "r214",
      "r215",
      "r511",
      "r561",
      "r562",
      "r563",
      "r564",
      "r608",
      "r628",
      "r629",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r128",
      "r134",
      "r258",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r117",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r117",
      "r542",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r117",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table Text Block]",
        "terseLabel": "Schedule of impact of these adjustments to the financial statement, as previously reported"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r128",
      "r134",
      "r258",
      "r438",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r648",
      "r650",
      "r653",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 38.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r682",
      "r706"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r17",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Acquired Finite-Lived Intangible Asset, Residual Value",
        "terseLabel": "Acquired Finite-Lived Intangible Asset, Residual Value"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired finite lived intangible assets, weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r31",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 43.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Additional Paid-in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional amount borrowed"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r480",
      "r481",
      "r482",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r76",
      "r93",
      "r302",
      "r600"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 41.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r93",
      "r302",
      "r312",
      "r313",
      "r602"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 51.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r93",
      "r231",
      "r241"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible amortization",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "AssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition, consideration transferred",
        "verboseLabel": "Asset acquisition total consideration transferred"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r537",
      "r538",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Asset acquistion consideration transferred equity interest issued and issuable"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Asset acquistion contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r21",
      "r111",
      "r181",
      "r190",
      "r196",
      "r212",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r544",
      "r549",
      "r585",
      "r638",
      "r640",
      "r677",
      "r699"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r39",
      "r111",
      "r212",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r544",
      "r549",
      "r585",
      "r638",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets:"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldInTrust": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Assets Held-in-trust",
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.",
        "label": "Assets Held-in-trust",
        "terseLabel": "Deposited trust account",
        "verboseLabel": "Trust account"
       }
      }
     },
     "localname": "AssetsHeldInTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldInTrustCurrent": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Assets Held-in-trust, Current",
        "terseLabel": "Assets held in the trust account"
       }
      }
     },
     "localname": "AssetsHeldInTrustCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Assets Held-in-trust, Noncurrent",
        "terseLabel": "Investments held in Trust Account \u2013 U.S. Treasury Securities Money Market Fund"
       }
      }
     },
     "localname": "AssetsHeldInTrustNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r556",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r429",
      "r439",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r429",
      "r439",
      "r526",
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs amount"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business combination equity interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAcquiredReceivablesDescription": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of receivable acquired in business combination.",
        "label": "Business Combination, Acquired Receivables, Description",
        "terseLabel": "Business combination description"
       }
      }
     },
     "localname": "BusinessCombinationAcquiredReceivablesDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Equity interest from business combination"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationControlObtainedDescription": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a description of how the entity obtained control of the acquired entity.",
        "label": "Business Combination, Control Obtained Description",
        "terseLabel": "Business combination, description"
       }
      }
     },
     "localname": "BusinessCombinationControlObtainedDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationReasonForBusinessCombination": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply.",
        "label": "Business Combination, Reason for Business Combination",
        "terseLabel": "Business combination, description"
       }
      }
     },
     "localname": "BusinessCombinationReasonForBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Redeem percentage"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r14",
      "r640",
      "r729",
      "r730"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r14",
      "r95"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r89",
      "r95",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r89",
      "r591"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal depository insurance coverage"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r108",
      "r111",
      "r140",
      "r141",
      "r146",
      "r149",
      "r151",
      "r161",
      "r162",
      "r163",
      "r212",
      "r266",
      "r271",
      "r272",
      "r273",
      "r277",
      "r278",
      "r326",
      "r327",
      "r331",
      "r335",
      "r342",
      "r585",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Sale of warrants (in Shares)",
        "verboseLabel": "Aggregate purchase of private placement warrants (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r683",
      "r705"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 45.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r263",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance under plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock shares subscribed but not issued"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r30",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Common stock shares subscribed but not issued value"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 42.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively",
        "verboseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r365",
      "r366",
      "r441",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Incentive and Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r200",
      "r580",
      "r581",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r200",
      "r580",
      "r581",
      "r728",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r200",
      "r580",
      "r581",
      "r728",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r166",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r170",
      "r171",
      "r200",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r200",
      "r580",
      "r581",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r117",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "terseLabel": "RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r25",
      "r679",
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible promissory notes"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible promissory notes \u2014 related party, net of discount"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r23",
      "r678",
      "r697",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r71",
      "r111",
      "r212",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r585"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Fund expenses"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r507",
      "r514"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r507",
      "r514",
      "r516"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r507",
      "r514"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r169",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r98",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r303",
      "r304",
      "r306",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Debt Instrument, Annual Principal Payment",
        "verboseLabel": "Debt instrument, annual principal payment"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r110",
      "r117",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r310",
      "r311",
      "r312",
      "r313",
      "r603",
      "r678",
      "r679",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r25",
      "r307",
      "r679",
      "r697"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "auth_ref": [
      "r693"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets pledged to secure a debt instrument.",
        "label": "Debt Instrument, Collateral Amount",
        "terseLabel": "Debt instrument, collateral amount"
       }
      }
     },
     "localname": "DebtInstrumentCollateralAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Debt instrument, decrease, forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r279",
      "r310",
      "r311",
      "r601",
      "r603",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "terseLabel": "Debt instrument, increase (decrease), net"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r48",
      "r309",
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument interest rate effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage",
        "verboseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r49",
      "r282",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50",
      "r110",
      "r117",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r310",
      "r311",
      "r312",
      "r313",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r50",
      "r692"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt instrument, periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Debt instrument, repurchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the debt instrument was repurchased, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Repurchase Date",
        "terseLabel": "Debt instrument, repurchase date"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt instrument face amount of debt repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r110",
      "r117",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r310",
      "r311",
      "r312",
      "r313",
      "r343",
      "r347",
      "r348",
      "r349",
      "r600",
      "r601",
      "r603",
      "r604",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r292",
      "r600",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r600",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "terseLabel": "Debt related commitment Fees and debt issuance costs"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r20",
      "r676",
      "r698"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r508",
      "r514"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r112",
      "r508",
      "r514",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Current portion of deferred consideration"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 37.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Long-term deferred consideration"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r508",
      "r514"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r503",
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r489",
      "r500"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease\u00a0right-of-use\u00a0assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan matching contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds": {
     "auth_ref": [
      "r727"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.",
        "label": "Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 48.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Gain on derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative",
        "terseLabel": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r579"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "periodEndLabel": "Fair value ending",
        "periodStartLabel": "Fair value beginning",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, Measurement input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Derivative, Loss on derivative"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r552",
      "r553",
      "r554",
      "r555",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Effect of Dilutive Securities"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DistributionsOnMandatorilyRedeemableSecurities": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 13.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distributions during the period on mandatorily redeemable securities.",
        "label": "Distributions on Mandatorily Redeemable Securities",
        "negatedLabel": "Interest on mandatorily redeemable ordinary shares liability",
        "terseLabel": "Interest on mandatorily redeemable ordinary shares liability"
       }
      }
     },
     "localname": "DistributionsOnMandatorilyRedeemableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r22",
      "r115",
      "r633",
      "r731"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Advances outstanding"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r41",
      "r115",
      "r269",
      "r271",
      "r272",
      "r276",
      "r277",
      "r278",
      "r633"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r136",
      "r140",
      "r149",
      "r150",
      "r151",
      "r156",
      "r157",
      "r563",
      "r564",
      "r686",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Basic Loss Per Share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net (loss) income per share, ordinary shares (in Dollars per share)",
        "verboseLabel": "Basic and diluted net income (loss) per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r140",
      "r149",
      "r150",
      "r151",
      "r156",
      "r157",
      "r563",
      "r564",
      "r686",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Dilutive Loss Per Share",
        "disclosureGuidance": "Diluted net income (loss) per ordinary share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net (loss) income per share, ordinary shares (in Dollars per share)",
        "verboseLabel": "Basic and diluted net income (loss) per ordinary share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r154",
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rates",
        "verboseLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r113",
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal tax rate",
        "verboseLabel": "Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "In-process\u00a0research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r491",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r61",
      "r62",
      "r63",
      "r119",
      "r120",
      "r121",
      "r123",
      "r130",
      "r133",
      "r160",
      "r213",
      "r342",
      "r350",
      "r480",
      "r481",
      "r482",
      "r510",
      "r511",
      "r562",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r629",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Shareholder issued and outstanding shares percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r88",
      "r211",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments Held in Trust Account"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Purchase of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r93",
      "r318"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r565",
      "r566",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value hierarchy of the valuation inputs"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r294",
      "r310",
      "r311",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r428",
      "r566",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r574",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "auth_ref": [
      "r580",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.",
        "label": "Fair Value, Concentration of Risk [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r294",
      "r389",
      "r390",
      "r395",
      "r428",
      "r566",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r294",
      "r310",
      "r311",
      "r389",
      "r390",
      "r395",
      "r428",
      "r566",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r294",
      "r310",
      "r311",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r428",
      "r566",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r570",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r570",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Initial measurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Re-measurement\u00a0of fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value measurement",
        "verboseLabel": "Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r294",
      "r310",
      "r311",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r428",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsHighestAndBestUseDescription": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reasons that a nonfinancial asset is being used in a manner that differs from its highest and best use.",
        "label": "Fair Value Measurements, Highest and Best Use, Description",
        "terseLabel": "Initial measurement, description"
       }
      }
     },
     "localname": "FairValueMeasurementsHighestAndBestUseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Change in fair value of conversion option liability"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible asset, Useful life",
        "verboseLabel": "Finite lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r19",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (Remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r232",
      "r236",
      "r240",
      "r244",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r240",
      "r660"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r232",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r240",
      "r659"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Finite lived intangible assets, remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 19.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "(Gain) loss on foreign currency exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r93",
      "r687"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "Gain (Loss) on Sale of Derivatives",
        "terseLabel": "Loss on initial issuance of private warrants"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r93",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 45.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on debt extinguishment, net",
        "verboseLabel": "Gain on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r18",
      "r222",
      "r224",
      "r226",
      "r229",
      "r640",
      "r675"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r227",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r93",
      "r223",
      "r225",
      "r228",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "verboseLabel": "Initial Public Offering [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r93",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible assets excluding goodwill"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development Expense"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r181",
      "r189",
      "r192",
      "r195",
      "r197",
      "r673",
      "r684",
      "r690",
      "r710"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 21.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement Abstract"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r492",
      "r496",
      "r502",
      "r512",
      "r518",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax examination, penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r132",
      "r133",
      "r180",
      "r490",
      "r513",
      "r519",
      "r711"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 22.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r487",
      "r488",
      "r496",
      "r497",
      "r501",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Long-term deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Net tangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r230",
      "r238"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities.",
        "label": "Interest Income, Debt Securities, Held-to-Maturity",
        "negatedLabel": "Income earned on investments held in Trust Account"
       }
      }
     },
     "localname": "InterestAndDividendIncomeSecuritiesHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r179",
      "r599",
      "r602",
      "r689"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 18.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease": {
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r749"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in interest income on deposit with financial institution.",
        "label": "Interest Income, Deposit with Financial Institution, Increase (Decrease)",
        "terseLabel": "Deposit interest income"
       }
      }
     },
     "localname": "InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 14.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Income earned on investments held in Trust Account"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasury": {
     "auth_ref": [
      "r688"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.",
        "label": "Interest Income, Securities, US Treasury",
        "terseLabel": "Investments held in Trust Account \u2013 U.S. Treasury Securities Money Market Fund"
       }
      }
     },
     "localname": "InterestIncomeSecuritiesUSTreasury",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r87",
      "r90",
      "r97"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 44.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r7",
      "r37",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r36",
      "r104",
      "r159",
      "r217",
      "r218",
      "r219",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r75",
      "r178"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 20.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseDepositLiability": {
     "auth_ref": [
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.",
        "label": "Lease Deposit Liability",
        "terseLabel": "Sponsors deposited (in Dollars)"
       }
      }
     },
     "localname": "LeaseDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (Remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Leases remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r111",
      "r191",
      "r212",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r545",
      "r549",
      "r550",
      "r585",
      "r638",
      "r639"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r111",
      "r212",
      "r585",
      "r640",
      "r680",
      "r703"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Liabilities assumed in a non cash transaction"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r47",
      "r111",
      "r212",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r545",
      "r549",
      "r550",
      "r585",
      "r638",
      "r639",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Warrant Liability \u2013 Private Placement Warrants"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Acquired licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r25",
      "r293",
      "r308",
      "r310",
      "r311",
      "r679",
      "r700"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Current portion",
        "terseLabel": "Current portion of debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Long term portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term deposit"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "verboseLabel": "Notes payable, noncurrent"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinimumNetWorthRequiredForCompliance": {
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r736"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework.",
        "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum",
        "terseLabel": "Minimum net worth to consummate business combination",
        "verboseLabel": "Minimum net worth to consummate business combination"
       }
      }
     },
     "localname": "MinimumNetWorthRequiredForCompliance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used for investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r89",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash flow from operation",
        "totalLabel": "Net cash used for operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r4",
      "r58",
      "r59",
      "r63",
      "r67",
      "r94",
      "r111",
      "r122",
      "r124",
      "r125",
      "r127",
      "r128",
      "r132",
      "r133",
      "r147",
      "r181",
      "r189",
      "r192",
      "r195",
      "r197",
      "r212",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r564",
      "r585",
      "r685",
      "r708"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 53.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "presentationGuidance": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r136",
      "r137",
      "r148",
      "r151",
      "r181",
      "r189",
      "r192",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Denominator for Basic Loss Per Share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r139",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Denominator for Diluted Loss per Share \u2014 Adjusted for Dilutive Securities"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of net shares reclassified to mandatorily redeemable capital stock.",
        "label": "Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value",
        "terseLabel": "Mandatorily redeemable ordinary shares"
       }
      }
     },
     "localname": "NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Deferred consideration for Romeg intangible asset acquisition"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoninterestBearingDepositLiabilities": {
     "auth_ref": [
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of all domestic and foreign noninterest-bearing deposits liabilities held by the entity.",
        "label": "Noninterest-Bearing Deposit Liabilities",
        "terseLabel": "Non-interest-bearing loans"
       }
      }
     },
     "localname": "NoninterestBearingDepositLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Offering costs paid through promissory note \u2013 related party"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r40",
      "r115",
      "r634"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 36.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Promissory note \u2014 related party"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r115",
      "r633",
      "r707"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Notes Payable, Related Parties",
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Notes payable, related parties",
        "verboseLabel": "Notes Payable, Related Parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r181",
      "r189",
      "r192",
      "r195",
      "r197"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Operating loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r615",
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities as of December\u00a031, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r618",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate\u00a0\u2014\u00a0operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r617",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in\u00a0years\u00a0\u2014\u00a0operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r5",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118",
      "r135",
      "r175",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued offering costs"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Other Commitments, Description",
        "terseLabel": "Underwriting agreement, description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherDeferredCostsNet": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.",
        "label": "Other Deferred Costs, Net",
        "terseLabel": "Offering costs amount"
       }
      }
     },
     "localname": "OtherDeferredCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r74",
      "r712"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Dissolution expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Component of Operating Income [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Net tangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Conversion option liability",
        "verboseLabel": "Conversion Option Liability"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermNotesPayable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.",
        "label": "Other Notes Payable, Noncurrent",
        "terseLabel": "Simple promissory notes"
       }
      }
     },
     "localname": "OtherLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "totalLabel": "Total other (income) expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOwnershipInterestsOfferingCosts": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of offering costs allocated to the other unit holders.",
        "label": "Other Ownership Interests, Offering Costs",
        "terseLabel": "Other offering costs"
       }
      }
     },
     "localname": "OtherOwnershipInterestsOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Other Significant Noncash Transaction, Value of Consideration Given",
        "terseLabel": "Non-cash\u00a0consideration in Semnur acquisition"
       }
      }
     },
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherUnderwritingExpense": {
     "auth_ref": [
      "r712",
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.",
        "label": "Other Underwriting Expense",
        "terseLabel": "Cash underwriting fees"
       }
      }
     },
     "localname": "OtherUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patent rights"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfOtherEquity": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to reacquire equity classified as other.",
        "label": "Payments for Repurchase of Other Equity",
        "negatedLabel": "Redemption of ordinary shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r79",
      "r535"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Acquisition consideration paid in cash for Romeg intangible asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Semnur, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r80",
      "r537",
      "r538",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant, and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToEmployees": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period.",
        "label": "Payments to Employees",
        "terseLabel": "Payment to employees"
       }
      }
     },
     "localname": "PaymentsToEmployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r29",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Series A preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preference shares, par value (in Dollars per share)",
        "verboseLabel": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r325",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Ordinary per share"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preference shares, authorized",
        "verboseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r29",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preference shares, shares issued",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preference shares, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 41.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredUnitsAuthorized": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of preferred units authorized to be issued.",
        "label": "Preferred Units, Authorized",
        "terseLabel": "Stock authority to issue"
       }
      }
     },
     "localname": "PreferredUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r38",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "verboseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDecommissioningFund": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of assets held in a decommissioning trust fund.",
        "label": "Proceeds from Decommissioning Trust Fund Assets",
        "terseLabel": "Cash withdrawn from Trust Account in connection with redemption"
       }
      }
     },
     "localname": "ProceedsFromDecommissioningFund",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Gross proceeds from business combination"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.",
        "label": "Proceeds from Issuance of Medium-term Notes",
        "terseLabel": "Proceeds from related party note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "terseLabel": "Proceeds from other loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from senior secured notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from sale of Private Placement Warrants",
        "verboseLabel": "Aggregate purchase price (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r82",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from related party payable"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "terseLabel": "Repayment of promissory note \u2013 related party"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r479"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r252",
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r16",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r250",
      "r640",
      "r691",
      "r704"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r250",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross": {
     "auth_ref": [
      "r248",
      "r606",
      "r607",
      "r624"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.",
        "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r69",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Credit losses on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r413",
      "r632",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.",
        "label": "Related Party Tax Expense, Due to Affiliates, Deferred",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "RelatedPartyTaxExpenseDueToAffiliatesDeferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r632",
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Debt discount amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r413",
      "r632",
      "r633",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r26",
      "r605",
      "r621",
      "r626",
      "r627",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related Party Transaction, Description of Transaction",
        "terseLabel": "Description of related party extension loans"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Related Party transaction, selling, general and administrative expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r413",
      "r632",
      "r635",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r630",
      "r631",
      "r633",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Outstanding balance",
        "verboseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r84",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedLabel": "Repayment of related party note payable"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-Term Debt",
        "negatedLabel": "Repayment on other loans"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayment of advances from related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Repayment of principal on the Scilex Pharma Notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r485",
      "r657",
      "r744"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 49.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Semnur-related IPR&amp;D",
        "verboseLabel": "In process research and development costs expensed"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r14",
      "r101",
      "r674",
      "r701"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r95",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r14",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Opening bank account"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r350",
      "r640",
      "r702",
      "r720",
      "r725"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 44.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Accumulated Deficit",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Retained earnings accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r119",
      "r120",
      "r121",
      "r123",
      "r130",
      "r133",
      "r213",
      "r480",
      "r481",
      "r482",
      "r510",
      "r511",
      "r562",
      "r716",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue not from contract with customer"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r65",
      "r111",
      "r176",
      "r177",
      "r188",
      "r193",
      "r194",
      "r198",
      "r199",
      "r200",
      "r212",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r585",
      "r690"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r616",
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of units amount"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r543",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Sale of stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Warrant price per share (in Dollars per share)",
        "verboseLabel": "Contribution per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r170",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.",
        "label": "Scenario, Adjustment [Member]"
       }
      }
     },
     "localname": "ScenarioAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of change in the fair value of conversion option liability"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r50",
      "r117",
      "r310",
      "r312",
      "r343",
      "r347",
      "r348",
      "r349",
      "r600",
      "r601",
      "r604",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Borrowings of the Scilex Pharma Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of changes in the fair value of warrant liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share",
        "verboseLabel": "Summary of reconciliation of basic and diluted loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareTables",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r232",
      "r239",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r232",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of the Company's Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r243",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r448",
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary Of The Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valued using the compound option pricing model",
        "verboseLabel": "Summary Of Share Based Payment Award Options Issued To Employees And Nonemployees Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r108",
      "r161",
      "r162",
      "r321",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r335",
      "r340",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r28",
      "r29",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Business Combination [Member]",
        "verboseLabel": "Series of Individually Immaterial Business Acquisitions [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.",
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 47.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Share based compensation arrangement,vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "verboseLabel": "Expected stock-price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock-price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock-price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited/Cancelled, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Cancelled, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding, Ending, Aggregate Intrinsic Value",
        "periodStartLabel": "Outstanding, Beginning, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending, Options",
        "periodStartLabel": "Outstanding, Beginning, Options",
        "terseLabel": "Share based compensation arrangement,Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending, Weighted average exercise price",
        "periodStartLabel": "Outstanding, Beginning, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r447",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term (in years)",
        "verboseLabel": "Term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Number of shares (in Shares)",
        "verboseLabel": "Preferred Stock shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Ordinary share, per share",
        "verboseLabel": "Preferred Stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.",
        "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]",
        "terseLabel": "Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent",
        "terseLabel": "Mandatorily redeemable ordinary shares liability"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r102",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r108",
      "r111",
      "r140",
      "r141",
      "r146",
      "r149",
      "r151",
      "r161",
      "r162",
      "r163",
      "r212",
      "r266",
      "r271",
      "r272",
      "r273",
      "r277",
      "r278",
      "r326",
      "r327",
      "r331",
      "r335",
      "r342",
      "r585",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r54",
      "r61",
      "r62",
      "r63",
      "r119",
      "r120",
      "r121",
      "r123",
      "r130",
      "r133",
      "r160",
      "r213",
      "r342",
      "r350",
      "r480",
      "r481",
      "r482",
      "r510",
      "r511",
      "r562",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r629",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r160",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r29",
      "r30",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued related to Semnur Acquisition , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of ordinary shares to Sponsor"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r342",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of aggregate ordinary shares (in Shares)",
        "verboseLabel": "Distribution to Sorrento , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Cancellation of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Stock issued during period shares purchase of assets"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "terseLabel": "Ordinary shares, subject to forfeiture (in Shares)",
        "verboseLabel": "Cancellation of shares held in escrow related to Semnur Acquisition , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r342",
      "r350",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, Options",
        "terseLabel": "Stock options excercised , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r54",
      "r342",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Aggregate purchase price value",
        "verboseLabel": "Shares issued related to Semnur Acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of ordinary shares to Sponsor (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r29",
      "r30",
      "r342",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Distribution to Sorrento"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Cancellation of ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r54",
      "r342",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options excercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Value",
        "negatedLabel": "Accretion of Ordinary shares subject to possible redemption amount"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r33",
      "r34",
      "r111",
      "r208",
      "r212",
      "r585",
      "r640"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 39.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Total Shareholders' Equity (Deficit)",
        "totalLabel": "Total stockholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r350",
      "r353",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubordinatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents domestic or foreign subordinated debt. Subordinated debt has a lower priority of repayment in liquidation of the entity's assets.",
        "label": "Subordinated Debt [Member]"
       }
      }
     },
     "localname": "SubordinatedDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r598",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r598",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r598",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r641",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Acquired technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "terseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r266",
      "r271",
      "r272",
      "r273",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 40.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September 30, 2022 and December 31, 2021, respectively, at redemption value of $10.41 and $10.00, respectively, per share",
        "verboseLabel": "Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Allocation of net income (loss)"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other.",
        "label": "Temporary Equity, Other Changes",
        "terseLabel": "Mandatorily redeemable ordinary shares"
       }
      }
     },
     "localname": "TemporaryEquityOtherChanges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "auth_ref": [
      "r13",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Ordinary shares subject to possible redemption per share (in Dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Public Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r139",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, ordinary shares (in Shares) , diluted",
        "verboseLabel": "Basic and diluted weighted average ordinary shares outstanding (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r136",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Basic and diluted weighted average ordinary shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r136",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, ordinary shares (in Shares) , Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=126898705&loc=d3e5864-122674"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=118255708&loc=d3e21951-110878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13572-108611"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13587-108611"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123422147&loc=d3e41457-112716"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919106-209958"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.12)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.2)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "805",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505872&loc=d3e30785-158569"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r745": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r746": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r747": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r748": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r749": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r750": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r751": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r752": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule I",
   "Subsection": "04"
  },
  "r753": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "7",
   "Subparagraph": "Schedule II",
   "Subsection": "05"
  },
  "r754": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "9",
   "Subsection": "06"
  },
  "r755": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001193125-22-295370-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-295370-xbrl.zip
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M SXM5;TN3<XL8)VL]O9O4$L#!!0    ( )> ?E66MS;N&@(  -L$   1
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MY+)QS"ZQ,;N=3/"TU'X"4$L#!!0    ( )> ?E7("?)C!!,  "U)   0
M9#,W-#8R-&1E>#4Q+FAT;>U<_5/;2-+^W57^'Z:XVRU2KW!L((2O4$6 3;B7
M32C@DG?OM[$TMB>1)>V,9..K^^.ONV=&&DNR"1?8][8J5U=9D#5?W4]W/]T]
MYOC]W:]7)\?O+T[/3[J=X[O+NZN+DXO_VWK5&QR_-+_!XY?V<W;\]N/Y;^SM
MN[./5Q]OWFQ\?G]Y=[&!'[!N!]X[$TDNU,GQ^>4G=GOWV]7%FXVYC/+)X7[O
ME4PV&(_E.'FS$8M13J..K]UK4Z[&,MG*T^RPG^5'S/X^3/,\G9I'HS3)M[3\
MIS@<5+^/^%3&B\,[.16:?1!S=I-..:QT>G7Y[L.;#27'$UCJ^.W)Q?U$#F7.
MZ&!O3XY?7I]XRWMS;\/<M=TT-K-Q\G,RU-D1S@+'7G6*EG$H)AAQ^>L[=GMS
M]F9CO/-Z=V][=SP8;.]M;^_N#@YV]@]Z7[(Q'N'NS<;5QW<?C:B>;,/M4M][
M JF??$AG8CH4RBRVTP_8=G][FZT1TV#_*=:]#64L[MG[-(YD,F9GZ33CR:(N
MLR?&V,G!7I_=\H2=)GF:R!0>\VC=69]DT6L>I^PTSM. G8$YC5*52,X.=G?Z
M.VO.2R#Y[K5OQ*'1;/-?HX%NIZZ"&S&6.E<\EVG";G.>BRGX" :__)*J*3O^
MY>.'N])53&0NMG3&0W&8I'/%,]#L%I@KOG2R[G1/ J(K'DEXPI.(O8,]QKC3
MPS7J?!*+^2S8A,\$XV$N(L8U"],BT2)F><K:41TPSLY%S.=<"7A;9:F5[F8^
M$>SGOPQV7Q^!OSN^/+$#CE]>GJ#+PX_VCUX$3"8P+DE$2,/F,I\P')HID7$[
M%PBAVQG)&-<M7_A[[[;';D58*)D[25W<AQ.>C 7N;BJU7K41^UEC+UFA=,$!
M$7!>'.9-?QH"3D8,/.).@)+AH(\(A-28?GE,8PF8 T=\$Q*[G6_#HIW3H;RQ
MI?;%6C01Q@4IES,%.D4,9"K5&>BFT P4  ]*^:\X06/QZW*&QH*T"*X'XM[D
M+XSMPOAN!_0#>@@%'DU/ %NZ=DB<8^\( 3J=POHZ3\.OH#^NV(S'A6!_[??Z
M_?Z 94*9"=AF'0.T;1C6V%:1P4>XEK@7*I2:=@$ 5X ,S7!K((?APM].0/#;
M'%9G@,-I'M<.X"]+(\I9\[3; ?0!?+58?JUU/1H\$3$]#X7*.9B1-LA;3,!$
MA:I+C% [2N,XG>O#U0%\[['Q&WG:Z=NK"S?5VX\WYQ<W6\#)KDZO;R\.W0]K
M74_=3VTP,\V;C?X&.[NXNKH^/3^__/"N_/WV^O3,_?[Y\OSN_9N-0;__TX;9
MSPT 8@'"?\,V,CX66T,E^-<MF6@9B4,^2V5D7SQW@W=_J@YU=U[[\-5/&^R3
MY7 @E)+/&>:X*5_X8_S/ED;Y\F;+(F;?Z[J/6&U3J'C?B(H,C6PW&/1W S ,
MA\D6:Y4S,&7VV0"3W=)[-1.I0[G;:369M,AU#D!%"\_LO%D,/HP<10G]A_90
M7_V(P$LBAW]N\!_$WP\X/Q6<_SQXW@OV#PZ"@_W]U7@NAK$,U\(9?6D LXT%
M#%84X+H=G*?=%@)67^-1MM(>799,Q6QYC7TLG>GAT["6PYAC=#LMY_AA;W^T
MO?VW&EQ%8>KAHXXFXB.#8+ W"%Z_WC.2J,&4;89 /I#FST2\"):A=V-66H'
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MDH9$)>8#(!!?/+,@J65D\(X6F)]_+[  :CV$L9H86)US#F5>U>UX?LB32VE
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M,Q*N26#4!"]LCNL"(H_BP;+="LF_:@%2)K>QC&SP,MC:1,R8]H>;A-HK$8K
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MZI=LZ<H^N[JZ7E,#/WZ)?_ ('M*?2?HW4$L#!!0    ( )> ?E4M?+;6  H
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MWC@&V8IHV^7]%MPC8]R[1/I+W_5@FOBE8QLP"B[F")U=">MT_N8L9N9!>,+
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MPTT:AZGS'X_PSB#=&SZ;/@-IP-F+5QE?"9(%._HP#&JU? &'.3KZ7K5*[X>
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M:?'F%AUXG[01X8_,WN?L<>A]U(CO.=$U;!!<VGOIH]H 5N3^@(R8-?VHW8-
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MK6XV911]WID^]U]:6ERMO;S7.M>:?GYXN ;1E+:DM*5MTY8:C>W0EMXL8N5
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M1\=U(;B#80O'KY!Z*/7E,;=;9T(QO%^2_SPP5X0R -0$_N8&,C,*Y9\=!T
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MC%\2.4,[2QJ=2SHQP_B&6;O/DSN% >42%G(V)0S$24B%I()@.E1NO8THL<,
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M-&E*Q@J*"WI8Q-(.["FQ?X6^,Y$%"Q8[AL1*4Q;TNM<LK34B0U<)(4.-+\P
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M9F%FBYPPLM(0JN57CN'+\S6HL'^S,?/"%;7($YY_N"&5J@RK@%<X\!HB[^?
M8H8G=H)%;@_J>I6"T?'.;P(7#:-#$()"[B&&L.@982ZQ9)$A>1Y0 4H!:@U
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M2L%S+&;#@#%C%7<Q.B(V@; ;IKPF?@.F\9W!C6 3NP9O?R3<M+!@17#/ Z:
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M'+$.M#O!N*&76?2$KSF W5$ ]WCO%WLKN*GD+_BF$=!U@M/<A]=+^CI]E_)
M)F H 0\I)#B)A(,D]VS>!FN0/UJ_+\QKYG@/PL#G[0S;5G';N<1M%T:T>;Z:
M1L7FY\ZW>^W^2[NGW74[O;O6Y?VWWFO8?]RF.OKGFN(@1;$9$^Y)D<KC08TN
M+ARI%=@O9Z0$.3*2RZ,762,![P1%@&&%8:']2NX;K7E1J>I9"D-9;DARH9^P
M'48 -."%K4OQ2__TLX82^%&+W72'U!H$MY/]'\M"H0=!P)Q@%:)U:K/:4KD
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M8@(NB3'()\,%%DB8X%X:=F?#%%](OAC$WX1-4#:ALQ (\02R"9VS3\@>80;
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MILUM(]G:X%]!]%1%R!&0KB3+6]=[.\+EI=I][;;&<MWJ?K],@$221!D$V$A
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M2=;+95)ADE"V(6\WK*"6.B2V[1C"#)LDD><SEE9Z.?- '!P'KZ8RE\'Q$C=
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MZ+67&+7\<LW7*42-;5Q,2D^EF>7IH)P,]TK>L8M31_([W8E-;LT5MS,ONJ'
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M\VXDI3>!@<VR.DSD<4-8.N1!7\Z+; 9/I*2=A1=/#05G:4$1N &'/&6H8-O
MV1Y5VGO6>U<T+6Q#\ QJ)I6V RII?);7?D<*=_H>L5K/1JS6=X75VBF5SE!1
MEV4K'5A@P6 !DF:Z"/8WJMVTM7'RDOK)@HJ=LM[&_Z!:/^Y%68#IE*T<,XP>
M\O0L[?MJ4GV,IC!0'*PQC'FG%.A])<UWF*$CY!GC/DWOJ*<"ECW&G:0_-R=&
M4!/H"M^&-&K5^DY-0Y:FQ<*=H^B@W8*6KU$/0].P5PE-VY(/O N8>\+>XB!.
MN<$"%@!<<;O314F K"M4:K:9P-&>)?@!H('#H5^I'8E-9(,^$YT&Q/ATZO&
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MYB9_X&&MK]Z]?/6/YQ[7NMNK'[I7XX=/L=8 )FC%>%"*ECZ('AV=_7C]X]Q
MZ+%N'/I\LJMV&M*9&]+9T:/E?(<OR<NKP[2T1F\LDKRNS&><O,4ZK<KI G82
MEA"E( )KDQZ"*%"1SS1962RH>'##SSO3SSO25P[@S*F*1(5/$>=<7!3@')'(
MS)<8">;($1/#Z9A=$M/Q.9'U/N2L,AT3LN(Q2S(<7RJ,U'::+C_M9*/IOAL*
M!@51$-ZWRO6Q)PI@VOUQ9VZF0"-9A35VS@G9O $(]%I,?J_0Y=Y-"J$&#+"[
MC)6$CR.4 E.5$:=26X<@=&$CGM:V2M8\<K0I9$X*)VMQ"Y(92Q!JRB&SF/>
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MBS#9#I2AUUZ0)FL0G4/X'U>#+G!LEY$,Z]L'F2P#7,S&".B&U'VG9+HSXRH
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M2L1MP9+%T=NW+]SIH!=L.![<_=1JS<4\.Z'.C'U;I];=7=?H]>L_Y[O3]*V
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M04Z6&<#YD.-)S2IPR@7&B H#>;0&!3^ZDJ5O"3:'- AQ"5IMZ#:8,V3:)IY
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MTIPS>$-)<2$!W 2IW]0K]AL(',K$NMT14/(&C? H6BUK")NCMVH?!9(@SM\
MGR89T'1N_=Y4F4TUZRC3KDRTP3)ULUX8&TO!3Z(NR<B4RU3TII*^E0E#9?W@
M5I)5\R4\+\*<6@=:+]]' 4#/VA\+,;$"^\-F(2;<WITI:3-GAQS1<K8G+?U
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M[!TUR%L5<'K&7:MV4V<Q1P(2$H",>V/<&_O9&U0243$?X&Q8P!V7O2>GRHJ
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MS*KA'-8-JQ7NC48:8_?492BKVV RKA[E5%7&')G7\-NU,6$4SQ,L&D:2D3R
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MCA[LT91AP&+A^$]],"_V.M*(FA0$_??1AP*IC"O<[O,CJAOAK>DP'M7/%I
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M:6+0K#\**'E[' 1K":\4JE8W6IU;4$:"8.K1\OA(_FFCRW8*3#<N)301@C\
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MPX6FHC-Q+))MRP#1OJ4NB<D#-(E[D3RC16JEL=AUG3191U$#DL/-17UXP,B
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MO=!A0ZOHJ0E_0#(_(M(V1#9>NU'IB%_%]OD47])/-J;$J9#;"@Z6W=73XV3
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M+.\.5F2QA)QD[.(&D79198:57U[7#&]O6I>$!%J/'?EPD+1D=OK.%>N=8)"
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MRG$^);P/$:!U?-!0YNW0*?X@S7]2BFD=SB<(RBM744RR7OE\ ^O;BRP2;@P
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M $W@X0H_*J,%P,=K4LF1>O_H>R#ON D'!Q"X5>-KT,:2+K6WU-W3K$25X<U
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M<M_$.J6 8#'O42S%7I.DTI0!1PQA?DHK>P=+WG-KT+B*?3H[B\NLS?F\TNC
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M[_KC&CJ1=,ZU(='M.7T+;HR/KH]7=P1[P+4H1U)ZR2K!-G3([+DWT]]>[U/
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MQ,AABK0W='QV#/-L+B\M.*X]1/*\*94<8K] UZ?A%]'<;/8"_IO'R$=;><E
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MY8L.G0!4UNT;6AWD$*@1%/T(TF 6OG^.,#'<A8)7GD4)@>!8T*[CGZ!Y;82
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MX-T7 M9 $Z12$E>S>MUH'Y8&E!HK?&JGE? DG3)]"@^<'$SURFXM94MW<,V
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M*'8#)XN*O2'*XWC=\?J\BX.,E(WO2+A>$>:IE<^33-RY&B;CS'&@X\"Y<*"
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M'S/\L(2@Z7X2(*8N)R%/ ^[6U165/UH9,+J'CB<=3\Z5)]$J\CTI:@$G4$G
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M@W<WI?V:Y"[^BI\O5?9VBZ'5I5@)(U$CHU54K']7SO4#OV.<!7J&1O-$;1$
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M%:*55B!IWAE&4 7\T )[HT).6C&%H,;9E6H<<R,Y.5,H']DEDK@,@73*)]B
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MBVHS/$:,+(C^L0,?4_Q&4]E8:/S8)/6NQ@&^6'?9%1/W'K_"2*3LI*2)NM/
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M*K3T,#^=&1F>J0F-15:,9&!R75%;@7/770L&<*ZZ/ET\8&AD[W9CJ75 S^F
M-NN "8^NX1"]*/QM+4N'F[M;.[VM_]?=7WOWZ>#+_QQ?> >G1][)Z=$?YQ=?
M_M<[.K@X^.%"\5!/,+)Z3,KT="3M?>#C4 )OK(N;<TG&8G^@%EAY,0ZIA8$#
M]MK#R,?9C;K+K:83L+ #011!#</UUV"3OT;DB3M/%[EKF*/TUFH#U@ ?!O%)
M84V.-7?L4L74QBL9T8;GLN*"?40LQ$U\I81VKFS9-Z,C&%[(-!:#PKL!KX0K
MADI]Q^F2$#PWG#6->YU)4!%=ECS$XE -(X?+-/H@4Q'FH%&_"V9,=<\3U-+T
M\:+<;%CJ@,V?<'(>-X2!+6+V(Y.Q[39JIM^&=YH6Z/89LX$4E9[.:QK2A;I:
M,MO\93SF26I(7EM3SYYXPLEOTA V9AVI"U"@&%[%PZN,]$,6P:2(+M*G,5"*
M@V2<**E46W!:KYR!*K%W/?MTDC4>.0[5;GZK-G[9 &X"S2$]<NQG<;N:+@6@
M)A(JEM!U!L"*<H]2!K="&,9R!^6MH9I&B=[:AZM!7W !Y*DNM];<=%ISQ;1F
MK[/V[H_S8^_L@_?YR]GA\?'1^0+'49$-C.E?:<NQYIU1P$4TRA=.A9^+Y<^B
M\+.@TI6Q(NFL!0<2I9!,2+XSI1@7T__(Z\$8"D>&X7=ZBC?/!N;&#_DR(47E
MN4:R*>#U.4J1(OA&Z7;R44,N#\A'E1%7U9WH&*'I Y-$5 "$SC"_K2==ZSH@
M=A5"U8]"&7Z(PRBIQDC*%0*.3^G!$(0K.5!*SY63]]AKE,9XT4 <&<L".W#5
MO&@KA'5#222B_Z0:R@TR&);J^B8!5Y814O5RY<U8Q163&N1*.J41_08T>!,G
M\U3 W/@)D_L4K%:V!RC=8P?NI@R--8^!T[O$%G(#+LA 0V-X="R0;1,@*=*9
M:^)RF%]).>Z(SUWD[#>^;.,1J?!:_0]EU[Z1<@,=^%.WM[.Q79TN9B[F-&_8
M9X-+,Y+Y6)0P2#.^I43&-=R#E@UGJS!-RJ@7! [-RS505E.%P\PQ[_FX3%61
MO::717=&(Y6E!('%E2SU5TUU_O7"Z1^(G4&B02KMJ2-5&C_+LE"!6*_ WFKH
MGN8:?8K39PQ09DQ-XDT+\+;Z%;L7<H"1C[S^3+A9"  .@BN:; KH_WL<Y9&T
M'?! JT+UKQ/0QU?:LBF[7A%HNYQ5A<!KM?1'IF1>)"Y,2C/Q7EMQ-0J-E6UC
M#*5]6:B0<94R0YJ\5C]D^Q.,^D$%K#006;JE\6 U)AAK&AU #$PA0;VTDKO(
M#!EP!2270#[U6=ASCQE-)WJ SR/PBKRDZHP=-*[+.T'&8W^,D^/'N>[08"+2
M\^@^$!BCP5O$M@\"@Z'(64I8#/A-"IK95^?6A)SN9^W)U+]($')Q+[,TX%FH
M\ NBSXWDCTH<N;R\21O>9YTW&F<VU)Q9&LU0T;X"(3?0.R?ZMO74</Y6E)B*
MAM>H]KBF%0YJ7$),FNJR6I]@K>:B5A2 Q6:Q\$*9 N:&*#FM6@BV6GLX6<!6
MJ3]$)[0$V@8!0E%#FNKMZ\(JRM :I%:2,K=ZK/>#CU&C&7..?[D=D2WGB*R:
M(])=>W=T?''\Y=/)Z<'%R=DINB1G'SX<?SDY_2?X)B>'QPMI\:/NB4K90=7(
MJ!@85K2I<O/H(5A7Q=4@6#!BI28P7X)_E]F/]U?Z4,G$9,4S.D%<U%N1--*7
M++D/Z0X^%!WZB8-K98E>?C>$ ]/RZ/SPX__YRP13SA+O%-&O+K'EF]KU]G4;
MS]0"C?J*L$WRI\Y&KR?V)&Z@^IF%V,2BE,4:B._* Q+E)(W;4LB,4+9DLLVP
M-M-LTB>5Q%">QN$]_JDYDIH'M<Q2>]M)[563VCV3=#DY_7#VY1.+;O@7(K/^
M\>7DX@0[=$^/O*.3/T^.CN$?G\\^GAS^[_?<\2=5!-87O@D+9]EW8L70?WA?
M3D-/2),,+^52*<U%DM=%=V[+;GO(IRW2C659NA((,OW9KMAB=*MA)?3S7CMW
MAZ5SY^O*;(/_<(:^ G8S<XC(AS5&$O\PW4=4,TXU< _?T9^'_W-@5F[][H^&
M;>+OIVWS@.WQ8X-XC0=31J(LV! -C!)DIN&;Y;//:_\CB>A9275Z+3BY/"H>
M[RQ2L"^S#]![*61B5$+9'Q-T(N>>T,\YD)2(E3%A9. F[RWZ@Z^_O@[B@:[S
MDR?JLGJ[]VOJF[1#6]7YW8ZE\[%7@@XRIMHZRXG"V5Q9V*@8"7H-?SOUXV4,
MB;6L^#YAJG(]C(2").PA1R-M%*$)=*0PQ$KQCHL,02TM_ JK_3F]3?#5N 13
M+('%&@PG2N4^2GE),%S$W)NZL-H"VUBJ4;W/.*KH[D=+*ETKS TTX$3& 1JT
M:!$%$<=8=+TL):VGFD44:"M1S+W*6  )*8A73>B.W'X)#GTB!?$4$O<)8'(L
M\1 [^$61-D;)ED?H@!3C5LH#M7EG8"HPV&\J?G5#<2729#H Q9VW0Q[\)IHA
ML>&=4$DXFXTT HUC%Q.?Y,I3L^/)/?)("Z5[<TUDK3H^P)>F2VNV&3_>7!>+
MW'QRC%9I'9G&4DEQP8K#TX*K<GY-889;I?,,U1%LNB14\ ?U?3((Y;4>C >0
MF: 7$7)L$DN3X^HYQV\Y$M97T8ADL_54G2614*-$;ZMS7[#"+@HC3%Q7DM65
MZ4?8F4Y#->[9AZ[WXNX/M.PQ"9)HL82D5M^B$MI6:&?KC$J0\Y9\C50FN.AE
M<IIF\=)H>^W=>9DK.6" O?](5>.)U,B+%C_^-W5+'=H333_' 9SE#Q9@3:IL
MLTF5<4*DN^7OP!]VN[UIOCX#":):#ZH4D,.-JH3 PQ1BG"1H3*/=@90@ANCZ
M0%J_M]N=Y]O./W_V39L!*]()T %IHV+SJT(<<>T%Q#.18@W3(]5D"7*9@^KC
M[$1KG(B^K(<<'UB(?U]&CP=8W8,V#X)<IUDMQ5EB""-%/F#[XKVVUOGK/6UF
ME::K?4,X=FR:#&8$D*2)DDK =*[*/+*1?3CT@F=MT@.4=X.G5 >YI:,R$R-)
MY%L"[+2ED+5^_M9GG)T2$)I5R:W<LM+=ET6?C<RU9AU+X?!'TZ[Y'*HH#X:I
MJH8UL1BGB#%*U==U:D+E(+.[&Z7=%Z$#=2BF$=:!'JKOE5^ICBJ3QIAOR**^
MC>2YI,&9'1><6;7@S,[:NS].#_XX.KDX/L+R'H\B--[AV>G1\>DY_.[P[-/[
MDU/XQX>3TX/3PY.#C][YQ<'%\:?CTXL?7P=T018H M>Q* K (J/AK%G*4W<(
MP0<K.4(]U0L+^V/2>_DUFHQ<=7JN1D6#FC>RZX&/MG6!C1)DJB\1Y]#C-O(C
M,$2M-W;IC5UZ8X)!9!#QQ74N'YZV/NTN</1%5E'B%]G%GK @B;K0.ZJBGMLK
MKJ*;<M"%#NI,5=L:79F;(WG7$R6;Z&B078\/!L\"?>,9RR" 51J"18$73G/H
M"=]4=JMQ<R5H<V@ V^V(#MD.)90[FL2$831S4[Y(_:8WRMN0]<3.?P""Q;.Q
M_ .YL9D/L,R82HQ'6%DA)5QU$)X#C)* F.QVD6^^&.CNAZCG_V.PR#[#ZC[0
MZCZ8I5BQ4W8 AP;@FWQ$[ID:8WGT%Q53;_GFIM?M[.[M<,+JT??]AU_**P%U
MD"4]Y#KEZ,%'!?7P$%9IQ@;VOX)D'&1W$D?CU3 9GD'8X;KS[UPX)NGT^$!:
M^927+ 9U]4D7!J6"Z:T@Y/IK#<< UDHH[L[?,L&1[L^;^B[+%>^4-MU4$Z]B
MTH%!4DB;,#WJ_=F7H^,OKP_//GX\^'Q^_$;_8[8M4*?9)<W&>].I6$Q]%<<C
M;,U+KGY;Z_#/>+OE9UZ+,<(L@RU*$)'Q37"31J%\+*S:2-L_EYLJPL:/;/[\
M%K$HT$ 7(P4(M.;1/W];0SMJC:OT=Z8_H]OXC(8WVT_5CVCZIG6&7O78O.GV
MV0//H&8QKKUK5ICZ CZ%B5E/$0'@/QG^!WG*L:ACT>]@46'#ZP@A\:D0M&FD
M4H/Q?-\W0#GIZ-,,(U$BI.'#%;@!<ZM]\<$ZW:_D ^VZ2K:!Y:*BP4BX/$GH
M;IR[<7.Y<1QYJXX>*^=?3;\FLWH=J[UVRONDLBMXB8%&LZ9.#FA>'AKJV,9^
M'5U&QB*<$GXSH>-ZCQ[CX0:4@RVO4#F%*:^O>8X=?Y\F!R$=P8O'U(1#:SD
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MSS N%U33Y3'OM-L]&G:TI/SR$9Z\_!(O+\[ABA3$4OV$*OKYHK HQ<E?;16
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M8$']8DN9/=/<,3=@M$8OW8[H%[$%POFUQ7MNAK]H*+,?GO0>GO?ME8B),VS
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M<QK%YK,E(AJZG-@G92)XEW9@K[(#<W>O?N\M^](?SJ69U;%Q3 3C1"9L*!U
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MX[O$02O!3Q&,6AH&61%*@Y#CD/?# "K\QA;$8*^) 97()78C^4.>MJXA-1T
M"EZYRXD$<!8^$JTZ+621K4.&!F*A"H6,"@+,"SH7XU/84[_#33Z^%@9>R$M=
M1TC92<$?^!C3( MF$^I:/%U[;W&NYF@5]< :LA-KB ?9HM$S-A506I^^ %?
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M?K,7Q2EWWX-X>)^$<RY2.O(.<5B& 3*5<FG5X KEHJ7C/SW(5^TL2%B,,3I
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M03L,<ATVV%-XCRF!7L/>.E$;I81P&+;::-IH=:.#C%9O$$7?51I3U_=O/ME
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M$LLJ1ETS*I8DH>-1;3[A&"$R'EV?> K=\XK/@RQ&M.'N\5NZ@Z?$VK_1$N!
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M&Q:[R9U$0HH!,_SQ916NXLCZ$E3W7>_D=@'&8&_4R*,'L?^1)2I'O/F<NYX
MUH#;L9PGE&)&O=A^^"83Y;-E]([1\1+Z!S+XZFFO>K80.MK :&_)M:+"EOYI
MM6Z=B;6;27&S9N0HA%A5"+GE%U+Q3)U4N@^)/"QI#P+N%,?"9?H__=;X_W(Q
MOKP'P RA54%B8E4S^CA@!HE9AZ@:T"+CJ2PESFOS;2N,I#DI+,, ZY?A9G@+
M D+X>##.76W>26$3?F0XF$NV(,BKRSB\]A*D5B&<ZRB;>%@>]$\6P'068HUD
M)8W%8D+$$/4\25N+9T8GCRB>.>EOO7AFEZ4H;^L*X[^!U\^MWU#M)M9'-)3M
M+8>TUE0]O+^,$=<-=Y^H5KB46]!4+&S^>(L0Q?+J$!(2_ZL%!UR]KMT;;:SW
MCDGFTAS.SFZY9/.YQEC'L<V#+R-J%/A>V>.6XJ8M?-2UCS?7X<I(G/I2\/8P
MR^AD8R#H1N;<P[SIM86%0&\-3S:6PF,$SI*)TVN-B3/HV:?'&TM1-^+FSB9.
MZQBI:P\&C;>5]X=?1')I'F9?';AK@4O>'7;MDZTZ6B;#L,&96\4(?"_@AS(1
MZ>2H<UM@&2//%0"4:H:[RF7JOJH/06\TQ)P'EO4$JFI0NQ+TOIN4J[*L>$'O
M574WH !3FPL%THOW_TMG!?V738K !R;!B1%>!(Z?N83FFA^ A_'* PX-SC#B
ML1>ZUD'".9UO6",K]5*?NRJ- _.R<CCZD$#4G# @!J&3E8E(V0)!FZ3PA1"U
MW$_X#28G2/QN1%L+"7(O2V0>2,'&-4R\80B^V[.[Q&D27(WY!=[.4KLN @O9
M/)7'VKA *Y,?\!"LYD1LJ0-&*<F@>A#L(:JR@+&3[P,NP?R+4A>2,\PDH4_Y
M$^7//$YL*]+2;$1&4OD*D7\!$\PFS*%4!SR!2[(H@EGAF!T$![=2%N$Q,+T>
MGNH13RL^O<R_QP/:TB2.K&J>S]HYU)! 9F9($.3O^K%T->,DQRCO#5_M=Q>&
M@4F:;7+2+#X<MTD?^$RRM;:C\M-RE "P9R8>PFI_*.1Z@#MJ+HX<16[>2EC(
M\G:@)!6"(/?B)%WF?PE07F0@++694DD@=WPA(HERD7.2X^UB=Q;'B3%]2!L
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M'N N#XVS5$4H_HEE<V+:3UBEPK<W(6X,%WY0_?&!1 [M-HN?AXD.ON>ED]%
M@T GC4EX]M.T4/Y-7E08A\;I52>Y9(.%I8V5P[!D7CMFZ@I/<#?1=]E7(MJ
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M:,;+Q@LO^@K[(?!L-S+V2<C89<GP[3,C[SE?<TW#''(^C>FXSDR/Z##L(D?
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MJEK(L6L 2/8]JV$U#+_7%,[(QNJ3.V2T)$!_$SIEO0$-6>UFQXY)&\16M,O
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MQ8ZMJ_+EW\H;$!?"8TSLX@#(@YWL;"(F\DHTT!$U6N<L93^E1RB=WDB<[R/
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M-K,JZ\\5"9TAJ*HX>DG2/0.8X-_2))^- ]A/.A5P,.VD =T3X/;%'(0U1>?
ML/.%N N.?PN<29[$:DBV[F#6' P]^:JL/F%"8O$"U8\IP2[D'U=CFB,F72GS
M').9#5A6M,8OQE^(@68L9TR8JT_O7B$2$4K4!N4+'ZUYI>Z&P,<0@,I?,)U7
M) KJ5(17P=!>[#&XC:SG,%RP,6]FY6 \5W)CEK7,H:%\3L$I!2)KN/WV"+UC
MO_% LYG:$UY-.]Q-3S#F_!06@_)+$81.V)-%1+X&&S[Z)_ZLXG(Z,%] H%69
M(DN#2DT_*WB^9MS<?AF90.(J;>PP'S(CS^Y J68Y*:AV<2B</"2I?%?YU1J+
MR1-B!$OYH+Y+CO+R&?[VCH3G.2L;=[(7W$FR'2'UTISI(!6T6VXBX!\Q?3"_
MDZ%[D?II,>[IN\$_R!VE1[\L*](UR@.])#2P)J<@LJEI90;IBY2>U/I.2(5)
M%WU.GP;Y9'B7WXQL>^:%8>X9Y0<(/Y++4A"DJX X47WLEAC8HA,F>(#%PLZ
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MRA!@=I;]T&^U$R]+61(^\'Z(#6]JP-Y4318GDY^S]9)H'#3X7-P9Q)"($=:
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MW[C*#5$<7Z]/+@QI#)+O<R[X2.MPB[OJHC!T$4E=.^SS!E8K?E56^1!&5@=
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MU:R;%GHY&+9;1O]<-."=;]*IT[" 3(#>P_PJ:\(9*>2!(!U7TA"H51L)!HU
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M'9:3<@@C1F'8@:75&BM_NC5<QD*I0$5?J;P3 ]E*."WU-G1-WEG%R*@<'2Y
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M9-T9GG@13>=]M"AS,;>6,<UKJV_) K05&,<!V+MKC)(MXZ[PL#?+U]+S/;&
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MK%K)!MC(TM.F*KT>1 VD?\YPZ'-<4U0R0;^<UB#X<1A0B_]-8]Q&%S>?]!-
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MI(6_0.Z /EO*OT"&DN#/J)U#&*=B3WO"Y1"*QE_,!WG*[P,Z-3Y>CBI&4AK
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M'*[\FF_T;'YO;S_:.KKF>ZX!M?DU#J^29.VM_*)5SO#'$[6;R=E<O6[TR;!
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MI81%\1!#2G#/_$YTKB/S[W:XT:3-&1WH_['WILUM8]F6Z/>.Z/_ J)?98=^
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M^BBT5N4(UM0+5:;HN][ 9XZG]C1D6,?HHY5V=X!73\_$E*,;^?W9QTG:U(M
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M=]AY<K0*'W?+^?N<5B!D(0L[0J(6D(\ITQI%GALFUT/'?4*T1656/PZV)V]
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MJ#!4<2UE7LX=W=<)#P-#&AR%O>P38>0?TE&3<M::_L=A?9T.3S 9VV?X C6
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MJY'>F#)YJ!K)MOYRZ A=Y6G0G5BH9T?+$S$3'=V+S,YJ#PWT5+4EPTDO:2H
M^#N+B8ZP%A.A[N6*ZJCC(*5#Y?,-[0G]*;THI_DB\XRO3)KN8ZI5C6>Z_Z_R
M>@C#<)DQR:7I1-_"&"DY)U#W4@4.$]*KLZ?!:W?< .D<N&?&G@F\.RAZZ"^
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M*TMI.6/RJAB"5MT"(J J/VEFP@E11)\D!0TO0\];YB.UJXSTU7[I7\]/7KV
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M:W1&5Y6J*!K/"UCI6 PBI/:#ARZC#?A1O2>'*+Y93,I*YJ=-=-!]-T,_1!]
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M8L8D'Q/78;E14Q!VC(80&Q!>(HT ;+A5(YV2BFAS2\FS=K7/B)?#*2\SJ-5
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M>8BUEPFWG#LC1\Z_D,-2.EH;=)P.#9CE$6OXFV20I(8JI3W!PPRT6!U"@+0
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M.VL ,<I1BH/7[H?"X^W+04172"RMDS"'2J%<=HSV#P--&.6 LDM4$.EB,3\
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MR>$6*FH>!M M)=@1:"VM[!E<9([=*=)V"4E,=!G#=,+V^0E1!X>^N#1=%N9
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M1Z;M*GC+["*'(T?[7Q ["\1TKYKKQTYF:S"X&6I412[>5; 9B1JS&E/VC*R
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M:$)M/!:F0]+CA  PDW\^YY=7"IRBEW!,0;B.^R0_>=31X1)">UF&LQ+^W9J
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MOW05#P]93E(6_GM9V/RZ3BT;VF)T5K3%13CD%J,7?Q^=^B\: 0A=FN+O,MK
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MGRX2Z9Q%QDF90B02S<BA+:ZU2'*?*5$,I!HQ&+#.+%CV'"(*+MSL^O0^?TL
M/&XY %>@-1#(!2G^ED>9+IF-'F7N8+^\_[5O&(Q!+CS_)9',U#ONG=A0IKQ"
MN5@PQSP&VS2@="[U4,?,G?7$)OUQYJ[NF00DKP%5X:YI82N+!:O$D;F. <=M
M(.'JX!:6?,)],Y"6^\,YY9_/.5AZ.JW*HG9--D.)!IH_]A\3#HI4$B(V&1J9
M#?W%90O1? ,0,'OB/2Y^=H+-:2;MUC5#C8<4'KS33 42J>Y$8L<M7,C6^?8)
MI8N,B_<YP^+FX2"$ EJ8VC2_/K8_1R[QB/0CQ_Z?/',1:[=I#"1&A-F"&R-7
MMF PH4A\4DYYJ8#"0_!.AAB%<0WA[:CG:BQ 4T9(>B>XK'AZ4N8LRY4-S8;_
ML_^NOX;[.JT'\UW5"NC8E6[6)EOEC-"$!C1@WQ]G),9<IBD^2DR1(\8#+0;7
MB'FB#7<?GRX&?#A3.VW33F(]BZO\AM%H/)*-IZ'3W&M(.QVRG$P6RO3NR$,"
M1^4).>HH.9]@PK=61[S!)L3[%+Z#,)AGA533:-12,<.>R?91?QJ]/&A;8K$J
MLPWF]L8ZVMT$)R&>;&<'9R$<WXW.BEUXVE,H;5^4X]%96TW5B7A=5JO)MNTX
M0WDWH<J+?>X2+U;X4\)M0MPE+;?ZV>)8-#BA#4DX<]PCNN>KA(Y&$)N7S.@O
MK"'1E[+K4&]]19;))T3#_\ YH_%=8WS7-+["3R2CJ46H1&DYBHZRN"J,(#EW
MG:9'S<?RG%N0 J#\9K^\%T9=2M^Z 7I/I8F?J4P_U_PL?6?\*&VR$);D:D8V
M.G/WWO1OH-D$AV/#)Y'B2\[3>3FC01RIJ'@I=_'@U9?H4946#_X/JJ"$95)0
MA63*$RTS!TJ22W2_LEAMV)UY/TG37A2U0&8Z$1_I.?0UB>U5H(Y9-V'[P)HE
M Y:.SCQB)SOE\RJ$'3$?'[;1'A^BY$:<\%1E!QXSS'9ORC3QE3 Y=66X#6J>
MELYU-^G*S2:N:!0UVNPM4C5"?_]B=ZN91Q<?^2/Q23V%K(T0<B(.WUUU&RVE
M4FZOC0X8"N%D;'51.7J*&X_-< X>Z$WTY$PZ*Y+T9#Q%52Q*J2,D/0DF#SJ<
M!M]=U-WH' O#3(HZ4L=*!QV;[5TALXWJGG5ATURI.A19@8,4OT#96?FNO04W
MIK)1@C5P27XQ<P.5?>L;I9/5PUXHVF02#\&3--3TVJQ$!TYXSE$UZJM8OM^K
M4%MI3/?WGYSM8 +.D1R["&KK 4 4;? ;!LB.>TH)4??5( 8Z!KK)T JX%>F0
M];:=4DO2@&TQJ1%GYYP9CSVN?L0FI7%K,I%!$1?]J%FS#_=[4Y,16,*I[C?=
MIOKD=K')SJ4<W!$TL7E9[IQ,##PF/S'@3*!?#=:R;C!!%M96P+L+7]?:JH7Q
M)5EQG9UL$-P/'C=84IIWT#WL"* IIY\_;,(0=_LG-O_59*=E[)@5T==*;C@!
MG'F,5*$XTFXX/LC(<&21$7'#DK,A1JP4_D$K6C5%G!5*+^A62$*3("3!6PE0
MN7]6+).<\,YG9]UJ%A^N$SW<MMQL6^ W:!LS!DMY*@?:%>Z&HDNS9&+*D-VA
M9)QTR'%_K%!8I/Q-<4<;OB^S]]RZ$]X:II23=.[H3.YHG42\HF*W' :>@54E
M%F%8Q5N#/1"2D@S35='.S-^)!D8267;B$+)@N56:OL0_2ER>7O<N]<$NN<EC
M#2DGF$T:0'2HQ+$8FY/&O\ #2Q(S1"*U^VK'K4F,S4PX3678$.=3296^S0I(
MG:'\M,/%N,C9IZ#WO6B;J\TB[9((\U+U/6CO1/("C_*B7W3%X)O[BL'G7C'(
MF_U3X\SVW_5],?/.Q)IRL+P%&ISXJPI12'2_4,>E4Z%9ZX\YD2'+G0-G9B>5
MQKP-C053$ &E(4]+%H"B'7'S_KEMJVY6>:(>@X+NN3CGM7B[BJ8M/WEN@S4]
MZ;U .S('7!Z8UBO)O*=5CYSHLA"6U'#EX$:!D:G>ZJD+MI=/?QP]=:G'F&I)
MEP5QCM//,,8#&0Z+59]M@YDNPXG\3'WSD[!_#?S_[%D4AWU@5=9(4DHN<)C8
M<F9D7M^'P!HD ))ID;\_^R/XN,%5^+UI@T48CUY,RR4.C_#_?JO**2VA;E-6
M]<-Q8OKC0>1BS?P8'FQYJ-IKQH>;=(NH$TT7K;7_UIG_;A>>2F41YEO(2@;7
M\Z),DB_J'6P635>ZIT$PA(;H,.+G!"T* QIG(3CI["^P'WO)"\MZ<"F4M0=0
M'4I@1>E*PBB6!'#TP.624\?<@2QNX@.[ UWT84QAB)+!NS6:*T$6W DM&K*5
M,RW0I>/W('G(A^&(MX@J_6+C9L%2UPX\W>5#DC+U&N^_&*,<;B,)<#!KVTST
MX\,D-G=]J7$A.\\V\KZ]PJ9)GP^@%!?Z$75$]4X6''DH6*/2#=.;(D[;*[&$
M7W]\Q9VV3 JI9K@@7#9UZN@ R)T3VMZ20AR[]USN!DS[6##,U'TP D4-4VV6
M0J/,1FV<)A\6P<*/)D4;WE_6"_> E2VO-&5QKT5!W8'G<]800]C%5.NT;;HN
M6$=$M<0D0@!>++D;<S)A)@XPW):1T9QN^:YL-X"A.N'+.(2Z)*UBP,\#("E5
MSH6&NQ;=0N8(64A+M7PW%B93C["?"O.JG4ER3X)"6E *S,UC5R$BY0W4MH6@
M?3OK%,BR'Y]AL0">_R]QT;XND0O]C*H!#)<PW:&Q;4R*[#CM,8[QC!;E-./<
M#VK< 3:.F:1N./K38X)/H5:B+1^0E3/9Z&&NW>8O*&</J(@5$,8<9F-\-QIT
M]4XS21KOB2MC8XHWFO-FNNVBS6:!A2[KGDO2#>PZ<2Z)R[4^.A0X,Y7J,U1L
MV(\OBS:<<L='CXXX,#TY/6&$9$T OIG#>WF<V*1MBEG)^N =1M4G[FD/TV2$
M7:(5O@ZJ7EDHZ$=+8-]$<;& #2 G&XE+!4G.VV++3DPQ@1IP,'6P?^'2=4>G
M$BL?90XZ:J+)3/:>52<$-E((EG#AXIU&RF7$&]NO91*!.!%6IAB>:[*1JQ"\
M3CJ?H'9Y"TXZ,_-7N %UA[DGKM#PQ22=87Y!I-Q+=&B.4PLGTGZ8K!+')(_%
MNF=5\I(-ZV"8T,9:@X29HDR[*!5@R%E8 ^%,I?0OG$;!#)?M 5RY\(,N&.TE
MH2?")[0+&5,DW;UTC(2I7Y4@8KX5)I7[F Z:6H\J?2CG&U@#D:L2,E"91:3I
M!P!/*-_DA%WL*]UEGH]D:Q!-K70Q2/,U?J7*9#C.PTC3+E>OT8%YN1"Q*);0
M5ZKG!#$8 U11+?EO*TI=;X0VK^;!'\=&IVC"D-,G@>OM*C[1QWD%E$'4$ #7
MA,\EZ\/=$Q$_5]8BT$"61J^[/\<UCBU8">%^75-JO&[HKL3. 4K@4IL^L$N;
M.GLA\F"E5V%_^(T^%B+&:M# &771(GT=Z6RT,VDB9M=3$$+=0B6EY3XW%10>
M?#OT<EAT5BZE0O_H:8PF+HJU53;T4C#<4FA+>7$(JP<!+91=D)C^<,HI<*8>
M-/,#*FIG;%.QZ!+N1N%4L^'"N+CFW#&@U#F8"%WS3:1W9F[@X#K"[8\4.E6;
M#@3CY\=#,AV;M-_.-?QL-XI5LAM/I"1 ?8I8]]GPAZGZ3J?JW9H7C^<A3I1C
M;5U;YG.R&S:=A;97=N(+Z1S9)7SYU1TF?DO1"%+;5V2 9(89-.OX9V2-"F4D
M])= 2BA8"XH."L2-DY(<XT>/'__%>D'%XUK3$X7+H<HP9O>-VM;5LH,7VG+9
MR7*4*<@M4+#K C4*P_Q]/LP2W?#>2_B_XU*+MNKQ-T=/1F? <8K;.SKGJBIX
MS6V_//A![H/CQ7;=&2^,@U,D*\.?7VTWW"S^.M@ >$8O:NG6QVPA5T6.$^L:
M4]@'-!YGWLR9Y2P85SB9XLNXP#/^"[X+ZV@(3QUE/B"EKOV [EOA\@]^'#0B
M_ IN08;%[#1,I,!Q^O*<-;&0J>)/+TM-^?FJ-+7L58A:5\V,ZDN4SJ=3>QC9
MX1RX;&E8*C^SO?:+3Y_5.Z_@]&W$R^5P(@M,C#4K<N$+*5QXZY.48\LZ7SF^
MT XY$(=:5HX=*F@7Q;H3W=*JI4Y7/%X0_FYL 9/XG[QT<:?G6]IM7SBMT[?W
MM9'/O3:2!(X67I)I89.FU(A:'#3TN^X']M.B[:8UG,2S<!/)S!2B&OCF]->3
MD6D\%[&G=20=;NN2O>6HXOAK.("*=L<+^=&8 ML?Q[=#'87G.P"7O;4[+Z A
M&+8^M?OIN:JVDD,^@PW3VS31%4R.VP5I(U;+I';/G.=@)Y50,<4[I*C# O#R
MD7(L4*JMJ8>[NJ6:X" EPD GQ85,C?M)A<Q#%\;FR79V$=Q:.CC#+</(_3!Z
MX*[XY(G5)_:X-ZL8%L#:W3@MC:5=. OY[=%?Z(_?T_^YS91]%-?51M68I;+
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M#>#(&4!/8>OF)9)X(LP2ZKTX"0^(.5_G1@ ;%!'S-M^VDZ*.W8,/D_<MD+?
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M?V.RNSHL8[(;/P%ZZ1UJ9<-ZY5R%HOJI@1%QXX=C[9,J+U2^@)&$51>&BH^
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MWI,(3JC6P!D$8EB@!-N4O<.8^@Y72E*KYSRE?-)\^Z!X: F#,/HGTTV<"IX
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M#T>G5()LVKHJ,+U8B*V2(6B% ^#%T[,3-J?TKU&?VEU?.14QL/8;L6)EIGY
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MF3AN2>[':!VF1[2QY! .[A/T+)=RYO[D]'1+YM=LIENC>F!B;E+:G&F/H<S
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M!($=8MMB^A;TR=1SD^Z_VL%0T$V](&9#]B.D)@#$5"SJ??&**-_<%P8^]\(
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MF@OT/XW5\..:OI?PII#G/%B!7LCS/*S9:E8D1PH_;6^\8R^@',0C+VT+6)#
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M,=O,>I\#ES,MEK+_^<WUGOHC_LF^?]_F4L=_YO['Z?W35_K.7BG\3\M?L8/
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M7U&SG VT* G\ #H8W^1C?Z[ 1(KQWY)Q#&;##$0/A!:>6,*<<+\Z]$1;#EV
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M]>7MPK=1ZOQ:AA!*[-7EY1O"2:^(&[F/*-/?-\CTJKC!'?;TQK"G23'Y[^]
MO3U^_N39\9/_]_P)TH=/2 /_H);7:RWK@>]^"^IUW*X9YC<!ES)L4K.GK\NZ
M-=)CQCD;25DW5NPE[T%ZD .&;8>CPS0Y/CP^#M2VIOVYZKGFMA^>@EAFPMF@
M8S,3.<U$VEE,%U](0TX:1^]AE0-W.:*F*-3.HN/_I>:/IKEY_X^V!9VXEI(Z
M =53XK6F4[HH4')8I0K<8--.DO&R:5!@Q_7<-7'98B*0%1SV.15=<^KZ,A_!
MML]1*V\".%]>7AZTXZ+,O^ ) D,[@'TB;@(>J+X-"GY41OH2WT+M9?"DI=D_
M;^KEV7GP[@)#F%B0AD7G+# X3NE-OVQ]QVM?<R)BY88_F31R.'9NQJ=G6*.2
M<9M[%'$N4YG"V4AV3(5G4* UI$D+%[PZ6@*GR[<2.?QNN/LR*R[$>:-CQBB?
MM+L(H3)R-?'2,,<J4*<"<V52#SG2[UI#/1UL</ .;9(2S! >_SL^!Y./RC=
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MK;IQ["#C;"F\"]V_5/6B&-]!^<R'*OG[LLIY&IZIPNM.>RO0G'#"4/7.E7G
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MW54^T*/UR!&=+)% SP?MXB:EE'EZZ-_:[-\U7P&^2[I5/^F!0)*'&=;$%(J
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MX867/\JZ]\)3L)-(1EQLUG%(IIRIDECP1?T9[EJ64JS)C%4\;*W$Q[?XZKU
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MI*RK,W9ZG9T89A*HY 7^5]7ZB[V 4GF%"?"%]">=!0U>2(=+8'=X'O9#=$A
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M!=\('>:@O$)\'!X<:2_]9 5WA-V^*/9#6=9"#Z3R8L9.&:MWD:VK80CY>YT
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MNJO<^ :X$DP40H0S0+8OFJT\5.%C68Q%G=V:F[_KV0/NS4\TE]R/[(=;&$-
M,VO#1Q2S)+C05W!)]>+I+0(C66V\%4^Y^ &N\F?%*WU@/!#UM[N9#9Y_C=]Z
MDD'-$8,:E]^"I;?-:,:1H[ 5P=/J][Y$:XX,J%)H;+EAE^XJ\'N2Y[+.JIBC
M%#O' .0<!XW4MKHTK,W6WK7ZHW2:F_96(01"_]4G<2=0.X_#?0G"=M__JQT9
M'?&E)EJ/ FI15139:."_*2]JXG5(2[@<Z75W:]U34 Q;7_<\-#JOT$5+3=^Q
MD2SVC+WY"(4FW"Q?.Q>=X$.4?@N^* 0GBWH.<1]3]7O$5N+DBOUWGB=QKL2Q
M.!PC#'GD=.I)A;L;#E^Y@DLP0N7-LS*C=:'3\,E6W+EI016(,EY#I$+)B^W'
M>(4:.&@- BTX07Q#:,ZF"!SW[_' "B3!E1"E="/3!=/EZK^-[5]"-1A$N"@B
MH5<31T.C2E+P9I@4?7B^C )%CB+#+FE =SL$16G]X-#I;-/R?8$-IN!L=YNL
MHL*&^FA8&/_ (F:?"BF+N%;W2CV/SZ(&I#!R'5*F@2)SI&4M[!:GZWR4Q(3U
MXXS!A+T8(Y<V+&SJ6K=\-X+Q%MI<!5413VO2$20X1/VIL7=@2J$+"Y3'H_B&
M]0.R'M\*D#PUNY8HB!R: 'U8#J.^UM"XUV:KF0L;61!'@UOD%V+ <83_&<$]
MR-"&_XA A:]6-9(6^=K@4P*_N<GZU'F/+RY334U&\4\Y/XC83V, >Q6ES;#A
M"M4VITW3/H&-"/0ZA72$=(-=:X0]0#!V;'-&G "-55RSO"85H6=0G9P#[EPW
M4T/@:V:*X)@P+%!@(WT1]ODBK(1TT!D1^D,'8]:_0C5E8BUCD>QX?$,06B@W
M*UT%[>R\;I ),",J(\26'8'5/PW>;^S[4:4$@>I0BD&3XS%##FCI U<20;\R
M29="#:-OCF+$W%6KDL>FEG>7H$H(X:T$H:8G4608?*9LF,4%7^U2#[F>W.;V
MCYX<*WAJ4Z^=),-^UPPT#%8V5A&B$<6Z7X[+$4.)UNICU-WU][Q>JB:W!X&9
MT)HE\P-.&1CJR3")!_(2I!<M2"0XY,2 ^$DV(&VSLJG@KY8;IS3PZS5 OPR.
MI?;3\%#-N05#T-AP6:4:)A8_1W0YSA/#^\S*>T+5FM"&6Z[A'OVC*'0@"(SG
M0YHD3-%0.>9A@Q!BYB>]&BW!.S0JQY.UHARKD)Y<^I3 *LH>%8(07 L2EK M
M4K'"/? G#]:I(.V4]0D@<O@K:"8+HPE9@C0K2I/U A-"Q&*0Z9[U51&:'R$I
M!((8"RR%RF+H78=Q]!TB\$9F%*G'R1!20\@I)"W(=[DV'#W08V&"07W+*,D(
M%*7& 7JCE'R(&E'!\K(R<%=65\DT")SB@F&SO7*GX++#;6ARY94\@V:K87X3
ML3OXZW#IHR,@6)+*F+8 LD'+@<Y18,Z>(:N5[-[Z+SB0.J9E.T15LXG/DK9S
M]:30L:^[(-E>VNY0X(F_"GSKP+"7PD0ZHG%QC18XPXH$N^[K!D6>[WDQ#2P<
M9,\0J<*I^>][4>O+5WDE:5VW%+P9QK=\OU6G0:U+'&G?"@ZADB3&-TE6%B#!
MR"@-![RXCHE>&F..&N#?O<H%90N-:HK,D79WK<9I,B)49KI.^)7DI-F%*"XQ
M7>VXZPY*@Y;K.&5FKS7ITFV3+B\]Z:)JRS#M9P2ZACQXPP_IW%&B\8+U- 2S
M#:Y7/3#-8& -J?!UPUW>S:2'@[(OI [^Y';\X_KT"O2CU( I8')8BF8-:8<C
M<><$1K^N?H!9KW MRPFQ>W<K&UD#15TEI3/JDH-3=$C0^QW=*));71KB&R_Z
M]B1[1  A.5:(<18#NCH9Q0.%_:SUM.+$E>>XHR.(47S=T^^887/R F);FD+:
MW0D.&]AUUQ%Y%.B<8^C41"<J]H--D&X^5A^IH.K0LHCOXF+2QN#X'.[*NJ.T
MP.NDN_1>;J=3^ZI&8"]/+Z8<)JVB%8TA4+B*V#^Q[W56MR/UYS<QK*NU8F)K
MX0:/R]%??BBX1E,SC;T;I\=C).$._A[>B;I9P=.M+^AP;:O#U0#W9]G)=3-9
M=$LH<@ZZ)]YO[%66LGB68S5(F*:(=PL.#GO!L*WOM_;\;/#BD_8<19.:"5ES
M #H@OE[LY#Z.V);KB,WQN;9,:%7)C>2 PH8$D)]%<%RU>1'ENK>'&*JE@@I#
M#UU_9S@FF5,C\GZKV]FJW./+F4@+O'/4%_.T 5^Z" AN!:_/]4B-/XMQ3M]<
ML0BHW%?WH]1VJ3A.,HX2B@G>Y1A'S"-!Z*NX*M@N@1:E'T?5C-QX/&J6<P7T
M_%]"547&(QD<*GYE4G-Y-HM&4Y.B6^6DQX0X8:D#S9F4M1@4G(,'7B7BG0Z2
M JEJP 2J43U+;V]M?)6"!IM6S #K?L?EF&\!B\JK+DGB&-!XQ]1>KGI@U3B[
M'51W(^>4471#YQUO!NAQRR$S4L8G]^'4L3B\M2Q=PXHNCSF62VTJ4Y7DK-0I
M:266U>@X*JMDKO4AIZ=,>8];Q]74)",BS8&Z\1B,03[^3G7]4HT)DD12:3-X
MI*PKMO;8FG@JS'YT&X*(]X5,!3T$8:'A4.B02!GJD?(KM5:.972$CSI6SS$U
M5H;VKH=-X,]R47E:8F-/:>;;V%''KH*R]]*<RUXTBL31:4[_/XD8;U9*R.O%
M^ 76&9U&WT DX^#OG#:>/5]ED2IC\.MM[-.C4@%X7N&,#S)XS!3;FBM<4L:Z
MN<24A]L)2(DI95YDJ:FPV.1.2GJ7:RSNR%^:TLMJ'=T7N9:0&CT'.:E20;G]
M8ZSP9'6AGG0H=4M4_*D*'CMG':Z*DP\AN4-P8+694%_2IT.>H=-^4HG0FJ(.
M*W-#"2**-S 15M7=P6&#+AE%,Q@ON9#N=ZH>$C/E187;B&&I=G_].P'(PP&<
M])'X)1OU':Y6TZ:WZ?_(DM0E:A%-6;]/6.B0Q[#X=&%*2D?Z0"-3DF1=) W/
MH>()BK-P70KKIB2W^?*D/,4F4A$R';^D@K+\UI:I AQ<ZT+SU.N57#2Z3G#@
MUW#<.B&/IL7!L(.^:"4IZ5[)PCV^S@0X,+/FG?+*HN^RN'3%D=F''E_G=<?O
M-]KX_4N.W]^K9M<RZ,[@XD^0/FE&M@B? "D2$U@*^^P^V[4KQ?]\#+;KRWGK
M@JNI:[].S'13G&ZEV-YSL#>Z?NT]\?"IQDDQXJV<8S2X06NO)AIIF]BVT^QL
M!^Z!NHWI>G'FO;%1,3>,+4HFG*O.-K;";G<WW%G?6ZH=OF+84_D$]^3K\HF:
M)?%S![;SZ,U-]VUX71EZ/G1;R")6>T9KFB/V.MVZYHCUN7V1X?PQSNG9\7L_
MY]O\<]["3>B>M&UVMNLFL^V%)?PFSYIV\*;06$UX=(S46>5XB:!"_21,N)1$
M4%),&Q6?&:]^_MMVM33\X!&\VX?O1W4'3)2/%@(_9/G&I];;3NPC4--KUNCO
M)D6_+ KE[ZZ* 2P8(:Q)W#/K'].)=KNY3JF)1GZQ/_T\SATM_UDT4[5&SW_;
M+ %;XUGR=)M,9 XN"()*GNJJLYK3];Z[XPE>QWO?.)HAL4N>W<HI6B([#[^M
MO,P< 7O(7#G(5V)A"ME[<43:6L)U0OK)-)!!=_T7)'("/\)\84*1^;0<UU4H
M*46C/TV0*$RY;$!B1M%MAX\GE=(75-@MU=Y,/@S/QQIR:\SJ3]B.)O^DV.L@
M'C/9]X#7#U5;K!BD$",GEKIYK/UR@L:*KGX2IQ38Y6,V3LHQOW:I6 ^-+5KF
M,F'M R[E3IW^WYS;ZD>(8'D96PT(* Z;G?U:O #O#1S5[6=7*94W\1ZH @1N
M =>KFS;U+FGZ=BK<YS4HKN-XNMSL_?E8O9U%\IT#PJK!TTJ7J-B]/*8[SXRH
M:%#/C-C8K;UZUYOMANKQ65XFW+2//8^FE#HA0.S6VSJ^U/ACYAM,;70^<)QI
MQ<SI;KE[JNZ^[[KQ^4[3]'4LDF=*L;\\O9#: -W3Q)7&OOBGE1V21MJZX^4?
ME#LMWZ.=E()E".Q!3.H69G;NS8(QCE("$XS3$LL:_$^9"#@*NFX<Q) N)/7!
MAE;RB3"*%T]OAIDJKU2GW]]O;U6,]]8(^]%&6-/*X$*<BY!_CK DJ7@Q;;U=
M7490$\:;!\54@>"[H#+^2(/ .7+4Q*9L>_$-RV?RX%7("EW:K1\(3OIH9(E=
M5>KP[RKJ8)-S^AJ0L_,I4AJC3;/JA"TX+FL@FDP80^+>=JBB.H3*X@I*V)A2
M'A4,TX<H$V>)#[2U:Y_X QJ\:JN'IZM,1X-6,#MBEH^V53&T*H#2N@1ZK>=H
MBD-X.5F336K\&:,%HEYV0[T:U8 +1K%(2\(NN"OOI".&%8WCQW9"R_QV'U0G
M9_Z6QC;1,@6S&_4L[7\B8?HZD$@3CBND]58?/NJXXPP2+D"::8 *U9[-;H2:
MB&Y>HH8E74)*Q00W5%I@%AG+VT98!5F8LZ:\$M[+>2*E=[5QWKR,O5@W 0U4
MUN&5Q_PWVYC_D\?\'X: >9]"BUB75S8KZE ;0B#]5!@T42;>W9 PL7,_'L5]
ML:5LW3/OB"TTN^ZD,4E1+8:(]<M8["(PB](:7^_39\,=P<J8Z+'U3XK-FF_=
M&O;K8M6YZO1N<0K&QK$A5>SP9OM6B&W<Z,R^TM&ZU-=I+)NK!R>CLK#=9:M:
M6)<'SGT SYZN!E2]X+$B)T2P0@P5Z$U-E-RF<43F"X=F:']6?]-V22BS2/&:
MX)YW5L$+1R"5LN\WN^N*Q?%9ZHJ<;(Y"=/>*1^:$&7&>6$JA &$3%D3N%%@
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MKQ'Z@S!/IG#84H_-@NIYZ,>FS1$@ ^FRD96>KS]1Y>//K@8]*%QK7=_(,0,
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M^%A()L=\*68:!7T+2QQ@%)L+F.=4O/*>@ITVTOZZ4'V^ZOBTTG.(YN;H-DR
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M2\++A'&D2BY:&UXS2T&4Z\EX**2G$#&C(>PLW@0JE$I1!0S\AWJO$@J4*WL
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MA%6B:A4;8IZX'"V0^K9/MNV3?:M]L@_HT&E[:E]A3^W]LQ]U[;9-]Y'3 /#
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MY^V2V\^#A0X."]89J:A*/'NI-UK,Y5I]D?:0]=!39- XM6N'QW;M]%B^+\L
M!R0#7BX3'-INA$Z$II5;%,B9-GD9WKN8.,#ZPG[-MAJU1D/6M5)B9OV@;N\?
MG-@GAT?3[*KQ/<%3DUXO#'[NRIBAT0ITSZM\ND+9<%CY"Q-#-!3-W6)F G8
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MSU/I@R,4J+,?AZ.$%Y>;)[._!TN/(AYT+2)[AL^1L#@V^O]1FY2?(^5@4.]
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M-WEB=P?1K2JPI#'Q*$QD5Q/3P ?M=^0\BG*CF ,/FKV+6^$L PNSH7N9O)P
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MI9V%RH27=7\4(<C":>I-L]SFHIE'SGLNN\I?B/8,+H]((G^!$%A<VRQK/'*
MI_8"0K9(I<XX/&%7-KDI2R48MP8E/_XK!5%+J76WHJ/M[2,;;OB&-S]%8C;G
MUX;9\&IW]GM(*_$?\SNUK2$@L<>14E4<V9>5<3J/GXYXBMPH'5","N*L0%CV
MS:.V];$G6)\1US3VJ;PHABF'<$9A+&-&0U?,J@7$H3*HR,6$6@S\%IGB4S(Z
M9"//>L[<?89I.DE]HLF]KBKU*4+K/1RM T!WL*11A"<%7@Y<0,OZ8<T@ 94D
M@!],.>7D>Y('5$=+M'B]%EU#A\7A7JTF)C(;Q"(5MOW#:7LP)L-GV:34)%KK
MKHS19XK>]US9$_AWT8! 1N@SM1T3HZ>RC">Q"8E\]+*>.Z*98_CT/2:=<S.I
MOL/5+%FK#B;0B8))2TL<T\S%N&R3>]HBN1'@$9#'R$GT2"SG'77=B$IZ[IR(
M[\_SN62+98PT@0"Q;ES5^SF+*2K8R!P0X,P!0AI/KA7X%7&:(K%UZ^HY7F20
M8KD%O$KP$[6_K--[9A[HEL;O>@M[K,1U'<S4%V:W**:FVC1U_RAB/1),O9"D
M+H*-_7,(1!6DG&%JKSC$*J^-33$MJ01K[:2=J4"FRJ&M-TG&3F6V45-^JKI8
M2=Z.^B/(FB"A1E"QMI[+L]3!C!2E66.+Y?JZ$5KK<^?5461-I>CT5C@VD1F
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MA;:%%XEF;9$'2LA@;3K, NAHIFT5];S:6TWIJ41F/KUD9K-LIBDV4DU*OCI
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MARK.L_F<!QMF+,IZ*N?LT[G*2<55*JZR^5REKKEG9[*7RG_[(JSE='6L13&
MPS$&P)V@RL\!"GA8$3=8<?5 ^^SB2^O?UN>K+^<7E[]99U=?KYN7?RQ&*#.8
M6FWI/*VV $\K8P'8>!F5=A5/%<]<T?7J\OEE7E,)Z"<)Z#(B\]G59?OJR\5Y
ML],Z+ZP9G8#GKRF;7X8*-N$EE;)?\9+2*?N-JHAM>0FA592UXBE;P%/V*4]C
M4G;&?/-D*^ZR,'>I@AX5=]D"[G*0XRZ3$C8L.5+D#QINT9HZC%H;<5$_K7C/
MPKRG"HU4O&<+>,_A5-[3+ACV(Y(X*F:T1&:TPF!*Q8PJ9K0L9G0TE1EEF1X5
M[UEB 5^MXCT5[]E\WG.LY8A4^2 OST;J%1NIV,@61[*_73:_G5]@&+N*:9?Y
M)157J;A*Z923DWGB3VUWE.@6D)A./&4&=*7&+*K&G%2>F(KA; '#.9TW)/54
MUF-5O&=1WG-:>6(JWK/YO*=1>W)(JF)&RV-&E3^G8D9;P(SJBX:D+F$QZROL
M92 #4]/X466%/8GY5,,S*N:S!<RG,:ENN8I.O3!#>:4A&_ /SJ\SMMSU72=Z
M#^L,/@R=GQ(!Q3R]:8/Y3N;%]0(DUE9X@7K2/"4+V!1.8IS-5IYXI.70Y:>W
M=6O2V8VQD<A1\AMWAP;3O'5!24"FZ3\XCW%VW?J_ \6<C0&%DDWMXW:UZ7/U
MPWW;DO_L?MAY-W$DX_Y>XP2_;&QZ[^BX8-_BSQ_T6)I%P32=3X$=IN14D/K^
M![-NF^1.AZ8WHJ($2^58TS+W^;'XO<L=<(MC3/59:W.3T,M+PS6)F=ZTKJ]N
M.M;5)POGQEZWX)_+CG73^NVBW6G=M,ZMZV^_?KDXLYIG9U??+CO8@^#3Q<W7
M>6:=/HT]+3(<=CD@ZH1D=>A=U\BPP#_^&CI1CRJ3O,CM)F%$-LLK@*5T7/N[
MU_T3(?'="1+@O\!^HM'8$-R7V9J!'B?K36]7(R_PPL""_R'^%.F6KT=;1V5#
MHM]=:^#<NY;4NQ$D3K<;#L%(>\2:X5L1A8TQ"HND-0GMWN!7T5G9J'TXX^_3
M;_4/N_/5#MKT\LCU2>>/#1]$J((QMM7-^C#&11-P>G("CLL=&7']+OHP^H8/
MXQ$T5,N=DE5+7Y1/P_N]$'Z-PJ'UR;V-4B=ZY,=5^NT;#^ TPDWNPE>B,+T;
M%*\,)Y7<2YXV( OH#8Y5!B;FW;O^HT4C[+&0&PPC * &WK["V0Q*$M9P%8#;
M:00@(SQGJ!9]PQI%;HPUXWW'B_Q'&P'J^#Z@)V 0/@H?CV W<7Z)41A["9%0
MGSX1MSWO+6=GCU.?K]?#_VCQ-G@"_U2V6P, =<, %A\B7CUXR8!H1537CR)8
MRAOY<)%W;@"'\>$2X7/TC/7PN[BC;X&G/&QT].80]MAU]BJV/9U1_18BC$'%
M[KI1L$4,NI-GR(6D3#S\UG4#).J1@US#B>-TB%](!DYBT.F#!U0.B Q8F[I(
MM8YU1]#M,G3WK&9LP4:Z:1PSYJ*#QJHC(YK$3( X3&;@Q58:D&4$WXH<+X8W
M]7K$-^"+_33HD<<'B,2]]V 5R_> 7?>0L +7[5'0_<&%C<)_\?0 -UC!^C6-
M 2YQC.^YA7T0'[I]I%=W_3 F0^Q6/@2?-8$L?2;D.A-R@_A94  2U\%=PD\:
M+W)_(@%G'"6-1N(MO&$':7_/Z@S@P.BMHB<! >#G,'K,'H*M(&>*T]L8Y!*R
M78!P'/HI?40 BNG3!.0JPK87IK>)Y=R&J7%[0LP!?&X]'Z$%0)QZEU^= ,0T
M7I+Z*F 8G"QR[T!U9@P!08!\/R'-.D(@Q*'5<^-NY-WJ*( 'G2!->B%*,7BT
MZZ<]6 $%0N\_:9SPQX2%0^0K@O$S5\:3P0GAAET6)X0WL//$\8+DL6*+LZQ'
M5UT!PN\Z FH*TQ@DSP70?['O=(NX)S*R<2RN3>=D1=0VR@#K,6#_Z029.E&7
MVD?!BL"<8^#- >)]0MK>P(U<U >0<B.T6BV!\$ @<;:3"OEGW.ZO3NRQ:BB-
MNNW![ [Q[$).C Q<*-@C$&&>$!2FMJXP>ZCDPYYU!79#[EL>B6GW)QH+J)E+
MNT+:S_GE"G=TZZ B$;)A0J;FG@66)TD:$*G4ITK3I/M>-$3Q)#M9D::-+Q,M
MK:34UEI;7=V#Z"+IP@ZA-X:BO6N]$:;3]5GSZM?,+@6)C)N(T%04IM:M:WE:
M0RUZM["$)-M0.DY NXYZ9"&K77[;:^]9?;>')H 5N]TT K4'D,!W'C*_E3,:
MP5%(08I2M!GP SASZ@O%0UQ7._L^/M'ZR>8O[@&9A=0K"#IXMCF9QKJ[! %[
M0,/II5V\9(55\:0K0:VJ!WBAP"I@U1F@,I=]*A"!M94'ES0E@B\HA&CW\=7A
MJQ 7PEMBVA'HC2'KNJAT1_1J5MP>!BY\(YIL@R/V]2.7E!]E>.M2P%9K]%+2
MI=TH H8'_^M'L!%6R#2E&W4P'9W1,K Q\@O'@7?!F=S@#@B>/A2G0IM<G$H8
MXQYZZ%%11]4R"D$C!OK23A!1\SG2?$'$@L%!WU3W@*_)TY4 %KP)='\@5H0Y
M4BZ^<=ZW@6:?T D+U''!HO"I<2[E]OOL5V&SH)@3+G)HPC'X$?TF"%/!'X,0
M=/CN0+Y^2XCQ2J<_4O\5P;!C).RZO33B&#^0"$**!)07_QE/Q'QY3<5*VE2J
ML'6:S6\!29N%7(\9.B(0;67/:N/E:0^KX[@_ 9(!+&4C2CD6")4$Q9H'6P'-
M$$1%US4M*LL9HG!BMHW6-%BG8LV)QV()+$!)-EBV@7O'3\G85#[:<;]3BF*6
MS$SO+O#Z(%\ C+!3;TCNIJ$#AAD8RYG(MW4S._<*Q'XTAH6;T-%=?L6;_QU]
M$+[GW@L&JO%E@"E""2"G<<M;I;]I#LLMH9EW\3OK=Q!/Z; ]A/_\OU^C\"&P
M02YMQ_%EW"%VHWMR5A7[.!!Y #UB=-*2$W9+L -7_".,_K0M^=-6A#1S/OH#
MD42Z#4<GA=2Z.+<N4PP]8$K,]'-7^5(KS)=J%'D:7BUW:FORI:R_ERE[J5%E
M+\U.0KDX^U?KIFU];UYVFK^UK+.KF^NQ))3%&<0S?)H+R/(R O37YI?FY5G+
M:G]NM3KM>1R:XFV-9TL"7N+YH@!SBXG&NV!8C##J%]S]8Z>V0[^+=>EW@TW2
M^H) ;\&X=B/^2S>-(D 1XF\?+(,!/N-:^ UO,>'"&<7P9_F3^L@ P,[$LHGL
MTUZ>)<$6BYIZR"/  2:FJ&??FOGCRR_[C!J*D^>44,BT<X$R&=+N'1+:+IIK
M/_<ZJBCE:.(@*KFF0 [^]:TF=&NVA?_;S3\BKT5#.O$)O>F]164.JQYR-9;Q
M\J32BGD@OKW(U=A6Y.+ZOU?"I^JR7ORR:F4D_AG5>=:MT_WS+@K3H*??1:.&
M/H3]$_CG\'!WLVOXRJC--MOMUHOT>MNP!FRE>4D%WZK6>,E\:DE#%=ELI' C
MNI@JWE.ZEU3P+2/OV5!-:K]\',J)!TOB2\6%_'][A;8%WL_W01A\BIPNI0L$
MSA!63>.W=XXS>H\GWJ'L&OCF#08,KIOQ55!O_-BO_T K\8<H+A.U95_))]%S
MO2_NG>.W@L1+'IL_O7C'2@./%\ TOQ_?VN<[5L_M>G"?,7L6X0PN_809($[R
MCQWO9_(^2(=O>V'R5CRZ\_&P=FR?HG%J;OLE6R1L]876EGVA^S7[L/ZJ]UDI
M?25FJ==8_.1AMM;(#6)W66K?DEO#3"5) 8(60T!HP:5BN@?VX?[1IK#<-;GD
MUV;$?>^GVWO[7S<*$20GC7KCP]@-OU+;I1E-S<:B<VME\>Q,S">9R**%:YF#
MX:.?[%7..:9G,^T72 C:JC.^.O_9""AMPQFK>,<S5,K#-8]W=,+$\2WI>VP6
M^!Y7HHHN+WSX#.I_4F_$USW-="V,K[>,*O9AO6$?X&3Y,27[I>YE37"J(J"-
M(*#R^)$VB'XJ3U:)PY?GLOE7V(<?N*%+O+0X9IE\'1(29WC^54K9%?HXJEM>
MG2BH'YW8I\?[ZQE3V% SL7S\^B*X=V6KJX'K4[.A3I3&B6Q2(CD#\0W^Y5L;
M'G&=.(T>]38?7\/ ?;2^.M&?;F)]@IO;0J;/FN%G .1%0&"\#(-N"0VM^OZI
M?5"OV<?[IU5$8P477L4UJKA&Y<VNXAH5)FQ(7&.C5=%21BRN.LTOU@KJ-%;M
M%?O;-OE82Z<TGS;V[?II41K0!GE8*\+9:,)9OBOJ%*S-DX/-)IK*[IFL">Z#
M)HA]X;%I[,:JNR4Y9-DMGY* :2L.63GKM]A"^G+1_/7BRT7GHM6VFI?G5OMS
M\Z;U^>K+>>NFK89.G;<^79Q==':MUO]^N^C\456\E_8E%7S+6'6ZT5QMN17O
MOL>C@;REU3^M!>Z6YB45?,O(@#94^2I?C:;(A\"I$8\\,P.'L'2[4>J6I'!S
MZ674$B37#)%FT&LR/+YDK+R,:>:-VHE]7"OR1ZUEYL.ZWOOV)4%LH\)92DY.
M3'OK4Y2O<!)-*5EVE;-<RFM?>N2H<6@?']6J'.:*GT_CY[U['%T7\V1>.9H>
MA[L];A%3C[O^S_<2%)\ $C<,B&N$0\7+J]M>74EBK;:F++QBSB_0VBK$X8@X
M4SX($[>@G&1;&;94QW"VMS2E-2I&C<QWXMCK>VZO4LDK'"BC?EX'!7TUW+W*
MJRI-AOTVG+'L657E@-(VG+%R'E1]LD3&PI=)&0L;GDF_3;U^RN477R"4N4&I
M]145;1<5+=^,.:E-B#-L$!55;K(R)T&& 8$-$XM&B[G,;"MP$YQ+#8M27L86
M^M T\'T)@[N.&PUUETJI1/;!R;Y=.ZWZKJSJPJNTH\H>+;L@B!'CPQ$AOLR+
MW\;8"*6J:,IC2=MI'=DGIXWU8^AKD3J_YOGY%4M\-DO\W8DB1RL0VD9&>.Y&
MWKV3>/>NQ@U+Q0/W[?W#NGWTNL' ZJ(K=;929]>(=ZM^X !I-WK 5K'!G=5W
M75E&M96\7/:,'F+5F(./2&)_S/(]2JKK'MKUTU=/Z:N08"$DV#X94*7_E"8A
M8AO.6*7_5)BPS/2?C=8\RYO84R7T;%4J0JGTZE.[<5"S&Z>'FYV%4!'0EA!0
ME<2S@BZS25YSD-+X"(7BR]A W="',P?_V#G86>.W5+[%+=/PSL+AT!.3KK!U
MTQDL"%]T@^ZRM;W21T1G9-XH.#:#G@'%5].G?L;>^\#S@0BBU$4H/-GS6$HW
MT'9BQ+,4A/)@1.4$*''XZ2KJ>8$3/5KQP(G@#7%Z^Q^WF\!7K%$8QY1N&[D]
M=\BI5E-Z+<B5VK10F]?IA-=BE1NUR&LP0=Z]KA9?7'Y:8&Z)?5(K#ME83HR9
MP^=NEW;"?&N_#CH*;);$Y&N#Y*E<8!&0O(W=+H+E(8QZL1OL? S"<4@(#)D"
MD)KE)#JVW#M^ZN+3?YL"I"E@N7:CMCC%J\C-'R,W^D%O>#+FU/;J+V10K7>T
MK@-7%D: ZZV_4HS/.5'T" RH.<1\^V:21-YMFF X&^[9*5W(%@<7[9]40=MR
MH<'V!FTK+\7JE<O*2U%*+P6)ZP'L"/A"-J3#[7M=+]FUF.U4SHK2OJ2";QEY
MW49SL66U<<-\-3?HNL)0LB=9/5)7XF^ N=1.PNZ?H Y=1>T$JU:_H]DD;9_2
MFCZO?;AG:'_//UQM#TR!>H$MD#>*1T[$9NZ'"8Z 8H"P6=M,DT$8 =+URN<3
M>:W3+,.=46#@H6DWP;R;Y.=0QWG*U5[$<;IZ0(SY=18_R%6:Q(D3]( );L!I
M9E_+,JAMPZ\%3N+.IK,Y*-&CV[+"R JSXVZA<\U$ )*@5:/3ZJZWTT=6N7:>
M8!3EPGPS;1.,6(?!)AHFSSS9AEDE&C36W21YXE%68X\TV!IY+8MD#!;ET'N?
M?:7EL*J>?8PYE?>UN)(2&2)%+1<.#N<DLCG(4)?U1=K+PCY#6/TMIDNXPZS0
M6Q*[L'TPPT0S?C#!8DHN"@)ZS/_)2L7QX2\?K"(=)K^M#]F73O;V1S]W/KZI
M[VZAT:5A^LHMKCQB6U[O'SN?8-L_CNJU&FBKAX#K!T6%,97E]2H7ONS:C;$+
M/WKU"Z^B3?,85LU>ST/(._[+BX>1X_7@V$(N=)V1ESC^5O'@#+K7 (N+X(QA
ML+(T>J/';.7<6L9]+G^BYH%]=+BFG'7['%NKFY"<#E/N,=WCY*.-5)'?3*?G
M&S=Q ""]EA,% +=8 XM(R5JVUAS#[O^Q\W8&C9_81Z?']L'!RT^XW]TP?OZJ
M"/ :O'T^!#BR&\='KWKY55NFLC>JV88S5FV9*DRHVC)M<#H\MV4J75)\29N#
MK&F[F1E*&+DLQ>WS79=9ZRZ>[+*.'6AVGR53*I(J;P>GQ2AJ!8V<[./&AH\T
MK.RGLFN4VW#&RGZJ,&&9]E/EP"^GE775:7ZQOEPT?[WX<M&Y:+6MYN6YU?[<
MO&E]OOIRWKII9U97Z]/%V44'K*[__7;1^6.KK*Z_;8=VJ/7W; :]U5M?,UN;
MG#;V[?IID;][@Q3&BJ2VE*26;WZ=GMH')Y7]M;7VUSYHI+TPI=YX&ZMVE^20
M9;? 2@*FK3CDF T&_V#FO/'"KN\Z$?"Z9/!AZ/R4FZM13RVQH)ZHZ?62 3"T
M^B^YPYS,8^DT-$#QWW2K+0.3^8A\)T+"_(0V]9ZMW1>'(X(0H65U7=\?.3VL
M)R!AA[^+=5D,\AMY:[2^)49LT>% 9(D#U&J_/,N0%(>'57UG%,.?Y4_J(^.X
M.Z8\FC<(*79[,*G^05.+T%K]( H>9E'6A.^.F=WB<?KXU:WN<B7)3:A5 :+P
M@JZ?]K"F+;"<N[L(-+6$.H6F(VP].W=/U:Q7J&@CZO8ZX:<PZKM>DHY5<M;J
M/VJL,G9"37V\@JMM^GY('9JO:#76(=,8E5-8&;#+PW>">GC5)^T4%<J5E#1-
M*FBRPEPGWV3@)!;\I+?T[2O(P-M'+I<4 7R3@6L!E.#X^!1HI-T!_4W-I-3B
MRB% "Y!:@$O.8/=B6,"-NE[L]JPWL>M:ER'<Z-'NGG456/]T@A2VQEAPQ 5+
M-KT!I_LYP:/E]OMT>Y;#^Y?I[MY_:? ?HL:T'K)TY#/C*P4F ][_T<KKDVM[
MXY/0Y:7!%RW7 >@S$+3*+]N"SU.?IH-ZDQHQ/[%*[]EP*4<1Z(J/L4"QX1BQ
M3JCV,PD)>)3 "WP.\%#^1MU58VO@W+O6K>L&@"I)%.*[[EW_$1&'BMR1MB.W
M[Q,S&+B%A 9O :8L< VI;A(;Z*>P&TGRXD$O(NXPQAS"' >HUR4+>#U&7V=W
M6R?,?BXSHU^D _>#"]<F6+G;V[.*;??GZ\:Z^M(%B+E13H&9'>C0E9;]25I+
M@8(B%&&AP2RL>4Q8C_"\6^#>!QQWNET614AW 9!<;#&E ;=-W#M :NRJH$BB
M#[@9=#WX*]$6S7;(WT0>GAITYK(N)L$F6^$%C*O7N^\%CK0<??33V_VB&QJ#
M@WX(BESE#X%_TZR/6Q>($:T/_\%YC#-2&D1Y*Y,,)JF>[^-V-7.Q?KAO6_*?
MW0\[[R9=?7U_KW&"7S8VNG=T7+!7\></NA_0(D<@;-.Q!A%RJ_\!1J?,O@ 8
M^P<C8,BV5X=L1T!_G%^"Z/[W=XX!0BJ G(50.T76]\G>H0?8-&XNB<-$O&TG
M3<)<8)'^)-;$$ED@R_WC@Z/&P8_]G;G1^N7ML#4):WZ_./M7ZZ9M?6]>=IJ_
MM:RSJYOK/>MB!AM[17C6&^L-T':GV6E];5UVVM;5)^OJNG73[%Q<7;;G%PP&
M!)XF&7B)Y?N+>(_L+V)2+;L':2SB4.0W.C[^I3 6,<6ME#E=,]?EK!]??MEG
M9*F</"?)7T9^!,ID2+MW2&B[: AV^CICJZF) XV=62L_W7,[YO8U/+>Z6[!0
M[KUN1.\/4/*M%@COWM]OHW<?QWQP]%<TB)X6L%S.O58WJFNN8816!UW<M1MY
M8<_J1^&0?O_DWD:9:=W(KK=&/[RY"+HNF;J[]'MG$(7IW6 Z9M1>#3/6('7.
M,AG_FJ;1+6E\W,B-'/))HDN*_1GHQ^F&<1(_#8DR 3B1Q3\IH^)ORVYVH6!S
MAL!H!KW6SY$;Q&/3S%14HJY%)9:?)V;7:H?VP>G)JIM(%2# YEY]XT>C(""U
MY*M_G6+X,M7"6S-T^5?C11N1^KX-9UPFE]H(@&W#&4M3,U]>E71_S2L[OH1Q
M3+:4%;+,#H/GS+I_->UUY?G :YIV/J-T7BEJ8"6'0Q>Q857:^7PU]-/4]'7,
M/G].#?TK6 H5F:V*S)9E"3VO/]@FD5CEBMLL5UPR<"-,K 4">[\JY64MYJB6
MYR7/$6"; X7GOJ0RS9YMFBV'19T-G.#.Q?3EON.)"4684?3@1)$3E"U@L-P6
MV93SR@"Z"#X!>&@&P57_=X:-+)#-5\*6S#PYL/>/C^VCPASH=8\BO,0J,D1*
M]&H=P/]K_/\E8,J+:]@*)6:WS<^H4@T1?.WH0J7'KJ>0((\<5A0!GF%^-99&
M.#A6'03%*/+NL5!LNP3&#./Z-\<+$&A7 9<MG+L$)>]^=9'F^81%PSX\/;4;
MKR L%NW"OL'2X@E8\N*"8E/E0\7YEV(> '8":&.J)..",E_J.-LA *93=J8"
M$G 8BK&F&DK2KY<S\:ANG^RO?'1=Y8HIN2NFTL57P)$O,-/9C1/+Y?PU0T3S
M+SWW-K'@BUVL0=X.=CQ#'Y= $SE_Y62Z]DGC=>??5$QW YANQ4Y?MHULY 2Q
MX!F4(6]AJX2N[,T@O!I*N_7<[79PD*-3@QDG4TN(=<*<P],K:6;]?LT&<;G>
MS+;</H[G(TKE&Z_T\340()D^[D0!" URD]_#'ZC_B#5P_1ZZ3SI1"L\TNUND
MD\^GDG/Z&67*E%54'.\7C4=:'U](N27% @BQ'5[PJ@9K/4I1MN&,50U6A115
M#=8FY"+S5-)0RTBVK<"M5%$LA4"@Y.HAA*?XTLU/2R^'5EJWCT].[-,U#]*M
MAV*Z&'ILEXZ:Y-FT9'='HZ>V5A]SU:M>0P<[:_R6RNVS)'%:QI)FX!-"Z%IO
M_#".=[>[GGE+)FC!K:^^AGFJ&G%\LF\?[&]*X?*VUBUO##G-R.*82D]5L7))
MBI4K]^6:C.[:BD.ND0.S)!#;BD-6+LPU=&'^ZL1>UV)9A9-Y )X >3F"Q1C,
ME!OF,Z$M^_'AI %TN7=_R+YTL@<H+.;1E<^&6XT#]7=Q)4V^D<L4U:RK_MB<
M*[K US2$QL?[S&T+T:R*3W"\'T?U6FV_?ES;^5@_LD\:-?OP8!,[L*XAJKRD
MCO^2J%+'26.UVJ1)8U7"0*5Q;\\A*XV[0HN5:=Q5+*3TL1#6XH-\1"0;GCFN
MO9=0T:Z\NR\<+&DY40 OC:_=B)3!5[<5)@X.;BPP-KA6E("QCD[>*G:RYM0U
M(W8R%WF]< SE!<BKR)Q:1_*J8BB;J=5NQ2$KBZY"BRJ&LADQE'//3S%X\J0H
M2JDLL%+YKP58Q]S8)0UV4&1C_\"NUZNNL"7!C)+$-JI 1J7V5OI-I?96:%$%
M,DJD')<QD"%5Z2J4L77.UL5\K0)1JF!&%<RHZ.LU@AD3"*P*9U3AC,JNJQ3X
MRJZKT.()=AW\X\"FC!=V?=>)Z. #/-A/M3U9Z4]K:E\0N%.O_Y([S\D\1E-#
M@Q7_33<&,TB9C\AW(C#,3VA3[[F%T(N#$J&( +.ZKN^+_ALD%?%WL2Y[(OF-
MO#5:W^JF401V*!U.$5R]5OOE63:I.#RLZCNC&/XL?U(?&<?=,477O"&IC#T4
MUY)HFA0:OA]$\<@LXIKPW3$+7CQ.'[^Z 5^J6%8SL<[=+BEPC(W[==M"'<^V
MW)]=/^W!6YW <N[N(E#N$AI<DHZPK?.S-*7)_6ZOA+'/SOX;M^<.:?Y'.[W]
MC]NEOK>?PJCO>DD:36Q";VBKLSW[%Y>?YM9 #PXG>?:1?O.^"BL9.(GUX$:N
M%?,!$'1]=8 ]JUC_>Q&^J2-'8V[\+$!%8XT7D!<3R*_K8OO*' '.]O_IAS+/
M.>M8S,D%"2Y\L GK>0D<IUO0/&S@6DZW&PY'3O (+X#W)DA<@!H.]KM-W+O(
M\:V1$R5(9 D\W@=4"KHX+2Y.@/:H&VX>8Z9<^ESB<>J5GY3^PA<XTG(8ZJ>W
M!T4W- 8' VO1BYL_!/Y-$Y^W+G -%)_^@_,89_0^B/)J$DE\R1OV<;N:OE,_
MW+<M^<_NAYUW$ZE]?Z]Q@E\V-KIW=%RP5_'G#[K1:Y'5"]MTK$&$O/=_DK"K
M])8@]?T/AO.<F5B'E!] _S/DZS0*T3% :,W I9TBS?%D[] #1!H7]>(<$>_8
M29,PYU^G/XDUL6(-*'+_^."H<? C:W$U$Z-?7H=8$^_^]XNS?[5NVM;WYF6G
M^5O+.KNZN=ZS+F9PL%>$9[VQW@!M=YJ=UM?69:=M77VRSCXW+W]KM:V+2ZO]
MN7G3^GSUY1S 30WLCC]8;\Y;GR[.+CJ[5NM_OUUT_IA?<!A@>JJR\#*B8U&#
MB/?(!A'3<]E-I+%6=T6&T6&CV!<G/FX4V$V98R$SSV?]6"W[*LL^(\1]\IS$
M3NE\$W234>[>(='NHDZ\Z>N,K:;:01[MS%KYZ?Z9,>>.X9_1C?]"#>%U??S2
MF+7:STC^G/OVHO"!X=V8">^GWB2LO,!;-O16FP [M/D=_^^WT;N/UXZ'XTGH
MYS-GA/;?A(M^L0MZY36KZS:NN]M-AZF/,Y?HCL_=OM?U)G7]KNYX'>^8.KO3
M[1*G'L!#;A0+39K^WOHKQ<',^.,;@0&[2T&!;5<>MA8GEZ(SO 8[V<[K:@Z?
M/I;L==G LM)DJ]38E^WQX3M!MV@V]2?W-DK!JN#?&B)@9[WQX'&*E3VGK=ZZ
MYL4^*U^Q=,E[TW/W9A5"->.K #/W:IRM=Q8.AV'03L+NGYRJE\:X3%O&E%BU
M@:=&88 ^=\S=>V;5U.R!&QH^O_35K0G:5;FQ924OI!1A C!ME(:^YIQF4Q'7
MNHJQBL0*22QSN:&W[2(0?K:*W$I&;NMSV(K0"@GMQDT<6+<GRT,J"JLHK**P
MEZ2PBDZ>3"<K[9"TOMZMY?BK+N(X18<59N^-94&'5AMD11Q&)5#F5]/:AM@$
MPLCMG:<10/3:C;Q0]+2!VZ"/YIS(M0*'SM.2Y>NK[HRTWNV0)N#,=\=/W?*B
MS--%U4I0HT*0];2P*SZR"C19'_NPPH]5X,?:WG(57U]["^0,S0_?=PC#QZV0
M#38]9O1ZF6I[7"4#-RJ=$CG3[IAOAO#+&R"[E600DJ&<B%,"4;(Y?&4IR%%9
M'A7_J*R."C>>B!MK>\-5-*/$MD05S7@R[?*?/X51VXWNO6Y9/=1/:^P_N?U/
MQ?E?)A96?O1YUFB(@Z(&P97I40(,6I$=\AQL:AS81X>E0:@RH))J7ON+JJHB
MA<,Z@/_7^/\EP;=E&S4+UF9L,1*5 S]6P$X.5S2TJ(JRK(]E=.DF%H[HV&#;
MI_+L/(\; HI<T#"7+X GI5/?2^#ZV1Q2>7%$J*(!Z\P79@2BGX /*W']3U">
MYHLY']F-XZ,J[KQT3-G<^YZ@-2]O),P"8V!6,_L%@,!=8#9XQD<YSOCJ$FLC
MH+0-9UR20KL1L-J&,U:<H<*$"A,J3%C^H.>-]NJN5V^ZXF%2UALG[8&5TZLZ
MTVUX,X0Y.M.5)6ECD4+F:8D_&]1@H6I$LLZT-T\CDG5+N"M,E]I2BJOH;B/H
M;I41KA=-,MM2,ER?PVX, <Y3W[H !6Y.3'$=27"WHL%UI,&7)<$ER[#ZB7W<
M.-@0 EIZ=[PJMW)9T]B[W<B=T+Y"'R >J;'H)3 HJBS,<B;?$4N^ 4P!=:9W
M%9TYOE]0K9?/K:G_J!&+KFNY-?4J/7--:6@>Q?F%4&1CS-HJ3V]%&%0FLVPJ
MZIS:!\> /;4JR[-$V+-\'#@]M1M'K]MAJHJ9EUA;QTHHCY*4*RV\TL*?DLA>
M*=N;1"HOC@A5+53%%]91/SX^V;</]D^JOA1+1I#-N^:J\FD]\GRWX8Q55GN%
M"57E4X4/%6>H,*'"A H3RE#Y5&5F;$)]5+VJCZKJH\:SY);J":[JHZHT\0VG
MO8525)<?AJGJHZKZJ(KN2I](UO=^NKVW_W6C4 7'"X)C.CYN*3FNSV$WAA!?
MM$ZJ7 ''^>JD3NRCTV/[X&!32CVJ6JF*#E\CKKL(-=5.3S><FJHH\RR?ZO[H
MI]4+TUO?W6#'<4D.6?880DG M!6'7(](<TF M16'K+A#A0L5+E2X,#/>#/\X
ML"GCA5W?=2)0CI/!AZ'S4VX.C[0C%\PKU$();LP=R2U0RHTU7N#0:[9'S12U
MNBZ8>5'.5)B= * ?RCSGK&/ASPK]%C[8A/70'^MUQQ_O#%S+Z7;#X<@)'N$%
M\-X$3N9$\.? \N#H=Y'C6R,G2K##00*/][W ";H>_#66'J5XSRH(@Q=?V,FS
MK_RD]!>^P)&6D][PZ>UAT0V-P<' 6DSIR!\"_Z;EMMRZ_3#"W!;_P7F,,YXT
M4':YF.Y8K]5^^6!)WKJ/V]6R7^J'^[8E_]G]L/-N(K7O[S5.\,O&1O>.C@OV
M*O[\0?<R6.1F@&TZUB!"O\O_)&%W1[XH2'W_@Y%)PZ9^!]DRHO\9NGP W?_^
MSA$GM?ZN_IV"2SOF$P(F)WN''F"2_CPFTZB#1+QE)TW"7+8-_4DNZO4 1%ZP
M?WQPU#CX<;@S-TZ_?$[0FB3[?+\X^U?KIFU];UYVFK^UK+.KF^L]ZZ* 0F9=
M[$L!M-Y8;XBV.\U.ZVOKLM.VKCY99\WV9^O3EZO?V[- :@CR%] %7D8R6*B?
M$<UW7=\70VG)"XN_BX79*ZNS37J!(%?6-_DOW32* %V(WZEQM\P0GW%%0J.%
M57UG%,.?Y4_J(P,".WRJ(G^I]G$OQZ*.#W^1KL["S^%C:[*2GGUMGI]?9VG2
MK N./H]@/YE1CV_-8ZS(H<89"N\=CA+3LGN)A<:7 X0 % C^L=/8F;6TP!C^
M5<]+S8PC\Q&)Q1HFBD^$_DKYO$901\G"Y84/_@#CR6J!+._]_39Z]W$LE9/^
MB@&;,0NM5%=;7:JARX81VB%T=]QSQ.I'X9!^_^3>1JD3/3+<&MD-U^B'-Q=!
MUZ4N;+OT>V<0A>G=8#IRU%X1.9[#G5XHT7SZ83C3?%P-JE+-GZPKG3GQP/KD
MAP\QX:UU-7(C)T';N]E-O'LO\=SX?9'>-#?J318)KQP.W;JW/('5;]#IG_^6
M5^1_&\[9EMTPR7J#(^1WE\V1BA-0_O;,%;:NM\-S@+WHG3V!)R[OEK=BB/%S
M@+Y;J:>;QL2;O?^D<4)Q&FY%#6C=]7S7"O+<'3_&/W9114UCMP<?6Z'23YUB
M_;323$OXEDHSK333EV-J^Z5C:I](-J($[X9Q L#V>E;"[AS+Z=UC,;>PKYU^
MW_,])Z$(7GL4!G$8E4.-?9%EI)^)KLTZ@/_7^/\JU'#RRP(*;]SU?[Y7P#T#
MV&)-EW"4-05@/P%<FQ*L5WT!U%=7B^?L<+B^&N^+++.2NUZ6;CQ5)3Z<4,_^
M@K=2:<2;(#PN,&CA@MAPG2@ +3?$5*=[5RK) ]<GS;<3@=YL-;M=N)-D@T3&
M$PQC";%FT#L'&P!PJ<>&<MOMIA'9!)\!:IWPJY/@[_GZJ'+X2/9K]O%^46W4
M2QK-ZR<Q3!7BL$"%P&"\GOXRG]/LV4CSXE)E%1I$94F46QB<#9S@SD5^WW>\
MR+K' 19H*CPX400H!IMU;D'[21ZW6P)\ N#0<(_,G735_YUAM#*/^'RNT@-[
M__C8/GH-W7 ;./_BT9*%<*5B\I5=4!)1@%$?-@9 .7%\RXOC%(W@;10'4UP&
M"*:KX(*!="%@I C\BP10*4V AGV(4Z!>VT^PM2[Z%\>:I8N'*LI0"819M@&@
M*, SIKF_E$^Z-6)A@I5 %,[0N@B4^G?5/U. NB(XK5PXS&<QU.OVR?Z$4:-E
M-Q?6648\!X,J05'9%R47)\UA"%#[KR,'QO?<V\2"I[8AP##=8Z!#YJI_#G Y
M%V"YCMRAEPY+:4R E&B\0@Y>)21>'%TJX5!9$2MC^QTP<&.!QYBM%%N.[X==
M)W%[F'$YBKQ[3$\2'J9X*P4!J7\:H&),1XF;$DZ=\)JAM.J(PZSX<J/>6$N!
ML#Y!AN=B2A5OJ.R!D@@&-G?C7)9]'+LH(H*><BI5&?=K\):-U,(K+79%S.JP
M=,P*+"O*LG=_CMP@=C==39V9$-D%1(O=<Y?_>Q$(^+08/*743P_LP_W7KAG<
M>OWTJ1A2Z:5;JI>6C]6+E/<8+N.1^J"A,NITNX!'6\/_%R5N";-K!EDSZ#49
M8%\R);Z40J%1.[&/:T7S=RJOQ3*DPE,09Z-EA3[%I406SE,95T[:K-5T[(7X
M^F8<<PEL:U- M27'K*IY)JJNQVO>B^]RGF8GJ^G%M^K1:Q-&5[RPDKVTX\QN
M_(1]&:^C$.L4>[\^?@.$N A4;\:L-6.Y$Q=/:G5[?W^.H>[K@823YO\MUYZH
MB*YL1%>N5FSU":W8-HOD*G-MK;36+3EF9:Y5&+$:<VUCXQ&;UF#]@EK[5 W6
MU_$M55)-E52SR1F %ZKM&)65(N>J&H^I+-\,.E=]Y.H7 4%&1LQ*&4ZM[Y_:
M^R>UUVE%6&7:/!='JLAI98I7AE=EBE<849GBY5=8-RZ^ZBE;O(JO5J&>0+EF
MUB6^.EV[WZR 3Q5C?6VK9NXS%Q/\,P'Q6A2[.A-K+>FOBK=NA*Z[)<>LC+P*
M(ZKTV"V-I'[R B?H5I'4=7Q+%4DM;21U8]U7Y8NW@CG3==V>X&<Q&/\8=T53
M([9I]"G\!M?@1@\XGP88G>S.&-.(P7(XJ594\RIAAQ/ALO[=9^%P& ;M).S^
M6=)X["&._GC]T7!K&([5ICM-]&$L 4\V.B:[G9KONG!^T2O.NO;A9BD-Y_=M
M[L(XG81+W7OQT*[O5UQ^U5R^:KI8F0 E%P1-8SIXY/K4AW?D1!L_NV-^@KYA
MJ%PC4+"[=BDY?F,)\Y[7C]V_[L678L[W,BZ^4N?+S<5OW)'S*//FG:UEZ3/2
M;A24XJO^6O#TPU<B[75/G'\='7X1]*@T^$J#+PGO-UTY(_C'B^,P>H2-):XE
M\&9CQ8#)  X*TLU.%BZBT57 :P7/2P"GSA9>76*L@B6LGS!8RMV60M&O5YI^
MQ>T-37_;F/T3='[3G"^?_C]GHOUKD?ZZ6P*OTY;XJ4A3606555 2.6%:!3RA
M._&P>WTE-)X6S+M*!F[T)0SN.FXT+*_+J$KN69&@6 !3*CE160JO+P$R.R'L
M]]T(\S=IWNJ&\_99!H'2YBC[3E(MC<TL)4<_J!_9C:-*]U_RW9?#Y5,_L1OU
M_5>^^ZJV<JU*S+;DF%5M984150.=JH%.40.=D>C#8-T^6GU5AEDUT=FH)CI/
MZLBABG)7WT-GNF9W4+./#D_LXX.-:9U3=<ZIJ&UUPTFF4MM^W3X^.=YT0JOL
MN+529[?DF)4=5V%$U2-G2WKDH(5V-G"".Q?[FZ+*4)EB&Z\<XC7C_UM_I=X]
MZ&-!$M^X<1)YW<3MX0?-H&?^07OR^O^S]ZZ]C2-)VNCW [S_@>C3 ]@ [=7%
MUZ[= 50N5[?GK2Y[+=<TYGQI4&+*YA1%JGFQR_/K3UPRDTF*E&5;%THBL-M3
MMLED9F1D9%R>B!"1%[K%1N"7/X9^B@%;^ >QTZV3B,O12 SK&78_.CVUC]J-
M*=>8<LUIG7E:ZV$.MNSC=GO;#VOC(5^N_K6ZJH-*"2(0#__P4<"D _1Z(PZ<
M3F4]=*PU8?;>)=4*0JH77P<U%$Z[#>!;3L[GHMD&[[?6*MAFY/T0[L%_1!3^
ME*'[UI$8U#@7:^ECV9%E-L[%AB,:Y^*..!<K5.'+P"U7@M>M"J_.!/RY\5V\
M3\M?0Y[.J7W>V7H?Q)8Z#)OSMC56]58=M\9(FTM7[8*NZH8I9L-NM4Y>FW5N
M@)E6&UKMRCH;-'\=S;E2W^NK42!A<)!A/\PVMV"JE>'U?UFUP;8A;7;J\Y6F
M85)M&R9MH.BJ7[;\)S$2423<?+^CD1! ]V<';LMZN)1^7FVU/$65;P91/@MQ
MPR2I)1+KV&Z?;UL)E/?N^H*#IV]@C:VN>-)8U_6T,'9EG8UUW?!$8UUOO8IZ
MG:OB!%8U@FY!8_4"L*2'< VZM2STM"CEY:RHO!R]77E1I,3*/U>2CE=!CZEH
M_K$I\KWN[5_5SM8"F-XYMD^74>JKT6(W]R;?E74V6FS#$PV8;WOT4^P0;R4/
M8!K</Q2+3I>@^&I8?KIFFJNNQ0($C+%VI7#;C7ZZ[DU>[/[510M=6Y^91@NM
MYTV\*^MLM-"&)^;00N&_&.;*KW#H"R>BY3_@ZG[H.2IIPP,7E4A)M2%HDB(J
MR+.7=5J3K)TJNI;HA/1O3;Y7*WL5XWD)K&8X_?C=@T G93B>.,$SZHBH!<:6
M$\&O \N#E=]'CD_*'^9R)/"XQ G!;^,$-$,JW'UHE>5W3$V%R',VKUY=MIAL
MA$6PTO)V_!5K6HT1\/G@Q"J<H]S_5 @$LI^*Z\#?&2;;0(#6@B:;_^0\Q\:!
M>M JA%2XVZT6J-SJ]'5QRD9LHGW<M2WUG_T//_U7)0NUNX>=,WP[-]7#D].2
MV<I??S#A=A;A[6"BCO40H5[V_R;A\"?UH2#U_0\Y,Y+EQ!U*%CP%%Z@:!NC'
M=XK4G,U1!4B?M$(.CSU@)_-QM"3U0B*>LI,F8<'4I%_),3T7*.0%W=.CD\[1
MGR<_S<W7B[>'-R1K[9]7%__W\K9O_;/W]:[WZZ5U<7U[<VA=E4BR5\F)M].S
MW=EL@GZ]OKOL6W?7UN>KK[VO%U>]+U;_KG=W^?OEU[O^^LBZX6SZZ?+B\O>/
ME[=\?W7;MH6N@S)RLEGX-1V+R!L6;-OKZ-X)O/\X:#""^**$8/JA%[@WD8B!
MY/3C]>BSNM[[^G;_Y,5#/XS32-S!-GWTP^'WQ?HW!!C $R%]&32R%X 5W@-#
M&+_8%[X@4_?/$[A!.IWV^<)V8]O.G]4N<>%]NNQ?W%[=W%U=?[6N/UO7M[_V
MOE[]?SWZN??UD_7Q6__JZV6_;UW?7-[2KU\ZKN_0C$[JIAE))K4DE\+M'DWP
M'MA#91?IV&E]N& %F7YJ?]BW/%"1K8'O!-^MX8,8PG_Y 0S^P^MA1"Y3!Y^Z
M<)YAMM95#$^[L25^B/$$_ZC>" /KLQA$J1,]\VYU^(BW#BU4SN67K2<8#)U#
M\";\#RGBDQ2^%)-&(JBF%V'W+3C^]R*RK?@!M7@A*W_9,)M8)*#L_Y5ZL8>G
M23T"X\ S,3P2B="0$Q9\)_9@"YS(&J0Q4"N.<=H#D!#T]R<O>8#Y"WQP#"J@
M?@KV"7XE\(1[\.\]1]'QHQKF(AM&$;5@0RR&VUYSIE?#;N:F AN!O05V\]A#
MEDA"V#XTM;QABD0']3.-D^B9-@+V%_X']U[N>XP;#[(R3L=C1^Y]&7WS?(2<
M&UA@#_O/:+_="\K]$,@T.,1]%#[!IBKFA+\AXUAQ.GRPB>F,<>)T\&^8%4W;
M]Y5Y&'GQ]QB9+81+!%=%7#+?!X%95LT%/2+C)S&DRRE_R>97_."XM%LP5;@5
MAWB^\?A.1$1DAIGW@ HR=^8Y.Z54_H#;?98?=&L/I(:8X"#[.C!3/B/9##1&
MFAMS(VE_^B&6[F,\FTAD?,(+X RB!9\.?- *-!!I3Y[(*_GW&_Z[BA6I0VFC
MRWCX@-OMPBT=>0-L[B'\\,EFY@ FB,5?*3:TDW.J&-$&$P4EPNB9636!W1")
MYC0DUSS\^^0!D7$;[D6 E!?F+L# D7@4H#O$5@K?@NT8P>&D:>&'X*R27!M5
M? K6E-##R*[ C$G)M_5W%YZ=!<K;@5Z(3M&">5/-7G*]P/;B[-$O TI;HOY,
MS$7,IKK+ND#S1^%F?ZG8E?P"'_"HD[(%KQ8Y$.6 EP"/>1BNL)Z!1B#B77U@
MMUE@1^+> TG,1TN[O?09+Q[#"F+3)>Z*(<AVH*^\LQ\%J@#_<(),,)SP83^T
MK@M_:"LQ8,HE?04(=]9.(]_,P&>!V0!['8Y()2AKS7(DU7OX=UNJ]U<WUZS3
MIS$:&7T0!9[KP6S[CB]D+S]4\-\8)U-3>5,;EZY]5M%QETF)7XAS.A[]1LH]
MEFUT<\$4)O*6PX?#R 5A 7<RSRZ']L2_\[A@7[E\>\C!Y6;TZ:4IX<ICQ'S&
M4Q RH"5&0P]TN\$S_5(G/X$PP_,/GP@?@8GAW@T3[B9*]X>:A3,.4VXQNN M
MOX:O]M1'K^F;M66!>3B )/[/L^/"QE)NP+(6-R*B?2PK,YA1ZLVQX3_A"OA3
M?B!;=V?^=;<.2]:,>@@QIZUN,*E]P0VH;PW@EPI:$,.HKLK7(RECF*N5A)F/
M@U;=SZE[ACQ0R@=EN@T<(,0!6-T=,4?ZWCCU$R<081K[SRSR2%WRPUC>&C.5
MNEDW4>RPOWP&2^'9"D=/3A0YTY5I*KQ*-;YV3NRSHRI>DVO,W3D@3QY1E[SQ
M07,D.?Z'?$R[&D ^@5&(<F?&\7R#J#((*F>A)R'GL$PB+T#.M0Y/C\O%7"55
M*24#B4E_GN@_P]VNO4#P<QH)ZS-<N7Q/_//*NH&GOR0N&54S']R#3X(1)Y^W
M<WO=GZ#?-<HN_S?+X5_Q:?7P:T_/>C;[S3G#W?+C5&J7*ME]M".R^PXV+I;L
MP=A.UOO8E32+@XPWZ45^KY9YXV=V^^C</CJ=;K9MTX7C<063EV7C-9S%R,R*
MOOPQ$4%<SVSYCGU4I;0 EU.OU6)!!-!E9VUY15YX/;MP5A<+P.6[534A8G)*
MS20#<8'R@@U+&LRON?SD<3FO(W^'./5"*N&J)=WG$(R_)_S\_$KBE'^CK?VK
M3F"8JO/K-AC!]%SI>+T50X&^KNO D&JU<&"\PV@YM[MG%0=@;RGFZO))L0"[
MMJ21D[9K]S-?9R"2G"YEVB*9CT:Z2JJ85CG0S1>KU75R[9%"R7F_5@*$3 A:
MA]QMZH%W])<>_R73!O%[7)"+A_AVV#^T[M'+$]"78C%,(XJGL6-*3G\L'.HV
M@K$](%^"WB2KS^%R&6;8<_;WVB?[V2G%C]"8RG#K#1/I[7+@V"?XG6=\O'UV
MS&.XSC.%]'P1P^?#B-;(?O?@0 3L_]+#*I]^\@#&RT/HN^0X%CZ(L#3AJ.@X
M#,0SBICO..]4KYV6$OK"?]8TN,-61C EA"7"<V,AZ*FAB!('[\(P<"F<&?-U
ML'B__&WJR\28CG-P*AWS+Q"3'+WPE3$,X2HOGGS"EK$),]  X_UB[7G[_)UY
MXQ5$D#W/?,U%/[4W2-6+[%+$R+-DF!S[5<61R ;&G8.3+A>3"_[LA-._2!08
M'R0>[34&2@91Z+A([V$DLG!XP5V,/W@CD"O.9 +BQ3&WI4Q,+48:P9;YR0/%
M$3$^E\#O8% X4T:<-O=UA %@4(E.,DQ]('C"\!-;J?AR$H*EZ<X7<BX%(VF/
MC[Q//A%331AW9%S>"]9)7\(3=3O'O.$Q3DHC)BQ?FA81G/\8-O:OU ,RD5!#
M I8>R#$>+J#>%#0BBU#F01*$RHB5\!TY7J2DXJ/CIR @_DJ!'3#$G@ 3.S#Z
M6>MO:@_ERP_"=\N/]QX=W1$+(3RX^^H"E3M#>6*M[H?Y_Z> #,J/5GO,]VY!
MOD_+8%Q3=%@0WOO]<.^5HKUGP;G7!^-NX+ -:KM!;6\^F[X*M2T5%-8@,)&C
M O0\0Y/I3< 2<_6C?[8K+](<O[[M+N8A%GL9;]/%.^^>DN*YAS8U&=/E;DV$
M&WIQ3 8N60'.#Q&KXK?H6F.4GP2$@3V)NEY8H@SNEX#9PL!_5I:FJ#(R/58V
M)V&<')0^H*',3P'KM$-2E6/K&%55I0#S*![EU]-*PC1!TP3++UB/(9O^VLFA
MGI<P01B%W)]/"(K1XSMT(J+0]_%E Q5GOJJARW$Z DO,4\ M+R$<(5L[4KLG
MXX?!7B(B3T50YMA@1T.U_4^^D_.C%IG.8/J0667Z@,I?RY#0L%%HD2$\&)7\
M%&RCH6%ZY/80;35D!9AYG Z'L%*$$#U+?%F5A4::N\FD?U^Q)WF*%\$8??1<
M00N4K@?%!!*\*B%7N0"Z@:N2+^G(N<8RA)-)&"7HD'SF_76%&+,MC*!3_&-F
MEGM1X7/I1)ZFO$>FR@2T+>&1HUY[<]A)%?#)5Y:>-*LS=Q9,1T+ )T@)46UC
MAI'A\QD\DPLP9B<16? R1L#''=VG,;F*"#3\]"!H<E-<% OQW73[R&DX_@SO
M$TP$O6\I<9GY:<V88\<54]ZOS+^';MC,@<(3+ME1/1QE%/CJE-(N\H[EX'5V
M9C23D7Q_#R>:D,(<:H!?!B@A70$BS4M*+6<;-P11^#*/8SXDG1(UZ"Y=9ESM
MD_,\3V#A ,0I^M&?PLB-1?#3WY.G<-J!KN4C.7DGD8>@UE!RO'+US.9Y1+![
MRL4$LQYZ$R?1GJ39D#*.4/ &EL4I%AV07&(8PN3"?5O".G,WTYX"?,J?X< Q
M9Z,W#@EL7NXP!$AAS\T<R 'QF=R)H.HNS8DOVTS34#YS2CCAK(6\<U<>!3CY
MY,5,8SZ3"W>I3_!AG)_TIJN32?RB7=C,04F54'@(<:(P%'!=3AI(P:U3!>A^
M!S&5$?)E56M*0,*FJ-D8:-R876P@P](X-B H)_N[Y"+7%SAZD]4-5WYEH,(I
M%4HSZP#Y'_CWWD--1KHU\>)13L]9,N2K2.[DJSUZLUX1?0D_G>YQQR#S C'P
M'HY++V(;-=:(@]VDF&HH.C![Z'/$AS730LZA[SS)4:I=]@I0)15A/@ .*,R4
M4 3JR".R->D"8^??H8H04DRB>"J=!)4!DDOT%D$8BPI/F%OWH76%0YOKIE=E
MAIQ6SU4<1)'+#04_@?1V20G&U\N&0IU?WW7*G@#V@FVW,,0(I]Z>.O8V9MO%
MJ</""?65GE3G<2;88I$N.N"B$'1T-QW3[WN8PN>S$=.3F7!$8Z4N4:(<B*SQ
MA(6P^1$R74QEBN,/DE[]S$+"+UVJ8,6%EETZM:M_>9$/+X\\OS"T&PY32O&F
M$P-7 QEAN9 11YTH!\G(+H.-#E,?@PKY>M<H!'X\&RDR6@F'V63*A5*E9T20
MKN8]%U:I?EW.XV6Q3HG+C$$./:*V& F^=YC_@#2?0SY5?6E^&#$5)>Z/]XG
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M$.N$^J,(8D?5NT7T ]=] 761M5\VLPMU]R46HJ@WEV7?8A8QEY<'Y6\@BRF
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M@$5/N+5T5M-<4O323X1TTS(WF7Z7+'ME5GCX5F (L[3P8:MC^.H[?W9.UE(
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MBCK;/S]7ZBR8F6*L6A+J> ?Z3N+0%T [G)?4*)$QHM O& _:O5?T1\7IX-_
M,ZC?&U_AKH:&\Q9#OYY+%_4$#%6'7+BFHE\20#9L6K*IJ[\\">$[A- I3@$^
M 2JT= L9?]66\,^SP7 WD70J4"/"6ST 5<*_$9$L>5S+_@GMUF%[N@P-TK]
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MPXU"WB="]-/!O\4PN0L5W9YO@6ACLEKZ0'I?8.$B% ]Q;XR>J17H[3]B[Y?
M\X&[HU3 ,J8//PF%1B^OT<XOYG98[\XW>GJ-Y?H?3A0Y1OK![@KN3R+R'IW$
M>Q2&;5TK[;QMMT\Z]EGC&%_-1J_/==*UN\=@ABUWHQNE?..%]R<Q$J YN,!W
MKHB>L*IE<&^-A% 9&CLLS)DR%^$8TU(<?$2=]N<+WXEC;^0)MQ[>\NGBNG;[
MO-5$0.O !&NLL+P*)FC2-#8)N+X+:VS2-!I.J%%!F%*";I(F6M\<C+7F7M0
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M<76,E]<5S- FL.:B37&1MG6/@Z,V4LFG^D;M@AI I^>G9JM3%';7UNP..>A
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M1&8_(9\*X1XPE\JG3ZW@H)LC+;^1[SA%;I$@V!]!2_$CDN+++OYN&]^=[J\
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MJYB%:2J.A]SN<44+7Q,PSEIH=> #'4^\7DB<[F/ 2#\LGP$^%#O3&.W<X>;
M0N)2/S(/5Y>I*PVO"M@3 P4P-&*8#BSY"(9 K\:Y@$00A>6+9P-DB^ABW!3
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MO-3FE9>!?@OV9S>Y\A8$4,\3QV.1HZG^O;Z;-BUUL]8LMO?)B8Q::ARBIO/
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M)&HE//JS/B\MJH*I<NNU*3-5[!\LP#:C>VQBW@ 1T',N OAG"Y&U"&A)DHN
MS$8.^5C&G)8Z*%N:O*IM=$_$7<<^F"3W?7?$7JW?@&O(*R?>*CM7\H_E5\'0
M _K]RP=SYNW(?_&$^X<WUR7T*1\,,)PHV&.!,V'3R.V'-IB1_6/KX-H)!\Z_
M/UOW=]?=P_@-XBOQ._YQ\3\=;E(*ZUARROVT1T/A-"[9R'E!6[CO!Q-?\Q\[
MULN3CQT5LN:'0ZLWQZ/&0'6W3B!)J[T4WQ/Z8Q81'P32SJ0\C=%((AYAY$*C
MOQ@*46)<:M')/6ZW*9,WO4U\_2+$GX +2?4 YE^T,2P14+C*YVU,89XAEMU'
MHNE")J6PJ0%UM2>H+_*GW7/!)JZB=EN^1WW_5^;!IF*KH7B<[\X+=3-RQCR;
MQ1%P-!?.&QP4ZRH$_AR$@JW0XPE?2'#II9HNO5L## 1;"#VBN-E9&1%@W$<O
MC'F<7!0YX*RL'+,4YZ+06>!/'[G#4)P36)JVO;SGK"?.F!H&:<)_#J?!L_LL
M/<EB#"+N0EZ;.9#Q&G_/\$9H')'H4,B?B,\(CP$ZB*_@3CA>+#J=%>M@*PSO
MD5&\#CU7R!V)(YT^\6)H[I7M^4Y Z4AQ3URY((Q*JB[BS@3;L(AM'[#^R,%C
MX0R>W9 G663R-_XU;N 5?P(#8U\L-L1FM-+5DO[ZH6(QK9-PR%UNXXF SD7F
M$5(N;F<>L- ?/<O0 G 2LJS%E^",4L3O)*2LPN357RER4\(X7J6HM G U'3]
M84->)L+3:"<$6GQ<$O=+!VE"R[[V!1)6/4]0)1A4?3&)^1F/1P(BS!X(FRKS
MV\C'K<,XJO<8VKS'SX"'M3_'7(=CW(I[+R$^+">*G/Y3#)X\\R;8+#P;L'V1
M&TTIN4[>H(/$2$,.1SGQ,0I!L(HYPO'7B^]$33ZRC!_S, @7D_"2/B*<$!H*
M=?4A_G0]%3>C#(,@U1I;XV?!:>G5?-&86P2<NB3S,,J/K&5S\*B81AQJ#@F!
M/E@QYY!-'#[-*7"40X@M(-*('U!\Q"V,X+D(M@7_$+@85P<BP"?\""1W(WX3
M.LEA01P5"U=<>!(%3.$(5C(4ITU,*FLN(J!I'0C.$E+3\ZVA2"($03#GBZ$@
M&;9ZY %.N84B8 W7@=:R.Q'+[#.7\C"6>Q,7XA3#HZB6_)854-06K_D73[*Y
MQQR"$,?+"'Z;HA3(VPZYDD/B'O?0<D$.#A#@#148"D&*R\8FP10K@)0>DG$S
MQ&?*#2E3)L2&U/$#MC7$E<,',+^QNIXYE)SD;R&,#O@!HLL0]E".0705W H,
M&@[?1 ACP- *HT[)HNDZOTAF0=4(;]/JOHI[\8#C%:GMY+JI;4V]$>H9E)3+
M%3<NDUY<[&&%)X\ :&FE>("YP.(:"6:4Q*%=)EXEH9$0N% 7#TC</_S@S]3,
M4CJ?V(M#<>V]^#-TC(D0:9L"7\^C,;&LPM*%OXL+(O/%R"7/\V4,C/#L!M&4
MI153$CY*-MRS ,G2L6Z5_LQ7CI_QF6EG"A,S(_@!.4'GT,0<DS.)-[./2NU(
MGLZ$5$OUO,51R%>LG=',9O,Y D5;2[GR#7WF3XL%G"YL8>ODSLD=YA3";N\H
MV%4&&2A\U(%@"+=>Q'/@/,Q1%3JE^#)O,1 2\\O6=!,>%U2Y7HGL!S&G&YDM
M<A]GBXCOI:4K?X5\ RR$'\N$!B\84U=AEE[6!+.0Q39A]H*>=8TOI7&YS$CF
M&:2D1TXV0KY&FG^#/\L;G$[+A(!@EUU/MM;D]RCE0RFV$@I4+E!J+@O8AV_4
MW,M0G-=T$'=&ZQ)F3I*(M':Y^"%84?Z+-+#2"23)Z5)$6!H!<0*(QG$7B <W
MY"8P?'+E:98OR"LXV7/$B%*8Q380G\2,P/H!BZ2W(Q)O4":R0QDWVKNE!$:6
ML!/U!PMU53I@'MP2W=<GMP?JVC=YE0CMA?*5LGF LB<3KY[X+V0$R"PI/(0D
MO/#RY+__>^J,^-3Y5T;NV(WB1$],"8H"5[ WK$TF%TV4$ RE0!<DY'NL=%1<
M$"9ENG)CQ?E-7CEV+$%$?MD2FN42W,JW<QD1DV8(_?3HXJ&\DY4\#YGW'.F&
M/72 *"M<2)E<K8>.C:TEV$I9>@F32/,]IL/2.\2UR/5<S&2 NP@_1<!+RI(0
M%%00+I5/9S#=+N=G-&0%H$Q&@\EHV+\ K<EHJ, FF(R&[=FK'<QH6 DAA:<"
MK) WL+UP*E2[[**K1=SF9"1Q95#Y"S5=5-%$Z<L)EQT5CU&M!)J[:.JP0#@_
MA;*)H2=>30P*:%QV,'JC-P\"YX5Z>TAU-(CS;WG9RM!Q1^C5('T9+$#N4<+W
M#] KCW5LY%R$7[Z(V-&K-,[C1ALWHF3X4L1<YQ7A:^&/4>A;V,L'URELR3B2
M'UM,NEL# [IC^=HE3%NJ:?;Z2$#N8HP]P: C//D!\,U LZG2=AM,+YX=!2A0
MO4_T0\EI9J3<8&1O<".GHUZ9U3\K3H3_X7KN>#KF&?!A$-VAI8*Y[^^$%>#K
M>V=?IYK,A<\!%Y!@GR62PWFM##E.6@O((<U)1U1%VDG^XTT38BZ,68\B!B,G
M%-$USG\);Z-FY KFC:AVBWQ.JS,FU1QL(TN>M0KFR=4H42%N/&LOQ8XYOMF4
M_Q XB:=%:)4PKA*F=!4-8D".['0(P:G2"R1 7&1:RLQ+E<\RZ<[9?1SFA]B[
MZ894V]<7?0-[FJ\W]E\-_2E>0O^>.D'$!0=/9$@ZQ<@M-5&E^4*7T!(ZYN1G
MZ+>LW!5^]XNSHWDWN6.U/PTQC!2\J60=Y<A<NK1PQ7U<H9QPO<F<8B\O,.([
M$%  *X%A%):UF56A1W!&?(J)&99:H<=ONGZ"(IR_J?Y,.+@U+A3,U^=N87[_
MP>TG';(9>9R)Q>BYG,30D0P'8X8H[U+$T)\O7XUGV16JYH%SR#E^.I;E@G]1
MW7ZI$' ,>GK("_JXHBI[>\:]5,4"1AA[P((WWFB<O<KP/<5.15R0?\:Q??PX
M1Y2]2I\ZAY;("_/J;=)2J7)ZRDQ&OAPIZ9)67T!\\Z0/(-I!#Q==.Y;%BW&Y
M(&\,# <_UE;T7;(Q1F<A1 BSL/=;K5:GYF^AJ**7$H9*#5U"EM#O !A7!8MD
M'BH]+P,$^ Z50Y5?ZYBE5,V,H[,@T#CSW,;I&!R"@V?>I7-#9\H:,Q.Z.W%Y
M8Z(LG4*;>D0_3@K@7)1."5C $*EXR+PIR>7QE( 17YU,S5!7=SH% (_(,DH5
M5^UY%]?YBA3/?N@D+0,N4Z8ACG4O*]4O4"V^&=(#:]&TCD+61VWK!78\9![E
M&^0H6$LE<TB]Z"!Y7R=TH</$,5J>R-0Q[98%HJ'97(H3:_'C,$/MG Z>1._%
M6Z72?.^!G!_?JMPN;2<K=&E#032G3QO?.5U$QLE=N;NII?V7D=<",IA/,"?!
M17&;-E5=O*FR\T0*A8##PVP/T48YZ[O<V 1U5!=+JXD=E6<NI,E X!_%HIE/
M!55>ZO>G&K-Z[ 43+'GV1"R_<Y9I]9Q00JG0-*3TNL.CQ!U-^?J'BM[VWC+T
MC\1[-*58SESBF(CK5"YYQ06(_'I-C^ '7VDH\Y IM1/<D=^G+MEK[ Q^U%8G
M\7Q1M[?CO':)/2 >78<:7(".,86<(8T.KC#U1NZCH](M9(KDDJKA,HV,Y96I
MW9AWY'[]Y@<9GRU'<2Y-;H97'NE;4\R[NR(++P!C6@[;Z8.]Q@'&0EVX9GR^
MBF@E;7S,O1:92M(28H\.0AXO\U,E6#]7KY\9,7F.X@P+!+"$IYIUI7OCRYMV
M72)KZ"W5;>$.SSA]/<9M4JT:22]3D@GGR0(E]406 X$.EUUC(C"="+A42]#*
M[BCM#F&9GM+1SNVSQJG=/&]Q974F-3! @35 )7+ ZZ!4($%D#":L>9YIC?E8
ME$Q/53A!^.1.5.8F^1K1(0 ,P25ZZ_CT%^HMKO8WT?::-/@A*!GX4^SNH914
M<@1H>ST4 %IB"T@XKC:9QG'CER13QIEM,K<1^4<M&%^!B=_)8="".SN;&2L-
M=YO'T@J\I=XZKBT_1M[QF;%:=M[!U5%F46;]A;Z32CT1Z@=\R4N;1L)B69RI
M3&S&QZ,*)5*U_0P[D(XL1LPB/,V4",U=7F-IUB$/Q!XM\NF+)N8<+3*-"4:"
M2+Q[287IBY6LNL GA&;$1/_D6%-5G<_I15D45(1*^#ER!\1+(&^H>)E++L76
M70D9.ME6@?N8;+CYV7!-DPUGLN%,<H_)AJO&)IALN.W9*Y,-APEN*V3#-=>=
M#;<1Q.L)*-+ YUIIC2C\R ;$+S^0JD7HX_HCW#4J^(MCWT'&U%_BJ<?^CY2Y
MD%6DI!7TQY7R%!*D<EXJ4,*:I425NTA;40Y.$DZQ@;0T>,,7W6W\B*BC'CX/
M=D3B%5]*<'JK<EJ>0^G!M)ZQ4AS>)K9;E6WV!41V& 73?C3E)9URUG[PZ'AB
MGO#,P.]/R8^8J*MSPA#^.B"W7ZH:2X&5N/2)^WJ8B8P/'\DD2*<7TM9HR1'<
MZJ&'Y+B86\EXY32Y,K $GER=(:8_TI/RT1%8FX^"T/AG]]#B!.F+!Y_5@WV.
M!TU<@7%*_H BE$I%Y9PW<E[XY_)-Z((AUQB:BF*&;_P)Q83$Y3(%,YQBXBHO
M87O5J(85G?X;$U.1OX$9ZK&AF%2<-$J?$A^.'>02^EA^BA-]XA@L]&=8/%@'
MR=G%I(J<U\0@VHR\9S?P)?O*E2O2#?%.#4+A1T-HW 3E4BXNX?I*T$[NM0+A
MF9!?N\_") ')S:4JX6$7!TQ.6< D1"Y80&Z/!:+Q$>U8BL#D&E#UX.0CI2+=
M9\;]Y++6F'_M]=!*[_T3$!'^TT>C'ZG!71N27W7V4EOA8K6SG,OK:PP8PP4'
M+\I-B8]7;7,FB)S?YW@S R=R) R 0*!Y36P79DB$[C-^"@=IOD1=8VY8<5>
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MVFX/.=BQ,?B <F.)@JIL]-1$IP$M+$#F1 QH-')>R"$;#.B[V"$>K)KP?5#
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M,N%Z/+]!9(H2O%Z+[JSW7IF_+/U:82(<E;$WL1B7]\*L($?0A1CZ4UTS[[U
M1!27UDAZ*:Q&,5XZ&RI.[TK@O.8:&:KP.?ZS*JN,C9"37"-$?U@S09(-5N3N
M9]!S*7$JF^:]1Z#JIS'.N\WLT931XL%WO2B&')C3H7$9^*;9IHRQ%9C='B*9
M/,Z3_.8VU)#;J25[S.NA,5NT+  .YB<KS.N%(7MZ42=9'%Z('LZ2RS6U$ D&
MI/V@>$-< NQ')HYTGOC"1_&_F$U TQ7#92(?9Q.\:H#(6DHH=8E[Y U11>%T
M(N-6M+#5(5PCL/H<L(W_(C$\Z[BQ'E('SJR+[A1>("!D^CPPLL*3=.ZF(R9<
MJ$ZK?E0_>#P\J,LR"]E6,%'F#2+FD-)?9Z&MYMGN85P"GY>KQUL88Z/A(U#]
MQA-4"_V)$M"ZA!<'1#B4LCL3T2<S;8I<"1C [T;XGC\S[838(^:4Z:<B<523
M9E=QDNH/QW,>^5(>R!N2K0KFWM8S!UI(^I K<:K,'^.0P#^8"H9KIN1OU7-6
M91-P[E3GJR,&^QW/ )YZY. 5)RB;PV$TF"X4.\[*!$$U!,G&X1*X9KD<:>#%
MH2_7FI][5/W<@PVYB)8+N>Y5XD/+)#X8V )3A6U@"ZJQ"0:V8'OVRL 68,+
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M 1$J<(H'.EL@!OE<CL1DQ-F&*<GH &+:,Z]/,0/EMYZC3M'&,1Z6$;%)6%E
MW2CICPJ'F%ZBPR/E"5SMC=)?GX2E-.+6B%LC;@L5MR*HN"@N[,I@($_F!SD[
M$7)QF? JA?)&;R@5**@9AX9YXPHRXI+B0/9$)20N+\+(VH8D)H@O<32E9!,2
M4S6WP-NAY\L .\^+P^=XIT[GC=.92]44X%ABT?, )N?51>]4I.TJ<<M3Y\TP
M,PK/@;HD[6Q8A,*+I'BL:CSCJPM& $$2L)D,"!/HV8L;/J4CP3,OQ-8U/C;5
MH;BP0-]+AH=MU1PUG&V:(Z\V)VZ8LQ^Y+ ]/<7*5T.4H-*,RJ]Z96") 4+AF
MQNFL$ W=H#\=8]Y(GX5:<VZQ%>Q9H'XZ0M,;B+XPF-$ QUQ-2/[=(F;K.Q.J
MBON/2-Y(@NM)$#Y\%MLR^",5K__-?X%7!G9R_HE<!+D(9&M=GJJI+ V34$5<
M!X/CH.$XG!L<!X/C8,K2#8Y#-3;!X#ALSUZMC..0([.K@\RP--($UA/M;"M/
M61 =)S?TV,A_L5Q0$Y.J\W$"2X%RO!7$/G:]=\E;%U)ZLA]PLX5,H0'KCQP"
MKHX3PO.RL3^8[?TG8Q-NZ6OC2P]#; %3QJP"9]9'T31F-VD/#GS&<WOC/.5%
MJ>7O7TPJ;;B'??06)0VKC'S9?5+.7-?V]8X$'HOX%T+@&0YUKO^J6X[RG<0#
M6 \E9N7YNNM$H$;2RI9./LYRZZ0][?'NI(QT-]0((R'*Y[W)58GHZL^WW*F2
MIII,>V;<"3"<8N_.)S925K7H#<&[&,4;!BN=M;/ @F.\$(*:?Q"'\A$SEJ]M
M*N+;!WP8^. M,<X W65N;QIGHF>1S@EA.\7$L2 )C$K);(D%Q(W]M,DD?&;'
M]"BR\^/HS9XUB$4:^@N<?7),+)TL?L&-VSO'Q9H%DR*^LN,*1-%@X')/ $BM
M@U>M0"L^*>$4Y;QX$'MCIB03QJVHI.X(QOT31(0&BL]E"VV3%?!]PMJ*B2^:
MZ&8VB%Q4@T*7CL=G)B-M@79))#X8:G'W^6&U\V,5 )N03T1?IG408^ N]6+>
MD42#NX75/OH@+X8.#K0TU"W*%UN*#A"SO-V/;$>C_"Y" -Y/T(T3T*;@O>H,
MA^[(16%DQXV7>5]FWLQ#'&(<\)O/"UA$:TTZ^6*:^K"\#8XV+E[HD\G([?.Z
M%14X2TSP,-$!!'AY]&9Q& +K%ND5M_TX>#ND=SJ/H"4\HLOY$6[)$.]*'APE
MD948/(S;V?(FX(NS+$Z%LURUC(I\Y%'.R.I=//K@4C?;,.)><>I-JNJ!I,<?
MA?)\IA5WF]YD8[85:N8W#_#"3?C=PT,^LX/_:"?VV1]-,;6,C "LT@=MQ,%^
M%C((( \$,D;Z$(OBJW1#JZ5BQ#*\$$;8>T6+KNJ/Z.'4 =6P9C8+$01!Z0"S
MS":'T--@-?PV42V(@S^!4 1-I+H)NZ'02U<Z^P+V.IIU Z>51ZG0*&_H@0P9
M,X=XID_Q=RX-*-"//\\/[]=;*=Y\@AWE?F=J'*6M4VD?LR>*3W^)3(+TNA,Q
M;E#-'JFG"2Z^C,6VTP?Q78L]7M'9O"M7>*DPZ!\!)X!=>89C?#MR^A0Y2E3B
M3WN@3KJ(KN*,V,V0D&FH;+\JR#D?02C8EI6?VNV3U6 *^,(LM;(<Q *J-\U_
M%B4,1J@H)T'>".G(I19_QX]QL:$5^K$1E5/P;XM^8#Q(&LV?R=SR] .,N*VC
M7CN97Y"NU#XD7/39LEY;9B)P\S'.+8N3$9+F.U9_T@22FB>IEA3V)]TR]*T1
M]DKC]=MOM%FZ(N@*LH,.WW^"+W"5D-N>L4[XP293WQPW(($?]Y6J!$)0_?SD
MQ" $Y2$$G1];WSI7=]8_.M]_[UH_NIW[W^]R'>X["QB$P@\L/ TW-,O,&X)L
M\+#QGW2SX'F%L].# T1V<\"&R'FAEB.BO@R*ECN6?5_':+Z%L;A3OCM_"J>6
MW*C"]S/(L[<I855,5$P'VT,Z;NXW5--$\2U]YAR'@;+L0$?3F_7U6/3"0*:.
MN4I'C1K[[D1/JQHS!T\[B5<TE(Y!SL_,@#^DP#42Q":;-Y.D=A)(@K$_0PX>
M\>J.8;_ITRF7R'X/!-NSPSL[3N!JLP[$G&%.#GR,7ES9P ;C-1-&01N0GB 6
M67C(%548',1E>O"IES$\69@>9X>I,/$P0VN*::4OF13C&RQR4S)7?,BOXJ$_
M OL'R:61ZLD%VQ!$./>$AMROVQ_!0.[P+8\IX>+!/AW\ IY=!3Z>M3H:WA4\
M@>_A4]#8+?6BY0 )*A01,BFPBU-@Z[7E<V"_@^XUXN/5/^]40NN&;J7_"^,P
M(2VXB.8.2RY8N)LVULGC2T [E,=6)_4U453 ']>?YH#I\BE7.7KBNR!4?K.,
M+_M].!*RY=@0&^2B;!UB!(IY_3>2%L+7A9B5@8\);[0V[M;D5H]PN>%=Y!'X
MDH3#650/91+5MC=1K54SB6H+$]7DB[SI:)25<V+RV!:GY<QGLDS26&709K7#
M7SQQML1 73YKSQ!T,QEXANX%9]-92Z:ID5-KCN>K,T'K5CWZ,S.GS5AD)5AD
MUK(FF;6,39;YT#N-LL;GC"&7'";WH.^A678SXROA790I?4$W@L7'QU;WU<%<
M-<H6TS=$?I_7#3'KWTL8?*$+:W2";'./K*SD*$L8B?@F^0IR26+\@'!-Z?4S
M<0%D(C*_K.(+I(TTVA-IU#32J!!I]'N&[U:Y?/TI%Q1A.!:%B,)[H]S5=-[S
M/=64Z>TI-TVV[V=- F+/LS_TU-ZLG&1*#*&LZ(":"RQN?M>A$7^# :\\&NJ"
M"ZV2.L.]LS-.K6XWSIMVK7V:D^& 1"MNI47T]GMO#Z!S^Z1>L\^:YS,KM66>
M-MS'(Q[^'_L>>U-.79Y=KKK^N-XS"X46 (^X",3@6;\?WQ\#TU D[DV#.S_F
MA'QX"OSIX]/<%GAQ@83+06_1XSL(G!=*1E4YEW# O3CJE.#3?:I&CZ-X7)$0
MZ:YAPM_-(X9SLOG3$3VEHXG ZP #L7I$U:/T%U1!E <='UE=ZHA$V@'<R:HR
M(BL<*2X6_+.P6OE%I#/,-(+YBTZL*L%:U$:H,;<OB+A<3@P70#_$?MUX=W)W
MON+FK"--YN^K:K.<FER;Y:[,A?IM^V2CZJTVGO9Q6E]MM5>9Y*>_YVN^K0S%
MES/?1U^PO=\VI#&D6>K;W#Z8/;_+7/\4@UW:F,TC=B:VDQ",\25RW)K,F)SO
M$G%+AYZEK%,QP@GF*(U W\(P)%S:^+_#+Y:\G;AN<81B?&G;M%PO^;MBY%HE
M8)9??+&S0.YKWA;*3O%I=P9<,C!)[V^?&I\6#9W8F2,M.!SO2O(1Z2.9V=8C
M>M-GOK$)'T=F5/8CD&.+-YS<,C,9%D50VVQ;B=LVJ\\G]K 7_'6-DT'-U+#0
MMK'0C-FW60ZJE\A!'U$XN'F2JW& B=W_\S' 2ER=-1JU$S"CFVWXI]4Z7*B7
M<#S06=^V3&(YHLRGLIW;B7P5>F.EW-W<D/[\3MT@7Q0L8+!WK9 ;H>9=AO:;
M?I>A?3GO*O%.,;=%(5@I& 89D\M=!LZ203/RM=>_Y(9&K!\49A$%[=_@AE_W
MU9/EIG@'QV<-DZE\UM<^MX))\Y<"J4*IO%_R"LZEF_]*A+VN/.Q>$#//[_>2
MHY9S[*MPP16%3\@LK^N5Z.J!KV_JQ]]D%(8>_T!9>BDA6L-,ZV.F^H.O1:^W
ME9GF1,$+929C#^["#?]=*T U1N'6O<O0WM!^U]YEC,)J7QD"2<CZKFJ7I1&8
MCSJTZT9?T^CIJ^KIFN81IWFIYGWO-_B:6Z"CV_73AMW.!"$S;+0.-EILZFT!
M&S7M9JMNGY;-1L;0VX5;^\+W@&XA'J ;CI87W]\'(6/6M0\W=^O0W-1&Q*9$
M[ V69VIR]MKW^LM4NE1 K+Z&[F?/'<D<[HP*&-!<&U\VRKO[Q1_;?^V>VNWS
MQCJNW$UV%5T 9TNU<@)&7S1#=,(91$1J@$'XL(1KU;F_*+XY;+O>.CH1:-I4
M;H.%/:).B UD%Q/9F46?H:SO[/=YA0W6^N25^$P]9SIP<4!@:- J0OZ3Z!T)
MO_2<$2TT?&(,2]8?M'8PB0+S_+(C!U'#$,970MEFU2'QA@96_\GQ'CF5M1%F
MELT?2ST5MUQ);Q@!-BY:J8("IG)\?\(X1+#"&/MXIO<ZH6)%,J'0SC[4FE@;
MC[J/]I=QG?S0L#_SFH,M62.E#17^AG#R8=3Q!E_A/[^'K*P^,8O1@QOGA363
MJ23NK:S/ SJ#M'9!  P2H-':R9/P?Q,A6!7^-9ST_W:\J1.\">@+';,^T3PC
M7>*8BP@^I6XR#N9?P+<OG&#D(_;%=.0H^1).>R'!"T98WHH(&V,N/?!%7T'H
M_WETWW_R$7A#F RWHH[]AS]@(]&2&>3^V!^X0U? J3J3:!HPT1M)M508,@?_
M',IU3/A\XVY)#R1[%/ZY7F,O)%-R1@+R6U;6CVE&$@@D2@[&&SR(WAF!&_YY
M- P8BZMM08+!!Q)AF' 6G8B?3]E\@;UB]3 ND05C/EM>&OR6C?XJBS5A[K)8
M,QN[-Y,?'$% ]59M1CF,D(9>3S7HRGE.[U4WYV7IP5^H;[9J\J/P$I")7'T$
ME^]X:K=YRR""5P])6L#/CU,7=A!+6OEU+-%8\%7QSO F&_7:+Q:'*$Q2J2<;
MI_3UMDDP2 .^P/NZ+WR>TR*+2KFKQJY,$5V#SXPWT1GP$T#0$%%?2@2-P?3=
MS]JYH5 KX63+NUHU6,(6(Y'J?<1Y3^+5J#'CU@2D]HH#EL/[U"]&ASE.9G.]
MN9CZ!6K(,ZD2'*4_W=DGKEU6+5"X", &@#@-1?61.\SE?#[-@>SFS=\,*@::
M[]C5!R;Z'Q8@$_2=J>C_/M-R4!@?(-0F3MP:7'2'HZ?<B C \:IYLWBM%5#B
MK,^V/$R<%7TQ>CL#DE^*8>>W:<EH%)!==&W05XLKI5@;.&M]O>"LZC\?AF?-
M10]8>R/Q/8497=0:N=QRHLJ#EE8#0G,O-^FZG%;D9B\WL)>KMBI? F)U%CUU
M!:C5QG9 K2X--(O^C_+[H6,+3U#!T8VDVB+'NC=.%"T*4LS)@+T2W4L"5KQ+
M-F!'C)L#3%1[\%Y;8!<$$37("=C$YTTS11---&MD@Q]E(PMLKDQ3>:)\TK'1
MK)P+Z>%CU^02JO8.X6>);H?8=UPV+PI50R**GX06>IH0C;"I6T#1$]J(:(AZ
M:)&/82Y/8(:#8!S,1<%"G]5^XY-16XX061U]I-PEH(.587-?:@JN ]DV=9^0
MU@UJIB?04GY@T)_QON1N^9OA'=C\:P'(V@*AO08,K[/3+<#P.FW]\F4>QE*]
MF0^RE/C>,C^GQVX4,_;F 9 ,[L;&<#<Z>-=O$&O#0,>\>R##O)MF7@-:8W)7
MMRIWE1J&\P!7-=)3UY]C1SW8,?S.2D(7_PFF\D]ZBYX5UUBAB/VXV:Q./<.N
M;7$1L.H%;''M9&MK#8PD+D02!^Z?;#]%<=@?O69FVW&B5%HXUX];%2HVV_U-
MKX2X+G_3C7J]"T+] =.<#ES/>F-.$.YJ!5CJG&<[T>FX42H<9I4Q+R0G>@<C
M3(]T[+^^Q8_<.F_XI\Z+$PST3A4R<;4KDL20OO5B/>_:P3\*6?_S8!K@YGWZ
M>^LX+@>5&6;;*^?WA0F2Y<@%,$&C72H3&#6]VA+]'RJ#>S^$^3R+^NOB@_QU
MF8/\3]I;-NC G(%Y8Q+?.5%:!?R@=$^J@I-I4@-L*@WPJ+% !02#O7@%\)>=
MO0XJRT;ONQ\*8Z/V<0F>O5^,(;%KU\Z=*B_!JI*]O'K(7U"HP$"B?@.:2EQ3
ME!-I1;(0/U-:0)PL+R!.CFME2XA=OF@VQS2%WRHK,$U=LU*V[UHQ%T8!%\9E
MHM#/7!B%G'WI<9#$7=N%80R3G>>935HAY?.,L4)VX5+YE@5U4Q$$VDT%+F^&
M$KK)]2XQH3P(*QJJKAW7STRD>DT;7H4P=>WX9"V=*C:)IE:I$B7"" NISDN#
M$9M%ILD "5NE'ND><4^F(^#$2T9%>^XSTT ".Y'B5:K\7T>)TD*PJK/3AJEC
M$B5"[2VH8VK7YM<QG9E2(U-J],$*!8&"N<$:"86_:0HEC.FSK.G#J^&3J((<
M5'#?+"&ID&2J(?.4XMI/<?;5 =3!B>^G/>!R%ZA[[Z"60T4JVXY7;1SFU3[@
M$NY3 PG(!0^MQCG?A&M44$G+UK[QYN56U)K*#%[[B7\/ OF9?=8XMQNF\8<1
M&8M%QH7" (\A.@5*K1]8/F+WZVB[.RXU#N:(#4ZI*^\?DDX<).DFH 8'6K1D
MNT1)".O_VZ>C12D<=AT.7ZT,F7*XC% 1+)YAZU>@M>%[N3LEG)82)\(2YB[%
MR2LW@E-V]&(!4P3"V=XMTZC"6W2O)<-\W-S]@9UA%*S%_FK!JYJ\%;RU%G2^
M.VVTC )L!(51@ LTF]^M_YYH^N^I"-%MB20Y;=LGFQ(C1N6ML"ZX)\LT*N\6
MW619*N]_3SV60.(U&N]2&N^6W5.@\9XW3:]G(R>,QEL%C?=,TWC/MTN2U.WZ
M:<-N&Z77*+U&Z35*;^4OLRRE-[L'A=%\E])\M^R^.K';K=/-.6F,YKM-PL)H
MOF4G.]1KF9@T51$ERR4[U.T6'+Y2=&"3[+#MVN&>+-,HP5MTKV4IP3-M/(P.
MO'**?W4NK@7>WV:K;KR_1E88';@*WE^])%EF3C6V0Y*<U&LFX<&HO4;M-6KO
M%EQE,_6LLPF^C;V\O]Z=X+LEUU33/CMME%.-8A3>79,21N$MO<+M1--X3Q4(
M3U5$R7).WX;=:M:,T]=HOT;[-=KO-MQKLV@NZ5Q?H_RNE.M;G1MK072R <:-
MJ6XS0L(HOU50?L\R$2BK(DJ64W[+JG,SFN^VJX1[LDRC^6[1I3:C^68G_%9$
M_:TNE&$%KRM3F[)E]U03!/C GR+:]$Y?5)59YRK8]?2[0#4GG38#S5[#H?X0
M>GF[(/#RF:M/[*/ =K96O(E77].'T9K7= D>M1H)O/T,^B7Z#^ UGEX\&R=T
ME1X#^8NZRNC%>0MQ;9+]$O]Y4G)18G37:K]\L>0A:.+,-;N^WFK:EOP'[/J_
MYG)AO7G<:..W$Q,_/CW+F+OX\Q<=(-LBA&R8MF,]!7C?_!=<59_^3AT$4$^X
MP!N0NKTX2[);2FQ(8/GCE@O,IC^/NI*:8\!GP['T$\H4_2E+P9O'Y<5K>%\2
M2B6_<=:'6+ZIMM=7%__3O;NW_M&Y?NC\VK4N;NYNCZVKC$/T'E%D-JF03;J^
M>>C>6P\WUN_7G=\OKQZZE[!/UY?=ZWO^T_W-]ZO+#O[YV]5UY_KBJO/=NG^
M/_SH7C_<F[VLTE[>=V]A7[YV[Y)FV7*;I+^]0KU5_D]*H[+<0:I73&<R8=Z
M=XPY/SGYV?B4L;#R..W#O$$_*U5V99KEC.=&<.#Z&0YJWP.-/41*WI!_U9(V
MZYNE(72OP#/OTPU/<\F);9*PAZ+CO:&KG,'_!M0/:1+XSR[.G'P0$3WFD?F!
MZL9MX(_=,/2#-^O:CV F4SC\@=6YOTAJ%!GFZ,HT/SFK'35JQX(B..&!<@&
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M] 2,]YY,/4X#]F@#'\%X\>#$]<&RD\*8SE\4BV/YM2>0F$,8$*C\[+@C0GZ
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M] RT3653\AOTJP\:(\'P@6()EWO \R=)9U0WWU"Z)V07>GEC+T6I_<W;O9F
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M;+()V=V$!<#MZ506+7G(^@G:/_KB/4C[8ZL34H+_- SY*;D&R6,UI!6^N-8
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M;LN)0)GNLW&/!?SJ:-;A:H>5D(L!B5X!%^]FPLE)%J#[I1Q_[]!]98.C_[#
MQZ6"A=/X,K.)&R3G=B<%K+B+[_<!;W 7C;>CPOH]NFV!*]>KW/.7OE^S_\D'
MN!@Y8=CY0=?#-,21:2#T0=-'-T-Z1>?5#3=@"WQPD?6*++)XTT$CS$IVP\<)
M4J:E\<Y5%;#-'UM5LU6J93)#EB7,DDV3I/ 5;7R35US1LA;/EBUK"S:J?GYF
M-TY/[68S*Y]BY3]82>L*C29C7BVEF&O,4Z)ME>$FVI4TFNIO6Y$)-::\I$IF
MUISRDH\8.)W!P,6]=4:6/DS6_JULATT<=P DXY+6ZCL3-W)&">FKO;$_8DY
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M7OV._;S6"W?K0%TJ]JHJSVTW7U7EN6W?J[; 5#09J^NV!@\>'=<[M$#=&K#
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MP,] "_2>\=Q&21T#4[PW6VH,XPILZ8(,Y!7WM*S;^J2$YKR5R3PVM_#F$L"
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MID$2@7GX5^)Q#S\U7-]DF3<Q0^K0$H)NX@F+[N TWA@ %<1 J4BH]Y$=</'
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M:-'OK'[W_.\I[,77%>0[ .H92%,G\F:T]66KP,[M&*_&91QT'-@JD6$0 BQ
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M?"-#JP$5IP3()U(OP_N-0K]KW6I8)C:WDC8Z&5T(+8RY.;0DTK&!Z\-#XN<
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MLRRPLDN*#3>N2;/>WBF>?5SH&H,5.$C"*H>'Z"]@S)4K%CNWI'5Z>L'@%%/
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M@"Q)$5T2P!D>(GLJ"+K>GELU]HW26U,)[( O.A$5IJ-F0_#!\J9X0LRD%&6
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MU)_XDS9E,%5GM58&67H./?0SP"I5](+ IM(H,M;.I5GOH'FBO/O7A 5B2%U
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M]#X13WWR.,L?0L(*VPC^A0/@U(G+<#4&[:50I8V8BBUKR:RCPN[YS.:"9>@
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M4LZ/^Z+L(Y&4)5>7]J>TL!*$W#/;V(ULYR?:5H&+5 M7WLP1\M;B/HED713
M)&GDQ^MZ5^XU ->"5*S5Z6,F.VOEX\<E&5E6X3_5)VA9VV=H+4/,W;=_;DT.
MUN Y.5A#V0AZ@Q[30H5<GBE0#855K3:"=);&[@:2.?504LX$.55%+88LY_>X
M$O6B<C;]AA" 63&'ZDZ(,Y_D""@P<^CK4G"2\]7&4)DL9HE$:T<R9+)B;6TV
MRAW.1+;1J/L0PG^LMVBS#'KO/U_>?: ?^^_?E7__*G0SNT<]=GEWE3YU'\[
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M8Q]8X$RPG9YX%D[^,3NX>)9'\5?[SS!2.^/XU3<TM)!.@GG1/V9)Q-Y8+G/
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MU%,6JI%/64[ C59-+ ZUJ8RB HXB7%D7-FW436EGMI+P=1:Y/NV==FO% (D
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MAW4M/2=0:9 +VQ"J[<1^1'T3I#FS$L[&B6_YH/%SU.4?6, BV_?GF6$*Z]D
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M9K"KB#G,F\7($W AJ1>04 S@W['GH.OT?- _>\_)/^S!1^A2*1.)8^#CA9<
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M9@$N+5 L'8 GG6KYXI;Q&OYHJITTR*@3]> W=725SK7TE\%"E$.(V%A2:2!
MA\5N8,"#6H"@N5^:[1-^7.,^LKKYHD+VV-**1U!J$URX0=8HT*5LZXYV'G!Z
MNZ""2A<GG^.K;^CJ1)2(+$?R15A4L<C"CN+:HF$S?B4Q_[K_IH;DF>)&BU3N
M%[O&UAY\\AF>$-R.Q>N6*\050%+WZ,%P\<U'>"O'#N<55[LV7I47N9IU("1$
M3(@<9970ZG#[KL50&+B@EFNMO9%TE]I:DEH&=5!+6V5_.,6.N2I[ ST'H%EP
M2V)L265O+$1?#W=(1U+BQX<!<S;7.@N9?MJA-JVYZD3NU"8[&P$_LT3&K1W
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MG^=4@-&ZB*(E/8WTOMBN/8VF30N]RZMB"MS:)7>2\LSM'+KL>1?0[?=.=WW
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M0[+2+;1# #E^%P*+#\:@9I!#S<N"6*!%1RKQ#"9\\$\3H$K\PU=9 :!K4"W
M)B5,.NV AO%-NG)O 1<@2 N'H]8CZ!970U6HCQ2TQ:R\N.90P;^H,JK*>K*Z
MP2]"&GC$A!T@ZG18<[G%6^AC5$<$9NB)R\,2;L<->9\L9-+TY7<<C%WREL9Q
MJ&L0LHY1 U_,AA\?0!NW;,!5"-PXX(ZC*F%C#DD*(S%.+,E->.3B2M>Z^WR^
MZ-81E,QGW,ZXG =LW'/_T3:7MOFHTV'37-N(/YA;T#6BZN#?TA@=Z)SD36!:
M50WH3\P 9=,22K&*A<DDP@1/@<(3GBZ+A\RFLZ:^[FBL,ZG&P4,989B-DEM
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MFZV36PT("TC)_>NK?D+OBY:6I"?^/-&"A;V.@?][D[U$11HUDI:_2']MX#D
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MDJ*79^Q6S9)$O^\65/;X^%WN!>ZK^2JF2LSXG<UO0-V9C4V\*/5HL"6]H_$
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M&DYN;S:O=%([813'*QK0E2* K\Q=%(N 8%WSI@RCN>HG90:4XAHR4.6&><G
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M9#P'P[4A]I)I><H8$[5 0J*.2+^H>5A;&N;IP9_!C-8?*EJ8P/<Q%DG_PA=
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M"/2ABDAS3S#.3)^D3#7055SR:CJ!!VNRPEJ=!ZW'BXBAJ'0>:BZHR>YW7 ,
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MPXV_#68!Z\%@L%2+!BNB'S>SXB/Q-0"+<:VY-D#/BP&'IZ'D)U@]V!>\M]5
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MW5VJ:$.B^4!#@_/0]?M*A!B(75$<< 2@Z2\2(H!_<DT_X;_@&U8>$\O&7!H
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MD*;-@L4\\TA[U4R+6@6T)R&.BF>?\;8M^A3[@$:N1XQ TZZAZ.' S!Q\$?^
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MULW;( RM@4Z^)Z4]#DHUE?-=F&LR*#W%D"\W[(@4M?:)>C;1T1UTB#-Z3>D
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MC CNX-O\T)AV.*/G2VV&VOQRK-*.U9LOUP5H./&9@:AX=CW39\Z;WQVW7AR
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MP;E^[5C6"/;?JG437P EJ%?1VOS4.].-AZO#QK$BFY80*MV00S\R55!F136
M(%_QKT"*PWP<4R GB9I!7V9Q!>JEB&DW(@E,$4 MB32^I:_!;\4VZ5>F:>%W
MNEVJ2+1*(ACTOHWDGA_<AM!#?\=9N07$E:"?V'8HHIPE,5T@GCT@MB'8/&T&
M-JMG%7LUFP'//'S6>W"KP?E*H[F(ER5M9DK)$>5@",'=V=#QXK$!#;M2UU]B
M3K\0@Y5SH8*"O4Z$7=7B+,.:-B9D3BG^;6RR?B$+<FGCL]7\IQ>QG]XJQ]M9
MIW_VMG-Q7C,34O@.F=OYAJQ48XG]*'9\1^1C6V3J@^&.MKQB9#<;7[6*FC50
M?=KIG9WN%-4)-).#)(W9U0R4$M$. \_UNM/+8[K?Z??..KV\)G7[0[2J-TA\
MSCWV9 &00 Z5]D)+5;*0B>_77Y_?@&$;Q0/TX[>G9YW!:2\CE&ODT&G3/8'A
MK'JH(V# VGO2+9M2=_##":GC:U@)+\HY_N""B<(!=C)&0B+9)8DM[A2"*B%V
M"IDSCV<XBJX[OD@J+<'G1K;M&N@\SR?L_'&W!:1Z*_<A?I5HK'GCP!EX0C7>
MB4_X5E&T6F$GK(9V*=L.RLD6'DV \NDNH;QY"ZFR[3/VP".:Z:\ND;'Q4)O7
M&DM)B/&%#G*X1X=FU"<X'V\XYHG&(* .A Z:M-@Z3B:/(>YW5?D-%^!$OKB.
M^F]?<1QP-<?']@;%*DQYOB^3[>Y!$%L&R^=+7UP!7E)>?!)+ZO?8W^N+&_R'
M 5N1"%O+_MRF-=HN^W9%%50\]0]]TD_ A1^I*,ERP<R ?PI+$QX#&T-B"Y08
M%,J&H%?RY%A^&4VS-@S=T9:O74]\A,_U2R:1*S@Y\9GQJQEZ6%. 94*G]>J8
M^!H_E?F[JFMM6R/="*F26R,];&ND7VN-M%)A\O*[F.5FM6_7OZR1B<+)EMN6
M$V##0DT'Z3Z!!TP2+YXU#HDD3GO]H^_'VIR\=)'A#_*1 <59^+=4JWS%@:N;
M,\NQ?-[D8[R(6C-UX](!]2U<^CZY=@B;\1:\&2-\8C*>,L;S['1L'@2 L,R0
MZMI\"UYI6S-+2&R4^C/]AS4+9U&'*;#FGFG'W"TQ82:OI-9_@&[Z&-I$]WZR
MO2<U P39:4QY $;=IWB-"A72A/')4MJ<<#2!_)>0*.E=BI2,V*6DFI.D553?
MZ:S7'3;23%\#C$F;?%]@W&G;;[3#>7+EI%)[7%6@,M6A*>F]2J+5(M#2(-U_
M_<_R*LC:"VKW4S&[JF!6]*'&9K171$*/S#$LYG^P?,S1#3U6;\EL[_*T8FV\
M\81&_WV1-;=E2VXKK+C=8TGM95%)[285M4TOJ#W,>Z<P.)*G"197F)5-2*02
M65DANVV![(MG<'FP; C,7GP]\HJ&/&U1<HZ#X<YSS=# "3F@5+MS2NF+^R05
M,H:]>AO6!<E-W 4($P"&Z8K>,3- &\06S=0K7G9K)KB8"ESTN/EG7'K'$]!%
M;<-2:":[@@;/+KT/^:]:'B%^RCQ?/M_1@/;1;(I<&3</MU?__$.[^N?'SS=7
MHT_:]=?;+P\W'[\"6_?FXLI$W45OP*J<AO%B:CY,%'/0XM?RCEN JW "5B'F
M4?"JL_G<7H!\-%U#1],M -U60LGOB#$^Z'+X_Q[P(1Y)4^VIRIHE#X4Y=Y0%
MO (SM#<3:.8.%>6<%@8O*$-6(%G6 $YU,4/*1@T='3MP3O@)T :9>R*&2$VA
M7(Y_^?ZN=I=*4UY*$IG:<EYO1T4+[ = U,>:<7HIKB?V29ND)%S/@ / 74KL
M07MV/=L$;1*#1P88U02+?^ESS&%*P4#G^31S%Q13F3WCNZ%GR")&CG?JX!>A
M'A]*W(O4=CC] 9W-79_YW<)*I39P7O3:K8C(0OH4= 2_G^G?F=(DTW,7N@V4
M' T=J2TB/V;!,V/.TH1)ZH\6=TB\G8SD1K_B/JU@(;UJY3R2G^%2S\(9=Y_Y
M7O 5$^NH%YH H0+!"(!KSYQ)-T0<E&^(.,BV0ZP4Z#^K*0R[ 3EW;S<7Y,/:
M02YNJ<)7>=X=PIP%*#TF%LJ&#QM,\TG?;HH$Q&4:F>ML\2(.I1=NKSM(M47\
M$F]*Q#1XE 6T&MRO#W#%, :VS\2<&5SET75-;CH"C_W.$OF"?$'Z57HYGI(#
MNCTLQ1^ M3"@(6A#O 7; ^H@:"R#7$$ CI /F>A(V (5DJCA/0([?! ,YG]B
M-(5/#Z3^G#2V _0\ X283UK3&(0HM1A-E\!0Y8O.XY]^"'I0M"?*UTB\EU*+
MX=\+.J#%^Q1[)F_!B>O^T;WO:O\8C>ZZVDVZK0=EK<)Z?CB&$])@0UQ:_ VO
M8L;4<6WWT4*PYVECO!DR$UN>D>(%BA[=:@'0:''$S(0QV4&9U^MZ;.*Y,R[^
MEZO\]#[IK(RZK,(%,[@BR!M>PNT,+'M9(@JQF6C9CS_FEE?8\S*?L6S'/LKV
MLA2CDC0^Q>6RUC04CERJF.)=1I>F\A1!$!N([AB",EL'-$O31ZC!I> Y-?6F
M[2#1QC 3D2/.^&*%,[K$W/(H3>0><T!QPS -'%/4RI'^&XY]T)_P.6 +!K .
M:N^ZHZS "GHX+2.CD3SN5SR];O-T+AP**,GK=G+##:,FT!E8OG15\\L"Z\B:
M]#A<1&J>+]M()SFZR"E6V'341P9;!X?8GN:P">:+"S0"V%*Z%4>9?U>\'XV@
MEC1%[9MDSCFGWQW%/'M6@/S0(9"!_(];!Z25MRS=S/2%0CLK;3W-FFA'_6.N
MSY'"@\)=.*XLTOYPVK&';!%#3G&\/79>R6Q4\3W\"G:.L334O3JX1VN2>D!\
MF?HI55?1FZ=ZM @SN3*5WH:H-EDE[Q1Z0\M$[)E38T2 HZ_(G_W@P;W"D:'B
M3>_I14"RTWBVZ)Z($32,-[_W+VLNG(*W@.J,9=."]LCN%T7:H&\B-MYI1P.%
M7*X_C.(,)C]2:^D,(O-($HSB3@IMD] [9G&*%4I*7(WWV=#MR/  X2G&1X"J
M"&+5 -TT"$W2;27]I#Q0H2,SN.#B>+)K?^+G"^G3X%:."6H\\$XR2[2)CAHX
M/ X:L0\''BH'YM8*4@&_D?R%1*%T^"-=/"R*VOG( 3&^XN\0J!N@RW@EH3+Z
M4G202+N2HZHU;O<HQE\&JI3;+2=1 "S%L *]A+_D80HPPFXVPMNA&O/W:&3M
M@NHK,\]KMLZWCZ']G&G4&*$YLI8SZ*7:Q"B_?P+_#CU$\\RE=FI@]QDA-005
M-.83XST:*Z2K^K3A;1J#G[DS8)=/EIS_A6F-9(_QE$;3-:B;/U:T@-U*PTP,
MRX,/L1H6&^Z;B%\360!.&W$"3G[4G5_$(C"R@61 %C"F228=U)D+'%_J:(7$
MC092=6UANN:< #XQ8*.^4J.)B=B/+N4YVGJ(]8C1)<57 8P$TQOV. L4[HD3
MS@< ?T8(.KOK "LX5> I]P>/V7QGU(\B) ^_(AY]'AEQ(U.8Q#%OU@<7SJ#B
M2F)H/%K@/HO6 EA=),>5Z+)F[QWA]4SL(Z,.,(L$N(CPY/#&L>Y\]\)Y0,1#
MKEPXVZ-#6Y6U;6.1'(P%T30%PO5\G,(@G1BFU"TF-(:.;"99Y.=S]P2?5YH8
MBY&@<LG&\)4[B_!0( 8%#\8Q&#K))GAEYIS?X7&C"]C51N21@9?8BXYV:_E3
MBW;(PU]\*6I,(H,IZVA=/&4B,CCO>3 L^EZ6AB<M50OKS%UR-X5P31R!:KXU
M!^ 8;<W7E$Z1&%ZB/>(BL38$[XCZ4>$)TU[!]=5(*[I448>7N?5$@FL:SD 0
M1>0>H'HE>%K\<,SKX$)Q]F59*5V#R H3N46<#B1&Z'.F<PW[%^&ZHI4EYQ-I
MT3@Z-U(WA+LP$"FZ'<$3X%+[+F<^R&5#.]"3(ZE4SI4. ]L6?.E'$V!XUP^!
M=, W5A9&J\,)*B=^CYU,8$<BG2H=J]L Q\D#(IZ(N>%+".9Y@"W"LE#@ U ^
M(L]U@N8=$4[6R;<B E!8@ G,S8DUH)7(I)"D<%VF!5"Z8V>=O7<+ I:[KLK:
M?79FG%*]WWWL'O*U)_?LKD+N=)W4J+WFQ%54JK=];=Y.2_.6U=XUHU"A@AM<
MLI@/<]^7),BK4U'A49R*6E<:23V%L@5CZ+*S)9@Z@UI?IG(6IJ"E'TQEG6&;
MA&<WX;EVY;CI1$R%+Q-%57:@[<-&<A*V,@='.J'J0.KPA'U? QHABCD,I/_3
MOSO)^7,B/-Z)\OK0\X+V9YSCE'+<)GVFT4!NI2ELYK5H!.JV(?UH5#$8A>&S
M87.N9Z)6-Y8A;[1P,.05^Q50&Y.95-3@5CCOY OC%\16FF)++]40BS.SVK[G
MJRMSH_2\#Y8?UZ8V/7=V:\X.EV04/H9^@ SL;#D#<[254$JDON8^$C$P7'$^
M=RVRQY7T2#!+//.$!R(PB<(/+,-'-U"\F+B^7O[K7"]Z!]U9G[H_A\'4]:B)
MC!D_B!>--]!26.-1,@DU6DQXQ-%!BOD]Z''!3-F HH4>>FG(*0YWVV?DL/*C
M5$K7>6:ZC286-\>D3\XWIL HN-XPH?IF/QS_)1):]#7SOAP0R_;(_ N0R1M-
M7Y>O_)705W&VG^RN^O/I''(01G 22;3Y]#SEU"-RBTE&*,WZZTGSV!H92S,]
MR-[?1:Z'BZE<4J[Q) ]_:G&9%8.P]GCZ]8?1B6P>7T>X6(IDNK"*QF4 >;DS
MFE)N8D]$3(E+Y*;P?!7B!VDE!%O2.AQ+5&3=D6D+R=ATRJ6(#JY'(!L'W2S"
M.\G9*.@E-M,! =+%GIA9PQQ3.G.2=,X=1S*# C\CI8I^\R30*(\/7!1.E7'"
MP99\UV9TW&1:.@(D\V.1X&ZI+WF>4KX=N9KH,4W'QKUQ,E&*\0L?]R,833QR
MZ9$7?Q+:VLSRA?\_F]B?SP#2YY'Q@/1I3&9C^^N%"I* :]E+]SD1\YW5B@N=
MPA1^0/ 0NB4-A+)\:G)L8_:E[ONN85'G,[($* 0J=]'5KO&EV!@-Q?HE-=/0
M/7LA4E"%H,/^8( =42816('-!Y 'P$_\"</Y[9T,>+ ?)QY8!1>1N,Z]J,]3
MP#?^PY-1,Q!LE+BY2?ZXBA409U^%(_$63@E<FV<0[(2K%J>B5RC\^CO(;#Y4
M\!>EI5>9S%\W^+E#':]8U+45]8N#R"VCI&\P34[ ,*TO^4IDG2O*V7L&%A#9
MQR 51B"X[-P\^C'8[8Z8%P-\SF>V+6N>(G9&R@AQ.2R^BAE:JI-<S8;SWDU=
MRBG11.=8M%)$4\'<PO%&10P.SK3^E^[(,M7S%<Y!T%#)\-.5K&:0Z[H&2I#)
ME37IUQ,I*C$"?8E )'>3!;I%Q"\_[BB,)\Z&QEL2HLN0(O&@,NH:*J39?20V
M"I<PJFSAND6J;I-^G+'V27$$.>%P%W#LO<S;K?!T)5>*?791EIN #.ED$C9I
M=0U>@Q4/)P%0B "<Q^;8<]S!4#+&AS$WA"OH?#,)3]L8FW5]I^P5TCW5<EN=
M/N,MNG#8"E 4"WBG+[_H93JO'1EC*IL#,I8@/[&8#7P*?N $XG./(Q-PH@O3
M0")&SL3J1/V7X  S#@60>+2V@$8T0(U#JA )*8)*H2(/S ;ST&L;4UX4(99)
M+-*4L&9SFQ 8>U%=A^<#Q2^4@VNDC]1@Y5ARRX7*!"OBZ;'1H*S\-#"!Z11G
M>G:][QIURL';']>81PEB47Z9@0UHO8#/-(5+PO,L\(XD$)RY$S*Y*NGI3MU_
MNC78T#QN!YC)Y..^')5@H]*G,ORSHTULQN05I+<F6*NO(S%3L1BV$10Y;_(1
M_G(%6LAO 6*)$JMX5&&B(=HS)0T%O'00KU!D_X=R-FXFLPUM*A=NL,!#5_NH
MVOS9]!)U9WCS5SFQ4EG:B53N/V&M6URJ=&XJ8K.*-.RW.\C"EHE*L@0@>5NH
M5A&=@DG.)LS<I;T%":X1[&X2"X!]51LPES<9C$VDX:KDWK>[F:D0B"$G_&Z0
MX-%13/Z VR$GCDT$ U@-<%)X8WU7JKN?^4)9N*?&\2PM0M\7)LZ'W8N=8@+X
M9_V07E9[OC=(GW4O=PIISOZYBE1#FZW=Z$ZQ4-Q=R'1G$WF43K[*< J*8I*_
MMB1;XCZ*?S '&P:/'',D6AI[I!?)B2XEVU-6UT>VY@J.-=OQ5@&J1'_>ZD#5
M[Y[O$E0B8U>XMCK:(X<&MQ,3\(CC!E0 +558X,MX'L5(V[9KKQJVR*I#J$]G
M13:N--?1ESCUW/!QRF,=K\L%]PELXT<.I];G5K'/C>B:T)C3-211$2.3M9#1
M"$^\R29P#]"_@Z/4'!;5>-GZLQ]2UY=;,K*HM(^7-\5Q;@RMRP>3;Q)5N6I/
M.LS)5^8:1@6V=DP;O#]+9(O*19[1B23ZA-CLD?N&L*(&UN'NL8[2QA[3_KRH
MG%,V!^J(UBY4/R8=4F('(N27KAN*JXVB\DN-B@ZP+(,'K2/-+]O.NP#-I=M0
M5YU=%K^]LI;4V7[E^RXV.!!E$1/<SW:45J[^][!2S.6+-IC^LH<,])Q&W.FV
ML/4DJ>^"A"MH<5LI.]R6I14EM^YIQL+*.H-L"<$:]0:#)7SN0.J.=ATP=MR)
M=3+"="S00:@WVJ=/5Z2>_-/R 72!'VHC\L;J'>W&,>#[I1IN U3- Q&-F5H3
M;%+!#3%5O\024/) "-M9YBHCJGC&C1' PZ$75YE_<3W49)WX>Q0=0 'P@&/I
MH"IB64:@;8#]#A6E*#V'/5(/;Q^NE+:S<QQ_I+0<!DT54SW L-7!7GP4K7#0
MY'U$0Q*,<R;BVY@CB%:N;M(0 E\F>H3.1+<\/B0TX/II'%#ZI#M3?::-#%'^
M'1^4:N=);^?A4M>GTAF J\52!2&6IYB_=)[D*1+!< $X34".H^__Z+/Y.P5N
M\3V)0^4/6&LN[ BPWMEW/PD3#RN;)QW-U&>@[XA ,>+\K]#AZ&?.7VY<5!(9
M-3Y/1A2L4K25H2X$'+QH[%B^S70ZK])3 -/3=83<&$R6?$ 4(99'Q90M4.D^
MI]>9&XV\ L*'5T>I"KQ5@.YYU W2MU%DH"$3>MA%PIK!@^,P$ ]'RU#;!J1Q
M3-NV,1Q/B:=_44<-N@B&2UF:O)9?F$Q\AX;N,]$;R1/9$2(Y7[A+I&DT1BK%
M>'\<5AV<\O8QR2%?ANZ@N<:[/,"_Y]C+P1!=:R0@T0:DH";=6 O+PI%!R-92
M@3436/28.UGE3&WK?%;*LFMT@'GQC+@7)Z= 8"B-C?J#-:3%!V9SWP(7%"@.
MIMAG!DO[A3 8.< ?887/H/]24W8$YAVP LL4(>E$K)1G%O_;\N:Z_,A@(67
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M()LE1;+2MV69Y8^",[C!Q  N QQ*TX/ L\8A]Y6"R:'HT%)S!NO!-?C$;AK
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M)OD1#:1JWEJ0BZ!EF4:Q.[\9E'Q>FI*WL$RVYYME'?\O@#+Z#:&,\CSN<IO
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MEEV.TV>;+*PQR&]PEC?)KTIZ2LZW47IV[ ^<2_GJ5N <]KHYDK(V<';D?"J
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M"%M_ :7=,IL+Y=^<N#0.YZ5A51R?A+)3=84V+%$M*[0<WA"!\,X'<,2:1X:
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MI[=6\O%DQ_O;<$'TF!/#?W))73*VC@B2<?7-PN552KNKZ^;*8FB'ZQ2*BN4
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M25Y8 C60=FR)XOIU(\Q_:]XVM4_,^:I](80S6SOQ?1<PCW^1/ ^\$.0PYPA
M&#8LS(/+X/@!2^5!N.]I<342*3Q> 1F8!T*1:'0U=ZQQZ&<+#"#J"*3<-T1-
M$2DMSS,-:VT=%091WQZW#?H4"7QL.N;4HC8?[J.#[:UAV?@%;&OH68$%1".O
ME;WB;<O'5P1<T(5P.HSV PG1Q\\\$VY2GC5LE.RT4_+Y.TB6[=?)LG6R[+ID
MV?Y^),MVJIZ0UQVLE6'M3668TLQ?9!VT:A&6%F$;I0562X35BBWELU18L1W*
M-L2.C\3Y&TUK9(ED^IAT-F4/J4S!;LTALCG$1BF*-8>H'(?H5J'M7!Z'&&W
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M"+Z&UZ<,-^3'R,,UU].PA29(6>S)O-06-G/P0\JOYQ?7I_QQM3A])X_Z%!8
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M6-6\H1(L7<B5Y6!)/BV7U_B9'N7-TP_I#L!AR;\A$H6C *$/JZ//8"? ",=
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MU]YWG7/W^>[YGN=\WW-&WA_OG,/FF$/FG'GSYF;J9A% (N.&, < Y.59 8\
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MZLLH=1&?)Y(I=JDF"2O\_J9L7;M6E$_!/2EYYN/F:*EH3<'ZR.R^T$4NSI'
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MK@Y0%I_$A!Z.?LE9GFWZAU$N#*D&[*<___G1]&J+QO%T\^%8L]%1L4^;S0W
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MURN9/W$5E!.__L"4JG K'])U*3!T:K2%P]:_^',@P>-VI.KA8PI@>U3+V/S
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MJ4![&V(FG&#/G1=$-UQ)[X'NKK=W4M-L4O=U%&X<5C&D_T),?>%D[?SOEGC
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M.N'B;)ZY.E-5)45!.%8^=?+Q7CAO%?9*WI;5JS1.SG=KD2XCTLTB=K5%YSY
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MH%J++[\[<5#3I ;DSXAS2J#T;G/1UE^HNW)+%9LFF@45-KH/$1 ^\X(!P<+
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MS6Q'QRE7<^BTL@D#VYE0ET)4O1/E!,W.*GU!M5DI$=N[A:)=:O3R=C7/S#V
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M-5R<[:E*UHBY3B'2 \ E!BDH4R\*D]?5SLT8)8> Q'6X'XZ,BAY_<:*@L9T
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MK1U^+?7Q[;(M"F?CZ.#&5"\A;:6\E&9^UE*:"?6.&@VWZH&69L0<'F)R*29
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M#]N=.,X$]],&N2Q$MK8C6\X4O8*$QM55EL$0<7Q]KOI"[:(]JX^F!2U)QJ5
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M7B[W&?563-= TAN.5SKV;:,\]3SMO>8M^,[5:HKCU,@/L4Q234*6EEE%15D
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MY_2+9#; Z7U$.S^ R8J(YWM?(+UNYROX)&B3JF%1R3P$0V(PC\D(I[<)JZD
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M&7K 90P;/KN5XQRH8B8MS<)J_M<&NLX%,4+ 'D_DH>^Q =\1C/$/>+D.Y@!
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M9RHF+,A[Y'AP9Z5Y_R!O.%.Y#>=&B)=Y&)5H8CK82E%<M4R-I@:?$NL1.>^
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M.67"2]>!A4U"V\Z]- "!-#U,[\W\-\+DX7H4F@V'3#?8Q1!#^BYWZ->*=,&
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M1S_%R_=:WI[8"?O611*"-[+XH<IAY.V^F3<O /5R95ZU+P\G';=[NW[' $0
M;R(G3EQTSOY+CXBF_9/4U(X1@=-2YW9*AL%;K:)LBX;!N=(+M=KC3[EC5"5Q
M/B9%= 8:#&GA'JN+,@$NFR] NM'3'W*([^#C"]!L?73:;E-PM+CB!/LV@?:;
MJYMW*$?GFJ#^8:+V 0[B>_[KA-6+PF&M5IFMO</G4;H%T?97K[8>@7=;N:KZ
M4!U-Q914IK^98%%OB7"EQ[)PS<^F^G;I6SUIY%P+!]B=68>Z7 66585& QO
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M3>#K7;W@8(FNB._:Y=CE;$DFQGKMP3\YF.DH3-)$);B%\&=;%MBTAMFFF0Y
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MSK.:;JB3^_9@JXP ?];CC9JM\ON9B;;[4OI:<O>4,N5C]M>W:]OE4]<Z'X9
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M@J&.,6%S,?)/1Z\/RB7\NW!M=P<OU3X%;7E7+5=Q>MS"@Z</8G]<F6;2!]J
MT"=UP('YMR7DIM8'!S\&?JI)/:U$W!N;^HBB\ZH8"VN!%+]_SFT60G/(Q>4>
M5?P'>C(1'-#%AETX%)OF7!FBD6[7QQGI\0=*XMW/UICSHIJVON6^R8^PXVG:
MR&[3U>,8/ 35,I#S<MZ1@$(=.G0=T)D2A>W@Z=3%IZCG;%"Y+3;13+J*)U\8
MILQ[<DGV P*!!5A&,T>GS_R9F+"7%FWN-7'^@PM 4T16NF!Q_-J _4<U!EC,
M"+L(6ID(.?U<L?EGLF^AD5-=^NG1Z^*1BLM'*3G7.QY$#DVM$QOCCAX/GL<
M=M8.8033#Q:%OF)T.EWE>;G&PJ5]H)2(];=WM\*&/S$"):7Y-[BF: -<U]$"
M3+1R@4=]!JYX#:!/-,^)8 L'*OO7S+YHPF=:0_1^Q],'1 QJTQ4,YNG# WG&
M]:NVIZSTJ=SKI5II9(QVQ_K<WMZO ZL>HJOJ?I^J-'F(XV_VV9)["X"5?J#R
M5S+W 3AVX\'!\\%?XTFR3G56-)ZNI\F2G"K?D18Q<E5&LC&9LJ(4A430H;SB
MG_(L[YX0\X9NDB!?]F'3OM(W0M8,__!Y68WN6_V??S$ O)W\G+JDR41!H"B9
M@Q>7VH2CK]?H7HEKK1M(-1-0#T3VYZ9TC$_W\"Z:8Q@%ULG)=:B+TR%"PLQ>
MC"OF)B I)4&TLAMC70:CM,$1"3'=E5*!V@=Z=(W'SXQ^455"VQ$G5K@Q/?PM
M^@![1[#\8-;(PHDU0V29P$B+:?YHKQX<H\O>(_Z])L?QI^;I3I?]6?XEY6CU
MA\&N@-B;6J>ENS['O-[9T' >E%M&[L9:#-,3.>L+R3H]_:<:F/,OG=8]AJ3E
M>BFJY0*?C]XY.P/V]@,_.GQEAE\8H<ONJ(<X[4SNQW9/I?2&5>I0H3>P%%_H
M%RP9W]7MX:P820(';F(ZXYIQSJ/J0$$R[A>=S@Y[ -L$.M@R6N&7@7$Q4L6Z
M$H_ZPZ;9_\><Y4Y#"G WO^.H^4<D]R!Z0.>N<)AC$46_.HHQI [(]H;1)D%L
M'"J[/3KTVZ#MN2]. NN5]05"O(<)K,\!>OW9;:,,%K;9Y(N!9P.^(A$W:X29
M0_M@-G^&-^$+!8IE)TA>,;OLJL)OB")W%8I3+<PE\;N<KPKXX4'\UHX;W@<
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ML!%8?A/3H/H^,/TWVZ<E68Y_P8:]TW;>UI^.[.9:6=<'AYQ'I'6[1X_79JD
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M"0:I[YF6]P*C.51HII5,%C2#R^9AMG4&!NP#$MDC.\^N-()$CBBLH8_SX,#
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ME Z06+S)L>(PK1@8,FB[)RM*,36_4N,,?X8V3J>YO, \%F<_X4OZ/U.D ':
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MMD\/MY=Y'-&4Y?RL%) ED0+D"H5KE:/,OWG * &L'SGQ"-%O,5P1PJ(N*6!
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M*UC=B)V=DC>_P@C[UR3& 1FO<'6K9305^W] >1WIZ'\!4$L#!!0    ( )>
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M6]-F\'YB+"E/.#U)(>1'K".[]Y%G,,;7%9+Z&/.GS:0LIQ(N/V7YE5L<.\^
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M/>_17[+Z.CAHOVB_YC34O4"3.CEJ8$M-513JX8H#%0GHM=.)E?T8;P!@_,(
MG-/]/$H%=GN/ 7E9UL%V.?'&H>M-8,+[W<6U"D+DEF#U7L*<%8M5?H2 Z745
MNPFO--0Q#87MJ^2D8)YT+V9%93YM.\(0'DII)-%M=V^L::0MW0)4'J;REW\J
MWT&]/WU,I4.=HJ$8&LKNV!/);HS@R#YA2R:O]0T?=,BXH8LK#'A2?9ECN[F_
M@L=.7GZE+)9C9:I3=I=V24-IKA?[Q+' HAB,9U=+H4NF?ZM[04[4V09#B5U
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M#<W@E6OOZ'T@GV,&=4]A//]^'1*^T35$[P:O 2Q2[T$.CMP+O<$T%1Y7U6R
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M+Q2$X:N>5WF%L4B%S4U@ )2@Y&[Z-L6RZ ]TNKS,OY6>+E_FIJ9ME16.;F!
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M*6>>LR?U*;-CYB')JG;@OB?)OG+TM#TIM/1MSS$2NRB^Q)=T5[F>>I8<+OT
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MP[R/,DWD%=:7&&%\SZN:HE7G6D>O"4+':MHW\^I'&HM,N);]A^G.['<==_)
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M5MF1'I)((8&T^>!^B?P:=+/Y I_*H:A<GE/QFKUM'$^9CN5!5@A/-LY6=Y]
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MH,*%?JZ->GPS5]U* #?2ZK4ZDJTV1HM^LN;QEYQDE4T1B4<.%&-A;P?/JX
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M]S69)A/:6DO\P6BKQX)U&/J5=C$0.K>HT5.'ODG:;!5'F^"M/Z/-08^?'UC
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M>*OQ;5,%4*<[7I=:+5:WFI;D$A7MNL<I,ND156-XN.BX+'9](_^J\)A#(?(
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M-3'0B.7M#6O0?$!9/CL4N4BT2Y-X!)YCLY2_$/J7<:GCNDJ'I;?L51PM.M'
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MC;:ST&%@C>BI^A:IF7U,^8XL),Q63*)@B[ME=M2"K(F2,%KEQJVB KHBR$G
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M%+JPBBML>[]1I^2E=(Y2X<R\5@IM:4)EPRG:O7"*^0']DM]Y_67&HW5W5'7
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MLO 09PIR"K,S(_#L1@%<#OW;X"QNA2Y;+?0<:*OE0,D=:+?I;3H!O3#.B-H
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M=#YF+M3.:)]<(2>&-C_-S<7G-AQ(+,7$=?UA0]'[I@;O0M2H9SC]@^83Q:K
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MR'?ZJJ!FTNC%XZ&3N</GBZ$WR9^[K/#$Z'%M6C@C2-[$AON\VJSYR'AGHZD
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M\:PQE!-(/&==T4($Y]-2&<A-473$,C1#&N<#HB\5]8YKL*V C_8O2.9<5'>
MFWG'^8N@(8(MY$]0I6A^X2?HN*0KY06<+]L840U_5CSW$2%'U,6.C] !S5?B
M$^ C.:4R 2MD4WD-&AMY-ME'TZF "S/!(.6N%!GX6CTZPA;:!PA\F/ !S1>G
M*<ACJ /_J$H"!I2-JON:,NXRM5QSO:88F  F%QP'CH&[4J9HUD&1X6_ M=!Q
M'QIT!V8X12$>R'A\FF(/OD!Q72G&F[B#5+/PPNJ5JA/8EP(7=2_6F;P2F(^E
MA*_2'$)_^.1!<]!53C6P%25A%#E@SE&X*.)-;9Q2Q5=C:_4$Y0X#)[]7M50?
ME9R@WJN;' X"/XB7/FF@'-_LI(''8#+TBDS=M%^^0)[;6,&^H!A7WU;5JKA6
MUYGOI;QL;D^ZIQYM; V/ RKUS3[QFC=:T*D96HS349YT>^<[>9"LH_TQFRHO
M:RVJ\E0X-X%YUY3N]8N2^E0"RY'PB>J;QF<^+AJ][K=3'Y1%N&O4I@/E;-%C
MX].J,[7;C$$4][(WAGJZ,?ND_CYK<'R_/IB[,N0?7:L0]QRAFRS=:4_7;E?E
M CV&2JJ-R$=_@'ZV=K3>EPF4474+.;[95-U$WI]XFK9.^"GXK7:Z=+*G(W%0
M =H/$$V N_JP;@Q[NS!%V\_=0\_2AO#WD;80QX3'LNX25>*G\6.)X3+GX!/X
M@$+G&8RWJ^<ZC,8;-'=4#_!WXB!!!;Y&TDDCXS72CZ1A^"1Y3E86=E&Q,VX5
MUJ^*"N[&3.HKGM%8@Z;-(1M;!W%4(S 'U7Q^/?I33:?VH,> Z:7): LPD'D#
MY6GX<<4H#_0-EJ J\*]G"KH<>N"@1]_"IY4I2 _RF7<':4!M*+\0$6I?LA?)
M1D=G\I$8Y'-<()*'O MF(UKDBV<Q<@?Y[; 5S4:'*I;#+(,#CP)+]5LH5KA"
M/Z@D#X[2.60.@N.UJ;&W82&A#LZ"M^*;/<N10.R!PVWD&#9.X0Y)ZF=PGT,6
MZP3*3 BP+"E^ 5%-/S/Z(9FQ--8$[=(/!,^#I^F\/&O@Y83%X3=2CKV6'P>W
MM9[B&L%K+;[D'>#)IF'%C>"6>FL&&3Q5-R>V IIGVA(\"*HW%'N6PI':MX[3
MD*'X4I&\N;K<AK&F\6:5J)+?("6?S-]</XP>DK*S#F >CCQG?L35^P.F;*'*
M]8;AE/2(;9=>K"H7KFP,HI 94^OOT\=5/+::&$?SL^J<V,TI,O,Z'A2YT10N
M[/#7&XY+;KA-U8L4M7:C=#& H^"K]2\+K2VNN\9IKLBR]/+6Y!TVYPNNITPU
M_A';1H*&]=(Z?TS/5,QQ2]!%JA[:<;3^FJ."2,M[(4YO,3\5#RHWF4Y(D+Q0
MXWS9Z.1^@U"^,C)"GZ&D^PMUWNIP-ZK64Q-LMY=(@^+X.K.70D1[;HI65I<]
M-8:HXG,7&FS5=LGI^G' Y(@_N@F:6?Z5VIF@GQM$1$,U]O_@&-S$>VS<!673
MR@P/H?5E+/T+Z%VNM^X!;)/T6OL +HYX2GR E_A7$K;P;[<.7("4V\=A-Y%M
MO'*#COA(O:P_2.PGO=9=(\IR!K0W\:M)S<1KG!2QF9B(/?47X"D8X;8)&\#F
MVHNQ?'0#]ZV^TRRG=NM>FPZ3]NH&&U?EM!*?#<5)<F*X?DJ$&4_7/O//Q!80
M%]T.81[X:OLN]#Z&<SMU#QKW4=-UX0UF$E];:-V5DTVD67J3XO$*4V<$'UMF
M6.N?@DW077.[@.X@OMKO0 VX=^W='O^RQ97/ND96/BGL:G]&CD]_T[J0MB]N
M5K,#DQ7":#!QL[Q+ZYX):YR'FDNEQVQ&&'ZKJ+4.7:EDJ)+;$4MS+_1IFUW[
M(;V_^33K9NR71A+W10C'>D/HZ:VUE$HZG"N,;Q49-G7ZW< \>FN'*].KXG);
M+#NK8'M+(!=-CV[\P;\:NZ5^L2@CI*0N2?+2>Z'IA7R-<Y]AC6J9[2#=4LT&
M^K"VV?SM%6$MF<*\@NE-9:)O:6<:HB5;8^G6T;+ZD #S%87!>Y6Q3]7M?%O?
M!%RWI6DW07-HTI9266#YAJ8E\O3\[H;]"G(:R;I-"<0Z61:I-H1,,#4!0[S7
M& P:NLL(72_XT'8[\1BNH+YO>@GTET<W9FHB\D/KY9H=:?_4*4'/F(=F$;@A
M^%^C!"KRWJ"WP/^XN&F/P_ML_Q!AB(2*-QY 7Y0]; C&!N6]L#+1>ZE[+7QT
M6<QBDP*%@Z\;K*C >[=N,RIP2=-.1=EVH?A*M(;JT7!._[ZLOKY0K\WKJ:O7
M'4B%S)W::S$"XPKMH.!E^BM$M/=*W2B\V85%0-@=.P8>@CE1GC3,K+M4)K0N
MMWS/0RR/S-I4ANF.\52,Q/#8$!9\5#]3=\S[M):G%;OHB.'$)#L+=A,[4M'2
M5TGZ49BWN+72/^/)@F4U30EI/6R:2WAOQWW&=W_75B_N&/>:1JXPRZ&Z;D!Z
M:6Z_J5K%*K^Y9$V-J.#RPL]4FPRH]RO]9\*PKM6LX>&Z=CMNJG]T,RC8[]Y7
M?TE"=CAG255$S(LQ3@"FEW,7+:G=6E ]_P_S:89]SU1.6/R.CJN\O>'5K70A
MWS^^\;XDV_V:M5R>Z>AM^JY2SCNH?ZWI+1^]H)U[)?]3[S"^)7U]E[^P(E[4
M/D5<$.[??% J]H]JH,FWN/^N&Z$:[P@8+P 6FR#=1_![67_O*?'S_+;N0JE+
M>G5'O4P2[]B*R,^$3V_*4A;Y1]1/5OWTF&.^ ZQUW&VX""IL6G4VL%=92D^1
M\G-^9N<'U=YTY_8P-1CWLR40B K[V3A!,],_N>XY.,,CPG0=<G3\H/\&A]@\
MUO*08-+7;@?H?/ZDCG.P:]KOMGEP?MR-9GM8'':O82R\TC_!\A/^Y5%I_(Z0
MG1ST,<A!6Q?B!CJ=M+7+EP#RGK4_(RK2[K:&X6_CCC1%X[5AY^O]L2_^?I8P
M;(%'C3$3JW'*T/5CLVTK"!IZ@63I%!J_Y)UI=S=2TDZTP(;"N)V-.OVLL*M6
M0/O;/]EL)?YXR S;B&E.-)T7'F2K(X9A[#5(Y:-BS_D!-7_*7*PZVJ2J:5 6
MPX_\B[>0+:,_JSC,>\EZEQDI:N.[14Z4=8EW>XU0_50\664AO:FA]&RH%%+)
M=8$U]VI+05=:*2N+V\OXS$TO?\XY*J!DU G.BY=$]$N#Y$&>WY0?U3$K!HJ9
M;+3K3UD,%S4?KOR7#P,7R(>$!$=%7_]?1/C-NB(]D'Z7'ZH8&Q$G_J)J]WRI
M'*%1+/M8$"V5=F:6T&2XR:6<+F]5H]4\Q6IV(769\F+95.8<];CT".Y9H"K\
MB>BNYH;G744H9.Q/R%5"">VG"N]# L,1D@/4I0JJI$.'617DV]!W4GIM#QR3
MMIK3#M>'MPM?PY\]+\D)1+#T<K:=_D.;)?^@/EJ_OB1,ARBCRS=J=S.AFBKB
M5^D*>CZ1G!;&MN+-X45".^R.YTG9"\QAR<I,]T9IJRGW5_TUW;FB'JN' BB+
ML\@99ZIM3(=+9],2C9-2[[+6ZDO"'00RK<'SD(R-+UY\.+VC:T/+P9SZ#B>=
M?6%V*RY_2)K8=).15#6E(;1D(;6VSIJJ9?XRG0O[P7^J?^4Y(!M$O%CLF29:
M@K6$9FL6?-,N*LCLJ92+2NT[CM0^JXQL#2LA458USD]-8E+K'H>=Y$N,/SUW
M2E=K?RVZ0OM4'-Q\F<$NB]"FLYY5N<IG<564X;5B@1?];?$2\436CQ1?F1L_
M--13V2:^ZEZA(2E'+_0D^U4_:5I*FT#Y1237WJ\=(HMB[6$-H6_A#G!'%X\6
M?!'X)Q^2U(KQD$\*7[F'.PW(5*?/-U>>9:D;!Y,'<?JQ6[0YO&.2MXQXP3-:
M#[M!/*7(@S]+6IYL+[HC/QBR0/9=Q77GJ"LTM3TORPZ+G]0+JZ*E06@5N4,&
MB/?3_LAW4]N9G<H1A35<OHJ5U"&$U0]"2-(G&KV[4&6"*KI9I7,TP=8)Y><U
MZY$9U4QPELA*_0=44W;4W@+O%:QB?X=(2?,$.=#MD'F2K[#"7::\A#AWN17=
MTW(L;TB'M1/@*946HENXE%Q-3",_IS/PIH)9K&WXS,1=_'1L6? KB2<6Y*Y6
MAJ%[.UT*!UM%EB&E$^JBH-CR7^:'@B?5WTPR<@S-SS@ROXVY3C\_4<#CZ?R"
MCXE18K,[J-B..W90\W7M_N;LX@VM#F!;V?:FNX+LJO,-1,UFJI?5*W\VXZKY
M4N(<[H!1%+Q<]$GWUAU19!/%[7?R. L:3">+EO<L!2>3!CJE_$N5S]H\:G(I
MY4TO\\XS[.N7)=S@NEMR@P$18;CLCLE_: O:*KC!Q27&5OZPLA*-J^!E531_
MF.@997HU4SJ4_BMWI3R+/2*^4'F8GQZH *SB#RXWH"5*SY:GS*75' .5?8W2
M"(SDC:(OY8T79#$W5'6)-G).Y(Z4I@N&Q3U23!%S U/4OG)7E^^@59W?C-$I
M3)5^%.,E^ZCJ+YO"&\&=P7TL2*B\)+"*S#ERL4CR-LXH,\IE@8[*CZHHURF:
M3DUATPB*3$31+J3'B1\I6QF?I:7L'^PMLH,5MWDK%,'9VX67E/OB1DF#U-2
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MME*KM@'>*39@^JO5Q)%*!6V"(N,<(LJDTWB!<HK 5TXN-R#;XC <V IDKFY
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MDHZBJ0E'<;3X.4)%W%PY/7:6NJR>M_SSSX>G__C[GAOO_K/AZ;]7R<!7NZO
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M"78DH^+%'82"0Z6<W$EX==8XFI\Q1A"DC9:+4D8J:I.'6>+$89XD8:A6NM2
M?,W[H.[;#Q]U??;AR;E__7WXTA=?M=[[;H?AT2:?VH>[HEBW7=/)E_T+46<C
M8-#%)&S10B8Q[U@^)7NNI")C%L9(FT$Q4Z9QK*1#I*K$0Q1._!2#&S=951TS
M6<-;:D#]S=^ [=._79CXZY]'+_SCGVWW/E]E>/[=GEJPR9?UP]XH\AW/%-2U
MD%S(I9CB@G-)L)S3F<B,Q3Q,VLEB?/("A)!X'$%*F,>0X^;QY;''2)3HHU1J
MU)%*VL&YJHJE!DR?_/'ZP+MOCQ__X]MM=__QH0%\OK86K-[+ EM]2,^<PU$/
M_.++;D>DY5^/S<ZXFI2?>BFC*.EB;FG"^2)(W+DR:.Q9&"SZ+!(>=0:#.'@:
MCXP\349%G**APT\Q,$OM;L>??S<V^<YO.L[_Z4\&\,$GM6#%]RSP_6X2V.V!
M AZ!94^#(_,>1<:FWXM-2KJ3G!I_*R,]YF9.9M2-@NR#UTMR(J]!<L.OP?/"
MKB+S0J]B\D.NX N"KY +@RY3BY;:V,#;;W4<?ONWQOOO_D4,/OR4#;Y>0P:;
MMB/!_@.EP,<S!P3YIX*(D(2G,>$Q3Y(.'GR<%AWQ*"LF[&%>7.C#PI^>/Y0E
M!-V')0;>0[QX]I#D?Q>7['>7F++4.D9__U;=\=__3@S>>X\-_O,?,ECU#1)L
MVU "G'=D R^G9!#@&@O"/ Z":.]PD. ; E+\@T!&0"#(#O0'>4%^H"#8%Q0'
M^X#2$!\ "?%^#@OU>HX,\WR&67*@8LV[@+;G/X#BO1:P@G:"JC!WP(D*?L9.
MB+O/S,B\65%0<KD<CCI'P!-/H:D5"W F:QY2S3U:(JR9+90(#N<K13.Y6O%T
M3IUD.MLB/935(CN4:9>/9_7+AW(&9$OIC>&-X?]GJ' 8: Y#E</ "74#W(/!
MSSCQ<0]8:9DW&7G%EZE0U#D2CK2(I50L("M9QZ#<ZKE2 7^V2"*:*5"*I_.T
MTD,Y=;*I[$;Y5%:K8BJK1S&2TZ?HRUU:@.XPT!T&NM=:P G8 7C!;H 7'O2<
M%Q/[@).4<9.557R97H(\1T&3%@DD^G$TO>HHO(HW"^$+9TK$XD.%"ME4ODXQ
MF5NOG,AI4DUD=ZA'<GK4O7D]ZH[\I048+PV?@$K/-:#:;P>H"7 %@M# Y_R#
M,0]Y\>FW.&E%5YCYR'-T.'&Q'$\_CJ-6'4&Q^(=AO-KITEKI5)%",5&@4XWG
M-6C&<UNTH[G=VM[\;FU[@5UG*UQ:+PT,AX'E,/!\M@.!GPL0!04 47C4(T%,
MVNV:Y((KG&SX.68I<9&&H1\GE7/F,)7\&017/ 41R2>*Y:KQ KUV+,^B&\WM
MT/<7=.D["KL,346=AH;B3N-2 I4.0Z7#P/98 VJ\MP.1KS,0!_@#<>C!Q[51
M*7>$"?E7>>FP\U6%^%,,1,5Q"K%J#E\AF$9Q))-0H7*\1*X9+=3K1_*MQH'\
M3F-G44==4W%'G:FDH\Y0NK1^-G \5@.!YS90ZWT 2/W\@"PX\@=I1/)=26SN
M-5$*Y (O%W>*#:$=IV/9<R2*8!K#DD["^:J1,IENL%AO["ULK.\J;#?9BMM-
MIM(VDZZLS:2&M"\IP'08F X#UWTU$+IO!9(7SR!\?( B,/R),BSQGB(Z^X8T
ML?12;2;Z#*^X?(&%9,W02/PQ(D,Z@*Y6=\-K#1T057U+27V#K:357%_::M9!
M6LU*:*M9!FMK6$H_&WANJX'([<6]>\?^]_(&:O_0IYJ0^/N:@YG7U?%%YQ7I
MR)/B0M)A'J)RE(GG]U%HLDX\6].,YAL;X3*3":JW&"'61@VTI5$!:VF4(%HL
M(D3KD@(LAX'UPN#Z':AUW0+D;DY [>$%=+XA/^B#8NX8(M(N&^+RSVC3H,>4
MA;AQ(931S\'P.^ADF8U<J6W 5]<9T.(&#5+=J$0T6*6(YB81LMG*1[4TUJ!;
M+4OI9T.-RW= [+P9*!S[7^ON 0S>08_J J-NFL*3+S3$9I\TI9=,:_.Q0Y(R
M1A</R;>Q"#(3C:;5D:OJ% 2A68)56$68NB8^VF:KQMB:.-B6QBILBV4I ?8+
MP^Y/ -]Y%9 <V Q4SH[M[>H.ZKP"[IO](ZY9P^+/V6+2YQO3"\<-N=@>10FC
M10BO:>#B9#HF12NG,>MJRVO,-22IE4O0V]B$)AL3;[-5$IJME826QJ7TTL!V
M& 0'7OS?_R:@V>_8WBZN3QL\_>Y8_4(OMX9&G^Z(2SK<G%HP5)^-Z5 7T1LE
MT!H]'RU3<$A:$9->5TWGFEE4L95!T=AH%$LSM=QFHY*;K51R2^-2^MD@=%H%
MY/LV JW3+E#O[/)#H[OWK5;?H(M=H1$G>^+B)MM2\GLM69AF?0&]3E'&4]8B
MI;5\O*::2ZMCLJO,-*;02F:H; 1&0S.!WF0C5C0WD6C-UJ4$JE:_"ZH<!M&^
M;X%BSP:@W[L3-.S?_ZC9S>-ZIZ_?^8&PH/F!F-C1SJ3\SJ8,M*4^KT*K+>%)
MY' I3XS5, 7E1DH-RTS@\JT8CL*&XM39D%4V&X9I:\)6-EN7TL^&VKW? -7N
M]<"X9SMH=-IWK]W5Y6J?C\>9B7"OF9&HF(&>Q+R6UC1476,.35Y75,W70L4L
M)5I-D9(,>#&C 26J;H0)I4UE H.M5&!K@E8W6^&<EL:E!#@. \=AD.S^&FAV
MK@.F75N?->_==;O;>=^E4=_])V="/"?&#T;;!^)S&KM2D9J6;(JHL8!355]6
M2]4CE7@-08=0T>K+%!QSD5S<F"_76?/DS=;"VI;&$D&+92D!KL-0O>L3(-NQ
M$N@<^]^R8]/CCEW;;@P=V'YVUG_KD?E ]Z'IB*C6T=AL8W\R7&K/+*]NS6-7
M-)4(\1:X#&'":4KK*(8"([L^QR!JR#1HS.G&)G.6IJTA5[ZT0+7#P-_Y'Z#8
M^A4P;OD.V+:NN]N[8_V%J0/K%A8]-T\N!KIU'PV/M!R*R52-)D+Y@^E$1D].
M);&KB(=HAXI+6C&*O.9R3::-I4^S"8W)-G5=DJVQ+MG249=F7%J YS"(MG\,
MU)N^! T;OWG<L6'5E=&MWRZ<V//MU%G7'?UG?+R:3X9$&HY%I=7.))2R)E.Q
MY-%L&G*XL*ID$,+/Z\>(,_K*92F]+&5"KU =UZO2Q/8V:F*[>S3QK=W:I01J
M'(87]W)TZS\#36N_O-6_YHO%HQL_GCJ[8VW?I?W[FL][^.M/^\;6G@S)8AV/
M*B4=3<0@9S/*2P[G,W(/0:HR)]"\U#&R(&FD4I0PS!/'#4LEL<-Z1RWBJ*%>
MV5(" H=!L>Y?H'[U1X\ZO_[HW*&5'QPZL^:SOJM;-]JN[G'1778)KKWHG< Z
M'YA#/!M>AC@5ARI92"?F'<VG9LZ6O=C^K.1#Q*J$R0INW$05+V9"4!,]+N='
MC1OY!\=M2PJ(' ;-=^\#VXI_7!WY^*\SIS[Y>]_5[U;:;F_:IKNURT-TTSF,
M><,KD7@],!MQZ6!Q\=D$>-ZI3$SFB0)"VGP9.>D8DIIP!%\1.TNAQQRNK(R:
MX3 C9X2LB&D%.WS:L*2 ]+L_@_HO_W*OYX,_S9UX[P_]5S_YE^W!M]]I'V[<
M)7JPRXOYT#F<^, G 7$K-*/D:DQ^SL6DDHQSF="4,P6(I%.EZ/A%!#;V)!8?
M?8)$.+A (T8>9Y+"Y[GDL&.B\M!C<LI2 IHOWWG6\L\_S!WZXV\'KKSWQZ:'
MG_Q'^^S;M<+GF_94@CU>Q.=NH8A' 3$E=R.2<V[%9J1=3\Y)NI)9$'\YORCV
M8DE)] 58V<'S*$C$.3PT_"P9'G:6A@@]PT0&GZY&!9T6+BG0\(_?'AY\YS<#
M<__SVZ:'?_N+!GSZF0!\MZX2;-E- /O<$< KH/A9<'CVX\CHU =Q"8EW4Y)C
M[V2F1MW*2X^\6909?J,L*^PZ/"?D&CHW^!H^+^@J.3_P*BT_X JSP/\RIW I
MS77^X:W^T;??LAU_Y[\UX/V_"< 7GU>"M6L)8/L..' ^4 1\/;- L'\RB R.
M>Q8;'OTD.3+RAXRHL,<Y,2&/"F*#'Y;$!3Z Q <\0"3XWT<G^MW#)_G>(R7Y
MW*4E>]^M3%E*?3V_?ZOIT!_>TES_X^\%X(._5X*O/B6 ]:O@8->F0N"Z,P-X
M.R6"(-<8$.$1"6*\0T&B;S!(\P\$68X?W[F!?J @R!>4!'L#2(@7@(=X/D>%
M>CS'AKD_(X:[/:,LJ:;AW[VE.?:[WPC NW]@@ __2@!??P0#&U?D@UVKT\"!
M#?' <^M!X+\S%(3N#@)1^_Q!G),O2#K@#=*</4&FBP?(<?S@R7=U T5NKJ#$
MW05 W)T!W., 0'OL!SC/I02PW[P#L-O_"3#N7P&*WWI #]T-&%$>@)X8_)R2
M$?.(D)]V!PW-NP''E5XIHR(N%K&PY_)YA#.Y(O+I;!GU5*:Z8C'=0#^9UE!Y
M(M7&/)'2P5Q([F<M)(^S#J<<8DVF3;^R-X;_90:<PX!S^PK0?->#RI#=@'G0
M'53&!SVO2(MY1,Y-NX,KR[N.Q)9=AE*0%TJ8N'.%U:0S>2+*J1P9;3%333^1
M8:@\D69F+J0VLX^G=#D:K#J6,E4UF3;%'DV?JGI5 /?2\ $@NJX =)]U@!V\
M"U2%NP%63!"H3(Y^1,M.O4,LSKN.095=1I"0YR$,_)EB#OE4@8!V,E?*.)&E
M9BYD&MC'TRU5\VFMW&.IO=QC*>/54^D3W*&,B>J^S/%7!O . ]YA(+NL $SO
M=8 3L!-P0]T )RH0L!.B'C,R4NY2"O*N$V!EE]%XU'D8C7"FE$U9+.333^1)
MF,>S557SF4;NL?3&ZJ-I';RCJ4,UA]+':H8SQVIZLL;X'=FCKPP0' :"PT!Q
M7@'87M^_? [""W8%U1'^@!MW\#$K-?DN/3?W1GE9Z64<!G4.22&<AC"I)XMY
MC(5\,7L^1\4]FE7'.Y+1Q)]+ZQ;,I(\*1C)'!3W9(\*VG!%1<^ZK>VD@.@PT
MYR\!Q_-[4..S _ #G $_U _41$?^P$U*NL?*S+E1451RF81$GL.0"*?@#.J)
MTNK*XX6UG*.Y*MY<5CU_-J-%>#A]0#2:-2SJS1ZN;<\=$EOSAL3F_%<'B%__
M:* ?^!)4>ZP%?*_M0.AW (B"?8$P,OP)/R[A/C<MZR8SM_@*%8(\3\ 13J%H
MM!,0#O-8D8A[.$_)G\JI$XUGV<2CF;V2WIQ!25ONH-2:/R"M+QB0&@I?'2 Y
M#"2'H7+_EX[]OP8(/;8!L?=^( GP!I*PT">U,7'W!,D9U[E9A1<K2^"G*6C\
M<7PY=0;)9$V4U?"&BZ3"@7RMN"?/++/G=LA;\_KEEH)^15UAOT);U"]7%;^Z
MEP;RM@\ T^D+P'=9#6K=M@"IYSX@]_=\+@\)?B"+BKXI24B])$S/.\TM@LQ7
M(K"'RHG4$6P%NQ_!J;%#1+7M)4II<Z%182UH5IH+>E6&HEZ5NJ17)2_M4TK+
M7AT@_V1@.PP"Y]5 XK(9R#WV J6O^Q-U<,!=5>3!J\JXI+.RM.P%46')(0X4
M.UR!I?:0*.QV+)-O0]2(S5"IO+Y4J]*76-3:$KM&4=JCD4)ZU")HKUH [56]
MJI>&<H>!L^]S(-K_'9 Y;P)*]]U X^WZ2!?H=U,?'G91'QMW2I.>?EB:5SQ:
M4X;I8:&H;51BE95(Y]=C.1(=4J10P51J.=2DE4#:=2)HMY8/[];R$#T:+J)'
M_:I ^4\&[M[/0>V+[;U_(U"[[GRN]W*^7Q?@?<T4%GRN(2;JN#$M95*94]PO
M*L:T<^%4:R6NJHY"%6B(+(D<RU?6HF4: =*@XR&;]5RD75^%LNO8Z&X-"]WS
MREX:* X#;^]G0+SW6Z!TV@!T+CN>UGDXW6GP\[AL#?4_;8L-FVU(3A[19!79
MI85H&Q]*K:_"5&D89(&,PI (2=7*:KQ$4X75ZIA8JYZ![=+3<79=!:Y;ZTCS
MJ@#%8: Z##5[/@/2/8[MO6\=,!S8]KC!?>\MJZ_+Q=80KY-M,<%3C4G)_8;,
MPC9%/KJAMHRBY2'9,C:!+V!42+@TCI)9+M)4D-1Z"LEL().Z'-GU9*)=2R9V
M:U[52P-MZP= L/M3('NQO?=^#^KV;WG8Z+;K>JN/TSE[J.NQKJB@45MBDKT^
MO;!)DXLRR(HI"B&<+>3A^)PJBH3!9"DI=,?74J'0XVCU!DQ%AP%+Z]+C*'8M
MCM+]R@#58: [#,)=GP+Y3L?VWKT&-.S;>*_99=N5+N]=9P9#]LWT1 8.ML8G
MMEE2"TS&;*1:75A>*X6RN")T#8-/%I=75RKP53P-BBW3P5E&/935:H Q[7H$
MHUN+I'=K7A6@.0R,+?\$HAV? .4.Q_;>^=W3QCWK;K<?V'2QWWO+R=' O1,#
M$0$]G7$)3<TI>?J&+(344$#FJ<N8E7(DKUQ"J,6**N0( 5==5B/6%O-TNL(:
MF[Z(9]>55G5KR]@]FE?UTL#<_$\@WO8?H-[V):C?_LWCYEVK;_3L7WM^W'O-
MT2F_W</#8?[MO3%QIO:D7*4M RXPYQ%9QA(&10OG8E4X(5Q!E9;(V,H"J4B=
M*]%HLR561]V:/$&/NJ#FU8&*E>^ JDW_ -(M'P'=EL^!9<M7]SNW?WUE>-_*
M4W,>WQR:]=W5.Q'JVS04%:OK2<P6=Z1!JYIS\-3&H@I< [0*7H?A%QO(M7EZ
MIBQ3*U"D:56J%*U%E:+K5:8K^I29TE<'Z [#BSN4\DT? N/&3YXW;_CL5O_F
MS\[.[/WXZ$F7E2/'?79TS 1[FR8.1LN'XS-Y?:FE%?8L#+ZCH!S>6E99W(SB
MYC:1^!G62E%R(U^28%%*XQL;9''6'FE"_8 L2?_J0*7#(%C_-Z!:_P%H6/OA
MP\XU'UZ<6/_!L9/;_SU^UOF;GE,^VZS'@SPULQ&1PJG8M,JQY$+B<"8",9!/
M*.XKI>;T(BO3NXE5279&=9R=SX^V*P4'[0V"R.YNP<'V$6&T;43TJ@#381!_
M_U>@6^/8_]_\X_K0RK_-+WS[[MBY+?_IOK!O;=-9]SVZ4[[>M2="(UCST<GD
MN<1<Y.&,LI+I/%3.5"DA;1)5GCA!JHB=J*P\.,YG18PKV6$39G;H9 \[='2J
M*JQ_DO.J -MAD*]^%YA6_N6^_=,_+\Y^](?Q<U__O?OJIB^M5W9OU%YTV2\Z
M[^7//!L813P3G@(_%9M3M)A2G'4R&YIRLA@5?P*!C5X@$B*/,\CAQWB4T*-2
M:O!1@R,;+>CH,#5H;NZ5@>H5[P#MRO]YWOSQ.Q<F_OK?$V<_>-M^8^4'C;<V
M?*.YL7.;\/H!5^8UKT#BM< H^-6(I,*K,9D95Y+RDB]E%<=?*"J+.0>''3R#
M0T2<HJ)"%UF8D)-\7-!)&2[PA X?<*+)4=<K ^+/?P],'_WWY?X__W;JV!__
MRW[C7W^R/%CYL?K^^M6"^SMW5-YW=B/<]PZ WP^*++P?$9=Y-S8E^59*1OSU
M[.SHJT5YD5>@A>&7,$6A%TDEP1<JRH+.5T$"S@F@_N>D,+^S.KCO6=,K YJ/
M_^MJ^Y]^,S[VSEO=I_[T._,/_WY/^?3KS_C/-JQE/-N]D_#<Q04&?'P+0'!(
MYI/(R*1'<;%Q#U(3HNYE)T?<*4@-NUV6'G(+F1%T$Y<5<*,\V_\Z(\?W6E6N
MSU5^GO=5:;[7%57!JWIH^?-;8[UOO]5UZ.VW&FZ^^WL%^.CO->#;S^E@TUH\
MV+L=!MR<\H&O>P8(]DT$D8$QS^-"(Y^FA(<]R8H,^2$_*NAQ24S (VBLWT-4
MG.\#?+SW_?($K_OT1,][54D>=_G)[G=K4U[5>-M_O]4Q^/NW&H[^X3=R\-[;
M//#I^Q5@]6<XL/4[*'#:E ?<=J8!'Z=X$.P2!2(]PD&L5PA(]@D$&7[^("?
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M?J 3J GW?%H=&_R G1)]JR(GY2JI-/<"&E-R&D9%+!2S<4?RA:3I' 5U,M-
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M_"N@;_\7J'FQ_P]\"Z1N&X#<>\<C9>"!6XIPKTORV.#3XK3H([R\M EF6=$
M!8VPX\F$5A2#:H555S:4BJN,Q>IJ76%#C;JP0Z L'!5(BD?YHI(Q/K]TO*:F
M=)SW2P'D%[\'Z WO@<IM_P("Q_Z7[/\&*%S7/5=Y;;NG\=]W31OF=DX;[;^@
M3(F<$N6D#7**"[OH"$1+.9Y@P=%H1A2;J84+. J(HD9::A34EK8(A:5#PIJR
M$6$U9%3 @8[QJZ!C-;_42P/686"]V+V.[2W=]S50.:]]HO78?-O@M^MR7<B!
MT_717K.:I(A1:69J3TUA80L;BC!78 @&<CE-A:]D2M$\K@@AX=? =4(NK$E4
M!>NK9<%'1$S$B)"!&!4P$&/\7PJ@' ;\^O< >\L'H';7)T"^]RN@V;_ZD=%M
MPTV3S_8+C<%[3U@.>DP9$B(&%!DI[:+\@L;J4KB!B22H:$2:A%S!Y!,X7"ZV
MEL]"JT4,E+FV MU=2T,/UU+1(R(*>E3PJEX:".O^ CB.[2W>^1^@W+T"Z)U6
MW3>Y?'_-ZKWI;&OP]J.V"/?1^OCP;DU:BDV:6U O*(:K.7"\A(FC\BNHS"H*
MF\L@"?A4@E)$QIO$1'RGF$ 8KB7@AT4$_(B0@!\5_%( [3"0OO\+J'9L;\F.
MCX%ZUQ?/C7N_OFMQ7GVYU6O=Z:[ S3.MX6Z#EMBP=D-*LEF9G:\5%\*D?"B>
MS\50JUAD)IU1R2VGU?#Q%)D(0S&*490V,9(R5(LJ'Q:AR2-"-'E4\$L!C,-0
MOO8OH&;S/X!LVT= N^.S)Z;=*VXU[__F0I?GJA.]?ILF.OX?9NXRK,D^_AO_
M26-W=Z*H-$AWUV ;@Q7;8&.C!H/1H[N[N[M$!17$P@ #\U(,4% Q4 1;\7.?
MU_7['_>#_PW>3^^#XP4>/OF\S^\9V_O+E&!\X:0CH;N#Q6QM=/>NJ>$%EY0'
M1N<4AR6EY<=E).2FY49EY16&9524!*<WEP6F]Y0'9%PK"TH;+ U.&2H.^;_X
M+T/RD>50K+06:HYN@A;5[=^/J^^:ZM/=,W'9;,\_5RP5KYVW,^H[3;$[=MS9
MN:'-U:N\T2LHK]8_*JU2D!A?&IT>69R<(RC(*0C(+RWVS6LHY>6=*//.NUSJ
MDS-8PL\:*O;+'"KZ&XA",Z0>7@:E2FN@3FDCM"MO^=QS=.N;B]I;QVX8[;@]
M9*%P:0!OT--/QK6>8C"JCG,\"]NY 1G-_(B$^N#XR)K(U)"JQ"R_BLP\[[+B
M0L_2NF*WTJX2U[*+)>XE0\7<@NM%7OG7"_\&HM&NEW%H&52@SZE&A75S7?(;
MIL\J;7@YI+%NY)[.MJ%;9G)GKV'UCUTBVM;WTVDEIUW<LTYZ^"4>\PF+; ^,
M#6X)3^8WQ6=X-:1GN]47YK'K:@J8=9V%SO7G"YFU-PK8%3<*..4W\O\&8M ,
MV0>70!5Z;[3*K/[><WCUN\NR*\?NJRZY,Z*U=>">J4S/+1O=ED$'3,6 (S7W
M/).3W.?F$WW:.SBDVS^2?R(TGML5F\PYEI;.["S(8G14YSAV=.12._M1PSGT
MIN$<1L/?01R:(?_ 8JA#ST?G@>4SY_8O'1\^('%O5&')M5'M37V/30YW/L!H
MU=PF6!;>H!#3KCFQ8BYSN"&7O/SYY_T$GN<$49RS,7'.?:F)M-[\%')O51JQ
MMSW=H>]LFOW9>VG$DW?32<?O9OP-)* 92J0DH4EJ\>^>78O>#&X1N_]LI^BU
MEW(KSHYK;3O^W/APPS-K]9(1.]/,!V2[N+L,NF"8[<J_R?7VO.'GSQX2A#@-
MQ80Y#J9&D0;S8^P'J^/L!MOC\$-GXW#7[\?A+SU*L#O_*/%O('6;&%3M0_O_
M#K&9"VM%'CU>+G3MU4Z)ODG9M<=>J^^N?VD@7SQNKIWQW,8\;M0>+WCF2.4_
M93$]'GNXN3SF>S%&!+Z41S'^Q$=I07:/"D)P(]4"VY&.4)O'9T-MGMP5V-P;
M"[,='@O_&\C=+ *-.T1^G5XM?._&$N3:JQ7"O5,[EW1,R6RJ?:\F5?1.7SG]
MK9E>[!L;BY!)>YS/))7D]MJ9SGSMQJ*]]G$EOP[VL'\=Q<6]3N;9O,[UL9XL
MYUM.-OE93)[P-W]]T=]\\JF_Q<28W]] Z7HAZ%PM=/?B(N3*[<7(F9E5HNVS
MNU94S\IL*YQ5DTZ;U5>)F377"YG%FOG,VMNXSE((SK/.).JLJR-QUIMA-QO@
MC)T-=\',Q+.MIM-=+3X6N)M_K/ P^]#H:?JAR]-DZAS7>.K*7T']"N3N:0ED
MX(H$<OK!(J3UYQKQJI^[5^?_E-V1^DO]4/1O ^7@.4MMWIRM$6>.8,'X0\90
M_CCA[/]P"/@Y+P?;7WXDZY\"BN6/:*KY]R2:Z;=,NLG70H;QUPHGHR_USH:?
M.YD&GT_\U8-CHLBEL^)(]W5QI.7)(J$*6"^9"_O6)H/"CBC0/!B$=G\O,%=C
M T:'!G8&)"";V '#' ML2PQX6%N!#\8" FW-( QK C$X(TC&&T"FG?Z? H+>
M7)F][ER=@^[OQK^ZW".*G+PDBC3=%4/*9I8)Y\#F14EP8$TD*&T+ ,U]GJ!_
MF 4F"E2P4K$'G#H.B%H8H.E8 E//'%P-3(%K: R^1H809*P/829Z$&.J TEF
MVI!AK@6Y%II08JD)Y7_5W2N"- X)(R6/19 L6"F<"-LD(T!ZI1_(;W0'U1U.
MH+V7#(8'\6!^V 9L92W!7L$,*(K&0%<V!):*/K@>U0.NJ@[XJFE!@+HF"#0T
M($I3#>*U5"%%ZRAD:ZM [E\U74*0DCL(DOY:&(F#5<("V"+&@[U+.'!H%0T4
M-MB#VA9;T-EN"<:[3,%JCQ%@]^F#O90ND ]H ^V@)CA+JP/[D!JX'SX*7H=5
M@']$&0)EE"!41@&B9.4A04X>DOX*W/:*@JO"8O#07@O^QMLAQ.H@".P4(9BJ
M!?XNQL#C6H%G$![<8DA_7%)IOYQSG7XP2EC?:56<;XX-;E\IK>Y?R%T>GTFG
MN+/$\]Q9AVM>,P[WO#\ZC'F_(4YXCY->>3^A3O[5_QL9]J 9Y!<#%\T08+0=
M!%8'( RO" **)@0QC<#7TQJ\ NW /8HTQTFF_6+E./]P*G;Y1J]T_>I8[_Z%
MVNKQF=+%G26=]IHAGO>>(0[R/CD\Y+TG/N>](DWPQBBO>0^ID[R'C@L#=S2#
M&YJ!I[D6@@VV083% 8C$*4 $";V\G(P@P,T:>'P[X(:3Y]P2Z3]=LIC?F86<
MKXP*]R^T>L]9QU:O&4J7]PSY-.\3Z:+/-/&&[P?B4]])T@O^<\I+WT>.KWR'
M::_Y?P,>: 9W-(.OQEH(U=\&4>92$&.K -%$#8B@&T$(QPKX/#OP%I!_>\0S
M?G R7+ZQ"ER_.)=[S#+JO&9H+;Q/U"Z?:<H9_D?R@-]'TK#?6]*H_PO*"__'
MM)=^M^FO_ <9+P/^!CQWBX*'_!+P5U\+$7K;_MN+2<#(0[R]!L0X&D*XBQ4$
M<NW -XCRFQOC],,ME?V5G>?^F5G&G7&JY7VBM_A^=#SN]X':Z_^!?"5@BOP@
M\"5E+/ );3SP#GTB<(@Q$73)>3SX;X"+9O!$,P2JKH%HG:V0:+(?DJWE(-E.
M#1(H!A#M; FA[GCP]Z/\]HEP^NZ9Q/[BFN,QZU+B_<FYQO<CH\7O ^UXP!3U
M;-![RE#P).5)\#/:\^ [C/&00:<7@DO.+T+/LIZ']OW%?QFX<DL@Y.@:B-/>
M"BE&^R#=4@;2<:J02M*#!(8%1+OB?@IXY&_^ J=97CQGVC/#<\JUD/?6I=)O
MTKDQ\!7C6/ $_4S("]H5P1AM)/2>T_/00>>QL(O,L? ^E]&(;O;?@=<N4?!"
M,X2IK(9$S2V0\>]G4BR/0#96!;*(NI!&-_N1X(+]',4E?10$,=X%1'->^Z1P
M)SQS?<?<2@.>LNN"1UAM@@?./6%WG2Y&W':Z&SG('(T\SWH6=8;]-.H$YVET
MA^O?@3>:P4=V"40JK884C<V0;; ;\BT.0;ZM$N39:_W,IAK/IC$Q'Q+<'2:C
M_.CC@G#.LX!$[B.?3/Y=;F'0L'MEZ'5.8\0UEV-15UA]T0.LH9CS+D]B3G$>
MQW:Y/HYM<W\<V^CQ=\!#,_!E%D,,^KXZ77T3Y!GL@B*S@U!DK?"["*_QI8!L
M^"''R>IUNJO=\T1?Q\=1 I>[@EBO&P&I?M=\<H,'O$K#SWO41IUU:XT]X]H3
M?\KU4D*WZ\.$#O='"<T>CQ+J/1\E5'N-Q/\-\':*@O_AQ1"GL JRU#="H?Y.
M*#&1@C)+V>]E6-7I4@?=-T4TLQ>Y;.Q(NC?E=GR@RV!DI-> (-'_7$"&X R_
M(**;5Q%SW*LQOM.S*['-HS^IQ>-6<@/WG^0:KX=)%=X/DTIYCQ+_!GS0#(&'
M%J,O+2LA1VT#%.MMAW*C?7.5YD<^5]DHO:\B:$Y44(R>%+,P=[(]*8,I?BX7
MXT*]^B)C_;L%J:%=@3F1;7XE<<V^M8GUO+;D6N_3J=7>UU(K>/=32WP?I!3Q
M'R3G\Q\F_0WXHAF"I1=!,MI[\]360REZ?U8:[/E98RK]J<Y:?K(>K_J\GJ)[
MO]S)>JC G7PQT\>E-SG8ZV1L5$!'9&)H<VAF5%U085Q50&52N5]S:@G_9%H1
M?R"]P.]>6J[__=3L@/NI60$/DO_FOPR"@XL@%<U0H+H.RK6V0(W>KF\-QE)3
MS99'7K9B%9\T$76&JQE6ETM<26=SO5DGTP.\VI/"_1MCXT)K(M.BRL/RXHM#
MRI+S@QK2<@*[TK,"SV=D!-W-2 ^^EYX6?#\U)>1!RM\ ?X<HA!U8!&DR:.]5
M70N5FIN@7F?'YV;#O6_;S0^^Z+*5>=!FKSU43[,Z7\$FG2KDLCJS_;A-:0+_
MZJ3HT+*XY*C"Z.SXG(CBY(RPVK34T(Z,I-"^S,2PX<R$L+OI"6'WTN+#[J?^
MS7\9(M".DX%F*$6?4]7J&W\W:FW]U*Z_\_5QT[VCW=:';W?::5UI<K3LJV81
MCY=Z,)OS?;DUV<'^96F1@H+DA*BL^(SXM-C"Y,3HJK2XJ-:,Z*@SF5%1UU%W
M,Z*B[J5'1=Y/_1OP0S-$[9>$K"/+H!Q]3M6JKO_1HK'Y0Y?.MI>GC'>,G+$X
M=.,X7O-"&\6BI][9H;W2S;FNA.=9GA_@5Y =)LC*B(M*24V+CT_*2XY.J$@+
MCV_."(WOR0R)OY8IB+^;(8B[EQX:>S_U;_[+$+-/$G*.+(4*Y970H++V:[OJ
MAG?=6AM?]!MMNG_63/IJ#TZCKY-LWM7L9-]4QW&JK/3R*"SQXV<5"$)2<J,C
MX[*2XR(S<I(%:65I0:D-&?XI)S+YJ9<S_5+O9O@GWTL/3+R?^C?@OUT$XO9*
M0/YAM'LKK(!FQ54S7<IK)GO5USP;T-DP?-[TX*4SMFJG3A!-VSKH=K5-;$9)
MG:=[3A7?-[4L.#BN.#(BHB Q-B0O*]$_ISC5)[LNW2N[*X.;?1%U-]T[\UZ:
M3]K]U+^! #1#XFX)*$2?4[5RRWZWR2[_V"._?.+BT66/!C76#PT82_7WVZAV
MG78P:3Q!PY=WL&AY+>ZN:0T^O+C:P,"(JO"PX/+X:'YI>H)7<6&R1U%-JFM1
M1QJ[^!SJ?IIKP?U4CYP'*7\#@6B&%+1[EQZ2A(;#B[]W22]YVW]HT=AU!?';
M-]76#5PSVG?JDK5*6S_!J/H,%5MXTIF:<<R5'=_N[171XN\?U!@J\*V/B>36
MIL:ZUN0GL*JKDIRKVU(8U6=3Z#5WDITK_DEFE3Q,^AL(WB8"Z3O%H.*@!+1(
M2<ST[!5_>66OZ*/[4F)#=X^NZ;]IL*=KT%*I?@"O7W*>C,GJ<R(EGN8P([NY
M'D''^3Z^QT("/3NB0SGMR9'.;;DQM-:*.&IK:SRYM3>>U#8<3VD:B:?5_AV$
MH;T[![TN:_>+S77N%'U_?K/(Z-T-0L-/]HE>>J2\LN>^WJZ680OYBNM8G=QK
M1,OD ;I]U$47>O Y#[;O65]/C]Y@7_:9J "GTTDACJ=RPD@]Y1$./2V1A%-G
M(NU.WXHDG'P6Y=#Q-,JA?6$0LT$8"K<*0],.D2^GU@D_N[$4&1Y=C0R,[1<[
M,ZJRO..I[K::1V9'"N[;:J3>=C"-ON6(#;G.(OD.N3,\KOFP7:X&>3"N1'I3
M+R?QB9=S_ D#Y8&XRRU!V,MG@FVOW JRO30>C.M](?@;2%HK!.4;A:!CK=##
MBXN1FVC_O_1RK="IB?V2;1-*:VI>Z.PL'#,YDOX,HQ;[A& 8,D*U]'W$Q'O\
MXTYR>>!#8]P/8E+N1;$=[B6[V=W+]<3>J^#:W&OULK[?ZVWU8-C+ZOZDM_7U
M-SY_ UFKA*!^%?+PU")DZ+(D<N'^8J3[[7J1EK=22ZO>*&TLF-3>F_K:1"[Z
ME;5Z\$N\ 6^"9.XZP;!ACG/L:./>1-)X((4P'D'#C2<ZV8QG,ZTF2ED6$XUL
M\Y<GV68O+[--7XVRS<?>L\U'%P8ERY#'G>+(8)\$TC\H@9P868PT?=PD5C%]
M8$7>M/*6E&F=_5'3)O)!T]9JWA_QNIR/)&/&1[H%]2,;X_"1B\5_]+.SG0ZU
MMYZ.)5I,IY--/Q52C#]5.QK.M-,,9L[0]&>OT_5F7Z,F%_2L7A@9.BF&])T7
M0X[=DD#JWRX3*OVV52+G^Z'52=]5MD;^T-T?^--4UNNGE0K[)TZ3_M-!E_R+
M9DCXQ3+!_O(PP_SVL;#X'61E^CL28S279&LPEXW5^U."T_E3A]<"](7F3R]!
M\\\-U,T%W>P01OI.BR*=5T21V@<22/'<2N%,V+DH 8ZLCD [MS_H[/$$(VD6
M6,@Y@JVR ]BKXH"J@0%G;4O@Z)H!5\\8_ P,0&"H"S'&6I!BH@DYIAI0:J8.
MM>9JT&JA"J?^ZNP)8:3CG#!2<U,$R7\FAJ3#6N$XV",9"C(K?4%YHQMH;G<"
M_;UD,#U@!]:';0 O:PDD>5.@*1H!4UD?W%1TP/LH6I#5-$"@K@;1&JJ0K*D"
MV5K*4*2M!)7:BM"D\S>=IX60ZJL(DO< 09(_+Q**AO7"0;!3W L.+&6#W&H:
M'-W@ -I;L&"XPQ+,=YN"S5Y#L-NO!R2I?_<?-( IK0ZNAU2!^]_>@Q($RRA"
MY'_[#G*0+B<#>?)'H$SA;VHNH/-O(4C"*()$P%(A/U@M[ 8;19Q@EP0)#B[!
M@?P**U!=;0K:ZPS <(,.F&_2!,QF-<!M.0H.6Y6!LDT1&-OE@;5##MQVRH#W
MSB/@O^L0"'9+0]2> Y"P1PHR]OX-T/>) EE.'!CJR\!-;SUXF>\ 'O8@>)$5
MP)VI#FRN'C"#38 >8PG4-!L@Y>' H8P ]K4.8-=, GPG&7#=%,">I?ZQO>+X
MV_8V[9?-&.V[S1O:K.T4[0-NFC:)_T2;(,PLZ']G<%);!AZZZX%GM@-\; \"
MCZ0 GL[JP/'4 U:@"3"BK< QU1;(>7@@EMJ#?0T1"$UDL.ND +Z;^@?7[SB'
MO4+[;7N7_M/F!?VK[1OZ)^P'^CO\1_I+PB?Z<_N9!0$#S4!!,[!4EP%79QWP
M37: G\T!X#O(@S=#'=S=](#M;PK.D59 3\8"-<<.2"4.X%!- OLFRA]"A^,<
MOILVA^NG_\9=8_S$/G#Z;COA-(M]ZS2%_^#TBO#1:<QAVNFQPR?GA8 3FH$J
M*PYLE67 TUX' <;;(=#Z  00Y(%/4P<N1P_<?$W!)<P:G!)Q0,LB *68!*0J
MRA^'1L<Y^P[Z;[MNQB_\.:=?N$'G'[@1YA?L*^9'_#OF).$#\[G#1^8CXC3K
M+FG:92'@M%<4'-$,;LK+@*^Y#H(-MX/ 4@I"\'(00%$#'Y8>>'B9 B?$&IAQ
M.*!G. "UD/R'7.DX1VR@_W;H</I%Z''^:7>>^0-_@_4-]\QE!O_:Y2WAG<L+
MX@>7$=(']FWR1\YURO2"P!G-0),1!T_%I1"@_C][,1'F^R$<*P<"LBH$..N!
MMX<I> 1@@!V%!^=4XAP]C_*;6D[[2:YW^DYL8WYS..GRQ?X<^S-AB//)[BEG
MBO#&=9SXGC-"GG(=IGQPNT;]X#[@N#!@[A$%QA%Q\%98"B%HOXC4W0HQ9OL@
MQE8&(HE'0<#0!7]74_#VQ?SR"+?[SDDD?65F.<XRBAF?:-7,:6JSRP=R%^<]
MJ=?M+?&*^R3QH?L$<=)]A/S.XQ9URO.JXWON!=I[[EGZ>Z^%  O-P#PD#KYR
M2R%,90W$ZFR!1-.]D(@Y G'V*A#EJ/U;X&+\W=_;^C,OQ&[:,Y8TY9I&>\O*
M=YYT*G=Y1:]W'7=L=W]./>4Q1KGD^8QRE_N(^HI[T_&=UV7:6UX_XRWOM-,;
MGY/."P,7- /[H#@$R"R!*.75D*B]&5)-=D.J]2%(L5/\G4#1_!K--/HD\+!Z
M'Q" G_2))$UPD^C/W;*93UV*.2/,:O<'3BW<N_03WL.T?MY-V@V?(=H+WTN,
M2=\^ITE^-_,U_QCK-;_=96' WBT*;E)B$/QO_U=:!:E:FR#3:"=D61V8R\3)
M?TTCJ4\G,O3?1KM:O SCX\8"0TDCOG'T>]QTEV'W?+?KG'+N-9=ZWA5FN^\E
MYU-^%YPN^Y]S&@DXS7P5T,5Z&=#F\C*@B?,RH('S:D'_9?#<+P:ATHLA46DE
M9&IN@%STWLBWV/\]#ROS*<=!Y6V&H\Y$$MOT:0S/YGYH$.E68!1CT#>)?=DK
MR^."1Y%WOUN5;R^GR?\4^WC@29=S0<==AH,[V>/!S9SQX'JW\>!J]XF@RK\
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MS-J_Q7ZU?X[[YC!B]YUXF_"==&L!_V4@'18#YA$)X"HN S^M=1!HO T",/N
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M.O\R@B3?09#P46$D"%8)><$F83;L%J7#80D2*"W%@^8*#!BL,0>S=2: V6
M=IMT@;Q%&QA;-<!ENQIX[E !_DXE"-TE#W%[9"%S[Q$HWG<8:O<?@O;]TG!&
MZB"<G5?=273^!73^300)>XP@?C\D$'=8(>0$ZX7)L%T$#_O%K$%&W R4)8U
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MTPGMKOFD%G8YI9'50*MC'F/4,/N=JIC#3A7,UTYEK"].12Y?& 7LK_0\SOR
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M@7ZW,NCUJX#>-170_><HZ+X\.J<[??2G[O>CW_1 Y2LZ!YVO^MX U-X:_I_
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M5*4JHQ95'O6ILFA"E4)+F@3:T<30F2:,GC1!#*#CQP@Z'DRBX\8<>DZLH.?
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M?TL;'_@H8[0?Y5;Z?@XWC0+,D#,XM!Z@;3- U4Z _/T *<?H(.(,$P2?XX'
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MPONQA\+S:8K*_6F)RO7Y&'&=>/0OG?, U>3^<TE^ IE],+EWU]\ K*X Z-\
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M<8,C:UZ])V=670!O>DVX8')UK$A"58IX;&6.5%1%B6QX>9U"2%FG<E#IF&I
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M$F#BJH]G0/G;@632#C](^D>!42=(_PQ@<8&!T5="Z%R30O-_RM#X3@<:WYM
M_?O!4/MA!.$*U1_]H7(]"BHWTJ!\HP3*-QLA_VDVY+=60G9K#Q1O?0WI3P^A
M>/,5%&^\_8=.TI^\&JC=!!12[BF4=SAI>Y\$1IX%K"\" Z\ !M< S1\8J-P4
M0OF.#/([JI#=U8'B76-(_["$PCT[2.XY0W3?!X+[$>#?3P7O?BF8^\W O;D$
MB=RGA]__FO@#>/#X']KHG\;VGT'M!E(/ 1&D[47:CJ0]E+1-OP4&_ BH_03(
M?P44'[%0>*D T4LY!"]5P7NI#;PP( 82UH0C\-*3""6H*7A)+Z*7M/F\I 7W
MBL1>D=!?IXFO_J%^\Z<S*!KS2*JY-VD[DO;@_P'&UP'M6X#*;Z1]!Q!1V/PW
M ,/QJ!$6$S+@O3*A3O>ZA#%A20PG1A-!!+T4.6J*.*H'1Y./HT7'T:!SV_^!
MTQM$F-$CR.MJF(-3L0:G[ 1.[L=PLBB&DZ8QG$(144TT$6W$3**+6,APDJ5$
M'SC)>F(KL8<XBO>2"_A;<A.O)??Q0O(2SR0<GBIP>*+ ,4^D_Q?.T!2<H3$X
M T*'8M$:0K$X@E/SIGC"&4XYF>'D>40E44^T$-.)3J*;6$RL8-[+US!_RS<Q
M;^4[\49^"'_)S^*%_$<\E=_#(_D+/)!SS'TECKG7CS+'_/$%G(DA.!/R_,:$
M(7EN0TNJRPBJBSO%$\QP&O$,IY[%<&JE1"WS7JV9^5MM"O-&=2;S6K6+^4NU
MAWFINI1YH;J*>:ZZ@7FFNIUYHGJ ^5/U-/-0]3OF#[6[S&VU%\QOZASSBSK'
M_JSQD5M?P T< &X0^7\S37 #*8Y!-"9FMA23,\7C#TX_FGDW((UYK5O O-*M
M8I[KC&>>ZK0P3W2F,X]U9C./=.8S#W06,_=U5C!_Z*QC[NIL9>[H[&-^USG)
M_*ISC?E)]RYS?< +]KL!''M-C^-=);[1X_A??P%G2?I6Y/\M5<$-T29H3(8,
MIJ\=\<[<"Z\&AC'/3!.9QR;9S /C4N8/XUKFCG$3\[MQ*_.;<3OSB]%<YF>C
M'N8GHZ7,3:/5S'7CS<P/QGO8[XR/L]>,OV&OF-QA+YH\YYTSY?AG3#G!:5-.
M>.H_<$-(VUH)G"WY_N'J!-5EV$"\L;7%4VL7/!@2@#M6,<RO5FG,+<L"YH9E
M)?.#Q3CF?Q83V6L64]EO+#K8*Q;S>)<M%O$N6:S@7;!8SSMGL9UWUN(0_[3%
M!?Y)RU_X1ZV>" ]9O1<=L.+$^SZQUXJ3?(:S)?UA4G .,G C*8Y1&GCM:(#'
M]A:X,]P>MX9YXL=A8;AFE\A\99?-7K0M8<_;5O/.VH[GG;:9Q#]I,XU_PF:V
MX)C-?,%1FU[A89M5PH,VFX4';/:*]MF<%NVQO2'::?M(LLWVK<(66TZZZ1,;
MOX ;KDCZ0G N$EK2BGCGJHS'+AKX;90A?APU%%\[N>"B4P!S9E0T<V)4*GMT
M9![OL&,9_Z!CC6"_0X-PKT.+:+?#=-$N^T[Q#OL>R7;[99*M]NL4-MOOD&ZR
M/RK=8']5NM;AGN(JA[]D?0ZT@APY^?+_P#F*P#FSX-QY>.HIP!^>$OSN)L=W
MHS5QR=T<IST<<,S#FSGH$<;N=4_@[7++X.\872#<ZEHAVNQ:)][DTB39X-*J
ML,ZY7;K6N4MQM?-B69_S*MD*IRWRY<X'E)8Z7U3J=;ZMO-#EA4J/"Z>R@.C^
M#YP30_K 8Q_R?/[D__T%^,97@@L^JCCA9X*#_G;8X^_&;/<+9+?X1O,W^*0(
MUGEGBU9[%8O[/*L45GB.DR[SF*"XU&.*K->]0VF1>[=RC_LRE6[W#:KSW?>H
M=KF?49OC_K/:;(]GZAT>G/HL8J8GI_8E_4?+K[V!W\A_?T=;_*4P%F=#A#@>
MI(3](?K8&3H4FT.=F/4AONSJX##^RJ!XX;+ ='%O0)YDD7^IM,>O6M;M.UX^
MSW>2TER?Z2J=/G-5.WP6J\WT6:,^PV>'QG2?$YK3?*YK3O']4[/5]QW!:4[V
MXS2^A'.C5Q?E?X.\[^4HX!1YOR-1/.R/4,3V2!ULC++$FB@'9D6D)[LD(HB_
M*#Q:N" L63PO-$MA;DBAXNS@"OFLH#JE]J FE>F!;:I3 SO4VP)Z-"8']&E-
M"MBJ/3'@B/:$P&]UF@(?:C<&_4UP6@T?T?P,YP7<#@:^)?VSY/N.)%"?'<]@
M1ZP$&^(TL2I^();%#V,6QXUFNV/]^5TQ$<+.Z'CQK,@TA1F1N8K3(DKD4\+'
M*$\.JU>=%-:B-B&T7:,I=+Y60^@R[?J033KC0@_JUH5>T:T-O:];&_9&IR:,
MZT>;T/K,7[[ +^' 5W'D.9/)^Z>2UZ!7[J9$(58EJ6%IL@D6)MM@?I(SVYGH
MPYN5$"*<'A\CGA*7K- :FZ4X*:90/B&Z0KDQNDYU?%2S^KC(J9IUD7.U:R*7
MZ(R)7*];&;EO0$7D1;WRR+L#RJ->ZY9'<?WH$-J?>1Q XT U.)](-2#?MSN3
M^NP,ZG-362Q+4\;"= /,2Q^"V>DCF?943][4E"#!Y.1(T<2D!(7FQ'3%AH0\
M>7U\J7)=?+5J35R#^IBX-LW*V-G:9;&+=$MCUPXHCMVC5Q1[7K\P]K9>8=RK
M 85QG"ZA4_0%]VD<OHLE[T_Y'R#][3GD_8D5=+\H4XYY67J8G6V)&5GVS)1,
M-UY+AK^@.3U<U) 6)QF7FB*M3<F652<7*5<E5ZJ6)]6KER:U:!4GSM(N3.S1
MS4]<K9>;N$L_)_$,\1OQ4B\GD1M Z!(ZG[E+<_$;F@,G*/>]Y+^WY)/W)P_<
M2W',SY5A=IX.9N2;HRUO&#,IUY5MRO'EUV>'".NRHB75F4G2RHP,67E&@5))
M>KEJ4=I8]8*TB9IYJ>TZ.:G=NEFI?7H9J3OTTU-/$[\2+_324[D!A&[&%_P6
M2>N!YL&1;/+^I+V!6IX5Q *Z[RR48D:A)MJ*S#"QR)9I+'1BQQ5X\6OR@X15
M>9'B\KP$A9+<=%E13JY2?G:I2FYVC7IV5K-F9M9T[?3,^;JIF2OUDC.WZ2=E
MGB1^)I[K)65R Y(S.=TON45K\3S-@X/D?;>1]MIR\GQEY/GH?D:)&*VE:IA8
M9HR&LJ',V+*1;'6I!Z^R)$!06APN*BJ*4R@H2E7,+<R19Q<4JV04C%%+RV_4
M3,F;JIV4UZ6;D+M\0%SN%KW8W./ZL;D_$<_TXG(Y^AZG^R4_TCB<IK'?5TAS
MD?17D?_L(6;1?5N% !,J53"^R@!U55884V7/E%>Y\4HJ_02%%:&BO(H8279Y
MLC2S+$N>5E:HG%):J9I8,EXCOJ15*[9XCDYT\=(!D46;]2**CA+7B2?T]7O=
MR$*N'YW/7*5Q.$[S8!>UOQO& ,MK^\^ R'-5D^^L83"N5@DU=0-0.=8<96.'
M,45U+FQ^G3<_IS98F%D;)4ZK251(J<Y03*S.5XH?4ZX24S56+:JJ13.BLD,[
MK+)7)Z1BHVYPQ>$!017?#PBN^%,WN/R=;D@YIQ-2]B^7TH%#5(-ME;0>Z\AW
MUO>? 0$MQ#BZ'S->$66-6BAN-$-!DPV3VS2*S6SRY*4U!@A2&L)%B0UQDKCQ
MJ=*8\3FRR/I2I?!QM:JAXR:J!XV=J1DP=I&6?]UZ;=^Z@SJ^===T?&L?:_O5
M_$UPVG[5G-9GSM+\WT?COXGR7]E OJ\)F$XT$E5D"XHG29#?HH:<R4;(;!V"
MM%8')KG5C4V8[,N+FQPJB)X<(XIL29:$3<J2ADPJD@5-'*/D/[%)Q7?"##7O
M"3T:GLUK-3V:]VFZ-W^MZ='T4-.C\:VF1P/W?SA&-=A)=5_7?PY%'KQS$OFN
M%O(]D\EW327O.XV']!G*2&D?@*29YHB?.0PQ,YV9J)E>;/C,0%YH>Z0@N#U!
M&# C7>PW(U_!9WJEHN?T!KG[M*E*HZ=UJ[A,6ZWJ/&V/JM.TRZK.4^ZK.K>]
M47-NY?X/!RIH+E+-^TA[01NMA2E $VE7S0!R.LA[S@'BNA01/4\3D?-,$#Y_
M*$+F.R!HOAL3,-^/]9L?RO.9%\/WFI<B\)B7(QS=529VZ1HG<>IJDX[LZE)T
MF-LGLY^[2SYB[@79B#E_R$9T_B4?T<$I?<G.NH_G4+VD/:<=:)U)-2#M$M+.
MF _$+"3_WRM$P!)E^"T9 -^E@^"]U!9>RYS@L<R3<5L6P+@NBV"=ER6PHY9E
M\!R7%O'ME]8(AB^=)+1;VBFR7;I<;+UT.W%6;+WDCGCHXE>2H8LXA:$+_V4S
M6; 5E/=\TFXGW2:RA97=0.XB\O]+R?^O!'S()HY>JPB7=>IP6F>(4>LL,7+]
M,#BN=X;]>B^,V!"$81NB&+L-R8S-AEQVZ(8*=O"&)I[5AID\BPV]?/,-6_B#
M-ISD#UK_&V_@VA?\@6LXP<#5_[*:]!?. F:3-6Y9 -3UDO]=#J2M J+6 ?YD
M#5VW ".V\V"S4XZA.S4Q9*<1!N^RA-6N8;#<[02+W5XPWQV,07MB8+8G#:9[
MBF"RIXXQVC.%,=RS@-'?NY[1VWN$T=OS$Z.WZRDS8.??[( =W#\L(?VYE/L4
MJGD]V=%2TLY<#\22;B!94K==@/U>8 C9=K/#0A@>DT'_F#KTCAE@P/%!T#UN
M YT3(Z%]P@-:)P*A>3(&&B<SH'ZJ#&JGFJ!Z:C943J^$\NF]4#I]%<JG'D'Y
MQ!LH'^?^8?X\6HM4]T;*O6(MK0/RX?$[@"#RXN[[2?\0>?"C@.E)8,!9!NH7
MA%#^2@KY%17(KN@0QE"\8D6,@/3KT5#X.@"2;V*(3(B_J83P:@L$5[O!O[H>
MO&M'P%R[3CPD7O[#S,5 \\J/9T"Y6X$$T@X^2/D?H?H?!ZQ. \;G )U+@.K7
M@.Q;!I(?!1!>EX%_706\&]H@@P7<M !^L@-N48/ZLQ\U1M' KUD?_RC3;S3A
M?Z-"_[Z)H(1^OT;-VYU_F$3ZU1L^G@$E4MXA]"/N)X#A'\Y_ ,.O *VK@/+W
M@/0&(/@9]#SB=Q']O@RXHP+<U03^T ?N#03N6P,/1WULU/^DYN@)O9"?T.;_
M=!KPC K^C";8<Q)Z?N8?:C=^/ -*IMS#2-O]+.E?!,RO /K? NK7 ?DM0/PK
MP-PF[7O$HT\\YI.. FG(Z=FJ]#QMX"75Y"\KX(T]\(Z:U?>1GSX+4O/I,RD]
M!$TZ;LL_<)JFX#3(YZH0,C-P$O*[0D=P/&]PB"!2B'RBDJ@G)A'3B-G$/&(1
ML0SOL IOL0&OL1VOL!\O<!+/< 5/J6A/Z'^/\8;"YC[P\#]P.D;@M/4I#D+9
M$)S<$ISB"' *'N!$(> $">#XV40IQ55+-!-M1#O>L7/PEEV UVPO7K$K\8)=
MAV?,%CQA]N Q<PP/F<NXS_R*>\QCW&7?X@Z?PVT!(?R_<'KDLP?H@-/2_AB'
MVD"JB2W%XTKQ!% \,>"DZ40AWDFK\%8Z'J\5)N&5PC2\4.C <X5Y>*:P$$\4
MEN&Q9#4>2C;AOF07[DJ.X+;D(GZ3_()?%/[$3]*WN*G(X;KL(S_*..8SG*$6
M. ,UBD.5XJ%8!IA07?K/@T9^. ]ZKQJ.URI)>*&<BV?*9?A3N1:/E)OP0+D5
M]Y1GX _E3MQ5[L9MI5[\KM2'7Y4VX&>E';BE= @WE2[@!^6?<4WE3WRM^A:7
M53GFDAK'7/S$A4]P)J1M0O[?F#!1_W@N9&0.3G\8_AHP&D]U@O!(.Q;WM-)Q
M1[,0OVE6XA?-<;BE.1$W-:?@NN8L_*C9A>\U%^);S>6XJKD67VMNQ5=:^W%)
MZRPN:-_$&9U'S$G=M\QQ78X].H!CC_P';I <W$ I. M%<);*=-7$^T%&>&XV
M& ^,1^*VD3=^-@S'#<,D?&^0@VL&)?C:L!I?&3;@DN$D7#"<QIPW[&#.&LYG
MSACV,J<,^YB31AN9XT:[F:-&)Y@CQM\R!TSNL7M-_N+M,N%X.TTYW@Y3CK_]
M"SA+TK<2@+,6@[.A.(8JX]E@+=RU,,&M03;X?I KOC8/Q$7S&)RS2,-IBWSF
MI$49<]R\ECEJWL@<-F]A#IE/9P^8=[+[S1>P>\V7LKO-U_)V66SG[; XS-MN
M<9FWQ?(V?Z/E2_YZ*TZPUHH3KOD/W%#2M^T_UF3Q<H00CX<IX*ZU,JX/T<85
M:PN<MW'$*5MO'+4-PR';!&:_;2:SQ[:0W653P>ZTJ6.WVS3QMMJT\K;8M/,V
M6<_E;[1>Q%]OO5*PUF:38(W-/L$JFW/"E;:_")?9/A,ML>7$O7:<>#&QZ L^
MZ--V\G@D;:].P(^C^/C67H)+(]1PRL$$AT?:8=](-^P:&<AL'QG-;'%,83<Z
M9K/K'8IY:QVJ^&L<QO)7V3<+5MJW"5;8SQ(NLY\O6F*_5-1KOTZ\R'Z7>*']
M2<D"^QN2>0Z/%>8ZO%.8X\@I=/Z'_F/=EZ3]FQMY/D_@DB>#LZ.%..&LA/VC
M];'3;0BVNCEAHYL/L]8MC%DU.IY=X9K&6^::QU_B4B)8[#)&N,BY7MCC/%'4
M[3Q-/,]YCJ3+:9'"'*=5TME.VZ0=SD<49SI?4YSA\D VS>6M;*H+UX_BE"_@
M'&G[)?WKM+U?(O][DCCLRV*?ER*V>^M@HX\YUOC:8Z6/![/4)XA=[!W%]G@E
M\;J],@7S/ N$<SW*19T>->(.]T;)3/=6A7;WF=+I[MV*4]V7R]K<-\DGNQ]0
M:G&_K#31XP^E"1ZOE9H].*5F3T[^)6^<Z?7C39XSB+Q.*/7YY#_WD _>%B#!
M^@ -] 698FF0'18%N3+=@7YL5T 8KS,@CM_AGRJ8Z9<CG.Y7))KJ6RF9XCM6
MH=5GHK3%9YILHL]<>;/W$J5&[_7*XWWVJM3[G%<9YW-;9:SO*Y4Z7T[Y$TJ?
M^9-J\!/E?I&TC])K;@^]<K?2:V9]J  K0U70&V:$!>%#T14^BND,\V)FA@;S
MIH=$\:>&) I:@S.$+4'YXHE!I9+FP!II8V"CXOB -OFX@-E*=0&+E&L"UJB.
M"=BE6A5P1JTR\%>UBL 7JA6!G$I%T >4/_. 7FW?4]YG2/]@'+ CGOP67?LB
M&?1&*:$[6@]SHBTQ*]H>TZ/<F2E1_NSDR'#^Q(@X05-XJK A/%M<'U8D&1M6
M*:T-K9=5A[;(JT)F*E>$+% I"^E3*PG9KEX<<E*]*/1GXKE:42BG^@F5S]SU
MI7$()^\?2]X_D;P_>;]5=%U"7W?'RM 9IX.9\8,P-7X86N-=F8EQ/FQ3; AO
M?$RT8&QTDK V.D-<'94OJ8HJEU9$ULG*(B<HE41.5RZ*F*]:$+%"+2]BJWIN
MQ'&-G,B;Q%/UG$A.C5#]DO[SN/ZSL".DNS.5:D#>;SE=>\@+=R9*T9ZDB2G)
MIFA)MD%SDA/3D.3%CDT,XM4D1/+'Q,<+*^+31&5QN9*2N!)I46RUK""V42DO
M=JI*3DR7:E;,,O7,F,T:&3%'-=-C?M1,CWVBD1[[7CT]EE/+B.54/W,KA+P_
MY7PPA>9A_QD0M1N+Z=I%7[>G2M"6JH9):49H2AN"^C1'IC;5G1V3ZL^K2 GC
MER7'"HJ3DT6%25F2_*0B:6YBE2P[<;Q29F*;2GK"'-74A*7J*0F;-)(2#FLF
M)7Q'/*;[=^K)"9P:H?J9ZS0.I_O/XBC_S=1VK23_N8"N'?3UE PA)F:JH#%+
M'^.RK%"3-8*IRG1ERC)]V>*,$'YA1K0@+SU1E).>(<Y**U#(2*M03$L=)T])
MG:R<E#I;-2&E5ST^98-&7,I!S=B4:\0CNO];/2Z%4R-4/]-_)MA_'K>;\M^0
M#RPENO* :?3UI!P6#;E*J,O5Q9@\<U3D#4-IGC-3E.O%YN<&\7)R(@59.0G"
MC.PT<6IVGD)R5IEB8E:=/#YKDG)LYBS5Z,Q%:E&9ZS0B,_=K1&1^K1&1\5 C
M,N.M>F0&IQ:5P:E^YDKLQ_.X[;G VB)@$=%!/G@RQ=%0 -06RE!5I(6R(C,4
M%]N@H'@DDUODP685!? RBL+YJ85QPN3"%%%B08XDOJ!$&I-?(XO*GZ 4D=>N
M$I;7HQJ:MU8])&^O>G#>9?7@W/OJ(;EOU4)R.=70G'^Y0'/Q .6\A73[RF@M
ME/:? 5&_7TSZ=*THE:*D3!T%Y<;(K1B"[ H')J-B-)-:X<LFEX?P$LJC!7'E
M2<*8LDQQ5%FA0GAIE6)H::,\N&2:<F!)MTI \6I5_^(]:G[%%XE[:OY%;U3]
MBSA5_T).Y3.G:0WLH9PWD/:R2O*]E?UG0, XHH+NB\:(D%NM@JP:?:376B"U
M=CB2ZER8A%HO-K8VB!==&\F/K$D0A->DBT*K\\5!U14* 6/&*_J-F2+WJ9JG
MY%75I^Q9M4O%H^J\BF?E7>(O%<\*3MFK_%^.9GW\3-::*O*=U'[/_' &1)Z#
M*"!/GC6.1>IX.9(;=)#0:(:X)AO$-(UDHIK<F? F?S:T,8P7W!C+#VQ,$?@W
MY A]&TK%7N/'*GB,;Y6ZU<^5C:Y?(7>IWTZ<D;N,NRUW&?M*[E+'?<"U]B,'
M: YNIGQ7C@7FC:.U0(PGRL>3?A/YCHE 7(L449/5$=%JA+!6*X2VC4!PFPL3
MV.;-^+<%L;YM4:QW:R+/LS63[]Y:+!P]N4;D/'F2>-3DV0HC6Y9*'5JV$J>D
M#I-^DSI,?"EUF, I.C3_RRZ: ^OJ/GX6J*.1U@)=:YMI#$@[M0V((7L4.D.(
MP)G*\)^E"[]9 ^'380/OCI'P['"'>X<?X]81QKAVQ++.'6GLJ(Y\GN.L*K[]
MK&;!\%DSA7:S>D6V,S>+;&8>)WX6V<QX+K:9SHEMIGU TL\6JGD?Z7:WT'HD
M&B93#4@[A[039Y+WZ@1\R9=[="MB=+<Z7!<8PGF!!9QZ[#"JQPF./9YPZ F$
M?4\D,[PGD;'KR69L>LK8H3WU[)">:3RKGAZ>9<\&OD7/$;[Y@IL\\_E/^>;S
MW@G,N[A_6$NY]Y)N)]FPE@^? R+O-XMJ, >(G@\$D%5U7P(X+N=CV HY[%9H
MP7:E,:Q76F'HRF$8TN>$P7U>L.H+@F5?-"SZ4C&HKP #^VH8T[[)C$G?/,9H
MU1K&L&\_8]#W/\9@Y6/&8/E;UF 9]P_+6X'YI#N==!MF V5S:1YTTQP@/QZR
M#/#J T:N 6S)EUML$L%LLS),-VO!>+,QC+98PG"+'0RV.$%_JR?TM@9CP-98
MZ&[-@,ZV,FAO:X3FM@YH;%L.]6V[H+;M$M2VWH?:YM=0V\0QG^EIIWE ]6ZA
MG*O)CN93SDDK@'#2]2$_[DRVU&X;>6#RQ49[ .U](J@?D$/M@ 94#QA Y> @
MPAK*!QVA?,@#\D/!1!QDAW*@>'@,I(=;H7!H <2'-D!TZ!CQ$]W_"?'!-\3?
M'YA#>;<MH/V M(LIY_1U0-1FP&\[X+*+]$G7G*RZX2% ZRB@<H*!XADQQ&?E
M$)U5A_"L'@1GS< _-P2\<PY@S[G32Y :DO/T$CI/B^X\+;@+5.CS)'">'GJ>
M_/Z%7XC'Q),/3*/<QU/-RU8#F1MI'="/^?=_!H=T;4EW$.GJGP TZ%>5S@,*
MEP#^URPU'>3YOU$"KJH#UW2!;TV _Y'G_WX$\$-_@TK-X77:A&_0!GRC@:"!
MOK$2N$F)W:2'W;Q)_/*!IL]G0%3SV-TT!P]0_D< &](U.PT,(%VURX#L:T#T
M+:CY)^C7\1,/N"4!?I:3*5 %?M6BQM0 N&T.W+6C1MD5>$!Q/* X'M(F^(@6
M_",J^B,J]J,=Q#'BU ?&4.US:;SC]P)!I.UZDO3/DOY%0.<*U9YTI:3+Z]?M
M/X/YG;A+_/'I/.2^D#2D9%"H)G^J 4^I)L]-@5?6P&MJF-]2D_1W$O".7C[O
M*([WM.#>4^+OJ>CO-W_@XYD#>7X%@C$"!PO"GO @0HE$(H<H)6J))KQ'*_[&
M#+Q%)UYC/O["(KS"<KS$:KS 1CS#3CS%03S!63S&=3S"?3RDGWA OWV?N/<?
M.#7RV2KD^66$D.YY ^F[=L1H(I"()3*((KQ#%=Z@GIXVB;2FXCEFD=9<TEJ
M/[&$M%:2UGK2VD;/WD?E.H4[^)9*=Q>_T6_\2M'_0D_Z^3]P&MH4!WE^)?6/
M<4A-P(F'@N./HKKX?C@/>H]DTLZE/,M(LY9R:R2MR933=-*:30KS2&L1;F,9
M::TAK<WT[#WX"<=Q U=H"MW&]U2=_U$6UU@.5_OA_0NGK49QD.=752(TJ"8T
M)G*+?\Z#7HN#\4(8AR?"##P4%N(/025N"\;A-\$$_")HPRUA.WX2=N*&L!L_
M"GOQO; /_Q-NQ%7A3GPM/(*O1)=Q2?P[+DB>XYR4PQE%#J<_<>H3W  Y.!WR
M_-HR0N7CF9"Z"=ZJ6..9LA,>RGUQ5Q:)WV7)^%F6@YNR$OPHJ\9WLO&X)IN(
M;V13<44V"U_)NG!)M@@7Y2MP7KX>9^4[<$9^!*?DEW%<^3:.J+S 054.!XC]
MQ#Y5COD,9Z@ 3H\/SE!,4!SZJOA+=P >:0[";?7AN*7FAA_4@G!5+19?J:7A
MDGH^SJN7X:QZ+4YK-."41@M.:$S#<8W9.*K9C2.:2W!(<S4.:&W!?JT#V*MU
M'KNU?\%VG:?,5EV.V3R 8S9]8N,G.!/2I^V%&\CB;S,17ADKX@'%\;.N'K[3
MM<)7 T;BO+X/3NN'X[A!(HX89.*002$.&%9@GV$=]AHV8K?A9.PRG($=AG.P
MW;"'V6JT@MEBM('99+2;V6!\BEEO?(-9;?*8[3-YQZXPI7?4)Y9]@AM(^A:T
MK&F+^WTP;3T6 EPWEN)K8W6<-3/#\8'#<&B0&_:9!V*W>31VF*=@FWDVMI@7
M8Y-Y);/1?"RSWKR)66?>RJPQG\FL-I_']IGWLBLLUK#++;:S2RV.LDLLKK&+
M+!_P>JS>\+JM./[\3\S[1+]^_\?<?A].6ZP]\-5P!A>&"G'*2AF'AAI@C_40
M;+=QPF8;'VRP#<-:FWBLMDEC^FQRF14V)<PRFRIVJ?4XMM=Z KO8>BJ[T'HV
M;X%U#Z_;>B5_GLUF?I?-0?X<F\O\V;9W!;-L_Q*TVW$?F/$%W%#:[DC[NA-P
MB;;74R[4ZSNRV#]<ANTC=+#)P1QK'4>@S]$=RQT#L<0QBEGLD,@L=,A@%CCD
ML_/MR]@N^VK>7/OQO$[[%GZ'?3M_EOT\0;O]4L%T^_7":?9[A5/LSXG:''X7
M379X*6IQY$23/C'Q$\^'T59/6^K7'J3O39Z/?/AN>N5L=99@G;,Z^EQ,L-35
M%HM=G;' U0?S7$.9N2ZQ3*=+"MOADL7.="[DS7"NX$]SKN-/<6H6M#E-$4YV
MZA1.<EHDFN"T1MSLM%/2Z'Q*TN#\LZ3>Y1G!2<:Y<.(O>>1(KS/2/T_^^W
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M- HT*W=8+-]E'!_PQ/PA%_X/NVF@."8?,=$?'2?LW$=/S:*X#J?Z%,?@/)#
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MM7R6Z3GNV7")<>$2Q%/.30F7>U?6^O; PQ9:.&UI@F/63CADXXO]MN'88YN
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MJMC_&NK7T7?1*L4V:2*JV0"1+9:(:'&$M-438:T!"&T+1TA;+(+;4A'4EH?
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MJ=2.60B$+J;_ITUTHT5SH#^W7*,&DW4Z,)HQ@N&,)7&$P8P$^NL#2 3TUB=
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M'1 IHG9&+;UW [TO[5%P&_4[Z;][5.#4IP.'/D/8]UO"KM\!MOWNL!GP@_5
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MR*_PCI7/LIUZRUF"#T5S'$@M+5(I7_-(*C]/X&L,/XN,58$T3@>A<88(CK=
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M\7>3/=\-:;WK _!'#4!G+]!@[ S";7E#B8%1C,%QZ$>O%;T!-,$+;DYBB1R
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M(QO^ KZ0<6=( ,S81GLBL3R9MN3BVC)TU"._&ZYOI0OZNT[(&*7GL.-9[#B
M'?NQ8R]V[&80[63P;(=S;R5@M_!J$]_:",/?@%<WH'&]"^OTP\D8Q@\AO^GH
M2F^ZUL(W0FA#'&U(IPT%V%VI/?#^G?#^[=BQ%3LVPR\WP;<WP/O7PS'7PD#7
M8,<J)I&5<.[E],E2_BWA4T]AZ9-X[@F\NUC__/?)&(M=>S",'V.^Z"JW'90[
M[0A C\UQ5\A&)2(_"WN+&(95L/@&9'='<F]D]T/V8&0/1]98+8+Q+L0?C\&Y
MY\/2'U4[WEA,SZSAV6ZFEU/@8[C\]XX]&)WXC:N<=]0US(QM8*ODPQ1@07XP
M=L<@.X7I(0?Y)<BN1G8#LKLANQ>RVXC"0<@:3LO'T L3B(BI3*-W8<7#NH]O
MW(NTN_'<7?3>G;H"_@C^!9>_YL!%UU#;[IINC&&Y$%_,PQ<=C)'9"D-^O!Y1
M&A+SB/P29%<S77=!?E=ZOP7Y?9$_$+G#\<!8>F.B;N'?-#XQ%2NGX*F;\*9Q
MKLHD(GBBH[+X5W#- 6-X&^578_O=0G?G5#S#6 J(B_MD1H<=^9'(3T1^!O+S
MD5Z*_&K=C!U3L&,R=L"RD3^(Z!R!)\;K>JZ.YUO78?U86C6&%HYV5-%> !^!
M;S42_0:>84I;0RJPD.5O)IC.5'L7UVYG";B%^>)F!:(G!!W1V)R$CDQT%*"C
M%!W5Z.BB<=@QAGX937R,(DY'\FPXGQRF6WGU !'S*-8MQU/&CJ)CX!TBFO62
M<6K\3M56IK*GF-[;66KN!;>"R;R>R/(SP<]#-W@&H,N*GC#TQ*(C!1U9M+8
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M$0-0:"MBS25PD#)W>55ZRZV*!:^:!:4FT#FQ&X7E>GQ1CR_J^5(]W*K>V%0
M>:V'4]1!8.H@+K5D;;60D9IWP5?J3=L:^'A%9PV(U^D@D><QM#F\$/WHM99)
M)D3Z54M>-$]=6-@;X):-+*Y-V-$57W3#%]V92+H3O-WQ1?<2YPTVW8VC5XF)
M;F1(W<C6NI*U-A\";_/=K]0=';6@]$<UH!2>QQ43 W1I4 7ZJXWZ#QR<[O6
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M9U68GUVA?F$*\8M6L%^B@OTS%.1?(+M_I>P!S;(%M,EJ8H8Q397%]!!X0N:
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MRBJ9"AE((7-)QH:D+]6$SHHXYWU@Z<8>(.AR+->BHITUJ& >;<#"-3/O^R?
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M:JECMU-D2_((K7E^@1D9X)NP(;81%V88<'54 RY"KL77$VL)]?A:8@-63VS
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M+(FGGQ"F"[OX!:H6#EI?SR+;PO0R5X# ]?E0XI '5AVQ%.LC6I@A7%5B"E3
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M6(T*H/0P'\Z4[Z%8<UPL6Y9+:,]T5=C275I[BM/J3#7;G1FZ1P<J($/U!Q-
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MUU?("QH4DL)&N:BP22HH:I&4%[6(_U.C!B1D0$,&QH+7H-G[?2!;\1E0KED
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MX8<A5J_?A-@^' RUO3\4-ANHF(.>[R.BJR<$T*E+@NC00V%"*RP6KH8-RTM
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MFC_YXFYQ9\QS-K_+$;JW%Z%SW7Q_WT%HNRF ZH?F$BI_K18L_"TEF@$J:Q)
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MUOC\--W(FK21I$TZRCA.TA7LIKQ4K*8"U,VF([6,IE-U]'X5Z6G_JC/0_'W
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M@K[P=C 5E@1KD2U $MD(+G/$P6.N&/C-6PT1\U= VH)E4+)P*=2++H']BY;
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M($GS@XN, # 5A8&M+0H<LY7 )HF#.UT2&#[R0 M7!:=D+2#EZX%=I1'8-)J
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M!0I\RT&5;PEH\RT"0[Z%8,$_'QSXYP*-7P0X_((0*L 'R0+XX5"  -58^XS
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MC.]H3QN_U9DP'M,9-_FM_<4$= ?-0?^I)1C<L0*#:S9@<'D&8"E.!/.M1'#
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MFIA<Q(A)W.4>D;"''1I_W"LXX2XVYAD2_YT5&OO#+2SF)STL>M(U/'J*]F_
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M3*[[Y4S9^<O)N>*W$[7\-^7?@,>/!E,0NE.,T,4:A'I:".@0[GYM1PFH\9P
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M0L>B#7!AL3B\7[(>II>L YA1RUZ$*O'G(.<,GG\%H<#["+'P?,<AA&QQ][>
M!<@(EB(]$"-HPA8BKM!$15#BDP--ONU@P"\)YOQ;P$Y@(S@+B -+4 S\A59#
MM-!*R!%>#KN$E\%^D:70)[($7F,3&,SYMYWX'L@]A5!</T(!]Q!BOD3(81 A
MLW&$#  A;1!!:G@M%&$901;GV :;"!(@1=@(<L3UH$)<"UK$56#(MQPL^):
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M-V5\VN^PR4F_*Z;'_!^:'O3_VWR?'UKL\4>+J0"TV!R(%AN"T'S]-Z [U2!
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M^M)Y[M4ER[PJBB=]RHH.^I84_T*\\2XI08_28G0K+4+7TD)T)IQF@E$T"VD
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M@/=U0?"Z(0N>-W3 XZ85XWK3A>7\FS][UF^1'/M;R=RVMV;S6-VJY+/XO4W
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M!+&*$<!N%C^.L_AP)XL7?V3QX!L"_X>A30!S*+]L.O\"Y?\(X$-[=[@#8/H
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M!2<+]9A#!7:<W7G> MMRPL0FLQ)DUV5D*JU**U"?2*G07I;4J+<DL<-H)&'
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M.B:]WV6-S#Z7K;)[7 [([7*Y(#_E>E]^B^M?BIM<46DCL=X5%:=9XXH*JV>
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M91GG@F4]USG+=NXSEGT\IRP6\)ZP6,IWS&(UWU&+S?R'+?8*'+0X([#?\K;
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M+0O=:=,=>M1V2>@5N\[0?]DM"OO*KB-,LFT/DVR(%;%\%,D;^(I3W)O4OY=
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MK23OE-T6)#PNZ%X?(CF8, Z5[FB3A1J2N1ES8H/?#8;C6\4$UF\Z-4/QEI"
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M/(Y+U%HPEWV1%+/.Z;3K,0N P$7T_UW47T[]5=2GA7=83P^^207-9@W,-MO
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MU2 YS@&)\<Y(2)B(N 0M8A-]$9,8@NC$&$0F)B,B,4<(2RP50A+KA:#$!6)
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M\!B_>9/)F6S^)IM]E\HVVKH<C)U&')[..#A,#*(W#;TQQ]"/3G]T>IKZRRV
MII#DL]"!N\PN%0C!O23G]Y&<WP_G?X!^>0@['B$Q>83%[Q$FF4<)KD?QQ2,(
M?.1N )%_A/YXV&;'.OIWFN[J/\)<<#[S #_+O,JQ*R;D9LGO=LG=Z+K/67LY
M60LQ=^H\X:R)/.4B/0TA>(9D_%E(PO,1CEO77R3Y^"T+X$L,]I?@_2_CV)=H
MS$O\T<MO@:^ 3<OHWQ&ZJOTX?8!_<]&;\%/BC_#Q?TCR>,RIZREGW<7407[C
MK$N<O%/G]\[ZQ)\A;7_UDEXC5O])8OX6=KQ-DO0.B\^_B,]WMTOOH>P]G/C>
M"]+[L+KWO]#TU<Q'F-: CXOO(08>EB)HI_^3Q)ZIOSSOU/GR*367_W6'CG[<
M*?)OLTO$/,4&GWP-6?DV!2))C'YO[I!AT-GH<!N.MMT/:)#M#6?]89X3YOW)
MNT+RY#@EI!7,=]8?S.X0<U+I)CGNDMD'#LF<FOH];.X[70YOO$[_#1O\BL[[
M$D;\!>S_<SBWN1OFY&D<9D>(V9'QJIRG4MAK'S[.&H2/TPYS8HDY)<3L4#%/
MK>FRUV(<=Z<LU=?PW"_AN9]CQV?8\0EV?*1S]:$NU@>PP/?AF>;NE'_!D-_&
MB6_R[@W^\I^GU%Y,[</<$?*<W093]S [(5R<K\8FLU,FF7;E\Y=5Z&O!_CYT
MC"%_(?*7(7LM7; 9V3N1NX]V'4;V49CM);3\:L+C%L+D7G0]I=_2>2]BK='Y
M:R>><=8B['>%R/5_U!^8R=$9A/=B:5,F^DK05X>>#OV-/OD3O/\/\/Y7L.,E
M_/$B_?("=CR/'<]AQR]ATD_#N)^D3Y[03QE"CZ+G)3SR@1[&DP^AQ< \W^=>
M.9[U<ZK^K^TAY8[O_&E3./V5A*Y<VE&![8UZECYY6H,,QPG:,(/L96A8@^Q-
MR-RI^[6?*#A+]\#R[Z)/[M3-\/;[F%)^:=\S<S-1\I^[,FXXQ09S ,Z[<FS"
M>HG8> [>_R1Q\;C2T5.$GAITM""_&_E#M' "^3.Z#3MNP8Z;L>-&[+A!I^MZ
M8O1:7:IK\,55Q,452+F<%AW#NV9?D\&Q4W!2_]LNCF'^*_MT, =_^>.K4-J2
M0#NRT5.*_;4ZP3BY3KW('T+^!/)G=!P[+B,^CFD+T;"'R#R$)R[0^?9JR*U8
M])".$)MG,7C/I+?-<X=.Q=?FP5B^CL.IG^+U0::8NUS-E.R%3@MMBB3"4M"5
MCYX*VE"/CG9T]*%C&!V3C(A%Z%BAL[4>F=N)BOTZB.8S^(O3\<X^^N,T/+O'
MY6WM=OU:N]Q8I^;\B(_1_7>6O6? ?2P[MS+57L>UJUD"KG#SI6U!C/Q8G>^2
MH7-=BW2V6[7.G-.H0^Z=.NC1KP,>(SK=<X'V><YJ[]S5VC-WLW;//4T[O<[2
M=J]+M<W[A+9XWZM-/L]JH^];6N_W#6"-. 7O,)6]%,O2$8-^EKVK(EE.N78^
MR\]Y_FXZZNVOLWS"=,@W20?\<K3/KU2G^5NUV[]%N_R[M6/>@+9;QK75,J,M
MEN7:9-F@#0&[M#[@L-8&7*S5 ==K5> ]6A'XK)8'O:VE0=]I2;#-@2 '7HMU
MU&#N M>2AER<0+H1!^=B^3O E']ZX%SM#0C4[L 8[0A.U];@ FT.J=3&T'IM
M"&W3NK!>K0T;UNJP*:T*G]6*\#5:'K%-2R,.:#;B?"V.O$8SD7=J8>336A#U
MAJ:BO]%DM$V343_"W)WTLTR6Y0Q2#'!..KJYMB<1WH<MVZ/<M#5BGC9&AFM=
M=)+6Q.1H54R)5L36:'ELDY;&=6I)W'PMCA_3HO@9S<2OT'3")DTE[-5DPKD:
M3[Q28XFW:R3Q"0TG_4-#25]K,,FFP<0?\9LLEGQ2G^O!A>"@L_:Q%5LVII+?
MX)LU";Y:F1BB94EQ6I*<H<7)!5J44J&%J?6:3FW35&JO)M.&-9$VI;&TI1I-
M7Z_A]-T:3#]; QF7JS_C-O5E/*[>C+^K)^-+=6?8'$BWJ0<\E^\XF>5*< [8
M1^JQE6OKL645MBS'-TO3O;0X/4 +,Z*U(#-%DUFYFL@JU5AVC4:SFS22TZ6A
MG $-YDQH(&>Q^G/7JB]WIWIRSU17WC%UYMVB]KQ'U9;W%_"%6O-8"7-!CDUM
MX.EBQF$):1XX#':!C5Q;A3U+2<F@,)K.<==DKD7C>>$:S4_4<'Z6A@J*-%!0
MJ?F%#>HO;%=?89]ZBD;5732CSJ)5ZBC:IK;B@VHMOD3-Q3>IL?AA-13_$7P&
M;&HH H4.F']VNAE<! Z ;6 -J?%24H\9TJ I;!DK=-5(D9\&BT,TOR1._27I
MZBW-5T]IN;K*:M59UJ*.LAZUEP^KM7Q:+>4KU%2^18WE!U1?<9'J*FZ0M>(A
MU53\3M45GZJZW*::,B=*;7JTBE@ YX&]8).IOU2:V@OZL6446P9Y[2_W46]%
MD+HKHM59F:*.RARU596HM:I:+=5-:J[N5%/U@!JJ)U5?LTRU-9MDK=FOZIH+
M5%ES0A4U#ZB\YF65U7RBLFJ;RJN<J+3I =+?J\WN(+#;['\!2[FV (QBSP#V
M]/+:53U7[34!:K5&J*4V44VUF6JL+51#7:7JZ^I55]<N:WV_:NK'55T_J\KZ
M]2JOWZNR^O-4TG"=BAON4V'#BRJL_TB%=385&=3:5&RUZ6Y2W^/@,-A>+ZT&
MBW@_ 09KX1N@@_<M]>YJ:O!70V.HZAKC5-N4)FM3GJJ;RE35;%5E<XLJFGM4
MWC*JTI9%*FE9JZ*6W2IH.5?Y+=<HM^5>Y;2\ #Y43K--N4V@T8';H427@@-@
M,U@.IL$(Z -MH*D9_M_B(FNKKZK;@E39%JV*]F25MV>KM+U8)1U5*NYH5%%'
MEPH[AI3?.:V\SE7*Z=RI[,XCRNR\2NF==RNM\WGP@=(Z;$IO!VTV9;3:='.+
M= '8"]:#):8&! 9!%U2IJ0W>UT'.W0G_[O)22;=%13WA*NR)5T%ONO)[\Y77
M6Z[<WCIE][4IJV^^,OLFE=ZW7&E]VY32=Z:2^ZY08A\K<-]SBN][3PF]9*P]
MH-NF)' =:?<Y8"=8C:X9,-KAJ &UH[<.JE35 _>$/A;,GZ.< 3]E#P8K<S!:
M&4/)2A_*5MI0D5*'JI4RW*SDX1XE#H\I87B)XH8W*W;XH**'+U/4\.V*&'X&
M_$N10S9%#8(!FZ+GVW1%-VM#MV,OT'(P!09!-WJ;2<>K^^$] ^@?@G]#55+'
MO90T85'B1)@2)N,4/YFFN,E<Q4R6*7JJ3E%3'8J<&E+XU(S"IM8K9&J_@J<N
M4=#4;0J8>A*\K<")[Q4T;K,C>,RFB]&Q#ZP'LV ,](-V*%H]NAGR*AQ#_P3\
M%^H8-^.FR,6^"I\-4-ALA$)G$Q0RFZ'@)04*6E*IP"5-"EC2)\N2*<U;LDK^
M2_;(;\D%\EURH[QG'P.ORV?QU_)=9)/?C /GTKZ=8!68!L.@!S2-X -T%T_"
M_Z%(J8O0#VV,@$8'K7*798V?_-<&RF]MI'S7)H(L^:PMEO=:J^:N[9#GVA%Y
MK%VB.6NWRG7MV4Q\UX 'Z' (V>I/Y;**;'JE36[@X#CC 2P%D^@< &V\KYVB
M#Q;"_1:C'WH4MQ+]:]"_ 0ZVV4W>V[SEOLTBEVTD/]M(/+:Q^&]GD=G.A+:=
MP;2= -J.X[:O Y#X[>;8!XCK5DC;EH\ 6>1F!TZCC6O!(GX^!KIYWT";*VAS
M/FU.6XW^]5+X9BEP&QP8CDZ:)-=]<Z7]\+G])%ZGDV@<(!$YP$)[!@O>&4QJ
M9[0YCD(Z R%G[ 87\?UM_!8"N1]2N/][@L!FQS9TK3 G]-#>^;RVTN;J5<0@
MYJ=ODN+1&XZ(@+V2+QS=XS!)+Z[5.6Z Y/-<$K^CV'$>=IR/'1>DD028K:E,
M;A>:X[%HU(4(NA!B?P%D_@)(]/EO\OMO^3N;'1O0M]2<T&/NSL+7M?BZ>"O\
MG_;&[Y/"#DJ6LR2?<^' %Z#[$G 9P+4ZCAU7X(\K\<?5V'$-2>"UV'$]R<?U
M+, GX/TG"*X3YE%A"+L><G\=A/Y:R/.U7_![FQUKT3F]D;&PA3C<P3R$G[/I
MO@3:&G8>^J'JWJ;^<I6S_G)R+XJIA]P*<*]N)SG_J8]TIX5DA/BX!SON(_&X
MCX7OO@[GG3KXXOZC@#^\[Y?2O1_P.YL=2W<R+^]A+$+)J_%S'C]+0F\X)EL(
M9:\;G+I^ZJR[G*R%/ 0>=M9$3(WB<0C!$_CD2?KF:7-J"78\EPUA8?%[GOA\
M?BF@0Y^_ O#'S_\-P&R>MVG!(=9%<T(Q?B["QVGHC;J1_O\)^HW.^YVZ?N:L
MN9@ZR'-.,F3J(2^<4@\Q>S5^[R[]":+RMT#I']AAMA'_LT%Z@_A\DR![ZQR
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M!2]!_W+)=Y6+/-:2?*TCX5E'LK$NG(; I]8SJ6]@4MO 8-L K]J XS; ,S=
MIC= H-=#EM=!WM9!R-9BPQJ;'9O0LX1VCH-^_J3%U(!H<R%MSIR1$F?1C][@
MU9(_=-$;CCYG*\G>=GCE=A*N'=BQDT1C5P233#R+#HO='B;8/0RJ/?ABSP+
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MVKQO4JOW(VKQ?E7-/I^JV=?V ^YBN;\\%+Y'2KB==&P-KTO"2/FX-HD]XP'
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MIE#1L96*BFU21&R/PF(G%!J[0L%Q.Q48>ZX"8J^7)?8A^<>^JGFQG\L28U,
MV&GV(Z%KC%2\V]2 0#4H!5!ZY8),;$H#R?PN,=Y5\?'>BDV8IYB$8$4G1"HJ
M,4$1B6D*3\Q36&*Y0I+J%9S$2$X:54#2,EF2MLL_Z8C\DJZ1;])]\DEZ23Z)
M'\DWD4PEP::MR)TU]V&9?4#)CAI0)2@&>5S+ ND@&<2#&*Y'I7@J(M5/8:D!
M"DT-4TA:K(+34A24EJW M!(%I-?*DMXA__1A^:7/RC=]L[S3#\LK_0IYIMTM
M][07Y)'VOCQ3O]?<5)O]OK2%R!V GK6ET0]I9N\-?0!R4DWMAWP7)((8OHL@
M50_-G*/@+!\%9EL4D!TL2W842)1_=H;\<PKEEU,EGYP6>>?,U]R<A?+(6:\Y
M.0?DFD/RGTU2G$V6D/V>7+*^E6L6ZZ>Y)PW9O<ANAIY5@Q*0Q^<LD,9W22".
M]U&94AAT-BC759;\N?(O\)-?0:!\"\+D0^!X8_C<PEQY%I;)'=+H5M@CET*(
M0^%JQP;N0DA( 2MTP;,0JG<!/"O?9C\3>=3<"V;NP7+6@ IYGP,RN)X"XGD?
MS?4PJ!M#4)9"5_D7>\J[S%>>91:YEP7+K2Q*KF4XM8P_*(=;E4.<RR&.Y>:!
M,G#_<E;C,DA*V:T$&ZMU*3:4DD&6V+38T'1S+YC9!Y3GJ &9/4!9.?@ )((8
MKH=#HX,1;2F! Y6YR+O24QY5/G*M9A*M81*S,LBM#")KJD.0V4QBA<1:(>E6
M2(R5;, *]Z^!,-1 0JK)GJJQH<JF!;2KS]P+5LC'0D<-*)=K&8A)YC66:Q'%
MZ(="6RK@@%5P<&BL>QV+;3T<IH$%I9$)O2G8,;FUX(L6'-=28@[W!>8A/Q#(
MEDU\#[=IAI@U/<'?O .^M]=A1LU>('Y>#RI 8;&C!I3*:SR?(\O13Y,LZ/6K
MD[P:I#G0>;7"Y]I8\#M88#OQ11>+3@^3>V^TH]#:2R-ZJP']T0O'ZS$/.B$[
MZX:T=9&U=I)!=V)#!XR%MK4"*RA#7T&9HP:4P.<H1(34.NH_ONCU;)-<$4G"
M@%S03Y(Q'SL&L>/_L_?>45$E6_AHD4&"39"@@(**"17%G!-&S!D#(HCDG#-(
M!B5(SCEG"2(9!17,:1SC&,;LC&E,H];[JKN9N?>^]X?,K/76[ZWGN+ZA^_3I
MVE_MVE6U]^ZJ.IO!8RMX;$>;&+ !!X:V'<K;CIA[.WOX,X+9;;#+K0CBMB!
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M,(40,511< 8FV%F8[&9C0IF+P7P>2VQC0%N 3K0 BEL L@MF\@[V6 ";6(!
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M)4TBI32&2"I/)A+*<XB8\C(BHKR)""L;$T%E9R*@#%]6"3.B$IPQI=L(HOX
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MR/!LV.4L5]R'V&9&%;YS$X,A+P^SC.T'8^?P ./&_)T#&H*_@R!7%M=E('<
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MSH/\YSJ-&O!H0)]MP&13ATY6@\I60:EE4%H)VJ.XEI#\7\E8V)4Z5"2'IAK
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M)^ /@))M*'\%9,YEZX 0-H\#1K#\#S 8UY4 !7D!(B\G3&3EQ A'3H+( -*
MI/P (J$@3<0&#22BBO)$6%&9""D.)8**\-F4=  $"TKLX$B,?DJ8@13] #C
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MZ[HW%W:;/KYBXGWCO/GA4UW6!<>:[&K+CSBVY9:[G$PI\C@;F^][*3PG^*?
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M77YJBW-ES%'/^M ZOV;_FN!VSZJ#QUTJ$KH<*[*['<K+3S@45[7W!S09')+
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MA2P%'$Z1P$4!#QY*./!5P4*@&@9"U&T@4L,*8L]80J*F!:1KF4&NMBF4Z)A
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M)NBL4@.C-2I@L48),&L5 +=.'AS7G0+R>CEP77\2/#>< -\-LL#><!RX_\A
MQ#_2$/-'P'VS&-#0YP1%1@H\3RX&/Z45$*"U'H),MD$@;A^P7:7!S_\4^$2H
M@%?"&7#/T@5ZL2%0JTR TF@&Y+,6X-1K!<1^F^_X(=O/N!O8#_8/[::P8_:O
M;5_BGMN\<YBPF<;-Q?]S^/\[[)4$ZC$I8)Q8#/X**X"CN1Z"C;<!UWX_!%)E
MP)\I#\PP-6 (M<$SPP#<"TW M=(<J/560&G#@',/]@>IW_X+80@WXW #/V7_
MD#")'2>^L'WI^!3SSO$Q9HHP%^"Q20Q<40?Z42E@'E\$'/D5$*RQ'L(-MT&8
M[0$()A\'#D,1V+PSX"?0!Y\T4_#,LP2W,LPOUUK['RXM^._D3N)7IXNDC\0A
MYRG\#<IKW"CUF=T$[;'M2]>[V+?DV]AWSG,!GJ@#'77P."P%_M*+(/CT<@A7
M7P=1^ML@RN8 A)-D(=A3&3B!VL#F&X-?LB4P<K _/8L=OM&K'+_0&LF?*!W4
MC\X77*<<A]Q?XV]X3N >>8UB)[QO8U]X7+5_0QNV?TN="_#:* 9NO]\%'9H/
M@<<60=BIY<!76P<"O6T@L#P ?.()"'=3A6!_/>"$F_UB"VU_,#/Q7[T+G3^Y
M5U _N-:[3;NT>[TC]_J\)@TQGQ%NL49QC]@W[,;\AW'/?/H=7KE?=)BDSP5X
MHP[NJ(,/NI[EHKT9*;<,!"KK0*BS#1+,#T*<PTF(IJE#N*_!]^!@JR\<@<,G
M5HKS!Y]<^I1GJ=<;>@WS-;65_8)\GO/,:9CWB' GY#KN0>AEA\><"_@Q5A?Q
MA7<G\:7G7/R/PVY)\-L_'[W=+H28D\M J+P6DK6W0HKI04BRE_L53]'X%NUM
M/!/.L7W/BR2]#4B@O_+-8#SW+&"/TRNX3UP:PD:=ST7=(UV.&2'<% P0[D2=
M)SX(Z2 ]#FQQFF V.SWSF0M@_",&'K_?!>V=!Q%HZ\6=6 K)2FL@76LK9!H?
M@'1;N:\I3F<^"MU-WT7[XUZ%AKI,!,9X/V8F!=SWS J]Z5K(O^92)1@FM\0-
MDGOC!YRO"[M(-V/;G.]&-I(?\FHI3]G5+N-^<P$^J(/G;@G@[)D'40<70 +:
M>FF*:R!;<POD&1[XGFLC-Y-)U'R7ZFK^(LZ7\#2"XW8O*-Q_A!4;/,Q(B;SD
MD1-S@5X:?YY6E]!%[4@Z1QU,:J9<2ZRCWHJII-T/*W5]S"EQ?<J>BW\=O'9)
M !=MWABT]9*/+X$LA=60I['Y5Y'^_L]%5G)3^7BMEYDNED\2/4EWHOV]KH8&
MLR]Q^"&]K(2H+I^,V':O@H06]\KD1K>6E#JWOM1*U^'4,K<;<47N=R+S/$9Y
MN1Z/.7,!OJB#-^H0_'L/Q $I2$-;+U=^%12I;_I>IK?O0[FYW&2IO=98GK/5
MO30WYZOQ3*_^J*" GI"(T+.<6'X3*R6NSC<GL<J[-*7<JSZMQ+,KO=!S,#W/
MZUI"MO?MZ S&@Y!TQBAW+H")KNM]=DI V Y)$*+S,@.]1Q2<7@FE:AN_5.GN
MG:HQ/?F\$JLU6N1H?3W+U6D@B>'5+6 'M$6&A#8$1T=7<1+BR_PSDHK\"M/R
M?*LSLGW:,[-\+V>F^5Y-3F'>%"0Q[X<E,A\&S\6_#DRT\R)0AT34(?O80B@^
MO>)7A=H_,[4Z>R:;C$^,U6(T[Y01K8;RJ$[GTST]VQ-8[(88;FAE1&1T<4A<
M?%Y0:G)60%YZFG]Y9K)_<U:B_\5LH?]P:CS[1EPL^VY$+/M!Z%R '^K 0KL[
M"B5YWSQT^;,02D\M_UZCNN%]H_;NEVU&QQ\UVIP9J<);]A=12.>RW3T;4WS9
M5?&!H<718=&Y$3'QZ:%)R<F\['1A4$E6+*<A.R;H?#8_:"B=SQT11@7=B8P,
MNA\V%ZB#*/BCG<=''5+1Z[/@Z *HD%OVM5YEW;M6K9W/SAG*W&^UTABN=; \
M7^;LV)I/]ZC)8/B7)+-#<N.#^>DQ_/C$J(3DV/",='YH459$2&U.:$A73FCH
M8$9HZ/6$T- [42$A]\+G EAH8P5L%8<8M/\ST.=&T1$IJ#ZYY%.S\MK)#LWM
M8SV&1V]U6*H/--I;G*MT(C84T]S+<[S\\])9(>G)7'ZB,")>$!N7'!F=EAX2
M59#%C:K."8SJ0+F<R8FZELB)O,WG1-R-F(M_'3AH=\>AQR)KCP24'I[_J_[$
MX@_M2JM?]IS9\NB"_I%K7>9J?2UV9JVUCH3J<A>WPD(/5F:.;W!B1F"4(#4L
M+CQ)D,03IJ0%Q.5FLF(KLIFQ;3F^\9>S_.*N)OD);D?[Q=R)G OP1QVXOW_)
M"#T6N>B]JN+0O.]-L@NG.A57/.O7V'CODL[AP5XSU<X.6].&)@*^M(9"SREW
M8R87,;B"/'9D>'9P+#>#G^B?EICJFY*=X95<EN61W)SMGC*0Y9E\-<DK\5:T
M=\*=R+D ]N_W,.@S(VF+&!3L$H>:@Y*?VV6D)OODESZ]HK;NQA7M@Q?[357:
MNC$F5>UX7$&C,RVMUM4WKL([***4%<XMXL:P\B.%C%QALGMV1AHMNR3#);LQ
MDY)S(8.6?2W1-?UVM&O:G<BY@(#?[V'0:R,574\5[Q"#AGWB'[J/S7L^*+?P
MX9W3:X9'-/=W#QDK-5RT-BKIQMEEGB6Y"%NHWI$-'@'<&F8(JXH3Y5T>'DLO
MBTV@E*0G.Y44I1)+ZM,(I;VII)+K"4X%M_G.>7<CYP("UXH"'_7(W"@*%=M$
MO[?M%GO3?U#\T:UCDC=&3ZVZ>$=C;]MU0_G*(4O]W'X[3-)YHC._B^+!.^OF
MQVKU"?)J#@AS;0SEDQL$L<3Z5*%#76&"?7U=(K;^?*)]_8TX7.7=2(?R>V%S
M 1S4(6Z-*.1M$(&Z32(?N[>*C%W?*G+CT4')2T_E5W4^TMA5?U=?KNB&N4[:
M55LKP2">&#) IOE?H#.\>AG^M!XVU[D[))30)8BT[TSE8SH+8ZP[ZP167>=C
MK+O^P[=I?1!JT_PP>"Z BXZ?M$H$2M:(_&Q=B[P<7([<>+1&9.#YP7F=S^37
M-(QK["I]HB>;^=!4(_ZNC6G8+0<[]@TG)^_KKG3:56]OIRML/_QP: !V2!!D
M,Y06;#E4%&(^U!!J-MR'\C#8[.+C0//>)P%S >$K12!S!=K_RY%[YQ<@UT86
M(/TOUHET3!Y<4/]:86WI*_5=62^T983/C%4BQFWT I\ZF/L\(6/='KL1R(]\
MR<11#LU^-,(=,QKO936:P3 ?+?$U?=3(-'[4QS1Z/,HTNCW!,+KQW'LN(':I
M"!0N0>ZWSD>&+T@A%VXM0-JG-XC5OC^TJ'A:?EW&E.K.^'=:1\+?&IX.?&NM
M[OL&K^O^AF+L,NEA09KTL\%/<K%VDU$XS&0"WNI-%M'B30G)]$V#D\G;;F>C
M=S?)AJ^?D0U>O)@32%N(/*P61X8Z))&>2_.0UOL+D*HO&\4+OQQ9G/;EU-K8
M+\K;0K]H[F=_,9!F?+8Z1?_LH$SY3%%W_.*AA?_BIVOWA:N/^1)I9/U%:&+Y
M-</4[&N1N<FW&@OC;V<M#;]=MC+X/F:E__WEG$P4(<B51G&DJTL":;PBB92_
M7BR2"ULD4^#(XF@XL9H'BIN8H+'3'?3WNX#Y$1+8R^#!^:0=N)W"@(^"-00J
M64*8LAD(5$T@1<T8<M4-H>R, 32<T8-.35VXIJ4##^;D>C6"=+6)(?47Q)"2
M6Q)(YL^EHHFP73(2;>Y D%[!@-/K:*"VB00ZVW%@L@L#F+UHV!U (^L0&CM'
MT. X:@1!QPP@0EH/XH[K0JJL-N3):D'Y"4UH.*D!77(:<&%.>AH0I+Y3%"D:
M$D'2'HHA<;!"- RV2/C#G@4><'@)&4ZLQ(/26@QH;K  @TTF8+'%$.RVZH'C
M=AV@[M "CYV:P-RE 9S=ZA"V1Q4$>U4@>:\R9.]3A))]"E"[7P$:YZ2A500I
MNH@@*;<0A/].7"0$5HKZP@9Q5]@^SQ'V+\2"]!(+.+7<&%17ZH'V:FTP6GL&
M+->I 7:]"N W*('S!@5P_4<>C:53X+=1#H(VG8"(3;(0N_DXI&R6AMPMTE X
M)\7=Z/A7$"1R%$$X,$_$&Y:)4F"U& XV2EC!SOG&<'"!+L@L.@/R2U1!=:DB
M:"T[#0;+Y<!T^0FP6G$<L"NE ;_R&#BM.@+458?!8_4A\%U]$ )6[X?@-?N
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M*^)UN=2$G*.TA;63^\-;R/?"Z\BCW"K*&*N,^L*[F#KI6DQ[,RO_.M!WB$,
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MNB\M?VD]MX0SL_$_#@<D@'!($ER.S@>W$XO 4V4Y>.NN X;%9O!TW UNGH>
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M!NWN] TB4+Q99*INA^CXV7UB=\\?E1H\I[R^NU5W?U.]^>GR2JQ67@G1-*W
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MC>WAR?4;HQ+JIF)BZ_;%QM2=CXUK>!:1V+04F-3XPR>I'MU7@@GD+A2PD[O
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MB"&3NO!ILYJPO19580L6E>$/S:LB/QM61Z-V30QJU,2B:DT<JOPO]"%G$,8
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MQ#2Q@]C'A")'B 7B!OGZ(^(-L<2(HOC_G_*OV:3_M7Y1HJ*&!A55#&BH9,N
M\IZ,*!O&B-(I3"A9R(R2-40;,TKT$2,L*#%!S!*[B8/$:?+7K_Y_^#H+L"BS
M-N[?SQ0,S Q##]U="JB$ M+=W=W='=(BB*"$"HHB!AA86-BQYJJ[^F[:M:ZQ
M=GN^FW5]E]WO_;YKK]\U6/,_Y[[/,\_Y'1]<Y!;^OL?(&X2P/B$?I_'A7Q#C
MJ6ST_]G('!V*S#*B$7,+.C%U9! 3/QQC-(OH9P@1O1(AHELO3'3:D1XVT1E
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M)&8=&Y4T.W88N2%I=N25I.EA(F5ZB$C-//A/]G1B#_JGS@%Q#6!^,SIPQ4Z
M[/TX_\, H2<H\#K#!,=O.>!P41;L+VJ!W453L+TTCYIWR86RON1+L[P<1I]]
M.8%A?CF;:7JY7&C&Y19AX\M];*/O-K(-OSLH8OC==;;!I1<B^M]^%M6[0#AZ
MYPEW.EOZ -;@^NO!^K=B?B76/F<2\X\!A'R##GX>P/XR'2Q_9,.LZWPPOZX
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MF('YV7E@=M8%9I[UHV:<C:",SR71#,_ET?3/U=#USG4R=,X-,;3/[V1HG;_
MT#K[A*%Y^B-+XQLBI''JGVS$]3>(^5V8WS@*4(ISS]@#$(/9_D<Q'S5YWAD
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M3D2ZSYE((N((OW<:Q)[YYR-V;WS0O?$C_M<@"OX3Q((K_J)P-D .C@4:P(%
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M.1G[@#784XSK /UWI!IK@"Q!#UQ8*0:-5<I05V5$559:TDO*'5@%91[LW-(
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MC9/%E/K))DKU9!^E<G*44CYUA%(^>8=2.OZ6IGB4T!6/_ GC*^N6_O4LU!!
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MP19IV_JCTC8+;DG;UKV1M*TC$G:U1!SA?^4DUF ">S V=0[5B#5HQ1JTX3I
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M*QR?B94[$6ZY,Q%%1!#V5UYA#>ZY?CD5.A6(.W^TP=WXN@W'LM%3%-9X"6#
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M@XH.W_6*&;Z[E6V^)Y6MOL]K-/M]KM'D][NRR5]4-*H@;_13X6M?U3Z<YV.
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M/?^]#T6JN7RJWH/RY/TD_]X7PG'RHR[P*_OF#PJ5OQB/OX. 1QP;CS@9BGP
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ME[@0?D,\()C)=HDC]P(O8[OSY_(C]5F@HH4<!P- )+_J2S@3UL1XPIC07RQ
M8XD.A"6C@"6C^4!/()CX+&$BL(2+X!).:HN35 _ZXD:"FGL1=>8B"O@!BLB%
M=X$%?Q#B"*0:S")RSV';K4N <DKCK.74GRN!@%7 =,*&&+^:_&O(OQ;08'-8
M3ZV]GHGG.B9]ZYD0KF<2N-Z&<"&8#*SG1+^>L5C/0;V^2W7QZSIJ[K44M&L^
M(7[EA"2.8)#^SE_*9X&\U4/L W(D#/-9W BX;0+L*$\G,(S&U.=ZVP'%#O+O
M(G8+!)/RW;1#VI.RAW;L80*XUU:U&7<?%_]]G.SW\<'>Q\&]EP'>R\;V4%SO
MIFC??9_M/"1$#)"[BW[6T;<"\B:1*Y0\[KM4YX F[&7_[P=T#@("0\GDGHL<
M<>(QE$R * Q.L5].LU^>8K^<83S.,0$Z)VW2Y21XC@__.<;B')T\RX;.4O>?
MO4,P%F<>J6HP&[@^DSN%O&'[ (^#JG- X\EG2#YMJ?;R%'&.>%I="[E,7%'C
M&8JU9[6 Y_0I#B@4;I@!MVC'BTS27@I7_2G!EZG[7V:GO\R@OG2&K[>)KXC?
M1FHPI3N!-')'D->+OMF3<SS_&5-R:%Y4\SRKKKE(-8F7U'A\+N=Q/>1M.? N
MA=('[)N/QZGN:?T7D],[7/2^X&1\EP_Y70;^+H-[EX[<?9/"[DN4<YAD'N(\
M0&X?\CI<(#]_/>H90/F\>N_+2^HZB%1S>1?_W_,XCVLA]]2UD.\X7G\TD"XP
M /ZP5?U!AS^9'#W@L_H7'\*'[/B')'U(!_]^25U_,%#C\1D0:ZCN197.@,1"
M=1ZF"*J]((_/HO3BGSLYI+\<LV[DKZ7\387Y%U7G ZK1/ZDS?Z=BEF[B>/P7
M6J0[2:7]'])]&!]"=2^G:M^%MKH&H:.NRTAW@DAG<GR@VH\BG8?))4<IU6(M
MVV^A@NYD^[/9_GRVOX1MK\2/U/WWJ3B_H]K]E@/W:PZ<>^RPN_SO'7[K\5T<
M4OU#VG]Q6UV#4-4^A"?J#U(\I'J0+7URHT]!Y(JE#^GTID!]%J6.[;>RY4ZV
M/YOMSV?;2]CV$-7U,/W;/G(6Y1T.Y#<YB%[CI[='3N>H.*4*E'3^1+I!]LJ(
M#?]9?_@+NO3-A#Y-IC].Y/+!EPBG#XGDR&+[A6R_@G[4<QBVLOV9;+^7[<]G
MVTO8]BIJ]HUDWLUA?!17J=PO<S!=Q#>XP"B>(XN$LU#=XG+ROVQ0U2"4Y!S%
MH6;&GK0EERNY L@318YD#M%LME_$]BO8?AW;;V'[,]E^+\[3CK-8BM-4^R>Q
MA;VQGU:<YNBXSJA\QI]^';E%9B]4.X@>0^+F;#5RW<T]==GO+<;B9<;B!4QB
MO*0]&)[LV6!RQ'"DI;#5;$Y/13A&.XYP?!Q&\\@^C/VT8R\6, ++L)-C8SO_
MNY56;.*W-]"387HHC=RU(R/X'SSDE/N#4O7'J=Y6JLJ1USDNKG!<G,=8\EG3
M'Q?R^) GE'[$D2.5K6>3HY <Y7P::LG33)Z99)Y-C@&LYM@8XF]6T+)E(]&Y
M-5(Y6\2G1:HH#CR!7SC=W^&4\CJGM^M&G/[X6)_EE'>2S\EA&)%S OGLL(U]
ML@E^Y FG[7&,=BI[/IM/0R%YRLE32YX6\G2RW;F,QB"?W/5\MQMSV-IL]F"/
M[#/,DO^*64H1W427A@I?FP#OC.?TRF7O:2XY)SG-'N)G>SCM;E?J<72-)N<D
MK))-P7*Y.P85 5BLC," 1CP6:*2B7S,;\S0+T:=9CME:=>C1:L,LK5YT:0]@
MIO9JS-#9@7:=XVC5?18M>I^@6?\W-!F(:'P"TM77+W'IOV1'?N( I]<=$YG?
M<:I=8RC#"ET#+-8=BP5Z5IBG[X0Y^I[H-0C$+(-(=!G$H],@%1VC<M ^J@BM
MAI5H,6Q"DV$G&@S[46^X$K5&6U%C=!15QL^@TO@35)C\AO+1X@C*U)#VP4@U
MF#-<]@]QR=WA3.WMP/S2BJD(E\!^$RW,-C)&M[$Y9IK8HWWT=+2.]D'SF& T
MCHE"PY@$U)FFH\8T%]6FI:@TK47%V#:4C9V#TG&#*!ZW$45F!U%@=@D%X]]%
MWH2?D6?.&>\)O$+^RZZJ.TCV, 7:[,&T@C\O<:3VYE3?;2%'^S@#-)N-0\-X
M*]1.<$3U!'=4FONCPCP4918Q*+%(0K%%)@HM"E PL0+Y$YN0.ZD;.9,6(6OR
M>F1.WH<,R_-(MWP#:58_(LU:5,%*A9O2$5QR'_9C#)AVK/>GSN 2,Y_+[BS&
MI(W]4S=9#U6335!N:8%22SL46TU#H947\JT"D6<=@1SK.&1;IR+3.@<9-J5(
MMZE#JNU,I-C.1[+=&B39[T:"_1DD.-Q&O,/WB)\B\O4?2'6@T^3=+]5@0AF#
M$,8@B#J#Z5B'._-+VE%NKX4B.R,4V)DAU]X*V?:.R'1P0X:#+](<0I#J$(64
M*8E(FI*)Q"F%2)A:C?BI[8AUG(L8QR%$.^U$E/-I1#J_A$B7;Q'A(HX@TEF%
M*_3Y!/GW2/M@J,%7$@OYOH=VM-*.:MI8Y*) CJ,!,AU-D>8T"2E.]DAVFH9$
M9R\D. <@SCD<L<YQB'%)0[1+'J*F52!R6@O"I\]!V/3E"'7=AA"WDPAVNXE@
M]Z^)1WPO_AL7 U3WP>RDQE]/#;Y,NH>$*4=7!/,KVE%.._)H1]IT/21/-T'"
M='/$3;=!K*LCHEW=$.7JBPC7$(2[12/,+1FA[CD(<2]#L$<C@CQZ$.@YB "O
M+?#W.@X_[QOP];Y'/.1[$7Y>*IQC[ ])=2"FGVN99BQE2CZ76KR#=M31MA+:
MD44[$CVU$>MAA&A/,T1Z6B+<TP&AGM,0XNF%8*] !'E%(M [$0'>F?#W*8&?
M3SU\?;OAX[L$WGZ;X>EW%)[^S\/#_R[Q%]^+_$R%I\)5=_)N(??J5$H!:OTY
M3$/;:0]E&PH8CS3V58R?!B)\1R'4UQ3!OA,1Y&N' -__Q]9Y@,=57&WXDR6K
MK[3JO??>>Y>L8A7+EF3+MFS+<K?EWGLOV,8%%UP  Z;W.)30 B:A)*$F(0E_
M( %""P$"(4 H2?9_9W<%#LGCY_CNWMV=[\PY9V;.-YJ9FZ.JRF)55E:IHJI1
MY57M*JON56GU=)74+%1QS3H5U>Y30>T9Y=?=H;RZGR!O(U_SGBRIUB$7\,&-
MX)T!^PBIY]Y)T"*S#H7W<[#'%'S338PTU[NJKM:BZMH@5=9&J:(V266UF2JM
M*U!)7;F*Z^I55-^FPOH)*F@84'[#?.4VKE%.XQYE-YU25M/MRFRZJ(PQ?^+Z
M%4*6U.B0N]N=\T"3'.>Q[(*';T"6]I/KHD<_]NG"3TWH6MGDK=*F !4WA:NH
M*5Z%8])4,"9/^6-*E==<HYSF%F4W=RNK98HR6^8HHW6ETEMW*;7UI%+:;E5R
MVV-*:GN#ZS^4TFJS2RIR>S?C@ID' O?@#/JE06D=UV'2X,')Y+M\UH&.]=BJ
MI-U#^6/]E#LV1#EC8Y0]-EE9[5G*;"]2>GN5TCJ:E-K1J92.24KNG*6DSN5*
MZ-RN^*[CBNNZ6;%=CRAFW!^X?J'83IOBD/@.FWU?V-7@'P/[,M+>K7,<ZU 6
M#A$+Z-(#36I%EVIT*>P9I<SQODKK#E3J^ BEC(]7\OAT)8W/4^*$,B5,J%?\
MA+&*[>E53,^@HGN6*+)WBR)ZCRJ\]T:%]CZDD-[_X_J9PGIL"I] UHB8LWE.
MSW3\B7[/ OJ%A<0",F\^L8 ^7>C2B'[EV(6FKY3)GHKO]U-L?[!B^J,5/3E)
M49.S%#FY2!&3JQ4^N5FA4\8K9,J @J<L5-#4C0J<>D@!4Z^7=>J/Y#?U-[).
M^3MB4\!DAYCG0YV<1[\PS/@$15X/-5RZ3)K%ZXE0HS;TJN7S(G3,P#[Q0RX*
MG^FCD)E6!<\,4]#,6 7.3$5R%3!4)NM0O?R'.N0W-%F6H7GRG;56/K/VRWOH
M&GD-_5">0\\B'\AKYK_D/6B3#W(5Y1\S]'P%?ECE6(>RR'D>2O=*8G$Y-D"G
M''1+7@S_1->@83?Y+?*595&@?!=%R&=1@KP79<AK4:$\%U7+8[A5HX=[Y38\
MI%'#%+P(OKL(0KD(\KCP:>0]!.Z_P&:74^ ? F_W.ORP45J^B;X1F<3KL4C-
M!JD NIK&YS%KI1#$?^TH>:WUEMM:>.Y:^/9:DI"U) %KLA$&P#4,/&MH4&NF
M.2:WUIA-/A#;U;?2\4#@5D',5OX#08<5-AVCWOLW.O8"K=WN/)-V)_P;:4!*
MH*D97..X'XJ0FL@;&;6+!'0GR=9.$L"=80B)STX&V9UYCD6/.VG,.PGD'3AQ
MQWK'HY"W0ZJW09JW012W?B9ML=GE$/1O]P['7J"E9B_09;2% _1)!Z6*RZ5L
M) $)0ZP4XW48_",DOD?AMT>\$!+0(R2C1\,=?_@Y:A(@LR;%;(3M<BQ^.X)#
MC^R1#L.Y#]^+X2')EW]"9_!O^UJ4RW8[]@*M!',.&)..$H>8K0I:FGNEE(B$
MG<+^N-/S#-CP=))IIZ#'->AQ#?8XASW.88]KT>/:#)(1DJ+K& BNZT/,X^)Q
M\#D*/@>YOX:8N ;>?_57B$V[#CJ>2S3_&&T1O YP:E W_YR4="WXUTE^F- #
M?JZ1=2BW7R)W0 [NP"]WDJ#?18)^-US['OQR 3TND!A<8-"Y0*.^0&!?H+(7
M*/ '^.,>_''/I\B_'',P8$\[2U\ 9MT-Q"!82;> ?QOX=SCW %VZ#N5'3C%[
M<QX:F1?!)C_&)H_AFXO!)*GH\5268['NT\3GT[,0 N_I$PCMX^F?\=D[R-^U
MF'K/H,[=U+.!.A;>21N\A_B[(%GNDUQ'YE[,O,M%YSS(TTX9V9/SK'.MAGT^
MQ%WZ-;YY!8+P&GK\D43L=1*$-_#)FS3L-XF+-ZGLFQ3\YHO(NYIIYF"H<Q.J
M%5//%.H99C\'5W(968<RLA]G9#V(67OR.SG."7GM>W,A]O-"\,^'YDF^Q.K?
MB8_/2)*_($GY!VWU2SJ?+PGJKS#V5QCRRY_KN_T?/D[>?^D>$',FB#F3=+P<
MYX&:M2!F+XIY+LK(GIC=,,@#^A?,[I_V,SG.P>9NT3_@5E_ &#^WGTGZ(7SV
MW]\^@^5=Y_S'KY#G[9S7PSGO,,HY%V'F8LP9K>9,$',FJ=D/TTX)??H&7O<5
M//<?\/[/M9*RU^M3]##/1OD8/3Z"_7T(,_L+[/#/,,5WX9EO8\0_8: W^-7(
M61QF_8>9BS![0I[XK_D'%Z==0JE3(GBYU*4"K&8PQE%^O]Z';[^KN92]F+)7
M4O8Z7+&5LG?K53CF*[#=W]" ?P6K?Q&V_#RV>)8[/Z>$9YRX3SKG/LP9&/=_
M3P=Z#+3UPFX!^D#1L.1TL(IP=2T8;90_@7"8K)<T2/C-I2[#A,D*0G,=(6I8
M[6[]!/9[$>;]&#YYA(;\$+;X$=^X'\WOQ5-FSN,'3C%K,&Z[1(>OOYV#<*5N
M%O!"]4ML\;QRP"D#HX'RV_6X>F@B4V@J@]1C+N4OHOSEE+_6SJ[OT1[=I4-X
MXA3E7T]DW*V;T.@\)5Z'YZZ5X\E"(W*U4P>S!^8#9VC_UM[4O+!9 'A1U"45
MG +=!^^_ .^_6QV4WT/YDRE_!MW6'*R^$(SE8*REW*V4NU=GB='3^.1*OG4"
M6QRC)D?QY+=K,)#+G5?S(.KWS1(ONICG7!S-_\?$YP/8X@<* 2^>4C+!*:96
MU6", :,#C!XP)H,Q72<U6\?1XPKT.()?#FD[D7% ^_ED'[_:@W5V$7T[L/!V
MHMF<-GRI_-6;)D[7]@NKHXN[GV9]#_K<1GNY@39R3N%$>A)8V>"44)=:ZM%,
M'3I F:#+B-.]Z+$'/7;AEQW$QS9MQ"N[M0F--J#Q.CKU-5ATM5XFBC^Q[S);
MZ6SA1LP6O^<9:AZ/@'>:^8\0QS3\->AVRL6;N@52KRCJE ).'CAEU*46BS>#
MTP'.!'#Z::73\<0<K789UDJ7U5H^:IN6CCJHQ:ZG->QZLQ:Z_4@+1K^@^1X?
M:I[GOS3/RZ:Y3C%S,$_&2P\D,?0@U_/Z3!2Y%5W^Y7XNVNMAT7:W8&UVC]4&
MCW2M]<S7:L]RK?2JTW*O9BWS[M02[QXM]IZL13Z#6N S7_-]EFNN[T;-]MVG
M6;XG-=-RHP8M#VB&Y05-\_M(T_QM&K!^)\\G,-PPY-_#\'(C<I;A[A@IT7ZZ
MV)VD!)L"1FN-Q5\K+&%:ZI>@8;],+?0OU'QKA>9:ZS7'VJ+9UBX-67LU&#!5
M,P)F:5K L 8"UFI*X"Y-#CRF24'G-3'H/O4%/:O>X _5$V)33ZC-<46>!O^!
M7/Q/VG$M<I*N_7*&F5UITD;T6XF=AH-\-#\H2'."HS44G*+!D!Q-#RG6M) J
M#80V:DIHFR:'=FM2V"1-#)NAWK#YZ@E?J?'AV]0=<5CC(J]59^0/U!'U#/*^
MVJ/_A=B^E2? NP"OOJD,&S#<'^6ZC_=;2,E68Y/%^&=.M(=F1%@U$!FN*5$)
MZH_*T,2H?/5%EZDGND83HL>H.Z9#XV)ZU!4S51VQL]4>NU1CXS:K->Z@6N*O
M5G/"W1J3\*2:$M]%_HG8OI5'J?M=8%_/,'\*CGVH!AM4FCTPTK)\>$8F8WOR
M*/7'6]07'ZP)\3'J3DC1N(1L=284J2.Q4F,3Z]66V*K6Q'%J2>K7F*29:DH>
M5F/R!C6D7*:ZU#.J3;U#-6E/(&^I)OUKQ,9KAYAYH-O!/<<0?Z(1[H]L)Q5<
M:_; \-DL])B"'A-2?-25$J".E B-34E0:VJZFE/S-":U5$VI-6I,&Z.&M [5
MI?>I-GVZ:C(6JCICK:HR]ZHBZY3*LVY36?;CR!O(EXC-+N7(_=3Y%O"OAN-?
MT>+<A\/K5=Q;@!Z#Z#&1&.G,\E!KAK^:,T/5E!FKALP4U65FJS:K2#59%:K.
M:E!5=ILJLR>H(F= Y;GS5)J[2B5YNU2<=U)%^;>H,/_'*BCX(_(/%1;8>,_(
MC%S _C>">8:T[P@<? ^R";Z_'+X_%ST&T*,'/=H*W-28:U%=;I!J<J-4E9NH
MBKP,E>?EJ2RO5*7YM2K);U%Q0;>*"J:HL'"."@I7*+]HA_**CRNW^&9EESR"
MO(I\KIP2FW**;=RWV<_%.0_^J4YB@;1O%[*!E'PINLQ"C\GH,8Y8:296:XI\
M5%$4H+*B<)46Q:FX*%5%13DJ+"Y607&U\DO&**^D4[FEDY13.DO99<N45;9-
MF>57*+W\1J55/*34BE>X?J;T"AOW;,I [@#G6C,/9,[$[7&>!\MU,>\'L<<D
M?--)C#02,^7EGBHN]U=A>8@*RF.45YZLW/(LY504*KNB0EF5#<JL;%=&59_2
MJP:55KU$*=5;E%QS1$DUYY58\R,EU+Z,_)W7-NXAU3;="LXUX!T#>_\D*% _
MN3[71;R?SOU>[-..G>KQ5VG]:.756)13$Z2LFDAEUB8HHS9=Z;5Y2JLM4VI=
MG9+KVI14WZ/$^NE*:%BD^(:-BFTXI)C&ZQ3=>+^B&G^)_(W7-L4TV/C,IINP
M^UGPCDZ6]@X0CZ2=*[G.Y_T J? $;-*&?VKP31'T+;/)1ZE-5J4TA2JY*59)
M8U*4."9;"6.*%=]<K=CF9L4T=RNZ9:JB6A8HHF6]PEL/**SUG$);[U5PVPL*
M:?V8US:%M3CD/!BGP#L$)=L]D[[1K$/A.G<&;1)JTLUG8]"E8H*4ARZI'>Z*
M;_=3;'N08MHC%=V>H*B.=$5VY"NBHUQA'8T*[>Q42&>_@COG*JAKC0*[+E-
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M)42_QQ8OPS%?4@GEUZ)_*Z6-PX83*7N LH<H>QYE+Z;LE=1KO>Z'!=\+U[U
MYW$W#?E.W0Z661'R&]U,S4;. C5/]#%G8)QVZD"/:7_<T#O.L'J!N'A& 6!%
M@I-,";GH7D[3J*?L-LH>1]E]E#Z5\@?Q_%SJ,TSY*^#KZ_'"#M /TIU<J3,@
MGL(65U+B<2QZC-J:4W7-$X;,^@MSRNY7SOD7L^7K16?3>I3XO-^Y!N-.Q5*'
M=# **+\"!MU Q+51AW&4WTOY4RA_!I$XA_(74?8*(F(CT;D+SGX$BYA5(;?3
MO3^JG7AR!Y&U7=^MO]AJGZMS++7ZN;,)/N#L>F[!%M<3%U?31DXK42?QR3%X
M_U%5HG\#^K=J/_&Q3SU@3 9C.AASP!BF[%7:PK]-:+">7Z[%%FNPXBH:] HB
M;#FXE\KKHVGRWM2=IGR!KO96-T?7>Q5Q<8(V<D1!U"<*K&1PLL$H J,2A 8P
M6FD1G5J''FO5K]7HL1(]EM->EG%G,5HMHH2%6&X^-9M+E,[1VYI-2S-/PC8K
MOLSU);KWQ^G.?DA7<@O7:QAV3J+/$;JZ_?*@%#_L%8)U8RDU!9P<ZE(,1J66
M$A^+U0).)S@]X$PF0@?!F4_Y*^A)-N.E_9J&)0>(G"GX8S+^,+.<Y@2B?J<\
M'8K]S1%8##'7,NR>C""W8\C90VJR%;NL<_&F;E;PPL"*TP*E49]<<(K!J0*G
M'M06+- )5B]1.I7R9U'V8EK/.N[L0;L3&N]RD[I='M2X4;]2E]LGZAIM^U8>
M-W,PB0QA*?!>Y BO]W!O2SBI!W99:AFE^>Z^FNT:H,%1$9KNFJ !MW1-<<M3
M_^@231I=I3[W!O6ZMVJ"^SB-]YBH<1XSU.4Y7QV>JS36:X?:O(ZIU?L&-7L_
MH#$^+VF,[\=JLMCL,@9YB*[\]@R&Y&R&>O/G%X;;[:0@ZTC+EI(6S<,F@_ZC
M-<7'HHG>0>KUB=($GT1U^V:HRS=/G;ZEZK!4:ZRE46V6L6JQ3%"SWU2-\9NC
M1K_EJO?;ICK_HZJUGE>U]0%567^IJH"_(3:[5"/W93BVWYXM="R#W5L WS-[
M8$A!%I*6#6&3*?AK0H"G.OVM:K>&JLT:HQ9KLIJM66H**%!C0)D: FI5']"L
MVL NU01.4G7@D"J#EJ@B:+/*@@^I-/A:E83<J^*0YU44^E<5A]J^E7L8WL^3
M@IXJ@_LSM.TD]5G/^Z7<GXM-IF&G/M* SG WM01;U!@<J/K@"-4%QZLF)$W5
M(3FJ"BE616BERD,;51;:KM*P7I6$S5!1^"(51FQ0?L0!Y45>H]S("\J)^@7R
MH7*B;<J-<LB=9BT.V"?@M >J\0.R%IX]C!ZS\AQK0,83)ZUQ4GVDMZHCK*J,
M"%5Y1(Q*(Y-4$IFAXLA\%466J3"J5@51K<J+'J_<F 'EQ,Q7=NQ:9<9>IHRX
MJY0>=[?2XI]1:OQ?N/Y;Z?$VN]Q&O:\!]QCIY[X&QUFLJZ$H"PU%*"&_RH<6
M94ECT*,JWD.EL7XJB@U286R$\F/CE1>;JMRX'.7$%2L[ODI9\6.4F3!.&0F3
ME98X5ZF)JY62M$=)26>4F'R7$I*?4D+*GY68\B_>VY2$F'3O+/A'X+-[2#\W
MC2$6>#V?>]/YK!<=VXF1!N*U/-55!4F^RDT,4'9BJ#(38Y21F*3TI$RE)14H
M-;E"*2D-2D[I4%+J)"6FSE9"VDK%I>U2;/HIQ:3?H:B,GR+O*CKC&\5DV+C/
M&$:=3X-Y""JP"YZ_T:Q#X?4\=)F*'A/P42NQ4HO/2HC5['0OI:?Y*RTM6"EI
MD4I.2U!2>IH2TW.5D%&J^(PZQ66.56QFGV*R9BH*@A29O4,1V2<5EG.;0G.>
M0-[F]=<*S[$I KD>^Y\$\R"<>F<7\6C6H9@_5:/+Y#'F+!*II89<CY@I(D8R
M\]R5G&U10G:@XK/#%9<3J]B<%,7D9"LZMUA1N=6*S&M1>-X$A>7/4&C^$H44
M;%-0P7$%%MRJ@,+'D3\IL/ K[MGL<LZD_^#OAXILA^.OA5LO@5O/(O6;A!Y=
MI*)CL%,5-BG -VFEKHHK]%%TH551A2&**(Q2>&&BPHHR%%I4H)#B2@47CU%0
M<;<"2Z8IH&18UM(M\B^]0GZE-\M2]BCR!UE*O^ ]F2-R%3A7@+\/>KIUDG,=
M"CQ_)N\G<K\3FS3RG7)TS<5FR=@DNM)3H>5^"BD/5'!YN((JXA18D:J BEQ9
M*\KD7]D@O\I.6:JF( OD VGTKCHDK^KS\JA^$/F-/*L_D5>5C?OD,=3W,*G_
M'CC]Y@''.I0%</P9O.]%E['8I9;O%&.K3'R6@'_"&UT56.\C:YU5?G4A2+0L
M]4GRK<^23WVQO.MKY=70+H^&27)OF"NWAK5R;3@@EX9K"6Y(0L-+O/XK\D^-
MJK?9SP:^W.Q'FB%MF.E8AS(/F<[[">C3#$VKY#NX5RG8)1J[!+?#_]L\Y=/J
M)\_60'FT1LB]-5ZCV]+EVE:@46T$<AL*M_6:A]H@D/@VR&0;9*T-XM *,6B%
M=[>2P;7:=(PZ[P=S^VS&B+G$XSSZQWF.O3B=W*^'EI2@2R9ZQJ-/&+:Q4K1/
MCX=&3[#(97P G1B=^?@81V<VG@YV/ $\GB :3V"-IS+CER&0Y6Z(8S<9TC@R
MIG%D;UWHT&5SG D#YI:%CG4HYMG$0]#37MZW0$<JT24/_9+Y7N2@%$B1OM,D
M]VEPN@$2C:D,\E-)/J9&.":VIS  32E"".(IG8Z%/5.&'8LJ)I^0^N%7_4\1
M\'#_B>@PT:;+%SCV FT<68>"3%V!#7A?MY3VR&?I%!$#50SFNQ;T\D TCR1G
M'@G&7(OYXP*-.<0L<D088.9@BSDTHMGX8S:&FVT6^6RDL4&JAR!T,Y^@$WX7
M^9K LVD?9MJVVK$.9:E9AX+T\+H9*8<:9B'Q?!Z*2_T0#W34B*P@$5Q!(KB"
M9&QY@&--RG(&N.5I"+981N>R#'\LPZE+*63I01H^Q'(Q9'48,KCH2P8%FW:M
M<YQ).[(.I7\;;0&I1O*V2XE<P[COCW@@))/?B7F_%3VVHL=6[+$5/;:BQU9X
M[E8&F2T,?EO:$()I,P;=O-MQ/LI&,N<-9-+K833K;-INSJ2%@BXD9 :@Y5V$
M;YUY)L]^8@ )1_P1#[/VA&J0M-.Q.^7R$<$OEWMR#ST.H<<A]#A,0G:8@?<P
M<7$(6QPBL"ZGLI=#] \2EP>>IS%\C-BT"=PE8,X 8SSE-AZA+[A"2H6>1QS'
M_M^>@R+'^I.SSOF0[XN9'[D&FUQ#G)XC,;X6/:Y+=OR!Z#HZV^NPQ;4$V;4
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M#L/].8;:XXF./3#;T6<=:=$R[+* 87#(S1M,*WBA8,6 D@1.)CCYM(X2L*K
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MBURLET/D9!'!F;2F=%IV&@-0JGZ.%?^B%)=O$/HLTHPKTZ6#\/P=R+KT[]:
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MY =/23[PQ.8#_L#[ XH%\D\"V:'&H%\"LR% >GH(_#4#ZNN![U6!+G+ )B)
M#RZ0+C$!/Z$&5223QH,(),$ *@$&+W&@@Q@85,5 !Q8#SB(&G%@,.)(8,*(8
MR/W%0((L!I)I,9!0B8)$111$"B*CP+! !^$_H&B@YG$@-\0"]$LKT"_!96>Y
M>1Z)-M!E'^!+ CWX@$W8@4WH0-4H0='$H'W P F2<_#@E0<#NAQXV,F"]I %
M[2$+?$(6Y<@ ) MR?UE0J"S(;61!8B@#D@EID)!(@;Q;"N@@N0%%HL[%!>EH
M,$@]O%!GPH++#EP'07ZO!G21!_H) YMP ILP EVH0)$[@%W (P$8"3S0]@-;
MJ !;* -;*--L3N@J@?90 CZA!!I/"8"5@! EQ.;!GHH@>5,$T9K",*@#\(<]
M&]!IU.\S Y<)= +/"9#+.[N"?@FZDB[J=2*@EP30CQ?8A 440PWL0@;TP0.V
M 0]2T%C@T@6YI0[(M[6!7V@!6V@!6VB"!Z$F: ]-&=2/38,+-+0&$* !HA)U
MD$RJ@81-%21"!U9!'3:@$X 5"E3T!Z;R\ +^"%*@@R!P4 .ZR *>X.'-W\2A
M!?J0@V;%1\U[6/YY_=R3 BY3H(<):!-CT";&H(\<!+8X"/K'0= >!X$3'=3_
M<S\*Z)^&(+$U %&C/DC*=)>!_AL_?QL9M0\%]=O$KN"R .ZK#?ZM /01!3Q.
M=PBB!SI2 IT(?LYW@,OI9W #!A+HSSTIX#H$]#@$]+ #>MB!/F(';&$+'GZV
MP(%M@3/9 .5M0.'6H']:@;'2$B2)%B"C,/MC<Q\*&,(\0\!MX*]!,&A><$D"
ME7D"@0\ O2A1[^& VZ&M%VJA";@ZVMX43^ ?'J2; 9 ' P2Y []PE]@\",H-
M.)8;ZO"9DZ"R(*EV <FK\R-0G^]0V!%0)'"5P^ R!I<:N&2.@GX +F;PF2H<
MR/_YWLV?U];W<8[\>85MO? VSXP- WJ$@38)X]]\&(8"APX!A@L)V_S-XF#0
M/X/N $?\! 6" -8%J&8.NJXF&$+D(X$/1('A%EQ4X#,AZAS87V?!QD"_YT,P
MWL>!T-_5B07])8YZ<Y$L#@SRL< 6L<"Y8X$1SX("8D!B'ST$RGX-N8'RK5!'
M^8#[%.)!/TS</ ]V)[@(D_\,]E'[3+;.A:#.)D%[!^?/[W+^3!!^G5M2 /0H
M /VU +1) >@C!< 6YX%#G0>5/G\>7)T ]QBR!6ZJ#V0I 3EB0,XN((<:E$_X
MZPR47^?!_GH7Y]>[-[_^HKV' _V>$_DU'](,_*.9X<^S2<#@U@ILT0J<L 4(
M;0'@EC'($ P9^X%,"2"/$SS2:,"CE6CK'I1?Y\&BROSU.S6HN9!?>TY0"_2H
M)/6O]W"@W^_+H,Y0_7E>"!@[;H+ XQ;PSUO@X7 ;V.(V:/S;0.!M5 'HA$=
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M>D?\B;! 'P]7)P<[&VLK*QL'!.RUWRM2NQFIR=#F:]$!:[#]TQ#&=O8SA'
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MZ!KR2*^O!;JTHT)>D=1.(VL1KUUL+UFU3.685"U<$'#ON9!J.DZG,I^8F+K
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MGMUI-<59:7(I@KN#"N%Q62GG2+).QA]*4KJ".X K\2S$T?<X$)B;Q3JWS+O
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M'(L_V5F[Y,P^4M_)[Q9R@4!C>U\.2[A/Y8D"&L#HK'SB?*L\'$1/7M9?+A-
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MV!-).F-4XQ$7F,)4LZD_](H1Y Z=O?BSY8&N'5*EN5SB!U"?R3@RQ%#_PB@
MIG7"8$1\;-#9A%U&94U-;#Q;AT+_<;[$V7BJW:2$%)[<UES7MI3'%@Q$]LX:
M;-',;1OM]IZ"496#8E_UZ/W(>.Y]8GC)O[[#<?PZ/HN07U1E\:8*#[7,N9%Q
MNM]5KX ;%7&]'ZT7X?!^ZN&"&ZD,%I9U./0$.1SY]/MT7XW8AECFV>WNL>YE
MAOGW[LNN-0W8_64F@=QW6Q)7']5=Y4C%&7](<^Q7C>Q"XO*B?5\C^SP<,)!
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M$L;Z*_/LFQ?I<#4!DU"Z>@I^:XO.(1_W6'Y>V%8_S0Y:EV5&Q''Y\M68HVL
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M]O B YB*AW,$FX",=OTG+/>DQI\A*]7G!B28I\;JY\)*/"!]6>$@C%ZE-DT
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M95;6H'U56HU)&BB#Q7=I8+H'".JZ4%<[P;%<M<%)VK8_4E [G$4)4MU\%;-
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MV)NHK=\JRTZ;9=FN2R;-WK.&&Q0BE!C=.1S,>LTUDW=9@,!U@D&YO7FX0&^
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MDI>='&ZO::Z;4A+1&IW\B9<;BV13:DV_CI^;<T@C7_B/1#/2GJ2Z'E]JN8E
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M_1=H&G9\[*HO44K3OQ1PUQ&_5/A</D!I>'1!M%SFU39]$9B*#=T]=O[]Z=?
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MNJ0:CB0;Y?%*50>1WVXF_(FS)WA;M/@91B)7N:Y=O$[U0V.8%JKG3*OESL5
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MN)KG =(U#;A]CF2EYDUFS7Y?JYK_Y*1;6&/^C44*2S*V?+&FS24I0WZ)SNI
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M'0LBD%Z<&5[,(E"+W*XBMR9B04O07M<@*$]28O[Z)8ZAP)W.$MGRMV]TZBL
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M'PWX[^BR/8#A\]ZSN#.9EG&[3:/]UU#?^V5*BF2.(J>*('C" 2)1P=863(%
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M!+UB/!7^%_DIB^#",0&:S,#SFX,!4\Z8^KG W2INF#*1)RD&1ZD(I]@$LQ^
M;$PX2%:$]=Z$4F_VR.DMC Z!WK$0XU3JDK6\HUMLA@[#9@P%3F*HDI31IIOQ
M!*3AR 4C(<?EOC=EA\NK"=+IF=6$#;XVTZCB:!6D-!G8)4-WC7YD-V8L9>[=
M%*DM=91LZ-S4///WO_@+(-].>_#QF$$K5,.:3?>D1DL- JLNJ17.,0)/#")H
MY&H#1(L.@O7O# &*W,#=DN@;C[%;H6XG4@4FQT S?(@^CR4$XB#MLD%?G+-<
MHNQR@@$3S)8W26^G54O\5F"2+9NT8SS*9SCZ8T;+O)246U6P:'"+AUOOR_M&
M\_(H92H8.(@VUB!<G MCIA*CC'@(9+D1D16/M@#'H^"=H<0!!1?1H]0\^(\?
M,&V\W+]X]H;A\US.5(V2EUDK4UMK)E!(J4?VQQ4&28Z+Q0U$.$R48_/VK'U*
M5N)5D3P5)LTQB7(7ZG;^0Z(Y<Q1DN!0!*I9_/2EBZ2T^A3>:\3E1QJC#50^\
M N/10]U3I@J0-E.3VS:'CIGB0:CJ-OX"$.$Y][X]<D\,@U7,N6RK[[Z9NV-0
MDV9Y3+:TY.O%#^3O.]VK3U.QV9%^QDNA)\R=-94)!!^UH"8JBQ(M^#[</]^=
M][S$_XLZ?J5]W\)RA(MNC-W])C;*WB8F>6 ("7?/_O-UG5L%J^Z"J<6*O?B'
M"J3"@.93>+"W19D$Z<-Y,;YIY8_;;TMQW)4?3,H^F&J8B ^5&O6/!F*SJ[32
MZTZKWL;#[F**^29MN+1O;&=;^5PCS;0KK(I_:52KBW9$O5_B?JMR04YQAVD9
M"_:-NC?7)['(2SI5T.'>1;+\S34G_M!\2H4[)IYO2HSEE#YGZ!!4R Z#O[N#
M"JFA5_17Y@GWD7/KO?20CPF-5S= 6;F6B:%(W4-;]/E)SO0#<=RK#7Q RSJ?
MCNLE/ /FH[5I=;Z=S?EA#'R'_73+9J4=\ _"\\?NY^>"OP"^%Z+K#3=;)0>)
MC$1?=ND?6A);V/Q(;X2A1;@Q2E/K%0PH%/M?Y"2$FGGZV^*M):?'?V82T 4/
M^[Z<[V.]:$U5AR:>J4VTW+Q$OXJY%T=;&Y5Q43B(]JGWS6Y>GI.0JMM]21B
M$@8SY9X[:5##T^IS?KWX'^>@2*XI*>=7>1)WO3<_TV2L5U'D^O%[:L;BTXZ
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M""H$EF;=1/]5B QY",SNOW@"O+S=->UDN=M"Q*X([S_^:Y7JO^.2,@SP-FO
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MX9D1$K>CVR4KZE^VW6*&V,\AKE]Y5ACRT%<9)+LW44-JXQCQC;3<@<5NBT\
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M*T2WODX;,03#O&$!"[6$B")$5UENP9R:$]2MPUF#U PJ/4FUY5NPQ5--,'3
MZDYS^D?3Q/7*N]:@CEM5>  5*/C-;#0^VER;]Q,T0>2N[\@Q/0#P<>UX?X':
M</[PVIKYGE3C(U4>.,D:TU-FXKN@<4K?4[O9 9E03$6OJ9[?&FJ@&*:-MKU+
M$+SNEC',LFJFX[QHF9^S*+M=U2%@8ZG(+@B4Q[4\[C7*;<**0$^=%*PU"B;A
MX(\HUCQ.9\WQC1"@ND[M4*N]% G7]C*<_+P0;O>E!O.3S;UU*?:.E!STOI[6
MQ+(FE(W>Z/&<'F0Z?^77ZB*WA_$^T#O&NCSB3# SV["L(O9S3LY'U'H'#!,0
MBNX X&J]P8B3?Z*F;7O6=[?<D#$SJH(/@8#1IY> F<\(T.X3B&X1(Y80#A %
M<)<P6?;DMD!INA2622=Z'C]NJ*J5K^T]2LQ7@A"*]I%+UCP'OB,L9QQ]O7L&
MG,#K]IGN0?3>8P7VONC;CU(+DAV7FQ9#3"SI+(B-TUX3RXKY*>RZ][?793-@
MK$\$G_/;%LC>36-R5^0JP]JM[G>:%C%'NX,@9OK@05&AD(^L8[8LJ26%RI#3
M@"E90;, O-=(KV5X5!AHN2QTA%T2O!\]HJ<,?'?1OY^-BWI8P4 CS-H++?''
MC-<*99XI2'MWHC:(I2H< \6A^32LKQ*BG@'2Z9_2+]BLO,;#XYVVISO =V4-
MT4%ON/*#M<M<)>,9#Y9*CM*:A2I;P8G*RLCV!_IEFVMS*#;BQS;A:9Y!+$AV
M(:6X-?8/SOC?9&?XBB35"1@ST9Q?"_?]H#L0XIZO%R[Q]F]&2F+7*$[F!VS4
M'E>VQUY$I*+03:.@4JC@<5/ZP\[).PLI\JR)?[;W_:98AO38+12/\.C\Y,:S
M]J;J#A3R0.(6&E"[VSF)R0Y*95("\@#_.(-8:M*#==X(*H>3HGJL7UI712ZQ
M3U^Y)YU.->-HL&O4<)/W+7S] AXX?4Q+.<G>%NA=6E@OY.)CTBOCY 82VC8#
M@91?C@'.>G1;?^\[_W,"M7]19"EBM'OVT#GRU/S?LGA,F6"F[Z=7?:2G ]%K
M'7!U]:)UY3;+=&0)F,W3!YP^4 IP$FTM9YZ8Z;#5Y\2L.7I[R"2&19J!TL$<
MA9-=+M<M!^_)Z\IJS5N6YMO$N,W1RRT*:P?SD# 8&S#>?[+L=.RPK'P&R/PZ
MD>^X^E[YV]PHZI??FYI)IDG!D05W684RQNL%+@<59])XY),1%)#MEW.8$GS"
M1=&+<G =0B>A*Y 2N_F]96$,G1LCLL'>Y"SK^^#B<">D8ODN%_-JM@\>Z_*C
MSG-O\C% 4@RQ&5R6BCVY?_D]:[&%Y>6W$7,6LQZ'0 WP)?>6X=9L!9ZQ4"QV
M\P7G.FQ4RBM%<&=]6DTGQSSA9[J!S+?2/"U7>\/Q@X=TCA<\O4YUJ?(Z&PV9
M"Q%G;[ =C8LPW< ?L2$^>\4#WS;8@_':X&9[^71.YF0@DR:'^)PWFYD.O+8#
M[3@B6JQ:-G,64="5TC5D()?9 D753-R'/].DSC,.ZT:3YM6/(A&FF*:<(!'Q
M($;&6VAJ:N9!Z7G5/NO!W(IPYAGE<BX$[F-1T'H1D'*L.BZ7K^;G+SAF2Y=M
M(H\.):Y.WS1U-I16/8'&N!RTN!>'AD;#A'P[*KXB]:[@Z^X-DW8%'0P8V(_P
MN&JA2W"97^^-GW<Z?R!0@QSP;=[*>:XIEPJRI/":[(CRN/>5^=?)JUU&7:3/
MY:CW>\G'?.HCY)*>[.OV7BAJQ59M4*O-5GY+:BBX=6\4-EXZ:("J^58WZL2Q
MRKR6VMPSY)$?5A%F*;SX=>.][97N'%!-JOAS8Y.F#LI FW>O*]584OR44ND\
MK4U#0*ER?I&L,<RB>P8_9S2D9@BZ.JC0P=K;-QQ5=)1E4Q%,S:U0I%@0K7E;
M:&RB[O/R=(KIVZ6E,)A1NJDZ#V[WC:H ?X1"D[:U[B8[:PZ[UL+!ADA'FJ/G
M2ZGB?![LI$#&Q$XO"GP/3X9PB,]I#"Y4Z,>=%P[)EHX9A(H+D"9<$LWI#D$=
M:IWX2-0TEQ3'#399@UUH,#'8+=*ZLS*5DM F SVGQBK?TY&7SF+\<+;;L)<:
ME)-T]$!HYD#-]=Z,C!FO8T<Q05AKC5U&\\_^RK DIST94JW[ ;'"S(NOZEO:
M,2Y6?/FK>R.9-" -Y5&WJIYS#ZU"N6'%Y!=&&:A7<L966&]0V$R=9ZJV3NH5
M\91IX@<:$CO#A4]R(Q^2(FOE5'>D1&ER5VS-R/+N;(1[*3F.W6F5RUHCJ'B=
M-ZS!>DMXBUR83*H6@# 2N:].<T=:34W.PBL'2RT,E4F%UOR><9@*.P3T1,Z1
MK%8<+X.OJH",3 H9U"V"G<$Y5(]]*X+3A'CSG-V;%DWWM$G:7RF*=EKI_\^C
M>43-^[6P6Z'&1]%^SC>_0O7^$1SM?Y<;0G++A*9XTH.?U0_,J,LQW$SU3NW?
M>S';3^F9ZAT!;Y,F'WW<[9QY$'%7!=%TY-$TIWW^TV2W31AY9<_[7627FSO]
M+T^0>V)<_5>8:8)6ZHKNO<^2=I.5N@GH\$LA;,,>"Z.X=4#26P\B2GRJQ?_Z
M&Z&Q65<(0Z1SHJ G4:DA=/F*VTW/ZKN^;DO=?K1<RS.@^ZE.@TO5X6,[F>!G
M\&9:&E3+E!P[L4_*%WU?J5)#B&-*9XXEO']Y;N6+\WP_G[^X(AQ75X,Q2V."
M6 8;!GF7EQ9_!DT[99A]3SZ?6.&716G^M<1^;OF]:[E]X"-3'7X4KZ+?( GQ
M5E*R\P]E]6%R5%1/%,@K)"8 !F*&,-T>G'3&"E5ZB.6@V9INE'FA?%]#KD?9
M'P1EK+>&)24F!LM^E0!NXN*2E.]0M#A'[U*SG9)4-_S\,<O(>GCHL.+7^KER
MP\XS22[2J D'9(L_B@]/3!P==S?SQ,W!YYROJ&]6(8>VSC@IM6J#9D1_",DQ
M5G-_VQQ&ILA#/L]3.1 2%05SL\'%/7$AGYO?19-9^!#:\.EAY 'O9$#Z;ILE
M)R9")3$[?Q'ACFJT^UTA&4M8'//><I+C-0HJ^#;S?[X/_D3+JN1[Q?T2>@//
MAD$I:.U)]U)Y!M@:MC"H9X>XZANCFZNIKNX1(@'E.%EO1ZZ1SUZY(;6_B_GP
M A?Z#"AXR#82>8JYJQIAK!06[YAS:T2#PH]@(>0D5!$/G:D1+1%I3)_O4YX!
M96U:IA=#0J -HG$_]+ODI>FVUJ<IKT&C0%!VVJ] BJ<IW+/ <I>GPLDI/4KI
M8\((GXCO,T;)I;("C&Y,HM\+++=''0)0!>92(1NFQ.\FEA$L?WYN/S!M:8L*
M<0ZMVD"T%O]>U L2IMF(EW41 LO*KI*<R+V/VG B4]J[;[QI[+]=(+05/IJS
MLSXN8_8^L6P=_RUXXAV!(4D.5H)!)HQ0O<^?OIRT.G%B<M$] PPE=(_0?OMN
M8WL6+Y.KTZ\7"Z'E(&"6STD0J]V# J$;:G=G!SMESX#H.]7V^,U[3?[YI]8B
MTU/:%@LB"K7)%-%>%<C@@#_GFG^Q7\SQEV? J%\EM[;D8_I#!EQ;"?;8IN>H
M&.IT&Y?-$RP%PMRP8!BX-O10RYVE\8TJYFMH<$8YTKZ8Y7YO'!?@G5'O^>7D
M<['ZT+4E4(I>2*B/:>QD)'^!38@K])R=9KQI\UT$5WMN2HZ%WR.Y_*M/70-#
M7IKHA\= (?"*<-!)):PV^N(5\I#6@O%;OE]1R)161VP+JBAR?JAEDN2/.S3-
MT5"C'3@)JPU]E'WU"^*?HJ^BCX8&-3)?1"_D6<AUC?-O*X/S#,>S>AP" $(2
M51)55RDS"K"(-TG*I3T1^WJ<?A59$TZ;/WUY1D::#BL[+$QH.C8%QL+S/A?;
M@J,SY3]8FW+?*^AHK;";"#Y,>N_J0"F^=+YI5.&^L^3Q3VZ)G&F-G_K%;24'
M::V"M=E=\#'R!R7$*= 9\0>8;%-S:OG!Q"T2D-%R"G+QG -<=5Y%&DG,^='5
M[N3W,*YA:NE5W0TOQ'>9DVDB*1SE&N2O<G6ID]0N)L(B^(5?^G\>"R_XU*O1
M/9%EQUA307OD%S/>?L"S7J8-4VZ/#J4$M^PZYE7!8#A#)0FW)+=V)]Z&7GY_
MERG.(?)IZQ99Z?<#5<KCP)/=?R=D7GL&V&'#_$=WLT16C/)K*:LN_H9QL;7M
M+_MT\PP _1O4S/]L<=WF^\$1H]^ES\>[0)C)WR52,W3LK@U#^L"C#V!I%Y$6
M&I+B#8_*\HQ&D?R:VM?)C#?[ DYR4J]ZL4EH2- ZD])]$8V3H>9&-;SA3M=0
M<V/:K:C7Q>@4GO2OTL0XF!O89=&T2K^ZQ5N+1S.:D3 /E<2S15:$9E9.A.3&
M<F\,W1PYL7C;QB8V]*(S!9 89_2!ASN;FNB^I2("T[>4]TCB?^W)F;96\=$W
M+X?'R44;OZ^IMN9U;G&@WJ7&=WI]J<&"7ERCV-]/:M$)8BP[.$02%0J-12#6
MZ= &2'/[0*YSIY%H=C$Y^7\YZ[$0]I1KL6?K%.2C8!RQ6<@S<I)09C9 J&NR
M&1,B0"0DP7K(=G1<JC_/Y7,5\-1\\T6L\UDLH9\L(O[A'?1 RM]5;W"7'E_0
M(S%7?>8Q2QM'CY-VP+63>"T*06*:%\ PA<I]0 B(N'Q!D05P >HG8@%7"V 3
M,* V)@E[D3=4("+M@-X;_CG/\I@DB=$W*%9<]SSB/$YN+!1Q53JQ2PPB[8*[
M.F P*GV8A6UUN$[1ZW^?3[FP@]WG]@QX6E-Z!GQ7>0;<;\%[W46>NCV> 6M&
MSX"'<T(BD\DCR=CW;!WM5-HE?+'3""%EG"@U=J^0W*<4M^6O^R#4L_*K$H#
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MLT X#6],?RI2$Q9R1ZAA'Y9S9A4D53>D3-)C,UZ[\V($E<\MFEN (6"EFD4
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MJ0]QX8.&^"W2O,],%XK5*8\FPA8I7L/$U[[RJIGBV9,EHB%O2U_%N"&Z"+\
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M2+U?:C'CW.7'UL4MGT"LEMVWJ]N>=!9Y%IWO%Y35%K)D4IM$-4JL:JI1XQY
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M7_Y0G!T);1B%G$L&RH=#E062"<G%@AA7-]8R_#[H.+TOX-?<?P!02P,$%
M  @ EX!^52%IY?PF; H E6D- !$   !G,S<T-C(T9S,W>#0T+FIP9^RZ=U04
MS_;HVPA(5@01%114Q(0"$@T(B("@Y"2B(I(EPPQ,SCD'AAGBD'/.04 !,8"H
M*(@8, <P@YCA#O@-Y_S.N>N]M>Y=;[T_OGNFNVOO79_J7=55U5VK>WYL_A&@
MZNS@Y !(24D!J9(?,/]V,\P](@X4EQ01%Z]KLLL(L#SHY"(C TAD\ZDN0=C?
M*K!>6^HX(*VUV5%["0!(_MI+W %%+U!H?$1HK*Y+T&+.S8LY53=NV=0 >29E
MZ._K(G,TW=IJT;=WT?=\P2_9I!8UI?C$R%B0&Q@4#P9)5-D%FWL2R.M,7%ST
M8@ZG6%!H:"PXYL_TPM$N.G%!7[[(>D5"%G(<C 0M,'^7&9KH&A03ZFU_S/NO
MD_T&W!/CXL*\0D'@>+<S9X,E9F7 '4@$XB2_,$ 7\ )" 1  !N(7$<7XOW+_
M6<S!:%#L'Q$IGP%'1H,B8Q>+E.@*B[GM7/R/_&[&?0OYE^S\MQJK_4N-W>)!
MD7&Q21*KYF*]XD&Q?U9"4LDSB7\IGN%)+G][$F/M_E9B07\K1\]$)_VEN(:#
MDO]2[&.B#_VE2-KQ[Z(/!D>%_]$0OP,$/!T/VDD.THOI$%W=D#CP&9NX1\"?
MXI@8^Q^V@]'_F>]@8HBW3RS(89-G- CX%SD8':+[W^R>2=&@1;L[)-HF@(G]
MPZR8'!H,BDL\% 0*^JM7N(>[)_W9*Q;2?QSM%ALA- STWXKWEG3P_V;W"H[^
M;7=/#+;Q_\NL&IP8%^\GZ=KN"]<K,C;\SQ9;MN#PE,1T, X$BHN)CHL-_P-1
M_M.S$,*_V%7^M'M&AD?\JT/I3X<DMK_,"SU'^NWO&(#4P4')95GRYW&Q5^DO
M^I;]70-KS&]*1F5171BMQQ?U-7_IZQ=+G5[4%?[DI!:I+:J_F_G/R__[+-*?
M%].' <.P,(DG6K)?^@?TVY*7GO&79??B_KAD_Z?%;'&_\V_+8IE?%].2D33_
M7T7ZU8+[_[YOL2WD_VC1Q6Z^Q.;W]H?OT%^^)?_A6_]7&_[6URZDI&W_JMGO
MZ@U*F/9%6SA@ E@ $,!4\OMK2/V;_(MM@5E@_[<9_I*_)Q @%AP=_3M48.F9
M.'!L2-+_&+_!(.,_0U[H]/_2X8#_T3.!@W_UX-]A>/[507]7)RDZ,C@TR3?Z
MZ,(0D_JW\\@N^B0)-<DFMZ@X'?J7LN7"$^/ \?]F6AJ7&!D>^=?L:>^U +DM
MVB2Z2A 8%.<8&AN:& 0*#5F,'AK_Y^2O^#OS@F7!XQ03KOO_0?VEP8G1_W8+
M66S\?[>X)(7_^VUF:5 TR#LH_-]LRX)#)5PH!.24=-C;Y>B?$YG\G^9_RZP0
M$9<(LXV.#/^SI9;_KOSA/\T+K1L2&A8$7IS)%))#$T'_);OOG^9_SZYT)MPN
M+CHN\5\:=\5OX*#C7XZ%,%SC8A>."J"X>,GM*BGT7QM.,5K2D/]A53ZS."7^
MAUTI<6'B^Q_FQ=&T]3>WT)VM/P!_VU<N)A<NH?2BOI #T)+]HXG$DBU2DGP$
M 'V2;>UK8#4@-3\V_Q90M@V).Q,::.<"+)E_!RQ;U( 0S (W?P\@ ,KR\O(*
M\LH*"LHKE!255F@L5U9>KK%:75U#77WU"N5%^>/PWT5*14E)99F*ZK)EJBN7
M+5NV<F&W;.5O9,7_FP+FSP,KY"7!BZ6E-@)+5DA)KY":?R"IJ.)\GY2U)$I9
MJ47YH^&D :DE,K)+Y>05%)6D_J=3<C^0_M.I"DC)2$DOD5DB*[=47E9:V43B
M7"$MLT'-6-;6(TA]8P)V]]*5W+RZ@YOT-#POG#$Q3<3=M)/;S//Z\/AC<)+9
MJOQZO/XAOG>(?4\!R%QSV.=)Z*<&0N\M\--IARVIA<1&0=_M9S-%31='GG_V
M#4LFI14W]X^^F+5P] M/(0M+6B[=>?EE!;!DB21:F<68Y);*FBV&L,%83482
M0<)&==G=6.[*A0@N>-[\8*)WYG$BCF?GI1&<9/IQ\]*% .3TS7J&)4$4:(;8
M^YB#0I_\%<+_/H(M?X<P/PXH2R^><P5@#7SV3EOW#=J[\<9]85/>.Y6(F'C@
M_K6N27IW*GEV<![X(0C_U@2)F0?L?G5/S0,7YIAK/]I_U<RU[=ZAHQ57<[IR
M/V?XK0RVXS5RU8<ZU%WQ/)!8.0^8UZATOT)/B>_, _A?:W/6^[JD6S3L*%T[
M&14U@YFQZ\U:?V_=:=-LYG"W(_I6P\\^S$=;[BV[LI*CX ,Y;S]R_3680[H4
M]L,'W^X7SI7A3WQ/(SFF+%G*V\=^5FJ<4Q=?4CKV23\9MHRJ%3 G-6%_S:-U
MQ 77 >.7U5^[=]P%F+0VW2L>''];%E'C%]<[+WER&XFI"=.?TA[?V3%#:GE[
M_[KSU(%,[0'S'VOG@1MS_!\*HKT^S=]5VJ][OYO5JHYJ6Y9B;O$%V?UMO.;V
M*;G<[],[N\-LT[R-'\Y>2VZKJF)5).4\Z.IOF+FRK"!@8'S@.Z%6[=7%)T>L
MNMZX%?9WW)WC=<^4X8SU_1ROI5[7"UZFQ2*\OOWQR/<A[.NQ/K[YCV*T2UQ2
M]Z\M+?=533Z45<CI]Q]XT=ED=2V^ZXJ,2]ZUB=CKQ1-#\\#UR(\MSYO>U^S8
MAK%LF1'L[G2]9^TX%6QQ.SC@34S.+/J.QM$W=*W92D=_T9D6ML^(SZLU0=W?
MIMV*1V-^R;WN_KS1DP!QQ0??M/ST["FK_CY*.$=XM:_\M,F]T#=1&)X"?NCV
MV<2ZFETKCP\<T=UOA%?O?^6/CHO:&;JK8_^QDRUQ=S-LR?#*B5,[1)._!F,G
MQ3_O_&JETZ&7&SWO,T;/,?ONVAV[V?@C8^HD;;RE WUCXN?$-/JU^LR[WLE)
M:^'7H7S9-OT*)>2.]=(IL:<?_'@X\7T[Z^3HX['^O?>G+L0^F3Q;WO_#[69*
MB</;6>3*ZKX>Y(7T/37@7..'TP%'+5 /MP<C[^5PJB?U3TK]7*=_U^#^(W_U
M#>/QF)]OV0:67U;K+1F-7;KOG<ZY\I%AH[>12.CRIFI2VZT +! #U[8R=)OX
M-FGF<>O5Y922''_X6JW3#XY>ZGC]KF;Z35S9+Q#2:B3QS<-D#PV_B.+><Q="
MX/>NM[T1ZY4-F'>'%\0DY!E&+WLI'OJ^/2U@^P\K7W\N7W DN^!U:+)CW=N)
M[YU:L];?=!Y;<\I\]X8*S ;WW%O[MC(^KW<ZN25N<N[%7HMY(' &_6$;#%YQ
MY\8^O^??]>Q]CP]O <<\J.R#>XT()HW?SU2%%^MKC^T:1C)_/G=F"9GP-;P!
MP[#W<.FQ\?OK9EHR*O-J@G\%WIKCBH>0UC?GF'9:QK/-]Y2F[[WVG;+:%UG5
M03CDC5Q74]?MPOAL_6I#/EECTA0]?^/M;NO"D_/ ZGG@>WYN"??7QO=?+\T#
M(QHRWD7*)QQ>A#WWOD,[T?^T_5;PFJ3UP[O7]IM7!'S?<F>FTV7NL^G7E/8L
MAK"]).RVEOL/J_@O(V];NR9L?P2T;'J%8DX4S@QKZ1B.-[[7L?Z1;A[Q>HUH
M.&&ZM&AHW  ,:6J(C[R/DLP7SPN2=5POH\NX]A8'@(G@M4]5GMY__*V^W&)O
M"UE]^),6P&\O_WS;).+7EN%$^EX,\G1'X3.SEXXFMT*6V*7 Z9<:OATV'&'[
M7+Q4WKYTW<[J@3BI'J')NJ&-'4_!CSM^=7] %QV,67=D.'9'6=)9^!=KW?"Q
MZ+#V-TE320_JT9D/ZB:O>X+!)HIWFAICVV,B=57.MKT/GL5/_<B<T?J14_)B
MNT[3!G;5G9D[(:N5@_%39$OS"VW5#W]8.3]<F*3F@6$7K8'KLX:"#[V7)0H/
ML=;D=5=+EY"$?__9Y$V[U.S821_&V#S@-KTB[K5H[.M=S99-&R_59P;?OIS4
M7P4:B$V:G =:M.J<2>  V>2]#/63.2_;BCX=?Y_\(K;B>\V7#??\/,-V!4_O
MZ L]2%\7\&I7U/@C"Y7K31W6CZWB)N:!I:E=7L\\V"_9HJB[Q-LJ-<D#VL,O
MW[+RHI;>FC$?[9\':GZN0U^;!-U+O&:<'A"Q4T4YKF)J[Z9 SUM:#^:Z!_R_
M@+='7CE0]-5L^,ZZRKKJ8$K8=;^9ZEFSSP>N2>9NR0GD?CY)VYSMI=]RUP6Y
M=U1:)4F%:WU4^KMA\H,)I[*!(VA#)9UMC]^UCS]HK(]L^WS8^J-K7,<7[0KP
MLK0W YT.S[Q'24U5H8U^(-7 FK*XUU9O40_*3Y%]/D]MS-K@V'C<ZL</S?:6
MZ'O?K=$E/^:!#X?3QL;K[3=)C?K:H5T"CML<>/HNJADI_W-BPNGPA]K="081
ML:%VJ]5>>IS4&%7*_EFL$?1@7V';BTO!P6WO](1KQYRVW'_:$?=R>]-+L]GZ
M[KM^H]HO6I*F*LWJDX7[Z][/CDX\.&X=+NG=AZY9SK+&]4AD]_Y?IS*,SH[W
M6_Z(//>D*;=I'G@EUWW__8MY8(I6- +>ES&Z5ON"?7SO*?AX]);P^CN*+>@=
MHRG=<_>/K[,98=H8K/3]LJ[2O#9M$'V!_<#?KJQ]],ZIG9WF4UG(\^^C\:^;
MJC3,F@^TQ":]AC_XR0[_NG;8+DI=??.U%AT]?WO?1I2@K3G@M,&&:\I)]P(F
M'TZ\3#Y6[7'K8VEH9>B=?:.RU89M[^*'+7Q?6L_$S06HVEL%3'3H*";_T.WV
MBYA OYHC]1U%(#[2X\;7T.Y?CB_ZW-1??\3.[FUP\]V?+V]5I:'-YE9LMIZ_
M^29Q[N9L!=+:+:[T]83)3';'JU*C!ZW?L9GP5;RCUS_AS!UGZ-U/=>8!;_>;
M]I!J^G"@^_5K6K^T9+W;1C7EDVPZIM=/A.=]>P_\(__(/_*/_"/_R#_RC_PC
M_\@_\H_\(__(/_*/_"/_R/]_9/[)_+R3G5V@NZ>;@]-1>T!*H6MP;FX]((^)
MMSUTT'Z)*@#$)X(2%SXG.AIT1E?N!B 'K 5D@6V 65!P4KRMN_O1A6(6\OZ/
MDJ4 8';T]\OD6SO_B___211#0I,67JC_E&R@8$D0DB(7OG_:D0**7TAG2=(K
M;7<?-)*D:P$@?ZDDO?M?TL8 4-"ZD#ZXV]8(D+(_#RRQ;)2DC0%I%.B/]&Y
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M%1.>C1@H%;B.([X4WC4Q0&KE'E/Q0FZE+KD3@C2[J=FS'W'CRLM*(T1L3[\
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MF&]1;B>T&114S*$A>APJ??L6NAWJ^U(#>C1&LYN5ZD<9JUK-,R5GI__@F)/
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M-)2:6FKDMY7B5WC')IMLDW]?OYPTFJ$G<YI8C)MM7\M!7&PO*6'%G)=.#6!
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M[S2DJ&45YTPDH=Z65>Q_OBJ':>)D7>;*T+9@%U72TS;=*?!E'%!R+F@CYP,
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MC>R71]? ^<S'1O?ADPRT4@\BA3P]U #)+!EN;X#<+M0I^@35R$W@)$+/9KV
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M:3U=?0;KW?A5",*^J@O!%.#.6;KRZ?@^$V$=A #6G_=?3!#JLL8?)LWDKSZ
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M*^AX8'?]8\SB;':M+]9E?9"E$_LK#&@^A#LUS]\<C_>P9U7C\,$CBJ-OT9-
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MG=Q,Y =)6V-F\<"2K<'%W-N2I1Y^W$:)V$[*><^#V=18X2+]+=B0(%W75U3
MSZGR3?G(R]#0UIBY7'5PT"7.%]5Q]T%.M?**G9C]D&>[84)J$&AJDV"I_+W6
M4X7/>(/51U,XW&93PYHPSD'C@B !Q\<PX,YF]VK?V]'9,WBV7(GNK;Z6O[7B
MK>ES44Q.E+&XI']#LOY'V?<5$W5_5XY?=$]'!]:X!!KXP&/#2<H!_*</F8FH
MSV;'<ED%T!A?B<SNUS> 5B?>U7F#OT0-:)]!N8MZM0A8ITN0;B:L"K!$M1<Q
M,/(LU";C=%A,>8,> E=D.U:=0IQ.C-8F(;]'A6JFHB<LRE1ST"==G#4WT7P
M5H'"A8PHI%8?C+U?=KY*C^O.\M>.QU<DR-5*PK1(DRJ/T.;W4'F .,'YMNHZ
MH1O0((.28VUU@*M5U515V4SM9.J]3+2:0W-?_Y=J FUMY#3%.1K0#Z\(IM&<
M+4I'6B3@D*2#;OM2$$NU>=S<4IKZ"G=5QDW5>L[W]5&*DYSZ")Y<P,GT"Y+M
MY2QW)LC+.2# /V)?EL%6!^C2;)+ZEGQ479;49Z0KUXD?Q&^3[Q,[1]C)""+"
MPG-2JVBS,UYZ7S1VU!CA'9;M%P6/44NU$TOZ5#,URS*F*<CJ4?%@V45E7_AN
M*4YQ<2%*4J,<ZSQ+<DQ6-VJVX#QKKZT.\%KUI=JQI$A)-WU)'Y)?,A;%.\F\
M]'WA&$F?[OS""/$1G>^,'^(3BJ!1OH(QK.,CJJ*T)2MO2^ZT)L]"YZ0W#=[%
M%:L[Z_)*Y<'O:L>5@[P>UTZOD$SZ7K^K8O9PUJN"VZI8Y=N:3I?YYK0T*,K?
M)FGKX)5;5L-JJ*#,X N6W^!]7N\MER&2R9MJOH%_ @#2[YC3-N7?\ 2"SYE<
M-P@=3)I54P5[&_W%8D9X!#.KIR)G>_UE/H#43:9;8$@[ $!")3:,J#)K_7AT
M9S:TYAZ&LA%D.8%=$8TWG\=^#)YJ6H^3>ZF,MW&')BO,LW 9 (!X!O6A33G6
M(DAOLNY:T\C9&VY71Y&[5]TW19-?!/4;VBF^7DF& $KP9(5Q%&41 " \S[2,
MJ%)5S6)69A;:XL(JV8 W?6&M7T4SO&?-#LK0)S._>2W0-3"_3-;I/5A3 0!!
M_[]IM-3'&B#<ES6KVE5(WC#?^$;P9=5"_4U!Y9)ONJ4"1\]'57!![.2N*AS?
M 0#@G_U7E5RV%"K],T^;$Q75B1>-<^1[5U[3_93=6-)3%2LC>$JU#%GO9+%V
MP?]G7?[<_Y2N^I3^3.8^4X]^?N(1 ZSJ]<H]NH7:KB6=VD0MT+-/DZ=^/7F?
M^H6H%@#@_9>R<[S[NG/+DV?WIN;+8\J[9Q5V++-TNA;7^"YNOU_J[:SM+"D%
MC5G7/E"6"P"('J-M)R/9J"W $GK2SNY[96XQWIV0\J%ES/; RDC?R-8]P&+G
M9VWG@*@Q%UKV@89WU\(ZPE:;LN_1@$!)B5V3P*HU?[6+(?W+PEO#H6=]79N[
M8&:7B2U8&&UL1.-[.&FX#X&46R,JJZ>K%1FY\4Z'#_+GFJS6-M10Z./F##3<
MYT[C;O0+EXE-R>C.L;SZ?,R/X=Y8P[#]/R4KM>,G8<Y&21N'(%DSMODWX5FH
MI+&%&.*SL_XC$>XRH:& Z#?V8*T=Z>YP;ZSZMS<R?[=WT[TWIK0NHB>NOMQD
MI2>'%C8LIT?[:.IP]! 7MSH#W67L;\MKQO .BEOXG]K95L<+V.C7,HWGLGJH
M$<\]%KJF?C07YH.K#>7&N[C7!G"%XU95S^4,CQ>G^S_%;[T@7;MQ>O-2R<_5
M'0U<"3!T:>TO\3F?@IJYXI/.OVNFBL/&)9DZN</K.,?E/U7:&JIA;)S<1-',
M6]U:OU.=$1I8ZZUJ\@%:EZA,+CZ63_('XR!&%+<= &"S_E7;?4K2<K8V_BH[
M7S!&$U:YI'@Y4P!"EVV$WH;45L9E+83U@!>L680HA9[S?8[X&W[+;@C7B#BR
M;5'!V?*2!G2QN;)+=:DL#/2(L:&B!^H$V0ER@"_,]("L1@:N7@;]@;;S=85-
MPQ3:E>&78=?T)>?V(4?5=11L0R4JDXJY:!GM2ID/YBP84=&%<TC_#OR%7QN]
M"KR+D.FS&5Q!G&@W$[^=-*\7E_60S*ZYE>="OBF7%4Z@1%!SBB]0#* 994SJ
MJ+1+%<^HT%7)P#;JX06&REO4Y^,N$^;3S-U[,TC<=]:X[+-<O&QLWGW.)_+M
MPB,<<N6]$AG'/O5X^51V[TI"Q4EV]OQWY3SVU'%6 I<%[TI-(R@JJS]G/I6[
M2D[GSI#N)PT6.$@@%6>+'H@7;GY<BA)-7+&W?(%PUOS24KS .@Y!N,AMZ0S8
M?,YXV?PL(UL_(/XK6UW%)9[,,VIRRE\7LE3IF^>7S%#P5_B5#LHG>[\I/BYK
M&!='=.&J.U)2>(UA9H]TM[JUXHE9N=;EQ,FYY>:H\N4%Z096"JGHK<XCRE(B
MT69Z*XI@ZA?C?(@;N=3V YN,W7B3)BVTO4Y$RH0U#Q'(.:CZ+V5;\@MK3"EC
M"[]5'XE:6,PTC_.>5[A.[S'.@4CD0MIF@F[D)!C+(.WYO<)S,&C1(\("A&?I
MF[(*Y,F*FYN8Z")0:^0\3"]TD=<3S%O8Z5$;Z><0[UO8%:(RHB$4V%SQ0+ '
M; 8%XP.@!$A9*0L> Z,G;T.\13 C<*A5J'5>>:C1Z(VC AFCL,>:;I>*X H=
ML_PZTI&_O/([BH0=!/U&7RH)A[S&^B3I88,X<#@;_A-/\[3" _%?1\U@!) J
M&D.+KA)%VLNE*:0@KKZ\BG0,4U0Y2-Y<] MTAGQSHPS202E;W@E]1#GG\0UB
MI=P%_&2DTRKKVPJ8;+JFN'@6NX 34$IC^Z!^E0^R[A4^J;S+:MI@ %UB$<.>
M0,:P-GA 03B6.^ 9 \^\5%>6IY)2U?Z%,1(]>T+QH%B#?%HV0<0M>%2Q6LA)
M/ %<)F@,6PO*YG]Q?U79R?\;<)VA9FEKBW*^ZG"JI?F[M:=9LXM6J;\C[4JJ
M5?,+II;=4R 3IU?<E+U?MJ_RH?2NN[(B1"H#G&:TL20UUNQ=M25*;)[(\IF9
M4^A@SD,D%L,,^_)S2P=U)0F@\B$M>-GRBJV:Y>Z1Y6-588 #C)TL3HU[UK7V
M,,6SW.:6R8Q#!=X-K?"M1=3:Y+R_2@Y;LM=_+#MH'A]ZJ+S!^'#.J3('+0DP
MR#C!HE6'H;9F?Y9=1I_.+Z8#,6^+5+#=.+=26>Y=?&Q%>?P! A T?>D[(@A2
M/*N0> ::^Z<JXFZZ"Q>6RJ6-B%<54VC!J#5 ,+01+0/7YSS$G(?NC7N$&P_?
MN30<]Q%9['H!=P)Y\T_*/F[D0^IA7I)HV&KX,>I4^!YD!H2/]$$=S7Z%XF(6
MQKFB3V!QP29,,X[F6H;QP?VY<TNY9Q@+&H<WB0Z 3Q$89"X42(P#1\)>$+]F
M[47 2(WK7) 'R6N"CJ'$Y!TS3R)?D&5_JB)H75W%4::C$ AL8:X@A8 +F7'
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M8>>UU8@SZ^&:0N1]!WAE,VKKTIL:3]29F2[JK>C5_\A3P-/4[*JX<E:B6FN
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MRF4&WP9JOZ*(_Q'ZTZA=D Q]_H\\%O27 @QRH)#CJ1X< HP<>9F#*9WC#^'
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M%YN]KDG)[=%E:SH!4^<7(:9W*E*;*G]F;HS>6QF6?6?#F+H[#^ A5(?EU]M
MU$)@HMF$YC&P5O>2RKAH:E5@IN/EE).JV?D;HVXH24#(!F/%BR*$^X1" /)=
M_4"Q!2PPJU=U@.5ZAK*3$,B4M_9@FM*1AX"#H@QEQTK>!JZ5Q4)9[J[2I["[
MJ]-DNO!S9C'R2GBCGJ7X35G'E'<];;^2?27'RM(CPR0P1%5 J?@S<KL;3JQ
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M2G@5W,2-R;R+W,&(0OYFGJ_'*' Y[]$5*\Z_^.P#UP![P;CN?X <;(PA!>A
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M>A\+,:XR'^F]*?IMK.L, %;K*EM"*JS5:^OG9RU01-9\3(R1;M$>"YTIJE;
M*\6X3+S<KA*MQ^XJ7G?+JL8CV]MYI##ZDF9IM:QX87T-^4/&3;.(RH\U&-+I
MJP-/J;\R%[@C\@)V@C4D,@(C"JS+1+^)E+<)&6MHIYIPQNFBDW48DYDA,E6S
MDF+3]>'LE$"+Z@V'[$[(2H$+UA>$ [QBQ<).%H\%/VDE\QQH:8UEW$]%\;7E
MW'\SEM;D\.;$CM>%\C8&5BB_\0;=Q5*"O])F#O&$?UE>TY&#O8636K+0[]2^
MAFQT<>$1RQ8D?T.KL0 ^'].M70?'!_HK%T-7W462_5"U33+A RV4_]%.EVZ
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M8L44;>#WH6.WVJ.N#%/O)B2^]&L'#Y9FN32+H1_),74(9 AOK%D/Q:\R:3Y
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M"ZH<>D$#DMTQC+RH/UY#1^98SHHX\-H:$>LUI-?/+UD-S5 W;3" ;8H5:S/
M=1)D516XBFAT: '=44:'#9+? 1I'8&W+#N$5Z'"#B+46FFQ95%P'(H;.#=-
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M@<[88\M![J%F!5+'+V[<*!D0W*HWT_DB2:U?\9/_,3J?)I"5FGG1G8H&X["
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M?9_L)K&W9A^M,H>*BA@G"W9(=[,+2B<P8-[02E;)H. &^6JZB_@Y@Q]]7Q[
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M"PMKVLEEID8\O]&$EK;4(G5M.D1MN]R2&&5LK435-<^W5X8*BX'KN 6('*R
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M,^F%O1_RD6=8WMW V+1;X4D)UV/38JXD9T5>SLP)OYB7%WH!#@D^CX8&GB/
M LY2$/YGZ4B_,R4HG]/E:._3_'D%:O_USN'^#_[6-_W/=^H??O&I"ORXA =6
MK2\&6_<0P7X')'#VS'WN$Y#Z."@T_D%$5/3=N-CP.\GQ(;<R$H-NYB0'W("D
M^%]'I/E>PZ3[7"-D>%^E9'I=I6=Z7BG)\KC,RIY/TVWO+>H=?G^1^?@'_Z4"
M7WW! S\M+09KUQ+!CIT(8',@![@YI0 ?CU@0Y!/Q/#P@]&EL4-"3I!#_QVEA
MOH^RPGT>YD5X/8!&>CY 1GG<QT2[WR/$N-TCQ[C>I<>ZW"V.FT\]7>\NJC_X
MWB+5]0_?Y8%OOBP&RW\D@@V_(<#NS=G ;E<2<+&*!MYV82#0,0B$N?B!:#<?
MD.#A!5(L7[[3O=Q!EK<;R/-Q 5!?9X#P=7J!]G-\@?-W>$X*L'].G5?U@_]8
MI#KVC[_QP"?O%8'%GQ/!+]_"P::?,\'NU0G@P,9(X+0M&'CL\@-^>[Q!R'X/
M$&'E!F(.N( $&R>0;.L(TBQ?>#+M[$&.O1W(<[ %4 <;@' \ #".U@#O-)\
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MG*/Q Q4'$T<J!I-'*KI21KBMJ<.O#1 M!J+%0+7Y&90ZKWOU'(3C8P?* ST
M.R+X,3,^]BXC/?U& 23_,AZ+/H>B$D]#2V@G<SE%LYG"TIDT!?MH2C7G2%(]
M=SJADW<H<9@WE#S,ZTH=XC>G#0D:TE_?*P/)8J#;+ ,LIW6@PG4GX'K: *Z?
M.Z@(#7K"CHFYQTQ.NU&8DW>9C$*=PY*)<X@BVHG\\N+CV96LH^D*SG1*#7<J
MJ9%_.+%/,)PR*.A.':QL21\0FC(&A(;,UP=(O_QN8!Q8!LH=UP*N\P[ =S\
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MJ&S)DXL;LJMDIJP&N2&K6Z'+Z58H\[H5TOP>N1CR^@#E#T.IQ<"S60U$MEN
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M8L(XNB!ZC%P8/E9<'#S*90:.RDO]QPRE?N-=I7[#$V7^O>.LUP5*+0;IZD^
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M<;S+C76X6QGWND:;_VM1:_^[BVJ/OO<W*?CL?0[X\:M"L'H)'FQ;!0-6FS.
M_:X$X&H5"7QL0T"08P (=_8%L:Y>(,G= Z1YNH$L+Q>0[^T,X#Z. .WK\(+@
M9_^"XF_WO-#?YGEI@,TS=N#K:FW_QR+]V#\62>;>_7LY^/)].OCI2SQ8^ST4
M;%^>!O:NB0.V&\.!R[9 X+7+%P3L]02A^]U!E+4+B#O@!))L'$&:K3W(LK,#
M>?:V .9P * <K '.T0J0+%]*:<[[0-%KJ^G[^R+)]-\7L1_^\^\T\/5[./#S
MI_E@S3<I8-,/T6#GSR' >J4?<%SM"=S7N0'?#<X@:),#"-MB!Z*VVH"X;0=
MXG8KD+)]/\C8L0]D[]P+\G?N ?!=NP%J]T[P?]BYKZBFUG -U),F]MY[QRXB
M(DWIO2<02""D%UI"2 @0 H30>^^]=P%11 6QHV#!@DNQ (*"7<'>OC/7.GOL
M*V#?GHLS& \PN/G>S);Y_DP(0T4>^;^ []89(#RT$/P,UH+$7 DB, <A$G\4
M(LBF$,K&@)A+^.T70/W&#V-_YL9S/GFF^7QPS_5]QRKV?\NH$+VAUXI?4QN#
M7E%.!H^1SX:,D2Y)1DD]H2]=^T('R8]#_Z$^"[U/&YC6_Y_A?S((T0Q^:(8
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M24Q*SHR)S\D-CRTM"(UM* J)/5L4''NM,"3F>H$DNCM?$MV3-QT(13/$[%L
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M2^ABNY0V#DAKX9BT)FZ4T<!=LNIX_)=&R!ET[R?YIP!*_P3(O V0\(43(E$
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M=4UNP6N7>@2L'?+VFYAD^:S=Y<-:>\Z'-?'(QWO\@X_W&O1AC?WL<PW Y0Z
MDX,4V+>&"ENF2?Y6@)'];#!X4!1Z#JI1VPZ8<#7LMQ.JW.LF5;3'5REG5ZA&
M^LX8O:0=2<:QVS/-([<56H5NK;0+VM+(]-O2Z<3:O,+%:_,Z-X_-.]W<MYQU
M<]_\R,UMYKV[VR;T^)7;30!G>P .D?Z];1WIOS,D?Q<%^@^S0^=)06@YJ4A9
M>-* O>*$-5_A<6?1[&,LF=2CP4H)1Z(TH@\GZH0?RC (/IAO$G"PPMSG0 /=
MZ\ 2&X\#@W:N!]8R7 [LL'<^\!OQD.&T[SW3<2\Z..Y!Q_G^; <X-@BP8PW
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M;8+AW$88QV. :0MT,9]7&ZOX-+&97QV7":CAB* J;A!2P5W"RGB*./^3%;,
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M$K,3P;T6QP*'Z$<"UE@?#)BVV>^_W6ZO_V'&'O\_&#O]'S*V^K]G;O9'YDP
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M;"]+_VG[2/IWVW=R9VV_*9RQ0<73-JAT\A>0\3V?=&]/PE>.@@&J% PD=S/
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MJUY79+?ADH@5QNWAXZ:MX;-FB\,/FB\*_].\*>*9>6/$G%EC))HV1*+)?!A
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M/\A<(;&?.2:YUWY*:H_]-NE=]H>D=]C_+K.5^5!FEOE>;A,3Y3<0T\34/.A
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M():R _=3_F%@_#'*/P68GF.@_YT &E=%4/V//%1^U(#*3X90_FD8E'X>2SA
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MP4&+E8+]%AL%^RQV2^VQ."FUR_*ZU';+)\(MEN]E-EFRH@U?6/\-[!A9RA>
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MDCDQ%J++$R!SV0O"[\.(9$A_7P3!E4;PKRP [\H N%</@;EZC7A,O/Z'ML5
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M7]>0HEIZG@8@J8G>MQ4(ZU!!4*<N KJ,X=]E#;]N9_AT>\&[.Q!>/3)X]B3
MHR<=[CV%D/94PZVG'2X](W#N60O'GCV"0\\9\K3@T'U'<.BZ*SAT*@2'CGD.
ML(_KZ[@FD![2Q-<5U,YKIN]KH_>E/0KOH??J [P&->$^I _ID!G<ANW@,NP*
MYV$?.(V$P'$D&@XCR; ?R8'=2!EL1YI@L[0?5DNG8#FR XM'3L)BY GR+BR&
MOL?BP;^P>$ A*%%^+]!J,D3:22VM83&U,ZF=0%LDHUT-'*;^*/WOA!CVRW5@
MN\( -BLL8+7"'I8KI5B\TA<6*T-AOC(69E-RF$X5P&2J%L93W3":FH#!U&;H
M3QV%_LK'H;?R3>@O_P;ZD[_#8))N8D*!C1V<B^U +Q^;27D7D$OM%&I'+P6"
ME]'_TR:ZT*+9T9];S*C">(,.#&<-83!K0>RA/RN%WD8_$HY%&^.AR\5.9V,9
MM#>V0&OC,#0WSD!]]B&HS5Z$VH;;Y&.HK;\+]9D_".LYZHV03E++?!<. NGL
M<]P$$#I%_T]=U_74WTA]^G/#[?3@N]2AM4<7&GL,H;[' FI[[*&Z1PK)'G^(
M]\@@VLO%=R\7F[W*+Z'B0.Y90?B+NT\2FO==]-N[OB0_LE#Z!9-#/#>1)N:[
MC/8\>Q)(9)\CUM'_4]>-NG:TJ.9[Z8'W4_\0H'%4!>)C]-K': R.L2@^3J]]
MW(&X R=8E)W@"?<$3SPG>)"?X*0^P<9/L",G:/"/7R8TTL<^)-^0'S#*7'>R
MS]4,-7^:8\"/1F[A'%1>@[./^@>I?Y3ZM.LZ].=J9^FSZ=%Q48TPCHN,XQ+C
MN,2"_#*]]B.,XPH+PBL\^5_E8G^5!_I5#O)5=NXJ<W&5N;AR@[Q./B:?HW_U
M_'4X);,\%K?Q.-BCO \*\#@&V)^B/C7U+\[OOT@>I?8U<F.!)U19 &FQ&%T$
MW*0Y>=J<11F+\F>513KSH2P,;G/1O\TQN<V!OLV!O?T0\,)Y\A2?OT;^C8[-
M7!-W<!ZRSXF'N0Y0U_L<X,B4F5\%]*BIR2$4GEK8?WE^82]$R4OD93%HB%@8
MTZB]QIS\W01XTQIXRQ5XAW&\RR+D/<Z-]QII8CC)W^< OT^A]YG,]]F1]Y]&
M \,J9J[E#P-1ES@'J.M(73/JZCT-J-_;?WEY8>_EC86]D'\OW)OSSKW]$ GP
M@2;P$8WC)\S)YYPC7[D WW)<OF,Q\CU//#]PL?N!@W^7@WV7$^ON&7*!KO?_
MM__@04)) LF:NQ_F+WK=W]&*7]&#GS%(%S^&NUA!)SU-C[Z>/GDSOL9.?(6'
MZ->/XG/ZW4]QE=[Y6?KVM^FZO\(=MO#_O0\%>N3!_8?%"_?D!% WAK\EIV8!
M]2JIU8!OT$Z-7FH,X[.%ZS ^QAKJ;*#.5K:Y&^_C(-[%22I?8KJ>I&]_%7]G
M1*^SI=?8LI)7'V!>6X/<VW\PH:X]/^U-W7#V+XD]R*9>"75JV(]F:G12HP__
M81QO81F'9B6':"UU-K+][7@%^SAT1_$BSN(V'L,M_OTL?_,99NUI]FSN.@QR
M<P&%6)5_"T3YJ,U<Z[._5O@";NQC$/L6P^%.8Y_RJ%/&OM12HX4:7=3H8^LC
MG*;+\!RFJ+..&IO9_BX\P5Q<QRD\CD?P*-6O,-I'V)M+^(TH_A\4G$H*W$.5
M>=9A?TW83WO\D[EXC;EXF?/B!610IY"M55"CCAHMU.CBH=K'GHY09X(ZJW"9
M<^,BQ^0"<W$.QS@K+N T/WV2+1WG>!QGAH]12<G1!10\Q!4JG+KB^5N__@LU
M]E>/NHN90Q?VRY\M1%(KF3K9[$L18Z]DR_74:&&VN_ P^JFSE#J3.,$Y>HQC
M<H2Y.(3#., H]C,;^X27L5?T,?9([F*W1(%=*O/L5%'NB<U_U<Z'RBU.+C5_
MXY+SO%B+XV2(:R(;7!%[X*(D&.=48O&P:BI.JN;@N%HQCJI5XHA:/0ZIM>*@
M>C?VJP_@(?4Q[%5?B=T:Z[%+8SMV:![ -LW3V*KU&#9KO81-VA]A5N<G;-!5
M8/T",^0G?>!C4RXK7&IO<9F[P67W4<9S15,'Y[5,<5K'$<=U?7!$-QP'=>/Q
MT"(Y]B[*Q>Y%)=BUJ H[]!JP7:\-6_5ZL%EO")OT)C"KMP8;]+=@1O\AK-4_
MB34&5[':X$5,&7Z,E48_8[FQ8H[)!;ZR /YCQV7(B=Z;R_UY&_H^OG?"2!5'
M#/2QW\@:>XREV&D<B&TFD=ABDH1-)AF8-<G'>M-2K#.MQEK31DR;MF.U:2^F
MS)9BI=D4EIO/8L)\-Y99',.8Q66,+KZ%I99W,&SU(X:L%!A\@(^H^RJ7]R<\
MZ'NE/(UQ:=O/4^!>QK++0A=;+<VPT<H1ZZV]L<XZ%-/6,5AEDX*5-EE8;E.
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MHWV +KN@0<LN.D83<I*<HCDZ16-PFI[_8>;C8>;C#+WV6>;C'.,X'TIXXKG
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M)1_P^4_P]E?,L95:R_V5=T5Q'&A8*D@AGV>3-,:2R)_'\C'*3P41?CH(]3=
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MQH=U:3"L3P-AP^H/GZ:^\/D:&[%"/1'K-<:V15VV:]5I.Z .^U'P"_ Y^#N
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MM3X/WWX&.Y[$CB=@.8_!?!Z!RQR%23[(H#F"'8<)HOMAJ/<2I'<3,'?"HN]
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M!ON3T)..GAST%.*!<O34H*>)?YW([<.B$;PSDQG65*Y.P<H+\-C5X%9FO*/
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MBYD&(!#U</^Z*P 90^VCX%T&P)<:IEUCD-_DO0<,EX$"KF6#M"*K!A5;2@Q
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MA=@X@3XY(=.Z&7$Y0I=C_#(^O/04:0DQL=CL1V%\+OQ S<V$I[D7C,?L-F(
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M[=SZZYMNV/:;W==O?W_'=1?_]C^%L>&=ER/J/WC9/O?-YR(N>^[1PMM_]N#
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M3<IZXQV$0HGI$\K1 VP99G!T_T"4D$[B)(QAO$QX B^1]>&$RN[;Z;KA\2>
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M*?I&(MV6Q+/<"0S'&T?Q?'&DP!>K%?MC,%D@5JT,1*LT@6BE/ABM, >CY<Y
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M: <V_DG-SOB9="SW6UQ%Z9=H)/PS!!Y[MH9&/EW)H@^7\=F#QR6\_D*5H*]
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MR$"'# S(P%O\') L'GW!]@'0+O\8&%=M_M.\+N,GZ^;LK^R[BC]S'*@^:2E
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MX+F79>#U#]C@_54DL&1KW2]K]U5]O^W(\6\R\H]>RBP^?"&O_.!G)57[SM?
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MO/=HCWQ'/1/UCG(Y^AWY3LPKRI/HIQ[/H^_17D3?H+^(N<Z8&0A9*@I!F(,
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MS9C$7V+^<+K%_([K8WW!#;!&\$.L0>>/S'[""/.IZRAK)L ;<V!M%@</^5E
MU9,&MOD:\'&0 5]W1> R-('M:P2>0BM@Q#F 1[HS4 K<@%1&^N5>0YUR.T";
M=&UE_""T,W^XG/:<<+[L]1U_V^N;TTOV)_P ^[W+D-<KUP]>3]T^LGO=1V;D
MKX,GYD##'.BZTL U7?-W'L1WQ;8830NX'&-@"ZS!,\81&&D$\,@C_J*44J=(
MU;1)]_W,'VXMGA.N[5[?":?9XRY7O+\YW^6,X?NY'UP&N6]<WW.>N0]S[A,_
M<'M('V<$."M$P6N3&-#E9H&GMC3XF:R!0%L9$+@H02!5"_S8)N 38 />D4[
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M@_-.\;\S"(:"%'AK+@2NR0K@VFT$+]<=P* K M5/'8CA.D!(-@1\GBG@RBW
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MT/AL!)KO3$"[WPRTGYB#S@.+_P4LL*QIO$L,;':( 6ZG.+C(28"KFA00#1>
MN^TR(+BN!3QS,SCR=X!=I!Q8IRJ"9;XRF%>H@5F#!IBV[@63#BTPN:0-QO>T
M?QJ_U9DP'M/Y9O);^[,)Z Z8@_XS2S"X9P4&-VW X-HT@.5&43#?+@H.6/XG
M8)!VB0-5>1;0]18 S7(94/%K@>BQ!5Q]=@)>* ^.\<I@GZ7VR[9D[Y1UC=:D
M59/.A.4QO>^69_6_6=S4_VS1;_#1\I/!D.5/PS>68/S(&DQNVH'I%7LP/>\
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M+KK3L!)=J9>5.%.C+7VLPGQ=<XGCSMH"=Y6R'+IN00;'-"LEP"8E,1P7'Y]
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MN\G ZW:GL<?M(5/7.QO,7>X>(??-G6]]M'3\#6T<_X-VO$OHX'0>';]W81[
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M/'UY9$'S6'1>\]&8W.;?H_.F?XR<VD1WFP8,+:C'X,):#/H>IM!9*&3@01W
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M&?N'77*V#Y?(6_\QIFCUZ*2BU1^/%2WO?U4TOX<J9O=0S?0N:GQO+^W!^I4
MPW0&>K=3/G7PFI, !1>I _\,$/4;!\)?2$#P"V4(>*''^+RT8'F\XK%=7GER
MG%X'<AU>1_';O4D6L'Z3)VCQME+8[&V+B,F[/C&C=RO$#=[ODM#_ZV=)_7=O
M)/5>HZ3>2Y34?8G2W]LT K"<SL \.H.M^P&J*7\JY2=? PB_!>#_C ,^G\7
MXXL\N'S5!*>O1HP]6K-LD,>RH,YOB@%L8XSD&& 25Q=SN%I8P:>!,_G5<8&
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M^XWW&'F/#YMXC(^9NH^?,',??V3JMN6KN>MFM'39A%9N:]'*?<VWKM(:'.T
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MYZ!4,^D@"\@P%Z56D8U\*#5.]I)C?"C] S]*WR)/R#N"$_C^2X;>RZ  O1=
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MC>PE)SB?E7_D?%!^R'FK\H;S2@6Y+U60[X4*\C]710$B^%P%!9]-\M]\,U5
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M/QO-C$$#HC\C!G5;8E!G,O1E X8"/*3.]Q_*OY %<#*'@2,Y'-B7(P;;IVK
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M;S<*;#]O%-CVS#"H%0V#9J(!T0]N0;V02>Y,7 ]T+>RC/=A"\U_30=VWA]:
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MH;RF@GC-",)U*^"Z/7"#7OL&-R-/<//S!!>@FYQX;W*PW62'NLE WN0-;M+
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MI1'K9\M:3**>*R[!ASIA[/'QU$BG1AXU2JA1S9'0R![009UNWG\%U3=PA.S
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M>E@W:!X<B^!8 <=Z.+91YAY=29N<P!>7V_(C=](ZCV/5G^FUG]I&T$4.7.C
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M=SF3"WD /.C(B9@<Q:,(@L?PR1.TS5/FUA+L>#85P<+B]QS]\[D%@ 9][@K
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MO"</O25_ZA%%/5+0Y/G87X'_&NEZ'7H&.Y["CB?0N8^AMQ]%;S^">GT(]?D
M=MR'*KX'97X7 _A.W0'7X[J-TLP]LB;O<8OL^S!..O(0/^9?[&=0_BS['HSG
M\,73^.()Q=$M,^ HI/PJW8L==V&'V8=Q^P_[,!90XV6.?1A;=0K-?5*'*?\$
MWK@)_?X [UY@>OG(=H+*[+LP^S#,<X>..&SXTM&=7W(,MX?QQ;WXXD[ZQ:V*
M@",)CFS*+V:JJ*;'->EJ[+@2.T[03R_77,I<P#2VC%981[G;F4KW8<51=/M)
MO'(G+?0TO?9M/OW6MIMIGP/F_=>R7\CS&T?^XV['5'0*7UR#+ZY0$/;'8'LJ
M'+F47TKY-93?1/D=E-U#3QRBO+F4MP /K-!N;62D[-(.)O9S*&$;)6[%DUMH
M57/?KCEA=C9,.O-%)^H.;K78I\0KP&7XXF+&R 7RI1YAU"$>CG0X\FGQ,NW$
MCG.P8SMV;,,?6VB7S;3+1L;+>JW&&]NTAK]:34DK\> *>HG91;2,D;04WK/Q
M&LO>$TSSMX.KP5%^/L34?SXV[6'.V"5/ZA- B9'P)&)WIC;0-]8Q;ZQ5+1S-
M6J5../K@&(5C0DMXMPAK%F+Q))Z;H#WFTXO&F2OFZA_@.]O)NS-X@:G]/I:9
MZUCRCH+S>;^3I7B;.\O[3(LV.;M2+R_X@N&*T0I+BI99<K3$J4B+G2NUT+E>
M"Z:T:G+*;,V?.JAY4\<U=^H2C4U;I]%INS0R_4(-3;]&@]/O5/_T7ZAOYCOJ
M<_E6O2Y6&_K +_Q8PLS9&Z;V V '[S?X$_80#JS ON7N4[5\IKN6S/350I<P
M3;K$:[YKNN:YY6FN6ZG&W*HUQ[U1(^X=&G;OTZ#[' UX+%*?QUKU>NQ4M\>%
MZO*X1IT>/U6[Q[-J\WP/? ^L/^"1$/OVSR-A]G\.VLCK2GY>'$SXAST3OL!S
MAN;-\M289Z!&/:,T[)6D(:\L#7@7JM^[7'W>=>KQ;E6W3[>Z?(;5Z3.I=M]5
M:O7=KA;?0VKRO5(-?K>KWN]IU?F]JSK_?P,K[^VXES#P:A/ZL-QO ZNC[;F/
M>7P^ACTCV#(<X*0A/W?U^_NJUS],/0%QFAV8IJ[ 7'4$EJ@]J%IM08UJ">Y4
M<_" &@D^&X*7JRYDBVI"]JLZY(0J0VY51<@3*@]]2V6AW_'*2A1BQQTQ]JVX
M>^/P@<F_@/F\'^6S0>SIPY8>;.D.=557J+?:PX+5%A:MEO D-8=GJ2FB0 T1
MY:J/K%-=9)MJ(GM5'3FFRJ@EJHC:J+*H?2J)NEQ%4:=5&/V8"J+_#KX%K$11
M=IR&\Q*6^%V$HFO!0C &!A+AYG==V-B!+:W1T]4<[:G&Z  UQ$2H+C9>M;'I
MJH[-555<B2KC:E01UZRR^&Z5QH^H.'ZABN+7JR#A/.4E7*;<!&:YA$>5E? &
M^$;9\58;<N*LN@&^"Y,)>U/I!V"",'"8UUZ6_$X^;\669FQI2)BBV@1W52?Z
MJBHQ5!5),2I/2E%94K9*DXM4DERIHN1&%:9T*C]E2'DID\I)6:.LE'.5F7J)
MTE-O4FKJ(TI)_2NO7RLUQ:JT9#M.FFW9\&Y.1^]E$&-GV/,O7?S<"AKY?1WV
M5(&*5%>5I7JI)"U(Q>E1*DI/5$%ZAO(S\I674:[<C#KE9+0K"V&2F3E?Z9FK
ME)JY4\F91Y24>8,2,A]2?.:?P5=*R+ JT2#=JBOAV4?HN2&+OIAMW__2"]KY
MN1'4\KM*;"KEM3AKI@JR/)6?[:^\['#EY,0I.R=563DYRLPM449NC=)R6Y6:
MVZ?DO'$EY:U00MXYBLN[2#%YIQ2=]Z"B\EY55.Z7BLZU*B8'9%MU.3R[<^Q[
M@2;!$"%H5YX]_U('*D$QOR_@-3=OFK+S/919X*.,@A"E%T0KK3!)*8592BXL
M5%)1I1*+FA1?U*VXHC'%%"U35#$S;/%AA1=?I]#B^Q52]'N%%GVAL$*K#>$%
M5AW-M=^0LP)),@[Z03MH!-6@%.05$F\621G%3DHM<55RJ9>22@.56!:A^+)X
MQ96E*[8L3S'E98HNKU=D>:<BRD<45K%8(16;%5QQ2($5U\J_XE[YE;\D__+/
M%%!F56"I'8?AV +'$CCF.') +:#.Y'] $<A&JJ272TG(M_BJ&8JM]E!TM:^B
MJD,461.CB)IDA==D*[2F6"&U-0JN;5-@[: ":A?*KW:C?&H/R+OV:GG5WBW/
MVA?D6?.IO*J)7(%/E57[D:<;2NU[@89 )V@\DP,"^7!GP)V,E(ZK1?_6.RNL
MT4TA35X*:@I08%.X IKBY=^4+K_F?/DV5\JGN5E>S7WR;)[0K.9U\FC>)_?F
M*^36?*=<FI^3:],'<FLD<FVP8S<<JROL>X'Z0!NH Q6@B' \&^Z4.NK? #]2
M);1%\F^?+I].#WEW^LBK,TB>G5&:U9DDC\XLN7>6R+VK7JY=77+I&M/,KI6:
MWKE+4SLODW/G3^34^;2<.]X%WVIJNU73VJS:#L?2&L8#=9P-FD$-/Y?RF@=W
M.MP)S? C&T,[I( N-&"/LSSZ7>0ZX"F7 3_-& C5](%831M(U=2!?#D/5,HR
MP!\,(. '%IM'_@($8S_:O_\Q*DO4U/<- ]!J@SD3M@ ,-C(?\MH *D$A/V?"
MG=2&_D<BA793_U[)"YGB/NRDF7-F:LH8&F:,!7^,!7<ND_I<)MRY#.*Y-/!<
M"IF+SIR+J)Z+B)V+F!HC0AI#K(TAAN9@PZC5AI7X=AR3>UOM9\%J6^PYH.QV
MVH ZQU!,:#_\P_ C&=WG2C,HUFD!@<Y"@IZ%!!N+6.@7HZ>6L-@M8>)=PF!;
M0F,NH0)+S&.85@*$[!)$Y&+$Z2*$V2*BZ(78L #%!,\(]9P-FO%U!:]YU#FM
M#_T_B/ZE"'^3_YE  R^4IBTAT%L!5CI+J]"5JPEVUA!HK&.17T\@L($%9F.J
M??/?AGKS."R SMQ@'D=\C.\@EM>]S.+T!<"&-5;-YRL#^+B3^M;R6H2O,ZAS
M_!C\U-</7L]EDLLJ:<I:N$T.9@O89H =YV#'#ORQ"SO.Q8[SL&./68B97/>6
MV3<^[1FS/Q)H#Z+Z/(3T[E_RW4_X&_M>E#'X^N@Z3;R6X>OL<?K@ BE\*?SP
M>O"G,S=+%I-_V2439!+PR;X?Y:#)B1 ('S;_ $<@>C'M<A0[+L6.8RQTQVB3
M8W3N8U3T,BIRZ5Y G[CD<;[W'H&3U891<Q8*5./K?+IP,GZ.6 <_O!X[I.GG
M.?(OAQUYE\MDWXMRPA& F_S$-28G@D].X9,;:)N;?.R;E$^SZ)YF\CM-)SL-
MR2TX\&8$_LV(^IOH$S=];3N3TT=3-6)B,75.-_?@;&?\P>M!/:=?Y. \X> Y
M)?L^%"- S+D<LS?DCK/R(29?\ ":_R':YF>,E\?,P746Y<?HGS^GH7].!1_%
M>8_>#&B/GWTD/?)OM5/G2G,7#76.VR<%45_/2^&_TI%_,9RW.G(O9_:$/.(0
M1"8W83N/\]^Y$(3!"[3-[['C#XR5_Z%-7F&">Y7._4<ZTA^IU)\H[$^O@D]5
M?RYS ;Y.H<YA^-C[6OK?38[\RST.SD<=>9<S]Y(\KQ_O)OGA+,Y_Y4+,^1CS
M:(N/:)>/"0X_9>'YC$'X.1WM<PB_N %0B2],-F*:8P_$5$<^Q.S!,+>4FO,P
MYCZ.(E K^UZ07C J^YF8)3)W@WS/0/F60?(-"N\K.JK]3HXK]#'*VMS'\3X*
MW9Q">8=OG'E"K,E!F!LY?Z[_[PX*)X<=)A=CSL.8^SAR;+F8[]2 -NW0Y^K7
M)]CQ3Y33!^BZ]U!R[Z*"WL:.-['C;PR6UU"F?Z8#O4JG^3TL+^&LW^K3'YZ,
M8LZ@/.3(0?SW&1 [IF'Q+.H30'VBX4M#DQ8XSJ(T47XGRK5?_X,=O\..%U%U
MOV72^C5V/(<=SZ+OGD:E/L'@>4S7TVWNPHI?T*3OZ@&\9O(N9O^'N0O#[+\X
M]5\VF',8[\M"?=ST5_E0CU#\%@]/)AS%E%^-9YLINY.R^RA[A++'*7<AW74Y
MGE_'$-G&4-D#QT4,GRMU,_^_D6_>0(<Y!8/AO$[V?1@G].,9$+,'Y"-'=S)[
M,)[1=+K[++I_ !R1<"3#D8/?2BB[!@\WV?9AW$C_N![=?PKE>M*V#V,YT\4Z
MF+=3_OEXXA*&]G7\WYR.^24Z_OW_N ?CD.SW[IH]&.;!T*_*?O7/0[;A[@2/
M&[[RAB.$\F-UK5*Q/8_>5DK9-93=1-D=E-U#>4.Z4&.TP )ZPW*FM U8L%-[
M;>= 3MAVI^QB<)G32V?V8)S!.<#L@7G%,?3,-&.VP3$\=1Q?7"H/./S@"&>:
MC(<C';OSM4]E>+N&\ILHOYWR>RAOD/+FTA(+64Y6:C/_WX@5Z[%T'9Y:@R?7
MT'-6VYY];/T!JV6U/2#J*<<49*8D5C9=;%L*G"C!E9[N!4<@'%%X. F.3,HO
MT";LV( =Z[!C+7:LP8Y5^&.EYN&))5K*;Y90ZT58OY 6FJ273-(W)^B;$_3-
M^;+:8$;Y;YE:[YMNG^HO ?MY?ZY9#K%C*V-D([Y83_]<0YNL5@P<*7!D:YD*
MX2AG=-;"T40K=,#11[FC6#&)1U;2.EOY:3\]][B&:8]!9H1!:CW *!^ V\ \
MG]KD8$Z[VU/_^\%VL(&?5S/%K60Y7"X7ZN0)ES]<X90>#T\:HR$'GB)X*N"I
M@Z<%GMEX8I"RYS%ZE]%C-ZD;;\ZF]W31NSH9'QV6/ZG=Z7.U.UO5/L5J>WV
M9?\DT_IAIM0=8!U8QL\+^7P2>^:[.FO^-#>-3_'2'.<@C4R)TO#41 U.R]#
MM#SU32]1[_1J]4QO5/>,#G7-Z%/GS#&USURLMID;U.)"KW&Y1(TN-ZK!Y2'5
MN[RB.M?/5.=F_0%WLMP?]T?O$1)N(AQ;SNMD "$?GXU@SY 7\)BF(3=W];OY
MJM<M5-WNL9KMGJ).]RQU>!2JW:-<;1YU:O%H4[-'KQIGS5'#K$6JF[5>-9[G
MJ8I%L-+S1I5[/JPRSS^KS.M+8.4],S"X!=XCA!R[6&;7A%%_,,;[03[KY7?=
MV#(;6V9[N:C3TU/M7H%J]8I4LW>"FKS3U>B3JP:?$M7Y5*O6ITDUOK-5Y3NL
M"M])E?NM4:G?+A7['5&AW_4J\'M0>7ZO*,__"^7[6VTH\&.NA.^"</I?I#EW
M@\X 0Z"',+F3S]NPI15;6ORGJ<G?0PT!?JH+"%5M8*RJ Y-5%9BERJ!"5015
MJ"RH7J7!'2H.'E!1\'P5A*Q47L@YR@FY2-DAURDSY'YEA+RLC-#/>+7RLQU7
MP75^-"$HH>ABPL YH ]T\G,+GS=B6SV^J0MU4DVHFZI"O541%J3RL"B5AB>H
M)#Q=Q1%Y*HHH54%$K?(C6I4;V:><R+G*BERNC,AM2HLZK-2H:Y4<=:^2HEX
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M5AN6P3%:Q:]  Z@T.2"0S?OD&OH \CV\$7XDHW<[&I!B7;LMFM9'H-'/PC_
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M[40O.[H<*SS=T)WNZ(/MH=@>!T<Z?C-W8911=BUE-U-V!V7W4NX0GI_+\%U
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M.J=1YRC\[+_"O@=FZE9'_?8Y^,[L0S%[0G[8?R)[/N1&_>>=K3\E&+Z'OOH
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M,BE;"4C)2IL4K8Q(P<J"Y*UZDZRU$TE;#R4IZW$D83U3M'G?&C.1->)NJQ(
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MAYZ=H"H;Z-K8$V,0G$AEJ$UJ ?V5?PD4R^O:D]-U/@EWQ)/%#FE7+H2OU<B
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M$D*R*LDDH[*/I)7K2$KY&DDJ_T*22DSX<^1DR!D%N:X:B#, &\!2@^==4']
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M0W77N1T\>&F4$YT+4H].5@M='(*0"E2F#(64H(\67"5+V)4>/X=FNO@,8+[
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M4!5<Q*]GYPN;F7D)K=YY&6VTO-(V:F9-,RVMH7:F0 SJ$+UM%J3OG0,E1Q=
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M3"+Z?&:A#H7G5D.YVM8OM;J')NO-%,9J;8V&RYP<K^52J!=3Z0$7XEF"VJC
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M)-@[3PB'EP;"J;4^H+#)'=1W$$%_KP-8',2"_1%K<#V& <\3%L X90;LTR;
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M0>!P OANBA#HJPULOO$OELCJ!R,%]Y66X_S)O=CU [G*[9U+$_4MH<OK%7Z
M\=S^%O,A]A'KALV([R#VN5>OW;C[1;L)RG0 #75P1QV\T/4L!^W-T%.+0:BP
M&D2:FR'&9!]$V9V$<)(R\+UUOP<&FG]A"^T^,1.</WAE4"8]"ZBO*>6,5ZX-
MK!>$3O9SIT'N(_L[0=>Q#X(OVSUF]^!&F&T.+VBM#B\]I^._#CMDP6?/;'2X
MG0<1)Q>#Z/PJB-?8! E&^R#.]M2O:*+*MW":P12?;?6>&XI_XQ=#&?=.IH]Y
M9K.>48HY3URJ>0^=+X3=PU^.&+*_*>RSOQ/6Z? @J 7_V+_>:911Y_3<:SJ
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MAY7 ?%3YI]FXRE?3294IDRG5=R;?5-^8_%*9, &E/P&VJ(,EZH ]( M.1^8
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M*,*^L*MR>&[;XO3,NH_XQ.J>ZS!FW/6&]:33H.T4K@_[U;K;[H=%!^Z7Z9\
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M&E890+>,'FR0T85)65W8):L#A_^GB5UX_C&$&BXC5'P/H2S@1@D@3 @#"6(
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M.$)3^!IL.(!0YQF$:F_@!G_&C;)A.2$99(G1H,(= KI\+# 5] 5;84]P%?,
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M: M+JEL?&5\[$1U3NS<FNO9\3&S]\_"$QGEV8L-/_\0Z\%X*Q..SD"^(SX(
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M_<=G(/,ZGO\0(>8SA&C?$9Z-D#T(($L0)9B )$$?9 G:^'JH@QI1&;2)"F!
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M=O_JE[:GUCRW_6W-$]MG:Q_9?5ISWVYA]5U[D+GC *MN.8#4[PZP<C&P6TL
M,NY<FA3A[\\ ^"D2@8GWPQ_O!\.!%[RI@O/T .'/U.CE[REI*]ZX%TJ])%?)
M/'=M7OW4I7OM$^<!N3^=1A4>.DTI/G#<HW3/\9CR'XY75/[C^$3ENM-'I2O.
M"PH774#N@BNL.><*LF?)(+,8..&YE!5X/NY_)EY'$%X3!Y_/8 /2SR!KGKD
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M0D]Q>]_.Q[U31D)GJ[G1B3H>=*!!$NVL5R-NJ37CW53I)#I01I/J*?9?TU[
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M\W9,/0,$2)K*QW-W^P7 YB: X3T M4< O&< 4E\!Q/$8.(2&YRB F2+ 3SC
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MAS ?LUTQV_8\@ GV<9VK "K7F:#XD T*#Z5 [I$BR#[2 NYC8Y!^; U23YQ
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MU0K.+=L5G%I.*S@U/Y9W;OK,<VXB7)<F(N/2^+=SV7\^#QS'^:_%*K*\ V>
M/;RI&[O?$NQ^V(=3>MF0V"<'\7TZ$--G047VVM/#>MV8(3U^?($]H0)^2V*$
MO1>GL#T7YW+<NLLEG+L;I69W=<LX=JWBVG=MD[7K.B5KM^@1UZ[SDXS]0B*-
MI*8[AC/8B6LPAN<_A!V\![/;L ?7] ,48A=-PGH4/2@ $8.2$#:D"B%#1A X
M9$WY#SG1? :]&)Z#04SWP4@^EY6) DXKLX0<5Y2P[5?4<VQ7+!*S'A@4MQK8
M*C%CQ4F)&0,/Q2V7?1*W7$K$+?N)V(QI]N-U,([KO@;SERT&Z.S#?8#9I8/8
MOX>Q?Z[%_H?5R&>4#5ZC// <U0+W43-P';6CG$==J=FCOC3'T5"Z_6@LTW8T
MC66]H9!_QH9: ?,-"X5,-ZP4-MFP1=AXPPEAX_4/A(W6?A(Q&B$B1FO^:0+W
MP :<_PK,7XSGWKP"^R_VX-QU (EC &&; ;RV LS:P0+["3&PFU $VPD=L-EI
M#M8[[6'&3C>PW.E/F>^,I$QW)M&,=^;2#7=6,?1WMC%U=RYGZNS<Q-+>=8RI
MO?,^4VO'1S[-;81/<ROAGV[SU',PS._%*M@V./4Y((!\[,')6P BL(OZ[ 28
MO1? :C\%1H<%P."(..@?402](SJ@>]0,=([:@?8Q-] Z%@":QZ)!XW@:J!TO
MH52/-U'*Q_LHI>.CE.*)0Y3B\;N4PM$/-/G#A"Y_Z ^,[]8L_NNS4$, =3CW
MPDT J9@=B774%[OP[(.8?P3 "#NQYAD&*%X0!+F+8L"[Q /92QK O6R$;$#F
M1V>0_M$?I/ F1/)*)DC\5 7B_UD(8C\/ ^?J7G0=.%=> ^<R <XE0G$N_FTY
MYB_"_'J<?3&>>QJ>=Q1F^Q["_&, ,TX"&)P%4,=.+G\%0.H:$SBWA8!S1PS8
M=WE(#43N&8#PO1D@='\V"-[W X$'<X#_03:P[M<"\_X28-P?!=K]HT#=QR+_
MX"/"\G[_;]V8W[C^S\\AI>.Y1^%Y^Q[']3\-8'$>0/<2@,I/ +*_ (C? !"Y
M R#TDA\$7K.![[4$,%[Q@/9*%>"5+L+._\H!X4W)*WPS?H47_BN\Z%_A1G^]
M$>$/?G,/O4.?_ZL9\\MQSV7LP6OP,.:? G#$;+/+ -H_ RC^AN=^"T#T+H#@
M0P#F:P#Z5PK@"S_ 9Q$DAJ3Q[Q61)C(&^#H3X)L'PC>C;U-_#@6/@^!Q$-SD
M!$^2X \F=_^K$O.S<,_-.0K@=P[S\;Q-K^+:7P>0NXWGCN,3?HS9SP"/&9'I
MOC\+82-QQ/WK.<C4YT%F(%<4_M=G4FH1ONB1D;^>Q^S]+R*G"40>NS8/26D!
MX1@ $;0$PG0"0OE3!&)0)BI!=1@]'W6AI6@0C: QM!7M1H?1.70#/44?$(&O
M_P]$20VI %%$LOB]A Z>EBD084<\11^*\$52A)%*$7HAFHN:T4(@M!ZT'*U"
MZ]!F/.8)M!^=0K_@3W\,7^#='T?QGH;H!-XQ_L+\&U%50O(X0J2(WW.GYF&$
MHYV),_' XPFEB' "181R4#F:A]I0%T4$^]%*G-L:-(IP%H)[X:O@<?@L^".\
M%WP KP7?P.^"!%X($7@N3."9,*'^C6A@U]?D M&0P>/ K\I3,]'#M9D!^*X&
M1#* (N*X'F+IJ CA+#A-U%=.!_6%LX3ZQ%E&?>0,4>\YZZAWG,W4&\Y.>,TY
M#"\Y%^ 9YQX\%'L%]\6^47?%"74'W?[+K6F(#G9]70D@.N) M/"K-LY#"_>%
MFAD>CP,0!6_<,^'4%]DDZH-L#O6.6T:]YM91+[FMU MN)_6<VTL]Y:Z@'G.'
MJ4?<,>H!=SMUGWN NLL]1]V4O4/]RGM)_<S[1OM1CM NH8OHPK\0 \PV%$78
MOXTX".=AB+/0Q[VI8PT?-5WAC7H0]4(UAGJBFDX]5"FD[JM447=4&JA;*@NH
MFRK=U'65I=2O*D/4-97UU,\JX[0K*OMHEU5/T2ZHWJ"=5?N=?E+M*_VX.J$?
M14?0871H&F*,^:9"0,SX@5CB<5CB,5GPX*NI!KPQ-H5G!@[P0-\;;NN%4[_I
M)5)7=;.I*[HEM$NZ-;0+NDVT\[H=]+.Z2^BG=9?33^FN9IS0'6,<TYU@'-$]
MPCRL>X6Y7^\)<X_>1]8N?<*:T"?,'6C[OQ!S8<S%[FU-!S(3CV.F"'RUE8"7
M5@KPT$(';IK/@*MFKG#1/) Z9S:'.F662CMNED<_:EK&.&1:RSA@VLS<;[J0
MM<^TA[7'9 7?+I,1OITF6_AWF.[CWV9Z5F#<])[ 1K.W J-F1&"#&>%?9T;X
MIJR=ALS@^_/QKCW IUD4O)S%@I<.(G!_ICC\8J,$%VQ-X/1,1S@ZTX<Z.#.<
MML\VGK[;-H,Y85/ VFY3P;?5NHY_BW6+P&;K3L&-5GV"HU9#0NNM-@BOLYH0
M&;$Z)C)L=9T]9/U29*4-$5YA0X0&;(C@<ALB,!VQI?V1_]X9WSZP@]]PI^":
M*PNN.@K!N=FR<,Q9#_8[V\)N9W=JAU,0?7QV-&/3[&36Z*PLOO6.10(CCI6"
MPP[U0JL=YHL,V7>S5]HO%QVP7\-99C\NMM3^@%B?_8_B/0[/Q!8[?!'M=B3L
M+D<BW#4+K^QI_OAXG1/V7GQYO^Z+O1/[YSE?.ISVX(?#'I*PUU,3=GA9PF8O
M)]JHIR]]K4<8<]@]CF_(+55@A6NNX'+7$N&E+G/9?2Z-HCW.'9S%SKWB74Y#
M$IU.8Y(+G?9(M3N=DVIS?B@UW^63>*LKX2!VBRL1F6[JT?8K//\[F/TC]KXS
M(0!'@P$.^C-@MY\8;/57A;$ 4U@;X$!;Y>])7^$7Q%SF&\W?YY,HN,0[0[C;
M*U]DD6>Y:(=GK=@"CU;Q^1Y=DBWNRZ6:W-=)-[KOD*EW/\&M<[_+K?-\+U7K
M2<1KO0@'B2+V=U,S>.J%G1/SS^/;RU%\JYM$N\(H& ]FPX9015@3:@@K0VVI
M92&N]-Y@?V9W4#A_9V"L8'M BG";?S:[Q:^(T^17)=[@VR@QS[=#JM:G7Z;:
M9YA;Y;-5ML+G"*_<YP:OS/>-3)D?D43B9?Z$@T2_^XIO;0]P!C]A[SR);_D'
ML/_N1./X_88(81B.Y,&**%WHC[*B%D<ZT3LCO)D+PD/X6\.B!9M"$X7K0S+8
M=<'YG)J@<O&Y0762%8%MTF6!2[@E 4.R10&;Y0H##LKE!_PBGQ_X2C8_B$CE
M!Q.)@F BACC?O7;'=< 97(C"&<1-/7_!WHO&X@&&8P1@(%8&^F*UH#O6@NJ(
M<:3/G^/);(H.Y*N/BA"LC8P3GAN1RJX,S^&4A1>+EX152Q:%ML@4A'9S<T-7
M\G)"QN2R0B;E,T.O*&2&_L[+#",RF>%$,BN<B".Q[U[B.MP(!3B+O?-@$LX
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MP9"L=\$XS[/@.+K'\RKX*.-=0*20A$\!$?_N1[P>#^,,=N#\1S%_%7;PWCJ
M!:BB&GM7#0UR:L0@LU81TFKU(;EV!I50ZTB/K7%G1%?[LR*JP_C#YL8(!5>E
MB 14Y8CZ59:)>5?62WI6+))VKU@IXUJQF>M2<93K7'&7ZU+^0=JUG$BZEA%Q
MMS(B]MVY9%P'W(/CY;@7\?9[.7;@KB: )E2*,E%*LP@D-LM"7(L6Q+2845$M
M,VGAS2[TT&8?1E!3,,N_*8K?MS%1T*LA2]BCH434M;Y.S+E^H<3L^@%)QWF;
MI!SJ#TO9S[LMY5#W7L*ACH@[UA(QQ/GN.,Y@)Z[!V-1SJ$:<02O.H WW 7;A
M0NSCR0NQ>RP4@,A.20CO5('01080U&E%!73.HOEV>M"]._T9G@O#F6X+X_A<
M.M(%9G<4"CFVUXC8M[>+SFQ?SK%I'Q.S;C\D9M5^BV/5]HYC-9^(6K?^@?W=
M =R'6^?B#/!\E\_'?8"Y38MP';H!LK&2Q/8"!/=3X-<O"KY+>>"]5 L\EYJ"
M^]*9E.M29\IYJ3=M]M)@NF-_-,.^/X5IVY_'9]U7Q3^C;[Z@1=]2(;.^42'3
MO@/"IGTWA$QZW@J9+"%")HM1]]]V5> ,\/R'\-Q[.K'_8P^OP=R"9;@& ]B_
M!['_K0)P&1: V<,2X#BL! [#NF"_QAQFKK$'VS5NE/4:/VK&FG":Q9IXFMF:
M++K)FG*&T7 STV"XEZ4_O)ZE-SS)TAV^SM)=]99/9XCPZ0P2?IV5?YMZ#K4&
M\Y?BN7?V8/_&'EZR$OLGYL9@+0O$/NHZ"C 3*ZO%9F$PVR(%IEM4P&2+'AAM
ML0##<7LP&'<'_?$ T!N/ IWQ5$IKO(C2'*^GU,<7T]3&1VBJ6_?25+;^0E/9
M_)JNO(G0E3<2AM+8WS:T_?59)#SWYN6X!IB=O18@#G-#-@-X8!^WWXX=>"=V
M\#UT4-\G JJ34J RJ8QT07G2#)3VVX'B?C=0V!\(\@=B@'<@"V0/5 'W0 ?(
M'!P"Z8,3('GP,DCM?PE2^P@EM9=0DGL([;NAKJD_CP8P?P7 W&& W T "9@=
MBKF>F&N/?=QL$O.Q+JM@+Y8]P02),T(@=E8<R0'GK :(GC,"]CD;Y HBYP)!
MY'P<")_/ Z'S]2!XOA<$SH\!__GCZ"'PG_L, F?(/_1A?COFUZP!R,=JGH25
M.&PWYF.N/>::'@'0/@Z@=!I !GNYV$7LX3\Q@?^J,+"NB@/SFAPPKJD#_1=#
MH'ZQ!OC5!6^(IGY39NH/ N(+[?46?&/&C74#?_"-\P WG^/73XC\UT)<^[J1
M/Y\!)>\ ",=LS\, =L< 3$X!:)X%4+@ (/DC /LJ@,!O /1;V/OO\"$1@+O8
M^>_)X@VQ*MX,8>=_9 GP9.KF;.K#H7@<S_#"?[X #0&\P,&^P)-X\03@]W?_
MU8!K7XRS3\5?CC@ X(7G/!//V0@/6?T2 .]G /%?\=QO C#O8/8#].0OSYCX
MLX7PYW  7DH!O%8$>*.%-^EF !_Q1O43OBE_QC>C+U.?2<$7G*^K ;Y-(#PY
M<N._2J>>0>'L(P\!>&/VS!\ #/&<5:_A[*\#<&[CN=_'O$?H*?H=O?O+>_0!
M?>+[\YG,5S'\F3@3HH:,_BPM?_S9G*G/I.!QD/:_/I."0R=[_HM(JV'7QWXI
MCMC8^UFZ0 #[+LQ"OB@:I:$B5(V:T4+4@Y:C56@=VH1VH$ET OV$'L W>(V^
M_?&LXPOZ_+\@/&4\=$4\%L3![P4U@#",\5?LD!<*1TDH#U6@>M3VU[.8/K0"
M#:,-:!RS=N///0*?X *.Z Z.ZB6.[ N\P5^=\OI_012PZ\O+XG$@23F<!<Y#
M6!^(@#40IBL06A#^6[$H$Q7_-8LFU($6XQDNPX0AS%R+F9O@+<[B-1S Y#.X
M;#?@.?[U%#[B]IEZ*H,H H_^A2ACUU>2Q..0 "(CA?-0 "*AC3,Q!R*"ZR&,
MZR$0"80_!>7!-[YR^,)7AUN@%3[P=<([5@^\9@W 2]9J>,': ,]86X'<)L3#
MR2G6/]#/U</;!?@%'K/VPD/62;C/^A7NLI[";?Y/<%.0P'4A K]-$2;PZS1$
M#=N_&@>("AN((GY5Y.(1XJ[A&N&D;''G>, 73@A\$(V#-Z(9\%*T"%ZPJ^ 9
MNP&>L-O@$;L+'K#[X3Y[$.ZRU\)M]F:XR=X%U]G'X%?V-?B)\Q0NB7V"'\0)
MG!,GU%ET1H)0IZ>(_XEHB0+1$@:B(0!$4P2_XH34<,64M>&SO 6\Y<V&%UP_
M>"P3"?>ED^&.= [<E"Z%Z](U\*MT,UR5[H"?I)? C]++X9+,:K@@,PKGN3O@
M+/<0G.%>@A.\A]01N0_403E"[9<GU*0\H>V;(O<WHH?Y>DQ$!V* QZ&/\]"1
M@O>:RO!<S0 >J-C +25W^$4I&*XHQ\)%Y30XKYP/9U7*X;1*'752I84ZKK*0
M.JK20QU164$=4AVA#JANIB95]]+VJ9VF[5:[0]NA_H:V39W0Q]'FOVR:AABQ
M_KRX3:?^X!L-/IKRPWLC-CS1DX9;6JKPLY8I7-"9!6=T?>&X;@0<T4V@#NIF
M4I.ZA=1>W0K:;MUYM%VZK;0)W4[:=MT^^C;=(?JX[@;Z9KT=C$UZ1QEC>K\P
MUNF_8(SH?V,.ZQ/&:@/"6#5%_V]_9N,+G16^,.$;P&UTW8(/KAN*P$4C.3AE
MH@]'S&QATLP==IL'41-FT=0VLV3:%K-LVB:S(OJ8:25]U+2>L=YT/F.M:3=S
MC>DRUK#I&M8JTRU\@Z;[^5::7N1;;O:8;ZG99[X^<\+7:TY8/7]B?O?'__P(
M\Q_CB]R-V0!7T \.=#AGQ0_'K*1@TD83=MI:PM:93K!IIB^UP3:,MM8VCK[&
M)I6^VB:7,613PEQI/9<U8-W(M\RZG:_?JH>_SVI0H,=J5'"QU2[!;NO30HNL
M[PDMM'DOV&Y#!!;8$G[$-]U4_DO,OX-O@#]Z8/OP!#CFABUH%@/V.(C!MEDJ
ML'&V":QSLH=A)P]J<'80;6!6%'W9K 1&GV,&L\<QG[78H8RORZ&&O].A17"A
M_2*A=OMEPFWV(R*M]MM$6NR/LIL<;K(;'-Z(U#L2(20XSY$(S)M%^+\C,_]\
MX_L5L\_BB_T1?VRBV$IW>E P[LJ&#>[R,.RA#X,>-K#,PX7J<_>E+78+HW>Y
MQ3 7NB:SVEVS^-I<"@5:72H%FYWKA1J=VX7KG7O9=4ZK1&N<-G.JG0YRJIRO
MB54ZOQ2M<"$B%:Y$" DB@>_>X@SNN__Y5.A$,-[Y8QN<P*];\%C6>PO!*A\N
M#/AJ0Y^O)2SVG45U^GC1VGV"&/.](YG-7O&L1J\T_GK/7(%:SU*A:H\:X2J/
M5G:%>[=HF?M*3JG[F'BQ^S[Q(H]+$H4>S\4*/(DH$D%"?Q&<\@K7_Z8WP/D@
MG#\VP5V1F(_-?'THWOT'\L&R0"GH"5*'14&FT!YD3[4&NM&: OP9]0%AS%K_
M&%:U7S)_I5^60+EOH5"I;Z5(L4\CN]"GDY/OLUP\UV>]1([/;LDLG_/HB426
M[U=.EA]A(V$D]-USW >_XCF?"L,98!/<'H-WWF@X"N_^0QFP)%0<.L-4H"W<
M")K#;*GZ4&=:3:@/O2HDF%D1'/5_&#OKZ*BN]?T_9RP^Q+%@$1*( '%W=W=W
M5T(2$@@$" E!$BQ8@KM#*5"L+85"E>JW;K=NU(52SN^9S'#+O>O^\5M=GS63
M"7.>=[][GWW>9W>?$T5;:K%V:TJE3DM*HUY3<KM!0W+/N+JD-48U25N-JY(.
MF%8D/6Y6GO2\65GR5Z9ER7\9E:>(XX@!T7_(UQR';S '-]C^)^C(3_'B?XCL
MY/O-_&Q=MB%6Y4S%BAP'+,WQ%!;E!$D69D=+V[*29/,S,Q5-F05:#1GE.G49
M=7HUZ0L,JM*[QU6DK3(J2QLV*4G;9UJ4]IA98=HM\X*T+\P*T^\9%Z:+XXHR
M1"4Q(/HJOF _O,*\/\6V/\XBZ'@Y<T"VE[+ZYV?]^4HL+YB,)06ST%7@)K07
M!$CFYT=(F_(29 VYZ?+:W%RMZIP2G<J<&KWR[!:#TNQ%XXJS^XP*LC::Y&?M
M,<W-.F.6DW73/#OK,[.<[#^-<[)%P]QL44D,'J):)7R1_7^U"#A+[<-5P*YJ
MNL!*.B#F8UFQ/A:73,#"DIE84.*,EA)?H:$X3%);%"NK+DJ55Q1F:Y45%FF7
M%%3I%A4TZ1?D=RKS\GN-LO,W&&?F[3+-R#MEEI[_C'E:_K_X^KMQ>KYHF)$O
M*HG!0SY@/]S* RZQW:>H?:".#J2>#H2O*RJ Q14Z:*\PP_P**S15SD%]A9=0
M4Q$LJ2R/EI:5)\M+RC(5A64%VOFE%;JYI0WZV24=RLR2Y89IQ4/&*<4[39*+
M3Y@E%3]MEEC\,5]_,TXJ%@V3BT4E,7C(V^GJ%;KS;/<Q:N]M4J_*K.-K-QUR
M>XT<S37&J*^=AII:!U36>@CEM8&2DII(:6%-@BR_.EV16YVGE555II-15:>7
M5M5FD%+9,RZQ<IU1?,6(25S%,=.8RB?)!Z8Q%;\:QU:(XX@RKD(T>,BKV>H5
MNK.U[ <ZXET+U*LRJ_C:P3B:2$W3.%0V6:"\V0XES:XH;/83\IO#)#E-<=*L
MIE1Y1F..(K6Q1#NYH48WL6&^?ES]$F5,_1K#J/KM1A%U1XW#ZZ^:A-6_9QQ>
M]XM1>)TX+J).5$;4B@8/>8'C_S+'P"EJ[:?VCD[UJDPO7UO;J<_/RMKT4=0^
M'@7MULCKF(OL#F\ALR-8DMX>+4EI3Y(EM67*$]H*M6(75&I'+VC6C6Q=I!_6
MNDH9TKIU7'#K8</ ULOD;</ ^3^/"YPO*H-:6+.UB/H/4>U6.\\^.,IV[Z'V
M<+=Z568I:5Y"??Z<UZV-K&X39"R9CK0E]DA9ZHZD)?Y"PI)P2=R2>$E,=YHT
MJCM/'MY=K@A=W*@=O+A3)V!QGY[?HF%]WT4'#;P7/:'T7ORF@7?7CP;>G:(^
MT?->^ ]/,@=GY@,'J3]"W?7+Z89[@<Z50#TI)&DK!23V*1'?-PEQ_3,1TS\7
M4?W>B.P/%L+[HX70_F1)<'^V-+"O1.;75R?WZ6M7>*WLU?98N4G';>4!7=>5
M%W5=5KZFZ]+[@X[+"E''93E9]@\7&SDG+%3O#AI>J;H[BCE8K=H90S>TCFYH
M$$B@4X]8KXO0]28(V3 -01MF(W"#*P(V^,%O0QA\-L0)WAO2!<\-!1+W#552
MUPVM4N?URV1SUV^0.ZW?IW!<?U[AL/X5A</0787].E%AOY:L$;4><I9]?I#Z
M.VA6AZB]<O"?59FB8>9@*Q"U'0C8(<!K1 F/D?%P'[6$ZZ@#7$;=X#SJCWFC
M$9B[,Q%..[/AN+-4L-_9),P:[9;8C@Y*9H[NEEB/GI-8C;XDL1KY7FJU_8'4
M<ILHL]SZ#\>8_UW4W\1V#ZSG^;B9XV ;QP'-<Y9J58:F,7@?X$&G['1(CEF'
MQ\'N\ 38'K'$S",.L#GB!NLC ; Z$@G+HRF8<30?TX]68^K1#DPY.H#)1T<P
MZ>AI3#SZ'"8>^5:8>.AO8<)!43+AP#_L[P>V,N?K-G).W*JZ.XI]L ?(I6;B
M82#T&.!%PSB'3G4F#?W4<PI,/#\.$\Z/Q_CS,V!^?C;,SKO"]((_3"Y$P?A"
M*HPO%L/H8A,,+R[#N(O#4%X\!H.+S\#@PA=0/OX7E.=$*!_[AQW,_7KFO9?Y
M[E#MS*%V_E$@F>X\_ S@?8[Z=.DV-*Q3K@!F3](97U= [Z82NC?,H'-C*K1O
MV$'KAC,4-_T@OQE%,B"]60[)S38(-P> FSSP#3KPF[3V-^Z2^T3\-YN8^_X=
MZITY=6QW(;53'J/^!>I?8OZO M9TZ9.? 4R>!91TZ]HO"1#NZ )W#(DY+WI3
M@5=M60C-8T'(PNP-7HS?9#'R)D^Z-[M4?RJ<'"37R$?D9_* B&.L9K\O5JT*
ML>U%;'?J1>JSO5[4=:2N)74G/@\8O03HLQGR-^C^WR7O28'W&<<'XU@,FP(?
M6[ HMP8^=6)AY@U\P3B^Y,7P2T[X7W'0?;6%'"<WR"?D)_+K&$M4JT+\50ES
MGG99=6<4]6\"#FSO=.J:4W?<FVR[2O=#U8H,^4RS.O*EP()<BP6I ?"=$6C(
M6"#/ 'ZV!WYCL?P[B\0_>#'XDQ? >YQX[K'#[S'1]RAR[QWRX1CS5:M"[*IT
MYCR2VEYLL_T=8-KK@"G_F<&'FA69ARLCJATB[%):;6J17U4K)!)JZ?!X2N!O
M$YH%YD2T(^Y0/S&5<:C^=)>X0G.'S%'-G3&7QQ"-IM-U3Z7C)K(9].NV1+4B
MX4]B218I^_]<D3A%+FAVA[Q$/L$#_("_\==_K(+<^R]$4_I;XTD0E42;[Z&*
MPY%XDTB21HI(+5E NC6K,^H5"=4NE0?819T#N(]CU'@,?^(*_L!M_([WF*9O
MF:X_QE8_?B(_DA_^"W$\O;Z9.?-AQER,ARB?PD_MB#L)(8F:%:(*TC26B_OH
M8?S]//(@=3939P=^P1[J'*+&*1[W K['=:J_AJ\Y<+[BO_B"W_R<?/8_$"?1
MZT\P8CX,(8[CJ\%$B+K6C(7](?AK5H@RV-9BZM;R:*ULSR+J+*?. '6&\ V&
MJ3-*G7W4.89/F8M/< T?X45\P$'\'K_Q#C/UEF;=Z@U!@T3-V+J'A0'SH<=\
MT/>;,A]&T]@WLR'J>>)O[3#\H4C"+[)<?"\KQ]>R!GPN;<.GLFY\(NO%1[+5
M^$"V >_+M^%=^2Z\)3^$-^2G\:K\$NXH;N,EK8_P@O:/N*TKXED]$3?U1=SX
M+\09^A"GT_];2"%.T84XF3%-8/^86N$WH[FXJ_3'U\IH?&:0CH\-"O&^017>
M-FC"&P8=>,U@*5XQZ,/+!NOPHG(SGE>.X#GE?MQ2GL#-<1?QC.$M/&WX(:X:
M_81+QB(NFH@X;R(*C_\7HHU"O<"HPIIQS-#%WU.,\..DR?C2W!8?F[KA'9,0
MO&::@)?,LO"\60ENF=?@AGD+KH_OQ%/C>_#DA'Y<G3"(RQ.VX-+$7;@X\3#.
M3WP,YR8]C<<FO8E3D[\3CEO<%XY.$87#&@X]PMAIS&GVP6R>]N0+6P%?6.K@
MTRF&>'OR%+P\Q1&WI_KBF>E1N#8]!9=GY.'BC#*<MZS#.<OY.&O9A=.6RX13
MEJN$$Y;KA6-6VX6C5ON$PU8GA8-6EX4#UB\)>ZV_E.RR^5,R:B-*1L@.LOT1
M1 ?&X,BIQYE3K2OPC@NG?2<I7K71Q6V;\7C*UA:79KGC\=DA.&,?CY/V&3AF
M7X@C]A7"(?L&X8#] F&?_2)AK_URR6[[-9*=]ILDH_8[)3OLCTBWV3\NW>KP
MK'38X1/I1L=?9>L=1>D0&70BCO^@NOGP)^I^RBG^33_Z?UYRGO4"KL^3XXJ3
M$<[-G8%3SG-QU,4/!UVBL,\E&;M=LH6=+L7"#I<JR3:71LE6ES;)L'.W=)/S
M2ND&YT'9>N=MLD'G_?*USJ?E:UR>5@RXO*?H=_U)L=)5E/>JD:UXA/O4_X;Z
M[P71;X52FUSA^PL^ LYX*''4TP+[O>RQV]L3(SZAV.83)PQ[IPL;O?,DZ[U+
M)8/>-=*U7LW2U5X+9:N\>N3]7@/RE5Z;%"N\=FDM\SJNU>-U67NIUVO:W=[?
M:R_R?J#5Y2,JB/Q1?O'@)2B0EUY.ZS>B6>?' .=XR3L90K_AKX<] >,Q$C@3
M6X)<L3$H $-!4<+:H"1A(#!+TA]8*%T96"%=$5 G6Q;0*E\:L$C1[;]2:Y'_
MD':G_PZ=A?Z'==K]+^BV!;RHVQKPM>[\P/O:\P-%+:)H>80??7@YI/]_@=[W
M&KWGXXG ";X>9#R[0K6P+<P4F\(M,1@^%ZLC?-$?'B;TAL<+R\+3)$O#<J6+
MPTID7:'5LH6A3?*.T Y%6VB/=FO(&IV6D*VZ32$']!I#SNG7A][6KPO]0K\N
M[)YN;9BH3;0>Y=L X"VV^UEJ7TH%3J>Q_7S=S9^W1DNP/LH(:Z*GH3_& 2MB
M/=$3$RQTQT0+7=')DH[H3&E;=(&L-:I<WA)5IVB*6J#5$-FM71>Y2J<V<K->
M=>1>_<K(,P85D3<,RJ,^)7_HE4>).N71HC9?M1[R)7/^:ASP-+WO>98^QUEV
M[./K#L:R(9Y^)UZ)E0F3T9,P"]V);NA,#!#:$R*$!0D)DI;X-&E3?*ZL(:Y$
M7A=7K:B):]:JBNO2KHA=J5L6NT&O)':707'L2651W-/*PKB/R6_ZA?&B+M$A
MV@_Y%\?!BVSSU0QZSAS@"#WX;K*%E_PUC*LW61]+4B:@*\4&':GST)KJBY:4
M4*$Q)592EYPBJ4G.DE8E%\HJDBH594F-6B5)'=I%2<MU"Q.']/,31PUR$X\K
M<Y*>5&8G?3 N.^E7_>QD43<G6=3)21*U'_(A^_TVM2ZIUJ'H/0\4T6^1C?E
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M?'V<T_TI7@:/3=''@:D3L'OZ3.R8X8RMEG[89!F!#58)&+)*QSJK/*RQ+L6
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M'WM:JNI^&$[$8K_F*2&G-4]MO4G'::99=S#5K(,\O =$M0<CE"1!?0](.6F
M>B^(>OU!?4_,$!DF(U#?$W,4JKT@#^A"_V;B_F*P?SY\2NDC_*!9?_A*Y7FE
MQIIU!Q5&FCA4^U&<20#4]^1D0'T_C&HM1K47I(/'7X+[]/WWZ/O_Q'IJ;*'2
M3OR* _@%)_ 3W>\/=.#?,WG?\=TWC.IKC:8*U7TIJCT98WLPM%1>WX#H:=8?
M5.LQTX@#U'LPPOGM9+8GESIEU*C%S_3;/])OWZ7?_IZ^_UOZ_J^Q@<?>QF/O
M9LL/\_AG\3%S\2'N<+A\A7<8Z=L\VO^1-Q[A=54,.KH0!3G?28F.)A\3J3F3
M.5/MP0ADFV*IE4Z= FI4X%/4<UC,9QLZV<JE>(]QO,,XWL1&'G,[7L%>O(SC
M> $7.)2?Y2GT$3/R,T\I$=?_!Z*>P/YX^#!>Z5@^?H8Q-:=1TY%M\J9>&+42
MV(Y,:A12HY(]74^-^=3HI,92:JS$,UB+I[$93V(45W&04\@9]LB3.,]OG1O;
M)?,743]?5\5I#6-K'PJ,Q:%Z$,XOC.,+]LU'F,"VV> UCHN7X$^M*.HD,^YL
M'K6(&I6XS#B>8!P7&,?CC.,Q]/'8@SB%K1P1>W",N3C"?W$(SW.4?([]5%"-
MVKU0/^OF(:H_PO073^N[2IYNC.=#'=5RI(*]:,0I: K;-IN]ZL$V!;,],=1)
MI4X.3J*8"I4\"^K9^ZW4Z:3.,FH,\+@;L8NY&!4.88?D'+9+;V*K_!-L4?R"
MS=HB-NF(V/@(]XW4#R#Z%Z>5-\D+?/^L:@E:2Q=7I*8X+YN!,PHGG-#VQA&=
M4!S4B<,^W33LT<W%+MUBC.I588=> [;K+<!6_<48UN_%9OU!;-3?AO4&!S!D
M<!;K#&Y@C?(3#!C^AGY#$7U&(E8^PF_4_8*7FS<YK=VRX91O2>_)Z?8Q4P&G
M#90XHIR(_>-LL=O0!2-&_MAF%($MQ@G89)R.#<:Y&#(NP:!)%=::-&*U23L&
M3):BWW0 *TTWH]=L#Y:;G<(R\Z>P=/S[Z)[P"Q9-%-&EH5/#W1F<:F=Q*G;D
M96<.O88#ZVQ>=@Y-5UV6M3%J;H*MXV=@XT1'#$WRQ-I)01B8'(7^R8E8.3D#
M*RSRL=RB%#T6-5ABT8+N*5U8-*4775.'L'#J*-JG'47;M,M8,/UUS)_Q YIG
MB&BR)#/^X4M>;E^=RTN8&W#> SC.U_TL T;MZ;FL)%@_U1!KID]&_PQ;]%HZ
M8YF5+Y9:A6*Q50RZK)/1:9V%#NL"M%F78X%-/>;;M*'%9BF:9JY!P\RMJ)]Y
M$'6V%U!K^Y)0;?>=4#5+%"H?8J?F8R=>]MQY"?;AY=V/-3;9Z47OS6E^'7/3
M9ZN/9;;FZ+:S1-<L1W3,]D#;[ "TSHY BWT\FNQ3T6B?@WK[8M3:5Z/&H1E5
M#HM0Z="/<L?-0IGC/J'4Z3&AQ.DYH6C.5T+AG+^)^ ].HO".*R_'ONHUF&.\
MQ.TA6WGI'_16K7^POG/2QD)'8[0Y347+G%EHFNN"AKD^J)L;@IIYT:B:EX2*
M>1DHGY>/TGGE*'%N0)%S!PJ=5P@%SNN%/)?=0J[+:2'']::0[?JYD.7V%Q&%
M+-=_>-6390<USX9Q#+ $&R6;>)D;X&<]S$V'FPPM+H9H<)V$6E<;5+G-086;
M!\K< U#B'HYB]S@4NJ>BP#T'>1XER/6H08[' B'+HT?(]%PGI'N."FF>)R6I
M7M<E*5Z?2E*\_Q12O$0AF:1H>)$YN!S*DBI*O0:SC0S% "L9QR+&T<(X:CT-
M4.DU'F5>EBCQMD>AMRORO7V1YQV"'.]H9/LD(M,G$QD^A4CWJ42:;XN0XMLM
M)/NN$1+]=@@)?L<D\?Y/2>+\/R9_$%$8PT_-;>I<8-N/Q:GO QI.8HW+$FPY
MX^A@;NKY^W(_/13[F:+ ;RIR_>V0[3\/F?Z>R/ /1%I .%(#XI 2D(;DP#PD
M!I8C(;!1B _L$F*#5@DQ0=LDT4%')5'!5R61P1^0WXBH0H@,4G.#.3A'O</4
M'Z7_W40&6'XMX<^MT:RSF8^B8&WD!ADA*W@R,H)MD!;LA)1@-R0%^R$A. 0)
M(3&(#TE&7&@V8D)+$!U:+T2%+10BPOJ$\+ MDK#PPY+0\"N2D/#WR*]$5"&$
MA*EY*H)E+]M]@-H[,NC],SD6R>(TUKG\O)QQY(;+D1$^#JGA$Y 4;HF$<'O$
MA[L@-L(;,1%!B(Z(0E1D(B(C,Q$1682PJ%J$1K4+P5&]0E#49B$P^J D(/J2
MQ#_F+8E_],]$E/A'B4* ABO4.)G,^8BZ6UF*#]+G]ZKNPZ$?KV,^BAE'1JR
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M]1:K[(/^;=MLVPNTP-@+M(NVL(<^::]4?(V4AD0C@8B98ESW@W^ Q/<@_/:
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M":!.,>!E4)=BL.K!:*?\7KT/W[ZB&90]C[*74/9*7+&!LK?I53CF*[#=/]&
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M6J:JX*VJ##FB\I#;5!;ZB$I#7U5IV)<J"[/\*!=(0>^ 5]_ \'HMJ>C.$F(
M?KLT![Z'3089>B?@F[&AKFH--JLY)%!-(9%J"$E0?6BZ:D-S51-:HNJP:E6%
M-:DB;(S*PR>H+&*Z2B,6JSARDXI(Q@JC;E%!U$/*C_XS\KGR8RQ<+2I ?DF]
M;P'W1 5^8'C=CJR%9R\B'9R%'I/1HYLX:8T9I89(3]5&^JDZ,E25D3&JB$I6
M>5262J,*5!)=KN+H>A7%M*DPIE<%L5.5%[M N7$;E!-W0-GQ-RDS_J(R$_Z
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M7(0@GM!J6]@S8:YM4<7X(U(O_*KW*0(>[M^##CT673/;MA=HS? Z%&3B8FS
M^\H%M$<^2Z*(<*BB']\UH9<SHIDD.3-),&:8C#\NT)C]C46." /,=&PQG48T
M#7],PW#3C$4^:VALD.I!"-V4)^B$KR#?$G@6[<1,&Y?9UJ$L,-:A()V\KD>*
MH(:I2!2?!^!23\09'34LBTD$%Y,(+B896^1M6Y.RB %N42*"+1;2N2S$'PMQ
MZ@(*6;"7A@^QG =9G0L9'/J:0<&BK2MM9](.KT/IW4A;0,J0S$U2#-= [GLA
MS@C)Y$]BO-^ 'AO08P/VV( >&]!C SQW X/,>@:_]4T(P;0.@Z[;9CL?90V9
M\VHRZ54PFI46;3+.I(6"SB%D^J#E;81OI?%,GMW$ !*$>"'.QMH3JD'23L=N
MEVN&!;]<X\(]]-B''OO08S\)V7X&WOW$Q3YLL8_ NH;*7@/1WTM<[GF>QO )
M8M%:<.>#V0_&&,JM.4!?<*V4 #T//HS]?SP'1;;U)R?M\R$_%V-^Y!0V.46<
MGB8Q/H,>9^-L?R Z2V=[%EN<(<C. '3Z5@0B?^H]ZYZ<1=1C$-PN,.O *3A!
M?TR9P93I=4H:]?,U*'?8YT*&Q;HGQSXW8IQ7<J\#":JK_8P2DM('B(T'\,D%
M!J('L,4#./!^*G(_?=7]?T(^U73JVG.,K@+<(O"2"9F06ZC_;9+C'?;R[['/
MM3Q@)T$/Z6=[<63[ _'P?(BQ9N,I9X@3>OR.I/U9!O[GB,_G&0A>H!$\CU.?
MH_#GL,5S?]=XL$>?I1^@CFG4*PQ,+]SE.#SW,KP?YS']M![DMW8QYD.&SR9Y
M\:JYD.&S4]_$-U?0XUW:RGL,_N\3GQ_01CXD+CZDXA\!]-%O?L;]C?4@QAX0
MXUDQQIFDQGX8XSR.6AEK06Q[4?I@25/U-4SC2UC'%[">SV% _X1%?@8;^P1>
M]3$L]$,<^#X&?!<#O0.3?AO./7P.QTOV-1B/VN<@_GL.Q)B+L:U'^0$^\PT<
M\PN54WX#97=0]CC8\R1=08^WT>,M]'@3)ODZK.^OZ/$7..8K,.N7K7M1;L,\
M#\ RG^'?^]:Y#V/URQ/V.0CC2;YW_1\Z?*U1U,E3_X!7?0#7O8(MWE0AY5=1
M]FC]46.HQSB]@![/H<?OX'6_A5]>1H\GT>,W,-)+,-3'X%:/PM(?)E@O\NX!
M2KC?NE/(-O]AK,$PGD-R^BH=C#D 6JMU:]/K<M>?Y0-6&#@)8&11?@EEUV#9
M9CV"'@^AQT7\<D&#E#V3LN=1]A*8[1I0M]!DKH&['Z<IW4J3>D!G"9PSU&SX
M+%!C+89Q'L:U=AV,<T ^N&H.XFGBXI*\P K$9E%@I%!^+MXMI2G64O9H2NZ@
M[![J,I'R!ZC/#,J?BP>64/Y:(F([& =UB+L'T6H_C>8:(F(OT62<*&.(L?["
M>.KRY[(M9WK9'NI&\[H@!^L:C'/8XE;K.1BQ8*11?AXU*Z.[JJ7\T93?3OE=
ME#^!;K.?\J=3]EPB<RD:K*?\77CF*-WZ+;R[@&8OXJW/_F,-QG)9K/,_O[<W
M.Z/)WV?OALYBBY/$Q5':R+7P_OWX9"^\?Y?RT;],V_#+%C42A6U@=((Q'HQ^
M,&: ,5\K^+?4NBMEOQ9BB_G4:AX>':*ES"':9X-MR!S$.&;H?YQM9X#<Y60[
M&LKH>H]8AP0W,,W4)PB<**VCG:R!]Z]$C^7X99FJL7RC%M%N%Z+'?/28BU_F
M$!^SN#O#NC)D%Y%[3%.L.X@>T62]1C1_:7T*5)]=GF&8>9CN_6Z&FANY'N/]
M ?1A"*&>HRC%!*8/=0H!)YJZ)%&73.J0#TXI.-7@-(#3"DXG&DP 9Y"RAWBU
M7+V4TH,ENZVK>"YH+/X80_0;N^^&Y7$_V^/0;C&6/9(*'2 MVXD^&]%E)799
M+!?JY@F>']X.I?08ZI,,3B8X^>"44OMJ6DD#6&W@=*/)),J>0;08%C)V[>PC
M>DZKB<AN).(;Z"L:Z.T:9-L-^% HPP[#_6F&VL,QMCTPF]!G)6G10NPRFV%P
MT-$-3#-X 6"%@Q(+3@HX6;2.?+!*P:H&JPFL#C4Z]*K!85!U(^:I=L1J58_<
MK:J1)U7A>(_*'9]4V:AW5.;\-6*QRB_!O96A[01IX'YD&Z_7QE)_NO@YV&?0
MA]S.-%)=+A[J&.6MUE&!:G:*4)-3G!J=4E3OG*4ZYP+5NI2KVJ5652XMJG#M
M4KGK9)6ZS5:)VPH5N>]4H?L)Y;O?K3R/WRC7XVWEFKY!+,I#[@'S+,/:4=*-
MO9G&<V"P 7Q_/BGR=.PS"9MTXZ]6+R<U>)A4Z^&C:H\@57I$JL(C7F6F5)6:
M<E1B*E*1J5*%GHTJ\!RC/,^)RO6<J6RO9<KRVJX,\W&EF^]2FOE_E.K]CM*\
MOT4L2D?N!/\4O/H0J<9.N/YZKLMX/T0J-@7]QI,J=^"O1N*DRMM5I68O%9O]
M5&@.58$Y6GGF1.5ZIRO'.T_9WJ7*\JY5AD^;TGUZE>8S32F^BY7LNT6)?D>5
MX'=.\?Z7%.?_EN(#OE5"@$4)_G!_\$["[P^09FPG%5[+=3'O9V5?O09$JH4^
ME :.4KZ?23F^WLKV"U2F7[@R_.*4YI>B5/]LI?@7*3F@2DD!S4H,[%9"X!3%
M!2U4;- F19.4107?KLC@QQ01\H8B0[Y65(C%*C=3[^,E]KU %:2:Y;8EVC/@
M^WT,^9WH,1H]H'(JBG!05K";TH*\E!+DI^2@$"4&12DA.%'QP>F*"\E7;$B%
M8D(;%1W:J:BP?D6&SU-X^ :%A5^KD(A;%1SQJ((B_ZK@R"\5$FE1:(3%>B[O
M47#W5MO/@T7FD_),*X.:H$<'*7H#,5).O.:3'J9'.2LQW*3X<!_%A@<J.CP<
MB5-41*HB(W(4$5FJ\,AZA45U*"1ZDH*CAQ04LU8!,0?D'W.S_&)_)=_8OW#]
M0OZQ%@4@I\$Z#/YNN.Q&4L_ER#Q>3^5>+Y^UH6,=MBK+@N\0(RD)(Q4;XZZH
M:+,BHOT5%A.JT)AHA<0D*20V2\&Q10J*JU% ?)O\XR?(+V&V?!-6RR=AG[P3
M;Y(Y\2%Y)OY9YJ3/>6^QR@W4^5IX_4Z#!C3;UZ' ]:>@2P]ZM.*?6GQ50HQD
MXYLD?!.5[*K01$\%)_HH*#%( 8F1\D^*EQ\?^B85R">Y"FF1=TJOS"DSY9FZ
M$MDK4]H9>:1=D'O:BUP_X3U96RKCN'$V,)C;H8;KVFWK4(P_4_?#];N@:LU\
M7H.>Q?@K$YO$8Y/PK%$*2/>07YI9ONG^\DD/DW=ZK,SI*?+*R)5G1KE,F4U(
MCSRRILDM:YE<LW;))?L&.66?1YY%/I1SUO=RR;+H&/7?1]J]%6Z_!CZ]&)X_
MJY,V 2WI1*_1V*4*F^03)ZG8) :;A!0ZR"?/55ZYGO+,]94I-QB)DD=>DMSS
MLN667RJ7_ 8YYW=J5,$4.18LUHB";3;B4,#(7$"64 "W*/A&#OD6V[DTQGXD
MTNY5XVD34)$9QEZ<'MM>G$;L4H8NV>B:B$TB\$\ U,E<YBSW$I-<2[SE4AHH
MI]((C2I-D&-IAD:4%LFA#.Y?9OP8HEX&>2[;C)!+ET%$2N'=I>\B\,U2<JE.
MV[.)-L+G5TRF3?"3:5PG\KZ=^S78I1 ;I>.?6/P3@M]\L(NISDG.M1X:6<N@
M4LO@4DM'5DL#KB5P:^GL:G%@+16L[4/FVAXL6TM&4 ,IJB%;J29KK":#K+9H
MO[$?"=SU@[9U*'.A0E.Y]O)^-+J43X1[\IU$[!*!K_S1QY/JN;:-TH@V!K16
M.'>KK]3"X-+"@-="9])"\+88"ZM0N*47F45@P2F:X?ZCX?ZC(4)-9&]-7UOG
M8?8.$ O@KIEE6X<R9XAXY#IF)FISOQ!=TOA.-/H$424SOG)#IY&])#^]<+IQ
M#/(]V*('6W1CBVYLT6UTL'2XW32X;A3OIJ"NE;:-%9V0N+&0LC%P_S'HT&'1
M+K WSK6O0X&2SD!Z>=T\#QMP/PM]XF?C V,?#D6Y8R/'J20X4^&5@R084[#%
M%&PQX//3FI1^;-%/Y]://_HQ6C^5F+P$(3.:!*GK@R1.?)U.\"L&)(MU+Y!Q
M)JUQ'LK<%7R-:\<R7+:4MH D\5DX>OE"$SWXKB.B89DW G&VK4F9BQYST6.(
M1&@HQK;P<8A&- =_S,&A<ZC4[*TT.C+%F1>H["L,S%]8UZ(8>X&N7H?2O8Z^
M&2E&TI!([OFM(0811T17RVI#L,<J[+$*/5:AQRIB8Q4#_BH&_U7$Q<IJVP9
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M0PF!' #9'?[;&G@Q@7)-")$40":+H%F@[@@G]!^S,2U"8P03VU*85 PAIC(
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M>IH&?*2!;J1!GZ2!7J2!+-) @=:!\-9M^'%'+ 31R8^@$[XB<9M K*"N'EM
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M883\#,KQ'_62UE?FSIM0>@]G_GH(:0.;="ZD'_BX2[JC%2;\(=#/>S!&[L%
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M@##X^$$<@D(@D!F)@$A )B 4D J(A227&<',ZA)*,C." ;G8V9.&$HPD'[^
MP&!"2&AX9/3:^,24M V;MV1D[<C-*RC:6U)6L?]@914,%])H:6J&)LZT$-7
M69V840I2(Z&5T$QH)S046@I-'9^ QCY_ <U]-0D-?O/V[3M0DO<?/OP*[?[T
MVV^?/W^!MG_[_OWWW_^@MI^:J(F:J(F:J(F:J(F:J(F:J.E_.XUMYK1>L6*5
MDXNCI;6=!<+"\J]FB)K^OTV__DWYJ]M_ _CM!34PIB9J^O\SC=X8^LORD>-[
M3O^E">G<&5KS[*\ O>59A_\2\+7O;-?'OV2"FJB)FOXEZ6'GN;\<FQ=VIV[K
M_(ORX3Q?8^*13PN6_]&>H(VXE;U:$'"G<(.UBD/IY$+E]^Y>;]Y C*SZ\A=,
M_-K9</S:7Y13$S51TW\KO1OL6G!H0IHXFQ^/K_MMH>)/':5Q%O+:ZWL7 K1L
M<M=@140"FQ8HOQFOPX8@"*M+S0* /=JSN]N."P ^A4D@" L[(XM+(V5 SU).
M/AT[7WN[@"N4 ;6!NH$9^T_5U[;>IPQXO#?G_/@"[,VFUW]EO*B)FOYMTZO[
MU]NO+EQ\LW1SI(]EYLN%RCO23.1)K^:>6*#\\1:CF=&MMOTU94"]*_<,0"AR
MD&+YMTVX6?O $D39!O7[T/XX'^-/&7!$9^X C=\=BH#U'', -XH\O%EO,0<P
MOTL)\/TH01V8H)?6L_;JHTCBQ>$UI@K+\!N+:LX\H B8GAYHJF_J??IU@5)J
MHJ9_21H_NS<IN'O!XN%]JW59$=J="Y5W;US&0!HX 3<IE]_?;# [LHR.4@;L
ML_LQ]&3R*)8_C!;] >!>3W&2/F[UYP&ZZ#>4 %OY_@00)BB43SK_/(+G^0L%
M0*O 3X 5)0L2S_\3H$]!$%\.^?SD0892L/:HS$]E#L!QAE(KWC:N=S>0YF&B
MH>617L@7>W2AJJ2X]$#]N85L$#51TS^:GIROV)3V;:'2]Z>W>FIP(A+U"Y3W
M9]O-CI[8#Q3+!TEO&,XD6XKK U_S3>;&A7H=)<!%GS]'EF@1)4".[)\ YJT4
MRI\%_!R\2!(%P$FY>8!P"H#U\\H17^Q:[>_*\P%VV)66JOGEB-$H!J#!/A^@
MB@ES2K*#ELP#+,&N*+\^G^7^$R+WD$(S_KA>D>AO8Z2IJJ)AL)*2'9QIR\3(
M8/^M._>?+E!.3?]YZ>W=LY1]>U)ZUKHKW%9=('J!XJ<'5VLSS6@]Y>7!P?2E
M/W26=R^E\M?;<']J-44:U68_QX43=F1-3X;-&SAZ%)AH5I\'D#Z%!:3,'YO<
MV%6.]]IDP[L$ Z@E*T>POI8E.6 CNOP1>3D2CP;L10$P5JP/!<!C>%"4)GM=
M(0@#:*O<Y*DG]"<@% . ]/5.0V%&6L+:F-BDS864 -3TGY>&SU2DAX51#MTA
MP-A--!8!?9+81_GA7+LYUSJ*8GG:GWXU8D%IHY5TX^:?H_LDMORR^3RMIZ-@
M@]:3C8N-F/)GNO/+*3@0%>1#SPL#0 W_E9]1Y2]0@U?G!0JP!P60&T8!VE$
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MTQM# _:(DZDD_T4T8#E*JRM1Y0VH<HR1VH<&Q*( Z-D?684"/$ #[%& KVC
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MD/Y6X2'\L[.%T,-B>CQ"D$P=T,-_&H_2N !4.6IU 4%T4$P<1 -X4-L+U]$
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M)]_82\3H-$)^QA)S>@%!$LA)8)0>L20'.&  HN2 G5@:Y)LDE[  \F9,B6
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M&Y1":6,!Y(.70B#53P8X@060.S&CF U.9 \Y$\X8 &HO&+O:@XI #F  SN2
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M/LUE%7R:RP&7G2L<9=<8[+%=]R&WT,[3-[0^62C;M/1P\-_(:HM*\CNJ7'#
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M(DRHPWY)-,C;HWU3HJF8T>'T*H]UV]<R'R88EE'^3-[ 5M"S>OP5JGO.=K@
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MI/PPOA7!P02M 6OSG70 %DT41^ JXQ'$A3-L*0#-+)F8IF2ASB[::K,N3L+
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M-.6K+?G>G84SL+Y74'A5\[]$SIG#VW8+G1VYVS$G%@6UOJQK836UYD&K$FV
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M9:3S-@5$/+W0/WT*Z?W^$F2+?0X;@^,UYK?:G'QZQC@I1-7K2'K^=V^;)XY
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M9!P+#KL@Z%V"W'6+O5@*FN;ZW,=9OX-B)]@21#+8RCP=)<GX423RSW63ZSW
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M]=Y+$Z-=N@4;J^<-+4YK:)I! B0I&YQD JSK)4FK=@H,*5E-BNDPA]\]E@Z
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M]3N1F-E$-JQ@I;4J7+BF\;N%ZO%'63[]@$AAHE8-RJB*A*Q^"BUF;RLOH_D
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M?[KF6('Q/_%2#O?=GT0U; _>>;*CND[J_(R<<R!Z1ZDH5+4C^__\I01RD!_
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MNK.FYT(Q]V_G.LCN)V<>(KERCHZZWD@#Q_"*'UF$61,_^D/A0PYO3!"+(2*
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M@+IG5^*:C@Q9=Q>K,3YV8C4TP\K=2^:<G*;9-WFS"N4H257A^V1TSC:/'2U
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MH,+:JK,*=HN\#&,QXJ;3Z&^IJPV(; -?.20T2)/@=P$!,X]/?;9%0[\W=/B
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M"M>CMPS6/V!ZI3G<T3^V\JK.JK= /,:H#NOG%(3M01$='?B(2E8(\+='EU=
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MJE?49S6[,<$1Q)7QM1J*MI@MN9A-S"J8%*ZT97$!4L65RIO4'9GFV[[A=O\
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MFZ O^Q<?F+%%E7B!U/%\6W^>L)S4XB*</PI?HS@4L)UFE&5<G)5,0+VW2K6
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M<D1CQ7"U7R>TEW\M+V!Y .8UC8Y&8H3Q(E?9+/Y$K)0JT0[9/(UWV:B%62<
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M9C6HK3:I9!I(^6D+E&9+(E.9!N8.#-T1)9%S0L6+(%R.MX^IBK!"(B#<?1&
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MVHDG76,S*.WM7JTZ$U'14AE-]=YRK3CN<DX]@H3$\,PA%(44W%MG7#A=-CZ
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MQ%5&C-NFL=7RB"&Z&&*)JC,#7F]D,ETA$1"+V4=%B^^(B(Y2LNB&&([+&8B
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M-H!6G_-WVL$H\6]_782DVK=<!*(2590KJJLM-C,B]H+,*K4B8P<I 4NE[O\
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M)8?Y_)2*TQ7NKJ9BF3<5-""56 LGCE74)N'7LJK.$5&I W"O5?I'[0O"W#?
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M/Y)=<#/P!JAO:J X&!L_K3M7? ,8+[X!+A0"W@ O;I=;#21/-&^ LS> \!L
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M__+U1MI9ZSYDDSJ)&6B3,/$4#PF")J,B".+ SO/N3IR.0YC2)_W #;51-\T
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MAP=AL\=!CE1<95*/+CJ?7*F\9N*&-"J".Y(B@9[KNN\@!E[^.*%%MCI)4P4
MVY$QF4W],.L@OIF 0UP1CU-?'5\#7A.^^ON\SYK>\!G*QUI2)L*0R)#F=VA
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MA H5?[@$]R_E<;DYUO'* XD)WSZ\"OH[Y9!(^LQJ(90$V4S15/KVU\">?U7
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MW!^CI^P?F:.5ER,C0]W.R.;/**Z*MEUF?3+^['^1>IQ\1R)_1\;R64WS%N-
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M<6LS!;GZ>ZORLKV0[ICE!<?:HCZ\,_9])=KVY"&=_!)$!Q9P81_WMGQ"U'P
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MSAO9G$;:EJ%6$6,\MG.\C>)LF4@Y1.(8/[!-,<B2O)032\TLN2LU'L?ZYDS
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MMT2!VTP TYCVBAAH@<XEUGKQ6!A_S8K<N?5E2E9B3EHZ!)PK7.#A=\N7V)/
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MPS^/\,^"!4$]A>OTTPO-!R?C"4(B#:DPQLT5BO;T8__CD$A8A07U8H]<M_*
M**!?]R\2'G+NS 74]N'A_%[QM1\JJ\Q-Y:;DN2"#5=0$U/M,6[]BD#DM6XY?
M5BY;.X8V!C"#VTWT65 Z; <5@PYWJ8*/H':%B9LMQ8+^4_&66LYX,0MIEIK0
M=_SAG\+$S!:=<A+1?EI)?!DWG*"%?_\0$F*ZAY+_:<N[,*KD5"RP7^#J\MX;
M^N5XR^(S']ZDHG)N^;E!K[I>\C0_C31G?%SDJ1H2D@12KP+]G.^B&BY3_GX2
MO/&G!;?\GK:;+:;_?K,\%7-]"3L56Y<S*)5H)<%:D>1C)KIT[C5G4CS04^.V
M^4@PH5K*)/N7;FEVM+S=Z5\B$/"/QX$OHD'B49-:XMXFEXG%&U]>$0,A"%?'
M$U0_-H(0H"\Y23<O8GW=#OA7B7/BE#LBW:_&S3#GPSKC/4,YNRY9!I%1:UK.
M<22'^FD-RT7C">LYUSEX)J^E:R%\N1'A0!HM*A[A?EDF9)4\>M8T1'2Q3)SL
MZOA0O>\S=8\KX!1%)&4'/#N7A@B1167U%=PVW)AA MPF\"E/?<Y%%++E?=J:
M4^]CVJ7/<R+9&P#+D&E_7_=H="T.1]@#S]6C5C> >\G4E5:1S=#M6_=IQ?Q0
MF[!F;ZR?9V]1DPX!^.X6H]N7A+8F9=M;FA27#6(G".>R!2?;"*+(_NJG6Z,I
MCRB(4I NQE2NGV)/9 !$8Q<)02!"CQG>:+3,7LC*BMPD1\ 1N++_=>B3%7VE
M%VRU%A_IM&6G9Z@KM"[00#I)>$J9\@8@V&EL(3'<X, 7RO*RF!U@]4?2D=]-
M+I+MDP,YS9>Z"?6]'I'&R9Z$_=F)#Z"S:6PLM;UE9(G)*4)'2&T+F/@L.-Q-
M8LL(GPN9K'P@Q%.%]H\LCOXY0R)YE\A^,0Q%;NLN<.K[V>RS=V!8>:$6Q[+Z
MLQ'KP9O2/7P-VRY+V@PV3)26=/%9(-3SX@:F7P[\N.CJ5$L;Z(M!Q5BR/V=E
MAM\3-[UP?C(M5 !:EU.@LXO$;QTK*K<---=[$D@?MQ!*4>4&JQBF:.(<%$CI
MJ-MX21F^,R\!X@&Q]M+IDP\_1&M^4BXFL?W56/,-XQ@G O>"*"?YMQ>I+)8N
M =Y^:BI=_FQVU!]V?R'7@^I]^V[<:!U\G=G6*^ D^V@"Q@V(VXW\Q_0HE<0V
MNV7.8@2\A)DZJF8P1XOORD^U"]O5*M-BWCU%%N%P'Y_YN"Z_)2U+54E>=#=%
M^0Z#"\2K5-3TZR*Y"EKWD,JZHOO1CC6''MZ!2$2@_%:C_1M@QW8LPH4E(;)4
M4G&IK"/Z=V44WB1E^83>+6^R"$A>,F6PX\]JN$![DH/#>O2/S2&QJPPF1#W#
M\0WRM4E\*1+V]^HN[B*/G>FDG:A"(U[$:G_<U+EPP:Y)>P1(Z#(S6=Q25;/H
M6O&>7Q8I\70#AK(&+/XR\KM2DZ<T5/MBM/WL_.RX%AA19FFMS6E&K4QOCFPJ
M6&*10<M(U]:W,'3_))"'3$[D-V7<F3 R!^G['3.L#Y*?!*YFF1'0%++]P07C
M =/.A5S\+VEHJ)T$L#=>.N%P%@JA!8^EL,FK)*/#R?;-_</#0QC(RSO)^.)J
MRV(R6.Q"] YV%@-M"\5QVA%Y [1#S^ VA._N%QZ\SF'S(NV/24.RA6)SY,%!
M5RV@OKE]Z"[YN>@E!0X=[(;J.;-_X*_8\[,_2G]?<?_*T.R+)Y6!C-WYNC!(
M+/_I872KSUU8)J,1<CR&BC*+<$*! R\*@84LWCWW6OR+:#ENN,3? ([GPLZ4
MO=[1]T"O+0OG@D88M  AR8P*-B;L(BZ"$]S?5RB^<OAR(UI^R",&ACESOOI#
M2F8SAR:U+/S<W%2ASGUR0%G1N!3;LX)B.])#AZ: -<ENG6@+FJ.J&$YP_!?2
M(LM%YAAE\^B_=/5F PH&/L446+J?4#FOX**S9CG(D<AC@,.G7 0$7.L6/N=D
M]^6G.-8C*I8]2N:E45H^/$@+(*]&#E(QFI%062Y+1I%!(!(>5\?4\&UV@D$]
MPA-EY'2;2,8M1)3+U"?2)\\VKK-29KY.W5XQ,%&+S2,SJ#M"0Z*JIBHD!ALM
M++;"Y8-Z)%=7WX)ZR<$1NF8KYDZ:.JLNNV79_N8!D);6ID7ZR;D%Z L$^KP!
MUI1/)S>0\D!0K[J/ EWK/]IJ^":17",'"0&Y\1/PJ-'?S'U-H\M!!];^_/5Y
MQ]>W_]--XZ_^.*VB::0N$^R#CU[O5JW5'R@GN*=I2V$0WE0@-R<#$ _L-#W(
M(JJ(Y](E(4.O&9)S3)"8KHQ\?]B2RX<W+(*+UK 7[HS;0KC,KBLF3$[^4:((
MFR\[(9:1+SN))3]8*MB"0HR)[B3N-J<Q>62W?K5T\(\5TV:I_D(5Q5_(N[Q\
M[5Y%H<.9TKR4:*8\0/L&K44W^[[YGI9'?$ JRB2WIII?''_"1M6<*0&AND<.
M*\7I$@+A".$2/"EB&;8@W.Z)ZSEJUAW\*T'BCE%1X'SBPKJYOTK:\/'#DFA<
MAC^A-[A@!.]BW?\UY^EQM*#ZYV/9:_OX#572K,*27] WIL*CQQX84XU$@;.,
MC&JH7^=IB?<!M)\]GGCSP;+(TK3M,B4ZF_)VB]9:I%SN]%]<!WKP/IV>;.?_
M ,GT@3ES[ 8+_.QN2TC<Y,<V:%=;W\HO<JC)D?'HETR[) =_(9SDV$\^O%Q
MH/X6R:\B!Y2DG$ 63HLAQ/1FP8U.94X24XN)8;DDS=JR"&1J<5<QVY#Q/:6
M"*.>[W>JF"5Q%\SU'',:\5G&;/2XA$L? = 3*6IR4,O@:50)JBJCLP&*- #&
MCVZT $J(6H_T' \>O2H=-3[+JK08O0;7?Z/3O!(? VSF:>5M?M&13\T.TM):
M6_L#I:_J&U!) 2.X7(H AH^H_Y8;/#SE5T3AD"@S+,7AX2E%$->Z><!.$$&)
MHJ(S08^*3]9EUOWQ+QT0]KXTT&UC%D^.=]E6*Y4G#:RIJ)FA!OA8!4SC4M1<
MY )$X6>AT]*(T/400GSP0U@2_S+1H<!K4$G1?53E:1F;4H8J/ZK811?,J]%S
MB99$,F7(TRW3="M"; NV_%;_-R);?^Q^$1+&[W*TJ2S20>=!FB<!.KFCH79"
M0WMVBMS3AEG+:'!'F?_EA_!D,C[_:## :U#^DBW.02S_61+X.V;=6A@"8FKG
M?.DLLOPG*00N)+J+T.SH_)XRBV"!1:*N0^6L4V>WI*Q.E^EC$82L31Z?)2OR
M+ONC/N'&FLU)&]2LV&_;2+)2:GIT8& :B_(7PA$X;'X\, J.33QJR!!6&@U7
M-CX^V0?P>^8L\/NLF/]6=%;^S76218Q2H</6Q/&J.LSH=5Z \L.7# Z%E"VF
MD7#-)0I<+D=X&O,I2T5K8)&Y-2_RO:6\W+2C@M-\*OZ'TI+\I;*9L\]*T*CS
MO+Q,!R$IX2BG1:W! U9+6BON*M*!SX0A-.HA*'0ANA"72*P$L]8HHR9',W"V
M2EPC.3AMG/ 4[Y]T;:-7?HH[D'DR!_U\7:B<J]9/!UI=[.2TXE8MS?.$#%/$
M)H<BL5N.Q9HBT\J6]!S8Z/0;#YGD_T]C.O__;6D*>P>\TE6XB-_CW5U1&\/#
MG5\-/ 7!A+*@*\>']X$O-S&!,-';RW]!,M<1=+9G=+TB=,,'[Q3:X.]"/0LK
M0'B\6^B'W-PDU<'*&O.+^*&S05>4=_FOOZ&@IT#H:*+ +\%? /_7OD$*5]CI
M%126(%T0](7\%.K,# N\@[5#%OI]8!+1J*]A[V\/0UZ&!0[!Y[-'HX4F)@9V
M>%S48F\ :A.3^ <94*]W809*P694>__Q+!PT<7- 8/?FE^#BZ?X1=-GB&N;<
M[PR1S4IX@@1_$%RW\#V'^D*#1<LG^[;T(7"S3@*__*-1_=T?O7%Q"F^/CA\?
M?0.W3"+? !^,E*_:%@[_Z:/H77[;>=\% 6Q7/++7?0S'; \HN%NP#5M%@3;8
MW;\$@@XKH':)%RW TQZ(W6G?4\!A3X!(]^_=I%#<VU?C[1.Q0=&'-P#G8P)0
M^;61 -I_M&4S8RX,ZJ][^GV&C.-Z>[_G\W .$=L1GTST/4Q0>?1[MNA?*4_[
MXZ^HDN;[W%ZH8M33)]8]!6I[1$C\1[GA"M)^_.3ZY(\B+I3 %-@>#>M1=#X\
M:GL#4+Z^ 8QZ><.]J9U\#\\05GUQJ43O ;OMXBZ4*L[UW>W!AW>V8L;^0-#5
MU19_=,%%?\%5>V'&NL _@84DB3Y=T@UX+QRW^,G4>/UWHUB7>WJXS]5QOK_.
M?TX^"YGLGYS@5?>>ACQ^W/N(\]JHA+,13*$-27[8"^S[LML^VWP;_ ;PN^A_
M)NG_ &=S2)7?!MNOCPJ:@[X!?@?'>B=>GB!"1L4?9>+61=H27PZOL@J>Y,7P
M]6:I08>6@CITEONU6*S13EJV.MA_/,B7I8/6KD_I2$9',;)$ HV:E6FFO8^_
MK<DQ%$_\:*HNTN%4NT);6K@M^E' ,C 7+=B87FM K6CFF)[?;C"&G[8R<,WF
M:<G@((R<GFN)S\!A"N=SOL8I*)I[8=2<C*BZ$W?'#B:5Q/(T<\$=0IJZH7P_
M.Z4@RY7<R"=["4?H?:0W*CM0:2&D;D&5)G>@&.9R636%P?V)I$PVF:7YTWJ*
MF"R: GXN@EP^! O]IQ$JO3A/U_[NDMVM@I4&"M<!F$T8GJ;T:T<M%A-08BJ^
M[-TLY5 .(Y-)Y3$0FH;>]JZ9->+F@ VH8&DJ5&JN@QI]D.CK44>RI4>')\SO
MFB%;88T9K#Y^C4:"?]T]12>,92^WH=A#4 Y6&6-R;(ZV.^!J5HM#!83%E^RN
M]4C\HC="G($W,FS66Z*0]1EHD++YR(A)I5U#T1FN1TJ(OXJT6@ZZS2]CI&7*
MTC-CQ#2H@G9*#^8T:Q X192KMZ4BX#'3KWW1XFEGD75'3)9-^Z/:5,O$T-<W
MJFDR)AP<?^;TFX0O1>L)*="V^HO ZEH$&:W<_1BLBD>;TYCW2C"ZT C[I;EE
MR?K![0951_.F<JFO([O6#12+6B0Q5K$1B$%K)T#"JF/?_/E]-9JI1&? D?FJ
M7J^-WNN[(=JU6NU?I^<<Z74QZ=XLQ5TY#*SV,\26<FXY41*"U@@9V>H9=TQ3
M9HLF<L1O "3UN)Z^>%>CAI9$47-SJ3T%%M0GNHH6![?1QW 4)2/NN ROA["8
MS!4^)RUU@@GOANI$3<6ZA!*-9@;\3I1523W9D$*63UBT4LN:9-^*)!*QZ3VQ
MX8'JC-)#R>2EFI&FPZ^SK-\=,</D\4>4UDOG/<*QG)#9Y?S39',<*#]_[(X9
M;J.8-A_X>$MR[@;2YM#3ZYC7.@6&VDM/?]OJ2Y _*6%A<6;GJF&_Z7RG/\ER
M1XS:<73O?;YKT *V;VI4+'KQSW!0$;(5P+_\L"DGI]<I4VU(/N9UC'02^ >[
M5=-(C[]*MVPY(H)LV^:YF)7E@M9;)ENDD9TT6VU5_X3L8;!Z4\_&OHL])=^\
M8OIK:#EL<;/R_YAIWA%J@F>(PR@T9=73KV\P[S1BZW7[ZV";OI;]'.TF/HPK
M'/<31=J>^TH#VP.W$R8G;89]19WT9$R$=@5I(?-M>'KS%^$?OR6T:-H]0IO-
MB]A)APTAD4<6$@D,S1A;AO'G\ 9G7%Q/"[?ROQSYB?S97XJX?87?#:\-N*S#
M@%QZ)W6TS<H^WG&.H.3JI):OECJS6J[H'=BH>KPN(HF6^*_H/9*_3B;[Q8>Z
MK38T Z-8#SL=M(2,HUKBHPC>@>+#AXFD<0ZA6R>?)D;YDN66_A OVB950P6:
M%<80\\RYE0[';F#SQ[VA _=='MI_IK^_<O;S6N$9I;-!=RC2ISY&B@U@Y!R-
M"(5I)%6K3Z]/X%9I#K*1I=^[K<^_,E8=8TE69FV1C_3]^+A>9A1W%TZOU&K\
M;BR]:MJ?_T-C=9V=G*RNQ7)INE-"[WF;VXCNC.U.7BR$CP'/;Y3P\-( E ^\
MZXC*F. M2]"9=+)DOK:PL%^,9UV@;S"&2:W05%V"DU:YP(&,85+9,/GN:NNC
M<:2@ K, L41Z]9H!"S_21)Y9U>D]#9=U!K[*OW''^PW5'HQ;=C7R#KO O U/
M9W'7<O/\S.M3S)WC"X2/)<,(W+QU5O<VF!M:XLBI]J!PGZ*(FJ#/Z@=S)0FU
MZWU5\=+ -())X:.Q6X%V\E#H7M%55K\7X<.4W#OM0=\J5_L)M=,F3?7+Q#.Y
M;69]+N9+W(D5](--.# G*.?%[$IP$H->1RK%<&ED309YO[).;UBA='1+N+:5
M]0@SJNEY68PK<V9Q@??'188,M7[5,_-B5XE65Z9QO&=<;"<XAN&PHM]L)/>>
M8T+)-+=.<,1?=KNG-R]!L,9;J":1M#C%'8^17_TG2+*J;(](-:MM:FU',I/O
MQ;;<9HK26EELX\_%.W8(-:B9=<_@"XONQ*GKC065DC9[AULLY._B=(R!;.,D
MH8<ST>K>KVT]JMN:KV'<G.?ZG]GI\#XJN^,3-;%Q@E<P,JI<B3F*[CJV=1K:
M&P4J/4=6O,2I](396"!#RL4LN@UGKD%^O7:&]-$5CLMH\A<K%R+RD7S9:)04
M.2=&M6%U-UB3YQ4UM1D&-;&[.)6/)$7,U36!JH*JX'B7VL^8?3G:'">*U4BO
MR:MAJ?<QUM,F#3YKJOAU(T^:%+25F"F_DP?,HU1X$76X\Y&_IK(;IHG2MT>>
M6* IZ0%3LO&F&"CW;";\G>NT"5Q&=B*J3.6/-)!+!X8;Y.1TN:Q1X >RWK\O
MF!._P;&+63FLQEV[LXCC)R'P+:QR$IJV2]>;$9W02!$6'K^<LCG&\99*,6J+
MEGY"2AJDU)6OQ3<66C)IYL[TQ9]GN,3[+4HOSV"?R08 Q2YI3ART[KL8S]JP
M8B:77<Y:B!98IV;TG1/;ZIJ49[/S(0^!9)&!$E0'S46'U9B#M8PC3]5H[JZ=
MV (4BBS%'D3AG1!2!=*)UA^4VJM:,Y3**FQ&&'^X<]N+6I$R.+N9'HE-8'P:
ML[K0"T/&8$A'&(;+OFI4%O1Y6&0X'UD_T]G^J[34=8OL;VU7O QMV]&.W!A/
M<9.$S_*L((>:S,HDO_1XPH^S1#9TXQS!.!?R-=^BP88U/D[X8V9&IOFH0FO$
M"%?R#$V]E/6[L-C/[Y@P.YVCA6*:DZ7%LXYU9K:E^-@@Q@',ACOL04KI- RE
MWA1'\41?P9-4A)R!WVW9E!0<RI>F(7I-GL)HEN1\E/4=+9:Z/A[Y$E^XXS_M
MI0P_QM$?4 [K3'@D6.3$A8NDY?%Z5)79'4F#:.5=>!J61,(-OY6S,7&P3YI5
M[SDN5WG7S _K36A*Z]_X*2!3EFM N*=#5#D@3YT?ZRT'V=HN90HXW&(-3+G6
MI']*127H+U]60O2=&--S@?9DK75[8;4&Q'+5A QE\^:_+"'IG29N3P?5'9!I
MUQ)&]S&U&9;E=AT'__PLF,,X<_>Z-3#YNZST'&&1[!J9@46=:MH]N2-[2SR&
M.0/?VB)(Z=DC+D96) \:<C+@ 7A/FI: KZ84T2_ $]W!H).<Y&@TY0UE]EAK
M>"+BEB=S)$NT(FUM)B<LZ!J]X\]K8G-D^",4L#HTM31B4.Y91C#NEU*K+-U-
MF./I9+$X.=EMRK)>,YG:$  I:)IFO57ZL>+L<ELU'=F2II@.0S%L\#TH*J_P
M[,S6+*:M555-.%"MVR1JU5%\I:>(,8!P:5T,&_.Z'/>[?AIL]5JTI)C>.)5V
M_R0W)24RW3@,_>1?EM4;;LT]G*FHJ8T^(9-^<\H@0L;1HUU;]6N6?GEXH^YS
MF'[XR!QJIS:YR""H-KG>B;18L"F]$?$G85]E4X=S:=D1U]9N];M"NZPM^27P
M_M]/,^)QR!U3&57I\V.SM$N'%G9Z\B<A+:\4VN, /A;F8\7%&@.^F>AN4HB]
M>  [Y4/5:;_:LVI.-#&VA(_.>U2OW[6FKH3WRVW:Z[5.Z.RM:F.F.OKQV?H3
MF*5L"M6:KDMGG1Y; L0;_O-5,@55SC4$]M/:5ACPZW"$-+)KR@NNRV'[/TB5
M10-FW#5'&<EJP]V-S^J$:38C#CV)4&,+9*HLIKZ]=@(>0P/"E<!TC3Q'_'^O
MU#J9\'>9A;\:>E:B,<:7V$]SI@OZO'=:,@#%_VH)GZ20XSUVR8>FZ_-1DFY<
M22888G95L:5R37=+3[%.<#2@CNZP[S;^$<NZ_H-\!G<C-E;%PW$:OG9+38M3
MJWQ.[H+$IJ8^Y-#YH7^XHCJ%PDD^I@%.046B4K<RO=>M.WI#>Y2QY>BJQ6AQ
MT;Y;?.WD0$=9+SU.6%[HF^:Z18"D4^Y7;S=/JS;*-'MPUF I!Y:2K4]%5 K;
MF"(3!F:N[8,<"?98KDUL^< O<J5)T[]V>ZC=#I1>U[')O'8)?EYZQ.\X0HU8
M_WZGH<,W5;QREYCE>WR4.14?NO$Q@(JW"K5@7UU0"*>,?"$/>JGITRCW)X]2
M9TAH@;Y3#.UZ&5Y0 XH\+K-JQAS: \Z1>::NX]M:CWH%VL[Y*0SVF)=3UBY.
MSY+V5G?FI;P3BK#<ZP8RQL:B.R2!96S%++A[<8P<,%:4#V(E-@7I#A=(VZ>U
MM4#<Y-5DN9392M4B#OK.@:]PXPB6\6-H,H$!G(/DZE.+/I?=W_6G9)-SE/B&
M*B(YQ^1T+'&'KR0^E;KCLX<P9R75,4ZE86["?;"$N*F[<27S37)0F3(Z\-FG
MQ0<6%3.VB#Q;9/E;*K(W65N^(.'3@:V.*,M_;N><D5?DE$U)*]=B?*?5:O(
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M00IS+ ]9BXKMY'LGXVX?]H_!_$UO"X,^&$,;D, -5:*1@RXZCCF,N-BI-4!
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M2.9ZH"XMUB&.MZBQ84Y=O:3$F\09S(TZ\)6*J&(R1UFT\8+Q9SNFHY=ITR2
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M]IW]*D[YO^]BR&!>_P#>J=\ASR%XKG ^P=OGY#M[AKV7L_\ ^]>-_P#@O?\
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M>0FMAEXE]ADV)M_9OAG@%MC0ZE.S:-=7B#-F$JFO5X=LU\.R(22IL< XS--
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MPO\ #6 9.WOPIX%.PM'FV-68C7:T9Y;8VE5R/:9<NG-/Q0#O,ETU%:J04%$
M1$,#S$LX!=-3ZD<BZ9JM7#)NERNG*9H2,,1RY(!@(X7(+42K+E Y@*LH!E"@
M8P 8.1YC:-A':.4)*0';L$G$0<C'D,G$1!3&TE$1$[Q&L/69]9@1F?61">8!
MF?6!F(D8GL,QO&TZ6T&C5JV29-6S=LS12!!%H@BFBV20*7I*BD@F4J2:12_E
M!,I (!>P!QVU)_O.;J>_SQ,'S^]S1,;3!<V_-$QVF)WWCM.@^[,2/NS$[Q(]
MIB=]]XV\IW[[^>_?20A5*LU%H9M6H!N+!159B*$-'(BS67X\Y5H*;8HMU%N
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M1Q5ZZNHY6!PX.M"1BIUW!3BH5=8QVIC*K%4,8X*G$QP.(F W4(CK$8@(& B
M@"Y@@?=@"[^\.VW*7>>\;3WGXSK*9F9F9F9F1Y9F9WF1]WW9F?,?<#M/;W![
M>[&WM>J5=ST>IK< X\MRH\)Y\/'*]#Q4"E5=$\QL;I<J%*4%%PX5.!2@8X@
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MJZLQ;X^C*PCDQI+F81,6IEIS(HOH>8MA81BA*8\+%UY:,(X1>N'G@K"9<.;
M>F"LMD[V4% K'I(8V_@GE4'KQ;**'$-;#S/%U-GB*V3R,U[T((ANC>_1BU M
MF*,5A_PRG1I\Y&TFV(0/$RUM,U%7(#X>#-UHX3-1!:QTCD(9;(&8L<5]\;>$
MG=:<U>M'N0Z*1<,(7K'<%.MHI5[-0-NM=Y2M[64BD8>KT* A:<S;&F(%&NP$
M-%.(:)M-C8P+QHB^.)]ED(95N)6M12YW"#03:ZEA-JOPWDLA=O8O*FTV-MT<
MQ3N(P[X@1&<5C<?CVUVTJRZ\2"YGH UKH$+'$3>HAG1*DW,\.XS"5<GBDKA:
MJN6H6J3<S%@R8UN6:>2.R5ZQ8=+YE_#3MCN65<P%>VV4RLO,6$J;C'M=9WDU
M-9W5E>'M\AYQA#SD?-0RM2C)IT#AA1G\(O7(Q4@?38MN5-("8N49)L*2]W5\
M7B+6-M6F'9L8XJ5++4+!RQA2ZVY5?*G&,>;U6:71K15L4RIT3K;DR/0KKL5T
M$46,D=X$0:$9"O<C#!X<EK((KJM!AP'+UU"57)A8MKO)MA>OQ:D?;3X?N0<)
M;KI_<A<,Q%O8S]'"KFBXUJVK#-GZB"J<:XABP2%;<O']5BI&LFDJ@PDKRY9U
M,)%\A"PK/U\@=UU*UE59/$=<%F0YG*V<@#7'#7%#,O;R5=MLA%,%?K(NMQ_B
MRBTYM2 0384M(JJ6D%8_PW(2*1PE&O3)0]X@$8UU$UH:0R4U[;"K7+:5+HK?
M<J(MM!C5C&H8SOX8.5\OY<RID?\ $VW@\7D:PT-^K6'^-EH5D]CL>9+A;Q#O
M+4>M1:,A9;?(0C:<I<S8YV6F5U8B3\I@#!@L^C7'!Q=,J*4J?TK CF:6:-$#
M(5$6*^,XTQ5L:%48&O67D4\18IMO]R=BP_'6?%V[2BI+JWL@<W+!N6QBH_PU
MQ%PZJ9GG?$9W_"SD77/(B8UV'N8"Q8QPP2TIFTB4*KO4]]CZXX\-#.-.NV%+
M=/7K!MJ6Q1*8Z5C73^MW-:=I-:H4I;5'5+Q;)KN3$@*Y:X^QLWDVR4;HD5FH
MAL5<'C!O&%C.Q5?*LK]HNDS)C;3KED"_S]X+O!-+A6<?;<4[V,?C;]2QG,8I
MID(6LMDC)867NLV*N65X\;@U0530UB3I8L1G[,Q[$\3VN(3NUDA ]*]<K6EX
M2VQ8!SX_%8H8*04:=62W4;-,BY[S]C/+,'-8::5S'4(Y8#"VO'[9Y:[']68V
M2,L-;L%S1BG\V^H$RREXX3U5J_C(WU+-ZK)LIHKQ)-KP2QS&%Q-SL6(YW 7L
M$N%!*X +F/8A=NX(<LW+6/NR%J@QQL"N$F*%(?$6"Z1V!).# )<IF*SM?,L<
M)R3!*K;H-5&/*2B*;30FXJP8!!O,ZDFR%H("YZ1?@?V"(QK&5*"M&!Z/8$J)
MANK6F4H&,8N)0O[G%CFS)2Z-K^NU.RL)6(R"SFXV9L*<_7+&(VBOQCQ9F^,T
M9.VG8R<A??8, )=2Q="WX(6RA:.IPY]C-FJQ0259]*Y!Y+%6JL5[59UNVU-B
MM;(;$HLAUVV84"K!3Q%TK #).KKS/%./XDKH7,&J90FO4=P^]!'X=V);"&(=
M5)U%G2C9;LQD-K[[)<G/+TJQ3%K1I\?7;,S)*2=R0B*U2H.L/&MJLTK'QRLL
M[EG\*E)OW[%FQ-)'!%5^@=PB0Q<WMEM/)J& "SDLUFLJV5*%%;DR3!:A/3"3
M.(58FU<8$%T/&7[KU+$[#"/B(HBF\FQ,P:$8VG24!0'4KL2Q\V/#B"U(6@JY
M5*B(%8L"G0I53(E5E0/.6X^#CFVW&FVJ.7,54R$L-N&YV^.I,---%,FR*-TR
MI/L$;Z%EK]K@'ZD=&90*6.E7E:G7T3,TNLOHDK)9NU=QE*@GPE7#H;$,C%(I
MK4E9<B$VQP2L5<RU(B W5,E+JR6U[-4JUF4V+@LM PA.>_<NQ8L95RUP+,DW
M(<UEO,RQ%&QD>&;]7&-@6+%])0\/VZC:[B96*OG\FHJ[JS'5;<BJ>$KD"8M$
MM/6^WX-LK!ZYQ&L,+)8X;+-YX^&\@QUIKLQ>7*%?8.[C=)&N&FZO/7&Q+2\D
M[*=DJQ3BV#B0C#7:#!J9 <@X%M+_ !%BN(10I4(JTK:*?&&.RY8JJ)$C'_:2
M,]BK<RH)LLO8YTWKMM/V>%+B/K2ZOX;JGTXX4XFX8B6\K6L7G!X4?2;9;R@5
M@<3<X=L!55LNNBE> *E:LY=@[;5\783M=T_AMH(\-TRY&62%!J(I( 1/(N'R
M%233)TE!(A>2)DZ0 I/R@ !VU\3]IYE/$O \\QSS9$YF9*9(IF_C)F2G?N4^
M<S/G.^OZ6?L2*7_Z&OVGXE2OW?":!&( >4('A7C6(%<3'NC&T0,1$;1$=HU=
M*9\63:A%W/,='8.+Q;)7 LZ>%R@K3HNK6!.KMF%C_"=DL<K&-KD6RQ%;J4]_
M=9Y].P,4X,T*>9A64Q")*R1/K5:\FWBT9A M90LF*Z[Q"#%IV5W"Q0"8$2X=
MFG4CI8RL9C:.]8HU;::C+M:&?SHL5&5;XXUQ*7=*I-R$L8*BZ04ZN1?$=;I\
M\5<=<3=LN7SU5IAX>(*Q5LI2W[-XM^T>AVAW5K3$Y!KF2$\2O\PR]$>PM!0R
M&UK$74I&^#'OJZGD TNYF5J5$2%A:D:)O80K=N$:XFFTZLWB5;K/W3<P@?WT
MX2[2IY.:O[]:;5N[A<=8@Y5S3$XVQGJ W28(2U?B6XS[176:0U:/-DIP,518
M9<1M!&'A@$KKQ9&\6-.3; @I65;0.O3DBB0M6*:KXTIL#,2G9/$#H+"'M3QI
MB[<,DWJ],D+18;,TQ9'3D'2EDJ\>U1\7:CHW)NA&3,E6O*GHUI)NH^+=)N&D
M*XFF5D>MH935?**BLE++"JT8ZT-%EHQEU>;:\MC,-?2DAD0>W%6LH@[M>& ]
ME5-ZUCEWE4;,KQIM7=C&E4@KDY-2K"$(G9X5K6*NY6C8L 41**]\*+*M9I1(
M1<;578FNJTEY-O(_BC;:<+UVRS>3W-S@&=06I\6M*3493ZJA;)2W,UW$>>N-
MK+>HLS9HN5A**D>3ZD-$NQCW*$%)S1Q:"[RN6$5K$*..D3<YD,*M$,"PQ+<<
MJ[:M,:2IF>FFI18Z$2(Y1X,K]+&DUX*U-)3[-.G8']^NQ@:&<\2 B"R3?/%(
M0!KAC)KN99R]-3B,IH46&X+E]/AG$%],?7NMY0HU2R+3GOU*JW:OQ=FK[_I*
M4743,-$GK)8Q2G4*4QD52]92J'*4W( <P !AN7*CJ%I].P/*ZNR5LB-]N:-I
MWCF@2B)B8F((1*-]B$9WB*U*XC(547*Q<R+ <ZYW&>V\Q,3($83M,3&X$03M
MN)$,Q,U'SUX@>&=N>0)W&]_KF1G5@A:*ID1$M694><-.UMHYCVLJXAX8M];6
MPIH@\D@9XK,UV(8.>A9&)?23HI&ZG.JV5VW6T*@^M3R>%Q;ES$%(MX@OT\7B
MG3*B8"TV<A?K5A%Q*M3)$X:Q5@)\6[L> KHM/_Y%BCEKXL'<1!>%I7LC>6<M
MA<=0*./LV!)<L1L(K-P.F5Q"&:_$;CD:?7/X+5Z\,\B&RM1JO=J_<,?L)$E"
MKSO-M6Q1:4KZ5I=FB=?7E3SKDE6E(9U9Q]6BBN[C2M?/%.SC('(YC!5EM \?
M=LRJ^\=X 6&C/IC&B^.:59)&0P5X&QT6U#BB\ M3UJQMR$D34S\D1S:Q^(SE
MNF"QDVD[&\-(XFKWBJSR,;BVU;F.!Y$2'I&_SRJ#JV%KZ3Y N33'E*L]X?QD
MG,LJM#O)IW&0ZT&WDWC9BF*RR3->RS5=@$5?+*8WFRTY%L2%*8RSQ(H<ZIW;
MBJ%<K3X+I :080DH>F+G+3+2)S%!"U=3J-V*6=,"Z0-9RK+95KG:>NNLA$V<
MT!)0PHDH B@(%2VLDCD>0($)W,AB9$=RCF+4O$FA;;?).0C4[&]PGD"BXG>X
MQMS.@Q3U+&UUR%:,@4)%ME"6C;^^;2\/+V^KQ4?#.JPW?M".GW0N_&,6)*IY
M/&VJIEJ_,J,D%R[.%MRIL4;=8."<;QC4I&HX!PWRK-OR!NZ"'0@4D:;!UU6-
M?.N+M>#2SP]6H;,U5!JF7:Y5,]8QF0N"2B8@:=2N*6O$#<]<"]PK9"7@EQ;?
M/$SQ#;K9A';ODVUL#[ELE5=M*/V$$TAH>!+)/1GW$4@G!O[4YM:(3,7 .7B+
MB,B9V!CU3(,).>9OWK%JXZ*H1D;N0K8T63]FT:=BS#)ZD=<L'BLU?2LU#)!X
M6OE$-AEM=5+QEB:;;5BK:6J@RP=.I5M7M@"_??7JR,<NZ3SE_"43F62 O)UN
MBVN:ZA6+")"+-JO6J-4X[$;N]V==VH1..9JWTBR6NJ7>XN:Y992"1B'+>H0+
M"N3%BE9Z29R4K'*ODT&D2<$V3(CIPXY.5)%1;RD5>9-M,9*MC7 <1:I7[*6P
M,'!VJLUE4Z(!OS2^];MH0J9B $B@C,!B9B\P6+J^*5*R,;]"GTB9TCY+A-AE
MB&%$*%=5:3<V6,7'3$IB=XVF-;EN"HF=]G6\)6F5FX4.2I&$LLQ5CIEYKS&K
MV.'5F\.2MH@)$6<3)S$6O&3\#*,I6,?L)-R!B**MG16LBT>,T*O$X3/"V>>+
MEM@,=Q'C7@!E+:.2QE5JKV.M 0CT[-;JUW1TY8AU:U6M5G.0];"^A^Q1RC]M
M/LH1 S,'[0?9QD4LD8Z-W'9#BFB%2\B=^8DN94M(D7@JPMM9JW)#8>:CF)MJ
M=MW9^'1L6A8-WC91G0']_N4U%91C)J9AY\)6'S'CR/:%0B@4$IV#FYA-^:Y3
M5 %(INFB4IU/-3\EP)5<[A7&N%@KFQPCQ#A*]@>>+="[E,I1M5<M5.)CDLXU
M^(4ZL8D#5O(7I8IR5''U7]K5J%_M">U&L2SD/\8<(WV+&1A+J>,Q6*L7:30[
M0874,)$K*"0P2-=@#29@2Y'>%EG-I=+!D*7S50KQ9I["+3%9F-^K2-NI(&"J
MURKR49/5FPU"5E;I4%C5\+!#1=DMCB*KUB>N)1K5EUU7PR'O+R1MGQ/(Q !Q
M'Q O+.@X!A!69G<=F7BL)7%=66H!6M4L)EVHN/I)?R+%"V,"/R]4!M9/#@"8
MK9P_C_"))'4")96PN9Q-2>?J=?P%H\A4M9?&5FT47FU%-<;WU:K LGLFV RN
MUC(R^0+%*XUN$LYP73\/A8(JIECK@P&G7:]6!%1C+^@:II0<O!VN'B)&*9HQ
MS=(]1ADFS3Z>V9MV7179@*^83$$!Y3)XK),8LBW>5/AW&X6R%TC(F6)\5C/M
M&LPS84.R-\F;,+G9G:&;%C'L$%*KT2SO1J"(0FL.3R WJW@EK6I5>4 ZY59
M+")2:X"9YW<W3[536S7.C?\ ;);7O&2Q$2NY.=4EIC>S/YR4@14:MF5@]8U2
M1923:1=U>X?1;)7'"0/H";8PJ<LP<'4/'2T6L87 Z:*O"\2X_.,F6IIH6KH1
M,@Q+59*ED(L(,8%G[\*A4;J L5@NT;#Z=HVU'.KLSLD-G#W<7(Q$7".&S/-*
M[5=M.U3;3LP+ CI;6?$*9(.)%E2GI!;UK<OGWF'PW\JT)&U6>IXEPCFM>_YK
MQ?:&5.AJ.@X<T!O#YFC+1//&CNW34$UBJ+.4E&1'*$17C^OM%CD9-PQC31TB
M,8A7QE<JK.'L8Q5::P6;:[5HU;4*V/O<.\68]N*NC'5M6<#0R6<HLP%'I6?L
MY*K/.!K762&F[#&+S-]+6K?- 8&NEDSD+]E-OA=TY"LXNDD>(+XX:T60L&55
M5D0QX"Y5D;-NQ-U2\+"^UFVT&</ENL.6=8F:U8&CQI%V2-M.+8Z!F[%+RF'L
M(RR$@8*WAVYL)PE0L4,[ JIJXU()6KATC&A'7*X]%PDPSN0G&6L>ZY8,_M'B
M55C@NUPHNIQ.[G.+-*C=>GB2D(DYB\G0J',E8@[TQ<B;2XZ*J].2NU[2ZBE[
MX_$M1Q-3SY93$5_<%.8LUZC<799(+0VM?MJ8+*)G0:SKGX3&0Y1*,=TVQX K
M#]G"7RIFC5J+**M"5^<O>)LC5%TYL,8QBYFPV*M6+'$J8DO.M%7R(7&2?HO5
MY,'3F0QJ]>L^LPI2]:K'!]XT]&*ZHL<)Y7B)D(361M436RF!XA9AKQ(0B&)I
MH3->:K#2-O(F-]>53!M0%RSF&UC7 "T0SN"5C;K;)CRR=A5^NJ_7B",8&>C+
M!Z2BC[R/A)7J9C\'.7&1Z15IK'&2<DW:YQ6/6"T)!VS\8W:,M=5EF$M8*E;)
M>(M./&+!S6Z\_C&<0]9PTM*LH><A6D@_;N]N+%>+R6$MA)N3B^'\-BB@X &A
M>Q1@%C((E<0QD9FBBE2RB3LIBQ5QN/IOFS3J(2J@U1,QG$5+90NS&;LY-+^6
M2B*5E&4D,58 ^90HHY+,6\G2Y4/4N_)9&*X9*PRV/=%NF9%N@B<YE#)(I)F4
M.83F.8A"E,<QQ HG,80$PF$I1,(B(@'/&I,H(S*(B((B*(B-HB)F9B(C>=HC
MRB-YV^,ZVJ&06L"*2(  9*9WDI$8B2F=HWF9C>9VC?X1IBY8I<ADC%^1,?1-
MIEZ/*7>DV>J1]R@%#)3=5>V"&>1;:P1*I3I'3D(E9T1\T.15(Y5D""15,X <
MO*S%%F2QENBIHJ.PL1B60PDL@& PJ]D5&II5+0A-:V"FK:=9S16P#D2CIXFZ
MO&Y/'Y!M==M=*Y7LG6; R#Q2T62LH,3">:!VCG PWVYP,=QGE+AGPPK)0,WX
M@RC97V$'=3H,C89"5Q=5ZG/,:@SD'M7K$3&6"FQ<B99HTFG=GK#6]3Q)),[(
MUG.G,,RFF6I)17T-*V-2SDK @03<IY)5*%E$3AROY>ID$XW'E,#"L1C*R;=2
M@M8I- Y&V"5(0TU'P9IE./31)G6--S#-?==!':RZ<;A<WB+]G*F1&;LCG1S"
MV91O4.+88VHJXRV,S*^S!^H2& G3UB4W3U<]/5P/3U<=^GGCGCOQSQWUSS@I
M X';FD2@>;?EYIB=N;;OMOMOMWV\M7XVWC??;>-]O/;UVW[;[>6^N -K\(_.
M5J;9*CD<J8CIK#)#I61M*E0A9X'E^<-LQRV2XB/O[:T0MEK<S'MH6:>U?S).
MO3XM4@3,V9&;@5!/EX_%^$HXRFZPUR<:OAKITUR*JDV\/@^+,+D,BN2%AUKV
M0GB6A?&R@ LJM\+85@V <E5BKE:8QN1;?0TEFUO%DRXQF;"ZW$>0X4R=>J,J
M8F&IQ[.%VTX4TY0VIQ%FI-4RYBK+EM?A,9(N3F02GKUA>7A?X/0>)63:;QZT
MDIJP1L'#T<[$^4K*WK,7*9&=1MEJL@6+D9-1NR8UB83CF%9CW;$[AYU0$/M.
MWD7+4T;6:J9<Z73D*)MQW$-3)T[<UI,PC)OQ:[-#*7;$W;5JS*["K->NZS4.
MO"N1&+K):Y*<=CLM1B1.3> YC"YW%M4AQ;$%.F_)4\A0J+A"4NJLAH/=%>RK
MM_68A&OUR!@6[*+C4(6&C8I&/@VI64,Q38,T6I&D4S(FD1K'-RI DR;E23*B
MW*FF!" 7I"S;?-FU9L$;6$][72QY2;CEAD<DTYF9-D[[F4S.Y;SO.M5*O%2G
M5JB"5Q6KI1 5PA: A2Q"!2N(B 7'+L Q$<H[1MVUNRK)22BY*.2=+,57[!XR
M3>MQX<,U'3=1 CI >0X6;F4!9(>0X.0H\AKE9&J=['WZ2[#*C+E*U57:3,PZ
ML=A#$C85,3$PQ)'# F)B8(8VF//5]#(2]+B6+14U;"4?\#( X*5E_P"Z<1RE
M\IG7Y_8+P9L@P-!1JJ^2L<7>SL+9-V]"_9!BI"3?RC]:I/:V1C)0U<K55;#7
M\E>L\O.L5*O[/)9 CTRG=V-6<2:S+:VJ25]C$NO34&*54$\>"Y*A<%>=X>R;
M*3@CI*C&T@Q%G)8.HBK7&AQ&5&V4MH1E*.37SB]9SK)8]:<Y8;)DOIKM5:K1
MS#8FJ\A:U.14VY0QHWB:[EP->Q3KIJLFB=-4B/#NRUEB_P">'ZE=JFUA!O9+
M@PK%KI=690[[*T7;<;UVM/8%8*Q8UCFP8G8&#R=1K<D2)GCRB:#H&;14Z[IQ
M7I)D<;#B$6=6]EH_P_E-WU[=2>/Z/%=1G$*U\]:RPJ-%V*J=&7PJCF,FMD )
MG7?2@6KR71F>52?L:\.6HQ"CJW$<'6N&K'V!!SSU&D]H6[\V%\K?"4X63#Z;
MZ<YU7PS;%#LJ\R?/\+%;)S62%I&';U*2FZ?0J3D1%R5[C7#]1LK5ZTK-?3=
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M]PQDEF]N\,==*Y@'FUYD;2'(F;'O>LG.^M:\)2Y0DUM4L'\3:U"*X'5;.K3
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M5*[JQ"$$FO0DPF:E0E7$R'C:DY6HT[C;(4$E9J396*4=-PCMW(MBO6J"Z#I
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M1:+(=6O2K,,NQ2;A%9N1T@JFLW51*X171,"R2J*A 4352,F)@534(('(9,3
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M2'&/4W5!>UME-U>1E?Q:2;;V=8UKB%8UFA773!VF==,TFB[2],;U=82M-N)
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MRO E$VQD0O(#BY(2N'&0(%!O/,K%UVV;KMYB.5*E)G]X<!!,-*8W<Y8%SEV
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M0^1^T&@FWG>#VMR="B5>Z1+3;FS#;<S<QY<E?H5W!)1(0$]4ECS,#OMS2/\
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MR#:LE*_13B4XE@NL*5D</=(VO@NNK%5<C5)+P)1]5MH+\D5@BD0)90==XMF
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MR*MFM[KU-KR+<K-LJ\J4H<  G$C$+/ X3 /<P*^)Q69Q;GX^(J.L_:_ >2X
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M0V!=)%UR. CI0!LU5G6#MY%+X4L4-KQ63 E#X0RJIG7><L(#%[I=->%K7(H
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MGY4#?CS18\F:4-YBO]RUI&F,/AHXR"-<&(8.H7BF+M45! C0#+'5X&N?.@*
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MF1:[,@[,1_O<%<)86F2W<^!<=15$RB+PN(,Q]ID0?U!T"]0F^03*N,DK\74
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MT95ED3-1CPRNU?)0;\00=<%EL&=;63KHI/W9]7(UYN:,JW7@H)IIHQL47L1
MRF/-HEU**T=_1Z'OG#XYM"/P6SN:?H_V(91]I.K'@^30C8"P_?7]*\!7GLX7
M_-SY(O+RZ63#'P"JF%SX^J2EJ*DP)(BD@M%4,$$'5-+"@S\B^JZ5]@US#WM'
MA<I<M/5A:Z_Z'7HKB)AQ>I><-YWPO6'-D2-=QRY5U9YT15ER@!1LLJJS@_HI
M3"]22]8K0&U^0H$H'#+C']MJQ?\8RZAKL_VHJ,4TS<U/3<D"=(E$^YU)-Y2A
MK,X4F,R"'(\GT3X):X8AK]7]?'!RN> D/^QG]-0-M7__K8S#YI0%I3F12&^5
MD7M*ZQU]8)^Q"%5)?>POU"67P<)[+:Q?;^RD7-::()5Q7Y-8?CP2YK'7VZ1F
MMM!O2F5QUE"2%D>@3U-7'M.MRDLO#T\6;?:51OR-@N1 19;MX#A_<C4GQWBU
M]1=RN=Q&WKV3N;[@\O3I#0I9894=:7:6CC%\E_9#KCDN20SU74^F.+B25P#D
MZ@U"*G/^*ZC(@T_I]F5<WHQB%#2/0$@?N&C)S<)6$47VP;(7R: 4'X.*7!3@
M2N2!:8JQ!5-2"O[QN7L+4TV-_150.S/S$;<-DT(OAL":H2&,R$.PX^0]@X9%
M0$+=892;C#J*QA4!"Z@_BO2*26PDAO?-T]WY44X\-PGV>EPL^O$W5>I+14;&
MQR=^R; D8.D]5N$_ZL G@+UFDF+5[D 6"Z>B@=M2.RJ9;?+I*EV>/_^[//S>
M/OTWN5!P!F\*,Z,Y,,0/1:FF5 L_E]LG7W,W?Z^"@Q:"F4Z6CH+TOGY$1?[-
M6N2QMUY?;<V K9#LV_9;^<@E".:T$[E4DSPF3Y1J&F2-),XCWD I?;]>>%:Z
M?/!F86:[;AY_,/J'/BPD06*Y4^.]&2Z*VG,D7#I'&%2-7$8MLYDLM7'BW_5]
M7#+#218AS(73ZOG[+&)C:B[:W?74_<:3KQ_!)Z133&/RDWO*;M@:=5,A0L"D
M(Q#>0O1J\CJ>5S(+<S+&]UNA=LY;<KG"M.['F8-;GQ]N9_G@'R#7WT3]3'-Z
M>O(B7M?U'_0=U G]9)!_:6N5ENWAM'PL*EPI@!OISGKP]7I+G!#H9+[[N9O2
MN%&D;,#T& ]-)9% J"F!:"V3SY(#2)<*E/X^)0N4Q%(?VH.#69+0B(1EP(#;
M45&=;=ETO'J\??%2#H5T\P4F@=Y3S.G5@M:QYT&L;!WE0>6W3#E<3##CE/>T
M*RYS<@SFWC=/S=]K5NO-QYG*5Y7?I0@E2^!B (1CS;B"X4I;:<Q>#*W+]B[/
MQ+K]2]/2[-D%P8+\WQR3V;H@UGP4*5G\5%:7M@)J\_4R6'8:RB%8N+"FY%:W
M;['S)D1DY$6#7WK\FG0A?X0<T881Y!IZU&(]+J[,4X%.%1B4V'CK[Q9AK\D*
M=([^XDD'A2.'=6<ZC2QO/[<\-G>B?V/"XG(3]+AIL+"TMM@(K@<FZ0/Q[%9!
M-?$T^5$+$7VRZ M.EPP8 -^F!>CMS-'Y'?A\[JOJ1GT16]8[*[:]R$N^.8ZU
M#$7+!6H=R5\%YDY$763?S</H*?K)P]X*Q_<V[VT0$O?+G-/]>M=LF6)X6N*U
MI'Y</C@1 ",<BILN*>P-B BK<P/\XOU'/'OQ36-C$\SW*H+5>N(A3DFJQN"F
MQ#A-\SG!4'NZ1I>^1AJ4+WA:U#(%#DPOH,<W<<M4&#S;](:>_X6>SSEU>@^?
M]#<$:A25C7"^>8QV6*"#-KF$; 4&FJOD#WGJ)*MPO" R/,E^\DEA>PER(=#]
MDYBO:+=&:Q5XS847LBD (F;'V2@JUY^"H_+14JJQ1,,^R1FP9Y=ZSWR>/\FX
MDUOW"ZG.QCWG=JO+W^C-FQV-470^^(B)B<C86M4'UD/E''-"\:L*-)45SL.)
M/?G29%#NH]+W'F:Y)$NPOT)-J>+(&7&R19+Y2-)CNOW1;Z ]>:4U"6D0.7:G
MCAJ\SUS[51513/3IAM]96!R%!@'O5N#[Q;ZMB+P51>S%5H_=\\T=^-9:SOF-
M?@-T755)^B!1!VWD_(04?9QWG[YGN?0B:X8CW5CCEDFW1Y-+;ZD\=1L;.(UL
MW=X^^77*%]FZ22.JTYW4\;FK6 PSM+@?1%'3+='L\B8-;0E?Z<)&+,)Q;$M1
MD<8&(>.)X/$N0)_]*+J]AR%^F?.6K>L._?S&S)U"DI_YY:Q[F/<(A"9U4,D'
M'!3?@''(GV0X>@5@^6E _W7"OY![&R%0C^?9ULSRSLO#6L6O;'^5/#/+8%N&
M["+[BK\CC@R-P=)+W(X4=3FX>"A^GX3UB@]BDY")1))Y%P;!UY1IJ:\ *,E'
MUU8VBTO9P8+)O2%(VO@HB_E$C29J2C;Q>"BSL R*AO8P%I4;;)R"VYS(V^=\
M'^_!K240<$ORZ1TC)61O*3O#EJ'P^J?5JG1KDC[\4PLZML56,7>R))HVEC*:
MO3-I$J8C.>\_JA6"?_#?WUQ?+\\.HW_OJ)2?3P$S<"8DQC*0E.!\A OPVN,I
M*D]VG'_3E4@B&"X ;!PLQ9J-6TR)N-C+6>>?^=2H6%M!:-,W@SF.63D5%T-A
M)+L%-Q#3!D])>OPXX!T Q=D)YH\HYG">B4EJ 2*2;^O9Q:+BQC(,J PY_!6P
M+K^Y96^LCGU#(?8B2.EP/_]ATRT\_,E?K.OQWE-9V=.'3_W^#VVOOQ2%A$FL
MR-/C2Z;;RTO>UM4S'ZGJ+/G+\TZ7C[AS:\FCSW7N.B;<:'B8^"^8F9-S\I&M
MO#<WY;XI$%- XW:9D=-MW+@FVG)]1G(I84K1MR)_MI774^?;*[%<#H7XYVU?
M/3[[<[P"WH7G7K7,'U &>WIZW;OGY6YT/F#?[,13;'Q;\6T[:/,.LW\A\=UX
MZ<G;Z-DJ"X>*0+DN\@3OH&L^I?YA?B\=5S-B][O2/9>8K79PU[L2]O$+<J7C
MC"VS]_?W9TUG$LAK?J\ IB49E:L1TX.GNV?IK4#H*T#!QELM^6T\\K>/?@6T
M^O>T>L04CEN9?[8/\^V4/VEY[CYC_O9+.M83&PMP]Y)]+C$I'7?E\W)X-W/S
M6.@K!K*&?#GC@?CW>$:D9USE=#T^#*_BA+\4SO2(GE/^%.N!0&]BJ K$-5I3
M(;XO6A(:+0]PL=YAH@ DBH%USQM*OR?G=;A;=#7/)[_#:\C)WN6<3Z?JQK[[
MU=^S3?%/#\HSV5"1DY_(2+U(9,Z7XENT-\_>+UW6)Y">@8.JSYXQ^Y^[KT@G
M9=QR'_WMMF*[KD;H89Z%3LF\ <\_ L2>7R2,Q%\!>6E'EQ!?U7D1@BVQSND7
M?Y^SR\OK/+U%Q2W!N <N"PX9_QW>+0>L5\!(Y!G<*.!V!Q+XTG'C-_,*.#,6
MZ7DF['X%/"+D#=BK20R88#X7FDO\E1@2D?&?ZE5VWWH%#).I[9"J58WLG=AV
MO8-'LM67E!0\D)A^!9AL+_$=&-G;2#S<I+T"G+1> =-&RS'/B1(W_GG0UE>
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M634").W*LLE@LQ9D*&.G=;,C-L$//_LX-JTW7>BWDYWB=A:& @@0Q4,B(>Q
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M7@&SI!NJDY.8B;<RASE*.+FK1S=8H7R6JU)D%$[JMVW*170V(B94QK7J&(9
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MMQWXT_KW_G\?K\=(C^WI([><?#S^[UW[;ZP/8P"/ >P_?@?U]A_E\?&G;O\
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M[&5!E$VUK(6)206K)Z[)O)J=DX&G8W5E%U*;27$I- V480*KJ?<*Q1CO-F2
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MURC*NBRKV:</$6@L.<M!-PL!9;,9#(*=2R%0A.*X8XN-*?$]D;0I=M;R=]-
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M^_W^.PC[\<_Y?;4_EY_C^/W_ '^GYX[3.W?MM\/2/AVCRW[[_G/E'D>QO@
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MK@UABBYS650#3,R0)SP^=J\[%XZC'5*MY/X35:-IN/WJ&;<\MI&*@(2QL[?
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MAIJ#87"9?;?1(3<,_+,UW#9;5=T&@EJ@4Q=/X\^-ZMWCJ6*WVT#@Z:ZPB;<
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M0:$%R)9T=%2F9JJ&QPVARW(H%7WI>P28F40KF%\ES#CH:&AQ$#BI5 4'QI7
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M C0%O,C]E1W#7W8N;Q(@BC'>9TT^TM 7/[?0*3++5,,6W4G+&Y9DI^@8\+/
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M'69U#G0WDE6W%G.2(C/2 P!=)!'=A>K_W$C'X\#M2X#/EXB?^W0N2:=%EV^
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M:R X:?XU8K2-$!B1Z:DR5TL>73-:;?]G:)3YPY&.TPD83EG<E?HC#]TT[&"
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M:3Z7*O("PTW]S:T=A57ZY[W$7.6&K-(FRI(()V=5+"$H>GN+F=\-J LEB(#
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M^>)1H8SC-K:&M3+2<M+Z.77P033,;\;>5D.Y=J V";;CBP/T4_#0&//=4T"
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M2S>#1.U-%N4$6]7:8^GZFC8\''-",]IHTM+T:N8F%O^ ,1*>T74O5CN50:T
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M=R+3/LU'K-V@9=U>U=?H)TP'7AV$TVJ,TZ/G<+I&]T+G1O1IT]10CW*;).<
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M)T<MN73.%N,?R5*ZEWUIR%Q>'BFXCK/U1@05T[FHIDG..<%NC<J-\7_^_]7
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M:#36H-+%OT0OK)33JN-7'"+I.">0'Q<,U\\=_W4SW5YN7SS[!7J?'Y3QPF^
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M1:.)&A&?I[-2$&GA1PP/VR$$'%6L&65@X&Z%&:U^SAU564 WA:#?P,6>$6_
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MY#W[XQ>?,M,N0;9#)8[+S8G+O0+$C97RL,LCMF8&C68%1+INKYIQ#UFB]=?
M$FOEA&G'/>&#5YX'4[MT04TE=R;SP&[MTTRO1P-?J$3Y./##-Y1VM3)Q?F=W
M7^LZ6=V:!USLJDZ%0#<06FM88NA4FNR O)1S"4L',=)IK^%LH_&:T/67*?4$
M$DK*J'@:9%+#:DJ;W]:1$[O0%!.\S%IYW+_2L=R%XW3V:+X9L*2>ZL+J)^+M
M$M!WB5TD<C(F\_K0!TTP$LH.2S*KU;O9P88VI7BFWU'XK3M^]5@PT%Y#>CA!
MN7L:"TC<ZHVC+:&PNFU!T"JGFHVKF?,5:4G5-9VMEM*>&J10J]7EEQWPWJ_
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M:@*Q-U8;I5*8\C#7K#9TOM&;,^7+/QRTY1Y8$KA?ZC*4.1@GF+(6=IV.EY<
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MK\MU,0B$A_/U%<DF^-F@8#6T3PBKTKN7CY>8G#7>Z,+K+1K!V8.;=3V(RQ4
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M.?:$)/:2Q75PI 93&\I N(ZFC%9HT:C.),.P>W+8Z7RM!=R>@7UHT(2*;D+
M#<\L")3(6XKMG0O6$HK02ZB8D&D5/]_%3O<7-% <9%F* 6H;2XU/<GB,_-;C
MH\Q^=,*?!3"I4[)CC$BET%]*6;T7:;]28/,0K9W5N'^8=6>I1VPF.<[M _&Q
M/,X6[4\))2;(>^UF()9YM'B+E#188/\/9U\=%$?T=3E((! @08/+X&[!W=U=
M@[L3+&AP=]?@[C(09'"908++ !,L!)D0W,GF5]_N'U_5;M7N5O_7];JKWGFG
MSSVWWWUUZ<Q[ZU,NNFC'S<N6FY0M!Z_X$PMTKYEV^%DZ++ZT<GOS?=3_7Q7,
M.PKQ5TG7Q8=/XN]JP*".>)\TT_3Q(L\EJ/\M=FBLX=>O1AU[!+0^J5>'OIJL
M/WA"I#9CGAL@84\1&T);E-0_:NKTHVS]2\]-"P R>YY;16^*C2B-)/80'3D5
ML^#2DM8Q<_+0-HT-O;RZ.P53#2RF5OM,-;0-G= 146O1)<PU?/W9FHHJY^GW
MFGH2$TC<]KP?8Z,B*#_2M&ZQNAIQ'%AY%I2W.F=K''+;VBY'8R_Y5,XW9H[[
MFF8!NEN"?C>=]XG -"5Y/FW1BCW-;,M3P)=.S$PB*9VY)/>\UUG#Z,I!<H8V
M38,S65*3J$8RP,$Z8OU1 8/HG(B5E,/K2):OIB>"BL--S!VY93]EX.G!U'Q$
M(QRY5?Q5_>&$X=$_A]Y2&UTJI#SI.=Q3O5?!X9SH*7M#:W*^J1=#P0<TM%0:
M'^W:(SF-+2JB7>?$TY7&1F/!O9Q:JP<>%\LM MLBX]H(%Y@;Z^.45T3P\SJ5
MAZ/N&GQU6*!T>)#EHYWS7-4>XXXRTS4?,L_B,4TK1^8\Q01W*^WD2"-SB(JV
M-P'3_G>37C'K&$B)CG=K5N5H0!-%>Z))/2C-3<#C17TYT,6I)IVH1H3K9BQ
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M/58M:/PS[3'%92<EH\^T2\2>O\A0SC6UXVR.+ ;?^>A.ZJN.65D7+!+P?FT
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M=2(W6S>&VX&T("E.8RK4-4V$KIA?0\=(#G,D)KISVE*YAA6""+?* HQA\9*
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MR"QX?L7<7CH]IVF<G(=>Q9GUBF$Z=A!V*G%86NTO/0$?6+8:/Y7'KEJ\V0&
MD.PX];8@?E!0$K9S.$_TE3#.?9794LU6RHN;DH:(=0D@@UZ_6FH._A9!=WF$
M%#2"R^L/^T9SEPNU2\ 40(UQ1E<?V[5G#Q>$T!5<+]G4MS-,?.&_GQRL(EYK
MH )_3&^U+E>9[@BZXHV)'T4RK29MJV+*B4,LVJ@-K^Q_K/)!B;"^0+@C:;:X
M-F#M"%7FC=62\L1)Y:VM[+<^!,""O&G=$Y;Q'T?,7!+,Z4'[A5.Q4GC%DXC
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MFF*U5O<5C! 47(]?6[+ BG1GB9TX0&NT]LG)Z$+WXH]8 >B,HJ*4H1BVJOS
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MN]6P^ [H:??5ZUJS52M;BGMC.:.-O]0W1213!F'">)Q.HF[<3.FWM,&G#AN
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MO=;;[D(-&KK[?L>MVB6IC?Y._8,@%2EU* @$E39T>O0CWC]9:R4"&GKC/X>
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M2;W]D7JW0?)NQPP#A2Y\!L@)5Q$&4=4$Y;4[#124M@".ZP/75^=ZH[1KIHE
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MV840Y4Y\"K<*;B7;UE]PB9*+QP2_SGU1-,Z#6J+/7^16C( E-Z&IT)O8LN0
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M6#H081&D$(L-MPMFNAB5JJ2 +!8'5,*&.0&W,(SH(9+-=1'*Y2"P'VD31+%
M$B+3RV41Q7!3;BK0!;D"W?00G0XNZ5 O9U6&P$8Q#I8!6'%\#-/B<1<2/HP$
MHWS!:-4]2$OQI;QBPJ$[5"+J$70Q*I,:O-[]ND1+=J?KAK$:4I'WZ*S?RU@-
MMPN^9WZZ&34ENCDD++?0(-- HW:%3#:%_) Y)'J1NFV)1)4*DYA9JN12P01?
M@"N6:DD]HI/L  5?I)/PZJB6T8UDG E$8W8Q <KQ'NE4V]V8CF4Z7::<=Z1A
M6I%VTD"U:LMA;S7?X;UM'B=X,&S_K_H^7!79;I1\[^%TF%:LMU11(&"NY*O!
M'!,L%]*L!+%=N]T,,_E,M*I54"RE]W(DWVA5 \6H0IJ<&U ++%>P>B')!((<
M%QTN$72B)I@5.Q$(CVHUN,3#= '.!,UNK0D9[5 Y0K>X')7!R]U.K= SV6RN
MD1>1'M+MQ'MQ7[L=KL5@34%RL*\@#-U7,QG#W9X4,!I,]6"H3E'!9,3VRZV,
ME$V5>(%.DK8$Q&PM*ZA A=0]0-[*N 7:G,:Q":^<CZA8DBD%44!+#=.*EJ^D
M21$M'4XTP(S+B/D0$2MX7$0V+-$@;"U9-3B \%GUG).E8O$BA),P#Y?$4"+>
MELQD*-[(!;J>INGK#8&M^G5OD4^4L58YK=5+/@LC1#.0)EO=C*QDVU Q6VQZ
M@*J(M4MLLU..%[5LJ&4*NFED9*!22SIUP\(9N,%8B6'4R^=1$M%+0C<'9:/Q
M0)1M9RI)N@*C&N)X"R#:8/M[?U,6VS4(2S5IR:H76Y!,5^J%6D'+59U.-T=+
MOGQ2* UWC*M&PT_C8 <!2K50F<]2'$ZU:X"/\I5]\6K=0 10QE*59"OKX\UD
MGJ[6LCV$AF.QM)]@LVR93D1,42K#NLH-!Z48C@F.F^S[4CW.8^!Y&"<\;DHF
M5/X7_G:8@/^OG/V6GJ9?<+@9;\LPKC< M11FPZ(73>6S61-GVT9&S<5";-Y(
M%;(NIRE2?(0NX'8 =[J :ADIK5YQ/>J0<&:92"-CIH$.J8=+!D,GDVS6+HMA
M$98Y-X5PB:$J1$)%T9\N F$8=<E )ZJ6 @4Y*<>U;JDLQDJ*9OHD'![F>@[G
MQO<0#NI!IJZE?  >S25KK;@3JH@!NTUB5"PDB'ZXVE:;?H?*^;FRE2G)C%V-
MXA6C&H.K<5%0Q&P*U'+#J!?W)B$]0NM*U^%J0;:JZ9"L1QDJ'"CYXMX"GU(D
ME$Y@2;Z0+K:]N*>92U0K-88CJU!+]%=CU6)5B%3"D3S7&2Y(=HJMI )X8X 5
MZ^^'B_YK2?MV,#10R&Y8@:\D.5 TL( [:ZTD@IE&LZ>'+0,5XYVJE,]G-;)9
M:1O!+-MDK5)+,/E0+5(N]Y_R]NDQH :'SJ$L"X >UP,D2B/IALA6:+T0$C.I
M8"UMFF6](.A5A3"I1,[R^+(9I5U#$G8BEJD)6#+0C.%E ,PH(48I>%W*.'P"
MKF 4+W4]_DR+U'6ZZEK7DZ.K\::_%0^+1=+)Z5:DV0GZ<QV_VQO#ZQ0TURV4
M?(4VG_3)2:X$YB.A&-YJ1X?;!>.)2 SD4MU(N)@$K"2;:D8K"9:G*STJ1KK9
M7;SLU+%XVM+(+H[5Q'+:JA=ZB*.E//ZPKYVL.GR>)>%BU2;HH4+78%FLJK=5
MA;31#(74-*S2KKHCS^-B#Z*(#I\H-1E1UO""QM8-WD8\;=BE.JTT'M2%9JA7
MU:%2(ANLX\'AJDBEUPX#.Q+N-B'Z0\*YHR1N$R .0\ &8E TB2Y02:<("Z>3
MNJSEHQFH68W4FQW&R82C< YE-)^++I0"6)<1=1-LSV&:\62FY\O5= (PAMXF
M(+1$@4E'6Y374APC(Y%)"\&C@JY$@'I9#'K:6E* K432#5<<X\V[!A,E43"Q
MJ, +D!),2DX1HI7^-I?A*C%F _F("76HLIR*2US46X,$%[')NJ&:I!:OZ!41
MB$%=N*[7689N\W):Y:S^ @4<<WIUH(.(#B! =K;)%X=D28K7,UD5C[7YFHN9
M'%D),&E:3*58+23[88PG0#N'IRL%W)<&M:A:0,.IL-",!%+A@AOF_60[7\P2
M'"F[(6BX^42SA10>*J@IHBTG!:E'4PD0,UPGE>;:E$8W&10*XXA>AHHF''0S
MI$JIE! J"(VB9;RKQ%,!&#&R6,NU,SYTL&#'!@T;)#;U,^\Q"FP!JW6/,K>_
M!/5>8350N"Z,M!B$5IB<G($:+=/C<+E\(I++,P$&*H;:JMOZ0:;@9WR:@A<A
MP0.!"E[I^,/)!NUIB<%"5JQ20W](-<6@Z^#+0C;%^;)$F_'+3::4#"1:K#_3
M U3:HW@Z,*DDJFTK1B)1"?)TNYYLK5 CE7BI0/;B?E7G\C'<WTVLFRE\OY&E
M<K!-A 6=;#MM/\6V(C30;U*5)7O=/*GJ/;+K]SDINCSHK-0UJ$!<%XR4X0^A
M\?4ZAO[P U"T7L?P(=<Z1640K&Y\!W/X@N46[Y6^C_=]M_GBZKS!:1-C<:5M
M,@K+Q4/C[H6Y@E ?@S@?X<.A^BC/(KY1&/*PHXP/@T=K#%RK>WVP#^7Y@>+-
MQ;=0'5KWRO0ZU?7WJ7H3\2U49PRA(2B,M$F93L?5CX40B/ A'A\:B(0",.R#
M/7X"\T$A%,8@(DBLU[T5^2WJR'%*7>B_)!V4F'9[?-T1!^LU3+B[9><Y0["X
M>L10Y??X_N^\P2$>8\)&BPZZQ-0Q'N?J]5&H1J"C'A]>'R4\;&W4QWM@E"!X
MGP_RS0.WD-V:ZOJ6 \(2#($A-7C4X_7 HQ#NP4<)EO6.\C6.\&%\W4V5/>NU
MU[=FK(W:U?_UF&Q3?FO5&-L8EJW>G3 3-A^7+0<M)K1-U7"V\GIWGM,_F->[
M!P>LC#'LX.W[-N,VI=_T3:YM6TC8<JK",.^%L7IME&,A=!0B//51!N&849QG
M6;3F8;U>'[)>_[; L5D=W2:G;/:Z/3*&>,<\T/K7[3<IM6TE;94WNXS!^1ON
M,&[EO?M@< 1!YT*;OGJ_-<%M5[#N?(EQ<+W@^@OOS5-^.,;NO?G"'1F["4<E
M?"!C-_',A'_IP VO;CX7UT_L+>?NO$T.&!K+FXQA=C3*4'E!XL:I_I$D\\!W
M*;$-/>O.A\AW:EL_5&)SG1-*;^YP"E1C+,:T::$MU"0NL_Z@E/&"T>$&O=I6
M@7=34S 8I>TBFE-89SS"2.VMJ=JLT);:TI3+.MKC\ ;)=1>V+)EB[/ZMO-#C
MWGN4"PGR6'?<XYN+0SCB&P2OX:6M%6R.>Z&Y,.;U$.CZ@LVM%NPH@CE."2S3
M7E]N<&4"4"8T>BM=ZI_AM+4#/@),XX/R(A'%'.N?>M,_D&A\D]-L^@W?[-Z[
MBT<869"<H8)-1===WYXPRXUO4>O@ZKL+]KLXWO\:@3>5'%S>MJ0U/*LH;[H
M;HQ#$#P7@J#U\IO?W+825I4UM2V8W'I@3[R\G2Z[TWIH\GCNR^YG+A4)'#NR
M\8_49I987_C_.J1L!0SK3RGZE^-A:Q5_7""1#VP"B?5_?&@@,3S3ZE\.B"VK
M_;C (;ZIAXA_ !YB>'7S*+(A)$T,.NN#$24QYJ"2K46D=\E)QH-.W[&_.RS'
M4TR?KC';+5?A^N>C;;?8X"BT]TG<MMG)]1;(=QF3;48-M:.]3QN\_V.WQAK]
M:@9C&AJFE2/#ZD<&]0^7938I].YZ!GB'-A7:Y@P8% GVSYYCMB ?V^_O#G5\
M0B/:@_X.>E=JNA-F7?,WN;Q]';):Y\;[9^"M$Q[\O7VQ_GF%XU0N$PSG\^LD
MS6T8;((DZX)]'.K[BX'+V'CM/;1U. 4F2J^_O'T%SF!N3)1?=W7[XH/S$R=*
M#R]N>YBW-1$WEOA @;!N7N\$PKLJ^$"  $,?;B@,S@K-]=<]/AYHV&(\WC<>
MMM#PD7(- SRLIP<?#TCL!,06#9L(B*C!<<KDP<,6([(3$1\T(H;IR$Y ;$?!
MQX!,#N 0D#J3*+/843CL.(GXR -BPTK$9,'$3D1L5N*#1<1\&!M)S7>--%*9
M[X-&2/?7R8,,&/LW0\.WHRGHAQP<D(L-7Q\:!.9"8Q(A8\=\QL1A?=^X(+"/
MM,_HPX(8>(R/%2R('787'WU88'U8],/)QP@7V,ZL=(N&;0$,%/O8A1$4VQE&
M)C1L,UCTF><&WCF)4+%CK//?S#D_[*! H'6HF'1!!-FYM+E9B0_:6TQ:8$SD
M!SN!\8$"PXM-5F!X_[V1Y*,.#&*XM+4!&9-I:6LB]7O?2UO_9FQ\Z)>V?(.D
M9,,B!CJ)L#&1 ;[?M.3?O(PQL?X/'30V!!3O)$M7_\WQ9&+U'[5P JT/)YY)
MAHN)"Y?_ZF#B^6@#PSL 1G]]:[+QSQW$Q8ZN;WT,Z.=@/7R2P6('N><.+X=_
MM&'1ST52?=)9F3_)PLB.;LZ9R!O?-S ^VF%D"(SA5@RD#PT$^_A@8\?W8B [
MAHZ)XA\Z>'@W;M299/%D!].2G3NXMFC8E@OCDQ(8.[@POA,86S1L,V"@&ST&
MBDVR]<^)S\[_Y="8V("/VOHGO-%K8)/,;4RT[;\<&Q/]UD?,;VS(3Y!)!HQ_
M<WHR<0/ 1PP62#^<('U<>"89+B9R^_<)C(GB[W_]\Z,-#$_?87BP]9%D$F6M
M$P?F?0)CXKKVOSJ0?-A35FS#CF <FF3K&3N8FNSP&BB^8\CXT*]F8/U@@@^@
MT4]-/),HFF [%DTFCNS[A\:.9283?=Z'#AH#GN'9 (U)A(P=Y!D31^9?C8P/
M.S#0#>'$.^F6,_[-X60'MV9\Z%<ST WAA)AL3&,'5[IV.)Q,W!SR46,:@^P$
MQ]:_9X).(FCL8'HR,1S\JU\UF8CL#R<TO!LW"&.3**+L(#8F;OWYEV\0GAC2
M/G3@P#: 8Q!2O),(&SN8O.XP-G8PI$RL?\>@L;7S4#>Y.:AAV^>!?K#G#0\J
MVWBH:=1@G/:Z)KROHT[A384FUU&GP\<+ZQ]6P] DFE:3^:2J#_UIEYO!PK<3
M%=M3\(&@@O#-]?E\GLD!"F(G*+:GX ,!A;</"H*8'*"83+1L,H,"'W@*[^0
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MYXPC[\C^<HY^PJJ+%CQW3>/**Z]<VA2G7W7)Z0N7/+EBY:H]\R?PYP#3?O_
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MI7\Y\9[5O34K:E][>>[W'MPC$3O^C:^ %VA[[^6\-N-T%MGMM0M_=,"CT1>
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MV/ Q2.DS8?K'-/)MOTS?0F2W#)')^:F8>F+%STB=/G];Q^9HPZUO)>UH E?
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MNBN1WO9J1:XXVSHRJ")0G\._3C"]3L3EI0^QI^K"]NDOR3J3[\033M+N[V(
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MP5[9FQ6?9"G3!^)*@>1+)0MQ' I\BG2+"76+_P29&PM>D#.>\V86")[M7CO
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M-^(@<VG2K"B/:DS07\2EB9^&.0()+',#U+A%;\)E/Z$7F*0P45R*#320^=+
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ME]$*E(/AB,_>?8=HNY9\H)7AH=&@M*QSSRWXF37PK0\3G845=>[;&VG:7!+
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M04W3*0MB[;7$[HT(CI]ZC[TW$M?-#Z _WT]079.F73"M[#,LFTL?9*TN1+2
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M\0@C\YOAF=O^O@RN#[^[X]]<#_3?[+EO\0JT.'.\=M"_3Z@_ 6HCYL.J'Y\
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M0A<9/65.BF-$N%?&)",)J0O%F#+[03D"]%TJ,TN3^\^$2QGO!O#Z7Y,^M%A
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M/ZA^WV;W_"5_Z!@X:_ X\!4.)5\!X>QEJ2D3+:+%$5=%(NI=LGU$+-EZ;D<
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M<7W*F#)440>SFA)0+4M&>)',+V$N,IP[WC9MH<]$.*.6L&Q&,:(AJR#D8;^
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MB>&4%X(F)>5^[X>@H9N-'B[)DL#ZJ=2!BU-=02&?-FZ .*4L@1B*ZP[AY=P
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MM_#E_N:2IM8UV4M_X)@K+E8T7+:D!%U^L>2=DLNO_\2(\_T#Y_ </A)HLF.
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MF')EGOR\7]>J'1SK8GI_ST. [7 GG>W.;I8YXP=MAZ3>AV"R_J;D=T[#TCL
MB_/EP5,.S0/V/?*.#[,D%E?_^N28O_=V!6>$ZL$]?%%GP[^X;@#I0;]9:]4+
MD6!#MU]G%N>H_Q&*[/^8$_?LWO(#'G^.SJV21M^5,1&,-G;<J!-B5&_=+-GA
M,N F;-F1F95FTF"L$Z_)%DTU_#$10_"X,(0T\%'73\W&VKJ73;FM<7UJ=]\4
M$*>+T),*BM7XKOT&+!W_W%\C^D[^M2VR:\8LN56Z[;NV;8]C#<,7BQ<-5/A;
MQ6IL,\>^$H+^Y_Z OV3L?VZPW2J\PPS#=ZNQBK7E,VZ2&9)2[>]1>&0%O,\V
MI\/#O3=#G[?B[?A(B)C!9EFYR]'59 +]V*O)!5K!QZKHX)IJ8%N7BNQ;LM/:
MGDDC&E:*1:,1BXAOB(,2^0G/0YK>_J453GEC@?J6ZY")6N'6B=50\[$Y;5?$
MMW55)749'%'?"($ 9D.:ZG-.R#.02X;)SI1PWX+^*E=/3*P[C<^;+KXM._>R
MGE![",E5XT![<PX?O[2NVAJH-9T#Z3.26_#2M^"[_'A&](_4I'O- MP_0ZSD
M^]V_@"RB'[W[>GG7EGI" K4*KBWAE=)-.%GL+TGC<YQ#%A)J?/$KQ-O)]3-#
M&47<FL8S"LV)4UE^[W7L&5&_2PN5RR\NH:_QI[2I'Q_'OD6J[ 7J>YIPCW^*
MK*U*1)Y!D#PCU6_MEC?;MM#0+@]?;T@-8=NU^:0Q3+<(D@9L'Z6S[J='Z9!Z
M4:,XT9CG>>5$ E[C"^YTS$GJ85LA)WAX>!M/G^4Z>CJZ6[F*O!U2RIL3$IS@
MT5/B,42HV5E?EYC$C;-^+6*=B$6R*:*S ZHR=AJ,_V.U'/"9RQ4=B+8;5>/*
M6UD+R9-=6TR4\ND87P;V:DGK?C**E)V5T2Q59A*[[K-^D(D1^*6JL7LGK'OH
M6==E[1[,=T[)+T8=X3J,GJT")2\80V:2@[.,)K'Y_1-(&$)?GC.VJ;9.[WM+
M^%J/0 *C_5'^RKS3G*OL0WW91_K2U=45/.#JHO MUJ(Q%F$P;1^+T(39_?OW
MMQB%D$"F!L/[I8;.]JA)N((('T_>^V\Z([LT6<387ON6T<;0^KZ&IZQ[<B!9
MMS:')?&I--Z1%Q*:E>Z4O!_QW3-+63\&M+6U0CWSWEYNPO/*J(14U=S >FTW
M -F6KI@')UU=]K"#UM:8/+]D#;#A0D"!]4#G,F=X *CN\)ZL;DL'&6^@<R*^
M7JMV&I00$KIV#F,.7&1SNZ\1$:$08?DY%!3<7TQ$5=A4'=TN;VRWD&=1,#NV
M9?%$\(15Z@*LN#.8 E:C5@OZ&NK#'*6XV0E.ETJ7FQ 4B4)6,6^5G_Z<IIO>
MT/L98]DU)G@*_P>ZYF:$=/Q(^H^M/_]2)OJS$V,PCT^!TMKMG PDT@G-TS>E
ME?7U*[G3/=%*P_N2FRV^4UV4KF2,&D>^MPN?WFOEBO9G9P%'8U"<NJ8VBUO4
M>74\K<D_(6IT:<"V%G?@JX.,YY=?F:Y>22<9OC\/J-UVJ&Y%%+QDGIS)W^30
MGDDQD-Z%:/A/7Y).UK0J/P%?]Y4]+0W(H914#OVR0=2<$N=VB\WY)\: -IY&
M\ 6((S2".] D:XE:W-DL'_/)W:C)KBS-9N7Q")36$LK\N$EQS[8DI[[6J6D!
M.F\B"T?G]-8KUGD@9\\U1=?%7F.H;LL+/D=S-K6[\N:YGM.;''MT1N7JV=R#
M 7QO-X=%Y>G9Q"_FW@=G8'%(&U=V(&DHD;==M%$9Q//4:][Z4^&>[<'">D,\
M>77Z\$\8)>BH9)Q3F#:SUAR[RUWC['&B"M>;&V6ZF!H<'PPH&CO_FL-A1#_7
MYA3[_:(@Z5A'Y)[Z0J;!4V.\!WY@N2/?[*N/Y43L)%:1>DH7C_3;R=+XE&ZI
MYSU4&&$R9W42GO3 .9?78]+7>:V4T"(Y"]3UQG=?)<>L&^;#4U1>G:1;MPIU
M-74T5%8H[J^Z!LP8(@[.=-AM=Z#H_)"_F2"E0=>QAB^2W9P-Y.7E6XVWSPGW
M-&R&8_BKJ+TYEF N'E,.\S FBCSIS-)GDC(R !Z8QY9V=ID2AS;3C"++@K.Y
MXBM(6R-S2^J(1KC1VDRH7BN.*8,]  XS>6K"=:<Z?#D;S3L2RN;[1;O&Y]-]
M93P)F.QB4 /7L;IR,)!$^!VGI8B<N<96RN=-^GV1G.0TT6T]J7<-:2*Z&Q6F
MB)U.NHJ7)&^K6[ !^E[2'-$Z)FD2;Q-06(6O0E;I+DUUM&S%>X_5MSE@@SPU
M+YO**:JKJVF5/1^JK]WG#I>1D:]<5X2S >6 K&6A;Q-GXUH/_0T%FXK)RH#Q
M[X!*%E3]\T E?!:NA$1 (=UO;]P!ZNWC=K/HEN_A^U&P;([.KXF7D0_5%P7N
ME*3G&25+ET#L-5+EBV,ZG!K]E?>\K*,V?A0#FF^_.#+;8:TI[4^Z7-JG?/^5
M3-6RA7O89O([2_[('./IBU%5LO'5W(L%4)A ?,1,PLO29H<^06O*Y[,QWU4Y
M"[+=#,\MZ'*>)+^VRA;\-]7LS[_:?UE'_^EC_M<I];<Y&/SQ,5XU[7AQTHY+
M0^T>*N;6J R,+3/I4]@[X7@UY=:\/V:-QUTOPS*'JF\)3]=I4283D.^1FUJ<
M>B^3K$7WN-0,Z#Z',*,0F)@EE.; C_)T>)LJ>\2/62M:-6U;_T!IQP':9UF:
MQHI'V(.W^:_V_-$XR*X87RL_M,/.L"S,Q,%N-0VTHAM0&C#&E"VV$+G]D,@2
M*?OF[I1?+YJ0;7RQT/,)5!*C\3PW$AC5PK,X,BC86)%EE6:A,U+K&EO2(AXU
MDKV(/K!%9ZO0GGK;NINYLK\=$O8F]U$4V][E1<XB>B%5/S]MZI\R"'X6\U=R
MSFL9C"DQQ!7 E!"UKR[O"C^RH[2!EC,+LOK4$+,70ZA%'A5U=HVFICY3!;AY
M:0&5Z?E]*["!\N;8*W0XNV'7M_/I(-@#8YNWY:_$Y<'? L^=W@>F+M;4=I=6
MS1DM9*\E^S/!&"(<^771SG'TQ?-5<EJ^M,.M.5VT#^PW_4V%/6LJZ,C>A(Y
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MP*7C7:^ O+HNT4PVPYCX?Y^^P3?S_PU02P,$%     @ EX!^531S>[F/RP8
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MZ;YXL^A,89F@2^#,Z.2!N"]S]#AD]E@4AG6!%;*MGIG ^&YWBS',.&U4RUQ
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MJL1.'<C6XIVF3Y#5U([S1UG!.?RN9L;SW$D5>O2*7+0 36-#C5&.5 FT(<&
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M-;EO&RZVUT%7U@26/(/&5_1P4J'MI;MA^V!V1<XQ)%A-098_$;XP?X<] 7Y
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M?[02C[G8'2MY@5G2=I0@0 L:7=*/H3UJ_"*VHFTTV5X"M&&9PW(8ZI$LTH"
MMB5TM![@A6?4JUTXBLR7PH7L>2!S[ ?FR>PUJ4,,*7AWN( N@I ]7M/NY)38
MXN@;<W%Z*[7W\JZ6O9R[L-!2;_8VF$)@S;P$>XKYRJ# W5,NTZ/@%6$:6@)B
MB<=D:C-"NK2!^@WQ0?<ZE8A*;O9C,_#/2DQ9NOB#?#T&'W<1?84>BDL^/$Q;
MCYNSIY/JC[WOOHZBP'8L^48Y@VW3%5%F88N;[%@!3%'Q)<808PNWA7Z8]@35
M3EM);4KNHBZ@5.T^0]E"/KXEA2PEFRT)(K>0'NE&D*[AQ(T&S!UBOZ(^^I#0
ME2.G9?!7(QE4-^[ZI#J*(SLE]#8YFOEP<RFIBU&[N)$TP&C774H\A<MNF,0@
M%2XH[*8;%T2PI=2J? Z"3X%)1A-/D;-$^T/-25*!XZ9?Q,^\FL5VQ!>\A3I?
M"0]Q8?4N]*>:*<KGM"RUF-5+G:HR@Q\A7U,6)!J01N2(D,/$GWF7-D&(_M(M
MBWJ)#J("G1'",MSF.CX=U+1,Z4']5:?+,J:(*[OANN2P,DE","E(=3?X&)%0
M^&'C&\(99=2B:()0XJ[3AF?A5M39T.=V,Q1'J)KV/F8Z96/3,=A!TNO:5_'M
MQ'N5O<$^Q!GECS9B"'&EC@O'"(O$/W0*\>:X.>6R_*<91E*V-#O3DU(JWI25
M#*D3;@(Q8YKY2=FM@7SN"/BQZR5.'^2#M8I+SB%JJU$08FO9J;P"Z#+)!<EF
M*)9\130%>A/\0& &VQ;]G+<1-AAPCE,%#W*=PQ;!AZTG<5S&_UY)O886J%]+
MPW$;Q>?%QMA3I*>"Z]CX[)>\A]AYT0;<^9BW 3IL*>;V^E@6#G-Y?B[K%^:]
MMKH!88'2CY)U= ]1G_ 9;0'Q&/\XU0STB7N:,O60%6<&V7/G!I:8)%K7RT23
MK.;]8-XD)6BK@(U:RD2\1I E/"-XP5,1AGCG./>R/G%NL-=&^;)G,1MWH)FE
M#-2ZE0PFO68>AW&.?E_[9NZ !4J<11GR8T(S@7U^,&$R;XKD5M82SEP1.3*7
MM4^0Y'^*<9M7XR*E#W*/SUM,?\?A:=]@=V$!%4XXJEXC".$K5'/P_ERX\EMF
M$ALG_W'P)+,_/]1_'<-7ZNZRE#Y+(K0Z3[?CG]6^$8FP0/%;87)M)[^+[UAE
M@JOD&I;[9AQGZY>4'5S-]"FB^ZGI9Y5QSDTT:<$U*P:-PE<" /ZGEJ(+9[7G
M\[?S[C3OQRWFU-2]SW!E%57U'- PKE:$^*VG'RK;[AQ"<RB^8K6>-IN?J*6(
M6" _I.1Z.I&QJ:@CHQ81H;B9>>$P0NZ:]6&O*.]8MM76=$DMV-T!)(Z'++<8
MDP9 EFMS:(-.SFM0=>:NH3<5EN22X/T%1W.?)C^038=&AO^0RJ"/?6Z*\3"X
M_3/12MA+"[7X$NR&-H< %L@S*29CCM*>*5&82/ADN1ACEKP@[R7Z3KBO!(X^
MY[-1E("^9A\C-$0_L=@M@F*,M#G4QP)2_Z)XJC_-3!%+\8'-EI')H4F!TFLD
M8AA6G$V\[RT0QA$/K[G%'R.NLC 4;M%."2 LQP(2="&2>Y/J78#D>$&WY1>Q
MNA+!DL_,O7O.BW",N5X_! BZRYI4OBGM_,Q3 BN:AS8;J5A ?$59EU=)D<C;
M)?!<2=YM47C"28F]('2/O;"5Q_)"\&5<CS6FO&7<*3/Y_)DL;>V .Z.E?)7S
MBCF4V?+ERK.Y%GD^!68)&\3T?/#N J&%U--SC/=#?')U$S=-3)H9S7-EG=!2
M.[" Z(RBOE)"+I!UE0?F\*472K[&MXBG%%W9;2T0*8,]*3R\8MKJO9RGLCLS
M-W")K"H P-[14A!%3-,;\D992OV*G$52:+5OO*=(4U$3VB1863;%TYYG7NJV
M>@H'I<B9J<LU95&T% ,+,.6USND .KP2D6&9<;!<+],^"E;2F[4CD%G4"4K:
MY*E<GYV[['3!9_ 2,_O"MNQ!;38P6LJN9D..)WJ2!I[#S@#4+W/>1<U5B7)3
M U<5$G*_;WQ2\ '*7$:4YT$?F+DI[D'/:^<UB 48'=5FZ(.H[(J]J+%T9&D?
MJC.249R,*@XH4X:ARC?"Y,=1QY:ME86C;IFY%ZQ#;]12VDJ*X5#YC)R(/%ON
M1LI-ZR^I)!8??%X40/@:,%WA3<!M!&1-A'6V=_)="*O-W&7-A.G:>0FP %VF
M^<HF()W+ EAF:=:JHXRF@YZ%,73<3EK!3AK-C95_E/K"5ICG2!TS<\\_0-FL
MI>9JJ6D:3_$ HD8M%IY.E:H,^"\.="B+>!MV&LM)G/-N3GDWV1]L]TO=.?O-
MO/*643\#$_^;G59>H5#:(#Q*O\@K4VV+X_)]#VQ7_)3.WE$DNR4^L.%^WAH1
MV7:=)%)XP\Q?.IWZXP^UH\*YK QA4$HOZ4IY7/2@Z,S^+XH8Y>(=_K(-!1LV
MT*5Y\JJE[\5#>2 S?\F&ORF]\B=U>/B1TK75*U-$1?B*WOVJ@D_J+O^Q_,&2
M;QL"I0N*!Y:>$ ?G,<V\Q85_18@!M8^EI6;=;>Y-3XZMK^_*R-I=6?TT$^N3
MISF4Q5JK4R8 0:T[U>=!1PVZRMRST_Y0:]L70(*RCC>=A#!C>74*R-/=]*J*
MG!B?G KCG#=.S]6VN1#K@5*'7/XDF]*%T,'?%/IKZUODKZR,1B6R('9K;2(R
M<O?:RB3D;I^597W(%*>6DA&DV+I=U8PLF@12K4.I_E":EAXB/\N@(8M0%W.L
M9C/^;>@IC2L^P?ND6HR?Z012E>#>6)<4Q^!G36HIPN >_*%V-O<P73-+ZD'T
MNS'[J[?0ZD+W5*RG5GN#2\F4-TZ.Q0**PII;Y$Q=->FM\ANQ_C>%>M/T2S@I
M<U==-=\CQJ@JBRL)U2V/X=AZ+RW1L,T=?Q45L)JM<86+67<,%RI4Q M_*&53
MLNQ1IDF=>5Y+]+'*DY*\D.ZR6M& USW5)R'>\4+A+2'<&JU<PR\S#"R $M_^
MH0XW/E4]S+A:RRX*BN96;E:<#B&76<DKO*I4!V29CO)"__Q[U@D*I)!E")/G
MD*;\H=8URJJV99RK7541%DW4'%4?#(E3XU7/O;C%U<7]CD(E1_G>.J?@I##/
ML% V2%K^FP+5#FY/O15?VEN5UK1W_I$-Z4J_BZTO,D1ND":=3-R*T'KGK-4S
MQ?5/,]L H'(%&/&'*A[(!6?&]_?4@QE[W3KUP2-^;UO($ \W<4,.I&<%JQ:3
ML]#"HG8 T@E,K7@*??R'4O6[(=KB-=W:)_M>V_9F^$^_R\U+X)_=J/5Z"/,5
MBNIW"%>+].I;"'U 5781M>8/)3KZ$C\:C^VRQ7T)?]QV&.?E5]YX 3OLEE!;
MC16OD%?1L5R+VBH'[+#.PM(OV($_5$[O!;I)?-010^J)\-[6K906/TA#.7G4
M+;@FFQR\0E&YC>QG\5)32^;J\$KVX*;^H8)[OO*2XOT[%W"&PAM: MF[_1+K
MRUF+W#RK4YF1*\HU"YFD6<LJ]C((.F^+G^&"_E ./4'2B_'N'3'B.^$US1C1
M9+_8NK,"EIM[%9??MZ*EPE5@..M0^6K.0MUM14TX^A]J1O?%PD/QF]N'%7/#
MZYM&9*_\XNIFY;NYN55>R&M9T5J.DL)FD<H".&ZZK,)&7,=O*NM7=T[YNGCO
M]J#2XO#.)F_5<K^4VMRB%+>ME2L*@U><*SLEWSJK7,WAA.AV*-_CKOZFKC5G
MX5(U@U- 5]+7U_: K3):\V00OZS5^*J<%)#J\/-<.M@JQ !:",&O@\,*<WK-
M=>&PG.HKK1GAN;?Z,S-O0+?5^($\H:W2'=D<F#,.#+X ZTX^GC,%'AST/-<9
M?MDE";H0L67:&6@?O'KD7AJ1,/]H2885/K&J.3,/UR<>!@$X/^R\[$CLLR0!
MN $KWW4-\A#K[YR:<P3S>FIOKB=FT:4Y*<_8_CTC:6PF5_,J8P[]C<@M4T*#
MH.M 4ZB.B>'9.13]P&%P$^G>6BP$1+P^Y3+D/<'A ORP,"^C>V.JAWBX8G?:
M9:&[H"8CDC>""LF\QQ$F+ 5%LG@!9[)+&.5.I>!M]-E3IH OD<O/VR;32PJ.
M/$]Q+5I<KIMZMD##CTX_D!^,G)?Q1+(R?G)6DM!]YWU0"T_M>"?;G7/&+#[[
M/FW*.8ND]MI+G3</)U;2U<]3OI:MXOFED8H?(V9GS%8\BK/-5,K6[IR3]43R
MVM$-M$\\T_1:MA6U[NRVI 6=%IW3DH=:=-3_!U5W'1?5\O<!?!5$+, $5$)1
M4$H$I!5%P@+I;EBVN[N[=]EDZ580,1"[&_7:K=?N[GZ\LO>^GM__Y_TZAYD]
M,_/YSAP=#\O:>%!="K^TWD1=@(1V'*G*0WUN0:Q&8Y8W' M9AS'6J<>#L!1Q
MY>GMH%U'RG>P(17[&.T5T&L[JE16>.J6<@H"<6W#F<I.%+C[U:K3Z T=Z2'3
MT<\:7XX?C_DDGGNBD'(?)MO&H%8C5K?NISY$/E.-I('1>$H.[27F:^56.AW'
M6G6.,17_<L$=QE]$SW'1K&IBY+$GI,?$N($\LH9XOZ6-$D3B*9Y3#I%GDQ.H
M)>03%7W47Q3JRJNT%NKTX _TE53U6!BCG]IU%$CT9]_?LH'XD"UJGDG2LP/E
M./)RUF/B6_('UO9R :6795IQAEK(P@6/ICY@+1TS0 ]C7CI\'M\NHVX>1X!)
MPQK)1#_Q6YD=\;[H$*&%M$&XMZR,3!;\E7*1$L1_%11"L?+#Q[A3'W-)AXIP
M)8;)_4:\O^YC@SW^M>:JQ$C8ICJ%!Q(EBCNE*T@U\J#D%V1O:7T@G(R52!UU
ME"&![N <;%'3@8V5N,#ZR];3N+>66V(P?H_Q/6X5P:@/*UE-Q&LW),\@A:ME
M ;M),!75<3;YIH!]( "C6L_LJ\%6= [5G<+YM'X1@7$OF\*P)?@SUIYB!J'?
M3$R"$B&&LP&!1)$^;_0ALJM@Z7XD^O- ZH8VS-'^JY:O6$[O0J$2E]BEPXCP
MOFVI1;L)$YODB:<)Q^OW^6\@'+7XC":3B(()^UZC:_=';'#%E.ZRLV1BQPQ(
M!)>P>_H]T1=QYIZ (D\\O\LQ,980V^[B[T_PL7)'QQ(_\N_O1')KH=9U"[E1
M<++Q&><+TI]/X9Q%[45]YVS'I!:B.8/8J\O9G)OXE/GV7 XA:U0<;R=1L6,-
M>S=^<[<+6T%0&#:S@<1<WEKV:I(K\@$[@72S ,U.)W<DZ-AD2N&\8/9WRC'[
M8]SQU'/;9[*<F*<Z#S"_,+?I3<S;3"MW#O,*4X@XP[S!Y.53F)^9BF4[6'Y,
MK1^2I632[2O9&J9VVRY&K?AB1S%#*'I9Z\2@"W^RCS,XPJEP-:-1L":O@C'$
M-RT=8OSB??3M8B;R^/9C6"LX%P80] +MG?9Q]'1-E'8O/5W%8O'I)8IC,!*=
M+0_*!=/W2(_&_Z2_EZCG_F*X21SL]C 7<,5;<VB5]>-;W]%*+:V:+EJIR9-)
MH"'U=5 *3:^+RY'2SF@\XY/I8U2$N6"ZLPI@QV0LXQ9O(5 ;.E?^3LGU;;[J
M751STT6&E-I9+X8T42]8"-FG:9.,>Y?TT);HC\QY3O.O];9;26=PHS</4<?U
M-[7D4\?W'E%]IOSJ[J,?H-JWF\$WJ N;;V9/IU(:=BQQI[9:[\]A4:&F3#M/
MVDWNS,W%E,Y=WLWG*)W;3*I<BF+3'OH4"J_W"3B:TM5MS))37G8L6VRD3F^E
MSQE'.64J&_F=5LJU[[DBVPVY9OTB9<-VRGY(F @T99^X&^58 Q&]09LRGHLJ
ML7-B'XN\<8)9_:(/^+3?&99#FK/^G70D#F@=+?Z,SY&^%(\GA)*WB^*)CD",
M4$&\FS%:Z$#:%3M1L(],]OXHA)*/_DY2>MK4=:_%4/IURT41C?Y%<E5H8HPC
MU0NN,6958P3AC.3T^?Q!!B$F@X]EF+US^.\9ZM^9Z"%3VGU6^%%8:&X3.@NV
MB=6")0( 4<87\K.J*+P7O(-KBWD4WLKH#EX4]Y[7$9Z)^WO]P$6Q 5WM@H.J
MZR83_V^E5,3CNRIF$RIY(-E )8I[25J=!N,2)*NB[G!#Q4BO4&Z-^/=Z@Q/,
M!G2NYU\V,XT&WE<C4\CAA>B+\2@N6Q=6(>>\T82DKN,(5>2H)$Z2,M-S*R=?
M<?/WK.?-!G3<Y<]L#34<XR4UB06]7&)]#^[W;&0Y47Z($VGR306P3^G?1AYE
M$VMW>&:PX=J\X;FR8Q5/U>MH\.'NZ=[!_\QYU.&+O</Q;9&73V(;&W/79+&C
MK5<C(UFWZ[9Z?&9UUB8.J_9[O*!MT_5MW/+-8?Q2#GW#,VP<NWM=4QF=[=+Q
M:O5E5E\;->(4*[^9XM' FE [>E@U=.@](6FJ"SI?F _KI88"OX <4MLAH<4*
MY4;4QY7.BGH,/NR2P@6[R5VD;,%^_-WRTZB[ZI_K:K&%JFF:8[A4UA2U'SX,
M\5790YA2=$B13_BR(D>>1+P:-D_62Y*Z_5  2+S?;=C,]*IWTTZFI2E=U)4T
M!G.6\@BM$P%0Y-.N%/XMGT!W2U'*1M#+0IG2*KK&C2FCT^&_G["0#;"ZJ[?Q
M ^0_5.-XF^D?%4S>(O@8N0MWL."K]!(W/_FTY#QWS,('DA#.*;>)TDF<J\-_
M5YVOBJ\(E ,4=^4NM,_R4ND3F*/THV1O09!DJWA3\DSQ'M&-A05B5U&ZZT;Q
M$5'^L+)D*IL,&;)XA4.MB18I8VH/01=)IZA?YY>*+ZJ2DQ"B"XHW(2=%\Q6I
MKBM%/?)1P\K<IGC5R)6*Y(7U(52*])1E*X0J*34MSNL5SS*,3;PHFEE;%%(J
MS-.]G_9+N$FEL*F9"G#7D.2#[$K[$\H-:6++*? -\?'&;7F31.)ZY\2E0EG=
MR@4/!;LM\Z?M$=Q150PKTVZ%XZ9<"5]&V_"&DBNYL3X:G";.[%3G:D0.;;7+
M+PKM6SXN$ JB&CVFP00K5+8UMOI*PQWP$/>R=0U4@;MM&0D/KSID?(4XG"DR
MC$.MC']>*T3W!ZS2/<9L=H$;;F$6_*,8?ZF7UBLP5=P5=2[8#%R<Z2 NILK7
MT(J?G?&Z=H P/AZH\R<\\3^O)1"I+E&U'PAOA^^E,EEG4:YR".8=U$E8AA%!
M3:TLUV=1]1F+=5#JDR4G-7=H2_T+-#-I&!<'W0+:W&&E/&,9XBYF:TU(SG4,
MWQ#$H52H:R=S?--IVDCVTR7^ZLWL _-OJ>ZRNYW/:;3L=38%,&^1=K&.& LD
MV]%;]![BH^5;=*-%M]9>TLP4C5]<IVH24N>3E/N%2YQ[U=,$MNR@R#$=T:6P
M7 UDS4GTB-HX]=+RL5HOY8ZU8>HP1?GBN<I&.73^;,6 O,19IMPGT0PK^1&3
M6]TGID5_QOP9Q=5)C!?*J)IR_?:T!A5!]R:N77%7>VK>&?D5[6%GB*)>"K.I
M'*.Y;2]SMCZS93D*H+-KU)5^5)^RODGS4-ZP7(CS5:PUWY@'DT>9ICNOEO=(
M;2. ?(1Q<>\AQL':]^MN(#5:2V=7*5>=VZ9)W:(L:LF(/2,_TO1AGI>LKVZ6
M\TS9%VGDL.))NB>#(XEQ[1\A?X.GMGK"R/EWF\CPGRMD#4Y(;,0FZR+4MMFE
M=??0A8[Y]7UH;YN:U/D6#2+<:KN$20'U-C_"!N9S&OUPTU:$6-?C?D: + ?Q
M)V<'6%((GH[L.CQAX;#B&CH,9# AOE5,;@'-;M*1'^2]JC]'69RRL2Z;TA0!
M,(,H/V<],PU1ISK6FT'43IL"M">PT_'JEA@VH*:L,8TUD)=FE;.X*3,M;BS(
M(IEI/JML5K.1P,IWW&"4L73#BE/=-E><@GO=/$=$!FYMB!/VYC;6401OD@VF
MKX+B13.,SH*1LPH-"8(ICKOTMWEGAQ7[2NMJ=1D.W)2F<@<&UU<H3N9.M9CD
MJN3)IDDR<?@QPVCIFUD!^CFR2L>AVG+!.YM"M*A-(NRG1K/A=/6@M4L_,J?>
M?$V7FM1AS-"\#2?IXS1%LZ;6>JH?.][5.0E'VM24EBE-Y[$'&V<T;*]F6EVM
MB)P,<Z E*BG=H#=UA+O6*DT5WD=T*#W+\;$6('2P52K.-N_J+L8R&K9U/*\.
MKNMH"\W^:NIM;D\::9C0%!1V5?>]@>YMUEXQC'6\IXG]]U[$+9OW@UB0#QNC
M(([%[)X'4'F:6_<N^,@EHHZ[B.*@Q6W/D#"W[>U&)'R$I&4=^E]5N.DO5";D
M1-\\M$=QWOH.])?4+UW9F)M+T.VEV%U!,:TK<5"W>ZV=N.01/YLB";;1ACB^
MGTY\#"GOO4*:43QR70JI/+6IXQGIX))YK<_)04$NS4?)?+>7S4_(V2-+Z[]0
M;:,HH6>C![,$_*2'P9Q61.IZQ[B9&MY>RSBX^&B+F7$D\*\F*..LVZ.F0L:N
MD3UU7YE]-I6XX;W@#IBU/E\07#2J\PQ?M&9;&X+W;C&VN9JG"E0WAO)@;E<;
M/O'VCGQAB>5\&U;X^QLF*Z3@>>L(<FQA7\<]6?Z:LE:*-'^Q9Q-88@DL:W"3
M@-W.U0](>'8^I@&NETW5]@+UBT$/N_?K3A0B.WRTR]>XM?2J;\5=:+2H7@:&
MU,>J1[M=L^J5!7:Y1B@WP:9*>B[7CP3U=P?5Q1:&M@O-N:NOM#@86^-J&YX;
MM@8\L^H,1+>==4?4V^TDABQNM4T%]S#;74%;NO:TNA<&MWUO^FOU8'-)P_$X
M6L/\^G<!S^KVU.G<SEK>JH_9]>CE7/JP@H;NM:O94G)ZYU*P4_J];08(>KG/
MEE'0(^'^&Q_#WOMX]2V!MSC-ZE\!NP< --KC-@XKR(L]BY&A)6=V1".OI'\8
M2$!9ER=M(J&1X45]P9B%/KC>51BKT]8-C]$/ 8#Z?>3Y-G5JUR-"=4G]X#4"
M._WBEC.$P>6^&U\0W<,S>M5$NH]FO9BXP7EFSS&B+P!@E=!GVU373BP=5E*Q
MK8;NF2[:7$)[DO"VCT2[%1[4,X7VVD?7_9;VV1FT[B[M"@!0!V8UVQ1UQT(>
MJV31@ _W6GKNIJG<U0E;-@1P+H=/6;>-8_&I[1)P&IR[NT,X&P  "YP-L*FT
M[7'2G26>6V=*CJ<G]@/$-Q(:>B>(7<*^=VM$6I_ZSAC1/N>'G>N%O]=X9O5_
M:OX@2_.S9,J6%/6Q]/B-;BIN0FW/#"4\[$U7G>*.3V='J#+)979'@?0) &"Z
M_9^:L.V=N:#$=7.#\6%Z8E^!(2=!NSY5[QAVO_-H[8"/M;U4-^02WUX@_?Y;
MK?A7@;]N4S4]*_'9/+EQ97K&AJWU] 3#NCKKW+ GG>/JD#[];;6FV2ZY;3S9
M> # N.E?=2H=CJA)W/X(&0(FM)]'78&JU7]CJN"U-"?L;:2B.@>_%LU8 R>T
M8=,7]A*[<9<F'"4OQ V<+(:\Q&0/YL,>84%M",0 CJ1J1('P0LH]C /!6+4$
M:R"VKZ[ ?275A?3C;Y!SQC\DXDD/CHM!Q^GE QK(#7IQRQW827J9TA=AIC/(
M&E0N?5WE)/0O^JU5!5@4PW[!$5P PW[\+/Q+.N_H3N!=4?J6 ^"QPO3F&=!Q
M@G*Y!?:6+R+Y(T[QSI=?1\EY"U9F8T9Q%<%/,&;.LW%$7!U[\(A;=;(V?//\
M&KHZNY$'5BB9,F<H3[Z3<!F.E+F6;4(NE[2L*$<=$"\+]D0'B+S&WL>2^9F'
M#E<!ZF?UWP3&6] -4: <XU;)"4B6?BR^ Y:B%92V(V:IPU*XR [E_" (\J'\
M\%@PAB\:<W"@XD?7Y(T7JI>V&>O]:W*:OHIW@K/K8;AN:*9E<LDQ>)CA5_)1
M1']M=N YQ$GMN[$CT=N%APZ\J(C;/&;CA"K6AD/6+*!BW1K1=9"@_3KV!(3?
M/%C\"X9H&)4\!_[4\B-P+?RJJ7A,'WJ*4'X 6KYS]\\^0>77P4=UFZH_;]:)
MYM;<W9"&=05?Z\85ET /M"])DL$C6Y8$'($#K%UC$.A)PK(]?7@EL+S7GL %
M[;' B1C(*^$>4B'L!]:9G(#X5EQ("42]3,JB.F-V!MA1;^/<1[,9TW",W<G8
MQ:C7ZY_@:C"QYD(\ 8L6#!"(.!/&B8C#[RZ"DC"$VXE$<@GQOG\4911)[?"!
M5D2>LG,?.I@*6[<$@Z4.&,]C+=0O_'C< "T!M1]_AJ8O3"3<ISU?CB->HH?.
MSR>ET>,=J)1+=/B.^<@2_HDN"VH3/\RP$/V<9^!>QL[@_D22<6NY[ (_/)GK
ME" @(#F-\S2$;9Q@!V>R@+UP< /\K&I^IQ\R5'&P=B^*+D_GP-&#TMN(9,PG
M"3]_.BY<G+FL"Q\DBO6[A4\44D9M(57SX-O(,(/9TOX>_LN(T*F0J7H?]G*4
M1GL-'H*^JN[+FX^=IMRV]"YNLF*2WQ+L-WGN*!#Q%J]S@ NM:YO2]AWNV#Q'
MJT5D-XQBK41:+ ]A*:AGQB^YY9A@?>[2)5@O793O+LPMK<\H/](J'GWK2<CM
M#<:V); UZQYI#L,U'9^91,295@<H"36[L2*G%8VT1L9W8$K,[WQ7HI\:[MJ_
M)S7S"K;F0BJWSVD=A![?LDWC _O9]YEQ!+%@_1+(&22UXVV.,^IP*RC>#;VA
M><+<H^BI9IG]"=(CWN*-:/JOZIZF5(8'R$,UD9$-R:,;&%88"/R3\08!S$YD
MYJ*REDQD7L0XSP&PUF-]1WSB@/ C^K*H9Y%-C6$T/_1DQ6T:%0.F$6@7L=V@
M=_08W+VL+'H?8<KB*$8@T<-G.>,XL7'$ &L#&;/!@WR1K*G_FY)*<9?OH0Q0
M--355%\JH.8^U4HE9M;0O*@OXM"T>MJ:V5;Z2%KV" 8S@)[7,TARX8*L.)*)
M.U<629[&.4/^2C9PL, -%#^.;T8A91?[0:R*&L-NG?606LW.';&:<9:U8WT-
MP2A?6N=-])<ME3P@;I'.)?63XB6 :BOILNA9>@V9(?P6<Y3\51@P:R7YL6!H
MA#?3C7UPW5H\Q!!J&4.PJR6+SQ(T6@.QC>BC[JYJ)NY77EJK)54I(F/<2;=E
M7[SWDDRR < /9@Y[?3<:1VY:8)Z+=ZW?(WJ*;ZV;1MA/6&0"5@X1KNGOIETG
MLG7]T5+B,^T\[PPB3CT$N,T4L8U=)[#[UT6;<+C*SFFB -SCUA[\+SRV*;K2
MB>!6/SDM@'#40H[Z00PTNWB](E!KWP..,C>RA5W%V,0M^<;7V+L;I4(5KJBG
M$E^(N]P558'#$]LXJ>V$V<T;H^@$7J/0BX3OTB<#MC#/LBDM+,'A:G==DV!:
MC81GY%O!![#Q_!3HV;)!_CCXB=5O>&^1/1$<OC=ZQ4R@H.*?>9:]AKBCV<0;
M1/"TG;PDU!@NF_L8C< LXC9B]I0>Y,)P]JM=N87XV$7[N Q"U(QC/!2AYI_9
M@;J]2<:Y2KRHJ>&(23)."2>6'(">Q+$C[RO9Q[Y%R5D5Q;Y,N;]H%/L==>V,
M2(Z%&OB/8L8TUK#=V7/58:R;[-EL5U8GVPXUF45AW2J^SJIF'5C)9M6P>L/)
M+":K=OH)UAV6+7$TQ#(W2ABJ.4R&^ QK-#-=] MQGQD@\BBZQ/04KEJA888*
MS&&;F F""=.CF06"\<.J/I&AUKY4SF$ -7KF6$:,VAG^EN&N)!5^8#C)/Z=<
M9KC+^L-F,N9(;[H?I7^3U@PK*X.^S@I2%-"%%@AC,3W/% SWI8?K[Q>&TX-U
MQU/"Z5':L:'M] "-KSN&=E3Y;Z)_0/O6_DX^0+O1FD-7TCJ;8# 2C5*/+9#0
M,);CR2H:SW0PU(N&,'YQ]Z8>4O^P*0:-U=<HCZ95]B!IWVFSNJY";U'OM\?E
M_Z2>:_%(=J?^W31]81_U2'VCVR#EK7K;L*H]JQI?I16^5=0#WY!>RRE@;U"C
M3 +URYTAW0F?NGRQU!]Q)Y@HG8]*F7Q,7H>:\J>_EM:Z*(+@5&& [!/B)\E)
M^@ %KCDI>8_>EU,@F8L=EZ 1ZW#Q0;?%#+SGY$HI ]?S)V4/Z!;*R@@I@IG2
M5*(3T4VR@G@(>$%<34)G,T2-Y.G++HLFD[<'K12^I'A-MA.SR);A)]0&2@89
MW_CCQ)N8<_!O1?N9BZJ?"N\R8[.ZA<',E&7!@FYF3N!) 9&9/6F[L(EI2QR:
M$/$:X1#/690ES,-]%\($!ZL^"+0"C\P/_*M\SE(KOY@_/K"([\W;.XG$?\P3
MVJH'>:)8U1YNMG"5<A-NN:!<0:J:S1?(_3+G\(:DK^/?\A*E@(!SW!^2ADE>
M/) XQE8'Z!)6FK9R+ *RT14KX$OTT94@7K<N.0/!?:N1QN=P@>J$ !3GF]IC
MX@.NI]S=IKP%NYKW<,;PKS8:,$]X=^IG5 QQWUMDZ1>YD:;")=LYFPSO_5]S
M8@S)$S=Q)LIL.\7*/8*D=9_81CZP*P]3Q:ML3ZJ(YU:VS$K/YQ@;34MR.6,;
M@/YU;&7=HHD8=I+LY+ 2T4WU55.I$(,)6 !/K+T'(A??T55#L&M6:IUAJ3$1
M&F_XA[E7-5'($>/B='H$_D]_)0LO&G[ I)0S>B_$2)A9!T&"BI,TUU%[5^]2
MTS .T7M4'*S?7+**B#TV+ECCADT:OI?06[\"=YW\4B?&MT//::X2JHMHZ@RB
MY^KQR@_$"]'!BJ\D_%PGQ072SG$SE<=(C&$E6*';2)]&^JGY3E\#&5*7T'&%
M'<IK=..JU0HY?5^41EY+?S#'*L^G/QPW0KZ+87LK^2AM";^ Y*_NYX\&?U:Y
M\9H+CB@LO(4KN^3+N,>C1LDRN*(Y4=*?7-#8%](WG)>V.L .38K\&!&KZI*]
M L<KG:7O"]SD$LFSE0ZR8/&/2*MTKKC(YYEDGQ@V]JH$))QB4[YJO#Z1\$9Y
M4_<:M$L1JZW,%\JZU(=7P*2I*G#D%$F"TN33(-ZD/#+VB-A#M-)6!^A77:H_
M32 J$ZRC0#%RH_E5OKWTHW$HY:E$9Y@>H1++]3"?<-&3VJEC!T0NHB4V5:BJ
M[N 3IBE.MQ75G)2[-A_-TTA!C0M2^.)/]9D1<:('5O3LEZ)H8\-8O3!99*M]
M4=4M[95HY.0FWVI]^?KZES5-F=YUC\#2A'R+)S0MY*[I)^S@3(YY/SS>[K:I
M&;[G'\7ZB_*]>1F4AFAJ&(+=+0^WLA#+,K9;2I#ZA!$F-NI<2*MQ%?K"S!KC
M&<QH>V^#"\:VVTZ!-;9@\^$OZQ-PL\KJ+>]Q#S-FF<[B>Y9Q#6\)X)!$?3_A
MY\P(PRC"-_M,W6%2ZK B'VIPH7K 0^MV4BM*3YG)5&LZW9A/O;'TN9Y#\UAP
MOC:.MG;&IUH0;:$]7K./OL:F9ECW<E[!Q!8L9WNIIVD1A[CVF&$R)V@IN#:<
M_7E!M?85^\:,K=H/["OV2M4/=OVP(@GK=DAN0[^:<9*H$ITQ1$Q8&Z,?(^J-
MOZN;+1J]P%VS7=@_0Z6I%TVS[U(2__DO3OZHB9:;FLM0MJE!?:ADJB%?)4S;
M41N@7!&/T"Y5I 4?4I^0OY\A5 /E;?9'%?-YL;;JP69+DOD9=+7)P<0KOJG?
M8#B9AM-5Z,?'>VJ NDO!5:IONG,S0E1RS6+[B_*9/-N;0H29+[4$0$<:%4VT
M8IG>KZ$X;:9VR)JXY)SZ4)U[L)]JM?GUC-'*4]ID^RNR3%[RL$(Z]$97Z"KM
MUI54:7-B.K<!>2F0]EA07E1JJP?XDU]$BRMTQB3_-A:D\W=J.X^L'%8(7H\+
M)+YB1_<,J"K[1T<R[$[*TM8FA']49',Y,LLOOFDA:L8D3$L04OH[M07A(#;E
MNHZ#WEP1W:G#X+)-;5NPD<FW6NQP(R)?-&['[?";T8#%!T_2-DW&F0  ?1,Y
M9%C!F[N>DAW+^SKLR%E9/UH#R=9D:!.5_"I2TA!&6>9[TWJ# I]D; @E?P
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M!9!SFDW!.FBP9NZT7.A4A6V]H:TI3VU[QP^N+&D!X;]5SV_D5U\%7K):LZZ
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M\%%.#W?2>6^NC*MF<COW'F=XLW'.9\YYU5*T(VW+ K4^"Z809-*S-\N%<5_
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M&%^NXE,*,U JFPVI"567>CM3P[TE6XWNAW5*UJV[EP(6N"W\KZUIKT)68D\
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MPG^D#^<.1E^)2H/&Q=.\3N;?2?IN+8(9 ]9MOP;K2'=89HTZF+%V7L\RL?W
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M@';.>ROTO.+LYN0OZ1$0-$ 28Y>[.T/3;SJO,A/LN =Z!\0V+,NO!MNO/U5
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M+6V45<BE"DXQN02M+"B%E&64IU3$5T97152'U836AM:%U4<T1#?&-Z4V9[5
M6]%MU'9A1T5G>]=(]_F>>[T?^E<,[#BP[V#X8.XAUE##\/&1^X=5CNP<\SR:
M>8QUO.W$Y/C[D^M/.9Q..4,]VW3N[/G7DVLO6EV*NHRX(K_:=^WB]9=3:M/;
M;MK-!-U*NXVXP[JKO-?\3__](P]./;SPZ/+C*T\N/3W_;/SY\(N.E^6O6*_S
MW\2]37J7^#YF-NB#\T>C3UJ?/G^^\:5_3O U_9OYMX_?>W]D_=3\V?\K^-?]
MW[#Y[__-)8*E*]2BEI&6%Z^H56_0J%XI6T5=7; F=6V0IKW6SG4KUKW3OK%^
M9$.U#FTC91-A,T(W:TOT5O=M)MMU=BS:\6+GU5V'=S?IB?6Q>X &(7L=#/6-
MUAK]-'YA,F4Z;M9K7F7!M\18@:RC;;QLK>QVV6ON4]GWWN&!X]7]XTX'G)M<
ME*Y<-X)[OD>Z9[27O[>3CX7O;C\=?PW_WP$? I\%W0Z^%#(1.A36&5X;H?BS
M#[#1>3&IL>%QGO&V"7L2-R:M2/J6_#+E=NIYP.&TCO3R# X0G9F5%07RR+8
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M5M:'+*S.EXA1:_ERD01U!I,D:$6W9?[BG<,<BCC'>8E]X3K.7H7/,04S]8B
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M>\V$,ER!$$TID-('1)%T1)R>IR/6%GQ/K!'(>8T!#-X2SCZ'5^Q<9I\1AC%
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M%%Z#8Q%$0+2'/\%CC9_Z?6#7.E/M9:C)9"D:@]ST+;1^\(7&MD  'E+T)G6
MNZ0K J:#%X3>CI[@'_3QX?FP7Y>I+QTRM.75_ --:OHL_ ;JZPC49V":\4/^
M$]!;6YBT$=RDZ/'?!6:):QWG@@V\Z8<*H!/#=KUFR*I_=HTC*.YL%'J BUNG
M4UTY-^OI^1&<<\;KB;LYES7C_/'@!.D1AW=@$G_2P7\@\H'&WM7@M=T&DPAT
M&5PN$'+ZNK(I.@ZNI2_O#*>T]D-B!H>M^^GORMDKKW6X#L[G7]M#4_3BPSOF
MRYX25/JOTECB)=YJ\57R/-+_1*64JMSMPJG4#PG+^*UTD]]$7B)3;F_&I@+_
M[N;(0QG:=@=I#>.E?K)D(3,$\Q2U,7N)7X31+(\<+?\GZTY\!:\?J/858A2V
MP)Z#AG &=S&EW[AGVR9)\KD!VA^B!_ (ZB#$X!CB3($/]"W[/'\2="#N''8)
MDOBN0GNA,OOMB!K:,E(B.2X9USHFWBRJU1P5GA)Z(-8"//\%83G?CS>2/86W
M')/'N:%_T#R?O<@WQ,'>F_L-OCX<+SZGM6ZY+@I1?5;O%=Q4'.;.Y\ME<KP#
MKT!2DN6/98@28AO09,$JGUPD"SMEOY9+0CR&MHMGUT4UWQ<*37&J4X*UALVP
M(V],NQ*7@XVHQN_0H#VR![&6R"YQA\\B[DV!F_UT[CBT<J=*1&U+;5XJ^-+,
M5_[A2^HE4!DOW 14#6*V^K(=TU%;=7C,0<15]MW[!K=(5&+W&6[$@,'/H@G]
MD4TT@:"K1;F%O\R\!SR$G6LT5RU$!VJ4F1!R2%\<LX-[6373NXD[39)E]PQ.
MYN4-"H2]>]8U?A=X[:Q7'.$=Z=D)VF(5;?)*&1K?6):Y&,DU.<=,Y\*:8][E
M\#'93+M;\ +^FJ[MQD.XO346>GO"#$F\YB0QB759!9.:REXI0BCSTN_))E [
MHI:+1^A%7M7" B;)=@I_(O"Z4VT Z;")H!M/?R:6J]L8VUC+E86,NV7><B<F
MFAXD^<V*B=2(C@ .7I$"E!UL.Y7GSC%V'-6'P [5H.8&=$ TJ.)"64QO10*T
MO)0HLP7_W6:4S 2?1,X7/@(?>O[FCX+?;*=A(&33?DUG+QPR0NKC KZP5<GD
M%S(RY)&\A)(VJ0>6GO9%;(>61]0)%R-LSX/\B5R9[73T'JQN^ZRU5\483*I+
MBAV"_0JYC$ GRXHD:/%;28+(G)8C2A=<BW 7;.-]\!3P=J#?;&>@J=S;;78:
M8O4]_1/5<H.+8*;\NA9/VR7M5W44^XJ;Y8^W7A+V2%>%7^3O$P5Y)F%7^5ZV
M,Y#[R&\SJ'[0G*+W4,KK'_&WRZ-JHFASI&L-M45MXF6:-UNW"6V5+N$<OKLT
MV7,#EB7TMYV)@.B7UB]J<E>KKE-IU5;!.RD;:_I 94NZZK84K169C8.I3P2'
M-3_#G7B7%6L])Z._Q-/^HYRP,ZU:M<7.NSI?Q?7>OWE1,GY'&>6G)+[Y3&&?
M*+3.)E4JR#.0PE[Q8)718PS=(Q';SN2^Y=%JSS?/Q&7(6^N'\<W0MQHQX0WA
MB)%$BLYSTZ603R8KU194?$BT_ ;=WZU$0F!F6S<)'@"/:ST:/]*:Y39UG?0Y
M$-[$IDL)OH8<ADWN3FTPXVGR&M5*YMG@M[([K'-N06(>>XKU6<$T#E1C;#@-
M'I.5U<K 4O!D=0ZX'B_3QX+C<I=IO#E_DIJ4EN#R8*WT,QCNMDHT"*JLW_$C
MP1^FA_6#_!/2VAH.;Q?GI3$#VXV[IHM"K^:0U)'HG*2UBA!D6["_U)K;LNF'
M\!/\P^8O7B.\Q;2^[J)\2/+ 5"?]QG$P0))(W$(M2=2<?4]5+IR4V"6G\^E!
M'R6EV-U-]X6QZ&8;.]X\KK :JYNF'Y $5S_4AK*E^A.J"U4<S2[%ENPTY:#T
M3F*D;+>X)&A8/"IXMNFT8)@7:1.(&1"]\6<MHUXN/E>]M::*O5CO:K2M_*-9
MJ;V:=4>Y6H4DO)!ME-L& 6('\>Y-0X+- @N;%&P3RC%*:N>UA8JW&]\VEP+U
MNN/UB95BM=FT+(ND:-<]3I!)CZB:@H)$QV41FYKX5X7';/+0!UB@T:OF6.\M
MT1]C?:<OL%E7U1I8::F.;%B6M5P17OTI(5J:JST1-%=$4' WB?DR\3J;*K0!
MNZ=XTRW#349VM7/PP=35+5*"K&1%0S7Q8_JM&A$9C#$8TJB;_<ZHO]&7.R/R
M0F:\)2PR F,*K,M$O854M EI(90SS7S:V>+3]1B=GBXR$1B),6GZ4&:R7ZWJ
M+8OH+)"5 9<L+PD'."6*%9T,#H/[U$SDV%)2F\K9GXOCZBK8_Z:OJ<[A+(J9
MK OB;/>K5'[G##J+I0)PD]4BP5/PBKRZ(P=[QTULS4)_D/L:L]%51<=J<Y&"
M;69C(?=B=+=V"S?.ST>Y"K[F+)(<A E620(/>(7\KW:J=!M\I(4A/DI>T0"*
M HI<:A#!^6V>!H1/B$[7(#PKOSF*=/3J?]2<_P:47\_UD\G:CFKVP!'-IU4(
MJ:7^K"*F<+_IO&Q%VB7]>?&'Z,7J(\)SOJ_E9GZSLT1,Q"JL>OGK$&^98YNE
MZ0?TL-G9N)KD7^^BLR_,,+FJ7=, O;O".^J.VE'JZWM=/DFTR5DN>L9?:769
MMQN=)[UNWM^\#.II.EFO)$VIVVVZ7+BDNDG_(\U3UZ#9&%6KZE9D^_;)M!*>
MLT($" Q6;WCYZ'&IVDSLG ^5-1%;KQ$/U*4W!A1<J/:KX6_]KO/4WXLBJ$+5
MGKXZF;=,Y"P1N0BO6D_FK<'2T+TCX56=]-P!!'>K_$3W*8)UUHNVMT1=TJNF
M>V27L$FU:LH?KS;#+-HGAX\J+Z;?^B:)#7 9A8>KJ(OIT?U&*KV\J^L ;5K6
M>?-YVLFD2XT[Z;M#/]64,VYZ=>M>L58X6BEM@%J+16)G3@H:.Q3']J%][V,#
M[\M+.JN!"UE8:ROP/$G3H& [A5XRI;+KO,S:AQQKQWC%)LZ8!5VT#>Q#)^[<
M@&ZDF7HSD;BR;QT<KC3+L44,_TR*KD=@0VA3]58XSLND^0C/<\3),Z /%N>%
M== SI.>_4YE'"^DI$=:5U;1+!>$[SC57\Z<D3:M38,]"J48R>M=+H5G[GZU)
M9'7<^Y:+!7_@'TCZ $7YFOJENTO^M"RE[8STR0Y>TU7QOXEG:\^*%H2F&#H$
M@5X"=0$/Y]@B_8HV6B8+F-SGR%_]3PQUU-'NQ;IQ9<O;[-6).^*;G!1-B?I:
M.]G$4 _#;'&)%U]U4'#.<51:RG.R1 6SD4'NW?[2^M5429?!]*#TE;G- .Q8
MVVC6SDZLJFE0=H;.TRMDX5Y,5;#HJ>-%R5L^W[*'/X2F<WO[5[9RJ5B73V-#
MZ7VS>VWICHF-*XS+$K?53->\"IVE^Z4XXX4H+TJ&'1]*3 *SY7E^)?J L?R0
M<U5A)7OT+ [*O3 <C3^Y=48?1/2+CNC()#WUW]WT@')ZTYF:);2KMNV:?Y@N
M:[]+E<!IQIR#I11<I7[/8\KAW&=#FZA)6]?W1M!61V>W+Z3;^(\UFAC%;N.K
M;S#/VDU1'P$(ZZ02 <>?,?> /["Z$MZ]AW4Q]^_!/ZSAK;-ZIK->1*>:;P#)
M_D\;RH#7;AN,P^QFNU35'HYX_2QQ,RAC3-P_D:NHS-P%PWMR&P=.PW^E/NNZ
M#C5%^[8.0)7^3^J3H6UN889^*-W.H+P(<=8S1/>@/?1G>S\)_JD,&"'QM;E0
M_R@O-_5@YVDL*=JQI14M]W]:EXZ8W7+TI[DO[2XK)W CU_\M\H(/TD_LM9:'
M5CH.&Z7%N>2^&V)CZE#'$^&CZ/7-QP41_J]K&;RC;DS=+RS&?K(B&7EB82'L
MYC;0VT<Q;46EY= +]91<?-]*A2ZUO\-*YAJ]MGFV^(G_QYHS0K.;6A?/)]B[
MRO=C219Y0F]D!UTV.MN46[E^:(>A+)?4"VL34P?:$95'],JF*KF;_Z<:'TF
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MR#Z;+L*.MO-I@IPIU?_]R/P5HJ_TMT43F0\91TK^5Q; -)>WI5>RFJOJ(I\
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M\A1)YH7;!*S(B@ZY2!_ ;9DJN>3A6[] 'N-PJ,9#><UJG6$8("8)5LP1%A'
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M>)DK**J=R7X*FBT32;- E7E9X3.0;/R>U@-*#,711G"';C!P/C1=Z^%>!:W
MS78_X5+TI?0HL*7Y!-L 7&GR)FX#CC>,**P'-M5:THC B9JYT67@?..FP"%@
MK;[0O1@*U[RVGPX/QY8+I(V5I5:T_OKK%8)R;IV8>#QW8^T(:E#2]AH5_6#X
M&=,#MLY79<SD*YROZ4^(#UEWZ(2*4OZJ^@ 2D3:M]BYU?-E#BY%V.#>CQH'9
MF"0QK>6 X>N-H?PV7YW^J.B:RS2=0%9M\Z\V2F7/^VSYS4"J"VNNL!K+,LP+
M./TY!TVYO*M)TPR_A-;A@'Y 7..+ZNBRN2YQVG#%?1N6QE=]F!=N?LO'J$VF
MQ\(AI4;C,1&<$VQ8*!F3V*/G2U>%A^G2Y%1?OM93&>I"UKBK VUVXRE@#%=K
M\I )*$^-D?+*DL>&($5L]F*]M=(F,54W7C4E[)=VHGJV;[EF%N#C N*18)7M
M/Q@*-7 >&G: F902_7UPH(2A>P:^R?;4WH.L$EYJ[D&%88_Q=] RWW+<&OKI
MTH;QX%+;&/0ZO(53JM?B[\D7=?OQO827VBMX2=:@YCIV.:$1?XD1PC;BD]#'
MOCPL"<5=-J"#Z#Q;(9J+K&._UK6;I.1.[4OC0<)N[5!#7U8S_E%?F"#%1^JF
MAIFP5,T3WW1T$7[>Y0#JAJVV[4#NHAB[77NO?@\Y51M:9R)P-?F6'5F9>(IY
M04(L5F9L#^.BO?HUODGH1.T5EW/(-ORS[39$CWE6W^[R+5E:_J1C=/FC_([6
M)\38U%?-BRE[8F8WVM$90;0Z(SO#L[CF";_*<;BI6'S$:I3^IX)<;=>13 3+
MV6W1%-=\KY8YU>]2>QI/,JY'?ZHGL)\%L2S7^.Z>&G.QJ,VQS/!:EF95H]NI
MFD]M;G.F>Y1=;(EF9N1M;?)G(ZF1]=^XEZ,WU2X5I 45U22(GGLN-CZ3]CMV
MZ_L5O=9#M,O5ZZ@C6N9PMY:%-*7S<_)F-)0(OJ2<JHL4;8ZF6L9(:H/\3)=D
M>L\^0[>BT_&FKD%UU9JBV0#.I8B;BB7^I>L:EDE3<SOK]LJ(*03+%KDJVL&\
M1+$N:**Q037,LU^O5U.=1FD7 />MM^(/H3+RVX;GJI[2R/IT=5AN<*U4O2WE
MGQHYX!YUWR0 U@7^,8C  L]U.C/TCY.+YBBTQ_H7'@*+R%C]/N19R?VZ0'1(
MSC,+';F3O-O,17JCEAIE"!1X56]!>)X[M1L1GE.*9AK"M G&5B%59+>Z,[JW
M);6U^3I-3E=-K79?,FAJUUR)XAE6:H8$]NHNX9&>J[3_8HU.#!Q$;]G0L"#4
M@?2H;E;-A1*^987Y:PYL?F#2)-.,MPPGHD3ZA_J0P,.Z6=HCGB<U'(W028N/
MQ"?;F-'KZ*&RINYRPK?\G*7-Y;YICQ;U5C7$I70Q*4ZA"]KNTK[Z.C=[L,>Z
M5M6S^1EVE36#X@OS>HR5"D;I]67]58*\BXL_DJW2P 6?J=_C1G2L9HP,U;;:
ML)-](QL!WE[7[MH+(J+=&7.R+&Q^E&&B:D8I>\FRZLUYE0M_T1^GV79-8X7$
M;FN[S-D=6ME,Y7-]8^OOBC)=KUA*I>GVGL:O"OG\_;J7Z@6E8Q:ULB_E?E@P
M@FM.'>CPY9?%"EJG"O-"?1OWBX6^$744Z2;7GS6C%!/L589S*K-5@/8]\+6D
M9\$)X=/<ELY\L5-J95NM1!1KWPQ+3X7.:,B0%_B&U4Y1?'>;:[JE6F._4W\>
MD%DU:ZT@CY*DK@+YQ]ST]G>*W:F.K2%*(.9[D[\J(N1[_43U+-_$FJ? 3+<P
MXU70WOZ=[@L49/50PX$#"9\[[<"SN9/;SD#.*3];YD.Y,=<:;2%AR)VZ<= J
MWSCS=^B'6[GA*TQTL--%P?NMG?!KR S"Y@YO7)7SI/4)7I9RNSD$>QUSJ"$2
MJPXY6^N+?O+U,8>@B]RJ#.EHE4.:M@>=8UV&4Y!S!',[W_ IYU2KJX&4<JP)
MTN?';*_7ZF:'7+:H-#]]$TT6_)>;1+\%G^Y T7I@ =9:? 3*[(?+'Q2Z+_2K
M^E7B9-%2)E=,!S-H/L0?G,5,"?5)V4'.<\:;]'!!"]<E?)*D0[C38Y3BN^Q1
MGYGPJHK4M:Z<3R;6^%?=J2X&G"G%C SV MI'=FKI4]9A'BFMAG=6N"RL1QP@
M#7#_(G^OC%HY6$AG(AV_2J+8B.E@^1\NI#I'/,#'60KJP-\CPD_&)?&^U-O<
M8-FXL!CA)T6K^W/Y*+6L]WU>I%C<GEY$D6!&IU*JM%F)5')DJYGYY%[Y^9)I
M]+G*\:EA[-.JBM!'@MOJ:^ZW9<&@H2<N6P[&M9[(OPOR](<(=F"'(J"<"AYD
ME!%O@E\)J=5=4%3*:E8K5!O:RG\)?72_(,5AWO*+F3:Z=RWFW/VZ2-U 48@6
MED>6KM?LI(-5%?B/XI747#PQ)81IP1I#"_@VZ"WWXY)GJ-VR5>FN]>)F8_:/
MVBO:,P5=%C>9JB3&+*6=JK0R'BR>0XDW3$Z^S5BC*PJUXTDT>O<#$B:V=.G!
MU+:.=4W[LVK;'+2V^9G-F/0^85+#=5I"Q=2ZX*+%Y.H:2[*&_L-X)N0;]['N
MA?N@9 C^;*E[BF 9VA2<J5[T1;,D+[VK7"HHMFT[5/VD/+PYI(A ZJM?F)Q
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M/28NMPP(<8X^(:VQF\MJZ61RVMNI_*XV8F5O"T[6WXQ6#S8AC4,.A&7(_@J
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M5^&,8XOUHD'I;E &^ *M?]0C0T#Z37-0R05K"'[>&L4Z:$F03IFR=*/Z8MM
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M:>9A.K>VGR!NZ,&HFMJ1QM86N+W= 7=T6!&.=@.ROJT*U="R4#\U+ $2OW5
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MO@M"@T%16! H"P\ L A_@(SP>X:)]'V&C_)Y2H[V?DI?D,;AW[]F.OS[W\C
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M3@&;OMP'=GT3"7R7AH#@'X) Q$I_$+O:!\2O]0+)ZSQ ^OK=(&O#3I"[80>
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MFF1@DIEJ:@572A**1'BEE(<U*M@8A[("VZUD8H>5#.R(@HX=E;W,BP;2BK\
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M@I;05LG<VZ9EQ;35LJ/;.UA1'0=8,8TS[-B&&<[_8>8NHZ)JP[[A;QJ[N[!
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ML&O\/C.;_">]V@,FZ%V!$[1CDH_4LT$?*->"WU.>!(]2GTN?T5\$/_!Z&3S
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M9'(_;U)*_:P]+_:+R7+I%VL5T1='-=X7[ ZOKT1MRE>:/O$KQ]#CJ] $\RW
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M38"=\]W ?)$3V"ZU ^?E5H!=80[$529 66T$S#4&P%VK!S[K="!011/"UN^
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M; FV)ZS ]H(UV-Q$/;<!FW>HSZA?-K]LT=\Y@,VX(]B^=9K>?QE<M>2!H*T
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M[G%\0VQT'B6TN[["'\:\P/>Y#>.ONCW##[H]P8]A[^.^>MS$3^'Z";_QYTB
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MSP7W6KCA]PY!.-VN0CW4:L2\J]&.9Z'.4W2N,DAVNBQ*=:PH27LD/]-@(+?
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MJNKL\RK;G+++^UW3R\8]4LLV>B:7[O-**KM"//=,+EOR2"Y#]Y12=%L.$U@
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MX54_H_RK:2:YUXM,LJ_/,,F\N<\D\^HMD\S+]_^R^L<SL!&@CN07_E]^^'D
M[S\ '&X 6#ZA![,/'&#\01 ,/DJ![D<ET/ZD!1J?#2BJG\TIRE_L*(I?7*CR
M2SY4V:40JM376)K$UPR:V+=2FNCW)CKA[ZOHA' =G2#NH!/ $\1MXMZ_]&P
MJ-\!4'3@__(O GA= ["[!6!R#T#_(PUTD TTD =440244!H44!%D41VD4!<D
MT)@BAI848;2G"*([A1_]*;P82>'&%"H7%E$YL('HH[+C))4--Q'[B$/_TK =
MH)B<O]0?\[]$\O\"L+T-8'0?0/,5D%P 160".>0 :>0EF<(@BA(@A++ CTK
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M@_@WQ$2+K(]*EIB.R)*>#"^2'PNM5!P-:5 9#FY7&PSJUU@5N$9K9<!ZG9Z
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M2BUHUTW*'S!(R%MK%)>[8!R3>\0D)O<V\=8H-A<-"8/E,!K@=CK90R' D4J
MW?4 "Z1[K6^AP40K+PRWR5+Z6K5HG2UF3,U-]AQU#1Z\E?7^0J6U8>*%-;'2
MN54I\IF5V<IIY<5JR64UF@FE+3JQ)?WZ4<43AA'%FXW"BP\9AQ7?, XO?FT4
M7O3=,*((#0C]G[V/ [B>!7"*=-\#M0#;2?Z&-M*[.@!&NKB@OUL*NKHT:,V=
MQHQU[;9LE6UN/"4MOH+Y32&BV8W14ADKDF13ZC,5$^L*56-K*S6B:IJTPZM[
M=4.KQ@R"*S<:!E8>, JL_).\OC(,JOAF$%2!^LL]3B+/ ]G#L0HR ]*_MY#\
M=:3_K>XEW;./ [KZQ:"E7Y5:WV=(7]EKS5+<X\R5U^W-G]49))S6$2F>U)X@
M'=^:+A_=DJ<4T5RN%MK4H!G4V*WMWS"JZ]LPK^_3L$_?N^%W?>\5+_1]ZI?T
M?.KQ!]V?W27/Y%ER%@_^F$$+Z;XD?YQTX'[2 3N&6*%Y1 CJ1A0I%<-Z=,5#
M%DRY@X[LF0.>/"FK @03^L-%8U?&2D3VILB$]>3(!W>7*OEWU:OZ='5J>'6.
M:'ETSFJ[=>[1<>N\I./6\5S'K?V+CEL;:KNU_MMU\CR<^#&#1H#-)'^JCW2_
M08#.48"&<0:HGN"#LDE92N&D%BUGPI0A?=R.-6G,C3-NC1]OU&B(8/CJ:-'@
MD22)@)$L:=_A8CFOH5I%]\%V99?!(36GP1EUQX%=Z@Z#Y]4=5CU5=^C_K.'0
MA[^X0,[BP3HR@W9R#LG]KR$=?"7);YX$*"<]N'"6"W)G)2!S3HV2,FM(%S]K
MS1B]WIDU?,:;,V0FB#=P7:2 [W2"L-=TAIC[5(&DR]IJ::>UK7+V:P<4;"?7
M*=I,+BI93YY5M)YXHF@U_DG):@R5K=;\VTDR@UUD!QO)_B?(_:\B';AM+4#-
M>M*_20].6V"#Y*U"$+]5D1*]59<:L=6<+F2K V/ @@>+[X(_N]="&)?[EEA>
MERVI HZ;\X3L-U>(V&QJ%K?:U"]AL6E*RFS3#N*,E-G&1U*F&SY*F\RCC,D<
MRO[LP KR+'8#3)/]#Y/[[R0=N&Z.]+_- .FDAT;OH8?PO3P0LD\*@O:I4_SV
M&5&]]]G0>>QS87#;Y\/DO"^8Q6%?%)O=OB0.Z[W9W)9[RWC-]C;RF^Q=*6"T
M=U+0<.\V(8.]IX0,]SP4U-_]05A_%XKH[431GRV29W#]*H!1DM]#\AM(?ND"
M0.9.@-A] $%'Z,#K!!NXGQ $MY/RX')*&QQ/F5+L3]E1;4^YT:Q/^=%9G IC
M,#L5QVAR.H/9Z'01B\'I>C:]T]WL.J?'.;1/;^'4.G.<4^OT?0[-D^\Y-4Y\
MX]8XCCP_V] /,+::G $R_Z9Y@+*M %F[ >(. @0? _ X30/[\TQ@<84#S*^(
M@-GO"F#ZAS887S4%HVOV%(-K[A3]:P%4W3\CJ-I_)M&T_LJET_BKDE[MKS9Z
ME>LC#,K7YQF4;APD;C(H_O624>':9R:%J]^9?S8Y0LX R6\A^14D/WL/0/QA
MDD]ZN/MOI(-?HH#)-0;0O\<.NO<$0/N>%&C=5P&-![J@_L ,5!_:@<I#-XK2
M(S^*XJ-PBOSC1*KLXURJS)-JJM23+IKDTS&:^-,M-+%GQXD[--$GKVFBCS__
MRR Y_VUD_I7; '+VDORC)/\T@-MY .LK $;7 33O4$']-3NHON8%I3=BH/!&
M#N3>JH+,.QV0?F<,DN^M0?R],XA^\ ;ACR$4P8_Q%/Y/.12^S]44WL_=%)XO
MXU3N+PM4KJ5CQ WB\;]TS )4D_O/)?D)9/;!Y-Y=+P%870/0OPF@=A= X36
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M]C2B_.UN3[ONZDW_NW,8TP7'!-:S#ED<I^V+N$[85?$<LVW@.V+3SG_89J7
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M*8_?-J(L_MC(TOCK(TL2'A%_FI0D<,;O,?K ZQ":B_$T#]+)^Y/^H0+RO87
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M*3"X5(CAEZ=BV.5VZ%U>"ITK6QGM*Z>A??DG:%_ZG=&^\"?!L1]8,O19K.5
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MQJ\;EAV_=WA6_#GB)^+%L*QX3H_0)70^<(_FXA<T!TY1[@?(?V_/)>]/'GB
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M(_90/NH&^=% (@:RHUE0/#8%TF.M4#BZ&.*CFR$Z^@GQ'=W_"O&1U\2?;UE
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M>8YC\P*-PLN,XU469HH;=N]P3.YPHKW.)+^^A;#Q.Y?(TRABOM,W<"W8QG6
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M*@?F@&58'TN/5E+'YY4L#\L82PEC+#)31Z&I/O),39!C9H-L,V=DFGDAPRP
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MS%2VF.F]CJ5F"G@*C./U&):?T2YV\IB]*[H,Z/%&3Q Z(M$13VM3T9'-""U
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M-,4]Q;EXN#@5/RF.Q:^(0_%K8E^\1>R*CHI]T5OB4/0%^-%\2M @58<B]>X
MBD$NR,BTU*!BL^$=Z Z"1OL5P+^*R?_;V8N^3"/:<KUHRMW%I=Q7G,M#Q*D\
M6AS+D\6A/$?L*DK%MJ+*<LQJ!>2I H)8 7$HWVCYN<ER>%XYO+OL!_,I0?W0
MTP4]9:  9(-4$$^;(]$=4HA^*(I7*?JA;?H.]N+:R46<.NO$OM(H-I5,Z)5,
M\)4,]$H"MS+#4E!1Q[UT44>^0J2ZP*\JX125D*5*R%#GJ^!3\(/Y+K6>Z.D(
M2D >R !)J@:%F+!V<)\R]+='/R+U4#;7*CMQZNXLMCU8X'NP\/9D<>O%A-XK
MV%)D[D4']\JU;&[I!9GN-0) IGK5\=F5 &+6XR+X,_A>!J"G"E2 (I!CW8<4
M2YO#:7,@U-V[,_JASOKNZ.\EXMB'A*L?B4Y_DIX!)!L#65P'PG,'L;@,#K44
MG ?CB\%TW&"^.)C^&#P.0)P'D2T.@K@-/ ?(I@=\)[W1U1F4@@)K#2B!-D?2
MYJ NZ.^&?E7_@3:3%H@#XDADF-1(M$; M4?BBT>P8Q1V/.IE^>/':#7Y,Z!'
MXXO1"!NMCN.E/T9/X7W(\Z,0R$?)(D>]"[Z1;GRD RAIJP'1YJBNECU /GS5
MA%X=W-P9;F[["+H119K&Q :>P(YQV#$>.Y[$CHDD0T]YDPBPX#ZM_AC P'H:
M7SQ-;$Z&<S]-?TQNY#/$Q*2#X#;?^4*ZH+,"Y-//:7PT5NT!HLTLO6+B:[I1
M(DY*)W29Y)+O RBK/&NMB;Q@:]F7HA+1:=CQ,OYX%7]4L\A5,^%7$_35-+ :
MH3,P? ;]\>HRDA9BXN4WP)^D,WJ+Z>=,_!U/"(<-5G=EH7^TB)8N=)ADU:GV
MP+350F98ZR&UUIJ(VB,R$Y_,=K;<G[/ 8#E%=C&+\F(FP<4$^>(NEI]J6H3Q
MKS%&%S;QN6/@CI3C[US\G3R$N1!?^XU!/^W5HI=T%#NM^MKVHLR7A_:A/%03
M66DF1R3I^&2].KD$.[;0+\W$1C.38#.!UHPOMHR'2#$^FOCPYCU\[H(4$5]I
MZ([&38$31=R?1_]T$3NE=Z95YV)KW66-_,][4)JM!$G5*'9:ZQ3[Z)\#+I;3
M6X\S9H\3&\>9<([3X<<8IT>)S2,TXC!?/GQ(LM$=C^X0='O19AV^=9AKU;O2
MJK/)2H1V6NLM^\6R+Z2M'M)V<DG;B:IM]\FH7[&YB1UW2,3NT">W&?2WZ?!;
M$WBD(V_3L%O_70-QL-X/8_F5UK_!9_XJ&?(7*90OX3&?PG,_AIW\$5:AF-*[
M,)S[#)*W871W8&"W"!K++[;6P]_GP^I6RGD:H'Z;Y#2<^Z1\\>][3XZ! V#W
M_W0?BHU\!\_\$G[WB?C#AR/1ER3O28[<E1*Y"<^]"N^_!#MZ'3O.8\=9[#@-
M\SH)&SN!'<=@N$<(W$-TI&+[>V4=>G;@PM.R73X"/^-2RZF@S?++R1@*WUIK
M$._ N6_BBROBA3M#T!6+>]/0D0<W+T5V1^RODGWX8P\,:Q>L:R<L;#MV;(-C
M;L6.9IAJ$TQYD\R!Z2['BBV$TB%"]J:L0M-*-*X"*ZU[,/XAECT8Z@> +IMK
M$+8P="UM,&&_'_+#:44"=F<@NP"[2_^]#V,M_'(U;'(5['(E3' Y$]@R[%@"
M.U[$0%X(YY[/_^=AQ1RLG8WG9N'AF?+/_S@90]5_[EI#Z8"TW0/BS+?TV.Z)
M_""&1!3RDY"=B>P"I)8BNP.RNR"[![+[('>@-&)' W8HME_#)%9-;+R*EI?Y
M]G1:\!*>G$H$394?P(-_XVUK_667=<BM- ]].^1KD6U$M@]R0T ,LI.1G<44
M58#L=LANC^Q*9'=#5F]Z8"!1.5R>IU^>E8E,;5/HF5KX^T)>K6>:57</709?
M@G^!!V:<M=9?UEJGG5G6Z>\5?#$-7TP5#V3[(SL,V;%,SRG(SL+;^4S;)<BO
M0'YGY'>C];WIB4%,ZR-E# O*XWSJ,2Q]%&\]8MXUTRHCB,T11/H(^0D\,&.O
M5?]\J^YIUFGY&7PQB3'R)+Q_//$Y3@*1'0'BD)^"_"SDYR._1$9AQR/8,0([
MADM?&4:<#N&=P7Q[(+X8P%CMSX3:C]CLRZCI2^_W9<3W1;_"%AO:[\!T3#HP
M!3S%5#N.J7^,^A,%8X2,%/E&Y/L@/QCYD8S(>'2DT.(L=.2CHP0=%>BH1&8/
MHJ,_HV8$$3M6NM,KW8B,*OI#G?/2A6COPJCK(I^#GP%CA"EUIJJ_Z"S;0A_7
M65*"82R#0QQM9+"-"WKT2'5'AR\Z0M 1A8YX=*2B,0L]^>AIAYX.Z.F*)7WP
MRA#I1"LZ$!'MZ8\*(JR<2"]CM)4QXLN8"<J(S3)L6*1NAW5C:6=*'6.TU#X&
M\KPORW!OWNNEL9=>CJ[2P\X@W6P\I<K&7[K8A$JE3;1TMDV03K9ITM$V6SK8
M%4J%79F4VW66,OL>4FH_4$H<1DFQPT0I<IPFA8YSI,!IC>0[[9(\I_/@(_"=
MY#G_0^88+'M@)GC0?D]+2M:;Y]U)$;MB3R6V5.H<I;-&*YV<C=+!V4LJG .E
MW#E<2IUCI)U+DI2XI$NQ2ZX4:4JD4--!"C3=),^UO^2Z/B(YVB<E2SM-,K5S
M)$.W1M)UNR1-=P%\!+X'_Y)Z=#V'WC%JWPE+7!_0#71F^>_ ]0K>+S/82IG>
M64IU>BG1F:18YR.%NF IT$5(OBY.<G4IDJ//EFQ]H63I*R13WU72W?I)FMM(
M235,D&3#2Y)DF".)QK628-PM\<;7P<?@K[Q^(#/0]90O:1WIZ "6MQZ@$K3G
M=2FV%&-;$7XI,-E+OE$C>0:#Y!@\)=O@+YG&4,DP1DNZ,5'2C.F28LR39%.I
M))DJ)=&]M\2[#Y,XCW$2Z_&BQ'C,DFC/U1+EN5,B/<^#/X*_\AK>C?X)Z!Q.
M"MB7]*LKZ !*>0U]DCQLR<&6;&S-]'22# ^=I'F8),7#6Y(] B71(UP2/.,D
MWC-%XCRS)182%./54:*]>TJ4SQ")\!DKX;[,+KZ-$NJ[4D)\=TBP[UGP(<^_
M!_!N](]%YY!@2PVH,X R25%;W0-;,K E#5M3?.TER<=5$GP,$N?C(;$^?A+M
M$R)1OE$2Z9LH$7Z9$NY7*&'^[274O[N$! R2X,#')2CP.0D,K)> H!7B']0J
M?D%GP/OB%_B=^ <^D.?0,5K5H: %W</@.J =R ?97$OGO13L2>1S\2 FT%FB
M O42&6B2\$!O"0T,!!$2$A0GP4%I$A2<)X'!91(0TE7\0P>(7^ACXAOZC/B$
MU8EWV#+Q"MLFGF&GP'OB&?JM>(7^RWPZSJ@PRSZ@KA'$8"0^X#$79' MA?<2
M0"SV1(&(4$<)"]5*2*A!@D(])3#,7_S#0D&,^(4GBR_DU">BG7A'5(I79#_Q
MC!PE'E&3Q3VJ1DQ12\48U0).BB'J'3%&_D5,D?^4B6H_5(3E'JC.H#2:^.,Q
M"Z1B3R*(Y?TH$,;SX$@["8S2B'^47GRC3>(3[2/>T<'B%1TIGC&)XA&3*>ZQ
M16**[23&V#YBC!LIAKA)XA8W0_1QBT&SZ.*.@;? 5Z*/_;N,0_80=0^6V@,$
M2J $N3QF@&00CTW1@&9*$._Y0^-\XIW$*UXG'@E&<4_P$E-"@!@3P\60& ?2
MQ VRJD]J+[JDGF"8:),GB&OR=-$D+Q"7Y$WBDG1(G).N\_BI:))^E,>1/Q#9
M5<BN@#(7@FR0RNM$5?\!$2"$:_[0-Y\D$<]D>S&E:L20IA>W-'?1$["ZM! 0
M+=JT9'%-SQ%->JFXI%>)<_H@<<P8*PX9+XI]^ARQ2U\OMNG[P16>_UGLT[Z3
M4<COFV"Y#ZL4Y($,D,RU>! %PG@=")7VA29X0M],&7;BEN4BVAR=:'*,XI+C
M)<XY@>*4$R&..0EBGY,A=I!GVUP(7"YY=.ZC %*6JXX8A"#DD)SGD'CGD#UF
M?RO#D-]3U:'04:QJ0#S2%$D$L:H&Q;5@=/NEHS\3_=DB;KEVHLUW%N="G3@4
M&<1.36)%3"1%!&T1G5;$%XKA5L7M+<>L%L,IBB<#N$T165(1)*'P H!W%WXK
M ]%11=O*00'(3%-[D/ !B.)Y"!3>'\KH!44Q(=:M$ Y4;"?.[9S%OHP%MHP%
MI=RDBLF P5NA!E>B96-/>XA\>\AD>TA<>SA%Q:L 8E8.(2HG>RK["'PK?=#1
MF?:UL]: TM4^)$!X2QAM#LR#_Q>@'_KLU@[]Y7#P]C9BUY%$HQ,+?&<6UTH6
MOB[XHBL3694J=L=8&M85@ZOHCZK^/!]C^>G7+F1K7;;R'3+(R@_X_K?2W7PZ
M$"YIJP%E6_8A1=#F($3X0(W<H8INN-6U$QP<NF9+TZ0[B4X/>%1/DH]>>LL?
M&?JPR/7UMTPV_0BD?@CLA]'](/-](91]B8F^<_@<1+$WY*P7V7RO;Z22-I:"
M_'S+O6B)/(^BS<&XT1?*[M[16O_I!@?L@>[>@#"3_B1: TG !F''8/ID"'8,
M4PD(?3*2/AD99=V34L0$!.<>07^,4#_% ID<3O8XC"Q^Z&V^]Y5TH)W%Z,RS
M[@.*I<VAM-D/%[K37CUZ-7!S>]PI;3480DQ4/604=CR*/T8[6_:EC,6.<2H9
M8;%]DCYY4AT3IHZIHC$3$**.0QT/H1Z_U+H?A;$Q]A,IQU5%Z,WD,;Z#Y3XP
M?]K,TBMZ]#H/QO?#E3Y1"::E%@)]-]=#S'M2P-/P[&>(C^>(CQ?TEJ1HFH_E
MWISI#+KI=*HZFN8EC'^)_I@Z3^3%+22P)_G\>U*&WESZ.1EW1787"<!<#]JK
M1Z\3P]I<\YE@U=5V/]"_]Z+(?]9$ZNQ$&O')+.)TKM%R1LD")O@%#.P%-'(^
MG3B/!LPE@Y_#/#%['Y^]8KX7*PU_Q_0E!M4]6"/1_[BZ_TFUSZI3Z7O5FOPW
M6$F(V@C>=F_.P_405:=8C4_6$2,;U<WKQ.AF=3X) VP3OMB$@HTOBFS@2^M:
MP G)PK0$=(?REC?#QPW_.CUGU:ON/U)[7^;*+_?DF'7(?]9#VLXI>;@6LD=M
M8%>_8D._'&'Q/\)$=(1./TP''T+) >;, ^O 'O,)R9'H]N.RX7D1EY?%4F-J
MJX,HG>NL>AX^+5:10T60VN[%::N%T,7FDUO53027Z)MKV'&+,7N3/KG)6+V!
MXZ_3R==HY!447&[^KQJ(NA_&%2YNE+_![WZ$SWP'Q_Q*<N13>,S'\.T/81'O
M,4#OF^]'&2IW&""W8%W7"=2K<(E+\*K7Z;CSYE-"EV#2!CD.ISC*U</RF1Q"
MPT&PRWK_1]-#]8>_BV4?Q)=PJS^+&[J\T!4B[\(QWY9T\R^U7H9OOXX=Y[#C
M-"SG),SG.%SF*$SR,(/F$'8<((CVP5!W$Z0["9CML.AM:&O&24U(VTSK-EGW
M7Z@:Q JQG,RI='\NEA\@OH$O+L*YSXF)=OBC)P(]"<C/Q.T%L@=FM!,[MF/'
M-IA6"Q-6,\RRB4E#W5FP$3LLYV&\1-C48\$B\V^U6GZAY JO_D)HP:W /# '
M?">6^HLZ&?2TM6O5R9RM^&(KOM@B02 :^<G(SB(4"[!?[</H(,M@BTM@>XOA
M=J_!"!?"2.>;]V%,0/:S],8KA/1L+%G!D-J&9TX1YA\SE/_Y[W,P7@%J#XC:
M2J3N0=EF#?658H_=6F0;D>V+[%"&8 QAFH+$+)F)'0WPRWJ89"WLLL;,:GL3
M!0.1.9QI8S3#ZDFFD2G\JY7GD?*<^7=<5$_=)FK4;P\]^#<N64-;A?URZW!O
M-$\%SMBI1Z8'\(>UAB,[#@^GT-OJ/I!\9)<@NP+9G9!5A>S>,@D[)M(O$V0,
MO3*9:74ZSV83M:NP;#M>NB"/$IN/H5MAM#E&+4-\D57W*]9I\%E\\32^>$H,
MR/5";B"(0'8<LE.0G<D4FH?\8N27(ZL3LJN8TGLS4@9AQ2-X9#PCYP6BMHXK
MB[%N"Z/I&'@/J/.('YBQQ:J?#$=4:7BR=6H>*S;(=4:N'KDF)/J 8$9 )/+C
M9!AV#,6.(=@Q6(K048[<3HR4;D1I7_X-Q9K'&3V3B9A7I#N1THV>KC+?774=
M? ,><.V!N?ZDIM\7F4XF@L?!2);#85P;@B\&,5\,(#[[TR>J_M"/\=H7._I@
M1R_LZ"D9Z,A%1S'RRI%;*5VY6DD+.V-U)^*B YYM3X16T!\5C*IR^J-<6"_E
M9_/O=2]@2GW926022]YC8"@8X$*:P;7>O->3^:([?=*-/JD23^3[,QI"T!&%
MCGATI#!2,]&3AYX29+9G]%8Q<OH2M<.X\@1>>EX*B> "1E(!H[F \9$O[P/U
M6]D/I &=SVLM2_\PT _T %VY5DE*T-G95CK9NZ!'AW0C.KRP/P ]H>B)0D\\
M'DA%3Q9Z"OA7AMS.6-03[PQFAE65JV>PL@:/+09;F/&. G47WM?FNQ)?5;<%
MNY$>D!(.8)GKH>H>H .OR[&EE/?;N3I(.R=7*7;02Y&=20IL?23?-E#R[,(D
MURY&<NP2)=LN3;+L<R73OE@R'#I(ND-W274<*"F.CTFRTV1)<IHAB4Z+),&I
M2>*=#H.;X'/PH[RD]N"@<YB[I?ZB4M/VH)3712QY!;R?I[>1/)VCY&FTDN-B
MD"QG#\ET]I4,EV!)<XF05)=827%)EF1-EB1I"B514R$)KE42[SI 8K6/2HQV
MLD1K9TB4;I%$ZIHD0G=$PG4WP>?@1WD>/8^C<Q!I8 ]2L(Z@E.>%()?E+AM;
M,K$QW6 GZ7IG2=/I)$5GE&2=ER3J_"5!%RKQNFB)TR5*K#Y#8O3Y$JTOETA]
ME42X#9!PPZ,2:I@L(89J"38LEB!#LP0:CDF X2Z/7X&_F?<"C4)?/Q]+:EX!
MBD$>KS.Q)XWW4K E"5L2C?:28-!(O$$OL0:3Q!A\),H0))&&"(DPQ$FX,57"
MC+D2:BR5$%.E!)GZ2J#[(Q+@/DG\W%\57X]%XN/1)-X>1\3;_3;X2GS<?Y:)
MZ!B.SM[0I,ZD/*4!^)_'+)#&M63>2\">.#X7XV$C4>Y.$NFNE7!W@X2Y>TJ(
MNY\$NX=*D$>T!'HD28!GEOA[%HN?5R?Q]>HM/MXCQ,M[HGCZ,./Z+!1WG\UB
M\CDL)N^;X MQ]_[9O!]IB*I#D8YW ,5!](&JO8!D[(GGO1ALB>)S$=@2YFTO
M(=X:"?+62X"W2?R\O<77)PA$B(]O@GC[9HB77Z%X^G40#_^>XNX_3$P!$\08
M,%T, 0O )G$+."3Z@.NB]_],W/Q_,I^%,Q!]5:1;%:"0E#R+QU15>\&>6-Z+
M!.'8$\)G _UMQ-_?27P#=.(=8!"O $_Q#/ 7C\ P<0^,%5-0JAB#\L087"&&
MX.[B%C)$]"'C1!<R%<P5;<AZ<0W9!RZ"/XDV^'MY%/G]T-<%NEH*\D &2 9Q
MV!/%>^$@!'L"@2_7O$+LQ2/$54RA>C&&NHLQS%<,8<'B%A8E^O!DD"VZ\':B
MC>@JKA$#1!,Q6EPBGA?GB)GB%+$:[!+'B OB&/Z1.(7_148BOS?Z.D'/2D .
M2 ,)("9,U7[(=T$0\ ->7'>/L!-CI+.X1>E$'VT47;27:*,#Q34Z7#31\>(2
MDR'.,47B%--)'&/ZB$/L*+&/?5KL8NO$-G:%V,3L0/@Y'C\0F^AO9"AZ>D"5
MVY-R%H),D SBVNH_Z P&_CSWX;H'%,X88R=NL<ZB3="*)L$@S@D>XI3@)XX)
MH>*0$"-VB2EBFY@G-NKFB42X9M)PRP;N1!+UQ&6 Y#N!C"GA??"-#$1VURC+
M7J0\D X200S7(D H" 2^7/.$)ACCR?\3[$27Y"0N*5IQ3-6+7:I);-+40*:S
MTC T#>Z?!L=++[4<;YH.UTR'VZ23&:212Z=! E+AW:EDCZG?2%]D=T9V,=0P
MNVT/$*^CH>_AUAJ4']>\H-$F:)L;-$&7:BN:#"=QR'05VRPF]&PFTQPFFAP_
MRV:J'+Z0"[?*A>^::S$#  0B%^Z?LQ"0,62? .\R +Z1'K2K/?(+S/> X3(0
MQ[5($))@J4%Y)Q,#4&@#8G69<)!L6W'(<Q2;?!:\ A:40C?+Q*X*RR7XH@1?
ME/"E$KA5B=I4 'DM@5,40V"*(2Y%9&U%D)'"^^ ;Z4K;2OEX;EL-B-<Q((SG
M@;39)PW]Z#5DBV@1Z5(@XD#SI!T+>RG<LHS%M1P[VN.+#OBB(Q-)1X*W([[H
MF&FYP::C.GJ5F.A AM2!;*T]66O%(? VW_U&.J*C"&0]5 .*Y'EP!C% E[KG
MHK] U7_@X'2O'=2511R9<.W.#BRRV-$%.ZKHDVYJX65B[\EDTA-?]*01/?ER
M#_JCQT! 3'0G+KNMXO/PW:XWP5=2AI[\+,L^H&3T1O,8"B7SRV<,T%Z#M?[C
M!#^W111)##* JH?TPH[>V-$'._I9]Z4,PHXAWI8"^) XR['4@Q$PF/X8-!K
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MM!--E*,XQFC$+I9)+IX))($!ED#0)&!H0I1E$T<BN7PB!#D1TI3(:IQ(9I!
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M?F>]9>'KZF79_->5AG3-X%JIY:"+2F*BDKCL##'M!-_M>%&DPQ?F\X#2K?N
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M93E4RY1:EM62U=%:?^A@W?_0GAAMCQT5V%&.'67840K;;H<=Q=A1Q+]"WBW
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MZ-I##%IF&.T$T6M?!J^)SK4)'!:=YB;X3 8COPI]929+#2@-)(!H7H=S/1A
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M]\\OF*9>WA^W]?4#Y3L/[Q]P>,>NB:>W8L/FEIJ+:[=67UZ^9<:5Q5MF7%V
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MW!R7J#HW$<GOG4UGMF\LHS4>4%"B&5I*N%!/K$&:<$&T!>,OL1;[<':D#^^
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M 5N^6@%V?K,,[/MV"3@P=1$X/.U'D/K]?) Y?2[(FS$'P&;.!NA9LP!A]DQ
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M<VUWHO>:G@1>8T\\?^6K(2&69B@<10;K)<C=C:+D<I<8.7U,C!R](D'VWY]
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M417HB"G 2'P)+,1E8">Q$"X2\^ Q8@[\1DHA?-1T)(Z>@OPQD[!T[$2LD9R
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M61'2$M4:T131*5@9<3BZ/N)N3&WD&T%-U-NH*L&[B K!A[!RP<?0,L&GX*&
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M?87N&?8:_9.N&PV/LW89'V$=-SG$NFVZC_7.;#?KE_E.5YAO=H/9>G>8K>7
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M7)"^*;@_[6!(;]KWH=WISX*[,C"H(P,#VC/1KRT3?5LST/MK,(1F((&R<P0
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MEG"K8C./"B[D5<(UO(IX@%<!;_/)XSL"^>3^#U;0# S2#+;N_R?_,D#,=8"
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MH]N_"1O]^E;$X :*Z_^"DGK745KW*Z:F9X#.@<5T#G11?OUT_A& M#, 4=\
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M;["M2]YK5Y-\R;XZ^8EM=0K.(JRK4M"2,*]*1K.98"!Y=Q2Y?RJY?RZY?PG
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M_.<[&'0Q1%H']OSS[($VB/>)#U\\AZFEV<NEWL>=HOQ+E$_[-J-LK=L \O<
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MJNK9^+N*9\-[9:]Z5/:J0R7O6E2<R552D6,T>SO(OS=0_C@Y^,)V@ ZB9CY
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MAOP@XBY.S*S@FZS0&Z_R]4<B_1>KV=\ZY#T@UKV ^4ZZ3'WJ>MP"IE-WW-.
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MS>HM;KO5F]R.ZVW07-%?KWE>?ZWF,_TU[G_HKW*7]'NUZ*W4_(7$>G_CQJF
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M^P\J'/NO*1W[WU9,7ON+<O(:235Y-5GU%Z>9\_W4'5C&ODA[VD[J^+YH.7-
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MCLO4+9"?A;.7;<!?\S@!3#]+?6K:7@9,J:F^H=M_81&0]T+NZ?9#'M#O/VL
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M>K9 W7T"JNZGH5[V&?2Z).@OY;I^B9:-#9PM6<^YM>R+))OOXQN!T'GL ZW
MS'8Z<AI8AV747T']573E?0H8]AM!W6\!9;\=Q/ZQ$/HY]?=S2ES/ 7X]+_CU
M[&CK6:'U#+Y_+:'-74?GN8[V<>TO0)_T)_*3DMNI5\_Z%O(UA76.6,@VZ 3<
MNH!IU'58#8R@<;3:0%=.YVZP#1!VZ'/:H]/<P>7A()=G@UR.[>3R:">7)+L"
MM=OAN]BY=K&2NWKX_0Y"%SY(^[SC!T+][5JZ6<\6:E;H3N;$+@4"EK,/KM*>
MRAF_B?I; <M!P&0WH*:1YK*=@XJ"&'*R8QQ'&<>QX<!Q^:_%&,=)3L\G.>&<
M3-8>QY+_B:X3K,")HX2V_L27VA,J.A:SK@VD@*$F];(-F+8YU'5F7<?OHCXU
M+>G6C1_NR)PA%\AC,B)PD?FXQ*7Y94O@BATG82X7'Y^F7:K=X 1X(Q.XR4:^
MV4U8X,W+Y%U^_S.1AFAEGLNIF\$PHUA?'_Z:ZW[MJ9@1U+0X"QA=!,0KNMV8
MF_+)%/(DN:/;)7E*Q>69$9?J9K0+M S/CP%>9!PO<SGR,B><?_)"?X6-_DH_
M865>92Y>_8S\RL_TU0,<$YGG!-8WZ(CVSB1'UG,DP[6@IL%-G=Y3Y!GRG&Z7
MXD7=21'YU,9KNI,;;](^O<.<O,^V^8BVX3,NES^7GUC"2>>+,N!+=NXOMP-?
M,8E?L8"O&,=7WZ&,W37]./NA_'08ZDZE[LA;@#GKJ"?O #W<&7EX,D7>&7GW
MX:F4_W%2Y!NVS_?L)S_1LOQ&RS!T:[V?[JFM;!-I);3_8LS#IX2\K=N1L-3Q
M][M"_*!]*L7_NR.AO4MF&>DEZ\@6,D@7>P"_TQ?^1E_Z"Y.G?4+'=_B1/_U!
MQY>ZW9!W'NY(#.V&F.HPT\4AWQ7R\"DA\@D5^0Z9+&CO3JEB^4TLOY7E=[+L
M;I:["M^C']]B -_0>7Y%/_H%_?#G[#R?,H&?\-/'_),?ZK3E'1'YB1CR72+_
M&(I!WI$PA/8TA+PC(>^2R"=4Y">VRD^-]:=>%'52J)&+KU'*$FOP&1WXIUC
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MJ]4Y9\Z<F3GO\<S\'W;)[?N32V[OERZY/3:7O&XGNFPN]W8Q+X SP2ZP#LR
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MN>\KTMQ]-9JSKT.N^T;DL@_C]_$'^XZ!$PP\2.M>B-K>KU@0R6)W.W"$K^T
MJ_'S-!C@?9NI ='FXHWP_ZWH1TST'BED/QSP(!S\D*O<CWC)Y0@<]T@0@RH2
MD  =91$^RD)SE(GE:*]C^]-1<P0*SGT4GGDF!/H(//.,SP#Z#SMP*KHVT]85
M9F<.[[MI<_UFQ@ T.6<W_!N]T:=)P6>@_RPX^#G2'.BS+B09OL@'D Q>#->^
MA(3G4A*.2UEH+V,1OLP4X0GJRW#F97L=CT2^%#)_">3YXG\ ]%_DP.XMS,WH
MG ;]^+IY%^-P'V, O2GHC3Y;"D*GW\5P<#BZ"\V!SHE$FLD-.Z[#CNO-+I4@
MQS^+W80=-Y,4W<S"=PN\_Q8"ZQ8Z\N8CX#KP*-]YB\F9;/Y&FWV7RG;:N@*,
MGD(<GLHX.$P,HC<5O=&7H!^=?NCT,/67FP%-(<EGH0-WFETJ$()[2,[O)3F_
M#\Y_/_WR('8\3&+R,(O?PTPRCQ!<C^"+AQ'X\%T (O\P_?&0S8[U].\4W=5W
ME+G@7.8!OI9QI6-73/!-DN]MTERCZUYG[66V%F).ZCSNK(D\Z2(]!2%XFF3\
M&4C"<^&.H^LODGS\A@7P)0;[2_#^EW'L2S3F)?[HY;?!U\"FY?3O,%W5=IP^
MP+\YZ(W_&?%'^/@]*+D_ZM3UI+/N8NH@+SCK$K,G=7[GK$_\"=+V9T_I-6+U
M#1+SM['C'9*D=UE\WB,^W]\A?8"R#W#B!\]+'\+J/OQ24U<Q'V%:/3XNNIL8
M>$@*IYU^3Q![IO[RG%/GRR?57/[7"1W]M%/D'V:7B'F*#3[Y!K+R73)$DAC]
MP9R08=#9Z' ;CK;=!VB0[4UG_6&^$^;][*F07#EN"6D!"YSU![,[Q-Q4NEF.
M4S+[P2&96U-_@,U]K\O@C=?J7[#!K^F\KV#$7\+^OX!SF],PL[=QF!TA9D?&
MJW+>2F&O?7@[:Q#>3CO,C27FEA"S0\4\M:;37HMQG$Y9IF_@N5_!<[_ CL^Q
MXU/L^$1GZV-=J(]@@1_",\WIE/=@R._@Q+=X]R9_^<9)M1=3^S G0IZUVV#J
M'F8GA(OSU=AD=LHDT:X\_K(2?<W8WXN.4>0O0OYR9*^C"[8@>Q=R]].NP\@^
M!K.]B)9?17C<3)C<@ZXG]1LZ[T6L-3I_[<33SEJ$_52(7/^M_L!,CLY O!=#
MFS+05XR^6O2TZR_TR1_A_;^'][^"'2_ACQ?IE^>QXSGL>!8[?@F3?@K&_01]
M\KA^QA!Z!#TOX9&/]!">?! M!N;Y/O?(\:R?D_5_8P^IN?C.CS:%T5^)Z,JA
M'>78WJ!GZ).G-,!P'*<-T\A>CH:UR-Z,S%VZ3P>(@B.Z&Y9_)WURAVZ"M]_+
ME/)+^YZ9FXB2_]R5<?U)-I@+<-Z78Q/62\3&L_#^)XB+QY2&GD+T5*.C&?E=
MR!^DA>/(G]:MV'$S=MR$'3=@Q_4Z5=<1H]?H8EV-+ZXD+BY'RF6TZ!*\:_8U
M&5QR$F;UO^/B&.:_LD\'<_"7'[X*H2WQM",+/2787Z,3C)-KU8/\0>2/(W]:
MQ['C4N+C$FTE&O82F8?PQ'DZUUX-N06+'M118O,(@_<,>ML\=^AD?&,>C.7C
MN)SZ25X?8(JYT]5,R9[HM-"F""(L&5UYZ"FG#77H:$-'+SJ&T#'!B%B,CI4Z
M4QN0N8.H.*#3T7P:?W$JWME/?YR"9_>ZO*,]KM]HMQOKU)R?\$]T_Y5E[VEP
M+\O.+4RUU_+952P!E[OYT+9 1GZ,SG5)U]FNA3K3K4IGS&G0H;D=.MV]3P?=
MAW6JQT+M]YC1OGEKM'?>%NV9=XIV>1[1#L^+M=WKA+9ZW:/-WL]HD\_;VN#[
M+6"-. GO,I6]%,/2$8U^EKTK(UA.^>Q<EI]S_-QTS,M/1[Q#=<@G40=]L[7?
MMT2G^%FUQZ]9N_VZM'-^OW98QK3-,JVMEA7:;-FHC?Z[M<'_L-;Y7Z@U_M=I
M=<#=6AGPC%8$OJ-E@=]K:9#-@4 '7HMQU&#N!->0AEP83[H1"^=B^3O(E']J
MP#SM\P_0GH!H[0Q*T[:@?&T)KM"FD#IM#&G5^M >K0L=TIK02:T.F]'*L+5:
M$;Y=R\(/:B;\7"V)N%K3$7=H4<136ACYIB:COM5$E$T3D3_!G$[Z>0;+<CHI
M!C@K#=U\MC<!WH<M.R+=M"U\OC9%A&E]5*+61F=K=72Q5L94:T5,HY;%=FAI
M[ (MB1O5XKAI3<>MU%3\9DW&[]-$_-D:2[A"HPFW:3CA<0TE_DV#B=]H(-&F
M@82?\$(F2SZISW7@?'"ZL_:Q#5LVI9#?X)NU\3Y:E1"LY8FQ6IJ4KB5)^5J<
M7*Y%*76:2FG59$J/)E*'-)XZJ='491I)VZ"AM#T:2#M3_>F7J2_]5O6F/Z:>
M]+^J._TK=:7;'$BSJ1L\F^>XF>4*<!;83^JQC<\V8,MJ;%F!;Y:E>6I)FK\6
MI4=I84:R)C)S-)Y9HM&L:HUD-6HXNU.#V?T:R!Y7?_82]>6L4V_.+G7GG*'.
MW$O4D7NSVG(?46ON_X OU9++2I@#LFUJ!4\5,0Z+2?/ 8; ;;.*SU=BSC)0,
M"J.I[+F:R+%H+#=,(WD)&LK+U&!^H?KS*[2@H%Y]!6WJ+>A5=^&(N@JGU5&X
M6NV%V]5:=+I:BBY24]&-:BAZ2/5%?P"? YOJ"T&! ^:?G6X"%X"#8#M82VJ\
MC-1CFC1H$EM&"UPU7.BK@:)@+2B.55]QFGI*\M1=4J;.TAIUE#:KO;1;;65#
M:BF;4G/92C66;55#V4'5E5^@VO+K92U_4-7EOU55^6>J*K.INM2)$IL>J206
MP#E@']ALZB\5IO:"?FP9P98!7OO*O-53'JBN\BAU5"2KO2);K97%:JFL4G-5
MHYJJ.M18U:_ZJ@G552]73?5F6:L/J*KZ/%54GU!Y]?TJJWY9I=6?JK3*IK)*
M)RILNI_T]RJS.PCL,?M?P#(^6PA&L*<?>WIX[:R:I[9J?[58P]5<DZ#&F@PU
MU!2HOK9"=;5UJJUMD[6N3]5U8ZJJFU%%W0:5U>U3:=TY*JZ_5D7U]ZJ@_D45
MU'VB@EJ;"@UJ;"JRVG07J>]Q<!CLJ)/6@,6\'P<#-? -T,[[YKJY:JSW4WU#
MB&H;8E73F"IK8ZZJ&DM5V61515.SRINZ5=8\HI+FQ2IN7J?"YCW*;SY;><U7
M*Z?Y'F4W/P\^5G:333F-H,&!VZ!$%X.#8 M8 :; ,.@%K:"Q"?[?[")KBX^J
M6@-5T1JE\K8DE;5EJ:2M2,7ME2IJ;U!A>Z<*V@>5US&EW([5RN[8I:R.H\KH
MN%)I'7<IM>,Y\)%2VVU*:P.M-J6WV'13LW0>V <V@*6F!@0&0"=4J;$5WM=.
MSMT!_^[T5'&7187=82KHCE-^3YKR>O*4VU.FG)Y:9?6V*K-W@3)Z)Y36NT*I
MO=N5W'N&DGHO5T(O*W#OLXKK_4#Q/62LW:#+ID1P+6GW66 76(.N:3#2[J@!
MM:&W%JI4V0WWA#[F+YBC['Y?90T$*6,@2NF#24H;S%+J8*%2!JN4/-2DI*%N
M)0R-*GYHJ6*'MBAFZ'1%#5VJR*';%#[T-'A/$8,V10Z ?INB%MAT>1=K0Y=C
M+] *, D&0!=ZFTC'J_K@/?WH'X1_0U52QCR5.&Y1PGBHXB=B%3>1JMB)'$5/
ME"IJLE:1D^V*F!Q4V.2T0B<W*'CR@((F+U+@Y*WRGWP"O*. \1\4.&:S(VC4
MI@O1L1]L #-@%/2!-BA:';H9\BH81?\X_!?J&#OMIH@E/@J;\5?H3+A"9N(5
M/).NH*7Y"EQ:H8"EC?)?VBO+TDG-7[I:?DOWRG?I>?)9>H.\9AX%K\M[R3?R
M66R3[[0#9].^76 UF )#H!LT#N,#=!=-P/^A2"F+T0]M#(=&!ZZ>*\M:7_FM
M"Y#ON@CYK$L F?)>5R2O=5;-6]<NCW7#<E^W5'/6;9/KNC.9^*X&]]/A$+(U
MG\EE-=GT*IO<P.ECC >P#$R@LQ^T\KYFDCY8!/=;@G[H4>PJ]*]%_T8XV!8W
M>6WWTMSM%KEL)_G93N*QG<5_!XO,#B:T'0RF'030#ARW8SV Q.\PUSY 7+=!
MVK9^ L@BMSAP"FU<!Q;S]5'0Q?MZVEQ.F_-H<^H:]&^0PK9( =OAP'!TTB2Y
M[I\G'8#/'2#Q.I5$XR")R$$6VM-8\$YC4CNMU7$5TFD(.6T/N(#?W\IW(9 '
M((4'?B (;'9L1]=*<T,/[5W :PMMKEI-#&)^VF8I#KUAB/#?)_G T=T/D_3B
M6IWE!D@^SR;Q.X8=YV#'N=AQ7BI)@-F:RN1VOKD>BT:=CZ#S(?;G0>;/@T2?
M^Q;?_XZ_L]FQ$7W+S T]YG06OJ[!UT7;X/^T-VZ_%'JZ9#DB>9\-!SX/W1>!
M2P&NU7'LN!Q_7($_KL*.JTD"K\&.ZT@^KF,!/@'O/T%PG3"/"D/8=9#[:R'T
MUT">K_F2[]OL6(?.J4V,A:W$X4[F(?R<1??%T];0<] /5?<R]9<KG?67V;TH
MIAYR"\"]NHWD_&?>TAT6DA'BXV[LN)?$XUX6OGO;G2=U\,5]QP!_>.\OI7L^
MXGLV.Y;M8E[>RUB$DE?AYUR^EHC>,$RV$,J>USMU_<Q9=YFMA3P('G+61$R-
MXC$(P>/XY GZYBES:PEV/)L%86'Q>X[X?&X9H$.?NQSPQ\_]!<!LGK-IX2'6
M17-#,7XNQ,>IZ(V\@?[_+_0;G?<Y=?W<67,Q=9!GG63(U$.>/ZD>8O9J_&ZN
M]$>(RE\"I+]AA]E&_$:]]";Q^19!]O99 %^\16R^]0[OO]00;6Z]W#RAB3Z@
MO;'H#608>S_JU/FT4]\+^FD_R)^<M9 ?3^<X:R&SIV;L3]:%H'Q.C'Q-8OP-
M,?HOQLFWQ.=W./[[2\ =X!GPIGXZ$>+C?#][*F2V_F!NZ.B2XPDE4W(\*66=
M'$_/-760 ["WP_H.MO4O&-@W\+NOX%9?P!(_IY,^@S'_4Q_:[TJ=O9W#U"'^
MGQQ[()ZS\TU3^W!WUA[,7@BS!V-V/XHY(5-MK\7\H#Y]JU%T3.M+K4#^.N1O
M0?XNY!Z KQ]&TS%X\\5Z%S9J3J>\04?^G<Y[G7>OP;EGGXAB3J28_1=/R+$/
MXJ?]%W+608Q/@FA;'.W*I$TEZ*I#3P<Z!I _COS%2%VAOV'':]CQ9^SX$W:\
M"MO\'2ST%0;O;V"J+\"Y?XTO?J7?ZAD\8?9\/.6$V7MQO[,&\9][,+["%Y_@
MBP_@NN_@BS?ANG]3)7J:]'OZY&7X]HO8\6OL^!7]\@R\_VEX_Y/8\0OL<-R0
M<3XZKB"4;V((W<=_SZ+K;=V-)^]RUCW,W@OSO..;3K+!G$HQAZ[>DBOZ?+$\
MB';$TE\9Z"G"=JL>IT\>5;<>QHX'L.,^^N6>'_=A;$;N+MT&T[X5%GXSD]E-
M3"@W,*A/X'%S=\DU]*!YSI#9=V%>S?.&+W?:\)VSI/>Z<X@]C2\>PQ</$1?W
M*1$].>@H15HM\EN1WX/L062/X_%%R%Z&S#7(W(S,W3IN9_W'B(SC=DLNP.+S
M&,3GTIMFS\6QDV!^-OH_=@ZU7SFG@?OPQ>V,DUL8(S<H&CVIZ,E'1P52ZY'?
MAOP>1L$@\L>1OPCYRY&YEM&Q%2^<0H\<(3HNTB'^^G1ZX"">/$#/[B>JS<ZJ
M_2?A<Z:WUUEZGF&*>\"#:9<EX$;[M.Q!F^:C+Q1)\?1P!C87HJ,*'0UH:&,D
M]*)CD%:/HV,:'2N0N0$+=FH/G^[&LIU8OH,>VH9GMS(J-M,?IKIY,LS#R7_#
M-/\0N 5<Q51["5/_!2P!Y\I;9\D??1'H2D)/#GI*:(=5>]6(G@XBH \]P]JN
M2?3,,$K6:+/+5FUTV:_UKF=KG>MQK7&[5:O='M'*.7_0"O=_:H4'L\Q)>(VI
M_4F6W=O!52Q[%[#D'&6:/80]I_FXZJ"[K_:[!6G/W!CM]$C3]GEYVCJO3)L]
M:[7)LUD;O#JUWJM?:[U'M<9[6JN\5VJESR8M]SE%RWR.:L;W,BWVO473OH]H
MD>^K6NCWF2;];/^&WT4Y:C#7,[5?Q.L1?CX0 ??%IAV!P.*N[;[SM=DO3!O\
M$K1N?J;66 JURE*IE99Z+?=OTS+_'LWX#VE)P*2F Y9I4<!Z+0S8K8G ,S0>
M>(E& V_2<-##&@KZO0:#/]- L.TG!#%7)CAN1;DRD70$'#"UCWAX)S:MCR3'
MPI:U@3Y:%12DY<$Q6AJ2JB4AN9H.+=6B4*L6AC5I,JQ#$^$+-!8^IM'PQ1J.
M6*.AB.T:B#A="R(O5%_D]>J)?$#=D2^I*^J?ZHRRV=%E$&G3D^9D$JG/Q:F.
M_2>[4QVUCS6DARNP91FVS$3.T^)(?TU%16@R.E'C,9D:BRG42&R%AF/K-!37
MJH&X'O7'#:LO?DJ]\2O5';]%7?&GJB/A/+4E7*?6A'O5DO""FA,_5E.B34T)
M-C4;Q-OT: ;]D$F*!4YEN=_&ZUH^6T8*LAA;IK!E,F&.QN/]-)(0HJ'$6 TD
MI:D_*4\+DDO5FVQ53TJ3NE,ZU9DRH([4";6E+E-KZD8UI^Y34]HY:DB[1G5I
M=ZLV[=>J2?L(V.RH377@ 5+AJUGBS\J5]H*-8 4_3_/Y)/:,X9MA?#.0ZJ,%
M:8'J38]2=WJRNC*RU)%1I/;,2K5EUJLUJTW-67UJRAI38]:,ZK/7JS9[KVJR
MSU9U]E6JRKY3%=G/@@^ S8$L!^XF#;X\7SJ#)7XG6 MFP"2?C6 /5$Y]H"?;
M4YW9_FK/"5=;;H):<C/4G)>OIKPR->35J#Z_177Y/:K-'Y8U?UK5!6M56;!;
MY05'559PA4H*[E!Q ;-^P7O IN)\)_)L^EDAL5#$."0%W0I6@D5@E,\&^%TO
M-G9B3UN^NUH*YJNI,$0-A;&J+TI5;5&.:HI+9"VN5G5QHZI*.E51,JCRDBF5
MEJQ62<D.%94>44'I<>67_DRYI4^#=Y5;\H/RBFT.%-ET2PEI-]@/-=GDW/]B
MZB]#H)?/.["E!9L:2]Q45^JKFK(@6<NB5%6>I,KR+%64%ZJ\HD)E%?4JJ6A7
M<46_BBHG55"Y0GF5VY1;>5C9E9<IJ_(V950^J?3*MY51\3VP*;/<IJPRFZY'
MYS'2WST5C$.P!(Q5..HO7:"9W]?S6@-MJ:KR5D65O\JJPU5:':\2:[J*K'DJ
MM):JH*9&^34MRJOI54[-F+)KERFS=HO2:T]36NTE2JF]5<FUOU!2[5M*JOE.
MR5:;4JH=N!K99U8Q%Y'^K@)38 CT@#90#ZJL\"XH2TG=/!75S5=!?8CRZV.4
MVY"LG(9L93<4*:NQ2IF-C<IH[%):XXA2FY8HN6FC$IM.54+318IKNEFQ3?^M
MF,8W%-OXK6(;;(JKMRF^SJ;CR#\=^5MJI>5@ O2#3E/_ =8ZN#?TL:@)[M?L
MINP67V6V!BBC-4+IK0E*:TM7:EN^DMO*E=16I\3V=B6T#RJN?5JQ[>L5W;Y/
MD>WG*Z+]1H6U_URA[:\KK.U?"F^U*:+%@8M(N_>##>A9 D:<-: V4 ]-JD1W
M<0OZV^#_'?#?+D\E=5N4T!VB^)YHQ?4D*[8G2S$]Q8K&>5&]+8KH[5-X[Z1"
M>U<KI'>/@GK/46#O]?+O?1C\5?X]7RN@F^RYBZP1G(..W<UP?S"%KD'0!9H!
MW:M2:%)^)_JACBE0E;A^-T4-^BABR%_A0V$*'8I3R%"J@H?R%#14KL#A>@4,
M=\E_>%26X16:/[Q3?L-GR7?X&GD/WR_OH=^!S^4S2.8Z0";?;],9M&\;>I:#
M<= '<*<:3 T*W87H9NH14Z#BA^ _HU+PA(?\%_K*LC 01,AO80+(D._"0ODL
MK);WPE9Y+1S0O(6+Y;%PL^9"I-P67B[7A7?)=?)Y\ ^Y39#)C]LT%QQ QP:P
M& R#;M "K#W$(+IST)T*18H?0S^T,7@1''")FWR6>6O><HO<EP=K[O(HS5F>
M)-?EV7)97NK8X+4<(<LG $1Z.7QW&61YV6W24GC-4KC_#!G<#)GD$EC* L9#
M/W/" L=9L Y0S\_ET.6\$?C_./JA1Q&+I:"EZ%\A^:QVD?LZDJ_U)#SK23;6
MA]$0^-0&)O6-3&H;&6P;X54;<=Q&>.9&R/1&"/0&R/)ZR-MZ"-DZ;%AKLV,S
M>I;2SC'0QY\TFQH0;2Z@S1G34L(,^M$;M$;R@RYZP='G;"/9VP&OW$'"M1,[
M=I%H[ YGDHECT6&QV\L$NY=!M1=?[%T(^*.]9_#[:\'#?!=RN.M?_"TV[+!I
M+;H6X;)ALP^'][6TN7@),;@<_KT:_>@-A+;[;9?F[99<3T$_'%T'79C@2?A.
MQXY#\UEPL.,(=IQI_B$HT[$GY2QS&).&'5T)Z(^CESGWH[S*][_Z<3_*"O01
M.NH#C>8<&%_/62<EH3=B!_KW2KX')/?3T7L$G"V3:#+!.W$A_K@(?GL)_KB4
M?CE.OUR.'5>P\%[)Y'<E@7V%N1X(YUT.N;\<0G^<#/[X)])EV'"I34O-62C0
MAJ^K-Q(#?#5Y#_&'WH##]/U9)]5?3.UEMA9BWXOBK(G<@$]N(BF_!<Y_*US[
M9]AQ!PG9'<3&'77.<SGF<=DTY';^\/;'^,[;)/'?V6^-78C>GBW$(6%3O(\8
MY&O1Z VDC3Z72FY7.G7=Z*RYW.ZLA=P%[G'61.YWUD0>GB,]BD\>,[>6D 0^
MF>38K&NND7^*N'B:#GWZ @#O?_IE?O>I_8DY0[2YA?ZM(&2R"-VXBXD_]/J>
M0/\M3IUWZZ=]*&8/RA-.S)[),361V;T:]K,RYO96^N9_\,=?&"M_9=%[C0GN
M=8+[]=.DO^&+O\&F_D9LOOZYNH\2A[2Y #\G\ZNPFXD_S)QKZB\/.W4^Y=0S
M>V.K^4=ILS'_56<]Q'X6YS]J(1^8)_EBQ^?$Z1?$Z)?TR5<,PJ\9(]\04-\0
M%U\C^&MS%L9;/YW_F+V9T_%DD)^>FFN>6&OV@IB;0LQ38\R-J>ME;@OY 3;U
M'<SG6YC=-S"QKW2)OB!@/J/C/L5Y'\,@/X)S?\@WS*T<'SAK$*;^\4MG#<)1
M^YCE_G.=]0=S8TF\'$]),3=T-.A[=:)C !T3L+4ER%^I3[#C']CQ(7:\SX!]
MEX'S#NSS35CIWPG6UPF<O\#6_P23?Y6_,F=?S-X3LP?C%\X:Q /_1_W!U&6^
MA]]]HTA]"=?]'%]\ L?\4,WHZ$;^D/.6T"5(7J$_:AVRM^@5['@).U[0F>BX
M@*Z[DG;>3#<^@+[G[<^-F3U[8G"OLP;Q7_]A@WD(\J?XXGWYZ2V%T(YXVI$)
M)R_!_AK\UTKH]>@9['@*.YZ YSX.WWX,OOTH[/5AV.>#V'$_K/A>F/G=#. [
M=0>Z?J&?(<W<(VOJ'K?(L0_C6F<=XJ?ZB^,,RI_EV(/Q'+YX&E\\H63",A<=
M9<BOTWW8<3=VF'T8M_^X#V,9+5[CW(>Q6R?@W-?J&/*/XXV;X.\/\NXEII>/
M[2>HS+X+LP_#/'?H?*<-7SK#^17G<'L$7]R'+^XD+FY3+#K2T5& _ JFBGHB
MKDU78<<5V'&<.+U4BY"YC&EL#;VP!;E[F4H/8\4%\/9K\<J=]-#31.W;?/JM
M?3?382?,^Z_EN)#G!6?]XQ[G5'0"7UR-+RY7./8G8GL6.HJ07X7\!N2W(;\'
MV0-$XACR%B%O&1Y8IX/:SD@YH'U,[*<@80\2=^/)7?2JN6_7G# [&::<^;(K
M;0>WN3BFQ,O!Q?CB/,;(V0JB'=&T(04=.>@HH<>KM1\[3L&.O=BQ!W_LHE]V
MTB_;&2];M1%O[-$F_FHCDM;CP75$B=E%M(:1M!J])^,UEKTGF.9O!U>!"_CY
M+*;^,[#I=.:, [+0GE DQJ$G#;OSM(W8V,*\L5F-Z&C7!O6B8P@=D^B8T2K>
MK<":Y5B\%,_-T!]+B*)IYHI%>@]\9S]Y-XN7F-KO9YFYCB7O G &[_>S%._Q
M97GW=-$.-V_:Y8^^"'0E:IU+IM:X%&J5:[E6NM5JN5NSELWIU-(Y"[1D[J@6
MSYW6HKFK-.6^19/N!S3A<8[&/*[6J,>=&O;XI88\W]&0U[<:]++9,01^&<P2
M9L[>,+6?"?;Q?EL(:0_IP#KL6^L[5VL]?;7*,TC+O:*UU"M%2[QSM-BG6(M\
MJC3E4Z^%OJV:\.W1N.^01GT7:L1OA8;\-FO0;[_Z_<Y1G]_5ZO6[2]U^SZK+
M\C[X'MA^Q*.1CNV?YT<[_CEH.Z_K^7EE!.D?]LP$ <L\+9YOT90E3).6>(W[
MIVO,/U\C 64:#K!J**!) P&=Z@_L5U_@N'H#EZH[:(,Z@_:J(^@LM05=H9;@
MV]4<_+2:@M]54\@/P,9[!^XC#;S*I#XL]WO Q@1'[6,QGT]ASP2VC(>Z:BS8
M5\,A01H,B=9 :+(6A&6K+ZQ(/6&5Z@ZO5U=XJSHB>M4>,:)6DL^6B+5JBMRE
MAL@CJH\\KMK(VU03^82L46^I.NH[7EF)(AVX(]&Q%?=0,CXP]1>PA/>3?#:*
M/4/8,H M_5'>ZHL*4'=TA+JB$]01DZ[VF'RUQ9:J)=:JYK@F-<5UJ2%N4/5Q
M4ZJ-7Z6:^.VJCC^LROA+51Y_J\H2'E=IPAO@6\!*%._ K>B\D"7^ *GH9K <
M3(&1-'3SNSYL[,&6S@0/M2=8U)H0JI;$6#4EI:@Q*4?U246J2ZY4;7*#:I+;
M59W2KZJ4"56D+%=YRE:5IIZFXM2+593*+)?ZF/)3_P:^44&*S8["9)MN0-\Y
M&:2]6<0!F"$-'.=UD"6_E\\[L:4=6UI2YZ@QU5?U:4&J2XM237JBK.F9JDXO
M4%5&N2HS:E6>T:JRS%Z59(ZI.'.I"C,W*3_S5.5E7:B<K)N4E?6H,K/^RNO7
MRLJT*3O#@6O-MFST[LR![^628^<ZZB]]_-P)6OE]$_;4@9HL;U5G^:LR.UP5
M.?$JSTE3:4ZN2G)+5)QK55%NDPISNY4/,<G+6Z*<O W*RMNOC+SSE9YW@U+S
M'E9*WI_!5TK-M2G-(,>F*]!SF-1S6SZQ6.#8_S((NOFY%33RNUILJN*U(M]3
MI?D6E12$J+@@1H6%R2HHS%)^8:'RBBJ56]2@[*).914-*:-X6NG%ZY1:?(J2
MB\]58O$))10_I/CB/RJ^Z$LE%-F46 @*;+H4/0<+'7N!EH(Q4M"^8D?]I0G4
M@@I^7\IK4;&["DK\E%<:J-S22.64)BB[+%V99?G**"M3>GFMTLK;E%+>K^3R
M*266KU%\!3-LQ3'%5%RGJ(H'%%G^>T65?Z'H,IL=,:4V75#DN"%G'91D&@R#
M;M *ZD$5*"XCWRR7<BM<E57IK8PJ?Z57A2FM.E8IU2E*KLY14G6Q$JW52K V
M*\[:JUCKA*)K5BJR9J<B:LY26,TU"JFY3\'65Q1B_4RAU3:%53EP#!V[T+$*
M'0N=-: .T&3J/Z <%$!5<JQ2.O0MI6Z>DNK]E% ?I/CZ2,4U)"JV(4,Q#06*
M:JA09&.#(AJ[%-8XJM#&Y0INW*[ QC,5T'B5_!OOD:7Q)5D:/I5_/9DK"*RS
MZ0CT=%N58R_0&.@%K;,U(%""[EQT9T"EDQOAO\UNBF[U462;O\+;0A76%J/0
MMA2%M.4HN+U$0>VU"FQOEW_[D"SM,YK?OD5^[8?EVWZY?-KOE%?[<_)N^U ^
MK62N+0X<1,?&&L=>H"'0!9I #2@G'2] =V83[6]!/U0EJD,*Z?908*^? GH#
MY=\;+DMOO.;WILNO-U^^O97R[6N6=U^?O/JFY-FW7AZ]!S2W]V*Y]?Z77'N?
MEEO/N^!;S>VVR;W+IKWH6-W >*"-"T [:.#G*EZ+T9V#[M1V]$,;HWJDT#XX
MX(";_(:]Y#UBD==(L.:-1,EC)$GN(UF:.U(BMY%:N8SP!R,0^)&5YI&_ ,(X
M#/<??IS&DC4-?<, M-EASH0M Z.MS(>\MH!:4,;/>>A.[X+_0Y&B^FG_H.0/
M3?$==Y7G0D_-F8+#3+'@3['@+F)27\2$NXA!O(@.7H201?#,19#J19#819"I
M*3*D*<C:%&1H(39,VNQ8CV^G,7FPTW$6K+'#40,JZ*8/:',B8J*&T3^.?BBC
M[R)I'F)=EY'H+"?I64ZRL8*%?B5\:A6+W2HFWE4,ME5TYBH:L,H\AFD]@,BN
M@D2NA)RN@)BM((M>C@W+8$SHF:"="T [OJ[AM9@V9P_!_T?AOX@(,?6?&3CP
M<LE]%8G>.K#>3=H K]Q(LK.)1&,+B_Q6$H%M+##;LQR;_[8UF\=A 7CF-O,X
MXDOX#F1YRV]9G+X V+#)IB5\900?]]+>1E[+\74N;4Z90C_M#4:O98WDM4&:
MLQG=I@:S"^PQP(Y3L&,?_CB ':=BQVG8<;I9B)E<#U4[-CZ=/N5X)-#ID.K3
M(-('?\5W_\G?./:B3*%OB-!IX[4:7Q=,$X/+I)C5Z$>O'W_JN5-R,?67 S))
M)@F?'/M1CIJ:"(GP,?,/<"2BY]$O%V#'1=AQ"0O=)?3))03W)33T8AIRT2%
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M-+L'8Q:G +,'YE7GT#/3C-D&Q_#49?CB(OFA(Q@=,4R3*>C(P>X2'58UWFY
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ML4YIOG6]_*P'Y&.]2-[66^1E_86\JM^4=_6W\JFRR;<2[F_.I)4X]@+U.6M
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M2#)&O<T_+C"P6-@F67P6FL*_.729[[ATR#ST:2&$VAQPF(3 3IY@0H88CG_
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M[SP(LS#_/Y_;^^.<$&8M",R-E9=@Y4!XV<^(N8 V.0NC.[V!_:S>WB!"NE%
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M1-E$1L-BE= >BK X!?2/41AQ1F%499Z,Q>R,5 "L(4-'D+T&9C63?P%F ^K
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M\5\CP_C>DV&\E.A#_G;(6,V$)\S:%PEVV,;D7I0!16 D^,@-YR(R8KQDA)@
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M=))8)ITE%TT7*/M#%ZYTG;HMW3;'G!Y<8$R-%QM0JV6ZU'ZY#G59>9!ZK#I
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MO6@S<[S;8!-RJ=(I;:# O;0[PZ^N.3&DM38FNJL\/+&W*"3C9%Y087^*=_%
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MK:J[J?;$G51O\C9J,F4KM5+;0NVF;J9.TS915\!C^D;J/5V+^JMOH,% V)!
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MCT+$>GF(VW $4C?(0MY&62B:D9(>=/Q+"!(YBB \F"7F#8O$76&Y!![62=G
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M6DUJ35E.G7QG^>WD&\M?6A.6H#$=@$,=[% '_ %I(,O* %5A'GBJ+P9/PY7
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MK1<'#]3#'^W-<'1.XO=(0ZKLG)]9BHL^YFJNGL@WV#Z692UW)\51_7*LJ_%
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M3!$L)I6^FW]2_F3V7?F]&2B_-0?%"7-0>#4-8(4ZF.^5!.Q>*2 >F 4N1^:
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M/952XI%++:26T_+<F^@Y;F<866[_8631WKAG>'YP3O?\@DNE_[!-I?^T^3<
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M7QO%C+[VB!M\&Y70_[9'4F_^G*3N_%^2NM\^2>I^_;FL?:, 6Z;(_ -D_BF
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MRT(S12J:J=/0FJ!K,:"] 1/2+5G0UID=;0(YT2J>!RUR>=&\BA_-6E>A::\
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M@?FL8EC#N@8[V41QF$T$=[()XS%V(;Q)W/^77G('&@^1^6?)_-\ (LE\[\<
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M6Q?%/+0JB?MBO#8!]4H34:LL"=660G]V<A<H\#D5X'X>P(VU#'"Y@@G.U[#
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ML3551E%SYTT)K^Z<&E*]:GI0U989 55'D=O3@ZK?30FN)I-"YQ)]1&\BCQ,
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M,X5A::8L=&;I0%OF-%ISA@VS/LU9>&Z*#[LB.5B\-"E*HC A02H_(4,V)[Y
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M,/L)X)@1,I$?9R%<1 (1?#\'&7\>9 ;B@ 1]?R:E"L$//3+X_3QFSW\A"MI
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MRYR;N"5.'>)%3LMYA4[#$OE.>R7RG"](YCH_Y>>X$'&$@XA]1W2<E]C_&VX
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M,T+^RV*L?=.R;T_FI..\HS#;=QOF[\3\/5C_?0"::.D*1P DCP-PT=:%SU)
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M H.#-Z%_X&,8[/\5!OM$&.P5A0?82_[-K/OJ]< PN3LI!VO)64B^5.KQR$.
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MA_\^)?.(<G?('6KU]ZBVO\%]*O8'N8_?_J\<B#ZUONY,B&K&?&>BM$/:H1)
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M^#<OVN5$NRP)XPXM&'7H$S-AV&$%@TXGZ'=Z$H'0ZXPFTJ';60*=SB9H=PY
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M@3TYS[C6:CCF0[REW^*;5R (KZ''GTG$7B=!> .?O$G#?I.X>)/*ODG!;[Z
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M?!%C!#1]!J_C^#QL/K'(=R7HETE1\=@HG/N#T,MOFJ\\II'X]#+(]S*P]3+
M]3+ ]#+P]=+Q]A+(O01W+S=/A>--A;A/@=!-@41-?@&!:_:@0X]=A\'9!>Y&
M;ENY C^LY#9>1T*3!W.M8@G\F^^3T"L2BF1%-W_$O1\>U0^WG ^GF\\@/Q^^
M/9^!91Z<:AZVF->($$3S,. \?C@7@C\74CL'TCK[UPS&'R'?$OQV[5_JW NT
M;JUS'<IT9"S2MDZJ10J15+Z+7B/9,*D_XH%H-5Q[-8G?*FRQRNI:DT+2L0J^
MO8I.=26V6-GJG.Q<B3%7F,T^1P@X2.4R2.K2]P'\!K$[SF/9O)&?;4;-K?0)
MJ-N.#-J.#W9(Z;S&(#;$?[M9@P(^UTGP>/4@V4&/[>BQ'3VVH\<.$K$=^&0'
M ]X..K?M-.[M!/RVE<X'$&\E+K>0.6\FD]X$H]EDU[8MSFF:!;MP&51TU#Y\
M0/B40]$SD5C$=A!\1&8-RI7(D<O%#2'Y/$+B=P0]CJ+'49+#8R8I(RDX1EP<
M)3:/]CL?!'2$F+B2N#S\"N61U1^R._8"+0&W#ZPQA^F/CM(.CDO95TEQ)\#'
MA7X#:U#X.82%A.='8N9&KO=D /:3;B AOI'X.(\>-Q$;-^&3F^APSV.+\SCT
M/(K?> <"[[\!5G7N:RVG?C.IVSAP6\&J!B<'G'C*ME&V[\"\R\TR?_04A,HY
M%S(@ WMS!N9&[B%6[\,W/PN5'J2M/$AL/$1\/L0@\# -X"&<^" %/_@P[__,
MZZ>: _8$L(>#6WN.OO F\%UGT?K<X<*XX)IO&9B3>,0EC[KF)R[*>4;)P'S(
MKSR<9[6^ %%XB63P)6+C-PR OZ4#?ID&\#*V^-WM"#]X^2_J.4,,@EU//0O!
M3 33!J;/?9=A/NK"&%@/\JPN6WNB'\YJ?<4U%V+6A3B>(8,>'V"/#TF0/R(1
M^3MM]6,ZOT^(BT\P^"<8[A]F-8*':P["TS4?8O;&F.?3FC-)S7X8<QZ'>3Z,
M.1O5K 69!D>= U-:*#P)>URK+V%:7]!0/M<5<,=CCA,6/L%Y?X>M?HAQ/H!)
M_XV[!LXA-?,09B_(+UQS$/\]_V#F8LR9(.:YL+GZ#H[YM0:#,8*RS5Z4'LKN
MH^PYE+M0?W4\&V4MG'FSZ]DH!S'#5?H3P?HJP?,*AGP9-OM;?FG.X##[7W[E
MPC9S$#_]'SK\6[[Z%_SNGXK1QW#=C^"8?U4MY0_5&_#MUS26>O3H]^CQ6_1X
M"1;Y @SL.5CF,^CQ-+S_*5CBDS#D7Q+,%T%YE$^/H.5#^L:Q]N-GKOD/L_[B
M_&4Z?.>:@_@0W[PC"W4)UQ^QQ<MPS!=53OD-Z-]*:9W8<"QE]U!V'V7/INP%
ME+V,>JW1?;#@>^"Z%^@\[J(AWZ';P#(K0GZGFZC9P%F@YHD^Y@R,DRX=Z#$=
MCQMZQQ56SQ,73\D&5@PX:910@.Y5-(U&RFZC[$[*[J;T293?B^=G49]^RE\*
M7U^#%[:"OI_NY"J= O$$MKB*$H]BT2/4UIRJ:YXP9-9?F%-VOW+-OY@M7R^X
MFM8CQ.=]KC48=RB!.F2!44SYU3#H)B*NC3IT4OX8RI](^5.)Q)F4/Y^REQ(1
MZXC.[7#V0UC$K JYC>[]$6W#DUN)K"WZ8?W%)L=<G7.IU=.N)GB_J^NY&5M<
M3UQ<0QLYJ10=QR='X/V'58/^3>C?JKW$QVYU@3$!C"E@S 2CG[*7:R/_UJ/!
M&GZY"ENLQ(K+:=!+B; EX%XNKWO1Y/VI.TWY EWM+9[.KO=JXN(8;>200JE/
M+%AIX.2!40I&#0A-8+32(MJU&CU6:;Q6H,<R]%A">UG,E05H-9\2YF&Y.=1L
M%E$Z4V]K!BW-/ G;K/@RKR_2O3]&=_93NI*;>3W#L',<?0[1U>V5#Z4$8:]P
MK)M J>G@Y%.7,C!JM(CX6* 6<-K!Z0)G A':"\X<RE]*3[(!+^W59"S90^1,
MQ!\3\(>9Y30G$(UWR:4([&^.P&*(N99A]W@TN1U#SDY2DTW89;6;/W6S@A<)
M5J+F*I/Z%(!3!DXM.(V@MF"!=K#&$*63*'\Z92^@]:SFRDZT.Z91;N<UTNT!
M=;K_1AV>GZC#R_Z]/&;F8%(8PM+AO<@AWN_DVL8H4@_LLLCBKCG>@9KA85.O
M>[2F>"2KQS-+$ST+-=ZK7..\:M7MW:0QWJT:[=VI43YCU>DS51V^<S3"=[F&
M^6U5F]\1M?K?H*'^]VM(P(L:$OBQFBUVAPQ!'J0KORV;(3F/H=[\^87A=@LI
MR&K2LD6D1;.Q26^PER8&6#36/U1C F(U.B!%(P.SU1%8J/; "HVPU&F89;#:
M+,/48AFMH4&3-"1HI@8'+5%CT&8-"CZL!NLYU5GO5ZWU)=7:_H'8'5*'W)OM
MW'Y[NL2Y#'97,7S/[($A!9E'6M:'32;BK]$V7[4'6S7<&J$V:[Q:K&D::LU5
MLZU8@VV5:K(UJ-$V5 TA':H/&:>ZD#[5A"Y4=>@&588=4$78M2H/OT=EX<^I
M-.+O*HNP?R]W,[R?(P4]40GW9VC;1NJSAL^+N#X+FTS&3MVD >U1GFH)LVAP
M6(@:PZ(U*"Q)]>&9J@O/5VUXF:HC:E05,5B5$<-5$3E&Y9%351HU7R71:U44
MO4^%,6=4$'-!^;&_1CY4?IQ=!;%.N<.LQ0'[&)QV7QU^0%;!L_O18WJA<PW(
M*.*D-5%JC/%77;15-=$1JHJ.5T5,JLICLE464Z32F$J5Q#:H.+95A7&C5!#?
MH_SX.<I+6*6<A#W*3KQ:68EW*3/I*64D_8W7[Y259'?(K=3[#+A'2#]W-SG/
M8ET!19EG*$(Y^541M"A7&H(>M4D^JD@(4FE"J$H2HE64D*3"A P5).8K/[%,
M>4FURDT:HISD3F4G3U!FRBQEI*Q0>NI.I::>4DK:G4I.>U+)Z7]52OJ_^6Q7
M*F+2O=/@'X+/[B3]7#^$6.#]'*Y-X;LQZ#B<&&DB7JLR/%2<&JB"%)OR4B*4
MDQ*O[)149:7F*#.U6!EIU4I/;U):^@BE9HQ32L8,)6<N4V+F=B5DG5!\UNV*
MS?XE\J[BLK]1?+:=ZXQAU/DDF >@ MOA^>O,.A3>ST:72>@Q&A^U$BL-^*R<
M6,W+\E-69K R,\.4GAFCM,QDI69E*B6K0,G9%4K*'J3$G&%*R.E6?.XTQ4*0
M8O*V*CKON"+S;U5$_N/(V[S_6E'Y=D4CUV/_XV#NAU-OZR >S3H4\Z=J=)DP
MQ)Q%(K74D^L1,Z7$2$ZAM]+R+$K."U%27I02\Q.4D)^N^/P\Q164*;:@3C&%
M+8HJ'*W(HJF**%JH\.+-"BT^JI#B6V0K>0SYBT)*ON*:W2%G3?H/_EZHR!8X
M_BJX]4*X]712OW'HT4$J.@0[U6*38GR36>&AQ)( Q958%5L2KNB26$65I"BR
M-%L1I<4*+ZM16-D0A9:-5$CY9-G*^V6MV*C@BBL55'&3+)6/('^2I>(+/I,Y
M(E>#<R7XNZ&GF\:YUJ' \Z?Q>2S7V[')8.ZI0M<";):&3>)J?!51%:3PJA"%
M544IM#I1(=49LE47R%I=J>":)@75M,M2.Q&9JP!(HW_M ?G5G9-/W0/([^1;
M]XG\:NU<)X^AO@=)_7?"Z3?T.->AS(7C3^7S&'09AET:N*<,6^7@LV3\$S78
M0R&- ;(.LBIH4#@2)TMCJ@(;<Q706";_Q@;Y-0V73],X>3?-DF?3*GDT[9-;
MT[4$-R2AZ47>_QWY5NZ-=L?9P%>8_4A3I;73G.M09B-3^#P:?89"TVJX!_<J
M';O$89>PX?#_-E\%M ;)MS5$/JW1\FY-DE=;ECS:BN7>1B"WH7#;&/-0&P02
MWP:9;(.LM4$<6B$&K?#N5C*X5KN.4.>]8&Z9P1@QBWB<3?\XV[D7IYWKC="2
M<G3)0<\D](G$-E:*#NCRD==HB]Q&V>C$Z,Q'Q3L[LU%TL*,(X%$$T2@":Q25
M&;48@2R/A#B.)$/J)&/J)'OK0(<.N_-,&# WSG.N0S'/)NZ#GH[A<PMTI 9=
M"M$OC?MB>J40B@R<+'E/AM/UD&A,8I"?1/(Q*=HYL3V1 6AB*4(03VQW+NR9
MV.]<5#'AF#0>?C7^20(>[C\6'<;:=<5<YUZ@=0/K4)!)2[$!GP<MHCWR719%
MQ$,5P[C7@EX^B&:3Y,PFP9AE,7]<H#&'FT6." /,3&PQDT8T W_,P' SS"*?
M=30V2'4?A&[:XW3"[R)?$WAV[<9,FU<XUZ$L,NM0D"[>#T6JH(:Y2!+?1^#2
M(,0''34@2TD$EY((+B496V)SKDE9P@"W)!/!%HOI7!;CC\4X=1&%+-I/PX=8
M+H"L]D,&YW_)H&#7]M7.,VD'UJ&,WTQ;0.J0PBU2"J^17 ]&?!"2R1_$?-Z$
M'IO08Q/VV(0>F]!C$SQW$X/,1@:_C6T(P;0!@V[8X3P?91V9\UHRZ34PFM5V
M;3%GTD)!YQ$R/=#R#L)WD'DFSUYB (E"@A$?L_:$:I"TT[&[Y(H!P2]7^'(-
M/0Z@QP'T.$A"=I"!]R!Q<0!;'""PKJ"R5T#T]Q.7^YZC,7R,V+4>W(5@3@5C
M%.4./D1?<*64 3V//HK]OS\'1<[U)Z==\R$_%C,_<@:;G"%.SY(87XL>UZ4Y
M_T!T'9WM==CB6H+L6H#.GD<@\F?^ZMB3LX1Z]($[!LPAX%2<HC^FS&C*##XC
M>?UX#<HMKKF0 7'LR7'-C9CS2NYR(T'U<YU10E)Z+[%Q+SZYCX'H7FQQ+PZ\
MAXK<0U]US^^03S23NHX]05<!;A5XV81,S(W4_R;)\Q97^7>ZYEKN=9&@!_2C
MO3AR_H%X8#[$K-EXT@?BA!Z_)FE_AH'_6>+S.0:"YVD$S^'49RG\66SQ[%\T
M >QAU]$/4,<\ZA4'9C#N\AR8>QG8C_.H?E@/\BN7F/F0@;-)7KAL+F3@[-0W
M\<V[Z/$>;>6O#/[O$Y]_HXU\0%Q\0,4_!.C#7_R(^YOU(&8/B'E6C#F3U.R'
M,>=Q-,NL!7'N1>F!)4W7ES"-+V =G\-Z/H,!?0J+_ =L[&-XU4>PT ]PX/L8
M\#T,] Y,^FTX]\ Y'"^ZUF \XIJ#^.\Y$#,7XUR/\F_XS%=PS,]53_DME#V2
MLL?!GB?K7?1X&SW>0H\W89*OP_K^A!Y_A&.^ K-^V;$7Y2;,<R\L\VG^O>^8
M^S"K7QYWS4&8)_G>_C]T^%)>U"E(?X=7_0VN^RZV>%.5E-](V</T6XVB'N/T
M/'H\BQZ_AM?]"GYY"3V>0(]?P$@OPE ?A5L] DM_D&"]GT_W4L(]CIU"SOD/
MLP;#/(?D[&4ZF#D 6JMC:]/K"M#O%0)6'#@98!11?@UE#\:RP_4P>CR 'O?C
ME_O41]FS*7L!92^#V:X#=1M-Y@JX^TF:TGF:U+VZCL"YEIH-G 5JUF*8\S"N
M=.E@S@'YVV5S$$\1%Q<5#%8D-DL"(X?R2_%N+4VQF;*'4?)(RAY+7291?B_U
MF47Y_7A@&>6O)R)V@G%81[AZ&*T.TFBN("+V$TWF1!DC9OV%>>KR9W(N9WK9
M%>JF>=TG-\<:C%NQQ7G'.1BI8.11?ADUJZ.[:J;\893?2?EC*'\BW>94RI])
MV?U$YG(TV$CY>_#,<;KU&_ET'YJ]@+?^\1]K,%;*[IC_><G5[$R3O]O5#5V'
M+4X3%\=I(U?"^P_BD_WP_CTJ1_\Z[< OV]1*%': T07&!#"F@C$+C(5:Q;_E
MCETI![486RRD5@OPZ'Q:RCRB?2[81N8AYIBA7_HXSP"YW=MY-)3I>H\YA@1_
M,*W4)PJ<)&V@G:R#]Z]&CY7X986:L'RKEM!N%Z/'0O3HQR_SB(\Y7)WE6!FR
MA\@]H6F.'40/:XI>(YJ_<#P%JL<E3S/,/$CW?@=#S?6\GN#S(?1A"*&>7I1B
M 3.$.L6 DTQ=LJA+(74H!Z<6G"9P6L!I!Z<+#2:"TT?9\WFW4N,I92R6[':L
MXKE/H_''**+?[+X;D,?"G(]#N]$L>R05.D1:MAM]-J/+:NRR5+[4+0B\,+P=
M2^DIU"<;G$)PRL&II?9-M)(6L#K Z4:3R90]BV@Q%C*[=@X0/6?51F2W$O$M
M]!4M]'8M<NX&?""688?A_BQ#[=$4YQZ8+>BSFK1H,7:9RS#8Y^D/IA6\"+#B
M04D%)P><(EI'.5BU8#6!U0;62+6ZC5>+6Y^&N"]0L_M:-7GL5:/':35XWJEZ
MSR=4Y_6.ZGR^1.P.^2FXYQG:3I$&'D1V\'Y]*O6GBY^'??I"R.TL'AKC&ZB1
M7C:U>T5JN'>"VKS3U.J=HZ$^11KB4Z%FWWHU^3:KT7>$&OS&J-YOBFK]YZK&
M?Y6J G:K,N"4R@/N4%G@+U0:^+9*+5\A=I4A=X)Y'</:<=*-_87F.3#8 +Z_
MD!1Y)O:9C$VZ\5=[L+=: BUJ#@Q14V"4!@4FJB$P77667-5:2E1CJ5*599 J
M@UI5$31*94&35!HT6\7!*U04O%,%UI/*M]ZN/.LOE6M[1WFVKQ&[\I';P#\#
MKSY"JK$;KK^1UQ5\GD\J-@W])I JC\1?K<1)H\U/M=9@55O#5&F-584U6676
M3)7:\E5B*U.QK59%MF85A'0H/V2\\D)F*"=TJ;)#MRDS[+@RPFY5>OA%I86_
MI?2(KY4185=&.-P?O-/P^T.D&3M)A=?SNI3/<XHO7P,B-4,?:B.]5!YF44FH
M3<5AD2H,BU=!6)KRPG*4&UZLG/ J94<T*BMBN#(CNY41.4UI48N5&K5%R21E
M2=$W*S'Z427$O*'$F"^5%&-WR W4^V2-:R]0 ZEFO7.)]BSX?@]#?A=Z#$,/
MJ)RJ$MQ4%.VOO*A@Y42%*3LJ1IE12<J(SE1Z=+[28LJ5&M.@E-A6)<=V*2EN
MJA+C%R@^?I/BXJ]43,)Y12<\HJC$/RDZ\0O%)-H5FV!WG,M['-S]3:[S8)&%
MI#PSZJ FZ#&2%+V%&*DG7LM)#_.3?)09;U%Z?(A2XR.5'!^/I"DI(5>)"25*
M2*Q5?.)0Q26-5$SR9$4GSU=4RGI%I!Q2>,H-"DM]2*&I?^3U<X6GVA6!G 7K
M*/A[X;*;23U7(@MX/YUKX_FN QV'8*NZ(O@.,9*3X:'4E  E)5N5D!RNN)18
MQ:8D*R8E2S&I18I.K5)4VF!%I'<H/'VBPC+F*C1CK4(R#LB6>4[6S <4E/E[
M6;,^X[/=(==0YROA];L-#1CN6H<"UY^&+F/1HQW_-..K&F*D&-]DX9ND;#_%
M9@8I.C-$49E1BLA,5'A6NL+X,C2K0B'9C<@(V7+&RYHS6T&YJY']LN1=J\"\
M^Q20]P*O'_.9K"V7<=R<#0SF3JCAAD[G.A3S9^JI</TQ4+7A?#\8/:OQ5R$V
M2<<F\45>BL@/5%B>5:'YX0K)CY,M/U76_!P%%Y0JJ*!>EL(V9*P"BV;(OVB%
M_(KVR+?X&GD77T">03Z03]&W\BVRZP3U/T#:O1UNOPX^O12>/Z>+-@$MZ4*O
M8=BE$9N4$R>YV"0%F\14NBFDS$_!I4$**@V5I30:25)@698"RHKE7UXKW_(6
M^91WR:MBFCPKELJ]8H>3.%0P,E>0)53 +2J^DENYW7DNC=F/1-J]9@)M BHR
MR^S%&>O<B].*7>K0I1A=,[%) OZ)@#I9ZWP44&.17XU-OK61\JY-D%=MACQK
M"^1>6R6W.KA_G?DQ1+T.\ERW%2&7KH.(U,*[:]]#X)NUY%)=SF<3;8;/KYI"
MF^ G,WB=Q.=.K@_&+I78*!__I.*?&/P6@ETL0[SETQPHCV8&E68&EV8ZLF8:
M<#.!VTQGUXP#FZE@<P_2[WRP;#,9P6!(T6"RE2:RQB8RR":[#IK]2.!N['.N
M0^F'"DWG=3R?AZ%+_22X)_=D8I<$?!6./D%4SZ_#2^X=#&CM<.[V4&D$@\L(
M!KP1="8C"-X19F$5"H\8C\PAL. 4P^'^P^#^PR!";61O;5\ZYF'V]Q(+X*Z;
MXUR',F\^\<CKJ-FHS?5*=,GCGF3TB:)*5GSECTX>XTE^QL/IQC'(C\468[%%
M-[;HQA;=IH.EP^VFP76C>#<%C5GMW%C1!8D;#2D;!?<?A0XC[=H#]N9^USH4
M*.DL9#SOAR_ !EPO0I_TN?C [,.AJ !LY#F=!&<ZO+*/!&,:MIB&+7I#?EB3
M,A5;3*5SFXH_IF*TJ51BRC*$S&@RI*X'DCCI=3K!?S$@V1U[@<R9M.8\E/Y5
MW,;KR!6X;#EM <GBNWCT"H4F!G*O)Z(!6>".^#C7I/2C1S]ZS"<1FI_B7/@X
MGT8T#W_,PZ'SJ-3<[30Z,L79]U'95QB8/W>L13%[@2Y?A]*]@;X9J4;RD$2N
MA:TC!A%/1)?+6B/88PWV6(,>:]!C#;&QA@%_#8/_&N)B=9-S Z"9<%M%@2N/
MTQ'2/I<_+RW[A^-<E$T;N;P%]6@Z$[;A U2MHRD7["0&D'#$@GB8M2>[D-UR
M)IM[7.^_%T^$^-B-'GO08T\<PB"SAXYM-YW,;O-@+@QK#D#=25SNH'UN_Y"D
M]3NM,<?'4/9DRNS8)PTRS^0Y2#L\1#^ 6 AE]X'U)T>1@?F0'\N) <$W)XG3
M4^AQFG9R.M_YAX'3V.(T@76*2IZZEGL@\R?,GIPOM1#<7E0;99Z+#$8IY:51
M5L1)\.G6W ;.01F8"[G1-1<R\.K8CR/G.I&!^9';/)UGE-R%'G>1!-U%?-Y%
MQW\7MKB+H+L+H+O@_7<^QWT?JX\ZCJ%N0\ LOT;*,&>A@&6Y? V*F6NY0S^<
M2V+F)2[?BW/Y^20/#\R'$">_)$:>I,T^26Q<HJT^11MY"EM<PK&78#*7'D'^
MK+'4M95Z5G$I^R;G,Y$M W,O/YX'&=B+\X2+F#UYV9S(KW\T%V+VR)@U(6]@
MCS?IO]ZB_WR;^'R'-O(N#>]=*O\.%7OGB1]Q?[,>9.!,TH%GY)K], VPLS;7
M7I3Q^IQ,_S.8S:<PJD]@/A_#N#Z"#7T MWL?QFG^NO\N[/IMG/,7*O ZRKT&
MYS;K/XR8LT#-/I#[7/, _ST'8N9B@O4M_.Y+>,1G<+M/5$7Y@RE[./QT-.5.
MT!OH\6?T> W&]7]T%K]WG&JP'NZZ#5/L!_4X6-=CHKM=ST1Y"R[_#6+'73_,
M0=SX(QW,.HA_8HN/% A>*+]* "M+?U2)?@O/?4%#]"Q,YFGTN.0X$W0*94\'
M80YN6D@8K*#\]83%#FI_$#>>(GQN1HN?X=H7=3N6,WM0;KUL#<:)RW0P<P#F
ML<=OR$QK^>IY>-73V.))N-WCRM4C\*D'5:_[86?WH,<%]+@;UG47C.\.&.!M
M\-Q;T>,F]+@1=GR.SN0Z?'*6!G4-=YTB@$[ N<W>$W/^YQ'7&HQ]B#F+U*P!
M>>L_YB \P+. %0I.'!CIE%] ,ZG0#<3&==CC+'XY0WQ<#<L\I4F4WTOYL^'K
M"RA_I0YK$Y;8AU=.$"$WT8T]H)UX; ><VYRLN]6U_L*<M/N1:_[E65?(FR8V
ML ;CG.,<C$B=5B(E95)^(0RZ4H>PQP$U4_XPRN^DRQQ#K2=2?B_ES](6[+$)
MMKZ!3^NX>PVEF"?'+(?O+M.'CK,O!M9?F%-_#;Y9 _*(JRG>ZNJ*3F&+H\3%
M0=K(/D53CV0PLM&_2)O18R-ZK"=.U])>UL"W5\&"5Q"KR]!C*?&Q&(0%W&%V
MQ\RE!K.)P%F@S-";1-#7CJ<_#\AS="6/>$EW(^?=G=/.SOD/,SSX@AE$?<+
MB:4NJ6!D4WH1^E=0VSKUP[?GP>CGPKQGH\=,[#%#TRA['MJ8E2%;B9C#7#4G
MN=Y+!+V(]SYU['HSIR";U\?I0G[*,'-3L'0UKT?HVO9ZF?D/>)_<P0T TTJ=
M(L")!R<5C!PPBD"JT%1X_Q3TZ%$+4=&.)<: TT/Y,]%H$9&[7B.Q9 >1T^XX
MV>42D?0WO/B=XS1F(P\RY-\6X3P"ZQBO^^CBMY(6K467I:1*_?07LXC//MG
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MA%]$?J.#-<YC =</=IZ',A?IY?TXKK6C6S,V^G_VW@,NJF39'Q^"HB J*F
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M$'*:@'_740(Y']#E-."+ EVX@$V8@!Y4P'\. G\E9<>'$9W<!<-C 1,[,YA
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MR/WY0:/\(+?A!XDA'T@F>$%"P@/R;AZ@ _<F[!+J7%R0CKJ#U,,.=28LN(S
MI0[R^]- %T&@'RNP"2VP"07092]H<A>P"W@E ".!%YH4L(4DL(4$L(4$V<^"
MKCAX'N+ )\3!PQ,'8'$@1!SQ\V!/49"\B8)H3:0)] 'X@] F[ +J[S,#EW$U
M!^\)D,M;6(%Q"8:2$NIS(J 7%]"/$=CD"&AF/[ +,= '#]@&O$C!PP*7$L@M
M%4&^K0#\0A[80A[80@Z\".7 \Y#C0_VQ:7"!!RT+!,B"J$0&)).G0<(F#1*A
M4].@#YNP0,#R BHZ U/9V@%_!"F0.@@<3@-=^ 'OA-G/OXES .A# AXK/JKN
MH?O']6-/"KBT@!Z:X)EH@&>B <:(.K"%.A@?ZN!YJ ,G4E?Y8S\*&)^J(+$]
M Z)&%9"4*4T"_3=__&UDU#X4U-\FM@(7'+BO OAO$: /.^#1VL!@AX".I$ G
M@A_U#G"9_PANP$0"^V-/"KB,@1[&0 \CH(<1&"-&P!:&X.5G"!S8$#B3 5#>
M #2N#\:G'I@K=4&2" <9A?;WG_M0P!2&] 2W@7^><0>/%US<0&4&5^ #0"]2
MU'<XX';8U@NUT 1<'6UO"A+XA^WNGP&0+3D,9@/\PH;KYT%0UL"QK%&'SP2!
MSH*DVA(DKQ;O0'_68=X^H$G@*F;@T@#7:7#Q^8-Q *[#X-_W^@+Y/[Z[^>/:
M^CV.SQ^7]]8+[^>9L=Y #V_P3+R9?[X,O8!#>P+#>7K__)O%[F!\NG4!1UR&
MN8( UA*HI@.&KAR80@0O 1^X#*9;<.T%_TZ(.@?VUUFP5V&_ZR$8W^/ T+_5
M"0;C)63_ST6R$##)!P-;! /G#@9&O 8:N H2^RO/0=MS,&O0OA[J*!]PGT@H
M&(<W?IX'NP]<A.%_!/NH?29;:R&HLTG0OL'YX[?;?R0(O\XM209Z)(/QF@R>
M23(8(\G %DG H9) IY.2P%4%<.]AAL!-58 L<2"' \@Y#N3L!^T3_CH#Y==Y
ML+^^Q?GU[<VO?Z)]AP/[71/Y50\I ?Y10O['V21@<BL#MB@#3E@*A)8"<.E+
MF"J8,J2 3"X@CQ:\TLC JW7'UCTHO\Z#1;7YZ^_4H&HAO_:<H!;H44GJG]_A
MP'Y_+X,Z0_7'>2%@[F@#@<<KX)^OP,NA'=BB'3S\=B"P'=4 .N$1$.[8N6LW
M,0GIWGUD!PX>HJ \?/08%34-+1T](Q/SB9.L;!R<7-R\?/R"0L(B8N(2DJ>D
M3\O*R2LH*:NHJJEK:&GKP/7T#8R,34S/FEM8(JQMD';V#D[.+J[N'I[>/KY^
MYP("SU^X>.G*U6O!H==OA$?<C+P5'1-[.SXA*3DE]6Y:^KW,K/LYN7GYA0^*
M2DK+RBNKJFOJZAL>/7[2^.QYTXN6EZVOVCLZNWMZ^P8&7P\-C[Q]/SKV\=/X
MQ-3TS.SG^2\+BTO+*ZMKZ]\W_U7"]?__>/_Q\%$])D)U>0_H\WY4I\E!KX^@
MNGT<U6\&T'$65,_945WG 7T70'5>%-5[*=!]&53_%8$!SJ LH(DR@2ZP@2'*
M"&8H*U@!,]BB[."(,H0;L(07RA3^P!9!*&-<1EDC!)@C#&6/*)1!XH!%$E$F
MN8.R208P2C;**@7 +,4HNU2@#%,++/,099JG*-LT ^.TH:S3A3)//[#/&Y2!
MW@$+?4"9:!)EHSE@I*\H*WU#F6GC^Z:C->HD!?#>Q0/S)1[4&;#\]R][83'8
M=A;[WS79WUOL+PT&L1<,#P\?GX" $-A@)Q'*"L ,)'OVD )+[-N_GPP8X^ A
M8 X*2F"0'Q8!)@$V 48!5@%F0=GEAV%^^A+$,C\, ^QR1A4UE,!(,C0V/6MA
M96UKY^CLZN'E>R[PPJ6K(=?#;T;%Q,4G)J?>3<\ PP4U6HI+0!=_]!#2P9\^
M\<,I4)T$O03=!/T$'04]!5W]\!%T=GP"='=J&G1X=F[N,W"2+U^_+H!^+RTO
M?_NV OJ^MKZ^L?$=UW\<X0A'.,(1CG"$(QSA"$<X^I^F]Q?V*LG(F&EHJ<LK
MG9&#[=[]OZT0COY_2PM_PY_J^!O \@0N,<81CO[_2>]:^_Z2/U086_&74\C3
M&[99G_X*\#(IY-Y? E;;:IXM_J42.,(1COY7Z,W3NK\<FPVW_*X\_0O^ZYM&
M$HC[2]ORO]=Z\L-T$J>V!71%!RJQJR5,;\?O[VXN"40X9JS\A1(+3PL*7_P%
M'T<XPM%_B3[W/MMV: +Z6!/I89F[O!U[J3'!78Z9/^#E=H"R\W!N8MB1L\7;
M\%]Y")# 8#!BK:QM +'\/U>WU;<!+"&I8;#=>W;NUBK"#F@1VWM0X(R1ZAG3
M)]@!V6<%SUY-+<_+KAS #G@;%U;_81OU?M+,7TU>.,+1?RQ-#337/M^>_2KA
M@J.A?/#D=OS&<Y+,J$]S'VS#?WM)_,?HYKPV@QV0I[W_!X#2L1<K?^T\S\_Y
M8;<Y]CFHTQ#_C_TQ)M@!]P5^;: Q[L(*""#]!=#!JL-L@-PO@&PW-L!ZCA47
M4(*07DA)OPVKB(E[]M(GI"R#8K*J![$"-C=[BO.*7XZM;L/%$8[^5^A#39RW
M1=.V[-<I-H+$,/P;V_&;@J1VH :.Z2OL_($+(C]'EG@.=D#*F3^&'L--K/PW
MSD?_ .P/P/J2+E3\<P.=\RPVP.6#?P*L/F+A3VO^WH*G-XP%4$G^&Z"(;0;Q
M./0;((S%$"MIAK]U8,"6K(TD&K/_ I!68^O%7%$ 7(2>C @/GXQ^NUALI"$C
M_G;"G;RZ[>8@'.'HG])H??+Y<VO;<;]47-;CW@NCSMN&WQEZYN?H<?N*E=^+
M^L+P!ZE@K0^L1DK^&A=<N=@ #PW_'%E'8[ !PAC_!.RZC(7_R?3WX(5Y8P&4
M,FT!V&$!!&SAPXPP:[4;;%L!9S K+1E;^3#Q=Q@ [CU; 1P8:4Y\J#G+%@ +
M9D5YICX$_AO"] 9+-[XW)WN9*(OS<K!SBRA@FP=_].7C4&]G>]? V#9\'/W?
MH[GN&NRQ/8H^54;8J7"1.V_#'KMKPT_TP^NQEP=[+XK]X;,'XK#Q9Z[P_.G5
M6&5DGOX]+C0P1];F-'++P!'"HD0)UQ8 ?3DFP'?KV-R/6>7XPH\VO.,Q -EH
M?!AFK"6/#@B"\D?0^3 /*" . L"8Q=H@ $L,'4[2HWVN8(X!J$H_KR=$^2?
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MMP;[C_2:IQ$+^VV4VF_/C<#D=[ILG1\P?'9SUGG?5H\3>@\%Q%*AN>2AAU#
M*8A7IT/X!1 ^QB25 @6X00#0MS_,# (8A )4(8!5*$ ,VHN]$  KM);+!P$<
M@P8QIA# /F@0$P$![&R' -JA6C9#M62# ##JXN<A@!8H8)D";\<.@I\A(=Y.
MTL,8@,WUJ7?]KU ?VG=V][UYO^W"&X[^K30_^&P[SK/TR[:JO(=AY%CKCU7G
MY __\@973';?N:WE S&,*&;$:O=6?]J#$15[$*![7!B$_Y0<G8^18,1#O5X%
M BB' K@W('V  HY =I,N00$[H-D<=/C#'D$ 7%! (02@!05 \T%?*" < LB
M LY# /U0 $80(P@!.$(!YR  )!301XH.P"R30-(@S"!F4T-<7DW'P,3<RM;!
MQ2L02TR*HW\OS?74I%]W-\2Z_/"M(=Q*FN['&BE,"S,A74[6/?S[85-"A\7F
M!P<*-'> #O]-2XC'F4+XD.H"#"8 4>(N%$ &65YHA@)@->B 60S 78@2>Z"
M4 B  PKP@@!4H0 K", 9"M"" **A@%,0 $88Q T!3$)G,7H(8%,6 B"' BY
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M:1\4( DQ);3$"6.# *!#$R.(@:8/L!T00!Z&EA# ,#T4\ 6",(8"1B" 5"@
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M/72 /08 4@V.Q ! <OL*#  DMQ^F@P*TT0&;T'<[3 H"\(8"H%%.'J3^ *.
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MX?20-R_F(@I, ET)C, <6AUPP&P"'8!9XX  7F#4<F#HJT7S AB $?0FC#
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M-[XX!-%$5):.;L(JU<G8BG[<RW+3J,1G;K*ANNAN*760APG#@N?KDL".(=T
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M)\IO]3UGN:]W+SRR*^J<3HQ&F!$KR8X+:6'BF>OB\-8*P4 5]6/7[>^FU<O
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MYBRI*Q.=\K(NL?W[DK*I04$ O<I [GO&)?I3&5_N;L+NT >D"P3?ZD=!B")
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MPAY$*--(>M*])-#C5KCO-52.@+JKV^V58/)(<68,*B*DK 23"."?=RD=8GJ
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MX3 BN7XD#M5V;A70E>@D)Q1OCWR&EEW;?H(EI5=7-/*4(H8^+_C)]NZPGKF
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M4M_^QUFY!Y_)J%Y-P4/MT03[8A7G,[(A^)5<!:AZYKM-LX-DKO/R0,U*ZU5
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M9H>+)S^=+1/4]$[E<%W*3@=\@!T KZS-GM%$H>-7D/6UL7SEDG-9 2T;-6N
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MS$RS=OTM"FKF9^)?>$E4[.>UMO^.Y<2=X%7VZ6O;0?#.K]W9SNP=9T/IVS?
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M19M.6AW4SCYPZ<CDK.2*V2S5G1'#T"^J7;,E&6Y(GFM\P-'$P1!=ZBRP,C.
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MP.0B-Y"NBF,I&E9\]6"C@K@_SQ^RLI OIO1;O(*G)\(WMQ'<U]6X+S#6;N;
MDANC2I$W@')L>L63@-*2#RE<'V\J;$_;+->.Y]']I;-\.QY%XX*@[*QMF19:
MZS9MKY.RET2'_ OL0<12/WT ZW?=AC'VCQ34Y#'J*?GI4](&*)]"^$24I=H"
MIG?.:'Z_CFB0&!HZ!O)=\%PE"/+MQQ?2TU:_1YW?*[C/7'Q-7-2^]?NZ5?\#
MV5;_.=IB+82QS/S3>,%&NIB&[CT<R\6X;7G;QF^)]SZ9XE:E_K"A$&O-,218
M6A('\13"BCBY7X+*TCA?NM6NTA7SQ O)3[:"2*UI$KIRNW1JGKT]".JFT2;V
M<@5YX0JNL'=O\"&HWDV?F(Y.;?@59DM,<H9I.L4LB=%(T<?7!!*TT LR/,^,
M(::H].VVUO%BV++!+L:QZ!D(,)^SV35LX<TEZ>_C ".5X$)8).PWP(<%WEKG
M3B(78#?)8M64>?S]?FU#CA"I$#(VR1N %)9ALT7YEC-6Y:2%.$ V$0\_VTIE
M+8$!FKIJM$;*R??Y:#UFM%A3%G+BG!JW[!4]H-1O-G:R/_!%KZ=7GH'3%#ON
M$T_P!]&D'?@'X:)[0<8%1QA0_/?UIZXY*Y36:S^HF5]L;-#%)2V? /^\+JCQ
M*NL-</ITFM%4P7-R=MT(WB<1)DV&22TUK-OMC%,J8J\8=RZ&_R42W[F<^"4_
M+:![@-VFWJ,Y71A!:9@:CK2O)W'=#"\1JONN5$6%^&8K(P6N*Z:UALAEOOO^
M_O4-D-[PFK9YHV$UYW8@B4PXD;"FRQ7^X;W-([V1'&!L4\I\_1F3VDL?H20C
MKNRI+\)3%$88Y7-]U#X2>K[JU;WET86R,+Q4^$-HEH0B_R;-&&'\4F_-Y*'2
MD99LE\&K0(-!5\]3%U:#0=8&4$3GXKH5D(N*:E<50D)95SPBYRR4+O"S^;8W
M70BKC$,="4G46L /K7=7N0=?H;(&B\XXX&/>Z!P/);%84A']^%>L- #@-QE,
MAG:;[4!;HU7]S22G1<,CX!9PZ32)>"X$ZSKRZWM:P*=[7Q8R1KT7+M*$F%5_
M#;/;,H-%?YBT6VD IF?JC&M%!NVTU>J[(< %_')^!OT% -;_DD8U-0P;(,@2
M!A D^Q E0ULK(S2:H/2\DP$N/0"I^U$#T.X_!I_]8W[A/_S*0QYF;=?A+&95
M%WY^_YAWA/#WO",XK)/W6?\8CFB-?(C"/(M4#$<AG%0AZ12?-_#K"&;#-E^B
M2&UKV$C>" &W&!T.HSL7@02D/M@>SF!>0MKV:+M2;%!.NX1P?PM]R?-# $P\
M->['6]/!O[.<#T&VN2G2-__ _5/)_A3Z;I-A9YST>.Q!%PV*8?5*$,+HJT(S
M85(V_-^)8%K9<70[-6*7*>$0 &M4;;!\$5TL .O3+AT Z=Y?W-WAP@RR[Y_J
M(BPH8X8,>#5) &06N6H)5S8Y*@E3U&'ZQ2&_I]WV1MNCR%XLCX)1$ZP6_0)$
M3L89/04%&4E\N]B64='^!<.AU.VA)D0?W>T.V-;U^(#?P_%4,UWZB[AB1N$K
M<1=RWZIHS0OVM=(^56OSN)R(B!1IZY9Q*@24\(3R=TZ<*[L\)/6MT:#[13[7
MR;V$[2@HDQTHNCA8^UU-F@N+[/@#%2XXJ80U\?L[&!;Q;F0G0"@+.OJXJ^.*
MJ8'O[G/YQM>RIQ;!$1BRN56LS?5 ?B6I:E]!6L]F0>,S^^4M+JXVY<Y\-AV$
MI#BDAO?*!+5(Y /64XB=4=&<XWF!^8&N6G<HN.(74C*ED!U1:1IX'$(Z=4SN
MN.U#K"R%[B*LI ]&&!^B7^/._T@@DHNU_G&L)3<W[1"M4_^E?MW])7%-[)14
MZ(OT=9?0)G'S&$[>.$=H/;7LXD*UKOK"(;YN7^M1K6@"HNAWP>$*_T*D/%-/
M!J%S2U'!GQ:^]"U[TH$,=UK)7FV.$;VLV4PS-NJ_)"24%:CEQ:X6- ?Z>%#:
M3_&[)_HN>9&J:UGL@*,[# B_K'7!4#%6H])>&P&.(?2=M:A"&K\R6BG6/G-4
M344_MS-K)<>>=>$R?@@C2#3%!3$2]<><4G-ZMII1H'UV=B[=:RK;^U7A2 P,
MYX?WL]^(&RQHN+,BB+MXP^*.,-AH$%@;QL9!%9:>[G]L-8X(JITO>"\X?%G6
M;5HKRG*6RFFWV327:?_D5HV.QRKJIJ[A.?[)89*0L]1[_L/TYRP!#T?%#&\&
MU.C/:ZK+JTF.\NX^'5 PJIKIGYH&</_$_8D[E.0=VBCY!9+OUY&:2Z'4:Z&?
M%SG>,>'$05.4-9=HAJ5"I4*%@?]N;@@/%PC+P%A^3&QM(FF'N/I->Z$2VY*W
M;D-<4%8>'U_K:C"D=,K5$YFR-3$T^!HP-!3"F+7)/)"O,Q>OYUT7<1VLJ<"G
MA*)-]*NU68U+X2$.AXMEC(7:^HT[\_TOF&STG#[S6CV+.-H*0Z>H"-:*.3W,
MQ5O[=I+!3(TQ8K$EA.\>-%LK[K1O>3-T[[1UUAC2^24DK)FL\[/83MUNV5T6
MDG/> '.U3;(X_1J6';(C?RP(5"EE!W*8I#UV40UYP\.;EF=2OQ]L\= 4^YZ,
M>B5-D(#)1MJ<B9A<75":"_.L3?$?<N1&GZ*LY)AZ>KG!K1'7_BK'NKN-VKM,
MR'TDC2J2+0IZD?N<7CEW>(%QVG"Z+S\-:9=U_;Y"S*R53H<!(0H1HRP'/DI1
MES9^DSI^M*]Y_$$TTBUH2<F3;X#:"3_-?UR5D<[ZC72]7JD]R[W>/<A%LG)&
MB?_V.E")+9V'B L?E6DM+OT6A_G\T9EP:#7O,$'Q/GP&MGB<IO]E)M')X5UI
MU5]""GY,*(;$;5DS3L1.(4+F&3/]N /]#?#E5CVLX"6_;L(S^26+QR5"9W=H
MY/P4[(\K4A _$7@4:I/+A'^K:QM,TB=G+A*[Y&0FG/.#%8NH+\O(%7Z;/BD.
M%-V2SA1?R*=\;F(2Y6FSL9?6Y X21_+XDB)H@H_?JF= 8GD.:8V9!3I[# V,
MV0SJBLT,S?+PPD"R%JOR+(=J@]M&0W@!!3I3)[F<V:D/;3J_?$CR;EY_]M33
M.'>%M31',S*_0LLY?[39H1P7YE([)I:\;]=:56VV0(I49HJOO?08,E^P.T^^
M>Q>%5<%DS,8F:*WY@]Q0B<\.&0>S4D/\,XIKOWJWL/OYR=(%, L'0WX=)]/#
M)BV[]-*6KZ/*@_LX5[]Q>,2=(4+]-KG.%:$1N^K$ONO$KI+[%,V-7&L6YXO#
M[PV)]N*Y1V_LQ4V]O(Z .R8D_HX,C9%8ZUN?GF;6D.9E$(Z-(RU8.'Z9R\8:
M6B)+RW]!)>U4^@?ZE3Y&? KT+=])8F[&PF1\%JG].5%*KA;)3V[X4F&G363+
M(1)8F\7O$VS3H,YJLNWF'2)I'+R[-9<?K:EA.P.JDLZ^:>="[^2W,]UI:N!2
M\Z,<FJX(3'55;G3@=P#4Y2.JE"=RO<---"1-.4RX\NH1Z9E/#_:FLN;N-W("
MT[&)AR5+)'U.EYAC%<MVF?T<GJ3]C5@M-FJ J'$DEAD8@D]7+B"<<EX&^\/L
MP=P1T>[85WLAY=NE3%(FE\TV,R^791NH%^&.N28+3'>@ B- 07>O+EQ:L$Z7
MT$(C_H\SB3ZGPYP(VG. :)OVQ2H^Q?GB\(##:A$3$0NR\7M/ 5N5S'TT/Y0>
MF805_<-P.1\"B''4$SDWA?8!P$?U!A!AK^TM(QC19ZB ,:_M1PHKN/S[KI*T
MC KF<V;TYK"#A):59^_<M&_Z:'BA<0!WA"X(T$=7>KC'C+J91:;H6&H/&]QZ
M6 CZ,(6(2%:2 A=KU6V;JADM#4]Y^_C)^PWPT?GDUSWE70Z,;FZ?UZDR5ZGU
MY&X.(4F.P:\%+N7\'!ZD\U>!NWO5GG*<KKJGTT&BN4IER,8K&J?$6KQMMJ\J
M+I/P9A&<>NGA1ZJAL&*[$QY/5]$5""RL6KR:6 @-QXS+A\5MOL+>/94;;:?;
M+V:XW&<5?*)+;X#2T_:>)P%#Q)J]FX\0..H(X2/#1>\J"IP67YDZ=6\YARP&
M04]I!,(>*:IU>^@,O:K3ZWCQTL*\G36B:162CP!X/5[DTZJ/JKPN3 #M1Z,%
M:4$8;B)LUD(J#.?[/65L(>6][]](LYY_\_<,1)XNFZ>FE#_:1=(U0-$,8VMD
M2P;$JIJV\N;796:_\S/[V4#[UM&4*=H,.316\@)0H;?ERW?OC-;\!JE(@UA2
M'%0<UA&^$OP*0^S]L-AD W,NG$,F\07@#9O4R?*"#OLL#!.?OOH&"%_LND_[
M>46C30W2O-!WR26-A0<=;57="+\("K5J[M;]?WA'_PVA,VKXOTHK?,@_I)65
M:06>M&MEB2#I^P_NZL!##$[@N97YUBL!61;#YS ,,11,<F,C^LQ+"?8(E4V@
M/X4QB=#GY$Y2!=VG-X ;;3G[PI^A"\DJJ1(>(CH.YXJ];$.Y!:R&(^G15WUZ
MQ%"8LZHR'Y.04GQ7O\5Y4AV403,"A\<!FB=%\2O5C)RHF[RZ8D26V5Q57TV;
M2_&S__SZHF-:Z^6%%AXMD@Y_T%T3/UVO !'TG_IBQ&>LAEH\4IUKHAPO%.!G
M69'Y]W;(W@<R5RRR(L=TX*B<:=5/5W8+S-7 6)<)Q0Q0Q?RF)_,9FPX47]&S
M>Q5?^;S=IC2C^LC.8:'@L5\AQ]&DY5E9"*.D\(W.F%^S<5\.U#'<0V<6*:9L
MCAWM6!N>_=S3/$B-(1\18>)L,3 >*#TV2P?;BVX+_4+Q#BC)'?"NM5/-+M;R
MZOLR*BY?N6[QZ/U2-41=RVG5:%*E]4J5X3@/GIZVS-H<=< 4CV9-V4B!@Z*Z
M@)BWJ:#&D%(9*F$HSZ1VBVYSH7EOAG*G."UKDQR05J(":3BDV3<(#FE9E%\T
M>>R8+ WVL1.NQ/Q.%@L2X942_E@"GXS=C=8TZP1A.-_Z3)NP>!KYP(>W[+!S
M@G#[V8!8+^1*R%)82;;7V87'ASWG+I5U:'D3ZD4KA*:"2^G^5#0>H\1:47[R
MC,T0B5QEDYW P\4YJ8T;> +$M@YB<UJ+6.W[88MM\L'EUT]GW@KK/<<QJJ>:
ME<"A>GVGB(-"INXRL*G4[,?DIZ$>\^KIUW/P6!L&.^:?M48#"),ID!_E@4EQ
M;Y"E:9+:XKI6V[[V-7=&N;7*:-F0^,? ."QA!U37 P>\:^]@13=/_>U7EI9W
M@L^GDY2R>*QE2UO,=Q_5'#-UJ(;'4>F,M CX[2[&W@"YB?#B@_B]CC61S8[T
M=.^'.1#DIKU(<LU%/01I6D-PF9+G>ZRM=66N;BLK[_;X,8,14-,SF5*T0.TN
M&D0( [./7^'N+XA6JVYP&A3L!<(9\$7$;#G5-$OZ8O,>JS6+.#3U?65UJ4.0
M?!NL[J2H,,OKJ+73+C87U$,AL\L1]C&P<%0!9A1[PR L$M@@T*\1X]#/S%+\
MPK*^0DD-R#E>"A\L.%*'@J)%&ZO? .,,A&RGRH.^JFT(#;%]D2:+'HJ8C0@"
MK"GK["BB)]L/UORE:A<I/9&:)-I:;J>ZA@V6 @1+E6%"6(5C[\6)C]MFIMBP
M">AHF 3"TIU59=@&4W_AT)U&#M#*CS!KO-#H2ZC#ZU"D4IC\=N#]?6,O-+(O
M..;"]GGSP,P9I#'IFQ@]7FX;(M<Z5Z:42(J<[*EL9X_W&CK#CTIL:%J^Z9'Y
M6+&ZZ$0*V;E^F%'^JD/(?W8AP>+492-K7?R1-_MRR-L):C-4-HQGC4+UH!UD
M/QS(6J6=K_DQ:J'$LT8-CALG*^X-D* O/A:Z7EI=T^3WY14THPV7NBI[(P/Y
M\5X"2N:%*KRRZF;DA=,Y@B\C()5?16H>O<YPWGBDGH,6T]'6MOJ$<I!_QS'+
MQ""+>]B%O.C[" TU7IHKW:\,NW@OU>N9J)Z5O/V\'*<,^85N9S\LA$$1LH\N
MGP=?HOS;B8X6YR/-_@HIL?%"2M$=4[G. M-BY02Y9FRHKR9)V 5\]7[-<8U
MSHV2ZB64("/SR^0L1Y5*R3N"B,S(3,3%+->2,7^U!95)9=B88.@U)CU94T<*
M,@-C.6@[IKI%SX!Q\".JNA:NW@Z&7-8F0)E>7)["Z//]E?CU&7)TT7QLP8A^
M\G)A3<W+$?VQQCCQ@FNG5*4_8MW"9Q^50]B6F=OB$+UP6X] +Y<(U3-29]H0
M*ZF?$;=*)@  F8S3]"%R4)Q.#>PZ"<N?;+BT8D79C0G6L7DM(HI<NM)/>YA9
MW30LGP/$X?H2?H9O'N,RM;LR:,SCZC"/*.2/P%#Q16($?6;T_+9(G%/(L=L2
M?-O1J>8C&?$"5M Y*X5J"GM96+L @V&68@*.:OD2RGIZ*5RP98$<U+AZ^HS.
M"PWD4$>*KWC(G\I@8IK#HRAJ@M4Q6$,S^WFHG<Q$1]/W-=PX^9A 9>8""<>B
M@>,R5#7'.1.C$<L<S2 ?'6T5!.D*'PAFS3RHE%$T=]\YJ(@8+3;<0#4IH#N$
M7BPL%M8?FSOL F,= -,KU4_Y,,#GC[CN\C+-0Y4S1/7LG;AX3XR6^!S:_9J8
M0O.?C4?Z7O*W#H$G+,*2N;=WM3<2*;CZ#3&Q#?4[+2^4)BJ,3(F@ZJ[ ;",[
M9+;X6,=3&E=<$3P5-146HCKW!7%5T*>YR3$?@K+.E26G2&M=!K*BEFMW'TD%
M]287RQ$GD$(T*,+;/C_RB-Y4=J9#DT+3!<^\1 $OA$E_9!%\V-X1[0%199RH
M$LJ.!-U\::Y<+K,'VC<VU;:QW:I$'#>)M=886I\2G_FTEM8W+-O:\Y4_-6QV
M%^"B-(1%RO34!7'+'E."<"1IWE&WN3+%;"S' V/TF]5O-2S$,J*2S$LX/0V6
M%S0ZEDL,0LI8%BMWG\XZCO(C<+)>SP2PE?VIY<B1TPZ:]!L[&A=!VHG5Y0;>
M20)S:AD9LX"&BE9G@]X'OE6?2FG5TB;;5UKO8>X*D@ F+"RD40RV6<)6&3Q'
M%2ES0BA#T5KU=XV$;772XFZ"X@/_)F5P,W8V!E8)/(I73:1S?S2]%H##VIKA
MA;@#A[&/$8<SY.NZVIAR,V,%7=(%"."WMNUX3#@X!^FQE0</"S1!7C?B0P(G
M(2]T CM(]<?2?'EYIOJ10\[6'['2/2?SXWAS%()EJ.=E,(LSZ-FU%^C*'8L1
M=NA;/)"5Z4S&:'Y,Y=61RY_XA/+64"<$GEI)4J50:6Z^ITJ0,KDCGV36J8O^
M0+"ABJ+E<J?#H/+U"82W\R1D!7X#4*M,XJ-PRV"$I95X]@NFSA J1&G2_G@7
M8N&"9 J03Z?]ED\L_:OT._W,YV1Z,\@L%S"8"_89*\D=26$K&\N7LZ[+^M 2
M]_Z9M0P"JD<+Y.-(@5M_]<-,G76QZ/+?M1X$N9*P67\S5QUL8Y@P3==.UI8#
M[LLN^ ]+$\.BC0[68-H6YQOO:F>F9]4[T7,6P\#!9 K9)!:B]O*+]5'+\HOU
M\KO_$'>F.XT^'QR-$HI7%7D#I*7,+C6!0(-><M9RRD$+#,:AJFA'"Y2[TG])
MKX$GU():*2EM2OQ!:5GUHHS1IIBHSW=E-&88WYA[2P.4_G@4Z',[9CH6FZ;H
M@Z5SJ56$.=6<7);89MH$-/4+HF<,"DMX#D<.:)>@TJH5>ZNX H'5G:X"TF&@
MS)9]'SX76L4<+M#BE>GN%]V(,5[AVSH#WB[BG2%#&U20IIJ6%H6F==LM6+R
MOBJE(?B#F+*12IQS8"\W5UR=8C\.!SI%18J$W9'VE^$P2,+:#FVP>!GQ9[N:
M7M5M--;!KN'7@?[4A9B*#=^7ED <S8KI7X8D!K^U90B8D'+]HUY*-(C0< Q[
M?->V204X*6E;,B-__17Z$WIKN]R2D+(I2VZM4%(^V( .3EM/=' A0YPJJ$DL
M]#P:W@_++3+F UCO9PTD#23,597F06+X(!SG';7WHQ1$>=VP WBDJ;%EEJ-1
M &*.)EV[;,Z<(2;?;#2SR.RT%";;*!FJ9]E*J>3EX3_SQPU*YO7Y$>"1A!
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MSHNB 8,;M?M$05MP&.I1Z1'D#]W=7V%>14:#IA ?T/W6O3):'PKR'O[&4EW
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M;A_L>EALA%AFG?HS %O\3[B1?$UK7= B2M4FQI Y WW-$YV8L6FCOW-3T9!
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MOTU&99]%>.+! ZSV&?Y\;5_Y?7LH(XH9S7>LL<)\W2Y^Q%$S/-2JL4VHJJ"
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M8=8^0$7:N1JV;1;TW1H:\TUX5G!!DH)NDT5_',U&D X+J$CN(Y,AJB7NV?K
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MHG;DZ49B&*S\B"9?\VA:*(Y8:!.0=%T1<[M^/6H2(V/=<C$J[.MDJ.W7V]<
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M ST6J9+8>)Z?)>6-"I7@_Y_[%0RJ6FI':66?ADB@;"W7B$PMM:(Q@#^U6VC
MX9O^"&- BW5Y4T;]I0M0.-0?Z;3^_\53_[]>!#PO_C]02P,$%     @ EX!^
M564P9RJ]. < ^4,* !$   !G,S<T-C(T9S0S=C4Y+FIP9^RZ=U@3W_;P.W00
M4$01%45LV%!ZLU%%044Z8D,Z2(<$TGOO/8&$! @U]-ZD2+&!O6/OO??*#>CW
M>\[YG?/>>Y_G?9][_SDK3&:OM?9GS]IK]IZ9/6'BZL0=P"3 S]\/T-#0  3J
M#S#Q<M[ZH.1,4&9N<F:6E>,Z.\#-VW^GMC:@EGF6??%V_U !RP4:>P MB^5;
M%V@"@/IO@680,"T4E)"5G)!AM3-FJN;RJ9HF2U8L;8$\T+"-BMBIO:/ 8].4
M;_V4[^&D7[UI3&F&63DI&:!=8% 6&*16=29M0;F@T-C,S+2I&OX9H(2$#'#Z
M7^7)O4]:SJ0^8XH-38%,UO!. 4TR_V@S(2<P)CTA;,ONL+\/]AL(RLG,3 Q-
M (&S=L4>BE.;C8 @( ?(5'\2 2L@%$@ 0  8R)I"IF7]7?NO9KS30!E_(C**
M!:>D@5(RIII4ZP93M7UV1FW_G<8-D_4UU_Y+CTW_J<>[LD IF1FY:JOY5+^R
M0!E_=4+=R=B<OY60I-R=__#D9/C\0\D _4/9$9N6^[<2F 3*^UO9DI[F^[>B
MSN,_FO:.2TWZDXC? 0(A6[U]U#NMJ7*\E55\)CC6,_,.\)=LS<GX-YMWVK_7
M\\Z)#PO/ /DM#4D# ?\DWFGQ5O_)'I*;!IJR!T'2/*..=GK^-D_+2X@#9>;X
MQH!B_AX504E!N7^-BLGRG[W/5!(2$D'_J?DP]0#_3_;0N+3?]J"<.,^HO\TF
M<3F969'JH1TT>;Y2,I+^RMCT24>(.B;O3! H,STM,R/I#V+TEV<RA'^R&_]E
M#TE)2OYGA^%?#G5L?YLG1X[6R]\Q (*Q,?5IT?QK/S6JK*=\T__1 P_,;TK;
M>$J=G*U[IO1Y?^N64ZV^G](-_N(TIJ@5)K_3_-?I_WT4K8]3Y6V ;6*BVI.F
M_M;] _VVE!04_FUQF/K>H_[^R^(\];WV'Y:I-K],E=4S:>(_BM:32??_>=]4
M+O3_9'1JF&MZ_M[^^'S_]FG^F\_R[QS^UN=/EK2\_N[9[^ZISY<F<\J6!#@!
MCD">.@/NP-]3ZE_DGVR3C,;+_YL*?\L_+B! !C@M[7>H@&YL)C@C/O=_S-\X
MD/U?(4\.^G\:<,#_&)F ]]\C^'<8(7\/T-_=R4U+B4O(C4C;,3G%-/[E.#I3
M/G7!5+WI32G^OO_4MEY23B8XZU],NIDY*4DI?U\]MX1.0KNF;&K=. 8,RMR:
MD)&0$P-*B)^*'IKUU\5_VN_*DY9)CW]ZDM7_!_W7 N>D_<LM9"KY_VK9F9OT
MK[<9W9@T4%A,TK_8IL<EJ+D$",@_=UO8SAU_7<CT_S+_2V6#Y,P<F%=:2M)?
MF9KQN_/;_C)/9C<^(3$&/'4E,\A+R ']A^H1?YG_M;IA;))/9EIFSC\E=^9O
MP'OKWX[), (S,R;W!J#,+/7M*C?AGQ,W+4V=R'^S&L5.71+_S6Z8,WGA^Q_F
MJ=FT\C<W.9P]W@#_L,^>*DZ>0JTIW6@JB2-_4E2LWJ#JXAT N*?>IE<#<P&-
MB:L3+P$CK_C,V(1HGYV YL0K8/J4!L1C)KF)ZP !,-+7US?0-S(P,)II.,UP
MIMD,(Z,99G-GS3*;-6ON3*,I^;/[SZ)A;&AH/-W89/ITD]G3IT^?/?DU??9O
M9.;_FP8F!H"9^NK@B[4TE@":,S6T9FI,W%1W=-K$L(:'.DH=C2GYDS@M0$-3
M6T=73]]@FJ'&_W2J[P=:?SE-  UM#2U-;4T=/5U]'2TC1[5SII;V8E-[':_@
MF%E+LK$.NK.Y)4W>2Y>9A1R)=73*P9WST5O."WUS]VU<KO.<TF:\M2\_+'[+
MH!+D8GX^_%["NQ;"T 7P_?=^*P1EQ%;A\,4''\K;1BX]_!B1F$<25;0?O?SH
MD^O6R*1\LKBRX]B5QY]G IJ:ZFBUIV+2T]5QG@IAL;VIMCJ"["6S=!RPW-F3
M$1P).??&<5GLW1P<SR?4+"[7Z>URW<D ]*R=!\^K@U":QV\)=P$EW/L[A/]U
M!"O^$<+$.&"D-77,F8 '\-&Z=:8U=-,9&A)_YO4J5W;!CRIWUX2(.RN5E[4/
MQ>M?.;7<^NK&7^]$YQY_%LQOWO?]I][EW6]#UUI[F=Y[U*6X>K5V6<4&/<6M
MD'%UI3)>0%PC].?#M<HSKU?[_W%<_>-HG73@_SBV_I.C\7_EF"3LDTU\WVU0
MF#F;9VU>^JZL<N+L1Y>W[SV$TW[<2(-\W&]!8!HHN@(NOSK6U.2PP&KNVQ]W
ML!<VK3AX/H&]N/&Q4XKC:ZKQCP>"-I?FTQ6?[<;NASUY/1W9LV.-2HE^N/78
MHJ1X"'*#6:N@C.>_?%7X()S2ZCYRZ]TC7M+5^R\F@.H(&]3)&^^_%BLZ5W^T
M._\"^N/;3U=TE!*._G!H:8(+;X<OY6WX=7SHO@6+LI>XMSU(N;=@ LB)9[3>
M!3ZW#'*6UO$VBZ[YAR9M+VVTV"]J8EJU,9L&9JQM^;!/_*(;1,_0!@R)K.E6
MYAMN??JN^'$OQX)J%4HYF>9BN#9[:<:5WM.9Z7D;WO=6>YAV]$.1F+&!I@'D
MD1.KU@=4OAC?%!VV^3+/1Z;# D3#F;->?_.0*1PK+Q5T7&Q^]DD3^*_\5_XK
M_Y7_RG_EO_)?^:_\5_XK_Y7_?V3BWL2$OX]/=%#(+C__'5L #8.^L5^_+ %]
M3):7K_<631, R,H!Y4S^'+ C)M9*[RR@!\P'=(!5@'-,7&Z65U#0CLEF)NO^
MCY;5*_Q/EW^_#+JP]C_X_Y]D6GQ"[N0+L1_J#12G#D+=Y.3O%VOR05F399FZ
M/-O+P=M.76X$@%)===GAG\KV *#LG"Q[.WC9 1I;!@!-MU9UV1[00H'^E!T
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M=!GJJN)9HP.*(TLMP*)2"I;A;%$Q(O-#ZU$H?G*P&4K)>>^\&'6/'3##$YU
M"QHW1A'KZX;'45:J9?4OD9?*>R7;D4TE;*P9LK&H.L4!.5IH$>2&_"HV=#J
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MACM98]XR,^=2Q=GZM[&K2_MK$$$W% ;5N9OETHL5IU8?+HB7/335+7C$L ,
MXCT,0,GK?Y@;#+W;_3&W[M"U=A_0FKTKFDZ"Q@)H=7(PV8VOFIWGMRRD:DU>
MQ[3=*KU\<_6QC-249;\.?!VTJUL?=O%0?=M&6.V>#XTUL/: 7;49L%=NT567
MX#[+G"J.P;'3%%7K$+'J8[5C /*MWG>XI]#8SI_8#X<.M%ICU^T1-; Q;?Z?
M:G9@0&[S*VLQ:<MFE6,Q@FFW*_!8:S65JJ;$AQ_3)%"-CH]4BY3'+4O(%_?8
MU&-)5_P%*B_26M<S%47$2TO?E>TES34T+]<C!JNI56IJ\^%IO(.0\HXYG-@4
M0K,7JR)JH$[.=/3WJ YD+'!EE]?214NO*",8FPT#E%WD4@ @O,4 I-L]L86A
MD*#V)/'E%.<FBE 6!:Z]S>_=]K6*P0MWW5]V@7MTZ5!I*O>)(:A40.Y74X-J
MBMQ]JS0:8M VKHA/_MCX6E8?Y5Z[N3!UVV#E"\EU5_<R&XEJ:7>)1*0TE)4(
MR-?45*&:VMD=JQ+F7VK;4VF9?+0Q5?DI:D9-2TG"ML+* XJ'KK.5%8II2U7%
M/R0+#0>*6\GOU!1<31EWSVS9G#_0^J7!/;FCX7T-?O?'FJ555=LH%;V5[JZS
M2G^6S5@Z6'Q0LM;P;?%"RBPU%8,!X!FC]CD_TPM&VG-=HW</H',+@W)[<* 5
MGO+VVZ!1VRTMB\'Q%KI-7\"I6IF-._.I (!?IJ:23WK"*.DUPX.PF=$'^E.A
MUX*RNOVAXYX%;628L6U(4Q4LPF)KHSTL6MNPWA;AIZ:6J*F<$Z;8:^GB(3GF
M:O36ODV8&4&!78;H8D]DZWITNFU0XU9TO@6RGH>NT1;7^F/ :DH]E^%9QYY0
M9Z<C!W/)\FCSWIFDI*#E'1>)1,\#+1I$3=N !DW";8NZNH5$@HZI2HK/4%.+
MU-3>HR\X">D)1[)8F ._#FLSG@1IM@_2RSUW-=VFG;$-JKM!J[6X77.6;J>#
MK5Z&[U)3EFK*_>AR\8/TL(%"(>? YYY%?%:05MLE[B?/78VO."]L8VK/<S46
MF*DJ.(8Z#RKOXK^KJ85JRGR$H "G;^U_)FLY\+G[8.'6H&EM1I)$S[V-R\7[
M;:&U@!BZ8'NUDK]8=T/%:8+K;PKV:42WTB[=HW^O\N>!'UU'2FR"YK3&*&9[
M)C6 Y5&VS)H(V84%D*H[?$]=<OESPB$UM4!-W1@N:MB<OKGO;@T_VJ#+K6IO
MT.J6L0I'3V+]E;+3MEVJQN(M"UJJ[/E)NL?+_0BBW]2C17E9N7//6N1OSWW;
MA8$L HV5KH8\ S?0ED&;\TJRXV#H?&4D";X+HMA@B["'BN84(1=#GSR8 2*C
MDD^G@JDHBXYO>0CDP^+1_ 3D2<I-R';DJ:QU4$?D@XB],#/DU_5ZL-<H4S,K
M>!CRR#W[G#?4\V.%($U*?'LT>!K95.&7-XWXDXS*UR?.S'@/T25XAV^&?,)#
MW;Y"AW'#LX:AEW"&=U*R^4*WDZ=RZGG]K;+< 4Y:41/H'&L':2;X$2,OO3GO
M$VTP;'7^.^IBUU^09G*'J0!")[ZX=2(+7%QTPB&;5V3;HIE34_!8MB9W1'2)
M4 ]ZR/^2ALC3XZ:$+LTW9'US-<OO8?R:R<[/IGK<3,N4U!H?NY;56MG=I,H>
M5:(+K^<\4<#P^: 9TM;4W6!GB6/(NCPOX0P7[[R[O!&3UCP"??N-P(SG'8RC
M1[*TF_<VTK/-ZNP+^G+LJC;B<G+W*PL/Y8!HBAW!>\ "*=B9G;>\8/F,7^!^
MVMGKF1GI0Y8C#S.QO68-RBQ*A[9D-%O:M!1+S#E14YM2EONSHCVH 6Q0"G?Z
M ";*VV8< B^BI8V/9EB</CKBF[GJV(/ZYUF+!]Z+)[)7=+M@>G)VM?Q(?IZ+
MKT<&30.Q5/Y.<:"?RI73/X 4M 67S=#3L]N//$2;Y)RL_8!>F'M&O CM##J'
M :,CP#>37Z$I>9^"[-%G(/I.A9@HJ-Z,W=AWT(T7&<A@!'J@&9F+@-6<1HH1
M".$OY ""C0Y%OD=T)5U N2(^[[)$,9%.CART*3)GNA=F&Q)_ 8"?)P?UZR$T
M2=XJ+X0CT5> 1603,I&_$#WXWL12I!G>.M 0F8>3./"1+W'+C7>@SF/QYS)@
M)-[<W@388<Z\JA+89Y8=WQCNR4A!J. EM)L)$(01-6>G 2*/LMB^#G&+;&D$
M03()/\Z\A^;(GO:\AJH*#2O70E^*O;AE, ^!!)X(*^<MB-\+7\)^O&,>G,^\
M:W<#_HR!-AQ$Y)/?GVZ!2"O/=[= +I8M*G\'-2O.YN1 #\D>P0*@EPNX<1&P
M4!%A^V;8&/^1W6*X&0]GN K.)--/U>>_;;[0U0A971]8]@R24-W/3H-TE8=!
M]T!M2IQBB=#ZHNP  FQQX79;/&R?)&>:"C9*=AE[D)_;^[;S?KZJL[C,)/]&
MBS.+#EE1]QR"A4BK#6*&H2O*.OP?0F4EJ>M^0(\4!4[SAJTEO1D+S[<\L;DS
M(#]X:*DR.C__\!WF:'Y;^V#^<<BR)ML8*TAC+=P_#+JBZMTZ)-1+D6GP!MI
MZCR*HLS-HK7\(#MF]Q7S2#DYXPP+XKG<5WD=Q*U@PX/["#?RG+>U$N3YX6M'
M"!\@(?HW2+N@!T?\2!A89_,S8@_LF2*7: 2WH.L1P/!(L K_%5X9O1<O0QAL
M[<8G(U)LKN*;$0/ZM@05$CQL2IQ.^-I41=A'L)='XUOP.=1K>!O<>1 9UXT+
M.Q",2\6^]SN&\\4JUGS'$;$9>A*\.]9PL Y_C+VZT1X_A\F4G< AZ)\IV3B
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M9PHD^@!LFDR$-DY95/ 2=2?23PQ#G?7=($Q$7;.-%>BAGIB%"2%H?74.M3&
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M7EFGP%1RU]2Z8--QRTP'<=&5OH86_-STUS6#A(FQ0)T_X8G_!2V!2'6)K/E
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M;:I[:Q7A:O;\@1E$CS7?>\\2RY?9=V\D[@SJ[O0F3?!TZUA"<AC7V4$E10(
MJKTL5YL";_Y /Y_UI+^'OG?-GIYB>F_,CJXPNC5(V:ZG-WMZM"GIYG%/V\2,
M7[.D<O^_;5@6// G[TW6T3X.S[BF9>,\GG],;<<;[OX@5-L:+L]S?JL+MW&\
M7\LP-PH 4-S[5Y5^W_2W;%K6MEZ%E+'&U.TEV1TC:[\C<0PJ;ETL'O0,:+XE
M\1X/;%XK%/]2H?^I:YMRM8E9FWM.:IAK3%UKU,080=L7E21H7<LJ%=#3O>FY
M<O=X>I.7R T D%O_4_O[;YH;LW;U!)K^6-/2J3%R8D1M809^4$8SPA#D&=HT
M2I<Z7MLX5_1KG)$#_E7[IX*FE[[HNP")JMA:^P*V E@FGHN8!WJ)@R _0R'%
MV]$[X.<2CV(34"Z!9W"^Z)OC[8G^F&E[O:OF0\_UKJN6P@46)7@O,E#X&'H>
M=1*;"#^#*2OJ1 Y@GR4<1R?C,P,>H]\0BL<A\& "[(_D<CVA8Z.PRIN8:AY;
MS2"^$^# 6TAMZ,_0\^2B0@[\+&5R_ DDFM(?X(R\1AWO^ 1[@QJTBU2ZCEW<
M-53^@>UL7%T%9QWCO:S>SU*@C)!1+$A!!LR=E;+Z#'P/:Z%_'/P^\X4C$;.%
M*=PQ7)PML^_T+G.3W-!OKF@7;^-"@!-%1F0&J$*HS%\*40LZXA[!HOBG%DI@
M'OP9CM.P^=S8(4SA/OV6]HLE6MVN&G1YD&8;9W%ELVH0$51MI[B8MPP<(?>,
MFP&Y)VU<\ #"E R,W8]](%BQO:B TEC9-ER<4U>O@Y9^L.QD+ZY &V_!EU?=
MTB_.A8)F:/>MPH!WJ?L7E('=5"?&TG'Y I=!93YKHU/;F***#KK66O*C90^K
MM)S8Z A#5CZRFG-ZJP/-JI670<>-?G[/J^_JYXZ-QPWQGPZ.S[NXK:>56;AM
M(%9K5Q+?T\;<63;0.0=ZIM*SU2['"UC6R%R94OVZWLL/"3QF+AWKCK?C#V^)
M0#XO36HVHS=4+-8X83JJGC#!V(\@$G0K/A;R(OL)@0-/B=U-;$62?$>3"E!_
MVR^AC<-,&3@ #X1L;*(ASL#D:@ J#9'&@*'_0/Z$',1ZHQNRG7!D[)(5G_&-
M.,O\7((SGFQWAX(E'-^T&+(-][[A%(R)OZVD(;P)0[2/R%ZB'$Q%AY#*,E]@
MFLC!RW]@CY-OS!-A'U)\[<R49]3$/BV(R_2J]X54,X/D?\+F,(.I>OA1YD)0
M)!+"#,FXAGK)C%D^"^/&7.9S'GV'Z6)72,UD!O2Z !O$2=8M()-()H-#(,*=
ME&"8M^!.]53X.<'T]"M(.!^T;!U*RSOJ$X)RX&7:^5)[.=R-EZO<M8Q:=K67
M^F_I*M!753[9";)7T0\< Z/*9Z1]1+A*^V-JD-$2\=Q&1+'$:_17ZA>N7?>-
MBAO6;19)U7,+5K*N^J3Q!\D+K-<+?KT)1;JE:>&P'QK?Z)^(*2K5W$6PI\H;
MHR_1(CA/NWW*G[>_, ]7_FAY(N8#KS5V$G- #745E640J*5\ QLVS7@N&@F?
M8W"=<QS:K5./WDZ#<BYW]98G#'B9$RNS>@M%CX%SNU(( ]4WVA(J#H.;FUI3
MOT+7U@]&/8.MM7Z=LP$B-0A&-]!TG,-MK:3I)0<-5%)_^4YA&+FH"H_OH$RK
M_E;^FG(! DIUH-;"MD?*:-6(O;-/TF.0%_X9 ;!EK60\!:S0%Q"RH$K!*.)\
M. 0G(WY$^I6]))U$74J92V[!P",.4JJQ1V<OH%S%I?^C2&-:PK%NV+2:T3@O
M'))W'^^$QV/!^,^$ZM+GA+^(F>L3B4=)X1&320+2"\\ZDI;\>P><YMYT"/6!
M]DFKP+C1-W#SL%YT.<8#-YN^HV0(/Y_^9-TRPFR&>_A2PB5&^*QW!!+#[G?*
M;FZ$(WT%5DTDJD 0PW%$$_C;41<Q/+Y7\59L#4^]-AO7P'-;2L>G<'MG07$"
M+FID9&M(@_>K<M3>B%?*%:S/J*GR3\A3Z$!97=$?F 1I=K("NUX2'G8=^U9<
M.?,5YJ1XG2V;(V!L\U35,O@Q8Q)K&N*E/A;Q&C5!YU?X$AVL"5MS Q.A$H?E
M8PXK,3/5Z&*%;1>F[A#4T'Q!*87=:\QEYB'&U&D02Y&>EMV%X:@X4\":$'2&
MP2/T'/JBWFMF-&JIAFI369 W/4:E(VQY%Y:Q'Y[5]A9N1)0VPPK:D(R&E*1M
M*&F=76@.ZF<M><8A9)+6EMI,:2QC28$TF84N3Z2YL\B5GZ$&5GTU,>\JZPKX
M4L(1=C!L4L@#]A[X+==MW.6(L'\4L<B8R9@),DD2&5&05NHH1A5,!-$PK(B4
MW!>,>\@?\=^8J]"JD"CF'YCCKN&L+9A=OU,VR!!%O8+>(QY%\\:.(C^@5>#\
MP&3:)GQ$SE>Z(R$Z?A$=35RXR$B_3KPZ_3!C#5'P.[6]TX\A'Z(\$NZF^%.Q
M)"-%0+T.HE#NT*)R7*BI-.5J#'4?[<:B<;29]/'3JVF>M/:1OTMW@326YR3H
M([&X[XA\TE/NINH4<@8W(]N+?)3S+<Y 6</9&IQ+T7*(TYY04CB9MFQ^D= J
M7\?O(OK*1 0^T2C5 /-(#A)>5C2)*>:M^HOT4=07=(0<(@J:QB$=$=KNI1V+
MY^HEO.N$B34^^.T$AI9>I2&\5._/9!#AJH6K5A'O*NX$%1#_5F1.BR(R9;:5
M@P:*^Y51>!'X$.L)_ 1\O85<^8C@:)J:<84@U+];V40$U%0'_DD<J_LQ]0.!
MI&#:$OUW[/?.6=R=.%6;%,? O6_656;CTQM4&9GX(];O*T,)4;700#@AU"R?
M*L-O5=CVEV6!8F;Q:^9D46_94=0%D6<EM"Q). 2\O@$OQ(#]E@<(JZ$Q"W8+
M7\!V.#F(?\"2_E&4"])T85AU+R-:T K>AGPN"():2G'\T_"*U)U\*=)YF8I/
M1ZD6K.3?1JLF71$FHS[\[J\\20E_+"J3[LEK1;<@7O#B,-=+2-QWV*\IM[F[
M\!-BKG('\%_]MG _$423ZGF/\*]&GE"\@3N-])CZE7.8;(0/<<@4_V(^9PFE
M,P7 F42='>/#&4OE^ 5REE W3JKFG*,6V^H :]DY;!GE.WLFNP5V@'6;;2B2
ML=K9R/4@%HV='-W)8K"#?&^PE&R721FL'ZS'MD0/9HV5;*"$,Z^*+\!&,VO%
M/H4'F"6BG'4*9H30&/6=&2@<YYO.G">X-FD2D\JWG1@7###>:2>3*8QAC0,T
MB:%0;2^<Q$A5IJV]P5BH<(ZJ9KC* ^=_H-^31T]\RE@B-MC47(:GY1+I$?V;
M.1ZRB;[=6%I H:/T%6N3Z8FZS9$7Z&':@?E<VD/MVHDGZ7YBVR^*/T1GM0R0
M\/2RIA[((OK4ALC\C[3=UH'DRS21I2>22(.9_YKO2YMH])DHI96*;2, <[7F
M2W$UYD^UIFQ&%42%J6C/WJGD <<F[%$<!$6%>2FPD)E>YY4Y4#>'5*49^KL.
M0#_)H*D> SLQ_LI-H,;*S0HSA)7M(6^%K4X(E]V /PC=)F,@$[R4<C_D7PY0
MV4?DZ]\I^Q:]3W$%<0X=+3^,\JFX+]N-KLA*E9[%*.-ETDG8EM!@21=.Z!4N
M]<$-.Y D#?B D2>D'9>](#Q!Q4M?$KO+;TF^D+(R!9*II#>KKXB+R;0E+:*/
MY$>S;XH3R2\<Z"(M9:^M#O!$NI8Y!DF6Y#'CRSW$,&95QB:1D@E=G2X\R40L
M"1>"F*39=4(YL])!+CCR[ZXT=:[XJS >L4/L*OA65B+R%X@R)@CC^)_C=@KH
M?,SBM_Q/?._92/X7?HR#AK^,>]U6!^")WBOEB&C1#,7ITGM"/_F)=)(@1-81
MY\&'2#<O+N/=DBZ9O9#7(I4XR+CO^'";LA?Y&V["=PBS] .EQ8+\&K^T#_QL
M+7V5A<?3+ ZYR/VL/N8YQ*U577:0<![P;2=,R,U";4,*/$.PI^YDR5/^4.V1
M-"ZOS=R\*IQ[P#0_1,CU-0YZ<CC]NG<.#,XTOBU78OIKKQ9M!KXQ?RJ-RX\Q
ME95O79=J^+ORV[+Q^C^KQ_K?U3- ]:[!1@'HZ*\D-0GRNPU9:]&?+$Y5<B#(
ME%2-RMMJ: :O7'M'[P/Y'#.H>PKC^??KD/"-KB%Z-W@-8)%Z#W)PY%[H#::I
M\+BJ9@,4H<QSJCF)'%X;JTM!?8L)TT[&C///T7 Q)URG:V]@! "<$HT/'5$H
MG6$Q[E[EN1H#OC<W0#>6 $Q6:%3$*=%F=2&Q<^$#U7[2N.FWU->(O8!F.8P2
M;ZL#7*FII:DKW703:7=S,!HNW7/-6?4X^NKH*<HS=-!"@G(QG3[=JG*B1P,.
M2KL9MC<%N417R"NHH&LN\U9DWU"OX7Y;$Z,\P6V*XBN$W)R%(?(]W(CI1$45
M%PSX2^+'-MKJ #W:#3*_\@_J2]*F["Q5@N1^TA;%7LGT* <Y44Q<<$96)TZ?
M3I#=$]N/LA/=9MM^48@XC4PWOGQ [:9=FCU%2=&,2H+(+Z@&(G?+\,H+"]#2
M>I7]= _I47GCJ!G"<^P]MCK *_7G6J?R4A7#_#EKA^*BJ33)1>YM&(C$2@?T
MYQ9$20[K_:;]+3FN#!GE)[1C'QM1P(KVW,)-!5-:O4JFI[QN]BD#KMS86%BA
M6/RV84P5V/M1PU2@=,*WIEW &;^R7@W"5L6JVM(Z7.F7W]ZLK'J3HFM$5&]:
M":^G@7,6G[?^A.SU?F>]!)5.W%#_%?(= )!]PP[;5$#S8R@A?V+C$&PHQ:.^
M!OXF]K/5@IR]F%4[&37#^ZQE/TH_D6&%HQP  "F-U#RB*NN:QF(VYL'J[V*I
MZ\'6X[AEL03+.=R'Q9/-:_ *;[7I%O[@1*7% Y\- $BFT1[8E%,#DOPZ]TY=
M)B5OW:W:&$KOBGOF6,KSD*W&+JJ?=XHQB+IXHM(TBNH/ (C.L:PCJD)='\C.
MR<587=GEZPCFS^PU*^C&=^P9(=F&5-97[_GZ9M;GB7K#;/9D $"X]=\T6N%;
M%R3:F^M1ZRZBK)MG>BW\O&*!X8:P>M%7_1*AD]?#&H0P?F)/#5XP"0 0G/Y7
ME5^REJ@"<H8M:Y6U:R^89BGV++^J_RZ_OJBO)EY.])+IF/+^B1+=_']&7<&<
M_Y2^]J3A5,Y><Y]AWMK#1GC-J^5_Z!?H>A9MU*W5@;P&M(6:5Q/W:IZ+&P
M_G\I.]]GH+>@*G5&?T:1(JZJUZ.D>ZEUHWM9O5]@U[T*G^FZC>458+N$KL'*
M @! _ ACVQG)0V\"E3-2=O;>K9P9Y[,16K5C*:LKN#K:+[KC#U#9]*>=9T!H
MN_/M>\&_5M>B1N)FFW+LTX+!*6M[)D#4J\YV2:!;ET9V1,).^[FW]< MKN/;
M<7"Z?53+.P3Y5QN"J#='5&Y?3P<J>OWM;E_4]U6Y'9WH'6&/VK(Q"-_;+;LQ
MSUW'MZ9B-MKSFXJP?_]JC55,V_<IN1G=WXFSUDL[N43I*ONVG\2G8=*6=E*H
M[\ZF#R2$Z[CF8M)"^P,-#N0[OUICQ;^MD?.SJY?ALSZMPY^Q=N6EUCI&:EA)
M<P0CUE?;B&>$NLYL-#)<[7]:7S%_K:!X)?^IG9V-_*#U"]NG\%U7[F@A\(Z&
MK6H:S8/[XAO">$FNG@U!/-&8%;5SN+_ZB]O[GQ)TG)>M7C^U;8GT^\KN9IX4
M%+:DX8?DC&]Q_1S)B>D_ZR=+PL>DF#?R?LWC7-?_5$5'F):Y?F(K53MW94?3
M3DUV6'"#C[K5%U2W2&UV];5^5-P? S6A>5T  (?]K]KF6YZ9O[GE1^6Y8CMM
M>/6BL@B6$(RI7 ^[!6VH3LQ= .^#S%_ECZR G?%[AOP3<=-A![X%>7B+?_'I
MJO)F3)FEND=]L3(<_)"Y#M@'<X'N!$]"+,B9#5V)"EZY%/8WQL'/'3X%6^)0
M25B*6S606C" &M787;P%O5:54L;#R.F7*WVQIR%(8 ]^4M8WT _"ZM@5D%W$
M'-]T") TWL&-L(T\MQ^?^X#"J;]9Z$JYH9"7C*-&T?++SE.-X&F5+-JHS(O
MIS38BE10)^W0?&/U3=JS,9>(\^B6WCW99-[;NL2\TSR"W+[P'O<CY5;)82ZE
M^FZYG.N8<:QJ,J=_.1%X@I,W[VT5GS-Y3!V1QT;T9&02E=6UGW*>*-REPP73
M9/O(0\63I%#@Z=+[D@7ICRK0XO'+]E3-%WG,JZ@@".O&((D7>.T;@]+/F"Y9
MGF;G&08E9_,T-3S2B4*3-K_J50E;G94^KWR:4K!L8<608J+/Z[)C\N8QB217
MGJ8[+8W?$FZ9G36S<;5D?&Y!701I8D&5):8JHCC+R$XCE[[1SXZQEDMU.3[*
M4KCF^1A?TGH>K6O_!E,OP:S-#.MJ%)-SX&T[B)1\=-/GRDU%)?7F-/N2K[6'
M8Q:4L2QC?.:6)!AFCYE$(O&@G6[@Z_G)IDIH5U&_Z P<5OJ0.!_I5?&Z$H@Z
M ;RQ@84I!7=$S\7VP_R]'V/?P(='K6><0;YKYP#%E21C&*@->%_X!\0"7DP(
M@A&AE15L1!R<D;H%^0;)BL*C5Z 3O O1HS'K1P4S1^&.MMZJ$".4>E;5-923
M(*+Z&YJ,&P+_Q%PLCX2^POFF&.!#>$@D!_&=0/>J0P03OHR:Q@PB UO"2J^0
MQ+I+%6GD$)ZAJH9\%%M:/41)+_T!/D6YL5X.[:961FR$/:2>F?T56D>] _C.
MS*)7-W46LS@,;5F9!Z>8&U1!Y_BB?U0-L>^6/*Z^PVY=9P1?9)/"'T/MV.MF
MP\!XMB?@*9/ NMA86:B6T30!)7%2 V=<V9!$BWI2.4[,*WX(7"GBKCT.6BIL
M"5\-SA-\]GQ9O5'P)^ :4\/6-93F?]'CU4N*=NN&V3-*5VB^H1S*:]7SBB=7
MWE6BUDX%WI"_6[JW^H'LCJ<*&"J3 X:9G6QI?5W>KH9R%:Y0;/W$RB^99"E$
MKBV#&_<6%50,Z<N3P54[=)"E$<#-V@C/Z"I[=3A@/W,GFUOOF7NU*USYM*"M
M?2+S8+%/<P=B<RFM(;7P;/DA:]Z:#Y4'+&/##E8UFQ[,.EDY24<&##&/L^FU
MX>C->9_DES##164,$/9-J1J^&S^S0EYPAQ /K$K:3P2!IRYY2P)#RSQ*2*=@
M!;^K(I[F.PA1A4+6@GP)=*8O1J\"06 M&#FD*?\!]AQL3^)#_%C$SB61^ ^H
M,O?S^..H&[]3]C&3 -H$]Y;&PE<BCM(F(_Y 94,%*%_TD;R7:!YV0:([YC@.
MO]B,;</3W2NQOOC?9VZI=XWVX#$$LW@_Y"212>'!0*1$2#3\.>E+[AXDG-R2
MX(HZ0%D5<A0MH6QW.X%Z3I'_KHI@](W (RPG$0C4SEI&#H64L!)!GZ%?6%$Y
M1^!B5F!\%.(%:T'(#&0]:[9;!M*!^7ID9*NA53X5:X7K@;?%XTF^H'913O4G
M2*90GGT9^D(PO)H%3Q4$+!+#'_'WNCZ!8_G[;-E<55&AG2( 5E6KKQ(3J\-5
MU=5S0"\4=[,G0;1R1MQEZ'M9SJ+I,*BTQ[4.YB,Y:DO9M\J#:R7\S94QYB:"
M$NAD) "1U0?UT5DE8(1N>=PBR'G-YF =-%@SWS4'.EUA6V]HJ\M26M_Q@RN*
MFT'X;U4+&_A5UX"7K=;,JR"JQ6W5?O U4V;P7(B[L6SZ \AZY>D1I:23'^4-
M</PH&47CL-LI=TH75/R@\BNF9HRB+:ZZ&%M'>P4J"5A&/PPI=+G%3(.4_>ZO
M<8H,PIWRG6P7HKEJ)<9*RJBN+?].=@9?2/<BGX$^6W&3HH=?\&^@)B%7NHAI
M L3'W_WE)??$S81N8_Z!'P>GH&GX>TC/L@>$7:CFM"5$%6;*BAFD8FRQ_P32
M"UR"RW**"_;W#CACF_026H?;S(!A.O'[4 NQ383>TL<X!5&T80.>2EJW'$38
M0/JV4$GX@PQQL2,^)]GZ2Z)#PNA]]#24F>&*G(#N8N26#&':&-348FP]P[),
MBF,P=BZXB3O"..C<1)C/J+=E<PF\53!(2T+<$U 13LB?@HG%1]'C^-P4%F8L
M[V?,/<QUGGE!(>8G#^A<@&OB?K5E\\VP0.5.*@%.4=R"KT)8Y0>+1R,WRC3K
MCZ V26DQ:]!,2;O?5S1: G$.QN:+T#8U$3K:N(-R"I9GB(?IX?0:3E$Q0J+M
M6N^#5&J<H[M1A:J/?FR4G^JY,P"3)K5]@R T0N8U;J%L@++JM\+&P^JMZ85G
MX4WF6^LZ$'7&\]$)R%)#G]]TY#@]T*D#K9'8Z@"<*QQ97C$ACY-7: 0=X124
M-.4]YS#*26OV<X:J9D;8<?VJ,7//\3Q!GQT?\5M!MW]717#LD\S!LKMX,/-$
M96GU1>8+X+8\-]9LT*,U$UAED+?A:-8)V(ZY(#8??MSQ-N<)_/>I#X8#:R=]
M$J08%T7/@2T$GJ(;X5=S/>@WD-5)2QA!J*M+]S ,F*ES'C+=,8..AUE"3*TM
MT9LH[9@36"?J).RG*@,5C!^3$TS=A?^46$CS)EQ8ZD83$<5S\+2+Q+..FQEH
MTH01Q6"3)-1UZ"_D"=0;E7(RA9:<'4C^DV9.V$J)I=T)DU&ZZ#/G>%#VT;T=
MNVE-=%NE@JXB7.'>0@<28=S;%:>(=[B]6:6D1&Y1_ -2#]<E]"UY-.>V=P/I
M'N>2(X_JQ2FR)?J3>(P,BJHFN$AO54PD2*0NF6V$-Y(%\6'$/'%Q:!&Q473-
M>RTQ1NSLB"5?%63;U&)<ANXU\C3NF_:O<AP>IV%E3L5?4MNO;B%$*8>7G"10
ME0%>-_!_*2<Y5I)."S;:$OT>+-E*1^;B_"S?R][A:LTN&3K<6Z/3ZJ7X9#UG
M"1Y/U4_QXN &M9<= TGC!;8S,(14Z?;</R%LR;>"UT6;)?3B6ZFM$K^RVM@P
M\8_*F4'O)&N!"SU8TB_ =Z,^2*>!W']714KQ>>*9I8_ 6T3FBLS"QZ+@JOJ4
MS\)KU8=7= DW@G<$*85WH>L\-HA#H+M&!XK@L-^_>18/!Q5H0(] /8(5D"V%
M$_A/8-4I/OPF^)?EG_ED9%706'X3BN$!$)A1C:-3!5,QX2-/B$7S8E&WJYMX
MCAB/_(_<H]C(]6NY<MR*Y6%<--XG$,%5XD^X6WGA^,VCBWGCB:=L=0 &)X[T
M%W 'QY.LR7=B/Z7,75?,WDXQ+3.S=92_ QZSNZAQ[FO8/ZE31R,Y\33;V(MN
M9ZE9;ZM>L5ALG[P,5C;;;^TVUASVQ&5CF9]9KP.V,)^P'KB',M^Q'H]6L/Y@
M?;8E^H_,*/&$JG)FM.A([AGF)-'RM0&,$\*:&"RC5C@A8"&#(;CH]HGA+_0<
M;6 2.;9[H2 ,7_6\RBN,12IL;@(#H 0E=].W*99%?Z#3Y67^K?1T^3(W-6VK
MK'!T P/*.6)+]-_IF:9UE5!ZF3$NYP(]4+\W.89VN69NM)&FT$WQ+Z0E:W^Z
MI5,)*M5H-;V1LWM$0>QJ6+GCB\_JUN1_2N_39A<=CD_7Z$LKEE(T\\LWS<-J
MFBNSG3?4R"O]?B6I<9#?;R7S(MA3ZU/26>REF5;V/7V<>DYEY.IA53HP=:F;
M<ACD-6^%:A:XT!FB08!^]:]P+K)JY%Z@=-5@=431RE_7?$]+4SR"]*Z>I9@)
M6QZFD&O@>I^[\@,(I'.)D@M_\BO=E.!L7]!4,Q48Q.["$GD]\N>&"MEQM'\<
M4#8&LRSTN92-]?9!24W8.N<(V1FLTZ_$L?O?TV+ ?AF#L+[ (-U-G)Y:*WE#
M/+"J7A),2@NM%C>0COG8B9M)WYTG2C))-;\21RK=-NM5?9+<I;_.?RD)8:Q+
M!8A!#-JJ<:(&AF+)+9$]PSSWFG"8T>(\032%L>W7]3/_S2E5!6(Q7Y:?(7K(
M)Z6 1=[\12N)PBS>V24%@DT\Z5RV((\G<0X5S.$EC5QO2_2W1&QY0OXDX2O9
M@Y1%0B_9O)6Q@D!IS))%?)!DT]QPOH-TE-,#7J/H[?\HNG"@QB.O5SA'1U]_
M4I"BS8R]P]^@<5A\CX=3(^>.YKY0^SM=YQ9+)_Q_5?17_9OLVQEQ=?EY#8G[
MK(Z%"5%?+-^*AP(D%D;IGAG)M:?*AASXUK7E]K\28@O"=F:IR,%ZL]@SO:<V
MOS0[,<+\OIP2I3?MJ\0&I)NF 2?.2#-/!FYUN&VZ";SWJ^5=L+;OI I++8*J
MU6D?S#.!?R<T&/\ -4>-,? AOOY/]8>A.3-\#2+HMK%N>BOT_J_KC23;J:J"
M0=-*6$%:I.$1O#[^G-Z(.!T)K2E'WO.'ZAI0 QXW:T)1I\<&:P?0/O]<3P/:
MU$3#>BQG@U9OCRN,#]%MQ\^*.**EX[?[C]9L) 1YU&AG$>:,7:SV)]SZ/<[8
M_KM%/JYF.^78!@<=@[IZ]8 VF*J/2%<_H1Y<:%+;4V][8-1!U.&Q,8K/M'/_
MOPWS7NM@G*FI!NT*3LSJ]>JG')_P%RHC^_G"8&4;^[2'M[*+_6QLFGP6^Z__
M46)MD;@L=9$F6AP3]TCU4'0H7*T4BL(7W% P10[NVQ4X4=+8 &D+_]K_J B-
M4O4@=9P:JVJ).ZB:KCP=CE*H%=<7W)7G*@ZX?Y$[RIO&8B59@G'_7Z6U=Y=G
MI216=)IRSL>D=$S*7Q[\O.U^(<1;V':MZ).3L;.EV!$ :'0L^_W%#<;6&AN.
M=-84^B<<:A\NCHC>VS:[=$FPH&5_V2?OPA9$18#3T;;-%6,!@#HX</H_UQ-L
M(]N&Y>V9Y:\2@EH-E<KH5<W/@.[!DYN8U13OJ4UC03E.YYKO@,8# )9;D-]G
M[:C+1E3JT=8)X([XEN9\R*VHUL9!V*B@IH9D.,!K7_U>N,;I2&,L? $ 8"*A
M?M>]&3]M:EWS!!0F/J 1ADZ-"JT_C)D<%%"W'M/J);>V83XZ[:N[AE$"EAH
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M7AVZ2=2LT-G]EE\N.F)^DP/FFAUTKCYY<$G3T0K+7A/5]9*1C@1&HYK25%&
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MT-2:9_A?YNSZ\]KQL;=,3LJ9@=NT0=+9[C?E/L)Y=I^$;FBZZ.I(:]=^UL#
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MD;?4#>.:P&]F,?X-_HB12(PO]-9ED$ZF*]4V%%QDO/P&+<2[7()GY-DW"AX
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MGC+$V<I^&JS@[./,=XT!-W(V[K["ZA&0.GQ9+7Q4_Y35S!.A7UA#J))H83U
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MRK;L:F93C37N"; ??\B_GSV3[./$XC33G=HPY#D5B'$5^7>E57B;\KS:2G]
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M_@LC>%9J5Z].,(^TIFN-\&!.=?M*L2GQ;XM.*@H_TI@KQ_S\K6.5&UTIIG/
M5-MO^IV@F;MU/BCUHT[JOBX+)\WKG"3/RO[=YJ!0)FYIGJ7<&[ZD8;#:T2_<
M<A=8Y-IF/ +&VY7JKD ON6&]@]2'*+U=/""C=&W[>N!TMK7EE"8O4=%X2?,V
M'+;>!/O]PLU7(([K@.$NG&RW4C<%<>"<[+Z*9E*B.[/0@E)26S,:D1W7O F=
MFAC2<!CY'<ZJNX3\]HLRO4)'NMXU3$?GV+W1BE _#K_KA;Z/_*F#H?<JG=&Z
M2B?+'MQT0KL@X4?]$^)2>$K=4&*67ZK)'A>X_OTO*>^S=R9>8-,XKET>=?O(
MF]K76 Z57&UY;V9G'6T:9[R7<*S>VU =/LU2I7OE%VK4:NO=;'1W"$_[ @+$
M+K/?=2YIWD1>WN[0E%YRJJ6L(3)K4R.Y[G;"$:O<W!7N85YKE/KE&3[KF6XA
M.J&VW%Y!..,BZIK5)ZMGET$KI.1K>:%]CV@#*1<6?6"<CV;W]G-F!85USN//
M]]S:HA1G._ZL/R9/GM=F+E(74Z>M:J0?*/-=[L!XD#=L*9/MES*PL)*[/EK<
M,UI #:IIKQ=G>OYN^B4K=V)96<JE-MZFZ<!WRL"*NUPGTN5^&6]/[I'%^P6J
M%,O\'2).=%674F((XK=-D5WQ\F_L5<8Y':GS4M^PV6 < DHIHN6SQ24D:.D>
MB327O6B:=&5*8:^C?%1T9,=/17,0OV6K*MJKM*$&&.P\R3)-\]36SC -.D)Q
M[&]6JDAA2^)5]KGN"Y:H+J5,Z=ZI;HUV;N\'X"!>,Z31>RGJ4\'YSOEF1^BD
M+:+/A-^1[_150<VDT8O'0R=SA\\70V^2/W=9X8G1X]JT<$:0O(D-]WFU6?.1
M\<Y&4P&"VY[3+47>DY<N91! Z<M%TXCXG/>]<OQ"\OW.5CPWZE=K._8@2-YH
MP4Q>6^I@+-EYIW$)-MQNHFXF>I*L6++"Y%%Z?6&N$<UYTK/"H$J^VG%8GQ'U
MMN6TSC>(U7!-Z^&UQW*+B'&^;YR$E]HE:5=@"+ELR<SZOM)+"]9;#3D/N_^U
M/$B^U#'#/"CJ4XN],2A(W1"J)[Q.6O*T;YR_&!82;#N!-@>?M+V,NKW\Q;)O
MM=75I'9/YE?*3NU9CK5VG.0O/X+%I P2C>/>RDV1CA.JHV\K*J0L;S$P6OEH
MJZ2&4UO4#U/IS)VM]VL3.3.(-2P;GES\BSM)<(ML*_ 65^34B5727]%5\BF*
M^]XIZO& U^:5E9BP;^G9FIWBP2UBZA5))5Y2^TIZ1'2)/4<>5>/) Q3'LR^*
M1JMX4<^D;X X;WN5)UB\\7'9"_71);.J2@#/IC/DQ4 ;^H/V2C-"N(19KK%6
MAW"^@H[9-H*CX)$HM>0%A'L/4M+@B@WQI:N)PXLZ*I*)I$9R]1[\ +*0ZHO'
M"5IK3V,GJDK8?1@]"^*O1?]&S9*,1.=[/59L04/7/2F^9%VYL**LH2ZM(;K*
MQ7P5;B'O-57Q%],QP_/*7A:BUV1^Y@WHQD0>$:<3!J_3"EOLT=JS1;D=C 55
M)-<VV_K"BLO-VZ'=-8;&1-X=&M]ZJ>(7L]%2DZGG?C#>C-2*5NB#O';*EQ 5
M:WX5VB]Z-K^W=,S\3=;N\J/=N="X:F/[+5X4U=#"K^ SSC1\S;3AYM71(K-$
MCL8>KY7R2.V"-=*"]%5CY\\LB>J_;IU2]GVQ%#16[9L_F'N$<JJSLV(<PZ75
M(>,DYU"#/G*"<*MYK5>O[+ENS:K;G+'E:WI^<O]4!]<I^!\H"\ HX5OZ)ZY6
M,HR55[Y8%LL]E3%&T2>4A5]4%TKE'NO <M6@E>6,]_26[COL(.9<BY)+9[=H
M*OA=O"&</<+G J#LIX0N'I]>)Y\@/1JN4XU6'/-8J"D'_):?ICL+2KKB&<N$
MK\SCV./$<F T%Y#\RUXH&"[K*)LL.JA(2KLK7:<:&VZK> '\X]$$*,#89:&4
M%<HW'1OI9:K%1BOCK3I==9%M5K]AU?/R@86D"&&:AI*6+!&# 6''Y2\@6P^=
M>@WLWK>O!L/8[874<BS5$%L["YN@;&/>04\Q%W#.H?6E,OY?E)RZ6UR-!H=!
M\C'H! ] ]0=YL=1<M<=\H<V?O-ET71] :S3N5O0RE 8+8Q_;JJ\H.<=[H M(
M31&)M2/#HF39^%D/B8J% 4M:*]-;)[2FU9":(W4EU/3&(/GYVHSZ*8R1+-SR
ML22:^\-T)N6E<(5A?MAHZ5I=K@=7^0J_OOAVA=O\22UMU<G=-=H^2D('2^Y&
M+VC-J^4RES:%%V_A1M;/3;$(QYA?AMZ5>ACJ/&J5.NVPQ;3RLOZ!EFE5X!(W
M[6PRL"!2MHA6W^U._\)XW3ZWF,3I:AZ1$B$@K%=#ETGVF^0>9&6@]N^"?G%G
M>7V3@^1,M2U^2S:38I8>EBOI]^ANBK>LZ"*ZRL#=E_0#2!%*@K^ Z5+,;3K<
MI9H]GRKHI]UL'"[R8L#8/O%Z]FC)"6D\MXY6('LKF%VX0W%(="Q)H]HO[0K>
MK/E'L<7-'FH!_'MG<[_PI]7OY.\17$.W"R4BL_BT.% 21$6EDZ6O"Z?+[>4#
M21.4%<J5P8CZOOJXFR>X"G3MWL!N4+A82[A:Y6PDB\]4_A M$Q:JSE(0,5^]
MIB!+N@7H3<05;IKYP6&JQ^!NMT#-'>A;%X6)(G/KIK&[D QX-G<)4BHT\;<B
M>>2UPB](=OXBB1@A)4Z0ST38P8-5PQ',+4+CA<SOS*H]9QQB&<\::F! +AP7
M?8]@&:]<MZ7FD6"/]F3^)'$9\31AG<R;&!9T09F&3W.+ ]JP:1U".J]QP!S.
MV-)0#):S7EG7\%]R0RSW:B+Y.\SC\^I%<F-D E5:JZ<$K5<LU_+=DH&9>$7[
M"5IQ5Y2II79-QPC-9N;;5I"?S4EI.E"]@G>OX9^\\<*!NJ2$<9*3)GE0@\))
MC[FEJS<2XO8RJGFQP#2+_F(!5^/#].K^QCO!-G5D58?SO%L6Y>X2VC2\CS\D
M2:GS"JJ2#QB3W;+5-5I2\SHUI=RHSU;?KIZH=@ 0BI+KH8FDGZ[<!(YA^>;,
M!K]P=\4^A_X(%0%>2)RTV7DE>E#EV]2A:*4EZ;*5E-I/*D=5.,O"25?;<VTJ
MO@&V_'W9)DV,"(O5@XB4&S <^JU8Z'P.V0SX-:IDP[F/M-/D$_G'E#:*J<(>
M=HG23<RJ"%252!.SOJE7RT-CW36.RG3_)^ -=8/S>_@0.*$A6;Q%)L'O2M[(
MV^3O9',4BUD:>;%R1;E:L56U.4NBBE)?B+FM?J$9ZG]*<Q4L=AD+?8".UL\6
M#H#/L%OBF5"A[+V$!<UGRJ2'H?-EF^5I\,C,L\JA<':,4'4?[O9?"/R /[DX
M0]%(D=5!8*]+0U\(6[0_9>-$O[5J1I]$3EPG_2N;001E%LK?XITQ=LHOV+_^
M"!"!5;N$@TO1S77EO+-6$'47%-5)I"7",Q;[VE_B<M-R$ELZR^B6\4 ^7K\\
M^HG26^?DSU5W$%:7#- )>VPYP#W8ID :^:4MZR4#@IM-YEJ^2-+@6_KDOQF=
MRQ#(RLR\Z!Y%LW&(?ZEZDD[C0M+LP9]:BC@_Y[L@\WA=W<LD\0+;CA7TS\+=
MK<S_(E1'DT.&DW2/]69TA6*B6>_OJUICF.-"T[")W?KW&+]<J\&QL*K?PDHL
M@%))A;$D^M9B7ZR:99=Z%C-RMT4\P(X)81\4#Y N<^3AYU3QNA_P>>H.8"7\
MO)8M,"#C66,H)Y!XSKJBA0C.IZ4RD)NBZ(AE:(8TS@=$7RKJ'==@6P$?[5^0
MS+FH[@ W\X[S%T%#!%O(GZ!*T?S"3]!Q25?*"SA?MC&B&OZL>.XC0HZHBQT?
MH0.:K\0GP$=R2F4"5LBF\AHT-O)LLH^F4P$79H)!RETI,O"U>G2$+;0/$/@P
MX0.:+TY3D,=0!_Y1E00,*!M5]S5EW&5JN>9Z33$P 4PN. X< W>E3-&L@R+#
MWX!KH>,^-.@.S'"*0CR0\?@TQ1Y\@>*Z4HPW<0>I9N&%U2M5)[ O!2[J7JPS
M>24P'TL)7Z4YA/[PR8/FH*N<:F K2L(H<L"<HW!1Q)O:.*6*K\;6Z@G*'09.
M?J]JJ3XJ.4&]5S<Y' 1^$"]]TD YOME) X_!9.@5F;IIOWR!/+>Q@GU!,:Z^
MK:I5<:VN,]]+>=G<GG1//=K8&AX'5.J;?>(U;[2@4S.T&*>C/.GVSG?R(%E'
M^V,V55[66E3EJ7!N O.N*=WK%R7UJ026(^$3U3>-SWQ<-'K=;Z<^*(MPUZA-
M!\K9HL?&IU5G:K<9@RCN96\,]71C]DG]?=;@^'Y],'=ER#^Z5B'N.4(W6;K3
MGJ[=KLH%>@R55!N1C_X _6SM:+TO$RBCZA9R?+.INHF\/_$T;9WP4_!;[73I
M9$]'XJ "M!\@F@!W]6'=&/9V88JVG[N'GJ4-X>\C;2&."8]EW26JQ$_CQQ+#
M9<[!)_ !A<XS&&]7SW48C3=H[J@>X._$08(*?(VDDT;&:Z0?2</P2?*<K"SL
MHF)GW"JL7Q45W(V9U%<\H[$&39M#-K8.XJA&8 ZJ^?QZ]*>:3NU!CP'32Y/1
M%F @\P;*T_#CBE$>Z!LL057@7\\4=#GTP$&/OH5/*U.0'N0S[P[2@-I0?B$B
MU+YD+Y*-CL[D(S'(Y[A ) ]Y%\Q&M,@7SV+D#O+;82N:C0Y5+(=9!@<>!9;J
MMU"L<(5^4$D>'*5SR!P$QVM38V_#0D(=G 5OQ3=[EB.!V .'V\@Q;)S"'9+4
MS^ ^ARS6"929$&!94OP"HII^9O1#,F-IK G:I1\(G@=/TWEYUL#+"8O#;Z0<
M>RT_#FYK/<4U@M=:?,D[P)--PXH;P2WUU@PR>*IN3FP%-,^T)7@05&\H]BR%
M([5O':<A0_&E(GES=;D-8TWCS2I1);]!2CZ9O[E^&#TD96<=P#P<><[\B*OW
M!TS90I7K#<,IZ1';+KU852Y<V1A$(3.FUM^GCZMX;#4QCN9GU3FQFU-DYG4\
M*'*C*5S8X:\W')?<<)NJ%REJ[4;I8@!'P5?K7Q9:6UQWC=-<D67IY:W).VS.
M%UQ/F6K\([:-! WKI77^F)ZIF..6H(M4/;3C:/TU1P61EO="G-YB?BH>5&XR
MG9 @>:'&^;+1R?T&H7QE9(0^0TGW%^J\U>%N5*VG)MAN+Y$&Q?%U9B^%B/;<
M%*VL+GMJ#%'%YRXTV*KMDM/UXX#)$7]T$S2S_"NU,T$_-XB(AFKL_\$QN(GW
MV+@+RJ:5&1Y"Z\M8^A?0NUQOW0/8)NFU]@%<'/&4^  O\:\D;.'?;AVX "FW
MC\-N(MMXY08=\9%Z67^0V$]ZK;M&E.4,:&_B5Y.:B=<X*6(S,1%[ZB_ 4S#"
M;1,V@,VU%V/YZ ;N6WVG64[MUKTV'2;MU0TVKLII)3X;BI/DQ'#]E @SGJY]
MYI^)+2 NNAW"//#5]EWH?0SG=NH>-.ZCINO"&\PDOK;0NBLGFTBS]";%XQ6F
MS@@^MLRPUC\%FZ"[YG8!W4%\M=^!&G#OVKL]_F6+*Y]UC:Q\4MC5_HP<G_ZF
M=2%M7]RL9@<F*X318.)F>9?6/1/6. \UETJ/V8PP_%91:QVZ4LE0);<CEN9>
MZ-,VN_9#>G_S:=;-V"^-).Z+$([UAM#36VLIE70X5QC?*C)LZO2[@7GTU@Y7
MIE?%Y;98=E;!]I9 +IH>W?B#?S5V2_UB449(25V2Y*7W0M,+^1KG/L,:U3+;
M0;JEF@WT86VS^=LKPEHRA7D%TYO*1-_2SC1$2[;&TJVC9?4A >8K"H/W*F.?
MJMOYMKX)N&Y+TVZ"YM"D+:6RP/(-34ODZ?G=#?L5Y#22=9L2B'6R+%)M")E@
M:@*&>*\Q&#1TEQ&Z7O"A[7;B,5Q!?=_T$N@OCV[,U$3DA];+-3O2_JE3@IXQ
M#\TB<$/POT8)5.2]06^!_W%QTQZ']]G^(<(0"15O/("^*'O8$(P-RGMA9:+W
M4O=:^.BRF,4F!0H'7S=848'W;MUF5."2IIV*LNU"\95H#=6CX9S^?5E]?:%>
MF]=35Z\[D J9.[778@3&%=I!P<OT5XAH[Y6Z47BS"XN L#MV##P$<Z(\:9A9
M=ZE,:%UN^9Z'6!Z9M:D,TQWCJ1B)X;$A+/BH?J;NF/=I+4\K=M$1PXE)=A;L
M)G:DHJ6ODO2C,&]Q:Z5_QI,%RVJ:$M)ZV#27\-Z.^XSO_JZM7MPQ[C6-7&&6
M0W7=@/32W'Y3M8I5?G/)FAI1P>6%GZDV&5#O5_K/A&%=JUG#PW7M=MQ4_^AF
M4+#?O:_^DH3L<,Z2JHB8%V.< $POYRY:4KNUH'K^'^;3#/N>J9RP^!T=5WE[
MPZM;Z4*^?WSC?4FV^S5KN3S3T=OT7:6<=U#_6M-;/GI!._=*_J?>87Q+^OHN
M?V%%O*A]BK@@W+_YH%3L']5 DV]Q_UTW0C7>$3!> "PV0;J/X/>R_MY3XN?Y
M;=V%4I?TZHYZF23>L161GPF?WI2E+/*/J)^L^NDQQWP'6.NXVW 15-BTZFQ@
MK[*4GB+EY_S,S@^JO>G.[6%J,.YG2R 0%?:S<8)FIG]RW7-PAD>$Z3KDZ/A!
M_PT.L7FLY2'!I*_=#M#Y_$D=YV#7M-]M\^#\N!O-]K X[%[#6'BE?X+E)_S+
MH]+X'2$[.>ACD(.V+L0-=#II:Y<O >0]:W]&5*3=;0W#W\8=:8K&:\/.U_MC
M7_S]+&'8 H\:8R96XY2AZ\=FVU80-/0"R=(I-'[).]/N;J2DG6B!#85Q.QMU
M^EEA5ZV ]K=_LME*_/&0&;81TYQH.B\\R%9'#,/8:Y#*1\6>\P-J_I2Y6'6T
M2573H"R&'_D7;R%;1G]6<9CWDO4N,U+4QG>+G"CK$N_V&J'ZJ7BRRD)Z4T/I
MV5 II)+K FONU9:"KK125A:WE_&9FU[^G'-40,FH$YP7+XGHEP;)@SR_*3^J
M8U8,%#/9:->?LA@N:CY<^2\?!BZ0#PD)CHJ^_K^(\)MU17H@_2X_5#$V(D[\
M1=7N^5(Y0J-8]K$@6BKMS"RAR7"32SE=WJI&JWF*U>Q"ZC+EQ;*IS#GJ<>D1
MW+- 5?@3T5W-#<^[BE#(V)^0JX02VD\5WH<$AB,D!ZA+%51)APZS*LBWH>^D
M]-H>."9M-:<=K@]O%[Z&/WM>DA.(8.GE;#O]AS9+_D%]M'Y]29@.44:7;]3N
M9D(U5<2OTA7T?"(Y+8QMQ9O#BX1VV!W/D[(7F,.2E9GNC=)64^ZO^FNZ<T4]
M5@\%4!9GD3/.5-N8#I?.IB4:)Z7>9:W5EX0["&1:@^<A&1M?O/AP>D?7AI:#
M.?4=3CK[PNQ67/Z0-+'I)B.I:DI#:,E":FV=-57+_&4Z%_:#_U3_RG- -HAX
ML=@S3;0$:PG-UBSXIEU4D-E3*1>5VG<<J7U6&=D:5D*BK&J<GYK$I-8]#CO)
MEQA_>NZ4KM;^6G2%]JDXN/DR@UT6H4UG/:MRE<_BJBC#:\4"+_K;XB7BB:P?
M*;XR-WYHJ*>R37S5O4)#4HY>Z$GVJW[2M)0V@?*+2*Z]7SM$%L7:PQI"W\(=
MX(XN'BWX(O!//B2I%>,AGQ2^<@]W&I"I3I]OKCS+4C<.)@_B]&.W:'-XQR1O
M&?&"9[0>=H-X2I$'?Y:T/-E>=$=^,&2![+N*Z\Y15VAJ>UZ6'18_J1=614N#
MT"IRAPP0[Z?]D>^FMC,[E2,*:[A\%2NI0PBK'X20I$\T>G>AR@15=+-*YVB"
MK1/*SVO6(S.JF> LD97Z#ZBF[*B]!=XK6,7^#I&2Y@ERH-LA\R1?886[3'D)
M<>YR*[JGY5C>D YK)\!3*BU$MW IN9J81GY.9^!-!;-8V_"9B;OXZ=BRX%<2
M3RS(7:T,0_=VNA0.MHHL0THGU$5!L>6_S \%3ZJ_F63D&)J?<61^&W.=?GZB
M@,?3^04?$Z/$9G=0L1UW[*#FZ]K]S=G%&UH=P+:R[4UW!=E5YQN(FLU4+ZM7
M_FS&5?.EQ#G< :,H>+GHD^ZM.Z+()HK;[^1Q%C283A8M[UD*3B8-=$KYERJ?
MM7G4Y%+*FU[FG6?8UR]+N,%UM^0& R+"<-D=D__0%K15<(.+2XRM_&%E)1I7
MP<NJ:/XPT3/*]&JF="C]5^Y*>19[1'RA\C _/5 !6,4?7&Y 2Y2>+4^92ZLY
M!BK[&J41&,D;15_*&R_(8FZHZA)MY)S('2E-%PR+>Z28(N8&IJA]Y:XNWT&K
M.K\9HU.8*OTHQDOV4=5?-H4W@CN#^UB04'E)8!69<^1BD>1MG%%FE,L"'94?
M55&N4S2=FL*F$129B*)=2(\3/U*V,CY+2]D_V%MD!RMN\U8H@K.W"R\I]\6-
MD@:IJ0&O%(\T_JX>P '(IV%M]0NU#U%!>:E^I6#0KP"-K$?,TQKGBIF<;YK]
MV;,$3) 7VR<9!;D$'))_@;Z[Q@ CX;OU#95'L<=X0<U'[)9<21N%K6&-8OAC
MS/(R=AWFD-7%]T1?Q!:(AZ,[ Q;)W5&+:ZZ:BU995Y;_-;,Q376VJ5.VD:(W
M-C%+Z9<-_+)=K"I]>I8]STWG'CM5Y*$=&V"60?A#URK5<VQUW8^RQN8UZ.7*
MGTV391/)60V^C,.TK5;7LD FV6*?N9I;;)H;<T((&:8&R*3OM%]<V2H(/UJ'
MD,#N-K2LXD=GJ+2QIJQ-P<B@7FS6D\XSFAMZ,NF<)76;8LR"UZ;] 9E27+_-
M5:)R)3::1TBV%:-PEO1NF5C\3.Y>E4L_KZBG.):FJ,;4CDQ?IE[#GA4%:.1\
MBN\U2">9Y(0AEY6IQIW"W.I_H&#1#8JOZ(F$1\^@?9&-9U)+VN5G..9T1^5V
M_K4H5_4I<8'O0=!%[N"T'=ZJ+C% O""&1O->,)[U2'A7>)<;2QLAWLOO*+XI
MW2O\D]8C?RO!(Z^K,N0>ONN!UZHI3D^A'9HX?0B;*G@$;.!"(JM@'=\H<:4&
M"1=(]Q9[B>_)R].<9?G*\9'=B@^J.[Y]ZBO 3><)X&UHB/8/XXO27]W'3E Y
M\]=R$=6_%%_^4?6)(I$H"NA*M4C>:\#(</EI4."K53V' .< <![<1?RDOT28
MJG7,:J2/=YI]$-E.IO-"D4V%AP0WD'6I<\7;D>T17V4GD5.^(M4<Y(ESK@9"
M!Q'NM! #6_FJ]J3^'6\6*UL?5G.0\UA74QC(7Z\UI&P2;2>V1!R7OL&?^S*5
M/'RJ,POXAH7B>LJ5!D]E/EUK_<4EF#9UBIH(]AGSX8+MO!VF*2DIPF<&1H1>
M&J<;\*U0W-8.=M8 9CP6GT0^UMZCN$,SM^[ACF$$-#.KC[/>-5PKJ."^L6:D
M#!>&F ]&Y$@V&,-\PQ5"W2)G"Q!(S(0O F#Q0MDPS> RB-6CV5"57]D 2BG.
M>7908NW$Q!6P%]LC=",2Q-=XE:)R29 #"7NFK(&6*3.JYDNGJ#S)QYC[U--I
MSRON ..8XW([--,YJ8F98!Q_9:@6LH@CO*C()+FM0Q\ZH":!=;*"V@;Q1SG*
M&LZXJ%C&45:,5%[B/<]YKYXIY"=<!;22*:&IX"3972\:=$7YPN$9LEWCI1&)
M^_A,T77I:&%@[8"L5O2Y/$5^2+(I)UN9)@,3.*H/BIK0R<!>5;47'=P+F!WM
MX4O@-:!2F"4/%EX4/504T<]*.$IR&4_Z556=?5Z^0LU,F*2T D3(*W6S9J,7
M3W,"_.58"$^ 2]5B?AGX3CA1. -BT1U%!Z!=I/T2*?0I.U"6#?O'KU64PUC(
M1E4C?,>+ OQ$$AQ!B(.L4&WD;M?*!.7\%FTR#126$S=('F(O(C-KO=0=WQ^?
M*Z_$XT*LRDW8<2\JD(9E.2X 'Z"G5+,Y=,M6_AE>N?D!]8L@Q+2U=)-HGK$B
M*U$2:A@:]UY6K]L40E(.TW*\J.JMQ'3'7: $.Z!<R:YL7L<G<QE-D50#/[\A
MNS1+F&RUR_PD%IF_Q.V1WC5>#O%2R/7;O3+5J=HVQW/@+-PL/8W7%7>S[^'B
M,F8-#]=4!17Q\ ;*N/0Y^.+:8=$7\'ULO\#I^ =^D_L8(E=29$<C+BNEDKU(
M<]5<]ECD)#FE>CTZG"8LO($F,OK3-J%:]M?H5O067Q8X&DL7V[H'88_D<^R.
MXO/59>*3X%YZ(VLR%,6<7O4,6L.>7^@*S^)YI?G C8*+T?&(@WA!P!ODM*S1
M/0]=I-QG/P>S:F:*+@'>W+?,6<!=_I7*SQI(N+U #LX1+TA= )Z2MD<]@CKD
MJP..P!KE;7<RH@<B[&O1Q> ZX7/E1VD8(UYU1D94>JA;Y?OS-P,5BJ^I?II
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M?2NG\LZ)IM3L%YRC 31(=*:$S%1*KJ2G<3?)?D9M%KDI8_T.REZI#[C$J_>
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MP-Z5KVNTE5JU#?!.L0'37ZTFCE0J:!,4&><042:=Q@N44P2^<G*Y =D6A^'
M5B!S=0,:Y^!G=0?B[UN=LVZTNY9>[O-"G9T,QA\[G$P>&LWDM_;D:>M:2QOE
MC? .?CVFE^78W53'YL:K69-HE7 *+5=.HJ6JB>7VLT'NX@9T^X.>-SC%/FAV
MRKC=[5QX9<P+<FH^%#XY&U-A'TL76'H+-.HVB*76BFJK;L#UO'CW3]*31S#:
MBG&XACL!T\C&85K5L@/RGPS* Z[ L"\0-.Z)?MRQ-^7&T('LLW,^N;,G?#%]
M,Q%,ZW"*6-N=KY<X##5-Z-8JQ_:FU1/[B$;R(%I/&X;K6"-0O7 $HA<O.R#?
M_ 60[-\*5$XNH'ZW__/FG1%W^W;%7SAT(.G8XH'"H05/@FTJC*,;3)9)['F&
MFE9(8Y7#P+00.E^\^R>8R+V8.FH_PE@Y #56.^(O.Z#8] 60.FT%VMT'@&6[
MS^/.K2%7QG9$'#^Q,V'T_-[2MF/NY?J),)YD(%G!L^<;V&U02V4SIIEFQ3O6
M*K&38"ZW8QJHW4@3HP=FJNJ%FKC+[J5!OF<+,&YW LV;W&\-;/19/+;%?_S\
MEM3.<SMAQB/N-,EX>$WU0*J"U5V@IW? 3+07^]^Q_/$V0@O62FY#-5(ZX):*
M3JB%V06UL)<=4&WX JAV; +FC;L?VM?N/S?]O=/DN;4A73<W9M:?WHF4S'E6
M<"<.UE0.I4MIO86:<CO,0.Q$U6/;,69T&]Z":"5:82WD)D@SU59J8S27VBI;
MEAM0K_\"&#:N!RW?;;DRMG++].F53MTW5T>:KF_,D9[>C>(<\:%53,5PRT<S
M1<3!(AFN#ZI"]2*T\&ZT'FK'&B!=>&-I)[&^N+/<5-A!:RCLJ%AV0+OV<V!9
M]=V=_B]6SYW\>$WO]2_=S(^_BY9=VY++.;,?09T/)!,.QU5BI[*XR+%" 6RD
MM+9L&"8I&4+*B@;1\L(!K"*_'Z_,ZR.I<OHHZIQ>ZK(#AE6?_=#QZ1<+Q_[V
M4?_5#S<V_O"EI_SQVAC.C5W9E/,>$-QB*!8YGU0.G<NBE\SD,PNGBZORIR"<
MW$E8=?8$DI<U@:[)',?R,\;Q@O0QDC!MC+SL0-,G_SHW]>[?AR[_]3/KXX^V
M*L%*K^H?-D51;^]/PU[Q*X"?/P@M/9V$*CB9@<M9R"-F'2\B9QPK+4\[!J&F
M'H534XX@:<ESZ(JD.2P]<9; 2'B-+@_^^4\C\W_\B^WAWU:HP7^V\\!W'K3G
M.\)P#SSBX;="THNOQ>3F7$XLRKB87IIZ/@>2?*X EGBV&)YPIA01?P:"C#L-
M0\6>1J!B3Z'0,:>PF.A%W+(;G7KGMZUG_OAW#7A_)1]\OK4"K'?!@WW^\*>^
MX46/PF*S[T4GI=Y)2$V\E981?R,K*_9Z7G;T]8+<J&O%N0>OE>9%7H7D1UZ%
MYD=<@1>$7T&]J'"Y >&V#P'?=0VH#G "_""_Y\*0F/O"R*QK@ECHN9I4T@(W
MGS7+A@DG*_&*43I-/T2I-/63JAI[\3Q;#T;0THVJ;>U&R-KL,%6[':+OZ"HS
M=[2569;5&\,;PQO#_U*#Z(7!92VH]G<"@@ _( J.OE\;GGE-% TY)T@B+O!R
M6+.<,N$4"Z,8993K!RL8#?WE;&LOH;JY!\MO=1C:[ A91Q=,W=D%,7:VE35T
M-D',R^IG \_OQ?T#7R .C'H@"<FX+HDL.R^.(YP09C#G>(6"*0Y",<HBZ <9
M%0U]-&93#XG3THVK:>M"B3H[$;*N#JC&W@ZI[VZ$F+I-4)-].0'1U@^!P&&H
M\7WQ[M\72/T//I0%I=^0AY5>D$7C3HI3&$>$N?Q#/(A\E(/5#[+*&_KHC*:>
M<G9K%Y[7T8$6V=L1\IXVF*ZO$6KL,\+J>G6P^N[E!&I?&)S7 K[/BW?_/D#F
M>_"A(B#MIC*D^*(R$KLH3Z@X*LGD30N+I6,U2.T0AVCJ8U4T==.8;9U$;E<[
M1MC;BE3TV^#Z02-,/Z"&&_L4B+K>Y?2S0>#]XMV_#U#X1#Y2^:7>T@057=*$
MH4^I8VCSBC3NC#1?/"&"JH=K</7]'(JUF\%HZRCG=+<21'U-6,6@":T;4B-T
M0S*DH5^,JNM=3C\;A%Y[@=33&RB](AYK?%-NZP(*+^M#4&?T!RG'M<E5LZH<
MT:2\5#DB1AOZ:XB-76Q:>W,%N]M<7M-?1Y0.Z?#:82E:.R+$& 8$&&/?<@*U
M6SX$PA<&S[U YN$-5)X1C[7>R;<-?OE7ZH(19^LCR"?J$IASQDS^(5VQ;%2)
MT'>+<(TMW/)V,[.RVT#C#JC+14-RDFI$@-.,\G#Z02[>V+^<?C0<6 M$'GN!
MW-T+J#W"?]![.?:_;][5AD#8.4L88;$QCG[,DL$]U%!<.Z"!Z=LEF$8+G]1N
MJ*KH4556#4@J!,-"JF*42]*,LDGZ(1;)T+^<@/@G0ZV[P^#F!33N84^,'H[]
M[YU[K=$?<J$Y%'>Z+88ZWY;!&F\LK.W60W0V!:JQ3H1O5_$HW9(JY@"?R1OF
M,J2C3)IFC$'1#=$IAH'E]'\-;GN PM43Z%Q#G]:Y)]RS>&7?:/8KO=01@CK=
M'4.<LV?1AVSYHHZZ4IU9C6C42K%M4B&YF\]C#%1QN<.55>)1&DLS1F'HABET
MP\!R^MD@=MT#E"Z>0.\2\M3D&O^@R2/S5KMOT<6>$-CB4#SZ4&]&15]KGJC9
M7*PUZF$6N1+=)I 2NZM$%?UT0=40I48T0JS1C!*K=,-$EGY@.0'QY@^!:/]:
M(''9#=3.'L!X(/BYQ3GV8:M;VLUNG[SSPZ'%"Q-)T+&!](K.SARAN:E(HS9!
MS+5Z9"M'A;?3Y=0^LI0UB!?SA]%B]0B&KQO"\O0#RPE(?C)(G7<#S7YW4.\4
M!)KV1S_L=$V^-NB3>78Z/'MN)AXZ.))*:^G)%AC:"]32IM(&7@.BA6'$=I)U
MY;U83>4 0ETS!%4KAV$R_1"BUC"PG'XVR/;O KI];L"\)^!9Z[Z(N[W.<9<F
M?1,7%R)2)X_&0>R3*13S4"9?U9.G$K27U#.;8;9R*Z8=:R;9$29Z;UD=M[_$
M*!TH-A@&2E7&_N4$))L^!+5.:X%BWTY@V.T"K#M]'W;M";DVZAQQ>MXO\O!B
M0-; ?"2B>2:!JI](YXD'\A4<>ZF1WH9L)-EP+9A&4@?<3.N"-+"[2TR"GB*3
MJJ? 9%Q60+KQA>%[H-Z] YAV''C6NLWSUL!.O[.S+KZSIUUCA\YXY;>>",08
M9@\RQ&,I NY GH)A+]-3VE$-^!:<%6TC-<.;J&V0QLKVTL;JCI)&:4>11=FY
MG(#,89#L60MTV[>"QLU[']@W.U^<W.YR9'&7__!%IZ2V\ZXEA@5?@G@FDL49
M2Q72'9\#I0>B(W0AZ]".;\*Q_1NA+92FTF9Z<[&-W5)HXSN2+"L@W_ AD.]8
M#>HV;7K>NG[']9%U.^=/;-@[<G%;2/NUW>G&\\X0\7%?4M5,%*MB+$U 'BJ0
MXOL@*G0/0@>W8XR03D)]:0?95-1.-1>T55KRVCB-N:W\9044ZSY\>1^E\?MU
M]WI7K3]Y]+LU8Q?6NG3<V1QIO+$S2WS.&<8^'D"B'HZI)$YF\+"CA:(7=Q"@
M W!%:1_ZQ=V#E_<.\KO+];GV"D.VG67,ZN(L*Z#\_D-@7//5T_:OOSD_]?F*
MB7,K-G;>7NU9]VACM.3Z[FSV.3<HY40P 7<DGH::SF+!)@NJ2\=+^46C,&'!
M"+(V;Q@CR1G"2[,'2;+, 8H\?8"N2.MG*I<34*_^$%B_^O3:\(<?3YWY]^==
MM[[85O_L.Q_)H\TQ[!M.6>47?$HQI\+1B(4D8MG13&KA;#X];Z:8F3,-86<=
M@E=E3*&XZ9/8ZK1) B]E@ER3/$[C)XW3EQ6H6_'/^]T?O']X\=WW[#?_M=+T
M[,M=4K#&M^KQCNCRVVYIF*N!^= +T65%9Y(0>8N9F.P3>?B,A2)BVO$R<LH\
MK#SY&(*2=!1-33B*H\7/$2KBYLKIL;/49?6\Y9]_/CS]Q]_WW'CWGPU/_[U*
M!K[:704V>)<_W1>!>>"3 +T5GEYX+38WZW)28=K%C)*4\[F0I'.%T(2S)?#X
MLQ!$W!D8,O8T$AES&HV*/H5#1YTB8 XNDI?5X:%W?MMWY'_^8'[RWK_EX./O
M..";G12PS1T#7 *A3P,C"QY&Q&7>BTE*N9.4EG K/2/N1G96S/7\[*CK13D'
MKY7D1EZ#Y$5<A>6'7T7DOWC^$'8%6QAZ&;^L^L;?_DWCB;?_J !_^[ :?+J*
M"M9NP8#=3A#@Z9$/ OW307A(XK/H\-@GB0>C'J=&1S[*C U_F!,7]C _/O1!
M47S(@Y*$X/NEB4'W(8E!]^!)@?>020'WT,G+"7 WO@\X![X"K("MH#K(!=2$
M!3VK.1AWGQ>??9V3!CG/*L O,N#T>1J!.TNB"@_A*J63:(YJ','7CL)J]2,0
MJ7&X5%D_5*PU#1;5-0P66LP#A:WF[N*V)??&\,;PO]; _C^&T, ?#7'9U[FI
MD//L?/QB)8P^7X'GSI(IPD/X2MD+PQBBQF$0&88ATKJA%X8278/#8!XL;#3W
M%;6:NXJ7WDL#UV'@^&\%-0'.0! <^%P8'GM?$)UUO2:I[ (W"[?(+JF89Z"Y
MAVEDT2$273Z.8VM&T3S],$)8-P25-@R4*<T#I;K&_F*3M;^HV=I1VFQM7D:@
M^B<#UW<KX/LY U%@P//:D)@'M9$9-X1Q)1?YJ=A3W +:/ O&.4S'BZ8H5/DX
MD:D=P7*-0TB!:0 FL?1#5-:^4D-3;XG%UEEJL]G*FIK-D*4'> Y#M<-0[;,5
M"'P. +&_/Y $13^4A*??%$<77Q(EH4_S<ZC'N:55LTRT<(I>+A\K9VB'\9RZ
M033?W(^06'NA:EM/65V+O=3:TEQF;6F 6%L,T*7WTL!S&'C>6X#0^P"0^/H!
M64#4(WE(VBW9P:++TGC4F=J,\@5^(7N. Q<<8A+D8S2:=IC$KA_ UEAZD1);
M#U33TEW6T-929FEO@%C:]-#&-C7,VKK40,U/AAJO+:#6:S^0>OL"A=_!Q\J@
ME-O*\((KBAC$65D*Z41M'O-(35G-- <C'6>4:X<IS/I^'*^Q!R5N[H"KVUJA
MI@XSU-RIAYD[5'!+NQS1V+K4?C*L!#6>6X#8<S^0>_D"E6_$#YJ Y#N:T+RK
MFBC8>74"85&>13\F+JZ>X2/%XVRBIK^BHKZ+5&5MP0E;K"AY>P/"T&F -W0I
M'4F1EHY:9&/;4GMIJ'$8^!Z;@<3="2@\?(#:._P'G7_277UPSG5#).2"(0Y[
M2I=.G5<55DV*X:*!:IRFLY)B:J8RF\Q$7JL1)^G08C1=2K3)+D:9[$*TN8./
ML;0M-<#_R2!PWPRD;DY Z>X-M)YA3PR^"??K [-NF,)++C7$H!9-:>190U'E
MB!PJL@LPFN8JDJF!06_24SAM*I*H4T90VL7X^NX:3'UW-=;<R<%9VI?:SP:A
MVV8@<]T'U&Y>0.\1^JS>.^Z!.2#C1F-8X7E;#/Q$4P9NLKZ@LE]5)G)\@&HS
MCV#2LZE-2CJ[34SE=PK*9=T\LJ&'3:CO81$;NIA$2_M2^]&PWV%PW03D+ON
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M M>=&<#;*1$$N<: "(]($.,="A)]@T&:?R#(<OSXS@WT P5!OJ DV!M 0KP
M/,3S.2K4XSDVS/T9,=SM&65)-0W_[BW-L=_]1@#>_0,#?/A7 OCZ(QC8N"(?
M[%J=!@YLB >>6P\"_YVA('1W$(C:YP_BG'Q!T@%OD.;L"3)=/$".XP=/OJL;
M*')S!27N+@#B[@S@'@< VF,_P'DN)8#]YAV W?Y/@''_"E#\U@-ZZ&[ B/(
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MM;#+J0KDI10=^F*2"7LAH0EW/KX3?SYND' ^;H9P(N$8829I@3"6?)PX_(I
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M7T%E5E'87 9)P*<2E"(RWB0FXCO%!,)P+0$_+"+@1X0$_*C@EP)HAX'T_5]
MM6-[2W9\#-2[OGANW/OU78OSZLNM7NM.=P5NGFD-=QNTQ(:U&U*2S<KL?*VX
M$";E0_%\+H9:Q2(SZ8Q*;CFMAH^GR$08BE&,HK2)D92A6E3YL A-'A&BR:."
M7PI@'(;RM7\!-9O_ 63;/@+:'9\],>U><:MY_S<7NCQ7G>CUVS31$?K_,'.7
M84WV\=_X3QJ[NQ-%I4&ZNP;;&*S8!AL;-1B,'MW=W=TE*J@@%@88F)=B@(**
M@2+8BI_[O*[?_[@?_&_P?GH?'"_P\,GG?7[/V-Y?IL873CH2NCM8S-9&=^^:
M&EYP27E@=$YQ6%):?EQ&0FY:;E167F%81D5)<'IS66!Z3WE QK6RH+3!TN"4
MH>*0_XO_,B0?60[%2FNAYN@F:%'=_OVX^JZI/MT]$Y?-]OQSQ5+QVGD[H[[3
M%+MCQYV=&]I<O<H;O8+R:OVCTBH%B?&ET>F1Q<DY@H*<@H#\TF+?O(927MZ)
M,N^\RZ4^.8,E_*RA8K_,H:*_@2@T0^KA95"JM ;JE#9"N_*6SSU'M[ZYJ+UU
M[(;1CMM#%@J7!O &/?UD7.LI!J/J.,>SL)T;D-',CTBH#XZ/K(E,#:E*S/*K
MR,SS+BLN]"RM*W8K[2IQ+;M8XEXR5,PMN%[DE7^]\&\@&NUZ&8>6007ZG&I4
M6#?7);]A^JS2AI=#&NM&[NEL&[IE)G?V&E;_V"6B;7T_G59RVL4]ZZ2'7^(Q
MG[#(]L#8X);P9'Y3?(970WJV6WUA'KNNIH!9UUGH7'^^D%E[HX!=<:. 4WXC
M_V\@!LV0?7 )5*'W1JO,ZN\]AU>_NRR[<NR^ZI([(UI;!^Z9RO3<LM%M&73
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MZ?\I(.C-E=GKSM4YZ/YN_*O+/:+(R4NB2--=,:1L9IEP#FQ>E 0'UD2"TK8
MT-SG"?J'66"B0 4K%7O J>. J(4!FHXE,/7,P=7 %+B&QN!K9 A!QOH09J('
M,:8ZD&2F#1GF6I!KH0DEEII0_E?=O2)(XY P4O)8!,F"E<*)L$TR J17^H'\
M1G=0W>$$VGO)8'@0#^:';<!6UA+L%<R HF@,=&5#8*GH@^M1/>"JZH"OFA8$
MJ&N"0$,#HC35(%Y+%5*TCD*VM@KD_E73)00IN8,@Z:^%D3A8)2R +6(\V+N$
M X=6T4!A@SVH;;$%G>V68+S+%*SV& %VGS[82^D"^8 VT YJ@K.T.K /J8'[
MX:/@=5@%^$>4(5!&"4)E%"!*5AX2Y.0AZ:_ ;:\HN"HL!@_MM>!OO!U"K Z"
MP$X1@JE:X.]B##RN%7@&X<$MAO3')97VRSG7Z0>CA/6=5L7YYMC@]I72ZOZ%
MW.7QF72*.TL\SYUUN.8UXW#/^Z/#F/<;XH3W..F5]Q/JY%_]OY%A#YI!?C%P
MT0P!1MM!8'4 PO"*(*!H0A#3"'P]K<$KT [<HTASG&3:+U:.\P^G8I=O]$K7
MKX[U[E^HK1Z?*5W<6=)IKQGB>>\9XB#OD\-#WGOB<]XKT@1OC/*:]Y ZR7OH
MN#!P1S.XH1EXFFLAV& ;1%@<@$B< D20T,O+R0@"W*R!Q[<#;CAYSBV1_M,E
MB_F=6<CYRJAP_T*K]YQU;/6:H71YSY!/\SZ1+OI,$V_X?B ^]9TDO> _I[ST
M?>3XRG>8]IK_-^"!9G!',_AJK(50_6T092X%,;8*$$W4@ BZ$81PK(#/LP-O
M ?FW1SSC!R?#Y1NKP/6+<[G'+*/.:X;6POM$[?*9IISA?R0/^'TD#?N])8WZ
MOZ"\\'],>^EWF_[*?Y#Q,N!OP'.W*'C(+P%_];40H;?MO[V8!(P\Q-MK0(RC
M(82[6$$@UPY\@RB_N3%./]Q2V5_9>>Z?F67<&:=:WB=ZB^]'Q^-^'ZB]_A_(
M5P*FR \"7U+& I_0Q@/OT"<"AQ@309><QX/_!KAH!D\T0Z#J&HC6V0J))OLA
MV5H.DNW4((%B -'.EA#JC@=_/\IOGPBG[YY)["^N.1ZS+B7>GYQK?#\R6OP^
MT(X'3%'/!KVG# 5/4IX$/Z,]#[[#& \9='HAN.3\(O0LZWEHWU_\EX$KMP1"
MCJZ!..VMD&*T#](M92 =IPJI)#U(8%A M"ONIX!'_N8O<)KEQ7.F/3,\IUP+
M>6]=*OTFG1L#7S&.!4_0SX2\H%T1C-%&0N\Y/0\==!X+N\@<"^]S&8WH9O\=
M>.T2!2\T0YC*:DC4W (9_WXFQ?((9&-5((NH"VETLQ\)+MC/45S21T$0XUU
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M/QUTR;]HAH1?+!/L+P\SS&\?"XO?05:FOR,Q1G-)M@9SV5B]/R4XG3]U>"U
M7VC^]!(T_]Q W5S0S0YAI.^T*-)Y112I?2"!%,^M%,Z$G8L2X,CJ"+1S^X/.
M'D\PDF:!A9PCV"H[@+TJ#J@:&'#6M@2.KAEP]8S!S\  !(:Z$&.L!2DFFI!C
MJ@&E9NI0:ZX&K1:J<.JOSIX01CK."2,U-T60_&=B2#JL%8Z#/9*A(+/2%Y0W
MNH'F=B?0WTL&TP-V8'W8!O"RED"2-P6:HA$PE?7!344'O(^B!5E- P3J:A"M
MH0K)FBJ0K:4,1=I*4*FM"$TZ?]-Y6@BIOHH@>0\0)/GS(J%H6"\<!#O%O>#
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MG=/EEE*3Y5B9L5*2RH-<AN&--#?,Y00?8G]4L-.IT"C.\: D;H=_EF^+;U%
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M/-2YX(5@(1"(SD_>( 2EVX3GFK<+O^_9(/3LZBKDUHT=PI>NRRWIN:J]J77
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M!-9Q 9E^+(9&Z4QS<N@L9-EUU+K@.KK8V,[+J.=LV_9/'%S3- ??.#^(6HY
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M+S-]:U=G/HEOM7R-.V'U$M=O/8Z[;OT<-VK]%#>%>8C]9GL;-X<=Q/_!72(
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M9#G88->!-6TS6+CO -. O6 4+07Z:=*@EW\8="ID0*=>%K3;Y$#KA#QH]2J
MY@#JIB)HC*+>*H'&+.J7$FB"XA_4;RU0^JH#RE_F 0:'1<!03A3,4=9*XF"K
M+@DXX^6 M5T'MM3-8.VZ$RSX>\$TX@ 8)1\"@]PCH%\J"WJU<J#;(@\Z70J@
M<UH1M"\H@?9UU!-ET)I$?5(&[9_*<]J@_$L'E+[K@,J,'AR=G@<8HAE,9$3
M2N9_/J6"5Y,$>\/E0,"L SQI"]BZ[ 1KGWU@$7H03!,.@W&6#!@5RX%AE0(8
M-"J"?H<2Z'<K@UZ_"NA=4P'=?XZ"[LNC<[K31W_J?C_Z30]4OJ)ST/FJ[PU
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MSQ9D#)[MEM7_^YRLWM_W9?6>O"4^_&2)[&!V$6!X!\D_"%!U&B#_$@62;S-
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MM#W1KV1]8DK%\L1F58N31XC;*A;'7ZF:'_NB;G84-58ZT@NPG>Q@'=G!^ :
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M)J6/.*R3.62_6?:@_1[9_?8GY?8ZW)3?Z?!<8;O#9\6M#JBT1&PA-J^ #OR
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MZVHNG<;52GJUJ^WT*M?&&92O+3(H73](W&!0O/J<4>'*1R:%R]^8?S0S3LX
MR6\E^14D/WL/0/QADD]ZN/LOI(/_1@&3*PR@?Y<==.\*@/9=*="ZIP(:]W5!
M_;X9J#ZP Y4';A2EAWX4Q8?A%/E'B5391[E4F<?55*G'W33))Y,T\2=;:&)/
MCQ.W::*/7])$'WW\EQ%R_MO)_"NW >3L)?E'2?YI +?S -:7 (RN 6C>IH+Z
M2W90?<D+2J_$0.&5',B]5@69-SH@_<88)-]:@_A;9Q!]YPW"[T,H@N_C*?P?
M<BA\'ZLIO!][*#R?IJC<GY:H7)^/$=>)1__2.0]03>X_E^0GD-D'DWMW_0W
MZ@J _@T M3L "B\!Y+ZQ@#1R@20*@!B*@3#*@" J 3]J "_J P^: 1?: @>Z
M 3L& "O& #-F A-64ABQBT*/JRETN('80Z'A\7^I)?GY)#^1Y(><(_GDWBW)
MO>O>!E"^!R#]%$#B*X (TI-,-I+)1?+X2)XPR9,@>;(D3XED:0 IZ4!#<P!T
M(+R)<"*5*"7(%P D#Q^2Q>/"OZ"B&@555"BH2JAH4%!!CXKREE24=:6A=! -
MI>+H4"*+#L5+B7IZ%.\@!H@Q!A2?8D"QM<0&1A3;2NPF#A-G&5'\)O&$\8OX
M6\:/XM\8WDL@XWMQ9'HGCLPKH3+)5E.DH :A_OV]#KD><RHJ.]-0T9^&\M%T
M*)M.AS)%]"A30X_2K0PHW4N,,*+T:F(-,<^$TIN)9>(@<9KIB_0UIH_2CYC>
M2;]A>BWSE?&5##*_E$&6E]+(^F(%5%.@H!;IN=JD]VN3]SJ:Y-6$BIH.-%3W
MH:%J!!TJ)].C4CX]*E8RH&(3(RIT$0-,J##.]$UAFOFKPCKF+PH;F3\K;&?^
MI+"/^8/"">9W"E>87RD\9'ZN^)KYF>)7EB<*R/I8 =D?$0\5D.-'J$FR=4G/
MU9>DH"%Y;T1V8V1(10,;*NIYT% GA ZUXNE1(XOAFWHIXQ?U.J9/:FW,']1Z
MF=^K#;.\4UW-\D9UEN6UZ@+K*]4EUI>JNUF?JQYC_5OM(NMCM?NL]]5>L=Y5
M^\+^EQIRWE9#KEO$337D_A'J?L\6I:")R#^?A5@J$60?YA94-"7[,/:G^VP8
MS?!>/XWQK5X!TRO=2N87.HTLSW4Z69_I#+ ^U1YC>ZP]Q?9(>QW;0^U-[/>U
M=[+?TS[,?D?G OM-G7MLUW1><E[6_L)]21MY?M5&W@O:R'=^A?_EFPH"6I+.
M;2M&CC39BP,YFW;&U"\V=K1WEEYT+\W#&)Z9)3(^-LUF?FA2PG+/N);UCE$K
MVU]&/>RW#(?9;QI.<%PWG.6X:KC(><5@.]<?!@>Y+AF<Y;I@>(?[%\.7O*<,
M/_.?,$2!8X8H>-00A8ZL\+]\*UY >\)9"-!-BE"F?'+5I;QRLJ ^=7"A>V 7
MP'#'-H;IIG4:RS6K?+8KEA7LERP:.'\S;^>Z8-['?<YLE.<7LRG>,V;K^$Z9
M;N8[8;J;_[CI"8&C9M<$#IH]$]QG]E%XMQF*[#)#T9W$\@IHP0=H1[JW"S>@
M)WGO+0J??63AI;<ZY9&G$>4O=WO:-5=O^M^=PY@N.":PGG7(XCAM7\1UPJZ*
MYYAM(]\1FP[^PS;] @>MQP3W6\\([;5:$-YCM5UDE]4AD66K7T6W63\4W6+]
M3GR3-4IL(!:)A170AF0[DN[_O7_[DO<!_/ Z4 P>!LC#+7]MRA^^EM1S/F[T
MI[P"F8]Y1+,?=DOA.N"2P[/7N81_MU.-P$['9J$=CEW"VQP&19<<)L0VV\^)
M;[+?++'!?H_D@OT9R?7V=Z3F'%Y+KW% Z6D'E)DBKRNA/<EV);W7E_3O0';X
M&,(%3T+YX&:(&%P,484S(:;48T%.] <#?)GW^(6Q[_2)Y][FE<ZWY)DON,FC
M3'B#>YW(@ENKV'K7'HFU+B.2LR[3TC/."S+3SLNRD\['Y"9<;LB-N[R0&W7Y
M*C_LBG+?#:V 3B3;D_3> "9X&\H,CR)8X&X$.UR*Y(?348IP)-* NB_"EGXY
MU(-Y:W 0QZ; :)X%_V3^]7Y90G.^12)K?"K%IKP;)%9[=4BM\AR0&?.8D!WQ
M6"L_Y+&D,.AQ2+'?XW?%7H^GBMV>GQ6[/%&QRPL5.E= %V8R WKX$$('?T72
MX,\8!K@8RPR_Q/+ D7A9V!.O0]T>:T6_.=J5>2'"CV-M6#C/FM!X@<G@-*&)
MH%S1L8 2B1'_&JDAOQ:9?K\>N5[?485NGS6*G3Z;E-M]]JFT^9Q7:?%]I-+L
M^U&YR0^5&_U0:25T([T[@ */R+>7:[%4N)!(#V>2&.%8$A?L39&"[<F:E$U)
M9G3KXQV9U\1ZLT]&A_",1T8+C$0D"P^&98GUAQ9*](142'<%-\BV!W7(MP8.
M*C8'3BHW!"RJU@?L4JL-.*-6$WA?K3KPO6I5$*K\'^4?H2<5O@8#_!4%<(ET
MWS,I-#B61@\'TCA@1[HX;,I0HZQ/,Z9;DV+'M#K)@WTT(9![,"Z"OR\F7K@[
M*DVL(S)7HC6B5+HYO$:N(:Q5H2ZT3ZDZ=)5*9<AZM?*0'>IE(2<U2D+N:)2$
MOE4O"4.UXC!4):\J/_K^+?85Z=XW2.<[1[KO\0PJ',BB@UU9;+ E6P3FLY4I
M:[(,:1,9-HPC::YL RE^W#U)8?P=";%"K?')HDVQ61+U,472-=&5<E5130KE
MD=W*I9%CJD41<^H%$=LT\B..:>9%W-;,BWRMD1>):GE1J+H2^@(\)-W["IG!
M:=)]#V=38'<N%;;EDNZ?+PAS^8J4R3P]VFB.)6-_EC-K=X8/5UM:,%]S2I10
M?7*B:$U2AD1E0KYT>7RY7$E<O4)A7*=R?NR(:D[,&O6LF"7-S)@CFADQ-S0S
M8E]I9,1^4\^(135"]4?H#W"/[.&W9-*W2/?=3[KGCD(*;"HDW;^('Z:*Y6"L
M2(<Z4&#.T)WGR-J6X\G9E!7(6Y<9(5B5'B=2GI8J7I*:*U684B*;EURKD)/4
MKIR9.*B6GCBMD9JP63,YX:!6<L)5K>3$%YK)B5_5DQ-1+24157_T+0C@=BS9
M ^F=1W))YRLB?8-T\/D2.I@IY8%593(P5*9)[2DQI6\KLF=I+'3GJ,WWYZG,
M#1,HS8D1*<I*%L_/S)+*R2B2S4RO5DA/:U5.21M034J=U$A(W:@9E[)?*S;U
M,O%<,R[UBWI<*JK'IZ+:C]Z0LW ]@>PADW3_ C(#\F/71M*]9BLH,%')!<-5
MDM!;I4YMKS2F;RJW9:XM=66O*/'E*2D*$2@HC!;.S4\4R\K+D$S/+9!)R:E4
M2,IN5HK/ZE.-R5JM'I6YJ!F9N5<S(O,B\8R\_ZP>F8EJ42L\(6?A,MG#\1R
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MA OA1T03U!APU!1PDPG:^#A:]-RV_P-G8LEPIN8$>5VCP0RG9\=PNJX,IQW
M<)JQ+*>>R7)JI2RG6D=,)*83G<0"HI=82:PE-A.[B(/$:>(J^T[U=_:-ZA/V
ME>H;]H4:QSY7XWC_?W!FI#_(["/]]R8V%(L3PQGX4CQ1+*>;QG+:A2RG54TT
M$5.(6<0\8A&QC%A-;"2V\]YK[>>]TSK)>Z-UA?=*ZS?VN=9C]HGV&_:Q-L=[
MI,WQ^WFHS0F^A#,W93A+\KG]6)C2=2C#F3LRW$ OJDT8RQDGL9QA+LOI5Q#U
M/$Z_A9C!>Z\_A_>WW@+>6[TEO#=Z*WFO]=;Q7NEMY;W4V\M[H7^,]TS_$N]/
M_9]Y#_0?\?XP>,V_:\ );AMPPM\_(OH2;K AN*'D^8<. &=-<=A8$B,8;H@;
MPUD%L9Q%',L-RF3?#2SAO3&KY?UEVLQ[:3J%]\)T%N^9:1?_J>E"_A/39?S'
MIFOXCTPW\1^:[N+?-SW,OV=Z@7_']!;_5[.'_%MFKX4WS3C1=3-._*,9)_GA
M/W#6I&U'_G^8)CA[BL5A($'C,8+&P\Z7>6L3R;X:FL(^&Y+/^W-P)>^153W_
M@54+_Y[5=/Y=JT[!'<MNP6W+7L%OEGV"7RTW"'ZVW"&X9750<-/JG.!'JYN"
M;ZT>BKZV^DMR>3"G<-&*DUZPXA3/_P=N&.G;JX(;23AK@W.E6KA8X;VS/?-J
ME ?SQ"&$?3 BGKT[/(OW^[ 2_J_#:OBW[)H$-^W:!-=M9PI_L.T2?F>[4/2M
MS7+159NUXJ]MMHJ_LMDGN6Q[2G+1]CO)6;M["J?L7BD>M^/D1^TXI2/$X8\H
M?X9S4 ,W2@G<:&5P'NK@O'3!>9KBA8<U'HYV8NZX^C(_NT2Q-YQ2>=^/RN=?
M'5DAO#)RG.BRXP3Q1<<IDO,.LQ3..<Q3...P6'K*?J7B2?L-BL?M=\J.VA^1
M'7&X+#_H<%N^U^&Y\FX'3F6G Z>ZPX%3V_X?N%&D[2HE;1DM:;KW5\<+/SW<
M]QV$7[V'X;JW!W/5*X2][!'//^^>*3SC5B0^.7J,Y+AKO?2HZR3%PR[39 ==
M.N3[7>8K[7->HKS'>;7R+N<M*CN=]ZMN=SZKNM7YEMHFER?JZUW>::QUX337
M?&+U%W"NI.U)WM]? 5R0(MX$*^%!L#I^#M3'MX%#<"G(F3D;Z,^>\(_B'_%+
M$1WPS97L\RZ5[O:JD>WT:I!O]VQ1WNHQ766+1Z?J)O<>M0WNR]77N:_76.N^
M2W.U^PFM5>[?:ZWP>*B]U..M]A(/3J>76-R/)Z?]&<Z=O+\O>6_RWT_"1+@=
M+L&O83)<"]/ A0ASG(QP8 Z'>['[PD(%NT+BQ=N#,Q2V!!;(-@:4*ZWWKU-9
MZ]>DNMJO5;W/MUUCA6^7YC*?7NTE/JMU>GVVZ2[R.:S;XW-E0+?/'P/F^?ZE
MU^7+#9A+S.G'[U\X3](/9/ TG/Q6-(/O8P7X)D:""S&J.!YK@@-QPYC=L6[L
MMNA P<:H:/&ZB!3IZO!L^<K08N7E(56J2X+'J2\.GJ"Y,&BJUH+ V3KS Q?H
M=@6L&# G8)-^9\!^@XZ "P8S W\W: ]\:3 ]B.M'?]I_X'QHRPXASTE;^_<)
MY/F2>#B7),2)1"7L3S+ SF1K9G.2,[LNT5>P*CY<O#PV0;HD)EV^*"I?94%D
MF=K\B!J-KO &K3GA+3H=8>VZ,T/GZ<T(76(P+72=X930W49MH6>,)X?^8MP2
M]LQH4AC7C^'$\ \8?*;_U?*,_/]/])J[D@*<36=Q/)V/@ZDR[$S7Q:8,*ZQ-
M=V17IGKQEZ2$B!<FQ4B[$U+D7?'9*IUQ16JS8BLUVV/&:D^/GJ [)6JJ7FM4
MIT%+Y"+#B9&KC9LC=Y@T19XP;8B\:3H^ZHG)^*CWQO717#]&7\(% G]0#7Y(
M)J]#GNMX-GF^;!:[LA2P.5L+:W/,L2)[!-N;Y<Y?D!$HZDJ+E,Y.393/3,E0
MF9Z4KS8UL4RS-:%&NR6^07="?*M>4]PL@X;8!4;UL2M-QL9N-:V-/6I6$_N#
M677<8^*=:74\9T(8?\F'<8@C[Y]&WI_T#^>1[\T'MN:)L#9?'2L*S-";/XQ9
MD.?*GYOC)^K(#E.8D1DGFY*1JCPY+4=M4FJQ9G-*E79#RCC=^N1)^F.39AC6
M),TW'I.XW+0R<;-91>+A@>6)UP:6)3TD_C8M2^),/F'\F3=A-!<3:1YDDO<G
M_?U%Y'N+@0V%Y/V+R/L7&V-!L0TSM\B)-ZO 6S@M/T32FALCFY23K-R<G:G6
MD%F@,2ZS7+LNHTZW.KU9ORIMFF%YVESCTM2EIL6I&P<6I1X85)AZ95!!ZH.!
MA6EOS0K3.%/"Y$O^C"3O3_/@//G.(Z2_NY1\+WFOU:4,EI8IHZ?<$'/+AS"S
MRD;RII5X"EN+@R03"R,5&PL2E.KSTU5K<W/5JW-+M2ISJG7+LQOU2[*F&!9E
M=9H49/::Y66N'YB3N6]0=N9EXMZ@G,PW9CE9G"EA\B7W8\C[I],X4/T/D/YV
M\K_KJ>U93M>%E7)T5>FA8XP5,ZW*@9U<Z2Z84.XO;B@+EXXMB9/7%*>J5!5E
MJY<7%FN5%%3I%A6,U\O/;S7,S>LPSLY;9)J9NW9@>N[>06FY%XF[@])S7YNE
MYW*F_63D<B:?N4OKX1MJMTY0#?:2[A;R?JNI!>REZ[P:&3IJ=3"]SARMM</9
M"36N_/'5OJ*ZJE!I=66,O*(B6:6T/$N]J*Q0LZ"T0B>W=)Q>5LDD@XSBF<9I
M13VF*46K!R85[1Z46'2.N$/WK\R2"CG3Y$+.Y$M^30(N4>MYA&JP:PS-@['
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M5/8 ^=1.I7;,0B!T,?T_;:(;+9H#_;GE&C68K-.!T8P1#&<LB2,,9B307Q]
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M;B]$P8OD)3%HB%@8TZB]QIR\;@J\:0N\Y0Z\RSC>8Q'R/N?&^\TT,9SD=SC
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M""6GLVEUR#09)3VDB530&A3P-9NE>5J>@*1\;<07&"*VP HQA4Z(*O2$K"@
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M^\\$R:1;+\+O])B_S#X+HQ/W,$ 7/TQ_/HYOL11?TV-^A77TZIOQ.7;2MQ[
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M^.<PY3^+;60<FSR4MP@KEJ,MG'I;F(O-;' SW>_FW?P^1V@31VCC7?(U:CF
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M@AF;FMW#^A!+.<.70OE_02OX<D[_21Y2#\\M.4<X+_;Q&-G-8V0'[*GC08T
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M:(D7HCP#(?.4(M(S!A%>*0CWRH'4NQ1A/@T(]>E!B.\X@GW7(<AO+P+]SB'
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M'U-F\AE([&0RYYM>!K_EN]]H"/I:07?:7-OJW!F4#45.ILTQ(]"/7BO-,$V
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M)I<K):6+DE-Z*BEU@!)3QR@A;8KBT^Y77-ICBDU?"YY13/I9\"G/_\+U:WH
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MZ,K O87HJ(2;-R"[._:WZ@#^V _#V@OKV@,+VX4=.^"8V[!C*TQU,TQYHQ;
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M()23G)>3>)>3/99]K='([V?4H=!19]2 >*0IR@$91@V*:W'HCBQ"?PGZRZ3
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MZ!:N!+<8]"2B)QV9N8IU*U6,6YVBW7HHRFV (MW&@FF*<'N$$?X4V 9.@H_
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MOVS+C M/;9GQZB)L>6S3S(N/;IIU:0YQTDZ\SMHXYR?CK5?\;!]<",C^W87
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M(_.JQ(Y]3H$MU<.W%OAX%J2?"\W^3!,N1(>B&/%ADG%T!U"'-Q+K< 92'<9
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M-R'#]-= S8AAQ?H_95N.7A$<0 WQCO+:N%DU]=P2:X2'<83Y%'>03?7Z&?2
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MA4ETS46*VJ:"2F-C?HVI(4]O;L@U6QIR7)9PGMOBA7+F/SK >7$<*(<, LC
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M[T%;D$Z"L]A.\Q38N-X\F\R;;57[,BQF?Y;.[,^M-OOS*\R^1P44D*'RPPE
M-6<JT'\^$[@^GGVC:<;<H5,S%K1<_FR+[Y<OCQBN+,Q3G%Z!Y?7N*&.TQPG)
MC9E*?%VQ&A5 Z6$^G"G?0['FN%BV+)?0GNFJL*6[M/84I]69:K8[,W2/#E1
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M^L#R.[J'UF0?%V4+/1E5W3TN2G#MZ2<8X*4)./#>2R7@L[=RP/P/4\"23^+
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M)#7^PE$#\7R\@WSN2(AR+JZ#,A#?3VD_VD]I2.RG!I/ZJ9[D?JK[(0'8R^-
MT=M/@F+(4++T38!;.P.0M\X%U#W+ "5V(R F[KZ+S3A\"UF8\C.L-/O' G+1
M#SDLQ*5C LS%- 7A?(J:?#;10!U.<-+/Q$<8)^./,SH2>Q@-23UE@92>,G=J
M3YDMK:?,FM;#^$^!$LA0#!E@D 'Y[9N M&8&8&S^$C!W+05E!S< >ORNNZ34
MP[>P.:DWD8B<ZS!"\97\,O3%;#[^7(:,/)Q:33^=9"P[==3#.IG0PNY*ZF8W
MI'1Q_*E='&=:%\>2WL4Q9'2S:Q\2@+\T#L"F/@E*9C\',-^\ 6BKIP/VICF
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M/0?=OCX'77TC2NA]LT7HZ&N5)?L']#<T/;>0V_&$I)O[CXM5TCV6<\1M'_>
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M7#@;H*\E@K,$'S@H"H*MMC XFXB"J^TJH%,W@JOG=G#A*8)SC#HXIN/E+S(
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M+XO5P"%O C9#!CQ\5( 9I@WT1$-PR3$#IU(K<*RV!?)N>W!H)X%]ER/8G:"
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MQ+4@35P%"GS+095O"6CS+0)#OH5@P3\?'/CG HU?!#C\@A JP ?) OCA4(
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M7K0'T[,.8'IZ!F"-,UCCSR<%KP?CS^\G;>4';P5!\-6>![YF2\&;M 8\Z9N
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M_HC,:?X0/KN1KC;U&)Q7AX'Y-1CP+9A$LY#/P/U:@)\Z ,X/L.#$(@X<&N/
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M)6#3:C>_37O=?3=?<_/9^-;=>P-Z^*Y&#__EZ!&X]']Y7 %PE6;Q^'R W6,
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M_Z&+SL'J$__=_TT _S]H[X\H^QG0?H%R =0()>0%>10":10#"90&45J+,*J
M &H"'^H#-YH"B^H"M!9 /R**R" JB"YBE-A [/\?T,2 00-S%IJ8L=#4DHYV
M;#1P9:-.  <U8KA0+8L;5<MY4'D.'RKW"Z#RB" J3PBA\GIA5-XJ@DI[B*.B
MJ'2>^%4,E1X2KXB/8JB,TXC^!Q5ZK8+BJ(82J/X-TVLP-F6AN0D++6@=YM9L
M-'&B=?ARH5X4-^JD\Z!6"2]J-@J@1K<@:@P+H_HR$51?(XKJF\10?2=Q4!S5
M3Q,_T,^\1[P@/GSY^1J4^P5)U$2IS]HH_5'G:]!4GT$S(Q9:&5 IZ6AMSD9+
M>S::>W*A21@W&J7PH&$!/^K7"J)>AS#J#HFB[J@8ZJX01YT-$JBS31)U]A+'
MI5#G,G&;>$K\+86Z^"_2J(,R'_50]IT!RKTQ_!HTTV/0DK#39:&#/@L=C5EH
M3[6P<^-"FV!NM$K@18O9 FA6*8RF<T31I$\<C1=*HO$R*31:(XU&FXB=,FAT
M2!:-SA$WB,?$6]E/QBC[@7AOA/*$XFL35'QJADJ/S;\&+2C?5IO!69H,NDP_
MB]!CH9L%&UV=N-#9CQMG1?.A0X8@VA6+H$V#.%IW2:+5D#1:C<J@Y0HYM%PO
MAQ;;Y-%BGP):G%3X9/&]P@>+^PI_6;Y6>&WU6>&E)2J]L$"59Q:H^L :U6[;
MH-IOME^#5CJ43^[MILJ@%^%#Z_";_FZ,/0>]O;C1,XP/W9.%T#5/#)VK)''6
M')G/CKUR'QV'Y?]Q&%-\[[!:Z6_[3<KO['<IO[4_HO+:_I+*"_L_5)XXO%1Y
M:/])[;X]:MRU1ZW;Q#5'U+XR"[4O.GT-VM'^7949]%9@T)\(IO6$TFR$6G,P
MV)4; P+YT#].^*-OEOC?WJ72;ST;Y%Z[=RJ\=!M2>NZV6.6IZX3JGZ[KU1Z[
M;%=_Z') _8'+.8V[KK<T?G=]KGG#Y:/.-1?4^\$9]2^[H/YI-]0_YH[Z1[X!
M'6GOGN2]_N3]H424"H,Q.BR,,6-CM"/7QT@?OG=A$<*O0E(EG@45R#P.J%9X
MX#='^9YOK^H=GV'UW[W'-'_S7JUUPVNS]G7/O3K7/$_I_N!Y0^^RUS/]\Y[_
M&)WQ1..3GFARQ M-]OF@R4Y?--[Q#>A"[N]+SAE"[ATE"9A M4C68##%D/4A
MV8;S.M&-]VE<L-"#F 2).U$YLK^%ERI>#VU0_2FX0_-JT(#.E< 1O8L!RPW.
M^Z\W.NLW97S:[[#)2;\KIL?\'YH>]/_;?)\?6NSQ1XNI +38'(@6&X+0?/TW
MH#O5($ ",()<)X'</U4&,%.9^2=+AWF59<9^G#F+^X]T/X$;*='B/R:FR5V)
M*U"Y$%VE<2:R6>=DQ%R#8V'SC(^$CIH>"EEIOC]XD^7>X+U6NX//6.\(OF.]
M+?B-S>80M)TDUH:BS<HPM%X>CE;CWX!>5/\0\KT8\NZ4:>>B]>3*P9M\->9Q
M@0'K=KX-YY=<3_XKV6'BY]*3Y$^FY*@>32K5/IA0I[\OKLUX=TROV8[H8<MM
MD<NLMT2LL]T4,66_(?R8P[KPZPZK(UXXKHA$QXE(=!B+0OO1:+1;%(VVA,U,
MT)?J'TZNE4"NDTGKR!.!#T42\&>I'-PIUV"NE9FS+Y6X\9TN"!8_FALGOS\[
M0VUW1H'.5%JEX9;D)M/)I$[+]0F#-FOC%]NOBEWI.!&[V6D\YJ#S6,QW+J.Q
M?SJ/Q'YV7A2'3@OBT7$H'AT&XM'^6S" ZA\U70,^P!Q^RA>$UV7"<*]*#*[7
M*,#E&F/6Z2HGOL/E_F)[BZ/DIPI2U+;DSM;=D%UJM#:SUGQE>JOU\M1>N[&4
M8<?1I''G18D;7(<3][C-3SSO/ICXT'T@Z:-K?S*Z]"2C4W<RSNI*1D?"8288
M--T'<JUT'OB0SPT/RKCA9C4O7*\3@.\:9>!,HP'K2+T#[]X:'['ME>%RDZ6)
M:FN+LG17%A0:C^=662S):;(9R>IR&,X<<AI*7^+:G[;6O3=UA^?<U-.>76GW
M/#O2/KAWI*-;6SJZM*:CTYQT^H1)1\>98(@(8#QY=Q8;_BQBP8U*-OQ0SP/?
M-9/[SY&$8ZVZK'TM=CQ3C5ZBDW6A<FNJXM0FRM-UEY;F&8\4E5DL**BW&<IK
M<^C+[7?NSAEQZ\A>Z=&6M<VK)>NX=U/6;>^F[+\]&W/0G7!MR$;G^FQT(F;-
M!,-H%A+9\&DVP.U2\MY:%EQJXH)SK;QPLH/<OU.;V=EAS;VYU5UD;7.0[$1]
MC.J2FA2=A56SC>:5%UOTE];8=!>W.'84]CBW%@R[-^5/>-;G;?:NS3OL4YUW
MTZ<Z_YU7=3YZ5.6C6U4>NE3ETJ=M+CK-!"-H%I,!7N63^U>2]S:PX&PK!TYT
M<L/A;E'8W:O!;.VVY%K?Y2J\HCU 9FE+I,K"IB3MH?HLH]Z:0O.NJDJ;MHHF
MA^;R+N?ZTGGNU27+O"J*)WW*B@[ZEA3_0KSQ+BE!C])B="LM0M?20G0FG&:"
M430+:0#WR;U_)N^\T,+ R4XV'.[AP-Y^8=@^J,IL'##C6M7K+#36[2>]L#-<
M>:@M0:NG)<.PHRG/;$Y#F75C7;U#;4V'<V75H%MIY5+/HHKU/OD5^WSS*GX@
M7GGG5:!G?@6Z%Y2A:T$I.G\+QM(L9 +<H3Y\5P]PNHV<IYL%>P=8,#5/$"87
M*,&:^2:<94.. B,#/I)#O:&*/7/C-#LZT_1;VF>;UL\IL:INJ;4O;VIU*F[H
M=\NO'_6<7;?6.ZMVCT]&W17BA7=F'7IDU:)[=C6ZYE2B\[=@/ ?^FOVE#Q>;
MR3N[R/OZ 7;,9V#3(CY8.R(/RT<,V8L7VO//6^ IWCLO6+YC(%J]N2]9MZXG
MV[AR;I%%:6>5;4%[B^/LMAZ7K#F+W--:5GNEM.SR3FJY2#SW2FY!CY0F=$MM
M0->T.G1.K_T:3 )X5$"S2'TX0S4XU$O>1?Z[>1' FB4<6#XF Z-C>JSY2VUX
M>T?=13M& F6;%T:JU"Y(U*Z8EVE8/)AOEM]?89W=UVB?WC/7*;E[V#5A[DJ/
MN+D[/&/FGO>,Z7KJ$=.%[K$=Z!K?BBZ)+>B4V/PUT[-PMP3@<N.7&NP= MA*
M^6N7 "PC_QE9*0'S5VHQ?2LLN3LF7(2:Q_VD:L;"%<N7Q&D4+4[3S1W)-<Y:
M6&J>.EQOD[B@PSYVWGRGJ'D3+N%#VUW#YIUU"QMZXAHVB"YA ^@<V8-.45UT
M5]3Y->^SO_3A;"O 0?+O*?+?]92_?#G 0O*?@?4BT+-!C6E?;\II6N?(7[W6
M6[QL=8ALP<H8Y9P5*9H9$]EZR<N+C>.7U9A'C[59AR\=L@M9.NX0M&3KK("E
MIV<%+'GL&+ 8'0-&T#%P&!V#A] A9.!KGE ?OJ=9/#X78#?U8)+\<P4Y^&)R
MX'YRT/:M M"R30'JMQFPJK;:\I1L<1?*VQPHF;4I4BYU,E$Y<6.F1NR&0IW(
M]54&H>OFF 2N'3#W6[O,RF?M%FOOM:>LO=8\LO9<]=G&<R7:>"U'&Y^E:.,[
M^C5WRH$^CP .#% /1LC_EP$L647^.YU/#EB[AP.5>R6A=*\64[#7@I.SQYDW
M?8^O<-+N,(FX77&R4;O2%,-VYJD&[:C0]-_1K.,SU:_O.35FZ#:UV<AUZJ2Q
MZ]0C(Y>MGTV<MZ"9TR8T=UF'YJYKON9'JL&Q;H"="\G_Q\B_R<'G;0#HI/SZ
MW0#%A]B0<TP8LHXK0?IQ(R;IN!TG[K@';]2Q(,&P8]&BP4>3)?V/SI;Q.5HF
M[WFD4<GM2*^J\Y$EZK..;-)P/'I"P_'((PW[0Y^U;0^@KLU^U+/=@_JVN]!@
M)F?;:0ZG>["49F %P +*[YK.WP-0<@@@ZR0;XL_S0O1%"8BZI 'AE\R9D$M.
M[,#+/ER^E\-XO2['"[A?SA1VN5PDZG2Y3L+A\EPIN\N+96PN;Y2UOG)<UOKR
M0UG+B_\HF)]');-SJ&)Z%M5,SGS-(>K!END9H'-@X7J [JT #=/YARF?/#S^
M @M"KO* ]W5!\+HA"YXW=,#CIA7C>M.%Y?R;/WO6;Y$<^UO)W+:W9O-8W:KD
ML_B]3<#L]P6")K?7"!G?/B!L=.=W8:/?_A8QN(GB^C=04N\Z2NM^P]3T#- Y
ML)C.@1[*;YS./P*0>08@]A) T/< 'K]RP/F1$,QZ) ,.CS7 [K$Q6#^Q92R?
MN#%F?_JS3)Y&LHV>)K/UG^5Q=)]5<VD_[^+6>C[*H_%B,X_ZRS,\ZB^>\JC]
MB3QJ3Y!7]0GRJSQ&@9FLHW-@R1J OBT 3=/Y1P$RS@'$D(<'_ 3@2BYN>Q?
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M2CPAD/[\:^92?@WEYU+?$VCO093M3-GF/U/M;P(HW::]WP,0?@C _Q* ]Q,
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M3C;!'^X6^':" SX>-QIONTS%JRZ!^-?X.-R?D(FG)Y0(3TZ8)=R>V"3>FKA
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M<CRW!4B?+R"Y38/$!8.1T#X&<>V3$=/AC>B.("&R(TH,;T\60]NSE4'M):J
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MU UC7;V/ 9.H.9J:CM2TN@R8TINKKM-C/TYNB\ 3QH1QW&$<3SIR,2HOAMV
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M<]3>EPFLXU*\*YU>@]0SIE)^7\#W.1E*9&1:("W+$2G98Y"4,PF).=.1D!N
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MO8BU1N>OG7C&68NPWQ4BU_]1?V F1V<0WHNE39GH*T%?'7HZ]#?ZY$_P_C_
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M0YYK1^2Q=HGFK-TJU[5G,_%= QZ@PR%DJS^5RRJRZ94VN8&#XXP'L!1,HG,
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M[RZ%+"^]75H"KUD"]Y\E@YLEDUP,2YG/>!A@3ICON!>L$S3PN0*ZG#\*_Y]
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M-?BZ<(887"K%KD(_>OWY4Z\=DHNIO^R723))^.38CW+$U$1(A(^:?X C$;V
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M ?U0MZ 6-\UK]Y9?QSSY=@3+IR-*7AU)FMN1)<^.8KEW6#6GHUVNYD"1CB7
M/.X6;M-Q'<$&66B'!+23.;;9[-A8S9A$QY"5GUA/J0&!/&<-*@G=,<WH;T5_
MAS2ORU4^O5[R[/.36S\+2C\+3#^3:G^J(ZC[:52_*:KTF\?]\-[<5 "!ZH<8
M]L-M^LB:^K"AUV;':G1,U?,5: 5UI@8$"GF?V4@,0-]CV] /90SL@0,BUF?
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M:"QWUH"XE@\R>)]4 ?^',H:C.PB:8FF @S2[:&ZKI]S:6=3:YSDF]$Y34&8
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MPRF\WYR!X2G'?2AF#X9Y)HHYC\.<C6J>S6*>G&N>$3,@<T_,=PQ.<S;I?\.
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MRB-GO>;D')!K#LE_-DEQ-EE"]GMRR?I6KEFLG^:>-&3W(KL9>E8-2D >G[-
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M_D#(-F *(6*HHN ,3+"S,-G-QH0R%X/Y/);8QH"V )UH 12W &07S.0=[+$
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MI5J!GX#? 4JL4?9.]O,H7.'%;.T+,)GE7H#1N#82T 2?8;A'75:(J')$B.I
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MX:"JPI<= @Y#[J!B\)P&4^Z^M+60MPAA^PQ57@YH#/X.!X8.X>5^5,!%246
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MP%47\94N_/G)"!XFPU.9A+A"YPXO#S.!$GU0GL_V@HWBK0,:Q=8 098Z9*H
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M\>7^/0_BR)?'9+&<"W.$V89\MCZC;TU(7QZ$_5#==VX'"UX:Q'CG@M2AD]5
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M6R87=-KEI[8X5\8<]:P/K?-K]J\);O>L.GC<I2*AR[$BN]NAO/R$0W%5>W]
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M%[_[=M[N=YP#'&]ZA-C\Z!-N^4- Y/ZKP8=,KD1$&UV.CMU],2%NY\74^/Z
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MYEX>\=BE-GJ4UA+[T+DK_CYU(.$6^6K2H./UA(NDFX*_ 4)1!Q[:.+RCBT"
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MN%X46C:*O!Q<(W+]R2;1"Y/'EK3/J&RN_GSF<,&,KD+Z1V/MN \8L[ /1-O
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MNTMLX3'7F,+;KO'%'^R22M$RN0Q-4\K0:#F,)'<A'>!^"<"U.@JY S0XT<L
MAP898,\P+\P.RU$W;]1AW;C!DK>[QTFDI<-+NJXM2*FR.5*CI#%!-[\^W3"[
M-L\LO;K<*KFJP3:^HLL^IGS$*;)\UB6\_(A+6/DME\C*]W;156@96XVF\=5H
MM!S&,,!B-L!?Y0"7FDCW=5'A\  -]HY08=L8#TR.25.'-ZUGZ1TRXVD;L!>J
M[_.0K.P)4"CN"E?/:X_3SFI--4AMR3%);"JQB&VLLXFJ[[ +JQMR"*[;XA14
M=\@YL.Z&4W#]6WIHPT_+\ 8TC6A$H^4P'N!Q/L#OI/\7VH#< 0KL&Z+ ]LT
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M/]*H8GUD@YKED4D-\R/S&N9'?],P/_Q:W?S0#S7S@ZA*J"QWJ1[@2"^Y \,
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M-X92.3&1RH$%-'9LH+'A!F*2QHJ[:2QX_%_JR6N@X 29?XG,_Q/ Y0& Q1,
MG9< &@B@3,@A,T@A)XCC:A!! 1! 4> G:UF-LL"-RA1.U*"L0ET*&YI06-"&
MPH@N% KZ40"CB4RBG K82@P0X_^"JFI4U"+]KZM"13UU\JA#P_6F#*CAP(1J
MOLRH',V"BIFLJ%#&AO)-["C?0PP1XQPHMY7811P@3A*7.%#^#OG:,^(#\8U
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M \PH,DI,$SN(?4PH<H18(&Z0KS\BWA!+C"B*__\I_YI-^E_K%R4J:FA04<6
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MF2C8%9ZE.!Y:I+HEI$IC+*A!:V/@(MWU 4OUU_D/&*[U'S$:\ALW6>5W<,:
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MA/I:X]@%"V=&U?68A]>MG1U:NWU.<.T)Y/;LT+HW,\/JB%'$ J*/Z$WG43+
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MO7@ _(;YUT(!OHL .!_!@#.A0G T5!KVA>O CO YU)901\;&$!^AX:!0D:'
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M+Q.*?^EO5F+^$LROQ]H7X=Q3<=X1F.U]!/-/ ,SY!L#H'( F.KGB%0#IGYC
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M-7^K[=_T2,N_2=3R;Q0U'^,J8W"2_NXC_]9NZKX>:F]*HQZB<19U%W5Y5J>
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MU90UU/]KJ7^IS5W7:\%YV A.P^/A.&R#J</.F#+L!8<-P;#?$ .[#6FPW5
MZPTUL-K0B<D;%F'2AHV"Q88C@OF&:X+Y\!>"^;H'PH2UHC!AC2A[C/WT?PM]
M7T6)OF@E,&NUN@9#B9I)>1A+31RX#7#?#DS="5CNUL&DW4:8N'L\+/;8P'R/
M,R;L\<+X/<$PVQ.'<7LR8;JW%&/VMF#TWGDPV;L6QGL/P&CO51CN^1Q&N_Z
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MUBCS:)LE<V];(G=MVR2?UG9$[M+V+/$ON4OK'W*7%E'NTOP/I#U1^^G_UIG
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MZ;-17N%[0%[F>T%>ZO>:O,3O>T*4%_N)LB?Q$>/_0CAP@4O],2ZS>Q*H=>*
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M+T^/6B5/C=JI2(D^J4B.?D&1%/TE\1<ARB4DJ_$RT\^+U/_'R;TG6UV#X>L
M?^[AYRVTHS9&'Y4QIBB+M41QK",*8SV0'QN W-AP9,?&(2LV#9EQN4)&7*F0
M%E<GI,9UR)+CYLF3XE;*$^*W*^+C3RCBXJ\K8N/O$@\(41[W!&YR')Q/Y5Q
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M_<+4AC7"E(:]@D/#!<&^\1W!OOXGP;Y.'(%#K2B3<(P^[B;'1NF6&DK#!90
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MZWN:_&<Y_LAI3$Z=JVJN&^JZRROJ/2&OJ>LA;SVNA\B #[2 CQF3S]@W=RR
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MV#U;Z-N>D;,H'U'YOT_%_G_T^"U:*9U#>4T-Z3S*2U#=*ZNJ.3RN/RA&XO$
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M;-E(=&Z-5,X6\6F1*HH#3^ 73O=W.*6\SNGMNA&G/S[69SGEG>1S<AA&Y)Q
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M8\R?N'Z%D"4U.N3N=N<\T"3'>2R[X.$;D*7]Y+KHT8]]NO!3$[I6-GFKM"E
MQ4WA*FJ*5^&8-!6,R5/^F%+E-=<HI[E%V<W=RFJ9HLR6.<IH7:GTUEU*;3VI
ME+9;E=SVF)+:WN#Z#Z6TVNR2BMS>S;A@YH' /3B#?FE06L=UF#1X<#+Y+I]U
MH&,]MBII]U#^6#_EC@U1SM@898]-5E9[EC+;BY3>7J6TCB:E=G0JI6.2DCMG
M*:ESN1(ZMRN^Z[CBNFY6;-<CBAGW!ZY?*+;3IC@DOL-FWQ=V-?C'P+Z,M'?K
M',<ZE(5#Q *Z]$"36M&E&ET*>T8I<[ROTKH#E3H^0BGCXY4\/EU)X_.4.*%,
M"1/J%3]AK&)[>A73,ZCHGB6*[-VBB-ZC"N^]4:&]#RFD]_^X?J:P'IO")Y U
M(N9LGM,S'7^BW[. ?F$AL8#,FT\LH$\7NC2B7SEVH>DK9;*GXOO]%-L?K)C^
M:$5/3E+4Y"Q%3BY2Q.1JA4]N5NB4\0J9,J#@*0L5-'6C J<>4L#4ZV6=^B/Y
M3?V-K%/^CM@4,-DAYOE0)^?1+PPS/D&1UT,-ERZ39O%Z(M2H#;UJ^;P('3.P
M3_R0B\)G^BADIE7!,\,4-#-6@3-3D5P%#)7).E0O_Z$.^0U-EF5HGGQGK97/
MK/WR'KI&7D,_E.?0L\@'\IKY+WD/VN2#7$7YQPP]7X$?5CG6H2QRGH?2O9)8
M7(X-T"D'W9(7PS_1-6C837Z+?&59%"C?11'R690@[T49\EI4*,]%U?(8;M7H
MX5ZY#0]IU# %+X+O+H)0+H(\+GP:>0^!^R^PV>44^(? V[T./VR4EF^B;T0F
M\7HL4K-!*H"NIO%YS%HI!/%?.TI>:[WEMA:>NQ:^O98D9"U)P)ILA %P#0//
M&AK4FFF.R:TU9I,/Q';UK70\$+A5$+.5_T#0885-QZCW_HV.O4!KMSO/I-T)
M_T8:D!)H:@;7..Z'(J0F\D9&[2(!W4FRM9,$<&<80N*SDT%V9YYCT>-.&O-.
M GD'3MRQWO$HY.V0ZFV0YFT0Q:V?25ML=CD$_=N]P[$7:*G9"W09;>$ ?=)!
MJ>)R*1M)0,(0*\5X'0;_"(GO4?CM$2^$!/0(R>C1<,<??HZ:!,BL23$;8;L<
MB]^.X- C>Z3#<.[#]V)X2/+EG] 9_-N^%N6RW8Z]0"O!G /&I*/$(6:K@I;F
M7BDE(F&GL#_N]#P#-CR=9-HIZ'$->ER#/<YACW/8XUKTN#:#9(2DZ#H&@NOZ
M$/.X>!Q\CH+/0>ZO(2:N@?=?_15BTZZ#CN<2S3]&6P2O YP:U,T_)R5="_YU
MDA\F]("?:V0=RNV7R!V0@SOPRYTDZ'>1H-\-U[X'OUQ CPLD!A<8="[0J"\0
MV!>H[ 4*_ '^N =_W/,I\B_'' S8T\[2%X!9=P,Q"%;2+>#?!OX=SCU EZY#
M^9%3S-Z<AT;F1;#)C[')8_CF8C!)*GH\E>58K/LT\?GT+(3 >_H$0OMX^F=\
M]@[R=RVFWC.H<S?U;*".A7?2!N\A_BY(EOLDUY&Y%S/O<M$Y#_*T4T;VY#SK
M7*MAGP]QEWZ-;UZ!(+R&'G\D$7N=!.$-?/(F#?M-XN)-*OLF!;_Y(O*N9IHY
M&.K<A&K%U#.%>H;9S\&57$;6H8SLQQE9#V+6GOQ.CG-"7OO>7(C]O!#\\Z%Y
MDB^Q^G?BXS.2Y"](4OY!6_V2SN=+@OHKC/T5AOSRY_IN_X>/D_=?N@?$G EB
MSB0=+\=YH&8MB-F+8IZ+,K(G9C<,\H#^!;/[I_U,CG.PN5OT#[C5%S#&S^UG
MDGX(G_WWM\]@>=<Y__$KY'D[Y_5PSCN,<LY%F+D8<T:K.1/$G$EJ]L.T4T*?
MOH'7?07/_0>\_W.MI.SU^A0]S+-1/D:/CV!_'\+,_@([_#-,\5UXYML8\4\8
MZ U^-7(6AUG_8>8BS)Z0)_YK_L'%:9=0ZI0(7BYUJ0"K&8QQE-^O]^';[VHN
M92^F[)64O0Y7;*7LW7H5COD*;/<W-.!?P>I?A"T_CRV>Y<[/*>$9)^Z3SKD/
M<P;&_=_3@1X#;;VP6X ^4#0L.1VL(EQ="T8;Y4\@'";K)0T2?G.IRS!ALH+0
M7$>(&E:[6S^!_5Z$>3^&3QZA(3^$+7[$-^Y'\WOQE)GS^(%3S!J,VR[1X>MO
MYR!<J9L%O%#]$EL\KQQPRL!HH/QV/:X>FL@4FLH@]9A+^8LH?SGEK[6SZWNT
M1W?I$)XX1?G7$QEWZR8T.D^)U^&Y:^5XLM"(7.W4P>R!^< 9VK^U-S4O;!8
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M!"AI]U[ZI'WX *J>P34&";:O00%_/_@'G+(??KL?SF]?DX(>^TDV#B0B^.0
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MQGC*GTS9@[#G>92[6!^CAWDVRH?H\1=8V/LPP/=@A._ []Z"#;])\+R.T_[
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M(L_6QY W>/V%O%O(')&S8!P%;]],QYFTJV83C[,<>W%ZT:<5W:K1I9#OI??
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MB@:]@@A;#NZE\OIHFKPW=:<I7Z"KO=7-T?5>15R<H(T<41#UB0(K&9QL,(K
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M%L#WS!X84I"%I&5#V&0*_IH0X*E.?ZO:K:%JL\:HQ9JL9FN6F@(*U!A0IH:
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M1S1=KQ'-7]B? C7@E)\SS#Q$]WXG0\WU7$_Q_@CZ,(10S]&48@$SD#I%@I-
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MN2[A_>Q+UH"TX9LZ4L1R?),?X*ELJY\RK8%*MX8KS1JK%&NRDJV92@HH5&)
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M?@*V,&M2NK%%-X-P-YU)-_[H)B:Z47H<(..6(69A@5E<#SGK@/NWHT.[37O
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M&"+]<Q\*^-\6Q)-F0!8=01"& )=4#M27& @C$:!N.$'=[*$G@';0DD TU%L
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M#/00(<-NB& 72-P%C)L1*)-1&02)(#!DL@&.NO>:L\X$1B0F$/,R 2^!$<C
MN )%RZ\M@0:JKNU#<0*/-?HL#GA=<S^0 >A$!L@I F3A 3;+ K+? >2@YB"$
MMK!MAC:Q4$($S*#1,(/&PPR,EP4HB@48$BM0(JLB>( OS0IB+#80P+&A-Z\#
M9YD5.*>LP-ED 3(PKT"1@/])P/>HYMH^% ?@<EJ!WXW40<P'9#D TJ6!+ )
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M@R!'8!>. FL703D PW) 7SYS A06!-5($+S:O03E68$"CH(L@:D<!H\>> Z
M1R0(M /P[ 2_4P4"_C_.W?Q\UI_'.?KS"5C_$*S=&1L Y @ =1+ N388^@.#
M]@.*\PM8^\YB'] ^O;N!(2Y#7L"!10+1C$#350%=B'@HL($SH+L%#Q7XG1A]
M#^RONV#/0K_G0[#.XT"89W7"07N)H%Y;)(L G7PXT$4X,.YPH,1S((.S(+ /
M>PCRGH<<0/ZFZ*M\P'M2D: =1J_=![L5/,2Q/YU]]#Z3]7,AZ+M),,[@_/SL
MTL\ X=>])1E C@S07C- G62 -I(!=)$.#"H=%#H]'3RU #<&60 SU02\9 $?
M!."S!_"A!OD3_[H#Y==]L+_.XOPZ>_/K?XQS.-#O.9%?\R'EP#[*Z7[>30(Z
MMTJ@BTI@A!6 :04 5W1 VJ#+4  \!0 _%C"DT8"A==/Z/2B_[H-%Y_GK>VK0
M<R&_]IR@%^C10>H?YW"@W^=ET'>H_K@O!/0=CX'CT0GLLQ,,#D^ +IZ RG\"
M&#Y!9X!)!$3$FTC(-I-OH:3:2K.-=CO]CIV[&)EV,[.PLNWEX.3BYN%%\ L(
M"HN(BDM(2LG(RLGO5SR@K*)Z4%U#4UM'5\_ T,C8U,S<\I"5M8VM'1+EX.CL
MXNKFX7G$R\?7+^!HX+'CP2$G3YT.#3M[+CPR*CHV[OR%BPF)29=24M,S+E^Y
M=CWS1G9.;GY!8='-DM+RBLJJFMJZ^MMW&N[=?]#8_+"EM;WC4>>3IUT]O7W]
M@T/#H\^>OQ@;GYAZ]?K-S.S;N7<+[S\N+BU__O)UY?OJ_Y3PY?\O+S\!(;K$
MI.@B4X R4Z,+30=*S8 N]AYTN=E!P?>A2\Z'+KH0*+L8NO#2Z-(K@.(KH<NO
M!A2@A=: /EH%)D '%F@E'$9KP1ZHP0FM!W>T(KR!)OS1J@@"NCB!5L89M#8B
M@#IBT/J(1RLD&6@D#:V2JVB=9 &EY*&U4@S44H;62S5:,;> 9NZB5=.$UDT;
M4,YCM':ZT>H9 /H902OH)=#0)%I%TV@=S0,E?4!KZ1-:3=^^K[H[H&]2 .,N
M >@O">#&@./O7_K"H;"--/;O5=E?:^Q/%0;3%T1 0$A(1$0,=$!"BM8"4,,6
M"@I*H(FMU-0T0!FTVX$ZZ'< A?S0"% )T E0"M *4 M:+S\4LV9+,,W\4 S0
MBY8VNBF!EF1QR-K&SM[!R<7=T\O7/_!XR*G0LQ%1L>?C$Y-3TC*N7,O, LT%
MW5K*RD$1?Y005L UF_AA%.A"@E*"8H)R@H*"DH*B3DZ!PKY^ XH[,PL*/#<_
M_PX8R?L/'SZ"<B\M+W_Z]!F4_>O*RK=OW_'EQQ.>\(0G/.$)3WC"$Y[PA*=_
M-8V=HE)74CJL9Z"KJJZE FW>_.\6"$__W]+'OTB?>?H7@.4W^, 83WCZ_Y->
M/NK_T_31FTG5?]J%-$4[Y;SZ,T!'>L2-/P5\>5S?O/BG0N )3WCZM]!(T^T_
M;9L-%X^%-?U)^O!Y2SE4[M*&Z=]O^8E"1FDS&P*Z$T+4^7129S=*'^AI*P]!
MN6=]_A,A/C85WVS]DW0\X0E/_RMZU]>\8=,$-%5_P1=9L+Q1\E)CJH\*IVAP
MQT: RI/&@N00@TW9!NF=OF);( @B-\C9 ) DNK:ZK;L!8,EY-P1MIB#9;%"*
M&] N0T4KIF6IK67] #<@ST;<YNR5JL*\FD'<@!?),7<F-Q!OC=[^6>>%)SS]
MQ]+,8-NMAQLG=Z:><K=0#9_>*+WQN#PG^FANR0;I+T)E?[1N_G-O<0,*#:E_
M ':X]^%,_WI2:*U_V&R+NP_JLB#\N3_&"C<@5^S7!II#W3@!P92_ $8X99@+
M5OD%4.[!!5C)MQ< 0A"S2:B;/<;)XLT-5T4N!>2)Q)RZ(9R U=7>LL*RCHDO
M&Z3B"4__%IJL3PZP:]DP>?BRHS@Y1!B]47K+"85-Z(9CW8D[??"4U%K+DLW'
M#;BL];/IL9_'F3[BN>LG@#H8YR!]4^V/#72><[@ 9VC_ -A/X4B?U?^]!<_T
M&0Y #=UO@!JN'L1W^V^ ) Y%?+YN\5L&=ES!VO.T0WR_ )1UN$HQ7QIL+,5&
M0TI 2,.VD2_VO"$KY5+JU<+;&_5!>,+3/TKC=S).'O^Z4>K[ZC.F@E30[L(-
MTKLBM=9:C_<'G.E]Z!.&/T@3Y_S EPORO]J%0 $NP%V+/UK6KD1<@)B]?P#(
MSN!(?V7]N_%" 3@ %1SK "XX ,'KTB%+[+G:;[SK 5K8,RU9Z],AV9=8 $&*
M]0 $5IB3$FF[;QU@'_:,\ML[$<:_(1PC.(KQO2W#WTI#5AC!)RAU$%<_^*,L
M4Z-]74^Z!R<V2,?3?Q_-]]3C]NW1]*HFSD53@,YS@^2):XZBI#^L'O?T8-]I
MF9\VNRT95_K;,*$_K!HGC^P#O]N%'G;+6IUU7M=P)' (42ZP#L!6A0T(7-\V
MJ;%G.=Z+8C3O%"Q 'D8ZA.UKJ6("3L#3GV.F0[YP0#(,@-6+/88!D%@R<+-A
M'%>PQ0+49IXTE=CQ!\ )"P#H2W=QPMGC?EY'O -.)> "X.F_CX;K,DX[.^,.
MW4& <1$EQP#L:?=EW"_':OURK3UPIA__PZ^&5' MM*)OW/RC=5=@I]]77F?U
M1#CZH&",=G$"*_V5^/IT' Y$!F;3,\,"P)K_P4^P]#>PQBOV!@9(@@$XAF&
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M:7$QL/0F.LQTK  C!6[UFC! %1P@^ U6!CB  ;:;= D.V 2/YN#-'[H' PC
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M5;?^>'/NW[5U%2L] G-,PIJ <("9BS!L B(1E@X1P9S>'#@ +@26>P =A\F
M!8!W4AQP@!(,H 8'\,$ +G# 3A@@"@[8!%N0OHDE)6RUJ!<+ *_0O7# '1C
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MRT4-P8!I<T*8&<"M"8*(, 'PO4F ,$]0Q&(#,'T4^ 9K"*OQ<F,!7#$!%E@
M'4S 62P S-7"VBH"[<$$].R  \@Q 5_DL++ !*RB_@J K2H8X!963SF/"5C
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M'E@$<A4+H(\)>,@.!\C"-*T)!^S#!&#/HU## )E82SDPP(#67P!6P^'3P7!
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M15$(6RD[(824O;V#B)28F!U2Z(_\G7$I&,XCP GE@6UOHG_8VSK4QIF@6UV
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MFS$X:MX9P5LJ;LUWJWSN>KM?JE]4[;8'J:\U;U@:B-^];"*W7$!-NF?HB/;
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MEVKN3Y)D\(-YTYP/CSC&/R-Q[PGXY8^R\R2N-G2O/!PC6/Z#!'W=E_/-TG<
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MYYUACX4-_#^8SO\?SKXR*(ZNW7:2$$A"@  !@A/<"6X!@F=PM\%A\$'#X)!
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M5W74#P!UB1\2AYX7]OY!#P ]5<IH_(6EE*N_F+>5M:/0-3V(:(XGU5&I9\X
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MN=T5?-SKD*QSNU"<!A;>K\*L_[%7)G$IR2OU "CJJ9*0N$<*;+7>_6!K[VQ
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MJ&TK[,W8^D4N)W^3B;SJ4.TG3TP_1/EFV@@$F)[[RA.[5T5S>VB",I2]I!2
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M<$-/3$4*9\IX ,^>0YR\EZ@Q<:[TKJB_:F\F1TS57=\<[H),H.2VZO6:I4/
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MU5_>TN?G=KESUF?S,'PJR;U.=0X9+&IXCDLS"IN(.R#3+=LU3V2CP],VJWH
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MADI'Y . :5WOQ8TI9!WXDPZHB>=@A%-RGE=+/C02J-7LR:_)_-Z_A*:OJDE
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MJ!7A,A_)$$\0;!5(^W>LR\C(R&[2<JYQ+;(G77M_=#,(^!.X^>T!H.EG[O\
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MOK O7W( :1]R+)%A)W&;3#8N6]N8[\Z,V1O]!L\_C<!9)X]M1N4CW'0[?^7
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M\PE2.-X]5##T._-<=^4]6R7.E/_EPGM\UN.G-_V+5#+AU/=7,^3K"F67U*^
M7\U_\,S^[?(]%P=K711(W<OAZ48]*9-_R\:SX@-E%SNGXEOG0PJZP,PD.G$Q
M>G[C8'=5Q@;9-PHE28"76KS,FARW3BU-<PG#,'DC1/35;%-B\8A,7)NCP>A
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M-+YRRCUN5PXQA;R#E5V61N<&ZX+FE+C:Q0(L7IB5>05$=K9E@V_81%(.%\*
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M0M@LKX(.W!4/IECGM!I'[5 *7;_I.J2F8@-: <'X.S4GTU;,0YLG"+)UPRP
M<9K:CBQN[/_N;5L<=BS_E[_^CU\4+Y?^>_#/7_$_SG@IJ\:>;:H(ZFRQLOSA
MX[SV6Y6C.V7#&K$OYFI:"+@O<.9R)Z7GLQ5Q8*,G155;W]G,;2.5-@]E9MQ'
M*"-EK7)7I]H&T!6#=R4*?PLZPF4R)<@@V:!/Q>"\AD<7*1UO#8I*I+6.TIM]
M']^:&$J(SH9E0N%^ZHDC0[&AKH7Z\[;&@4D>,JZ\I1HJ)=>>W/ADG_-@ $E,
MCQ]%40$SCNZCN-_R[7,'OXKY5"$;SQV[R[VA^]U6 JQBI(_/"M3? 5.<.Z2X
MN$:;\$@Y8C3]"JG,0\XO/>^GR5%R%D@E>-AR<+Y_C9]7;@1NY_?3A:\"IK#\
M?[3WG4%-<-VZ8 =!Z4B5#@E-0E&D2H?0(2&44!.0$A"0+A::TB% 0A5%0@DD
MU"1T"QT"2(>$(E6E"DJSO-]YOSDS=^Z=[\]WSMR9^^.>-<_/-;-F]MZSGCU[
M]GJ>/G@V1VL@3NF34;!1 E ?'\5B+1OC^@^&??F(FDZ3TZ_OY"H7OSHS&3;^
M);+A8BPM8%OLRR-)>IN*,W5")_?-@@56* #]\)W'YT/A%Y(JWMYSYVG8 W)E
MCW FHYK;&H,G])AZ<5I,S@EH28+,9JP$+A1DI?Q5?(-Z%LJ-2N5X@Y3885IX
M]O:IU9C'VI/B!OV+UCW*%QGS6>-O"9L(E#S3#E_8_=JQ"5!XFLQZ<OU2VPEB
MR>M,WDQJ;=8\8$O^&<9$KDY;9OYJ6$*Y>;HP6=A&N)$XY(SH#IC_\%SHRZ /
MCH0#@M08[]Q-N@3Q^:7-X>?V0#?<O\G7PYF "44Z'=YP1L5\Z[R,G*XY%5=^
MU&'>YO+G+[-/,Y3H"Y6<P"(GLN'J#7[_:+Q&D-W;*.8Y==,4NJ]OLTH<2/^^
M&9N9+0:1RRXIX>]8[0<24_"S33?^K*R\S_W/^1Z)G$_7I0>_J9T_O<[Q]"+#
M=5TUX<K) VVKOS$:RI7W-/FJFO35*!YX%NI^F'JZ"FMPQTZP<^QS*Z2%E+?A
MN7[!3$<WP(YE;[5\MSL1_[5FK76#1QCR,$%=@>^HT-;\5K,"]^WX0.V"NB<]
M=^"-MFO9^Y M:8X3C;JV$CU<>XD[?#[F_D(2"\4-F8YJA>W2AP?';^IU%H=6
M>14>!N,'"9?ZEP ](P-U\<+3&<US[]A^5X2R4/B2O)J-+/YYV(R\O2V:X_2N
M4']1!P$*WK&;L:N;GCNC2XYS33>MY$RUM5W->YWD[^<15_P-#2^@(ZN8;TL/
M:C"NGRDW.RL^3>8FNUV3VQ/*!F=]EG?_Z\U!$;#HOA*P :KELL[A=Z5<_QD:
M^9UCO>++JF,AC@*!S)$DY1L+@*!=#ORGTH=#ZOVAZ*1N/8>3R)5Y"\CZNB)F
MH MOQ3\]%DAAG!PB4AM#E!S8F9QV] K4U!7OZ_O<?L/Y^\[1PCGY4<:&9PU&
M[SO,$LK1:#,3=&ZV)$!LW<# Y<6+U)9_HJ-'QE0"'2$]*#U56IW+\)\1S:#)
MH,,@_<5L[&*-G1OA96](65G,QW55]E#;K3(I_70 *] ,9NMJ)]$D_J#01FYR
MK'R@3[!P:2$&7XOOS-/R&V6RAIOMO3>18(CXYFWFR$%;[.8RAKHG7!(UT3AW
MCZ&DRWT F?*MN\C>-R#B7-/PP1/HJ?" ?$'".DD56HWSFVY/#L<Q;[4%4"3?
M,COS*&]51)8G+<C4Y>P4NMUC0KF#'VJF\,8TIVL<VZ5F'*VO:'.ZN[Z2&G&>
M!\L/18@J5JLM7CW/#913'2(&M<Z Z.H6;DM>B%_3?#_J/[?!9(;[+9Z=;S4-
M0Z4&*1.+IH_O'J31EL5;DF,*=XJ' E&8,4+&[[M)%5K7N.%A<!5'RTY)/"VE
M\,N#-W@PT>01W7F?3[Y;K*SPZX?N=Y4%E5R;+F,^PAMGT1FH^3-LO5NB/OQ)
M8+E 0@5^-B0"M EM4I95&Q4;WN[N,["\!^R9/.C35M7/EBS."3O1R8AP_<7P
M6I>Z)CBHR?/BY6[ ,7Z:G<=2'_V"^24V[R)H9F)2R'92R"369G#2M -CC[7H
M*M-+=DES'ZJNZ^_*!1+"K!RD+B3RG$L+%S9E-G7#RE,..KH:\5MCPR_<K81:
M(P_5EON)2XT*VQ8W&VZY"BK\Z.A(9:D?*#>@NMLM&Q$[//-:SA#;LMSJ2*;Y
MU&+*Z[<HR>9<AX_/^9'QVF"[>"D";.J!TK<:J;)"[TO8F!86_EJYZ/IV$B-Y
M1EM5AJZ]I2B_1JG'KK@$APG6GEBO[H(U[/ D"6[*;:F=;DC"SQFLBUW8?+IN
MM$X!YL?CZ[$$54OVIPB,*L],?B+77>YY6^,"C@LSLG0IKZ[\[XN/]2U;:"9+
MIBWE'&<_0JS$!%CU :$AI0";&C6"=X\$FQ"[]3?QL7-<[,/A%TH&"ZDL=HD9
M2L//[<G'A*<BN>3/+9>%B_-JD9*/V!CIL9M0MO)Y*[)?Z'2XW Q03.YEO'S5
MU7\NJK*@1X^1?4^_K9L]HN/^[8DA]%>RF=24&4@IY4<,@"0+)'X9P+T'7CUW
M6]1$F_'LIB.Z+!6%<O=RFDO\P";XRATFZFZO]C=)L7?13[,%7.[OCM?^8(&;
M&A=\DLY6BGDB&743?6CR#6N<M6356<*-<2ZN;J@='.9=456Z5DU>PUV7O/ /
MABB?(=ELUX)[\"\]D_4/?Y>'SZU/5WI,/[>&6M^1_VJFK7MHN?<"8OE)+BAZ
MZG!T.#P0?M;R2P;9WR[5C4R</N%AIOQ*/Q8D^Y]G[/G\QS$#&4E4*73!149K
MFFZN33AX<,]8 [:^KO6D#=M,U?B"?,SS=Q),\\3 ^'M\79B)G"^J-9(S\ATW
ML&H[?V8"174Z'D_8IC"8;;VAP"Y/U; QS%V9%JU#[YP+9'YI?JQQ:P-%T3B+
M09%*\G_W44W#?=%)?!B[P!LE4A5#6IZKMSW$N# >Q&A7%Q63,)PHR=0\3/((
M9&;#/XCC&-'\:97_/L]N,3U6-<^!7%FK' >)JK8UL66:X]"]/!N4.ZR/BX!X
M)<G"4]8!C)D<-QA,1 )UEX._=J2WQ4!1NSH5-:I_8I=(;8,U"@'+@7VQ@9:C
MVD>&Q8-VB[YSM98:UV^BSB[0N*PB&PM,C\1K>Z@UAD=?CX R=0*6;\[]M4E%
MW6C&<;6QQNT<5=^6W5-GXUU9,NBOL@M\X]\@K:PAKIWU4B,H[SZY)X2.K@(S
M#P6$7QT>W43$ FH<IR(?=41Q> QB@W(1\^D-,_J'* V>>8LB<JBG[>Q1RX.M
M5<(';W&@8^U$3M@H.-C 7BXU\UFR34/UY+?):]C6>*<OY,4H'^"YS([.#V)[
MLE4.,.F,S4^ULYM(F*QS4YUY*N:5H<<DIP!;L'Q[P\->L'R$Y,O/#6/[YFU*
M5'1)X&+\-%3>'L\1L!@/:#N"X8YTS7L;F_OM>_IL)8!*=WUO)R=*3@95%=G(
M9K\X>T@V4CW],I3T\R6:RL1,CLN@GV-R3^LU^A1"?R(PO"5#%K_CB7^757Y)
M(TJ X\H1?2K:Y'7-J4-=[<2I=PU]#[)Q>/2G2]\G;=&3IY5X<W6[L]1?<[UE
M _XG]GE&8P2&+==0/MB!K=!&Q;*ZF^.[&4)!=DJXME E "4R-S+4F#\'FV/L
M?<R-V7K04$L*@(IUAXAR*[%FD.N=JP285?EH9%?\-&/#=6R56W7X?,9ZBN)@
ML)T"/0'?)]1[P4U3^7YDA^9VIO6NHU '-FB?B+,R'VYEN5,$!G"4@89YH5#9
MM*H&03^-ST(H,;O=5L 4X3-TM9$>1;EI]2KS=^KYF]Q%2,%=PN/CWE5&)J^]
M0<=3/[OWYZK.>3G%K7]>8J(K@G82;&&%6X^UVN;0^G>?-3G^&@V7@Z6O/V??
M= 2W>WZ J-8ZX;H#1RT>]HFHNV.Q%SF6,M:"9Y78<Y.9T[#V.5%RU0J%3 :)
M'&EI'@,$0ADMJ\J?/8OW0M6ZFD2BR$].<O^L+R;)H*VR7LF@@>_O#H&OEP"X
MZTH'78C386(^>,D=ZH<2>NH_KTX$I7V&^NQ_;GELZF;EC;^\H>7KKS7 &Q8J
M!?3*7LX,NWN5:(!^SA:'/&Z]D\=6>)([-/Y=:2I"9?%NIP)M3V(Z.^46<')G
MKF(TXV@2/O0HL9F]0?\636M#M3#H[Z:[P?+)[R!0VVQ# 6D0*@GGV&"V?^I*
M1@VXLXQ%6]F/S@2'#LMNPWC.PD?& HZO.8@5"DS_"' <(]94>5[45+_6*<FV
MZC#9HU>:N[4!S@HRB86#UV&S)$MA'E;&7W?\\Q=V@0&-?_2MAZ<.BQ,9;1L>
M.\]:^*F9^5O\!>H9'Z%LK'N[6L^C(F$#I"0F5X729*@P2-@ TX ADV<USB-Q
M7!<,.-52)2<6AK<)@4H!<1796Z?'Y##EFA4=OP6L_WPT(D(\I['H!7F=T"S9
M*XO#X8P0AM34_-0B?:3G<D9M51!A2^Y=5HT[L(?!:(<+W7ZZC/IM?DK&\:FX
M;%&;:9@#6T8OY\LVK1<88 Q+M]>ZEL*S>=J3TE,O&W_]$U@[R18C,N5H =]B
M.Y)O3N.\3<1[?I#E.H-K3')KS9A4YJ4BAK=\4R/9D*]QX0")'1"*UR_2*>55
MV!LKZOMV_G\PI)3-YX,30%^!VH)I2+TIWLN9T2LMDC!#@[]&JKTT0#%[2,>\
M1:,/M%^.1UNL:;_?7\_,]N0/X8XLDEFM? !W4_\"=]"P=A_S/+[-3L"9#X+D
MLE%0X^QK*=CIBSED:<.,;LSO9': ;.Y644)W1JF>/3&7G"/!S3>[^$TI=V[M
M\J5BA2,J_W:OY%!GFE:D+$$U#D90A>*2.9ZYK'NOZUQ4CY+/IE5QXSNW"=?9
MGO3[BW:M,K"&9;QC\/:[46'J&9"R<TCGK"?,\G+9\ZF,CB2A]E='L3Q<AC6Y
M_>(DQKY%\^\^U6Q+;O>G(NRMY"MC0/=62/S=3AP:%]\V5_F Y6J"5&<]V?P5
M?]6NK3*;ZA$:^&01E@'#@Q]N(]A8/2?4C$B6O>-,F];<F_8 45,Q+>I'QS]D
MWM3ISI@XKP(%TO#7D,4''7X51S29B1H;Z2%D#I$6>L++ 7+P'H9W]&@OY-W=
MV@@G#D9-%U>0<L1Y0>F)/XBN\GEW$WOYO2V%[IC&&T("_%S\:KQQ%,;'>Z_*
MVOI.]2[7W;XI@JV1L7L2]N2PE*:*G,^?)U+O*,58N&3)"%S5.E_ETEZAFC#B
M"\XN66SGG7=%85TVY^'%,J/==>&KBQ;BO=N>'6MURN>X3,;+C,"C\ANB1 J7
MGTW2T71R?+RQLM%%5ELMG 6YDT+/R48EAKM"W<+2& 2 .YJ[\O/+TK(*2^>H
ME>7?ZAXO0KR\II,S;4-.7Y@!=!T[FC Z6A6>-S9-/78*%_;6..MK9Z%3*E&"
M$P;ANZ ;,QRO>U^LMGG+8[;AWGK>15+EA@^G*N:##5:SNM"F*R3A;J? 3O3:
MDD.(T%<&#)$LD.!_;6CT'C Q)4/7G'2W4DVDZ)SP^SDN9XJ@:Z].UXO;@0P9
MYER</<WOQ_R%-M/#MOC+_L$ L6G^T;<&SG1VP#9Q+P2C - &R\DAXY":F+,,
MS=V2UP1%3JL.&PQ]CW/W\]O$W30A[H-M6_):/2T'[N+ R<<6J#63"^&!KA>=
M?HL=+\4 P1.*R' ^%OU)M$E,S-["_E!S_6J@=*\HEX.-2,*:$U3Y95O%X!>E
MR#!UVP-[:AS)L"X^<=:BMM_/5UR%ZH=OD8/IB'D.R85'M7P?LE)M09%I3KZ"
MAXL^49@^?[G.7W4YJ').U P"[HX\/VZ+Q9=*-)$L_ -<JGIM^<]>72$!#/L-
M-MJ@S?:$!6_IHL[ML/;TI\[<FGERLQ^[0</GD3,^LW>*MT:"0^_=RQZQ"Y":
M%4WU4)"[#[;AZLY8]*=V)=?X5+>,\><F\1"GZ(ZOT)&UM7/^=A3WAI,$EH'C
MV89?Y6'?8>%SL.[5E0%1J&B2TZ)=$9O%L\?K.SB>D;[1K>4.KD"]GSQTS-J#
M8%:?Z]F@ -LZ03KIE+KN:5>2$Z=<%_"=:HJ_:%H%1YP=!JP@K!7D=FLSS#?,
MLT6_!\SG?D?D 0T2%;5UB3.\KQ##)P'%VH]Y"NOW HSJKN$Y_4:U4/'I'@YV
M!S,IKVU)RZR2V]=M@,%+M+^KJ#N'(X-RCY'TT&NQ]$MV@%5=.5:BX\*#N@>S
M;]X\^%-;YB[O"%S2#Z>$A^PP(ZE)PAH:OCEO1#&! 7+PU-4#A*K0>CWY[XOP
MK.1].R+ !S-,H\9JQU..-5E<H)KVH>1"V_9:5Q$V# RW7?M2%<#]"L)@[HES
M(1B+1IR_??=WKBUUL:V$@B>OF_@8?CMF')H\4/?^KGSZ'C1\56<&YOJQCE S
M@M]P[*EJ]MMKZJD+$8RVEX5Z#:1,S4BOA9,X/VZ)#V5-@/LLA!05YT*U/4>O
M+H'[5FG;;>7N5#7BM[@-X!7H-7;[0UN]0VM=;]8G:MSSEFL4W]JY\O,#$ZM#
M%(F@1AC/.\;S+2]^A1C(7K[?PM?ZP5^,E+SQ WJMH2'<U5E98(0^=.@B=5BD
M[M*'?T6;M>S RNPIM8!&9)J1B!JFA-90#4=F\"##;GSE)YI_6/_7V?$0>6[\
M7 %T"=5D\P[(T.=MG<?,P%T6H?&(-</I*7Y]BX]I1$ <UC-U<-H@Z=O3VU_N
ML7XHW5$7%NZ*TBQ=)0B@[?%2KCFSH#"%NA[2C^&O?'+%@9TV0A2T9?FRZD"T
M,>*#<-B)TW.N$IF/M.!9G@7O0KU<;[U ;]U!DLLE1IG^RKP$57(AP"S]Y!:#
MZNR#/:=W ?#DWP@7/XNK]S4O1TA+BSA8RUK(9L=BF0%0"8+*]]V9]E-#!@9-
MEBJQP7_U97W^>ZG^KW;@V-Z_O-?]NQ[)R2 O?8]YVW4E'F6 :J<8F%#?;:)X
M=S%L6I(\X?H34R;V1RSA&7F==>#\DP)I]\M3:-WS4SGUZ<D_!$ZE#QG03YXR
MH!_K<FI8-]])N$.;6 N4E$7UR& 27R/,S#Z6%^!,;<W3@>*@OT-9G)?MGDC<
M%0DVHQ[V3W'7L^Y]N_<C]P+;E?_4K;X\())Y@?V+CZ@I[$H)RV"ZR))Y%(MV
MU5Z1(@[K_' N2L*HXJ4$P(A>;F2$JL,9&!DA!P8N9]V(LNOJB;KLU3#W4^B%
MR.X7HW[JS0O5W]Z=NW?$F+1E<L20*?*[OWS_GY^C2SB01DFS00KZ[([;J"X:
M>*1^]O[W9-_R\(QJF>VPZ=?DR;'J0(",*7^N@3N3J.YB?J*U)L;K"\.1Q.^G
MWX6?YGP"-BF= :ODJ%:O(-9@SD\,IAI,2_^%V>U_L=1],W7T? 92_+;Y?TGF
M_9? *1A0XI6*8J;1%EIKF,)RCX$MAH]DG8$8']- KGR"JM90JXW$0,J\B5VO
MX)+4R#$MV,";%F7<<8$'D:D&>8Z%Q^Q!6,O(:HG+7G[ANH07FN>[ND,[6I2Y
M5.)[76GP@?,YS.U/'8:G;=*+6BZ$ -M+$F;#&_"U4[_%[JT*"/=-YFY"YF9@
M(W\"'7+7.:H:S4H=U,*VX#V ,5H#R-#E2D!DO(4RN^6Q5MR&"I9KQ6*@]2L_
MMXAH#60R&@ JF%*O$]<!3X "1ZH?W8QJDOKEF'^W2JV).U 4F:P'QQ*(.YD5
MVYT^>QZFUO[OIL(Z- ,$!$+_9 =O$^N9FQ@A/B$&'8T9\A0MP9'"MD=7G50S
MMIS^* >!-(<%$X=E?\(+UH^+TYVJGG,("0[(%&(]\08Q=ZBX4I[@:JG&6-Y9
M.V<LQ)*>1FQH+_]X_B09E9EIJ8#$J&V[@P_] W+MC1HI@?.$ZE\[K/==5#H9
MX&U&>Q4:U:M=:Y:Q\[!JVRRS-G>G_-T%06; @^U(KI^-VHIJ2^I/<K8VOYG[
MR-#&R1 C]E2,&FW^50GS,H=F=Y^D[E!H0,!R?3P[Y74++01/KKB#SNI&\9X"
M>E]UP6']?&"7:XW*Z@RR:^6"R+V/ZDD$D#/P%21]/T-=J.X<N,%(P^4D*U=-
MH> QZ)*77]>;'&PZC?S>#OHG)P5VAYA(B4VNRE8F+<W0N#H4-F-TM-X5S]*E
MXJ\-^@SU9FL3%UN:MNGH*;Z#TLJ6SA<V2)S<F)\Z#1PMZ[^#N$L1L"E1#8:$
M3>0[-,6L^>;O_+HM!R9=;3C8-PJ%W_LS,4R/@9QKL?1C .TJN2Z\5(=4.Q$Z
MGU\_+U5XGNYHO[E3%^:']U. P1P9Q;V5;FN^N\XWUB+_A..57)WTV\3LQ?5@
M0F@J54\*'@([@NIND/XD7'&PT!$M\@VB>ER?-+UW)*53CV32G8?&<U:'_39W
MRO7\]"6*>VUFK&V-J% )O1A1UMC2)++6[N E+.]!VO79U-Q*KU36G5!N# B*
M&IO^%M":_8B^7_@8ZK6*84GJ\%MDFWK5.-,LZ5>DI'S"3EV8X+O-ZRSVF?6Y
M0_[L#MSCQ4<OP.A^8X=G(30FV;/1M)D.,ZI %;9?'1;K(#ES?5Q(VQ[KS6A"
M70E^\(U]V63\QX(L%[WJ2+NI0K* ^Z6J0Y(2?V[XM1E'5R%%=#.CIRHN5XWZ
MF.^,Q=EF:'"0\.M.B5)R#2Q_=VAXYVZFS70LOIA;EGS44X81A'/+.&L&VH3D
M83GI.=S#DT^1-Y8Z'O\L\MT2M!.AE&>BHRXM<]!S\BY=^'G!M#7:$*IOO<UA
M:>^OSF,C<7M.<X+M.4OB'-@5=6I2-E33KECUD)H84C$],J$BEQXD(%;V)K,-
MX:"+WW*TF%;>7;SX:#XKH+]_J/F;-US'?%J)+)WII0BK,1[JZXQ81^'I,;D(
M +$F[P;_/>ET[;<I\E_#7H[[I^Q$V/>7HLAJWBU/I##%>(,K(Y_&7X_%2][9
MYJ&:VWU?&7)(:ZN9:G[^T=1/28W8V&1A5WBK<$+66463X"#B<" @-WE47"(.
MK TQX1)794(*O<^BPZ)*XWW:;8+CYADAM><AD_4R<GK\6U,_AH[X75<:]E4]
MN^T*1X#4!'R&V\6-M-V8V.[ZIL7+9)D#ITN3\#SY8KT^K$K9T*Z?K\]T7_FP
M4DVJI%8J\L=W^YT:XPHO.UI#W\O UF2;J95V@-(V9'1"8=BHL:/6[\M08UNQ
ME"4VAA[D"P*X4V;F]B&>G7KU<U'A+BEQ=4GM"$>/=Z-X]+TZL?',3*]*.919
M9DB,<CKTG/_2Z*KTSJ^G@\240]KHE]I&9 ;W=X':22N(Z8"$29%OIBORCO.,
M+1HI-EYL=(R2 //F>GNO38@9NB_'E'YV ]=H']THC8DX^-%QR'W3?D+EC]FZ
M+K?M[T+&#N#3<[(+=>ZZ:KHKQD\9XJVY$5N1IL.DRJVH.P]Y-2@>AA&VN+>]
M-.)&N=+AAWKG58E!'G'3_RZSM+QMFKGI"$WX/U2W_FW8!?IY+$-@$W."$_&^
M[*>@T;:)44R4<=8\>3_%V<Z\CDQ\\MIX?IA8Q./,O$Z^B4*8R3G8P8](T+CI
M!E<SH<DL*&MO"@B=9G^5#8T1]=N!$@HLONPZ7[;4?.JN+G9',+=:$^X8Q6 *
MI:/51A/AD"2.^ ]_Y1&GR4Y0*?7'Z4B4I&W%VK6=]"))+7 L!SR38PGJ>704
M%GIHL\;A5T,0FS&-';RNP]XO,6#76N>5LQ>[1OWZI_2A.,*O<Q&B] RQ.J,
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M^_3#]2?B5]?$'P"QFM_#9LQI3.B(&Z84/=#(Q C1R5(,1H'>A;J/.8J.C?'
M_$+SO:.Q&(S>PCC<+^S\'^UH, /V8#HZ@M9XZCIZ-W56PU;T?G*SQ!Z-)\F0
M G0/L?/04\QTP@<O ",F0!<48Q\0;G]3H99*#._M0,T7.I[<@UK*@]>=0>WD
M6(DNH\@L$T0 Z@IC<U0S>@.-YC&,[J.NGJ^+.4N=\:47:5%<?P>/M%"</-Z(
M7"6;5;L-N4^B$F8CJX1E\&FHJ;Q'!T6H7,YN]U;4.&OU/"9ZD''RLQ%B>RWD
MUAC"NQ)^S!)QH&2P^@)"7)@@,$4\D^^%CB'W2;L.4)%G1?YN':A@/F/N9M0Q
M]IN/)+BZ\\#-2+BR><=@.;RIEE&%A+^IW,*[A]A5$I#;B.A3=NYG(+?(.%LO
M(H](<^98(*]S?3^XP.V/@6Z8P"U[-PW$P)>U9ZO]X7&-Z[FWX2>KLW(N(+S+
M3??5(OJ*';9.16Y23K>8CS3@%+Y? #M_X<386UCSJ>A^7UA[/ZO2#?:F*YKS
M&![9?"9''WZS]M@^?<3!2LJ66,2YDHNS?1'!G!GO5L*8MXG7?L(21B\>#8,=
M&GE5$0X3#M[CS(3]ZN9#=L+);09[DQ%3&VYL'D/ *Y>:*^ GV 4O7])FHE==
M1E,!5$//:8H>*J*LA>R 6L>>1R*B=H#/$7^@F'M3B#+4DRULHA+-F,,@P[%:
MST]2:FF&HP!914%ULT@=9)M2-/$+28=YCAA'7)F-(GP@4".G$RH(!ILW$MKQ
M=V9_)>42=9Y^)V<*OEP,(>7R($=,B7+.W))9A(^LF0P: <((!X41+&BC$>/X
MJU3D)CO\<XK0G$I$4"J>!).R%5_.-Q(),EPGAM HW51<1)@F<J6[X OY15DK
M\(%<K_#/>$OV?%<G_!JF>)8+@48_^>@$4:V><VXMH:NTID,?_[8(7^2&#RLH
MH;["W<\WRS3&J<2/P[5Q$,'XQA <F3]UICD^G_GX82QQ:DO,F<N$!?4Z;2WX
M8/6S0CU<1]D:RB@NH.A8^D^<4<&1L(78^_GK7&C8]U(7LX6X(TR/!_8$1M_8
MZ6J\O!/?RL>=:88K/N#6U]XF/\%>K*Q/=\0*2EZ&[L?&%U[=<!,+5NR9$8K3
M8;3=7T%8,B(:J<.O']K4(L7%]W@I=+"GVH;)1MCDAIMIN=AUU:R08UC#BO -
M_M@IJOVFM=A4QO9[ ?AS5[N&QW"/S@4T#^)FGH@N<,:"C\XB!6#-.N&IHYC;
MS:=#-F,ZZW>L/X\Y4FIJNA+S@?[JYF9^-%)Z/(4+1WHUA+,;D:;YQUGSD#,(
M$D8;TC=%0<<C&X(A-"IJ[7HV;1E::\9:QF7,K>L^O-7DX6-Z'$\2L7XEBT#,
MR&MD_"!P\01Z#?[=82:-A:<&':2J\.[.<*HO_I"I+EU*(%]KX@*\)8,%[$7L
ME[4_F;',VU(L_2W#%A=&:Z(U)A^FEE&1@7Z484J.4PX%1M&;]HT63NZZNIUC
M*.,/K&&ME2)J< RR2"*QHL_D_\1:4)]P>Y)"*(_81W;OH\QDCJ\K(/<S%TR;
M15U.(UY^RO8K,S]ZG@DMMJU>0K^DR!9=H"7)IJ ?4==*GB7NI&P5K0Y D3/X
M(VNOD>?SCIH$4)92QT?+60WUQ_MDC'O5@/H3?6MYKK"9>EGE@;I'*5'N3]A#
M+I>-^;>0;DJ_KK4CT27OIE:0=U(YE[BL=5VEO7Q&8JM>Y3M:?WV9H(>ZKZH$
M-87B4&X8KR"O+W[L/Y44I:QS+" 9%[A-M2))J(X75<SA8\=[FA@Z?;Z5LVD'
M.V?Q'U,^-/LB/<DC=;IQGT@WU+F[*"2]\GC')<3B(E?C6I(NY=&%.TS0A8CN
M[_3Z4V\K#M!,!N[R'2FJ[A!$ 1G>AHQ+)C$:C^\R(7;7)CJT$?<7OC$.([(I
ME2/?9>\0^]H%>=L1-JI/XG:$$?N6\!#"%F;.WX: QB1SXQ%?_4#L,:3 /I;M
MC$)/07,78OJ&7?/O$7^V)4@7$QZKM$1Y^!^L;P)__$[H*IX7[FHTD@/!Y?NB
M69]QN#4P5@3NOM%9MHQ@>/)BWFUV3>M\R5)F?]%#H93^A7F7OX]&R[7A'J2&
M'B*P%92#.Z2LE>3"U>5,)KG R)FUG?3D1(7TL93=?%^\172FL%S0+7!B=/%
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M#HQU"3/YWVC?@M \/>K[3>D<*'6CC8CC1VT"OC'=L96UH_+,/'I!3IY HLL
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MV>#'N1PRK6<;I]:KIDO :7#L[E[,V0  U,+9 *M*W1XMW5GLOG6VY%A:W !
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MA_@3X<>3WO#>(GM#.7Q/].K90$'Y/_,L.YFXH]G$&T+PM)V\>-1X+IO[&(W
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MJ/+-0_0R2?;[K?2*C#7-F]15+M'E_0> !P)V]LE!\V=K^^) 0W9%&]I , !
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MM8<8^ $9+0A#@%MP\RA=Z@1MTUS1[W%&#OA7[9L*FE[Z8L-Y2$3%EKH7L.7
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M)%@ R$-3_#(SW^:ZF UTWOE0W)/-UJF0-F:+%FH(SX! \];:P[_4 I%7]MX
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M1J)R-*XC"ZA_J[D1[A'>/&=03W0#=SC9,:Z:,Q?:GVC*,=JS)'D=FV5Y)YG
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MH4MV<9GW&7[-W2PAXX7:CNW*M/#6L!^R\DLG<-K9(9MG "*.>T@\UP!L=-G
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M^&+\"W<05U$LW =8;XXKSP:]&O^'QT$^^B_F?4?&.2T"&Z /N]0 J/K9^AD
ME1OTG8!$GHV= SJD''(#\%A<G9W)#1>>BL_E#O'O^@WS$K!SCA_ 60A])Y^C
M,<,MKSE5QI>Z%DZ[W@Z]S+FD22 =!N8K*5F- "13Q]W@3A&;_;9S]PGR'"_S
M=.BEX5[VC:8W+;/9C^M![6GV!\MYY =GB>D+:12G4K\L:P+GJ=HMK@!@RI?[
MS>,&B8XX[N0Y8[^'I[%C>KR;"]E;V__1SF+G-X<AH6QA72$QA?W C&02.65Z
M<>QG8(HJV_=O8$1RW[&.>YT_>JB>]7IG6M-3UL\!!PV;];V+"S>QY[9("4?8
M977:[=_8/ZJ$L7I.AS;"5P-(9/V."JZ&?[VW4.);.E 7+_I8WJ9,%]ZOY(&H
MX TQLM)>,)%LM:V.;T^UBDG#D^@;?8(P)7.O_0_T-:>Z1RQ24U[6E@I!Z@O%
M=@%&N\W3\FOI5RL2\%.,!QF/\%&LR=&[L6!V](:;J(6SU_X9.H=;T:T13@'^
MU$0)YG"MY!E\&VX 5X5OYN:6$S MUY3AA#[E/HEV1L-XOAL0Y""OR?YO)!E<
MV87PF_E3+6OP/7BVS!Y[@-4#1FPY^JQ,CY+0L*T8,H*T;^Q'MB#3-WC"G^$2
M^Q-P&]3?F8>#\M_53EB53"MU0<]+IW*DZ'PQJ;0;80MOIQ]$Q@I2-UK!>GR?
M]U,X&AMGOQN>CRSMH&,6PWOS!O20[I D$/FDR63W(J'*.R7/X7[YEO35<(#D
M2M0.Z(7(W[L)&N83['L@(YK5/HR^K#M914?G6<Z+.4A4E9CU!C88%I5L@&=H
M&K<8H5;EZJAT:),4]29 WL(&^V;(%6.TVZ#Y[9!I!-$U[Q)=A8_6BUE1\&3+
MTN):"#5V;)D&K=6NB?P7?*'@>P>#E\4&^QIP!"]H.X9.&%A@RD?\NKFB<#B[
M+96Y S(VW"Y>#LVPY*:U@0<,=R+;0)':PWLVB$I#[8V@GF]?_T0[MS1>\U8]
MICP0=U8Z5RZD5<OIA-<%!NEATK74"LEDRM-PO2B6OGS]9(&!V6)'QU]PS/6>
MZBK*:$V <H@Z"2N0OZ%-I=Z7^= 7Y;^4R!B!FVZ)GC+Q\!5"?]93SY/\6@[/
M3HA/XJ;7E:OL.3+U1D4VYSC*ES5R?E-'2_X X?EKQ/E XR8_X37NPK .01BW
MVE.*'^+YV1FP(-Z76K9B!'VKBI(O0LD(55J)O*%8BR\CI7GYHD3X1TJSX :L
M#POE9\$>GNG8%^B:71.J@L@U.OF@=(MRF_2/Q J62+)$(^0@T44AGCLD3!2L
M3UG$?X__&_H85V%-GDY8*!IJUX=\AT]9SLMN:0\JVJ1KU5>@6V*Y<C\)%XV2
MRW/'"R32;<E*OJO8(13''@M>>OQ"NW#$;@_"1CY9[&4NEC'RGQ)Q50;D+'IN
M(!/O"M.UN3E$_FM5;/)BW"1W#/7#XL0?/$901X'([@@R$_U:W2[M;5XJITEF
MU@^#%E&QY2,Q6? _T[?L?_B%ND])+?AJU<.0U^@]V;#' >2P*,7N%+P;NU*=
M($WIGB.?)M[9]AJT$DUL"B9<$Q34QF;#^,>JI*04;%"W,:0;A92V'D:$(O[;
M[CQ,P07:1Q;KDE^"D:KM98_9SH93%0?+KNM""37;5ZH'2/KX5.5,RJ[ ][(,
M^FBW;V(3TVSC*#C-,6A3S7?(ZP1;3*X4?Y9)7TV-+XO3SJ81MS6I4'IOW%OY
M/\S9@2W2");:[:'(P(FUR>&/<,,U.ZM@MC=?9WC%1IAO=!GL*Z5UZML<WVTS
ME1F< W& [":P+7"K))([S>V<L)=[ST;)G\*[I/YA\D$6X,?T/? 0<[K6&4XI
M>:4:@OYD$!71T*&XL=([D"IPNC@'*G8;$MR'8FUVXYL@;[6/T4ET'Y^L:Q'>
M8B1KG 5G2IR4^_G#6Y_+$_&66*/D&]82<%ZD0FO<F@1K$(7-"+839JFJ#%&J
M'5B1]I)R++U?G2[W*#8J7D@3M^;)8'%9;+#$3B@., FO\AO<='P^UF#S#5N'
M:%3S]/6F//23UM4PE1ZH&M!2BY<J?%2[TU](;\I_Q3P42Z3^ 45";Q'!C8__
MYD.VL] 3**;LU-O5/47YFEV6>[0S*H\JH*A#/J!_G Y)DS71,9AXIJ(UP%YP
M3/+9C84KA:MMK=%R+$&Y77>A+1!UT60V\6E%RO_5Q11%R,/-9],=)/<-&V/"
M1/7JP_X_!'ER9[<\/$@$V7J@-MA'(=127M(*)#5\+8,)C;7-%=MSZ=4;"9&I
MXXUG2(F1.IT]!?>I5Q72'J[UE8%,I=4J$<31"&<WIY'*.3_KGY,IA,@:A"++
MM3+/IQ[=M,^@I2^-S-+\8%A\,&4H*V!M@I3 66K%$F)<-T%=TQ3F!TY970<K
MO/*<)8S5F=-FNL-VWY2F+V3?C%R@OLMI\,E6> /0VFT2-E=@=4+0QNL2S&\X
M!D6SS]>60Z,J5U;/!@_FK#0.@/J4A[HX4!AQ0G4#5/AXR2/!QK4%XCKPK/4D
M_@MH#!^OWR%0L?UJ\OB]%1+S3/QLMM2P WN5PM(F8<LC&,IW:*;/3!D)J5M;
M+KH//[4.XD? [OSQ=0_D%UA'+ ;9IHIY5<&2H]D+]8_%:U)F:U"A,L)?N93_
M>\,7:2]>L98B\D8O6Q/P?8@OWE#GK'O*VE;]2G.QO,ND58FR=NC7*QR2]ZEO
M2D]'C%<PQ04;7DK'"'ZMY0F;<:&U'H]!E^*)M</5UUE.U=0J^W*V:89A9195
M9]0\26:KURO[PH_*7\C #0<EN#AN+2QT%4RR'L+>HC?QV;4YC=7,-]7SZF+*
M/8R-U8PL1YVU,3?97W5 FQ9NE%.4R1M:)2ND"6MY@A%AA/4%K!DC P=Z7Y4$
MDF(ZKY=-+9"T'BE_G@XT(I7WXJ)JQQ%_!KM4Q5(V>K;J\F@''2XHPYC8JC3)
M-(X,J.@=2[20;#IND"P%Q2T6\N'TW(80ZM0X+\M>&ASL;)K"L/'<JW5BOG*<
MJEC!?K/J@G@T=P5@TWV0T44\U6YBCB]8T;R%":0OKOO)LHX;4\UE?0B>;;C-
M?NYY2/,7YYNCOWPQUW/U>M$BGH1SH8O$PXB9;4F\N/RVID4\ARU':H_QG&)W
MFU-Y*4$O]"=X&L_]ZNF\)XZ%,G=PTVJ%,!&\S"%VIN(;B:-:_3!Q?F3C)/3*
MENTUPZA=++LJ&C$&'=)=1%9X[E39PUV. FD1O''UB* 9^I>SJ(,GG4#8T5(@
M/I#WN\%)E+]EON6&<'*LKXG WQM4K_V <SUW*#.Q<,=&R3 ZRVJQ8#[\#_M2
M^W6UGL!JWJL\FG>BGBT_G';;LD+:'3O.N%?<&(1JPX4-GCL57?QFQ_V295B+
M53R_'CG,KFU/,+XEQ#2[Z,5YFKKGFCMI[=5"U;28:T9K>4A0FF:?!/!L4]@(
M#SE>%U?SQULQ^<$HB4UM^U9K2XAK.EV](4]15VX\F28W?] MB#EJ0%1(T&;-
M"ODHSQWR-K'*\84X2&!O585_PD:1X-V-Q;<+.X?&E:HSCO>YE5<DGNGX4TD,
MO]1<0FSPG5X+4Z:Z?C!MH57;-:I?,-DKCDC)' $I;-=CPO7"SL'9Q%,95WO'
MD-XG/F[OH,2'OV^:1'WDZU]C0^]R\S1.8)K63%'UL(^M3).D<:>3UNQLH%,*
MH8$S]-,9>[K[&+&)Y]H2F'/"7S7L8$WQC:^^RW9SR]-?YM#79"EUP/.5U\6Y
MO K2Q.%0X&)A;#\!:,A@=64 IL3&UK' T?#+]53N"M\$\P#7[(;K]O%<UK0H
M++S'J\)%2K"5>'=H+CJWT+8O!"%F)'6ZP/<3J<TC<%'XX;H4>*%O8E4+]-RM
M47L".KKFD?P8M'-5H_ NM(>X:]!)E%PXIS=!N#XCI,-3,"LQK^D!_BF\KS8;
M>^>;:MJ)C7<[H'F%.M@OD$]",E>]$T;!K43##I8BNW!JCT1V*B.@O5 Z.3&C
M::8X.+R]QB"4^FXU?N6_<+NI<<53[2-DI>CEU:Z""PB!R!OXI/,JG-[]3K,J
M(Z1MG_)08GICECP\O-;R0G+;=Y-QFPAW>ZJN$X3:ETF?X;-7YPM*T7G$B@%]
MU<W"!=UDHW]&7)N3SBUQ6\-)U<_P1DN*_+9OMN&2Y*K;.[6=\(D]5XKQ%ZR6
M"9:BY@OU%0L+O^]]7OFZQ+]MB-A=1M*^)&=65$-#U-F$"^6;:;?("[:L9!RD
M@F'+6/<8=JZG@71VP+D#I8.DXWM*RP^3'[=F5W93)V@.$"4T5[")7$DO*LNE
M%C%VI&VD\UBS0ZG,BVRS:RZ'">2>^5;<"O!V#99>!N#FY^6/ 9DZL_(I,,PC
M$C\ _Y9NHRS@!F^FTC*X^I#KC%O<'ZX3V5V\\M.^A=<%TX>_EBSA3VG:4!:&
MSU>^JBC&/+GVA&J47A)/>HD<3&VF;D'&AH33_\#^+CM97Z#-)UL+$E6<(5)1
MBT+2,%SR1%:C ,J72_9R/E421,^+8XF/A&LV/:30^"G!A^E!V%87,FL+LN1$
M5OY2\]^#[H5<T]AZ;O$)_6)Y7-E,C0O[0055&5N43_@M*]VTCCP@9@;'T*H%
M&UV\F1?1P>,9>;8MLW=X%B@:,NJX1;=KR+*DTK553-:O\F8]O["9$*86IM22
MI\GS@U[29HM^NTQB;L.7'3/E$OM6#M#S;W?"M0-%-BU:*53"J,=8Z\J^5K,*
MOE9V&7)35I!$ZCE!!FJ=E+#V/N,7/_78XIPONU_U?\S/'DRN7518VY,FN5'\
MO,V9J2HK:YA84%%I;[Z4W$J:I]L6%$@-DDO7'F+T";8>0JA_"CUZ%;3?_Q7O
M$_J?TD\2)G-TA2M3S)I!H!24L=>2+B4#G!)J8N QX&_&7.<K/"4[YJ =^121
MTP-3_I"N5C^B65&6BS%ZQ'_9-C*HM/WY%N8!AD/21;8-LR<PG'.,G>LLY_8"
M6_;W$O_'KNUZ2;9C?S!3**6<(-$::B_'1&?2QP-C\QH9+ !,FLB:PAT7L(=]
MA5OMG P\YD7M6T-8@)DZTXD(^MOT@G0'S12,4/R1P[1$ZA[$-[>/G@+O2TQD
M3H7] H)9/Z!AYV6 *[1PS]Z*6CFG_2MAB6R<44:42-A\&7F4Z#DUD*(19N:<
MHR7Q'R:T,!SQ3?Y760%HF]-;C@8^LEM=3C.FM%VM^*D?92 0:!H^SB%^5WZC
M1)+KY.4YHZDDR9V$F?0R4: _E6GAESJ=YDQ'@W:UE D;IK8^KYA?<UN/5*K-
MY9B>N,)PA\PDW=#&9:=1]BE[XS6T4]*W_K;,><+W3NUL"Z;8^:7T>J>QU:.\
MJ%6H.USQH'$I>I5048.0#I)<34^R=E,<=!OB5](V*K/\'C*:)>N=%.P@O'<G
MOS1G\'G+CK)_>O_1V5=LZP!0]\K[31=)]L3FVI59?N0.4W;<,/66IMQ/QXB6
MV3NQ69_X-0/7N*L*FAIIW+!B)\T&+EPJ0I9R+Y5?)!)Y:PDK,M4\"TD>^PY<
M15W]GWQ=9(QVG 3M8:?V'^-,(\0TE')*B!?52S@GR0'P',"=TDK @&[:LNUG
MN$'TKM@$[DOF)M_5O"-L9X>GX#4@MJ^:M8;YH-Z!U<DBJZ:SK5G?H#'L3C:O
M4L<)X\S=/I[SG;,O9@]P%B#['.6>YP8ZG (G\VQZ(QAL)*;V$G,6,E%1SVR&
M>W@766%P4@7.'@N/V6;'O@/MBYG'N0PQ?#*!KY"K0P]O$SC2,XX^3U)?HZ#O
M$<OEA8QLT39N$W.V<$&YCOF8?RTCD_4 KXY&V9^PS3X3 3_DLX.!NQ,NZ_I.
M_:I]9Q'2VC0S9(7TS<JO0!]COOQ$V2[&5ZE\:Q]KO#@Y>AS;2SAQPSZ.&9<Z
M_.>4R*4N6^K<FA75_=1SYC*I@L8UEG,>T,-TX:6_&5[J^5L7,U/E-S9:6%H)
ML 'BS!$\<Z !A[&)G0)*<:MU]62J=:-)<H=ZI;:3XTXSF?'2=+K>L#E=PCBM
MF;?1B[5(WK,AAMTD'NU0#!3@,SM7D#_TOC?+*3V=(DD<=5-+ [N:-JN>5G*9
M_E=U0/IR1HS^<]0(LUN%;)C*CI6<<\@$EN*OFR4X4.!K +%31:>$,BRLU(DY
MC-XMYQ0GH6CEC;3]Z#I26B09>4?Y[45&SM$_KBE%KK*W-?6BPLH4O0Z=37@K
MD"*])"KC!+*-_+F(ARRD"M.FPT_H'A$OX<.,GUY6\"'6MS5E\',@H+$//L0(
MUQ7#1.9D/@A;,??2#T$O6(3"6N@@VV7S5JB;,S:B&.K@/%T_ IT''O]'S>>-
M;C!#"R$K;11X#UJ)IX ]T%C:;5  /BRX!;+!LZDG03YX(&(\V (.K6\!WX-=
M:\J@3+"N'N0=$;[5Q/#T0A<LG4<1;*2>XVWG1^=_Y^7C<:F3>6IL2SB7=Q%-
M7Y\%>B*1:\K @_#".CUW0+5#O8VK4KJA)"Y-3J=\Y)9*#?D;N#QQ_R8Z=Z?P
M9/A\WE_\_ZU?P]-@_?]1WDA![4W@9E6RJ@8X8IR&# &M.CHE *A3]^?I@".*
M^RF?N%-DH\..<\O$4SU_\R;S'ZXIXYU$^;71@$?#*=4$P+IV+S(7F% =2F[@
M_#1*\\8"UMI3*10 4GX(*P7>RT9YWN :A5?_H\HP3LUSSJ'.:4H59T>K!RSG
MR!K^1U[,8=4LSY5QZDU9*0N <5IYV') H*CQ;.6&B%G_4:OP<*-%[I;_0M(N
M[2DJY]Z1%)=<(OB(@\O79"\3+:U4)=X5?".M#/[.OTZYN8Z,GZ8_M?F#76/G
M&)Y+2RM8XG>2583%W)FB#\2>2E!XA1R>Q1;LH[Q-3.?WTG8'&_$V1OVZ"&P7
MZ[CM*O0^X&I8(!ZDW1-]$JGINP$W(94AKF@1E#&S,H_RRU@1"6=Q-CLL>#VF
MXJ2N6X8>!@2V >A$[AW]:I$5;['PFW F+Y)C*YC&RRJ_R9_)(V7.QM?R% G1
M6 9O5]!35,5[Z?X+>03:V&Y!-H*%.D_!67Z:<";_%'Z9'8E?QAW+QV!/L,KM
M #8-[8\?03>C8X-JD$XDT?T^L@+6V%;"+= I;1G_M%PAR,/_)]O*JL/N2EZ7
M;40_BS=ONXC:"_?%;T4 @7U0)/P2E[OOAEGH55L(7HJ,TIS$?^AK^3OQZ=IA
MYB=LD9I=VH*N4T[9YH609)JX1_ ER<*@27"H4.E>![W&[]@JH'9TFB82SZJ!
M^>X8R_R068S"QBNE*Q"-CI>Q&[ZJ7A57"4?(]P7N@DY(HMW%$%/0;EL-Q:!O
MU:^QMRT^^&EL1L,3QEMT>LV7DF9D3E5O1@J<H,^/LX).JN<&HE"Z;,B] EHN
M<K9M@49A[=(UAK'YW=!R[:6BE91T]=42M.">\GG9HRWCY*\JTZ(721\0/_O5
MB<]3#KE4"_?1[UF=X^]DYTGD.F;Y$5"EJ:S,)A]6,0B_"M(5 E)+FEJFH!1M
M/"(QT&+]BD1&1HJ+3E#/,EG/P(> 5>*GFEO4)MXQU3N:B#Q3.8%.R.^2VS!R
MTL9+@YAE&[>*<UA*/WLAEWW>1<9O!-RMH[ KW+WBY>HT8#OWA1( :DAV\E;@
M6MYGZ57N[,TEDJG<S*B7H@CN/M]G A[/U@7"C_":K5G8#-!-E*J:CXWAVBLB
MT69BF8R#NN5Y28:0_M1GH@_(NBA<N!$^Z=O--\-;7!C8=^BU=1-: /&$W<J_
M)!T (H\7MQ-.244B;FZ3^*C0/;50-)G_.,KWO_QK?6'\PG^V5H'%H6.M3R%_
MPPU"&T6DQAF8)E.KI(1-DI.*FEP[T0\9O.F5,%J2&WF+/R@*]TW%K016+OGH
M'NRQ]1,D&[$(=LMW5/$X-;+11N_*!Q(W'9ZS1Y2I5FW"!;V*JDB ;R>M]UV$
M-8B:7;:C(7R1]2]D%$H0%,LCZFLX$5)=S4 E*-YG=L])%]XS;-_D(7#2"")#
M\'9%O\][;)WDADL<\DSPTF8FO -; H743<O/H'ZV>!<>++&N0DI6;3MK.%(F
M2W36WJF<%ZI5C1#/>D'R@Y1.I[$2'?WNJAO"2G8^N*=F3]DOJM+\L<)4O-_D
M3@C>1M?G$_\DO-* Y-NAI4HQ]:$7108QICA9BRM8E-7>@BQ@-KC>XD[)H[RO
M0JDIQ3Z&D[3XC*^Z,?2<!)':B:$*=53$,1]Y94@SV/%. :(\SI/54CZ96\VK
M,0^QS92-ICGL?XL$^F).; 91T\<92EB@_ !XA-R7.P*GO7PE*5R"4X*0R7-=
M?0UOXOWAC:NBPX?)_8;[L+#PK<X?#MEZ6RV#/L?O4-R$]H;H90Z0TFNQN 0J
M==HF:(<2K69CGR!?+M?$$]XA>^C?"V<7,K4)@M5;BU5U_!7Q<?)W^/*0 FD0
MML9KHLB >CN5\#\AP5816 X<SYUM[%%<()W4.\C+"Z=J1-+S6T<I1R33XC[)
MW451(<X2J8#O-49X#S_IQ.*GH[^LB.@S9 .PW[A,KR,9=#7:MH(1]5MU?/H)
MI8-B*&Z/C"M;'?Q&_(_8N/Z&,%4XSPG"1W#82HUBR"\ , Q:UI#2=$Y5+04Z
M-<4@30<5+=I5<;#TL_) \$EQJ:Q@_5'!0_$")QCG\H]:]:">J(7ZJCTQ[WEI
M0O.C0O^L[ 9R<?VF%367RI9'[:YZ4W' GZ"_252Z'U#74J1K#LFCZ#=7KA9]
M9>=2:6V>95:E,YMVE>_)<JZWKJQ,^6,I)89%M9M0<H@_5<>B5KK?4270]]M/
ME,U@Q:ZL$8X 8ZGS6O:1YY;4-FZD3,^\63M$79K2;_Y%2XFB&JWHW?Y9VK5,
M5_=7RL6L"_8ADL\<\ZHI@H=<'J6KV8_YOQ*[^JNLP,RTFEC6[I3-50WLA"AG
M_6W.>'\?]6_.W^YO%.. ??9$\2_NX55%@JF\*Y2@QL\@4'RHS@ 6;7]GF0\F
M)/]C(H,^D6]TPV"P_US56S#3_;5\!HC;Z\76X(%50_Q4\ _Y0<,/_O+BRMHZ
M'-_>6+T,NYC<:/RO&R)[M4?0K7Y?E7^07>ZO9>N0E?:#HF)8ONH+O@\>1U8W
M>$D5Q2XU(Q+:]E)SLGAI<K&A0]@22==\%_CXW50&XS?=/TKI&&I_67@"=5CM
MC/O##\CI]2;U\:(?-7ZJU=O=JWH5ULENAC'2SY%AFDWBBW[MBDYAK_L3R6-^
MO?T[82"F7)V.74=,9,=Z5^.UHE^64_K]VUVJ;+7CDI?JLY4_(WW5+?)I?H.*
ML1(/]\^23"'-89S@%KY[-8#AJ$OIY('K>:59/WN>%[2G/NC873P]IJ_%NM0<
M#-4[5FSQ$IF?$^/6^NNIE#*;_<J;]"O+ZR3;V-DEQOX/I4%9U[LOEYU-_;N]
MI$(4LZ>IG\ ,KJ[M(9F]=E=1*?^NQ75_T8FV:Q0RUIH5Z\6NG$\E&7T8\4B6
MIBO[S\,_?S:&AF8E)B=$;(P-'S5F,FEO:E?K!_)(C*G1D^H5K*[QHQWV.FN:
MQV"OW:4YR4JR1>1YG,TK=HH<N?DEUCW?&).R$CI&&&AJ5@N=N3BFK/X4\UXP
MO?H!ZY+7><-E]J.U=]2UP S;<[)MW(R5=L(87D?QR^X&[H:LI>T2;G"J<[,]
M=U.,1QW,903GF]NXQ[PNZ/MX:]?^5!EXK793I71P_4I<( //%._L,J%Y6:/:
MV,BWU 5-\Q!.S/): OP[.*&J%C9X7=7UP;$NBY1]\!R[8$D?]'3E%?X;Z$BQ
MO/.,*"/S?6N-D)<ZH]%54!HSNT;"#P\.-1W#W;RN:Q]B;BY>BA=HF!U9,AG)
M73677P9KBBL[711+,M^VO).=3OVK@29=$C/=<D8<'NQMFB2$O<YK-_ ON00K
M$G O.Z,81#M71?%'(\'%6SL.:.LS/[?DJF^F+JB_H13&_&6QD_T*]C,625"O
M$4VCR-HE5GZ>?\^N0SP7&UY%QKN1\T<N%L_(OM\?71J?=[ VJ9Q5*)4>J325
MQ+&.$H^6SRG44R95ODNII9%)'X*>,U?2_%PF<9Q88PZ]*0@O WNO%)VJ"*^9
M4.I F"BI+8>(YYC[*A^1JPIZ2/E4,/D&=0H="$JE?V+VKSW,]N=L.&B?>X,^
MKF=U 9^^LUI7O)!1+@XO-3/7,Q05KJR9^?V$IZR?R;/(Q]A? L_1G@&SUL*L
M F[*_I+L/BB]JS0/A694O2Q<#YX3WBE^!.KIR67M("NOIU()%B7%D^K!], 8
MZE<P96TTLQF,W7LQ\Z98VO$TY[0HW43*-PMM!/2B0OY'FDMI GXA=U]%(;8W
MT4QL1BT!-ZEK$,+:Q8S?\-(]\/9,;6=[>W:>VF ,S8M2EO,W%SK*?:GV):[2
MOW*>E^>+GB7\)IP3# 50*0P\P_D#HQ(YN)NQS;FFI:TG*]C<8XC+=36*\+("
M*UT*):4X6+TJQZM,)7^6 !#F2M0!5N0'PJG.E^B?,===_1EA;96M[S)SFJ1Z
M24Y*73'6D1];;4,V%W$,S[*-I4\TM0D3*Q&%L_]M<J&8[CQ$5^,5N]9M;>I_
MV4K<?J1[JNY'=D_K;6QV7E.#C#R]\(8E-'ME:;+A57QMY1AUKK^*]%LJ=ZZE
MA_ 90SQ"3W9F<R/)-B]/-Y]L*0Q!3U(7EDPE?:(UEMW*^LC86'D\WHTUBW3#
M;Q=G/LW;R9E+9"T87%@QIY35I*V\4$[4+B)2*Y.1N^2%1!?2"LI%\KPL7UH;
M=6Y<#:.5[NZWB?6"*7(:!_ XZP=,I0>IE0T_RUMHA>KN2BI]$RPBAC,B"#_)
MCLR(S&BJ-VMK[$-Z&1OT'6'>YQQWO,]IX:[OGU;<R_.H+R\=YD6HUI2W\&*A
MB$H3+ZGR'K&/5["]@/R2QX_UH<7QNGTIC(^\>XZ'V$_!N;WFPI>"!W732Z8)
M%BLNERWB^_'^5#C@R15W"5E8Y38%Z21JC*FCIB)[?!<P;.&+CLWL(.AT#Z&
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MZA:[3'0MR%*,0NT4"[BUR'<EE=R%'%'-*$Y$FE2#Z=<0CIH;4XAP .] $:(
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MQ8YFE3\^"SJO @H724:HAY: C"[UNHK<\CI 3'+,L0'CJR?%KX \F&[!Z^$
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M8(**%J.&6>K@X#RX&;#VV@K?!*<[W4,2H1DV3&07/)XJ ZD06+83/ &=S]L
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M9DC13O$K=EOF>.E"WHCXR7*&P!@:J2P6^_J,5Y.DWYV7@!;%5YL.>!4PAN'
M[>&-K?+GK^0?+GPH[!!B&4GB&G%\7(^T13HKY(/\M'R"]V?57.5LYQV 3IUB
M<QNZ @+T<+:;U*FRBLN5)11Z\COD!>E;A0<5I+A R2@E&')*)E)M]WZO^ Z,
M=+ZH7@S2;&="CM ^&L <!4RN.,#6 ^T%J[E/@*_I28)8,#WVM&@SN"Y$(RV
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M)K&J/]HHZ<AQBMP5+8(F5">_D=#%=9*Z64YR#Z.!W$MU4/K(#FK_KP7LRU<
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M=#),VM*78K&U%;KTKJH.M:=!]GS_>WXF6!;B.,5$GL(;&=,8 WOF50']FN^
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M,:IAH(;<W"M@MG6S65T==%Y?&UDXV(*7CK@QZO$FI''"AC2/65 +]Y\&[[5
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MO-Y2*ZL3X6 ^W_^>Y4]TDUKQ+FH[IHG>B6RL[H(W<KOAC?P% X85GP/#AE7
MN7+S@YZE.\[._K!]^NS2J.X;*_/K3VU$J_<'5(NF=DLX([D:9G^9B=:#L)&[
M,/7X#IP3VTYL1+6178A6:C.LA>&&NMDM4#>G=:& <?GGP+9R.6C]?LWEB45K
M9D\MVMY[8W&\X]K*(LVIS1CA@6!F]4R2B#:>KR /EVL) W #IA]E1O9BK? >
MO W63;1#N\CU%5TT1UDGLZ&LLWK!@'GI9Z#QN^]O#WZ^>/_QCY;T7_O"U_GH
M^T3MU37%PM,[4(S#X532OA0.?J9 A)XHDR'&H,JJ482Z<@2M+1_&UI8-X74E
M@T0]9(!B*!J@&XOZ&0L&;-]]^F/G)Y\?/?2W#P>O?+"RZ<<O FH?+4T27M]4
M2#_G#R.<B,:C#V?0X/L+6)5[2[AELQ6"DAF8L'@:45,XA1873&$E^9-X:=XD
M498[09'G3% 7##1__,^S,V^_.W+IKY^Z'GVX5@\6!=;\N"J!<6M'#OYR:"GR
MW&XX]%0&IO1X'J'H*(1<<*2<FG<(2LLY!&-D'T0RL@Z@F9G[L=49^_&L]#D2
M.^T57!K^\Y_&#K_U%_>#OWUI!/]>+P;?^S.?;8@AW/=/1=Z,RJVXFE1<="F]
M/.]"+C3[7!$L\VPI(OU,!3+M-!25>AJ&3CF%P"2?0F&23V*P22?QN,03A 4;
MGWGS]VVGWWK7!-Y;) 6?K:T&R[V)8-LNY).0V/*',<F%=Q,SLF^G9:??S,E+
MO5Y0D'P-4IAXK;0XX6I%\>ZK4$C\%5A)_!5X2=QE9&GL9<QS90L%Y.L^ %*?
M): F;#N01H0^DT<EW9/'%UR5)<//2K(I1T4EO#D^0C[-(>K&64SK")WC&*0(
MFOJ)8G<?3M;:BU&V]:*T[3T(0T</S-K97>7L;*]J7)#?&GYK^*WA?VF#XGF#
M]U)0LVL[D(6% D5DXCUE;/Y512+LK"R#?%1<Q)L35LEG>#C=.)MF':YF-PS2
M^*Y^4DU+'U[:YFEH[T%I.[L1QJYNF+VKO:JAJQGF7)"?&\2AS^\/0H J/.&^
M.BKOFCJ^ZIPJA71,GL?=+RZ3S0A1NG$>R3K,KFX88'*;^RC"UEZ"I+T;H^CJ
M0FF[.^&FG@Y8?6\3S-'K@#MZ%@(HUGX 9)X&2<CS=_\A0+-K]P-M1.[UVACH
M>6TBX;@JBWU 7BS=(X;5C@OQUF$>K6& Q6[NH_';NHGBSDZLHJ<#5=O7CK ,
M-,'M W9$7;\%4=^[$$#YO,%K*9 &/W_W'PRT(;L?Z,)R;NBC*B[HX_$G:M.J
M#ZKSQ;/R"LV$!&T>$9(= [SJYEXFM[V++.KNP,G[V]"Z03?2.FQ'6(>,2/N
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M:C<B7&WS!20_-4@"UP!EX Z@"0H!NM#=C_016;?TL:67=4FH,]HLRC$EA'M
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MP+1U$W!L\0;N[<%W>[PC+H^&1)^>BX^9W9.4/S":@6KNS6-:VHLE*E>Y3N2
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M@L':D:(A[7S\UO!;P_^OH=K3P/0T"#P-PFA?(-H=^528FG*?EY-_@PVIN,2
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MU-9#S09K9:/17-ECTD'[3!I8GU$![S?*X/V&EWG10/,T"+=]!A0[O@=:KU5
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M)C O^I]G+1^]>7[JK_\]=>;]-WJN+WJ_Z>:*;TS7-ZZ37]OIP[T:&$Z^&IZ
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M&AP<UA05&=B8&">JSTKRK-N;RJO=G^Y1VY[)KCV9R:J[E>%1_4\&K^)^^M]
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M($<>SD::)U;)57_8OJ#X@\Z:S ^F2O$?;#7"/CCK^T\0S(035!OV!,N1,2'
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MQ*BE7R,8Q@W0K$(O<3#BBYYX[_-^%-ZY8'?6V6@._4P*GWPZ3T@\7>&-.WW
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M3FIJP"#JWHP.'420^N/H_ L(DG$+06*&I)$P6"3E!ZND!;!9E@6[%*B@/9<
M1@NP8+G$ >R7V0)VA2405YD!;8T)L-<: G^]/OANT 7)1FV(VJ0!R5O4(&_K
M;BC?M@OJE7;"0245.*&\ T[.J.$H.O\,.O\Z@D0_0I"@[PJ(-RR0XL!R:1JL
MER& DIPSJ,K;@XZB-1C-,0?+>29@-]\0G!?J 7Z1#I 7:X'[$@W@+D6KXK)=
M$+!<!<)7*$/"RFV0O6HKE*S> M6K-T/SFDW0-J.RD^C\ 73^/PCB/X(@ I!%
MW&$>0H+%4EAT+>QAHXPE*,N:@JJ< 6C+[P$#!2TP55 '*T55L)^U"YQG[0#\
M;&4@S]X&[G.V '?.)O"9NP$D\]9!U/PUD#)_%>0L6 FEJ/*%,P$G%1FPTY(#
MK+8\$/8H M5\/M =E@.5L [<6%N!X*T"+J%J@$G4 H<<7; MU0>;&D.P;C("
MJPX3L.PV!8M3J,MF8'[7',Q'4>\MP/P+:MH"T)^_6X'Y)QNPF+"=&6!VR("#
MYK\G(_+@IJL(=-/YX&Z_'!CX=4!UWPINGBJ #U(#ESAMP&3M 8>]!F!7902V
MC<9@TVX*UD?,P*K/'*PN6(#E3=1S2[!\A_J,^F7YRPK]G2U83MB!U5O[F?V7
MP4E=%@@:<D#15OSOA(AMNQQ8N'7 H&\%JF GD +5 1^C#=AT/< 4&H)CI3$X
MU)F"7:L9V'69@^T)"[ Y:PDVUZW >@CUQGK:>LKZ)_KCJPU8?;!'_\0!;%XX
M@NU,P!G-@%65_>]4@J&I !Z&\X%GLQQX+NN 3=D*#.Y.H/JK RE2!_ I^N"2
M9P3.9:: V6\&CDT6X-!A"0[=5F!_RAKL!FRF[1[9_+![9?O-;M+VL]T/FX_V
M8/O&$>Q&G,#^*08<9@+8[3* VR7[WZD$6TT!!/^>$%DM R_GM2!PVPH<]DYP
M]]4 6J@NN"48 "'+&'#%9N"RS^(WMM[JEW.;]4_,8=L?3KUVWYTNVGUQO&,_
MY?C"_H/C!_MQI^]VKYW X9DS.#[$@M-M%\#,!%S0#$0566#LD />;@7PT9L'
M?A9+P<]Q+?@0MX#0704\/#6 *=&=IL<8_J2DF7XGY5M\)919?<;OM_F$:[*;
M=.VT_^ARS&$">];Q/?:&XUOL<\=7V/>.H]AOF"'L;^>[KH"]C@.7R_B9@:NR
M#)"598&-\MHE#V+=N2 Q6P(2^]40@-L,(MJ.:2%7_3O/7_<+.\)PRCW)[ ,M
MV_(]I=CFG=L^NS?$!H<Q0IO3*_P1S M\O_,(_JKS,_R0\Q/\./8^[JOK3?PT
M;H#P&W^.!/A^MYD!#LWP[\D(;ZLLB%3D(5A[#H0;+X)PFY40BMWX4T+>_L6/
MK?;1VT=W7!!L]-HCUNPE*]UZE)%O]XQ6YC!$V8]Y0F[&/G0[Y'*?U.MZEW@)
M=XOX"'^=]!9_A?2%>($T3>HG3Y..4Z;=CE)G!G@E&6!NEOGO;^,#M\M!A.9L
MB#%<"+%6RW]&.ZW_%$'8]CZ8L?NU6*@]ZAM@..P9:?Z8EV1SGY/M<(=9C+G)
MJ'2Y3J_'7:6V$2Y3CI(N4LZX7: ,NIVAO"3W4Z8H)Z@_*4=H/ZD=C)_4-L9/
MRDR A+8M#MI"?5$A:/N+45>$1/UYT\GF2S\GV:]Y'^^Z^5445>59*%?S<:#(
MX(XHQ'S0*];V*C_-Z1(WS^4\IP1_EE5-/.5^@'R2T4DYP>BE':-?IG?3A^F'
M&1/T#O?OC!;F=\8!UG=Z/7MF0$;7@+=>!L1H$XU \R2J*D":[IQO&2:+)C)L
M5HRE.J]_ENBF]"":K7$SU,O@2F"@Q06_2+LS/HF8DYZ9KB?X!<0>;CGYB$<M
MM8O=2N]@=;NWL\XQ6UGWF4WLM\Q&]E?F?H^OS"KN5V8E]YO[3("V41J$: .4
MK$/;SQ892-TI-YVE/6LJUW#^FUS+I<]S'%8_3"=L&TQ@J%^.%AB<#?6S."D)
MM3LFCG4^(DK%'?+.(1WTW$MM%531FW@'F W<0^PZ;C]G/W>04\U]Q=G'^\PI
MXW]FEPB^L(J%,P/&!FGP0IMX")HC?I,T9.R0_9ZGH3!1I#?G9;'IPB>%MBMN
M9;MN'4BEJ9U)X.KW1ON8=X=)[ X%13JW!R3BF_TRW!I\"VBUWN7NU5YUK$IA
MNT>Y\#BW5'B%MU<XPBWRG.(6>'WRR//^S,GU_LR>"3#1Z_=%6W XVD23T#S9
MRC*?BU3EWI;J*#ZK,)Q[K\1R^=4"[.9S6635OA2VWM%X3_..:+%=2WB8<V-(
M++Y6DDJN$N?2ROU*F"6B&DZ1;PLWWZ>;G^MS@9_C,\3/]OW(RQ1-<3-$GSS2
M19\X,T$_@DB#WW)IB$1;<.IZ*?2CA_1DZ4[95_LTY)Y4Z\ZZ66&^[.)>S*;^
M/-+N[DSFGLX4@5E+O,BN/CK8N3HB"E\1FD0N"<ZB%TJ*F'D!^SC9X@.\#/_#
M@C3_L\(4_T>"9/%[?G+ )"\I8(J;&/#)8R;@@>Z#&&V@,6@+3E\K]:MPD_3[
M"F7ID?V[9.[7:2I>K3);>K;,<>/Q(N*NKES&GM8,GFE]BH]M=4(@ICPV E\<
M%>^6'YY.SP[-9Z4'EWND!-7S$R6=@GC)*6&LY*XP-NB=("9XDA\3-,5#<6<"
M/+2)2Y9*0=P*M(VOEOJ^=[W4V^HM4D,-2M*W&M45+M6:+.G?9[_A:"E^9WLA
M3;<QQ\.T.L/+ICQ%C"E*#,7EQL6X9<:DT%.C<EF)$:4>L>&U_.BP@\*(L#[/
M\+";GF'A;X3AX9/\\+!)7GC8%'<F($";>#":(1%MXKDKI#Z7KY9Z5;=.ZE'+
M!JGKS6KRYQJ,%Q^OL5M_J-)5I;F$HKV_D&U2D2NT+L[T<\I-"\9E)$>Y)2<F
MT>+CLYC1L7L]PF-J^"'1K<*@J!.>@='746-"2?1'OB1JDA<4.<6="7BBLT/1
M)IZR%(&"9<C'?<N0D0/+D;OM:Z0&VG;+GVHR7'2TWF9=6XW+COH*LM:^$J;1
MWD*^56Z>KV-&ML0U.3."%)>60(M,R6"&)A=R)(E5/'%"L\ OH<?3-^$*ZJ50
ME##)]XN?Y/G'37%G M[H&D2@;3Q],0+%BY'Q_0N1IVWSD<'.5<CYCIUR)]KT
M%QQJLEK35.^L7%U#TBRM=#?,+^-:9NSU=D@N#'")S0\C1N3$4D.RTMP#,O/9
MHO0*KG?: 8%GVE&A(.T2:D0@3)OD>Z9,\;R2I[@S 1$Z/WHA ED+D:]E\Y%'
MC;.1VQUSD('#RY%3AW?('NW<,[^MW7)U7;/3MO(&HGI!+5T_L]K#/+G2TRZV
MS-\YHB0$'UP<3187)M-]\G-9PKPR#UYN \\C]S"?G7L!]0PUR?/(GN)R,S]Y
MS 3$"Z4@?@$">?.0IU6SD-O-LY"K7;.0<SU+D.,]2C*=1W7F-G:9K]QWT&%+
M<2M>-;N)NB>E@6T:6R>P":\1.055!;GZ5T82O2L2J?RR;(9':0F+65+'890<
MXM)*SJ*>>M!*/GC0BSYSW MF!D'S$4B>A[PM5D3NUBH@5]L4D?-'%9"^WD7(
MX;XMTBTG-&?7'#-=5G+4;F-NE^O.U ZR=FP[TRB\A6\I:?*Q\SL0Z.S5$([C
MU<>3V+695,;^8CIU_WZF6TT'BU1SFD7<_YA%K)E@D:J^,MTJ9@;A<Y'IC%G(
MPW)9Y'JC/'*N0Q[I/2:+'#D]'VD]LU&J[K2Z8EF_T9*\/IMU:<>QRG$])/7P
MHPR]P,-<4]$A+RMAI]B>VQ&&8;;'N=+:T@GDMB(W0FL-!==ZD.;2>@KUD(IM
M>4_#-O^@N3;,#&)G(<_RI9";U;+(A18YI/>P+-*%]N^6BW.0NLMKI2HN[9(O
MN*B_(/V\U:JXLY@MX:<)NP+[:5J^)SGZ@EY/$\X)?TOWXR&VU&.QCJ1C:<[X
MGD(7EYYJ'*:GG>#4TT]P/':?X-@]3G X^IWHT/6;-),?*=+(O1($N5PO@_0=
ME$&ZT/[==$86J;FFB)0-+D?R![?+IM_0G1MWW7Q9V%6']0%7<$H^ ]3=_,ML
M3?8EX1[Z13\C\H5@4^*%&$O7\VG6SN<+[1S/5SO8GV]WM#O?[VA[X;ZC[?EQ
M1YNSWS'69\!Y)D.Y"'*U"D'ZFZ60KBYT?I\T4G51#BF^-0O)?K@827VT53KV
MH:9BZ .3A>+[=BN]_G'9P+U'WL:\RU2AW1&HN=T1:>%O!^NZW([1=[J=:NAP
MN]#$]G:UJ?6==C.K._WFEG?OFUG=?F=F<>N+A?G-WU8SN8FNP=EZ!#G2CB!-
M_WXKX*PT4GA-'DE_,!M)'%DI%36J)!,TJJDH&C%:(!BQ7L8>P:RACQ WNHTP
MMA)&N,HNS[U5,,\#=SN,1*K;C21K6H_D:EN.5.B8CS;IFHWV[#%]<04UNL=T
M9$K7^/E/O9E<J$&0[A8$:3Z,SD?[;\%E:23UCCP2\WX^$C:^1DH\KBSC]5Y3
MD?O><)[[>\LEY/>.*_#O<:M=)BCKG298&^TG!%ML)_RV67T(43;_$+O#]$.Z
MBO''HEV&'VMVZT^VJ^I-GE3;,S6(>J6F^W%J1L<:$:2E T&J3B!(_@4$21Z4
M0B*>R"&2KXL0WZ]KI?C?E&28W]3DJ=_U9A.^F\UW^6&[R.F'\U*[G\3EUC]I
M*RU^<E:;_1*N-?[EO\Y@.G2#WG3\1MWIK,W:OTNV:/ZNVZH!G=O4H5])#6XH
MJ<+(C-K:T/G=Z/PSZ/QK"!+V$$'\)Q41(2Q"V+!:B@I;9 BP4Q8+6O(.8*B(
MUN<YEF _SPRP\XV!N-  :(OT@+U$!X1+M<!OF3J$+E>%^!6[(&N5"I2NW@%U
MJ[?#P37*<'RM$ER<40VZ!P7]Z/P!! F]AR ^SQ'$XY<"0H<%"!&62V%AO;0]
M*,E8@:JL&6C+&8&AO#Z8*^B"C:(6."EJ@.LL57";O0L8LU6 .V<[^,S=!D'S
MMD#,_$V0OF C%"U<#]6H XO60>>,BGK1^1?1Z[^-(-[#".(^CB DD$&P,!>Q
MA\52EK!*R@0V2NN#LHP.[);1!"U95="3W0G&<MO!0DX);.6V@I/\9G"5WPAN
M\NO 76$-\!16@4AQ!80J+H,$Q260-6L)%,]:#/MF!!:[9<!"4Q;L4$ZZ\N!L
MI @NMO/!!;<,G)FKP=%[ ]B%; 7K!&6PR%8!\[V[P+1:%4P;U<"D71V,CVB
M<:\F&)U'7=<"PR'4&VTPG$+]U 8CT/J-^F4,VE],0>?S#,!REPQ8J<N" \I9
M6QY<#10!;S,?<*[+P)6Q&IP]-X*C9"O8Q6X'ZXR=8%FT&RPJU<"\7AW,6C7
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M?C3=</;C5.O%-^-=U@Y$497.A7JHG0STV7/,3V)\Q"?2XI!7HDV[(-.AA5>
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M8)V@SL-E(9V'9X2T']X3TK[_1DC[WI>?;"#/P<1Z(.<?H&GO/_F99P%B?Z-
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M>#_V4'@^35*Y/RU1N3X?(ZX3C_ZE<QZ@FMQ_+LE/(+,/)O?N>@G ZBJ _@T
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ME=T1%2#8'!DEWA">+%D;EB5;'5*DM#*X4F59T&2UI4%3-18'SM1<%#!/>V'
M(IT>_U6Z\_VWZ'?['S3H\K]H,"?@5X/.@.<&LP*Y(?0[_@/G35-V,'E.FMJ_
MC2?/E\C#^40A3B8HXF"B 78G63%;$YW8#0D^@C5Q8>*5,?&29=%ILB61><J+
M(DI5%X97J_>$-6C.#VO5[@KMU)D3TJLW.V2904?(!L,9(7N-VD/.&D\/^<FX
M-?0/HVFAW!"&+6'O,/C(T-+R!_G_'VB9^R(9.)?&XD0:'X=3I-B=IH,MZ998
MG^; KD[QY"]+#A8O3HR6],4GRWKBLI2[8PM5Y\94:'1&UVG-BIJJ,R-RIEY;
M9+=!:\02PY:(M<;-$;M,FB).FC9$W#2=$OG$9$KD6^/Z*&X(HT_A H#?J ;?
M)9'7(<]U(HL\7Q:+/9GRV)JEB?799EB5-8X=R'3C+TH/$/6D1DCFI23(YB2G
M*\]*S%.=F5"JT19?K=4:UZ S-:Y-KREVKD%#S"*C^IC5)G4QVTUK8HX/JX[Y
M;EA5[&/BC6E5'&="&'_*NW:()>^?2MZ?](_FDN_- [;GBK ^3PVK\H=A(&\,
MLRC7A;\@VU?4E14J/SLC5CHC/45I>FJVZK24(HWFY$JMAN3).O5)T_3K$F<;
M5B<N-)Z4L-*T(F'KL/*$H\/+$JX-+TU\2/QM6IK(F7S ^".O0JDO)E _R"#O
M3_H'"\GW%@&;"LC[%Y+W+S+&HB)K9D&A(V]NOI>P(R]8KBTG6CHM.TFI.2M#
MM2$C7WUR1IE6;7JM3E5:LWYE:H=A6>H"XY*4Y:9%*9N'%Z8<&E&0\L6(_)0'
MPPM27P\K2.5,"9-/^3V"O#_U@POD.X^1_MX2\KWDO=:6,%A>JH3^,D,L*!O%
MS"T=S^LH]A"V%07*M11$*#3FQRO6YZ6IU.3DJ%7EE&A69%?IE&4UZA=GSC L
MS.PVR<\8&):;L7%X=L:!$5D95XA[([(S7@W+SN1,"9-/N1]-WC^-VH'J?XCT
M=Y+_W4C;GI5T75PA0T^E'KHF63(=E?;L] HWP=0R/W%#:9BDKCA65EV4HEQ9
MF*565E"D69Q?J5.8/T4O+Z_-,">WRS@K=XEI1L[ZX6DY^T>DYEPB[HY(RWDY
M+"V',QTB/8<S^<A=&@]?T7;K)-5@/^EN(^^WEK:  W3MK9:BJT8;LVK-T%8S
MEIU:[<*?4N4CJJT,D5151,O*RY.42\HRU0I+"S3R2\JU<THFZV463S-(+YIC
MG%K8;YI<N'9X8N'>$0F%YXD[=/]B6&(!9YI4P)E\RL^)P&7:>AZC&NR91/V@
M#EA%'KB/KEV3)>BHU\#T*<,P=8HM,Z7>B5\SV4M861<D7U8;*2VJ25#*KTY7
MS:W*T\B:5*J57EFKFU(Q53^I?+910GF?25S9FF$Q9;N'1Y>=)7XEG@^+*>5,
M"9/83_B!QL/Y?&J'"F!'+?G.!F!9$]#="'0TB=#:K(KFJ<:HGVK%U#1/X%4T
M>PA*F@+$A8WADKR&.%G6E%3EC/H<M=3)Q9I)=57:\;5->K&U'091-;W&$=6K
M3<*K=YJ&59\>%E;]LVE8U3/3\"K.)'P29_PIWU [G"H&]E63[R3]P1;R?=.
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M7T+RPT,HW'P!A1NO_Z&;]*>O!6JV  64>S+E'4;:7J> \>< JTO \"\ @VN
MQG<,E&\*H71'"MD=%4CO:D/AKC$DOUE _IXMY.XY073?&X+[X>#?3P'O?@F8
M^\W O04$B=RGA]__DO@->/#X']KI6W5#9U![@90C0#AI>Y*V VF/)FW3KP'=
M[P'5'P#9SX#"(Q;RS^4A>BZ#X+D*>,^U@&<&Q'#"BG  GGL0(01M"I[30O2<
M)I_G-.!>D-@+$OKK#/'Y/]1O_7 &16T>037W(FT'TA[Y/\#X.J!U"U#^A;3O
M "(*F_\*8#@>;83%A!1XJT2HT;T.84Q8$&.)B40@08LB1YLBCNK!4>?C:-!Q
MU.C<SG_@]$80P^@1Y'75S< I6X%3<@0G\V4X:23#25(93KZ0J"*:B'9B#M%#
M+&8XN>7$(#BYC<1V8A]Q'&_E+N)ON9MX*7<?S^2>XP\Y#D_E.3R1YY@GDO\+
M9V@*SM 8G &A3;%HCJ)8',"I>E$\80RGE,1PLERB@J@G6HE91#?11RPE5C%O
M9>N8OV5;F->RW7@E.X*_9.?P3/8]GLKNX9'L&1[(..:^(L?<&T*)8W[[!,[$
M$)P)>7YCPI \MZ$%U64<U<6-X@EB./4XAE/+9#C5$J*&>:O:S/RM.H-YI3*'
M>:G2P_RETL\\5UG./%-9P_RILHGY0V4G\T3E$/.[RAGFH<HWS&^J=YG;JL^8
M7]0XYB<UCOU1_3VW/H$;K@MN!/G_81K@AE,<(ZA-AME03$X4CQ\X_2CFC6XJ
M\U(GGWFA4\G\J3V%>:K=RCS1GL4\UI['/-)>R#S07LK<UU[%_*:]@;FKO9VY
MHWV ^57[%/.S]C7F!YV[S'7=9^PWNAQ[38_C726^TN/X7WX"9T'ZEN3_+53
MC=(BJ$U&C:3/#GACYHD7PT.9/TP3F,<F6<P#XQ+F-^,:YHYQ$_.K<1OSBW$G
M\Y/1 N9'HW[F!Z/ES$VCM<QUXZW,=\;[V&^,3[#7C+]BOS"YPUXR^9-WWI3C
MGS7E!&=,.>'I_\"-(FTK17 VY/O'JA%4ES'#\<K&!D^MG/%@E#_N6$8S/UNF
M,K<L\ID;%A7,=^:3F?^9M[#7S&>R7YEWL5^8]_*NF"_A739?Q;MHOI%WWGPG
M[YSY$?X9\XO\4Q8_\8];/A$>L7PK.F3)B0]\8+\E)_<1SH;TQTC V4O!C:<X
M)JCCI8,!'MN9X\Y8.]P:XX'OQX3BFFT"\[EM%GO)IIB]8%/%.V<SA7?&>AK_
ME'4'_Z3U/,%GU@L%QZT'A$>MUP@/6V\5'K+>+SI@?4:TS^:&:+?-([D=-J_E
MM]EPDBT?V/P)W%@%TA>"<Y:C(:V -RY*>.RLCE\F&.+[":/QI:,S+CGZ,V<G
M1#$G)Z2PQ\?G\HXZE/(/.U0+#MHW"/?;MXKVVL\2[;'K%N^RZY?;:;=";KO=
M!OFM=KLD6^R.2S;9796LM[^GL,;^+^F@/8T@!TZV\C]P#B)P3BPX-QZ>>@CP
MFX<<?G65X9N)&KCL9H8S[O;XS-V+.>P>RNYWB^?M<4WG[YJ8+]SN4B[:ZE(K
MWN+<)+?)N4U^@U.G9+U3C\):IZ720:<UTE6.VV0KG0XI+G>ZI#C@=%MIL?,S
MY7YG3GD1T?<?.$>&](''WN3Y_,C_^PGPE8\<+GJKX*2O"0[[V6*?GRNSTS>
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MV:9M_!&;3O%';/R%-WS],_[P=9Q@^-I_64OZB^<"\\@:MRX":@?(_ZX$4M<
MD1L /[*&+MN <3MYL-XMP^C=&ABUVP@C]UC <L\86.QUA/E>3YCM#<*(?=$8
MMB\5IOL*8;*OEC':-X,QW+>(T=^_D=';?XS1V_<#H[?G*:.[^V]6=Q?W#\M(
M?P'E/H-J7D]VM(2T,S8",:0;0);4=0]@MQ\81;9]V%$A##^30O\S->A]9@#=
M$R.@<\(:VB?'0^ND.S1/!D#C5#343Z5#[70I5$\W0>7T/"B?60VE,_NA>.8J
ME$X_@M+)5U ZP?W#PEX:BU3W1LJ]?#V- _+A<;N 0/+B;@=)_PAY\.. Z2E
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MSMP0"C,^@7.@Z9?TK]/T?IG\[RGBJ ^+ YX*V.FEC<W>9ECG8X?5WN[,<N]
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MC7?4+W__'DX:?2N2M+TIW_&D.Y)^S)AT-4\#2N< ^8L ^SEI7R7^1WQ#?"<
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M:Y">NXE4=U&ICE+)+E+I?L(/]-,W*?J;],0;'[C^ 4Y)%9R4/+]0"1Q+L<"
ML"#L"0_2#J'\XBFW#-(J)*T*W$,=Z33A#J;C5\PBK2Y2Z26M):2UDIZ_'M]A
M.W69@[B&L_CRW4G(0WR.E[A"3[U,7/H$3EF1:D&>7X&0J+QO%W88?<>&:NQ,
M>?J39B3I)9-6#ND4D\XD>FH]OL=4ZB9M^!JSJ:MVDU8?Z0R0QAK*?@O.4WN<
MQ4F<IDY\BIYR@BKY&3WY.,/A&/LOG)J$:B$DY @9Q4-M(F^ 9T(+W.?;XV>>
M!W[@A>![?BR^YJ?A*WX>/N>7XK*@&A<%4W!>T()S@ADX(YB#TX(%."E8C,\$
MJW!,N!%'A+MQ6/@9#HJOXH#<;]@K^0N[%3CL^@^<)I_B(/^OP:,KQ:$LPU.9
M.NXJ&..FO!6^ECCA<P5?7%0(QSF%!)R69N"DM "?2<MQ3%J#H](&')9-PR%9
M!P[(YF&_K ][9<NQ1[8>NQ1W88?B<6Q7NHHMRO>Q4>45UJMP6*?*8>TGO/O?
MRW1IV!#W:7C_JB;$KU2/;V6:N*(\ F=5QN&DJAN.J@7BD%H4]JLG8Z]Z%G:K
M%V*7>CEVJ-=BNT8CMFI,QQ:-V=BDL0 ;-9=@O>8:K-7:AC5:A[%:ZPI6ZMS!
M,IT76*K+,4L^L/@#' WE%S2MW*4I[L9PFH*,&5S1%>.\IC(^TS'"(;W1V*OO
MB)T&WMAF$(K-!K'8:)"*]88Y6&=8A#6&E1@TK,,JPV:L-&S'<J.Y6&;4AZ5&
M*['8:!/3;[R?Z3,^S_2:_,(L,'W&=)MRS#RBZQ.&SH'N6Y"^%4VU--V?H:GV
MN!D/ATVDV&.J@VW#S;%IQ#BL&^&&03-_K#2+P'*S! R8I6.)62X6FQ5CD=DD
M])G5,[UF+4R/V2QFOMD"9I[Y --EOIZ98[Z;[;0XS<ZR^(&=:?F4;;?DV+;_
M\*<Y37NVP!<TM9ZB:?X07??8D/<<*8>-H]2P9K0)5EI98\#*$8NMO-!G'8Q>
MZV@LL$I"MU4&NJSRF;E6I4RG534SVZJ1Z;!J8V=8S67;K?K9Z=:#O&G6.W@M
MUI_QIMI\QVNR><QKL'U+<+PIG_"0<O_> 3CG AR92'[+&=A$L:P=R\?*,<I8
M.DX?B^PLT6-GAVX[-\RU\T>G71AFV<5BIET*TVZ7Q4P?5\BTCJM@6\;5L<WC
M6MC&<;-X#>-Z>?5V*_AU=EOXM79'!#7V5P75]@\%DQS^)CC^I]RQHV6.]$]X
M /MHJ=M$U]44RS):@OO'R[# 41M=CB/0Z62+#B<GM#MYH=4I""U.D4RS8P+3
MZ)C&-#CFLO6.)6R=8Q5;X]C(JW:<P9_D.)]?X3@@*'?<*"AU.B@L<;HB+':Z
M)RQV?B4L<N8$G_(3:5TDW2/DO[?[ 8,^P%):9A:ZDN>:*$&GJSIFNAICNMMH
MM+@YH,G-#0UN?JAW"V7JW&*8&M=DILHUDZUT+6#+72MX9:Z3>26NK?PBURY!
MH>L28;[K>F&>ZSY1KMM%48[;7>*E,-N-^XA@B.N4\QG2W1](-0@BGT$^?"'%
M,X_BF.4I1ING"EJ\#-#H98%Z[W&H\W9!M;<W)GD%,15>D4R95SQ3XI7&%GGF
MLH6>I;Q\SQI^KN=408YGIS#+<Y$PPW.M*-UKCSC-ZSQQ6YSJ_9<HU9L3I7ES
MPC2O]WSM3NTP= XU= 8T=/Y"/KR;XIE-<4SWY:/95PE3_'10ZS<"5?XVJ/1W
M1)F_!TK\_9DBOS"FP"^&R?-+9G/\LMALOR)>IE\5/]VW29#FVR%,\5LH2O8;
M%"?Z[2+.R"7X_2).\'].<*($/T[XD2^\@:-#[P'1EF<5>?"%M 7KI'C:J![-
M 0PF!\I0':2)BB!3E :-1G&P/0J"7)$7Y(.<H& F*RB2R0A*8-.#TMG4H'Q>
M2E %/REHBB A:(8P/JA'%!NT2AP3M$,<'71:+CKH)^(9W7.B(6*"..$0%ZD/
M'"+=K='4#K35F$_;GID4RU2JQV2*I2I4 66AZB@.,T)!F"5RP\8B.\P9F6&>
M2 \+8%+#PIGDL#@V*2R530C+Y<6'E?%CPR8+HL/:A%%A\T4182O$X6';Y<+"
M3A(_$G_29TX4'OH.X1#GJ.[[27=C++ DAO;Y%,MTBF4*Q55%L91%R*$P4@5Y
M4?K(CC)#1I0MTJ(F("7*'4E1?DQ"5"@3'Q7#Q$8ELS%1V;RHJ!)^1%2M(#RJ
M51@:-4\4$K5<'!2UE?A,+C#J![F@J#_$09&<:(C@2$XXQ"G*=0]IKTT ^H;.
M@.*H!A1/#<511O$4Q B1$ZN$C%@=I,4-0W*<%1+C'1 ?[XK8>!_$Q <S4?%1
M3&1\(AL>G\F&QA7Q0N*J^4%Q+8* N+E"_[@!D5_<%K%OW#'B!O%4[!O+B?S>
M(QSB..6Z@[17)9'G3"2_1310/!442R%]/3N!A[1$&9*3-)&09(RXY)&(21Z'
MJ!1G1*9X(3PED E+B6!"4N+9H)1T-C"Y@.>?/(GOF]PL\$[N%'HE+Q%Y)F\2
M>20?$7LD?R?V2'HB\DAZ*_),Y(0?.4RY;DVF.2D5Z"([,(VHI<_%%%,V75/I
MZPEI"HA-5T-TA@$B,LP1GFF+T,P)",ET1U"F'P(S0QG_S!C&-S.%]<[,9;TR
MRWD>F0U\MXQ9 M>,?N'$C U"EXQ#(N>,KT4NZ8^%+NEOA!/3N'_8/W0>1Q:@
MGYA%-*6_/P/*)U(S@'C:ED?ER"$\5QDAN3H(RAN&P/S1\,^WAU_^1/@4>,.[
M( B>!5&,1T$2XY:?S4[,+V6=\^MY3ODS^1/R^P3C\]8)'/(."!SROZ+K(X%#
M[M^"\3G</^RBO-=F SU$&^E-IFLID45;\?@\\MX%Y'V+^/ OD<&W1 />I4;P
M*K. 1]D8N)<YPJW< Z[E_G I#X=S>3SC6)[!C"\O8NW+:EF[LC;>V+(>WIBR
M-7S;LGU\F[+/^;:E#_BV):_YML4<W[;H/4/O1*W(I_% >E.)*KHO)-(*R7.4
MD'XY>5^R21Y5$KA6J\"E1@_.-</A6#L:$VKM,+[.!0YUWK"O"X9=733&UJ7
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M;+\-)QG'<<9QC'$<P23;G<9!CLE^[& 4A[";O[&+F=F!-[$=7W.D_L C5'Z
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M^.<PY3^+;60<FSR4MP@KEJ,MG'I;F(O-;' SW>_F7?PY1V@31VCC/?(5ZCB
MQ<QW.O,=T\TC@WWV6D#]">HOI2.?!G2HJ;:>NIL(T\F2G^4HV<E\[*)-V*VM
MO%)EGR&PWYQE$N,XQ#@4ITC%]K3B:],/,Q>'QP@;.70,.$B+?Y >Y^ 'LU?F
MY##?"4,\,MAG'\55.>RO!74--G#LMSZT(W. '"8T\301RET2#B].,2>GF9.S
MS,DYEND76+9?M)^[6X>GH4M< BYSH"_W$>;B,G-Q^1S?Y[RX]'<4<A*G+N08
M+ 98@,"50V9%74-^3&<_(%;LR)R8VY%YL#MR>0X.*PV5<M="<<?.=57@:>;D
M)L?F.5J'YQG'"RS37N2IZ"7.SY<XV"^/$";UY8/D47(=61SG.(YQB.+.J&U<
ME=A?(_95A_T3GYO3?&).XP:45Z3<QG_OU'FP2_+@VTON",#KG*__YM@H[(SB
MFUOO<8Y^P-/$ASP</^H@[/#'6PCGYT=GYZ[&4)V[(T-O]JX0.5TXS[,DG XU
M ;_0=?Z (GR'*KK5!GQ%I_<%G=YG=+Z?TOE^3 _W$3W>!_1][]-O_H<^]STZ
MS[<Y6(K[,/[)P%_GNZ_A/NY _M?=*8IO"GUAUHD+<SL"PNQ5&8HK5'ZEX_L1
M[O@>0=2,IEXJ/D$NO6,I[M%QOD?'^0[:\1;C^#?C>(-Q_(-QW&$<?Z>O_1M]
MZ4OTCL_3A=^BCWZ.27R&G[C!Z)^F[[].%05/D6O_LRORZ^Q5&?KX'.;LEQ/U
M?'&7N7@+\>Q'!F//9_ME3'_-[)49MV:_(:.'[0^R_1&VOXCM3G%ZK.4TV8+'
M.9$O,1>/\>]'V>/S;/4<7;@B^V?F./M0##_-7A4A8L9TF#LC]L>&?7&G5B!U
MHJB1Q/:S< 4%G!YEG)(U;+D1%SDNCZ*;[0_.7IEQAG&<H@<_R3$YSH/X*'-Q
MF#\YR @/<'3V<43W/71%QKZY&!3ZBKM2_CT[Q31P$Q+VQ9S]<&0?O*D12HT8
MMI_"MK-XF!3RT"S#$8[+8<Z/0VAE^]W8SSCV,H[=6,R16,4E9#-GQAXN*2>9
M%<4U*Z]PE#ZGJ_]M]FH,!8K_@UFA_S&47XSSW.RA)L(%YN(4Y\5Q6%/'E7WP
MIT8XVX]E^REL/YL]+&#[I=C*>;J%<6QF'!L9QP;&,8.%6,>YL89_K^(G5[*5
M%<S8U.P>U@=8RAF^%,K_"UK!%W/Z3_.0>G1NR3G,>;&7Q\@N'B/;84\=#VH$
M4B."<<>QY52VG\795T"-4DPSCA6,8SG'91GGQQ(,,Q.+^&<EQAGAV.QU*V>9
MH1M8P-D\G[-NF$?<?.HK>%<+>(;+RGD=:O-Q%P_M;2J*C7(MZAEP=EE0QXDZ
MWM0(ID8D->*ID4J-;!X-!=0H9<^KJ=-(C7:VVX]Y?#7(G@\P,WT<#\6]1-T\
M"KJ$-] E^A*=XE^)?):_*3:=#92;X-OYN%ZB_$>":6TQEJOJ8*E@A$G!&N,B
M%RP4^V)$'(KY*E$85DG D&HJ!E6S,:!:B#[5,O2JU:!;K1E=:MWH4)^/=O4E
M:-6808OF+C1IGD2CYA4T:/T##=I?H%[G5R*?Y2:7U%-<WG?Q5#-#EO/U)$^!
M8XQGH9X:%FKI8;Z6*8:T[="O[8Y>'7_TZ(2A2R<:G3J)Z-!-1YMN#EIUB]"B
M6XDFW08TZ'6@7F\(M7J3J-%;BRK]G:B4G$"%Y"K*)6^@S. ;\@>1S_*X%4]C
MB@M#;8$5MLK=D/E\;Y#Q]'&I[3/01(_$ )T2"[1)'-%BX(EF@T T&DC18!"#
M>H,DU!IFH,8P#U6&I:@TK$&Y42O*C/I18CR&8N-5*#39A@*38\@W?0)YIG>0
M9_8E^8/(9SG/T\IN1Y8"9-*)90T?>[G$=S*>-L;28JZ"9A,]-)B:H,[4%C6F
MKJ@R]4&E63#*S2)19A:'4O,4%)MGH<B\$ 7FE<BW:$2>13=R+$>0;;4"63P)
M9E@?1KKU9:3;O((TF\_);T3.UW*<=&9)H+@BAF78J!O[S<=VOFYF//6,I9:Q
M5%MKH\+*$&76EBBQ=D21M0<*K?U18!.&/!L9<FT2D&.3CBS;/&3:EB+#K@YI
M=AU(M1]&BOTR)#ML0J+C0?(8$AQ?0H+3I^17(N=K.G'J;F2YL<03F$>Z2!-?
MU_+]2L92QEA*'-11Y*"/? =3Y#K8(MO!!5F.WLAT#$*ZHQ1ICK%(=4Q&BE,6
MDIR*D.A<C03G-L2[#"'6=0EB7#<@VNT >10RMQ<@<_^$_,+G<KY')T[-M2PU
M)GSHQ$DKJ?.F/M\K96E8R+SDN:H@VT47F2Y&2'>U1*JK(U)</9#DZH=$UU D
MN$4ASBT!L6X9B'$O0+1')60>S8CR[$>DYR0BO&8@]=J'<._S"/.^33[B\Y^)
M?)9=U%O),F-4L2ODSQR0*CXOY7L%C".7,6:2-$]M)'L:(-'3#/&>=HCS=$&,
MIS>BO8(@\Y(BRBL6D=ZIB/#.A=2G#.&^C0CS[46HWP1"_-8AV'\/@OS/(=#_
M%OF0SW\B<@3[T8G[*<O@X4 Z0%)/RDDAW\OASS*8EQ3&D^BK@3A?/<3X&D/F
M:XU(7T=(_3P0[N>',+]0A/I'(\0_&2$!V0@.*$%08#T" [L1$#0&_Z U\ O>
M#=_@L_ )?I:\S^<_PB](/LMF:BT)4MP5Q7&@8:DF)7R>1S(82S)_'L_'F$!5
M1 7J0AIDB/ @"X0&V2,XR!5!03X(# Y&0' D_$,22";\0HO@&UH+G[!.>(>-
MPBML%3S#=\(C_#3<PV^2>WS^ SS#Y+-LH-8$=?M8 C>% 16DD&3Q=0J)Y\]D
M?(P(%2$L3!O!81($AIDB(-P&?N'.\ WW@H\T$-Y2*;RD<?",2",%\(BLAGMD
M.]PB%\ U:AHN43O@''4*3E$WR%T^OP^72/DL:]C^PG >#[1&]:2497 >']-)
M(I$1*=\+B:3OB-2 7Y0>?&3&\)99PE/F  ^9.]RC_> 6'0K7Z&BXQ*3 .287
M3K$5<(QMA4/L/-C'+H==W#9R K9QU\F[L(O]GOP)^Q@YIJ7*.\3:J%$=I=P5
MRB(I)):$RX!@EL7^M"L^<:KPC->!6[P!7!/,X9Q@"Z<$%S@F>,,A,0CVB9&P
M2TR$;5(V;)+*8)W4!*ND05@F+8-%\E9R#.;)UV"6]#;,D[Z%1>(?L$R48VF4
M\@ZQ9NI4S.T*I<<H=X5DU V-8\W/DMB;5L4M68!SBA8<4O5AGV8,VS0KV*0Y
MPCK- U;I_K!,#X=%>AS,TS-@EE$$TXQZF&3TP3AC,8PR-L$PXPBY H.,?\,P
M_1L8I?\.XS0Y)F*4=XC54:MD;E<HA<21"&H')K'_*?2>M(Y.M"JV66JPRM&%
M>:X!S'+-8)IK"Y-<%QCG>L.($]DP3P:#O!22#TE>#?3SNZ"7/P[=O/7D('3R
M+I-7H9O[!?D5>CER+*!.._M810JHET$2270R<Y *^-'4>V0"SCGTWWF 90%@
M7*P)@Q(]2$J-B 7T2^VAQP5-M]2?2*%3F@#MTFQHE99#H[05ZJ4+H%:Z&JJE
M>Z!2>@$J)2] M>0C\CW4BG_' +4:Y^X.RR6I)(Y]CJ!V8!:])^V12S[]-RVC
M92E@4@Y(JM2@4ZL#K5H)-&M-H%%K#?5:)ZC6>D&E-ACB6AF$6C92J[C<A":^
M=H!,T>#3J-;0L-4\P\E'OUO]#?EY]EN":ICC(I+)_B81&:UR"+5]V6<W6B/[
M,NK3+IK0/DOJZ<&;5*#1H@UQ"XN=5B/"$WVK'2<V%_8V+FAM/-#:F."V'.5M
M/VTT\FTT[VWTNZTTJJU/\83\-B?A5^2GV3O$RDD>22=Q>?_=%7*OH/^NICYU
MC>G/);3..K1JZMUB"+WTN+WTN'TLO/I8]/1;<G+S1#O@KKP4<H"3?9!)'6 G
M!FCL!VCF!]82&N?^Q_D[=\CG;.,^ZMC78L4=8B1I;E<HD'WVK 4<:5&MJ&M,
M;Z[?0P_>#ZC1([-H!$;4"(O14>9B(8NN,18\XRPX)EB +%)<FLK%;1$G^B)V
M;!$3N(B>>Q''8Q'-] 3-\SC-ZOB'_+UO44G-0I)6KKP[+*2.QR'[[-1.?>H:
M<RCUA@'-47K@"6K3KK(P!Z98B$\QCA6,8YKY6*DH1!G':BME0;2.)\-U')-U
MG'#KBI5?#;QNG&SFSVGDUSQ-.!ZK/T<9=;,99@+S'<Z4^;+/S@S9FKK&"ZD_
M"6@LH^;TW/[+#%%<H;)Q;D]DBQC8RF+\$1;FV_6!'9P?NS@N>UAX[.7<V,LQ
MV:OX^G8.ZMY!OK^:[">76,#1M.^^.WMECN(;>J(X;0+89S?FV8;]-::N[BKF
M?N:A_1?%7L@>L@_**U0.$MIW*/8HCM(0'-><NV.'1?I9"QH&QG&><^,\%YOS
MG&3GVPCGYGDV=HY.YCSGYKF_(;.;:_* \MMQ%'=&V2GNBN+4T6/*U+;/:1Z<
MVWM1&* S4%Z5HN "E'?L/-@74>Q37.'X7&-.KALHO[7D61XKS_(D^!R/U>>8
M]%N<5+=6 K?9\&TV=OL*DJDMI;8O<^W(/ILQ1'W^6/W0W%[/F3DMQ3]+/[A+
MY^FY_9 '=^K,WJ7ST'[(*QR?.UK*;V]]F^/R#N?HNQR3]WC W^5D^P\GUW_6
M _>8S'N*^R%$<]Y;/+?_H/C&$,4=,N[X$T%TI]'TI*GX'KGX!B6SWQ+Z.?W4
M)_1U']/7*;\I= 'NT7$IORET-=WU1OKGG7B#KO$U)NQ57*?;?1-_H\=[Z:$[
M4A1793S]_[LJ0X.:$OQ(?_<=G/$U?*DII5X\=3*HD4^W6,;V:]A^(]MO8_O=
M;'^0[2]@^Q-X@?[N-AWB<_29S]"UWJ!+OTX'?XT)NH+/Z*E__S_?#/KP51F*
MJR+N0X5]U*4S-L9[L,-;]+K_8BY>@XP:BF_'R&+:"YC^,MQD',IOR&C#5<;Q
M))WE$XSC\NR5&2OHGV=PGH[Y'"?M&3X[Q8A.XC^,Z$<.L?S_\-^[4C@T4-P
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MLG:B?PPZAJ"C9Y:E!M06E)CK/_@?)$%5XG)%HO+@/OG.$E*@EZ!"DP06^DA
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MPZ>_I/L^(6F^C"2_:9+L][HD^6^21/^#X#KX@M=_!_!N=$U$YRA2T<$LL;U
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MYEHZ[Z5@3R*?BP<Q@<X2%:B7R$"3A =Z2VA@((B0D* X"0Y*DZ#@/ D,+I.
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M]&>+N.7:B3;?69P+=>)09! [-8D5,9$4$;1%=%H17RB&6Q6WM1RS6@RG*)X
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M7<4VBPD]F\DTAXDFQ\^RF2J'+^3"K7+AN^9:3%\ @<B%^^<L!&0,V2? NPR
M;Z2:=K5%?H'Y'C!<!N*X%@E"$BPU*.]D8@ *;4"L+A,.DFTK#GF.8I//@E?
M@E+H9IG856&Y!%^4X(L2OE0"MRI1FPH@KR5PBF((3#'$I8BLK0@R4O@ ?".=
M:5LI'\]MK0'Q.@:$\3R0-ONDH1^]AFP1+2)="D0<:)ZT86$OA5N6L;B68T=;
M?-$.7[1G(FE/\+;'%^TS+3?8M%='KQ(3[<B0VI&MM25KK3@$[O'=;Z0].HI
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M?&HS. +> 3^8?S?\9?2-4;<'L_3WTI+>@/8J/=-84K42!QLIMG%"OBOR]5)
M;.03H_F,E3P)14\D.N+0D8*\3.06X)4R2<-+J?14"KV:3'\D,3(3B?H$60_4
M"<37P5?@'^8_>XQ ;S^6EJZ@@][RI[HBEKQ\KN=B3XZ+G60[.$N6K4XR;0SH
M<4>/#WH"T1.&GFCT)* G#3TY/"LQ5XGBZ,E8^B.&$1-M,TFB;&9A\1JP&UP$
MGX ?Y1FU!P>=O=2?YDC#RD$1R.5U%NER.N^EZFPDQ=5!4IPUDNRHDR0'HR38
M>TB\G:_$V05)K%VXQ-C'2K1]LD0Y9$JD0Z%$.+25<,>N$N8X0$*=1DJ(TXL2
M[#13@IQ6@9T2Z'@>?"2!#M_)&'0,0F<WTJ_VI!PE($_5/7B=RO4D;$G ECB]
MG<3IG"36U55B7/02[6*42&<OB7#VEW"7$ ESB9)0EP0)T:1+L"9?@ES+)="U
MBP1H^XN_=J3X:5\4'^U,L%J\M3O%2WL.?"!>KM_(2'3T0U\5J48%*7&AJKV
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MR6L3U]T0K8N! \79BF."@]@FL= D,YFG,-&E,=&D,WC2Z;1TOI0.MTIOK<5
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MNTZZ<L9KRY[#;?<U[1UV;..N9T^MVSGUS&HS_Y^N^/\;\/\WYS1/OS@3_M]
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MY(A/0(YY.)3&6B:MQ4ECM#G(Y1UV(KO3AN,=MY8)NZT864\-6M5C1%<>?]2
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M/M]R>XWSH%]GS8MH:DKKE=#L+S9BF_D&; M+CVME5./:J-7W]P\Z8@=61^[
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M<7M6T>7X@IR+2;#,<^FHM*%L3,J9 MR14\7XI)-PXN%!%.G0((9\< !+.3"
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M57@B&+$W4BKUA9$*?QBN]D.&0+C$& @76P*!8KO?/<KN&3YY$2CG30'2U8M
M1=SV6]R#J5>Y1^!GV4=I?:QB44=YF;:)2;;$F$Q7'955&R5Q/1&<P!LN$_G#
MI=) "*D(AN#J8!"F"P6+3:% L37H+K8%'27VP&@"*LB@_A@R? T9OET$A)"!
M'Y]ZE7<8?I:;0>]E%TC:6:6Z1A;1%F,Q7'7T<G>$S/&&"7Q_J$P8")5*@D&D
M(A2 :\*!$GTX4&P)NTLL84>)-62&V0*C"53>-Z@@@VP59-@>=TNP+_6JX !B
MB)]*[^7D2MO8"'T]&^^(L6FN*)/IB5#9OC"1%PAB*T(!M"0<0"HB?K@FZB\Q
M1#TEYJBCQ!RQP"QA(]P6'$V0X3&@^0@RS)T"Y)!!M"WNEG!/ZE5A/&)(D,3H
MX1V5MG)+#/6<,D>,2ZF-LAB>,*U\9"<5P G"P_LH'U)1YX-K8UZ8J=X!JXF9
M8>:H$6X)ZQ#6T&@"ZON&RCF08>4]@VAGZE7Q7L20\!"C1Y N:^45&NNY:$<=
MCU0;X="]809S>"<5]N-YT>%]E >I:/# =8T.F*'1##?5&^ U=54(<T2-M(9&
MTXA!.^V>0;%B$1!OW7%+$I=Z5;(+,22.9_0(DV4M@CQC/1_AJ!/@:R-\JB_$
MH@>'=U(^ C<V?!=4BU(TNQ#5+35P?9,>86S0(DVQ2I0YHD!90Z,):(8-4U\
MZMGW#)(M.V[)MJ5>E<7!AV1[Z#WB1%F+\*BQOJ+$42<L&[D1"G)I(3^#4><A
ML1MKAW=!*&6[&5'57HVL;M&@#(VJ4E-,7FJ.2M'6T&@"6LA0]6_#\F^ ='/<
M+?F6E*N*;?"SBIWT'EF"K$6<;JP7%SCJQ"AW6$ST!P24L)=%JZ^EE+<X<()C
M-G3E<5VIYE@E6M>J0!L:I1A3O1ACC@K+K*'1=,\PY06@F34%*"&#;&/<'\J-
M*==4FV%G*[?2>I5[I:VR(\8&:8ZC3@9SAV4XOU],BGIXE$8GG=YA(?![JLL4
M?<HR=:>T3-<JPNJ;A%A3O0!GCO)QEO!H^I^&9=\ ^?JX/U3KDZ]I-I2<TVZD
M]JIW2-J4!_4-R@Q[G:JP-JQ"!_P*8EVMB-1BXU".&ZG<DPJBO%]$4'<)"%5M
M/(*^B4LTUG.(-75LHB4\FD 59-!-?@%H9TX!*LB@6+O]3_7:(S]6K2T^7[V.
MTJ?;(FK7[JUNU"398E79KG 5S._78NM<*F*K64KJTPAXWPN8LD$.O?(XBUK5
M7D[5-Y=3C U,2DT=]*4U,IK^IV'I-T"U>ON?VF^/7-=_6W3!]"UIP+2NXIAQ
MN[;)&&]N,*?8H]8\3]"&#-OTQ%:-BM#+E5#/,$7203I/U4UC:SNHY=4M5(:A
MD4HWQ6@T<V0T 1UDJ(8,55]- 9600;UJV^WJ%8D_F9877+0NPY]TK. >=ZY5
MMM9N,[0$$TR!VBRWS8*(#O\N!,GP[QU4$/L)"L$ 4:;J)E9HCA%YNE8B1]]$
M8IGJ2>7FZ&BZ9_CPOF')-T"[?.M?AJ6';U@7YUVJ751V)KB V1=;+&JK7ZOU
M^_?;K,ZC/KT%65=IP#7SJ[ =P[<'F.$W#QKY\3*EYEB91->&%>J;<7QC YY;
M4S>:0#5DT$,&W8PI0+WX&Z!;LN6.>>'!7UWSLJ^$YB(OM,PF]G3-Y06CZZHM
MG@-.G2,[4&E!1:4F7"-;CVLE51$ZT%IZ)[*JHA.I4W>@U+K64KF^&2TV-& J
M3+'1!/2O0X8/(,.74X#FFV^ 8<$FX)B[_V9@9MK5EAD%IP8_+HMU?"VT1389
MJMR':Y6./+_,6AJI,.-BP^\/AF=_=#6M#5'-:8-F_M82@[8%5J5O0J@,C4B9
M*3::@/ZUQX#A_?&@^HLIH&KA-\ R9_T=[Y>[?VKZ[-"9@6F9K:>F$EQM"\6Z
MR':#W'/$)7;F^X=_#P'/@HO2S?@8-/LW8*"Y'VDLAV;^"FCFES<6F:H:B_3&
MAA*-*3::@&'"8\#XWGA@^'PR,,Q9 %S35_\:^VC+V;ZI.]HN?I#C&_R(I&];
M*I;7[:P6^E-M_-I"#]>!#K!L^##52H@,OSL8GOM1-<S[,[\H5FQ6Q K,5;%\
M4TW=: +&5Q\#IG?' ^.GDX%E^MS;H2E++W:]M[+CXJ2]@1\^R#<-?D:6=ZP4
M"AKVJ#GA-!/+5V@O=Y?6TETX']E!".!MI-#PW%]J942&9WZ8E1\IL8HCQ39E
M.-]:%1E-H.;EL< \Z7E0\]%DX)X\XTKK6[,[S[^^/'1C4KSY\I0"Q<D91'[7
M:FYYRSX9O3Y-0XT4ZLE!I!GO1]O*O%@'RD-P(=SDVI):FKNHENDI='&\!2Z!
M-]\E]>;5JCVC"5A>' NL;ST/K%,^_#7V^K2>H1<_C?ST^FK+K?<.**]\FL<;
MFE=&/[&>3NK:SR.TI8EQS?D*=$.)&AE#:F%1='51!*LO"!.,>2&**2=$KSD:
M+#=G!;GFC*#0G!Y4C"I@'S\6.%[[UQW_ZV_U]8U[K>['%[^TW7ESK>K/*?'\
M'V=FT;Y;"L.?V83%#,132GO3F+#CV9S"8P6"O(X284X;4GRT%2W-;,')TIN)
M\M1FBB*EB:%,;F2KDAKYJL1&2>5H^LWUW%C@?GE<;]MSXV(GGWO3=N>EF95@
MTFK^G<]VT7Y=D(2[MN8HZE)<(>S" 43!4#(FYW0F+O-D+C%MH)"<T@^C'CF!
MI"?V81B'>W',@SVD\@/=5%9"-Y,=?YS+WG=<R!E-IWQ/C.FO>_J)6-<S3]LO
M/S>Q$KPZ@P\F+Z>!69MQ?RW;@[RYZ5#QSWM2<JXG9*9?3<Q)_B$U/_%25N&A
M[_.*#WQ75))P$0;??P&%V'<>@]Q['H_:<XY4NOLL%;WS;#EZQQ /,YIZ D^.
MB34]/<8Q\.1SE7>?G\@';WU&!9_.QX+Y*Q!@]88"L'5;UM\[=R7?WK_O\*U#
M"0=N)A_:_UMZXMY?CR;M_B4O>>?/12D[?H:EQMU IFW_"9V^[2=<^M;KQ(S-
MUZF9FWXLSQI-#>$GQS@ZGQA;>>&QY_C@Q3>HX+W)9>#+Z3"P>&XN6/U-&MBX
M/!%L7QT/=J_?"Q(V[0*)6^- ZO9M(#-NZ]V<G9O_SM^UZ4[Q[HU_P?=L^*MT
M[_K;V'WK_B3L7_,G-7[U'^4)H\G9^-@8]>"8L7SPU-,4\.I+&##YK1(P\X-L
ML."3%+!LQD&P=LX^L&7!3K!S\3:P?]EF<&C%1I"\:CW(6+T69*]9 _+7K@9%
MZU8!^/J5H'3#"H#=N!P0-RX#U$U+ 6OS: (LZ.L#;]HXP%LP$7#630?,W<L!
M+7'[7[3TP[]0<G.ND!#("P0<\4P9A3E8RN3W(;GB;EB%O*M8HNHLDJL["E3:
M]GRMKCVWNKHMQZ1OR[896K-=AM:C?D-3=M@0RPGK']8_AO]#!C9DX$][#O A
M W?=EZ <,C /;[_-2$W\F9Z=^P,5ACI/+B.?PI/9_64,84\I1]:%%*B.P<7:
M]A*9KJU(I6\MU!A;\JM-S7FFFN9<F[DYI];<E.,W1_,"-<'\@/EA 0YD$$"&
M"LC @PRLW2L ZT#<[?(CB3>8F7F7Z47H<S0T]22)R.W%TR7'RUC*8Z5\;1M2
M6-T*EQJ;2Y0U344:2V-AM;6AP&1KR+?9&_(\]FB!U^Z'<A<^/,!]:2RH@ Q"
MR,"'#&S(P(Z/N\U.3+K!2LN_Q,S#G&4@:0-4/+^'1)5UXLO5[67<ZI;2"E,3
M4F)IA"MLT+<P1WVQSADKK''%"ARN2&&MRU]4ZZJ%LA<_/,"##,+[!L':+P%G
MUPK W1=WFWLPZ08G.?\2*[MLB EC]-.Q%<>I%$4'D5G5BN,8FS "2T.IV!Y#
MRIUU<'5MM*3:$RTR>Z*%3H^_V.5V0]F+7;66DMJ'!OB000091".&&8 ;MP+P
M=\?=YL<GW> EYE_B9)2=814R^IFEPBXZ2=5.850W$]DU#3B^/881N:(HN2<*
M5WLC)7IOI,CJ#10[O;7%3H^]Q.DQE[C<1IBK]F$! 6003WT.B"%#Q9H9@+]M
M!:C8&7>[8F_2#<'!_$O\E+(SG%QF'PLNZF3B*EOI-,/(?H[ <]5AA>Z1O=SP
M3J[$X \5C>RX?+82AZ^FQ.DUP)P>'=SE?EC_99#,OV>HV+("B+9OORW>E7A#
MM#__4L7ALC/\3&8?ITC4R4*K6YAD8P.=::\C<VNCN ION%3F#\$UP5!)3=!3
M; O:2FP!$\SNKX8[O%JXTZ-&N-P/"U1 !LFP8=Y$(%P] P@WK0"2K=O_DL8=
M_EFZ)^^2. %S1IC*[./GBHYQ$)H6%MY47TYWU%'9[@B>[PNAI<$ 7!/QE9@C
MMI$=E#6H@]L#&H3#IT(Z/0JDR_VP@! R2"&#=-CP[0P@WK <R#9M^TN^]?#/
MBAVYE^5[T4/21,8)4::H4U"D;N%B3/5LBC/**/>$B+Q  "V)^.!5,3O,%#/
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M&+E=1;R,=HPHN84J2VSB*PXV52H/--F5^QOK*A.",<U!5YTFT5*G23(^.""
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M+[=<\*[$<<6K G?YQUG^FK>2(TVNQB7;7HC,89T.+7,_%E3'.^3?XKO?=VO
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M3*#;8P[]1Y8PN&D%@RLV,+@X"E@N8L!\!0,.M/^S*<Y* ?"4A.&C-PG>EC/
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M%N:T_UO3K^UH#D<E03CH"L/!8@+LG*?"VGL6+"/FPRQE$4SRE\*H:CD,UZZ
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MN)AMQ)S,FL5U.,-78&]:A/B.Y"29K8DYBI/Q)6KK8VLUU\3,T5T5W6,P$;G
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M[I:SV?>#G,V>5_)6NU#1<@<J6TRABL5V5)W)49K#'33_:ZC_2RA_@!QXSD:
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M3#]+G[ @9A$^1!1!-T5(%P <)FBC>)KX@WC_!<V47TSY*6<IG^KN_C/U_A:
M'F4K3V<_H=RW0+E ^P3@)3C(37^6GQ FQ @I0H'0( P(:\*=H!N#Z;^80/H
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M $UK 4I)DS.G &))#8/V \PF'[4_P0+3L[Q@?$X,C,XI@>%Y/3 X;P4&%UQ
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M]OWS[($VB/>)#U\\AZFGV<NGWB><HOS+E$_[-J-LK=L \O< Q!X""#ZAW!=
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MCDJL=5DEN=IEB]1*EP/2$RY7I)>Y/I19ZOI!9M05948^([W(%:5F@@ZT=V>
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MD 1XJP3P7H=N#BW_^0Y&Q#_?!6DA1HGM_WSOXC'Q[G^HIOQLJGT,[=V/]NU
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MZ5?7HO*IZU9[U6[0\JC=K^U>>YF\H>5>\Z.6>[6DY5XEJ>=4D@H-5YF#$R7
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MOK<2DWKG"Q-Z>X7QO8."7>\98=S*9X5Q*[X5QBZ3Q+'=9*DDCAOF2 /'Q@5
M7QO[(C4;20D_9W:P#18#(=V UPKZ+_KSZ6OIP=;I8\)Z,XQ?/Q)V&R9AW 8G
MC-W@CC$; S!Z8Q1&;4S#R(U%&+&I"3:;NF&]:0!6FX[#8M/3L-SP%2S728)E
M/UE+UFC81^V!)1P36->V3O8#ZN;2&B8M \)[ =\UK#^]N0,MZT3Z\U&# BQW
MZL-\ERFQA=FNB3#=Y0B3W>XD$,:[8V&T.PN&>RIAL*>=]$-_SP'H[KX.O=T?
M07_GGS#8(<%@D&S7,$B]_N7 $FHVDF+JIJUF&_33_U-W-GVYXR P@=Y\Y#[
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M/+P'1-Y_*/\?^P_R?2"/GL-X^&R0B]"<!7F-;OL+>N??^)_T%[]"<SKDKWM
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M3 :>9!RWN0"YS<'^COR0=#;P'0K<827NW"%?D#^)-,2231R7J9LO/PMG#]N
MO^9^')A^AOK4M+P$&%)3?7UX_X5%0-X+N3N\'W*??O]9'>!Y&J47:!)>HN=_
ME0OT-QC'?P(()Y^W>/&_Q49^:QOP]CDBWY?S_5_WX\R3[X5BGM./ 1'4];P
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MK2.)<;X:XGTD0>8Y*E\-YM7!27\@A%GA^T6,L)71-3&R6BX6*_WT4>IO@>*
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M3PM:RSIV%+$ODA*231+X?1A-FV\5,)NF:48C,(6FQ:Y5&V/:C#&ZS0HCV\;
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M/?Q^.Z$+'Z1]WOXCH?XV#=VL9PLURX=/YL0L ?R7L0^NU)S*&;^1^EL TT'
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M6NC;J@G?'HW[#FG4=Z%&_%9HR&^S!OWVJ]_O7/7Y7:->O[O5[?><NBSO@N^
M[0<\%NE8_GE!M.//0=MY7<_GE1&$?^@S$P0L\[1XOD53EC!-6N(U[I^N,?]\
MC024:3C JJ& )@T$=*H_L%]]@>/J#5RJ[J -Z@S:JXZ@L]46=*5:@N]0<_ S
M:@I^1TTAWP,;[QVXGS#P:A/Z,-WO 1L3'+F/Q5R?0I\)=!D/==58L*^&0X(T
M&!*M@=!D+0C+5E]8D7K"*M4=7J^N\%9U1/2J/6)$K02?+1%KU12Y2PV11U4?
M>4*UD;>K)O))6:/>5'74M[PR$T4Z<&>B8RGNX61L8/(O8 GO)[DVBCY#Z#*
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M.[U46>DURDQO47IZG](R)I22L5))&3N4F'&6XC.N4FS&/8K)> %\J-ATF^)
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M%?IFD;%<BXD*UVJBS+65C.8Z0)2XS(D"EQ>\.1ZL2X$>X"EK9R1S6K<#=!A
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MR_(1(7E^PC]2D' K8!!1@F./0:>.D6)_>0SR">7)G%K,"@")TA@# ''LZ 0
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M_0DCO6&L])$QT[?OU,+0?@;3[SRL .R_G>'_\/S_<GL1+BYN;AX>7MB 7T!
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M]\#2V>VNG8?#+6<?FQMN_A;7O(),K_J%&/T>&&KP6UBX[N7HR$.78H8,6J3
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MI06DM8A"\FNCHLK*PQ.KBX(SZW,%A4U9_.KF-%Y+2Z)_>T,"K[M<Q#M7\#=
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M88B@*$&(CQ;P@XS /]8*?%.Q/UBY^*^>Q<3/'E6N4]0&Z@>W-H_WY&[&)&F
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M(^ZS<^-O>9:DC+C79%VFMN4,4<[E]KKTYW:0!S-:W*XDUE-O1-=0;T?\"0A
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MG9X1?J?9<5YMO"1:2UBZ:W-<%K$I(]>IL3C/L:DA#]=\+A=?-Y3N5'TYZ4]
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MPQ>G(=R4XS7\I,-]IPGL$\)SNQ?.CS%OG1]B)IUF ACK)< ==: =D@'VD7G
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MNCE>$'C871!Z6@\DLRP&\GW,!FK8IA>ZV287[_J8GG_.-.M^Y6'6-3$M$+9
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M"]C/W02$N1N ,G<=,.>M >Z\51 \;R7$S%\.2=,"9MLEP/"@))C*2H.U_"S
M*,T!NU,+ &.\%&SM5X*-^UJP\ML(EA%;P#QI.YCE[@33TMU@4K<'3%KW@G'/
M/C"^N!^,;AX HR<HKP^"T8>#8/CE$!C^. 0&<.@'RE<#./AE&L!\VW\=+ Y)
M@>V166!_8@[@-!: @]%2L,>L CNW=8#QW0PVH=O 2K03++-V@T7Q7C"OW@]F
MS0? K/,@F/8? M.1PV#R2!9,7LF"\7LY,/XL!T8_CGPW@B-?#.'(E!'(?IR&
M?QR,#DB"U4$IP,K. D>%.>"DM@"<#):"H\TJP)'7@[WW%K +V@&VL;O!)GT?
M6!4< ,O*0V#9<!@L3LN!>=\1,+\D#V:C1\'LQ3$P?8?R2>&[R7>%S\:@\-$8
MCKTS ?E)$SCR;X#%5@DPV2\)MONE '=H%A".S@&2Z@(@Z2T%HN5J(! W )ZY
M%1P"=P$V:A_8I1P$V[S#8%-V!*QKY<&J]1A8]BB Y>!QL+AS BR>*8+YI-)W
MLT_*GTR_*[\W!>6W9J X808*KZ8!+%$'L[V2@-TK!80#L\#ER!QP4UD %)VE
MX&:^&LCXC4"B;P>"_QYP##\(#@ER@,TZ"G9%"H"I.@$V34I@?48%K/M/@M4U
MM1^63]2_6K[1F++XI#EI_N/W,R"U%Y9P\JDE*(U;@N*_ 59;),!RMR3@T*YP
MV2L-5%D9\%":#W2MI4 W60TT^TU H>P$LN]^( ;+@E/L,7!,4_SED*?R$UNF
M]MVN3N.;;=NIKS9GM3];7]*9LGJH]\YJ0O^-Y2>#%U8_],:M0>NQ#6B,VH+J
M?5LX^6^ ->I@NU,2"#LD@?+[NYQ#L\'K^'Q@:2P%EN%J8-EN!H;+;G#W.O33
M+?#H-U*DTA="HNHG?*;F1X="G??82OUW=HV&;VW/F+RVN6#VROJ.^3.K%Y9/
MK*<L'MG^-+Z+ ?T;=J!S!0N:EZ<!;% '[+;_]K_'#BGP/C ;.,?F@9_:$O#3
M7PU^EIM_^1#V?&5ZR'ZB^9UX[Q:B]I84JSU!2#%XZ9AC\MR^Q&+<KL9ZS+85
M\\BZU_Z!]8C#':NG#C=M/V!&L#\LAQW Y((#&)S#@6X?#G3^#;#=+ XXU,,-
M[7\OM+O]T.[FR<\%OLIB$.BL_BDPV_PY +?WO2]%_C63I?*"%J@U[AIA^(@8
M;S&*3[.]@\O'WK0OQUW#-N"OV'4Z7;(;(@QB'A,&L.\<S^.^87H<?UF>P8-I
MNQ,8MCF!_K_QCX,3VGBTC;^_/Y $'GI.!,O-@3"E1;_"3ZW\'&ZT>3+8;N_+
M -+1)VRZV@-/COYM]R"S:ZY1-I=)2=@AYRS<!:<BI_..U<Z]N%92CT.?2Y?#
M+7('[A6IG? 9U^S\W;:!^,NRE@@F-40P_C< LTD<B&C[,]#NYJ+'(QCM[HC#
M,A!U8L'7&(T5[V(,-KV,M-D[%NQT[&X 5>,:V]M@F,DS'_ (L^VCQ#ETNZ8Z
MG2'E$MN)I>060KU;DU,GI<'I$K76:9Q20_KH7.GRQ;Z,_,.FQ!7,BUW![-\
M.]3A=W-Z_?[W7O1XA*/G9\S!63]%Q^9]3%1=-I&DN^%)G.6>NY&X8U>#734N
M^GL:]+']++J\@C#M#"&NF9;@W$#)<*EQ+72K<JFBEI-:::6D?H\BT@./(K=W
MY'S*)WPN]:M=-O6G53;UE^6_ 5BT<]W0\7W0Y@U"YR-JNR2(]DM_39&?^S9-
M9<FS#*UUH\EFNT?BL,<N1I#4>X,\##H"?"Q:?'EV]:PPQVK/6&(Y/85<[)Y#
M+:"6T7(IC?1LM[.,3+?_,#)I;RCI'A^<TSR^.*30?]BDT']:_QO@L$$<J.CX
M'+2W0M'FC477K.2]4E,9<C*O<A07/<X]M?H_&2:[AA(Q1_NB">H=X52#)H&7
M16T UZZ"$^Q8[",DYGLEN&9[9KIGT(OHJ1ZUGDFT,\P$CRO,1,]7M 3F>Y*(
M^<DQCOD-$\?\;OMO  X=EX;VKC]*!#HGHBWB/]-W2[[+/33K6>'Q^:-%&BNO
MYACM[$^UD>\4X=6:HUSU:\(8%F4"7[M"7J!C#C><F.$;YY;BG>:>P,IGQ#$K
MF=',=B\A<Y 5Y?V,'N4S21;Z3#E%^GS%1OI\P_P;@$>[^W?O\=#F%:+-F[1)
M_&OV#HG7A0>DQLJ.SKE5IKIBJ,!@Q]E,JR-MR3C5NC@7O7*AAWEAF#<F.^C_
M$'+7455@[:/'GW,.#1("2DIW=W<=NKN[N[M+.@5!0A00%!4;N\5V='Q''7/L
M3A2#YVYF[EWW_3'<=?_XK,,:G/7LL_<^R/? 3$E8;UEU=&=Q4T)K87=*8_Y@
M>GW>1%9-[M[LJMRS.=4%CS-J"M\E5!=^CJHN_!9<73@?M!R,)'<ADX^"Y:1Y
MFP4IV+N&,C<L17VY19'AP79-YM^VFO*?'764/CSDK;5[?8C9UJYHA\VMR1X#
MC5G^/76%81W5E='-%0T):\LZ4FI*-J17%(]EE1;MSBDN.IU37/(@L[3T;6)I
MZ:?HTI*O(:4EWX*7@]'D'F23YJPBZVA;3<%^8<K'S>*4IU.RU#N[59DN;S?A
M.SEA+W5@DZ?&]H$@T['>*/NASD3WWM8,_XZF_-#FM651];5U\575;2EEE>O3
MBRHV9^673^?DEI_(R:FXFY5?]28IO_)C3$'%U]""BF\AR\%8<@]R27,N_MY]
M)S\L# K VPD1RJ-=$I3?]RDRSNXRXCTR19?</>ZA/CD28+)Q(,*NKS?>K;,K
MS:^Y/3>DKJ4DJK*I)KZDH24YO[XG/:=V)#.C9GMV6LW1G-3:_V1GUK])SJS[
M&)-5.Q>65?LU=#D83\Z@@'3W6A[ =2MA?H0/7D[QP]T#J^'*C#S#J7T&/ >F
M;<6W;W53&QWS,]HP$F;;-1CKVMR7XE/7DQU<T5446=Q1%9?7UIB4V=*=EMH\
ME)'4M"TKH>EP=GS3;]E)K6^2DYL_Q*8TSH6E-'X-70XFD>=?S$7!)F[ /F[X
M/,X%3_:L@-^/<L/Y([*THP?UN'?OM5XSL=-%97B;KT'/EA#KULW1SO4;D[PK
M!C,#B_H+PG/7E\=D]*Q-2.[N3(GO&DB/Z9S,C.R<R8SHNI(9L^YU4FS7AYBX
MCKFPN/:OH<O!5'(.Y:3]VSCAXQ 'W-[&"M?WL\'EDYQPZH04[<!1'<[M!RU%
M-NUS4NS;Y:W7OCW(8NW62(?*+0D>1:/I_CF;\D+2-I9&)@[5Q<8.M"5&;MB0
M$KIA2UKPA@-I01LNI84.ODH,W_ Q.F+]7%A$[]>0Y6 F.8=J#OC>S09W-C/!
MM9TL<.$@"YPYRPZ'SXI3IT]KLH\?-Q<<..(@USGCJ=VP-\"T<G>X7='..-?L
M[:G>J=MR A(FBT.CM]1$AH^WQ@:/]27XCXTG^H[M3_(9NYCD-_XB+F#L<V3@
MR+>0H)'YX.5@W@K !E:XWT^#W[8PP>QN9CAQA D.762!/9=$*),7U%B'SYFL
M6G>:+M5TPEVMZJB?8=&A4*OLF1B'U/W);O'[LKRC]A0%A.ZN#@G<U1+NNVM]
ME-?T6+3']+X8]UT78SQVO8CTFOX:ZCWU/=!GVX^ Y6 )*WQLH\+-82J<W\8(
MQ_8QPOX3C#!]A14F;ZR&D>M*3+U7#5>V7+81J[[@HE@\ZZ.=?3;8).5TM'7<
MJ23[R!.9+B''"SW]CU?Y>!]K\?<XVA?D>G0\V/GH_A"G8Y>(ET$N1^?]70\M
M>+O-+ ^KJ7"WA_3_*!6.[Z3!OAD:3)UA@K'K;#!TEQ]Z[\HSM-[1XZRY92E8
M?--1.ON&ETKR;T$ZL=<BC<.O)EH$7<FP];M2:.]UN<K9[7*+F_/E/@_'RUL\
M[2\?\*)?N>)%O_R*?/S-S>$"NCB<1^?E/&L!N#8(<'*2 OMV4V';41J,7&""
MOEMLT/E$B-+T1(FIZK'.BL*_S%9E/J*O27KH(1OS,$ Y[$&$9N"#!%W?!QF&
MGO<+3=SN5YL[WV^Q<GC09T-_,&YK^V"_G<W#BW8V#Y[;V=R?L[6YA];_+[?6
M 9P=!=B_ V#K 0IL/$V%GFM,T/)J!=2_%:.6O55BRGNCS9'VQH0W[HVM8,0;
MES7!;WRE_-^$R7F_B5/T>).NXOHF7\WI3:6FP]LF;;NW/3HV;S?K6;W;I6_Y
M_I2^Q?O[!A;OWNF;O_FE;_X:EW5A"&!F$F#;;H#A8P#=%RG0<(L1JK[Q4(J^
MB5&SOBDP)7W39(OZ9L05,F_%ZS?ON-ISWE/(;3Y0U/E[E)C#]R0)^O<L*=OO
M)3+6/^ID+7YTR)O_&% P_3FI:/+S@)+1KPO$(R7#GY^)K\LZ/ XP1?9@^!!
MUSF ^ANDP9\S0BZNI*2B"#4691G#4(W%'_78O=",TQ7M>!S1A=<.??BM,7B5
M)48)F)-O0$PP6\@(2X0-R#< >M@IJHM#:W1PJY@6'B#.B6GB(W%-?+:L'=L
M-NXC\T\!U%X%*+P+D/&+%1*0AQ*.@M0 E*1YH2(C25-F>S1DM4$+=@ND<YBB
M"Z<1>G/I8R"W+D;P:&,\CR9FK%3#0EX5K.%3PG9^11S@5\ MJ^1QURHY/$&<
M7=8F<@;=Y QJ+P(4W 9(?@40A8P0A)P4+^2C.).]H*,T@R4J,YJB%I,A&C#K
MHCF+%MJPJ*,CJRJZLRFA+YL"!K/+812[-"9Q2&+."G$L6[$&&SE%<1VG" YS
M"N-6+F&<6M8Z<@9ULP#Y-P$2_P((G0/P00 79 ,[Y*98X"JJ,8I2]5":IHF*
M-#549U!"748Y-&*407-&2;1A$D<'IC7HQB2,/LR"&,2\&J-8^#&9A1=S67BP
MG)6;?!'DQBY6+NQ9%MK+4=%:@P$="3=M)O0P9$$/*W9T=^%"UR!>=$Y<A4[Y
M@NA8*XSV':)(WR"&]%%QM)N20+L]DFA[6 IMSQ!7I='V ?%2!FT_$=\)_&_2
MOVQ1:CE_K\%6[9_W03PTF=#;@ 6]+=G1RYD+/?QYT2UN-;KF"J%+E2@ZM8FA
M8Y\$.FR21(>MY-_=)8WV!V5(L<DB_1)Q5P[ISXD/\DB?)_!O"\0/.LK-TU%V
M.>A UD!7^><]"&]U)O3394%_<W;T<^1";Q]>](H10(\L870O7X.NS1+HTB.%
MSL,RZ+Q%%IUVRJ'C?GET/*Z CN<5T>$6\50)'=X3WY31 95_$=\=4.FK RI\
M<4#YY:"C+!4=E?YY#\)/E1$#M5DPV)0=@^VY,,"+#_TC!- W712]2\31<ZT4
M>G3)HON /+J-*J+KE!*Z[%%&E\,JZ'Q6%9VOJZ'37^KH]$;]I].<QG>G!8VO
M3JCQQ1G5/CJCRGMG5%K.WVMP4:"AC\(_[X.$:3!CA!$[1MAR89@['X:$DFN6
MO 8#"J30KT86?=H4T'N],GIN5$6/"75TWZF![@>TT.VD]H+K99T?KO=UO[F\
MTOOB\D7_H\LO_?>NJ//6#;5>N:/&"W=46PXZR5#178Z& ;(T#)-GQ&@U9HPS
M8,,X*RZ,=>''Z  AC(@3Q] <&0PN5\2 1M4%OVZ-G[X#VC^\1W7GO;;I?_/<
M8_C5XXC1%_=9DT_NMTW?NSTW>^WVR?R%^R_3YYYH]-0+]?_R1IV'WJBU''26
MIJ*7- V#25]%D\Y+4&'"9%TV3#'GQ&1'/DST$<:X*(F%Z'3Y'Q'%*M]":S7G
M@MIT/P7T&G[T&S9Y[[O%_*WW3LO77@>L7WF>LGWA\1O]B?L3^T<>'^GWO7Y:
MW_5!\SM^:'+3'PU_\T?]Y: +68.?! W#2>\FD/9/(^>1J<V*6::<F$7GPPP/
MX1^IH5)SB4F*'V-S-=Y%5NB]#FLP>1'<:?$TH-_FL=\F^T<^6YT>>.UVN>MU
MU.V.UR6W_W@^<O_-Z[W+5=\?#I<#T.92$%K.!J'IZ2 T7@ZZ2E$QD'3OXL_>
M4\A:LDG[YVNP8($1!Q98\W[/=Q'^G!,H]38]5OE%4H;.D[@BXX>1U59WPYKI
MMX+7.?T>-.CZ6\"8^Q7_'9Z7_&:\+OB=\9[UO>USVO>U]\G >=<3(>AP+)1\
M%0E#RYDP-%\.>DA0,83,CU_L+;'%_T<K Y:H,6&Y/ON/<HN5G\H<A5X7^4H]
MS8U4>9">K'\[.=?\>GR9[97H>L<+D6VNY\)Z/4Z'#GN?")[P/1:TR_](T-&
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M1E][Q0V^C4KH?]LCJ3=_3E)W_B])W6^?)'6__ES6OE& +5-D_@$R_Q1 Y16
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M@W<]O <_N?@.H8/_$-KZ#Z+-4I@-\* &X$H'P*E!"LR,46 G:;\M>P&&#Z^
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M&-:RKL$N-E$<81/!G6S">(Q="&\2]_^EC]R!ID-D_EDR_S> 2#+?^S& XQ<
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MCS:JV!Q=KV9U=%S#XNB,AL6QWS0LCKQ5MSC\2\WB$*H2*DM=7@MPM(?<@2&
MT7& OAT K?L!JH\"%)QE@-0KK)!XC1]BK\E2(J]I,X1<-6?QO^K X7W%D]O]
M2B"?RY5( <?+B<+TR]EK;"Z7BEM>;I0TO]PK;7IY7-;X\HRL\94;LL:7WLD8
M7?PA8W0!98S._]O)#H ] ^0U, JP@=R!MKW_S,\G#9QZF0&B;K)"R#T>"+PG
M#K[W5*B>]PT9W.Y;,SG==V&UO^_+87L_E,OJ?AR/Q?UT7M/[1?S&]^M7&S[H
M%M1_L%E([\$^(=V'EX1T[[\6TKDW+Z1]%X6U__RW ^0,)C8!#$P"M.\A\X_\
M,S_Y"FG@FS3P>\@"WB]YP?V5.#B_4J+8O]*AVKPV9;!\;<=H]MJ5V>2-'ZOA
MFS V_3<)'+IOLU9HO2WCU'S;S*7^;@.WZKMM/"KOCQ'W>)3??N!1?KW H_P*
MN9?:MA%@B+P..\@=K#E,YI\!2"+SP_X \"8=[O*)#1R^\H+M-U&P^B9',?NF
M3C6:UZ?JSYO3=+[;,6A]=V54_^'+J/HCE$GI9SRSPL\L%KF?%:PROUI9I7\-
ML4DM[&"37#C%+H$/V"5^?603__GS7S:2UV$7N8.U!__O_-!; ![W >C/ :R0
M!<R0&XQ0$/10 K11@:*.ZA05U*,JHBE5#JVI,NA(DT1/FC@&T40QAD$8,Q@$
ML8QQ-;8PKL)!)G[<SL2'QXB;3+SXXE_6;0>HFR'W[_0_\T-N [@] +!^"F#\
M!<A<!M#"%:"&O*"$0B!/UB&#<A0)5*&L04V*,.I3!-&,L@IMJ7SH3.5!'RHW
MAE$Y,8G*@84T=FR@L>%Z8IS&BGMH+'CB7]:2UT#A23+_,IE_!\#U$8#E,P#=
MUP :"*!,R"$S2"$GB.-*$$$!$$!1X"=K68FRP(W*%$[4H*Q /0H;FE)8T);"
MB*X4"OI3 &.(+**""MA*]!.C_X*J:E34(OVOIT)%?77RJ$M#;3,&U'!D0C4_
M9E2.84'%+%94*&=#^29VE%]'#!*C'"BWC=A-'"1.$9<Y4/X>^=P+XA/Q@T V
M5/@O\LM0)[-U%:EH0!BI4M%0FX;ZQ@RH:\^$6C[,J!')BFKI;*A2PHXJ:SE0
MN9/H7X'*FXA)8B=Q8 4J'2>/%XC;Q#/B _&=0(X%%>3X]7\H(_M2J*E$00/2
M_XOO 2S^;HRI.@U-#!G0V)8)#3Q94"^,%762V5&K@ ,U:U:@1BO9^EYBF LU
MQKE0?8K80QSF1O6SQ WB,3=JO.->T)CG^J&!7//$-PWD_/J_S2V!.O(4-):A
MH+DT%:WD_OF]%&L]!K2T8D)S5Q8T"6)#HW@.-,A9@?H57.2[<6[4Z^)!W0W$
MII6H.TE,\Z+.#'&2N,+[4^<A[[SN&]XYW:^\GW21]X,NKGR_2 ]YWOV#^[^A
MP>)\"0K:B%/03I**]@I4=-!F0'LS1K1U9$%K/S:TC%Z!YNE<:%K,@R:U*]&D
MC6_!N)?_E_$0_T^CL57?C:96SQOM7?W-Z.CJ.:/S I^-_A1X;_12X(W1G,!+
M(US]W!A7/S/&54]-D/^)"?(MA2:2%+1>0T%[TM_.Y-%-EHKNY#S<C!C1Q98%
M'3W9D1[&B;9)/#]L\GB_65?PSUDUKOYLV2GPR:)?\(/%B/ [\PGAM^;3(F_,
M#HJ^,CNSYH79[VN>F#T7>V3^><U]\P71NQ8H?,<2A6Y9HL ?EKAZ*307HR"=
M=*Z+ .7OWP'PD:*B'SD/7W(>WI;,Z.',/N\6P/G%.7;E!Z>,56\=B@5>T6N$
M7]BUB#ZS72?VQ&9 _"_K4<F'UE-2#ZSV2=^S.B'SI]55V?]8/9&];OU)^JK-
M@N0E6Q2_:(=KSMNAR"P=A9=":S+7:1693_K?CZPCF*PIE-S/$$W:KV 3IKD
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M/+0JB?MB7)J >F6)J%6>A&I+H3\[N0L4^)P*<#\/X$8I URN9(+SM2QPHDX
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MR&=6?E'+HO2RFU7AY1B;_,L9-KE7-]GD7KQGDWOVBU7V*;(M-;YX!\< 6G8
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MT9@(\<:Y!]/0_VGP*(6":YD,^#E'%"[GB,/I/"4XG&M"VY,]B[4]PY6[*35
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MT^C@YP'L+@-,_PW ]*X(3'K*!Z-G C!XI@EZSXU Y_E4T/IC)FC\X0AJ+[Q
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MVHO\^G0Z?=?J=?ANTV_W/6+0YON[X7R_E[JM 42S-9"HM@81941Q(L2#@6L
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M6]FGI^P3.SGEE-AQLYOBA\U>B!\P_R(^;D[$]B)[S G[WQ!+S)V%[FW'!N*
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M6D3W_@FW&R<P=QS=<V<F[K7Q=6VZ.*S,4(!E&8;4XO09M(Y4>V9KB@>[*2F
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ME+3L6REET;=5>D;_#](S^AY(35_V06KZ4B(U?0F1G#&!_7@=C&+?UV#^LD4
M';VX#C"[>"7Z]R#ZYUKT/U0CSV$>N \K@MNP'K@,FX/3\"S*8=B)FC/L1;,;
M#J+;#$<SK8=36)8;\D5G;*AA3]VP0-QLPPK.E U;.),WG.!,7G^?8[KV ]=T
MB'!-U_R3G;@&-F#]^S%_$<Z]J1_]%STX>QU _ A \&8 ]ZT LW>PP&:G),S:
MJ0K6.PW :FPJ6([9P(PQ9Y@^YD--'0NCS,82:)/'LNDF8Q4,X[%6IN'8<J;!
MV":6_JYC3/VQ>TR]'>]%=+<1$=VM1'0BFX7G8)C?@RK8NE+X'!! +GIPXA:
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M^9NIU_PQ>,4_#"_XY^$I_RX\D'P)]R2_4'>D"'4;N?6-FQ,@!NCZAM) #*2
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M'C8G[ WF1'2=.1$1LG8"9(;(U^-=&X /LREX,9L%+VRY<&^F%/QJI0;GK:?
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M.O 8.O@>.FCOXX+FN"QHC*LCAJ ^;@YJ^V>!ZGYG4-GO!\H'HD#Q0 8H'*@
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M:X>^G@$E[@ (P6RWPP"SC@%,.0F@>P9 Y3R S"4 WB\ [-\!Z#?1^V^+(%R
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M")R5(M09Y+0TH4X)D?H*T9, HL<!HL,&HLO%5ZR0%G9,71\^*D^#-XISX+G
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MZ]Z(]2X5/IF#V5'# 'YHYTY; :QV8#Y:N@X*J\HX@.Q!-.,C+! _S@.Q8[+
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M8LS):_("H/<*ZRYQOD.\3TB[4SXF[DGY$#E%B3;PA0&#8_KDFZD4*K8,UCV
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M]Y@^M(Z:0//H-&@<M87RJ!L41_TA.QH-05I\CW)B.=I"+"98F2,4UD>>Y"1
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M_B<\"4=BQ@HEIJXT@-G*29BRT@*35]G#=)4;)JWRP\15$3!9E0SCH7P8#=7
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M,:[/(<;M:T2[B>.(<57A.NM\FOS[I7TPU.!KB65\W4<[VFE''6TL=5,@W]D
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M! Z<;@E<:@E)T&(&^\5ICD%F,1W;8@)X<;?C@4N+*6C1/@J'[RZ\GX9/UCH
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M'M/^N*%WG&'U G'QM +!B@(GA1+RT+V"IE%/V2V4W4[9W90^B?+[\/PLZC-
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M5>6S2A6^NU7N>TJEOG>HQ._G*O9[6\66KQ&;2I [P;R.8>TXZ<;^?/,<&&P
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MJ9Z!9P8\R]!%4/>S@'>PW/H^%"?P'$/=QXKZ3EZ0=ABTC0QH&Q'0-CQ )^S
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M/0O9@_*-45?Y@'R2YT _O+!^'RP9> AC?SK[J'TF&^="4'>3H)W!^?E9ZL\
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M]-;=Z.D8 48:W.HU8( J.$!@%58'.( 6MIOT&QRP!1[-P;L_= \&X(<#;L$
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MS!PRT=-O8/CVL) 6P^^&Q- !&+.+$#',Z85/<4 0;*H6PSV ;J #?#$ $>@
MC# )'KJW8 !@ <9;,CA #J9*^!0GQ T#P+LFAA,##Q^@+3! $8:4,,!+%CC@
M,PQQ% X8A0$RX0#XMOQWZC  ;*A%(J_!1BE,_R ('PV 9?(^:&.DM$43$X"\
M8>S@$QYSI;#AZ5^>?L;1;_J(=96U.RO(1(J+=2\U*1&F0XHLTD-_?</ZS6OT
M]4] (N@ C'D["$*7XA$F +90"U];A"#88K .!@"V>!B! 9!"!Y1A /:B X8(
MX !\F*(.8!0!BZPQI839K0\& '9<Y3(& +:<=)\8#BA&!WS"&*328=4X#@?
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MS0FB%P"W)@@B0 ? ]R8!0C]!$8L)0/=1X!NL(8S.RX4!<$8'F&$ M-$!9S$
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M!:/?P Q*!!. WGFQ!%+=:(#;F !T)V8<8X$3NH0NA"X& +86C#G; XM KF$
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M(9F# 1[6MLX('V8;Q'%'-UF6V?HF%F9'.UD68U$M 2T/182#HVJ0%T(_2-O
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M5%_SXE0(T.0_<BXS>DZ^"V?2TL:H)3</RK?]Z#&*+E1FYU++Y]99J8\_Y((
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M4_WP!/!?E&O$;EW)H4<K>#_\&-NMJ_"K3CBTBW\FQKTA:/)"<$'"^,^0M-.
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M]Z7XFHR> +*5^.#U>B""AD>)K6Q!^FU,7!RM6@#Y#:U)&0I4UF?,4WXL\ E
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MC%J **^R'NR*$G_+3]&;=:Y8C[*S_#QEG"#B_<SE:>$'KJ(#X=>Z%K ^8Q]
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M:0VCDI[3CP02(WBS'7\_X8Q,U#5.KS-I50K?2-$T4@YA>W?Z+K&8 @!1+!:
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M.*K4'_#A XJ+03Z5ES'BP22ZU+!8!Z=)9_XZ3"=HT\T][<[.Z.T%DSRP^;7
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M/NPXDZ%2C4*:/$E@X1N7K?"XI 423U7H'^EUE"(Y$BZ7% T??K5I4@-,0'V
M#^@[3-P+4]ZL8 HG1_7$(Q0??3VG&2C4GV.#QLB)<]-Y"!80MAT"GF'7Z+]
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M:5PJ*TD:8+AOT"?<_RZ<07K.Y\=GFSM";VSQR@9;PA[>I$U>C'\JF/P</J\
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M"O@>Q[MO>DB:NWG$*G.^_TU8VQW=TEDW4@T"C0G))"?"E]UL=_,#-U% *:M
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MR20]_C;O-1!SX2P(GY1':^&YL6] J&&Q.5+H5'G< LU'+^"*^0.VYUZGEZS
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M)9%)\1'7/PD"G6D^"<=>A)5GK6:CSI+(,=  $10P9(@L\JII?=&A" XC]B+
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M<)/UQ Y=E-N'F#P_[9.JK3TQ$1)!V5E1YI91-O?=FXSCDK@C*MWFXQ96:A/
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M)7U)_GCX?<J;U%=IS].?9#S,O)MU*WL\YS+H-'@PMS.O'E(&E<(X<"("ALQ
MQ:'W8/RQ[C@G_"K" N),XB_22_)URBEJ!ZV<+F3@F5FL0^P SE:N#<^"/XW_
M3?!4>$UT4MPEJ<CG%V"D:;*]A3OD&Q3+BV87:Q=_+'FDO%IZJJRGO+&BO%):
MQ561J]$U>;49=8GUAQKV-H8V[6[>U>+;ZMVVO=VK8WNG=]>.;K\C 3W!O1%]
M!_ICCQX>R!Z$#Q&&:<<XQT4G"D^6G:H=:1OM.WWBS(6S-\X].O_VPO=+NF.F
MERVOK+ZZ\9K7>-#U@S=2;D)OD6X+[LCNEMRKO%_[H.EAVZ.NQSU/^I\./KOT
M_.&+CZ^T7YN^L7IK\\[YO>>'@(^1GV(_'_Z2_C7C6^KWN!_A/[U^V4Z83W[^
MFCI:5W62=(_IZQHX3 LVC#?*-H9,A\V S8290$W!LS)G)YD=G!-LOGWNQGFK
MYCM:;%W@MM#5TF61HY7-XJ5+YBV=L4Q[V=?EKZSOK[BZ<G35T=5M:ZIM%&OY
MZ\BV"+M,^SB'R/7^CNY.&S:LV;C8><XF0Q? Y=/FEUON;[V^[:+KB-N0>X]'
MNV>35\WV<N]B']D.L:_ C[.3M8ON3PN@[J8$4H*HP9002B@EC!).C:#MH4<R
M][+W<??S#X@.2M3WA<)H14Q1;'&<,KXTH3RQ(JDRN>JP*D656IU6G5Z=49U9
ME56979:C!!6!"W/S\X00+I0!(\-Q" 0R%Y6!3L9$8_?B@O ["-N(3J0UY,44
M<ZH139/VF?Z2<8]YE76:/<CIY-;SRO@R 4](%6'$$$EF_N&"6.E!661AF#Q8
M$5BTNWAW2: RN#2L++(\JB*A,KT*HL)5LVIDM=5UW?6C#;<;WS<;M%BU.K<%
MM:=VD#M+NP:Z[_9H]"[N\^R//TH>4 V>&7I[S.SXIA,'3^).E8^<&GUY9N99
MAW.AYT$7!!>;+IT=>WY%]ZKEM0WCNZY'WP#=)-^2W*ZXTWRW]][Q^Z<?G']X
MX=&YQZ-/AIYV/:MY+GU!?IGQ:L_K_6_VO0U_M^O]U@^K/YI^_/3I\N?F+\RO
M,=]LOWWXWO@CX:?)S^9?_K_N3F1-S?]K6DP= ]U0/;2^R*!X6JFAPHAOC)N>
M.2-JYBZ3C::+9QG,>C/[LEGW'(4Y?BYV'G(^R")A0=A"=TN;1>96@-6SQ1>7
M]"PM7\99#K..6Q&P<M.JY:MGKOZYYIG-E;5#ZQIMY78,>ZA#XOHP1R\GAPU+
M-IHX:SB_W73/Y>+FH2VM6\NW25QI;DCW#(\8SS OW^U;O.U\ENXP]S7TG?![
MO_/)KAO^YP*&=W<&U@85!PO5XP 6EA8>%1&TQS/2::_UOKG[#?9_._#\X(VH
MT4,]T34QTEAJ'"0^(2$TT2/)+MGRL.'A+RD/4R^D]::K,D29N*S4[/ <-] J
ML"GX>^Z#O-.0-J@<1H*G(\*1VU#+T<;H#YCKV %<)9Y)R"9&D#:3K2@ZE&?4
ML[1FNH2!9,:P?-AK.::<+]Q;O"&^2L 50D2'Q#X2V_RY!1H%SZ279'V%*KE(
M@2_**HXJV:UT+;4K6U)N5J%?\;/R?=4SU;WJZS5CM>?J1NJ/-PPU#C0=;3[:
M,M ZW':B_73'Q<[K7?>[7Q[YTJO=9])O==1NP&TP>"AA&':,?;S\1._)RZ?>
MCAJ=7GW&YVSL.<QYQ86^BW?&M"ZON++K:LXUZ?C0]=<WY]_ROIUSI_CNV?N:
M#_P?YC]Z_&3#4]*SJR_6O,2\NO+&_BWGW>L/_A]5G[6_[/U:_>W3#Y>?\%_=
MD[]XQ:A?#UO0I]&AHZ[H,M1@$P,M0"5+T&@Y:A?R/OHH*C;&'?T+Q?.*QJ#1
M.HOBL+\P"WYTH$!TZ(,9J AJTZGKJ-V4V8W;4/M)+6);%(XH1?!1O82N0T_1
M,_ ?/ &T" ]96()Y@+_]38E<+M:_MP.Y0&!_<@]R.1=6?P:YDVTIO(PD,8WA
M <@K]"U1+:B-5*K["*J?LG:!-OHLQ>1+'\*\I.$.#F$N/WF\";%&.KMN.V*?
M6"G(050+RF'3D4;<1P>%R#SV;K<VY 1S[7P&:HA^\K,!W*<.?&L<[E4%.V8!
M/U Z5',!+BI*X,^$/Y/MA8PC]DFZ#U 09X7^KIW(8!Y]WA;D,=:;CT28JNO
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M!QE1WDJR0ZYGS2<2D#M YP@_D(R]*00I\LE6%D&!HL^EDV 8C><GR754_3&
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M/J)'NXIK^!F?6A=5CD0QZ^^770W(JS8HG;\EH_Q(R<3*9F6(E#@S5>E%MP
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M5"A54&D7L9(247K%K9#L5G+#6D6Z7+!,^Q"Q'/>I:SX',=Q54<%*Z]<2[&-
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MW=.]D_^9\ZC#!WN'X],B+Y_"-C;FIF2QHZS7(B)8M^NV>7QF==;&CZCV>[S
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M+/Z/8IQ5KZQ78*JX:^I<L!FX9::#N.@J'T,K?E[&Z]I!PL18H,Z/\,3O@I9
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M6K89N5K2LJ8<=4"\*F@.VE_D.?X^ELS//'2X"E _=^ F,-:";H@$Y1BW24Y
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M1^Z%7F^:"H^K;C% $<I\I]J3R.%UL;I4U+>8,.UDS#B_7 T7<V+&=.T-C "
M4Z+QH2,*I3,LP=VK.E=KP/?E^>O&$H!K%1H5<4JT65U$[%KT0+6?-&[Z+?4U
M8A^@10ZCQ-OJ %=JZVCJ*E?=1-K=7(R&2_=8<U8]CKXZ>HKR#!VTB*!<0J=/
MMZJ<Z-& @](>ANU-08;HBGB%E73-9=Z*G!OJ-=QO:V*4)[C-47R%D)N[*%B^
MAQLQG:BHYH(!_TA\V49;':!7NU[F6_%!?4G:G).M2I#<3]JBV"N9'N4@)XJ)
M"\_(ZL49TPFR>V+[47:BVVS;+PH1IY'IQE<,J%VU2W.F*"F:44D0^0750.1N
M&5YY82%:VJ"RG^XN/2IO&C53>(Z]QU8'>*7^7.=44:9BF#]G[U!<-)4EN<B]
M# .16.F _MS"*,EAO>^T[Y+CRN!1OD([]K$1!:SLR"O:5#BES;-T>NKK%N]R
MX,H-3465BB5O&\=4@[T>-4X%2B=\:]X%G/D[Z]4B;%6LZBUMPU6^!1TMRNHW
MJ;HF1,VFE? &&CAWR7GK+\A>KW?62U#IQ/4-7R$_  #9-^RP3?FW/(82"B8V
M#<&&4MT;:N%O8C];+<@Y2UAUDU$SO<Y:]J/T$QE6.,H! )#22"TCJJJ^>2QF
M0SZLX2Z6F@*V'L<MBR58SN$^+)EL7H-7>*E-M_ ')RHM[O@< $ RC?; IIP:
MD>37>7?JLRCYR;?J8BA]*^Z98RG/@[<:NZF^7JG&0.J2B4K3**H? " ZQ[*.
MJ$IU0P [-P]CG<&N2":8/[/7K* ;W[%G!N<8TEA?O1;H6UB?)^H-<]B3 0#A
MUG_3:*5/?:!H;YY[G9N(DCS?]%KX><5"PPUAS>*O^A"AD^?#6H0P?F)O+5XP
M"0 0G/Y755RREJK\<X<MZY1UZRZ89BOV++^J_R&_OGAC;;R<Z"G3,>7]$R6Z
M!?\9=05S_ZOT=2<-IW+WFC<:YJ\[;(37OEK^EWZAKG?Q!MTZ'<AS0%ND>35Q
MK^:YN!$ X/\W91=X#_055J?-[,\L5L15][F7]BRU;G K;_ -Z+Y7Z3U=MZ&B
M$FR7T#U850@ B!]A;#LC^>A-H I&ZLZ^NU6SXKPW0*MW+&5U!]5$^T9W_@4J
MG_ZTZPP(;7>^8R_X]^I:U$3<;%..&[5@<.JZW@D0]:JSW1+HUJ61G9&PT[YN
M[;UPRXSQ'3@XW3ZJ]1V"_+L-0=2;(RIO8V\G*CKE=H\/ZL>JO,XN](ZP1^TY
M&(3/[=;=F.<SQK>E83;8\YN+L=]_M\8JINW[E+S,GA_$V2G2+BY1NLJ^_1?Q
M:9BTM8,4ZK.S^0,),6-<2PEID?V!1@?RG=^ML>+?ULC]U=W'\$Y)[_1CK%MY
MJ:V>D196VA+!B/71-N$9H3-F-1D9,^Q_65\Q?Z^@>*7_53N[FOB!*8LZIO!G
MK-S12N =#5O5/)H']\$WAO&29G@T!O)$8U;4S>7^[B]NWW^5H/.\;'7*U/80
MZ8^5/2T\*2@LI/&GY(Q/2<-<R8GIOQHF2\+'I)HW\'[/X]P9_U65G6%:9LK$
M-JIVWLK.YIV:G+"@1F]UFP^H?K':/,/'^E%Q?PS4A.9U P <]K]JFT]%5L'F
MUI]5YTKLM.$UB\LC6$(PIBH%=@O:6).8MQ"^$;)@E1^R$G;&]QGR;\1-AQWX
M5N3A+7XEIZLK6C#EEII>]<6J</!#9C)P(\P%NA,\";$P=PYT)2IHY5+8=XR#
MKQM\"K;4H8JP%+=J(*UP #6JJ:=D"WJ=*K6<AY'3+U?Y8$]#D,!>_*3L;Z"?
MA-6Q*R"[B+D^&1 @:;R#*V$;>5X_/N\!A=-PLV@&Y89"7CJ.&D4K*#]/-8*G
M5;%HH[(N I_28"O20%VT0PN,-3=IS\9<(LZG6_KVY)!Y;^L3\T_S"'+[HGO<
MCY1;I8>YE)J[%7*N8^:QZLF<_N5$X E._ORWU7S.Y#'U1!X;T9N91536U'W*
M?:)PDPX73I/M(P^53))"@:?+[DL69CRJ1(O'+]M3O4#D/K^RDB"L'X,D7N!U
M; C,.&.Z9'F:DV\8E)S-U]3R2">*3-J"ZE>E;'5VQOR*:4K!LD650XJ)WJ_+
MC\E;QB229O T/>GI_-9PRYSL64VK)>/S"NLC2!,+JRTQU1$EV49V.KGLC7Y.
MC+5"JLOU5I;!-<_'^)!2>+3N_>M-?02S-BNLNTE,SH6W[R!2"M#-GZLV%9<V
MF-/M2[_6'8Y96,ZRC/&>5YI@F#-F$HG$@W:Y@J\7K#550;N+^T5GX+"RA\0%
M2,_*UU5 U G@C?4L3!FX,WH>MA_FY_48^P8^/"J%<0;YKH,#%%>1C&&@=N!]
MX5\0"W@)(1!&A%95LA%Q<$;:%N0;)"L*CUZ!3O J0H_&I(P*8H["'6V[52E&
M*/6LZFLH)T%$S3<T&3<$_H6Y6!$)?87S237 A_"02 [B!X'N68\((GP9-8T9
M2 :VAI5=(8EUERK3R<$\0W4M^2BVK&:(DE'V$WR*<B-%#NVA5D5L@#VDGIGS
M%5I/O0/XP<RFUS1WE; X#&UYN3NGA!M82>?XH']6#['OECZNN<-N2S:"+[))
MX8^A=NSD.3 PGNT!>,HDL"XV516I932-?VF<U, 95SXDT:*>5(T3\TH> E>*
MN.N.@Y8*6\-7@_,%GSU>UFP0_ VXQM2P=8UE!5_T>'5(\6[=,'MFV0K--Y1#
M19UZ?LGDJKM*U+JIP!OR=TOWUCR0W?%0 4-E<L PLXLM;:C/W]58H<(5B:V?
M6 6EDRQ%R'7E<./>XL+*(7W%6G#U#AUD:01PLS;"([K:7AT.V,_<R>8V>.1=
M[0Y7/BUL[YC(/%CBW=*)V%Q&:TPK.EMQR)J_YD/5 <O8L(/5+:8'LT]63=*1
M 4/,XVQZ73AZ<_XG^27,<'$Y X1]4Z:&[\;/JI07WB'$ ZN3]A-!X*DA;TE@
M:+E[*>D4K/!/5<3#? <AJE3(6I$O@<[T)>A5( BL%2.'-!<\P)Z#[4E\B!^+
MV!D2B?^ *G<[CS^.NO$G91\S":#-<"]I+'PEXBAM,N(O5 Y4@/)!'\E_B>9A
M%R:Z88[C\$O,V'8\W:T*ZX/_<^:6>M=H#QY#,(OW0TX2F10>#$1*A$3#GY.^
MY.U!PLFM"3-0!RBK@H^B)93MKB=0SRGR/U41C+X)>(3E) *!.EC+R*&04E8B
MZ#/T"RLJ]PA<S J(CT*\8"T,GHEL8,UQS40Z,%^/C&RUM*JG8JTP!7A;/)[D
M ^H0Y=9\@F0)Y3F7H2\$PZM9\#2!_V(Q_!%_[XPG<"Q_GRV;JRHKM5,$P.H:
M]55B8DVXJJ9F+NB%XF[.)(A6SHB[#'TORUT\'0:5]LZHAWE+CMI2]JV*H#H)
M?W-5C+F9H 0Z&0E 9,U!?71V*1BA6QZW&')>LSE(!PW2+)B1"YVNL*TWM#7E
MJ6WO^$&5)2T@_+?J18W\ZFO RU9KUE40U>*Z:C_XFBDK:![$S5@^_0$D17EZ
M1"GIY$?Y QQ?2F;Q..QVRIVRA94_J?S*J9FC:$NJ+\;6TUZ!2OV7T0]#BEQN
M,=,AY7_Z:YPBDW"G8B?;A6BN7HFQDC)KZBI^D)W!%S(\R6>@SU;<I.CA%_P:
MJ4G(E2YBF@#Q\4]_><H]<+.@VYA_X<?!*6@:_A[2H_P!81>J)3V$J,),63&3
M5((M\9M >H%+<%E.<<'^V0%G;)->0NMPFQDP3!=^'VH1MIG05_88IR"*UJ_'
M4TG)RT&$]:1OBY2$O\@0%SOB<Y*MOR0Z)(R^D9Z.,C-F(">@NQEYI4.8=@8U
MK03;P+ LD^(8C)T+;^*., XZ-Q,6,!ILV5P";Q,,TI(0]P14A!/REV!BR5'T
M.#XWE849R_L5<P]SG6=>6(3YQ0,Z%^*:N5]MV7PS+$"YDTJ 4Q2WX*L05OG!
MDM'(#3)-RA'4)BDM9@V:*>GP_8I&2R#.0=@"$=JF)D)'&W=03L'R#?$P/9Q>
MRRDN04BTW2G>2*7&.;H'5:3ZZ,M&^:J>.P,PZ5+;-PA"(V1^TQ;*>BBK82ML
M/*S!FE%T%MYLOI7<B:@WGH].0)89-OI.1X[3 YTZT1J)K0[ N<*1Y9<0\CGY
M14;0$4YA:7/^<PZC@K1F/V>H>E:$'=>W!C/O',\#]-GQ$;\-=/M/503'/LD<
M++^+!S-/5)757&2^ &[+=V7- 3U:,X%5#GD;CF:=@.V8!V+SX<<=;W.>P/^<
M^F XL';2)T%*<%'T7-@BX"FZ$7XUSYU^ UF3%,((1%U=NH=AP$R=^Y#IAAET
M/,P28NILB=Y$Z<"<P#I1)V$_51NH8/R8W"#J+ORGQ"*:%^'"4E>:B"B>BZ==
M))YUW,Q DR:,* :;)*$FH[^0)U!O5,G)%-K:G #RWS1SPE9*+.U.F(S239\U
MUYVRC^[EV$-KIMLJ%705X0KW%CJ "./>KCQ%O,/MRRXC)7*+XQ^0>KDNH6_)
MHSFWO1I)]SB7''E43TZQ+=&?Q&-D4%0-P45ZJW(B02)UR6HGO)$LC \CYHM+
M0HN)3:)K7NN(,6)G1RSYJB#'II;@,G6OD:=QW[3_5.#P. TK:RK^DMI^=2LA
M2CD<<I) 5?I[WL#_HYSD6$4Z+=A@2_1[L&0K'9F'\[7\*'^'JS.[9.IP;XU.
MJY?BU^HY(7@\53_%DX,;U%YV#""-%]C.P!#2I-OS_H:P)=\*7Q=OEM!+;J6U
M27S+ZV+#Q#^K9@6^DZP#+G)G2;\ WXWZ()T&<OM3%2G#YXMGE3T";Q&9*[.*
M'HN"JAM2/PNOU1Q>T2W< -X1J!3>A2:[KQ<'0W>-#A#!87]^\RP>#BK0@!Z!
M>@4K(%N*)O"?P&I2O?G-\"_+/_/)R.K L?QF%,,=(#"CFD:G":9BPD>>$(OF
MQ:)NUS3S'#'N!1^Y1[&1*>NX<MR*Y6%<--X[ ,%5XD^X67GA^,VC2WCCB:=L
M=0 &)X[T#W 'QX.L*7!B/Z7,2RYA;Z>8EIG9.LIW_\?L;FJ<VQKV+^K4T4A.
M/,TV]J([6&K6V^I7+!;;.S^3E</V7;>--9<]<=E8YF?6:_\MS">L!VZAS'>L
MQZ,5K+]8GVV)_B,S2CRANH(9+3J2=X8Y2;1\G3_CA+ V!LNH$T[P7\1@""ZZ
M?F+X"3U&&YA$CNU>* C#1SV_Z@ICL0J;E\  *$%K>^C;%,NB/]#I\G*_-GJ&
M?)FKFK955C2ZD0'E'+$E^A_T+%-R%91>;HS+O4 /T.]=&T.[7#LOVDA3Z*;X
M%='6:G^Y9E )*M5H-;V)LWM$0>QJ67GC2\[JUA1\RMBHS2D^')^AT9=5+J5H
M%E1LFH_5M%3E.*^OE5?Y_DY2XR!_WDKF1;"'UKNTJ\13,ZW\1\8X]=RJR-7#
MJ@Q@VE)7Y3#(<_X*U6QPD3-$@P#][E_A/&3UR+U &:K!FHCBE;^O^9&>KG@$
MZ5L]6S$+MCQ,(=? ]=YWY0<02.=2)1?^Y'>Z*<79OJ"I82HPB-U%I?(&Y*_U
ME;+C:+\XH&P,9EGH<RD;Z^6-DIJP]<X1LC-8I]^)8_>_I\6 _3(&(:70(-U-
MG)Y6)WE#/+"J01)$2@^M$3>2CGG;B5M(/YPG2K)(M;\31QK=-NM5?Y+<I;\N
M>"D)9B2G <0@!FW5.%$C0Q%R2V3/,,^[)AQFM#I/$$UA;/M]_:Q_<TIUH5C,
MEQ5DBA[R2:E@D1=_\4JB,)MW-J10L(DGG<<6Y/,DSJ&"N;RDD>MMB?Z6B"U/
M*)@D?"5[D+I8Z"F;OS)6$""-"5G,!TDVS0OG.TA'.3W@-8G>_H^B"P=JW?/[
MA'-U])23@E1M5NP=_GJ-PY)[/)P:.6\T]X7:S^DZMT0ZX?^KXG\:WN3<SHRK
M+\AO3-QG=2Q*B/IB^58RY"^Q,,KVS%Q;=ZI\R(%O75=A_SLAMB)L9Y:*':PW
M2SPR>NL*RG(2(\SO*RA1>M.^*JQ_AFD:<.+,=/-DX%:'VZ:;P'N_6]X%:_M.
MJJC,(JA>G?[!/ OX/:'1^!>H)6J,@0_Q\7NJ/PS-G>EC$$&WC7756Z'W?U]O
M)-E.514.FE;""M,C#8_@#?'G]$;$Z4AH;07RGA]4UX@:<+]9&XHZ/39(.X#V
M_L_U-*!-332D8#GKM7I[7%%\L&X[?G;$$2T=O]UOM&8#(="]5CN;,'?L$K4?
MX=:?<<;VWRT*<+7;*<?6.^@8U-6K![1!5'U$AOH)]> BD]J>>ML=HPZD#H^-
M47RFG?O_;9C_6@?C3$TS:%=P8E:GJ)]RO,-?J(SLYXN"E.WLT^Y>RF[VL['I
M\MGL?_Y'B;7%XO*TQ9IH<4S<(]5#T:%PM5(H"E]X0\$4.;AM5^!$26/]I:W\
M:_^C(C1*U8.T<6JLJC7NH&JZ\G0X2J%67%]X5YZG..#V1>XH;QZ+E60+QOU_
ME=[14Y&=FEC99<H]'Y/:.:E@>=#S]OM%$"]A^[7B3T[&KM821P"@R;'\SQ<W
M&%MKK#_255ODEW"H8[@D(GIO^YRRD"!!Z_[R3UY%K8A*?Z>C[9LKQP( ]7#@
M]/]<3["-;.N7=V15O$H(;#-4*:-7M3P#N@5-;F;64+RF-H\%Y3J=:[D#&@\
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MND\7/LWJ-O>5',VCB]^5"XN6DM*K DJ'J[N .RM7I]\!3P?J8PY ;H);O1=
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MM]Q-<67\,/S31"*O.G<R92-W++4XC<PY%0I,[V:_=OZ>&<3V-'R>:<#ZHSD
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MXAA@+V</(C4CD7T&N 88S+:)Z<Y:Q6+YNH!+F2]M\R%R)FU7([B1R5,_"[_
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MZ;IU=U.A0O>%_[4U_57H2MQQX++(K3E]67MB=5(J( X)KT)B868I4J?&[%G
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M*:L;P5I<S)A$SM='_WNG_/^E' FT4;2Z90K] II@@&* T-U;S!@EZ-;5#8P
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M_,WHVJ)C!_&-]BA:G[$0@$:TS:$J,/3Z[K0/V/;RGP&IN"^R4:N?!"17\-0
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M9=015+5O,6>0*HR6-W0G$+0D#UNWP*9%X77W$\[R;U>( NRXZ4IU!PO6!U&
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M1FLY*X$?N%).)3MQ6S+G?^R!\")P!\?+;0RTAO/XJA7K7_[\0]>!=;P)7?\
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MD;*E:X/?B/X1&3;>$*0)%CA!V"@&6ZD0E/L+ /1#YG6$=*U3=4NA5D722S)
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ME/>"AB@8ZK4>C>J#FF4..F@TM$5L3YVC5##QV@X5I4K$0M2A!=^Y(F!(6K7
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MVM6@]>L-5R>6;9@]LVQW[ZWE\?8;:XM49[9C!(>"&34S2<+J\7P9>;A<31B
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M#Z#I$0]@Z1'WD1GA]]$98?>QF4L)"->^!01[/P/<L(V@-L(;U,5$/*_;G_)
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MX+6E$ 3NS@1A/LD@QG\_2 R*!6DA42!K7P3("PL'A>'[ "0B%)1&AH"*R&
MC0H&L*B@%XCHP!?HF(#GN$4':E:\"1@[_@UH02L!-V(KX,?X 4%"Y'->6LH#
M3E[^K9K2RBO52,QY$I%\&DNO.8[D<(_":H6'*Z5U\V5*R<$2G6RNV*28+:I7
MSA8VJ0X4M*H/Y/=H)@L&-2-%0^K%]+/A9\/_SU#C,3 \!K['((CV!<+]D<\%
MJ2D/N3GYMUB0BBMT..8\A4 YA:?5'$>SN4?@PMH%J$0\7ZZ4S97J%+,0D^I
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M5LBHY_#X#@9'ZJ2R]"X2J]%-8K:XR#7N%@K#[5Q,@+_\3<#W&&2[O@3:'6N
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M47:"$5I/LY;:> U%5EECOM7HR+6U. J,[8W%FL4%:CT&\=9_ ^W&SX!MP]?
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MOJW1('I[!$C8M0^D[ X!&7N#0(Y7 ,CW]@=%GA\\)3Z^H-S7!U3Z>0.8GQ=
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MT?_\%QW\XS=X\.F?H&#%VP5@[?OI8,NG"6#/%]' ?WD8"/TF!$2M#@3Q:_U
MTGH?D+;!"V1MW MR-^T&!9MV <CFG:!LRPX W;(=(+9N ^AM6P#!$WG[ZP(5
MG_X:5*[_,X#N?0]@ SX'I/"U@!RW Y!2_  N)QP@B^.?06%IC\H(.?>+&45W
M"GBEM_+$%3>RE577,W7P:QEFY-6T!M255"?Z<DH[YG)R/_92\CCN8M(\[G3*
M,=RAM).X@^FG?K"?#=\9*CT&J,< V_.>YZOT.:"$K0'4V.V DNP'"%EA %T4
M_Q0&37M4@<^]7T(KNE/(+;N97U=Y/4<!NY:E15S-,*.NI#=@+J<YL9=2.W"7
M4@;P%Y.G\.>2#Q&.IQXCS*:?($QG_'  ZC%4>0S(W>\!DM_G@!:Z!C"BMP-Z
MHB^@9(0!?$'\4V1YVJ,J3.Z]<FKQ;0B[_$9!;=6U/#GB2K86?3G+C+V48<=?
M3&LA7$CM(EY(&29=2)DCG4@[0IK+.$Z:R#Q&'GU-H.H[ WK7NX#JNPS4A*P&
MK*AM@+G?!]#3]@%R;MPS;$G:(P0B]UXE"7*KE%EQO4@ NYHO15W.U6 O99GP
M%S+MQ//I+M+YM![*N=1QRJFT><I\QE'*9.81ZE#VD>J![,,_&(!]\FL 6_=G
M@-WY+J#Y+ /LX%6O[F(X\=Z E1(*:-EQSXA%J8_05;EW87C(K7)ZY34(#W&E
M4(*YE*?&7\@V$<]GVLGG,EJI9]/ZJ\^FS= .9QRF364=I@UG'Z+WY"PPNG)_
MN%<&N,= V/$NJ/'^#/""OGEUD\*/\0+<Q!# S(Q]1LU/?80OS[V+Q$!N0JF5
MU\HXR,O%==B+^2KB^1P3Y6Q68_69C';ZZ?1AQO'T@XSIK 7&<,Y\34_N069;
MWD&F._^' W"/ >$QD+:_ UA>GP)AP$I0&[()U$;N 8+X(,!-C7[&S$U^2('D
MW,7!(3<0).C52B;R8DDM[ERA@GPZSUA](MO..)K57K.0.<P\D'60-9PSQ^K.
MFV.WYL]RF@IF.8["'PX@/ ;DNK\ ZK9W '?OIT#DMP*(@S8"<?AN4!<;\*PV
M.?(A+ROQ=DU1UC4*M/@B%E=Y!D%'':_@$0Z52"FS15KZ=+Z5.9'KY(SF]'"'
M<Z9YW?D'>.Z"&9ZC<(9O*Y[A68H/_&  Z3&@/ ;:UG\!_NY/@-AG.9 &K@>R
M?3N!+-KOL20Q[(XH??\U7G[&^9J*PI-D=,5A+ 5Y ,XB3%365@^7*FH&B@V<
MGD([KZN@7=">/R)L*9P6VHNGA!;(M%!?,BW0E?YPWQL86_X%:G=]#*0O;Q#\
MUP%ER+:GJDCO^\KXD.NRU-@+=;FI)WEE>?,,1/D4B8 :P=")?7 >K:M2PFHK
MT_!:2BS"IN(646-QG\@&F1092R=%VK))D;)\JE;QF@#*8\"L_0M@;OXGJ'NY
M__=^"52^:X F:,MC7?C>V]K8P,N:Y,@SBIS$0R)(SA2GJGR(AD7U$*FD-@R+
M[D34LANA"KZMPE!K+FNL,Y1U2G1EXQ)EQ;A85CDA%D,GZ^J@DZ(?"J __C7
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M'A,6-Q'])^"S10*B-J"]%[T_*_?*_&Y2F?>A2W7!L\.:"^X/ZBR[TF\A=_H
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M)9&C1R20GC-22//8/*3Z\5*DY/%6B>P)E7E)$WK+(\?--P0^PNX0/'3:PWM
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M-D$=;+*UP*I4!RQK]<"B51_,>PS!K-\(3$^@+AB#R2T3,'F*>F<*)E]0LZ:
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M/G1IP]US/N!PAS3H>,OI//ZZTWW"%=)KPD72%Z>SI%G2L,LLZ2AYUODP96Y
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M(^X<BZ>K7(CBZ9X.\34]+@K!'!'&V!\2I. />&63NCV**1V\:EHKMX71Q#G
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M:BW..[=:G24=L#Y#&K0YY73!=MAIW':0],[N".D'MI\$V ,N@.TB [9C#D!
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MQ?8VV$9U=SF$=8\YAW2M<PWJ6G8+[#I#/' -['SO$MB!+D$=Z+P29E/@5A7
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MPHTI5"XLHG)@(S% 9<<9*AMN(O81A_ZA<3M ,3E_J=_G?Y'D_PE@>PO Z!Z
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MKU*06ZZ1F].@G97=I9>>-6J0FCEGE)RYS20I\[A)8N9?Q!NCI$PT) Q6P@B
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MZ?01RP;QX+0_PKF1]_<A[TW^^VFH"'?")/@I5(8;H1JX%&Z&T^'VS-$P3_9
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MI4+YNV(HWVJ$_/MYD-]> ]GM?5"\_3FDWS^"XJT74/SN]3]TD?ZT :!F"U!
MN2=3WF&D[74:&'<>L+H,#+L&Z-\ -+]AH')+".6[,LCOJD)V3P>*]XP@_=4"
M"O=M(;GO!-$#;P@>A(/_( 6\!R5@'C0#]Q<0)/* 'O[@<^)7X.&3?VBG?ZH;
M/(/:"Z0< <))VY.T'4A[%&F;? D,^190^QZ0_P0H/F:A\%P!HN=R")ZK@O=<
M&WBF3PPCK @'X+D'$4)04_"<7D3/:?-Y3@ON!8F](*&_SA*?_4/]U@]G4#3F
M$51S+])V(.T1_P.,;@+:MP&5GTG[+B"BL/FO (;C42,L)F3 6V5"G>YU"2/"
M@AA#3" ""7HI<M04<50/CB8?1XN.HT'G=OX#IS><,*5'D-?5, .G8@5.V1&<
MW)?A9)$,)TUE.(5"HHIH(MJ).40WL83A)"N(?G"2C<1V8A]Q'&\EE_"WY!9>
M2A[@F>0Y_I!P^%V!PU,%CGDJ_;]P!B;@#(S Z1,Z%(O62(K% 9R:%\43QG#*
M20PGSR4JB'JBE9A%=!$]Q#)B-?-6OH[Y6[Z%>2W?C5?R(_A+?A[/Y-_B=_E]
M/)8_PT,YQSQ0XIC[@RASS*^?P!D;@#,FSV]$&)#G-K"@NHRENKA1/$$,IQ''
M<.J9#*=60M0P;]6:F;_5IC.O5.<P+U6[F;]4>YGGJBN89ZIKF3]5-S%_J.YD
MGJH>8GY3/<L\4OV*^57M'G-'[1GSLSK'_*C.L3]HO.?V)W##AH ;3O[?5!/<
M,(IC.(V)J0W%Y$3Q^($;&L6\&9+*O-3-9U[H5C)_ZDQF?M=I99[JS&*>Z,QC
M'NLL8A[J+&,>Z*QF?M79P-S3V<[<U3G _*)SFOE)YP;SO>X]YN:09^Q70SCV
MAA['NTY\H<?Q/_\$SH+T+<G_6ZB"&ZE-T)B,'$%?.^"-F2=># ME_C!)8)X8
M9S$/C4J87XUJF+M&3<PO1FW,ST8=S(^&"Y@?#'N9[PU7,+<,!YB;1EN9;XSV
ML5\9G61O&'W!7C.^RUXV_I-WP83CGS/A!&=-..&9_\"-)&TK)7 VY/O'J!-4
ME]'#\,K&!K];.>/A2'_<M8QF?K),96Y;Y#/?650PWYA/8OYGWL+>,)_!?F'>
MR5XS7\B[:KZ4=\5\->^2^4;>!?.=O//F1_AGS2_Q3UO\R#]N^51XQ/*MZ) E
M)S[P@?V6G.0CG WICY:"LY>!&T=QC-? 2P=]/+$SQ]TQ=K@]V@/?C@[%#=L$
MYC/;+/:R33%[T::*=]YF,N^L]53^:>N9_%/6\P0GK!<)CEOW"8]:KQ4>MMXJ
M/&2]7W3 ^JQHG\UWHMTVCR4[;%XK;+/AI%L^L/D3N#&*I"\$YRRA):V(-R[*
M>.*L@9_'&^#;\:/PN:,S+COZ,^?&1S&GQJ>PQ\?E\HXZE/(/.U0+#MHW"/?;
MMXKVVL\2[;'K$N^RZY7LM%LIV6ZW06&KW2[I%KOCTDUVUZ7K[>\KKK7_2]9O
M3RO(@9.O^@^<@PB<$PO.C8??/03XU4."7USE^&J")JZXF>&LNSU.N'LQA]U#
MV?UN\;P]KNG\71/RA=M=RD5;76K%6YR;))N<VQ0V.'5(USMU*PXX+9/U.ZV5
MK7;<)E_E=$AIA=-EI3ZG.\I+G)^I]#IS*HN)GO_ .3*D#SSQ)L_G1_[?3X O
M?"2XY*V*4[[&..QGBWU^KLQ.WP!VFT\4?Y-WLF"#5Y9HP+-(W.]1J;#:8Y)T
MI?L4Q17NTV5];IU*2]UZE'O=5JKTN&U27>2V3[7;[9S:?+<?U.:Y_Z'>Z<ZI
MSR7F>'!JGS)XM/S2"_B9_/=7M,5?"65Q/EB(DX%*.!@\%+M#1F%KB".S,=B'
M'0@*Y:\)C!.N#$@3]_GG2I;ZE4A[?:MD/3Z3Y0M]IBHM\)ZETN6]0+73>YG:
M'.]UZK.]=VG,\CZE.=/[IN9TG]\TVWS>$)SF-%].XU,X5WIU4?[?D?>]&@F<
M(>]W+)*'@^&*V!FA@\V1%E@7:<^LCO!@EX<'\I>&10D7AR:)%X9D*BP(+E"<
M%U0NGQM8J]01V*0R*Z!==49 IWJ[?Z_&-/]^K:G^V[5;_(]I3PGX4J<IX)%V
M8^#?!*?5\![-CW">P)T@X$O2/T^^[U@\]=EQ#';%2+ I5A-KXX9A9=QH9EGL
M!+8GQH_?'1TN[(J*$\^-2%68'9&C.#.\6#X];*+RM-!ZU:FAK6I30CHTFD(6
M:36$K-2N#]ZB,RGDL&YMR#7=FI 'NC6AKW2J0[E!M FMC_SE _P8!GP62YXS
MB;Q_"GD->N5N21!B;:(:5B098TF2-18E.K%="=Z\N?'!PEEQT>+IL4D*;3&9
MBE.C"^13HLJ5&Z-J52='-JM/BIBA61NQ0+LZ8KG.Q(B-NA41!X:41US6*XNX
M-Z0L\J5N620WB ZA_9$G_C0.5(.+"50#\GU[,ZC/3J<^-X7%RE1E+$G3Q\*T
MD9B7-H[I2/'@S4@.%$Q+BA"U),8K-">D*3;$Y\KKXTJ4:^.J5*MC&]0GQK9K
M5L3,TRZ-6:I;$K-^2%',/KW"F(M#"V+NZ!7$OAA2$,OI$CJ%G_" QN&K&/+^
ME/\ATM^93=Z?6$WW2S/D6)BIAWE9%IB=:<=,SW#EM:;["9K3PD0-J;&222G)
MTIKD+%E54J%R95*%:EEBO7I)8JM64<)<[8*$7MV\A &]G(0]0[,3SA$_$\_U
MLA.X(80NH?.1>S07OZ Y<(IRWT_^>UL>>7_RP'T4QZ(<&>;EZF!VGAG:<T<S
M4W-<V*9L'WY]5K"P-C-*4I61**U(3Y>5I><K%:>5J1:FUJGGI[9HYJ9TZ&2G
M].AFIO3KI:?L&IJ6<I;XB7BFEY;"#2%TTS_AYPA:#S0/CF61]R?M3=3RK"86
MTWU7@12S"S317FB*ED(;IK' D9V4[\FOS@L45N9&B,MRXQ6*<])DA=DY2GE9
M)2HY6=7J69G-FAF9L[33,A;IIF2LT4O*V#$T,>,T\0/QIUYB!C<D*8/3_93;
MM!8OTCPX3-YW!VFO+R//5TJ>C^YG%XO15J*&EE(C-)2.8NI*Q[%5)>Z\BF)_
M04E1F*BP,%8AOS!%,:<@6YZ57Z22GC]1+36O43,Y=X9V8FZW;GS.JB&Q.=OT
M8G).#HW)^9[X0R\VAZ/O<;J?\BV-PUD:^P,%-!=)?RWYSUYB+MVWEPLPI4(%
MDROU45MIB8F5=DQ9I2NON,)74% >(LHMCY9DE25),THSY:FE!<K))16J"<63
M->**V[1BBN;K1!6M&!)1N%4OO/ X<9-X2E^_U8THX ;1^<AU&H>3- _V4/N[
M:2*PJF;P#(@\5Q7YSFH&DVJ44%T[!!5U9BBM&\T4UCJS>;5>_.R:(&%&3:0X
MM3I!(;DJ73&A*D\I;F*92G1EG5ID9:MF>$6G=FA%GTYP^6;=H/*C0P++OQX2
M5/Z;;E#9&]W@,DXGN/1?KJ0!1Z@&.RIH/=:2[ZP?/ ,"6HE)=#]QLB)*&[50
MU&B*_"9K)J=I/)O1Y,%+;?07)#>$B1(:8B6QDU.DT9.S91'U)4IADVI40R:U
MJ ?6S='TKUNJY5>[4=NG]K".3^T-'9^:)]J^U7\3G+9O%:?UD?,T_P_0^&^A
M_-<TD.]K F81C40EV8*BJ1+DM:HA>YHA,MI&(K7-GDEJ<V7CI_GP8J>%"**F
M18LB6I,DH5,SI<%3"V6!+1.5_%J:5'RFS%;SFM*KX=&\7M.]^8"F6_/GFNY-
MCS3=&U]KNC=P_X<35(/=5/<-@^=0Y,&[II+O:B7?,XU\UPSROC-Y2)NMC.2.
M(4B<8X:X.:,1/<>)B9SCR8;-">"%=$0(@CKBA?ZST\2^L_,4O&=5*'K,:I"[
MS9RA-&%FCXKSS %5IYG[5!UG7E5UFOY U:G]E9I3&_=_.%1.<Y%JWD_:B]MI
M+4P'FDB[<C:0W4G><SX0VZV(J(6:B%AHC+!%HQ"\R!Z!BUP9_T6^K.^B$)[W
MPFB^Y\)D@?O";.&$[E*Q<_<DB6-WNW1<=[>B_8)^F=V"/?*Q"R[)QL[_53:V
MZR_YV$Y.Z5-VU[X_A^HC[?D=0-L<J@%I%Y-V^B(@>@GY_SXA_)<KPW?Y$/BL
M& ZO%3;P7.D(]Y4>C.M*?\9E93CKM#*>';\RG>>PHI!OMZ):,&;%5*'MBBZ1
MS8I58JL5.XGS8JOE=\6CEKV0C%K**8Q:\B];R8*MIKP7D78'Z3:1+:SH 7*6
MDO]?0?Y_#>!--G'">D4X;U"'XP8#C-]@@7$;1\-AHQ/L-GIB[*9 C-X4R=AN
M2F*L-^6PHS:5LR,V-?$L-\WAF6_JXYMMVL8?ONDT?_C&GWG#UC_C#UO'"88-
M_,L Z2^9"\PC:]RZ&*CM(_^["DA="T1N /S(&KIL \;NY,%ZMQRC=FMBY&Y#
MC-AC <L]HV&QUQ'F>SUAMC<(P_=%PW1?*DSV%<)X7RUCN&\Z8[!O,3-T_T9&
M;_\Q1F_?]XS>GM^9(;O_9H?LXOYA.>DOH-RG4\WKR8Z6D';&1B"&= /(DKKN
M >SV R/)MIL>%<+@A Q#3ZA#[X0^AIP<#MV3UM Y-0[:I]RA=2H FJ>CH7$Z
M'>IG2J%VI@FJ9^9!Y>P:*)_=#Z6SUZ%\YC&43[V"\DGN'Q8MI+5(=6^DW,O7
MTSH@'QZW"P@D+^YVD/2/D <_#IB<!H:<9Z!^20CESZ207U.![)H.803%:Y;$
M6$@_GP"%S_TA^2*:R(#XBPH(K[="<+T'_.L;P;MQ#,R-F\0CXOD_S%D&-*]Y
M?P:4LQV()^V@PY3_,:K_2<#R+&!T ="Y JA^#LB^9"#Y5@#A31GX-U7 ^TX;
M9+" 6^; ][; ;6I0?_"EQB@*^"GS_1]E^IDF_,]4Z%^V$)30+S>H>;O[#U-)
MOVK3^S.@!,H[F'[$[10PYMWY#V#P&:!U'5#^&I!^!PA^ #V/^$5$OR\#[JH
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MX/A91 G%54,T$^U$!]ZP\_&:78R7;!]>L&OPC-V /YAM>,KLPQ/F!!XQ5_&
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M_T\"/E-:\%QA (^5%G!;Z0C7E9YP614 YU52.*V*A^/J=#BL+H3]ZFK8K>Z
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M+G8_<]+]O WXA<*_G)U!+C:C$S:91;'_X$3\2!1))86DFK3@3_3@=\RA@U^
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M39U!4-R7MC\=6$<6DV'2S?>:F(]JQE/&N(K2-)"7+D%.NCDRTQV0GN&!M(P
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M%E"?)7E:,9!80N]9I@%9N021Y6:05M@CO,(-895^"*T,14AE-((KDQ%4E8V
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M(_)[<GE:0D)-;GY.<EIF$E0T\]A("J.)KE#N"OG6 Z[-C(B16-"Q&]%,ZPT
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MC0*AB@&XU:\+'!RZYDK3U)-$IQ<\JC?)1Q^SXX\,_5CD^D<Z)IL!!-( ! [
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MQZ([V-B#@XD>HYU^_7$=I'T?RARG'H,,&K40>\U%CG,[5NN'.DC[7@VC-G$
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MB%4/VW]%IAN]W(S7N^I=\#=PTXX%SFGO+N>T;RP%@YW3=#^Y(,\+>?[  H)
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M@ Q?0(:O.8V*!,APS!U1EOA"JM+1/8A'1FIRB\EM#B&YR\:E]EA8]/YJ.G/
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MK,BZ<B.^65B)ZQBY/<".O'G0*8^7JG6=I3)]&TYL:,8+30T$?G7=6 )5D,$
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M3GX$F-Z9!(R?3@7&>8N >^::7V,?;#W;/WUGV\7W<OQ#'Y -;<NDRKI=5>)
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M%(O%?04*64^N5MF=;=!T9=G+NS)]VHZ,F*[A6$Q;FQW3^7)B.A>4/3>FO5^
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M1T[CVA)/X1N23N'K[Q,H>6D\*'SK45#T^3.@$#*@UL\ I=OG -S^I: T<0-
M9^S\&Y9_\(\B=,JO>>1CU[-9^3]D"DNNI,L1EU/*T9>.5I5^FV3!7SSB)EP\
M7$NZ<*B9=/90'ZDO<8C4GC1$;CPZ2(XD#Y)K[Q. 089BR% "&8J7O0ZP:V<
MXK;9@+QW*2 =W@!PJ;MNHW(.W83#4W\I(N3\F,<HNIK-1US.E&*^2]/@+J;H
MB1>.6LCG$VNHYXY$:.<.=] &$OMI[4?[:0W)_?1P2C_=G]I/]]TG ']Q/"AY
M\U$ @PR():\#PIKI@+IE-J#O7@IH"1L .7G7;7S6H1OHXK2?X:6Y/Q112[[/
MXZ*^.R;&7<Q0D\ZGZ:EGDRWTX20/\TQBC'4R\3BK([F'U9#2PZY-ZV'[TGO8
MKHP>MC.CA_6? @C( (,,<,B _OIU0%D]'; V?0$X.Y< ]H'U@)FX\S8E_= -
M?%[Z=30J[QJ<!+M<R,9>S!41SV4IJ</IE<S3*5;VJ:-^[LFD%EY72C>O(:V+
M'TKOXGLRNOB.S"Z^):N;5WV? /*%\0 ^Y5& F/D,P'WU&F"LF@9X&V<!P?:O
M 7_/.L ]&/<W*^7@#6IVVG5\2?Y5- [Q'8R..U\@( _G*!BG,RLY)U-M_,'D
M6F%O<H>H,;V]+)C17N;.:B^S'FLO,V5WB*IR.H3ZG,[_&$!!!@1D0$$&XJ+7
M  >:QD<NALJV? 7*XM8 X?X=?_..)-QDI:=>I^;G7<6C$=^A*/ASQ5S:Z3P9
M>RBK0C"0YA#WI]1+F]-;I<&L%IGS6(NL.J=%9LAME5;DM4K*\]K$FOSVLO\4
M0$,&Y!N/ C1DH"Q\%?"7OP_$W\P$T@V+@&S;:B#=O0V($P[\(3B:\C,[*_<J
MM03^+0Z/']G8G2J4\ :.58B/I[OD'6E-RE!6D]*1TZ@RY3:J*O.;E.4%S0I5
M88M<4=@JE1>V2OY3 //\>(""#!C(0/_R52!:^AZ0K?P4*-<N *I-*X$J;O-M
MQ;Z]O\L.)_TH2CMVF9-?<HZ*Q@WBJ/1.N$#05*"2U657JT/':LL=N?7EAOSZ
M<FUA?;FJJ$$M+VY428N;%.*2%GE928OL/S5J0$,&+&1@S7\%FKW?!<KEGP#-
MZOE NV$YT&[;<%.[>]=/Y0F'+JF.II^5Y!3T\1#85BJ!45?*$OKA$H6KL%)K
MS?=4Z@NCE>KBN@IY24PG@=67E\$;-$)XHXH/;U;P$<WR_Q3 0@8,9"C];!+@
MS'L9R+YZ!ZB7?@1T*^< _;HEMZJVK/W%L'/;%<.!_>>KCAX]H3F6VRHNQD;8
M6(:'3!59L *5'J&I*(?9JQ2P2)48$=$+D745?%1,RT75EW-0C6HVJDG)1C4K
M_E.@%#)@(0/^LV< ?^[+0+'P+:#]^@.@7_X%,'VSZ(9EX\H?;#LV?NO8%W?*
MFG2H0Y^14Z?,QWB$"$8UBUBF(W/4<IR\4H0Q&WF86B,'&ZEB8:.53&R=CH&M
M+V=@&S1T;)/R?MTUO/XH('[Z__BXR[ JL_\-](M-F]B)+8+2W=W=O=ET=W=W
MMZ" A(*"8F)A)];8CJT8H"BB*(J WF<YO_\Y+V;@7'-]KG'>^+V?M9[-?NYU
M/<Q,5-/^WZC CU9E 72HBXWOTY$?/F2D]OZ8E6[O26>3NX?=72_M\0OMWA&6
MLJ\^KG!'5?KFK25%317YM6V%.;LZ<G-.[\[-.=.>FWUN9V[6^=;<K(O;<S,O
M->=F]C12VZ:"##XVI-,,N9MFH%9R/IKEEF&7PCKL51'^T:4I-=AMH/#VG*7J
MXW/VQM>/N[).'_ ).=@1G+RS);J@OBYY<_GFO,:\\NJV])(='<DEQW>G%IUI
M3RLXMS,]_WQK1M[%[1FYEYHS<WH:J6U302;-D$$S%&R<@3K:>W=(+\5NV=6_
M#RH*?NU6%WE_7E^B]YJ%W)W+MD87S[@PCQ[U"MZ]/S"IL3TBOW)[0E7^MNR&
MU*WE.^)JFMLC:XYTQ%2=W15?=JXML>3\CJ2BBRW)A9>:4O)[MOW_01;-D$DS
M% M.QS:).6B37(1]4OP_C\FN^71.1:#OAI[ D[O&,M>N6QN<NNCLM/^41^#V
MH_[Q-0?"<@IWQU6D[4ROB]E>TA+:O*TML/G0SN!MY]K":\^W1E5=V!Y3?JDY
MMO1R4WQQS[;XXBL-4T$VS9"UA!UE?]X.$9N-#M$%Z!);\NVTY/+WUQ27OWBD
MS7_[L:'4A3N6>D>N.3KLNN3F5W?&)[;T>'!FYN'HDK@#J34A>XNV^>ZI;_'<
M<V"[5_O%[?[-%UN"ZB\UA]9>;@JO[MD667&E/JKBZI20,YL-.31#U3I>;-\T
M$WN%YHQU"\W[V",\[_E#.;Z[O1HKKKPP$#_QV$)[[UU[VZ8;+._*'J_(W N!
MJ8EG(O/#3J94^'47UKH?JZMW.;Z_@4E[M'MGSS;OUIYM?DU7&@+JK]8';[FV
M-;AV:LBE&?)HABUKN;%SPS1TK9GQY<*J&2_OK^.]W2L^_W*?RKJ3KW6E#[PT
MU6Y]:FM9^S?3K?".1TCJS8#XR.L1F0%7DPO<>PK+G'OJJAQZ]E?;]?Q5[=1]
MH\;EP/5:MX[KM9ZM-VI]FF_4^#3>V#P5Y,]B0\%B=FQ;S8G.55RC)Q=SO;X]
MC^-6[PK>BP.B2XZ_5Q3:UZ^EL/V-H7[-*W/;PI=V[JG/6('13WRC A^')WD\
M3,YP?EB8:_>POL#Z[WU%U@]O%-I<NUMB=^9.F>/1VQ7.!VY7L';?KG!MGQH*
M:8:2A0SLH,]270O8'U^=SKC5.XMQX<.*F4>'A/GW?)(3;?ZHKK+Y@[YAX7LS
MV[1WMJ[1_2Y^@?U>H9Y]H3$NKQ,3'5[FI=H^WYQA]:PUT^+IT2R+9_<RK6X]
MSK&^]##/]O3?^?9''Q0X')X:BF<2;*;?G7L6L#TZS4NN_\5+SG^8Q7%X9,6<
MCA'AU4W?Y,2KOZJK%GS5-TS[:FX=\]6.&?25Z>GUV=N?-1@:[#@0'V[;GQ5M
M];8LSN)-0X+9Z]V))J]/4H\2S1^^3+3XZV6*Y:7G:587IH;R&02-,\F3(USD
MZGEN<N8.+^GZQL>U:WSE_&T3PFLK)^0D\B<T5-)^&>C%_K(P#_YE9^<UYN+L
M^MW;S>E;B)?MEUA?JZ'T /-/A4&F'S>'&']H"3,<V!=N,' V7'_@8;C1ZS?A
MI@_[(DSO]T=.!=73R//=#'+M."<Y>9F+''C(P]:&N3QU6+VP'*)K\Z @E@I-
MA1@8:@;!W, +MJ8LN%@Y_O:RM9D(<K0<BW(V&TUF&?_(<3,<*7/7_U;GJ?NU
MU4MG^*"W]O!9'ZWA>SXZG_I]=#^\F]*G9D)N'&*0$Z<XR-X;'&3[<VZV+5C
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M]6L.$J)(Y\M08F"0C9A&!#";K*'KL0)+V99B)=M"FF4>!-GX(,(V"U)L,Z#
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M;@U%EXUAZ+(^')V_!3VI!L&4'4.N,_4,(IO</X_Z4VC,?E]HR_.B8*;PX]Q
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MT]@26,06QV:.&,[CB.(:C@@>X!+&WXBW!/X70S2#[7NI_B< LBD_]A< _]L
M+@\ ;%X!Y0(8(P_HHS!HTSHT4!Y44!444!MDT8"10G-&'&T9471AA-&;$<10
MA@\36-R8R^)@/8N% RP&5[  =Q(7V(!__A>== Y6'?]G_S<!_'ZGO3^D[*=
M^P7*!5 CE) 7Y%$(I%$,)% :1&DMPJ@" J@)?*@/W&@*+*H+T%H ?8E((ITH
M)SJ)$6(]L>^_0!,#!@W,66ABQD)32SK:L=' E8TZ_AS4B.9"M4QN5"WC0>79
M?*C<)X#*PX*H/"Z$RNN$47F+""KM)HZ(HM(YXA<Q5/J#>$E\%$-EG$+T/ZC0
M:Q441S640/5OF%J#L2D+S4U8:$'K,+=FHXD3K<.'"_4BN5$GC0>UBGE1LT$
M-;H$46-(&-67BJ#Z:E%4WRB&ZCN( ^*H?HKX@7[F/>(Y\>'+S]>@W"](HB9*
M?=9&Z8\Z7X.F^@R:&;'0RH!*24=K<S9:VK/1W(,+34*YT2B9!PWS^5&_1A#U
MVH51=U 4=4?$4'>Y..JLET"=K9*HLX<X)H4ZEXC;Q!/BG13JXK](HP[*?-1#
MV;<&*/?:\&O03(]!2\).EX4.^BQT-&:A/=7"SHT+;8*XT2J>%RUF":!9A3":
MSA9%DUYQ-%X@B<9+I=!HM30:;21VR*#105DT.DO<(!X1;V0_&:/L!^*]$<H3
MBJ],4/&)&2H],O\:M*!\6VT&9V@RZ#+U+$*/A6X6;'1UXD)G7VZ<$<6'#NF"
M:%<D@C;UXFC=*8E6@])H-2*#ELOET'*='%ILE4>+O0IH<4+AD\7W"A\L[BO\
M9?E*X9759X47EJCTW )5GEJ@Z@-K5+MM@VJ_VGX-6NE0/KFWFRJ#GH0WK<-W
MZKLQ]AST\N1&CU ^=$\20M=<,72NE,09LV4^._;(?70<DO_;853QO<,JI7?V
M&Y7?VN]4?F-_6.65_465Y_:_JSQV>*'RA_TGM?OVJ''7'K5N$]<<4?OR#-2^
MX/0U:$?[=U5FT$N!03\BB-830K,18LW!(%=N] _@0[]8X8\^F>+OO$JDWWC4
MR[UR[U!XX3:H],QMD<H3UW'5/UW7J3URV:;^A\M^]0<N9S7NNM[2^,WUF>8-
MEX\ZUUQ0[P=GU+_D@OJGW%#_J#OJ'_X&=*2]>Y#W^I'WAQ"1*@Q&Z[ PVHR-
M48Y<'R.\^=Z&A@N_#$Z1>!J8+_/(OTKA@>]LY7L^/:IWO(?4?_,:U?S5:Y76
M#<]-VM<]]NA<\SBI^X/'#;U+GD_USWG\;73: XU/>*#)84\TV>N-)CM\T'C[
M-Z +N;\/.6<PN7>D)& \U2))@\%D0]:')!O.JP0WWB>Q04(/HN,E[D1FR_X:
M5J)X/:1>]<>@=LTK@?TZEP.&]2[X+S,XY[?.Z(SOI/$IWT,F)WPOFQ[U^\/T
M@-\[\[V^:+';#RTF_=%B4P!:K ]$\W7?@.Y4 W\)P'!RG7AR_Q09P QEYN],
M'>9EIAG[4<8,[M_3? 5N)$>)7TU(E;L<FZ]R/JI2XW1$D\Z)\#D&1T/G&A\.
M&3$]&+S"?%_01LL]07NL=@6=MMX>=,=Z:]!KFTW!:#M!K E!FQ6A:+TL#*W&
MO@$]J?[!Y'O1Y-W)4\Y%Z\F1@]=Y:LRC? /6[3P;SL\Y'OR7LT+%SZ8ERI](
MSE8]DEBB?2"^5G]O;*OQKN@>L^U10Y9;(Y9:;PY?:[LQ?-)^?=A1A[5AUQU6
MA3]W7!Z!CN,1Z# :B?8C46BW, IM"9OIH _5/XQ<*YY<)X/6D2L"'PHEX,\2
M.;A3IL%<*S5G7RQVXSN5'R1^)"=6?E]6NMJN]'R=R=0*P\U)C:83B1V6Z^('
M;-;$+;)?&;/"<3QFD]-8] 'GT>CO7$9B_G0>COGLO# 6G>;'H>-@'#KTQZ']
MMZ _U3]RJ@9\@-G\E"\(KTJ%X5ZE&%RO5H!+U<:L4Y5.?(?*_,3V%$7*3^8G
MJVW.F:6[/JO$:$U&C?F*M!;K92D]=J/)0XXCB6/."Q/6NPXE[':;EW#.?2#A
M#_?^Q(^N?4GHTIV$3EU).*,S"1T)A^E@X%0?R+72>.!#'C<\*.6&FU6\<+U6
M +YKD('3#0:LPW4.O'NJO<6V583)390DJ*TIS-1=D5]@/)93:;$XN]%F.+/3
M82ACT&DP;;%K7^H:]YZ4[1YS4DYY=*;>\VA/_>#>GH9NK6GHTI*&3K/3Z!,F
M#1VG@\$B@''DW9EL^+.0!3<JV/!#'0]\UT3N/UL2CK;HLO8VV_%,-GB*3M2&
MR*VNC%4;+TO375*2:SQ<6&HQ/[_.9C"WU:$WI\^Y*WO8K3UKQ<S6S*V>S9G'
MO!HS;WLU9KWS:,A&=\*U/@N=Z[+0B9@Q'0RE64A@PZ=9 +=+R'MK6'"QD0O.
MMO#"B79R_PYM9D>[-?>F%G>1-4V!LN-UT:J+JY-U%E3.,II;5F315U)MTU74
M[-A>T.W<DC_DWI@W[E&7N\FK)O>0=U7N3>^JO+>>57DXLS(/W2IST:4RASYM
M<]!I.AA.LY@$\#*/W+^"O+>>!6=:.'"\@QL.=8G"KAX-9DN7)=>Z3E?AY6W^
M,DN:(U06-"9J#]9E&O54%YAW5E;8M)8W.C25=3K7E<QUKRI>ZEE>-.%=6GC
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M.6S=$_.+35?,*^LYL6C9&8<6'7%HUAZ'IFUQ:#*=__2!+K5_DV_=(>^\ELO
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MFH)OJC6$O%:M#T$50HE0)!0(^7]!NMP_I\O;+=K_1<H^3LZSGRZY.^FX-5X
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M8@7EKH./5(L/L ?^@N,T,E?@%=R'ES0X_X^O]P"KZEB__]?>I] /O8D-;%@
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M]\).,N?[J-O?#:Q<QAR0V=0N705DTA/';Z#_VZ2'L,WF"-D\&L']DQ'4[X&
M+?[PWQ(N^&U)$'VV9(I>6XH5,[;4J=S[V]33^U?JN/9OUW7I/ZGKW']7UWGS
ME[K.&R5]I_5DG63@U/<WY]GG#M,"#5!W'36[5@/-O4 5K6H>M9-IC2*V _X[
M :_=1O#<8XT9>QS@L=<)[GMGP&UO *;OBX+KOF1AZKY<P7E?I3!E7[,X:=\R
MA>.^+8H)^XXIQ^^[K1B_]W/EN-V2:MQ.23UV!QF0=!XB[T/MH?XF:J]:!RRD
M;CV]>)&\!T0_'+T;"*0G]SP$N!Q58-)Q#28>MX'CB3&8<,()XT_.P+B3 1A[
M,@IC3J7"X501[$\U8-2IQ1AY>KTP_/0AP>[T#<'NU,>"W8D_Q6'')''844DQ
M[,C?'*3^5M9[[7I>"[2E3=0MIV[6/B".NL''@)GTI"YG@/'G@9$75;"YK('U
M92M87QD-JRN38'G5'197_6'^>!3,'D\G93"]U@R3:RMA<GTW--<OD7=A?/4W
M&%^18'))$AY%/HNTGG7O9KU;=K$-Z,-SCP*)IX"0L\P_=5TN N.N ".N 9:T
MJ\:W53"X:P2]NQ;0O3L".G<GD&E0/^,'U3-14-[+A.)>)<1["R'<8^7N'0'N
MT]#?HW&^1Y/\C 3A[M]LVLAK<1O'(WD/Z#"0SSHG4C>$NC.IZTS=,=2UNPV8
MWP6,[M.'TYL++^EQHM%PX6$)O#(2>)6>_S4NCM^0%Z7R7TQQ$GQ+?A!Q)R=F
M5O!M5NBMU_CZ$Y'^BU7L;^WR'A#K7L!\)UVB/G4];P)3J&O_-&!#71/J&M"J
M*U^GUW^+O", [S*.]QC'!^9<$-L!'X\%/G4!/O<!OF0<7W$2^(H7_M?+@6_8
MP-^P4M^\S\^_\%7ZBT7[M'M 1>=X#5P%0F\!,YBV2?> 4<\S]]354%='UGV/
M?"3OP0SMA7Q!OE*Q3$/@6Q,N3*V!'T8#/T\&?N-"^0].RG]R0I;F/'(6Y#IY
ME_SP%W..:_> 4OFC,&I[LLZ37F#;O\K<_P<PI*[BH>X70_L@WP_MP_PXM"?R
M*_E#A^49#9T'D>^+<83VV2#R61 Y#DX$4N]0'/(S0?[U%Y+Q6*W?-["GU^=[
MT&=B&O$CT22#E/R/_8<^TD]VD'WD"#E-+I$GR8M#9T$>#.YS_#FTW_'G_T R
ME?<^Z'&-1M#?C^(W8XB\%^-%PDD**2#5C^P_=)/59 /92G:1 RSO./[ >?R.
MZ_@-]_$+&^]G)NXG?O,C?^.'_P/)4M[[H-\WL64N"$8,Y<*#!)%X:/>#RDC#
M8"[^Q!*6NH)-L)8ZFZBSG3I[6-YAUOHTOL-E?(NG\#7>Q%=LP"_YFY_S3W[V
M?R#94-?*DG&8LTV( >/189N(4X?:0]X/2B.%U*VFWEQJ+:3.4NJLI,XZZO13
M:2=U]K/;'&<+/,:N^P0^P$O,Q*=XEQ'*NU/_^3^0[*@[C'[?2L/N),-XC-DF
MAI,AZ7E"4H?@-T4"?A*S\9U8BJ_$>GPF-N-CL0,?*;KQ@6(UWE-LP+N*;7A;
MN0?_41[!&\JS>%5U':^HGL>+ZH_QO.[/>%9?PCT#"<\8#F'P-](HZH\T8!PZ
MD&SY:F/*>)@;L['XU60JOM?XX2NC2'QJF(H/#0OPGF$EWC)JQ!M&K7C-: E>
M,5J!EXS6X@6C?CROV8GG-(=P7W,&SVBNX:[Q\[AM^BENFOV":^82KII+PI5'
MN#R$Y& (R5ZI?=R.O8HQ\?-P4_QH,QQ?6#KB0W,/O&T6A-?,X_"B12:>MRS&
M?:L:/&,U%T];M^&.]5(\:;,2MVS6XZ;M-ERWW8?';4_@ZK#+N#SL&5RP^U X
M._Q'X?0(23Q)3I#C_T :KX8T#H./^_F-P^VWXQ3XQMX GPPWPUNV(_"2G1/N
MC_#!4Z,B\.3H%-RPS\,UAW)<<:C'I3'-N#BF77AL3+=P;DRO<';L)N'TV)W"
MJ;&'Q1-CSXO'QMT6CXQ[6SPX_GO%OO&28@_9/5Y2[N+KHT@3M</)CTX<:J=R
M^.90^]ID)5YQT,>S8ZQP>_P$7'?TP.5)P;@P.0[GIF3@])1"X>242N&XTVSA
MJ--\\;#3(O&0TPKQ@%.?8I_35L5>IWW*W4ZGE#N=KBMW.+VJW.;\M:K?65)O
M<I'4&\D&9TGU*-(4##[NZ#-W3C,<7O]%[GH =US4N.%DBDM3[7%VFBM.NOGA
MJ'LD#KDG"P?<<X2][B7B;O<:<:?[',4.]P7*[>Z=RJWNJU1;W#:I-[OM4F]T
M.Z:SWOVR[CKWYW77N'^AN]KC3]V5'I)NCQ:=%>Y_(['>W[EQ*N T\T( M0.Y
MSJ8/ONPEX+R'!B=G#L=A[RG8[^.%/;ZAV.$;+VSWS1"W^!8H-ON6*S?ZU*O6
M^\Q3]_ETZ*SU6:;3Z]VGN\I[NUZ/]R']Y=Z/&2SSOFNPU.<3@R4^OQDL]I'T
M%VG1([H/D6^Y_,*+GI/>]VX8_58$O09?3S&68W[ZV.]OC=V!$S 0Y(XMP8'"
MIN!H87UPBK@V*$?1&U2L6A54I>X);-19'MBJVQW8J;\T8+7!DH!^PT4!^XS:
M \YH%@;<UBP(^$ S/_ 7HY9 R; Y4#(80K\Y0,N/S/M'K/>_PNDYZ?LNQE*?
MKX<8R]X0-7:$FF-+^!ALC)B&OD@_H3<R7%P9F:!8$9&A[([(5RV-*-=9$EZG
MNRA\GGY[6(=!6]@*H_EA&S3-H;N-FT)/FLP-O6G2&/J.R>RPGXP;PB0-,2*&
MQ* A5,OW;/]W@KF\B08>I^\[F\0U+GWX;L:R/5+ IBA3K(L9C=XX9ZR,\Q*6
MQ86(2^-B%4OB4I4=L3GJA;'%.@MBJO5:8N88S(MN,YP;W:UIC.XS;HC:85H7
M=<RL)NJ:6774FV95T3^85D9+QD13&249$<.'?./+I0]S<">>WI^^[V0ZU_GT
MX=L8RZ8XKC/C-5B9.!S+DR=C:?(,+$X.%-J3HQ0+DI.4\Y,RU<U)A;IS$ROT
M&A,;#!H2YAO5)G0:5\>O,:F,WV96'G_$O#3^BGE)_*OFQ?'?FQ7'2R;$F&A*
MXB0C8BCS!?OA2\S!$\GT_O3?1[.!G?1_F]*HS^]Z4@S1E6:+)>D3T)'AAK:,
M6<+\C'#%O/1XY9ST=/7LM#R=NK12O9K46H.JU'E&Y2F+C$M35ID6)V\Q*TP^
M9)Z??,DB+_E%B]SD[\QSDR73O&3)F&CRDB2CAWS,=GB..;C&^I_ATNL@O=\V
MOO9Q.=C#[Y9FZF-1EA7:LL=B?HXKYN7X"'-R0L6&G%AE77:*JCH[1Z<RNUBO
M/*O:H"1SKE%19KMQ04:/:6[&9K/L] ,66>D7+#(RGK?(2/_&/"-=,LU,ETR(
M)C--,GK(^VR'9YCWR]0\2?^]MY YX.MJQK*4.6G/U4%KGCF:"^PQM] 9LPMG
M"G6%06)U092BLB!)55:0J5.27ZA7E%]ID)_7:)2;VV:<E;O<-"-GHUE:SC[S
ME)SS%LDYSY*OS)-S)-.4;,F$:%*R)$UJEF0D\Q;;X0[;_P(UCQ6S'4KHM_BZ
MO(CZC*6E4(&YQ::873(2=:6345TV0Z@L\Q?+2B,4):4)RL*2='5^2;YN3G&9
M?E9QO6%&4:LFM:C+)+EPO5EBX1[S^,*SYG&%]\B79G$%DBDQB<^7-$,8R;S&
M?O<$V_\L-0]5T.^4T_N7T>^0%L;3R->Z"@VJ*^U04>6(LFHW%%?["H75H6)>
M5:PRIRI5E5F9HY->6:*76E%KD%31;)10WFD<6]YG$EVVRRRJ[+191-G3Y'.S
MB%+))+)4,HXLD311)9)15+$6^6S:X_)Y+&KMI__=5$V_4<4<D$92P^_*:PU1
M4F^-PH:QR&^8BMP&+R&[(4C,:(A2I#4D*5/J,]6)]84Z\?55>K%U<PVBZA8;
M1=3V&H?5[C )J3UI&EQ[QS2HYC.3X&K).+A*TH14248AE7\C[PE>8@Z.47L7
MK4!?/?M!'3"?U/)]22-]SUP=Y#29(6O>*&0T3T9:LP=2FF<)2<WA8D)SG")N
M7IHR>EZ>*G)>N4YX4Z->2%.[0=#<588!<[=K9LT]KO&;^Z3&=^XG&K_&/XS\
M9DM&?@V2X2R9>BU/,@?GV :'J+]MKGP.".@@<TD%E^.Y+4#Z @');1HD+AR&
MA/;QB&MW14R'-Z([@H3(CB@QO#U9#&W/5@:UEZ@"VNO5LQ8NT/59N$+/:^$6
M_9D+CQK,6/B$P8RVCPQFM/YN,&.^9#"C1=+W;/Z;Q]G_3K+.^YJ!C2WR.2"@
ME=3/!XH74+\#B%\"1"W51WB7!<*Z1R-DV60$+W-'T#(_!"P/$_R7QPE^R])%
MGV4%"J]EU<H9RYI5[LNZU=.7;=:9UGU89^JRZSI3NS_0F;KT-]VI2R3=J8O)
MHK]YC&U^F/7=V0ZL60@L)DU\7TGM7&HG=0.1/4# :A&^:S3P7F,#K[5C,'.M
M$SS[9F!&GS\\^B+@MBX1T]=E"Z[KR@27=7-$I[XEBLE]ZQ63^@XH'/NN*AW[
MWE5,6/.K<L)J235A%5GY-Z>8\WW4[5_*ODA[VD;J^+YH&7- [1A:HZ!U]-^;
M@&E;=."\U01.6X=ARK:QF+S-&9.V>V+B]@ X;H_"A($4C!\HP+B!6HP96"@X
M#*P11@_L$48-7!1&#OQ'&+GM9W'D%DD<V2\I1F[ZF\/R/7'47$>]I2O8#_A:
MOAK(&MH#"NT'O.F+I^VD!Z0W=]BOAU$'3#'RP#",.#@6PP\ZP>[@# P[% #;
M0]&P.90.Z\.EL&)R+0\OA\7A 9@?.0NS(R_"[. /,#\@">;[AMBK94\7K\>5
M[(O4;.OCM4C=_,WTO]N <.KZ[07<#E#_"#TXO:GM*<#LC Z,SYE <\Z:V,/H
MW&3B </S 3 X'PO]\]G0.U\-W?/MT#F_'NKSAZ$Z_R1?/X/..0FZ9\D9"7JG
MM6RA'5[#7'=2=PYU2ZB;1MVH@X#_4<#])/7/4)^^W.8"8'J9/OAQ$>KK!A"O
MFT*X80O<< !NTFO?Y&+D"2Y^GN $=(L#[RU>;+?8H6XQD;=8P"T:^%LTRD](
M_\6Z];P6MFC/X532$F=3-XYU#> ?<:<?GTB+/.HJ8$5?;O($H'^;/OPN??8]
M>OY[]/SW38%G;8@]\/PD+H:X,'V1B[*7N AYB0//R[S@7F:G>IG)?.4FH8%_
MY0\B_<6*K;P6=P/5AW@=R/=AG0<"J>M&7<<;P(A;@,4=P.@90/TLM5\@_R:O
MD=<9QYL&7 R;<$%N";P[ GB?!N%#+A _9CX^X2#\"0?@3]GI/V6G_NP$82&?
M?TW^)-(@;?(>$-LZ[S200.U UM>-]9U 73OJFCT'&+P(B*]2\S_D7?(!D<^C
M?#RT+_&Y#O"E$? U<_(MV^;!6. G5^ 7+DY^Y<+HUTJ:%UYPO[%-?F<E?V=%
M_OB2/!BD0=X#8MX36>]@UMGM:6#\?6 8?\V$NKH/=67-3X;V05@-&E[M7HA\
M+N4G\HM #5W@3\W0\T'D>V)<M(?'Y8=U#3X;E7U#8J-+C&/P.2DO#2(9C*;/
M'CGD^?D>XX@S\281)'70<TNH^1_[#^O_QSF,<]#>$_,,>7?PA,.?^&/PCIA'
M^1V/G,&0]SYDOZ^4]Q[X"GD?9!*904)( LDEY63VT%[,8K(<VC,I\CF,;=39
MS7(/X3><9+D7\3-NXT=VFA_P.1[P&_G.G.^@O4/GGPSN?6CH]W4M^$G&=B@7
M\GZ0/_[>#RJB3@UUYN)7M+'43C9!#W764F,3RQJ@QE[6^BB^PEE\B>M4?X[=
MY2,VX0_\OW9G2'[]\!](9M0UH?\W-(:DX"LLA]IDRM!^4!@UDZB72ZTR=H-Z
M=H=F:K13HPN?824UUK'\?I:W$^_C %O@)-[&)7;AI_$&WL&KC.S?K,'++(VM
M/[A3]2B2)77-Z/<U>FP3ONJ9,1:Y3<:SW:93UY^:,=1+IU8!=2KQ'MOD';;)
M6^C F^P;K[-OO(H-+'\;+]T]>)ZY>!;G<0^W<)?M\10COL-6DG?*;@D2GA"T
MKP^1; P8ATI[M,E$#<G8B#FQP.\ZH_"M8C+K-Y.:H7A+2,#K8A9>%HOQ@J(:
MSRGFX+ZR%<\H%^.N<CF>4JW!;=5FW%+MQ$WU(=Q0G\4U]0U<U7T9E_6^P 6#
M/W#>D#W62,+9?R#9J;3'JN3;W:QX>9FK\:N)!E\96N%]/0>\KC<5+^K[X5F#
M2-PU3,$=HUP\:52&FYHZW- TX9IF(:X:+\45XU6X9+(!%TRVXS&3 SAG>AIG
M3*_CM.G+.&[^%8Y8_(E#EA(.#+'?0A(>,GB;W7 .(R,YU)#WA\M#G@IO:8SP
MHL8&SY@ZXDGS&;AN$8PK5G&X:)V!QZP+<-:F F=L&W#*MADGAG7@^+!E.&JW
M!D?L^G'(;@\.##^._<.O8.^(Y[!KY&?"P,C?A6VC)&$KV2(S4A+ZAQ@\5L;A
MY L.L>]PN']I(J< #G-WA^OBEJT9K@YWP&,C77%FM!].V$?@F$,2#H_)QL&Q
MQ=@_MAI[QS9BS]CYV#5NL;!S7(\P,&Z]L'W<@+!U_&&A?_QCPN;Q3XL;)GPD
M]DWX15SC*(F]9/6$_T;> _J.NN]S:'W!#7B*7)]*SS-1Q(4Q&IP:/QQ''2?C
MX"1/[)T<C%U38K'#*0W;G?*PU:E,Z'>J%38[SQ4V.K>)ZYV[Q'7.:\2USEL4
MO<[[%:N<SRA6.C^I6.'RKK+;Y4?E4A=)V>DB*626/,)OU/^<^J]Y D_[T/.1
M\_3B)Z?1>SH9X("+-7:[CL? =#=L<?/'9O=(;'!/PCKW+&&M>Z'0ZUXAKG)O
M$%>ZMRA6N"]6+'/O47:Y;U1VNN]6+78_H5KD?EW=[O&FNLWC@;K50U+)S/>0
ME(.X:_G!B5/0#$Z[LSC]<\I]C/[SF#]PP O8XZ'&]AGFZ)_I@ U>+NCS\4:O
M3RA6^L0)*WS2A&4^N6*73XG8Z5.C6.PS5]GATZ9L]^E6M?GTJ5N]!W1:O(_J
MS/.^HMOD\[+N')]O=1M]))W9/I*:J ;QUO(MZ_L6_?_3U+Y"[WDR@EXG%-C!
MJ6:KKX -OB98.VL$5@5,QHI 3W0'!:(S*$I8')0D= 1EB0L#"Q4+ BN4\P,;
M5,V!\]5- 9TZ<P)Z=6<';-6M#SBD5Q=P4;\FX'G]ZH"O]*H")=W*0$FG,D!2
M#Z&2^9(Y>(53_2UY#R@&.$)V1@*;P[C&Y/>K@XRP/&08ND(=L23,#1WAL[ P
M/%QH#8\76\+3Q'GA>8JYX:7*QK!:54-8D[HNK$.G)G2E7E7H9OV*T/T&9:'G
M#4I#[QF4A'YA4!PFZ16'2KI$AZB+0[1\XLUV8+VO4?M, M?89$LL_584UYB,
MHSO< $LBK= >-19MT:Z8'^.#>3$APMR8&+$Q)D5LB,E6U,44*6NBJU15T8TZ
M%5%MNJ51R_6*HS;J%T;M-2B(.FN8%W77,#?J,X/<J#_U<Z,DO=Q(29?H/.1]
M]H-GF(,KU#[)Y<8N+GTV<AFVBDO";GKR13&Z:(LSQ_QX>\Q+<,:<Q)F8G1@H
MU"5&"36)B6)50H:B(J% 6990KBZ);] IBF_5+8COTL^+6V>0$[?+,"ONM%%&
MW!WRB6%ZW!\&Z7&27D:<I)L1*^D\Y&WVPSO,P05J'\T MLO[+XQE&3\O8ARM
MB4K,2S+%G.21:$B9C+I4#U2G^@N5J>%">6J\6)J:IBA.S546II2J\E/J=')2
MFG6SDCOU,Y+7&J0E[S1,23IIE)STI%%2TD>&24F_&R0E27K)B9+N$#HRKX=J
ME\'GZ'T/9M'K9#('?-_)6%H91U.J@(8T8]1FV*$ZTQ$5F=-1EN4KE&2%"$59
M,6)!9HHB+S-;F9-9K,K*J%:G9S3IIF8LUDM.[S5(3!\PC$\_;A27_H11;/H'
MAK'IOQG$I4EZ1#<N5=*-3Y5T9%YD_[M.K=/9O!;I?S?D ,OE_1?&T\2\U#.F
MJFPCE.?8H#1W+(KSIJ(PSPOY>4%";EZ4F)V7*&;F92K2\PI4*;F5ZJ3<.3H)
M.>UZ<3FK]&-RMAE$Y1PUC,RY81B1\[YA1/:O^A%9DEYDEJ0;F3F(CLRSL=HS
M4<?S>3T6L!WXNI36H)74,YY*OI84Z*.PT +Y1?;(+79"=O$,9!;["^G%X4)J
M<;R87)RF2"S.4\87EZEBBQK4T45MNA&%/7IAA5OT0PL/&P077B/O&@07_*(?
MG"_I$=V0/$GG(4^Q_UU@O8_0?V\E*VD).D@3J2RD[^1W>:5J9)69(J-\!-(J
M)B*U<CJ2*WV06!DBQ%=&"[&5R6)T9;8BLK)$&5Y1IPJMF*\37+%,-[!\LYY_
M^2']6>57]?W*W]+S*_M)SZ]4TIU5(ND,4JSEB33MF:@#%;P>RGDMT ZTD@92
MPL_97):G5PM(KM4@L<X&\75C$5OOC)AZ3T0U!""R(4((;T@00ALRQ.#Z0D5@
M?;72O[Y9Y5??I?:IVZ#C5;=?U[/N,GE#Q[/V1QW/&DG'LUI2SZPBE5JN,@<G
M2H'=7'JOK:;WKP+FD6J^+ZBE[ZNG[VD$HN?J(Z+)'&'S1B%TWD2$-$]'4+,/
M IN#$= <(\QJ3A%\FW-%[^9R<6;S',6,YL5*]^9UJNGS]JJFS;NH<FW^M\JU
MZ0>5ZQQ)Y=I(9DNJ:4,\QIP?IOXV6L.>>OD<$#";E/%S-K43Y@&1\^E]VA28
MM5 #WW8;^+2/@7>'$[PZ/#!ST2QX+@J'!R]D]T69PO1%Q8+KHGK!95&[Z+2H
M5S%ET2[%I$7G%1,7O:"8V/Z]8F*;I)BX@+3^S2GF>M\<7@]-[(MSZ3M)#2F@
M=AJUHVG3@A;1_R^E_URFAVG+3>&ZW Y3EX^#RPH7.*_PA%-/ *;T1&)23S(F
M]N3!L:<*XWOF"V-[>H0Q/0."0\\9P7[ELX+]BF^%T<LD<70762J)]D,<F<VQ
M<0'0V\J^2,U&4LK/6>UL@\5 :!?@LX+^B_Y\REIZL'6&&+O>'&/6#X?#AO&P
MW^""T1L\,6IC($9NC,:(C>D8OK$8PS;-@>VF+MALZH?UIN.PW/0TK#9\!:MU
MDF#51]:2-5KV4;M_"<<$UK6U@_V NGFTALG+@(@>8-8:UI_>W(F6=1S]^8@!
M 58[#6&QRXS8P7S7.)CM<H;I;D\2!)/=<3#>G0W-GBH8[6DC?3#<<P#ZNZ_#
M8/=',-SY)XQV2# :(-NU#%"O;SFPA)J-I(2ZZ:O9!GWT_]2=05_N/ ",I3<?
MO@^P/ @8'U%"_[@A=(Z907W,#JIC8Z$\[@SQ^$P(QT,XV/""/\Z+[3@[U'%Z
MS./TNL?/DI>Y.*'//4:_?90<T;*1FBM9U]8UVG,X.1O9!JQO\ Y@)CVYRP'6
MG[Z<2U18G (T+$KO,4"XH,>!A?[VH@7A0OC2..(B_R44!SU.N%?D Z'RS5],
M]!4VXI5#A*;ZRN?\'?K^R])?K*'NDLW, >M;1-T4ZH:QKM['@*G4'$=-.VJ:
M70(,Z<U5U^BQGR"W1.!)?<(X;C...W9<C,J+86?@'N.XS\GX/@?[^[S(GV5C
M/TN!^S3XS[Y.?N1[Z2^Z^H>>A[,?R#S*-C@-^-&:3[W(_%\!;*EI>A/0?Q(0
MGY;W7\CSY%_R?@C]_HOT^R\; ?\V!5ZG47F3B_2WIP#O,H[WY!M4.>!_P([_
M 1/^(1OSP^OD(_(SD0:9+Y_#89JR3P QU)Y%W:E#9V"L[[#M[P(ZSPYIOD+>
M)&_+9U&&SH7(^R$?*8!/V#:?,B=?6 )?T:A\.QEXP#A^X,+@1_:-GUJ G]<1
M)OB7VX1_\)?O!ZDY#.2R[G',M?\-P)7U=6!]K:AK] *@_.?^B[P/\OG0O3&/
M[H4,G@EA++\: '^8#IT%D?\"EPLU^>%Q$@=CJ?T?]\.\,HBD'#[D]V7D]PYD
M,O$D#^\!D?<?*O['_H-\'\BCYS >/AOD(K1G05ZCV_Z"WODW_B?]Q:_0G@[Y
MZQX0'1M(@N70WH,5L1OTW!+<2""))9G0W@\C[\7,)6W0GDE9P?+7X'=L9+G;
M\0L]]\\X@I]P%C_@&G6>';P7Y5LFZ='[4+X:XJ\S& ;45IORG<D05D.YD/>#
M?*#=#TIF??)8AW+JU%.CF1KM+'\IOD,/R^]CV9O9/#M8Z_TL]SB;["(]^QU\
MB+?P/G_C/9;P#DMZ9VB'Z%$D(^KJT>\+AOPD8S;4)HZLGP<U@UB+6&IE4*>0
M&E74F$V-%M:P@UVDB^6O9%GKV%6WL.OLPALXC%>9BY=Q'2_@15Y&GS$CO^(^
M2WW(O4>03*AKJ -)(?*3+M$,YN)'YN(;N%#3!Y\BG/5)HDXV:U5"C6K\&XUX
MB7WC!<;Q/+JIL9KE;<!=MLE3V(?;[!>W<!DW\0PC^1"/,W-7(=^U]/\BF:JT
MC[F1'W>C*["/ZK--3:@[C#ETI*8[>U8 :Q.-YY#*$O/P-$JI44N-.=1HQ0WV
MT6OLHU?9-ZZP32XQ%Q?8+\[C,6;C#DZS!4X)W^&$*.&X0L(QY7\C60S=7F9,
M_\VAYC/&\JE"CSDU8SU'X;[@A*=$+]Q2A."Z(AY7E1FXK"K 154Y'E/7X9RZ
M"6=UVG!:IQ.G=%?BA.X&'-,;P!&]@SBL?PX'.;CM-W@;>XT>8+=&PDZRXQ\,
M[K^8\U+G$/>!+?"&%8<_$Q'/Z1G@*5TKW- ?BRN&T_"8D1_.:B)P2I.$$R99
M.&92A",FE3ADVH"#ILW8;]J!?:;+L,=L+7:9;<5.\_T8,#^#;>9/8*O%6]AD
M]0 ;K"2LMY:PCO3)6&F1_^FI!R,X9([AD,MIYRZ'_)O\_+B5$I=-3'#6? 1.
M6$[&$2M/'+ )PC[;&.RV3<7.83D8L"O!=KMJ;!W>B"W#6[%Y^!)L&K$*&T9L
MPKJ1N]$W\@36C+R&WE&O8N7H;X7EHR5A&>D>HFN(P3V@\1SJG:@_E=J<<LXY
MTO<Y<*JU,\3!$=;8,VH\=MA/QS8'/_2/"<>FL0G8,#8#Z\;EHV]<&=:,K\7J
M\4U8-;X=/>.7"2LFK!.631@0NB8<$3HG7!:6./Y+Z'#\2E@X41+:R +'_^8'
MUOM]ZC[G#MSP!,YZ<$IWY?J.T\[N\6H,C#='OZ,]-DQR1M_DF>B=$HQ53M'H
M<4K&<N=L=#L7H<NY4NATGBTL=IXO+'+I%-I=>L4VERUBJ\L!<;[+8V*SRSVQ
M:>IGXMRI?XJ-4R4M+G_SS21.0]2_PV']$OWO41]J,Y9MT^G_N1S8X&R"-5.'
M8^6TB5@^W1U=;K/0Z1Z!Q>X)Z'!/QT+W/*'-O51H]:@56MR;Q&;W#K')O4<Q
MQWV38K;'7D6]QUEEG<=3RAJ/CY75'K\KJCPD&;%2QEW+9\S_BYS>;@;09]#_
M[I/W/ORHS>_6,"<KW8VP;(8-.CW'89&7*]J]?;# .P3S?6+0[),BS//)%N;Z
M% F-/I5B@T^C6.^S0%'KW:VH]EZOK/3>I2SW/J4J\WE25>+SH:K8YU=EL8^D
M*/+^"U'F0^;@/NM_E=[W.)<_.[@4V\!85OMSC<F<=/KHH\/7 FU^#I@_RQG-
M_IZ8&Q"(QH!(S Y($.H#,H3:@'RQ.J!,K RH5Y0'M"C* CJ5)0%K544!.U0%
M <?5^0$WU;D![Y%?5#D!DC+'7U(\RMLSN?RAYD4N-PY%,0=<_JQA+,N"N;YB
M3A8&J#$_T!1-02,Q)V02&D+<41<Z"S6A8:@*C1,J0U.%\M <L32T1"P.K5$4
MAC8I\T,7*W-#5ZNR0[:ILT*.JC-"K^FDA[ZM3@_]2946(BD'"984Z4.\[LME
M&37/T?ON)5R>HX>Q+&$L;<Q)<ZB(.6$FJ ^W0VW$!%1%3D-EE _*HX)1&A4M
M%$<E"851F6)^5*&8%U6IR(F:H\R*;%=E1*Y4I45N4:=$'M9)CKRJDQ3YIDYB
MY(_JQ$A)E1@A*8DB,5Q2))&76-?KU#R= .R,YQJ;RXUNQK*0L32'TW,Q/[51
M1JB*L4%Y[%B4QKJ@.&XF"N,"41 ?(>3%)P@Y\>EB5ER^F!%7KDB+FZU,B6M3
M)<6M4"7&;E;'QQ[4B8V]K!,3^QKY01T3*ZEB8B2E3&RTI)!Y5MZ/H^;Q9.TY
MG-5<EB]A//,9SVPNPZH94WF\ 4H2+%&4:(^"I"G(2_) 3O(L9"6'(3,Y5DA/
M3A52DW/$Y.1216)2G2(^J549F[1,%9VT21V5=$ G(NF23GC2RSKAB=^KPQ,E
M57B"I(R0B9<4,G=9UXO4/4S_O9G+\14I0+N\_\)XJAE+&5\+DW61EVJ&G+21
MR$J;B(STZ4A/]T%J1C!2,J*%I(PD(2$C2XQ++Q9CTFL44>G-RHCT+E58V@9U
M2-H^=7#:!750^@OJH+3OU$&IDBHH15(&RR1+"IG;S/DY:N_+!-9S*=Z53J]!
M&AA3*;\OX/N<#"4R,DV0EF6'E.SQ2,J9BL2<F4C(#4!<;@1B<A.$Z-QT(3*W
M0 S/J5*$YC0I@G.6* -S^E3^.7O4LW+.J_URGE?[9G^K\LN2E'Z9@RC\,B3%
M+'*#.3]%_5U<@J_)IO>7]X!(#2D@6?P^-1=(S#="?($U8@L=$%,X!=%%[H@L
M\D-$42C"BF(16I0J!!?E"H%%Y:)_4:/"KVB1PJ=HC=*K<)=R9N%9E6?1?95G
MX==*SP))Z9DO*3SS),7,7"U7F/MC\GFD?%X/?&TCLTDYR>%W*85<<Q<#4:7Z
MB"@S0UCY"(243T!PA2N"*F8BL#(0_I61F%69"-_*+,&GLD3PJJP7/2L7BAX5
MJQ1N%3L4TRM.*UPKGE&XEG^I<"V3%*ZEDF):"2G6\ACK>H@:M,KH*N*U0&I(
M,3]GE-#WE=/[5M'_URCA7ZN!7YT-?.L<X%,_&5[U;IC9X O/AA#,:(B%!QO0
MK:% F-90([@VS!=<&E:(3@W;Q,D-)\1)#4^)D^H_%R?52>*D&E(MB9.'."6?
MB:I@.U"K@_9P#JD@>?R<0NVH6NHWT/_/H?]MTH?;/#-,;QZ.:<WCX-KBC*DM
M,^#2,@O.+>&8,C\1D^=G8]+\<CC.;\+X^=W"N/G]PICY1P6'^4\*#BV?"@[S
M),&AB<R51(<YDCB&R,\FVDZ=%37LB[2&=:2$9/*[>&J'S 5\FP&/!?3?[2(F
M+C+"A,46&+]X),8MGH"QBUTP9HDG')8$PGY)%$9WIF)49R%&=C9@>.=BV'5N
MP+#.0[#IO &;)1_!9M$?L.V0!-MVLE#+_GK.#[3HG;2$3=2L(KG\G-S$-J ]
MF]7&^B^B_^X$)BP#1O>H8+=*@V&K+&&[:B1L5D^ ]>JIL%H]$Y:K@V#1&P?S
MWBR8]5;"M+<5)KV],.[="TWO91CUO@/-JE]AW$,7L8(LU[)K/L<E:BV<Q[Y(
MBEGG=-KUF(5 X&+Z_R[JKZ#^:NK3PMMLH ??K()FBP9&6RQ@N&4$#+:,)U.A
MO\4;>EM"H;LE">JM!5!MF0WEEBZ(6^BYMYR"T/\<Q/YO(&Z6H-PD0;512S_K
MV$T;.)^:522'G^.7L@V6T_^OHO_L QPW J-H$VVVTX/3HQON$:'>IP]A'Q?#
M^[@ W3^*</&U?QIP@!/0 0[P!SBP'&!#'V C'I#_\9N#A!YSWZ?D=T+/O5>+
M_%SDQ:SK["[M.9R4E6P#_A'?C?(9'.H/4'\W/?A^P(3^W. H?3 M*TZIB2$G
M&OK;TUP8GV$<9QC'6<9QCHN!<QSHS^5H'PA^CH6?8P7.T=B?HW$_^Q.1_J*G
MESE@GBNIF\4\QU#7?P?@OA>8Q-!'4]/J)&#\</_E(O6ODL=E&,<UQG&=^;AA
MI5T,/S$!>))QW.8"Y#8'^SOR0]+9P'<H<(>5N'.'?$'^)-(@2S9Q7*9N@?PL
MG#UL _Z:YW%@RAGJ4]/J$J"AIOKZT/X+BX"\%W)W:#_D/OW^LWK \S1*+] D
MO$3/_RH7Z&\PCO\$$DX^;_'B?XN-_-8VX.US1+XOY_N_[L>9)]\+Q3QG' ,B
MJ>M] 7"ZS/Q? RQNLNWE\R^/[K^\_/ <RM!^R%L/]T-4-"@&P,<FVF>4?,G%
M\C>,XUM.S-^Q;WQ?1Q/!SOV "7[ PA^\31C'@P>H9+ZSV+[1K+,OZ^MT@_I#
M]R 9/'K^Y<TAK?\Z@_*_]D)T@%^8D]^MAIX+(O][-6%#ST:5[X>1_WT8)EMB
M8TJODC?H.&V&_+[ET'OY3,@$_'T/2-S_[_[#H^<PY.=A:.^).4NG?PU_T*'^
MQH!_I8-]]-D;/PSM/WP*[9D([=Z'Z1"R[[>&]GX85VCO 8F$]CR*_#P.^2R(
M?%].,\M?B-^QE.7WL-RU5-F,GS# \O?C 8[C.UQD:NXP1>]0[[O!IY,\1+XG
MY<.AO8BWY!@&SUW(?M]H"/.A7#S<#PIAG>)9GTSJ%%&CBBF?S?);6'X[R^]B
MN2OQ&?I8KW[6:R<^PB%\@#-XEZ[_'3KVMZCZ)DN0L_[Z$*]!>Q[CA<&](%E7
MCZB'7HT'V^0WC*/F-&K.8BTBV>S)U,FA1@G+K\9[:'SD'$87RUW%;K.>Y6YE
MN7O9"L=PG[EXAA?1T_P33^%'W(9VETI^O?,(DCZUA8>/FU$2 ^;2C'4<1<TI
MS)DG]8+P'\0R]C1JY.%?*,.S[!OW,(>7Z'R6W\%RNUG^:EZ^&W&#;7(-!SF,
MG,$EW&0D;^ Q?#-X8DA^DNZY?S#X>!NE-H8_![?X%/B$;?(.^\5K&$L]5];'
MAUIAU$F@1@8SG,\AJ@Q74$N-.=1HI<9BEK><JFMQ&EMPDKDXCA,XRD@.\Z(^
MR/8XP.S*)YAD]CW"X*UEO)P><)CY3+[]3BE?^CK,I2GK-YRUF$@]=UR&/W4B
MV>.3J)%%C4)JE%.CCE?"7/: -NITLOQ55-_(*V0G=O$G.SBP;E?<PS;E)]BB
M_@7].A(VZTK8] CR'LQ/Y!,+#@&6'/(X_-]F7#>5!JRG!1X3['%:X8SC*B\<
M40?CH&X,]NNF8*]>-G;K%V&G?B5V&#1@NT$SMAET8(OA<O0;KL,FPP%L,#J,
M]487T&=T#VLTGV&UR>]8:<+YX1%6D-\XO'XYC$/J: Z%]AS^.>0_)D]!\E1D
M8(0C1K8XH!F//<;3L</$#]M-P[#%-!Z;S=*PT2P7&\Q+L,Z\&GWFC5ACL0"]
M%DNQRK(7/99;L,+R )99G4.7U=/HM/X8BVU^0X>MA/:'V&CY@?H?C &>F\BI
M9Q*UQ]-K<'C;-YS3JJ4N=EJ88ZN5/3;9.&&]K2?6#@M$KUT45@U/1,_P#"P?
MD8]E(\K0-;(.2T?.PY)1'5@\J@<=HS9AX>@]:!M]&JVCGT2+_0>8Y_ +FAPX
MRI$Y]G_S->O^QF1.1:[ >7+(F9Z/L6QE+)OM!6P8:8(UH^VPRMX1R\=,1_=8
M7RP=&XHEXV*Q:'P*VL=G8^'X(BR84(76"8UHF;  S8[=:')<ASF..X79CB>$
MAHDWA+J)[P@U$W\2JB=*0M5#'+5\PBG_>4XMUSWI]V;09[A3FY_[G+B^8FYZ
M)ABBV]$:2R:-0<=D%RR<,A,+I@1BOE,DFIT3,,\Y'7.=\]'H4H;9+G6H=VD1
MZER6"#4N:X0JE^U"A<M1H7SJXT+9U#>$DJD_",53):%(QN5OWF.][U+_$I<_
M!WVXY/("UC*6%9QJNJ;2>SKKH=W%'*U31Z%YVF0T37?'G.E^F.T6BGJW6-2Y
MIZ#&/1O5[L6H=*\6RMWG"F7N'4*)^TJAR'V+6.!Q2,SWN"SF>;PBYGA\3R0Q
MVT,2LMV'<).$-ZGU)+7/TG_OYK)C@Q_K+N]]S*3O].!:VTV)>>XFF#-C.!H\
M)Z!NYC34S/1&E5<0*KVB4.Z=B#+O#)1X%PA%WA5"H?=L(=^[3<CU7B%F>V\2
ML[P/B!G>%Q3IWB\HTKR_%5.])2U>DC#(3$EXB76^3OT3G.:W!]%G<-FQE+$L
M9"PMWO0;S$N#EP8U/C:H\AV+"C\7E,WR1,DL?Q3[AZ/0/PX%_FG(\\\5<OQ+
MA6S_.B'3?[Z8[M\MIOIO$)/]]RJ2_,\K$OV?4R3X?ZV(]Y?>DZ2(H*"\^,2X
MT(CH$*CU)#%^EI8$/TF0>8[*5T-X=7#2[P]E5OA^$2-L871S&%D=%XM5_H8H
M"[!$2: ]BH(FHR#('7G!?L@-#D%.2 RR0I*1$9(MI(<4"ZDA-4)R2+.8&+)4
M3 A>IX@+WJ.("3FKB ZYIX@*^5(1%2R)@P1)8G2@EKO4N!C.13 7QQLBY!,Q
M=*&,9RYCJ64<%<Q62; >"D/,D1<Z$CEACL@.GX;,<&]D1 0A+2(2J1&)2([(
M$)(B"H2$B"HA+J))C(E8+$9%K%5$1NQ2A$><481%W%6$1GRA" V71)FP,!*J
MY38USD>S=Y"UI#.*.6 \]8RG@GDI9CQY$6ID1YH@,\H.Z='CD!KM@I083R3%
M^",Q)AP)L7&(BTU#;&R>$!U;(43&-HKA,1UB:$RO(B1FAR(HYI0B,.8I14#,
M9XJ :$F4"8PBD5IN4N-,'#! 5L72A9*Y\HX,XREB++E\S8P1D1JK07*<#1+C
M'9"0, 5Q">Z(3?1%3&((HA-C$)F8C(C$'"$LL50(26P0@A(7B@&)J\19B=L5
M?HDG%+Z)MQ4^B9^*/@E_BC[QDN@;-T2L)#[.>A]/XE6:""SGXGP!:8B7=X2H
MSWC2^3F9/TM(,D1LL@6B4T8A*G4B(E*G(3S5"V%I@0A-BT1P6B*"TC(1D%8L
M^*?5"GYIK:)/6H_HE;95]$P[)LY(NT4^%F>D_B'.2)'$&<DD21(]R276_U J
M^T(*KQ NS)M)#2DFZ221/V.:$9FAA[!,4X1FVB$X:QR"LIP1F.V!@&P_S,H.
MA5].''QSTN"=4P"OG&K!,Z=%\,A9)KCE](O3<XZ(KCDW1=?L#T77K-]%UTQ)
M=,V0Q&D9DC M71+.4V=O!J]2+L@[2"/U*D@^WR?S^]@L()R+Y* \)?SS-? K
ML(9OP6AX%TZ$5^$TS"ST@F=1(&841<&C*!EN13F87E0.UZ(FP:5HJ>!<M%&8
M4G1(F%QT39A4]+XPJ? W85*^)$S.&R)7$DY19R";UR1II5X=*2'9_)R02R>8
M3_U"P*>$;JA,'^[E9G KM\/TBK&85N$$UPIWN%3ZPKDR%$Z5<9A2F8')5268
M6#4;CE6+,;YJ'<96'<"8JJMPJ'P'8RI^$<:42<*84BUC2R3A*#4VRZ>#2%.>
M]F10 =^GD1@:M^!2.A&:68\J8&JM$E/J-9C48(F)#2/AV# >$V:[8/SL&1@W
MVQ]C9T?"878R[!OS,;JQ!B,;VS"B<0WL&O=@6.-%V#:^B6$-/V%8O02[.E(K
M"78UDB _+6@MZ]A>S+Y(2DD.2>3WX31MLZJ!&31-4QN!B30M#BVZ&-5J@I&M
MUAC>.@IVK8X8UCH5M@MFPF9!$*P7Q,)J028L%Y3!HJT99FT],&W; 9.V<S!N
M>QDFK3_ M(7>HIG>8IZ6 =9O126=,/5J2"%)X^?H&K8!3?3,.8 K3>S$5NJW
M W:+Z0J7ZL&TRX18PZ1[%'&$IMN5>,.H.Q2&W4DPZ"Z ?G<#]+H[H=.]&>JN
MXU!U/0WUTB^@TRE!=PG7]8NU;&C@;,EZSJEE7R39?!\_&PB=RS[0 DQKHR.G
M@7582OWEU%])5]ZK@'Z? =1]IE#VV4#L&PVACU-_'Z?$=1S@U_&"7\>.MHX5
M6L?@^]80VMRU=)YK:1_7_ KT2G\A/RFYC7KUK&\A7U-8YX@%;(,.P*T3F$Q=
MAU7 ,!I'\_5TY73N>EL!8;LNISTZS>U<'@YP>3; Y=@.+H]V<$FR,U"[';Z3
MG6LG*[FSF]]O)W3A [3/VW\DU-^FI8OU;*9FQ=#)G-@E0, R]L&5VE,Y8S92
M?PM@-@ 8[0+4--)<MG-041!]3G:,XPCC.&H+')/_6HQQG.#T?((3SHED[7$L
M^9_H.LX*'#]":.N/?ZT]H3+$(M:U@10PU*0>M@'3-I.ZSJSKF)W4IZ89W;KA
MPQV9T^0\>4Q&!"XP'Q>Y-+]D!ERVX23,Y>+CD[5+M>N< *]G C?8R#>Z" N\
M<8F\S^]_(=(@+<QS.74S&&84Z^O+7W/=IST5,XR:IF< @PN >'EH-^:&?#*%
M/$EN#^V2/*7B\LR 2W5CV@5:AN=' 2\RCI>Y''F9$\XKO-!?9:._VD=8F=>8
MB]>^(+_Q,WUU/\=$YCF!]0TZK+TSR9'U',YP3:FI=V-([RGR#'EN:)?BQ:&3
M(O*IC3>&3FZ\3?OT'G/R(=OF$]J&+[A<_E)^8@DGG:_*@*_9N;_>!GS#)'[#
M KYA'-\\0!F[:_HQ]D/YZ3#4G43=X3<!$]911]X!>K@S\O!DBKPS\O[#4RG_
MXZ3(=VR?']A/?J9E^9V68?#6^EE#3VUEFT@KH/T78QX^)>3=H1T)LR'^>5?(
M+&B?2O'_[DAH[Y)92GK(6K*9#-#%[L<?](6_TY?^RN1IG]#Q #_QIS\.\?70
M;LA[#W<D!G=#-$,8#\4AWQ7R\"DA\@D5^0Z9+&CO3JEB^8TLOX7E=[#L+I:[
M$C^@#]^C']_1>7Y#/_H5_?"7[#R?,X&?\=.G_),?#VG+.R+R$S'DNT3^-1B#
MO".A#^UI"'E'0MXED4^HR$]LE9\:ZT^]*.JD4",7WZ*4)=;@"SKPSS&?97>P
MW"XVRRHVSSK6;2N;:P_K=XQ-=Y&.^B[^S9^^Q&R\,+0+(O,L>7IH=T*KK1C:
MD5 ,QO0[K%@_!VHZ,V]>U MAL\=1(QWOLDW>0AF[80U>8QPO,XX7&<>_T,WN
MNAKWL8%==X#E'^ E<X;=^2:>8#0W&/TUEB[S^!#R*8W+@S'\]T-X?V1,7[%]
M/F8NWL4$YFPZM?RH$T&-1):?P58N8/QEO$1KJ-"(ZXSC&N.XBF4L<PUKOQD7
ML!OGF(LS_.84:WV2+7*"M9/OIY(Y_@B2J-7^0^[20]W\+1A2TQ+W8$^]*=3R
M9#T"J1&%2TAB^9D<I@IPEG&<9APGF8\3C.,8%N,H5N PV^0@MK-W'L1>1K*;
M$>_BQ;2#-1P8[+G_C?SP88X4@P\"DG=$7AX<!M3,GS$U;:DWCEJNK(LW8PZA
M1@Q[7 HSG85]**1&.35JJ3&7&@M8YE)L8YML82XV#^Z/G&3KW&!4;[+7?C=X
M!:T9HG>(/W@I?\,A_UWYAD03X":'F,LZ\E"L3UTS:HYD;292SXU:?M0)8PWC
MV/-2T2]D8Y-0A(UB!=:+]5BG:,9:10?6*%=@M7(#5JIV887J.):K'T>W[JOH
MTOL&G?H2EAC\-S]2]R-K#D,<3JYS^CMCQ>F'0_]!QK)?QPB[55;8KN. ?CUG
M;-3WQ'J# /091F*-80)6&Z5CI5$N>HQ*L-RH&LLT<]"E:<-233>6:-9AD?$.
M=)@<PT*3Q]%F\@;FFSY LYF$>?_@:^J_P6GF]E@ZX3'4'LVIEO%LY??]IDIL
MUIA@G8D=>DTG8*79-"PW]T&W>3"66D1CB442%EEFHL,R'PNMRM%F58=6JV:T
M6"]!LW4OFFRV88[-833:7L9LVY=0-^Q;U-I)J)$9]C<?4_-Y+C^N<(HYPN%]
MP!'8R'C6\/M5C&6EM2&6V5BA<Y@#%MDY8>'P&5@PPA_S1X2C960<YHU,0=.H
M;,P9583&455H&#T']:/;46O?@VK[S:BR/X *APLH=W@.I0Y?H62,A&(9AR'L
M);PSGM.1"W/@"NR92GUG:C,>+L_0R5@6C];%PM%F:'48B>8Q$S%W['0TCO-!
MP[@@U(^/0NWX1-1,R$#5A'Q43BA'A6,#RAQ;4>*X#,43-Z!PXE[D3SR'O(G/
M('?2%\B>)"%[XB,X2GB54\H37/H<(]O=6']Y-X3Q=#C1<S&6%D<%FB:88/;$
M8:B?- XUDUU0-<43E5/\4>X4AC*G6)0XIZ#8.0=%SB4H<*E%GDLS<ETZD>W2
MATR774*&RVDA?>I30NK43X64J7\**2X2!G'6\CSUKG*:/S@3V,1EQPHN@3H\
MN,:=1M_)O,QF7FJ=C5#E8H6*J?8H=9V,XFEN*)KFBX+IP<B?'H4\MT3DN&4B
MVZT0F6Y5R'"?BS3WQ4AQ7R,DN^\0$MU/"@GNMX5X]X^%./<_B"3$N0TQ71*>
MH=X%7[8#I_D^LM2;7H<QS6$L=<Q--?-2[J:/$G=S%'J,1/X,1^3.<$6.IQ>R
M/ .0.3,<&3/CD38S#:E>>4CV*D>25R,2O-J%.*]50JS7=B':Z[@0Y?6$$.GU
MH1#A];L0,5/2XBD)D>0.]<[XLR]RBE]-%G%9/(\QU3.62N:EE!3.U$&>ERFR
MO>V0Z3T.&3[.2/.=@51?/R3[A2+)+P:)?BE(\,M!W*Q2Q,RJ1_2L-B%R5H\0
M/FNK$#;KJ! RZX80/.M](=CO-R()P;Y:0GPDX0EJG@BB[^92> 5I"Z#G9$Q5
MC*>$><DGV7Y*9/@9(VV6#5+\'9 4,!F) 6Z(#_1!7& 08@.C$//_L74>X'$6
MU_I_)5F25;WJO??>N[3JO5N]698M]]X[MC'8&(/I&$S']!!ZAQ!""800 J3\
M287<T$()O5W*_G^SNP;?W/OPO.SNMZMSSIPY,W/>X_GF:YROSL9Q=33.JJUQ
MK5H;=[DT-QYV:6R\W*6A\2<N=8U/N-0V_@-\[5+;8'.IK;>YU!G4V5Q^CL[;
M2($O!0?!CB;Z "S#GH78,<'WT'L--OJIORE$O<UQZFE.5U=+@3I;*M316J_V
MUC:UM?:II754S:TS:FQ;K8:V[2YU;8=<K&W'7*K;;G6I:GO<I;+M-9?*UJ]<
M*EML+I7--I<J@R:;RZ/HO8GT]\)6QB'8"E:!Q2WHQS_#?#^?SSUMWNIJ#U1'
M>[3:.E+4VI&KELY2-7=:U=C9HH:N;M5W#:NN:UK6KI6J[MJJJJXS72JZ+G$I
MZ[K9I;3K,9>2KK^YE'1^"6PN)1TVE])V!QYJEZZ'%AWMD$[K<.S*6=YAZC_P
M'6SKXWT7W[=W>:JEVZ*FG@@U]":JOC=+=7U%JNVKDK6O4=7]':KJ'U!E_Z3*
M^Y>IK'^32OI/5U'_12Z%_3>ZY/<_XI+7_V>7O+XO7/)Z;2[Y/4YTVUSNZV9>
M &>#G6 MF 43H!]T]L(YH$P-\]U4.^"GFL$050_&JG(H315#>2H?*E/9<*U*
MAUM5,MRGHN$Q%8[,*G]D@_)&]BEGY )EC9Q0YLA#RACYHS*&/U?&D$V9@S:7
MS $PW^9R)VGW9>!,L!5=*\'"/D<-J&>^U#H [R(EKAJ5RL>\53(>H.+Q2!5-
M)*IP(DL%$T7*FZQ2[F2C<B:[E#TYK*RIA<J86J/TJ=U*G3JJY*GKE#1UOQ*G
M7E'BY*=*G+ I:1R,V90\:M,MR+\02K8/; !+P208Y'K',)P#W=43<+\I^/]"
M=^7,^"MK)D29BV*4L2A%Z8MRE;:X5*F+K4I9W*JDQ?U*G)U4PNP*Q<WN4.SL
MV8J>O5I1L_<J8O9%12[^6%$S9*P+;8HVF+;I.NCQ.<[=06O (C &^KC>BF[K
M JD,FE2P&.X!=4Q>X:6$E1;%KPQ3W,IXQ:Y*5\RJ?$6OJE#4J@9%KNY2Q.I1
MA:U>HM#5FQ6\^J""5A]7X.H[%;#Z>06L^E"!*VP*6N[$,ILNIWUG@BV3Q")8
M (9 )[H;9N">L_!_*%+62O2OD6+7NRALDX]"-@<H>'.X@C8G*'!+A@*V%((J
M6;:T:-Z6^?+?,BV_+6OENV6_?+9<(N\MMVGNYJ?DM?EM>6_Z3CX;;/(U6 \[
M6>0XI6<]F 7CH)=KS4OH@^52T6KTKT/_1BEFJQ2V PZX>X[\]OK*9V^@O/=&
MR&MOHN;NS93'WF*Y[ZW5G+V=<MT[*I>]&+^7/]A[%)Q@X$%:]T#4]GS)@D@6
MN\N!P_QL.UB%GV? (._;30V(-I=L@/]O03]B8G9+H?O@@ ?@X ==Y7'86RZ'
MX;B'@QE448 $Z B+\!$6FB-,+$?Z'-N?CIA;H.#<1^"99T.@#\,SS_H4H/^0
M Z>C:Q-M76YVYO"^AS8W;&(,0)-S=\&_T1MSAA1R%OK/@8.?)\V!/NMBDN%+
M? ')X*5P[6,D/)>1<%S&0GLYB_#EI@A/4%^.,R_?XW@D\F60^6.0YTO_#=!_
MB0.[-C,WHW,&#.#KEIV,P[V, ?2FHC?F7"D8G?Z7PL'AZ"XT!SHG$FDF-^RX
M'CMN,+M4@AW_+'8S=MQ"4G0+"]^M\/Y;":Q;Z<A;#H/KP6/\YDTF9[+YFVSV
M72K;:.MR,'8:<7@ZX^ 0,8C>-/3&'$,_.OW1Z6GJ+[< FD*2ST('[C*[5" $
M]Y*<WT=R?C^<_P'ZY2'L>(3$Y!$6OT>89!XEN![%%X\@\)&[ 43^$?KC89L=
MZ^C?:;JK_PASP?G, _PL\RK'KIB0FR6_VR5WH^L^9^WE9"W$W*GSA+,F\I2+
M]#2$X!F2\6<A"<]'.&Y=?Y'DX[<L@"\QV%^"][^,8U^B,2_Q1R^_!;X"-BVC
M?T?HJO;C] '^S45OPD^)/\+'_R')XS&GKJ><=1=3!_F-LRYQ\DZ=WSOK$W^&
MM/W52WJ-6/TGB?E;V/$V2=([+#[_(C[?W2Z]A[+W<.)[+TCOP^K>_T+35S,?
M85H#/BZ^AQAX6(J@G?Y/$GNF_O*\4^?+I]1<_M<=.OIQI\B_S2X1\Q0;?/(U
M9.7;%(@D,?J]N4.&06>CPVTXVG8_H$&V-YSUAWE.F/<G[PK)D^.4D%8PWUE_
M,+M#S$FEF^2X2V8?."AS:NKWL+GO=#F\\3K]-VSP*SKO2QCQ%[#_S^'<YFZ8
MDZ=QF!TA9D?&JW*>2F&O??@X:Q ^3CO,B27FE!"S0\4\M:;+7HMQW)VR5%_#
M<[^$YWZ.'9]AQR?8\9'.U8>Z6!_  M^'9YJ[4_X%0WX;)[[)NS?XRW^>4GLQ
MM0]S1\AS=AM,W</LA'!QOAJ;S$Z99-J5SU]6H:\%^_O0,8;\A<A?ANRU=,%F
M9.]$[C[:=0C91V&VE]#RJPF/6PB3>]'UE'Y+Y[V(M4;GKYUXQEF+L-\5(M?_
M47]@)D=G$-Z+I4V9Z"M!7QUZ.O0W^N1/\/X_P/M?P8Z7\,>+],L+V/$\=CR'
M';^$23\-XWZ2/GE"/V4(/8J>E_#(!WH83SZ$%@/S?)][Y7C6SZGZO[:'E#N^
M\Z=-X?17$KIR:4<%MC?J6?KD:0TR'"=HPPRREZ%A#;(W(7.G[M=^HN"P[H'E
MWT6?W*F;X>WW,:7\TKYGYF:BY#]W9=QPB@WF )QWY=B$]1*Q\1R\_TGBXG&E
MHZ<(/37H:$%^-_*':.$$\F=T&W;<@ATW8\>-V'&#3M?UQ.BUNE37X(NKB(LK
MD'(Y+3J&=\V^)H-CI^"D_K==',/\5_;I8 [^\L=7H;0E@79DHZ<4^VMU@G%R
MG7J1/X3\">3/Z#AV7$9\'-,6HF$/D7D03UR@\^W5D%NQZ"$=(38/,WC/HK?-
M<X=.Q=?FP5B^CL.IG^+U0::8NUS-E.R%3@MMBB3"4M"5CYX*VE"/CG9T]*%C
M&!V3C(A%Z%BAL[4>F=N)BOTZ$\UG\!>GXYU]],=I>':/R]O:[?JU=KFQ3LWY
M$1^C^^\L>\^ ^UAV;F6JO8YK5[,$7.'F2]N"&/FQ.M\E0^>Z%NELMVJ=-:=1
M!]T[=:9'OPYXC.ATSP7:YSFKO7-7:\_<S=H]]S3M]#JL[5Z7:IOW"6WQOE>;
M?)[51M^WM-[O&\ :<0K>82I[*9:E(P;]+'M71;*<<NU\EI_S_-UTU-M?AWW"
M=- W20?\<K3/KU2G^5NUV[]%N_R[M6/>@+9;QK75,J,MEN7:9-F@#0&[M#[@
MD-8&7*S5 ==K5> ]6A'XK)8'O:VE0=]I2;#-@2 '7HMUU&#N M>2AER<0+H1
M!^=B^3O E']ZX%SM#0C4[L 8[0A.U];@ FT.J=3&T'IM"&W3NK!>K0T;UNJP
M*:T*G]6*\#5:'K%-2R,.:#;B?"V.O$8SD7=J8>336A#UAJ:BO]%DM$V343_"
MW)WTLTR6Y0Q2#'!..KJYMB<1WH<MVZ/<M#5BGC9&AFM==)+6Q.1H54R)5L36
M:'ELDY;&=6I)W'PMCA_3HO@9S<2OT'3")DTE[-5DPKD:3[Q28XFW:R3Q"0TG
M_4-#25]K,,FFP<0?\9LLEGQ2G^O!A>!,9^UC*[9L3"6_P3=K$GRU,C%$RY+B
MM"0Y0XN3"[0HI4(+4^LUG=JFJ=1>3:8-:R)M2F-I2S6:OE[#Z;LUF'ZV!C(N
M5W_&;>K+>%R]&7]73\:7ZLZP.9!N4P]X+M]Q,LN5X!RPC]1C*]?68\LJ;%F.
M;Y:F>VEQ>H 69D1K06:*)K-R-9%5JK'L&HUF-VDDITM#.0,:S)G00,YB]>>N
M55_N3O7DGJ6NO&/JS+M%[7F/JBWO+^ +M>:Q$N:"')O:P-/%C,,2TCQP".P"
M&[FV"GN6DI)!832=XZ[)7(O&\\(UFI^HX?PL#144::"@4O,+&]1?V*Z^PC[U
M%(VJNVA&G46KU%&T36W%9ZJU^!(U%]^DQN*'U5#\1_ 9L*FA"!0Z8/[9Z69P
M$3@ MH$UI,9+23UF2(.FL&6LT%4C17X:+ [1_)(X]9>DJ[<T7SVEY>HJJU5G
M68LZRGK47CZLUO)IM92O4%/Y%C66'U!]Q46JJ[A!UHJ'5%/Q.U57?*KJ<IMJ
MRIPHM>G1*F(!G ?V@DVF_E)I:B_HQY91;!GDM;_<1[T50>JNB%9G98HZ*G/4
M5E6BUJIJM50WJ;FZ4TW5 VJHGE1]S3+5UFR2M6:_JFLN4&7-"574/*#RFI=5
M5O.)RJIM*J]RHM*F!TA_KS:[@\!NL_\%+.7: C"*/0/8T\MK5_5<M=<$J-4:
MH9;:1#759JJQME -=96JKZM775V[K/7]JJD?5W7]K"KKUZN\?J_*ZL]32<-U
M*FZX3X4-+ZJP_B,5UME49%!K4['5IKM)?8^#0V![O;0:+.+]!!BLA6^ #MZW
MU+NKJ<%?#8VAJFN,4VU3FJQ->:IN*E-5LU65S2VJ:.Y1><NH2EL6J:1EK8I:
M=JN@Y5SEMURCW)9[E=/R OA0.<TVY3:!1@=NAQ)="@Z S6 YF 8CH ^T@:9F
M^'^+BZRMOJIN"U)E6[0JVI-5WIZMTO9BE714J;BC444=72KL&%)^Y[3R.E<I
MIW.GLCN/*+/S*J5WWJVTSN?!!TKKL"F]';39E-%JT\TMT@5@+U@/EI@:$!@$
M75"EIC9X7P<Y=R?\N\M+)=T6%?6$J[ G7@6]Z<KOS5=>;[ER>^N4W=>FK+[Y
MRNR;5'K?<J7U;5-*WUE*[KM"B7VLP'W/*;[O/27TDK'V@&Z;DL!UI-WG@)U@
M-;IFP&B'HP;4CMXZJ%)5#]P3^E@P?XYR!OR4/1BLS,%H90PE*WTH6VE#14H=
MJE;*<+.2AWN4.#RFA.$EBAO>K-CA,Q4]?)FBAF]7Q/ SX%^*'+(I:A ,V!0]
MWZ8KNED;NAU[@9:#*3 (NM';3#I>W0_O&4#_$/P;JI(Z[J6D"8L2)\*4,!FG
M^,DTQ4WF*F:R3-%3=8J:ZE#DU)#"IV84-K5>(5/[%3QUB8*F;E/ U)/@;05.
M?*^@<9L=P6,V78R.?6 ]F 5CH!^T0]'JT<V05^$8^B?@OU#'N!DW12[V5?AL
M@,)F(Q0ZFZ"0V0P%+RE0T))*!2YI4L"2/EF63&G>DE7R7[)'?DLND.^2&^4]
M^QAX73Z+OY;O(IO\9APXE_;M!*O -!@&/:!I!!^@NW@2_@]%2EV$?FAC!#0Z
M:)6[+&O\Y+\V4'YK(^6[-A%DR6=ML;S76C5W;8<\UX[(8^T2S5F[5:YKSV;B
MNP8\0(=#R%9_*I=59-,K;7(#9XXS'L!2,(G. =#&^]HI^F AW&\Q^J%'<2O1
MOP;]&^!@F]WDO<U;[MLL<ME&\K.-Q&,;B_]V%IGM3&C;&4S;":#M.&[[.@")
MWVZ.?8"X;H6T;?D(D$5N=N TVK@6+.+G8Z";]PVTN8(VY]/FM-7H7R^%;Y8"
MM\&!X>BD27+=-U?:#Y_;3^)U.HG& 1*1 RRT9[#@G<&D=D:;XRBD,Q!RQFYP
M$=_?QF\AD/LAA?N_)PAL=FQ#UPIS0@_MG<]K*VVN7D4,8G[Z)BD>O>&("-@K
M^<+1/0Z1].):G>,&2#[/)?$[BAWG8<?YV'%!&DF V9K*Y':A.1Z+1EV(H LA
M]A= YB^ 1)__)K__EK^SV;$!?4O-"3WF[BQ\78NOB[?"_VEO_#XI[$S)<ECR
M.1<.? &Z+P&7 5RKX]AQ!?ZX$G]<C1W7D 1>BQW7DWQ<SP)\ MY_@N Z81X5
MAK#K(??70>BOA3Q?^P6_M]FQ%IW3&QD+6XC#'<Q#^#F;[DN@K6'GH1^J[FWJ
M+U<YZR\G]Z*8>LBM /?J=I+SG_I(=UI(1HB/>[#C/A*/^UCX[NMPWJF#+^X_
M"OC#^WXIW?L!O[/9L70G\_(>QB*4O!H_Y_&S)/2&8[*%4/:ZP:GKI\ZZR\E:
MR$/@86=-Q-0H'H<0/(%/GJ1OGC:GEF#'<]D0%A:_YXG/YY<".O3Y*P!__/S?
M ,SF>9L6'&1=-"<4X^<B?)R&WJ@;Z?^?H-_HO-^IZV?.FHNI@SSG)$.F'O+"
M*?40LU?C]^[2GR J?PN4_H$=9AOQ/QND-XC/-PFRM\X!^.)-8O/-MWG_A89I
M<]L5Y@E-] 'MC4-O$,/8YS&GSF><^GZC'_>#_-E9"_GA[AQG+>3D73/V)^M"
M4#XC1KXB,?Z:&/UOQLDWQ.>W./Z[8^!.\"QX0S_>$>+K?'_RKI"3]0=S0D>W
M'$\HF9;C22EKY7AZKJF#[(>]'=*WL*W_AH%]#;_[$F[U.2SQ,SKI4QCSQWK?
M?E;JR=,Y3!WB_\FQ!^)Y.]\TM0\/9^W![(4P>S!.[D<Q=\C4V&LQWZM?WV@,
M'3/Z0LN1OQ;YFY&_$[G[X>N'T'04WGRIWH&-FKM3_DE'_A>=]SKO7H-SGWPB
MBKDCQ>R_>%*.?1 _[K^0LPYB?!),V^)I5Q9M*D57/7HZT3&(_ GD+T+J<OT#
M.U[#CK]BQY^QXU78YN]AH:\P>'\+4_T-G/O7^.)7^IV>Q1-FS\?33IB]%P\X
M:Q#_N0?C2WSQ$;YX#Z[[-KYX Z[[#U6AIUE_H$]>AF^_B!V_QHY?T2_/PON?
M@?<_A1V_P ['"1D7HN-*0OEFAM#]_/<<NM[2/7CR;F?=P^R],,\[OOD4&\Q=
M*>:FJS?EBCX_+ ^F'7'T5R9ZBK'=JB?HD\?4HT>PXT'LN)]^N?>'?1B;D+M3
MM\.T;X.%W\)D=C,3RHT,ZA-XW)Q=<BT]:)XS9/9=F%?SO.$KG#9\ZRSIO>X<
M8L_@B\?QQ</$Q?U*0D\N.LJ05H?\-N3W(GL(V1-X?"&RER)S-3(W(7.7CMM9
M_U$BX[C=DHNP^ (&\?GTIMES<?04F,]&_X?.H?8KYS1P/[ZX@W%R*V/D1L6@
M)PT]!>BH1&H#\MN1W\LH&$+^!/(7(G\9,M<P.K;@A=/HD<-$QR4ZR%^?20\<
MP)/[Z=E]1+796;7O%'S&]/8Z2\^S3'$/>C+ML@3<9)^6/6G3//2%(2F!'L[$
MYB)T5*.C$0WMC(0^= S1Z@ETS*!C.3+78\$.[>;J+BS;@>7;Z:&M>'8+HV(3
M_6&JFZ?"/)S\MTSS#X-;P=5,M<>8^B]B"3A?/CI' >B+1%<R>G+14TH[K-JC
M)O1T$@']Z!G1-DVA9Y91LEJ;7+9H@\L^K7,]5VM=CVNUVVU:Y?:H5LSYHY9[
M?*SEGLPRI^ UIO:G6';O %>S[%W$DG.$:?8@]ISAZZH#'G[:YQ:LW>ZQVN&9
MKFUS\[5E;KDV>=5IHU>+UGMW:9WW@-;XC&FUSXQ6^JS0"M^-6N9[FI;Z'M&L
MW^5:Y'>K9OP>U4*_5[7 _U--^=O^!WX?[:C!W,#4?@FOA_F\/Q+NBTW;@X#%
M0]O\YFF3?[C6^R=J[;PLK;84::6E2BLL#5H6T*ZE ;V:#1C6XL IS00NU<+
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M%LRHIG"-J@IWJ:+PB,H+KU1IX9TJ*636+_P7L*FDP(E\FWY:1"P4,PY)0;>
M%6 A&./:(-_U86,7]K07>*BU<)Z:BT+56!2GAN(TU17GJK:D5-:2&M64-*FZ
MM$N5I4.J*)U66>DJE99N5W'98166'5=!V4^55_8,>$=YI=\KO\3F0+%-MY:2
M=H-]4).-SOTOIOXR#/JXWHDMK=C45.JF^C(_U98'RUH>K>J*9%559*NRHD@5
ME94JKVQ0:66'2BH'5%PUI<*JY<JOVJJ\JD/*J;I<V56W*[/J*654O:7,RN^
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MM2JRKU\1?5,*ZUNET+[="NX[3T%]-RB@[Q'P=P7T?J7 'K+G;K)&<!XZ=K7
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M:]^/TH.^5G,>#Z_Y^#IU@#D(>AQ$./NAUV.I4^?)^HNIA>R08R^*J4WL=2;
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M*0S.XL (8!3*5\8THHJRU<@V1+A;$?EN 8_-X+$)^MB(5QMPYWHP7<<Z,20
M[%+(:ECL*MCF*HP 6I ]B"Q._1GYS))(#%FLGR68*9*9*C<3;I0K"(BB; E
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MA*^8+%$.L!"3ZF+P6"K 7I>R0HR=<-=B.AITH84OKIS/?N#R2G@E*Q!(+4<
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MB$L)D.& J+0 $1XA2(1DA B_G CA&2E&N$:BP4;*L!,6S(*)40@>1R$H'86
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M\4)8>N[%P(3"LX'Q1:>'"C:'2<-H+CA4+)2EC>#0I3WSTZFM6F_.Z.H^NW#
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M12>+1E/U$8?I' 5GND3%BJZ>:$1UU/2I[O1]U'#&'FJAL9O:SMY%'>?LH*Z
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MXF6P>78.'%XLA&-KPD%E2P"<VLT$PT,TL)1W!<?C1'!3P@-#!0>^JE@(5,=
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MHC90/[BU>;PG=S,F20->$\[#S.?XZSY/<*.^=^V?^-VP'_?Y$^#_/PZ^A^8
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M*(;=<S-!?GD\*&X( _4= :![@ FF1SS [H0K$%6(0%-S J8F#CA:6 C6P8!
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M^R;V.>.RPVOJL,,;RDR USH)\/C]+&C_; @\/ _"CB\&@?HJB-7?#+%6>T%
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MY-\.NZ6 ?& 6,&3G@*_"0O!77PX!!NL@T&8;^)/04\Q+'KR#E( 1K0X>J=I
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MQS5^6KW4_&HYJ3EE,77JG<6W4V\L?FE.6(#Z=( #ZF"+.N .2 -)5@:H"O/
M0VTQ>!BL!(;U!J"Y; <*<R^0^8> &"L/SJ+CX%2@!(X5*H!K4 .'T^I@WZ<)
MV$M:@+FG_<MV3.>;]4O=*:M)O4G+3WJO+;_IO;#ZI?W,"DY-QW\<]DJ!TWYI
M<#LT&SR.S@-/U<7@K;<*F)8;P--Y!WAX[@<J5PY<!0I 2E$"8JXJ$$HU %^K
M!8ZM.N#0HP?V@_J O6/X#?/$:,KVI?&D]3N35U:?3)]9?S<:LP']1[:@.QV
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M(9?P@VGY@0+O+/]$EL@ODY/L6\05^M3RXIF=_%B?J_Q8UA-V#.NY5S3K-57
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MRE<#./AE&L!\VW\<+ Y)@>V166!_8@[@-!: @]%2L,>L CNW=8#QVPPV8=O
M2K@3++-V@T7Q7C"OW@]FS0? K/,@F/8? M.1PV#R2!9,7LF"\7LY,/XL!T8_
MCGPW@B-?#.'(E!'(?IR&?QV,#DB"U4$IP,K. D>%.>"DM@"<#):"H\TJP)'7
M@[W/%K +W@&V<;O!)GT?6!4< ,O*0V#9<!@L3LN!>=\1,+\D#V:C1\'LQ3$P
M?8?R2>&[R7>%S\:@\-$8CKTS ?E)$SCRWP"+K1)@LE\2;/=+ >[0+" <G0,D
MU05 TEL*1,O50"!N +S75G (V@78Z'U@EWH0;/,.@TW9$;"NE0>KUF-@V:,
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M;3>JBNDW+8\>-R^-WFU9''W*JC#ZOF5Q[">CDGC4+4U S;)$5%T._=C)7:#
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MF^6<VK=:N;1N#7%KW-K)H_['&1[U6T]XU'Y?6*UV WE5K__;KJ4[0.[@QDF
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M F0M@+:$.Q%,D$_$6$QF-1-]Q"0Q_3^@@C(%54C_JRU1H:**-A7EC6DH;<>
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M&."0+(I#JBDQTDFQR2 E2O90(N02\CO%(G_^@P6X_JLQ/W<\_R3F7P!P_AG
MZC> *;<Q^SZ ZA\ 2@1 GK!!EO! FDAAGCQ($!7@$BT0)P; )B; (E9 )_:
M&W4$;X8$/P#'_S(@@HN.K$9PH1$L,KGR#^;N&#\#!(@?S\>Y.UT#L+P)8'0/
M0/,1@,)3 )G/ )(X!CZAX1S9F,D%4<('!HZ%(D)\'Q5$"S% 3+^=@[@@@?#7
M'] 0_" F>",D>/&3=<C(/R#:!A29I$<1/622(44T32BB8D4C"DXT(A= )S*Q
M="*532>2Y4@CLA!9@JQ$UB(;Z42P'=F+'$7.(3>0WVE$\D_D"T+^WXSG&Z!K
M&R(&X^,PIHB&.8VHV=.(LB^=*$;1B3"=3N1*&$2N#FE#NAA$MA<90#8@(\@N
MY""=R)Y"KB$/\;]YC7RF?Y(CM(]RA#[.A_\!T<=L(W1M8PU$F_KK7$9_&HWH
MSJ81+4\ZT0BC$[5D!E')9Q#E:F0>TL$DRDN1?F0MLA'9CK\_AIQ +C&^*-]G
M?%1^R7BK\I'^1H4P7B.OOO'R7Q CS#9!US93H8BI&GZ-8S+!?AA;TXBA*XXQ
MB$YTXQE$)YM)M,N81*L>:6,1K2ZD%UF-;&!]UAIA?=+:S?JH=83U7NM'UI]:
M=U@OM?Y@/M/^P'RJ35B_(X^11_\#8H+9T]&US>4118I88DTL)E/$W))&ICG2
MB8DO@TR)PK&F,<GD0M9GPVJ1#X;-(N\-%HJ\-5@B^L9@A>AK@T'15P8;15\8
M[!#]P^" Z#.#TZ*_&]P0?6#X3/2NX0?1VX:$?1.Y;DA$Q_GM7Y!I"D LT;5G
MH7_;R &9K8K@NK UH\@L[(>E!_V3>2CSW?0$UNMI.2(OS,I$GYO6L9^:MK)_
M-UDD]LADF=A#DU7B]TTVB-\UV<JY8[*7<\OD!\X-DU\Y5TV><"^;ON->-"7<
M\Z:$<PXY:T;$S_P+8H'YUI*8B_[O( 7$&6OBK 7$R9CZ8F]%>SO'B?["QI_Y
MQ#J:]7!FFN@]JT+V;:LJ\9N639S?+-JYURRZ>;^8]TE<,1_D7S+?)+AH/BHX
M;WY$\ISY3Y*GS!]*GK!X*WG4@@@.6Q+^(4LB<="2\ [\"S(+<^>@>SMROYY#
M>.*8O%3ALZ<>]=K=C'KB/)MVW\F3<=,AC'7-/I%]94XVY^+L$MZ/MG/Y9VWG
M"4[9+)0Z:;-$^H3U2IECUNMDCUB/R!VRWB=WT/JT<,SZMG"/]4NY41LBN\.6
M2&^W)5+;9A,!PI\(L<5<1P[FH__[X#C&G\?P%\(K?PUXY#N9NN5M15WU<J%?
M] @0.>,6+?Z#2RKOF'.>X+!3F=0!QUJ9,8<6N;T.G<+=]DOE1^U6*>RP&U+<
M;K=3::O=4>4M=K^H;+1[JCSD\$EAO0,1KG,DLHC,6B<B-1%BSP/B*@K$&[TS
M ,<1S(6W(0)X'"R$&T%:<"EH&G4FP)YQW-];])!O&&?,.X&_VS-#:J='H>QV
M]PKAB%N]PF;75L6-+HN5AUQZ5=8[#ZJM==ZBOL9Y3&/ ^4>-?N>'&BM=WJFL
M<".*?6Y$OM>=R"&R$R%.Z/X>Z/[^-'@;RH#?(T3@080XW KGPT\1*G J8@IU
M)-R&,1;J+CH:',39%A@MV.R?(CWLER.WWJ=88:UWM=* 5Z/**J\%:BL]>]3[
M//HUEWL,:2WUV*6]Q/T'G2[WVSJ+/=]H+/(BJHN\B=(B'Z* ""="7,9K / Q
M&.!>),!OL72X$B<"EV+$X%2L/!R.,Z3VQEK1MT<[BVZ.\.-L" L7#(;&RZP.
M3A>N#,I7[ TH4U[F7ZNVQ+]%H\NO4VN1;Z]VA\]:W7:?;9/:?([HM?K\IC_?
M]Z5.BS_1: D@*BV!1 E1F AQ9^ : 'B"M[D;Z#N7$BDXE\R$TTFB<#A)%O8D
M3Z*V)9G3-R8XB*R+\^:LC@D1K(B*D5D6D2SL"<]67!Q:I-(94J7>'MRHV1:T
M0'M^T!+=YL#5>HV!F_7K PX8U 5>-JP->JY7&_Q%JS:$J-6%$A5$:2+$DX)Q
M][Z'SO<SWN+.I:+OI-/A2!H3]J5+PO8,;=B8/HV^-G6.2'^2!V=Y0J"@)RY2
M9E%L@G!A=+IB6U2^ROS(,O7FB%JMAO#Y.G5ABR?5A*[4KPH=-JP(W3NY//1'
MH[*P)P;EX9]TRB.(1D4D4464)S+>AS?HWK?0_R]B_LE,W.MG4S"638>=V7S8
ME*,!Z[)-:/V9-JSEZ:[BW:E^_([D,.FVQ%AA2T**8E-<MDI];+'ZW)AJK>KH
M9IV*J Z]LLA>@^+(]9,+(W<9%42>,<Z/?#2Y(/J#;F$,T2R*)6J(RD3&_ZAC
MO ^_CM<@ ]T_%V L'YTKGX(M^3Q87Z *J_*-:<MS9S&[LYW$%F;Z2+2FAT@W
MIT;+U:<D*<Y-SE2I2BQ0KTBHT"J-;] MBFO7*XA;9I@;N]8H.W:G<5;L2>/,
MV/M&6?'O)V4G$*V<1**.J$Z$^ ,\Q#[\)P7@%#K7P0* W;CEV(H,%7-AH$09
M^HHG4]U%ELR. @>Q^;F>O*;L0*FZK$BYZHQXA8KT-.72M#RUHM0RS?R46IW<
MY%:]K*0EANF):XQ2$[<9IR0>GY*<>-<X-?FM7EH*T4Y/(1KIJ41M(N-KX2ZN
MQ8OH_\?1?<<P>T<9>F<YP)IR,5A1H0!+RO6ISC)S1FN)';NIR)U76^ O6947
M)EN6&RM?G)VB7)"5K9:;6:R9E5&CDY[>HI>:WFV8E+;:*"%MJW%\VM$IL6FW
MC./3_]1/S" ZB&92)E&;R)^X%FXF8!_0_P\78@TP>Z0*W;L:W;M:!);4R,&B
MFDE46_4T>E/E;-':<E=N9:FOH+0X1*:P*%H^KS!)*3L_4S4CKU S-;=*)RFG
M62\^9[%!;';_Y.CL+<:1V8>-([)O&$?EO-&/SB$Z,;E$,S:7J$WD^?A:&.\#
MKH/]I5@#S-Z(_CE0C^Y=3X=%]=+0UJ!--=>9TFMKK44J:YS%2ZJ\^0650=(Y
M%9'"S+($Q;32=)7DDGR-A.(*[=BBQDE1A9WZX84K#$,+-AF%%!PT"B[XS2BD
M\)5^6"'1"2\BFHC:1!Y' US&/AS#&NQ!]QS!_'5-Z%WHX8MP&]HZ3P!-+>I0
M.V\*K;+9BEG2Z""6W^#)RZX+D$RO#9=-F1NGD%B3JAQ;G:L6556F&5Y9KQ-2
ML5 OJ+S/(*!\V-"O?/]DW_*KD_W*7^H%E!/MP'*B$51.U"9R+Q[@1UR+A[ &
M.VNQ!IB]>CZZ;QOFHXLWM/.@9J$R5+0;4L4+S!EY;7-$,UO=.*GS_?A)\T*E
MXYICY**;DA4C&K-50AM*U /K:[7\ZQ?H^-0MG^15MT'?HVX?\A]]C]H7NEZU
M1,N[EF@@JA.YCGTXB=?"/NS!5IS_NE: WH7HGNC!]5T E=WB4-(M#P7=DZB<
M[FGT]"X;5O)B9['X1=[<F,X@041'I$SHPD1A4'NFHO^"(A6?MAHUS[963;?6
MI=HNK>MUG%OWZCJU7M)UFO^'EO-\HN'20M1<6XC*1"[C9](1O Y&L?_#F+^J
M Z ;L^>C!U<M!RCH8T+V"BG(6*$)*2NF4 E]5HR8/@>1B%X/L=#E_MR@9>$"
M_Z5QTCY+T^0\E^3+N_54*3GWM*@X="]1L^M>ISZG>X_&[.Z?-&9W/5>;L_B+
MRIS%1-EN$5&:R)GQ&M3@.L#Z#V+^LF[T?U21>O3@$E2C5'3QA+4\B%NG!-'K
M#*B(==-I(6MM&8%K75A^@SYL[\$0CL>::)[KFA2!TT"NM/U A>R<U<U"F]7=
M"K-6KU6<N7JWDM7JBXI6JYXK6JW\HF"U@LC/7$&$$SF*U^).7 ,;,'\%YB_&
MN3?WH_^BA^=L0/]"%PX=$86@$6D(V*H)?ENG4-Y;K6@>6^WI;B,>3.>1 !&'
MD0BVW4B"N.V6+*[UEE()JRV- HO-75(S-@]*3]^\2WK:E@O2TS8]ES;;^$7:
M;)A(FPW]D[W8@\VH@ZLQOZ<7>X!SKT8=RT</3MX*$(XNZKV' I=]7'#>)P^.
M8[K@,&8*=F.SJ-EC3I3-F#=MUE@PW7(LAFD^EL::/E8D:C96QS89ZQ2;,C8@
M;CPVRC':?U[<:-\SSN0]7[B&NPG7<!?A360;KOU!S%^&^0LPOQ;G7K@%>X >
M&KD'P'<_.NAA"F:=8('Y23[,.*D(TT_IPK13IF!V>A:8GG:"J:=]J"FGPRBC
M,PDTPS,Y-/TS572],^T,W3/]#)VSVQG:9\\QM$\_8VB=_,32_(&(:)[X)^MQ
M_?5A?@?FUP\!%./<TW8!1&&V[V',1TV>=0K [$<&&%QB@\XO$J#]BSQH7]4&
MK:M30/.:%>( &K]Z@_IO8:#V6S*H7"\$Y>N-E-*-)93"C6%*_L912GC] 27\
M]1TEO$9H<E?_R4KL_R+,;QSZ>@:5CG./.H3YF.V(V5;G *:BC^O] J!^G0DJ
M#WF@_% &%!^I@/PC71 ^G@*RCRU YG<[D'[B"9)/0D'P- GXSXJ0><![W@>\
M/[8!]X^SP'G^!#A//P'G=_(/NC&_>>CK&53&/LP_BOF8[8#9%IAM_#. ]F\
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MEKHI?X?Z5>$%];/"%]HE14*[B%Q SO\+,AFSC200]&]C/H+U,,):&.+:U+.
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M#@LL6@\)S%MO\<U;_N2;SR,2%LU_P?O. 5R'6RNP!CC?Y?-P'6!NPT+L0R=
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M%"_\9_.1?H#G6-CG.(GGOP/\\>=_J</>%V#MD_#;(0< W'#.,W'.QCADK8L
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MJX&Y\J<!!.< .#@-YF6T_VO(KW2 WW <UR5P,RP-<$L)-^5: '>-<&-F"?
MQ_$0;X8/\0/_$2ZZ1SW(1N08<AMYB;SYB^KQ4R'\5AS6/&#?^$]&8?YQ $.<
MKQKFRF*NQ!6<^WCNC?$3&>3>M].1AQ1NR$5P0\H%>"H %#+<(*L#O#( ^!,W
MRV]QD_@.;P;O\0;X 3]X/F##/V"A/V#(AZO(C;_('S\5PE8%8LV=,=L"YVQP
M'D#U$H T_FO<&]].9+Z?C(P_(8(M1=7&+.3-^ D)#;/8^'X\@,]2* M8$S()
MF0Y?_\94',?X_[J+U'_["9FA;S\9L^\OB$ -K5L%C1MAJ*.OZR+C)Q+6B#L2
M@B3\?YY(;$%V?7LZY!QR&[[ '_ 9_@];7P%>U95]O^Z3>$($ H$$B4.,N+N[
MN[L[(0D)! ($"9(@">[N4JQ86PJ%NO_:J7<H;:DP=:.]_W7S'E-F_O/-MWIO
M7GAG[;./[;7GG),__B,+\OM_01Q/?6L\&:(!H<5W2'8X$7Y$#)%)E!(-Q%RB
M3YV=464DI%TJ?V$7>0[@(8Z1XPG\AJOX%7?P"]ZGF[ZFNWX=RWY\3WQ'_.N_
M($ZDUI]@2G],H"\F0E1:\%-[PHL()U+4&:)JHG7,%P_13_M7L.0A\HR09QM^
MQ![R'"+'*99[$=_B!MG?P'UVG"_Y+S[G-^\1G_T/B).I]2<9T1^&$,?QJ6\&
M4<>:MK ]A"!UABB;=2TC;P-+ZV!]YI-G"7D&R3.,KS!*GAWDV4>>8[A+7WR*
MZ_@8+^%#=N+W^8U_T%/OJ/-6;PEJR%08RWN8Z],?NO0'=?]X^L-H&MMF%D1=
M'_RI%8E?-5+QHZ( WRJJ<%_1C'OR3MQ5].%3Q0 ^5JS"AXKU^$"Y!>\I=^$=
MY2&\I3R-UY67\:K&';RL^3%>U/H.=W1$/*<KXI:>B)O_!7&&'L3IU/_F<H@6
M.A"GT*9);)_Q5OC9:#8>& 3AOD$</M//PB?Z)?A OQ;OZK?B+?UNO*&_"*_I
M+\<K^FOQDL$(7C#8CN<-]N.VP0G<&G<)SQK>QC.&'^&:T?>X;"SBDHF("R:B
M</Z_(-IHJ!*,$JQIQPP=_&EAA.\F3\$7IG;X9+PG_F$2CC?&)^/E";EX84(Y
M;IO6XZ9I.VY,[,'3$_OQU*05N#9I"%<F;<)ELUVX9'88%\R>P+G)S^")R6_C
MU)1OA./F#X6C%J)P6(U#CV%L&'.:_6L6ASWQN9V SRVU<=?"$.].L< K%DZX
M,S4 STZ/Q?7IZ;@RHQ"79E3B@F4CSEG.P5G+7IRV7"R<LEPIG+!<)QRSVBH<
MM=HG'+8Z*1RTNB(<L'Y9V&O]A6R7S6^R'3:B;#NQC=CZ&$1'VN#$J<>-4ZT'
M\ ]W3OO.<KQNHX,[-A/QM)T=+L_TPOE9X3CCD(23#MDXYE""(P[5PB&'9N&
MPUQAG\-\8:_#$MENA]6RG0X;93L<=LJV.1R1;W$X+]_L^)Q\U/%3^0:GGQ3K
MG$3Y,#'D3#C]#>GPX??DO<LI_NU ZG\N.<_Y C=<E;CJ;(1SLV?@E-ML''4/
MQ$'W6.QS3\-N]SQAIWN9L,V]5K;%O46VV;U3-NK6)]_HMDR^WFU(L<YMBV+(
M;;]RC=MIY6KW9S0&W=_76.'QO<8R#U$YH()BZ6-X2/ZOR/]^*/56!+F)JWR_
MZ"_@C+<!COJ88[^O W;[^6"[?P2V^"<*HWY9P@:_0MDZOPK9D%^]?(UOFWR5
M[SS%2M]^Y0K?0>4RWXT:2WUW:2[V/:[9[WM%:Y'O&UI]?M]JS??[2[/77]0@
ME(_C1V\N02%<>CFMWXQCG!\/G..2=S*<>B-(%WN")V)[B"TVA7I@0V@PAD-C
MA36AJ<)@2*YL14B)?%E(M7QI<*-B<7"'<E'P?(V^H&6:\X.&M7J"MFG/"SJL
MW15T4:<S^"6=CN#[.G-"'FK-"1$U"8WVQ_"=/Y=#ZO\7J7VO4WN>3P%.\'F0
M]NR*T,26R/'8&&6)H:C96!4=@!51D<) 5)*P."I3MBBR0+X@LES1&U&GF!?1
MJNR.Z-;HC.C7Z@A?K=T>OEFG-?R ;DOX.;VFB#MZC1&?ZS5&_J[3$"EJ$9J/
MX^M@X!W6^SER7\X 3F>R_GSNYL^;XV18%VN$U7'3L"+>$4L3?- ?'R;TQ<<)
MO7%ILNZX''EG7+&B([9*V1[;J-$:.U>S.:9/JS%FI79#S(AN7<Q>O9J8,_K5
M,3?UJV+O$K_J5L6*VE5QHA:?FH_P!7W^>B+P#+7O!88^QQEV[.-S&VU9GT2]
MDV2 9<E3T)\\$WTIGNA)"1:ZDJ.%N<G)LO:D3'EK4H&B.;%<V9A8IU&?V*99
MF]BK59VP3*<R8;UN><(N_;*$DP:EB<\8E"1^0ORL5Y(DZA#:A-8C_)/]X"76
M^5HV-6<^<(0:?#>QB4O^:MHUD*:'A>F3T)MN@^X,5W1D!* ]/4)H24^0-::E
MR^K3<N6U:26*ZM0:C<K4%LWRU&ZMTM0E.B4IPWI%*3OT"U*.&^2G/F60E_KA
MN+S4G_3RTD2=_#11.S]5U'J$C]CN=\AU6<I#47L>**7>(C84 <MIU\(L'<S+
MGH"YV99HSW%&2[8O&K-#A;KL6%E-5HJL*BM;7I%5I"C+K%269#9J%F5V:A5D
M]NOD9:[1R\W<II^=>=0@*_/:N,S,]X@?]#,S1=VL3%%;#2T)[[$=;I+K(CF/
MEU'[5U+[$T/EC/4+&.OF:Z CWQBM^=/05." ^@(OU.0'"Y7YT4)Y?I*L-"]3
M7IQ7H"C,*U?FY]5KY.9V:&7G+M3)S%VEFY&[13\M]XA!:NX5@Y3<=XCO]5-S
M15U"A] FM"2\F<J^0!\\P;H?J>)8J*'F8SB\JAJ87T*]42Q'<[$AZHO-45-B
MCZH2=Y27! BE)1%"<7&"K* X79Y?G*?(+2Y59A?5:F06M6NE%RW03BU<J9M<
MN%DOL?"0?D+1DP;Q16\2W^DE%(FZ"86B#J%-:$EXA6/@&GUPFG4_6,=V8/BY
M@5C1 '3QLV;J\MH* U16F*&LP@8EE;-15.F'@LHP(:\R3I93D2K+JLB19U04
M*](JJI4IY:V:2>4]V@GERW7BRD=U8\H/Z$677]2/*G^->* 752;J1)>)VFIH
M27B>8^!)ML$)UGTOP\XMK6R'-F )GW,8EM?R\_):71373D!!W0SDU3DAI]X+
M6?7!0F9]M)!>ER1+K<N4)]<5*A+K*I5QM4T:,;7=FE&U ]H1M1MUPFOVZX;6
M7M +J7U%+Z3F6]W0&E$GM%K4)K3"U+C),7">;7"$==_5#HS,I>[L9%_DLX6V
M5-*6@A9-Y+08(:O% AFM]DAK=4=*:P"2VR*$Q-9X(;XU71;;FB>/;BU31+8T
M*,-;.C5"6Y9H!K>LUPILWJOMWW).Q[_E)1V_YJ^U_9O^TO)O$K7\&T7-1[A.
M'YQF?0^0?WLW=5\/M3>E40_1.(^ZB[H\JU- 2J<!DKHF(:'+&O'=SHCM]D9,
M=PBBNF.$B.YD(:P[6Q;:72(+[JJ5!W3-4?AU]2M]NH8UO+MV:WIVG=7TZ'I!
MTZ/S*TV/N7]J>G2(FIX=HH;G'!4N22?UI%-JY-^T@'/"0J"?LFAN/]N!SWPB
ME8A9J(/(128(7S058?TS$=KOAI!^?P3UAR.P/Q[^_>F";W^!X-U?)?/L;Y6[
M]_?)71>M4<Q>M%/AO.BTTFG1;>)+A5/?0Z73 E'I-/]OG&4?.,2Z;N^C#Q9S
M3AB03B>Q'9:S'U"39ZX$XHG0E3+X#QK =W B?%99PGN5([Q6><)C52#<5T7!
M;74R7%?GP&5UF>"TJDEP6-4CS%HU*+-?M4UFN^JDS&;5+9G-X!<RFY5_R&V6
MBRHL4^$XVWTOZSY*";2:G/VKZ(,U] 'U> &E:LIZZO\-U+_4YJXC6G :-8+C
MZ&0XC%ICUJ@39HYZP7Y3,.PVQ<!V4QIL-A7 :E,-+#=U8OJF99BV:;-@L>F8
M8+[IAF ^^IE@OO%W8<H&49BR7I0]PD'6?QOK/DR)OFPM,&^=.@=#B9I)>1A+
M31RX W#?"<S:#<S8JX-I>XTP=>]D6.RSAOD^)TS9YX7)^X)AMB\.D_9EPG1_
M*2;L;\'X_8M@LG\#C/<?@M'^ZS#<]RF,]OP*H]TBC':)PB/L(O]&UGW5,-!'
M[E;*P0IRYI O@7H\Y #@2=D^ZS U^#%J<.I3XU/:,#QM2$R"P6E+P@'ZISV)
M$.B=CH?NZ1SHG*Z&UNDN:)X>A/+T+BA.G2->)1Y >?(O:)P0_XU-]/M:^KN?
M]>Y@G:OW 'GD3*(L#1W;%4,-?)KU?P*81&UL1*FJ?T4.S6MZD%\UAG#5C).<
M)4&M?8T:]QJ#L.M<<*]+6T0YX*^SH:^Q<M>.$-3;5^\2/Q/BO[&.;;V4=>_:
M!=2QS@7D3CX%A)TE/SEG702F7P8F4I<;/@WH/@LHGJ/6OD/-?X>:_XXQ\#SM
M>(%VO$ [7O($7J8=+W,Q?H63_2N<9%YA)W^%%7R%A;[R,O$5?_\K\=<8EF]5
M[<QI. 04L<XIY\C/NGI2EL^\#DREZ1-N 09W *T7R?TJ\08AY4+>UF  I >\
M:P2\9\J@=!KP(<7"QPS0/Z4=GW(Q^B<7OW]RTKM+A]]EX]Y]DL'CF\1]XH<Q
M].X%FNBFDC.<!\@=SOIZ/J/:%6-.7I.7 +W76'>)\Q_$AX2T.^53XJZ4#Y%3
ME&@#7QHP.*9/OIE,H6+-8-T5^)%V_,C X"=.Q#]QTON9C?XS.]8OK. O],<O
M'XVAA?VLE&V=3G]'W@"\Z&<[UG<*ZVM$7IU'^9=/U?F71SM$OE'O$OEW+D3!
M\G2 WPV!AZ;J4S+.ZIM"I!M+:M0G9$;4-Z6RH<7K8Q#US:FSIX CE8IX*D'-
M#6<B@(@CLHARHI'H_)_YA_\\)?.$>G?('6KU#ZBVO\%#*O9'N8_?_E<.Q)!:
M7W\B1 U3_C1);8>T0\6;B"32B"*BEF@C>HA^8@4Q1)X1\FP;VYGQ!PZ1XR1^
MQ47\C!OX$:_319]3^?\\ENMXH,YY/%#C6S5$X_$0QQE3YQ.0,)FP@6J73 B1
MJ,X'59"KD3QSR3,?OV )?L(@>8;),\HFV<[R][+,(VRJL[A/7WR!%VC!)VS"
M[_!/?ON?8]DAD9^H\+$:8[D/(P/Z0A^BYCBVR01^.OVQ?% T.=/)5\3ZU)"G
MA=[MPE=LDR^QE#RK< _KR+.)'#M9]@%VGQ-XG[[X!V[B;;R+-VG5ZRSE-9;V
MBCI3]3C$B7JT0XN^4$(TT(6H9T1;Z O!EO[U8#U#R9E(OAQRE9&GCK:W<7AT
MXSTL),, >59SN*XGQQ9R[,9+],4+],4=7,<M#N:;M/0&V^-I\CTE$W%=_I\0
MIVC0#O7E-R:TPXC^,!B/WW2FX5\:CK@G]\7'\BB\+T_%VXI\O*ZHP"O*!KRH
M;,?SRGFXK5R$6\IEN*FQ!C<T1O"TQG9<USB JQJG<%GS"BYIO82+.I_AG.XO
M.*LOXC1Q2H*!B)-JC%T^/$6%WSFT?S)5XF?:\97!!'RJ:XEW=%WQJEX07M"/
MPW/ZF7C6H A/&U3AND$CKAK,P>5Q/;@TKA\7#%?BO.$PGC#<@C.&>W'*Z#A.
M&CV)XT;/XXCQ9S@X_A?LGR!B+['GOR!RBI4N(?J7%7"/4\O''-;OFRGQGJ$>
M7C4RPVV3F7AF@C>NFD;@TL0DG)N8C;.32G!J4C5.3&K",;,.'#7KQ6&S)3@T
M>14.3-Z ?9-W8.^40]@]Y0GL-+^)'>8?88O%#\*FJ:(P2HQ,$X6-CT&T56UZ
MN^?$:="%4SF?S_/GYZ9IX6ES$SPYU1)/3'/%R>F!.#HC!H<LTW# ,@][K<JP
MVZH6NZR:L<.J$]NL%F"KU0 V6Z\51JTW"R/6>X4-UJ>$=3;7A6&;MX4UM@^$
M57:B;)!82:Q009#P^TQ.>[.!#[CDO>0#/.O-Y<V-L;:##.=L#'#"S@*'9CI@
MWRP?[)H5CNT."=CBD(E-#@48<2C'!H<Z89U#JS#DV"6L=5PDK'9<*0PZ;I"M
M=-PI6^YX5#;@^*1LJ=/+\L7.]^6+G!_*%SJ+LCXU%JCQ(Z?3N^1]/9!ZBQK\
M,O%$ '"2R]]A%UWL=9F(':ZVV.SFCA&W(*QSC\&0>PI6N^=@T+U(6.%>*2QS
M;Q &W-N%)>Z]LG[WI;*%[FOE?>Y;Y//=#\I[W<\IYKG?471[W%-T>OZFF.LI
MRCO^"_]RIP_(_SSU][5(X%P48UR^'^!GN[PTL-G+!!M\9F#(UQFK?'VQPC<<
MRWP3L,0W7>CWS1,6^I8*"WQK9+V^S;)YOIVR;M^%\D[?046'[XABCN]>99OO
M:66K[[,:S7Z?:C3Y_:)L\A<5C2K(&_U4N.^KVH?S; QP*9[U)P[& CLC&&<'
M"1@.,,2J0 LL#YJ%)<&>6!0<C 7!,>@-3A;F!6<)7<&%PMR@"MF<H'I96U"[
MO"6H5]X<M$S1&+1>61^T2Z,NZ(1&;?!3FM7!'Q(_:52%B$I",89@%3YC?5]A
MW:\GL V2J748>NQ)EO(?C#%IQ\I0?2P),\/"<%O,CW##O(@ =$9$H",B06B+
M2!=:PG.%YO 266-XM:P^O%E>&]ZMJ E?K*P*7ZM1$;Y=LSS\J&9I^%6MDHAW
MB1\T2R)$C>((44DH2M3XF$O\\^2[3.Y37&(/9@([^-Q(.P;IC\71NI@?/0'=
MT9:8&^.,]A@?M,:$HBDF5FB(21'J8K*$FIA"655TA:PRND%>'CU741J]4%D2
MO5JC*'J+9D'T8:W\F,M:>3%O$M]IYL6*&H0R+V8,"@GOL:ZWJ/\ODO=X-N/\
M7&I.:M!A:N$!AH7SX[70&6^,]H1I:$EP0&.")^H3@E"3$(6JA$2A(B%=*$O(
MDY4FE,F*$^KD10GMBH+X!<J\^)4:.?&;-+,3#FIE)5S2SDQX33LCX8%61J*H
MD9DP!N4CO,5^\ Q#KG/D/Y+/?LA0=)1835L6T:[.9 5:DPW1E&*.NA1[U*2X
MH3+%'^4IX2A-B1.*4U*%PI0<64%*L2POI5J>D]*JR$[I46:F+-=(3QG13$O9
MKY62<D$[)>5E[>24;_@N:A(:A/(17F4?O,XZG\EC.Q11;S$,W4"LH!;NI5UM
M_%U#N@%J,LQ0F6&-L@P7E&3XH"@C! 49,4)>1K*0FY$E9&<4RC(S*N49&4V*
MM(QN94K&@$92Q@;-Q(Q]6O$9YX@7M>,RON+S+\WX#%&#4#["B_3W97*=D/8"
M4?]NJ6 [$ -\[Z1?&MDN53EZ*,LQ17&.)0IS'9&?ZX7<W"!DYT8A*S=1R,C-
M$-)R\V6IN>7RY-P&>6)NIR(^9XDR-F>=9DS.'LWHW+-:4;G/:T7FWN?S3XVH
M'%&",EJ-Y]+8%\AUM!38S="3,@UK:MD7J^D#^J.&MI46:J.@T 1YA5.173@3
M647NR"CR1UI1.%*+XH3DHC0AJ2A7EE!4*HLKJI/'%'4HHHKZE1&%0QKA1;LT
M0XM.:X84W2:^T PI?*@16B@JQU"@PHTLCLEBZE[R[ZCC>* L64GT-0#-M*."
M/LDO4R*KS! 995.05FZ#E'(7)%7X(+$B!/$5,8BK2!9B*K*%J(IB661%C2R\
MHET>6MZG""Y?HPPLWZ$14'Y*P[_B%G%/P[_\=Z5_F3B&@%)1(>$:?7"*$F _
M^;<VLQTH20:(GE;V ]I24D_=2;\DU^@CL78BXFMG(+;. 3%U'HBN"T1D?00B
MZA,05I\AA-87",%UE;+ NA:9?]U\N6_=*H5WW3:%5]T)I6?=L\1G2L_:WQ2>
MM:+"L^9O7**_CY%C=PO;H8/C@7*DG^@D:N=0=[53=]">F!8=1+88([S5 F&M
M=@AIFXW@-A\$M84@L"T&_FTI\&O+%7S:R@6OMD:91]L\F7O;"KEKVQ:Y2]LQ
MN7/;T\0_Y<ZMO\J=6T2Y<_/?D/9$'63]M\\%UL\#EE.*+)C/OD!4\#V[A]J7
MGX=URQ'0;0"_>1/A.V\&?.;-@G>/.[QZ_.'1$P'WG@2X]61B=D\Q7'KJ!*>>
M3L&A9YDPJV>3S+[GB,RNY[K,MN<3F>V\7V2V7>(8[#I5.,%VWTO^S>1;TP<L
MZ:?V7,QV6 (4$ZE$-!% N"_1QNPE1G!9,AE.2ZSAN-0)#DL],6MI$&8NC8;]
M0 KL!O)@.U %ZX%V6 TLQHR!C9@^<%"8.G"%^!!3E_PD3.T755BDPB'Z>P?K
MO)[<*Y;2!\NI_U<"E8/4_ZOH@]74_Y2*7H3C6L!F2 ]60R:P'#+'C"$;3!]V
MQK1A+TP=#H'%<"S,.<%.'BZ!V7 3)@TO@.FZ(4Q8MP_CAR_!9/@=F*S]$>/7
MB!B_FE@E"A+VSE?=DK.&W$O(V4F>VF&@D-(PA9(]<A3PW00X;R8_];G%5AE,
MM^MAPG83C-\^!2;;K6&\W0E&.[R)4!CN2,"X'3DPV%$-_1V=T-NQ$KK;=T!G
M^QEH;W\1VMN^AL[6OZ"[183N9A6D$UK#K/=RUK-'RL%0#I:0+V,;^^%.ML$N
M8/9NP);:V&(_-?A!P/"P$KI']:%UQ 2:1Z9 XX@UE$><H3CB ]F1" C2XGN$
M$\N1)F(1P<H<IK ^_#0G 0KE0S^S$XK_QD;Z?-70WSF8\AU UAX@[@ 02&GJ
MRJ_:'B7_<6#\*<" ^ES[G #9>>K;\^.("< %"\*&8$!ZD0')108#%SG)7ZQ0
M78UTD2076)D+U+D7WN!W'A /"7$,:UGW?OI[SG;.R>3.83WCJ<6#3I+_M&H/
MC#F_:G(1T*<VU[A&C<WJX!GJ[&=T@1O4V<_2CF?-&0PR,+_%X/"V'W G6K4Q
M]$ZMZD\TW=G SUFAVQ3WM^F+VS\2?XYA*?W>29_7L-YYK&\B>8//D?^B:@_,
MY*N T5. +K\JE_(OSQ,O$2\3K\B!5[6!UPR -XP9D)D!_T>Q\ \&YQ](&[6E
M(]Q<##]BFWS$#O\1&_@C.O+#%XA[?/]Q#-ULZWKZO(#U3B)W".OJJMX#8W:3
M;7^;OI?R+Z^H\R_O2OM0B _4>8FQ?(B2@3%]<H\^^<(4N$_!\HT#10O](1W?
M_8Y]XWM.=C^P37Z@LW^@8W^X0WPRAD:ZIXAU3[D$A%X'W)XE/WDGDM?@5?K^
M\?S+IX_M![FOSH5\J\Z%?"_=(*(!_*P'_$:?/#17WY@J'>U/5)^0D?YBS*._
M7"/=$O+T&$1-,^K;B52C$]6Z7]J#X4#XCFEN$1E0G0JI(]K5^0=I+\C*L?R#
MZI3,5F(W5*=D3D*U%^19_(6WJ)OOXP_\^N_\QZ]J_ S5J11I3X:H2ZVO-.&;
MA/%J.Z3]*!Y$&)%,Y$.U'Z4)JKT@TNF4I>08Q)\8)L<H.;:S[+WX!4=9_EGJ
M]6OD>'$L\_" ;U*NXQNH[BWY2OU\]"[J4^MK&_)M'"$]I7R,)>$"U2D=*1^4
M2:X2\M22IY4<W>3H8\D#Y%A%CG7DV,0R=[+, VRJ$_B<OOB,JO^?;,A/R/X1
M+?V0)7WP/R".H];7TX4HU^9/>NI<C+0?92:_Y4W."/R$%#9W'GG*R5-/CG9R
MS"/'0G(,D&,5.=:SO,UXCVWR+@ZS%<[@=?KB50Z@E]F)7J3ES[/4Y\<R52)N
M/P;12(N^D+%?L'LH^0Z#,5_\0E\\P&S6*Q!?(!9WV2\^1B%Y*LG12(YV<LPC
MQT)R+"/':I:_@65NQ2WL8V\XCF?HBZ?P'*[2PBOTV&6VWB5U;WD<8[D/3G=C
M%P&S2XN:VOA5,"3O9-;1GIQ>>(?]XG4DDBN;/,4LM8I>;L0-S.%T-0_7L8@\
MR\FQEARCN, V.<?^>9;_.TU+3K*$$[)O<$S^!XXJ11S1$''X,8BFJHMW?B&^
M-N+0XW3SF886/I ;XTWY=+RD<,)MA1]N**-P79F"*QHYN*11@@N:U3BGV82S
MFATXK=6#DUK].*&]$L>TU^&(]E8<TMF/ SJGL%_W.O;JO8G=^M]@I\%?V&[
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M?7%U,\%"KE+07[E/4-%<_@L+Z.\6^K:,W.G[@:@C[(/'R7^2_)3G)FQ"O0N
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MX+."@< *+H(K.*DM3U(-].6-!#7W,NK,913P Q212^\!2WXEQ#%(.9AEY%[
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M$+,57R'HL-RFH]1[WP;'7J UVYQGTNZ ?R.-2!DT-8MK O?#$5(3^2*N.TE
M=Y!L[2 !W!&!D/CL8)#=4>!8]+B#QKR#0-Z.$[>O<SP*>1ND>BND>2M$<<OG
MTF:;70Y"_W9M=^P%6F+V EU$6]A/GW1 JKI8RD62D C$2C$^A\ _3.)[!'Y[
MV <A 3U,,GHDTO&'GR,F 3)K4LQ&V ['XK?#./3P;ND0G/O071@>DGSQ)W0&
M_[:O1;EHEV,OT HP9X,Q\0AQB-EJH*7YETK)2,1)[(\[O4^##4\GF78*>ER!
M'E=@C[/8XRSVN!(]KLPB&2$INHJ!X*I>Q#PN'@>?I>"SD/LKB(DKX/V7?X/8
MM/. X[E$\X[2%L%K Z<.=0O/2BE7@G^5%( )O>#G&EZ'<O,%<@ODX!;\<BL)
M^FTDZ+?#M>_ +W>BQYTD!G<RZ-Q)H[Z3P+Z3RMY)@3_#'W?@CSL^1?[EF(,!
M>^H9^@(P1UQ##(*5<@/X-X%_BW,/T(7K4.YSBMF;\\#PO @V^04V>03?G \E
M246/)W(<BW6?)#Z?G(D0>$\>1V@?3_Z:S]Y!/M,BZCV=.G=1ST;J6'PK;? .
MXN].R7*WY#8\]V+F7<X[YT&>=,KPGIQGG&LU[/,AGM+O\<W+$(17T>,O)&*O
MDR"\@4_>I&&_25R\267?I. W7T#>U0PS!T.=FU"ME'JF4<\(^SFXDLOP.I3A
M_3C#ZT',VI,_R7%.R*L_F0NQGQ>"?SXT3_(E5C\C/CXG2?Z2).4KVNK7=#Y?
M$]3?8.QO,.373^O'_1]^3MY_X1X0<R:(.9-TG!SG@9JU(&8OBGDNRO">F%TP
MR/WZ%\SN>_N9'&=A<S?H*[C5ES#&+^QGDGX(G_WW#\]@>=<Y__$[Y#D[Y_5R
MSCNX.N<BS%R,.:/5G EBSB0U^V'&4D*OOH/7?0//_0K>_X564/8Z?8H>YMDH
M'Z/'1["_#V%F?X<=_@VF^"X\\VV,^%<,] :_&CZ+PZS_,',19D_(8_\U_^#B
MM$LX=4H&+Y^Z5($U&HQ.RN_3^_#M=S6'LA=1]@K*7HLKME#V+KT"QWP9MOL'
M&O#O8/4OP):?PQ;/<.=I2GC*B?NX<^[#G(%QST]TH,= 6Q_L%J0/% M+S@2K
M!%?7@]%*^>,)ATEZ40.$WQSJ,D28+"<TUQ*BAM7NTB]AO^=AWH_@DX=HR ]@
MB_OXQCUH?A>>,G,>/W.*68-QTP4Z?/O#'(0;=;. %Z[?8HOGE =.!1B-E#]6
MCZJ;)C*9IC) />90_D+*7T;Y:^SL^@[MUFTZB"=.4O[51,;MN@Z-SE'B57CN
M2CF>+#0LESMU,'M@/G"&]A_M3<T'FP6!%T-=TL$ITMWP_COA_;>KC?*[*7\2
MY4^GVYJ-U1> L0R,-92[A7+WZ PQ>@J?7,JWCF.+H]3D")[\80T&<K'S:AY$
M_;Y9XD47\ZR+H_G_@OB\%UO\3&'@)5)*-CBEU*H6C%%@M('1#<8D,*;IA&;I
M&'I<@AZ'\<M!;2,R]FL?G^SE5[NQSDZB;SL6WD8TF].&+Y1_^-+$Z=I^8W5T
M<??0K.] GYMH+]?01LXJDDA/ 2L7G#+J4D\]1E.'-E#&ZR+B= ]Z[$:/G?AE
M._&Q51OPRBYM1*/U:+R63GTU%EVEEXCB3^R[S%8X6[@1L\7O.8::1Z/@G6;^
M(\PQ#7\%NIUT\:5NP=0KACJE@5, 3@5UJ<?BH\%I V<\.'VTTFEX8K96N0QI
MA<LJ+7/=JB6N![3([92&W*[7 O?[--_C><WS^E!SO?^EN3XVS7&*F8-Y/%&Z
M-X6A![F:UZ=CR*WH\B\.<-$>+XNVN8=JDV>\UGME:HUWH59Y5VJ%SP@M\QFM
MI;[M6NS;K46^D[30;T#S_>9IGM\RS?'?H%G^>S73_X1F6*[5@.5>3;<\KZD!
M'VEJH$W]UA_EN22&&X;\.QA>KD7.,-P=)27:1Q>[@Y1@8Y"'5EL"M=P2H24!
M21H*R-:"P&+-LU9ICK5!LZW-FF7MT*"U1P-!4S0]:*:F!@VI/VB-)@?OU*3@
MHYH8<DX30NY6;\@SZ@G]4-UA-G6'VQQ7Y$GP[\W'_Z0=5R(GZ-HO9IC9F2%M
M0+\5V&DHQ$_S0D(T.S16@Z%I&@C+T[2P4DT-JU%_^$A-#F_5I/ N38R8J D1
MT]43,4_=D2LT+G*KNJ(.J3/Z2K5'_TQM,4\A[VML[+\0VP_R&'AWPJNOJ\ &
M#/='N.[E_692LE789!'^F1WKI>E15O5'1VIR3)+Z8K(T(:90O;$5ZHZMT_C8
M4>J*:U-G7+<ZXJ:H+7Z6QL8OT9B$36I).*#FQ,LU.NEVC4IZ7$W)[R+?([8?
MY&'J?AO85S/,GX1C'ZS#!M5F#XRTM!">D<W8GNJJOD2+>A-#-3XQ3EU):>I,
MRE5[4HG:DJLU)KE!K<DM:DGN5'-*GT:ES%!3ZI!&IJY78]I%&I%^6O7IMZ@N
MXS'D+=5E?HO8>.T0,P]T,[AG&>*/CX3[(]M(!=>8/3!\-A,])J/'^#0_=:0%
MJ2TM2F/2DM22GJG1Z04:E5ZNIO0ZC<P8I<:,-HW([%5]YC3592U0;=8:U63O
M457.257FW*2*W$>1-Y"O$9M=*I%[J/,-X%\.Q[^DV;D/A]<KN3<?/0;08P(Q
MTI[CI9:L0(W.#E=3=KP:L],T(CM7]3DEJLNI4FU.HVIR6U6=.UY5>?VJS)^K
M\OR5*BO8J=*"$RHIO$'%A;]04=%?D*]47&3C/2,S<B?VOQ;,TZ1]A^'@NY&-
M\/UE\/TYZ-&/'MWHT5KDKI'Y%HW(#U%=?HQJ\I-559"ERH("5124J[RP7F6%
MS2HMZE))T605%\]64?%R%99L5T'I,>677J_<LH>05Y OE%=F4UZIC?LV^[DX
MY\ _V4XLD/;M1-:3DB]!EYGH,0D].HF5T<1J78F?JDJ"5%$2J?*2!)66I*ND
M)$_%I:4J*JU58=DH%92U*[]\HO+*9RJW8JER*K8JN_(2959>JXRJ!Y1>]3+7
MSY599>.>35G(+>!<:>:!S)FXW<[S8+DNXOT ]IB(;]J)D9'$3&6EMTHK U5<
M&::BRC@55*8JOS)'>57%RJVJ4DYUH[*KQRJKIE>9-0/*J%VLM-K-2JT[K)2Z
M<TJNNT])]2\AG_':QCVDUJ8;P;D"O*-@[YL(!>HCU^>ZD/?3N-^#?<9BIP;\
M5=[@H8(ZB_+J0I13%ZWL^B1EU6<JL[Y &?452A\Q0JDC6I72T*WDAFE*:ERH
MQ,8-BF\\J+B15REVY#V*&?E;Y)^\MBFNT<9G-EV'W<^ =V22M*>?>"3M7,%U
M'N_[287'8Y-6_%.';TJ@;]E-?DIOLBJM*5RI3?%*&96FY%&Y2AI5JL31M8H?
M/5IQH[L4VSQ%,<WS%=6\3I$M^Q71<E;A+7<IM/5YA;5\S&N;(IH=<@Z,D^ =
MA)+MFD'?:-:A<)TSG38)->GBLU'H4C5>*D"7]#9/)8X-4/S8$,6-C5;LV"3%
MM&4JNJU046V5BF@;J?#V=H6U]RFT?8Y".E8KN.,B!75<+FO'G0KH?%:!'?_@
MM4U![0XYB^V/3W,\F]G0T[5F'0HR:S:Q@#YCT64$=BE#EQQ\E-SKHNAN7X5W
M6Q76':[0[CB%=*<JN#M70=VE2+VL/:T*[.E50,],67I7R+]WE_QZ3\FG]S9Y
M]S[!]3WY]GPGOVZ;72Z;YCB7]Z+Y4&$HR"JH^A RL) V.8_VP&?5Z%>(;=+1
M)X[OA_5[R#K%7P%3@I!(6?H3Y=^?(;_^0OGV5\NG?[2\^L?+LW^ZW/L7RZU_
MFUSZX5?]9F,_1&G*7Y$OY3*%;'ZR32?!. 3VKB7T"\L<ZU#F+<</O&[G7@/Z
ME/%Y]@+X-SI%8J.@N2[RG^,KKSF!<I\3*K?9,7*=;0:67(1.?G:#8V)Q-LZ<
MO<"QL68VO,;\47G60S1ZN.9,N/],,LE!FXZ!L6^Y8R_0NK4_KD/I-NM0N%<%
M+<I'4M MFN\%(Q;$<[DW@0.G6P:76D82M)3!?FFZ8Y!92L>VE !>VNMXX-)2
M"EJRG\+ANXOOI>&3M0[!=X=L=CFTDKX1W,VHNG(SL;B%?@EI0^J18B2=^[&;
MI!#$@GCR7IL]I$TD?IL"$;CE)I*P30SVFQAL-S'P;FQP'+RT$0=NA'-OV(5
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MA&(_Q19;%5,<IJCB&$46)RNB)$OA)44**ZU6:.DHA91V*;ALJH+*AF0MWZS
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M1WP.M_M$E90_DK+'PD_'4^XDO8$>?T&/5V%<_T=G\4?[J08;X:X[,,4!4$^
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M[ 'V0P?LE7(_(43&NP4BX $=.S?H0+A H^$&'2XW,&!ND$EN .0!RN0!"?*
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MS/<0^%L&Y&<_X+&=@* =((^4($]$/^<[P&/ST[D!'0GT:T\*>"Q!/BQ!/BQ
M/BQ &[$ NC '@Y\Y,&!S8$QF(/-F(/&CH'V:@K[2! 2)1T!$8;2VO@\%=&%.
MON U\+^.-ZA>\ B#+'-X AL ^:)$G\,!KT,;'_1"$S!UC+TI3L ^'+>N.T".
M]!!T MC%":'UBZ <@&$YH"^?"06%!4&U'0A>;=^#\OR _ - DL!4K,%S&#S*
MX!$["=H!>':!W[<' OD_S]W\>C:>QPGX]?AO? C6[XSU!_GP!W7BS[T^&/H!
M@_8%BO/U7__.8F_0/KTZ@2$N0I[ @;4#63,&35<-="&2YX -G ?=+7BV@]^)
MT?? _KX+-@SZ<SX$ZSP.A'E6)P*TETCJ]46R2-#)1P!=1 #CC@!*# <)A('
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MZN[I?=T_,/AVZ-WPR.C'3V/CDU.?IV?GOLQ_6UC\OKSR8PWU7R5\^?_#RT]
MB"XQ&;K(VT"9J=&%I@>E9D07FP5=;@Y0<!YTR?>CBRX"RBZ!+KPLNO1*H/@J
MZ/)K  7HH#5@@%:!"="!.5H)UF@MV ,U.*+UX(96A!?0A!]:%2>!+D+1RCB/
MUD8D4$<T6A\):(6D HUDH%5R#:V37*"4 K162H!:RM%ZJ48KIAYHIA&MFL=H
MW3P%RGF.UDXG6CU]0#]OT IZ#S3T :VB";2.9H"2OJ*UM(16T^H:RLT!?9,"
M&'<)0']) #<&''__UA<.A6VFL?]=E?V]QOY283!]000$A(1$1,1 !Z1D:"T
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M %O.X^!_.O9GXX7\<0 JN#8 G'$ 0C;P(0OLN=I5_HT '>R9EMR-?$C^/19
M>-M&@ !6F)-VT89G X '>T;Y<T/DD3\A7&]P%&/M:::?E9:\J,!^89E#N/K!
MGV7Y.-C3\;+S]>@F?#S]Y]%,5QUNWQY-GVIBG;6%Z)&;L$>OGQ G^VGUN*<'
M>\[*_;)9VE1<_,\71/ZP:IPR;BK_V2X.8[<LU)33AH8CA2,3=X0V -BKL &!
M&]LF-?8LQQ=QC.:=A@4HP.!#V+Z6.B8@%,X?PN1#/G! *@R U8L]AP'LL/+
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MJ39:G-0P')"R!\,D=S3" 0=@5IT#XY? ^%B=U%4XP L&@(_^D#4,T \'Z,(
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MQJJ"#WJH<TR8E4T&BU@3X!8)7<8$W, "P"*002S 05@>L*(#9AA !BN),4S
M<2P ; 7C A:@&A.0CP6 3;2T80%@&]9F=L(!(;!B*,(!KC" $QQ@#@-@!7.:
M,$ '/!,R, #J* S "P=DPP",<, W$TP ,1R JH.%<_ 5*Q3J%H958O6D@)X<
M0C/(Z-@$%0T=SV^RNQA/&VB^&_<>BN6.T@1_*^5]V]!?78U%CT/4_ERUAVCZ
M8.RFPS!SR,+D9V/Y]K"0%LOOAB0Q 5BSBQ 9S.F%3W% $&RJ%LL]@+(Q ;Y8
M@'.8 *PP"1ZZ/\("P *,3U1P@"),E? I3H@?!H W32PG!AX^0"0P0!%6+F&
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MI-GZ1X^/N;#GAV73$.8>2ZS="Q#DBRD"R^@A=4R 'A9@-R;@$K8,S$62!]@
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M3EUS;V_B.]M$1'8S*"\O_4FDZ2=SFY0NA\N9U_=G6QHU5.^6VFUP?:S#KF%
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M8BNEU$TKDHD+1Y?S#,9VIT@IVTV:="SU"][*^^'YK"39739%CZTNAJ1*Y+.
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M4&8>&?E<2N'AE462W:\?F=9HI037!W!QWR;8U3.0XSP_\[;C&_G"XJ?PN+K
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M.5@OI_\?XMXZKJUN6Q=.7;"6MK0X%"M>W*&X.PD:*!(H$CQH@=+B[B[%W2%
M</=B(4#0X@0K[O#UW>_9Y^[]';OGWGWVS6_^D_E;:\ZY5N8:XQG/>,9*ZRU
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M@L)+-7%?I6B^;886W10%BOME,S:T24B90&;?N&HM,P33LTS$ 7(":_F+I?#
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M4RL,&^@-NA,Y.A$Y^@4"H?@BL:JSYE_HN%:4F+G%&^Y;\%$7W===7O"N2[P
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MDJLGF[B\Y </*5NNHK>O_$;3>J).T$SJ5XH@9'GU@,6ZNLX4VJ]U]RL+)-+
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M-2Z392GR*^FJ^)I.(9$@2_+5^Z3F*6A9^([&&+'$(6J?H\(I7EJ1&:#=$@8
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M]9Z(+^:&0X7P_;CRKMDWCOS3?LYE?MY'\95;+3G)'M\.'6V6XYLH;?NG'VE
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M[PNL.P,CO2/3==\&^AZA\(\[ATNP(LK*#1;&0Q[/IA*6ZUHT[DK=SI*/M1,
MAG5X9-D5;S==0;"XFC?*4,+9(QN_P/%*%HUI<H;.>)Y)!O0=S<-= <H1JR"Z
M/'N+D-(9O]P8M:B%U)F7PQ^>LA&R>>JS+LKL=U][F(_D25W5(J8>6S(23:3<
M'+Q*B9PA92#T'S+[JXR8#;,@YZRZ#UEF^T"=.]>:)ZTL_![..O2SXG013,%E
M?AAGDS*4\[M;L/6O4M=M%.4S>6@MV2Q!;KG!W[:X<DO_QIQ2^C^RPOY+WF]S
M1U=Q?MZW8<GIDSBNT2"-Q4+_$RK?WLF0?0\  -RKQ6),04B;OY#7H,9LZ W
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MU6O<[8OJK5-C=KK8@I=ILN&^V-@5DSG9O/)XEDA&]6S1'-40X9893FV:1;U
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M9:![53IJUQ-GP$2]:+<>XUI[R2X4&)0$8E..G3/\,MM\<UM?\FW, 0@)DWD
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MC>QOD?M/N]V+%0&9/DUV_U=[WQW59+/MC0U4!%2*TJ5*5WH31)#>2P*$II0
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MQ<,7@\_7FC;%HDBP"OSM^_E^#Q6L@GP-!#ZCA)!]Q2P8\OO&T#A@7]\]!=*
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MDPO,54C0XJA=K[-ZE_A#S?1S6;6=AR3!\8=['?L;@W=+68BK#0$H&\5(%96
M",UE$&PE*$O'T[8_6'45\U9O=*7TDA7UC7*OC^XT5!Q99@'>.'>18\W8>N+T
M#J#$OD0#G389M<\2@AGS2U.2C YT$K4TE\DLFE^1H18538G/Q]<!JRN%FZ*7
MA[<V!8O%YPB>FQMBKY9Q3!7.TY=NF'L=/54@LC6=CR[SW]%,G&IU=N"Y/J9]
M65)7@"9SL)[H!!?:&-6W4J=(JRP,.Y'1^!%MK^'Z+&#6XPJGP: -#\,I@XBG
M)1_!&_H.2W9%]QSN@2%,;\$[9%(9V#@A8U]6DN0;)-E$_W)LN2'"M.*Z.>V
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M]'PX7F ;L36C\8(7)-8BQA%#;E(8]F34AUECWEX\2'7&$ZRE:E;(K6#3QM,
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MFQ 5@-W]\T>C\/-\O7]^\=5_[+6J&V>#O!$?R5;O=(T/PZN%DZ6E6SXF#,A
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M'*(RIYP9;:$IIAE5)D5&QJ*R9F[T'I8>=(PH LQ3YNL'L[6YO#&A9I%T&-%
M_G+#$>$+I_.U[GE-89'$1H<$#YZ&(8U: 1ISS="$J4^J3_EY2RM-^[@S/*IJ
M*;6)$QRU9HI3!5_<5WR<E4ITD/@Q60GA\SFU;>_<&*;/4';X+GEN/GS9CP"
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MJ\0T_JYC33H&PAS2+)A6KS?3@;\_UEEK0A+JK6-$UKR?-HH^TYQ979+EANI
M)ZACO>4Y:5-OJGRR277(7%:7,8-698HG<3?I+.8[,4KPE:M7)ZG[IV3*5K5;
M#8UG/,*MS*7TY9\I!@\,0[5$S4<S1'H_B@*FM6RR-=3-VJMNLV $NM;YC1P?
MV&O!:1JX6:\PCIZGW^ 24[PX9?7,@.5Y];2@4U=OEPR;DAHUM6F;K.>5(/[\
M:*#-.5^ZI%83D&!K1 \,10@*T\X/+(?9BB[2&E#";"G5@,5NM3.Z.57'+F\<
MS('ZD'1IX+C%MKD7<&.PLAM"+?%G$]Q_4/XNS?W/Y:+L_\Y.FFS_&'E^WK0U
M0@!U=<VJ:'_<\PVMJ+J+1?QJ HB.M IXDH0GMC?ND+(H0:'O^=(=$HX&UWQ_
MN@5BGO%@J2DVTA:RW/+V(#F^W=_D)A HQ';R'%"$$7]PN1*%/KK*V04 X[.-
MLIEZI-2/ 6/+#RUI]78,=E2VI#:91:X76^->Z*.>D=W/1'DX%$_G]]+"&UU-
M06H;XBP.%_@0TRU62\-10GG#5I?0;1OJ;RET[<7NV'>@1%_7E8V-LR2#!E'W
M_,V=,"9UKZ'Z7L#-FBE:^^3>@(A]T/14T@>Q,CJAMJDO/9%-"E79H1X)2B@%
MO,D&CI.)*.C.K9R\;4*X>6 V9%I>5*&7O'*/OZ&L+(2KL>@E&9ACTMNI7&J/
MD#*/!U&8L\Q"5G;?ABR]1/"[B9^&G9P-==+HLVR(OZSZ &>_2T-&4_'0Z8^N
M\WAD7M&I:XZT.'VQR'*I[XJ;"*NPN#'VN&8@>_@>$W9WKPL%&8 ?.[(>R-?1
MM#Y*SGK*V"-AF>Y=W]EW[A7A1!NJ%5.7;>AL1TNI;NU3FP%>+;AKIHF,5CPO
M##!5<W!-V[]*KJGF'^ 2*:02:ZO$\P/\8/5 &<51FSUB@8T5VM='->O)QD;;
MV]@QR?(&( [#C ,4+BQ7.[X'*^TZ3*20>G0'_$]EZT6=I"FL8 GT#W0NV6_A
M-EYRRK#S%WHH="@8#&@B!#823=Y.(#N[YNZZ#JIY2G*U<A5W6T^BZGA'1J,M
MK30"M@Y?I51<OW+=@,#XC [ [&/LY6B"I]0(NI7E'CA>PFH)4@K1I7 +SKW<
M'^JKB\:(]WETUMX\S 2XFE32\V?"\BM-F\&OWANR=]6E8#_Z6-"&/AX@KIOI
MT>@.]AE_*DEBL08.>=AF4A*L=;HS1I\\(P9%IN"Z%@SO(E9=GSV[F]CNT:N[
MU=JHSX1\$TMY*-:.<2#,[_O+KVZ>J*,MSTQ/2<P'XL'U1-< D\;$J[LB8QL/
MST^W2%M,23_QF[ )")%)Q5WW(G2?NAP#!CMOVL%]FN?&$09C#XJ=$FLMTX$>
MRO@)_H+!3Y_++Z.7-H5G[^251&I?D4YG$9/G&!>M3!NZWY-+63+=Q)FDH.A%
M-$CUCS4Z<U^T#%A2<-!T?QS4UNBU&@_/B/6+L:OOA:;+ X$2=M>&IF19=+Q8
M3=JZ0>V@KM>QCR-3?%DZT\>6PS'A$A1W0-*J2*,6":,W-M) <L&9#,+HO4FE
M;$>61"(*_)BVE-V;KA3"7L7@/C[OE-S1ES_$+?*2Q4P>O8JZ=O>N)3[A@Y60
M, U.J$WU>=85(3RANO!ZJM>!E5H-R;Z"M7+YP+W0L+:3 EB)J]^(,BG&I288
MN3<UR B!&AAK'QNHK8ZS&-6B-,NF!DN$@P]GW#?F<"B$PCC^!=7&LO1Z3+4:
M#7.,DETEMO?+K0\,4?.;M^P'VQD*"WV(*RY8RH943\_P&P5$4?QL;;89L1![
M#-U/+#1N%IB7F,W;&=E'V*.T?0)(L8-S"X!(#:"JE0,#<,.Q1.[N&FII-468
M<=1)'XI(7Y^ ^YF1IUPK3O-5NH$.IWSM)_S+7I@!]/=IO('K*IW%?>:;%*,F
M89/3XB7+([$*!>U7Y)NL!/JP^![1="?/-&QOK:)EW?Z%O<T93V)W-/=<%ZA
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M&&" ! O! T$2B)S?>;A5_WNKOON=JO-R'LY>_=*]=NV]NGMW5?=#_]OX]P5
MKJNIHPG P,#$B,*( @#^H0%J__7^[]G_&>3_;@R,?Q\!%/@8C9BL6!@4 $P*
M#"P*C']C %8 !@ 3$^L_'O#_,5P\''PL; ),#,+_>%-R  8V)B8 @P#[OW$<
M7&P\'$PL;%P,/  ^!0$E%34-G471*BT'N)!3S,Q\98U+6L6IN LI;A):@ !*
M!86$T4NHAL=W<DLZ)_"X!">_'UG^+R;+?\DP</YG2@ V!B86#BX>/L%_M,-_
M\C Q,3 QL?'Q<4GQ,0EP_B.Q 3@4N)14''C4G&*T]"KF!44K:S1<XB9F%N!"
M?%.GY54D'5!"2D;5,B@X/K^D:UTR)#0,THGH#M_GEE9SCG@/@X]\YTE(KOZW
M!2#&^F_*%%@4@.> OW]E)_Z_ 6;J0"9T-DK[53>:O+N71]"N>I#(*_\<=WZ7
M'"JT2E%6K@0V3C=VDR,0JY=$+]>Z2[2Y2_;"1='?"@RX(,C((]/K:<F@_A2^
M&-? I!:R$-(HO 0Y5L=<(93?4=6'=B?WKFHFFJ;-3JHN'X'4!+HBBX, 'DT^
MFH\".[7W\!YB2=3TT+ ,GF]T[^[!YKV3B7"X'@W\@V)YI6/@>ZFO@JLW2D)3
MU[RM V,>VB$+K\ >,W8*-22B<SSFJ2]>^ZU1>WO?.S392(MI,9N*%6NZYTV!
MTKAC,!M9U;JP%H$%AWB\2R!HNUGH\9Y]=NGZ?/KY"#W41G8_WO'5>)CEM7[.
MY);_/?\D@/V'BU1;^&YVTQWIF\[[UQ[BTM.]^M,$+YZ1.=C8M.<IG?"^^]BN
M,:XO!<'W"!X5_I ;4*RV$E*VLLQ%?M#46UJ'G/?>F4(@9K5,8@XU871IL.:$
M%3:: P_FJN>T;\A<@[9??K4\C8Z>=ZB?-/%5M=J:61H1,(:S0T(XM+^\L$CY
MI!JCS#592'O_>0"FK>=<B5;$BN#JPLP9>L*_+V%(1&L.=;2 +UXXU:$LL'!L
MX:4XL#AD1H^=%0*NALY6#_4)JAVSO;$Q;SP)%NH?6()Z>"JH]^X450WF6^O4
M7EZ(U:"BS*>8BLZ!,NS?R?"RBPP;5NP*W(@C7C(@*'ZB^9Y9(MJJ:EGI"ZV*
MF;ZOYUF*%;VFY\\2Y!<"Q<FS]2F\#][='F)-1&4RI88%N(9_Y2LNHQ,V"H..
M"]OF.C43/:E!<VWCS=\\8_4V*,CZ9=(,(_(*2I7?Y72[?;P_K4\BC"D>9G.K
MC'W!RD'3Z,K/D0/^?@XTXE,%42<%D$P)+RK$*+BCVJPN^A4EP<1;.W]7UUHK
MHF>+UFW.%*W^N+Q0;/0NLQCTHJG+6B079& 9?(I!A%Q&V#82#LMY;/1FR9AO
M)IAU1UTC??)/UX<ZK7;3Z?DR8]-(7N8%ML^6R0/I[ HD*%(68\DSG^,:QM))
M?C^5IOK)RO+*9BU V-7+28<W1W1\EV]7(P+ SXYS%'>$17QV<>>>D-M6(?/D
MLKZ14C\1>69;-<0D3=@J9@/#IM0@DNBOH7VUL9.@.[5K;>][>6/FJ5B]M.,1
M;]-E=>RWY''I>K'70ANR]V6-P^P\1?!&P.1,E6BQ;T;44U]SFIR$UHKQB^1B
MJ6DTJ]K?^7Q; \E']  MA&^]I5:0:I;:WTU\ D+P4DL%7]UEJTT=\MS3XB#G
M&Q,KK$FO\79(H>A\([96 @U9LVA=I#37+>:.;X9&UL7X"2WSY>^#4P8YM?)'
M\$81"_?'[5*=Z]&_LM-I05V98?Z)$=)+>D);?N)G 6$49\A,BZ_D7M3?N>MU
M@AKA-?DR;!AU4ZG4IQ/:E01-%&:6K]1SU-NTR_EYDXDFN,OI4\5UJ+G'VC+D
MV)M9OQ 8?H%.+/@W+EM6C5%^MI 2MJP+=B));3+=J4'CQ,A0\K1@MVT+"A4\
M2YC+%,NN549:NH.RVQ$[(;%FGI;IIA'=[]? L05"RHJO_3XD-.DS6;%'0XG<
M&8CLN<&-'^':F0Q%8HX=EE.N+]_:>>OS;#N;UOD@)#8@69V?< 3#:]H8CC,(
MN,&%6H)@K7RWHAKL*I<<C4MF\I<3/O*IS=^6VON;= ^DSRR;.SL\W]>XGTO9
MR*\864M3:6 7-=>E:.!X5!$0^[)88UA.#VO)<$]VQ)JNVD+^ <[;N^G>8:<S
MWS/39-.<B0E-8B-. ^T*A(/0=RK7OP\%]/K,/D3_/G>R,A3U]]90\_"O9=FE
M%FFNO-C>IE]>%/YX/)\[I0#WT/*#7LG[F"&&]J*14T!(  YQT(-P>C5+FG5&
MS@8J?_OEK^<BQBP[5[Z7#;Y# !#-7!XRN1L_[D_2@!R#D6I-7#\13+5N))>;
MU&.Y/%PYL:?I>FD68HNEGTLPUE7ABL?\MGZE;6'HJWCXILWE+<=QHF3>H+L[
M5ZXDQ@H@"C MQO66H'<E[+7UL/YY:/[C<#JT^#8HP)^&VVO47VZE6A#KB%_,
M*&P-\Q-A/#YK)X/$WW^ "#M+W5M?Q6P <<S\PFDTMYJ-)8VP'S[0.Y3 =<UQ
M<*IL+MERG"RMZ5FWHE>AH7E\#==T0@(1/ZY2KB$ZLWY +H7>>-99&2-,PW$H
MC:PD1NP++38?\1CK[BH(^MBOE+_*?9OL;]LCCD2AA-1-=;^M,+BYWF=1<#Z(
MJC)J>AZ E;^J5UH+5O93U7^M;#SOMRAYC3"+S"QB$J8/]5-30N8WQVY=N''B
MI_9C>DG\MTD<!IL!M+T?HAGS7&-@GR.0@9,\39<">@Z>C66J/V%S$RN3.Q\A
MAG>>+S;O*[E2N$8XF/+DRIR'S36:HIK/O:UV,B:,+&"Z4LBAMV2](W8:0$L.
MEK]C9E9];E%[=5D),6%8G7^:SFFK+_&,0T69%#TM]#J6M:K/X7<<M5E(7JTW
M'U=^M1?H_UR*I=J<V5755>=)@P\)+/VXIIYS#_]/)Y$-%'J<HU6<^#QQ4U!@
M9FAH>O^9E\+WET^Z-TK*47*S86RF 5*Q%BN/5D*HC+8[%]HYA#/$9H%9ZUD\
M;W0#WEPNA2OA=MY<+5]EV&3/@/<_P$[.2)C=E].VV?7^0B 71L\\O?HR175A
MJ5*-7&CFVVK1\';1)W$A-_4Z)S8R02J!VO4O&C)EO62)3LTMN%4ITXPV]WX@
MKI5*Y+2%5\E$YH:.!7XV&YI8MDCY]?0S"14D2&_GQ>!)7PVT W7&H>.T8Y:^
M;Y$/:2D/_UGLO2CK0SE&+$P4 2XLU;XBOR(]VI7O;+_#W@T_ZA;6'?SE='>]
M($)AAD.R0<0_EH7AT Y(,/Z3M'VE>G.022P>.B[&JE\D7KI<J[!;7@>2J?ON
M/>:6QZ4]VD=A*OF[ :+#X))-ES\+XCN,7P1B;5ST,.ZPF(1X>?DHK]125$V[
M%7L='8\FX+/K\%9Y7#C#QIGZ".<_6C@K/*P/K6U(5YV%^^A,\R6=*MJB)N[G
M;0QRS>P2? &IW AUR*VMAMGFOC^0'>])5X\$U[T%L$<Q/Q)64M=_$%(7X.O-
MGFL$[:5^1%9,M%:#3!1(X^8P<AR.TZU_2QW-M6:,]P%BN%)0=WYGBO9K\BDE
M_P#5=UMBG:VKIQ>CT0QO3)V[!7X&V>9SWJ7+)H%U:K,X<-))UQ]L!F(M>5'V
M!J^VT8MVYR"EQ0_,* 2(M:/6EUPMH+M^D2I-!&%9;R68>"D^HY9)0SZE;^'K
MN:VTRSSSAQ#]5EQDTH+S7%C%L"CC>CV9MQ@DH7R!;9]AH\.3HYEL7#"32X/.
MT1JDL6\PNC/PDI2?1?O-$ZU+R[C7V$ST5W[C&G UXM1R0.B<3?K5:AC#G[=,
MLG%5Q6A'#$R$/[4!3V(,_P$JJX : =J,17;H'.O)JN9BU.3^[-3O5!C*5S7%
MBLNP5(N!F:5;4UOGU\\Y43TNKI'!3W[@$7<H7@MH.HA6MUI:!QRY$8&7H[U9
M(T"W]<HJTN>8W:0B[;%!A=N@Z/,G,8T71A*66TP$BEZ>"^U[/\U&G/F.+:.>
MTY%3=%3^*=7//JJ,?@@,%:Z^X;5.[T#;#5?6:6QBG :'2:-3'),Q0[7<1WJZ
MQLI!VK[ -<G&_$/MH*+&"5M =U[8UU01N'>[%M%&Y/YWKE)4E$9S'6U@I!@E
MSV_8%7O(><SK/"(WP3O#XODIQ+61YVYY^3EGZ]9\N>ZMO5[=.\923#K .V>5
MZ\BX>#F*\I7GA27UIF<JE[#[;>2*@;U8&[H?U!I^J)O64H[V^QJW>5[@F9^X
M]E5IMO25DE !3@\G5W"#.&(D7DG?B[?A?E\K"6DBKG90&NO^ONC] UV.F%R4
MLI+6*,G(GA'Q#&E?+'MH 2IC_X)YM?AS8Z:'?9<-S/8+!4DFF8YSZQP]S5U*
MEGA*H"XPJ\?OK%/>TMZ&S+0U_'BGVX+OA[1]+XXWS+>?JG')D9^^P+MKLB%1
M]AU78 GEN2O57=08UZ\;+?42EI)*?VKYLV(NG9JT2-,Y1#5$AS/9K7)H6=T]
M])KI4'$P64E?A4N&+CK51'4.*63CXHZ0V=A*&(J1/FS15 *U;MITS#GF+A91
MA@]FSFKFO,O_^6'!"X_UG29)A/>!C)=%NH.GRS<,7UM =DHI&S+0=)D51U1G
M.FA4-=HUTJ=$JG2WM/R&DQ-(JY97\&($!7@SR$-AHY$27GD0;^IQW,VY*HYY
MCN%(746'5N!%)*[9!'NV6N(T;((A1\ :DLP5(U/6SY13NOGZ9X1TYI>!0RMO
M"=1T"4E"-EF-*P-,T3LNR+#RHZUME'.IH+O[(FER;+!L/]_6]0I^,><P9?<?
M^*1'H>-+_."6[QB]=Y$^G=I6L2H3!YJO8F-ITIM]H3I ,48<%S&&=T<-7A3:
M4<0)? ?X5JD>OUW"6V,_0B3I'K\F_W=X?'Q0?9X!8%O,3\M#8^8U"1$DU$1V
M6U6S!HQ<RGG%">)7+J,<%IW1H["KLO-%'R\P%-D*//LCB=OM1IVU?'4;4]R<
M--4U#7NS(4-4&GA[X\1SL%*0H,P0(L9&?:B:+<N):9[>;8VZ]T$4:!E.5:&G
MJF2RL9<VN7NSV5-HO?(G(45AJDQ%>Q5S[JB N2&U-830!6)>RPPG*OFYV9#A
M+@([=IUGR'O;Q!Q"QSP%41-J=A%D%V/?NR1D\Y44F>FQ\$0(#JSXHF;LLC/5
M$L M05"IJ)KQPM\RYTB&>V5,K;>,)5R#3[IL_,='Q+H&H^[*EJ7LASIW$2WC
M0BN?L /U!1=FA<0C)<CQ<TR8<Z9V'5F_  (<\[XT;JV<^HE\0GI;^-/"PFM>
MU$+6>^SLZG.FU@6FG?%KJI0L2L/%W+,(\FTHX0Q_Q[9MCBVT&W,'-M",WG\C
MSI&,/?A19NN948-29V2?VM?C5'A\(8Z3,VZT;\:8LXDH/$N=7>F;1S='</1H
MU:'$;A#L:YX\>&T0;Z\D!"3P+ B;3WC[>!J+3:CRM8^:#=+T*)X9Y7X7';8B
MY]'I[0\J8V_'U)&,ITXI0BK(&C_,?*M:-]$ 7:U]+%0&B4YL.?JQCL+P3ZU2
MC\RZ<3ES-E5->_!7SB]ZS(,-%+;=&:-?O$/ &1HF)_-T)1;)G#:UR_L-:A;N
M($U>-?%^]&,=P4CTM'M6F7(1 7L(13!],KO8@20\K$=?39<E:4",1>[J ]3#
MNV3 94.3(+I8N=6F=>;=,*VZ\@2CA@N]</G#1LX_@,^#U,L!W*3/:]DOO1L^
M"$;#KYS1-K:191BX[DYY?.#*?*<F>G[BS<8@=!YY5^D%+A<EAJ?QK&II]W3.
M6S4M63CE'4.#3N.T._WI=GV.LIM%2=_7"[ZD[R>+T<6:?%KP+<4KVV7YX[=Z
M PV:W@.-4CV\6]XRE!]ST4#(FMBHOC9D)H.1P0K?5;V(TMP9F/.UZ+_K#0A*
MUV#<]("GHXH2OPRW]?<&]P5N\$K.V[DY>I9^2C0,LICD*N,2F7PM&'^[=#F9
M3(4F,OT*8F1?G?[)?%%NE8"()S:)A&&: Z&"<AX ;4*^')S+LE\N&XIYX?-(
MY%^Z9[IUMIKJ[];/;>Y\A#*Y9FWDE\=@ZH<?P1XQ=&[?3U4MZ,9Y!^O>XO4H
M1@.CZ?%M*862*;;(3L0F5RAG,U18!EB)DNQ0:E?-Q.6N:-6:KK.@+YJR^^[D
M7E^N65Z.BGQ4=T>^,!=!3EVTBHA'3!X(FX[$.KTC.Q"RRY^E9N8GCC0E]35K
MEC0US..^"Z!RWDH[)M^XDY/.2%%3$2D=,CF_3Z"A=6882=<II)[9^GQ$?7)!
M7CQ*XHT65R]=.TX$W[.7A$T@ Y.M\G_E?J0__P8UI3VH9BUB6^I]1<J-E7,(
M$U92Z3'$\4U*ZV+R6L?+: SKRN4.IQ6XGX'%S5'_W,8%W%#T!F.1#W(5H;;.
M%HKJN'_Z^3'RAQ6,.OSV4W-UZ"H8 +HAO2#+M [$)Y\)2](DX^;Q(8+0&%N,
MB\UM^@&LZ-/C._],-BOQC%EJX5S]GM-X!C8Q=_?/1NBX3!PGUX'E:W;QYDXA
M:^!*S73B^3WW6+R@<*4+870-CB#G_$0^\0?%J.JN/Q\Y1YA-01/&K&QC5D^1
M[ _D<UP^CT6DGYLA]\=V6Q?BEB7(<<';"Q_.\P":RT5O^KU*5[>O7-;GD7$M
MO"DL%.VG =Z2;I</#NN.;4:(J%Z3:M\9*R(<AQWS5\<J;]#M&EWFM9OQ!/%.
M<=U<TWEGF$<Z7+22'H=SR:P@O0ARM_6=% (A!?91XHG!!<@X7TH8._T1Q4"7
MWS2 %D.''9=W5B9,OL @_)SQFU_'@#?DW%M%T<>B?(<.&YHQ[TP/">6PSIB8
MYVSNE!=(T!SZI0?R"CCY![#_NW.V',3KT-K]W7SK]ZK%#\V6N.\:_E,\5I!4
MCOC=#U,_%[J(K54[X+HA??FL_%:?TE7G_E8BQQ$;D;3TK11C-U,4R\!7NYC5
M#\$[=6DB,]"MF@1S^)OE1Y73&'OA]W=;%#4[,&_&/(4E ZG(EZHV.J[?G\P&
M.?.)@W6KN*J.K,%R5#SR#QT%_#@9RSU#M_;5!Y[\ 8->Y4,2MKZ3T@?]Q.+6
M_BRIOF??NC"P6\+Y.DOY*<V+F]]CY$>1CR>:F/ZR#7"JBBNCC3:6-%&'J07K
MM%K2X!SS%K: #,^ ;KKDQ&UG%Q+W#?T6+&=FQ3:V%;#-'G<]2RFI9I][/,_0
M? !M;!U-'771L:6U22DXA0%?>T]\?DK\[%E$-,P$%7W@]P8]LKENZ[H:UL]R
M"K!UFEDVNWQ<4,Q2?B>*7;.N(U4*I!+@;G)R2(&YY0L3-YHP:XZSOG43NA>H
ML[S+:'2MHHV$:&0%730K9+B^\(H4BTC<'@S9'IR!K;/(@)-):M':*0,>HNVZ
MIVK>WC>&,</4-VK8F0XJF[S!FZ*%8E/,_-E/'H\>'8^9'?@#+>8VP(VB-K]@
M?AG9'S[2_5T?B[7G./7R6!/]\$E=3F9)N2?JU9U^&AXLC 93U[;0C_@G-RN1
M036Y[M*2EHJ*^=4F=%BVQRXQ#@,MTIQ^P<,;8EMVB5*MG1KNB(0-MX9BI*J8
M"+&H^;WIK5/Q\KXQD$UM)U:Y[X+:-VS?>@\\K^F:)D2ROW;POG7^R.T0QK,&
MQ^V8"NKH-H"8N?"T&#SWHV65\EK-X]-/=FYB751\MSJYD2EJPR0>S2=YR['N
MX[]M[>YS,P<1HO71_"87>08-$5H>6W#%7RVYUG?L[_+9&(NZV&W;19\Z5*]Z
M.PQ)+H,;A$@BK.$PZG-UZ6?3+RV:%!OW;+ZZUG+8S#J-B6LYFP@(JMZ_CHUX
M]>'$PS8&QP8=7>#+-APN5:D5VFV!0 QJT,\'9J+Z##^P<T^0F**Q+Z+*$['H
MGFV*OC,(UD=VRP?4I,MM(VX+&[9]/77 2/-$!S\UZF[.*(@&.8!EW\O9-6_N
M1<Z]VY?@44@UZRPT@CI:J^&AJ+M\_LU#Q*BE_WQL;&/3/%9%FPV?7YVMCB1F
M\\2+3]K;G7FYGZ9B-9K"AS7M_4"T:;1+?IE?FPCNRZ]4.WQVLLV'<J'\*4"$
M(YM^Y]K89JLSF[,==Z=(KQ"<MNF@_/OHF&,/UYL2ZW#ZEH7K]PFS/P,7F>^.
MXFL/$YD,F*',_OB.ZEG#D,GMVERMEK4MG^* U92Y3Y?=;%9]NM$RISNZ?]XG
M7:]V@@6E.3D*4]JIWY5DQ1PJ(^=Y9UA6AS(<XA@K^SAI"SHKNR8:](+?=JCC
M5HB4D-Q(>[H:,363D-B7\_F&05YQ9P3V$3*><PIW]ZJG/A=1WV+I(@+-&C>V
M<HG'"Y&>\K!K6E""H[#$+G"EG+8)"[9;L0ECPU9ZCFIH#. S:%HX@AXY1&UX
M1U'; 3&0\MQONY[XP&%+1D4_(XL#S"Z/,;]XL+^L]<3ZZ"M=&>!K!"-"UJ>A
M_!R;T<Q%AC;O6.-UNIFQY?N<2QAMS-=X\ JB/"A3V3 2\K?"#K5*+%[15-;&
MY5I8;<T(Y2L@UDUF))>YNO(3R,K<6*I.0#J >2A27A!BHOT,4SK 6=$7KN+.
M^'#8O%-0IR>AQDP%[^# U-;?IDT<-]9NU_^E]IA'R#-= 7+>,)^HA/68;^W6
M-<KH/TCMI1(H<1'T(*@<!K^(_5W+^OF;OKPX":3(ES"&<G_.DNK*D^KYM=?F
M^H?_<]IVZ9/V5E[/U^-4LJ0[M6(J%\GW&7$$Y-QG'TJ2PXD?CKDL7)#=L>70
M@7+*G]ET]TNZV*-L&?5B$M<4!4F6(N8,R(@^EF"$;[]_+5Y'$<\Q[&QQ*VS&
MU?QRU,<6G]E*!%(BG1G%:Y>JVU,/Y&&+UA4\GI)=.9C)J'T\E O:&.5I<**)
M@BHP:SBHT.1P)]?&3Q-B+[6F>/8!,78S%]F?TGA\62S?=W8TM:0\A TED;BG
M2OEK.=P*I&A&1[BV%5Z$OW/^1'#(WM+$\NUTD*;M6]C$[L)^^$"$I$8TQEQG
M+X>+U45D71.EF5 2C3H[HQ^KF%=G$-!$\BMYFKK;7B\5,)K-,N>L2:=Q0^.T
M"LA7_?UK3?2\:0$I39^E=0;&:'L%/->3-$K!#?'8H^+IIT_'DW="8-_\BG2S
MM6M#,LU4NZI\YFJ'.A$.S._54@BL_:IY@H9B*5=&,;CU+7BFM+=:7E;(X_?;
MGX[(V"$OQ)"B'#%=HE)P\;.T(@*Y-[\YA>#Z@7?L\7S&7Z#B$K[R+:NMPLP"
MX#F(FGVY)[E5,==H+?>A"2_>)HX..,!-)T!H.J!9LM#A,%RXM\#>ABB&.J-N
M>C?91\"!P1](<QB)Q7[E&D:IQ4:IG98DAOSP*?SO@?%Y0,%]9Z,O@DBZ\J+)
ME@JWX=!6XUH2/\F,%U_&#,3JZC8Q'6F)P_U;Q]W%H)[80GPNHN09J6_C:77)
MBT'(6O!D !A6Z+!?V?;5(K18G$PQY9D(OM+R81YN2,5"8X_EZV6:NW!!*V28
M0C'VXE[KT'=U@6EJ9#W8](. S?U 8AQ%C"ID^YRF?7#'OJ[Z3NA^U@'+A^FE
MXNL.W[V3DC-APYK(MT754L;C53V60B2=KRI9&T2XJ-Y.?1+1I#<Q3IM+I?DI
MYA5N%HDA^!3N[/4E^RA!SBTYDL<B1X?F25;Q8QZHI-CA"#O[J I^,E/5OWI.
MEMS651A@E5%W1N.]':RZ7CX?O?*I,X)TTOAX-*\UF#I_V08;!(=G12B$0S-[
M^ ["SBLQ*].^UG9Z[[2;;6T6_]A=UMB9U:B&,];A(NAU5\8V)'0[S%].C:D;
MMHN;,C?E_>CNY7G?6EZ B(_Y2%O3";89Q$!_2:O./_(B(K5(H'&T*%:M%50U
M?.<EWZWH?<$_J=%5]2$L7&I 'BVRKY^PU^D\:&':/Z8<&J7>> 8T N0SK,]C
M[(@@K--]*/;#56D73GE<16I!TK @.M.-%)\??XK--1QV#8<I$;(%P,$-,0ZA
MFF<E>5W2--C!73\G8C4_2<$77RR4UVRI" D+$7 ^"$Y33KE:"'XU\KI@*T%7
MX,OW-)SKM.4(?LD>+%!KJ3RSS8'^>O>:T*IE"X+3=D.@F&3&+MY3J,3C]TRJ
M;\4EZ_\_7!VN+',CZM GP8<#I-P?VEZU"[C@Z^6.Y;S4ASW3<4,<\=FVR@@;
M=B?S\YLN)[7(3H14N::H$2_K WCX*97)>@L=/[(= H/RV\"V1<+FX7S=+4;6
MI:2ZK=>2&G$*F.9B["%?-:/ZEG;$-DG+O""*X1UG@ H:#A%PC:1]F<4& -M,
MGQ"FM/9MNH_L>=I#]%CIJJ(2;PQN0]AHT+8N)Z=/_O>^6-++W6$_OX!)MR]7
M*9)577D@_6QZ]I]"22-\7#F@H]3%SY-*=F0:IQ%_>)L+-)3ZF?:9PMWK8-!H
M_&8]F@266'^Y)W^P6V#,;\;UGZ:8>(*S/C*%W6^T+$^O>'$D)/!8GH,O-*'9
M(BYM@]1R,53Z?7R%A7W%!#/DC$X-M<)U[F+\6%K]N[1K*.L9^XW;VUGW16.#
M44X]*%P9 &IU_5Z38PY*.G@K1?R9[_C-\1"[>8$M]!MCY?6\HG_M>HN<,+'X
M!J K>Y&RRWAP/$T1+AF4/Q4L*U&9>/AG>RAC.W9U&R7'?GOSD)*86"WEYY1)
M*_0#_@VYG-'G]8$<AT+4.8W3(94XQD5+UBH%D[Z\SZ2\4%I"XOO(4%-[4V,#
M?HQSY4'X7)T"QRC!ZJ=DNP<Z\S<P=\*A;P#%UG%WAV^QW4]^R &?7-+&2\FF
M^G64]1^W7[EKA](BTX3A0D;"P"PMAF(C7$NAYN7FP5>6QB O3[K#%0:0O<_,
M9;2:(VY+S4UXHCA3[TA+GWK*-"-:]8P*R0+?/Y4K7R=P:]I=*Q,0VA!UF<A1
MSC[P:4GO3RX>3W].//$7GR9-M"LA&*RZTJZ8_8QU47#K70JPR$YX9<?(_;G6
M\A A^4NR*BJ_"E=Z&]T)"(%@VIF<B5"87CPOV?Z 8*MW"[#TU>3M:C^H]UF4
MUXW U@"6]-&G\A ]RJ9=9Y] ,Q^$WAS5+X/'!H>6R0)8MYPC%XYZB3,:%U^=
MV%!AT@?;4=T=RS3@?<^:6:Q0M9XBTJD<E"G$,YK.'=<@J@>LM6R#2U"PF)M.
MF6NWZG"1_@/4/O8$D5DAO1\_DWGYUVZ50,,\5>].=W2&>[Q'K*3^)'5H478]
MR=D[Y=NA(%+XK">*2/^IT?-C]2<"NZ9E?8F:Z#\2)KZ,RR1Q, 'B<#?I11O/
M3C<*F[>0O8,!-V_SPC0V@6"XDIWG];9:OOL H6+QX%F$)+#85>:9<"/0"C2P
M[)9AN/*!\[Z/(@]4^JR+((!3PD_&X K5V"_SW\TQ.%LI&Q'1,G1%]*FL>;.-
MFS)ZX"<,RU4BTJ3SB?B]ML $3?LC3:<GDU87]5-;Z_M[)K5[-A\]=-'->G:/
M9S-)<Y& LU-38+A(7SJAC_0O-;=^N;U:/,TRCA/EZJF[ZV;>MXX>;Z,<HK<V
MG3JEB+H$">' ,.>B6@T-9>2Y&"[[1U$W9P"I"IAH+M_S%CR1,]MX:HLRW3V1
M&>#94N&NK"M?7B^VKG+7NZ5A\5/P=1&;9AR04(9^9BA($\^Y7>W8.G#\I86N
M09U6T-;LZE)(>Q<'6X:?4372RB&@"3S:3.S3^],+A8J4SU8#2;Y?DN?\#L)P
MH8:P4/'J4WFBEV!X1F6UQ8/]UFNSC*/[0M>M>:*1F];F8N3/7K_VPGG3&$QC
M<W^B>$&T\XI_!/S' 5;#WN*NES"PW'%WI;EDE;T?X7K9OT]%D6_M'.\6F0@:
M'U!D7ZN@:ONCO<Z8Z9A)PG/5IOR&];=\TV$QJYM_A6@PIA.$&T E5JNG0[L'
M[=/6MUJA*&H+WK"L,WP;XCWTIZ["&)3F*R_J9=S"BY^V,U,WC=4S,#N7*[+[
MLK/]VQ_[/W3Z/HB(FO0VXQ175ZA,!J1 LI-=!ZBMVDF 23Z*L JV:Z\R9O)I
M "M]O"L(7[\/1)LQ)?I1P]"NX(G/ZKJUH\-=O:VG-^0.-@?JX7T:^(PEUOF<
M>E@Y5&26;^HRPW6>,71Z7T!R)MX4;4F8-D^2A\<GS6,<;H*9*8%ENUX G'P'
MC?NX%QY:G2=Z3 N5Z!%8SLQ%>+"15\MD.$]]3[Q)6SZ9 -3AC9AYV]PGN;J,
MS@(&+\5^TNG#W^=XKOU4[?U'PWHH_J<#Y>)D7G/?^,D2[U:K,?QX664.Z>2)
MM)%>UIPA3EE,>#F+@)XXEN5YT!O1T]GDPV\/76%/???4ICI>#JK"EJX4>DP#
M>.&9$).A#GL51_PH+L5$Q \]E_</E2K+YJ%,?3YK.U[<FNLO<D+<$6G56AGT
MY_?ORF3CBPGH-<\9^83X"\N<%K4%+',6*)O3B=R6/_K$<&,=J(+\RF ^1V&L
M!-(S])6.Q!LR=#!=C;##7ET2AUC5CI[O]:.Z79D38+^V5U9ALX(*$2QG#[3:
MR5&T*"]@VL;P/G7\IS)U."#*B2EH*^84)9]\ID&2K2#JBRE@X'4U(M(^1HBU
M2)Y6<?/>WU5WQ:+-=H:GDXW'J99EYI3V\//.T.G]=J)JP[:4.R0W#41NG_;%
MDVA(54"'BE0#QY(+<FT7?^H3+L]A-:-^5\;ZTM)^S/Q=P5.EX7H=B^%$C8$D
MV)]R2<%SCL/-8>T99R'[#88P8Q5>*?,35^[I0C':_[&A(3Q=%PKU?Q_S;%)A
MZ7T_1)O5+:4KQ8)_0S<)QADA(Z#M /1=-)-_O^%?=(6^ -D-4AXO[V29@/.*
M.J6+Q&)7NTW]N-8I>:BG+B<DQ1DWE:LOWGUX(<*0CUL>A@;LDV=;=VT9;YLD
MV&+L;:->D!QJ]R5L^UQ>.:IH*OE73>(?+?T5+JQW*#VIO-*^O%Q[Y]RSC#J\
M*_69]^B^;!Z+B\#/'[&N4<4VS:7NZF@UP_3(7O$!S5 @YPLVM&.C^KTC5"$]
M=^B(]>Z!4!\&"RR*:%J1P).0L>X78N[J<6Y$-#1859R?V-V!\.P![A+:&=;<
MZDW+=ZB]+A;G84/=>D_4T)X[,<U %$[!EN*(402'-MYB=J[=[=?1R'+!Z%'B
MXEO;C"<.W;$/Q#(NV0<1F>,783HJZ>INDQXN,T18Z'E+JS,/EZ =_]GPI!W*
M6H&ZONB3;&N'5JV-_'2;+RQ9I.5S.)2ZRA-XWSZ7687S2XD[F4P*O*A-Y$-3
MK-PVB?M*_0,D2&T=5H&+JT;7'=3L6O63CX31<\F_, TM"X]Z]Y)<OTLA;YGV
MD#LJ:R%F+2SV;4D^CFT]Q7K\XJ/&O&D*-*D)=S-3ZD.PA^!L40?;%PB4?DQ#
MTV,[<E[B18MWM7M8@"/ISGU)^ND*E,Q,>]-*$=.A>H/W+-D.=6S'(OD]85VY
M0WUG?&;J^"SDFD["_/:,*58#6C6S#;$V[]3@@)[K[*47*WT25F'.X#4\TK+:
M*:?#2,I<#&"49^%%]B]4G,SKTR#@>M!=@Q"W.>1\HLDYP?)=1$,[?XU8]M<,
M6_):2TX7)LM7"W__>]NO&Y2\ZRHI/+\\0)D36=C"'F(#0RSQN'I\C\55IT&.
M4_Z]TA;9UZ,B9@N)PKYLT@1<IHG#S@H4I52[RO ?!)J++UP<[A;>Z!;S9AB\
ME*:<A5H5=(L!Q$6S)-1A_6,S,_&_9;?A.8>$CI]/=E(*3$XH8Z&$TBT!E\85
M]L05>A*1Q:Q/A->(1.;P*D]7!-,D<)ZB*A(LAY]A6>1?-;0(,KR0KNJ\RFD.
MEQ[N;7V,O\!HOHI0+*IK^^*$@T($]_#O4Q)9X]?!N35M$_3$_;KIQTW'5J :
MP=HC-V^C%?3VN-?1.<6++[BU+Q[O2CG:@^D\8)QCK:[P'Q'WE$,=[TU5*;'@
M6>AON]%#6LV=_2?06Y M8TWM^DY/Q^IV,F>-C6T 76);1FGF! %O6-.Z(:MQ
MTB0395=FE<&'M8'#FXXPHPWJPG/GH7*'W1RMBT$%))5YI*2[^&Q2K!9VAUL?
M+'C""2A?PU]BPB'QXXUPH;[#^_6V1^&&EQ.#T=?F[0DOS?B"HXAVT!LJQU5_
MHVXN?H7H1F,U&:D:K3K@B+TR? _2*$"1K]^Y8+;C&BZ2Z[)$GG_/R%/#>XCO
MKY-_VRO DGXQ<=.8DAU&A_;#H"VC')(>8W:Z\(-S6."!7<C@VMS"6/C&V^HO
MIU_.NP?58!5NI:JW4F:->=V$GG2VB Q;ZEJ*=K==ET[!!K@SOH+SNE2T@A>/
M)UTSTG;U74VU65Y62B!:ADZSQZW V[%&M3;I6(O4(<8?BB#PNH1S+D@^(4-]
M.Q ^.9+MH]W<MA;XEH?!>Z%@M;SCYRS'TT+I^C&W"0BC^EXW;'>AP2\3NG_F
MVP%.Z?$ TJO$FN'A8-3S$Z0GNJ9SX/(0,96T'C+@R3UF _O\UP(8U?P_"=WZ
MHZ[/YL'T3NE %\8![N*+@B*6Y?R-UFW->@-)AYRC]D:DCT=.5)MWV \IQ=T*
M1[YS;]]+NS[OZ&]".L2F9^1Z^-9,\$\=10>9%:0<E5:/!>BQB]>\KTX$I?-[
MK^Q#ZVQ]0,4F1"%%Q$4@3S(^WQ"Q#)#UFSU/<G(=@T*>)3<F@>_C>5-A4WS#
M*@F*]2W(""2Y@2G3#PUN95CD4!,3+I^Y-F9G^)/ "UA,W!5&L.\?,227Q])
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MN;'5KRK,! U!4'!%$#)&P7&C-?)X7O^M5>E#ZGW4 L<WZ)]_@';9T>?AKZY
MS]$W;:B?)F%V]_0G7?+"L89&SB_N+HK:\'H'OV^A5+XJS&1\</ARG&-D2Z:S
M:L&JF$GY?,;E^[[1G2 0^O?#/\"=A]9GG/9[CG\ ?JY?N]X?)%[E_?58^0<
MGS^'_I 9L0\X$?XC]'KIX'\X*?U/G^OOEK:/>J_UV&YE'T9\_J2]GM'^&Y&;
M];GV>=GM,'* [.SE2YKUOY#/*Y-_2!6_V_P#.+/=0)Y7'AS(G)!]C7UVYS_Z
M^)D-)VRXMN<6]@^@EON2=G@C]7=M[G'DS_E'M5]O]?[8=OSMF?Q_A?POA1Q[
MBQQV2'^5$ UL,HC\"V%4;VP[9D,G#911DK\=> K^]%OBX;]Z:2FX^P?XE-JZ
M5VGK47N"OHMBN;;(=6KOT)JAG-T9HJ14 C<]PUM,O)P+#JVD->6LF@N8S ]A
MSEP\%N#*>OL#SZY/ *5"VUUTZFT>U=I F*>D:9:*-LH1*[$Q#?DZY;*P('9"
M\:7VF']TOJNN3N[Q]?)5G5+Y;;KU/P"N#K<PPG.L)+1'ERBO@<,@C84@Y\CP
MAFXR,S6KRWE.:M<*V6=07+\.2\W ^G2<=JP<0_^K:AUOGBW.R">*E<Q%U%1]
MH*JH?# HZW^'.FB%4R-9OU+_+)6#EZ[?OKC"T9A>^H)IU[@7@L-48?M ]O8T
M2.C(ZEJ5-4 6_,KR-O,W5\O)I=5JJ(%-A:U4Y5[G0*^#@;=^ ^( -4*<KW@Y
M<<G:_6/2<D@N Y37D7?7OU#FE>_QX8I2E+B#%].T-I@XZV/:KU_&_*\4CYAF
M!66D[9'C1PZ;LY$+KPYEL(.-W[P>8!6C;CUX6JOS^//K.-'@Y'BE=44BIU$T
M08="K7&YU9/L9\L.-(+]98I6^._SD/<LBHT ,O/+@R.)C</_"FO?^/D&X/>H
MDN*A_2O9X\.4?P#>N1>;JRL]%[Z?+3R'FV^&\6[_ 238##P>?6.F^G\'+4Z3
M_#7*/3\YL;WO#FCN>H&,_/F\X5?IH\_S59==#=1!SBOM@)N7KSV,=#\C.F,M
MJO^V3([\>3XWN6K]MX+U1F28.>1&[77!P9-\-/@/M.(42G?GH$1V\M==J7SQ
M=N,A/^SGP5L(T^^W;/]#P_7WUT8_Q&[77]=/#F:V3S+_SOM\^//O0E71L(_[
M8XO&'\O<Q,?79;GUG7^D_\<T)N]#;Z%/MC)(FV>G@R_95G_/Q4J]/8%=<9Y=
M3SX'ROQ2>M[94!>PM?FA>?FUQ<&7OV^_NIRT_@,8Y$;1O<B1^\4Q/'W]IU)1
M\-7Z_!TX\[&=[?])ZS#W/;O/)>54U$0L4W,AZ$3!VINYE7?RKNO<E2/+@_[Z
MZ4W6,.@N:OH?P*<RU> U@6'/NE56&'%H-"3=D?<2BMOIV'1(T.Z<9&).C,?;
M'?U_,.^6075U3;C@(4 @$-S='4)PA^#N<G#W@P1W2' ([NX.!S^X!'>'@Q,(
M[NXV[S=?S=2=J7O?^7=KJJOVG[UJUZJU>O?33_?3[/?QJW_(A/[B5*?F,^9J
ML6LFOAC9%,?FCH]1X;T#M..<'F/;N>$PMJ 4I_&$9_HV7J/$]IZ]1E%73E'@
ML-5!ESW>7&*KL]&XQETF>WFQA*K7[%D2D\)C/TZ!3I1$+IM/D9XT,"PSC15@
M&H&XT  DS[[R.YV_*=RR>0G:!M0.E*=,V'36S*R@'P3:I*K3UWV%OA6>5&N(
MY*& 0 Z.R4+*?]/=61%5YZ=D>2V8H#2NK#OIO,J*VXQ"_[E%=ZRH?9$'%Y2(
MK4I#'RUB27AKBQPOHBNS4&P;:O?MQ%[*!E)AT53&5 M)XH:OFF19=9MHMXD9
M1F9\M/V&.K*,P)M)"[:5R0 I00DKWIA>MNTL,T3IC8[MOBDW);[<64.7J;$O
M+4>KK_;SJU_R.LX'RM/IH9:[UL>FEMCE4GR,!?3A[$D >8O]VKXN*SIHF7I,
MB':E%$)MWO!OKQ$&V/ZXE]+6SK7'$*2N78*@?9K$?TT5R>FS:G<H$P+W]!(Q
MYMNBMOFN@5%6/?9\45:D+LI4C/;S5F=JV%4!CCQ"0EW+KH/'1IWSD\:=U;6)
M_;]S1K"]Y TMX#R33_H-/VW3A45*&WWQPF=>C)S'7$SW*4R6JWV4'B60W0_5
M@DEZB8*9F"/B*S#;PC [LW75HN&)VA]BD#^E&:<P>BORVK"MVXJ%-^.=9)M:
M8,%=Z7J6KUB?A]-:!96?F&B1U].T4&5)[3@]#+>_\"' AFG!?>"=HJY#!N98
MDUWE)_\UN\*, L:_A,5(7Q&?78/2_IWTL+<M[ZVCZ+BUC(TYRW7%'^BZ9+$T
MX:[&R.FZQ"XDLV]H7P[Z[NR^, @C*7'$8MR\+J1XF^65A@:#4=[RFS*T]Z+;
MS0.K:B>$>S4<O5/!R!IG:B0H=93HH_B.;>X9JTN5,ITS4'$^A'&.2L;!TI?Q
M]1>?6!.$X0LW]=SLUD/M;?Q_,0*SHVM'Y :IL%2.<$M!$QE'OE<RQ3VPROJ@
M"+!(?N/SMDB#W[C?XR3?F4C//X#(?'-O. ,ET+NP4G\'W&@.(Y-.Z3)19[0S
MYFQSNK=4X;\IX#%__\3((3KO.CO9)NM)RF(T1.6TOSR,F2_\-IOSYTFF:VO2
M7EE$_'KBWS@&![+%I).!2)85[^2'Y$F.V,6HO\B/@TZO#U-\2NV62F''M&J:
MJ<7\$4FQGB9E+:)DHX@[YFVD'N4NUVU_'D<RU*=&JV[7_@MP$48XGI+\@V<0
M19O5[0\6PQ52+4V2;A%[VB!6<4*;&?:M^!"XQ/!^!#E)_51X[\%//KP5ICMV
MY:Y^,FM5W(;U] 2J]A ._,8XMJV='PI@K!%\8?*(9RW#/\@#8=T#\D;==1W"
M?[""EO],F3C&\=C P9[M.$L+7GAN/CSRC.JT67AQ3GF4-$@L3)V@*%O70CTV
MHFI?"S[11IJ" \+$&^?S"9TG(9V.54_S>E1?PZ5C?WD6].7'Q!!7%$K1'1\>
M+"KD)%3>L&2NBM:L:M58B7?6'%T7']@?;[S*.R)6 4I!D$K.^ ;OK!FY*\[I
M4$\(@AG/)K0C B.!UB(']\QP4.<#^[W'F]J;"L)5'P @_'H)<:R4S5#61CWH
MRS@Z$*\;JI#]J#",C/DM?G&/08*;)M8DZL>7Y8B_%(LV@18)49SE##.C6;F&
MI5W?9;&^[]4$5A: 439*@[P^#B:X[OJ$>N;GM.8(!?.8+6HMRE,G*SAW_FJ@
M5F96+92$<W=@QAR S<N::Z"Q_%GH8I+8&+=>PAXJ'0=XB9E7^T8=.* 2ITU<
M)'D75)<R>>[8E:\9>BAS8G.J^&U5[ LW8+&HT_Q70,J)#"2!:DAWXQMP@+]O
MV+^'P)(H8T4W;@DQTDV58'ULCD1(O8!3R,!6<4QXV[YV7E'I4]D=U,^;"E)6
ME%#&4=4S#W9'3YMBM..%645L,#F;4I40%,=V#K-(3,%TZ8TC_CE$:K\_U=WH
MTZ#CSIKL8X9XA'IY(J2GIC9P(ESK7F"DUHS:5)O%9UV2V2':L<" >9+QQPK>
MMH'2WJ29Y7MD8^!-221_\ @9)2=Q'7J$8:;>0:4!#_#@R7MCXZ3MK/10XNA4
M>+017:L5A8!^K2.Y27<D8[2X@&$$V9,G X>&6H?ZS',KFG965,D'&9,YV9ZP
M06I\,J0_/*0P#H[&KW;#&FWXVR;N71.FG=./?&I#)-/)>03G[=J"2?#/'&5$
M)P6*SR)?YK]IX!'?*/(?%:7'C0I1!W,^=2RM77I\Y1SJT\FOUO].DC ^,S2\
MDZ)125R-0(VZI!F+)/>FY2#]W8B=H.411I/N9:T5]M7^'7"941&S(9J_C_XL
M5%E#XN!6M=5<(XT^\/QM>%)X=P+DJ::7@51 -33 /+)NROG(@"3VBN];. .>
M++I)2GWM2E^>/?KJQ22%>D1T>[4CY>HAI^SL(#AJ0[O67_B'1_ G'K372R?B
M.'?VZR53[N[E-([DFTX_W3N@/7OBI\MI2-;!%8DA/!2$6I:HBRY'<V]CQY21
MZLBHZD+==LO.75NC&R:D$<BZ+&NW+!9OB<U$_4LEI$@?L1A)IZ9T-CDO0;@T
MMQQTJC8^(X1BV)6+0QE.&=*R*H!CCKMAA)=&&3%+G\!^E6[N:2)SM_RSBHE3
M4A2-J?7+4.()8A#J;]Z["+@<3V* LE4)4:[E^2OUY,P*P-JX)*WCA *'CJO_
M&880DO%+N0FS]&<'2J)E-&+;D$$.G-B$D7ZX$P=MA0+<PJ#%H3)WIO>88M6T
MPRJP*N?E$(7$%3HXRG^I"_;>Y:W6+J1<\*+ 5,4:TOH-_-[TM_9GNJ8V-&MV
M"NT7?106=60H^P AIW/D9C-"V.F7CI\GR8(NF4:30)K_)@26FRH<67,_]ODN
MI\HKR0*>$YY'!D6>S/ '1=J)7SENN,<WHKQYZZBCS5BIKT_ 8XR%+Z-Y]&3D
M *L4AR$BO0[_U-R[ JQWP'XBJK>#[;^7==@3UXWN/5D?1@)>0[O? :W[HT:]
M1;F_7\GYK@2$TJEVJ#6K8-X!0+K74OZW^+=SE[<*UG> CV7G]=_QL__B'\<4
M2-FR&1ZVN^V^TL/=+2];M@N"VM-RD'FLZ2-W,MCDWJ[/<])6=;31Q8FCUJME
M27D?^%UZ<&1+=EB*(BS[KZSP3V")&]X3K-D"=J;%ES_B+8MS&]/<MI&UMG<&
MQT 0 %NAQZHQS&A+,'I30>+DF@+#'*&!V6.[Z@T_TM/<DPS2OJ+]<![^QA%K
M@18Q#-OB(RSA$C^9ZR&\W>K@M[*0F3>86W%"FG_Z88%OK#B:=\%6JD6EW.6H
M7;NQP:/W#!R(&EXWT "EZN ;=7UZR8=#[60[J6;.J3T8S; UP(+,B3=#JH].
M-;2F]1-P&]LI&*4=-9%ZI"C&Q71/M>:8<]I)@C/X#W[UK:IMC]^;IN?K,,II
MW'U$WKJ0&QTH$GZ#GJD.F:@AD_I6@M?7A.=MNMK=F.RG\(I=[$^:36ZZ\JGT
MZ&JXL?'GV[J>,KFX.&+%M99EZ5C<XMDV)QJU=D=B":[,:8*C)/QAC=/M0Q.+
M^(U<YH7T*F0]Q$H57<_.G4C"[P@?24_!<-;VOZD)"]'+;=4.M4:I^ <(E2YE
M+-G$8T I^35J:A3G#:;X<FD[,)C./D2Q>#FW*L@,@IAR@;P[JZVGI+ME'A\;
M9CL#173Q&D[].$"KW@U.JI5W*1_")^@KI#,_-=P\ZJ53%N3)VAB2V_6Z]]4A
MQ0_"57_F0U++G'_!F]<_1#:PJ?%+XG(3J,B(+LFYC00+%IS0RM!!'2B+L=5E
MJGCKM SD.MC(\&4I'XDW&ACU=)T1Q^21Q[!G*MUC^GHP^_7C1")[U?"?!6'W
MT__0UEAQ.SI[9TN=A$X22%0G+-'4Q TM6)O:H6\&1DLLI9SZWEEBU^I,=5E<
M36E>:$(:/G.8K28?R=DZQQ_K]QS2E;AEDRRD/CGJL!RS@0KR9O6Z63P2^HR@
M<TLQPY70GR;:*7\"Q04'Q;(W\X32#=S2[1=B^@NXV/&VS#Y_"([?%DRQI$O(
M>@XC?FE-/SV;/;G+7\SDL3MR=]7GGRRKZC:.!JY\J(8R"1]188,XZE1*XTM6
M00HJRF3TUYR1XAS?[!*:VJ/*9HBJ8Z.I0<$7KC$-)>[/)(:E=JN#=4V-D QH
MO:WFL8V9%X&0\QJ044< Z?:O5J=G<;2Y)@/5L)W,"'EDTVX#MO,8W@]<FK-/
ME.V"_:@^Z(4UH>/]U,95(7_&&IT_K;8Y!:8P1NO^=NYD+[#>_4X0A".&!F'T
M,\YGB[>,JU%*ZE7I3_]IT76QS%H?S'D]D[)M(X<399;0^EGS=*4&/KCY,RY=
M*)%3N<S) '95_)*$J8Z:N2IE)::F]@=9 A;\>B8<>AW-R%SO!!C&@&3E^'<
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MNI&'4M*_O /Z"7A=?N\$>M[__"TRBL"R^]:0;F@ZNOV?P:C TE?KZH#CP'?
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MR69(%\^74?OXDTY1KTO_//;) D)%@,*FDZDBGH,RC '0R/VW%J:7:^*33I*
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M> OUZ'5EU=829-F'U0-GRZ1AZ]!#&/.<1K:OK_?37F'F/&X$D;)5-T;OZ.Q
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MQ4-9:QI5M@B,ITG.T(JZERK]B>T@"C\#N/9'@RFR(> 3"O$2/''D6XN/84M
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MIC%1O%<6QAJQDQQU=X3K#[ZQ+UD!>'0!ID:R1G694^L!C]=D6]E&4WGO@/Z
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MU9]O)B"^ ;[_M77-M?:%W.R'1XN9KVUM)M?.UK?KA"?"E)_%UQJ@PO>[/6^
MK;\1'Q(0@'TS\:IWDW=6F_9G-<%H.JBHX;;O98RBKSM(A/(5+>%?VJI1?MK<
M3U!X/3G^.O'CGVS^>[+AY \P@130IPW\]N@8<,,1->$C@IH%M8JQL1W.;+5W
MN13U)RAL'\T?6E'81 ><"Y.9%%,?%Q6TR=G,'1_KRC0Z!:RDAS'>V*@4CCVH
M>M;.I?+$E]5K]A#&;OFP[Q"%6N8'W>;4"K&'#5<&(3801C=1XEY4C:QN2])M
M)IU$37E'K#Y*Q?M>[W[/O2-_OMSZNU MO]YV>>7!!_)\315E?*XJ>0/P[U'^
M%]7=/]G\%V#3%'=R>WIG9#:VA]9R[<S;89Y%27Q-IJ)6A_;L<C:5E?U@\\PS
M?-=&.XL^VF(W=9R@: 8VMI]%N-%7T!L0<<(+UO-T:1P@N@B2.DRC?R%SCF\3
M)A\>A4QN#^_+TR:=& =9T$O(;!%Q]GQYM=R2*-CE8F1_8AON1XJ3Z5MV0'5'
MMUKC.]SO$.CFF;P.N/7Q7;YQCCN>/\9(/#9.5G(*%+(HX\T1:\W$UJ^MS3(T
M_,P.=F7;@3/5O8REL0N5>89O]+K/,8(PG*ZFH?A8KU<1?#)K[[?VS36>/"-L
M;^UN;0?[[N8BBE@;YG#(_.<RU?]"+F,8>RU)?0-,H;\!C(BG2&_> *_(3\FO
MRS-YST-EU]ZSW9O1W4>?WP A3<E=_@QV_WNMA/^_(6[DQC= A57W==_715GW
MP1?QO[,+^@O"6CS*7B^/_ZS?G-_OU#T1BF]5[YWGCF1^^L]AGO\WR$:,:#+H
M#=!.(>[%D_VR>38HXI[]!O#BRCY\%OSH Y_K \BC4KCZ\PM6X>^K^@/#]0UP
M^]C]XA:_9$B2S-&L]]D?C2^I/ZE\G*V5^2?R9TU.(V!8"]2#&=6JQ4@STB2S
M^#%ZT/70HB^/ZLGEYOPHP>ZWJ-)LBM^N+O^-(R]G5T7ADJ27(+A3MZPAB-BL
M09$AVB!QKO%ZX+UEI)D'ZX:P._BWQ]T)>YRA:EVZ[@64,YU7F5B?1:4A<8P:
M7E@HC#;1EY)!3[(.C(JWAH'DQLS\T\GY":EFQ  XZS.H XD>(Y)2+A-4#+C'
M2]FW_\B576.G$MA=_,+[Q &I:3QJDZKF>WYIDN0K4C7!Z)6+;P80.WXZ5::N
M@R60OK0!\MI91N-;L#44V3K;MCP]*,<TE]0@F79>-4L0N+B5G[.-!TRA(&\1
MT'Z33[N>XU'_C_=S_Y]0TO</0K\0]@O#:1JH!2ZU=%[H*A0N7XP#?,I]#_Z<
M0\<B97D2NH?ZAD2V_/)F(B1N/&H,RX4RPX0C8?RP'I[10P/[4BXK' K!UH"M
MJS@15UH,>>??\LM:<XYU[P/M@<,1Z[1>0\1_7AH5A^.&1O& XORR+V?JK[2,
M^[-="0(NL0F%7Q=UI]X Q_S=;P"^)K,+7<]KGS> 3\3I[L8^Y0YWD)'PT>5E
MTHWJTU_(.Y>EVFZQ50LYN'R]Q%P=ZAP5[[?\T^8]O;M+>Y1W._]W5?#G>0WU
M&"U.[+[L4+8F^*=\C1QY]#@O&AJ4FQ:'5+T!-)S$3A-"VNNRAI[[Q5TH[O^B
M9.SDJ^--N81_G<EK\4K@*B6"M\F'A/O(H W1?Y\J)3&E]!N@MNY%H?FY10SE
MK,N%\ASKI<-_K>B/K.I862"%&+=8U-\88O*4;'?O&("_'K AOD']['/_4^XA
M-B]-Y4DDP#(0][6M^Y9A]FSI@;7ML>-KA]3=Y;E;PB6Q.$?.C<_#\!/CB^?7
M$^6R]89_:N&_H19\I9QL;U"!,XXP[]4:?"=HC"G(1<NMB*Z!L3^IE0>-#3/(
M*8LSD#\V/LO?8)0H]G%\N$RX2)YY(KVI8;EUD3X;3*O]HW@!':CA6&FI*J_T
MIF,8N ^)K7LW$RNVYJU!3++OTZDR*ERCGW_F9^!TEDVB"WEX>B4NA#; *>L_
MT+&9#@L7)C[BT7EQG6L@NF6< L[J\R,_$='1R>?1(NE_C,'G>C\9*# 5SI7P
ML;H).WM?(8Z89=10Q0V\/Y3M.?\L5R!6<@-SI%N*JUJVNM[9UE$_,1<H]T'5
M$7BPL\.\K>77#C:RTO%6#NHD!^+9I.KFKMTY3A1N:IX8W3:)7-!]D=6WGS?D
M3 E#OL]S1 0]O%- VD\ (,AHXT[]NV&FK/]/QF^2^V]F_7^N@?__:.%)9:6(
M66]04>PO\J%P"T^\=GUYO*:M,*9\8!3I$M\F/TJ5TW*Z'9:B0 /:WB,0/AKV
MEM%>OD9SO7XJ.';Z#1\]O!80TD^6=^U.1?GJRXOW17+0[0'(9=.2ARD^O]Z;
M[2#XHN>;_2 TZ?X2Y8DTZ7J_2W8KEGLRF7DR.N%>]L'OI1]YA?Y6&.E:E_V@
MRK[AM$E["4.;30:W_AJ0(#*[7&:??&=0QX;FN]NO@?_C/L6%[XNX$!?E6(:Q
MAR#I?_S%()D%LU-%8"(Z$X 8VJBH).#EV&SS)*^>?=GGQ)/WBJS!%5LU$SAF
MEL?GM(LAM!KWI^D/=2#GVC%O0I&?\9C.QD9U"W^[@&'4+2_CF9[#G.LAQN!.
ME;S-56J."8:>1.8<SR+DR4:.?,;%T/CD4MR2BW(D4V:K2>#17$7B]%[XJFR$
MV% OM81=T6"NI,9^-!5\R**14OUW &7_'9JR#P4GW?^/87<JA"YI/VD?M*%@
MZ054H#._DC]3$FYO8)L<5^+AHH^B ZKX20#^]?D"H)  B'R#&X8YF\K5!_W/
MLL!JTP(R8<G-59,44.JP=<W0S$WMT)E/_LFR4)5ZB)B2Q/?X-TTWW\**YV A
M[TF>*_J/XM:4 OW^$Y*)U 7=[_IUG8TYM-P=O"QZ/UFDB]\E[=:1Q3=4F*(F
MXN' B"2E[Z4R?;.SC*=G_#8CE,]X#=L/^S5Y,Z<M9R<MD.+1GJ^KSH.00.E+
M,; B#]><DL*B+Y_0GO8:;BR#O((CBH6MR%%@QTAO1XVAA#B.6[A6WRWL-" &
MHQ?4QL--3, **JVAI1FC0X.0#<>J*:/]3@4$LVG(JOIQXBO0)GK+'M-\[V$:
MW:* <QT%"IY:.8MS(:[)*@KBOO^'E=)$(T2Y %G_>;ZE20E^96$UO"8B;%&Z
M8'!G)'O7@<9<2\#.@/IC!I?MV)*&>7\RM5X?FU"S8IGL6:^9<9BP;C464DB.
M;\TG28]8;#RD,TF@M,3'Q_;"!+L44@KY'>-C<EH3;_?&PNL>$;=^S"^,?W[E
M?9E<=Y[X_!,&V[Y<#];@Y'"K7@T?V*(#\XMA4%&6+%I:,MB-'H/^G9)O[U(:
MAM3TANR7TC4-]]TQ=FVP;/_<V4)N3ML,KP[+2KCB'14($Q/OMV(%FP;SE:6G
MCN:>Q&A1<70=*6L10'OZ.RO<&<NO1,E')#IKEW1NZ+^6+)$R2[S,B\299_@;
M!3RF&#C;5WAZ+6HS')PP? QX'Y0_5?/Q6>]$.9M13W^F^X,G)0W$2M=<\M)$
M<K. M" K\*M^W'$H3M=),+VU,=#08Z6-Q)F6A!O78/XLW4C(2A9+&&K.AM-O
MR85,RQW&9H%1*I'_32]?M$>2"D>.+%%,'?@J-7;YK[4>?N"R$$0;1KO,UJ3"
M8*,^BEW**/[9'D$5-B-AV]Z<)6;))IXBXSU]&=XL<5+$YSZ'4:QJ:F-<\$IG
M[L:OBHI%XQ5#EL_:BUH-7CTR5#R1#G)L85J)J%X7R&1Y7/_BAKI==A91@KMM
M<GJ+R6?DXQ*'CX+C%Z@ 4CWU5,6?#02*Q^5QJA@^,$RRL*G?7D4.&&*9!(\Y
M;?I]Q8OGTNO:QM*??W?L)D%U&E1\[5=#[%M,W<ENH=(7JF@Q>]-C:)6-LB<!
MT6WAE$QC(-"<$'=;/8*^O)5I8#\G'5;01TSBM .R]G^+*S097>J77V0[)D8K
M8IY#*.L_R$Y$RG)@P$1#=>BR9&P619L+L#=RD--&& C,FJ'#-3^N=*FK.6RV
MGE^+O8R+W"^^9#B01U0IGWSLB["L=?+R@;76V[.*'-GAE*.6U]F9PA%[ Z#V
MJV)5F%&ZW8/(W-:S[[WBY1CC$6FO]^K^+U]+#:,Q2? NR*.E0!4<68FE:EC[
MAB@$1K-<!2^E:M[W]0QF*V89!.TS"ASL2LV1YJ:OZ*P=>1'PM9/$DK#B;S8W
M7J'V\=JD0W53 $VZ&73AEG>6LA3Z(1.V[/V_]:/HHX80/KOW/!*K=NKYSZ>$
M:QX@30P5K2RWPCM_S4PMK:_3H2<7G,J<*RY#N8G;%1SMA ^UX@#O9C]VL=JP
M&&1J-#UY'Q7-T+LHB+*^VVP46C4 ^L6?Q5K>209B?U8&N)G,<TB/F7>[NE-R
MZ]C1 SOB Y+=JP.U![\#+WY<L@X'GA+3?5GS]2Z"K1DBNZ#\1H26?CWKKOD?
MEX>9PN[I4(A5N-3/26W@M;YJ?(!;JGG7CVK&-\!2'WO9&Z!,G.&%"5KMU$ES
M6[/*9B UEV50L>;+:FADK_P73HH75N@@/=P#.C"I>):;+]E(VK#KR/RJ.7SN
M"4'PM5\7SH8>?8>G!$26__W((^-E;,8H4K"SN=7F*<UB@:!S9-' :0EFLN-T
M9.IC[2;?V1H($>=0%TJ[<+/NXD_-$,&K[34MA/(Q>_@1+@K75%Z35NDI3=K%
MS[Y;]=Q/L]K^M-).*/.NJY]<J33.$ER[;*?S,6FYADGO+O-AUCS9H((LM\&D
M7]\\JC07V6S>N,ZN>K%5H< 7(D<#MDM I=/$'M&A<)4/X$?9 ZQA&8+U#=H@
M"[<Y/ST_N,?=RJG*0M)\6!8V[9UK.YU-G?!K!C:GC[%VWB6):7\:T,'^O:J'
MKO=EV)!(7;)K7N^ 7;-?($$I69BCY'AO^LR/HEOW;+6B#66=FB"A@M<]O;I;
M&?Q(XA'E+.FF>'T,-4RUF9] VT "50QP T70M*N)M[KF\O%=BJY%[19_R@03
MP0'#X)!!L%$P9$D;NE.I'4+KJZB8=J&W6Y.MV3BXB'SL(2]+/QA9KG4,@IU"
ME/TNK,$>]FQP>SK5\4X2_@RT47FGUGNP\_R1Q[?Z='VI*M\KGL2Z%53G$IUP
M^N-,7 V-9C5TP401%BKRW<AC8)S,F9K*(G6QOS%_JW%I3>NK$TTNV90.9 W?
M ">?]SU[_K"2[-:#$J&+6XH[]ZC((X+95U<6=V4%[Z%6."%?[]/=*P^1TEM"
M!Z5CUG?-,;6U?4M+?$R!);B+*2H1SDG-,2.%1/UP#7%<>:9KZ9;?%HM';A]"
M$_%<W F+-N*R:FP]#.K4"M8]0H5/5N66?X/ K73'S&UI?4"@/;51* 6]=W!W
M"U.3#$OE@PMVKAZCA8<Z\)AO*M@UWR=4 X8&U<$P\<#<PI0(&_IC#\?W,+@U
M\4.WJ4/@0+NGVZK%?$OZOE^X81/)ZQ*C_C(K<@5Y+72I;0NDTHN^7AX(^4)<
MP4TUKN :KQ-=?V/^93VQI5C:[0/A>]6;_=RHHOEFB%,E+[D-II)CA3*XRG&M
MSD;K6;YFH;XM>DRQEX@Q>!ZR$EK5NRT,E+B6R6+V4XS_W>U)T(H;F0'+K4AC
MZ7F9WI:[;RHI=4YV4 ![KNJZ?=-4$Z2&RM-&TU?W/N+6]+2G""*T<((SA=$$
MYL\F-QAY":P_=+(X EFA.2X)NK+2'6-(I'!+_^!&%>>&_31URN:!*-UMY*E:
ME%E4[N (OKW'L?MP=Y?"6'[7_)3A=6IB4Y.@JE>B#UFL3W FW9$&X<B$:4C!
M?TDS"U"O:G0W*DS:QEV4+]9%YNVE."KF^<!!G!)JN9M TQ]_D*+S[-IRLY;
MJG*QHK/H%<=8:4C>TYSC@M/US9DJ@%Q<MDFGJF!<CIGO&_6"_?@U8MG(.\>4
ML-$L\PS!-X#$TEQ?TW2;T\H3^>\3YCB9U[KYZK2[!-.E=_H?_$F\:E3A9$CU
MTB75C3OLS#L4L5D*W[NF<2@U_?+F9T@>C,_NH)/T#PAE&HZ6I";\F>#*,J[
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M 5S]Z:O[2CR+$0)L.^U\E 5H.0GQ^H,O@AOQ1'0*8:/I04.)%3R'^"RRCLM
MS]?DVS91[=K4FM+Y'+>5H]RT5=6!(J$Q_D43R&QS\+:^9?WL^#Y4I)\;/E[
M+)I79J02Z*LQ._4^9M5K3@GJ=4&3W""Q'8FZDH^ NG^@Q$67+N<(:LRY2GP4
M .BZT,"]$]4_2Y*'D]>RS(H E+CK.J0G8+&2M^N%3XX$H8=F<V'0TZ2B9^PE
M'0*E[[&BUBGX+*83BB$$MLHBMZ<WO!I*Y/W!>^&3B[8[3'JSZ8OJ]+;%V91$
M>K8[6](6\+OM.SFU%3HRVAY=$LQK<&Q<(7K>\3M26-W)JR/WUZD4V6ND/-Z[
M8+#Q3PMM>T"G]IJ7<RND,KCS*U-Z._G.=[6JI7C2%DP$F\I6HT7K>$-<D^K(
M<C"@68_Z4'^/@J;0<5'6P=O/R#AB*ZRK5#AP[L6HN&*>5!A\QXPW7^[HO%:%
MX.>V5/%E>;D'05P?S#=+QTXW/6<PC90YMVR:ZT#Q Q1 1)!]KL.TPB$U0D++
M(Z"K,IR1!\87,,7[Z3YENZA(F(+[U8O%)GFB4Y9'Y^1!=&/.**N1XCY8!;PQ
MZD"Z:&P&3\IN[D9KJF&V9C_@>$!7"<_,!4G.Q7V'C9\U22_"-9EE<;1;YF<G
M2I<SOAI8G8/0=JP(?@.\6R^KBW&H.]%G4PQQH30,//X<7HVZ20-.7["CBYE_
ME&2*H1B=K^OI H1CUX>O?H@A'38#UJOYG(+@"KSH8/$N$-D/9/W 5'$G!:5[
MA,VI^43+GG'VCZPP(RK*BYD_<I;8S=RB4E+^/'H!\:+)FI)R00S2(RW(GK\P
M!"#GR7XD*?=); ;/[>#P8F$B3Z^[&'S[(]IEI\("T?JDCS$D6M&O/:R-A97T
MEDV6"-I1GQ'6DFDD]%?X033TZ==X##(J"G1I7(-Z;@ILV@$C(M81)QM+IY!W
MSY"S#!'9)/.P)8PJD[O9Q>AYEE&:,N,5/&:2_8R8!>YJA*WDI<POR;I#EK!,
M\AYV[[;[,$RUQT,_)INAWZ"WRAU7W9QKN+#*!37G",ZOG'+_!OL5WT%/O)B;
M+/^P@ J [,YG#(L(#6@:;1+G(KCJ<=OQ"I[U:SG5.L&9_ 3V2A\B&]H*E2G#
MID+U@S/A=BAF)-A@ZQ-#)*9\F;TH-E;7N0N<1$?J [?U:U,[%YDM+6$E"EUS
MB)?0F\D/2A1C%2ZO\AE$B+ !:$1D6$_#>EPPO;%_Y,?9?[RF>68:O3>$>@J)
M>F^MI-@=I4BWH/VNSRKCO0Z7MDW52NP BF98YXZWE"5!Y4_.?JV7IOH>#?%>
M/=30+HF MB.<*N:N)*GB 2BPY3(P$E1HU2TRP[+-5S6&=^KE,Y2X4E>*1F?6
M6=]&R:CIM)4:H+D9%"SX*6;'+#$XBN;-X!)!WTU,O,>3*?Z5-AXG42S-^5_#
M38ZB7+]+8)*B^YN,CB-JX_?@5CK/PI9@_>5$*-Y9I$H2["@8 AN.C67A-CX:
ML/F\&B.FJO(1O)PY3WI7/6OIE-1ASY 64[$RS)M;YK@ADYR5^5?VB:LV.\2$
MHD-LA'TE[(JI,>HQ16NEL5HE?&7ZT$J4!UE]%L[\O OYE.8S,UIUS#=MJ_6J
MRIFRA!%MW$U<(<85S26,JG-U=3Q#9$ =8->D[;&\"/+^$N/=@F7XQ+&R0BJ>
M_1V^@?,GI6VZ2)(/40,1=L(*,-^E2Q[W=7B@D3E-/U?#T\QF9_='Y[VQGBF[
ML)Y*?<3:R2W%%6K4G1"=\=MZB%:=_7O,"-:^68>0LYK"H@..J-P3@X#R[ %S
M!.,T3F(1,QLU[7&X+HI.-D6+)T_7T+TJ@Y>:,'FFY59<NT(""G+Z2.APV_(A
ML#,&._-^I\$:&0V1=#/WP[=DU.IV[$_5BJ<DLM"C4!5_*97._.%*8JU[:FVS
MX=31,Z/2SN5&/U+'3X2%:(1K^0Y"@CD1DF('=5"&BBPR# :.X/:A#&4[TLE/
MCXQ<.(F&M)M1# *9,1Z[FJ4_G>QQ/&241%D)U8YGG M"T.EC#.\6H [HK<JG
MN_[D>:$>W!).%'EZ"]V!#](Q-+SW<2>7@\RD$_>&UAT##@0Y&C]2^2^J>_U]
M+Z#OH 3([/U./?!L@6%1 0='5F\ 3T?EDDU/QXF4B7Z,'V?*NSI:O2SU2;ZP
M&-W5-]#?B<&C\79'11*]IBE_1*@_[D_16'L\(^->V:@ (R@2P6WLUF73FULU
MANH-S4?1I/Y-,<8?JI>:P.M#(JGX^;JI?<WJ=^,,\H4A A 9?=HX) >K!K;5
M]R0NV.;M=$R=.9V5#;U:[]$DU)#W?>C3T]@4!-NR^(MH HA33TH[%U?A;!'K
M\- _135.JM;IZEM69GHDWNI1:[;@C:[Q<,B$?0?"S94J<@]O-\CO'R#VC*L0
MZKI: (6\^87)O4H=N%1];SUWFVR;J4,UHF>,%H;LY>%&3HY%EV;>I>K&@$N2
MN\VX<="B\#3&*\>(0-'E9_?Q6\ 4]%]G+*'U $HJ@>DW #WI=+_G**3R %+Q
M5/D&*&['_GDD[ <ZC62TI_5R[9MN61X"6TXG(F!::$V2-TDI%418.NKV('@F
M[N5RJ)#U[;=/*?4<G/@)>RP/M2ZZ^#G(-<QL7M#5>1DI^YV6UK;;[@/M2%W)
MVBIF+;A "_TGL_W4T=(U&-W*T'D@+G:X'KLJV>7].TE6;!X?>@E8''H3=)]]
MW6^^8M.IJ_?>9BC>OQ8UCN[(-;7+ZLI_M\.S;+E_UJ_Q*F#</_WI-W^)4]#0
M5!4<+]7O(S873,\.?\MH*4SAR*.@I/(!(S>B=.<F$%%OLZ:UU<,S.T>0C^59
MJ/E$69]WI%D_:57;WH>R2_6=-+MX9"6)()5(>"?40)BAA/1CTE-B,WFAMZ>%
M8&0%K)4.Q>?OO9<C>Q]2[45=NHQ*0'.!F*M-4W:Q&.S+* LARRMSHK!+$=6[
MFU!?C!_ZSGQ5H>N)9_:6N3EPIW$!N+>K:-3E&J$I=$X8)0^=H#RY'(9.FSE1
MXL\N(GI"YHOJ]BW)4#M0!<M-OY&J#JA2_62H5IHV1:/)C%T;J"%B:_ZMSJ%/
M.:Y)$;QP(>"@9*R7RK@_MVQ??71@L>1+05,A!W>EX.Q+FB"YF673T([9ZO'R
MT3FA5A_",63Q23=H60OEL_5G?CP#"6%??_I!-F%MJ^V5X^46 ?#OPJI)Z7I5
M1V9#PI74:2$F)C*5H3*/%YZ:H['V='Y2_I,:"Q>VI[AA.WIVA\T&19)F8\74
M5*/,$EVPN0,U1-I12G=N) XZPB_,LY(*_<+KZE<<@G!)RV%L@OZY_=MQOW2]
M-NHI5O7+JYEL%:2;R?IV8_3*I5NJ%J+\)7Y?X11?R1+MQT+UO9V68;>A@ZZJ
M/59%,JYON>P'77KK<A4WI)'$]#PVEW+J,3I"\HQ0SW9QV2>,O->1D7IP\PI%
ME$KRSZI,4&4*S@M&.5AB@'S8NL!SJQ5?:3J*7H&$-T5>1A]/UHW,4)C@*X*/
M$IYQAS-=P?0>UX@ZW5X!#I6ES<>/25-DL%O7H* _IV\ FY(;[W9X7/]J;?Y%
M?>$2[9.;N+BZXVL8'M\"O1:"*+3&:4G"YJ5B=2@0TIZT!%^*(B0S?![V.1$G
M5(EJ?-K?.>>H*\6XZT@^OFM]XH/V#?MDM9'UX(F>4U!O2VNY#59GI+V.TJW&
M0JP"GKMN+/<DSNAD$K=R] 3$QB3@(3)9JPN,UD!M@L.?^F./59AHJ7J].-QE
M9%^>,<GG],NSS#F+R>=!'0[>AM;%-NKNW:3VS$(<%N+(R+65I$6ZGJ+>ML@@
MZ4U\N2@,D;%,:BG#&10Q(+,%3.D1'ZZ][O1[325GT+$GY!BQC(0%RY$FW,N]
M<!W0:.+'PS+TR\8K/BJIMYAUV]OG<CC#^L][;0WY_N[OT.^TLHJ7N]*^V%&(
MC&L [B^"[(=#=M 9__8E8*<N5S.2@Z4C:V[)Z<88I/2*M:2\% -HHW]2M9Y;
M9;[6]JPZTI0L8CI5$5_'827+_$S:^T5ZO5!@MNBC=2O-Z@OBK-JM(TEY2X2A
MG/MT9FWI\4/K*A)K_ZKR8%?)Z(IHZC&+C#$2W)@E_6*-MO5%?OG,8NI0#8MH
M6-&G<?-+RW HV)'DDH?R'3$YB<\6-P'[+V,UX;NKJ3Z$4^'%^<Y5$RA&S>!
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MB9^B]FN-HXQ@WBJBTZ&M:-<)>EN*\:NVCH(2F53KO?<,"HKYV&5[^5")HC!
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ME>*/W45VHIC%:2LW7OK5SH_B;N*#7"=4E0C=IO;29<C=TW$ ZE,[N 6O%*H
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MI;9>6FTX=D5/HHE\E$*=7B*0ER>D&'+MK1804;>;^IGZDL*3W N'J=OU=SD
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MDHOOHK*/E.R]U+:L@#O6B'8D2!_[=&P(DS;(>9I$'UTNRE#3L*&?%,R9,,Q
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M>_M"DF<B:86K'&9-<6XS,5:5'9XY0IBF*9[)WQ)$T[ Q9<:(5$.CIFI7KU!
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M*,?T9@?6(D$GR+Q)P%5A/7F#O2HLL<-*H,-\'/,/-9U9;( Z/K;Q* Q6Z >
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MN!EGB^-$:G0B6H- $UP_#!(Y!C_T)4+^P_6(YM$Z6Q4^M6!$]-2O%K';=W_
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M OQN_K@^^CY=&KQ@%5R /'QG;*>8_\NIY?^S(B-L<<O9^L?/[?'GM-]V^5_
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M@"RKY98.TK,7(D[4B2#X>5OOJ0?#Y<FU&TB*].O*%%. NY<,F%$]^GH@)S'
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M6@JJ6M8-TW2RG5N/3W^"$8/_^"Z%M%5^CN"). =MW<X.U.ESG5TTBWK.FN&
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M$>IEYO:1"@AP,VJ/6X9UB7>JO)6@.NY029LWV999HI 8J>S3V AU7L?VZ;5
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MRQ(1%;F?VTB1]!J/ W .B#_4+U48WPJUR.K5NE?.YD8YB;@'2"2-V:IG,4^
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MU^_:-.&C\=Y^FN\O6Y5Z)QI?JI9:O9QK@WH:B<\+G!1Q]M"JHGL\+<I*B_P
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M)E28  RW:*^9S+AN*?J3D;P?5,?30(&=FL0JFU77*DQ0-:C9V3UBL_AKR8R
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M.>.$U.^-@ID>Q*L15)XHRT\;JE6.=U@9+>FH*U690=W16P]0[JVB2V4?K]E
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M)JKL17OC1586#XAEB\,>J@&PI?OX[X@1RHY9^5\(/W#FL'5&FLK(8)YI'1J
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MT9G=#KV-C1916WSQ3;NT1FF":B%7L;#-7V,<@#BH$%<)N!BQU7C'AA8?."6
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M>PKVGD'NY!X%+W1<=]-RDFQD0;NAIZ%DI73F)-,Y>&2'NE8!Y6=_%#AUX*A
MI4EIW5>I2:/L79=VJFS"@T-M2W$=FV2DR:=4"L%C9A@-!%&3(6RD8,BY"JP8
MD#8)<A4HQU+F)K+K4 _ @S)L61AEVIFKUX9*ZL]:):T<PFF5C61V=$>-6$+2
M(&9%E,9]GCE"RJ1-K=,"G?V%NML98X=E:?8V*;5:LJ+L)84BFEBL2(UN*O,T
M:3254G'M@B.:-'=6P8OI4+$Z5ZT:4B[")K$]8]ET39=8-OU^&LE8YNNYI28
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M4\MX;+V]C!XCCI*77K"G:TF[]M<^)1;+020M]VAZ]@B[+5M?,3HL&E;/ AA
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M/%UUP6^;&,OR(EVZIM#+YVJ,P>8-B]3)O]T5\;6F9$G$>?PH<&H;&*/>6R!
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M?.P:S,V2'NS+VS ^O(>N:5%C"@ @%6A$">]8B]Q6W61V(#Q2@![!8%QK$<7
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M/L%)D7O+E+C2!Y3NMUE['5-F;:M=XEP*IKP33_>+E4&M#*C5@]NFO5R3#D1
M(: .+3Y+*?:9&$F0>>PC:T!X/XXAEU&QU\I$5C@RSO+ZN>9&EE>("0$%W9D4
M'E5;A,FMTOO&:[S45DDZMZ>WU4/9HADK48JGKY[*\=:M#:<UV1E@BCCE=E_&
M.@,QSP#IILD#<:W<ANL:R(L(SRDEY[&R+,.G4V&>:Z]6D);!C=:05B3$$E2'
MY-AA/3J8A_(G+<.6O+[SJ8R)..3;5WAEA:U(T;=/0:\1%9F0WHI(6+E67M
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MQ1XS")AQ_<^^^1>F0-V[?H,U4Y2S((SJVF#^Y]#2H78RP[:^D354LNF$V&3
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M/M(C\ #O!@ 1^@D $0   &<S-S0V,C1G-#=J-34N:G!G[+IW6!3-UNC;Y&Q
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MP)F[8@['JLW&0!"0#62H?PF %1 *Q ,@  QD3B&&F7_7_JL9SU10^I^(C&/
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MT^[&[*O=2FT(W5WE3*GU I61R&_6.93PR7)+3K$C9;7N6\4W0N-O"OFFY9=
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MTN/,5A 4ABUL(#&7MYZ=3')!/F#'D&X6H-GIY,X8'9M,*5P4R/Y..69[C.M
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M?2]SOCZS=2T*H+-ITI5^5)^RO$ES5]ZHN[C"6['>?&,13!YNFN64+.^36D<
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M^U>!OVY7-3\K\=HRK2DQ/6/CM@9ZC*&WWK(PY$G7I'JDUV![K6F^<VX[3^8
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M9M%,R@V%O'0"-8)64'Z>:@1/KV+1QF1=!#ZEP5:E@;IIAQ8::V[2GHV[1%Q
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M7B!V_J62/Y%/HL<CN11-#,O/C;(5N\GI-D4/*S;;2='%/MAD2-F-?;\LB3*
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M8=[\?1QQ 82DI/Z0&.+65 ]/ O%T>KO]7E)ZQI11-'EAEFQ=#OD'T%*=3ST
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M+];V&E7&R!;;/1:_$<SLKN ELB]4A_9K'@!+7+NZ>^TH9UN1[58%NQOB&X&
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MJ ]#8\FKJ34.:A1G*N3-.6RB=.$T#/M8-'.T!H<57&Y/PV_@KY:_P)_FD@A
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M?KN8R>9;G>"W<;KX"QN.03',\Y8*:$S5ZIJYX,'<U88!4)?Z4!L/"B).*&^
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MIO>(I:<R ]J+)%.3,IMFBX+#VVOU HGO-L-7W@NWFVI7+,T^0EJ&7%[KRK_
MQ>$Y Y^T7D4SN]^IUV2&M.U3'$K*:,R6A8=;S"_$MWTW&[8+,;>GJCI^J'VY
MY!DV=VT!OPQ9@*\<T%7?+%K4333X9\:W.6G=DK8WG%3^#&\TI\IN^^;H+XFO
MNKU3V0F>V+,E*&_16BE_.6*Z4%^YN.C[WN=5KTO]VX;QW>4$S4MB5F4--$R>
MB[M0L85RB[AHZVK:03(8MH)QCV;G>AK(8 :<.U V1#B^IZSB,/%Q:TY5-WF2
M^@!>3'$%FXA5U.+R/'(Q;3 ]FLIAS TETR\R3:YY+#J0=^9;22O V354=AF
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MWD4'2ZVKN:5KMI_5'RF7)CEK[E0M"-4H1_%GO2#905*GTWBQEGIWS0U!%;,
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M#A5Y,6!LCW@->Z3DF#2>6T<KD+T6S"C<JC@@.I*D4>V5=@5OT/RCV.AF#[4
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M65U\3_19;(%X*+HM8('<';6XYJJY:)5U6?EO,QO35&>;.F7K*'IC$[.4?M'
M+]O.JM*G9]GSW'3NL9-$'MK1 689A-]WK5(]Q5;4?2MK;%Z)7JS\WO2O;#PY
MJ\&7<9"VR>I:%L@D6^PS5W"+3;-BC@DAPZ0 F?2-]I,K6P7AA^L0$MC=AI95
M?.L,E3;6E+4I&!G4\\UZTEE&<T-/)IVSJ&Y]C%GPTK0W(%.*ZS>[2E2NQ#KS
M,,GF8A3.DMXN$XN?R-VK<NEG%?44Q](4U:C:X>G]ZI7LZ5& 1LZG^%Z!=)()
M3AAR49EJW";,K?X'"A9=H_B*'DEX] S:)]E8)K6D77Z*8TYW5&[A7XER59\0
M%_CN!UWD#DY;X$WJ$@/$"V)H-&\%8UD/A+>%M[FQM&'BW?R.XNO2W<)?:3WR
MUQ(\\JHJ0^[ANP9XJ9KH]!C:JHG3A["I@@? 6BXDL@I6\XT25VJ0<)YT=[&7
M^(Z\/,U9EJ\<&]FM>*>ZY=NKO@1<=QX'WH0&:7\Q/BG]U;WL!)4S?Q474?VA
M^/(/JX\5B4110%>J1?)6 T:&RT^" E^MZBD$. > L^$NXCO].<)4K696([V\
MD^S]R!8RG1>*K"\\(+B&K$Z=)=Z";(GX+#N.G/ 5J68BCYQS-1 Z@'"GA1C8
MRA>UQ_5O>--9V?JPFOV<A[J:PD#^&JTA9;UH"[$QXJCT%?[4EZGDX9.<6< 7
M+!374RXU>"KSZ5KK#R[!M*E3U$2P3YD/%FSA;35-3$D1/C$P(O32.-TNWPK%
M3>U 9PU@QF/Q">0C[3V*6S1SZT[N*$9 ,[/Z*.M-PY6""NXK:T;*4&&(>7]$
MCF2M,<PW7"'4+7"V ('$-/@\ !;/EPW1#"R#6#V:M57YE0V@E.*<9P<EUHY/
M7 I[L3U"UR%!?(U7*2J7!#F0L"?*&JA?F5$U5SI1Y4D^PMRCGD)[6G$+&,,<
MD]NAF<))3<P$X_C+0K6011SA144FR&T=>M%=:A)8)RNH;1"_EZ.LH8SSBGZ.
MLF*X\@+O:<Y;]30A/^$RH)5,#$T%)\AN>]&@2\IG#D^0+1HOC4C<RV>*KDI'
M"@-K=\EJ11_+4^0').MSLI5I,C"!HWJGJ G]%]BMJO:B@[L!LZ,]? &\ E0*
ML^3!PO.B^XHB^FD)1TDNXTD_JZJSS\J7JID)$Y16@ AYH6[6K//B:8Z!/QP+
MX7%PJ5K,+P/?",<+IT(LNJ-H'[2=M%<BA3YD!\JR8?_X58IR& M9IVJ$;WE1
M@.](@B,(<9"EJG7<+5J9H)S?HDVF@<)RXAK)0^Q%9&:MD;KC>^-SY95X7(A5
MN1X[ZD4%TK LQWG@/?2$:@:';MG$/\4K-]^C?A*$F#:5KA?--E9D)4I"#8/C
MWLKJ=>M#2,HA6HX75;V)F.*X'91@^Y3+V)7-J_ED+J,IDFK@YS=DEV8)DZUV
MF1_$(O.GN)W2V\:+(5X*N7Z+5Z8Z5=OF> :<CINE)_&ZXF[V'5Q<QJSAX9JJ
MH"(>WD 9DSX37U@[)/H<OH?M%S@%?\=O<A]%Y$J*[&C$1:54LAMIKIK%'HT<
M)Z=4KT&'TH2%U]!$1E_:>E3+_AS=BM[@RP)'8NEB6_<@[(%\IMUA?*ZZ3'P<
MW$UO9/T+13&G5#V!5K+G%KK"TWE>:3YPH^!\=#SB()X7\ HY*6MTST,7*/?8
MS\2LFFFB"X W]S5S.G";?ZGRHP82;BF0@S/%\U+G@2>D[5$/H [YBH!#L$9Y
MTYV,Z($(^UIT(;A:^%3Y7AK&B%>=DA&5'NI6^=[\#4"%XG.JGR90%1[5#H:J
M6P.60'F:@>X2N!XTV?<BE^'IPDF*48"T%E*.U=A7:)1?-&OS752W0:^47>H;
MX-HHMF8 E!G0#:9!']RUT%:XS_X:XH64"A@R%0;3W\H78&T5@Q2+,$G>%N5<
MS#>E2+4=_10U"QB,G@S0:UCH&O=&:!!J=1@"ST=9_)O2 &,&72B3&HZ5F^1F
M_;N\'$6'[F7R=^5)[;O(,^H0[>" 2F SX>#>!?+P, =7V!O+YDLD?O7GZ2.E
M.NO><E?9RCJ_W*_RPV9:\G;E"./"R*4J@_Y50"+@K$MV;]'\('H<$J%S^'"V
MG?EA<25YM-FQ;%:)U015/LOJ,IXEGTJH-8ZC7P]+-V2S[7R.Z=OY/2XC='\D
M0INENB8EP?(QVE7R:XH,RVNZBI\9/*CGLF;K>Q@V"5/T ]GU8>XZ(=_7YX;V
MA>B72[;6+)]L:ZO-5I.8-3H>C5N-Z (9@XOCM?=9BS,M6HA;&K].^Z_ )?0#
ML5ELYW.=8,NB73 B5MEFJR<"-$,83?A;3F'5&OPACU0DPW<)R!E?<9U(&1^#
MYTH6AZ['W65O?4[B_RK+7);@L]0O;>_@T:"Q]@AZ1.Q5^0Y](%E0N!^]*QN3
M48H>EP-Q=]#=R@&ATK_OTCR?'>AC(,?E$&8'3K?SP'C0O=J)\"?E^\IL)%AU
MN3 0R54O3K^&D !&G ;A:$)#"Y!6T-9G"W(3FNQR#TV&I]BQT9W(&+H"HL-0
MQ0[H!'R^8#T\$/Z1SH?MD0EQ3G >XA?J!G<B-3YGX8_(?-<AB FY:3<7]43'
MTGZ ;MH[%1QPHW9-@1C\H?5(CX%F$9JXX5 Q?B]T*+0'K_#9"$=CSUVGPF\P
MKMT19!/ZB-:M\;#\4S%.<]R<6S ;=#3-2/L&YAM6QMX V_3%(6^AL;HI/NN@
M?N*YJQ.LPK?8/45*L=;J!RW&HFLE\YHGDUIR1C8NKV3\UW^7R)2H(5:87A\X
MR7*4]=WCA'D*O],QVXA(=+-=#+.4C=7#&W]4$,5?&@Y7;\E6UBNH@Y/668?6
MBB*/6M3L$8$C3<]Y5ST^&^FB\X[+];_EHV>OT9U0%U>1ZIG4R<7)5CK]0-:+
MNF@FD11A?L.A1D(F*Y\>\-;H(VKS'*^_)GWB^$FW1,FS<='V >\KUUE^L)J+
M>BQVG*U9B68;WHO$H\8?PI!(3\-1\<* D_H>F8_G;!V@N.SDI]6H%]M8B:5@
M;>48TW7AX*)!)A?1HLPMQF1)<F*F(5[Z+N*%/EB^.V"%+DRYQ--)FZ)>X$0A
ME)JU-@_PL]#J"KEQE)Q2J#' "C S5;]=:4QXHSNK:HOHU]Y5;PZ83_P!/GOZ
M$Z%@G),)[X :;3WQF?#)\O=Z@\9:.$9O"[IFO-))P<Z$9=H>\'>$@#@ *0-T
M^&]XN&<JG@TO<5J+746B;)F8#ME3;M"E8**"/NTO#,MHT+*PHH1*8A'V;T00
M?@M]%)"'AZ+'/6.Q%O2@TPTL %UKVX&-1LWE@=HT0UH!IG75O\A0$_WZ$0DU
M^!GMQP@J]D,[-F !5DYD>X+H';S/Z1>Z'GMNNPM=B?D6W9RC+W+,MG27EUY)
M_M%I5[$FQK9M=<W>$)?FW_0I/N3&8-8ZUV0KGP_:O3&?E)AGGC?"RNZB(=U1
MY9RLVYV%54N2B]L]*".C>UNVT><%/VL:QV+Y4.JK>#Q7G663J,V>8HJ5?9G%
M-]BI"PJACCWDUJRLMI^T\J1K+;\8T='A34O8!<$K&^QY5I_RNB[A#]<M9ENI
MSGZ_X:8R<M9[W1O@7N'PM@+&XLQC+6M8+Y-RFLYR\Z-N-BSE7P^66/-$%I\<
M\W=IC>L-XP9%AL-X?;^Z>#9=^PQ,*3"UN//Z,G.:-@ADB4\:7HL*HPCK;4ER
M<(YE@XSNDVZR*!:Y?C$H52\<\G3=FI39A[0C(:Q@3%.19''&_<91TJ^)[?4T
M>494=AU;T1_L:RY2V?J4&M/5N]RFZ2D:NH-.NQ$:8S.%R(.;\Q<V'%?),XSU
M*]7YB476F<#XJ%F6(.!,\"A3B&:Y3YXA!5SH%JF30OT.FXCW\ (;$KX%4>=G
MU!O@Z1GQ5BL,)-K6_0LOC/QE#H:W!WTS)L,??<+T<B39+4R['5GN<(O(0_[8
MU.,1:'C^!"M"]&2,J5M 0 D?+='$@,A')B[.#?IE0+"?/OFZG=@RMR+M3(SM
M\ L_A]G9;,.NH)<6!9?TY"YO>5CN7N2H2ZC:0^I4S*:HJD8Q#+4LBJ'D,+N;
MX9C*$(SD? Y32JZ+O#V.*'\HABQPRS]>-K\YN_AZE1]QK^PE>;OL9?4T>F(M
M1 69%XN?,QVYNI3=O#%"9M@,,4FZQ..,XKF*-R\[6TRS-+;D?V.XX?P2)>N
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MA_I]=!N^!I@?6H)7:TC^WMAS,, S&;- =BXSL !XBKT6FPY_FWT=\T(VIO]
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M-]"H:4YQ*AQ%[;(&9)>DGM!354?LX[H<3"MID&8A#U,LE)%?&S"M6P-TN_R
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M^+*[T6GYMQ*R,Z^GY:=>R2E*NEQ8DG"QK"SN J)\WWD,+/H<$1YUEHJ,/,M
M19SAH,-.5V%"3TL7%*C_Q^\/#+W]N\'Y__E]T\.__]4 /OU, KY;Q08;MI/
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M_JHFVO[[C8ZA-]^H/_3'W]6 =]\2@4_?KP3+/R. C=_!@=LZ"/#:F@D"W))
MF$<LB/&) @E^X2 M( 1D!^T%^<&!H"C$'T!#_0 BS =@PKV?$R.\GE,C/9]5
M1KH_XT6Y/Q5&OZJ.KC^\89O\PQOJ4V_^5Q5X[RT&^.(] ECY'QC8]%4^V+$B
M'7BL20#^&Z-!R-9P$+4C&,3M"@+)N_U!^AY?D.WN _(]O$"1IR<H\_( <.\]
M .V]&^!]W #9]:.4[K<3L%Y9W>!_O:&>_Z\WA __Y[_HX)]_Q(,E?X6"%1_D
M@K6?I( M2V+![F\B@,_R8!#T?2 (7^T'8M9Z@_CUGB!Y@SM(W[@'9&UR [F;
M=@'(YIV@>,L. -VR'2"V;@/H;5L P15Y^ZL"I4O>!&7KWP70/1\#K._7@!2R
M%I"C=P!2HC? 988 9$',4R@L^6$Q(?-> 2/_=BZOZ&:VN/1ZAK+\6IH6?C75
MA+R27(>ZG.1 7TILPUQ*Z,->3!C#78B?PYU*/(H[F'P"=R#EY"_VF^$G0YG+
M '498+L_=GV5O@:4X#6 &K4=4!*\ 2$]&*#S8Y[ H,D/2_%9]PII^;?SN,4W
M<JK+KF4J8%?3-8@KJ2;4Y90ZS*5D!_9B4CON8F(__D+")/YLPD'"L:2CA)F4
MXX2IU%\.0%V&<I<!Z?8Q('E_#6A!:P C8CN@QWD!2FHPP.?&/$&6)#\LQV3=
M+:$6W(*P2Z[G5I5?S98C+F=HT)?23=B+J3;\A>0FPOFD3N+YQ"'2^<19TO'D
MPZ39U&.D\;2CY)%7!,I_,J!W?02H7DM!9>!JP K?!IC[/ $]>2\@9T4_Q18F
M/T0@LNZ6D2 WBYBEU_(%L"LY4M2EK!KLQ70C_GR:C7@NQ4DZE]Q-.9LT1CF9
M/$>92SU"F4@[3!W,.%S1GW'H%P.P+]\$L'7O NS.CP#-<RE@!ZQZ>1?#B?$
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M7E&7O7%-9\6Y2Q8[CIYUT.H8)%K4'J?A2HZP:=D'/7A)G7Z^T6U!0:'-$>*
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ML/06 L]\)7A@-@&/J ALA@HPO#2!&JP'KK'&X)QA#OA"*W"LM %L@QTXM&,
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M@477P@8V2YF!HK01*,OH@H;L?M"5VP=&<JI@+J\,-G/V@,.<78"?JPBN<W>
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MD6T'0B+;KI+7OXG/0=$M7P.CFW^&F6R E<QPLYT&OPXQP*DI!CBTC@%V;>2
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M1:D]J4E?>L*4/>^X/5_&,0_1I*,!TK%'PA4C#L>IAAQ*U0PXF*/K>[#4P/-
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MW#"MNL$TN;++(J%BU#JV8JUM=/EVNZCRDW:1Y?=LH\K?V425HW5T.5JMA(D
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MM6/>D>3)N24^B']#3+3(^JADB;F(+.F9\"+YR=!*Q8F01I6QX ZUD:!!C:'
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MY$R]]LAN_;:(90:M$8-&+1&[C9LC3IDT1MPTF1+YQ'A*Y!NCABAN",./X0*
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M,C_EP8B"U%>F!:F<"6'\,;]%D/>G>7"1?.=QTM]70KZ7O-=@"8.5I<KH*S/
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M$3,UZR(6:M=$K-"IBMBD6Q%Q<%AYQ&6]LHB[P\HB7^B617)#Z!#:'WCL3^-
M-;B80#4@W[<O@_KL=.IS4UBL2E7&TC1]+$H;C?EI$YC.% _>S.1 P?2D"%%K
M8KQ"2T*:8F-\KKPAKD2Y+JY:M2:V4;TJMD.S(F:^=FG,,MV2F W#BF+VZQ7&
M7!Q>$'-;KR#V^;""6$Z7T"G\B/LT#E_%D/>G_ ^3_JYL\O[$&KI?EB''HDP]
MS,^RP)Q,.V9&ABNO+=U/T)(6)FI,C95,3DF6UB9GR:J3"I4KDRI4RQ(;U$L2
MV[2*$N9I%R3TZ>8E#.KE).P=GIUPCOB9>*:7G< -(W0)G0_<I;GX!<V!4Y3[
M ?+?V_/(^Y,'[J<X%N?(,#]7!W/RS-"1.Y:9EN/"-F?[\!NR@H5UF5&2ZHQ$
M:45ZNJPL/5^I.*U,M3"U7CT_M54S-Z53)SNE5S<S94 O/67W\+24L\1/Q%.]
MM!1N&*&;_A$_1]!ZH'EP/(N\/VEOII9G#;&$[KL+I)A3H(F.0E.T%MHP306.
M[.1\3WY-7J"P,C="7)8;KU"<DR8KS,Y1RLLJ4<G)JE'/RFS1S,B<K9V6L5@W
M)6.M7E+&SN&)&:>)'X@_]1(SN&%)&9SNQ]RBM7B1YL$1\KX[27M#&7F^4O)\
M=#^G6(SV$C6TEAJAL70,4U\Z@:TN<>=5%/L+2HK"1(6%L0KYA2F*.079\JS\
M(I7T_"JUU+PFS>3<F=J)N3VZ\3FKA\7F;->+R3DY/";G>^(/O=@<CK['Z7[,
MMS0.9VGL#Q;07"3]=>0_^XAY=-]1+L#4"A5,J=1'7:4EJBKMF+)*5UYQA:^@
MH#Q$E%L>+<DJ2Y)FE&;*4TL+E)-+*E03BJ=HQ!6W:\44+=")*EHY+*)PFUYX
MX0GB!O&$OGZC&U' #:'S@6LT#B=I'NRE]G=S%;"Z=N@,B#Q7-?G.&@:3:Y50
M4S<,%?5F**T?RQ36.;-Y=5[\[-H@849MI#BU)D$AN3I=,:$Z3RFNJDPENK)>
M+;*R33.\HDL[M*)?)[A\BVY0^;%A@>5?#PLJ_TTWJ.RU;G 9IQ-<^B]7TH"C
M5(.=%;0>Z\AW-@R= 0%MQ&2ZKYJBB-(F+10UF2*_V9K):9[(9C1[\%*;_ 7)
MC6&BA,982>R4%&GTE&Q91$.)4MCD6M60R:WJ@?5S-?WKEVGYU6W2]JD[HN-3
M=UW'I_:QMF_-WP2G[5O-:7W@/,W_@S3^6RG_M8WD^YJ!V40344FVH&B:!'EM
M:LB>;HB,]M%(;;=GDMI=V?CI/KS8Z2&"J.G1HHBV)$GHM$QI\+1"66!KE9)?
M:[.*S]0Y:EY3^S0\6C9HNK<<U'1K^5S3O?FAIGO3*TWW1N[_\ G58 _5?>/0
M.11Y\.YIY+O:R/=,)]\UD[SO+![2YB@CN7,8$N>:(6[N6$3/=6(BYWJR87,#
M>"&=$8*@SGBA_YPTL>^</ 7OV16*'K,;Y6ZS9BI-FM6KXCQK4-5IUGY5QUE7
M59UFW%=UZGBIYM3._1\.E]-<I)H/D/:2#EH+,X!FTJZ< V1WD?=< ,3V*")J
MD28B%ADC;/$8!"^V1^!B5\9_L2_KNSB$Y[THFN^Y*%G@OBA;.*FG5.S<,UGB
MV-,AG=#3HVB_<$!FMW"O?/S"2[+Q"WZ5C>_^2SZ^BU/ZF#UU[\ZA^DE[02?0
M/I=J0-K%I)V^&(A>2OZ_7PC_%<KP73$,/BM'PFNE#3Q7.<)]E0?CNLJ?<5D5
MSCJMBF<GKDKG.:PLY-NMK!&,6SE-:+NR6V2S<K78:N4NXKS8:L4=\9CESR5C
MEG$*8Y;^RS:R8&LH[\6DW4FZS60+*WJ!G&7D_U>2_U\+>)--G+1!$<X;U>&X
MT0 3-UI@PJ:Q<-CD!+M-GAB_.1!C-T<RMIN3&.O-.>R8S>7LJ,W-/,O-<WGF
MF_OY9INW\T=N/LT?N>EGWH@-3_DCUG."$8/_,DCZ2^<!\\D:MRT!ZOK)_ZX&
M4M<!D1L!/[*&+MN!\;MXL-XCQY@]FAB]QQ"C]EK <N]86.QSA/D^3YCM"\+(
M_=$PW9\*D_V%,-Y?QQCNG\$8[%_"##^PB=$[<)S1V_\]H[?W=V;8GK_98;NY
M?UA!^@LI]QE4\P:RHR6DG;$)B"'= +*DKGL!NP/ :++MIL>$,/A$AN&?J$/O
M$WT,.SD2NB>MH7-J K1/N4/K5  T3T=#XW0ZU,^40NU,,U3/S(?*V;50/GL
M2F>O0?G,(RB?>@GED]P_+%Y$:Y'JWD2YEV^@=4 ^/&XW$$A>W.T0Z1\E#WX"
M,#D-##O/0/V2$,J?2B'_3 6RSW0((RA^9DF,A_3S25#XW!^2+Z*)#(B_J(#P
M6AL$UWK!O[8)O.O'P5R_03PDGOW#W.5 R]IW9T Y.X!XT@XZ0OD?I_J?!"S/
M D87 )TK@.KG@.Q+!I)O!1#>D(%_0P6\[[1!!@NX:0Y\;PO<H@;U!U]JC**
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M+;G),UO\.]]LT6N!60_W#QLH]W[2[28;UO;V<T#D_>91#18 48L!?[*J;BL
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M&$:Z:E<!V>> Z$M0\T_0K^-['G!+ OP@)U.@"ORD18VI/G#;#+AK2XVR"_"
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M1G&0YU=5(C2H)C0F<O-_SH->B(/P5!B+)\)T/!06X%=!!6X+)N-GP53\*.C
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M4"A,B*\2Q\4W*\3$SY9&Q??*(N/6R2/B]\K#XR\HA<??D8?'_26+B..&4/S
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M(Z:3]YL)N)-EG=@E@-U\)8SKUL+8;B/8=EO 9L%86"UPQ)@%[AB]( "C%D;
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M/L,F:BTF0Z1-<1T0*:9V9AV]=R.]+^U12#OUN^B_>U7@U*\+AWY#V ]8PF[
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M!/)VLLC1[X.OU)V/= !U;34@VIS2U;$'*(ROVM!K@IM[P\U=;T,WHDC3F-C
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M#59L])V*B7Y(T=&MBHI9KLB8G8J(>1E\J(CH;Q09?4L/H6.,48>"%O1(@.N
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MQ#RM'D1*=WJZF_WNJBO@*W"+:[?L]2=C^GV,Z602N!.,8CD<SK6A^&(P\\5
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MMB3Q7CR(Q9ZH(%=%!+HKW.:I4)N?@FUF!=EL"@P,DRTP5M; %%F#LF4)*E%
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M[@HQ>RG8[*,@DY\"_4VR^5M D*S^$;*:XF2!B 5 1LSF2IG,[4%/^0<,DU_
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MX.N]''_T:(\=G9CX.H4Z]Z08!T!7.'X*N;UQ3@MDN1'2V$ 67?\R2<JG]O.
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MQ6IX T);$D-7%-65Z@NB^*K\*,&0%R$9<R-D8VZ8:LH)T_[7 <]+DX#GS9G
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M/FLHEYP^6$1+/0EC)/>CF,?Z,*RDWE)V8B^><[2'R#G20^$>/D'C'3Y!?^B
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M_GE?2LZ/"9GI5Q-SDK]/S4^\E%5XY+N\XD/?%I4D7(3!#WZ#0ARX@$7NOT!
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M[D!1C;L&RE'\X(  ,HCO&43K/P.\/:L _T#<+?[AI.N\Y/Q+G.S281:,.<#
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M9.4=!>65;;E&0VNVT]B476NJS0N9:O)#9GM!R%1=6&LR%-8:]45AP_T"-,C
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MP!>?%(+E7V2"M8N/@2TK#H&X-?O!_O6[P>&-.T#REFT@$_KQ*W?[1E"\<SU
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M36_@1[O^P#<.[P.>.GT(N.?\,? &<W!*"%C$@.]J=GB(<,-'F0^A.LL0:2J
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MJ_^']52>-!%R<1\A7<<99.=E!JE_P$$J)F:Q%8"?*P.;9L=#9E$8E%?Z0E/
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M++NU<'';!.<@*3C$*<(N4PW6Q5JPW*P'\VT&,&LU@ND>$Y@<,H-Q-[U5SUO
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ML*J@#R%EP1^#2T(& XM"AOP+0S[[%81\\9D,F#2#)YW]Y]V<E,5LR.>GO5.
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MS_D'H;,)40$'D<,,(D%S"&,AFR"6LZW#&L8J;& LAS!C"238%T*6?1Z4V>=
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MZ)]%L')"[+^@2#-(2S @+\$.)9I#28$#BAJ<D#/BAHS]-$AYS8)$Q%R(I2V
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M:A0N2M7-&<XQSEQ08IXR5&>3,+_=/F;N/*?(N>,N88/;7$/GGG$+'7SL&CJ
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M-A*^W6(X_(3%@O#;EO,BWEK,C4#SP4@TZX]$T]Y(-.Z)0J/IH _5/X2+:L#
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MS_7*&SQVJJSS.*FRQO,WU96>KU7'/5%MS M5EWY!9;$7*H], UVH!I[D>_X
M[T)9\$<$!VY'\,*=""&X&B$'YZ,,X424(^M0I"_WWH@(_IUA2<+;0K/%-P<7
M2TT$5<NN#VR67QO0I;3*?Z[*"O\EJN-^J]7'_+9JC/H=UESL=TUKD=]SK07^
MJ#E$S/='C7G^J#X8@&K303?^+Y>8$'(=NLS<C&/@:CP77(GC@W/QDG L41?V
M)]JR=B9X<F^-"^'?&!,GLBXZ76)U9)[,BH@R^67A]4I+P]I4%H?VJ2\*6:BY
M,'A<>RAXH\[<X/VZ@\&7=?N"_]3M#?FLTQV"VH165RAJS@E%C<YIH =YMQ_
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M;$0IDPF4GL[4\\A-U/]QRE] ^7-H[_6D9,7DH1F; 6*V P3N(@?<SP4N!\3
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M+@.NEWN!\^(NL%Y\ M8S!/:3KQFB_/9U7YY!S=I+^4<! BC;A;(MOP/0_Q%
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M%E2]23VP^IAZ0-4]]8#*O]4"*U$EL *5@\I1:3JWJ ^GZ1S80SW85$/G0A/
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M5A&]('!M)?!?.PA\/]\'_A\_@\ /" )7_@/S+R.4WT=];UK]Y1E0.NT[:B^
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MCE]L@_# )@Y?6V?A"^M2?&I=CX^L6_"!]2*\9[T<[UBOQ=O6F_$?ZQUXP_H
M7K,YA5=L+N,EV[MX?MB[PCV[[X6GATOB;7)KN*1XXG\@.5)_H@$D1WK?R7R=
M+'^VQA_C'?!@C#.^L/?&1Z,C\-[H%+PU.A^OVU?B%?LY>-%^@?"\?:?PG,-*
MX;[#.N$9AZW"TPY[A*?&'!5OCSDOWAIS2[PY]@WQ\7%?*2Z/^U-Y89RD.D_.
MC9/40Z@>(DUA_9U4D)P%2*Y\=37 'RXF^':R#3Z>. YO.T['JXZ!^->D.-R?
MG(FG)Y<(=R;7"K>F-(DWIRP4KT_I4CP^9;7BZI2-BLM3!I07IQQ07IAR2G5^
MRC75.:=_J4XY?:8^[OR;SA%G2?<0.2CC]-](+KK:[5UW#G4<9C_S$/'Q=%U\
MX&*,UYSM\)SK%#P]W0>WW")PW3U%N.*>)UYR+Q<?<Z]7G'-K5IYQZU"=<ENF
M/NFV1GW<K5_GJ-MNW2-N1_4.N5W4.^!V5W^?^X?ZN]Q_-MCA+AENUV*P[1](
MTT6M/J>;#_V -SFTO>2KQ LS]/",IR6>\!J/J[X>N. 7+)SUBQ=.^68JCOL6
M*8_Z5JD.^32J#_BTZN[W6:*WU[M'?[?W>H.=WML-![P/&FWW/JO9ZOVDIM_[
M'<U&[P?&ZWTDXSXMFK4^DM&CR/KRUO)G <!_0H'G.>T]S=?; 2I<]S?%Q4![
MG F>AA,A_L*1D"CQ0$B*8F]PKFI7<*G.CJ!:W>U!3?I; Q<:] =V&6T*Z-5L
M".@W7A>PUW1MP$FS-0'7S58'O&;6$_"MV?) R6Q9H&1*3+JU&#]$\N34YJN=
M<E^@[WN*'OQZ#+UOI(CS81J<C!B!(U%.V!_M+>R.#A,'HA*46Z,RU?V1A;H;
M(RKUUT<T&/:%MVAZPQ<;KPKK,>T)VV"V/'2G17?H4<NEH9>M.D/_9;4X["NK
MCC#)LCU,LB!FQ/11)&_@*TYQ;U+_7@)];S*]!CG+]\=C#' PSA9[$B9B('&&
ML"4Q2-R4$*M<GY"J7AN?J[<ZKM1@96R-T?+8N<;=,0M-E\9TFR^.7FO9$;W-
M:F'4(>L%41=L6J/NV[1$?V[3'/VG];QHR9)8$'-B]A#YKQH^80Y>CF?^.>5?
MH?\]FP$<X_L#23K8E6R);:GCL#G-35B?YB^N28M4KDI-4J](R=+K3BXRZ$RN
MU"Q.FFW2D3C?K"UQB45KPFJKYOA^FZ;X_;9SXL\-:XQ_>EA#_"?#ZA-^MZE/
MD*R));%HB)?,'_(#^^ '4?3^K/N-3'K_'*ZS<ZF?!>Q*5V!KAADV9CF@+]M5
M6)WM*Z[(#E-V9\6KEV2FZRW*R#=<F%&F:4VO,VE)FV?>E-IA.2>UQWIVRD;;
MNI0]PVJ23]M5)]^VJTSYB/QF6YDB61,K8EF5(ED\Y#NVP]OTWL^P_E>I?X:^
MZT@AO3]]\%;ZP VY)EB3/PHK"YRQK,!+[,P/42[*CU4OS$O5:\W-,6C.*=$T
M95>;-&;/,:_/:K.LS5QF796YWK8B8Y==6<;)X2493PPOSGB?_#JL.$.R(=8E
M&9(EL7C(U[P&7D]D.[#>EZA_L@387TKO7T1]?NXMU*"G>#BZ2R9C2<D,H;TD
M4+&@.$K=7)2D.[<HRZ"QL%!37U!I4I,_V[PJO]6R/*_+NC1WK6U1[@Z[@ISC
MP_-S;@S/RWF7_#PL+T>R(=;Y.9(5L7S(YY$<#]CV3S#_YZE_E$N>W60SEZ2]
M_+R\U!!+RVVQJ,(1"RO=A?D5LQ1-%1&JQO($W?JR#/V:LGRCJM(RD_*2>K.2
MXA;+HN(EUOE%O;:YA=OML@N/#L\LO#8\H_!M\M.PS$+)-K- LLXJD*R(Y4,^
MYG7X7(9V+TS>ASI40\]'UE51G[$LJ=)#>XTE%M2.0W/M-&%NK:_84!NJK*V)
MTZFJ3M4KK\XU+*DJ,2ZJK#'-KVBRR*E89)55OLHFO6SKL-2RPW8I95>')Y>]
M27X<EEPJV:242M8I)9)5:HED^9#W> W>S='NA<G[4/L;@/YZKO?KJ$\OVE:O
M0O-L,\QMM,?L1A>AKM%+K&X,5E;,CE:7SD[6+6K(,LBO+S+*J:\RR:J;8YY>
MVVZ94MMCG533;YM0<W!87,UEN]B:UX;%5C^PC:N2;(AU?*5D12P?\A\N?9\L
MT.Z%':7^[KGTO?3AR\F"1JZY^;EAG@GJFD>@NF4R*EIF"*4M_HJBE@A5?G."
M3LZ\=+VL>?F&Z4WEFI2Y#::)<Q>8Q\]99A4S9Y-U5.-^FXC&B[;AC2_;1LS^
MWB:B0;*.;)"L(NLERZAZR>(A+_%ZO"[O![+>!YO8%UO8#YJ!3C*/[^L6 )5M
M1BA;:(OB]O$H[)@FY'7XBMD=H8K,]EA56GN*3O+"'+W$MA+#N+8Z3?2"%M/(
M!5WF8:WK+4-:]UH%MSYF%=3Z@E70_.^L@EHDRZ!FR2)X'FF2S!]R/X_MP+8_
MSGKOI=XF6I(5;4 [7V>WTW?0DQ=TZB*WRQS9W?;(['9&>K>GD-(=*"9U1RKB
MNQ-5L5V9.E%=A7H12ZL-0I?.,PKJ7&(<T-EG.JMSMYEOYSESG\[GS'T6?V/F
MLT@R\^T@[62A9/J0)YF#<VR#P_(^U&*@CRPE+=2NZ:+WIB=.7R4@>;4Q$GOM
M$-\[ 7%KIB-FC:\0M29$C%@3JPA=DZH,[LU3!?:6Z\SJ;=3S7=UAX+6ZU]!S
M]4ZC&:O/:#Q6W]-XK/I:X]XC:=R72\;NRR1CC^Z_D??"3C+G^ZC;WPVL7,8<
MD-G4+ET%9-(3QV^@_]NDA[#-Y@C9/!K!_9,1U.^!@"W^\-\2+OAM21!]MF2*
M7EN*%3.VU*G<^]O4T_M7ZKCV;]=UZ3^IZ]Q_5]=Y\Y>ZSALE?:?U9)UDX-3W
M-^?9YP[3 @U0=QTUNU8#S;U %:UJ'K63:8TBM@/^.P&OW4;PW&.-&7L<X+'7
M">Y[9\!M;P"F[XN"Z[YD8>J^7,%Y7Z4P95^S.&G?,H7COBV*"?N.*<?ONZT8
MO_=SY;C=DFK<3DD]=@<9D'0>(N]#[:'^)FJO6@<LI&X]O7B1O =$/QR]&PBD
M)_<\!+@<56#2<0TF'K>!XXDQF'#"">-/SL"XDP$8>S(*8TZEPN%4$>Q/-6#4
MJ<48>7J],/ST(<'N] W![M3'@MV)/\5AQR1QV%%),>S(WQRD_E;6>^UZ7@NT
MI4W4+:=NUCX@CKK!QX"9]*0N9X#QYX&1%U6PN:R!]64K6%\9#:LKDV!YU1T6
M5_UA_G@4S!Y/)V4PO=8,DVLK87)]-S37+Y%W87SU-QA?D6!R21(>13Z+M)YU
M[V:]6W:Q#>C#<X\"B:> D+/,/W5=+@+CK@ CK@&6M*O&MU4PN&L$O;L6T+T[
M CIW)Y!I4#_C!]4S45#>RX3B7B7$>PLAW&/E[AT![M/0WZ-QOD>3_(P$X>[?
M;-K(:W$;QR-Y#^@PD,\Z)U(WA+HSJ>M,W3'4M;L-F-\%C.[3A].;"R_I<:+1
M<.%A";PR$GB5GO\U+H[?D!>E\E],<1)\2WX0<2<G9E;P;5;HK=?X^A.1_HM5
M[&_M\AX0ZU[ ?"==HCYU/6\"4ZAK_S1@0UT3ZAK0JBM?I]=_B[PC .\RCO<8
MQP?F7!#; 1^/!3YU 3[W ;YD'%]Q$OB*%_[7RX%OV,#?L%+?O,_/O_!5^HM%
M^[1[0$7G> U<!4)O 3.8MDGW@%'/,_?4U5!71]9]CWPD[\$,[85\0;Y2L4Q#
MX%L3+DRM@1]& S]/!G[C0OD/3LI_<D*6YCQR%N0Z>9?\\!=SCFOW@%+YHS!J
M>[+.DUY@V[_*W/\',*2NXJ'N%T/[(-\/[</\.+0G\BOY0X?E&0V=!Y'OBW&$
M]MD@\ED0.0Y.!%+O4!SR,T'^]1>2\5BMWS>PI]?G>]!G8AKQ(]$D@Y3\C_V'
M/M)/=I!]Y @Y32Z1)\F+0V=!'@SN<_PYM-_QY_] ,I7W/NAQC4;0WX_B-V.(
MO!?C1<))"BD@U8_L/W23U60#V4IVD0,L[SC^P'G\CNOX#??Q"QOO9R;N)W[S
M(W_CA_\#R5+>^Z#?-[%E+@A&#.7"@P21>&CW@\I(PV N_L02EKJ"3;"6.INH
MLYTZ>UC>8=;Z-+[#97R+I_ UWL17;, O^9N?\T]^]G\@V5#7RI)QF+--B 'C
MT6&;B%.'VD/>#THCA=2MIMY<:BVDSE+JK*3..NKT4VDG=?:SVQQG"SS&KOL$
M/L!+S,2G>)<1RKM3__D_D.RH.XQ^WTK#[B3#>(S9)H:3(>EY0E*'X#=% GX2
ML_&=6(JOQ'I\)C;C8[$#'RFZ\8%B-=Y3;,"[BFUX6[D'_U$>P1O*LWA5=1VO
MJ)['B^J/\;SNSWA67\(] PG/& YA\#?2*.J/-& <.I!L^6ICRGB8&[.Q^-5D
M*K[7^.$KHTA\:IB*#PT+\)YA)=XR:L0;1JUXS6@)7C%:@9>,UN(%HWX\K]F)
MYS2'<%]S!L]HKN&N\?.X;?HI;IK]@FOF$JZ:2\*51[@\A.1@",E>J7W<CKV*
M,?'S<%/\:#,<7U@ZXD-S#[QM%H37S./PHD4FGK<LQGVK&CQC-1=/6[?ACO52
M/&FS$K=LUN.F[39<M]V'QVU/X.JPR[@\[!E<L/M0.#O\1^'T"$D\24Z0X_]
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MOWV4'-&RD9HK6=?6-=IS.#D;V0:L;_ .8"8]N<L!UI^^G$M46)P"-"Q*[S%
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MF2^?PV&:LD\ ,=2>1=VI0V=@K.^P[>\".L\.:;Y"WB1ORV=1ALZ%R/LA'RF
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MDR[1#.;B1^;B&[A0TP>?(ISU2:).-FM50HUJ_!N->(E]XP7&\3RZJ;&:Y6W
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M)MI.G14U[(NTAG6DA&3RNWAJA\P%?)L!CP7TW^TB)BXRPH3%%AB_>"3&+9Z
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M*[?#](JQF%;A!-<*=[A4^L*Y,A1.E7&84IF!R54EF%@U&XY5BS&^:AW&5AW
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M9VHS'B[/T,E8%H_6Q<+19FAU&(GF,1,Q=^QT-([S0<.X(-2/CT+M^$343,A
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ME@U2_!V0%# 9B0%NB _T05Q@$&(#HQ 3E(BHH$Q$!A4C/*@684&MPO_'UGF
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MW?XMVN7?K1WS!K3=,JZMEAEML2S7)LL&;0C8I?4!A[0VX&*M#KA>JP+OT8K
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M@I94*G!)DP*6],FR9$KSEJR2_Y(]\EMR@7R7W"COV<? Z_)9_+5\%]GD-^/
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M<R^,CWZ\_^/DR9R.)X/\^-1<\\1:LQ?$G!1BGAIC3DQ=)W-:R/>PJ6]A/M_
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MQ]^J;O]F=?IWJ\-_2&WS%JAUWG(US]NB1LL9JF<1K+/<)*OE4=58_JJ:@"^
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M%T DUT).UY#)K[;9,8ZN/G[61GMK>"W"UQF8'C^*?MH;@%[?6<D#?DY"A0Q
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M#WI=+G&VS>B\R:GG+B<1>M )0\H>.Z46\K23K-GK(,3KR]CQ>\;L[UD8?\^
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MF$1'+V@&5BO]X*P!I='F>*@J4Z^"VDW]!P[8*WD@DF1!&B'9&27)&/,Q_[C
MP&)AFV+Q66 *_^:FRP+'H4/FH4\+(-3F!H<I".S4"29DB.'$>_R=S8YA3.U$
M5R,^KG;N \IHEA+:I$BH69"I_Z#7>P@."$<G@4$>6 @68<=B#R99_+$4.Y9C
MQTH6W%5,_JLR' 6_50A;-<SUE0".MP+BO/Q1:=G;]GTH6D(^A:ZV-G,>$#[
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MI=.)F'0-$97N YX2,:GO "7V*%L?\K8B1%H#=V<I@-"1S,3[J< D\%'%Y^,
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M\%X69BV!^HI KL#*O\G<P')L4!Z 6)F5#]G%C4$&SL8^\&#.2C' !&" -C&
M,1F@4'WTCP.X\0 \1#UF/0J\Y[VG,4EA?-A-R3+07(!ZSD+3389<9;R7TX1\
MU%<$3<F/*K#R/HQ,)A?"Y%^8/4%,7H)9&_)G/@1M8X88UQ+V80,>S"1@!_NT
M0Z/:HC(V*,0:-UKYL)_78]Z%R1)1E0EEGX<#/4];"CM$TXV$GB517Q%\A9?)
M^^SB.);Z'%F#N1 KCO-KSW%$73C.N!<<+U_P"$!?"<($$PC[#& .Z4;!?BC(
M%^.$=R+N0S3A\9"U'V<I]*P!54V$KA6U,0;!B12!VGCVD;_R+Y8<>8-[<@;/
M)V$<\4".0SJ8"V'6:B1 )RGHMYG,@P,P&62@DZ5#P:DH/-F"D$3<' ]O.O82
M'/K/9!YTK;:1.0L9?6 W^PP:GD.<>CIP9$)]K-Q+Z-_E$'8N9'!=2#;YZ[P0
M9CT(<TY('7@PF[<;T4_J8>Q'H(L:"*A")<KQA3*T1\D+UC.IQF$(D8.NQ="%
M^6PY00933R;7$T7^6@_R]SP(LP^GG"-K, _RW\^/80*X\VB7BQ@WSF.@/0?#
M.X,&[H.0DZA(#[YX[!:99(!^"-D2N"S@SJEO!*>>&9RZE0S6B_QU)LG?UX0P
M03*S'H0YN($Y'X3Y 7LP!\(\6/0%QM+G:)-G&'">K"7D$0SK 1KQ?@$A=WO_
M(P?R%7'55R)(OK/VPS!K,)CS.%0Y'CBS%F0YZ]?9[^B<7]!)/J&#O$=4]Q9&
M\QK1Y4L8S'-$HD]8YY(F@$(>XNEZ<AWD+N/./L(^ X-9 \'D %(Y:R &]W\P
M>S#></ >,<UG\/A&9/#9&/(!GOEK>.[/X=D_QB#U #SNHL/>P@!Q'?'4%41E
MS#-BV6=R."&2\D%3A$--J8AH2DD+&J<)WV3D%W%D,^=O,GD Y@P*)O_QBJ.R
MAQS<ASY^0TQS'7'5-<01UQ'+G$=<UX<HHA<\NJ&/#@Q:[&>C;$7YNU&^'LS"
MF-2 1R7BB7)TFA+$5H6(:_*@BVQR%3'=%U;^@\E]!'!R$,P9%$S^XQZG"0?W
MH72PFIV?-$(7=6B3.K3)$=9>E*DP^5FHRT*8YC*4O@HZU8;9;"9I&#!3$ 4G
M81!) (\X&#;[/- D:*0$K7,<)OX'2S:3]W B[&> ,'F(WSBFQ,ANX)A?#LL<
MN5#F,)*,N"H9;9*$V"X>MA$#'E'@$0[["$6T%XSX,@B#> !LY#!LQ)<5[1NC
M?K:0Y0DF$=!*-H8Q)DMTFR63><H0L_=C, ]QFF/B99QN$,<9!MAK,/A0GBBL
M3 *0P^LQ*%450\94E*N!<MGG<=K!1FQ@(]:P$4OPL  /,]BI">Y@G\69B%B^
MC/5$'>8I0\RZ"V;O!_,$:.;DWS9.W9,XPYT79]AEAF!KZ (>,<H4P_ L!<BC
M[#$H6Q4U54/9,S&4SD79BU#N<EC$&@SKFU#^3I2M#RNQQ"MWUM-KMY-<6$X+
M(N''K'T?S&ZS31PPZ=9DSI#KPAD>#W&&:8QH*),/90J#LS@P AB%\I4QC:BB
M;#6R#1'N5D2^6\!C,WAL@CXVXM4&W+D>3->Q3@P) +L4LAH6NPJVN0HC@!9D
M#R*+4W]&/K,D$D,6ZV<)9HIDILK-A!OE"@*B*%L"D$'Y"K!$992OBO+54/X,
ME#\7Y2TF*_&/R80L1\TU48NEJ-42:'<QZU39$ECS"> -ZZG<#!81RFI_+T[]
MF:EQ%V'_5(+I"^7#Y0&TH MV_D$,D 1D(4,1,E0@8P)DJ$'&3)0Y#Y:ZE,S'
MM^9!VTR6:#9:;A9JJ $KGHGVF($>/0,C /-$*N94: U6CA+3(:9;8TS]N^$.
MZ0BP<Q\K\%X3UY=@"EQ$>%"^(,H7!<0A0QJ0APPEM,)8R)D(.=-0WBP6$W6P
MG(Y:3(,U3(4UJK%V,P5AI$LGDS!63"(W6"O@F!V)S%.Z?.&*60G")<'4LE68
M_1/9<F QWL_'M#<'G\T&GUG<_) Q##+$4 <)8 1DC82LT9 U#G(F0XXZ_C\7
M92\%J[70T#96]FP<K'LL>ID*+%\9HXPR>J,RVH/)AC,G1+E#CHD(>PW,1B;_
MPOQ<"<S#>PU '9]- Z>I0CQD*K\@4>,5(5.XAY/)7))D$I<LF<BE %G*D#4!
MH]A4R)M%QG(M)BI<JX@RUV8RFFL?4>*R( I<WK#F>+ N!7J IZR=D<QIW8Z0
M8029VYFEVN+L_,M\0 .8CFMJ^&P2,$&4BTP0X2,3A@TCJH*B9+R .!G'+TU4
M^.6),O]H,D9@'!DM,(4H"<PDB@(+B(+@2C)2<!.1%]Q+9 7-B8R@)QDA$$.D
M!8J(%'\'D>2[#WP&*+%ECNN#/&;+_"I)]D^V<P!U8 JN303&X_.Q@(H8+U$6
M%2#*(L)DC+ 8&2TL212%98F"B (9):)"1HI,(O(B,XB<R'PB([J"C!#=1*1$
M]Q))47,B+NI%AHO&$C'1(B(JT@[\!KP#*+%$V7N9GT?A"J]@UKX ,YG<"S 1
MU\8#*N S!O<H2? 0!7$^HC!<D(P:+D)&BHD3^>'21';X2"(S7)F,$)](I,75
MB:3X?"(AOI*(B^L0,?%]1%3<G(B(>Q!A\6@B)%Y !,5;B8#X;> M$1B.<1ME
M[X*\]7"#-1&>S 74@<D PFFB HS&YXK@,E**F\A+\A)927XB(SF,C) 4(]*2
MDD124HY(2"D!XXFXU#0B)C67B$IK$A'I]418>A<1DCY$!*1="+]T!.&5SB,\
M4BV$6^HFX9)\2[@EF6=7PQ8@;XTL>^\1DP.:"DP$QC)Y%T 1GX\$%[D1W$1F
M!"^1'L%')&4$B82,*!&7%2=BLB. 44145H6(R$XBPG(SB9#<(B(@MYKPR6TC
MO'*&A%O.D7#)P9>5Q8PH"V=,]B:"J'< )?K,.3AR[)_+%XYDYX"F .,!981+
M2OAL%" '+C*RW$1:EH=(RO$1<7D!(C9*F(B,&DZ$1TF18;A)4&$T$5!0)7P*
MTPFOPCS"K0"G71$CGB)&?47$W0IP4!7@RXX"AU&W4#%X3B,I:U_:)LA;CK!]
MG@([!S0)?\<"HT>Q<S_RX"(KST6DY;F)Y$@>(CZ*EX@I"A 1)6$B-%J,\,-8
M^,;($)XQ"H1+&;&_,@)EY=GL@RN4X;0K(U!0M@8P*XW)!)I0.#@H(<Y2PMP)
M.>LA=RG<[]F<'- $O%;AY']&@8L<[AD!2.*UN"(W$1O-2T24^8F0RC#"-U:4
M<(\39QOO>'EV\D:5V4"$V%\5\97J.O:/IZJ8C501D(Q/!Q!WCX/3._83@-A?
MB;T>:9$R>QW0%& \WH\!%T5\-A(\9/ 7)D?$<5T,GXN,Y2:"X_D(WP0,<!,Q
M@$T68W=D-68!%;Z@!C]>;1HG%\-L)& .,X#SKN:#^Q D3$8@, D<)L&3G4C)
M9F8]$K,7C%D'-(Z= QJ+:Z,A2P$R90$IO!;'=3%\+JR*&!S5Y)V,05X-D\LT
M(?9@.@,#F@9TH0%=:. +&I,!M(<& E<-Q%<:\.=G(GB8"4]E!N(*]5OL/,PT
M2K1!>2FS%VP">QW0!&8-$&0I0:8\((W7$K@N!KG"*%9 #7$8P@0R [&V!GC,
M!H^YS.2"@7T!VF0A.M!"Z&*A*ON F85+V \97@B[7.",^Q#;S*O&=ZYC,&3G
M858S^\&8<WB *9/^R@&-PM\1D"N!ZV*0.PQR^5$D%\)73)8H!UB(274Q>"P5
M8*]+62'&3KAK,1T-NM#"%U?.9S]P>26\DA4(I)8C@%H&SU'S KX'KWX)HA:$
MYO/0=-/Q=](49A\:[("S!DEB&CO_(P2YO',A$\V+B1S?!9A\").78.5#,,FO
M P]M8?;$IR/%3KKJ,(N>\.5-:(]-S(-_S0C9@+ZAG<_9%_21=3;+$ICO;&8=
MSG3V7K Q@#S>2VHPZW\@'W*Y6;D?CLS5'.>&<7(V<1P>5CX$.MD%QT,7//8Q
MDQ#:9#^,:3\JLP_$]Z(]]L!#U(7'M"N#?4[M]M>LM2@+YG#.XP&7<9Q]8%)0
MGQCD"BYC.5%_R1S,OPSF0EAK43B.)^,$LO(3<#;,P<-:G/W<'"L8F"4$6#(/
M1,(7S!QQ#X)H8T021H_Q/4KF0=Y,U'<B9Q\6LP9'#/458.0R>9\M')G,6I3]
M?Y=%V+D0)C=APW'$!_?)>,)&?,$C +;AK\A^6)P/;-,+,;<7ON2.Z,&ME!#G
M*X0X?B/S4%\U?*R".LN"ZO#UD,_HE\DS[>7(-"9_K4,97!/BSG%$T>7_S(4,
M[I%A]G DPD;2T&>9#</,LVI2H>0D5"P>!<9Y$Q*-,3L207OX&S(#=1[/[(-"
MG<6A9T%=CG-K0O[*@S!U8Q9?#Y[1.BCGS[4GY*\\R-_7:=2"1R/Z;",FFWIT
MLEI4MAI*+8?22M$>)76$%/Q.)L.NE* B2335,*;.9AR],O7T(W^=2_+?>1!F
M8?[?G]L[>$X(LQ8$YL;*2[!R(+SL9\1<1)N<@]&=6<]^5F]O$"'=**"KGZA
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MOV@@X1/-(+PB=81'Y +A%GE%N(4IZ^=('<A9 ;GS)!%G !.!L9),W@7U!^2
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MKJ6-^5YUE1G^K87)H5W9\3&]J3')IQ*C<OJCPXI/AX>4]X2'5'<.!30)'!+
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MGA53G$:S/9DCR1S^Q9@@06]X5.(9?D)ZB[\HI\$WKZ#&I[RXTKNQI-R[I[2
MV5N4R[J0G>US.2739R3A3_SKX(\Z_'X_*>7 7,@YN@A*3JZ"*NVMW^N-#G^H
MMU9[5>=H]KB<['PSG^$U)/+A]PIY@@Y!6%)36&QZ#3\YMSP@J[#8K[BD@%-;
MEN?;49;ATU,J\NW/3>,,IZ7Z74W\$\!''0+0WOS]3DP:>GWFHPYE*JN@1FOK
MER;#0Y,M5JK/FAS,[E>3G*\4T9CGLUB!9U*X@J;XX*3J*$%&:9@PMR HO2B'
M5U":$5!5GN;?5I'DUUV>Z'\^7Q@P)$K@74GZ$\!?_1^'W^^CI.^? X7R"Z%2
M>>6O^E-;/K4:''K=8:$ZUFIO^D^],V&PC,KLSF,&MJ1S!#5)@8FE<1$9^5%Q
MN9GAJ46I(;FE24%EY0E!314Q_"Z4<X7108,9T4&7D_\$!*$./-3A]SL0F?ME
MH!A=KZN55_QH.K7Y0X?^@9<]9B<?=MB97FTB$,Y7N7F>+O+@U6?[1)6E!23F
M)X:F9\3%Y*9$)Q<E1&:5QH275$2%UU>&AW=5AH7U%86'7<P,#[N4^B?^=0C<
M*@4)Z#F1O4\&2H_,ASJEY=]:-3=.=NGO?W;.5/E>-\9DN!7OU%-+]F@NHP=4
MYK,B"[.XPLRTH/3DI*C<N 1A450L.BTQ117!T;65_)C.RD!!;S%?<"&++QA.
M^Q,0C#H$;9&"1/18Y.Z;#15R\Z%1:=GG#HT-;_KT]HY=,%6\T6=C/-#AB.]H
M=&'45;G[EY0P([/S?84I68&BN/2(G,C4^,+@I+127F)^.5=85<$1GJ[D)/06
M^\5?R.;&#:?]"0A&NSMDLQ0DHP[Y>V=#E=S<7RV*2SYVJZ][>4%WU\-AX^-7
M^JV->KL='%M:B?2*>@HWK](C/*V$'1]?@"Z6N:'905DQ!?X9*25L46X92U11
MSA2U5C#3>HM9*1>RO9.'17\"0E"'<+3]4]'Y*-HS"^IDYWP_?6+1NW-JJY]=
MUME^=\1087#0TN!,G[U#72>!5M3JYI=13P\35GO'199S4X)*@C/]"@5YWOE)
M11YY626TW+(R:EYSF7M>;S$]ZT(V(W,X[4] *.H0M4$2TK=(0NEN:6@Z-/M3
MM\*"5X.JRQ_=TMIT[9;^T7-7+/1;+MAA*WJ=J#F=9'92&RU8T,2,#J[G)/K5
M\$6LJLAL>H4PGU*>64@N+RDBE3<6DRK.%9*++V:Z%@ZG_@D(0]L_9ITD9&^6
MA,J=4C_;#TJ_[3\ZY\EUE46W'FAL'!S5.])YTTRG]@H&4WC1T37M/,D[IH<:
M&-+I&>EWFAWOU<9+IK6$I[LVQV<1FS)RG1J+\QR;&O)PS>=R\75#Z4[5EY/_
M!(2C#K_?3\K?) 'UVR6FNO=*/KU\6/K6J,+"H7&-3;V/=>6:1TVURF[96&>.
M.!#C+SE[A@VZ<;D#C!"O\SY1M+Z .')O>!+A;'PJKB=#A.TI3K<[VY"!Z3V7
M;M=Y.1G;/I+P)R!RA3BDH.U?NE[\5^MF\8D+6\1OW]\N.31^;/'9EQI;6I[I
MR%6.&6OF/K0R3[IO[QAQAT )N.G&8EUG^--&?()=KO(BG*Z$"QRN),1BKF3&
MVUPI2;"ZTB2T'.E/L!J^'FLU<%/P)T"P7!RR5HI!S6JQCSVKQ.[?6HP,C>^0
MZGES;&GS6_6M%:^U9?->&:BFO+ T%#RSMPEZ2L3[CE%=/<>\Z-0G7"^7QR%L
MI\<Q?@Z/DP/L'F8'VCPH";(<K0LV'^T,-AL="3:]?2_H3T#<4G$H7"KVJW4)
M<G-H+C(TMEBL^^V.64U3"LO+/ZINR?F@=2CYO;Y2]#L+K:!)>V/.),G*:Y*&
MI;WUQKN^#7 FO@TCX]_&NCF\27&W>YU-MWE5Q+!Z5>UA\;+5T^QE/]/TQ8T_
M FF+Q*!Z 7*]1P:Y<%D&Z9Q<(M[P=>><LN\*R[._JVQ._*ZY+_*;GCS_F[F*
M[S?[4Y[?2'KNW^A&Y&_>9L[? BSQW\*L<=]C,=AO*7:8KUGVUE^*'"P_5SJ:
M?V["FWWJP9M\NNCT)Z!@+G*S51HYWS<+.7U=!JG]L4RB&';/S03YY?&@N"$,
MU'?X@^X!%I@>H8/="5<@JA"!IN8$+$T<<+6P$*R# 8&N#23J6T&&@27D&YI#
MF9$IU!F;P&D38^@U_1-W:L21\QU22-L%*:3J[FRD %9*IL/>N;%P>$DP**SQ
M!=5-#-#>X0K&>PE@<Q '3K)8H!S!@.=1&V K6 'ON 6$*9I!C)(I)"L;0Z:*
M$12H&$+Y27UH4-6#-K4_,= DCK3V2"(55R20G%<R8BFP1DH .^;P8/]"%GHL
MJ*"\A@B:&QS 8(L-6&RW!/N=9D#<;0+4/4; W&L(OOL,@+=?#T(/Z$+T01T0
M'M(&T:%3D'M8$\ID-:#ZC[2VBR/E PB2=1M!A#!//!+62/K#YMF>L&L>&0XM
M<@2%91A076D!.FN,P7B= 5BOUP7[#=I V'0*7#=I GVS.GAM40/.%E7T!GP2
MPK:I0/0V91!N5P+1=D7(WO$G*GK0\:\@2-PC! F#!>(<6"Y!@W72SK!5!@M[
MYUF"W$)C4%RL"^I+M4!WF3H8KU %RQ4J@%FI!+A5BN"\ZCB05RN ^^ICX+GF
M*/BLD0?NFB/ 7RL'$6ME(>:/ &.#!%#1^X2KG QX'IL/OBI+P%][-02:;H8
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M]>YW?,DX[SA!FPGP0AT8J(,WNI_EH[T9J; (8E57@5!W,R1:[(-XQV,03=6
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MM7N4H'%&&EK%D*+S"))Z T$$;R7%0F"IN ^LD72'+;.<8<]<+,@NL(3CBTU
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MH<$<,0(L$L? <@DS6"^IC\Z)%NR;K09R,DIP8LYQ4)TK#Z?FR8+>_$-@,O\
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M[#?KR_8_S8<<P'0Z +]1 AQW2J++KA2PT.[F'IX#_!.+(%AS)808;H1@VUW
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M4NF[V2?E3Z;?E=^;@O);,U"<, .%5], EJB#V5Y)P.Z5 L*!6>!R9 ZXJ2P
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MNYUO>QYU_</SHNM_/!ZX_>KYUOF*SS?[2_YH?3$0+>8#T>14(!JM!%TDJ1A
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MW>;<6>(Q^?5G:]NS:$D_@Q8KN=-$SJ ?X/ XP$[2WV-S /TG:=!QF1GJ;W-
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ME57JQQ";Y,\=;!(_3[*+XSUV\1_OV<2^?_^7S>1]V$7N8,W!_SL_Y": ^UT
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MUREE-K=9QF1NEXSQW%GBJ8SQ_D5IXWTH9;P7)9<[4TON(7D?;%VZ Z, W=,
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MP5HJ-VXDIFF<>(3XC7A%O/T?.F8 *LG]SUZ:?X',_PW \4\ T_MD]F, Y8\
M"D@%&60G,WG(S+4@@B*P#B5A#<H#'ZK":M0&;C0&3K2F<* SA0U]*<P816'$
M3 H-JRA4[*90<(P"N(<X39S['ZKW >0LG?_2?++W#G?(WC\$T'@&(/L*R%P
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MV-^&ZQ#[/X3S7X8.WH$..G\4_0L]/'TW0,(>'L3M487H/<94^!Y+6LB>><R
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M"0WGR,9,+H@3/C!P+!01XONH(3J($6+^USF(&Q(,?_X!#<$/8H(W0H(7/]F
MC/T#HFM$D2D&%#% IAA31-N,(FHV-*+D0B,*070B%T\G,KET(EV)-".+D67(
M:F0]LIE.!#N1_<AQY )R _F51J3_0#XCY/^-*-\(7=L8,1*-PY0B6I8THN%(
M(ZK^=*(<0R?"3#I1*&,0A0:D ^EA$/E^9 C9A(PA>Y##=")_!OD)>8C_S2OD
M$_VC J%]4"!T$>__!\00LTW0M4VU$%WJSW,9PQDTHC^71G2\Z40K@DXT4AE$
MK9!!5&N1!4@7DZ@N1P:1]<AF9"?^_@1R"OF>\5GU/N.#Z@O&&[4/]-=JA/$*
M>?D7+_X%,<%L,W1M"S6*F&O@US@F,^R'J2V-&+OC&$/H1#^10?1RF42W@DET
M&I$.%M'I0?J1M<@FUB>=,=9'G;VL#SK'6.]TOF7]H7.']4+G=^9ONN^93W4)
MZU?D,?+H?T#,,'LFNK:E(J),$6NLB=54BEA:T\@,9SHQ\V>0:3$XU@PFF5K,
M^F1<*_;>N%7LG=%BL3=&R\1?&ZT2?V4T+/[2:+/X<Z-=XK\;'1+_S>BL^*]&
M-\0?&/\F?M?XO?AM8\*^B5PW)N(B?OD79(82$&MT[3GHWW8*0.:J([@N["TH
M,@?[8>U%_V@9SGP[,XGU:D:>V'.+"O%GY@WLI^;M[%_-ED@\,ELA\=!LC>1]
MLTV2=\VV<^Z8[>?<,ON&<\/L9\XULR?<*^9ON9?-"?>B.>%<0,Y;$,ES_X)8
M8;ZM-.:B_SO) ''%FKCJ '$QI3X[VM#>S'.A/[<+9#ZQC64]G)TA?L^FF'W;
MID;RIG4+YQ>K3NY/5KV\'RT'I*Y:#O._M]PBN&PY+KAH>4SZ@N5WTF<L'TJ?
MLGHC?=R*"(Y:$_X1:R)UV)KP#OT+,@=SYZ%[.W._G$-XXYA\U.&3MP'URM."
M>N(ZEW;?Q9MQTRF"]9-C,OOJO%S.Y;EEO&_MY_//VR\0G+%;+'/:;IGL*=O5
M<B=L-\@?LQU3.&)[0.&P[5GAA.UMX3[;%PKC=D1^ESV1W6E/9';,)0*$/QEB
MC[G.',Q'__?#<8B>QP@4PLM +7CD/Y6ZY6M#7?-QHU_V"A([YQ$K^8U;.N^$
M:X'@J$N%S"'G>KD)IS:%_4[=PKV.RQ7''=8H[7(84=[IL%MEN\-QU6T./ZIM
M=GBJ.N+T46FC$Q%N<";RB-QZ%R(S&>+( ^(N#L07O3,(QQ'*A3=A G@<*H0;
M(3KP?<@,ZER0(^-DH*_X$?\(SH1O$G^O=Y;,;J]B^9V>5<(QCT:EK>[MRIO=
MEJJ.N/6K;70=UECONDUSG>N$UI#KMUJ#K@^U5KN]55OE090'/(ABOR=10.0G
M0US0_;W0_0-I\":< ;]&B<&#*$FX%<F'[Z+4X$S4-.I8I!UC(MQ3?#PTA+,C
M.%:P-3!-=C0@3V&C7ZG2>M]:E2&?9K4U/HLT5GOW:0YX#6JO]!K16>ZU1W>9
MYS=Z/9ZW]99ZO]9:XD/4E_@2E25^1 D13H:XB6H \"$4X%XTP"_Q=+B:( ;?
MQTG F7A%.)I@3.V/MZ'OC'45WQH5P-D4$2D8#D^46QN:*5P=4JC<'U2ANB*P
M7F-98)M63T"WSA+_?MTNO_7ZG7X[IG3X'3-H]_O%<*'_"[VV0*+5%D34VH*)
M"J(T&>+)P#4 \ 1O<S?0=[Y/IN!"*A/.IHC#T11YV)<ZA=J18DG?G.0DMB'!
ME[,V+DRP*B9.;D54JK O,E=Y:7B)6G=8C69G:+-V1\@BW84AR_1;@]<:- =O
M-6P,.F34$'S%N#[DF4%]Z&>=^C"BT1!.U!"5R1!O"D3N?0^=[P>\Q5U(1]_)
MI,.Q#"8<R)2&G5FZL#ES!GU]^CRQP10OSLJD8$%?0K3<DO@DX>+83.6.F$*U
MA=$5FJU1]3I-D0OU&B*63JD+7VU8$SYJ7!6^?VIE^+<F%1%/C"HC/^I51A&M
MJFBBCJA.1M2'U^C>M]#_+V/^Z6S<Z^=2,)%+A]VY?-B2IP4;<LUH@]EVK)69
M[I*]Z0'\KM0(V8[D>&%;4IIR2T*N6F-\J>;\N%J=VMA6O:J8+H.*Z'ZCTNB-
M4XNC]Y@419\S+8Q^-+4H]KU^<1S1+HDG&HC:9$1_U"'JP\^B&F2A^^<#3!2B
M<Q52L*V0!QN+U&%-H2EM9?X<9F^NB\3B;#^I]LPPV=;T6(7&M!3E^:G9:C7)
M19I5254ZY8E-^B4)G09%"2N,\^/7F^3&[S;-B3]MFAU_WR0G\=V4W"2BDY=,
M-!'UR9! @(?8A_^D 9Q!YSI<!+ 7MQS;D9%2+@R5J<) Z52JM\2:V57D)+$P
MWYO7DALLTY 3K5";E:A4E9FA6IY1H%&27J%=F%:OEY_:;I"3LLPX,WF=27KR
M#M.TY)/34I/OFJ:GOC'(2".ZF6E$*S.=:$Q&M!;NXEJ\C/Y_$MUW K-W5:!W
M5@*LJY2 555*L*S2D.JNL&2TESFP6TH\>?5%@=(U!1'R%?GQBJ6Y::I%.;D:
M^=FEVCE9=7J9F6T&Z9F]QBD9:TV2,K:;)F8<GQ:?<<LT,?,/P^0LHH=HIV03
MC<G\@6OA9A+V ?W_:#'6 +/':M"]:]&]:\5@69T"+*F;0G74SJ"W5,\5KZ]T
MYU:7^PO*2\/DBDMB%0N*4U1R"[/5LPJ*M=/S:_12\EH-$O.6&L7G#DZ-S=UF
M&IU[U#0J]X9I3-YKP]@\HA>73[3C\XG&9)Z)UH*H#[@.#I9C#3![,_KG4".Z
M=R,=EC3*0D>3+M7:8$ZOK[<5JZYSE2RK\>4758?(YE5%"[,KDI0SRC/54LL*
MM9)*JW3C2YJGQ!1W&T86KS(.+]IB$E9TV"2TZ!>3L.*7AA'%1"^RA&@C&I-Y
M' MP!?MP FNP#]US#/,WM*!WH8<OP6UH^P(!M+1I0OV":;3J5AMF6;.31&&3
M-R^W(4@ZLSY2/FU^@E)R7;IJ?&V^1DQ-A79D=:->6-5B@Y#* :.@RE'C@,J#
M4_TKKTT-J'QA$%1)=(,KB59()=&8S+U$@&]Q+1[!&NRNQQI@]MJ%Z+X=F(\N
MWM3)@[K%JE#5:4R5+K)D%'3,$\]N]^"D+PS@IRP(ETUHC5.(;4E5CFK.50MO
M*M,,;JS7"6Q<I.?7L'**3\,F0Z^& \A_#+WJG^O[U!,=WWJBA:A/YCKVX31>
M"P>P!]MQ_AO: ?H7HWNB!S?V %3W2D)9KR(4]4ZA\GIGT#-[[%BI2UTE$I?X
M<N.Z0P117=%RX8N3A2&=V<J!BTK4_#KJ-+P[VK4]VI?KNK5OU'-MWZ_OTOZ]
MOLO"WW5<%Q(MMS:BX=Y&U"9S!3^3CN%U,([]'\7\-5T O9B]$#VX9B5 T0 3
M<E?)0-8J;4A;-8U*&K!AQ TXB47U>TF$KPSDAJR(% 0N3Y#U6YZAX+VL4-&C
MKT;%M:]-S:EWF89#[P;->;W[M.;V?J<UM^>9QKREG]7F+26J#DN(RF3.B6I0
MA^L ZS^,^2MZT?]111K1@\M0C=+1Q9/6\R!A@PK$;C"BHC;,I(6MMV<$KW=C
M!0S[L7V'PSA>ZV)Y[NO2!"Y#^;*.0U7R\]:V"NW6]BK-6;M>>?;:O2HV:R\K
MVZQYIFRS^K.2S2JB.'L5$4[F.%Z+NW$-;,+\59B_%.?>.HC^BQZ>MPG]"UTX
M?$P<0L9D(6B[-@1LGT;Y;K>A>6UWI'N,>3%=QX+$G,:BV YC29+VVW*XMMO*
MI6RV-0NLMO;(S-HZ+#MSZQ[9&=LNR<[8\DS68O-G68M1(FLQ\D_V8P^VH@ZN
MQ?R^?NP!SKT6=:P0/3AU.T DNJCO/@K<#G#!]8 B.$_H@].$.3A,S*'F3KA0
M=A.^M#D3H73KB3BFY40&:^9$B;C%1 /;;*);8MK$D*3IQ#C'Y.!%29,#OW&F
M[OO,-=Y+N,9["&\R.W#M#V/^"LQ?A/GU./?B;=@#]-#H?0#^!]%!CU(PYQ0+
M+$_S8=9I99AY1A]FG#$'B[-SP/RL"TP_ZT=-.QM!F9Q+HAF?RZ,9GJNA&YSK
M9.B?&V3HG=_)T#U_@:%[]C>&SNF/+.UOB)CVJ7^R$=?? .9W87[C"$ ISCUC
M#T ,9OL?Q7S4Y#EG "R^98#1]VS0^U$*=']4!-UKNJ!S;1IH_V2#.('6S[Z@
M^4L$:/R2"FK7BT'U>C.E<F,9I71CE%*\<9P27G] "7]^2PE_(C2%:_]D-?9_
M">8WCWPY@\K$N<<<P7S,=L9LFPL T]''#7X$T+S.!+6'/%!]* ?*C]1 \9$^
M"!]/ _G'5B#WJP/(/O$&Z2?A('B: OS?2I %P'LV +S?=P#W]_/ >?8$.$\_
M N=7\@]Z,;]UY,L95-8!S#^.^9CMA-E6F&WZ X#N+P"JMP"$3V@@_T829-\(
M0/!6 ?AOU8#W3A>X[Z:"Y/L9P/Y@!V(?W('Q,03HGY*!]KD$X%,;@A?91VSN
MQTO(4^0C\NF_M&%^E>@,; (@%N?N?Q[ \3+ +,PVQFPMS%:\!R#S&(#_'H!'
M6, E') @?! CLL @2D 1#0"BCTQ#K!$G^'.#2/"&+/H+B?X\>\!Q$"PT.87<
M^P<UF)^+^7'XK8"+  Y7 69BMN%M /7[@'7&;!PZ!_/9!("%T @#_ULVPD7X
MB"RBA&@B!H@%8H]X__4L"-X023.R',%%3_;^ Z*!;JFE_P5U0XHH3J.(M!5%
M^$X4X090A!-+$8DL&F&7(0U(!T78/4@_LA;9B&RCB/@X<A#Y!KF*W$>>(Q\
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MS?@%7O@O\*)_@0O]Y68$W_C5/>0/Y,-_:<;\,EQSZ?OP&CR*^:<![#';_#N
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M^!U6SO/[227/_X5B7@"1RPLD,OF!1(#PO_+2%?N -;@8@36(%9V_H/<BHW$
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MU FK$;4)K7 U;G(,G&<;'&'==W4 (W.H.[O8%_ELI2U5M*6P51.YK4;(;K5
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MB$#"8[$V9BTV@NOBR7!>; .G)<YP7.*%F4N",6-)#!P&4V$_F ^[P6K8#';
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MX%X&(_L"B5@BF^!$LY>=:B\KMI=?W$.MN_MU@@)UUQ^$. 8I![/\40YFE&U
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M68'XR&8A+FJN$!.U3(B.VB2+BCXLBXR^*HN(?I_XB1 E"!%1*CP=P["7]3Y
M[FTYU/ZY[(O$_"S&N?R\FG841BN1$ST.F=&3D!9MA91H1R1'>R QQA\),6&(
MCXE#7&PJ8F-S$1-;AJBX1D3&=0OA<8-"6-R($!I_4!82?UD6G/".+#C^!T*4
M!<>)0H@:5\EQ,IWS$7DW,Q0?ILX?E,[A4(\WT1_EM",G44!:O#Z2XR<@,6$:
MXA,<$)<P"S$)OHA.#$%48C0B$Y,1D92-\*02A";5(R1ICA"4O%@(3-X@!"3O
M%_Q2+LG\4MXDOA?\DD45DD3!GW@RF7TA6Y4'&BT!5I4!BXANZO$ZVE7"OV72
MQL047<2E&",FU1Q1J;:(2'5&>*H7PM("$9H6B9"T1 2G9R(PO0@!Z37P3^^
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M3CNNT8XK&&9/V(2+;)-S.$8K+N$TK3I)3YU@RTFGIZ2LV3$UI-=C/X($U67
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M<(Q\N\D]FLGP/XN:D\]NOF^D/\KHCVS:D1*JA\00$\2%FB,FU ;1H4Z(#/5
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M4S M_1032W[#I&)&\!**1.QCV9O)-4QI.M@*]+6K]J%4MZGVH;!9$49[O.L
M9]II7:V%:=7C8%$] >;5%IA2;8O)U<XPJ_'"I)I@3*R)A6E-!B;4EL"DMAG&
MM?TPJET'P]H#&%=[%0:U'\.PYA<85E--5*FP4]J+TT(I3BDV0)G>W?V?^U"B
M9],'_)L;[;*G75,)TU8=F+0:$A-AW#H-1FWV,&QS)7QAT!9.)$._K0!Z;770
M;9L+G;95T&K;#8VV\]!H?1V:K0^@U<(HOEF%L?-0G<#2'HX'2K'9\^D#(F^^
M:A]*Z#SV V(F_V9)3"*,^A30Z].#3I\1M/O,H-5G"<V^&=#H<X>B+PCROE@(
M?>QH?6S$/E:B;RD[NG31)@7LW!>X$'Y%_$XPDNT6Q^X%7LER%RW@1^JS0,5+
MV \&@2A^U8]P)JR)R80QH;],@,9R'0C+QP'+QW- 3R$8^"QG(+"<B^!R3FK+
MDE4#?5D30<V]E#IS*07\($7DDGO XE\)<0Q2#F8IN>>S[+;E0 6E<?8JZL\U
M0.!:8!9A0TQ>1_[UY-\ :+ XC%!KCS#PW,B@;X0!X0B#P!$;PH5@,##"B7Z$
MOAAAIQ[I5EW\NI&:>P,%[?J/B)\X(8EC&&)]%ZW@6"!OS3#;@!R)HQR+FP'W
M+8 =Y>D4NM&8^EQO)Z#81?X]Q%Z!8%"^EW9(>U+VT8Y]# #WVZHVXQ[@XG^
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MAQ5"?6+ 2@4G%XP2,*I!: 2CA1;1KK7HL49]6H4>*]!C&>UE*7<6H=5"2EB
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M+GP3@>L5V'0$_#U@;NYUK$,90F;"\R=!ESNY/QI=JJ&,!5#H-&P6BTU"L4E
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MOC\'FQRCO1Q'C^/$QG%\<MPL$L469C/8,?JJ8Z?XWEW\AK@\\J46FJDR,#O
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M'=PX8K.+Z.L$VXAY*O9###&WD@I=A9SP=RQ!W(D^FYQ#XQ)Y@QD BP\A^J/
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M-W(#Z=\94J_#\/Q=J8YS4)>CS[Q(<AKLTF=21?PUQLT;7 MX06"%@Q5#G9+
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MN#_X%X.] SZ[SJQ#0>9 "_JA2=WH,0;?-! G%<1( ;[)Q#>)D6Z*"O556'"
M0H.#%1(2J>"0! 6%IB/YLH96*C!LI +"NV0)GRK_B$7RB]@JG\AC\HZ\49Z1
MC\HK\@WD"^XQ?IHC^<#=UN#X4^1B9#;T:$JM8^E^"[ZI+R37)T;R\4T&ODG
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M(XT$/%JW;]R#\NL\6%2=O[ZG!I4+^;7G!+5 CPI2?[^' _UY7P9UANJ/\T+
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M!M,7A(.S9<O6K=N #G!WH+0 U(!/0$ (-+&;F)@$*(.4#*B#@A(HY(=&@$J
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M?8&53\,&K_ T#) $ [",PP!-,  5/,LQ"P/LO@<7$@;8U0 'L,$ M7" !SJ
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MH"^2W$4"T)NQ2(T P+(#\%$!0;GH &<$ )8-CD, 8+%]/0( B^V?,, !NNB
M-?BS'3H$ _C# 7 OIQ26?X H8( I!7@5, !\SPP2, 3/%W^#(PIXT &#<,!:
MRN\)&Y>*6^$8AMU#A=8^IR]DE#1VO<"^UO>_2%,=]469B;$1H:>"C_MXN#C8
MH@?F34[*W-3H-L>/7@'<FB!H*SH OC<)$/H;%+%( +J/ M]@#2$&[P$$P!D=
M8(( :*(#PA  F*N%V"H"[4,'#%#" ;O0 <M2B"K0 6NV_PB 5!4,T(28*1?0
M 8N(Z1H>M"+2J+=A@$ZX5PI?L5J+@TD1" >\]T&S*1(+.&#MC0_I?JZ#"KI6
M7N?2K_5A/,1E^,T_.AT.2_\^6OG\87'^[>SLVT7TST>K4\\'N-J8&QQ14Y21
M/"C S<Z$GH!08X$MV\'S\N$(HX<]>9&+*) 4NA (QQR>'7!!5H$.0.8X8( V
M1"X'0E\M6A1& )ZB5V&* ,#RR6<0 %AVH @7#H E8OL1>T7@B^+P)5)$^N 2
MW".$+TAUP><'1-[\/#$Z@!8.&(%+ 0>LW5Z?QXAHN:1UG,+R,+R$?2\X.JV@
MKF7H#<)]P=)_&,T_'^YINW_K1EU565%!?GX!^LK?K3!74_7#HKSLC+04Q/C;
M4&9!A@88WHX8-S"#$D("T <OAD"J#PU0B02@.S'/$0N<4!*Z$$<0 -A:,#+;
M XM +B, 1] !#YC@ $F8IM7@ #9T #*/0@P#Y""6<F" $?5_ %@+AZ>#X8 .
MW7\ 6,O[O?,?CTY(TQG#9O14,;DC%FXG8B_7=FQROM$L]F"C_QLTV]E0>B4U
M+BKL-"H(<G:PLW- ]V(L%028J(C0'J[H6RA/(D8>+(^"7 *!K8&LB"(  NA2
M(K9IP(-_^*MJB'%QF^8? %XC@S68JA"KK'# Q2W_ -# !0? W/@WB%44^#O[
M<50P0!,,T Z?'S)A@+64#2D,X@.*=HCW%^9#Z CVLHLJ&CJ>3*SHQ'0XRM3E
MXH:'(]/8%^6PA*)O']_-OG[Q='QDH*_W4=\P>LJK.RLRV-/1TM3@B+JRG+2X
MB  O#WH>I8^%!+$(@EX_ACP*.N#$/P)4(@(MF)<S@=PK COLP@H!@&V C$
M8)O1*Q"+J+"7^H<0"]+P%^:\X #X3O$K[#  +-FSU@^?8@1A@+6DC2E.<@$=
MQ"+J,R]2",+9O9]7UL@CJO AAF,DV]W=3L9F5=X?64"680E+_QQ]?=;W\,Z-
MVLK2PKRKV9GIZ1F78:=EG+$Q4).3%.'C9&.DHR(EPML&7^%$[D:#+6!V[D,
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M084(AV[CB,B)?<MOVEKLVJ+6I'0]HV?6RJDK9!*7G?T9[LL_''@9E^6F>%6
MB_7<&H^==L&9<D4&Q>10TVBP&'-\N,:N4;87<%%6+FY>"&T"<QFU.YN\B(P!
MB 7JA8[LGT7@#YB"0M,/: +MVJ@B,#NOA&T/BPJ]NI]S6>^K/]^@&"^R_W#$
M9097,T7P3S)4I/+NWX;5KLPJ_7@FL'?9D&SUU6VAY() C@@75[F:N:6 Y,H]
MH5E5.4,([R[!,%@4(!K&=;Y+)/00^Y/4X#M^M9*61?YO-(K;5W/%;9F^7:;7
M*MNN;9OCQI6%J>Y=816IZF4U):>QG-_R=\S):,\23^B1%PQA_*E;=ZK@[XJH
MQBFI/L^$B/98R)6G3/D'_)]H\].G"H\7'O.#JSYJN?]&8_QU;7<N]5WN[=X:
MZPOK2Y#3M<H7<V+1T9B8<:M9.>7[:G0X6)S9?JYL9A]AI7Z14CPXW^LTRC70
M$"P&0<(I^6-TV-,77G>Y"_*5FAZG_D@3Z]5@JDZ'%UH*W:HHR'B)8\X&K?M+
M8,ZV3Y9S$N23EL3F<BCY 9F";9XD2%JC*0+!B@M6]?K6<DK64K/M\]ZQ/#G!
MB"B]8#Y_RB#N9E6X#DMM5#0@,B[SV_"VY'^KX_S+;NC0C[M_-FY_?O@>'O,7
MAQ=91'IE%,HK!+;B!<(]2[W(D6G7X"_-)D/QFR;Q=YKSS<IFJC9FJ$3*JE$6
M=3%XTLUK*L!6R#)6?4'UH5GK?%B,9_Y4:FZ-?>,9@<H/-\@O>X:XU3C$*PXO
M_SAL2OXDQ9?))^R:V:A?KUN> 7$>TO67I*OW%/:NV?,$65B)>/T/3[#!=6;5
M7RV#)ZZ#IVT/O$@LZ@4JC98K2&V]+"*RA4PN]VY!^,K-VST/58.M>5172E^L
M+;S47^O$KX^7<SW'.B$C[''4<[[N6P,BHS#\YS05N11#>O6+:%#-TD0'>.O
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M[<LUI-.+OQ&"U->HO+AG?K7@0OU>ZQ(LMUA+OAT;2ZSM46!=HQ;*%P1GPK'
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MMTT6DUI/R0XRF_I>J3)[>A(H'4X6RTW#<A-ID="7>1U@9+ ]J1E=!*7$(@N
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MG'D^<'6K:K'0KA\7NI@Z$+J Z"<!]!C$#@D98))>:Y+I>7\,]IM\-F>%[V1
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MB#8$ZRCS]$,%A'7R2GO+<8J4+9L<L@:0:M(0U98.&NOEYY43Z92Z,RT";:5
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M^-J2(DBWGU,=; @:YPXMQY&;C-D8<PJD%^R,9 Y/<)??Q%'NL#;$ P,;-A:
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M4(,6YZM:-%1IJ"QQJ+[0ET4R((*Q$ZG@LP,!R(G4Q D!$<PQ\?-O])4&YI-
M5:J-^JN".;3OO&9G87P^;#RHPVBA&E(<0<A+J@>:!49>VNS3WT=D6U8N)SFY
M,XI?F>4:W91 SO6HSM M_?*VG87I-JAG$\C-S%M>-):Y'<PS6W2K#"M"-"V5
MI1= "R'CUI32/"ULC%5H=]B25Q&$7ZW,]V+;I^CMU).16T.,I!=UQ&I+Z4W!
M#^JMB!]JN_&E8Q@V)MSR@_4PPEW(6RK3/Z7U H#0:/"FP ]91;0ZW!>Z['2"
MG\==\'X$)2J0DK\E>=4@QQ:)085AX8UV<?$33C%20:1?0.VBZ&F.%_XMPO8S
M-P86]"AB$\E@[(\CE]01UWGYFP4+/,D1?F-*[/=NJ]7QL2Y1?9PD)0;DC.R&
MC8+AK\740"\4+9($01Q.9NFOQYF*@@,M@!;R@L N27 /4+)G1%DNIAH >*S^
M?]A[ZZ"XFFY?F)"0! T2W-T=AJ )[A#<W6$&@@P$EP!A<!O<-3 P,,/@%H*[
M.R3!=0@0+!#(]SSGO-^Y;YU[WW/NK?OOW55[5]=OK^[5>Z_N7MU=O=82?!U_
M96L=X\CV'&_![O43/).1)6324!9%,L68+'8\1$%#P[&L<%/^8TYIB2#* R1I
M'E!%\RE7=3U3 ^)53#G4&>/KQ?#@T%;!;>*\3#'XE-,[TIY"RK%";:-Z.#5,
MP.ET2!NM<Y^&=27-71]Q<W352J"7;A7-&6>M$1X_KM3$YTCQM#6"(4N0(4N
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MV<XOE[)[]5$GU< 5I-(?!ZN+2T>E0IJA!M^,VL%8O+%',,2,_FL6 %IL_\8
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M%AOENHPMOJ*8C>+U5V5#G"9:7+!.1R<*FV0-ZFQSME&:<R8OSUFUSN!?I1V
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MZ9>:'5!BKE:SE%'1LOSY7=HW?8T#3$[V1S^K.OUH6>-'JINP'@06]:F:ED<
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M22N=>U'3EX1>BQ2[LR>GMVX8:<VH@"-1\V^8;:P.!^OM=I&]/8T6GK3NRE9
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M%/S2A$'3EL,50'&Q3WIDU<+&+,926VJ#8J<5'.S@D<']I%/FX/W2985NBAH
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ML-$_8.;_&WCQOZ;^%RS_@L?_AC.W_F#\BU=_PZ+_# _VF]39/>#^[W(3_3^
M'0/_F:N!Y?'B?<+?)/^R8O]]??_;O_?//!W_BRK^.\GO7_]:"O_B2_^%</[;
M_^+T3SG_!;D3<KY4"7_6N1_F"]+=\V<;U]%L]_FU)_3QW+E$ETTKX*-$]&XF
MS5;6P"1G0M[.?WBH^K<8[RUV!%V^<@&2SO<.;_'L8_[72[R\W0TWR:F[BIG
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MXH B8ODUU%0#/-2QX:J=CYV*YNIH^:5C4BS?V;"@D5-<P MSPG'')=8%:6Y
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MXJ#3&80S.IMSR"[*Q5J\G8$0P!*P UT8!37+%AF%3JD\<CPOA3XVP\UKP'[
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M-VZT3-)>\\:<XJKL&ZNFW,\X1Y$3JD3=L,8VF$T3+/0"]'@#'1T0_B?MI*S
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M%>)4 KN\+.]P_+"%%EY4(]ZXDW(P_1]02P,$%     @ EX!^54:X9D'DZP<
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M^C?Y%]LD,\G^;RO\)7]?0(!T<&KJ[U !G9@,<'I<SO\X?V-!=G^&/#GH_V7
M ?]C9 *>?XW@WV$$_S5 ?W<G)S4Y-CXG+'77Y"FF\6_[T9[RJ0LFZD5W2O'U
M_I>V=1.S,\"9_V;2R<A.3DS^Z^JY+602VCUE4^M&T6!0QO;X]/CL:%!\W%3T
MT,P_+_[3?U>>M$QZ?-,2+?X?]%\3G)WZ;[>0J>3_N\4_)_'?;S,ZT:F@/=&)
M_V:;$1NOYN(A(-^<'7O\=_UY(=/[T_QOE?63,K)A'JG)B7]F:N;OSN_XTSR9
MW;CXA&CPU)5,/S<^&_1?JH?]:?[WZ@8QB5X9J1G9_Y+<6;\!S^U_.2;#",A(
MG]SJ@S(RU;>KG/A_3=ST5'4B_\-J&#-U2?P/NT'VY(7O?YBGSJ95O[G)X>SV
M#OC;/F>J.'D(-:?TR1J \<$_4J10+Z'JXCUU\9#:[@',!S0FKD^\!@P]XC)B
MXJ.\_(%I$V^ &5,:$(>9Y"9N @3 4$]/3U_/4%_?<);!=(-9<V<:&LZ<.W_V
M[+FS9\^?93@E?VS^NV@8&1@8S3 RGC'#>,Z,&3/F3*YFS/F-S/K_T\#$46"6
MGCIXA:;&,F#:+ W-61H3M]4=G3XQJ.&FCE);8TK^2)PFH#%-2UM'5T]_NH'&
M_W2J[P>:?SJ- 0TM#<UI6M.T=77TM#4--ZB=LS2UEIK8:7L$1<]>EH6UUYG#
M+6[T7+YB;O"QF T.V;@+7KJ6O)!W]]_'YCC.*VG"6WGS]\1MZU>"G$POACZ(
M_]!,&+@$?CCFLU)02FP1#EY^]+&L=>C*XT]A";DD47G;\:M//CMO#T_,(XLK
MVH>O/?TR"Y@V31VMUE1,NCK:CE,A++4ST5)'D+5LMK8]ECMG,H)CP1?>;5@1
M<S\;Q_,*F1N;X_#>4F<R %TKQ_Z+ZB"4IG';0IU \0_^"N%_'\'*OT.8& 4,
M-:?V.0MP SXZVY\M2]AFTS:2$)0P>F:&XW6?NWE5'W])^PI^?=QU6/9R3+<V
MH^U]^VT+S="9H^=_W8SHO+LMM'Z)Z8;EJMC1I["8%U_FC=[SF-OXOJ?N<QKZ
MJV6*B0BI= Y'[]!]WMWC,@&<\O5VVF(&CYP )(GC_)T).QY<5;RT1[^('++Q
MD-M, %LF@&\K>G0@?3^_H!_QMMDQ&@>J\SX?N/MC['):LVLK_Z#C]??&EZ*3
M-O[HN<.? !QGGT^D3P#GT..^?_!WOZVH#7VP]\VI"<#GW-BY<=[.W/#O&R>
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MMH%]V-NK=@SXWO;[LLO$WSK :W=$8$80*5@6TK3G9.C=L,][C2*6[]NX/^A
MPD%()"U*>J@VNC?F7.R]N/<)TQ)-DI8G;SCLF1*<&IF6F)Z5 <O$9S&R!3DR
MD!*LRFW,:X?T0 =@)^!G$&>19U CZ-.8D]AAW!"^G]!'[":UDYLI==0J6BE=
MSI PN2P2&\[)Y,;Q]O)W"=R%&T16X@420\E$_H>"1]*KLA.%W?):A:*(58PH
M.:P,+]U6MJ'<HF)&Q<_*%U775$/5S37%M>PZ9'U*0T3C]B:GYA4M)JU Z^NV
MT?83':V=RBY.-^I(2D]$[_8^QZ/+CAD?&^]_-3 Z.#S4>EPYS#V!.IEZ*N*T
M]\CZ,_//:IQ]>>[*^=X+%1<YEZ"7HZ_X7K6[-O\Z</W)C3.C33<EMY"W8^YL
MOVM]S_C>Q_O7'W0_E#^"/PY_LN'IC*?/GAU[7O BZ^6.5XM?O7L]\$;T-O==
MZ/L-'V9^>#$V\%'V*>>S[Q?S+V-?CW\3?H_^L?K'RY\5OPZ,&XRW3.R;F%"/
M@F>:%=K6.@3=/KVGT[4,YADN,C*?L6CF F/367-,C&<;S-&:\W/NV+PGIM?G
MCRRXNO".V?U%]Q??-;^YY*K%A:6GEPTN[UW18=EL5;=2M:I\=<F:HK5RZ\)U
M!>N%-EQ;IGHTD#;@';".:">T,]H%XXK;B-Z$VHS8@MB*<$.ZHSUPGD0OJC=S
M&\]'LKU@A]2WT$^Q4[FKW%\54+^[); KZ&CP<,C9/5="KX7="+^Y]T[$O7T/
M]S\]\.+@Z\CW49\.?8W^&0O$:<9KQ$\D_$S\GO0U^=/AL91WJ6_27J8_RWB<
M>3_K3O9HSE70&?! ;F=>/:0,*H5QX$0$#)F!BD/OQ?AC/7".^-6$141CXCCI
M-?DFY12U@U9.%S+PS"S6(78 9PO7FF?&G\[_+G@NO"$Z*>Z25.3S"S#2--F^
MPAUR)X5ET9QBK>)/)4^4UTM/E?64-U:45TJKN"IR-;HFKS:C+K'^4,.^QCU-
MNYMWM?BV^K1M:_?NV-;IT[6CV^](0$]P;WC?P:.QQP[W9P_ !PE#M..<8=&)
MPI-EIVI/MXWTG3EQ]N*Y6^>?7'A_\<=EG2LF5\VOK;GN?,-[-.AFY*V4V] [
MI+N">[+[)0\J']8^:GK<]J3K:<^SH\\'7EQ^^?C5IS=:;TW>6;RW_N RYO4Q
MX%/$Y]@OA[^F?\OXGOHC[F?8+^]QFPG3R>,_35OSNG:2SG$]'7W[Z<$&\8;9
M1I 9L)DP8]@LJ EX=N:<I+F1\X)-M\UW7K!ZH8/9ED7NB]W,-RYQL+!>NGS9
M@N4S5VBM^&;YQNKARNNK1E8?6].VMMI:L8Z_GFR#L,VTB[./V.#OX.'HY+36
M>:G+/%>#C<#&SYM>;WZXY>;62VZGW0<]>CS;O9J\:[:5^Q1OE^T0^PK\.#M9
MN^C^M #J;DH@)8@:3 FA[*&$4L*HX;2]] CF/O9^[@'^05&D1'U=*(Q6Q!3%
M%L<IXTL3RA,KDBJ3JPZK4E2IU6G5Z=49U9E5697993E*4!&X,#<_3PCA0ADP
M,AR'0"!S41GH9$PT=A\N"+^#L)7H2%I+7DHQI1K2IM&^T%\S'C"OL\ZP!SB=
MW'I>&5\FX FI(HP8(LG,/UP0*XV4112&RH,5@46[BW>7!"J#2T/+(LJC*A(J
MTZL@*EPUJT966UW773_2<+=QK%F_Q:+5I2VH/;6#W%G:U=]]OT>C=VF?U]'X
M8^1^U<#9P??'YPZ[GH@\B3M5?OK4R.NSQN?LS^^Y +HHN-1T^=R5E]=TKIO?
M<!K==3/Z%N@V^8[D;L6]YON]#X8?GGETX?'%)^>?CCP;?-[UHN:E]!7Y=<:;
MO6\/O-O_/NS#KK$M']=\,OGT^?/5+\U?F=]BOMM\__BC\6?"KUF_FL?]Q^]/
M9$V=_S<TF=KZ.GMTT7HB_>+II08*0[X1;D;FS"CC7;.<39;.UI_];L[5N=WS
M%*;X^=@%R(4@LX1%H8L]S*V7F%H %B^67EK6L[Q\!<<29A6W,F"5ZVK+-<9K
M?JU]87UMW>#Z1ANY+<,.:I^X(=3!V]'>:9GS+!<-E_>N#S9>VC2XN75+^5:)
M&\T=Z9'A&>,5ZNV[;;./[?;E.TQ]#7PG_,9V/MMUR_]\P-#NSL#:H.)@H7H<
MP$+3PJ+"@_9Z13CNL]H__X#^@>\'7T;>BAHYU!-=$R.-I<9!XA,2]B1Z)MDF
MFQ\V./PUY7'JQ;3>=%6&*!.7E9H=EN,.6@TV ?_(?91W!M(&E<-(\'1$&'(K
MRA)MA/Z(N8GMQU7BF81L8CAI$]F"HDUY03U':Z9+&$AF#&L[>QW'A/.5>X<W
MR%<)N$*(Z)!XN\0F?WZ!1L$+Z6597Z%*+E+@B[**HTIV*]U*;<N6E<^MT*OX
M53E6]4+UH/IFS97:\W6GZX<;!AO[FXXU'VOI;QUJ.]%^IN-2Y\VNA]VOCWSM
MU>J;==3BF&V_^T#P8,(0[#A[N/Q$[\FKI]Z/&)Y9<W;[N=CSF N*BWV7[EW1
MO+KRVJ[K.3>DHX,WW]Y>>,?G;LZ]XOOG'DY[Y/\X_\G39T[/22^NOUK[&O/F
MVCN[]YP/;S_Z?U)]T?JZ[UOU]\\_-_Z"CW=/J < 1OU[W((^@]XSXH8N0PTT
M,= "5+($C9:C=B$?HH^A8F,\T.,HGG<T!HW67A*''<<L^MF! M&ACV:BPJE-
MIVZB=E/F-&Y%'2"UB&U0.*(4P4?U$KH./4?/Q'_T M B/&1Q">81_NYW)=)2
MK/=@!W*1P.[D7J0E%U9_%KF3;2Z\BB0QC> !R&OTS5$M*&<JU>,TZBAEW2(M
M]#G*K*]]"-.2AGLXA*G\Y' 38JUT3MTVQ'ZQ4I"#J!:4PV8@#;E/(H7(//9N
M]S;D!'/=0@9JD'[RBSY\>QWXSBC<NPIVW Q^L'2PYB)<5)3 -X:_D.V#C"+V
M2[H/4A#GA/YNG<A@'GW!9N1QUKM/1)BJZ^#M")BB9<=@!:RYCEZ-@+VKVL)]
M -]5&I#7!#^JZ#I 1VR1LK=>0AR1Y,XW1=SD^'YT@=D<S[YE!#/KVS00 UO9
MD:/RA\4U.7'NPD[69.5>A'M7&.^O@Q\ML=UJB-BDF&FZ"*'++AI;#+UP\<3H
M>VC+J>A^7VA'/[/*#?JN.YK]%!;1<C97!W:[[OA^'7AD%7E++/Q\Z:5YOO!@
M]JP/:Z",NX0;OZ )5RX="X4>&GE3&085##Y@SX:.]_# .V&D=MU]R7##QEN;
M1^&P*LNY<M@)5N'KU]39J+57410 V=A[AJR-#"]O)=DB-[ 6$@G(':#SA)](
MQKX4@A3Y; N+H$#1Y]-),(S&RY/D.JK>%8"D)"-[F,1.TM(R%.$K49-QGA!'
M6).#Q'_$4R)FXBOQNIM=\1VX>_.^$?,(FL]_D#+Y7R^%$/.XX"/&!!E[0>D<
M_"?F;#H5#Z:'98?B3:E7PB=PURF(3=:XEV3!7 H!3JY\%DS,D7^]T$3 2[%=
M:'R39%-),7Z&<"/-!5?$*\Y:C0OD>(5]P9FQ%FUTP*UGB.:XX*FTDT].$%2J
M^>?M\=UEM9TZN/?%N&(W7&AA*>4-]F&!2:8!5BEZ&C8-"^9/N(9@23S#V7-Q
M!8RGCV,)AJTQ9Z_B%S=HMK?B@E4OBK2QG>7KR5>P <7'TW]A]0N/A"[!/"S8
MX$+%C$E<3)9@CS \'MG@Z4='S]3@9%VX-A[V; M,_A'K5'>7] QSJ:HAW0[#
M+WV]YP FONBZ\VT,2+YWUAZL)KW]X6K\BA'A2#W.:6A3JP0;W^LEU\2<:C]-
MTL<D-]Y.R\-LJ&&&',?H588Y^V.F*P\8UV%2Z=L?!.#.7^\^/8I]<CZ@91 [
M^T1TH2,&=&P.,0!CT@5+O8*^VW(F9#.ZJV&'TP7TD3)CXS7HC[0WMS?SHA&2
MX10.#.'5&,9J0A@7##,7(F;AQ?1VA&^*G(9#- :#J12DO1.+NA*E,<N>?A5]
MYZ8/=QWI]'%MMB>1T+"&B2=DY#?1?^(Y.#RM%O?A,(/*Q%&"(BE*G+LCC.*+
M.V2L19/@23>:.0!WQ6 A:QGK==TO1BSCK@1#>T^WPH92FZE-R8<IY11$H!_Y
M-#G7(9<,)6O/^$X-(W5?W\[6D_(&UC/M)?!:+)TD%(O-:;-YOS"FE&><WJ00
M\A/6D=W[R;,9$QL*2?V,Q3/F4%91"5>?L_S*YQZ[P("46-6LH%V6YP@O4I.D
MTU%/*/;B%XD[R5N%ZP*0I S>B/T-TB+N,:, LB5EXDH%L[%A^*B4_J &4'VF
M;:W($[10KBH]D _(I8H#"7M)%=)1_U;B;<DW>VLB3?S!L)*TD\*^S&%NZ"[K
MX]$3V[2K/E#[&\KYO93]U:7(Z63;"KUX.<FIY*F_(3%*46]72#0H=#,T)XHI
M=I>4C-/'AWN;Z9I'?:OF42.[YO">DC^V^"(\22/U6G&?B;=4>;O(1.V*>+L5
MA)+BC09U1"WRDXOW&-D7PWM^T!I.O:\\2#4:N,^S(RM[0N"%)%@[(BZ92&\:
MWF5$Z*E+M&TG'"AZ9Q!*8)&K1GY(/\#W=_#SM\.7*C^+.N#ZK#N"0W KZ%S>
M-C@D)ID3#__FE\T:1?!M8EF.2-1T%&<)^NCIC04/"+_:$R3+\4^5&L)\W$_F
M=[X_;B=D+=<+>ST:P09C"WQ1S"]8['HH,QS[4/\<2XK7.WDI_RZKMFV1V)+1
M7_Q8(*%]9=SG[:=2\Y9R(BE[#N%9<G+D#@ES#:EH706#02K4=V1N)SX[42EY
M*F&U/!1M$9XMJN#W\!WHW=QLSNM<33:)-1&%9EYD!F]O9"30?UC?H8_0S^C5
M,Y80[PXC)-8EI.;C0H+\NP+.-Y#6T B<BQ(5Z!7KAO!C))MIQR_R>4,?X@Y:
M;Z*OY/;J;:8O)7*/1XFE-65-38)/E1'R5!ZJU(]*X/@5,4$:K)#"Y0<[&(4%
M*WT\Z [B+VOK: +Q)MV;M%W$P*$$L57;J\:3 DSCG4(J3Z]V!D7%OE)9D./.
M?%S*/CB;85L\>ULCK45^:>U&FHGTA"Z=*B4N'.2)!HY!&G4%YMUELI/<BK9Y
MY#?L[(8WV6PFL2;T )(^6IF_;2OM0+G'FAO42MDW73^J >'-P -1^@BT(9%_
M:NBZ;!4WK(](#F O[VS.&F<ZM:@.:-*9C;.]K] 6UGBN05"395VZ\RCYA-,]
M;F7G83#5HI(DF+_H@F(1;!M^CDP/EIU>F.\"NQQA+6J"QWF&"$H0TU>.\<<0
MO[14?#2ZO+NY] %>4+6F>!].)IHKGXX]CSM4\ N[->VF9"/FY=Y883_FK >.
M?P1S<Z4#WP +UDKB:>(*NBC*EXS^2M.B)+J&<$7A7&HZ-J7 E+(Z];WX('EE
M.$WPEI3@?H3WAOC,BL5S(>W7LN&TX"YW(I1FPD_EOQ1*/HP_(8O@NF*B\@/8
M&U(^B0J9W+!:@0/#SGT:SX'N:OF-FT>_H?F+S<,U=8A*0A5)Y=/ESV4;>.-2
M5;X;.DQ2+J*G: FO"]:'WN C>&YNP5P4YY5E.J>/&Z9YB96/$[4KBT]432MS
ME(>6S>6ME\XJ3D'A)+/D"PZ["L.DRT*7\5Y*:K8.<%Z)W2PU."M%!IKUS!,X
M9-OIXO"FGM*TPOMUYMS4@L*JX\A3XJ*R"\DBP<N2X#TB'D:!W[J;DRK?LZ*&
M7209T>0R%^*2VV86C1]I4QXOQ+5'<TX5;&DZ@+06N]6.)&L(6%7W]ICRUE48
M;7G+,2D=6!'/MI5(-:$,)BZB-:NH?MA:N;EPW3%3CD?^B^XH1)GH79M;$D7@
MWF02TLR]5[]=_=APL:IRQ1+61TFJ9CQC,6Y7G7G]./21;'7U'6@;S;CB#K0I
MCU9J"GT2M[U( @O<_:TP!_9DXY*"SW"FQ>H""2(+ (27T*=JSM:OPN&E2:I'
MV'PJJGP4<R_WAW(V)C:V4B'%6.T.D:$QRUU!!=J874N*\T584P 0L#! ]=VZ
M+?3U!;2J<2J3TE/VFK(PUZ[$EO0CYI'\",DB0"$M)[)<KN1;$W<N62^I)OD
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MZKG]D:+R\L$CU82K)6WM6=DQ\L]-WZ-BI:3ZKITR";AVB1-<>+OTZN(*H;[
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M/-DO"@;X0(+[0&FC7^ R:%G_+_AGZ 45$K$7MHB;B1B T?*ZD9O@\PY\1@[
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MY=29[#I>7XLLYR@GM; 1=(&UBS0+_(21F]:4^YG6OV=-W@?J4N=Q2!.YW40
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MD%]-%LLZQ; \<?Y=87C"2;$-/R341M#.97K">5*.^WI#[DK.C#D\WARF>NZ
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M0M6R@#TDF(KJ.(]\2\ ^&(!1=3'[*K&E;</5IW'>35]%8-RK^A!L(?ZLM;N
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MDE#?HT*U4S#C_+,T7,Q)EQG:FQ@! *=$XT-&%$IG6(*[7WZNRH#OR0[0.1"
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MU6<9FQ<-6L(9M9X^YD*&W.F<^>'O=W^S=ASSS/]1\VO'\'/7KK?B^)@(CF6
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MIRQ/RBJXF6X;\@SEFK5IQ^(B>/9YRUAT*DA[I1]F(>C:G$EJ$V33C+?"1I1
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ME*=.4W;*S_5[4&#2S'(5I4ML37]#G2_<#(VD%O.71QVF+>+.<?.A/65U?7U
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MM%RXA6[0UX">IMUOT\W81SM6\RNHDW9>D^APD_9#>.VVH>(^N>_$:]D[<L[
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MRLC_$N6$RLL^AXH1=%]\(WZ!O3ZF%)%Q29T'A#:X6Z59_-]X,K.=]YC@A[C
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M+D/"+] 3(E]Q(:7!>PS9(Q8YS.2\Y5),YYMGUF3+6NN'L<W@MSH1[@WNB(%
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MFP9/$@[663?8$AOU[R632&K-"*V-W*9DE?A1[LC"TY?2O$3O0OSHH_R,#>L
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M! -?7N_&N\"IP;(&/VE\2F;WO%.MRPYKWR<_E)+5G"N-C*PWO1#=]M^LWRY
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M^.4 7T$WQU[69O98[R3R(E&C648>%4JE)90\P79F"W4^?TFEAOJ8>RT[A_8
MK8N#Z9^0+7Y3@0#.9T<=<Q=4T?V=^%7]SL0GM:OF2$K(6^1?@7[*8NF)BMV4
MKV+IMG[:9&%:W"2Z#W_JIGT,(RIV_,\I.9>Z;8D+S6OJ!HCGC!5B&8FIKV0\
M($=H(C&_*3[*Q=N64S.D-V)--+4(V 0R%O">.9* P\C4+AZAK,VZ;CK1NMD@
MND.\4M_%\" 9C"@FBZS5;<D244ZK%L7ZT)9)>S?%TUN$XQW+@&)T;M<:_(>^
M]T8IH;=+($HD;K8TT>M(\QI)Y9?)?]4%9:VFQ&L_QXQ1>Q2<33/I":)SCCG
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MYN3='XC#)!4>K$^MI)6(Q4>J#>6)M*/8HY4+2K2$:=7OTNM)>-R'D.?4M:0
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M[ZI&"XA0\P^XI'LZ?!5.ZIPK'0_/;-O!N !]:YE<QH%'-M(S9\$YUM4Q0GC
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M/6O%A_)J.U=)S<E_VO1R2>31YGPE'A!H&ZO>Y$XSGP>FVG\U[(0L_&WS(7D
M?5+O#44D95[W)&5.[J\.)Y4Z>6OK+/6^R"5-@[7. 9'6N\ B]P[342C1H5Q_
M%7[)C^@?I#U,Z^\1 %GEZSHW &=R;6VGP8)D5?-E\&TD8KL%+0N(M%R%>>Y[
MC7>15(=5^BFH$^]4[S4LFQ;;G8,5E5,Z6K&HW(36S=C4Y+"F(^BO2$[#9?17
M0(SY%3;2_:YQ.C;'X8U.@@7PA#TO# /4?[M8!I_R&>VK]8K<P2TG=0N2OC<^
M(2]'IC4,)6<%I)L="9'[G_^1\GY'5_(%/HWGWN/5L)^ZN7.M]7#9M;;W%F[.
ML99QIGM)QQM]C;61TZPU^E<!X2:=KM'#3G^']'8L(B'\"O==]Y+6S=05G4XM
MF66GVRJ:HG,V-U,;;B<=M2DM/9%>EG4F>4"!\9.![1&F%^LJ'56D*R&AKUUS
MJG9V!;Q23KU>$#[PB+$W[>*B#ZP+L=S^9;Q9(1'=\X3SO;>UJ:6YSC\:CRM3
MYW582K2E]&FKFYD'*_Q7.+$>% Q;RN8&I.U=6,W?$"OM&RVBA]1U-DJSO7^U
M_%14NG!L'/52.U_S=. ;;>_*NWP7RI5E"L&>_*.+#X@T:=;Y.R2\V)H>M<P8
M(NR8HKCJ$]C<KTYP.=K@H[UIM]$T!)+3)"MF2\LH\-(],GD^=]$T^:JTXGYG
MY:C8Z*X?JM808=LV3:Q/>5,=,-AUDG4:^-3>P3@-/DIS7M:JUE BEB1J'/,]
M%RS17$Z;TKM3VQ[KVKD,0$($K3!H\%$UID/S70LMSO I>]20C;RCWAFH@5LI
MHQ>/AT_E#Y\OA=^D?NJQ(1-CQW7HD*P090L7&?#IL!6BXUU-YB*4L#^O7XJ^
MIRY=RB*!\I>+II&)>>_[E<3%U/O=[41^S,_V3OQ!B++9BIM]MC8@>*KK3M,2
M?+C#1/U,[!15M62EV:O\QL)\$Y;WI&^E49-ZK>N((2OF;=L9O7\(I^FZSLMG
MC_4?,L[UOFD24>Z0HEN)H]2*)3,;!\HO+]A@,^8][/W/^B#U<M<,RZ"8?]L<
M32$AVJ9P ^ESREJ@>^/ZV;B0Y#J(='G$I.T5].V5+Y9_K:^MI71ZL[_0=NK.
M\6SUXV1_A%$<-FV09!S_G_PT^3BQ-O:VJDK.\94"H]6/MLGJ>/4ERQ ZD[VS
M_7Y],F\&N99C)U!*?_(GB?ZAVHM\I55Y#5*-_&=LC7**ZKYOFG8\X+-E534N
M'EAZKFZG='";E'Y55DV4U;^2'Y5<YLY1QM1Y"P#5B=Q+DM$:0<PS^1L@P==1
MXPV5;GI<\4)[;,FLFC+ N^4L=3'0@7UGO )'B)>P*T%;;1CO"^2<:R<Z!AV-
MT<I>P(3O(#4#J=J86+Z&/+*HJRJ53&FFUNXA#J(+Z?Y$@JB]_@Q^LJ:,.X S
M<V#A.NQ/S"S92&R^SV/55BQ\_9/2R[95"ZLJFAHRFF)KW"S7D#;J/G.-<#$3
M-SZO[N>@!C#[DV"O?DST46DF:?0YH[+''ZT[5Y+?Q5I00W'OL&\LKKK2NAW>
M76=L3A;<80AMEZM^LINM==D&_@?3K6B=9*4AQ&>G<@E9M?9GL>.B9_/[R\?,
MWVSKK3S6FP^/JS5U_B.(H1O;A%5"UMFF+]EV_((&1G2.Q-G4Y[-*&:U;L%9>
ME+EZ[/R993'+;MBF5'Q;+(=,-?OG#^8?I9WN[JX:QW)K=\HZQ3O<9(B>(-YF
M6>?3KWBN7[OZ-F]LY=J^'_S?M:$-*N$'V@(H1OR6^2]?)QO&*:A<K(CGG\X:
MHQH0*R(O:8OE2J_U4*5FT*I*UGMF6^\=;@A[KE7-9W+;P"IACV (;X_XN0BH
M^"%C2L=G-B@GR(]%ZC6C5<>]%H*50,"*,TQ745E/(FNY^)5E''><5 F,Y@.R
M_[@+1<,57163)8=4*1EWY>LU8R/M52^ O[Q: !44OSR<ME+]IFL3LT*SV&1C
MO=5F:BYQ+=HWG$9!(;"0$B7. &D9J3(I%!1Q0OD"MO?2:]<BG@/[ZW"<VUE,
MK\33C?'UL_ )Z@[V'>PT>P'O/-98KA#^P:CINZ6U6&@$K!R#3? "-+_1%TLM
M-7LL%SL"J5O,-PQ!C&;3;E4_2VVTLO9S;8:JLO."!_J@]#2)5#<R(D:12YSS
MDFDX.+"DO3JS?4)[1AVE-5I?1L]L#E%>J,]JG,(:R2&L'\MB^=_-9]->BE<:
MYT>,EJ_3YWOQU:^(&XMO5WG,G]3649O:6Z<;H"5U<90>S*+V@GH^>VE+9.E6
M?G3CW#2K>(SE9?A=N9>QP:M>K=<-6\RHK%BVMVU:#;3$0S>;"BR(5BQB-/9Z
M,C^S7G?.+:7P>EI'I$6)2-NU\.6R V:E%U4=K/NS8)FTN[*QQ4EVMM:>^$<Q
MDV:1'U&JF?>8'JJWG-@2IL;(WY_R'4@3RT(_0YERW&,ZTJ.9/9\N6L:XU3Q<
MXL-"\/W2#=S1LI/R1'X#HTCQ5C2[>(?JL.1X"J@Y(.\)W0+^I=KJX0BW 8']
ML_F?A=,:=PKWB*YCV\4RB45Z1AHL"Z%C\LGRU\73E8[*O2D3U%7J5:&H]K[V
MA(<WM!IR[]W(;5*YV<KX.O5L-$?(5G^7+!<7:\[14*E0N[8H1[X5Z$\F5![@
M_- (S6-HMT<P> ?^VD-C8^C<AFG<'C0+F<U?@I:+S<)M: %UG?@SFENX2"9%
M*<D3E#-1;NA@S7 4]X@"?=#YW3GUYTU#K.,Y0XTLV(WG9N@3+1=4ZK?6/1+M
MT9TJG"2M()\FK5?XDL-"+JHSB&D>"4 '/JU+S!0T[[5$LK8VE4*5G%>VM<*7
M_##KO;IHX0[+^()&B=(4G427UQMH(1M4*W1"CU1@)E'5>9)1VA-C;JM?VS4"
MW,)^VPX)<WEI+0=K5PKN-?U5,%Z\MR$E:9SLE%D9TJ1R,> >F=I-I+2S@FY9
M+#+/8KY8P ?]V#Z]7P4GN>:NG-I(@6_;HOQ=8KNF]XF'96D-/B$URKVF5(]<
M;9V.TKI>2ZLT&7*UMVLG:IT E*;F>X'1S#/5FZ$Q'/^\V=!G_J[XY_!OL2K(
M!TV0M[JNP@YI_%NZ5.V,%'VNFE;_K\99$\FQ\C*UCGR[JJ^ O7!_KAF,D^#Q
M!@B5\X.&P[]4"UW/HUN @&:-8CC_D6Z:<J+PN-I.-57<QRU3>T@Y5<&:,GER
MSE?M&F5XO"?HK,X,? +=U#:YOD<.0Q.:4J5;%3+BKNR-LD/Y3C%'M9@#*DO5
M*RNUJFV:+3DR38SV8MQM[0MP:.!I\!I4ZC86_@ ?:YPMW@L]P_^1SH2+%>]E
M''@^6R$_ E^HV*+,0$9FGU,/17+CQ)K[2&_@0N [\J^;*QR+EMB<1([Z#.R%
MN$WW0S%.\DNG90W(E.0-RG^*&61(=K'R+=$=YZ#^C/\7B )1>*U;)+04V])0
M*3AG@S!/44F#3%XF/FMUK/\IK32OH'#ELTP>60^4XPTK8I^H??4N@7QM%VES
MRX)<\,?6@_Q#'2JT65C>MD&V5W2KQ5(OE,B:_,N?_"^C\UDB185%$-NG:C4-
M"2S73M*#;A1P#_'46L+[,=\-G2?HZ5TN2Q39=ZUD?A+O;F?_#Z&Z6IRR7.1[
M;+=BJU03+89 ?\U:XQPW!L@E=QO>X\)*'4C@$36_Q-5X$*V:CN IS&VE_G@M
MQR']'&[B_QWU #\N1OPP(DB^W%E G-<DZK\C%^@[@%7(\WJNR(B.YXRAG403
M>>M+%J*$D)'.0F])8J.68UGR!#\(>ZEJ=%Z+;P/\='\@*N^2M@O:(C@A7 0/
M$6VE_@M72^87_PN?D/6DO4 *%9NB:I%/JN=^$O2HMM3Y$;87_$+^"_C)3FO,
MP$K%5$$3:*?,I?J!W2JD.!L*4>]*4T"OM:.C[.']@,B/C1P$/[M,01_#7<1'
M30JP5]VLN0]6\)=KE>"-NE)@ I1:= (X#NU*FP*NAZ,CWT#KX!-^#/@.PG*)
M0;W0\<0TU1YB@>J&6DJT\ =I9A'%M:LT)_'/16[:?KP[=14P'T^+7 T>QK[[
M%<!SL-4N=8@-H^ T)6#)4[FI$LT=O'+5%U-[[03U#B.OL%^SU!"3FJ3=IY\<
M"0'?R9=^&9"2V.("(F-P!795H6TYH%R@S&^NXEY4C6OLJ&E776_H+O117[%T
MIMS3CC:U1R8 U896OT3PC0YR:847$TQ,(-_>_4X9HNCJ?,RE*RO:2VJ\5:XM
M4,%UM6?CHI0!C<AZ-'*B]I;IF9\;:-#_<AF <TA/4&L^6,F5/#8]K3E;_[<I
MA.99\<;8R#3EGC+<YPQ.7&8(Y:\*^TO?+B:\1^@GRW<Z,G7;-?E G[&:;B?Q
M,QQDGJL?;?!G Q5T_4*>?RY=/U'P.Y&A:Q#_&_I6-UT^V=N9/*2"'/>2+8"G
M]HA^#'>[.$VWC+^'F:,+$^ZG;"6/BX_GW"5KI$\3QY+#%:ZA)XF]*KUW*-&I
MG>LTFF@"[V@>$.^D(:(J8JVLFT$EZN0?*<.(2<J\G!S\DFIGPFI\F28FM!<W
M:Z]ZQ^)-8(=3+KX>YFE&X$Z:^<)&[(>62>_#C@/3RU.Q-F!O]DU,  H32C$!
MY!\JPS30'^\T; 7\P,F O47.J-/0/O23X [:A-G1?J(2S+%L'YJ+C<X6HG'H
MIX1@M !]%\I%=>AG[U+T#OK+:1N6BPU5K4 X1B<!#9$;MM)L2)5A4%D!$J-W
MRAZ$).K2XV\C8E(;FH-L([9X5Z+!^ .GV^AQ?)S*$Y8USN _AZVV";29,&!=
M4OH"IIM_9"V#%:;R>#.\R[ W=!XR3>_C78>L(*U.O]!*_+7R!/1W^VF^";K>
MYD_= 9UJ&5;:#&UMM&51H=,-<^*KX'GFK:&#X$9CJ7<Y$JU[ZSP-'4HLE2A;
M:ROM6&N;;]5(JH5-<NJIPBV-PYAA:3L; /:1Z/.61WQ#(&#.%6O<;QI/RX_:
M]QBDFDKQJN80&I4UM?$^<US58YN9=:PPI\&%VYJFL*P7P-&;S)'BKD"#\83L
MIL=4@T15[S!*'P<XB[[8_G"P^M*&Z[S6JAQKOV!MP1%+H>A&VE33;ZE]-&3<
M(&\(Q ULU1R/)'VTYJ$#3Q<('A-%6]^+"6:;Y:ET4*79?%*&%H2;YBM&IRXS
MBI6KHJ,,66IFH%COJXWTH.N\P5"'?60&G"#46WQ4$L9S<ZRZMN*I*4R3F+_0
M:*]U2,TTC ,F1_W63P!G!5;K9D(!'C 9"]<Y_D7@2(O@L6D7G,NH,#Z$-U1P
M#"_@=_F^^@>(7<IKW0.D-.HI^0%9$EA-VB._/+H($5KIF(#?0O\65!KUY$?Z
M%<,A\@#EM?XZ69&W5W>+N);22KXF*%%;R(GXTT 1D8:3'IOQO?A<1RE>B&WD
MOS5T6Y3T7OUK\Q'*/OU@T^J\=O*3L31%20XW3(FR$)FZ9X'9^ +RDL=AW(M8
MX]B#W<<)?K?^0?-^>J8^LLE"$>J*;;OR<LD,:W]*(E%E[HX2XLN-ZP+3\ GZ
MZQX7L1WD%\<=F)'PK;_;%UBQN/I9S\CJ)\4]G<^HB9EOVA<R]B?,:G5B<\)8
M369^CF]YPS-QG>M02[G\N-T(XR\-O=ZI)YT*5_.[XAF>Q7X=L^L_9"YK/<.Y
M%?^YF<)_$<:SW11[^^JLY;(NURK36U6678-A-S"/V=[ESO:INM(1S\TIVMX6
MS,<R8YN_"Z_%;VU<+,D**VM(D;WT76A^H5SK.F!<JUEN/TB_%-S('-8Q6[B]
M*J(M6UQ0-+VE0O(UXVQ3K&Q;/-,V6M$8%F2YJC+ZKC8-:'I=;QM:@!OV#-UF
M> Y#WE:N"*[<V+)$F5G8VW1 1<V@V/Y6 _$NUD6:C6$3S"W $-^U1B/(=!NA
M[X<>VF\G'R-5]/<M+X%EE;'-V6!487BC$MR1\5>#&O*.>VB10!M#_S/)X!+?
MC08K\I>;A^X$LM_^-QF!RNA$\T'L1<7#IE!\4,$+&QN[E[[/*L26QRTVJS D
M](;1AHE\=^NW8"*W#-U4C.L03JS"ZNA>3><-[RL:&XL-NH*^AD;]P738TJV[
M'B<RK=0-"EUNN$K&^J[2CR):W3@DC-]Q8!%AN OM2=/,ALL58ML*Z[<"U/K(
MHDMGF>^83L?)C(^-$:''##/UQWW/Z 0ZJ9N>'$Y.<K#BM_"C56T#U93OQ06+
MVZL#LYXL6%[7DI31QV6X1?9WW6=]"W1O]^&/\:QKYHMSG&H;]LHOSUUFKM5P
M*F\M65LG*;JR\!/=+@ON_\+\D32L9PUG>*2^TX&?'AC;"HD.> XT7I91G<Y;
MTU51\^),$X#IE?Q%2^JW%=7._\U^FN78-Y47D;BCZYI@7V1M.U,L#$QLOB_+
M];QNJU1F._N:OVG4\PX97H/]E:,7=/*O%O[;/TQHS=S0$RBN2I1T3I$610:V
M'I)+ V.:&,JMGK\:1FC&.P.FBX#5+D3_$?I6L:S_M/1Y84=OL=PML[:K42%+
M=&Y'E6<CI[?DJ$L"HQHG:WYXS;'< =8Y[S9>@E1V[7H[Q*<BK:]$_:DPN_N#
M9E^F:V>$%DKXT18,Q$3\:)X S@Q,;7@.S?"*,M^ G9T_&+XB87:/=0(TE/*E
MUPF^4#BIZSSBGO&K8QY2F'"SU1&11MQK&HNL"DRR_D!^>E6;OJ%4%R=#''K(
MWHV\B4VG;.OQ)X&"9YW/R*J,N^T1Q-N$HRVQ1'W$A<9 _'-@@#4"7^!59\K&
MZURR],OPV?95) .[2+%VBTV?"\YV>IIH&2?;$&-QPLYFO6%6Q#4;H/L5F&JQ
MD;^]%,:_R6DN#+T/$6*O)X?AW+5H]:-2[_E!=;\KW&QZQJ2::7 .*X#Z4["0
MJV ^JSHB>,EYEQTMZ1!Z1$]4]$AW^XS0_% ]66VEO*FC]6VL%M.I#<%U]^K+
M(7=&.2>'W\_ZQ,^L?,X[)J)E-8@N2)=$+9.'*$.\OZH_:N-6[BUE<[&>WQ5Q
M?,QRI/H_(0)<I!X6DSP-<\/_$.$7YZK\8.9=8;AJ;%2"]+.FT_NE>@2H6OZQ
M*%8N[\XN8R@(LULE4]FNQ6H%JC7<8OIR]:6*J>PYVG&94?QS0$WD$\E=\*;W
M754X;%J6E*^&DSI/%]^'1<:C%">X1Q-2S82/<*JHM^%OE,SZ/B0N8PVO$VF,
M[!2_1CYY7U:2J&CIE5P'PX<.:^$A0ZQA0UF$'E7'5F[2[6;#=37DS_*5S$(R
M-2.":R-:(TO$#O@=[U.*%[C3DE79GLWR=G/^S\;K^O,E?38O%5"18%6RSM;:
MF8^4SV8DFR:EW^6L,Y1%.HD4.J/W80676+SX2&97S\:V0WF-72YZQ^+<=D+Y
MD#*QY18KI69*4WC90GI]@RU=Q_YI/A_Q7?C4\,I[KV(0^6*Q=X9D"=X6G@LN
M^*I;5)3=5ZV4E#MV':U_5AW='E%&H:UNGI^>PJ8W/(XX)929?GCOE*_1_5QT
ME?%O:6CK%1:W(DJ7R7E6XZZ<Q=?0AM=+13[,MZ5+I!,YW]/\%1["\'!O=8?T
MFF<52%&/7NA-#:A]TK*4,8'VDTRMOU\_1!'#V<,9PMS*W\L?73I:]%D4F'I8
M5B\EPOY5^2N]/!E MC9SOJ7Z'$?;/)@ZB+<,_X<Q1W!<]I:5*'K&Z.,V2:>4
M> EGR2M3'25WE(?"%BB^:?B>/&T56-_WLN*(]$FCN"96'H+54+L4@/0 X[=R
M-[V3W:T>45S'%VHX*5UB1/L@C")_ AH\Q1HS7-7+*9\#AMHF5%X -Z S:MG0
M+(F-_A>DI>VH_P>Z5[2:^PVFI,P3Y<&WP^;)OB J3X7Z,NK:XU%R3\>SOJ$<
MT4U IE1;R5[Q4FHM.8WZG,DB6HIF<?XF9B;O$F;BRT-?R;SQ$$^M.@+;U^U6
M/-@FL0XIG] 0 \=7_K0\%#VI_6I64.,8 ::1A1WL]8;YR2*!0!\0>ER*D5L\
M(=5VPKF+7JCO#+3DEFYL=X(Z*K:WW!7EUEQH(NNVT'UL/H6S6=<LEY/G\/>:
M)*$K)/_JWWJBJERRM/-. 6]!D_E4R8J^I=!DRMYNN?!R];,.K[I\6F7+RX(+
M+,?&Y4DW^9[6_%! 0AJO>.+*[[JBCBI^:&F9J5TXK*(,=!>]K(D5#I,\HTVO
M9<N',G_FKU+F<$<D%JN/"#.#58!-^L'M)KQ$[=WVE+VTEF>D<Z_3FH&1@E',
MI8+QHASVQIH>R2;>R?R1\DS1L(1'JBE2?G":UE_I[O8-LFD+6W$FC:TQC&*]
MY![3_.'2!"/X,_B/14G5ET4VB25/*97(WB:8%":E(MA9_5$3XSX%[ :+6T;0
M%!*:;B$S0?I(W<[Z)"_G?N=N51RJNBU8J0K-W2Z^K-Z?,$H>HJ4'O5(] @/=
MO8"#L%_3NMH76C^RBO92^TK%8EX%FCF/V&= UZJ9O*_@@=Q9(C8DB!^0C8+=
M@@XK/\/?W.. D<C=QJ;J8_ACHJCN(_Z/4LT8A:_EC&(%XNS*"FX#[I33(_3&
M7L0728=C.X,6*3TQJWN^EH_5V%95_K%P<; VU]RMV$0SF%K8Y<PK1F'%+DZ-
M(3/'4>"A]XR?*O'2C0VR*&#BH7N-YCF^IN%[17/K6NQ*]8^6R8J)U)PF?]81
MQC:;>T4PFVIUS%[#+S7/C3LIAHU3@Q3R=[K/[EP-3!QK0"E0;P=64?6].US>
M7%?1H6)ET2^U&B@76*U-?=E,WI*&S7$6T6OS@:!L.6'XVUVF<2<W64;(_B[%
MD!SYW0JI])G2LR:?>4'52',N3].,J1^9N5R[ECLK!@"50IK_=5@OF^2"HU?4
MZ::=XOS:O^!0R4V:O^2)3,#,8GQ6C&?3RSJ59WF63&?U=N'U&'?M:6F1_R'(
M3>GDLAW9IBTSPH(0%@B^%XWG/!+?%=_EQS-&2/<)NTIOR?>)?V?T*=_*B.@;
MFBREE_\&X+5FBLM3> >88 CCTD6/@(U\6&(3K1>:9.[T$/$"^;Y2'^D]966&
MJZ)0/3ZZ5_5!<\=_0'L5N.4Z ;H-#]']9GU6!VH'N$D:5^$Z/JKYC^8O/*8]
M62*1Q  ]Z5;9>Q"*CE2>@43^.LUS&' -@N8A/>0/YDN4K5G/KD4'!&>XA]#M
M5*8@'-U<?%AT$UV?/E>Z'=T>]45Q"CWM+]',09^XYH,P-HCT9(09N>I7]:<,
M[P2S.+F&B+I#O,?ZNN)@X0:=,6VS9#NY->J$_ WQW)^M%A!373G 5SR<,-"N
M-GFK"YDZVT\^R;9K4-5%<<]:CA1M%^PP3TE+$S\SLJ(,\@3]7O\JU6W=8%<0
ML!#QQ"3J\<X^U1V&I7T/?PPKJ)5=>X+SKNEZ417_C2TK;;@XS'(H*D^VT13A
M'ZD2ZQ>Y6H%@<B9R"8!*%RJ&@8,K8$X?N+&FL+H)DM-<"QS@Y/J)R2L1'ZY7
M^"8T1 CZE&-*68@3!7^FKH.7J[-JYLNG:+RIQ]G[M=,9SZON ./8X_*[P.F\
M].1L*$&X*EP'6Z51/G1TDM+>:0#;JZ5 #8JB^B;I1R7&&<ZZI%K.4U>-5%\6
M/,][KYTI%B9= W2R*>'IT"3%71\&?%7]PND9NAWT 272 2%;<D,^6AQ<OU=1
M+_E4F:8\+-N<EZO.4$!)/,T'55WX9&"?IM:'">T#+,Z.R&7H.E MSE&&BB])
M'JI*F.=D/#6U0B#_HJG-O:!<J64G35+; #+LE;85W.0C $]"/YV+D0E(N58J
MK(#>B2>*9\ <IK/D(+R+<D FA__-#5;D(H&)ZU25"!ZV2=.,W/&A 3_0)&<(
MYJ$K-9OXVW4*4:6P39?*@,25Y$V*E]2'S,[9(/<D#B3F*ZN)A#";>C-^PH<.
M9. YS@N@!]AIS6P>T[I->%90:7E _RP*,V\KWRR99ZK*29:%&X<FO%<TZC>'
M4=3#=#P?NG8;.=UY%R3##ZI7<:M;UPNI?%9+--TH+&S*+<\1I]H<LO^52BR?
M$_;([YJNA/FHE(;M/MG:=%V'\WEH%F&1GR$:2GNY]PAI!;M.0( U(24"HHDV
M+G,.L;A^6.Q%8C\W('@Z\4'8XCF&S)>5.##(*VJY;!_:6C.7.Q8]14VKW8 -
M9XB+;V+)K&49FS$=]TML._:/4!$\&L^4VGN&X(^4<QR.$?.U%=)3T#YF,V<R
M',.>7O,,7LN=7^R.S!+X9/@AS:)+L8FHDW1!T!OTC*+9LP!;I-[O. >W@3,E
MEP%?_EOV+."N\&KU)Q 6;R]20G.D"](70*?EG3&/X"[EFJ"C"*B^[4E%#4"4
M8SVV&%HO?J[^*(]@)6K.*LAJ+VV[\D#A%J!*]24]  S61,9T0N':]J 5< $X
MV%.&-$)FQP'T&C)+/%4U!I#7P^KQH&,5J/X*;BQTT]R%?-+V:O^!-L9PP4%P
M=E OE '_ZZF#=R#+'&^B/FBYB*70X CSO7(1WE$U1+4$EQ5L5\_'_=-*-+NP
MSS%S@:'8F2 #R,$V>#;#0S";TS!D(<81WI8'F;*88H7<>++2K+08/A3DJ;KT
MKU-_J,_H/D2?UX;IA@95 W^33IX]D("(<')'?/%<H4P6T'B).5JNMQVH=%>L
M;0C(_Z8\9F&D[E*/,BV.7JDQ&MX$)0.N^E3/-O GV>>4#%\D1G(=+(]+JZEC
M+<X5<\ML9KCZ14Z/Z0+U;%*]:0+S5D2F,9?KX'?2T"GL<QNE_T\FMENI;U&3
M'#^30[6PKL2XNJZG](71BWXQ9YZACV67--TPF-L8X:D7"_W]_M&]DOQVR]59
ME-/L[76Y6@J[3B]@\&M1?3!K:&FB[B%G:;95!_/+$S?I)HO<PO\E_Y8Z^-TB
MN8I8-YR,5W?8&\@@<!BKA7C/*Z[90#P64$H4Q%X1->L;H9>H$^.(?-G2\,V$
MI^*]WQEBLKK";04Q5_O:_AX1"YGJCV/'I3[5'[!'LD7%A[#[BG%9Y=@I)9!P
M#]NG'A0N_U^7%OCMQIX">6Y'<0=HEH,7+H ?U$]!/JL_5N>BH9IKQ<%HOG9I
MYDV4 K 20)0'AH<7H>V0O=]V]#8\S>T!EHI,=^!B>]!Q3!7,1."JW?!IY%+1
M9F0P\C-3B#BBDQ)<D (T(-P#Z4;K_"X@G]"%[L-0,WK;83[FC8UG_(0\=/>J
M>-!6W88B*?13YY49!\\EP821<"GQ('PXO)^H\MN*Q.(OW6<@[W"^PW%T&_:$
MT0MZ6?^JF@">LN07S8.<S;,SOD.%QK7Q_T =AM*P]_!X_72_3?!R\J6["Z(A
MMCL\1\OQ]MI';::2FV4+6J=1VO)&-Z^N9OU_?Y>HM)AA-H39&#S5>H+SP^NT
M9;JPVSG7A,KT\]R,<]7-M2.;?U:1I5^;CM5NSU4WJNA#4S;9AM=+HD]8M=Q1
MP:/-+P4WO+Z8F))+SJL-?Y1CYVW0G]:6UE :V?1II:DV)O-PSJN&6#:9$F5Y
MQZ-'PV:;D!GTWN0GZ?">:+@I?^;\6;]"+;!STRT#/E9OLO[DM);T61UX.W*2
M+7:"5\DG3#_%8='>QA/2Q4%G#'T*/^]Y>D!US25 !VJ7VMG(E5!]]3CS+?'0
MDB%F-\F2[.VF5%EJ<K8Q4?XAZI4A5+DO:(T^0KW"VT67IEWD0B/5X$:[1\0%
M>'V5TC1&22L&C8@*RDXW[%*;DM[I+V@ZHI;K[FO_#EI(_@=\\0XDPZ$$%S/1
M!3?;>Q-SD#.5'PU&T%8\SF /N6>]T<NA[J15NC[H3Y2(/ RK@_3$'V2D=SJ1
MBZQPV8C?0&/LV;@>W5]IU*?ADJ)ENM\XGM6DX^ E2=7D$GQR5 AQ!WL25$"$
M8Z>\X_$V[(C+/W@0MM&^"Q^+62J#=1G&C")<YVYXE:4EEQM&)=41YW6?HNCX
M3]WXH$5X)9GK#6'WB&4NO['-^$O[O=A:W+_D=K^AQ#G7VEM9?CWU9[=#U88X
M^X[U=0?"W%K_,*?[49M#.9O<4VU"(>3PSG)&9IESR82H>TN&]<94\G+N=A?7
MK$@M[?2BC8X=:-O)7!#ZHF4"A^-':ZP1"-SUUFV2#D>:.5[Q=:[0Z* M*H:[
M]E/;<W(Z?C$J4VZV_6;%QD:VK. 6A:YM<A38_"H;>L0_W;=;[.5ZQT/&V^KH
MN1_U[X 'Q2,[BEA+LT^V;>"\3LEKN< OC+G=M%)X*U1F*Y!8_?(L/^1U[O^8
MMJBRG"8:EFM+YS%U+Z"T(G.;IV!9=E[+%I$B^5G36TEQ#&F[*TL-S;-N43#]
M,LU6U1+WKT:UYI53@;X73)MW5#<:QHO&M93(EF8];!XC_Y;<V<A09L7D-G!5
MRT/]+24:>[]R4Z9VK\=, PUD.NEU6^%Q=M/) J2U<''3*8TRR]2X5EN87&*;
M TR,F6L- <Z'CC&'@:O]"HQIT&*/:+T<7NZTC?R(++*C$-M1;6%6HQ&9E95H
MLR% LGW#9&1Q]&]+*+(KY+LI%?GD%V%0HJD>$;I=Z&JG.V0!^I]=(Q&%119.
MLJ%D7]:XAD4DG/3)&DL.BGYBYA/\D-]&%/_E5ZC?@Z_R*-'-P;E.OXF+N(/=
M3OPZ=G5):%E?_NJVQY6>)<[ZI)K]E&[5/)JF9@S+6,^A&<N.<7M9SNDLT6C>
MEPBU[);$U^NX^J=JV"*/PE,5"UMS2V_5!) /*EY3=RE>U\YD)M?#=(A]I?0E
MVYFO3]LG&"=F1\R64N0KO,ZK7FH$"W)SI0QK<UOA=Y8'(2Q3<P[+NZK&\.G,
MVKJKHO&EPYDO)3?2YO%2Y*?"3T@&J<=X75=^ S;UJS-)86GCPSQ(_!=VK9@B
MV24KH63(9(R,&JTBHL2?_E$U([6!LT4S+1P370'RO>XJG:!SO5M3_ZA^VJC9
M5/5)E"CHU_1)9Y?>UPKIPBH6D%T,T^+!F-0I["HH/CQ%>!GF>3U2\)"]/5Y)
M;S%5PZR,#5@]HLE+P$HD,<77L23:RHH56$C1K[J36$C*=E8X%A,^3? #*_9Z
M+C^+:;L>)N28]UK'I=%,A^"!G#CC27%+T1S#1=H$2J#^=A%9VZ%[F:*H3R2_
MAOTK2"9^>;V69^%_.N_%V;=NL42F ,W'H-]9G8WWQ1,*UMB&4I>4_;!Z%]G7
M])AS4GR8L)$>=H._3E_K]4YVE\SN](A1]CF:%R0/ZHZ&\,ST#IYH<[ZA=3.5
M5OJG>6CAI^KCMN2488SK%G[8;GZ(D>?U46;2T;J8-?7Y?RRSJ+02+B1DR"D7
M1=&L537A=?V\B;0U!7>$?[-2D\S2'O[,D*W*VY(R#W^ K0KH "C'*WBFX]69
MU?^!575GJ4W"*@:?:5?[D!W-WE:0P\_CBY+<Q(O%E!"K@B)?Z9&CS=? ;;M*
M>NEGC#,IK?6D]FTUQ D3C*/"O)<U9YA;A*OS9=Q B26Q2?A>WAJ2)A^G>NU1
MKRD'EK>.++@DF*A'2X.$KS7R"K7X!.]%S47I0/4E.E]NR=O&SE9:$Z<*A.HU
M(1.E3X&1'J :AI8WJW*5RG#=W*( 5;PZN.R<.IE[L K4)%>/I'*TN7E3Z@<
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MT%5S78*Y'H#VJBB6UW7?*H+0&?0GU2=D+?7_4"OKC9SGC+>4B0(7=DN60;R
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M3;?0JU$]@TQSG@8.PO\37 +.%DYC9('&4K\*(42OH.9[PJDU&U(&$%^Z:U0
MZLNZ&E"*9?'WN4?@O=+Q]A@Y3+69SU';4TKI*9J8JB>4#FUM'9FG PA&:(H_
MN(4]*O(M/(P_(2 +D8G3W3G89/DU^]?X?LT27H)\1=TBFJ_2GMY5OEMEK>_.
M/:;^Q%F9O$PKX5^+[ 4GB_T# J +LLWN%F2G"G3(Q!8#?*Z'!&#=H\Z3Q7(C
MRG;+W_"[<L<I%XB&)4]2<R3FR%AMN3PP8!Q(4_YP7PS;--\<>M#5T&B.BW!
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MK"[MF]S,,G1[JV5-\5:A):]-8(9U\HR8KNIZ; _#[J#J<?TD'7Z0H",,_=:
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M+4#6T+A$87EUI0Q;Q5$AF!(-C*'70ADMNE*Z30NG=:G+J%VJ%P4H=@-MR_M
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M;K>YB:ZW:Y->U%CK?[W6/O#Z:\:C?_J=%+SS!@=\^EX%6/T9!FS] 0H<-N4
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M<+Y33B3W5ZXTQBMW)O65KQOY58BGPZMH+NY5"L_V59ZOS50%WVJJV=]RZGB
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M_=6E7E'DQ$51I/F.&%(^NTPX%S8O2H;]:Z) >5L@:.WU H-#3#!5= )K50?
M:>" J(T!JJX5,/0MP,W0#+A&)N!G; 3!)@80;JH/L6:ZD&RN YD6VI!GJ06E
M5EI0\5<]?2)(T[ P4OI(!,F&E<))L$TR$F16^H/"1@]0V^$".GO(8'0 #Q:'
M;,%.S@H<%,V!HF0"-!4C8*H:@-L1?>"JZ8*?NC8$:FB!0%,3HK74(4%;#5*U
MCT".CBKD_57S100IO8T@&:^$D7A8)2R +6(\V+.$ P=744%Q@P.H;[$#W>U6
M8++3#*QW&P-VKP$X2.L!>;\.4 ]H@:N,!K /JH/'H2/@?4@5^(=5($A6&<)D
M%2%:3@$2Y14@^:_ ?8\HN"DN!D^=M1!@LAU"K0^ P%X)0IRT(8!E CRN-7@%
MX\$]EO2;E4;]Z9KG\IU>ROQ&K>9\=6YT_T)I\_A,[O;\1#K)G2.>X\XY7O6>
M=;SK,^,X[O.:..DS07KI\]AIZJ_^_\BP&\V@L!BX:(9 X^T@L-X/X7@E$%"T
M()AA#'Y>-N =9 \>T:1Y3@KU)S/7];M+">LKK<KMBW.#QV>G-L]/E&[N'.F4
M]RSQG,\L<8CWT?$![QWQ&>\E:9(W3GG%>^ TQ7O@_&?@@69P1S/PM-9"B.$V
MB+3<#U$X18@DH:>7BS$$NML CV\/W CRO'L2[0<KF_&-4<3Y0J_T^$QM\)IS
M;O.>I73[S))/\3Z2+OA^(%[W>T]\XC=%>LY_1GGA]]#YI=\(]17_;\ 3S>"!
M9O#37 MA!ML@VD(:8NT4(8:H"9$T8PCE6 .?9P\^ O(OSP3Z=TXFZRNST.VS
M:X7G'+W>>Y;:ROOHU.W[@7*:/T,>])\AC?B_(8T%/*<\#WA$?>%_B_8R8(C^
M(O!OP&N7*'@J+($ C;40J;_MO[V81(P")#AH0JRS$42PK"&(:P]^P91?W%B7
M[^YI["_L?(]/C'+NK$L=[R.MU6_&^9C_>Z>^@/?DRX'3Y/M!+RCC08^I$T&W
M:9-!P_3)X(NN$R%_ UPT@Q>:(4AM#<3H;H4DTWV08B,/*?;JD$@QA!A7*PCS
MP$. /^67;Z3+-Z]D]F>W7,\Y5JG/1]=:OQEZJ_][ZK' ::<SP>\HPR%3E,<A
M3ZG/0F[3)T*'7)X++KH^#SO#?!;6_Q?_9>#*+X'0(VL@7F<KI!KOA0PK6<C
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M4^?LIJGO<1^H4_B/U$G"[!_]GPPNZLO 4V\]\,QW@*_= >"1%,'+50,X7OK
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M:J,4)&W<#EF;MD'!'P%!6A3L%,6 H"(!5.WEP#!>#RR;'<!PE :ZBQPX<U6
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MB1@31H)AE9 W;!)FPRY1&AR2(('R4CQHK<" X1H+,%]G"I@-AF"_20_(6W2
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MMGP+)"S?!!DK-D(1JF3E0L!*1@3,E,0 HRP.^".20-)?#A2+]4#";P,'VA[
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MA="7'L*S10=%7Y4KB#VI5%UTJU1_W>4"ZYT#683#/:G4(UT);+V6:*Y977B
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M L9MJF!\#'TL?6J_C2ZI_3*ZK?[=\+GZ%Z/WZG-&7]4_HC-FC$#CK3%H3IJ
MUL0"P 3-\.]^$/Z *! /B8&SB@30]98!W6(M..,W XF*GFH>^P ?( -V4;)@
MDZ+PVRI7^9=EJ<I/BYHC/\R;U;Z9=:E_-3NI\<7TO.9GT^N:LZ9CFN]-WVF^
M-?NB^=H4M%^9@LXS,] =M0"]!PL 4QET#?[=@T#[M[.,*+@J20!+>QFP3-<
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M)W0I-4+J7$*BXNG8;+7C4<7:AR.J]0^$-1OMHW>;[@X9,E\.7F.Y,VB=]?;
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ME 595*)(H3I%G%R+*!I2A-&<(H VE%7D6GC1B\J#051.C*9R8!J5#8NIK-A
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M7"]D<'&/D/[//PL97'@BJ'_^G;#>.11=:=LP.0/D#(ZL!^@@\ZN_S3](YI\
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M"44<K2@BZ$ 10@^*  905F$DA1=3J#Q81.7"1F* RHDS5 [<3.PG#O]+XTZ
M8G+^4K^M_R]D_E4 NUL QO< M)X#F0N@A"P@CUP@@ZO(3!$00TD01CD00&58
M1:Z%%W6!!XV!"ZV  QTI;.A%8<80"@/&4RB80P&L)CJ)46*.6/\OJ*Y%06UU
M"NJJ4U%/FXHZAC34MJ&AE@<#:M"94"V!&55R65"Y@@V5FMA1J9L#E88Y47&"
M6,N%BO/$%FY47"8.$J>(WXG[Q'/NKXH?N#\I(?>';Q21]_T_^+Z'FF2^G@H%
M#52I:*A!Z%/1P(J&>FX,J!O$A-IQS*B9Q8KJI6RH7L^!:AV<J#; A:KCW*@Z
M3:SG0=5-/*BRD]C'BRHGB%]XOZK<X?VD^HSWO>I[GK=JR/-:%?F(5:]4D?^5
MRK^A#IEOJ$A!$\)4Y=OG080%#4V<&='(GPD-HIA1+XT5=0LY4+N&$[5;N5"K
MEQNU1GA0<PTO:LX2"^1>MO%]U=S-]T7S*-\GS?.KWFO>YGNC^93OA=8[OF=:
MN.IO311XJHF"3S11:"74_S:?]+\%8:E(19MO?YMB0D,K!P:T\&9"LS 6-$EB
M0Z-<3C2LX$*#1IXO^IV\G_4'^#[JC:_ZH#>]ZKW>>OYW>IOYW^HM\;_6.\C_
M2N\L_W.]&_Q/]1[S/]1_*_"7'@K=UT/AN[HH<E</1>_H_AL:?YM/^M]&BH(.
MWSZ+(.?"B9P)1VL&M'=G0IM@%K2*8_]DF<GUP;R8YZU9+>]KT]95KTQZ^5^8
M#/,_-UXC\+?QK.!3XT7!)\;;!1\9[Q-\:'Q*\"_CJX)W3!X)WC)^(WS=&$6O
M&J'X%2.4^)WXS0@EOX=FW^:+D_FDO]W(>P]E"GJ2_? P9T!7)Z:/SGXL;QTC
MV5_:IW ]L\WC?6)3L>J1=2/_ ZL.@?N6 X+W+,>$[EA,"_]IL4'XEL56X9L6
M>T2N6QP7N6IQ6?0WBX>B/UN\D3AG\57JK#E*GS%'F5/_ :V^S2?M[49X2U#0
M3YZ"_N1L^AG1WOG8,K[P]&!YXDYG?^ :SWW/.9/W3Z=B_IL.-8+7[5N$_K#K
M%KEL.RSZJ^V$V"\VL^(7;39*G+=9DCQG<TCRK,T%J5.V]Z2.V;Z2.6SS5>Z@
M#<KO)_;9H,)*:"M,09=5@-ZDN0-% $/(6M"5*>_HNM1GP18,#P)<F._X!;#=
M\(GBNN*9PG?)/4_P@EN9\#F7.K&SSFWBIYUZ)4\ZC4@==YR4.>JX7O:PPQ:Y
M0PY[Y0XXG)+?YWA389?C,\6=CI^4MCNB\C9B*[%E!704 /0@W1M VC]4$#!"
M##Y$R5&>1:E3[D<8TFZ&V3->#O%FNQ@4RGW6/Y[_I&^&\#'O0K$C7I42!ST;
MI/9[=,CL=>^7V^TV)K_L.J.XTW5!:;OK3N5M+D=4MKC\IK+1]9'JO.M[M?6N
MJ+;.#=7F_@.ZD-G>I#F_?0812=['"L++> GX*UX!;L3I4"[%6#'^%.7&=B(\
MD/LP/4I@?W"RR)[ ;/%E_V*IG7[5LMM\F^2W>'<I;O(>5%[TFE"9]URGMMYS
MJ_J<YWZ-6<]SFM.>]S4GO=YH3GBAYFIB_!OO?T-W,MN?M'\XN8Y8;OB0R N/
MDP7@9HHX_)*B3CF39,9P+-Z)]4",+_?NJ#"!G>'Q(EM#TR4VA>3++ 27R6T(
MK%6<"VA57NO?JSKM-ZH^Z3>M.>&[J#7NNTM[U/>4SK#OGSJ#?B]U!OQ0I]\?
M=?K\47LE]"*S@TEW1['#IP0.>)[*"7?3N>"W#$$XFZE,.9INQ+ OU9YU*<F+
M>VM\L,#&F&C1#5')DG,163(SX44*DZ&52A/T1M6QD [UD>!!S:&@-=K]@1MT
M>P-WZ'4''M/O"KRNWQ'T7+\]Z(M>6S!^HTOH? ]]2'>'LI(U8(''*<QP/8,%
M+F>SP?F<57 \5X&R/T>?MI1EP[(EW9UK(26 ?RXQ0F0Z/EYR36RZ[%ATGL)(
M5*GR8$2M6E]XJT9/6*]V9^B8;CM]5K^5OM6@F7[(L)'^FV%#Z%/#^M!/!O5A
MJ%\7AGHKH1_I[G F>)/  #?3:?!K#A-<R&>%4P6\<+!0%I8+=&A;\BR9Y[-=
MN&8S?/DGTT)%QI-C)(834V0'$K(5>N.*E+MB*]7:HQLU6Z*ZM)LBA_7J(Z<-
M:B,V&59'[#>NBKAH7!GYR*@B\J-A110:$/HK80#I[B@&>) ,\$<6C<QGA--%
MI/U+N&%/J11L*]&B+A29,\_F.W).YGJO&LL*%A[,B)+H34V4Z4K)4&A/RE=N
M22Q3:TRHTZR+:]>ICAW0KXR=-"R+630JB=EC4AQSSJ0H]H%Q4>Q[HZ(X-"0,
M5L(@1L 8"MQ.(^V?2X4S10QPK)01]I=SPLX*"=A4H4Y=5V;"-%ELSS%6Z,DW
MF!<HW),3+MZ1%2?=DI$JWYB6HUR76J)6G5*C69'<HE.:U*=?E#AA6)"PP3@O
M89=);L(9TYR$^R8YB>^,<Q+1*"<)#0F#[V$(%=[& SD'I+<**'"BE 8'*TG[
M5Y'VKQ&%#36JU.DJ(\;Q<EOVP5(WWIXB?Z'V@E"QYKP8Z?J<9/GJ["REBLQ"
MM=*,2LVB]":=@K0>_=S4,<.LE'7&&2E+INDIITS34NZ:IJ>^,4Y/12/"<"4,
M!7A,VOL*Z?^SQ0!'*JBPIX8&V^M88;%>&&;KE2D3=0:,PS76;+V5+CSMY;Z"
MS:4A8G7%45)5A8ER9?D92L5Y^:H%N>6:N3D-.EG97?KI6:.&J9ESQLF9.TR3
M,D^8)F;^2;PV3LI$(\)P)8P N$O:^Q?2G2=)^QX@/W8MU5-@4R,SK&L6@,EF
M!<IHDQY#7X,E:T>=$W=SM;= 7660:&5%A&1I6;QL44F:8EYQKFIV4:E&1F&=
M=FI!AUY2_K!A0MY:X[C<;28QN4=-8W)O$:^,8W/1B#!<":,!;J63?2@$.%H)
ML*<>8!MIKPVM-)AN6P5C[7*4@39M6E>K.4M+LP-77:/GJLKZ .'2VC")PII8
MF=RJ%(7,RFR5M/)B]>2R&JV$TE;=V))!@ZCB::.(XBW&X<6'3<**KYN$%[\P
M#B_Z:A11A(:$P??>Q %<RP(X3=KW8"W 3C)_8SOIKDZ \6X>&.R1ANYN35I+
MEPES78<=1V6[.U])JY]0?C-=++LI6CJC(4DNI3Y3*;&N4"VVME(SJJ99)[RZ
M3R^T:M(PI'*345#E0>.@RC_(ZW.CX(HOAL$5:+#2PR3R/)!].%Y!UH#T]U8R
M?QWIO]5]I#T'N*![4!Q:!]6H]0-&C)5]-FS%O2X\>3T^ EE=P2)IG9$221T)
M,O%MZ0K1K7G*$2WEZJ'-C5K!33TZ 8T3>GZ-BP:^C?L-?!I_,_!I^-O M_Z3
MOF\]?J/WO3ODF3Q'SN*A;VO02MJ7S)\B#3Q(&K!SE!U:QH6A;ER)4C&FSU \
M:LF2.^+$F3GLQ9<R%"B4,!@N%ML?*QG9ER(;UINC$-)3JAS07:_FV]VEZ=TU
MKNW9-:_CWK57U[WK%UWWSJ>Z[AT?==W;4<>][=^ND>?AY+<U: +80N;/#I#V
M&P'HF@!HG&*"ZFE^*)N1HQ3.:--RILV8TJ?LV9,FW;GCUOBOBIJ@"X6OCA8+
M&4^2#!S/DO$;*Y;W'JU5\ACI4'$=&55W'EFOX32\6\-QY(*&X]!C#<?!#YJ.
M _B#B^0L'JHC:]!!SB&Y_S6DP?O)_)89@'+2P87S/) [+PF9"^J4E'DCAOAY
M&^;H#2[LX>M]N.GK@U<%K8L4])M+$/&>RQ#WF"V0<EU;+>.\MDW>8>VPHMW,
M.B7;F65EFYES2C;3CY2LI]XK6T^BBO6:?SM%UF WV8--9/^GR?T/D09N7PM0
MLX'T-^G@M&T<D+Q=&.*W*U&BM^M1([9;,-"W.S(';O-D\]L6P.F]+8S'8VOL
M*M>MJ8).6_*$';94B-IN;I&PWCPH:;EY5MI\\Q)Q5MI\TP-ILXWO9$P74=9T
M >6^=["!/(L] '-D_\?(_7>1!JY;(/VW!2"==&CT7D8(W\<']/W2$+Q?@^*_
MWYCJL]^6P7._*Y/[?E\6E_TA;([[HSCL]R=QV>S+YK7:5[;*?%^3@.F^?D'C
M?3-"1OMV"!ON.RULM/<O(8,];T4,=J.H_BX4^]XR>08W# %,D/F]9'XCF5^Z
M#2!S%T#L?H#@HPS@?9(#/$X*@?LI!7 ]K0-.I\TH#J?MJ7:GW6DVI_T9+$^'
M,9F?CF,V/9/!:GRFB,WP3#V'_ID>3MTS4UPZ9[9R:Y\]P:U]YAZ7UJDWW)HG
MO_!JGD"^[VT<!)A<3<X 6?_F18"R[0!9>P#B#@&$' ?P/$,#APLL8/DK%UC\
M*@KFORF"V>\Z8'+9#(RO.% ,KWA0#*X$4O7^B*#J_)%$T[Z:RZ!YM9)1_6H[
MH^JU<2:5:XM,RM</$3>8E*X^8U:\\H%%\?)7UN_-C),S0.:WDOD59'[V7H#X
M(V0^Z7"/GTB#_T(!TRM,8'"7$_3N"H+.76G0OJ<*FO?U0..^.:C]90^J?[E3
ME!_X4Y0>A%,4'B92Y1[F4F4?55.E'W73I!Y/TB0>;Z6)/SE!W*:)/7I!$WOX
MX5]&R/EO)^M?N0,@9Q^9?XS,/P/@?@' YE< XVL 6K>IH/&"$]1>K +EE^*@
M^%(>Y%^I@>QK79!Y;0)2;VQ XHT+B+WU 9%W=(K0NWB*P/L<"O^':LJJ#ST4
MOH]35-Z/VZ@\GXX3UXF'_](Y#U!-[C^7S$\@:Q]"[MWM%P#K*P &-P#4[P H
MO@"0_\H&,L@#4B@(XB@.(B@+0J@, J@)J]  ^- <>- .N- =.#$0V#$&6#$3
M6+"2PHQ=%$9<0V' C<1>"@U/_$LMF9]/YB>2^?3S9#ZY=RMR[WJW 53N <@\
M 9#\ B"*C&0F!YG)0^;QDWDB9)XDF2='YBF369I (AUH: & CH0/$4ZD$J4$
M^0* Y.%#LO&X\"^HI$Y!554*JA&JFA14U*>B@A45Y=QH*!-,0^DX!I3,8D")
M4J*>$24ZB %BC DEIIA0?!VQD1G%MQ-[B"/$.6:4N$D\9OXL\8;Y@\17IG>2
MR/Q. EG>2B#K2JA"9JLK45"3T/CV7I=<CP4555QHJ!1 0X5H!I1+9T#9(D:4
MK6%$F58FE.DE1IA19@VQEIAG09DMQ#)QB#C#\EGF&LL'F8<L;V5>L[R2_<+\
M4A997\@BVPL99'^^ JHK4E";=*X.Z7X=\EY7B[R:4E'+D88:OC14BV! E61&
M5,YG1*5*)E1J8D;%+F* !17'6;XJ3K-^45S/^EEQ$^LGQ9VL'Q7WL[Y7/,GZ
M5O$*ZTO%!ZS/E%ZQ/E7ZPO98$=D?*2+G0^*!(G)]#[7(;#W2N092%#0B[XW)
MWA@;4='0EHKZGC34I3.@=CPC:F8Q?=4H9?ZL4<?R4;V-];UZ+^L[]6&VMVIK
MV%ZKS;*]4EM@?ZFVC?V%VA[V9VK'V?]6O\3^2/T^^WWUE^QWU3]S_JF.W+?5
MD><6<5,=>;^'>M]FBU'05/2?ST*LE FR'Q:65#0C^V$2P/#)*)KIG4$:\QO]
M I:7>I6LSW4;V9[I=K(_U1U@?Z(SQO%(9XKCH<YZC@<ZFSGOZ^SBO*=SA/..
M[D7.F[KW.*[ION"^K/.9]U<=Y/M9!U==U$'^"RO\;[Z9$* 5:6X[<7*DR;XX
MDK-I;T+];&M/>VOES?#"(HSIJ7DB\R.S;-8'IB5L]TQJV>\8MW+\:=S#><MH
MF/.FT037=:-9KJM&B]Q7#'?R_&YXB.=7PW,\%XWN\/YD]&+5::-/ B>-4/"X
M$0H=,T+AHRO\;[[U*D 'PD48T%V:4*%\=-.CO'2VI#YQ=&7XRSZ0Z8Y=#,M-
MFS2V:];Y'%>L*CA_M6S@_L6BG>>B11_O>?-1OI_,IU:=-5_/?]IL"_])LST"
M)\Q."AXSOR9XR/RIT'[S#R)[S%%TMSF*[2*65T!+?D![TMZNO(!>Y+V/&'SR
ME8,7/AJ4AU[&E#\]'&C7W'P8?W,)8[GHE,!^SC&+ZXQ#$<])^RJ^XW:-_$=M
M.P2.V/8+'K(9$SI@,R.\SWI!9*_U3M'=UH=%EZU_%MMA\T!LJ\U;B<TV*+F1
M6"065D!;,MN)M/^W_O8C[P,%X%60.#P(5(!; 3J4W_VLJ.=]W1E/>P>Q'O>,
MYCSBGL)ST#6';Y]+B< >YQK!74[-PDM.72([' ?%MCE.B&]QF)/8[+!%<J/#
M7JD%A[-2&QSN2,\YOI)9ZX@RTXXH.T5>5T(',MN-=*\?Z>\@3OA YX''H?QP
MDRX.E^AJ<)9N1CT>[,QX*-"/=:]_&.<NWWC>'=[I_-N\\H4V>Y:);/2H$UUP
M;Q7?X-8CN<YU1&K6=5IFQF5!=MIE66[2Y;C\A.L-^7'7Y_*CKE\4AMU0_INA
M%="9S/8BW1O( F]"6>%A!!O<C>"$7R,%X$R4$AR--*3NC[!C7 [U9-T>$LRU
M.2B:;R$@66"#?Y;PG%^1Z%K?2O$IGP;)-=X=TJN]!F3'/"?D1CS7*0QY;E,<
M]#RLU._YFU*OYQ.E;J]/2EU>J-3EC8J=*Z K*UD#1GA/9X _(VGP1PP37(IE
MA9]B^>!HO!SLC=>E[HRU9MP2[<:Z$.'/M2XLG&]M:+S@9$B:\$1PKMA88(GD
M2$"-])!_BVR_?X]\K]^H8K?O6J5.W\TJ[;[[5=M\+ZBV^#U4;?;[H-+DCRJ-
M_JB\$KJ3[@ZDP$/R[>5:+!4N)C+"V21F.)[$ _M2I&%GLA9E<Y(YPX9X)]:U
ML3Z<D]%TOO'(:,&1B&21P; L\?[00LD>>H5,5TB#7'MPAT)KT*!2<]"D2D/@
MHEI]X&[UVL"SZC5!]]6K@]ZI506CZO]1^1YZ4>%+","?40"_DO8]FT*#XVF,
M<#"-"Y;2)6!SACIE0YH)P]H4>Y8U29Z<HPE!O(-Q$0)],?$BW5%IXAV1N9*M
M$:4RS>$U\@UAK8IUH7W*U:&K52OI&]3+Z4L:9?13FB7T.YHEH6\T2L)0O3@,
MU<BKZO>^?8M]2=K[!FF^\Z1]3V10X6 6 ^S.XH"MV:(PGZU"69ME1)O(L&4>
M27/C&$CQY^U)"A/H2(@5;HU/%FN*S9*LCRF2J8FNE*^*:E(LC^Q6*8T<4RN*
MF-,HB-BAF1]Q7"LOXK967N0KS;Q(5,^+0K65T _@ 6GO*V0-SI#V/9)-@3VY
M5-B12]H_7PCF\I4HDWGZM-$<*^;^+!?V[@Q?GK:T$/[FE"CA^N1$L9JD#,G*
MA'R9\OAR^9*X>L7"N$Z5_-@1M9R8M1I9,=NT,F..:F7$W-#*B'VIF1'[52,C
M%M4)M>]A , ]L@^_))/>(NU[@+3G4B$%-A>2]B\2@*EB>1@KTJ4.%%@P=><Y
ML;?E>'$W906MJLN,$*I*CQ,M3TN5*$G-E2Y,*9'+2ZY5S$EJ5\E,'%1/3YS6
M3$W8HI6<<$@[.>&J=G+B<ZWDQ"\:R8FHGI*(:M_[&@QP.Y;L ^G.H[FD^8I(
M;Y &GR]A@)E2/EA=)@M#95K4GA(SQK8B![;&0@^NVOP OLK<,,'2G!C1HJQD
MB?S,+.F<C"*YS/1JQ?2T5I64M &UI-1)S83435IQ*0>T8U,O$\^TXE(_:\2E
MHD9\*JI_[S4Y"]<3R#YDDO8O(&M ?NS:1-IKMH("$Y4\,%PE!;U5&M3V2A/&
MIG([UMI2-\Z*$C^^DB*Z8$%AM$AN?J)X5EZ&5'IN@6Q*3J5B4G:S<GQ6GUI,
MUAJ-J,Q%K<C,?5H1F9>(I^3])XW(3%2/6N$Q.0N7R3Z<R '82_I[6R59@QK2
M',1P+1?TU4E 1YT:I:G6D*&VQIJEHLJ%H[C2AR>_/)@_IRQ2.*,T7BRU)$TR
MJ3A/-KZH7"&FL%$IJJ!'-3Q_M7IH_KPF/6^/5DC^1:V0O">:(7D?->AYJ$ZH
M?>]^-,#%;V>1K,&N<K(&M60-2/^-$7U-'-#1+ +-S<J4VF9]6D6C)7-Q@Q-[
M7KT7=U9=X*KTFG"AY.I8T82J%(G8RASIJ(H2N?#R.D5Z6:=*<.F86F#I>G7_
MTET:?J7G-/Q+'A$?U/V+42V@&%6_=SN>?$T@_7^ G('MY-[G&\D:M)#N(C\&
MM[>S0F.'(-1TRE/*.W6H11UFC+GM]JR9;>Z<J2W^O(G-=(&XIFCAZ,8DL8B&
M+,G0^B*9X+H:^8"Z=D7?VA$5[YHY5:^:)37/FK/$ S7/ZO>J7E7XC<KWKG[[
MFI!/VIOLP68R?[:-K %IT,YN@(9>1JCJXX/2?ADH[->@Y/0;,Z3WV3(G][JR
MQ_?X<,5T!_-%=$4*A'8F" =WI(L%=!1(^K97R7BUM<IYM XIN+6N57)IW:'L
MW'I:V;GE+R67YG?*+DVHY-+X;Q?)63Q$SN&..K(&9/Z:+K(&?:0]28=6C  4
MCG)![I@X9(ZK4%+'#*@)8U:,,:-.+)$C7NQA(X'<P<-A? %#L0)^0ZE"WH.Y
MHAX#Y1*N_<U23OW],@[],W+V?=OD[/I.$O?D['K>R-MUH[Q=U[^=)FNPIYJL
M 5G[&7+O(_UD#4B*U)(.S9L"R)AFAY09(4A8JP"Q:W4HD3-FM- 9>\;@&3>6
M@&D_=M]I.J?75#2/QU32*M?); &G-:7"]FL:1&TG>L6M)Z8D+">V2EI,'"?N
M2%B,OY:T&$,I\]'_D?[_#I>1-6@"6$_N?_4 Z?]1TO\3I/])AV:N(_V_P "1
MB[P0MB@%](UJ$+31D.*_T9KFL^C,Z+GHQ>RV&,3JLAC![KB0P&F_D,%MLU#$
M:S5?M\I\OEO ='Z-H,G\9B'C^2-"QAMN"QFM?R5L-/=5Q' 61;^WF^S!1K+_
M4V3^()G?.DGZ=Y;T)^G0Q$VD_T@+^NWD )\E(?!:D@>/96UP73:E."_;41V7
MW6CVR[X,-LMT)JOE&&:+Y516T^5\=N.E:@[#I0XN_:5Q;KVE16[=I4/<.DLW
MN'5VON31WOZ95WL;\A&K_K^M'0!KR?J/D/D=9.UKR+WG+P(D;P.(6"+S]P X
M'60$N\,\8'M8#*R/*('5$5VP/&H.YD?M*:9'/2C&1P.HAD?#:09'$QCTCF4Q
MZ!PK8](ZUL*D<6R$6>W8!A;58_N)/UA4CSYG43G\B57YT/]CXRS JLJW]__N
M?9K#.71W**$"!J"$='=W=Y>$(J$B6"ABHV)B=W=WCH[.G5!'9ZPQQQYU=/\6
MQESO_/_/?3[/WB#L=ZWUC;W>[YP+IT!(O[**]!>2_G32;UD-U%'N1=N!--*.
M/@@$'"4/?(H/A_,2#+Z@@D$7]3'PH@7LOAL(V^^<8'/)"P,N!:/?Y1A87TYC
M++\O8"R^KV'Z?-_"FE^9R9I>6<&:7-U-7&:-OW_(&E]^S3.ZQ/&_91'ISR3]
MMM5?SJ!V >D'2)^T TX"P\\"]M\Q&'!5B#Z_2&%^0Q5F-_1A^FL?F-RT@?%-
M1QC=<H?AK4 8_!8%_=]3H?=[(71OUT'[]@1&ZTX7HWEW':-Q]Q"C?N\ZHW;G
M*:/V^[O_83;I3R3]>M(OW0UD'"+]$X#_&<#U(C#X>\#Z)\#T!@O#APK0?Z0,
MO<=:T'EL!*TG?:'Q9 #4G]I#[4]7J/SI"^5GX5"BAD3^O "R%W50?#D)TE<+
MH/!J R2OCQ _0?SJ\?\PF?0;MM :V -D'@%B3M/X7P"<+P,#?P0LKH/R!'3N
M YI_":'^3@;5]ZI0_EL+\K\-(/M@!L4/5E#X: <Q-Q1"S@,\+AC@Z(7,T<N0
MJR4F$E1PCB8Z1X/,D0!W\1^:2+^"]+.H]K%4=_]+@-,/@"UI]R%M_3N ^A^
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M8IQ8,=<TOGR%>6SY]CXQY:>(.\1K\]@RSHPPC?N&7VD]G"F@<:@$MM21[VP
M%C4!G8W I"816IK5T#S&!/5C;)C:YF&\RF9/06E3H+BH,4*:WQ OSQZ=II)9
MGZN>-JI$*WEDM4Y"79-^7-TDP^C:V2:1-<M-(VJVFH77G# /K_G=++SZE5E$
M-6<:,8(S^98?:1R.EP"[:LAWDG[/6/)]XX!VHJ6%AX;QRAC9:HCJMGY,19L#
M6]+JQB\8[R?*:0E3R!P7*TL;EZR4/#9+-7%,D49<<Y5V=%.#;D33!/VPQIE&
M(8U+C8,:-IL$-APS#6RX91(T^J5)4#UG_&^^H_5XB&JPC>J_AO07MP*SR(>W
M$:,G 353Y*ALUT7I5 L43AW$Y+:[\++:O07I4X+%R9.C%!(G)\KB)F4H1T_,
M5XV84*$1-F&45G#;>-W UDY]_];%!KZM&PU]QA\A?C7T:7ENZ#/NHZ'/6.Y_
M.$,UV$-CL'$,U:"-:C 9F-8.C"$O/&(Z>:\9"BB8J8'<6:;(FF7#I,\:RB;/
M\N GS P0QLX,%T?/B%.(F)&J&-J9JQ3<6:H2,+U.W;=CG*9W1X>VY[1N'?=I
MZW7=IATBKNFZM3_3=9OR0<]M,O<_'*%UN)W&?@WI+YI"WK,#F#"#O!]YX>)Y
M0,Y\/M(7*"-EH0&2NJT0WSV$B>EV92,7^O#"%X8(0A9&BX(6)$G\%V1)?1<4
MR;SF5RMYS&]6&=[5KN;2-5_=J6NMQK"N_<1/&L/F/M4<-N=OS:&S.:VAL_[+
MWE%4 [) RTE_+N7=3MICNLC_+P3R%P-)9(MB>Q01M4(+$2O-$+;2%L$KAS*!
M*ST8_Y4!K._*<+[7RGB!Q\HTH=N*?+'KBDH%IQ4-TJ$K)LD<>N;)A_2L5AK<
MLY>XHC1X^1.E04O?*P]:PJE\2^]9W"K27]A):X&L6.L"\M]+R'_WD/\E+QJS
M#@C:*(#?)F7X;-*']V8+>&X>!(\MSG#;XL6X;@EBG+=$L<.V)/$<MV3S[;>4
M"@9O&2D<N*5-9+MYMMAFRPKQ@"V[)/VW?"?NO^F1I-_&MPK]-G!2Z_7_93V-
M_V+2GS67_#?EWK",_.<J('L]D$!>/&0;X+F+// >!0S=JP;'?8:PWV>%(?L'
M8?!^9PS:[XV!!X)A>R"&L3F0RO0_D,]8'QC!6AT8RUH<G,[K>W IS_S@-I[9
MP;,\LP/W>6;[WO!-]W*";UE.^G-)?THWT-SSY0QH$XW!=B!L-^"]CSSP(<#N
M&!_6)Z6P/*4&B],&Z'O: GU.V\'\S#"8G?&$Z=D@F)R-@?&Y-!B=*X;!^5'0
M/S\)>N<70.?"!D;[PG%HG[\-[7,O&>TS?Q,<^Y7YO9_%6@2,7?'Y#"A_*Y!,
MVN'[2?\P,.P8Z9\"+,\Q,/Y.")VK4FC^1QD:/^I XR=3J/_4#VH_#R%<H?J+
M/U2N14'E>AJ4KY= ^48CY+].A_SF<LAN[H+BS<N0_OH8BC?>0/'Z^W_H)/WQ
M*X':#4 AY9Y">8>3MO=Q8.AIP.8\T.<28'@5T/R9@<H-(93OR2"_IPK9?1TH
MWC>!] \K*#P8",D#9X@>^D#P, +\AZG@/2P%\[ 9>#"3()&']/"'EXD_@$=/
M_Z&-_FED[QG43B#U !!!VEZD[4C: TC;[ = [Q= [5= _CN@^(2%PFL%B%[+
M(7BM"MYK;>"5(=&'L"$<@=>>1"A!3<%K>A&]ILWG-2VX-R3VAH3^.DE\]P_U
M&[^<0=&81U+-O4G;D;3[_0<PN09HWP14;I/V/4!$8?/? 0S'HT983,B C\J$
M.MWK$B:$%3&8&$X$$?12Y*@IXJ@>'$T^CA8=1X/.;?T'3K\O84Z/(*^K80%.
MQ0:<LA,XN1_#R:(83IK&< I%1#711+014XE9Q'R&DRPF>L!)UA*;B5W$87R4
MG,/?DAMX*WF(5Y+7>"'A\%R!PS,%CGDF_5\X(S-P1B;@# D=BD6K/\7B"$[-
MF^()9SCE9(:3YQ&51#W10DPF.HFYQ$)B&?-1OHKY6[Z!>2_?CG?R _A+?AJO
MY+_@N?P!GLA?X9&<8QXJ<<R#7I0YYH]OX$R-P)F2YS<AC,AS&UE178907=PI
MGF"&TXAG./4LAE,K)6J9CVK-S-]J$YAWJE.9MZJSF+]4NYC7JHN95ZHKF)>J
MZY@7JEN99ZK[F#]53S*/57]D_E"[S]Q5>\7<5N>8W]0Y]I;&9VY^ ]='#UQ?
M\O_FFN#Z4!Q]:4S,[2@F9XK''YQ!-/-!+XUYJUO O-&M8E[JC&:>Z[0PSW0F
M,T]UIC-/=.8PCW06,@]UEC%_Z*QA[NML9N[I[&'NZ!QG?M>YRORJ>Y^YIO>*
M_5&/8Z_J<[PKQ/?Z'/_R-W!6I&]-_M]*%5Q_;8+&I'\_^MH1'RR\\*9/&//"
M+)%Y:IK-/#(I9?XPJ67NF30Q=TQ:F=LF[<QOQC.96\9=S*_&BYD;QBN9:R8;
MF9]-=K$_FAQEKYI\SUXRO<>>-WW).V/&\4^9<8*39ISPQ+_@^I.VC1(X._+]
M@]4)JLN@/GAG9X?G-BYXU#\ ]ZQCF-^MTYB;5@7,=:M*YF?+4<Q_+,>R5RTG
MLM];=K"7+&?S+EHNX%VP7,8[9[F6=\9R*^^TY0'^2<MS_.-6O_$/6S\3'K#^
M*-IGS8GW?&&W-2?Y"F='^H.DX!QDX(92',,T\-;1$$_M+7%OL#UN#O+$+X/"
M<'5@(O/=P&SVO%T)>]:NFG?:;C3OI.TX_G';2?QCMM,%1VSG" [;=@L/VJX0
M[K?=*-QGNUNTQ_:D:)?===%VNR>2+7;O%3;9<=(-7UC_#=Q@1=(7@G.1T))6
MQ =793QUT<#M84;X9=@ 7'9RP7FG .;4L&CFV+!4]O#0/-Y!QS+^?L<:P5Z'
M!N%NAQ;13H?)HAWVG>)M]EV2K?9+))OMURALM-\FW6!_6+K._HITM<,#Q14.
M?\EZ'&@%.7+RI?^"<Q2!<V;!N?/PW%. /SPEN.,FQX_#-7'!W0(G/1QPQ,.;
MV>\1QNYV3^#M<,O@;QM>(-SL6B':Z%HGWN#2)%GGTJJPQKE=NMIYEN)*YX6R
M'N<5LF5.F^1+G?<I+78^K]3M?%=YOLLKE2X73F4>,?=?<$X,Z0-/?<CS^9/_
M]Q?@>U\)SOFHXIB?*?;[#\0N?S=FJU\@N\DWFK_.)T6PQCM;M-*K6-SC6:6P
MS'.4=(G'&,7%'A-DW>X=2@O<YRIWN2]1F>N^3G6.^R[56>ZGU&:XWU*;[O%"
MO<.#4Y]&3/7DU+ZE]VCYK3=PF_SWC[3%7PAC<3I$B*-!2M@;8H#MH0.P,=2)
M61OBRZX,#N,O#XH7+@E,%W<'Y$D6^)=*N_RJ97-]1\MG^XY3FNDS6:739Z9J
MA\]"M:D^J]2G^&S3F.QS3'.2SS7-";Y_:K;Z?B XS?%^G,:W<&[TZJ+\KY/W
MO1@%G"#O=RB*A[T1BM@:J8/U4598%>7 +(OT9!=%!/$7A$<+YX4EBV>'9BG,
M#"E4G!Y<(9\65*?4'M2D,CFP375B8(=Z6T"7QOB 'JUQ 9NUQP8<TAX3^(-.
M4^!C[<:@OPE.J^$SFE_AO("[P< /I'^:?-^A!.JSXQELBY5@79PF5L3WP9+X
M0<S"N.'LW%A__JR8"&%G=+QX6F2:PI3(7,5)$27R">$CE,>'U:N."VM1&Q/:
MKM$4.D>K(72)=GW(!IU1H?MUZT(OZ=:&/M2M#7NG4Q/&]:)-:'WE+U_@MW#@
MNSCRG,GD_5/):] K=T.B$"N2U+ XV13SDVTQ)\F9[4STX4U+"!%.CH\13XA+
M5FB-S5(<%U,H'Q-=H=P87:<Z.JI9?53D1,VZR)G:-9&+=$9$KM6MC-RC5Q%Y
M7K\\\KY>>=1;W?(HKA<=0OLK3P-H'*@&9Q.I!N3[=F92GYU!?6XJBR5IRIB?
M;HC9Z?TQ/7THTY[JR9N8$B08GQPI&IN4H-"<F*[8D) GKX\O5:Z+KU:MB6M0
M'Q'7IED9.UV[+':!;FGL:KWBV%WZ1;%G#0IC[^H7QKW1*XSC= F=HF]X2./P
M8RQY?\I_'^EOS2'O3RRC^P69<LS.TL?T;"M,R;)G)F2Z\5HR_ 7-Z>&BAK0X
MR:C4%&EM2K:L.KE(N2JY4K4\J5Z]-*E%JSAQFG9A8I=N?N)*_=S$'08YB:>(
MV\1K_9Q$3H_0)72^<I_FXO<T!XY1[KO)?V_*)^]/'KB;XIB3*\/T/!U,R;=
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ME[M)/S;WJ$%L[J_$"_VX7(Z^Q^E^RR\T#B=I[/<4TEPD_17D/[N(:73?5B'
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M"V4G/);[XKXL$G=DR;@ER\$-60E^D57C1]EH7)6-Q?>RB;@DFX;O9+-P0;8
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MC59QT@TJ2KY3A2GS59"R4ODIS+BI)Y67^BZ/7X-K7+^F1]!U'WIG9CIWQ(P
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M3%50_2S9ZQ^6K7XC>%K6^E=EJ_N#['5_E;T6[H_NR:3>(]#3SU4#:G35@,I
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MYPYG<1F1X"PXC\ 7(^BX$7QQ!/TQ8BJ . \G6QP.<1MV%I!-#_U& ]#5$S2
M:E<-*)LVI]#FV%[H[X-^H_X#;28MD!?B2&28U$BTQL*UQ^&+\=@Q 3NN"W7^
M\6.2,?DSH"?ABTD(FV0<QTM_3+J+]R'/UT$@KR.+G/ ^^$I]^$@W4-]9 Z+-
MJ;V=>X#"^:H=O6:XN2_<W'T\NA%%FL;$!F[ CJG8,0T[;L2.&21#-X61"+#@
MWF+\,8"!=0N^N(78O!G.?0O]<?,"/D-,S'P&7.4[GZL7.IM!%?U<R$<SC#U
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MXQ]R[L$P?@#H@J,&X0Y#-]$&._9'(C^)5F1C=S&RJ[&[X=_[,-;#+]?")M?
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M/ I5ZEFA$L\Z%7MU4Y%77Q5X#U.^]T3E^=RL7)_9RO%Y3-D^6Y7E<Q1<!G\
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M5!3=*JA;*39$!$2:=*3W7D)+2 _I?5JF]TS/])*9R61*IO<^F?1>24()34!
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MNLP029\1(O_' =?K$X#KW1G ]LF:N\:O$L]5K*#7"8^9H\),1T2(<(>$!'^
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M#D)5@6V3JC$=94I,%[,<,_3VX!1!3CJ%E=-.H17<7HQ2VHU1E'<\3<#YZHO
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M]/PH6_MSH\LO/3.."U[Y)QF\/[4$?#&K$"R=GPG6?I,$-J^,!3O7QH!]&P^
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M;[[%2MEXBY^ZX0=IVI/J<#\[RE?S_"A#[[.CI;^/'\\";_R3"*9.18*YLPK
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MR^?S>W(DHJY,I;0C7:MH3[.4MZ=ZE*TI457MR:@RF!Y5>3*B*CN4)3.J?%R
M"!G(D($R]W5 @@RE6^8"]NZ5@'U@VP/6T9@[C(3D6[3TW&OD(N1%/)IX%DUB
M],,9O)Y"GJ@K3RQKSU:6MV5HU:TGK14M:7Y-77I$$\@(5[HRPY6VK'"E,3NB
M,61'*AX7($$&"F2@0@;RFNF M7DNX.Y8 7A[MS[@QL3<8<<FW6*FY%ZEYZ(N
M4)"D,W@"LZ^$SN^"<:3M!:+RUISRBN9,G;8IW::K3P_J@UD!O3,[8+#D!/15
MN4&]-C>HT^2%M(\+D"$#]?T7  TR4%=/!]Q-<P!_ZW(@V+4%"/8?NEMV)/%'
M3D+.-68Z\@*]B'2&C&'UXBB"3B1+WEHD4 _M!ANS=57UF2YC*-MG=.;X3*9<
MGTF7YS-J\OU&54' 4/Z$ !GZ7HX&&>B0@;YJ&BA;/P<(-RT#XFV;@7C/@=]%
M!Q-N"XYG7^,E(2ZR<DAGZ$A6+XDH[,"4EK? RRH;"A15=3D&<S3;8W7FNJW&
M?+=56^"QJ@L]EO(BKUE6Y#-)B_U5CPM0( ,=,I1"!N;*:4"P]DL@7K\42#=O
M K(=^_^0[3WQD_1PYG51'.Q2V4G"&58ALY>.$;83J.5-**ZNKDANKLDUV3UY
M3H>QP.G0%+H<Y<4NFZS8;97 /!81W&L6PGVFQP6HCPP,R,!>.16:_V<#V=IO
M@&+#!J#<NO>><E?L+\K]Z3<41XLN2Q.QYP19I:<X<'X[C5#>B&7IHS 9N C
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MT\\_(P*OC&> *6_BP2<?PL%7,W/!\J]2P=K%)\"6%4? KC4'P('U>\#1C3M
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MM.<F0KDO""@-EA!B080W!';,]P&II6Q06DT'31$[,-AB#6;;S8 D9@C4W3K
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M"=8N,.$L'W84&!WTE1SN"U/LG1>OV=F5KM_:,<>T86ZI54UKG7U%<YMS2>.
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MJ-^JLG#4MJQ@C4-)_D['HOQSCH7Y#QT*"S[;%1:@35$!6A7EHV51'IK/!B,
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M/ZX2]>(K4)?0^9<G<0 _SO2!:K"/;CVW4O[:=H#Q3LKO NB9)PB=/0HPM]>
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MAO[Q./#3"\#//Q#I/UA"_7K^N/@\D'I=/@,$>-T%7%GG8:RS_=NL^_NL^T>
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MUK,-:,]F-+/^"^F_VX!1G<#0+A4<5F@P8(4U[%<,AMW*4;!=.1XV*Z?">F4
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M:BO/4DM%D9HK*M54V:#&RG8U5/:IKG)<M57+5%VU2;:J_:JLND#E52=45O6
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MEVJ1_SHM]-^E\8 S-19P3",!-VLH\!$-!OY! T&?JC_(_B,"F2OCG:>B7)5
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MT:;UZD''(#HFT#&ME;Q;CC7+L'@&STW3'TN(HBGFBD7Z%_C6<>?=2;S$U/X
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M 8GO@..U0US;(8WM%_/;VP'DI!7>W6IW8#%MZT='*ZBI<.X#*D!O)J])E<1
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M\9$ >?Z8YNPDX()@^M\.5V0#_AI@"EXIRG/9EA%1R)"$C,&0(0\9*H &Y(R
MG+&0,Q%RID+.;)2Y$.6OA&8VDNG0Y%18C!YL<PIZSF18G2[&BDGD+O"1FX76
M!=C1[.Y2< \PQ>W"]+)1AN<>+L7[A;B^ 'SFBPN2><+B9*Z -&1Q($D1LH9
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M$BG3>3_@3T'P- 7^_!3XTI,Q,TW&+*V+N%L7'";]"5!B.)IW'H\^RI[!<D#
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MFKJ^<3)W_,W=RO97;QOKEWYVEB\"[0\\"W;<_RS<R>3I(>=_"MJ@)OCDG(+
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M1YDV@D.GP92/9S8M?7O.T/#%Y;WV/UTT"SE_VCJUH]VAI.Z86WU)C7=;5GE
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MYR,/%9X)BJTZZ9M4W^F1WMSFFM?>XES656=7>:+2\6A+F5/#L8& )JCQ."2
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MK5P?-#B$7ZMT2^LK\"[MRCA8UY08WE(;&]-9?BBQIR@\XW1>:&%OBG]Q7V)
MY<F$@)JV@8#+(7ZT!$T!AX)9"K02'!I7<M>"?&XW7/M[Y[Y]+SHMW.XWVT=>
MKG'..%7L5=J2'5!7EQK:4AX?U548$]^3'95V)CTROR\AI+@O-KBB.R:XIGT@
MX',0IZEL/\Q,!5J]4)T> X?V#7,_=>U8^^:DL<G3;G.W.VTVA\[5.65TE7F4
M-N;[UE5F!+44)D=T9L?']J3&)I])C,[IBXDL/GLHO+S[4'AUQT! D\ A 1S2
MV'X8<*@!A^/@T+5^SH>>[6M?G38R>73:S/U&IU74F4:'C-8JMY+:(N^C)3F!
MS3GI89VIR=$]\8F)9V+BL_HB8XO/AAXN[PF-JNX<"&C24"$NAXQ)TK1DICP]
MJJ].6U:,^]R];LZ[,]O6OCRWQ^1!GZG[Y9.6ATXVVZ4?JW4IJ2CS.II7Z-^<
MEA/2&9\1U7TX+?YT1$I&;TA*<5_@D?*>P+BJSH'@+PZ9X% *#O7Z:K1MQ=B/
MI]?.?GMNZYIG5W;MNWMAG_NY4^:1[6VV:;6-3L5%U1ZUF66^QQ.*@CH.YT6>
M#,N).W4P*_6,?W91KT]J>8]/<E7G0$"3P2$1'++!H7R&'&W4'_JE<\68=WUK
M9_UV9;/!HQ\-]]VX:NQVJN] 1-,)Z]2*%L>BG :WFN0:GV/1%8%M8:7A)P*+
M8WI\BE).>Q85G''++>]VSZKN' BX')*TQ6GN)"E:"0Y-"X9\/+E\].OS:V8^
MN[5I]4_W=NR]>-/(M?/B_O"C9ZQ2"KOL"]):7:IBCWDUA-7[MP34AG1X54>=
M<*U,[':JS.EQK*@XZ5A2W3$0T!1P2 :'_(F2M&:Z[-?6!:J_GUX^ZOG5-=-_
M>;A^Y8\/MQF=N;?'^?@/IB'E%RP2,T[9Y,5V.)2'-+L<]6WT;'*K\VMUK UN
MMZF)ZK2L3NJRJ"GHM*ZK;1T(:"HXI(!#T81!M'[ZX(^="Y1_/;]LQ,^W#:;<
M>;QNY84G6_=T_+S;L?:N:6#>58O8A#Z;]/!N^P*_#J=RMQ:W&OLF[WJKQH!C
M!QI"CYO4QS0;UZ>UF#06-@T$- T<TD:)T;()$K1IFO2;4_,5?[FV;-C-AROU
M+CQ?N[+GY>;=C<]VV18_,/%)_=$BXO!EF_B@LPYI7J==<OKW@%AT!)3O;PNM
MW-=ZN-JH-:EF3TOF@$#3APC1[)&BM%I'_&/'5,FG%^9Q;MY;I'[^Z4J]DZ_7
MKFA^L]&PXM5.B\S')JYQ/UD$A-ZT"_>]ZA3C=LDMP>&\5XKU6;]T\]Z#F:9G
MPK*-3QW.W=.3D+^K)VU H)G@4#!"A#:.$WEU>HK8[5O3I,X_7C2LZ_6*J<<^
M&BRK>K]A2^X?._<EO#2UB7ALY>K_P-['XZY+H-,MSU#;'WTCK'X(/'3@6LAA
MTZN1,<978N+V7$J,WW4I+6$@H#FJ@K1"4^A#N[;0@ZNCA,[_HC>XZ]4BS89/
MR_7*OJY>E/MU_;JD/W<:1OZQWR3PE;6EYPM'>^>G[LYVC[W=K'\)\#1_&.1M
M]B#,Q^3^(;^]/\4&[+F7&+CK;NK!@8#F@4.#NL#3L\H"%QYJ"'6]TI.K_Z2O
M58+8/X.NG)= UZ^(I#O7!W[9O\WSH\UNYW=.QG:_>YA:O?$]8/XZT,+L58BE
MZ6\1UOM^/6RS]V6<[>X72?:[GJ<Y# 2T7%'@[0D.N713DG3^-DRT[D\]^6(Z
M=W@:7:030U=,#Z7K%OA1PV7N=/]J!VJSSIHZ;;2@'EO,OOIN,_T2N'W?YY =
MQG]&&!I].KQSSZ>X7;L^)NW>^2%MST#PJ4F&G.N3(!V/I 5J/P\7+Z)Z\JET
MEGH47: =2)=-]*1KISG1[;-MJ,D""VJ]:#]U7+*/NBW;2[V7&]& %;MI\,I=
M-&S53GIHM2&-,=A.$]9LHRD#PKE.4=)V48S4O),1+*":$BETHMPA.E75G\X9
M[DH7C[:A!CIF=+/N/KI7;P^UF+:+VLTPI,XS=U"/6=NIS^QMU'_.5AHT9PL-
MG;N91L[;1&/F;:1'Y@\$K=TBI/H'$9)'.4(I5$LBDHX=[$MU%9WHS"$65'_8
M/KIRQ$ZZ07L;-1RSA>X;MY%:C-] [7364Z<)ZZC;Q+74$_"9M(;Z3S*@0;JK
M:1@0.2#02/@/86/$:=!4&1H]6X$F+5*CF:M'T\QM4VG&OD4TQ68=/>*^ZT-4
MX($W89$.+P*/>#SQ3O'_V3TSY+YS7L0]A^+#=^PJ8V_9'(V_:=V4>,.J*_F:
MQ=G4L_O[TKX5_Y_A0!]0NG+Q8J/U&]<M6VFPE(A)_)_ ZCN'__<XA(-#L)X,
MC4'$D<SGD+5U*LTT7D13;=;3!+?=[Z,#S%^'1SH^/QCG]=@G.?"A>T;83\YY
MA^XX%L?<LJLX<M/V:.(-Z^/)UZVZTBY9]*;WFGT[Z"$U(1H.#S-LB@P] F\_
M;:$:S5TUFN9OGDISC1;3+,L-7U*=C?Z(][5^>3C,_7%H=, #_X2(.UZI,3?=
MLA.O.Q>F7G4HS[QL5YMST:8I[X+UB<+N R<*.RQ.Y7PK:!0X1(!#Q&1IFCA#
MGF;J#Z4%*T?3HDU3:='NQ33??-/G;,=];U*][9_%!_L\C(P,NQ,4%WO#-SGY
MBF=FUD67_/QSCJ7%?7;596=LCE5V6;14MUAUE#;:G"SX5M H>%:1X'!(5YHF
M@T,V.!2MT*9E&Z?2LEU+:(G9YD\%]J:OLCR<'B<'!MR+#HOZ,2PZZ7) 0O9Y
MK[2B7M><BE-.Q37=]E7UG3:-C4U6Q^J/VK965MMW%G\KZ&'& 1[F87!(G2Y'
M<Q<,H24K>"M4*G<NH>6F6SZ6VN[_K<#-]9<,O^#;\<%Q5P\=RC@?%%=T!N'"
M2??,^BZ7HJ9.YYKF8_9'FVOL&HZ5.S37E#BUEWTKN!P.@4,,(HXT<,@'A[+E
MVK2&K5#9L>1SM<F6=Y76!UZ6NK@_S/$.^S'Y8.*EF/"\WM#HBN[ I+HNO^QC
M;=[%S<V>U:TUSK6M)8YUS87.34?S7-LJOA4TFLM!C,9.E*(9X% X?PBM6,Y?
MH;)]R:<ZXZUO:RW-7U0Y>=XO](R\GN&?>BX^I*@G*JJJ/32^_GA@>E.]7WY+
MK4]Y6YE'37N>:VUKMONQ^DR/UJIO!9=#%#@< 8?,:;*T>+XJK5HVBC:LU?O:
MN&W)^\:]6U\UF%L\.6KO=;?4+>IBEG?&J:2#1>TQ$57'(F,;:D.2CU<<S&XM
M"2AI+_"M[D@'CU2OQL9DG^;J;P6-&<+C$,]VR(!#"3C4+!M)CZW1^]R\=<D?
MS49;7S8?L'A8;^MSO=PINC?/,Z,SS;_H6'QH=4WTX8:RB(3FPM",MMS@@HZL
MH*K.1-_JSGB_AF-'_)MKOQ5<#H?!(8'MD &'LGDJ]"@X'%^C]ZEMRY*W[;NW
M/FO?;WGOF)7OQ2J'Z.Y"]_3F+-^BVN3@JK(CD0T%AX\T9T6FMJ6%YW8FAY5W
MQ016=44?K&^*#CI^]%O!XX"H)U%'DN9.X]!R<*A?.H*V&$SYT+EY\:L3N[8^
M/F%B>;/9PO=LK7UT1ZEK>D.N=U%%>F!505)X0^:1F.:4Z.2V^*CLSMA#)5V1
M895=$6%UQR/"FNJ^%306'*+!(1D<\J=R:"4X-"[EKLQXU[UI\:^G=VY]V&-L
M>;7=W/=4@^WAY@KG])I"S\*B;/^JK+20^N2DP\U'$A+:#L=E=$;$%76%'*[L
M"HJJ:PX^U%3WK?B+0PHX%$X=3*OG<E=%?.Y</?GW,QL7/3^W8\N],WLM+W29
M^70U64<UU#BFE96Y%^86^%:F9 ?5QV5$'C^4>J0M-#FM(RBIH,L_L:K++^YH
MBW_LL?IO!8T#AQAP2-,91(O H7:N$FU>HOFQ>[7NZ_,;%CZ^O'WSS?-[+'I[
M]GNWMEH=JFZP3RVH=BU(+_6N.%(86'<H+[PI)#NF-2 SI=TG,[?3*[.JTR/E
M:(MGTK'Z;P6-4^5QR!@_B)9B[JR?J_BY?<GPWT^OFOCRROH%#V]LW73E\F[S
M[EX3K\8NB\C29KODK ;GO(0:S_*H"O_:X-+01K^BP\V>A4EM;H79[<Z%%>U.
M.77-SIG'ZK\5] @XQ(X4HUGC)6BYGC0]-D?APXG%&K^=6Z7S^.:Z>7?N;MEP
M[L;. VT7]GE6GSX0GM]EDY32XI@3?<R])*3>M]JO-KC>H_K0,>>JA&;[JJP6
MVZKR%INR^B;;HJ:Z;P6-!X<X<,@=)TZKITA];9DM]^;4(K4G5U:.O7_?8,[5
MAYLV]-PQW-]X;:][R06ST(PS5O&QW?:9H9VNA7YMWN7N+4$UCL<CZVR:CC18
M'DL_=J"Q"&AL,*]MKOE6T 05(9HP0I06C!6C=9,'?>B<S7E^?I'*3W>6C[KV
MR^HY?8\WK&]]N,.DZJZ1<^Z-_0<3KUA&1YRW2_$[[93C<M*]R+;3I\RB+:AR
M?VMDC7'+D5JCE@R@O&9?>UO%MX(F@D.*I@@M'2-*FW3%7YUFJR+TY:\^7*K=
M^WSUG,X7Z]8=?;)M;^$O1G:I#\R\#]^V#@FZYA#M>=$EP>F<9YIUKU_6@5-!
MN28]$?E&)V,+=YU,*3(\D5]D>++ZFT&3E05IYG!A6J4M\J%CHNBCBWKBU^[/
M53CS;.F8]C>KYM2_7FM0\MO6G1DOC<SCGAUP"GUHX^U[US'0]:9[F/T//H>L
MK@;&F%T.C3.Y="C!Z$)<XJ[S*<D[SN>F;#]7EOJMH*G@4* A1!M'"+T\HRUT
M_>Y8T3-/YRBWO5TR]NB'E;.+WZ]9D?5NRY;X/XSVAK\V-_=_86?O_L3%Q?$7
M3P^;!WX^%C\%^>^_%QZX[\[A(*/;1T)VWTH)-;R9$[[]Q^)O!DU7$J050P7?
M=:H+W+HI+W#FR5B)UK=S5&N_+!Y3^'7Y]/0O!HN/?-FR)N*+T=: CQ:[/?ZP
MW^?TQO6 [2MO2\M? VP.O BQ,WT>Z6#\+-K1Z&F\\^XG*2Z&C[/=MC\J=/]6
MT%Q% =JH2&Y<D"2]C^4%6]Z.E:SY,D<UG^IKI]"E4Z+IZKFA=/,2/VJTVIU:
MK'>@]INMO[ANM_C3V]#L4\ NDP\A>XS?1QH9O8LQWO,N8=^N/U)-#'_/-MW^
MMF#_MX)6<,CU$^+D])5!I/EW1:$J.DXZC\Y02:+SM"+I8IT NFJJ)]TXVXGN
M66!+S1=;4+OE9M1EI0GU6FU, PR,:/#:W31BW2X:O=Z0'MFP@R9OW$8S-VVE
M>9N_%3\>%R'=I\1(TX_BI)PJB^32\=()5$\IG,[2\*7ZHUSHBO$V=+WN 6HX
MU83NG[&7VLS:0YWF[*+N\PRIS_SM-'#!-AJBOY5&ZF^AT0LWT_A%FVCJX@TT
MZYO1TR9"&L^)D-*?Q06RJ*IH/!TC%4HGRGO1::H.=)Z&!5TZ8A]=H[V3;AV[
MG1KI;*7F$S93VTF;J)/NQO^+O?.*:NK;%^ZFVGOOO5= %*4CO?<2 B&$0" A
ME! ((1 2()1 @-![[[V#(D504,""Y5BQ %944+'K[]O^SQUW? \']/$^G(<Y
M?%S37=9><XV] S"D3( E90S!TD80*F,($3(&$'U,'X3']"!9]F]IZ15#RFZ*
M(IE?%X@FP :),-@QWQ_V+:&"U$HBG%QK!ZH;K$!WLQF8;C4&F^T&X+!##YQW
MZ@)YEPYX[-(&VFXM\-NM"0%[-" (A;M7'<+WG@;^OK\%0M#&"=XS!P+09P5/
M;AD(5-9!@LYV2+(X! GXDQ#GK@%\AA'P0FU^< 7XSX')I(^,+.J43P'MK5>9
MWP2UFOF*TA#XTJV-_9S4Q7GFTA<R2KP:]I!PAW?#X5[XW_!?A_\Z_$>'0.F%
M$'%B&<0IKX4DU"'%_! DXTY" ED#!'XF$,&U_18:[33-3B1/,3.\W_KF^[WV
M+@EXZ5'%?DZIYXZ[M8:.N7:&/R7U13YVOAIUFW [^JKCG:B_ 4+1SN*@#L%2
M"X%_?!DD**V%-*WMD&EZ"-+M3D&JJQ8D^)C]$@3A/D=$NDYQX[W?!*;ZOV3D
ML,=]"D-'/<LC'KO71H^06V(?NG7&WW?M3[CE?#5IP.EZPD7B3<'? &&H Q=M
M'.[1A2! ^R(97=MG:FZ#7.-#D&,K#YG.VI#J9?D]@>7X,8;G_C9<X/<B."EX
MC)D9_IB>_WL?)OZ>1TW2'?>6M%ODKLQAUTO9EXB7LL^[#*5VN%Y/^!N ASJ$
MH YA1Q9 '-H7:8IK( =U*# Z! 48><AUTH$L#^MOJ?[$*6&(URM^-&LL1,A[
M%)@FN,?(3;KM4Y)^P[,ZY[I[<\%5<E=1G_/YDB[2Q?RS;@,9+90KR7_#_SJ$
M'UX ":A#!MH7>1I;H<3@$!1;RT.AH^Z//(K-YTQ?TKOD8/KSV$C.X_"XZ'O!
MR4FWF-E9U^E%!4.>E:4#[DV5?>2.JG.DSLI6<D]Q@WM_3JW'8-K? .%H7X2B
M:_O(0PL@268)9*%]4:B^%<KU#T&YE?RO4@>]+T5NF ]Y/FYO,H/\QQ)XO ?\
M&.&MD,3,JZR,H@&_@O(^GXJJ7EI33:=G>VT3N;VVEMI=5NEY,;_,^W+FW_"_
M#GRT<5)0AQSYU5"LO@4J]0Y"M87\]TJ<WG0Y"?NVV(OR/)?)>I3"C;HEB$@=
M"HO-ZPM.*3D?D%UYCE%2<\:WMJZ%?J:^RO-,?9E79V613V]A ?U2]M\ $:A#
M&.H0C39.JO1BR)-?!66GMT -ZE!G+O^ESDYOJL89^ZK"@_JDP)=]*RTP=C ^
M-.U"5'1^1VA":1L[O:J155!;RZQHJ/)O;BSV:6O,IY^KR?'K*<[R[\O]&_[7
M0?#[*QW4H>#4*JA0VPQUN@=^-IG)?VK"ZKUM<+(;KZ9XW"^B<:YD,6,O)''2
M.@01^2T1<65UH2G5E<$Y=:5!I8U%@?5-.<S6Y@S_LW5I =VEJ:R+^7\#1*(.
MO%V2$/?["QFI15!T:B54H0Z-N@>^MYJ>^M"&T7O5ZFC_I,[-\T:9)Z<_UR^V
M,RTHK448EE\;'5U6'I%8712:69_++6S*XE0WI[%;6A(#SS0DL+O*A>P+!7\#
M1**=Q=LI"?'[YD$6ZE!R<B74J&V"9IW]7]J-3TV>L]%[WHZW?]#DXG6ETH/3
M4T@7M&6RTNJ2N?GE\5%E!='QU=F1:?5IO+RFY+"*EH2PYA8!IZU1$-)9$1/2
M6_0W_.,0CCHDH XYJ$/9R150I[H1VG3V?>HR.OGFO)7N6"?.[G:;L^>E6O?@
MCE*:H#&7F5:1'IQ?F!1>EA4OJ$X1)-<+^3E-L5%E+=%1C:T1O-:FB/".RHCP
MGN*_ :+^QR$1=<A#Y\J*D\NA477CC[/:>S_V&,J][K/4?=QC;W>]G>C1VT .
M;JOPBJDI]$LMS@[*RTX/+4U)CJZ.3TBLCX[/;(J(+6X)BZUKY4:W-'.C.ZI"
MHGN*_X9_'")0A^2]<Z$ =:B26P[-*AN^=6COF>HS//%\T$+[01\6.]A)\.AL
M<64WUGI&EY714W(+ G)3<[BE\1F155%IPOJPY/0F3E)A2U!234N L*4Y,/Y<
M=6#<^9*_ ?BH0R3JD(HZ%*'S=2WZ_&Y36??EO-;NMP,&LF/7S#5O#=C:]O4X
M4L^<)055-U+Y!=6TY/0R9HZP*+@X*B^\,C0GMBXH*[61F9G7S,BH;*:GMS3[
MI9ZK9B2?+_D;(!IMWBBTN]/19V?)D?G0<&+)CW/*:S]<U-SQZIJ^].-;IAI7
MK]I@NOL=*(U=SJS2,Y2HK$;OI,1:1C:_,J@HI#2L/+ XNH91F%3O4Y#3Z%50
MWN11V-;HF=M1Y9UUON1O^,<A>KLD9*$.Y8?G0?/QQ9^[E5:_&=3<.G9'[_#=
M!\;JEVY:6Y\=LB=77R0R\[O<(E+.>@IC6N@9H0VL_,"ZD%+?FJA*KZJ$&O>J
MK#JWJK)ZUZJ6.K>RSDIR<4_QWP Q:T4A=JL$Y.Z6A.I#<W^>E5TXU:>X8OR&
M^L:'C[4/77MBI';^OJ5EXPT[4LD0@9'>3PJ+[:'&AG7YI :>8V;[GN$4>K9%
MEI);A>4N+9F5Q-;2*D)K<Y534W<9L?9"X=\  K2[$[:(0^$N"6@X*/FY6V;>
MBRL*2QZ,J*R[-JY]N&_<0*WML85YY7U;8LXMO(_PFC,G?(C"#[KLG>#;[Y_F
M<9&3[78A,I]X05CHV)M5C.LM*;'K;2RQ[^DMQ)WKS_T;( YU2-TD#F4[Q*%M
MG_C;?BG)A_>.S;\VIKKAXFNMP^VO]%5KGYF9%HQB\"F/\=3HAR1_[GTJEWF7
M'NE]BQ5+'N8F$*]&I#@,Q:9C!U,R,0.Y6=8#%5E6 V>R; 8'T_X&$*+MGX6N
M*6NVBG[JVB7Z],9.L6NCT@LO3*AL.C.E=:3VG9YRT1L3P_37&$SL*T=BV LW
M:N!S;SI]E!'@\3@HV/5A:*C3_:APA[OQD79W4OF8V[DQUK=+!9:W&@7FM[K_
M"DA<)0J%ZT2A9:/(RX'5(M>?;!*],"&U^,RTRN;JSQJ'"Z9U%=(_&FO'?<"8
M\3X0;(/>4QS]IF@DK[=,=\KK8$^7ESP:X7FTK\,S(<-N+)6)&<T.L!XM"K1\
M6A-D_J3UKX#4%2)0M5+D0\\29/C. J1W8K-XZR>I954_E3;G_SQ](.6']@G!
M#R/5L!\V.H$_",9^/]PM/;_[8,A?F?:DSQR\TW0X ?\AAHA[G^!B-Y5&PDQF
MNUJ_*R);OJNBF+]M=/\;H& I,M6V$+ER:1[2^V@!TOQYBV0E2"_/!?E-B:"Z
M)PJTI#A@>)()ULHT<-2@ D7'%6CZSL T(D"PB0/PS.PAVAP+0@O,KU0KFY]9
MUE8_"FTLOE=@S+_7V?X-DS5SD:'..4C7T%RD\>UBT3+8-C<'I)8)X<3Z<%#:
M'@@:^^A@<)0*%K*NX'"2"&X*>/!2PH&?"A:"U# 0>MH&(M6M(%;#$A(U+2!=
MRPQRM4VA1,<$JG3_AJNMXDA'CP12?U,2*?ZU5"P3=LR-@T-+0D%FM3_(;_2$
MT]M=07>/(YCNMP/L(0P0CUJ#NY0ET&3,P?^8&03)FD+H<6.(/&$$ CE#2) S
M@+23^I![2@^*_XK.=C&D]K(84O! 3"0-EHO%PO:Y7-B[R!>.+'>'$VN(H+S!
M'K0V6X/A-G.PVF$"N%V&0-QM )0]>N"U5Q=\]^E P'YM"-ZO!6$'-"'R !IF
M!]4A\>!I2#_T-]2=%T$*AA$DZ;682#2L$ N&C9(^L&.^*^Q?[(!>%S9P:I49
MJ*TQ!)UU>F"R7ANL-VJ"W29U(&PZ#2Z;58&R104\MRB#SU8E8&Q5!-96!>!L
MDX=PE.CM?P,P-XF![UY)\)99 *P32R!4>15$:&\"OMD>B'20 IZ[/'#]U2&(
MIP\!\6;@EVX-/OEV/[Q*\=^HU4Y?R(TNGUW/N$Z3NLD?G/O=WQ&&/";P-SR?
MXQYZ/;4;ISVT??9'_NOP?\D!?5;X[9$$'^D%P#Z^!'B*JX"OM0D$)GL@VEX*
M(LD*$.:G"9P00PB,M03_5.P/>B[^JW<Q\;-'E>LTI8'RP:W-XSVIRVO2N9\V
MX31$?X&_Z3N*&_&[;S?J?\MNW/=/0,#_./@=G0]<V<40I; *8C4W@=!H#\1C
MI4% 4H0H'VW@!9L"AX_Y$9B$_\+(<IGV*71_[U7N-4FM]7E+;O:;<.U@OG+I
M"WQ.O,)^ZG@[^"[N(><:[G'0H,-HP)\ %NK 0-<O3'0=]_M=D!CYE2!4WPC)
MAGL@"2,-0J(2"+QT(2K0XE=8A/W78*'+QX!TZJ1O'NV-=PGCE4=UX M*8_ S
MU_:0,9>+O"?H@_RNX[^BKN+O1O0[/N3V$AZS_P0$HNWOCSJP#L__YUV0.+2S
MDDYOA'3]/9!F+0/)!&404O5!P+3Z$1GF.!T:2YX,2J%-^&<S7_@4!8][5H0]
MI31$/G8[&SU"NAA[S_FZ\(KC=6&?TZWH;N)]WCGGA]P_\8\#$W5@H]W-1QLG
MX=2*?]Z)R=+;#5F6,I"!5X$4BL%WH2_F<PS'^7U$M.<$-]'_>4 &9Y2>'_'(
MJTSPP+U.>)=\-OE?KOUI@TX#&1>(5U*Z7(;CSY#N1#6[WN?]"0A"'0)0!\Z!
M>1"#.B2AG96AM@%R=7=#GKD,Y.!4OV>Z&GU*H=E-"8/<)J(CZ,_#XH.?!J5&
M/F3DQM_Q+DD9=J_)NDIIRQDD7\CM<>G+;2<-9+2X74NLI]R*J:'<C?P3$(0V
M;P#:O"'[YT$LVCBI:.-DJVZ  IW=4&PJ\[/03O5SGHOQ5*87[G5*@/MX; AS
M))S/NQ4DC+_*2$NY[).7V>=5GM/CT9#73>TL.$.^4-! [L^I<1]*K? 8CB_S
MO!W])X"-.K!0!]Z^N2 \LA R4(<\E?50HKT+RDVDOY;9JGXH=C*9R*?BQ]-]
M/1_$![&'(WG\ 6Y,PH7 I+0N1E9V.[THKXU67=CLW594[]E37.%Q,;_4:R"C
MD'8M(=_GIN!/0/#_./Q^3RL1[:RL$\N@4'D=E&OM_%EM)/VIRD;U786CZ?-B
MLN-(MC=M.(G)N1S#Y?>$1R6<X\2GMP2FY33XYQ74^)475_HVEI3[=I<6T'J*
M<NF7LK/]KB9G^@W'_XE_' )1A]_O)R4?7@ YQY="B?):J-+:\;W>4.I#O97J
MZSH'TZ?E)*?;^9X^@VE^G!XAF]_.YR4V\03I-9RDW/*@K,+B@.*2 F9M69Y_
M>UF&7W=IFG]?;BIS*#4EX'K"GP .ZA"$]N;O=V)2T?LS'W4H4UH+-9H[OC09
M')ULL51YWF1O^K#:V>E:$95V,8L>?"Z9Q6^*"TFLCN)GE/*$N07<]*(<=D%I
M1E!5>6I@6T5B0%=Y0N#%?&'08%H\^UKBGP#.NG\[_'X?)?W0?"B470*5BFM^
MU6ML_]2J?_1-N[G*6*N=R;_JG0@#911:5QXMN"6=R:])#$XHC8W(R(^*S<T,
M3RE*"<TM3>26E<=SFRIB.)TH%PJCN0,9T=RK27\"N*@#&W7X_0Y$YJ%Y4(S.
MU]6*JW\T:6S[T*YW^%6WJ?+C=EN3ZTT$PL4J-^^S15[L^FR_J++4H(3\A+#T
MC-B8W.3HI*+XR*S2F/"2BJCP^LKP\,Y*'J^W*)QW.3.<=R7E3_SC$+Q# N+1
M:R+[X#PH/;8(ZA16?6M5WS+9J7?H^043Q0==&..A5KQC=RW)J[G,(Z@RGQY9
MF,429J9RTY,2HW)CXX5%40+TM,04581$UU9R8CHJ@_D]Q1S^I2P.?RCU3T (
MZL#=+@$)Z+'(/3@7*F060:/"RL_MIS>_[=4],';)1/Y6K[51?[L#OKW1Q;.N
MRCVPI(06F9WO+TS."DZ+38_(B4R)*PQ)3"UE)^27LX15%4SAV4IF?$]Q0-RE
M;%;L4.J?@!"TNT.W24 2ZI!_8"Y4R2SXU2*__&.7VL97EW3V/AXR.GFMS\JP
MI\O>H:65Z%%13V;E57J%IY8PXN(*T,DR-RR;FQ53$)B17,)(RRVCIU64T]):
M*VBI/<7TY$O9ODE#:7\"0E&'<+3]4]#S4;1_#M1)S_]^]M32J0NJZYY?U=YU
M?]A ;F# 0O]<KYU]70>!6M3J%I!1[\$35OO&1I:SDKDE(9D!A?P\W_S$(J^\
MK!)J;ED9):^YS#VOI]@CZU*V9^90ZI^ ,-0A:K,XI&\7A])]DM!T=.ZG+KG%
MKP=45CVYH[GUQAV]XQ>NF>NU7++%5O0X4G(Z2(S$-FH(OXD6'5+/3 BHX:31
MJR*S/2J$^>3RS$)2>4F1<WECL7/%A4)2\>5,U\*AE#\!/+3]8S:*0_8V<:C<
M(_'SS!')=WW'YX_>5%IZY]'I+0,CNL<Z;IMJUU[#8 HO.[BF7G3VC>FF!(=V
M>$<&G&7$^;2QDZ@MX>FNS7%9Q*:,7,?&XCR'IH8\7/.%7'S=8+IC]=6D/P'A
MJ,/O]Y/RMXI!_2ZQZ:X#XL^N2DG>&9%;,CA^>FO/4QV9YA$3S;([UE:9P_;$
MN"M.WKP!-Q:KWS/4YZ)?%+4W*);4$YY(.!^7@NO.2,-V%Z?;GF_(P/1<2+?M
MN)J$/3,<_R<@<K4H)*/M7[I)]%?K-M&)2]M%[S[<)3XX?F+9^5>GM[<\UY:I
M'#-2SWUL:9;XT,XAXAZ!''3;C4Z_Z1E('?8+<;G.CG"\%LZWOQ8OP%S+C+.^
M5A)O>:U):#'<%V\Y=%-@V7^;_R> OTH4LM:(0,TZD8_=:T4>WEF&#([OENA^
M>V)%\SNU'15OM*3S7NNK)+^T,. _M[/F/B/B_<<HKMYC/AZ449:/R]-0AN/3
MF #[ITE!MH^S@ZT?E7 M1NI"S$8Z0DQ'AD-,[C[@_@F(72$*A2M$?K4N1VX/
M+D &QY:)=+W;/:=I6FY5^4>5[3D?-(\FO==3B)XRU^1.VADQ)YTM?2:I6.H[
M7[SKNR GXCL>"?].X&;_-MG=]DVVA_7K(D_+U]5>YJ]:O4U?]=%,7M[Z(Y"Z
M5 2J%R,WN^<AEZ[.0SHFEXLV?-TSO^R[W*KL[TK;$KZK'XS\IBO+^6:FY/_-
M3L/[F[.N^S</0](W7U.G;T$6^&\\*]QW 0;[+=D6\S7+SNI+D;W%YTH'L\]-
M>--/W7CC3Y<=_P04+$!NMTHB%WOG(&=OSD-J?ZP4*X9]"S)!=E4<R&_F@=KN
M0- Y3 >38QY@>\H5B$I$H*HZ ET=!RQ-+(1H8X"O8PT)>I:0H6\!^09F4&9H
M G5&QG#6V AZ3/[$O1I1Y&*[!-)V20*INC\7*8 UXNEP8($ I):'@-QZ?U#9
MZ@E:NUW!Z  !K(_@P%$:"^1C&/ ^;@T,.4M@GS0'GKPIQ"B80)*B$60J&4*!
MD@&4*^M!@XHNM*G^B?XF4:2U6QRIN":&Y+R>)Y(,ZR7XL'L^&PXMH:/'@@**
MZXF@OMD>]+=;@_DN"[#;8PK$?<9 V6\(M ,&X']0']B'="'LL Y$']$&X5$M
M2#NJ ;E2ZE F?1JJ_TCK&5&DO!]!LNXBB! 6BD;">O% V#;7&_8N),'1I0X@
MMQ(#*FO,07N]$1AMU >K33I@MUD+"%LUP'6K.GAL4P.?[:K W*Z"/H"5@;=3
M":)W*H)PEP*D[9*'[-U_HJ(;'?\:@L0^01 >+!9EPBHQ*FR4=((=\[!P8*$%
MR"PQ OEE.J"V0A-T5JJ!T6H5L%BM!)@U"H!;*P].:T\":9T<N*\[ =[KCX/?
M>EE@K3\&G TR$+%!&F+^"'AN%@,*^IQPE9D'WB<6@;_2<@C46@?!)ML@"+</
M6.[2X!]P$GPC5("6H &>6;I +38$<I4)N#:: >FL!3CW6 &AS^8[?M#V,^X&
M]H/]0[M)[*C]:]N7N.<V[QS&;:9PL_%?A__?8:\DD*7F ?WX(@A06 YLS740
M8KP-./;[(8@L P$,>6#PU( NU ;O# /P+#0!]TIS(-=;@6L;!ERZL3^(??9?
M' =QTPXW\)/V#QTGL&.$%[8OG9YBWCD]QDPZS@9X;1(#=]2!>G0>,(XM!+;\
M<@A17P?AAMN 9WL 0DC'@$U7!!97 _P%^N";9@K>>9;@48;YY5YK_\.M!?^=
MU$'XZGR1^)$PZ#*)O^'Z&C="?F8W3GEL^]+]+O8MZ3;VG<ML@#?J0$4=O [/
M@P#IA1!R:AF$GUX+4?K;(,KF (0392'$6QG80=K XAN#?[(ET'.P/[V+';Y1
MJYR^4!I)GUS;R1]=+KA/.@UZOL;?\!['/:*-8,=];F-?>%VU?T,9LG]+G@V@
M;10#C]][08?F0I#40N"=7 9\M;4@T-L& LL#P"<<AW /50@)T -VN-DOEM#V
M!R,3_]6GT.639P7Y@WN]QY3;&=H[4H_O:^(@XYGC+>8([A'KAMUHP!#NF6^?
MPRO/BPX3U-D ']3!$W7P1=>S'+0W(^66@D!E+0AUMD&"^4&(<S@!T933$.YG
M\#TDQ.H+6^#PB9GB\L$WESKI74I[0ZUAO":WLEZ0SK.?.0]Q'SG>";V.>Q!V
MV>$Q^P)^E-E)>.'307CI/1O_=M@M"?[[YZ+3[0*(.;$4A,IK(%E[*Z28'H0D
M>[E?\:[JWZ)]C*?#V;;ON9'$MX$)U%=^&?3GW@6L,6H%YXE; V_$Y5S4/>+E
MF&''FX)^QSM1YPD/0MN)CX-:G,<9S<[/?&<#Z!O$P.OW7M#>.1"!ME[<\260
MK+0:TK6V0J;Q 4BWE?N:XJSQ4>AI^BXZ /<J+,QM/"C&YS$C*?"^=U;83?="
M_C6W*L$0J25N@-03W^]R7=A)O!G;YG(WLI'TD%OK^I15[3;F/QO@BSIX[Y8
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M:AGP7BT%S#5'T,G_,/#7'H2$M0<@<]U^*)F5O$YT_$%T_ <(POB,(%28+T*
MI:(86"5F"IO$]=!SH@D'YZJ"S#P%.#7_)*@LD 6-A=*@N^@H&"\Z#.:+#X+-
MXOU@OV0O."W9#6Y+=H'7TAW 6+H=@I=MA8AE6R!^5@"+/J^M#DF M<P<P!V?
M!P3%14#47 [.QFN :+\1G*C; <_: [BH V"??!BP>5)@6RX#F'I9L#ES'*Q[
M3H#UT$FPNG,2+!^? HMG\F ^H0!F4PH_3*<5OYA^59PV^:GXP01FY-\.!R4
M(ST'\++S@*BP"%PTE@/): V0L)O V7T[$ +V C[B(. 2CX!]CC38E<F";=T)
MP+3) :;[%-@,R(/U+06P>J0(EL^4P.*UTD_S2>6O9M/*GTR_JGPP_:DR:0I*
M,P%VV\3 &G7 'IT#3C+S@'1J$9!/+P>*X1J@8#:!F]M.<&'L Z>PP^ 8+PWX
MS.. *Y8#^^I38->L -@.);#M5P;,L"K8/%0#J_'3/RU?J7^UF%2?-I_6F#+_
MIO'6_)?ZA#FHS038HPXVJ /NL"0X2\\#BMQ"\%!=!A[Z:\#+:C-0778!F7X
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M?E+\9/)=\;T)*+XS!?D)4Y![/0-@@3J8'A '[ $)(!R> R['YH.;TF(@:Z\
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M;C.Z7UWWZ']Q.6+PV7G9Z*/S+>-W3L],7CE]-'WN_-/XF2L8/'$#W;]HH/6
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MM<W!\=7;PV*J)B(BJ_9'1E2=CXRJ>1X26[?J&U?[TR.N&EPV C'X+N2PXKO
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M<\T6HDJMYR)J;:?#6BD3(;V.H\$[G$>"YER' @_1!@(OTOH"G[CUA7YQZ(\
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MX>-)28,GAR3UGUR3U'O\1E+OKV\2>@]!<B-+?0C-C2(TC.]A!SZ#ZN,(Y5]
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M5R;76)<EMMH6)_11"N(GJ+EQ^QQSXI:=LN.?..0F?;7.3P&S@E0P*DP#_?7
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M14!SD[5/\W9;KZ8I.X^F@_;N3=?L/9K?VG@W_S3W;0%COQ8P6 _B$;J?C_<
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M30X*OS0YO>VYR>_;'IL\$WEH^FG;/=,UX3MF('C;' 1NF@/?'^:P=3TP%2$
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M2'<EQBBTQ2>K-,5E:=3'%&G71%7I5T8V&Y9%])H4AX^9%8;OML@//V69&_[
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MM/'B@K31XEGLF;31_E4IHWT@:;07)-8[4XGO(7X>3/^Z R,(M4\A5(WG%QQ
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M@],&_"]-6^[_T'19X'N#9<%$IS^$:"+U_E"B.A7QQAX$8]Z+9L*')#8\3>?
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M?3RC*/W3M.(,8E22B7>_3*([%0D%>)T(< T?-2X58^;#W'>DE@;[Z^BPLUX
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MA>O)N Z8_X^68 ^P]E@M9N\ZS-YU;.BOEX,E]7I41]UT>DO-')&&*@]>346
M1$59N$Q):9Q\84FJ4EY1CFIV88EF1D&M3FI^JWY2_E+#A+PAX[B\;:8Q>4=-
MH_.NF<;FOS*(RR<Z\05$,Z& J$WU='(O3*X#[H.#%=@#K+T9\^=P(V;O1CHL
M:92&CB9MJG6^!;VAP8Y=4^\F5E[K)RBN"97.KXX1YE0F*V969*FDE1=I))=5
M:R>4-NO%EG0;1)6L-(HHWF(27GS8)*SX-Y/PDA<&D25$)ZJ4:"*UJ1[& 5S!
M=3B!/=B'V7,,ZZ]OP=R%.7P)/H:V+Y" EC9U:%@PC5;3:LLL;W86+6KRX>?-
M#Y;,:HB239^7J)!2GZ&<4%>@%EM;J1E5TZ@37KU8/[1JT#"X:I-18-5!XX"J
MGXT#JY[K!U<1[9 JHA%:1=2FNI,$\"WNQ2/8@]T-V .LO68A9M\.K(]9O*F3
M#_6+E:&ZTX@J6V3%*.R8*Y+3[LG-6!@H2%T0(9W8&B\7UY*F&-V<IQ+15*X>
MTMB@%=2X2,=__@H]W_D;#;SG'T#_,?!N>*;KVT"T_!J(!E*=ZBJNPVF\%@[@
M&FS'^:]O!QA8C-D3<W!C#T!-KQB4]\I#<:\>E=\[G9[58\]*6^HFFK3$CQ??
M'2H1W14C$[$X11C:F:,8M*A4Q;^C7LVGHUW3LWV9MGO[!AVW]OVZKNW?Z[HN
M_$/+;2'1<&\C:AYM1&6J*_B>= RO@W%<_TU8?W470"_67H@YN'8%0/$@$_)6
M2D'V2DU(7SF-2AZT9<0/.K.C![Q%(U8$\4*71TD$+4N4]E^6*>?37R3OV5>K
MY-;7IN+<VZ_FV+M>?6[O/HTYO=]IS.EYJC9WZ6>5N4N)LN,2HC35N<D>U.,^
MP/Z/8/WEO9C_,8HT8@XNQVB4@5D\>1T?$M<K0=QZ0RIZ_0Q:^#H'1L@Z=U;@
MB#_';R2<Z[TVCN^Q-EW"=;A VFFX6G;NFE:A_9I>A=EKUBG.6K-7R7;-947;
MU4\5;5=]5K!=2>1GK23"J8[CM;@;]\!&K+\2ZR_%N;<.8?[%')Z_$?,79N&(
M,1$('9.&X.V:$+A]&N6WW9;FO=V)[CGFS70;"V8[CT5S',>2Q1RVY?+LME6(
MVVYKEK#>VB,U<^N(](RM>Z2G;[LD/7W+4VG+S9^E+3<1:<O1?]J/:[ 5X^ :
MK-\W@&N <Z_#.%:$.3AM.T 49E&_?12X'^"!VP%Y<)G0!><)"W"<F$W-F7"E
M["?\:+,GPN@V$_%,JXE,UHR)4A'+B?D<\XENT6D3PV*F$^-<DX,7Q4P./.$:
M[_O,,]I+>$9["'^J';CW1[#^<JR_".LWX-Q+MN$:8 Z-V0<0<! SZ%$*9I]B
M@=5I <P\K0@SSNC"]#,68'EV-EB<=06SL_[4M+.1E,FY9)K1N7R:P;E:NOZY
M3H;NN2&&SOF=#.WS%QC:9Y\PM$Y_9&E^0]B:I_YI ^Z_0:S?A?4;1P'*<.Z9
M>P!BL7; 4:R/,7GV&0#+;QE@^#T'='X2!^V?Y$'[9VW0^GD::/YBBYQ!XU<_
M4/\M$M1^2P.5JR6@?+694KK63RE<VT3)7SM.":_>HX2_OJ6$OQ":W,__M K7
M?PG6;Q[]<@:5A7.//8+UL;8+UK:] &"&>5S_)P#UJTQ0N<\'Y?LRH/A !>0?
MZ(+PX320?6@-,K\[@O0C'Y!\% $2CU-!\*04+0#^TT'@_[$#>'^<!^[31\!]
M_!&XOY-_Z,7ZK:-?SJ"R#V#]XU@?:SMC;6NL;?HC@/9O ,HW (2/:"#[1@RD
MWTB Q%LY$+Q5 ?X[;>"],P:Q]].!\\$>V!\\@/$Q%.B?4H#VN13@4QO"B^PC
M+N['2^@Q^H@^_5<;UJ^>/ .; (C#N0><!W"Z## 3:QMA;0VL+7\'0.HA@. ]
M )^P@$>X($H$P";2P" *0!$U **+IB$;Y Q_/B 2O"%/_@^)_CQ[P'$0;#0Y
MA>[\0RW6S\/Z\?A'@1<!''\ F(&U#6X"J-X%[#/6QJ%SL3Z' + 0C3#PO^4@
M'A(@::2 U)$^LD0.R.>OSX+@#9$THV4(-SW9^P]$#;.EANX7J@84D9]&$4EK
MB@B<*<(+I @WCB*BV33"*4?S40=%.#UH *U!&] VBHB,HX/H&_0#NHN>H0^
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MA?94X2'MD>(;V@-%0KNO2.CWE C]+KHS2?%OQ!AK3Y,#8B:#KYBYS; ?TPR
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MW=*Y8Z[Y_"TNY8)-+G42&YU;I-8[=4J/./7)#CL.R:UV'!6N<AR77^EX2G[
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M2,2&+Y&*"5\M'16^728R_*1L1/@=F<B(=Y*1$400%4'XB/?5Y"GA>5S_@_$
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ML_\!<3RU_C@CQL,0XBB^ZIM!U+&A+>P/(5!=(<JBKZ7DK6=K[?1G#GD6DF>
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M[#M4.,9^WTW^C>1;T0LL[*/V7,!^6 @4$2E$%.%/N"_4QO2%1IBV<#R<%]K
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MIY^'2OA,DG,]-?@@I<!\8A;?5]&6_$IJ;\JEZ%)MA)<:(;1T D+*;!!4YHS
M,D\$E ? OSP"?N4)\"G/@'=Y$;S*:P3/\EF">_DBP;5BG6QZQ7[9M(J+,I>*
M=V4NY;_(7,I$V30)I2J<+E3=U+.E@=J[175#RQRBM95CL9FZB_8DT)[06CG\
M:PS@6VL*G]K)\*YU@%>=*SSK?.!1%P+W^ABXU:?"M3X?T^HKX5+?!J?Z/F%J
M_1IA2OU>P:'^@F#?\)9@7_>38%\KCL"A1I1).$8?=Y-CHW1+#:7A0DJ KBYJ
M7[X6=P!I_"RZG=J/O_=HU8%KFQ&FMXW'M#9KN+0YPGFF!YQF^L-Q9CBFS$R
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MZ4\3L?&3_/*)&\27_-[OA#B"_ZC!;.=\1,XH\OF2SYE?L2+?N!. (66RSAE
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MJ!=IQR4F)I>Y&%W.5EU5?9FQN+R18".7*>@O?4U0T5Q\A+F,=S-C6TKNM+U
MY"&.P:/D/TY^RG,3=J'>.4!^0:J[$%>E?2AJ7".>)VY0)+U D7*3HN!%4PH$
M)L2OT(Z[3,9>Y:+\*B?<U_C@O\8!]AH=?/TB\3;Q'?';2 VF?#>027^CR.MS
MFOQG.?[(:4Q.G:MJKAOJNLO+ZCTA=]7UD#<>UT-DP'M:P(>,R2?LFWL6P)=3
M"29)7W'A^XH3X==\^+ZAT]]P7'Q#)[Y]D_@,E8QY-C^*(;<?>1W):_$,8$3_
MM*5ZSW_O0Y%J+A^K]Z \>3_)O_>%<)S\J O\RK[Y@T+E+\;C[T#@$<?&(TZ&
M(A] <;/ZIM0KQ(OJO0:/:P\F(YI;I.96[<&0;DJ5SH!(MY260G5#J+071+H7
M1/JK,=*9F.7$&F(C5&=B]N,1E>!#ZLP'#-R?-%:ZB4.J>TA[/WZ%:N^'5(.X
M!]59$-7>"WTU#-3U&&D_RN,S.=*=(-(MI04CM9A':&#[[530W6R_C^TO8?LK
MV/Y:ZN7-9-M%CD.X3V7Z'9[%-WB3(?H67_);4MU#NGOC<W7MXYW']8>1VH>T
M[T'CB?J#=#?)%*CN! DE7R)YLLA1/'(6Y3Z:V/XLMMS#]OO8_A*VOX+MKV/W
M;*%O>T;.HGQ Y?\N%?O_T>,W:*5T#N6N&M)YE-M0W2NKJCD\KC\H1N+Q *;\
MAC5]FHX?&(OO$,78I9 C%Y^R3SY"#=MO8ONS\#;M>(-VO$8[[F(EA^QZMKV-
MO7" [9_&=<;B.?ZK9VCY54;Q"E2GEBX] 5'VGW^0Z!=HDM.(OIG3IRGD\\1[
M'!=O4?>_2MW_,O+I61ENTHX;M.,:^^59]LM5VG&%=ES"$$?"!IQGGYS!$5IQ
M 2=IU7%&ZAA[3CH])57-CJ@AO1_Y(TA070;\O7J(?P0]<HYAO*S(YT)_?,D5
M3E\2R)'!5O-QCG:<H1VG:<=)VG&<=ARE'8>Q# >QFB-S"_9B'W;S7^SDM[?C
M0T;GIY'JW18U-JLA[8/Y33KJQL?I(TZ];RJD4JB2/AJ2<SPNPIY\;FPI "<0
M29XDCKA,1CJ?#&7L^6IZW$2>=O+TD&,AVUW.IV28_]O%$7*,3\UEK.+#/<0(
MK^38E$Z7+1?^P9^<4K[FH_S^&$X_TM8[J?3,*>]IF0Y'MC%;F$C.J>3S9(M!
M?/JBL55(QF99)C;*\C$L+\,Z>0W6R)NP2C$+0XI>K% NP:!R-99I;,,2C4/H
MUWP:B[1>P4*=;]"G^Q#S]43,>P)2#>9C3FDO3U;M_SC/]R?'<IGAM'M 6Q^[
M-$VQ5=L:&W5<L$[7&VOT0C"D%X,5^LD8U,_",OT"+-$OPV+]6BPR:,$"@]GH
M,UB(>08K,7?49O2,.H!NP_.8;7@'G4;?8I:QB'9BILD_^'*BJL1]C=/J>>*8
M _6_-;"#4]QF$SG6CS+$D.$$#!K98ZFQ&_I-_+#0) Q]H^,P;W0*YH[.0L_H
M0G2/J4#7F'ITC)F)6:9S,=-T&5K'KD?+V#UH&O<4&L?=0H/9EZ@;_Q"U$\3_
MP,=VJAJ,M ?EA#OY^;K=B5J#GP]-8HXY5@^+QIEBOID5YHYW0O<$+W1-"$2'
M>03:S>/19IZ&%HL<-%L4H]&B"@T3FU$W<39J)RY"]:35J)JT Q633Z#<\CK*
M+.^AU.H!2JS$_\#_D>^:!Y=@+K6'?*AU^+J!:<C0-&H^QF2>I1:Z)QNCP]("
M,ZWLT6+EBB9K'S18AZ#..AHUUHFHMLE I4T>*FS*4&9;AU+;=I38SD>1W0H4
MVFU%@?U1Y#D\2WR,W"F_(V>*^ \<.%\Q_;KBHZK![ MBJD.LX5*WC&G(_.G,
M\Z?*T6HW"HWV9JASL$:-@Q,JIWBB8HH_RJ:$H61J+(JGIJ!P:A8*IA8AW[$:
MN8ZMR'&:@VRG 60Z;T*&\R&DNUQ&FLO[2)WV*R$BU>4?O$BNI\E_-)0Z0]J#
M0JP, 1;1CNX90"O[ILY)#U7.8U#N/ DE+@XH<G%%@8L/\J<%(W=:)+*G)2!K
M6CHRI^<C8WHYTEP;D>HZ&RFN2Y#L-HQ$MP-(<+^(!(^W$>_Q,R&JX*["#:89
M9\E_D!I_&U/1=<0 TY_Y_*R#MC70CG(W;12[&:/ S1RY;K;(=G=&IKLG,MS]
MD>81AE2/6*1XI"#9(P=)GB5(\*Q'O%<'XKP6(7;&.D3/V(<H[_-"E/?K0J3W
MCX0H 2.8(>)9Z?_^BF _4']O2:#V)Y8P]9E+.]IH1PWM*)JA@5PO0V3-&(?T
M&59(G3$5R3/<D.3M@P3O8,1[1R'..Q&Q/IF(\2E"M&\-HGS;$>&W .%^:Q#F
MOT<(]3\KA 3<)7X@1"'$_]_ E5!5'6@WT^"-R>R'%/8#7[OCF><S-I1PR V0
M(=W/ "E^8Y#D-PD)?O:(\YN&&'\O1/D'$.&(#(A#1$ ZP@/S$198A="@-@0'
MS4=0T"H$!N]"0/ 9P3_D#O$](0K^P2H$!%'[,P9'R+>3W,/I3/\SJ#GYVLF?
MZQF/$L8CDW8D!>LA/L@$,<'FB JV062P$\*#W1$6[(O0D%"$A,0@.#0%0:&Y
M" RK0$!8"_S">N$;OA(^X3O@'7%:F!%QF_B6$(49X:+@+2%,Q+D8=1V(W&N9
M @_D\'GDZRQ*E&I^7D#[TJ*I^2*T$1ENA/!P,X2&6R$D8@J"(EP1&.&-@(@@
M^$=&P2\R";Y1V?")*H5W=".\HGO@&;T<'C';X!YS$FXQM^ :\PU?'\$M6AR!
M._$4.?9+=2!RKZ8D65+ L4"TY;(?:%=>*C4?^RDR5HG@& ,$QI@B(&8B_&+M
MX!OK I]83WC'!6!&7#B\XA+@$9\)]_ABN,77PS5A-J8G#, E80N<$X_#*?$%
MXBLX)?P-YP01SO$J2'<C2_?B;"3ORA+56:!NOC87,=_/8[[+WR72EK 4 7Y)
M>O!.,H%7T@1X)EG#(]D1[LEN<$OVA6MR**:GQ,(E)0W.J05P2JV!8VHGIJ0N
M@4/:)MBG'85=VG7B"^(A[%-%V*>H<"1#=29K/;F75ZK. G7RM8%2L9BV9% :
MQ-*6(-KBF:D%UPQ#3,\<"Y?,27#.M(=3YC0X9GEA:E8@IF1%P2$K&7;9N;#-
MKH)-=CNL<_IAF;,!DW,.8U+.<\1GF)3] ).S14S.8N9*'&#,MY)_#;F7U:G.
M K43M7Q?4$W=15LB*=?\BJE]"^686J /AP(3V!5,@&VA-6P*I\*ZT U6A;ZP
M+ S#Y*)X3"K*PL2B,I@7MV!"<1_,BM=A7/%!C"U^!J;%GV)LT9\85\@,7D*!
MB#UL>R.YABA-^YN!GE;5/I3*%M4^%'8K0FB/5PW@3#NM*[4PJ7(4+"K'P+S2
M A,J;3&^TAEF59X85Q6(L571,*U*PYCJ(IA4-\*XNA=&U:MA6+T/HZHOPZ#Z
M8QA6_0[#2JJ)"A6V2WMQFBC%*<7Z*-,[._]S'TKD3,: OW.E7?:T:R)AVJP#
MDV9#8BR,FR?!J,4>ABW3"&\8M(02B=!OR8->2PUT6V9#IV4YM%IV0J/E+#2:
M7X-F\WUH-3&+;U1AY#Q4.["XB\\#I=C,N8P!D3-7M0\E> [' 3&5O[,DQA%&
M/0KH]>A!I\<(VCUFT.JQA&;/%&CTN$'1$P!Y3S2$'@ZT'G9B#YWH6<R!+EVT
M20$[^S87PF^(!P0SV4YQY%[@0;:[8!X_4I\%*ES$<= /1/"K/H0S84V,)XP)
M_24"-);J0%@Z"E@ZF@_T!(*)SU(F DNY""[EI+8D4?6@+VD@J+D74V<NIH#O
MIXA<]#FP\ ]"'(%4@UE,[KELNV4I4$9IG+F<^G,EX+\*F$[8$.-7DW\-^=<"
M&FP.ZZFUUS/Q7,>D;ST3PO5, M?;$"X$DX'UG.C7,Q;K.:C7=ZHN?EU'S;V6
M@G;-1\2OG)#$$0S0WP7+^"R0MVJ(?4".^&$^BQL!MTV '>7I!(;1F/I<;SN@
MV$'^7<1N@6!2OIMV2'M2]M"./4P ]]JJ-N/NX^*_CY/]/C[8^SBX]S+ >]G8
M'HKKW13MN^^SG8>$B'YR=]+/6OJ63]Y$<H60QWV7ZAS0A+WL__V SD% 8"B9
MW'.1(TX\AI()$(7!*?;+:?;+4^R7,XS'.29 YZ1-NIP$S_'A/\=8G*.39]G0
M6>K^L_<(QN+,(U4-9@/79W(GDS=T'^!Q4'4.:#SY#,FG+=5>GB+.$4^K:R&7
MB2MJ/$.Q]JP6\)P^Q0&%P@TSX!;M>)%)VNTPU9\2?(FZ_R5V^DL,ZNTS?+U#
M?$7\-E*#*=D)I)([G+Q>],V>G./YSYB20_.BFN=9=<U%JDG<5N/QN9S']9 W
MY<#;%$KOL6\^'*>ZI_5?3$[O<='[C)/QYWS(/V?@/V=P/Z<CG[].8?<%RCA,
M,@YQ'B"W-WD=+I"?OQ[U#*!\7KWWY;:Z#B+57-[&__<\SN-:R)?J6LAW'*\_
M&D@7& !_V*K^H,.?3(X>\%G]BP_A0W;\0Y(^I(-_WU;7'PS4>'P&Q!JJ>U&E
M,R Q4)V'*81J+\CCLR@]^.=.#NDOQZP;^6LI?U-A_D75^8!J]$_JS-^IF*6;
M.![_A1;I3E)I_X=T'\;[4-W+J=IWH:VN0>BHZS+2G2#2F1QOJ/:C2.=A<LA1
M0K58P_:;J: [V/X<MK^ [2]EVROQ(W7_?2K.[ZAVO^7 _9H#YTMVV.?\[SU^
MZ_%='%+]0]I_<4==@U#5/H0GZ@]2/*1ZD"U]<J-/@>2*H0]I]"9??1:EENVW
ML.4.MC^'[2]@VTO9]A#5]3#]VSYR%N4M#N37.8CN\M,[(Z=S5)Q2!4HZ?R+=
M('MEQ(;_K#_\!5WZ9D*?)M,?)W)YXPN$T8<$<F2R_0*V7TX_ZC@,6]C^++;?
MP_87L.VE;'L5-?M&,N_F,#Z*JU3NESF8+N(;7& 4SY%%PEFH;G$Y^5\VJ&H0
M2G*.XE S8T_:DLN57/[DB21'$H=H%MLO9/OE;+^6[3>S_5ELOP?G:<=9+,-I
MJOV3V,+>V$\K3G-T7&=4/N%/OX[<(K,7JAU$CR%Q<[8:N>[F2W79[PW&XB7&
MX@5,8KRD/1B>[-D@<D1SI"6SU2Q.3X4X1CN.<'P<1M/(/HS]M&,O%C("@]C)
ML;&=_]U**S;QVQOHR3 ]E$;NVI$1_ \><LK]0:GZXU1O*E7ER.L<%U<X+LYC
M+/FLZ8\+>;S)$T(_8LF1PM:SR%% CC(^#37D:2+/+#+/(4<_5G-L#/$W*VC9
MX$AT;HU4SA;S:9$JBOU/X!=.]_<XI;S*Z>VZ$:<_/M9G.>6=Y'-R&$;DG$ ^
M.VQCGVR"+WG":'LLHYW"GL_BTU! GC+RU)"GF3P=;'<>HS' )W<]W^W&7+8V
MASW8+?L$L^6_8K921!?1J:'"UR; 6^,YO7+9>YI+SDE.LX?XV1Y.N]N5>AQ=
MH\DY":MD4[!<[HX!A3^6*,/1KQ&'A1HIZ-/,PGS- O1JEF&.5BVZM5HQ6ZL'
MG=K]F*6]&C-U=J!-YSA:=)]%L]Y':-+_#8T&(AJ>@'3U]6TN_9?LR$\<X/2Z
M8R+S.TZU:PQE6*%K@"6Z8[%0SPKS]9TP5]\3/08!F&T0@4Z#.'08I*!]5#;:
M1A6BQ; "S8:-:#3L0+UA'^H,5Z+&:"NJC8ZBTO@95!A_A'*3WU V6AQ!J1K2
M/ABI!G.&R_XA+KD[G*F]'9A?6C$5X1+89Z*%.4;&Z#(VQRP3>[2-GHZ6T=YH
M&A.$AC&1J!\3CUK3-%2;YJ#*M 05IC4H']N*TK%S43)N $7C-J+0["#RS2XA
M?_S;R)WP,W+-.>,]@9?)?]E5=0?)'J9 FSV85O#GI8[4WISJNRSD:!MG@":S
M<:@?;X6:"8ZHFN"."G,_E)N'H-0B&L46B2BRR$"!13[R)Y8C;V(C<B9U(7O2
M8F1.7H^,R?N0;GD>:9:O(=7J1Z1:BRI8J7!3.H)+[L.^C '3CO5^U!E<8A9P
MV9W-F+2R?VHGZZ%RL@G*+"U08FF'(JMI*+#R0IY5 '*MPY%M'8LLZQ1D6&<C
MW:8$:3:U2+&=A63;!4BR6X-$^]V(MS^#>(<[B'/X'G%31+[^ ZD.=)J\^Z4:
M3 AC$,P8!%)G,!UK=V=^23O*[+50:&>$?#LSY-A;(<O>$1D.;DAW\$&J0S!2
M'"*1/"4!B5,RD#"E /%3JQ WM0TQCO,0[3B$**>=B'0^C0CGVXAP^1;A+N((
M(IQ5N$*?3Y!_C[0/AAI\);&([[MI1POMJ**-A2X*9#L:(,/1%*E.DY#L9(\D
MIVE(</9"O+,_8IW#$.,<BVB75$2YY")R6CDBIC4C;/I<A$Y?CA#7;0AV.XD@
MMYL(<O^:>,3WXK]QT5]U'\Q.:OSUU."#TCTD3#DZPYE?T8XRVI%+.U*GZR%I
M^O]CZSS XRJN-OS)DM576O7>>^^]=UG5EF3+MFS)<K?DWGOOQ@477, VF-YC
M>@N8!$P(-0E)^ ,$"#U (/26[/_>W14X)(^?X[M[=W>^,^><F3G?:&:NG]JR
MP]62':\Q.6EJRLE58TZ)ZG.J59?;I-K<3M7D351UWG15Y2]09?XZ513L4WGA
M52HKO%.E11=54O0^\@.O+2HMM,G]V/X68QZ(]/,H:<9>4O+-</$5Z#&$;M/0
M8P)ZM!>X:4R^CYH*0M10$*.Z@F35%&2INJ!05845JBQL4$51N\J+QJNL>)I*
MBX=54K)&Q25[5%1ZI0I*;U=!V1/*+WL7^9[7%N[9Y)XZVYF\5X%]>!Q4 *Z_
MD31T&?I VS0%>W3AJ^929]67>*NF)%!5)9&J+$E4>4F&RDKS55I:II*R6A67
MM:BHO%N%Y5-54#%/^16KE%>Y2SF5)Y5==:NRJGZ%O(U\QWNRI$J;G,<'UX%W
M$NR#I)X[)T"+C'4HO)^)/2;AFTYBI*':4565)I57^JFT,DPEE7$JJDQ5856.
M"JJ*E5]5K;SJ9N56CU-.39^R:^8HLW:%,FIW*+WNN-+J;E%JW06EU/^-Z[<(
M65*M3>YHL<\#3;"=Q[(-'KX&6=A+KHL>O=BG'3_5H6MIG;L*ZWR47Q>LO+IH
MY=8G*:<^2]GUA<IJJ%!&0Z/2&SJ5UCA)J8TSE=*T5,E-VY38=$P)S3<IOOE1
MQ36_P?5K)319K)*(W-+)N&#, X&[KY]^:4!:Q768-'A@(ODNG[6B8S6V*FAQ
M4?88+V6."5#&F BECXE76DN:4EORE-Q2IJ36.B6VMBFA=8+BVZ8KKFVQ8MHV
M*[K]B*+:;U!D^\.*Z'B-ZU>*;+,H"HENM5CWA5T%_F&P=Y/V;IQI6X<R;Y!8
M0)<N:%(3NI2C2V[7**6.]512IZ\2QX8H86RTXL<F*VYLEF+'%2EF7+6BQXU1
M9%>W(KH&%-ZU0*'=&Q32?4C!W=<IL/M!!73_']<O%-1E4? XLD;$.)OGQ#3;
MG^AWS*5?F$<L(+/G$ OHTXXNM>A7C%UH^DJ8Z*KH7B]%]OHKHC=<X1/C%#8Q
M3:$3\Q0RL5S!$QL4.&FL B;UR7_2//E-7BO?R?OE,_D:F2??+Z_)?Y1YTN>(
M13X3;6(\'^K8;/J%8<8G*/)JJ.'"1=)T7H^'&C6C5R6?YZ%C"O:)'G10\#0/
M!4PSRW]:D/RF1<IW6B*2*9_!(ID'J^4]V"JOP8DR#<Z6Y_25\IB^1^Z#I^4V
M>)=<!Y]!/I3;M'_)?< B#^1*RC]LT/,E^&&9;1W*D/T\E,ZEQ.)B;(!.&>@6
M/Q_^B:Y^PT[R&O*4:<A7GD,A\AB*D?M0BMR&<N4Z5"Z7X2:-'NZ6T_"@1@U3
M\!!\=PA".01YG'<1>0^!^\^U6.4X^/O!V[X*/ZR5%J^C;T0F\'H,4K%&RH&N
M)O%YQ$HI /%>.4IN*]WEM!*>NQ*^O9(D9"5)P(ITA %P!0//"AK4BBFVR:T5
MQB8?B.WRF^AX('#+(&9+OT;088E%AZGWGK6VO4 K-]O/I-T*_T9JD )H:@K7
M*.X'(J0F<D=&;2,!W4JRM94$<&L00N*SE4%V:Y9MT>-6&O-6 GD+3MRRVO8H
MY,V0ZDV0YDT0Q8U?2!LL5MD/_=N^Q;87:*&Q%V@W;6$O?=(^J>0R*1V)08(0
M,\6X'0#_((GO(?CM03>$!/0@R>BA8-L??@X9"9"Q)L78"-MN6_QV$(<>W"$=
M@',?N!O#0Y(O^Y3.X-_6M2B[M]OV BT%<R88$PX1AYBM#%J:>844BP0=Q_ZX
MT_4DV/!TDFF[H,=I]#B-/<Y@CS/8XRQZG$TA&2$INIJ!X.H>Q'A</ X^0\%G
M(/>GB8G3\/ZKOD4LVK;/]ERB.8=IB^"U@E.!NMEGI+BSX%\M>6%"%_BY1M:A
MW'*)W HYN!6_W$:"?CL)^AUP[3OQRWGT.$]B<)Y!YSR-^CR!?9[*GJ? 7^"/
M._''G9\A_[+-P8 ]Y11] 9A5UQ*#8,7="/[-X-]JWP-TZ3J4^^UB[,UY<&1>
M!)O\$IL\BF\N^).DHL>3:;;%NA>)SXO3$0+OXE&$]G'Q-WSV#O*YYE/O?NK<
M23UKJ&/N;;3!.XF_\Y+I'LEQ9.[%F'>Y8)\'N6B7D3TYS]C7:ECG0YRE/^";
MER$(KZ+'7TG$7B=!> .?O$G#?I.X>)/*ODG!;[Z O*MIQAP,=:Y#M7SJF4 ]
M@ZSGX$H.(^M01O;CC*P',=:>_%FV<T)>_=E<B/6\$/SSD?$D7V+U<^+C"Y+D
MKTA2OJ:M?D/G\PU!_2W&_A9#?O.T?MK_X6'G_9?N 3'.!#'.)!TKVWF@QEH0
M8R^*\5R4D3TQVV&0>_4OF-T/UC,YSL#F;M37<*NO8(Q?6L\D_0@^^^\?G\'R
MKGW^X_?(<U;.ZV*?=QAEGXLPYF*,,UJ-,T&,,TF-_3 ME-"C[^%UW\)SOX;W
M?ZFEE+U:GZ&'\6R43]#C8]C?1S"SO\,.WX<IO@O/?!LC_@T#O<&O1L[B,-9_
M&',1QIZ0Q_]K_L'!;I= ZA0+7B9U*0&K 8P.RN_5!_#M=S6+LN=3]E+*7H4K
M-E+V=KT"QWP9MOM'&O#O8?4OP):?PQ;/<.=I2GC*CON$?>[#. /CWI_I0(^!
MMF[8S4<?*AR6G Q6'JZN!*.9\L<1#A/UH@8(OUG499@P64)HKB)$#5:[7;^"
M_5Z >3^*3QZF(3^(+>[G&_>B^=UXRICS^(5=C#48-U^BPW<_SD$X4C<3>('Z
M';9X3AG@%(%10_DM>DQ=-)%)-)4!ZC&+\H<H?S'EK[2RZSNU0[=K/YXX3OG7
M$!EWZ'HT.D>)5^.YL[(]66A$KK+K8.R!^= >VG^R-C4W;.8#7AAU200G1_?
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MT\>I)*-/Q9FS59BY3 59VY2?=4QYV3<J-_N7RLGY*_*U<G,LO&=D1LYC_^O
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MATG\#J/'$?0X0G)XU$C*2 J.$A='B,TCP[8' 1TF)BXG+@^]3'ED]0<MUKU
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M U[U=[CNN]CB3151?C5EC]$?-)9Z3-#SZ/$L>OP67O<;^.5%]'@"/7X%([T
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M;>M(C[$7!UU*^3P+NR2@2QCZ^F(73_1Q;F%0'0._;(;7-3&H-/E#ENG(&FG
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M23Z(_!^?HT/"OW4 _.U@KFNWK4,90J;!]7OAUNT44<_GY>B2@TV2T".2^ G
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M7TL/'1 /3Q]'3X?"X8 S, !&+]8# WA@R"#$C79<P0T#<+OXH+T\TQ\ 'PP
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M<!\E'P: 2F" .W# 21C@!1R0 !<2#L!P0>A@  S_0 L&<(4#]L$ N^& IS
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MHR_\K-HY<?@^#!C@(<R+88!OTGZ[?U. 02;C>ASC=L5"]5^IA'Q&(;D/,*.
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M5LBPH(A0#Z1N)#(PG =[5E;(+0J,/2L QYJ1I\<?N01'A/K_K!U/#PFD/S(
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MS=?K#9S6HN9N=M%6M>H9Y74Q;SB9"<8O>TBXQ.5G3P^G/^3;5[G\I=EL[=U
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M-*B1&@^R@!:GCM-+*69=F<*>E"UK:_[4[ PKFBET+Y/UL.[22 XKFSQ_'NN
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M,LLGL[]0N&2@&#"!%/=(J^R)MR]^(.N7PDB,T8E=PV2^3VJW?$#E^)*FG3)
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M-"/G],Z>B"Y5V,FB/8(_!\$3%K9KM.,6MN-VR_ZA>Q+H;NS.'5*[QHJY[.[
M!MH2J7^%9DHA*0GFN >=F Z(2$<.)S)MGL\[KILO>P2'2% U02 [(I4@8"T8
M>Y^'*(=ZYH^11> F#X)HCY5GZL?C=;\_=GM[N_M4N&EAE)&I#LAG&$O/-F1E
M]3T,.;(C#>'&?9_NV(3*3."6?F1_X6;(*F,AQ_ODV(O%^LT\(2+].GR#;<P7
M2OWT#B%50S33)@EZ=-T/"*QOX98Q@!.LD5M9J'-O:CW&GW.<DK()=T$M2[8_
M^#![2 13CP3]8C9>*7]"3$RMJ0VC5 PW+"/Y+95F/VIV(4K:AADY134S07>$
M*0B_VKNX$]4H2Z5>#"(I0CDD*3I4@I:1VM'*:"[S(@*/6YJ@1EVDO0HZP0"T
M*$[SV\&PCF-Q_2RN):_C[@VUH]-=EVW<X<;X]:[X]?N<UZ6VB>B'0J6?T9C>
MM2W'P5#2#_Z2*RN#W?_+HWG:J4LZ!;/M.\^.F1G5"I/YI5KY4H++F0DWF5HN
M(7DA3.L#J;.%G0$?^."[!!+/M(2?/I,AQI>02"@5&A%KEC6@Q.@*?AT=DL,:
MX,3G.I%SMT-L*%S!*MQJJ7-UBR<7#,U=VLY_L$^_^89YMWGK0P)C([&],R(3
M_@$+&%X)8=Q"J# .A8&[UPLCQ:/[,P35! (J8-E+B)-7NT:HV(9)*J/%1A("
MROF$60FX2JF?F%1VVB+:Y!74%2!2RNOGML3"]5+99"NP?+LD MY+*5O/!(\G
MQ,6=I99Z'.:;.9#K!F$ .\&#/%I\KF'_!D#;9Y0H!H@>QXR;/A@.P]_^Q*.9
M=EG)D*+$,"G58Y(K/P<SD5^N2%>5=&C*'%AL)0^;L)_$3XFB-[V-,!^X9*@9
MRA2EXU7/:AW L^%K<.%OA#Q;6HW$TNZJM4HN93ZQTIS,<A:4I+W14V"'R('D
MT^ANCK.U_S"DR1B'[L>#:@;%!"^#O>P:YD2CLNI<CP%4[4J&72"9XNH*+(NM
MIVB6&:X<LL%G4Z*VL63Z)A,G+&F]GH3.3E*4,NA<.]7EP7>GN0KI ..(=;S/
M-^F9QF6W/&(J5]BA4LXN,7_B8KA&NX]ZIC=:;:C>2'CV/1G[B13FQ<VK34BE
M^?9Q]X?,L#;$O!J3,DN3".!&Y;.4'+'H.>BG/1G,6*W2>.QC0!@_!I@?[9I7
M.I6$<GTF7<1ZL]-8%2?Z;B$%.WH+;I9L:.P^O3(-"<>F&GWPP@#&[4OJ6$X6
M4A5W' 4B+00P R6[V8#B-K,TI'<@?%S]DQ *4XSC=<Y$(]NLTO&9%H'JTC/-
M4>>M;EF;P 2#<VQX<>VR[*R$/V=SK_(!#>U/^I56"^*A"@Z#V,]D< F-I% ,
MV&'!32),=W;T7<91BNX;#.Z-RU2A>ZU.(4XX3_.HUMA8"]S8!67)3?*VA!]'
M7=;\71(,35=V4NF6H48CP"Y089%#TRJNUD1B>I<Z!RN+HC &7RV9#(%JG=^M
MZ><F'95L>"S.V&?PE*3F?V:9SH)5WP6-%3SK5.CV]>O]4+!>)P@"UJPR%_#0
M&9CA4;\!JC.9PC2Y4C_/;5;GD$RKFP+;;2>XZ, Q+-VH,+)<*@T?9)>_A1AK
MX/'(]*M<CT,7MIK$(1#5@W80TU?"Y>EKF,=VC-$LXG53W )'9:R4K_&UXK)S
M"%%1^AY/THO96K2 U:F3*LJM@^I<9^1:*O'5;"MM"P\<W!_KC2ML\<Y Z:>^
MC_X*\F ]QNI15LL8HCEK#%P\$@&*UR[2,#N/SIK1,MA:U0OKM(]Z4GJ0<Z?@
M&K;9C\LCE]>9TJ$!#N/KVU;$R[>(0NH/\JS-5:NO/4 S:H6C3]QA/OM'KL@
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M=I8<!06-[S$\/#SW8WCXG:5;SOJ/1FDQ/ZKL^_![X7/NX1:/S2D7!W!%\$Z
M!.,GM(L Y _>Q%(=:Q>_^+*_(77<=4UE;YRGR>:H,V3W<$P=;&9E];"_>IW_
MZ&GQX[?]XFN[UL.19JNKNVJSW[RAY<5^M3A:06&M<.,J@\<B5!:SQ29 <7@?
MRRMMAT""G"U-0F+P\Y8Q3N$DXAP%;8.$TY"R\].CXX"<3?.=AP4*2N> #0OW
MQ+#-CTV^QR?OVUL1=*W"3(09"7!4*A0R!>DRL@RP)>598O1@*J](>0"2O?'$
MQ./$-_/8EV=A&Y1;86%AKWSVV566LXS$C+M1](GD;]VFIK]O5)NXS_9A_N.@
M&/1=Q*=1C=;S#U"P=U,>)7?0AB+*EC2ZWS.6D-"T5<E5L'!G>E7;6T@&I;_-
M*>+:? '1@.8'AE\Z!GX^\;?NB CI9=Q9E01&?Q;X.ELW<?6!$1I7J&N]4N!+
M$3(%[U9!GDQ@^3*)<:#:=C*E]: 9VV.U*HKF8*!6]G7"L'!-2C]F8:+\"(%^
M)W%2;!BK"*YO4!>;ZHB)P@GK-Y.^UK"JTP)6^2]-D3RZ$G(YLI8XI"WZ!PH2
MS+)=YEDNE7 C;<CRW9']6&9#7'7TJ'R8&L)M$,EC1L5JR"D .NK.2P-6E*<%
M0I&14N-QN,!:UDFV)9QCK,@0=>7:U.^!QR)F>.H+.(L:$12ZBML( _ *H'E'
MHDY-7M(6I;?C<=^+1K^MW+;S=G^;VA@_&TKX0?3CZA?7DF;<=>D"?]T^P_+I
MZ\*N3_K[$_'7AEZ0%M)_A!_^6X%\06YXL\]PQE($)*-)1%IBM G0LEYP_13Y
MAMVP)]+**'W2WOFG9>G($0IDA3!5!AZ78U0$6+"C;4.6)Z1>;)#^(G:CV,Z>
MNFB@CALV;"&?.?LT]#RHZ]'Z6B$Y,Q,O+D]?Q0$8@[X*-JQW+Y@EC@'0^#/1
M*GW^2'4Z/=< VP$:XY3&G-1I9Y'DO*:T.NW-PBQE.Y ]&\J]F?Z[85=S$?A^
MN[' BY0ECQN'DL12N1E3!4D2.OEWX:$;7_^,N"-8<:91(156VVS/^W/E1"6(
MVGM>JD3WB7HZ "W^BJDPC8Z_L2,^LA@HIX;/A,)#9M/&DTHVH[XD>1F\!ZU?
M'7L%_"A<;=>4>I"&'0I$=9&-IHOJ2TWEK54'#*=FUL,N S<&\D^-I$=1E$A*
MBD)'FE[:#9U/GK1CZZJ5F*1A$:6NA2B7'04_KIB_E*_2"]$A$',7:,B;VMF8
M9*$#:M,IZG% S?7<TP*+]9M7O-#;!TTLA513-7)A$"P M)"+)ZX2=;E, L1]
MF,RN>S D!P0ML;B+SG?+"_<(.#A$<BLH2'MY+C(_Q :'L QEU9I2\A_;?W+8
M"BLSL!#&7Q'BQ%BIR<X<EY)[^0IV1@4E&.G2U/N['M\?P2R,#^)AHIG>4<XM
M?>X6<[C550J]7()2G5 ?JGT=&.=X"&=6G6OJU7QQ"2!.E,2VZ+NF6NYC7T<F
MIWF\3!FSL)3!PO+(^2(&D!DS%+W1T.5K2ZE/CRSOX'1J[TT#YA:N/379NO-Q
MVXF_.)5:>8$VD ^O#VFIQ!I940I[J7\X7 #'Y,9]/+PS4A^DNJ;Y541;*199
M+V*R05QV1/;#2EKT&N4\NXGJED@O,L9H<?720^KD_A5AZ'8HJ?NZ)^?EM<N:
MUO+_V@__[GHO)!,-)+7BJ1&66%U'8Z/L(C ]T[4:8XK]Z'4!R\$D$&260>&O
M0*H$[\A R5(':F@CR+0H30+87_7/X-1J\D]6H ;A+MC+@>A5\MH'N[$BT->?
MOPY,5:J&W IO^' =/Y-FC)F HNPQ U$-I*1,H/T3$O _@6!.<SG%?;^GTT#B
M_[2LA.I$U=]AP@OCGG6>RGE$5P3E.+^0&*M-"X4-![/>9#AO$ME&JLMD&VD8
MY1BKPZ*$6HLX+%,2 \:4X',\&LZE 64'2MMDHCC2!!VAF9Z'DTZZ8H6>18L1
M@4.D3L-0!RK8F__RY$H=700C6%$HPJ3*W;1%7S^"PQDC<8&,? PV!S4!SAM(
MQ&<^]S[_(6QS>$)OXWS6;1&[L3-Y7IKAV;UYM;&F$_OS3.P?"_SGA_? NWGU
ML>;YCV'P;P7FA)*35@_O*[Q5@[DJMZ7EIJR!(:52&?+LC1+35,;R05C_KUTQ
MF2;L2Z,X)Q8?VS"1C 3:-DB.T$@W85/UU5T2 ->U!\EJF4.6CA&61IJ'[LB2
MJNU;,PZC7R4-_.T_";-8-F8.WG%%:B+799'K"X036PG 2A0%ZN]XK106*4*0
M[2+J1)(8HETRZ%D4G,XCT D>\.H^HN$WAO#!I72 &:Y4=%?9.H]LWW*Q.T[3
M:20FQH!1J!B398ZHD\XJ>]6,P&'++58+8YPRT5:[@F)A1G[B<4Q>_@ )+OZI
MB([/!*T\LG",7%21GT-[E9%BKLA_NG+&X L@D@8/8TRX>0 ](WX@2K"K0%_T
M>R\T4T1LA0FO^O_<16'T>Q<%V[_LHOCQYRZ*D__;713_VREVRFM4+76QXP'U
MGY[UUT]#EAY)>,[U# <[0UFXB;)$,<F); /)69;[$+@H!6A,*B7ACZO.VCRV
MRR+*L*J2C>HE.Z;*)*KX620B\"K)\PYY4@'A$4"Z?8%;>+!\ZXS09%@-&Q1#
M%(>4-O5/&+TIDB2B?7J.[02=F)=\.-9 GU!)+G[6-'YC LK^16]<,PLN'KL&
M\94:S,Q>"@+N6MF-T]GHBO#B93M1K#2,5$%.5)PQ,H5.AX$Q&E!8 D%DA.S<
M1=".)E"H(I4HFWX0[&,<UN_Y[-)"&OA;CF#<X#Z=T>@GZ3X@/H8&<BKQM_,X
MB0DH*)!\F$S74 <C$NB_CF+"/&)7,KPJ[&8;*2H[;)ZOOLV43QNDI"5*D@?.
M-##3P):QQH8&15J#[B@Z.LJ,?PPW7]@"\B=YSI<+;"JWC;39TE#)%9X@6$VK
M-EF>4'0/9M&A%P%!(J@3F0.95PPLT2R\O],Y'\YR+WP 6,E'6B][K6E'5"EF
MNZZVF0R_PE:H".6,WH'^L'T*U'QNG"JKE1+WPJO*#J9M=PG+PGG"@CSP*5.W
M)HC@K31'.+5'G5^B#JD\I[W-:&ZAJ3_;T5.8Q+XE7TA3(1OKT7&>J*)HJY//
M(A5LX@F4I?W>DSXB[RKQ\8E!^^>-C'Q-TPZ$</>+<(I)6GBRLC'N8?,E763(
ME,VUYO=)*ZEA^RL'V='EQL0#FG/D<>+C^=CRLR(;Q[.ODGO[?ZQ1TBAY-P_^
MO%V/^MAHBC?[]EW;.7_,T,X8'EOP8B@[ORUR+:G/_:?H^6\%JE) -0:K:QD-
M-M/;X\LX)>,% ?3/S#K;6:4(28Z1+R@*I'1K8 D*-*8@R)R1"BBP"X-%&M_#
M49V#;[:^F')V)2'[<63R]&<=7 O;K?K8" =S^DBDZ_$(3$@@36:<=T9+?#J[
M6ZLC'^^AE3ZK]G/@XS 5M593:*C['.E!A*?CCJ7QLBNS@,'E[%*EHI722)C%
M)A($8W8Q@EQ>L!D'U<08(I 01W;@K!U^,V-A(F6-E!E!!D':*AT]'RJ0H,$]
M'A.(!C)F0@M PA9#%^L;P*S0"(JRW(!4%]'_C.%*ZXDRCJ*K.+HF'NN&C)S1
M,AL.[&N6#I8^&RT'9G5H+[E4Y0UD08]NJK3;,4!WN%[;HS4=I3^3&X["-C1_
MTT#5;3.*B,J*N;EC2,<Y 8=^C!H*U:AOQ(9/JMQ3MY%2/B/9EQ(/D9*_(6)%
M!UO88\1&'>!E4%)\^FFI60^);KEOA::>S<MH63G;$]<8BO:)5G%TQI?O&/K[
M0)?]<:IV=SYN";TD=C$8N"0)FU-#KNIBI<JSW!#F='(&SPRF3>?V3B-[\!Y=
M*M<]4\.78E=/Y#GS1B,Y$,]:&5G182M4JT,E<I(=A%.K]HM$LN;C1FHF/@SB
M<A?TC+R8)"<+^9$BU923S(N#^H&]K%W"8;Q*]K9V8$M_[TRARNVR3U3*2A8#
M>]TK'5V]8'?9[KE"_\Z9$9<]BB9- X[_@,()@GLW3;DU7(+A^J+Z2-MM804>
M,+9C89;-?(TQ[EC;9\TLSJ#&+75S@:T-1#1&/X%*X[C]]4BK6BO<))&&)G$2
MAT8E'4=]_].IJD);XPET=H_<C-&%39E(:0]7C,$SH6)/ED/ZW/_Q9KG_+>;[
M+;UWF!OT$\RW&\2D/QAO<#A?<#59-YA:T6;^! A_H2HT!(T$I'\AI_)/SYL3
M++K#M5BV7()E5$"NRS7'$W/,/B ]&+K&NSM8]5T]\5'IM\Y3)+,?\G=$6B5B
M$OXT\,Q9[+I!8DKB%IZQPC95C7MF*VOMQ:M_GZH:H:.OXT1U9V6DE5]NS[0H
MY;0\[:3K4)VA]HM#+A\U6/VHT]O>"9\.Q13"T>TUT86KK_5(RV@1P[4F%M8%
M[]ON+S$6T\DL,+19';.YS(D540J;#&<*%&2N"I>$70_JJSJ%I#&X4>U9%67E
M0G(8+42RJ1E'J=;\0"JJ:B8Z$.:8=K,4MIQ_[/D0^[WGPT_T3MNB*N3OE,W^
M9ZXMU<^Z2!B4ZXD+R,F2-&%52(<+\V94+M$-V^"GV5"1E</LE6!%N/PRT:5!
M98L!\$4)V%SL?6KT@0+1U63YDK#L.=O7S>$Y%ON/J\(#;O.181\LVR(<D3E-
M()C0&B.$APT?NQU:ILXV>VP<.AHZU*QDG-J(V$O'%D\Q1:@5:60'YLA:P)J?
MJAK"9)*M5!I_Z4N)]^$J'[P64VL0]RG-K+;:JPY$<^EPNW@9G<-FL<O7#A<L
M,(UNG^..= ]J(KGUEAH2<.-_+0PF CU<5;;[.9%IW6HBZ_(YR;#,#E&ZM3W&
M*<0)-L @.7PB3%+.HUJ499*W88QKO9AUSFM_^%#QSPM=Q9ZUEAW*XCX^O5;]
M<XK\7_^!G1@8*?QG\/0O!49WO9884=#=WHU&#(JC3]I1SHL:_9BOH2W11^"9
M"6(TY8$^^V@R;8AM$_(TY!C@><E7R/5%QII]DJ/"9+UHS-@YJU?T9&,4IB3"
M? ["$\(#4T^;FI*T%)_T([%12<D^H#$Q-1_X,;I>'_"G<]OJL5-JYVY[+9P_
M$A'W<1LH!':)S-,=VS<1>!2WB&!M:R;23]>E6IEJLSLI[VQL&A5D%Y#L9!"6
M3@Z@:L_4$ZO.("10&G;6-5VS9]?QG"H5NE@U"43E?5P*9DI6>DGMUX]PO^L4
M#ZQ/0U^F]5P:*7'Q 7XL/Z%")E+?(R]"/FGN>Y2FLJY3M))A)N=:5T7_JF?&
M&]E!F<PV_?I)O#5ZEAO#5$NPK*A0>R%G4,0&V!:<$JG=N>A(0F\H+F%<4LF'
M=U\U;:JZ8*YFZML@;_Y(29*F2R_D40.V@Z5M<KM?/\S>R56>@]2A3+MH2:MB
M4BY9&]"B$__D(]%<2BHM?%.W2VYN;,4^#5K9J)I"MP=9/J6O3L;)CGHSQX2G
MBGR+JAU<)[NOD8"$G7^ONF3D.2,/XKJ$4;)+4(5W"+LYC#C>)7@E*K'PV*5R
M7Y3"T;*HQ%[5((N@AB;3I:;23NBAR4:XM=*/1YQ(%Z$O]UT9V]84/-'(?!@,
MAX=@CIHR8-L+GX/]YZ8[K$58E86)["1WVJ3*^>2:*B<6<+HNW91K70NNNIHP
MC&9>*RL.JTU#LID P\ZT(A;D,[4")K8T^6"SQ@BQ_5&;9<A"K("+&;D2?G3
M#7<CE)5.::?'!L;3(MZ]Z4Y4W>6] Z;F6571PS.1>CYH8\2=F.+"JK6=CXZ]
ML^C9'$]]KV39&CKV#88,*!T5E6C5Y (3WH3;:J?7&R#*/%OR[+=A_&Z[BMX
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M.&^6GO?&@,]^-]W92OLPV_SOE7O"Q"Z]O95WY%K;D$:_*5QU'?;Q/)R'^H4
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M-J>*727.":^.OV]26Z!'(.+_IG;>8_$BYF1P3)D-Z'*/$H32/$?FVX&8CZ$
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M=]".7O"IL-C/ZD$/6>=)$,D\;J =2.AYA30)5T-<W[9^J4&0M@'EV[8.=WD
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M1(=AH3 X@KP XXK@3G8-]=!CAB%;WX:-ZK#J4D.CX1(!<,E#A*3<[73Q!/0
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M&"QN(?Z-G42HK?TYAUT,;D6HO4.$'#M2.067<N_UE^FD&Y&J.MY[$UY@K+E
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M6X/']<0_=,/&JB*!"-HG^(>TZ%P1C/L-B9O(2*^QR*@X$,0'"@ZV:PK."PA
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MLA0T,1SKVL9A*"@G&Q#]*<X<UXDYJJHH/(XUMQR6<%]^\6.+O9WES\?2!+,
M@_#+8XEYMS3V)I>S=UZY3K6<**$[<6UC6SI:M[I!D0B+9(<8]CYVMBN3, )'
M=J:UJ\YP>Q$]?-X*D,@$?I'UG=U;^'HB?=)WRMBP4/*K3R.DH<[-?J3"Q\]&
M,5ZVAS QJ!I):7X<[OAX3FHK%F@C$EU6R+QNKU?YG'CIK?/1A SQ&VLY5DKE
M;^F-ECH$(C$Y'GM4S=UNRKTT@E.?/Q\?W>6TM%)\-2@\F68RUD=Z8J5<'>$
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M CC;#HWILDLC\S#[DIK,?]PE]CPN=5^70IOI/K&).BMW>D7OIX5E=]($?[?
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MS-()'*-F5,NRVU,QX),E8<ZQK6/3BG[W,@.FP=1MAI?H7U!R7#KWQ]<$-9U
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MTM$Z?%$[87-[.\NP>ZV=2()2?3#? 5_O=E&'=;9EHUWO2!B#8K[+R[S6>,'
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M.O#5Z<+.@BIX;X$"X7:"RXV^N^4NTJSHL3>O^P/BS 5?(6/<O52^-_WH2NE
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M9OG6E;H#=NX>)P;>VF!8GJZ?MC7##TRKD%]%*G2#'*FLN>OSQ!?M,L+8?PZ
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M$@ZW13@\,W1EZ2KB<F4P@_V^#<_Y"< Y5ORBH-,G #]=K.Z;I1V\CZ./ND^
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MN/R2[OQ>6[*/D_#91_0/>0]X'UHMVQYG7#T)]0Z:CO[7WQX.]HF:CEZV^2+
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M%'ALU?V?_&B;N</(O85;G_LGAY\ \9 5<,$#\,;U@* M5/6%MX^-ZI2!"T\
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M<$7BO]R]%?"R?.;EE"VX\_'[/\;WX@UW.8;W*["ZPX?[9XNVKNMZN;>TK5\
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MS9JBFK 079GUG463H">THMZR6#7YT^ETXZYEX<60S"F*">D8N:C_?!U]D[&
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M,7I[?'TO]JPT1RNP5N()@$3(?[EG@X)[E)>$2_$U#+<$AV*9-*JWTJH_3,Q
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M8.:3QR76WI<-/RPFDDR94*Q-#CXDV)C(1_"J\ IHZ>^O&##9&)+4"Z(%X21
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M"@,76^$*?5MY#_4DCE:#J])K7X#$2%V,ZVP_^<I,6/GTR4$%,8@V;+C0"WS
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M)66?<-D^)/7-D2=LC,+KW]&A*-&ZOR.QD,NK;E3=ZI41[;M-/;_=4"/[>7.
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MC3E^7JD*;P9R8"6IQ8QNVG7TS51V1\- _7LN3)H%A&:U_T2:<R%-6VG2T-7
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ML?S#TOSPI(;Y='*,"6S76Z>#>GH"E5#;/Q=R?C0O.V#,1]%G*AI75_STXSA
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M$X5*.%WE:._?1-;TXVUU [OEULO.B%Y/A051ZM4.[8L*_8MBIDLV[>K>&2:
M^\^3J+DH?WV40UDAKY9)*1]RQ,4>"J/I*.S>EFX67O+HF7G5+&R-^4=]!0F^
M9U ^C6<2&<+]I+(<Q@N-;#L60/%39HD?><;I27)G?EY^%K4TF7)&!ZAH5J2P
M>V\'RMAFDY0W/#GD#A/ XJ+8A.NH5>B1:.F1B-5<SLW%D5.6@!3J !&A2A#=
M]1!^1$;<R!1M2Y[8PF8@\A9Q-T7;]3.6:B=C*,#$42L59IF4:Q#$A)/])5H'
M&9$JFF4?U\H&=N?TY5.]'=N)B%0US:&D-]B,U$5J*_!W8COXP5Z44M'XSW4U
M[C!1[<S@MD??^,IPMI-R6Q[!%8;!SJ*B4([G@T]Z%G=%(C?VL"73Q4K-.II-
M+G2VGULG6L?45D)(WH EQ!X7,UY5311J"=[G:-JEM$P3;X>0-AN^$T$LN]/)
M@6.9*%[R>F%7SK+&8]&VQU\2<5'FN>P3D,3I3.M0@LGVJ9"')K[789CQZ^^L
M51+"G!0[-GQ"ZNRJ%)7 5>3J %_I+AJ5WE9@RXSQ[@:W(-E@!XMD,H2G.HR;
M&$::J!U\C.TQ6DC-C".>D#(YMC)Y3*F^9,&5[8")G>%NP,&[5]EO!@)W-NRT
M;]"'4Q+#4M%M^F7FLXZF9H_AAOKA(!.5=@\B5'3=MBTC_9:M-QG$\34KF0X]
M20ASX*U;HIBL[Z\#)2<(^WO7@YUM^,)D7_*$<02096S7WB<DH8Z]A:JRO\+
MV8C;"DPM'*_N'2S$^E&O+9K8I#:_%\:TZD:F-:_9P#:E!Z?LS$!!_JI#[4%V
M@1BF?L=GZ,(T_H4YKQ<?F5>3KTF=U%GOL+]$\!*[:?]0)6_A.>.\*)%M*B9&
MS.)"$82(T04@0G\^LRP^,JK1^77G+G.+U.S6<;G-&:B0VNXB5".>TFBXE0RQ
MT;R*(V\M\-7O@/42*<GJ:6IAZ+.J"'L@+"?I&+C/;_=Z'O'#0<1K#!L\2O[]
MDUP/CJP69R[[O3L"?)UX_?(%+[]6"L5_R_U1SE_")Y@#/M_'L;'@QQP,F]42
M(/]]9TPF3=($3^]7F.X^ 19!17T2&[379^3F[XUV:F.4CTMF:[\60$/D(SQ"
MB^E)%Q=P3_G+<Y/FR17]:,8I5I20L$0B,E(51RV]'Y(2(YCH] @$$F!,M#'?
M&W-T9UAB"@P0:DF3[AKHTQ@B+"'Q$8P-Y':VT RN!/A6Z<:H5"9.N0Q.C(TV
MT1VY%J?=A'A27CI(4!>IN_O@I)-!LILOSL6>J+,)W&4QJI^Q^)5,+RJ=?96@
M8W9Z;L>X=LFZH+Q\+O)3XX1?;>[R\)>R85Y.!$%+0)Z+7U;=RG?,:)8L3P7+
MCH=/):C!X7?5>(4O%!MZ;\Z%F"O5;#AQV?%*/,-OX_A:P!5>G,H4/P3AO.0C
MQTVAK,.WJW6"YYC76G8!UAU;-HV@0/TR@72L!ZL>]/Y%]@H*TQ+__+Q(9>.W
M#-SMRG7^8W&_:[AB@IVK24S#:&.1Z+[^Y;&_D@FS-;>5.K7YV+&S>6,@.)V(
MPZ"!U)JF4NFAGU%Y#^Y'P*:Y \SRI_;;A-O<< 8BKJ8!BWQ40RZHY3%J/X!'
ML[M;NY0Y#1W;2^Q4VP;<8%/*U</G"H0"3E?1^Q7Z'N_:._T5YR,W;R)P<\S:
MT4TQ94:0>R)51*/,CAN,,N>=6!2EVT/W,$,O0HQ]PVX#V/F/QM9#1&>/:6.*
M_^KIJ ]X!O,5$&GB4:I?7XP *)C*(UQ0H^DJZD=]*=0L'7IS7GP@RD!>76NK
MG1\2#4U.:6 .%/.V N,B5%(8- "E:[3GISCZDDG92B[GK\M $-6LWI6;84[#
M^L+-WOH[^6SH5VMEI:LXAS\)]6JVF-R*19O>OWLO^!L!1_I5S8!$M(M!/7L]
MQP[9&(_[*Y0</70%XWE3_7CZZ,?0&,N%?AUF5Z]^'0V1<2QCC JJAKAUDXC?
M34D_$'(L%QOIB2O;7F(0,0S"H:4#?K% 2"42;<1A$3+DL-@9#8_-&L^Y)8-3
M^._T/L S*+2L0T@)\$-/ J:YHRLF&;Z^_#?(N!"T!1"(R@!OG'&X;=3V9D<'
M,22LHF?8%/WE\_=46]9J.W-RA3JT/HX>OA3H"_Z<U-OPTMW5A*Y7.3(J3P3^
M-$&/C_LR0W*7:6'.L87J123$ 36(94_P/9]4(/]N_8,%I<&X<W("9BWUE(Q(
MEJ[;$VHSNLG+/&]+$.Y)'_LRMF^0SS[[+*LYLWWME\+CO#W1]M!J?2"Y1%_+
M?.&9NV>/U> =%/O5JN&6!Y<Y1KWY?/XXX6E6V\4@S8V&\=S:KDE(*+FM_$1!
M*($W@%T$GQ2G89&,+FYZI5$I(?[4V,/+F;V*D[76!M%&3G$_<-UGGQO5#B*2
M;[6)U87$'R6E8\ 0@-^RV\)_EA:S%R#"&DYI24=2%6V&8 TBBGB9\NFT=046
M<%4T7Y.ZZGOVV7S<6Z9,:+H=PZG_4U*;O9GMRTG.M"?BLYQ0&D#@F=;(Y%WX
M+@_ I:N@)\,E[J2GZ&_GOGN7VFH?]MB.[!C.&PQS/JC,N?DMGJ=\M52C^A6#
MN\0U\FIPEE9S4Y:SN. FOR?=,Q90"^="G]$$-2%7:<0(DQ&,/-&9E"[J\+I-
M#5ZI_W*IO5AW(<[6P[I:HLXS+AAJ$O 6?:_@J_V5I/]!HL)I4N-6,"-;< %5
MWN$A.>, QZQBW1%_40WL>BW]F=K9'FB?181O5](/^D@5@N6B6[3!MKQ) D_W
MXO1T,C0T$G<VGUJP74=)DJ=7%-27JL_."LLFDD/(IQ=O04OAEM#:6-@LC6E.
MKO&0D)/_ V&!5+@T  KGW)$4>W,:.FJ:%$\9Q^?=)L2$.[>#_S_"WC(H#J#I
M]\4=@KN[P^(>('@6]\47=W=W=]O%$CS(XNZV. 1W"$YP22 )A.3D><^M^]X/
M]YRW/T[55%=W3?^K?S53/=#M%SRA)W:2L_=-%N<\_;H;0FJKWB;*VP[N3@M"
MXJ$^XSGJD7Q$VD&/HIZ9J3>*U21CWJI"UI3]Z@Q\)2 8.IX]8"8DS>#F+5]:
M:"^KJ[FC?P-NS^TIL*;=E5O7O&FS32.4>'0DVJ#*IQI&ZC#NCAS8IG=EAATB
M[.0YC6&\S*WR28 K3\2HH^HNH-M!GP2WO!W5U<72U]K10S=Q^TC=2\G0T=1G
M_.-R3@TM]^6<L+6S6B?IA&6/R[/BZ8$D7[-94'\2SPYN/^88,[--=;[!^/&9
M;$N:V:#B\,Q7I5VOQK'?=05)\_;-%"'F+/3X*<).8M6+=C*V'B21X&U->DI9
M]N*<25- AUK([W6'QK@UX'U>4^TA*)"[+N'D%V2&#$^< CE/56I7, X5"&(*
M".LA<EG'"7!&*[RZW#"0?FVNI+M\]4A![<VX_5$KN;)$T'!UR^'U':/69R C
M'*3=I5Y#PW_!G7:2<C+='N^:DI@V99B0 S_2033'\81I<5]8_FPD=DR%%,U\
MZ[C>G3#VN6Z)I[Q$\%PG<BJ"V!IC<A3[-6[E?>%R9'38\<<EG6!%CT^A8S<.
M#7L!_"":K_QNHV0PBBTUW.8$:+D:.VZK@K5JG7P/2TX%]AG%+L'1UQPX_#M-
M-/IW;F[U?BAP!43#E94&ZQL".F;FBF:&"12,?Y4IJM!@=R!=?YP$!,^(%2X^
MA;;96T,>D3F9I'@];SIH:K&;NNF_P.M/>*+BJ!U&377<Q-\PL"M7@$@>"+DQ
MU#6X1N2;=2I1'@V$6AD+S=@S<\5=VKJC8W*^AQ?^=MLPB5?S#*J471+NE8JK
MW^UQ>K%:7]S&S.NK,7324]3UMXJRR:!((4E-SL,HZ:3".Y5V.,8[YV"F8OB:
MR%F2U_(^Z=S61#"L-A>.W6LW?\5EWCEB-J%_UFA=PPV= E5G65/THHH]K6>]
M^CG;4BYC'M1WB+\OR.-9*@45VQ"SE7/TQ8M(J8>I:"FR;'RR+(MMSHO9MR-D
MQF]H'IY7"\%-;]@5FZJ_$HHA^>+KM)>?N_EHKP6"2><V69A^#0957+,J)=JS
M ,&_Z9>3X^6*=G34%1[/<)<D'..8F+<@%[>>:"H>71+:8TP\DALF8GYBH';2
M5V?,KF@%7QWP$F=$,O5CRH39>S)\T5MCF*E:>F,YYZP]/5:K0QAME<R"Q!M?
MAGA7T@;"$I3$PK&%DY8NL>+?JH=FO;)>V%Y[+B2UP'+I:+F5S)IK SE*,M7$
M@E -&:0P5N!  E&\RZ%JUM*E3,@OO6,2CZAQSK3A$:BCN];"C '!W8E]8J,M
M83M"U+5^1V5&^\@G$EBBOP&J+M$TT!%EZ$.8Y(C1%<'U:A*U3,!:(38T]PO%
M>S]$9Z93)F,=5[UO*:\P_?K."(P$,]O]<"[60!*-+J7%=BX.+'N60.26BE_J
M+"X<3S3KAC=.!D.-.I>(:',%'6AIWR\EDYVNI*22CV011N#],4RDGUE3W-S$
M;>I55UB#NJ^^AX^%</DYW=AF?MX=3&@W3$@XLF*UX$391G72@(M97U0<MIQ7
M26Q*.OKF";\OG XG\/"SJZ5EK 1[_GZKH.W^YEM%Q=*E"EJB7B2VUF&K"]Y5
MTXSQP@OG4XI(7-.JB\04MLBB.WBYX73"RJ7?U6G])?"TLXN)@\T_.2K^XT@(
M!?2#U?E\!?,MEL;VA]RO2I/3DUCF(CZKX"ZS@\O5RUBU1[&D#H-QX6@\.V&&
MU%"16.6Z:@."%0^"LEP?]<2&:J&@,HD3&X/MZ#$'+E=G 7*77*QN@K2$K<+\
MRSTM$X5O1OG,VACO*9<;=<A75R,:O"B[NJYN3\;R'K8+T9"@C<(4(G@#7U;<
MS98:"(#E7[+6'@8Y8.L9JE'(_F:"'\?5NAG]!5&5^E:'2OH)B!<J&'.<"9B(
MW'K!W.UGPYU7.BZW)DSN\0%E>YI\*J?HV:6%XT):!K#1:]':50MO)7JTQSS.
MF?/)B9BO&N:5P>U#=O,"58;QZ!2@I8_=2A:) YQM/>UP_8\+Z$8*%2D=87,'
M-^MMA@'3:[E#KV8JC<N!B#P=/V1*$W=ROG,^U!&I&;5KVY1O$M1PUK:WB#<I
M34K$6@Z7N65&Y)I/+N[D'.3Y-A^S!4"[C2JH^<8WIC$]4N:XI)3TH3IMB=[*
M[$;J^=\X0WC80P,^<;*0,>LVP0];V)V# MFV]YOO5;,3NRT0H>9.U]$^+IMN
MJW%9V_8E)]!6E-,L9Q2EZK2K@V/7[D;RJ?:O1 YK[;$4061#6&AWZ\T:OD)%
MBG=KH.LUO,^2&BU=P;1]=*6R/8YJ_J:M[;:4!/N_ LZ4W*@<H 93L4^[SC>M
M!,.U1=E(=@3!\7=GR3.<(X>,NY4G5PHV.)$+\3/TO#4I&/QG'48^/(8@@\KG
M;RGU/\5.MJYIF:;R-"E7?Q3H%R::%"I:KA!4.[J^TP(BNCD-8G2+$DS/J3;O
M78:J,L=U'J--;71HR,_N**X-#3@7PJUVN&FT%F$;M $-Y^=]^G5* AKRJ$S$
M27!Z.!G>D#7>8OW%=3.!MO;(9CV:'(G\6QL!4B]B]_4Y(,[(_C4),ZSIG O3
M5 PSCL%4:#K:0CMW8:3'LW#(%C#A!D:G4,I][\M[^+$[L(I8! )O1V)R[!?T
M49U)$K7[O>Y'1IUT2N(;M)6G7-1\X,H878GXGFG+VGC&K=FW1ZO=V;*[P[C&
MF6],1-UO;<I+RN7\4MF;ZR,6*84G&\>,ZSSYH12)4<+T!&E=8B:S&;N=*$/$
M08JPL]S;Z]*#JP_87]K]ZH<3&OGT;##]309=>;&ZS<EF^ZN,IKNNX@B7&$P/
ME'Z>4.5$GW[Q%4VJ.<Y.?U>>7;5'EIB'S=BF*7HH*1EHC6L8MO8VD?*QN!27
M ^[D(]43W)-EF]@F5%]KW^G"O%-<L^(.X,#7$4AOHE8*,?Y8Y-#'Q,_(<*[Q
MG)[P(=>4),CE:-I4&=0U$10 +=OZ)?$^<@L%UEQZF-<?=<]H9O]I-*H$_(N-
MQ*!NW,1]Q50_=6!\MA.^-6U+Y(U_1C#E&Y?#.9K/?5I0[2??QU<M44#8Q[^7
MYYHI_M9IQ5=<O/6*RVTA?:^^X[U*:,ISMEWE/)QG'+X[GOR>2*P1F..,D5*K
M4U';ZK*0#3-A8$[VQ3PK^;"QG7N1PCCB:=QG@LCZ7I.XYS<_NTW#_+WPIGI,
M\KB(1*HNEZ*3%\G> 6\$B+ =6!#,$S_*_3Z5_OR@VLI-V[6#11F5C''5QA3&
MF/"&D"RE 9L< * S]0/?0&4$[VX*1>N'.6A H^!AKS<Z*R(E@_+>5G.;6DFI
MGUS?75,]ZMQBBW.]MR=^%3-X<(D:1::SU>9<&7L'.:P(B^UJV+E^S_"9_$O2
MSQVPE,C*&2JD5LRS,P.40S\A<!T"NI!Y9%V?5%FOH_%CON)U'AUS/".M9.<V
M.5*R)Y[!]TLZ1=B&DY+$<ECA)]69'/*W";MA?VU>O6K*XG4"25,<_R"\HGJ;
M6A2\ID7"3A,M7-DAD]Y.2>0P.[Y1I"I_63T[P[VEM"I*64N8C:W$R!S(6"XT
M;JQ3+_UY+D+0-MEKCVOB;*/V^NM>WR5K3*H5'97VN22)KN3TD MY%Z$ "YVH
M P5=H4%$0^,;NWM^;HS^N&:-+*/Y-F2)_:U$;R8K*"B."'=+0>1*YZU$X)_U
MN)WNU%V=8!&J9(D+F6&&GA^P^DY?47U?(M+8%O88V/H^J3MAMNKQ@<E,._A)
MC53:+XDUB?[@4R4]0DT@MFX\[KYX&>8.!3S@?9T--'8VSX0WI42\0X4<Y:O:
MPG=LU68.R8E)RX;ZS^^8+VYGM)K*K):JQXIP,S&TD%+)?^.)[ ER"N=]%8;5
M4RW<F:(T#"VB-JG9:E/&B;::Y-SY;F*,W-^4,E )3O&2W^KJ6':2J.4:QN,*
M(C.1=4/S&!$QOM9X;2ZYP&,\V<9#KTHK\ L@&;Y\U.4C?AS]PHW6N'5<^NSV
M 4\;BFE*#U9===&>1CW$K&TI.NFH8\Z^3ZS]>NMF04 =E&C&K^$,)<RUMH?D
MVO8,PQNFI-."QK2Z)/ 0U3#X(*F2H:W_G3'GZEP>3&:X'\[[=FV*^+NRON>W
M#)*PSS*R][_,.$P_F5]EF4:ZUPN/V4TV2,"J05L&A311C92ID<D^95PN!R C
M;.J AS*#:VD,N(W"-I0POS [WG3D[MK::J=?)X\V3PUD2\B4TH7ZF10OL!Y'
M%[30GUR'WYQ8LMAPR*-O2'0JP&D8-]%_X%8-9/*7\5AUV.20O<:0#,3Z/##U
MH7#.H\JZY(TV8>GPC39<ZRD558;;&>O5_&&07"^K46:+!)O:-U'='N1LNM'*
MJ4#"*-O3+.4!;QM%=86=@"NQ:#:5^';*LHS]N>5R;#")&RH\#?PYS.01Y^3C
M3"@<,23NY!V-RXYZTA!5/VSBP:VH)(7$/XG!E+I8O,B61P8:G _BGV_IT^@-
MY#A:+.']"5*.(A^;3/LK+?.G] 6U]WRKL0/-&LO%8,8MGL^%K1<]FBDA\\L&
M&X&II7(Z$IY[5YTKI[X[Z+4VI3/X-QA-;1@_-P6@4=J+>WU."<)HBVZJN6Y$
M[D==B6\2N+K=$/:!2/445**?]RG+)W>MFB!?SV74KH,%1KPI$^C9'1$5IV'Z
MEEK8Q@B#:N(WW,<1^.Q#VS5CPC5K"2HU_.N-B>3QAOBH/#Y& @*]V.30GNP4
M*COL5GGLE'N]VKB('>V><9FJ/[PU7&@7_6QVB2[#?44SB3W)1J>G5(,?/QEC
M(C,["BW[L86436?L!IFJN@;BQ)JL9H@Z5LU) D<VL]2]/^47<EMUE]E:QLT6
MENGQ)UK;%_FSSJZ.\'-\F=IPDJ].GCSE9IV6<^$O/!VM]C(DH+ZNJ&*M0)S-
M0>6/G6P@0B9YHD/K6(U6O!:;Q&-R8M4045I:](/LB> NQ;5CE;@Z\Z'\N?>S
M9F @;)<K*CXODHKQFK5B O4&Y!PFJ=/8DF3>"V$3%YI*V1*%M5.?_*Z)7OM4
M9"ZQJVR8PA+FYM:2.(]M@SBCK@0!&=!S)FR:E6$/SA$6HH\\-3$O0AFFCZE(
MT:IL7X#X DE;"#@^)",19Q?O97SF9/3NH[S=2X=?4 TU+XW)I#SW[B2Q[,V-
M9HS56-&JJJHV]/RUM=[@DO891ANW&',N'UN1;A+OA5 XM7G9!LU+?3W"8?:T
M/.V)]V C@),O31)GF)(=Y^I_YTWIL%V:;%6N(&)#BS?!1I''<KGH=]3S2#/$
M\#4TRR<;509%C$Q_)!5, /@UZI?(Q21T$E)0[BS0B-2DU&IS-3-)-38^A7P3
M?B?C3%+)V>.U[>8_4^%J4D+DI6]KGQV_9X@IZ<N2N 5P<42_.D0]Q#4#X$L:
MO)D^E"NW^IZ; D-0#:H18NXF'D ;.JC7I=@T]"8/HV_,=Q'ZI2%NH4X*F.X8
MMHFZ>2 .\!"^K,OHPSFT/<GM[YDZ/+75Y4G$-!<NHC;E0L5FC";$EN9NY>*.
MKL-$.+U'0*>1VH\GTS^*@VSR&X(J\\W8W 5N85I^N-4:;7!6O]4'Q9G/AKO.
MH'ZT08W4;$46<VY<D"@$M7>)D$_Q-M"C<\S/61+1KND#C[[!M+2S31.=NE_$
MEK[&9QTD@[(MPIZFVBD:.#VR5,^1M;ZMN,03@N7-T**JN"QK;X>SH*T,%SD5
M^?*.PORZ_DUQ;,5N=W7&[[='I"M[U/JQ@X[JUG7&V#+B7I+:(1R^+5E%ACE$
M9*\18PQ<VRRS)D^M]W.^O[@>JN7@/8'VKA5T)#%.<U:T*B3J?7$%0D7?(]DX
M8KZ;=EK%"A]V\V';8V9,>B(])]^A9Z2 >8^<#4/]X%%MQ\?P:17F7L-"5?$K
M&,AMQ],T<,+_\EA\FT6C-Q?>=0$A$!,QNQ.]/;D/#'XC-Y1TK^^JMS43N\C8
M]A?!;N^AMG_-W=Y7HU6]JO=D?&S;]Q/448TXDI/RQ>9\S3?G578+:6">D,$I
M],[T/0,R"KR91%#D\V:QLO5Y]98+GHL-S^D;V$B1Q:A]-H;-UCL^3SQ=KI@>
M',9X_J3*'/H86VWMBDD$$((A]20XA%0?'8CC;KI?7[0,,34(39&_?VSEX(>R
MI+23&$GKGMV_+S%0+<2S>W0Y(/UMD6+"9OC.\[U97??9F:.GB'H=13<8_*;O
M4G@.1A<.^FS%%44P:GS"!.&B;4VF,/S .6\B8L]( ,/*"HK==S_P0_6L5*;+
M'_DR!98G=C0!0-9T6EWY"3#%.J;0"*-0OC!O=N) $[F$*/4I"LT*Z_LTQNY9
M7.S4/YJS:HJ@%*S2"/9&^JP]0!(9:YMA!*8(VX*"V3'/V>Z./9JL=1WJ5!:K
MVGZA[?X;04G99H,&9V!3^-;E_;Y#U#,4I;RVMM$Z/>!Z@8+>@4N=_0YSI0%E
MU6U&,^:3ENE<2B5EG[J6,_4#2ME3,  RQLZ=M\_9J,F=HM4XA9RV \9W3#C5
M,U8FM&F0JO018!OE*]255D)N_BT9-V13L4S$;8V[X3TU8Q=8/W>=9+N_!*&K
M^!D[?>$M@6SRF8RS-?'=/;+GU\L*Y]<3[29#%])@UW/G4+D"X6XAZN%JRBCP
M05O,1^6*VFF53K(JCR(OV;Q>#*0A.T]+^G63 W?EKJ"8Q3VI<$RK=]B^OR=0
MV76[R;SZ<,:45<!*-%++.S /^4=LYB?#F&>E(PTN1J-9 /D\V]3>5(V Z@D7
M*1G982M*E548S4--[":DD(6M]8.S(3W8#N1)!]1WF?$8.2JM.JC->^:QLZJ:
M#&3A;Y4$^B[!B,B[]9M%LNP,O;Z*N_TB;;X4S#0&LV?9V2[SP3UIL.* =B8T
M(_?JO5E6(O=)\KSK'K?47\D8!7 ILA1WX<QH.D'+R6VYI@<OI,O(Y//LAU*I
M4QGH5/>!&'G:)#DN6D/:G;2E>W@?=,RSC(9FG0-+T!X>E(8%?44)+])<X^KN
M&+#&ZJL9ZW32.#MN>*Y6>*F0POK*_R*H\GB:"&L3Z96G(V0C>A4FTFER%+Z?
MBAZX.S;HZ[(PI324R7R@UCE-N?F+H&7;Y3; Q)":M04\6!MY*390<P:(ZG3A
MUM#KSU1E&M"()1.\ 4G3>))A8_@G51;VV9 ['Y8L",IEID[":\A;<$?'Y&8L
M9@/7R=ES3=XX^#R=YE?\0ZR)F]3IM5(67/ J*0U4K:"5XX+#OW/\8UWJ0'^0
M^(YNVZ7C+'QL;%7;!X]^KY&XA<6D<)21!,#*F1%G,6JC#WJ6[<$;?RL>+-5(
M..;&E-T/U+6 !:Q[CPZ#J<LSKPXYD@TSU*.W4G]376D[T\]ZL0]9WYT**S81
M[#<_T8X+"\FUFWEZYY,F&WG3<%TS_KYHJ[[N/&K\-AF6\10<^N>S75 #SI\O
M4[_"@W^E2W?\64\/=PT)7@[_T3^R.WB?.FSQ^_/G[W\1%+[S2<4-S/U/+R@,
MG*E(CB^_><[I./7FWPO@;)=]G\XLJ!-WJ.5@O?J*:<!E773">:HB)PL$,N.+
M F&>2L^-:G ;%].$Y, >7<$K>^9AE9=#5E;KCON!YZWHV&X@!R#"DCCK5U T
MDK8@PQRAU&+'T1P1U74?T G;8SWQ:5YRVNBDWM )6=_EW@7XHN7DQ.UJ'FF6
MP>=37>C.Q'GJ] )@OZN)>F-C>Z98?E1]Q#K<'=]E7B%&IE*3*#"9/+9V.E3!
MJ<P]I5]C1H"M[P7-QO<47^QX5=WS+=L)*,K<2R"6FTO(_#/Y$N6:A4UF'NYN
MP]2L[J'F+T!;LDCYE51O#62MKCQ@&A;+JQ&V#EM\I=H,"W&RGI<97/YL@JW]
MQY=RXDFJ\B^"R%&8BZ.,]^.?$E!<?\YKV!"OS"\?.OD-BX"W#:L_I,-I_R*$
M0@,3ML]TKV7^(ABN?/GY%^%F?5SF3>'O]#NW/Z'<G_\BA!B'NO:<5O3U';^?
MF[)-J%M%XA6PJ]]]U9GB8A\8K9<@7HGB*<%2XJAS(%MX'Y6&,%MA,WVNC][#
M,TDS?,KYZ/13]&AM0CA_NO>+<8TI:^[%C8RSOLLH\R:ITT/%FAHFYE[@C,-Z
M$S>MTAD%TUMPOYH:O&&7<]W)U-OEU-/ F9=$ETEE ;->KV&4MH-W]#F3J:DA
ML!IDJ#<#E_5^*1',;LE<:&JF;$TE%&AY^&RB-*ZDW%J[M>[WK"1W^*G-9JJ6
M6=L>KZ@V"X-9E[TLE@'($"QPO+X_0.4;!\,TZSN@,@57UML^'D$VO!@!@FWN
M+ 2#^^O9!R3">P6OG!Q<UJ!9480$'DN@(!]RYJ^/B"B*;Q64_NRVE[C/A]_/
MO'>8E#XG:?=Y&H&9\^(__P!-CKLY$;NRGGM#"]10ZO$W%,+YT/9$,)>2I3I5
MFY5L03OO,,7)/"\(DJ;.LD*,U'N$&/!%O3AM"VH[/J.@:ZNR%0^4RU9_E$-J
M$Y+->^&%F0+5#R1>S!2J1EI(C2WU=8GS1;Y%6(U5<:!:<LKOC[ >C3#JFD):
M ;SA;8G%3FF\?BG5T]*E+ U.6R-%27H^>X =PO8;5:?06*8&;IX,B>L5'J]Z
M7\,VK1/)B)C0/1FYVA.?4A-5 ^M<IJA21RX3)Y/)S&:Q[]DZR;QR*.H]937=
MFO12.UU/#4:3#> 9WRNX"0N>5F-@)1B4+'P^,OS90Z^YI;!G5YF^0R1W-IB9
MT0V1W6"&$U#[? 3N1KI"5GCT>>LD2D'K$J2NUNU2#]2J=MU.2_?;=1>AP<(V
MNW@AA23JZ 2F5B[_6I:299[Z.I$0<$_>U0F87\IBCHJ14.$!=4<7XB^;@3X?
M-!U*N78TL8CS2\T+XNYS/>0,F9AX)5@;'*(E$EXFJ5?-Q]:G^A^=8,?FUBE"
M&Q-Z]?%U=GR,AT]:G3LM52P332'!N<D5S @K?9"3J/6U AVJP?=C:HOTE7Y/
MC2E%6Z[9@?56%7R/2CJ]%&6?.KVR:YF]H3;%V]OLN]OZR^8#*5'*BC.^:E:,
M4Y#M'I[[] D?Z"76Q_'-\DES@9955A[K2]=U%?:\8:LF%'D##UU"EG8'\&G!
M [^5V%.!7MW".Z&M&624V(;Y5V31E&%FE&.(("&^MD3?MHA=5^E@(]SL]GM!
M"*Q]*_-1I5>] :V?R2%#I5(BA:O^E)E"K"!('A(G:70H9A3A!3GF4$ 7QIDA
M5U&9N4JBL![EL@ZI-)'K(".:PR9D('1T:68D9Z1Y[) M]3JD($Y&5#A,C,6F
M0.4R%G0S$HSD0/@"^:BFQ.:X8KG4=[+R(LO&=--"DDKE[MHE8E=2L_!D/EG.
MWV%1^9A2T/SMC=/B6 Y;@^04@3CJQC"MJ]&:<X7_^W3S+MSMU(D]("R]/R',
MSO$=6YU.&=X"%0\Q3M92\Z>C4*BA'&.G)B IH=KV^_Q;!K_L:A^],-Z>V^L9
MT+;7*L=6+486Y(5)[4(K!HJ]9]<5B]AF"&O)9V[[3@,J%&\364M;]S(D9S^?
M?-+X(2V\0QWM*#I;MB519URI#R-<Q[O14!,1CYEAKYK[(I-ALTC<S["$63-8
MH6C)60':1A=:/3A0?'-OZ#RS:J0CX"+HPCNVND5_78GV6*^$\0Z-.XI7,N<W
MBPD4ZP_[B"R##YV5C9__#N<&,1/,KU3H-)EA4J0%7YW[SWE[NU\GUL\K]6RY
M4M3FGW#]N'//AM6H&58,[-+4QI3C9#K30;0A7M0B_XHN% 2#N]_\1+:!_*1J
M*F-F6-Z5.MHX,>L4DGBYL]_D,PA83UTG2Q.9,A.@"P:CJAL(@@TMLH!#9E7D
MMDE]*Y$Q%4QC1ZP,9FU>*UE>C"HFT**;ON>3QB #R[N]W^'=TZEV7ZP;)ICZ
MV-7!9P252:GVAJ# F)C;NGTKEF'R7O58C"FE55]]_DD1@:EH?5:K%D)5"P,K
MH?KKOH2?)K<QNJUL2,&LV^+YZH4^UQ(,'.(<U^V8I,8-\3,Y>/W[&'F)P8>3
M#;07YXWS-:%P VBST$'$IL&X::34/?4/34?SY)7K)VH%IDGUFI9V;)C*%Z?+
M"_WG(MX:W([9*((Y5ALZE4&WQQT23V7/&4T5Y:$N29^J_<2OE=[TY7[0M?/M
MSC14"CR1'Y3Q*)+<)]\7TR<IZYIH7#V4&3L$AG6 <@^T:GDZI>)A]3TKWZ[%
MSA<FC< ?;W7V?]P7 &IE_&P D\G,P]5@60,OSMH9>ZE^E8\7I <H%%(!F[D-
MOY@F IXE3"3>A3KZ26PZYG(E7)$5JJ5MI<$2V93!]5A^\&I5I(HE35WM@DS;
M,+Z$<\%. 81F'-GQ,$<=PBMC?#3K\6"2.[=7P4JBO05!QV-F7_JG$N/B=ANP
MYKB70G[=<V;&2>IOG%I&$S*1+__H-<[XS?'Q:9IK9VK(23?/!#MZ2V9K[[_>
M;F1RN!SD+4S'T^[0_!E,M3.KH[N>X_002'*TV$%]PN)HZ%BFNDQ>F2Q8RH]P
M3&^W((M(!<V@5EMB8EZSQ0%.4&(G9'-'8FV\ X)=)NNGR?A9 -$8^N:\0K'Z
MK,DMGH[9B.:>[0E(XTJT)EQ#ZR+<-.Z%HY]24%,H&!([+^8UO\*6'7>%=AU;
M.-=J;MZ:9%=<LV9F9^+%=8LYD&\^AGAUAK3 TYQ44<&F4PU9.-E-HT:E:C5[
M<I,$U&B6S0YS<NBU5S0G#6=B:H'-3V8&L_S[%;K\#B*?S.C=/JGTE7+Z.4MW
M<#/DNE9%@QF/SM?[A,L#?5A7/BLQBR2RJIW@,5A(\?A=8F:TQWQ, A6V?5&Z
M>N%Y4 TVR/[D0!D;^<A2\E)PW%&NP?/Z(/-N 5N_H+8W,]77U%-*I^'/QW-Q
M:-L5-V67:4T+/C")_=:93N,RIK:52\ HJ))&=[*"]N**).,A8T_O$[= #D<F
M"?=JP :'#R^@+V]IT"T?""7?/#\!R:L6\-Q--L];:LGZ['\0FI[MPO5?!-=Q
MH2M :]WQ%N,DW+[T<;$[O+ANO55W?E5LQF][9\H!.^1=D+2;K[3JJQ -W&X'
MR1D6Y=0.9EA,9(<Q>L&'NMST]GAZ"I*F%DTL+P2^5. 8(O91$\W);6I-4 H8
MH(DP&FLHTO<D17L2\#5,EZGG. ^\KTYIS=1%.E..Z8I/)JR8E=U6?K/>;/M]
MZ1<4P[&A,EJ4/&D-4QP($M<I!*SM^D!4L>U'@],:JPPOW6H!B3,S5\\O_O""
M=F7LX]+Z>T(5.(M.EMZ$"^A%5*"%MQYF2 8K;./ 2NJA7T=X$.&V-::.Y<\
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MFH! 4)"@T5$,ME52:Z//NZ#6DOA)_E-!X@+C?$&,&&*"%W4[@",!G$!>Q9Y
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MZ6%$$%W_MBXB0OK.7]A[G?7YCATX?)<=%?B1%6LQ97C*2_;W)9TK"S^_()&
MA0A3V-:8-%T(O3&2W'DR[3##*06.!!:&G7AWG#*59#K??&+JD=L?T L#O&1E
M@KWB8-!!6G\$^S^WCY3$:I_JLV*1,_5R-*K [ 6Q^ "\=YA ;43V! P\5?L
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M!#^%-+.7ZZ/6HK$L<H\V#IY,?=DBXA0'O@K)D/&GV\/\2C.:%35KW!3*S!2
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M&G8(_FYDFT; .S.N)OBB^4PQ^'M<FU:=%Y]+=8S!6KI6_>OY6BP\_F#OB(V
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MM4HM^Z"-K 'RK, <YNY!)/:?SHQ;.I(D,BZ1:E*W"XT_@RED1"[V"Y_UH]M
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M"SS6AO$>[T/#1;3BCN9Q(Y&?C?2F%R.()6&U-[P[FC9@W5P/T,8Q%75 ,U:
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M6MRA-!8$U.<<;.IBE)?+Z6,\X=3DX3?3-&B1&-\>)A+@")KSFFV'HB.G&5D
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M[@^-K6QOX?K5U'P \,N&\0$LI&;B/1B:91=F!+,U,H*/AA(N_*])COX;]]\
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M-]9%_5HR,&-(71LRX##0AZEF:3+J!0-CT (5\:?3V! UTY,)4&T)C1B,Z13
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M1A4*<Y\4Y:OX&GLI0'R"E1YSOF$;.:3X\7#.5&JZZYMWU%GCS!-V^DZ@W8L
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ME 93@AQ6ALAX.M[CB^V!N47T>A6&@/2)".G4SS+:3)1@'KN5'(0JZGX-Y_,
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M,N"QS#-W!BWUBDJ#<W,EPSP7=<L&A_/#YB3(]0#C4WEPF':F48R/PUGX>9
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M4^7>[9QL6\H PF;OBA!FPZL-BRX9-(/2P51T073S6]_!*QI/68XWO2S0@*I
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M41O?0CQ!9_FY)+-.L+V?2FYN\21!F3TGX R/LCE[)57(NI3_O6]#0<2B]Q/
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M0C;8.U&BSQ![L6Z9\>7:]V7TOX&;%P#VTHG/D[GW Q5S?%KHRIOXCJ150[S
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M@M^J.LUT3ET&A/U".81.=\-_M444J,19KB\O@K7@HPE])LJ&C+C??R$I (%
MN6IU>\Z-SJ97]^]%?*F!\6AY_2O)?6PO1]!SOR>5;%0AILOZ?3L^_DAG?Q5#
M>4C48^;(J7*$K=5L<#F_.4U@O^ZBEO_!)Z14A58C[QTWS\HC_\U(NPCP,2Z3
MHK:4_V?QIP%BCN1&E64=,57'/K144?C>CMFFQI;[QLHO%6#_F/T)F$\_2M_R
MA9N50R+1JK^%GTQY>9]16WJ R*PC9XK9#2* K"Y2JVLLJ[U^O#!M&@0>0ZM_
M>Y$=504VG''[A:!4-?!8^%Y+%5'<(^' 3US#<;-8R45\HT94G$ 5,LJ>AB<H
MF(.RS1X95DMT\]Y_OI*.;NJG< TET2*1DYDQ,5V2B:=O?Z$DL,S&HZ[\5=)9
ML77N!-1@]5;EQ/([1ZWWE(Y,PTUK\2AA3G*9\Q=F#:,?@J3^-LANAST!(V8N
M:\M' ;*%"(R+A1!1DZ"4K@/B'2/$J1.^>+X!5.70P]AAV62))=43ZJ4F.DQ4
M6-'M%'%A"F+"\SK9UI_>9-=D\M,:-NOA><GK]@QCHP/#RV$JQ.6PXQ.%8%@>
MVX:7!!\BNC&7^ZKZX'R*KS].D<FE@D.'DK&D]!7R!SM/*W9ZC+(JX73GX<I+
M8M7D:%LD"'HBK\&OF3#[!":^;^:!&A*QE1UG*6NR0LV*4@<^5K5ME G$YN]8
M941]8A4H.6($WIG;AS<[*$*X/Q#UW'SZPA&B_MU1625F2P-Y1N'3%^B[<K<@
MK=*.."Z23&3#;I^U$*+F0,Q&=+4*$AR"LZ0G +P>_,"U;WK)-#SX>>6.LN-A
M*?5V\5GI*>1R^ ^$[>PG/BB^KO?]X^9_Q:!OC^[U?/DXUL.WZK6FUMJMC\=7
MNP3B6967R$%5+O?1% $%5#G6BX#[<*L@$> 3H++1)N .XV-?:Q#*:*M.$9;*
MI?Q=COW#EM:#*'=%Z:';T#_'NQ%Z(^P;B(/3=Y/O43W-(T!4ABI<WRB>)R.J
M7AO%MD&=P_2_/0]%Q_G,1?<L;?JGF*/(<E4^N:V?D8X1/9\(8\2TC#70UK (
M%!6+@*22[G-:<GKUJ4IF3_WJ46>2$3:6TD334+!3'%L7W0?Q%8+9Z SPK!/I
MZ>E^#KP@BRFZQGX_SV]E9\VYA5]B,(#7&C$,KV4NI"W&KV--EB,W'7DG%?(#
MQML'= B>@+GVLP"#*V)E/YG/>A7:9W;'6YS;9P"Y9_F9541O',DC_1;E!3&+
ML 0<^/!_*?#_VK:&I#)3H Q&:2V0&ET"I\M*_*I**V5BBQ%8B9I:EI;S8VZX
MPP$HI^"P^OSQ KRQQAS0I$P>5 $H8VW)H>W2'M-2H+'S'7]0D&EC65XIU0>F
MSK\?!V:EC4A[)T7X70ZI+,R&M#FJ^97Y]$66B]]T$^G'Z,1TN.6R+%"YR$HA
MXD(]Y4!)*R8?P9>T:%6_(0/KTPR;RU,I'1R5L>^,NL!%0\\O26KL*W2<.6U9
MS%^MWZ^,+LV</U%&]V61CK"A6."'Y-5 \"KI.O Z\/%&4DWT _WVQ(?A+LMG
MEN?#*^M][H-'2R0N&G/ W_GE>+84Q[[PK>3M[SD'NSH/1Y2\===51M4B5])%
MCCD?-'6C^;!\1/M/!\YFU"\]2P*OXE(7[O5?ZV?<94W6JC<6E72FO1*ELO*U
MNMDOO!/6;O7O43I\Y$CF&'X8W3-D69J<6E=^D8G-TU1U?S'Y,8-MI7DCW_L)
M0*289!.XX\4)<]ZS/V$*&7GU#S*>3(@$Q3 .\+9Z"B?U"WKQ^R2^V_XT6,[1
M*N9%;0.J._+9S6CM@FZEKOR@5+0B_Y'6I/#-H^V7;I)IYH_XZCS#JR;/?U<1
M*Z\*O*1LPC#Z=JU'7^TTHYDN;_^F(Y<%)U_,?*I$Z$J+21Y,9Q[F#@?!TFN0
M"I32$S F1OC>LV0'TV/@O*,\4ODGJG+K!=B?5/3J%3\;9R1,SW>>QZEGB9SP
MA*6$T7E(:7ZQU:'H/ZZI:71U4I,.I:2B<3+ _ZPCIR<9S/4_3?;YE3#OF_\W
MPV"5G59N=IJESLLQ;/L)G?N&-SAT;)QMH:KS5?/R"11P&\;D5&=?(>T8?DE@
M8)A2U.40_>,K,+.>-/WW.#7_Q% Y^7[1*[CU;K44,;D\?!T VDKRL;/D8A.8
M0R3>X,;F$X"YD9S)Z+<TJU-,4QDSI)QL-$][2^'VD]P,\8:PC<N)98/UA]^1
M_^8Y+!0[?7#-^R(I.&BJ:76>S[;WK0;"OOY"JP $9W/O=-O3*GQKBT83B@88
M$MH XO5ST)%TXD3Z3_PS13$8IK]$1>7Z>0?)W[.DB#8(RZHK0!",)$8:*G!_
MC8))-HMQVN;=K%WA;CY%$PV*^4H%>S(HFQN#M'SZ1/!_4M1ZS[[G4^$?ZW+_
M2H[N. ^A4(C/(RKRA0OMB3-=#RA_["D@?;XZ0(H-[:H%IU(D;!,*0WOP68+B
M#\(Z)@;H/)8,F_)0@53$_^'&NBRS%C_2CM?VZ$(B=X$!M2]Z(V9^]9;$2^B/
M@JA&WPKS J?':N9UM[V[G?#K/A!U>RP.N)J$E(!0%J U14,JD7*)""!ACN3_
M;+\_D==&(*R*)]"9J>V9I1V=NCUN>5S(7O7Y+-ZR=H@)] 0@C)9))F5 TZ?X
M6Z=MQLR&WZ)HY0E )FGQ7TVX]FBI)N#Z %,,_+\]%%?/V ?>C!C+S8V7W2W_
M,Y/\_YZ,T'9I=O:J+(_B3@7C#$59O +<]/;6?3U+286P#.I/BC3>HS NOB3
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M$C!/B<9HG40GV<D"U74PEA\O)1Y2KX,JCS&[I>!*NC+T[!Q,\N?.GD7@BIN
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MV0%C>QAR%^A8_.8.EZ.>(?C/6D03M81K@VV28VDLQ \*KKP?BII+A8P@OJ6
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MY)-!L:#P,LU9?-4=1//ZQU!?4\LPS]^^+ WOZOH"$\.B^42J*KX<I5Q=YE^
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MT$&@BK>#:-M0VB#M59_1DH,PN22,Q/;-OK>S^+@.[BBAB;\[,_'07(1R'.]
M<Z62?-=HTMZ@D@58X$I=CE>N:V/%\,"JOT\O^$Q21KS8!32*_=H]?$=R+BY;
M<"'?6_W": GM];!-/)^*BR;AQ O,9:HK8Q)QK8N++M(7. E!R4@056--&1N
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M;M/^T/7G'7/JN^;HSK!_\MRNL47A5\C0NSG;SM6NC<W8 $RE?;$B1:)V3C$
M6/O*&A88A:7+4*##MX1+&Q_SKBY9%NL, NK57,$'7WP,C#"HE?J'TW?Q$4\M
ML&1#]DF*V)M[I9F?A+Q]W9H-76IT([>PK X[JJZ?9_FE/&.SXQJ/CH!A?2\L
MP;+SHA?X5)V=7E4A?"E%]B<%;X.=YV(7S5DY;5Y-),OK51L<-0/5*F5GA^A*
M]CNK!G-N_(W:8D3VLZ*23WO&DL-Y[ =U"VI3N,!/#37+$H30_)D=L1=7JOT'
MC-.YCFI8M;);>!$3!E.X1Z:V'+]-@AM19XN_R@6K?->Y[8CWU_D(^WB-3;WD
M4B/NI_QV1RC"^_BJ**J(8G*[2A&U>B1!@/EU*#E _DBZ"O#%L7FO\N@+K/XN
M-?QAT-QBABU6$#-=8;.04<14@ZQ!"$^BN[#TRC);#9#1#I;14"< &>G1@&Q3
M@PT:/YQA6AG/ZEZ/Q&.#QLDV==.?DF.-.CF,^NEF"0+^5V1@DN1&<O1LRW1#
M[><'#K.J4,PZZO!3Z$5FE(/+9X6]\_J)]"EU<N!T"S^O2EHK-<@)05J7*5B_
MIVG,APA3S$T@YCOFK4K?<2F/F%&L'"!"BQD?4'9_R$F6P3,0-$ZV8W>AG]DG
M7;\O<UGPAP0%(2U8QF25$Z>154D[L'.C0D AQM7G$A$V5U& T8P@J'GJLM/.
MY:NC<Q192ZW,.X*;0X\_V@I_K71;:3XBPC4VJ9M.!C91TW$"3"%?_D25ITH#
M^?*6FS<O_7?S&0+_SF=LVOT[GX'^*T8O+'NUE/FB<7'. QH_Z)>K:[IJZ]Y0
MK%W_]**F5K?8.8555:AV.IE,6\JPKB>Q-TWSLZ3_BW3&B;+HW[,;?RJ]7Q2R
MD)OX'G;IY:E;%.L=N3.7KWQ7^R?/*&5DG+0#6E1T&!+N].%D:"7@960*=- ]
MWIP6=R6>8>884H!0RFE"7YXTV1]@\?XA8;8R:)!@MO(I8/U6GWW'?FZ(I^0V
MTYG!V4#<\L__%?]6:=4YY"17I:/61TG!T>O #)U BLRO2-Q^TL?C(H,;W!D0
M24&0(W?$BWSJ]\1GGH/ AJJ]-9BV"A\:2*>3J:@U^$$%@0VT@5P>5ZE[]#K"
MQ][C<Z_VGYJELN_VIY0]%$P.:T*/W="O%H=E+W/*V E#3^S*GEL'2;PUE3.?
M"AGB?3D3@<]9^,RJCFY$378U/I.<?^O4A&2-59L=U"04&;6'&CB[.@Z_H<$F
MRC[E>21DR/)ESU%8G_=>J#=W13P+$REPTCB,ORF;D.ZBCI%N-%J.&C=UG>O>
M:TNF#YD*Y$JRD9&X8DY/C245[WF- %_:S-_6;KB;A*F]X8Y8X_%I=)PNX\O0
M\**I+PX(8W&23I6XAC[3U9D,T;)BW0GUAIW;R0&"KU*BO:-W,X\A S+9!<SN
ME.[OR0U-&0HP]2)39*25BGU]+3;=P;PZTMS8/8=A7#-3I\D&0X+<7FCFZ@QV
MOSU7J%H%M]: #CNDY8B'Y?-;:^9-PO2YA7A5)$=TE\%\\Z:)9U+?__9?12BJ
M7)!+/NW8'89"Q&IN=K@8G 0\%E@4%6.[<C7^Q5;EEK6^_92!8;H03XQ!2?H1
M'IM?Q_-S4TA/)>X+'J"%PW1I<K\Q>R+9X\)#/=8M5C$2-4B"*B:3O/J\+!F8
MC8C4% !>N:VH>GT&]"Q(I-UQ4G/(PE-V2#),(X^&W8[$4Q_+3H[F.5?I#J')
MH]0T;J"_M7K!<Y:X"?M(N_7LR8PJ=-%2?O>C.X3%U\*ZB:34_+4ND"F.\?;V
M=7=+)@.X47(R],BB@\\F0/GE.^1*<31^WO^H!VHW:@&@8;B#M$GR_8,P2]0L
M#S9"),F,Z;4[.^+P(BJ&NHBIJH%K%]:>0)DXC<[[.Y*^&P5!9G1(L/:<KQ4(
MXN1X9RH5%=PT1=N7"1B[<B0-T#6?>G*'*L9$!D5D575X2F.+Q4.S)S,+VX?7
M%GW#%D[>T7X=:HO8T+KA*G<=!*%G+5]JB8A 0^PY-BGRQ4=1Z;1'1V)N5$_5
M/+@7>5QP*VR#.5W/M$\,1>_0N(_)RUT;);^9M1NL(XJ-_'O:?\,X2KA/W5.4
MCY8+ 6ET+[0V.JJUZS99>0&BW>IF97#P#VIE7<L^M09!#>_,9L6J1W)E#>&D
M@9L;5=MZ4I0Y,,HHF%3REW/+."BB6\3TLY$N7Y=0BG$7WE0//#P]+N 0R]L@
MW?7I=ZD./<^\%['1KS5>[P[<.94&D4.\SB<L<^4*%$D/+S9:UXL3W,+*.Q41
M#%O49T#-MI\)_FUO]4NIZXDY0X^M&V?\+SMB7XVF!T-&;+KP*,B?I_T'%HTI
M_^1IX%7+Z"@]2<I ^J+6K]#HM?&OJN^8VX34B-F >)MY[ZKQ7^3Q+^B>7U?5
M4<G>MD?<,DE(NZCR7&"Q,."?/,%/.UN0Q"R9S;59/?#3YZ? 3*/UX,!78>@P
MB$<#HX$]$2EQL?KLPAUF[T S)= &VG7;14=S#S<GU8&YV7'/:)D\M[A@6E$L
MV6OUW S,R BD-YH!1Q$5X5+94>LF@<0;M ?"N<9WSC1^]0]3$Q"TDX)[9L>6
M*(HX,#H[T_CFHY@\@I0.)?M*39%P#3@;-=Q\),6D,09 =SI>/ZZUN=?6)'.^
MHSYF-1AU!1UFMM=>ZZKH:P4^&+L+1BTA@+:U ^3]WV+$ Q\KSXTCLY]04,8O
M2Y:&,,'X+S"C=RUS6HC:AU(W90OEZRQ#Y^F0$ *F D>;_00T7RP)0XS-XH-\
MX)YN/N(.P_@KOQDB_WVGQDU[D_410)5I#?!@LX!T0D(GH3]'(UZ_!BE]K8HG
M@*PL>ISUKR*2 \T'A&?NT74+)$?SB5\,W260WKE+!'6N2N X##"041RLJ@(!
MF"PJA(::)7<OU6/^XU):4!#.4<N*&I^M"2_6R$51BJ4[(4+]P/=O>$%=%>Z@
MF:_DL?/I3H?L+C^?D%>>/6J#3KVU;;UO'/^H.>0VPE0HXJU'!O-V:W8]<)T[
M7GB0:)F5+E&G(ZK-_LJQ;'JL1JV:?_=P;6M8Q4I!91W\9?VHYQ7N/ C6IF/H
M,/:3>!JCUJ"!KN\P>R$PZ3F"]$%X;MCZ[)U^NW$'HFP4-#3L\AWN(38<\;3R
M5IN*$[8_UGU>V&^'_\<Y5<1=55SV@>:,16_+K5Q[*0G*63SCW-V4(Y=DE!"N
MC0[=ZVE"PU#-Q-0)]P>LGC^U?;E8^EC30 W>H*$-(XLE]L"SW.LGFE'!:)1,
MR4VKYW5M'^TK]2.!H[G@YT^*Y5*4]=]!E]PZ #]B[CN(2VQ+:J[-2F/VSCL9
M 3'5!DX-&'?\$V0&OF W<,JC/Z# R^>4TEU+=J26;9!/Y[]/5MS6QHSX41-!
MN*SKE?0MU9\>@1K JNB1 <%C508*QJ<:#:]C"S>@:8W&7A$'_C>[AGAN7 CV
MDK$>9_:F=X;$KP&\,04I5]0+=Z>,#^W>!LZX$!<U$#/:3VQN%=G&6/_AZGU3
M2H2()MC/NB)%VAI.JW*[BD,UNANZ4NHYSY)"G[G59['D&52.S6P?_Z=0U46Q
M6J:6I"*I>(34<U7OU;D5RHL9P^O+V^970K(?V.]$2"@NZ,.5</:G$"D(FV0:
M.5\ N4$4F$ZK'O\'SWGRO+AE#\$+OD&$.54.RK*6ATXP]>,5JW>\8XY/*;:"
M&6<5Y=,_EA"U@HGG;1[,R&8(%PA\WJ"Y!K5_JQS[/NUS3_./<%-7\#Y[>LFH
ME&X37]+/7>)XQ+V1^L;I8NN8)CHBY^\0+3!#,_M5!B9KDHD5[E)?3JNG\1WL
M4:$J.F\/(8Y]I@V1O]LD(02G\Y3"PAQHY5^1ROC,B@;$FN5#K7XOL2:GY:J9
M][:Z5BEFT>@0-3!L-/,B[H[B>4?BJ2?-0ZG.-=(1E8]]#>TR9?)-?\KMSR>5
M+.=BO![C&K&A=4$C:MKN!O[W7)BC(,SVDUX7%9A4R8\D0B :.$[;G="66!/#
M/26:2;C,$U^7_W45$^ <7-_Y^-V:R!/"(<,N6G(AY%R) 9YJHWU+EA[S9.*!
MLL8'HV87DO^6RO-<#5823C&I[XJI4<\".QPG221<X>2#7+3()6ZKOU6Y>D26
MNX<Z*F4[^QS%O#.: =G6E89P/ ;SM7&'U6<CEF"X$+^IBI!:5YU^:)6CJY))
M!NV0.20#NA^@ORC1#E$)#7YB/FM0,+D7(R <.R9K1;<4:7U6^/P[(BF)E365
MD2E;X4'I+@$D'GMQX7-A('GU!NK$Q::5"7XIWB-CNJ6;V;@V E2:\I)88],X
MM\5^]@(NVYN /_C&U-5^([J@O).IV3HU9#;/1PVS+/4OAJNTN;"(=,B;>E=_
M\Z6\Q@CPH6FV40WP$%=0:UEVX \.9-A@3UQ%I\%D6-0G,'VB*;#)2C!E2)EQ
M3PE7TSY([ 9-61OV)NNT&;WN*OBZPM(<CJB'";6CG(3C/;-5*OD[S@*G:.66
MF\?,;5U"^?-K3*80\EU? )7/IYSCZ>AXH."Z9'_8'1&;..S@@VZZ;*0ZYINN
M]A4.P]ZH(+3M4XNJ5.1,-V,H3L2*.H"OG0M+4X%9B*-!Z TU1,.OURVC=A%H
M753/>7+V*;0:X[$%ZIXEN(:5UY.UBN&T?FI9IMIUSB?5;>>9$OV"5L5SS%.9
M$9,F=T,4CTB@!F2&))2D@CHO'R]1>Q__,C_JTLL.OWN I9@F@RCW]P1H-H:[
MGV-VU0O]PDI8&MSY E<>VFX=5C]/EWF+C&Z\!]5$NKZAJ+0M\X\UF*_X,"/'
MV-O.IFQFAP:](3@4F-),8XN!; S,1XZO_T7'GVAYQ.69KKOAA$,"#,_6FL8I
MBZ1T.*KOP1517^]]V,+AN%6^7KOQ*P]S_NS7N;$TT7RV."9Z+6RY0143U5LJ
M,AF4=;8:W+(FVW :^A$DT7B54U,L(Z.8[Z'X.-<KRF8Y9L,W,Q#NN>54;9@:
M:#,Y_R%>Z&M!V[1#:!I)^]0B$0+P[Q_)/&O)M5[ E)6AQO*;;@A[/(+V@5J\
M!S.(,QIB_M&])-BJ179D@A#.V">OM^#HU(?BXK=/;RS1M1 76Q&$>:>T*&Z5
M!\?+:DGC,\P#%8#$C(>RE!TCZRYFZ:R?Z8*PL'D%RT/6XE6+<T67A%Q[WBES
MYS0B-CP=JNP]^J(NJ#_/*1@+GC0934+?.HM0A5)FE4MHB<"3=S.:5:!#7[5+
M;E5@5UJZ6_T$A-7.JMORF6H_='1JJBC#WC/.8]DKELG! Q!XG/B%E"-'T-T6
M+O$=FI%&84V()+NS<5E369D2I5)?NE:[YP /)24R#R>QB\F]S<]V7#RHWS3;
ME6!('XFO.6KR:H ?[-*G\)O?M6ARJ4VH[8'Y67:<MI?1D->Z;H/]3<PVUKH8
M8,[/LJ)VXK#\G+*R_4U[!&,L8C$G7FV!4!3XB@YS;"[V+,X[=@Q#Y;ZV4J:I
M\%72A$>7;G3;Y.+T6=W"TH4A[5;BMS<4P8\%>J6CFR++29B6>^]6[W!<&+-U
M"!\#B<XIY@.N">IRE&^)FU HQE42(RP"\((_3,I )C,*XOQF-EUT<#"U>.I5
ME;O;H\#F,B22 O[32\1)7:*Y1GQ#GI8$5<R5D*D[9O),WX#^KZTKVUJ/F(YT
ME,\=/RY.M7NY"NFG)@5J&%!^=G-7993F4_K*LA_QRPNN)"H'#=Y^'ET5:\Q*
MR3];4AZRG*/9[:RYU#+3)#4WRHTJ68G,=T]>T\3 55"EK8%J\O,?$.1"&34J
MZ') NO<!G-ZK*8Z<H0?2T;7S6Q/1-@6S%N5@$:I;#>3Q*5ML^JXJ1!4YC)C+
M4'34N[NH[B"Y*"["&W]AV<".(?(==)D"&UI0D-)(#3610Y<T[\O)K0M1-<!@
M.TUI:7P\^[4T_,/+ENLKI==F0M*#HZ$XKJ1F%JZAH<<.</PAO!YQ:VZZFO=:
M@-F<A231\TIISA)'6")=U@ANLV)4 FHU6JE?W@<LS(';T"7E1B+7>7^,W_\:
M8NS%:<34!W2!QFKMXCIZ.Q= V( KW?[!_1CR\^@0]&!2RV\Z453V11<[F:+?
M/&27<=3AHL73O4V>*1MR2P;OG=7OL=Q.P#;;ZBZV99H,T^RVNP=0I^]N&7<Z
MATZLS!1"-NJ?;1?LF2GHYKHS,6]F:Z8)$@MT 4BUJXIK0[@K,1?+M'?X,P==
MG%$3.C3K:^92L([U.<3[?FA>,N:-/7"/*N[(@,$/9:/^I*B=<ZUWS!4N>O_X
M%N_\JPMAXB<;@5'.T3\.E6KM+<<09UPO7H/)O&NYTK7UT[CL%9MKAE42=J(4
M,69J.;<+/$#DG^)W@U[S4!-4S4.3[YZ(%^FI9:Q?(L).7,X?$EAH*TM%2]#M
M-9IN#MFI<Y.A*>:.LM!&ZU#&LS*"E1!OP5YRVE*:6 _.(L,F4$S5"H'$1;$3
MK]L@T%S';0&/9";+IHR?6S-__=3K#3M_8%A4J8S:M60[_R"$<D,'!*N)M3B\
M4D#0JU..M>^0C0J0$$\/<V7WXM@==K*63*7GO \[?Y(]H ^J']=[!=_AOM4$
M1:HZ8BH-%.73=M;3\M9<K_FZJB(S!P.7U#V2E-9H/8ZCT<.>8;+4JZ:Y.E]8
MS3_JHR30/I=VHGJ$/,?"[BG7-OPYU2!4UZ4B/FFQ.^%1->9(B#H)9B@'>9)7
M<]ODW]V>N/U??"LK*^=JNYR(KK1L>F/%GWO61ZI&]][\8?OQOG \)YSOL._&
MMY4'H;L6Y^!C:EA)-:O\_.]]<,R[!DW-X_:CG#"-T=%O9SQD%(%^6S6F%UHS
M"M+?[<:22T/(.2Q^,IEJX^\?[FMKQTX;F R8>!'U?B$MO/=-ZGH<ZMWUV-B'
MZ /2=J]P]O#N-?KKJX\W(1OO>J_M#72](/4H8J]7K"CJ<?ODC2U;NU^$[=_7
MC34?]NQ[YO2S*.9[B['J>.[5I8&A;X4UJ5M&QG*LE4LI3T\4313V;K]L%WD9
M/?R?(T2\X!M>B[XW_J'GU2>9R"]>9S_[++WK7L[5//<T_-3I'>\<N<KGRV%=
M<=ZGS17]=+UWZVY-GKWY3(ZR8=?S]O7J3^3,0)2<7/;\>ZW^-TG_N8:U2//Z
M+^?NF__6$&\2EN1'ZGVQ$>OY(8[<<[VE_+O^VR^>879TQ3==:5F'>G;"TR%A
MQOC[=X0J3AD4ZD7//@Q4>+";/;I?L_SYP\=;S*W7?T/P-P1_0_ W!']#\/\;
M!&D./]T6Q )GO8%Y'AAQE)H$ZHEN<PX_BN:S-F/#0Y00/9JHZB!ZP3U&)\1O
M)>F.R!=60$MK_N[F2N*&T[V@96SF561HESJ68.A[T3I7NY0@=/.SRR)V=3(O
MN:0534YO-?!RNL<BWF=8,I>A\<DC@(YJ;;-DPBF6#F-^E3KK! ZD ;,1$&W^
M+'%I19\UE=,#6<O>\NP@;;PD3U:6E))FSHCKZ;LY"/WW5N"AP:I@*R&>BRP!
M,U(P/FZ%;;"[WA?L="YE[^9GB\8U[-G5+ZD,_"@:B-*@BA)<H^$0S-4ZHVI5
M1P4UFUIIE-C<R8Q@W<)7F)Y9K6)/1P5(:)8O7+.Y&@,S*]54=310<]?5=JU#
M<4^VJGO!7_.W(IRK/YHL.?'PN/-X7!8(*!!-X.&)$N4Y,I\HRJ/\2R2;S2<J
M!./F.UB_1/N6+YH&TK!")RL#:<I . )-?0Q&V*=3:12Q_VA2O.XBUF@:4Y86
MR-280J#)4PA4A5K@E>;)IQ[%NX;S?H?Y_/]7_N82O#/Y].,II7_$9O_^)7GA
MR3_&G;=NM7]%IWR'4[HAIW^J8&Y];/P'8ZOQA_?JAXT:2]_G];R>[JU'L#%F
M]7W)D:BT>#$G79 03M3]J$X0?#8+M_3DL"KW-] NCO3F#[_WK8>75*I6OMR'
MJ:Q8450R;/*2$$V-<&IIN6F'F&S0-@0$&4_/J?='H*(>'BWMBNRA#\[,JCWO
M!%(;QT&&F(:V:N@L("!Q=0@7K7!A A#-K1#-DF!\TQ//9K_B.9YPO("GP,.'
MGX?GA"4/CT*0,L_17X+?FA6D_"^C_!(6J2#P+Z/\L@P ;@6PH3'!*L!?706!
MMOEW^W_4+GP\=I^!-TO0BZ,C2N'*<U6>#63BTESL=X>ZH"G3R @-'CZ1[G*P
M@_V44^"@50*OC88VYZ1^Z^O"/BEZQ",F.MBEN'[6?QF;,IJB:O[\QFKW>BUZ
M7Y2QC5-?"'6"M&/T0&JSHR0F2W#T;0GMFTW#I^TVSS18B<T!#%3&B:Z^J9&S
MW<D$>609E>/0JQ&D#AF3Q;Q5=/73!!XI'BGWHQX!R4J_(.?EX8FN3.;A_R64
M13HJT_[M#!W-DVA:%=@*0%,6 %8)_ *;1@'\ZF*@7\C_JVGSF3'!"-@OR%$E
M-*9,":W&W.$_(*]H-YR_TCRRJR9ZDN>?"_\-4$L#!!0    ( )> ?E7_'-*M
M$&$! +F^ 0 1    9S,W-#8R-&<W-7,V."YJ<&?LO0G4[.A9'GC;[1V,,<NP
MD\NUS8 UM[6KI.OV=52EJE*I))5**BU5MC%:2UMIETI2<F@@; [$++8Q'" ^
M+&%(S$ "V(9 QFP!$H;C &$)(0&&A+ YQC$#2<#=H_KKO]U]MU[ F9,YQ_6?
M6WU_Z7V?[WO?[UT_Z7[]V*\_]MM7/IZ;+697'GC@.0]T#W17KCSV.\FO^%65
MW0#!I'S(=%++?<A.#V!K9B#\$ 1>>?BU;6;:D5M=M=Q]D+SFV@=^]+W7K@;.
M:Z[IN  )V<3U [8O7*47-W8?V91S[;4W7_QP>Z,]9 >W,J^VAS@I;[2ON78!
M?F/X^^DR>.WJ!4D5O>8:?;IQU1"DJY.T<*^.'D*NVQ $71U1#\$6@9LCZG^[
MBD ( D($"*/7X=$-C+@!8U<O/]=NOGCX?KAPO!LR,[L<;_CM-=<N!3L>CP\=
MT8?28@_"%$6!$ (BR/6!XGK9)9797D_*EY]!;N$P;FD7058%:7+U]+MII77U
MFFO77GSU29_S0([]^#A97<07HS@VZ,;NP4VJ<E B#-Z+;Y#]<<9[:OX^3//%
M8?_4C'LP..SOQRX(3\U\.-R3LZQDUWMJSG+392XHNV5:%[8[D+_\WD#3IGHV
M0--F4.,]H8(XKLNJ,*NTN#?@DPB>2J,;Z6D46H'9O?595DQP>";"#&1N4@[6
M5-Y'*;/D&2EEEMY'%R?#>#JKN!=?YMQG58<; QL*/NX7)]=P[!M>6AS,ZJ:9
M97%@FR<' ;.TK,[N\C#X!,7M;%50Q>[-VR9PX6AT7-U^]=:-.#C-\$9L)L/B
MM-<=US/KN+IV<S_"2X)\&#S3W($(W@UY,:4[1S_-R'G"Q?\:\RK<S R*:S=G
M0>Q>%<V#>^,.)HF>3V&4>L@,/O?E+?UJM72+Y&XRQHTK\X* 3VTSOKH)[B1!
MB.MBVEP_A<&K$'H#P6\@U 7#5-G<@_PJ@C]!/P1,_'%ZY4+JJYI;G.SQ"2[D
M(>+B_N()I[F-"!D]!#T$7Y#,"S/S _MJ-9CDDX:EB^J8%M$%R<77JU[UJHWO
M7LT*UXN#O5]=M7W7CJX&Y=7!PK+8K=R'KDJQ:Y;NU<$[ZB'T'\RD'L2_H"NO
MFL.56Y3.U<PM!JC4=LORH0'YB6%.8WAI'*?'(-D/?QNB[@7K,&XYQ(ZK07*U
M&DB<U*Y/(?G&!=,3TSXIK[RNN(? 2F/G?K!V&J?%L\(=QT/:O..:1(N;E3B]
M"I/XU<D=]R;"=OG$Z-?_1WXN1OC_VF0Q_ 8,/6.3)6_ C]-_U&0_:K)/;;+G
MK/"1M5CL!HS<P)!G8;'8X_0?M=B/6NS%",^R4+EW4?+P4-W=$(:FR3$KDS$K
M]^;)XJ[#\'6$V%S:*0E ^ T4>AB\B_9.G-0)O.X9H3Q!>0?&I'"'J\\$XTF4
M]\)(BTV:QC?/#>"3G>+D"%<_3P\2)SV6G_\DK$N..\ V?GVP$C.(RV=9RYW^
MDYE%Z9[*Z]=<N]5T7+N+X7*D4_=UXQ@XE7\3P8F+>3WITE,Q^>[).V_"$/8$
MU^6UIV*[K*8Y:3I_@N^N$OMNON!@[MV;(!6"&$VOE6C'R7MZ3.^GM$*/%S3-
M@*,U7:ISOW'F5&_.J>."$6J!IK%U%(LT -$7GS$]T)\^4_K"GNGUB7GXK.DQ
M"& T$\TB"^%B>KXY,WB@12^&F_OU=$RKT_%>G8WWT7R\WG*3XWX^WN]YADZ7
MDV-Z]D-F3 L,?3S]63,T)DUI<L6,A<ULO-Y,VZ,U;TN;;4GO\3_'*3L^VB)#
M0]MAA.W<5^69G%[<NP"\C?A9_@')0=#UGC8'<>GC5#Z+3"]D>BW(@VA3VKR0
MGJ5/TJVG]!.?]8P^+N:#6M@)'0WB#??V"^9.NDL=TI-!VD$O]F*R3OGA]F08
M@*'WZ\EP;=#( )0(PV()\J#_V4)>M&MM.I\BT\#>3E4AF_OC5F_7@30^Y[N*
M]85V%Y 3N=LWTWC=RYLH7W9;5)J(ZCJ)B%4O^HZZ8S<,5"\67"IP$W^_\[E!
M=;D":96H+<=%AX'2] (07FV@G:'/8E.'6\>(*7V'^)EYJ$I+QYLM*L-.XF"N
MD8T\%@8\=#7UMR8;+ [+ .O$, 4F$:YH<>9N#[L+P-Q*.,1-\&68+?5#1@19
MGM=E81)-*@_Z'<1?,./U8"[K[70R&(1UTID_9<:3J2*HTYDJB_YBOVOWNVEW
M 9A:['$FL#*FB).9Q@5V,^TY1F;VOJFHG1YL1_QDC$J*Z'+3?>NHT7%_(3(7
M[F;SP(F<F8J2^:H_=OOL A "I-[GE*@2-BHNR;&SU;7,,F:P:\!RO#LXJ:EG
MA36':PMY.O$O  $FYG0]QH/=(:OM9$=X4;Z*,M-,\N4ASXFN*G*@ <W!T)B3
M14Q/)L:0M(^8,PK:L?B6+ BM$&-',2X ]1JI(]2V,M9<&]Y,C?E]%&>KK6 6
M+6KMO0;I[,6>,AVKJ)SHV 4+#-\M(GW#9N02E>*M3":XJ^]U5.<O /O-$$P5
MLM$8=*V+2S=I4\+O3"#UJF6#;%#D"+"XWV)4J: -<T@]R &:C56/^GY;Y6)D
MS<&:%_HU*J6KLPX].$!M9=W9FTT\QP H&^WH(!A93$PJ="R'6YS=AJB_ I<2
MR$HDY)&TQ5H@O0QY@Y-Q%O4R9N^DH.&#%X"8!39<:75,B6QU=^_%H->:SFR8
M50P!X$'A+,P0:V,_F&?(V#OSZ,_6JQ;@+<RKK) ?S[G"@9"-1O3SLQU&F+^B
M&S_7YA5PH")H97C=NDZ),;ZJ**G>69M^S=>@C_AEDZL$OY07JLCE9<K2]G&#
M0<AQ+ICXJ*I9[5S('=0CMW7G8[S#L)'EH VR[2/6Y*H"I.!, FF&EL$CPW4;
MFF6@9.51-FC/UQ(^(P?SGVQ=BU?[.:K;"#B_ %SF*U,+=[X]G2<\%49("\PK
MVF*F6D]X(>EM"=+)<6#9T+$QTT;# $ R(EC>X9JE 5!Z.L0P2V@:('7*"\#]
MRL-&B3A: P<69!;>*%WTLL35R9!+MXV,^R7/J)Y!"83C*3PM*?F8:'+R(&E-
M2:[V$H3(^\G*'6WR^MR-99C=C#$5/^; <M%X==Y4U9B(\6T @9N,'X)%:1TP
M#=(L'3HHNYISY3FW6 #=]NCYN,;0\'R]R.HC@>'<!6"P\%>+$3ZI,3 CX'KJ
MN::W(_R\WB/.R,TRN."R4LK1<H_S\YF,%"W.Z=62UMI I%"VQ;,MZ>KJ@K3]
M<RDH92-@HQ> O.!9HN4M=TLM&DN7X+EOK@AUH_#LC,C!6NZ7)7@<[WECI,.N
M+^!;@O ="<GM>*+S_%S.P<T%8,F+-H#9H%.G.N5;A%>L"L1I'-Y=KQ&MRXVE
M/2E"*(?9K%DF7HD#KM;-1SN)Y[F@[:+5]& [%56! GTV[.T4( M7%VF8Z;86
M D*2.CIH5IDC&:%":IF,UY/MQFJ6F\$$4 FJJAJVZ[8=AS73$ZL&!NI^2VG'
M=;?%+@!#'S@X>Q<,IBZ8M9Q3@/%(<01(QQUQ">MS?!JIIJ%G<D;G0K\"9ZH&
M%&MRF:]A!C6LV%B*#GB<2$>6.Z_RH>QV=CI. L'D\G%3LPZX:CP+HR9H/P^Z
MC<G->WOF;0I-MR%DS$]JG$8 =VTG\L&/) !1-AEXI!N/[^T+P+B21-A?8D+*
M*!5#^TNN6VNF79&[A=ZPPTKV:ZW"QA#O,Y4G2/EQP_+Q3I(\@,UZ'.V04<!W
M%0A5@X%? %8'@P7GM59[!4A+'$@*(1"O"HLLBIHHX68KVE!LJ7+&B3QOC^1R
MZW/+\,#M8C834'I$F98W%:JYU#/^N1<9.>'$F-BN$92PZKH4DQA20@+XF.E$
M>K'A.3R$;'_;X4%8*U#EK<V=1CM;B./4A2F6;1:YC'60CCS(GG6(LM4:71]Q
MU]-7**RA$>#QT;X1)9*&\D%'NR'V27-D;5%C,): N0*N(Y=/RBPD(WE#&$PN
M5H46E19W#@Z[UNXFK,]Q4[+)EIH0ZX,H&6-OC+"2]W9\!$/2Q6%NI JV[_/L
MBB)2HYR,O8UELV;;H\AF+'5%%.^VYR0EB?/]!A7*R+8%85B"7;] V>UXI:T5
M,=^9-INP>+URT;W8^WVP&'.<CWHSS2-+453HP.AWF3U/%VU0\^<48&J+?B84
M0C@.#-Q>=Z$7ZOY@8 M@AOO[%2KX*X19;.UV01_:?E1[;=$KE-11N!Z@8[(C
M9O/6@]"]"ZCG1$\#!>$M@R6V]"J-%.C6,K: %255"&O8RD+).;H$*HN2W/8
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M6=P04([N^()B>BG'N?'Y"(E[DO2\RD\I[NT*H6=#E)M<",H/9=2EH.CCT[X
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M%XT@&.QFDL3AT!A7/$/LG0E0(@V'4BO,Q\$Y1N,,UJ[S\;F<4Q(5W[$A7?A
M>[3+2EIY+!8K9 BTWK!RHXBMW95/+O@T[9&@92%ZB_5#Q\,G0X&(%O48VUI)
M0WBE#.[/E0-#X0U;N #>#)EW5O5A+P_26TS7,S-V070L-+(+4A&[F83Z;) A
MA+6-^L5I E./GM9\&WCDB$HP_K*CQW.Q$1D6M\(]98WL4AC+A)MSZW01$>/]
M$)Q:+M%L">'&1WUB9Z*#D_DHIEH1AY-Z;'?FM(%39:(:DW,W.MXM<T5C!;%+
MQ[(7C4?P9KD320D1MC($R<>0(\R\YG<>M2-'PK;1(!Z6)XJF8<ARY+=4I(SE
M:HFNF0ICSH^#VU,WWB +3!0;72E(T,%=99UT#1YS'"AK1\D*) +?8':-U0[@
M'+T>JSS,($]QO\:&%#!F*=MC8O1RVQE'QZ 4- &9N2:WTT)CP\5\1(M<*X^-
MNI^.Z*T<'%Q_V\$ /0$$:>,MO3A@U_P,\Q>[XH MHCISCKY]?J,\.7)ZL&>(
M#=IOMX)$2T(C$",]D59$OL Y-.[]U65TWB=XY&J24%=E:+)9$G=$))BR@LX;
M?81.D_/NW$Y2!87<XN,CO\S0$2SI?JN%6@+H8.*.=1PP0&ZJU M0$XOMBD/T
M%1Y$.]W!XL!+V'D+UA =89&:J<MS.6=MNO$0"_E-034\&-5S?"J;HVI6C8+Q
M%I\-E:"OSJ<*SQ^#&!-[?#DN8ZF::7.F,W" XJP:)1M P2H]/J< ?-]8!Z6/
MPVU.0RI+9P1NBK$VWZY0Q/.Q/99G:S &\5'%V_/!O0#9=P>W*,4C' N9J?$%
MO.Z!>![/J/,S*<W#9- =A>9A611L)^*D.-I)Q7SO;JQX94WPQ"_1* HU54HG
M0L>/CXJXW6[E<F0QY3"R:X'ISH*;S08\+TK%85UZ6*--MIZ9X*RUW=3P#DO/
M5&VG;8*"EY9K4(@,#?+$%MHCF>;E6RA%.4?'V8AC5K,QRX30"!ZI[7F&T1,/
M $(4WYN^99XV Y94G2;)WI<9;C8]ALY^-YOW0K%W/&99DO5\S"?488MOX.FV
M%:<46+O3\U8560AD-E1;6MJ M)3Q/CCBR*$'VSLH I8N#$:H.IBR1Z@@J79&
M1WFF5R"A<2AT/3:4H[[;>9NXAH<R]/SNW!1J)FQH"D5%2O/8S=@PPG!^+'H6
MT,) AI$K1>"4T&X(B7<KT !$U#5'HXW$BY6%SE/36A%#5)P'1S0_%TO[MB9$
M(S$7JW*7+^$Y;&[[CI2$$Z+#8H>4FW(R,L* $9#@I7FJM@ZN"@*%/(0W1C$8
M$-G@#'E<C<Y=@(>LCK>)155DX.Y$I@:7;F),[=-#KT6KH\DA-&4/#1DLH),>
MZ ^6W\N"7(])(ZRABH_#Y')G:<7WM&@W08(2.\@#X_JTKQJ9"667I,ZZT@$S
M<(\#Q9@,1I1 #+4B6<'-$'Q#%2Q"K%R1GNAUP :PSCM+^.PN(&_FHR%> $;G
M]3MO48.;53C<XQT+).]">1+ V0Z'%;X72IHO]:4I[A:)KHA-6?O,THODZ+AV
M-]J2&Z=%N63OW# _US;WW4Z_^&HWY) "#"GB-<ON^"GG,_.=L=.T-31$%*&/
M9S1;'^=;( ?K\RM&I-0X,2+Q/BPP_7"5;U'96X Q*H_R40BSFCB& \34IPC1
MHUB9,=-NFO=VRB$3A5N%"82,/!/I)_.%<19Y+8\(MX!9<V[PT_E4J 7(RME9
M V9^O5R@@+(CO*T7SW*UZG8C9E.M3*Q"4@G*E<!8'!(]\A:MKRW"T#MOIE6E
MIO+K0\;Z':%5*$"U9+TQML=EO-)84 5B&2<!,L0/P$8_(!ZN=ZYQ:'A"VO32
M;+[C)QU0'F5E#92[LZ?LRR+C"+@G#&[1H*7%8D/;%5CTBO&Y!85B>&R7E"DT
MS+1/R?X8H1ICF2G:\%!D ^Y1V>@-9\2%MBV$\T80E[N^.02E*(G"NMKHNEWQ
M[;*MUX7M;3+%MY."$CQFC$\9K-YEE'=H#T8@=_@0O%)5K)N60NVCJ?!0<JYM
M#&XHIC'79*/0EI4\J1FDIR61D*96,*E2@1%C"DP3W#K@!_-(MIL6R0N.4%6X
MX+A%GQTG8#/3.7.E;\_E'#;TX@#> >K6@@QU6\F%.[7=I32KNHA>#4UC7,$$
MH$2'R(LIV]3,WLL0:T/)0%%3J*7H9 SYB;[79L[TLIRS@6:T99UFAFVG-B$*
M80+;ML_Z@;WBM\ABY !X/$1!E#/PN)3X*G'7+3'+-V9B5G2XV4A3DM,]6UF>
M\[+-DRN4\[80F@WUZ'C*0@=T";D;<<6M=':\I/PANVQBLJF4P[ZKNH$,YP@0
M+RK*W2C5RC<IZ.#L86K2II?!(=GV>8NLPR-H$HXYW=5!MYGF<TR2**LW*BYS
MI"&G1_T1'W<DR)-V DD'PI/N=JNSIR3@BM&H#03JUDY<D:BQ\ON-/H7(.M&I
MA+7]U)KMK$#Q8#[ JNVV+Z<ITVU)F0I/&Q,2I]>G"<,F>B[:A\J3&#*4'J/>
MG-@GI:6,BV#51A4\-9:KD4F$FF?,YHL<PVW"TI9E"A5DT_1K")GW5=KTL^A0
M6>9:$JJS+V>ETXM"<B0Q)$F2.$IU+6#T%%<)>CO3$G+O'6A>0*@&)P]^6BHM
M7+;+V=*/#])*=W!D:%\0O(L*>(RKY_U#S<FE:$-V68>78#^.RUI$.5O?SP_'
M+EC-E8IW0#7FXHDV]+X.E.8%:L0L"64R3[ )J8,K,0ZR;)9?/GGL3V^\DYL1
MY$LI1-6&,5,Y<)^0Z&PJ3 U\3R[@(!*'[++A=SC'^_C.&%/+=9VGLT@VEQ@]
M46E@$2U+GRPO7]/"CQ#AZ'#3B\ AG?D[9D8I0:5 O1"Z99_VX XK9_(ZARPW
MHU?+,GK\67ZI@J*"S'K  ,KUW#P_]$>9-I7TFIW:"MBH4KMR_'B>S8X21M3M
MB.LF\\Q?H*6;U#Q>E=)"3\UPN74DF-T4G;;.S!5:R\LCLRK-<Z\WH1,'U>11
MQ#2'<KZ273)!VB#@(^[TGI=NH3"%)[4X3H*ZX+O.<BQ1E!)X=VP399$1JFQB
M3B_[A*,5YTT,J-E8_&I!BBJ[P7#37*VG2N]IK2TIP XI<$#I#4<ENW+G0<4,
M-ZNB]V=S&%YNV%6LC==DXHW4H= 66_*\RML,.FZPL*<W^]5A9D_+-FPJ"!BE
M#K@8E5.OVQ.+L"E641ZEO%Q:+3VG.37>;#S[]-+-#%V,M!;L=T,!<([8+@ZL
MI:XB(P.-P(U5J/QR"$C<U(*M>H+%IMB5X7*2R;"QG1R.O7 DE&FZ[^9@XZJC
M]<B&!1ORPVA[)";^Y;/1B 67J=3A(%$20]XM!MTM\YT%*.U0+\5'$/?@!,B]
MW?EM@UAE<?M47"7&T#VP!GOQ0#\.1LWEJQVG]]&)'M2D\O1@_Q+Z."E6 W.W
MJJ6+=QGX&>J9VE#(ZAZ14='IS0-<&P/&:<=I-Y1JE[CGX' &!SNPD"@5Z$X/
MY,E\#_()F/<%>'],80_Q'9X>]HA?B8MJ6BW.+WAO:Z+0@IZM>T'?@HI=MUAZ
MG,FSU3AWC+COL#*J%UD8A^'JR2^GW//KW"_?=FT/XJ@'*!4\ L/9##R.Y:FK
M$B'! *NB7'6#[N8++TR!7=-A\*&#"FU4FR1L;F3(O7RQ%N+KY9C?'[ P4LSQ
M7,:RQJ=T3D$1$\HZNA_O31YVJW9NK\?LT#\;.KJ@9&A7%14ZVYJ</;A*,M$I
MJ"//_?*8%6=\6E8AVX6VLBYQ<XPZ**Y(/4[71U;,+7RY2U6&"O?;E%1;_DA$
M#"@U*.4Y%42<'A)(AP0Y#-WT^6$K274;79J@PHP\Q!,TI-:;9HDN$47HE(EX
M+&-/"SF\]@)1LTF=T@,WBI<+R;=&(UNC5@#H=]+")6V !,Z)OA=SM[(/<.5X
M@<\$K#JKO-R1>9$3CH(L,VJST$4W-AEKB1]ZM.X@=['V*6F,&YYRL ;3$1(<
M(C;X&CJ+3$W"R%NSX[#<C*VCP=OA0ML*0RY?5CM]P0I.N\D%8;>CQ; BV7EO
M>O*FBS9%2"#**NGPQ6"ON"X"'H)?OIF&UOW2!]$Y7X[L=0ZBDDK"J62[*[:U
M&]>+)%CPNM4>3$'" \-.E X@F"P2BM61M)450\Q<N>WUD5Z=FT<3Y>>KG4((
M6TR+G/5:0N(Y@!J<[5H-@)]>64!WX'1[V,OH88V[9&:#> HFWCR4;*4R\P7C
M%-2NXET4/V\1T/NY(BAIDC.83P7U>F4M5@WJY9:,>&G8S49PM9118(QLAH5/
MP#Z:Q^AD%@)U"D5+/UU8BHM:L$;)FGE^5X06@GS;#GFV;=5]%*0KA=SP*&A#
MB4(ED)M(Q8+%A[@ ]V3C]1.HZ>/,ZA'B@#8CU>>!;@L+EJC[6AU>IH IM-JY
MK,"%O<,4U)C?=.FHE19EWE''N\KRX4M? E8C2(="*9 %(6=5E6N'0*X<^=PO
M&X)8<;JNMB!:ED$@\%3FH19)")4F+O-2CT!QTU,6X7E$[ &;PFTK7M6)M6B;
M[6Y8E*[S#=O3=R'#GKM1K%M.=^OU1O>ES4S5"B]I2*@2RRR#R1CI6Y E9B,Q
MIY+QI) <D;%2+-IJ?&NS0R6NH.P6R_W"Z(?&\W &M(]HR;NJI4/-D)=7O1!3
M=-?8HM5O4F]C*BP\Y=N,(1F(P\MYFM%#W%.:%8J'O4)8.[2)Y[-=D:^TXG ^
M6R: E_URK+)'8RI61-@I<J>II*<"\VK2$E@>U;EW&.%]J1YVXACJ-'ZUA$TR
M]G1JY6L<AQUW,UN2@-%D<ZX<4KGC\HWFK@T,5ON$!+P#QQ<Q*?%@C+1D2W!T
MI-K;2E2J;1$L<4H,5U%?\8OFJ!2$(VU4BB*V>3?J+MO;Y*  )CBO"![P6PME
M9(3W]&V1$#T]<85J,:2#T[:\5H$QU&JKRX=@P]<8[.LA/G(Z00UI9)LVER^2
MY8NP2U1O[;6PXR-#XEFT#.FPG98*JW!C%F.V$$8(<J@ZRG47T[J:<GH\BXAJ
M[>U6)BGM\%"0)9J/J.UY8YS$")'2PY(:$D[/U86TT<,X4)#:60*E(LL;9<S*
MF1J&(*JU6WL9I*9OF-5QD1>((XCB:A3[XQA7"M(ZE\0U1I)HC&<4Q"=DE^+9
M>!?"B]._VP_&"C%9D@LZ=!( *5B?-$E]K&WJN;X>FIZ0-M=RM#Q2'MX2CM=6
M]7G?!@WGQ=JTQIXXRZJC54/:%A"/7;S:',0-)^N3B$FZ3'4DMHCYQMY%LNW+
M;@,H4I>0(P+'=U"O.P+9'H[G>)BE0=6,B?B8A?IJ&^6K<3HF<INJ =#@CL=-
MQ+,8ZFAY#0M#5/*7L\A=CQK8$@Z-U/F@>"!C4_'ZU"S1\S,I"(KK+09OA?E8
M64E!H&[I,!C'_G&W@0$(S&V%-0]1L)SS(]H?260D]6*9@RJXXG5X4*V4]JCM
MJ+[AS\^[Q,?(6M1=6*X.M.DM5O()9->/ME!9NRO09_.JECH1%'*</V D>MAV
MZP,2"1$,H<MQJ+:B>LBG8$D)F^S\<G+B2@</YD*DS>2NI2Q<QBEB47J="@KU
M1!=E'#Y4V$H!TBTW2H69)K.:W*G30%RG*$$SF3]/NB%,9=O-Y0L\4,92\(YL
M9T2+[\B"D'!K" XKJ&;]N13$\9;,=CN&RA4-1 X62,_+CG2%]6P,Z1FLDE"]
ME$%56G!5?&X>PWO5%>661, XPY=#'S056]R'J*+340/"]%EK#WZ#CM:*O ?-
M%=YJD[47@8 1S<XYQ=$C_;"J*E>9Z'@ 5*BO);JZL?.YM072/9?!*>V<NGZ&
MC)H.@@!"1'>FQHWM [=@EM7(LQLE7,[4?'?>3"O!.IZM,(30VJ$2Y1BR: JQ
ML8O4S"2S(2(^D^R,- IW\%6VC6E[LL'V;#XF2\VJP$X!^3D:5]Q6G"\O_\$+
M%YEP-(,=,A(RSK-[;;$MG; *\L8&X]E0CVRK=7" @&U+Y$23*X5G=&ZM.?AL
MFLQM.V9ZP>4 %D%FY_96)<BAN*5HLL[L+*5*:\?7&W@7"V69#FU\,-%0;+F2
MTT!5'3_(+2P'063]FM<\<=+#^1B'NTZO>!:GBMSW>(R'+TX#O+%(RLI,;'?!
MW!PN/!0$S@W((48X::/74<*CKMLP1ERG< >[CF#4",=,'($A^ +X=O:[H)G+
M0ULNH9UG"?TD]KN@5T6P#Q(S?A)-70_X.(- )#6@H>,9,X9A"L9H$J<@!H5Q
MB)R0M[#OP7_7&+*;.,'I*)9););ES<LCZ&XAW''W;N'=(FA<9U:DAV=XRLC#
M%X<LW@B>T.B%2!:)N39ECZYCA(=>QT@+OFX1)G;=,TW,14>.B2+6P^!=O/>"
M=NY>$(2D,!*F[.L0Z5K7(6M8$!+#1M==$J$<%"4H#*%NH3OW4M83Z.E?>4WN
MRW^O88K[+,L][][A";>OR]V+Q@9EE1;=/0Z14=S\(W.(S,4!F#=,^^*,G](<
MIG*:^I.NW9\IN-M5,8HTO9'I7H=0$[_NXAATW711Z#ID(SB$X(Z%VO M_/L9
MQVUC''TWN>U0'^0&CMU J%N'^CR)ZOX@9>I51[-PZ?VPC,_@=)][<=T?W?;-
M9.\Z-\%;C+<N/+,P^3_'PCVS0/C76;@[3F/Z___"G:_>[HBWO/INQWWX2:>_
MWAAZTJ*J,ZE(O2!V;TI%D P1XRDH[H-S>0254EOW/K?J=LP[J&^/-AMI?X,U
M2RTH RMV5XU;9*=9W=P4M7LAU?T(G@IF4YA).5BTF]C=S9D9E_>"NHWH;C11
M&DJ.\B;\..?EA;LI!;,]W5*"WGWF*8X)#C>.-W'X(>CB<S*%\Z5[$?HW2>P.
M0O^>A'425#>EP#;+6W075^XPE#LF?0^13@?LWNL,L;&Y_TA%D5E2W3B=GW<Z
MQ_#F[>?BG>9^V^VG1IB9AR#NSAA/9KV\_G3,MGOS7@-?W'AJWI.@-T]?5^$G
M<UY<OC]G<S[H4*D&,][?A* +$[C%?_O-^X.<CBI,RZ!R;YGWG9>?1NK!N<^*
M7RCC-[[QC0])L_&KKS[QBW";)FX1/YOX=+NE/&YV=QK6+8.38K.Z&.1>5O<4
M1<?-26<F3Y?@;@KF*22;3TNW=4]',#XMV<5IBT]+==OYB\\RE-]7);?TI1S-
MRO;G15IGSU)CS_ZLOQO[TS 7%L"<J\RKY^&O7HQ_[M*>1/34.!?> 3V9Z;[^
M<D$R.1V&:=X5CIY>WK^6X'=,HKR0]T(ZW1_<ZW+Z3[K\]!B'U'%OG@[>O&2^
M^/WIV4X'G]Z4Y-5DJBB7G-5]%'8'ISVXQDWH\;SQQ+5G,->SP]S)?>ORTP-T
M%YYT)__EU:=GMTX>=B?W^>+]E_E^#OD$Q4?4$"ZCP$<-X2D!/B*& $/_<YO"
M':'^V9O$Q4(JTFKS[!:V.A7"=RFG"N[=?MS!?&%V/#U^=E;(W\2HAT@(I2#D
MDI%_!ESTS='HDIQ^!N3C89!+\O%?>97OE5R?=/-IDLM?(6'?)R<_G TL0T/E
MU+9;7/9*$C.[&@=681;=59AX"!J4<QO5BY\\''/':<CGJS(SN_GB8>Q;_X.9
MIU3K1^SST4$^.LA'!_GH(!\=Y*.#?'20_ZD&>?$3_XLZ-W%><^UX[;4W'_NW
M5R97'OAK?DX@?UV,!Q[[\2LO>^&5/W_.%S[XP,NN/.=E#SSXL@<>^^DK?^/*
M U<>>-Z5!Q]XX,JMSPN?^[SGO^!%#SSXXN=\S$!@?/R5!Y[[G.=<N?*BY[_P
MA1_S_.<]]\'G/>?!YS[_@1=<>>&+7O8)G_A)G_QI^J]]^N=HQC>^_7_YE$]]
MVS?]TK_^U1?#Y+%]U[M_Y=K+1Q2];;[^+>_Y]5>\$E_7/X2@A)E_KEK^R;?_
MDQ\<D#_[-.8+'GC2R%<>&*"'P5_XHA</]YV777G@P><\^.!S/NY%+_G8%S_P
MW <?>,X##S[WRO.>_[)/>,$G?LXGP2\<!KQ&KU7MK6_[QE_YU4_^-&6CFU__
MR__ZY0B1UU_R#6__]A]ZUR_]"8:/RJHY_I,?^,&?^,47O0(EQ_);?NUW/OCN
M5TZLEBF^XR<?^XTK'_O@ X,V'GS9E==>^>*__."'O^@??_X_O_/G51]XXV-7
M?O9+'_G#WWWDS[_WOWSG:]^_>Q1Z[0^];9]_^ /?]I=OUO_\!6]XYY\\=N61
MZ__R'7_:?<=C5P[O3F\\_Y>_Z.>^^2_>_AD?>E/].R_]T_R1*^]YQQ^ '_]%
M7_R3;_NI?U_^TS__=^0_N/V'?\<+OO:__-X??NV'_M/WO_?[K0^]]LN_Z.?^
M^+V5_4C[MI^^\<I'_MUC5^+7_N*?O?+#G_[_] ]?_:V?_^IW_XWW_>J_?/27
MW_<?X/F_^:P/_.>WOO<#W#^J1H]<>=UG/?KF?_R___Y7_<I+NR_YOE\3/__T
M\X:7_8GXR+>.OO>][W_#US[ZQM?]MW=]X=?^P+?,/_B^+PJN_=C[?O&K'WW_
MJ[6_^-KHL2O_X1MWO_Q9?_#H[I^]Y]%O>-T//FH;/V*^Z8M^+GU'O7^T^(_I
M&U[Z6S\N_LPCW_&;SWOLRC]_?_W)W9=]WS^[Q'_GG[SHL2L/O>D=_]=7_/BC
M/_S='_KV^'U__#6/_MZ_?/3/\';^X6MO_,]_^;,?^HN7/&K_[>_#?_VU'_S=
M1_[[CX ?_J/?_%=?\-B5\ ,?_,H/_X/OSU_WWK_UVX]=>?E7?_C'U>]\ZQ_^
MEV^53S\_^M+?5A^5_N(#__TSDO?^T;<]\@L?VK_W_WP/^,.CEW[@VJ^]J7_U
M(W_G\*V/B,9+/_2QR]>WO_>57_ ;_] T_N K_OA'WOQ<[@<_[H?5[_RAW_CP
M?_OA/_[,G]S_S7?NWA;_O2]X^8W/^,7/Z+:?MWMK^XGY_!5?]CW_X'5?_)M_
M]AW,JXC7?^_ODOWO7MT1Z[?,[7=]_LL^Z^>^_.U__OO_XNN^YSN^[P??_$?L
MY_S#Z4]_$O9)T+7?_?/#CWSAJS_S6[[L==_[U6]%W_-;#QG5MQ;/^=[N4_[6
M>/MM/S)[\W^](?S=Z5<^\I[7O^@/EI_V=O.M7_KF]#4?I[S$IS[]MZS)ZW_F
M/_ZK[_OZUW_F]HM?\1E?KY$_^=N?^=9O__V_^^G6&[[T;=/KKW2__-N_Y'V_
M\XF?O?Z</SB\S7-BZJN-XF>U[_F!%RR^T_V6C_ONMW_,[!M_'OYM]\<^]DN*
M5_[JI_VOSC?_Z>R#LT]OC<_-/_E-O_B6E_S\UUC)^Q_XB:]/W5>\Y0>_:?UU
MW_/'Q%=\YKL*)>2?,_V&[_*_YM7?_9ORMR4O>,E/?NX_>C?]X+^Y]G4?6'W>
MQW[3?SU\RNM?_PM_\SVO7/[=GW_AM>\)-C_T$_('7[E6OOE3H^LV\!^^;_9U
M_^H?_M.?^H4O_>SW+W[F:Y[WTNN[3_JJ]<?_Z0=_^>]W^<^_ZD?>]+=^X'U_
MVZ9_]#=^[U^0[R1?_M/O^(3E?WKA&V8O_L(?^OGO_IWI_.>VVQ>^ZI=NL+_Q
M]]]%O_-7_NCUW_9K[U=>\4W?^/R_O7S_:[[E7;WQ(,Q#O__E[_C'ZG?A*/RA
MK[SZ=7_'?.=G?=8U["M^Z>T??,D/3/[^MWYV]G\C?[CXJC_>O%D$'.2;%B_Y
M1/%CONK_>.>;?^![MODG?,HV^^1/1M[P>5_X7<]]A?:ICWSBZS[X:;^U^[)?
M^)E7_WKS9\UGO&7TJ> X\_[>N__MT?_U?__=;WK9=[WNH3_[;\*/_>*KWOW]
M;]W2GUUUZ^T?OO%+?^HOW]**CUWY?]EYZZ@XWJ9MD!!"@.#N[NX2$@CN[C 0
MW <8W +!;7!W=[=! \$=@@2&&22XNP7?W[?O[C[/N^?;L_O]L6?W[+Y]=?][
MG:ZKNNJNJKN["P*@+U,&/AVFO2OZO?=M0H_IU6.?B<2MC?]YJ%\&36?F()U;
MO?P?;X?^UU#UI.M[?@KZQ)$_E1?R H%WKW/W0J>%7^2 +RL/%US2@8_#[J2!
M'R&Q]VD?ZD2OI.J!6M'_ 3W;SJX7&RJ4WJO$TD (;"87;>+V771OJN3+ X/W
M5X>O9UV_1IZ61O(+>'1 7CFW/V;_([[^SZ%97.,+_^J(0O87,G"M^_[P1(S.
M#)U:UB,/.\-M?2W+!J!V,\WZ%DR9]%GG1[C'KB$IJR4D5@:+;=03W>?<>O>X
MD5:1+'-"XDL$ L.;S&X$^C9B'!4U%\;-\%VMZ$AJZ;@/#DG1V.ET, CSH#?H
M.5=JP&B/?G,%R(>A%$_ZN?2^7L[9!GJ$+[<M-J48XF2O:.PRU=$LHD5B^:=+
M(%>"!CI'-WJ4KU@I9.OB]!'I1QYCZW01E(Q8HRMA127?+EZWU?/Z)Y7!?<>
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MI5G 0P(I4#A.068QD&&SLT0D[6GRWL&_1M>-N\T<Q3V(O:2YF4#DWY*RB2J
M!*TI\I'9!JT_>#\U!:_H<;0Q@ZS5!$)=78QSYS0[AT/,H5JWQ)N%IO)TR*W4
M*H!&;]VHPGP;>CSZ,%>=H"I+.^YTOM]H[8+TT5A+)ZUDWIU6X0V&9(+S+AL#
MT<=-:<A0EAA%],R805A9K>S8I\1?R9I"O5\XCIQYS[FW9*,:-CYW2P]E1,/#
MBS<JN?=&[?ECJK6<?A7*M\CEP*,(#&/=[6%>2X;^^CL]?3G04J>.Y7I=A72X
M%8SLU(XCJ-Y!8)6I@&N3A'=Y-3&W+$8R,L%<_\ZD;#D<F;@@,9/LC=3F WFJ
MM1*N)7Y"1Y7/RO0 JSF]HV-%3:M3ZSB07,[J<L%'^5>0KNA/*)O\]X_O%3AM
MJQRJ!7ZGR6?OD@VV&>5]@HF19[DHKH?-H]26TLF",JF))I0KY^;\ZA03DDS6
M6[++2>WIS/L%R<) Y#YKF7^17A'2I6=VI4P# 5H^;<?_6^/JH_8_V+CJ*=_H
M&?N.>E+IOOMJF1T!6C>\+;;\3L[^R+J7U:APG+?P&](Z;3C4882C&EMC*\SW
M@4=-IGG+%#( ',C68[T&B8+95#+[FMI8 "1$PHUKR'"AFX\'QM92@9H5;!P-
M"5MT0:6__%**/.DGHH-V &8M4]5&^;#C[H^_?SPR3E\P'"XQNO^];8Q'A"Y.
M<(=S-8-!)"'NV?Y>A.9B$C24;:*V 'Y5$K&A-6(1(2.L_<\)HP=[8<9Z66NL
M*6P)?*$LR3#;R.I4-H6O-GT9PCS).UF?]=YV(]1DP%;(W#T40M/(:7#DOCP
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M30""Y!'>1$C;B"FJ1&!E-9[&"X&>$JHJC!/4BAXG^U335XF\&Y\(0W=LLF3
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MQ"(LG5C!\1F;G@Z]E0PE@-327'1LT),X/K0=UAAN8%=C,0I$'=Q_W&=%N:I
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MEAM-"YU!D*\Z5]5LQ=(>Z+H##ARI:D=4T^K]C+NSGC_^E]'_9?3_'XR^Y=M
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M34'%.^QJT'AV4REFT2F^=%\IR8"\=W0!^G>7V[]Y?IXKL2NJ\:6SLP_KI.T
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M(B9F'Y*6WCNFK+7_M*/T#,7M(6?"Q%:2<J2IPV1\J>QS;33H)2^RGNFQ;C*
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M#X(S<8:;'+E$G_.*&M#EQ5-EC:I&O2K_2?%K[>VB@UQO@_H+6,S;I,Z\R@7
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ML2_TK;K)X<TLI%&W-4_,8$[@.-];+_Z%:XB!:(-BN XQ]Y%[&2;8;$7\(UD
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MJ'YY2S_V."CU4(U*NW:KRNG>D-I595^J6&*?4LV2/PU_&+2ZV4^3ANAA*LJ
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M1-.SU7_6WI'(L*P(P]R1$M#_P763"U_1_CH<I*.[8I3M)<9[$>!8TP*TBF&
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M10EU=)9:#&,4#UM_T1NO?)@D@E*'%8V<+->U69Y-_.,I7%V$LQEZB:U0IBM
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MS9,XMBYXYS0G CQKS=MK[9&>A-<*\GE53CML9:GD9WJ[^:)MT\:.!06S!TF
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M;ZE#:MB604=8[1BZ7;\<%NQ0Q12T-7$Q>8^3R ->E2O432GFN/M8?M!E2&H
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M*%)"\&AUN=NB'NC,VF=93\31@!%S=F82[%V>SX'G+-!LN.&03^)F)TO(_U,
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M89R 3FW$#$#3<L4YOI23U^BY\@_WKV)O>.Y5M/>?+A$-5<HF9/1@Y"-JA4:
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M4^'KB2!#G:#52X!"*G>EQ<D^]J@GMVT!+J-'8>W5OE Z%B*4EY?DFAZF2Y,
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M_TO,_WG$N.#9?JNVPNB$F>XT]KL\:C=]L&JZ=?VL%"\ZH=A"#5)9)A+ZGO+
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M$=7B&7DV&U9C( QUCX2/+$I0O$_1]@26PNM3Y @P^AUA=O9O]L6*^0-R<K4
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MH&C'.G$KI#GZ2:,8P\-91UD#>NY,? 5M^YAEW#"IK\4J>Y</^#;LR#^2UV6
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M@H^QMB71@@I'NV.DT,%;+Y]UJ<S]A6X=/CD_F2:3E>@,83,TP4X2WO*!<]S
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MT=Y!*O(XT;7EW$^4.Z>2EOIV!7JGO#DEXEH.RGCQY)0!MG"8Q 2 A[/FM0Q
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MS5)<J'*6/=&]U(7$KDI9F0 A!NIQ)Y?M39M>[TO3:"/9P6)F[JA*.&4JZ<0
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M*PZ/X-KWP_LFUR3@EN5AU4BX5%FXN]*+$>7Z\""M(JJ1#;[PR&+ZNC1^( G
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M'D';79^FTNKXKD)*'ZM22IM#"14:='8M.EF3IRJ<!Q\6")B$MC <?F' $9B
M7,I#*0[ETV8!7%]5!9 W( :%:,))VSA5CC\F,U"YR7Q..7!#\KGRFX*[UU7N
MRL^<[+N3Y2CW-[!0/@;$%:MERM/JKPJN?JAQ57[HY%^>*E]'+@S>R"\LIJ5?
M%/R\J?*S^-&ILO*)!KBC@R-:O)UR$D;$+;!5^53!XC]469PVX(@6G&(3I\KP
M>^+S7TF0T"^4()/$+EIRN_F1@M4_5EF-7SOB<Z?X_:GR^9$SV."*#0(>-=?%
M^;?AB8++?ZS/P?)CL6W(/S]5)O_"F/?B!P&P<@R/PX4_"^@HBG*+_KX7%"S_
M4Y7E61N"Y;M6'-G,J;+^CL[B[" Y4^IOP_%P=K+:^AOAL !EJIG_I6!=[<R6
M?7"J["O:[TIFR*8'S4S]4#N'E8V"Z=<GR^&8N=_'< @-8W]#<7U:K0.VI?26
MA@ ]AHU_MC/K]JI""K7SFFC-R9N3BUO:H).VZ(@F3U4TG]AJY<=B1P7,_L2$
MD8:&.P/1OA<48J@=\ IM"!&46CE5SC_1*+,V3^:/G&Y\ED3!=AQ%"?7N_9
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MS/Z-NO&4/;(HPBB )^I1Z6-6%IZLCV!8=#VP]._HGN8R@VA4E]TZ?62XI]W
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M"YB*ML&]L/!_PLN&HE>WK; 4!7%CVU[T5"O4"SG$_-UA][L?Q;! CLE+B->
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M5/ZW)/1@7P&+%IS _J=UD>V'T+]+3SB<$XI^;9\)#ZEWNQ5.>\*'U68IM4Y
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MO1*M4>T"_#)REW1%_OK_ %!+ P04    " "7@'Y5-0F2)_X3  #,*P$ %0
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M\FFNG)@].B5D&LCW 5*)/N,?RT0@]LKK!)WN7#1P:N&+&BS=+MVZXNP&,C5
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M]LB]R+<%QH.K[6\SS@9^VHL\6RGI;R-%)D10%5BFK';=!'BT9GF$\G_^?.B
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MB/5F';3%L&A=M%SP8/:*\HLDR>IKNK-:&.'R"+:A,-TZQ]6^.#:I<B!U%$
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M?WKG%@P$7L0H_X%GXV6)HHM7/%J>T6U%L,\6>U<)/P=%''(84NH'XY_>8>
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M,Z>W3>#FB,^>WRU5TGO9!:H -EA]6GI%*QH@-^D#6J55WMOJ0(<]&KJF6IC
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MP+5[]+*Q#F8+!1YYS3 Z'[=( WD4(P5X=.?0HA-'?6?A:Y8^/Z)\I?!I<GK
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MMI?XZ\X>EZC>KUR$85:E)>=P7;(E%OX]>6644 .4Z8@=^HHE;RUD$4FL9[&
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M^! ][*=IS?#WY#66!0R0H\/]4?O'LLVT&0)Q8\"35,;WY#F4 0L0HB,-2FN
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M$H.Q @3;S0U($+8!_^UQW[?@C2#YG.5Y]J,Y2L)_*=<<HE6ZH4J8YBYI-&:
M>!W7C"Z>GW.$=VFHEX@2=# )6E"9I^E44H$'4.(@]>Y=A??9X6RQ0-CF>]:5
MSHG9ZU=1+B=^J_GI1QTG]LR7<-,WP2WFIO9X<-(F&1TQQJ4(@Q<)FH;>)\!?
M+$GG')"<T ]E%OXI<2V+V0;KPHS%+Q_])R2*N38($.E.X#2(*"H8B3Z=+1[S
M("V"D @EOLXC;(R!NJK:*TD"P)PD,A^JT5F@T)<008-<:DTU-9K3F[N9\ Y6
M]PP6WXD-K?JQL.G9@>%#$JK9*\HODB2KXQ=GM2Q"-L V&)83RUD/.P)8NA-0
MF2Y2=.+ZPIN:(2&"HCNAE+FJ.">N+JR)5+BO<%!^#>F?K&G;]8JM3>VB=5E'
MKB9M)8C<G$QP!RUCURF$H+VXV2"SEJQ83=7@JXI,EG=XRLPV%58NPK^JN*@5
MS-U2RO8Q/W58PU?=>3 0G\'<47>;^)"[/ Y16T,%=MTP'L8BNHMT&NR_ 8'H
MR"*E<VMXA8HPCVMYMDQ N;TAU!IC=7)_=NQW(XO,8)ZIKF@SEN4[5ASH?]U[
ML/59'T]*]Q)8!/FD;/K?\_@U*-%=$H2H.:77Y(%G]ROVP0O:S4_/E:Q^-?'X
M?GA.&RR6[?()<IIBS>5"'/_3&]^XVL[-1&,H;*+%5*GZX\_!6(OWY8_?F/EG
MIDHSZG#+G\NLVS( _P[>>8K7]9;?'K-^^>IW9R.AJYC= &O'=R]^_]MBT\B#
M9K\\W*C"08>&BI696^9$8.P[ZP>6L#D\<+4ZB50HY;9LY)^*;YY(ZWKIT*9V
M&[4:=%5#/#QP,M]S!ZV:M[B!H,$O/SZ=2!(4Q6SQ1Y#C1:N<Y?>D2'?G;""7
MMNLK,9=XWTCNS&R>*S8/<G.2C>L9S]/NXB:'[(6UXO;B((&)Y,L;7H3CC>>V
M^V,G_J'JB!#U-S\[<'C H'L<R*'5<=Q@*-E%*S'72N<UQ @=GE:,X%,&EA]G
M%_4A5G.X)3I5$K;!N!SZRD?0)4 D.)^PZ#'OW6M:]W:.A2[/N:!_H0==MOW\
M[%1'<2+!Z[@>=9FV\S-#%UQAS[J:!AF6I#RNZ7K:EUE>/LK7KV0^CW7@VO6@
M0!4P;8&XO/"R[XHG]L2R6^"Q[CH3.T?5DMSTH7CA,M?)CFO7A@F:;)1%OLS2
M5Y27,?[0L<FXBHLL7Y-[S((*9=Q66':GV=:Y(Y^Q8,F@\2%>O2=G_ZJY\"""
MVZ[U\9P[/I:0YTP=E@_UDX&E5F X<%KA2<7U ?U8\T&(SH=*RH"0PL6*VPZ/
M:T.YIZ0-"J'RE3CKP](=0.\5:[X8&J;HLQ&(?YU5:;1Q< CJNC >Q5(Z2?JD
M\ 4PC P0B,'2R6/U?.;&]YF7<Y+_O%Q_0^4RBV[P,E^4"/7*YIR=L5T/( J3
M(?&UR=C:C/W!P=>XJ!T>'4ZK0@P;YG*H_/ \:ZLH>V8HFY%%1PX/F8[H>,_J
MD)Z=&DHU-KIX;*UQ:9+Z<'PMTSR.)E_L+=U\"2O#.BW1/+ R[-FID[1NDA^(
M%$M])-X48-87U7]F* ^;W:6*@\V/.LN&H\'/3@TYZS3$]=<L -1)(O.B^+(%
M#GU:VPR1*5SF[ 80JB7<.7-3'4[U<V'SLP/#7+UEO%_OJ1[_BZJ=;.4?PB6*
M*H)D?U-/COFAK3ZPQ(WM$@]I,Z2:7P'U0-=1LWG00.#[= "J91Q!3A9"/63L
M$RP#V%S)9S<4NEX'W7$I+%P[W,EB.L?6QZF>/HI ::_];"X!E+.LFR(=[FL<
ME%]'Q69KZG8]4VG3NW#BT9'M65O"+3>I%;G#EG'V(82@HR0SH.J',$[0V]TR
MR%<!7]'[3W:Q,D=.[JZHJED P(N:R!=%@<I>9BZ!OX[U> OJDZ%;LO8\=D)T
M7M0ZWI52Z.-A-Z# #,U9TBXZH=KEV&+ \J*\L7Z^7"_NIHD3K?E:ZA@_H'15
MY8(EJ/=,)]^AD\5'8=2SEB((B!>5B*%Y^_.Z_Y=A$:B,3CH%&+HKX3PN5819
M1X%BK:0K13ONC'A3(?QCXU-%)(@990#548+8(^9\6<CL42A<VI3<"<#2=E-F
MX;+B+VW]9ZA\WL2K,L8^8UD#0>BH* S9#5E=%3$36 Y;3W6R&?)%&E,P!X:.
M"K[Z57QV<.:N8&/K.M_2+9:(G7N6([^.XKDF=.NVKLOGJHA)/=K^CB.LZUGN
M:AQRR,"H=)2U!31>1VM!A\1;#W3N(4.Y/"R<_,)X=%2.Y6D8/MK;>81*Y<IR
MY&@)4B=#=!V56G4KU+5!IT.SPMO,2IMC,!\'1ABD\7\"TCM_,F8]2^4U=#U/
M8KF#!B9#TT((@E*GHZSAS:K,FX+[S]"5>*I9+_B0 %7KN*2_;0")E,TPD]Q-
MQZ"Z.*IE  "4JV57-TZY7DS-6K0LG*#MQKU_S=+G4C[%#NMQ:HI.U?"31@=0
M9C?L?5=*H1>+W8 "<^V#%*I=CBT&+( ONZ?4^OER/1N:)DXX1^K8V3[^R!Z7
M654$:7211H\_L#FXQK_;OEK+MVT5NJ#HG)B\"M\,8S$;BA-(YV/W!)OE>.$O
M<D +"FVJ,9DJ  'N[&8 %#K-%%F$'6Y.%T 9/N29A$$"G-H]+[?%J2^+I!UR
M14OFJ0YGQ,4S?O5*X!#>>JBK2'<X:7<$C G0M@Y_1/=2_IYYYS$JG:O(.('&
M>.IE0  4K,,G,5K!KJ<8G9H63B ZCI^)V?GE+5P&Z3/J1.';V)PFG?1N(JJ%
M0Y>A?UDT  >6[]>7>,:DM[(NL]5+EN)_%J*\"+QV'<SIITB0A@FP:=<-L2.E
MT-9B/D]AN8Z[EM<^FSTQ/( UN_'RNEESO639HD^TG)W9=4+<X6Y0GJ.HSC,@
M4=1P__$.W*G3$&[Q=\,F3 @)X,FNPP'C6F6I'$E[SU(X3C(ZCF6(CP>@1T<X
MP1W*XRSB[2GI$ZU,9T>3S2_! 00H6<?>O7DC?Z?3?Z:3Z]A9[@>.HD"5,H0'
ME*ICBSY"J:X78CW:%2ZS.O;I5Q6:I;/\8E&B_!H]Y560KW>.)):Q,!.L6B\4
MH\/*9-"(9FTLAZ,#F+.<?X\L.TUEKJLJC]/G!GR38_@6_:C_Q-]TRG0P/^M6
M+/M\CJGY- 0F0*QM)P)3X-^#I$(]Q_8 :O>ZP*C=Q1,:)!< "M"K(\[^,GB)
MRR#91#S.%O7PFE5E4>*Y!,L%S;&B=EAP)Y=T1C.D@ Z@Q:[;@#M-U/__.2A0
M1#8)V%"H\5QG^0+%):U8J#K)"KK%VG&2:=W.U"L%'BBTHN,6P2S'(Y"DENR5
MN,2+OL0W*VZ)A7=R\TO/5RN+#R#'KO^!G15M]B-%>;&,7_"("U&=]T;H I3H
M ^-V=]U,QQ>IB!1@V&[XPV56E 4>?U_>R"R!BKX>N,XFN!E&Y^1JFS8>Q>
MZNQ>^B>'=S=I4>85&6;708@N5EF5EAS:H"88E;M*]CHHXP,#Z+)]T_\E6!/I
MBMF"B,NA:??1^=E'=T?*.NAA P)HL5L#H8UJPG;2$UZ8B3"765IB]<R>,, 4
M6U>H"/.X%E,B%DRJ'XS?G1]'!Z$#T )LV_7K],I'"K[!G2<QAFE[:IAX $YT
MY!WX(\BQI&7QY0V;/7&!Z@+WD-'/?!B+.$W_B0@2H'7+R0JC*&XDN MB;*YN
MO F<+P)H@3%-TXDBA0O@R@OW2>V(NZOR<(DW^K-%G<ULJ.-RMQN,_EVZ1SA@
M@0JF.MPAP?-SCIXQIO;-W-F0_306<L)N#QXF0/%V71TW:8ERO&7?;/HD]\&<
M5AC;M-T90FP ;W8=&'B?AZV:U@=^C8W1-,1?>[N'OXJ+D&P$N8EX);O J*?M
MV% #"M#K+K-AOQ(.W5UL5<CA;JJ5>L(ZF+9+9!!>@',=P2E7Z"4KR.'#3?J8
M5T5Y$8: MXKW^/SLTS1=(6)0@.[MND/N-GZ:QVQSM^LNSZ(*PWQ%0OM2V+;+
M>7<T;>^'&E" 5[N.C]U4QY<8<HP%J=>"6@]-.&QSAM$N_=WQ%/F!1!#R5E$]
M;Z"JF_BNTH Z@)'D101-<YXY?C?*[H>J8=J+\G#0 /=VG4:]F.Q-G$'U1,R)
M)Q1]KLKO:5PCXWI593KH@!]/>PX8@!:@64>&D=T9J=Z!X_%7BP:98=Q&5/)I
M[HL4$;*Y.=?A(**Q ;-%%S#0+@H0-]Q&5/)ISIB*" %N="3P[ O1?,8284S<
M1IWDIJXMVN:&CQ#@1LM=G<82[PQQ$G:3XL8LGQV_ <W>/4V_MP(Z@ \=UWIN
M*P)/X3L!&]#\Z!/^1N30 7SH<+IL"[ 9%2P#C?-T)^NG":_R$M  &NSZ7P"@
M#RC!;WG^#>$U,$CP_O B6F$*BI+L)U]1&ZEVC;765\\?<;F4/,DP^^).T>?3
MMN@M:@D8CCKRGFPMW?'J)4$JIN9V"YIY>L*GDY+P $KL^E](<L,"+_3$.W19
MU448.)\UXVD*:9KSN2PT@"V['I.K"CUF/;0Q*L2DP8THP&E:18H( 0JU>$/"
M,*_(00Q_XMMYK)-NHMYI(2:VQ@\/M#@Y-IZ5-C0.7&QVGNL$_#3-8R,Q*$CK
M=D-@&J_SOU#2'D^*3GOZSU(\TXZ3Y0.#B+(;\_(0),10(7YED1-7U(2BFV:L
MK1(^B#V'(2W!VV9S4*^(%XM%G,3XKQA[<SPHNV,3]4/U,$TS?3QHB'QW]3Y[
M.FAN*Q4C8YE8O5 =3-O:'PH9HEU/QM8VJ#6/TS!^P5M_Z 8>]_E.X/,)QS9)
M@8/8L!L,LSU=2.['=I_OLEU/?!LM!@>1IN.:$+D9&$?\SZ;_3"?8X83W B @
M2-,ZDJCT?5R;*RZ#3C.AMAT0A^F/M3H"I8!"C-F]($3JJ#RB?-5WB7'F,];C
M':K3:7N6A-@ Q@YM9V#-0H2B^DA DC6H"2V[,,T/3PD?Q)Y=3\EVN@$RW'C6
MP][#%-$TO8B2R""N[#I+MH5LG9[W&'R=]#F22F(CWPG5P#3C2$8BACC7$5SR
M1Y;_2:XK->OR/:K/\.M ?,AN@5MT0I]/\Y*>"CR($[N>C^T!A4W@3;2S8M*:
MW884Z;3M%@64$)]V(U6^XLU^<HVX65"[9UKYZ9'&-%EB X((L>O5V$YICV'.
M\F:J;NZ\B\\(Y#KHTK ?3_O$8 !:B&<=CI"M4&>ZV6P^_YLTPM,#BDC*'9D]
M.K<#"FG"2]\PM!"!FOPK]8BY#)*P2C9WK!FBM?66VEA$#I^#^J.E%:9Y$*L/
M/,2VCO"1K_$*VURC25;LAL*;YMP[&C- Z9%=YTWK8Q*D$.L_1E%,>UL(8H*8
ML>^8:3*=%<V=6Y+SC(0ZM89U/^WN(8<[M8ZH)J:YI&I #?%OU]G3]R'65ZC3
M$$\DWU 45ZO.*RSI8P7;T^(DTS[Y4P<+D=RN1A^H(K $?VZKAOQF2S?HK438
M4NMB7+:T\^/'CU]?X_!//!1?@]K0"[/\Y=<P6WVHE43NUL9U@F62NH8DG\1K
M"$K#&+4Z^'ETV0'ZBH#]BD[-T/JNT,7\XY&.&S_B-SX"YPPJS><?#\V,_2!)
M@!&OK$J&Z:&$CL@8E?\(\5-XI'Y):L\:UCMZ7C7A IN_)UF!HG_^C&=(!'XA
M7L08\<ND<EIA?;@N;Z;&''.Z$P)D<V=W 8.R-HD*;7+;X>_!D-4I71]5J'PE
MSOJPV*SYD:5L-&NNR[*9ID]4L$W'BO@0Q@EZDRFER7L<2^LD<E;A2V L>%PP
M0$5A)^G7>PDX!.L4T )#,A/^8'6-XH(#2CDYYZNY3(V$LYVP+89I:/\LO4YQ
M"9#GC $+R"3]OMCS9;TR1:-HO;)[N?0!Y7ANF2UNTBA^C:,*;Y[6-ZL57B?R
M.$@8@ IA%>FA76+E.'&&*'Z$;.K'@08NJ5I.RK>I7W^9!$6QN0@E6$C!-AB6
MF5-ZJTNI !X4N&LWGUY/-.$$O/\P1F(HZ$5ZO11HF4T-A 0ZL)L:)[ZL@AK)
M$2U\EH,ZFQG[8CN&0W)Q8[::?S156%YN_8(^"=Z"Q0$"D&37*V*")"<Q#9UH
M])+Q;;!"6Y<.6]*.P0]+" P@S6Z8)DE1&D<QJ5!*T8HL":@-'L-F"+-K2?#A
M ;39]:.(AR://\EQ[=;2X+, 4">)#.#0KF_% H?>6";FR!1:*AI<+D5>]@C%
M_Z)DXG_,[TG\$C!G;OT=HS43R&5E?F1  52NP2TBHW+8L;_]!!XFAN+GA+,9
M0V> 4ONB FK5X&/0K5;7$\P0_8IF#!W1A0(]?\-:6E4KKJ:WGL%RN[D[R!J>
M^QIFR KH5L/F7J3;X$VLV_XS6%XW09J2NMV7%=#M\#UY@<)?G[/7#Q&*&]7B
M'ZA6\3^:FS!?\&I1KH&5CO%4FPODP% F-RO+G@@70,;PO;>8C$82T$;<?82*
M:V@[+5P&13K<US@H/Z#NX;MFD^IVO3QJT[MPS=217^GW)O[S]R;^DQ^VP7J6
MRNODN@1WV.[,ZU(0 %7;W:4^XKYGBPN2Q?*Y=BX+G$/,Y[ND4(=F#ORM^H?$
M" 'B[![^]P0D(=.W6!;ZFWX,N=!%J]@3586A(V)I'Y*8*3;#8P #W%NN]NX!
M]Z[7/G>#0+A8ZKB1N*E!>85>49*]U+B><U0+QU\YA0TI$B<I%G1\A(S55@TV
M$&6L(RWVE[<PJ8KX%5V1@A'Q4U7K58X[F;8=CC,GN1<,T:>,'&!02X6P//LW
M"A6^-\;35%:G1YSZ/S(15H 7Z_<&L<%8KN\2;'QCW*0J:STG?%Z3Y4)@XDJT
M[O*%'+Z#*&55O #%=J,10*&)R,+C-8G6%++KHU)5?A19!B #+-L-7[#)LB\&
MK0NZ12;ML0[_SUV09!=)F5T$6^6TKH,P3N)R+5AF91I31$Y77=5/C;72*L,%
MB+/K39J52Y3WEJ0K1 HDUT)QOE-.J_G'8W<5#D;>49:&!U!GUY^T'<BV*:Q8
ME<LLC__#+5S!;X@1NDNBH8E &80 AW;]0IV@W[&>%=G;:8)1N4N'H9LW)C:
M,1W.FV\H?R:?/%[Q<:=U<B3^3"C1"@OM+B6FCFP-,O" :\-VKW'TL^+P0O1Z
MC\T_GKC+UJWI:]G' [!A]P)'7RSI\EA0&XS+7<92 SPQP &D*3E@.,EH-A?/
MN_(P=7I-:$8#&V!1W:4SU)5ZAH,,(,&NBZ2]Z8AE?8K3>L*]1T&1I==9SO@;
MYWM2[ GKP%U"0TU?V2#( .U:2K^C\C%(G^.G!#4U#:%O;N]!+)J[N@0ZOC4
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MXW?54Q*'[?OI";Q$I0.)IEA\=Q>=E%F0!@3PH2,_T67P$I=!<A_$!1X$$BR
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M11K=8EGH;_IVL3"02;$GJ@I#]]2E%T$Q4VR&QP &N+?KA?&!>U\63?N#0+B
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M!B_FJ8D!T1\O0+O;B\&M*\R5R$_%<Q;B^!E%ET7^+8E+9 *^U1[ ;IN,ZL:
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M?>A(XX##48#*8N*N 1K_^/&=ET&M.V4(A!])MJYV_6")^^*T,?N2?5\[Z^O
MD& :12QD5T:EN"NH"P/GVX,A4;P*6P"L481 VN',]^[4-GG2L#@M&QE:=L)X
M@]X>U@'>!O=I+MFW\ELSF;U>/U+Z'GC+DAS42.(2V=YQ@8,D"\H;4MGEOOT7
MR;*E_A"F -^WE?HN9SVQCB+(\=104"258U5X7=IZDB!GE -T%%&,YI@;RP+G
MCD+IDN?VEB?/E!1/KT /9D3ZOG/3=RY5 3:*<$:I^:_)'NPZ\#JMJO"ASB0,
MTD2$XV0X'<N$ZX9<V63K. _?79JL<H2W=!NO$#[":\[ V3'H[4^S4E2C"%X\
MEE+Z$?([,&"6+F@HSZ92M:NQQ8$EB3><*E]CF2EM$2>=&TWX7A:OZ6*=%EF0
M1+,D6KR2B6)/?GL@*.,L2_%>[I#1> 1#Y]5+H_#-<'PT?7$"[+EUW)#%@+R8
M!BK3Y,[/2N$_G X-L$]>PX"T"=1 !=#EUO527IA4-_EXS9DV[ 39V]^(2%$!
M5+GUM1Q+*5W8^!T8,$N5/)0W(E*UJ['%@07PY=:A8IZOL6Q$;!$GVXA<&*G?
M%N!H%^"?DI)AG59,1B^W/#5&/F<[(8 "J-F PT-6QS!(5I#1V_E[+>X'K]5Q
M^RPN, Q ZP8\$"I:%U>+9"V8R)8BG-3JWG(U"&B:(SB@:P,N!$NZ]CW'#U>Z
M=!8WX ^0*/]K\$:OT0K5WVG#Q/=7"A48P:=JAR4'%&Z_\OGAWK)8X>TV=4#<
MA9_X24V%@Y(#"G=L<M=E?:XV09;-EV6A'MF%1*@/@S=5M[(:-( YM]9W6T*I
M>7#:F 'R[5-6TSF?+PDN@"BWMK<YHGRO[]89DR[_;JWP)X1IHH0'?$@25@HM
M=TK"O1A4KZYER5<#3(V*L(!KI&Z#&ZJ<-S<!K<DC#?4[;=P LI2QU_Y")L$$
MD.0V6J$KHWQJY#1GH'S=>%14N I+'$@ 3VX##LSR-)9%S 9ATLOT)@I[W11)
M%"<K6K$XSNDJ?(?R'&&Q3U+8B2'P>F F_1HX#DIU7  C6@X%R"V\P@@)KD*=
M-JHE^_!Y:E>@)%@ +9N( FA>"LY O&9,.E]WER0:$ZF7 P%0L);7P):"?4_M
M)C4MG<JUK'V9QG_$^?JJRLDW7R[6:+&.<17Z_8#3)<JR\N5D"[Z+0T1^VL6T
MDK+D&,K$PYE&_.4&%GT.(DZ-X09&@(ED",243J+G?543^Z' X3K(4(- <LE,
MH2^[/&SIQ-X\?]JP 'H<7X$(-C19^-,:H?R.OD'A#@30A8&;VKFE%C(@GY'C
M6Q <2>6A\F G!M#[O0<5"M39X\ #^'-\X\$:?[XW,ZZ(E&UT/KAU-LS"D&8/
MSQZ"/9UEI-Y6;GL&SV^&%;4/B4^>'!C E]LK#D1,7*#H+@Z>J=D>(WA7*NO"
MP'DY2#?%FAP;0)P)5\1MLD-9CL#XJ.,VC5QG4_-TBZ$ *C;AAZC?*;:2NZV8
M;+[\U&)U"53+ 0 HUX0/8J!R?2_:YK0L799-^!]^2_'/7;P1++.\9DQ*+^YB
MV>CD:%D$ %"OVQB!.T1LW&OT0LLPU&O'7K"$<MO__LE30%3?7.\*: !VW-KV
M]'0A3<H#[_OT(<"T1IBHT@2W/<'CKTK:$'8$:(",N&Y-^*=@@P[!# ^8>O(0
M?EH'6$00U(6@\N?F',*1&!! DXELC/<%141>3=]&9-W&.;COY+4E GH)A1E6
MGP)& JA:RX:&7,4O:9*E^"X-P'U1JTD=EGKN)TONP/H?  Y NR9.U7\$& =$
MT#=BKL09*K\B2,V\MDS.:<WR:H  Q1LY/(^BN'HN>6T2QB_!!BRJ)^[ ))[@
ME**&"N#!A%E[E9(M-<YC8FYW;XM#/( =F,3^*F?UYD$-%<"#V]C];A['FR!$
MTFJ44)?F9I^?"*#!^Q\E7 !IKHLRMR5]1"_U :<>=<<=&=!IFH :Z  :39S&
MLY*)\V5]\EPNAK?)59"MO_Q1!)O;;)$>3=%E=(%H7S;TN0S_M,P3\^ !\MWZ
M QX1&:AQF*.( A!\L]V&#,BT]B<*:(!B+6X= 725KH_+6MDS8Y1=%65"_5D2
MW:=)6/U'0)O>@Y@B_(78#*%U %J =K<A -VE8X'P5GD5I8T;0!XK/)M;.4\0
M 13Y+!A1EYU])$.MO$K6*E6L3)WH(4P!T_PB>R(%J#;A':EK2\=;=(W"38!1
MM$AOX@VB,99/*'Q$JX"FK%J1-2*@T\@J)N*71^?-94%H<V3BV8T>;%4^L[E!
M,JX 8""XS:5XG'"&&-89#; MY2ZS8U?W"$6!(HJ/8."GY7L;A!,@V4"^!@V2
MR;:!CCZR>S]DSWW :52$>;Q#)2A1^*NT+X,[S6E<#R# IXF@"GHZE"U(DVR=
M;J+RN (\03AMVDCY<8)SJPP/H'6W/J'NG>KJ4&E6Y.L4Q_\13I#BCLWUM[-I
M^6%[H -H=!O$T967V%!S7.W7RA-SA6-IM0<PX!.=%O51 O2Z]?H<MFGW*/^1
MXGS]B,HY/;I)\56Z?=G$-&A40*Y*=Y9(89I?K#9&H,JL6[\1A39?=F\?'_)D
M7:88IZ_T@G'P0OXBCLG2> Q3PC2_X=Y8 <)-A*+,5BM,+*4<S8L\HW?(B R2
MDV2P!Y/92]+.@4?):K  *MQZAEJ!\F1/7&Q1=";\Q$Y:L]N$TSRYE$$"6')[
MR:,5 EAMPRCB$,>E6,+4.L*.[%+$- ]$-- !-)H(H"$[ICB-9LL<X;9KZ,<:
M)8LUHFLPRO*KM-A$E^AK$*%%2GZNXZ<7:7TD1WZL0 @.,8V^A^EG6IL=^\H
M!HN)*)_#(MT^D_V>;LBT\P/%JS79A,]V").?RP/:.L#Q*PJR@JSU\V1V3=2S
MOPRRF!C507Z;?=G$*QHKLT@O">H0Q3ORB&P6[8#=L'LA6+#_M"(C/&L*&(,F
MW%%U]&SCEEG@@.Y1KH-]1H"D>)%>T]W+\C[-":SRTRF1T;8(9\2<( I$>$M8
M3%;DCW*5R$*2'8K"M#RM16\4^@)&I8F[4.UOK/QLY*+-\A_K.%PWD_@,H_8'
M5D_R/ ^>[5<RK4US<76B%V TF8@DJS\4>I2#PH+Z_%N?BH49S-B+F(:FY9IP
MH U@O#A.2DO-C5MB*J+HNL $1[45K<2]1Z_EG\3INU4>T "?ZHTH?91\>C_7
MSLB_,P40"7Z6/]%7/Y-YY;__#U!+ P04    " "7@'Y58#!#Y&+:   ^'0P
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M9WY,D")L*' -% <L#:T6!R!-N/A>;_]^C#+*#D"'+-W2/,^4']1=?CN30UV
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M8G-W_]M@?_CS!=9IS%^"34(.\D>2M><E;,V+?%Y>QFB$N&G%G51FF%_<25^
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M<I+0<H74Z8-4G? 4S:UNT"^6)DEZ3*)%G(Q&8=-P7^,.3!#5NTF3J%P /M*
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M2L,?5"U-L=TQUU%M8, Y*?<)IPH^K$668?Y$BY<TW"2O-!<7C;=?$H;8E^C
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M--%$BJ)*T?*N9$E:[::XX2D^@!Q&K?B@<4IAU-Y&[)2NSD($5A[5PKO5?%U
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M?(KX_3(L;E08OYX6X[[2((GYYK**#%Q$2.-TB=AI:%O%.BXGR-$'<]H[3A#
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M>/+(;KPY:"VH47Z'F\15,\3:2>UCW2WN94R[+?HDA\6PX),<$\MN:,59I K
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M064F2^',W9L8<"YG-,I9U=^<7ZF17W#\LB=B; A:@Q?LIN34!!/G6GQD2K>
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MJ+-\NR>#4V[2B!;N/E*'-%5%3Y\$I%GJR]7'8]WA K$NK#I[T\F'XG6F8S8
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M;N2=0TW0+8D'>4CZE%WA8U;$Y6U:9IM'_/*2XY>@Q ^XP/DKOCFED30\-*
M%BV:2#4LK\TZTR5NU9T>R-#U;DL!5200I>$BG+0A()$IJ@2,4[;J*%H!\TK
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M(]&),;2&8=$EBOQW3"_6;X['/'L-$OXY-38F.L%=CE#S/LP<K]JCND.-%>?
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M%OY^&1QC$KT\[@.BQ0=<X/P51S=9SJ?:.C=XQ (7T ),UYTCZ<@P$AJ($;E
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M4NT?(. XSSNL-G*V7,-E=CAD*7LNE:W"V IMRA],=()R E.\]U7,VR/6H2H
M6FUI.#3VF4*P\N]\[5LOCYT;M1:6.I8,!R0M\[4_%K;,E)?*V.ZN@C>:=WR%
M";!HU>KTA7B8.FGNYRPA,E:I<RQECC3E[D=FR<OI0AF[!0WTAX^3I#L1E"B]
MH( $LBPH:)(^.>4F+Y;19CTX=0>.8SV%D-5J1!6R(^)%@D+H=/2E5L@K5PA-
MAGVI4F#;Y; S%V3+3CI>RBLCT7)D_F C:,!!>W!T6%O64+HD;F(\#\2L'7>]
MVR-=W!A2 5OBF$HWB"B9V@F%:A-DS+_59-IM6Q?K'3N2'G$%L%%PUE.R!TYJ
M'FZ[2R!WH-5;"+D94FN>A2>J?@PB?)L^GO(<IQ'..?,3WD2C)Y@'T9%BH/@J
M/9[V0K=DM23T$_9)7+B))>(<J#@QB=5%<=KUM3M?H(VTKOW#PDS/YE<<'V/#
M7IYL%8;Y"4=U%DF,BTO&6KE)HT]D8/D/JA0K30*0B56Z,@WRBWA')/1TE"NU
MH@2@N5!&Z!ID0!E!:\$\^/E(6$_+A,S%:8%OL#3+::0AU"PWQF-_]*LV9/19
M(T1:.?/X4IUV'/RZ"M7RYSJ*/1W?L49__M/[O_WE'U53M.NJ=P$ /\8)+LHL
MQ=4\(</?L!T4_$8X["NI:5+?/700/!FQ>1QG$\Q$9*/>L9!5AUS+0#1T>E#I
M%"2.><C>@J1\HX^8$M-4Q"O]AH!QR8#'02(@;X"J%FYB#VTNJZ%V&F",#WL_
MD!@?<Z#XFN5O1C=D/5_BN_@51[?$WM*7^#G!+,7[ 1=Q= J2J6OSQI1 (VY3
M*8>!*Z> .(EWC 9JB2!&Y0+5=%PD8OLF+6PD/PO'PY!^%H@7A%97F%]AZER:
MD,57DL9009:,USY\ZG;=&SX.PBUCAIW?TIG&1"?Z6A\06B&8KIZC23TOL*1-
MD$>O0?[[1RQYCV:T%93M#+@;^-RJ ?J5-W%RUUNAR [N5M2B%N"TM6GK*.(A
M.^"7:M]B\Y)C5E1#C31E%["K9DJ^AZ$S:=ULSS3MW4-20_W=VU= NM>[=65C
M#&SOY&R^QM+3LUXC\#V<BC?YSLBOM(4[-(XJ<7Q71-2@C6&[R@Y!+(T/!\W
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MZ%?:W.D[RU.Z[Z>K3"G>&6"NL@.9 0PA4W=R#)J&=UW8\ [> :<[!CK0Z0X
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M3H\OW.+6[NP!MAG;=/(D]Z+AV;9^M\C>$>3-QXOR T_6C1__H[C/:J@OVF@
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M'FP!I+7\S$,+P!I-LW!U%SD0C5=3:C0/_NR(@Q*KX_F/.P>'GHXELE?_&B%
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M/#,V U<R]3E&N+0Q7+=1\NTAB?WR2=$ZJCL.!#</EI0_2K(B)1K!SUV'IJ<
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M=].EZEQ8=IR4AU@/)[K?5,18@)S!X[^BB"[E.MJ[M!^]S2,7$U*P2\QC#4Q
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MR>..H5[TTK*O8<=RR,#[1U?L@[=>F)9^_,FLD=4VR]-"+TQ+JS^EU%Z=$BW
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M3DXGZ@[&UR1_86&\B%F$;@25[8$#HOV!F3H218T0^1NEUE(1_:?,"T&.]I(
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M6\?;@D,D'<D'Y_S,ID6:Q2';G]Q:[V1]:"%:L@V3F8>K1P/-U D.7)W[]&(
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M/^X(%/GL<3?$)S>!MV]\=.,=%%$P=^0==VOY>>MK6AEC=)CZPQ?Q<+OWJU;
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MT9-MT_Y !)$CAM@:3C@@/3GK8PSQ:Z^Q0?0'(HA<-=3&<,Q!WZ,S"F/H:@0
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MOLEJ4@S"UK=TS1^SCHLMA>D?_GJK%E5F9O^-7T&HHQOSO[+Y[[:@M%_![B5
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M4$L! A0#%     @ EX!^54U2(4]N @  O@4  !$              ( !; ,
M &0S-S0V,C1D97@R,S(N:'1M4$L! A0#%     @ EX!^59:W-NX: @  VP0
M !$              ( !"08  &0S-S0V,C1D97@R,S,N:'1M4$L! A0#%
M  @ EX!^5<@)\F,$$P  +4D  !               ( !4@@  &0S-S0V,C1D
M97@U,2YH=&U02P$"% ,4    " "7@'Y5+7RVU@ *   P>@  &
M    @ &$&P  9#,W-#8R-&1E>&9I;&EN9V9E97,N:'1M4$L! A0#%     @
MEX!^5=%],-]7\ @ ,\59  X              ( !NB4  &0S-S0V,C1D<S$N
M:'1M4$L! A0#%     @ EX!^53V7S?+;8   ^(H  !$              ( !
M/18) &<S-S0V,C1G,C1P-#DN:G!G4$L! A0#%     @ EX!^54%'JIV_#P$
MCR ! !$              ( !1W<) &<S-S0V,C1G,C1Q-#DN:G!G4$L! A0#
M%     @ EX!^5=CP7H0-=@< \G<* !$              ( !-8<* &<S-S0V
M,C1G,S=G-#4N:G!G4$L! A0#%     @ EX!^52%IY?PF; H E6D- !$
M         ( !<?T1 &<S-S0V,C1G,S=X-#0N:G!G4$L! A0#%     @ EX!^
M5=U0GREA]P  F\\! !$              ( !QFD< &<S-S0V,C1G,SAA-#,N
M:G!G4$L! A0#%     @ EX!^533V2+Z"GP  HK0  !$              ( !
M5F$= &<S-S0V,C1G-#)N-30N:G!G4$L! A0#%     @ EX!^531S>[F/RP8
MT,D) !$              ( !!P$> &<S-S0V,C1G-#)X-C(N:G!G4$L! A0#
M%     @ EX!^564P9RJ]. < ^4,* !$              ( !Q<PD &<S-S0V
M,C1G-#-V-3DN:G!G4$L! A0#%     @ EX!^59V8(WB#K 8 WK8) !$
M         ( !L04L &<S-S0V,C1G-#5M-3<N:G!G4$L! A0#%     @ EX!^
M5<QS6&P[P08 Y-$) !$              ( !8[(R &<S-S0V,C1G-#5V-3@N
M:G!G4$L! A0#%     @ EX!^5<SL4@^(^@$ 3"T" !$              ( !
MS7,Y &<S-S0V,C1G-#9H-3(N:G!G4$L! A0#%     @ EX!^53[2(_  [P8
M$?H) !$              ( !A&X[ &<S-S0V,C1G-#=J-34N:G!G4$L! A0#
M%     @ EX!^54:X9D'DZP< ?_,* !$              ( !LUU" &<S-S0V
M,C1G-#=L-38N:G!G4$L! A0#%     @ EX!^5=7Q5QGX+@$ U00" !$
M         ( !QDE* &<S-S0V,C1G-C1P-C$N:G!G4$L! A0#%     @ EX!^
M5?\<TJT080$ N;X! !$              ( ![7A+ &<S-S0V,C1G-S5S-C@N
M:G!G4$L! A0#%     @ EX!^53'7Z4B3)P  @L@! !$              ( !
M+-I, '-C;'@M,C R,C Y,S N>'-D4$L! A0#%     @ EX!^534)DB?^$P
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I;'@M,C R,C Y,S!?<')E+GAM;%!+!08     &@ : 'D&   30$\    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
